cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
COAD	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	25.37	6.31e-72	1.9e-64	0.97	0.85	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	25.01	8.53e-71	1.28e-63	0.97	0.84	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	24.69	8.98e-70	1.93e-63	0.97	0.84	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	24.69	8.98e-70	1.93e-63	0.97	0.84	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	24.69	8.98e-70	1.93e-63	0.97	0.84	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	24.68	9.64e-70	1.93e-63	0.97	0.84	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	24.33	1.23e-68	1.68e-62	0.99	0.84	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	24.09	7.07e-68	9.25e-62	0.97	0.83	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	23.64	2e-66	2.08e-60	0.98	0.83	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-23.51	5.51e-66	4.27e-60	-0.97	-0.83	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-23.51	5.51e-66	4.27e-60	-0.97	-0.83	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-23.23	4.53e-65	3.1e-59	-0.95	-0.82	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-23.17	6.86e-65	4.3e-59	-0.96	-0.82	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-23.17	6.86e-65	4.3e-59	-0.96	-0.82	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	22.7	2.44e-63	1.5e-57	0.94	0.82	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	22.67	3.03e-63	1.81e-57	0.95	0.82	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-22.63	3.95e-63	2.28e-57	-0.94	-0.82	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	22.61	4.75e-63	2.7e-57	0.99	0.82	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	22.54	7.86e-63	4.38e-57	0.97	0.81	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-22.06	3.19e-61	1.52e-55	-0.94	-0.81	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-21.92	8.85e-61	4.04e-55	-0.94	-0.81	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	21.92	8.98e-61	4.04e-55	0.95	0.81	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	21.92	8.98e-61	4.04e-55	0.95	0.81	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	21.31	9.91e-59	2.57e-53	0.96	0.8	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
COAD	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-21.27	1.39e-58	3.34e-53	-0.94	-0.8	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
COAD	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-21.04	7.99e-58	1.77e-52	-0.94	-0.8	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	21.03	8.49e-58	1.87e-52	0.96	0.8	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-20.92	2.04e-57	4.38e-52	-0.94	-0.79	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
COAD	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-20.9	2.29e-57	4.86e-52	-0.94	-0.79	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
COAD	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	20.87	2.93e-57	6.18e-52	0.93	0.79	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	20.87	2.99e-57	6.26e-52	0.95	0.79	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	20.63	1.88e-56	3.73e-51	0.92	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
COAD	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	20.53	4.1e-56	7.91e-51	0.94	0.79	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-20.27	3.15e-55	5.89e-50	-0.92	-0.78	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-20.25	3.6e-55	6.61e-50	-0.9	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	20.25	3.74e-55	6.83e-50	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
COAD	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-20.22	4.66e-55	8.4e-50	-0.93	-0.78	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
COAD	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-20.19	5.95e-55	1.07e-49	-0.92	-0.78	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	20.07	1.5e-54	2.6e-49	0.9	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-20.07	1.56e-54	2.68e-49	-0.9	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
COAD	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-19.94	4.17e-54	7.01e-49	-0.91	-0.78	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	19.9	5.71e-54	9.51e-49	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	19.9	5.71e-54	9.51e-49	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	19.89	6.24e-54	1.03e-48	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
COAD	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-19.86	7.95e-54	1.29e-48	-0.91	-0.78	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
COAD	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	19.74	2.05e-53	3.31e-48	1.38	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
COAD	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	19.73	2.21e-53	3.55e-48	1.39	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
COAD	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	19.68	3.14e-53	5.01e-48	0.91	0.78	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	19.65	4.2e-53	6.65e-48	0.92	0.77	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-19.64	4.4e-53	6.87e-48	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-19.64	4.4e-53	6.87e-48	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
COAD	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	19.6	6.09e-53	9.41e-48	1.38	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
COAD	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	19.6	6.09e-53	9.41e-48	1.38	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
COAD	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	19.52	1.15e-52	1.74e-47	0.92	0.77	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-19.46	1.84e-52	2.77e-47	-0.9	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
COAD	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	19.44	2.21e-52	3.3e-47	0.95	0.77	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-19.39	3.2e-52	4.74e-47	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-19.38	3.48e-52	5.01e-47	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-19.38	3.48e-52	5.01e-47	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-19.35	4.45e-52	6.29e-47	-0.88	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	19.34	4.83e-52	6.8e-47	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-19.32	5.4e-52	7.57e-47	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	19.31	5.88e-52	8.16e-47	0.9	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	19.28	7.52e-52	1.04e-46	0.92	0.77	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	19.25	1.01e-51	1.38e-46	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	19.21	1.31e-51	1.78e-46	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	19.19	1.6e-51	2.15e-46	0.9	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
COAD	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	19.18	1.75e-51	2.35e-46	0.92	0.77	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-19.17	1.8e-51	2.39e-46	-0.9	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-19.14	2.32e-51	3.06e-46	-0.88	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
COAD	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-19.1	3.2e-51	4.21e-46	-0.9	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	19.1	3.26e-51	4.27e-46	0.9	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	19.08	3.82e-51	4.93e-46	0.88	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	19.08	3.82e-51	4.93e-46	0.88	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	19.08	3.82e-51	4.93e-46	0.88	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	19.06	4.33e-51	5.57e-46	0.88	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	19.03	5.48e-51	7e-46	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	19.03	5.6e-51	7.12e-46	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-18.99	7.6e-51	9.5e-46	-0.88	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-18.99	7.6e-51	9.5e-46	-0.88	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-18.97	9.01e-51	1.12e-45	-0.92	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	18.92	1.3e-50	1.58e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	18.92	1.3e-50	1.58e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	18.92	1.3e-50	1.58e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	18.89	1.71e-50	2.04e-45	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	18.89	1.71e-50	2.04e-45	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	18.88	1.76e-50	2.08e-45	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	18.88	1.77e-50	2.08e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	18.88	1.77e-50	2.08e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-18.88	1.88e-50	2.2e-45	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
COAD	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	18.86	2.18e-50	2.54e-45	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
COAD	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	18.84	2.49e-50	2.88e-45	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
COAD	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	18.79	3.67e-50	4.23e-45	1.45	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
COAD	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	18.75	4.91e-50	5.65e-45	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	18.73	6.01e-50	6.89e-45	0.88	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
COAD	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	18.73	6.17e-50	7.03e-45	1.34	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
COAD	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	18.71	7.04e-50	7.97e-45	1.33	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
COAD	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	18.68	9.19e-50	1.03e-44	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	18.66	1.01e-49	1.13e-44	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	18.6	1.67e-49	1.83e-44	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	18.6	1.67e-49	1.83e-44	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	18.6	1.67e-49	1.83e-44	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	18.6	1.67e-49	1.83e-44	0.9	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	18.58	2e-49	2.18e-44	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
COAD	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	18.54	2.64e-49	2.84e-44	1.44	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	18.54	2.64e-49	2.84e-44	1.44	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
COAD	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	18.54	2.64e-49	2.84e-44	1.33	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
COAD	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	18.53	2.98e-49	3.19e-44	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	18.53	3.02e-49	3.22e-44	0.88	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	18.51	3.34e-49	3.55e-44	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	18.47	4.84e-49	5.12e-44	0.84	0.76	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-18.41	7.37e-49	7.71e-44	-0.88	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
COAD	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	18.4	7.99e-49	8.32e-44	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	18.4	8.46e-49	8.79e-44	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
COAD	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	18.37	1.04e-48	1.03e-43	0.95	0.75	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	18.37	1.06e-48	1.05e-43	0.97	0.75	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	18.36	1.09e-48	1.08e-43	0.97	0.75	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	18.34	1.3e-48	1.27e-43	0.91	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	18.34	1.32e-48	1.28e-43	0.88	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	18.33	1.41e-48	1.35e-43	0.9	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
COAD	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	18.33	1.43e-48	1.37e-43	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
COAD	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	18.28	2.23e-48	2.12e-43	1.4	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
COAD	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	18.27	2.32e-48	2.21e-43	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
COAD	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	18.25	2.71e-48	2.53e-43	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
COAD	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	18.25	2.71e-48	2.53e-43	0.9	0.75	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	18.25	2.74e-48	2.55e-43	0.95	0.75	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	18.22	3.39e-48	3.15e-43	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	18.18	4.71e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	18.18	4.71e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	18.18	4.71e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	18.18	4.71e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
COAD	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	18.18	4.74e-48	3.83e-43	0.95	0.75	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	18.18	4.84e-48	3.89e-43	0.95	0.75	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	18.16	5.45e-48	4.36e-43	0.95	0.75	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	18.16	5.45e-48	4.36e-43	0.95	0.75	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	18.16	5.63e-48	4.46e-43	0.88	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	18.16	5.63e-48	4.46e-43	0.88	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	18.16	5.63e-48	4.46e-43	0.88	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	18.16	5.78e-48	4.55e-43	0.95	0.75	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	18.16	5.78e-48	4.55e-43	0.95	0.75	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	18.15	6.03e-48	4.73e-43	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	18.13	7.05e-48	5.47e-43	0.95	0.75	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-18.11	8.04e-48	6.2e-43	-0.91	-0.75	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
COAD	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	18.11	8.55e-48	6.57e-43	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	18.11	8.55e-48	6.57e-43	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	18.06	1.25e-47	9.5e-43	0.88	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	18.04	1.45e-47	1.1e-42	0.89	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	18.01	1.85e-47	1.4e-42	0.89	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
COAD	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	17.97	2.49e-47	1.86e-42	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	17.97	2.49e-47	1.86e-42	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-17.97	2.54e-47	1.89e-42	-0.89	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
COAD	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	17.97	2.58e-47	1.92e-42	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	17.96	2.71e-47	1.99e-42	0.94	0.75	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	17.93	3.58e-47	2.62e-42	0.95	0.75	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
COAD	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	17.92	3.77e-47	2.75e-42	0.87	0.75	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	17.89	5.01e-47	3.63e-42	0.95	0.74	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	17.88	5.15e-47	3.71e-42	0.95	0.74	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-17.88	5.38e-47	3.86e-42	-0.87	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	17.87	5.54e-47	3.97e-42	0.87	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-17.79	1.05e-46	7.41e-42	-0.93	-0.74	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	17.78	1.18e-46	8.35e-42	0.89	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	17.74	1.57e-46	1.1e-41	0.86	0.74	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	17.74	1.64e-46	1.14e-41	0.94	0.74	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	17.7	2.27e-46	1.57e-41	0.85	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
COAD	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	17.66	2.95e-46	2.03e-41	1.27	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
COAD	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-17.65	3.17e-46	2.18e-41	-0.89	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	17.64	3.54e-46	2.42e-41	0.91	0.74	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	17.62	4.19e-46	2.84e-41	0.95	0.74	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	17.6	4.91e-46	3.32e-41	0.88	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	17.49	1.17e-45	7.78e-41	0.94	0.74	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	17.47	1.38e-45	9.16e-41	0.93	0.74	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	17.47	1.44e-45	9.53e-41	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	17.45	1.62e-45	1.07e-40	0.93	0.74	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	17.45	1.67e-45	1.1e-40	0.93	0.74	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	17.45	1.67e-45	1.1e-40	0.93	0.74	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	17.39	2.74e-45	1.77e-40	0.88	0.74	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	17.37	3.18e-45	2.04e-40	0.92	0.73	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	17.32	4.61e-45	2.94e-40	0.93	0.73	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	17.31	5.15e-45	3.26e-40	0.92	0.73	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	17.31	5.15e-45	3.26e-40	0.92	0.73	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	17.31	5.18e-45	3.28e-40	0.92	0.73	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
COAD	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	17.3	5.33e-45	3.37e-40	0.91	0.73	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	17.29	6.12e-45	3.85e-40	0.92	0.73	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	17.29	6.12e-45	3.85e-40	0.92	0.73	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-17.28	6.22e-45	3.85e-40	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-17.28	6.22e-45	3.85e-40	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-17.28	6.22e-45	3.85e-40	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-17.28	6.32e-45	3.89e-40	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
COAD	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	17.24	8.73e-45	5.35e-40	1.31	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
COAD	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-17.23	9.49e-45	5.8e-40	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
COAD	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	17.23	9.65e-45	5.88e-40	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	17.21	1.13e-44	6.79e-40	0.91	0.73	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	17.21	1.13e-44	6.79e-40	0.91	0.73	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	17.21	1.13e-44	6.79e-40	0.91	0.73	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	17.19	1.28e-44	7.69e-40	0.88	0.73	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	17.18	1.45e-44	8.72e-40	0.93	0.73	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	17.17	1.58e-44	9.37e-40	0.89	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	17.14	1.99e-44	1.17e-39	0.91	0.73	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	17.14	1.99e-44	1.17e-39	0.91	0.73	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	17.11	2.41e-44	1.4e-39	0.92	0.73	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	17.11	2.41e-44	1.4e-39	0.92	0.73	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	17.11	2.59e-44	1.51e-39	0.91	0.73	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
COAD	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	17.09	2.82e-44	1.63e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	17.09	2.82e-44	1.63e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	17.09	2.82e-44	1.63e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	17.08	3.19e-44	1.83e-39	0.92	0.73	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	17.08	3.19e-44	1.83e-39	0.92	0.73	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	17.08	3.2e-44	1.83e-39	0.92	0.73	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	17.08	3.2e-44	1.83e-39	0.92	0.73	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	17.08	3.25e-44	1.85e-39	0.92	0.73	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	17.07	3.38e-44	1.92e-39	0.9	0.73	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
COAD	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	17.06	3.64e-44	2.06e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	17.06	3.64e-44	2.06e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	17.06	3.64e-44	2.06e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	17.06	3.83e-44	2.17e-39	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
COAD	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-17.05	3.97e-44	2.23e-39	-1.23	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
COAD	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-17.02	5.18e-44	2.89e-39	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-17.01	5.53e-44	3.08e-39	-0.93	-0.73	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	17	5.89e-44	3.26e-39	0.87	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	16.99	6.3e-44	3.46e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	16.99	6.3e-44	3.46e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	16.99	6.3e-44	3.46e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	16.99	6.3e-44	3.46e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	16.99	6.6e-44	3.62e-39	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	16.98	7.04e-44	3.8e-39	0.89	0.73	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	16.98	7.04e-44	3.8e-39	0.89	0.73	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	16.98	7.04e-44	3.8e-39	0.89	0.73	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	16.98	7.04e-44	3.8e-39	0.89	0.73	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	16.98	7.04e-44	3.8e-39	0.89	0.73	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-16.96	8.15e-44	4.37e-39	-0.88	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-16.9	1.32e-43	7.04e-39	-0.87	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
COAD	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	16.84	2.12e-43	1.12e-38	1.3	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
COAD	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-16.81	2.71e-43	1.42e-38	-0.87	-0.72	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
COAD	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	16.78	3.53e-43	1.83e-38	0.86	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	16.73	5.31e-43	2.72e-38	0.87	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	16.72	5.63e-43	2.87e-38	0.89	0.72	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
COAD	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-16.7	6.75e-43	3.41e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
COAD	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	16.65	1e-42	4.98e-38	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	16.64	1.11e-42	5.48e-38	0.85	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
COAD	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
COAD	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
COAD	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-16.63	1.16e-42	5.67e-38	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
COAD	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	16.62	1.24e-42	6.03e-38	0.86	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-16.59	1.63e-42	7.92e-38	-0.85	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
COAD	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	16.57	1.99e-42	9.62e-38	1.28	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
COAD	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	16.56	2.07e-42	1e-37	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	16.56	2.13e-42	1.03e-37	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
COAD	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-16.52	2.76e-42	1.33e-37	-1.21	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
COAD	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	16.52	2.83e-42	1.36e-37	0.89	0.72	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	16.52	2.88e-42	1.38e-37	0.89	0.72	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
COAD	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	16.52	2.88e-42	1.38e-37	0.89	0.72	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	16.47	4.28e-42	2.03e-37	0.91	0.72	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
COAD	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-16.42	6.52e-42	3.07e-37	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
COAD	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-16.4	7.6e-42	3.56e-37	-0.87	-0.72	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	16.34	1.23e-41	5.68e-37	0.89	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-16.31	1.53e-41	6.95e-37	-0.87	-0.71	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	16.29	1.89e-41	8.58e-37	0.85	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
COAD	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-16.28	1.9e-41	8.62e-37	-0.83	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	16.23	2.92e-41	1.31e-36	0.88	0.71	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	16.17	4.89e-41	2.19e-36	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
COAD	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-16.14	6.25e-41	2.78e-36	-0.87	-0.71	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-16.06	1.2e-40	5.32e-36	-0.87	-0.71	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	16.02	1.63e-40	7.14e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-15.99	2.04e-40	8.88e-36	-0.84	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-15.99	2.04e-40	8.88e-36	-0.84	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	15.99	2.04e-40	8.88e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	15.99	2.04e-40	8.88e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	15.99	2.04e-40	8.88e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	15.99	2.04e-40	8.88e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	15.99	2.04e-40	8.88e-36	0.84	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-15.97	2.41e-40	1.05e-35	-0.84	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	15.96	2.49e-40	1.08e-35	0.79	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
COAD	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-15.95	2.91e-40	1.25e-35	-1.15	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
COAD	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-15.93	3.32e-40	1.43e-35	-0.88	-0.7	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-15.91	3.77e-40	1.61e-35	-0.85	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-15.9	4.13e-40	1.76e-35	-0.88	-0.7	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	15.84	6.54e-40	2.75e-35	0.83	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	15.82	8.07e-40	3.38e-35	0.83	0.7	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
COAD	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	15.82	8.07e-40	3.38e-35	0.83	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-15.79	9.84e-40	4.04e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-15.79	9.84e-40	4.04e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-15.79	1.05e-39	4.29e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
COAD	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-15.77	1.21e-39	4.93e-35	-0.8	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
COAD	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	15.72	1.82e-39	7.27e-35	1.19	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
COAD	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-15.69	2.18e-39	8.59e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-15.69	2.18e-39	8.59e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-15.69	2.18e-39	8.59e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-15.69	2.18e-39	8.59e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-15.69	2.18e-39	8.59e-35	-0.87	-0.7	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
COAD	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-15.62	3.85e-39	1.5e-34	-0.82	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	15.52	9.03e-39	3.39e-34	0.79	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-15.52	9.09e-39	3.41e-34	-0.8	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-15.47	1.37e-38	5.03e-34	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	15.43	1.87e-38	6.85e-34	0.82	0.69	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	15.42	2e-38	7.29e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	15.42	2e-38	7.29e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	15.41	2.23e-38	8.13e-34	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
COAD	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	15.39	2.52e-38	9.1e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
COAD	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-15.39	2.52e-38	9.12e-34	-0.84	-0.69	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
COAD	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	15.39	2.63e-38	9.47e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	15.39	2.63e-38	9.47e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	15.39	2.63e-38	9.47e-34	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	15.38	2.76e-38	9.91e-34	0.87	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
COAD	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-15.36	3.2e-38	1.12e-33	-0.81	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-15.35	3.49e-38	1.22e-33	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
COAD	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-15.32	4.41e-38	1.52e-33	-0.8	-0.69	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-15.28	5.99e-38	2.03e-33	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-15.28	5.99e-38	2.03e-33	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	15.28	6.1e-38	2.06e-33	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	15.2	1.16e-37	3.87e-33	0.84	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-15.15	1.74e-37	5.68e-33	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-15.15	1.74e-37	5.68e-33	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-15.14	1.83e-37	5.95e-33	-0.8	-0.69	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
COAD	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	15.14	1.84e-37	5.98e-33	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	15.14	1.96e-37	6.36e-33	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-15.09	2.92e-37	9.41e-33	-0.85	-0.69	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	15.09	2.93e-37	9.43e-33	0.82	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
COAD	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	15.08	3.08e-37	9.88e-33	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	15.01	5.49e-37	1.73e-32	0.78	0.68	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	15	5.91e-37	1.84e-32	0.85	0.68	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	15	5.95e-37	1.85e-32	0.84	0.68	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
COAD	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	14.98	6.86e-37	2.12e-32	0.82	0.68	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	14.97	7.31e-37	2.26e-32	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
COAD	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.97	7.47e-37	2.31e-32	0.77	0.68	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-14.94	9.64e-37	2.94e-32	-0.85	-0.68	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-14.93	1.05e-36	3.19e-32	-0.77	-0.68	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-14.91	1.17e-36	3.52e-32	-0.79	-0.68	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-14.91	1.17e-36	3.52e-32	-0.79	-0.68	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
COAD	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-14.91	1.21e-36	3.65e-32	-0.83	-0.68	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
COAD	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-14.9	1.3e-36	3.91e-32	-0.73	-0.68	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
COAD	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	14.89	1.43e-36	4.22e-32	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	14.89	1.46e-36	4.32e-32	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-14.87	1.6e-36	4.72e-32	-0.85	-0.68	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	14.87	1.69e-36	4.97e-32	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
COAD	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	14.85	1.87e-36	5.49e-32	0.79	0.68	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
COAD	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	14.82	2.57e-36	7.45e-32	1.23	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
COAD	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	14.81	2.7e-36	7.83e-32	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
COAD	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-14.8	2.92e-36	8.42e-32	-0.78	-0.68	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-14.8	2.92e-36	8.42e-32	-0.78	-0.68	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
COAD	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-14.78	3.36e-36	9.64e-32	-0.76	-0.68	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	14.78	3.47e-36	9.91e-32	0.83	0.68	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	14.77	3.67e-36	1.05e-31	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
COAD	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-14.77	3.79e-36	1.08e-31	-0.78	-0.68	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
COAD	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	14.74	4.57e-36	1.29e-31	0.92	0.68	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
COAD	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	14.68	7.82e-36	2.19e-31	1.19	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
COAD	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	14.65	9.37e-36	2.58e-31	1.14	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
COAD	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	14.65	9.37e-36	2.58e-31	1.14	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
COAD	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-14.63	1.17e-35	3.21e-31	-0.79	-0.67	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
COAD	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	14.61	1.31e-35	3.56e-31	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
COAD	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	14.61	1.31e-35	3.56e-31	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
COAD	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	14.61	1.31e-35	3.56e-31	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
COAD	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	14.58	1.68e-35	4.53e-31	0.93	0.67	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
COAD	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	14.58	1.71e-35	4.6e-31	1.13	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
COAD	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	14.58	1.72e-35	4.61e-31	1.14	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
COAD	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	14.48	3.82e-35	1e-30	0.94	0.67	Shingles;	chr7:38346957	chr7:38343894~38350022:-
COAD	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	14.47	4.05e-35	1.06e-30	1.21	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	14.47	4.05e-35	1.06e-30	1.21	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
COAD	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-14.46	4.39e-35	1.15e-30	-0.82	-0.67	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
COAD	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	14.46	4.46e-35	1.17e-30	0.82	0.67	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	14.45	4.79e-35	1.25e-30	0.82	0.67	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
COAD	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	14.44	5.02e-35	1.3e-30	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
COAD	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-14.44	5.16e-35	1.34e-30	-0.78	-0.67	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
COAD	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	14.43	5.81e-35	1.5e-30	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
COAD	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	14.41	6.65e-35	1.7e-30	0.72	0.67	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	14.41	6.65e-35	1.7e-30	0.72	0.67	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	14.41	6.65e-35	1.7e-30	0.72	0.67	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	14.41	6.65e-35	1.7e-30	0.72	0.67	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	14.41	6.86e-35	1.75e-30	0.79	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
COAD	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-14.4	7.33e-35	1.87e-30	-0.77	-0.67	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
COAD	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	14.39	7.82e-35	1.99e-30	0.92	0.67	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
COAD	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	14.35	1.05e-34	2.67e-30	1.11	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
COAD	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	14.34	1.2e-34	3.04e-30	0.91	0.67	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
COAD	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	14.33	1.27e-34	3.2e-30	0.7	0.67	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
COAD	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-14.32	1.32e-34	3.33e-30	-0.79	-0.67	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-14.31	1.51e-34	3.8e-30	-0.82	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
COAD	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	14.3	1.64e-34	4.09e-30	0.72	0.67	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	14.3	1.64e-34	4.09e-30	0.72	0.67	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
COAD	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	14.28	1.83e-34	4.54e-30	0.93	0.67	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
COAD	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	14.28	1.86e-34	4.63e-30	0.72	0.67	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
COAD	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	14.28	1.89e-34	4.7e-30	0.81	0.67	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
COAD	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-14.27	1.97e-34	4.88e-30	-0.75	-0.66	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	14.26	2.24e-34	5.54e-30	0.72	0.66	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	14.26	2.24e-34	5.54e-30	0.72	0.66	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	14.26	2.24e-34	5.54e-30	0.72	0.66	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	14.26	2.24e-34	5.54e-30	0.72	0.66	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
COAD	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	14.26	2.26e-34	5.58e-30	0.81	0.66	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	14.26	2.26e-34	5.58e-30	0.81	0.66	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
COAD	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	14.26	2.26e-34	5.58e-30	0.81	0.66	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	14.26	2.26e-34	5.58e-30	0.81	0.66	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	14.26	2.26e-34	5.58e-30	0.81	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	14.26	2.27e-34	5.59e-30	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
COAD	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	14.24	2.52e-34	6.2e-30	0.72	0.66	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
COAD	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-14.24	2.61e-34	6.39e-30	-0.85	-0.66	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
COAD	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	14.24	2.66e-34	6.49e-30	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	14.22	3.02e-34	7.35e-30	0.82	0.66	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
COAD	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	14.22	3.07e-34	7.47e-30	0.93	0.66	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
COAD	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	14.21	3.33e-34	8.1e-30	1.1	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
COAD	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	14.21	3.34e-34	8.1e-30	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	14.21	3.34e-34	8.1e-30	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
COAD	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	14.21	3.34e-34	8.1e-30	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	14.19	3.74e-34	9.05e-30	0.8	0.66	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
COAD	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-14.19	3.87e-34	9.34e-30	-0.78	-0.66	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-14.18	4.16e-34	1e-29	-0.78	-0.66	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
COAD	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	14.16	4.9e-34	1.18e-29	0.72	0.66	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
COAD	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	14.15	5.41e-34	1.3e-29	0.8	0.66	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
COAD	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	14.14	5.9e-34	1.41e-29	1.09	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
COAD	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-14.12	6.61e-34	1.57e-29	-0.78	-0.66	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
COAD	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	14.12	6.89e-34	1.62e-29	0.8	0.66	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	14.09	8.3e-34	1.95e-29	0.79	0.66	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
COAD	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	14.08	9.32e-34	2.18e-29	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
COAD	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	14.07	1.04e-33	2.41e-29	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
COAD	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-14.05	1.18e-33	2.72e-29	-0.78	-0.66	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
COAD	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-14.04	1.32e-33	3.04e-29	-1.02	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
COAD	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	14.01	1.64e-33	3.75e-29	0.71	0.66	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
COAD	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-13.99	1.88e-33	4.27e-29	-0.8	-0.66	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
COAD	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	13.96	2.45e-33	5.54e-29	1.09	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
COAD	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	13.92	3.25e-33	7.29e-29	0.71	0.66	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	13.92	3.25e-33	7.29e-29	0.71	0.66	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	13.92	3.32e-33	7.44e-29	0.71	0.66	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
COAD	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	13.91	3.47e-33	7.77e-29	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
COAD	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	13.87	4.91e-33	1.08e-28	0.84	0.65	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
COAD	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-13.86	5.5e-33	1.21e-28	-0.69	-0.65	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	13.83	6.94e-33	1.51e-28	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
COAD	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	13.81	7.81e-33	1.69e-28	0.7	0.65	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	13.79	9.66e-33	2.08e-28	0.87	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
COAD	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	13.79	9.69e-33	2.08e-28	0.81	0.65	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	13.79	9.69e-33	2.08e-28	0.78	0.65	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	13.78	1e-32	2.15e-28	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
COAD	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-13.78	1.01e-32	2.16e-28	-0.76	-0.65	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-13.76	1.19e-32	2.55e-28	-0.77	-0.65	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-13.76	1.21e-32	2.59e-28	-0.77	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
COAD	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	13.72	1.61e-32	3.39e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	13.72	1.61e-32	3.39e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	13.71	1.74e-32	3.66e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
COAD	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	13.71	1.74e-32	3.66e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	13.71	1.74e-32	3.66e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	13.71	1.74e-32	3.66e-28	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	13.69	2.01e-32	4.21e-28	0.79	0.65	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	13.68	2.28e-32	4.76e-28	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
COAD	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	13.68	2.33e-32	4.87e-28	0.7	0.65	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
COAD	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	13.66	2.56e-32	5.34e-28	0.78	0.65	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	13.66	2.56e-32	5.34e-28	0.78	0.65	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-13.66	2.7e-32	5.6e-28	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
COAD	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	13.65	2.8e-32	5.82e-28	0.76	0.65	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	13.64	2.98e-32	6.16e-28	0.78	0.65	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
COAD	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	13.6	4.22e-32	8.69e-28	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	13.6	4.22e-32	8.69e-28	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
COAD	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	13.6	4.22e-32	8.69e-28	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	13.6	4.38e-32	9.01e-28	0.79	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	13.59	4.6e-32	9.44e-28	0.77	0.65	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
COAD	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	13.58	4.82e-32	9.89e-28	0.7	0.65	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	13.58	4.82e-32	9.89e-28	0.7	0.65	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
COAD	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	13.58	5.18e-32	1.06e-27	0.74	0.65	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
COAD	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	13.55	6.2e-32	1.27e-27	1.05	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
COAD	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	13.51	8.88e-32	1.8e-27	0.76	0.64	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	13.5	9.24e-32	1.86e-27	0.87	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
COAD	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-13.5	9.33e-32	1.88e-27	-0.76	-0.64	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
COAD	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	13.49	1.01e-31	2.03e-27	0.69	0.64	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
COAD	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	13.48	1.09e-31	2.19e-27	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
COAD	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-13.48	1.11e-31	2.22e-27	-0.75	-0.64	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-13.48	1.11e-31	2.22e-27	-0.75	-0.64	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
COAD	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	13.45	1.34e-31	2.69e-27	0.75	0.64	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	13.45	1.37e-31	2.74e-27	0.76	0.64	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.44	1.49e-31	2.96e-27	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.44	1.49e-31	2.96e-27	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
COAD	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-13.44	1.53e-31	3.04e-27	-0.75	-0.64	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
COAD	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	13.43	1.66e-31	3.29e-27	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
COAD	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	13.43	1.66e-31	3.29e-27	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
COAD	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	13.43	1.66e-31	3.29e-27	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
COAD	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-13.42	1.78e-31	3.52e-27	-0.76	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	13.42	1.78e-31	3.52e-27	0.77	0.64	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	13.42	1.78e-31	3.52e-27	0.77	0.64	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-13.42	1.82e-31	3.59e-27	-0.85	-0.64	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
COAD	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	13.42	1.84e-31	3.62e-27	0.75	0.64	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	13.39	2.18e-31	4.28e-27	0.75	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
COAD	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	13.39	2.31e-31	4.54e-27	0.75	0.64	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	13.39	2.31e-31	4.54e-27	0.75	0.64	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
COAD	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-13.35	3.05e-31	5.93e-27	-0.74	-0.64	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.35	3.05e-31	5.93e-27	-0.74	-0.64	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-13.35	3.05e-31	5.93e-27	-0.74	-0.64	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	13.35	3.05e-31	5.93e-27	0.74	0.64	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	13.35	3.05e-31	5.93e-27	0.74	0.64	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	13.35	3.05e-31	5.93e-27	0.74	0.64	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
COAD	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	13.35	3.05e-31	5.93e-27	0.74	0.64	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-13.34	3.31e-31	6.43e-27	-0.74	-0.64	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	13.34	3.46e-31	6.7e-27	0.79	0.64	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
COAD	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	13.33	3.56e-31	6.9e-27	0.84	0.64	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
COAD	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	13.33	3.61e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	13.33	3.65e-31	6.99e-27	0.74	0.64	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	13.33	3.72e-31	7.12e-27	0.87	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	13.31	4.24e-31	8.08e-27	0.74	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	13.3	4.42e-31	8.42e-27	0.74	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
COAD	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	13.3	4.52e-31	8.61e-27	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	13.3	4.66e-31	8.86e-27	0.79	0.64	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	13.29	4.96e-31	9.43e-27	0.75	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
COAD	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-13.28	5.38e-31	1.02e-26	-0.75	-0.64	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	13.28	5.51e-31	1.04e-26	0.8	0.64	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
COAD	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	13.27	5.83e-31	1.09e-26	0.74	0.64	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	13.27	5.83e-31	1.09e-26	0.74	0.64	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	13.27	5.83e-31	1.09e-26	0.74	0.64	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-13.26	6.07e-31	1.13e-26	-0.75	-0.64	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-13.26	6.07e-31	1.13e-26	-0.75	-0.64	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
COAD	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-13.26	6.07e-31	1.13e-26	-0.75	-0.64	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-13.26	6.07e-31	1.13e-26	-0.75	-0.64	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-13.25	6.92e-31	1.29e-26	-0.73	-0.64	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	13.25	6.92e-31	1.29e-26	0.73	0.64	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
COAD	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	13.25	7.08e-31	1.31e-26	0.74	0.64	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	13.24	7.25e-31	1.34e-26	0.86	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
COAD	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	13.24	7.33e-31	1.35e-26	0.77	0.64	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
COAD	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	13.24	7.33e-31	1.36e-26	0.89	0.64	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
COAD	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	13.23	8.24e-31	1.52e-26	0.73	0.64	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	13.23	8.29e-31	1.53e-26	0.8	0.64	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
COAD	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-13.22	8.48e-31	1.56e-26	-0.75	-0.64	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
COAD	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-13.21	9.06e-31	1.66e-26	-0.84	-0.64	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	13.21	9.27e-31	1.7e-26	0.8	0.64	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	13.2	1e-30	1.83e-26	0.79	0.64	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
COAD	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	13.2	1.01e-30	1.84e-26	0.75	0.64	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-13.2	1.01e-30	1.84e-26	-0.75	-0.64	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	13.2	1.02e-30	1.85e-26	0.79	0.64	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
COAD	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-13.2	1.05e-30	1.91e-26	-0.75	-0.64	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-13.2	1.05e-30	1.91e-26	-0.75	-0.64	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-13.19	1.08e-30	1.97e-26	-0.76	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
COAD	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	13.19	1.1e-30	1.99e-26	0.76	0.64	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	13.19	1.13e-30	2.06e-26	0.78	0.64	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
COAD	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	13.19	1.14e-30	2.06e-26	0.74	0.64	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
COAD	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	13.19	1.14e-30	2.06e-26	0.74	0.64	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
COAD	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-13.17	1.24e-30	2.24e-26	-0.77	-0.63	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
COAD	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-13.16	1.34e-30	2.42e-26	-1.02	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
COAD	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	13.13	1.72e-30	3.08e-26	0.69	0.63	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
COAD	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	13.13	1.77e-30	3.17e-26	1.09	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
COAD	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	13.13	1.81e-30	3.25e-26	0.84	0.63	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
COAD	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-13.12	1.92e-30	3.44e-26	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
COAD	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	13.12	1.94e-30	3.46e-26	0.73	0.63	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
COAD	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	13.12	1.94e-30	3.46e-26	0.73	0.63	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-13.12	1.95e-30	3.48e-26	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-13.12	1.95e-30	3.48e-26	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	13.12	1.95e-30	3.48e-26	0.76	0.63	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-13.12	1.98e-30	3.53e-26	-0.86	-0.63	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-13.12	1.98e-30	3.53e-26	-0.86	-0.63	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
COAD	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	13.11	2.1e-30	3.74e-26	0.8	0.63	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
COAD	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	13.11	2.11e-30	3.75e-26	0.94	0.63	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
COAD	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	13.1	2.15e-30	3.82e-26	0.8	0.63	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-13.1	2.22e-30	3.94e-26	-0.8	-0.63	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	13.1	2.31e-30	4.08e-26	0.77	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	13.1	2.31e-30	4.08e-26	0.77	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
COAD	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	13.09	2.33e-30	4.12e-26	0.8	0.63	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
COAD	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-13.09	2.47e-30	4.34e-26	-0.75	-0.63	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	13.09	2.47e-30	4.36e-26	0.78	0.63	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	13.09	2.48e-30	4.36e-26	0.77	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
COAD	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	13.09	2.51e-30	4.41e-26	0.9	0.63	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
COAD	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	13.09	2.51e-30	4.41e-26	0.9	0.63	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
COAD	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	13.09	2.51e-30	4.41e-26	0.9	0.63	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
COAD	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	13.08	2.59e-30	4.52e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	13.08	2.59e-30	4.52e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	13.08	2.63e-30	4.6e-26	0.75	0.63	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	13.08	2.63e-30	4.6e-26	0.75	0.63	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	13.07	2.73e-30	4.72e-26	0.79	0.63	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	13.07	2.82e-30	4.87e-26	0.78	0.63	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	13.07	2.82e-30	4.87e-26	0.78	0.63	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	13.07	2.82e-30	4.87e-26	0.78	0.63	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	13.07	2.84e-30	4.9e-26	0.78	0.63	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
COAD	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	13.07	2.86e-30	4.92e-26	0.9	0.63	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
COAD	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-13.07	2.87e-30	4.94e-26	-0.73	-0.63	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	13.07	2.91e-30	4.99e-26	0.78	0.63	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	13.07	2.92e-30	4.99e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
COAD	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	13.07	2.94e-30	5.02e-26	1.06	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
COAD	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-13.06	3.07e-30	5.23e-26	-0.74	-0.63	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-13.06	3.15e-30	5.36e-26	-0.74	-0.63	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-13.06	3.16e-30	5.37e-26	-0.74	-0.63	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-13.06	3.16e-30	5.37e-26	-0.74	-0.63	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-13.06	3.16e-30	5.37e-26	-0.74	-0.63	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-13.06	3.17e-30	5.38e-26	-0.79	-0.63	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
COAD	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-13.05	3.22e-30	5.46e-26	-0.74	-0.63	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	13.05	3.32e-30	5.61e-26	1.09	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
COAD	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-13.05	3.38e-30	5.7e-26	-0.74	-0.63	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	13.05	3.39e-30	5.71e-26	0.68	0.63	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
COAD	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	13.05	3.39e-30	5.71e-26	0.78	0.63	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	13.05	3.39e-30	5.71e-26	0.78	0.63	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
COAD	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-13.04	3.51e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
COAD	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.74	-0.63	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.73	-0.63	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-13.04	3.52e-30	5.88e-26	-0.73	-0.63	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	13.04	3.64e-30	6.07e-26	0.78	0.63	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	13.04	3.64e-30	6.07e-26	0.78	0.63	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	13.04	3.64e-30	6.07e-26	0.78	0.63	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	13.04	3.67e-30	6.12e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	13.04	3.67e-30	6.12e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	13.04	3.67e-30	6.12e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
COAD	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-13.04	3.68e-30	6.12e-26	-1.01	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
COAD	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	13.04	3.73e-30	6.18e-26	0.74	0.63	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	13.04	3.73e-30	6.19e-26	0.78	0.63	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
COAD	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	13.02	4.06e-30	6.7e-26	0.73	0.63	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
COAD	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-13.02	4.07e-30	6.7e-26	-0.74	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	13.02	4.11e-30	6.7e-26	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	13.01	4.42e-30	7.2e-26	0.79	0.63	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
COAD	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	13	4.73e-30	7.69e-26	0.73	0.63	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	13	4.78e-30	7.77e-26	0.75	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
COAD	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	13	5.04e-30	8.17e-26	0.74	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
COAD	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	12.99	5.12e-30	8.3e-26	0.81	0.63	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
COAD	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-12.99	5.44e-30	8.79e-26	-0.97	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
COAD	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	12.99	5.45e-30	8.79e-26	0.78	0.63	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	12.99	5.48e-30	8.82e-26	0.77	0.63	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
COAD	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-12.98	5.72e-30	9.21e-26	-0.78	-0.63	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	12.98	5.74e-30	9.24e-26	0.79	0.63	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
COAD	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	12.98	5.75e-30	9.25e-26	0.74	0.63	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-12.98	5.92e-30	9.49e-26	-0.72	-0.63	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-12.98	5.92e-30	9.49e-26	-0.72	-0.63	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-12.97	6.03e-30	9.64e-26	-0.73	-0.63	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
COAD	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-12.97	6.03e-30	9.64e-26	-0.73	-0.63	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	12.97	6.08e-30	9.71e-26	0.78	0.63	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
COAD	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	12.97	6.36e-30	1.01e-25	0.71	0.63	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
COAD	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-12.97	6.42e-30	1.02e-25	-0.74	-0.63	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	12.97	6.44e-30	1.02e-25	0.78	0.63	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-12.97	6.46e-30	1.02e-25	-0.86	-0.63	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-12.97	6.46e-30	1.02e-25	-0.86	-0.63	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
COAD	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	12.96	6.5e-30	1.03e-25	0.75	0.63	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
COAD	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-12.96	6.53e-30	1.03e-25	-0.84	-0.63	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
COAD	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
COAD	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
COAD	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-12.96	6.68e-30	1.05e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
COAD	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	12.96	6.83e-30	1.07e-25	0.78	0.63	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	12.95	7.11e-30	1.12e-25	0.78	0.63	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
COAD	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-12.95	7.31e-30	1.15e-25	-1	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
COAD	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	12.95	7.51e-30	1.18e-25	0.78	0.63	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-12.94	7.78e-30	1.22e-25	-0.85	-0.63	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-12.94	8.06e-30	1.26e-25	-0.84	-0.63	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
COAD	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-12.94	8.08e-30	1.26e-25	-0.78	-0.63	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	12.94	8.12e-30	1.27e-25	0.78	0.63	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
COAD	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	12.93	8.51e-30	1.32e-25	0.67	0.63	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	12.93	8.51e-30	1.32e-25	0.67	0.63	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
COAD	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	12.93	8.59e-30	1.34e-25	0.89	0.63	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
COAD	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-12.93	8.77e-30	1.36e-25	-0.75	-0.63	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
COAD	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	12.93	8.81e-30	1.37e-25	0.82	0.63	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
COAD	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	12.92	8.91e-30	1.38e-25	1.07	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	12.92	9.15e-30	1.42e-25	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	12.92	9.44e-30	1.46e-25	0.74	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
COAD	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	12.92	9.46e-30	1.46e-25	0.78	0.63	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	12.92	9.51e-30	1.46e-25	1.08	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	12.91	9.63e-30	1.48e-25	0.82	0.63	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
COAD	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	12.91	9.78e-30	1.5e-25	0.95	0.63	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	12.91	1e-29	1.54e-25	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
COAD	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	12.91	1.04e-29	1.59e-25	0.78	0.63	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	12.91	1.04e-29	1.59e-25	0.81	0.63	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	12.9	1.05e-29	1.61e-25	0.79	0.63	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	12.9	1.1e-29	1.69e-25	0.78	0.63	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
COAD	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	12.9	1.11e-29	1.69e-25	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
COAD	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	12.89	1.15e-29	1.75e-25	0.67	0.63	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
COAD	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-12.89	1.18e-29	1.8e-25	-0.73	-0.63	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	12.89	1.18e-29	1.8e-25	0.78	0.63	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
COAD	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-12.89	1.18e-29	1.8e-25	-0.73	-0.63	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
COAD	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	12.89	1.19e-29	1.81e-25	0.73	0.63	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	12.89	1.21e-29	1.85e-25	0.77	0.63	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	12.88	1.23e-29	1.87e-25	0.8	0.63	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	12.88	1.25e-29	1.89e-25	0.78	0.63	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	12.88	1.25e-29	1.89e-25	0.78	0.63	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
COAD	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	12.88	1.29e-29	1.96e-25	0.73	0.63	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	12.88	1.3e-29	1.98e-25	0.77	0.63	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
COAD	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-12.88	1.32e-29	1.99e-25	-0.72	-0.63	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-12.88	1.32e-29	1.99e-25	-0.72	-0.63	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-12.88	1.32e-29	1.99e-25	-0.72	-0.63	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	12.88	1.32e-29	1.99e-25	0.71	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-12.87	1.37e-29	2.07e-25	-0.72	-0.63	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	12.86	1.47e-29	2.21e-25	1.07	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	12.86	1.47e-29	2.21e-25	1.07	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	12.86	1.47e-29	2.21e-25	1.07	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	12.86	1.47e-29	2.21e-25	1.07	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	12.86	1.54e-29	2.31e-25	0.78	0.63	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-12.85	1.56e-29	2.34e-25	-0.7	-0.63	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
COAD	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	12.85	1.63e-29	2.43e-25	0.74	0.63	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	12.85	1.63e-29	2.43e-25	0.74	0.63	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	12.85	1.63e-29	2.43e-25	0.74	0.63	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	12.85	1.63e-29	2.43e-25	0.74	0.63	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
COAD	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	12.85	1.63e-29	2.43e-25	0.74	0.63	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	12.85	1.66e-29	2.47e-25	0.78	0.63	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-12.84	1.67e-29	2.48e-25	-0.85	-0.63	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-12.84	1.67e-29	2.48e-25	-0.85	-0.63	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
COAD	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	12.84	1.68e-29	2.49e-25	0.75	0.63	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
COAD	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	12.84	1.69e-29	2.51e-25	0.74	0.63	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-12.84	1.72e-29	2.55e-25	-0.72	-0.63	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-12.84	1.72e-29	2.55e-25	-0.72	-0.63	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	12.84	1.73e-29	2.56e-25	0.78	0.63	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	12.84	1.73e-29	2.56e-25	0.78	0.63	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	12.84	1.78e-29	2.63e-25	0.78	0.63	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	12.84	1.79e-29	2.64e-25	0.83	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
COAD	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	12.84	1.8e-29	2.65e-25	0.72	0.63	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-12.84	1.8e-29	2.66e-25	-0.77	-0.63	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
COAD	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-12.83	1.82e-29	2.68e-25	-0.73	-0.62	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	12.83	1.85e-29	2.72e-25	0.74	0.62	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
COAD	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	12.83	1.89e-29	2.78e-25	0.73	0.62	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	12.83	1.93e-29	2.82e-25	0.77	0.62	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	12.83	1.93e-29	2.82e-25	0.77	0.62	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	12.83	1.93e-29	2.82e-25	0.77	0.62	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	12.82	1.96e-29	2.88e-25	0.74	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
COAD	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-12.81	2.13e-29	3.1e-25	-0.72	-0.62	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	12.81	2.13e-29	3.11e-25	0.78	0.62	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-12.81	2.21e-29	3.22e-25	-0.73	-0.62	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	12.81	2.28e-29	3.31e-25	0.78	0.62	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	12.81	2.28e-29	3.31e-25	0.78	0.62	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
COAD	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-12.8	2.37e-29	3.44e-25	-0.74	-0.62	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
COAD	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-12.79	2.56e-29	3.72e-25	-0.85	-0.62	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	12.79	2.57e-29	3.73e-25	0.77	0.62	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	12.79	2.57e-29	3.73e-25	0.77	0.62	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
COAD	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	12.79	2.57e-29	3.73e-25	0.77	0.62	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
COAD	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	12.78	2.76e-29	4e-25	1	0.62	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
COAD	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	12.78	2.78e-29	4.02e-25	1.06	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	12.78	2.83e-29	4.09e-25	0.71	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
COAD	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	12.78	2.83e-29	4.09e-25	0.78	0.62	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
COAD	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	12.77	3e-29	4.32e-25	0.8	0.62	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
COAD	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	12.77	3e-29	4.32e-25	0.8	0.62	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
COAD	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-12.77	3.07e-29	4.41e-25	-0.72	-0.62	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-12.76	3.21e-29	4.61e-25	-0.71	-0.62	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-12.76	3.21e-29	4.61e-25	-0.71	-0.62	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
COAD	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	12.76	3.28e-29	4.7e-25	1.06	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
COAD	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	12.76	3.29e-29	4.71e-25	0.78	0.62	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	12.76	3.29e-29	4.71e-25	0.78	0.62	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	12.76	3.29e-29	4.71e-25	0.78	0.62	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-12.75	3.56e-29	5.08e-25	-0.74	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
COAD	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-12.75	3.66e-29	5.21e-25	-0.76	-0.62	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-12.75	3.66e-29	5.21e-25	-0.76	-0.62	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-12.74	3.67e-29	5.22e-25	-0.67	-0.62	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
COAD	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	12.74	3.77e-29	5.36e-25	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
COAD	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-12.74	3.89e-29	5.52e-25	-0.74	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	12.73	4.03e-29	5.72e-25	1.06	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-12.72	4.4e-29	6.15e-25	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
COAD	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	12.72	4.4e-29	6.15e-25	0.72	0.62	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	12.72	4.46e-29	6.21e-25	1.08	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	12.72	4.46e-29	6.21e-25	1.08	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
COAD	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	12.72	4.51e-29	6.26e-25	0.73	0.62	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-12.72	4.51e-29	6.26e-25	-0.69	-0.62	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-12.72	4.51e-29	6.26e-25	-0.69	-0.62	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-12.72	4.51e-29	6.26e-25	-0.69	-0.62	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
COAD	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-12.72	4.61e-29	6.4e-25	-0.73	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-12.71	4.86e-29	6.74e-25	-0.75	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
COAD	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-12.71	4.91e-29	6.79e-25	-0.82	-0.62	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
COAD	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-12.7	5.11e-29	7.06e-25	-0.72	-0.62	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
COAD	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-12.7	5.19e-29	7.16e-25	-0.84	-0.62	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	12.7	5.25e-29	7.25e-25	0.72	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
COAD	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-12.7	5.26e-29	7.26e-25	-0.83	-0.62	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
COAD	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-12.7	5.4e-29	7.45e-25	-0.71	-0.62	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
COAD	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-12.69	5.45e-29	7.51e-25	-0.85	-0.62	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
COAD	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	12.69	5.49e-29	7.56e-25	0.78	0.62	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
COAD	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-12.69	5.6e-29	7.7e-25	-0.72	-0.62	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	12.69	5.6e-29	7.7e-25	0.78	0.62	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
COAD	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-12.69	5.62e-29	7.73e-25	-0.74	-0.62	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	12.69	5.64e-29	7.75e-25	0.79	0.62	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-12.69	5.78e-29	7.94e-25	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
COAD	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	12.69	5.83e-29	8.01e-25	0.72	0.62	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
COAD	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	12.68	5.88e-29	8.05e-25	1	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
COAD	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	12.68	5.88e-29	8.05e-25	0.78	0.62	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	12.68	5.93e-29	8.11e-25	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
COAD	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	12.68	5.97e-29	8.16e-25	1.08	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	12.68	5.97e-29	8.16e-25	1.08	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
COAD	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	12.66	7.21e-29	9.77e-25	0.74	0.62	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	12.65	7.51e-29	1.01e-24	0.76	0.62	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-12.65	7.85e-29	1.06e-24	-0.77	-0.62	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-12.64	8.16e-29	1.1e-24	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
COAD	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	12.64	8.25e-29	1.11e-24	1.05	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
COAD	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-12.63	8.89e-29	1.19e-24	-0.73	-0.62	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-12.63	8.89e-29	1.19e-24	-0.73	-0.62	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-12.62	9.49e-29	1.27e-24	-1.07	-0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	12.62	9.65e-29	1.29e-24	0.77	0.62	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	12.61	1.02e-28	1.37e-24	0.69	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
COAD	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-12.6	1.13e-28	1.51e-24	-0.72	-0.62	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	12.6	1.15e-28	1.53e-24	0.77	0.62	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-12.59	1.24e-28	1.64e-24	-0.68	-0.62	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-12.59	1.24e-28	1.64e-24	-0.68	-0.62	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
COAD	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	12.59	1.26e-28	1.66e-24	0.78	0.62	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	12.59	1.26e-28	1.66e-24	0.78	0.62	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	12.59	1.26e-28	1.66e-24	0.78	0.62	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
COAD	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	12.56	1.59e-28	2.09e-24	0.72	0.62	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	12.56	1.59e-28	2.09e-24	0.72	0.62	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-12.55	1.68e-28	2.19e-24	-0.68	-0.62	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-12.55	1.68e-28	2.19e-24	-0.68	-0.62	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	12.55	1.68e-28	2.2e-24	0.77	0.62	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
COAD	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-12.54	1.88e-28	2.45e-24	-0.73	-0.62	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
COAD	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-12.53	1.92e-28	2.5e-24	-0.69	-0.62	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
COAD	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-12.53	1.94e-28	2.53e-24	-0.72	-0.62	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-12.53	2.04e-28	2.66e-24	-0.71	-0.62	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
COAD	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	12.51	2.4e-28	3.12e-24	0.81	0.62	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
COAD	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	12.5	2.6e-28	3.36e-24	0.74	0.61	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
COAD	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	12.49	2.7e-28	3.49e-24	0.71	0.61	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	12.49	2.75e-28	3.55e-24	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
COAD	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-12.48	2.87e-28	3.64e-24	-0.72	-0.61	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-12.48	2.89e-28	3.67e-24	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	12.48	2.98e-28	3.79e-24	0.76	0.61	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-12.47	3.12e-28	3.95e-24	-0.69	-0.61	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
COAD	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	12.47	3.17e-28	3.98e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	12.45	3.68e-28	4.6e-24	0.8	0.61	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	12.45	3.68e-28	4.6e-24	0.8	0.61	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	12.44	3.89e-28	4.85e-24	0.93	0.61	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	12.43	4.29e-28	5.34e-24	0.75	0.61	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	12.43	4.37e-28	5.42e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	12.43	4.37e-28	5.42e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	12.43	4.37e-28	5.42e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	12.43	4.37e-28	5.42e-24	1.07	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
COAD	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-12.41	4.93e-28	6.09e-24	-0.68	-0.61	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
COAD	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	12.41	5.09e-28	6.29e-24	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	12.41	5.23e-28	6.45e-24	0.78	0.61	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	12.41	5.23e-28	6.45e-24	0.78	0.61	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	12.41	5.23e-28	6.45e-24	0.78	0.61	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	12.39	6.06e-28	7.43e-24	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
COAD	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-12.38	6.24e-28	7.63e-24	-0.68	-0.61	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	12.38	6.5e-28	7.94e-24	0.7	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
COAD	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	12.38	6.62e-28	8.05e-24	0.76	0.61	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	12.38	6.62e-28	8.05e-24	0.76	0.61	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	12.38	6.62e-28	8.05e-24	0.76	0.61	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	12.38	6.62e-28	8.05e-24	0.76	0.61	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	12.38	6.62e-28	8.05e-24	0.76	0.61	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-12.37	6.69e-28	8.13e-24	-0.71	-0.61	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-12.36	7.62e-28	9.24e-24	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
COAD	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-12.35	8.15e-28	9.87e-24	-0.73	-0.61	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
COAD	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	12.35	8.22e-28	9.94e-24	0.78	0.61	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	12.35	8.29e-28	1e-23	0.78	0.61	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	12.33	9.58e-28	1.16e-23	0.76	0.61	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	12.32	9.87e-28	1.19e-23	1.04	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	12.32	9.95e-28	1.19e-23	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
COAD	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	12.32	1.02e-27	1.22e-23	0.75	0.61	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
COAD	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-12.32	1.06e-27	1.27e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-12.32	1.06e-27	1.27e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
COAD	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	12.31	1.07e-27	1.28e-23	0.71	0.61	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	12.31	1.09e-27	1.3e-23	0.76	0.61	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	12.31	1.1e-27	1.31e-23	0.76	0.61	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	12.29	1.27e-27	1.51e-23	0.81	0.61	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	12.29	1.27e-27	1.51e-23	0.81	0.61	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	12.29	1.27e-27	1.51e-23	0.81	0.61	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	12.29	1.29e-27	1.54e-23	0.76	0.61	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	12.29	1.32e-27	1.56e-23	0.78	0.61	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
COAD	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	12.29	1.33e-27	1.58e-23	1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	12.29	1.33e-27	1.58e-23	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	12.29	1.33e-27	1.58e-23	0.82	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
COAD	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	12.28	1.44e-27	1.71e-23	0.79	0.61	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	12.27	1.47e-27	1.74e-23	0.77	0.61	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	12.27	1.47e-27	1.74e-23	0.77	0.61	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	12.27	1.47e-27	1.74e-23	0.77	0.61	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	12.27	1.47e-27	1.74e-23	0.77	0.61	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
COAD	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-12.27	1.47e-27	1.74e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	12.26	1.62e-27	1.91e-23	0.77	0.61	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
COAD	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-12.26	1.63e-27	1.91e-23	-0.71	-0.61	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
COAD	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-12.25	1.7e-27	1.99e-23	-0.77	-0.61	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
COAD	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	12.25	1.7e-27	1.99e-23	0.66	0.61	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
COAD	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	12.24	1.89e-27	2.19e-23	1.03	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	12.24	1.89e-27	2.19e-23	1.03	0.61	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	12.24	1.89e-27	2.19e-23	1.03	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	12.24	1.89e-27	2.19e-23	1.03	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	12.24	1.89e-27	2.2e-23	0.7	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	12.24	1.89e-27	2.2e-23	0.7	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
COAD	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	12.24	1.93e-27	2.24e-23	0.77	0.61	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	12.23	1.98e-27	2.29e-23	0.76	0.61	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	12.23	2.02e-27	2.34e-23	0.77	0.61	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
COAD	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-12.22	2.15e-27	2.48e-23	-0.98	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
COAD	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	12.22	2.3e-27	2.64e-23	0.76	0.61	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
COAD	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-12.21	2.36e-27	2.7e-23	-0.65	-0.61	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
COAD	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	12.2	2.5e-27	2.85e-23	0.63	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
COAD	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-12.2	2.69e-27	3.05e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-12.2	2.69e-27	3.05e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	12.19	2.77e-27	3.15e-23	0.8	0.61	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-12.19	2.84e-27	3.22e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-12.19	2.84e-27	3.22e-23	-0.67	-0.61	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-12.18	3.01e-27	3.4e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
COAD	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-12.18	3.11e-27	3.51e-23	-0.69	-0.6	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
COAD	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-12.17	3.4e-27	3.81e-23	-0.89	-0.6	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
COAD	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	12.17	3.41e-27	3.82e-23	1.02	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
COAD	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-12.16	3.62e-27	4.06e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-12.16	3.62e-27	4.06e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	12.15	3.8e-27	4.26e-23	0.74	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
COAD	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	12.15	3.84e-27	4.3e-23	0.63	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
COAD	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-12.15	3.97e-27	4.44e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
COAD	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	12.14	4e-27	4.47e-23	0.76	0.6	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	12.14	4e-27	4.47e-23	0.76	0.6	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	12.14	4.01e-27	4.48e-23	0.69	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
COAD	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	12.14	4.25e-27	4.74e-23	0.77	0.6	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
COAD	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	12.13	4.39e-27	4.89e-23	0.64	0.6	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	12.13	4.41e-27	4.91e-23	0.7	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
COAD	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	12.13	4.57e-27	5.08e-23	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	12.12	4.81e-27	5.35e-23	0.78	0.6	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	12.12	4.87e-27	5.4e-23	0.79	0.6	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	12.12	4.87e-27	5.4e-23	0.79	0.6	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	12.12	4.87e-27	5.4e-23	0.79	0.6	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-12.11	5.38e-27	5.95e-23	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	12.1	5.86e-27	6.46e-23	0.78	0.6	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	12.1	5.86e-27	6.46e-23	0.78	0.6	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
COAD	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	12.09	6.31e-27	6.94e-23	0.62	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
COAD	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	12.09	6.34e-27	6.97e-23	0.78	0.6	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-12.08	6.41e-27	7.05e-23	-0.77	-0.6	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
COAD	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	12.08	6.73e-27	7.39e-23	0.71	0.6	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	12.07	6.94e-27	7.6e-23	0.79	0.6	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	12.07	7.11e-27	7.77e-23	1.03	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
COAD	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	12.07	7.26e-27	7.93e-23	0.62	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
COAD	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-12.07	7.28e-27	7.95e-23	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
COAD	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	12.06	7.67e-27	8.38e-23	0.72	0.6	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	12.06	7.7e-27	8.41e-23	0.66	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
COAD	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-12.05	8.58e-27	9.33e-23	-0.78	-0.6	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	12.04	8.9e-27	9.68e-23	0.77	0.6	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	12.04	8.93e-27	9.71e-23	0.67	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
COAD	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.03	9.62e-27	1.04e-22	-0.7	-0.6	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
COAD	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	12.02	1.03e-26	1.11e-22	0.68	0.6	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
COAD	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	12.02	1.04e-26	1.13e-22	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
COAD	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	12.01	1.1e-26	1.19e-22	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
COAD	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	12.01	1.13e-26	1.22e-22	0.66	0.6	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
COAD	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	12.01	1.14e-26	1.23e-22	0.76	0.6	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
COAD	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	12.01	1.16e-26	1.24e-22	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
COAD	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-12.01	1.16e-26	1.25e-22	-0.69	-0.6	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
COAD	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	11.99	1.3e-26	1.4e-22	0.68	0.6	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
COAD	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	11.97	1.49e-26	1.59e-22	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-11.96	1.62e-26	1.72e-22	-0.81	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
COAD	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	11.95	1.78e-26	1.9e-22	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
COAD	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	11.94	1.91e-26	2.02e-22	0.69	0.6	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
COAD	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	11.94	1.91e-26	2.02e-22	0.69	0.6	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
COAD	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	11.94	1.91e-26	2.02e-22	0.69	0.6	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
COAD	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	11.94	1.91e-26	2.02e-22	0.69	0.6	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
COAD	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	11.93	2.04e-26	2.15e-22	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
COAD	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-11.93	2.13e-26	2.25e-22	-0.68	-0.6	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	11.93	2.16e-26	2.28e-22	0.67	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	11.92	2.27e-26	2.4e-22	0.68	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	11.92	2.28e-26	2.4e-22	0.69	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
COAD	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-11.91	2.4e-26	2.52e-22	-0.69	-0.6	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	11.91	2.41e-26	2.53e-22	0.76	0.6	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-11.91	2.41e-26	2.53e-22	-0.78	-0.6	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
COAD	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	11.91	2.45e-26	2.57e-22	1.03	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
COAD	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	11.91	2.47e-26	2.59e-22	0.69	0.6	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
COAD	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-11.9	2.62e-26	2.74e-22	-0.88	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
COAD	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-11.9	2.62e-26	2.74e-22	-0.62	-0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
COAD	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	11.9	2.74e-26	2.86e-22	0.66	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
COAD	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-11.9	2.74e-26	2.86e-22	-0.7	-0.6	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	11.89	2.82e-26	2.95e-22	0.77	0.6	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
COAD	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	11.88	3.02e-26	3.15e-22	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
COAD	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-11.88	3.07e-26	3.2e-22	-0.71	-0.6	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
COAD	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	11.88	3.22e-26	3.35e-22	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
COAD	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	11.87	3.3e-26	3.43e-22	0.7	0.6	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	11.87	3.34e-26	3.47e-22	0.77	0.6	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
COAD	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	11.86	3.56e-26	3.69e-22	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
COAD	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	11.86	3.68e-26	3.82e-22	0.62	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
COAD	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-11.83	4.53e-26	4.67e-22	-0.65	-0.59	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
COAD	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.82	4.82e-26	4.96e-22	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	11.82	4.88e-26	5.02e-22	0.77	0.59	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	11.81	5.14e-26	5.29e-22	0.77	0.59	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	11.81	5.52e-26	5.65e-22	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	11.81	5.52e-26	5.65e-22	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	11.81	5.52e-26	5.65e-22	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
COAD	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	11.8	5.64e-26	5.77e-22	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
COAD	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	11.8	5.76e-26	5.88e-22	0.68	0.59	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
COAD	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	11.8	5.9e-26	6.01e-22	0.68	0.59	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	11.8	5.93e-26	6.03e-22	0.76	0.59	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	11.8	5.93e-26	6.03e-22	0.76	0.59	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
COAD	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	11.79	5.98e-26	6.08e-22	0.68	0.59	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
COAD	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	11.79	5.98e-26	6.08e-22	0.68	0.59	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
COAD	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	11.79	6.21e-26	6.3e-22	0.76	0.59	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
COAD	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-11.79	6.44e-26	6.53e-22	-0.68	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
COAD	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	11.78	6.52e-26	6.6e-22	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	11.78	6.54e-26	6.63e-22	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
COAD	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	11.78	6.61e-26	6.69e-22	0.76	0.59	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	11.78	6.92e-26	7e-22	0.77	0.59	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
COAD	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	11.77	7.18e-26	7.25e-22	0.76	0.59	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	11.76	7.84e-26	7.86e-22	0.74	0.59	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	11.76	7.86e-26	7.88e-22	0.78	0.59	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	11.76	7.88e-26	7.9e-22	0.78	0.59	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
COAD	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	11.76	7.94e-26	7.95e-22	0.69	0.59	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	11.76	8.12e-26	8.07e-22	0.78	0.59	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs958953	ENSG00000231760.4	RP11-350J20.5	11.74	8.81e-26	8.75e-22	0.76	0.59	Lung cancer;	chr6:149840735	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	11.74	9.24e-26	9.15e-22	0.77	0.59	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	11.73	9.69e-26	9.57e-22	0.78	0.59	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	11.73	9.81e-26	9.69e-22	0.73	0.59	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
COAD	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-11.71	1.13e-25	1.11e-21	-0.59	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
COAD	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	11.71	1.15e-25	1.13e-21	0.83	0.59	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
COAD	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	11.7	1.22e-25	1.19e-21	0.73	0.59	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	11.7	1.27e-25	1.24e-21	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
COAD	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	11.7	1.27e-25	1.24e-21	0.71	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	11.68	1.4e-25	1.36e-21	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	11.68	1.41e-25	1.36e-21	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	11.68	1.41e-25	1.36e-21	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	11.68	1.41e-25	1.36e-21	0.6	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	11.68	1.44e-25	1.39e-21	0.76	0.59	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
COAD	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-11.68	1.45e-25	1.4e-21	-0.69	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	11.67	1.53e-25	1.46e-21	0.7	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	11.67	1.61e-25	1.54e-21	0.77	0.59	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
COAD	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	11.66	1.65e-25	1.58e-21	0.64	0.59	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
COAD	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.66	1.67e-25	1.6e-21	0.59	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	11.66	1.68e-25	1.6e-21	0.75	0.59	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	11.66	1.68e-25	1.6e-21	0.79	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
COAD	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-11.65	1.79e-25	1.7e-21	-0.59	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	11.64	1.89e-25	1.79e-21	0.59	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	11.63	2.07e-25	1.95e-21	0.77	0.59	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	11.63	2.07e-25	1.95e-21	0.77	0.59	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
COAD	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	11.63	2.08e-25	1.95e-21	0.59	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
COAD	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	11.62	2.25e-25	2.1e-21	0.72	0.59	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	11.62	2.32e-25	2.17e-21	0.76	0.59	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
COAD	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-11.62	2.34e-25	2.18e-21	-0.69	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	11.61	2.5e-25	2.33e-21	0.78	0.59	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-11.61	2.5e-25	2.33e-21	-0.68	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
COAD	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	11.6	2.65e-25	2.46e-21	0.73	0.59	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
COAD	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	11.6	2.65e-25	2.46e-21	0.76	0.59	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
COAD	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	11.6	2.73e-25	2.52e-21	0.73	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
COAD	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	11.59	2.81e-25	2.6e-21	0.64	0.59	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
COAD	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-11.58	3.16e-25	2.9e-21	-0.67	-0.59	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	11.58	3.17e-25	2.91e-21	0.7	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-11.57	3.36e-25	3.08e-21	-0.66	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
COAD	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	11.57	3.36e-25	3.08e-21	0.59	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
COAD	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	11.56	3.56e-25	3.27e-21	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	11.56	3.58e-25	3.28e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	11.56	3.6e-25	3.29e-21	0.74	0.58	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
COAD	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	11.55	3.82e-25	3.48e-21	0.64	0.58	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
COAD	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-11.55	3.86e-25	3.52e-21	-0.68	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
COAD	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	11.55	3.96e-25	3.61e-21	0.74	0.58	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
COAD	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	11.54	4.21e-25	3.71e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-11.54	4.29e-25	3.78e-21	-0.76	-0.58	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
COAD	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	11.54	4.31e-25	3.8e-21	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
COAD	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	11.53	4.45e-25	3.92e-21	0.73	0.58	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
COAD	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	11.52	4.9e-25	4.31e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
COAD	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	11.52	4.91e-25	4.32e-21	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-11.52	4.97e-25	4.36e-21	-0.78	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
COAD	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	11.52	5.05e-25	4.43e-21	0.72	0.58	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	11.52	5.05e-25	4.43e-21	0.72	0.58	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	11.52	5.05e-25	4.43e-21	0.72	0.58	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-11.51	5.23e-25	4.58e-21	-0.68	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
COAD	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	11.5	5.6e-25	4.9e-21	0.87	0.58	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
COAD	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	11.5	5.77e-25	5.05e-21	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
COAD	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	11.49	6e-25	5.24e-21	0.74	0.58	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
COAD	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	11.49	6.1e-25	5.31e-21	0.72	0.58	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-11.49	6.12e-25	5.33e-21	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
COAD	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-11.49	6.34e-25	5.5e-21	-0.84	-0.58	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
COAD	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	11.49	6.35e-25	5.51e-21	0.72	0.58	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
COAD	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-11.49	6.4e-25	5.55e-21	-0.75	-0.58	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
COAD	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	11.48	6.46e-25	5.59e-21	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	11.48	6.46e-25	5.59e-21	1.02	0.58	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	11.48	6.46e-25	5.59e-21	1.02	0.58	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	11.48	6.46e-25	5.59e-21	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
COAD	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	11.48	6.48e-25	5.61e-21	0.88	0.58	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
COAD	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	11.48	6.49e-25	5.61e-21	0.77	0.58	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-11.48	6.56e-25	5.67e-21	-0.8	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
COAD	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	11.48	6.56e-25	5.68e-21	0.72	0.58	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
COAD	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	11.48	6.58e-25	5.69e-21	0.74	0.58	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	11.48	6.58e-25	5.69e-21	0.74	0.58	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	11.48	6.58e-25	5.69e-21	0.74	0.58	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
COAD	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	11.48	6.78e-25	5.85e-21	0.68	0.58	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
COAD	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	11.47	7.05e-25	6.07e-21	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	11.47	7.15e-25	6.15e-21	0.75	0.58	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	11.47	7.24e-25	6.22e-21	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
COAD	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	11.47	7.36e-25	6.32e-21	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-11.46	7.64e-25	6.55e-21	-0.67	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
COAD	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	11.46	7.85e-25	6.72e-21	0.72	0.58	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
COAD	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-11.46	7.91e-25	6.77e-21	-0.72	-0.58	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	11.45	8.15e-25	6.97e-21	0.73	0.58	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
COAD	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	11.45	8.21e-25	7.01e-21	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
COAD	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	11.45	8.21e-25	7.01e-21	0.65	0.58	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	11.45	8.34e-25	7.13e-21	0.81	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
COAD	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	11.44	8.8e-25	7.5e-21	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	11.44	8.93e-25	7.61e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
COAD	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	11.44	9.02e-25	7.68e-21	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-11.44	9.31e-25	7.92e-21	-1.02	-0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
COAD	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	11.43	1e-24	8.5e-21	0.74	0.58	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
COAD	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	11.43	1e-24	8.5e-21	1.03	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
COAD	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	11.42	1.03e-24	8.72e-21	0.86	0.58	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
COAD	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-11.42	1.05e-24	8.85e-21	-0.66	-0.58	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-11.42	1.05e-24	8.85e-21	-0.66	-0.58	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
COAD	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-11.42	1.06e-24	8.99e-21	-0.82	-0.58	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
COAD	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-11.41	1.12e-24	9.47e-21	-0.8	-0.58	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	11.41	1.15e-24	9.68e-21	0.7	0.58	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	11.41	1.16e-24	9.81e-21	0.76	0.58	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	11.41	1.18e-24	9.92e-21	0.76	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
COAD	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-11.39	1.29e-24	1.08e-20	-0.81	-0.58	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
COAD	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-11.39	1.29e-24	1.08e-20	-0.81	-0.58	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
COAD	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	11.39	1.31e-24	1.1e-20	0.86	0.58	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
COAD	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	11.39	1.31e-24	1.1e-20	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
COAD	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	11.39	1.36e-24	1.13e-20	0.58	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
COAD	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	11.39	1.36e-24	1.14e-20	0.68	0.58	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	11.39	1.37e-24	1.14e-20	0.76	0.58	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
COAD	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	11.39	1.38e-24	1.15e-20	0.74	0.58	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
COAD	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	11.38	1.39e-24	1.16e-20	0.75	0.58	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	11.38	1.39e-24	1.16e-20	0.75	0.58	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	11.38	1.39e-24	1.16e-20	0.75	0.58	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
COAD	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	11.38	1.43e-24	1.19e-20	0.68	0.58	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	11.38	1.48e-24	1.23e-20	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
COAD	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	11.37	1.53e-24	1.27e-20	0.57	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
COAD	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-11.37	1.55e-24	1.29e-20	-0.85	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
COAD	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	11.37	1.59e-24	1.32e-20	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	11.36	1.62e-24	1.34e-20	0.75	0.58	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	11.36	1.65e-24	1.36e-20	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	11.36	1.67e-24	1.38e-20	0.58	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
COAD	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-11.35	1.78e-24	1.46e-20	-0.69	-0.58	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
COAD	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	11.35	1.83e-24	1.51e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	11.34	1.89e-24	1.55e-20	0.58	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	11.34	1.98e-24	1.62e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
COAD	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-11.34	2e-24	1.64e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
COAD	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-11.34	2e-24	1.64e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
COAD	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	11.32	2.25e-24	1.83e-20	0.86	0.58	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
COAD	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	11.32	2.25e-24	1.83e-20	0.86	0.58	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
COAD	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	11.32	2.32e-24	1.89e-20	0.71	0.58	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
COAD	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-11.32	2.34e-24	1.9e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
COAD	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	11.31	2.39e-24	1.94e-20	0.74	0.58	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
COAD	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-11.31	2.45e-24	1.99e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
COAD	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	11.31	2.52e-24	2.04e-20	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
COAD	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	11.31	2.54e-24	2.05e-20	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
COAD	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	11.3	2.57e-24	2.08e-20	0.93	0.58	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
COAD	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	11.3	2.58e-24	2.09e-20	0.71	0.58	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	11.3	2.58e-24	2.09e-20	0.71	0.58	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
COAD	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	11.3	2.59e-24	2.09e-20	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	11.3	2.7e-24	2.18e-20	0.72	0.58	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
COAD	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	11.3	2.71e-24	2.19e-20	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
COAD	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	11.3	2.73e-24	2.2e-20	0.73	0.58	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	11.3	2.73e-24	2.2e-20	0.73	0.58	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
COAD	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	11.29	2.85e-24	2.27e-20	1.01	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
COAD	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	11.29	2.92e-24	2.32e-20	0.86	0.58	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
COAD	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	11.28	2.97e-24	2.36e-20	0.81	0.58	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	11.28	2.97e-24	2.36e-20	0.81	0.58	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
COAD	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	11.28	3.01e-24	2.39e-20	0.7	0.58	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
COAD	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	11.28	3.01e-24	2.39e-20	0.7	0.58	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
COAD	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	11.28	3.02e-24	2.4e-20	0.74	0.58	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
COAD	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-11.28	3.11e-24	2.47e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
COAD	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-11.28	3.11e-24	2.47e-20	-0.8	-0.58	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
COAD	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	11.28	3.15e-24	2.48e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	11.28	3.19e-24	2.51e-20	0.58	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
COAD	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	11.27	3.24e-24	2.55e-20	0.68	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	11.27	3.27e-24	2.57e-20	1	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	11.27	3.27e-24	2.57e-20	0.99	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	11.27	3.28e-24	2.58e-20	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	11.27	3.41e-24	2.67e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
COAD	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	11.26	3.51e-24	2.75e-20	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	11.26	3.71e-24	2.9e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
COAD	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	11.25	3.74e-24	2.92e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
COAD	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	11.25	3.78e-24	2.95e-20	0.73	0.57	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
COAD	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	11.25	3.81e-24	2.97e-20	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
COAD	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	11.25	4e-24	3.09e-20	0.72	0.57	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	11.24	4.07e-24	3.14e-20	0.75	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
COAD	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.09e-24	3.15e-20	-0.77	-0.57	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
COAD	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-11.24	4.12e-24	3.18e-20	-0.71	-0.57	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
COAD	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	11.24	4.16e-24	3.2e-20	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
COAD	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	11.24	4.2e-24	3.23e-20	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	11.23	4.44e-24	3.41e-20	1	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	11.22	5.01e-24	3.83e-20	0.72	0.57	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	11.21	5.12e-24	3.91e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	11.21	5.36e-24	4.09e-20	1	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
COAD	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	11.2	5.61e-24	4.27e-20	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
COAD	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	11.2	5.86e-24	4.45e-20	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
COAD	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	11.19	6.13e-24	4.65e-20	0.73	0.57	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	11.18	6.42e-24	4.87e-20	1.02	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
COAD	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-11.18	6.5e-24	4.92e-20	-0.67	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	11.18	6.62e-24	5e-20	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	11.17	6.89e-24	5.2e-20	0.97	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	11.17	6.96e-24	5.25e-20	0.69	0.57	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-11.17	6.98e-24	5.25e-20	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-11.17	6.98e-24	5.25e-20	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-11.17	6.98e-24	5.25e-20	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-11.17	6.98e-24	5.25e-20	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-11.17	6.98e-24	5.25e-20	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	11.17	6.98e-24	5.25e-20	0.75	0.57	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
COAD	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	11.17	7.3e-24	5.48e-20	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
COAD	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-11.16	7.7e-24	5.76e-20	-0.66	-0.57	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
COAD	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	11.16	7.76e-24	5.81e-20	0.56	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	11.15	8.04e-24	5.95e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	11.15	8.25e-24	6.09e-20	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
COAD	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	11.14	9.04e-24	6.65e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	11.14	9.04e-24	6.65e-20	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	11.13	9.55e-24	7.01e-20	0.68	0.57	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
COAD	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	11.13	9.87e-24	7.24e-20	0.56	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
COAD	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	11.12	1.02e-23	7.49e-20	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	11.12	1.03e-23	7.58e-20	0.73	0.57	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-11.12	1.04e-23	7.6e-20	-0.72	-0.57	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
COAD	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	11.12	1.05e-23	7.71e-20	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
COAD	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-11.1	1.16e-23	8.49e-20	-0.71	-0.57	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-11.1	1.16e-23	8.49e-20	-0.71	-0.57	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
COAD	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	11.1	1.19e-23	8.71e-20	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
COAD	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	11.1	1.21e-23	8.84e-20	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
COAD	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	11.09	1.31e-23	9.52e-20	0.79	0.57	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
COAD	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	11.09	1.32e-23	9.56e-20	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	11.09	1.34e-23	9.71e-20	0.75	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
COAD	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	11.09	1.34e-23	9.71e-20	0.98	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	11.09	1.34e-23	9.71e-20	0.98	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	11.09	1.34e-23	9.71e-20	0.98	0.57	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
COAD	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-11.09	1.34e-23	9.71e-20	-0.7	-0.57	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
COAD	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	11.09	1.34e-23	9.74e-20	0.9	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
COAD	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	11.08	1.37e-23	9.86e-20	1	0.57	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
COAD	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	11.08	1.41e-23	1.02e-19	0.77	0.57	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
COAD	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	11.08	1.42e-23	1.02e-19	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
COAD	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-11.07	1.48e-23	1.06e-19	-0.58	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
COAD	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	11.07	1.49e-23	1.07e-19	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
COAD	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-11.07	1.51e-23	1.08e-19	-0.74	-0.57	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-11.06	1.65e-23	1.18e-19	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
COAD	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	11.06	1.67e-23	1.19e-19	0.6	0.57	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
COAD	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	11.05	1.7e-23	1.21e-19	0.72	0.57	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
COAD	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	11.05	1.78e-23	1.26e-19	0.74	0.57	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-11.04	1.94e-23	1.37e-19	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	11.04	1.95e-23	1.38e-19	0.79	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
COAD	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-11.03	1.98e-23	1.4e-19	-0.58	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
COAD	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	11.03	2e-23	1.41e-19	0.91	0.57	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
COAD	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	11.03	2.02e-23	1.42e-19	0.74	0.57	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
COAD	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	11.03	2.1e-23	1.48e-19	0.76	0.57	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
COAD	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	11.03	2.12e-23	1.49e-19	0.72	0.57	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
COAD	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	11.02	2.18e-23	1.53e-19	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	11.02	2.18e-23	1.53e-19	1.01	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	11.02	2.2e-23	1.54e-19	0.72	0.57	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
COAD	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	11.02	2.21e-23	1.55e-19	1	0.57	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	11.02	2.21e-23	1.55e-19	1	0.57	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	11.02	2.21e-23	1.55e-19	1	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	11.02	2.21e-23	1.55e-19	1	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-11.01	2.45e-23	1.72e-19	-0.73	-0.57	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	11.01	2.45e-23	1.72e-19	0.75	0.57	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	11.01	2.45e-23	1.72e-19	0.75	0.57	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	11	2.49e-23	1.74e-19	0.63	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
COAD	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	11	2.53e-23	1.77e-19	0.73	0.57	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	11	2.54e-23	1.77e-19	0.74	0.57	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
COAD	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	11	2.58e-23	1.8e-19	0.7	0.57	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
COAD	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-10.99	2.7e-23	1.88e-19	-0.63	-0.57	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	10.98	3.07e-23	2.13e-19	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
COAD	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	10.98	3.08e-23	2.14e-19	0.95	0.56	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-10.97	3.1e-23	2.15e-19	-0.62	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	10.97	3.12e-23	2.16e-19	0.66	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
COAD	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-10.97	3.27e-23	2.26e-19	-0.62	-0.56	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-10.97	3.27e-23	2.27e-19	-0.64	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
COAD	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	10.97	3.29e-23	2.28e-19	0.68	0.56	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	10.96	3.42e-23	2.36e-19	0.67	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
COAD	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	10.96	3.43e-23	2.37e-19	0.74	0.56	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
COAD	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-10.95	3.71e-23	2.56e-19	-0.58	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-10.95	3.76e-23	2.59e-19	-0.69	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
COAD	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-10.95	3.83e-23	2.63e-19	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-10.95	3.84e-23	2.64e-19	-0.75	-0.56	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
COAD	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-10.94	3.92e-23	2.68e-19	-0.58	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	10.94	3.92e-23	2.68e-19	0.65	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
COAD	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	10.94	4.08e-23	2.79e-19	0.84	0.56	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
COAD	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	10.93	4.19e-23	2.86e-19	0.98	0.56	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
COAD	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.93	4.21e-23	2.87e-19	-0.62	-0.56	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	10.93	4.37e-23	2.98e-19	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
COAD	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	10.93	4.37e-23	2.98e-19	0.96	0.56	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
COAD	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	10.93	4.39e-23	2.99e-19	0.93	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
COAD	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	10.93	4.44e-23	3.03e-19	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
COAD	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-10.92	4.54e-23	3.09e-19	-0.68	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
COAD	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	10.92	4.58e-23	3.12e-19	0.69	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-10.92	4.68e-23	3.19e-19	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	10.92	4.7e-23	3.2e-19	0.68	0.56	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	10.92	4.78e-23	3.25e-19	0.73	0.56	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
COAD	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-10.92	4.8e-23	3.26e-19	-0.58	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
COAD	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-10.92	4.85e-23	3.3e-19	-0.69	-0.56	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
COAD	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	10.91	5.04e-23	3.42e-19	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	10.91	5.04e-23	3.42e-19	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
COAD	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-10.91	5.22e-23	3.54e-19	-0.62	-0.56	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	10.89	5.68e-23	3.84e-19	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
COAD	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-10.89	5.68e-23	3.84e-19	-0.78	-0.56	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	10.89	5.74e-23	3.88e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
COAD	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-10.89	5.79e-23	3.91e-19	-0.68	-0.56	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
COAD	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	10.89	5.8e-23	3.91e-19	0.99	0.56	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	10.89	5.8e-23	3.91e-19	0.99	0.56	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	10.89	5.8e-23	3.91e-19	0.99	0.56	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	10.89	5.8e-23	3.91e-19	0.99	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	10.89	5.93e-23	3.99e-19	0.65	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	10.88	6.14e-23	4.12e-19	0.73	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
COAD	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	10.87	6.68e-23	4.46e-19	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
COAD	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-10.87	6.89e-23	4.6e-19	-0.76	-0.56	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-10.87	6.89e-23	4.6e-19	-0.76	-0.56	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	10.87	6.97e-23	4.66e-19	0.74	0.56	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
COAD	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-10.86	7.11e-23	4.75e-19	-0.62	-0.56	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
COAD	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	10.86	7.18e-23	4.79e-19	0.76	0.56	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
COAD	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-10.85	7.65e-23	5.09e-19	-0.58	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
COAD	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-10.85	7.7e-23	5.12e-19	-0.61	-0.56	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
COAD	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	10.85	7.7e-23	5.12e-19	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	10.85	7.76e-23	5.16e-19	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
COAD	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	10.85	8.05e-23	5.34e-19	0.63	0.56	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	10.85	8.21e-23	5.44e-19	0.75	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
COAD	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-10.84	8.25e-23	5.46e-19	-0.61	-0.56	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	10.84	8.27e-23	5.48e-19	0.69	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
COAD	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	10.84	8.32e-23	5.51e-19	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
COAD	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-10.84	8.43e-23	5.58e-19	-0.77	-0.56	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
COAD	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	10.84	8.45e-23	5.59e-19	0.62	0.56	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
COAD	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	10.84	8.59e-23	5.67e-19	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
COAD	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	10.84	8.68e-23	5.73e-19	0.61	0.56	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
COAD	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-10.84	8.69e-23	5.74e-19	-0.74	-0.56	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	10.84	8.86e-23	5.85e-19	0.72	0.56	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-10.83	8.91e-23	5.87e-19	-0.75	-0.56	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-10.83	8.91e-23	5.87e-19	-0.75	-0.56	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	10.83	8.97e-23	5.91e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
COAD	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	10.83	9.31e-23	6.12e-19	0.82	0.56	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
COAD	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	10.83	9.5e-23	6.24e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-10.82	9.69e-23	6.36e-19	-0.74	-0.56	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	10.82	9.95e-23	6.53e-19	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
COAD	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-10.82	9.97e-23	6.54e-19	-0.99	-0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
COAD	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	10.81	1.07e-22	7e-19	0.61	0.56	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
COAD	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	10.81	1.07e-22	7.02e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	10.81	1.09e-22	7.1e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	10.81	1.09e-22	7.1e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	10.81	1.09e-22	7.1e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	10.81	1.09e-22	7.1e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	10.81	1.09e-22	7.1e-19	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
COAD	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	10.8	1.13e-22	7.36e-19	0.78	0.56	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
COAD	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	10.8	1.17e-22	7.6e-19	0.71	0.56	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
COAD	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	10.8	1.17e-22	7.61e-19	0.74	0.56	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
COAD	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-10.79	1.21e-22	7.87e-19	-0.63	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
COAD	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	10.79	1.27e-22	8.27e-19	0.77	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
COAD	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	10.78	1.31e-22	8.5e-19	0.74	0.56	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
COAD	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	10.78	1.33e-22	8.59e-19	0.85	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
COAD	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	10.78	1.34e-22	8.71e-19	0.72	0.56	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
COAD	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	10.78	1.38e-22	8.95e-19	0.7	0.56	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
COAD	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	10.78	1.38e-22	8.95e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	10.78	1.38e-22	8.95e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	10.78	1.38e-22	8.95e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
COAD	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	10.77	1.43e-22	9.23e-19	0.56	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
COAD	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	10.77	1.45e-22	9.34e-19	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
COAD	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-10.77	1.46e-22	9.43e-19	-0.77	-0.56	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
COAD	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	10.77	1.47e-22	9.47e-19	0.59	0.56	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
COAD	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	10.76	1.5e-22	9.69e-19	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	10.76	1.5e-22	9.69e-19	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	10.76	1.5e-22	9.69e-19	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	10.76	1.5e-22	9.69e-19	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
COAD	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-10.76	1.55e-22	9.96e-19	-0.61	-0.56	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-10.76	1.55e-22	9.96e-19	-0.61	-0.56	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
COAD	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	10.76	1.55e-22	9.96e-19	0.94	0.56	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
COAD	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	10.76	1.56e-22	1e-18	0.73	0.56	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	10.75	1.68e-22	1.08e-18	0.92	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
COAD	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	10.74	1.75e-22	1.12e-18	0.83	0.56	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
COAD	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	10.74	1.75e-22	1.12e-18	0.83	0.56	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
COAD	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-10.73	1.98e-22	1.26e-18	-0.83	-0.56	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
COAD	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	10.73	1.98e-22	1.26e-18	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
COAD	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-10.72	2.03e-22	1.3e-18	-0.61	-0.56	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
COAD	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	10.72	2.09e-22	1.33e-18	0.73	0.56	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-10.72	2.1e-22	1.34e-18	-0.73	-0.56	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-10.72	2.1e-22	1.34e-18	-0.73	-0.56	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-10.72	2.13e-22	1.36e-18	-0.57	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
COAD	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	10.72	2.14e-22	1.36e-18	0.76	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
COAD	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	10.72	2.15e-22	1.36e-18	1	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
COAD	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-10.71	2.24e-22	1.42e-18	-0.61	-0.56	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	10.71	2.3e-22	1.46e-18	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	10.7	2.38e-22	1.5e-18	0.78	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
COAD	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	10.7	2.45e-22	1.54e-18	0.76	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	10.7	2.45e-22	1.54e-18	0.76	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
COAD	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	10.7	2.51e-22	1.58e-18	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
COAD	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	10.69	2.55e-22	1.6e-18	0.89	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
COAD	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-10.69	2.56e-22	1.61e-18	-0.57	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
COAD	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-10.69	2.62e-22	1.64e-18	-0.76	-0.55	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
COAD	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	10.69	2.64e-22	1.65e-18	0.73	0.55	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
COAD	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	10.68	2.77e-22	1.73e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
COAD	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	10.68	2.77e-22	1.73e-18	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
COAD	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	10.68	2.84e-22	1.77e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
COAD	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.68	2.9e-22	1.81e-18	-0.61	-0.55	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
COAD	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	10.67	2.95e-22	1.84e-18	0.73	0.55	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	10.67	3.14e-22	1.95e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
COAD	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-10.67	3.15e-22	1.96e-18	-0.61	-0.55	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
COAD	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	10.66	3.18e-22	1.98e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-10.66	3.2e-22	1.99e-18	-0.74	-0.55	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
COAD	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	10.66	3.22e-22	2e-18	0.7	0.55	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
COAD	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	10.66	3.31e-22	2.05e-18	0.63	0.55	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
COAD	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	10.66	3.31e-22	2.05e-18	0.64	0.55	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
COAD	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	10.66	3.35e-22	2.07e-18	0.59	0.55	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
COAD	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	10.65	3.44e-22	2.13e-18	0.81	0.55	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
COAD	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	10.65	3.49e-22	2.16e-18	0.91	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
COAD	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-10.65	3.62e-22	2.24e-18	-0.76	-0.55	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
COAD	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	10.65	3.63e-22	2.24e-18	0.91	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	10.65	3.63e-22	2.24e-18	0.91	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	10.64	3.74e-22	2.31e-18	0.54	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
COAD	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	10.63	4.01e-22	2.47e-18	0.59	0.55	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
COAD	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-10.63	4.13e-22	2.54e-18	-0.61	-0.55	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-10.63	4.13e-22	2.54e-18	-0.61	-0.55	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
COAD	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-10.63	4.19e-22	2.58e-18	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	10.63	4.21e-22	2.59e-18	0.56	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
COAD	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-10.62	4.28e-22	2.63e-18	-0.76	-0.55	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
COAD	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-10.62	4.46e-22	2.74e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	10.62	4.52e-22	2.78e-18	0.55	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-10.62	4.56e-22	2.79e-18	-0.57	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.59	5.33e-22	3.25e-18	-0.62	-0.55	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-10.59	5.68e-22	3.46e-18	-0.57	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
COAD	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	10.58	5.74e-22	3.49e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-10.58	5.82e-22	3.54e-18	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-10.58	5.82e-22	3.54e-18	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
COAD	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	10.58	6.02e-22	3.66e-18	0.72	0.55	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
COAD	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	10.57	6.2e-22	3.76e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	10.57	6.36e-22	3.86e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
COAD	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-10.57	6.42e-22	3.89e-18	-0.76	-0.55	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-10.56	6.74e-22	4.08e-18	-0.65	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
COAD	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-10.56	6.76e-22	4.09e-18	-0.56	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	10.56	6.8e-22	4.11e-18	0.56	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-10.56	6.87e-22	4.15e-18	-0.62	-0.55	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-10.56	6.87e-22	4.15e-18	-0.62	-0.55	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	10.56	7.02e-22	4.24e-18	0.56	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	10.56	7.13e-22	4.29e-18	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
COAD	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-10.56	7.16e-22	4.31e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-10.56	7.16e-22	4.31e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-10.56	7.16e-22	4.31e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-10.56	7.16e-22	4.31e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-10.56	7.16e-22	4.31e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-10.55	7.43e-22	4.46e-18	-0.57	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
COAD	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	10.55	7.48e-22	4.49e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	10.55	7.48e-22	4.49e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	10.55	7.61e-22	4.55e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	10.54	7.99e-22	4.77e-18	0.66	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	10.53	8.6e-22	5.12e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
COAD	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	10.53	8.61e-22	5.12e-18	0.62	0.55	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	10.53	8.86e-22	5.26e-18	0.59	0.55	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
COAD	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-10.52	9.02e-22	5.35e-18	-0.63	-0.55	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
COAD	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-10.52	9.02e-22	5.35e-18	-0.63	-0.55	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
COAD	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-10.52	9.02e-22	5.35e-18	-0.63	-0.55	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
COAD	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-10.52	9.05e-22	5.37e-18	-0.63	-0.55	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	10.52	9.17e-22	5.44e-18	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	10.52	9.28e-22	5.5e-18	0.65	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	10.52	9.33e-22	5.53e-18	0.62	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
COAD	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-10.51	9.88e-22	5.83e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
COAD	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	10.5	1.09e-21	6.39e-18	0.62	0.55	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
COAD	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	10.5	1.1e-21	6.45e-18	0.98	0.55	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	10.5	1.1e-21	6.45e-18	0.98	0.55	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
COAD	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	10.5	1.11e-21	6.51e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
COAD	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-10.49	1.14e-21	6.66e-18	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
COAD	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-10.48	1.22e-21	7.11e-18	-0.61	-0.55	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	10.48	1.24e-21	7.22e-18	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	10.48	1.24e-21	7.24e-18	0.55	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-10.48	1.25e-21	7.33e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
COAD	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	10.48	1.26e-21	7.34e-18	0.8	0.55	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
COAD	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.48	1.28e-21	7.48e-18	-0.61	-0.55	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
COAD	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	10.48	1.29e-21	7.52e-18	0.71	0.55	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
COAD	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-10.48	1.29e-21	7.54e-18	-0.65	-0.55	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
COAD	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	10.47	1.33e-21	7.75e-18	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	10.47	1.35e-21	7.87e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	10.47	1.35e-21	7.87e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	10.47	1.36e-21	7.94e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	10.47	1.36e-21	7.94e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	10.47	1.38e-21	8.02e-18	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	10.46	1.43e-21	8.29e-18	0.75	0.55	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	10.46	1.43e-21	8.3e-18	0.56	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	10.46	1.43e-21	8.3e-18	0.56	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
COAD	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	10.46	1.45e-21	8.44e-18	0.98	0.55	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
COAD	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	10.46	1.49e-21	8.64e-18	0.69	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-10.46	1.49e-21	8.67e-18	-0.55	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
COAD	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.45	1.52e-21	8.83e-18	-0.6	-0.55	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
COAD	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-10.45	1.53e-21	8.88e-18	-0.59	-0.55	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
COAD	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	10.45	1.55e-21	8.97e-18	0.62	0.55	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	10.45	1.55e-21	8.97e-18	0.62	0.55	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	10.45	1.56e-21	9.03e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	10.45	1.56e-21	9.03e-18	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	10.45	1.56e-21	9.03e-18	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	10.45	1.56e-21	9.05e-18	0.97	0.55	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
COAD	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-10.45	1.57e-21	9.1e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	10.45	1.58e-21	9.14e-18	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	10.45	1.58e-21	9.15e-18	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
COAD	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.45	1.59e-21	9.19e-18	-0.61	-0.55	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
COAD	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-10.44	1.62e-21	9.38e-18	-0.59	-0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
COAD	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-10.44	1.65e-21	9.49e-18	-0.59	-0.55	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-10.44	1.67e-21	9.59e-18	-0.65	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
COAD	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-10.44	1.73e-21	9.91e-18	-0.65	-0.55	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
COAD	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.43	1.78e-21	1.02e-17	-0.6	-0.55	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
COAD	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-10.42	1.91e-21	1.09e-17	-0.59	-0.55	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-10.42	1.92e-21	1.1e-17	-0.6	-0.55	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	10.42	2e-21	1.14e-17	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
COAD	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-10.41	2.03e-21	1.16e-17	-0.63	-0.54	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
COAD	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-10.41	2.04e-21	1.16e-17	-0.67	-0.54	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
COAD	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	10.41	2.08e-21	1.19e-17	0.79	0.54	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
COAD	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	10.4	2.18e-21	1.24e-17	0.68	0.54	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
COAD	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	10.4	2.19e-21	1.24e-17	0.64	0.54	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
COAD	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-10.4	2.25e-21	1.28e-17	-0.55	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
COAD	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	10.4	2.29e-21	1.3e-17	0.74	0.54	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-10.4	2.31e-21	1.31e-17	-0.59	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	10.4	2.31e-21	1.31e-17	0.59	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
COAD	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	10.39	2.38e-21	1.35e-17	0.76	0.54	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
COAD	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-10.39	2.41e-21	1.35e-17	-0.63	-0.54	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
COAD	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-10.39	2.41e-21	1.35e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
COAD	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	10.39	2.42e-21	1.36e-17	0.62	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	10.39	2.49e-21	1.39e-17	0.99	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
COAD	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	10.39	2.5e-21	1.4e-17	0.53	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
COAD	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	10.38	2.53e-21	1.4e-17	0.62	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
COAD	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	10.38	2.55e-21	1.4e-17	0.53	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
COAD	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.38	2.59e-21	1.43e-17	0.72	0.54	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-10.38	2.61e-21	1.44e-17	-0.61	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
COAD	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	10.38	2.61e-21	1.44e-17	0.53	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
COAD	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	10.38	2.68e-21	1.47e-17	0.53	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
COAD	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-10.37	2.75e-21	1.51e-17	-0.62	-0.54	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
COAD	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	10.37	2.78e-21	1.52e-17	0.8	0.54	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
COAD	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	10.37	2.78e-21	1.52e-17	0.8	0.54	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
COAD	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-10.37	2.81e-21	1.54e-17	-0.55	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-10.37	2.81e-21	1.54e-17	-0.55	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	10.37	2.81e-21	1.54e-17	0.62	0.54	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-10.37	2.84e-21	1.55e-17	-0.61	-0.54	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
COAD	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	10.36	2.99e-21	1.63e-17	0.68	0.54	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
COAD	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	10.36	3.04e-21	1.66e-17	0.59	0.54	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	10.36	3.11e-21	1.7e-17	0.61	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
COAD	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-10.35	3.22e-21	1.75e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
COAD	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-10.35	3.23e-21	1.76e-17	-0.69	-0.54	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
COAD	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	10.35	3.34e-21	1.81e-17	0.65	0.54	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	10.35	3.34e-21	1.81e-17	0.55	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
COAD	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-10.35	3.38e-21	1.83e-17	-0.64	-0.54	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
COAD	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-10.34	3.56e-21	1.93e-17	-0.61	-0.54	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
COAD	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	10.34	3.57e-21	1.94e-17	0.67	0.54	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
COAD	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	10.33	3.83e-21	2.07e-17	0.62	0.54	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	10.33	3.89e-21	2.1e-17	0.61	0.54	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
COAD	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
COAD	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-10.32	4.11e-21	2.2e-17	-0.61	-0.54	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	10.31	4.38e-21	2.34e-17	0.66	0.54	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
COAD	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	10.31	4.46e-21	2.38e-17	0.71	0.54	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
COAD	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-10.3	4.7e-21	2.51e-17	-0.62	-0.54	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-10.3	4.81e-21	2.56e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-10.3	4.81e-21	2.56e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-10.3	4.81e-21	2.56e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-10.3	4.89e-21	2.6e-17	-0.64	-0.54	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-10.29	4.97e-21	2.64e-17	-0.64	-0.54	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
COAD	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-10.29	4.97e-21	2.64e-17	-0.61	-0.54	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
COAD	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	10.29	5.02e-21	2.67e-17	0.59	0.54	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	10.29	5.02e-21	2.67e-17	0.59	0.54	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	10.29	5.02e-21	2.67e-17	0.59	0.54	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
COAD	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-10.29	5.1e-21	2.7e-17	-0.61	-0.54	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
COAD	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-10.28	5.32e-21	2.82e-17	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
COAD	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-10.28	5.54e-21	2.93e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
COAD	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	10.28	5.61e-21	2.96e-17	0.79	0.54	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
COAD	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-10.28	5.67e-21	2.99e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-10.28	5.67e-21	2.99e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-10.28	5.67e-21	2.99e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	10.27	5.77e-21	3.04e-17	0.54	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	10.27	5.77e-21	3.04e-17	0.54	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
COAD	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-10.27	5.97e-21	3.14e-17	-0.62	-0.54	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-10.27	6.07e-21	3.2e-17	-0.55	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-10.26	6.51e-21	3.43e-17	-0.55	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
COAD	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-10.26	6.56e-21	3.45e-17	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	10.25	6.65e-21	3.48e-17	0.71	0.54	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
COAD	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	10.25	6.69e-21	3.5e-17	0.62	0.54	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-10.25	6.74e-21	3.53e-17	-0.54	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	10.24	7.19e-21	3.75e-17	0.9	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
COAD	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	10.24	7.33e-21	3.82e-17	0.61	0.54	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	10.24	7.33e-21	3.82e-17	0.61	0.54	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
COAD	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	10.24	7.43e-21	3.87e-17	1.06	0.54	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
COAD	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	10.23	7.73e-21	4.03e-17	0.79	0.54	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
COAD	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	10.23	7.73e-21	4.03e-17	0.79	0.54	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
COAD	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	10.23	7.84e-21	4.08e-17	0.55	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-10.22	8.36e-21	4.34e-17	-0.61	-0.54	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
COAD	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	10.22	8.39e-21	4.35e-17	0.96	0.54	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
COAD	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	10.22	8.44e-21	4.38e-17	0.76	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	10.22	8.58e-21	4.44e-17	0.55	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
COAD	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	10.22	8.71e-21	4.51e-17	0.51	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
COAD	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	10.22	8.75e-21	4.53e-17	0.66	0.54	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
COAD	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-10.22	8.77e-21	4.54e-17	-0.71	-0.54	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
COAD	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	10.22	8.79e-21	4.55e-17	0.54	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-10.21	8.96e-21	4.63e-17	-0.7	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
COAD	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	10.21	9e-21	4.64e-17	0.61	0.54	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
COAD	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	10.21	9e-21	4.64e-17	0.61	0.54	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.21	9.45e-21	4.87e-17	0.67	0.54	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
COAD	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-10.21	9.46e-21	4.87e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
COAD	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-10.2	9.57e-21	4.92e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-10.2	9.68e-21	4.98e-17	-0.53	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
COAD	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	10.2	9.84e-21	5.05e-17	0.84	0.54	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
COAD	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	10.2	1.01e-20	5.19e-17	0.61	0.54	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-10.19	1.04e-20	5.32e-17	-0.6	-0.54	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-10.19	1.04e-20	5.33e-17	-0.6	-0.54	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-10.19	1.04e-20	5.33e-17	-0.6	-0.54	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-10.19	1.04e-20	5.33e-17	-0.6	-0.54	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	10.19	1.09e-20	5.55e-17	0.56	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	10.18	1.13e-20	5.75e-17	0.55	0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
COAD	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-10.18	1.14e-20	5.82e-17	-0.61	-0.54	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-10.18	1.14e-20	5.82e-17	-0.61	-0.54	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
COAD	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	10.17	1.19e-20	6.03e-17	0.79	0.54	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
COAD	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	10.16	1.29e-20	6.54e-17	0.58	0.54	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
COAD	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-10.16	1.29e-20	6.56e-17	-0.64	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
COAD	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.16	1.33e-20	6.75e-17	0.67	0.54	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
COAD	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-10.16	1.34e-20	6.81e-17	-0.72	-0.54	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-10.16	1.34e-20	6.81e-17	-0.72	-0.54	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
COAD	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-10.16	1.34e-20	6.81e-17	-0.72	-0.54	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
COAD	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	10.16	1.36e-20	6.86e-17	0.58	0.54	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	10.16	1.36e-20	6.86e-17	0.58	0.54	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
COAD	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-10.16	1.36e-20	6.87e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-10.16	1.36e-20	6.87e-17	-0.64	-0.54	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
COAD	cis	rs11155671	0.53	rs9371504	ENSG00000231760.4	RP11-350J20.5	10.16	1.36e-20	6.88e-17	0.67	0.54	Testicular germ cell tumor;	chr6:149862944	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs9371505	ENSG00000231760.4	RP11-350J20.5	10.16	1.36e-20	6.88e-17	0.67	0.54	Testicular germ cell tumor;	chr6:149863012	chr6:149796151~149826294:-
COAD	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-10.15	1.4e-20	7.05e-17	-0.59	-0.54	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
COAD	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-10.15	1.43e-20	7.21e-17	-0.58	-0.53	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
COAD	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	10.15	1.47e-20	7.39e-17	0.65	0.53	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
COAD	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-10.14	1.5e-20	7.58e-17	-0.58	-0.53	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
COAD	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-10.14	1.51e-20	7.6e-17	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
COAD	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	10.14	1.54e-20	7.76e-17	0.62	0.53	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	10.14	1.54e-20	7.76e-17	0.62	0.53	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-10.14	1.55e-20	7.77e-17	-0.59	-0.53	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
COAD	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	10.14	1.58e-20	7.95e-17	0.61	0.53	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	10.13	1.59e-20	8.01e-17	0.61	0.53	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	10.13	1.59e-20	8.01e-17	0.61	0.53	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-10.13	1.61e-20	8.11e-17	-0.59	-0.53	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	10.13	1.63e-20	8.2e-17	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
COAD	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-10.13	1.64e-20	8.25e-17	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
COAD	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-10.12	1.79e-20	8.96e-17	-0.77	-0.53	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
COAD	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-10.12	1.79e-20	8.96e-17	-0.77	-0.53	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
COAD	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	10.11	1.89e-20	9.42e-17	0.55	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-10.11	1.93e-20	9.62e-17	-0.59	-0.53	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
COAD	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	10.1	2.08e-20	1.04e-16	0.58	0.53	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
COAD	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	10.1	2.12e-20	1.05e-16	0.6	0.53	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
COAD	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-10.09	2.18e-20	1.08e-16	-0.61	-0.53	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-10.09	2.18e-20	1.08e-16	-0.61	-0.53	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	10.09	2.2e-20	1.09e-16	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
COAD	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-10.09	2.26e-20	1.12e-16	-0.63	-0.53	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
COAD	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-10.09	2.26e-20	1.12e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-10.09	2.26e-20	1.12e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.08	2.3e-20	1.14e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-10.08	2.37e-20	1.17e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-10.08	2.37e-20	1.17e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-10.08	2.37e-20	1.17e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-10.08	2.37e-20	1.17e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
COAD	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-10.08	2.39e-20	1.18e-16	-0.56	-0.53	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
COAD	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	10.08	2.43e-20	1.2e-16	0.76	0.53	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
COAD	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-10.08	2.44e-20	1.2e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-10.08	2.44e-20	1.2e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-10.08	2.44e-20	1.2e-16	-0.59	-0.53	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
COAD	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	10.07	2.49e-20	1.23e-16	0.65	0.53	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
COAD	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-10.07	2.54e-20	1.25e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
COAD	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	10.07	2.56e-20	1.26e-16	0.61	0.53	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
COAD	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	10.07	2.57e-20	1.26e-16	0.61	0.53	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	10.07	2.57e-20	1.26e-16	0.61	0.53	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	10.07	2.57e-20	1.26e-16	0.61	0.53	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-10.07	2.57e-20	1.26e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
COAD	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-10.07	2.59e-20	1.27e-16	-0.93	-0.53	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
COAD	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	10.06	2.71e-20	1.33e-16	0.89	0.53	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
COAD	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	10.06	2.71e-20	1.33e-16	0.62	0.53	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	10.06	2.74e-20	1.34e-16	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
COAD	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.06	2.79e-20	1.36e-16	0.67	0.53	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
COAD	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	10.06	2.79e-20	1.37e-16	0.62	0.53	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
COAD	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-10.06	2.83e-20	1.38e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
COAD	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-10.05	2.88e-20	1.41e-16	-0.6	-0.53	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-10.05	2.93e-20	1.43e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
COAD	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-10.05	2.96e-20	1.45e-16	-0.61	-0.53	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
COAD	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-10.05	3.02e-20	1.47e-16	-0.56	-0.53	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
COAD	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	10.05	3.04e-20	1.48e-16	0.62	0.53	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
COAD	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.04	3.06e-20	1.49e-16	0.67	0.53	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
COAD	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-10.04	3.15e-20	1.53e-16	-0.54	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
COAD	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-10.04	3.23e-20	1.57e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-10.04	3.23e-20	1.57e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-10.04	3.23e-20	1.57e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-10.04	3.28e-20	1.59e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-10.03	3.31e-20	1.6e-16	-0.53	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
COAD	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-10.03	3.38e-20	1.63e-16	-0.73	-0.53	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
COAD	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-10.03	3.38e-20	1.63e-16	-0.73	-0.53	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
COAD	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-10.03	3.38e-20	1.63e-16	-0.73	-0.53	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
COAD	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	10.03	3.4e-20	1.64e-16	0.6	0.53	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
COAD	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	10.03	3.41e-20	1.65e-16	0.61	0.53	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	10.03	3.45e-20	1.66e-16	0.57	0.53	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
COAD	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	10.03	3.53e-20	1.7e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-10.02	3.6e-20	1.72e-16	-0.69	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
COAD	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-10.02	3.62e-20	1.73e-16	-0.66	-0.53	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
COAD	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-10.02	3.62e-20	1.73e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	10.02	3.69e-20	1.76e-16	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
COAD	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	10.02	3.74e-20	1.78e-16	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
COAD	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	10.02	3.76e-20	1.79e-16	0.64	0.53	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-10.02	3.77e-20	1.79e-16	-0.73	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
COAD	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-10.01	3.84e-20	1.82e-16	-0.56	-0.53	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
COAD	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-10.01	3.93e-20	1.86e-16	-0.58	-0.53	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	10.01	3.97e-20	1.88e-16	0.53	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
COAD	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-10.01	3.98e-20	1.88e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-10.01	3.98e-20	1.88e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	10.01	3.98e-20	1.88e-16	0.64	0.53	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
COAD	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	10.01	4.01e-20	1.89e-16	0.61	0.53	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	10.01	4.01e-20	1.89e-16	0.61	0.53	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
COAD	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-10	4.09e-20	1.92e-16	-0.6	-0.53	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-10	4.15e-20	1.95e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
COAD	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	10	4.24e-20	1.98e-16	0.7	0.53	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
COAD	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10	4.26e-20	1.99e-16	-0.6	-0.53	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10	4.26e-20	1.99e-16	-0.6	-0.53	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
COAD	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-9.99	4.42e-20	2.07e-16	-0.6	-0.53	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
COAD	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-9.99	4.5e-20	2.1e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
COAD	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-9.99	4.53e-20	2.12e-16	-0.73	-0.53	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
COAD	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-9.99	4.72e-20	2.2e-16	-0.62	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
COAD	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-9.98	4.94e-20	2.27e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-9.98	4.99e-20	2.29e-16	-0.56	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	9.98	5.04e-20	2.31e-16	0.61	0.53	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	9.98	5.04e-20	2.31e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
COAD	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-9.97	5.12e-20	2.34e-16	-0.62	-0.53	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
COAD	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-9.97	5.2e-20	2.38e-16	-0.54	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
COAD	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-9.97	5.22e-20	2.38e-16	-0.79	-0.53	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
COAD	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-9.97	5.24e-20	2.4e-16	-0.54	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
COAD	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-9.96	5.5e-20	2.5e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-9.96	5.79e-20	2.63e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-9.95	6.09e-20	2.76e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-9.94	6.35e-20	2.87e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
COAD	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-9.94	6.54e-20	2.95e-16	-0.61	-0.53	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-9.94	6.55e-20	2.95e-16	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
COAD	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-9.94	6.64e-20	2.99e-16	-0.57	-0.53	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
COAD	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-9.94	6.69e-20	3.01e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-9.94	6.69e-20	3.01e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	9.94	6.77e-20	3.04e-16	0.71	0.53	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
COAD	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-9.94	6.79e-20	3.05e-16	-0.64	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
COAD	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	9.93	7.03e-20	3.15e-16	0.61	0.53	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
COAD	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-9.93	7.08e-20	3.17e-16	-0.6	-0.53	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
COAD	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-9.92	7.39e-20	3.3e-16	-0.53	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-9.92	7.41e-20	3.31e-16	-0.58	-0.53	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
COAD	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-9.92	7.5e-20	3.34e-16	-0.68	-0.53	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-9.92	7.52e-20	3.34e-16	-0.65	-0.53	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
COAD	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-9.92	7.6e-20	3.37e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
COAD	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-9.92	7.6e-20	3.37e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
COAD	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	9.92	7.83e-20	3.48e-16	0.88	0.53	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
COAD	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	9.91	7.98e-20	3.53e-16	0.62	0.53	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	9.91	8.06e-20	3.56e-16	0.66	0.53	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
COAD	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	9.91	8.15e-20	3.6e-16	0.54	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-9.91	8.25e-20	3.64e-16	-0.58	-0.53	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
COAD	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	9.91	8.41e-20	3.71e-16	0.66	0.53	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
COAD	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-9.9	8.52e-20	3.76e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
COAD	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-9.9	8.61e-20	3.79e-16	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
COAD	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	9.9	8.68e-20	3.82e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
COAD	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	9.9	8.99e-20	3.95e-16	0.57	0.53	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-9.9	9.04e-20	3.97e-16	-0.62	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
COAD	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	9.89	9.22e-20	4.03e-16	0.7	0.53	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
COAD	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-9.89	9.29e-20	4.05e-16	-0.71	-0.53	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
COAD	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-9.89	9.38e-20	4.1e-16	-0.61	-0.53	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
COAD	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-9.89	9.49e-20	4.14e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-9.89	9.49e-20	4.14e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-9.88	1.03e-19	4.48e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
COAD	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	9.88	1.04e-19	4.51e-16	0.77	0.52	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
COAD	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-9.88	1.04e-19	4.51e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-9.88	1.04e-19	4.51e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
COAD	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	9.88	1.04e-19	4.52e-16	0.61	0.52	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-9.87	1.05e-19	4.57e-16	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-9.87	1.06e-19	4.59e-16	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
COAD	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-9.87	1.06e-19	4.6e-16	-0.55	-0.52	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
COAD	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	9.87	1.07e-19	4.62e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
COAD	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	9.87	1.07e-19	4.63e-16	0.61	0.52	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
COAD	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-9.87	1.09e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-9.87	1.09e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
COAD	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-9.87	1.1e-19	4.74e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-9.87	1.11e-19	4.8e-16	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
COAD	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-9.86	1.13e-19	4.86e-16	-0.58	-0.52	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
COAD	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	9.86	1.14e-19	4.89e-16	0.61	0.52	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	9.86	1.14e-19	4.89e-16	0.61	0.52	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
COAD	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-9.86	1.17e-19	5.03e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
COAD	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-9.85	1.21e-19	5.19e-16	-0.7	-0.52	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-9.85	1.25e-19	5.35e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-9.85	1.26e-19	5.41e-16	-0.54	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	9.85	1.28e-19	5.45e-16	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	9.85	1.28e-19	5.45e-16	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	9.85	1.28e-19	5.45e-16	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	9.85	1.28e-19	5.45e-16	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	9.85	1.28e-19	5.46e-16	0.68	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
COAD	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-9.85	1.29e-19	5.49e-16	-0.6	-0.52	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
COAD	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	9.85	1.29e-19	5.5e-16	0.76	0.52	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
COAD	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-9.84	1.31e-19	5.57e-16	-0.6	-0.52	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-9.84	1.31e-19	5.58e-16	-0.6	-0.52	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
COAD	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
COAD	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-9.84	1.33e-19	5.65e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-9.84	1.36e-19	5.77e-16	-0.66	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
COAD	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	9.84	1.37e-19	5.82e-16	0.77	0.52	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
COAD	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	9.83	1.42e-19	6.02e-16	0.7	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
COAD	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-9.83	1.48e-19	6.27e-16	-0.7	-0.52	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	9.83	1.49e-19	6.3e-16	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
COAD	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-9.82	1.54e-19	6.49e-16	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
COAD	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	9.82	1.57e-19	6.59e-16	0.98	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
COAD	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-9.82	1.58e-19	6.66e-16	-0.59	-0.52	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-9.82	1.58e-19	6.66e-16	-0.59	-0.52	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-9.82	1.58e-19	6.66e-16	-0.59	-0.52	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
COAD	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	9.82	1.61e-19	6.75e-16	0.61	0.52	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	9.81	1.67e-19	6.97e-16	0.56	0.52	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
COAD	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	9.81	1.68e-19	7.01e-16	0.63	0.52	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
COAD	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-9.81	1.69e-19	7.05e-16	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
COAD	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-9.81	1.71e-19	7.12e-16	-0.7	-0.52	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
COAD	cis	rs11155671	0.53	rs9371504	ENSG00000216906.2	RP11-350J20.9	9.8	1.74e-19	7.26e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149862944	chr6:149904243~149906418:+
COAD	cis	rs11155671	0.53	rs9371505	ENSG00000216906.2	RP11-350J20.9	9.8	1.74e-19	7.26e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149863012	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-9.8	1.78e-19	7.41e-16	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-9.8	1.78e-19	7.41e-16	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-9.8	1.81e-19	7.54e-16	-0.58	-0.52	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
COAD	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-9.8	1.82e-19	7.54e-16	-0.62	-0.52	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
COAD	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-9.8	1.82e-19	7.55e-16	-0.6	-0.52	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-9.8	1.82e-19	7.55e-16	-0.6	-0.52	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
COAD	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	9.8	1.83e-19	7.62e-16	0.81	0.52	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
COAD	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-9.79	1.87e-19	7.77e-16	-0.57	-0.52	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-9.79	1.93e-19	8e-16	-0.59	-0.52	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
COAD	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	9.79	1.94e-19	8.04e-16	0.61	0.52	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
COAD	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	9.79	1.94e-19	8.05e-16	0.67	0.52	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-9.79	1.96e-19	8.1e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-9.79	1.96e-19	8.1e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-9.79	1.96e-19	8.1e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-9.79	1.96e-19	8.1e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-9.79	1.96e-19	8.1e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
COAD	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	9.78	2.04e-19	8.42e-16	0.61	0.52	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
COAD	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-9.78	2.04e-19	8.42e-16	-0.82	-0.52	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
COAD	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-9.78	2.06e-19	8.51e-16	-0.57	-0.52	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-9.78	2.06e-19	8.51e-16	-0.57	-0.52	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-9.78	2.06e-19	8.51e-16	-0.57	-0.52	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
COAD	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	9.78	2.08e-19	8.57e-16	0.57	0.52	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
COAD	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-9.78	2.08e-19	8.57e-16	-0.63	-0.52	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
COAD	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-9.78	2.09e-19	8.61e-16	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
COAD	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	9.78	2.09e-19	8.62e-16	0.71	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
COAD	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	9.78	2.09e-19	8.62e-16	0.71	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
COAD	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9.78	2.1e-19	8.66e-16	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
COAD	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	9.78	2.13e-19	8.76e-16	0.85	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
COAD	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-9.78	2.14e-19	8.79e-16	-0.63	-0.52	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-9.78	2.14e-19	8.79e-16	-0.63	-0.52	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-9.78	2.14e-19	8.79e-16	-0.63	-0.52	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-9.78	2.14e-19	8.79e-16	-0.63	-0.52	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
COAD	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	9.78	2.15e-19	8.86e-16	0.6	0.52	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
COAD	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	9.77	2.17e-19	8.91e-16	0.77	0.52	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
COAD	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-9.77	2.2e-19	9.03e-16	-0.6	-0.52	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	9.77	2.22e-19	9.1e-16	0.65	0.52	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
COAD	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-9.77	2.28e-19	9.34e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-9.77	2.3e-19	9.42e-16	-0.71	-0.52	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-9.76	2.35e-19	9.63e-16	-0.58	-0.52	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
COAD	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	9.76	2.41e-19	9.84e-16	0.69	0.52	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
COAD	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-9.76	2.47e-19	1.01e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-9.75	2.6e-19	1.06e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
COAD	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-9.75	2.64e-19	1.08e-15	-0.59	-0.52	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
COAD	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-9.75	2.65e-19	1.08e-15	-0.61	-0.52	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
COAD	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-9.75	2.65e-19	1.08e-15	-0.56	-0.52	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-9.75	2.65e-19	1.08e-15	-0.56	-0.52	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-9.75	2.65e-19	1.08e-15	-0.56	-0.52	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
COAD	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-9.75	2.65e-19	1.08e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-9.75	2.67e-19	1.09e-15	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-9.75	2.67e-19	1.09e-15	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
COAD	cis	rs7078219	0.523	rs10883366	ENSG00000257582.4	LINC01475	-9.74	2.71e-19	1.1e-15	-0.56	-0.52	Dental caries;	chr10:99528028	chr10:99526350~99531177:-
COAD	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-9.74	2.72e-19	1.1e-15	-0.6	-0.52	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
COAD	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-9.74	2.77e-19	1.12e-15	-0.62	-0.52	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-9.74	2.77e-19	1.12e-15	-0.62	-0.52	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-9.74	2.77e-19	1.12e-15	-0.62	-0.52	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-9.74	2.77e-19	1.12e-15	-0.62	-0.52	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-9.74	2.77e-19	1.12e-15	-0.62	-0.52	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
COAD	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	9.74	2.77e-19	1.12e-15	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
COAD	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-9.74	2.81e-19	1.14e-15	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-9.73	2.9e-19	1.17e-15	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-9.73	2.94e-19	1.19e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
COAD	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	9.73	2.94e-19	1.19e-15	0.81	0.52	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
COAD	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-9.73	2.97e-19	1.2e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
COAD	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-9.73	3.06e-19	1.23e-15	-0.72	-0.52	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
COAD	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
COAD	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-9.73	3.08e-19	1.24e-15	-0.6	-0.52	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-9.72	3.1e-19	1.24e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-9.72	3.1e-19	1.24e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-9.72	3.1e-19	1.24e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
COAD	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-9.72	3.12e-19	1.25e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
COAD	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-9.72	3.12e-19	1.25e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
COAD	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-9.72	3.12e-19	1.25e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
COAD	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-9.72	3.12e-19	1.25e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	9.72	3.14e-19	1.26e-15	0.53	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
COAD	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.72	3.14e-19	1.26e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
COAD	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	9.72	3.18e-19	1.27e-15	0.6	0.52	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	9.72	3.2e-19	1.28e-15	0.62	0.52	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
COAD	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-9.72	3.22e-19	1.29e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
COAD	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	9.72	3.25e-19	1.3e-15	0.6	0.52	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
COAD	cis	rs7078219	0.505	rs7916751	ENSG00000257582.4	LINC01475	-9.72	3.27e-19	1.31e-15	-0.56	-0.52	Dental caries;	chr10:99525893	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs6584281	ENSG00000257582.4	LINC01475	-9.72	3.27e-19	1.31e-15	-0.56	-0.52	Dental caries;	chr10:99526723	chr10:99526350~99531177:-
COAD	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	9.72	3.27e-19	1.31e-15	0.6	0.52	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	9.72	3.27e-19	1.31e-15	0.6	0.52	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
COAD	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-9.71	3.36e-19	1.34e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
COAD	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-9.71	3.38e-19	1.35e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-9.71	3.38e-19	1.35e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-9.71	3.39e-19	1.35e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
COAD	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-9.71	3.39e-19	1.35e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
COAD	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-9.71	3.39e-19	1.35e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
COAD	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-9.71	3.39e-19	1.35e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-9.71	3.43e-19	1.36e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
COAD	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-9.71	3.44e-19	1.37e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-9.71	3.44e-19	1.37e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
COAD	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	9.71	3.46e-19	1.38e-15	0.62	0.52	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
COAD	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-9.71	3.51e-19	1.39e-15	-0.56	-0.52	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
COAD	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-9.71	3.53e-19	1.4e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
COAD	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.7	3.6e-19	1.43e-15	-0.65	-0.52	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
COAD	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-9.7	3.62e-19	1.44e-15	-0.6	-0.52	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-9.7	3.68e-19	1.46e-15	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-9.7	3.68e-19	1.46e-15	-0.6	-0.52	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
COAD	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-9.7	3.73e-19	1.48e-15	-0.57	-0.52	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
COAD	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-9.7	3.8e-19	1.5e-15	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
COAD	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-9.7	3.81e-19	1.51e-15	-0.57	-0.52	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
COAD	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-9.69	3.84e-19	1.52e-15	-0.61	-0.52	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
COAD	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-9.69	3.85e-19	1.52e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-9.69	3.93e-19	1.55e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-9.69	3.93e-19	1.55e-15	-0.51	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
COAD	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-9.69	3.93e-19	1.55e-15	-0.59	-0.52	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	9.69	3.93e-19	1.55e-15	0.56	0.52	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
COAD	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-9.69	3.95e-19	1.56e-15	-0.69	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
COAD	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	9.69	3.96e-19	1.56e-15	0.6	0.52	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-9.69	3.97e-19	1.57e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-9.69	3.97e-19	1.57e-15	-0.63	-0.52	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
COAD	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-9.68	4.24e-19	1.66e-15	-0.59	-0.52	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
COAD	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	9.68	4.28e-19	1.68e-15	0.7	0.52	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-9.68	4.33e-19	1.7e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-9.68	4.33e-19	1.7e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
COAD	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	9.68	4.37e-19	1.71e-15	0.96	0.52	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
COAD	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	9.67	4.46e-19	1.75e-15	0.71	0.52	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
COAD	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-9.67	4.51e-19	1.77e-15	-0.56	-0.52	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
COAD	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.67	4.61e-19	1.8e-15	0.65	0.52	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
COAD	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-9.67	4.65e-19	1.82e-15	-0.56	-0.52	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
COAD	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-9.67	4.68e-19	1.83e-15	-0.63	-0.52	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
COAD	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	9.66	4.79e-19	1.87e-15	0.59	0.52	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
COAD	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	9.66	4.83e-19	1.89e-15	0.61	0.52	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-9.66	4.83e-19	1.89e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-9.66	4.88e-19	1.9e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-9.66	4.88e-19	1.9e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-9.66	4.88e-19	1.9e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-9.66	4.88e-19	1.9e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-9.66	4.88e-19	1.9e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-9.66	4.93e-19	1.92e-15	-0.56	-0.52	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
COAD	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-9.66	4.97e-19	1.94e-15	-0.53	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
COAD	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-9.66	5e-19	1.95e-15	-0.58	-0.52	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
COAD	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-9.66	5.02e-19	1.96e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-9.66	5.04e-19	1.96e-15	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	9.66	5.07e-19	1.97e-15	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
COAD	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-9.65	5.15e-19	2e-15	-0.52	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
COAD	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	9.65	5.16e-19	2e-15	0.62	0.52	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
COAD	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	9.65	5.23e-19	2.03e-15	0.68	0.52	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-9.65	5.25e-19	2.04e-15	-0.51	-0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
COAD	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	9.65	5.34e-19	2.07e-15	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	9.65	5.34e-19	2.07e-15	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	9.65	5.34e-19	2.07e-15	0.96	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	9.65	5.35e-19	2.08e-15	0.53	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
COAD	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-9.65	5.41e-19	2.1e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-9.65	5.41e-19	2.1e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-9.65	5.41e-19	2.1e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-9.65	5.41e-19	2.1e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
COAD	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	9.65	5.46e-19	2.12e-15	0.6	0.52	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
COAD	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-9.64	5.5e-19	2.13e-15	-0.55	-0.52	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	9.64	5.5e-19	2.13e-15	0.68	0.52	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
COAD	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-9.64	5.55e-19	2.15e-15	-0.56	-0.52	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
COAD	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	9.64	5.58e-19	2.16e-15	0.6	0.52	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	9.64	5.58e-19	2.16e-15	0.6	0.52	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	9.64	5.58e-19	2.16e-15	0.6	0.52	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
COAD	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	9.64	5.58e-19	2.16e-15	0.6	0.52	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-9.64	5.63e-19	2.18e-15	-0.64	-0.52	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
COAD	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-9.64	5.65e-19	2.18e-15	-0.7	-0.52	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
COAD	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-9.64	5.67e-19	2.19e-15	-0.55	-0.52	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
COAD	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-9.64	5.68e-19	2.19e-15	-0.62	-0.52	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
COAD	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	9.64	5.68e-19	2.19e-15	0.6	0.52	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
COAD	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-9.64	5.69e-19	2.2e-15	-0.62	-0.52	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
COAD	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	9.64	5.73e-19	2.21e-15	0.6	0.52	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
COAD	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-9.64	5.76e-19	2.22e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
COAD	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-9.63	5.94e-19	2.29e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
COAD	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-9.63	5.96e-19	2.3e-15	-0.69	-0.52	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-9.63	5.96e-19	2.3e-15	-0.57	-0.52	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
COAD	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	9.63	5.97e-19	2.3e-15	0.65	0.52	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
COAD	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-9.63	5.97e-19	2.3e-15	-0.6	-0.52	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
COAD	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	9.63	6.06e-19	2.33e-15	0.69	0.51	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
COAD	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	9.63	6.22e-19	2.39e-15	0.66	0.51	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
COAD	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	9.63	6.31e-19	2.43e-15	0.64	0.51	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
COAD	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	9.62	6.43e-19	2.47e-15	0.58	0.51	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	9.62	6.56e-19	2.52e-15	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	9.62	6.56e-19	2.52e-15	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
COAD	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-9.62	6.66e-19	2.55e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-9.62	6.66e-19	2.55e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-9.62	6.66e-19	2.55e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-9.62	6.66e-19	2.55e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
COAD	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-9.62	6.71e-19	2.57e-15	-0.55	-0.51	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-9.62	6.71e-19	2.57e-15	-0.55	-0.51	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
COAD	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	9.62	6.71e-19	2.57e-15	0.6	0.51	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
COAD	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-9.62	6.77e-19	2.59e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-9.62	6.78e-19	2.6e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
COAD	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	9.61	7.05e-19	2.7e-15	0.75	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
COAD	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-9.61	7.09e-19	2.71e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
COAD	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	9.61	7.16e-19	2.73e-15	0.61	0.51	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-9.61	7.24e-19	2.76e-15	-0.63	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
COAD	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-9.6	7.42e-19	2.83e-15	-0.7	-0.51	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
COAD	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-9.6	7.42e-19	2.83e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
COAD	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-9.6	7.62e-19	2.9e-15	-0.62	-0.51	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
COAD	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-9.6	7.68e-19	2.92e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
COAD	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-9.6	7.68e-19	2.92e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	9.6	7.69e-19	2.92e-15	0.56	0.51	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
COAD	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-9.6	7.71e-19	2.93e-15	-0.59	-0.51	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-9.59	7.85e-19	2.98e-15	-0.62	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
COAD	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-9.59	7.89e-19	2.99e-15	-0.62	-0.51	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	9.59	7.89e-19	2.99e-15	0.62	0.51	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-9.59	7.89e-19	2.99e-15	-0.62	-0.51	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-9.59	7.89e-19	2.99e-15	-0.62	-0.51	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
COAD	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-9.59	7.89e-19	2.99e-15	-0.62	-0.51	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-9.59	7.89e-19	2.99e-15	-0.62	-0.51	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
COAD	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	9.59	7.98e-19	3.02e-15	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
COAD	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	9.59	8.02e-19	3.04e-15	0.68	0.51	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
COAD	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	9.59	8.09e-19	3.06e-15	0.76	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
COAD	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	9.59	8.33e-19	3.15e-15	0.61	0.51	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
COAD	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-9.58	8.52e-19	3.22e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
COAD	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
COAD	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
COAD	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.58	8.55e-19	3.23e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
COAD	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-9.58	8.58e-19	3.24e-15	-0.61	-0.51	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
COAD	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-9.58	8.58e-19	3.24e-15	-0.62	-0.51	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
COAD	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	9.58	8.66e-19	3.27e-15	0.72	0.51	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-9.58	8.72e-19	3.29e-15	-0.58	-0.51	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
COAD	cis	rs6584283	0.846	rs11190135	ENSG00000257582.4	LINC01475	-9.58	8.84e-19	3.33e-15	-0.55	-0.51	Ulcerative colitis;	chr10:99527091	chr10:99526350~99531177:-
COAD	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-9.58	8.87e-19	3.34e-15	-0.55	-0.51	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
COAD	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-9.58	8.91e-19	3.35e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
COAD	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	9.58	8.94e-19	3.37e-15	0.59	0.51	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
COAD	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-9.57	9.17e-19	3.45e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-9.57	9.17e-19	3.45e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
COAD	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-9.57	9.23e-19	3.47e-15	-0.55	-0.51	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
COAD	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-9.57	9.26e-19	3.48e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
COAD	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.57	9.33e-19	3.51e-15	-0.54	-0.51	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
COAD	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	9.57	9.34e-19	3.51e-15	0.75	0.51	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
COAD	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	9.57	9.4e-19	3.53e-15	0.65	0.51	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
COAD	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	9.57	9.43e-19	3.54e-15	0.79	0.51	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
COAD	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-9.57	9.46e-19	3.55e-15	-0.64	-0.51	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
COAD	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-9.57	9.56e-19	3.59e-15	-0.57	-0.51	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
COAD	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-9.57	9.59e-19	3.6e-15	-0.61	-0.51	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	9.57	9.62e-19	3.61e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
COAD	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	9.56	9.8e-19	3.67e-15	0.95	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
COAD	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-9.56	9.82e-19	3.68e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
COAD	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-9.56	9.87e-19	3.7e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-9.56	9.95e-19	3.73e-15	-0.62	-0.51	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
COAD	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-9.56	1e-18	3.74e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-9.56	1e-18	3.74e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
COAD	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-9.56	1.03e-18	3.86e-15	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
COAD	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-9.55	1.05e-18	3.92e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
COAD	cis	rs6584283	1	rs6584283	ENSG00000257582.4	LINC01475	-9.55	1.06e-18	3.95e-15	-0.57	-0.51	Ulcerative colitis;	chr10:99530544	chr10:99526350~99531177:-
COAD	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-9.55	1.08e-18	4.02e-15	-0.63	-0.51	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	9.55	1.08e-18	4.02e-15	0.52	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	9.55	1.08e-18	4.03e-15	0.69	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
COAD	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-9.55	1.08e-18	4.03e-15	-0.62	-0.51	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
COAD	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	9.55	1.09e-18	4.05e-15	0.6	0.51	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	9.55	1.09e-18	4.06e-15	0.64	0.51	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
COAD	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	9.55	1.09e-18	4.07e-15	0.61	0.51	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
COAD	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-9.55	1.11e-18	4.14e-15	-0.6	-0.51	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-9.55	1.11e-18	4.14e-15	-0.62	-0.51	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
COAD	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	9.55	1.12e-18	4.16e-15	0.63	0.51	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
COAD	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	9.54	1.14e-18	4.22e-15	0.69	0.51	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
COAD	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	9.54	1.15e-18	4.25e-15	0.65	0.51	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
COAD	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-9.54	1.15e-18	4.26e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
COAD	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	9.54	1.16e-18	4.31e-15	0.9	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
COAD	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-9.54	1.17e-18	4.35e-15	-0.64	-0.51	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
COAD	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	9.54	1.19e-18	4.4e-15	0.72	0.51	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
COAD	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	9.54	1.19e-18	4.4e-15	0.72	0.51	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
COAD	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
COAD	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.54	1.19e-18	4.4e-15	-0.56	-0.51	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
COAD	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-9.54	1.2e-18	4.44e-15	-0.58	-0.51	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
COAD	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	9.53	1.21e-18	4.49e-15	0.65	0.51	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
COAD	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-9.53	1.23e-18	4.54e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
COAD	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-9.53	1.23e-18	4.55e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-9.53	1.24e-18	4.57e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
COAD	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	9.53	1.27e-18	4.7e-15	0.48	0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
COAD	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
COAD	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-9.53	1.28e-18	4.7e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
COAD	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	9.53	1.28e-18	4.73e-15	0.6	0.51	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	9.53	1.28e-18	4.73e-15	0.6	0.51	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	9.53	1.28e-18	4.73e-15	0.6	0.51	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	9.53	1.28e-18	4.73e-15	0.6	0.51	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
COAD	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-9.53	1.29e-18	4.75e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
COAD	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	9.52	1.29e-18	4.76e-15	0.74	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
COAD	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-9.52	1.3e-18	4.79e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-9.52	1.3e-18	4.79e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-9.52	1.3e-18	4.79e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-9.52	1.3e-18	4.79e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
COAD	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-9.52	1.35e-18	4.94e-15	-0.6	-0.51	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
COAD	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-9.52	1.35e-18	4.95e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-9.52	1.35e-18	4.95e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
COAD	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-9.52	1.36e-18	4.98e-15	-0.6	-0.51	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	9.52	1.36e-18	4.98e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
COAD	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-9.52	1.36e-18	5e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-9.52	1.37e-18	5e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
COAD	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-9.52	1.37e-18	5.01e-15	-0.67	-0.51	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
COAD	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-9.51	1.43e-18	5.23e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-9.51	1.43e-18	5.23e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
COAD	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-9.51	1.43e-18	5.23e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
COAD	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	9.51	1.44e-18	5.25e-15	0.74	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	9.51	1.44e-18	5.25e-15	0.74	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	9.51	1.44e-18	5.25e-15	0.74	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
COAD	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	9.51	1.44e-18	5.27e-15	0.59	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
COAD	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	9.51	1.47e-18	5.38e-15	0.54	0.51	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
COAD	cis	rs7078219	0.505	rs11190140	ENSG00000257582.4	LINC01475	-9.5	1.53e-18	5.55e-15	-0.56	-0.51	Dental caries;	chr10:99531836	chr10:99526350~99531177:-
COAD	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-9.5	1.54e-18	5.59e-15	-0.64	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
COAD	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-9.5	1.55e-18	5.64e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	9.5	1.56e-18	5.67e-15	0.6	0.51	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-9.5	1.57e-18	5.71e-15	-0.58	-0.51	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-9.5	1.57e-18	5.71e-15	-0.58	-0.51	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
COAD	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	9.49	1.6e-18	5.82e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
COAD	cis	rs17264034	0.821	rs460234	ENSG00000250786.1	SNHG18	9.49	1.62e-18	5.87e-15	0.75	0.51	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543022	chr5:9546200~9550609:+
COAD	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	9.49	1.68e-18	6.11e-15	0.72	0.51	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	9.49	1.71e-18	6.21e-15	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
COAD	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-9.48	1.74e-18	6.28e-15	-0.7	-0.51	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
COAD	cis	rs6584283	0.846	rs10883370	ENSG00000257582.4	LINC01475	-9.48	1.78e-18	6.46e-15	-0.56	-0.51	Ulcerative colitis;	chr10:99531715	chr10:99526350~99531177:-
COAD	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-9.48	1.81e-18	6.52e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-9.48	1.81e-18	6.52e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-9.48	1.81e-18	6.52e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
COAD	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	9.48	1.83e-18	6.62e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
COAD	cis	rs7078219	0.505	rs7085798	ENSG00000257582.4	LINC01475	-9.47	1.87e-18	6.75e-15	-0.55	-0.51	Dental caries;	chr10:99528590	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs10883362	ENSG00000257582.4	LINC01475	-9.47	1.88e-18	6.77e-15	-0.55	-0.51	Dental caries;	chr10:99527227	chr10:99526350~99531177:-
COAD	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-9.47	1.89e-18	6.82e-15	-0.62	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
COAD	cis	rs7078219	0.505	rs10883367	ENSG00000257582.4	LINC01475	-9.47	1.92e-18	6.92e-15	-0.55	-0.51	Dental caries;	chr10:99528233	chr10:99526350~99531177:-
COAD	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-9.47	1.92e-18	6.92e-15	-0.67	-0.51	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
COAD	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	9.47	1.92e-18	6.93e-15	0.59	0.51	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
COAD	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-9.47	1.94e-18	6.98e-15	-0.61	-0.51	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	9.46	1.98e-18	7.14e-15	0.66	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
COAD	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-9.46	1.99e-18	7.17e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-9.46	1.99e-18	7.19e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
COAD	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.46	2.01e-18	7.25e-15	-0.54	-0.51	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
COAD	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-9.46	2.03e-18	7.31e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
COAD	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	9.46	2.03e-18	7.32e-15	0.73	0.51	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
COAD	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	9.46	2.06e-18	7.41e-15	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
COAD	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	9.46	2.06e-18	7.42e-15	0.6	0.51	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
COAD	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	9.46	2.06e-18	7.42e-15	0.6	0.51	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	9.46	2.06e-18	7.42e-15	0.6	0.51	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	9.46	2.06e-18	7.42e-15	0.6	0.51	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
COAD	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-9.46	2.07e-18	7.45e-15	-0.56	-0.51	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
COAD	cis	rs6584283	0.846	rs7917446	ENSG00000257582.4	LINC01475	-9.46	2.09e-18	7.52e-15	-0.56	-0.51	Ulcerative colitis;	chr10:99526450	chr10:99526350~99531177:-
COAD	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-9.46	2.11e-18	7.57e-15	-0.61	-0.51	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
COAD	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-9.45	2.18e-18	7.82e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-9.45	2.18e-18	7.82e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
COAD	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	9.45	2.18e-18	7.82e-15	0.59	0.51	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
COAD	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-9.45	2.25e-18	8.06e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-9.45	2.25e-18	8.06e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
COAD	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-9.45	2.27e-18	8.12e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-9.45	2.27e-18	8.12e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-9.45	2.27e-18	8.12e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-9.45	2.27e-18	8.12e-15	-0.69	-0.51	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-9.45	2.28e-18	8.15e-15	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
COAD	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	9.44	2.29e-18	8.18e-15	0.72	0.51	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-9.44	2.29e-18	8.2e-15	-0.53	-0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
COAD	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-9.44	2.31e-18	8.26e-15	-0.57	-0.51	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
COAD	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.44	2.31e-18	8.28e-15	0.55	0.51	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
COAD	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	9.44	2.42e-18	8.64e-15	0.63	0.51	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
COAD	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-9.44	2.42e-18	8.64e-15	-0.68	-0.51	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
COAD	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-9.44	2.42e-18	8.64e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-9.44	2.42e-18	8.64e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-9.44	2.42e-18	8.64e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-9.44	2.42e-18	8.64e-15	-0.61	-0.51	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	9.44	2.43e-18	8.66e-15	0.62	0.51	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
COAD	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	9.43	2.45e-18	8.73e-15	0.59	0.51	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
COAD	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	9.43	2.48e-18	8.83e-15	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
COAD	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-9.43	2.56e-18	9.12e-15	-0.68	-0.51	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	9.43	2.59e-18	9.21e-15	0.6	0.51	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	9.43	2.62e-18	9.31e-15	0.59	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
COAD	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	9.42	2.63e-18	9.34e-15	0.6	0.51	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
COAD	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	9.42	2.64e-18	9.37e-15	0.54	0.51	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
COAD	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	9.42	2.67e-18	9.46e-15	0.69	0.51	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
COAD	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	9.42	2.69e-18	9.53e-15	0.66	0.51	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
COAD	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	9.42	2.69e-18	9.55e-15	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	9.42	2.77e-18	9.82e-15	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
COAD	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	9.42	2.78e-18	9.84e-15	0.62	0.51	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
COAD	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	9.42	2.78e-18	9.85e-15	0.6	0.51	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-9.42	2.81e-18	9.94e-15	-0.64	-0.51	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
COAD	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	9.41	2.83e-18	1e-14	0.6	0.51	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
COAD	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-9.41	2.85e-18	1.01e-14	-0.64	-0.51	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
COAD	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.41	2.9e-18	1.02e-14	-0.54	-0.51	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
COAD	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	9.41	2.9e-18	1.02e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-9.41	2.91e-18	1.03e-14	-0.59	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
COAD	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.41	2.91e-18	1.03e-14	-0.55	-0.51	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.41	2.91e-18	1.03e-14	-0.55	-0.51	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.41	2.91e-18	1.03e-14	-0.55	-0.51	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
COAD	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-9.41	2.99e-18	1.06e-14	-0.69	-0.51	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
COAD	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-9.41	3.01e-18	1.06e-14	-0.54	-0.51	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
COAD	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	9.4	3.03e-18	1.07e-14	0.59	0.51	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
COAD	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	9.4	3.05e-18	1.08e-14	0.95	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	9.4	3.05e-18	1.08e-14	0.95	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	9.4	3.05e-18	1.08e-14	0.95	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
COAD	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-9.4	3.12e-18	1.1e-14	-0.59	-0.51	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	9.4	3.18e-18	1.12e-14	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	9.4	3.18e-18	1.12e-14	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
COAD	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-9.4	3.19e-18	1.12e-14	-0.59	-0.51	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-9.4	3.22e-18	1.13e-14	-0.63	-0.51	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
COAD	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	9.4	3.23e-18	1.13e-14	0.51	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
COAD	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-9.39	3.29e-18	1.15e-14	-0.54	-0.51	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-9.39	3.29e-18	1.15e-14	-0.54	-0.51	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
COAD	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	9.39	3.34e-18	1.17e-14	0.62	0.51	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-9.39	3.39e-18	1.19e-14	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-9.39	3.41e-18	1.19e-14	-0.61	-0.51	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-9.39	3.41e-18	1.19e-14	-0.61	-0.51	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
COAD	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	9.39	3.46e-18	1.21e-14	0.85	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
COAD	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	9.39	3.48e-18	1.22e-14	0.63	0.51	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
COAD	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-9.38	3.5e-18	1.22e-14	-0.69	-0.51	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
COAD	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	9.38	3.58e-18	1.25e-14	0.69	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
COAD	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-9.38	3.63e-18	1.27e-14	-0.61	-0.5	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
COAD	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-9.38	3.66e-18	1.28e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
COAD	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-9.38	3.66e-18	1.28e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
COAD	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-9.38	3.66e-18	1.28e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-9.37	3.83e-18	1.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
COAD	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-9.37	3.94e-18	1.37e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
COAD	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-9.37	3.94e-18	1.37e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-9.37	3.97e-18	1.38e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
COAD	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	9.37	4e-18	1.39e-14	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
COAD	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-9.36	4.05e-18	1.4e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-9.36	4.05e-18	1.4e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
COAD	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	9.35	4.38e-18	1.51e-14	0.6	0.5	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
COAD	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-9.35	4.39e-18	1.51e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-9.35	4.39e-18	1.51e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-9.35	4.39e-18	1.51e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-9.35	4.39e-18	1.51e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-9.35	4.39e-18	1.51e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
COAD	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	9.35	4.4e-18	1.52e-14	0.59	0.5	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
COAD	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	9.35	4.45e-18	1.53e-14	0.62	0.5	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
COAD	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-9.35	4.56e-18	1.57e-14	-0.55	-0.5	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
COAD	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-9.34	4.71e-18	1.62e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-9.34	4.73e-18	1.63e-14	-0.6	-0.5	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
COAD	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.34	4.88e-18	1.68e-14	0.63	0.5	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
COAD	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-9.34	4.88e-18	1.68e-14	-0.61	-0.5	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
COAD	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-9.34	4.92e-18	1.69e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
COAD	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-9.34	4.95e-18	1.7e-14	-0.56	-0.5	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
COAD	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-9.33	5.04e-18	1.73e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
COAD	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-9.33	5.04e-18	1.73e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
COAD	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-9.33	5.04e-18	1.73e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
COAD	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-9.33	5.04e-18	1.73e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-9.33	5.04e-18	1.73e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-9.33	5.04e-18	1.73e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
COAD	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	9.33	5.09e-18	1.74e-14	0.6	0.5	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-9.33	5.15e-18	1.76e-14	-0.75	-0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
COAD	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-9.33	5.27e-18	1.8e-14	-0.59	-0.5	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-9.33	5.3e-18	1.81e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
COAD	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-9.33	5.3e-18	1.81e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
COAD	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-9.33	5.3e-18	1.81e-14	-0.68	-0.5	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	9.32	5.36e-18	1.83e-14	0.51	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
COAD	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-9.32	5.38e-18	1.83e-14	-0.62	-0.5	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
COAD	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-9.32	5.4e-18	1.84e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-9.32	5.4e-18	1.84e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
COAD	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-9.32	5.5e-18	1.87e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
COAD	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	9.32	5.65e-18	1.92e-14	0.6	0.5	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
COAD	cis	rs858239	0.676	rs199359	ENSG00000230658.1	KLHL7-AS1	-9.32	5.67e-18	1.93e-14	-0.61	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23298895	chr7:23101228~23105703:-
COAD	cis	rs7078219	0.523	rs4129134	ENSG00000257582.4	LINC01475	-9.31	5.8e-18	1.97e-14	-0.54	-0.5	Dental caries;	chr10:99524588	chr10:99526350~99531177:-
COAD	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	9.31	5.84e-18	1.98e-14	0.65	0.5	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
COAD	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.31	5.93e-18	2.01e-14	-0.54	-0.5	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.31	5.93e-18	2.01e-14	-0.54	-0.5	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
COAD	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	9.31	5.97e-18	2.02e-14	0.59	0.5	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	9.31	5.99e-18	2.03e-14	0.51	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
COAD	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-9.3	6.23e-18	2.11e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-9.3	6.32e-18	2.14e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
COAD	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	9.3	6.41e-18	2.17e-14	0.53	0.5	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
COAD	cis	rs17264034	0.821	rs605126	ENSG00000250786.1	SNHG18	9.3	6.45e-18	2.18e-14	0.72	0.5	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541754	chr5:9546200~9550609:+
COAD	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-9.3	6.47e-18	2.19e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-9.3	6.47e-18	2.19e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-9.3	6.47e-18	2.19e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-9.3	6.47e-18	2.19e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-9.3	6.47e-18	2.19e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-9.29	6.6e-18	2.22e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
COAD	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	9.29	6.68e-18	2.25e-14	0.51	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
COAD	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-9.29	6.68e-18	2.25e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
COAD	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	9.29	6.7e-18	2.26e-14	0.51	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
COAD	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-9.29	6.72e-18	2.26e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
COAD	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-9.29	6.82e-18	2.3e-14	-0.6	-0.5	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
COAD	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-9.29	6.83e-18	2.3e-14	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
COAD	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-9.29	6.86e-18	2.31e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-9.29	6.87e-18	2.31e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
COAD	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	9.29	6.88e-18	2.31e-14	0.64	0.5	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
COAD	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-9.29	6.93e-18	2.33e-14	-0.6	-0.5	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
COAD	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-9.29	6.97e-18	2.34e-14	-0.69	-0.5	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
COAD	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-9.29	7.02e-18	2.36e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-9.29	7.03e-18	2.36e-14	-0.6	-0.5	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
COAD	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	9.28	7.07e-18	2.37e-14	0.66	0.5	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
COAD	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-9.28	7.07e-18	2.38e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-9.28	7.07e-18	2.38e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	9.28	7.1e-18	2.38e-14	0.59	0.5	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	9.28	7.1e-18	2.38e-14	0.59	0.5	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
COAD	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-9.28	7.17e-18	2.41e-14	-0.81	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
COAD	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-9.28	7.26e-18	2.44e-14	-0.5	-0.5	Breast cancer;	chr11:743813	chr11:779617~780755:+
COAD	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-9.28	7.27e-18	2.44e-14	-0.59	-0.5	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
COAD	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-9.28	7.31e-18	2.45e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
COAD	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-9.28	7.31e-18	2.45e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-9.28	7.39e-18	2.48e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-9.28	7.39e-18	2.48e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-9.28	7.39e-18	2.48e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-9.28	7.39e-18	2.48e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-9.28	7.46e-18	2.5e-14	-0.6	-0.5	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
COAD	cis	rs17264034	0.821	rs422309	ENSG00000250786.1	SNHG18	9.28	7.5e-18	2.51e-14	0.74	0.5	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544284	chr5:9546200~9550609:+
COAD	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-9.28	7.54e-18	2.52e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
COAD	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-9.28	7.57e-18	2.53e-14	-0.59	-0.5	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
COAD	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-9.28	7.57e-18	2.53e-14	-0.59	-0.5	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
COAD	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	9.27	7.67e-18	2.57e-14	0.54	0.5	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
COAD	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	9.27	7.68e-18	2.57e-14	0.64	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
COAD	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-9.27	7.73e-18	2.58e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-9.27	7.73e-18	2.58e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-9.27	7.78e-18	2.6e-14	-0.6	-0.5	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
COAD	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	9.27	7.91e-18	2.64e-14	0.81	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
COAD	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-9.27	7.93e-18	2.65e-14	-0.53	-0.5	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
COAD	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-9.27	7.99e-18	2.67e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-9.27	7.99e-18	2.67e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-9.27	7.99e-18	2.67e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-9.27	7.99e-18	2.67e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-9.27	7.99e-18	2.67e-14	-0.62	-0.5	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
COAD	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	9.27	8.01e-18	2.67e-14	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	9.27	8.06e-18	2.69e-14	0.79	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	9.27	8.06e-18	2.69e-14	0.79	0.5	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
COAD	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-9.26	8.12e-18	2.71e-14	-0.81	-0.5	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
COAD	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.26	8.35e-18	2.78e-14	-0.55	-0.5	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
COAD	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.26	8.35e-18	2.78e-14	-0.55	-0.5	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.26	8.35e-18	2.78e-14	-0.55	-0.5	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.26	8.35e-18	2.78e-14	-0.55	-0.5	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.26	8.35e-18	2.78e-14	-0.55	-0.5	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
COAD	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-9.26	8.35e-18	2.78e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
COAD	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-9.26	8.37e-18	2.78e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-9.25	8.74e-18	2.9e-14	-0.6	-0.5	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
COAD	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-9.25	8.79e-18	2.92e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-9.25	8.83e-18	2.93e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
COAD	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-9.25	8.84e-18	2.93e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
COAD	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-9.25	8.84e-18	2.93e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
COAD	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.25	9.12e-18	3.02e-14	-0.55	-0.5	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
COAD	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-9.25	9.34e-18	3.09e-14	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-9.25	9.34e-18	3.09e-14	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-9.25	9.34e-18	3.09e-14	-0.64	-0.5	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-9.24	9.37e-18	3.1e-14	-0.77	-0.5	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
COAD	cis	rs6584283	0.875	rs1548962	ENSG00000257582.4	LINC01475	9.24	9.39e-18	3.1e-14	0.54	0.5	Ulcerative colitis;	chr10:99529978	chr10:99526350~99531177:-
COAD	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-9.24	9.43e-18	3.12e-14	-0.68	-0.5	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-9.24	9.5e-18	3.14e-14	-0.58	-0.5	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	9.24	9.54e-18	3.15e-14	0.59	0.5	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	9.24	9.59e-18	3.17e-14	0.54	0.5	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
COAD	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-9.24	9.6e-18	3.17e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-9.24	9.6e-18	3.17e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
COAD	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.24	9.64e-18	3.18e-14	-0.53	-0.5	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.24	9.64e-18	3.18e-14	-0.53	-0.5	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
COAD	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	9.24	9.74e-18	3.21e-14	0.64	0.5	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	9.24	9.74e-18	3.21e-14	0.64	0.5	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	9.24	9.74e-18	3.21e-14	0.64	0.5	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
COAD	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	9.24	9.77e-18	3.22e-14	0.65	0.5	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
COAD	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	9.24	9.83e-18	3.24e-14	0.82	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
COAD	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.24	9.84e-18	3.24e-14	-0.53	-0.5	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-9.24	9.94e-18	3.27e-14	-0.54	-0.5	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
COAD	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	9.24	9.97e-18	3.29e-14	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	9.23	1e-17	3.31e-14	0.7	0.5	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
COAD	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-9.23	1.01e-17	3.31e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
COAD	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	9.23	1.03e-17	3.37e-14	0.64	0.5	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
COAD	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-9.23	1.04e-17	3.4e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-9.23	1.04e-17	3.4e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-9.23	1.04e-17	3.4e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-9.23	1.04e-17	3.4e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
COAD	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	9.23	1.04e-17	3.41e-14	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
COAD	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-9.23	1.05e-17	3.45e-14	-0.61	-0.5	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
COAD	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-9.23	1.06e-17	3.48e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
COAD	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-9.23	1.06e-17	3.48e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
COAD	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	9.23	1.07e-17	3.51e-14	0.64	0.5	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	9.23	1.07e-17	3.51e-14	0.64	0.5	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
COAD	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-9.22	1.09e-17	3.56e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-9.22	1.09e-17	3.56e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-9.22	1.09e-17	3.56e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
COAD	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-9.22	1.13e-17	3.69e-14	-0.59	-0.5	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
COAD	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.71e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
COAD	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.22	1.14e-17	3.72e-14	0.58	0.5	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
COAD	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	9.22	1.14e-17	3.72e-14	0.64	0.5	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.72e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.72e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-9.22	1.14e-17	3.72e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-9.22	1.14e-17	3.73e-14	-0.59	-0.5	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	9.22	1.15e-17	3.75e-14	0.57	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
COAD	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	9.21	1.18e-17	3.86e-14	0.6	0.5	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
COAD	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	9.21	1.19e-17	3.87e-14	0.58	0.5	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	9.21	1.2e-17	3.91e-14	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
COAD	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-9.21	1.21e-17	3.93e-14	-0.65	-0.5	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
COAD	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-9.21	1.22e-17	3.95e-14	-0.64	-0.5	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
COAD	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.21	1.23e-17	3.98e-14	0.59	0.5	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
COAD	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-9.21	1.23e-17	3.99e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-9.21	1.23e-17	3.99e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
COAD	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	9.2	1.24e-17	4.04e-14	0.64	0.5	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	9.2	1.24e-17	4.04e-14	0.64	0.5	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	9.2	1.24e-17	4.04e-14	0.64	0.5	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
COAD	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	9.2	1.25e-17	4.05e-14	0.65	0.5	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
COAD	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-9.2	1.27e-17	4.11e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-9.2	1.27e-17	4.13e-14	-0.59	-0.5	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-9.2	1.27e-17	4.13e-14	-0.59	-0.5	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-9.2	1.27e-17	4.13e-14	-0.59	-0.5	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
COAD	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-9.2	1.27e-17	4.13e-14	-0.67	-0.5	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
COAD	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-9.2	1.32e-17	4.27e-14	-0.65	-0.5	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-9.19	1.34e-17	4.32e-14	-0.6	-0.5	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
COAD	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-9.19	1.34e-17	4.32e-14	-0.53	-0.5	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
COAD	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	9.19	1.34e-17	4.33e-14	0.64	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	9.19	1.34e-17	4.33e-14	0.64	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
COAD	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-9.19	1.34e-17	4.33e-14	-0.58	-0.5	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	9.19	1.36e-17	4.37e-14	0.58	0.5	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	9.19	1.36e-17	4.37e-14	0.58	0.5	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
COAD	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-9.19	1.36e-17	4.39e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-9.19	1.36e-17	4.39e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
COAD	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-9.19	1.38e-17	4.43e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-9.19	1.38e-17	4.43e-14	-0.6	-0.5	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
COAD	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-9.19	1.38e-17	4.43e-14	-0.56	-0.5	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
COAD	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-9.19	1.38e-17	4.45e-14	-0.6	-0.5	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
COAD	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-9.19	1.38e-17	4.45e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-9.19	1.4e-17	4.48e-14	-0.6	-0.5	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
COAD	cis	rs7078219	0.524	rs1548963	ENSG00000257582.4	LINC01475	-9.19	1.4e-17	4.49e-14	-0.54	-0.5	Dental caries;	chr10:99529946	chr10:99526350~99531177:-
COAD	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
COAD	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-9.18	1.43e-17	4.59e-14	-0.6	-0.5	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
COAD	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	9.18	1.43e-17	4.59e-14	0.7	0.5	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
COAD	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	9.18	1.44e-17	4.6e-14	0.59	0.5	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
COAD	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	9.18	1.46e-17	4.67e-14	0.73	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
COAD	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	9.18	1.46e-17	4.69e-14	0.81	0.5	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	9.18	1.46e-17	4.69e-14	0.81	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
COAD	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-9.18	1.49e-17	4.76e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
COAD	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-9.18	1.51e-17	4.83e-14	-0.7	-0.5	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
COAD	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	9.17	1.53e-17	4.87e-14	0.59	0.5	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
COAD	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	9.17	1.55e-17	4.96e-14	0.53	0.5	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
COAD	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-9.17	1.56e-17	4.96e-14	-0.58	-0.5	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
COAD	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-9.17	1.56e-17	4.98e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
COAD	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-9.17	1.57e-17	5e-14	-0.6	-0.5	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
COAD	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-9.17	1.58e-17	5.04e-14	-0.59	-0.5	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
COAD	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	9.17	1.59e-17	5.08e-14	0.64	0.5	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
COAD	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	9.17	1.61e-17	5.12e-14	0.75	0.5	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-9.17	1.61e-17	5.14e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-9.17	1.61e-17	5.14e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
COAD	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-9.17	1.61e-17	5.14e-14	-0.64	-0.5	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-9.17	1.61e-17	5.14e-14	-0.64	-0.5	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-9.17	1.61e-17	5.14e-14	-0.64	-0.5	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
COAD	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	9.17	1.62e-17	5.14e-14	0.5	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
COAD	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-9.16	1.64e-17	5.2e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
COAD	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-9.16	1.64e-17	5.21e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-9.16	1.64e-17	5.21e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-9.16	1.64e-17	5.22e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
COAD	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	9.16	1.65e-17	5.22e-14	0.65	0.5	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
COAD	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.65e-17	5.23e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-9.16	1.66e-17	5.27e-14	-0.53	-0.5	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
COAD	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-9.16	1.67e-17	5.29e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
COAD	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	9.16	1.69e-17	5.35e-14	0.66	0.5	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
COAD	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	9.16	1.69e-17	5.35e-14	0.66	0.5	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-9.16	1.7e-17	5.37e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-9.16	1.7e-17	5.38e-14	-0.8	-0.5	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
COAD	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-9.16	1.71e-17	5.4e-14	-0.65	-0.5	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-9.16	1.71e-17	5.4e-14	-0.65	-0.5	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
COAD	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-9.16	1.71e-17	5.41e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-9.16	1.72e-17	5.43e-14	-0.6	-0.5	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
COAD	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-9.16	1.72e-17	5.44e-14	-0.55	-0.5	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-9.16	1.72e-17	5.44e-14	-0.52	-0.5	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
COAD	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-9.16	1.73e-17	5.47e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
COAD	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-9.16	1.74e-17	5.49e-14	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
COAD	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-9.16	1.74e-17	5.5e-14	-0.57	-0.5	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
COAD	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-9.15	1.79e-17	5.63e-14	-0.65	-0.5	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
COAD	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-9.15	1.81e-17	5.7e-14	-0.68	-0.5	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
COAD	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	9.15	1.83e-17	5.77e-14	0.59	0.5	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	9.15	1.84e-17	5.79e-14	0.58	0.5	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
COAD	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-9.15	1.86e-17	5.84e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
COAD	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-9.14	1.89e-17	5.93e-14	-0.66	-0.5	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
COAD	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	9.14	1.89e-17	5.93e-14	0.65	0.5	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
COAD	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-9.14	1.89e-17	5.94e-14	-0.59	-0.5	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	9.14	1.89e-17	5.94e-14	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
COAD	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	9.14	1.91e-17	5.99e-14	0.81	0.5	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
COAD	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-9.14	1.91e-17	6e-14	-0.59	-0.5	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
COAD	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-9.14	1.91e-17	6.01e-14	-0.46	-0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
COAD	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-9.14	1.92e-17	6.04e-14	-0.65	-0.5	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
COAD	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	9.14	1.93e-17	6.04e-14	0.52	0.5	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
COAD	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-9.14	1.93e-17	6.07e-14	-0.61	-0.5	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
COAD	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-9.14	1.94e-17	6.07e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
COAD	cis	rs7078219	0.505	rs6584282	ENSG00000257582.4	LINC01475	-9.14	1.94e-17	6.08e-14	-0.54	-0.5	Dental caries;	chr10:99526738	chr10:99526350~99531177:-
COAD	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-9.14	1.96e-17	6.13e-14	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-9.14	1.96e-17	6.14e-14	-0.59	-0.5	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
COAD	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	9.14	1.99e-17	6.23e-14	0.65	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	9.14	1.99e-17	6.23e-14	0.65	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
COAD	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-9.13	2.02e-17	6.31e-14	-0.58	-0.5	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
COAD	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-9.13	2.04e-17	6.38e-14	-0.66	-0.5	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
COAD	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	9.13	2.06e-17	6.42e-14	0.73	0.49	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
COAD	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-9.13	2.07e-17	6.44e-14	-0.59	-0.49	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-9.13	2.07e-17	6.44e-14	-0.59	-0.49	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-9.13	2.07e-17	6.44e-14	-0.59	-0.49	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-9.13	2.07e-17	6.44e-14	-0.59	-0.49	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
COAD	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	9.13	2.07e-17	6.45e-14	0.64	0.49	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	9.13	2.09e-17	6.5e-14	0.64	0.49	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs12539499	ENSG00000228775.6	WEE2-AS1	9.13	2.13e-17	6.64e-14	0.65	0.49	Bitter taste perception;	chr7:141930467	chr7:141704338~141738346:-
COAD	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-9.13	2.13e-17	6.64e-14	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
COAD	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	9.13	2.13e-17	6.64e-14	0.6	0.49	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
COAD	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-9.13	2.14e-17	6.66e-14	-0.66	-0.49	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	9.13	2.15e-17	6.68e-14	0.59	0.49	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
COAD	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	9.13	2.15e-17	6.69e-14	0.63	0.49	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
COAD	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-9.13	2.15e-17	6.7e-14	-0.61	-0.49	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-9.13	2.15e-17	6.7e-14	-0.61	-0.49	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-9.13	2.15e-17	6.7e-14	-0.61	-0.49	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-9.13	2.15e-17	6.7e-14	-0.61	-0.49	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
COAD	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-9.13	2.16e-17	6.71e-14	-0.66	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
COAD	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	9.13	2.16e-17	6.71e-14	0.61	0.49	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
COAD	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	9.12	2.19e-17	6.82e-14	0.63	0.49	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
COAD	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-9.12	2.2e-17	6.82e-14	-0.58	-0.49	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
COAD	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-9.12	2.27e-17	7.02e-14	-0.58	-0.49	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
COAD	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	9.12	2.27e-17	7.02e-14	0.75	0.49	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
COAD	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-9.12	2.29e-17	7.1e-14	-0.55	-0.49	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
COAD	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	9.12	2.31e-17	7.17e-14	0.56	0.49	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
COAD	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-9.11	2.32e-17	7.2e-14	-0.53	-0.49	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
COAD	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-9.11	2.32e-17	7.2e-14	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	9.11	2.4e-17	7.43e-14	0.69	0.49	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
COAD	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-9.11	2.41e-17	7.47e-14	-0.56	-0.49	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
COAD	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	9.1	2.56e-17	7.93e-14	0.5	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
COAD	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-9.1	2.57e-17	7.94e-14	-0.59	-0.49	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
COAD	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-9.1	2.59e-17	8e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-9.1	2.62e-17	8.1e-14	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-9.1	2.62e-17	8.1e-14	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-9.1	2.62e-17	8.1e-14	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
COAD	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-9.1	2.63e-17	8.12e-14	-0.53	-0.49	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-9.1	2.65e-17	8.18e-14	-0.62	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
COAD	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	9.09	2.67e-17	8.22e-14	0.67	0.49	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
COAD	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	9.09	2.67e-17	8.22e-14	0.61	0.49	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
COAD	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	9.09	2.68e-17	8.26e-14	0.63	0.49	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
COAD	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
COAD	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	9.09	2.69e-17	8.28e-14	0.59	0.49	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
COAD	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-9.09	2.81e-17	8.64e-14	-0.57	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
COAD	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-9.09	2.82e-17	8.67e-14	-0.53	-0.49	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
COAD	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-9.09	2.82e-17	8.67e-14	-0.58	-0.49	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
COAD	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
COAD	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-9.09	2.83e-17	8.69e-14	-0.59	-0.49	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
COAD	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-9.09	2.85e-17	8.74e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
COAD	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-9.08	2.88e-17	8.82e-14	-0.56	-0.49	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
COAD	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-9.08	2.89e-17	8.86e-14	-0.58	-0.49	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
COAD	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	9.08	2.95e-17	9.02e-14	0.64	0.49	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
COAD	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	9.08	2.95e-17	9.03e-14	0.57	0.49	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
COAD	cis	rs6584283	0.766	rs7911680	ENSG00000257582.4	LINC01475	-9.08	2.99e-17	9.13e-14	-0.55	-0.49	Ulcerative colitis;	chr10:99533711	chr10:99526350~99531177:-
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	9.08	2.99e-17	9.14e-14	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
COAD	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	9.08	3e-17	9.17e-14	0.63	0.49	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	9.08	3e-17	9.17e-14	0.63	0.49	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	9.08	3e-17	9.17e-14	0.63	0.49	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	9.08	3e-17	9.17e-14	0.63	0.49	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	9.08	3e-17	9.17e-14	0.63	0.49	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
COAD	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-9.08	3.02e-17	9.21e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
COAD	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-9.08	3.02e-17	9.21e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
COAD	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-9.08	3.02e-17	9.21e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-9.08	3.02e-17	9.22e-14	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
COAD	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-9.08	3.05e-17	9.29e-14	-0.65	-0.49	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-9.08	3.06e-17	9.33e-14	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-9.07	3.09e-17	9.43e-14	-0.59	-0.49	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-9.07	3.09e-17	9.43e-14	-0.59	-0.49	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-9.07	3.09e-17	9.43e-14	-0.59	-0.49	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-9.07	3.09e-17	9.43e-14	-0.59	-0.49	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-9.07	3.09e-17	9.43e-14	-0.59	-0.49	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-9.07	3.1e-17	9.46e-14	-0.59	-0.49	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
COAD	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.07	3.11e-17	9.47e-14	0.63	0.49	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
COAD	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	9.07	3.14e-17	9.58e-14	0.57	0.49	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
COAD	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-9.07	3.16e-17	9.62e-14	-0.65	-0.49	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
COAD	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	9.07	3.21e-17	9.77e-14	0.64	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-9.07	3.22e-17	9.81e-14	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-9.07	3.22e-17	9.81e-14	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-9.07	3.22e-17	9.81e-14	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
COAD	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	9.07	3.24e-17	9.86e-14	0.64	0.49	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
COAD	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	9.07	3.28e-17	9.97e-14	0.6	0.49	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
COAD	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	9.06	3.31e-17	1.01e-13	0.54	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
COAD	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	9.06	3.34e-17	1.01e-13	0.59	0.49	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-9.06	3.38e-17	1.02e-13	-0.59	-0.49	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	9.06	3.38e-17	1.02e-13	0.59	0.49	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
COAD	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	9.06	3.38e-17	1.02e-13	0.59	0.49	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
COAD	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-9.06	3.41e-17	1.03e-13	-0.65	-0.49	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
COAD	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	9.06	3.41e-17	1.03e-13	0.58	0.49	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
COAD	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	9.06	3.42e-17	1.04e-13	0.63	0.49	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	9.06	3.42e-17	1.04e-13	0.63	0.49	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
COAD	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	9.06	3.43e-17	1.04e-13	0.59	0.49	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
COAD	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-9.06	3.44e-17	1.04e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
COAD	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	9.06	3.44e-17	1.04e-13	0.45	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
COAD	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-9.06	3.51e-17	1.06e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-9.06	3.51e-17	1.06e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-9.06	3.51e-17	1.06e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-9.06	3.51e-17	1.06e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
COAD	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	9.06	3.51e-17	1.06e-13	0.61	0.49	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
COAD	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-9.05	3.52e-17	1.06e-13	-0.58	-0.49	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
COAD	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-9.05	3.52e-17	1.06e-13	-0.58	-0.49	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	9.05	3.59e-17	1.08e-13	0.64	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
COAD	cis	rs977987	0.806	rs11643209	ENSG00000261783.1	RP11-252K23.2	-9.05	3.62e-17	1.09e-13	-0.64	-0.49	Dupuytren's disease;	chr16:75297146	chr16:75379818~75381260:-
COAD	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-9.05	3.66e-17	1.1e-13	-0.48	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
COAD	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	9.05	3.67e-17	1.1e-13	0.57	0.49	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
COAD	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-9.05	3.68e-17	1.11e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
COAD	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-9.05	3.75e-17	1.13e-13	-0.57	-0.49	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
COAD	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-9.05	3.76e-17	1.13e-13	-0.65	-0.49	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
COAD	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	9.05	3.76e-17	1.13e-13	0.59	0.49	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	9.05	3.76e-17	1.13e-13	0.59	0.49	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	9.05	3.76e-17	1.13e-13	0.59	0.49	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	9.05	3.76e-17	1.13e-13	0.59	0.49	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	9.05	3.76e-17	1.13e-13	0.59	0.49	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	9.04	3.77e-17	1.13e-13	0.63	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
COAD	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-9.04	3.83e-17	1.15e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	9.04	3.87e-17	1.16e-13	0.65	0.49	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-9.04	3.88e-17	1.16e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
COAD	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.04	3.94e-17	1.18e-13	-0.53	-0.49	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
COAD	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	9.04	4e-17	1.2e-13	0.65	0.49	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
COAD	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-9.04	4e-17	1.2e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-9.04	4e-17	1.2e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-9.04	4e-17	1.2e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-9.04	4e-17	1.2e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-9.04	4e-17	1.2e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
COAD	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-9.04	4.01e-17	1.2e-13	-0.81	-0.49	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
COAD	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	9.04	4.02e-17	1.21e-13	0.72	0.49	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
COAD	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-9.03	4.19e-17	1.25e-13	-0.64	-0.49	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
COAD	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-9.03	4.21e-17	1.26e-13	-0.71	-0.49	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
COAD	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-9.03	4.28e-17	1.28e-13	-0.59	-0.49	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
COAD	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-9.03	4.3e-17	1.28e-13	-0.65	-0.49	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-9.03	4.3e-17	1.28e-13	-0.65	-0.49	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
COAD	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-9.02	4.34e-17	1.3e-13	-0.65	-0.49	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
COAD	cis	rs7078219	0.543	rs7092009	ENSG00000257582.4	LINC01475	-9.02	4.34e-17	1.3e-13	-0.54	-0.49	Dental caries;	chr10:99517482	chr10:99526350~99531177:-
COAD	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	9.02	4.4e-17	1.31e-13	0.6	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
COAD	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-9.02	4.41e-17	1.31e-13	-0.55	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
COAD	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-9.02	4.41e-17	1.32e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
COAD	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	9.02	4.42e-17	1.32e-13	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
COAD	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-9.02	4.44e-17	1.32e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
COAD	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-9.02	4.44e-17	1.32e-13	-0.53	-0.49	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
COAD	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	9.02	4.58e-17	1.36e-13	0.59	0.49	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	9.02	4.58e-17	1.36e-13	0.59	0.49	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
COAD	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	9.02	4.64e-17	1.38e-13	0.59	0.49	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	9.01	4.66e-17	1.38e-13	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
COAD	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-9.01	4.66e-17	1.38e-13	-0.58	-0.49	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
COAD	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	9.01	4.67e-17	1.38e-13	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
COAD	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-9.01	4.67e-17	1.38e-13	-0.55	-0.49	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
COAD	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-9.01	4.71e-17	1.4e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
COAD	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-9.01	4.85e-17	1.44e-13	-0.57	-0.49	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
COAD	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-9	5.05e-17	1.49e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
COAD	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-9	5.05e-17	1.49e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
COAD	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	9	5.08e-17	1.5e-13	0.59	0.49	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
COAD	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-9	5.09e-17	1.51e-13	-0.66	-0.49	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
COAD	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	9	5.16e-17	1.52e-13	0.57	0.49	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
COAD	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-9	5.22e-17	1.54e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-9	5.22e-17	1.54e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
COAD	cis	rs6584283	0.875	rs10748783	ENSG00000257582.4	LINC01475	-9	5.24e-17	1.55e-13	-0.53	-0.49	Ulcerative colitis;	chr10:99526115	chr10:99526350~99531177:-
COAD	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	8.99	5.35e-17	1.58e-13	0.63	0.49	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
COAD	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	8.99	5.47e-17	1.61e-13	0.64	0.49	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	8.99	5.47e-17	1.61e-13	0.64	0.49	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	8.99	5.47e-17	1.61e-13	0.64	0.49	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
COAD	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-8.99	5.5e-17	1.62e-13	-0.59	-0.49	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
COAD	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-8.99	5.56e-17	1.63e-13	-0.53	-0.49	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
COAD	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-8.99	5.63e-17	1.66e-13	-0.58	-0.49	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	8.99	5.66e-17	1.66e-13	0.69	0.49	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
COAD	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-8.99	5.71e-17	1.68e-13	-0.53	-0.49	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
COAD	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.98	5.77e-17	1.69e-13	-0.59	-0.49	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
COAD	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	8.98	5.84e-17	1.71e-13	0.63	0.49	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
COAD	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-8.98	5.92e-17	1.73e-13	-0.68	-0.49	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
COAD	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-8.98	5.96e-17	1.75e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
COAD	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	8.98	6.05e-17	1.77e-13	0.67	0.49	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
COAD	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	8.97	6.13e-17	1.8e-13	0.57	0.49	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
COAD	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-8.97	6.14e-17	1.8e-13	-0.63	-0.49	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-8.97	6.16e-17	1.8e-13	-0.58	-0.49	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-8.97	6.16e-17	1.8e-13	-0.58	-0.49	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-8.97	6.16e-17	1.8e-13	-0.58	-0.49	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-8.97	6.16e-17	1.8e-13	-0.58	-0.49	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
COAD	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	8.97	6.23e-17	1.82e-13	0.63	0.49	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
COAD	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	8.97	6.24e-17	1.82e-13	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
COAD	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-8.97	6.25e-17	1.83e-13	-0.52	-0.49	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
COAD	cis	rs7078219	0.505	rs4409764	ENSG00000257582.4	LINC01475	-8.97	6.34e-17	1.85e-13	-0.53	-0.49	Dental caries;	chr10:99524480	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs4129133	ENSG00000257582.4	LINC01475	-8.97	6.34e-17	1.85e-13	-0.53	-0.49	Dental caries;	chr10:99524813	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs4129132	ENSG00000257582.4	LINC01475	-8.97	6.34e-17	1.85e-13	-0.53	-0.49	Dental caries;	chr10:99524880	chr10:99526350~99531177:-
COAD	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-8.97	6.36e-17	1.86e-13	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
COAD	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-8.97	6.37e-17	1.86e-13	-0.58	-0.49	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
COAD	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-8.97	6.43e-17	1.87e-13	-0.59	-0.49	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-8.97	6.43e-17	1.87e-13	-0.59	-0.49	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
COAD	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8.97	6.46e-17	1.88e-13	-0.54	-0.49	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
COAD	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-8.97	6.5e-17	1.89e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-8.97	6.5e-17	1.89e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-8.97	6.5e-17	1.89e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-8.97	6.5e-17	1.89e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
COAD	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-8.96	6.81e-17	1.98e-13	-0.58	-0.49	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-8.96	6.81e-17	1.98e-13	-0.58	-0.49	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-8.96	6.81e-17	1.98e-13	-0.58	-0.49	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
COAD	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-8.96	6.84e-17	1.99e-13	-0.54	-0.49	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-8.96	6.84e-17	1.99e-13	-0.54	-0.49	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
COAD	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	8.96	7e-17	2.03e-13	0.57	0.49	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
COAD	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	8.96	7e-17	2.03e-13	0.59	0.49	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
COAD	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	8.96	7.02e-17	2.04e-13	0.59	0.49	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
COAD	cis	rs7078219	0.505	rs1548964	ENSG00000257582.4	LINC01475	8.95	7.12e-17	2.06e-13	0.52	0.49	Dental caries;	chr10:99529896	chr10:99526350~99531177:-
COAD	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	8.95	7.14e-17	2.07e-13	0.69	0.49	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
COAD	cis	rs7078219	0.524	rs6584277	ENSG00000257582.4	LINC01475	-8.95	7.18e-17	2.08e-13	-0.54	-0.49	Dental caries;	chr10:99518298	chr10:99526350~99531177:-
COAD	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-8.95	7.28e-17	2.11e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
COAD	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	8.95	7.29e-17	2.11e-13	0.65	0.49	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
COAD	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-8.95	7.31e-17	2.11e-13	-0.58	-0.49	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-8.95	7.31e-17	2.11e-13	-0.58	-0.49	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-8.95	7.31e-17	2.11e-13	-0.58	-0.49	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-8.95	7.31e-17	2.11e-13	-0.58	-0.49	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
COAD	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-8.95	7.34e-17	2.12e-13	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
COAD	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-8.95	7.35e-17	2.12e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
COAD	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	8.95	7.47e-17	2.16e-13	0.62	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
COAD	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-8.95	7.47e-17	2.16e-13	-0.58	-0.49	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-8.95	7.47e-17	2.16e-13	-0.58	-0.49	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-8.95	7.48e-17	2.16e-13	-0.58	-0.49	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
COAD	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-8.94	7.67e-17	2.21e-13	-0.58	-0.49	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-8.94	7.68e-17	2.22e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-8.94	7.69e-17	2.22e-13	-0.66	-0.49	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
COAD	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-8.94	7.72e-17	2.23e-13	-0.58	-0.49	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
COAD	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	8.94	7.8e-17	2.25e-13	0.74	0.49	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
COAD	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-8.94	7.89e-17	2.27e-13	-0.57	-0.49	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-8.93	8.19e-17	2.36e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-8.93	8.21e-17	2.36e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-8.93	8.21e-17	2.36e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-8.93	8.3e-17	2.39e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	8.93	8.54e-17	2.45e-13	0.53	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
COAD	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-8.93	8.57e-17	2.46e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-8.92	8.78e-17	2.52e-13	-0.65	-0.49	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
COAD	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-8.92	8.83e-17	2.53e-13	-0.57	-0.49	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-8.92	8.83e-17	2.53e-13	-0.57	-0.49	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
COAD	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-8.92	8.84e-17	2.53e-13	-0.54	-0.49	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
COAD	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-8.92	8.88e-17	2.55e-13	-0.58	-0.49	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
COAD	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-8.92	9.17e-17	2.62e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-8.92	9.17e-17	2.62e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-8.92	9.17e-17	2.62e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	8.92	9.26e-17	2.65e-13	0.51	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
COAD	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	8.91	9.29e-17	2.66e-13	0.62	0.49	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
COAD	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-8.91	9.32e-17	2.67e-13	-0.57	-0.49	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
COAD	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-8.91	9.43e-17	2.7e-13	-0.64	-0.49	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
COAD	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-8.91	9.5e-17	2.71e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
COAD	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	8.91	9.54e-17	2.73e-13	0.57	0.49	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
COAD	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-8.91	9.59e-17	2.74e-13	-0.59	-0.49	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
COAD	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	8.91	9.6e-17	2.74e-13	0.51	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
COAD	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-8.91	9.61e-17	2.74e-13	-0.58	-0.49	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
COAD	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-8.91	9.67e-17	2.76e-13	-0.67	-0.49	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
COAD	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	8.91	9.83e-17	2.8e-13	0.59	0.49	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
COAD	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-8.91	9.86e-17	2.81e-13	-0.64	-0.49	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
COAD	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	8.91	9.86e-17	2.81e-13	0.69	0.49	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
COAD	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-8.9	1.05e-16	2.98e-13	-0.58	-0.49	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
COAD	cis	rs10246939	0.543	rs7786202	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141906099	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs7802271	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141909624	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.52	rs7782886	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141909958	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs994808	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141911091	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs7808421	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141911592	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs7789123	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141911699	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs11767119	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141912316	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs11769089	ENSG00000228775.6	WEE2-AS1	8.9	1.05e-16	2.99e-13	0.64	0.49	Bitter taste perception;	chr7:141914310	chr7:141704338~141738346:-
COAD	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-8.9	1.06e-16	3e-13	-0.62	-0.49	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
COAD	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-8.89	1.07e-16	3.03e-13	-0.52	-0.49	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
COAD	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-8.89	1.08e-16	3.07e-13	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-8.89	1.11e-16	3.14e-13	-0.62	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
COAD	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	8.89	1.11e-16	3.15e-13	0.63	0.48	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
COAD	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-8.89	1.12e-16	3.16e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
COAD	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-8.89	1.12e-16	3.18e-13	-0.57	-0.48	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
COAD	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.89	1.13e-16	3.21e-13	0.58	0.48	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
COAD	cis	rs7078219	0.543	rs10786557	ENSG00000257582.4	LINC01475	-8.88	1.14e-16	3.24e-13	-0.52	-0.48	Dental caries;	chr10:99523571	chr10:99526350~99531177:-
COAD	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-8.88	1.14e-16	3.24e-13	-0.58	-0.48	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
COAD	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	8.88	1.16e-16	3.28e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
COAD	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-8.88	1.16e-16	3.29e-13	-0.54	-0.48	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
COAD	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	8.88	1.2e-16	3.38e-13	0.58	0.48	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
COAD	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
COAD	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-8.87	1.22e-16	3.45e-13	-0.58	-0.48	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
COAD	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-8.87	1.22e-16	3.45e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-8.87	1.23e-16	3.47e-13	-0.58	-0.48	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-8.87	1.23e-16	3.47e-13	-0.58	-0.48	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
COAD	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-8.87	1.24e-16	3.49e-13	-0.57	-0.48	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
COAD	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-8.87	1.25e-16	3.52e-13	-0.54	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
COAD	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-8.87	1.3e-16	3.66e-13	-0.57	-0.48	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	8.86	1.35e-16	3.79e-13	0.57	0.48	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	8.86	1.35e-16	3.79e-13	0.57	0.48	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	8.86	1.35e-16	3.79e-13	0.57	0.48	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	8.86	1.35e-16	3.79e-13	0.57	0.48	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	8.86	1.35e-16	3.79e-13	0.57	0.48	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
COAD	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-8.86	1.39e-16	3.9e-13	-0.58	-0.48	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
COAD	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	8.85	1.4e-16	3.93e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
COAD	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-8.85	1.45e-16	4.05e-13	-0.56	-0.48	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
COAD	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	8.85	1.45e-16	4.05e-13	0.65	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
COAD	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-8.85	1.45e-16	4.05e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-8.85	1.45e-16	4.05e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-8.85	1.45e-16	4.05e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-8.85	1.45e-16	4.05e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-8.85	1.45e-16	4.05e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
COAD	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-8.85	1.48e-16	4.14e-13	-0.52	-0.48	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-8.85	1.48e-16	4.14e-13	-0.52	-0.48	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
COAD	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-8.85	1.48e-16	4.14e-13	-0.57	-0.48	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
COAD	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-8.84	1.52e-16	4.24e-13	-0.51	-0.48	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
COAD	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	8.84	1.53e-16	4.28e-13	0.65	0.48	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	8.84	1.54e-16	4.29e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	8.84	1.54e-16	4.29e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	8.84	1.54e-16	4.29e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	8.84	1.54e-16	4.29e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
COAD	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-8.84	1.54e-16	4.3e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-8.84	1.54e-16	4.3e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-8.84	1.54e-16	4.3e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
COAD	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	8.84	1.55e-16	4.31e-13	0.58	0.48	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
COAD	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-8.84	1.55e-16	4.32e-13	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
COAD	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	8.84	1.56e-16	4.35e-13	0.64	0.48	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
COAD	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	8.84	1.58e-16	4.39e-13	0.56	0.48	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
COAD	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
COAD	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.39e-13	0.58	0.48	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.4e-13	0.57	0.48	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	8.84	1.58e-16	4.4e-13	0.57	0.48	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
COAD	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.84	1.61e-16	4.47e-13	-0.52	-0.48	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.84	1.61e-16	4.47e-13	-0.52	-0.48	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.84	1.61e-16	4.47e-13	-0.52	-0.48	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
COAD	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-8.83	1.63e-16	4.53e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-8.83	1.63e-16	4.53e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
COAD	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-8.83	1.66e-16	4.62e-13	-0.64	-0.48	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
COAD	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-8.83	1.67e-16	4.64e-13	-0.55	-0.48	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
COAD	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-8.83	1.68e-16	4.67e-13	-0.66	-0.48	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
COAD	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	8.83	1.69e-16	4.68e-13	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-8.83	1.69e-16	4.68e-13	-0.54	-0.48	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
COAD	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-8.83	1.7e-16	4.72e-13	-0.58	-0.48	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-8.83	1.7e-16	4.72e-13	-0.58	-0.48	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
COAD	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8.83	1.71e-16	4.75e-13	0.63	0.48	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-8.83	1.71e-16	4.75e-13	-0.63	-0.48	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-8.83	1.71e-16	4.75e-13	-0.63	-0.48	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
COAD	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	8.83	1.72e-16	4.76e-13	0.57	0.48	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	8.83	1.72e-16	4.76e-13	0.57	0.48	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-8.82	1.73e-16	4.79e-13	-0.64	-0.48	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
COAD	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	8.82	1.75e-16	4.86e-13	0.62	0.48	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	8.82	1.75e-16	4.86e-13	0.62	0.48	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	8.82	1.75e-16	4.86e-13	0.62	0.48	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
COAD	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-8.82	1.77e-16	4.91e-13	-0.57	-0.48	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
COAD	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-8.82	1.8e-16	4.97e-13	-0.53	-0.48	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
COAD	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-8.82	1.81e-16	4.99e-13	-0.66	-0.48	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
COAD	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-8.81	1.85e-16	5.1e-13	-0.5	-0.48	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
COAD	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.81	1.87e-16	5.15e-13	-0.59	-0.48	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
COAD	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-8.81	1.89e-16	5.22e-13	-0.56	-0.48	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
COAD	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	8.81	1.89e-16	5.22e-13	0.69	0.48	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
COAD	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-8.81	1.91e-16	5.26e-13	-0.66	-0.48	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
COAD	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-8.81	1.93e-16	5.31e-13	-0.63	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
COAD	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	8.81	1.93e-16	5.33e-13	0.55	0.48	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
COAD	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
COAD	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
COAD	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
COAD	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-8.81	1.94e-16	5.33e-13	-0.53	-0.48	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
COAD	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-8.81	1.97e-16	5.41e-13	-0.5	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
COAD	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	8.8	1.98e-16	5.44e-13	0.56	0.48	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
COAD	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	8.8	2.01e-16	5.52e-13	0.62	0.48	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
COAD	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	8.8	2.01e-16	5.52e-13	0.62	0.48	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
COAD	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-8.8	2.02e-16	5.54e-13	-0.52	-0.48	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
COAD	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	8.8	2.03e-16	5.57e-13	0.57	0.48	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
COAD	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-8.8	2.07e-16	5.66e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-8.8	2.07e-16	5.66e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
COAD	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	8.8	2.09e-16	5.72e-13	0.65	0.48	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
COAD	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-8.8	2.11e-16	5.77e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
COAD	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-8.79	2.12e-16	5.79e-13	-0.65	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
COAD	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	8.79	2.13e-16	5.8e-13	0.6	0.48	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
COAD	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-8.79	2.14e-16	5.83e-13	-0.56	-0.48	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-8.79	2.14e-16	5.83e-13	-0.56	-0.48	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
COAD	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-8.79	2.16e-16	5.88e-13	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
COAD	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-8.79	2.25e-16	6.13e-13	-0.52	-0.48	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
COAD	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-8.78	2.34e-16	6.38e-13	-0.52	-0.48	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
COAD	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-8.78	2.35e-16	6.38e-13	-0.51	-0.48	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
COAD	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	8.78	2.35e-16	6.38e-13	0.57	0.48	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	8.78	2.35e-16	6.38e-13	0.57	0.48	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	8.78	2.36e-16	6.43e-13	0.6	0.48	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	8.78	2.42e-16	6.56e-13	0.63	0.48	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
COAD	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-8.78	2.42e-16	6.58e-13	-0.54	-0.48	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
COAD	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	8.77	2.45e-16	6.64e-13	0.63	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
COAD	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-8.77	2.47e-16	6.71e-13	-0.66	-0.48	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	8.77	2.48e-16	6.73e-13	0.62	0.48	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	8.77	2.5e-16	6.79e-13	0.64	0.48	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
COAD	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-8.77	2.56e-16	6.95e-13	-0.52	-0.48	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
COAD	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	8.77	2.58e-16	6.98e-13	0.57	0.48	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.77	2.58e-16	6.98e-13	-0.53	-0.48	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
COAD	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-8.77	2.58e-16	6.99e-13	-0.6	-0.48	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
COAD	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	8.76	2.64e-16	7.14e-13	0.74	0.48	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
COAD	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-8.76	2.67e-16	7.22e-13	-0.51	-0.48	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
COAD	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	8.76	2.69e-16	7.26e-13	0.63	0.48	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
COAD	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-8.76	2.72e-16	7.34e-13	-0.57	-0.48	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-8.76	2.72e-16	7.34e-13	-0.57	-0.48	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
COAD	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-8.75	2.83e-16	7.63e-13	-0.58	-0.48	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
COAD	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	8.75	2.87e-16	7.72e-13	0.71	0.48	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
COAD	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-8.75	2.9e-16	7.8e-13	-0.58	-0.48	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-8.75	2.9e-16	7.8e-13	-0.58	-0.48	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
COAD	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-8.75	2.94e-16	7.9e-13	-0.57	-0.48	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
COAD	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.75	2.94e-16	7.9e-13	-0.58	-0.48	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
COAD	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	8.75	2.95e-16	7.93e-13	0.62	0.48	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
COAD	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	8.75	2.96e-16	7.97e-13	0.5	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
COAD	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-8.74	3.07e-16	8.26e-13	-0.51	-0.48	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.74	3.09e-16	8.3e-13	-0.54	-0.48	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.74	3.09e-16	8.3e-13	-0.54	-0.48	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
COAD	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-8.74	3.09e-16	8.31e-13	-0.64	-0.48	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
COAD	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-8.74	3.15e-16	8.45e-13	-0.53	-0.48	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
COAD	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-8.74	3.15e-16	8.45e-13	-0.51	-0.48	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
COAD	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	8.74	3.16e-16	8.47e-13	0.68	0.48	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
COAD	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	8.73	3.2e-16	8.59e-13	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	8.73	3.2e-16	8.59e-13	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	8.73	3.2e-16	8.59e-13	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
COAD	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	8.73	3.21e-16	8.6e-13	0.56	0.48	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	8.73	3.21e-16	8.6e-13	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
COAD	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-8.73	3.23e-16	8.66e-13	-0.64	-0.48	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
COAD	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	8.73	3.26e-16	8.75e-13	0.64	0.48	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
COAD	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-8.73	3.27e-16	8.77e-13	-0.57	-0.48	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-8.73	3.31e-16	8.87e-13	-0.53	-0.48	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	8.73	3.33e-16	8.91e-13	0.68	0.48	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
COAD	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	8.73	3.37e-16	9.01e-13	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
COAD	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-8.72	3.43e-16	9.18e-13	-0.53	-0.48	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
COAD	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-8.72	3.44e-16	9.18e-13	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
COAD	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-8.72	3.44e-16	9.2e-13	-0.64	-0.48	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
COAD	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-8.72	3.45e-16	9.23e-13	-0.56	-0.48	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	8.72	3.49e-16	9.33e-13	0.65	0.48	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
COAD	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	8.72	3.52e-16	9.4e-13	0.66	0.48	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
COAD	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-8.72	3.54e-16	9.45e-13	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
COAD	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	8.72	3.6e-16	9.6e-13	0.58	0.48	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
COAD	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	8.71	3.72e-16	9.9e-13	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
COAD	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-8.71	3.75e-16	9.98e-13	-0.53	-0.48	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-8.71	3.77e-16	1e-12	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-8.71	3.77e-16	1e-12	-0.64	-0.48	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-8.71	3.78e-16	1.01e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
COAD	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-8.71	3.79e-16	1.01e-12	-0.56	-0.48	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
COAD	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-8.71	3.79e-16	1.01e-12	-0.54	-0.48	Temperament;	chr17:14075460	chr17:14024514~14025488:+
COAD	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	8.71	3.79e-16	1.01e-12	0.57	0.48	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-8.71	3.82e-16	1.01e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
COAD	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	8.71	3.83e-16	1.02e-12	0.63	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
COAD	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-8.71	3.84e-16	1.02e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
COAD	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-8.71	3.85e-16	1.02e-12	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
COAD	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-8.7	3.95e-16	1.04e-12	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-8.7	3.95e-16	1.04e-12	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	8.7	3.96e-16	1.05e-12	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	8.7	4.07e-16	1.07e-12	0.63	0.48	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-8.7	4.1e-16	1.08e-12	-0.54	-0.48	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
COAD	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8.7	4.11e-16	1.08e-12	-0.57	-0.48	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
COAD	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-8.7	4.17e-16	1.1e-12	-0.62	-0.48	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
COAD	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-8.7	4.17e-16	1.1e-12	-0.62	-0.48	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
COAD	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	8.69	4.22e-16	1.11e-12	0.57	0.48	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-8.69	4.35e-16	1.14e-12	-0.56	-0.48	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-8.69	4.38e-16	1.15e-12	-0.49	-0.48	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-8.69	4.43e-16	1.16e-12	-0.54	-0.48	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
COAD	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-8.69	4.44e-16	1.17e-12	-0.59	-0.48	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
COAD	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	8.69	4.46e-16	1.17e-12	0.55	0.48	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
COAD	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	8.68	4.48e-16	1.18e-12	0.59	0.48	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
COAD	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	8.68	4.58e-16	1.2e-12	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-8.68	4.61e-16	1.21e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
COAD	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
COAD	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
COAD	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
COAD	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	8.68	4.61e-16	1.21e-12	0.57	0.48	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
COAD	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-8.68	4.63e-16	1.21e-12	-0.52	-0.48	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
COAD	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-8.68	4.66e-16	1.22e-12	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
COAD	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	8.68	4.66e-16	1.22e-12	0.51	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-8.68	4.67e-16	1.22e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
COAD	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-8.68	4.73e-16	1.24e-12	-0.52	-0.48	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-8.68	4.73e-16	1.24e-12	-0.52	-0.48	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
COAD	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-8.68	4.76e-16	1.25e-12	-0.58	-0.48	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
COAD	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	8.67	4.81e-16	1.26e-12	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
COAD	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	8.67	4.81e-16	1.26e-12	0.6	0.48	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
COAD	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-8.67	4.85e-16	1.27e-12	-0.6	-0.48	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
COAD	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	8.67	4.86e-16	1.27e-12	0.62	0.48	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	8.67	4.88e-16	1.27e-12	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	8.67	4.88e-16	1.27e-12	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
COAD	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	8.67	4.88e-16	1.27e-12	0.61	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
COAD	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-8.67	4.9e-16	1.28e-12	-0.52	-0.48	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
COAD	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	8.67	4.9e-16	1.28e-12	0.64	0.48	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-8.67	5.05e-16	1.32e-12	-0.52	-0.48	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.67	5.07e-16	1.32e-12	-0.52	-0.48	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
COAD	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-8.67	5.12e-16	1.33e-12	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
COAD	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-8.66	5.26e-16	1.37e-12	-0.55	-0.48	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
COAD	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	8.66	5.32e-16	1.38e-12	0.56	0.48	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	8.66	5.32e-16	1.38e-12	0.56	0.48	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-8.66	5.32e-16	1.38e-12	-0.56	-0.48	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-8.66	5.32e-16	1.38e-12	-0.56	-0.48	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-8.66	5.32e-16	1.38e-12	-0.56	-0.48	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-8.66	5.32e-16	1.38e-12	-0.56	-0.48	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
COAD	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-8.66	5.32e-16	1.38e-12	-0.56	-0.48	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
COAD	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-8.66	5.35e-16	1.39e-12	-0.57	-0.48	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
COAD	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-8.66	5.35e-16	1.39e-12	-0.56	-0.48	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
COAD	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-8.66	5.38e-16	1.4e-12	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
COAD	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	8.66	5.47e-16	1.42e-12	0.57	0.48	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-8.65	5.5e-16	1.43e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-8.65	5.5e-16	1.43e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-8.65	5.5e-16	1.43e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-8.65	5.5e-16	1.43e-12	-0.53	-0.48	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.65	5.56e-16	1.44e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
COAD	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	8.65	5.61e-16	1.45e-12	0.68	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
COAD	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	8.65	5.64e-16	1.45e-12	0.67	0.47	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
COAD	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-8.65	5.68e-16	1.46e-12	-0.58	-0.47	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
COAD	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-8.65	5.73e-16	1.47e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	8.65	5.75e-16	1.48e-12	0.63	0.47	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
COAD	cis	rs7078219	0.505	rs10883365	ENSG00000257582.4	LINC01475	-8.65	5.77e-16	1.48e-12	-0.51	-0.47	Dental caries;	chr10:99528007	chr10:99526350~99531177:-
COAD	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	8.65	5.77e-16	1.48e-12	0.63	0.47	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
COAD	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-8.65	5.83e-16	1.5e-12	-0.52	-0.47	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-8.65	5.83e-16	1.5e-12	-0.52	-0.47	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
COAD	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-8.65	5.83e-16	1.5e-12	-0.52	-0.47	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
COAD	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-8.65	5.85e-16	1.5e-12	-0.52	-0.47	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
COAD	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-8.65	5.87e-16	1.51e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
COAD	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	8.64	5.9e-16	1.51e-12	0.57	0.47	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-8.64	5.96e-16	1.53e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
COAD	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-8.64	5.97e-16	1.53e-12	-0.56	-0.47	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-8.64	5.97e-16	1.53e-12	-0.56	-0.47	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	8.64	5.98e-16	1.53e-12	0.51	0.47	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
COAD	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-8.64	6.06e-16	1.55e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
COAD	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	8.64	6.11e-16	1.56e-12	0.78	0.47	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	8.64	6.11e-16	1.56e-12	0.78	0.47	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-8.64	6.13e-16	1.57e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-8.64	6.13e-16	1.57e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-8.64	6.13e-16	1.57e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-8.64	6.17e-16	1.58e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
COAD	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	8.63	6.3e-16	1.61e-12	0.58	0.47	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
COAD	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	8.63	6.34e-16	1.62e-12	0.56	0.47	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-8.63	6.41e-16	1.63e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-8.63	6.41e-16	1.63e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.63	6.41e-16	1.63e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
COAD	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-8.63	6.48e-16	1.65e-12	-0.58	-0.47	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
COAD	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-8.63	6.5e-16	1.65e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.63	6.52e-16	1.66e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
COAD	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	8.63	6.53e-16	1.66e-12	0.57	0.47	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
COAD	cis	rs7078219	0.543	rs4919342	ENSG00000257582.4	LINC01475	-8.63	6.53e-16	1.66e-12	-0.52	-0.47	Dental caries;	chr10:99522796	chr10:99526350~99531177:-
COAD	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.63	6.56e-16	1.67e-12	-0.54	-0.47	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
COAD	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-8.63	6.59e-16	1.67e-12	-0.65	-0.47	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
COAD	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-8.63	6.63e-16	1.68e-12	-0.67	-0.47	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
COAD	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-8.63	6.71e-16	1.7e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-8.62	6.75e-16	1.71e-12	-0.5	-0.47	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	8.62	6.78e-16	1.72e-12	0.63	0.47	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
COAD	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-8.62	6.8e-16	1.73e-12	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
COAD	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	8.62	6.81e-16	1.73e-12	0.63	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
COAD	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	8.62	6.83e-16	1.73e-12	0.62	0.47	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
COAD	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-8.62	6.86e-16	1.74e-12	-0.53	-0.47	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
COAD	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-8.62	6.98e-16	1.77e-12	-0.58	-0.47	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-8.62	6.98e-16	1.77e-12	-0.58	-0.47	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
COAD	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	8.62	7.19e-16	1.82e-12	0.82	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
COAD	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	8.62	7.19e-16	1.82e-12	0.59	0.47	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
COAD	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-8.61	7.23e-16	1.83e-12	-0.6	-0.47	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
COAD	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-8.61	7.23e-16	1.83e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
COAD	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	8.61	7.25e-16	1.83e-12	0.55	0.47	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
COAD	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	8.61	7.29e-16	1.84e-12	0.74	0.47	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
COAD	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8.61	7.3e-16	1.84e-12	0.55	0.47	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
COAD	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-8.61	7.4e-16	1.87e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
COAD	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	8.61	7.58e-16	1.9e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
COAD	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	8.61	7.65e-16	1.92e-12	0.56	0.47	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	8.61	7.65e-16	1.92e-12	0.56	0.47	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	8.61	7.65e-16	1.92e-12	0.56	0.47	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
COAD	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-8.6	7.77e-16	1.95e-12	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
COAD	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-8.6	7.83e-16	1.97e-12	-0.64	-0.47	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
COAD	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	8.6	7.85e-16	1.97e-12	0.63	0.47	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	8.6	7.85e-16	1.97e-12	0.63	0.47	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	8.6	7.85e-16	1.97e-12	0.63	0.47	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	8.6	7.85e-16	1.97e-12	0.63	0.47	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	8.6	7.85e-16	1.97e-12	0.63	0.47	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
COAD	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	8.6	8.05e-16	2.02e-12	0.55	0.47	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
COAD	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-8.6	8.14e-16	2.04e-12	-0.62	-0.47	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-8.6	8.18e-16	2.05e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
COAD	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-8.6	8.23e-16	2.06e-12	-0.61	-0.47	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
COAD	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	8.59	8.33e-16	2.08e-12	0.57	0.47	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
COAD	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-8.59	8.43e-16	2.11e-12	-0.57	-0.47	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
COAD	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	8.59	8.57e-16	2.14e-12	0.71	0.47	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
COAD	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-8.59	8.63e-16	2.15e-12	-0.55	-0.47	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
COAD	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	8.59	8.65e-16	2.16e-12	0.57	0.47	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	8.59	8.71e-16	2.17e-12	0.63	0.47	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	8.59	8.75e-16	2.18e-12	0.48	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
COAD	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	8.58	8.89e-16	2.22e-12	0.58	0.47	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
COAD	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-8.58	8.89e-16	2.22e-12	-0.8	-0.47	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
COAD	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-8.58	9.16e-16	2.28e-12	-0.68	-0.47	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
COAD	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-8.58	9.19e-16	2.29e-12	-0.62	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
COAD	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	8.58	9.29e-16	2.31e-12	0.48	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	8.58	9.29e-16	2.31e-12	0.48	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.58	9.34e-16	2.32e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.57	9.45e-16	2.34e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
COAD	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	8.57	9.5e-16	2.35e-12	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
COAD	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	8.57	9.56e-16	2.37e-12	0.53	0.47	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
COAD	cis	rs7078219	0.505	rs10883372	ENSG00000257582.4	LINC01475	-8.57	9.81e-16	2.43e-12	-0.51	-0.47	Dental caries;	chr10:99532726	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs10883373	ENSG00000257582.4	LINC01475	-8.57	9.81e-16	2.43e-12	-0.51	-0.47	Dental caries;	chr10:99532727	chr10:99526350~99531177:-
COAD	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	8.57	9.84e-16	2.43e-12	0.69	0.47	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
COAD	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	8.57	9.88e-16	2.44e-12	0.66	0.47	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
COAD	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-8.57	9.91e-16	2.45e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-8.57	9.91e-16	2.45e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
COAD	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-8.57	1e-15	2.47e-12	-0.51	-0.47	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-8.57	1e-15	2.48e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
COAD	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-8.57	1e-15	2.48e-12	-0.58	-0.47	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
COAD	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-8.57	1.01e-15	2.49e-12	-0.55	-0.47	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
COAD	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	8.56	1.02e-15	2.52e-12	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	8.56	1.03e-15	2.55e-12	0.67	0.47	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-8.56	1.04e-15	2.57e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-8.56	1.04e-15	2.57e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
COAD	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-8.56	1.05e-15	2.6e-12	-0.62	-0.47	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
COAD	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	8.56	1.06e-15	2.62e-12	0.72	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
COAD	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	8.56	1.07e-15	2.63e-12	0.66	0.47	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-8.56	1.07e-15	2.64e-12	-0.54	-0.47	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
COAD	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-8.56	1.07e-15	2.64e-12	-0.55	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
COAD	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-8.55	1.09e-15	2.69e-12	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
COAD	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-8.55	1.09e-15	2.69e-12	-0.66	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
COAD	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	8.55	1.1e-15	2.71e-12	0.6	0.47	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
COAD	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-8.55	1.11e-15	2.72e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-8.55	1.11e-15	2.72e-12	-0.65	-0.47	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-8.55	1.11e-15	2.73e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
COAD	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	8.55	1.11e-15	2.73e-12	0.57	0.47	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
COAD	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-8.55	1.12e-15	2.74e-12	-0.57	-0.47	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
COAD	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-8.55	1.12e-15	2.74e-12	-0.57	-0.47	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
COAD	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-8.55	1.12e-15	2.76e-12	-0.52	-0.47	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
COAD	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-8.55	1.13e-15	2.78e-12	-0.58	-0.47	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
COAD	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	8.55	1.14e-15	2.79e-12	0.66	0.47	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-8.55	1.14e-15	2.79e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
COAD	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-8.55	1.14e-15	2.79e-12	-0.5	-0.47	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
COAD	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-8.55	1.14e-15	2.79e-12	-0.5	-0.47	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
COAD	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	8.55	1.15e-15	2.82e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	8.55	1.15e-15	2.82e-12	0.67	0.47	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
COAD	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	8.54	1.16e-15	2.84e-12	0.56	0.47	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-8.54	1.16e-15	2.84e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
COAD	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	8.54	1.17e-15	2.86e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	8.54	1.17e-15	2.86e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-8.54	1.17e-15	2.87e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
COAD	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	8.54	1.19e-15	2.9e-12	0.82	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
COAD	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	8.54	1.19e-15	2.92e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
COAD	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	8.54	1.2e-15	2.94e-12	0.58	0.47	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
COAD	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	8.54	1.2e-15	2.94e-12	0.78	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-8.54	1.22e-15	2.98e-12	-0.78	-0.47	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	8.53	1.24e-15	3.01e-12	0.67	0.47	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
COAD	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-8.53	1.25e-15	3.03e-12	-0.57	-0.47	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-8.53	1.25e-15	3.04e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
COAD	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	8.53	1.26e-15	3.06e-12	0.59	0.47	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
COAD	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	8.53	1.27e-15	3.07e-12	0.59	0.47	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
COAD	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-8.53	1.27e-15	3.08e-12	-0.58	-0.47	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
COAD	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	8.53	1.29e-15	3.13e-12	0.52	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
COAD	cis	rs10885997	0.626	rs2301179	ENSG00000266200.5	PNLIPRP2	-8.53	1.3e-15	3.13e-12	-0.53	-0.47	Phospholipid levels (plasma);	chr10:116645109	chr10:116620953~116645143:+
COAD	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-8.53	1.3e-15	3.13e-12	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
COAD	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-8.52	1.35e-15	3.27e-12	-0.5	-0.47	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
COAD	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	8.52	1.35e-15	3.27e-12	0.5	0.47	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
COAD	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	8.52	1.36e-15	3.28e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
COAD	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-8.52	1.37e-15	3.31e-12	-0.81	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-8.52	1.37e-15	3.31e-12	-0.81	-0.47	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
COAD	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	8.52	1.38e-15	3.33e-12	0.75	0.47	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
COAD	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	8.52	1.38e-15	3.33e-12	0.63	0.47	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
COAD	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	8.52	1.38e-15	3.34e-12	0.55	0.47	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
COAD	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-8.52	1.39e-15	3.35e-12	-0.5	-0.47	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
COAD	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-8.52	1.4e-15	3.39e-12	-0.55	-0.47	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
COAD	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-8.52	1.41e-15	3.4e-12	-0.62	-0.47	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
COAD	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-8.52	1.41e-15	3.4e-12	-0.58	-0.47	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
COAD	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-8.52	1.41e-15	3.4e-12	-0.61	-0.47	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
COAD	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	8.52	1.41e-15	3.41e-12	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-8.51	1.45e-15	3.5e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
COAD	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	8.51	1.46e-15	3.52e-12	0.63	0.47	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-8.51	1.47e-15	3.53e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	8.51	1.48e-15	3.57e-12	0.58	0.47	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	8.51	1.5e-15	3.6e-12	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
COAD	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	8.51	1.51e-15	3.64e-12	0.5	0.47	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
COAD	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-8.5	1.52e-15	3.66e-12	-0.57	-0.47	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
COAD	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	8.5	1.54e-15	3.7e-12	0.63	0.47	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	8.5	1.54e-15	3.7e-12	0.63	0.47	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	8.5	1.54e-15	3.7e-12	0.63	0.47	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-8.5	1.54e-15	3.71e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-8.5	1.56e-15	3.75e-12	-0.49	-0.47	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
COAD	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	8.5	1.57e-15	3.77e-12	0.64	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
COAD	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-8.5	1.59e-15	3.81e-12	-0.56	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
COAD	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-8.5	1.59e-15	3.81e-12	-0.56	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	8.5	1.59e-15	3.83e-12	0.62	0.47	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
COAD	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	8.5	1.6e-15	3.84e-12	0.56	0.47	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
COAD	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	8.49	1.63e-15	3.9e-12	0.63	0.47	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	8.49	1.63e-15	3.9e-12	0.63	0.47	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
COAD	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-8.49	1.63e-15	3.91e-12	-0.53	-0.47	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
COAD	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-8.49	1.63e-15	3.91e-12	-0.5	-0.47	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
COAD	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-8.49	1.63e-15	3.91e-12	-0.57	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
COAD	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-8.49	1.65e-15	3.95e-12	-0.42	-0.47	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
COAD	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	8.49	1.65e-15	3.95e-12	0.88	0.47	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
COAD	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	8.49	1.65e-15	3.96e-12	0.62	0.47	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	8.49	1.69e-15	4.05e-12	0.62	0.47	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
COAD	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	8.49	1.7e-15	4.06e-12	0.64	0.47	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
COAD	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	8.49	1.7e-15	4.06e-12	0.58	0.47	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	8.49	1.7e-15	4.07e-12	0.62	0.47	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-8.49	1.71e-15	4.1e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
COAD	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.49	1.72e-15	4.1e-12	0.5	0.47	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.49	1.72e-15	4.1e-12	0.5	0.47	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
COAD	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.49	1.72e-15	4.1e-12	0.5	0.47	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
COAD	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-8.48	1.73e-15	4.14e-12	-0.56	-0.47	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
COAD	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	8.48	1.73e-15	4.14e-12	0.64	0.47	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
COAD	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-8.48	1.75e-15	4.18e-12	-0.79	-0.47	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
COAD	cis	rs7078219	0.505	rs41290504	ENSG00000257582.4	LINC01475	-8.48	1.75e-15	4.18e-12	-0.51	-0.47	Dental caries;	chr10:99533278	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs7908704	ENSG00000257582.4	LINC01475	-8.48	1.75e-15	4.18e-12	-0.51	-0.47	Dental caries;	chr10:99533561	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.505	rs7893840	ENSG00000257582.4	LINC01475	-8.48	1.75e-15	4.18e-12	-0.51	-0.47	Dental caries;	chr10:99533584	chr10:99526350~99531177:-
COAD	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	8.48	1.77e-15	4.22e-12	0.62	0.47	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	8.48	1.81e-15	4.32e-12	0.66	0.47	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	8.48	1.81e-15	4.32e-12	0.66	0.47	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
COAD	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-8.48	1.82e-15	4.35e-12	-0.55	-0.47	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
COAD	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	8.48	1.82e-15	4.35e-12	0.74	0.47	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
COAD	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-8.48	1.85e-15	4.4e-12	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
COAD	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-8.47	1.86e-15	4.44e-12	-0.8	-0.47	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	8.47	1.86e-15	4.44e-12	0.63	0.47	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	8.47	1.87e-15	4.44e-12	0.49	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	8.47	1.87e-15	4.44e-12	0.49	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	8.47	1.87e-15	4.44e-12	0.48	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-8.47	1.87e-15	4.46e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-8.47	1.87e-15	4.46e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-8.47	1.88e-15	4.48e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
COAD	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	8.47	1.89e-15	4.5e-12	0.47	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	8.47	1.9e-15	4.51e-12	0.62	0.47	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
COAD	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	8.47	1.9e-15	4.52e-12	0.54	0.47	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
COAD	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	8.47	1.9e-15	4.52e-12	0.55	0.47	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
COAD	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-8.47	1.92e-15	4.55e-12	-0.58	-0.47	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
COAD	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	8.47	1.92e-15	4.57e-12	0.56	0.47	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
COAD	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-8.47	1.93e-15	4.59e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
COAD	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-8.47	1.95e-15	4.62e-12	-0.49	-0.47	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
COAD	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	8.47	1.96e-15	4.64e-12	0.49	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	8.46	1.99e-15	4.72e-12	0.47	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	8.46	1.99e-15	4.72e-12	0.53	0.47	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
COAD	cis	rs7078219	0.505	rs10883371	ENSG00000257582.4	LINC01475	-8.46	2e-15	4.73e-12	-0.5	-0.47	Dental caries;	chr10:99532698	chr10:99526350~99531177:-
COAD	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-8.46	2e-15	4.74e-12	-0.56	-0.47	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	8.46	2e-15	4.74e-12	0.56	0.47	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
COAD	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-8.46	2.04e-15	4.83e-12	-0.61	-0.47	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
COAD	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	8.46	2.04e-15	4.84e-12	0.59	0.47	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
COAD	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-8.46	2.06e-15	4.87e-12	-0.51	-0.47	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-8.45	2.15e-15	5.09e-12	-0.51	-0.47	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
COAD	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-8.45	2.2e-15	5.2e-12	-0.57	-0.47	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	8.45	2.23e-15	5.26e-12	0.62	0.47	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-8.45	2.24e-15	5.29e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
COAD	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-8.45	2.26e-15	5.34e-12	-0.63	-0.47	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
COAD	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	8.45	2.26e-15	5.34e-12	0.62	0.47	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-8.44	2.29e-15	5.4e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
COAD	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	8.44	2.32e-15	5.47e-12	0.58	0.47	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
COAD	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	8.44	2.33e-15	5.49e-12	0.58	0.47	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	8.44	2.35e-15	5.53e-12	0.64	0.47	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-8.44	2.37e-15	5.58e-12	-0.53	-0.47	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	8.44	2.4e-15	5.65e-12	0.64	0.47	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	8.44	2.4e-15	5.65e-12	0.64	0.47	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
COAD	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-8.43	2.45e-15	5.75e-12	-0.62	-0.47	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
COAD	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	8.43	2.47e-15	5.8e-12	0.64	0.47	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-8.43	2.51e-15	5.89e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
COAD	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-8.43	2.51e-15	5.89e-12	-0.54	-0.47	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
COAD	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	8.43	2.51e-15	5.89e-12	0.5	0.47	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
COAD	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-8.43	2.51e-15	5.9e-12	-0.55	-0.47	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-8.43	2.53e-15	5.95e-12	-0.52	-0.47	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
COAD	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	8.43	2.54e-15	5.96e-12	0.6	0.47	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
COAD	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-8.43	2.56e-15	6e-12	-0.54	-0.47	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.43	2.59e-15	6.07e-12	0.51	0.47	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
COAD	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	8.42	2.59e-15	6.08e-12	0.63	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
COAD	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-8.42	2.6e-15	6.09e-12	-0.5	-0.47	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
COAD	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	8.42	2.64e-15	6.18e-12	0.64	0.47	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
COAD	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-8.42	2.66e-15	6.22e-12	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-8.42	2.7e-15	6.33e-12	-0.52	-0.46	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	8.42	2.73e-15	6.39e-12	0.57	0.46	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
COAD	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-8.42	2.76e-15	6.45e-12	-0.53	-0.46	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-8.42	2.76e-15	6.45e-12	-0.53	-0.46	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
COAD	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	8.41	2.79e-15	6.52e-12	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	8.41	2.79e-15	6.52e-12	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
COAD	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	8.41	2.8e-15	6.55e-12	0.46	0.46	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
COAD	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-8.41	2.8e-15	6.55e-12	-0.54	-0.46	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
COAD	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-8.41	2.85e-15	6.65e-12	-0.52	-0.46	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
COAD	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-8.41	2.86e-15	6.67e-12	-0.55	-0.46	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
COAD	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-8.41	2.9e-15	6.76e-12	-0.53	-0.46	Temperament;	chr17:14007232	chr17:14024514~14025488:+
COAD	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-8.41	2.9e-15	6.76e-12	-0.5	-0.46	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
COAD	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-8.41	2.91e-15	6.78e-12	-0.61	-0.46	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-8.41	2.91e-15	6.78e-12	-0.61	-0.46	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-8.41	2.91e-15	6.78e-12	-0.61	-0.46	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
COAD	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	8.41	2.93e-15	6.83e-12	0.62	0.46	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
COAD	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	8.41	2.94e-15	6.85e-12	0.55	0.46	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
COAD	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	8.4	2.98e-15	6.93e-12	0.6	0.46	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	8.4	2.99e-15	6.96e-12	0.62	0.46	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	8.4	3e-15	6.99e-12	0.62	0.46	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
COAD	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-8.4	3.01e-15	7.01e-12	-0.57	-0.46	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-8.4	3.01e-15	7.01e-12	-0.57	-0.46	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
COAD	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	8.4	3.05e-15	7.09e-12	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
COAD	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-8.4	3.1e-15	7.21e-12	-0.5	-0.46	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-8.4	3.1e-15	7.21e-12	-0.5	-0.46	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-8.4	3.13e-15	7.28e-12	-0.51	-0.46	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
COAD	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.39	3.17e-15	7.35e-12	0.5	0.46	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
COAD	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	8.39	3.2e-15	7.43e-12	0.66	0.46	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-8.39	3.2e-15	7.43e-12	-0.53	-0.46	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
COAD	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	8.39	3.21e-15	7.45e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
COAD	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	8.39	3.22e-15	7.46e-12	0.62	0.46	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
COAD	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-8.39	3.25e-15	7.54e-12	-0.54	-0.46	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
COAD	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-8.39	3.25e-15	7.54e-12	-0.54	-0.46	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
COAD	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	8.39	3.25e-15	7.55e-12	0.55	0.46	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
COAD	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-8.39	3.32e-15	7.68e-12	-0.78	-0.46	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	8.39	3.32e-15	7.69e-12	0.66	0.46	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	8.39	3.32e-15	7.69e-12	0.66	0.46	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	8.39	3.32e-15	7.69e-12	0.66	0.46	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	8.39	3.33e-15	7.72e-12	0.65	0.46	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	8.39	3.37e-15	7.79e-12	0.62	0.46	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	8.39	3.37e-15	7.79e-12	0.62	0.46	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	8.39	3.37e-15	7.79e-12	0.62	0.46	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	8.38	3.39e-15	7.84e-12	0.63	0.46	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
COAD	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	8.38	3.44e-15	7.95e-12	0.54	0.46	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
COAD	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-8.38	3.44e-15	7.96e-12	-0.56	-0.46	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
COAD	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-8.38	3.44e-15	7.96e-12	-0.56	-0.46	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
COAD	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-8.38	3.45e-15	7.98e-12	-0.51	-0.46	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-8.38	3.54e-15	8.18e-12	-0.51	-0.46	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	8.38	3.6e-15	8.32e-12	0.64	0.46	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	8.38	3.6e-15	8.32e-12	0.64	0.46	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
COAD	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.37	3.64e-15	8.4e-12	-0.57	-0.46	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	8.37	3.69e-15	8.52e-12	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
COAD	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-8.37	3.72e-15	8.59e-12	-0.5	-0.46	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
COAD	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	8.37	3.76e-15	8.66e-12	0.67	0.46	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
COAD	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	8.37	3.78e-15	8.71e-12	0.48	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
COAD	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	8.37	3.82e-15	8.8e-12	0.58	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-8.37	3.86e-15	8.88e-12	-0.62	-0.46	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
COAD	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-8.36	3.87e-15	8.92e-12	-0.72	-0.46	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
COAD	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-8.36	3.91e-15	8.99e-12	-0.53	-0.46	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
COAD	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-8.36	3.92e-15	9.02e-12	-0.73	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
COAD	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-8.36	3.93e-15	9.03e-12	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
COAD	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-8.36	3.97e-15	9.12e-12	-0.74	-0.46	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	8.36	3.99e-15	9.17e-12	0.64	0.46	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
COAD	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	8.36	3.99e-15	9.18e-12	0.76	0.46	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
COAD	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-8.36	4e-15	9.19e-12	-0.64	-0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
COAD	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	8.36	4.02e-15	9.24e-12	0.52	0.46	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-8.36	4.03e-15	9.26e-12	-0.54	-0.46	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
COAD	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-8.36	4.04e-15	9.27e-12	-0.55	-0.46	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
COAD	cis	rs7078219	0.543	rs7095491	ENSG00000257582.4	LINC01475	-8.36	4.04e-15	9.28e-12	-0.51	-0.46	Dental caries;	chr10:99514301	chr10:99526350~99531177:-
COAD	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	8.36	4.04e-15	9.28e-12	0.63	0.46	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
COAD	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	8.36	4.09e-15	9.39e-12	0.6	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
COAD	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	8.36	4.09e-15	9.39e-12	0.6	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
COAD	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	8.36	4.11e-15	9.44e-12	0.7	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
COAD	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-8.35	4.17e-15	9.56e-12	-0.52	-0.46	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
COAD	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	8.35	4.2e-15	9.63e-12	0.76	0.46	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
COAD	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	8.35	4.27e-15	9.79e-12	0.59	0.46	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
COAD	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	8.35	4.3e-15	9.85e-12	0.56	0.46	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
COAD	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	8.35	4.32e-15	9.89e-12	0.52	0.46	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
COAD	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	8.35	4.32e-15	9.9e-12	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
COAD	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	8.35	4.32e-15	9.9e-12	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
COAD	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	8.35	4.33e-15	9.91e-12	0.64	0.46	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.35	4.4e-15	1.01e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-8.34	4.46e-15	1.02e-11	-0.53	-0.46	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-8.34	4.46e-15	1.02e-11	-0.53	-0.46	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	8.34	4.47e-15	1.02e-11	0.63	0.46	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
COAD	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	8.34	4.51e-15	1.03e-11	0.54	0.46	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
COAD	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	8.34	4.53e-15	1.03e-11	0.54	0.46	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
COAD	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	8.34	4.58e-15	1.05e-11	0.58	0.46	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-8.34	4.62e-15	1.05e-11	-0.52	-0.46	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	8.34	4.63e-15	1.06e-11	0.57	0.46	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
COAD	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	8.34	4.63e-15	1.06e-11	0.74	0.46	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
COAD	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-8.34	4.68e-15	1.07e-11	-0.56	-0.46	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
COAD	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	8.34	4.71e-15	1.08e-11	0.57	0.46	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
COAD	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	8.33	4.73e-15	1.08e-11	0.61	0.46	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
COAD	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	8.33	4.75e-15	1.08e-11	0.62	0.46	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	8.33	4.75e-15	1.08e-11	0.62	0.46	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
COAD	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-8.33	4.79e-15	1.09e-11	-0.6	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
COAD	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-8.33	4.79e-15	1.09e-11	-0.59	-0.46	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
COAD	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-8.33	4.79e-15	1.09e-11	-0.54	-0.46	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-8.33	4.79e-15	1.09e-11	-0.54	-0.46	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
COAD	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	8.33	4.81e-15	1.1e-11	0.61	0.46	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
COAD	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	8.33	4.81e-15	1.1e-11	0.61	0.46	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
COAD	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	8.33	4.81e-15	1.1e-11	0.61	0.46	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-8.33	4.86e-15	1.11e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	8.33	4.88e-15	1.11e-11	0.64	0.46	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
COAD	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-8.33	4.89e-15	1.12e-11	-0.54	-0.46	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
COAD	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	8.33	4.9e-15	1.12e-11	0.57	0.46	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
COAD	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-8.33	4.92e-15	1.12e-11	-0.55	-0.46	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-8.33	4.92e-15	1.12e-11	-0.55	-0.46	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-8.33	4.92e-15	1.12e-11	-0.55	-0.46	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
COAD	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-8.33	4.92e-15	1.12e-11	-0.55	-0.46	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-8.33	4.93e-15	1.12e-11	-0.53	-0.46	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
COAD	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.33	4.95e-15	1.13e-11	0.76	0.46	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
COAD	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-8.32	5.22e-15	1.19e-11	-0.57	-0.46	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-8.32	5.22e-15	1.19e-11	-0.57	-0.46	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
COAD	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	8.32	5.3e-15	1.21e-11	0.7	0.46	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
COAD	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-8.32	5.35e-15	1.22e-11	-0.54	-0.46	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-8.32	5.35e-15	1.22e-11	-0.54	-0.46	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
COAD	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.32	5.38e-15	1.22e-11	-0.56	-0.46	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
COAD	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-8.32	5.38e-15	1.22e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	8.31	5.44e-15	1.24e-11	0.54	0.46	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
COAD	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	8.31	5.45e-15	1.24e-11	0.65	0.46	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
COAD	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	8.31	5.47e-15	1.24e-11	0.8	0.46	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
COAD	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-8.31	5.48e-15	1.24e-11	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
COAD	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-8.31	5.51e-15	1.25e-11	-0.81	-0.46	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
COAD	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-8.31	5.52e-15	1.25e-11	-0.51	-0.46	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
COAD	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-8.31	5.69e-15	1.29e-11	-0.56	-0.46	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
COAD	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	8.31	5.71e-15	1.29e-11	0.65	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
COAD	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	8.31	5.75e-15	1.3e-11	0.57	0.46	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
COAD	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	8.3	5.79e-15	1.31e-11	0.61	0.46	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
COAD	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	8.3	5.88e-15	1.33e-11	0.56	0.46	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
COAD	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	8.3	5.92e-15	1.34e-11	0.57	0.46	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
COAD	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	8.3	5.93e-15	1.34e-11	0.54	0.46	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
COAD	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	8.3	6.04e-15	1.37e-11	0.58	0.46	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
COAD	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	8.3	6.05e-15	1.37e-11	0.56	0.46	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	8.3	6.05e-15	1.37e-11	0.56	0.46	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
COAD	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	8.3	6.06e-15	1.37e-11	0.59	0.46	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
COAD	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-8.3	6.13e-15	1.38e-11	-0.73	-0.46	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-8.3	6.13e-15	1.38e-11	-0.73	-0.46	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
COAD	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-8.3	6.13e-15	1.38e-11	-0.73	-0.46	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
COAD	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-8.29	6.33e-15	1.43e-11	-0.73	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
COAD	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-8.29	6.38e-15	1.44e-11	-0.58	-0.46	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
COAD	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.29	6.39e-15	1.44e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
COAD	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-8.29	6.42e-15	1.45e-11	-0.56	-0.46	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-8.29	6.42e-15	1.45e-11	-0.55	-0.46	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
COAD	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-8.29	6.42e-15	1.45e-11	-0.55	-0.46	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-8.29	6.42e-15	1.45e-11	-0.55	-0.46	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
COAD	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.29	6.42e-15	1.45e-11	0.5	0.46	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
COAD	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-8.29	6.48e-15	1.46e-11	-0.6	-0.46	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-8.29	6.48e-15	1.46e-11	-0.6	-0.46	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
COAD	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	8.29	6.5e-15	1.46e-11	0.66	0.46	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-8.29	6.53e-15	1.47e-11	-0.62	-0.46	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
COAD	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	8.28	6.71e-15	1.51e-11	0.48	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
COAD	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	8.28	6.76e-15	1.52e-11	0.6	0.46	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-8.28	6.76e-15	1.52e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-8.28	6.76e-15	1.52e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	8.28	6.94e-15	1.56e-11	0.63	0.46	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
COAD	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-8.28	7e-15	1.57e-11	-0.56	-0.46	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-8.27	7.12e-15	1.6e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	8.27	7.14e-15	1.6e-11	0.64	0.46	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
COAD	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-8.27	7.23e-15	1.62e-11	-0.54	-0.46	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-8.27	7.33e-15	1.64e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
COAD	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-8.27	7.38e-15	1.65e-11	-0.56	-0.46	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
COAD	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-8.27	7.38e-15	1.65e-11	-0.56	-0.46	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-8.27	7.38e-15	1.65e-11	-0.56	-0.46	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
COAD	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	8.27	7.39e-15	1.65e-11	0.6	0.46	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
COAD	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-8.27	7.44e-15	1.66e-11	-0.6	-0.46	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
COAD	cis	rs7078219	0.505	rs7077040	ENSG00000257582.4	LINC01475	-8.26	7.51e-15	1.68e-11	-0.5	-0.46	Dental caries;	chr10:99521257	chr10:99526350~99531177:-
COAD	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-8.26	7.61e-15	1.7e-11	-0.78	-0.46	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
COAD	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	8.26	7.77e-15	1.73e-11	0.47	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
COAD	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-8.26	7.85e-15	1.75e-11	-0.57	-0.46	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
COAD	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-8.26	7.85e-15	1.75e-11	-0.54	-0.46	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
COAD	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	8.26	7.92e-15	1.76e-11	0.48	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
COAD	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	8.26	8e-15	1.78e-11	0.6	0.46	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
COAD	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-8.26	8.02e-15	1.79e-11	-0.58	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
COAD	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-8.25	8.02e-15	1.79e-11	-0.64	-0.46	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
COAD	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-8.25	8.04e-15	1.79e-11	-0.56	-0.46	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
COAD	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-8.25	8.17e-15	1.82e-11	-0.48	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
COAD	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	8.25	8.2e-15	1.82e-11	0.55	0.46	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
COAD	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-8.25	8.27e-15	1.84e-11	-0.56	-0.46	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
COAD	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-8.25	8.29e-15	1.84e-11	-0.58	-0.46	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
COAD	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	8.25	8.3e-15	1.84e-11	0.6	0.46	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-8.25	8.39e-15	1.86e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
COAD	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	8.25	8.44e-15	1.88e-11	0.68	0.46	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
COAD	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-8.25	8.46e-15	1.88e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-8.25	8.46e-15	1.88e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-8.25	8.46e-15	1.88e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-8.25	8.46e-15	1.88e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
COAD	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-8.25	8.51e-15	1.89e-11	-0.53	-0.46	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
COAD	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	8.25	8.55e-15	1.9e-11	0.71	0.46	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
COAD	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-8.24	8.59e-15	1.91e-11	-0.54	-0.46	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	8.24	8.68e-15	1.92e-11	0.6	0.46	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	8.24	8.68e-15	1.92e-11	0.6	0.46	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	8.24	8.68e-15	1.92e-11	0.6	0.46	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
COAD	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	8.24	8.68e-15	1.92e-11	0.61	0.46	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
COAD	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	8.24	8.73e-15	1.94e-11	0.68	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-8.24	8.87e-15	1.96e-11	-0.63	-0.46	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-8.24	8.9e-15	1.97e-11	-0.69	-0.46	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-8.24	8.9e-15	1.97e-11	-0.69	-0.46	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
COAD	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	8.24	8.9e-15	1.97e-11	0.6	0.46	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	8.24	8.9e-15	1.97e-11	0.6	0.46	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-8.24	8.91e-15	1.97e-11	-0.52	-0.46	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-8.24	8.92e-15	1.98e-11	-0.49	-0.46	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	8.24	8.97e-15	1.99e-11	0.61	0.46	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
COAD	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	8.24	9.03e-15	2e-11	0.73	0.46	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
COAD	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	8.24	9.04e-15	2e-11	0.6	0.46	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
COAD	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-8.24	9.11e-15	2.01e-11	-0.54	-0.46	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-8.24	9.11e-15	2.01e-11	-0.54	-0.46	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
COAD	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	8.24	9.11e-15	2.01e-11	0.65	0.46	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
COAD	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	8.23	9.3e-15	2.05e-11	0.6	0.46	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
COAD	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	8.23	9.3e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	8.23	9.31e-15	2.05e-11	0.61	0.46	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
COAD	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-8.23	9.33e-15	2.06e-11	-0.54	-0.46	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-8.23	9.33e-15	2.06e-11	-0.54	-0.46	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
COAD	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-8.23	9.43e-15	2.08e-11	-0.5	-0.46	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
COAD	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	8.23	9.44e-15	2.08e-11	0.61	0.46	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	8.23	9.44e-15	2.08e-11	0.61	0.46	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-8.23	9.47e-15	2.08e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-8.23	9.47e-15	2.08e-11	-0.51	-0.46	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	8.23	9.67e-15	2.13e-11	0.64	0.46	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	8.23	9.67e-15	2.13e-11	0.64	0.46	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	8.23	9.71e-15	2.13e-11	0.6	0.46	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	8.23	9.72e-15	2.14e-11	0.61	0.46	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	8.23	9.73e-15	2.14e-11	0.64	0.46	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
COAD	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	8.22	9.88e-15	2.17e-11	0.54	0.46	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
COAD	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-8.22	9.88e-15	2.17e-11	-0.54	-0.46	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
COAD	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-8.22	9.89e-15	2.17e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
COAD	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-8.22	9.93e-15	2.18e-11	-0.59	-0.46	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
COAD	cis	rs17264034	0.821	rs374218	ENSG00000250786.1	SNHG18	8.22	9.95e-15	2.18e-11	0.64	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9548331	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	8.22	9.95e-15	2.18e-11	0.64	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
COAD	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	8.22	1.01e-14	2.2e-11	0.64	0.46	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	8.22	1.01e-14	2.2e-11	0.64	0.46	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	8.22	1.01e-14	2.2e-11	0.64	0.46	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
COAD	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	8.22	1.01e-14	2.21e-11	0.64	0.46	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
COAD	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	8.22	1.01e-14	2.22e-11	0.52	0.46	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
COAD	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-8.22	1.02e-14	2.25e-11	-0.52	-0.46	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	8.22	1.03e-14	2.25e-11	0.6	0.46	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
COAD	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	8.22	1.03e-14	2.25e-11	0.7	0.46	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
COAD	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-8.22	1.03e-14	2.25e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-8.22	1.03e-14	2.25e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	8.22	1.03e-14	2.26e-11	0.49	0.46	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	8.22	1.03e-14	2.26e-11	0.61	0.46	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
COAD	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-8.22	1.04e-14	2.28e-11	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
COAD	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	8.21	1.05e-14	2.29e-11	0.68	0.46	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
COAD	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-8.21	1.05e-14	2.29e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-8.21	1.05e-14	2.29e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-8.21	1.05e-14	2.29e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-8.21	1.05e-14	2.29e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-8.21	1.05e-14	2.29e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	8.21	1.09e-14	2.37e-11	0.6	0.46	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	8.21	1.09e-14	2.37e-11	0.6	0.46	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
COAD	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-8.21	1.09e-14	2.38e-11	-0.54	-0.46	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
COAD	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	8.21	1.09e-14	2.38e-11	0.56	0.46	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
COAD	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	8.21	1.09e-14	2.39e-11	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
COAD	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-8.2	1.12e-14	2.44e-11	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	8.2	1.12e-14	2.44e-11	0.62	0.46	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
COAD	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-8.2	1.13e-14	2.45e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-8.2	1.13e-14	2.45e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-8.2	1.13e-14	2.45e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-8.2	1.13e-14	2.47e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
COAD	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.2	1.16e-14	2.52e-11	-0.55	-0.46	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-8.2	1.17e-14	2.55e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
COAD	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-8.2	1.18e-14	2.57e-11	-0.53	-0.46	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
COAD	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-8.19	1.19e-14	2.59e-11	-0.5	-0.46	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
COAD	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-8.19	1.2e-14	2.6e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-8.19	1.2e-14	2.6e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-8.19	1.2e-14	2.6e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-8.19	1.2e-14	2.6e-11	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	8.19	1.21e-14	2.62e-11	0.64	0.46	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
COAD	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.19	1.21e-14	2.63e-11	-0.57	-0.46	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
COAD	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.19	1.21e-14	2.63e-11	-0.57	-0.46	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
COAD	cis	rs7078219	0.58	rs10883361	ENSG00000257582.4	LINC01475	-8.19	1.23e-14	2.67e-11	-0.5	-0.45	Dental caries;	chr10:99523211	chr10:99526350~99531177:-
COAD	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-8.19	1.25e-14	2.71e-11	-0.64	-0.45	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	8.19	1.25e-14	2.71e-11	0.65	0.45	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	8.19	1.25e-14	2.71e-11	0.65	0.45	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	8.19	1.25e-14	2.71e-11	0.65	0.45	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	8.19	1.25e-14	2.71e-11	0.65	0.45	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	8.19	1.25e-14	2.71e-11	0.65	0.45	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
COAD	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-8.19	1.27e-14	2.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-8.19	1.27e-14	2.75e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
COAD	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-8.19	1.27e-14	2.75e-11	-0.57	-0.45	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
COAD	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-8.18	1.28e-14	2.76e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
COAD	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	8.18	1.28e-14	2.77e-11	0.45	0.45	Breast cancer;	chr11:750849	chr11:779617~780755:+
COAD	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-8.18	1.3e-14	2.81e-11	-0.6	-0.45	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
COAD	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.18	1.3e-14	2.81e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
COAD	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-8.18	1.31e-14	2.82e-11	-0.61	-0.45	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
COAD	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-8.18	1.31e-14	2.84e-11	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
COAD	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	8.18	1.32e-14	2.86e-11	0.57	0.45	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
COAD	cis	rs7078219	0.543	rs10786556	ENSG00000257582.4	LINC01475	-8.18	1.35e-14	2.91e-11	-0.5	-0.45	Dental caries;	chr10:99518567	chr10:99526350~99531177:-
COAD	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-8.17	1.36e-14	2.94e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-8.17	1.36e-14	2.94e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-8.17	1.36e-14	2.94e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
COAD	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-8.17	1.36e-14	2.94e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
COAD	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	8.17	1.36e-14	2.94e-11	0.61	0.45	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
COAD	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	8.17	1.37e-14	2.95e-11	0.47	0.45	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
COAD	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.17	1.38e-14	2.98e-11	0.49	0.45	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
COAD	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	8.17	1.39e-14	3e-11	0.63	0.45	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
COAD	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-8.17	1.4e-14	3.02e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-8.17	1.4e-14	3.02e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	8.17	1.4e-14	3.02e-11	0.63	0.45	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
COAD	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	8.17	1.41e-14	3.04e-11	0.57	0.45	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
COAD	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-8.17	1.42e-14	3.05e-11	-0.55	-0.45	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
COAD	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-8.17	1.42e-14	3.05e-11	-0.41	-0.45	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
COAD	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-8.17	1.45e-14	3.11e-11	-0.65	-0.45	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
COAD	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	8.17	1.45e-14	3.12e-11	0.55	0.45	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.16	1.47e-14	3.16e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	8.16	1.48e-14	3.17e-11	0.6	0.45	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
COAD	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-8.16	1.49e-14	3.2e-11	-0.73	-0.45	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
COAD	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-8.16	1.49e-14	3.2e-11	-0.6	-0.45	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
COAD	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	8.16	1.49e-14	3.2e-11	0.63	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	8.16	1.49e-14	3.2e-11	0.63	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
COAD	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	8.16	1.49e-14	3.2e-11	0.62	0.45	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
COAD	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-8.16	1.51e-14	3.23e-11	-0.72	-0.45	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
COAD	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	8.16	1.53e-14	3.27e-11	0.57	0.45	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
COAD	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-8.16	1.55e-14	3.32e-11	-0.75	-0.45	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
COAD	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-8.15	1.56e-14	3.34e-11	-0.65	-0.45	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
COAD	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-8.15	1.56e-14	3.35e-11	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-8.15	1.56e-14	3.35e-11	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-8.15	1.56e-14	3.35e-11	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
COAD	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	8.15	1.56e-14	3.35e-11	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	8.15	1.57e-14	3.36e-11	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
COAD	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	8.15	1.57e-14	3.37e-11	0.51	0.45	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
COAD	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-8.15	1.59e-14	3.4e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-8.15	1.59e-14	3.4e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-8.15	1.59e-14	3.4e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
COAD	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	8.15	1.59e-14	3.4e-11	0.55	0.45	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
COAD	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-8.15	1.61e-14	3.45e-11	-0.52	-0.45	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
COAD	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	8.15	1.64e-14	3.5e-11	0.61	0.45	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
COAD	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	8.15	1.64e-14	3.5e-11	0.61	0.45	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
COAD	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	8.15	1.64e-14	3.5e-11	0.65	0.45	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
COAD	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	8.15	1.65e-14	3.53e-11	0.62	0.45	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
COAD	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-8.15	1.65e-14	3.53e-11	-0.62	-0.45	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
COAD	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-8.14	1.68e-14	3.58e-11	-0.69	-0.45	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	8.14	1.7e-14	3.62e-11	0.6	0.45	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
COAD	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	8.14	1.71e-14	3.64e-11	0.67	0.45	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
COAD	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-8.14	1.71e-14	3.65e-11	-0.58	-0.45	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
COAD	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-8.14	1.73e-14	3.68e-11	-0.6	-0.45	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	8.14	1.77e-14	3.76e-11	0.6	0.45	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	8.13	1.78e-14	3.79e-11	0.66	0.45	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
COAD	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-8.13	1.79e-14	3.8e-11	-0.49	-0.45	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-8.13	1.79e-14	3.8e-11	-0.49	-0.45	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-8.13	1.79e-14	3.8e-11	-0.49	-0.45	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
COAD	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-8.13	1.79e-14	3.81e-11	-0.53	-0.45	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
COAD	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-8.13	1.8e-14	3.83e-11	-0.55	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
COAD	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-8.13	1.81e-14	3.83e-11	-0.68	-0.45	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
COAD	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	8.13	1.82e-14	3.86e-11	0.55	0.45	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
COAD	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-8.13	1.83e-14	3.88e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-8.13	1.83e-14	3.89e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
COAD	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	8.13	1.83e-14	3.89e-11	0.62	0.45	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
COAD	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-8.13	1.84e-14	3.91e-11	-0.54	-0.45	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
COAD	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-8.13	1.85e-14	3.91e-11	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
COAD	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	8.13	1.86e-14	3.95e-11	0.6	0.45	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
COAD	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	8.13	1.87e-14	3.97e-11	0.68	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	8.13	1.87e-14	3.97e-11	0.68	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
COAD	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-8.13	1.89e-14	4e-11	-0.72	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
COAD	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	8.12	1.89e-14	4.01e-11	0.58	0.45	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
COAD	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-8.12	1.93e-14	4.08e-11	-0.55	-0.45	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
COAD	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-8.12	1.94e-14	4.11e-11	-0.49	-0.45	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
COAD	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-8.12	1.98e-14	4.19e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-8.12	1.98e-14	4.19e-11	-0.73	-0.45	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
COAD	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-8.12	1.99e-14	4.2e-11	-0.58	-0.45	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
COAD	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-8.12	2e-14	4.23e-11	-0.6	-0.45	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
COAD	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-8.12	2.01e-14	4.25e-11	-0.72	-0.45	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-8.11	2.03e-14	4.27e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
COAD	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-8.11	2.03e-14	4.27e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
COAD	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	8.11	2.03e-14	4.27e-11	0.49	0.45	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
COAD	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	8.11	2.03e-14	4.28e-11	0.59	0.45	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	8.11	2.03e-14	4.28e-11	0.59	0.45	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
COAD	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-8.11	2.04e-14	4.3e-11	-0.49	-0.45	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
COAD	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-8.11	2.06e-14	4.34e-11	-0.62	-0.45	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
COAD	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-8.11	2.08e-14	4.39e-11	-0.53	-0.45	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
COAD	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-8.11	2.08e-14	4.39e-11	-0.53	-0.45	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
COAD	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-8.11	2.13e-14	4.49e-11	-0.51	-0.45	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	8.11	2.14e-14	4.5e-11	0.59	0.45	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-8.1	2.18e-14	4.59e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
COAD	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-8.1	2.2e-14	4.62e-11	-0.55	-0.45	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
COAD	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-8.1	2.25e-14	4.73e-11	-0.56	-0.45	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
COAD	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-8.1	2.26e-14	4.75e-11	-0.48	-0.45	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-8.1	2.26e-14	4.75e-11	-0.48	-0.45	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
COAD	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-8.1	2.26e-14	4.75e-11	-0.48	-0.45	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
COAD	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-8.1	2.26e-14	4.75e-11	-0.48	-0.45	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
COAD	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-8.1	2.27e-14	4.76e-11	-0.53	-0.45	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
COAD	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	8.1	2.27e-14	4.77e-11	0.64	0.45	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
COAD	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-8.1	2.28e-14	4.78e-11	-0.52	-0.45	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
COAD	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	8.1	2.29e-14	4.79e-11	0.59	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
COAD	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-8.1	2.29e-14	4.8e-11	-0.64	-0.45	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
COAD	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-8.1	2.29e-14	4.81e-11	-0.54	-0.45	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
COAD	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	8.09	2.31e-14	4.83e-11	0.65	0.45	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
COAD	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	8.09	2.36e-14	4.94e-11	0.64	0.45	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
COAD	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-8.09	2.37e-14	4.96e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
COAD	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-8.09	2.37e-14	4.96e-11	-0.73	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	8.09	2.39e-14	4.99e-11	0.6	0.45	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
COAD	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	8.09	2.4e-14	5.01e-11	0.63	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	8.09	2.4e-14	5.01e-11	0.63	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
COAD	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	8.09	2.41e-14	5.04e-11	0.68	0.45	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-8.09	2.43e-14	5.07e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-8.09	2.43e-14	5.07e-11	-0.67	-0.45	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-8.09	2.43e-14	5.07e-11	-0.67	-0.45	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
COAD	cis	rs17264034	0.861	rs1651285	ENSG00000250786.1	SNHG18	8.08	2.46e-14	5.14e-11	0.64	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547829	chr5:9546200~9550609:+
COAD	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-8.08	2.48e-14	5.18e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-8.08	2.48e-14	5.18e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-8.08	2.49e-14	5.18e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-8.08	2.49e-14	5.18e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-8.08	2.49e-14	5.18e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-8.08	2.49e-14	5.18e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
COAD	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-8.08	2.49e-14	5.18e-11	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
COAD	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	8.08	2.51e-14	5.24e-11	0.69	0.45	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
COAD	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	8.08	2.55e-14	5.3e-11	0.58	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
COAD	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	8.08	2.55e-14	5.31e-11	0.61	0.45	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
COAD	cis	rs17264034	0.808	rs1706987	ENSG00000250786.1	SNHG18	8.08	2.55e-14	5.31e-11	0.64	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547853	chr5:9546200~9550609:+
COAD	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-8.08	2.61e-14	5.44e-11	-0.48	-0.45	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
COAD	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	8.07	2.62e-14	5.46e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	8.07	2.62e-14	5.46e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
COAD	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-8.07	2.63e-14	5.46e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
COAD	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-8.07	2.63e-14	5.46e-11	-0.52	-0.45	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
COAD	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	8.07	2.66e-14	5.52e-11	0.48	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
COAD	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	8.07	2.68e-14	5.57e-11	0.47	0.45	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
COAD	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-8.07	2.68e-14	5.58e-11	-0.41	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
COAD	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	8.07	2.7e-14	5.61e-11	0.73	0.45	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-8.07	2.74e-14	5.68e-11	-0.5	-0.45	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
COAD	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-8.07	2.75e-14	5.71e-11	-0.41	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
COAD	cis	rs17264034	0.861	rs1398337	ENSG00000250786.1	SNHG18	8.06	2.82e-14	5.84e-11	0.64	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9547986	chr5:9546200~9550609:+
COAD	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	8.06	2.83e-14	5.86e-11	0.51	0.45	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
COAD	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	8.06	2.87e-14	5.93e-11	0.61	0.45	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
COAD	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-8.06	2.98e-14	6.16e-11	-0.7	-0.45	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
COAD	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	8.05	2.99e-14	6.18e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
COAD	cis	rs7078219	0.543	rs7096296	ENSG00000257582.4	LINC01475	8.05	3e-14	6.2e-11	0.49	0.45	Dental caries;	chr10:99518059	chr10:99526350~99531177:-
COAD	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	8.05	3.03e-14	6.24e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
COAD	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	8.05	3.06e-14	6.3e-11	0.69	0.45	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	8.05	3.06e-14	6.3e-11	0.69	0.45	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	8.05	3.06e-14	6.3e-11	0.69	0.45	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	8.05	3.06e-14	6.3e-11	0.69	0.45	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	8.05	3.06e-14	6.3e-11	0.69	0.45	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-8.05	3.07e-14	6.33e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
COAD	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	8.05	3.08e-14	6.33e-11	0.69	0.45	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	8.05	3.08e-14	6.33e-11	0.69	0.45	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
COAD	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	8.05	3.09e-14	6.36e-11	0.64	0.45	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
COAD	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	8.05	3.1e-14	6.38e-11	0.63	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
COAD	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-8.05	3.11e-14	6.4e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
COAD	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	8.05	3.12e-14	6.42e-11	0.56	0.45	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-8.05	3.12e-14	6.42e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
COAD	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-8.05	3.13e-14	6.44e-11	-0.48	-0.45	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
COAD	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-8.05	3.14e-14	6.45e-11	-0.59	-0.45	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
COAD	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	8.05	3.15e-14	6.49e-11	0.5	0.45	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
COAD	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-8.05	3.18e-14	6.55e-11	-0.5	-0.45	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
COAD	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-8.04	3.19e-14	6.56e-11	-0.62	-0.45	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
COAD	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-8.04	3.2e-14	6.59e-11	-0.7	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-8.04	3.23e-14	6.63e-11	-0.73	-0.45	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
COAD	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-8.04	3.28e-14	6.73e-11	-0.72	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
COAD	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	8.04	3.29e-14	6.76e-11	0.56	0.45	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
COAD	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-8.04	3.29e-14	6.77e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
COAD	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-8.03	3.41e-14	6.99e-11	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
COAD	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	8.03	3.45e-14	7.07e-11	0.54	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
COAD	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-8.03	3.46e-14	7.1e-11	-0.79	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
COAD	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	8.03	3.47e-14	7.11e-11	0.6	0.45	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
COAD	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	8.03	3.48e-14	7.14e-11	0.51	0.45	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
COAD	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-8.03	3.51e-14	7.18e-11	-0.56	-0.45	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
COAD	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	8.03	3.51e-14	7.18e-11	0.65	0.45	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	8.03	3.51e-14	7.18e-11	0.65	0.45	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
COAD	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.03	3.52e-14	7.21e-11	0.51	0.45	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.03	3.52e-14	7.21e-11	0.51	0.45	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
COAD	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-8.03	3.53e-14	7.22e-11	-0.56	-0.45	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-8.03	3.54e-14	7.24e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
COAD	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	8.03	3.55e-14	7.26e-11	0.46	0.45	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
COAD	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-8.03	3.56e-14	7.29e-11	-0.53	-0.45	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
COAD	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	8.03	3.61e-14	7.38e-11	0.57	0.45	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
COAD	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-8.02	3.65e-14	7.46e-11	-0.51	-0.45	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
COAD	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-8.02	3.66e-14	7.47e-11	-0.58	-0.45	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
COAD	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-8.02	3.66e-14	7.48e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
COAD	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	8.02	3.68e-14	7.52e-11	0.53	0.45	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
COAD	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	8.02	3.69e-14	7.54e-11	0.48	0.45	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.02	3.72e-14	7.59e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.02	3.72e-14	7.59e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.02	3.72e-14	7.59e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	8.02	3.75e-14	7.65e-11	0.56	0.45	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
COAD	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	8.02	3.77e-14	7.69e-11	0.55	0.45	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.02	3.77e-14	7.69e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
COAD	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-8.02	3.78e-14	7.7e-11	-0.55	-0.45	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
COAD	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	8.02	3.78e-14	7.71e-11	0.61	0.45	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
COAD	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	8.02	3.78e-14	7.71e-11	0.61	0.45	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
COAD	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	8.02	3.79e-14	7.72e-11	0.63	0.45	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
COAD	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-8.02	3.81e-14	7.76e-11	-0.48	-0.45	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
COAD	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	8.02	3.87e-14	7.88e-11	0.72	0.45	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	8.02	3.87e-14	7.88e-11	0.72	0.45	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	8.02	3.87e-14	7.88e-11	0.72	0.45	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	8.02	3.87e-14	7.88e-11	0.72	0.45	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	8.02	3.87e-14	7.88e-11	0.72	0.45	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
COAD	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	8.01	3.88e-14	7.89e-11	0.7	0.45	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
COAD	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-8.01	3.89e-14	7.91e-11	-0.54	-0.45	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
COAD	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-8.01	3.91e-14	7.95e-11	-0.57	-0.45	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
COAD	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	8.01	3.92e-14	7.97e-11	0.6	0.45	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
COAD	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-8.01	3.94e-14	8e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-8.01	3.94e-14	8.01e-11	-0.57	-0.45	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
COAD	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-8.01	3.97e-14	8.06e-11	-0.51	-0.45	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
COAD	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-8.01	3.97e-14	8.07e-11	-0.54	-0.45	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
COAD	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-8.01	3.97e-14	8.07e-11	-0.53	-0.45	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	8.01	4e-14	8.13e-11	0.61	0.45	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
COAD	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	8.01	4.02e-14	8.16e-11	0.7	0.45	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	8.01	4.02e-14	8.16e-11	0.7	0.45	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
COAD	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	8.01	4.04e-14	8.2e-11	0.6	0.45	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
COAD	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	8.01	4.05e-14	8.21e-11	0.63	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
COAD	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-8.01	4.07e-14	8.26e-11	-0.51	-0.45	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	8.01	4.08e-14	8.27e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	8.01	4.08e-14	8.27e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	8.01	4.08e-14	8.27e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	8.01	4.12e-14	8.35e-11	0.6	0.45	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-8.01	4.12e-14	8.36e-11	-0.59	-0.45	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
COAD	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	8	4.16e-14	8.42e-11	0.47	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
COAD	cis	rs6584283	0.713	rs1332100	ENSG00000257582.4	LINC01475	8	4.17e-14	8.44e-11	0.5	0.45	Ulcerative colitis;	chr10:99541589	chr10:99526350~99531177:-
COAD	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	8	4.17e-14	8.45e-11	0.7	0.45	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
COAD	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-8	4.23e-14	8.55e-11	-0.73	-0.45	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
COAD	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-8	4.25e-14	8.61e-11	-0.53	-0.45	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
COAD	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-8	4.32e-14	8.72e-11	-0.5	-0.45	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
COAD	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-8	4.32e-14	8.74e-11	-0.59	-0.45	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
COAD	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-8	4.38e-14	8.85e-11	-0.64	-0.45	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
COAD	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-7.99	4.46e-14	9.01e-11	-0.54	-0.45	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
COAD	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-7.99	4.46e-14	9.01e-11	-0.54	-0.45	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
COAD	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-7.99	4.46e-14	9.01e-11	-0.54	-0.45	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-7.99	4.54e-14	9.16e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	7.99	4.56e-14	9.19e-11	0.85	0.45	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
COAD	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	7.99	4.57e-14	9.22e-11	0.54	0.45	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	7.99	4.57e-14	9.22e-11	0.54	0.45	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
COAD	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	7.99	4.62e-14	9.31e-11	0.7	0.45	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
COAD	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	7.99	4.65e-14	9.37e-11	0.61	0.45	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	7.99	4.65e-14	9.37e-11	0.61	0.45	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	7.99	4.65e-14	9.37e-11	0.61	0.45	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
COAD	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-7.98	4.72e-14	9.48e-11	-0.54	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
COAD	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-7.98	4.74e-14	9.52e-11	-0.72	-0.45	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-7.98	4.76e-14	9.56e-11	-0.49	-0.45	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
COAD	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	7.98	4.79e-14	9.61e-11	0.58	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
COAD	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	7.98	4.8e-14	9.65e-11	0.57	0.45	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
COAD	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-7.98	4.81e-14	9.67e-11	-0.71	-0.45	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
COAD	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-7.98	4.83e-14	9.7e-11	-0.66	-0.45	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
COAD	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	7.98	4.85e-14	9.73e-11	0.68	0.45	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	7.98	4.96e-14	9.95e-11	0.49	0.45	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
COAD	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-7.98	4.97e-14	9.96e-11	-0.55	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
COAD	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-7.98	4.97e-14	9.97e-11	-0.58	-0.45	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
COAD	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	7.97	5.04e-14	1.01e-10	0.59	0.45	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
COAD	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-7.97	5.04e-14	1.01e-10	-0.54	-0.45	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-7.97	5.07e-14	1.02e-10	-0.52	-0.45	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
COAD	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-7.97	5.07e-14	1.02e-10	-0.58	-0.45	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
COAD	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.97	5.08e-14	1.02e-10	-0.57	-0.45	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
COAD	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-7.97	5.16e-14	1.03e-10	-0.56	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
COAD	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.97	5.21e-14	1.04e-10	-0.45	-0.45	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
COAD	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-7.97	5.22e-14	1.04e-10	-0.65	-0.45	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
COAD	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	7.97	5.23e-14	1.05e-10	0.58	0.45	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	7.97	5.23e-14	1.05e-10	0.58	0.45	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
COAD	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.97	5.3e-14	1.06e-10	0.53	0.45	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
COAD	cis	rs9368481	0.761	rs9348746	ENSG00000224843.5	LINC00240	7.97	5.36e-14	1.07e-10	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26956992~27023924:+
COAD	cis	rs9368481	0.761	rs9379952	ENSG00000224843.5	LINC00240	7.97	5.36e-14	1.07e-10	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26956992~27023924:+
COAD	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	7.96	5.37e-14	1.07e-10	0.62	0.44	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	7.96	5.38e-14	1.07e-10	0.61	0.44	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
COAD	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	7.96	5.38e-14	1.08e-10	0.7	0.44	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	7.96	5.38e-14	1.08e-10	0.7	0.44	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	7.96	5.38e-14	1.08e-10	0.7	0.44	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	7.96	5.38e-14	1.08e-10	0.7	0.44	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
COAD	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-7.96	5.41e-14	1.08e-10	-0.5	-0.44	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
COAD	cis	rs17264034	0.861	rs1614229	ENSG00000250786.1	SNHG18	7.96	5.41e-14	1.08e-10	0.64	0.44	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9546883	chr5:9546200~9550609:+
COAD	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	7.96	5.45e-14	1.09e-10	0.61	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
COAD	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-7.96	5.5e-14	1.1e-10	-0.54	-0.44	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
COAD	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	7.96	5.55e-14	1.11e-10	0.64	0.44	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
COAD	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	7.96	5.56e-14	1.11e-10	0.47	0.44	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
COAD	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-7.96	5.58e-14	1.11e-10	-0.72	-0.44	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
COAD	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	7.96	5.63e-14	1.12e-10	0.56	0.44	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
COAD	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-7.96	5.67e-14	1.13e-10	-0.55	-0.44	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
COAD	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-7.96	5.71e-14	1.14e-10	-0.55	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
COAD	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-7.95	5.74e-14	1.14e-10	-0.55	-0.44	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
COAD	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-7.95	5.74e-14	1.14e-10	-0.58	-0.44	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
COAD	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	7.95	5.77e-14	1.15e-10	0.54	0.44	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
COAD	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	7.95	5.78e-14	1.15e-10	0.46	0.44	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
COAD	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-7.95	5.79e-14	1.15e-10	-0.63	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
COAD	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	7.95	5.91e-14	1.18e-10	0.57	0.44	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
COAD	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-7.95	6.04e-14	1.2e-10	-0.51	-0.44	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
COAD	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-7.95	6.08e-14	1.21e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-7.95	6.08e-14	1.21e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-7.95	6.08e-14	1.21e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-7.95	6.08e-14	1.21e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-7.95	6.08e-14	1.21e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
COAD	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-7.94	6.13e-14	1.22e-10	-0.71	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-7.94	6.13e-14	1.22e-10	-0.71	-0.44	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
COAD	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-7.94	6.19e-14	1.23e-10	-0.54	-0.44	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
COAD	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-7.94	6.21e-14	1.23e-10	-0.51	-0.44	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
COAD	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-7.94	6.27e-14	1.24e-10	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
COAD	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	7.94	6.33e-14	1.26e-10	0.46	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-7.94	6.35e-14	1.26e-10	-0.52	-0.44	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
COAD	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-7.94	6.37e-14	1.26e-10	-0.58	-0.44	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
COAD	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	7.94	6.38e-14	1.26e-10	0.56	0.44	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
COAD	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-7.94	6.43e-14	1.27e-10	-0.52	-0.44	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
COAD	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	7.94	6.45e-14	1.28e-10	0.5	0.44	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
COAD	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-7.94	6.46e-14	1.28e-10	-0.55	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
COAD	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-7.94	6.47e-14	1.28e-10	-0.58	-0.44	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
COAD	cis	rs9368481	0.761	rs9357030	ENSG00000224843.5	LINC00240	7.93	6.52e-14	1.29e-10	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26956992~27023924:+
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	7.93	6.54e-14	1.29e-10	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
COAD	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-7.93	6.56e-14	1.3e-10	-0.54	-0.44	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
COAD	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.93	6.58e-14	1.3e-10	0.51	0.44	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-7.93	6.58e-14	1.3e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
COAD	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-7.93	6.6e-14	1.3e-10	-0.55	-0.44	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
COAD	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-7.93	6.67e-14	1.32e-10	-0.55	-0.44	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
COAD	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-7.93	6.69e-14	1.32e-10	-0.6	-0.44	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-7.93	6.69e-14	1.32e-10	-0.6	-0.44	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
COAD	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-7.93	6.71e-14	1.33e-10	-0.76	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
COAD	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	7.93	6.86e-14	1.35e-10	0.56	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
COAD	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	7.92	7.05e-14	1.39e-10	0.58	0.44	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
COAD	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-7.92	7.06e-14	1.39e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-7.92	7.3e-14	1.44e-10	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
COAD	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-7.92	7.31e-14	1.44e-10	-0.71	-0.44	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
COAD	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	7.92	7.34e-14	1.44e-10	0.54	0.44	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
COAD	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-7.91	7.49e-14	1.47e-10	-0.49	-0.44	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
COAD	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-7.91	7.49e-14	1.47e-10	-0.49	-0.44	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
COAD	cis	rs9326248	0.569	rs473172	ENSG00000254851.1	RP11-109L13.1	-7.91	7.52e-14	1.48e-10	-0.68	-0.44	Blood protein levels;	chr11:116937254	chr11:117135528~117138582:+
COAD	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	7.91	7.57e-14	1.49e-10	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
COAD	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-7.91	7.58e-14	1.49e-10	-0.56	-0.44	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
COAD	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-7.91	7.59e-14	1.49e-10	-0.54	-0.44	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
COAD	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	7.91	7.61e-14	1.49e-10	0.59	0.44	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
COAD	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	7.91	7.63e-14	1.5e-10	0.63	0.44	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	7.91	7.63e-14	1.5e-10	0.63	0.44	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	7.91	7.63e-14	1.5e-10	0.63	0.44	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	7.91	7.63e-14	1.5e-10	0.63	0.44	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	7.91	7.63e-14	1.5e-10	0.63	0.44	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
COAD	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	7.91	7.68e-14	1.51e-10	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
COAD	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	7.91	7.68e-14	1.51e-10	0.52	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
COAD	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-7.91	7.77e-14	1.52e-10	-0.54	-0.44	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
COAD	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	7.91	7.79e-14	1.53e-10	0.59	0.44	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	7.91	7.81e-14	1.53e-10	0.59	0.44	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
COAD	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-7.9	7.96e-14	1.56e-10	-0.54	-0.44	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
COAD	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	7.9	8.09e-14	1.58e-10	0.61	0.44	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	7.9	8.12e-14	1.59e-10	0.59	0.44	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-7.9	8.15e-14	1.6e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-7.9	8.15e-14	1.6e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
COAD	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-7.9	8.3e-14	1.62e-10	-0.54	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
COAD	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	7.89	8.46e-14	1.65e-10	0.54	0.44	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
COAD	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-7.89	8.47e-14	1.66e-10	-0.51	-0.44	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
COAD	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-7.89	8.48e-14	1.66e-10	-0.47	-0.44	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
COAD	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-7.89	8.48e-14	1.66e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-7.89	8.49e-14	1.66e-10	-0.59	-0.44	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
COAD	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-7.89	8.49e-14	1.66e-10	-0.53	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
COAD	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	7.89	8.68e-14	1.7e-10	0.58	0.44	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
COAD	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	7.89	8.69e-14	1.7e-10	0.45	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
COAD	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	7.89	8.76e-14	1.71e-10	0.63	0.44	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
COAD	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	7.89	8.83e-14	1.72e-10	0.55	0.44	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-7.89	8.83e-14	1.72e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-7.89	8.83e-14	1.72e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-7.89	8.83e-14	1.72e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
COAD	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-7.89	8.84e-14	1.73e-10	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
COAD	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-7.88	9e-14	1.75e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
COAD	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	7.88	9.07e-14	1.77e-10	0.55	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
COAD	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	7.88	9.36e-14	1.82e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	7.88	9.42e-14	1.83e-10	0.61	0.44	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
COAD	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	7.88	9.49e-14	1.84e-10	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-7.88	9.52e-14	1.85e-10	-0.58	-0.44	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
COAD	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	7.88	9.57e-14	1.86e-10	0.58	0.44	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
COAD	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-7.87	9.6e-14	1.86e-10	-0.48	-0.44	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
COAD	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-7.87	9.63e-14	1.87e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-7.87	9.63e-14	1.87e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-7.87	9.63e-14	1.87e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
COAD	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	7.87	9.64e-14	1.87e-10	0.46	0.44	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
COAD	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	7.87	9.64e-14	1.87e-10	0.46	0.44	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
COAD	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-7.87	9.69e-14	1.88e-10	-0.5	-0.44	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	7.87	9.85e-14	1.91e-10	0.53	0.44	Height;	chr6:109374782	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-7.87	9.97e-14	1.93e-10	-0.59	-0.44	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-7.87	9.97e-14	1.93e-10	-0.59	-0.44	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-7.87	9.97e-14	1.93e-10	-0.59	-0.44	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
COAD	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-7.87	1.01e-13	1.97e-10	-0.55	-0.44	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
COAD	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	7.87	1.02e-13	1.97e-10	0.47	0.44	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
COAD	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	7.86	1.03e-13	2e-10	0.59	0.44	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
COAD	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.86	1.05e-13	2.03e-10	0.59	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
COAD	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	7.86	1.05e-13	2.03e-10	0.58	0.44	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
COAD	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-7.86	1.07e-13	2.06e-10	-0.54	-0.44	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
COAD	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	7.86	1.08e-13	2.09e-10	0.49	0.44	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
COAD	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	7.86	1.09e-13	2.1e-10	0.64	0.44	Migraine;	chr16:75350086	chr16:75379818~75381260:-
COAD	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-7.85	1.1e-13	2.12e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-7.85	1.1e-13	2.12e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
COAD	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-7.85	1.1e-13	2.13e-10	-0.5	-0.44	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
COAD	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-7.85	1.12e-13	2.16e-10	-0.72	-0.44	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-7.85	1.12e-13	2.16e-10	-0.72	-0.44	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-7.85	1.12e-13	2.16e-10	-0.72	-0.44	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
COAD	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	7.85	1.12e-13	2.16e-10	0.7	0.44	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
COAD	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-7.85	1.12e-13	2.16e-10	-0.55	-0.44	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
COAD	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	7.85	1.12e-13	2.16e-10	0.62	0.44	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
COAD	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-7.85	1.12e-13	2.16e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-7.85	1.12e-13	2.16e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
COAD	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-7.85	1.12e-13	2.16e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
COAD	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-7.85	1.12e-13	2.16e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
COAD	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.85	1.12e-13	2.17e-10	0.58	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
COAD	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-7.85	1.14e-13	2.2e-10	-0.58	-0.44	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
COAD	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	7.85	1.15e-13	2.21e-10	0.61	0.44	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	7.85	1.15e-13	2.21e-10	0.61	0.44	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	7.85	1.15e-13	2.21e-10	0.61	0.44	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
COAD	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	7.84	1.17e-13	2.25e-10	0.51	0.44	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
COAD	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	7.84	1.18e-13	2.27e-10	0.57	0.44	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
COAD	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	7.84	1.18e-13	2.27e-10	0.54	0.44	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
COAD	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	7.84	1.19e-13	2.29e-10	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	7.84	1.19e-13	2.29e-10	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
COAD	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-7.84	1.21e-13	2.32e-10	-0.45	-0.44	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
COAD	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-7.84	1.22e-13	2.35e-10	-0.59	-0.44	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
COAD	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-7.84	1.22e-13	2.35e-10	-0.57	-0.44	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
COAD	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	7.84	1.23e-13	2.35e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	7.84	1.23e-13	2.35e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
COAD	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-7.84	1.23e-13	2.36e-10	-0.54	-0.44	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
COAD	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-7.84	1.23e-13	2.36e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
COAD	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-7.84	1.23e-13	2.36e-10	-0.54	-0.44	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
COAD	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-7.84	1.24e-13	2.37e-10	-0.51	-0.44	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
COAD	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	7.83	1.25e-13	2.39e-10	0.58	0.44	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
COAD	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	7.83	1.25e-13	2.39e-10	0.5	0.44	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
COAD	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-7.83	1.25e-13	2.39e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
COAD	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	7.83	1.26e-13	2.42e-10	0.57	0.44	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	7.83	1.26e-13	2.42e-10	0.57	0.44	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	7.83	1.26e-13	2.42e-10	0.57	0.44	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-7.83	1.27e-13	2.44e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-7.83	1.27e-13	2.44e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	7.83	1.28e-13	2.45e-10	0.52	0.44	Height;	chr6:109367528	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	7.83	1.28e-13	2.45e-10	0.52	0.44	Height;	chr6:109368704	chr6:109382795~109383666:+
COAD	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	7.83	1.29e-13	2.46e-10	0.71	0.44	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
COAD	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-7.83	1.29e-13	2.47e-10	-0.51	-0.44	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
COAD	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	7.83	1.3e-13	2.48e-10	0.57	0.44	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
COAD	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	7.83	1.31e-13	2.51e-10	0.51	0.44	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
COAD	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	7.82	1.33e-13	2.53e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	7.82	1.33e-13	2.53e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	7.82	1.33e-13	2.53e-10	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
COAD	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	7.82	1.33e-13	2.54e-10	0.53	0.44	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
COAD	cis	rs9368481	0.554	rs2754603	ENSG00000224843.5	LINC00240	7.82	1.34e-13	2.56e-10	0.55	0.44	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26956992~27023924:+
COAD	cis	rs9368481	0.761	rs9357028	ENSG00000224843.5	LINC00240	7.82	1.34e-13	2.56e-10	0.55	0.44	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26956992~27023924:+
COAD	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-7.82	1.34e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-7.82	1.34e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-7.82	1.34e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-7.82	1.35e-13	2.56e-10	-0.47	-0.44	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
COAD	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-7.82	1.37e-13	2.6e-10	-0.56	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
COAD	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	7.82	1.37e-13	2.61e-10	0.84	0.44	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	7.82	1.37e-13	2.61e-10	0.84	0.44	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	7.82	1.37e-13	2.61e-10	0.84	0.44	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	7.82	1.37e-13	2.61e-10	0.84	0.44	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
COAD	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-7.82	1.37e-13	2.61e-10	-0.6	-0.44	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
COAD	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	7.82	1.38e-13	2.62e-10	0.64	0.44	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	7.82	1.38e-13	2.62e-10	0.64	0.44	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
COAD	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-7.82	1.4e-13	2.66e-10	-0.55	-0.44	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
COAD	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	7.81	1.44e-13	2.73e-10	0.62	0.44	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
COAD	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-7.81	1.44e-13	2.74e-10	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-7.81	1.44e-13	2.74e-10	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
COAD	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-7.81	1.45e-13	2.75e-10	-0.52	-0.44	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
COAD	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	7.81	1.46e-13	2.77e-10	0.58	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
COAD	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	7.81	1.48e-13	2.81e-10	0.54	0.44	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
COAD	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	7.81	1.49e-13	2.82e-10	0.49	0.44	Temperament;	chr17:14068990	chr17:14024514~14025488:+
COAD	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-7.81	1.5e-13	2.84e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
COAD	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-7.8	1.51e-13	2.87e-10	-0.57	-0.44	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-7.8	1.51e-13	2.87e-10	-0.57	-0.44	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-7.8	1.51e-13	2.87e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
COAD	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-7.8	1.53e-13	2.9e-10	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
COAD	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-7.8	1.53e-13	2.9e-10	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	7.8	1.54e-13	2.91e-10	0.61	0.44	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
COAD	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-7.8	1.54e-13	2.92e-10	-0.53	-0.44	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
COAD	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	7.8	1.54e-13	2.92e-10	0.53	0.44	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
COAD	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	7.8	1.56e-13	2.95e-10	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
COAD	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-7.8	1.56e-13	2.96e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
COAD	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-7.8	1.57e-13	2.97e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
COAD	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	7.8	1.57e-13	2.97e-10	0.57	0.44	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
COAD	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	7.8	1.58e-13	2.98e-10	0.64	0.44	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
COAD	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-7.8	1.58e-13	2.99e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
COAD	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-7.79	1.63e-13	3.08e-10	-0.46	-0.44	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
COAD	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	7.79	1.64e-13	3.09e-10	0.54	0.44	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	7.79	1.64e-13	3.1e-10	0.52	0.44	Height;	chr6:109391084	chr6:109382795~109383666:+
COAD	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	7.79	1.64e-13	3.1e-10	0.68	0.44	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
COAD	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-7.79	1.66e-13	3.14e-10	-0.53	-0.44	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
COAD	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	7.79	1.68e-13	3.16e-10	0.58	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
COAD	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	7.79	1.68e-13	3.16e-10	0.62	0.44	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
COAD	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	7.79	1.68e-13	3.17e-10	0.55	0.44	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
COAD	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	7.79	1.69e-13	3.18e-10	0.58	0.44	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	7.79	1.7e-13	3.21e-10	0.57	0.44	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-7.78	1.72e-13	3.23e-10	-0.48	-0.44	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
COAD	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-7.78	1.77e-13	3.34e-10	-0.54	-0.44	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
COAD	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-7.78	1.78e-13	3.35e-10	-0.49	-0.44	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
COAD	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-13	3.39e-10	0.68	0.44	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-13	3.39e-10	0.68	0.44	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-13	3.39e-10	0.68	0.44	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-13	3.39e-10	0.68	0.44	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
COAD	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	7.78	1.82e-13	3.42e-10	0.54	0.44	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
COAD	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	7.78	1.82e-13	3.42e-10	0.71	0.44	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
COAD	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	7.77	1.84e-13	3.45e-10	0.57	0.44	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
COAD	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	7.77	1.84e-13	3.46e-10	0.58	0.44	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
COAD	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	7.77	1.84e-13	3.46e-10	0.58	0.44	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	7.77	1.84e-13	3.46e-10	0.58	0.44	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
COAD	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	7.77	1.84e-13	3.46e-10	0.58	0.44	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
COAD	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	7.77	1.84e-13	3.46e-10	0.6	0.44	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
COAD	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-7.77	1.89e-13	3.54e-10	-0.57	-0.44	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
COAD	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	7.77	1.9e-13	3.56e-10	0.57	0.44	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
COAD	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	7.77	1.9e-13	3.57e-10	0.7	0.44	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
COAD	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-7.77	1.92e-13	3.6e-10	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
COAD	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-7.77	1.93e-13	3.61e-10	-0.37	-0.44	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
COAD	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-7.77	1.93e-13	3.62e-10	-0.52	-0.44	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
COAD	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-7.77	1.93e-13	3.62e-10	-0.52	-0.44	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
COAD	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-7.77	1.94e-13	3.63e-10	-0.88	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-7.76	1.96e-13	3.67e-10	-0.5	-0.44	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-7.76	1.96e-13	3.67e-10	-0.5	-0.44	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
COAD	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-7.76	1.97e-13	3.69e-10	-0.52	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-7.76	1.97e-13	3.69e-10	-0.52	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
COAD	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-7.76	1.99e-13	3.72e-10	-0.54	-0.44	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
COAD	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	7.76	2.01e-13	3.77e-10	0.54	0.44	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	7.76	2.04e-13	3.8e-10	0.54	0.44	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	7.76	2.04e-13	3.8e-10	0.54	0.44	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	7.76	2.04e-13	3.8e-10	0.54	0.44	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
COAD	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	7.76	2.04e-13	3.81e-10	0.57	0.44	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	7.76	2.04e-13	3.82e-10	0.58	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
COAD	cis	rs7615952	0.543	rs4645102	ENSG00000272840.1	RP11-379B18.6	7.76	2.06e-13	3.84e-10	0.58	0.44	Blood pressure (smoking interaction);	chr3:125705597	chr3:125774714~125797953:+
COAD	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-7.75	2.08e-13	3.88e-10	-0.52	-0.44	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
COAD	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	7.75	2.08e-13	3.88e-10	0.68	0.44	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
COAD	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-7.75	2.09e-13	3.9e-10	-0.49	-0.44	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
COAD	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-7.75	2.09e-13	3.9e-10	-0.48	-0.44	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
COAD	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	7.75	2.12e-13	3.95e-10	0.82	0.44	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
COAD	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	7.75	2.14e-13	3.98e-10	0.57	0.44	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	7.75	2.16e-13	4.01e-10	0.58	0.44	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	7.75	2.18e-13	4.06e-10	0.48	0.44	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
COAD	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	7.75	2.18e-13	4.06e-10	0.66	0.44	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	7.75	2.18e-13	4.06e-10	0.66	0.44	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	7.75	2.18e-13	4.06e-10	0.66	0.44	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
COAD	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	7.75	2.19e-13	4.07e-10	0.51	0.44	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
COAD	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-7.75	2.19e-13	4.07e-10	-0.71	-0.44	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
COAD	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-7.75	2.19e-13	4.07e-10	-0.71	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
COAD	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-7.75	2.19e-13	4.07e-10	-0.71	-0.44	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-7.75	2.21e-13	4.1e-10	-0.46	-0.44	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
COAD	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	7.74	2.25e-13	4.17e-10	0.53	0.43	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
COAD	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-7.74	2.25e-13	4.18e-10	-0.64	-0.43	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
COAD	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-7.74	2.3e-13	4.26e-10	-0.54	-0.43	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
COAD	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-7.74	2.31e-13	4.28e-10	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
COAD	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	7.74	2.31e-13	4.28e-10	0.61	0.43	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
COAD	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	7.74	2.32e-13	4.3e-10	0.56	0.43	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
COAD	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	7.74	2.34e-13	4.33e-10	0.48	0.43	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
COAD	cis	rs9322193	0.923	rs958953	ENSG00000216906.2	RP11-350J20.9	7.73	2.37e-13	4.38e-10	0.6	0.43	Lung cancer;	chr6:149840735	chr6:149904243~149906418:+
COAD	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-7.73	2.37e-13	4.39e-10	-0.54	-0.43	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
COAD	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-7.73	2.39e-13	4.42e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
COAD	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	7.73	2.41e-13	4.46e-10	0.48	0.43	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
COAD	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-7.73	2.43e-13	4.49e-10	-0.54	-0.43	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
COAD	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-7.73	2.44e-13	4.5e-10	-0.5	-0.43	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
COAD	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-7.73	2.44e-13	4.5e-10	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
COAD	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-7.73	2.45e-13	4.52e-10	-0.49	-0.43	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
COAD	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	7.73	2.46e-13	4.54e-10	0.57	0.43	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
COAD	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-7.73	2.46e-13	4.55e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
COAD	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-7.73	2.5e-13	4.61e-10	-0.71	-0.43	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
COAD	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-7.72	2.54e-13	4.67e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
COAD	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	7.72	2.55e-13	4.7e-10	0.57	0.43	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	7.72	2.55e-13	4.7e-10	0.57	0.43	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
COAD	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	7.72	2.56e-13	4.71e-10	0.67	0.43	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
COAD	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-7.72	2.58e-13	4.74e-10	-0.61	-0.43	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
COAD	cis	rs7615952	0.512	rs2979351	ENSG00000272840.1	RP11-379B18.6	7.72	2.58e-13	4.76e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125644755	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs2979336	ENSG00000272840.1	RP11-379B18.6	7.72	2.6e-13	4.78e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125638626	chr3:125774714~125797953:+
COAD	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-7.72	2.61e-13	4.81e-10	-0.52	-0.43	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
COAD	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-7.72	2.67e-13	4.9e-10	-0.53	-0.43	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
COAD	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-7.72	2.67e-13	4.9e-10	-0.53	-0.43	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
COAD	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-7.71	2.7e-13	4.96e-10	-0.53	-0.43	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
COAD	cis	rs7615952	0.512	rs4679430	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125639049	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs34651730	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125639796	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs2979334	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125639980	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs11929125	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125640599	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs11921452	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125640906	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs2922175	ENSG00000272840.1	RP11-379B18.6	7.71	2.74e-13	5.03e-10	0.58	0.43	Blood pressure (smoking interaction);	chr3:125642516	chr3:125774714~125797953:+
COAD	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	7.71	2.76e-13	5.07e-10	0.53	0.43	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	7.71	2.76e-13	5.07e-10	0.53	0.43	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
COAD	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
COAD	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-7.71	2.77e-13	5.08e-10	-0.51	-0.43	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.71	2.77e-13	5.08e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-7.71	2.79e-13	5.11e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-7.71	2.79e-13	5.11e-10	-0.68	-0.43	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-7.71	2.79e-13	5.11e-10	-0.68	-0.43	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	7.71	2.79e-13	5.11e-10	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
COAD	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-7.71	2.8e-13	5.13e-10	-0.51	-0.43	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
COAD	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	7.71	2.8e-13	5.13e-10	0.64	0.43	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	7.71	2.8e-13	5.13e-10	0.64	0.43	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	7.71	2.8e-13	5.13e-10	0.64	0.43	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
COAD	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-7.7	2.85e-13	5.21e-10	-0.66	-0.43	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
COAD	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	7.7	2.85e-13	5.22e-10	0.57	0.43	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	7.7	2.86e-13	5.24e-10	0.56	0.43	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	7.7	2.86e-13	5.24e-10	0.56	0.43	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
COAD	cis	rs7078219	0.505	rs10883362	ENSG00000228778.1	RP11-129J12.1	-7.7	2.87e-13	5.25e-10	-0.47	-0.43	Dental caries;	chr10:99527227	chr10:99527081~99528261:+
COAD	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	7.7	2.87e-13	5.25e-10	0.57	0.43	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
COAD	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	7.7	2.87e-13	5.25e-10	0.52	0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
COAD	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	7.7	2.9e-13	5.3e-10	0.56	0.43	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
COAD	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-7.7	2.9e-13	5.3e-10	-0.57	-0.43	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
COAD	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-7.7	2.91e-13	5.32e-10	-0.6	-0.43	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
COAD	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-7.7	2.92e-13	5.34e-10	-0.5	-0.43	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
COAD	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	7.7	2.93e-13	5.36e-10	0.53	0.43	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
COAD	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-7.7	2.94e-13	5.37e-10	-0.42	-0.43	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
COAD	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	7.7	2.95e-13	5.39e-10	0.56	0.43	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
COAD	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-7.7	2.95e-13	5.39e-10	-0.53	-0.43	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
COAD	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	7.7	2.99e-13	5.46e-10	0.52	0.43	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
COAD	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-7.69	3.06e-13	5.58e-10	-0.53	-0.43	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-7.69	3.06e-13	5.59e-10	-0.47	-0.43	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-7.69	3.1e-13	5.65e-10	-0.57	-0.43	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
COAD	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-7.69	3.12e-13	5.67e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-7.69	3.12e-13	5.67e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-7.69	3.12e-13	5.67e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-7.69	3.12e-13	5.67e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	7.69	3.12e-13	5.69e-10	0.6	0.43	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
COAD	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-7.69	3.14e-13	5.71e-10	-0.51	-0.43	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
COAD	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-7.69	3.15e-13	5.73e-10	-0.53	-0.43	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
COAD	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	7.69	3.15e-13	5.73e-10	0.57	0.43	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-7.69	3.15e-13	5.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	7.69	3.17e-13	5.76e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
COAD	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-7.69	3.17e-13	5.77e-10	-0.57	-0.43	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
COAD	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	7.69	3.18e-13	5.77e-10	0.53	0.43	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	7.69	3.18e-13	5.77e-10	0.53	0.43	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
COAD	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-7.69	3.18e-13	5.77e-10	-0.49	-0.43	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
COAD	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	7.69	3.18e-13	5.78e-10	0.56	0.43	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
COAD	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-7.69	3.18e-13	5.78e-10	-0.52	-0.43	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
COAD	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-7.69	3.2e-13	5.82e-10	-0.52	-0.43	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
COAD	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	7.69	3.23e-13	5.86e-10	0.4	0.43	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
COAD	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.69	3.23e-13	5.87e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.69	3.23e-13	5.87e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.69	3.23e-13	5.87e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
COAD	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-7.69	3.23e-13	5.87e-10	-0.46	-0.43	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
COAD	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-7.68	3.28e-13	5.95e-10	-0.49	-0.43	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
COAD	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	7.68	3.3e-13	5.99e-10	0.56	0.43	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-7.68	3.34e-13	6.05e-10	-0.49	-0.43	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-7.68	3.34e-13	6.05e-10	-0.67	-0.43	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
COAD	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-7.68	3.35e-13	6.07e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
COAD	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-7.68	3.35e-13	6.08e-10	-0.71	-0.43	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
COAD	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	7.68	3.35e-13	6.08e-10	0.45	0.43	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
COAD	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-7.68	3.36e-13	6.09e-10	-0.7	-0.43	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
COAD	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-7.68	3.38e-13	6.12e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-7.68	3.38e-13	6.12e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
COAD	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-7.68	3.42e-13	6.19e-10	-0.52	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-7.68	3.42e-13	6.19e-10	-0.52	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
COAD	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	7.67	3.49e-13	6.3e-10	0.68	0.43	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
COAD	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-7.67	3.51e-13	6.34e-10	-0.52	-0.43	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
COAD	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	7.67	3.52e-13	6.35e-10	0.57	0.43	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
COAD	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-7.67	3.52e-13	6.37e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-7.67	3.52e-13	6.37e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
COAD	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	7.67	3.56e-13	6.42e-10	0.66	0.43	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	7.67	3.56e-13	6.42e-10	0.66	0.43	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	7.67	3.56e-13	6.42e-10	0.66	0.43	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	7.67	3.56e-13	6.42e-10	0.66	0.43	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	7.67	3.56e-13	6.42e-10	0.66	0.43	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	7.67	3.56e-13	6.43e-10	0.47	0.43	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
COAD	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-7.67	3.58e-13	6.46e-10	-0.58	-0.43	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
COAD	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-7.67	3.58e-13	6.46e-10	-0.37	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
COAD	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.67	3.6e-13	6.5e-10	0.57	0.43	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.67	3.6e-13	6.5e-10	0.57	0.43	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
COAD	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-7.67	3.66e-13	6.6e-10	-0.47	-0.43	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
COAD	cis	rs9368481	0.729	rs9379950	ENSG00000224843.5	LINC00240	7.67	3.66e-13	6.6e-10	0.54	0.43	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26956992~27023924:+
COAD	cis	rs9368481	1	rs9368481	ENSG00000224843.5	LINC00240	7.67	3.66e-13	6.6e-10	0.54	0.43	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26956992~27023924:+
COAD	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	7.66	3.68e-13	6.62e-10	0.62	0.43	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
COAD	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	7.66	3.68e-13	6.63e-10	0.5	0.43	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
COAD	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	7.66	3.69e-13	6.65e-10	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
COAD	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-7.66	3.69e-13	6.65e-10	-0.5	-0.43	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	7.66	3.7e-13	6.66e-10	0.57	0.43	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	7.66	3.72e-13	6.68e-10	0.47	0.43	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
COAD	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-7.66	3.73e-13	6.71e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
COAD	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	7.66	3.74e-13	6.71e-10	0.57	0.43	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
COAD	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	7.66	3.76e-13	6.76e-10	0.54	0.43	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
COAD	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	7.66	3.77e-13	6.77e-10	0.57	0.43	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-7.66	3.77e-13	6.78e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
COAD	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-7.66	3.79e-13	6.8e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-7.66	3.8e-13	6.81e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-7.66	3.8e-13	6.81e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-7.66	3.83e-13	6.87e-10	-0.49	-0.43	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-7.66	3.84e-13	6.88e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	7.65	3.92e-13	7.02e-10	0.59	0.43	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	7.65	3.92e-13	7.02e-10	0.47	0.43	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
COAD	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-7.65	3.93e-13	7.04e-10	-0.52	-0.43	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	7.65	3.93e-13	7.04e-10	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
COAD	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	7.65	3.97e-13	7.11e-10	0.55	0.43	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	7.65	4.01e-13	7.18e-10	0.46	0.43	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-7.65	4.07e-13	7.27e-10	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
COAD	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-7.65	4.07e-13	7.28e-10	-0.49	-0.43	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
COAD	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	7.65	4.1e-13	7.32e-10	0.52	0.43	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
COAD	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	7.65	4.11e-13	7.34e-10	0.57	0.43	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
COAD	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-7.65	4.16e-13	7.42e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
COAD	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-7.64	4.2e-13	7.49e-10	-0.47	-0.43	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
COAD	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	7.64	4.2e-13	7.5e-10	0.69	0.43	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	7.64	4.21e-13	7.52e-10	0.51	0.43	Height;	chr6:109358652	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-7.64	4.22e-13	7.52e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
COAD	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	7.64	4.23e-13	7.55e-10	0.6	0.43	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
COAD	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-7.64	4.24e-13	7.56e-10	-0.52	-0.43	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
COAD	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	7.64	4.29e-13	7.64e-10	0.53	0.43	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	7.64	4.29e-13	7.64e-10	0.53	0.43	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-7.64	4.3e-13	7.66e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
COAD	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
COAD	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
COAD	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
COAD	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
COAD	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-7.64	4.3e-13	7.67e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.64	4.32e-13	7.68e-10	0.45	0.43	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	7.64	4.32e-13	7.69e-10	0.45	0.43	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-7.64	4.35e-13	7.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-7.64	4.35e-13	7.73e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
COAD	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	7.64	4.4e-13	7.83e-10	0.56	0.43	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
COAD	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	7.64	4.41e-13	7.84e-10	0.69	0.43	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
COAD	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	7.64	4.42e-13	7.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
COAD	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	7.64	4.42e-13	7.85e-10	0.42	0.43	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
COAD	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	7.64	4.42e-13	7.85e-10	0.42	0.43	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
COAD	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-7.64	4.43e-13	7.87e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
COAD	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-7.64	4.43e-13	7.87e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
COAD	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	7.63	4.47e-13	7.94e-10	0.55	0.43	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
COAD	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	7.63	4.49e-13	7.97e-10	0.64	0.43	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
COAD	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-7.63	4.5e-13	7.98e-10	-0.5	-0.43	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
COAD	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	7.63	4.5e-13	7.99e-10	0.49	0.43	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
COAD	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-7.63	4.55e-13	8.08e-10	-0.52	-0.43	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
COAD	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-7.63	4.58e-13	8.13e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
COAD	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-7.63	4.58e-13	8.13e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.63	4.59e-13	8.15e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.63	4.59e-13	8.15e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	7.63	4.69e-13	8.31e-10	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	7.63	4.69e-13	8.31e-10	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
COAD	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	7.63	4.7e-13	8.33e-10	0.45	0.43	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
COAD	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-7.62	4.74e-13	8.39e-10	-0.53	-0.43	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
COAD	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	7.62	4.75e-13	8.41e-10	0.56	0.43	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
COAD	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	7.62	4.79e-13	8.48e-10	0.62	0.43	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	7.62	4.79e-13	8.48e-10	0.62	0.43	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
COAD	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	7.62	4.83e-13	8.53e-10	0.55	0.43	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
COAD	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	7.62	4.83e-13	8.55e-10	0.61	0.43	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
COAD	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-7.62	4.88e-13	8.62e-10	-0.53	-0.43	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-7.62	4.88e-13	8.62e-10	-0.53	-0.43	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-7.62	4.88e-13	8.62e-10	-0.53	-0.43	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-7.62	4.88e-13	8.62e-10	-0.53	-0.43	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-7.62	4.88e-13	8.62e-10	-0.53	-0.43	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
COAD	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	7.62	4.89e-13	8.64e-10	0.67	0.43	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
COAD	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	7.62	4.93e-13	8.71e-10	0.52	0.43	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	7.62	4.93e-13	8.71e-10	0.52	0.43	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-7.62	4.93e-13	8.71e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
COAD	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-7.62	4.96e-13	8.74e-10	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
COAD	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-7.62	4.99e-13	8.81e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
COAD	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-7.62	5.01e-13	8.84e-10	-0.53	-0.43	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-7.62	5.01e-13	8.84e-10	-0.53	-0.43	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
COAD	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	7.62	5.03e-13	8.87e-10	0.53	0.43	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
COAD	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	7.61	5.06e-13	8.91e-10	0.68	0.43	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	7.61	5.06e-13	8.91e-10	0.68	0.43	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	7.61	5.06e-13	8.91e-10	0.68	0.43	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.61	5.07e-13	8.93e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.546	rs2976733	ENSG00000272840.1	RP11-379B18.6	7.61	5.09e-13	8.95e-10	0.56	0.43	Blood pressure (smoking interaction);	chr3:125695294	chr3:125774714~125797953:+
COAD	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	7.61	5.1e-13	8.97e-10	0.45	0.43	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-7.61	5.11e-13	8.97e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
COAD	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	7.61	5.12e-13	8.98e-10	0.66	0.43	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
COAD	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-7.61	5.15e-13	9.02e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-7.61	5.15e-13	9.02e-10	-0.46	-0.43	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
COAD	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	7.61	5.21e-13	9.13e-10	0.55	0.43	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
COAD	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	7.61	5.25e-13	9.2e-10	0.48	0.43	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
COAD	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	7.61	5.25e-13	9.2e-10	0.48	0.43	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
COAD	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-7.61	5.26e-13	9.21e-10	-0.48	-0.43	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
COAD	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-7.61	5.31e-13	9.29e-10	-0.45	-0.43	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
COAD	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	7.61	5.31e-13	9.29e-10	0.66	0.43	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
COAD	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	7.61	5.31e-13	9.29e-10	0.59	0.43	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
COAD	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	7.61	5.31e-13	9.29e-10	0.53	0.43	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
COAD	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	7.61	5.32e-13	9.31e-10	0.57	0.43	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
COAD	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	7.61	5.33e-13	9.32e-10	0.82	0.43	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
COAD	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	7.6	5.41e-13	9.45e-10	0.48	0.43	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
COAD	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	7.6	5.41e-13	9.45e-10	0.7	0.43	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
COAD	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-7.6	5.45e-13	9.51e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-7.6	5.47e-13	9.54e-10	-0.47	-0.43	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
COAD	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-7.6	5.48e-13	9.57e-10	-0.47	-0.43	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
COAD	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-7.6	5.54e-13	9.66e-10	-0.65	-0.43	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
COAD	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-7.6	5.54e-13	9.66e-10	-0.48	-0.43	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
COAD	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-7.6	5.58e-13	9.72e-10	-0.53	-0.43	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
COAD	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-7.6	5.59e-13	9.75e-10	-0.51	-0.43	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	7.6	5.61e-13	9.78e-10	0.6	0.43	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-7.6	5.64e-13	9.81e-10	-0.46	-0.43	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
COAD	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-7.6	5.64e-13	9.81e-10	-0.47	-0.43	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
COAD	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	7.6	5.66e-13	9.85e-10	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-7.6	5.67e-13	9.87e-10	-0.53	-0.43	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
COAD	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	7.6	5.69e-13	9.9e-10	0.67	0.43	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	7.6	5.69e-13	9.9e-10	0.67	0.43	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	7.6	5.69e-13	9.9e-10	0.67	0.43	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
COAD	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-7.59	5.78e-13	1.01e-09	-0.63	-0.43	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
COAD	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	7.59	5.82e-13	1.01e-09	0.62	0.43	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
COAD	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	7.59	5.92e-13	1.03e-09	0.61	0.43	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
COAD	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	7.59	5.97e-13	1.04e-09	0.55	0.43	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
COAD	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-7.59	5.98e-13	1.04e-09	-0.66	-0.43	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
COAD	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	7.59	5.99e-13	1.04e-09	0.51	0.43	Height;	chr6:109407238	chr6:109382795~109383666:+
COAD	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	7.59	5.99e-13	1.04e-09	0.5	0.43	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
COAD	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-7.59	6.03e-13	1.05e-09	-0.55	-0.43	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
COAD	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	7.59	6.04e-13	1.05e-09	0.56	0.43	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.59	6.05e-13	1.05e-09	-0.46	-0.43	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-7.58	6.12e-13	1.06e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-7.58	6.12e-13	1.06e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-7.58	6.15e-13	1.07e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-7.58	6.15e-13	1.07e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
COAD	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	7.58	6.15e-13	1.07e-09	0.54	0.43	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
COAD	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-7.58	6.16e-13	1.07e-09	-0.52	-0.43	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
COAD	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-7.58	6.2e-13	1.07e-09	-0.46	-0.43	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-7.58	6.24e-13	1.08e-09	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-7.58	6.24e-13	1.08e-09	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
COAD	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	7.58	6.25e-13	1.08e-09	0.82	0.43	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
COAD	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	7.58	6.31e-13	1.09e-09	0.48	0.43	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
COAD	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	7.58	6.33e-13	1.09e-09	0.49	0.43	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-7.58	6.33e-13	1.09e-09	-0.52	-0.43	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	7.58	6.42e-13	1.11e-09	0.56	0.43	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
COAD	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-7.58	6.43e-13	1.11e-09	-0.53	-0.43	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-7.58	6.46e-13	1.12e-09	-0.46	-0.43	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
COAD	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	7.57	6.51e-13	1.13e-09	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
COAD	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	7.57	6.53e-13	1.13e-09	0.64	0.43	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
COAD	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	7.57	6.54e-13	1.13e-09	0.59	0.43	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
COAD	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	7.57	6.55e-13	1.13e-09	0.64	0.43	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
COAD	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-7.57	6.56e-13	1.13e-09	-0.51	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
COAD	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	7.57	6.59e-13	1.14e-09	0.55	0.43	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	7.57	6.66e-13	1.15e-09	0.55	0.43	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
COAD	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-7.57	6.66e-13	1.15e-09	-0.47	-0.43	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
COAD	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-7.57	6.66e-13	1.15e-09	-0.47	-0.43	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
COAD	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-7.57	6.66e-13	1.15e-09	-0.47	-0.43	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
COAD	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-7.57	6.71e-13	1.16e-09	-0.52	-0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
COAD	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	7.57	6.73e-13	1.16e-09	0.61	0.43	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	7.57	6.74e-13	1.16e-09	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
COAD	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-7.57	6.77e-13	1.17e-09	-0.52	-0.43	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
COAD	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-7.56	6.91e-13	1.19e-09	-0.81	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
COAD	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.56	6.94e-13	1.19e-09	0.53	0.43	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
COAD	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-7.56	6.95e-13	1.2e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-7.56	6.95e-13	1.2e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-7.56	6.95e-13	1.2e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-7.56	6.96e-13	1.2e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
COAD	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	7.56	6.99e-13	1.2e-09	0.66	0.43	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
COAD	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-7.56	7e-13	1.2e-09	-0.46	-0.43	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
COAD	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-7.56	7e-13	1.2e-09	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
COAD	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	7.56	7.02e-13	1.21e-09	0.47	0.43	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	7.56	7.08e-13	1.22e-09	0.82	0.43	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
COAD	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	7.56	7.1e-13	1.22e-09	0.54	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
COAD	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-7.56	7.12e-13	1.22e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-7.56	7.12e-13	1.22e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
COAD	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-7.56	7.12e-13	1.22e-09	-0.45	-0.43	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
COAD	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	7.56	7.14e-13	1.23e-09	0.56	0.43	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	7.56	7.14e-13	1.23e-09	0.56	0.43	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
COAD	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	7.56	7.15e-13	1.23e-09	0.52	0.43	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	7.56	7.15e-13	1.23e-09	0.52	0.43	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-7.56	7.18e-13	1.23e-09	-0.46	-0.43	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	7.56	7.21e-13	1.24e-09	0.57	0.43	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
COAD	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-7.56	7.21e-13	1.24e-09	-0.54	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
COAD	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-7.56	7.23e-13	1.24e-09	-0.46	-0.43	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
COAD	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-7.56	7.23e-13	1.24e-09	-0.46	-0.43	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
COAD	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	7.56	7.32e-13	1.26e-09	0.55	0.43	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	7.56	7.34e-13	1.26e-09	0.46	0.43	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
COAD	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-7.55	7.5e-13	1.29e-09	-0.52	-0.43	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
COAD	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-7.55	7.5e-13	1.29e-09	-0.52	-0.43	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
COAD	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-7.55	7.52e-13	1.29e-09	-0.46	-0.43	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
COAD	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	7.55	7.56e-13	1.29e-09	0.55	0.43	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	7.55	7.57e-13	1.3e-09	0.56	0.43	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
COAD	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	7.55	7.63e-13	1.31e-09	0.49	0.43	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
COAD	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-7.55	7.65e-13	1.31e-09	-0.69	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
COAD	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-7.55	7.66e-13	1.31e-09	-0.61	-0.43	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
COAD	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-7.55	7.67e-13	1.31e-09	-0.5	-0.43	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
COAD	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	7.55	7.72e-13	1.32e-09	0.67	0.43	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
COAD	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	7.55	7.72e-13	1.32e-09	0.56	0.43	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
COAD	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	7.55	7.74e-13	1.32e-09	0.47	0.43	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
COAD	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	7.55	7.76e-13	1.33e-09	0.53	0.43	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
COAD	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-7.55	7.8e-13	1.33e-09	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
COAD	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	7.55	7.81e-13	1.34e-09	0.49	0.43	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-7.54	7.86e-13	1.34e-09	-0.5	-0.43	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.673	rs16834637	ENSG00000248787.1	RP11-666A20.4	-7.54	7.92e-13	1.35e-09	-0.66	-0.43	Blood pressure (smoking interaction);	chr3:125886628	chr3:125908005~125910272:-
COAD	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-7.54	7.92e-13	1.35e-09	-0.46	-0.43	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
COAD	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-7.54	7.92e-13	1.35e-09	-0.39	-0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
COAD	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-7.54	7.95e-13	1.36e-09	-0.52	-0.43	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
COAD	cis	rs6584283	0.846	rs11190135	ENSG00000228778.1	RP11-129J12.1	-7.54	8.02e-13	1.37e-09	-0.47	-0.43	Ulcerative colitis;	chr10:99527091	chr10:99527081~99528261:+
COAD	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	7.54	8.06e-13	1.38e-09	0.45	0.43	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.54	8.19e-13	1.4e-09	0.51	0.43	Height;	chr6:109357369	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-7.54	8.33e-13	1.42e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-7.54	8.33e-13	1.42e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-7.54	8.33e-13	1.42e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-7.54	8.33e-13	1.42e-09	-0.48	-0.43	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
COAD	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-7.53	8.39e-13	1.43e-09	-0.51	-0.43	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	7.53	8.4e-13	1.43e-09	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
COAD	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-7.53	8.44e-13	1.44e-09	-0.47	-0.43	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
COAD	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	7.53	8.49e-13	1.44e-09	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
COAD	cis	rs7078219	0.523	rs10883366	ENSG00000228778.1	RP11-129J12.1	-7.53	8.52e-13	1.45e-09	-0.47	-0.43	Dental caries;	chr10:99528028	chr10:99527081~99528261:+
COAD	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	7.53	8.52e-13	1.45e-09	0.56	0.43	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
COAD	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-7.53	8.61e-13	1.46e-09	-0.66	-0.43	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
COAD	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	7.53	8.65e-13	1.47e-09	0.52	0.43	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	7.53	8.65e-13	1.47e-09	0.52	0.43	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
COAD	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	7.53	8.72e-13	1.48e-09	0.56	0.43	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	7.53	8.72e-13	1.48e-09	0.56	0.43	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	7.53	8.77e-13	1.49e-09	0.56	0.43	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
COAD	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	7.53	8.78e-13	1.49e-09	0.47	0.42	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
COAD	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	7.53	8.8e-13	1.49e-09	0.47	0.42	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
COAD	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	7.53	8.82e-13	1.5e-09	0.45	0.42	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
COAD	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	7.52	8.88e-13	1.51e-09	0.67	0.42	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
COAD	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.52	8.92e-13	1.51e-09	0.74	0.42	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
COAD	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	7.52	8.92e-13	1.51e-09	0.63	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
COAD	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	7.52	8.98e-13	1.52e-09	0.53	0.42	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	7.52	8.98e-13	1.52e-09	0.53	0.42	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	7.52	8.98e-13	1.52e-09	0.53	0.42	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
COAD	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	7.52	9.03e-13	1.53e-09	0.55	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
COAD	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-7.52	9.05e-13	1.53e-09	-0.51	-0.42	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
COAD	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	7.52	9.12e-13	1.54e-09	0.48	0.42	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
COAD	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	7.52	9.15e-13	1.55e-09	0.55	0.42	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	7.52	9.15e-13	1.55e-09	0.55	0.42	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
COAD	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-7.52	9.16e-13	1.55e-09	-0.52	-0.42	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
COAD	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-7.52	9.22e-13	1.56e-09	-0.51	-0.42	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
COAD	cis	rs7078219	0.505	rs7085798	ENSG00000228778.1	RP11-129J12.1	-7.52	9.28e-13	1.57e-09	-0.47	-0.42	Dental caries;	chr10:99528590	chr10:99527081~99528261:+
COAD	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-7.52	9.32e-13	1.57e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-7.52	9.32e-13	1.57e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
COAD	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-7.52	9.32e-13	1.57e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
COAD	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-7.52	9.32e-13	1.57e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
COAD	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	7.52	9.32e-13	1.58e-09	0.44	0.42	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
COAD	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-7.52	9.32e-13	1.58e-09	-0.51	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
COAD	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	7.52	9.33e-13	1.58e-09	0.5	0.42	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
COAD	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	7.52	9.34e-13	1.58e-09	0.56	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
COAD	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.52	9.39e-13	1.59e-09	-0.5	-0.42	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	7.51	9.56e-13	1.61e-09	0.45	0.42	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	7.51	9.6e-13	1.62e-09	0.51	0.42	Height;	chr6:109494237	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	7.51	9.6e-13	1.62e-09	0.51	0.42	Height;	chr6:109496073	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	7.51	9.6e-13	1.62e-09	0.51	0.42	Height;	chr6:109347707	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	7.51	9.6e-13	1.62e-09	0.51	0.42	Height;	chr6:109498586	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	7.51	9.6e-13	1.62e-09	0.51	0.42	Height;	chr6:109499759	chr6:109382795~109383666:+
COAD	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	7.51	9.62e-13	1.62e-09	0.54	0.42	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-7.51	9.76e-13	1.64e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	7.51	9.86e-13	1.66e-09	0.84	0.42	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	7.51	9.86e-13	1.66e-09	0.84	0.42	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
COAD	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	7.51	9.87e-13	1.66e-09	0.53	0.42	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
COAD	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	7.51	9.95e-13	1.67e-09	0.51	0.42	Height;	chr6:109507271	chr6:109382795~109383666:+
COAD	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	7.5	1.01e-12	1.69e-09	0.52	0.42	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	7.5	1.01e-12	1.69e-09	0.52	0.42	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	7.5	1.01e-12	1.69e-09	0.52	0.42	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-7.5	1.01e-12	1.7e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-7.5	1.01e-12	1.7e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-7.5	1.01e-12	1.7e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
COAD	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
COAD	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	7.5	1.02e-12	1.71e-09	0.62	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	7.5	1.02e-12	1.71e-09	0.62	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
COAD	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-7.5	1.02e-12	1.71e-09	-0.51	-0.42	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
COAD	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	7.5	1.02e-12	1.71e-09	0.64	0.42	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
COAD	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-7.5	1.02e-12	1.71e-09	-0.45	-0.42	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
COAD	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	7.5	1.02e-12	1.71e-09	0.8	0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
COAD	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-7.5	1.02e-12	1.71e-09	-0.45	-0.42	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
COAD	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	7.5	1.03e-12	1.72e-09	0.45	0.42	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-7.5	1.04e-12	1.74e-09	-0.48	-0.42	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
COAD	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-7.5	1.04e-12	1.74e-09	-0.5	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
COAD	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	7.5	1.04e-12	1.75e-09	0.48	0.42	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
COAD	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	7.5	1.05e-12	1.75e-09	0.56	0.42	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
COAD	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-7.5	1.06e-12	1.77e-09	-0.53	-0.42	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-7.5	1.06e-12	1.77e-09	-0.53	-0.42	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
COAD	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.5	1.06e-12	1.77e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.512	rs4234285	ENSG00000272840.1	RP11-379B18.6	7.5	1.06e-12	1.77e-09	0.56	0.42	Blood pressure (smoking interaction);	chr3:125685633	chr3:125774714~125797953:+
COAD	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-7.5	1.07e-12	1.78e-09	-0.47	-0.42	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
COAD	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	7.49	1.09e-12	1.81e-09	0.5	0.42	Height;	chr6:109640141	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	7.49	1.09e-12	1.81e-09	0.5	0.42	Height;	chr6:109642186	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	7.49	1.09e-12	1.81e-09	0.5	0.42	Height;	chr6:109646187	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	7.49	1.09e-12	1.81e-09	0.5	0.42	Height;	chr6:109652694	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	7.49	1.09e-12	1.81e-09	0.5	0.42	Height;	chr6:109655791	chr6:109382795~109383666:+
COAD	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-7.49	1.1e-12	1.83e-09	-0.51	-0.42	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
COAD	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-7.49	1.1e-12	1.84e-09	-0.52	-0.42	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	7.49	1.11e-12	1.85e-09	0.57	0.42	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	7.49	1.11e-12	1.85e-09	0.46	0.42	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
COAD	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-7.49	1.11e-12	1.85e-09	-0.47	-0.42	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
COAD	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-7.49	1.11e-12	1.85e-09	-0.47	-0.42	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
COAD	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	7.49	1.12e-12	1.86e-09	0.49	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
COAD	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-7.49	1.12e-12	1.86e-09	-0.49	-0.42	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-7.49	1.12e-12	1.86e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
COAD	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	7.49	1.13e-12	1.87e-09	0.65	0.42	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
COAD	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	7.49	1.13e-12	1.87e-09	0.51	0.42	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	7.49	1.13e-12	1.88e-09	0.52	0.42	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	7.49	1.13e-12	1.88e-09	0.52	0.42	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
COAD	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.49	1.14e-12	1.89e-09	-0.51	-0.42	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
COAD	cis	rs5769707	0.967	rs739241	ENSG00000188511.11	C22orf34	7.48	1.15e-12	1.91e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49414524~49657542:-
COAD	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	7.48	1.15e-12	1.91e-09	0.5	0.42	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
COAD	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-7.48	1.16e-12	1.93e-09	-0.56	-0.42	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
COAD	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	7.48	1.17e-12	1.94e-09	0.51	0.42	Height;	chr6:109503623	chr6:109382795~109383666:+
COAD	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-7.48	1.17e-12	1.94e-09	-0.52	-0.42	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
COAD	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-7.48	1.17e-12	1.95e-09	-0.56	-0.42	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-7.48	1.18e-12	1.96e-09	-0.56	-0.42	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-7.48	1.18e-12	1.96e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-7.48	1.18e-12	1.96e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-7.48	1.18e-12	1.96e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
COAD	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-7.48	1.19e-12	1.97e-09	-0.52	-0.42	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
COAD	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-7.48	1.19e-12	1.97e-09	-0.63	-0.42	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
COAD	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-7.48	1.19e-12	1.98e-09	-0.51	-0.42	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
COAD	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	7.48	1.2e-12	1.98e-09	0.59	0.42	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-7.48	1.21e-12	2e-09	-0.54	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
COAD	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-7.48	1.21e-12	2e-09	-0.61	-0.42	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
COAD	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	7.48	1.21e-12	2.01e-09	0.64	0.42	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
COAD	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-7.47	1.22e-12	2.01e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
COAD	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	7.47	1.22e-12	2.02e-09	0.54	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
COAD	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.47	1.22e-12	2.02e-09	-0.5	-0.42	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
COAD	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-7.47	1.22e-12	2.02e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-7.47	1.22e-12	2.02e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
COAD	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	7.47	1.22e-12	2.03e-09	0.39	0.42	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
COAD	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	7.47	1.23e-12	2.03e-09	0.52	0.42	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	7.47	1.23e-12	2.03e-09	0.48	0.42	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	7.47	1.23e-12	2.04e-09	0.64	0.42	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
COAD	cis	rs6584283	0.846	rs7917446	ENSG00000228778.1	RP11-129J12.1	-7.47	1.24e-12	2.06e-09	-0.47	-0.42	Ulcerative colitis;	chr10:99526450	chr10:99527081~99528261:+
COAD	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	7.47	1.25e-12	2.06e-09	0.55	0.42	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-7.47	1.25e-12	2.07e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	7.47	1.27e-12	2.09e-09	0.62	0.42	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
COAD	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	7.47	1.27e-12	2.1e-09	0.59	0.42	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
COAD	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	7.47	1.27e-12	2.1e-09	0.54	0.42	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
COAD	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-7.47	1.27e-12	2.1e-09	-0.56	-0.42	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
COAD	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	7.47	1.29e-12	2.13e-09	0.44	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
COAD	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	7.47	1.29e-12	2.13e-09	0.5	0.42	Height;	chr6:109634150	chr6:109382795~109383666:+
COAD	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	7.47	1.29e-12	2.13e-09	0.61	0.42	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
COAD	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	7.47	1.29e-12	2.13e-09	0.49	0.42	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	7.46	1.3e-12	2.14e-09	0.49	0.42	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	7.46	1.3e-12	2.14e-09	0.8	0.42	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
COAD	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	7.46	1.3e-12	2.15e-09	0.5	0.42	Height;	chr6:109501402	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	7.46	1.3e-12	2.15e-09	0.5	0.42	Height;	chr6:109501429	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	7.46	1.32e-12	2.18e-09	0.5	0.42	Height;	chr6:109608105	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	7.46	1.32e-12	2.18e-09	0.5	0.42	Height;	chr6:109618620	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	7.46	1.32e-12	2.18e-09	0.5	0.42	Height;	chr6:109620772	chr6:109382795~109383666:+
COAD	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	7.46	1.32e-12	2.18e-09	0.43	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
COAD	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	7.46	1.33e-12	2.19e-09	0.51	0.42	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
COAD	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	7.46	1.33e-12	2.2e-09	0.55	0.42	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
COAD	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	7.46	1.34e-12	2.21e-09	0.52	0.42	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
COAD	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	7.46	1.34e-12	2.21e-09	0.44	0.42	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
COAD	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.46	1.35e-12	2.22e-09	0.47	0.42	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
COAD	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	7.46	1.36e-12	2.23e-09	0.61	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	7.46	1.36e-12	2.23e-09	0.61	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
COAD	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-7.46	1.37e-12	2.25e-09	-0.64	-0.42	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-7.45	1.39e-12	2.29e-09	-0.53	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
COAD	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	7.45	1.4e-12	2.3e-09	0.54	0.42	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
COAD	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	7.45	1.4e-12	2.3e-09	0.48	0.42	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
COAD	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-7.45	1.41e-12	2.32e-09	-0.46	-0.42	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
COAD	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-7.45	1.42e-12	2.34e-09	-0.45	-0.42	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
COAD	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	7.45	1.44e-12	2.37e-09	0.51	0.42	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
COAD	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-7.45	1.44e-12	2.37e-09	-0.53	-0.42	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-7.45	1.44e-12	2.37e-09	-0.53	-0.42	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
COAD	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-7.45	1.46e-12	2.4e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-7.45	1.46e-12	2.4e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-7.45	1.46e-12	2.4e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-7.44	1.47e-12	2.41e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-7.44	1.47e-12	2.41e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
COAD	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-7.44	1.48e-12	2.42e-09	-0.52	-0.42	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
COAD	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	7.44	1.48e-12	2.43e-09	0.74	0.42	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	7.44	1.48e-12	2.43e-09	0.74	0.42	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
COAD	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	7.44	1.48e-12	2.43e-09	0.68	0.42	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
COAD	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	7.44	1.48e-12	2.43e-09	0.53	0.42	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
COAD	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-7.44	1.49e-12	2.45e-09	-0.5	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
COAD	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	7.44	1.5e-12	2.45e-09	0.55	0.42	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	7.44	1.5e-12	2.45e-09	0.55	0.42	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	7.44	1.5e-12	2.45e-09	0.55	0.42	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	7.44	1.5e-12	2.45e-09	0.55	0.42	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	7.44	1.5e-12	2.45e-09	0.55	0.42	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
COAD	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-7.44	1.5e-12	2.45e-09	-0.52	-0.42	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-7.44	1.5e-12	2.45e-09	-0.52	-0.42	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
COAD	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-7.44	1.5e-12	2.46e-09	-0.56	-0.42	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
COAD	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	7.44	1.51e-12	2.47e-09	0.55	0.42	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	7.44	1.51e-12	2.47e-09	0.55	0.42	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
COAD	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-7.44	1.51e-12	2.47e-09	-0.56	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
COAD	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	7.44	1.51e-12	2.47e-09	0.41	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
COAD	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	7.44	1.53e-12	2.5e-09	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
COAD	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	7.44	1.53e-12	2.51e-09	0.72	0.42	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
COAD	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-7.44	1.54e-12	2.52e-09	-0.52	-0.42	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
COAD	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-7.44	1.55e-12	2.54e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
COAD	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-7.44	1.55e-12	2.54e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
COAD	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	7.44	1.55e-12	2.54e-09	0.45	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
COAD	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-7.43	1.56e-12	2.56e-09	-0.5	-0.42	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
COAD	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	7.43	1.57e-12	2.56e-09	0.51	0.42	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
COAD	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	7.43	1.57e-12	2.56e-09	0.54	0.42	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
COAD	cis	rs7078219	0.523	rs4129134	ENSG00000228778.1	RP11-129J12.1	-7.43	1.58e-12	2.58e-09	-0.46	-0.42	Dental caries;	chr10:99524588	chr10:99527081~99528261:+
COAD	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	7.43	1.58e-12	2.59e-09	0.51	0.42	Height;	chr6:109346560	chr6:109382795~109383666:+
COAD	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	7.43	1.6e-12	2.61e-09	0.5	0.42	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
COAD	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	7.43	1.6e-12	2.61e-09	0.5	0.42	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
COAD	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-7.43	1.6e-12	2.61e-09	-0.65	-0.42	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-7.43	1.6e-12	2.61e-09	-0.65	-0.42	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-7.43	1.6e-12	2.61e-09	-0.65	-0.42	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-7.43	1.6e-12	2.61e-09	-0.65	-0.42	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
COAD	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.43	1.6e-12	2.62e-09	0.5	0.42	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	7.43	1.61e-12	2.62e-09	0.5	0.42	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	7.43	1.61e-12	2.62e-09	0.5	0.42	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
COAD	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	7.43	1.61e-12	2.63e-09	0.5	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
COAD	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-7.43	1.62e-12	2.64e-09	-0.49	-0.42	Height;	chr6:109497253	chr6:109382795~109383666:+
COAD	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	7.43	1.62e-12	2.64e-09	0.54	0.42	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
COAD	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	7.43	1.63e-12	2.65e-09	0.51	0.42	Height;	chr6:109518783	chr6:109382795~109383666:+
COAD	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.43	1.64e-12	2.67e-09	-0.41	-0.42	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
COAD	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-7.43	1.64e-12	2.67e-09	-0.5	-0.42	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-7.43	1.64e-12	2.67e-09	-0.5	-0.42	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
COAD	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-7.43	1.64e-12	2.68e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-7.43	1.64e-12	2.68e-09	-0.48	-0.42	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
COAD	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	7.43	1.64e-12	2.68e-09	0.51	0.42	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
COAD	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	7.43	1.65e-12	2.68e-09	0.59	0.42	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
COAD	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	7.43	1.65e-12	2.69e-09	0.45	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
COAD	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	7.43	1.66e-12	2.7e-09	0.53	0.42	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
COAD	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	7.42	1.66e-12	2.71e-09	0.51	0.42	Height;	chr6:109526846	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	7.42	1.66e-12	2.71e-09	0.51	0.42	Height;	chr6:109533040	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	7.42	1.66e-12	2.71e-09	0.51	0.42	Height;	chr6:109534269	chr6:109382795~109383666:+
COAD	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.42	1.67e-12	2.72e-09	-0.43	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
COAD	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	7.42	1.67e-12	2.72e-09	0.52	0.42	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
COAD	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	7.42	1.68e-12	2.73e-09	0.63	0.42	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
COAD	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-7.42	1.68e-12	2.74e-09	-0.49	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
COAD	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	7.42	1.69e-12	2.74e-09	0.63	0.42	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	7.42	1.69e-12	2.74e-09	0.63	0.42	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	7.42	1.69e-12	2.74e-09	0.63	0.42	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
COAD	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	7.42	1.69e-12	2.74e-09	0.55	0.42	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
COAD	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	7.42	1.7e-12	2.76e-09	0.51	0.42	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
COAD	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.42	1.7e-12	2.77e-09	0.52	0.42	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	7.42	1.71e-12	2.77e-09	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
COAD	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-7.42	1.71e-12	2.77e-09	-0.5	-0.42	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
COAD	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	7.42	1.71e-12	2.78e-09	0.47	0.42	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
COAD	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	7.42	1.71e-12	2.78e-09	0.59	0.42	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	7.42	1.73e-12	2.8e-09	0.59	0.42	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
COAD	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	7.42	1.73e-12	2.8e-09	0.5	0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
COAD	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-7.42	1.74e-12	2.82e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
COAD	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	7.42	1.74e-12	2.82e-09	0.84	0.42	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
COAD	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	7.42	1.74e-12	2.82e-09	0.31	0.42	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
COAD	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-7.42	1.75e-12	2.84e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
COAD	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.42	1.75e-12	2.84e-09	-0.51	-0.42	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
COAD	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-7.41	1.78e-12	2.88e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
COAD	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-7.41	1.81e-12	2.93e-09	-0.66	-0.42	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
COAD	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	7.41	1.81e-12	2.93e-09	0.44	0.42	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
COAD	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-7.41	1.82e-12	2.95e-09	-0.5	-0.42	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
COAD	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	7.41	1.82e-12	2.95e-09	0.43	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
COAD	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	7.41	1.84e-12	2.97e-09	0.56	0.42	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
COAD	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	7.41	1.84e-12	2.97e-09	0.63	0.42	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
COAD	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	7.41	1.87e-12	3.02e-09	0.47	0.42	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
COAD	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	7.4	1.88e-12	3.03e-09	0.56	0.42	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
COAD	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	7.4	1.88e-12	3.04e-09	0.52	0.42	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
COAD	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-7.4	1.9e-12	3.06e-09	-0.51	-0.42	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-7.4	1.9e-12	3.06e-09	-0.51	-0.42	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	7.4	1.9e-12	3.07e-09	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
COAD	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	7.4	1.92e-12	3.09e-09	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
COAD	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.4	1.93e-12	3.11e-09	0.44	0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
COAD	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	7.4	1.93e-12	3.11e-09	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
COAD	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-7.4	1.94e-12	3.12e-09	-0.5	-0.42	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	7.4	1.94e-12	3.12e-09	0.63	0.42	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	7.4	1.94e-12	3.12e-09	0.63	0.42	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
COAD	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-7.4	1.94e-12	3.12e-09	-0.5	-0.42	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-7.4	1.94e-12	3.12e-09	-0.5	-0.42	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
COAD	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	7.4	1.94e-12	3.13e-09	0.54	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
COAD	cis	rs754466	0.651	rs11813532	ENSG00000204049.1	RP11-126H7.4	7.4	1.95e-12	3.13e-09	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77878233	chr10:77866875~77869610:+
COAD	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	7.4	1.95e-12	3.14e-09	0.58	0.42	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
COAD	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	7.4	1.95e-12	3.15e-09	0.55	0.42	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	7.4	1.96e-12	3.15e-09	0.55	0.42	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
COAD	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	7.4	1.96e-12	3.15e-09	0.43	0.42	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
COAD	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-7.4	1.96e-12	3.16e-09	-0.53	-0.42	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
COAD	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.4	1.98e-12	3.19e-09	0.49	0.42	Height;	chr6:109634847	chr6:109382795~109383666:+
COAD	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	7.4	2e-12	3.21e-09	0.53	0.42	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
COAD	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	7.4	2e-12	3.21e-09	0.53	0.42	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
COAD	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-7.39	2.02e-12	3.24e-09	-0.44	-0.42	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
COAD	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	7.39	2.02e-12	3.25e-09	0.59	0.42	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
COAD	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-7.39	2.03e-12	3.26e-09	-0.36	-0.42	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
COAD	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-7.39	2.05e-12	3.29e-09	-0.52	-0.42	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
COAD	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-7.39	2.05e-12	3.29e-09	-0.47	-0.42	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
COAD	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-7.39	2.06e-12	3.3e-09	-0.63	-0.42	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
COAD	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	7.39	2.07e-12	3.32e-09	0.55	0.42	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
COAD	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-7.39	2.07e-12	3.32e-09	-0.43	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
COAD	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-7.39	2.07e-12	3.33e-09	-0.53	-0.42	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	7.39	2.08e-12	3.33e-09	0.55	0.42	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
COAD	cis	rs7078219	0.505	rs10883367	ENSG00000228778.1	RP11-129J12.1	-7.39	2.1e-12	3.37e-09	-0.46	-0.42	Dental caries;	chr10:99528233	chr10:99527081~99528261:+
COAD	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	7.39	2.11e-12	3.38e-09	0.61	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	7.39	2.11e-12	3.38e-09	0.61	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
COAD	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	7.39	2.11e-12	3.39e-09	0.54	0.42	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
COAD	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-7.39	2.12e-12	3.39e-09	-0.5	-0.42	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-7.39	2.12e-12	3.39e-09	-0.5	-0.42	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
COAD	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.39	2.12e-12	3.4e-09	-0.72	-0.42	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
COAD	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	7.38	2.13e-12	3.41e-09	0.53	0.42	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
COAD	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-7.38	2.13e-12	3.42e-09	-0.56	-0.42	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
COAD	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	7.38	2.14e-12	3.42e-09	0.51	0.42	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
COAD	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-7.38	2.14e-12	3.43e-09	-0.61	-0.42	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
COAD	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-7.38	2.14e-12	3.43e-09	-0.5	-0.42	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
COAD	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	7.38	2.15e-12	3.44e-09	0.5	0.42	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
COAD	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	7.38	2.15e-12	3.44e-09	0.59	0.42	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
COAD	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	7.38	2.18e-12	3.48e-09	0.52	0.42	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
COAD	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	7.38	2.18e-12	3.49e-09	0.49	0.42	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
COAD	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-7.38	2.19e-12	3.5e-09	-0.46	-0.42	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
COAD	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	7.38	2.21e-12	3.53e-09	0.5	0.42	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-7.38	2.21e-12	3.53e-09	-0.51	-0.42	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-7.38	2.23e-12	3.55e-09	-0.5	-0.42	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
COAD	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	7.38	2.24e-12	3.57e-09	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
COAD	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-7.38	2.24e-12	3.57e-09	-0.52	-0.42	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
COAD	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	7.38	2.26e-12	3.61e-09	0.53	0.42	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
COAD	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-7.37	2.26e-12	3.61e-09	-0.49	-0.42	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
COAD	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	7.37	2.26e-12	3.61e-09	0.49	0.42	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-7.37	2.3e-12	3.67e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-7.37	2.3e-12	3.67e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.37	2.31e-12	3.69e-09	-0.48	-0.42	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
COAD	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.37	2.32e-12	3.69e-09	0.51	0.42	Height;	chr6:109546439	chr6:109382795~109383666:+
COAD	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.37	2.32e-12	3.69e-09	0.51	0.42	Height;	chr6:109551060	chr6:109382795~109383666:+
COAD	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	7.37	2.32e-12	3.69e-09	0.64	0.42	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
COAD	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-7.37	2.33e-12	3.71e-09	-0.68	-0.42	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
COAD	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	7.37	2.33e-12	3.71e-09	0.54	0.42	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-7.37	2.33e-12	3.71e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
COAD	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.37	2.33e-12	3.71e-09	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
COAD	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.37	2.34e-12	3.72e-09	-0.43	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
COAD	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-7.37	2.34e-12	3.72e-09	-0.48	-0.42	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-7.37	2.34e-12	3.72e-09	-0.48	-0.42	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
COAD	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-7.37	2.34e-12	3.72e-09	-0.48	-0.42	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
COAD	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-7.37	2.34e-12	3.72e-09	-0.9	-0.42	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
COAD	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	7.37	2.35e-12	3.74e-09	0.55	0.42	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
COAD	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-7.37	2.35e-12	3.74e-09	-0.49	-0.42	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
COAD	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	7.37	2.36e-12	3.75e-09	0.51	0.42	Height;	chr6:109690255	chr6:109382795~109383666:+
COAD	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.37	2.36e-12	3.75e-09	0.5	0.42	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.37	2.36e-12	3.75e-09	0.5	0.42	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
COAD	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	7.37	2.37e-12	3.77e-09	0.63	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
COAD	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-7.37	2.37e-12	3.77e-09	-0.5	-0.42	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	7.37	2.37e-12	3.77e-09	0.5	0.42	Height;	chr6:109672088	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	7.37	2.39e-12	3.8e-09	0.48	0.42	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-7.37	2.4e-12	3.81e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
COAD	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-7.37	2.4e-12	3.82e-09	-0.49	-0.42	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
COAD	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	7.37	2.41e-12	3.82e-09	0.31	0.42	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
COAD	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	7.36	2.41e-12	3.83e-09	0.43	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
COAD	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-7.36	2.42e-12	3.84e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
COAD	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.36	2.42e-12	3.85e-09	0.31	0.42	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
COAD	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.36	2.45e-12	3.89e-09	0.49	0.42	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
COAD	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-7.36	2.45e-12	3.89e-09	-0.72	-0.42	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
COAD	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	7.36	2.46e-12	3.9e-09	0.43	0.42	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
COAD	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	7.36	2.48e-12	3.93e-09	0.45	0.42	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
COAD	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-7.36	2.48e-12	3.93e-09	-0.46	-0.42	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
COAD	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	7.36	2.49e-12	3.94e-09	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
COAD	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	7.36	2.5e-12	3.96e-09	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
COAD	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	7.36	2.52e-12	3.99e-09	0.47	0.42	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
COAD	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-7.36	2.52e-12	3.99e-09	-0.5	-0.42	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
COAD	cis	rs881375	0.692	rs2075049	ENSG00000226752.6	PSMD5-AS1	-7.36	2.56e-12	4.05e-09	-0.45	-0.42	Rheumatoid arthritis;	chr9:120953218	chr9:120824828~120854385:+
COAD	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	7.36	2.56e-12	4.05e-09	0.55	0.42	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
COAD	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-7.35	2.58e-12	4.07e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
COAD	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-7.35	2.58e-12	4.07e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
COAD	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-7.35	2.58e-12	4.07e-09	-0.48	-0.42	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
COAD	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109498751	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109500687	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109494148	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109494760	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109495102	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109496680	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	7.35	2.58e-12	4.08e-09	0.49	0.42	Height;	chr6:109497088	chr6:109382795~109383666:+
COAD	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-7.35	2.59e-12	4.09e-09	-0.46	-0.42	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
COAD	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	7.35	2.59e-12	4.09e-09	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
COAD	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	7.35	2.61e-12	4.12e-09	0.56	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
COAD	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-7.35	2.63e-12	4.14e-09	-0.5	-0.42	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
COAD	cis	rs7615952	0.611	rs2971298	ENSG00000248787.1	RP11-666A20.4	-7.35	2.65e-12	4.17e-09	-0.63	-0.42	Blood pressure (smoking interaction);	chr3:125883870	chr3:125908005~125910272:-
COAD	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	7.35	2.65e-12	4.17e-09	0.47	0.42	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
COAD	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-7.35	2.68e-12	4.21e-09	-0.47	-0.42	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
COAD	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-7.35	2.69e-12	4.23e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	7.35	2.71e-12	4.26e-09	0.55	0.42	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	7.35	2.71e-12	4.26e-09	0.55	0.42	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	7.35	2.71e-12	4.26e-09	0.55	0.42	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-7.35	2.72e-12	4.27e-09	-0.6	-0.42	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
COAD	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	7.34	2.74e-12	4.3e-09	0.49	0.42	Height;	chr6:109507364	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	7.34	2.74e-12	4.3e-09	0.49	0.42	Height;	chr6:109507366	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	7.34	2.76e-12	4.33e-09	0.5	0.42	Height;	chr6:109676091	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-7.34	2.77e-12	4.34e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
COAD	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.34	2.79e-12	4.38e-09	-0.49	-0.42	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
COAD	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-7.34	2.8e-12	4.39e-09	-0.55	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
COAD	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.34	2.82e-12	4.42e-09	-0.42	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
COAD	cis	rs5769707	0.967	rs12485195	ENSG00000188511.11	C22orf34	7.34	2.84e-12	4.46e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49660223	chr22:49414524~49657542:-
COAD	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	7.34	2.86e-12	4.48e-09	0.49	0.42	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	7.34	2.89e-12	4.52e-09	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
COAD	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	7.34	2.89e-12	4.53e-09	0.46	0.42	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
COAD	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.33	2.9e-12	4.54e-09	0.49	0.42	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
COAD	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	7.33	2.91e-12	4.55e-09	0.54	0.42	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
COAD	cis	rs5769707	0.935	rs739239	ENSG00000188511.11	C22orf34	7.33	2.92e-12	4.58e-09	0.43	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49414524~49657542:-
COAD	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	7.33	2.94e-12	4.6e-09	0.63	0.42	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
COAD	cis	rs5769707	0.874	rs9616714	ENSG00000188511.11	C22orf34	7.33	2.94e-12	4.6e-09	0.43	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49414524~49657542:-
COAD	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.33	2.96e-12	4.64e-09	-0.36	-0.42	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.33	2.96e-12	4.64e-09	-0.36	-0.42	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
COAD	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	7.33	2.97e-12	4.64e-09	0.5	0.42	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	7.33	2.97e-12	4.64e-09	0.5	0.42	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.33	2.97e-12	4.64e-09	0.5	0.42	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.33	2.97e-12	4.64e-09	0.5	0.42	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
COAD	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	7.33	2.98e-12	4.66e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
COAD	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	7.33	2.99e-12	4.67e-09	0.56	0.42	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
COAD	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	7.33	3.01e-12	4.69e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	7.33	3.01e-12	4.69e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	7.33	3.01e-12	4.69e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
COAD	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	7.33	3.01e-12	4.7e-09	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
COAD	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	7.33	3.02e-12	4.71e-09	0.49	0.42	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
COAD	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	7.33	3.02e-12	4.72e-09	0.55	0.42	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-7.33	3.03e-12	4.73e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
COAD	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-7.33	3.04e-12	4.74e-09	-0.5	-0.42	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
COAD	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	7.33	3.08e-12	4.8e-09	0.44	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
COAD	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	7.32	3.12e-12	4.85e-09	0.46	0.42	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-7.32	3.13e-12	4.87e-09	-0.51	-0.42	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
COAD	cis	rs7078219	0.543	rs10786557	ENSG00000228778.1	RP11-129J12.1	-7.32	3.13e-12	4.88e-09	-0.45	-0.42	Dental caries;	chr10:99523571	chr10:99527081~99528261:+
COAD	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-7.32	3.13e-12	4.88e-09	-0.51	-0.42	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
COAD	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	7.32	3.14e-12	4.88e-09	0.53	0.42	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
COAD	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	7.32	3.14e-12	4.89e-09	0.5	0.42	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
COAD	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-7.32	3.15e-12	4.9e-09	-0.47	-0.42	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
COAD	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	7.32	3.21e-12	4.99e-09	0.59	0.42	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
COAD	cis	rs7078219	1	rs61872688	ENSG00000257582.4	LINC01475	-7.32	3.21e-12	5e-09	-0.45	-0.42	Dental caries;	chr10:99513789	chr10:99526350~99531177:-
COAD	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-7.32	3.22e-12	5e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-7.32	3.22e-12	5e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-7.32	3.22e-12	5e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-7.32	3.22e-12	5e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-7.32	3.22e-12	5e-09	-0.46	-0.42	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
COAD	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	7.32	3.23e-12	5.03e-09	0.5	0.42	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
COAD	cis	rs7078219	0.505	rs7916751	ENSG00000228778.1	RP11-129J12.1	-7.32	3.25e-12	5.04e-09	-0.46	-0.42	Dental caries;	chr10:99525893	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs6584281	ENSG00000228778.1	RP11-129J12.1	-7.32	3.25e-12	5.04e-09	-0.46	-0.42	Dental caries;	chr10:99526723	chr10:99527081~99528261:+
COAD	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	7.32	3.26e-12	5.07e-09	0.49	0.42	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-7.32	3.26e-12	5.07e-09	-0.49	-0.42	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
COAD	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	7.32	3.26e-12	5.07e-09	0.54	0.42	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
COAD	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-7.31	3.31e-12	5.14e-09	-0.59	-0.42	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
COAD	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.31	3.33e-12	5.17e-09	-0.54	-0.41	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
COAD	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-7.31	3.34e-12	5.18e-09	-0.51	-0.41	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
COAD	cis	rs1912483	0.505	rs3760372	ENSG00000228782.6	CTD-2026D20.3	7.31	3.35e-12	5.19e-09	0.46	0.41	Coronary artery disease;	chr17:47302636	chr17:47450568~47492492:-
COAD	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	7.31	3.35e-12	5.19e-09	0.6	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
COAD	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-7.31	3.38e-12	5.24e-09	-0.51	-0.41	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
COAD	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-7.31	3.38e-12	5.24e-09	-0.51	-0.41	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
COAD	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-7.31	3.38e-12	5.24e-09	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-7.31	3.39e-12	5.26e-09	-0.52	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
COAD	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	7.31	3.4e-12	5.27e-09	0.44	0.41	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
COAD	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-7.31	3.41e-12	5.28e-09	-0.5	-0.41	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	7.31	3.42e-12	5.29e-09	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
COAD	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	7.31	3.43e-12	5.32e-09	0.54	0.41	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	7.31	3.43e-12	5.32e-09	0.54	0.41	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
COAD	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-7.31	3.44e-12	5.33e-09	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
COAD	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-7.31	3.44e-12	5.33e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
COAD	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-7.31	3.45e-12	5.34e-09	-0.62	-0.41	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
COAD	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-7.3	3.51e-12	5.43e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-7.3	3.51e-12	5.43e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-7.3	3.51e-12	5.43e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
COAD	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	7.3	3.52e-12	5.45e-09	0.59	0.41	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	7.3	3.52e-12	5.45e-09	0.59	0.41	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	7.3	3.52e-12	5.45e-09	0.59	0.41	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	7.3	3.52e-12	5.45e-09	0.59	0.41	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
COAD	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	7.3	3.53e-12	5.47e-09	0.48	0.41	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-7.3	3.57e-12	5.52e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
COAD	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-7.3	3.58e-12	5.53e-09	-0.43	-0.41	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
COAD	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	7.3	3.59e-12	5.55e-09	0.46	0.41	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
COAD	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.3	3.64e-12	5.62e-09	0.5	0.41	Height;	chr6:109584789	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.3	3.64e-12	5.62e-09	0.5	0.41	Height;	chr6:109588639	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.3	3.64e-12	5.62e-09	0.5	0.41	Height;	chr6:109589051	chr6:109382795~109383666:+
COAD	cis	rs7078219	0.965	rs10883358	ENSG00000257582.4	LINC01475	-7.3	3.65e-12	5.64e-09	-0.45	-0.41	Dental caries;	chr10:99514100	chr10:99526350~99531177:-
COAD	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-7.3	3.67e-12	5.66e-09	-0.43	-0.41	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
COAD	cis	rs7078219	0.965	rs11190141	ENSG00000257582.4	LINC01475	-7.3	3.67e-12	5.66e-09	-0.44	-0.41	Dental caries;	chr10:99532633	chr10:99526350~99531177:-
COAD	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.3	3.68e-12	5.68e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
COAD	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	7.3	3.68e-12	5.68e-09	0.46	0.41	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
COAD	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	7.3	3.68e-12	5.68e-09	0.31	0.41	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
COAD	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	7.3	3.69e-12	5.7e-09	0.44	0.41	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
COAD	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-7.3	3.7e-12	5.71e-09	-0.51	-0.41	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
COAD	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	7.29	3.73e-12	5.75e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
COAD	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-7.29	3.73e-12	5.75e-09	-0.47	-0.41	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
COAD	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.29	3.73e-12	5.76e-09	0.5	0.41	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
COAD	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	7.29	3.78e-12	5.82e-09	0.42	0.41	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
COAD	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	7.29	3.81e-12	5.87e-09	0.64	0.41	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	7.29	3.81e-12	5.87e-09	0.64	0.41	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	7.29	3.81e-12	5.87e-09	0.64	0.41	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	7.29	3.81e-12	5.87e-09	0.64	0.41	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
COAD	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	7.29	3.81e-12	5.87e-09	0.64	0.41	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
COAD	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	7.29	3.82e-12	5.88e-09	0.54	0.41	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
COAD	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-7.29	3.83e-12	5.89e-09	-0.45	-0.41	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
COAD	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-7.29	3.83e-12	5.89e-09	-0.45	-0.41	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
COAD	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	7.29	3.86e-12	5.94e-09	0.49	0.41	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
COAD	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-7.29	3.86e-12	5.94e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
COAD	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-7.29	3.86e-12	5.94e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
COAD	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	7.29	3.87e-12	5.96e-09	0.46	0.41	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
COAD	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-7.29	3.9e-12	6e-09	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
COAD	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-7.29	3.9e-12	6e-09	-0.44	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
COAD	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-7.29	3.9e-12	6e-09	-0.44	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
COAD	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-7.29	3.9e-12	6e-09	-0.44	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
COAD	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	7.29	3.93e-12	6.05e-09	0.55	0.41	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	7.29	3.93e-12	6.05e-09	0.55	0.41	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
COAD	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-7.29	3.94e-12	6.05e-09	-0.5	-0.41	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
COAD	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-7.28	3.95e-12	6.07e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
COAD	cis	rs754466	0.651	rs10824583	ENSG00000204049.1	RP11-126H7.4	-7.28	3.97e-12	6.1e-09	-0.52	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77859644	chr10:77866875~77869610:+
COAD	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.28	4e-12	6.13e-09	-0.44	-0.41	Breast cancer;	chr11:825777	chr11:779617~780755:+
COAD	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	7.28	4.01e-12	6.16e-09	0.49	0.41	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
COAD	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	7.28	4.02e-12	6.17e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
COAD	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-7.28	4.02e-12	6.17e-09	-0.44	-0.41	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
COAD	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-7.28	4.03e-12	6.18e-09	-0.63	-0.41	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
COAD	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-7.28	4.05e-12	6.2e-09	-0.45	-0.41	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-7.28	4.05e-12	6.2e-09	-0.45	-0.41	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
COAD	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-7.28	4.06e-12	6.23e-09	-0.54	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
COAD	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-7.28	4.08e-12	6.26e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
COAD	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	7.28	4.09e-12	6.27e-09	0.55	0.41	Height;	chr6:109482392	chr6:109382795~109383666:+
COAD	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-7.28	4.1e-12	6.28e-09	-0.58	-0.41	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
COAD	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	7.28	4.1e-12	6.28e-09	0.31	0.41	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
COAD	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-7.28	4.11e-12	6.3e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
COAD	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.28	4.12e-12	6.3e-09	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
COAD	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.28	4.12e-12	6.31e-09	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
COAD	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	7.28	4.12e-12	6.31e-09	0.5	0.41	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
COAD	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.28	4.14e-12	6.34e-09	-0.53	-0.41	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
COAD	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	7.28	4.15e-12	6.35e-09	0.56	0.41	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
COAD	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	7.28	4.16e-12	6.36e-09	0.86	0.41	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
COAD	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	7.28	4.16e-12	6.37e-09	0.69	0.41	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	7.28	4.16e-12	6.37e-09	0.69	0.41	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	7.28	4.16e-12	6.37e-09	0.69	0.41	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	7.28	4.16e-12	6.37e-09	0.69	0.41	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
COAD	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-7.28	4.18e-12	6.39e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-7.28	4.18e-12	6.39e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
COAD	cis	rs7078219	0.965	rs7081858	ENSG00000257582.4	LINC01475	-7.28	4.18e-12	6.4e-09	-0.44	-0.41	Dental caries;	chr10:99514808	chr10:99526350~99531177:-
COAD	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	7.27	4.2e-12	6.43e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
COAD	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-7.27	4.21e-12	6.44e-09	-0.62	-0.41	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
COAD	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	7.27	4.22e-12	6.46e-09	0.58	0.41	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
COAD	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-7.27	4.25e-12	6.5e-09	-0.54	-0.41	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
COAD	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	7.27	4.26e-12	6.51e-09	0.54	0.41	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
COAD	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	7.27	4.28e-12	6.54e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	7.27	4.28e-12	6.54e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
COAD	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.27	4.28e-12	6.54e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
COAD	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	7.27	4.29e-12	6.54e-09	0.59	0.41	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
COAD	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	7.27	4.3e-12	6.56e-09	0.4	0.41	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
COAD	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	7.27	4.32e-12	6.6e-09	0.51	0.41	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
COAD	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-7.27	4.33e-12	6.61e-09	-0.45	-0.41	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
COAD	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	7.27	4.36e-12	6.65e-09	0.54	0.41	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	7.27	4.36e-12	6.65e-09	0.54	0.41	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	7.27	4.36e-12	6.65e-09	0.54	0.41	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
COAD	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-7.27	4.37e-12	6.67e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
COAD	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	7.27	4.4e-12	6.71e-09	0.49	0.41	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
COAD	cis	rs9368481	0.743	rs9368480	ENSG00000224843.5	LINC00240	-7.27	4.43e-12	6.75e-09	-0.52	-0.41	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26956992~27023924:+
COAD	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	7.27	4.43e-12	6.75e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
COAD	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-7.27	4.44e-12	6.77e-09	-0.47	-0.41	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-7.27	4.44e-12	6.77e-09	-0.47	-0.41	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
COAD	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	7.27	4.44e-12	6.77e-09	0.55	0.41	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
COAD	cis	rs754466	0.651	rs10824582	ENSG00000204049.1	RP11-126H7.4	7.26	4.5e-12	6.85e-09	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77843930	chr10:77866875~77869610:+
COAD	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	7.26	4.53e-12	6.89e-09	0.67	0.41	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
COAD	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-7.26	4.54e-12	6.9e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	7.26	4.54e-12	6.9e-09	0.5	0.41	Height;	chr6:109592105	chr6:109382795~109383666:+
COAD	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-7.26	4.54e-12	6.9e-09	-0.51	-0.41	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
COAD	cis	rs754466	0.651	rs7895188	ENSG00000204049.1	RP11-126H7.4	-7.26	4.54e-12	6.9e-09	-0.52	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77863620	chr10:77866875~77869610:+
COAD	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.26	4.62e-12	7.02e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
COAD	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.26	4.63e-12	7.04e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
COAD	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	7.26	4.67e-12	7.1e-09	0.54	0.41	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
COAD	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	7.26	4.71e-12	7.15e-09	0.46	0.41	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	7.26	4.71e-12	7.15e-09	0.46	0.41	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
COAD	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.25	4.76e-12	7.23e-09	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
COAD	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-7.25	4.8e-12	7.28e-09	-0.45	-0.41	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-7.25	4.83e-12	7.32e-09	-0.65	-0.41	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-7.25	4.83e-12	7.32e-09	-0.65	-0.41	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-7.25	4.83e-12	7.32e-09	-0.65	-0.41	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-7.25	4.83e-12	7.32e-09	-0.65	-0.41	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
COAD	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
COAD	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
COAD	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
COAD	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
COAD	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
COAD	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
COAD	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
COAD	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
COAD	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
COAD	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
COAD	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
COAD	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
COAD	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
COAD	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-7.25	4.84e-12	7.32e-09	-0.53	-0.41	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
COAD	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-7.25	4.84e-12	7.33e-09	-0.5	-0.41	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
COAD	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-7.25	4.85e-12	7.35e-09	-0.5	-0.41	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
COAD	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-7.25	4.86e-12	7.36e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
COAD	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	7.25	4.86e-12	7.36e-09	0.5	0.41	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
COAD	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	7.25	4.87e-12	7.37e-09	0.43	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
COAD	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	7.25	4.88e-12	7.38e-09	0.6	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
COAD	cis	rs860818	1	rs858287	ENSG00000226816.2	AC005082.12	7.25	4.9e-12	7.41e-09	0.8	0.41	Initial pursuit acceleration;	chr7:23209594	chr7:23206013~23208045:+
COAD	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-7.25	4.9e-12	7.41e-09	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
COAD	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-7.25	4.9e-12	7.41e-09	-0.52	-0.41	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
COAD	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	7.25	4.94e-12	7.45e-09	0.5	0.41	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
COAD	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-7.25	4.95e-12	7.45e-09	-0.54	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
COAD	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-7.25	4.95e-12	7.45e-09	-0.59	-0.41	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-7.25	4.95e-12	7.45e-09	-0.59	-0.41	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
COAD	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	7.25	4.98e-12	7.49e-09	0.73	0.41	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	7.25	4.98e-12	7.49e-09	0.73	0.41	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
COAD	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	7.25	5.02e-12	7.55e-09	0.54	0.41	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
COAD	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-7.25	5.02e-12	7.55e-09	-0.59	-0.41	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
COAD	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-7.25	5.02e-12	7.55e-09	-0.61	-0.41	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.25	5.03e-12	7.56e-09	-0.47	-0.41	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
COAD	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-7.24	5.04e-12	7.58e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
COAD	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-7.24	5.05e-12	7.59e-09	-0.5	-0.41	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
COAD	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-7.24	5.05e-12	7.59e-09	-0.5	-0.41	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
COAD	cis	rs754466	0.724	rs11002318	ENSG00000204049.1	RP11-126H7.4	7.24	5.07e-12	7.62e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77874049	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs11818687	ENSG00000204049.1	RP11-126H7.4	7.24	5.07e-12	7.62e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77877951	chr10:77866875~77869610:+
COAD	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-7.24	5.09e-12	7.65e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
COAD	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-7.24	5.1e-12	7.65e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-7.24	5.1e-12	7.65e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-7.24	5.1e-12	7.65e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
COAD	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-7.24	5.12e-12	7.68e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-7.24	5.12e-12	7.68e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-7.24	5.12e-12	7.68e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-7.24	5.12e-12	7.68e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
COAD	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	7.24	5.12e-12	7.69e-09	0.49	0.41	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
COAD	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-7.24	5.14e-12	7.72e-09	-0.46	-0.41	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
COAD	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	7.24	5.15e-12	7.73e-09	0.46	0.41	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
COAD	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	7.24	5.21e-12	7.81e-09	0.58	0.41	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
COAD	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	7.24	5.21e-12	7.81e-09	0.55	0.41	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
COAD	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.24	5.21e-12	7.81e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
COAD	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-7.24	5.21e-12	7.82e-09	-0.36	-0.41	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
COAD	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-7.24	5.27e-12	7.89e-09	-0.5	-0.41	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
COAD	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-7.24	5.29e-12	7.92e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-7.24	5.29e-12	7.92e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
COAD	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.23	5.36e-12	8.03e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
COAD	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-7.23	5.36e-12	8.03e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
COAD	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.23	5.38e-12	8.05e-09	-0.54	-0.41	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.23	5.38e-12	8.05e-09	-0.54	-0.41	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
COAD	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	7.23	5.42e-12	8.1e-09	0.46	0.41	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
COAD	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	7.23	5.43e-12	8.12e-09	0.63	0.41	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
COAD	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-7.23	5.47e-12	8.17e-09	-0.44	-0.41	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
COAD	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-7.23	5.48e-12	8.18e-09	-0.45	-0.41	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
COAD	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-7.23	5.48e-12	8.19e-09	-0.67	-0.41	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
COAD	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-7.23	5.48e-12	8.19e-09	-0.67	-0.41	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
COAD	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-7.23	5.5e-12	8.21e-09	-0.43	-0.41	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
COAD	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	7.23	5.52e-12	8.23e-09	0.53	0.41	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
COAD	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-7.23	5.52e-12	8.24e-09	-0.45	-0.41	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-7.23	5.52e-12	8.24e-09	-0.45	-0.41	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
COAD	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	7.23	5.54e-12	8.26e-09	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
COAD	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	7.23	5.55e-12	8.28e-09	0.6	0.41	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
COAD	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-7.23	5.56e-12	8.28e-09	-0.53	-0.41	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
COAD	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	7.23	5.59e-12	8.33e-09	0.59	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-7.23	5.62e-12	8.37e-09	-0.5	-0.41	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
COAD	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-7.23	5.62e-12	8.37e-09	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
COAD	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-7.23	5.64e-12	8.4e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-7.23	5.64e-12	8.4e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
COAD	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	7.23	5.64e-12	8.4e-09	0.58	0.41	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	7.23	5.64e-12	8.4e-09	0.58	0.41	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	7.23	5.64e-12	8.4e-09	0.58	0.41	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
COAD	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	7.23	5.66e-12	8.43e-09	0.6	0.41	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
COAD	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.22	5.7e-12	8.48e-09	0.5	0.41	Height;	chr6:109586733	chr6:109382795~109383666:+
COAD	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-7.22	5.71e-12	8.49e-09	-0.5	-0.41	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
COAD	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-7.22	5.74e-12	8.55e-09	-0.53	-0.41	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
COAD	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	7.22	5.76e-12	8.57e-09	0.54	0.41	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
COAD	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	7.22	5.83e-12	8.67e-09	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
COAD	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.22	5.85e-12	8.69e-09	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
COAD	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-7.22	5.85e-12	8.69e-09	-0.45	-0.41	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
COAD	cis	rs7615952	0.558	rs7641353	ENSG00000272840.1	RP11-379B18.6	7.22	5.87e-12	8.73e-09	0.55	0.41	Blood pressure (smoking interaction);	chr3:125621035	chr3:125774714~125797953:+
COAD	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-7.22	5.88e-12	8.73e-09	-0.5	-0.41	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
COAD	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	7.22	5.9e-12	8.77e-09	0.59	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
COAD	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	7.22	5.91e-12	8.77e-09	0.4	0.41	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
COAD	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-7.22	5.92e-12	8.8e-09	-0.52	-0.41	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
COAD	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-7.22	5.93e-12	8.81e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-7.22	5.93e-12	8.81e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-7.22	5.93e-12	8.81e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-7.22	5.94e-12	8.81e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
COAD	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.22	6.01e-12	8.91e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
COAD	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-7.22	6.01e-12	8.92e-09	-0.5	-0.41	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
COAD	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	7.22	6.04e-12	8.96e-09	0.55	0.41	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
COAD	cis	rs7078219	1	rs7078219	ENSG00000257582.4	LINC01475	7.21	6.06e-12	8.98e-09	0.45	0.41	Dental caries;	chr10:99514608	chr10:99526350~99531177:-
COAD	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-7.21	6.07e-12	9.01e-09	-0.37	-0.41	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
COAD	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	7.21	6.08e-12	9.02e-09	0.43	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
COAD	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-7.21	6.11e-12	9.06e-09	-0.59	-0.41	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
COAD	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-7.21	6.13e-12	9.09e-09	-0.53	-0.41	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
COAD	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-7.21	6.14e-12	9.1e-09	-0.53	-0.41	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
COAD	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	7.21	6.19e-12	9.16e-09	0.6	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
COAD	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-7.21	6.2e-12	9.17e-09	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-7.21	6.2e-12	9.17e-09	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-7.21	6.2e-12	9.17e-09	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-7.21	6.2e-12	9.17e-09	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
COAD	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-7.21	6.2e-12	9.18e-09	-0.52	-0.41	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
COAD	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	7.21	6.22e-12	9.2e-09	0.59	0.41	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
COAD	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	7.21	6.22e-12	9.2e-09	0.59	0.41	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
COAD	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	7.21	6.25e-12	9.22e-09	0.48	0.41	Height;	chr6:109506513	chr6:109382795~109383666:+
COAD	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	7.21	6.25e-12	9.23e-09	0.5	0.41	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
COAD	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-7.21	6.3e-12	9.29e-09	-0.6	-0.41	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
COAD	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.21	6.38e-12	9.4e-09	0.5	0.41	Height;	chr6:109558247	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.21	6.38e-12	9.4e-09	0.5	0.41	Height;	chr6:109564443	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.21	6.38e-12	9.4e-09	0.5	0.41	Height;	chr6:109571489	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.21	6.38e-12	9.4e-09	0.5	0.41	Height;	chr6:109576414	chr6:109382795~109383666:+
COAD	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.21	6.38e-12	9.4e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
COAD	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-7.21	6.41e-12	9.43e-09	-0.56	-0.41	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-7.2	6.44e-12	9.48e-09	-0.5	-0.41	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
COAD	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-7.2	6.48e-12	9.53e-09	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
COAD	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	7.2	6.48e-12	9.54e-09	0.58	0.41	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
COAD	cis	rs754466	0.606	rs11002315	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857627	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs11002316	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857753	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs11002317	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857890	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs11815015	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77865724	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs56138814	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866037	chr10:77866875~77869610:+
COAD	cis	rs754466	0.651	rs10824584	ENSG00000204049.1	RP11-126H7.4	7.2	6.5e-12	9.56e-09	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866189	chr10:77866875~77869610:+
COAD	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	7.2	6.54e-12	9.61e-09	0.5	0.41	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
COAD	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	7.2	6.57e-12	9.66e-09	0.5	0.41	Height;	chr6:109693890	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	7.2	6.57e-12	9.66e-09	0.5	0.41	Height;	chr6:109694672	chr6:109382795~109383666:+
COAD	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-7.2	6.58e-12	9.67e-09	-0.45	-0.41	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
COAD	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-7.2	6.59e-12	9.68e-09	-0.5	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
COAD	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.2	6.59e-12	9.68e-09	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
COAD	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-7.2	6.63e-12	9.74e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-7.2	6.63e-12	9.74e-09	-0.46	-0.41	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-7.2	6.67e-12	9.8e-09	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
COAD	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-7.2	6.71e-12	9.86e-09	-0.61	-0.41	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
COAD	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	7.2	6.72e-12	9.86e-09	0.49	0.41	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
COAD	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	7.2	6.74e-12	9.89e-09	0.46	0.41	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
COAD	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	7.2	6.75e-12	9.91e-09	0.54	0.41	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
COAD	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.19	6.85e-12	1.01e-08	-0.54	-0.41	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
COAD	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-7.19	6.9e-12	1.01e-08	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
COAD	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	7.19	6.97e-12	1.02e-08	0.61	0.41	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
COAD	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-7.19	7.12e-12	1.04e-08	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-7.19	7.12e-12	1.04e-08	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
COAD	cis	rs754466	0.651	rs10762767	ENSG00000204049.1	RP11-126H7.4	7.19	7.13e-12	1.04e-08	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77885312	chr10:77866875~77869610:+
COAD	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-7.19	7.13e-12	1.04e-08	-0.44	-0.41	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
COAD	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	7.19	7.14e-12	1.05e-08	0.84	0.41	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
COAD	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	7.19	7.16e-12	1.05e-08	0.49	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
COAD	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	7.19	7.18e-12	1.05e-08	0.46	0.41	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
COAD	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	7.19	7.19e-12	1.05e-08	0.84	0.41	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	7.19	7.19e-12	1.05e-08	0.84	0.41	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
COAD	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-7.19	7.25e-12	1.06e-08	-0.57	-0.41	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
COAD	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	7.18	7.29e-12	1.07e-08	0.46	0.41	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
COAD	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	7.18	7.4e-12	1.08e-08	0.52	0.41	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
COAD	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	7.18	7.4e-12	1.08e-08	0.53	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
COAD	cis	rs1400745	0.756	rs799683	ENSG00000258738.1	RP11-73E17.2	7.18	7.42e-12	1.08e-08	0.45	0.41	Monocyte count;	chr14:34880030	chr14:34874343~34876459:+
COAD	cis	rs1400745	0.756	rs799682	ENSG00000258738.1	RP11-73E17.2	7.18	7.42e-12	1.08e-08	0.45	0.41	Monocyte count;	chr14:34880778	chr14:34874343~34876459:+
COAD	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	7.18	7.43e-12	1.08e-08	0.51	0.41	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
COAD	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-7.18	7.43e-12	1.08e-08	-0.64	-0.41	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
COAD	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	7.18	7.46e-12	1.09e-08	0.42	0.41	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
COAD	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	7.18	7.54e-12	1.1e-08	0.46	0.41	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
COAD	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-7.18	7.56e-12	1.1e-08	-0.5	-0.41	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
COAD	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.18	7.58e-12	1.1e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.18	7.58e-12	1.1e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-7.18	7.58e-12	1.1e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.18	7.58e-12	1.1e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-7.18	7.58e-12	1.1e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
COAD	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	7.18	7.58e-12	1.1e-08	0.63	0.41	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
COAD	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	7.18	7.58e-12	1.1e-08	0.67	0.41	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	7.18	7.58e-12	1.1e-08	0.67	0.41	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	7.18	7.58e-12	1.1e-08	0.67	0.41	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
COAD	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-7.18	7.6e-12	1.1e-08	-0.5	-0.41	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
COAD	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-7.18	7.63e-12	1.11e-08	-0.61	-0.41	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	7.18	7.73e-12	1.12e-08	0.43	0.41	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
COAD	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	7.17	7.74e-12	1.12e-08	0.54	0.41	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
COAD	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-7.17	7.75e-12	1.13e-08	-0.44	-0.41	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
COAD	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.17	7.76e-12	1.13e-08	-0.42	-0.41	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	7.17	7.79e-12	1.13e-08	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
COAD	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-7.17	7.81e-12	1.13e-08	-0.39	-0.41	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
COAD	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-7.17	7.86e-12	1.14e-08	-0.48	-0.41	Height;	chr6:109501793	chr6:109382795~109383666:+
COAD	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	7.17	7.88e-12	1.14e-08	0.53	0.41	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
COAD	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-7.17	7.92e-12	1.15e-08	-0.5	-0.41	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
COAD	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-7.17	7.99e-12	1.16e-08	-0.53	-0.41	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
COAD	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-7.17	7.99e-12	1.16e-08	-0.47	-0.41	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
COAD	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-7.17	8.02e-12	1.16e-08	-0.49	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
COAD	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-7.17	8.07e-12	1.17e-08	-0.55	-0.41	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
COAD	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	7.17	8.09e-12	1.17e-08	0.42	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
COAD	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	7.17	8.11e-12	1.17e-08	0.45	0.41	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	7.17	8.11e-12	1.17e-08	0.45	0.41	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
COAD	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	7.17	8.13e-12	1.18e-08	0.48	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
COAD	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	7.17	8.15e-12	1.18e-08	0.57	0.41	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
COAD	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-7.16	8.23e-12	1.19e-08	-0.53	-0.41	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
COAD	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	7.16	8.24e-12	1.19e-08	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
COAD	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-7.16	8.25e-12	1.19e-08	-0.59	-0.41	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	7.16	8.26e-12	1.19e-08	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
COAD	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	7.16	8.28e-12	1.2e-08	0.54	0.41	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
COAD	cis	rs7078219	0.505	rs11190140	ENSG00000228778.1	RP11-129J12.1	-7.16	8.29e-12	1.2e-08	-0.46	-0.41	Dental caries;	chr10:99531836	chr10:99527081~99528261:+
COAD	cis	rs7615952	0.673	rs34209763	ENSG00000248787.1	RP11-666A20.4	-7.16	8.36e-12	1.21e-08	-0.64	-0.41	Blood pressure (smoking interaction);	chr3:125880752	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.8	rs35390120	ENSG00000248787.1	RP11-666A20.4	-7.16	8.36e-12	1.21e-08	-0.64	-0.41	Blood pressure (smoking interaction);	chr3:125880966	chr3:125908005~125910272:-
COAD	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	7.16	8.36e-12	1.21e-08	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
COAD	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-7.16	8.36e-12	1.21e-08	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
COAD	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	7.16	8.38e-12	1.21e-08	0.52	0.41	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
COAD	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-7.16	8.39e-12	1.21e-08	-0.53	-0.41	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
COAD	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	7.16	8.52e-12	1.23e-08	0.54	0.41	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
COAD	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-7.16	8.53e-12	1.23e-08	-0.88	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-7.16	8.55e-12	1.23e-08	-0.48	-0.41	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
COAD	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-7.16	8.58e-12	1.24e-08	-0.37	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
COAD	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	7.16	8.59e-12	1.24e-08	0.38	0.41	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
COAD	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-7.16	8.61e-12	1.24e-08	-0.4	-0.41	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
COAD	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-7.16	8.61e-12	1.24e-08	-0.4	-0.41	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
COAD	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	7.16	8.61e-12	1.24e-08	0.49	0.41	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
COAD	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-7.16	8.64e-12	1.25e-08	-0.5	-0.41	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
COAD	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	7.16	8.65e-12	1.25e-08	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
COAD	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	7.15	8.76e-12	1.26e-08	0.84	0.41	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
COAD	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-7.15	8.79e-12	1.27e-08	-0.48	-0.41	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
COAD	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-7.15	8.82e-12	1.27e-08	-0.63	-0.41	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
COAD	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.15	8.88e-12	1.28e-08	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
COAD	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-7.15	9e-12	1.3e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
COAD	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	7.15	9.02e-12	1.3e-08	0.62	0.41	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
COAD	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-7.15	9.04e-12	1.3e-08	-0.49	-0.41	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
COAD	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.15	9.13e-12	1.31e-08	0.46	0.41	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
COAD	cis	rs7078219	1	rs6584278	ENSG00000257582.4	LINC01475	-7.15	9.13e-12	1.31e-08	-0.44	-0.41	Dental caries;	chr10:99518342	chr10:99526350~99531177:-
COAD	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-7.15	9.13e-12	1.31e-08	-0.43	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
COAD	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	7.15	9.13e-12	1.31e-08	0.58	0.41	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
COAD	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	7.15	9.21e-12	1.32e-08	0.5	0.41	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-7.15	9.21e-12	1.32e-08	-0.46	-0.41	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
COAD	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-7.15	9.25e-12	1.33e-08	-0.53	-0.41	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
COAD	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	7.14	9.28e-12	1.33e-08	0.61	0.41	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
COAD	cis	rs6584283	0.846	rs10883370	ENSG00000228778.1	RP11-129J12.1	-7.14	9.28e-12	1.33e-08	-0.46	-0.41	Ulcerative colitis;	chr10:99531715	chr10:99527081~99528261:+
COAD	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	7.14	9.32e-12	1.34e-08	0.53	0.41	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
COAD	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-7.14	9.43e-12	1.35e-08	-0.54	-0.41	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
COAD	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	7.14	9.49e-12	1.36e-08	0.51	0.41	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
COAD	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	7.14	9.5e-12	1.36e-08	0.4	0.41	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
COAD	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.14	9.55e-12	1.37e-08	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
COAD	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-7.14	9.55e-12	1.37e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-7.14	9.55e-12	1.37e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
COAD	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-7.14	9.56e-12	1.37e-08	-0.51	-0.41	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
COAD	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-7.14	9.59e-12	1.37e-08	-0.43	-0.41	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
COAD	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	7.14	9.59e-12	1.37e-08	0.54	0.41	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-7.14	9.6e-12	1.37e-08	-0.46	-0.41	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
COAD	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	7.14	9.61e-12	1.38e-08	0.54	0.41	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
COAD	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	7.14	9.64e-12	1.38e-08	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
COAD	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-7.14	9.69e-12	1.39e-08	-0.44	-0.41	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-7.14	9.69e-12	1.39e-08	-0.44	-0.41	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
COAD	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-7.14	9.7e-12	1.39e-08	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
COAD	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	7.14	9.71e-12	1.39e-08	0.35	0.41	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
COAD	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	7.14	9.72e-12	1.39e-08	0.47	0.41	Height;	chr6:109424139	chr6:109382795~109383666:+
COAD	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	7.14	9.76e-12	1.4e-08	0.5	0.41	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
COAD	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-7.14	9.77e-12	1.4e-08	-0.55	-0.41	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-7.14	9.77e-12	1.4e-08	-0.55	-0.41	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.14	9.78e-12	1.4e-08	-0.47	-0.41	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
COAD	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-7.14	9.8e-12	1.4e-08	-0.49	-0.41	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
COAD	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	7.14	9.84e-12	1.41e-08	0.5	0.41	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
COAD	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-7.13	9.92e-12	1.42e-08	-0.43	-0.41	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
COAD	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	7.13	9.93e-12	1.42e-08	0.46	0.41	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	7.13	1e-11	1.43e-08	0.49	0.41	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
COAD	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-7.13	1e-11	1.43e-08	-0.67	-0.41	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
COAD	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	7.13	1e-11	1.43e-08	0.48	0.41	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
COAD	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	7.13	1.01e-11	1.44e-08	0.29	0.41	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
COAD	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-7.13	1.01e-11	1.45e-08	-0.61	-0.41	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-7.13	1.01e-11	1.45e-08	-0.61	-0.41	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
COAD	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-7.13	1.02e-11	1.46e-08	-0.55	-0.41	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
COAD	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.13	1.02e-11	1.46e-08	0.49	0.41	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.13	1.02e-11	1.46e-08	0.49	0.41	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	7.13	1.03e-11	1.46e-08	0.5	0.41	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	7.13	1.03e-11	1.46e-08	0.5	0.41	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	7.13	1.03e-11	1.46e-08	0.5	0.41	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	7.13	1.03e-11	1.46e-08	0.5	0.41	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
COAD	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	7.13	1.03e-11	1.47e-08	0.46	0.41	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
COAD	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-7.13	1.04e-11	1.48e-08	-0.49	-0.41	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
COAD	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-7.12	1.05e-11	1.49e-08	-0.51	-0.41	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
COAD	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	7.12	1.05e-11	1.5e-08	0.48	0.41	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
COAD	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-7.12	1.05e-11	1.5e-08	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
COAD	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-7.12	1.05e-11	1.5e-08	-0.52	-0.41	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
COAD	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	7.12	1.06e-11	1.51e-08	0.57	0.41	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
COAD	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	7.12	1.07e-11	1.52e-08	0.46	0.41	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-7.12	1.07e-11	1.52e-08	-0.47	-0.41	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
COAD	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-7.12	1.07e-11	1.52e-08	-0.62	-0.41	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
COAD	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	7.12	1.08e-11	1.53e-08	0.46	0.41	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
COAD	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	7.12	1.08e-11	1.53e-08	0.5	0.41	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
COAD	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-7.12	1.08e-11	1.54e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
COAD	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	7.12	1.09e-11	1.54e-08	0.77	0.41	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
COAD	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-7.12	1.09e-11	1.54e-08	-0.66	-0.41	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
COAD	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	7.12	1.09e-11	1.54e-08	0.52	0.41	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
COAD	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-7.12	1.09e-11	1.55e-08	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
COAD	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-7.12	1.1e-11	1.56e-08	-0.42	-0.41	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
COAD	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-7.12	1.1e-11	1.56e-08	-0.46	-0.41	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-7.12	1.1e-11	1.56e-08	-0.46	-0.41	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
COAD	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-7.12	1.1e-11	1.56e-08	-0.38	-0.41	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
COAD	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-7.12	1.1e-11	1.56e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-7.12	1.1e-11	1.56e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-7.12	1.1e-11	1.56e-08	-0.38	-0.41	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
COAD	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-7.12	1.1e-11	1.56e-08	-0.58	-0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
COAD	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	7.12	1.1e-11	1.56e-08	0.58	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
COAD	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.12	1.1e-11	1.57e-08	-0.53	-0.41	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
COAD	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-7.12	1.11e-11	1.58e-08	-0.6	-0.41	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
COAD	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-7.11	1.11e-11	1.58e-08	-0.5	-0.41	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-7.11	1.11e-11	1.58e-08	-0.58	-0.41	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
COAD	cis	rs6584283	0.766	rs7911680	ENSG00000228778.1	RP11-129J12.1	-7.11	1.11e-11	1.58e-08	-0.46	-0.41	Ulcerative colitis;	chr10:99533711	chr10:99527081~99528261:+
COAD	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-7.11	1.12e-11	1.59e-08	-0.5	-0.41	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
COAD	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.11	1.12e-11	1.59e-08	0.48	0.41	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
COAD	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-7.11	1.12e-11	1.59e-08	-0.52	-0.41	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
COAD	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.11	1.12e-11	1.59e-08	-0.53	-0.41	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
COAD	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-7.11	1.13e-11	1.59e-08	-0.67	-0.41	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
COAD	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	7.11	1.14e-11	1.61e-08	0.61	0.41	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
COAD	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	7.11	1.14e-11	1.61e-08	0.61	0.41	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
COAD	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.11	1.14e-11	1.61e-08	-0.35	-0.41	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
COAD	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-7.11	1.14e-11	1.61e-08	-0.52	-0.41	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
COAD	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-7.11	1.15e-11	1.62e-08	-0.43	-0.41	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
COAD	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-7.11	1.16e-11	1.63e-08	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
COAD	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-7.11	1.16e-11	1.64e-08	-0.54	-0.41	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
COAD	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	7.11	1.17e-11	1.65e-08	0.53	0.41	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
COAD	cis	rs9393777	0.528	rs34843552	ENSG00000224843.5	LINC00240	7.11	1.18e-11	1.66e-08	0.59	0.41	Intelligence (multi-trait analysis);	chr6:27274136	chr6:26956992~27023924:+
COAD	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	7.1	1.19e-11	1.67e-08	0.47	0.41	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
COAD	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	7.1	1.19e-11	1.68e-08	0.43	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
COAD	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	7.1	1.2e-11	1.69e-08	0.45	0.41	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
COAD	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	7.1	1.2e-11	1.69e-08	0.47	0.41	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
COAD	cis	rs1400745	0.718	rs799681	ENSG00000258738.1	RP11-73E17.2	7.1	1.21e-11	1.7e-08	0.45	0.41	Monocyte count;	chr14:34881373	chr14:34874343~34876459:+
COAD	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-7.1	1.21e-11	1.71e-08	-0.45	-0.4	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.515	rs7630575	ENSG00000248787.1	RP11-666A20.4	-7.1	1.21e-11	1.71e-08	-0.55	-0.4	Blood pressure (smoking interaction);	chr3:125963487	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	7.1	1.22e-11	1.71e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
COAD	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	7.1	1.22e-11	1.71e-08	0.6	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
COAD	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	7.1	1.22e-11	1.71e-08	0.49	0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
COAD	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	7.1	1.25e-11	1.75e-08	0.51	0.4	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
COAD	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	7.1	1.25e-11	1.75e-08	0.5	0.4	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
COAD	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	7.1	1.25e-11	1.76e-08	0.57	0.4	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
COAD	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	7.1	1.25e-11	1.76e-08	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
COAD	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	7.09	1.26e-11	1.77e-08	0.62	0.4	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-7.09	1.26e-11	1.78e-08	-0.47	-0.4	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
COAD	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-7.09	1.26e-11	1.78e-08	-0.51	-0.4	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
COAD	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-7.09	1.26e-11	1.78e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
COAD	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	7.09	1.27e-11	1.78e-08	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
COAD	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-7.09	1.27e-11	1.78e-08	-0.49	-0.4	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
COAD	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.09	1.27e-11	1.79e-08	0.49	0.4	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
COAD	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-7.09	1.28e-11	1.8e-08	-0.46	-0.4	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
COAD	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-7.09	1.29e-11	1.81e-08	-0.52	-0.4	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
COAD	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-7.09	1.29e-11	1.81e-08	-0.52	-0.4	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
COAD	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-7.09	1.29e-11	1.81e-08	-0.52	-0.4	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
COAD	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	7.09	1.29e-11	1.81e-08	0.84	0.4	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	7.09	1.29e-11	1.81e-08	0.84	0.4	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
COAD	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-7.09	1.29e-11	1.81e-08	-0.48	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-7.09	1.3e-11	1.82e-08	-0.49	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
COAD	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-7.09	1.3e-11	1.82e-08	-0.57	-0.4	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
COAD	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-7.09	1.3e-11	1.83e-08	-0.37	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
COAD	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	7.09	1.3e-11	1.83e-08	0.45	0.4	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
COAD	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.09	1.31e-11	1.83e-08	-0.35	-0.4	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
COAD	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-7.09	1.31e-11	1.83e-08	-0.6	-0.4	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
COAD	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-7.09	1.32e-11	1.84e-08	-0.47	-0.4	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
COAD	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	7.09	1.32e-11	1.84e-08	0.42	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
COAD	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-7.09	1.32e-11	1.84e-08	-0.47	-0.4	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
COAD	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-7.09	1.32e-11	1.85e-08	-0.59	-0.4	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
COAD	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-7.09	1.33e-11	1.86e-08	-0.44	-0.4	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
COAD	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-7.09	1.33e-11	1.86e-08	-0.47	-0.4	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	7.08	1.33e-11	1.87e-08	0.44	0.4	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
COAD	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-7.08	1.34e-11	1.87e-08	-0.52	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
COAD	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	7.08	1.34e-11	1.88e-08	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
COAD	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-7.08	1.35e-11	1.88e-08	-0.62	-0.4	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
COAD	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	7.08	1.35e-11	1.88e-08	0.52	0.4	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
COAD	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	7.08	1.35e-11	1.89e-08	0.42	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
COAD	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	7.08	1.36e-11	1.9e-08	0.5	0.4	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
COAD	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	7.08	1.36e-11	1.9e-08	0.5	0.4	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
COAD	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-7.08	1.38e-11	1.93e-08	-0.49	-0.4	Height;	chr6:109531713	chr6:109382795~109383666:+
COAD	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	7.08	1.38e-11	1.93e-08	0.49	0.4	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
COAD	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-7.08	1.39e-11	1.94e-08	-0.44	-0.4	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-7.08	1.4e-11	1.96e-08	-0.48	-0.4	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
COAD	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-7.08	1.41e-11	1.96e-08	-0.49	-0.4	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-7.08	1.41e-11	1.96e-08	-0.49	-0.4	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
COAD	cis	rs860818	1	rs858233	ENSG00000226816.2	AC005082.12	7.08	1.41e-11	1.97e-08	0.81	0.4	Initial pursuit acceleration;	chr7:23201914	chr7:23206013~23208045:+
COAD	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	7.07	1.42e-11	1.98e-08	0.5	0.4	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
COAD	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	7.07	1.43e-11	1.99e-08	0.52	0.4	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
COAD	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-7.07	1.43e-11	1.99e-08	-0.6	-0.4	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-7.07	1.43e-11	1.99e-08	-0.6	-0.4	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-7.07	1.43e-11	1.99e-08	-0.6	-0.4	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
COAD	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	7.07	1.44e-11	2.01e-08	0.84	0.4	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
COAD	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	7.07	1.44e-11	2.01e-08	0.48	0.4	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
COAD	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-7.07	1.46e-11	2.03e-08	-0.57	-0.4	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
COAD	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-7.07	1.46e-11	2.03e-08	-0.49	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
COAD	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-7.07	1.47e-11	2.05e-08	-0.62	-0.4	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
COAD	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	7.07	1.48e-11	2.06e-08	0.67	0.4	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
COAD	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	7.07	1.49e-11	2.07e-08	0.63	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
COAD	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	7.07	1.5e-11	2.08e-08	0.57	0.4	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
COAD	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	7.06	1.51e-11	2.09e-08	0.43	0.4	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
COAD	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	7.06	1.51e-11	2.1e-08	0.59	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
COAD	cis	rs7714584	1	rs76872831	ENSG00000197083.10	ZNF300P1	7.06	1.52e-11	2.1e-08	0.65	0.4	Crohn's disease;	chr5:150791997	chr5:150930645~150946289:-
COAD	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	7.06	1.52e-11	2.11e-08	0.6	0.4	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
COAD	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	7.06	1.52e-11	2.11e-08	0.57	0.4	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-7.06	1.53e-11	2.13e-08	-0.64	-0.4	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-7.06	1.54e-11	2.13e-08	-0.43	-0.4	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
COAD	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	7.06	1.54e-11	2.14e-08	0.84	0.4	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-7.06	1.55e-11	2.14e-08	-0.6	-0.4	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
COAD	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-7.06	1.56e-11	2.16e-08	-0.48	-0.4	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
COAD	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	7.06	1.56e-11	2.16e-08	0.49	0.4	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
COAD	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	7.06	1.57e-11	2.17e-08	0.5	0.4	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-7.06	1.59e-11	2.2e-08	-0.48	-0.4	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
COAD	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	7.05	1.6e-11	2.22e-08	0.43	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
COAD	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	7.05	1.63e-11	2.25e-08	0.65	0.4	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
COAD	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-7.05	1.63e-11	2.25e-08	-0.56	-0.4	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	7.05	1.63e-11	2.26e-08	0.53	0.4	Height;	chr6:109454855	chr6:109382795~109383666:+
COAD	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	7.05	1.65e-11	2.28e-08	0.47	0.4	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
COAD	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	7.05	1.66e-11	2.29e-08	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
COAD	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	7.05	1.66e-11	2.29e-08	0.8	0.4	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-7.05	1.67e-11	2.3e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
COAD	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-7.05	1.67e-11	2.31e-08	-0.49	-0.4	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
COAD	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	7.05	1.67e-11	2.31e-08	0.57	0.4	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
COAD	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-7.05	1.68e-11	2.31e-08	-0.44	-0.4	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
COAD	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-7.05	1.68e-11	2.32e-08	-0.61	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
COAD	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-7.04	1.7e-11	2.34e-08	-0.64	-0.4	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
COAD	cis	rs860818	0.793	rs5014167	ENSG00000226816.2	AC005082.12	7.04	1.71e-11	2.35e-08	0.77	0.4	Initial pursuit acceleration;	chr7:23202684	chr7:23206013~23208045:+
COAD	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-7.04	1.71e-11	2.36e-08	-0.52	-0.4	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
COAD	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	7.04	1.72e-11	2.37e-08	0.51	0.4	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
COAD	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-7.04	1.72e-11	2.37e-08	-0.44	-0.4	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
COAD	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	7.04	1.74e-11	2.39e-08	0.41	0.4	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
COAD	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	7.04	1.74e-11	2.4e-08	0.57	0.4	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	7.04	1.74e-11	2.4e-08	0.57	0.4	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
COAD	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	7.04	1.75e-11	2.41e-08	0.47	0.4	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
COAD	cis	rs860818	1	rs858286	ENSG00000226816.2	AC005082.12	7.04	1.75e-11	2.41e-08	0.78	0.4	Initial pursuit acceleration;	chr7:23209844	chr7:23206013~23208045:+
COAD	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	7.04	1.75e-11	2.41e-08	0.55	0.4	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
COAD	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	7.04	1.77e-11	2.44e-08	0.49	0.4	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
COAD	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	7.04	1.78e-11	2.45e-08	0.42	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
COAD	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	7.04	1.78e-11	2.45e-08	0.52	0.4	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-7.04	1.79e-11	2.46e-08	-0.6	-0.4	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
COAD	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-7.04	1.8e-11	2.47e-08	-0.46	-0.4	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
COAD	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	7.03	1.82e-11	2.49e-08	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
COAD	cis	rs7078219	0.505	rs10883365	ENSG00000228778.1	RP11-129J12.1	-7.03	1.83e-11	2.52e-08	-0.44	-0.4	Dental caries;	chr10:99528007	chr10:99527081~99528261:+
COAD	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	7.03	1.83e-11	2.52e-08	0.49	0.4	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
COAD	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	7.03	1.84e-11	2.52e-08	0.51	0.4	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
COAD	cis	rs754466	0.651	rs11002322	ENSG00000204049.1	RP11-126H7.4	7.03	1.84e-11	2.52e-08	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77889895	chr10:77866875~77869610:+
COAD	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.03	1.84e-11	2.52e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
COAD	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-7.03	1.85e-11	2.54e-08	-0.46	-0.4	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
COAD	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-7.03	1.86e-11	2.55e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
COAD	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-7.03	1.86e-11	2.55e-08	-0.46	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
COAD	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-7.03	1.86e-11	2.55e-08	-0.44	-0.4	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
COAD	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-7.03	1.86e-11	2.55e-08	-0.66	-0.4	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
COAD	cis	rs7078219	0.965	rs11190126	ENSG00000257582.4	LINC01475	-7.03	1.86e-11	2.55e-08	-0.44	-0.4	Dental caries;	chr10:99512032	chr10:99526350~99531177:-
COAD	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-7.03	1.88e-11	2.58e-08	-0.56	-0.4	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
COAD	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	7.03	1.89e-11	2.58e-08	0.5	0.4	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
COAD	cis	rs754466	0.651	rs55738779	ENSG00000204049.1	RP11-126H7.4	7.03	1.89e-11	2.59e-08	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77892637	chr10:77866875~77869610:+
COAD	cis	rs754466	0.512	rs67607593	ENSG00000204049.1	RP11-126H7.4	7.03	1.9e-11	2.6e-08	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77889292	chr10:77866875~77869610:+
COAD	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-7.02	1.92e-11	2.62e-08	-0.47	-0.4	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
COAD	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	7.02	1.93e-11	2.63e-08	0.6	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	7.02	1.93e-11	2.63e-08	0.6	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
COAD	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	7.02	1.93e-11	2.63e-08	0.6	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
COAD	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	7.02	1.93e-11	2.64e-08	0.52	0.4	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
COAD	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.93e-11	2.64e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
COAD	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.02	1.93e-11	2.64e-08	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
COAD	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-7.02	1.94e-11	2.66e-08	-0.7	-0.4	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
COAD	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-7.02	1.96e-11	2.68e-08	-0.55	-0.4	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
COAD	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-7.02	1.97e-11	2.69e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
COAD	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-7.02	1.97e-11	2.69e-08	-0.43	-0.4	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
COAD	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	7.02	2e-11	2.73e-08	0.38	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
COAD	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	7.02	2e-11	2.73e-08	0.6	0.4	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	7.02	2e-11	2.73e-08	0.6	0.4	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	7.02	2e-11	2.73e-08	0.6	0.4	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
COAD	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-7.02	2e-11	2.73e-08	-0.6	-0.4	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
COAD	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-7.02	2.01e-11	2.73e-08	-0.57	-0.4	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
COAD	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-7.02	2.02e-11	2.75e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-7.02	2.02e-11	2.75e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
COAD	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	7.02	2.03e-11	2.76e-08	0.57	0.4	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
COAD	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	7.01	2.04e-11	2.77e-08	0.58	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
COAD	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-7.01	2.04e-11	2.78e-08	-0.49	-0.4	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
COAD	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-7.01	2.05e-11	2.8e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
COAD	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-7.01	2.08e-11	2.83e-08	-0.43	-0.4	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
COAD	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-7.01	2.09e-11	2.85e-08	-0.47	-0.4	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
COAD	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-7.01	2.1e-11	2.85e-08	-0.47	-0.4	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-7.01	2.13e-11	2.89e-08	-0.48	-0.4	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
COAD	cis	rs754466	0.651	rs2004382	ENSG00000204049.1	RP11-126H7.4	7.01	2.14e-11	2.9e-08	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77890593	chr10:77866875~77869610:+
COAD	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	7.01	2.14e-11	2.91e-08	0.76	0.4	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
COAD	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	7.01	2.15e-11	2.91e-08	0.49	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
COAD	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-7.01	2.15e-11	2.91e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.01	2.15e-11	2.91e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.01	2.15e-11	2.91e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.01	2.15e-11	2.91e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
COAD	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-7	2.17e-11	2.94e-08	-0.45	-0.4	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
COAD	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7	2.19e-11	2.97e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
COAD	cis	rs7078219	1	rs11190130	ENSG00000257582.4	LINC01475	-7	2.22e-11	3.01e-08	-0.44	-0.4	Dental caries;	chr10:99515449	chr10:99526350~99531177:-
COAD	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-7	2.23e-11	3.03e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
COAD	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-7	2.24e-11	3.03e-08	-0.44	-0.4	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
COAD	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-7	2.24e-11	3.04e-08	-0.52	-0.4	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
COAD	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-7	2.25e-11	3.05e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
COAD	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7	2.26e-11	3.06e-08	-0.46	-0.4	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
COAD	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	7	2.26e-11	3.06e-08	0.45	0.4	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
COAD	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	7	2.27e-11	3.08e-08	0.84	0.4	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
COAD	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-7	2.28e-11	3.08e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
COAD	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	7	2.29e-11	3.09e-08	0.43	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
COAD	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-6.99	2.3e-11	3.1e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
COAD	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-6.99	2.3e-11	3.1e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
COAD	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-6.99	2.3e-11	3.1e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
COAD	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-6.99	2.3e-11	3.1e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-6.99	2.3e-11	3.1e-08	-0.38	-0.4	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
COAD	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	6.99	2.34e-11	3.16e-08	0.45	0.4	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
COAD	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-6.99	2.34e-11	3.16e-08	-0.46	-0.4	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
COAD	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	6.99	2.34e-11	3.16e-08	0.75	0.4	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
COAD	cis	rs7078219	0.543	rs7096296	ENSG00000228778.1	RP11-129J12.1	6.99	2.35e-11	3.17e-08	0.45	0.4	Dental caries;	chr10:99518059	chr10:99527081~99528261:+
COAD	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-6.99	2.35e-11	3.17e-08	-0.45	-0.4	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
COAD	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	6.99	2.42e-11	3.27e-08	0.49	0.4	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
COAD	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	6.99	2.42e-11	3.27e-08	0.45	0.4	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
COAD	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	6.99	2.43e-11	3.28e-08	0.29	0.4	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	6.99	2.43e-11	3.28e-08	0.29	0.4	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	6.99	2.43e-11	3.28e-08	0.29	0.4	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	6.99	2.43e-11	3.28e-08	0.29	0.4	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	6.99	2.43e-11	3.28e-08	0.29	0.4	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
COAD	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-6.98	2.46e-11	3.31e-08	-0.68	-0.4	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
COAD	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	6.98	2.47e-11	3.32e-08	0.53	0.4	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	6.98	2.47e-11	3.32e-08	0.53	0.4	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	6.98	2.47e-11	3.32e-08	0.53	0.4	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
COAD	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-6.98	2.47e-11	3.32e-08	-0.44	-0.4	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
COAD	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-6.98	2.48e-11	3.33e-08	-0.47	-0.4	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
COAD	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	6.98	2.48e-11	3.34e-08	0.44	0.4	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
COAD	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-6.98	2.5e-11	3.36e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-6.98	2.5e-11	3.36e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
COAD	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-6.98	2.5e-11	3.36e-08	-0.44	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
COAD	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.98	2.52e-11	3.39e-08	-0.42	-0.4	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
COAD	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-6.98	2.53e-11	3.4e-08	-0.43	-0.4	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
COAD	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-6.98	2.53e-11	3.4e-08	-0.43	-0.4	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
COAD	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-6.98	2.53e-11	3.4e-08	-0.43	-0.4	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
COAD	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-6.98	2.53e-11	3.4e-08	-0.47	-0.4	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.98	2.55e-11	3.42e-08	0.47	0.4	Height;	chr6:109490935	chr6:109382795~109383666:+
COAD	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	6.98	2.56e-11	3.44e-08	0.58	0.4	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
COAD	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.98	2.56e-11	3.44e-08	0.6	0.4	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.98	2.56e-11	3.44e-08	0.6	0.4	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
COAD	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	6.98	2.58e-11	3.46e-08	0.6	0.4	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
COAD	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-6.98	2.58e-11	3.46e-08	-0.45	-0.4	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
COAD	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	6.98	2.58e-11	3.46e-08	0.42	0.4	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
COAD	cis	rs7078219	0.524	rs6584277	ENSG00000228778.1	RP11-129J12.1	-6.97	2.59e-11	3.47e-08	-0.45	-0.4	Dental caries;	chr10:99518298	chr10:99527081~99528261:+
COAD	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-6.97	2.59e-11	3.47e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-6.97	2.59e-11	3.47e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
COAD	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-6.97	2.6e-11	3.48e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
COAD	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	6.97	2.6e-11	3.48e-08	0.48	0.4	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
COAD	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-6.97	2.62e-11	3.51e-08	-0.47	-0.4	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
COAD	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-6.97	2.62e-11	3.52e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
COAD	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-6.97	2.65e-11	3.55e-08	-0.43	-0.4	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
COAD	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.97	2.65e-11	3.55e-08	-0.43	-0.4	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
COAD	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-6.97	2.68e-11	3.58e-08	-0.68	-0.4	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	6.97	2.68e-11	3.58e-08	0.46	0.4	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
COAD	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	6.97	2.69e-11	3.6e-08	0.76	0.4	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
COAD	cis	rs1400745	0.729	rs28472856	ENSG00000258738.1	RP11-73E17.2	6.97	2.7e-11	3.61e-08	0.44	0.4	Monocyte count;	chr14:34862951	chr14:34874343~34876459:+
COAD	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-6.97	2.7e-11	3.62e-08	-0.43	-0.4	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
COAD	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-6.97	2.71e-11	3.62e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
COAD	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-6.97	2.72e-11	3.64e-08	-0.47	-0.4	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-6.97	2.74e-11	3.66e-08	-0.46	-0.4	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
COAD	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	6.96	2.75e-11	3.68e-08	0.52	0.4	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
COAD	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-6.96	2.77e-11	3.71e-08	-0.43	-0.4	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
COAD	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	6.96	2.77e-11	3.71e-08	0.43	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
COAD	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-6.96	2.79e-11	3.72e-08	-0.47	-0.4	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
COAD	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	6.96	2.81e-11	3.75e-08	0.53	0.4	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
COAD	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-6.96	2.82e-11	3.76e-08	-0.48	-0.4	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.96	2.84e-11	3.79e-08	-0.59	-0.4	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
COAD	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-6.96	2.84e-11	3.79e-08	-0.59	-0.4	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
COAD	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	6.96	2.85e-11	3.8e-08	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
COAD	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	6.96	2.85e-11	3.8e-08	0.6	0.4	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
COAD	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-6.96	2.86e-11	3.81e-08	-0.43	-0.4	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
COAD	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	6.96	2.86e-11	3.81e-08	0.66	0.4	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
COAD	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	6.96	2.86e-11	3.81e-08	0.53	0.4	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
COAD	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-6.96	2.89e-11	3.85e-08	-0.35	-0.4	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-6.96	2.89e-11	3.85e-08	-0.35	-0.4	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
COAD	cis	rs12468226	0.623	rs12471811	ENSG00000273456.1	RP11-686O6.2	6.96	2.9e-11	3.86e-08	0.71	0.4	Urate levels;	chr2:202586164	chr2:202374932~202375604:-
COAD	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	6.96	2.91e-11	3.87e-08	0.51	0.4	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
COAD	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	6.95	2.91e-11	3.88e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
COAD	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	6.95	2.91e-11	3.88e-08	0.52	0.4	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
COAD	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-6.95	2.91e-11	3.88e-08	-0.52	-0.4	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
COAD	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-6.95	2.92e-11	3.89e-08	-0.46	-0.4	Height;	chr6:109360458	chr6:109382795~109383666:+
COAD	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-6.95	2.93e-11	3.89e-08	-0.4	-0.4	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
COAD	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	6.95	2.94e-11	3.9e-08	0.45	0.4	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	6.95	2.94e-11	3.9e-08	0.45	0.4	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
COAD	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	6.95	3e-11	3.98e-08	0.35	0.4	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
COAD	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-6.95	3e-11	3.99e-08	-0.67	-0.4	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
COAD	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.95	3.01e-11	3.99e-08	-0.61	-0.4	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
COAD	cis	rs5769707	0.967	rs9616333	ENSG00000188511.11	C22orf34	6.95	3.02e-11	4.01e-08	0.42	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49657199	chr22:49414524~49657542:-
COAD	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-6.95	3.03e-11	4.03e-08	-0.62	-0.4	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
COAD	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-6.95	3.05e-11	4.05e-08	-0.37	-0.4	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
COAD	cis	rs6584283	0.716	rs10786558	ENSG00000257582.4	LINC01475	-6.95	3.05e-11	4.05e-08	-0.42	-0.4	Ulcerative colitis;	chr10:99527853	chr10:99526350~99531177:-
COAD	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	6.95	3.05e-11	4.05e-08	0.45	0.4	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	6.95	3.05e-11	4.05e-08	0.45	0.4	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
COAD	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	6.95	3.05e-11	4.05e-08	0.43	0.4	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
COAD	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
COAD	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-6.95	3.06e-11	4.05e-08	-0.46	-0.4	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
COAD	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	6.95	3.08e-11	4.09e-08	0.45	0.4	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
COAD	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-6.94	3.09e-11	4.1e-08	-0.63	-0.4	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
COAD	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	6.94	3.11e-11	4.12e-08	0.44	0.4	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
COAD	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	6.94	3.11e-11	4.12e-08	0.57	0.4	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
COAD	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.94	3.11e-11	4.13e-08	0.41	0.4	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
COAD	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-6.94	3.13e-11	4.14e-08	-0.43	-0.4	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
COAD	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-6.94	3.15e-11	4.17e-08	-0.53	-0.4	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
COAD	cis	rs1400745	0.718	rs1200414	ENSG00000258738.1	RP11-73E17.2	6.94	3.15e-11	4.17e-08	0.44	0.4	Monocyte count;	chr14:34861687	chr14:34874343~34876459:+
COAD	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-6.94	3.16e-11	4.19e-08	-0.47	-0.4	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
COAD	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-6.94	3.18e-11	4.21e-08	-0.41	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
COAD	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	6.94	3.18e-11	4.21e-08	0.57	0.4	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
COAD	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.94	3.21e-11	4.24e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
COAD	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-6.94	3.21e-11	4.25e-08	-0.59	-0.4	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
COAD	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	6.94	3.22e-11	4.26e-08	0.54	0.4	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
COAD	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.94	3.24e-11	4.28e-08	-0.47	-0.4	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
COAD	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	6.94	3.24e-11	4.28e-08	0.44	0.4	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
COAD	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	6.94	3.25e-11	4.3e-08	0.46	0.4	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
COAD	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-6.94	3.27e-11	4.32e-08	-0.5	-0.4	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
COAD	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	6.93	3.3e-11	4.36e-08	0.45	0.4	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
COAD	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	6.93	3.32e-11	4.38e-08	0.5	0.4	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
COAD	cis	rs7078219	0.543	rs7092009	ENSG00000228778.1	RP11-129J12.1	-6.93	3.36e-11	4.44e-08	-0.44	-0.4	Dental caries;	chr10:99517482	chr10:99527081~99528261:+
COAD	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-6.93	3.38e-11	4.45e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
COAD	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-6.93	3.38e-11	4.46e-08	-0.52	-0.4	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
COAD	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-6.93	3.4e-11	4.48e-08	-0.34	-0.4	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
COAD	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	6.93	3.43e-11	4.51e-08	0.45	0.4	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
COAD	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-6.93	3.45e-11	4.54e-08	-0.62	-0.4	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
COAD	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-6.93	3.45e-11	4.54e-08	-0.47	-0.4	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	6.93	3.45e-11	4.55e-08	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
COAD	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	6.93	3.46e-11	4.55e-08	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
COAD	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	6.93	3.46e-11	4.56e-08	0.63	0.4	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
COAD	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	6.93	3.48e-11	4.58e-08	0.45	0.4	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
COAD	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-6.92	3.48e-11	4.58e-08	-0.51	-0.4	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
COAD	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	6.92	3.48e-11	4.58e-08	0.51	0.4	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
COAD	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	6.92	3.52e-11	4.63e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	6.92	3.52e-11	4.63e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
COAD	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	6.92	3.53e-11	4.64e-08	0.45	0.4	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
COAD	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	6.92	3.54e-11	4.65e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	6.92	3.54e-11	4.65e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	6.92	3.54e-11	4.65e-08	0.58	0.4	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
COAD	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	6.92	3.54e-11	4.65e-08	0.53	0.4	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
COAD	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	6.92	3.6e-11	4.73e-08	0.48	0.4	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
COAD	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.92	3.62e-11	4.75e-08	-0.43	-0.4	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
COAD	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	6.92	3.65e-11	4.78e-08	0.6	0.4	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
COAD	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-6.92	3.65e-11	4.79e-08	-0.47	-0.4	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.92	3.66e-11	4.8e-08	0.47	0.4	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-6.92	3.67e-11	4.81e-08	-0.45	-0.4	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-6.92	3.68e-11	4.83e-08	-0.47	-0.4	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
COAD	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	6.92	3.69e-11	4.83e-08	0.59	0.4	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
COAD	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	6.91	3.7e-11	4.85e-08	0.56	0.4	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
COAD	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	6.91	3.72e-11	4.87e-08	0.53	0.4	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
COAD	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-6.91	3.72e-11	4.88e-08	-0.48	-0.4	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
COAD	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	6.91	3.75e-11	4.91e-08	0.51	0.4	Height;	chr6:109414295	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	6.91	3.75e-11	4.91e-08	0.51	0.4	Height;	chr6:109416225	chr6:109382795~109383666:+
COAD	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-6.91	3.77e-11	4.93e-08	-0.43	-0.4	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
COAD	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-6.91	3.77e-11	4.93e-08	-0.43	-0.4	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
COAD	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-6.91	3.77e-11	4.94e-08	-0.44	-0.4	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
COAD	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	6.91	3.79e-11	4.96e-08	0.56	0.4	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
COAD	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	6.91	3.8e-11	4.97e-08	0.53	0.4	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
COAD	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-6.91	3.85e-11	5.03e-08	-0.47	-0.4	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-6.91	3.85e-11	5.03e-08	-0.47	-0.4	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	6.91	3.85e-11	5.04e-08	0.46	0.4	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
COAD	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.91	3.87e-11	5.06e-08	-0.42	-0.4	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
COAD	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-6.91	3.88e-11	5.07e-08	-0.63	-0.4	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
COAD	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-6.91	3.89e-11	5.09e-08	-0.47	-0.4	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
COAD	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	6.9	3.94e-11	5.14e-08	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	6.9	3.94e-11	5.14e-08	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
COAD	cis	rs860818	1	rs860818	ENSG00000226816.2	AC005082.12	6.9	3.96e-11	5.17e-08	0.81	0.4	Initial pursuit acceleration;	chr7:23210744	chr7:23206013~23208045:+
COAD	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	6.9	3.96e-11	5.17e-08	0.5	0.4	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
COAD	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	6.9	3.97e-11	5.18e-08	0.37	0.4	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
COAD	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	6.9	3.97e-11	5.18e-08	0.37	0.4	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
COAD	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-6.9	3.99e-11	5.2e-08	-0.51	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
COAD	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	6.9	4.02e-11	5.24e-08	0.46	0.4	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
COAD	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	6.9	4.02e-11	5.24e-08	0.83	0.4	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
COAD	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	6.9	4.02e-11	5.24e-08	0.83	0.4	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
COAD	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	6.9	4.03e-11	5.25e-08	0.56	0.4	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
COAD	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	6.9	4.03e-11	5.26e-08	0.59	0.4	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
COAD	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-6.9	4.04e-11	5.26e-08	-0.42	-0.4	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
COAD	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.04e-11	5.27e-08	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-6.9	4.05e-11	5.28e-08	-0.38	-0.4	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
COAD	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-6.9	4.05e-11	5.28e-08	-0.45	-0.4	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
COAD	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.9	4.08e-11	5.31e-08	-0.47	-0.4	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
COAD	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-6.9	4.08e-11	5.31e-08	-0.51	-0.4	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
COAD	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	6.9	4.09e-11	5.32e-08	0.59	0.4	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	6.9	4.09e-11	5.32e-08	0.59	0.4	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
COAD	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	6.9	4.11e-11	5.35e-08	0.57	0.4	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
COAD	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-6.9	4.15e-11	5.4e-08	-0.47	-0.4	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
COAD	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-6.89	4.17e-11	5.43e-08	-0.51	-0.4	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
COAD	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	6.89	4.19e-11	5.44e-08	0.51	0.4	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
COAD	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-6.89	4.19e-11	5.46e-08	-0.38	-0.4	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
COAD	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	6.89	4.2e-11	5.46e-08	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
COAD	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	6.89	4.22e-11	5.48e-08	0.47	0.39	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
COAD	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-6.89	4.22e-11	5.48e-08	-0.53	-0.39	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
COAD	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-6.89	4.22e-11	5.49e-08	-0.41	-0.39	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
COAD	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	6.89	4.22e-11	5.49e-08	0.47	0.39	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
COAD	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	6.89	4.23e-11	5.49e-08	0.61	0.39	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
COAD	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	6.89	4.23e-11	5.49e-08	0.61	0.39	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
COAD	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	6.89	4.23e-11	5.5e-08	0.48	0.39	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
COAD	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-6.89	4.26e-11	5.53e-08	-0.58	-0.39	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
COAD	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-6.89	4.26e-11	5.53e-08	-0.37	-0.39	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
COAD	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-6.89	4.26e-11	5.53e-08	-0.37	-0.39	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
COAD	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	6.89	4.26e-11	5.53e-08	0.49	0.39	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
COAD	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	6.89	4.26e-11	5.53e-08	0.49	0.39	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
COAD	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	6.89	4.26e-11	5.54e-08	0.53	0.39	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	6.89	4.26e-11	5.54e-08	0.53	0.39	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
COAD	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-6.89	4.27e-11	5.55e-08	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
COAD	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-6.89	4.27e-11	5.55e-08	-0.46	-0.39	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
COAD	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-6.89	4.3e-11	5.58e-08	-0.43	-0.39	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
COAD	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-6.89	4.3e-11	5.59e-08	-0.45	-0.39	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
COAD	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	6.89	4.31e-11	5.59e-08	0.53	0.39	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
COAD	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-6.89	4.31e-11	5.6e-08	-0.5	-0.39	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
COAD	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-6.89	4.32e-11	5.61e-08	-0.36	-0.39	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
COAD	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-6.89	4.36e-11	5.65e-08	-0.48	-0.39	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
COAD	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	6.89	4.38e-11	5.68e-08	0.59	0.39	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
COAD	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	6.89	4.39e-11	5.69e-08	0.48	0.39	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
COAD	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-6.89	4.39e-11	5.69e-08	-0.46	-0.39	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
COAD	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-6.89	4.4e-11	5.7e-08	-0.46	-0.39	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-6.88	4.44e-11	5.75e-08	-0.56	-0.39	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	6.88	4.45e-11	5.77e-08	0.47	0.39	Height;	chr6:109424122	chr6:109382795~109383666:+
COAD	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-6.88	4.47e-11	5.78e-08	-0.43	-0.39	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
COAD	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	6.88	4.48e-11	5.79e-08	0.48	0.39	Height;	chr6:109706514	chr6:109382795~109383666:+
COAD	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	6.88	4.48e-11	5.8e-08	0.54	0.39	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
COAD	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	6.88	4.49e-11	5.81e-08	0.3	0.39	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
COAD	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-6.88	4.5e-11	5.82e-08	-0.42	-0.39	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
COAD	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	6.88	4.5e-11	5.82e-08	0.47	0.39	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
COAD	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	6.88	4.51e-11	5.83e-08	0.47	0.39	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
COAD	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	6.88	4.51e-11	5.83e-08	0.48	0.39	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	6.88	4.51e-11	5.83e-08	0.48	0.39	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
COAD	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	6.88	4.55e-11	5.88e-08	0.47	0.39	Height;	chr6:109332929	chr6:109382795~109383666:+
COAD	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-6.88	4.55e-11	5.88e-08	-0.52	-0.39	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
COAD	cis	rs7615952	0.515	rs4441610	ENSG00000248787.1	RP11-666A20.4	-6.88	4.55e-11	5.88e-08	-0.55	-0.39	Blood pressure (smoking interaction);	chr3:125962464	chr3:125908005~125910272:-
COAD	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-6.88	4.55e-11	5.88e-08	-0.43	-0.39	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
COAD	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-6.88	4.58e-11	5.92e-08	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-6.88	4.58e-11	5.92e-08	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-6.88	4.58e-11	5.92e-08	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
COAD	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-6.88	4.59e-11	5.92e-08	-0.49	-0.39	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-6.88	4.59e-11	5.92e-08	-0.49	-0.39	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
COAD	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	6.88	4.61e-11	5.95e-08	0.48	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
COAD	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-6.88	4.63e-11	5.98e-08	-0.47	-0.39	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
COAD	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-6.88	4.63e-11	5.98e-08	-0.58	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
COAD	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-6.88	4.65e-11	5.99e-08	-0.37	-0.39	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
COAD	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.88	4.66e-11	6.01e-08	-0.58	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.88	4.66e-11	6.01e-08	-0.58	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.88	4.66e-11	6.01e-08	-0.58	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
COAD	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	6.88	4.68e-11	6.03e-08	0.49	0.39	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	6.88	4.68e-11	6.03e-08	0.49	0.39	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
COAD	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	6.87	4.69e-11	6.04e-08	0.46	0.39	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
COAD	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-6.87	4.72e-11	6.08e-08	-0.64	-0.39	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
COAD	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-6.87	4.72e-11	6.09e-08	-0.47	-0.39	Height;	chr6:109731677	chr6:109382795~109383666:+
COAD	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	6.87	4.73e-11	6.09e-08	0.57	0.39	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	6.87	4.74e-11	6.1e-08	0.56	0.39	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
COAD	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-6.87	4.75e-11	6.11e-08	-0.51	-0.39	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
COAD	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-6.87	4.75e-11	6.12e-08	-0.49	-0.39	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
COAD	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-6.87	4.76e-11	6.13e-08	-0.44	-0.39	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
COAD	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	6.87	4.79e-11	6.17e-08	0.47	0.39	Height;	chr6:109738751	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-6.87	4.8e-11	6.18e-08	-0.61	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
COAD	cis	rs754466	0.606	rs12356375	ENSG00000204049.1	RP11-126H7.4	6.87	4.82e-11	6.2e-08	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77834756	chr10:77866875~77869610:+
COAD	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	6.87	4.86e-11	6.25e-08	0.35	0.39	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
COAD	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	6.87	4.89e-11	6.28e-08	0.48	0.39	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
COAD	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-6.87	4.89e-11	6.29e-08	-0.41	-0.39	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
COAD	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	6.87	4.92e-11	6.33e-08	0.42	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
COAD	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.87	4.95e-11	6.36e-08	0.42	0.39	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	6.87	4.96e-11	6.36e-08	0.52	0.39	Height;	chr6:109655182	chr6:109382795~109383666:+
COAD	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	6.86	5.04e-11	6.44e-08	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
COAD	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	6.86	5.04e-11	6.44e-08	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
COAD	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	6.86	5.07e-11	6.47e-08	0.51	0.39	Height;	chr6:109357908	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	6.86	5.07e-11	6.47e-08	0.51	0.39	Height;	chr6:109359747	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	6.86	5.07e-11	6.47e-08	0.51	0.39	Height;	chr6:109361318	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	6.86	5.07e-11	6.47e-08	0.51	0.39	Height;	chr6:109366911	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	6.86	5.07e-11	6.47e-08	0.51	0.39	Height;	chr6:109371573	chr6:109382795~109383666:+
COAD	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	6.86	5.1e-11	6.51e-08	0.73	0.39	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
COAD	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-6.86	5.13e-11	6.54e-08	-0.54	-0.39	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
COAD	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	6.86	5.14e-11	6.56e-08	0.41	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
COAD	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	6.86	5.15e-11	6.58e-08	0.52	0.39	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
COAD	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6.86	5.17e-11	6.59e-08	0.51	0.39	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
COAD	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	6.86	5.19e-11	6.61e-08	0.51	0.39	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
COAD	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	6.86	5.24e-11	6.68e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
COAD	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	6.86	5.25e-11	6.69e-08	0.46	0.39	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
COAD	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	6.86	5.27e-11	6.71e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
COAD	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-6.85	5.28e-11	6.73e-08	-0.42	-0.39	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
COAD	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-6.85	5.29e-11	6.74e-08	-0.34	-0.39	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
COAD	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-6.85	5.29e-11	6.74e-08	-0.47	-0.39	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-6.85	5.29e-11	6.74e-08	-0.47	-0.39	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-6.85	5.29e-11	6.74e-08	-0.47	-0.39	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
COAD	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	6.85	5.29e-11	6.74e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
COAD	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-6.85	5.3e-11	6.75e-08	-0.48	-0.39	Height;	chr6:109636120	chr6:109382795~109383666:+
COAD	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	6.85	5.32e-11	6.77e-08	0.43	0.39	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
COAD	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	6.85	5.32e-11	6.77e-08	0.43	0.39	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
COAD	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-6.85	5.33e-11	6.78e-08	-0.49	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
COAD	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.85	5.33e-11	6.78e-08	0.5	0.39	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
COAD	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-6.85	5.36e-11	6.82e-08	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
COAD	cis	rs754466	0.606	rs11002309	ENSG00000204049.1	RP11-126H7.4	6.85	5.36e-11	6.82e-08	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835173	chr10:77866875~77869610:+
COAD	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-6.85	5.42e-11	6.89e-08	-0.55	-0.39	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
COAD	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-6.85	5.43e-11	6.9e-08	-0.49	-0.39	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
COAD	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	6.85	5.43e-11	6.9e-08	0.55	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
COAD	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-6.85	5.44e-11	6.91e-08	-0.43	-0.39	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
COAD	cis	rs7078219	1	rs7081330	ENSG00000257582.4	LINC01475	-6.85	5.46e-11	6.93e-08	-0.43	-0.39	Dental caries;	chr10:99514708	chr10:99526350~99531177:-
COAD	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-6.85	5.49e-11	6.98e-08	-0.51	-0.39	Height;	chr6:109444615	chr6:109382795~109383666:+
COAD	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	6.85	5.51e-11	6.99e-08	0.52	0.39	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
COAD	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	6.85	5.51e-11	7e-08	0.51	0.39	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
COAD	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-6.85	5.52e-11	7e-08	-0.43	-0.39	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
COAD	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	6.85	5.53e-11	7.02e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	6.85	5.57e-11	7.06e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
COAD	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	6.85	5.58e-11	7.07e-08	0.46	0.39	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
COAD	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	6.84	5.61e-11	7.1e-08	0.53	0.39	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
COAD	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-6.84	5.62e-11	7.11e-08	-0.4	-0.39	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
COAD	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-6.84	5.62e-11	7.12e-08	-0.47	-0.39	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
COAD	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	6.84	5.63e-11	7.13e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
COAD	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-6.84	5.76e-11	7.29e-08	-0.51	-0.39	Height;	chr6:109405874	chr6:109382795~109383666:+
COAD	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	6.84	5.77e-11	7.29e-08	0.3	0.39	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
COAD	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-6.84	5.78e-11	7.3e-08	-0.53	-0.39	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
COAD	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	6.84	5.8e-11	7.33e-08	0.48	0.39	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
COAD	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-6.84	5.86e-11	7.39e-08	-0.39	-0.39	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
COAD	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-6.84	5.9e-11	7.45e-08	-0.76	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
COAD	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	6.84	5.91e-11	7.45e-08	0.46	0.39	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
COAD	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-6.84	5.91e-11	7.46e-08	-0.4	-0.39	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
COAD	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-6.84	5.93e-11	7.48e-08	-0.46	-0.39	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
COAD	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-6.83	5.94e-11	7.49e-08	-0.45	-0.39	Height;	chr2:231516587	chr2:231508426~231514339:-
COAD	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-6.83	5.94e-11	7.49e-08	-0.43	-0.39	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
COAD	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	6.83	5.96e-11	7.51e-08	0.45	0.39	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
COAD	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	6.83	5.98e-11	7.54e-08	0.51	0.39	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
COAD	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	6.83	5.98e-11	7.54e-08	0.51	0.39	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
COAD	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-6.83	5.98e-11	7.54e-08	-0.51	-0.39	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
COAD	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-6.83	5.99e-11	7.54e-08	-0.42	-0.39	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
COAD	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.83	5.99e-11	7.55e-08	-0.66	-0.39	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	6.83	6.01e-11	7.57e-08	0.62	0.39	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	6.83	6.02e-11	7.58e-08	0.46	0.39	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
COAD	cis	rs7078219	0.505	rs6584282	ENSG00000228778.1	RP11-129J12.1	-6.83	6.02e-11	7.59e-08	-0.43	-0.39	Dental caries;	chr10:99526738	chr10:99527081~99528261:+
COAD	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	6.83	6.06e-11	7.62e-08	0.51	0.39	Height;	chr6:109375003	chr6:109382795~109383666:+
COAD	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-6.83	6.08e-11	7.65e-08	-0.49	-0.39	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-6.83	6.08e-11	7.65e-08	-0.49	-0.39	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
COAD	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	6.83	6.1e-11	7.68e-08	0.51	0.39	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
COAD	cis	rs7078219	0.505	rs10883371	ENSG00000228778.1	RP11-129J12.1	-6.83	6.18e-11	7.77e-08	-0.43	-0.39	Dental caries;	chr10:99532698	chr10:99527081~99528261:+
COAD	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-6.83	6.23e-11	7.82e-08	-0.47	-0.39	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
COAD	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-6.83	6.23e-11	7.82e-08	-0.47	-0.39	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
COAD	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-6.83	6.23e-11	7.82e-08	-0.47	-0.39	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
COAD	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	6.83	6.29e-11	7.89e-08	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
COAD	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-6.83	6.29e-11	7.89e-08	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-6.82	6.3e-11	7.91e-08	-0.46	-0.39	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
COAD	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-6.82	6.32e-11	7.92e-08	-0.43	-0.39	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-6.82	6.32e-11	7.92e-08	-0.43	-0.39	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	6.82	6.36e-11	7.98e-08	0.44	0.39	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
COAD	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-6.82	6.39e-11	8.01e-08	-0.44	-0.39	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
COAD	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-6.82	6.39e-11	8.01e-08	-0.5	-0.39	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
COAD	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	6.82	6.4e-11	8.02e-08	0.53	0.39	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
COAD	cis	rs6584283	0.875	rs10748783	ENSG00000228778.1	RP11-129J12.1	-6.82	6.41e-11	8.03e-08	-0.43	-0.39	Ulcerative colitis;	chr10:99526115	chr10:99527081~99528261:+
COAD	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	6.82	6.42e-11	8.04e-08	0.44	0.39	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
COAD	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	6.82	6.44e-11	8.06e-08	0.56	0.39	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	6.82	6.44e-11	8.07e-08	0.52	0.39	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
COAD	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	6.82	6.49e-11	8.12e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	6.82	6.49e-11	8.12e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	6.82	6.49e-11	8.12e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	6.82	6.49e-11	8.12e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	6.82	6.49e-11	8.12e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
COAD	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-6.82	6.49e-11	8.12e-08	-0.48	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
COAD	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-6.82	6.5e-11	8.13e-08	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
COAD	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-6.82	6.56e-11	8.2e-08	-0.56	-0.39	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-6.82	6.56e-11	8.2e-08	-0.56	-0.39	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-6.82	6.56e-11	8.2e-08	-0.56	-0.39	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
COAD	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	6.82	6.56e-11	8.2e-08	0.48	0.39	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	6.82	6.56e-11	8.2e-08	0.48	0.39	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	6.82	6.56e-11	8.2e-08	0.48	0.39	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	6.82	6.59e-11	8.23e-08	0.47	0.39	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
COAD	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	6.82	6.59e-11	8.23e-08	0.47	0.39	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	6.82	6.59e-11	8.23e-08	0.47	0.39	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	6.82	6.59e-11	8.23e-08	0.47	0.39	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	6.82	6.59e-11	8.23e-08	0.47	0.39	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
COAD	cis	rs754466	0.606	rs10824581	ENSG00000204049.1	RP11-126H7.4	6.82	6.64e-11	8.29e-08	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77839743	chr10:77866875~77869610:+
COAD	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-6.81	6.72e-11	8.4e-08	-0.41	-0.39	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
COAD	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.81	6.73e-11	8.4e-08	-0.46	-0.39	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
COAD	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-6.81	6.74e-11	8.41e-08	-0.51	-0.39	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
COAD	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	6.81	6.79e-11	8.47e-08	0.53	0.39	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
COAD	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	6.81	6.79e-11	8.47e-08	0.51	0.39	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
COAD	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	6.81	6.85e-11	8.55e-08	0.65	0.39	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
COAD	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	6.81	6.86e-11	8.56e-08	0.38	0.39	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
COAD	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	6.81	6.88e-11	8.58e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
COAD	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.81	6.98e-11	8.69e-08	-0.56	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
COAD	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	6.8	7.16e-11	8.91e-08	0.54	0.39	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	6.8	7.16e-11	8.91e-08	0.54	0.39	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
COAD	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	6.8	7.17e-11	8.92e-08	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
COAD	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.8	7.24e-11	9.01e-08	-0.41	-0.39	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.8	7.24e-11	9.01e-08	-0.41	-0.39	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
COAD	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	6.8	7.25e-11	9.02e-08	0.49	0.39	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
COAD	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	6.8	7.27e-11	9.04e-08	0.59	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
COAD	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-6.8	7.29e-11	9.07e-08	-0.5	-0.39	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
COAD	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-6.8	7.32e-11	9.1e-08	-0.53	-0.39	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
COAD	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-6.8	7.37e-11	9.16e-08	-0.44	-0.39	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
COAD	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	6.8	7.37e-11	9.16e-08	0.48	0.39	Height;	chr6:109715504	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	6.8	7.37e-11	9.16e-08	0.48	0.39	Height;	chr6:109715560	chr6:109382795~109383666:+
COAD	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	6.8	7.39e-11	9.18e-08	0.53	0.39	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
COAD	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	6.8	7.41e-11	9.2e-08	0.47	0.39	Height;	chr6:109732518	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	6.8	7.41e-11	9.2e-08	0.47	0.39	Height;	chr6:109738307	chr6:109382795~109383666:+
COAD	cis	rs754466	0.606	rs11002308	ENSG00000204049.1	RP11-126H7.4	6.8	7.45e-11	9.25e-08	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835038	chr10:77866875~77869610:+
COAD	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	6.8	7.48e-11	9.28e-08	0.49	0.39	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	6.8	7.48e-11	9.28e-08	0.49	0.39	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
COAD	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-6.8	7.51e-11	9.32e-08	-0.47	-0.39	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
COAD	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-6.79	7.51e-11	9.32e-08	-0.48	-0.39	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
COAD	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	6.79	7.52e-11	9.33e-08	0.43	0.39	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	6.79	7.55e-11	9.36e-08	0.46	0.39	Height;	chr6:109454233	chr6:109382795~109383666:+
COAD	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	6.79	7.55e-11	9.37e-08	0.61	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
COAD	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-6.79	7.57e-11	9.39e-08	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-6.79	7.59e-11	9.41e-08	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-6.79	7.59e-11	9.41e-08	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	6.79	7.61e-11	9.43e-08	0.41	0.39	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	6.79	7.61e-11	9.43e-08	0.41	0.39	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
COAD	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	6.79	7.62e-11	9.45e-08	0.56	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
COAD	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-6.79	7.63e-11	9.45e-08	-0.63	-0.39	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
COAD	cis	rs7078219	0.505	rs4409764	ENSG00000228778.1	RP11-129J12.1	-6.79	7.65e-11	9.48e-08	-0.43	-0.39	Dental caries;	chr10:99524480	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs4129133	ENSG00000228778.1	RP11-129J12.1	-6.79	7.65e-11	9.48e-08	-0.43	-0.39	Dental caries;	chr10:99524813	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs4129132	ENSG00000228778.1	RP11-129J12.1	-6.79	7.65e-11	9.48e-08	-0.43	-0.39	Dental caries;	chr10:99524880	chr10:99527081~99528261:+
COAD	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	6.79	7.68e-11	9.52e-08	0.45	0.39	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
COAD	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	6.79	7.75e-11	9.59e-08	0.41	0.39	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	6.79	7.75e-11	9.59e-08	0.41	0.39	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	6.79	7.75e-11	9.59e-08	0.41	0.39	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	6.79	7.76e-11	9.61e-08	0.47	0.39	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
COAD	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-6.79	7.76e-11	9.61e-08	-0.46	-0.39	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
COAD	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-6.79	7.77e-11	9.61e-08	-0.57	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
COAD	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	6.79	7.88e-11	9.74e-08	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	6.79	7.89e-11	9.76e-08	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
COAD	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.79	7.94e-11	9.81e-08	-0.43	-0.39	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
COAD	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	6.78	8.02e-11	9.91e-08	0.59	0.39	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
COAD	cis	rs1400745	0.756	rs3783316	ENSG00000258738.1	RP11-73E17.2	6.78	8.03e-11	9.91e-08	0.43	0.39	Monocyte count;	chr14:34867986	chr14:34874343~34876459:+
COAD	cis	rs1400745	0.756	rs3783314	ENSG00000258738.1	RP11-73E17.2	6.78	8.03e-11	9.91e-08	0.43	0.39	Monocyte count;	chr14:34868178	chr14:34874343~34876459:+
COAD	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.78	8.03e-11	9.92e-08	0.5	0.39	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
COAD	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.78	8.05e-11	9.94e-08	-0.59	-0.39	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	6.78	8.08e-11	9.96e-08	0.41	0.39	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
COAD	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	6.78	8.12e-11	1e-07	0.53	0.39	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
COAD	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	6.78	8.15e-11	1e-07	0.72	0.39	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
COAD	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	6.78	8.15e-11	1.01e-07	0.52	0.39	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
COAD	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.78	8.18e-11	1.01e-07	0.5	0.39	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
COAD	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	6.78	8.31e-11	1.02e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
COAD	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	6.78	8.34e-11	1.03e-07	0.41	0.39	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
COAD	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-6.78	8.38e-11	1.03e-07	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
COAD	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-6.78	8.38e-11	1.03e-07	-0.42	-0.39	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
COAD	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	6.78	8.4e-11	1.03e-07	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
COAD	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-6.78	8.43e-11	1.04e-07	-0.41	-0.39	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
COAD	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-6.77	8.48e-11	1.04e-07	-0.49	-0.39	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-6.77	8.48e-11	1.04e-07	-0.49	-0.39	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-6.77	8.48e-11	1.04e-07	-0.49	-0.39	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
COAD	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	6.77	8.58e-11	1.06e-07	0.3	0.39	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
COAD	cis	rs7078219	0.524	rs1548963	ENSG00000228778.1	RP11-129J12.1	-6.77	8.59e-11	1.06e-07	-0.43	-0.39	Dental caries;	chr10:99529946	chr10:99527081~99528261:+
COAD	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109380457	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109380990	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109382524	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109384228	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109385087	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109387685	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109388256	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	6.77	8.6e-11	1.06e-07	0.51	0.39	Height;	chr6:109395761	chr6:109382795~109383666:+
COAD	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-6.77	8.67e-11	1.06e-07	-0.5	-0.39	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
COAD	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-6.77	8.71e-11	1.07e-07	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
COAD	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	6.77	8.77e-11	1.08e-07	0.51	0.39	Height;	chr6:109449796	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	6.77	8.77e-11	1.08e-07	0.46	0.39	Height;	chr6:109361200	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	6.77	8.77e-11	1.08e-07	0.46	0.39	Height;	chr6:109367335	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	6.77	8.82e-11	1.08e-07	0.44	0.39	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	6.77	8.87e-11	1.09e-07	0.44	0.39	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
COAD	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	6.77	8.88e-11	1.09e-07	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
COAD	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	6.77	8.88e-11	1.09e-07	0.41	0.39	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
COAD	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-6.77	8.9e-11	1.09e-07	-0.49	-0.39	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
COAD	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.77	8.93e-11	1.09e-07	0.5	0.39	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
COAD	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	6.77	8.93e-11	1.09e-07	0.46	0.39	Height;	chr6:109465777	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	6.77	8.93e-11	1.09e-07	0.47	0.39	Height;	chr6:109740895	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	6.77	8.93e-11	1.09e-07	0.52	0.39	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	6.77	8.93e-11	1.09e-07	0.52	0.39	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	6.77	8.94e-11	1.09e-07	0.52	0.39	Height;	chr6:109480428	chr6:109382795~109383666:+
COAD	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-6.77	8.94e-11	1.09e-07	-0.51	-0.39	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-6.77	8.94e-11	1.09e-07	-0.51	-0.39	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
COAD	cis	rs1930961	1	rs6004667	ENSG00000271138.1	IGLVIVOR22-1	6.76	8.97e-11	1.1e-07	0.56	0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25437306~25437823:-
COAD	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-6.76	8.99e-11	1.1e-07	-0.51	-0.39	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
COAD	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	6.76	9.02e-11	1.1e-07	0.46	0.39	Height;	chr6:109427644	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	6.76	9.02e-11	1.1e-07	0.46	0.39	Height;	chr6:109430292	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	6.76	9.04e-11	1.11e-07	0.46	0.39	Height;	chr6:109462738	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	6.76	9.04e-11	1.11e-07	0.46	0.39	Height;	chr6:109464011	chr6:109382795~109383666:+
COAD	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	6.76	9.09e-11	1.11e-07	0.5	0.39	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	6.76	9.09e-11	1.11e-07	0.5	0.39	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	6.76	9.09e-11	1.11e-07	0.5	0.39	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
COAD	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	6.76	9.09e-11	1.11e-07	0.51	0.39	Height;	chr6:109452743	chr6:109382795~109383666:+
COAD	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6.76	9.18e-11	1.12e-07	-0.43	-0.39	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	6.76	9.18e-11	1.12e-07	0.46	0.39	Height;	chr6:109424305	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	6.76	9.18e-11	1.12e-07	0.46	0.39	Height;	chr6:109425054	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	6.76	9.18e-11	1.12e-07	0.46	0.39	Height;	chr6:109426518	chr6:109382795~109383666:+
COAD	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-6.76	9.26e-11	1.13e-07	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.76	9.26e-11	1.13e-07	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
COAD	cis	rs453301	0.571	rs2929456	ENSG00000253981.4	ALG1L13P	-6.76	9.29e-11	1.13e-07	-0.45	-0.39	Joint mobility (Beighton score);	chr8:9225906	chr8:8236003~8244667:-
COAD	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	6.76	9.3e-11	1.14e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	6.76	9.3e-11	1.14e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
COAD	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-6.76	9.32e-11	1.14e-07	-0.55	-0.39	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
COAD	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-6.76	9.34e-11	1.14e-07	-0.47	-0.39	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
COAD	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-6.76	9.35e-11	1.14e-07	-0.7	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
COAD	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-6.76	9.36e-11	1.14e-07	-0.5	-0.39	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
COAD	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-6.76	9.38e-11	1.14e-07	-0.48	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
COAD	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	6.76	9.38e-11	1.14e-07	0.49	0.39	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
COAD	cis	rs7078219	0.965	rs11190141	ENSG00000228778.1	RP11-129J12.1	-6.76	9.41e-11	1.15e-07	-0.42	-0.39	Dental caries;	chr10:99532633	chr10:99527081~99528261:+
COAD	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	6.76	9.46e-11	1.15e-07	0.47	0.39	Height;	chr6:109405536	chr6:109382795~109383666:+
COAD	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	6.75	9.61e-11	1.17e-07	0.43	0.39	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
COAD	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-6.75	9.62e-11	1.17e-07	-0.46	-0.39	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
COAD	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-6.75	9.69e-11	1.18e-07	-0.59	-0.39	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
COAD	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	6.75	9.69e-11	1.18e-07	0.34	0.39	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
COAD	cis	rs7078219	0.505	rs1548964	ENSG00000228778.1	RP11-129J12.1	6.75	9.76e-11	1.19e-07	0.42	0.39	Dental caries;	chr10:99529896	chr10:99527081~99528261:+
COAD	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-6.75	9.92e-11	1.21e-07	-0.47	-0.39	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
COAD	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	6.75	9.94e-11	1.21e-07	0.47	0.39	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
COAD	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	6.75	9.95e-11	1.21e-07	0.48	0.39	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
COAD	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	6.75	9.95e-11	1.21e-07	0.48	0.39	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
COAD	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	6.75	9.96e-11	1.21e-07	0.53	0.39	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
COAD	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-6.75	9.97e-11	1.21e-07	-0.44	-0.39	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
COAD	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.75	1e-10	1.22e-07	0.4	0.39	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
COAD	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	6.74	1.01e-10	1.23e-07	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
COAD	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	6.74	1.02e-10	1.24e-07	0.57	0.39	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
COAD	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-6.74	1.02e-10	1.24e-07	-0.47	-0.39	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	6.74	1.03e-10	1.25e-07	0.51	0.39	Height;	chr6:109428824	chr6:109382795~109383666:+
COAD	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	6.74	1.03e-10	1.25e-07	0.59	0.39	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
COAD	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	6.74	1.03e-10	1.25e-07	0.39	0.39	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
COAD	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	6.74	1.03e-10	1.26e-07	0.47	0.39	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-6.74	1.03e-10	1.26e-07	-0.48	-0.39	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
COAD	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-6.74	1.04e-10	1.26e-07	-0.67	-0.39	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
COAD	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	6.74	1.04e-10	1.27e-07	0.47	0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
COAD	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	6.74	1.04e-10	1.27e-07	0.5	0.39	Height;	chr6:109407148	chr6:109382795~109383666:+
COAD	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-6.74	1.05e-10	1.27e-07	-0.42	-0.39	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
COAD	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	6.74	1.06e-10	1.28e-07	0.49	0.39	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	6.74	1.06e-10	1.28e-07	0.49	0.39	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
COAD	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	6.74	1.06e-10	1.28e-07	0.49	0.39	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
COAD	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	6.73	1.07e-10	1.3e-07	0.51	0.39	Height;	chr6:109446728	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.73	1.07e-10	1.3e-07	-0.57	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
COAD	cis	rs6584283	0.875	rs1548962	ENSG00000228778.1	RP11-129J12.1	6.73	1.07e-10	1.3e-07	0.42	0.39	Ulcerative colitis;	chr10:99529978	chr10:99527081~99528261:+
COAD	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	6.73	1.07e-10	1.3e-07	0.59	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
COAD	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	6.73	1.07e-10	1.3e-07	0.48	0.39	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
COAD	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-6.73	1.08e-10	1.3e-07	-0.41	-0.39	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
COAD	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	6.73	1.08e-10	1.31e-07	0.45	0.39	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
COAD	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	6.73	1.08e-10	1.31e-07	0.41	0.39	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
COAD	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-6.73	1.08e-10	1.31e-07	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
COAD	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	6.73	1.09e-10	1.31e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	6.73	1.09e-10	1.31e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	6.73	1.09e-10	1.31e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	6.73	1.09e-10	1.31e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
COAD	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	6.73	1.09e-10	1.32e-07	0.5	0.39	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
COAD	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	6.73	1.09e-10	1.32e-07	0.56	0.39	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
COAD	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-6.73	1.09e-10	1.32e-07	-0.49	-0.39	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-6.73	1.09e-10	1.32e-07	-0.49	-0.39	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
COAD	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	6.73	1.1e-10	1.33e-07	0.47	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
COAD	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-6.73	1.1e-10	1.33e-07	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-6.73	1.1e-10	1.33e-07	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-6.73	1.1e-10	1.33e-07	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
COAD	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.73	1.1e-10	1.33e-07	-0.63	-0.39	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
COAD	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	6.73	1.1e-10	1.33e-07	0.46	0.39	Height;	chr6:109390116	chr6:109382795~109383666:+
COAD	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-6.73	1.11e-10	1.33e-07	-0.58	-0.39	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
COAD	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.73	1.11e-10	1.34e-07	0.57	0.39	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
COAD	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	6.73	1.11e-10	1.34e-07	0.43	0.39	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
COAD	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	6.73	1.11e-10	1.34e-07	0.45	0.39	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
COAD	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-6.73	1.11e-10	1.34e-07	-0.41	-0.39	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
COAD	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.73	1.11e-10	1.34e-07	0.45	0.39	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
COAD	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.73	1.12e-10	1.35e-07	0.5	0.39	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
COAD	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-6.73	1.12e-10	1.35e-07	-0.33	-0.39	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
COAD	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-6.73	1.12e-10	1.35e-07	-0.49	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
COAD	cis	rs860818	1	rs10634	ENSG00000226816.2	AC005082.12	-6.73	1.13e-10	1.36e-07	-0.76	-0.39	Initial pursuit acceleration;	chr7:23200977	chr7:23206013~23208045:+
COAD	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.73	1.13e-10	1.36e-07	-0.57	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
COAD	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-6.72	1.13e-10	1.37e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
COAD	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	6.72	1.14e-10	1.38e-07	0.45	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
COAD	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.72	1.14e-10	1.38e-07	0.41	0.39	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.72	1.14e-10	1.38e-07	0.41	0.39	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.72	1.14e-10	1.38e-07	0.41	0.39	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
COAD	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-6.72	1.14e-10	1.38e-07	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
COAD	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	6.72	1.15e-10	1.38e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	6.72	1.15e-10	1.38e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	6.72	1.15e-10	1.38e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
COAD	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-6.72	1.15e-10	1.39e-07	-0.47	-0.39	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
COAD	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	6.72	1.15e-10	1.39e-07	0.47	0.39	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
COAD	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	6.72	1.15e-10	1.39e-07	0.51	0.39	Height;	chr6:109352730	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	6.72	1.15e-10	1.39e-07	0.51	0.39	Height;	chr6:109353355	chr6:109382795~109383666:+
COAD	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	6.72	1.16e-10	1.39e-07	0.5	0.39	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
COAD	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	6.72	1.16e-10	1.39e-07	0.53	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
COAD	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-6.72	1.16e-10	1.39e-07	-0.45	-0.39	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
COAD	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-6.72	1.16e-10	1.39e-07	-0.68	-0.39	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
COAD	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-6.72	1.16e-10	1.39e-07	-0.57	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
COAD	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	6.72	1.16e-10	1.4e-07	0.49	0.39	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
COAD	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-6.72	1.16e-10	1.4e-07	-0.48	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
COAD	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	6.72	1.17e-10	1.41e-07	0.51	0.39	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
COAD	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-6.72	1.19e-10	1.42e-07	-0.45	-0.39	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
COAD	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	6.72	1.19e-10	1.42e-07	0.45	0.39	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
COAD	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-6.72	1.19e-10	1.43e-07	-0.62	-0.39	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
COAD	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-6.72	1.2e-10	1.44e-07	-0.45	-0.39	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
COAD	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	6.71	1.2e-10	1.44e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
COAD	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-6.71	1.2e-10	1.44e-07	-0.47	-0.39	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
COAD	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-6.71	1.21e-10	1.45e-07	-0.54	-0.39	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
COAD	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	6.71	1.22e-10	1.46e-07	0.44	0.39	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	6.71	1.22e-10	1.47e-07	0.41	0.39	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
COAD	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	6.71	1.22e-10	1.47e-07	0.41	0.39	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	6.71	1.23e-10	1.47e-07	0.51	0.39	Height;	chr6:109465229	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	6.71	1.23e-10	1.47e-07	0.51	0.39	Height;	chr6:109423238	chr6:109382795~109383666:+
COAD	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.71	1.23e-10	1.47e-07	-0.65	-0.39	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
COAD	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	6.71	1.23e-10	1.47e-07	0.4	0.39	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
COAD	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	6.71	1.24e-10	1.48e-07	0.56	0.39	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
COAD	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	6.71	1.24e-10	1.48e-07	0.4	0.39	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	6.71	1.24e-10	1.48e-07	0.51	0.39	Height;	chr6:109352852	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	6.71	1.24e-10	1.48e-07	0.45	0.39	Height;	chr6:109470427	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	6.71	1.24e-10	1.48e-07	0.45	0.39	Height;	chr6:109470900	chr6:109382795~109383666:+
COAD	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	6.71	1.24e-10	1.49e-07	0.46	0.39	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
COAD	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	6.71	1.25e-10	1.49e-07	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
COAD	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-6.71	1.25e-10	1.49e-07	-0.6	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
COAD	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	6.71	1.25e-10	1.49e-07	0.45	0.39	Height;	chr6:109360263	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-6.71	1.25e-10	1.5e-07	-0.57	-0.39	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
COAD	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.71	1.25e-10	1.5e-07	0.44	0.39	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-6.71	1.25e-10	1.5e-07	-0.43	-0.39	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
COAD	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	6.7	1.27e-10	1.52e-07	0.42	0.39	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
COAD	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	6.7	1.28e-10	1.52e-07	0.41	0.39	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
COAD	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	6.7	1.28e-10	1.52e-07	0.76	0.39	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
COAD	cis	rs7078219	0.897	rs10883360	ENSG00000257582.4	LINC01475	-6.7	1.28e-10	1.53e-07	-0.42	-0.39	Dental caries;	chr10:99521401	chr10:99526350~99531177:-
COAD	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-6.7	1.28e-10	1.53e-07	-0.47	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
COAD	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	6.7	1.29e-10	1.53e-07	0.4	0.39	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-6.7	1.29e-10	1.54e-07	-0.4	-0.39	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
COAD	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	6.7	1.29e-10	1.54e-07	0.44	0.39	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
COAD	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	6.7	1.29e-10	1.54e-07	0.51	0.39	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	6.7	1.29e-10	1.54e-07	0.51	0.39	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
COAD	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	6.7	1.29e-10	1.54e-07	0.41	0.39	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
COAD	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-6.7	1.3e-10	1.54e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
COAD	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-6.7	1.3e-10	1.54e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
COAD	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-6.7	1.3e-10	1.54e-07	-0.39	-0.39	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
COAD	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	6.7	1.3e-10	1.55e-07	0.4	0.39	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	6.7	1.3e-10	1.55e-07	0.4	0.39	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
COAD	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-6.7	1.3e-10	1.55e-07	-0.44	-0.39	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	6.7	1.3e-10	1.55e-07	0.45	0.39	Height;	chr6:109368228	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	6.7	1.3e-10	1.55e-07	0.45	0.39	Height;	chr6:109370741	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	6.7	1.3e-10	1.55e-07	0.45	0.39	Height;	chr6:109371524	chr6:109382795~109383666:+
COAD	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-6.7	1.3e-10	1.55e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-6.7	1.3e-10	1.55e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
COAD	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-6.7	1.31e-10	1.55e-07	-0.37	-0.39	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-6.7	1.31e-10	1.55e-07	-0.37	-0.39	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-6.7	1.31e-10	1.55e-07	-0.37	-0.39	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
COAD	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	6.7	1.31e-10	1.56e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	6.7	1.31e-10	1.56e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	6.7	1.31e-10	1.56e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
COAD	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.7	1.31e-10	1.56e-07	-0.45	-0.39	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
COAD	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-6.7	1.32e-10	1.57e-07	-0.41	-0.39	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
COAD	cis	rs858267	1	rs858307	ENSG00000226816.2	AC005082.12	6.7	1.32e-10	1.57e-07	0.82	0.39	Blood protein levels;	chr7:23168805	chr7:23206013~23208045:+
COAD	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	6.7	1.32e-10	1.57e-07	0.51	0.39	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	6.7	1.32e-10	1.57e-07	0.51	0.39	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	6.7	1.32e-10	1.57e-07	0.51	0.39	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
COAD	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-6.7	1.32e-10	1.57e-07	-0.42	-0.39	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
COAD	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.7	1.33e-10	1.58e-07	-0.33	-0.39	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
COAD	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	6.7	1.34e-10	1.59e-07	0.44	0.39	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	6.7	1.34e-10	1.59e-07	0.44	0.39	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	6.7	1.34e-10	1.59e-07	0.44	0.39	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
COAD	cis	rs944002	1	rs62006947	ENSG00000259444.1	RP11-736N17.8	6.7	1.34e-10	1.6e-07	0.54	0.39	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099033	chr14:103094723~103098885:+
COAD	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-6.69	1.36e-10	1.61e-07	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
COAD	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	6.69	1.36e-10	1.61e-07	0.45	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
COAD	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-6.69	1.36e-10	1.61e-07	-0.45	-0.39	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
COAD	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	6.69	1.37e-10	1.62e-07	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	6.69	1.37e-10	1.62e-07	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
COAD	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-6.69	1.37e-10	1.62e-07	-0.51	-0.39	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
COAD	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	6.69	1.37e-10	1.63e-07	0.41	0.39	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
COAD	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	6.69	1.38e-10	1.63e-07	0.28	0.39	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
COAD	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-6.69	1.38e-10	1.64e-07	-0.45	-0.39	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
COAD	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	6.69	1.39e-10	1.64e-07	0.51	0.39	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
COAD	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-6.69	1.39e-10	1.65e-07	-0.39	-0.39	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
COAD	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	6.69	1.4e-10	1.66e-07	0.31	0.39	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
COAD	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	6.69	1.4e-10	1.66e-07	0.39	0.39	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
COAD	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-6.69	1.4e-10	1.66e-07	-0.51	-0.39	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
COAD	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-6.69	1.4e-10	1.66e-07	-0.46	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
COAD	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	6.69	1.4e-10	1.66e-07	0.56	0.39	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
COAD	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-6.69	1.41e-10	1.66e-07	-0.45	-0.39	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
COAD	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	6.69	1.41e-10	1.67e-07	0.51	0.39	Height;	chr6:109347085	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	6.69	1.41e-10	1.67e-07	0.51	0.39	Height;	chr6:109347277	chr6:109382795~109383666:+
COAD	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-6.69	1.42e-10	1.68e-07	-0.63	-0.38	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
COAD	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-6.69	1.42e-10	1.68e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
COAD	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	6.69	1.43e-10	1.69e-07	0.7	0.38	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
COAD	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-6.69	1.43e-10	1.69e-07	-0.39	-0.38	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
COAD	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.69	1.43e-10	1.69e-07	0.4	0.38	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
COAD	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-6.68	1.43e-10	1.69e-07	-0.37	-0.38	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
COAD	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-6.68	1.44e-10	1.7e-07	-0.44	-0.38	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
COAD	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-6.68	1.44e-10	1.7e-07	-0.45	-0.38	Height;	chr6:109432968	chr6:109382795~109383666:+
COAD	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-6.68	1.44e-10	1.71e-07	-0.48	-0.38	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
COAD	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-6.68	1.44e-10	1.71e-07	-0.4	-0.38	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
COAD	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	6.68	1.44e-10	1.71e-07	0.5	0.38	Height;	chr6:109640682	chr6:109382795~109383666:+
COAD	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	6.68	1.45e-10	1.71e-07	0.51	0.38	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
COAD	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	6.68	1.45e-10	1.71e-07	0.44	0.38	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
COAD	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-6.68	1.45e-10	1.71e-07	-0.55	-0.38	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	6.68	1.46e-10	1.72e-07	0.52	0.38	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-6.68	1.46e-10	1.72e-07	-0.44	-0.38	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
COAD	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	6.68	1.46e-10	1.72e-07	0.3	0.38	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	6.68	1.46e-10	1.72e-07	0.3	0.38	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
COAD	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-6.68	1.46e-10	1.72e-07	-0.41	-0.38	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
COAD	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-6.68	1.46e-10	1.72e-07	-0.51	-0.38	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
COAD	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-6.68	1.46e-10	1.72e-07	-0.51	-0.38	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
COAD	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	6.68	1.47e-10	1.73e-07	0.44	0.38	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
COAD	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	6.68	1.47e-10	1.74e-07	0.47	0.38	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
COAD	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-6.68	1.49e-10	1.75e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-6.68	1.49e-10	1.75e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-6.68	1.49e-10	1.75e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-6.68	1.49e-10	1.75e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
COAD	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-6.68	1.49e-10	1.76e-07	-0.49	-0.38	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
COAD	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-6.68	1.49e-10	1.76e-07	-0.51	-0.38	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
COAD	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	6.68	1.5e-10	1.76e-07	0.45	0.38	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
COAD	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	6.68	1.5e-10	1.77e-07	0.49	0.38	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
COAD	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	6.68	1.51e-10	1.77e-07	0.41	0.38	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
COAD	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-6.68	1.51e-10	1.78e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-6.68	1.51e-10	1.78e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
COAD	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-6.67	1.52e-10	1.78e-07	-0.57	-0.38	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
COAD	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	6.67	1.52e-10	1.78e-07	0.42	0.38	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
COAD	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	6.67	1.52e-10	1.79e-07	0.51	0.38	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	6.67	1.52e-10	1.79e-07	0.51	0.38	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
COAD	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	6.67	1.53e-10	1.8e-07	0.49	0.38	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
COAD	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	6.67	1.54e-10	1.8e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
COAD	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-6.67	1.54e-10	1.81e-07	-0.51	-0.38	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-6.67	1.54e-10	1.81e-07	-0.51	-0.38	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
COAD	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	6.67	1.55e-10	1.82e-07	0.54	0.38	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
COAD	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	6.67	1.55e-10	1.82e-07	0.4	0.38	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
COAD	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-6.67	1.55e-10	1.82e-07	-0.55	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-6.67	1.55e-10	1.82e-07	-0.55	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
COAD	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	6.67	1.57e-10	1.85e-07	0.48	0.38	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
COAD	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	6.67	1.58e-10	1.85e-07	0.44	0.38	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
COAD	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-6.67	1.58e-10	1.85e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
COAD	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	6.67	1.59e-10	1.87e-07	0.48	0.38	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
COAD	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	6.67	1.59e-10	1.87e-07	0.44	0.38	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
COAD	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	6.67	1.6e-10	1.87e-07	0.52	0.38	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	6.67	1.6e-10	1.87e-07	0.47	0.38	Height;	chr6:109706740	chr6:109382795~109383666:+
COAD	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	6.67	1.6e-10	1.87e-07	0.65	0.38	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
COAD	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	6.67	1.6e-10	1.88e-07	0.57	0.38	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
COAD	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	6.66	1.61e-10	1.88e-07	0.45	0.38	Height;	chr6:109383239	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	6.66	1.61e-10	1.88e-07	0.45	0.38	Height;	chr6:109383248	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.66	1.61e-10	1.88e-07	-0.55	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
COAD	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.66	1.61e-10	1.88e-07	0.45	0.38	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
COAD	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	6.66	1.61e-10	1.88e-07	0.37	0.38	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
COAD	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	6.66	1.62e-10	1.89e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	6.66	1.62e-10	1.89e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	6.66	1.62e-10	1.89e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
COAD	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.66	1.62e-10	1.89e-07	0.5	0.38	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
COAD	cis	rs754466	0.606	rs11002310	ENSG00000204049.1	RP11-126H7.4	6.66	1.62e-10	1.89e-07	0.49	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836272	chr10:77866875~77869610:+
COAD	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	6.66	1.62e-10	1.9e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	6.66	1.62e-10	1.9e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
COAD	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	6.66	1.62e-10	1.9e-07	0.44	0.38	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
COAD	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	6.66	1.63e-10	1.9e-07	0.4	0.38	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109382188	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109384807	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109390638	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109391534	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109393881	chr6:109382795~109383666:+
COAD	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	-6.66	1.63e-10	1.9e-07	-0.46	-0.38	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
COAD	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	6.66	1.63e-10	1.9e-07	0.45	0.38	Height;	chr6:109383848	chr6:109382795~109383666:+
COAD	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	6.66	1.63e-10	1.9e-07	0.78	0.38	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	6.66	1.63e-10	1.9e-07	0.51	0.38	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	6.66	1.63e-10	1.9e-07	0.51	0.38	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
COAD	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-6.66	1.63e-10	1.9e-07	-0.44	-0.38	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
COAD	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	6.66	1.63e-10	1.9e-07	0.46	0.38	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
COAD	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-6.66	1.64e-10	1.91e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-6.66	1.64e-10	1.91e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-6.66	1.64e-10	1.91e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
COAD	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-6.66	1.64e-10	1.91e-07	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
COAD	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.66	1.64e-10	1.91e-07	-0.41	-0.38	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	6.66	1.65e-10	1.92e-07	0.51	0.38	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
COAD	cis	rs453301	0.507	rs2929306	ENSG00000253981.4	ALG1L13P	-6.66	1.65e-10	1.93e-07	-0.44	-0.38	Joint mobility (Beighton score);	chr8:9227399	chr8:8236003~8244667:-
COAD	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-6.66	1.66e-10	1.93e-07	-0.41	-0.38	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
COAD	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	6.66	1.66e-10	1.94e-07	0.44	0.38	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	6.66	1.66e-10	1.94e-07	0.44	0.38	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
COAD	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-6.66	1.67e-10	1.94e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
COAD	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	6.66	1.67e-10	1.95e-07	0.45	0.38	Height;	chr6:109351795	chr6:109382795~109383666:+
COAD	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.66	1.67e-10	1.95e-07	0.47	0.38	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
COAD	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-6.66	1.67e-10	1.95e-07	-0.71	-0.38	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
COAD	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-6.66	1.68e-10	1.96e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
COAD	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	6.66	1.68e-10	1.96e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
COAD	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-6.66	1.68e-10	1.96e-07	-0.4	-0.38	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
COAD	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-6.66	1.68e-10	1.96e-07	-0.44	-0.38	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
COAD	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-6.66	1.69e-10	1.97e-07	-0.45	-0.38	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
COAD	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-6.66	1.69e-10	1.97e-07	-0.57	-0.38	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
COAD	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-6.66	1.7e-10	1.97e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-6.66	1.7e-10	1.97e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
COAD	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-6.65	1.7e-10	1.98e-07	-0.43	-0.38	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
COAD	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	6.65	1.72e-10	2e-07	0.45	0.38	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
COAD	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	6.65	1.72e-10	2e-07	0.49	0.38	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
COAD	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-6.65	1.72e-10	2e-07	-0.41	-0.38	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
COAD	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-6.65	1.73e-10	2.01e-07	-0.53	-0.38	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
COAD	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	6.65	1.73e-10	2.01e-07	0.46	0.38	Height;	chr6:109739615	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	6.65	1.73e-10	2.01e-07	0.4	0.38	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	6.65	1.74e-10	2.02e-07	0.46	0.38	Height;	chr6:109358227	chr6:109382795~109383666:+
COAD	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.65	1.75e-10	2.03e-07	-0.42	-0.38	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
COAD	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-6.65	1.75e-10	2.03e-07	-0.39	-0.38	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
COAD	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	6.65	1.76e-10	2.04e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
COAD	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-6.65	1.76e-10	2.04e-07	-0.45	-0.38	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
COAD	cis	rs6584283	0.656	rs7080361	ENSG00000257582.4	LINC01475	-6.65	1.76e-10	2.04e-07	-0.41	-0.38	Ulcerative colitis;	chr10:99518015	chr10:99526350~99531177:-
COAD	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-6.65	1.76e-10	2.04e-07	-0.37	-0.38	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
COAD	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	6.65	1.76e-10	2.04e-07	0.39	0.38	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
COAD	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	6.65	1.76e-10	2.04e-07	0.56	0.38	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
COAD	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-6.65	1.77e-10	2.05e-07	-0.36	-0.38	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
COAD	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-6.65	1.77e-10	2.05e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
COAD	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-6.65	1.77e-10	2.06e-07	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-6.65	1.78e-10	2.06e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	6.65	1.78e-10	2.06e-07	0.52	0.38	Height;	chr6:109618283	chr6:109382795~109383666:+
COAD	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-6.65	1.79e-10	2.08e-07	-0.5	-0.38	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
COAD	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-6.65	1.8e-10	2.08e-07	-0.66	-0.38	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
COAD	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-6.65	1.8e-10	2.08e-07	-0.57	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
COAD	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	6.64	1.81e-10	2.09e-07	0.41	0.38	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
COAD	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	6.64	1.81e-10	2.09e-07	0.51	0.38	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
COAD	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	6.64	1.83e-10	2.11e-07	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
COAD	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	6.64	1.83e-10	2.12e-07	0.47	0.38	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
COAD	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	6.64	1.84e-10	2.12e-07	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
COAD	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	6.64	1.86e-10	2.14e-07	0.28	0.38	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
COAD	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	6.64	1.86e-10	2.14e-07	0.51	0.38	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	6.64	1.86e-10	2.14e-07	0.51	0.38	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
COAD	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	6.64	1.86e-10	2.14e-07	0.44	0.38	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	6.64	1.86e-10	2.14e-07	0.44	0.38	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	6.64	1.86e-10	2.14e-07	0.44	0.38	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	6.64	1.86e-10	2.14e-07	0.44	0.38	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	6.64	1.86e-10	2.14e-07	0.44	0.38	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
COAD	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	6.64	1.88e-10	2.17e-07	0.45	0.38	Height;	chr6:109392096	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-6.64	1.89e-10	2.18e-07	-0.43	-0.38	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-6.64	1.89e-10	2.18e-07	-0.55	-0.38	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
COAD	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-6.64	1.89e-10	2.18e-07	-0.4	-0.38	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
COAD	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-6.64	1.9e-10	2.19e-07	-0.45	-0.38	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
COAD	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-6.64	1.9e-10	2.19e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
COAD	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	6.64	1.9e-10	2.19e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
COAD	cis	rs1930961	1	rs6004667	ENSG00000272942.1	CTA-246H3.12	6.64	1.9e-10	2.19e-07	0.55	0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25434324~25435070:-
COAD	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.64	1.91e-10	2.19e-07	-0.4	-0.38	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
COAD	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	6.63	1.92e-10	2.2e-07	0.44	0.38	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	6.63	1.92e-10	2.2e-07	0.44	0.38	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
COAD	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	6.63	1.92e-10	2.21e-07	0.44	0.38	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
COAD	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	6.63	1.92e-10	2.21e-07	0.53	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	6.63	1.92e-10	2.21e-07	0.53	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
COAD	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	6.63	1.92e-10	2.21e-07	0.68	0.38	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
COAD	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	6.63	1.93e-10	2.22e-07	0.5	0.38	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	6.63	1.93e-10	2.22e-07	0.5	0.38	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	6.63	1.93e-10	2.22e-07	0.5	0.38	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	6.63	1.93e-10	2.22e-07	0.5	0.38	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	6.63	1.93e-10	2.22e-07	0.5	0.38	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
COAD	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	6.63	1.94e-10	2.23e-07	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
COAD	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-6.63	1.94e-10	2.23e-07	-0.4	-0.38	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
COAD	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-6.63	1.95e-10	2.24e-07	-0.44	-0.38	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
COAD	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	6.63	1.95e-10	2.24e-07	0.5	0.38	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
COAD	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-6.63	1.96e-10	2.25e-07	-0.47	-0.38	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-6.63	1.96e-10	2.25e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
COAD	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	6.63	1.97e-10	2.26e-07	0.52	0.38	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	6.63	1.97e-10	2.26e-07	0.52	0.38	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
COAD	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	6.63	1.97e-10	2.26e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	6.63	1.97e-10	2.26e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	6.63	1.97e-10	2.26e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
COAD	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	6.63	1.97e-10	2.26e-07	0.45	0.38	Height;	chr6:109443332	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.63	1.97e-10	2.26e-07	-0.56	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
COAD	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	6.63	1.97e-10	2.26e-07	0.52	0.38	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
COAD	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-6.63	1.98e-10	2.27e-07	-0.46	-0.38	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
COAD	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	6.63	1.98e-10	2.27e-07	0.45	0.38	Height;	chr6:109440234	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.63	1.98e-10	2.27e-07	-0.54	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
COAD	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-6.63	1.99e-10	2.28e-07	-0.47	-0.38	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
COAD	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-6.63	1.99e-10	2.28e-07	-0.47	-0.38	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
COAD	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	6.63	1.99e-10	2.28e-07	1	0.38	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	6.63	1.99e-10	2.28e-07	1	0.38	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
COAD	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-6.63	1.99e-10	2.28e-07	-0.49	-0.38	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
COAD	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	6.63	1.99e-10	2.28e-07	0.43	0.38	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-6.63	2e-10	2.29e-07	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
COAD	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	6.63	2.01e-10	2.3e-07	0.39	0.38	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
COAD	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-6.63	2.01e-10	2.3e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
COAD	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	6.63	2.01e-10	2.3e-07	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
COAD	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	6.62	2.02e-10	2.32e-07	0.45	0.38	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
COAD	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	6.62	2.03e-10	2.32e-07	0.43	0.38	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
COAD	cis	rs453301	0.571	rs2929454	ENSG00000253981.4	ALG1L13P	-6.62	2.03e-10	2.32e-07	-0.44	-0.38	Joint mobility (Beighton score);	chr8:9226344	chr8:8236003~8244667:-
COAD	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	6.62	2.04e-10	2.33e-07	0.41	0.38	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
COAD	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	6.62	2.05e-10	2.35e-07	0.52	0.38	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	6.62	2.06e-10	2.36e-07	0.45	0.38	Height;	chr6:109476101	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	6.62	2.06e-10	2.36e-07	0.45	0.38	Height;	chr6:109477209	chr6:109382795~109383666:+
COAD	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
COAD	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	6.62	2.07e-10	2.36e-07	0.99	0.38	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
COAD	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-6.62	2.1e-10	2.39e-07	-0.4	-0.38	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	6.62	2.12e-10	2.41e-07	0.41	0.38	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
COAD	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-6.62	2.12e-10	2.41e-07	-0.48	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	6.62	2.12e-10	2.42e-07	0.42	0.38	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	6.62	2.13e-10	2.42e-07	0.67	0.38	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	6.62	2.13e-10	2.42e-07	0.67	0.38	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	6.62	2.13e-10	2.42e-07	0.67	0.38	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
COAD	cis	rs860818	1	rs858245	ENSG00000226816.2	AC005082.12	6.62	2.14e-10	2.43e-07	0.84	0.38	Initial pursuit acceleration;	chr7:23183108	chr7:23206013~23208045:+
COAD	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-6.62	2.14e-10	2.43e-07	-0.56	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
COAD	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-6.62	2.14e-10	2.43e-07	-0.46	-0.38	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
COAD	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	6.62	2.14e-10	2.44e-07	0.42	0.38	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
COAD	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-6.61	2.15e-10	2.45e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
COAD	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	6.61	2.16e-10	2.46e-07	0.51	0.38	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	6.61	2.16e-10	2.46e-07	0.51	0.38	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
COAD	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-6.61	2.16e-10	2.46e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
COAD	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	6.61	2.17e-10	2.46e-07	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	6.61	2.17e-10	2.46e-07	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	6.61	2.17e-10	2.46e-07	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
COAD	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	6.61	2.17e-10	2.47e-07	0.42	0.38	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	6.61	2.2e-10	2.49e-07	0.56	0.38	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
COAD	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	6.61	2.2e-10	2.5e-07	0.46	0.38	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
COAD	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-6.61	2.2e-10	2.5e-07	-0.41	-0.38	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-6.61	2.2e-10	2.5e-07	-0.41	-0.38	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
COAD	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	6.61	2.21e-10	2.5e-07	0.43	0.38	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
COAD	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-6.61	2.21e-10	2.51e-07	-0.75	-0.38	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
COAD	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	6.61	2.21e-10	2.51e-07	0.5	0.38	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
COAD	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-6.61	2.22e-10	2.52e-07	-0.5	-0.38	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	6.61	2.23e-10	2.53e-07	0.41	0.38	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
COAD	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	6.61	2.23e-10	2.53e-07	0.42	0.38	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
COAD	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	6.61	2.23e-10	2.53e-07	0.4	0.38	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
COAD	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	6.61	2.26e-10	2.56e-07	0.42	0.38	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
COAD	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	6.61	2.27e-10	2.57e-07	0.46	0.38	Height;	chr6:109447092	chr6:109382795~109383666:+
COAD	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	6.61	2.27e-10	2.57e-07	0.4	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
COAD	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-6.61	2.27e-10	2.57e-07	-0.44	-0.38	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
COAD	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	6.61	2.27e-10	2.57e-07	0.56	0.38	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
COAD	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	6.6	2.27e-10	2.57e-07	0.5	0.38	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
COAD	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	6.6	2.28e-10	2.58e-07	0.5	0.38	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	6.6	2.28e-10	2.58e-07	0.48	0.38	Height;	chr6:109332622	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.6	2.29e-10	2.59e-07	-0.54	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
COAD	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-6.6	2.29e-10	2.59e-07	-0.48	-0.38	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
COAD	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	6.6	2.3e-10	2.6e-07	0.39	0.38	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
COAD	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	6.6	2.31e-10	2.61e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	6.6	2.31e-10	2.61e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
COAD	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	6.6	2.31e-10	2.61e-07	0.5	0.38	Height;	chr6:109438349	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	6.6	2.31e-10	2.62e-07	0.42	0.38	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
COAD	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	6.6	2.31e-10	2.62e-07	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
COAD	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	6.6	2.33e-10	2.63e-07	0.45	0.38	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
COAD	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	6.6	2.33e-10	2.64e-07	0.99	0.38	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
COAD	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	6.6	2.33e-10	2.64e-07	0.99	0.38	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
COAD	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	6.6	2.34e-10	2.64e-07	0.44	0.38	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	6.6	2.34e-10	2.64e-07	0.44	0.38	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	6.6	2.34e-10	2.64e-07	0.44	0.38	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
COAD	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	6.6	2.35e-10	2.65e-07	0.49	0.38	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
COAD	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.6	2.35e-10	2.65e-07	-0.49	-0.38	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
COAD	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-6.6	2.35e-10	2.65e-07	-0.49	-0.38	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
COAD	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	6.6	2.36e-10	2.66e-07	0.51	0.38	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	6.6	2.36e-10	2.66e-07	0.51	0.38	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	6.6	2.37e-10	2.67e-07	0.51	0.38	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-6.6	2.37e-10	2.67e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
COAD	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-6.6	2.37e-10	2.68e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-6.6	2.37e-10	2.68e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-6.6	2.37e-10	2.68e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
COAD	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	6.6	2.37e-10	2.68e-07	0.39	0.38	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
COAD	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	6.6	2.37e-10	2.68e-07	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
COAD	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	6.6	2.38e-10	2.68e-07	0.5	0.38	Height;	chr6:109354040	chr6:109382795~109383666:+
COAD	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	6.6	2.38e-10	2.69e-07	0.48	0.38	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	6.6	2.38e-10	2.69e-07	0.48	0.38	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
COAD	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	6.6	2.39e-10	2.69e-07	0.6	0.38	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
COAD	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	6.6	2.39e-10	2.69e-07	0.46	0.38	Height;	chr6:109741670	chr6:109382795~109383666:+
COAD	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-6.6	2.39e-10	2.69e-07	-0.4	-0.38	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
COAD	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-6.6	2.4e-10	2.71e-07	-0.47	-0.38	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
COAD	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	6.59	2.41e-10	2.72e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
COAD	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	6.59	2.42e-10	2.72e-07	0.4	0.38	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
COAD	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	6.59	2.42e-10	2.72e-07	0.4	0.38	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
COAD	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	6.59	2.44e-10	2.74e-07	0.4	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
COAD	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-6.59	2.44e-10	2.74e-07	-0.44	-0.38	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
COAD	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.59	2.44e-10	2.74e-07	-0.46	-0.38	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
COAD	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	6.59	2.44e-10	2.75e-07	0.29	0.38	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
COAD	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	6.59	2.44e-10	2.75e-07	0.45	0.38	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
COAD	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	6.59	2.45e-10	2.75e-07	0.42	0.38	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	6.59	2.45e-10	2.75e-07	0.42	0.38	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
COAD	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-6.59	2.45e-10	2.75e-07	-0.48	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
COAD	cis	rs754466	0.706	rs7099526	ENSG00000204049.1	RP11-126H7.4	6.59	2.45e-10	2.75e-07	0.5	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77897947	chr10:77866875~77869610:+
COAD	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	6.59	2.45e-10	2.76e-07	0.65	0.38	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
COAD	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	6.59	2.46e-10	2.77e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
COAD	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-6.59	2.47e-10	2.78e-07	-0.5	-0.38	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
COAD	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-6.59	2.47e-10	2.78e-07	-0.36	-0.38	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
COAD	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.59	2.48e-10	2.78e-07	0.45	0.38	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.59	2.48e-10	2.78e-07	0.45	0.38	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.59	2.48e-10	2.78e-07	0.45	0.38	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.59	2.48e-10	2.78e-07	0.45	0.38	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
COAD	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-6.59	2.48e-10	2.79e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
COAD	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	6.59	2.49e-10	2.8e-07	0.48	0.38	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
COAD	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-6.59	2.5e-10	2.81e-07	-0.52	-0.38	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
COAD	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-6.59	2.5e-10	2.81e-07	-0.51	-0.38	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
COAD	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	6.59	2.51e-10	2.82e-07	0.41	0.38	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
COAD	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	6.59	2.51e-10	2.82e-07	0.42	0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
COAD	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	6.59	2.51e-10	2.82e-07	0.99	0.38	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
COAD	cis	rs1930961	1	rs6004673	ENSG00000272942.1	CTA-246H3.12	-6.59	2.52e-10	2.83e-07	-0.53	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25434324~25435070:-
COAD	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	6.58	2.55e-10	2.86e-07	0.49	0.38	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.58	2.55e-10	2.86e-07	0.42	0.38	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
COAD	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	6.58	2.58e-10	2.89e-07	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
COAD	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.58	2.58e-10	2.89e-07	-0.45	-0.38	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
COAD	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	6.58	2.58e-10	2.89e-07	0.44	0.38	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
COAD	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-6.58	2.59e-10	2.9e-07	-0.37	-0.38	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
COAD	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	6.58	2.6e-10	2.91e-07	0.41	0.38	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	6.58	2.61e-10	2.92e-07	0.5	0.38	Height;	chr6:109441033	chr6:109382795~109383666:+
COAD	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-6.58	2.61e-10	2.92e-07	-0.46	-0.38	Migraine;	chr4:56879297	chr4:56960927~56961373:-
COAD	cis	rs6584283	1	rs6584283	ENSG00000228778.1	RP11-129J12.1	-6.58	2.62e-10	2.93e-07	-0.43	-0.38	Ulcerative colitis;	chr10:99530544	chr10:99527081~99528261:+
COAD	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	6.58	2.62e-10	2.93e-07	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
COAD	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.58	2.63e-10	2.94e-07	-0.45	-0.38	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.58	2.63e-10	2.94e-07	-0.45	-0.38	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
COAD	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	6.58	2.63e-10	2.94e-07	0.5	0.38	Height;	chr6:109469907	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	6.58	2.63e-10	2.95e-07	0.51	0.38	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	6.58	2.65e-10	2.96e-07	0.52	0.38	Height;	chr6:109645257	chr6:109382795~109383666:+
COAD	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-6.58	2.65e-10	2.96e-07	-0.4	-0.38	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
COAD	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	6.58	2.67e-10	2.99e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
COAD	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.58	2.67e-10	2.99e-07	-0.55	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
COAD	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.58	2.68e-10	2.99e-07	-0.49	-0.38	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
COAD	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-6.58	2.68e-10	2.99e-07	-0.45	-0.38	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-6.58	2.68e-10	2.99e-07	-0.45	-0.38	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-6.58	2.68e-10	2.99e-07	-0.45	-0.38	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-6.58	2.68e-10	2.99e-07	-0.45	-0.38	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-6.58	2.68e-10	2.99e-07	-0.45	-0.38	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
COAD	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	6.58	2.69e-10	2.99e-07	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
COAD	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
COAD	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	2.99e-07	0.51	0.38	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	6.58	2.69e-10	3e-07	0.52	0.38	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
COAD	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	6.57	2.7e-10	3.01e-07	0.44	0.38	Height;	chr6:109375548	chr6:109382795~109383666:+
COAD	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	6.57	2.7e-10	3.01e-07	0.4	0.38	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	6.57	2.7e-10	3.01e-07	0.4	0.38	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
COAD	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.57	2.7e-10	3.01e-07	0.54	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
COAD	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-6.57	2.71e-10	3.02e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
COAD	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	6.57	2.72e-10	3.03e-07	0.49	0.38	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	6.57	2.72e-10	3.03e-07	0.49	0.38	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
COAD	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	6.57	2.74e-10	3.04e-07	0.4	0.38	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
COAD	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.57	2.76e-10	3.07e-07	-0.43	-0.38	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
COAD	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	6.57	2.77e-10	3.08e-07	0.43	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
COAD	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-6.57	2.78e-10	3.09e-07	-0.44	-0.38	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
COAD	cis	rs58873874	0.579	rs10040318	ENSG00000248544.2	CTB-47B11.3	6.57	2.79e-10	3.11e-07	0.67	0.38	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157375741~157384950:-
COAD	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-6.57	2.8e-10	3.11e-07	-0.4	-0.38	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
COAD	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	6.57	2.8e-10	3.11e-07	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
COAD	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-6.57	2.8e-10	3.11e-07	-0.57	-0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
COAD	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	6.57	2.81e-10	3.12e-07	0.51	0.38	Height;	chr6:109694120	chr6:109382795~109383666:+
COAD	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-6.57	2.81e-10	3.12e-07	-0.39	-0.38	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
COAD	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	6.57	2.81e-10	3.12e-07	0.4	0.38	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
COAD	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	6.57	2.81e-10	3.12e-07	0.4	0.38	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
COAD	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.57	2.81e-10	3.12e-07	-0.65	-0.38	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
COAD	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	6.57	2.82e-10	3.13e-07	0.43	0.38	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	6.57	2.82e-10	3.13e-07	0.43	0.38	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
COAD	cis	rs2439831	0.85	rs7181039	ENSG00000275601.1	AC011330.13	-6.57	2.83e-10	3.14e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43886914	chr15:43642389~43643023:-
COAD	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-6.57	2.84e-10	3.15e-07	-0.38	-0.38	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
COAD	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	6.57	2.85e-10	3.16e-07	0.49	0.38	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
COAD	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	6.57	2.85e-10	3.16e-07	0.47	0.38	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
COAD	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	6.57	2.85e-10	3.16e-07	0.43	0.38	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	6.57	2.85e-10	3.16e-07	0.43	0.38	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	6.57	2.85e-10	3.16e-07	0.44	0.38	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
COAD	cis	rs5769707	0.605	rs2071900	ENSG00000188511.11	C22orf34	6.57	2.85e-10	3.16e-07	0.43	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49658527	chr22:49414524~49657542:-
COAD	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	6.57	2.86e-10	3.17e-07	0.6	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
COAD	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	6.56	2.86e-10	3.17e-07	0.44	0.38	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
COAD	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	6.56	2.87e-10	3.18e-07	0.47	0.38	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
COAD	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-6.56	2.87e-10	3.18e-07	-0.4	-0.38	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
COAD	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-6.56	2.87e-10	3.18e-07	-0.4	-0.38	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	6.56	2.88e-10	3.19e-07	0.39	0.38	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
COAD	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-6.56	2.9e-10	3.21e-07	-0.44	-0.38	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	6.56	2.91e-10	3.22e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
COAD	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	6.56	2.91e-10	3.23e-07	0.49	0.38	Height;	chr6:109656105	chr6:109382795~109383666:+
COAD	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	6.56	2.91e-10	3.23e-07	0.99	0.38	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	6.56	2.91e-10	3.23e-07	0.99	0.38	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
COAD	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	6.56	2.93e-10	3.24e-07	0.5	0.38	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
COAD	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	6.56	2.93e-10	3.25e-07	0.49	0.38	Height;	chr6:109340338	chr6:109382795~109383666:+
COAD	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	6.56	2.94e-10	3.25e-07	0.57	0.38	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
COAD	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-6.56	2.94e-10	3.25e-07	-0.39	-0.38	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
COAD	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	6.56	2.95e-10	3.26e-07	0.49	0.38	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	6.56	2.95e-10	3.26e-07	0.49	0.38	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
COAD	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	6.56	2.95e-10	3.26e-07	0.51	0.38	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-6.56	2.97e-10	3.28e-07	-0.59	-0.38	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
COAD	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	6.56	2.97e-10	3.28e-07	0.45	0.38	Height;	chr6:109354092	chr6:109382795~109383666:+
COAD	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	6.56	2.97e-10	3.29e-07	0.35	0.38	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
COAD	cis	rs453301	0.571	rs2929305	ENSG00000253981.4	ALG1L13P	-6.56	2.99e-10	3.3e-07	-0.43	-0.38	Joint mobility (Beighton score);	chr8:9227707	chr8:8236003~8244667:-
COAD	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	6.56	2.99e-10	3.31e-07	0.38	0.38	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
COAD	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.56	3.01e-10	3.33e-07	-0.48	-0.38	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
COAD	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.56	3.02e-10	3.33e-07	-0.49	-0.38	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
COAD	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.56	3.03e-10	3.34e-07	0.45	0.38	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
COAD	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-6.55	3.04e-10	3.35e-07	-0.79	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
COAD	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	6.55	3.07e-10	3.39e-07	0.51	0.38	Height;	chr6:109582583	chr6:109382795~109383666:+
COAD	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	6.55	3.07e-10	3.39e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
COAD	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-6.55	3.08e-10	3.4e-07	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
COAD	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	6.55	3.09e-10	3.4e-07	0.4	0.38	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	6.55	3.09e-10	3.4e-07	0.4	0.38	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	6.55	3.09e-10	3.4e-07	0.4	0.38	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	6.55	3.09e-10	3.4e-07	0.4	0.38	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	6.55	3.09e-10	3.4e-07	0.4	0.38	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-6.55	3.09e-10	3.41e-07	-0.51	-0.38	Height;	chr6:109485060	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-6.55	3.1e-10	3.42e-07	-0.4	-0.38	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
COAD	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	6.55	3.13e-10	3.45e-07	0.52	0.38	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	6.55	3.13e-10	3.46e-07	0.52	0.38	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
COAD	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-6.55	3.14e-10	3.46e-07	-0.44	-0.38	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
COAD	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.55	3.15e-10	3.47e-07	-0.55	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
COAD	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-6.55	3.15e-10	3.48e-07	-0.47	-0.38	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
COAD	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-6.55	3.15e-10	3.48e-07	-0.47	-0.38	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
COAD	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.55	3.16e-10	3.48e-07	0.45	0.38	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.55	3.16e-10	3.48e-07	0.45	0.38	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.55	3.16e-10	3.48e-07	0.45	0.38	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
COAD	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	6.55	3.16e-10	3.48e-07	0.44	0.38	Height;	chr6:109397362	chr6:109382795~109383666:+
COAD	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	6.55	3.17e-10	3.49e-07	0.43	0.38	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	6.55	3.17e-10	3.49e-07	0.4	0.38	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
COAD	cis	rs34375054	0.672	rs2291248	ENSG00000279233.1	RP11-158L12.4	6.55	3.17e-10	3.5e-07	0.37	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125134762	chr12:125138245~125141711:+
COAD	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	6.55	3.19e-10	3.52e-07	0.5	0.38	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	6.55	3.21e-10	3.53e-07	0.49	0.38	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	6.55	3.21e-10	3.53e-07	0.49	0.38	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	6.55	3.21e-10	3.53e-07	0.49	0.38	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
COAD	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	6.55	3.21e-10	3.53e-07	0.43	0.38	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
COAD	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	6.54	3.21e-10	3.53e-07	0.47	0.38	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	6.54	3.21e-10	3.53e-07	0.47	0.38	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	6.54	3.21e-10	3.53e-07	0.47	0.38	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
COAD	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	6.54	3.22e-10	3.54e-07	0.42	0.38	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
COAD	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	6.54	3.22e-10	3.54e-07	0.4	0.38	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
COAD	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-6.54	3.23e-10	3.55e-07	-0.82	-0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
COAD	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-6.54	3.23e-10	3.55e-07	-0.44	-0.38	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
COAD	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	6.54	3.24e-10	3.56e-07	0.47	0.38	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
COAD	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	6.54	3.24e-10	3.56e-07	0.47	0.38	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
COAD	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-6.54	3.25e-10	3.57e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
COAD	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-6.54	3.25e-10	3.57e-07	-0.6	-0.38	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
COAD	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-6.54	3.25e-10	3.57e-07	-0.6	-0.38	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
COAD	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-6.54	3.25e-10	3.57e-07	-0.38	-0.38	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
COAD	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	6.54	3.26e-10	3.58e-07	0.51	0.38	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	6.54	3.26e-10	3.58e-07	0.51	0.38	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
COAD	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	6.54	3.26e-10	3.59e-07	0.43	0.38	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	6.54	3.26e-10	3.59e-07	0.43	0.38	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	6.54	3.26e-10	3.59e-07	0.43	0.38	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
COAD	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	6.54	3.27e-10	3.59e-07	0.54	0.38	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	6.54	3.27e-10	3.59e-07	0.54	0.38	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs3124498	ENSG00000268707.1	RP11-247A12.7	6.54	3.27e-10	3.59e-07	0.54	0.38	Blood metabolite ratios;	chr9:129103214	chr9:129170434~129170940:+
COAD	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	6.54	3.29e-10	3.62e-07	0.46	0.38	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
COAD	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-6.54	3.29e-10	3.62e-07	-0.44	-0.38	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
COAD	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-6.54	3.29e-10	3.62e-07	-0.44	-0.38	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
COAD	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	6.54	3.31e-10	3.63e-07	0.42	0.38	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
COAD	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-6.54	3.31e-10	3.63e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
COAD	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	6.54	3.31e-10	3.63e-07	0.5	0.38	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
COAD	cis	rs7078219	0.965	rs11190134	ENSG00000228778.1	RP11-129J12.1	-6.54	3.32e-10	3.64e-07	-0.42	-0.38	Dental caries;	chr10:99522443	chr10:99527081~99528261:+
COAD	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	6.54	3.32e-10	3.65e-07	0.43	0.38	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
COAD	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-6.54	3.33e-10	3.65e-07	-0.45	-0.38	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-6.54	3.33e-10	3.65e-07	-0.45	-0.38	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-6.54	3.33e-10	3.65e-07	-0.45	-0.38	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
COAD	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-6.54	3.33e-10	3.65e-07	-0.45	-0.38	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
COAD	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	6.54	3.34e-10	3.66e-07	0.44	0.38	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
COAD	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	6.54	3.34e-10	3.66e-07	0.45	0.38	Height;	chr6:109446727	chr6:109382795~109383666:+
COAD	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	6.54	3.35e-10	3.67e-07	0.46	0.38	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
COAD	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	6.54	3.35e-10	3.67e-07	0.46	0.38	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
COAD	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-6.54	3.38e-10	3.7e-07	-0.64	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
COAD	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	6.53	3.4e-10	3.72e-07	0.44	0.38	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
COAD	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.53	3.4e-10	3.72e-07	0.45	0.38	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
COAD	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	6.53	3.4e-10	3.72e-07	0.48	0.38	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
COAD	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	6.53	3.4e-10	3.72e-07	0.47	0.38	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
COAD	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	6.53	3.41e-10	3.73e-07	0.56	0.38	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
COAD	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-6.53	3.43e-10	3.75e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-6.53	3.43e-10	3.75e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
COAD	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.53	3.43e-10	3.76e-07	0.4	0.38	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
COAD	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	6.53	3.44e-10	3.77e-07	0.47	0.38	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
COAD	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	6.53	3.45e-10	3.77e-07	0.44	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
COAD	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-6.53	3.45e-10	3.78e-07	-0.44	-0.38	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
COAD	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	6.53	3.46e-10	3.79e-07	0.51	0.38	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-6.53	3.48e-10	3.81e-07	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
COAD	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.53	3.49e-10	3.82e-07	-0.45	-0.38	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
COAD	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-6.53	3.49e-10	3.82e-07	-0.45	-0.38	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
COAD	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	6.53	3.49e-10	3.82e-07	0.44	0.38	Height;	chr6:109409679	chr6:109382795~109383666:+
COAD	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-6.53	3.49e-10	3.82e-07	-0.46	-0.38	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
COAD	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	6.53	3.5e-10	3.83e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
COAD	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-6.53	3.51e-10	3.83e-07	-0.49	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-6.53	3.52e-10	3.84e-07	-0.43	-0.38	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	6.53	3.54e-10	3.87e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	6.53	3.54e-10	3.87e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	6.53	3.54e-10	3.87e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	6.53	3.54e-10	3.87e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	6.53	3.54e-10	3.87e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
COAD	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-6.53	3.55e-10	3.88e-07	-0.39	-0.38	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
COAD	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	6.53	3.59e-10	3.91e-07	0.47	0.38	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
COAD	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.53	3.59e-10	3.92e-07	0.45	0.38	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
COAD	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-6.53	3.59e-10	3.92e-07	-0.44	-0.38	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
COAD	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.52	3.6e-10	3.93e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.52	3.6e-10	3.93e-07	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
COAD	cis	rs860818	1	rs1637224	ENSG00000226816.2	AC005082.12	6.52	3.61e-10	3.94e-07	0.84	0.38	Initial pursuit acceleration;	chr7:23188781	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-6.52	3.61e-10	3.94e-07	-0.59	-0.38	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
COAD	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.52	3.61e-10	3.94e-07	-0.54	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
COAD	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	6.52	3.62e-10	3.95e-07	0.46	0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
COAD	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-6.52	3.64e-10	3.97e-07	-0.39	-0.38	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
COAD	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	6.52	3.65e-10	3.98e-07	0.41	0.38	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
COAD	cis	rs754466	0.58	rs10430530	ENSG00000204049.1	RP11-126H7.4	6.52	3.67e-10	4e-07	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77823054	chr10:77866875~77869610:+
COAD	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	6.52	3.68e-10	4.01e-07	0.49	0.38	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
COAD	cis	rs860818	1	rs858247	ENSG00000226816.2	AC005082.12	6.52	3.69e-10	4.02e-07	0.82	0.38	Initial pursuit acceleration;	chr7:23181664	chr7:23206013~23208045:+
COAD	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-6.52	3.69e-10	4.02e-07	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
COAD	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	6.52	3.7e-10	4.03e-07	0.29	0.38	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
COAD	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-6.52	3.71e-10	4.04e-07	-0.39	-0.38	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
COAD	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.52	3.71e-10	4.04e-07	-0.47	-0.38	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
COAD	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-6.52	3.71e-10	4.04e-07	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
COAD	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-6.52	3.72e-10	4.05e-07	-0.41	-0.38	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
COAD	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-6.52	3.72e-10	4.06e-07	-0.44	-0.38	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
COAD	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	6.52	3.72e-10	4.06e-07	0.47	0.38	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
COAD	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	6.52	3.73e-10	4.07e-07	0.32	0.38	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
COAD	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	6.52	3.74e-10	4.07e-07	0.47	0.38	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	6.52	3.74e-10	4.07e-07	0.47	0.38	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	6.52	3.74e-10	4.07e-07	0.47	0.38	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-6.52	3.74e-10	4.07e-07	-0.47	-0.38	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-6.52	3.74e-10	4.07e-07	-0.47	-0.38	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-6.52	3.74e-10	4.07e-07	-0.47	-0.38	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
COAD	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-6.52	3.75e-10	4.08e-07	-0.44	-0.38	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
COAD	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-6.52	3.76e-10	4.09e-07	-0.39	-0.38	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
COAD	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-6.52	3.77e-10	4.1e-07	-0.41	-0.38	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
COAD	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-6.52	3.79e-10	4.12e-07	-0.39	-0.38	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
COAD	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-6.52	3.8e-10	4.13e-07	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
COAD	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	6.52	3.81e-10	4.14e-07	0.55	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
COAD	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	6.51	3.81e-10	4.14e-07	0.5	0.38	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	6.51	3.81e-10	4.14e-07	0.5	0.38	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
COAD	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	6.51	3.83e-10	4.16e-07	0.5	0.38	Height;	chr6:109530435	chr6:109382795~109383666:+
COAD	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	6.51	3.85e-10	4.19e-07	0.41	0.38	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
COAD	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	6.51	3.86e-10	4.19e-07	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
COAD	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	6.51	3.86e-10	4.19e-07	0.39	0.38	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-6.51	3.88e-10	4.21e-07	-0.41	-0.38	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
COAD	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	6.51	3.9e-10	4.23e-07	0.43	0.38	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
COAD	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-6.51	3.93e-10	4.26e-07	-0.33	-0.38	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
COAD	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-6.51	3.94e-10	4.27e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
COAD	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-6.51	3.94e-10	4.27e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
COAD	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	6.51	3.94e-10	4.27e-07	0.44	0.38	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
COAD	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-6.51	3.95e-10	4.28e-07	-0.47	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
COAD	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-6.51	3.95e-10	4.29e-07	-0.46	-0.38	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-6.51	3.95e-10	4.29e-07	-0.51	-0.38	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
COAD	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	6.51	3.97e-10	4.3e-07	0.42	0.38	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
COAD	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.51	3.97e-10	4.31e-07	0.39	0.38	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
COAD	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-6.51	3.97e-10	4.31e-07	-0.39	-0.38	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
COAD	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-6.51	3.98e-10	4.32e-07	-0.64	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
COAD	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	6.51	3.99e-10	4.32e-07	0.37	0.38	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
COAD	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	6.51	3.99e-10	4.32e-07	0.42	0.38	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
COAD	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	6.51	3.99e-10	4.33e-07	0.39	0.38	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
COAD	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-6.51	4e-10	4.33e-07	-0.5	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	6.51	4e-10	4.34e-07	0.39	0.38	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
COAD	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	6.51	4.02e-10	4.35e-07	0.55	0.38	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
COAD	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-6.51	4.03e-10	4.36e-07	-0.43	-0.38	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
COAD	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	6.5	4.03e-10	4.37e-07	0.46	0.38	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
COAD	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	6.5	4.04e-10	4.37e-07	0.51	0.38	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
COAD	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	6.5	4.04e-10	4.37e-07	0.46	0.38	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
COAD	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-6.5	4.04e-10	4.38e-07	-0.42	-0.38	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
COAD	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	6.5	4.06e-10	4.39e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	6.5	4.06e-10	4.39e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	6.5	4.06e-10	4.39e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	6.5	4.06e-10	4.39e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	6.5	4.06e-10	4.39e-07	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
COAD	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-6.5	4.06e-10	4.39e-07	-0.54	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
COAD	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-6.5	4.06e-10	4.39e-07	-0.5	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
COAD	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.5	4.06e-10	4.4e-07	0.39	0.38	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
COAD	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.5	4.1e-10	4.44e-07	-0.45	-0.38	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
COAD	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.5	4.1e-10	4.44e-07	-0.45	-0.38	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
COAD	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-6.5	4.11e-10	4.44e-07	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
COAD	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	6.5	4.12e-10	4.45e-07	0.49	0.38	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
COAD	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-6.5	4.12e-10	4.45e-07	-0.46	-0.38	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
COAD	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	6.5	4.12e-10	4.45e-07	0.36	0.38	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
COAD	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-6.5	4.14e-10	4.47e-07	-0.33	-0.38	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-6.5	4.14e-10	4.47e-07	-0.33	-0.38	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
COAD	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-6.5	4.14e-10	4.47e-07	-0.44	-0.38	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
COAD	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	6.5	4.15e-10	4.49e-07	0.4	0.38	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
COAD	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	6.5	4.16e-10	4.49e-07	0.44	0.38	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
COAD	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-6.5	4.16e-10	4.5e-07	-0.41	-0.38	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	6.5	4.19e-10	4.52e-07	0.41	0.38	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
COAD	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.5	4.19e-10	4.53e-07	-0.43	-0.38	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
COAD	cis	rs1400745	0.756	rs10136352	ENSG00000258738.1	RP11-73E17.2	6.5	4.2e-10	4.53e-07	0.42	0.38	Monocyte count;	chr14:34865349	chr14:34874343~34876459:+
COAD	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	6.5	4.21e-10	4.54e-07	0.42	0.38	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
COAD	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-6.5	4.23e-10	4.56e-07	-0.27	-0.38	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
COAD	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-6.5	4.24e-10	4.58e-07	-0.43	-0.38	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
COAD	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-6.5	4.26e-10	4.59e-07	-0.41	-0.38	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
COAD	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	6.5	4.26e-10	4.6e-07	0.61	0.38	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
COAD	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	6.49	4.28e-10	4.61e-07	0.42	0.38	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
COAD	cis	rs7849270	1	rs3124499	ENSG00000268707.1	RP11-247A12.7	6.49	4.29e-10	4.62e-07	0.54	0.38	Blood metabolite ratios;	chr9:129106712	chr9:129170434~129170940:+
COAD	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	6.49	4.29e-10	4.62e-07	0.58	0.38	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
COAD	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	-6.49	4.29e-10	4.62e-07	-0.43	-0.38	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
COAD	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	6.49	4.29e-10	4.63e-07	0.38	0.38	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	6.49	4.3e-10	4.63e-07	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
COAD	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.49	4.31e-10	4.65e-07	-0.41	-0.38	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
COAD	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.49	4.33e-10	4.66e-07	0.45	0.38	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
COAD	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	6.49	4.34e-10	4.67e-07	0.39	0.38	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	6.49	4.36e-10	4.69e-07	0.43	0.38	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	6.49	4.36e-10	4.69e-07	0.43	0.38	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.546	rs11718647	ENSG00000272840.1	RP11-379B18.6	6.49	4.39e-10	4.73e-07	0.56	0.38	Blood pressure (smoking interaction);	chr3:125633178	chr3:125774714~125797953:+
COAD	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	6.49	4.4e-10	4.74e-07	0.41	0.38	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
COAD	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	6.49	4.4e-10	4.74e-07	0.43	0.38	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
COAD	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.49	4.41e-10	4.74e-07	-0.54	-0.38	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
COAD	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-6.49	4.42e-10	4.75e-07	-0.43	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
COAD	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-6.49	4.43e-10	4.76e-07	-0.46	-0.38	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
COAD	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	6.49	4.43e-10	4.77e-07	0.48	0.38	Height;	chr6:109429207	chr6:109382795~109383666:+
COAD	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-6.49	4.43e-10	4.77e-07	-0.47	-0.38	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
COAD	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	6.49	4.46e-10	4.8e-07	0.44	0.38	Height;	chr6:109402736	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	6.49	4.46e-10	4.8e-07	0.44	0.38	Height;	chr6:109403734	chr6:109382795~109383666:+
COAD	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.49	4.46e-10	4.8e-07	-0.48	-0.38	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
COAD	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	6.49	4.5e-10	4.83e-07	0.36	0.38	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
COAD	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6.49	4.51e-10	4.85e-07	-0.63	-0.38	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
COAD	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	6.49	4.52e-10	4.85e-07	0.39	0.38	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
COAD	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-6.48	4.54e-10	4.88e-07	-0.48	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
COAD	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	6.48	4.55e-10	4.89e-07	0.43	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
COAD	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	6.48	4.56e-10	4.89e-07	0.49	0.37	Height;	chr6:109479396	chr6:109382795~109383666:+
COAD	cis	rs453301	0.682	rs2929308	ENSG00000253981.4	ALG1L13P	-6.48	4.56e-10	4.9e-07	-0.44	-0.37	Joint mobility (Beighton score);	chr8:9226611	chr8:8236003~8244667:-
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	6.48	4.57e-10	4.91e-07	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
COAD	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	6.48	4.58e-10	4.92e-07	0.29	0.37	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
COAD	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	6.48	4.6e-10	4.93e-07	0.48	0.37	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
COAD	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	-6.48	4.6e-10	4.94e-07	-0.44	-0.37	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
COAD	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	6.48	4.62e-10	4.95e-07	0.47	0.37	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	6.48	4.62e-10	4.95e-07	0.47	0.37	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
COAD	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	6.48	4.64e-10	4.98e-07	0.51	0.37	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
COAD	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	6.48	4.65e-10	4.98e-07	0.47	0.37	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	6.48	4.65e-10	4.98e-07	0.47	0.37	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
COAD	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	6.48	4.67e-10	5e-07	0.49	0.37	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
COAD	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-6.48	4.67e-10	5e-07	-0.48	-0.37	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
COAD	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-6.48	4.67e-10	5e-07	-0.48	-0.37	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
COAD	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-6.48	4.69e-10	5.02e-07	-0.41	-0.37	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
COAD	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	6.48	4.69e-10	5.02e-07	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
COAD	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-6.48	4.7e-10	5.03e-07	-0.52	-0.37	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	6.48	4.71e-10	5.04e-07	0.41	0.37	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
COAD	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	6.48	4.72e-10	5.05e-07	0.4	0.37	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
COAD	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.48	4.72e-10	5.05e-07	-0.54	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.48	4.72e-10	5.05e-07	-0.54	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
COAD	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	6.48	4.73e-10	5.06e-07	0.49	0.37	Height;	chr6:109613205	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	6.48	4.73e-10	5.06e-07	0.49	0.37	Height;	chr6:109617741	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	6.48	4.73e-10	5.06e-07	0.49	0.37	Height;	chr6:109619295	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	6.48	4.74e-10	5.07e-07	0.51	0.37	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
COAD	cis	rs7078219	0.965	rs11190134	ENSG00000257582.4	LINC01475	-6.48	4.74e-10	5.07e-07	-0.41	-0.37	Dental caries;	chr10:99522443	chr10:99526350~99531177:-
COAD	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.48	4.75e-10	5.08e-07	-0.45	-0.37	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
COAD	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-6.48	4.77e-10	5.1e-07	-0.71	-0.37	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
COAD	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	6.48	4.77e-10	5.1e-07	0.49	0.37	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
COAD	cis	rs453301	0.571	rs2929452	ENSG00000253981.4	ALG1L13P	-6.48	4.78e-10	5.11e-07	-0.43	-0.37	Joint mobility (Beighton score);	chr8:9226955	chr8:8236003~8244667:-
COAD	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	6.48	4.78e-10	5.11e-07	0.42	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
COAD	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	6.47	4.79e-10	5.12e-07	0.47	0.37	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-6.47	4.81e-10	5.13e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
COAD	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-6.47	4.85e-10	5.18e-07	-0.47	-0.37	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
COAD	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-6.47	4.85e-10	5.18e-07	-0.47	-0.37	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
COAD	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.47	4.86e-10	5.19e-07	0.44	0.37	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
COAD	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	6.47	4.87e-10	5.19e-07	0.5	0.37	Height;	chr6:109415050	chr6:109382795~109383666:+
COAD	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	6.47	4.87e-10	5.2e-07	0.72	0.37	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
COAD	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	6.47	4.89e-10	5.22e-07	0.47	0.37	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
COAD	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-6.47	4.89e-10	5.22e-07	-0.46	-0.37	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
COAD	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-6.47	4.92e-10	5.25e-07	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
COAD	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	6.47	4.93e-10	5.26e-07	0.27	0.37	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	6.47	4.93e-10	5.26e-07	0.27	0.37	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	6.47	4.93e-10	5.26e-07	0.27	0.37	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	6.47	4.94e-10	5.26e-07	0.3	0.37	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
COAD	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-6.47	4.95e-10	5.28e-07	-0.49	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
COAD	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-6.47	4.96e-10	5.29e-07	-0.47	-0.37	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
COAD	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	6.47	4.96e-10	5.29e-07	0.44	0.37	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-6.47	4.96e-10	5.29e-07	-0.44	-0.37	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
COAD	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-6.47	4.99e-10	5.32e-07	-0.46	-0.37	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-6.47	4.99e-10	5.32e-07	-0.46	-0.37	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
COAD	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	6.47	5e-10	5.33e-07	0.41	0.37	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
COAD	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	6.47	5.01e-10	5.33e-07	0.41	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	6.47	5.01e-10	5.33e-07	0.41	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
COAD	cis	rs7829975	0.572	rs28446104	ENSG00000173295.6	FAM86B3P	-6.47	5.02e-10	5.34e-07	-0.45	-0.37	Mood instability;	chr8:8938391	chr8:8228595~8244865:+
COAD	cis	rs7078219	1	rs6584278	ENSG00000228778.1	RP11-129J12.1	-6.47	5.03e-10	5.36e-07	-0.41	-0.37	Dental caries;	chr10:99518342	chr10:99527081~99528261:+
COAD	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	6.47	5.05e-10	5.38e-07	0.48	0.37	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
COAD	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-6.47	5.05e-10	5.38e-07	-0.46	-0.37	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
COAD	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-6.46	5.07e-10	5.4e-07	-0.4	-0.37	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
COAD	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-6.46	5.1e-10	5.43e-07	-0.36	-0.37	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
COAD	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	6.46	5.12e-10	5.45e-07	0.56	0.37	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
COAD	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-6.46	5.12e-10	5.45e-07	-0.36	-0.37	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
COAD	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	6.46	5.13e-10	5.46e-07	0.41	0.37	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
COAD	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	6.46	5.14e-10	5.46e-07	0.5	0.37	Height;	chr6:109372084	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	6.46	5.14e-10	5.46e-07	0.5	0.37	Height;	chr6:109375848	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	6.46	5.15e-10	5.48e-07	0.51	0.37	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
COAD	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-6.46	5.16e-10	5.49e-07	-0.36	-0.37	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
COAD	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	6.46	5.25e-10	5.57e-07	0.35	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
COAD	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	6.46	5.26e-10	5.59e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
COAD	cis	rs7615952	0.546	rs2979333	ENSG00000272840.1	RP11-379B18.6	6.46	5.27e-10	5.59e-07	0.57	0.37	Blood pressure (smoking interaction);	chr3:125641499	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs111812401	ENSG00000272840.1	RP11-379B18.6	6.46	5.27e-10	5.59e-07	0.57	0.37	Blood pressure (smoking interaction);	chr3:125642651	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs2979350	ENSG00000272840.1	RP11-379B18.6	6.46	5.27e-10	5.59e-07	0.57	0.37	Blood pressure (smoking interaction);	chr3:125643371	chr3:125774714~125797953:+
COAD	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.46	5.27e-10	5.6e-07	-0.44	-0.37	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
COAD	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	6.46	5.31e-10	5.63e-07	0.48	0.37	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
COAD	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-6.46	5.32e-10	5.64e-07	-0.34	-0.37	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
COAD	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-6.46	5.33e-10	5.66e-07	-0.44	-0.37	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	6.46	5.33e-10	5.66e-07	0.44	0.37	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
COAD	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	6.46	5.34e-10	5.66e-07	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
COAD	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-6.46	5.34e-10	5.67e-07	-0.39	-0.37	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
COAD	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-6.46	5.35e-10	5.67e-07	-0.47	-0.37	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	6.46	5.35e-10	5.67e-07	0.47	0.37	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
COAD	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.46	5.36e-10	5.68e-07	-0.43	-0.37	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
COAD	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	6.45	5.37e-10	5.69e-07	0.41	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
COAD	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-6.45	5.38e-10	5.71e-07	-0.41	-0.37	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
COAD	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.45	5.39e-10	5.71e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
COAD	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	6.45	5.39e-10	5.72e-07	0.44	0.37	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	6.45	5.4e-10	5.73e-07	0.44	0.37	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
COAD	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-6.45	5.47e-10	5.79e-07	-0.59	-0.37	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
COAD	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-6.45	5.47e-10	5.79e-07	-0.59	-0.37	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
COAD	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-6.45	5.47e-10	5.79e-07	-0.59	-0.37	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
COAD	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-6.45	5.49e-10	5.81e-07	-0.44	-0.37	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
COAD	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-6.45	5.49e-10	5.81e-07	-0.44	-0.37	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-6.45	5.49e-10	5.81e-07	-0.44	-0.37	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
COAD	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	6.45	5.5e-10	5.82e-07	0.45	0.37	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
COAD	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	6.45	5.5e-10	5.82e-07	0.27	0.37	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
COAD	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	6.45	5.51e-10	5.83e-07	0.49	0.37	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
COAD	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-6.45	5.51e-10	5.83e-07	-0.46	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
COAD	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-6.45	5.51e-10	5.83e-07	-0.42	-0.37	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-6.45	5.53e-10	5.85e-07	-0.41	-0.37	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
COAD	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-6.45	5.54e-10	5.86e-07	-0.4	-0.37	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
COAD	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	6.45	5.54e-10	5.86e-07	0.74	0.37	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
COAD	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-6.45	5.59e-10	5.91e-07	-0.33	-0.37	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
COAD	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.45	5.59e-10	5.91e-07	-0.49	-0.37	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
COAD	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	6.45	5.63e-10	5.94e-07	0.53	0.37	Height;	chr6:109369898	chr6:109382795~109383666:+
COAD	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	6.45	5.63e-10	5.94e-07	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
COAD	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-6.45	5.63e-10	5.94e-07	-0.4	-0.37	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
COAD	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	6.45	5.63e-10	5.94e-07	0.36	0.37	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
COAD	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	6.45	5.64e-10	5.94e-07	0.46	0.37	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
COAD	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	6.45	5.64e-10	5.95e-07	0.54	0.37	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
COAD	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-6.45	5.65e-10	5.96e-07	-0.44	-0.37	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
COAD	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-6.45	5.65e-10	5.96e-07	-0.43	-0.37	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
COAD	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-6.45	5.65e-10	5.96e-07	-0.4	-0.37	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
COAD	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	6.45	5.66e-10	5.97e-07	0.5	0.37	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
COAD	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-6.44	5.68e-10	5.98e-07	-0.4	-0.37	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	6.44	5.68e-10	5.98e-07	0.48	0.37	Height;	chr6:109486036	chr6:109382795~109383666:+
COAD	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	6.44	5.71e-10	6.01e-07	0.61	0.37	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
COAD	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-6.44	5.73e-10	6.04e-07	-0.61	-0.37	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
COAD	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	6.44	5.75e-10	6.05e-07	0.44	0.37	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
COAD	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	6.44	5.77e-10	6.07e-07	0.39	0.37	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
COAD	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-6.44	5.77e-10	6.07e-07	-0.5	-0.37	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
COAD	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-6.44	5.77e-10	6.07e-07	-0.5	-0.37	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
COAD	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-6.44	5.77e-10	6.07e-07	-0.48	-0.37	Height;	chr6:109380015	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-6.44	5.79e-10	6.09e-07	-0.41	-0.37	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
COAD	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	6.44	5.79e-10	6.09e-07	0.42	0.37	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	6.44	5.79e-10	6.09e-07	0.42	0.37	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
COAD	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	6.44	5.8e-10	6.09e-07	0.49	0.37	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
COAD	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-6.44	5.8e-10	6.1e-07	-0.46	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
COAD	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	6.44	5.81e-10	6.11e-07	0.27	0.37	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-6.44	5.82e-10	6.12e-07	-0.28	-0.37	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
COAD	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	6.44	5.83e-10	6.13e-07	0.51	0.37	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	6.44	5.83e-10	6.13e-07	0.51	0.37	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	6.44	5.83e-10	6.13e-07	0.51	0.37	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	6.44	5.83e-10	6.13e-07	0.51	0.37	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
COAD	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	6.44	5.83e-10	6.13e-07	0.48	0.37	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
COAD	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-6.44	5.84e-10	6.13e-07	-0.41	-0.37	Height;	chr2:231516587	chr2:231501990~231502201:-
COAD	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-6.44	5.85e-10	6.14e-07	-0.45	-0.37	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
COAD	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	6.44	5.87e-10	6.17e-07	0.4	0.37	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
COAD	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	6.44	5.9e-10	6.19e-07	0.42	0.37	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
COAD	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	6.44	5.9e-10	6.19e-07	0.51	0.37	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
COAD	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-6.44	5.91e-10	6.2e-07	-0.47	-0.37	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
COAD	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	6.44	5.93e-10	6.22e-07	0.45	0.37	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	6.44	5.93e-10	6.22e-07	0.45	0.37	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
COAD	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	6.44	5.95e-10	6.24e-07	0.46	0.37	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
COAD	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-6.44	5.96e-10	6.25e-07	-0.41	-0.37	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
COAD	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-6.44	5.98e-10	6.27e-07	-0.44	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
COAD	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	6.44	5.98e-10	6.27e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	6.44	5.98e-10	6.27e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	6.44	5.98e-10	6.27e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	6.44	5.98e-10	6.27e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	6.43	6.02e-10	6.31e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	6.43	6.02e-10	6.31e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
COAD	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	-6.43	6.02e-10	6.31e-07	-0.43	-0.37	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
COAD	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-6.43	6.03e-10	6.32e-07	-0.47	-0.37	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
COAD	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-6.43	6.03e-10	6.32e-07	-0.41	-0.37	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
COAD	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.43	6.04e-10	6.32e-07	0.54	0.37	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.43	6.04e-10	6.32e-07	0.54	0.37	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
COAD	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-6.43	6.06e-10	6.35e-07	-0.48	-0.37	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-6.43	6.06e-10	6.35e-07	-0.48	-0.37	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-6.43	6.06e-10	6.35e-07	-0.48	-0.37	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-6.43	6.06e-10	6.35e-07	-0.48	-0.37	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
COAD	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	6.43	6.07e-10	6.35e-07	0.44	0.37	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
COAD	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-6.43	6.07e-10	6.36e-07	-0.4	-0.37	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
COAD	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-6.43	6.12e-10	6.4e-07	-0.45	-0.37	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
COAD	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	6.43	6.13e-10	6.41e-07	0.42	0.37	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	6.43	6.13e-10	6.41e-07	0.5	0.37	Height;	chr6:109339681	chr6:109382795~109383666:+
COAD	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-6.43	6.14e-10	6.42e-07	-0.38	-0.37	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
COAD	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-6.43	6.16e-10	6.44e-07	-0.43	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
COAD	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	6.43	6.16e-10	6.44e-07	0.45	0.37	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
COAD	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	6.43	6.16e-10	6.44e-07	0.45	0.37	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
COAD	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	6.43	6.16e-10	6.44e-07	0.45	0.37	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
COAD	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	6.43	6.16e-10	6.44e-07	0.45	0.37	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
COAD	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	6.43	6.18e-10	6.45e-07	0.53	0.37	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
COAD	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	6.43	6.19e-10	6.47e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
COAD	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	6.43	6.2e-10	6.48e-07	0.48	0.37	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
COAD	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-6.43	6.22e-10	6.5e-07	-0.41	-0.37	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
COAD	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	6.43	6.23e-10	6.51e-07	0.48	0.37	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
COAD	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	6.43	6.23e-10	6.51e-07	0.45	0.37	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
COAD	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-6.43	6.24e-10	6.51e-07	-0.4	-0.37	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
COAD	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-6.43	6.26e-10	6.54e-07	-0.56	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
COAD	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-6.43	6.3e-10	6.57e-07	-0.4	-0.37	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
COAD	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	6.43	6.3e-10	6.57e-07	0.44	0.37	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
COAD	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	6.43	6.3e-10	6.57e-07	0.44	0.37	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.43	6.3e-10	6.57e-07	-0.44	-0.37	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
COAD	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	-6.43	6.31e-10	6.58e-07	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
COAD	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-6.43	6.31e-10	6.58e-07	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
COAD	cis	rs754466	0.606	rs11002306	ENSG00000204049.1	RP11-126H7.4	6.43	6.32e-10	6.59e-07	0.48	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77831761	chr10:77866875~77869610:+
COAD	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	6.43	6.33e-10	6.6e-07	0.28	0.37	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
COAD	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-6.43	6.35e-10	6.62e-07	-0.45	-0.37	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
COAD	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	6.43	6.35e-10	6.62e-07	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
COAD	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	6.43	6.35e-10	6.62e-07	0.39	0.37	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
COAD	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-6.42	6.37e-10	6.64e-07	-0.48	-0.37	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
COAD	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-6.42	6.38e-10	6.65e-07	-0.44	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
COAD	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-6.42	6.42e-10	6.69e-07	-0.63	-0.37	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
COAD	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.42	6.47e-10	6.74e-07	-0.39	-0.37	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
COAD	cis	rs7078219	0.965	rs7081858	ENSG00000228778.1	RP11-129J12.1	-6.42	6.49e-10	6.75e-07	-0.41	-0.37	Dental caries;	chr10:99514808	chr10:99527081~99528261:+
COAD	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	6.42	6.51e-10	6.77e-07	0.45	0.37	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
COAD	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-6.42	6.53e-10	6.79e-07	-0.41	-0.37	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
COAD	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-6.42	6.54e-10	6.8e-07	-0.24	-0.37	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
COAD	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	6.42	6.58e-10	6.84e-07	0.39	0.37	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	6.42	6.58e-10	6.84e-07	0.39	0.37	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
COAD	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-6.42	6.59e-10	6.85e-07	-0.39	-0.37	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
COAD	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	6.42	6.62e-10	6.87e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
COAD	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	6.42	6.62e-10	6.87e-07	0.43	0.37	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	6.42	6.62e-10	6.87e-07	0.43	0.37	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
COAD	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	6.42	6.63e-10	6.88e-07	0.48	0.37	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
COAD	cis	rs1056107	0.763	rs10115594	ENSG00000225513.1	RP11-165N19.2	-6.42	6.63e-10	6.88e-07	-0.46	-0.37	Colorectal cancer;	chr9:112174198	chr9:112173522~112173971:-
COAD	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-6.42	6.66e-10	6.91e-07	-0.4	-0.37	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
COAD	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-6.42	6.67e-10	6.92e-07	-0.48	-0.37	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-6.42	6.67e-10	6.92e-07	-0.48	-0.37	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-6.42	6.67e-10	6.92e-07	-0.48	-0.37	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
COAD	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	6.42	6.68e-10	6.93e-07	0.39	0.37	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
COAD	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-6.42	6.69e-10	6.94e-07	-0.43	-0.37	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
COAD	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-6.42	6.7e-10	6.95e-07	-0.62	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
COAD	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-6.42	6.71e-10	6.96e-07	-0.46	-0.37	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
COAD	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.42	6.72e-10	6.97e-07	0.44	0.37	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
COAD	cis	rs7078219	1	rs61872688	ENSG00000228778.1	RP11-129J12.1	-6.41	6.76e-10	7.01e-07	-0.41	-0.37	Dental caries;	chr10:99513789	chr10:99527081~99528261:+
COAD	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	6.41	6.78e-10	7.03e-07	0.53	0.37	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
COAD	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	6.41	6.78e-10	7.03e-07	0.44	0.37	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
COAD	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-6.41	6.8e-10	7.05e-07	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
COAD	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.41	6.81e-10	7.06e-07	0.44	0.37	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-6.41	6.89e-10	7.13e-07	-0.42	-0.37	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
COAD	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-6.41	6.89e-10	7.13e-07	-0.57	-0.37	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
COAD	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-6.41	6.91e-10	7.15e-07	-0.48	-0.37	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
COAD	cis	rs10885997	0.967	rs11197775	ENSG00000266200.5	PNLIPRP2	-6.41	6.91e-10	7.15e-07	-0.43	-0.37	Phospholipid levels (plasma);	chr10:116636627	chr10:116620953~116645143:+
COAD	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-6.41	6.95e-10	7.18e-07	-0.39	-0.37	Height;	chr11:118703185	chr11:118704607~118750263:+
COAD	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-6.41	6.95e-10	7.18e-07	-0.39	-0.37	Height;	chr11:118703207	chr11:118704607~118750263:+
COAD	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-6.41	6.96e-10	7.19e-07	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
COAD	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-6.41	6.96e-10	7.19e-07	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	6.41	6.96e-10	7.19e-07	0.38	0.37	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
COAD	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	6.41	6.98e-10	7.21e-07	0.47	0.37	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-6.41	7e-10	7.23e-07	-0.43	-0.37	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
COAD	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	6.41	7.01e-10	7.24e-07	0.59	0.37	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
COAD	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-6.41	7.02e-10	7.24e-07	-0.62	-0.37	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
COAD	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-6.41	7.06e-10	7.28e-07	-0.44	-0.37	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
COAD	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-6.41	7.07e-10	7.29e-07	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
COAD	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	6.41	7.12e-10	7.34e-07	0.42	0.37	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
COAD	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-6.4	7.13e-10	7.35e-07	-0.46	-0.37	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
COAD	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	6.4	7.16e-10	7.38e-07	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
COAD	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-6.4	7.17e-10	7.39e-07	-0.41	-0.37	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
COAD	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-6.4	7.17e-10	7.39e-07	-0.41	-0.37	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
COAD	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	6.4	7.17e-10	7.39e-07	0.48	0.37	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	6.4	7.17e-10	7.39e-07	0.48	0.37	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	6.4	7.17e-10	7.39e-07	0.48	0.37	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	6.4	7.17e-10	7.39e-07	0.48	0.37	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	6.4	7.17e-10	7.39e-07	0.48	0.37	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
COAD	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-6.4	7.18e-10	7.39e-07	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
COAD	cis	rs7078219	0.965	rs10883358	ENSG00000228778.1	RP11-129J12.1	-6.4	7.2e-10	7.41e-07	-0.41	-0.37	Dental caries;	chr10:99514100	chr10:99527081~99528261:+
COAD	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	6.4	7.21e-10	7.42e-07	0.4	0.37	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	6.4	7.21e-10	7.43e-07	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
COAD	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-6.4	7.23e-10	7.45e-07	-0.46	-0.37	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
COAD	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-6.4	7.24e-10	7.46e-07	-0.43	-0.37	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-6.4	7.24e-10	7.46e-07	-0.43	-0.37	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
COAD	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-6.4	7.24e-10	7.46e-07	-0.46	-0.37	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-6.4	7.24e-10	7.46e-07	-0.46	-0.37	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-6.4	7.24e-10	7.46e-07	-0.46	-0.37	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
COAD	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	6.4	7.29e-10	7.5e-07	0.82	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
COAD	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-6.4	7.32e-10	7.53e-07	-0.43	-0.37	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-6.4	7.32e-10	7.53e-07	-0.43	-0.37	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
COAD	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	6.4	7.35e-10	7.56e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
COAD	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-6.4	7.38e-10	7.59e-07	-0.32	-0.37	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
COAD	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	6.4	7.39e-10	7.6e-07	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	6.4	7.39e-10	7.6e-07	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	6.4	7.39e-10	7.6e-07	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
COAD	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.4	7.4e-10	7.6e-07	-0.44	-0.37	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
COAD	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-6.4	7.4e-10	7.6e-07	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
COAD	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-6.4	7.43e-10	7.63e-07	-0.43	-0.37	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
COAD	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-6.4	7.44e-10	7.64e-07	-0.41	-0.37	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-6.4	7.44e-10	7.64e-07	-0.41	-0.37	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
COAD	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	6.4	7.46e-10	7.66e-07	0.44	0.37	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
COAD	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-6.4	7.48e-10	7.68e-07	-0.42	-0.37	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
COAD	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-6.39	7.54e-10	7.74e-07	-0.58	-0.37	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
COAD	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-6.39	7.56e-10	7.76e-07	-0.45	-0.37	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
COAD	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.39	7.57e-10	7.77e-07	0.39	0.37	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
COAD	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.39	7.59e-10	7.78e-07	-0.54	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
COAD	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-6.39	7.61e-10	7.8e-07	-0.39	-0.37	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
COAD	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	6.39	7.63e-10	7.82e-07	0.39	0.37	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
COAD	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	6.39	7.63e-10	7.82e-07	0.4	0.37	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
COAD	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	6.39	7.65e-10	7.84e-07	0.56	0.37	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
COAD	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	6.39	7.65e-10	7.84e-07	0.56	0.37	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
COAD	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	6.39	7.65e-10	7.84e-07	0.56	0.37	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
COAD	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-6.39	7.66e-10	7.85e-07	-0.38	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
COAD	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	6.39	7.67e-10	7.85e-07	0.54	0.37	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
COAD	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	6.39	7.7e-10	7.88e-07	0.82	0.37	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	6.39	7.7e-10	7.88e-07	0.82	0.37	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
COAD	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	6.39	7.7e-10	7.88e-07	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
COAD	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-6.39	7.71e-10	7.89e-07	-0.44	-0.37	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	-6.39	7.73e-10	7.92e-07	-0.44	-0.37	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
COAD	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.39	7.74e-10	7.92e-07	-0.44	-0.37	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
COAD	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-6.39	7.74e-10	7.92e-07	-0.32	-0.37	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
COAD	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	6.39	7.76e-10	7.94e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
COAD	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-6.39	7.78e-10	7.97e-07	-0.46	-0.37	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
COAD	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	6.39	7.79e-10	7.97e-07	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
COAD	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	6.39	7.8e-10	7.98e-07	0.39	0.37	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
COAD	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.39	7.84e-10	8.01e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.39	7.84e-10	8.01e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.39	7.84e-10	8.01e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
COAD	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-6.39	7.84e-10	8.01e-07	-0.48	-0.37	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
COAD	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-6.39	7.84e-10	8.02e-07	-0.6	-0.37	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
COAD	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	6.39	7.86e-10	8.03e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
COAD	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	6.39	7.9e-10	8.07e-07	0.76	0.37	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
COAD	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-6.39	7.92e-10	8.09e-07	-0.42	-0.37	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
COAD	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	6.39	7.93e-10	8.1e-07	0.43	0.37	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
COAD	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-6.39	7.93e-10	8.1e-07	-0.49	-0.37	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
COAD	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-6.39	7.94e-10	8.11e-07	-0.46	-0.37	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-6.39	7.94e-10	8.11e-07	-0.46	-0.37	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-6.39	7.94e-10	8.11e-07	-0.46	-0.37	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
COAD	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-6.39	7.94e-10	8.11e-07	-0.4	-0.37	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
COAD	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	6.39	7.96e-10	8.13e-07	0.56	0.37	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
COAD	cis	rs860818	1	rs858276	ENSG00000226816.2	AC005082.12	6.38	7.97e-10	8.14e-07	0.71	0.37	Initial pursuit acceleration;	chr7:23212934	chr7:23206013~23208045:+
COAD	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-6.38	7.98e-10	8.15e-07	-0.32	-0.37	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
COAD	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	6.38	8.01e-10	8.17e-07	0.45	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
COAD	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.38	8.01e-10	8.17e-07	0.37	0.37	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
COAD	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-6.38	8.01e-10	8.18e-07	-0.43	-0.37	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
COAD	cis	rs754466	0.606	rs56402185	ENSG00000204049.1	RP11-126H7.4	6.38	8.04e-10	8.2e-07	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77826090	chr10:77866875~77869610:+
COAD	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	6.38	8.09e-10	8.25e-07	0.39	0.37	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
COAD	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	6.38	8.11e-10	8.26e-07	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	6.38	8.11e-10	8.26e-07	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
COAD	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	6.38	8.17e-10	8.33e-07	0.82	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
COAD	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-6.38	8.2e-10	8.35e-07	-0.34	-0.37	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-6.38	8.2e-10	8.35e-07	-0.34	-0.37	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-6.38	8.2e-10	8.35e-07	-0.34	-0.37	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
COAD	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	6.38	8.22e-10	8.37e-07	0.45	0.37	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
COAD	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	6.38	8.23e-10	8.38e-07	0.38	0.37	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
COAD	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	6.38	8.27e-10	8.42e-07	0.77	0.37	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
COAD	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-6.38	8.27e-10	8.42e-07	-0.52	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
COAD	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-6.38	8.28e-10	8.43e-07	-0.45	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
COAD	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	6.38	8.32e-10	8.47e-07	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
COAD	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.38	8.38e-10	8.52e-07	-0.48	-0.37	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.38	8.38e-10	8.52e-07	-0.48	-0.37	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.38	8.38e-10	8.52e-07	-0.48	-0.37	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
COAD	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.38	8.4e-10	8.54e-07	0.37	0.37	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
COAD	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-6.38	8.42e-10	8.56e-07	-0.48	-0.37	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
COAD	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-6.38	8.42e-10	8.56e-07	-0.48	-0.37	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
COAD	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-6.38	8.42e-10	8.56e-07	-0.48	-0.37	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
COAD	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	6.38	8.42e-10	8.56e-07	0.4	0.37	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
COAD	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-6.37	8.46e-10	8.6e-07	-0.42	-0.37	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
COAD	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-6.37	8.48e-10	8.62e-07	-0.46	-0.37	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
COAD	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	6.37	8.48e-10	8.62e-07	0.42	0.37	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
COAD	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	6.37	8.5e-10	8.64e-07	0.52	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
COAD	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-6.37	8.5e-10	8.64e-07	-0.46	-0.37	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
COAD	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	6.37	8.55e-10	8.69e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
COAD	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	6.37	8.56e-10	8.69e-07	0.82	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
COAD	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-6.37	8.57e-10	8.7e-07	-0.38	-0.37	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
COAD	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-6.37	8.57e-10	8.7e-07	-0.55	-0.37	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
COAD	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	6.37	8.59e-10	8.72e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
COAD	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	6.37	8.63e-10	8.75e-07	0.45	0.37	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
COAD	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	6.37	8.66e-10	8.78e-07	0.43	0.37	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
COAD	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-6.37	8.69e-10	8.82e-07	-0.61	-0.37	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
COAD	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	6.37	8.72e-10	8.85e-07	0.52	0.37	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
COAD	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	6.37	8.73e-10	8.86e-07	0.55	0.37	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
COAD	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	6.37	8.8e-10	8.92e-07	0.59	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
COAD	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-6.37	8.82e-10	8.94e-07	-0.4	-0.37	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
COAD	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	6.37	8.82e-10	8.94e-07	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
COAD	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	6.37	8.84e-10	8.96e-07	0.46	0.37	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
COAD	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-6.37	8.85e-10	8.96e-07	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	6.37	8.85e-10	8.96e-07	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
COAD	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	6.37	8.88e-10	8.99e-07	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
COAD	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	6.37	8.89e-10	9e-07	0.43	0.37	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
COAD	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	6.37	8.91e-10	9.02e-07	0.54	0.37	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
COAD	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	6.37	8.91e-10	9.02e-07	0.54	0.37	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
COAD	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.36	8.93e-10	9.04e-07	-0.47	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
COAD	cis	rs7078219	0.505	rs7077040	ENSG00000228778.1	RP11-129J12.1	-6.36	8.95e-10	9.05e-07	-0.41	-0.37	Dental caries;	chr10:99521257	chr10:99527081~99528261:+
COAD	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	6.36	8.95e-10	9.06e-07	0.5	0.37	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
COAD	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	6.36	8.97e-10	9.07e-07	0.57	0.37	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
COAD	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	6.36	8.99e-10	9.09e-07	0.35	0.37	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
COAD	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.36	9.01e-10	9.11e-07	0.37	0.37	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.36	9.01e-10	9.11e-07	0.37	0.37	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
COAD	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-6.36	9.05e-10	9.15e-07	-0.4	-0.37	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-6.36	9.05e-10	9.15e-07	-0.4	-0.37	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
COAD	cis	rs34375054	0.672	rs2291247	ENSG00000279233.1	RP11-158L12.4	6.36	9.11e-10	9.2e-07	0.36	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125134407	chr12:125138245~125141711:+
COAD	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.36	9.13e-10	9.21e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.36	9.13e-10	9.21e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.36	9.13e-10	9.21e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
COAD	cis	rs2921036	0.545	rs4840975	ENSG00000173295.6	FAM86B3P	-6.36	9.15e-10	9.23e-07	-0.45	-0.37	Neuroticism;	chr8:8505748	chr8:8228595~8244865:+
COAD	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-6.36	9.19e-10	9.27e-07	-0.46	-0.37	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
COAD	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-6.36	9.23e-10	9.31e-07	-0.47	-0.37	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
COAD	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	6.36	9.25e-10	9.33e-07	0.44	0.37	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
COAD	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-6.36	9.25e-10	9.33e-07	-0.45	-0.37	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
COAD	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-6.36	9.25e-10	9.33e-07	-0.36	-0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
COAD	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.36	9.26e-10	9.34e-07	-0.38	-0.37	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.36	9.26e-10	9.34e-07	-0.38	-0.37	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	6.36	9.27e-10	9.35e-07	0.44	0.37	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
COAD	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	6.36	9.33e-10	9.4e-07	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
COAD	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-6.36	9.36e-10	9.44e-07	-0.58	-0.37	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
COAD	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-6.36	9.36e-10	9.44e-07	-0.58	-0.37	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
COAD	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-6.36	9.38e-10	9.45e-07	-0.4	-0.37	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
COAD	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-6.36	9.39e-10	9.46e-07	-0.43	-0.37	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
COAD	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-6.36	9.41e-10	9.48e-07	-0.44	-0.37	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
COAD	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	6.36	9.42e-10	9.49e-07	0.55	0.37	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
COAD	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.35	9.44e-10	9.51e-07	0.49	0.37	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
COAD	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.35	9.5e-10	9.56e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.35	9.5e-10	9.56e-07	-0.55	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
COAD	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	6.35	9.5e-10	9.57e-07	0.43	0.37	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
COAD	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	6.35	9.51e-10	9.57e-07	0.56	0.37	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
COAD	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	6.35	9.53e-10	9.59e-07	0.38	0.37	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
COAD	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-6.35	9.53e-10	9.59e-07	-0.22	-0.37	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
COAD	cis	rs9951698	0.687	rs478399	ENSG00000266969.1	RP11-773H22.4	6.35	9.54e-10	9.6e-07	0.42	0.37	Intelligence (multi-trait analysis);	chr18:13093797	chr18:12984694~12991173:-
COAD	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.35	9.55e-10	9.61e-07	-0.56	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
COAD	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	6.35	9.57e-10	9.63e-07	0.59	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
COAD	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	-6.35	9.59e-10	9.65e-07	-0.44	-0.37	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
COAD	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	6.35	9.6e-10	9.65e-07	0.59	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
COAD	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-6.35	9.62e-10	9.67e-07	-0.45	-0.37	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
COAD	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	6.35	9.63e-10	9.68e-07	0.5	0.37	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
COAD	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	6.35	9.63e-10	9.68e-07	0.48	0.37	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
COAD	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-6.35	9.65e-10	9.7e-07	-0.44	-0.37	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
COAD	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	6.35	9.67e-10	9.71e-07	0.52	0.37	Height;	chr6:109455700	chr6:109382795~109383666:+
COAD	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-6.35	9.72e-10	9.77e-07	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
COAD	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	6.35	9.74e-10	9.78e-07	0.49	0.37	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.35	9.76e-10	9.8e-07	0.59	0.37	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
COAD	cis	rs944002	1	rs2297067	ENSG00000259444.1	RP11-736N17.8	-6.35	9.76e-10	9.8e-07	-0.5	-0.37	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100448	chr14:103094723~103098885:+
COAD	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	6.35	9.77e-10	9.81e-07	0.27	0.37	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
COAD	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	6.35	9.83e-10	9.86e-07	0.42	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	6.35	9.83e-10	9.86e-07	0.42	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
COAD	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	6.35	9.86e-10	9.89e-07	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	6.35	9.86e-10	9.89e-07	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
COAD	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-6.35	9.87e-10	9.89e-07	-0.39	-0.37	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
COAD	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	6.35	9.88e-10	9.9e-07	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
COAD	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.35	9.89e-10	9.91e-07	-0.54	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
COAD	cis	rs9393777	0.546	rs9366673	ENSG00000224843.5	LINC00240	6.35	9.93e-10	9.95e-07	0.57	0.37	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26956992~27023924:+
COAD	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-6.35	9.96e-10	9.98e-07	-0.51	-0.37	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
COAD	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-6.34	9.98e-10	1e-06	-0.51	-0.37	Height;	chr6:109625358	chr6:109382795~109383666:+
COAD	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-6.34	1.01e-09	1.01e-06	-0.39	-0.37	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
COAD	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-6.34	1.01e-09	1.01e-06	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
COAD	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-6.34	1.01e-09	1.01e-06	-0.6	-0.37	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
COAD	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	6.34	1.01e-09	1.01e-06	0.48	0.37	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
COAD	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	6.34	1.01e-09	1.01e-06	0.47	0.37	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
COAD	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	6.34	1.01e-09	1.02e-06	0.4	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
COAD	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	6.34	1.02e-09	1.02e-06	0.49	0.37	Height;	chr6:109427303	chr6:109382795~109383666:+
COAD	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-6.34	1.02e-09	1.02e-06	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
COAD	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-6.34	1.02e-09	1.02e-06	-0.45	-0.37	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
COAD	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-6.34	1.02e-09	1.02e-06	-0.34	-0.37	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
COAD	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	6.34	1.03e-09	1.03e-06	0.49	0.37	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
COAD	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	6.34	1.03e-09	1.03e-06	0.55	0.37	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
COAD	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-6.34	1.03e-09	1.03e-06	-0.41	-0.37	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
COAD	cis	rs6940638	0.662	rs7759694	ENSG00000224843.5	LINC00240	6.34	1.03e-09	1.03e-06	0.48	0.37	Intelligence (multi-trait analysis);	chr6:27273177	chr6:26956992~27023924:+
COAD	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	6.34	1.03e-09	1.03e-06	0.7	0.37	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
COAD	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	6.34	1.03e-09	1.03e-06	0.44	0.37	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
COAD	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	6.34	1.03e-09	1.03e-06	0.56	0.37	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
COAD	cis	rs1400745	0.729	rs1741196	ENSG00000258738.1	RP11-73E17.2	6.34	1.04e-09	1.03e-06	0.41	0.37	Monocyte count;	chr14:34877814	chr14:34874343~34876459:+
COAD	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	6.34	1.05e-09	1.04e-06	0.53	0.37	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
COAD	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.34	1.05e-09	1.05e-06	-0.5	-0.37	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.34	1.05e-09	1.05e-06	-0.5	-0.37	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-6.34	1.05e-09	1.05e-06	-0.5	-0.37	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-6.34	1.05e-09	1.05e-06	-0.5	-0.37	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
COAD	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	6.34	1.05e-09	1.05e-06	0.4	0.37	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
COAD	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-6.34	1.05e-09	1.05e-06	-0.44	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.34	1.05e-09	1.05e-06	0.41	0.37	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
COAD	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	6.34	1.05e-09	1.05e-06	0.28	0.37	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
COAD	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.34	1.05e-09	1.05e-06	0.44	0.37	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
COAD	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-6.33	1.06e-09	1.05e-06	-0.45	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
COAD	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.33	1.06e-09	1.05e-06	0.48	0.37	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
COAD	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	6.33	1.06e-09	1.06e-06	0.42	0.37	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
COAD	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-6.33	1.06e-09	1.06e-06	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
COAD	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-6.33	1.06e-09	1.06e-06	-0.43	-0.37	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
COAD	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.33	1.06e-09	1.06e-06	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.33	1.06e-09	1.06e-06	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
COAD	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	-6.33	1.06e-09	1.06e-06	-0.43	-0.37	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
COAD	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-6.33	1.06e-09	1.06e-06	-0.76	-0.37	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-6.33	1.07e-09	1.06e-06	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
COAD	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-6.33	1.07e-09	1.06e-06	-0.43	-0.37	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
COAD	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	6.33	1.07e-09	1.06e-06	0.41	0.37	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
COAD	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	6.33	1.07e-09	1.06e-06	0.54	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
COAD	cis	rs453301	0.598	rs10104303	ENSG00000233609.3	RP11-62H7.2	6.33	1.07e-09	1.07e-06	0.39	0.37	Joint mobility (Beighton score);	chr8:8977018	chr8:8961200~8979025:+
COAD	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	6.33	1.08e-09	1.07e-06	0.43	0.37	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
COAD	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	6.33	1.08e-09	1.07e-06	0.45	0.37	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
COAD	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	6.33	1.08e-09	1.07e-06	0.45	0.37	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
COAD	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	6.33	1.08e-09	1.07e-06	0.63	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
COAD	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-6.33	1.08e-09	1.07e-06	-0.43	-0.37	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
COAD	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	6.33	1.08e-09	1.07e-06	0.4	0.37	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
COAD	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-6.33	1.08e-09	1.07e-06	-0.44	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
COAD	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	6.33	1.08e-09	1.07e-06	0.4	0.37	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
COAD	cis	rs1790761	0.52	rs1551884	ENSG00000231793.4	DOC2GP	-6.33	1.08e-09	1.07e-06	-0.45	-0.37	Mean corpuscular volume;	chr11:67632130	chr11:67612653~67616257:-
COAD	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-6.33	1.08e-09	1.07e-06	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-6.33	1.08e-09	1.07e-06	-0.44	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
COAD	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	6.33	1.09e-09	1.08e-06	0.63	0.37	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
COAD	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	6.33	1.09e-09	1.08e-06	0.41	0.37	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
COAD	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	6.33	1.09e-09	1.08e-06	0.53	0.37	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
COAD	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	-6.33	1.09e-09	1.08e-06	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
COAD	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	6.33	1.1e-09	1.08e-06	0.52	0.37	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
COAD	cis	rs7078219	0.505	rs41290504	ENSG00000228778.1	RP11-129J12.1	-6.33	1.1e-09	1.08e-06	-0.41	-0.37	Dental caries;	chr10:99533278	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs7908704	ENSG00000228778.1	RP11-129J12.1	-6.33	1.1e-09	1.08e-06	-0.41	-0.37	Dental caries;	chr10:99533561	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs7893840	ENSG00000228778.1	RP11-129J12.1	-6.33	1.1e-09	1.08e-06	-0.41	-0.37	Dental caries;	chr10:99533584	chr10:99527081~99528261:+
COAD	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	6.33	1.1e-09	1.09e-06	0.38	0.37	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
COAD	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	6.33	1.1e-09	1.09e-06	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
COAD	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	6.33	1.11e-09	1.09e-06	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
COAD	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-6.33	1.11e-09	1.1e-06	-0.47	-0.37	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
COAD	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	6.33	1.11e-09	1.1e-06	0.46	0.37	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
COAD	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	6.33	1.11e-09	1.1e-06	0.39	0.37	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
COAD	cis	rs7078219	0.543	rs4919342	ENSG00000228778.1	RP11-129J12.1	-6.33	1.11e-09	1.1e-06	-0.41	-0.37	Dental caries;	chr10:99522796	chr10:99527081~99528261:+
COAD	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	6.32	1.12e-09	1.11e-06	0.54	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
COAD	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	6.32	1.12e-09	1.11e-06	0.39	0.37	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
COAD	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.32	1.12e-09	1.11e-06	-0.46	-0.37	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
COAD	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.32	1.13e-09	1.11e-06	0.38	0.37	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	6.32	1.13e-09	1.11e-06	0.38	0.37	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
COAD	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	6.32	1.13e-09	1.11e-06	0.51	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
COAD	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-6.32	1.14e-09	1.12e-06	-0.46	-0.37	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
COAD	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	6.32	1.14e-09	1.12e-06	0.45	0.37	Height;	chr6:109458989	chr6:109382795~109383666:+
COAD	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	-6.32	1.14e-09	1.12e-06	-0.41	-0.37	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
COAD	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.32	1.14e-09	1.12e-06	0.43	0.37	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
COAD	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	6.32	1.14e-09	1.12e-06	0.43	0.37	Height;	chr3:53082835	chr3:53064283~53065091:-
COAD	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-6.32	1.14e-09	1.12e-06	-0.44	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
COAD	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	6.32	1.14e-09	1.13e-06	0.42	0.37	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
COAD	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	6.32	1.15e-09	1.13e-06	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	6.32	1.15e-09	1.13e-06	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
COAD	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-6.32	1.15e-09	1.13e-06	-0.44	-0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
COAD	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	6.32	1.15e-09	1.14e-06	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
COAD	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.32	1.16e-09	1.14e-06	0.38	0.37	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
COAD	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	6.32	1.16e-09	1.14e-06	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
COAD	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	6.32	1.17e-09	1.15e-06	0.39	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
COAD	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-6.32	1.17e-09	1.15e-06	-0.46	-0.37	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-6.32	1.17e-09	1.15e-06	-0.46	-0.37	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-6.32	1.17e-09	1.15e-06	-0.46	-0.37	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-6.32	1.17e-09	1.15e-06	-0.46	-0.37	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
COAD	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-6.32	1.17e-09	1.15e-06	-0.46	-0.37	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-6.32	1.17e-09	1.15e-06	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
COAD	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-6.32	1.17e-09	1.15e-06	-0.37	-0.37	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
COAD	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-6.32	1.18e-09	1.15e-06	-0.38	-0.37	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-6.32	1.18e-09	1.15e-06	-0.38	-0.37	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	6.32	1.18e-09	1.16e-06	0.43	0.37	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
COAD	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	6.31	1.18e-09	1.16e-06	0.4	0.37	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
COAD	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-6.31	1.19e-09	1.17e-06	-0.45	-0.37	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
COAD	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-6.31	1.19e-09	1.17e-06	-0.45	-0.37	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
COAD	cis	rs7078219	1	rs7078219	ENSG00000228778.1	RP11-129J12.1	6.31	1.19e-09	1.17e-06	0.41	0.37	Dental caries;	chr10:99514608	chr10:99527081~99528261:+
COAD	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-6.31	1.19e-09	1.17e-06	-0.44	-0.37	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
COAD	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-6.31	1.2e-09	1.17e-06	-0.49	-0.37	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-6.31	1.2e-09	1.17e-06	-0.49	-0.37	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
COAD	cis	rs10885997	1	rs10885997	ENSG00000266200.5	PNLIPRP2	6.31	1.2e-09	1.17e-06	0.44	0.37	Phospholipid levels (plasma);	chr10:116638460	chr10:116620953~116645143:+
COAD	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	6.31	1.2e-09	1.17e-06	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
COAD	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-6.31	1.2e-09	1.18e-06	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
COAD	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.31	1.2e-09	1.18e-06	0.44	0.37	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	6.31	1.2e-09	1.18e-06	0.45	0.37	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
COAD	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.31	1.21e-09	1.18e-06	-0.45	-0.37	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
COAD	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	6.31	1.21e-09	1.18e-06	0.48	0.37	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
COAD	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.31	1.21e-09	1.18e-06	-0.41	-0.37	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
COAD	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	6.31	1.21e-09	1.19e-06	0.55	0.37	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
COAD	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	6.31	1.21e-09	1.19e-06	0.55	0.37	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
COAD	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	6.31	1.22e-09	1.19e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	6.31	1.22e-09	1.19e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
COAD	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	6.31	1.22e-09	1.19e-06	0.5	0.37	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
COAD	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	6.31	1.22e-09	1.19e-06	0.45	0.37	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
COAD	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-6.31	1.22e-09	1.19e-06	-0.49	-0.37	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-6.31	1.22e-09	1.19e-06	-0.49	-0.37	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
COAD	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	6.31	1.22e-09	1.19e-06	0.73	0.37	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
COAD	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	6.31	1.22e-09	1.19e-06	0.73	0.37	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
COAD	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	6.31	1.22e-09	1.19e-06	0.73	0.37	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
COAD	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	6.31	1.22e-09	1.19e-06	0.73	0.37	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
COAD	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	6.31	1.22e-09	1.2e-06	0.52	0.37	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
COAD	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.31	1.23e-09	1.2e-06	0.48	0.37	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
COAD	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-6.31	1.23e-09	1.2e-06	-0.42	-0.37	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
COAD	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.31	1.23e-09	1.2e-06	0.45	0.37	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
COAD	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.31	1.24e-09	1.21e-06	-0.53	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
COAD	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-6.31	1.24e-09	1.21e-06	-0.44	-0.37	Migraine;	chr4:56940917	chr4:56960927~56961373:-
COAD	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	6.31	1.25e-09	1.22e-06	0.45	0.37	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
COAD	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-6.31	1.25e-09	1.22e-06	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
COAD	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	6.3	1.25e-09	1.22e-06	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
COAD	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-6.3	1.25e-09	1.22e-06	-0.36	-0.37	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
COAD	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	6.3	1.25e-09	1.22e-06	0.27	0.37	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	6.3	1.25e-09	1.22e-06	0.27	0.37	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	6.3	1.25e-09	1.22e-06	0.27	0.37	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	6.3	1.25e-09	1.22e-06	0.27	0.37	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
COAD	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-6.3	1.26e-09	1.23e-06	-0.42	-0.37	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
COAD	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-6.3	1.26e-09	1.23e-06	-0.46	-0.37	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
COAD	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-6.3	1.26e-09	1.23e-06	-0.46	-0.37	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
COAD	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	6.3	1.26e-09	1.23e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	6.3	1.26e-09	1.23e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
COAD	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	6.3	1.27e-09	1.23e-06	0.38	0.37	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
COAD	cis	rs1056107	0.831	rs10981305	ENSG00000225513.1	RP11-165N19.2	-6.3	1.27e-09	1.24e-06	-0.43	-0.37	Colorectal cancer;	chr9:112197858	chr9:112173522~112173971:-
COAD	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-6.3	1.27e-09	1.24e-06	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-6.3	1.28e-09	1.24e-06	-0.4	-0.37	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-6.3	1.28e-09	1.24e-06	-0.4	-0.37	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
COAD	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	6.3	1.28e-09	1.25e-06	0.41	0.37	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
COAD	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	6.3	1.29e-09	1.25e-06	0.34	0.37	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
COAD	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	6.3	1.29e-09	1.25e-06	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
COAD	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	6.3	1.29e-09	1.25e-06	0.51	0.37	Height;	chr6:109409645	chr6:109382795~109383666:+
COAD	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	6.3	1.29e-09	1.25e-06	0.34	0.37	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
COAD	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.3	1.29e-09	1.26e-06	-0.43	-0.37	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
COAD	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-6.3	1.29e-09	1.26e-06	-0.47	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
COAD	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-6.3	1.3e-09	1.26e-06	-0.43	-0.37	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
COAD	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	6.3	1.3e-09	1.26e-06	0.46	0.37	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
COAD	cis	rs860818	1	rs860817	ENSG00000226816.2	AC005082.12	6.3	1.3e-09	1.27e-06	0.75	0.37	Initial pursuit acceleration;	chr7:23211850	chr7:23206013~23208045:+
COAD	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	6.3	1.3e-09	1.27e-06	0.42	0.37	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
COAD	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	6.3	1.3e-09	1.27e-06	0.42	0.37	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
COAD	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.3	1.31e-09	1.27e-06	0.48	0.37	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
COAD	cis	rs7078219	0.897	rs10883360	ENSG00000228778.1	RP11-129J12.1	-6.3	1.31e-09	1.27e-06	-0.4	-0.37	Dental caries;	chr10:99521401	chr10:99527081~99528261:+
COAD	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-6.3	1.31e-09	1.27e-06	-0.44	-0.37	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
COAD	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-6.3	1.31e-09	1.27e-06	-0.37	-0.37	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-6.3	1.31e-09	1.27e-06	-0.41	-0.37	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	6.3	1.31e-09	1.28e-06	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
COAD	cis	rs5758659	0.652	rs6519301	ENSG00000182057.4	OGFRP1	6.3	1.31e-09	1.28e-06	0.37	0.37	Cognitive function;	chr22:41989963	chr22:42269753~42275196:+
COAD	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-6.3	1.32e-09	1.28e-06	-0.39	-0.37	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
COAD	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-6.3	1.32e-09	1.28e-06	-0.4	-0.37	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
COAD	cis	rs1056107	0.863	rs1320460	ENSG00000225513.1	RP11-165N19.2	-6.29	1.32e-09	1.28e-06	-0.43	-0.37	Colorectal cancer;	chr9:112194345	chr9:112173522~112173971:-
COAD	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	6.29	1.33e-09	1.29e-06	0.44	0.37	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
COAD	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-6.29	1.33e-09	1.29e-06	-0.21	-0.37	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
COAD	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-6.29	1.33e-09	1.29e-06	-0.62	-0.37	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
COAD	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-6.29	1.33e-09	1.29e-06	-0.63	-0.37	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
COAD	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-6.29	1.34e-09	1.3e-06	-0.43	-0.37	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
COAD	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	6.29	1.34e-09	1.3e-06	0.45	0.37	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
COAD	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	6.29	1.34e-09	1.3e-06	0.45	0.37	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
COAD	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	6.29	1.34e-09	1.3e-06	0.45	0.37	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
COAD	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.29	1.35e-09	1.3e-06	-0.48	-0.37	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
COAD	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	6.29	1.35e-09	1.3e-06	0.45	0.37	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
COAD	cis	rs860818	1	rs858256	ENSG00000226816.2	AC005082.12	6.29	1.35e-09	1.31e-06	0.77	0.37	Initial pursuit acceleration;	chr7:23176017	chr7:23206013~23208045:+
COAD	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	6.29	1.35e-09	1.31e-06	0.38	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
COAD	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.29	1.36e-09	1.31e-06	0.59	0.37	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
COAD	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	6.29	1.36e-09	1.31e-06	0.27	0.37	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	6.29	1.36e-09	1.31e-06	0.27	0.37	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
COAD	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-6.29	1.36e-09	1.32e-06	-0.4	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
COAD	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	6.29	1.36e-09	1.32e-06	0.3	0.37	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
COAD	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	6.29	1.36e-09	1.32e-06	0.38	0.37	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
COAD	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.29	1.37e-09	1.32e-06	0.44	0.37	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
COAD	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-6.29	1.37e-09	1.33e-06	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
COAD	cis	rs4950322	0.518	rs11811023	ENSG00000278811.3	LINC00624	-6.29	1.37e-09	1.33e-06	-0.36	-0.37	Protein quantitative trait loci;	chr1:147109536	chr1:147258885~147517875:-
COAD	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	-6.29	1.38e-09	1.33e-06	-0.42	-0.37	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
COAD	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	6.29	1.38e-09	1.33e-06	0.56	0.37	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
COAD	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	6.29	1.38e-09	1.33e-06	0.56	0.37	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
COAD	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-6.29	1.38e-09	1.33e-06	-0.52	-0.37	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
COAD	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.29	1.38e-09	1.33e-06	0.4	0.37	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
COAD	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	6.29	1.38e-09	1.33e-06	0.52	0.37	Height;	chr6:109352277	chr6:109382795~109383666:+
COAD	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-6.29	1.38e-09	1.34e-06	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
COAD	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.29	1.38e-09	1.34e-06	0.39	0.37	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
COAD	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-6.29	1.39e-09	1.34e-06	-0.47	-0.37	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
COAD	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	6.29	1.39e-09	1.34e-06	0.4	0.37	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
COAD	cis	rs7078219	0.965	rs11190126	ENSG00000228778.1	RP11-129J12.1	-6.29	1.39e-09	1.34e-06	-0.4	-0.37	Dental caries;	chr10:99512032	chr10:99527081~99528261:+
COAD	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-6.29	1.39e-09	1.34e-06	-0.62	-0.37	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
COAD	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	6.29	1.39e-09	1.35e-06	0.38	0.37	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
COAD	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-6.28	1.4e-09	1.35e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
COAD	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	6.28	1.4e-09	1.35e-06	0.43	0.36	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
COAD	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.28	1.4e-09	1.35e-06	-0.42	-0.36	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
COAD	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-6.28	1.41e-09	1.36e-06	-0.4	-0.36	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
COAD	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	6.28	1.41e-09	1.36e-06	0.4	0.36	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
COAD	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	6.28	1.41e-09	1.36e-06	0.38	0.36	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
COAD	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	6.28	1.41e-09	1.36e-06	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
COAD	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-6.28	1.41e-09	1.36e-06	-0.48	-0.36	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
COAD	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	6.28	1.41e-09	1.36e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	6.28	1.41e-09	1.36e-06	0.39	0.36	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
COAD	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-6.28	1.42e-09	1.37e-06	-0.34	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
COAD	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	6.28	1.42e-09	1.37e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
COAD	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-6.28	1.42e-09	1.37e-06	-0.35	-0.36	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
COAD	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.28	1.42e-09	1.37e-06	0.42	0.36	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
COAD	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-6.28	1.42e-09	1.37e-06	-0.44	-0.36	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
COAD	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	6.28	1.43e-09	1.37e-06	0.3	0.36	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
COAD	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	6.28	1.43e-09	1.38e-06	0.38	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
COAD	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-6.28	1.43e-09	1.38e-06	-0.42	-0.36	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
COAD	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	6.28	1.43e-09	1.38e-06	0.97	0.36	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	6.28	1.43e-09	1.38e-06	0.97	0.36	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	6.28	1.43e-09	1.38e-06	0.97	0.36	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
COAD	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	6.28	1.44e-09	1.38e-06	0.72	0.36	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
COAD	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-6.28	1.44e-09	1.39e-06	-0.38	-0.36	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
COAD	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	6.28	1.44e-09	1.39e-06	0.45	0.36	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
COAD	cis	rs10885997	0.967	rs4751994	ENSG00000266200.5	PNLIPRP2	6.28	1.45e-09	1.4e-06	0.43	0.36	Phospholipid levels (plasma);	chr10:116638048	chr10:116620953~116645143:+
COAD	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-6.28	1.46e-09	1.4e-06	-0.41	-0.36	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
COAD	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	6.28	1.46e-09	1.4e-06	0.46	0.36	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
COAD	cis	rs1790761	0.52	rs4930461	ENSG00000231793.4	DOC2GP	6.28	1.46e-09	1.41e-06	0.45	0.36	Mean corpuscular volume;	chr11:67627424	chr11:67612653~67616257:-
COAD	cis	rs1790761	0.52	rs7124513	ENSG00000231793.4	DOC2GP	-6.28	1.46e-09	1.41e-06	-0.45	-0.36	Mean corpuscular volume;	chr11:67628243	chr11:67612653~67616257:-
COAD	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	6.28	1.47e-09	1.41e-06	0.38	0.36	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	6.28	1.47e-09	1.41e-06	0.38	0.36	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	6.28	1.47e-09	1.41e-06	0.38	0.36	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
COAD	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-6.28	1.47e-09	1.42e-06	-0.44	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
COAD	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-6.27	1.48e-09	1.42e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
COAD	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-6.27	1.48e-09	1.42e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
COAD	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	6.27	1.48e-09	1.42e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
COAD	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.27	1.49e-09	1.43e-06	0.58	0.36	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
COAD	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-6.27	1.49e-09	1.43e-06	-0.45	-0.36	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
COAD	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	6.27	1.49e-09	1.43e-06	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	6.27	1.49e-09	1.43e-06	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
COAD	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-6.27	1.49e-09	1.43e-06	-0.5	-0.36	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
COAD	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	6.27	1.49e-09	1.43e-06	0.53	0.36	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
COAD	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.27	1.5e-09	1.44e-06	-0.38	-0.36	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.27	1.5e-09	1.44e-06	-0.38	-0.36	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
COAD	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	6.27	1.5e-09	1.44e-06	0.49	0.36	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	6.27	1.5e-09	1.44e-06	0.48	0.36	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	6.27	1.5e-09	1.44e-06	0.48	0.36	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
COAD	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-6.27	1.5e-09	1.44e-06	-0.41	-0.36	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
COAD	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-6.27	1.51e-09	1.45e-06	-0.45	-0.36	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
COAD	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	6.27	1.52e-09	1.45e-06	0.42	0.36	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
COAD	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-6.27	1.52e-09	1.46e-06	-0.49	-0.36	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
COAD	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	6.27	1.52e-09	1.46e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	6.27	1.52e-09	1.46e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
COAD	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-6.27	1.52e-09	1.46e-06	-0.38	-0.36	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6.27	1.52e-09	1.46e-06	-0.38	-0.36	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
COAD	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	6.27	1.53e-09	1.46e-06	0.38	0.36	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
COAD	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	6.27	1.53e-09	1.47e-06	0.45	0.36	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
COAD	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-6.27	1.53e-09	1.47e-06	-0.38	-0.36	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
COAD	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	6.27	1.54e-09	1.47e-06	0.71	0.36	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
COAD	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	6.27	1.54e-09	1.47e-06	0.26	0.36	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
COAD	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.27	1.55e-09	1.48e-06	0.48	0.36	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
COAD	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.27	1.55e-09	1.48e-06	0.48	0.36	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
COAD	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	6.27	1.55e-09	1.48e-06	0.41	0.36	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
COAD	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-6.27	1.56e-09	1.49e-06	-0.4	-0.36	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
COAD	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-6.27	1.56e-09	1.49e-06	-0.4	-0.36	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
COAD	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	6.27	1.56e-09	1.49e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
COAD	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-6.27	1.56e-09	1.49e-06	-0.4	-0.36	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
COAD	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-6.27	1.56e-09	1.49e-06	-0.54	-0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
COAD	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-6.27	1.56e-09	1.49e-06	-0.54	-0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
COAD	cis	rs860818	1	rs858254	ENSG00000226816.2	AC005082.12	6.27	1.56e-09	1.49e-06	0.78	0.36	Initial pursuit acceleration;	chr7:23177584	chr7:23206013~23208045:+
COAD	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-6.27	1.56e-09	1.49e-06	-0.34	-0.36	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
COAD	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-6.26	1.56e-09	1.49e-06	-0.43	-0.36	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
COAD	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	6.26	1.56e-09	1.49e-06	0.61	0.36	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	6.26	1.56e-09	1.49e-06	0.61	0.36	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
COAD	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	6.26	1.58e-09	1.51e-06	0.39	0.36	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
COAD	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-6.26	1.58e-09	1.51e-06	-0.52	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
COAD	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-6.26	1.58e-09	1.51e-06	-0.46	-0.36	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
COAD	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	6.26	1.59e-09	1.52e-06	0.42	0.36	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
COAD	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	6.26	1.61e-09	1.54e-06	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
COAD	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	6.26	1.62e-09	1.54e-06	0.43	0.36	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
COAD	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-6.26	1.62e-09	1.54e-06	-0.45	-0.36	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
COAD	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	6.26	1.63e-09	1.55e-06	0.38	0.36	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	6.26	1.63e-09	1.55e-06	0.38	0.36	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	6.26	1.63e-09	1.55e-06	0.38	0.36	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
COAD	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-6.26	1.63e-09	1.55e-06	-0.43	-0.36	Migraine;	chr4:56937339	chr4:56960927~56961373:-
COAD	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6.26	1.64e-09	1.55e-06	-0.38	-0.36	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6.26	1.64e-09	1.55e-06	-0.38	-0.36	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6.26	1.64e-09	1.55e-06	0.38	0.36	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
COAD	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	6.26	1.64e-09	1.56e-06	0.41	0.36	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
COAD	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	6.26	1.64e-09	1.56e-06	0.38	0.36	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-6.26	1.64e-09	1.56e-06	-0.49	-0.36	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-6.26	1.64e-09	1.56e-06	-0.49	-0.36	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
COAD	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-6.26	1.64e-09	1.56e-06	-0.37	-0.36	Asthma;	chr2:102392894	chr2:102438713~102440475:+
COAD	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	6.26	1.64e-09	1.56e-06	0.38	0.36	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
COAD	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-6.26	1.64e-09	1.56e-06	-0.48	-0.36	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
COAD	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.26	1.65e-09	1.56e-06	0.45	0.36	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	6.26	1.65e-09	1.57e-06	0.48	0.36	Height;	chr6:109436760	chr6:109382795~109383666:+
COAD	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-6.26	1.65e-09	1.57e-06	-0.44	-0.36	Migraine;	chr4:56943905	chr4:56960927~56961373:-
COAD	cis	rs860818	1	rs858302	ENSG00000226816.2	AC005082.12	6.25	1.65e-09	1.57e-06	0.8	0.36	Initial pursuit acceleration;	chr7:23204624	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858301	ENSG00000226816.2	AC005082.12	6.25	1.65e-09	1.57e-06	0.8	0.36	Initial pursuit acceleration;	chr7:23204704	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	6.25	1.65e-09	1.57e-06	0.8	0.36	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	6.25	1.65e-09	1.57e-06	0.8	0.36	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
COAD	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-6.25	1.65e-09	1.57e-06	-0.54	-0.36	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
COAD	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-6.25	1.66e-09	1.57e-06	-0.46	-0.36	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
COAD	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	6.25	1.66e-09	1.57e-06	0.56	0.36	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
COAD	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	6.25	1.66e-09	1.57e-06	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
COAD	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-6.25	1.66e-09	1.57e-06	-0.43	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
COAD	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	6.25	1.67e-09	1.58e-06	0.34	0.36	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-6.25	1.67e-09	1.58e-06	-0.43	-0.36	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
COAD	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.25	1.67e-09	1.59e-06	-0.38	-0.36	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
COAD	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-6.25	1.68e-09	1.59e-06	-0.44	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
COAD	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-6.25	1.68e-09	1.59e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
COAD	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-6.25	1.68e-09	1.59e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
COAD	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-6.25	1.69e-09	1.6e-06	-0.32	-0.36	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
COAD	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-6.25	1.69e-09	1.6e-06	-0.44	-0.36	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
COAD	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	6.25	1.69e-09	1.6e-06	0.31	0.36	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
COAD	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	6.25	1.7e-09	1.61e-06	0.41	0.36	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
COAD	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	6.25	1.7e-09	1.61e-06	0.4	0.36	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
COAD	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	6.25	1.7e-09	1.61e-06	0.44	0.36	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
COAD	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	6.25	1.7e-09	1.61e-06	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
COAD	cis	rs4568518	0.53	rs11764965	ENSG00000279048.1	RP11-511H23.2	6.25	1.7e-09	1.61e-06	0.26	0.36	Measles;	chr7:17959127	chr7:17940503~17942922:+
COAD	cis	rs7615952	0.688	rs7624806	ENSG00000248787.1	RP11-666A20.4	-6.25	1.7e-09	1.61e-06	-0.51	-0.36	Blood pressure (smoking interaction);	chr3:125880231	chr3:125908005~125910272:-
COAD	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	6.25	1.71e-09	1.61e-06	0.46	0.36	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
COAD	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-6.25	1.71e-09	1.62e-06	-0.45	-0.36	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
COAD	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-6.25	1.71e-09	1.62e-06	-0.4	-0.36	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
COAD	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-6.25	1.72e-09	1.62e-06	-0.4	-0.36	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
COAD	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-6.25	1.72e-09	1.62e-06	-0.4	-0.36	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
COAD	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	6.25	1.72e-09	1.63e-06	0.55	0.36	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
COAD	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	6.25	1.72e-09	1.63e-06	0.71	0.36	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
COAD	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	6.25	1.73e-09	1.63e-06	0.32	0.36	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
COAD	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-6.25	1.73e-09	1.63e-06	-0.31	-0.36	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-6.25	1.73e-09	1.63e-06	-0.31	-0.36	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
COAD	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	6.25	1.73e-09	1.64e-06	0.8	0.36	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
COAD	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	6.25	1.73e-09	1.64e-06	0.46	0.36	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
COAD	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	6.25	1.73e-09	1.64e-06	0.38	0.36	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
COAD	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	6.25	1.74e-09	1.65e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
COAD	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-6.24	1.75e-09	1.65e-06	-0.51	-0.36	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-6.24	1.76e-09	1.66e-06	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
COAD	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-6.24	1.76e-09	1.66e-06	-0.46	-0.36	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
COAD	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-6.24	1.76e-09	1.66e-06	-0.36	-0.36	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
COAD	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-6.24	1.76e-09	1.66e-06	-0.43	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
COAD	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.24	1.77e-09	1.67e-06	0.38	0.36	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
COAD	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-6.24	1.78e-09	1.68e-06	-0.36	-0.36	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
COAD	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	6.24	1.78e-09	1.68e-06	0.46	0.36	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
COAD	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	6.24	1.78e-09	1.68e-06	0.46	0.36	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
COAD	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-6.24	1.78e-09	1.68e-06	-0.31	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
COAD	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.24	1.78e-09	1.68e-06	-0.4	-0.36	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
COAD	cis	rs1790761	0.52	rs12805884	ENSG00000231793.4	DOC2GP	-6.24	1.79e-09	1.69e-06	-0.45	-0.36	Mean corpuscular volume;	chr11:67620506	chr11:67612653~67616257:-
COAD	cis	rs754466	0.606	rs55854323	ENSG00000204049.1	RP11-126H7.4	6.24	1.79e-09	1.69e-06	0.47	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830146	chr10:77866875~77869610:+
COAD	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	6.24	1.79e-09	1.69e-06	0.42	0.36	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	6.24	1.79e-09	1.69e-06	0.42	0.36	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
COAD	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-6.24	1.79e-09	1.69e-06	-0.49	-0.36	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
COAD	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	6.24	1.8e-09	1.69e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	6.24	1.8e-09	1.69e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
COAD	cis	rs7078219	1	rs11190130	ENSG00000228778.1	RP11-129J12.1	-6.24	1.8e-09	1.7e-06	-0.4	-0.36	Dental caries;	chr10:99515449	chr10:99527081~99528261:+
COAD	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-6.24	1.8e-09	1.7e-06	-0.31	-0.36	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
COAD	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	6.24	1.8e-09	1.7e-06	0.74	0.36	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
COAD	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	6.24	1.8e-09	1.7e-06	0.43	0.36	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
COAD	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.24	1.81e-09	1.7e-06	0.37	0.36	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
COAD	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-6.24	1.81e-09	1.7e-06	-0.43	-0.36	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
COAD	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-6.24	1.81e-09	1.71e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
COAD	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	6.24	1.82e-09	1.71e-06	0.47	0.36	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
COAD	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-6.24	1.83e-09	1.72e-06	-0.42	-0.36	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
COAD	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.24	1.83e-09	1.72e-06	-0.46	-0.36	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
COAD	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.24	1.83e-09	1.72e-06	-0.46	-0.36	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
COAD	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	6.24	1.83e-09	1.72e-06	0.53	0.36	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
COAD	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	6.24	1.84e-09	1.73e-06	0.39	0.36	Height;	chr11:118758322	chr11:118704607~118750263:+
COAD	cis	rs987724	0.727	rs6776157	ENSG00000240875.4	LINC00886	-6.24	1.84e-09	1.73e-06	-0.34	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156825693	chr3:156747346~156817062:-
COAD	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	6.23	1.85e-09	1.73e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
COAD	cis	rs1056107	0.897	rs1972322	ENSG00000225513.1	RP11-165N19.2	-6.23	1.85e-09	1.74e-06	-0.42	-0.36	Colorectal cancer;	chr9:112197447	chr9:112173522~112173971:-
COAD	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	6.23	1.85e-09	1.74e-06	0.48	0.36	Height;	chr6:109581800	chr6:109382795~109383666:+
COAD	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	6.23	1.86e-09	1.74e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
COAD	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	6.23	1.86e-09	1.75e-06	0.52	0.36	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
COAD	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-6.23	1.86e-09	1.75e-06	-0.41	-0.36	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
COAD	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-6.23	1.87e-09	1.75e-06	-0.39	-0.36	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
COAD	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	6.23	1.87e-09	1.75e-06	0.41	0.36	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
COAD	cis	rs754466	0.58	rs10430529	ENSG00000204049.1	RP11-126H7.4	6.23	1.87e-09	1.76e-06	0.46	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77822865	chr10:77866875~77869610:+
COAD	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	6.23	1.87e-09	1.76e-06	0.38	0.36	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
COAD	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	6.23	1.88e-09	1.77e-06	0.43	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
COAD	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	6.23	1.89e-09	1.77e-06	0.38	0.36	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
COAD	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	6.23	1.89e-09	1.77e-06	0.38	0.36	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
COAD	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
COAD	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
COAD	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-6.23	1.89e-09	1.77e-06	-0.38	-0.36	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
COAD	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	6.23	1.89e-09	1.78e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
COAD	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-6.23	1.9e-09	1.78e-06	-0.33	-0.36	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
COAD	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	6.23	1.91e-09	1.79e-06	0.45	0.36	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
COAD	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	6.23	1.92e-09	1.8e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
COAD	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-6.23	1.92e-09	1.8e-06	-0.32	-0.36	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
COAD	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-6.23	1.92e-09	1.8e-06	-0.46	-0.36	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
COAD	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-6.23	1.92e-09	1.8e-06	-0.4	-0.36	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
COAD	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-6.23	1.92e-09	1.8e-06	-0.59	-0.36	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-6.23	1.92e-09	1.8e-06	-0.59	-0.36	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
COAD	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	6.23	1.93e-09	1.81e-06	0.42	0.36	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
COAD	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-6.23	1.94e-09	1.81e-06	-0.41	-0.36	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
COAD	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.22	1.95e-09	1.82e-06	0.38	0.36	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
COAD	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	6.22	1.95e-09	1.83e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
COAD	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	6.22	1.96e-09	1.83e-06	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
COAD	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	6.22	1.97e-09	1.84e-06	0.44	0.36	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
COAD	cis	rs10129255	0.642	rs11624918	ENSG00000223648.3	IGHV3-64	6.22	1.97e-09	1.84e-06	0.29	0.36	Kawasaki disease;	chr14:106664672	chr14:106643132~106658258:-
COAD	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	6.22	1.97e-09	1.84e-06	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
COAD	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	6.22	1.97e-09	1.84e-06	0.45	0.36	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
COAD	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-6.22	1.98e-09	1.84e-06	-0.35	-0.36	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
COAD	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	6.22	1.98e-09	1.84e-06	0.51	0.36	Height;	chr6:109564272	chr6:109382795~109383666:+
COAD	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	6.22	1.98e-09	1.84e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
COAD	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.22	1.98e-09	1.84e-06	0.48	0.36	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
COAD	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-6.22	1.98e-09	1.85e-06	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
COAD	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-6.22	2e-09	1.86e-06	-0.43	-0.36	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
COAD	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-6.22	2e-09	1.87e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
COAD	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-6.22	2.01e-09	1.87e-06	-0.42	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
COAD	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-6.22	2.01e-09	1.87e-06	-0.48	-0.36	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
COAD	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-6.22	2.01e-09	1.87e-06	-0.33	-0.36	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	6.22	2.01e-09	1.87e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	6.22	2.01e-09	1.87e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	6.22	2.01e-09	1.87e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	6.22	2.01e-09	1.87e-06	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
COAD	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-6.22	2.02e-09	1.88e-06	-0.39	-0.36	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
COAD	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-6.22	2.02e-09	1.88e-06	-0.37	-0.36	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
COAD	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-6.22	2.02e-09	1.88e-06	-0.59	-0.36	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
COAD	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-6.22	2.02e-09	1.88e-06	-0.42	-0.36	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
COAD	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	6.22	2.02e-09	1.88e-06	0.37	0.36	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
COAD	cis	rs7078219	0.58	rs10883361	ENSG00000228778.1	RP11-129J12.1	-6.22	2.04e-09	1.89e-06	-0.41	-0.36	Dental caries;	chr10:99523211	chr10:99527081~99528261:+
COAD	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	6.22	2.04e-09	1.89e-06	0.76	0.36	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	6.22	2.04e-09	1.89e-06	0.76	0.36	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	6.22	2.04e-09	1.89e-06	0.76	0.36	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	6.22	2.04e-09	1.89e-06	0.76	0.36	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
COAD	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
COAD	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	6.22	2.05e-09	1.9e-06	0.38	0.36	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
COAD	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	6.22	2.05e-09	1.9e-06	0.42	0.36	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
COAD	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-6.22	2.05e-09	1.9e-06	-0.49	-0.36	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
COAD	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-6.22	2.05e-09	1.9e-06	-0.39	-0.36	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
COAD	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	6.22	2.05e-09	1.9e-06	0.91	0.36	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	6.22	2.05e-09	1.9e-06	0.91	0.36	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	6.22	2.05e-09	1.9e-06	0.91	0.36	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	6.22	2.05e-09	1.9e-06	0.91	0.36	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
COAD	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	6.21	2.06e-09	1.91e-06	0.47	0.36	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
COAD	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-6.21	2.06e-09	1.91e-06	-0.21	-0.36	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
COAD	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-6.21	2.06e-09	1.91e-06	-0.37	-0.36	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
COAD	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-6.21	2.06e-09	1.91e-06	-0.46	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
COAD	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	6.21	2.07e-09	1.92e-06	0.67	0.36	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
COAD	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.21	2.07e-09	1.92e-06	0.47	0.36	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
COAD	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	6.21	2.07e-09	1.92e-06	0.52	0.36	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
COAD	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	6.21	2.07e-09	1.92e-06	0.74	0.36	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
COAD	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	6.21	2.09e-09	1.94e-06	0.48	0.36	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
COAD	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-6.21	2.1e-09	1.94e-06	-0.33	-0.36	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
COAD	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	6.21	2.1e-09	1.95e-06	0.48	0.36	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
COAD	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	6.21	2.12e-09	1.96e-06	0.45	0.36	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
COAD	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	6.21	2.12e-09	1.96e-06	0.32	0.36	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
COAD	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	6.21	2.12e-09	1.96e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
COAD	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	6.21	2.12e-09	1.96e-06	0.56	0.36	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
COAD	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-6.21	2.12e-09	1.97e-06	-0.38	-0.36	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
COAD	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-6.21	2.14e-09	1.98e-06	-0.38	-0.36	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
COAD	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	6.21	2.15e-09	1.99e-06	0.44	0.36	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
COAD	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	6.21	2.16e-09	1.99e-06	0.46	0.36	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
COAD	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	6.21	2.16e-09	2e-06	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
COAD	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	6.21	2.16e-09	2e-06	0.51	0.36	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
COAD	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-6.21	2.16e-09	2e-06	-0.46	-0.36	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
COAD	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	6.21	2.17e-09	2.01e-06	0.45	0.36	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
COAD	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-6.2	2.18e-09	2.01e-06	-0.41	-0.36	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
COAD	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-6.2	2.18e-09	2.02e-06	-0.41	-0.36	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
COAD	cis	rs1790761	0.554	rs12787511	ENSG00000231793.4	DOC2GP	-6.2	2.19e-09	2.02e-06	-0.46	-0.36	Mean corpuscular volume;	chr11:67634164	chr11:67612653~67616257:-
COAD	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-6.2	2.19e-09	2.02e-06	-0.32	-0.36	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
COAD	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	6.2	2.19e-09	2.02e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	6.2	2.19e-09	2.02e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	6.2	2.19e-09	2.02e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
COAD	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.2	2.19e-09	2.03e-06	-0.41	-0.36	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
COAD	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.2	2.2e-09	2.03e-06	0.38	0.36	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
COAD	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	6.2	2.2e-09	2.03e-06	0.47	0.36	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
COAD	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-6.2	2.2e-09	2.03e-06	-0.33	-0.36	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
COAD	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.2	2.21e-09	2.04e-06	0.58	0.36	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
COAD	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	6.2	2.22e-09	2.05e-06	0.5	0.36	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
COAD	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	6.2	2.23e-09	2.06e-06	0.43	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
COAD	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	6.2	2.24e-09	2.07e-06	0.42	0.36	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
COAD	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	6.2	2.25e-09	2.07e-06	0.45	0.36	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
COAD	cis	rs1056107	0.831	rs11787835	ENSG00000225513.1	RP11-165N19.2	-6.2	2.26e-09	2.08e-06	-0.43	-0.36	Colorectal cancer;	chr9:112188318	chr9:112173522~112173971:-
COAD	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-6.2	2.27e-09	2.09e-06	-0.45	-0.36	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
COAD	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	6.2	2.28e-09	2.1e-06	0.61	0.36	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	6.2	2.28e-09	2.1e-06	0.61	0.36	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	6.2	2.28e-09	2.1e-06	0.61	0.36	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
COAD	cis	rs16828019	0.777	rs35080169	ENSG00000235358.1	RP11-399E6.1	6.2	2.28e-09	2.1e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40989287	chr1:41242373~41284861:+
COAD	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-6.2	2.29e-09	2.1e-06	-0.46	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
COAD	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	6.2	2.29e-09	2.1e-06	0.56	0.36	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
COAD	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.2	2.29e-09	2.11e-06	-0.37	-0.36	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-6.2	2.3e-09	2.11e-06	-0.45	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
COAD	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-6.2	2.3e-09	2.11e-06	-0.47	-0.36	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
COAD	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	6.2	2.3e-09	2.11e-06	0.42	0.36	Height;	chr6:109471826	chr6:109382795~109383666:+
COAD	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	6.19	2.31e-09	2.12e-06	0.45	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
COAD	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-6.19	2.31e-09	2.12e-06	-0.52	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
COAD	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-6.19	2.32e-09	2.13e-06	-0.38	-0.36	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
COAD	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-6.19	2.33e-09	2.13e-06	-0.47	-0.36	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
COAD	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	6.19	2.33e-09	2.14e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	6.19	2.33e-09	2.14e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	6.19	2.33e-09	2.14e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	6.19	2.33e-09	2.14e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	6.19	2.33e-09	2.14e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
COAD	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	6.19	2.34e-09	2.14e-06	0.38	0.36	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
COAD	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	6.19	2.35e-09	2.15e-06	0.42	0.36	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
COAD	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-6.19	2.35e-09	2.15e-06	-0.51	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
COAD	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-6.19	2.35e-09	2.15e-06	-0.38	-0.36	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
COAD	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	6.19	2.35e-09	2.16e-06	0.4	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
COAD	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	6.19	2.35e-09	2.16e-06	0.72	0.36	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	6.19	2.35e-09	2.16e-06	0.38	0.36	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
COAD	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-6.19	2.36e-09	2.16e-06	-0.38	-0.36	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
COAD	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-6.19	2.37e-09	2.17e-06	-0.41	-0.36	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
COAD	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-6.19	2.37e-09	2.17e-06	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
COAD	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.19	2.37e-09	2.17e-06	0.37	0.36	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
COAD	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-6.19	2.37e-09	2.17e-06	-0.46	-0.36	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
COAD	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-6.19	2.38e-09	2.18e-06	-0.39	-0.36	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-6.19	2.38e-09	2.18e-06	-0.39	-0.36	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
COAD	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-6.19	2.39e-09	2.19e-06	-0.46	-0.36	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
COAD	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-6.19	2.39e-09	2.19e-06	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
COAD	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-6.19	2.4e-09	2.19e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-6.19	2.4e-09	2.19e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-6.19	2.4e-09	2.19e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-6.19	2.4e-09	2.19e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-6.19	2.4e-09	2.19e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
COAD	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-6.19	2.4e-09	2.19e-06	-0.34	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
COAD	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	6.19	2.4e-09	2.19e-06	0.41	0.36	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
COAD	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	6.19	2.4e-09	2.2e-06	0.42	0.36	Height;	chr2:231516534	chr2:231508426~231514339:-
COAD	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	6.19	2.4e-09	2.2e-06	0.37	0.36	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
COAD	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-6.19	2.4e-09	2.2e-06	-0.41	-0.36	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-6.19	2.4e-09	2.2e-06	-0.41	-0.36	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
COAD	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-6.19	2.41e-09	2.2e-06	-0.32	-0.36	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
COAD	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	6.19	2.41e-09	2.2e-06	0.52	0.36	Height;	chr6:109479488	chr6:109382795~109383666:+
COAD	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	6.19	2.41e-09	2.21e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
COAD	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	6.19	2.41e-09	2.21e-06	0.48	0.36	Height;	chr6:109359125	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	6.19	2.41e-09	2.21e-06	0.48	0.36	Height;	chr6:109360679	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	6.19	2.41e-09	2.21e-06	0.48	0.36	Height;	chr6:109365409	chr6:109382795~109383666:+
COAD	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	6.19	2.42e-09	2.21e-06	0.62	0.36	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
COAD	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	6.18	2.44e-09	2.23e-06	0.48	0.36	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
COAD	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	6.18	2.44e-09	2.23e-06	0.48	0.36	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
COAD	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	6.18	2.44e-09	2.23e-06	0.36	0.36	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
COAD	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-6.18	2.45e-09	2.23e-06	-0.33	-0.36	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
COAD	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-6.18	2.45e-09	2.24e-06	-0.43	-0.36	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-6.18	2.45e-09	2.24e-06	-0.43	-0.36	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
COAD	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	6.18	2.45e-09	2.24e-06	0.48	0.36	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
COAD	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-6.18	2.45e-09	2.24e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-6.18	2.45e-09	2.24e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-6.18	2.45e-09	2.24e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-6.18	2.45e-09	2.24e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
COAD	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-6.18	2.46e-09	2.24e-06	-0.31	-0.36	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
COAD	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-6.18	2.47e-09	2.25e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-6.18	2.47e-09	2.25e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-6.18	2.47e-09	2.25e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-6.18	2.47e-09	2.25e-06	-0.48	-0.36	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
COAD	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	6.18	2.48e-09	2.26e-06	0.51	0.36	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	6.18	2.48e-09	2.26e-06	0.51	0.36	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
COAD	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	6.18	2.5e-09	2.28e-06	0.43	0.36	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
COAD	cis	rs17264034	1	rs17264034	ENSG00000250786.1	SNHG18	-6.18	2.5e-09	2.28e-06	-0.53	-0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557490	chr5:9546200~9550609:+
COAD	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	6.18	2.52e-09	2.29e-06	0.44	0.36	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
COAD	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.18	2.53e-09	2.3e-06	0.47	0.36	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
COAD	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	6.18	2.54e-09	2.31e-06	0.44	0.36	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	6.18	2.54e-09	2.31e-06	0.44	0.36	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
COAD	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-6.18	2.54e-09	2.31e-06	-0.4	-0.36	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
COAD	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-6.18	2.54e-09	2.31e-06	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
COAD	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	6.18	2.55e-09	2.31e-06	0.43	0.36	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
COAD	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-6.18	2.55e-09	2.32e-06	-0.3	-0.36	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
COAD	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-6.18	2.55e-09	2.32e-06	-0.44	-0.36	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
COAD	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-6.17	2.57e-09	2.33e-06	-0.39	-0.36	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
COAD	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	6.17	2.57e-09	2.33e-06	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
COAD	cis	rs4568518	0.53	rs10269921	ENSG00000279048.1	RP11-511H23.2	6.17	2.57e-09	2.33e-06	0.25	0.36	Measles;	chr7:17958317	chr7:17940503~17942922:+
COAD	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	6.17	2.59e-09	2.35e-06	0.43	0.36	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
COAD	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-6.17	2.59e-09	2.35e-06	-0.38	-0.36	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
COAD	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	6.17	2.6e-09	2.35e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
COAD	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	6.17	2.6e-09	2.35e-06	0.47	0.36	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
COAD	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	6.17	2.6e-09	2.36e-06	0.36	0.36	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	6.17	2.6e-09	2.36e-06	0.36	0.36	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	6.17	2.6e-09	2.36e-06	0.36	0.36	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
COAD	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	6.17	2.61e-09	2.36e-06	0.44	0.36	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	6.17	2.61e-09	2.36e-06	0.44	0.36	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
COAD	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-6.17	2.61e-09	2.36e-06	-0.38	-0.36	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
COAD	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-6.17	2.61e-09	2.36e-06	-0.38	-0.36	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
COAD	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.17	2.61e-09	2.36e-06	0.43	0.36	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.17	2.61e-09	2.36e-06	0.43	0.36	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
COAD	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-6.17	2.62e-09	2.37e-06	-0.38	-0.36	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
COAD	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-6.17	2.63e-09	2.37e-06	-0.37	-0.36	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
COAD	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	6.17	2.63e-09	2.37e-06	0.36	0.36	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	6.17	2.63e-09	2.37e-06	0.36	0.36	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
COAD	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-6.17	2.63e-09	2.38e-06	-0.44	-0.36	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
COAD	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	6.17	2.64e-09	2.39e-06	0.47	0.36	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
COAD	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	6.17	2.65e-09	2.39e-06	0.47	0.36	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
COAD	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	6.17	2.65e-09	2.39e-06	0.48	0.36	Height;	chr6:109416945	chr6:109382795~109383666:+
COAD	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	6.17	2.65e-09	2.39e-06	0.47	0.36	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
COAD	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	6.17	2.65e-09	2.39e-06	0.47	0.36	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
COAD	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-6.17	2.66e-09	2.4e-06	-0.38	-0.36	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
COAD	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-6.17	2.66e-09	2.4e-06	-0.56	-0.36	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
COAD	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	6.17	2.67e-09	2.4e-06	0.55	0.36	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
COAD	cis	rs9393777	0.528	rs35982103	ENSG00000224843.5	LINC00240	6.17	2.67e-09	2.4e-06	0.62	0.36	Intelligence (multi-trait analysis);	chr6:27275355	chr6:26956992~27023924:+
COAD	cis	rs7615952	0.932	rs13321217	ENSG00000248787.1	RP11-666A20.4	-6.17	2.67e-09	2.41e-06	-0.5	-0.36	Blood pressure (smoking interaction);	chr3:125912928	chr3:125908005~125910272:-
COAD	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-6.17	2.67e-09	2.41e-06	-0.38	-0.36	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-6.17	2.67e-09	2.41e-06	-0.38	-0.36	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
COAD	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.17	2.67e-09	2.41e-06	0.44	0.36	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
COAD	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-6.17	2.67e-09	2.41e-06	-0.41	-0.36	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
COAD	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	6.17	2.68e-09	2.41e-06	0.44	0.36	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
COAD	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.17	2.69e-09	2.42e-06	-0.45	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
COAD	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-6.17	2.69e-09	2.42e-06	-0.43	-0.36	Migraine;	chr4:56950140	chr4:56960927~56961373:-
COAD	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-6.17	2.69e-09	2.43e-06	-0.43	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
COAD	cis	rs1056107	0.763	rs10759529	ENSG00000225513.1	RP11-165N19.2	-6.17	2.69e-09	2.43e-06	-0.44	-0.36	Colorectal cancer;	chr9:112176651	chr9:112173522~112173971:-
COAD	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	6.17	2.7e-09	2.43e-06	0.44	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
COAD	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	6.17	2.71e-09	2.44e-06	0.91	0.36	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
COAD	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-6.17	2.71e-09	2.44e-06	-0.44	-0.36	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
COAD	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-6.17	2.71e-09	2.44e-06	-0.44	-0.36	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-6.16	2.72e-09	2.45e-06	-0.38	-0.36	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
COAD	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	6.16	2.72e-09	2.45e-06	0.27	0.36	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	6.16	2.72e-09	2.45e-06	0.27	0.36	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	6.16	2.72e-09	2.45e-06	0.27	0.36	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
COAD	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	6.16	2.73e-09	2.46e-06	0.38	0.36	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
COAD	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-6.16	2.74e-09	2.46e-06	-0.43	-0.36	Migraine;	chr4:56956882	chr4:56960927~56961373:-
COAD	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-6.16	2.74e-09	2.46e-06	-0.38	-0.36	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-6.16	2.74e-09	2.46e-06	-0.38	-0.36	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-6.16	2.74e-09	2.46e-06	-0.38	-0.36	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-6.16	2.74e-09	2.46e-06	-0.38	-0.36	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-6.16	2.74e-09	2.46e-06	-0.38	-0.36	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
COAD	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	6.16	2.74e-09	2.47e-06	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	6.16	2.74e-09	2.47e-06	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
COAD	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-6.16	2.75e-09	2.47e-06	-0.37	-0.36	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-6.16	2.75e-09	2.47e-06	-0.37	-0.36	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
COAD	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	6.16	2.75e-09	2.47e-06	0.6	0.36	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
COAD	cis	rs754466	0.58	rs10824571	ENSG00000204049.1	RP11-126H7.4	6.16	2.75e-09	2.47e-06	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772173	chr10:77866875~77869610:+
COAD	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.16	2.75e-09	2.47e-06	-0.45	-0.36	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
COAD	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-6.16	2.76e-09	2.48e-06	-0.42	-0.36	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
COAD	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-6.16	2.76e-09	2.48e-06	-0.44	-0.36	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
COAD	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.16	2.76e-09	2.48e-06	0.38	0.36	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
COAD	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-6.16	2.77e-09	2.49e-06	-0.39	-0.36	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
COAD	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-6.16	2.77e-09	2.49e-06	-0.39	-0.36	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
COAD	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-6.16	2.78e-09	2.5e-06	-0.45	-0.36	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	6.16	2.78e-09	2.5e-06	0.4	0.36	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
COAD	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-6.16	2.79e-09	2.5e-06	-0.46	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
COAD	cis	rs860818	1	rs858232	ENSG00000226816.2	AC005082.12	6.16	2.79e-09	2.51e-06	0.82	0.36	Initial pursuit acceleration;	chr7:23202100	chr7:23206013~23208045:+
COAD	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	6.16	2.8e-09	2.51e-06	0.37	0.36	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
COAD	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	6.16	2.8e-09	2.51e-06	0.31	0.36	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
COAD	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-6.16	2.81e-09	2.52e-06	-0.46	-0.36	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
COAD	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	6.16	2.81e-09	2.52e-06	0.48	0.36	Height;	chr6:109373851	chr6:109382795~109383666:+
COAD	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	6.16	2.81e-09	2.52e-06	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
COAD	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	6.16	2.81e-09	2.52e-06	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
COAD	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-6.16	2.81e-09	2.52e-06	-0.39	-0.36	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
COAD	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	6.16	2.82e-09	2.53e-06	0.51	0.36	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
COAD	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	6.16	2.83e-09	2.53e-06	0.55	0.36	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
COAD	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-6.16	2.83e-09	2.54e-06	-0.39	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
COAD	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	6.16	2.84e-09	2.54e-06	0.42	0.36	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
COAD	cis	rs1056107	0.831	rs10125827	ENSG00000225513.1	RP11-165N19.2	6.16	2.84e-09	2.54e-06	0.42	0.36	Colorectal cancer;	chr9:112182226	chr9:112173522~112173971:-
COAD	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	6.16	2.84e-09	2.54e-06	0.4	0.36	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
COAD	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	6.16	2.85e-09	2.56e-06	0.52	0.36	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
COAD	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	6.16	2.86e-09	2.56e-06	0.26	0.36	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
COAD	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	6.16	2.86e-09	2.56e-06	0.62	0.36	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
COAD	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	6.16	2.86e-09	2.56e-06	0.47	0.36	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
COAD	cis	rs9393777	0.557	rs7759741	ENSG00000224843.5	LINC00240	6.15	2.88e-09	2.58e-06	0.62	0.36	Intelligence (multi-trait analysis);	chr6:27273264	chr6:26956992~27023924:+
COAD	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	6.15	2.89e-09	2.58e-06	0.43	0.36	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
COAD	cis	rs58873874	0.579	rs56666304	ENSG00000248544.2	CTB-47B11.3	6.15	2.91e-09	2.6e-06	0.64	0.36	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157375741~157384950:-
COAD	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-6.15	2.91e-09	2.6e-06	-0.52	-0.36	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
COAD	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	6.15	2.91e-09	2.6e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
COAD	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	6.15	2.91e-09	2.61e-06	0.39	0.36	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
COAD	cis	rs4950322	0.515	rs11239954	ENSG00000278811.3	LINC00624	6.15	2.92e-09	2.61e-06	0.34	0.36	Protein quantitative trait loci;	chr1:147246045	chr1:147258885~147517875:-
COAD	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-6.15	2.92e-09	2.61e-06	-0.44	-0.36	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
COAD	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.15	2.92e-09	2.61e-06	-0.51	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.15	2.92e-09	2.61e-06	-0.51	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
COAD	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-6.15	2.93e-09	2.62e-06	-0.41	-0.36	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
COAD	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	6.15	2.93e-09	2.62e-06	0.37	0.36	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	6.15	2.93e-09	2.62e-06	0.37	0.36	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
COAD	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	6.15	2.94e-09	2.63e-06	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
COAD	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	6.15	2.94e-09	2.63e-06	0.37	0.36	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
COAD	cis	rs7404843	0.925	rs72774861	ENSG00000263335.1	AF001548.5	6.15	2.94e-09	2.63e-06	0.72	0.36	Testicular germ cell tumor;	chr16:15415777	chr16:15726674~15732993:+
COAD	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	6.15	2.95e-09	2.63e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	6.15	2.95e-09	2.63e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	6.15	2.95e-09	2.63e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
COAD	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	6.15	2.95e-09	2.64e-06	0.33	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
COAD	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	6.15	2.96e-09	2.64e-06	0.71	0.36	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
COAD	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	6.15	2.96e-09	2.64e-06	0.71	0.36	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
COAD	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	6.15	2.97e-09	2.65e-06	0.51	0.36	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
COAD	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.15	2.97e-09	2.65e-06	0.37	0.36	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
COAD	cis	rs1056107	0.731	rs10114892	ENSG00000225513.1	RP11-165N19.2	-6.15	2.97e-09	2.65e-06	-0.45	-0.36	Colorectal cancer;	chr9:112173696	chr9:112173522~112173971:-
COAD	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	6.15	2.97e-09	2.65e-06	0.47	0.36	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
COAD	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	6.15	2.99e-09	2.66e-06	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
COAD	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-6.15	2.99e-09	2.67e-06	-0.61	-0.36	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
COAD	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-6.15	2.99e-09	2.67e-06	-0.61	-0.36	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
COAD	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-6.15	3.02e-09	2.69e-06	-0.54	-0.36	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
COAD	cis	rs1056107	0.831	rs7856196	ENSG00000225513.1	RP11-165N19.2	-6.15	3.03e-09	2.7e-06	-0.43	-0.36	Colorectal cancer;	chr9:112181635	chr9:112173522~112173971:-
COAD	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	6.15	3.03e-09	2.7e-06	0.37	0.36	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
COAD	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	6.15	3.03e-09	2.7e-06	0.48	0.36	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
COAD	cis	rs754466	0.58	rs11002289	ENSG00000204049.1	RP11-126H7.4	6.14	3.04e-09	2.71e-06	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772822	chr10:77866875~77869610:+
COAD	cis	rs7078219	0.505	rs10883372	ENSG00000228778.1	RP11-129J12.1	-6.14	3.04e-09	2.71e-06	-0.4	-0.36	Dental caries;	chr10:99532726	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.505	rs10883373	ENSG00000228778.1	RP11-129J12.1	-6.14	3.04e-09	2.71e-06	-0.4	-0.36	Dental caries;	chr10:99532727	chr10:99527081~99528261:+
COAD	cis	rs7078219	1	rs7081330	ENSG00000228778.1	RP11-129J12.1	-6.14	3.05e-09	2.71e-06	-0.39	-0.36	Dental caries;	chr10:99514708	chr10:99527081~99528261:+
COAD	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.14	3.06e-09	2.72e-06	0.58	0.36	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
COAD	cis	rs6479891	0.643	rs1255495	ENSG00000232075.1	MRPL35P2	-6.14	3.06e-09	2.72e-06	-0.74	-0.36	Arthritis (juvenile idiopathic);	chr10:63634690	chr10:63634317~63634827:-
COAD	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.14	3.07e-09	2.73e-06	0.58	0.36	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
COAD	cis	rs9368481	0.761	rs7775041	ENSG00000224843.5	LINC00240	6.14	3.08e-09	2.74e-06	0.45	0.36	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26956992~27023924:+
COAD	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	6.14	3.08e-09	2.74e-06	0.39	0.36	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
COAD	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-6.14	3.08e-09	2.74e-06	-0.45	-0.36	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
COAD	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-6.14	3.08e-09	2.74e-06	-0.45	-0.36	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
COAD	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	6.14	3.09e-09	2.75e-06	0.41	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
COAD	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	6.14	3.1e-09	2.75e-06	0.37	0.36	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	6.14	3.1e-09	2.75e-06	0.37	0.36	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
COAD	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-6.14	3.1e-09	2.76e-06	-0.42	-0.36	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
COAD	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-6.14	3.11e-09	2.76e-06	-0.41	-0.36	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
COAD	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-6.14	3.11e-09	2.76e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-6.14	3.11e-09	2.76e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-6.14	3.11e-09	2.76e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
COAD	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-6.14	3.11e-09	2.76e-06	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
COAD	cis	rs1056107	0.671	rs7875332	ENSG00000225513.1	RP11-165N19.2	6.14	3.11e-09	2.76e-06	0.44	0.36	Colorectal cancer;	chr9:112165255	chr9:112173522~112173971:-
COAD	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.77e-06	0.37	0.36	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
COAD	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.77e-06	0.37	0.36	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
COAD	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	6.14	3.13e-09	2.78e-06	0.59	0.36	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	6.14	3.13e-09	2.78e-06	0.59	0.36	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	6.14	3.13e-09	2.78e-06	0.59	0.36	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
COAD	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-6.14	3.13e-09	2.78e-06	-0.37	-0.36	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-6.14	3.13e-09	2.78e-06	-0.37	-0.36	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.78e-06	0.37	0.36	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.78e-06	0.37	0.36	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.78e-06	0.37	0.36	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.78e-06	0.37	0.36	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
COAD	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	6.14	3.13e-09	2.78e-06	0.37	0.36	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
COAD	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-6.14	3.13e-09	2.78e-06	-0.47	-0.36	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
COAD	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	6.14	3.14e-09	2.79e-06	0.64	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
COAD	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.14	3.15e-09	2.8e-06	0.47	0.36	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
COAD	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	6.14	3.16e-09	2.8e-06	0.46	0.36	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
COAD	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-6.14	3.16e-09	2.8e-06	-0.38	-0.36	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
COAD	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	6.14	3.17e-09	2.81e-06	0.43	0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
COAD	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-6.14	3.17e-09	2.81e-06	-0.41	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
COAD	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-6.14	3.18e-09	2.82e-06	-0.49	-0.36	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
COAD	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	6.14	3.18e-09	2.82e-06	0.85	0.36	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	6.14	3.18e-09	2.82e-06	0.85	0.36	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	6.14	3.18e-09	2.82e-06	0.85	0.36	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	6.14	3.18e-09	2.82e-06	0.85	0.36	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
COAD	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-6.14	3.2e-09	2.83e-06	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
COAD	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-6.14	3.2e-09	2.83e-06	-0.52	-0.36	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
COAD	cis	rs860818	1	rs858303	ENSG00000226816.2	AC005082.12	6.14	3.2e-09	2.83e-06	0.75	0.36	Initial pursuit acceleration;	chr7:23203879	chr7:23206013~23208045:+
COAD	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.14	3.2e-09	2.83e-06	-0.41	-0.36	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
COAD	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-6.13	3.23e-09	2.86e-06	-0.39	-0.36	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
COAD	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-6.13	3.24e-09	2.87e-06	-0.38	-0.36	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
COAD	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-6.13	3.25e-09	2.87e-06	-0.37	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
COAD	cis	rs5758659	0.652	rs5751195	ENSG00000182057.4	OGFRP1	6.13	3.26e-09	2.89e-06	0.37	0.36	Cognitive function;	chr22:41983997	chr22:42269753~42275196:+
COAD	cis	rs1056107	0.763	rs60623018	ENSG00000225513.1	RP11-165N19.2	-6.13	3.28e-09	2.9e-06	-0.43	-0.36	Colorectal cancer;	chr9:112175922	chr9:112173522~112173971:-
COAD	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	6.13	3.29e-09	2.91e-06	0.47	0.36	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
COAD	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	6.13	3.29e-09	2.91e-06	0.5	0.36	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
COAD	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-6.13	3.33e-09	2.94e-06	-0.33	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
COAD	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	6.13	3.36e-09	2.96e-06	0.41	0.36	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
COAD	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-6.13	3.36e-09	2.96e-06	-0.33	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
COAD	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-6.13	3.36e-09	2.96e-06	-0.33	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
COAD	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	6.13	3.37e-09	2.97e-06	0.46	0.36	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
COAD	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.13	3.38e-09	2.97e-06	-0.4	-0.36	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
COAD	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.13	3.38e-09	2.98e-06	-0.41	-0.36	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.13	3.38e-09	2.98e-06	-0.41	-0.36	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.13	3.38e-09	2.98e-06	-0.41	-0.36	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.13	3.38e-09	2.98e-06	-0.41	-0.36	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.13	3.38e-09	2.98e-06	-0.41	-0.36	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
COAD	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	6.12	3.39e-09	2.98e-06	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
COAD	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-6.12	3.39e-09	2.98e-06	-0.42	-0.36	Height;	chr2:231490121	chr2:231508426~231514339:-
COAD	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-6.12	3.39e-09	2.98e-06	-0.42	-0.36	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
COAD	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-6.12	3.39e-09	2.98e-06	-0.4	-0.36	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
COAD	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	-6.12	3.39e-09	2.99e-06	-0.39	-0.36	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
COAD	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	6.12	3.39e-09	2.99e-06	0.27	0.36	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
COAD	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-6.12	3.39e-09	2.99e-06	-0.82	-0.36	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-6.12	3.39e-09	2.99e-06	-0.82	-0.36	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
COAD	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.12	3.39e-09	2.99e-06	-0.41	-0.36	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.12	3.39e-09	2.99e-06	-0.41	-0.36	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
COAD	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.12	3.4e-09	2.99e-06	0.47	0.36	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
COAD	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	6.12	3.4e-09	2.99e-06	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
COAD	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-6.12	3.43e-09	3.02e-06	-0.41	-0.36	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
COAD	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-6.12	3.43e-09	3.02e-06	-0.44	-0.36	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
COAD	cis	rs17264034	0.95	rs17328408	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538184	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs11951006	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539123	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs11951779	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539567	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs11958229	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539877	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs78826326	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539890	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs75336098	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9540744	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs17262778	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541048	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs77836114	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541339	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs17328904	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543158	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs17328932	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543337	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs74982463	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543473	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.95	rs17263150	ENSG00000250786.1	SNHG18	6.12	3.43e-09	3.02e-06	0.6	0.36	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544166	chr5:9546200~9550609:+
COAD	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-6.12	3.44e-09	3.02e-06	-0.45	-0.36	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
COAD	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.12	3.44e-09	3.03e-06	-0.37	-0.36	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.12	3.45e-09	3.03e-06	0.38	0.36	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
COAD	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-6.12	3.45e-09	3.04e-06	-0.47	-0.36	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
COAD	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	6.12	3.46e-09	3.04e-06	0.48	0.36	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	6.12	3.46e-09	3.04e-06	0.48	0.36	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
COAD	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	6.12	3.47e-09	3.04e-06	0.82	0.36	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	6.12	3.47e-09	3.04e-06	0.82	0.36	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
COAD	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-6.12	3.47e-09	3.04e-06	-0.42	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
COAD	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-6.12	3.47e-09	3.05e-06	-0.38	-0.36	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-6.12	3.47e-09	3.05e-06	-0.38	-0.36	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-6.12	3.47e-09	3.05e-06	-0.38	-0.36	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6.12	3.47e-09	3.05e-06	-0.38	-0.36	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.12	3.47e-09	3.05e-06	-0.38	-0.36	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
COAD	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.12	3.47e-09	3.05e-06	0.42	0.36	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
COAD	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-6.12	3.49e-09	3.06e-06	-0.43	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
COAD	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-6.12	3.49e-09	3.06e-06	-0.39	-0.36	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
COAD	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
COAD	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-6.12	3.49e-09	3.07e-06	-0.38	-0.36	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
COAD	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	6.12	3.51e-09	3.08e-06	0.42	0.36	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
COAD	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-6.12	3.51e-09	3.08e-06	-0.37	-0.36	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
COAD	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	6.12	3.52e-09	3.09e-06	0.5	0.36	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
COAD	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-6.12	3.54e-09	3.1e-06	-0.41	-0.36	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-6.12	3.54e-09	3.1e-06	-0.41	-0.36	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
COAD	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.12	3.54e-09	3.11e-06	0.43	0.36	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
COAD	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-6.12	3.55e-09	3.11e-06	-0.43	-0.36	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
COAD	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.12	3.57e-09	3.13e-06	0.37	0.36	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
COAD	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	6.11	3.58e-09	3.14e-06	0.48	0.36	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
COAD	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-6.11	3.59e-09	3.15e-06	-0.59	-0.36	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
COAD	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	6.11	3.6e-09	3.15e-06	0.37	0.36	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-6.11	3.61e-09	3.16e-06	-0.37	-0.36	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
COAD	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	6.11	3.63e-09	3.18e-06	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
COAD	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-6.11	3.64e-09	3.18e-06	-0.56	-0.36	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
COAD	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.11	3.65e-09	3.2e-06	-0.37	-0.36	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
COAD	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	6.11	3.65e-09	3.2e-06	0.5	0.36	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
COAD	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	6.11	3.65e-09	3.2e-06	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
COAD	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-6.11	3.66e-09	3.2e-06	-0.37	-0.36	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
COAD	cis	rs7615952	0.546	rs4428131	ENSG00000272840.1	RP11-379B18.6	6.11	3.66e-09	3.2e-06	0.55	0.36	Blood pressure (smoking interaction);	chr3:125627635	chr3:125774714~125797953:+
COAD	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-6.11	3.66e-09	3.2e-06	-0.41	-0.36	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-6.11	3.66e-09	3.2e-06	-0.41	-0.36	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
COAD	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	6.11	3.67e-09	3.21e-06	0.37	0.36	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
COAD	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	6.11	3.68e-09	3.22e-06	0.36	0.36	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
COAD	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-6.11	3.68e-09	3.22e-06	-0.46	-0.36	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
COAD	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
COAD	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	6.11	3.68e-09	3.22e-06	0.77	0.36	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
COAD	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-6.11	3.69e-09	3.23e-06	-0.41	-0.36	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-6.11	3.69e-09	3.23e-06	-0.41	-0.36	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
COAD	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-6.11	3.69e-09	3.23e-06	-0.42	-0.36	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-6.11	3.69e-09	3.23e-06	-0.42	-0.36	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
COAD	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-6.11	3.69e-09	3.23e-06	-0.42	-0.36	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
COAD	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-6.11	3.69e-09	3.23e-06	-0.41	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
COAD	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-6.11	3.7e-09	3.23e-06	-0.39	-0.36	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
COAD	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	6.11	3.7e-09	3.24e-06	0.43	0.36	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
COAD	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	6.11	3.71e-09	3.24e-06	0.69	0.36	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
COAD	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	6.11	3.72e-09	3.25e-06	0.28	0.36	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
COAD	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-6.11	3.74e-09	3.27e-06	-0.48	-0.36	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
COAD	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-6.11	3.74e-09	3.27e-06	-0.45	-0.36	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
COAD	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.11	3.75e-09	3.27e-06	0.35	0.36	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
COAD	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	6.11	3.76e-09	3.28e-06	0.36	0.36	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
COAD	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	6.11	3.77e-09	3.29e-06	0.38	0.36	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
COAD	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	6.1	3.78e-09	3.3e-06	0.37	0.36	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	6.1	3.78e-09	3.3e-06	0.37	0.36	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
COAD	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	6.1	3.79e-09	3.3e-06	0.6	0.36	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
COAD	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-6.1	3.79e-09	3.3e-06	-0.28	-0.36	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
COAD	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-6.1	3.79e-09	3.3e-06	-0.28	-0.36	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
COAD	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	6.1	3.79e-09	3.31e-06	0.42	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
COAD	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	6.1	3.8e-09	3.32e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	6.1	3.82e-09	3.33e-06	0.39	0.36	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
COAD	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	6.1	3.83e-09	3.34e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	6.1	3.83e-09	3.34e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	6.1	3.83e-09	3.34e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
COAD	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	6.1	3.84e-09	3.35e-06	0.39	0.36	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
COAD	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-6.1	3.86e-09	3.36e-06	-0.43	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
COAD	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	6.1	3.87e-09	3.37e-06	0.48	0.36	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	6.1	3.87e-09	3.37e-06	0.38	0.36	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	6.1	3.87e-09	3.37e-06	0.38	0.36	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
COAD	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.1	3.87e-09	3.37e-06	0.38	0.36	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
COAD	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-6.1	3.87e-09	3.37e-06	-0.37	-0.36	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
COAD	cis	rs7615952	0.546	rs2979340	ENSG00000272840.1	RP11-379B18.6	6.1	3.89e-09	3.38e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:125622540	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs2979338	ENSG00000272840.1	RP11-379B18.6	6.1	3.89e-09	3.38e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:125624282	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs2922171	ENSG00000272840.1	RP11-379B18.6	6.1	3.89e-09	3.38e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:125624349	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs112919177	ENSG00000272840.1	RP11-379B18.6	6.1	3.89e-09	3.38e-06	0.54	0.36	Blood pressure (smoking interaction);	chr3:125627226	chr3:125774714~125797953:+
COAD	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	6.1	3.89e-09	3.39e-06	0.38	0.36	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
COAD	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	6.1	3.89e-09	3.39e-06	0.39	0.36	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
COAD	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.1	3.9e-09	3.39e-06	0.37	0.36	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
COAD	cis	rs7078219	0.543	rs7095491	ENSG00000228778.1	RP11-129J12.1	-6.1	3.9e-09	3.39e-06	-0.39	-0.36	Dental caries;	chr10:99514301	chr10:99527081~99528261:+
COAD	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	6.1	3.9e-09	3.4e-06	0.37	0.36	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	6.1	3.9e-09	3.4e-06	0.37	0.36	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	6.1	3.9e-09	3.4e-06	0.42	0.36	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
COAD	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	6.1	3.9e-09	3.4e-06	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
COAD	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	6.1	3.91e-09	3.4e-06	0.39	0.36	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
COAD	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.1	3.91e-09	3.4e-06	-0.44	-0.36	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
COAD	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	6.1	3.92e-09	3.41e-06	0.36	0.36	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
COAD	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.1	3.92e-09	3.41e-06	-0.5	-0.36	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
COAD	cis	rs7615952	0.611	rs2947646	ENSG00000248787.1	RP11-666A20.4	6.1	3.93e-09	3.42e-06	0.55	0.36	Blood pressure (smoking interaction);	chr3:125874759	chr3:125908005~125910272:-
COAD	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-6.1	3.95e-09	3.44e-06	-0.38	-0.36	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
COAD	cis	rs5758659	0.652	rs133321	ENSG00000182057.4	OGFRP1	6.1	3.96e-09	3.44e-06	0.36	0.36	Cognitive function;	chr22:42009318	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	6.1	3.96e-09	3.44e-06	0.36	0.36	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs133324	ENSG00000182057.4	OGFRP1	6.1	3.96e-09	3.44e-06	0.36	0.36	Cognitive function;	chr22:42010367	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	6.1	3.96e-09	3.44e-06	0.36	0.36	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs133330	ENSG00000182057.4	OGFRP1	6.1	3.96e-09	3.44e-06	0.36	0.36	Cognitive function;	chr22:42013452	chr22:42269753~42275196:+
COAD	cis	rs58873874	0.737	rs12654973	ENSG00000248544.2	CTB-47B11.3	6.1	3.97e-09	3.45e-06	0.69	0.36	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157375741~157384950:-
COAD	cis	rs58873874	0.579	rs74804793	ENSG00000248544.2	CTB-47B11.3	6.1	3.97e-09	3.45e-06	0.69	0.36	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157375741~157384950:-
COAD	cis	rs10515750	0.656	rs112839393	ENSG00000248544.2	CTB-47B11.3	6.1	3.97e-09	3.45e-06	0.69	0.36	Lung function (FEV1/FVC);	chr5:157282304	chr5:157375741~157384950:-
COAD	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	6.09	4e-09	3.47e-06	0.5	0.36	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
COAD	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.09	4.02e-09	3.49e-06	-0.37	-0.36	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
COAD	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	6.09	4.05e-09	3.52e-06	0.38	0.36	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
COAD	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	6.09	4.06e-09	3.53e-06	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
COAD	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	6.09	4.08e-09	3.54e-06	0.48	0.36	Height;	chr6:109381443	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	6.09	4.08e-09	3.54e-06	0.48	0.36	Height;	chr6:109382480	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	6.09	4.08e-09	3.54e-06	0.48	0.36	Height;	chr6:109387972	chr6:109382795~109383666:+
COAD	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	6.09	4.1e-09	3.56e-06	0.42	0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-6.09	4.1e-09	3.56e-06	-0.45	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
COAD	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	6.09	4.1e-09	3.56e-06	0.39	0.36	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
COAD	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-6.09	4.12e-09	3.57e-06	-0.43	-0.36	Migraine;	chr4:56957291	chr4:56960927~56961373:-
COAD	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	6.09	4.12e-09	3.57e-06	0.41	0.36	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
COAD	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-6.09	4.13e-09	3.58e-06	-0.38	-0.36	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
COAD	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	6.09	4.13e-09	3.58e-06	0.38	0.36	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.09	4.13e-09	3.58e-06	0.4	0.36	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
COAD	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-6.09	4.13e-09	3.58e-06	-0.42	-0.36	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
COAD	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	6.09	4.14e-09	3.59e-06	0.49	0.36	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
COAD	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	6.09	4.14e-09	3.59e-06	0.4	0.36	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
COAD	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	6.09	4.15e-09	3.6e-06	0.49	0.35	Height;	chr6:109741085	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.09	4.17e-09	3.61e-06	0.43	0.35	Height;	chr6:109370985	chr6:109382795~109383666:+
COAD	cis	rs6920372	0.731	rs9386799	ENSG00000260273.1	RP11-425D10.10	6.09	4.17e-09	3.61e-06	0.45	0.35	Height;	chr6:109333398	chr6:109382795~109383666:+
COAD	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-6.09	4.17e-09	3.61e-06	-0.45	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
COAD	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
COAD	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-6.09	4.18e-09	3.61e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
COAD	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-6.09	4.18e-09	3.62e-06	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	6.09	4.18e-09	3.62e-06	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	6.09	4.18e-09	3.62e-06	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
COAD	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-6.09	4.19e-09	3.62e-06	-0.41	-0.35	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
COAD	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.09	4.19e-09	3.63e-06	0.58	0.35	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
COAD	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-6.09	4.2e-09	3.63e-06	-0.33	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
COAD	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	6.09	4.2e-09	3.63e-06	0.36	0.35	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	6.09	4.2e-09	3.63e-06	0.36	0.35	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
COAD	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	6.09	4.21e-09	3.64e-06	0.56	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
COAD	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-6.08	4.22e-09	3.64e-06	-0.59	-0.35	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
COAD	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	6.08	4.22e-09	3.65e-06	0.41	0.35	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
COAD	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	6.08	4.23e-09	3.65e-06	0.33	0.35	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
COAD	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6.08	4.23e-09	3.66e-06	-0.37	-0.35	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	6.08	4.25e-09	3.67e-06	0.52	0.35	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
COAD	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-6.08	4.25e-09	3.67e-06	-0.41	-0.35	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
COAD	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-6.08	4.25e-09	3.67e-06	-0.39	-0.35	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
COAD	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.08	4.27e-09	3.69e-06	0.49	0.35	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
COAD	cis	rs7078219	0.543	rs10786556	ENSG00000228778.1	RP11-129J12.1	-6.08	4.27e-09	3.69e-06	-0.4	-0.35	Dental caries;	chr10:99518567	chr10:99527081~99528261:+
COAD	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.08	4.29e-09	3.7e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.08	4.29e-09	3.7e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
COAD	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.08	4.29e-09	3.7e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.08	4.29e-09	3.7e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-6.08	4.29e-09	3.7e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
COAD	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	6.08	4.3e-09	3.71e-06	0.85	0.35	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	6.08	4.3e-09	3.71e-06	0.85	0.35	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
COAD	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-6.08	4.31e-09	3.72e-06	-0.39	-0.35	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
COAD	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-6.08	4.31e-09	3.72e-06	-0.31	-0.35	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
COAD	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	6.08	4.31e-09	3.72e-06	0.58	0.35	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
COAD	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	6.08	4.33e-09	3.74e-06	0.72	0.35	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
COAD	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-6.08	4.34e-09	3.74e-06	-0.37	-0.35	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
COAD	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-6.08	4.35e-09	3.75e-06	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
COAD	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	6.08	4.36e-09	3.75e-06	0.46	0.35	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
COAD	cis	rs58873874	0.579	rs77042939	ENSG00000248544.2	CTB-47B11.3	6.08	4.37e-09	3.77e-06	0.68	0.35	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157375741~157384950:-
COAD	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	6.08	4.39e-09	3.78e-06	0.72	0.35	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
COAD	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-6.08	4.41e-09	3.8e-06	-0.47	-0.35	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
COAD	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-6.08	4.42e-09	3.81e-06	-0.39	-0.35	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
COAD	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.08	4.42e-09	3.81e-06	0.36	0.35	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
COAD	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	6.08	4.42e-09	3.81e-06	0.43	0.35	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
COAD	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-6.08	4.42e-09	3.81e-06	-0.42	-0.35	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
COAD	cis	rs12699921	0.735	rs4466298	ENSG00000279048.1	RP11-511H23.2	-6.08	4.44e-09	3.82e-06	-0.25	-0.35	Fibrinogen levels;	chr7:17952391	chr7:17940503~17942922:+
COAD	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-6.07	4.45e-09	3.83e-06	-0.4	-0.35	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
COAD	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-6.07	4.47e-09	3.84e-06	-0.42	-0.35	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-6.07	4.47e-09	3.84e-06	-0.42	-0.35	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
COAD	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	6.07	4.47e-09	3.84e-06	0.85	0.35	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
COAD	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	6.07	4.47e-09	3.84e-06	0.85	0.35	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
COAD	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.07	4.48e-09	3.85e-06	0.4	0.35	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
COAD	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-6.07	4.51e-09	3.87e-06	-0.39	-0.35	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
COAD	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-6.07	4.51e-09	3.88e-06	-0.37	-0.35	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
COAD	cis	rs1056107	0.897	rs10817282	ENSG00000225513.1	RP11-165N19.2	-6.07	4.51e-09	3.88e-06	-0.42	-0.35	Colorectal cancer;	chr9:112194636	chr9:112173522~112173971:-
COAD	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	6.07	4.55e-09	3.9e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
COAD	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	6.07	4.55e-09	3.9e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
COAD	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-6.07	4.55e-09	3.91e-06	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
COAD	cis	rs860818	1	rs858304	ENSG00000226816.2	AC005082.12	-6.07	4.56e-09	3.91e-06	-0.71	-0.35	Initial pursuit acceleration;	chr7:23203534	chr7:23206013~23208045:+
COAD	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	6.07	4.57e-09	3.92e-06	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
COAD	cis	rs1056107	0.897	rs7851034	ENSG00000225513.1	RP11-165N19.2	-6.07	4.58e-09	3.93e-06	-0.42	-0.35	Colorectal cancer;	chr9:112193100	chr9:112173522~112173971:-
COAD	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	6.07	4.59e-09	3.94e-06	0.39	0.35	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
COAD	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	6.07	4.62e-09	3.96e-06	0.38	0.35	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
COAD	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	6.07	4.62e-09	3.96e-06	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
COAD	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-6.07	4.64e-09	3.97e-06	-0.48	-0.35	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
COAD	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.07	4.65e-09	3.98e-06	-0.4	-0.35	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
COAD	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	6.07	4.68e-09	4.01e-06	0.47	0.35	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	6.07	4.68e-09	4.01e-06	0.47	0.35	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
COAD	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	6.07	4.69e-09	4.02e-06	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
COAD	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-6.06	4.71e-09	4.03e-06	-0.38	-0.35	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
COAD	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-6.06	4.71e-09	4.03e-06	-0.39	-0.35	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
COAD	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	6.06	4.71e-09	4.03e-06	0.54	0.35	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
COAD	cis	rs1056107	0.763	rs7024998	ENSG00000225513.1	RP11-165N19.2	-6.06	4.73e-09	4.05e-06	-0.44	-0.35	Colorectal cancer;	chr9:112175379	chr9:112173522~112173971:-
COAD	cis	rs1400745	0.812	rs72678789	ENSG00000258738.1	RP11-73E17.2	-6.06	4.74e-09	4.05e-06	-0.39	-0.35	Monocyte count;	chr14:34878995	chr14:34874343~34876459:+
COAD	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	6.06	4.75e-09	4.06e-06	0.5	0.35	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
COAD	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-6.06	4.79e-09	4.09e-06	-0.4	-0.35	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
COAD	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	6.06	4.81e-09	4.11e-06	0.44	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
COAD	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-6.06	4.83e-09	4.13e-06	-0.21	-0.35	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
COAD	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	6.06	4.84e-09	4.13e-06	0.58	0.35	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
COAD	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-6.06	4.85e-09	4.14e-06	-0.44	-0.35	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
COAD	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-6.06	4.85e-09	4.14e-06	-0.44	-0.35	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
COAD	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-6.06	4.85e-09	4.14e-06	-0.44	-0.35	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
COAD	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	6.06	4.86e-09	4.15e-06	0.45	0.35	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
COAD	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	6.06	4.87e-09	4.15e-06	0.39	0.35	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
COAD	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	6.06	4.87e-09	4.15e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
COAD	cis	rs453301	0.653	rs7005133	ENSG00000253981.4	ALG1L13P	6.06	4.87e-09	4.16e-06	0.43	0.35	Joint mobility (Beighton score);	chr8:9043712	chr8:8236003~8244667:-
COAD	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	6.06	4.87e-09	4.16e-06	0.47	0.35	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
COAD	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.06	4.87e-09	4.16e-06	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
COAD	cis	rs75422866	0.85	rs73111212	ENSG00000274902.1	RP1-197B17.4	6.06	4.88e-09	4.16e-06	0.95	0.35	Pneumonia;	chr12:47577638	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.85	rs73111216	ENSG00000274902.1	RP1-197B17.4	6.06	4.88e-09	4.16e-06	0.95	0.35	Pneumonia;	chr12:47577671	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.85	rs73111217	ENSG00000274902.1	RP1-197B17.4	6.06	4.88e-09	4.16e-06	0.95	0.35	Pneumonia;	chr12:47577693	chr12:47731908~47732351:+
COAD	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	6.06	4.88e-09	4.16e-06	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
COAD	cis	rs9368481	0.645	rs10456350	ENSG00000224843.5	LINC00240	-6.06	4.9e-09	4.18e-06	-0.43	-0.35	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26956992~27023924:+
COAD	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-6.06	4.9e-09	4.18e-06	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
COAD	cis	rs3126085	0.515	rs11204995	ENSG00000237975.5	FLG-AS1	6.06	4.9e-09	4.18e-06	0.39	0.35	Atopic dermatitis;	chr1:152386692	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs1923506	ENSG00000237975.5	FLG-AS1	6.06	4.9e-09	4.18e-06	0.39	0.35	Atopic dermatitis;	chr1:152387224	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs1923503	ENSG00000237975.5	FLG-AS1	6.06	4.9e-09	4.18e-06	0.39	0.35	Atopic dermatitis;	chr1:152388344	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-6.06	4.9e-09	4.18e-06	-0.37	-0.35	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
COAD	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	6.06	4.9e-09	4.18e-06	0.41	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
COAD	cis	rs4950322	0.58	rs17359629	ENSG00000278811.3	LINC00624	6.06	4.91e-09	4.19e-06	0.35	0.35	Protein quantitative trait loci;	chr1:147121537	chr1:147258885~147517875:-
COAD	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-6.06	4.92e-09	4.19e-06	-0.41	-0.35	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-6.06	4.92e-09	4.19e-06	-0.41	-0.35	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
COAD	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	6.06	4.94e-09	4.21e-06	0.4	0.35	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
COAD	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	6.05	4.96e-09	4.22e-06	0.37	0.35	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
COAD	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
COAD	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	6.05	4.96e-09	4.22e-06	0.84	0.35	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
COAD	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	6.05	4.98e-09	4.23e-06	0.77	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
COAD	cis	rs7615952	0.546	rs2922194	ENSG00000272840.1	RP11-379B18.6	6.05	5e-09	4.25e-06	0.55	0.35	Blood pressure (smoking interaction);	chr3:125613419	chr3:125774714~125797953:+
COAD	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	6.05	5e-09	4.25e-06	0.37	0.35	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
COAD	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	6.05	5e-09	4.25e-06	0.49	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
COAD	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.05	5.01e-09	4.25e-06	0.35	0.35	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
COAD	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	6.05	5.02e-09	4.27e-06	0.49	0.35	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
COAD	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.05	5.02e-09	4.27e-06	0.39	0.35	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
COAD	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.05	5.03e-09	4.27e-06	-0.4	-0.35	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
COAD	cis	rs58873874	0.737	rs10476052	ENSG00000251405.2	CTB-109A12.1	6.05	5.03e-09	4.27e-06	0.79	0.35	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157362615~157460078:-
COAD	cis	rs58873874	0.737	rs78832945	ENSG00000251405.2	CTB-109A12.1	6.05	5.03e-09	4.27e-06	0.79	0.35	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157362615~157460078:-
COAD	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	6.05	5.04e-09	4.28e-06	0.42	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	6.05	5.04e-09	4.28e-06	0.42	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
COAD	cis	rs4568518	0.53	rs12699921	ENSG00000279048.1	RP11-511H23.2	6.05	5.04e-09	4.28e-06	0.25	0.35	Measles;	chr7:17954871	chr7:17940503~17942922:+
COAD	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	6.05	5.04e-09	4.28e-06	0.54	0.35	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
COAD	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	6.05	5.04e-09	4.28e-06	0.44	0.35	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
COAD	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	6.05	5.08e-09	4.31e-06	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
COAD	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	6.05	5.09e-09	4.32e-06	0.37	0.35	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
COAD	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	6.05	5.11e-09	4.33e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
COAD	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.05	5.11e-09	4.34e-06	0.36	0.35	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
COAD	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.05	5.13e-09	4.35e-06	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
COAD	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-6.05	5.13e-09	4.35e-06	-0.4	-0.35	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
COAD	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	6.05	5.14e-09	4.35e-06	0.43	0.35	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
COAD	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-6.05	5.14e-09	4.35e-06	-0.37	-0.35	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-6.05	5.14e-09	4.36e-06	-0.42	-0.35	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
COAD	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	6.05	5.2e-09	4.4e-06	0.36	0.35	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
COAD	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	6.05	5.2e-09	4.4e-06	0.36	0.35	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
COAD	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-6.05	5.2e-09	4.4e-06	-0.45	-0.35	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
COAD	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-6.05	5.22e-09	4.41e-06	-0.28	-0.35	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
COAD	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	6.04	5.24e-09	4.43e-06	0.39	0.35	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
COAD	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	6.04	5.24e-09	4.44e-06	0.84	0.35	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
COAD	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.04	5.26e-09	4.45e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
COAD	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-6.04	5.26e-09	4.45e-06	-0.38	-0.35	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
COAD	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	6.04	5.28e-09	4.46e-06	0.55	0.35	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
COAD	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-6.04	5.31e-09	4.49e-06	-0.35	-0.35	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
COAD	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	6.04	5.33e-09	4.5e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
COAD	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	6.04	5.34e-09	4.52e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.04	5.36e-09	4.53e-06	0.54	0.35	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
COAD	cis	rs754466	0.58	rs2579176	ENSG00000204049.1	RP11-126H7.4	6.04	5.37e-09	4.53e-06	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769592	chr10:77866875~77869610:+
COAD	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	6.04	5.37e-09	4.53e-06	0.5	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
COAD	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	6.04	5.37e-09	4.53e-06	0.5	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
COAD	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	6.04	5.38e-09	4.54e-06	0.39	0.35	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
COAD	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	6.04	5.41e-09	4.56e-06	0.62	0.35	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
COAD	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.04	5.41e-09	4.56e-06	0.49	0.35	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
COAD	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-6.04	5.41e-09	4.56e-06	-0.39	-0.35	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
COAD	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	6.04	5.42e-09	4.57e-06	0.43	0.35	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
COAD	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.04	5.42e-09	4.57e-06	0.37	0.35	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	6.04	5.43e-09	4.58e-06	0.36	0.35	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
COAD	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	6.04	5.46e-09	4.6e-06	0.35	0.35	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
COAD	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	6.04	5.49e-09	4.62e-06	0.37	0.35	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
COAD	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	6.04	5.49e-09	4.62e-06	0.36	0.35	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
COAD	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-6.04	5.49e-09	4.63e-06	-0.56	-0.35	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
COAD	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.04	5.5e-09	4.63e-06	-0.39	-0.35	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
COAD	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.03	5.53e-09	4.65e-06	-0.49	-0.35	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.03	5.53e-09	4.65e-06	-0.49	-0.35	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.03	5.53e-09	4.65e-06	-0.49	-0.35	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
COAD	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	6.03	5.53e-09	4.66e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
COAD	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-6.03	5.54e-09	4.66e-06	-0.37	-0.35	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
COAD	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-6.03	5.55e-09	4.67e-06	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
COAD	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	6.03	5.56e-09	4.68e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
COAD	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-6.03	5.56e-09	4.68e-06	-0.38	-0.35	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
COAD	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-6.03	5.56e-09	4.68e-06	-0.36	-0.35	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
COAD	cis	rs1930961	1	rs6004673	ENSG00000271138.1	IGLVIVOR22-1	-6.03	5.56e-09	4.68e-06	-0.49	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25437306~25437823:-
COAD	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-6.03	5.57e-09	4.68e-06	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
COAD	cis	rs3126085	0.515	rs7514696	ENSG00000237975.5	FLG-AS1	6.03	5.59e-09	4.7e-06	0.38	0.35	Atopic dermatitis;	chr1:152391398	chr1:152168125~152445456:+
COAD	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	6.03	5.6e-09	4.71e-06	0.5	0.35	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
COAD	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-6.03	5.61e-09	4.72e-06	-0.38	-0.35	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
COAD	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-6.03	5.66e-09	4.76e-06	-0.43	-0.35	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
COAD	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	6.03	5.7e-09	4.79e-06	0.36	0.35	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
COAD	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-6.03	5.71e-09	4.79e-06	-0.43	-0.35	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
COAD	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-6.03	5.71e-09	4.79e-06	-0.43	-0.35	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
COAD	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	6.03	5.71e-09	4.79e-06	0.63	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
COAD	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	6.03	5.72e-09	4.8e-06	0.58	0.35	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
COAD	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-6.03	5.74e-09	4.82e-06	-0.44	-0.35	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
COAD	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.03	5.75e-09	4.82e-06	-0.51	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
COAD	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-6.03	5.76e-09	4.83e-06	-0.2	-0.35	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
COAD	cis	rs7404843	0.704	rs112251447	ENSG00000263335.1	AF001548.5	6.03	5.77e-09	4.84e-06	0.71	0.35	Testicular germ cell tumor;	chr16:15428015	chr16:15726674~15732993:+
COAD	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-6.03	5.77e-09	4.84e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
COAD	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-6.03	5.77e-09	4.84e-06	-0.46	-0.35	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
COAD	cis	rs58873874	0.737	rs10476050	ENSG00000251405.2	CTB-109A12.1	6.03	5.77e-09	4.84e-06	0.79	0.35	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157362615~157460078:-
COAD	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.03	5.77e-09	4.84e-06	0.36	0.35	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
COAD	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.03	5.78e-09	4.85e-06	0.35	0.35	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
COAD	cis	rs7955901	0.904	rs7313973	ENSG00000258053.1	CTD-2021H9.3	-6.03	5.78e-09	4.85e-06	-0.42	-0.35	Type 2 diabetes;	chr12:71050278	chr12:71047402~71118247:-
COAD	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	6.03	5.79e-09	4.86e-06	0.21	0.35	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
COAD	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	6.03	5.8e-09	4.86e-06	0.48	0.35	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
COAD	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	6.03	5.82e-09	4.88e-06	0.53	0.35	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
COAD	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	6.03	5.82e-09	4.88e-06	0.52	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
COAD	cis	rs12935418	0.733	rs35115578	ENSG00000261061.1	RP11-303E16.2	-6.02	5.84e-09	4.9e-06	-0.51	-0.35	Mean corpuscular volume;	chr16:80946392	chr16:81030770~81031485:+
COAD	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	6.02	5.86e-09	4.91e-06	0.37	0.35	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
COAD	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-6.02	5.87e-09	4.92e-06	-0.38	-0.35	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
COAD	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-6.02	5.88e-09	4.92e-06	-0.39	-0.35	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
COAD	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-6.02	5.88e-09	4.92e-06	-0.39	-0.35	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
COAD	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	6.02	5.88e-09	4.93e-06	0.43	0.35	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
COAD	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	6.02	5.89e-09	4.93e-06	0.37	0.35	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
COAD	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.02	5.92e-09	4.96e-06	0.37	0.35	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
COAD	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-6.02	5.93e-09	4.96e-06	-0.28	-0.35	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
COAD	cis	rs5758659	0.569	rs133294	ENSG00000182057.4	OGFRP1	6.02	5.94e-09	4.97e-06	0.37	0.35	Cognitive function;	chr22:41986801	chr22:42269753~42275196:+
COAD	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-6.02	5.98e-09	5.01e-06	-0.38	-0.35	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
COAD	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	6.02	6e-09	5.01e-06	0.45	0.35	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	6.02	6e-09	5.01e-06	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	6.02	6e-09	5.01e-06	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
COAD	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	6.02	6.02e-09	5.03e-06	0.38	0.35	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
COAD	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	6.02	6.03e-09	5.04e-06	0.47	0.35	Height;	chr6:109403951	chr6:109382795~109383666:+
COAD	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-6.02	6.04e-09	5.04e-06	-0.4	-0.35	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
COAD	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	6.02	6.05e-09	5.05e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	6.02	6.05e-09	5.05e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	6.02	6.05e-09	5.05e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	6.02	6.05e-09	5.05e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
COAD	cis	rs9393777	0.546	rs35589403	ENSG00000224843.5	LINC00240	6.02	6.07e-09	5.07e-06	0.59	0.35	Intelligence (multi-trait analysis);	chr6:27251712	chr6:26956992~27023924:+
COAD	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	6.02	6.07e-09	5.07e-06	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
COAD	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-6.02	6.13e-09	5.11e-06	-0.38	-0.35	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.546	rs11717632	ENSG00000272840.1	RP11-379B18.6	6.02	6.13e-09	5.11e-06	0.55	0.35	Blood pressure (smoking interaction);	chr3:125602286	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.546	rs2922197	ENSG00000272840.1	RP11-379B18.6	6.02	6.13e-09	5.11e-06	0.55	0.35	Blood pressure (smoking interaction);	chr3:125603188	chr3:125774714~125797953:+
COAD	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-6.02	6.14e-09	5.12e-06	-0.37	-0.35	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
COAD	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	6.02	6.14e-09	5.12e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	6.02	6.14e-09	5.12e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	6.02	6.14e-09	5.12e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
COAD	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	6.02	6.15e-09	5.13e-06	0.37	0.35	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
COAD	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.01	6.17e-09	5.14e-06	-0.4	-0.35	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.01	6.17e-09	5.14e-06	-0.4	-0.35	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
COAD	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	6.01	6.18e-09	5.15e-06	0.77	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
COAD	cis	rs4568518	0.53	rs6970593	ENSG00000279048.1	RP11-511H23.2	-6.01	6.19e-09	5.16e-06	-0.25	-0.35	Measles;	chr7:17949736	chr7:17940503~17942922:+
COAD	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	6.01	6.2e-09	5.17e-06	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
COAD	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	6.01	6.21e-09	5.18e-06	0.47	0.35	Height;	chr6:109351533	chr6:109382795~109383666:+
COAD	cis	rs453301	0.653	rs11784393	ENSG00000253981.4	ALG1L13P	6.01	6.22e-09	5.18e-06	0.42	0.35	Joint mobility (Beighton score);	chr8:9045624	chr8:8236003~8244667:-
COAD	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	6.01	6.23e-09	5.19e-06	0.5	0.35	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
COAD	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-6.01	6.24e-09	5.19e-06	-0.45	-0.35	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
COAD	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	6.01	6.24e-09	5.19e-06	0.49	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
COAD	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	6.01	6.25e-09	5.2e-06	0.63	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
COAD	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.01	6.27e-09	5.22e-06	-0.43	-0.35	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
COAD	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-6.01	6.27e-09	5.22e-06	-0.3	-0.35	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
COAD	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-6.01	6.29e-09	5.23e-06	-0.36	-0.35	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
COAD	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	6.01	6.31e-09	5.25e-06	0.37	0.35	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
COAD	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	6.01	6.33e-09	5.26e-06	0.63	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
COAD	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-6.01	6.33e-09	5.26e-06	-0.4	-0.35	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
COAD	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	6.01	6.33e-09	5.26e-06	0.35	0.35	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
COAD	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	6.01	6.37e-09	5.29e-06	0.37	0.35	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	6.01	6.37e-09	5.29e-06	0.37	0.35	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
COAD	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	6.01	6.38e-09	5.3e-06	0.43	0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
COAD	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-6.01	6.39e-09	5.3e-06	-0.41	-0.35	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
COAD	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-6.01	6.39e-09	5.3e-06	-0.41	-0.35	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
COAD	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	6.01	6.39e-09	5.3e-06	0.48	0.35	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
COAD	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	6.01	6.4e-09	5.31e-06	0.64	0.35	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
COAD	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-6.01	6.46e-09	5.36e-06	-0.32	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
COAD	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.01	6.48e-09	5.37e-06	-0.5	-0.35	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
COAD	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	6.01	6.48e-09	5.37e-06	0.43	0.35	Height;	chr6:109763331	chr6:109382795~109383666:+
COAD	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	6.01	6.49e-09	5.38e-06	0.38	0.35	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
COAD	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-6.01	6.5e-09	5.38e-06	-0.4	-0.35	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
COAD	cis	rs1056107	0.897	rs7867278	ENSG00000225513.1	RP11-165N19.2	-6	6.5e-09	5.39e-06	-0.41	-0.35	Colorectal cancer;	chr9:112196676	chr9:112173522~112173971:-
COAD	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	6	6.51e-09	5.4e-06	0.38	0.35	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
COAD	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	6	6.52e-09	5.4e-06	0.45	0.35	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
COAD	cis	rs58873874	0.737	rs11749762	ENSG00000251405.2	CTB-109A12.1	6	6.52e-09	5.4e-06	0.77	0.35	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157362615~157460078:-
COAD	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	6	6.52e-09	5.41e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
COAD	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-6	6.54e-09	5.42e-06	-0.37	-0.35	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-6	6.54e-09	5.42e-06	-0.37	-0.35	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-6	6.54e-09	5.42e-06	-0.37	-0.35	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
COAD	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-6	6.55e-09	5.42e-06	-0.41	-0.35	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
COAD	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-6	6.56e-09	5.44e-06	-0.4	-0.35	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6	6.56e-09	5.44e-06	-0.4	-0.35	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
COAD	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6	6.56e-09	5.44e-06	-0.4	-0.35	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
COAD	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-6	6.6e-09	5.46e-06	-0.43	-0.35	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
COAD	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-6	6.61e-09	5.47e-06	-0.36	-0.35	Height;	chr11:118781100	chr11:118791254~118793137:+
COAD	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	6	6.61e-09	5.47e-06	0.38	0.35	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
COAD	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6	6.64e-09	5.49e-06	-0.49	-0.35	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
COAD	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6	6.65e-09	5.5e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
COAD	cis	rs58873874	0.737	rs75326191	ENSG00000251405.2	CTB-109A12.1	6	6.66e-09	5.51e-06	0.74	0.35	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157362615~157460078:-
COAD	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-6	6.68e-09	5.53e-06	-0.46	-0.35	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
COAD	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-6	6.7e-09	5.54e-06	-0.36	-0.35	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
COAD	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	6	6.7e-09	5.54e-06	0.47	0.35	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
COAD	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
COAD	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6	6.72e-09	5.55e-06	-0.37	-0.35	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
COAD	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	6	6.74e-09	5.57e-06	0.42	0.35	Height;	chr6:109478720	chr6:109382795~109383666:+
COAD	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	6	6.74e-09	5.57e-06	0.46	0.35	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
COAD	cis	rs7078219	0.714	rs10883369	ENSG00000257582.4	LINC01475	-6	6.74e-09	5.57e-06	-0.39	-0.35	Dental caries;	chr10:99531610	chr10:99526350~99531177:-
COAD	cis	rs5769707	0.777	rs5770622	ENSG00000188511.11	C22orf34	6	6.75e-09	5.57e-06	0.37	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49657900	chr22:49414524~49657542:-
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	6	6.77e-09	5.6e-06	0.46	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
COAD	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6	6.78e-09	5.6e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6	6.78e-09	5.6e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6	6.78e-09	5.6e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6	6.78e-09	5.6e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
COAD	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-6	6.78e-09	5.6e-06	-0.35	-0.35	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
COAD	cis	rs75422866	0.85	rs73111226	ENSG00000274902.1	RP1-197B17.4	6	6.79e-09	5.61e-06	0.96	0.35	Pneumonia;	chr12:47582204	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.702	rs12426387	ENSG00000274902.1	RP1-197B17.4	6	6.79e-09	5.61e-06	0.96	0.35	Pneumonia;	chr12:47582915	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.85	rs12423789	ENSG00000274902.1	RP1-197B17.4	6	6.79e-09	5.61e-06	0.96	0.35	Pneumonia;	chr12:47583112	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.702	rs73111229	ENSG00000274902.1	RP1-197B17.4	6	6.79e-09	5.61e-06	0.96	0.35	Pneumonia;	chr12:47583333	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.85	rs73111231	ENSG00000274902.1	RP1-197B17.4	6	6.79e-09	5.61e-06	0.96	0.35	Pneumonia;	chr12:47584539	chr12:47731908~47732351:+
COAD	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6	6.81e-09	5.62e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6	6.81e-09	5.62e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
COAD	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-6	6.81e-09	5.62e-06	-0.46	-0.35	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
COAD	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-6	6.82e-09	5.62e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	6	6.83e-09	5.64e-06	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
COAD	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	6	6.86e-09	5.65e-06	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
COAD	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	6	6.86e-09	5.65e-06	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	5.99	6.87e-09	5.66e-06	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
COAD	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-5.99	6.87e-09	5.67e-06	-0.28	-0.35	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
COAD	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-5.99	6.88e-09	5.67e-06	-0.39	-0.35	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
COAD	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-5.99	6.89e-09	5.68e-06	-0.37	-0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
COAD	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-5.99	6.89e-09	5.68e-06	-0.37	-0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
COAD	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	5.99	6.92e-09	5.7e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
COAD	cis	rs17264034	0.948	rs112941079	ENSG00000250786.1	SNHG18	5.99	6.93e-09	5.71e-06	0.59	0.35	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9545986	chr5:9546200~9550609:+
COAD	cis	rs17264034	0.796	rs113140904	ENSG00000250786.1	SNHG18	5.99	6.93e-09	5.71e-06	0.59	0.35	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9546023	chr5:9546200~9550609:+
COAD	cis	rs1056107	0.931	rs2274519	ENSG00000225513.1	RP11-165N19.2	-5.99	6.95e-09	5.73e-06	-0.41	-0.35	Colorectal cancer;	chr9:112235008	chr9:112173522~112173971:-
COAD	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-5.99	6.96e-09	5.74e-06	-0.35	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
COAD	cis	rs3126085	0.515	rs11204994	ENSG00000237975.5	FLG-AS1	5.99	6.99e-09	5.76e-06	0.38	0.35	Atopic dermatitis;	chr1:152386164	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs7534951	ENSG00000237975.5	FLG-AS1	5.99	6.99e-09	5.76e-06	0.38	0.35	Atopic dermatitis;	chr1:152390496	chr1:152168125~152445456:+
COAD	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	5.99	7.05e-09	5.8e-06	0.54	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
COAD	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-5.99	7.1e-09	5.84e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
COAD	cis	rs9368481	0.761	rs6918835	ENSG00000224843.5	LINC00240	5.99	7.1e-09	5.84e-06	0.44	0.35	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26956992~27023924:+
COAD	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	5.99	7.12e-09	5.85e-06	0.36	0.35	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
COAD	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	5.99	7.12e-09	5.85e-06	0.36	0.35	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
COAD	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	5.99	7.12e-09	5.85e-06	0.36	0.35	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
COAD	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	5.99	7.12e-09	5.85e-06	0.39	0.35	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
COAD	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-5.99	7.13e-09	5.86e-06	-0.41	-0.35	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-5.99	7.13e-09	5.86e-06	-0.41	-0.35	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
COAD	cis	rs4568518	0.616	rs17661083	ENSG00000279048.1	RP11-511H23.2	5.99	7.13e-09	5.86e-06	0.25	0.35	Measles;	chr7:17965230	chr7:17940503~17942922:+
COAD	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	5.99	7.16e-09	5.89e-06	0.45	0.35	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
COAD	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-5.99	7.17e-09	5.89e-06	-0.4	-0.35	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
COAD	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	5.99	7.17e-09	5.89e-06	0.38	0.35	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
COAD	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	5.99	7.19e-09	5.91e-06	0.74	0.35	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
COAD	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	5.99	7.19e-09	5.91e-06	0.74	0.35	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
COAD	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	5.99	7.2e-09	5.91e-06	0.63	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
COAD	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.99	7.2e-09	5.92e-06	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
COAD	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-5.99	7.23e-09	5.94e-06	-0.34	-0.35	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
COAD	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-5.98	7.27e-09	5.96e-06	-0.36	-0.35	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
COAD	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-5.98	7.28e-09	5.97e-06	-0.4	-0.35	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
COAD	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.98	7.28e-09	5.97e-06	0.51	0.35	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
COAD	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	5.98	7.28e-09	5.98e-06	0.44	0.35	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
COAD	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-5.98	7.29e-09	5.98e-06	-0.4	-0.35	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-5.98	7.29e-09	5.98e-06	-0.4	-0.35	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-5.98	7.31e-09	5.99e-06	-0.4	-0.35	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-5.98	7.31e-09	5.99e-06	-0.4	-0.35	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-5.98	7.31e-09	5.99e-06	-0.4	-0.35	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
COAD	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	5.98	7.32e-09	6e-06	0.37	0.35	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
COAD	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	5.98	7.35e-09	6.03e-06	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
COAD	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-5.98	7.39e-09	6.06e-06	-0.4	-0.35	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
COAD	cis	rs1056107	0.797	rs4979087	ENSG00000225513.1	RP11-165N19.2	-5.98	7.39e-09	6.06e-06	-0.43	-0.35	Colorectal cancer;	chr9:112179920	chr9:112173522~112173971:-
COAD	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-5.98	7.41e-09	6.07e-06	-0.36	-0.35	Asthma;	chr2:102394777	chr2:102438713~102440475:+
COAD	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-5.98	7.42e-09	6.08e-06	-0.4	-0.35	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
COAD	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-5.98	7.42e-09	6.08e-06	-0.4	-0.35	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
COAD	cis	rs4568518	0.53	rs4721672	ENSG00000279048.1	RP11-511H23.2	5.98	7.45e-09	6.1e-06	0.25	0.35	Measles;	chr7:17946475	chr7:17940503~17942922:+
COAD	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	5.98	7.45e-09	6.1e-06	0.39	0.35	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
COAD	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	5.98	7.46e-09	6.1e-06	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
COAD	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	5.98	7.49e-09	6.13e-06	0.34	0.35	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
COAD	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-5.98	7.52e-09	6.15e-06	-0.43	-0.35	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
COAD	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-5.98	7.53e-09	6.16e-06	-0.41	-0.35	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
COAD	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-5.98	7.55e-09	6.17e-06	-0.45	-0.35	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
COAD	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	5.98	7.55e-09	6.18e-06	0.29	0.35	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
COAD	cis	rs4392868	0.514	rs4329243	ENSG00000245080.5	RP11-320N21.1	-5.98	7.56e-09	6.18e-06	-0.44	-0.35	Radiation response;	chr8:95093463	chr8:95066808~95073182:-
COAD	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	5.98	7.58e-09	6.2e-06	0.4	0.35	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
COAD	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-5.98	7.59e-09	6.21e-06	-0.46	-0.35	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
COAD	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-5.98	7.6e-09	6.21e-06	-0.44	-0.35	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
COAD	cis	rs5758659	0.652	rs133336	ENSG00000182057.4	OGFRP1	5.98	7.6e-09	6.21e-06	0.36	0.35	Cognitive function;	chr22:42020299	chr22:42269753~42275196:+
COAD	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-5.98	7.6e-09	6.21e-06	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
COAD	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-5.98	7.6e-09	6.21e-06	-0.39	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
COAD	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-5.98	7.61e-09	6.22e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-5.98	7.61e-09	6.22e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
COAD	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-5.97	7.65e-09	6.24e-06	-0.4	-0.35	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
COAD	cis	rs860818	1	rs1621012	ENSG00000226816.2	AC005082.12	5.97	7.65e-09	6.24e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23163714	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs1637244	ENSG00000226816.2	AC005082.12	5.97	7.65e-09	6.24e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23163715	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858315	ENSG00000226816.2	AC005082.12	5.97	7.65e-09	6.24e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23164348	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858314	ENSG00000226816.2	AC005082.12	5.97	7.65e-09	6.24e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23164932	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858313	ENSG00000226816.2	AC005082.12	5.97	7.65e-09	6.24e-06	0.79	0.35	Initial pursuit acceleration;	chr7:23165118	chr7:23206013~23208045:+
COAD	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
COAD	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
COAD	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
COAD	cis	rs860818	0.655	rs6968416	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158042	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs9639457	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158090	chr7:23206013~23208045:+
COAD	cis	rs860818	0.655	rs6461696	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158225	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs6461697	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158468	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs6949272	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158750	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs12700419	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23158881	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs7807516	ENSG00000226816.2	AC005082.12	-5.97	7.65e-09	6.24e-06	-0.79	-0.35	Initial pursuit acceleration;	chr7:23163147	chr7:23206013~23208045:+
COAD	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-5.97	7.68e-09	6.26e-06	-0.71	-0.35	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
COAD	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	5.97	7.69e-09	6.27e-06	0.38	0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
COAD	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-5.97	7.72e-09	6.29e-06	-0.28	-0.35	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
COAD	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-5.97	7.73e-09	6.3e-06	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
COAD	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-5.97	7.74e-09	6.31e-06	-0.36	-0.35	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
COAD	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	5.97	7.74e-09	6.31e-06	0.41	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
COAD	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-5.97	7.77e-09	6.33e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-5.97	7.77e-09	6.33e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
COAD	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-5.97	7.77e-09	6.33e-06	-0.37	-0.35	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
COAD	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-5.97	7.78e-09	6.34e-06	-0.46	-0.35	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
COAD	cis	rs410285	1	rs410285	ENSG00000253239.1	IGLVI-70	5.97	7.8e-09	6.35e-06	0.5	0.35	Classic bladder exstrophy;	chr22:22027370	chr22:22026076~22026593:+
COAD	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-5.97	7.8e-09	6.36e-06	-0.37	-0.35	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
COAD	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	5.97	7.8e-09	6.36e-06	0.42	0.35	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
COAD	cis	rs754466	0.58	rs1054608	ENSG00000204049.1	RP11-126H7.4	5.97	7.81e-09	6.36e-06	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77783550	chr10:77866875~77869610:+
COAD	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	5.97	7.82e-09	6.37e-06	0.43	0.35	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
COAD	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	5.97	7.84e-09	6.38e-06	0.76	0.35	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
COAD	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-5.97	7.84e-09	6.38e-06	-0.45	-0.35	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
COAD	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-5.97	7.84e-09	6.38e-06	-0.45	-0.35	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
COAD	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.97	7.85e-09	6.39e-06	-0.41	-0.35	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
COAD	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	5.97	7.86e-09	6.39e-06	0.3	0.35	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
COAD	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	5.97	7.89e-09	6.41e-06	0.36	0.35	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-5.97	7.9e-09	6.42e-06	-0.41	-0.35	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
COAD	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-5.97	7.9e-09	6.43e-06	-0.37	-0.35	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
COAD	cis	rs5758659	0.622	rs129856	ENSG00000182057.4	OGFRP1	5.97	7.92e-09	6.44e-06	0.35	0.35	Cognitive function;	chr22:42003392	chr22:42269753~42275196:+
COAD	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-5.97	7.93e-09	6.45e-06	-0.4	-0.35	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
COAD	cis	rs7078219	0.714	rs10883369	ENSG00000228778.1	RP11-129J12.1	-5.97	7.94e-09	6.45e-06	-0.39	-0.35	Dental caries;	chr10:99531610	chr10:99527081~99528261:+
COAD	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-5.97	7.94e-09	6.46e-06	-0.4	-0.35	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
COAD	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	5.97	7.96e-09	6.47e-06	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
COAD	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-5.97	7.97e-09	6.48e-06	-0.36	-0.35	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-5.97	7.97e-09	6.48e-06	-0.36	-0.35	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
COAD	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.97	7.99e-09	6.49e-06	-0.39	-0.35	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
COAD	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	5.97	7.99e-09	6.5e-06	0.46	0.35	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
COAD	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	5.97	8.02e-09	6.52e-06	0.38	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
COAD	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	5.97	8.02e-09	6.52e-06	0.42	0.35	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
COAD	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	5.97	8.03e-09	6.53e-06	0.53	0.35	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
COAD	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	5.97	8.05e-09	6.54e-06	0.4	0.35	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
COAD	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-5.96	8.07e-09	6.56e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
COAD	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-5.96	8.07e-09	6.56e-06	-0.37	-0.35	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-5.96	8.07e-09	6.56e-06	-0.37	-0.35	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-5.96	8.07e-09	6.56e-06	-0.37	-0.35	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
COAD	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-5.96	8.08e-09	6.56e-06	-0.58	-0.35	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
COAD	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-5.96	8.09e-09	6.57e-06	-0.4	-0.35	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
COAD	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-5.96	8.09e-09	6.57e-06	-0.46	-0.35	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
COAD	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	5.96	8.1e-09	6.58e-06	0.34	0.35	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
COAD	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-5.96	8.13e-09	6.59e-06	-0.39	-0.35	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
COAD	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-5.96	8.15e-09	6.61e-06	-0.4	-0.35	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
COAD	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-5.96	8.16e-09	6.61e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
COAD	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.96	8.18e-09	6.63e-06	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
COAD	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	5.96	8.18e-09	6.63e-06	0.44	0.35	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
COAD	cis	rs7615952	0.736	rs9866347	ENSG00000248787.1	RP11-666A20.4	-5.96	8.19e-09	6.64e-06	-0.52	-0.35	Blood pressure (smoking interaction);	chr3:125951082	chr3:125908005~125910272:-
COAD	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	5.96	8.19e-09	6.64e-06	0.38	0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
COAD	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-5.96	8.21e-09	6.65e-06	-0.3	-0.35	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
COAD	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-5.96	8.22e-09	6.66e-06	-0.52	-0.35	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
COAD	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5.96	8.22e-09	6.66e-06	0.34	0.35	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
COAD	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-5.96	8.22e-09	6.66e-06	-0.34	-0.35	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
COAD	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-5.96	8.26e-09	6.69e-06	-0.45	-0.35	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-5.96	8.26e-09	6.69e-06	-0.45	-0.35	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
COAD	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.96	8.26e-09	6.69e-06	-0.44	-0.35	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
COAD	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	5.96	8.27e-09	6.69e-06	0.36	0.35	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
COAD	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-5.96	8.3e-09	6.72e-06	-0.4	-0.35	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
COAD	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	5.96	8.32e-09	6.73e-06	0.54	0.35	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
COAD	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	5.96	8.34e-09	6.75e-06	0.41	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
COAD	cis	rs5758659	0.652	rs133303	ENSG00000182057.4	OGFRP1	5.96	8.35e-09	6.75e-06	0.36	0.35	Cognitive function;	chr22:41999238	chr22:42269753~42275196:+
COAD	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-5.96	8.37e-09	6.77e-06	-0.4	-0.35	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
COAD	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	5.96	8.38e-09	6.78e-06	0.3	0.35	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
COAD	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	5.96	8.39e-09	6.78e-06	0.53	0.35	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
COAD	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	5.96	8.39e-09	6.78e-06	0.4	0.35	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
COAD	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	5.96	8.39e-09	6.78e-06	0.44	0.35	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
COAD	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	5.96	8.42e-09	6.8e-06	0.41	0.35	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
COAD	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-5.96	8.42e-09	6.81e-06	-0.47	-0.35	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
COAD	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-5.96	8.43e-09	6.81e-06	-0.37	-0.35	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
COAD	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-5.96	8.45e-09	6.83e-06	-0.4	-0.35	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
COAD	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	5.96	8.46e-09	6.83e-06	0.29	0.35	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
COAD	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.96	8.48e-09	6.85e-06	0.34	0.35	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
COAD	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	5.96	8.48e-09	6.85e-06	0.44	0.35	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
COAD	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	5.96	8.49e-09	6.86e-06	0.3	0.35	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
COAD	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.96	8.5e-09	6.86e-06	-0.44	-0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
COAD	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102411180	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102411191	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102412435	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102412461	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102412524	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102415109	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102415289	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102417501	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102418383	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102419319	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma;	chr2:102419875	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	5.96	8.5e-09	6.86e-06	0.36	0.35	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
COAD	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	5.96	8.51e-09	6.86e-06	0.52	0.35	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
COAD	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-5.95	8.52e-09	6.87e-06	-0.44	-0.35	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
COAD	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-5.95	8.53e-09	6.89e-06	-0.36	-0.35	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
COAD	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-5.95	8.54e-09	6.89e-06	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
COAD	cis	rs11079159	0.565	rs4794563	ENSG00000263096.1	RP11-515O17.2	5.95	8.55e-09	6.9e-06	0.39	0.35	QRS duration;	chr17:55304524	chr17:55271504~55273653:-
COAD	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-5.95	8.67e-09	6.99e-06	-0.45	-0.35	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-5.95	8.67e-09	6.99e-06	-0.45	-0.35	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
COAD	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	5.95	8.67e-09	6.99e-06	0.5	0.35	Height;	chr6:109548647	chr6:109382795~109383666:+
COAD	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-5.95	8.67e-09	6.99e-06	-0.44	-0.35	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
COAD	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	5.95	8.68e-09	6.99e-06	0.35	0.35	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
COAD	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.95	8.69e-09	7e-06	0.36	0.35	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
COAD	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	5.95	8.76e-09	7.05e-06	0.39	0.35	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	5.95	8.76e-09	7.05e-06	0.39	0.35	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
COAD	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	5.95	8.79e-09	7.07e-06	0.46	0.35	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
COAD	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	5.95	8.82e-09	7.1e-06	0.44	0.35	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
COAD	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-5.95	8.83e-09	7.11e-06	-0.39	-0.35	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-5.95	8.83e-09	7.11e-06	-0.39	-0.35	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
COAD	cis	rs58873874	1	rs75720504	ENSG00000251405.2	CTB-109A12.1	5.95	8.84e-09	7.11e-06	0.83	0.35	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157362615~157460078:-
COAD	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-5.95	8.85e-09	7.12e-06	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
COAD	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	5.95	8.85e-09	7.12e-06	0.41	0.35	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
COAD	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.95	8.87e-09	7.14e-06	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
COAD	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	5.95	8.88e-09	7.14e-06	0.35	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
COAD	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-5.95	8.88e-09	7.14e-06	-0.37	-0.35	Height;	chr11:118749988	chr11:118704607~118750263:+
COAD	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	5.95	8.88e-09	7.14e-06	0.41	0.35	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
COAD	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	5.95	8.9e-09	7.15e-06	0.5	0.35	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
COAD	cis	rs4568518	0.53	rs6967917	ENSG00000279048.1	RP11-511H23.2	5.95	8.91e-09	7.16e-06	0.25	0.35	Measles;	chr7:17944674	chr7:17940503~17942922:+
COAD	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	5.95	8.94e-09	7.18e-06	0.71	0.35	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
COAD	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	5.95	8.94e-09	7.18e-06	0.71	0.35	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
COAD	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	5.95	8.96e-09	7.2e-06	0.33	0.35	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	5.95	8.97e-09	7.2e-06	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
COAD	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-5.95	8.97e-09	7.2e-06	-0.39	-0.35	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
COAD	cis	rs453301	0.598	rs2921383	ENSG00000253981.4	ALG1L13P	5.94	8.98e-09	7.22e-06	0.43	0.35	Joint mobility (Beighton score);	chr8:9034711	chr8:8236003~8244667:-
COAD	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-5.94	8.99e-09	7.22e-06	-0.38	-0.35	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
COAD	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	5.94	8.99e-09	7.22e-06	0.54	0.35	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
COAD	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	5.94	9e-09	7.23e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
COAD	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-5.94	9.02e-09	7.24e-06	-0.37	-0.35	Height;	chr11:118764443	chr11:118704607~118750263:+
COAD	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-5.94	9.03e-09	7.25e-06	-0.43	-0.35	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
COAD	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-5.94	9.04e-09	7.26e-06	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
COAD	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	5.94	9.06e-09	7.27e-06	0.42	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
COAD	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	5.94	9.08e-09	7.28e-06	0.36	0.35	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
COAD	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-5.94	9.11e-09	7.31e-06	-0.37	-0.35	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
COAD	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	5.94	9.15e-09	7.34e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
COAD	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-5.94	9.19e-09	7.37e-06	-0.43	-0.35	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
COAD	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	5.94	9.2e-09	7.37e-06	0.34	0.35	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
COAD	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	5.94	9.21e-09	7.39e-06	0.46	0.35	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
COAD	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-5.94	9.22e-09	7.39e-06	-0.58	-0.35	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
COAD	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-5.94	9.24e-09	7.4e-06	-0.46	-0.35	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-5.94	9.24e-09	7.4e-06	-0.46	-0.35	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-5.94	9.24e-09	7.4e-06	-0.46	-0.35	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-5.94	9.24e-09	7.4e-06	-0.46	-0.35	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
COAD	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	5.94	9.24e-09	7.41e-06	0.33	0.35	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
COAD	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-5.94	9.26e-09	7.43e-06	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
COAD	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	5.94	9.27e-09	7.43e-06	0.44	0.35	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
COAD	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-5.94	9.3e-09	7.45e-06	-0.35	-0.35	Asthma;	chr2:102393077	chr2:102438713~102440475:+
COAD	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	5.94	9.32e-09	7.47e-06	0.51	0.35	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
COAD	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-5.94	9.33e-09	7.47e-06	-0.44	-0.35	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
COAD	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-5.94	9.33e-09	7.47e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
COAD	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-5.94	9.33e-09	7.48e-06	-0.35	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
COAD	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	5.94	9.33e-09	7.48e-06	0.52	0.35	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
COAD	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-5.94	9.35e-09	7.48e-06	-0.37	-0.35	Height;	chr11:118761813	chr11:118704607~118750263:+
COAD	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.94	9.36e-09	7.5e-06	-0.39	-0.35	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
COAD	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	5.94	9.37e-09	7.5e-06	0.49	0.35	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
COAD	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	5.94	9.37e-09	7.51e-06	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	5.94	9.37e-09	7.51e-06	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
COAD	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	5.94	9.4e-09	7.52e-06	0.35	0.35	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
COAD	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	5.94	9.43e-09	7.54e-06	0.39	0.35	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
COAD	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	5.94	9.45e-09	7.56e-06	0.42	0.35	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
COAD	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	5.94	9.46e-09	7.56e-06	0.41	0.35	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
COAD	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	5.93	9.48e-09	7.58e-06	0.37	0.35	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
COAD	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	5.93	9.5e-09	7.6e-06	0.32	0.35	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
COAD	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	5.93	9.51e-09	7.6e-06	0.48	0.35	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
COAD	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-5.93	9.58e-09	7.65e-06	-0.37	-0.35	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
COAD	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	5.93	9.65e-09	7.7e-06	0.43	0.35	Height;	chr6:109423330	chr6:109382795~109383666:+
COAD	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	5.93	9.65e-09	7.7e-06	0.43	0.35	Height;	chr6:109423487	chr6:109382795~109383666:+
COAD	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-5.93	9.66e-09	7.71e-06	-0.41	-0.35	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
COAD	cis	rs4392868	0.514	rs2341400	ENSG00000245080.5	RP11-320N21.1	-5.93	9.67e-09	7.72e-06	-0.42	-0.35	Radiation response;	chr8:95091310	chr8:95066808~95073182:-
COAD	cis	rs453301	0.653	rs7853	ENSG00000253981.4	ALG1L13P	5.93	9.69e-09	7.73e-06	0.42	0.35	Joint mobility (Beighton score);	chr8:9033304	chr8:8236003~8244667:-
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-5.93	9.7e-09	7.74e-06	-0.42	-0.35	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
COAD	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	5.93	9.71e-09	7.74e-06	0.42	0.35	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	5.93	9.71e-09	7.74e-06	0.42	0.35	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
COAD	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	5.93	9.71e-09	7.75e-06	0.36	0.35	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
COAD	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	5.93	9.74e-09	7.77e-06	0.34	0.35	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
COAD	cis	rs1056107	0.931	rs7847972	ENSG00000225513.1	RP11-165N19.2	5.93	9.75e-09	7.78e-06	0.41	0.35	Colorectal cancer;	chr9:112214590	chr9:112173522~112173971:-
COAD	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	5.93	9.76e-09	7.78e-06	0.35	0.35	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
COAD	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	5.93	9.76e-09	7.78e-06	0.3	0.35	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
COAD	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	5.93	9.81e-09	7.82e-06	0.41	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
COAD	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.93	9.82e-09	7.82e-06	0.5	0.35	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
COAD	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-5.93	9.82e-09	7.83e-06	-0.37	-0.35	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
COAD	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	5.93	9.84e-09	7.84e-06	0.45	0.35	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
COAD	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-5.93	9.84e-09	7.84e-06	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
COAD	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-5.93	9.84e-09	7.84e-06	-0.41	-0.35	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
COAD	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	5.93	9.86e-09	7.85e-06	0.46	0.35	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
COAD	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-5.93	9.87e-09	7.85e-06	-0.36	-0.35	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-5.93	9.88e-09	7.86e-06	-0.36	-0.35	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
COAD	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	5.93	9.9e-09	7.87e-06	0.53	0.35	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
COAD	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	5.93	9.92e-09	7.88e-06	0.44	0.35	Height;	chr6:109415411	chr6:109382795~109383666:+
COAD	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	5.93	9.93e-09	7.89e-06	0.47	0.35	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
COAD	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-5.93	9.93e-09	7.9e-06	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
COAD	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-5.93	9.94e-09	7.9e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
COAD	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-5.93	9.95e-09	7.9e-06	-0.43	-0.35	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
COAD	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-5.93	9.97e-09	7.92e-06	-0.45	-0.35	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
COAD	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-5.93	9.97e-09	7.92e-06	-0.39	-0.35	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-5.93	9.97e-09	7.92e-06	-0.39	-0.35	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-5.93	9.97e-09	7.92e-06	-0.39	-0.35	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-5.93	9.97e-09	7.92e-06	-0.39	-0.35	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-5.93	9.97e-09	7.92e-06	-0.39	-0.35	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
COAD	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-5.93	9.97e-09	7.92e-06	-0.37	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
COAD	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	5.93	9.98e-09	7.93e-06	0.34	0.35	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
COAD	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.93	9.99e-09	7.93e-06	0.38	0.35	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
COAD	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-5.92	1e-08	7.97e-06	-0.39	-0.35	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-5.92	1e-08	7.97e-06	-0.39	-0.35	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-5.92	1e-08	7.97e-06	-0.39	-0.35	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
COAD	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	5.92	1e-08	7.97e-06	0.34	0.35	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
COAD	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-5.92	1.01e-08	7.99e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
COAD	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	5.92	1.01e-08	8e-06	0.32	0.35	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
COAD	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	-5.92	1.01e-08	8.02e-06	-0.4	-0.35	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
COAD	cis	rs6584283	0.713	rs1332100	ENSG00000228778.1	RP11-129J12.1	5.92	1.01e-08	8.05e-06	0.39	0.35	Ulcerative colitis;	chr10:99541589	chr10:99527081~99528261:+
COAD	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-5.92	1.02e-08	8.07e-06	-0.32	-0.35	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
COAD	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	5.92	1.02e-08	8.08e-06	0.71	0.35	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
COAD	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-5.92	1.02e-08	8.08e-06	-0.43	-0.35	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
COAD	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	5.92	1.02e-08	8.1e-06	0.51	0.35	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
COAD	cis	rs7829975	0.617	rs4841071	ENSG00000253981.4	ALG1L13P	5.92	1.02e-08	8.11e-06	0.39	0.35	Mood instability;	chr8:8933634	chr8:8236003~8244667:-
COAD	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	5.92	1.02e-08	8.12e-06	0.47	0.35	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
COAD	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	5.92	1.03e-08	8.14e-06	0.83	0.35	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	5.92	1.03e-08	8.14e-06	0.83	0.35	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
COAD	cis	rs58873874	0.737	rs9313608	ENSG00000251405.2	CTB-109A12.1	-5.92	1.03e-08	8.14e-06	-0.78	-0.35	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157362615~157460078:-
COAD	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-5.92	1.03e-08	8.16e-06	-0.42	-0.35	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
COAD	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-5.92	1.03e-08	8.17e-06	-0.37	-0.35	Height;	chr11:118742526	chr11:118704607~118750263:+
COAD	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	5.92	1.03e-08	8.19e-06	0.44	0.35	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
COAD	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	5.92	1.03e-08	8.19e-06	0.39	0.35	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
COAD	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-5.92	1.04e-08	8.21e-06	-0.42	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
COAD	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	5.92	1.04e-08	8.23e-06	0.47	0.35	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
COAD	cis	rs1056107	0.931	rs10981316	ENSG00000225513.1	RP11-165N19.2	-5.92	1.04e-08	8.26e-06	-0.4	-0.35	Colorectal cancer;	chr9:112211522	chr9:112173522~112173971:-
COAD	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-5.92	1.05e-08	8.28e-06	-0.34	-0.35	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
COAD	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-5.92	1.05e-08	8.31e-06	-0.37	-0.35	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
COAD	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	5.92	1.05e-08	8.32e-06	0.56	0.35	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
COAD	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-5.91	1.06e-08	8.33e-06	-0.37	-0.35	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-5.91	1.06e-08	8.33e-06	-0.37	-0.35	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-5.91	1.06e-08	8.34e-06	-0.37	-0.35	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
COAD	cis	rs1056107	0.931	rs7041185	ENSG00000225513.1	RP11-165N19.2	-5.91	1.06e-08	8.34e-06	-0.41	-0.35	Colorectal cancer;	chr9:112225084	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.898	rs3736985	ENSG00000225513.1	RP11-165N19.2	-5.91	1.06e-08	8.34e-06	-0.41	-0.35	Colorectal cancer;	chr9:112228093	chr9:112173522~112173971:-
COAD	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-5.91	1.06e-08	8.35e-06	-0.37	-0.35	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
COAD	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	5.91	1.06e-08	8.36e-06	0.41	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
COAD	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	5.91	1.06e-08	8.36e-06	0.2	0.35	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
COAD	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-5.91	1.06e-08	8.37e-06	-0.28	-0.35	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
COAD	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-5.91	1.06e-08	8.38e-06	-0.36	-0.35	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
COAD	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	5.91	1.06e-08	8.39e-06	0.64	0.35	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
COAD	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	5.91	1.07e-08	8.41e-06	0.62	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	5.91	1.07e-08	8.41e-06	0.62	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
COAD	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	5.91	1.07e-08	8.44e-06	0.4	0.35	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	5.91	1.07e-08	8.44e-06	0.4	0.35	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	5.91	1.07e-08	8.44e-06	0.4	0.35	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	5.91	1.07e-08	8.44e-06	0.4	0.35	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
COAD	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-5.91	1.07e-08	8.44e-06	-0.39	-0.35	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
COAD	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-5.91	1.07e-08	8.45e-06	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
COAD	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	5.91	1.07e-08	8.45e-06	0.41	0.35	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
COAD	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	5.91	1.08e-08	8.47e-06	0.43	0.35	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
COAD	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	5.91	1.08e-08	8.47e-06	0.43	0.35	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
COAD	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-5.91	1.08e-08	8.49e-06	-0.37	-0.35	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
COAD	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-5.91	1.08e-08	8.49e-06	-0.37	-0.35	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
COAD	cis	rs9368481	0.761	rs4358615	ENSG00000224843.5	LINC00240	-5.91	1.08e-08	8.49e-06	-0.41	-0.35	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26956992~27023924:+
COAD	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-5.91	1.08e-08	8.5e-06	-0.38	-0.35	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-5.91	1.08e-08	8.5e-06	-0.38	-0.35	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
COAD	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-5.91	1.08e-08	8.5e-06	-0.49	-0.35	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
COAD	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-5.91	1.08e-08	8.51e-06	-0.37	-0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
COAD	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-5.91	1.08e-08	8.51e-06	-0.37	-0.35	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
COAD	cis	rs58873874	0.579	rs35536103	ENSG00000248544.2	CTB-47B11.3	5.91	1.09e-08	8.56e-06	0.65	0.35	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157375741~157384950:-
COAD	cis	rs58873874	0.579	rs75099611	ENSG00000248544.2	CTB-47B11.3	5.91	1.09e-08	8.56e-06	0.65	0.35	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157375741~157384950:-
COAD	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-5.91	1.09e-08	8.57e-06	-0.3	-0.35	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
COAD	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-5.91	1.09e-08	8.57e-06	-0.47	-0.35	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
COAD	cis	rs4568518	0.501	rs6966247	ENSG00000279048.1	RP11-511H23.2	5.91	1.09e-08	8.6e-06	0.24	0.35	Measles;	chr7:17949624	chr7:17940503~17942922:+
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.91	1.1e-08	8.61e-06	0.39	0.35	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
COAD	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	5.91	1.1e-08	8.62e-06	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
COAD	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-5.91	1.1e-08	8.63e-06	-0.34	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
COAD	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	5.91	1.1e-08	8.63e-06	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
COAD	cis	rs4392868	0.514	rs12548426	ENSG00000245080.5	RP11-320N21.1	-5.91	1.1e-08	8.64e-06	-0.42	-0.35	Radiation response;	chr8:95092958	chr8:95066808~95073182:-
COAD	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	5.91	1.1e-08	8.65e-06	0.48	0.35	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
COAD	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-5.91	1.1e-08	8.66e-06	-0.39	-0.35	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
COAD	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-5.91	1.1e-08	8.68e-06	-0.39	-0.35	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
COAD	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-5.91	1.11e-08	8.69e-06	-0.48	-0.35	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
COAD	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	5.9	1.11e-08	8.73e-06	0.43	0.35	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
COAD	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	5.9	1.11e-08	8.74e-06	0.71	0.35	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
COAD	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.9	1.11e-08	8.74e-06	0.4	0.35	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
COAD	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	5.9	1.12e-08	8.76e-06	0.24	0.35	Measles;	chr7:17943674	chr7:17940503~17942922:+
COAD	cis	rs4392868	0.514	rs4323439	ENSG00000245080.5	RP11-320N21.1	-5.9	1.12e-08	8.79e-06	-0.43	-0.35	Radiation response;	chr8:95093533	chr8:95066808~95073182:-
COAD	cis	rs4392868	0.514	rs4236831	ENSG00000245080.5	RP11-320N21.1	-5.9	1.12e-08	8.79e-06	-0.43	-0.35	Radiation response;	chr8:95093705	chr8:95066808~95073182:-
COAD	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	5.9	1.12e-08	8.79e-06	0.37	0.35	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
COAD	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-5.9	1.12e-08	8.81e-06	-0.4	-0.35	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
COAD	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	5.9	1.13e-08	8.86e-06	0.53	0.35	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
COAD	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-5.9	1.13e-08	8.88e-06	-0.4	-0.35	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
COAD	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	5.9	1.14e-08	8.9e-06	0.37	0.35	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
COAD	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	5.9	1.14e-08	8.9e-06	0.35	0.35	Asthma;	chr2:102423587	chr2:102438713~102440475:+
COAD	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-5.9	1.14e-08	8.9e-06	-0.4	-0.35	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
COAD	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-5.9	1.14e-08	8.93e-06	-0.41	-0.35	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
COAD	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-5.9	1.15e-08	8.96e-06	-0.5	-0.35	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
COAD	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-5.9	1.15e-08	8.96e-06	-0.45	-0.35	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
COAD	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-5.9	1.15e-08	8.97e-06	-0.41	-0.35	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
COAD	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	5.9	1.15e-08	8.97e-06	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
COAD	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	5.9	1.15e-08	8.97e-06	0.43	0.35	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
COAD	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	5.9	1.15e-08	8.98e-06	0.54	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
COAD	cis	rs9368481	0.678	rs62402024	ENSG00000224843.5	LINC00240	-5.9	1.15e-08	9e-06	-0.42	-0.35	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26956992~27023924:+
COAD	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-5.9	1.16e-08	9.03e-06	-0.39	-0.35	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
COAD	cis	rs1056107	0.933	rs7866603	ENSG00000225513.1	RP11-165N19.2	-5.9	1.16e-08	9.05e-06	-0.4	-0.35	Colorectal cancer;	chr9:112202052	chr9:112173522~112173971:-
COAD	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	5.9	1.16e-08	9.05e-06	0.42	0.35	Migraine;	chr4:56881468	chr4:56960927~56961373:-
COAD	cis	rs754466	0.58	rs2579178	ENSG00000204049.1	RP11-126H7.4	-5.9	1.16e-08	9.05e-06	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769457	chr10:77866875~77869610:+
COAD	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	5.9	1.16e-08	9.07e-06	0.21	0.35	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
COAD	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	5.9	1.16e-08	9.08e-06	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
COAD	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	5.9	1.17e-08	9.15e-06	0.43	0.35	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
COAD	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	5.9	1.17e-08	9.15e-06	0.43	0.35	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
COAD	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	5.9	1.17e-08	9.15e-06	0.33	0.35	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	5.9	1.17e-08	9.15e-06	0.33	0.35	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	5.9	1.17e-08	9.15e-06	0.33	0.35	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
COAD	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	5.89	1.18e-08	9.17e-06	0.52	0.35	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
COAD	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	5.89	1.18e-08	9.18e-06	0.25	0.35	Measles;	chr7:17943746	chr7:17940503~17942922:+
COAD	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	5.89	1.18e-08	9.18e-06	0.38	0.35	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
COAD	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-5.89	1.18e-08	9.19e-06	-0.36	-0.35	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-5.89	1.18e-08	9.19e-06	-0.36	-0.35	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-5.89	1.18e-08	9.19e-06	-0.36	-0.35	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
COAD	cis	rs754466	0.58	rs1866437	ENSG00000204049.1	RP11-126H7.4	5.89	1.18e-08	9.2e-06	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77767008	chr10:77866875~77869610:+
COAD	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-5.89	1.18e-08	9.21e-06	-0.32	-0.35	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
COAD	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	5.89	1.18e-08	9.22e-06	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
COAD	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-5.89	1.18e-08	9.22e-06	-0.38	-0.35	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
COAD	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	5.89	1.18e-08	9.22e-06	0.4	0.35	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
COAD	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-5.89	1.18e-08	9.23e-06	-0.38	-0.35	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
COAD	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-5.89	1.19e-08	9.24e-06	-0.48	-0.35	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
COAD	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-5.89	1.19e-08	9.26e-06	-0.47	-0.35	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
COAD	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-5.89	1.19e-08	9.26e-06	-0.44	-0.35	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
COAD	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	5.89	1.19e-08	9.26e-06	0.63	0.34	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
COAD	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-5.89	1.19e-08	9.26e-06	-0.35	-0.34	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
COAD	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-5.89	1.19e-08	9.27e-06	-0.45	-0.34	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
COAD	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-5.89	1.19e-08	9.29e-06	-0.37	-0.34	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
COAD	cis	rs58873874	0.579	rs11738062	ENSG00000248544.2	CTB-47B11.3	5.89	1.19e-08	9.29e-06	0.6	0.34	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157375741~157384950:-
COAD	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	5.89	1.19e-08	9.29e-06	0.35	0.34	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	5.89	1.19e-08	9.29e-06	0.35	0.34	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
COAD	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-5.89	1.19e-08	9.3e-06	-0.3	-0.34	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
COAD	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	5.89	1.2e-08	9.32e-06	0.43	0.34	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
COAD	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	5.89	1.2e-08	9.32e-06	0.39	0.34	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
COAD	cis	rs754466	0.58	rs2579177	ENSG00000204049.1	RP11-126H7.4	5.89	1.2e-08	9.34e-06	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769487	chr10:77866875~77869610:+
COAD	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	5.89	1.2e-08	9.34e-06	0.49	0.34	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
COAD	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	5.89	1.2e-08	9.35e-06	0.73	0.34	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
COAD	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	5.89	1.2e-08	9.35e-06	0.42	0.34	Height;	chr6:109749564	chr6:109382795~109383666:+
COAD	cis	rs7829975	0.535	rs4841005	ENSG00000173295.6	FAM86B3P	-5.89	1.2e-08	9.38e-06	-0.41	-0.34	Mood instability;	chr8:8643720	chr8:8228595~8244865:+
COAD	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-5.89	1.21e-08	9.38e-06	-0.4	-0.34	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
COAD	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-5.89	1.21e-08	9.38e-06	-0.4	-0.34	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
COAD	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-5.89	1.21e-08	9.38e-06	-0.39	-0.34	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
COAD	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	5.89	1.21e-08	9.4e-06	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
COAD	cis	rs58873874	0.579	rs10037386	ENSG00000248544.2	CTB-47B11.3	5.89	1.21e-08	9.4e-06	0.6	0.34	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157375741~157384950:-
COAD	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-5.89	1.21e-08	9.42e-06	-0.43	-0.34	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
COAD	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	5.89	1.21e-08	9.42e-06	0.43	0.34	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
COAD	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	5.89	1.21e-08	9.42e-06	0.43	0.34	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
COAD	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	5.89	1.21e-08	9.43e-06	0.4	0.34	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
COAD	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	5.89	1.21e-08	9.43e-06	0.37	0.34	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
COAD	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-5.89	1.22e-08	9.46e-06	-0.28	-0.34	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
COAD	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-5.89	1.22e-08	9.46e-06	-0.38	-0.34	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
COAD	cis	rs5758659	0.569	rs133293	ENSG00000182057.4	OGFRP1	5.89	1.22e-08	9.48e-06	0.35	0.34	Cognitive function;	chr22:41986793	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	5.89	1.22e-08	9.48e-06	0.36	0.34	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
COAD	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-5.89	1.22e-08	9.49e-06	-0.42	-0.34	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	5.89	1.22e-08	9.5e-06	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
COAD	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-5.89	1.22e-08	9.5e-06	-0.3	-0.34	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
COAD	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	5.89	1.22e-08	9.51e-06	0.36	0.34	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
COAD	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	5.89	1.23e-08	9.53e-06	0.35	0.34	Asthma;	chr2:102446780	chr2:102438713~102440475:+
COAD	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-5.89	1.23e-08	9.53e-06	-0.55	-0.34	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
COAD	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-5.89	1.23e-08	9.56e-06	-0.45	-0.34	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
COAD	cis	rs6964833	0.554	rs2527380	ENSG00000123965.13	PMS2P5	-5.89	1.23e-08	9.57e-06	-0.48	-0.34	Menarche (age at onset);	chr7:74690372	chr7:74894116~74897835:+
COAD	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.89	1.23e-08	9.57e-06	-0.37	-0.34	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
COAD	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-5.89	1.23e-08	9.57e-06	-0.22	-0.34	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	5.89	1.23e-08	9.58e-06	0.38	0.34	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
COAD	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-5.89	1.23e-08	9.58e-06	-0.35	-0.34	Asthma;	chr2:102438096	chr2:102438713~102440475:+
COAD	cis	rs58873874	0.579	rs79615135	ENSG00000248544.2	CTB-47B11.3	5.89	1.23e-08	9.58e-06	0.65	0.34	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157375741~157384950:-
COAD	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-5.89	1.23e-08	9.58e-06	-0.38	-0.34	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
COAD	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-5.89	1.23e-08	9.59e-06	-0.48	-0.34	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-5.89	1.23e-08	9.59e-06	-0.48	-0.34	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-5.89	1.23e-08	9.59e-06	-0.48	-0.34	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-5.89	1.23e-08	9.59e-06	-0.48	-0.34	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
COAD	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	5.89	1.24e-08	9.59e-06	0.65	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
COAD	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-5.89	1.24e-08	9.59e-06	-0.45	-0.34	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
COAD	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-5.88	1.24e-08	9.61e-06	-0.23	-0.34	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
COAD	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	5.88	1.24e-08	9.61e-06	0.44	0.34	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
COAD	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	5.88	1.24e-08	9.61e-06	0.36	0.34	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	5.88	1.24e-08	9.61e-06	0.36	0.34	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
COAD	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-5.88	1.24e-08	9.62e-06	-0.37	-0.34	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
COAD	cis	rs1056107	0.931	rs3849123	ENSG00000225513.1	RP11-165N19.2	-5.88	1.24e-08	9.62e-06	-0.4	-0.34	Colorectal cancer;	chr9:112215901	chr9:112173522~112173971:-
COAD	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-5.88	1.24e-08	9.62e-06	-0.27	-0.34	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
COAD	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-5.88	1.24e-08	9.62e-06	-0.27	-0.34	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
COAD	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	5.88	1.24e-08	9.62e-06	0.41	0.34	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	5.88	1.24e-08	9.62e-06	0.41	0.34	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
COAD	cis	rs5758659	1	rs5751255	ENSG00000182057.4	OGFRP1	5.88	1.24e-08	9.64e-06	0.37	0.34	Cognitive function;	chr22:42252402	chr22:42269753~42275196:+
COAD	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	5.88	1.24e-08	9.65e-06	0.35	0.34	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
COAD	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	5.88	1.24e-08	9.66e-06	0.34	0.34	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
COAD	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	5.88	1.25e-08	9.66e-06	0.36	0.34	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
COAD	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-5.88	1.25e-08	9.67e-06	-0.37	-0.34	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
COAD	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	5.88	1.25e-08	9.68e-06	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
COAD	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-5.88	1.25e-08	9.68e-06	-0.35	-0.34	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
COAD	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-5.88	1.25e-08	9.71e-06	-0.37	-0.34	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
COAD	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-5.88	1.26e-08	9.73e-06	-0.39	-0.34	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-5.88	1.26e-08	9.74e-06	-0.39	-0.34	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-5.88	1.26e-08	9.74e-06	-0.39	-0.34	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-5.88	1.26e-08	9.74e-06	-0.39	-0.34	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
COAD	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-5.88	1.26e-08	9.75e-06	-0.37	-0.34	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
COAD	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	5.88	1.26e-08	9.78e-06	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	5.88	1.26e-08	9.78e-06	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	5.88	1.26e-08	9.78e-06	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	5.88	1.26e-08	9.78e-06	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5.88	1.26e-08	9.78e-06	-0.43	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
COAD	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	5.88	1.26e-08	9.78e-06	0.35	0.34	Asthma;	chr2:102437614	chr2:102438713~102440475:+
COAD	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-5.88	1.26e-08	9.78e-06	-0.34	-0.34	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
COAD	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-5.88	1.27e-08	9.8e-06	-0.37	-0.34	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
COAD	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	-5.88	1.27e-08	9.8e-06	-0.39	-0.34	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
COAD	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-5.88	1.27e-08	9.81e-06	-0.3	-0.34	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-5.88	1.27e-08	9.81e-06	-0.3	-0.34	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-5.88	1.27e-08	9.81e-06	-0.3	-0.34	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-5.88	1.27e-08	9.81e-06	-0.3	-0.34	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
COAD	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	5.88	1.27e-08	9.84e-06	0.39	0.34	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
COAD	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	5.88	1.27e-08	9.84e-06	0.39	0.34	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
COAD	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.88	1.27e-08	9.84e-06	-0.44	-0.34	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.88	1.27e-08	9.84e-06	-0.44	-0.34	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
COAD	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.88	1.27e-08	9.84e-06	-0.44	-0.34	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.88	1.27e-08	9.84e-06	-0.44	-0.34	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
COAD	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	5.88	1.28e-08	9.87e-06	0.34	0.34	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
COAD	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	5.88	1.28e-08	9.87e-06	0.4	0.34	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
COAD	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	5.88	1.28e-08	9.87e-06	0.35	0.34	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
COAD	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-5.88	1.28e-08	9.89e-06	-0.35	-0.34	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
COAD	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	5.88	1.28e-08	9.9e-06	0.42	0.34	Height;	chr6:109403287	chr6:109382795~109383666:+
COAD	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	5.88	1.28e-08	9.91e-06	0.4	0.34	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	5.88	1.28e-08	9.91e-06	0.4	0.34	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
COAD	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-5.88	1.28e-08	9.92e-06	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
COAD	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	5.88	1.29e-08	9.95e-06	0.41	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
COAD	cis	rs7615952	0.8	rs2062773	ENSG00000248787.1	RP11-666A20.4	-5.88	1.29e-08	9.96e-06	-0.48	-0.34	Blood pressure (smoking interaction);	chr3:125920805	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.799	rs13315434	ENSG00000248787.1	RP11-666A20.4	-5.88	1.29e-08	9.96e-06	-0.48	-0.34	Blood pressure (smoking interaction);	chr3:125922551	chr3:125908005~125910272:-
COAD	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-5.88	1.29e-08	9.96e-06	-0.3	-0.34	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
COAD	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-5.88	1.29e-08	9.97e-06	-0.41	-0.34	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
COAD	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-5.88	1.29e-08	9.97e-06	-0.41	-0.34	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
COAD	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	5.88	1.3e-08	1e-05	0.51	0.34	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
COAD	cis	rs1056107	0.897	rs10817298	ENSG00000225513.1	RP11-165N19.2	-5.88	1.3e-08	1.01e-05	-0.4	-0.34	Colorectal cancer;	chr9:112244396	chr9:112173522~112173971:-
COAD	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	5.88	1.3e-08	1.01e-05	0.4	0.34	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
COAD	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-5.87	1.31e-08	1.01e-05	-0.37	-0.34	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
COAD	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	5.87	1.31e-08	1.01e-05	0.33	0.34	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
COAD	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	5.87	1.31e-08	1.01e-05	0.43	0.34	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
COAD	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-5.87	1.31e-08	1.01e-05	-0.38	-0.34	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
COAD	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-5.87	1.32e-08	1.01e-05	-0.48	-0.34	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
COAD	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-5.87	1.32e-08	1.02e-05	-0.42	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
COAD	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	5.87	1.32e-08	1.02e-05	0.37	0.34	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
COAD	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	5.87	1.32e-08	1.02e-05	0.48	0.34	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
COAD	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	5.87	1.32e-08	1.02e-05	0.33	0.34	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
COAD	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-5.87	1.33e-08	1.02e-05	-0.33	-0.34	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
COAD	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-5.87	1.33e-08	1.02e-05	-0.4	-0.34	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
COAD	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-5.87	1.33e-08	1.02e-05	-0.39	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
COAD	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-5.87	1.33e-08	1.02e-05	-0.39	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
COAD	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-5.87	1.33e-08	1.02e-05	-0.51	-0.34	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
COAD	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	5.87	1.33e-08	1.03e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
COAD	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	5.87	1.34e-08	1.03e-05	0.51	0.34	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	5.87	1.34e-08	1.03e-05	0.51	0.34	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
COAD	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.87	1.34e-08	1.03e-05	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
COAD	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	5.87	1.34e-08	1.03e-05	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
COAD	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-5.87	1.34e-08	1.03e-05	-0.58	-0.34	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-5.87	1.34e-08	1.03e-05	-0.58	-0.34	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
COAD	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	5.87	1.34e-08	1.03e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
COAD	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	5.87	1.34e-08	1.03e-05	0.36	0.34	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
COAD	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	5.87	1.34e-08	1.03e-05	0.32	0.34	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
COAD	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	5.87	1.34e-08	1.03e-05	0.37	0.34	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
COAD	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	5.87	1.34e-08	1.03e-05	0.41	0.34	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
COAD	cis	rs9309473	0.519	rs2421586	ENSG00000163016.8	ALMS1P	-5.87	1.35e-08	1.04e-05	-0.41	-0.34	Metabolite levels;	chr2:73672592	chr2:73644919~73685576:+
COAD	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.87	1.36e-08	1.04e-05	0.33	0.34	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
COAD	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	5.87	1.36e-08	1.04e-05	0.35	0.34	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
COAD	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	5.87	1.36e-08	1.05e-05	0.64	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
COAD	cis	rs440932	1	rs440932	ENSG00000173295.6	FAM86B3P	5.87	1.37e-08	1.05e-05	0.45	0.34	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8228595~8244865:+
COAD	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	5.87	1.37e-08	1.05e-05	0.52	0.34	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
COAD	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	5.87	1.37e-08	1.05e-05	0.35	0.34	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	5.87	1.37e-08	1.05e-05	0.35	0.34	Asthma;	chr2:102388870	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	5.87	1.37e-08	1.05e-05	0.35	0.34	Asthma;	chr2:102389644	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	5.87	1.37e-08	1.05e-05	0.35	0.34	Asthma;	chr2:102389988	chr2:102438713~102440475:+
COAD	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-5.87	1.37e-08	1.05e-05	-0.38	-0.34	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
COAD	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-5.87	1.38e-08	1.05e-05	-0.39	-0.34	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-5.87	1.38e-08	1.05e-05	-0.39	-0.34	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
COAD	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-5.87	1.38e-08	1.05e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
COAD	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-5.86	1.38e-08	1.06e-05	-0.39	-0.34	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-5.86	1.38e-08	1.06e-05	-0.39	-0.34	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
COAD	cis	rs7955901	0.904	rs7138300	ENSG00000258053.1	CTD-2021H9.3	-5.86	1.38e-08	1.06e-05	-0.41	-0.34	Type 2 diabetes;	chr12:71045809	chr12:71047402~71118247:-
COAD	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.86	1.38e-08	1.06e-05	0.41	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
COAD	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-5.86	1.39e-08	1.06e-05	-0.46	-0.34	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-5.86	1.39e-08	1.06e-05	-0.46	-0.34	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
COAD	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	5.86	1.39e-08	1.06e-05	0.5	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
COAD	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-5.86	1.39e-08	1.06e-05	-0.35	-0.34	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-5.86	1.39e-08	1.06e-05	-0.35	-0.34	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-5.86	1.39e-08	1.06e-05	-0.35	-0.34	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-5.86	1.39e-08	1.06e-05	-0.35	-0.34	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
COAD	cis	rs9368481	0.761	rs3931464	ENSG00000224843.5	LINC00240	-5.86	1.39e-08	1.07e-05	-0.41	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26956992~27023924:+
COAD	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-5.86	1.39e-08	1.07e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
COAD	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-5.86	1.4e-08	1.07e-05	-0.35	-0.34	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
COAD	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-5.86	1.4e-08	1.07e-05	-0.33	-0.34	Height;	chr20:49316942	chr20:49280319~49280409:+
COAD	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-5.86	1.4e-08	1.07e-05	-0.39	-0.34	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
COAD	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	5.86	1.4e-08	1.07e-05	0.46	0.34	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
COAD	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-5.86	1.4e-08	1.07e-05	-0.39	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
COAD	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	5.86	1.4e-08	1.08e-05	0.36	0.34	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
COAD	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-5.86	1.41e-08	1.08e-05	-0.41	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
COAD	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	5.86	1.42e-08	1.08e-05	0.27	0.34	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
COAD	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-5.86	1.42e-08	1.08e-05	-0.39	-0.34	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
COAD	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	5.86	1.42e-08	1.08e-05	0.44	0.34	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
COAD	cis	rs8062405	0.728	rs8056890	ENSG00000251417.2	RP11-1348G14.4	-5.86	1.42e-08	1.09e-05	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28802743~28817828:+
COAD	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	5.86	1.43e-08	1.09e-05	0.73	0.34	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
COAD	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	5.86	1.43e-08	1.09e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
COAD	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	5.86	1.43e-08	1.09e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	5.86	1.43e-08	1.09e-05	0.44	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
COAD	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102394452	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102399227	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102402540	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102402571	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102403325	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102403679	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.09e-05	0.35	0.34	Asthma;	chr2:102404807	chr2:102438713~102440475:+
COAD	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-5.86	1.43e-08	1.09e-05	-0.46	-0.34	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	5.86	1.43e-08	1.09e-05	0.46	0.34	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
COAD	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	5.86	1.43e-08	1.09e-05	0.41	0.34	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
COAD	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-5.86	1.43e-08	1.1e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-5.86	1.43e-08	1.1e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-5.86	1.43e-08	1.1e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
COAD	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	5.86	1.43e-08	1.1e-05	0.47	0.34	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	5.86	1.43e-08	1.1e-05	0.47	0.34	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	5.86	1.43e-08	1.1e-05	0.47	0.34	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	5.86	1.43e-08	1.1e-05	0.47	0.34	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
COAD	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	5.86	1.43e-08	1.1e-05	0.35	0.34	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
COAD	cis	rs4568518	0.619	rs13238312	ENSG00000279048.1	RP11-511H23.2	5.86	1.44e-08	1.1e-05	0.26	0.34	Measles;	chr7:17968821	chr7:17940503~17942922:+
COAD	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.86	1.44e-08	1.1e-05	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
COAD	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
COAD	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
COAD	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-5.86	1.44e-08	1.1e-05	-0.44	-0.34	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
COAD	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	5.85	1.45e-08	1.11e-05	0.43	0.34	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
COAD	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	5.85	1.45e-08	1.11e-05	0.4	0.34	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
COAD	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	5.85	1.45e-08	1.11e-05	0.47	0.34	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
COAD	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.85	1.46e-08	1.11e-05	0.4	0.34	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
COAD	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	5.85	1.46e-08	1.11e-05	0.38	0.34	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
COAD	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-5.85	1.46e-08	1.11e-05	-0.45	-0.34	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
COAD	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-5.85	1.47e-08	1.12e-05	-0.41	-0.34	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	5.85	1.47e-08	1.12e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
COAD	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	5.85	1.48e-08	1.12e-05	0.37	0.34	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
COAD	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-5.85	1.48e-08	1.12e-05	-0.36	-0.34	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
COAD	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-5.85	1.48e-08	1.12e-05	-0.31	-0.34	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
COAD	cis	rs4950322	0.542	rs4950384	ENSG00000278811.3	LINC00624	5.85	1.49e-08	1.13e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147177310	chr1:147258885~147517875:-
COAD	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-5.85	1.49e-08	1.13e-05	-0.42	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
COAD	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-5.85	1.49e-08	1.13e-05	-0.39	-0.34	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
COAD	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	5.85	1.49e-08	1.13e-05	0.48	0.34	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
COAD	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.85	1.49e-08	1.13e-05	-0.43	-0.34	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
COAD	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-5.85	1.49e-08	1.13e-05	-0.4	-0.34	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
COAD	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	5.85	1.49e-08	1.13e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
COAD	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	5.85	1.5e-08	1.14e-05	0.35	0.34	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
COAD	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	5.85	1.5e-08	1.14e-05	0.43	0.34	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
COAD	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	5.85	1.5e-08	1.14e-05	0.33	0.34	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
COAD	cis	rs7829975	0.617	rs4841072	ENSG00000253981.4	ALG1L13P	-5.85	1.51e-08	1.14e-05	-0.4	-0.34	Mood instability;	chr8:8933743	chr8:8236003~8244667:-
COAD	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-5.85	1.51e-08	1.14e-05	-0.33	-0.34	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
COAD	cis	rs7615952	0.546	rs11711150	ENSG00000272840.1	RP11-379B18.6	5.85	1.51e-08	1.15e-05	0.54	0.34	Blood pressure (smoking interaction);	chr3:125596819	chr3:125774714~125797953:+
COAD	cis	rs9659323	0.65	rs17013645	ENSG00000231365.4	RP11-418J17.1	-5.85	1.51e-08	1.15e-05	-0.4	-0.34	Body mass index;	chr1:118942226	chr1:119140396~119275973:+
COAD	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	5.85	1.52e-08	1.15e-05	0.54	0.34	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
COAD	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	5.85	1.52e-08	1.15e-05	0.65	0.34	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	5.85	1.52e-08	1.15e-05	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
COAD	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	5.85	1.52e-08	1.16e-05	0.35	0.34	Asthma;	chr2:102407218	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	5.85	1.52e-08	1.16e-05	0.35	0.34	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
COAD	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-5.85	1.53e-08	1.16e-05	-0.33	-0.34	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
COAD	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-5.85	1.53e-08	1.16e-05	-0.53	-0.34	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
COAD	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-5.85	1.53e-08	1.16e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-5.85	1.53e-08	1.16e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-5.85	1.53e-08	1.16e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
COAD	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-5.85	1.53e-08	1.16e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
COAD	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-5.84	1.54e-08	1.17e-05	-0.48	-0.34	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
COAD	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-5.84	1.54e-08	1.17e-05	-0.32	-0.34	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
COAD	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-5.84	1.54e-08	1.17e-05	-0.33	-0.34	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
COAD	cis	rs754466	0.58	rs12354903	ENSG00000204049.1	RP11-126H7.4	5.84	1.55e-08	1.17e-05	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77776707	chr10:77866875~77869610:+
COAD	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-5.84	1.55e-08	1.17e-05	-0.45	-0.34	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-5.84	1.55e-08	1.17e-05	-0.45	-0.34	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-5.84	1.55e-08	1.17e-05	-0.45	-0.34	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-5.84	1.55e-08	1.17e-05	-0.45	-0.34	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-5.84	1.55e-08	1.17e-05	-0.45	-0.34	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
COAD	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	5.84	1.55e-08	1.17e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
COAD	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	5.84	1.55e-08	1.17e-05	0.36	0.34	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
COAD	cis	rs754466	0.58	rs10824575	ENSG00000204049.1	RP11-126H7.4	5.84	1.55e-08	1.18e-05	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77789289	chr10:77866875~77869610:+
COAD	cis	rs911186	0.786	rs13211901	ENSG00000224843.5	LINC00240	5.84	1.56e-08	1.18e-05	0.56	0.34	Autism spectrum disorder or schizophrenia;	chr6:27219833	chr6:26956992~27023924:+
COAD	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-5.84	1.56e-08	1.18e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-5.84	1.56e-08	1.18e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-5.84	1.56e-08	1.18e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-5.84	1.56e-08	1.18e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
COAD	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	5.84	1.56e-08	1.18e-05	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
COAD	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	5.84	1.56e-08	1.18e-05	0.37	0.34	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
COAD	cis	rs58873874	0.579	rs11551374	ENSG00000248544.2	CTB-47B11.3	5.84	1.57e-08	1.18e-05	0.64	0.34	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157375741~157384950:-
COAD	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-5.84	1.57e-08	1.19e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-5.84	1.57e-08	1.19e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
COAD	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-5.84	1.57e-08	1.19e-05	-0.38	-0.34	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
COAD	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-5.84	1.58e-08	1.19e-05	-0.37	-0.34	Height;	chr11:118773873	chr11:118704607~118750263:+
COAD	cis	rs7829975	0.508	rs4841006	ENSG00000173295.6	FAM86B3P	-5.84	1.58e-08	1.19e-05	-0.4	-0.34	Mood instability;	chr8:8643964	chr8:8228595~8244865:+
COAD	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	5.84	1.58e-08	1.19e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	5.84	1.58e-08	1.19e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
COAD	cis	rs453301	0.522	rs2929309	ENSG00000253981.4	ALG1L13P	-5.84	1.58e-08	1.19e-05	-0.4	-0.34	Joint mobility (Beighton score);	chr8:9226261	chr8:8236003~8244667:-
COAD	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-5.84	1.58e-08	1.19e-05	-0.4	-0.34	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
COAD	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	5.84	1.58e-08	1.19e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	5.84	1.58e-08	1.19e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
COAD	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	5.84	1.58e-08	1.19e-05	0.57	0.34	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
COAD	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-5.84	1.58e-08	1.19e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-5.84	1.58e-08	1.19e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
COAD	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-5.84	1.59e-08	1.2e-05	-0.46	-0.34	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
COAD	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
COAD	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	5.84	1.59e-08	1.2e-05	0.46	0.34	Height;	chr6:109441837	chr6:109382795~109383666:+
COAD	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	5.84	1.59e-08	1.2e-05	0.38	0.34	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
COAD	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-5.84	1.59e-08	1.2e-05	-0.37	-0.34	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
COAD	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	5.84	1.59e-08	1.2e-05	0.35	0.34	Asthma;	chr2:102418659	chr2:102438713~102440475:+
COAD	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	5.84	1.59e-08	1.2e-05	0.44	0.34	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
COAD	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	5.84	1.6e-08	1.2e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
COAD	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-5.84	1.6e-08	1.2e-05	-0.36	-0.34	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
COAD	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	5.84	1.6e-08	1.2e-05	0.39	0.34	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	5.84	1.6e-08	1.2e-05	0.39	0.34	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
COAD	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.84	1.6e-08	1.21e-05	0.39	0.34	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
COAD	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	5.84	1.61e-08	1.21e-05	0.41	0.34	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
COAD	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-5.83	1.62e-08	1.22e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
COAD	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-5.83	1.62e-08	1.22e-05	-0.45	-0.34	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
COAD	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-5.83	1.63e-08	1.22e-05	-0.46	-0.34	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
COAD	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	5.83	1.63e-08	1.23e-05	0.61	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	-5.83	1.63e-08	1.23e-05	-0.4	-0.34	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
COAD	cis	rs9368481	0.729	rs10946881	ENSG00000224843.5	LINC00240	-5.83	1.63e-08	1.23e-05	-0.41	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26956992~27023924:+
COAD	cis	rs62402013	1	rs62402013	ENSG00000224843.5	LINC00240	-5.83	1.63e-08	1.23e-05	-0.41	-0.34	Schizophrenia;	chr6:26947221	chr6:26956992~27023924:+
COAD	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	5.83	1.63e-08	1.23e-05	0.42	0.34	Height;	chr6:109747119	chr6:109382795~109383666:+
COAD	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	5.83	1.63e-08	1.23e-05	0.42	0.34	Height;	chr6:109747411	chr6:109382795~109383666:+
COAD	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	5.83	1.63e-08	1.23e-05	0.42	0.34	Height;	chr6:109748819	chr6:109382795~109383666:+
COAD	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	5.83	1.64e-08	1.23e-05	0.27	0.34	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
COAD	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	5.83	1.64e-08	1.23e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
COAD	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	5.83	1.64e-08	1.23e-05	0.39	0.34	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
COAD	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-5.83	1.64e-08	1.23e-05	-0.39	-0.34	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
COAD	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	5.83	1.64e-08	1.23e-05	0.44	0.34	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
COAD	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	5.83	1.64e-08	1.24e-05	0.5	0.34	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
COAD	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	5.83	1.65e-08	1.24e-05	0.5	0.34	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
COAD	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-5.83	1.65e-08	1.24e-05	-0.27	-0.34	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
COAD	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	5.83	1.65e-08	1.24e-05	0.42	0.34	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
COAD	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.83	1.65e-08	1.24e-05	-0.38	-0.34	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
COAD	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.83	1.65e-08	1.24e-05	-0.38	-0.34	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
COAD	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	5.83	1.66e-08	1.25e-05	0.5	0.34	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
COAD	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-5.83	1.66e-08	1.25e-05	-0.39	-0.34	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
COAD	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	5.83	1.66e-08	1.25e-05	0.41	0.34	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
COAD	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	5.83	1.66e-08	1.25e-05	0.46	0.34	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
COAD	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	5.83	1.66e-08	1.25e-05	0.47	0.34	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
COAD	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	5.83	1.66e-08	1.25e-05	0.47	0.34	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	5.83	1.66e-08	1.25e-05	0.47	0.34	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
COAD	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-5.83	1.66e-08	1.25e-05	-0.27	-0.34	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
COAD	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	5.83	1.67e-08	1.25e-05	0.36	0.34	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
COAD	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	5.83	1.67e-08	1.25e-05	0.43	0.34	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
COAD	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-5.83	1.67e-08	1.26e-05	-0.42	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
COAD	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	5.83	1.67e-08	1.26e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
COAD	cis	rs1426063	0.614	rs7684790	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75090873	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs7671634	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75090883	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs78046076	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75091818	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs74670563	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75094656	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs115338890	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75094719	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.541	rs116304289	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75095072	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs76204704	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75097804	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs80030693	ENSG00000249717.1	RP11-44F21.3	5.83	1.68e-08	1.26e-05	0.81	0.34	QT interval;	chr4:75099929	chr4:74955974~74970362:-
COAD	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	5.83	1.68e-08	1.26e-05	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
COAD	cis	rs860818	1	rs858282	ENSG00000226816.2	AC005082.12	5.83	1.68e-08	1.26e-05	0.81	0.34	Initial pursuit acceleration;	chr7:23210416	chr7:23206013~23208045:+
COAD	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	5.83	1.68e-08	1.26e-05	0.38	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
COAD	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	5.83	1.68e-08	1.26e-05	0.41	0.34	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
COAD	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-5.83	1.69e-08	1.26e-05	-0.39	-0.34	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
COAD	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-5.83	1.69e-08	1.27e-05	-0.43	-0.34	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
COAD	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-5.83	1.69e-08	1.27e-05	-0.47	-0.34	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.83	1.69e-08	1.27e-05	-0.47	-0.34	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
COAD	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	5.83	1.69e-08	1.27e-05	0.3	0.34	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
COAD	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-5.83	1.69e-08	1.27e-05	-0.3	-0.34	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
COAD	cis	rs8062405	0.728	rs11642449	ENSG00000251417.2	RP11-1348G14.4	-5.83	1.7e-08	1.27e-05	-0.38	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.728	rs9931989	ENSG00000251417.2	RP11-1348G14.4	5.83	1.7e-08	1.27e-05	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28802743~28817828:+
COAD	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	5.83	1.7e-08	1.27e-05	0.42	0.34	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
COAD	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	5.83	1.7e-08	1.27e-05	0.42	0.34	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
COAD	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	5.82	1.7e-08	1.28e-05	0.46	0.34	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
COAD	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-5.82	1.7e-08	1.28e-05	-0.39	-0.34	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
COAD	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-5.82	1.7e-08	1.28e-05	-0.33	-0.34	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
COAD	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	5.82	1.72e-08	1.28e-05	0.53	0.34	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
COAD	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	5.82	1.72e-08	1.29e-05	0.36	0.34	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
COAD	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	5.82	1.72e-08	1.29e-05	0.42	0.34	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
COAD	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	5.82	1.72e-08	1.29e-05	0.34	0.34	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
COAD	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-5.82	1.73e-08	1.29e-05	-0.46	-0.34	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-5.82	1.73e-08	1.29e-05	-0.46	-0.34	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-5.82	1.73e-08	1.29e-05	-0.46	-0.34	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
COAD	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	5.82	1.73e-08	1.3e-05	0.39	0.34	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
COAD	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-5.82	1.73e-08	1.3e-05	-0.55	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
COAD	cis	rs3126085	0.515	rs11204998	ENSG00000237975.5	FLG-AS1	5.82	1.73e-08	1.3e-05	0.37	0.34	Atopic dermatitis;	chr1:152393179	chr1:152168125~152445456:+
COAD	cis	rs5758659	0.714	rs133376	ENSG00000182057.4	OGFRP1	5.82	1.73e-08	1.3e-05	0.38	0.34	Cognitive function;	chr22:42070901	chr22:42269753~42275196:+
COAD	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	5.82	1.74e-08	1.3e-05	0.59	0.34	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	5.82	1.74e-08	1.3e-05	0.59	0.34	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	5.82	1.74e-08	1.3e-05	0.59	0.34	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	5.82	1.74e-08	1.3e-05	0.59	0.34	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-5.82	1.74e-08	1.3e-05	-0.59	-0.34	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-5.82	1.74e-08	1.3e-05	-0.59	-0.34	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	5.82	1.74e-08	1.3e-05	0.37	0.34	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
COAD	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	5.82	1.74e-08	1.3e-05	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
COAD	cis	rs3126085	0.515	rs4322234	ENSG00000237975.5	FLG-AS1	5.82	1.74e-08	1.3e-05	0.36	0.34	Atopic dermatitis;	chr1:152381292	chr1:152168125~152445456:+
COAD	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-5.82	1.74e-08	1.3e-05	-0.42	-0.34	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
COAD	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
COAD	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.3e-05	0.44	0.34	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
COAD	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	5.82	1.75e-08	1.31e-05	0.38	0.34	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
COAD	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	5.82	1.75e-08	1.31e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
COAD	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	5.82	1.75e-08	1.31e-05	0.42	0.34	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
COAD	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-5.82	1.75e-08	1.31e-05	-0.33	-0.34	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
COAD	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-5.82	1.76e-08	1.31e-05	-0.36	-0.34	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
COAD	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	5.82	1.76e-08	1.31e-05	0.32	0.34	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
COAD	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	5.82	1.76e-08	1.31e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
COAD	cis	rs71386933	0.509	rs34400689	ENSG00000260886.1	TAT-AS1	5.82	1.76e-08	1.31e-05	0.69	0.34	Post bronchodilator FEV1;	chr16:71969555	chr16:71565789~71578187:+
COAD	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-5.82	1.76e-08	1.31e-05	-0.54	-0.34	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
COAD	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	5.82	1.76e-08	1.32e-05	0.24	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
COAD	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-5.82	1.76e-08	1.32e-05	-0.48	-0.34	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
COAD	cis	rs58873874	0.737	rs11739062	ENSG00000251405.2	CTB-109A12.1	5.82	1.77e-08	1.32e-05	0.78	0.34	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157362615~157460078:-
COAD	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	5.82	1.78e-08	1.32e-05	0.49	0.34	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
COAD	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	5.82	1.78e-08	1.33e-05	0.62	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
COAD	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	5.82	1.78e-08	1.33e-05	0.31	0.34	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
COAD	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	5.82	1.78e-08	1.33e-05	0.45	0.34	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
COAD	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	5.82	1.78e-08	1.33e-05	0.35	0.34	Asthma;	chr2:102423717	chr2:102438713~102440475:+
COAD	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-5.82	1.79e-08	1.33e-05	-0.39	-0.34	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
COAD	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-5.82	1.79e-08	1.33e-05	-0.32	-0.34	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
COAD	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	5.82	1.79e-08	1.34e-05	0.3	0.34	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
COAD	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-5.81	1.79e-08	1.34e-05	-0.36	-0.34	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
COAD	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	5.81	1.8e-08	1.34e-05	0.37	0.34	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
COAD	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-5.81	1.8e-08	1.34e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
COAD	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	5.81	1.8e-08	1.34e-05	0.38	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
COAD	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.81	1.8e-08	1.34e-05	0.44	0.34	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
COAD	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	5.81	1.81e-08	1.34e-05	0.35	0.34	Asthma;	chr2:102410644	chr2:102438713~102440475:+
COAD	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-5.81	1.81e-08	1.34e-05	-0.44	-0.34	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
COAD	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-5.81	1.81e-08	1.35e-05	-0.39	-0.34	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
COAD	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-5.81	1.81e-08	1.35e-05	-0.39	-0.34	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
COAD	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-5.81	1.81e-08	1.35e-05	-0.44	-0.34	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
COAD	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-5.81	1.81e-08	1.35e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
COAD	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-5.81	1.81e-08	1.35e-05	-0.42	-0.34	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
COAD	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-5.81	1.81e-08	1.35e-05	-0.37	-0.34	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
COAD	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-5.81	1.81e-08	1.35e-05	-0.35	-0.34	Asthma;	chr2:102401592	chr2:102438713~102440475:+
COAD	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-5.81	1.82e-08	1.35e-05	-0.38	-0.34	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
COAD	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	5.81	1.82e-08	1.35e-05	0.42	0.34	Height;	chr6:109350642	chr6:109382795~109383666:+
COAD	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-5.81	1.83e-08	1.36e-05	-0.33	-0.34	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
COAD	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-5.81	1.83e-08	1.36e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-5.81	1.83e-08	1.36e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-5.81	1.83e-08	1.36e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-5.81	1.83e-08	1.36e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
COAD	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	5.81	1.83e-08	1.36e-05	0.4	0.34	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
COAD	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	5.81	1.83e-08	1.36e-05	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
COAD	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	5.81	1.84e-08	1.37e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
COAD	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-5.81	1.84e-08	1.37e-05	-0.39	-0.34	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
COAD	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	5.81	1.85e-08	1.37e-05	0.44	0.34	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	5.81	1.85e-08	1.37e-05	0.44	0.34	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
COAD	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	5.81	1.85e-08	1.37e-05	0.44	0.34	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
COAD	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	5.81	1.85e-08	1.37e-05	0.44	0.34	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
COAD	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	5.81	1.85e-08	1.38e-05	0.35	0.34	Asthma;	chr2:102427715	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	5.81	1.85e-08	1.38e-05	0.35	0.34	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	5.81	1.85e-08	1.38e-05	0.35	0.34	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
COAD	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-5.81	1.85e-08	1.38e-05	-0.36	-0.34	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
COAD	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-5.81	1.85e-08	1.38e-05	-0.39	-0.34	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
COAD	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.81	1.86e-08	1.38e-05	-0.37	-0.34	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
COAD	cis	rs453301	0.653	rs1045529	ENSG00000233609.3	RP11-62H7.2	-5.81	1.86e-08	1.38e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9032588	chr8:8961200~8979025:+
COAD	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-5.81	1.86e-08	1.38e-05	-0.37	-0.34	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
COAD	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-5.81	1.86e-08	1.38e-05	-0.56	-0.34	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
COAD	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	5.81	1.87e-08	1.38e-05	0.69	0.34	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
COAD	cis	rs858267	1	rs858308	ENSG00000226816.2	AC005082.12	5.81	1.87e-08	1.38e-05	0.75	0.34	Blood protein levels;	chr7:23168727	chr7:23206013~23208045:+
COAD	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-5.81	1.87e-08	1.38e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-5.81	1.87e-08	1.38e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
COAD	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	5.81	1.87e-08	1.39e-05	0.35	0.34	Asthma;	chr2:102426252	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	5.81	1.87e-08	1.39e-05	0.35	0.34	Asthma;	chr2:102427407	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	5.81	1.87e-08	1.39e-05	0.35	0.34	Asthma;	chr2:102432614	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	5.81	1.87e-08	1.39e-05	0.35	0.34	Asthma;	chr2:102433405	chr2:102438713~102440475:+
COAD	cis	rs453301	0.606	rs7462373	ENSG00000173295.6	FAM86B3P	-5.81	1.88e-08	1.39e-05	-0.38	-0.34	Joint mobility (Beighton score);	chr8:9041808	chr8:8228595~8244865:+
COAD	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-5.81	1.89e-08	1.4e-05	-0.36	-0.34	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
COAD	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	5.81	1.89e-08	1.4e-05	0.39	0.34	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
COAD	cis	rs4568518	0.616	rs4721675	ENSG00000279048.1	RP11-511H23.2	5.81	1.89e-08	1.4e-05	0.25	0.34	Measles;	chr7:17965079	chr7:17940503~17942922:+
COAD	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	5.81	1.89e-08	1.4e-05	0.47	0.34	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
COAD	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	5.8	1.89e-08	1.4e-05	0.27	0.34	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
COAD	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	5.8	1.9e-08	1.4e-05	0.42	0.34	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
COAD	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.8	1.91e-08	1.41e-05	0.38	0.34	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
COAD	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-5.8	1.91e-08	1.41e-05	-0.3	-0.34	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
COAD	cis	rs7615952	0.932	rs7629977	ENSG00000248787.1	RP11-666A20.4	-5.8	1.91e-08	1.42e-05	-0.46	-0.34	Blood pressure (smoking interaction);	chr3:125930730	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.932	rs7630077	ENSG00000248787.1	RP11-666A20.4	-5.8	1.91e-08	1.42e-05	-0.46	-0.34	Blood pressure (smoking interaction);	chr3:125930833	chr3:125908005~125910272:-
COAD	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-5.8	1.91e-08	1.42e-05	-0.36	-0.34	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
COAD	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-5.8	1.91e-08	1.42e-05	-0.42	-0.34	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
COAD	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-5.8	1.92e-08	1.42e-05	-0.29	-0.34	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
COAD	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	5.8	1.92e-08	1.42e-05	0.46	0.34	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
COAD	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-5.8	1.92e-08	1.42e-05	-0.39	-0.34	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
COAD	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	5.8	1.93e-08	1.42e-05	0.39	0.34	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
COAD	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-5.8	1.93e-08	1.43e-05	-0.35	-0.34	Asthma;	chr2:102374328	chr2:102438713~102440475:+
COAD	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	5.8	1.93e-08	1.43e-05	0.64	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
COAD	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-5.8	1.93e-08	1.43e-05	-0.34	-0.34	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
COAD	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	5.8	1.93e-08	1.43e-05	0.39	0.34	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
COAD	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-5.8	1.94e-08	1.43e-05	-0.46	-0.34	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
COAD	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	5.8	1.94e-08	1.43e-05	0.41	0.34	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
COAD	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	5.8	1.94e-08	1.43e-05	0.45	0.34	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	5.8	1.94e-08	1.43e-05	0.45	0.34	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	5.8	1.94e-08	1.43e-05	0.45	0.34	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
COAD	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-5.8	1.94e-08	1.43e-05	-0.36	-0.34	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	5.8	1.94e-08	1.43e-05	0.38	0.34	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
COAD	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	5.8	1.95e-08	1.44e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	5.8	1.95e-08	1.44e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	5.8	1.95e-08	1.44e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	5.8	1.95e-08	1.44e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
COAD	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	5.8	1.95e-08	1.44e-05	0.35	0.34	Asthma;	chr2:102431747	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	5.8	1.95e-08	1.44e-05	0.35	0.34	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	5.8	1.95e-08	1.44e-05	0.35	0.34	Asthma;	chr2:102432120	chr2:102438713~102440475:+
COAD	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-5.8	1.96e-08	1.44e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
COAD	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	5.8	1.96e-08	1.44e-05	0.43	0.34	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
COAD	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-5.8	1.96e-08	1.44e-05	-0.38	-0.34	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
COAD	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	5.8	1.96e-08	1.45e-05	0.45	0.34	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
COAD	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-5.8	1.96e-08	1.45e-05	-0.46	-0.34	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
COAD	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	5.8	1.96e-08	1.45e-05	0.39	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
COAD	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	5.8	1.96e-08	1.45e-05	0.39	0.34	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
COAD	cis	rs1790761	0.504	rs61894496	ENSG00000231793.4	DOC2GP	5.8	1.97e-08	1.45e-05	0.39	0.34	Mean corpuscular volume;	chr11:67624436	chr11:67612653~67616257:-
COAD	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	5.8	1.97e-08	1.45e-05	0.32	0.34	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
COAD	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	5.8	1.97e-08	1.45e-05	0.29	0.34	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
COAD	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	5.8	1.98e-08	1.46e-05	0.29	0.34	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
COAD	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.8	1.98e-08	1.46e-05	-0.51	-0.34	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
COAD	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	5.8	1.98e-08	1.46e-05	0.54	0.34	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	5.8	1.98e-08	1.46e-05	0.54	0.34	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	5.8	1.98e-08	1.46e-05	0.54	0.34	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
COAD	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	5.8	1.98e-08	1.46e-05	0.42	0.34	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
COAD	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	5.79	2e-08	1.47e-05	0.29	0.34	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
COAD	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	5.79	2e-08	1.47e-05	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
COAD	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
COAD	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	5.79	2e-08	1.47e-05	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
COAD	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	5.79	2e-08	1.47e-05	0.42	0.34	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
COAD	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	5.79	2e-08	1.47e-05	0.42	0.34	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
COAD	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	5.79	2e-08	1.47e-05	0.42	0.34	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
COAD	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-5.79	2e-08	1.47e-05	-0.35	-0.34	Height;	chr11:118746590	chr11:118791254~118793137:+
COAD	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	5.79	2e-08	1.47e-05	0.37	0.34	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	5.79	2e-08	1.47e-05	0.37	0.34	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
COAD	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	5.79	2e-08	1.47e-05	0.33	0.34	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
COAD	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-5.79	2.01e-08	1.48e-05	-0.42	-0.34	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
COAD	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-5.79	2.01e-08	1.48e-05	-0.36	-0.34	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
COAD	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-5.79	2.01e-08	1.48e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
COAD	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-5.79	2.02e-08	1.48e-05	-0.43	-0.34	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
COAD	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	5.79	2.02e-08	1.48e-05	0.41	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
COAD	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-5.79	2.02e-08	1.49e-05	-0.42	-0.34	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
COAD	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-5.79	2.02e-08	1.49e-05	-0.39	-0.34	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-5.79	2.02e-08	1.49e-05	-0.39	-0.34	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-5.79	2.02e-08	1.49e-05	-0.39	-0.34	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
COAD	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-5.79	2.03e-08	1.49e-05	-0.46	-0.34	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
COAD	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	5.79	2.03e-08	1.49e-05	0.39	0.34	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
COAD	cis	rs1056107	0.931	rs7019056	ENSG00000225513.1	RP11-165N19.2	-5.79	2.04e-08	1.5e-05	-0.4	-0.34	Colorectal cancer;	chr9:112248160	chr9:112173522~112173971:-
COAD	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	5.79	2.04e-08	1.5e-05	0.36	0.34	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
COAD	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	5.79	2.04e-08	1.5e-05	0.36	0.34	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
COAD	cis	rs754466	0.58	rs12356063	ENSG00000204049.1	RP11-126H7.4	5.79	2.05e-08	1.5e-05	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798373	chr10:77866875~77869610:+
COAD	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	5.79	2.05e-08	1.5e-05	0.35	0.34	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
COAD	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-5.79	2.05e-08	1.51e-05	-0.41	-0.34	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
COAD	cis	rs1056107	0.897	rs7851129	ENSG00000225513.1	RP11-165N19.2	-5.79	2.05e-08	1.51e-05	-0.4	-0.34	Colorectal cancer;	chr9:112193127	chr9:112173522~112173971:-
COAD	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	5.79	2.06e-08	1.51e-05	0.57	0.34	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
COAD	cis	rs4950322	0.58	rs1813002	ENSG00000278811.3	LINC00624	5.79	2.06e-08	1.51e-05	0.34	0.34	Protein quantitative trait loci;	chr1:147112579	chr1:147258885~147517875:-
COAD	cis	rs58873874	0.579	rs80253028	ENSG00000248544.2	CTB-47B11.3	5.79	2.06e-08	1.51e-05	0.64	0.34	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157375741~157384950:-
COAD	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	5.79	2.06e-08	1.51e-05	0.4	0.34	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	5.79	2.06e-08	1.51e-05	0.4	0.34	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
COAD	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	5.79	2.06e-08	1.51e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
COAD	cis	rs7615952	0.736	rs9862893	ENSG00000248787.1	RP11-666A20.4	-5.79	2.06e-08	1.51e-05	-0.51	-0.34	Blood pressure (smoking interaction);	chr3:125968131	chr3:125908005~125910272:-
COAD	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-5.79	2.06e-08	1.51e-05	-0.29	-0.34	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
COAD	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-5.79	2.07e-08	1.52e-05	-0.35	-0.34	Height;	chr20:49235382	chr20:49280319~49280409:+
COAD	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	5.79	2.07e-08	1.52e-05	0.27	0.34	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	5.79	2.07e-08	1.52e-05	0.27	0.34	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	5.79	2.07e-08	1.52e-05	0.27	0.34	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
COAD	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-5.79	2.07e-08	1.52e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-5.79	2.07e-08	1.52e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
COAD	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	5.79	2.08e-08	1.53e-05	0.37	0.34	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
COAD	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	5.79	2.09e-08	1.53e-05	0.37	0.34	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
COAD	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-5.79	2.1e-08	1.54e-05	-0.27	-0.34	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
COAD	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.79	2.1e-08	1.54e-05	-0.58	-0.34	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
COAD	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	5.78	2.1e-08	1.54e-05	0.45	0.34	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
COAD	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	5.78	2.11e-08	1.54e-05	0.46	0.34	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
COAD	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	5.78	2.11e-08	1.54e-05	0.41	0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
COAD	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	5.78	2.11e-08	1.55e-05	0.42	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
COAD	cis	rs7615952	1	rs7616044	ENSG00000248787.1	RP11-666A20.4	-5.78	2.12e-08	1.55e-05	-0.46	-0.34	Blood pressure (smoking interaction);	chr3:125930511	chr3:125908005~125910272:-
COAD	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-5.78	2.12e-08	1.55e-05	-0.36	-0.34	Height;	chr11:118747911	chr11:118791254~118793137:+
COAD	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-5.78	2.12e-08	1.55e-05	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
COAD	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-5.78	2.12e-08	1.55e-05	-0.37	-0.34	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
COAD	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-5.78	2.13e-08	1.56e-05	-0.27	-0.34	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
COAD	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-5.78	2.13e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
COAD	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-5.78	2.13e-08	1.56e-05	-0.47	-0.34	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
COAD	cis	rs6993244	1	rs6993244	ENSG00000233609.3	RP11-62H7.2	5.78	2.13e-08	1.56e-05	0.39	0.34	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8961200~8979025:+
COAD	cis	rs4950322	0.58	rs972368	ENSG00000278811.3	LINC00624	5.78	2.13e-08	1.56e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147111142	chr1:147258885~147517875:-
COAD	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
COAD	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.78	2.14e-08	1.56e-05	0.44	0.34	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.78	2.14e-08	1.56e-05	0.44	0.34	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
COAD	cis	rs11079159	0.606	rs876720	ENSG00000263096.1	RP11-515O17.2	-5.78	2.14e-08	1.56e-05	-0.39	-0.34	QRS duration;	chr17:55289154	chr17:55271504~55273653:-
COAD	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	5.78	2.14e-08	1.56e-05	0.41	0.34	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
COAD	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	5.78	2.14e-08	1.56e-05	0.41	0.34	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
COAD	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	5.78	2.14e-08	1.56e-05	0.29	0.34	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
COAD	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.78	2.14e-08	1.56e-05	0.4	0.34	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.78	2.14e-08	1.56e-05	0.4	0.34	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
COAD	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-5.78	2.14e-08	1.57e-05	-0.31	-0.34	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
COAD	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-5.78	2.14e-08	1.57e-05	-0.32	-0.34	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
COAD	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	5.78	2.15e-08	1.57e-05	0.55	0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
COAD	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	5.78	2.15e-08	1.57e-05	0.36	0.34	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
COAD	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	5.78	2.15e-08	1.57e-05	0.36	0.34	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
COAD	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	5.78	2.15e-08	1.57e-05	0.36	0.34	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
COAD	cis	rs4950322	0.542	rs17159924	ENSG00000278811.3	LINC00624	5.78	2.15e-08	1.57e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147199463	chr1:147258885~147517875:-
COAD	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-5.78	2.16e-08	1.57e-05	-0.55	-0.34	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
COAD	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	5.78	2.16e-08	1.58e-05	0.38	0.34	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
COAD	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	5.78	2.16e-08	1.58e-05	0.38	0.34	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
COAD	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-5.78	2.16e-08	1.58e-05	-0.39	-0.34	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-5.78	2.16e-08	1.58e-05	-0.39	-0.34	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-5.78	2.16e-08	1.58e-05	-0.39	-0.34	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
COAD	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-5.78	2.17e-08	1.58e-05	-0.39	-0.34	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
COAD	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-5.78	2.17e-08	1.58e-05	-0.39	-0.34	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-5.78	2.17e-08	1.58e-05	-0.39	-0.34	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
COAD	cis	rs1056107	0.931	rs6575	ENSG00000225513.1	RP11-165N19.2	-5.78	2.17e-08	1.58e-05	-0.41	-0.34	Colorectal cancer;	chr9:112218687	chr9:112173522~112173971:-
COAD	cis	rs7955901	0.904	rs10879240	ENSG00000258053.1	CTD-2021H9.3	-5.78	2.17e-08	1.59e-05	-0.41	-0.34	Type 2 diabetes;	chr12:71049505	chr12:71047402~71118247:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.78	2.18e-08	1.59e-05	0.38	0.34	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
COAD	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-5.78	2.18e-08	1.59e-05	-0.44	-0.34	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
COAD	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-5.78	2.19e-08	1.6e-05	-0.39	-0.34	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
COAD	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	5.78	2.19e-08	1.6e-05	0.44	0.34	Height;	chr6:109430398	chr6:109382795~109383666:+
COAD	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	5.78	2.19e-08	1.6e-05	0.83	0.34	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	5.78	2.19e-08	1.6e-05	0.83	0.34	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	5.78	2.19e-08	1.6e-05	0.83	0.34	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
COAD	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-5.78	2.19e-08	1.6e-05	-0.49	-0.34	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-5.78	2.19e-08	1.6e-05	-0.49	-0.34	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
COAD	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	5.78	2.2e-08	1.6e-05	0.44	0.34	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
COAD	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-5.78	2.2e-08	1.6e-05	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-5.78	2.2e-08	1.6e-05	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
COAD	cis	rs4568518	0.502	rs4544985	ENSG00000279048.1	RP11-511H23.2	5.78	2.2e-08	1.6e-05	0.23	0.34	Measles;	chr7:17944184	chr7:17940503~17942922:+
COAD	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	5.78	2.2e-08	1.6e-05	0.25	0.34	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
COAD	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	5.78	2.2e-08	1.6e-05	0.25	0.34	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
COAD	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	5.78	2.2e-08	1.61e-05	0.48	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
COAD	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-5.78	2.21e-08	1.61e-05	-0.39	-0.34	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
COAD	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-5.78	2.21e-08	1.61e-05	-0.21	-0.34	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
COAD	cis	rs12699921	0.935	rs6461363	ENSG00000279048.1	RP11-511H23.2	5.77	2.22e-08	1.62e-05	0.24	0.34	Fibrinogen levels;	chr7:17952527	chr7:17940503~17942922:+
COAD	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-5.77	2.22e-08	1.62e-05	-0.4	-0.34	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
COAD	cis	rs6479891	0.908	rs11818738	ENSG00000232075.1	MRPL35P2	5.77	2.23e-08	1.62e-05	0.63	0.34	Arthritis (juvenile idiopathic);	chr10:63604971	chr10:63634317~63634827:-
COAD	cis	rs5758659	0.652	rs133335	ENSG00000182057.4	OGFRP1	-5.77	2.23e-08	1.63e-05	-0.35	-0.34	Cognitive function;	chr22:42020052	chr22:42269753~42275196:+
COAD	cis	rs2842992	0.747	rs4709378	ENSG00000237927.1	RP3-393E18.2	-5.77	2.24e-08	1.63e-05	-0.53	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159806403	chr6:159586955~159589169:-
COAD	cis	rs9309473	0.519	rs13027816	ENSG00000163016.8	ALMS1P	-5.77	2.24e-08	1.63e-05	-0.41	-0.34	Metabolite levels;	chr2:73670564	chr2:73644919~73685576:+
COAD	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-5.77	2.24e-08	1.63e-05	-0.46	-0.34	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
COAD	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	5.77	2.24e-08	1.63e-05	0.44	0.34	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
COAD	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-5.77	2.24e-08	1.63e-05	-0.22	-0.34	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
COAD	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.77	2.25e-08	1.64e-05	0.48	0.34	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
COAD	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	5.77	2.25e-08	1.64e-05	0.6	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
COAD	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	5.77	2.26e-08	1.64e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
COAD	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	5.77	2.26e-08	1.64e-05	0.25	0.34	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
COAD	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	5.77	2.26e-08	1.64e-05	0.41	0.34	Height;	chr6:109421257	chr6:109382795~109383666:+
COAD	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	5.77	2.26e-08	1.64e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
COAD	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-5.77	2.26e-08	1.65e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
COAD	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	5.77	2.26e-08	1.65e-05	0.41	0.34	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
COAD	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-5.77	2.27e-08	1.65e-05	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
COAD	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.77	2.27e-08	1.65e-05	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
COAD	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	5.77	2.27e-08	1.65e-05	0.41	0.34	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
COAD	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	5.77	2.27e-08	1.65e-05	0.41	0.34	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
COAD	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-5.77	2.27e-08	1.65e-05	-0.38	-0.34	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
COAD	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	5.77	2.28e-08	1.65e-05	0.43	0.34	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
COAD	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	5.77	2.28e-08	1.66e-05	0.46	0.34	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	5.77	2.28e-08	1.66e-05	0.46	0.34	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
COAD	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	5.77	2.28e-08	1.66e-05	0.34	0.34	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
COAD	cis	rs58873874	0.737	rs11745566	ENSG00000251405.2	CTB-109A12.1	5.77	2.28e-08	1.66e-05	0.76	0.34	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157362615~157460078:-
COAD	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-5.77	2.29e-08	1.66e-05	-0.4	-0.34	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
COAD	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-5.77	2.29e-08	1.66e-05	-0.38	-0.34	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	5.77	2.29e-08	1.66e-05	0.36	0.34	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
COAD	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	5.77	2.29e-08	1.67e-05	0.42	0.34	Height;	chr6:109415123	chr6:109382795~109383666:+
COAD	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-5.77	2.3e-08	1.67e-05	-0.36	-0.34	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
COAD	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	5.77	2.3e-08	1.67e-05	0.44	0.34	Depression;	chr6:28240757	chr6:28943877~28944537:+
COAD	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-5.77	2.3e-08	1.67e-05	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
COAD	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-5.77	2.31e-08	1.67e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
COAD	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	5.77	2.31e-08	1.68e-05	0.21	0.34	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
COAD	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-5.77	2.32e-08	1.68e-05	-0.46	-0.34	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
COAD	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	5.77	2.32e-08	1.68e-05	0.42	0.34	Height;	chr6:109416903	chr6:109382795~109383666:+
COAD	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	5.77	2.32e-08	1.68e-05	0.42	0.34	Height;	chr6:109417941	chr6:109382795~109383666:+
COAD	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	5.77	2.32e-08	1.68e-05	0.42	0.34	Height;	chr6:109420812	chr6:109382795~109383666:+
COAD	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	5.77	2.33e-08	1.69e-05	0.46	0.34	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
COAD	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	-5.77	2.33e-08	1.69e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
COAD	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	5.76	2.33e-08	1.69e-05	0.3	0.34	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
COAD	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-5.76	2.33e-08	1.69e-05	-0.54	-0.34	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
COAD	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	5.76	2.33e-08	1.69e-05	0.29	0.34	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
COAD	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-5.76	2.35e-08	1.7e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
COAD	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
COAD	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
COAD	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-5.76	2.35e-08	1.7e-05	-0.39	-0.34	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
COAD	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	5.76	2.36e-08	1.71e-05	0.43	0.34	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
COAD	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-5.76	2.36e-08	1.71e-05	-0.43	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
COAD	cis	rs7615952	0.736	rs11921945	ENSG00000248787.1	RP11-666A20.4	-5.76	2.37e-08	1.72e-05	-0.47	-0.34	Blood pressure (smoking interaction);	chr3:125924876	chr3:125908005~125910272:-
COAD	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	5.76	2.38e-08	1.72e-05	0.59	0.34	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
COAD	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-5.76	2.39e-08	1.72e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
COAD	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.76	2.39e-08	1.73e-05	0.43	0.34	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
COAD	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-5.76	2.39e-08	1.73e-05	-0.45	-0.34	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
COAD	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-5.76	2.39e-08	1.73e-05	-0.36	-0.34	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
COAD	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	5.76	2.39e-08	1.73e-05	0.41	0.34	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
COAD	cis	rs7615952	0.611	rs7632305	ENSG00000248787.1	RP11-666A20.4	-5.76	2.4e-08	1.73e-05	-0.56	-0.34	Blood pressure (smoking interaction);	chr3:125915924	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.673	rs9841194	ENSG00000248787.1	RP11-666A20.4	-5.76	2.4e-08	1.73e-05	-0.56	-0.34	Blood pressure (smoking interaction);	chr3:125916896	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.673	rs9289270	ENSG00000248787.1	RP11-666A20.4	-5.76	2.4e-08	1.73e-05	-0.56	-0.34	Blood pressure (smoking interaction);	chr3:125918136	chr3:125908005~125910272:-
COAD	cis	rs1056107	0.897	rs7867328	ENSG00000225513.1	RP11-165N19.2	-5.76	2.4e-08	1.73e-05	-0.41	-0.34	Colorectal cancer;	chr9:112196925	chr9:112173522~112173971:-
COAD	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-5.76	2.4e-08	1.73e-05	-0.39	-0.34	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
COAD	cis	rs860818	1	rs858293	ENSG00000226816.2	AC005082.12	5.76	2.41e-08	1.74e-05	0.75	0.34	Initial pursuit acceleration;	chr7:23206705	chr7:23206013~23208045:+
COAD	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	5.76	2.42e-08	1.75e-05	0.37	0.34	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	5.76	2.42e-08	1.75e-05	0.37	0.34	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	5.76	2.42e-08	1.75e-05	0.37	0.34	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
COAD	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	5.76	2.42e-08	1.75e-05	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
COAD	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-5.76	2.42e-08	1.75e-05	-0.39	-0.34	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
COAD	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	5.76	2.43e-08	1.75e-05	0.46	0.34	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
COAD	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	5.76	2.44e-08	1.76e-05	0.57	0.34	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
COAD	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-5.76	2.44e-08	1.76e-05	-0.39	-0.34	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
COAD	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	5.76	2.44e-08	1.76e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	5.76	2.44e-08	1.76e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	5.76	2.44e-08	1.76e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	5.76	2.44e-08	1.76e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	5.76	2.44e-08	1.76e-05	0.51	0.34	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
COAD	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-5.76	2.45e-08	1.76e-05	-0.34	-0.34	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
COAD	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-5.76	2.45e-08	1.76e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-5.76	2.45e-08	1.76e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
COAD	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	5.76	2.45e-08	1.76e-05	0.46	0.34	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	5.76	2.45e-08	1.76e-05	0.46	0.34	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	5.76	2.45e-08	1.76e-05	0.46	0.34	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	5.76	2.45e-08	1.76e-05	0.46	0.34	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
COAD	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	5.75	2.46e-08	1.77e-05	0.46	0.34	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
COAD	cis	rs7955901	1	rs7955901	ENSG00000258053.1	CTD-2021H9.3	-5.75	2.46e-08	1.77e-05	-0.4	-0.34	Type 2 diabetes;	chr12:71039513	chr12:71047402~71118247:-
COAD	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	5.75	2.46e-08	1.77e-05	0.4	0.34	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	5.75	2.46e-08	1.77e-05	0.4	0.34	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
COAD	cis	rs858267	1	rs858309	ENSG00000226816.2	AC005082.12	5.75	2.47e-08	1.77e-05	0.79	0.34	Blood protein levels;	chr7:23166854	chr7:23206013~23208045:+
COAD	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-5.75	2.47e-08	1.77e-05	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
COAD	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	5.75	2.47e-08	1.78e-05	0.36	0.34	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
COAD	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-5.75	2.47e-08	1.78e-05	-0.29	-0.34	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
COAD	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	5.75	2.47e-08	1.78e-05	0.38	0.34	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
COAD	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-5.75	2.48e-08	1.79e-05	-0.32	-0.34	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
COAD	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	5.75	2.48e-08	1.79e-05	0.25	0.34	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
COAD	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	5.75	2.49e-08	1.79e-05	0.46	0.34	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	5.75	2.49e-08	1.79e-05	0.46	0.34	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	5.75	2.49e-08	1.79e-05	0.46	0.34	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
COAD	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-5.75	2.49e-08	1.79e-05	-0.34	-0.34	Asthma;	chr2:102377873	chr2:102438713~102440475:+
COAD	cis	rs860818	1	rs1728344	ENSG00000226816.2	AC005082.12	5.75	2.5e-08	1.79e-05	0.84	0.34	Initial pursuit acceleration;	chr7:23210425	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858281	ENSG00000226816.2	AC005082.12	5.75	2.5e-08	1.79e-05	0.84	0.34	Initial pursuit acceleration;	chr7:23210948	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs858280	ENSG00000226816.2	AC005082.12	5.75	2.5e-08	1.79e-05	0.84	0.34	Initial pursuit acceleration;	chr7:23211255	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs6955934	ENSG00000226816.2	AC005082.12	5.75	2.5e-08	1.79e-05	0.84	0.34	Initial pursuit acceleration;	chr7:23211880	chr7:23206013~23208045:+
COAD	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-5.75	2.5e-08	1.8e-05	-0.35	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
COAD	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-5.75	2.5e-08	1.8e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-5.75	2.5e-08	1.8e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
COAD	cis	rs4950322	0.518	rs4950305	ENSG00000278811.3	LINC00624	5.75	2.51e-08	1.8e-05	0.33	0.34	Protein quantitative trait loci;	chr1:147117711	chr1:147258885~147517875:-
COAD	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-5.75	2.51e-08	1.8e-05	-0.38	-0.34	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
COAD	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	5.75	2.51e-08	1.8e-05	0.39	0.34	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	5.75	2.51e-08	1.8e-05	0.39	0.34	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
COAD	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.75	2.52e-08	1.81e-05	-0.46	-0.34	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
COAD	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	5.75	2.52e-08	1.81e-05	0.39	0.34	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
COAD	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-5.75	2.53e-08	1.82e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-5.75	2.53e-08	1.82e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-5.75	2.53e-08	1.82e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
COAD	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-5.75	2.55e-08	1.83e-05	-0.36	-0.34	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
COAD	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.75	2.55e-08	1.83e-05	0.37	0.34	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
COAD	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-5.75	2.55e-08	1.83e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-5.75	2.55e-08	1.83e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-5.75	2.55e-08	1.83e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
COAD	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	5.75	2.55e-08	1.83e-05	0.5	0.34	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
COAD	cis	rs9368481	0.761	rs4713062	ENSG00000224843.5	LINC00240	5.75	2.56e-08	1.83e-05	0.41	0.34	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26956992~27023924:+
COAD	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-5.75	2.56e-08	1.83e-05	-0.37	-0.34	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
COAD	cis	rs453301	0.624	rs6987558	ENSG00000233609.3	RP11-62H7.2	5.75	2.56e-08	1.84e-05	0.38	0.34	Joint mobility (Beighton score);	chr8:9005011	chr8:8961200~8979025:+
COAD	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-5.75	2.56e-08	1.84e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
COAD	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5.75	2.57e-08	1.84e-05	0.43	0.34	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
COAD	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-5.75	2.57e-08	1.84e-05	-0.36	-0.34	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
COAD	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	5.75	2.57e-08	1.84e-05	0.41	0.34	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
COAD	cis	rs35538253	0.522	rs12934297	ENSG00000260886.1	TAT-AS1	5.75	2.58e-08	1.85e-05	0.64	0.34	Post bronchodilator FEV1;	chr16:71988922	chr16:71565789~71578187:+
COAD	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
COAD	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-5.75	2.58e-08	1.85e-05	-0.38	-0.34	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
COAD	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	5.75	2.58e-08	1.85e-05	0.33	0.34	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
COAD	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	5.75	2.58e-08	1.85e-05	0.44	0.34	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
COAD	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.75	2.58e-08	1.85e-05	0.33	0.34	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	5.75	2.59e-08	1.85e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
COAD	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	5.74	2.6e-08	1.86e-05	0.37	0.34	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
COAD	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	5.74	2.6e-08	1.86e-05	0.35	0.34	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
COAD	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-5.74	2.6e-08	1.86e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
COAD	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-5.74	2.6e-08	1.86e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
COAD	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-5.74	2.61e-08	1.87e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-5.74	2.61e-08	1.87e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-5.74	2.61e-08	1.87e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
COAD	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-5.74	2.61e-08	1.87e-05	-0.42	-0.34	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
COAD	cis	rs1426063	0.8	rs28861517	ENSG00000249717.1	RP11-44F21.3	5.74	2.62e-08	1.87e-05	0.46	0.34	QT interval;	chr4:75092995	chr4:74955974~74970362:-
COAD	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	5.74	2.62e-08	1.87e-05	0.45	0.34	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
COAD	cis	rs4568518	0.53	rs10950690	ENSG00000279048.1	RP11-511H23.2	5.74	2.62e-08	1.88e-05	0.25	0.34	Measles;	chr7:17941687	chr7:17940503~17942922:+
COAD	cis	rs2281603	0.951	rs73267743	ENSG00000259116.1	RP11-973N13.4	-5.74	2.63e-08	1.88e-05	-0.36	-0.34	Lymphocyte counts;	chr14:64511424	chr14:64514154~64540368:-
COAD	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-5.74	2.63e-08	1.88e-05	-0.42	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
COAD	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	5.74	2.63e-08	1.88e-05	0.38	0.34	Height;	chr3:53091453	chr3:53064283~53065091:-
COAD	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-5.74	2.64e-08	1.89e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-5.74	2.64e-08	1.89e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
COAD	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-5.74	2.64e-08	1.89e-05	-0.38	-0.34	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-5.74	2.64e-08	1.89e-05	-0.38	-0.34	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
COAD	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	5.74	2.64e-08	1.89e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
COAD	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.74	2.64e-08	1.89e-05	0.36	0.34	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
COAD	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-5.74	2.64e-08	1.89e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
COAD	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-5.74	2.64e-08	1.89e-05	-0.36	-0.34	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
COAD	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	5.74	2.65e-08	1.89e-05	0.42	0.34	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
COAD	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-5.74	2.65e-08	1.89e-05	-0.39	-0.34	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-5.74	2.65e-08	1.89e-05	-0.39	-0.34	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-5.74	2.65e-08	1.89e-05	-0.39	-0.34	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-5.74	2.65e-08	1.89e-05	-0.39	-0.34	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-5.74	2.65e-08	1.89e-05	-0.39	-0.34	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
COAD	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-5.74	2.65e-08	1.89e-05	-0.38	-0.34	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
COAD	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102374753	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102379885	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102381261	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102381819	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102382514	chr2:102438713~102440475:+
COAD	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma;	chr2:102382943	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
COAD	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	5.74	2.65e-08	1.9e-05	0.34	0.34	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
COAD	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	5.74	2.66e-08	1.9e-05	0.45	0.34	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
COAD	cis	rs9890032	0.934	rs3760318	ENSG00000263531.1	RP13-753N3.1	5.74	2.66e-08	1.9e-05	0.43	0.34	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30863921~30864940:-
COAD	cis	rs4841097	0.876	rs6601288	ENSG00000173295.6	FAM86B3P	5.74	2.67e-08	1.9e-05	0.43	0.34	Platelet distribution width;	chr8:9085920	chr8:8228595~8244865:+
COAD	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	5.74	2.67e-08	1.9e-05	0.39	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
COAD	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	5.74	2.67e-08	1.91e-05	0.39	0.34	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
COAD	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	5.74	2.68e-08	1.91e-05	0.34	0.34	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
COAD	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-5.74	2.68e-08	1.91e-05	-0.41	-0.34	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
COAD	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-5.74	2.68e-08	1.91e-05	-0.37	-0.34	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
COAD	cis	rs1056107	0.933	rs10981311	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112203076	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.843	rs10981312	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112203105	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.902	rs2182810	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112204169	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs7021460	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112205095	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs6477896	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112205498	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs6477897	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112205658	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs7861162	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112207436	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs7861447	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112207493	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs7861788	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112207709	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs4644329	ENSG00000225513.1	RP11-165N19.2	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Colorectal cancer;	chr9:112207713	chr9:112173522~112173971:-
COAD	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-5.74	2.68e-08	1.91e-05	-0.39	-0.34	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
COAD	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	5.74	2.68e-08	1.91e-05	0.43	0.34	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
COAD	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	5.74	2.68e-08	1.91e-05	0.53	0.34	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
COAD	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	5.74	2.68e-08	1.92e-05	0.38	0.34	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
COAD	cis	rs4568518	0.53	rs10226084	ENSG00000279048.1	RP11-511H23.2	5.74	2.7e-08	1.92e-05	0.24	0.34	Measles;	chr7:17957989	chr7:17940503~17942922:+
COAD	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-5.74	2.71e-08	1.93e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
COAD	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	5.74	2.71e-08	1.93e-05	0.45	0.34	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
COAD	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.74	2.72e-08	1.94e-05	-0.39	-0.34	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
COAD	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-5.74	2.72e-08	1.94e-05	-0.38	-0.34	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
COAD	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-5.74	2.72e-08	1.94e-05	-0.49	-0.34	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-5.74	2.72e-08	1.94e-05	-0.49	-0.34	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-5.74	2.72e-08	1.94e-05	-0.49	-0.34	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-5.74	2.72e-08	1.94e-05	-0.49	-0.34	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-5.74	2.72e-08	1.94e-05	-0.49	-0.34	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
COAD	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	5.74	2.73e-08	1.94e-05	0.36	0.34	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
COAD	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	5.73	2.74e-08	1.95e-05	0.37	0.34	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
COAD	cis	rs9368481	0.729	rs9379948	ENSG00000224843.5	LINC00240	-5.73	2.74e-08	1.95e-05	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26956992~27023924:+
COAD	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-5.73	2.75e-08	1.96e-05	-0.44	-0.34	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
COAD	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-5.73	2.75e-08	1.96e-05	-0.36	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
COAD	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	5.73	2.75e-08	1.96e-05	0.26	0.34	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
COAD	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	5.73	2.76e-08	1.96e-05	0.38	0.34	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
COAD	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	5.73	2.76e-08	1.96e-05	0.41	0.34	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
COAD	cis	rs71327718	1	rs71327718	ENSG00000248787.1	RP11-666A20.4	-5.73	2.76e-08	1.96e-05	-0.57	-0.34	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125908005~125910272:-
COAD	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	5.73	2.76e-08	1.97e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
COAD	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-5.73	2.77e-08	1.97e-05	-0.32	-0.34	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
COAD	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	5.73	2.77e-08	1.97e-05	0.25	0.34	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
COAD	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	5.73	2.77e-08	1.97e-05	0.42	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
COAD	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	5.73	2.77e-08	1.97e-05	0.4	0.34	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	5.73	2.77e-08	1.97e-05	0.4	0.34	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
COAD	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	5.73	2.78e-08	1.97e-05	0.35	0.34	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
COAD	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-5.73	2.78e-08	1.98e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
COAD	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-5.73	2.78e-08	1.98e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
COAD	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	5.73	2.79e-08	1.98e-05	0.46	0.34	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
COAD	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	5.73	2.79e-08	1.98e-05	0.38	0.34	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
COAD	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-5.73	2.8e-08	1.99e-05	-0.38	-0.34	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
COAD	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-5.73	2.8e-08	1.99e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
COAD	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	5.73	2.81e-08	1.99e-05	0.36	0.34	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
COAD	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	5.73	2.82e-08	2e-05	0.37	0.34	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
COAD	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-5.73	2.82e-08	2e-05	-0.38	-0.34	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
COAD	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-5.73	2.82e-08	2e-05	-0.38	-0.34	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
COAD	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-5.73	2.82e-08	2e-05	-0.36	-0.34	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
COAD	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-5.73	2.82e-08	2e-05	-0.23	-0.34	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
COAD	cis	rs7615952	0.515	rs7637246	ENSG00000248787.1	RP11-666A20.4	-5.73	2.83e-08	2.01e-05	-0.48	-0.34	Blood pressure (smoking interaction);	chr3:125959863	chr3:125908005~125910272:-
COAD	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-5.73	2.83e-08	2.01e-05	-0.32	-0.34	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
COAD	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	5.73	2.83e-08	2.01e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
COAD	cis	rs754466	0.58	rs11002293	ENSG00000204049.1	RP11-126H7.4	5.73	2.83e-08	2.01e-05	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778207	chr10:77866875~77869610:+
COAD	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-5.73	2.84e-08	2.02e-05	-0.36	-0.34	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
COAD	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.73	2.84e-08	2.02e-05	-0.45	-0.34	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
COAD	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	5.73	2.84e-08	2.02e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
COAD	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	5.73	2.84e-08	2.02e-05	0.46	0.34	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
COAD	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-5.73	2.85e-08	2.02e-05	-0.5	-0.34	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
COAD	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	5.73	2.85e-08	2.02e-05	0.45	0.34	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
COAD	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	5.73	2.85e-08	2.02e-05	0.35	0.34	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
COAD	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-5.73	2.85e-08	2.02e-05	-0.39	-0.34	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
COAD	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-5.73	2.85e-08	2.02e-05	-0.44	-0.34	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
COAD	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	5.73	2.85e-08	2.02e-05	0.29	0.34	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
COAD	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-5.73	2.85e-08	2.02e-05	-0.39	-0.34	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-5.73	2.85e-08	2.02e-05	-0.39	-0.34	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-5.73	2.85e-08	2.02e-05	-0.39	-0.34	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-5.73	2.85e-08	2.02e-05	-0.39	-0.34	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
COAD	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	5.73	2.86e-08	2.03e-05	0.35	0.34	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
COAD	cis	rs453301	0.719	rs34004903	ENSG00000253981.4	ALG1L13P	-5.73	2.86e-08	2.03e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9035094	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	5.73	2.87e-08	2.03e-05	0.39	0.34	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
COAD	cis	rs7615952	0.932	rs6438948	ENSG00000248787.1	RP11-666A20.4	5.73	2.87e-08	2.03e-05	0.44	0.34	Blood pressure (smoking interaction);	chr3:125931202	chr3:125908005~125910272:-
COAD	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-5.73	2.88e-08	2.04e-05	-0.38	-0.34	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
COAD	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.72	2.88e-08	2.04e-05	0.42	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
COAD	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	5.72	2.88e-08	2.04e-05	0.65	0.34	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
COAD	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-5.72	2.88e-08	2.04e-05	-0.39	-0.34	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
COAD	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-5.72	2.89e-08	2.05e-05	-0.32	-0.34	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.72	2.89e-08	2.05e-05	0.38	0.34	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
COAD	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	5.72	2.89e-08	2.05e-05	0.34	0.34	Asthma;	chr2:102446466	chr2:102438713~102440475:+
COAD	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	5.72	2.9e-08	2.05e-05	0.38	0.34	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
COAD	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-5.72	2.9e-08	2.05e-05	-0.39	-0.34	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-5.72	2.9e-08	2.05e-05	-0.39	-0.34	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-5.72	2.9e-08	2.05e-05	-0.39	-0.34	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
COAD	cis	rs453301	0.686	rs6748	ENSG00000253981.4	ALG1L13P	-5.72	2.9e-08	2.05e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9033292	chr8:8236003~8244667:-
COAD	cis	rs1045529	0.524	rs34251783	ENSG00000253981.4	ALG1L13P	-5.72	2.9e-08	2.05e-05	-0.39	-0.34	Myopia (pathological);Myopia;	chr8:9033866	chr8:8236003~8244667:-
COAD	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	5.72	2.9e-08	2.05e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
COAD	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-5.72	2.9e-08	2.05e-05	-0.41	-0.34	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
COAD	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-5.72	2.9e-08	2.06e-05	-0.36	-0.34	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
COAD	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	5.72	2.91e-08	2.06e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
COAD	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	5.72	2.91e-08	2.06e-05	0.44	0.34	Myopia;	chr6:28302807	chr6:28943877~28944537:+
COAD	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	5.72	2.92e-08	2.06e-05	0.38	0.34	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
COAD	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-5.72	2.92e-08	2.06e-05	-0.52	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
COAD	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-5.72	2.92e-08	2.06e-05	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
COAD	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	5.72	2.92e-08	2.06e-05	0.49	0.34	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	5.72	2.92e-08	2.06e-05	0.49	0.34	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
COAD	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	5.72	2.92e-08	2.07e-05	0.4	0.34	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
COAD	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	5.72	2.92e-08	2.07e-05	0.43	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
COAD	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	5.72	2.93e-08	2.07e-05	0.39	0.34	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
COAD	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	5.72	2.93e-08	2.07e-05	0.36	0.34	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
COAD	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	5.72	2.94e-08	2.08e-05	0.43	0.34	Depression;	chr6:28303421	chr6:28943877~28944537:+
COAD	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-5.72	2.95e-08	2.08e-05	-0.38	-0.34	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-5.72	2.95e-08	2.08e-05	-0.38	-0.34	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
COAD	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-5.72	2.95e-08	2.09e-05	-0.31	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
COAD	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	5.72	2.96e-08	2.09e-05	0.31	0.34	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
COAD	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	5.72	2.96e-08	2.09e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
COAD	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-5.72	2.97e-08	2.1e-05	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
COAD	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-5.72	2.97e-08	2.1e-05	-0.42	-0.34	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
COAD	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	5.72	2.97e-08	2.1e-05	0.52	0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
COAD	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	5.72	2.98e-08	2.11e-05	0.4	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
COAD	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	5.72	2.98e-08	2.11e-05	0.34	0.34	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
COAD	cis	rs362272	0.545	rs2749782	ENSG00000248840.2	RP11-357G3.2	-5.72	2.99e-08	2.11e-05	-0.37	-0.34	Serum sulfate level;	chr4:3338034	chr4:3312512~3313058:+
COAD	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-5.72	2.99e-08	2.11e-05	-0.4	-0.34	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
COAD	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-5.72	2.99e-08	2.11e-05	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
COAD	cis	rs1790761	0.559	rs10896190	ENSG00000231793.4	DOC2GP	5.72	2.99e-08	2.11e-05	0.4	0.34	Mean corpuscular volume;	chr11:67638652	chr11:67612653~67616257:-
COAD	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	5.72	2.99e-08	2.11e-05	0.58	0.34	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
COAD	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-5.72	2.99e-08	2.11e-05	-0.42	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
COAD	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-5.72	2.99e-08	2.11e-05	-0.39	-0.34	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
COAD	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-5.72	2.99e-08	2.11e-05	-0.52	-0.34	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
COAD	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	5.72	3e-08	2.11e-05	0.3	0.34	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	5.72	3e-08	2.11e-05	0.3	0.34	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	5.72	3e-08	2.11e-05	0.3	0.34	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
COAD	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-5.72	3e-08	2.12e-05	-0.56	-0.34	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
COAD	cis	rs2115630	0.936	rs11073663	ENSG00000225151.9	GOLGA2P7	5.72	3.01e-08	2.12e-05	0.38	0.34	P wave terminal force;	chr15:84717037	chr15:84199311~84230136:-
COAD	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-5.72	3.01e-08	2.12e-05	-0.43	-0.34	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
COAD	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-5.71	3.04e-08	2.14e-05	-0.37	-0.34	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
COAD	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-5.71	3.04e-08	2.14e-05	-0.4	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
COAD	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	5.71	3.04e-08	2.14e-05	0.41	0.34	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
COAD	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-5.71	3.05e-08	2.14e-05	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
COAD	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-5.71	3.05e-08	2.15e-05	-0.35	-0.34	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
COAD	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	5.71	3.06e-08	2.15e-05	0.38	0.34	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
COAD	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.07e-08	2.16e-05	-0.44	-0.34	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
COAD	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-5.71	3.07e-08	2.16e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
COAD	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-5.71	3.07e-08	2.16e-05	-0.29	-0.34	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
COAD	cis	rs453301	0.686	rs6748	ENSG00000173295.6	FAM86B3P	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9033292	chr8:8228595~8244865:+
COAD	cis	rs1045529	0.524	rs34251783	ENSG00000173295.6	FAM86B3P	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Myopia (pathological);Myopia;	chr8:9033866	chr8:8228595~8244865:+
COAD	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-5.71	3.07e-08	2.16e-05	-0.39	-0.34	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
COAD	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-5.71	3.08e-08	2.17e-05	-0.43	-0.34	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
COAD	cis	rs453301	0.598	rs1025395	ENSG00000233609.3	RP11-62H7.2	5.71	3.09e-08	2.17e-05	0.37	0.34	Joint mobility (Beighton score);	chr8:8979093	chr8:8961200~8979025:+
COAD	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	5.71	3.09e-08	2.17e-05	0.36	0.34	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
COAD	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	5.71	3.09e-08	2.17e-05	0.41	0.34	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
COAD	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-5.71	3.09e-08	2.18e-05	-0.36	-0.34	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
COAD	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	5.71	3.11e-08	2.18e-05	0.35	0.34	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
COAD	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	5.71	3.11e-08	2.19e-05	0.35	0.34	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
COAD	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	5.71	3.11e-08	2.19e-05	0.35	0.34	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
COAD	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.71	3.12e-08	2.19e-05	-0.44	-0.34	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
COAD	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.13e-08	2.2e-05	-0.43	-0.34	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.13e-08	2.2e-05	-0.43	-0.34	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.13e-08	2.2e-05	-0.43	-0.34	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.13e-08	2.2e-05	-0.43	-0.34	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-5.71	3.13e-08	2.2e-05	-0.43	-0.34	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
COAD	cis	rs362272	0.545	rs2749783	ENSG00000248840.2	RP11-357G3.2	-5.71	3.13e-08	2.2e-05	-0.37	-0.34	Serum sulfate level;	chr4:3324371	chr4:3312512~3313058:+
COAD	cis	rs9309473	0.519	rs2421584	ENSG00000163016.8	ALMS1P	-5.71	3.14e-08	2.2e-05	-0.4	-0.34	Metabolite levels;	chr2:73671725	chr2:73644919~73685576:+
COAD	cis	rs9601248	0.903	rs2783129	ENSG00000227676.3	LINC01068	5.71	3.14e-08	2.2e-05	0.45	0.34	Major depressive disorder;	chr13:79594585	chr13:79566727~79571436:+
COAD	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	5.71	3.14e-08	2.2e-05	0.44	0.34	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
COAD	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	5.71	3.14e-08	2.21e-05	0.46	0.34	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
COAD	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-5.71	3.14e-08	2.21e-05	-0.53	-0.34	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
COAD	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	5.71	3.14e-08	2.21e-05	0.38	0.34	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
COAD	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	5.71	3.14e-08	2.21e-05	0.32	0.34	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
COAD	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-5.71	3.15e-08	2.21e-05	-0.42	-0.34	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
COAD	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-5.71	3.16e-08	2.22e-05	-0.44	-0.34	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
COAD	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	5.71	3.16e-08	2.22e-05	0.35	0.34	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
COAD	cis	rs9368481	0.7	rs6911401	ENSG00000224843.5	LINC00240	-5.71	3.16e-08	2.22e-05	-0.4	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26956992~27023924:+
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	5.71	3.17e-08	2.23e-05	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
COAD	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	5.71	3.18e-08	2.23e-05	0.46	0.34	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
COAD	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-5.71	3.18e-08	2.23e-05	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-5.71	3.18e-08	2.23e-05	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
COAD	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-5.71	3.18e-08	2.23e-05	-0.47	-0.34	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
COAD	cis	rs1056107	0.933	rs6477891	ENSG00000225513.1	RP11-165N19.2	-5.71	3.19e-08	2.23e-05	-0.39	-0.34	Colorectal cancer;	chr9:112200029	chr9:112173522~112173971:-
COAD	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-5.7	3.19e-08	2.24e-05	-0.36	-0.34	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
COAD	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	5.7	3.2e-08	2.24e-05	0.37	0.34	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	5.7	3.2e-08	2.24e-05	0.37	0.34	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
COAD	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-5.7	3.2e-08	2.24e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-5.7	3.2e-08	2.24e-05	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
COAD	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	5.7	3.21e-08	2.24e-05	0.38	0.34	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
COAD	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	5.7	3.21e-08	2.24e-05	0.39	0.34	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
COAD	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-5.7	3.21e-08	2.24e-05	-0.31	-0.34	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
COAD	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-5.7	3.21e-08	2.25e-05	-0.39	-0.34	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-5.7	3.21e-08	2.25e-05	-0.39	-0.34	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
COAD	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-5.7	3.21e-08	2.25e-05	-0.36	-0.34	Height;	chr20:49254902	chr20:49280319~49280409:+
COAD	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-5.7	3.21e-08	2.25e-05	-0.25	-0.34	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
COAD	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	5.7	3.21e-08	2.25e-05	0.62	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
COAD	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	5.7	3.21e-08	2.25e-05	0.45	0.34	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
COAD	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	5.7	3.23e-08	2.26e-05	0.4	0.34	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
COAD	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	5.7	3.23e-08	2.26e-05	0.52	0.34	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
COAD	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	5.7	3.24e-08	2.26e-05	0.32	0.34	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
COAD	cis	rs7615952	0.736	rs13063122	ENSG00000248787.1	RP11-666A20.4	-5.7	3.24e-08	2.26e-05	-0.47	-0.34	Blood pressure (smoking interaction);	chr3:125925017	chr3:125908005~125910272:-
COAD	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-5.7	3.24e-08	2.27e-05	-0.44	-0.34	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
COAD	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.39	-0.34	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
COAD	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	5.7	3.25e-08	2.27e-05	0.36	0.34	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
COAD	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-5.7	3.25e-08	2.27e-05	-0.44	-0.34	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
COAD	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-5.7	3.25e-08	2.27e-05	-0.38	-0.34	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
COAD	cis	rs1056107	0.897	rs1887518	ENSG00000225513.1	RP11-165N19.2	5.7	3.27e-08	2.29e-05	0.4	0.34	Colorectal cancer;	chr9:112195177	chr9:112173522~112173971:-
COAD	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	5.7	3.28e-08	2.29e-05	0.3	0.34	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
COAD	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	5.7	3.28e-08	2.29e-05	0.44	0.34	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
COAD	cis	rs754466	0.606	rs3740250	ENSG00000204049.1	RP11-126H7.4	5.7	3.28e-08	2.29e-05	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77820343	chr10:77866875~77869610:+
COAD	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5.7	3.28e-08	2.29e-05	-0.42	-0.34	Migraine;	chr4:56881195	chr4:56960927~56961373:-
COAD	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	5.7	3.28e-08	2.29e-05	0.5	0.34	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
COAD	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	5.7	3.29e-08	2.29e-05	0.25	0.33	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	5.7	3.29e-08	2.29e-05	0.25	0.33	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	5.7	3.29e-08	2.29e-05	0.25	0.33	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
COAD	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-5.7	3.29e-08	2.3e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
COAD	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	5.7	3.29e-08	2.3e-05	0.56	0.33	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
COAD	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	5.7	3.3e-08	2.3e-05	0.42	0.33	Height;	chr6:109422189	chr6:109382795~109383666:+
COAD	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-5.7	3.3e-08	2.3e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
COAD	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	5.7	3.3e-08	2.31e-05	0.35	0.33	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	5.7	3.3e-08	2.31e-05	0.35	0.33	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
COAD	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	5.7	3.31e-08	2.31e-05	0.45	0.33	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
COAD	cis	rs9951698	0.687	rs10221384	ENSG00000266969.1	RP11-773H22.4	5.7	3.31e-08	2.31e-05	0.38	0.33	Intelligence (multi-trait analysis);	chr18:13035832	chr18:12984694~12991173:-
COAD	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	5.7	3.32e-08	2.31e-05	0.75	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
COAD	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-5.7	3.32e-08	2.31e-05	-0.44	-0.33	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
COAD	cis	rs754466	0.58	rs1344966	ENSG00000204049.1	RP11-126H7.4	5.7	3.32e-08	2.31e-05	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77774769	chr10:77866875~77869610:+
COAD	cis	rs754466	0.58	rs11002294	ENSG00000204049.1	RP11-126H7.4	5.7	3.32e-08	2.31e-05	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77780830	chr10:77866875~77869610:+
COAD	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-5.7	3.33e-08	2.32e-05	-0.36	-0.33	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-5.7	3.33e-08	2.32e-05	-0.36	-0.33	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-5.7	3.33e-08	2.32e-05	-0.36	-0.33	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-5.7	3.33e-08	2.32e-05	-0.36	-0.33	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-5.7	3.33e-08	2.32e-05	-0.36	-0.33	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
COAD	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-5.7	3.34e-08	2.32e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-5.7	3.34e-08	2.32e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
COAD	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	5.7	3.34e-08	2.32e-05	0.41	0.33	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
COAD	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	5.7	3.35e-08	2.33e-05	0.45	0.33	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
COAD	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-5.7	3.35e-08	2.33e-05	-0.34	-0.33	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-5.7	3.35e-08	2.33e-05	-0.34	-0.33	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-5.7	3.35e-08	2.33e-05	-0.34	-0.33	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
COAD	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-5.7	3.35e-08	2.33e-05	-0.44	-0.33	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
COAD	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-5.7	3.35e-08	2.33e-05	-0.44	-0.33	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
COAD	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	5.69	3.38e-08	2.35e-05	0.38	0.33	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
COAD	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-5.69	3.38e-08	2.35e-05	-0.34	-0.33	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-5.69	3.38e-08	2.35e-05	-0.34	-0.33	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
COAD	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-5.69	3.39e-08	2.36e-05	-0.4	-0.33	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
COAD	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	5.69	3.41e-08	2.36e-05	0.41	0.33	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
COAD	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	5.69	3.41e-08	2.37e-05	0.58	0.33	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
COAD	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-5.69	3.41e-08	2.37e-05	-0.45	-0.33	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
COAD	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-5.69	3.43e-08	2.38e-05	-0.44	-0.33	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
COAD	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	5.69	3.45e-08	2.39e-05	0.3	0.33	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	5.69	3.45e-08	2.39e-05	0.3	0.33	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
COAD	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-5.69	3.46e-08	2.4e-05	-0.36	-0.33	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
COAD	cis	rs6584283	0.716	rs10786558	ENSG00000228778.1	RP11-129J12.1	-5.69	3.47e-08	2.41e-05	-0.36	-0.33	Ulcerative colitis;	chr10:99527853	chr10:99527081~99528261:+
COAD	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-5.69	3.47e-08	2.41e-05	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
COAD	cis	rs362272	0.545	rs2236052	ENSG00000248840.2	RP11-357G3.2	5.69	3.47e-08	2.41e-05	0.38	0.33	Serum sulfate level;	chr4:3316686	chr4:3312512~3313058:+
COAD	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	5.69	3.48e-08	2.41e-05	0.43	0.33	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
COAD	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-5.69	3.49e-08	2.42e-05	-0.29	-0.33	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-5.69	3.49e-08	2.42e-05	-0.29	-0.33	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-5.69	3.49e-08	2.42e-05	-0.29	-0.33	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-5.69	3.49e-08	2.42e-05	-0.29	-0.33	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
COAD	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-5.69	3.49e-08	2.42e-05	-0.36	-0.33	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-5.69	3.49e-08	2.42e-05	-0.36	-0.33	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
COAD	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	5.69	3.5e-08	2.43e-05	0.5	0.33	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
COAD	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-5.69	3.5e-08	2.43e-05	-0.38	-0.33	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-5.69	3.5e-08	2.43e-05	-0.38	-0.33	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
COAD	cis	rs3126085	0.515	rs10788835	ENSG00000237975.5	FLG-AS1	5.69	3.51e-08	2.43e-05	0.36	0.33	Atopic dermatitis;	chr1:152358469	chr1:152168125~152445456:+
COAD	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-5.69	3.52e-08	2.43e-05	-0.5	-0.33	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
COAD	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-5.69	3.52e-08	2.43e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-5.69	3.52e-08	2.43e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
COAD	cis	rs453301	0.686	rs11785634	ENSG00000253981.4	ALG1L13P	-5.69	3.52e-08	2.44e-05	-0.4	-0.33	Joint mobility (Beighton score);	chr8:9035087	chr8:8236003~8244667:-
COAD	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	5.69	3.52e-08	2.44e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
COAD	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	5.69	3.53e-08	2.44e-05	0.34	0.33	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	5.69	3.53e-08	2.44e-05	0.34	0.33	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
COAD	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-5.69	3.53e-08	2.44e-05	-0.38	-0.33	Height;	chr3:53069965	chr3:53064283~53065091:-
COAD	cis	rs7829975	0.606	rs6422352	ENSG00000253981.4	ALG1L13P	-5.69	3.53e-08	2.44e-05	-0.4	-0.33	Mood instability;	chr8:8936683	chr8:8236003~8244667:-
COAD	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-5.69	3.53e-08	2.44e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-5.69	3.53e-08	2.44e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
COAD	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-5.69	3.54e-08	2.45e-05	-0.42	-0.33	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
COAD	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	5.68	3.55e-08	2.45e-05	0.25	0.33	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
COAD	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-5.68	3.55e-08	2.45e-05	-0.35	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
COAD	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-5.68	3.55e-08	2.45e-05	-0.35	-0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
COAD	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
COAD	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.55e-08	2.45e-05	-0.43	-0.33	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
COAD	cis	rs3126085	0.515	rs11204984	ENSG00000237975.5	FLG-AS1	5.68	3.55e-08	2.45e-05	0.36	0.33	Atopic dermatitis;	chr1:152359511	chr1:152168125~152445456:+
COAD	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	5.68	3.56e-08	2.46e-05	0.44	0.33	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
COAD	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	5.68	3.56e-08	2.46e-05	0.35	0.33	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
COAD	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-5.68	3.58e-08	2.47e-05	-0.38	-0.33	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
COAD	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	5.68	3.58e-08	2.47e-05	0.59	0.33	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
COAD	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.68	3.58e-08	2.47e-05	-0.43	-0.33	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
COAD	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	5.68	3.58e-08	2.47e-05	0.42	0.33	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
COAD	cis	rs9309473	0.519	rs2421583	ENSG00000163016.8	ALMS1P	-5.68	3.59e-08	2.48e-05	-0.4	-0.33	Metabolite levels;	chr2:73671658	chr2:73644919~73685576:+
COAD	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.59e-08	2.48e-05	-0.43	-0.33	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
COAD	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.59e-08	2.48e-05	-0.43	-0.33	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-5.68	3.59e-08	2.48e-05	-0.43	-0.33	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
COAD	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	5.68	3.59e-08	2.48e-05	0.32	0.33	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
COAD	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.68	3.6e-08	2.48e-05	0.37	0.33	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
COAD	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-5.68	3.61e-08	2.49e-05	-0.36	-0.33	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
COAD	cis	rs754466	0.58	rs10824573	ENSG00000204049.1	RP11-126H7.4	5.68	3.62e-08	2.49e-05	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77781211	chr10:77866875~77869610:+
COAD	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-5.68	3.62e-08	2.49e-05	-0.41	-0.33	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
COAD	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-5.68	3.62e-08	2.49e-05	-0.41	-0.33	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
COAD	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	5.68	3.62e-08	2.5e-05	0.37	0.33	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
COAD	cis	rs1056107	0.898	rs7037927	ENSG00000225513.1	RP11-165N19.2	-5.68	3.62e-08	2.5e-05	-0.39	-0.33	Colorectal cancer;	chr9:112205143	chr9:112173522~112173971:-
COAD	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-5.68	3.62e-08	2.5e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-5.68	3.62e-08	2.5e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-5.68	3.62e-08	2.5e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
COAD	cis	rs7615952	0.8	rs12489350	ENSG00000248787.1	RP11-666A20.4	-5.68	3.63e-08	2.5e-05	-0.46	-0.33	Blood pressure (smoking interaction);	chr3:125925273	chr3:125908005~125910272:-
COAD	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	5.68	3.63e-08	2.5e-05	0.36	0.33	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
COAD	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	5.68	3.63e-08	2.5e-05	0.45	0.33	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
COAD	cis	rs1056107	0.933	rs7865225	ENSG00000225513.1	RP11-165N19.2	-5.68	3.63e-08	2.5e-05	-0.39	-0.33	Colorectal cancer;	chr9:112211969	chr9:112173522~112173971:-
COAD	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-5.68	3.63e-08	2.5e-05	-0.51	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
COAD	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-5.68	3.64e-08	2.5e-05	-0.34	-0.33	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
COAD	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-5.68	3.64e-08	2.51e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
COAD	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	5.68	3.65e-08	2.51e-05	0.52	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
COAD	cis	rs453301	0.653	rs1562211	ENSG00000253981.4	ALG1L13P	-5.68	3.65e-08	2.51e-05	-0.39	-0.33	Joint mobility (Beighton score);	chr8:9044914	chr8:8236003~8244667:-
COAD	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	5.68	3.65e-08	2.52e-05	0.4	0.33	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
COAD	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	5.68	3.65e-08	2.52e-05	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
COAD	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-5.68	3.66e-08	2.52e-05	-0.35	-0.33	Height;	chr11:118760944	chr11:118791254~118793137:+
COAD	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	5.68	3.66e-08	2.52e-05	0.46	0.33	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
COAD	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-5.68	3.66e-08	2.52e-05	-0.34	-0.33	Asthma;	chr2:102374909	chr2:102438713~102440475:+
COAD	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	5.68	3.67e-08	2.52e-05	0.42	0.33	Height;	chr6:109350188	chr6:109382795~109383666:+
COAD	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	5.68	3.67e-08	2.52e-05	0.52	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
COAD	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	5.68	3.67e-08	2.53e-05	0.55	0.33	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
COAD	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-5.68	3.67e-08	2.53e-05	-0.35	-0.33	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
COAD	cis	rs711830	0.965	rs6755777	ENSG00000226363.3	HAGLROS	-5.68	3.67e-08	2.53e-05	-0.51	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176178498	chr2:176177717~176179008:+
COAD	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-5.68	3.68e-08	2.53e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-5.68	3.68e-08	2.53e-05	-0.19	-0.33	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
COAD	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.68	3.68e-08	2.53e-05	0.43	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
COAD	cis	rs2281603	0.951	rs61985707	ENSG00000259116.1	RP11-973N13.4	-5.68	3.7e-08	2.54e-05	-0.36	-0.33	Lymphocyte counts;	chr14:64512846	chr14:64514154~64540368:-
COAD	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-5.68	3.7e-08	2.55e-05	-0.38	-0.33	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
COAD	cis	rs1056107	0.933	rs7038215	ENSG00000225513.1	RP11-165N19.2	-5.68	3.7e-08	2.55e-05	-0.39	-0.33	Colorectal cancer;	chr9:112208523	chr9:112173522~112173971:-
COAD	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	5.68	3.71e-08	2.55e-05	0.36	0.33	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	5.68	3.71e-08	2.55e-05	0.36	0.33	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
COAD	cis	rs1056107	0.872	rs10981315	ENSG00000225513.1	RP11-165N19.2	-5.68	3.71e-08	2.55e-05	-0.39	-0.33	Colorectal cancer;	chr9:112210139	chr9:112173522~112173971:-
COAD	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	5.68	3.71e-08	2.55e-05	0.36	0.33	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
COAD	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-5.68	3.72e-08	2.55e-05	-0.38	-0.33	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
COAD	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	5.68	3.72e-08	2.56e-05	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
COAD	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	5.68	3.73e-08	2.56e-05	0.52	0.33	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
COAD	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	5.68	3.73e-08	2.56e-05	0.42	0.33	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
COAD	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-5.68	3.73e-08	2.56e-05	-0.46	-0.33	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	5.67	3.75e-08	2.58e-05	0.45	0.33	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
COAD	cis	rs2281603	0.951	rs1982440	ENSG00000259116.1	RP11-973N13.4	-5.67	3.75e-08	2.58e-05	-0.36	-0.33	Lymphocyte counts;	chr14:64494049	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs12589947	ENSG00000259116.1	RP11-973N13.4	-5.67	3.75e-08	2.58e-05	-0.36	-0.33	Lymphocyte counts;	chr14:64515453	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10142835	ENSG00000259116.1	RP11-973N13.4	-5.67	3.75e-08	2.58e-05	-0.36	-0.33	Lymphocyte counts;	chr14:64526733	chr14:64514154~64540368:-
COAD	cis	rs711830	1	rs1562315	ENSG00000226363.3	HAGLROS	-5.67	3.76e-08	2.58e-05	-0.51	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176180754	chr2:176177717~176179008:+
COAD	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	5.67	3.76e-08	2.58e-05	0.48	0.33	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
COAD	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	5.67	3.76e-08	2.58e-05	0.45	0.33	Height;	chr6:109573151	chr6:109382795~109383666:+
COAD	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	5.67	3.77e-08	2.58e-05	0.29	0.33	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	5.67	3.77e-08	2.58e-05	0.29	0.33	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	5.67	3.77e-08	2.58e-05	0.29	0.33	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
COAD	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.67	3.77e-08	2.59e-05	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
COAD	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-5.67	3.77e-08	2.59e-05	-0.41	-0.33	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
COAD	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	5.67	3.78e-08	2.59e-05	0.52	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
COAD	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-5.67	3.78e-08	2.59e-05	-0.38	-0.33	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
COAD	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	5.67	3.78e-08	2.59e-05	0.37	0.33	Height;	chr3:53073584	chr3:53064283~53065091:-
COAD	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-5.67	3.78e-08	2.59e-05	-0.5	-0.33	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
COAD	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	5.67	3.78e-08	2.59e-05	0.57	0.33	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	5.67	3.78e-08	2.59e-05	0.57	0.33	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
COAD	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-5.67	3.8e-08	2.6e-05	-0.38	-0.33	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
COAD	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	5.67	3.8e-08	2.6e-05	0.26	0.33	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
COAD	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	5.67	3.8e-08	2.61e-05	0.49	0.33	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
COAD	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	5.67	3.81e-08	2.61e-05	0.41	0.33	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
COAD	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	5.67	3.81e-08	2.61e-05	0.42	0.33	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
COAD	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-5.67	3.81e-08	2.61e-05	-0.36	-0.33	Height;	chr11:118746590	chr11:118704607~118750263:+
COAD	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	5.67	3.81e-08	2.61e-05	0.52	0.33	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
COAD	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	5.67	3.82e-08	2.62e-05	0.29	0.33	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
COAD	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	5.67	3.82e-08	2.62e-05	0.36	0.33	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
COAD	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	5.67	3.83e-08	2.62e-05	0.67	0.33	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
COAD	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	5.67	3.83e-08	2.63e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
COAD	cis	rs1790761	0.554	rs3758938	ENSG00000231793.4	DOC2GP	-5.67	3.84e-08	2.63e-05	-0.43	-0.33	Mean corpuscular volume;	chr11:67634891	chr11:67612653~67616257:-
COAD	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-5.67	3.84e-08	2.63e-05	-0.37	-0.33	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
COAD	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	5.67	3.85e-08	2.64e-05	0.55	0.33	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
COAD	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-5.67	3.86e-08	2.64e-05	-0.38	-0.33	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
COAD	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-5.67	3.86e-08	2.64e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
COAD	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	5.67	3.86e-08	2.64e-05	0.46	0.33	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
COAD	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-5.67	3.87e-08	2.64e-05	-0.38	-0.33	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
COAD	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	5.67	3.89e-08	2.66e-05	0.37	0.33	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
COAD	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	5.67	3.89e-08	2.66e-05	0.55	0.33	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
COAD	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	5.67	3.89e-08	2.66e-05	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
COAD	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.67	3.89e-08	2.66e-05	0.34	0.33	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
COAD	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-5.67	3.9e-08	2.66e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-5.67	3.9e-08	2.66e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
COAD	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	5.67	3.9e-08	2.66e-05	0.35	0.33	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
COAD	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	5.67	3.9e-08	2.67e-05	0.38	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
COAD	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-5.67	3.91e-08	2.68e-05	-0.49	-0.33	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
COAD	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-5.67	3.93e-08	2.68e-05	-0.19	-0.33	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
COAD	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	5.67	3.93e-08	2.68e-05	0.32	0.33	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
COAD	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	5.67	3.93e-08	2.69e-05	0.54	0.33	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
COAD	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	5.66	3.93e-08	2.69e-05	0.47	0.33	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
COAD	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	5.66	3.93e-08	2.69e-05	0.43	0.33	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
COAD	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	5.66	3.94e-08	2.69e-05	0.48	0.33	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
COAD	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	5.66	3.95e-08	2.7e-05	0.25	0.33	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	5.66	3.95e-08	2.7e-05	0.25	0.33	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	5.66	3.95e-08	2.7e-05	0.25	0.33	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
COAD	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	5.66	3.96e-08	2.7e-05	0.56	0.33	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	5.66	3.96e-08	2.7e-05	0.56	0.33	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	5.66	3.96e-08	2.7e-05	0.56	0.33	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
COAD	cis	rs2028299	0.92	rs2043880	ENSG00000259677.1	RP11-493E3.1	5.66	3.97e-08	2.71e-05	0.44	0.33	Type 2 diabetes;	chr15:89889294	chr15:89876540~89877285:+
COAD	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-5.66	3.97e-08	2.71e-05	-0.38	-0.33	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
COAD	cis	rs9659323	0.622	rs28653656	ENSG00000231365.4	RP11-418J17.1	-5.66	3.98e-08	2.72e-05	-0.39	-0.33	Body mass index;	chr1:118943807	chr1:119140396~119275973:+
COAD	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-5.66	3.98e-08	2.72e-05	-0.34	-0.33	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
COAD	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-5.66	3.99e-08	2.72e-05	-0.34	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
COAD	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-5.66	3.99e-08	2.72e-05	-0.35	-0.33	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
COAD	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	5.66	4e-08	2.73e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
COAD	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	5.66	4e-08	2.73e-05	0.43	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
COAD	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	5.66	4e-08	2.73e-05	0.3	0.33	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
COAD	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-5.66	4.01e-08	2.74e-05	-0.42	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
COAD	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	5.66	4.01e-08	2.74e-05	0.46	0.33	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	5.66	4.01e-08	2.74e-05	0.46	0.33	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	5.66	4.01e-08	2.74e-05	0.46	0.33	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
COAD	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-5.66	4.01e-08	2.74e-05	-0.31	-0.33	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
COAD	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-5.66	4.02e-08	2.74e-05	-0.31	-0.33	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
COAD	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-5.66	4.02e-08	2.74e-05	-0.31	-0.33	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
COAD	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-5.66	4.02e-08	2.74e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
COAD	cis	rs58873874	0.737	rs75022277	ENSG00000251405.2	CTB-109A12.1	5.66	4.03e-08	2.74e-05	0.75	0.33	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157362615~157460078:-
COAD	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-5.66	4.03e-08	2.74e-05	-0.34	-0.33	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
COAD	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-5.66	4.03e-08	2.75e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
COAD	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-5.66	4.04e-08	2.75e-05	-0.27	-0.33	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
COAD	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-5.66	4.04e-08	2.75e-05	-0.43	-0.33	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-5.66	4.04e-08	2.75e-05	-0.43	-0.33	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
COAD	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	5.66	4.04e-08	2.75e-05	0.35	0.33	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
COAD	cis	rs1426063	0.614	rs75846524	ENSG00000249717.1	RP11-44F21.3	5.66	4.05e-08	2.76e-05	0.78	0.33	QT interval;	chr4:75083172	chr4:74955974~74970362:-
COAD	cis	rs5015933	0.815	rs3896021	ENSG00000232630.1	PRPS1P2	-5.66	4.05e-08	2.76e-05	-0.33	-0.33	Body mass index;	chr9:125262019	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs35216121	ENSG00000232630.1	PRPS1P2	-5.66	4.05e-08	2.76e-05	-0.33	-0.33	Body mass index;	chr9:125263999	chr9:125150653~125151589:+
COAD	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-5.66	4.06e-08	2.76e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
COAD	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	5.66	4.08e-08	2.78e-05	0.36	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
COAD	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	5.66	4.1e-08	2.79e-05	0.42	0.33	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
COAD	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-5.66	4.1e-08	2.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
COAD	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-5.66	4.11e-08	2.79e-05	-0.34	-0.33	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
COAD	cis	rs1056107	0.933	rs6477912	ENSG00000225513.1	RP11-165N19.2	-5.66	4.11e-08	2.8e-05	-0.38	-0.33	Colorectal cancer;	chr9:112308937	chr9:112173522~112173971:-
COAD	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	5.66	4.11e-08	2.8e-05	0.38	0.33	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
COAD	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	5.66	4.12e-08	2.8e-05	0.23	0.33	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
COAD	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	5.66	4.13e-08	2.81e-05	0.47	0.33	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
COAD	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	5.66	4.13e-08	2.81e-05	0.43	0.33	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
COAD	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	5.66	4.13e-08	2.81e-05	0.46	0.33	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
COAD	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-5.66	4.13e-08	2.81e-05	-0.38	-0.33	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
COAD	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	5.65	4.15e-08	2.82e-05	0.45	0.33	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	5.65	4.15e-08	2.82e-05	0.45	0.33	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	5.65	4.15e-08	2.82e-05	0.45	0.33	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
COAD	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	5.65	4.15e-08	2.82e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	5.65	4.15e-08	2.82e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	5.65	4.15e-08	2.82e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	5.65	4.15e-08	2.82e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	5.65	4.15e-08	2.82e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
COAD	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	5.65	4.16e-08	2.82e-05	0.35	0.33	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
COAD	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.65	4.17e-08	2.83e-05	-0.44	-0.33	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
COAD	cis	rs453301	0.597	rs7001187	ENSG00000173295.6	FAM86B3P	-5.65	4.17e-08	2.83e-05	-0.39	-0.33	Joint mobility (Beighton score);	chr8:8935272	chr8:8228595~8244865:+
COAD	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-5.65	4.17e-08	2.83e-05	-0.36	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
COAD	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-5.65	4.17e-08	2.83e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
COAD	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	5.65	4.17e-08	2.84e-05	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
COAD	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-5.65	4.2e-08	2.85e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-5.65	4.2e-08	2.85e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-5.65	4.2e-08	2.85e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
COAD	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	5.65	4.21e-08	2.86e-05	0.41	0.33	Height;	chr6:109355573	chr6:109382795~109383666:+
COAD	cis	rs1426063	0.614	rs114977200	ENSG00000249717.1	RP11-44F21.3	5.65	4.21e-08	2.86e-05	0.78	0.33	QT interval;	chr4:75088736	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs77625282	ENSG00000249717.1	RP11-44F21.3	5.65	4.21e-08	2.86e-05	0.78	0.33	QT interval;	chr4:75089646	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs75112697	ENSG00000249717.1	RP11-44F21.3	5.65	4.21e-08	2.86e-05	0.78	0.33	QT interval;	chr4:75089725	chr4:74955974~74970362:-
COAD	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.65	4.22e-08	2.86e-05	-0.37	-0.33	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
COAD	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	5.65	4.23e-08	2.87e-05	0.36	0.33	Height;	chr20:49286482	chr20:49280319~49280409:+
COAD	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-5.65	4.23e-08	2.87e-05	-0.39	-0.33	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
COAD	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-5.65	4.24e-08	2.88e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-5.65	4.24e-08	2.88e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
COAD	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	5.65	4.25e-08	2.88e-05	0.34	0.33	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
COAD	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.65	4.25e-08	2.88e-05	-0.44	-0.33	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
COAD	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	5.65	4.26e-08	2.89e-05	0.44	0.33	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
COAD	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	5.65	4.26e-08	2.89e-05	0.39	0.33	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	5.65	4.26e-08	2.89e-05	0.39	0.33	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
COAD	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-5.65	4.27e-08	2.89e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
COAD	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	5.65	4.27e-08	2.89e-05	0.45	0.33	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
COAD	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.65	4.27e-08	2.89e-05	0.35	0.33	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
COAD	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.65	4.29e-08	2.9e-05	-0.37	-0.33	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
COAD	cis	rs9309473	0.519	rs2421667	ENSG00000163016.8	ALMS1P	-5.65	4.29e-08	2.9e-05	-0.41	-0.33	Metabolite levels;	chr2:73605332	chr2:73644919~73685576:+
COAD	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	-5.65	4.29e-08	2.9e-05	-0.41	-0.33	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
COAD	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-5.65	4.29e-08	2.91e-05	-0.39	-0.33	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
COAD	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	5.65	4.3e-08	2.91e-05	0.47	0.33	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
COAD	cis	rs7615952	0.866	rs6438949	ENSG00000248787.1	RP11-666A20.4	-5.65	4.32e-08	2.92e-05	-0.45	-0.33	Blood pressure (smoking interaction);	chr3:125931221	chr3:125908005~125910272:-
COAD	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	5.65	4.33e-08	2.93e-05	0.48	0.33	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.65	4.33e-08	2.93e-05	-0.39	-0.33	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
COAD	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	5.65	4.33e-08	2.93e-05	0.48	0.33	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
COAD	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	5.65	4.33e-08	2.93e-05	0.28	0.33	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
COAD	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	5.65	4.33e-08	2.93e-05	0.6	0.33	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
COAD	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	5.65	4.33e-08	2.93e-05	0.6	0.33	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
COAD	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	5.65	4.34e-08	2.93e-05	0.36	0.33	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
COAD	cis	rs453301	0.598	rs2921383	ENSG00000233609.3	RP11-62H7.2	5.65	4.34e-08	2.94e-05	0.38	0.33	Joint mobility (Beighton score);	chr8:9034711	chr8:8961200~8979025:+
COAD	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	5.65	4.35e-08	2.94e-05	0.34	0.33	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
COAD	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	5.65	4.35e-08	2.94e-05	0.41	0.33	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
COAD	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-5.64	4.36e-08	2.95e-05	-0.31	-0.33	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
COAD	cis	rs9393777	0.528	rs7745603	ENSG00000224843.5	LINC00240	5.64	4.37e-08	2.95e-05	0.46	0.33	Intelligence (multi-trait analysis);	chr6:27122625	chr6:26956992~27023924:+
COAD	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	5.64	4.37e-08	2.96e-05	0.36	0.33	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
COAD	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	5.64	4.38e-08	2.96e-05	0.44	0.33	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	5.64	4.38e-08	2.96e-05	0.44	0.33	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
COAD	cis	rs2115630	0.691	rs2292462	ENSG00000259728.4	LINC00933	-5.64	4.38e-08	2.96e-05	-0.4	-0.33	P wave terminal force;	chr15:84657523	chr15:84570649~84580175:+
COAD	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	5.64	4.38e-08	2.96e-05	0.44	0.33	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
COAD	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-5.64	4.38e-08	2.96e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
COAD	cis	rs1426063	0.614	rs6534447	ENSG00000249717.1	RP11-44F21.3	-5.64	4.4e-08	2.97e-05	-0.75	-0.33	QT interval;	chr4:75080682	chr4:74955974~74970362:-
COAD	cis	rs5758659	0.714	rs6002607	ENSG00000182057.4	OGFRP1	-5.64	4.4e-08	2.97e-05	-0.36	-0.33	Cognitive function;	chr22:42100502	chr22:42269753~42275196:+
COAD	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-5.64	4.4e-08	2.97e-05	-0.38	-0.33	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
COAD	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-5.64	4.4e-08	2.97e-05	-0.32	-0.33	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
COAD	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-5.64	4.4e-08	2.97e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-5.64	4.4e-08	2.97e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
COAD	cis	rs362272	0.524	rs2749781	ENSG00000248840.2	RP11-357G3.2	-5.64	4.41e-08	2.98e-05	-0.38	-0.33	Serum sulfate level;	chr4:3344890	chr4:3312512~3313058:+
COAD	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-5.64	4.41e-08	2.98e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
COAD	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-5.64	4.42e-08	2.98e-05	-0.38	-0.33	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
COAD	cis	rs9309473	0.5	rs2421582	ENSG00000163016.8	ALMS1P	-5.64	4.42e-08	2.98e-05	-0.4	-0.33	Metabolite levels;	chr2:73671293	chr2:73644919~73685576:+
COAD	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-5.64	4.42e-08	2.98e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-5.64	4.42e-08	2.98e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
COAD	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-5.64	4.42e-08	2.98e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
COAD	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-5.64	4.43e-08	2.99e-05	-0.39	-0.33	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
COAD	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	5.64	4.43e-08	2.99e-05	0.31	0.33	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
COAD	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-5.64	4.45e-08	3e-05	-0.36	-0.33	Height;	chr20:49227804	chr20:49280319~49280409:+
COAD	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-5.64	4.46e-08	3.01e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
COAD	cis	rs75422866	0.85	rs73111210	ENSG00000274902.1	RP1-197B17.4	5.64	4.46e-08	3.01e-05	0.95	0.33	Pneumonia;	chr12:47576949	chr12:47731908~47732351:+
COAD	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-5.64	4.46e-08	3.01e-05	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
COAD	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	5.64	4.46e-08	3.01e-05	0.36	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
COAD	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	5.64	4.47e-08	3.01e-05	0.36	0.33	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
COAD	cis	rs860818	1	rs858316	ENSG00000226816.2	AC005082.12	5.64	4.47e-08	3.01e-05	0.78	0.33	Initial pursuit acceleration;	chr7:23163511	chr7:23206013~23208045:+
COAD	cis	rs860818	0.793	rs4722233	ENSG00000226816.2	AC005082.12	-5.64	4.47e-08	3.01e-05	-0.78	-0.33	Initial pursuit acceleration;	chr7:23157792	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs6960118	ENSG00000226816.2	AC005082.12	-5.64	4.47e-08	3.01e-05	-0.78	-0.33	Initial pursuit acceleration;	chr7:23160709	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs6964671	ENSG00000226816.2	AC005082.12	-5.64	4.47e-08	3.01e-05	-0.78	-0.33	Initial pursuit acceleration;	chr7:23161183	chr7:23206013~23208045:+
COAD	cis	rs860818	1	rs6461699	ENSG00000226816.2	AC005082.12	-5.64	4.47e-08	3.01e-05	-0.78	-0.33	Initial pursuit acceleration;	chr7:23162679	chr7:23206013~23208045:+
COAD	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	5.64	4.47e-08	3.01e-05	0.45	0.33	Height;	chr6:109712525	chr6:109382795~109383666:+
COAD	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	5.64	4.47e-08	3.02e-05	0.44	0.33	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
COAD	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	5.64	4.47e-08	3.02e-05	0.44	0.33	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
COAD	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-5.64	4.48e-08	3.02e-05	-0.32	-0.33	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
COAD	cis	rs1056107	0.574	rs9886804	ENSG00000225513.1	RP11-165N19.2	5.64	4.48e-08	3.02e-05	0.41	0.33	Colorectal cancer;	chr9:112159787	chr9:112173522~112173971:-
COAD	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	5.64	4.48e-08	3.02e-05	0.41	0.33	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
COAD	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	5.64	4.49e-08	3.02e-05	0.62	0.33	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
COAD	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	5.64	4.49e-08	3.02e-05	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
COAD	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	5.64	4.49e-08	3.02e-05	0.41	0.33	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
COAD	cis	rs7955901	0.904	rs4760894	ENSG00000258053.1	CTD-2021H9.3	-5.64	4.49e-08	3.03e-05	-0.4	-0.33	Type 2 diabetes;	chr12:71045143	chr12:71047402~71118247:-
COAD	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-5.64	4.5e-08	3.03e-05	-0.37	-0.33	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
COAD	cis	rs754466	0.58	rs2289309	ENSG00000204049.1	RP11-126H7.4	5.64	4.51e-08	3.04e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77811350	chr10:77866875~77869610:+
COAD	cis	rs754466	0.58	rs11002301	ENSG00000204049.1	RP11-126H7.4	5.64	4.51e-08	3.04e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77814320	chr10:77866875~77869610:+
COAD	cis	rs754466	0.58	rs10824577	ENSG00000204049.1	RP11-126H7.4	5.64	4.51e-08	3.04e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77817650	chr10:77866875~77869610:+
COAD	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-5.64	4.51e-08	3.04e-05	-0.45	-0.33	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
COAD	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	5.64	4.51e-08	3.04e-05	0.43	0.33	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
COAD	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-5.64	4.52e-08	3.04e-05	-0.36	-0.33	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
COAD	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	5.64	4.52e-08	3.04e-05	0.44	0.33	Height;	chr6:109737797	chr6:109382795~109383666:+
COAD	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-5.64	4.53e-08	3.05e-05	-0.44	-0.33	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
COAD	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	5.64	4.53e-08	3.05e-05	0.38	0.33	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
COAD	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-5.64	4.53e-08	3.05e-05	-0.35	-0.33	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
COAD	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-5.64	4.54e-08	3.06e-05	-0.43	-0.33	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-5.64	4.54e-08	3.06e-05	-0.43	-0.33	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
COAD	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-5.64	4.55e-08	3.06e-05	-0.34	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
COAD	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-5.64	4.55e-08	3.06e-05	-0.43	-0.33	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
COAD	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-5.64	4.56e-08	3.06e-05	-0.43	-0.33	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
COAD	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	5.64	4.56e-08	3.06e-05	0.41	0.33	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
COAD	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-5.64	4.56e-08	3.06e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
COAD	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-5.64	4.56e-08	3.06e-05	-0.45	-0.33	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
COAD	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-5.64	4.56e-08	3.06e-05	-0.45	-0.33	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	5.64	4.56e-08	3.06e-05	0.36	0.33	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	5.64	4.56e-08	3.06e-05	0.36	0.33	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	5.64	4.56e-08	3.06e-05	0.36	0.33	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	5.64	4.56e-08	3.06e-05	0.36	0.33	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
COAD	cis	rs711830	0.931	rs6755766	ENSG00000226363.3	HAGLROS	-5.64	4.57e-08	3.07e-05	-0.51	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176178477	chr2:176177717~176179008:+
COAD	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	5.64	4.57e-08	3.07e-05	0.47	0.33	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
COAD	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	5.64	4.57e-08	3.07e-05	0.34	0.33	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
COAD	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-5.64	4.58e-08	3.08e-05	-0.38	-0.33	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
COAD	cis	rs58873874	0.649	rs75791619	ENSG00000248544.2	CTB-47B11.3	5.64	4.59e-08	3.08e-05	0.63	0.33	Bipolar disorder (body mass index interaction);	chr5:157370204	chr5:157375741~157384950:-
COAD	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-5.64	4.59e-08	3.08e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
COAD	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-5.64	4.59e-08	3.08e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
COAD	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	5.63	4.6e-08	3.09e-05	0.35	0.33	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
COAD	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	5.63	4.6e-08	3.09e-05	0.34	0.33	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
COAD	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	5.63	4.61e-08	3.1e-05	0.39	0.33	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
COAD	cis	rs1056107	0.931	rs11792718	ENSG00000225513.1	RP11-165N19.2	-5.63	4.63e-08	3.11e-05	-0.39	-0.33	Colorectal cancer;	chr9:112253684	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs10981332	ENSG00000225513.1	RP11-165N19.2	-5.63	4.63e-08	3.11e-05	-0.39	-0.33	Colorectal cancer;	chr9:112254003	chr9:112173522~112173971:-
COAD	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	5.63	4.63e-08	3.11e-05	0.36	0.33	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
COAD	cis	rs3126085	0.515	rs6671146	ENSG00000237975.5	FLG-AS1	5.63	4.63e-08	3.11e-05	0.36	0.33	Atopic dermatitis;	chr1:152381996	chr1:152168125~152445456:+
COAD	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	5.63	4.63e-08	3.11e-05	0.24	0.33	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
COAD	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-5.63	4.63e-08	3.11e-05	-0.43	-0.33	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-5.63	4.64e-08	3.11e-05	-0.43	-0.33	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
COAD	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	5.63	4.64e-08	3.11e-05	0.64	0.33	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
COAD	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-5.63	4.65e-08	3.12e-05	-0.49	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
COAD	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	5.63	4.66e-08	3.12e-05	0.36	0.33	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
COAD	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-5.63	4.67e-08	3.13e-05	-0.36	-0.33	Height;	chr20:49262572	chr20:49280319~49280409:+
COAD	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	5.63	4.67e-08	3.13e-05	0.39	0.33	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
COAD	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-5.63	4.68e-08	3.13e-05	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
COAD	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-5.63	4.68e-08	3.13e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
COAD	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	5.63	4.68e-08	3.14e-05	0.42	0.33	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	5.63	4.68e-08	3.14e-05	0.42	0.33	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
COAD	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-5.63	4.68e-08	3.14e-05	-0.29	-0.33	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
COAD	cis	rs7617480	0.61	rs4955420	ENSG00000225399.4	RP11-3B7.1	5.63	4.68e-08	3.14e-05	0.37	0.33	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49260085~49261316:+
COAD	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-5.63	4.69e-08	3.14e-05	-0.46	-0.33	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
COAD	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	5.63	4.69e-08	3.14e-05	0.46	0.33	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
COAD	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	5.63	4.7e-08	3.15e-05	0.4	0.33	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
COAD	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	5.63	4.71e-08	3.16e-05	0.25	0.33	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
COAD	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	5.63	4.72e-08	3.16e-05	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
COAD	cis	rs453301	0.719	rs34004903	ENSG00000173295.6	FAM86B3P	-5.63	4.73e-08	3.17e-05	-0.38	-0.33	Joint mobility (Beighton score);	chr8:9035094	chr8:8228595~8244865:+
COAD	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-5.63	4.73e-08	3.17e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	5.63	4.73e-08	3.17e-05	0.2	0.33	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
COAD	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-5.63	4.73e-08	3.17e-05	-0.35	-0.33	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
COAD	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-5.63	4.74e-08	3.17e-05	-0.39	-0.33	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
COAD	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-5.63	4.74e-08	3.17e-05	-0.42	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-5.63	4.75e-08	3.18e-05	-0.2	-0.33	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
COAD	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	5.63	4.75e-08	3.18e-05	0.41	0.33	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
COAD	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	5.63	4.75e-08	3.18e-05	0.42	0.33	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
COAD	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-5.63	4.76e-08	3.18e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
COAD	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-5.63	4.76e-08	3.18e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
COAD	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-5.63	4.76e-08	3.19e-05	-0.34	-0.33	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
COAD	cis	rs911186	0.509	rs6934329	ENSG00000224843.5	LINC00240	5.63	4.78e-08	3.19e-05	0.56	0.33	Autism spectrum disorder or schizophrenia;	chr6:27190254	chr6:26956992~27023924:+
COAD	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	5.63	4.78e-08	3.2e-05	0.43	0.33	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
COAD	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-5.63	4.78e-08	3.2e-05	-0.38	-0.33	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-5.63	4.79e-08	3.2e-05	-0.38	-0.33	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-5.63	4.79e-08	3.2e-05	-0.38	-0.33	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
COAD	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-5.63	4.8e-08	3.21e-05	-0.35	-0.33	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
COAD	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	5.63	4.83e-08	3.23e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
COAD	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-5.63	4.83e-08	3.23e-05	-0.4	-0.33	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
COAD	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-5.63	4.83e-08	3.23e-05	-0.4	-0.33	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
COAD	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-5.62	4.85e-08	3.24e-05	-0.37	-0.33	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
COAD	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-5.62	4.85e-08	3.24e-05	-0.37	-0.33	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
COAD	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-5.62	4.85e-08	3.24e-05	-0.36	-0.33	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
COAD	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	5.62	4.86e-08	3.24e-05	0.29	0.33	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
COAD	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-5.62	4.86e-08	3.24e-05	-0.44	-0.33	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
COAD	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-5.62	4.86e-08	3.24e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
COAD	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	5.62	4.86e-08	3.25e-05	0.42	0.33	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
COAD	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-5.62	4.87e-08	3.25e-05	-0.54	-0.33	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
COAD	cis	rs9659323	0.689	rs7545737	ENSG00000231365.4	RP11-418J17.1	5.62	4.87e-08	3.25e-05	0.4	0.33	Body mass index;	chr1:118991200	chr1:119140396~119275973:+
COAD	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-5.62	4.89e-08	3.26e-05	-0.55	-0.33	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	5.62	4.89e-08	3.26e-05	0.36	0.33	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
COAD	cis	rs4950322	0.518	rs61838938	ENSG00000278811.3	LINC00624	5.62	4.89e-08	3.26e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147105943	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.529	rs11809327	ENSG00000278811.3	LINC00624	5.62	4.89e-08	3.26e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147106679	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.563	rs11809328	ENSG00000278811.3	LINC00624	5.62	4.89e-08	3.26e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147106681	chr1:147258885~147517875:-
COAD	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-5.62	4.9e-08	3.27e-05	-0.27	-0.33	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
COAD	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-5.62	4.9e-08	3.27e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-5.62	4.9e-08	3.27e-05	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
COAD	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-5.62	4.91e-08	3.27e-05	-0.42	-0.33	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
COAD	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	5.62	4.92e-08	3.28e-05	0.35	0.33	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
COAD	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-5.62	4.92e-08	3.28e-05	-0.41	-0.33	Height;	chr6:109417511	chr6:109382795~109383666:+
COAD	cis	rs4568518	0.501	rs12699920	ENSG00000279048.1	RP11-511H23.2	5.62	4.93e-08	3.28e-05	0.23	0.33	Measles;	chr7:17953326	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.53	rs4721674	ENSG00000279048.1	RP11-511H23.2	5.62	4.93e-08	3.28e-05	0.23	0.33	Measles;	chr7:17953754	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.53	rs7802064	ENSG00000279048.1	RP11-511H23.2	5.62	4.93e-08	3.28e-05	0.23	0.33	Measles;	chr7:17955230	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.53	rs7802331	ENSG00000279048.1	RP11-511H23.2	5.62	4.93e-08	3.28e-05	0.23	0.33	Measles;	chr7:17955352	chr7:17940503~17942922:+
COAD	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.62	4.93e-08	3.28e-05	0.35	0.33	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
COAD	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	5.62	4.93e-08	3.28e-05	0.39	0.33	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
COAD	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	5.62	4.93e-08	3.29e-05	0.32	0.33	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
COAD	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	5.62	4.94e-08	3.29e-05	0.43	0.33	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
COAD	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	5.62	4.94e-08	3.29e-05	0.26	0.33	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
COAD	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.62	4.94e-08	3.29e-05	-0.51	-0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
COAD	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-5.62	4.95e-08	3.29e-05	-0.39	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
COAD	cis	rs453301	0.658	rs13271797	ENSG00000173295.6	FAM86B3P	-5.62	4.95e-08	3.3e-05	-0.38	-0.33	Joint mobility (Beighton score);	chr8:9028444	chr8:8228595~8244865:+
COAD	cis	rs754466	0.51	rs55893027	ENSG00000204049.1	RP11-126H7.4	5.62	4.95e-08	3.3e-05	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77828451	chr10:77866875~77869610:+
COAD	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	5.62	4.96e-08	3.3e-05	0.39	0.33	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
COAD	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	5.62	4.97e-08	3.31e-05	0.37	0.33	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
COAD	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.62	4.97e-08	3.31e-05	0.37	0.33	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
COAD	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	5.62	4.98e-08	3.31e-05	0.38	0.33	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
COAD	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.62	4.98e-08	3.31e-05	0.37	0.33	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.62	4.98e-08	3.31e-05	0.37	0.33	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
COAD	cis	rs8062405	0.656	rs7189927	ENSG00000251417.2	RP11-1348G14.4	5.62	4.98e-08	3.31e-05	0.37	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28802743~28817828:+
COAD	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.62	4.99e-08	3.32e-05	0.35	0.33	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
COAD	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-5.62	5e-08	3.32e-05	-0.43	-0.33	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
COAD	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-5.62	5e-08	3.32e-05	-0.4	-0.33	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
COAD	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-5.62	5e-08	3.32e-05	-0.36	-0.33	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
COAD	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	5.62	5e-08	3.33e-05	0.34	0.33	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
COAD	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	5.62	5e-08	3.33e-05	0.34	0.33	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
COAD	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	5.62	5e-08	3.33e-05	0.47	0.33	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
COAD	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	5.62	5.02e-08	3.34e-05	0.26	0.33	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
COAD	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	5.62	5.02e-08	3.34e-05	0.26	0.33	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
COAD	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	5.62	5.02e-08	3.34e-05	0.32	0.33	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
COAD	cis	rs5015933	0.778	rs867547	ENSG00000232630.1	PRPS1P2	-5.62	5.03e-08	3.34e-05	-0.32	-0.33	Body mass index;	chr9:125269184	chr9:125150653~125151589:+
COAD	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	5.62	5.03e-08	3.34e-05	0.35	0.33	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
COAD	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	5.62	5.03e-08	3.34e-05	0.32	0.33	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
COAD	cis	rs210138	0.832	rs375555	ENSG00000197251.3	LINC00336	5.62	5.03e-08	3.35e-05	0.57	0.33	Testicular germ cell tumor;	chr6:33589964	chr6:33586106~33593338:-
COAD	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	5.62	5.04e-08	3.35e-05	0.32	0.33	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-5.62	5.05e-08	3.36e-05	-0.32	-0.33	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
COAD	cis	rs11155671	0.53	rs9371504	ENSG00000268592.3	RAET1E-AS1	5.62	5.06e-08	3.36e-05	0.36	0.33	Testicular germ cell tumor;	chr6:149862944	chr6:149863494~149919507:+
COAD	cis	rs11155671	0.53	rs9371505	ENSG00000268592.3	RAET1E-AS1	5.62	5.06e-08	3.36e-05	0.36	0.33	Testicular germ cell tumor;	chr6:149863012	chr6:149863494~149919507:+
COAD	cis	rs7078219	0.576	rs989979	ENSG00000228778.1	RP11-129J12.1	-5.62	5.06e-08	3.36e-05	-0.34	-0.33	Dental caries;	chr10:99562666	chr10:99527081~99528261:+
COAD	cis	rs9659323	0.65	rs12086486	ENSG00000231365.4	RP11-418J17.1	-5.62	5.07e-08	3.37e-05	-0.38	-0.33	Body mass index;	chr1:118946419	chr1:119140396~119275973:+
COAD	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	5.62	5.07e-08	3.37e-05	0.4	0.33	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
COAD	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	5.62	5.07e-08	3.37e-05	0.46	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
COAD	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	5.62	5.07e-08	3.37e-05	0.37	0.33	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
COAD	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	5.62	5.08e-08	3.37e-05	0.34	0.33	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
COAD	cis	rs858267	1	rs858267	ENSG00000226816.2	AC005082.12	5.61	5.1e-08	3.38e-05	0.7	0.33	Blood protein levels;	chr7:23170510	chr7:23206013~23208045:+
COAD	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-5.61	5.1e-08	3.39e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
COAD	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	5.61	5.11e-08	3.39e-05	0.3	0.33	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
COAD	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	5.61	5.11e-08	3.39e-05	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
COAD	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.61	5.12e-08	3.39e-05	-0.43	-0.33	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
COAD	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-5.61	5.12e-08	3.4e-05	-0.44	-0.33	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
COAD	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-5.61	5.13e-08	3.41e-05	-0.35	-0.33	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
COAD	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	5.61	5.14e-08	3.41e-05	0.4	0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
COAD	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	5.61	5.14e-08	3.41e-05	0.4	0.33	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
COAD	cis	rs2732480	0.557	rs923397	ENSG00000273765.1	RP11-370I10.11	5.61	5.14e-08	3.41e-05	0.37	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48360920~48361377:+
COAD	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.61	5.15e-08	3.41e-05	0.35	0.33	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
COAD	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	5.61	5.15e-08	3.42e-05	0.33	0.33	Asthma;	chr2:102440033	chr2:102438713~102440475:+
COAD	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-5.61	5.15e-08	3.42e-05	-0.58	-0.33	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
COAD	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	5.61	5.16e-08	3.42e-05	0.39	0.33	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
COAD	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-5.61	5.16e-08	3.42e-05	-0.38	-0.33	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-5.61	5.16e-08	3.42e-05	-0.38	-0.33	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
COAD	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	5.61	5.16e-08	3.42e-05	0.41	0.33	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
COAD	cis	rs13256369	1	rs9329166	ENSG00000173295.6	FAM86B3P	5.61	5.16e-08	3.42e-05	0.49	0.33	Obesity-related traits;	chr8:8719145	chr8:8228595~8244865:+
COAD	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-5.61	5.17e-08	3.43e-05	-0.28	-0.33	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
COAD	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	5.61	5.18e-08	3.43e-05	0.38	0.33	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
COAD	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	5.61	5.2e-08	3.44e-05	0.45	0.33	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	5.61	5.2e-08	3.44e-05	0.45	0.33	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
COAD	cis	rs12935418	0.616	rs2549854	ENSG00000278985.1	RP11-303E16.9	5.61	5.21e-08	3.45e-05	0.35	0.33	Mean corpuscular volume;	chr16:80993034	chr16:80982319~80984094:-
COAD	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	5.61	5.21e-08	3.45e-05	0.39	0.33	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
COAD	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-5.61	5.21e-08	3.45e-05	-0.35	-0.33	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
COAD	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-5.61	5.21e-08	3.45e-05	-0.35	-0.33	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
COAD	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.61	5.21e-08	3.45e-05	0.35	0.33	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
COAD	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.61	5.22e-08	3.46e-05	-0.34	-0.33	Height;	chr11:118761813	chr11:118791254~118793137:+
COAD	cis	rs7078219	0.714	rs10883368	ENSG00000257582.4	LINC01475	-5.61	5.22e-08	3.46e-05	-0.37	-0.33	Dental caries;	chr10:99530241	chr10:99526350~99531177:-
COAD	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	5.61	5.22e-08	3.46e-05	0.37	0.33	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
COAD	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	5.61	5.22e-08	3.46e-05	0.37	0.33	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
COAD	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-5.61	5.23e-08	3.46e-05	-0.36	-0.33	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
COAD	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	5.61	5.23e-08	3.47e-05	0.76	0.33	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	5.61	5.23e-08	3.47e-05	0.76	0.33	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	5.61	5.23e-08	3.47e-05	0.76	0.33	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	5.61	5.23e-08	3.47e-05	0.76	0.33	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
COAD	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-5.61	5.23e-08	3.47e-05	-0.32	-0.33	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
COAD	cis	rs453301	0.653	rs7853	ENSG00000233609.3	RP11-62H7.2	5.61	5.23e-08	3.47e-05	0.37	0.33	Joint mobility (Beighton score);	chr8:9033304	chr8:8961200~8979025:+
COAD	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-5.61	5.23e-08	3.47e-05	-0.38	-0.33	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
COAD	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
COAD	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	5.61	5.24e-08	3.47e-05	0.45	0.33	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
COAD	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	5.61	5.24e-08	3.47e-05	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
COAD	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	5.61	5.24e-08	3.47e-05	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
COAD	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	5.61	5.24e-08	3.47e-05	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
COAD	cis	rs7615952	0.515	rs4267608	ENSG00000248787.1	RP11-666A20.4	-5.61	5.24e-08	3.47e-05	-0.44	-0.33	Blood pressure (smoking interaction);	chr3:125961657	chr3:125908005~125910272:-
COAD	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-5.61	5.26e-08	3.48e-05	-0.43	-0.33	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
COAD	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-5.61	5.27e-08	3.48e-05	-0.4	-0.33	Migraine;	chr4:56879851	chr4:56960927~56961373:-
COAD	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-5.61	5.27e-08	3.48e-05	-0.4	-0.33	Migraine;	chr4:56880007	chr4:56960927~56961373:-
COAD	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-5.61	5.27e-08	3.48e-05	-0.4	-0.33	Migraine;	chr4:56880190	chr4:56960927~56961373:-
COAD	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-5.61	5.27e-08	3.48e-05	-0.4	-0.33	Migraine;	chr4:56880659	chr4:56960927~56961373:-
COAD	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	5.61	5.27e-08	3.48e-05	0.41	0.33	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
COAD	cis	rs6940638	0.662	rs6915678	ENSG00000224843.5	LINC00240	5.61	5.27e-08	3.49e-05	0.41	0.33	Intelligence (multi-trait analysis);	chr6:27268087	chr6:26956992~27023924:+
COAD	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-5.61	5.29e-08	3.5e-05	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-5.61	5.29e-08	3.5e-05	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-5.61	5.29e-08	3.5e-05	-0.37	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
COAD	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	5.61	5.3e-08	3.5e-05	0.39	0.33	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
COAD	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-5.61	5.3e-08	3.5e-05	-0.38	-0.33	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
COAD	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-5.61	5.3e-08	3.5e-05	-0.29	-0.33	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
COAD	cis	rs1056107	0.966	rs4979094	ENSG00000225513.1	RP11-165N19.2	-5.61	5.3e-08	3.51e-05	-0.39	-0.33	Colorectal cancer;	chr9:112283837	chr9:112173522~112173971:-
COAD	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	5.61	5.32e-08	3.51e-05	0.36	0.33	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
COAD	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-5.61	5.32e-08	3.52e-05	-0.42	-0.33	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
COAD	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-5.61	5.33e-08	3.52e-05	-0.37	-0.33	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-5.61	5.33e-08	3.52e-05	-0.37	-0.33	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
COAD	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	5.61	5.33e-08	3.52e-05	0.59	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
COAD	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-5.61	5.33e-08	3.52e-05	-0.34	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
COAD	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-5.61	5.33e-08	3.52e-05	-0.43	-0.33	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-5.61	5.33e-08	3.52e-05	-0.43	-0.33	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
COAD	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	5.61	5.34e-08	3.53e-05	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
COAD	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	5.6	5.37e-08	3.54e-05	0.35	0.33	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
COAD	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	5.6	5.37e-08	3.54e-05	0.32	0.33	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
COAD	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	5.6	5.37e-08	3.55e-05	0.45	0.33	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
COAD	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-5.6	5.38e-08	3.55e-05	-0.4	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
COAD	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-5.6	5.39e-08	3.55e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
COAD	cis	rs9348729	1	rs9348729	ENSG00000224843.5	LINC00240	5.6	5.39e-08	3.56e-05	0.5	0.33	Intelligence (multi-trait analysis);	chr6:26664040	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs1104871	ENSG00000224843.5	LINC00240	5.6	5.39e-08	3.56e-05	0.5	0.33	Intelligence (multi-trait analysis);	chr6:26665007	chr6:26956992~27023924:+
COAD	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	5.6	5.39e-08	3.56e-05	0.45	0.33	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
COAD	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-5.6	5.4e-08	3.56e-05	-0.37	-0.33	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
COAD	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-5.6	5.4e-08	3.56e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
COAD	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-5.6	5.4e-08	3.56e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
COAD	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-5.6	5.4e-08	3.56e-05	-0.31	-0.33	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
COAD	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	5.6	5.4e-08	3.56e-05	0.46	0.33	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
COAD	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	5.6	5.4e-08	3.56e-05	0.4	0.33	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
COAD	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-5.6	5.41e-08	3.57e-05	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-5.6	5.41e-08	3.57e-05	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
COAD	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	5.6	5.41e-08	3.57e-05	0.48	0.33	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
COAD	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	5.6	5.41e-08	3.57e-05	0.45	0.33	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
COAD	cis	rs2732480	0.557	rs2409004	ENSG00000273765.1	RP11-370I10.11	5.6	5.43e-08	3.58e-05	0.37	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2450994	ENSG00000273765.1	RP11-370I10.11	5.6	5.43e-08	3.58e-05	0.37	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48360920~48361377:+
COAD	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	5.6	5.45e-08	3.59e-05	0.45	0.33	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
COAD	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	5.6	5.45e-08	3.59e-05	0.36	0.33	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
COAD	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-5.6	5.45e-08	3.59e-05	-0.34	-0.33	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
COAD	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	5.6	5.45e-08	3.59e-05	0.41	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
COAD	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-5.6	5.45e-08	3.59e-05	-0.37	-0.33	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
COAD	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	5.6	5.45e-08	3.59e-05	0.49	0.33	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
COAD	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	5.6	5.46e-08	3.6e-05	0.36	0.33	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
COAD	cis	rs911186	0.786	rs3800307	ENSG00000224843.5	LINC00240	5.6	5.46e-08	3.6e-05	0.51	0.33	Autism spectrum disorder or schizophrenia;	chr6:27218013	chr6:26956992~27023924:+
COAD	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-5.6	5.47e-08	3.6e-05	-0.35	-0.33	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
COAD	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	5.6	5.47e-08	3.6e-05	0.38	0.33	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
COAD	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	5.6	5.47e-08	3.6e-05	0.28	0.33	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
COAD	cis	rs3126085	0.515	rs2275264	ENSG00000237975.5	FLG-AS1	5.6	5.47e-08	3.6e-05	0.35	0.33	Atopic dermatitis;	chr1:152359057	chr1:152168125~152445456:+
COAD	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	5.6	5.47e-08	3.6e-05	0.42	0.33	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
COAD	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-5.6	5.48e-08	3.61e-05	-0.41	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
COAD	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	5.6	5.49e-08	3.61e-05	0.36	0.33	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
COAD	cis	rs58873874	0.737	rs78565801	ENSG00000251405.2	CTB-109A12.1	5.6	5.5e-08	3.62e-05	0.75	0.33	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157362615~157460078:-
COAD	cis	rs58873874	0.737	rs79951742	ENSG00000251405.2	CTB-109A12.1	5.6	5.5e-08	3.62e-05	0.75	0.33	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157362615~157460078:-
COAD	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-5.6	5.5e-08	3.62e-05	-0.4	-0.33	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
COAD	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	5.6	5.52e-08	3.63e-05	0.32	0.33	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-5.6	5.52e-08	3.63e-05	-0.4	-0.33	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
COAD	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	5.6	5.52e-08	3.63e-05	0.23	0.33	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
COAD	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	5.6	5.52e-08	3.63e-05	0.36	0.33	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
COAD	cis	rs711830	1	rs2113559	ENSG00000226363.3	HAGLROS	-5.6	5.53e-08	3.64e-05	-0.53	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166371	chr2:176177717~176179008:+
COAD	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-5.6	5.54e-08	3.64e-05	-0.43	-0.33	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
COAD	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-5.6	5.55e-08	3.65e-05	-0.39	-0.33	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
COAD	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	5.6	5.55e-08	3.65e-05	0.45	0.33	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
COAD	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	5.6	5.55e-08	3.65e-05	0.45	0.33	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
COAD	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	5.6	5.55e-08	3.65e-05	0.45	0.33	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
COAD	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	5.6	5.55e-08	3.65e-05	0.28	0.33	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
COAD	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-5.6	5.56e-08	3.66e-05	-0.32	-0.33	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
COAD	cis	rs4853012	1	rs4853012	ENSG00000257800.1	FNBP1P1	5.6	5.57e-08	3.66e-05	0.48	0.33	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74120680~74123218:+
COAD	cis	rs10078	0.515	rs6872510	ENSG00000225138.6	CTD-2228K2.7	5.6	5.57e-08	3.66e-05	0.57	0.33	Fat distribution (HIV);	chr5:481495	chr5:473236~480884:+
COAD	cis	rs7404843	0.85	rs6498553	ENSG00000263335.1	AF001548.5	-5.6	5.57e-08	3.66e-05	-0.63	-0.33	Testicular germ cell tumor;	chr16:15446045	chr16:15726674~15732993:+
COAD	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-5.6	5.57e-08	3.66e-05	-0.2	-0.33	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
COAD	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-5.6	5.58e-08	3.66e-05	-0.41	-0.33	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
COAD	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.6	5.59e-08	3.67e-05	-0.46	-0.33	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
COAD	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.6	5.59e-08	3.67e-05	-0.46	-0.33	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
COAD	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.6	5.59e-08	3.67e-05	-0.46	-0.33	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
COAD	cis	rs4950322	0.518	rs4950304	ENSG00000278811.3	LINC00624	5.6	5.59e-08	3.67e-05	0.32	0.33	Protein quantitative trait loci;	chr1:147116685	chr1:147258885~147517875:-
COAD	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	5.6	5.6e-08	3.68e-05	0.43	0.33	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	5.6	5.6e-08	3.68e-05	0.43	0.33	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
COAD	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	5.6	5.6e-08	3.68e-05	0.38	0.33	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	5.6	5.6e-08	3.68e-05	0.38	0.33	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
COAD	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	5.6	5.62e-08	3.68e-05	0.44	0.33	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	5.6	5.62e-08	3.68e-05	0.44	0.33	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	5.6	5.62e-08	3.68e-05	0.44	0.33	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
COAD	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	5.6	5.62e-08	3.69e-05	0.49	0.33	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
COAD	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-5.6	5.63e-08	3.69e-05	-0.4	-0.33	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
COAD	cis	rs12280210	0.655	rs76169968	ENSG00000254851.1	RP11-109L13.1	5.6	5.63e-08	3.69e-05	0.58	0.33	Lobe attachment (rater-scored or self-reported);	chr11:117212250	chr11:117135528~117138582:+
COAD	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-5.6	5.63e-08	3.69e-05	-0.44	-0.33	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
COAD	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-5.6	5.63e-08	3.7e-05	-0.38	-0.33	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
COAD	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-5.59	5.65e-08	3.7e-05	-0.34	-0.33	Height;	chr11:118749988	chr11:118791254~118793137:+
COAD	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	5.59	5.66e-08	3.71e-05	0.4	0.33	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	5.59	5.66e-08	3.71e-05	0.4	0.33	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
COAD	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	5.59	5.67e-08	3.71e-05	0.44	0.33	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-5.59	5.67e-08	3.72e-05	-0.4	-0.33	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
COAD	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.59	5.68e-08	3.72e-05	-0.46	-0.33	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
COAD	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-5.59	5.71e-08	3.74e-05	-0.43	-0.33	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
COAD	cis	rs492146	0.765	rs316133	ENSG00000243236.5	GSTA9P	-5.59	5.73e-08	3.75e-05	-0.36	-0.33	Epilepsy (remission after treatment);	chr6:52982753	chr6:52939726~52957521:-
COAD	cis	rs7078219	0.576	rs989979	ENSG00000257582.4	LINC01475	-5.59	5.74e-08	3.76e-05	-0.34	-0.33	Dental caries;	chr10:99562666	chr10:99526350~99531177:-
COAD	cis	rs9393777	0.557	rs36034627	ENSG00000224843.5	LINC00240	5.59	5.75e-08	3.76e-05	0.58	0.33	Intelligence (multi-trait analysis);	chr6:27269584	chr6:26956992~27023924:+
COAD	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	5.59	5.75e-08	3.76e-05	0.39	0.33	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
COAD	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-5.59	5.75e-08	3.76e-05	-0.41	-0.33	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
COAD	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	5.59	5.75e-08	3.77e-05	0.43	0.33	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
COAD	cis	rs7683574	0.56	rs9684176	ENSG00000186234.7	FAM86MP	5.59	5.76e-08	3.77e-05	0.44	0.33	Lung cancer;	chr4:9714762	chr4:9692495~9702954:+
COAD	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	5.59	5.77e-08	3.77e-05	0.36	0.33	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
COAD	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-5.59	5.77e-08	3.78e-05	-0.21	-0.33	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
COAD	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-5.59	5.78e-08	3.78e-05	-0.43	-0.33	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
COAD	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-5.59	5.79e-08	3.78e-05	-0.37	-0.33	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
COAD	cis	rs1056107	0.866	rs4500150	ENSG00000225513.1	RP11-165N19.2	-5.59	5.79e-08	3.79e-05	-0.39	-0.33	Colorectal cancer;	chr9:112268310	chr9:112173522~112173971:-
COAD	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	5.59	5.79e-08	3.79e-05	0.56	0.33	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
COAD	cis	rs7078219	0.714	rs12413565	ENSG00000228778.1	RP11-129J12.1	-5.59	5.79e-08	3.79e-05	-0.38	-0.33	Dental caries;	chr10:99525359	chr10:99527081~99528261:+
COAD	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-5.59	5.8e-08	3.79e-05	-0.41	-0.33	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
COAD	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-5.59	5.8e-08	3.79e-05	-0.39	-0.33	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
COAD	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-5.59	5.8e-08	3.79e-05	-0.4	-0.33	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
COAD	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	5.59	5.8e-08	3.79e-05	0.39	0.33	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
COAD	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	5.59	5.81e-08	3.8e-05	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	5.59	5.81e-08	3.8e-05	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	5.59	5.81e-08	3.8e-05	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
COAD	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.59	5.81e-08	3.8e-05	-0.43	-0.33	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
COAD	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-5.59	5.81e-08	3.8e-05	-0.28	-0.33	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
COAD	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	5.59	5.82e-08	3.8e-05	0.45	0.33	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
COAD	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	5.59	5.82e-08	3.8e-05	0.39	0.33	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
COAD	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	5.59	5.82e-08	3.8e-05	0.4	0.33	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
COAD	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	5.59	5.83e-08	3.81e-05	0.41	0.33	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	5.59	5.83e-08	3.81e-05	0.36	0.33	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
COAD	cis	rs453301	0.658	rs13271797	ENSG00000253981.4	ALG1L13P	-5.59	5.85e-08	3.82e-05	-0.39	-0.33	Joint mobility (Beighton score);	chr8:9028444	chr8:8236003~8244667:-
COAD	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.59	5.85e-08	3.82e-05	-0.36	-0.33	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
COAD	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	5.59	5.86e-08	3.83e-05	0.43	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
COAD	cis	rs10078	0.571	rs890977	ENSG00000225138.6	CTD-2228K2.7	5.59	5.86e-08	3.83e-05	0.57	0.33	Fat distribution (HIV);	chr5:476795	chr5:473236~480884:+
COAD	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	5.59	5.87e-08	3.83e-05	0.54	0.33	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
COAD	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	5.59	5.87e-08	3.83e-05	0.38	0.33	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
COAD	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	5.59	5.87e-08	3.84e-05	0.49	0.33	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
COAD	cis	rs9659323	0.65	rs12066653	ENSG00000231365.4	RP11-418J17.1	-5.59	5.88e-08	3.84e-05	-0.38	-0.33	Body mass index;	chr1:118939885	chr1:119140396~119275973:+
COAD	cis	rs28374715	0.662	rs513280	ENSG00000247556.5	OIP5-AS1	-5.59	5.88e-08	3.84e-05	-0.41	-0.33	Ulcerative colitis;	chr15:41190602	chr15:41283990~41309737:+
COAD	cis	rs7955901	0.904	rs1913201	ENSG00000258053.1	CTD-2021H9.3	-5.59	5.88e-08	3.84e-05	-0.39	-0.33	Type 2 diabetes;	chr12:71046045	chr12:71047402~71118247:-
COAD	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	5.59	5.89e-08	3.85e-05	0.28	0.33	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
COAD	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	5.59	5.91e-08	3.85e-05	0.44	0.33	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
COAD	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-5.59	5.91e-08	3.86e-05	-0.45	-0.33	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
COAD	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	5.59	5.91e-08	3.86e-05	0.36	0.33	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
COAD	cis	rs754466	0.51	rs10824579	ENSG00000204049.1	RP11-126H7.4	5.59	5.93e-08	3.87e-05	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830927	chr10:77866875~77869610:+
COAD	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-5.58	5.95e-08	3.88e-05	-0.43	-0.33	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
COAD	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-5.58	5.97e-08	3.89e-05	-0.29	-0.33	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
COAD	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.58	5.97e-08	3.89e-05	-0.34	-0.33	Height;	chr11:118764443	chr11:118791254~118793137:+
COAD	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	5.58	5.97e-08	3.89e-05	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
COAD	cis	rs992157	0.764	rs1870124	ENSG00000261338.2	RP11-378A13.1	5.58	5.98e-08	3.9e-05	0.42	0.33	Colorectal cancer;	chr2:218323017	chr2:218255319~218257366:+
COAD	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	5.58	5.99e-08	3.9e-05	0.26	0.33	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
COAD	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	5.58	5.99e-08	3.9e-05	0.44	0.33	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
COAD	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	5.58	5.99e-08	3.91e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
COAD	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	5.58	5.99e-08	3.91e-05	0.45	0.33	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
COAD	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-5.58	5.99e-08	3.91e-05	-0.45	-0.33	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
COAD	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-5.58	5.99e-08	3.91e-05	-0.39	-0.33	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
COAD	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	5.58	6.01e-08	3.92e-05	0.41	0.33	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
COAD	cis	rs6479891	0.686	rs61855876	ENSG00000232075.1	MRPL35P2	5.58	6.02e-08	3.92e-05	0.55	0.33	Arthritis (juvenile idiopathic);	chr10:63597781	chr10:63634317~63634827:-
COAD	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	5.58	6.02e-08	3.92e-05	0.52	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
COAD	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-5.58	6.02e-08	3.92e-05	-0.34	-0.33	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
COAD	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	5.58	6.03e-08	3.93e-05	0.34	0.33	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
COAD	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-5.58	6.05e-08	3.94e-05	-0.4	-0.33	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
COAD	cis	rs8002861	0.935	rs9533672	ENSG00000274001.1	RP11-5G9.5	5.58	6.05e-08	3.94e-05	0.3	0.33	Leprosy;	chr13:43877044	chr13:43877715~43878163:-
COAD	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	5.58	6.07e-08	3.95e-05	0.47	0.33	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
COAD	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-5.58	6.07e-08	3.95e-05	-0.35	-0.33	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
COAD	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	5.58	6.07e-08	3.95e-05	0.54	0.33	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
COAD	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-5.58	6.09e-08	3.97e-05	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
COAD	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	5.58	6.11e-08	3.97e-05	0.35	0.33	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
COAD	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	5.58	6.11e-08	3.97e-05	0.48	0.33	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	5.58	6.11e-08	3.97e-05	0.48	0.33	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	5.58	6.11e-08	3.97e-05	0.48	0.33	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
COAD	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	5.58	6.12e-08	3.98e-05	0.37	0.33	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
COAD	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	5.58	6.13e-08	3.99e-05	0.28	0.33	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
COAD	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-5.58	6.13e-08	3.99e-05	-0.46	-0.33	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
COAD	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-5.58	6.14e-08	3.99e-05	-0.37	-0.33	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
COAD	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-5.58	6.14e-08	3.99e-05	-0.55	-0.33	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
COAD	cis	rs4950322	0.547	rs56864370	ENSG00000278811.3	LINC00624	5.58	6.14e-08	4e-05	0.32	0.33	Protein quantitative trait loci;	chr1:147111847	chr1:147258885~147517875:-
COAD	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-5.58	6.15e-08	4e-05	-0.33	-0.33	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-5.58	6.15e-08	4e-05	-0.33	-0.33	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-5.58	6.15e-08	4e-05	-0.33	-0.33	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
COAD	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-5.58	6.15e-08	4e-05	-0.19	-0.33	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-5.58	6.15e-08	4e-05	-0.19	-0.33	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
COAD	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-5.58	6.16e-08	4.01e-05	-0.3	-0.33	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
COAD	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-5.58	6.17e-08	4.01e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
COAD	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	5.58	6.19e-08	4.02e-05	0.36	0.33	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	5.58	6.19e-08	4.02e-05	0.36	0.33	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	5.58	6.19e-08	4.02e-05	0.36	0.33	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
COAD	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	5.58	6.19e-08	4.02e-05	0.32	0.33	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
COAD	cis	rs711830	0.965	rs2072590	ENSG00000226363.3	HAGLROS	-5.58	6.19e-08	4.02e-05	-0.5	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176177905	chr2:176177717~176179008:+
COAD	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	5.58	6.2e-08	4.02e-05	0.37	0.33	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	5.58	6.2e-08	4.02e-05	0.37	0.33	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-5.58	6.2e-08	4.02e-05	-0.35	-0.33	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
COAD	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.58	6.21e-08	4.03e-05	0.35	0.33	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
COAD	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.58	6.21e-08	4.03e-05	0.35	0.33	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
COAD	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	5.58	6.21e-08	4.03e-05	0.38	0.33	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	5.58	6.21e-08	4.03e-05	0.38	0.33	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	5.58	6.21e-08	4.03e-05	0.38	0.33	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
COAD	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-5.58	6.23e-08	4.04e-05	-0.4	-0.33	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
COAD	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	5.58	6.23e-08	4.04e-05	0.39	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
COAD	cis	rs860818	0.793	rs10230879	ENSG00000226816.2	AC005082.12	-5.58	6.23e-08	4.04e-05	-0.8	-0.33	Initial pursuit acceleration;	chr7:23158939	chr7:23206013~23208045:+
COAD	cis	rs911186	0.812	rs6932590	ENSG00000224843.5	LINC00240	5.58	6.25e-08	4.05e-05	0.48	0.33	Autism spectrum disorder or schizophrenia;	chr6:27281152	chr6:26956992~27023924:+
COAD	cis	rs2980439	0.525	rs2980508	ENSG00000253981.4	ALG1L13P	5.58	6.25e-08	4.05e-05	0.38	0.33	Neuroticism;	chr8:8314210	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-5.57	6.26e-08	4.06e-05	-0.39	-0.33	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
COAD	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-5.57	6.26e-08	4.06e-05	-0.19	-0.33	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
COAD	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-5.57	6.26e-08	4.06e-05	-0.44	-0.33	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
COAD	cis	rs711830	0.931	rs717852	ENSG00000226363.3	HAGLROS	-5.57	6.26e-08	4.06e-05	-0.53	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166895	chr2:176177717~176179008:+
COAD	cis	rs711830	1	rs2249131	ENSG00000226363.3	HAGLROS	-5.57	6.26e-08	4.06e-05	-0.53	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176167367	chr2:176177717~176179008:+
COAD	cis	rs711830	0.965	rs2857532	ENSG00000226363.3	HAGLROS	-5.57	6.26e-08	4.06e-05	-0.53	-0.33	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176168555	chr2:176177717~176179008:+
COAD	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-5.57	6.26e-08	4.06e-05	-0.42	-0.33	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
COAD	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-5.57	6.27e-08	4.07e-05	-0.44	-0.33	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
COAD	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	5.57	6.28e-08	4.07e-05	0.35	0.33	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
COAD	cis	rs453301	0.686	rs11785634	ENSG00000173295.6	FAM86B3P	-5.57	6.28e-08	4.07e-05	-0.38	-0.33	Joint mobility (Beighton score);	chr8:9035087	chr8:8228595~8244865:+
COAD	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-5.57	6.28e-08	4.07e-05	-0.46	-0.33	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
COAD	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	5.57	6.29e-08	4.07e-05	0.47	0.33	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
COAD	cis	rs4568518	0.616	rs13223642	ENSG00000279048.1	RP11-511H23.2	5.57	6.29e-08	4.08e-05	0.24	0.33	Measles;	chr7:17965352	chr7:17940503~17942922:+
COAD	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	5.57	6.3e-08	4.08e-05	0.38	0.33	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
COAD	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-5.57	6.3e-08	4.08e-05	-0.4	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
COAD	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	5.57	6.31e-08	4.09e-05	0.48	0.33	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	5.57	6.31e-08	4.09e-05	0.48	0.33	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
COAD	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	5.57	6.32e-08	4.09e-05	0.43	0.33	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
COAD	cis	rs858239	0.863	rs466225	ENSG00000226816.2	AC005082.12	5.57	6.32e-08	4.09e-05	0.34	0.33	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23206013~23208045:+
COAD	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-5.57	6.35e-08	4.11e-05	-0.41	-0.33	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
COAD	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	5.57	6.35e-08	4.11e-05	0.48	0.33	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
COAD	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	5.57	6.36e-08	4.12e-05	0.4	0.33	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
COAD	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	5.57	6.36e-08	4.12e-05	0.41	0.33	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
COAD	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-5.57	6.36e-08	4.12e-05	-0.42	-0.33	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-5.57	6.36e-08	4.12e-05	-0.42	-0.33	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-5.57	6.36e-08	4.12e-05	-0.42	-0.33	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
COAD	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-5.57	6.37e-08	4.12e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
COAD	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-5.57	6.37e-08	4.12e-05	-0.18	-0.33	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
COAD	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-5.57	6.37e-08	4.12e-05	-0.48	-0.33	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
COAD	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-5.57	6.37e-08	4.12e-05	-0.48	-0.33	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
COAD	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-5.57	6.38e-08	4.13e-05	-0.36	-0.33	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
COAD	cis	rs4950322	0.563	rs6686480	ENSG00000278811.3	LINC00624	5.57	6.38e-08	4.13e-05	0.33	0.33	Protein quantitative trait loci;	chr1:147111986	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.563	rs6700783	ENSG00000278811.3	LINC00624	5.57	6.38e-08	4.13e-05	0.33	0.33	Protein quantitative trait loci;	chr1:147111987	chr1:147258885~147517875:-
COAD	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.57	6.39e-08	4.13e-05	-0.46	-0.33	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
COAD	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	5.57	6.39e-08	4.14e-05	0.19	0.33	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
COAD	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-5.57	6.39e-08	4.14e-05	-0.38	-0.33	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
COAD	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-5.57	6.4e-08	4.14e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-5.57	6.4e-08	4.14e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
COAD	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-5.57	6.41e-08	4.14e-05	-0.37	-0.33	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
COAD	cis	rs1056107	0.931	rs7040713	ENSG00000225513.1	RP11-165N19.2	-5.57	6.42e-08	4.15e-05	-0.38	-0.33	Colorectal cancer;	chr9:112255041	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs10817304	ENSG00000225513.1	RP11-165N19.2	-5.57	6.42e-08	4.15e-05	-0.38	-0.33	Colorectal cancer;	chr9:112259006	chr9:112173522~112173971:-
COAD	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.57	6.42e-08	4.15e-05	-0.35	-0.33	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
COAD	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-5.57	6.42e-08	4.15e-05	-0.42	-0.33	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
COAD	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	5.57	6.42e-08	4.15e-05	0.41	0.33	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
COAD	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	5.57	6.42e-08	4.15e-05	0.38	0.33	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	5.57	6.42e-08	4.15e-05	0.38	0.33	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
COAD	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-5.57	6.43e-08	4.16e-05	-0.31	-0.33	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
COAD	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-5.57	6.44e-08	4.16e-05	-0.33	-0.33	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
COAD	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-5.57	6.46e-08	4.17e-05	-0.44	-0.33	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
COAD	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.57	6.46e-08	4.17e-05	0.35	0.33	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
COAD	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	5.57	6.48e-08	4.19e-05	0.39	0.33	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	5.57	6.48e-08	4.19e-05	0.39	0.33	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
COAD	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.57	6.48e-08	4.19e-05	-0.37	-0.33	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
COAD	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-5.57	6.49e-08	4.19e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-5.57	6.49e-08	4.19e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	5.57	6.49e-08	4.19e-05	0.36	0.33	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
COAD	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-5.57	6.5e-08	4.19e-05	-0.39	-0.33	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
COAD	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	5.57	6.5e-08	4.2e-05	0.43	0.33	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
COAD	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-5.57	6.51e-08	4.21e-05	-0.42	-0.33	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
COAD	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-5.57	6.52e-08	4.21e-05	-0.2	-0.33	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
COAD	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-5.57	6.52e-08	4.21e-05	-0.37	-0.33	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
COAD	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	5.57	6.52e-08	4.21e-05	0.31	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
COAD	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	5.57	6.53e-08	4.21e-05	0.54	0.33	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
COAD	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	5.57	6.54e-08	4.22e-05	0.36	0.33	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	5.57	6.54e-08	4.22e-05	0.36	0.33	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
COAD	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-5.57	6.54e-08	4.22e-05	-0.35	-0.33	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-5.57	6.54e-08	4.22e-05	-0.35	-0.33	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
COAD	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-5.57	6.54e-08	4.22e-05	-0.35	-0.33	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
COAD	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-5.57	6.54e-08	4.22e-05	-0.33	-0.33	Asthma;	chr2:102399682	chr2:102438713~102440475:+
COAD	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-5.57	6.56e-08	4.23e-05	-0.55	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
COAD	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-5.57	6.58e-08	4.24e-05	-0.43	-0.33	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
COAD	cis	rs7615952	0.673	rs115942855	ENSG00000248787.1	RP11-666A20.4	-5.56	6.58e-08	4.24e-05	-0.59	-0.33	Blood pressure (smoking interaction);	chr3:125883117	chr3:125908005~125910272:-
COAD	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-5.56	6.59e-08	4.25e-05	-0.63	-0.33	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
COAD	cis	rs362272	0.505	rs3129310	ENSG00000248840.2	RP11-357G3.2	-5.56	6.59e-08	4.25e-05	-0.37	-0.33	Serum sulfate level;	chr4:3299661	chr4:3312512~3313058:+
COAD	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-5.56	6.6e-08	4.25e-05	-0.36	-0.33	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
COAD	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	5.56	6.6e-08	4.26e-05	0.25	0.33	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
COAD	cis	rs1056107	0.933	rs11542205	ENSG00000225513.1	RP11-165N19.2	-5.56	6.61e-08	4.26e-05	-0.38	-0.33	Colorectal cancer;	chr9:112221986	chr9:112173522~112173971:-
COAD	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	5.56	6.61e-08	4.26e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	5.56	6.61e-08	4.26e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-5.56	6.62e-08	4.27e-05	-0.35	-0.33	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
COAD	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	5.56	6.64e-08	4.28e-05	0.43	0.33	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
COAD	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-5.56	6.64e-08	4.28e-05	-0.45	-0.33	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-5.56	6.64e-08	4.28e-05	-0.45	-0.33	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
COAD	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-5.56	6.64e-08	4.28e-05	-0.35	-0.33	Height;	chr11:118781100	chr11:118704607~118750263:+
COAD	cis	rs911186	0.73	rs2393911	ENSG00000224843.5	LINC00240	5.56	6.65e-08	4.28e-05	0.45	0.33	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:26956992~27023924:+
COAD	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-5.56	6.65e-08	4.28e-05	-0.37	-0.33	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
COAD	cis	rs911186	0.74	rs6938200	ENSG00000224843.5	LINC00240	5.56	6.65e-08	4.28e-05	0.55	0.33	Autism spectrum disorder or schizophrenia;	chr6:27263371	chr6:26956992~27023924:+
COAD	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	5.56	6.66e-08	4.29e-05	0.38	0.33	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
COAD	cis	rs73198271	0.813	rs56007835	ENSG00000173295.6	FAM86B3P	-5.56	6.66e-08	4.29e-05	-0.43	-0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8228595~8244865:+
COAD	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-5.56	6.66e-08	4.29e-05	-0.31	-0.33	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
COAD	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-5.56	6.68e-08	4.3e-05	-0.37	-0.33	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
COAD	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-5.56	6.68e-08	4.3e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
COAD	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-5.56	6.71e-08	4.32e-05	-0.46	-0.33	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-5.56	6.71e-08	4.32e-05	-0.46	-0.33	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
COAD	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-5.56	6.72e-08	4.32e-05	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
COAD	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-5.56	6.72e-08	4.33e-05	-0.38	-0.33	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
COAD	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	5.56	6.73e-08	4.33e-05	0.21	0.33	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
COAD	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-5.56	6.73e-08	4.33e-05	-0.38	-0.33	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
COAD	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	5.56	6.73e-08	4.33e-05	0.45	0.33	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
COAD	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	5.56	6.75e-08	4.34e-05	0.44	0.33	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
COAD	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	5.56	6.77e-08	4.35e-05	0.4	0.33	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
COAD	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-5.56	6.77e-08	4.35e-05	-0.54	-0.33	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
COAD	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-5.56	6.78e-08	4.36e-05	-0.33	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
COAD	cis	rs1056107	0.966	rs7041688	ENSG00000225513.1	RP11-165N19.2	-5.56	6.78e-08	4.36e-05	-0.39	-0.33	Colorectal cancer;	chr9:112272619	chr9:112173522~112173971:-
COAD	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	5.56	6.79e-08	4.37e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	5.56	6.79e-08	4.37e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
COAD	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-5.56	6.79e-08	4.37e-05	-0.19	-0.33	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
COAD	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-5.56	6.8e-08	4.37e-05	-0.35	-0.33	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
COAD	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-5.56	6.81e-08	4.37e-05	-0.41	-0.33	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
COAD	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.56	6.82e-08	4.38e-05	0.37	0.33	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
COAD	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-5.56	6.83e-08	4.39e-05	-0.18	-0.33	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
COAD	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	5.56	6.83e-08	4.39e-05	0.36	0.33	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
COAD	cis	rs2361718	0.522	rs11867921	ENSG00000279259.1	RP11-334C17.3	5.56	6.85e-08	4.4e-05	0.42	0.33	Yeast infection;	chr17:80147371	chr17:80147250~80148596:+
COAD	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-5.56	6.85e-08	4.4e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
COAD	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	5.56	6.86e-08	4.41e-05	0.35	0.33	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
COAD	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	5.56	6.86e-08	4.41e-05	0.35	0.33	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
COAD	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	5.56	6.86e-08	4.41e-05	0.49	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
COAD	cis	rs1930961	0.702	rs7286366	ENSG00000272977.1	CTA-390C10.10	-5.56	6.88e-08	4.41e-05	-0.82	-0.33	Bipolar disorder with mood-incongruent psychosis;	chr22:25514348	chr22:25476218~25479971:+
COAD	cis	rs5015933	0.815	rs10114168	ENSG00000232630.1	PRPS1P2	-5.56	6.88e-08	4.41e-05	-0.32	-0.33	Body mass index;	chr9:125273170	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs10819044	ENSG00000232630.1	PRPS1P2	-5.56	6.88e-08	4.42e-05	-0.32	-0.33	Body mass index;	chr9:125278750	chr9:125150653~125151589:+
COAD	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-5.56	6.88e-08	4.42e-05	-0.33	-0.33	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
COAD	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	5.56	6.89e-08	4.42e-05	0.51	0.33	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
COAD	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	5.56	6.89e-08	4.42e-05	0.51	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
COAD	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-5.56	6.9e-08	4.42e-05	-0.38	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
COAD	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	5.56	6.91e-08	4.43e-05	0.4	0.33	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
COAD	cis	rs1056107	0.831	rs7856158	ENSG00000225513.1	RP11-165N19.2	5.56	6.92e-08	4.44e-05	0.39	0.33	Colorectal cancer;	chr9:112188892	chr9:112173522~112173971:-
COAD	cis	rs9951698	0.66	rs472702	ENSG00000266969.1	RP11-773H22.4	5.55	6.93e-08	4.44e-05	0.38	0.33	Intelligence (multi-trait analysis);	chr18:13058495	chr18:12984694~12991173:-
COAD	cis	rs4568518	0.619	rs9648238	ENSG00000279048.1	RP11-511H23.2	5.55	6.94e-08	4.45e-05	0.25	0.33	Measles;	chr7:17965614	chr7:17940503~17942922:+
COAD	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	5.55	6.95e-08	4.46e-05	0.38	0.33	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
COAD	cis	rs440932	0.757	rs330943	ENSG00000173295.6	FAM86B3P	5.55	6.96e-08	4.46e-05	0.43	0.33	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8228595~8244865:+
COAD	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-5.55	6.98e-08	4.47e-05	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-5.55	6.98e-08	4.47e-05	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-5.55	6.98e-08	4.47e-05	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-5.55	6.98e-08	4.47e-05	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
COAD	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-5.55	6.99e-08	4.48e-05	-0.35	-0.33	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
COAD	cis	rs4604234	0.708	rs11966262	ENSG00000272129.1	RP11-250B2.6	-5.55	7e-08	4.48e-05	-0.74	-0.33	Cancer;	chr6:80294867	chr6:80355424~80356859:+
COAD	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-5.55	7.01e-08	4.49e-05	-0.34	-0.33	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
COAD	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-5.55	7.01e-08	4.49e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-5.55	7.01e-08	4.49e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
COAD	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-5.55	7.01e-08	4.49e-05	-0.62	-0.33	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
COAD	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	5.55	7.01e-08	4.49e-05	0.45	0.33	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
COAD	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	5.55	7.02e-08	4.5e-05	0.37	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
COAD	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.55	7.02e-08	4.5e-05	-0.42	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
COAD	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-5.55	7.03e-08	4.5e-05	-0.38	-0.33	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
COAD	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-5.55	7.04e-08	4.51e-05	-0.32	-0.33	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
COAD	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	5.55	7.04e-08	4.51e-05	0.39	0.33	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
COAD	cis	rs28374715	0.662	rs521890	ENSG00000247556.5	OIP5-AS1	5.55	7.04e-08	4.51e-05	0.42	0.33	Ulcerative colitis;	chr15:41180945	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs691906	ENSG00000247556.5	OIP5-AS1	-5.55	7.04e-08	4.51e-05	-0.42	-0.33	Ulcerative colitis;	chr15:41182438	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs691907	ENSG00000247556.5	OIP5-AS1	-5.55	7.04e-08	4.51e-05	-0.42	-0.33	Ulcerative colitis;	chr15:41182459	chr15:41283990~41309737:+
COAD	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	5.55	7.06e-08	4.52e-05	0.37	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
COAD	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	5.55	7.06e-08	4.52e-05	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
COAD	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	5.55	7.06e-08	4.52e-05	0.25	0.33	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	5.55	7.06e-08	4.52e-05	0.25	0.33	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	5.55	7.06e-08	4.52e-05	0.25	0.33	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
COAD	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-5.55	7.06e-08	4.52e-05	-0.35	-0.33	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
COAD	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	5.55	7.07e-08	4.52e-05	0.43	0.33	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
COAD	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	5.55	7.08e-08	4.53e-05	0.44	0.33	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
COAD	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	5.55	7.08e-08	4.53e-05	0.44	0.33	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
COAD	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-5.55	7.11e-08	4.55e-05	-0.34	-0.33	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
COAD	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-5.55	7.12e-08	4.55e-05	-0.29	-0.33	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
COAD	cis	rs9309473	0.519	rs12618600	ENSG00000163016.8	ALMS1P	-5.55	7.13e-08	4.56e-05	-0.39	-0.33	Metabolite levels;	chr2:73663555	chr2:73644919~73685576:+
COAD	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	5.55	7.15e-08	4.57e-05	0.41	0.33	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
COAD	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	5.55	7.15e-08	4.57e-05	0.57	0.33	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
COAD	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	5.55	7.15e-08	4.57e-05	0.42	0.33	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
COAD	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	5.55	7.15e-08	4.57e-05	0.32	0.33	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	5.55	7.15e-08	4.57e-05	0.32	0.33	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.55	7.15e-08	4.57e-05	0.32	0.33	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
COAD	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
COAD	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
COAD	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
COAD	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
COAD	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
COAD	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
COAD	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
COAD	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
COAD	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
COAD	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
COAD	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
COAD	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
COAD	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
COAD	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	5.55	7.16e-08	4.58e-05	0.45	0.33	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
COAD	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-5.55	7.18e-08	4.59e-05	-0.49	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
COAD	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-5.55	7.19e-08	4.59e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-5.55	7.19e-08	4.59e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-5.55	7.19e-08	4.59e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
COAD	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	5.55	7.19e-08	4.59e-05	0.45	0.33	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
COAD	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.55	7.19e-08	4.59e-05	0.37	0.33	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
COAD	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-5.55	7.2e-08	4.6e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
COAD	cis	rs9659323	0.65	rs12093893	ENSG00000231365.4	RP11-418J17.1	-5.55	7.21e-08	4.6e-05	-0.38	-0.33	Body mass index;	chr1:118948196	chr1:119140396~119275973:+
COAD	cis	rs603446	0.967	rs180350	ENSG00000254851.1	RP11-109L13.1	-5.55	7.22e-08	4.61e-05	-0.39	-0.33	Triglycerides;	chr11:116739332	chr11:117135528~117138582:+
COAD	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	5.55	7.23e-08	4.61e-05	0.23	0.33	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	5.55	7.23e-08	4.62e-05	0.23	0.33	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
COAD	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	5.55	7.25e-08	4.62e-05	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
COAD	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-5.55	7.26e-08	4.63e-05	-0.31	-0.33	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
COAD	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-5.55	7.27e-08	4.64e-05	-0.47	-0.33	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
COAD	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-5.54	7.29e-08	4.65e-05	-0.37	-0.33	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-5.54	7.29e-08	4.65e-05	-0.37	-0.33	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
COAD	cis	rs8002861	0.87	rs4942255	ENSG00000274001.1	RP11-5G9.5	-5.54	7.29e-08	4.65e-05	-0.29	-0.33	Leprosy;	chr13:43877708	chr13:43877715~43878163:-
COAD	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	5.54	7.3e-08	4.66e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
COAD	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	5.54	7.35e-08	4.68e-05	0.41	0.33	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
COAD	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	5.54	7.36e-08	4.69e-05	0.58	0.33	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
COAD	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-5.54	7.37e-08	4.69e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
COAD	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	5.54	7.38e-08	4.7e-05	0.36	0.33	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	5.54	7.38e-08	4.7e-05	0.36	0.33	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
COAD	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-5.54	7.38e-08	4.7e-05	-0.33	-0.33	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
COAD	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-5.54	7.39e-08	4.7e-05	-0.39	-0.33	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
COAD	cis	rs453301	0.631	rs13250781	ENSG00000173295.6	FAM86B3P	-5.54	7.39e-08	4.71e-05	-0.38	-0.33	Joint mobility (Beighton score);	chr8:8935833	chr8:8228595~8244865:+
COAD	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.54	7.39e-08	4.71e-05	-0.36	-0.33	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
COAD	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-5.54	7.39e-08	4.71e-05	-0.36	-0.33	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
COAD	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-5.54	7.4e-08	4.71e-05	-0.42	-0.33	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-5.54	7.4e-08	4.71e-05	-0.42	-0.33	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-5.54	7.4e-08	4.71e-05	-0.42	-0.33	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
COAD	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-5.54	7.4e-08	4.71e-05	-0.42	-0.33	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-5.54	7.4e-08	4.71e-05	-0.42	-0.33	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
COAD	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-5.54	7.41e-08	4.72e-05	-0.37	-0.33	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
COAD	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	5.54	7.41e-08	4.72e-05	0.36	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
COAD	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.54	7.41e-08	4.72e-05	-0.45	-0.33	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	5.54	7.42e-08	4.72e-05	0.37	0.33	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
COAD	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.54	7.42e-08	4.73e-05	-0.4	-0.33	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
COAD	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	5.54	7.44e-08	4.73e-05	0.59	0.33	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
COAD	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	5.54	7.45e-08	4.74e-05	0.25	0.33	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
COAD	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-5.54	7.46e-08	4.74e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
COAD	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	5.54	7.46e-08	4.74e-05	0.47	0.33	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-5.54	7.46e-08	4.74e-05	-0.47	-0.33	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
COAD	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	5.54	7.47e-08	4.75e-05	0.38	0.33	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
COAD	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	5.54	7.47e-08	4.75e-05	0.45	0.33	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
COAD	cis	rs36093924	0.646	rs7285557	ENSG00000182057.4	OGFRP1	-5.54	7.47e-08	4.75e-05	-0.33	-0.33	Intelligence;	chr22:41952786	chr22:42269753~42275196:+
COAD	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-5.54	7.5e-08	4.76e-05	-0.56	-0.33	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
COAD	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-5.54	7.5e-08	4.76e-05	-0.56	-0.33	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
COAD	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-5.54	7.5e-08	4.76e-05	-0.56	-0.33	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
COAD	cis	rs9951698	0.634	rs9952698	ENSG00000266969.1	RP11-773H22.4	5.54	7.51e-08	4.77e-05	0.37	0.33	Intelligence (multi-trait analysis);	chr18:13021631	chr18:12984694~12991173:-
COAD	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-5.54	7.54e-08	4.78e-05	-0.36	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
COAD	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	5.54	7.54e-08	4.78e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	5.54	7.54e-08	4.78e-05	0.34	0.33	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
COAD	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-5.54	7.55e-08	4.79e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
COAD	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-5.54	7.55e-08	4.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
COAD	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-5.54	7.55e-08	4.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-5.54	7.55e-08	4.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-5.54	7.55e-08	4.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-5.54	7.55e-08	4.79e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	5.54	7.56e-08	4.8e-05	0.37	0.33	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
COAD	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	5.54	7.57e-08	4.8e-05	0.32	0.33	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
COAD	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	5.54	7.58e-08	4.81e-05	0.41	0.33	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
COAD	cis	rs4950322	0.58	rs4950308	ENSG00000278811.3	LINC00624	5.54	7.58e-08	4.81e-05	0.32	0.33	Protein quantitative trait loci;	chr1:147120092	chr1:147258885~147517875:-
COAD	cis	rs58873874	0.737	rs76634949	ENSG00000251405.2	CTB-109A12.1	5.54	7.59e-08	4.81e-05	0.74	0.33	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157362615~157460078:-
COAD	cis	rs58873874	0.737	rs79339674	ENSG00000251405.2	CTB-109A12.1	5.54	7.59e-08	4.81e-05	0.74	0.33	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157362615~157460078:-
COAD	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-5.54	7.6e-08	4.82e-05	-0.44	-0.33	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
COAD	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-5.54	7.62e-08	4.83e-05	-0.32	-0.33	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
COAD	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	5.54	7.62e-08	4.83e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
COAD	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	5.54	7.62e-08	4.83e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
COAD	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	5.54	7.63e-08	4.83e-05	0.4	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	5.54	7.63e-08	4.83e-05	0.4	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-5.54	7.63e-08	4.83e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-5.54	7.63e-08	4.83e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
COAD	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	5.54	7.63e-08	4.84e-05	0.35	0.33	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
COAD	cis	rs1790761	0.52	rs12800028	ENSG00000231793.4	DOC2GP	-5.54	7.65e-08	4.84e-05	-0.44	-0.33	Mean corpuscular volume;	chr11:67635814	chr11:67612653~67616257:-
COAD	cis	rs10078	0.571	rs2721028	ENSG00000225138.6	CTD-2228K2.7	5.54	7.65e-08	4.85e-05	0.56	0.33	Fat distribution (HIV);	chr5:443734	chr5:473236~480884:+
COAD	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-5.54	7.66e-08	4.85e-05	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
COAD	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	5.54	7.66e-08	4.85e-05	0.29	0.33	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
COAD	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	5.54	7.67e-08	4.85e-05	0.4	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
COAD	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-5.54	7.67e-08	4.85e-05	-0.38	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
COAD	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	5.54	7.67e-08	4.85e-05	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-5.53	7.67e-08	4.85e-05	-0.35	-0.33	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
COAD	cis	rs2732480	0.557	rs2732454	ENSG00000273765.1	RP11-370I10.11	5.53	7.67e-08	4.85e-05	0.37	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48360920~48361377:+
COAD	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	5.53	7.68e-08	4.86e-05	0.35	0.33	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
COAD	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	5.53	7.69e-08	4.87e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	5.53	7.69e-08	4.87e-05	0.58	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
COAD	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-5.53	7.7e-08	4.87e-05	-0.32	-0.33	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
COAD	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
COAD	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	5.53	7.72e-08	4.88e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
COAD	cis	rs5758659	0.714	rs5751220	ENSG00000182057.4	OGFRP1	-5.53	7.73e-08	4.89e-05	-0.37	-0.33	Cognitive function;	chr22:42120201	chr22:42269753~42275196:+
COAD	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-5.53	7.73e-08	4.89e-05	-0.39	-0.33	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
COAD	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	5.53	7.74e-08	4.89e-05	0.38	0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
COAD	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-5.53	7.74e-08	4.89e-05	-0.36	-0.33	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
COAD	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	5.53	7.74e-08	4.89e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
COAD	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	5.53	7.74e-08	4.89e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
COAD	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	5.53	7.74e-08	4.89e-05	0.44	0.33	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
COAD	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-5.53	7.75e-08	4.89e-05	-0.48	-0.33	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
COAD	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	5.53	7.77e-08	4.91e-05	0.51	0.33	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
COAD	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-5.53	7.78e-08	4.91e-05	-0.35	-0.33	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
COAD	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	5.53	7.8e-08	4.92e-05	0.47	0.33	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
COAD	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-5.53	7.8e-08	4.92e-05	-0.38	-0.33	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
COAD	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-5.53	7.8e-08	4.92e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-5.53	7.8e-08	4.92e-05	-0.38	-0.33	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
COAD	cis	rs9368481	0.672	rs3931463	ENSG00000224843.5	LINC00240	-5.53	7.81e-08	4.93e-05	-0.4	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26956992~27023924:+
COAD	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	5.53	7.81e-08	4.93e-05	0.18	0.33	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
COAD	cis	rs5758659	0.652	rs1063392	ENSG00000182057.4	OGFRP1	-5.53	7.82e-08	4.94e-05	-0.34	-0.33	Cognitive function;	chr22:42058946	chr22:42269753~42275196:+
COAD	cis	rs7674212	0.541	rs2045746	ENSG00000230069.3	LRRC37A15P	5.53	7.83e-08	4.94e-05	0.35	0.33	Type 2 diabetes;	chr4:103162421	chr4:102727274~102730721:-
COAD	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5.53	7.83e-08	4.94e-05	0.38	0.33	Height;	chr3:53073764	chr3:53064283~53065091:-
COAD	cis	rs1056107	0.902	rs10124118	ENSG00000225513.1	RP11-165N19.2	-5.53	7.83e-08	4.94e-05	-0.38	-0.33	Colorectal cancer;	chr9:112240354	chr9:112173522~112173971:-
COAD	cis	rs453301	0.686	rs4840389	ENSG00000173295.6	FAM86B3P	-5.53	7.83e-08	4.94e-05	-0.38	-0.33	Joint mobility (Beighton score);	chr8:9026993	chr8:8228595~8244865:+
COAD	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-5.53	7.84e-08	4.95e-05	-0.45	-0.33	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
COAD	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-5.53	7.84e-08	4.95e-05	-0.45	-0.33	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
COAD	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-5.53	7.84e-08	4.95e-05	-0.45	-0.33	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
COAD	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	5.53	7.85e-08	4.96e-05	0.43	0.33	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
COAD	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	5.53	7.86e-08	4.96e-05	0.8	0.33	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	5.53	7.86e-08	4.96e-05	0.8	0.33	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	5.53	7.86e-08	4.96e-05	0.8	0.33	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
COAD	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	5.53	7.9e-08	4.98e-05	0.37	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	5.53	7.9e-08	4.98e-05	0.36	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
COAD	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	5.53	7.93e-08	5e-05	0.4	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
COAD	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	5.53	7.94e-08	5.01e-05	0.35	0.33	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
COAD	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.53	7.94e-08	5.01e-05	0.39	0.33	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
COAD	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-5.53	7.94e-08	5.01e-05	-0.42	-0.33	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
COAD	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-5.53	7.95e-08	5.01e-05	-0.42	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
COAD	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-5.53	7.95e-08	5.01e-05	-0.41	-0.33	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
COAD	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-5.53	7.96e-08	5.02e-05	-0.41	-0.33	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
COAD	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	5.53	7.96e-08	5.02e-05	0.2	0.33	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
COAD	cis	rs7584330	0.518	rs78358347	ENSG00000234949.2	AC104667.3	-5.53	7.98e-08	5.03e-05	-0.7	-0.33	Prostate cancer;	chr2:237504923	chr2:237591020~237595981:+
COAD	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-5.53	7.99e-08	5.04e-05	-0.36	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-5.53	7.99e-08	5.04e-05	-0.36	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
COAD	cis	rs17264034	0.95	rs17328863	ENSG00000250786.1	SNHG18	-5.53	7.99e-08	5.04e-05	-0.53	-0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9542919	chr5:9546200~9550609:+
COAD	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-5.53	8e-08	5.04e-05	-0.59	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
COAD	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-5.53	8e-08	5.04e-05	-0.4	-0.33	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
COAD	cis	rs453301	0.562	rs1038248	ENSG00000173295.6	FAM86B3P	-5.53	8.01e-08	5.05e-05	-0.39	-0.33	Joint mobility (Beighton score);	chr8:9183348	chr8:8228595~8244865:+
COAD	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	5.53	8.02e-08	5.05e-05	0.39	0.33	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
COAD	cis	rs5015933	0.815	rs28533069	ENSG00000232630.1	PRPS1P2	-5.53	8.03e-08	5.06e-05	-0.32	-0.33	Body mass index;	chr9:125251379	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.807	rs7043132	ENSG00000232630.1	PRPS1P2	-5.53	8.03e-08	5.06e-05	-0.32	-0.33	Body mass index;	chr9:125255561	chr9:125150653~125151589:+
COAD	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	5.53	8.05e-08	5.07e-05	0.39	0.33	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
COAD	cis	rs732716	0.752	rs11085072	ENSG00000267769.1	CTB-50L17.9	-5.53	8.05e-08	5.07e-05	-0.4	-0.33	Mean corpuscular volume;	chr19:4368145	chr19:4454014~4455286:+
COAD	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	5.53	8.05e-08	5.07e-05	0.38	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
COAD	cis	rs1056107	0.933	rs10759546	ENSG00000225513.1	RP11-165N19.2	-5.53	8.05e-08	5.07e-05	-0.38	-0.33	Colorectal cancer;	chr9:112260664	chr9:112173522~112173971:-
COAD	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	5.52	8.08e-08	5.08e-05	0.5	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
COAD	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-5.52	8.09e-08	5.09e-05	-0.35	-0.33	Height;	chr11:118760944	chr11:118704607~118750263:+
COAD	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	5.52	8.1e-08	5.1e-05	0.31	0.33	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
COAD	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-5.52	8.12e-08	5.11e-05	-0.41	-0.33	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
COAD	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-5.52	8.13e-08	5.11e-05	-0.38	-0.33	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-5.52	8.13e-08	5.11e-05	-0.38	-0.33	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-5.52	8.13e-08	5.11e-05	-0.38	-0.33	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
COAD	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-5.52	8.15e-08	5.12e-05	-0.43	-0.33	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
COAD	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5.52	8.16e-08	5.13e-05	0.35	0.33	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
COAD	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	5.52	8.18e-08	5.14e-05	0.34	0.33	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
COAD	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-5.52	8.18e-08	5.14e-05	-0.55	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
COAD	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-5.52	8.19e-08	5.15e-05	-0.5	-0.33	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
COAD	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	5.52	8.19e-08	5.15e-05	0.42	0.33	Height;	chr6:109331033	chr6:109382795~109383666:+
COAD	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-5.52	8.2e-08	5.16e-05	-0.35	-0.33	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-5.52	8.2e-08	5.16e-05	-0.35	-0.33	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
COAD	cis	rs6844506	0.565	rs10008153	ENSG00000244512.3	RN7SL28P	5.52	8.23e-08	5.17e-05	0.37	0.33	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr4:184306031	chr4:184278936~184279233:+
COAD	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	5.52	8.24e-08	5.18e-05	0.34	0.33	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
COAD	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	5.52	8.24e-08	5.18e-05	0.37	0.33	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	5.52	8.24e-08	5.18e-05	0.37	0.33	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	5.52	8.24e-08	5.18e-05	0.37	0.33	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
COAD	cis	rs1056107	0.966	rs1538770	ENSG00000225513.1	RP11-165N19.2	-5.52	8.25e-08	5.18e-05	-0.38	-0.33	Colorectal cancer;	chr9:112300069	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.966	rs7869209	ENSG00000225513.1	RP11-165N19.2	-5.52	8.25e-08	5.18e-05	-0.38	-0.33	Colorectal cancer;	chr9:112301133	chr9:112173522~112173971:-
COAD	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.52	8.25e-08	5.18e-05	0.33	0.33	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
COAD	cis	rs28374715	0.787	rs11856169	ENSG00000247556.5	OIP5-AS1	5.52	8.26e-08	5.19e-05	0.44	0.33	Ulcerative colitis;	chr15:41255740	chr15:41283990~41309737:+
COAD	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-5.52	8.28e-08	5.2e-05	-0.42	-0.33	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
COAD	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	5.52	8.28e-08	5.2e-05	0.2	0.33	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
COAD	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	5.52	8.3e-08	5.21e-05	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
COAD	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	5.52	8.3e-08	5.21e-05	0.34	0.33	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
COAD	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	5.52	8.31e-08	5.22e-05	0.31	0.33	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
COAD	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-5.52	8.31e-08	5.22e-05	-0.35	-0.33	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
COAD	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-5.52	8.31e-08	5.22e-05	-0.35	-0.33	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
COAD	cis	rs7078219	0.714	rs10883368	ENSG00000228778.1	RP11-129J12.1	-5.52	8.32e-08	5.22e-05	-0.37	-0.33	Dental caries;	chr10:99530241	chr10:99527081~99528261:+
COAD	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	5.52	8.32e-08	5.22e-05	0.37	0.33	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
COAD	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	5.52	8.32e-08	5.22e-05	0.44	0.33	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
COAD	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	5.52	8.32e-08	5.22e-05	0.25	0.33	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	5.52	8.32e-08	5.22e-05	0.25	0.33	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	5.52	8.32e-08	5.22e-05	0.25	0.33	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
COAD	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-5.52	8.33e-08	5.23e-05	-0.35	-0.33	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
COAD	cis	rs5758659	0.653	rs133383	ENSG00000182057.4	OGFRP1	5.52	8.38e-08	5.26e-05	0.36	0.33	Cognitive function;	chr22:42077599	chr22:42269753~42275196:+
COAD	cis	rs1056107	0.931	rs7869523	ENSG00000225513.1	RP11-165N19.2	-5.52	8.38e-08	5.26e-05	-0.39	-0.33	Colorectal cancer;	chr9:112220269	chr9:112173522~112173971:-
COAD	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-5.52	8.38e-08	5.26e-05	-0.35	-0.33	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
COAD	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-5.52	8.39e-08	5.26e-05	-0.37	-0.33	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
COAD	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-5.52	8.39e-08	5.26e-05	-0.41	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
COAD	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	5.52	8.4e-08	5.27e-05	0.24	0.33	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
COAD	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-5.52	8.42e-08	5.28e-05	-0.23	-0.33	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
COAD	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	5.52	8.42e-08	5.28e-05	0.43	0.33	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
COAD	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-5.52	8.43e-08	5.29e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
COAD	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	5.52	8.44e-08	5.29e-05	0.59	0.33	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
COAD	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.52	8.45e-08	5.29e-05	0.41	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
COAD	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	5.52	8.45e-08	5.3e-05	0.43	0.33	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
COAD	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-5.52	8.46e-08	5.3e-05	-0.28	-0.33	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
COAD	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-5.52	8.48e-08	5.31e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-5.52	8.48e-08	5.31e-05	-0.4	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
COAD	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-5.52	8.48e-08	5.31e-05	-0.39	-0.33	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
COAD	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	5.52	8.48e-08	5.31e-05	0.24	0.33	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
COAD	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	5.52	8.49e-08	5.32e-05	0.4	0.33	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
COAD	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-5.52	8.49e-08	5.32e-05	-0.36	-0.33	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
COAD	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-5.51	8.52e-08	5.33e-05	-0.34	-0.33	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
COAD	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	5.51	8.53e-08	5.34e-05	0.36	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
COAD	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-5.51	8.53e-08	5.34e-05	-0.45	-0.33	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
COAD	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-5.51	8.53e-08	5.34e-05	-0.45	-0.33	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
COAD	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-5.51	8.53e-08	5.34e-05	-0.43	-0.33	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
COAD	cis	rs2115630	0.846	rs8024538	ENSG00000259728.4	LINC00933	-5.51	8.54e-08	5.35e-05	-0.41	-0.33	P wave terminal force;	chr15:84825188	chr15:84570649~84580175:+
COAD	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-5.51	8.55e-08	5.35e-05	-0.41	-0.33	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
COAD	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	5.51	8.56e-08	5.36e-05	0.36	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
COAD	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-5.51	8.6e-08	5.38e-05	-0.37	-0.33	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
COAD	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	5.51	8.63e-08	5.4e-05	0.38	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
COAD	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-5.51	8.65e-08	5.41e-05	-0.35	-0.33	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
COAD	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	5.51	8.65e-08	5.41e-05	0.4	0.33	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
COAD	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	5.51	8.65e-08	5.41e-05	0.46	0.33	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
COAD	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-5.51	8.66e-08	5.42e-05	-0.56	-0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
COAD	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	5.51	8.66e-08	5.42e-05	0.36	0.33	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
COAD	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-5.51	8.67e-08	5.42e-05	-0.4	-0.33	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
COAD	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	5.51	8.67e-08	5.42e-05	0.25	0.33	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	5.51	8.67e-08	5.42e-05	0.25	0.33	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
COAD	cis	rs4568518	0.619	rs6946266	ENSG00000279048.1	RP11-511H23.2	5.51	8.68e-08	5.42e-05	0.23	0.33	Measles;	chr7:17967965	chr7:17940503~17942922:+
COAD	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-5.51	8.68e-08	5.43e-05	-0.25	-0.33	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
COAD	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-5.51	8.7e-08	5.44e-05	-0.39	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
COAD	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-5.51	8.7e-08	5.44e-05	-0.35	-0.33	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
COAD	cis	rs1426063	0.614	rs115690958	ENSG00000249717.1	RP11-44F21.3	5.51	8.72e-08	5.45e-05	0.75	0.33	QT interval;	chr4:75078364	chr4:74955974~74970362:-
COAD	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	5.51	8.73e-08	5.46e-05	0.4	0.33	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
COAD	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	5.51	8.73e-08	5.46e-05	0.33	0.33	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
COAD	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-5.51	8.76e-08	5.47e-05	-0.38	-0.32	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
COAD	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	5.51	8.77e-08	5.48e-05	0.24	0.32	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
COAD	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	5.51	8.78e-08	5.48e-05	0.36	0.32	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
COAD	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-5.51	8.81e-08	5.5e-05	-0.37	-0.32	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
COAD	cis	rs7688540	0.8	rs28531997	ENSG00000211553.1	AC253576.2	-5.51	8.83e-08	5.51e-05	-0.49	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:136461~136568:+
COAD	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.51	8.83e-08	5.51e-05	-0.36	-0.32	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.51	8.83e-08	5.51e-05	-0.36	-0.32	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
COAD	cis	rs4568518	0.561	rs4579426	ENSG00000279048.1	RP11-511H23.2	5.51	8.84e-08	5.51e-05	0.23	0.32	Measles;	chr7:17968636	chr7:17940503~17942922:+
COAD	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	5.51	8.85e-08	5.52e-05	0.57	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	5.51	8.85e-08	5.52e-05	0.57	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	5.51	8.85e-08	5.52e-05	0.57	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
COAD	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-5.51	8.87e-08	5.53e-05	-0.57	-0.32	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-5.51	8.87e-08	5.53e-05	-0.57	-0.32	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
COAD	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-5.51	8.87e-08	5.53e-05	-0.35	-0.32	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
COAD	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	5.51	8.93e-08	5.56e-05	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
COAD	cis	rs754466	0.58	rs17516020	ENSG00000204049.1	RP11-126H7.4	5.5	8.94e-08	5.57e-05	0.45	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778976	chr10:77866875~77869610:+
COAD	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	5.5	8.94e-08	5.57e-05	0.53	0.32	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
COAD	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	5.5	8.94e-08	5.57e-05	0.25	0.32	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
COAD	cis	rs4718428	0.705	rs4718430	ENSG00000226824.5	RP4-756H11.3	-5.5	8.96e-08	5.58e-05	-0.41	-0.32	Corneal structure;	chr7:66967037	chr7:66654538~66669855:+
COAD	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-5.5	8.98e-08	5.6e-05	-0.48	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
COAD	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-5.5	8.99e-08	5.6e-05	-0.18	-0.32	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-5.5	8.99e-08	5.6e-05	-0.18	-0.32	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
COAD	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	5.5	8.99e-08	5.6e-05	0.51	0.32	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
COAD	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-5.5	8.99e-08	5.6e-05	-0.39	-0.32	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-5.5	8.99e-08	5.6e-05	-0.39	-0.32	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
COAD	cis	rs7078219	0.714	rs12413565	ENSG00000257582.4	LINC01475	-5.5	9e-08	5.6e-05	-0.37	-0.32	Dental caries;	chr10:99525359	chr10:99526350~99531177:-
COAD	cis	rs11846409	0.872	rs74091715	ENSG00000274576.2	IGHV2-70	-5.5	9e-08	5.61e-05	-0.33	-0.32	Rheumatic heart disease;	chr14:106637731	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.932	rs74091721	ENSG00000274576.2	IGHV2-70	-5.5	9e-08	5.61e-05	-0.33	-0.32	Rheumatic heart disease;	chr14:106638262	chr14:106770577~106771020:-
COAD	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	5.5	9.01e-08	5.61e-05	0.32	0.32	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
COAD	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-5.5	9.02e-08	5.61e-05	-0.18	-0.32	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
COAD	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-5.5	9.02e-08	5.62e-05	-0.37	-0.32	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
COAD	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-5.5	9.02e-08	5.62e-05	-0.37	-0.32	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
COAD	cis	rs453301	0.653	rs11784393	ENSG00000233609.3	RP11-62H7.2	5.5	9.03e-08	5.62e-05	0.36	0.32	Joint mobility (Beighton score);	chr8:9045624	chr8:8961200~8979025:+
COAD	cis	rs7560272	0.723	rs4346412	ENSG00000163016.8	ALMS1P	5.5	9.05e-08	5.63e-05	0.39	0.32	Schizophrenia;	chr2:73616444	chr2:73644919~73685576:+
COAD	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-5.5	9.05e-08	5.63e-05	-0.36	-0.32	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
COAD	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-5.5	9.05e-08	5.64e-05	-0.18	-0.32	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
COAD	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	5.5	9.06e-08	5.64e-05	0.25	0.32	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
COAD	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.5	9.07e-08	5.65e-05	-0.45	-0.32	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
COAD	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-5.5	9.1e-08	5.66e-05	-0.36	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
COAD	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-5.5	9.1e-08	5.66e-05	-0.33	-0.32	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
COAD	cis	rs754466	0.58	rs12357670	ENSG00000204049.1	RP11-126H7.4	5.5	9.12e-08	5.67e-05	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798422	chr10:77866875~77869610:+
COAD	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5.5	9.12e-08	5.67e-05	0.35	0.32	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
COAD	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	5.5	9.13e-08	5.68e-05	0.3	0.32	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
COAD	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	5.5	9.14e-08	5.68e-05	0.44	0.32	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
COAD	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-5.5	9.14e-08	5.69e-05	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
COAD	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	5.5	9.15e-08	5.69e-05	0.36	0.32	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
COAD	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	5.5	9.15e-08	5.69e-05	0.36	0.32	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
COAD	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	5.5	9.15e-08	5.69e-05	0.36	0.32	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
COAD	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	5.5	9.16e-08	5.7e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
COAD	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	5.5	9.19e-08	5.71e-05	0.52	0.32	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
COAD	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-5.5	9.21e-08	5.72e-05	-0.37	-0.32	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
COAD	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-5.5	9.21e-08	5.72e-05	-0.35	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
COAD	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	5.5	9.22e-08	5.73e-05	0.4	0.32	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
COAD	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-5.5	9.23e-08	5.73e-05	-0.39	-0.32	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
COAD	cis	rs2378497	0.564	rs115883774	ENSG00000232679.1	RP11-400N13.3	5.5	9.24e-08	5.74e-05	0.33	0.32	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:222041705~222064763:-
COAD	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	5.5	9.24e-08	5.74e-05	0.42	0.32	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
COAD	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-5.5	9.25e-08	5.74e-05	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
COAD	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-5.5	9.26e-08	5.75e-05	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
COAD	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-5.5	9.27e-08	5.75e-05	-0.31	-0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
COAD	cis	rs2337406	0.925	rs34064152	ENSG00000274576.2	IGHV2-70	-5.5	9.28e-08	5.76e-05	-0.33	-0.32	Alzheimer's disease (late onset);	chr14:106700364	chr14:106770577~106771020:-
COAD	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	5.5	9.28e-08	5.76e-05	0.33	0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
COAD	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	5.5	9.29e-08	5.76e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	5.5	9.29e-08	5.76e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
COAD	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-5.5	9.32e-08	5.78e-05	-0.34	-0.32	Height;	chr11:118773873	chr11:118791254~118793137:+
COAD	cis	rs453301	0.686	rs4840389	ENSG00000253981.4	ALG1L13P	-5.5	9.33e-08	5.79e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9026993	chr8:8236003~8244667:-
COAD	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	5.5	9.33e-08	5.79e-05	0.43	0.32	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
COAD	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-5.5	9.37e-08	5.81e-05	-0.37	-0.32	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
COAD	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	5.5	9.39e-08	5.81e-05	0.41	0.32	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
COAD	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	5.5	9.39e-08	5.81e-05	0.41	0.32	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
COAD	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	5.5	9.4e-08	5.81e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
COAD	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-5.5	9.4e-08	5.81e-05	-0.34	-0.32	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
COAD	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-5.49	9.41e-08	5.82e-05	-0.35	-0.32	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
COAD	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	5.49	9.41e-08	5.83e-05	0.42	0.32	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
COAD	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.49	9.43e-08	5.83e-05	-0.36	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
COAD	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-5.49	9.43e-08	5.83e-05	-0.36	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
COAD	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	5.49	9.44e-08	5.84e-05	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
COAD	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-5.49	9.45e-08	5.85e-05	-0.36	-0.32	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
COAD	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	5.49	9.46e-08	5.85e-05	0.42	0.32	Depression;	chr6:28317705	chr6:28943877~28944537:+
COAD	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	5.49	9.46e-08	5.85e-05	0.42	0.32	Depression;	chr6:28323463	chr6:28943877~28944537:+
COAD	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-5.49	9.46e-08	5.85e-05	-0.29	-0.32	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
COAD	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-5.49	9.46e-08	5.85e-05	-0.43	-0.32	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
COAD	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-5.49	9.47e-08	5.86e-05	-0.42	-0.32	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-5.49	9.47e-08	5.86e-05	-0.42	-0.32	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
COAD	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-5.49	9.47e-08	5.86e-05	-0.42	-0.32	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
COAD	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-5.49	9.47e-08	5.86e-05	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-5.49	9.48e-08	5.86e-05	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
COAD	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	5.49	9.48e-08	5.86e-05	0.25	0.32	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
COAD	cis	rs453301	0.592	rs4841084	ENSG00000233609.3	RP11-62H7.2	5.49	9.48e-08	5.86e-05	0.36	0.32	Joint mobility (Beighton score);	chr8:9026395	chr8:8961200~8979025:+
COAD	cis	rs453301	0.653	rs2956244	ENSG00000233609.3	RP11-62H7.2	5.49	9.48e-08	5.86e-05	0.36	0.32	Joint mobility (Beighton score);	chr8:9027656	chr8:8961200~8979025:+
COAD	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-5.49	9.49e-08	5.86e-05	-0.34	-0.32	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-5.49	9.49e-08	5.86e-05	-0.34	-0.32	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
COAD	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	5.49	9.5e-08	5.87e-05	0.35	0.32	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
COAD	cis	rs2337406	0.587	rs11624678	ENSG00000274576.2	IGHV2-70	5.49	9.52e-08	5.88e-05	0.32	0.32	Alzheimer's disease (late onset);	chr14:106650408	chr14:106770577~106771020:-
COAD	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-5.49	9.53e-08	5.89e-05	-0.35	-0.32	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
COAD	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	5.49	9.53e-08	5.89e-05	0.36	0.32	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	5.49	9.53e-08	5.89e-05	0.36	0.32	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
COAD	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.53	rs11723970	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Bone mineral density;	chr4:9978838	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.805	rs882222	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.53	rs882223	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Bone mineral density;	chr4:9980001	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-5.49	9.53e-08	5.89e-05	-0.41	-0.32	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
COAD	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-5.49	9.55e-08	5.9e-05	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
COAD	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-5.49	9.55e-08	5.9e-05	-0.27	-0.32	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
COAD	cis	rs9393777	0.513	rs6904071	ENSG00000224843.5	LINC00240	5.49	9.56e-08	5.9e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27079477	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs34388707	ENSG00000224843.5	LINC00240	5.49	9.56e-08	5.9e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27082617	chr6:26956992~27023924:+
COAD	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	5.49	9.56e-08	5.91e-05	0.3	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
COAD	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-5.49	9.57e-08	5.91e-05	-0.35	-0.32	Height;	chr11:118786602	chr11:118704607~118750263:+
COAD	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-5.49	9.57e-08	5.91e-05	-0.35	-0.32	Height;	chr11:118791319	chr11:118704607~118750263:+
COAD	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	5.49	9.6e-08	5.92e-05	0.34	0.32	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
COAD	cis	rs1426063	0.614	rs78681370	ENSG00000249717.1	RP11-44F21.3	5.49	9.6e-08	5.92e-05	0.75	0.32	QT interval;	chr4:75081556	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs17000212	ENSG00000249717.1	RP11-44F21.3	5.49	9.6e-08	5.92e-05	0.75	0.32	QT interval;	chr4:75081611	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs77018380	ENSG00000249717.1	RP11-44F21.3	5.49	9.6e-08	5.92e-05	0.75	0.32	QT interval;	chr4:75081621	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs76325897	ENSG00000249717.1	RP11-44F21.3	5.49	9.6e-08	5.92e-05	0.75	0.32	QT interval;	chr4:75084747	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs76093954	ENSG00000249717.1	RP11-44F21.3	5.49	9.6e-08	5.92e-05	0.75	0.32	QT interval;	chr4:75087994	chr4:74955974~74970362:-
COAD	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-5.49	9.61e-08	5.93e-05	-0.38	-0.32	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
COAD	cis	rs5015933	0.815	rs937482	ENSG00000232630.1	PRPS1P2	-5.49	9.61e-08	5.93e-05	-0.32	-0.32	Body mass index;	chr9:125354538	chr9:125150653~125151589:+
COAD	cis	rs4950322	0.547	rs61838945	ENSG00000278811.3	LINC00624	5.49	9.61e-08	5.93e-05	0.32	0.32	Protein quantitative trait loci;	chr1:147111477	chr1:147258885~147517875:-
COAD	cis	rs9818758	0.607	rs113186424	ENSG00000225399.4	RP11-3B7.1	-5.49	9.62e-08	5.93e-05	-0.57	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs34784192	ENSG00000225399.4	RP11-3B7.1	-5.49	9.62e-08	5.93e-05	-0.57	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:49260085~49261316:+
COAD	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	5.49	9.65e-08	5.95e-05	0.37	0.32	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
COAD	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	5.49	9.67e-08	5.96e-05	0.76	0.32	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
COAD	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	5.49	9.67e-08	5.96e-05	0.33	0.32	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
COAD	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	5.49	9.68e-08	5.96e-05	0.28	0.32	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
COAD	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	5.49	9.7e-08	5.97e-05	0.4	0.32	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
COAD	cis	rs4950322	0.58	rs7541393	ENSG00000278811.3	LINC00624	5.49	9.7e-08	5.97e-05	0.32	0.32	Protein quantitative trait loci;	chr1:147117186	chr1:147258885~147517875:-
COAD	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	5.49	9.7e-08	5.97e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
COAD	cis	rs12935418	0.583	rs2244452	ENSG00000278985.1	RP11-303E16.9	-5.49	9.7e-08	5.98e-05	-0.34	-0.32	Mean corpuscular volume;	chr16:80991767	chr16:80982319~80984094:-
COAD	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	5.49	9.72e-08	5.99e-05	0.37	0.32	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
COAD	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	5.49	9.72e-08	5.99e-05	0.37	0.32	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
COAD	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-5.49	9.73e-08	5.99e-05	-0.44	-0.32	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
COAD	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	5.49	9.73e-08	5.99e-05	0.31	0.32	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
COAD	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	5.49	9.73e-08	5.99e-05	0.33	0.32	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
COAD	cis	rs7615952	0.932	rs13086087	ENSG00000248787.1	RP11-666A20.4	-5.49	9.73e-08	6e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125927438	chr3:125908005~125910272:-
COAD	cis	rs4950322	0.748	rs17356680	ENSG00000278811.3	LINC00624	5.49	9.74e-08	6e-05	0.35	0.32	Protein quantitative trait loci;	chr1:147354934	chr1:147258885~147517875:-
COAD	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-5.49	9.75e-08	6e-05	-0.43	-0.32	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
COAD	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	5.49	9.77e-08	6.01e-05	0.36	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
COAD	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	5.49	9.78e-08	6.02e-05	0.46	0.32	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
COAD	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-5.49	9.78e-08	6.02e-05	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
COAD	cis	rs3809863	0.782	rs7220606	ENSG00000228782.6	CTD-2026D20.3	5.49	9.78e-08	6.02e-05	0.34	0.32	Glaucoma (primary open-angle);	chr17:47297429	chr17:47450568~47492492:-
COAD	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-5.49	9.8e-08	6.03e-05	-0.34	-0.32	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
COAD	cis	rs860818	0.655	rs1406079	ENSG00000226816.2	AC005082.12	-5.49	9.8e-08	6.03e-05	-0.73	-0.32	Initial pursuit acceleration;	chr7:23155078	chr7:23206013~23208045:+
COAD	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-5.49	9.82e-08	6.04e-05	-0.22	-0.32	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
COAD	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	5.49	9.82e-08	6.04e-05	0.32	0.32	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
COAD	cis	rs5758659	0.714	rs6002626	ENSG00000182057.4	OGFRP1	-5.49	9.83e-08	6.05e-05	-0.36	-0.32	Cognitive function;	chr22:42121985	chr22:42269753~42275196:+
COAD	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-5.49	9.83e-08	6.05e-05	-0.41	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
COAD	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-5.49	9.84e-08	6.05e-05	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
COAD	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.49	9.84e-08	6.05e-05	0.45	0.32	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
COAD	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-5.49	9.84e-08	6.05e-05	-0.36	-0.32	Height;	chr3:53085518	chr3:53064283~53065091:-
COAD	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5.49	9.84e-08	6.06e-05	0.31	0.32	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
COAD	cis	rs7615952	0.673	rs3811677	ENSG00000248787.1	RP11-666A20.4	-5.49	9.85e-08	6.06e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125929237	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.932	rs3811679	ENSG00000248787.1	RP11-666A20.4	-5.49	9.85e-08	6.06e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125929440	chr3:125908005~125910272:-
COAD	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	5.49	9.87e-08	6.07e-05	0.35	0.32	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	5.49	9.87e-08	6.07e-05	0.35	0.32	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
COAD	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	5.49	9.88e-08	6.07e-05	0.27	0.32	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
COAD	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-5.49	9.88e-08	6.08e-05	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
COAD	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.48	9.9e-08	6.09e-05	0.35	0.32	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
COAD	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	5.48	9.91e-08	6.09e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
COAD	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	5.48	9.92e-08	6.1e-05	0.33	0.32	Height;	chr11:118758322	chr11:118791254~118793137:+
COAD	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	5.48	9.92e-08	6.1e-05	0.36	0.32	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
COAD	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-5.48	9.94e-08	6.11e-05	-0.39	-0.32	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
COAD	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-5.48	9.95e-08	6.11e-05	-0.42	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
COAD	cis	rs9951698	0.687	rs498685	ENSG00000266969.1	RP11-773H22.4	5.48	9.96e-08	6.12e-05	0.39	0.32	Intelligence (multi-trait analysis);	chr18:13088674	chr18:12984694~12991173:-
COAD	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	5.48	9.96e-08	6.12e-05	0.45	0.32	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
COAD	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-5.48	9.96e-08	6.12e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
COAD	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	5.48	1e-07	6.15e-05	0.53	0.32	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
COAD	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-5.48	1e-07	6.15e-05	-0.36	-0.32	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
COAD	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-5.48	1e-07	6.16e-05	-0.29	-0.32	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
COAD	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	5.48	1e-07	6.17e-05	0.43	0.32	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
COAD	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-5.48	1.01e-07	6.17e-05	-0.43	-0.32	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
COAD	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-5.48	1.01e-07	6.17e-05	-0.37	-0.32	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
COAD	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	5.48	1.01e-07	6.18e-05	0.52	0.32	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	5.48	1.01e-07	6.18e-05	0.52	0.32	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
COAD	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-5.48	1.01e-07	6.18e-05	-0.31	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
COAD	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.48	1.01e-07	6.18e-05	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
COAD	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-5.48	1.01e-07	6.2e-05	-0.45	-0.32	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
COAD	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-5.48	1.01e-07	6.2e-05	-0.46	-0.32	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
COAD	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	5.48	1.01e-07	6.2e-05	0.35	0.32	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
COAD	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	5.48	1.01e-07	6.21e-05	0.32	0.32	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
COAD	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	5.48	1.01e-07	6.22e-05	0.5	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
COAD	cis	rs7615952	0.546	rs2979306	ENSG00000248787.1	RP11-666A20.4	-5.48	1.01e-07	6.22e-05	-0.49	-0.32	Blood pressure (smoking interaction);	chr3:125593286	chr3:125908005~125910272:-
COAD	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	5.48	1.02e-07	6.23e-05	0.33	0.32	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	5.48	1.02e-07	6.23e-05	0.33	0.32	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
COAD	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	5.48	1.02e-07	6.26e-05	0.23	0.32	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	5.48	1.02e-07	6.26e-05	0.23	0.32	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
COAD	cis	rs75422866	0.85	rs73111226	ENSG00000257433.4	RP1-197B17.3	5.48	1.02e-07	6.28e-05	0.81	0.32	Pneumonia;	chr12:47582204	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.702	rs12426387	ENSG00000257433.4	RP1-197B17.3	5.48	1.02e-07	6.28e-05	0.81	0.32	Pneumonia;	chr12:47582915	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.85	rs12423789	ENSG00000257433.4	RP1-197B17.3	5.48	1.02e-07	6.28e-05	0.81	0.32	Pneumonia;	chr12:47583112	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.702	rs73111229	ENSG00000257433.4	RP1-197B17.3	5.48	1.02e-07	6.28e-05	0.81	0.32	Pneumonia;	chr12:47583333	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.85	rs73111231	ENSG00000257433.4	RP1-197B17.3	5.48	1.02e-07	6.28e-05	0.81	0.32	Pneumonia;	chr12:47584539	chr12:47706085~47742294:+
COAD	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-5.48	1.03e-07	6.28e-05	-0.32	-0.32	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
COAD	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	5.48	1.03e-07	6.29e-05	0.37	0.32	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
COAD	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	5.48	1.03e-07	6.3e-05	0.46	0.32	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
COAD	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	5.48	1.03e-07	6.32e-05	0.41	0.32	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
COAD	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	5.48	1.03e-07	6.34e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
COAD	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	5.48	1.04e-07	6.34e-05	0.36	0.32	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
COAD	cis	rs9393777	0.557	rs6933999	ENSG00000224843.5	LINC00240	5.48	1.04e-07	6.34e-05	0.46	0.32	Intelligence (multi-trait analysis);	chr6:27107150	chr6:26956992~27023924:+
COAD	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	5.48	1.04e-07	6.35e-05	0.23	0.32	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
COAD	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-5.48	1.04e-07	6.35e-05	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
COAD	cis	rs911186	0.947	rs9379962	ENSG00000224843.5	LINC00240	5.48	1.04e-07	6.37e-05	0.48	0.32	Autism spectrum disorder or schizophrenia;	chr6:27177532	chr6:26956992~27023924:+
COAD	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	5.47	1.04e-07	6.37e-05	0.44	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
COAD	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	5.47	1.04e-07	6.37e-05	0.24	0.32	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	5.47	1.04e-07	6.37e-05	0.24	0.32	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
COAD	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-5.47	1.04e-07	6.37e-05	-0.32	-0.32	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
COAD	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	5.47	1.04e-07	6.37e-05	0.41	0.32	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
COAD	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	5.47	1.04e-07	6.38e-05	0.44	0.32	Height;	chr6:109713188	chr6:109382795~109383666:+
COAD	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-5.47	1.04e-07	6.38e-05	-0.54	-0.32	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
COAD	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-5.47	1.04e-07	6.38e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
COAD	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-5.47	1.04e-07	6.39e-05	-0.44	-0.32	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
COAD	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	5.47	1.05e-07	6.39e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	5.47	1.05e-07	6.39e-05	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	5.47	1.05e-07	6.39e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	5.47	1.05e-07	6.39e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
COAD	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-5.47	1.05e-07	6.4e-05	-0.33	-0.32	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
COAD	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	5.47	1.05e-07	6.4e-05	0.3	0.32	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
COAD	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-5.47	1.05e-07	6.4e-05	-0.35	-0.32	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
COAD	cis	rs9393777	0.513	rs61240102	ENSG00000224843.5	LINC00240	5.47	1.05e-07	6.41e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27157125	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs13219181	ENSG00000224843.5	LINC00240	5.47	1.05e-07	6.41e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27168446	chr6:26956992~27023924:+
COAD	cis	rs911186	0.891	rs6914824	ENSG00000224843.5	LINC00240	5.47	1.05e-07	6.41e-05	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:27171269	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs67540232	ENSG00000224843.5	LINC00240	5.47	1.05e-07	6.41e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27173087	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs13194053	ENSG00000224843.5	LINC00240	5.47	1.05e-07	6.41e-05	0.54	0.32	Intelligence (multi-trait analysis);	chr6:27176104	chr6:26956992~27023924:+
COAD	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-5.47	1.05e-07	6.41e-05	-0.36	-0.32	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
COAD	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-5.47	1.05e-07	6.42e-05	-0.18	-0.32	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
COAD	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-5.47	1.05e-07	6.43e-05	-0.35	-0.32	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
COAD	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	5.47	1.05e-07	6.43e-05	0.31	0.32	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	5.47	1.05e-07	6.43e-05	0.31	0.32	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	5.47	1.05e-07	6.43e-05	0.31	0.32	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
COAD	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	5.47	1.05e-07	6.43e-05	0.29	0.32	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
COAD	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-5.47	1.05e-07	6.43e-05	-0.42	-0.32	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
COAD	cis	rs6723226	0.503	rs4952262	ENSG00000276334.1	AL133243.1	-5.47	1.05e-07	6.44e-05	-0.32	-0.32	Intelligence (multi-trait analysis);	chr2:32372166	chr2:32521927~32523547:+
COAD	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-5.47	1.06e-07	6.45e-05	-0.41	-0.32	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
COAD	cis	rs58873874	0.737	rs11466784	ENSG00000251405.2	CTB-109A12.1	5.47	1.06e-07	6.46e-05	0.76	0.32	Bipolar disorder (body mass index interaction);	chr5:157494643	chr5:157362615~157460078:-
COAD	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-5.47	1.06e-07	6.46e-05	-0.4	-0.32	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
COAD	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	5.47	1.06e-07	6.47e-05	0.44	0.32	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
COAD	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	5.47	1.06e-07	6.47e-05	0.4	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
COAD	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	5.47	1.06e-07	6.47e-05	0.5	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
COAD	cis	rs5015933	0.815	rs3962622	ENSG00000232630.1	PRPS1P2	-5.47	1.06e-07	6.48e-05	-0.32	-0.32	Body mass index;	chr9:125259218	chr9:125150653~125151589:+
COAD	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-5.47	1.06e-07	6.48e-05	-0.31	-0.32	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
COAD	cis	rs9393777	0.528	rs9467989	ENSG00000224843.5	LINC00240	5.47	1.06e-07	6.49e-05	0.46	0.32	Intelligence (multi-trait analysis);	chr6:27096496	chr6:26956992~27023924:+
COAD	cis	rs4657482	0.64	rs10918304	ENSG00000236364.3	RP11-525G13.2	-5.47	1.06e-07	6.5e-05	-0.24	-0.32	Testicular germ cell tumor;	chr1:165895450	chr1:165890795~165900683:-
COAD	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	5.47	1.06e-07	6.5e-05	0.42	0.32	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	5.47	1.06e-07	6.5e-05	0.42	0.32	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
COAD	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	5.47	1.06e-07	6.5e-05	0.43	0.32	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
COAD	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-5.47	1.06e-07	6.5e-05	-0.21	-0.32	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
COAD	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	5.47	1.06e-07	6.5e-05	0.32	0.32	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
COAD	cis	rs7404843	0.777	rs6498552	ENSG00000263335.1	AF001548.5	-5.47	1.07e-07	6.51e-05	-0.62	-0.32	Testicular germ cell tumor;	chr16:15446044	chr16:15726674~15732993:+
COAD	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	5.47	1.07e-07	6.51e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	5.47	1.07e-07	6.51e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
COAD	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-5.47	1.07e-07	6.52e-05	-0.45	-0.32	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
COAD	cis	rs9309473	0.539	rs6732440	ENSG00000163016.8	ALMS1P	-5.47	1.07e-07	6.52e-05	-0.39	-0.32	Metabolite levels;	chr2:73599972	chr2:73644919~73685576:+
COAD	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-5.47	1.07e-07	6.52e-05	-0.33	-0.32	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
COAD	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-5.47	1.07e-07	6.52e-05	-0.2	-0.32	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
COAD	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.47	1.07e-07	6.53e-05	-0.33	-0.32	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.47	1.07e-07	6.53e-05	-0.33	-0.32	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
COAD	cis	rs1056107	0.931	rs7855745	ENSG00000225513.1	RP11-165N19.2	-5.47	1.07e-07	6.54e-05	-0.38	-0.32	Colorectal cancer;	chr9:112220183	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs7859107	ENSG00000225513.1	RP11-165N19.2	-5.47	1.07e-07	6.54e-05	-0.38	-0.32	Colorectal cancer;	chr9:112220518	chr9:112173522~112173971:-
COAD	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-5.47	1.07e-07	6.56e-05	-0.57	-0.32	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
COAD	cis	rs2281603	0.951	rs11158544	ENSG00000259116.1	RP11-973N13.4	-5.47	1.08e-07	6.57e-05	-0.34	-0.32	Lymphocyte counts;	chr14:64529769	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs12588886	ENSG00000259116.1	RP11-973N13.4	-5.47	1.08e-07	6.57e-05	-0.34	-0.32	Lymphocyte counts;	chr14:64530226	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	5.47	1.08e-07	6.57e-05	0.37	0.32	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
COAD	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	5.47	1.08e-07	6.58e-05	0.33	0.32	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
COAD	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-5.47	1.08e-07	6.59e-05	-0.35	-0.32	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
COAD	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.47	1.08e-07	6.6e-05	0.38	0.32	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
COAD	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	5.47	1.08e-07	6.61e-05	0.35	0.32	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
COAD	cis	rs7829975	0.572	rs28730413	ENSG00000253981.4	ALG1L13P	-5.47	1.09e-07	6.62e-05	-0.39	-0.32	Mood instability;	chr8:8937937	chr8:8236003~8244667:-
COAD	cis	rs4568518	0.74	rs12699925	ENSG00000279048.1	RP11-511H23.2	5.47	1.09e-07	6.63e-05	0.24	0.32	Measles;	chr7:17971039	chr7:17940503~17942922:+
COAD	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	5.47	1.09e-07	6.64e-05	0.36	0.32	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
COAD	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-5.47	1.09e-07	6.65e-05	-0.33	-0.32	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
COAD	cis	rs77926410	0.604	rs11053801	ENSG00000245648.1	RP11-277P12.20	-5.47	1.09e-07	6.65e-05	-0.41	-0.32	Mean corpuscular volume;	chr12:10443518	chr12:10363769~10398506:+
COAD	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-5.47	1.09e-07	6.66e-05	-0.36	-0.32	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
COAD	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	5.46	1.09e-07	6.67e-05	0.39	0.32	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
COAD	cis	rs189798	0.592	rs10111263	ENSG00000173295.6	FAM86B3P	-5.46	1.09e-07	6.67e-05	-0.4	-0.32	Myopia (pathological);	chr8:9111923	chr8:8228595~8244865:+
COAD	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	5.46	1.1e-07	6.67e-05	0.43	0.32	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
COAD	cis	rs9309473	0.519	rs2421670	ENSG00000163016.8	ALMS1P	-5.46	1.1e-07	6.67e-05	-0.39	-0.32	Metabolite levels;	chr2:73659534	chr2:73644919~73685576:+
COAD	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-5.46	1.1e-07	6.68e-05	-0.55	-0.32	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
COAD	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-5.46	1.1e-07	6.68e-05	-0.32	-0.32	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
COAD	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-5.46	1.1e-07	6.68e-05	-0.32	-0.32	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
COAD	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-5.46	1.1e-07	6.68e-05	-0.34	-0.32	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
COAD	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	5.46	1.1e-07	6.69e-05	0.41	0.32	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
COAD	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-5.46	1.1e-07	6.7e-05	-0.45	-0.32	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
COAD	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-5.46	1.1e-07	6.71e-05	-0.19	-0.32	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
COAD	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	5.46	1.1e-07	6.72e-05	0.37	0.32	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
COAD	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	5.46	1.1e-07	6.72e-05	0.39	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	5.46	1.1e-07	6.72e-05	0.39	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
COAD	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	5.46	1.1e-07	6.72e-05	0.42	0.32	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
COAD	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	5.46	1.11e-07	6.73e-05	0.35	0.32	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
COAD	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	5.46	1.11e-07	6.74e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
COAD	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	5.46	1.11e-07	6.74e-05	0.35	0.32	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-5.46	1.11e-07	6.75e-05	-0.36	-0.32	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
COAD	cis	rs9393777	1	rs9393777	ENSG00000224843.5	LINC00240	5.46	1.11e-07	6.76e-05	0.63	0.32	Intelligence (multi-trait analysis);	chr6:26974248	chr6:26956992~27023924:+
COAD	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-5.46	1.11e-07	6.76e-05	-0.37	-0.32	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
COAD	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	5.46	1.11e-07	6.77e-05	0.37	0.32	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
COAD	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	5.46	1.11e-07	6.77e-05	0.37	0.32	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
COAD	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	5.46	1.11e-07	6.77e-05	0.35	0.32	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
COAD	cis	rs4568518	0.74	rs12699927	ENSG00000279048.1	RP11-511H23.2	5.46	1.11e-07	6.77e-05	0.24	0.32	Measles;	chr7:17972129	chr7:17940503~17942922:+
COAD	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.46	1.11e-07	6.77e-05	-0.41	-0.32	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
COAD	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-5.46	1.11e-07	6.78e-05	-0.39	-0.32	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
COAD	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-5.46	1.11e-07	6.78e-05	-0.44	-0.32	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-5.46	1.11e-07	6.78e-05	-0.44	-0.32	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
COAD	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-5.46	1.12e-07	6.78e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-5.46	1.12e-07	6.78e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
COAD	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.46	1.12e-07	6.78e-05	0.36	0.32	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
COAD	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.46	1.12e-07	6.78e-05	0.36	0.32	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
COAD	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	5.46	1.12e-07	6.78e-05	0.51	0.32	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
COAD	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	5.46	1.12e-07	6.79e-05	0.38	0.32	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
COAD	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-5.46	1.12e-07	6.81e-05	-0.54	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
COAD	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-5.46	1.12e-07	6.81e-05	-0.33	-0.32	Height;	chr11:118742526	chr11:118791254~118793137:+
COAD	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	5.46	1.12e-07	6.81e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
COAD	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-5.46	1.12e-07	6.81e-05	-0.37	-0.32	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
COAD	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-5.46	1.12e-07	6.81e-05	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
COAD	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.46	1.12e-07	6.82e-05	0.35	0.32	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
COAD	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	5.46	1.12e-07	6.83e-05	0.37	0.32	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
COAD	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	5.46	1.13e-07	6.84e-05	0.36	0.32	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
COAD	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-5.46	1.13e-07	6.84e-05	-0.42	-0.32	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
COAD	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-5.46	1.13e-07	6.84e-05	-0.52	-0.32	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
COAD	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-5.46	1.13e-07	6.85e-05	-0.28	-0.32	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
COAD	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	5.46	1.13e-07	6.86e-05	0.43	0.32	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
COAD	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	5.46	1.13e-07	6.86e-05	0.43	0.32	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
COAD	cis	rs7560272	0.723	rs1320374	ENSG00000163016.8	ALMS1P	-5.46	1.13e-07	6.86e-05	-0.39	-0.32	Schizophrenia;	chr2:73601183	chr2:73644919~73685576:+
COAD	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	5.46	1.13e-07	6.86e-05	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
COAD	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-5.46	1.13e-07	6.87e-05	-0.37	-0.32	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
COAD	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	5.46	1.13e-07	6.87e-05	0.31	0.32	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
COAD	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-5.46	1.13e-07	6.87e-05	-0.37	-0.32	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
COAD	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	5.46	1.13e-07	6.88e-05	0.61	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
COAD	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-5.46	1.13e-07	6.88e-05	-0.49	-0.32	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
COAD	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	5.46	1.14e-07	6.89e-05	0.37	0.32	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
COAD	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	5.46	1.14e-07	6.9e-05	0.44	0.32	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
COAD	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-5.46	1.14e-07	6.9e-05	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
COAD	cis	rs9309473	0.519	rs4852951	ENSG00000163016.8	ALMS1P	-5.46	1.14e-07	6.91e-05	-0.39	-0.32	Metabolite levels;	chr2:73642669	chr2:73644919~73685576:+
COAD	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Height;	chr20:49278705	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Height;	chr20:49282523	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Height;	chr20:49283115	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Height;	chr20:49287143	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Height;	chr20:49291523	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-5.46	1.14e-07	6.92e-05	-0.35	-0.32	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
COAD	cis	rs9659323	0.613	rs72705339	ENSG00000231365.4	RP11-418J17.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Body mass index;	chr1:118929246	chr1:119140396~119275973:+
COAD	cis	rs9659323	0.596	rs6656528	ENSG00000231365.4	RP11-418J17.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Body mass index;	chr1:118934971	chr1:119140396~119275973:+
COAD	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
COAD	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-5.46	1.14e-07	6.92e-05	-0.37	-0.32	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
COAD	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-5.46	1.14e-07	6.92e-05	-0.32	-0.32	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
COAD	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.46	1.14e-07	6.93e-05	0.36	0.32	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
COAD	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-5.46	1.15e-07	6.94e-05	-0.37	-0.32	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
COAD	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	5.46	1.15e-07	6.95e-05	0.37	0.32	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
COAD	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-5.46	1.15e-07	6.95e-05	-0.18	-0.32	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-5.46	1.15e-07	6.95e-05	-0.18	-0.32	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-5.46	1.15e-07	6.95e-05	-0.18	-0.32	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
COAD	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-5.46	1.15e-07	6.95e-05	-0.54	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
COAD	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-5.46	1.15e-07	6.95e-05	-0.18	-0.32	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-5.46	1.15e-07	6.95e-05	-0.18	-0.32	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
COAD	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	5.45	1.15e-07	6.97e-05	0.4	0.32	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
COAD	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	5.45	1.15e-07	6.98e-05	0.46	0.32	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
COAD	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	5.45	1.15e-07	6.98e-05	0.37	0.32	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
COAD	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.45	1.15e-07	6.98e-05	-0.35	-0.32	Height;	chr11:118808920	chr11:118791254~118793137:+
COAD	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-5.45	1.15e-07	6.98e-05	-0.42	-0.32	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-5.45	1.15e-07	6.98e-05	-0.19	-0.32	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
COAD	cis	rs7955901	0.904	rs1512991	ENSG00000258053.1	CTD-2021H9.3	-5.45	1.15e-07	6.98e-05	-0.38	-0.32	Type 2 diabetes;	chr12:71028988	chr12:71047402~71118247:-
COAD	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-5.45	1.16e-07	7.01e-05	-0.34	-0.32	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
COAD	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
COAD	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.16e-07	7.02e-05	-0.42	-0.32	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
COAD	cis	rs4950322	0.518	rs61838951	ENSG00000278811.3	LINC00624	5.45	1.16e-07	7.02e-05	0.33	0.32	Protein quantitative trait loci;	chr1:147116081	chr1:147258885~147517875:-
COAD	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	5.45	1.16e-07	7.03e-05	0.31	0.32	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	5.45	1.16e-07	7.03e-05	0.31	0.32	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	5.45	1.16e-07	7.03e-05	0.31	0.32	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
COAD	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-5.45	1.16e-07	7.04e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	5.45	1.16e-07	7.04e-05	0.37	0.32	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
COAD	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.45	1.16e-07	7.04e-05	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
COAD	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	5.45	1.16e-07	7.05e-05	0.32	0.32	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	5.45	1.16e-07	7.05e-05	0.32	0.32	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
COAD	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	5.45	1.17e-07	7.05e-05	0.43	0.32	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
COAD	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	5.45	1.17e-07	7.06e-05	0.46	0.32	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
COAD	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-5.45	1.17e-07	7.07e-05	-0.35	-0.32	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
COAD	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-5.45	1.17e-07	7.07e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-5.45	1.17e-07	7.07e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-5.45	1.17e-07	7.07e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
COAD	cis	rs711830	1	rs2857540	ENSG00000226363.3	HAGLROS	-5.45	1.17e-07	7.07e-05	-0.52	-0.32	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176161970	chr2:176177717~176179008:+
COAD	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.45	1.17e-07	7.09e-05	-0.28	-0.32	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-5.45	1.17e-07	7.09e-05	-0.28	-0.32	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
COAD	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	5.45	1.17e-07	7.1e-05	0.35	0.32	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
COAD	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-5.45	1.18e-07	7.1e-05	-0.18	-0.32	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
COAD	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	5.45	1.18e-07	7.1e-05	0.57	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	5.45	1.18e-07	7.1e-05	0.57	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	5.45	1.18e-07	7.1e-05	0.57	0.32	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
COAD	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	5.45	1.18e-07	7.12e-05	0.47	0.32	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
COAD	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-5.45	1.18e-07	7.13e-05	-0.34	-0.32	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
COAD	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	5.45	1.18e-07	7.13e-05	0.33	0.32	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
COAD	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-5.45	1.18e-07	7.13e-05	-0.4	-0.32	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
COAD	cis	rs2665103	0.61	rs1972460	ENSG00000259429.4	UBE2Q2P2	-5.45	1.18e-07	7.14e-05	-0.27	-0.32	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82355142~82420075:+
COAD	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	5.45	1.18e-07	7.14e-05	0.23	0.32	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	5.45	1.18e-07	7.14e-05	0.23	0.32	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
COAD	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	5.45	1.18e-07	7.14e-05	0.52	0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
COAD	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-5.45	1.18e-07	7.15e-05	-0.3	-0.32	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
COAD	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-5.45	1.18e-07	7.15e-05	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
COAD	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	5.45	1.18e-07	7.15e-05	0.32	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
COAD	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	5.45	1.19e-07	7.16e-05	0.36	0.32	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
COAD	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-5.45	1.19e-07	7.16e-05	-0.28	-0.32	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
COAD	cis	rs4604234	0.541	rs11963917	ENSG00000272129.1	RP11-250B2.6	-5.45	1.19e-07	7.16e-05	-0.71	-0.32	Cancer;	chr6:80294843	chr6:80355424~80356859:+
COAD	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.16e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.16e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
COAD	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-5.45	1.19e-07	7.16e-05	-0.44	-0.32	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
COAD	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	5.45	1.19e-07	7.17e-05	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
COAD	cis	rs7955901	0.904	rs4760785	ENSG00000258053.1	CTD-2021H9.3	-5.45	1.19e-07	7.18e-05	-0.39	-0.32	Type 2 diabetes;	chr12:71045165	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.904	rs4760895	ENSG00000258053.1	CTD-2021H9.3	-5.45	1.19e-07	7.18e-05	-0.39	-0.32	Type 2 diabetes;	chr12:71045347	chr12:71047402~71118247:-
COAD	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	5.45	1.19e-07	7.18e-05	0.46	0.32	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
COAD	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	5.45	1.19e-07	7.18e-05	0.46	0.32	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
COAD	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-5.45	1.19e-07	7.19e-05	-0.34	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
COAD	cis	rs453301	0.686	rs1045527	ENSG00000253981.4	ALG1L13P	-5.45	1.19e-07	7.19e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9032531	chr8:8236003~8244667:-
COAD	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-5.45	1.19e-07	7.19e-05	-0.54	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
COAD	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-5.45	1.19e-07	7.2e-05	-0.43	-0.32	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
COAD	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.21e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.21e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.21e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	5.45	1.19e-07	7.21e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	5.45	1.2e-07	7.21e-05	0.35	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	5.45	1.2e-07	7.21e-05	0.37	0.32	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
COAD	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-5.45	1.2e-07	7.21e-05	-0.36	-0.32	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
COAD	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-5.45	1.2e-07	7.23e-05	-0.45	-0.32	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
COAD	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-5.45	1.2e-07	7.23e-05	-0.45	-0.32	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
COAD	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	5.45	1.2e-07	7.24e-05	0.24	0.32	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
COAD	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	5.45	1.2e-07	7.24e-05	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	5.45	1.2e-07	7.24e-05	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
COAD	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-5.45	1.2e-07	7.25e-05	-0.49	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
COAD	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-5.45	1.21e-07	7.27e-05	-0.23	-0.32	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
COAD	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.45	1.21e-07	7.28e-05	-0.33	-0.32	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
COAD	cis	rs9818758	0.607	rs9850917	ENSG00000225399.4	RP11-3B7.1	-5.45	1.21e-07	7.28e-05	-0.57	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs9847839	ENSG00000225399.4	RP11-3B7.1	-5.45	1.21e-07	7.28e-05	-0.57	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:49260085~49261316:+
COAD	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
COAD	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	5.45	1.21e-07	7.28e-05	0.32	0.32	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
COAD	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	5.45	1.21e-07	7.28e-05	0.34	0.32	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
COAD	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-5.45	1.21e-07	7.28e-05	-0.42	-0.32	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
COAD	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	5.45	1.21e-07	7.28e-05	0.52	0.32	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
COAD	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-5.44	1.21e-07	7.3e-05	-0.4	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
COAD	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	5.44	1.22e-07	7.32e-05	0.44	0.32	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
COAD	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	5.44	1.22e-07	7.33e-05	0.36	0.32	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
COAD	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-5.44	1.22e-07	7.33e-05	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
COAD	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-5.44	1.22e-07	7.33e-05	-0.41	-0.32	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
COAD	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	5.44	1.22e-07	7.34e-05	0.38	0.32	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
COAD	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-5.44	1.22e-07	7.36e-05	-0.4	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
COAD	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	5.44	1.22e-07	7.36e-05	0.65	0.32	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
COAD	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	5.44	1.22e-07	7.37e-05	0.34	0.32	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
COAD	cis	rs13256369	1	rs885000	ENSG00000173295.6	FAM86B3P	5.44	1.23e-07	7.38e-05	0.45	0.32	Obesity-related traits;	chr8:8711365	chr8:8228595~8244865:+
COAD	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	5.44	1.23e-07	7.39e-05	0.42	0.32	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
COAD	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-5.44	1.23e-07	7.39e-05	-0.41	-0.32	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
COAD	cis	rs7078219	0.714	rs11190139	ENSG00000257582.4	LINC01475	-5.44	1.23e-07	7.39e-05	-0.36	-0.32	Dental caries;	chr10:99528342	chr10:99526350~99531177:-
COAD	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-5.44	1.23e-07	7.39e-05	-0.19	-0.32	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
COAD	cis	rs754466	0.58	rs2289308	ENSG00000204049.1	RP11-126H7.4	5.44	1.23e-07	7.39e-05	0.4	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77819493	chr10:77866875~77869610:+
COAD	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-5.44	1.23e-07	7.4e-05	-0.4	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
COAD	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-5.44	1.23e-07	7.4e-05	-0.28	-0.32	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-5.44	1.23e-07	7.4e-05	-0.28	-0.32	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
COAD	cis	rs2439831	1	rs28628574	ENSG00000249839.1	AC011330.5	-5.44	1.23e-07	7.4e-05	-0.55	-0.32	Lung cancer in ever smokers;	chr15:43509840	chr15:43663654~43684339:-
COAD	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	5.44	1.23e-07	7.41e-05	0.4	0.32	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
COAD	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-5.44	1.23e-07	7.42e-05	-0.35	-0.32	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
COAD	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-5.44	1.23e-07	7.42e-05	-0.39	-0.32	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
COAD	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	5.44	1.23e-07	7.42e-05	0.4	0.32	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
COAD	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	5.44	1.23e-07	7.42e-05	0.4	0.32	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
COAD	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-5.44	1.24e-07	7.42e-05	-0.47	-0.32	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
COAD	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	5.44	1.24e-07	7.43e-05	0.24	0.32	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	5.44	1.24e-07	7.43e-05	0.24	0.32	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	5.44	1.24e-07	7.43e-05	0.24	0.32	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	5.44	1.24e-07	7.43e-05	0.24	0.32	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
COAD	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-5.44	1.24e-07	7.43e-05	-0.37	-0.32	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
COAD	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-5.44	1.24e-07	7.45e-05	-0.33	-0.32	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
COAD	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	5.44	1.24e-07	7.46e-05	0.28	0.32	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
COAD	cis	rs7829975	0.582	rs448231	ENSG00000253981.4	ALG1L13P	-5.44	1.24e-07	7.46e-05	-0.38	-0.32	Mood instability;	chr8:8932549	chr8:8236003~8244667:-
COAD	cis	rs4604234	0.573	rs11961361	ENSG00000272129.1	RP11-250B2.6	-5.44	1.24e-07	7.47e-05	-0.69	-0.32	Cancer;	chr6:80294840	chr6:80355424~80356859:+
COAD	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-5.44	1.24e-07	7.47e-05	-0.4	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
COAD	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	5.44	1.25e-07	7.49e-05	0.42	0.32	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
COAD	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	5.44	1.25e-07	7.5e-05	0.47	0.32	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
COAD	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-5.44	1.25e-07	7.5e-05	-0.36	-0.32	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
COAD	cis	rs711830	1	rs6433571	ENSG00000226363.3	HAGLROS	-5.44	1.25e-07	7.51e-05	-0.5	-0.32	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174850	chr2:176177717~176179008:+
COAD	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-5.44	1.25e-07	7.52e-05	-0.4	-0.32	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
COAD	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	5.44	1.25e-07	7.53e-05	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	5.44	1.26e-07	7.54e-05	0.36	0.32	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
COAD	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-5.44	1.26e-07	7.54e-05	-0.32	-0.32	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
COAD	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	5.44	1.26e-07	7.55e-05	0.33	0.32	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
COAD	cis	rs603446	0.967	rs3741301	ENSG00000254851.1	RP11-109L13.1	-5.44	1.26e-07	7.56e-05	-0.39	-0.32	Triglycerides;	chr11:116760675	chr11:117135528~117138582:+
COAD	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-5.44	1.26e-07	7.56e-05	-0.35	-0.32	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
COAD	cis	rs7615952	0.932	rs1976458	ENSG00000248787.1	RP11-666A20.4	-5.44	1.26e-07	7.57e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125928669	chr3:125908005~125910272:-
COAD	cis	rs1056107	0.931	rs7025680	ENSG00000225513.1	RP11-165N19.2	-5.44	1.27e-07	7.59e-05	-0.38	-0.32	Colorectal cancer;	chr9:112224434	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.872	rs3780514	ENSG00000225513.1	RP11-165N19.2	-5.44	1.27e-07	7.59e-05	-0.38	-0.32	Colorectal cancer;	chr9:112226051	chr9:112173522~112173971:-
COAD	cis	rs2281603	0.808	rs10132424	ENSG00000259116.1	RP11-973N13.4	-5.44	1.27e-07	7.6e-05	-0.34	-0.32	Lymphocyte counts;	chr14:64527157	chr14:64514154~64540368:-
COAD	cis	rs28374715	0.662	rs28554139	ENSG00000247556.5	OIP5-AS1	5.44	1.27e-07	7.6e-05	0.43	0.32	Ulcerative colitis;	chr15:41238886	chr15:41283990~41309737:+
COAD	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-5.44	1.27e-07	7.6e-05	-0.33	-0.32	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
COAD	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-5.44	1.27e-07	7.61e-05	-0.43	-0.32	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
COAD	cis	rs9659323	0.65	rs1155949	ENSG00000231365.4	RP11-418J17.1	-5.44	1.27e-07	7.61e-05	-0.38	-0.32	Body mass index;	chr1:118953956	chr1:119140396~119275973:+
COAD	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-5.44	1.27e-07	7.62e-05	-0.32	-0.32	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
COAD	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	5.44	1.27e-07	7.62e-05	0.38	0.32	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
COAD	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-5.44	1.27e-07	7.62e-05	-0.32	-0.32	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
COAD	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-5.43	1.27e-07	7.63e-05	-0.34	-0.32	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
COAD	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	5.43	1.27e-07	7.64e-05	0.36	0.32	Height;	chr3:53085313	chr3:53064283~53065091:-
COAD	cis	rs7615952	1	rs9289275	ENSG00000248787.1	RP11-666A20.4	-5.43	1.28e-07	7.65e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125929816	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.866	rs1976459	ENSG00000248787.1	RP11-666A20.4	-5.43	1.28e-07	7.66e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125928643	chr3:125908005~125910272:-
COAD	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-5.43	1.28e-07	7.67e-05	-0.29	-0.32	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
COAD	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	5.43	1.28e-07	7.67e-05	0.43	0.32	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
COAD	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-5.43	1.28e-07	7.67e-05	-0.33	-0.32	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
COAD	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-5.43	1.28e-07	7.68e-05	-0.39	-0.32	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
COAD	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-5.43	1.28e-07	7.69e-05	-0.41	-0.32	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
COAD	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	5.43	1.29e-07	7.7e-05	0.4	0.32	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
COAD	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	5.43	1.29e-07	7.7e-05	0.36	0.32	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
COAD	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	5.43	1.29e-07	7.7e-05	0.36	0.32	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
COAD	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-5.43	1.29e-07	7.72e-05	-0.4	-0.32	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
COAD	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.43	1.29e-07	7.72e-05	-0.48	-0.32	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
COAD	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-5.43	1.29e-07	7.72e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
COAD	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	5.43	1.3e-07	7.76e-05	0.41	0.32	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
COAD	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	5.43	1.3e-07	7.76e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	5.43	1.3e-07	7.76e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	5.43	1.3e-07	7.76e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	5.43	1.3e-07	7.76e-05	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
COAD	cis	rs7078219	0.714	rs12414770	ENSG00000257582.4	LINC01475	-5.43	1.3e-07	7.76e-05	-0.36	-0.32	Dental caries;	chr10:99528481	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.714	rs60386053	ENSG00000257582.4	LINC01475	-5.43	1.3e-07	7.76e-05	-0.36	-0.32	Dental caries;	chr10:99529104	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.686	rs12412391	ENSG00000257582.4	LINC01475	-5.43	1.3e-07	7.76e-05	-0.36	-0.32	Dental caries;	chr10:99529178	chr10:99526350~99531177:-
COAD	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	5.43	1.3e-07	7.77e-05	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
COAD	cis	rs4718428	0.705	rs4718430	ENSG00000273142.1	RP11-458F8.4	-5.43	1.3e-07	7.77e-05	-0.26	-0.32	Corneal structure;	chr7:66967037	chr7:66902857~66906297:+
COAD	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-5.43	1.3e-07	7.78e-05	-0.41	-0.32	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
COAD	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-5.43	1.3e-07	7.78e-05	-0.41	-0.32	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
COAD	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-5.43	1.3e-07	7.81e-05	-0.33	-0.32	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
COAD	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	5.43	1.31e-07	7.81e-05	0.36	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
COAD	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-5.43	1.31e-07	7.82e-05	-0.2	-0.32	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-5.43	1.31e-07	7.82e-05	-0.2	-0.32	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
COAD	cis	rs28374715	0.662	rs28587487	ENSG00000247556.5	OIP5-AS1	5.43	1.31e-07	7.83e-05	0.43	0.32	Ulcerative colitis;	chr15:41203262	chr15:41283990~41309737:+
COAD	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-5.43	1.31e-07	7.83e-05	-0.36	-0.32	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
COAD	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-5.43	1.31e-07	7.83e-05	-0.36	-0.32	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
COAD	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-5.43	1.31e-07	7.84e-05	-0.34	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
COAD	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	5.43	1.31e-07	7.85e-05	0.33	0.32	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
COAD	cis	rs1056107	0.931	rs7871559	ENSG00000225513.1	RP11-165N19.2	-5.43	1.32e-07	7.86e-05	-0.38	-0.32	Colorectal cancer;	chr9:112225574	chr9:112173522~112173971:-
COAD	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-5.43	1.32e-07	7.87e-05	-0.39	-0.32	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
COAD	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	5.43	1.32e-07	7.88e-05	0.43	0.32	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
COAD	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-5.43	1.32e-07	7.89e-05	-0.36	-0.32	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	5.43	1.32e-07	7.89e-05	0.44	0.32	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	5.43	1.32e-07	7.9e-05	0.36	0.32	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
COAD	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.43	1.32e-07	7.91e-05	0.44	0.32	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
COAD	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	5.43	1.33e-07	7.92e-05	0.59	0.32	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
COAD	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-5.43	1.33e-07	7.93e-05	-0.35	-0.32	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
COAD	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-5.43	1.33e-07	7.93e-05	-0.35	-0.32	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
COAD	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	5.43	1.33e-07	7.93e-05	0.35	0.32	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
COAD	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	5.43	1.33e-07	7.93e-05	0.38	0.32	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
COAD	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-5.43	1.33e-07	7.93e-05	-0.47	-0.32	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
COAD	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-5.43	1.33e-07	7.93e-05	-0.47	-0.32	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
COAD	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	5.43	1.33e-07	7.93e-05	0.3	0.32	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
COAD	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	5.43	1.33e-07	7.94e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
COAD	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	5.43	1.33e-07	7.96e-05	0.44	0.32	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
COAD	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-5.43	1.33e-07	7.96e-05	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
COAD	cis	rs9309473	0.5	rs4852308	ENSG00000163016.8	ALMS1P	-5.43	1.33e-07	7.96e-05	-0.39	-0.32	Metabolite levels;	chr2:73606908	chr2:73644919~73685576:+
COAD	cis	rs7637701	0.818	rs10936038	ENSG00000240875.4	LINC00886	-5.43	1.33e-07	7.97e-05	-0.31	-0.32	Breast cancer;	chr3:156814877	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.818	rs11711674	ENSG00000240875.4	LINC00886	-5.43	1.33e-07	7.97e-05	-0.31	-0.32	Breast cancer;	chr3:156815164	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.818	rs1560415	ENSG00000240875.4	LINC00886	-5.43	1.33e-07	7.97e-05	-0.31	-0.32	Breast cancer;	chr3:156819569	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.818	rs1560416	ENSG00000240875.4	LINC00886	-5.43	1.33e-07	7.97e-05	-0.31	-0.32	Breast cancer;	chr3:156819630	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.818	rs9837271	ENSG00000240875.4	LINC00886	-5.43	1.33e-07	7.97e-05	-0.31	-0.32	Breast cancer;	chr3:156820949	chr3:156747346~156817062:-
COAD	cis	rs7615952	0.741	rs13314845	ENSG00000248787.1	RP11-666A20.4	-5.43	1.33e-07	7.97e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125925939	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.733	rs13314847	ENSG00000248787.1	RP11-666A20.4	-5.43	1.33e-07	7.97e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125925945	chr3:125908005~125910272:-
COAD	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	5.43	1.34e-07	7.98e-05	0.34	0.32	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
COAD	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-5.43	1.34e-07	7.98e-05	-0.42	-0.32	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
COAD	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-5.43	1.34e-07	7.98e-05	-0.47	-0.32	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
COAD	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	5.42	1.34e-07	7.99e-05	0.29	0.32	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
COAD	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-5.42	1.34e-07	8.01e-05	-0.35	-0.32	Height;	chr20:49306363	chr20:49280319~49280409:+
COAD	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	5.42	1.34e-07	8.02e-05	0.34	0.32	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
COAD	cis	rs9309473	0.519	rs13009035	ENSG00000163016.8	ALMS1P	-5.42	1.34e-07	8.02e-05	-0.39	-0.32	Metabolite levels;	chr2:73618582	chr2:73644919~73685576:+
COAD	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-5.42	1.35e-07	8.08e-05	-0.29	-0.32	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
COAD	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-5.42	1.36e-07	8.1e-05	-0.34	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
COAD	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-5.42	1.36e-07	8.1e-05	-0.4	-0.32	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
COAD	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	5.42	1.36e-07	8.11e-05	0.55	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	5.42	1.36e-07	8.11e-05	0.55	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	5.42	1.36e-07	8.11e-05	0.55	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
COAD	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	5.42	1.36e-07	8.11e-05	0.42	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
COAD	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-5.42	1.36e-07	8.11e-05	-0.36	-0.32	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
COAD	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-5.42	1.36e-07	8.11e-05	-0.35	-0.32	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
COAD	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	5.42	1.36e-07	8.12e-05	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
COAD	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	5.42	1.36e-07	8.12e-05	0.35	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
COAD	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	5.42	1.37e-07	8.15e-05	0.33	0.32	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
COAD	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	5.42	1.37e-07	8.18e-05	0.41	0.32	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
COAD	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	5.42	1.37e-07	8.18e-05	0.24	0.32	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
COAD	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	5.42	1.37e-07	8.18e-05	0.3	0.32	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
COAD	cis	rs7078219	0.714	rs11190139	ENSG00000228778.1	RP11-129J12.1	-5.42	1.38e-07	8.19e-05	-0.37	-0.32	Dental caries;	chr10:99528342	chr10:99527081~99528261:+
COAD	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-5.42	1.38e-07	8.19e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	5.42	1.38e-07	8.19e-05	0.53	0.32	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
COAD	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	5.42	1.38e-07	8.2e-05	0.43	0.32	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	5.42	1.38e-07	8.2e-05	0.36	0.32	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
COAD	cis	rs2281603	0.951	rs73267744	ENSG00000259116.1	RP11-973N13.4	-5.42	1.38e-07	8.22e-05	-0.34	-0.32	Lymphocyte counts;	chr14:64511461	chr14:64514154~64540368:-
COAD	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-5.42	1.39e-07	8.23e-05	-0.37	-0.32	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-5.42	1.39e-07	8.23e-05	-0.37	-0.32	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-5.42	1.39e-07	8.23e-05	-0.37	-0.32	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-5.42	1.39e-07	8.23e-05	-0.37	-0.32	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
COAD	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-5.42	1.39e-07	8.23e-05	-0.38	-0.32	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
COAD	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	5.42	1.39e-07	8.25e-05	0.23	0.32	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
COAD	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	5.42	1.39e-07	8.25e-05	0.28	0.32	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
COAD	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	5.42	1.39e-07	8.25e-05	0.28	0.32	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
COAD	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-5.42	1.39e-07	8.26e-05	-0.43	-0.32	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
COAD	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-5.42	1.39e-07	8.27e-05	-0.54	-0.32	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
COAD	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	5.42	1.4e-07	8.29e-05	0.43	0.32	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
COAD	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-5.42	1.4e-07	8.29e-05	-0.33	-0.32	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
COAD	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	5.42	1.4e-07	8.29e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
COAD	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	5.42	1.4e-07	8.29e-05	0.41	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
COAD	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	5.42	1.4e-07	8.3e-05	0.43	0.32	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	5.42	1.4e-07	8.3e-05	0.43	0.32	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	5.42	1.4e-07	8.3e-05	0.43	0.32	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
COAD	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-5.42	1.4e-07	8.3e-05	-0.36	-0.32	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
COAD	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-5.42	1.4e-07	8.31e-05	-0.33	-0.32	Height;	chr11:118786602	chr11:118791254~118793137:+
COAD	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.42	1.4e-07	8.31e-05	-0.33	-0.32	Height;	chr11:118791319	chr11:118791254~118793137:+
COAD	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-5.42	1.4e-07	8.31e-05	-0.35	-0.32	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
COAD	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.42	1.4e-07	8.32e-05	-0.44	-0.32	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
COAD	cis	rs7404843	1	rs7404843	ENSG00000263335.1	AF001548.5	-5.42	1.4e-07	8.32e-05	-0.61	-0.32	Testicular germ cell tumor;	chr16:15436851	chr16:15726674~15732993:+
COAD	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.41	1.41e-07	8.35e-05	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
COAD	cis	rs28374715	0.662	rs113913466	ENSG00000247556.5	OIP5-AS1	5.41	1.41e-07	8.35e-05	0.43	0.32	Ulcerative colitis;	chr15:41190902	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs28493087	ENSG00000247556.5	OIP5-AS1	5.41	1.41e-07	8.35e-05	0.43	0.32	Ulcerative colitis;	chr15:41194306	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs28382348	ENSG00000247556.5	OIP5-AS1	5.41	1.41e-07	8.35e-05	0.43	0.32	Ulcerative colitis;	chr15:41195736	chr15:41283990~41309737:+
COAD	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-5.41	1.41e-07	8.36e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
COAD	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	5.41	1.41e-07	8.36e-05	0.39	0.32	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
COAD	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	5.41	1.41e-07	8.37e-05	0.35	0.32	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
COAD	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.41	1.41e-07	8.38e-05	-0.42	-0.32	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
COAD	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-5.41	1.41e-07	8.38e-05	-0.56	-0.32	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
COAD	cis	rs2281603	1	rs2281603	ENSG00000259116.1	RP11-973N13.4	-5.41	1.42e-07	8.38e-05	-0.34	-0.32	Lymphocyte counts;	chr14:64459379	chr14:64514154~64540368:-
COAD	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.41	1.42e-07	8.39e-05	-0.43	-0.32	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
COAD	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	5.41	1.42e-07	8.39e-05	0.23	0.32	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
COAD	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	5.41	1.42e-07	8.4e-05	0.48	0.32	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
COAD	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	5.41	1.42e-07	8.4e-05	0.34	0.32	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
COAD	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	5.41	1.42e-07	8.41e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
COAD	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-5.41	1.42e-07	8.41e-05	-0.41	-0.32	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
COAD	cis	rs911186	0.782	rs34569203	ENSG00000224843.5	LINC00240	5.41	1.42e-07	8.41e-05	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:27186205	chr6:26956992~27023924:+
COAD	cis	rs7615952	0.8	rs13086460	ENSG00000248787.1	RP11-666A20.4	-5.41	1.42e-07	8.43e-05	-0.44	-0.32	Blood pressure (smoking interaction);	chr3:125927574	chr3:125908005~125910272:-
COAD	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-5.41	1.42e-07	8.43e-05	-0.44	-0.32	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
COAD	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.41	1.43e-07	8.44e-05	0.35	0.32	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
COAD	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.41	1.43e-07	8.44e-05	0.35	0.32	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
COAD	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	5.41	1.43e-07	8.44e-05	0.41	0.32	Depression;	chr6:28327262	chr6:28943877~28944537:+
COAD	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	5.41	1.43e-07	8.45e-05	0.53	0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
COAD	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-5.41	1.43e-07	8.45e-05	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-5.41	1.43e-07	8.45e-05	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-5.41	1.43e-07	8.45e-05	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
COAD	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	5.41	1.43e-07	8.48e-05	0.36	0.32	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
COAD	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	5.41	1.44e-07	8.5e-05	0.43	0.32	Height;	chr6:109732047	chr6:109382795~109383666:+
COAD	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-5.41	1.44e-07	8.5e-05	-0.2	-0.32	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
COAD	cis	rs9951698	0.703	rs8097125	ENSG00000266969.1	RP11-773H22.4	5.41	1.44e-07	8.5e-05	0.41	0.32	Intelligence (multi-trait analysis);	chr18:13005474	chr18:12984694~12991173:-
COAD	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	5.41	1.44e-07	8.5e-05	0.38	0.32	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
COAD	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-5.41	1.44e-07	8.5e-05	-0.34	-0.32	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
COAD	cis	rs1056107	0.931	rs10759536	ENSG00000225513.1	RP11-165N19.2	-5.41	1.44e-07	8.51e-05	-0.38	-0.32	Colorectal cancer;	chr9:112229222	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.898	rs10733586	ENSG00000225513.1	RP11-165N19.2	-5.41	1.44e-07	8.51e-05	-0.38	-0.32	Colorectal cancer;	chr9:112229903	chr9:112173522~112173971:-
COAD	cis	rs453301	0.653	rs7005133	ENSG00000233609.3	RP11-62H7.2	5.41	1.44e-07	8.51e-05	0.36	0.32	Joint mobility (Beighton score);	chr8:9043712	chr8:8961200~8979025:+
COAD	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	5.41	1.44e-07	8.52e-05	0.22	0.32	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
COAD	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-5.41	1.44e-07	8.53e-05	-0.55	-0.32	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
COAD	cis	rs4950322	0.518	rs61838936	ENSG00000278811.3	LINC00624	5.41	1.45e-07	8.54e-05	0.33	0.32	Protein quantitative trait loci;	chr1:147098422	chr1:147258885~147517875:-
COAD	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	5.41	1.45e-07	8.55e-05	0.32	0.32	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	5.41	1.45e-07	8.55e-05	0.32	0.32	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
COAD	cis	rs453301	0.686	rs3989373	ENSG00000253981.4	ALG1L13P	-5.41	1.45e-07	8.56e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9053798	chr8:8236003~8244667:-
COAD	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	5.41	1.45e-07	8.58e-05	0.34	0.32	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	5.41	1.45e-07	8.58e-05	0.34	0.32	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	5.41	1.45e-07	8.58e-05	0.34	0.32	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
COAD	cis	rs453301	0.686	rs1045527	ENSG00000173295.6	FAM86B3P	-5.41	1.45e-07	8.59e-05	-0.37	-0.32	Joint mobility (Beighton score);	chr8:9032531	chr8:8228595~8244865:+
COAD	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	5.41	1.46e-07	8.61e-05	0.42	0.32	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
COAD	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	5.41	1.46e-07	8.61e-05	0.28	0.32	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
COAD	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-5.41	1.46e-07	8.64e-05	-0.29	-0.32	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
COAD	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-5.41	1.46e-07	8.64e-05	-0.4	-0.32	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
COAD	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-5.41	1.47e-07	8.65e-05	-0.37	-0.32	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
COAD	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-5.41	1.47e-07	8.65e-05	-0.53	-0.32	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
COAD	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	5.41	1.47e-07	8.66e-05	0.37	0.32	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
COAD	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	5.41	1.47e-07	8.67e-05	0.37	0.32	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
COAD	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.41	1.47e-07	8.67e-05	0.41	0.32	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
COAD	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-5.41	1.47e-07	8.69e-05	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
COAD	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-5.41	1.47e-07	8.69e-05	-0.43	-0.32	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
COAD	cis	rs7615952	0.866	rs13063119	ENSG00000248787.1	RP11-666A20.4	-5.41	1.47e-07	8.69e-05	-0.46	-0.32	Blood pressure (smoking interaction);	chr3:125925004	chr3:125908005~125910272:-
COAD	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	5.41	1.47e-07	8.69e-05	0.36	0.32	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
COAD	cis	rs1056107	0.931	rs10817295	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112235310	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs10118422	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112236116	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs4979089	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112236816	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs2027384	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112237954	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.898	rs7021564	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112240034	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.866	rs12351043	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112241012	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs7864927	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112241713	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs10759541	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112243277	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs7032120	ENSG00000225513.1	RP11-165N19.2	-5.41	1.48e-07	8.71e-05	-0.38	-0.32	Colorectal cancer;	chr9:112243865	chr9:112173522~112173971:-
COAD	cis	rs7615952	0.932	rs13314869	ENSG00000248787.1	RP11-666A20.4	-5.41	1.48e-07	8.71e-05	-0.45	-0.32	Blood pressure (smoking interaction);	chr3:125925826	chr3:125908005~125910272:-
COAD	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	5.41	1.48e-07	8.72e-05	0.23	0.32	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
COAD	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-5.41	1.48e-07	8.72e-05	-0.34	-0.32	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
COAD	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	5.4	1.48e-07	8.73e-05	0.42	0.32	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
COAD	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-5.4	1.48e-07	8.74e-05	-0.42	-0.32	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-5.4	1.48e-07	8.74e-05	-0.42	-0.32	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-5.4	1.48e-07	8.74e-05	-0.42	-0.32	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
COAD	cis	rs453301	0.686	rs6987107	ENSG00000253981.4	ALG1L13P	-5.4	1.48e-07	8.74e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9036071	chr8:8236003~8244667:-
COAD	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-5.4	1.48e-07	8.74e-05	-0.34	-0.32	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
COAD	cis	rs71403859	0.685	rs12927044	ENSG00000260886.1	TAT-AS1	5.4	1.48e-07	8.75e-05	0.75	0.32	Post bronchodilator FEV1;	chr16:71896202	chr16:71565789~71578187:+
COAD	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-5.4	1.48e-07	8.75e-05	-0.34	-0.32	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
COAD	cis	rs492146	0.765	rs316131	ENSG00000243236.5	GSTA9P	-5.4	1.48e-07	8.75e-05	-0.35	-0.32	Epilepsy (remission after treatment);	chr6:52983351	chr6:52939726~52957521:-
COAD	cis	rs492146	0.729	rs316130	ENSG00000243236.5	GSTA9P	-5.4	1.48e-07	8.75e-05	-0.35	-0.32	Epilepsy (remission after treatment);	chr6:52983402	chr6:52939726~52957521:-
COAD	cis	rs492146	0.765	rs316129	ENSG00000243236.5	GSTA9P	-5.4	1.48e-07	8.75e-05	-0.35	-0.32	Epilepsy (remission after treatment);	chr6:52984107	chr6:52939726~52957521:-
COAD	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-5.4	1.49e-07	8.76e-05	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
COAD	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	5.4	1.49e-07	8.76e-05	0.56	0.32	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
COAD	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-5.4	1.49e-07	8.76e-05	-0.4	-0.32	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
COAD	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-5.4	1.49e-07	8.78e-05	-0.37	-0.32	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
COAD	cis	rs1056107	0.931	rs2418199	ENSG00000225513.1	RP11-165N19.2	-5.4	1.49e-07	8.8e-05	-0.38	-0.32	Colorectal cancer;	chr9:112242888	chr9:112173522~112173971:-
COAD	cis	rs73198271	0.751	rs617813	ENSG00000173295.6	FAM86B3P	-5.4	1.5e-07	8.81e-05	-0.38	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8228595~8244865:+
COAD	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-5.4	1.5e-07	8.81e-05	-0.38	-0.32	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
COAD	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-5.4	1.5e-07	8.83e-05	-0.34	-0.32	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
COAD	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	5.4	1.5e-07	8.85e-05	0.23	0.32	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
COAD	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-5.4	1.51e-07	8.87e-05	-0.49	-0.32	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
COAD	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-5.4	1.51e-07	8.87e-05	-0.42	-0.32	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
COAD	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	5.4	1.51e-07	8.87e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	5.4	1.51e-07	8.87e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	5.4	1.51e-07	8.87e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	5.4	1.51e-07	8.87e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	5.4	1.51e-07	8.87e-05	0.38	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
COAD	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	5.4	1.51e-07	8.87e-05	0.36	0.32	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	5.4	1.51e-07	8.87e-05	0.36	0.32	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
COAD	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	5.4	1.51e-07	8.88e-05	0.35	0.32	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
COAD	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	5.4	1.51e-07	8.9e-05	0.33	0.32	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
COAD	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-5.4	1.51e-07	8.91e-05	-0.38	-0.32	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
COAD	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	5.4	1.51e-07	8.91e-05	0.41	0.32	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
COAD	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	5.4	1.51e-07	8.91e-05	0.41	0.32	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
COAD	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.4	1.52e-07	8.92e-05	-0.34	-0.32	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
COAD	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.4	1.52e-07	8.92e-05	-0.34	-0.32	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
COAD	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.4	1.52e-07	8.92e-05	-0.34	-0.32	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
COAD	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.4	1.52e-07	8.92e-05	-0.34	-0.32	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
COAD	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.4	1.52e-07	8.94e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.4	1.52e-07	8.94e-05	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
COAD	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	5.4	1.52e-07	8.95e-05	0.37	0.32	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
COAD	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-5.4	1.52e-07	8.95e-05	-0.36	-0.32	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
COAD	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-5.4	1.52e-07	8.96e-05	-0.39	-0.32	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
COAD	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-5.4	1.52e-07	8.96e-05	-0.52	-0.32	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-5.4	1.52e-07	8.96e-05	-0.52	-0.32	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-5.4	1.53e-07	8.97e-05	-0.18	-0.32	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
COAD	cis	rs4657482	0.606	rs3790655	ENSG00000236364.3	RP11-525G13.2	-5.4	1.53e-07	8.98e-05	-0.23	-0.32	Testicular germ cell tumor;	chr1:165893086	chr1:165890795~165900683:-
COAD	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-5.4	1.53e-07	9e-05	-0.52	-0.32	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
COAD	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	5.4	1.53e-07	9e-05	0.29	0.32	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	5.4	1.53e-07	9e-05	0.29	0.32	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
COAD	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	5.4	1.54e-07	9.02e-05	0.34	0.32	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
COAD	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	5.4	1.54e-07	9.02e-05	0.34	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
COAD	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-5.4	1.54e-07	9.04e-05	-0.39	-0.32	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
COAD	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-5.4	1.54e-07	9.04e-05	-0.36	-0.32	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
COAD	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-5.4	1.54e-07	9.04e-05	-0.34	-0.32	Height;	chr20:49310319	chr20:49280319~49280409:+
COAD	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-5.4	1.54e-07	9.04e-05	-0.42	-0.32	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
COAD	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-5.4	1.54e-07	9.06e-05	-0.39	-0.32	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
COAD	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-5.4	1.54e-07	9.07e-05	-0.19	-0.32	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
COAD	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	5.4	1.55e-07	9.08e-05	0.36	0.32	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
COAD	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	5.4	1.55e-07	9.08e-05	0.36	0.32	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	5.4	1.55e-07	9.08e-05	0.36	0.32	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	5.4	1.55e-07	9.08e-05	0.36	0.32	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	5.4	1.55e-07	9.08e-05	0.36	0.32	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
COAD	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	5.4	1.55e-07	9.1e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
COAD	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	5.4	1.55e-07	9.11e-05	0.28	0.32	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
COAD	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-5.4	1.55e-07	9.11e-05	-0.39	-0.32	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
COAD	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	5.4	1.55e-07	9.11e-05	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
COAD	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-5.4	1.55e-07	9.12e-05	-0.2	-0.32	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
COAD	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-5.4	1.55e-07	9.12e-05	-0.35	-0.32	Height;	chr11:118747911	chr11:118704607~118750263:+
COAD	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	5.39	1.56e-07	9.13e-05	0.36	0.32	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
COAD	cis	rs11681884	0.892	rs11123159	ENSG00000228251.1	AC012442.6	5.39	1.56e-07	9.13e-05	0.66	0.32	Stroke;	chr2:113076453	chr2:112590796~112591939:+
COAD	cis	rs7688540	1	rs7688540	ENSG00000211553.1	AC253576.2	-5.39	1.56e-07	9.15e-05	-0.49	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:267367	chr4:136461~136568:+
COAD	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	5.39	1.56e-07	9.16e-05	0.38	0.32	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
COAD	cis	rs7647973	0.516	rs12490393	ENSG00000225399.4	RP11-3B7.1	5.39	1.56e-07	9.17e-05	0.36	0.32	Menarche (age at onset);	chr3:49158699	chr3:49260085~49261316:+
COAD	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-5.39	1.56e-07	9.18e-05	-0.4	-0.32	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
COAD	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-5.39	1.56e-07	9.18e-05	-0.41	-0.32	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
COAD	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-5.39	1.56e-07	9.18e-05	-0.41	-0.32	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
COAD	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-5.39	1.56e-07	9.18e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
COAD	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-5.39	1.57e-07	9.18e-05	-0.35	-0.32	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
COAD	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	5.39	1.57e-07	9.2e-05	0.38	0.32	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
COAD	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-5.39	1.57e-07	9.2e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
COAD	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-5.39	1.57e-07	9.2e-05	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
COAD	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.2e-05	0.31	0.32	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
COAD	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	5.39	1.57e-07	9.2e-05	0.42	0.32	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
COAD	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-5.39	1.57e-07	9.2e-05	-0.36	-0.32	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
COAD	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	5.39	1.57e-07	9.21e-05	0.44	0.32	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
COAD	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-5.39	1.57e-07	9.21e-05	-0.19	-0.32	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
COAD	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	5.39	1.57e-07	9.21e-05	0.37	0.32	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
COAD	cis	rs9309473	0.5	rs6546862	ENSG00000163016.8	ALMS1P	-5.39	1.57e-07	9.22e-05	-0.37	-0.32	Metabolite levels;	chr2:73633221	chr2:73644919~73685576:+
COAD	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.39	1.57e-07	9.22e-05	0.31	0.32	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
COAD	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.39	1.58e-07	9.23e-05	-0.33	-0.32	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
COAD	cis	rs9309473	0.519	rs1815027	ENSG00000163016.8	ALMS1P	-5.39	1.58e-07	9.25e-05	-0.39	-0.32	Metabolite levels;	chr2:73604713	chr2:73644919~73685576:+
COAD	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-5.39	1.58e-07	9.27e-05	-0.45	-0.32	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
COAD	cis	rs1003645	0.569	rs7222922	ENSG00000275944.1	RP11-104J23.1	5.39	1.59e-07	9.28e-05	0.45	0.32	Blood protein levels;	chr17:36008654	chr17:36001419~36011618:+
COAD	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	5.39	1.59e-07	9.29e-05	0.37	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
COAD	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	5.39	1.59e-07	9.31e-05	0.33	0.32	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
COAD	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	5.39	1.59e-07	9.31e-05	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
COAD	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	5.39	1.59e-07	9.32e-05	0.43	0.32	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
COAD	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-5.39	1.6e-07	9.33e-05	-0.29	-0.32	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
COAD	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	5.39	1.6e-07	9.37e-05	0.58	0.32	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
COAD	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-5.39	1.61e-07	9.39e-05	-0.37	-0.32	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
COAD	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	5.39	1.61e-07	9.39e-05	0.38	0.32	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
COAD	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-5.39	1.61e-07	9.4e-05	-0.39	-0.32	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
COAD	cis	rs9659323	0.622	rs6689568	ENSG00000231365.4	RP11-418J17.1	-5.39	1.61e-07	9.43e-05	-0.37	-0.32	Body mass index;	chr1:118960338	chr1:119140396~119275973:+
COAD	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	5.39	1.61e-07	9.43e-05	0.54	0.32	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
COAD	cis	rs453301	0.598	rs10104303	ENSG00000253981.4	ALG1L13P	5.39	1.62e-07	9.43e-05	0.37	0.32	Joint mobility (Beighton score);	chr8:8977018	chr8:8236003~8244667:-
COAD	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	5.39	1.62e-07	9.46e-05	0.28	0.32	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	5.39	1.62e-07	9.46e-05	0.28	0.32	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
COAD	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	5.39	1.62e-07	9.46e-05	0.42	0.32	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
COAD	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-5.39	1.62e-07	9.47e-05	-0.2	-0.32	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
COAD	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	5.39	1.62e-07	9.48e-05	0.35	0.32	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
COAD	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	5.39	1.62e-07	9.48e-05	0.36	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
COAD	cis	rs453301	0.657	rs36056437	ENSG00000253981.4	ALG1L13P	-5.39	1.62e-07	9.48e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:8935355	chr8:8236003~8244667:-
COAD	cis	rs1056107	0.931	rs7867823	ENSG00000225513.1	RP11-165N19.2	-5.39	1.63e-07	9.49e-05	-0.38	-0.32	Colorectal cancer;	chr9:112245813	chr9:112173522~112173971:-
COAD	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	5.39	1.63e-07	9.5e-05	0.45	0.32	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
COAD	cis	rs453301	0.597	rs7001187	ENSG00000253981.4	ALG1L13P	-5.39	1.63e-07	9.5e-05	-0.38	-0.32	Joint mobility (Beighton score);	chr8:8935272	chr8:8236003~8244667:-
COAD	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	5.39	1.63e-07	9.5e-05	0.22	0.32	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	5.39	1.63e-07	9.5e-05	0.22	0.32	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	5.39	1.63e-07	9.5e-05	0.22	0.32	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
COAD	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	5.39	1.63e-07	9.51e-05	0.29	0.32	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
COAD	cis	rs2281603	0.951	rs1453004	ENSG00000259116.1	RP11-973N13.4	-5.39	1.63e-07	9.51e-05	-0.33	-0.32	Lymphocyte counts;	chr14:64530237	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	5.39	1.63e-07	9.51e-05	0.35	0.32	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
COAD	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	5.39	1.63e-07	9.51e-05	0.36	0.32	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	5.39	1.63e-07	9.51e-05	0.36	0.32	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	5.39	1.63e-07	9.51e-05	0.36	0.32	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
COAD	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	5.39	1.63e-07	9.52e-05	0.36	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
COAD	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	5.39	1.63e-07	9.52e-05	0.22	0.32	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	5.39	1.63e-07	9.52e-05	0.22	0.32	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
COAD	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	5.39	1.63e-07	9.53e-05	0.45	0.32	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
COAD	cis	rs9309473	0.5	rs12472502	ENSG00000163016.8	ALMS1P	-5.38	1.64e-07	9.54e-05	-0.38	-0.32	Metabolite levels;	chr2:73632057	chr2:73644919~73685576:+
COAD	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	5.38	1.64e-07	9.55e-05	0.31	0.32	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
COAD	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	5.38	1.64e-07	9.55e-05	0.63	0.32	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
COAD	cis	rs7078219	0.714	rs11190136	ENSG00000228778.1	RP11-129J12.1	-5.38	1.64e-07	9.56e-05	-0.37	-0.32	Dental caries;	chr10:99527924	chr10:99527081~99528261:+
COAD	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	5.38	1.64e-07	9.57e-05	0.37	0.32	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
COAD	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-5.38	1.64e-07	9.58e-05	-0.4	-0.32	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
COAD	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	5.38	1.64e-07	9.58e-05	0.36	0.32	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	5.38	1.64e-07	9.58e-05	0.36	0.32	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
COAD	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	5.38	1.65e-07	9.59e-05	0.31	0.32	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
COAD	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	5.38	1.65e-07	9.59e-05	0.32	0.32	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	5.38	1.65e-07	9.6e-05	0.35	0.32	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
COAD	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-5.38	1.65e-07	9.6e-05	-0.47	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
COAD	cis	rs1056107	0.643	rs1001643	ENSG00000225513.1	RP11-165N19.2	-5.38	1.65e-07	9.63e-05	-0.41	-0.32	Colorectal cancer;	chr9:112162883	chr9:112173522~112173971:-
COAD	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	5.38	1.65e-07	9.63e-05	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
COAD	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	5.38	1.65e-07	9.63e-05	0.43	0.32	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
COAD	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	5.38	1.65e-07	9.63e-05	0.56	0.32	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	5.38	1.65e-07	9.63e-05	0.56	0.32	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	5.38	1.65e-07	9.63e-05	0.56	0.32	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
COAD	cis	rs5758511	0.689	rs56906457	ENSG00000237037.8	NDUFA6-AS1	-5.38	1.66e-07	9.64e-05	-0.42	-0.32	Birth weight;	chr22:42232329	chr22:42090931~42137742:+
COAD	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-5.38	1.66e-07	9.64e-05	-0.4	-0.32	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
COAD	cis	rs453301	0.686	rs10217044	ENSG00000173295.6	FAM86B3P	-5.38	1.66e-07	9.65e-05	-0.37	-0.32	Joint mobility (Beighton score);	chr8:9037242	chr8:8228595~8244865:+
COAD	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	5.38	1.66e-07	9.65e-05	0.69	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
COAD	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-5.38	1.66e-07	9.65e-05	-0.31	-0.32	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
COAD	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	5.38	1.66e-07	9.66e-05	0.49	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
COAD	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-5.38	1.66e-07	9.68e-05	-0.35	-0.32	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
COAD	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	5.38	1.66e-07	9.68e-05	0.49	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	5.38	1.66e-07	9.68e-05	0.49	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	5.38	1.66e-07	9.68e-05	0.49	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
COAD	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	5.38	1.66e-07	9.68e-05	0.33	0.32	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
COAD	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	5.38	1.66e-07	9.69e-05	0.53	0.32	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
COAD	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	5.38	1.67e-07	9.69e-05	0.43	0.32	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	5.38	1.67e-07	9.69e-05	0.43	0.32	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
COAD	cis	rs13256369	0.774	rs11777719	ENSG00000173295.6	FAM86B3P	5.38	1.67e-07	9.71e-05	0.43	0.32	Obesity-related traits;	chr8:8723528	chr8:8228595~8244865:+
COAD	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	5.38	1.67e-07	9.71e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	5.38	1.67e-07	9.71e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	5.38	1.67e-07	9.71e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	5.38	1.67e-07	9.71e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	5.38	1.67e-07	9.71e-05	0.48	0.32	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
COAD	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-5.38	1.67e-07	9.72e-05	-0.43	-0.32	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
COAD	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	5.38	1.67e-07	9.74e-05	0.27	0.32	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
COAD	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	5.38	1.68e-07	9.77e-05	0.56	0.32	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
COAD	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-5.38	1.69e-07	9.79e-05	-0.34	-0.32	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-5.38	1.69e-07	9.79e-05	-0.34	-0.32	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-5.38	1.69e-07	9.79e-05	-0.34	-0.32	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
COAD	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-5.38	1.69e-07	9.83e-05	-0.34	-0.32	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
COAD	cis	rs7615952	0.546	rs2979306	ENSG00000272840.1	RP11-379B18.6	5.38	1.69e-07	9.84e-05	0.48	0.32	Blood pressure (smoking interaction);	chr3:125593286	chr3:125774714~125797953:+
COAD	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	5.38	1.7e-07	9.86e-05	0.36	0.32	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
COAD	cis	rs9500256	0.903	rs726783	ENSG00000215190.7	LINC00680	-5.38	1.7e-07	9.86e-05	-0.39	-0.32	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57946074~57961501:-
COAD	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-5.38	1.7e-07	9.86e-05	-0.54	-0.32	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-5.38	1.7e-07	9.86e-05	-0.54	-0.32	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-5.38	1.7e-07	9.86e-05	-0.54	-0.32	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
COAD	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-5.38	1.7e-07	9.87e-05	-0.43	-0.32	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
COAD	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	5.38	1.7e-07	9.87e-05	0.36	0.32	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
COAD	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-5.38	1.7e-07	9.88e-05	-0.39	-0.32	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
COAD	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	5.38	1.7e-07	9.88e-05	0.32	0.32	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
COAD	cis	rs5015933	0.815	rs3861866	ENSG00000232630.1	PRPS1P2	-5.38	1.7e-07	9.89e-05	-0.31	-0.32	Body mass index;	chr9:125258595	chr9:125150653~125151589:+
COAD	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-5.38	1.71e-07	9.9e-05	-0.39	-0.32	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
COAD	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	5.38	1.71e-07	9.91e-05	0.34	0.32	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
COAD	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-5.38	1.71e-07	9.91e-05	-0.38	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	5.38	1.71e-07	9.91e-05	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
COAD	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-5.38	1.71e-07	9.93e-05	-0.41	-0.32	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
COAD	cis	rs7617480	0.61	rs10865954	ENSG00000225399.4	RP11-3B7.1	5.38	1.71e-07	9.94e-05	0.35	0.32	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:49260085~49261316:+
COAD	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	5.38	1.72e-07	9.94e-05	0.27	0.32	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
COAD	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	5.38	1.72e-07	9.96e-05	0.36	0.32	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
COAD	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	5.37	1.72e-07	9.96e-05	0.39	0.32	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
COAD	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	5.37	1.72e-07	9.98e-05	0.3	0.32	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	5.37	1.72e-07	9.98e-05	0.3	0.32	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
COAD	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-5.37	1.73e-07	1e-04	-0.37	-0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
COAD	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	5.37	1.73e-07	1e-04	0.34	0.32	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
COAD	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-5.37	1.74e-07	1e-04	-0.42	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
COAD	cis	rs1056107	0.863	rs7041663	ENSG00000225513.1	RP11-165N19.2	-5.37	1.74e-07	0.000101	-0.38	-0.32	Colorectal cancer;	chr9:112240538	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.898	rs1831118	ENSG00000225513.1	RP11-165N19.2	-5.37	1.74e-07	0.000101	-0.38	-0.32	Colorectal cancer;	chr9:112240552	chr9:112173522~112173971:-
COAD	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	5.37	1.74e-07	0.000101	0.27	0.32	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
COAD	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	5.37	1.74e-07	0.000101	0.37	0.32	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
COAD	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	5.37	1.74e-07	0.000101	0.36	0.32	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
COAD	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5.37	1.75e-07	0.000101	0.39	0.32	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
COAD	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-5.37	1.75e-07	0.000101	-0.39	-0.32	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-5.37	1.75e-07	0.000101	-0.39	-0.32	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
COAD	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	5.37	1.75e-07	0.000101	0.58	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
COAD	cis	rs9309473	0.519	rs12991161	ENSG00000163016.8	ALMS1P	-5.37	1.76e-07	0.000102	-0.38	-0.32	Metabolite levels;	chr2:73644244	chr2:73644919~73685576:+
COAD	cis	rs5758659	0.652	rs133358	ENSG00000182057.4	OGFRP1	5.37	1.76e-07	0.000102	0.33	0.32	Cognitive function;	chr22:42046535	chr22:42269753~42275196:+
COAD	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	5.37	1.76e-07	0.000102	0.28	0.32	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
COAD	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-5.37	1.76e-07	0.000102	-0.34	-0.32	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-5.37	1.76e-07	0.000102	-0.34	-0.32	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-5.37	1.76e-07	0.000102	-0.34	-0.32	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-5.37	1.76e-07	0.000102	-0.34	-0.32	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-5.37	1.76e-07	0.000102	-0.34	-0.32	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
COAD	cis	rs9393777	0.513	rs9368450	ENSG00000224843.5	LINC00240	5.37	1.76e-07	0.000102	0.52	0.32	Intelligence (multi-trait analysis);	chr6:26652261	chr6:26956992~27023924:+
COAD	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-5.37	1.76e-07	0.000102	-0.35	-0.32	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
COAD	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-5.37	1.77e-07	0.000102	-0.34	-0.32	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
COAD	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-5.37	1.77e-07	0.000102	-0.36	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
COAD	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-5.37	1.77e-07	0.000102	-0.44	-0.32	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
COAD	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	5.37	1.77e-07	0.000102	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
COAD	cis	rs28374715	0.662	rs28827035	ENSG00000247556.5	OIP5-AS1	5.37	1.77e-07	0.000102	0.42	0.32	Ulcerative colitis;	chr15:41200092	chr15:41283990~41309737:+
COAD	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	5.37	1.77e-07	0.000102	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
COAD	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	5.37	1.77e-07	0.000102	0.28	0.32	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
COAD	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.37	1.77e-07	0.000102	-0.34	-0.32	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
COAD	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	5.37	1.77e-07	0.000103	0.5	0.32	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
COAD	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-5.37	1.78e-07	0.000103	-0.32	-0.32	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
COAD	cis	rs5015933	0.788	rs490978	ENSG00000232630.1	PRPS1P2	-5.37	1.78e-07	0.000103	-0.32	-0.32	Body mass index;	chr9:125265972	chr9:125150653~125151589:+
COAD	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-5.37	1.78e-07	0.000103	-0.31	-0.32	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
COAD	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-5.37	1.78e-07	0.000103	-0.31	-0.32	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
COAD	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-5.37	1.78e-07	0.000103	-0.31	-0.32	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
COAD	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-5.37	1.79e-07	0.000103	-0.42	-0.32	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
COAD	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-5.37	1.79e-07	0.000103	-0.43	-0.32	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
COAD	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-5.37	1.79e-07	0.000103	-0.38	-0.32	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-5.37	1.79e-07	0.000103	-0.38	-0.32	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-5.37	1.79e-07	0.000103	-0.38	-0.32	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
COAD	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-5.37	1.79e-07	0.000103	-0.39	-0.32	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
COAD	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-5.37	1.79e-07	0.000103	-0.56	-0.32	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
COAD	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-5.37	1.79e-07	0.000103	-0.41	-0.32	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
COAD	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	5.37	1.79e-07	0.000103	0.33	0.32	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	5.37	1.79e-07	0.000103	0.33	0.32	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
COAD	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	5.37	1.79e-07	0.000103	0.33	0.32	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
COAD	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	5.37	1.79e-07	0.000103	0.4	0.32	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
COAD	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-5.37	1.8e-07	0.000104	-0.39	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
COAD	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	5.37	1.8e-07	0.000104	0.25	0.32	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
COAD	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	5.37	1.8e-07	0.000104	0.36	0.32	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
COAD	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-5.37	1.8e-07	0.000104	-0.26	-0.32	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
COAD	cis	rs453301	0.686	rs2409120	ENSG00000173295.6	FAM86B3P	-5.37	1.8e-07	0.000104	-0.37	-0.32	Joint mobility (Beighton score);	chr8:9025061	chr8:8228595~8244865:+
COAD	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-5.37	1.8e-07	0.000104	-0.28	-0.32	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
COAD	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	5.37	1.8e-07	0.000104	0.49	0.32	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	5.37	1.8e-07	0.000104	0.49	0.32	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	5.37	1.8e-07	0.000104	0.49	0.32	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
COAD	cis	rs950169	0.92	rs11637666	ENSG00000259728.4	LINC00933	5.37	1.8e-07	0.000104	0.46	0.32	Schizophrenia;	chr15:84035122	chr15:84570649~84580175:+
COAD	cis	rs7224610	0.702	rs3829578	ENSG00000263096.1	RP11-515O17.2	5.37	1.81e-07	0.000104	0.35	0.32	Urate levels;	chr17:55304149	chr17:55271504~55273653:-
COAD	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	5.37	1.81e-07	0.000104	0.42	0.32	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
COAD	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	5.36	1.81e-07	0.000104	0.48	0.32	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
COAD	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	5.36	1.81e-07	0.000104	0.43	0.32	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
COAD	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	5.36	1.81e-07	0.000104	0.3	0.32	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
COAD	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-5.36	1.81e-07	0.000104	-0.36	-0.32	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
COAD	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	5.36	1.81e-07	0.000104	0.39	0.32	Depression;	chr6:28314871	chr6:28943877~28944537:+
COAD	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	5.36	1.81e-07	0.000104	0.34	0.32	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
COAD	cis	rs7529073	0.74	rs340883	ENSG00000274895.1	RP11-478J18.2	-5.36	1.81e-07	0.000104	-0.38	-0.32	Schizophrenia;	chr1:213972363	chr1:213983793~213986419:-
COAD	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	5.36	1.81e-07	0.000105	0.34	0.32	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
COAD	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	5.36	1.81e-07	0.000105	0.34	0.32	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
COAD	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	5.36	1.82e-07	0.000105	0.35	0.32	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
COAD	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	5.36	1.82e-07	0.000105	0.42	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
COAD	cis	rs603446	0.934	rs180351	ENSG00000254851.1	RP11-109L13.1	-5.36	1.82e-07	0.000105	-0.36	-0.32	Triglycerides;	chr11:116736925	chr11:117135528~117138582:+
COAD	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-5.36	1.82e-07	0.000105	-0.38	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
COAD	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	5.36	1.82e-07	0.000105	0.43	0.32	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
COAD	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-5.36	1.82e-07	0.000105	-0.29	-0.32	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
COAD	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-5.36	1.82e-07	0.000105	-0.35	-0.32	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
COAD	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.36	1.82e-07	0.000105	0.43	0.32	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-5.36	1.82e-07	0.000105	-0.19	-0.32	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
COAD	cis	rs711830	1	rs1549334	ENSG00000226363.3	HAGLROS	-5.36	1.83e-07	0.000105	-0.49	-0.32	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174469	chr2:176177717~176179008:+
COAD	cis	rs754466	0.605	rs10824578	ENSG00000204049.1	RP11-126H7.4	5.36	1.83e-07	0.000105	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77818486	chr10:77866875~77869610:+
COAD	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-5.36	1.83e-07	0.000105	-0.33	-0.32	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
COAD	cis	rs9309473	0.519	rs6746971	ENSG00000163016.8	ALMS1P	5.36	1.83e-07	0.000105	0.38	0.32	Metabolite levels;	chr2:73442334	chr2:73644919~73685576:+
COAD	cis	rs1056107	0.933	rs943621	ENSG00000225513.1	RP11-165N19.2	-5.36	1.83e-07	0.000105	-0.37	-0.32	Colorectal cancer;	chr9:112231510	chr9:112173522~112173971:-
COAD	cis	rs5015933	0.788	rs372225	ENSG00000232630.1	PRPS1P2	-5.36	1.83e-07	0.000106	-0.32	-0.32	Body mass index;	chr9:125261770	chr9:125150653~125151589:+
COAD	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	5.36	1.84e-07	0.000106	0.4	0.32	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
COAD	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	5.36	1.84e-07	0.000106	0.34	0.32	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
COAD	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-5.36	1.84e-07	0.000106	-0.57	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
COAD	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-5.36	1.84e-07	0.000106	-0.35	-0.32	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
COAD	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-5.36	1.84e-07	0.000106	-0.28	-0.32	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
COAD	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	5.36	1.84e-07	0.000106	0.33	0.32	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
COAD	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-5.36	1.84e-07	0.000106	-0.52	-0.32	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
COAD	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	5.36	1.85e-07	0.000106	0.31	0.32	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
COAD	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-5.36	1.85e-07	0.000106	-0.41	-0.32	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
COAD	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.36	1.85e-07	0.000107	-0.45	-0.32	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
COAD	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	5.36	1.85e-07	0.000107	0.37	0.32	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	5.36	1.85e-07	0.000107	0.37	0.32	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
COAD	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-5.36	1.85e-07	0.000107	-0.18	-0.32	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
COAD	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	5.36	1.86e-07	0.000107	0.34	0.32	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
COAD	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	5.36	1.86e-07	0.000107	0.37	0.32	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
COAD	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-5.36	1.86e-07	0.000107	-0.46	-0.32	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
COAD	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-5.36	1.86e-07	0.000107	-0.36	-0.32	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
COAD	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	5.36	1.87e-07	0.000107	0.43	0.32	Height;	chr6:109708527	chr6:109382795~109383666:+
COAD	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	5.36	1.87e-07	0.000107	0.28	0.32	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	5.36	1.87e-07	0.000107	0.28	0.32	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
COAD	cis	rs1056107	0.898	rs943620	ENSG00000225513.1	RP11-165N19.2	-5.36	1.87e-07	0.000107	-0.38	-0.32	Colorectal cancer;	chr9:112231228	chr9:112173522~112173971:-
COAD	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.36	1.87e-07	0.000107	0.54	0.32	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
COAD	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	5.36	1.87e-07	0.000108	0.41	0.32	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
COAD	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-5.36	1.87e-07	0.000108	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
COAD	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	5.36	1.88e-07	0.000108	0.39	0.32	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
COAD	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	5.36	1.88e-07	0.000108	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
COAD	cis	rs7647973	0.58	rs4955432	ENSG00000225399.4	RP11-3B7.1	5.36	1.88e-07	0.000108	0.36	0.32	Menarche (age at onset);	chr3:49229339	chr3:49260085~49261316:+
COAD	cis	rs7647973	0.6	rs11920267	ENSG00000225399.4	RP11-3B7.1	5.36	1.88e-07	0.000108	0.36	0.32	Menarche (age at onset);	chr3:49238531	chr3:49260085~49261316:+
COAD	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-5.36	1.88e-07	0.000108	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
COAD	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-5.36	1.88e-07	0.000108	-0.39	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
COAD	cis	rs9309473	0.519	rs4852950	ENSG00000163016.8	ALMS1P	-5.36	1.89e-07	0.000108	-0.37	-0.32	Metabolite levels;	chr2:73637543	chr2:73644919~73685576:+
COAD	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-5.36	1.89e-07	0.000108	-0.49	-0.32	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5.36	1.89e-07	0.000109	0.35	0.32	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
COAD	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	5.36	1.89e-07	0.000109	0.63	0.32	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
COAD	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-5.36	1.9e-07	0.000109	-0.53	-0.32	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
COAD	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	5.36	1.9e-07	0.000109	0.31	0.32	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
COAD	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	5.35	1.9e-07	0.000109	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	5.35	1.9e-07	0.000109	0.35	0.32	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	5.35	1.9e-07	0.000109	0.35	0.32	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
COAD	cis	rs9291683	0.53	rs73227883	ENSG00000250413.1	RP11-448G15.1	-5.35	1.9e-07	0.000109	-0.4	-0.32	Bone mineral density;	chr4:9977655	chr4:10006482~10009725:+
COAD	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.35	1.9e-07	0.000109	-0.32	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
COAD	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	5.35	1.9e-07	0.000109	0.36	0.32	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
COAD	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	5.35	1.91e-07	0.000109	0.35	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
COAD	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-5.35	1.91e-07	0.000109	-0.31	-0.32	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
COAD	cis	rs7647973	0.58	rs12637576	ENSG00000225399.4	RP11-3B7.1	5.35	1.91e-07	0.000109	0.36	0.32	Menarche (age at onset);	chr3:49199901	chr3:49260085~49261316:+
COAD	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-5.35	1.91e-07	0.000109	-0.35	-0.32	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-5.35	1.91e-07	0.000109	-0.35	-0.32	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
COAD	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	5.35	1.91e-07	0.000109	0.36	0.32	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
COAD	cis	rs7078219	0.714	rs10883363	ENSG00000228778.1	RP11-129J12.1	-5.35	1.91e-07	0.000109	-0.36	-0.32	Dental caries;	chr10:99527823	chr10:99527081~99528261:+
COAD	cis	rs989978	0.532	rs10883364	ENSG00000228778.1	RP11-129J12.1	-5.35	1.91e-07	0.000109	-0.36	-0.32	Red blood cell count;	chr10:99527829	chr10:99527081~99528261:+
COAD	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	5.35	1.91e-07	0.00011	0.22	0.32	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
COAD	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-5.35	1.92e-07	0.00011	-0.26	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
COAD	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-5.35	1.92e-07	0.00011	-0.26	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
COAD	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-5.35	1.92e-07	0.00011	-0.38	-0.32	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
COAD	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	5.35	1.92e-07	0.00011	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
COAD	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	5.35	1.92e-07	0.00011	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
COAD	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-5.35	1.92e-07	0.00011	-0.36	-0.32	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-5.35	1.93e-07	0.00011	-0.36	-0.32	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
COAD	cis	rs2281603	0.951	rs12586212	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64513329	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs61615397	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64514346	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10133243	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64514807	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs3783724	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64516759	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs3783723	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64516821	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs12587136	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64518570	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs58893738	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64519093	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs28626711	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64521561	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10133411	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64522206	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs17101896	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64526205	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs59512674	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64526295	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs61985711	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64526540	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10143170	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64527045	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10138256	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64528494	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs10149286	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64528518	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.951	rs1453009	ENSG00000259116.1	RP11-973N13.4	-5.35	1.93e-07	0.00011	-0.34	-0.32	Lymphocyte counts;	chr14:64528976	chr14:64514154~64540368:-
COAD	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-5.35	1.93e-07	0.00011	-0.48	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
COAD	cis	rs1056107	0.931	rs10759540	ENSG00000225513.1	RP11-165N19.2	-5.35	1.93e-07	0.000111	-0.37	-0.32	Colorectal cancer;	chr9:112239394	chr9:112173522~112173971:-
COAD	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	5.35	1.93e-07	0.000111	0.54	0.32	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
COAD	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	5.35	1.93e-07	0.000111	0.29	0.32	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
COAD	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-5.35	1.93e-07	0.000111	-0.43	-0.32	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
COAD	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	5.35	1.94e-07	0.000111	0.28	0.32	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	5.35	1.94e-07	0.000111	0.28	0.32	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	5.35	1.94e-07	0.000111	0.28	0.32	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	5.35	1.94e-07	0.000111	0.28	0.32	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
COAD	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	5.35	1.94e-07	0.000111	0.44	0.32	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
COAD	cis	rs1056107	0.933	rs4979099	ENSG00000225513.1	RP11-165N19.2	-5.35	1.94e-07	0.000111	-0.36	-0.32	Colorectal cancer;	chr9:112319336	chr9:112173522~112173971:-
COAD	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-5.35	1.94e-07	0.000111	-0.25	-0.32	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
COAD	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	5.35	1.94e-07	0.000111	0.42	0.32	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
COAD	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-5.35	1.94e-07	0.000111	-0.4	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
COAD	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-5.35	1.94e-07	0.000111	-0.4	-0.32	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
COAD	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	5.35	1.95e-07	0.000111	0.35	0.32	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
COAD	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	5.35	1.95e-07	0.000112	0.36	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
COAD	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-5.35	1.95e-07	0.000112	-0.29	-0.32	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
COAD	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-5.35	1.95e-07	0.000112	-0.34	-0.32	Height;	chr11:118737916	chr11:118704607~118750263:+
COAD	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.35	1.95e-07	0.000112	-0.39	-0.32	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
COAD	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-5.35	1.95e-07	0.000112	-0.39	-0.32	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
COAD	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	5.35	1.95e-07	0.000112	0.48	0.32	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	5.35	1.95e-07	0.000112	0.48	0.32	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	5.35	1.95e-07	0.000112	0.48	0.32	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	5.35	1.95e-07	0.000112	0.48	0.32	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	5.35	1.95e-07	0.000112	0.48	0.32	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
COAD	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	5.35	1.96e-07	0.000112	0.37	0.32	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
COAD	cis	rs9500256	0.967	rs4928431	ENSG00000215190.7	LINC00680	5.35	1.96e-07	0.000112	0.38	0.32	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57946074~57961501:-
COAD	cis	rs5015933	0.788	rs2945039	ENSG00000232630.1	PRPS1P2	-5.35	1.96e-07	0.000112	-0.32	-0.32	Body mass index;	chr9:125281525	chr9:125150653~125151589:+
COAD	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	5.35	1.96e-07	0.000112	0.36	0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
COAD	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	5.35	1.97e-07	0.000112	0.28	0.32	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
COAD	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	5.35	1.97e-07	0.000112	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
COAD	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	5.35	1.97e-07	0.000112	0.42	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
COAD	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	5.35	1.97e-07	0.000112	0.53	0.32	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
COAD	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-5.35	1.97e-07	0.000112	-0.37	-0.32	Height;	chr3:53074760	chr3:53064283~53065091:-
COAD	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	5.35	1.97e-07	0.000113	0.42	0.32	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
COAD	cis	rs34779708	0.733	rs7081597	ENSG00000271335.4	RP11-324I22.4	5.35	1.97e-07	0.000113	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35314552~35336401:-
COAD	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	5.35	1.97e-07	0.000113	0.33	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
COAD	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-5.35	1.98e-07	0.000113	-0.4	-0.32	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
COAD	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-5.35	1.98e-07	0.000113	-0.56	-0.32	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
COAD	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-5.35	1.98e-07	0.000113	-0.33	-0.32	Height;	chr11:118737823	chr11:118791254~118793137:+
COAD	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	5.35	1.98e-07	0.000113	0.38	0.32	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
COAD	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.35	1.99e-07	0.000113	0.34	0.32	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
COAD	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-5.35	1.99e-07	0.000113	-0.39	-0.32	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
COAD	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-5.35	1.99e-07	0.000114	-0.39	-0.32	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
COAD	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-5.35	1.99e-07	0.000114	-0.43	-0.32	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-5.35	1.99e-07	0.000114	-0.43	-0.32	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-5.35	1.99e-07	0.000114	-0.43	-0.32	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
COAD	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-5.34	2e-07	0.000114	-0.56	-0.32	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
COAD	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	5.34	2e-07	0.000114	0.37	0.32	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
COAD	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-5.34	2e-07	0.000114	-0.35	-0.32	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
COAD	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	5.34	2.01e-07	0.000114	0.34	0.32	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
COAD	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	5.34	2.01e-07	0.000114	0.25	0.32	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
COAD	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	5.34	2.01e-07	0.000114	0.25	0.32	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
COAD	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-5.34	2.01e-07	0.000114	-0.21	-0.32	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
COAD	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	5.34	2.01e-07	0.000114	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	5.34	2.01e-07	0.000114	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	5.34	2.01e-07	0.000114	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
COAD	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-5.34	2.01e-07	0.000114	-0.36	-0.32	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
COAD	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.34	2.01e-07	0.000114	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	5.34	2.01e-07	0.000114	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	5.34	2.01e-07	0.000114	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	5.34	2.01e-07	0.000114	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
COAD	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	5.34	2.01e-07	0.000114	0.35	0.32	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
COAD	cis	rs210138	1	rs210144	ENSG00000197251.3	LINC00336	5.34	2.01e-07	0.000115	0.51	0.32	Testicular germ cell tumor;	chr6:33579653	chr6:33586106~33593338:-
COAD	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-5.34	2.01e-07	0.000115	-0.21	-0.32	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
COAD	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-5.34	2.02e-07	0.000115	-0.34	-0.32	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
COAD	cis	rs13256369	1	rs13266699	ENSG00000173295.6	FAM86B3P	-5.34	2.02e-07	0.000115	-0.44	-0.32	Obesity-related traits;	chr8:8712803	chr8:8228595~8244865:+
COAD	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	5.34	2.02e-07	0.000115	0.41	0.32	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
COAD	cis	rs11846409	0.818	rs2516909	ENSG00000274576.2	IGHV2-70	5.34	2.02e-07	0.000115	0.32	0.32	Rheumatic heart disease;	chr14:106630317	chr14:106770577~106771020:-
COAD	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-5.34	2.02e-07	0.000115	-0.32	-0.32	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
COAD	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.34	2.02e-07	0.000115	0.35	0.32	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.34	2.02e-07	0.000115	0.35	0.32	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.34	2.02e-07	0.000115	0.35	0.32	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
COAD	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	5.34	2.03e-07	0.000115	0.35	0.32	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
COAD	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-5.34	2.03e-07	0.000115	-0.38	-0.32	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
COAD	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	5.34	2.03e-07	0.000115	0.71	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
COAD	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-5.34	2.03e-07	0.000116	-0.41	-0.32	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
COAD	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-5.34	2.03e-07	0.000116	-0.46	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-5.34	2.03e-07	0.000116	-0.46	-0.32	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
COAD	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-5.34	2.04e-07	0.000116	-0.41	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
COAD	cis	rs4950322	0.518	rs56151278	ENSG00000278811.3	LINC00624	5.34	2.04e-07	0.000116	0.32	0.32	Protein quantitative trait loci;	chr1:147117421	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.518	rs4950306	ENSG00000278811.3	LINC00624	5.34	2.04e-07	0.000116	0.32	0.32	Protein quantitative trait loci;	chr1:147117838	chr1:147258885~147517875:-
COAD	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-5.34	2.04e-07	0.000116	-0.57	-0.32	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
COAD	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-5.34	2.04e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-5.34	2.04e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
COAD	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-5.34	2.04e-07	0.000116	-0.36	-0.32	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	5.34	2.04e-07	0.000116	0.36	0.32	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
COAD	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	5.34	2.04e-07	0.000116	0.49	0.32	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
COAD	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-5.34	2.04e-07	0.000116	-0.38	-0.32	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
COAD	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-5.34	2.04e-07	0.000116	-0.27	-0.32	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
COAD	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.4	-0.32	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
COAD	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	5.34	2.05e-07	0.000116	0.32	0.32	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
COAD	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-5.34	2.05e-07	0.000116	-0.38	-0.32	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
COAD	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	5.34	2.05e-07	0.000116	0.35	0.32	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
COAD	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.39	-0.32	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-5.34	2.05e-07	0.000116	-0.39	-0.32	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
COAD	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-5.34	2.05e-07	0.000117	-0.41	-0.32	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
COAD	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-5.34	2.05e-07	0.000117	-0.57	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
COAD	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	5.34	2.05e-07	0.000117	0.41	0.32	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
COAD	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-5.34	2.05e-07	0.000117	-0.42	-0.32	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
COAD	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	5.34	2.05e-07	0.000117	0.28	0.32	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
COAD	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.34	2.06e-07	0.000117	-0.39	-0.32	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
COAD	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	5.34	2.06e-07	0.000117	0.37	0.32	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
COAD	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	5.34	2.06e-07	0.000117	0.41	0.32	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
COAD	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	5.34	2.06e-07	0.000117	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	5.34	2.06e-07	0.000117	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
COAD	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-5.34	2.06e-07	0.000117	-0.5	-0.32	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
COAD	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-5.34	2.06e-07	0.000117	-0.53	-0.32	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-5.34	2.06e-07	0.000117	-0.53	-0.32	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
COAD	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	5.34	2.07e-07	0.000117	0.27	0.32	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
COAD	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	5.34	2.07e-07	0.000117	0.35	0.32	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
COAD	cis	rs4568518	0.616	rs11766489	ENSG00000279048.1	RP11-511H23.2	5.34	2.07e-07	0.000117	0.23	0.32	Measles;	chr7:17964047	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.616	rs11766586	ENSG00000279048.1	RP11-511H23.2	5.34	2.07e-07	0.000117	0.23	0.32	Measles;	chr7:17964342	chr7:17940503~17942922:+
COAD	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-5.34	2.07e-07	0.000117	-0.31	-0.32	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
COAD	cis	rs7560272	0.723	rs7585119	ENSG00000163016.8	ALMS1P	5.34	2.07e-07	0.000117	0.39	0.32	Schizophrenia;	chr2:73497552	chr2:73644919~73685576:+
COAD	cis	rs7560272	0.723	rs7562047	ENSG00000163016.8	ALMS1P	5.34	2.07e-07	0.000117	0.39	0.32	Schizophrenia;	chr2:73498041	chr2:73644919~73685576:+
COAD	cis	rs7078219	0.714	rs12360459	ENSG00000228778.1	RP11-129J12.1	-5.34	2.07e-07	0.000117	-0.36	-0.32	Dental caries;	chr10:99526397	chr10:99527081~99528261:+
COAD	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	5.34	2.07e-07	0.000117	0.35	0.32	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
COAD	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-5.34	2.07e-07	0.000117	-0.42	-0.32	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
COAD	cis	rs7829975	0.56	rs56094035	ENSG00000173295.6	FAM86B3P	-5.34	2.07e-07	0.000117	-0.38	-0.32	Mood instability;	chr8:8694112	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.539	rs4841012	ENSG00000173295.6	FAM86B3P	-5.34	2.07e-07	0.000117	-0.38	-0.32	Mood instability;	chr8:8694200	chr8:8228595~8244865:+
COAD	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	5.34	2.07e-07	0.000117	0.36	0.32	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
COAD	cis	rs711830	1	rs711830	ENSG00000226363.3	HAGLROS	5.34	2.07e-07	0.000118	0.48	0.32	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172583	chr2:176177717~176179008:+
COAD	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	5.34	2.08e-07	0.000118	0.35	0.32	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	5.34	2.08e-07	0.000118	0.35	0.32	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	5.34	2.08e-07	0.000118	0.35	0.32	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
COAD	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-5.34	2.08e-07	0.000118	-0.43	-0.32	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
COAD	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-5.34	2.08e-07	0.000118	-0.42	-0.32	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
COAD	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	5.34	2.08e-07	0.000118	0.32	0.32	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	5.34	2.08e-07	0.000118	0.33	0.32	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
COAD	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	5.34	2.08e-07	0.000118	0.35	0.32	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
COAD	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-5.34	2.09e-07	0.000118	-0.28	-0.32	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
COAD	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	5.34	2.09e-07	0.000118	0.37	0.32	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
COAD	cis	rs7615952	0.543	rs4645102	ENSG00000241278.1	ENPP7P4	5.34	2.09e-07	0.000118	0.34	0.32	Blood pressure (smoking interaction);	chr3:125705597	chr3:125848223~125909372:+
COAD	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	5.34	2.09e-07	0.000119	0.22	0.32	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
COAD	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	5.34	2.09e-07	0.000119	0.47	0.32	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
COAD	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	5.33	2.1e-07	0.000119	0.22	0.32	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	5.33	2.1e-07	0.000119	0.22	0.32	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
COAD	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	5.33	2.1e-07	0.000119	0.41	0.32	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
COAD	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	5.33	2.1e-07	0.000119	0.22	0.32	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
COAD	cis	rs7078219	0.714	rs12360459	ENSG00000257582.4	LINC01475	-5.33	2.1e-07	0.000119	-0.36	-0.32	Dental caries;	chr10:99526397	chr10:99526350~99531177:-
COAD	cis	rs10078	0.515	rs1053299	ENSG00000225138.6	CTD-2228K2.7	5.33	2.11e-07	0.000119	0.53	0.32	Fat distribution (HIV);	chr5:470645	chr5:473236~480884:+
COAD	cis	rs10078	0.571	rs890973	ENSG00000225138.6	CTD-2228K2.7	5.33	2.11e-07	0.000119	0.53	0.32	Fat distribution (HIV);	chr5:471379	chr5:473236~480884:+
COAD	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-5.33	2.11e-07	0.000119	-0.38	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
COAD	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	5.33	2.11e-07	0.000119	0.43	0.32	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
COAD	cis	rs1056107	0.931	rs1969946	ENSG00000225513.1	RP11-165N19.2	-5.33	2.11e-07	0.000119	-0.37	-0.32	Colorectal cancer;	chr9:112269241	chr9:112173522~112173971:-
COAD	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-5.33	2.11e-07	0.000119	-0.39	-0.32	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-5.33	2.11e-07	0.000119	-0.39	-0.32	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
COAD	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	5.33	2.11e-07	0.000119	0.47	0.32	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
COAD	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	5.33	2.11e-07	0.000119	0.33	0.32	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
COAD	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-5.33	2.11e-07	0.000119	-0.32	-0.32	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-5.33	2.11e-07	0.000119	-0.32	-0.32	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-5.33	2.11e-07	0.000119	-0.32	-0.32	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
COAD	cis	rs1056107	0.897	rs7026917	ENSG00000225513.1	RP11-165N19.2	-5.33	2.11e-07	0.000119	-0.37	-0.32	Colorectal cancer;	chr9:112228592	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs3908938	ENSG00000225513.1	RP11-165N19.2	-5.33	2.11e-07	0.000119	-0.37	-0.32	Colorectal cancer;	chr9:112228940	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.898	rs1417111	ENSG00000225513.1	RP11-165N19.2	-5.33	2.11e-07	0.000119	-0.37	-0.32	Colorectal cancer;	chr9:112229033	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs3908939	ENSG00000225513.1	RP11-165N19.2	-5.33	2.11e-07	0.000119	-0.37	-0.32	Colorectal cancer;	chr9:112229058	chr9:112173522~112173971:-
COAD	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	5.33	2.12e-07	0.00012	0.42	0.32	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
COAD	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	5.33	2.12e-07	0.00012	0.41	0.32	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-5.33	2.12e-07	0.00012	-0.54	-0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
COAD	cis	rs4568518	0.619	rs4470902	ENSG00000279048.1	RP11-511H23.2	-5.33	2.12e-07	0.00012	-0.23	-0.32	Measles;	chr7:17968687	chr7:17940503~17942922:+
COAD	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-5.33	2.12e-07	0.00012	-0.29	-0.32	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
COAD	cis	rs12699921	0.933	rs6942635	ENSG00000279048.1	RP11-511H23.2	5.33	2.12e-07	0.00012	0.24	0.32	Fibrinogen levels;	chr7:17948242	chr7:17940503~17942922:+
COAD	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-5.33	2.12e-07	0.00012	-0.31	-0.32	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
COAD	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-5.33	2.13e-07	0.00012	-0.29	-0.32	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
COAD	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	5.33	2.13e-07	0.00012	0.41	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
COAD	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	5.33	2.13e-07	0.00012	0.42	0.32	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
COAD	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-5.33	2.13e-07	0.00012	-0.5	-0.32	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
COAD	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-5.33	2.13e-07	0.00012	-0.39	-0.32	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
COAD	cis	rs9393777	0.513	rs6913660	ENSG00000224843.5	LINC00240	5.33	2.13e-07	0.00012	0.53	0.32	Intelligence (multi-trait analysis);	chr6:27123646	chr6:26956992~27023924:+
COAD	cis	rs911186	0.679	rs67330695	ENSG00000224843.5	LINC00240	5.33	2.13e-07	0.00012	0.53	0.32	Autism spectrum disorder or schizophrenia;	chr6:27135875	chr6:26956992~27023924:+
COAD	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	5.33	2.14e-07	0.000121	0.42	0.32	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
COAD	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-5.33	2.14e-07	0.000121	-0.34	-0.32	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	5.33	2.14e-07	0.000121	0.34	0.32	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
COAD	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-5.33	2.14e-07	0.000121	-0.41	-0.32	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
COAD	cis	rs9393777	0.513	rs926300	ENSG00000224843.5	LINC00240	5.33	2.14e-07	0.000121	0.53	0.32	Intelligence (multi-trait analysis);	chr6:27091664	chr6:26956992~27023924:+
COAD	cis	rs911186	0.786	rs72842197	ENSG00000224843.5	LINC00240	5.33	2.14e-07	0.000121	0.53	0.32	Autism spectrum disorder or schizophrenia;	chr6:27099304	chr6:26956992~27023924:+
COAD	cis	rs7529073	1	rs7529073	ENSG00000274895.1	RP11-478J18.2	-5.33	2.14e-07	0.000121	-0.37	-0.32	Schizophrenia;	chr1:213974546	chr1:213983793~213986419:-
COAD	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	5.33	2.15e-07	0.000121	0.34	0.32	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
COAD	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	5.33	2.15e-07	0.000121	0.32	0.32	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
COAD	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.33	2.15e-07	0.000121	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.33	2.15e-07	0.000121	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
COAD	cis	rs8062405	0.625	rs8060365	ENSG00000251417.2	RP11-1348G14.4	5.33	2.15e-07	0.000121	0.38	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28802743~28817828:+
COAD	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	5.33	2.15e-07	0.000121	0.33	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
COAD	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.15e-07	0.000121	-0.41	-0.32	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.15e-07	0.000121	-0.41	-0.32	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.15e-07	0.000121	-0.41	-0.32	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.15e-07	0.000121	-0.41	-0.32	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
COAD	cis	rs5015933	0.788	rs359594	ENSG00000232630.1	PRPS1P2	-5.33	2.15e-07	0.000121	-0.31	-0.32	Body mass index;	chr9:125273062	chr9:125150653~125151589:+
COAD	cis	rs9659323	0.596	rs11589179	ENSG00000231365.4	RP11-418J17.1	-5.33	2.15e-07	0.000121	-0.37	-0.32	Body mass index;	chr1:118954962	chr1:119140396~119275973:+
COAD	cis	rs9659323	0.65	rs10923705	ENSG00000231365.4	RP11-418J17.1	-5.33	2.15e-07	0.000121	-0.37	-0.32	Body mass index;	chr1:118955781	chr1:119140396~119275973:+
COAD	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.15e-07	0.000121	-0.42	-0.32	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
COAD	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	5.33	2.15e-07	0.000121	0.42	0.32	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
COAD	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-5.33	2.16e-07	0.000122	-0.46	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
COAD	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-5.33	2.16e-07	0.000122	-0.34	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
COAD	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	5.33	2.16e-07	0.000122	0.34	0.32	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	5.33	2.16e-07	0.000122	0.34	0.32	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
COAD	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	5.33	2.16e-07	0.000122	0.34	0.32	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	5.33	2.16e-07	0.000122	0.34	0.32	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
COAD	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-5.33	2.16e-07	0.000122	-0.53	-0.32	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
COAD	cis	rs10078	0.515	rs890984	ENSG00000225138.6	CTD-2228K2.7	5.33	2.16e-07	0.000122	0.53	0.32	Fat distribution (HIV);	chr5:479425	chr5:473236~480884:+
COAD	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-5.33	2.16e-07	0.000122	-0.43	-0.32	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-5.33	2.16e-07	0.000122	-0.43	-0.32	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-5.33	2.16e-07	0.000122	-0.43	-0.32	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
COAD	cis	rs1056107	0.872	rs7874660	ENSG00000225513.1	RP11-165N19.2	-5.33	2.16e-07	0.000122	-0.37	-0.32	Colorectal cancer;	chr9:112261573	chr9:112173522~112173971:-
COAD	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-5.33	2.17e-07	0.000122	-0.38	-0.32	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
COAD	cis	rs7221109	0.921	rs4890117	ENSG00000278834.1	RP11-458J1.1	5.33	2.17e-07	0.000122	0.33	0.32	Type 1 diabetes;	chr17:40622236	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.921	rs1013971	ENSG00000278834.1	RP11-458J1.1	5.33	2.17e-07	0.000122	0.33	0.32	Type 1 diabetes;	chr17:40624926	chr17:40648300~40649718:+
COAD	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	5.33	2.17e-07	0.000122	0.28	0.32	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
COAD	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	5.33	2.17e-07	0.000122	0.34	0.32	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
COAD	cis	rs4568518	0.742	rs13245422	ENSG00000279048.1	RP11-511H23.2	5.33	2.17e-07	0.000122	0.23	0.32	Measles;	chr7:17976352	chr7:17940503~17942922:+
COAD	cis	rs453301	0.631	rs17700611	ENSG00000173295.6	FAM86B3P	-5.33	2.17e-07	0.000122	-0.37	-0.32	Joint mobility (Beighton score);	chr8:8936144	chr8:8228595~8244865:+
COAD	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-5.33	2.17e-07	0.000122	-0.43	-0.32	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
COAD	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-5.33	2.17e-07	0.000122	-0.18	-0.32	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	5.33	2.17e-07	0.000122	0.2	0.32	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
COAD	cis	rs1930961	1	rs6004673	ENSG00000272798.1	CTA-390C10.9	-5.33	2.18e-07	0.000123	-0.43	-0.32	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25436312~25436915:+
COAD	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	5.33	2.18e-07	0.000123	0.28	0.32	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	5.33	2.18e-07	0.000123	0.28	0.32	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
COAD	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	5.33	2.19e-07	0.000123	0.27	0.32	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
COAD	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	5.33	2.19e-07	0.000123	0.33	0.32	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
COAD	cis	rs5758659	0.935	rs134879	ENSG00000182057.4	OGFRP1	5.33	2.19e-07	0.000123	0.34	0.32	Cognitive function;	chr22:42268195	chr22:42269753~42275196:+
COAD	cis	rs10028773	0.632	rs34481394	ENSG00000248280.1	RP11-33B1.2	5.33	2.19e-07	0.000123	0.37	0.32	Educational attainment;	chr4:119327219	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.666	rs35231872	ENSG00000248280.1	RP11-33B1.2	5.33	2.19e-07	0.000123	0.37	0.32	Educational attainment;	chr4:119327221	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.7	rs35653026	ENSG00000248280.1	RP11-33B1.2	5.33	2.19e-07	0.000123	0.37	0.32	Educational attainment;	chr4:119327223	chr4:119440561~119450157:-
COAD	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	5.33	2.19e-07	0.000123	0.32	0.32	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
COAD	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	5.33	2.2e-07	0.000124	0.38	0.32	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
COAD	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	5.33	2.2e-07	0.000124	0.37	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
COAD	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	5.33	2.2e-07	0.000124	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	5.33	2.2e-07	0.000124	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	5.33	2.2e-07	0.000124	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	5.33	2.2e-07	0.000124	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	5.33	2.2e-07	0.000124	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
COAD	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-5.33	2.2e-07	0.000124	-0.34	-0.32	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
COAD	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	5.32	2.2e-07	0.000124	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
COAD	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	5.32	2.2e-07	0.000124	0.36	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
COAD	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-5.32	2.21e-07	0.000124	-0.4	-0.32	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
COAD	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	5.32	2.21e-07	0.000124	0.52	0.32	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
COAD	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-5.32	2.21e-07	0.000125	-0.27	-0.32	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
COAD	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.32	2.22e-07	0.000125	0.44	0.32	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
COAD	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	5.32	2.22e-07	0.000125	0.32	0.32	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
COAD	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	5.32	2.22e-07	0.000125	0.32	0.32	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
COAD	cis	rs7560272	0.723	rs7609249	ENSG00000163016.8	ALMS1P	5.32	2.22e-07	0.000125	0.38	0.32	Schizophrenia;	chr2:73586693	chr2:73644919~73685576:+
COAD	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-5.32	2.23e-07	0.000125	-0.39	-0.32	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
COAD	cis	rs34779708	0.801	rs12255409	ENSG00000271335.4	RP11-324I22.4	5.32	2.23e-07	0.000125	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35314552~35336401:-
COAD	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	5.32	2.23e-07	0.000126	0.29	0.32	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
COAD	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	5.32	2.24e-07	0.000126	0.44	0.32	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
COAD	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.32	2.24e-07	0.000126	-0.59	-0.32	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
COAD	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.32	2.24e-07	0.000126	0.32	0.32	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
COAD	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-5.32	2.25e-07	0.000126	-0.31	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
COAD	cis	rs9487051	0.872	rs9487043	ENSG00000219700.1	PTCHD3P3	5.32	2.25e-07	0.000127	0.33	0.31	Reticulocyte fraction of red cells;	chr6:109289271	chr6:109288571~109290503:-
COAD	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-5.32	2.27e-07	0.000127	-0.39	-0.31	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
COAD	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-5.32	2.27e-07	0.000127	-0.19	-0.31	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-5.32	2.27e-07	0.000127	-0.19	-0.31	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
COAD	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-5.32	2.27e-07	0.000127	-0.31	-0.31	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-5.32	2.27e-07	0.000127	-0.31	-0.31	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
COAD	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	5.32	2.27e-07	0.000127	0.34	0.31	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-5.32	2.27e-07	0.000128	-0.34	-0.31	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
COAD	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	5.32	2.28e-07	0.000128	0.39	0.31	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
COAD	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	5.32	2.28e-07	0.000128	0.38	0.31	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
COAD	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.32	2.28e-07	0.000128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
COAD	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	5.32	2.28e-07	0.000128	0.28	0.31	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	5.32	2.28e-07	0.000128	0.28	0.31	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	5.32	2.28e-07	0.000128	0.28	0.31	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	5.32	2.28e-07	0.000128	0.28	0.31	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
COAD	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	5.32	2.28e-07	0.000128	0.34	0.31	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
COAD	cis	rs5015933	0.815	rs10819043	ENSG00000232630.1	PRPS1P2	-5.32	2.29e-07	0.000128	-0.3	-0.31	Body mass index;	chr9:125274966	chr9:125150653~125151589:+
COAD	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-5.32	2.29e-07	0.000128	-0.27	-0.31	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
COAD	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-5.32	2.29e-07	0.000129	-0.53	-0.31	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-5.32	2.29e-07	0.000129	-0.53	-0.31	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
COAD	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-5.32	2.3e-07	0.000129	-0.41	-0.31	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
COAD	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-5.32	2.3e-07	0.000129	-0.33	-0.31	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
COAD	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-5.32	2.3e-07	0.000129	-0.33	-0.31	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
COAD	cis	rs5015933	0.815	rs10819041	ENSG00000232630.1	PRPS1P2	-5.32	2.3e-07	0.000129	-0.31	-0.31	Body mass index;	chr9:125268558	chr9:125150653~125151589:+
COAD	cis	rs858239	0.712	rs199650	ENSG00000226816.2	AC005082.12	-5.32	2.3e-07	0.000129	-0.32	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23206013~23208045:+
COAD	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-5.32	2.3e-07	0.000129	-0.56	-0.31	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
COAD	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
COAD	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-5.32	2.3e-07	0.000129	-0.32	-0.31	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
COAD	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-5.32	2.3e-07	0.000129	-0.27	-0.31	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
COAD	cis	rs13256369	0.708	rs9644772	ENSG00000173295.6	FAM86B3P	5.32	2.31e-07	0.000129	0.47	0.31	Obesity-related traits;	chr8:8700175	chr8:8228595~8244865:+
COAD	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	5.32	2.31e-07	0.00013	0.2	0.31	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
COAD	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-5.31	2.32e-07	0.00013	-0.33	-0.31	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
COAD	cis	rs9309473	0.5	rs2421668	ENSG00000163016.8	ALMS1P	-5.31	2.32e-07	0.00013	-0.37	-0.31	Metabolite levels;	chr2:73657969	chr2:73644919~73685576:+
COAD	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	5.31	2.32e-07	0.00013	0.38	0.31	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
COAD	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-5.31	2.32e-07	0.00013	-0.42	-0.31	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
COAD	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	5.31	2.32e-07	0.00013	0.49	0.31	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
COAD	cis	rs34779708	0.733	rs4007271	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.702	rs4007272	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs4934740	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.702	rs4244995	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs4244997	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs4298846	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs4391768	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs7914468	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs7914560	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs4444023	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs12243593	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs3936502	ENSG00000271335.4	RP11-324I22.4	5.31	2.32e-07	0.00013	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35314552~35336401:-
COAD	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-5.31	2.32e-07	0.00013	-0.2	-0.31	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
COAD	cis	rs13434265	1	rs13434265	ENSG00000272359.1	U4	-5.31	2.32e-07	0.00013	-0.37	-0.31	White blood cell count;	chr3:196762551	chr3:196747192~196747324:-
COAD	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	5.31	2.33e-07	0.00013	0.46	0.31	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	5.31	2.33e-07	0.00013	0.46	0.31	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
COAD	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	5.31	2.33e-07	0.00013	0.67	0.31	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
COAD	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	5.31	2.33e-07	0.00013	0.3	0.31	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
COAD	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-5.31	2.33e-07	0.00013	-0.39	-0.31	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
COAD	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	5.31	2.33e-07	0.00013	0.34	0.31	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
COAD	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	5.31	2.33e-07	0.00013	0.34	0.31	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	5.31	2.33e-07	0.00013	0.34	0.31	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	5.31	2.33e-07	0.00013	0.34	0.31	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	5.31	2.33e-07	0.00013	0.34	0.31	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	5.31	2.33e-07	0.00013	0.32	0.31	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.35	0.31	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
COAD	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	5.31	2.34e-07	0.000131	0.49	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
COAD	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	5.31	2.34e-07	0.000131	0.49	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
COAD	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-5.31	2.34e-07	0.000131	-0.27	-0.31	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
COAD	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-5.31	2.34e-07	0.000131	-0.56	-0.31	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-5.31	2.34e-07	0.000131	-0.56	-0.31	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-5.31	2.34e-07	0.000131	-0.56	-0.31	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-5.31	2.34e-07	0.000131	-0.56	-0.31	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-5.31	2.34e-07	0.000131	-0.19	-0.31	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
COAD	cis	rs11079159	0.606	rs4239193	ENSG00000263096.1	RP11-515O17.2	5.31	2.34e-07	0.000131	0.37	0.31	QRS duration;	chr17:55299163	chr17:55271504~55273653:-
COAD	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	5.31	2.34e-07	0.000131	0.36	0.31	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
COAD	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-5.31	2.34e-07	0.000131	-0.36	-0.31	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
COAD	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-5.31	2.34e-07	0.000131	-0.44	-0.31	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
COAD	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	5.31	2.34e-07	0.000131	0.42	0.31	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
COAD	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	5.31	2.35e-07	0.000131	0.56	0.31	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
COAD	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	5.31	2.35e-07	0.000131	0.35	0.31	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
COAD	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-5.31	2.35e-07	0.000131	-0.18	-0.31	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
COAD	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-5.31	2.36e-07	0.000132	-0.4	-0.31	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
COAD	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-5.31	2.36e-07	0.000132	-0.2	-0.31	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
COAD	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-5.31	2.36e-07	0.000132	-0.52	-0.31	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-5.31	2.37e-07	0.000132	-0.53	-0.31	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-5.31	2.37e-07	0.000132	-0.53	-0.31	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
COAD	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-5.31	2.37e-07	0.000132	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-5.31	2.37e-07	0.000132	-0.21	-0.31	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
COAD	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	5.31	2.37e-07	0.000132	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
COAD	cis	rs1056107	0.933	rs10981354	ENSG00000225513.1	RP11-165N19.2	-5.31	2.38e-07	0.000133	-0.36	-0.31	Colorectal cancer;	chr9:112308436	chr9:112173522~112173971:-
COAD	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	5.31	2.38e-07	0.000133	0.29	0.31	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
COAD	cis	rs34792	0.637	rs2450356	ENSG00000207425.1	Y_RNA	5.31	2.39e-07	0.000133	0.37	0.31	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14915457~14915556:-
COAD	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-5.31	2.39e-07	0.000133	-0.35	-0.31	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-5.31	2.39e-07	0.000133	-0.35	-0.31	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-5.31	2.39e-07	0.000133	-0.35	-0.31	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
COAD	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-5.31	2.39e-07	0.000133	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
COAD	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-5.31	2.4e-07	0.000134	-0.31	-0.31	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
COAD	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-5.31	2.4e-07	0.000134	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-5.31	2.4e-07	0.000134	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-5.31	2.4e-07	0.000134	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-5.31	2.4e-07	0.000134	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
COAD	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-5.31	2.41e-07	0.000134	-0.43	-0.31	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
COAD	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	5.31	2.41e-07	0.000134	0.42	0.31	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
COAD	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	5.31	2.42e-07	0.000135	0.33	0.31	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
COAD	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-5.31	2.42e-07	0.000135	-0.21	-0.31	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
COAD	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	5.31	2.42e-07	0.000135	0.49	0.31	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
COAD	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.31	2.42e-07	0.000135	0.3	0.31	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
COAD	cis	rs7615952	0.546	rs16836896	ENSG00000272840.1	RP11-379B18.6	5.31	2.42e-07	0.000135	0.5	0.31	Blood pressure (smoking interaction);	chr3:125592418	chr3:125774714~125797953:+
COAD	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-5.31	2.42e-07	0.000135	-0.39	-0.31	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
COAD	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	5.31	2.42e-07	0.000135	0.21	0.31	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
COAD	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	5.31	2.42e-07	0.000135	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
COAD	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	5.31	2.42e-07	0.000135	0.38	0.31	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
COAD	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-5.31	2.43e-07	0.000135	-0.27	-0.31	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
COAD	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-5.31	2.43e-07	0.000135	-0.35	-0.31	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
COAD	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	5.31	2.43e-07	0.000135	0.34	0.31	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	5.31	2.43e-07	0.000135	0.34	0.31	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	5.31	2.43e-07	0.000135	0.34	0.31	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
COAD	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.31	2.43e-07	0.000135	-0.39	-0.31	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
COAD	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.31	2.43e-07	0.000135	-0.39	-0.31	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
COAD	cis	rs4568518	0.804	rs6943454	ENSG00000279048.1	RP11-511H23.2	5.31	2.43e-07	0.000135	0.24	0.31	Measles;	chr7:17985543	chr7:17940503~17942922:+
COAD	cis	rs1056107	0.737	rs7041381	ENSG00000225513.1	RP11-165N19.2	-5.31	2.43e-07	0.000135	-0.36	-0.31	Colorectal cancer;	chr9:112309799	chr9:112173522~112173971:-
COAD	cis	rs72615157	0.606	rs941288	ENSG00000242294.5	STAG3L5P	5.3	2.43e-07	0.000135	0.24	0.31	Lung function (FEV1/FVC);	chr7:100179185	chr7:100336079~100351900:+
COAD	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-5.3	2.43e-07	0.000135	-0.2	-0.31	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
COAD	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-5.3	2.44e-07	0.000136	-0.41	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
COAD	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	5.3	2.45e-07	0.000136	0.36	0.31	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
COAD	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-5.3	2.45e-07	0.000136	-0.18	-0.31	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-5.3	2.45e-07	0.000136	-0.18	-0.31	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
COAD	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	5.3	2.45e-07	0.000136	0.46	0.31	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
COAD	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	5.3	2.45e-07	0.000136	0.46	0.31	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
COAD	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.3	2.46e-07	0.000137	0.34	0.31	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
COAD	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	5.3	2.46e-07	0.000137	0.3	0.31	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
COAD	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	5.3	2.47e-07	0.000137	0.67	0.31	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.3	2.47e-07	0.000137	0.35	0.31	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.3	2.47e-07	0.000137	0.35	0.31	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
COAD	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-5.3	2.48e-07	0.000138	-0.42	-0.31	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
COAD	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-5.3	2.48e-07	0.000138	-0.28	-0.31	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
COAD	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	5.3	2.48e-07	0.000138	0.39	0.31	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
COAD	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-5.3	2.48e-07	0.000138	-0.35	-0.31	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
COAD	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	5.3	2.48e-07	0.000138	0.34	0.31	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	5.3	2.48e-07	0.000138	0.34	0.31	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	5.3	2.48e-07	0.000138	0.34	0.31	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
COAD	cis	rs987724	0.519	rs9820830	ENSG00000240875.4	LINC00886	-5.3	2.49e-07	0.000138	-0.3	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:156747346~156817062:-
COAD	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-5.3	2.49e-07	0.000138	-0.42	-0.31	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
COAD	cis	rs6964833	1	rs6967152	ENSG00000277053.3	GTF2IP1	-5.3	2.49e-07	0.000138	-0.4	-0.31	Menarche (age at onset);	chr7:74684983	chr7:75185385~75237696:-
COAD	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-5.3	2.49e-07	0.000138	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
COAD	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	5.3	2.49e-07	0.000138	0.3	0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
COAD	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.3	2.5e-07	0.000138	-0.38	-0.31	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
COAD	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	5.3	2.5e-07	0.000139	0.24	0.31	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
COAD	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	5.3	2.5e-07	0.000139	0.24	0.31	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
COAD	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	5.3	2.5e-07	0.000139	0.24	0.31	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
COAD	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	5.3	2.5e-07	0.000139	0.24	0.31	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
COAD	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	5.3	2.5e-07	0.000139	0.46	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
COAD	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	5.3	2.5e-07	0.000139	0.35	0.31	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
COAD	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	5.3	2.51e-07	0.000139	0.36	0.31	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
COAD	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	5.3	2.51e-07	0.000139	0.57	0.31	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
COAD	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-5.3	2.51e-07	0.000139	-0.35	-0.31	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	5.3	2.51e-07	0.000139	0.35	0.31	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
COAD	cis	rs5015933	0.788	rs662637	ENSG00000232630.1	PRPS1P2	-5.3	2.51e-07	0.000139	-0.32	-0.31	Body mass index;	chr9:125258887	chr9:125150653~125151589:+
COAD	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	5.3	2.51e-07	0.000139	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
COAD	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-5.3	2.51e-07	0.000139	-0.43	-0.31	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-5.3	2.51e-07	0.000139	-0.43	-0.31	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-5.3	2.51e-07	0.000139	-0.43	-0.31	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
COAD	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-5.3	2.52e-07	0.000139	-0.54	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
COAD	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	5.3	2.52e-07	0.00014	0.24	0.31	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
COAD	cis	rs10129255	0.642	rs11624918	ENSG00000224373.3	IGHV4-59	5.3	2.52e-07	0.00014	0.19	0.31	Kawasaki disease;	chr14:106664672	chr14:106627249~106627825:-
COAD	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.3	2.52e-07	0.00014	0.34	0.31	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
COAD	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	5.3	2.52e-07	0.00014	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	5.3	2.52e-07	0.00014	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	5.3	2.53e-07	0.00014	0.65	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	5.3	2.53e-07	0.00014	0.65	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	5.3	2.53e-07	0.00014	0.65	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
COAD	cis	rs7078219	0.714	rs888208	ENSG00000257582.4	LINC01475	-5.3	2.53e-07	0.00014	-0.36	-0.31	Dental caries;	chr10:99536106	chr10:99526350~99531177:-
COAD	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-5.3	2.54e-07	0.00014	-0.4	-0.31	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
COAD	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-5.3	2.54e-07	0.00014	-0.29	-0.31	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
COAD	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-5.3	2.54e-07	0.00014	-0.39	-0.31	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
COAD	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	5.3	2.54e-07	0.00014	0.27	0.31	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
COAD	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.3	2.54e-07	0.000141	-0.43	-0.31	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
COAD	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-5.3	2.54e-07	0.000141	-0.55	-0.31	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
COAD	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.55e-07	0.000141	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
COAD	cis	rs7615952	0.512	rs4234285	ENSG00000241278.1	ENPP7P4	5.3	2.55e-07	0.000141	0.33	0.31	Blood pressure (smoking interaction);	chr3:125685633	chr3:125848223~125909372:+
COAD	cis	rs13256369	0.901	rs13251887	ENSG00000173295.6	FAM86B3P	5.3	2.55e-07	0.000141	0.44	0.31	Obesity-related traits;	chr8:8711168	chr8:8228595~8244865:+
COAD	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-5.3	2.55e-07	0.000141	-0.28	-0.31	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
COAD	cis	rs9818758	0.505	rs67286839	ENSG00000225399.4	RP11-3B7.1	-5.29	2.56e-07	0.000141	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:49260085~49261316:+
COAD	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	5.29	2.56e-07	0.000142	0.33	0.31	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-5.29	2.56e-07	0.000142	-0.32	-0.31	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-5.29	2.56e-07	0.000142	-0.32	-0.31	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
COAD	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.29	2.56e-07	0.000142	-0.39	-0.31	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
COAD	cis	rs1056107	0.866	rs4979093	ENSG00000225513.1	RP11-165N19.2	-5.29	2.57e-07	0.000142	-0.36	-0.31	Colorectal cancer;	chr9:112275820	chr9:112173522~112173971:-
COAD	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-5.29	2.57e-07	0.000142	-0.33	-0.31	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-5.29	2.57e-07	0.000142	-0.33	-0.31	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
COAD	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	5.29	2.57e-07	0.000142	0.34	0.31	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
COAD	cis	rs12935418	0.616	rs77336552	ENSG00000261061.1	RP11-303E16.2	-5.29	2.57e-07	0.000142	-0.45	-0.31	Mean corpuscular volume;	chr16:80942989	chr16:81030770~81031485:+
COAD	cis	rs7078219	0.714	rs11190136	ENSG00000257582.4	LINC01475	-5.29	2.58e-07	0.000142	-0.36	-0.31	Dental caries;	chr10:99527924	chr10:99526350~99531177:-
COAD	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	5.29	2.58e-07	0.000143	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
COAD	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-5.29	2.58e-07	0.000143	-0.34	-0.31	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
COAD	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-5.29	2.58e-07	0.000143	-0.43	-0.31	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
COAD	cis	rs7615952	0.546	rs2979307	ENSG00000272840.1	RP11-379B18.6	-5.29	2.59e-07	0.000143	-0.46	-0.31	Blood pressure (smoking interaction);	chr3:125590730	chr3:125774714~125797953:+
COAD	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	5.29	2.6e-07	0.000143	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
COAD	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-5.29	2.6e-07	0.000143	-0.34	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
COAD	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.29	2.6e-07	0.000143	-0.59	-0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
COAD	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-5.29	2.6e-07	0.000144	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-5.29	2.6e-07	0.000144	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-5.29	2.6e-07	0.000144	-0.36	-0.31	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
COAD	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	5.29	2.6e-07	0.000144	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
COAD	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-5.29	2.6e-07	0.000144	-0.34	-0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
COAD	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	5.29	2.6e-07	0.000144	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
COAD	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	5.29	2.61e-07	0.000144	0.43	0.31	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
COAD	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-5.29	2.62e-07	0.000145	-0.36	-0.31	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
COAD	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	5.29	2.62e-07	0.000145	0.37	0.31	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
COAD	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	5.29	2.62e-07	0.000145	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
COAD	cis	rs9291683	0.552	rs3796832	ENSG00000250413.1	RP11-448G15.1	-5.29	2.62e-07	0.000145	-0.39	-0.31	Bone mineral density;	chr4:10014241	chr4:10006482~10009725:+
COAD	cis	rs1056107	0.933	rs10116045	ENSG00000225513.1	RP11-165N19.2	-5.29	2.62e-07	0.000145	-0.36	-0.31	Colorectal cancer;	chr9:112285580	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs6477908	ENSG00000225513.1	RP11-165N19.2	-5.29	2.62e-07	0.000145	-0.36	-0.31	Colorectal cancer;	chr9:112285627	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs4979095	ENSG00000225513.1	RP11-165N19.2	-5.29	2.62e-07	0.000145	-0.36	-0.31	Colorectal cancer;	chr9:112286527	chr9:112173522~112173971:-
COAD	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.29	2.63e-07	0.000145	-0.27	-0.31	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
COAD	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-5.29	2.63e-07	0.000145	-0.41	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
COAD	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-5.29	2.63e-07	0.000145	-0.41	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
COAD	cis	rs453301	0.686	rs6987107	ENSG00000173295.6	FAM86B3P	-5.29	2.63e-07	0.000145	-0.36	-0.31	Joint mobility (Beighton score);	chr8:9036071	chr8:8228595~8244865:+
COAD	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-5.29	2.64e-07	0.000145	-0.39	-0.31	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
COAD	cis	rs4987094	0.656	rs3781884	ENSG00000270179.1	RP11-159N11.4	5.29	2.64e-07	0.000146	0.52	0.31	Schizophrenia;	chr11:113346642	chr11:113368478~113369117:+
COAD	cis	rs7560272	0.723	rs7566315	ENSG00000163016.8	ALMS1P	5.29	2.64e-07	0.000146	0.36	0.31	Schizophrenia;	chr2:73564681	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	5.29	2.64e-07	0.000146	0.36	0.31	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
COAD	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-5.29	2.64e-07	0.000146	-0.36	-0.31	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
COAD	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	5.29	2.64e-07	0.000146	0.28	0.31	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
COAD	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	5.29	2.65e-07	0.000146	0.41	0.31	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
COAD	cis	rs6452524	0.569	rs7720588	ENSG00000271862.1	RP11-343L5.2	5.29	2.65e-07	0.000146	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83049376~83050964:-
COAD	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	5.29	2.65e-07	0.000146	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	5.29	2.65e-07	0.000146	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	5.29	2.65e-07	0.000146	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
COAD	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-5.29	2.65e-07	0.000146	-0.34	-0.31	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
COAD	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-5.29	2.66e-07	0.000146	-0.32	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
COAD	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-5.29	2.66e-07	0.000146	-0.4	-0.31	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
COAD	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	5.29	2.66e-07	0.000146	0.33	0.31	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	5.29	2.66e-07	0.000146	0.33	0.31	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
COAD	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	5.29	2.66e-07	0.000146	0.42	0.31	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
COAD	cis	rs12935418	0.579	rs7197606	ENSG00000278985.1	RP11-303E16.9	5.29	2.66e-07	0.000147	0.35	0.31	Mean corpuscular volume;	chr16:81019914	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.672	rs9921914	ENSG00000278985.1	RP11-303E16.9	5.29	2.66e-07	0.000147	0.35	0.31	Mean corpuscular volume;	chr16:81022506	chr16:80982319~80984094:-
COAD	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-5.29	2.67e-07	0.000147	-0.36	-0.31	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
COAD	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-5.29	2.67e-07	0.000147	-0.38	-0.31	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
COAD	cis	rs7647973	0.516	rs4499638	ENSG00000225399.4	RP11-3B7.1	5.29	2.68e-07	0.000147	0.35	0.31	Menarche (age at onset);	chr3:49165349	chr3:49260085~49261316:+
COAD	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	5.29	2.68e-07	0.000147	0.4	0.31	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
COAD	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	5.29	2.68e-07	0.000147	0.37	0.31	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
COAD	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	5.29	2.68e-07	0.000147	0.36	0.31	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	5.29	2.68e-07	0.000147	0.36	0.31	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
COAD	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	5.29	2.68e-07	0.000147	0.36	0.31	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	5.29	2.68e-07	0.000147	0.36	0.31	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
COAD	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	5.29	2.68e-07	0.000147	0.46	0.31	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
COAD	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	5.29	2.68e-07	0.000147	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
COAD	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-5.29	2.68e-07	0.000148	-0.4	-0.31	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
COAD	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-5.29	2.68e-07	0.000148	-0.38	-0.31	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-5.29	2.68e-07	0.000148	-0.38	-0.31	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-5.29	2.68e-07	0.000148	-0.38	-0.31	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
COAD	cis	rs362272	0.545	rs3129308	ENSG00000248840.2	RP11-357G3.2	-5.28	2.69e-07	0.000148	-0.35	-0.31	Serum sulfate level;	chr4:3307545	chr4:3312512~3313058:+
COAD	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-5.28	2.69e-07	0.000148	-0.42	-0.31	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
COAD	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-5.28	2.69e-07	0.000148	-0.31	-0.31	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
COAD	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-5.28	2.69e-07	0.000148	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-5.28	2.69e-07	0.000148	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
COAD	cis	rs12935418	0.55	rs35595567	ENSG00000261061.1	RP11-303E16.2	-5.28	2.69e-07	0.000148	-0.43	-0.31	Mean corpuscular volume;	chr16:80999761	chr16:81030770~81031485:+
COAD	cis	rs7829975	0.56	rs6994131	ENSG00000173295.6	FAM86B3P	-5.28	2.69e-07	0.000148	-0.37	-0.31	Mood instability;	chr8:8693448	chr8:8228595~8244865:+
COAD	cis	rs4568518	0.587	rs4576329	ENSG00000279048.1	RP11-511H23.2	5.28	2.7e-07	0.000148	0.23	0.31	Measles;	chr7:17967529	chr7:17940503~17942922:+
COAD	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	5.28	2.7e-07	0.000148	0.36	0.31	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
COAD	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	5.28	2.7e-07	0.000148	0.46	0.31	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
COAD	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	5.28	2.7e-07	0.000148	0.4	0.31	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
COAD	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-5.28	2.7e-07	0.000148	-0.43	-0.31	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
COAD	cis	rs7078219	0.714	rs10883363	ENSG00000257582.4	LINC01475	-5.28	2.7e-07	0.000148	-0.35	-0.31	Dental caries;	chr10:99527823	chr10:99526350~99531177:-
COAD	cis	rs989978	0.532	rs10883364	ENSG00000257582.4	LINC01475	-5.28	2.7e-07	0.000148	-0.35	-0.31	Red blood cell count;	chr10:99527829	chr10:99526350~99531177:-
COAD	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.28	2.71e-07	0.000149	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
COAD	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	5.28	2.71e-07	0.000149	0.41	0.31	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
COAD	cis	rs1387259	0.723	rs2732488	ENSG00000257735.1	RP11-370I10.6	5.28	2.71e-07	0.000149	0.39	0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48350945~48442411:+
COAD	cis	rs1387259	0.758	rs2634670	ENSG00000257735.1	RP11-370I10.6	5.28	2.71e-07	0.000149	0.39	0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48350945~48442411:+
COAD	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-5.28	2.71e-07	0.000149	-0.33	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
COAD	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	5.28	2.71e-07	0.000149	0.48	0.31	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
COAD	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	5.28	2.71e-07	0.000149	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	5.28	2.71e-07	0.000149	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
COAD	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	5.28	2.72e-07	0.000149	0.42	0.31	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
COAD	cis	rs2732480	1	rs2732480	ENSG00000273765.1	RP11-370I10.11	-5.28	2.72e-07	0.000149	-0.31	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48360920~48361377:+
COAD	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-5.28	2.72e-07	0.000149	-0.46	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
COAD	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	5.28	2.73e-07	0.00015	0.42	0.31	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
COAD	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	5.28	2.73e-07	0.00015	0.33	0.31	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
COAD	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	5.28	2.73e-07	0.00015	0.32	0.31	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	5.28	2.73e-07	0.00015	0.32	0.31	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
COAD	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	5.28	2.74e-07	0.00015	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
COAD	cis	rs1056107	0.933	rs7047691	ENSG00000225513.1	RP11-165N19.2	-5.28	2.74e-07	0.00015	-0.36	-0.31	Colorectal cancer;	chr9:112289887	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.83	rs10739340	ENSG00000225513.1	RP11-165N19.2	-5.28	2.74e-07	0.00015	-0.36	-0.31	Colorectal cancer;	chr9:112295272	chr9:112173522~112173971:-
COAD	cis	rs492146	0.765	rs316132	ENSG00000243236.5	GSTA9P	-5.28	2.74e-07	0.00015	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52983168	chr6:52939726~52957521:-
COAD	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	5.28	2.75e-07	0.000151	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
COAD	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-5.28	2.75e-07	0.000151	-0.33	-0.31	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
COAD	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-5.28	2.75e-07	0.000151	-0.35	-0.31	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
COAD	cis	rs1056107	0.931	rs7033486	ENSG00000225513.1	RP11-165N19.2	5.28	2.75e-07	0.000151	0.37	0.31	Colorectal cancer;	chr9:112248027	chr9:112173522~112173971:-
COAD	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-5.28	2.75e-07	0.000151	-0.39	-0.31	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
COAD	cis	rs1056107	0.931	rs7852473	ENSG00000225513.1	RP11-165N19.2	-5.28	2.76e-07	0.000151	-0.37	-0.31	Colorectal cancer;	chr9:112245751	chr9:112173522~112173971:-
COAD	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	5.28	2.76e-07	0.000151	0.36	0.31	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
COAD	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-5.28	2.77e-07	0.000151	-0.42	-0.31	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
COAD	cis	rs385076	0.502	rs13013695	ENSG00000272716.1	RP11-563N4.1	-5.28	2.77e-07	0.000151	-0.37	-0.31	Interleukin-18 levels;	chr2:32166162	chr2:32165046~32165757:-
COAD	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	5.28	2.77e-07	0.000151	0.32	0.31	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
COAD	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	5.28	2.77e-07	0.000151	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	5.28	2.77e-07	0.000151	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
COAD	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	5.28	2.77e-07	0.000152	0.36	0.31	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
COAD	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	5.28	2.77e-07	0.000152	0.37	0.31	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
COAD	cis	rs4448343	1	rs4448343	ENSG00000271155.1	RP11-435O5.5	-5.28	2.77e-07	0.000152	-0.35	-0.31	Height;	chr9:95504088	chr9:95506235~95507636:+
COAD	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-5.28	2.78e-07	0.000152	-0.35	-0.31	Height;	chr20:49246745	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-5.28	2.78e-07	0.000152	-0.35	-0.31	Height;	chr20:49249247	chr20:49280319~49280409:+
COAD	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	5.28	2.78e-07	0.000152	0.28	0.31	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
COAD	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	5.28	2.78e-07	0.000152	0.32	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
COAD	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	5.28	2.78e-07	0.000152	0.41	0.31	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
COAD	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-5.28	2.79e-07	0.000152	-0.4	-0.31	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
COAD	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	5.28	2.79e-07	0.000152	0.31	0.31	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	5.28	2.79e-07	0.000152	0.31	0.31	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-5.28	2.79e-07	0.000152	-0.35	-0.31	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-5.28	2.79e-07	0.000152	-0.35	-0.31	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-5.28	2.79e-07	0.000152	-0.35	-0.31	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
COAD	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-5.28	2.79e-07	0.000152	-0.35	-0.31	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
COAD	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	5.28	2.79e-07	0.000152	0.35	0.31	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	5.28	2.79e-07	0.000152	0.35	0.31	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	5.28	2.79e-07	0.000152	0.35	0.31	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
COAD	cis	rs492146	0.765	rs622902	ENSG00000243236.5	GSTA9P	-5.28	2.79e-07	0.000152	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52981676	chr6:52939726~52957521:-
COAD	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	5.28	2.79e-07	0.000152	0.34	0.31	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	5.28	2.79e-07	0.000152	0.34	0.31	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
COAD	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-5.28	2.79e-07	0.000152	-0.29	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
COAD	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-5.28	2.79e-07	0.000152	-0.29	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
COAD	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	5.28	2.79e-07	0.000153	0.33	0.31	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
COAD	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-5.28	2.79e-07	0.000153	-0.21	-0.31	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
COAD	cis	rs28374715	0.662	rs522063	ENSG00000247556.5	OIP5-AS1	-5.28	2.79e-07	0.000153	-0.39	-0.31	Ulcerative colitis;	chr15:41184011	chr15:41283990~41309737:+
COAD	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	5.28	2.8e-07	0.000153	0.5	0.31	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	5.28	2.8e-07	0.000153	0.5	0.31	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
COAD	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	5.28	2.8e-07	0.000153	0.36	0.31	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
COAD	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	5.28	2.8e-07	0.000153	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
COAD	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-5.28	2.8e-07	0.000153	-0.19	-0.31	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-5.28	2.8e-07	0.000153	-0.19	-0.31	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
COAD	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.28	2.8e-07	0.000153	0.39	0.31	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
COAD	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.28	2.81e-07	0.000153	-0.42	-0.31	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
COAD	cis	rs28374715	0.662	rs8038983	ENSG00000247556.5	OIP5-AS1	5.28	2.81e-07	0.000153	0.42	0.31	Ulcerative colitis;	chr15:41181118	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs111522288	ENSG00000247556.5	OIP5-AS1	5.28	2.81e-07	0.000153	0.42	0.31	Ulcerative colitis;	chr15:41187971	chr15:41283990~41309737:+
COAD	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-5.28	2.81e-07	0.000153	-0.34	-0.31	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
COAD	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	5.28	2.81e-07	0.000153	0.37	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	5.28	2.81e-07	0.000153	0.37	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	5.28	2.81e-07	0.000153	0.37	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	5.28	2.81e-07	0.000153	0.37	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	5.28	2.81e-07	0.000153	0.37	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
COAD	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	5.28	2.81e-07	0.000153	0.34	0.31	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
COAD	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	5.28	2.82e-07	0.000154	0.35	0.31	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
COAD	cis	rs1056107	0.51	rs10981336	ENSG00000225513.1	RP11-165N19.2	-5.28	2.82e-07	0.000154	-0.37	-0.31	Colorectal cancer;	chr9:112268732	chr9:112173522~112173971:-
COAD	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	5.28	2.82e-07	0.000154	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
COAD	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-5.27	2.82e-07	0.000154	-0.4	-0.31	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
COAD	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.27	2.83e-07	0.000154	-0.36	-0.31	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
COAD	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	5.27	2.83e-07	0.000154	0.58	0.31	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
COAD	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	5.27	2.83e-07	0.000154	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	5.27	2.83e-07	0.000154	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	5.27	2.83e-07	0.000154	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	5.27	2.83e-07	0.000154	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
COAD	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	5.27	2.83e-07	0.000154	0.53	0.31	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
COAD	cis	rs3126085	0.515	rs2146119	ENSG00000237975.5	FLG-AS1	5.27	2.84e-07	0.000155	0.35	0.31	Atopic dermatitis;	chr1:152396422	chr1:152168125~152445456:+
COAD	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	5.27	2.84e-07	0.000155	0.19	0.31	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
COAD	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	5.27	2.84e-07	0.000155	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	5.27	2.84e-07	0.000155	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
COAD	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-5.27	2.84e-07	0.000155	-0.42	-0.31	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
COAD	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	5.27	2.85e-07	0.000155	0.38	0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
COAD	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	5.27	2.85e-07	0.000155	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
COAD	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-5.27	2.86e-07	0.000156	-0.34	-0.31	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
COAD	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	5.27	2.86e-07	0.000156	0.23	0.31	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
COAD	cis	rs362272	0.545	rs3135146	ENSG00000248840.2	RP11-357G3.2	5.27	2.86e-07	0.000156	0.34	0.31	Serum sulfate level;	chr4:3305911	chr4:3312512~3313058:+
COAD	cis	rs9625935	0.518	rs9625870	ENSG00000279159.1	RP3-394A18.1	-5.27	2.88e-07	0.000156	-0.21	-0.31	Tonsillectomy;	chr22:29865230	chr22:29978950~30028236:-
COAD	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	5.27	2.88e-07	0.000157	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	5.27	2.88e-07	0.000157	0.36	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	5.27	2.88e-07	0.000157	0.36	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	5.27	2.88e-07	0.000157	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
COAD	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	5.27	2.88e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	5.27	2.88e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
COAD	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	5.27	2.88e-07	0.000157	0.41	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
COAD	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	5.27	2.89e-07	0.000157	0.34	0.31	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
COAD	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	5.27	2.89e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	5.27	2.89e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	5.27	2.89e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	5.27	2.89e-07	0.000157	0.28	0.31	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
COAD	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-5.27	2.89e-07	0.000157	-0.5	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-5.27	2.89e-07	0.000157	-0.5	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
COAD	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-5.27	2.89e-07	0.000157	-0.35	-0.31	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
COAD	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5.27	2.89e-07	0.000157	0.48	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
COAD	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	5.27	2.89e-07	0.000157	0.58	0.31	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
COAD	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.27	2.89e-07	0.000157	0.38	0.31	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
COAD	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-5.27	2.9e-07	0.000157	-0.37	-0.31	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
COAD	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	5.27	2.9e-07	0.000158	0.34	0.31	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
COAD	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	5.27	2.9e-07	0.000158	0.33	0.31	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	5.27	2.9e-07	0.000158	0.33	0.31	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	5.27	2.9e-07	0.000158	0.33	0.31	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	5.27	2.9e-07	0.000158	0.33	0.31	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
COAD	cis	rs7647973	0.58	rs11130184	ENSG00000225399.4	RP11-3B7.1	5.27	2.9e-07	0.000158	0.35	0.31	Menarche (age at onset);	chr3:49192497	chr3:49260085~49261316:+
COAD	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-5.27	2.9e-07	0.000158	-0.27	-0.31	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-5.27	2.9e-07	0.000158	-0.27	-0.31	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
COAD	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-5.27	2.9e-07	0.000158	-0.37	-0.31	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
COAD	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	5.27	2.9e-07	0.000158	0.57	0.31	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	5.27	2.9e-07	0.000158	0.57	0.31	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
COAD	cis	rs9951698	0.703	rs7234960	ENSG00000266969.1	RP11-773H22.4	5.27	2.9e-07	0.000158	0.4	0.31	Intelligence (multi-trait analysis);	chr18:13018072	chr18:12984694~12991173:-
COAD	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-5.27	2.91e-07	0.000158	-0.17	-0.31	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
COAD	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-5.27	2.92e-07	0.000158	-0.39	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
COAD	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	5.27	2.92e-07	0.000158	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
COAD	cis	rs13256369	0.802	rs35382339	ENSG00000173295.6	FAM86B3P	5.27	2.92e-07	0.000159	0.45	0.31	Obesity-related traits;	chr8:8701745	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs11781257	ENSG00000173295.6	FAM86B3P	5.27	2.92e-07	0.000159	0.45	0.31	Obesity-related traits;	chr8:8702153	chr8:8228595~8244865:+
COAD	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-5.27	2.92e-07	0.000159	-0.34	-0.31	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-5.27	2.92e-07	0.000159	-0.34	-0.31	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-5.27	2.92e-07	0.000159	-0.34	-0.31	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-5.27	2.92e-07	0.000159	-0.34	-0.31	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
COAD	cis	rs13217239	0.646	rs11756275	ENSG00000224843.5	LINC00240	5.27	2.92e-07	0.000159	0.36	0.31	Schizophrenia;	chr6:27039334	chr6:26956992~27023924:+
COAD	cis	rs55823223	0.618	rs11867339	ENSG00000267801.1	RP11-552F3.9	5.27	2.93e-07	0.000159	0.47	0.31	Psoriasis;	chr17:75866012	chr17:75876372~75879546:+
COAD	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-5.27	2.94e-07	0.000159	-0.39	-0.31	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
COAD	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	5.27	2.94e-07	0.000159	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
COAD	cis	rs9309473	0.519	rs13022145	ENSG00000163016.8	ALMS1P	-5.27	2.94e-07	0.00016	-0.37	-0.31	Metabolite levels;	chr2:73636346	chr2:73644919~73685576:+
COAD	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	5.27	2.94e-07	0.00016	0.43	0.31	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
COAD	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.27	2.95e-07	0.00016	0.34	0.31	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
COAD	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-5.27	2.95e-07	0.00016	-0.36	-0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
COAD	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-5.27	2.96e-07	0.00016	-0.31	-0.31	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
COAD	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	5.27	2.96e-07	0.000161	0.35	0.31	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
COAD	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	5.26	2.96e-07	0.000161	0.28	0.31	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	5.26	2.96e-07	0.000161	0.28	0.31	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	5.26	2.96e-07	0.000161	0.28	0.31	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	5.26	2.96e-07	0.000161	0.28	0.31	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
COAD	cis	rs7078219	0.743	rs11190128	ENSG00000257582.4	LINC01475	-5.26	2.96e-07	0.000161	-0.35	-0.31	Dental caries;	chr10:99515392	chr10:99526350~99531177:-
COAD	cis	rs7078219	0.686	rs12412214	ENSG00000257582.4	LINC01475	-5.26	2.96e-07	0.000161	-0.35	-0.31	Dental caries;	chr10:99516499	chr10:99526350~99531177:-
COAD	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	5.26	2.97e-07	0.000161	0.31	0.31	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
COAD	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-5.26	2.97e-07	0.000161	-0.19	-0.31	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-5.26	2.97e-07	0.000161	-0.19	-0.31	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
COAD	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	5.26	2.98e-07	0.000161	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
COAD	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	5.26	2.98e-07	0.000161	0.35	0.31	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
COAD	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-5.26	2.98e-07	0.000162	-0.32	-0.31	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
COAD	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	5.26	2.98e-07	0.000162	0.3	0.31	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
COAD	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	5.26	2.98e-07	0.000162	0.3	0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
COAD	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-5.26	2.98e-07	0.000162	-0.38	-0.31	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
COAD	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	5.26	2.98e-07	0.000162	0.32	0.31	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
COAD	cis	rs9393777	0.513	rs13195210	ENSG00000224843.5	LINC00240	5.26	2.99e-07	0.000162	0.5	0.31	Intelligence (multi-trait analysis);	chr6:26646293	chr6:26956992~27023924:+
COAD	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	5.26	3e-07	0.000162	0.41	0.31	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
COAD	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-5.26	3e-07	0.000163	-0.29	-0.31	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
COAD	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	5.26	3e-07	0.000163	0.38	0.31	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
COAD	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	5.26	3e-07	0.000163	0.48	0.31	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
COAD	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	5.26	3e-07	0.000163	0.48	0.31	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
COAD	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-5.26	3.01e-07	0.000163	-0.22	-0.31	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
COAD	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-5.26	3.01e-07	0.000163	-0.42	-0.31	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-5.26	3.01e-07	0.000163	-0.42	-0.31	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
COAD	cis	rs7818688	0.697	rs75349998	ENSG00000253528.2	RP11-347C18.4	-5.26	3.01e-07	0.000163	-0.44	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94978690	chr8:94974573~94974853:-
COAD	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	5.26	3.01e-07	0.000163	0.35	0.31	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
COAD	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	5.26	3.01e-07	0.000163	0.35	0.31	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
COAD	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	5.26	3.01e-07	0.000163	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
COAD	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	5.26	3.01e-07	0.000163	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	5.26	3.01e-07	0.000163	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
COAD	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-5.26	3.01e-07	0.000163	-0.4	-0.31	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
COAD	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	5.26	3.01e-07	0.000163	0.35	0.31	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
COAD	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-5.26	3.02e-07	0.000164	-0.35	-0.31	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
COAD	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-5.26	3.02e-07	0.000164	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
COAD	cis	rs9309473	0.5	rs10189578	ENSG00000163016.8	ALMS1P	5.26	3.02e-07	0.000164	0.38	0.31	Metabolite levels;	chr2:73501482	chr2:73644919~73685576:+
COAD	cis	rs754466	0.874	rs61855849	ENSG00000204049.1	RP11-126H7.4	5.26	3.03e-07	0.000164	0.43	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77900176	chr10:77866875~77869610:+
COAD	cis	rs754466	0.874	rs10430531	ENSG00000204049.1	RP11-126H7.4	5.26	3.03e-07	0.000164	0.43	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77900367	chr10:77866875~77869610:+
COAD	cis	rs9309473	0.5	rs2421664	ENSG00000163016.8	ALMS1P	-5.26	3.03e-07	0.000164	-0.37	-0.31	Metabolite levels;	chr2:73631754	chr2:73644919~73685576:+
COAD	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	5.26	3.03e-07	0.000164	0.48	0.31	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
COAD	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	5.26	3.03e-07	0.000164	0.33	0.31	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
COAD	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	5.26	3.03e-07	0.000164	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
COAD	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	5.26	3.03e-07	0.000164	0.35	0.31	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
COAD	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	5.26	3.04e-07	0.000164	0.27	0.31	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	5.26	3.04e-07	0.000164	0.27	0.31	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	5.26	3.04e-07	0.000164	0.27	0.31	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
COAD	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	5.26	3.04e-07	0.000165	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
COAD	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	5.26	3.05e-07	0.000165	0.36	0.31	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
COAD	cis	rs711830	1	rs1318778	ENSG00000226363.3	HAGLROS	-5.26	3.05e-07	0.000165	-0.48	-0.31	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176173103	chr2:176177717~176179008:+
COAD	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-5.26	3.05e-07	0.000165	-0.32	-0.31	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
COAD	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	5.26	3.06e-07	0.000165	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
COAD	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	5.26	3.06e-07	0.000165	0.39	0.31	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs3735147	ENSG00000224316.1	RP11-479O9.2	5.26	3.06e-07	0.000165	0.39	0.31	Aortic root size;	chr7:66505541	chr7:65773620~65802067:+
COAD	cis	rs7078219	0.714	rs12414770	ENSG00000228778.1	RP11-129J12.1	-5.26	3.06e-07	0.000166	-0.36	-0.31	Dental caries;	chr10:99528481	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.714	rs60386053	ENSG00000228778.1	RP11-129J12.1	-5.26	3.06e-07	0.000166	-0.36	-0.31	Dental caries;	chr10:99529104	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.686	rs12412391	ENSG00000228778.1	RP11-129J12.1	-5.26	3.06e-07	0.000166	-0.36	-0.31	Dental caries;	chr10:99529178	chr10:99527081~99528261:+
COAD	cis	rs11846409	0.932	rs10151046	ENSG00000274576.2	IGHV2-70	-5.26	3.06e-07	0.000166	-0.31	-0.31	Rheumatic heart disease;	chr14:106633095	chr14:106770577~106771020:-
COAD	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	5.26	3.07e-07	0.000166	0.28	0.31	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	5.26	3.07e-07	0.000166	0.28	0.31	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
COAD	cis	rs440932	1	rs440932	ENSG00000253981.4	ALG1L13P	5.26	3.07e-07	0.000166	0.42	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8236003~8244667:-
COAD	cis	rs9309473	0.539	rs6745560	ENSG00000163016.8	ALMS1P	5.26	3.07e-07	0.000166	0.38	0.31	Metabolite levels;	chr2:73599990	chr2:73644919~73685576:+
COAD	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	5.26	3.08e-07	0.000166	0.41	0.31	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
COAD	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-5.26	3.09e-07	0.000167	-0.31	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
COAD	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-5.26	3.09e-07	0.000167	-0.53	-0.31	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
COAD	cis	rs987724	0.519	rs12492968	ENSG00000240875.4	LINC00886	-5.26	3.09e-07	0.000167	-0.3	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824048	chr3:156747346~156817062:-
COAD	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	5.26	3.09e-07	0.000167	0.48	0.31	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
COAD	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-5.26	3.09e-07	0.000167	-0.33	-0.31	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
COAD	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-5.26	3.1e-07	0.000167	-0.36	-0.31	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
COAD	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	5.26	3.1e-07	0.000167	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
COAD	cis	rs12935418	0.672	rs2549883	ENSG00000278985.1	RP11-303E16.9	-5.26	3.1e-07	0.000167	-0.34	-0.31	Mean corpuscular volume;	chr16:81022273	chr16:80982319~80984094:-
COAD	cis	rs5015933	1	rs5015933	ENSG00000232630.1	PRPS1P2	-5.26	3.11e-07	0.000167	-0.31	-0.31	Body mass index;	chr9:125375139	chr9:125150653~125151589:+
COAD	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-5.26	3.11e-07	0.000167	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
COAD	cis	rs13217239	0.646	rs7768407	ENSG00000224843.5	LINC00240	-5.25	3.11e-07	0.000168	-0.36	-0.31	Schizophrenia;	chr6:27049016	chr6:26956992~27023924:+
COAD	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-5.25	3.12e-07	0.000168	-0.32	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
COAD	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	5.25	3.13e-07	0.000169	0.33	0.31	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
COAD	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-5.25	3.13e-07	0.000169	-0.34	-0.31	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
COAD	cis	rs5015933	0.778	rs2184062	ENSG00000232630.1	PRPS1P2	-5.25	3.13e-07	0.000169	-0.32	-0.31	Body mass index;	chr9:125308231	chr9:125150653~125151589:+
COAD	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-5.25	3.14e-07	0.000169	-0.43	-0.31	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
COAD	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-5.25	3.14e-07	0.000169	-0.32	-0.31	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-5.25	3.14e-07	0.000169	-0.32	-0.31	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
COAD	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	5.25	3.14e-07	0.000169	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
COAD	cis	rs1056107	0.931	rs7870866	ENSG00000225513.1	RP11-165N19.2	-5.25	3.14e-07	0.000169	-0.37	-0.31	Colorectal cancer;	chr9:112268290	chr9:112173522~112173971:-
COAD	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	5.25	3.14e-07	0.000169	0.33	0.31	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
COAD	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-5.25	3.14e-07	0.000169	-0.42	-0.31	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-5.25	3.14e-07	0.000169	-0.42	-0.31	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
COAD	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	5.25	3.14e-07	0.000169	0.62	0.31	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
COAD	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	5.25	3.14e-07	0.000169	0.62	0.31	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
COAD	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-5.25	3.15e-07	0.00017	-0.32	-0.31	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
COAD	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	5.25	3.15e-07	0.00017	0.37	0.31	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
COAD	cis	rs8396	1	rs11737481	ENSG00000271817.2	U3	-5.25	3.15e-07	0.00017	-0.35	-0.31	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700098	chr4:158700691~158700909:+
COAD	cis	rs7626444	0.584	rs11711813	ENSG00000272359.1	U4	-5.25	3.16e-07	0.00017	-0.36	-0.31	Monocyte count;	chr3:196740467	chr3:196747192~196747324:-
COAD	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	5.25	3.16e-07	0.00017	0.33	0.31	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
COAD	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	5.25	3.16e-07	0.00017	0.23	0.31	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
COAD	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	5.25	3.17e-07	0.00017	0.36	0.31	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
COAD	cis	rs2281603	0.951	rs60908674	ENSG00000259116.1	RP11-973N13.4	-5.25	3.17e-07	0.00017	-0.33	-0.31	Lymphocyte counts;	chr14:64514181	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.904	rs59440409	ENSG00000259116.1	RP11-973N13.4	-5.25	3.17e-07	0.00017	-0.33	-0.31	Lymphocyte counts;	chr14:64514249	chr14:64514154~64540368:-
COAD	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	5.25	3.17e-07	0.000171	0.32	0.31	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
COAD	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-5.25	3.17e-07	0.000171	-0.29	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
COAD	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	5.25	3.18e-07	0.000171	0.22	0.31	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
COAD	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	5.25	3.18e-07	0.000171	0.28	0.31	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	5.25	3.18e-07	0.000171	0.28	0.31	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
COAD	cis	rs4568518	0.74	rs10429191	ENSG00000279048.1	RP11-511H23.2	5.25	3.18e-07	0.000171	0.23	0.31	Measles;	chr7:17969474	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.74	rs10428925	ENSG00000279048.1	RP11-511H23.2	5.25	3.18e-07	0.000171	0.23	0.31	Measles;	chr7:17969582	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.74	rs11535159	ENSG00000279048.1	RP11-511H23.2	5.25	3.18e-07	0.000171	0.23	0.31	Measles;	chr7:17970686	chr7:17940503~17942922:+
COAD	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	5.25	3.19e-07	0.000172	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	5.25	3.19e-07	0.000172	0.37	0.31	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
COAD	cis	rs4568518	0.619	rs34058374	ENSG00000279048.1	RP11-511H23.2	5.25	3.2e-07	0.000172	0.23	0.31	Measles;	chr7:17968959	chr7:17940503~17942922:+
COAD	cis	rs8002861	0.87	rs4942254	ENSG00000274001.1	RP11-5G9.5	5.25	3.2e-07	0.000172	0.27	0.31	Leprosy;	chr13:43877684	chr13:43877715~43878163:-
COAD	cis	rs1056107	0.931	rs10759538	ENSG00000225513.1	RP11-165N19.2	-5.25	3.21e-07	0.000172	-0.37	-0.31	Colorectal cancer;	chr9:112234047	chr9:112173522~112173971:-
COAD	cis	rs6061231	0.631	rs927133	ENSG00000273619.1	RP5-908M14.9	-5.25	3.21e-07	0.000173	-0.26	-0.31	Colorectal cancer;	chr20:62397053	chr20:62386303~62386970:-
COAD	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	5.25	3.21e-07	0.000173	0.48	0.31	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
COAD	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-5.25	3.21e-07	0.000173	-0.33	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
COAD	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-5.25	3.22e-07	0.000173	-0.46	-0.31	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
COAD	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	-5.25	3.22e-07	0.000173	-0.35	-0.31	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
COAD	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-5.25	3.22e-07	0.000173	-0.42	-0.31	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
COAD	cis	rs4780805	0.564	rs8045821	ENSG00000259925.1	CTA-363E6.2	-5.25	3.23e-07	0.000173	-0.52	-0.31	Sleep duration;	chr16:19386621	chr16:19343647~19401693:-
COAD	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	5.25	3.23e-07	0.000174	0.55	0.31	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	5.25	3.23e-07	0.000174	0.55	0.31	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
COAD	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	5.25	3.23e-07	0.000174	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	5.25	3.23e-07	0.000174	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
COAD	cis	rs867371	0.502	rs8025964	ENSG00000259429.4	UBE2Q2P2	-5.25	3.23e-07	0.000174	-0.25	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82355142~82420075:+
COAD	cis	rs9818758	0.607	rs13068038	ENSG00000225399.4	RP11-3B7.1	-5.25	3.23e-07	0.000174	-0.56	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs12715434	ENSG00000225399.4	RP11-3B7.1	-5.25	3.23e-07	0.000174	-0.56	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49257592	chr3:49260085~49261316:+
COAD	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	5.25	3.24e-07	0.000174	0.66	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
COAD	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-5.25	3.24e-07	0.000174	-0.43	-0.31	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
COAD	cis	rs6940638	0.615	rs9393801	ENSG00000224843.5	LINC00240	5.25	3.24e-07	0.000174	0.38	0.31	Intelligence (multi-trait analysis);	chr6:27274902	chr6:26956992~27023924:+
COAD	cis	rs7647973	0.516	rs4955419	ENSG00000225399.4	RP11-3B7.1	5.25	3.24e-07	0.000174	0.35	0.31	Menarche (age at onset);	chr3:49163259	chr3:49260085~49261316:+
COAD	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	5.25	3.25e-07	0.000174	0.35	0.31	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
COAD	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-5.25	3.25e-07	0.000174	-0.33	-0.31	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
COAD	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-5.25	3.25e-07	0.000174	-0.46	-0.31	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
COAD	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	5.25	3.25e-07	0.000174	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
COAD	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-5.25	3.25e-07	0.000174	-0.39	-0.31	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
COAD	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	5.25	3.26e-07	0.000175	0.31	0.31	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
COAD	cis	rs5015933	0.815	rs10124754	ENSG00000232630.1	PRPS1P2	-5.25	3.26e-07	0.000175	-0.31	-0.31	Body mass index;	chr9:125327479	chr9:125150653~125151589:+
COAD	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-5.25	3.26e-07	0.000175	-0.27	-0.31	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
COAD	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	5.25	3.26e-07	0.000175	0.74	0.31	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	5.25	3.26e-07	0.000175	0.74	0.31	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
COAD	cis	rs2115630	0.691	rs61322921	ENSG00000259728.4	LINC00933	-5.25	3.26e-07	0.000175	-0.37	-0.31	P wave terminal force;	chr15:84620407	chr15:84570649~84580175:+
COAD	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-5.25	3.26e-07	0.000175	-0.35	-0.31	Height;	chr11:118808920	chr11:118704607~118750263:+
COAD	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-5.25	3.26e-07	0.000175	-0.39	-0.31	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
COAD	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-5.25	3.27e-07	0.000175	-0.36	-0.31	Height;	chr20:49254660	chr20:49280319~49280409:+
COAD	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-5.25	3.27e-07	0.000175	-0.18	-0.31	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-5.25	3.27e-07	0.000175	-0.18	-0.31	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
COAD	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-5.24	3.27e-07	0.000175	-0.34	-0.31	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
COAD	cis	rs7615952	0.546	rs2976733	ENSG00000241278.1	ENPP7P4	5.24	3.27e-07	0.000175	0.33	0.31	Blood pressure (smoking interaction);	chr3:125695294	chr3:125848223~125909372:+
COAD	cis	rs5015933	0.815	rs13291322	ENSG00000232630.1	PRPS1P2	-5.24	3.27e-07	0.000175	-0.31	-0.31	Body mass index;	chr9:125348076	chr9:125150653~125151589:+
COAD	cis	rs7560272	0.695	rs13022149	ENSG00000163016.8	ALMS1P	-5.24	3.27e-07	0.000175	-0.38	-0.31	Schizophrenia;	chr2:73414387	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	5.24	3.28e-07	0.000175	0.38	0.31	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
COAD	cis	rs5015933	0.815	rs16928051	ENSG00000232630.1	PRPS1P2	-5.24	3.28e-07	0.000175	-0.31	-0.31	Body mass index;	chr9:125308738	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs4991998	ENSG00000232630.1	PRPS1P2	-5.24	3.28e-07	0.000175	-0.31	-0.31	Body mass index;	chr9:125314702	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs13291655	ENSG00000232630.1	PRPS1P2	-5.24	3.28e-07	0.000175	-0.31	-0.31	Body mass index;	chr9:125348274	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs12338077	ENSG00000232630.1	PRPS1P2	-5.24	3.28e-07	0.000176	-0.31	-0.31	Body mass index;	chr9:125345427	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs10986716	ENSG00000232630.1	PRPS1P2	-5.24	3.28e-07	0.000176	-0.31	-0.31	Body mass index;	chr9:125345606	chr9:125150653~125151589:+
COAD	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-5.24	3.28e-07	0.000176	-0.4	-0.31	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-5.24	3.28e-07	0.000176	-0.4	-0.31	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-5.24	3.28e-07	0.000176	-0.4	-0.31	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-5.24	3.28e-07	0.000176	-0.4	-0.31	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-5.24	3.28e-07	0.000176	-0.4	-0.31	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
COAD	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	5.24	3.28e-07	0.000176	0.37	0.31	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
COAD	cis	rs5015933	0.705	rs13288223	ENSG00000232630.1	PRPS1P2	-5.24	3.29e-07	0.000176	-0.31	-0.31	Body mass index;	chr9:125335388	chr9:125150653~125151589:+
COAD	cis	rs4950322	0.58	rs17355419	ENSG00000278811.3	LINC00624	5.24	3.29e-07	0.000176	0.31	0.31	Protein quantitative trait loci;	chr1:147110094	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.58	rs72706428	ENSG00000278811.3	LINC00624	5.24	3.29e-07	0.000176	0.31	0.31	Protein quantitative trait loci;	chr1:147110219	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.563	rs61838944	ENSG00000278811.3	LINC00624	5.24	3.29e-07	0.000176	0.31	0.31	Protein quantitative trait loci;	chr1:147110275	chr1:147258885~147517875:-
COAD	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	5.24	3.29e-07	0.000176	0.31	0.31	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	5.24	3.29e-07	0.000176	0.35	0.31	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	5.24	3.29e-07	0.000176	0.35	0.31	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	5.24	3.29e-07	0.000176	0.35	0.31	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
COAD	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	5.24	3.3e-07	0.000176	0.34	0.31	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
COAD	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-5.24	3.3e-07	0.000177	-0.36	-0.31	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
COAD	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-5.24	3.3e-07	0.000177	-0.28	-0.31	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
COAD	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-5.24	3.31e-07	0.000177	-0.37	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
COAD	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	5.24	3.31e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
COAD	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	5.24	3.31e-07	0.000177	0.34	0.31	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
COAD	cis	rs7647973	0.516	rs4308307	ENSG00000225399.4	RP11-3B7.1	5.24	3.31e-07	0.000177	0.35	0.31	Menarche (age at onset);	chr3:49155783	chr3:49260085~49261316:+
COAD	cis	rs453301	0.631	rs28572014	ENSG00000173295.6	FAM86B3P	-5.24	3.31e-07	0.000177	-0.37	-0.31	Joint mobility (Beighton score);	chr8:8936097	chr8:8228595~8244865:+
COAD	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-5.24	3.31e-07	0.000177	-0.36	-0.31	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
COAD	cis	rs10800713	0.56	rs10800706	ENSG00000260088.1	RP11-92G12.3	-5.24	3.31e-07	0.000177	-0.45	-0.31	Tandem gait;	chr1:200526967	chr1:200669507~200694250:+
COAD	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	5.24	3.32e-07	0.000177	0.37	0.31	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
COAD	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	5.24	3.32e-07	0.000177	0.35	0.31	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
COAD	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-5.24	3.32e-07	0.000177	-0.55	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	5.24	3.33e-07	0.000178	0.35	0.31	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
COAD	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	5.24	3.33e-07	0.000178	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
COAD	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-5.24	3.33e-07	0.000178	-0.35	-0.31	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
COAD	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	5.24	3.33e-07	0.000178	0.34	0.31	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
COAD	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.24	3.34e-07	0.000178	-0.31	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
COAD	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.24	3.34e-07	0.000178	-0.31	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
COAD	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-5.24	3.34e-07	0.000178	-0.34	-0.31	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
COAD	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	5.24	3.34e-07	0.000178	0.33	0.31	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
COAD	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	5.24	3.34e-07	0.000178	0.33	0.31	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
COAD	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	5.24	3.34e-07	0.000178	0.48	0.31	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
COAD	cis	rs7647973	0.58	rs35218722	ENSG00000225399.4	RP11-3B7.1	5.24	3.34e-07	0.000178	0.35	0.31	Menarche (age at onset);	chr3:49238372	chr3:49260085~49261316:+
COAD	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-5.24	3.34e-07	0.000178	-0.36	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
COAD	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-5.24	3.34e-07	0.000178	-0.32	-0.31	Height;	chr11:118737916	chr11:118791254~118793137:+
COAD	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-5.24	3.35e-07	0.000179	-0.34	-0.31	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
COAD	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-5.24	3.35e-07	0.000179	-0.32	-0.31	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	5.24	3.35e-07	0.000179	0.34	0.31	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
COAD	cis	rs1383484	0.64	rs12101685	ENSG00000259728.4	LINC00933	-5.24	3.36e-07	0.000179	-0.43	-0.31	Height;	chr15:83974905	chr15:84570649~84580175:+
COAD	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	5.24	3.36e-07	0.000179	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	5.24	3.36e-07	0.000179	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	5.24	3.36e-07	0.000179	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	5.24	3.36e-07	0.000179	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	5.24	3.36e-07	0.000179	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
COAD	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-5.24	3.36e-07	0.000179	-0.18	-0.31	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-5.24	3.36e-07	0.000179	-0.18	-0.31	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-5.24	3.36e-07	0.000179	-0.18	-0.31	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-5.24	3.36e-07	0.000179	-0.18	-0.31	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
COAD	cis	rs1056107	0.933	rs7037658	ENSG00000225513.1	RP11-165N19.2	-5.24	3.37e-07	0.00018	-0.36	-0.31	Colorectal cancer;	chr9:112309244	chr9:112173522~112173971:-
COAD	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	5.24	3.37e-07	0.00018	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
COAD	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	5.24	3.37e-07	0.00018	0.48	0.31	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
COAD	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	5.24	3.38e-07	0.00018	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
COAD	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-5.24	3.38e-07	0.00018	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
COAD	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	5.24	3.39e-07	0.00018	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	5.24	3.39e-07	0.00018	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	5.24	3.39e-07	0.00018	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
COAD	cis	rs911186	0.812	rs35454259	ENSG00000224843.5	LINC00240	5.24	3.39e-07	0.000181	0.52	0.31	Autism spectrum disorder or schizophrenia;	chr6:27286696	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.502	rs3823427	ENSG00000224843.5	LINC00240	5.24	3.39e-07	0.000181	0.52	0.31	Intelligence (multi-trait analysis);	chr6:27288567	chr6:26956992~27023924:+
COAD	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-5.24	3.39e-07	0.000181	-0.39	-0.31	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
COAD	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	5.24	3.39e-07	0.000181	0.48	0.31	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
COAD	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	5.24	3.39e-07	0.000181	0.48	0.31	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
COAD	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	5.24	3.39e-07	0.000181	0.48	0.31	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
COAD	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	5.24	3.4e-07	0.000181	0.34	0.31	Monocyte count;	chr11:307036	chr11:310139~311141:-
COAD	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-5.24	3.4e-07	0.000181	-0.34	-0.31	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
COAD	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	5.24	3.4e-07	0.000181	0.35	0.31	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
COAD	cis	rs10078	0.528	rs2434697	ENSG00000225138.6	CTD-2228K2.7	5.24	3.41e-07	0.000181	0.52	0.31	Fat distribution (HIV);	chr5:466696	chr5:473236~480884:+
COAD	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-5.24	3.41e-07	0.000182	-0.41	-0.31	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
COAD	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-5.24	3.41e-07	0.000182	-0.34	-0.31	Height;	chr11:118737823	chr11:118704607~118750263:+
COAD	cis	rs2028299	1	rs12910992	ENSG00000259677.1	RP11-493E3.1	5.24	3.41e-07	0.000182	0.37	0.31	Type 2 diabetes;	chr15:89829233	chr15:89876540~89877285:+
COAD	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-5.24	3.41e-07	0.000182	-0.31	-0.31	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-5.24	3.41e-07	0.000182	-0.31	-0.31	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
COAD	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.24	3.41e-07	0.000182	-0.31	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
COAD	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	5.24	3.41e-07	0.000182	0.34	0.31	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
COAD	cis	rs9818758	0.607	rs11710247	ENSG00000225399.4	RP11-3B7.1	-5.24	3.42e-07	0.000182	-0.53	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:49260085~49261316:+
COAD	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	5.24	3.42e-07	0.000182	0.33	0.31	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
COAD	cis	rs7829975	0.56	rs4841013	ENSG00000173295.6	FAM86B3P	-5.24	3.42e-07	0.000182	-0.37	-0.31	Mood instability;	chr8:8694503	chr8:8228595~8244865:+
COAD	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-5.24	3.43e-07	0.000182	-0.4	-0.31	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
COAD	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-5.24	3.43e-07	0.000182	-0.38	-0.31	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
COAD	cis	rs1056107	0.966	rs7043856	ENSG00000225513.1	RP11-165N19.2	-5.23	3.43e-07	0.000183	-0.36	-0.31	Colorectal cancer;	chr9:112325876	chr9:112173522~112173971:-
COAD	cis	rs1056107	1	rs4363271	ENSG00000225513.1	RP11-165N19.2	-5.23	3.43e-07	0.000183	-0.36	-0.31	Colorectal cancer;	chr9:112326251	chr9:112173522~112173971:-
COAD	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	5.23	3.43e-07	0.000183	0.41	0.31	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
COAD	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-5.23	3.45e-07	0.000183	-0.34	-0.31	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
COAD	cis	rs5015933	0.872	rs491283	ENSG00000232630.1	PRPS1P2	-5.23	3.45e-07	0.000183	-0.31	-0.31	Body mass index;	chr9:125255437	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs558352	ENSG00000232630.1	PRPS1P2	-5.23	3.45e-07	0.000183	-0.31	-0.31	Body mass index;	chr9:125258497	chr9:125150653~125151589:+
COAD	cis	rs1056107	0.933	rs2418201	ENSG00000225513.1	RP11-165N19.2	-5.23	3.46e-07	0.000184	-0.36	-0.31	Colorectal cancer;	chr9:112271580	chr9:112173522~112173971:-
COAD	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-5.23	3.46e-07	0.000184	-0.38	-0.31	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
COAD	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	5.23	3.46e-07	0.000184	0.37	0.31	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
COAD	cis	rs2115630	0.875	rs8039472	ENSG00000259728.4	LINC00933	-5.23	3.47e-07	0.000185	-0.39	-0.31	P wave terminal force;	chr15:84818413	chr15:84570649~84580175:+
COAD	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	5.23	3.48e-07	0.000185	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
COAD	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-5.23	3.48e-07	0.000185	-0.31	-0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
COAD	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	5.23	3.48e-07	0.000185	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
COAD	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-5.23	3.49e-07	0.000185	-0.18	-0.31	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-5.23	3.49e-07	0.000185	-0.18	-0.31	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
COAD	cis	rs362272	0.524	rs7435601	ENSG00000248840.2	RP11-357G3.2	-5.23	3.49e-07	0.000185	-0.35	-0.31	Serum sulfate level;	chr4:3367918	chr4:3312512~3313058:+
COAD	cis	rs6964833	1	rs3846966	ENSG00000277053.3	GTF2IP1	-5.23	3.49e-07	0.000185	-0.39	-0.31	Menarche (age at onset);	chr7:74698811	chr7:75185385~75237696:-
COAD	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-5.23	3.49e-07	0.000185	-0.39	-0.31	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
COAD	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-5.23	3.49e-07	0.000186	-0.25	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	5.23	3.5e-07	0.000186	0.36	0.31	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
COAD	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-5.23	3.5e-07	0.000186	-0.55	-0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
COAD	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-5.23	3.5e-07	0.000186	-0.39	-0.31	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
COAD	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-5.23	3.5e-07	0.000186	-0.41	-0.31	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	5.23	3.5e-07	0.000186	0.22	0.31	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	5.23	3.5e-07	0.000186	0.22	0.31	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
COAD	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	5.23	3.5e-07	0.000186	0.57	0.31	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	5.23	3.5e-07	0.000186	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
COAD	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-5.23	3.5e-07	0.000186	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
COAD	cis	rs9393777	0.513	rs13190754	ENSG00000224843.5	LINC00240	5.23	3.51e-07	0.000186	0.51	0.31	Intelligence (multi-trait analysis);	chr6:26587178	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9379895	ENSG00000224843.5	LINC00240	5.23	3.51e-07	0.000186	0.51	0.31	Intelligence (multi-trait analysis);	chr6:26592479	chr6:26956992~27023924:+
COAD	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	5.23	3.51e-07	0.000186	0.47	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
COAD	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-5.23	3.51e-07	0.000187	-0.36	-0.31	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
COAD	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.23	3.52e-07	0.000187	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5.23	3.52e-07	0.000187	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.23	3.52e-07	0.000187	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
COAD	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	5.23	3.53e-07	0.000187	0.37	0.31	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
COAD	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-5.23	3.53e-07	0.000187	-0.34	-0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
COAD	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-5.23	3.53e-07	0.000187	-0.35	-0.31	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
COAD	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.54e-07	0.000188	-0.27	-0.31	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
COAD	cis	rs5015933	0.703	rs7037034	ENSG00000232630.1	PRPS1P2	-5.23	3.54e-07	0.000188	-0.31	-0.31	Body mass index;	chr9:125382358	chr9:125150653~125151589:+
COAD	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-5.23	3.54e-07	0.000188	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
COAD	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-5.23	3.54e-07	0.000188	-0.31	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
COAD	cis	rs896854	0.684	rs10098778	ENSG00000253528.2	RP11-347C18.4	5.23	3.54e-07	0.000188	0.33	0.31	Type 2 diabetes;	chr8:94979792	chr8:94974573~94974853:-
COAD	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-5.23	3.55e-07	0.000188	-0.35	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
COAD	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	5.23	3.55e-07	0.000188	0.32	0.31	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	5.23	3.55e-07	0.000188	0.32	0.31	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
COAD	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.23	3.55e-07	0.000188	0.41	0.31	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
COAD	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.55e-07	0.000188	-0.27	-0.31	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
COAD	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-5.23	3.55e-07	0.000188	-0.34	-0.31	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
COAD	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-5.23	3.55e-07	0.000188	-0.37	-0.31	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
COAD	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-5.23	3.55e-07	0.000188	-0.37	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
COAD	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	5.23	3.56e-07	0.000189	0.63	0.31	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
COAD	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-5.23	3.57e-07	0.000189	-0.32	-0.31	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
COAD	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	5.23	3.57e-07	0.000189	0.34	0.31	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
COAD	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-5.23	3.57e-07	0.000189	-0.54	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
COAD	cis	rs7818688	0.697	rs80217195	ENSG00000253528.2	RP11-347C18.4	-5.23	3.57e-07	0.000189	-0.44	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974625	chr8:94974573~94974853:-
COAD	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-5.23	3.57e-07	0.000189	-0.32	-0.31	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
COAD	cis	rs440932	0.798	rs330942	ENSG00000173295.6	FAM86B3P	5.23	3.57e-07	0.000189	0.39	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	5.23	3.58e-07	0.000189	0.36	0.31	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
COAD	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	5.23	3.58e-07	0.000189	0.23	0.31	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
COAD	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	5.23	3.58e-07	0.00019	0.47	0.31	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
COAD	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-5.23	3.58e-07	0.00019	-0.4	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
COAD	cis	rs9393777	0.588	rs11967935	ENSG00000224843.5	LINC00240	5.23	3.58e-07	0.00019	0.52	0.31	Intelligence (multi-trait analysis);	chr6:26560444	chr6:26956992~27023924:+
COAD	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	5.23	3.58e-07	0.00019	0.33	0.31	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
COAD	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	5.23	3.59e-07	0.00019	0.42	0.31	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	5.23	3.59e-07	0.00019	0.42	0.31	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
COAD	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-5.23	3.59e-07	0.00019	-0.55	-0.31	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
COAD	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	5.23	3.59e-07	0.00019	0.39	0.31	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
COAD	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.59e-07	0.00019	-0.27	-0.31	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.59e-07	0.00019	-0.27	-0.31	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.59e-07	0.00019	-0.27	-0.31	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-5.23	3.59e-07	0.00019	-0.27	-0.31	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
COAD	cis	rs7647973	0.516	rs4955418	ENSG00000225399.4	RP11-3B7.1	5.23	3.6e-07	0.00019	0.35	0.31	Menarche (age at onset);	chr3:49163194	chr3:49260085~49261316:+
COAD	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-5.23	3.6e-07	0.00019	-0.53	-0.31	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
COAD	cis	rs4657482	0.606	rs2241965	ENSG00000236364.3	RP11-525G13.2	-5.22	3.6e-07	0.000191	-0.24	-0.31	Testicular germ cell tumor;	chr1:165896457	chr1:165890795~165900683:-
COAD	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-5.22	3.61e-07	0.000191	-0.36	-0.31	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
COAD	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	5.22	3.61e-07	0.000191	0.66	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
COAD	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-5.22	3.61e-07	0.000191	-0.41	-0.31	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
COAD	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	5.22	3.61e-07	0.000191	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	5.22	3.61e-07	0.000191	0.48	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
COAD	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	5.22	3.61e-07	0.000191	0.4	0.31	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
COAD	cis	rs362272	0.545	rs2748447	ENSG00000248840.2	RP11-357G3.2	-5.22	3.61e-07	0.000191	-0.36	-0.31	Serum sulfate level;	chr4:3336104	chr4:3312512~3313058:+
COAD	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-5.22	3.61e-07	0.000191	-0.37	-0.31	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
COAD	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.22	3.61e-07	0.000191	-0.28	-0.31	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
COAD	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	5.22	3.61e-07	0.000191	0.35	0.31	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
COAD	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-5.22	3.62e-07	0.000191	-0.18	-0.31	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
COAD	cis	rs1930961	0.702	rs60835827	ENSG00000272977.1	CTA-390C10.10	-5.22	3.62e-07	0.000191	-0.77	-0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25473570	chr22:25476218~25479971:+
COAD	cis	rs1930961	0.702	rs73410917	ENSG00000272977.1	CTA-390C10.10	-5.22	3.62e-07	0.000191	-0.77	-0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25476723	chr22:25476218~25479971:+
COAD	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	5.22	3.62e-07	0.000191	0.74	0.31	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
COAD	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	5.22	3.62e-07	0.000191	0.74	0.31	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
COAD	cis	rs7078219	0.714	rs888208	ENSG00000228778.1	RP11-129J12.1	-5.22	3.62e-07	0.000191	-0.36	-0.31	Dental caries;	chr10:99536106	chr10:99527081~99528261:+
COAD	cis	rs7529073	0.683	rs340882	ENSG00000274895.1	RP11-478J18.2	5.22	3.62e-07	0.000191	0.35	0.31	Schizophrenia;	chr1:213972388	chr1:213983793~213986419:-
COAD	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-5.22	3.63e-07	0.000192	-0.2	-0.31	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
COAD	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-5.22	3.63e-07	0.000192	-0.35	-0.31	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
COAD	cis	rs34779708	0.643	rs4275563	ENSG00000271335.4	RP11-324I22.4	5.22	3.63e-07	0.000192	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35314552~35336401:-
COAD	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	5.22	3.64e-07	0.000192	0.54	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
COAD	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	5.22	3.64e-07	0.000192	0.35	0.31	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
COAD	cis	rs7647973	0.58	rs2334958	ENSG00000225399.4	RP11-3B7.1	5.22	3.64e-07	0.000192	0.35	0.31	Menarche (age at onset);	chr3:49214931	chr3:49260085~49261316:+
COAD	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-5.22	3.64e-07	0.000192	-0.25	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
COAD	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-5.22	3.64e-07	0.000192	-0.25	-0.31	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
COAD	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-5.22	3.64e-07	0.000192	-0.3	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
COAD	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-5.22	3.64e-07	0.000192	-0.27	-0.31	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
COAD	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	5.22	3.64e-07	0.000192	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	5.22	3.64e-07	0.000192	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
COAD	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	5.22	3.64e-07	0.000192	0.35	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
COAD	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
COAD	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
COAD	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
COAD	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
COAD	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
COAD	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	5.22	3.64e-07	0.000192	0.33	0.31	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
COAD	cis	rs13256369	0.802	rs13280101	ENSG00000173295.6	FAM86B3P	5.22	3.64e-07	0.000192	0.44	0.31	Obesity-related traits;	chr8:8705263	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-5.22	3.64e-07	0.000192	-0.33	-0.31	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
COAD	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-5.22	3.65e-07	0.000193	-0.43	-0.31	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
COAD	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-5.22	3.66e-07	0.000193	-0.42	-0.31	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
COAD	cis	rs930421	0.689	rs13418277	ENSG00000226491.1	FTOP1	-5.22	3.66e-07	0.000193	-0.43	-0.31	Attention deficit hyperactivity disorder;	chr2:42755029	chr2:42797225~42798712:-
COAD	cis	rs10078	0.571	rs2721014	ENSG00000225138.6	CTD-2228K2.7	5.22	3.66e-07	0.000193	0.52	0.31	Fat distribution (HIV);	chr5:463424	chr5:473236~480884:+
COAD	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	5.22	3.66e-07	0.000193	0.41	0.31	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
COAD	cis	rs13256369	0.851	rs13271698	ENSG00000173295.6	FAM86B3P	5.22	3.67e-07	0.000193	0.45	0.31	Obesity-related traits;	chr8:8710029	chr8:8228595~8244865:+
COAD	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	5.22	3.67e-07	0.000194	0.39	0.31	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
COAD	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-5.22	3.67e-07	0.000194	-0.25	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
COAD	cis	rs13217239	0.646	rs9379956	ENSG00000224843.5	LINC00240	5.22	3.68e-07	0.000194	0.36	0.31	Schizophrenia;	chr6:27065956	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs7747454	ENSG00000224843.5	LINC00240	5.22	3.68e-07	0.000194	0.36	0.31	Schizophrenia;	chr6:27066474	chr6:26956992~27023924:+
COAD	cis	rs10078	0.559	rs2671891	ENSG00000225138.6	CTD-2228K2.7	5.22	3.68e-07	0.000194	0.52	0.31	Fat distribution (HIV);	chr5:456271	chr5:473236~480884:+
COAD	cis	rs10078	0.571	rs2671890	ENSG00000225138.6	CTD-2228K2.7	5.22	3.68e-07	0.000194	0.52	0.31	Fat distribution (HIV);	chr5:456342	chr5:473236~480884:+
COAD	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-5.22	3.68e-07	0.000194	-0.33	-0.31	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
COAD	cis	rs453301	0.686	rs7017868	ENSG00000253981.4	ALG1L13P	-5.22	3.68e-07	0.000194	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9015783	chr8:8236003~8244667:-
COAD	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-5.22	3.69e-07	0.000195	-0.53	-0.31	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
COAD	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-5.22	3.69e-07	0.000195	-0.19	-0.31	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
COAD	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-5.22	3.69e-07	0.000195	-0.4	-0.31	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
COAD	cis	rs453301	0.686	rs7814328	ENSG00000253981.4	ALG1L13P	-5.22	3.69e-07	0.000195	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9018719	chr8:8236003~8244667:-
COAD	cis	rs13256369	1	rs12550458	ENSG00000173295.6	FAM86B3P	5.22	3.69e-07	0.000195	0.44	0.31	Obesity-related traits;	chr8:8710322	chr8:8228595~8244865:+
COAD	cis	rs13256369	1	rs12545771	ENSG00000173295.6	FAM86B3P	5.22	3.69e-07	0.000195	0.44	0.31	Obesity-related traits;	chr8:8710467	chr8:8228595~8244865:+
COAD	cis	rs711830	1	rs1051929	ENSG00000226363.3	HAGLROS	-5.22	3.7e-07	0.000195	-0.48	-0.31	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172026	chr2:176177717~176179008:+
COAD	cis	rs13256369	0.95	rs12548792	ENSG00000173295.6	FAM86B3P	5.22	3.7e-07	0.000195	0.44	0.31	Obesity-related traits;	chr8:8710521	chr8:8228595~8244865:+
COAD	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-5.22	3.7e-07	0.000195	-0.32	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
COAD	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-5.22	3.7e-07	0.000195	-0.41	-0.31	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
COAD	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	5.22	3.71e-07	0.000195	0.28	0.31	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
COAD	cis	rs5015933	0.902	rs2270746	ENSG00000232630.1	PRPS1P2	5.22	3.71e-07	0.000196	0.3	0.31	Body mass index;	chr9:125359313	chr9:125150653~125151589:+
COAD	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-5.22	3.71e-07	0.000196	-0.45	-0.31	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
COAD	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-5.22	3.71e-07	0.000196	-0.33	-0.31	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
COAD	cis	rs3126085	0.515	rs12760712	ENSG00000237975.5	FLG-AS1	5.22	3.72e-07	0.000196	0.34	0.31	Atopic dermatitis;	chr1:152383074	chr1:152168125~152445456:+
COAD	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-5.22	3.72e-07	0.000196	-0.2	-0.31	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
COAD	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	5.22	3.72e-07	0.000196	0.28	0.31	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
COAD	cis	rs7615952	0.641	rs4490307	ENSG00000248787.1	RP11-666A20.4	-5.22	3.72e-07	0.000196	-0.39	-0.31	Blood pressure (smoking interaction);	chr3:125993833	chr3:125908005~125910272:-
COAD	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-5.22	3.72e-07	0.000196	-0.52	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
COAD	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	5.22	3.72e-07	0.000196	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	5.22	3.72e-07	0.000196	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
COAD	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	5.22	3.73e-07	0.000196	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
COAD	cis	rs5015933	0.778	rs10819046	ENSG00000232630.1	PRPS1P2	-5.22	3.73e-07	0.000196	-0.3	-0.31	Body mass index;	chr9:125349961	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs10986718	ENSG00000232630.1	PRPS1P2	-5.22	3.73e-07	0.000196	-0.3	-0.31	Body mass index;	chr9:125350617	chr9:125150653~125151589:+
COAD	cis	rs4568518	0.616	rs10950691	ENSG00000279048.1	RP11-511H23.2	5.22	3.73e-07	0.000196	0.23	0.31	Measles;	chr7:17966511	chr7:17940503~17942922:+
COAD	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	5.22	3.73e-07	0.000197	0.33	0.31	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	5.22	3.73e-07	0.000197	0.33	0.31	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
COAD	cis	rs1056107	0.933	rs10739341	ENSG00000225513.1	RP11-165N19.2	-5.22	3.74e-07	0.000197	-0.36	-0.31	Colorectal cancer;	chr9:112310497	chr9:112173522~112173971:-
COAD	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	5.22	3.75e-07	0.000197	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
COAD	cis	rs5015933	0.762	rs515985	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125300583	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs521308	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125308475	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.815	rs3126227	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125319157	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.778	rs1759434	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125325260	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs416340	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125339363	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs487228	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125340327	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs430184	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125340911	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.788	rs828290	ENSG00000232630.1	PRPS1P2	-5.22	3.75e-07	0.000197	-0.31	-0.31	Body mass index;	chr9:125341826	chr9:125150653~125151589:+
COAD	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
COAD	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	5.22	3.75e-07	0.000197	0.55	0.31	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
COAD	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	5.22	3.75e-07	0.000197	0.28	0.31	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
COAD	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-5.22	3.75e-07	0.000197	-0.33	-0.31	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-5.22	3.75e-07	0.000197	-0.33	-0.31	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
COAD	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	5.22	3.75e-07	0.000197	0.57	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
COAD	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	5.22	3.76e-07	0.000198	0.3	0.31	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
COAD	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	5.22	3.76e-07	0.000198	0.3	0.31	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
COAD	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	5.22	3.76e-07	0.000198	0.3	0.31	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
COAD	cis	rs58873874	0.579	rs3815829	ENSG00000248544.2	CTB-47B11.3	5.22	3.76e-07	0.000198	0.56	0.31	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157375741~157384950:-
COAD	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	5.22	3.77e-07	0.000198	0.36	0.31	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
COAD	cis	rs71403859	0.554	rs12920245	ENSG00000260886.1	TAT-AS1	5.22	3.77e-07	0.000198	0.66	0.31	Post bronchodilator FEV1;	chr16:71995170	chr16:71565789~71578187:+
COAD	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-5.22	3.78e-07	0.000198	-0.41	-0.31	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
COAD	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
COAD	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	5.22	3.78e-07	0.000198	0.74	0.31	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
COAD	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	5.22	3.78e-07	0.000198	0.35	0.31	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
COAD	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	5.22	3.78e-07	0.000199	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
COAD	cis	rs9309473	0.5	rs4852952	ENSG00000163016.8	ALMS1P	-5.21	3.79e-07	0.000199	-0.38	-0.31	Metabolite levels;	chr2:73642780	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.5	rs4852953	ENSG00000163016.8	ALMS1P	-5.21	3.79e-07	0.000199	-0.38	-0.31	Metabolite levels;	chr2:73642781	chr2:73644919~73685576:+
COAD	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	5.21	3.79e-07	0.000199	0.37	0.31	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
COAD	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	5.21	3.79e-07	0.000199	0.5	0.31	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
COAD	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-5.21	3.79e-07	0.000199	-0.42	-0.31	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
COAD	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-5.21	3.79e-07	0.000199	-0.33	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
COAD	cis	rs5015933	0.788	rs10114684	ENSG00000232630.1	PRPS1P2	-5.21	3.79e-07	0.000199	-0.3	-0.31	Body mass index;	chr9:125340586	chr9:125150653~125151589:+
COAD	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	5.21	3.79e-07	0.000199	0.34	0.31	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
COAD	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-5.21	3.8e-07	0.000199	-0.28	-0.31	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-5.21	3.8e-07	0.000199	-0.28	-0.31	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
COAD	cis	rs492146	0.765	rs423475	ENSG00000243236.5	GSTA9P	-5.21	3.8e-07	0.000199	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52979785	chr6:52939726~52957521:-
COAD	cis	rs492146	0.765	rs419427	ENSG00000243236.5	GSTA9P	-5.21	3.8e-07	0.000199	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52980088	chr6:52939726~52957521:-
COAD	cis	rs492146	0.765	rs316141	ENSG00000243236.5	GSTA9P	-5.21	3.8e-07	0.000199	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52981360	chr6:52939726~52957521:-
COAD	cis	rs492146	0.765	rs316140	ENSG00000243236.5	GSTA9P	-5.21	3.8e-07	0.000199	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52981390	chr6:52939726~52957521:-
COAD	cis	rs492146	0.691	rs316138	ENSG00000243236.5	GSTA9P	-5.21	3.8e-07	0.000199	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52981621	chr6:52939726~52957521:-
COAD	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	5.21	3.8e-07	2e-04	0.34	0.31	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
COAD	cis	rs13217239	0.646	rs62401067	ENSG00000224843.5	LINC00240	-5.21	3.81e-07	2e-04	-0.36	-0.31	Schizophrenia;	chr6:27050322	chr6:26956992~27023924:+
COAD	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-5.21	3.81e-07	2e-04	-0.38	-0.31	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
COAD	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-5.21	3.82e-07	2e-04	-0.33	-0.31	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
COAD	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-5.21	3.82e-07	2e-04	-0.33	-0.31	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
COAD	cis	rs5758511	0.68	rs5758651	ENSG00000237037.8	NDUFA6-AS1	-5.21	3.82e-07	2e-04	-0.37	-0.31	Birth weight;	chr22:42213142	chr22:42090931~42137742:+
COAD	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	5.21	3.82e-07	2e-04	0.34	0.31	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
COAD	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-5.21	3.82e-07	2e-04	-0.43	-0.31	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
COAD	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	5.21	3.82e-07	2e-04	0.39	0.31	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
COAD	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-5.21	3.82e-07	2e-04	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
COAD	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-5.21	3.83e-07	0.000201	-0.4	-0.31	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
COAD	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-5.21	3.83e-07	0.000201	-0.4	-0.31	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
COAD	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-5.21	3.83e-07	0.000201	-0.4	-0.31	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
COAD	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	5.21	3.83e-07	0.000201	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
COAD	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	5.21	3.83e-07	0.000201	0.29	0.31	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
COAD	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-5.21	3.83e-07	0.000201	-0.28	-0.31	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
COAD	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	5.21	3.84e-07	0.000201	0.42	0.31	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
COAD	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	5.21	3.84e-07	0.000201	0.3	0.31	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
COAD	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-5.21	3.84e-07	0.000201	-0.35	-0.31	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
COAD	cis	rs1056107	0.933	rs3808879	ENSG00000225513.1	RP11-165N19.2	-5.21	3.85e-07	0.000201	-0.36	-0.31	Colorectal cancer;	chr9:112299198	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.933	rs10981350	ENSG00000225513.1	RP11-165N19.2	-5.21	3.85e-07	0.000201	-0.36	-0.31	Colorectal cancer;	chr9:112304611	chr9:112173522~112173971:-
COAD	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	5.21	3.85e-07	0.000201	0.4	0.31	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	5.21	3.85e-07	0.000201	0.4	0.31	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
COAD	cis	rs911119	0.913	rs3004145	ENSG00000270001.1	RP11-218C14.8	5.21	3.85e-07	0.000201	0.38	0.31	Chronic kidney disease;	chr20:23602239	chr20:23631826~23632316:-
COAD	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-5.21	3.85e-07	0.000201	-0.34	-0.31	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
COAD	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-5.21	3.85e-07	0.000201	-0.34	-0.31	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
COAD	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	5.21	3.85e-07	0.000202	0.41	0.31	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
COAD	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-5.21	3.85e-07	0.000202	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
COAD	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.21	3.86e-07	0.000202	-0.38	-0.31	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
COAD	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	5.21	3.86e-07	0.000202	0.36	0.31	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	5.21	3.86e-07	0.000202	0.36	0.31	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
COAD	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	5.21	3.86e-07	0.000202	0.33	0.31	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
COAD	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
COAD	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-5.21	3.86e-07	0.000202	-0.32	-0.31	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
COAD	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-5.21	3.86e-07	0.000202	-0.33	-0.31	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
COAD	cis	rs13256369	0.802	rs13281933	ENSG00000173295.6	FAM86B3P	5.21	3.87e-07	0.000202	0.44	0.31	Obesity-related traits;	chr8:8705155	chr8:8228595~8244865:+
COAD	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	5.21	3.87e-07	0.000202	0.35	0.31	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
COAD	cis	rs5758659	0.737	rs10854749	ENSG00000182057.4	OGFRP1	5.21	3.87e-07	0.000202	0.33	0.31	Cognitive function;	chr22:42051337	chr22:42269753~42275196:+
COAD	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-5.21	3.87e-07	0.000202	-0.33	-0.31	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
COAD	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	5.21	3.87e-07	0.000202	0.47	0.31	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
COAD	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-5.21	3.87e-07	0.000203	-0.28	-0.31	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
COAD	cis	rs492146	0.783	rs613764	ENSG00000243236.5	GSTA9P	-5.21	3.88e-07	0.000203	-0.35	-0.31	Epilepsy (remission after treatment);	chr6:52975437	chr6:52939726~52957521:-
COAD	cis	rs9951698	0.703	rs10221326	ENSG00000266969.1	RP11-773H22.4	5.21	3.88e-07	0.000203	0.39	0.31	Intelligence (multi-trait analysis);	chr18:13036035	chr18:12984694~12991173:-
COAD	cis	rs7637701	0.818	rs4680305	ENSG00000240875.4	LINC00886	-5.21	3.88e-07	0.000203	-0.3	-0.31	Breast cancer;	chr3:156815614	chr3:156747346~156817062:-
COAD	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-5.21	3.88e-07	0.000203	-0.4	-0.31	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
COAD	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-5.21	3.88e-07	0.000203	-0.36	-0.31	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
COAD	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-5.21	3.88e-07	0.000203	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-5.21	3.88e-07	0.000203	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-5.21	3.88e-07	0.000203	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-5.21	3.88e-07	0.000203	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-5.21	3.88e-07	0.000203	-0.47	-0.31	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
COAD	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	5.21	3.89e-07	0.000203	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
COAD	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-5.21	3.89e-07	0.000203	-0.35	-0.31	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-5.21	3.89e-07	0.000203	-0.35	-0.31	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
COAD	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	5.21	3.89e-07	0.000203	0.28	0.31	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
COAD	cis	rs7560272	0.723	rs1052161	ENSG00000163016.8	ALMS1P	5.21	3.89e-07	0.000204	0.36	0.31	Schizophrenia;	chr2:73601411	chr2:73644919~73685576:+
COAD	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	5.21	3.9e-07	0.000204	0.39	0.31	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
COAD	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	5.21	3.9e-07	0.000204	0.4	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
COAD	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	5.21	3.9e-07	0.000204	0.31	0.31	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
COAD	cis	rs2281603	0.694	rs12385910	ENSG00000259116.1	RP11-973N13.4	-5.21	3.9e-07	0.000204	-0.31	-0.31	Lymphocyte counts;	chr14:64533252	chr14:64514154~64540368:-
COAD	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-5.21	3.9e-07	0.000204	-0.54	-0.31	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-5.21	3.9e-07	0.000204	-0.54	-0.31	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-5.21	3.9e-07	0.000204	-0.54	-0.31	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
COAD	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-5.21	3.9e-07	0.000204	-0.38	-0.31	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
COAD	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	5.21	3.9e-07	0.000204	0.41	0.31	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
COAD	cis	rs7955901	0.901	rs10784891	ENSG00000258053.1	CTD-2021H9.3	-5.21	3.9e-07	0.000204	-0.38	-0.31	Type 2 diabetes;	chr12:71036018	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.901	rs10879238	ENSG00000258053.1	CTD-2021H9.3	-5.21	3.9e-07	0.000204	-0.38	-0.31	Type 2 diabetes;	chr12:71036158	chr12:71047402~71118247:-
COAD	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-5.21	3.9e-07	0.000204	-0.36	-0.31	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
COAD	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	5.21	3.91e-07	0.000204	0.45	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
COAD	cis	rs1056107	1	rs1056107	ENSG00000225513.1	RP11-165N19.2	-5.21	3.91e-07	0.000204	-0.36	-0.31	Colorectal cancer;	chr9:112324847	chr9:112173522~112173971:-
COAD	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	5.21	3.91e-07	0.000204	0.37	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
COAD	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	5.21	3.91e-07	0.000204	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
COAD	cis	rs362272	0.505	rs60208975	ENSG00000248840.2	RP11-357G3.2	-5.21	3.91e-07	0.000204	-0.34	-0.31	Serum sulfate level;	chr4:3362803	chr4:3312512~3313058:+
COAD	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-5.21	3.92e-07	0.000204	-0.28	-0.31	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
COAD	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	5.21	3.92e-07	0.000204	0.33	0.31	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
COAD	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	5.21	3.92e-07	0.000205	0.54	0.31	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
COAD	cis	rs4841097	0.876	rs6601288	ENSG00000253981.4	ALG1L13P	5.21	3.92e-07	0.000205	0.4	0.31	Platelet distribution width;	chr8:9085920	chr8:8236003~8244667:-
COAD	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
COAD	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
COAD	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	5.21	3.92e-07	0.000205	0.32	0.31	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
COAD	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	5.21	3.93e-07	0.000205	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
COAD	cis	rs13256369	1	rs883648	ENSG00000173295.6	FAM86B3P	5.21	3.93e-07	0.000205	0.44	0.31	Obesity-related traits;	chr8:8712011	chr8:8228595~8244865:+
COAD	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-5.21	3.93e-07	0.000205	-0.52	-0.31	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
COAD	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	5.21	3.93e-07	0.000205	0.37	0.31	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
COAD	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-5.21	3.93e-07	0.000205	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-5.21	3.93e-07	0.000205	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
COAD	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-5.21	3.93e-07	0.000205	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
COAD	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-5.21	3.93e-07	0.000205	-0.42	-0.31	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-5.21	3.93e-07	0.000205	-0.42	-0.31	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-5.21	3.93e-07	0.000205	-0.42	-0.31	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-5.21	3.93e-07	0.000205	-0.42	-0.31	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
COAD	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-5.21	3.93e-07	0.000205	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
COAD	cis	rs9951698	0.678	rs478006	ENSG00000266969.1	RP11-773H22.4	5.21	3.93e-07	0.000205	0.39	0.31	Intelligence (multi-trait analysis);	chr18:13054104	chr18:12984694~12991173:-
COAD	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	5.21	3.93e-07	0.000205	0.42	0.31	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
COAD	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	5.21	3.93e-07	0.000205	0.42	0.31	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
COAD	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	5.21	3.93e-07	0.000205	0.42	0.31	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
COAD	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	5.21	3.94e-07	0.000205	0.41	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
COAD	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	5.21	3.94e-07	0.000205	0.36	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
COAD	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-5.21	3.94e-07	0.000205	-0.4	-0.31	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
COAD	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	5.21	3.94e-07	0.000205	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	5.21	3.94e-07	0.000205	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
COAD	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-5.21	3.94e-07	0.000205	-0.35	-0.31	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
COAD	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.21	3.94e-07	0.000205	-0.41	-0.31	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
COAD	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	5.21	3.94e-07	0.000206	0.3	0.31	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
COAD	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	5.21	3.95e-07	0.000206	0.36	0.31	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
COAD	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-5.21	3.95e-07	0.000206	-0.32	-0.31	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
COAD	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	5.21	3.95e-07	0.000206	0.47	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
COAD	cis	rs492146	0.765	rs597348	ENSG00000243236.5	GSTA9P	-5.21	3.96e-07	0.000206	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52980599	chr6:52939726~52957521:-
COAD	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-5.21	3.96e-07	0.000207	-0.35	-0.31	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
COAD	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	5.21	3.97e-07	0.000207	0.35	0.31	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
COAD	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.21	3.97e-07	0.000207	-0.32	-0.31	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
COAD	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	5.2	3.98e-07	0.000207	0.33	0.31	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	5.2	3.98e-07	0.000207	0.33	0.31	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
COAD	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	5.2	3.98e-07	0.000207	0.42	0.31	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
COAD	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	5.2	3.98e-07	0.000207	0.32	0.31	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
COAD	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	5.2	3.98e-07	0.000207	0.35	0.31	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
COAD	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-5.2	3.98e-07	0.000207	-0.56	-0.31	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
COAD	cis	rs5758511	0.68	rs5758652	ENSG00000237037.8	NDUFA6-AS1	-5.2	3.99e-07	0.000208	-0.37	-0.31	Birth weight;	chr22:42216402	chr22:42090931~42137742:+
COAD	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	5.2	3.99e-07	0.000208	0.61	0.31	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
COAD	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	5.2	3.99e-07	0.000208	0.34	0.31	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
COAD	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	5.2	3.99e-07	0.000208	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
COAD	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	5.2	3.99e-07	0.000208	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
COAD	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	5.2	4e-07	0.000208	0.38	0.31	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
COAD	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-5.2	4e-07	0.000208	-0.28	-0.31	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
COAD	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-5.2	4e-07	0.000208	-0.35	-0.31	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
COAD	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	5.2	4e-07	0.000208	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	5.2	4e-07	0.000208	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	5.2	4e-07	0.000208	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
COAD	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.2	4e-07	0.000209	0.32	0.31	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
COAD	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-5.2	4.01e-07	0.000209	-0.55	-0.31	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-5.2	4.01e-07	0.000209	-0.55	-0.31	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
COAD	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.2	4.01e-07	0.000209	0.32	0.31	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
COAD	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-5.2	4.01e-07	0.000209	-0.32	-0.31	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
COAD	cis	rs2439831	0.681	rs956391	ENSG00000275601.1	AC011330.13	5.2	4.01e-07	0.000209	0.4	0.31	Lung cancer in ever smokers;	chr15:43325295	chr15:43642389~43643023:-
COAD	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	5.2	4.01e-07	0.000209	0.59	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	5.2	4.01e-07	0.000209	0.59	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
COAD	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	5.2	4.01e-07	0.000209	0.34	0.31	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
COAD	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	5.2	4.02e-07	0.000209	0.33	0.31	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
COAD	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	5.2	4.02e-07	0.000209	0.35	0.31	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	5.2	4.02e-07	0.000209	0.34	0.31	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
COAD	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-5.2	4.02e-07	0.000209	-0.3	-0.31	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
COAD	cis	rs5015933	0.762	rs359587	ENSG00000232630.1	PRPS1P2	-5.2	4.03e-07	0.00021	-0.31	-0.31	Body mass index;	chr9:125296098	chr9:125150653~125151589:+
COAD	cis	rs7078219	0.714	rs11190137	ENSG00000257582.4	LINC01475	5.2	4.03e-07	0.00021	0.34	0.31	Dental caries;	chr10:99528187	chr10:99526350~99531177:-
COAD	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-5.2	4.03e-07	0.00021	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
COAD	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	5.2	4.04e-07	0.00021	0.34	0.31	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
COAD	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.2	4.05e-07	0.00021	0.3	0.31	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
COAD	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-5.2	4.05e-07	0.000211	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
COAD	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-5.2	4.06e-07	0.000211	-0.33	-0.31	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
COAD	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	5.2	4.06e-07	0.000211	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
COAD	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	5.2	4.06e-07	0.000211	0.47	0.31	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
COAD	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	5.2	4.07e-07	0.000212	0.3	0.31	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
COAD	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-5.2	4.07e-07	0.000212	-0.32	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
COAD	cis	rs13217239	0.646	rs4269366	ENSG00000224843.5	LINC00240	-5.2	4.08e-07	0.000212	-0.36	-0.31	Schizophrenia;	chr6:27048634	chr6:26956992~27023924:+
COAD	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	5.2	4.08e-07	0.000212	0.35	0.31	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
COAD	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-5.2	4.08e-07	0.000212	-0.33	-0.31	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-5.2	4.08e-07	0.000212	-0.33	-0.31	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-5.2	4.08e-07	0.000212	-0.33	-0.31	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-5.2	4.08e-07	0.000212	-0.33	-0.31	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
COAD	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-5.2	4.08e-07	0.000212	-0.33	-0.31	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
COAD	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	5.2	4.08e-07	0.000212	0.33	0.31	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-5.2	4.09e-07	0.000212	-0.35	-0.31	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
COAD	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	5.2	4.09e-07	0.000212	0.41	0.31	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
COAD	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-5.2	4.09e-07	0.000212	-0.39	-0.31	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
COAD	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	5.2	4.1e-07	0.000213	0.34	0.31	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
COAD	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	5.2	4.1e-07	0.000213	0.38	0.31	Depression;	chr6:28363475	chr6:28943877~28944537:+
COAD	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.2	4.1e-07	0.000213	-0.27	-0.31	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
COAD	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	5.2	4.11e-07	0.000213	0.41	0.31	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
COAD	cis	rs440932	1	rs378974	ENSG00000173295.6	FAM86B3P	5.2	4.11e-07	0.000213	0.42	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8228595~8244865:+
COAD	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	5.2	4.11e-07	0.000214	0.31	0.31	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
COAD	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-5.2	4.12e-07	0.000214	-0.2	-0.31	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
COAD	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	5.2	4.12e-07	0.000214	0.38	0.31	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
COAD	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	5.2	4.13e-07	0.000214	0.37	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
COAD	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	5.2	4.13e-07	0.000214	0.32	0.31	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
COAD	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-5.2	4.14e-07	0.000215	-0.38	-0.31	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
COAD	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-5.2	4.15e-07	0.000215	-0.41	-0.31	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
COAD	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-5.2	4.15e-07	0.000215	-0.31	-0.31	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
COAD	cis	rs1056107	0.933	rs12376681	ENSG00000225513.1	RP11-165N19.2	-5.2	4.15e-07	0.000215	-0.36	-0.31	Colorectal cancer;	chr9:112297115	chr9:112173522~112173971:-
COAD	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-5.2	4.15e-07	0.000216	-0.35	-0.31	Height;	chr20:49241753	chr20:49280319~49280409:+
COAD	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-5.2	4.16e-07	0.000216	-0.35	-0.31	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
COAD	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	5.2	4.16e-07	0.000216	0.47	0.31	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
COAD	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-5.2	4.16e-07	0.000216	-0.35	-0.31	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
COAD	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-5.2	4.16e-07	0.000216	-0.33	-0.31	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
COAD	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-5.2	4.17e-07	0.000216	-0.33	-0.31	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
COAD	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-5.2	4.17e-07	0.000216	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
COAD	cis	rs911186	0.68	rs34783558	ENSG00000224843.5	LINC00240	5.2	4.17e-07	0.000216	0.52	0.31	Autism spectrum disorder or schizophrenia;	chr6:27203921	chr6:26956992~27023924:+
COAD	cis	rs3126085	0.515	rs10788836	ENSG00000237975.5	FLG-AS1	5.19	4.17e-07	0.000216	0.34	0.31	Atopic dermatitis;	chr1:152377659	chr1:152168125~152445456:+
COAD	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-5.19	4.17e-07	0.000216	-0.32	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
COAD	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	5.19	4.17e-07	0.000216	0.3	0.31	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
COAD	cis	rs4568518	0.804	rs12154596	ENSG00000279048.1	RP11-511H23.2	5.19	4.18e-07	0.000217	0.23	0.31	Measles;	chr7:17986681	chr7:17940503~17942922:+
COAD	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	5.19	4.18e-07	0.000217	0.35	0.31	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
COAD	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-5.19	4.18e-07	0.000217	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	5.19	4.18e-07	0.000217	0.35	0.31	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
COAD	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-5.19	4.18e-07	0.000217	-0.41	-0.31	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
COAD	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	5.19	4.18e-07	0.000217	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
COAD	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	5.19	4.19e-07	0.000217	0.35	0.31	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
COAD	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	5.19	4.19e-07	0.000217	0.33	0.31	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
COAD	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	5.19	4.19e-07	0.000217	0.36	0.31	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
COAD	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	5.19	4.19e-07	0.000217	0.4	0.31	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
COAD	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	5.19	4.19e-07	0.000217	0.4	0.31	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
COAD	cis	rs7688540	0.8	rs9328737	ENSG00000211553.1	AC253576.2	-5.19	4.19e-07	0.000217	-0.48	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:136461~136568:+
COAD	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	5.19	4.19e-07	0.000217	0.36	0.31	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
COAD	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	5.19	4.2e-07	0.000218	0.45	0.31	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
COAD	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-5.19	4.21e-07	0.000218	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
COAD	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-5.19	4.21e-07	0.000218	-0.45	-0.31	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
COAD	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.19	4.21e-07	0.000218	0.26	0.31	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
COAD	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	5.19	4.21e-07	0.000218	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	5.19	4.21e-07	0.000218	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	5.19	4.21e-07	0.000218	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
COAD	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	5.19	4.21e-07	0.000218	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	5.19	4.21e-07	0.000218	0.35	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
COAD	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	5.19	4.21e-07	0.000218	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
COAD	cis	rs12935418	0.672	rs1453328	ENSG00000278985.1	RP11-303E16.9	5.19	4.21e-07	0.000218	0.34	0.31	Mean corpuscular volume;	chr16:81019240	chr16:80982319~80984094:-
COAD	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-5.19	4.22e-07	0.000218	-0.38	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
COAD	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	5.19	4.22e-07	0.000219	0.28	0.31	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	5.19	4.22e-07	0.000219	0.28	0.31	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
COAD	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	5.19	4.23e-07	0.000219	0.36	0.31	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
COAD	cis	rs4568518	0.71	rs6966083	ENSG00000279048.1	RP11-511H23.2	5.19	4.23e-07	0.000219	0.23	0.31	Measles;	chr7:17976921	chr7:17940503~17942922:+
COAD	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-5.19	4.23e-07	0.000219	-0.37	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
COAD	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	5.19	4.24e-07	0.000219	0.74	0.31	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
COAD	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	5.19	4.25e-07	0.00022	0.41	0.31	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-5.19	4.25e-07	0.00022	-0.41	-0.31	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
COAD	cis	rs801193	0.935	rs3800820	ENSG00000272831.1	RP11-792A8.4	-5.19	4.26e-07	0.00022	-0.33	-0.31	Aortic root size;	chr7:66682191	chr7:66739829~66740385:-
COAD	cis	rs440932	1	rs365309	ENSG00000173295.6	FAM86B3P	-5.19	4.26e-07	0.00022	-0.41	-0.31	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.951	rs13270852	ENSG00000173295.6	FAM86B3P	5.19	4.26e-07	0.00022	0.44	0.31	Obesity-related traits;	chr8:8709343	chr8:8228595~8244865:+
COAD	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	5.19	4.27e-07	0.000221	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
COAD	cis	rs6840360	0.642	rs2709842	ENSG00000251611.1	RP11-610P16.1	5.19	4.27e-07	0.000221	0.29	0.31	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151407551~151408835:-
COAD	cis	rs13256369	0.802	rs11995449	ENSG00000173295.6	FAM86B3P	5.19	4.27e-07	0.000221	0.44	0.31	Obesity-related traits;	chr8:8702388	chr8:8228595~8244865:+
COAD	cis	rs7818688	0.697	rs11781757	ENSG00000253528.2	RP11-347C18.4	-5.19	4.28e-07	0.000221	-0.45	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975663	chr8:94974573~94974853:-
COAD	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	5.19	4.28e-07	0.000221	0.21	0.31	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
COAD	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-5.19	4.28e-07	0.000221	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
COAD	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-5.19	4.28e-07	0.000221	-0.34	-0.31	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
COAD	cis	rs5015933	0.815	rs13297440	ENSG00000232630.1	PRPS1P2	-5.19	4.28e-07	0.000221	-0.31	-0.31	Body mass index;	chr9:125324921	chr9:125150653~125151589:+
COAD	cis	rs9309473	0.5	rs1528169	ENSG00000163016.8	ALMS1P	-5.19	4.28e-07	0.000221	-0.38	-0.31	Metabolite levels;	chr2:73442058	chr2:73644919~73685576:+
COAD	cis	rs1790761	0.501	rs4930210	ENSG00000231793.4	DOC2GP	-5.19	4.28e-07	0.000221	-0.37	-0.31	Mean corpuscular volume;	chr11:67637255	chr11:67612653~67616257:-
COAD	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	5.19	4.29e-07	0.000222	0.35	0.31	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
COAD	cis	rs9309473	0.5	rs12996463	ENSG00000163016.8	ALMS1P	-5.19	4.29e-07	0.000222	-0.37	-0.31	Metabolite levels;	chr2:73428368	chr2:73644919~73685576:+
COAD	cis	rs362272	0.505	rs13104157	ENSG00000248840.2	RP11-357G3.2	-5.19	4.29e-07	0.000222	-0.35	-0.31	Serum sulfate level;	chr4:3365223	chr4:3312512~3313058:+
COAD	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	5.19	4.29e-07	0.000222	0.34	0.31	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
COAD	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	5.19	4.3e-07	0.000222	0.31	0.31	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
COAD	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-5.19	4.3e-07	0.000222	-0.37	-0.31	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
COAD	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-5.19	4.3e-07	0.000222	-0.31	-0.31	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
COAD	cis	rs58873874	0.737	rs9313608	ENSG00000248544.2	CTB-47B11.3	-5.19	4.31e-07	0.000223	-0.68	-0.31	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157375741~157384950:-
COAD	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-5.19	4.31e-07	0.000223	-0.37	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
COAD	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	5.19	4.32e-07	0.000223	0.31	0.31	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
COAD	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	5.19	4.32e-07	0.000223	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
COAD	cis	rs9951698	0.703	rs7233600	ENSG00000266969.1	RP11-773H22.4	5.19	4.32e-07	0.000223	0.4	0.31	Intelligence (multi-trait analysis);	chr18:12986001	chr18:12984694~12991173:-
COAD	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	5.19	4.32e-07	0.000223	0.48	0.31	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
COAD	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	5.19	4.33e-07	0.000223	0.29	0.31	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
COAD	cis	rs9951698	0.703	rs6505776	ENSG00000266969.1	RP11-773H22.4	5.19	4.33e-07	0.000223	0.4	0.31	Intelligence (multi-trait analysis);	chr18:12984145	chr18:12984694~12991173:-
COAD	cis	rs6452524	0.563	rs10473863	ENSG00000271862.1	RP11-343L5.2	5.19	4.33e-07	0.000223	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83049376~83050964:-
COAD	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	5.19	4.33e-07	0.000223	0.44	0.31	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
COAD	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-5.19	4.33e-07	0.000224	-0.28	-0.31	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
COAD	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-5.19	4.34e-07	0.000224	-0.52	-0.31	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
COAD	cis	rs7560272	0.723	rs12995433	ENSG00000163016.8	ALMS1P	-5.19	4.34e-07	0.000224	-0.37	-0.31	Schizophrenia;	chr2:73414198	chr2:73644919~73685576:+
COAD	cis	rs4761702	0.922	rs11106975	ENSG00000257252.4	RP11-486A14.2	-5.19	4.35e-07	0.000225	-0.38	-0.31	Immature fraction of reticulocytes;	chr12:93327178	chr12:93317135~93377736:-
COAD	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	5.19	4.36e-07	0.000225	0.33	0.31	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
COAD	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	5.19	4.37e-07	0.000225	0.29	0.31	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	5.19	4.37e-07	0.000225	0.29	0.31	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	5.19	4.37e-07	0.000225	0.29	0.31	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
COAD	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	5.19	4.37e-07	0.000225	0.34	0.31	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
COAD	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-5.19	4.38e-07	0.000226	-0.35	-0.31	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
COAD	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-5.19	4.38e-07	0.000226	-0.35	-0.31	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
COAD	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-5.19	4.38e-07	0.000226	-0.35	-0.31	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
COAD	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	5.19	4.38e-07	0.000226	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
COAD	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-5.18	4.38e-07	0.000226	-0.34	-0.31	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
COAD	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-5.18	4.39e-07	0.000226	-0.4	-0.31	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
COAD	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	5.18	4.39e-07	0.000226	0.41	0.31	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	5.18	4.39e-07	0.000226	0.41	0.31	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
COAD	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	5.18	4.39e-07	0.000226	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
COAD	cis	rs2732480	0.577	rs2634680	ENSG00000273765.1	RP11-370I10.11	5.18	4.39e-07	0.000226	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2634678	ENSG00000273765.1	RP11-370I10.11	5.18	4.39e-07	0.000226	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2732479	ENSG00000273765.1	RP11-370I10.11	5.18	4.39e-07	0.000226	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.537	rs1061986	ENSG00000273765.1	RP11-370I10.11	5.18	4.39e-07	0.000226	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48360920~48361377:+
COAD	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-5.18	4.39e-07	0.000226	-0.33	-0.31	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
COAD	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	5.18	4.4e-07	0.000227	0.23	0.31	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
COAD	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-5.18	4.4e-07	0.000227	-0.28	-0.31	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
COAD	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	5.18	4.4e-07	0.000227	0.27	0.31	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
COAD	cis	rs13256369	0.851	rs13267036	ENSG00000173295.6	FAM86B3P	5.18	4.4e-07	0.000227	0.44	0.31	Obesity-related traits;	chr8:8709175	chr8:8228595~8244865:+
COAD	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-5.18	4.41e-07	0.000227	-0.4	-0.31	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
COAD	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-5.18	4.41e-07	0.000227	-0.4	-0.31	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-5.18	4.41e-07	0.000227	-0.4	-0.31	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
COAD	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	5.18	4.41e-07	0.000227	0.48	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
COAD	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-5.18	4.41e-07	0.000227	-0.34	-0.31	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
COAD	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	5.18	4.42e-07	0.000228	0.55	0.31	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
COAD	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-5.18	4.42e-07	0.000228	-0.41	-0.31	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-5.18	4.42e-07	0.000228	-0.41	-0.31	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-5.18	4.42e-07	0.000228	-0.41	-0.31	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-5.18	4.42e-07	0.000228	-0.41	-0.31	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
COAD	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	5.18	4.42e-07	0.000228	0.81	0.31	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
COAD	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	5.18	4.42e-07	0.000228	0.4	0.31	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
COAD	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	5.18	4.43e-07	0.000228	0.34	0.31	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	5.18	4.43e-07	0.000228	0.34	0.31	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
COAD	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-5.18	4.43e-07	0.000228	-0.32	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
COAD	cis	rs28374715	0.662	rs72737786	ENSG00000247556.5	OIP5-AS1	5.18	4.44e-07	0.000228	0.41	0.31	Ulcerative colitis;	chr15:41208163	chr15:41283990~41309737:+
COAD	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	5.18	4.44e-07	0.000229	0.41	0.31	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	5.18	4.44e-07	0.000229	0.41	0.31	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
COAD	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	5.18	4.44e-07	0.000229	0.42	0.31	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
COAD	cis	rs2281603	0.951	rs12385918	ENSG00000259116.1	RP11-973N13.4	-5.18	4.44e-07	0.000229	-0.32	-0.31	Lymphocyte counts;	chr14:64533227	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	5.18	4.45e-07	0.000229	0.35	0.31	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
COAD	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-5.18	4.46e-07	0.000229	-0.47	-0.31	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
COAD	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-5.18	4.46e-07	0.000229	-0.36	-0.31	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
COAD	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-5.18	4.46e-07	0.00023	-0.32	-0.31	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
COAD	cis	rs13256369	0.755	rs12680167	ENSG00000173295.6	FAM86B3P	5.18	4.47e-07	0.00023	0.44	0.31	Obesity-related traits;	chr8:8704957	chr8:8228595~8244865:+
COAD	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	5.18	4.47e-07	0.00023	0.32	0.31	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
COAD	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	5.18	4.48e-07	0.00023	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	5.18	4.48e-07	0.00023	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	5.18	4.48e-07	0.00023	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
COAD	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	5.18	4.48e-07	0.00023	0.33	0.31	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
COAD	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	5.18	4.48e-07	0.00023	0.35	0.31	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
COAD	cis	rs58873874	0.579	rs77042939	ENSG00000251405.2	CTB-109A12.1	5.18	4.49e-07	0.000231	0.61	0.31	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157362615~157460078:-
COAD	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-5.18	4.49e-07	0.000231	-0.38	-0.31	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
COAD	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	5.18	4.49e-07	0.000231	0.31	0.31	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
COAD	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-5.18	4.49e-07	0.000231	-0.39	-0.31	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
COAD	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-5.18	4.49e-07	0.000231	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
COAD	cis	rs7688540	0.76	rs7687833	ENSG00000211553.1	AC253576.2	-5.18	4.5e-07	0.000231	-0.46	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:136461~136568:+
COAD	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	5.18	4.5e-07	0.000231	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
COAD	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-5.18	4.5e-07	0.000231	-0.44	-0.31	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-5.18	4.5e-07	0.000231	-0.44	-0.31	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
COAD	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-5.18	4.51e-07	0.000232	-0.35	-0.31	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
COAD	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	5.18	4.51e-07	0.000232	0.4	0.31	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	5.18	4.51e-07	0.000232	0.4	0.31	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
COAD	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	5.18	4.51e-07	0.000232	0.42	0.31	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
COAD	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-5.18	4.52e-07	0.000232	-0.53	-0.31	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
COAD	cis	rs7647973	0.56	rs7638154	ENSG00000225399.4	RP11-3B7.1	5.18	4.52e-07	0.000232	0.35	0.31	Menarche (age at onset);	chr3:49261942	chr3:49260085~49261316:+
COAD	cis	rs58873874	0.737	rs11744671	ENSG00000251405.2	CTB-109A12.1	5.18	4.52e-07	0.000232	0.74	0.31	Bipolar disorder (body mass index interaction);	chr5:157494223	chr5:157362615~157460078:-
COAD	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	5.18	4.52e-07	0.000232	0.65	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
COAD	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	5.18	4.54e-07	0.000233	0.58	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
COAD	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	5.18	4.54e-07	0.000233	0.37	0.31	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
COAD	cis	rs7646881	0.5	rs2082838	ENSG00000272087.1	RP11-379F4.7	-5.18	4.55e-07	0.000234	-0.46	-0.31	Tetralogy of Fallot;	chr3:158588105	chr3:158693120~158693768:-
COAD	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-5.18	4.55e-07	0.000234	-0.27	-0.31	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
COAD	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-5.18	4.56e-07	0.000234	-0.34	-0.31	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
COAD	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	5.18	4.56e-07	0.000234	0.4	0.31	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
COAD	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-5.18	4.56e-07	0.000234	-0.27	-0.31	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
COAD	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-5.18	4.57e-07	0.000234	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-5.18	4.57e-07	0.000234	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
COAD	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	5.18	4.57e-07	0.000234	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
COAD	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-5.18	4.57e-07	0.000234	-0.42	-0.31	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
COAD	cis	rs4568518	0.71	rs12699929	ENSG00000279048.1	RP11-511H23.2	5.18	4.57e-07	0.000234	0.22	0.31	Measles;	chr7:17972634	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.71	rs12699930	ENSG00000279048.1	RP11-511H23.2	5.18	4.57e-07	0.000234	0.22	0.31	Measles;	chr7:17972635	chr7:17940503~17942922:+
COAD	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	5.18	4.57e-07	0.000235	0.34	0.31	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
COAD	cis	rs911186	0.812	rs3800316	ENSG00000224843.5	LINC00240	5.18	4.57e-07	0.000235	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:27288323	chr6:26956992~27023924:+
COAD	cis	rs1790761	0.692	rs10896179	ENSG00000231793.4	DOC2GP	5.18	4.58e-07	0.000235	0.35	0.31	Mean corpuscular volume;	chr11:67549457	chr11:67612653~67616257:-
COAD	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-5.18	4.58e-07	0.000235	-0.43	-0.31	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
COAD	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	5.17	4.6e-07	0.000236	0.34	0.31	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
COAD	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-5.17	4.6e-07	0.000236	-0.17	-0.31	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
COAD	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	5.17	4.6e-07	0.000236	0.33	0.31	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
COAD	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	5.17	4.6e-07	0.000236	0.33	0.31	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
COAD	cis	rs492146	0.765	rs673197	ENSG00000243236.5	GSTA9P	-5.17	4.61e-07	0.000236	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52979459	chr6:52939726~52957521:-
COAD	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.17	4.61e-07	0.000236	0.41	0.31	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
COAD	cis	rs7617480	0.519	rs6790914	ENSG00000225399.4	RP11-3B7.1	5.17	4.61e-07	0.000236	0.35	0.31	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49260085~49261316:+
COAD	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-5.17	4.62e-07	0.000237	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	5.17	4.62e-07	0.000237	0.35	0.31	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
COAD	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-5.17	4.63e-07	0.000237	-0.41	-0.31	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-5.17	4.63e-07	0.000237	-0.41	-0.31	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-5.17	4.63e-07	0.000237	-0.41	-0.31	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.17	4.63e-07	0.000237	-0.41	-0.31	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-5.17	4.63e-07	0.000237	-0.41	-0.31	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
COAD	cis	rs453301	0.658	rs6986044	ENSG00000253981.4	ALG1L13P	-5.17	4.63e-07	0.000237	-0.37	-0.31	Joint mobility (Beighton score);	chr8:9017276	chr8:8236003~8244667:-
COAD	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-5.17	4.63e-07	0.000237	-0.47	-0.31	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
COAD	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.17	4.64e-07	0.000237	0.35	0.31	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
COAD	cis	rs7829975	0.807	rs519019	ENSG00000253981.4	ALG1L13P	-5.17	4.64e-07	0.000237	-0.36	-0.31	Mood instability;	chr8:8737594	chr8:8236003~8244667:-
COAD	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	5.17	4.64e-07	0.000237	0.56	0.31	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	5.17	4.65e-07	0.000238	0.54	0.31	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	5.17	4.65e-07	0.000238	0.54	0.31	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
COAD	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-5.17	4.65e-07	0.000238	-0.34	-0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
COAD	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	5.17	4.66e-07	0.000238	0.74	0.31	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	5.17	4.66e-07	0.000238	0.74	0.31	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
COAD	cis	rs7209700	0.547	rs10514919	ENSG00000228782.6	CTD-2026D20.3	-5.17	4.66e-07	0.000238	-0.36	-0.31	IgG glycosylation;	chr17:47264763	chr17:47450568~47492492:-
COAD	cis	rs5742933	1	rs55792400	ENSG00000253559.1	OSGEPL1-AS1	-5.17	4.67e-07	0.000239	-0.33	-0.31	Ferritin levels;	chr2:189686708	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.947	rs62185871	ENSG00000253559.1	OSGEPL1-AS1	-5.17	4.67e-07	0.000239	-0.33	-0.31	Ferritin levels;	chr2:189686980	chr2:189762704~189765556:+
COAD	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	5.17	4.68e-07	0.000239	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
COAD	cis	rs4964805	0.507	rs4964786	ENSG00000257681.1	RP11-341G23.4	5.17	4.68e-07	0.000239	0.3	0.31	Attention deficit hyperactivity disorder;	chr12:103810805	chr12:103746315~103768858:-
COAD	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	5.17	4.68e-07	0.000239	0.27	0.31	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
COAD	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	5.17	4.68e-07	0.000239	0.46	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
COAD	cis	rs6452524	0.506	rs7891	ENSG00000271862.1	RP11-343L5.2	5.17	4.68e-07	0.000239	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83049376~83050964:-
COAD	cis	rs453301	0.522	rs1964356	ENSG00000233609.3	RP11-62H7.2	5.17	4.69e-07	0.00024	0.35	0.31	Joint mobility (Beighton score);	chr8:8995760	chr8:8961200~8979025:+
COAD	cis	rs5015933	0.902	rs2841333	ENSG00000232630.1	PRPS1P2	-5.17	4.69e-07	0.00024	-0.31	-0.31	Body mass index;	chr9:125364368	chr9:125150653~125151589:+
COAD	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-5.17	4.69e-07	0.00024	-0.47	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
COAD	cis	rs9309473	0.519	rs2421545	ENSG00000163016.8	ALMS1P	-5.17	4.69e-07	0.00024	-0.37	-0.31	Metabolite levels;	chr2:73412348	chr2:73644919~73685576:+
COAD	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-5.17	4.69e-07	0.00024	-0.4	-0.31	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
COAD	cis	rs11089937	0.626	rs4821784	ENSG00000211639.2	IGLV4-60	5.17	4.69e-07	0.00024	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22162199~22162681:+
COAD	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-5.17	4.7e-07	0.00024	-0.27	-0.31	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
COAD	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	5.17	4.7e-07	0.00024	0.35	0.31	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
COAD	cis	rs5015933	0.815	rs3104550	ENSG00000232630.1	PRPS1P2	-5.17	4.7e-07	0.00024	-0.31	-0.31	Body mass index;	chr9:125348573	chr9:125150653~125151589:+
COAD	cis	rs13256369	0.708	rs11783670	ENSG00000173295.6	FAM86B3P	5.17	4.7e-07	0.00024	0.44	0.31	Obesity-related traits;	chr8:8701884	chr8:8228595~8244865:+
COAD	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-5.17	4.7e-07	0.00024	-0.35	-0.31	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
COAD	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-5.17	4.7e-07	0.00024	-0.26	-0.31	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
COAD	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	5.17	4.71e-07	0.000241	0.38	0.31	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
COAD	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	5.17	4.71e-07	0.000241	0.38	0.31	Temperament;	chr17:13996939	chr17:14024514~14025488:+
COAD	cis	rs2732480	0.577	rs2732466	ENSG00000273765.1	RP11-370I10.11	5.17	4.72e-07	0.000241	0.36	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48360920~48361377:+
COAD	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	5.17	4.73e-07	0.000241	0.32	0.31	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
COAD	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-5.17	4.73e-07	0.000242	-0.3	-0.31	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
COAD	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-5.17	4.73e-07	0.000242	-0.3	-0.31	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
COAD	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-5.17	4.73e-07	0.000242	-0.32	-0.31	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
COAD	cis	rs453301	0.686	rs7814328	ENSG00000173295.6	FAM86B3P	-5.17	4.73e-07	0.000242	-0.36	-0.31	Joint mobility (Beighton score);	chr8:9018719	chr8:8228595~8244865:+
COAD	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
COAD	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
COAD	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
COAD	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	5.17	4.74e-07	0.000242	0.31	0.31	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
COAD	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	5.17	4.74e-07	0.000242	0.4	0.31	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
COAD	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	5.17	4.74e-07	0.000242	0.28	0.31	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
COAD	cis	rs5758511	0.68	rs1033460	ENSG00000237037.8	NDUFA6-AS1	-5.17	4.75e-07	0.000242	-0.37	-0.31	Birth weight;	chr22:42223302	chr22:42090931~42137742:+
COAD	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-5.17	4.75e-07	0.000242	-0.2	-0.31	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-5.17	4.75e-07	0.000242	-0.2	-0.31	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
COAD	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-5.17	4.75e-07	0.000243	-0.31	-0.31	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
COAD	cis	rs17772222	0.597	rs17700521	ENSG00000258789.1	RP11-507K2.3	-5.17	4.75e-07	0.000243	-0.46	-0.31	Coronary artery calcification;	chr14:88849531	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	5.17	4.76e-07	0.000243	0.37	0.31	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
COAD	cis	rs10515750	0.53	rs2288068	ENSG00000248544.2	CTB-47B11.3	5.17	4.76e-07	0.000243	0.59	0.31	Lung function (FEV1/FVC);	chr5:157287128	chr5:157375741~157384950:-
COAD	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-5.17	4.76e-07	0.000243	-0.35	-0.31	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
COAD	cis	rs11089937	0.626	rs11089933	ENSG00000211639.2	IGLV4-60	5.17	4.76e-07	0.000243	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22162199~22162681:+
COAD	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-5.17	4.77e-07	0.000243	-0.33	-0.31	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
COAD	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-5.17	4.77e-07	0.000243	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
COAD	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	5.17	4.78e-07	0.000243	0.34	0.31	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
COAD	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-5.17	4.78e-07	0.000243	-0.28	-0.31	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
COAD	cis	rs7829975	0.572	rs28446104	ENSG00000253981.4	ALG1L13P	-5.17	4.78e-07	0.000244	-0.38	-0.31	Mood instability;	chr8:8938391	chr8:8236003~8244667:-
COAD	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-5.17	4.79e-07	0.000244	-0.38	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
COAD	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-5.17	4.79e-07	0.000244	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-5.17	4.79e-07	0.000244	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-5.17	4.79e-07	0.000244	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-5.17	4.79e-07	0.000244	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-5.17	4.79e-07	0.000244	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
COAD	cis	rs754466	0.606	rs7084705	ENSG00000204049.1	RP11-126H7.4	5.17	4.8e-07	0.000244	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836917	chr10:77866875~77869610:+
COAD	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-5.17	4.8e-07	0.000245	-0.43	-0.31	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
COAD	cis	rs55823223	0.564	rs1463485	ENSG00000267801.1	RP11-552F3.9	5.17	4.81e-07	0.000245	0.42	0.31	Psoriasis;	chr17:75855710	chr17:75876372~75879546:+
COAD	cis	rs1387259	0.69	rs1601985	ENSG00000257735.1	RP11-370I10.6	5.17	4.81e-07	0.000245	0.38	0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48350945~48442411:+
COAD	cis	rs7818688	0.697	rs76215523	ENSG00000253528.2	RP11-347C18.4	-5.17	4.82e-07	0.000245	-0.44	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974787	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs3802192	ENSG00000253528.2	RP11-347C18.4	-5.17	4.82e-07	0.000245	-0.44	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975243	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11784140	ENSG00000253528.2	RP11-347C18.4	-5.17	4.82e-07	0.000245	-0.44	-0.31	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975252	chr8:94974573~94974853:-
COAD	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-5.17	4.82e-07	0.000245	-0.25	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
COAD	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-5.17	4.82e-07	0.000245	-0.29	-0.31	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
COAD	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	5.16	4.83e-07	0.000246	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	5.16	4.83e-07	0.000246	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	5.16	4.83e-07	0.000246	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	5.16	4.83e-07	0.000246	0.34	0.31	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	5.16	4.83e-07	0.000246	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
COAD	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-5.16	4.83e-07	0.000246	-0.38	-0.31	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-5.16	4.83e-07	0.000246	-0.38	-0.31	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
COAD	cis	rs9309473	0.5	rs4286298	ENSG00000163016.8	ALMS1P	-5.16	4.83e-07	0.000246	-0.37	-0.31	Metabolite levels;	chr2:73654981	chr2:73644919~73685576:+
COAD	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-5.16	4.84e-07	0.000246	-0.33	-0.31	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
COAD	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	5.16	4.84e-07	0.000246	0.36	0.31	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
COAD	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-5.16	4.85e-07	0.000247	-0.37	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
COAD	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	5.16	4.85e-07	0.000247	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
COAD	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-5.16	4.86e-07	0.000247	-0.49	-0.31	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
COAD	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-5.16	4.86e-07	0.000247	-0.34	-0.31	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
COAD	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-5.16	4.86e-07	0.000247	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
COAD	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-5.16	4.86e-07	0.000247	-0.39	-0.31	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
COAD	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-5.16	4.87e-07	0.000248	-0.18	-0.31	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
COAD	cis	rs6840360	0.642	rs2709838	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2724580	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709834	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs6845648	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2724571	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709833	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.667	rs2709832	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709816	ENSG00000251611.1	RP11-610P16.1	-5.16	4.87e-07	0.000248	-0.29	-0.31	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151407551~151408835:-
COAD	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-5.16	4.87e-07	0.000248	-0.38	-0.31	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
COAD	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	5.16	4.88e-07	0.000248	0.39	0.31	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
COAD	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	5.16	4.88e-07	0.000248	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	5.16	4.88e-07	0.000248	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
COAD	cis	rs12935418	0.616	rs2549858	ENSG00000278985.1	RP11-303E16.9	-5.16	4.88e-07	0.000248	-0.33	-0.31	Mean corpuscular volume;	chr16:80993389	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs2549859	ENSG00000278985.1	RP11-303E16.9	-5.16	4.88e-07	0.000248	-0.33	-0.31	Mean corpuscular volume;	chr16:80993398	chr16:80982319~80984094:-
COAD	cis	rs6452524	0.534	rs72765386	ENSG00000271862.1	RP11-343L5.2	5.16	4.88e-07	0.000248	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83049376~83050964:-
COAD	cis	rs7560272	0.723	rs4852927	ENSG00000163016.8	ALMS1P	-5.16	4.88e-07	0.000248	-0.37	-0.31	Schizophrenia;	chr2:73414429	chr2:73644919~73685576:+
COAD	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	5.16	4.89e-07	0.000248	0.42	0.31	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
COAD	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-5.16	4.89e-07	0.000248	-0.38	-0.31	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
COAD	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-5.16	4.89e-07	0.000248	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
COAD	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-5.16	4.89e-07	0.000249	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
COAD	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	5.16	4.9e-07	0.000249	0.31	0.31	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
COAD	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.16	4.9e-07	0.000249	0.36	0.31	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
COAD	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-5.16	4.9e-07	0.000249	-0.27	-0.31	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
COAD	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-5.16	4.9e-07	0.000249	-0.34	-0.31	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
COAD	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-5.16	4.9e-07	0.000249	-0.52	-0.31	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
COAD	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-5.16	4.91e-07	0.000249	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-5.16	4.91e-07	0.000249	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
COAD	cis	rs7221109	0.884	rs7226035	ENSG00000278834.1	RP11-458J1.1	5.16	4.92e-07	0.00025	0.32	0.31	Type 1 diabetes;	chr17:40626034	chr17:40648300~40649718:+
COAD	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	5.16	4.93e-07	0.00025	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
COAD	cis	rs860818	1	rs858277	ENSG00000226816.2	AC005082.12	-5.16	4.93e-07	0.00025	-0.73	-0.31	Initial pursuit acceleration;	chr7:23212642	chr7:23206013~23208045:+
COAD	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.16	4.94e-07	0.000251	-0.39	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
COAD	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	5.16	4.94e-07	0.000251	0.33	0.31	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
COAD	cis	rs198389	0.568	rs12406667	ENSG00000242349.4	NPPA-AS1	5.16	4.95e-07	0.000251	0.32	0.31	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813794	chr1:11841017~11848079:+
COAD	cis	rs3813567	0.759	rs12595350	ENSG00000261143.1	ADAMTS7P3	-5.16	4.95e-07	0.000251	-0.51	-0.31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661122	chr15:77976042~77993057:+
COAD	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	5.16	4.95e-07	0.000251	0.44	0.31	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
COAD	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.16	4.96e-07	0.000251	0.47	0.31	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
COAD	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	5.16	4.96e-07	0.000252	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	5.16	4.96e-07	0.000252	0.55	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
COAD	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-5.16	4.96e-07	0.000252	-0.37	-0.31	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
COAD	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	5.16	4.96e-07	0.000252	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
COAD	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-5.16	4.96e-07	0.000252	-0.27	-0.31	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
COAD	cis	rs9368481	0.569	rs10946868	ENSG00000224843.5	LINC00240	-5.16	4.97e-07	0.000252	-0.38	-0.31	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26956992~27023924:+
COAD	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	5.16	4.97e-07	0.000252	0.45	0.31	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
COAD	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-5.16	4.97e-07	0.000252	-0.33	-0.31	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
COAD	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	5.16	4.98e-07	0.000252	0.33	0.31	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
COAD	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	5.16	4.98e-07	0.000253	0.33	0.31	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
COAD	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-5.16	4.98e-07	0.000253	-0.45	-0.31	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
COAD	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-5.16	4.99e-07	0.000253	-0.18	-0.31	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
COAD	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	5.16	5e-07	0.000253	0.57	0.31	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	5.16	5e-07	0.000253	0.57	0.31	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
COAD	cis	rs4950322	0.744	rs2353987	ENSG00000278811.3	LINC00624	5.16	5e-07	0.000253	0.32	0.31	Protein quantitative trait loci;	chr1:147355845	chr1:147258885~147517875:-
COAD	cis	rs9951698	0.66	rs12955780	ENSG00000266969.1	RP11-773H22.4	5.16	5e-07	0.000253	0.4	0.31	Intelligence (multi-trait analysis);	chr18:12982761	chr18:12984694~12991173:-
COAD	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	5.16	5e-07	0.000253	0.39	0.31	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
COAD	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	5.16	5e-07	0.000254	0.3	0.31	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
COAD	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	5.16	5e-07	0.000254	0.18	0.31	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
COAD	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	5.16	5.01e-07	0.000254	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	5.16	5.03e-07	0.000255	0.34	0.31	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
COAD	cis	rs13256369	1	rs10098234	ENSG00000173295.6	FAM86B3P	5.16	5.03e-07	0.000255	0.43	0.31	Obesity-related traits;	chr8:8719182	chr8:8228595~8244865:+
COAD	cis	rs13256369	1	rs10088439	ENSG00000173295.6	FAM86B3P	5.16	5.03e-07	0.000255	0.43	0.31	Obesity-related traits;	chr8:8719189	chr8:8228595~8244865:+
COAD	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-5.16	5.03e-07	0.000255	-0.37	-0.31	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
COAD	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	5.16	5.03e-07	0.000255	0.38	0.31	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
COAD	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	5.16	5.03e-07	0.000255	0.27	0.31	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
COAD	cis	rs7560272	0.695	rs780393	ENSG00000163016.8	ALMS1P	-5.16	5.03e-07	0.000255	-0.37	-0.31	Schizophrenia;	chr2:73474542	chr2:73644919~73685576:+
COAD	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-5.16	5.03e-07	0.000255	-0.37	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
COAD	cis	rs7078219	0.714	rs10883359	ENSG00000257582.4	LINC01475	5.16	5.03e-07	0.000255	0.35	0.31	Dental caries;	chr10:99514276	chr10:99526350~99531177:-
COAD	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-5.16	5.04e-07	0.000255	-0.18	-0.31	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-5.16	5.04e-07	0.000255	-0.18	-0.31	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
COAD	cis	rs5015933	0.902	rs1874943	ENSG00000232630.1	PRPS1P2	-5.16	5.04e-07	0.000255	-0.3	-0.31	Body mass index;	chr9:125361055	chr9:125150653~125151589:+
COAD	cis	rs11089937	0.626	rs9622968	ENSG00000211639.2	IGLV4-60	5.16	5.04e-07	0.000255	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.667	rs5757081	ENSG00000211639.2	IGLV4-60	5.16	5.04e-07	0.000255	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22162199~22162681:+
COAD	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	5.16	5.04e-07	0.000255	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
COAD	cis	rs4448343	1	rs16909919	ENSG00000271155.1	RP11-435O5.5	5.16	5.05e-07	0.000256	0.34	0.31	Height;	chr9:95503498	chr9:95506235~95507636:+
COAD	cis	rs453301	0.598	rs1025395	ENSG00000254340.1	RP11-10A14.3	5.16	5.05e-07	0.000256	0.36	0.31	Joint mobility (Beighton score);	chr8:8979093	chr8:9141424~9145435:+
COAD	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
COAD	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
COAD	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-5.16	5.05e-07	0.000256	-0.34	-0.31	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
COAD	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	5.16	5.06e-07	0.000256	0.3	0.31	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
COAD	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
COAD	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
COAD	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	5.16	5.06e-07	0.000256	0.31	0.31	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	5.16	5.06e-07	0.000256	0.34	0.31	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
COAD	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	5.15	5.07e-07	0.000256	0.37	0.31	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
COAD	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	5.15	5.07e-07	0.000256	0.32	0.31	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
COAD	cis	rs2732480	0.538	rs2468943	ENSG00000273765.1	RP11-370I10.11	-5.15	5.08e-07	0.000257	-0.35	-0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48360920~48361377:+
COAD	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-5.15	5.08e-07	0.000257	-0.52	-0.31	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
COAD	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	5.15	5.09e-07	0.000257	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
COAD	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	5.15	5.09e-07	0.000257	0.35	0.31	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
COAD	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	5.15	5.09e-07	0.000257	0.45	0.31	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
COAD	cis	rs17826219	0.561	rs4794869	ENSG00000263531.1	RP13-753N3.1	5.15	5.09e-07	0.000257	0.73	0.31	Body mass index;	chr17:30364082	chr17:30863921~30864940:-
COAD	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-5.15	5.09e-07	0.000257	-0.42	-0.31	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
COAD	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-5.15	5.1e-07	0.000257	-0.32	-0.31	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
COAD	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	5.15	5.1e-07	0.000257	0.26	0.31	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
COAD	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-5.15	5.1e-07	0.000258	-0.31	-0.31	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
COAD	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-5.15	5.11e-07	0.000258	-0.38	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
COAD	cis	rs9309473	0.519	rs7598901	ENSG00000163016.8	ALMS1P	-5.15	5.11e-07	0.000258	-0.38	-0.31	Metabolite levels;	chr2:73448717	chr2:73644919~73685576:+
COAD	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-5.15	5.11e-07	0.000258	-0.38	-0.31	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
COAD	cis	rs7560272	0.723	rs6743576	ENSG00000163016.8	ALMS1P	5.15	5.11e-07	0.000258	0.37	0.31	Schizophrenia;	chr2:73587206	chr2:73644919~73685576:+
COAD	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	5.15	5.11e-07	0.000258	0.35	0.31	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	5.15	5.11e-07	0.000258	0.35	0.31	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
COAD	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.11e-07	0.000258	-0.26	-0.31	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
COAD	cis	rs6452524	0.534	rs9293328	ENSG00000271862.1	RP11-343L5.2	5.15	5.12e-07	0.000258	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.534	rs11746747	ENSG00000271862.1	RP11-343L5.2	5.15	5.12e-07	0.000258	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83049376~83050964:-
COAD	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	5.15	5.12e-07	0.000259	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
COAD	cis	rs2281603	0.57	rs10136732	ENSG00000259116.1	RP11-973N13.4	-5.15	5.13e-07	0.000259	-0.3	-0.31	Lymphocyte counts;	chr14:64484255	chr14:64514154~64540368:-
COAD	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-5.15	5.13e-07	0.000259	-0.42	-0.31	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
COAD	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	5.15	5.13e-07	0.000259	0.35	0.31	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
COAD	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-5.15	5.13e-07	0.000259	-0.33	-0.31	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
COAD	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-5.15	5.14e-07	0.000259	-0.41	-0.31	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-5.15	5.14e-07	0.000259	-0.37	-0.31	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
COAD	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.14e-07	0.000259	-0.26	-0.31	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.14e-07	0.000259	-0.26	-0.31	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.14e-07	0.000259	-0.26	-0.31	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.14e-07	0.000259	-0.26	-0.31	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
COAD	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	5.15	5.14e-07	0.000259	0.36	0.31	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	5.15	5.14e-07	0.000259	0.36	0.31	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
COAD	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	5.15	5.14e-07	0.00026	0.27	0.31	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
COAD	cis	rs12935418	0.616	rs2549863	ENSG00000278985.1	RP11-303E16.9	-5.15	5.14e-07	0.00026	-0.32	-0.31	Mean corpuscular volume;	chr16:80995762	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs1469123	ENSG00000278985.1	RP11-303E16.9	-5.15	5.14e-07	0.00026	-0.32	-0.31	Mean corpuscular volume;	chr16:80995944	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs1469124	ENSG00000278985.1	RP11-303E16.9	-5.15	5.14e-07	0.00026	-0.32	-0.31	Mean corpuscular volume;	chr16:80996049	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs1469125	ENSG00000278985.1	RP11-303E16.9	-5.15	5.14e-07	0.00026	-0.32	-0.31	Mean corpuscular volume;	chr16:80996163	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.523	rs1469126	ENSG00000278985.1	RP11-303E16.9	-5.15	5.14e-07	0.00026	-0.32	-0.31	Mean corpuscular volume;	chr16:80996284	chr16:80982319~80984094:-
COAD	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	5.15	5.15e-07	0.00026	0.27	0.31	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
COAD	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-5.15	5.15e-07	0.00026	-0.35	-0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
COAD	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.15	5.15e-07	0.00026	0.32	0.31	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
COAD	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-5.15	5.15e-07	0.00026	-0.31	-0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
COAD	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-5.15	5.15e-07	0.00026	-0.27	-0.31	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5.15	5.16e-07	0.00026	-0.27	-0.31	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
COAD	cis	rs1790761	0.504	rs61894496	ENSG00000255318.1	RP11-655M14.13	5.15	5.16e-07	0.00026	0.39	0.31	Mean corpuscular volume;	chr11:67624436	chr11:67618279~67627304:-
COAD	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-5.15	5.16e-07	0.00026	-0.42	-0.31	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
COAD	cis	rs13217239	0.646	rs10946898	ENSG00000224843.5	LINC00240	-5.15	5.16e-07	0.00026	-0.36	-0.31	Schizophrenia;	chr6:27036105	chr6:26956992~27023924:+
COAD	cis	rs896854	0.654	rs13248607	ENSG00000253528.2	RP11-347C18.4	5.15	5.17e-07	0.000261	0.32	0.31	Type 2 diabetes;	chr8:94974409	chr8:94974573~94974853:-
COAD	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-5.15	5.17e-07	0.000261	-0.34	-0.31	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
COAD	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	5.15	5.17e-07	0.000261	0.31	0.31	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
COAD	cis	rs896854	0.684	rs10099059	ENSG00000253528.2	RP11-347C18.4	5.15	5.17e-07	0.000261	0.32	0.31	Type 2 diabetes;	chr8:94974744	chr8:94974573~94974853:-
COAD	cis	rs896854	0.684	rs10099941	ENSG00000253528.2	RP11-347C18.4	5.15	5.17e-07	0.000261	0.32	0.31	Type 2 diabetes;	chr8:94974780	chr8:94974573~94974853:-
COAD	cis	rs7078219	0.743	rs17094148	ENSG00000228778.1	RP11-129J12.1	-5.15	5.17e-07	0.000261	-0.35	-0.31	Dental caries;	chr10:99520522	chr10:99527081~99528261:+
COAD	cis	rs75422866	0.51	rs73105845	ENSG00000274902.1	RP1-197B17.4	5.15	5.17e-07	0.000261	0.76	0.31	Pneumonia;	chr12:47741824	chr12:47731908~47732351:+
COAD	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-5.15	5.17e-07	0.000261	-0.31	-0.31	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
COAD	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-5.15	5.18e-07	0.000261	-0.31	-0.31	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
COAD	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.15	5.18e-07	0.000261	-0.42	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
COAD	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	5.15	5.18e-07	0.000261	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	5.15	5.18e-07	0.000261	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
COAD	cis	rs987724	0.778	rs2321295	ENSG00000240875.4	LINC00886	-5.15	5.19e-07	0.000261	-0.28	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944556	chr3:156747346~156817062:-
COAD	cis	rs492146	0.819	rs612483	ENSG00000243236.5	GSTA9P	5.15	5.19e-07	0.000261	0.34	0.31	Epilepsy (remission after treatment);	chr6:52975160	chr6:52939726~52957521:-
COAD	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	5.15	5.19e-07	0.000262	0.35	0.31	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
COAD	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-5.15	5.2e-07	0.000262	-0.33	-0.31	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
COAD	cis	rs7829975	0.684	rs488904	ENSG00000173295.6	FAM86B3P	-5.15	5.22e-07	0.000263	-0.34	-0.31	Mood instability;	chr8:8730061	chr8:8228595~8244865:+
COAD	cis	rs7560272	0.723	rs62153184	ENSG00000163016.8	ALMS1P	5.15	5.22e-07	0.000263	0.37	0.31	Schizophrenia;	chr2:73546742	chr2:73644919~73685576:+
COAD	cis	rs7829975	0.572	rs28730413	ENSG00000233609.3	RP11-62H7.2	-5.15	5.22e-07	0.000263	-0.34	-0.31	Mood instability;	chr8:8937937	chr8:8961200~8979025:+
COAD	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	5.15	5.22e-07	0.000263	0.34	0.31	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
COAD	cis	rs6452524	0.561	rs4331874	ENSG00000271862.1	RP11-343L5.2	5.15	5.23e-07	0.000263	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83049376~83050964:-
COAD	cis	rs13256369	0.802	rs12681326	ENSG00000173295.6	FAM86B3P	5.15	5.23e-07	0.000264	0.44	0.31	Obesity-related traits;	chr8:8708879	chr8:8228595~8244865:+
COAD	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	5.15	5.23e-07	0.000264	0.52	0.31	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	5.15	5.23e-07	0.000264	0.52	0.31	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	5.15	5.23e-07	0.000264	0.52	0.31	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
COAD	cis	rs210138	0.706	rs444697	ENSG00000197251.3	LINC00336	5.15	5.23e-07	0.000264	0.44	0.31	Testicular germ cell tumor;	chr6:33607232	chr6:33586106~33593338:-
COAD	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-5.15	5.24e-07	0.000264	-0.43	-0.31	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
COAD	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-5.15	5.24e-07	0.000264	-0.33	-0.31	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
COAD	cis	rs9368481	0.524	rs12530345	ENSG00000224843.5	LINC00240	-5.15	5.24e-07	0.000264	-0.37	-0.31	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26956992~27023924:+
COAD	cis	rs2581828	0.618	rs7615099	ENSG00000280417.1	RP11-5O17.1	5.15	5.25e-07	0.000264	0.33	0.31	Crohn's disease;	chr3:53109885	chr3:53046166~53048122:+
COAD	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	5.15	5.25e-07	0.000264	0.35	0.31	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	5.15	5.25e-07	0.000264	0.35	0.31	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
COAD	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-5.15	5.25e-07	0.000264	-0.38	-0.31	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
COAD	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	5.15	5.25e-07	0.000264	0.35	0.31	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
COAD	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-5.15	5.26e-07	0.000265	-0.42	-0.31	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-5.15	5.26e-07	0.000265	-0.42	-0.31	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
COAD	cis	rs10256972	0.791	rs11971790	ENSG00000229043.2	AC091729.9	-5.15	5.26e-07	0.000265	-0.34	-0.31	Endometriosis;Longevity;	chr7:1015946	chr7:1160374~1165267:+
COAD	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	5.15	5.26e-07	0.000265	0.54	0.31	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
COAD	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-5.15	5.27e-07	0.000265	-0.37	-0.31	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
COAD	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-5.15	5.28e-07	0.000265	-0.49	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
COAD	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-5.15	5.28e-07	0.000266	-0.35	-0.31	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
COAD	cis	rs58873874	0.737	rs75326191	ENSG00000248544.2	CTB-47B11.3	5.15	5.29e-07	0.000266	0.63	0.31	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157375741~157384950:-
COAD	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.15	5.29e-07	0.000266	0.36	0.31	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
COAD	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.15	5.29e-07	0.000266	0.36	0.31	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
COAD	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	5.15	5.3e-07	0.000266	0.35	0.31	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
COAD	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-5.15	5.3e-07	0.000266	-0.37	-0.31	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
COAD	cis	rs5758511	0.68	rs5758692	ENSG00000237037.8	NDUFA6-AS1	-5.15	5.31e-07	0.000267	-0.37	-0.31	Birth weight;	chr22:42273023	chr22:42090931~42137742:+
COAD	cis	rs748404	0.601	rs530118	ENSG00000249839.1	AC011330.5	5.15	5.31e-07	0.000267	0.38	0.31	Lung cancer;	chr15:43186313	chr15:43663654~43684339:-
COAD	cis	rs73376930	0.664	rs4779585	ENSG00000259721.1	RP11-758N13.1	-5.15	5.31e-07	0.000267	-0.36	-0.31	Colorectal cancer;	chr15:32702576	chr15:32717270~32719007:-
COAD	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	5.15	5.31e-07	0.000267	0.37	0.31	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
COAD	cis	rs34779708	0.733	rs4102764	ENSG00000271335.4	RP11-324I22.4	5.14	5.34e-07	0.000268	0.34	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35314552~35336401:-
COAD	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-5.14	5.35e-07	0.000269	-0.31	-0.31	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
COAD	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	5.14	5.35e-07	0.000269	0.27	0.31	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
COAD	cis	rs7209700	0.547	rs7219925	ENSG00000228782.6	CTD-2026D20.3	-5.14	5.35e-07	0.000269	-0.36	-0.31	IgG glycosylation;	chr17:47264274	chr17:47450568~47492492:-
COAD	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	5.14	5.36e-07	0.000269	0.39	0.31	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
COAD	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	5.14	5.36e-07	0.000269	0.34	0.31	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	5.14	5.36e-07	0.000269	0.34	0.31	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
COAD	cis	rs5015933	0.902	rs2291858	ENSG00000232630.1	PRPS1P2	-5.14	5.36e-07	0.000269	-0.3	-0.31	Body mass index;	chr9:125366503	chr9:125150653~125151589:+
COAD	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	5.14	5.36e-07	0.000269	0.32	0.31	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
COAD	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-5.14	5.36e-07	0.000269	-0.38	-0.31	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
COAD	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.000269	0.35	0.31	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.000269	0.35	0.31	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.000269	0.35	0.31	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
COAD	cis	rs5015933	0.902	rs10819047	ENSG00000232630.1	PRPS1P2	-5.14	5.37e-07	0.00027	-0.3	-0.31	Body mass index;	chr9:125365133	chr9:125150653~125151589:+
COAD	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	5.14	5.37e-07	0.00027	0.34	0.31	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
COAD	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.00027	0.34	0.31	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.00027	0.34	0.31	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.00027	0.34	0.31	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.00027	0.34	0.31	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	5.14	5.37e-07	0.00027	0.34	0.31	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
COAD	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.14	5.38e-07	0.00027	-0.41	-0.31	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
COAD	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.14	5.38e-07	0.00027	0.36	0.31	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
COAD	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-5.14	5.39e-07	0.00027	-0.51	-0.31	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
COAD	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-5.14	5.39e-07	0.000271	-0.38	-0.31	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
COAD	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.14	5.39e-07	0.000271	-0.38	-0.31	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
COAD	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	5.14	5.39e-07	0.000271	0.34	0.31	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	5.14	5.39e-07	0.000271	0.34	0.31	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
COAD	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-5.14	5.4e-07	0.000271	-0.38	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
COAD	cis	rs7584330	0.518	rs74970394	ENSG00000234949.2	AC104667.3	-5.14	5.4e-07	0.000271	-0.68	-0.31	Prostate cancer;	chr2:237534840	chr2:237591020~237595981:+
COAD	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-5.14	5.4e-07	0.000271	-0.32	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
COAD	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	5.14	5.4e-07	0.000271	0.34	0.31	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
COAD	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	5.14	5.41e-07	0.000271	0.47	0.31	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
COAD	cis	rs5742933	0.652	rs10210345	ENSG00000253559.1	OSGEPL1-AS1	5.14	5.42e-07	0.000272	0.29	0.31	Ferritin levels;	chr2:189754760	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.744	rs13009889	ENSG00000253559.1	OSGEPL1-AS1	5.14	5.42e-07	0.000272	0.29	0.31	Ferritin levels;	chr2:189763842	chr2:189762704~189765556:+
COAD	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-5.14	5.42e-07	0.000272	-0.3	-0.31	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
COAD	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	5.14	5.42e-07	0.000272	0.88	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
COAD	cis	rs9291683	0.935	rs1860910	ENSG00000250413.1	RP11-448G15.1	-5.14	5.42e-07	0.000272	-0.37	-0.31	Bone mineral density;	chr4:10273846	chr4:10006482~10009725:+
COAD	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-5.14	5.43e-07	0.000272	-0.41	-0.31	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
COAD	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	5.14	5.43e-07	0.000272	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
COAD	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-5.14	5.43e-07	0.000272	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
COAD	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	5.14	5.44e-07	0.000273	0.59	0.31	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
COAD	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	5.14	5.44e-07	0.000273	0.29	0.31	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
COAD	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-5.14	5.44e-07	0.000273	-0.54	-0.31	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-5.14	5.44e-07	0.000273	-0.54	-0.31	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
COAD	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	5.14	5.45e-07	0.000273	0.44	0.31	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
COAD	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-5.14	5.45e-07	0.000273	-0.38	-0.31	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
COAD	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	5.14	5.45e-07	0.000273	0.34	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
COAD	cis	rs7647973	0.6	rs12631989	ENSG00000225399.4	RP11-3B7.1	5.14	5.45e-07	0.000273	0.34	0.31	Menarche (age at onset);	chr3:49236563	chr3:49260085~49261316:+
COAD	cis	rs7647973	0.6	rs13064780	ENSG00000225399.4	RP11-3B7.1	5.14	5.45e-07	0.000273	0.34	0.31	Menarche (age at onset);	chr3:49237393	chr3:49260085~49261316:+
COAD	cis	rs9309473	0.5	rs6757996	ENSG00000163016.8	ALMS1P	5.14	5.45e-07	0.000273	0.36	0.31	Metabolite levels;	chr2:73545124	chr2:73644919~73685576:+
COAD	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-5.14	5.45e-07	0.000273	-0.39	-0.31	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
COAD	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	5.14	5.45e-07	0.000273	0.41	0.31	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
COAD	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-5.14	5.45e-07	0.000273	-0.2	-0.31	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-5.14	5.45e-07	0.000273	-0.2	-0.31	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
COAD	cis	rs6452524	0.534	rs10037377	ENSG00000271862.1	RP11-343L5.2	5.14	5.46e-07	0.000273	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83049376~83050964:-
COAD	cis	rs7647973	0.58	rs11716334	ENSG00000225399.4	RP11-3B7.1	5.14	5.46e-07	0.000273	0.34	0.31	Menarche (age at onset);	chr3:49192663	chr3:49260085~49261316:+
COAD	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-5.14	5.47e-07	0.000274	-0.29	-0.31	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
COAD	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-5.14	5.47e-07	0.000274	-0.33	-0.31	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
COAD	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-5.14	5.49e-07	0.000275	-0.53	-0.31	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
COAD	cis	rs28374715	0.662	rs10851403	ENSG00000247556.5	OIP5-AS1	5.14	5.49e-07	0.000275	0.41	0.31	Ulcerative colitis;	chr15:41173889	chr15:41283990~41309737:+
COAD	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	5.14	5.49e-07	0.000275	0.35	0.31	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
COAD	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-5.14	5.49e-07	0.000275	-0.38	-0.31	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
COAD	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-5.14	5.49e-07	0.000275	-0.32	-0.31	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
COAD	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	5.14	5.51e-07	0.000276	0.39	0.31	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
COAD	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-5.14	5.51e-07	0.000276	-0.4	-0.31	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
COAD	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	5.14	5.51e-07	0.000276	0.4	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-5.14	5.51e-07	0.000276	-0.4	-0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
COAD	cis	rs1930961	0.702	rs8137667	ENSG00000272977.1	CTA-390C10.10	-5.14	5.52e-07	0.000276	-0.76	-0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25512529	chr22:25476218~25479971:+
COAD	cis	rs10078	0.515	rs2672739	ENSG00000225138.6	CTD-2228K2.7	5.14	5.52e-07	0.000276	0.48	0.31	Fat distribution (HIV);	chr5:443332	chr5:473236~480884:+
COAD	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-5.14	5.53e-07	0.000277	-0.35	-0.31	Height;	chr20:49267648	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-5.14	5.53e-07	0.000277	-0.35	-0.31	Height;	chr20:49272073	chr20:49280319~49280409:+
COAD	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	5.14	5.53e-07	0.000277	0.35	0.31	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
COAD	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-5.14	5.53e-07	0.000277	-0.38	-0.31	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
COAD	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-5.14	5.55e-07	0.000278	-0.2	-0.31	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
COAD	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-5.14	5.55e-07	0.000278	-0.2	-0.31	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
COAD	cis	rs61270009	0.955	rs4269995	ENSG00000247828.6	TMEM161B-AS1	5.14	5.55e-07	0.000278	0.32	0.31	Depressive symptoms;	chr5:88405406	chr5:88268895~88436685:+
COAD	cis	rs6490294	0.649	rs7306804	ENSG00000257595.2	RP3-473L9.4	5.14	5.56e-07	0.000278	0.44	0.31	Mean platelet volume;	chr12:112003285	chr12:111369282~111403310:+
COAD	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	5.14	5.56e-07	0.000278	0.26	0.31	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
COAD	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	5.14	5.57e-07	0.000278	0.51	0.31	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
COAD	cis	rs5015933	0.788	rs461961	ENSG00000232630.1	PRPS1P2	-5.14	5.57e-07	0.000279	-0.31	-0.31	Body mass index;	chr9:125290977	chr9:125150653~125151589:+
COAD	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	5.14	5.57e-07	0.000279	0.28	0.31	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
COAD	cis	rs9309473	0.519	rs2178154	ENSG00000163016.8	ALMS1P	-5.14	5.57e-07	0.000279	-0.37	-0.31	Metabolite levels;	chr2:73434610	chr2:73644919~73685576:+
COAD	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-5.14	5.57e-07	0.000279	-0.4	-0.31	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
COAD	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	5.14	5.57e-07	0.000279	0.39	0.31	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
COAD	cis	rs12935418	0.552	rs2549835	ENSG00000278985.1	RP11-303E16.9	-5.14	5.57e-07	0.000279	-0.33	-0.31	Mean corpuscular volume;	chr16:80989005	chr16:80982319~80984094:-
COAD	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	5.14	5.57e-07	0.000279	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	5.14	5.57e-07	0.000279	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	5.14	5.57e-07	0.000279	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	5.14	5.57e-07	0.000279	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
COAD	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	5.14	5.58e-07	0.000279	0.28	0.31	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
COAD	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-5.13	5.58e-07	0.000279	-0.29	-0.31	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
COAD	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	5.13	5.58e-07	0.000279	0.31	0.31	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
COAD	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	5.13	5.59e-07	0.000279	0.36	0.31	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
COAD	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	5.13	5.59e-07	0.00028	0.29	0.31	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
COAD	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	5.13	5.6e-07	0.00028	0.31	0.31	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	5.13	5.6e-07	0.00028	0.31	0.31	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
COAD	cis	rs492146	0.765	rs367836	ENSG00000243236.5	GSTA9P	-5.13	5.6e-07	0.00028	-0.34	-0.31	Epilepsy (remission after treatment);	chr6:52978333	chr6:52939726~52957521:-
COAD	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-5.13	5.6e-07	0.00028	-0.31	-0.3	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
COAD	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	5.13	5.6e-07	0.00028	0.31	0.3	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	5.13	5.6e-07	0.00028	0.31	0.3	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
COAD	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-5.13	5.61e-07	0.00028	-0.28	-0.3	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-5.13	5.61e-07	0.00028	-0.28	-0.3	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
COAD	cis	rs1670533	1	rs935972	ENSG00000273179.1	RP11-20I20.4	5.13	5.61e-07	0.00028	0.51	0.3	Recombination rate (females);	chr4:1051383	chr4:1167778~1168174:+
COAD	cis	rs2281603	0.857	rs3783722	ENSG00000259116.1	RP11-973N13.4	-5.13	5.62e-07	0.000281	-0.32	-0.3	Lymphocyte counts;	chr14:64531248	chr14:64514154~64540368:-
COAD	cis	rs5758511	0.68	rs739147	ENSG00000237037.8	NDUFA6-AS1	-5.13	5.62e-07	0.000281	-0.37	-0.3	Birth weight;	chr22:42275060	chr22:42090931~42137742:+
COAD	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	-5.13	5.62e-07	0.000281	-0.35	-0.3	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
COAD	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-5.13	5.63e-07	0.000281	-0.37	-0.3	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
COAD	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	5.13	5.64e-07	0.000282	0.35	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
COAD	cis	rs8002861	0.935	rs7319725	ENSG00000274001.1	RP11-5G9.5	5.13	5.65e-07	0.000282	0.27	0.3	Leprosy;	chr13:43871285	chr13:43877715~43878163:-
COAD	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	5.13	5.66e-07	0.000283	0.31	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
COAD	cis	rs11846409	0.629	rs76295389	ENSG00000274576.2	IGHV2-70	5.13	5.66e-07	0.000283	0.29	0.3	Rheumatic heart disease;	chr14:106650437	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.698	rs71419854	ENSG00000274576.2	IGHV2-70	5.13	5.66e-07	0.000283	0.29	0.3	Rheumatic heart disease;	chr14:106650440	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.5	rs71419855	ENSG00000274576.2	IGHV2-70	5.13	5.66e-07	0.000283	0.29	0.3	Alzheimer's disease (late onset);	chr14:106650444	chr14:106770577~106771020:-
COAD	cis	rs7078219	0.743	rs11190133	ENSG00000228778.1	RP11-129J12.1	-5.13	5.68e-07	0.000283	-0.35	-0.3	Dental caries;	chr10:99518968	chr10:99527081~99528261:+
COAD	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-5.13	5.68e-07	0.000284	-0.54	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-5.13	5.68e-07	0.000284	-0.54	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-5.13	5.68e-07	0.000284	-0.54	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
COAD	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-5.13	5.69e-07	0.000284	-0.37	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
COAD	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-5.13	5.69e-07	0.000284	-0.31	-0.3	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
COAD	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-5.13	5.7e-07	0.000284	-0.33	-0.3	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-5.13	5.7e-07	0.000284	-0.33	-0.3	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
COAD	cis	rs7811142	1	rs6972167	ENSG00000078319.8	PMS2P1	-5.13	5.7e-07	0.000284	-0.41	-0.3	Platelet count;	chr7:100482390	chr7:100320992~100341908:-
COAD	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	5.13	5.71e-07	0.000285	0.31	0.3	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
COAD	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	5.13	5.71e-07	0.000285	0.67	0.3	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	5.13	5.71e-07	0.000285	0.67	0.3	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	5.13	5.71e-07	0.000285	0.67	0.3	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	5.13	5.71e-07	0.000285	0.67	0.3	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
COAD	cis	rs453301	0.686	rs3895823	ENSG00000253981.4	ALG1L13P	-5.13	5.71e-07	0.000285	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9016136	chr8:8236003~8244667:-
COAD	cis	rs5015933	1	rs2841329	ENSG00000232630.1	PRPS1P2	-5.13	5.72e-07	0.000285	-0.31	-0.3	Body mass index;	chr9:125372053	chr9:125150653~125151589:+
COAD	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-5.13	5.73e-07	0.000285	-0.32	-0.3	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
COAD	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	5.13	5.73e-07	0.000286	0.35	0.3	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
COAD	cis	rs9368481	0.546	rs12664610	ENSG00000224843.5	LINC00240	-5.13	5.74e-07	0.000286	-0.37	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26956992~27023924:+
COAD	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	5.13	5.75e-07	0.000286	0.35	0.3	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
COAD	cis	rs9302635	0.515	rs36033103	ENSG00000260886.1	TAT-AS1	5.13	5.75e-07	0.000287	0.69	0.3	Blood protein levels;	chr16:72108139	chr16:71565789~71578187:+
COAD	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-5.13	5.76e-07	0.000287	-0.28	-0.3	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
COAD	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	5.13	5.76e-07	0.000287	0.31	0.3	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
COAD	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	5.13	5.76e-07	0.000287	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
COAD	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	5.13	5.76e-07	0.000287	0.35	0.3	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	5.13	5.76e-07	0.000287	0.35	0.3	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
COAD	cis	rs10078	0.559	rs2037077	ENSG00000225138.6	CTD-2228K2.7	5.13	5.76e-07	0.000287	0.48	0.3	Fat distribution (HIV);	chr5:447111	chr5:473236~480884:+
COAD	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	5.13	5.76e-07	0.000287	0.25	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
COAD	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	5.13	5.76e-07	0.000287	0.52	0.3	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
COAD	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	5.13	5.76e-07	0.000287	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
COAD	cis	rs7647973	0.58	rs12629759	ENSG00000225399.4	RP11-3B7.1	5.13	5.76e-07	0.000287	0.34	0.3	Menarche (age at onset);	chr3:49199961	chr3:49260085~49261316:+
COAD	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-5.13	5.77e-07	0.000287	-0.27	-0.3	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
COAD	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-5.13	5.77e-07	0.000288	-0.51	-0.3	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
COAD	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	5.13	5.78e-07	0.000288	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
COAD	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	5.13	5.79e-07	0.000288	0.4	0.3	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	5.13	5.79e-07	0.000288	0.4	0.3	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	5.13	5.79e-07	0.000288	0.4	0.3	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
COAD	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	5.13	5.79e-07	0.000288	0.34	0.3	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	5.13	5.79e-07	0.000288	0.34	0.3	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	5.13	5.79e-07	0.000288	0.34	0.3	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
COAD	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-5.13	5.79e-07	0.000288	-0.31	-0.3	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
COAD	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-5.13	5.79e-07	0.000288	-0.31	-0.3	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
COAD	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	5.13	5.79e-07	0.000288	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
COAD	cis	rs2732480	0.538	rs2468943	ENSG00000269514.1	RP11-370I10.12	-5.13	5.79e-07	0.000288	-0.38	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48198387~48202031:+
COAD	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	5.13	5.79e-07	0.000289	0.33	0.3	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
COAD	cis	rs34792	0.688	rs153783	ENSG00000207425.1	Y_RNA	5.13	5.8e-07	0.000289	0.38	0.3	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508509	chr16:14915457~14915556:-
COAD	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-5.13	5.8e-07	0.000289	-0.31	-0.3	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
COAD	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	5.13	5.8e-07	0.000289	0.33	0.3	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	5.13	5.8e-07	0.000289	0.33	0.3	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
COAD	cis	rs1930961	0.702	rs8141205	ENSG00000272977.1	CTA-390C10.10	-5.13	5.8e-07	0.000289	-0.76	-0.3	Bipolar disorder with mood-incongruent psychosis;	chr22:25512200	chr22:25476218~25479971:+
COAD	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-5.13	5.81e-07	0.000289	-0.42	-0.3	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
COAD	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-5.13	5.81e-07	0.000289	-0.35	-0.3	Height;	chr20:49219081	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-5.13	5.81e-07	0.000289	-0.35	-0.3	Height;	chr20:49220669	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-5.13	5.81e-07	0.000289	-0.35	-0.3	Height;	chr20:49223054	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-5.13	5.81e-07	0.000289	-0.35	-0.3	Height;	chr20:49225123	chr20:49280319~49280409:+
COAD	cis	rs12935418	0.672	rs6564814	ENSG00000278985.1	RP11-303E16.9	5.13	5.81e-07	0.000289	0.34	0.3	Mean corpuscular volume;	chr16:81016567	chr16:80982319~80984094:-
COAD	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-5.13	5.82e-07	0.00029	-0.37	-0.3	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
COAD	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-5.13	5.83e-07	0.00029	-0.32	-0.3	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
COAD	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.13	5.83e-07	0.00029	-0.36	-0.3	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
COAD	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	5.13	5.84e-07	0.000291	0.35	0.3	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
COAD	cis	rs12468226	0.938	rs16824590	ENSG00000273456.1	RP11-686O6.2	5.13	5.85e-07	0.000291	0.36	0.3	Urate levels;	chr2:202272624	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs77018809	ENSG00000273456.1	RP11-686O6.2	5.13	5.85e-07	0.000291	0.36	0.3	Urate levels;	chr2:202273166	chr2:202374932~202375604:-
COAD	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	5.13	5.85e-07	0.000291	0.36	0.3	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
COAD	cis	rs13217239	0.646	rs10946897	ENSG00000224843.5	LINC00240	-5.13	5.85e-07	0.000291	-0.35	-0.3	Schizophrenia;	chr6:27027472	chr6:26956992~27023924:+
COAD	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
COAD	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
COAD	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	5.12	5.86e-07	0.000291	0.36	0.3	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
COAD	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-5.12	5.86e-07	0.000291	-0.32	-0.3	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
COAD	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-5.12	5.87e-07	0.000292	-0.36	-0.3	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
COAD	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	5.12	5.87e-07	0.000292	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
COAD	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	5.12	5.87e-07	0.000292	0.39	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
COAD	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	5.12	5.88e-07	0.000292	0.35	0.3	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
COAD	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.12	5.88e-07	0.000292	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
COAD	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	5.12	5.89e-07	0.000293	0.34	0.3	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
COAD	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-5.12	5.9e-07	0.000293	-0.37	-0.3	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
COAD	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	5.12	5.9e-07	0.000293	0.41	0.3	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	5.12	5.91e-07	0.000294	0.35	0.3	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	5.12	5.91e-07	0.000294	0.35	0.3	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
COAD	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	5.12	5.91e-07	0.000294	0.54	0.3	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	5.12	5.91e-07	0.000294	0.54	0.3	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
COAD	cis	rs58873874	0.737	rs78738433	ENSG00000248544.2	CTB-47B11.3	5.12	5.91e-07	0.000294	0.64	0.3	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157375741~157384950:-
COAD	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	5.12	5.91e-07	0.000294	0.38	0.3	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs1060107	ENSG00000173295.6	FAM86B3P	5.12	5.92e-07	0.000294	0.43	0.3	Obesity-related traits;	chr8:8703889	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs4840350	ENSG00000173295.6	FAM86B3P	5.12	5.92e-07	0.000294	0.43	0.3	Obesity-related traits;	chr8:8703932	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs1060106	ENSG00000173295.6	FAM86B3P	5.12	5.92e-07	0.000294	0.43	0.3	Obesity-related traits;	chr8:8703942	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs11249883	ENSG00000173295.6	FAM86B3P	5.12	5.92e-07	0.000294	0.43	0.3	Obesity-related traits;	chr8:8704027	chr8:8228595~8244865:+
COAD	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-5.12	5.92e-07	0.000294	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-5.12	5.92e-07	0.000294	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
COAD	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-5.12	5.92e-07	0.000294	-0.4	-0.3	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
COAD	cis	rs13217239	0.646	rs6937880	ENSG00000224843.5	LINC00240	-5.12	5.93e-07	0.000294	-0.35	-0.3	Schizophrenia;	chr6:27032457	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.621	rs12527231	ENSG00000224843.5	LINC00240	-5.12	5.93e-07	0.000294	-0.35	-0.3	Schizophrenia;	chr6:27033509	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs12523820	ENSG00000224843.5	LINC00240	-5.12	5.93e-07	0.000294	-0.35	-0.3	Schizophrenia;	chr6:27033723	chr6:26956992~27023924:+
COAD	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	5.12	5.93e-07	0.000294	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
COAD	cis	rs1056107	0.866	rs10817308	ENSG00000225513.1	RP11-165N19.2	-5.12	5.93e-07	0.000294	-0.36	-0.3	Colorectal cancer;	chr9:112273585	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.966	rs10981338	ENSG00000225513.1	RP11-165N19.2	-5.12	5.93e-07	0.000294	-0.36	-0.3	Colorectal cancer;	chr9:112273741	chr9:112173522~112173971:-
COAD	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	5.12	5.94e-07	0.000295	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	5.12	5.94e-07	0.000295	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
COAD	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	5.12	5.94e-07	0.000295	0.45	0.3	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
COAD	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-5.12	5.94e-07	0.000295	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-5.12	5.94e-07	0.000295	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
COAD	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-5.12	5.95e-07	0.000295	-0.39	-0.3	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
COAD	cis	rs12468226	0.938	rs1474002	ENSG00000273456.1	RP11-686O6.2	5.12	5.95e-07	0.000295	0.36	0.3	Urate levels;	chr2:202290195	chr2:202374932~202375604:-
COAD	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-5.12	5.95e-07	0.000295	-0.41	-0.3	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
COAD	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.12	5.96e-07	0.000295	-0.38	-0.3	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
COAD	cis	rs240993	0.715	rs7776346	ENSG00000230177.1	RP5-1112D6.4	5.12	5.96e-07	0.000296	0.27	0.3	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111277932~111278742:+
COAD	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-5.12	5.96e-07	0.000296	-0.31	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
COAD	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-5.12	5.97e-07	0.000296	-0.34	-0.3	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
COAD	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	5.12	5.97e-07	0.000296	0.48	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
COAD	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	5.12	5.97e-07	0.000296	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
COAD	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-5.12	5.97e-07	0.000296	-0.41	-0.3	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
COAD	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	5.12	5.98e-07	0.000296	0.28	0.3	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
COAD	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	5.12	5.98e-07	0.000297	0.34	0.3	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
COAD	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-5.12	5.98e-07	0.000297	-0.32	-0.3	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
COAD	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	5.12	5.99e-07	0.000297	0.36	0.3	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
COAD	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	5.12	5.99e-07	0.000297	0.36	0.3	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	5.12	5.99e-07	0.000297	0.36	0.3	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
COAD	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-5.12	6e-07	0.000297	-0.53	-0.3	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-5.12	6e-07	0.000297	-0.53	-0.3	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-5.12	6e-07	0.000297	-0.53	-0.3	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-5.12	6e-07	0.000297	-0.53	-0.3	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-5.12	6e-07	0.000297	-0.53	-0.3	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	5.12	6e-07	0.000297	0.21	0.3	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
COAD	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-5.12	6.01e-07	0.000298	-0.59	-0.3	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
COAD	cis	rs6452524	0.534	rs7724935	ENSG00000271862.1	RP11-343L5.2	5.12	6.01e-07	0.000298	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.506	rs7707143	ENSG00000271862.1	RP11-343L5.2	5.12	6.01e-07	0.000298	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83049376~83050964:-
COAD	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	5.12	6.01e-07	0.000298	0.33	0.3	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	5.12	6.01e-07	0.000298	0.33	0.3	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
COAD	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-5.12	6.02e-07	0.000298	-0.17	-0.3	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
COAD	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-5.12	6.04e-07	0.000299	-0.39	-0.3	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
COAD	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-5.12	6.04e-07	0.000299	-0.32	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
COAD	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	5.12	6.06e-07	3e-04	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
COAD	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-5.12	6.06e-07	3e-04	-0.52	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
COAD	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	5.12	6.07e-07	3e-04	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
COAD	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-5.12	6.07e-07	0.000301	-0.32	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
COAD	cis	rs5758511	0.68	rs1033459	ENSG00000237037.8	NDUFA6-AS1	-5.12	6.07e-07	0.000301	-0.36	-0.3	Birth weight;	chr22:42223061	chr22:42090931~42137742:+
COAD	cis	rs13256369	0.802	rs34762800	ENSG00000173295.6	FAM86B3P	5.12	6.09e-07	0.000301	0.44	0.3	Obesity-related traits;	chr8:8701784	chr8:8228595~8244865:+
COAD	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	5.12	6.09e-07	0.000301	0.6	0.3	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
COAD	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-5.12	6.1e-07	0.000302	-0.32	-0.3	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
COAD	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.12	6.11e-07	0.000302	0.37	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
COAD	cis	rs7560272	0.723	rs780395	ENSG00000163016.8	ALMS1P	-5.12	6.11e-07	0.000302	-0.37	-0.3	Schizophrenia;	chr2:73473726	chr2:73644919~73685576:+
COAD	cis	rs7560272	0.695	rs780394	ENSG00000163016.8	ALMS1P	-5.12	6.11e-07	0.000302	-0.37	-0.3	Schizophrenia;	chr2:73473803	chr2:73644919~73685576:+
COAD	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	5.12	6.11e-07	0.000302	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
COAD	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-5.12	6.12e-07	0.000303	-0.54	-0.3	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
COAD	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	5.12	6.12e-07	0.000303	0.37	0.3	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
COAD	cis	rs4448343	0.927	rs1355620	ENSG00000271155.1	RP11-435O5.5	-5.12	6.13e-07	0.000303	-0.35	-0.3	Height;	chr9:95507886	chr9:95506235~95507636:+
COAD	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-5.12	6.13e-07	0.000303	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
COAD	cis	rs17264034	0.95	rs55970326	ENSG00000250786.1	SNHG18	5.12	6.13e-07	0.000303	0.47	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557008	chr5:9546200~9550609:+
COAD	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	5.12	6.13e-07	0.000303	0.34	0.3	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	5.12	6.13e-07	0.000303	0.34	0.3	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	5.12	6.13e-07	0.000303	0.34	0.3	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
COAD	cis	rs5758511	0.689	rs5758691	ENSG00000237037.8	NDUFA6-AS1	-5.12	6.14e-07	0.000303	-0.37	-0.3	Birth weight;	chr22:42272498	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.634	rs1001587	ENSG00000237037.8	NDUFA6-AS1	-5.12	6.14e-07	0.000303	-0.37	-0.3	Birth weight;	chr22:42274105	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.68	rs1001586	ENSG00000237037.8	NDUFA6-AS1	-5.12	6.14e-07	0.000303	-0.37	-0.3	Birth weight;	chr22:42274287	chr22:42090931~42137742:+
COAD	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-5.12	6.14e-07	0.000303	-0.42	-0.3	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
COAD	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	5.12	6.14e-07	0.000303	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
COAD	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	5.12	6.14e-07	0.000303	0.34	0.3	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
COAD	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-5.11	6.14e-07	0.000304	-0.38	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
COAD	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-5.11	6.15e-07	0.000304	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
COAD	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	5.11	6.15e-07	0.000304	0.34	0.3	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
COAD	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-5.11	6.16e-07	0.000304	-0.52	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
COAD	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	5.11	6.16e-07	0.000305	0.36	0.3	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
COAD	cis	rs2732480	0.577	rs2732481	ENSG00000273765.1	RP11-370I10.11	5.11	6.16e-07	0.000305	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.557	rs2732484	ENSG00000273765.1	RP11-370I10.11	5.11	6.16e-07	0.000305	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2732486	ENSG00000273765.1	RP11-370I10.11	5.11	6.16e-07	0.000305	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.517	rs2634676	ENSG00000273765.1	RP11-370I10.11	5.11	6.16e-07	0.000305	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48360920~48361377:+
COAD	cis	rs13256369	0.802	rs12681925	ENSG00000173295.6	FAM86B3P	5.11	6.17e-07	0.000305	0.43	0.3	Obesity-related traits;	chr8:8704139	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs12680019	ENSG00000173295.6	FAM86B3P	5.11	6.17e-07	0.000305	0.43	0.3	Obesity-related traits;	chr8:8704188	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-5.11	6.17e-07	0.000305	-0.33	-0.3	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
COAD	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-5.11	6.18e-07	0.000305	-0.32	-0.3	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	5.11	6.18e-07	0.000305	0.34	0.3	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	5.11	6.18e-07	0.000305	0.34	0.3	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
COAD	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	5.11	6.18e-07	0.000305	0.39	0.3	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
COAD	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	5.11	6.18e-07	0.000305	0.39	0.3	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
COAD	cis	rs12935418	0.583	rs2549841	ENSG00000278985.1	RP11-303E16.9	-5.11	6.19e-07	0.000306	-0.32	-0.3	Mean corpuscular volume;	chr16:80989967	chr16:80982319~80984094:-
COAD	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-5.11	6.19e-07	0.000306	-0.33	-0.3	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
COAD	cis	rs13256369	0.901	rs12679831	ENSG00000173295.6	FAM86B3P	5.11	6.19e-07	0.000306	0.44	0.3	Obesity-related traits;	chr8:8708901	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.901	rs12681327	ENSG00000173295.6	FAM86B3P	5.11	6.19e-07	0.000306	0.44	0.3	Obesity-related traits;	chr8:8708904	chr8:8228595~8244865:+
COAD	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-5.11	6.19e-07	0.000306	-0.35	-0.3	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
COAD	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.11	6.19e-07	0.000306	-0.26	-0.3	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
COAD	cis	rs2732480	0.557	rs2732441	ENSG00000273765.1	RP11-370I10.11	5.11	6.19e-07	0.000306	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2732448	ENSG00000273765.1	RP11-370I10.11	5.11	6.19e-07	0.000306	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48360920~48361377:+
COAD	cis	rs1056107	0.931	rs3849126	ENSG00000225513.1	RP11-165N19.2	-5.11	6.2e-07	0.000306	-0.36	-0.3	Colorectal cancer;	chr9:112261060	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs6477904	ENSG00000225513.1	RP11-165N19.2	-5.11	6.2e-07	0.000306	-0.36	-0.3	Colorectal cancer;	chr9:112261254	chr9:112173522~112173971:-
COAD	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-5.11	6.2e-07	0.000306	-0.27	-0.3	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
COAD	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-5.11	6.2e-07	0.000306	-0.31	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
COAD	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	5.11	6.21e-07	0.000307	0.44	0.3	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
COAD	cis	rs9890032	0.618	rs55872374	ENSG00000263531.1	RP13-753N3.1	5.11	6.23e-07	0.000308	0.37	0.3	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30863921~30864940:-
COAD	cis	rs1056107	0.931	rs6477905	ENSG00000225513.1	RP11-165N19.2	-5.11	6.23e-07	0.000308	-0.36	-0.3	Colorectal cancer;	chr9:112261381	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs10981334	ENSG00000225513.1	RP11-165N19.2	-5.11	6.23e-07	0.000308	-0.36	-0.3	Colorectal cancer;	chr9:112262415	chr9:112173522~112173971:-
COAD	cis	rs77204473	1	rs17120177	ENSG00000254851.1	RP11-109L13.1	5.11	6.25e-07	0.000308	0.68	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116956653	chr11:117135528~117138582:+
COAD	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	5.11	6.25e-07	0.000308	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
COAD	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	5.11	6.26e-07	0.000309	0.27	0.3	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
COAD	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-5.11	6.26e-07	0.000309	-0.52	-0.3	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
COAD	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-5.11	6.26e-07	0.000309	-0.33	-0.3	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
COAD	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-5.11	6.26e-07	0.000309	-0.3	-0.3	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
COAD	cis	rs58873874	0.737	rs12654973	ENSG00000251405.2	CTB-109A12.1	5.11	6.27e-07	0.000309	0.61	0.3	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157362615~157460078:-
COAD	cis	rs58873874	0.579	rs74804793	ENSG00000251405.2	CTB-109A12.1	5.11	6.27e-07	0.000309	0.61	0.3	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157362615~157460078:-
COAD	cis	rs10515750	0.656	rs112839393	ENSG00000251405.2	CTB-109A12.1	5.11	6.27e-07	0.000309	0.61	0.3	Lung function (FEV1/FVC);	chr5:157282304	chr5:157362615~157460078:-
COAD	cis	rs362272	0.505	rs10155132	ENSG00000248840.2	RP11-357G3.2	-5.11	6.28e-07	0.00031	-0.34	-0.3	Serum sulfate level;	chr4:3367773	chr4:3312512~3313058:+
COAD	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	5.11	6.28e-07	0.00031	0.35	0.3	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
COAD	cis	rs1056107	0.7	rs10981292	ENSG00000225513.1	RP11-165N19.2	-5.11	6.28e-07	0.00031	-0.38	-0.3	Colorectal cancer;	chr9:112168294	chr9:112173522~112173971:-
COAD	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-5.11	6.3e-07	0.000311	-0.34	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
COAD	cis	rs7560272	0.564	rs4852939	ENSG00000163016.8	ALMS1P	5.11	6.3e-07	0.000311	0.36	0.3	Schizophrenia;	chr2:73629642	chr2:73644919~73685576:+
COAD	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-5.11	6.31e-07	0.000311	-0.5	-0.3	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
COAD	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-5.11	6.31e-07	0.000311	-0.34	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
COAD	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-5.11	6.32e-07	0.000311	-0.37	-0.3	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
COAD	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	5.11	6.32e-07	0.000311	0.34	0.3	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
COAD	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	5.11	6.34e-07	0.000312	0.31	0.3	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
COAD	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-5.11	6.34e-07	0.000312	-0.33	-0.3	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
COAD	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-5.11	6.34e-07	0.000312	-0.33	-0.3	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
COAD	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	5.11	6.34e-07	0.000312	0.43	0.3	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
COAD	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-5.11	6.34e-07	0.000312	-0.31	-0.3	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-5.11	6.34e-07	0.000312	-0.31	-0.3	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
COAD	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-5.11	6.35e-07	0.000313	-0.46	-0.3	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
COAD	cis	rs12935418	0.523	rs2549845	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80990520	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.552	rs2549847	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80990617	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2602449	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80990668	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2549848	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80990693	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2316923	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80991216	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2098726	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80991670	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.552	rs2113196	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80991885	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2113197	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80991901	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2549852	ENSG00000278985.1	RP11-303E16.9	-5.11	6.35e-07	0.000313	-0.32	-0.3	Mean corpuscular volume;	chr16:80992410	chr16:80982319~80984094:-
COAD	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-5.11	6.35e-07	0.000313	-0.3	-0.3	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
COAD	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-5.11	6.35e-07	0.000313	-0.31	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
COAD	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-5.11	6.35e-07	0.000313	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
COAD	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	5.11	6.36e-07	0.000313	0.39	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
COAD	cis	rs1056107	0.931	rs10481637	ENSG00000225513.1	RP11-165N19.2	-5.11	6.36e-07	0.000313	-0.35	-0.3	Colorectal cancer;	chr9:112334457	chr9:112173522~112173971:-
COAD	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	5.11	6.37e-07	0.000313	0.31	0.3	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
COAD	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-5.11	6.37e-07	0.000313	-0.34	-0.3	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
COAD	cis	rs9818758	0.607	rs13077498	ENSG00000225399.4	RP11-3B7.1	-5.11	6.37e-07	0.000314	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276545	chr3:49260085~49261316:+
COAD	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-5.11	6.38e-07	0.000314	-0.31	-0.3	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
COAD	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	5.11	6.38e-07	0.000314	0.54	0.3	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
COAD	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	5.11	6.38e-07	0.000314	0.35	0.3	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
COAD	cis	rs3809912	0.595	rs12605006	ENSG00000266969.1	RP11-773H22.4	5.11	6.38e-07	0.000314	0.35	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:12992262	chr18:12984694~12991173:-
COAD	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	5.11	6.38e-07	0.000314	0.52	0.3	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	5.11	6.38e-07	0.000314	0.52	0.3	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
COAD	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-5.11	6.39e-07	0.000314	-0.38	-0.3	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
COAD	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	5.11	6.39e-07	0.000314	0.32	0.3	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	5.11	6.39e-07	0.000314	0.32	0.3	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	5.11	6.39e-07	0.000314	0.32	0.3	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-5.11	6.39e-07	0.000314	-0.32	-0.3	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-5.11	6.39e-07	0.000314	-0.32	-0.3	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
COAD	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-5.11	6.39e-07	0.000314	-0.32	-0.3	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
COAD	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-5.11	6.39e-07	0.000314	-0.32	-0.3	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
COAD	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	5.11	6.39e-07	0.000314	0.26	0.3	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
COAD	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-5.11	6.39e-07	0.000314	-0.44	-0.3	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-5.11	6.39e-07	0.000314	-0.44	-0.3	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
COAD	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-5.11	6.39e-07	0.000314	-0.45	-0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
COAD	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	5.11	6.39e-07	0.000315	0.35	0.3	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
COAD	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	5.11	6.4e-07	0.000315	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
COAD	cis	rs12935418	0.672	rs3826048	ENSG00000278985.1	RP11-303E16.9	5.11	6.4e-07	0.000315	0.34	0.3	Mean corpuscular volume;	chr16:81023230	chr16:80982319~80984094:-
COAD	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	5.11	6.41e-07	0.000315	0.33	0.3	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
COAD	cis	rs36093924	0.646	rs4822069	ENSG00000182057.4	OGFRP1	-5.11	6.41e-07	0.000315	-0.31	-0.3	Intelligence;	chr22:41955477	chr22:42269753~42275196:+
COAD	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	5.11	6.42e-07	0.000316	0.26	0.3	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
COAD	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	5.11	6.42e-07	0.000316	0.34	0.3	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
COAD	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	5.11	6.43e-07	0.000316	0.91	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
COAD	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.11	6.43e-07	0.000316	-0.32	-0.3	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
COAD	cis	rs13256369	0.802	rs13255789	ENSG00000173295.6	FAM86B3P	5.11	6.43e-07	0.000316	0.43	0.3	Obesity-related traits;	chr8:8705281	chr8:8228595~8244865:+
COAD	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	5.11	6.43e-07	0.000316	0.63	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	5.11	6.43e-07	0.000316	0.63	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
COAD	cis	rs9818758	0.556	rs9880309	ENSG00000225399.4	RP11-3B7.1	-5.11	6.44e-07	0.000317	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49266896	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs34343820	ENSG00000225399.4	RP11-3B7.1	-5.11	6.44e-07	0.000317	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272101	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs10049462	ENSG00000225399.4	RP11-3B7.1	-5.11	6.44e-07	0.000317	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272251	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs9311439	ENSG00000225399.4	RP11-3B7.1	-5.11	6.44e-07	0.000317	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272975	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs67831908	ENSG00000225399.4	RP11-3B7.1	-5.11	6.44e-07	0.000317	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276080	chr3:49260085~49261316:+
COAD	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	5.11	6.44e-07	0.000317	0.29	0.3	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
COAD	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	5.1	6.46e-07	0.000317	0.34	0.3	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
COAD	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-5.1	6.46e-07	0.000317	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
COAD	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	5.1	6.46e-07	0.000317	0.77	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
COAD	cis	rs2439831	0.867	rs2470134	ENSG00000275601.1	AC011330.13	5.1	6.46e-07	0.000317	0.45	0.3	Lung cancer in ever smokers;	chr15:43557688	chr15:43642389~43643023:-
COAD	cis	rs7829975	0.572	rs28446104	ENSG00000233609.3	RP11-62H7.2	-5.1	6.46e-07	0.000318	-0.34	-0.3	Mood instability;	chr8:8938391	chr8:8961200~8979025:+
COAD	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	5.1	6.46e-07	0.000318	0.32	0.3	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
COAD	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	5.1	6.47e-07	0.000318	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	5.1	6.47e-07	0.000318	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	5.1	6.47e-07	0.000318	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
COAD	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	5.1	6.47e-07	0.000318	0.53	0.3	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	5.1	6.47e-07	0.000318	0.53	0.3	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	5.1	6.47e-07	0.000318	0.53	0.3	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
COAD	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	5.1	6.47e-07	0.000318	0.29	0.3	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
COAD	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-5.1	6.47e-07	0.000318	-0.39	-0.3	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
COAD	cis	rs9399135	0.627	rs6930223	ENSG00000232876.1	CTA-212D2.2	-5.1	6.48e-07	0.000318	-0.38	-0.3	Red blood cell count;	chr6:135103065	chr6:135055033~135060550:+
COAD	cis	rs7078219	0.743	rs11190133	ENSG00000257582.4	LINC01475	-5.1	6.49e-07	0.000319	-0.34	-0.3	Dental caries;	chr10:99518968	chr10:99526350~99531177:-
COAD	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	5.1	6.49e-07	0.000319	0.33	0.3	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
COAD	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	5.1	6.49e-07	0.000319	0.29	0.3	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	5.1	6.49e-07	0.000319	0.29	0.3	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
COAD	cis	rs9847710	0.791	rs6808387	ENSG00000280417.1	RP11-5O17.1	5.1	6.49e-07	0.000319	0.31	0.3	Ulcerative colitis;	chr3:53045716	chr3:53046166~53048122:+
COAD	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	5.1	6.5e-07	0.000319	0.29	0.3	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	5.1	6.5e-07	0.000319	0.29	0.3	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
COAD	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	5.1	6.5e-07	0.000319	0.29	0.3	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
COAD	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-5.1	6.5e-07	0.000319	-0.33	-0.3	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-5.1	6.5e-07	0.000319	-0.33	-0.3	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
COAD	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	5.1	6.51e-07	0.00032	0.31	0.3	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
COAD	cis	rs61270009	0.955	rs10214154	ENSG00000247828.6	TMEM161B-AS1	-5.1	6.51e-07	0.00032	-0.32	-0.3	Depressive symptoms;	chr5:88249502	chr5:88268895~88436685:+
COAD	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	5.1	6.52e-07	0.00032	0.37	0.3	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
COAD	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	5.1	6.52e-07	0.00032	0.27	0.3	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
COAD	cis	rs453301	0.631	rs13250781	ENSG00000253981.4	ALG1L13P	-5.1	6.53e-07	0.000321	-0.36	-0.3	Joint mobility (Beighton score);	chr8:8935833	chr8:8236003~8244667:-
COAD	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-5.1	6.53e-07	0.000321	-0.32	-0.3	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
COAD	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-5.1	6.53e-07	0.000321	-0.38	-0.3	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
COAD	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-5.1	6.54e-07	0.000321	-0.31	-0.3	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
COAD	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	5.1	6.55e-07	0.000322	0.32	0.3	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
COAD	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	5.1	6.58e-07	0.000323	0.52	0.3	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	5.1	6.58e-07	0.000323	0.52	0.3	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
COAD	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-5.1	6.58e-07	0.000323	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-5.1	6.58e-07	0.000323	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-5.1	6.58e-07	0.000323	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
COAD	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-5.1	6.58e-07	0.000323	-0.41	-0.3	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
COAD	cis	rs6676180	0.555	rs12060730	ENSG00000231365.4	RP11-418J17.1	-5.1	6.59e-07	0.000323	-0.32	-0.3	Monobrow;	chr1:119228079	chr1:119140396~119275973:+
COAD	cis	rs7078219	0.743	rs17094148	ENSG00000257582.4	LINC01475	-5.1	6.59e-07	0.000323	-0.34	-0.3	Dental caries;	chr10:99520522	chr10:99526350~99531177:-
COAD	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.1	6.6e-07	0.000323	0.37	0.3	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
COAD	cis	rs9309473	0.5	rs10865398	ENSG00000163016.8	ALMS1P	-5.1	6.6e-07	0.000324	-0.37	-0.3	Metabolite levels;	chr2:73514370	chr2:73644919~73685576:+
COAD	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	5.1	6.61e-07	0.000324	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	5.1	6.61e-07	0.000324	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
COAD	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-5.1	6.61e-07	0.000324	-0.35	-0.3	Height;	chr3:53070344	chr3:53064283~53065091:-
COAD	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-5.1	6.62e-07	0.000324	-0.47	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
COAD	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	5.1	6.63e-07	0.000325	0.36	0.3	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
COAD	cis	rs75422866	0.51	rs73105819	ENSG00000274902.1	RP1-197B17.4	5.1	6.63e-07	0.000325	0.74	0.3	Pneumonia;	chr12:47727190	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	5.1	6.63e-07	0.000325	0.74	0.3	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
COAD	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	5.1	6.63e-07	0.000325	0.29	0.3	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
COAD	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	5.1	6.63e-07	0.000325	0.27	0.3	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	5.1	6.63e-07	0.000325	0.27	0.3	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
COAD	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	5.1	6.63e-07	0.000325	0.58	0.3	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
COAD	cis	rs728616	0.867	rs7893241	ENSG00000234382.2	RP11-40F6.1	-5.1	6.64e-07	0.000325	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:80233664~80245367:+
COAD	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	5.1	6.64e-07	0.000325	0.4	0.3	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
COAD	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	5.1	6.64e-07	0.000326	0.47	0.3	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
COAD	cis	rs5015933	0.815	rs359597	ENSG00000232630.1	PRPS1P2	-5.1	6.65e-07	0.000326	-0.29	-0.3	Body mass index;	chr9:125274312	chr9:125150653~125151589:+
COAD	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	5.1	6.66e-07	0.000326	0.44	0.3	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
COAD	cis	rs9951698	0.667	rs6505775	ENSG00000266969.1	RP11-773H22.4	5.1	6.67e-07	0.000327	0.39	0.3	Intelligence (multi-trait analysis);	chr18:12978184	chr18:12984694~12991173:-
COAD	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	5.1	6.67e-07	0.000327	0.26	0.3	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
COAD	cis	rs5015933	0.788	rs466614	ENSG00000232630.1	PRPS1P2	-5.1	6.68e-07	0.000327	-0.31	-0.3	Body mass index;	chr9:125265428	chr9:125150653~125151589:+
COAD	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	5.1	6.69e-07	0.000328	0.4	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
COAD	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	5.1	6.69e-07	0.000328	0.41	0.3	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
COAD	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	5.1	6.69e-07	0.000328	0.35	0.3	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	5.1	6.7e-07	0.000328	0.35	0.3	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
COAD	cis	rs2028299	1	rs4932143	ENSG00000259677.1	RP11-493E3.1	5.1	6.7e-07	0.000328	0.37	0.3	Type 2 diabetes;	chr15:89828835	chr15:89876540~89877285:+
COAD	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-5.1	6.7e-07	0.000328	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	5.1	6.7e-07	0.000328	0.34	0.3	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
COAD	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-5.1	6.7e-07	0.000328	-0.45	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
COAD	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	5.1	6.7e-07	0.000328	0.27	0.3	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
COAD	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	5.1	6.7e-07	0.000328	0.33	0.3	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
COAD	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	5.1	6.71e-07	0.000329	0.32	0.3	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
COAD	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	5.1	6.71e-07	0.000329	0.32	0.3	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
COAD	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-5.1	6.71e-07	0.000329	-0.36	-0.3	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
COAD	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-5.1	6.71e-07	0.000329	-0.36	-0.3	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
COAD	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-5.1	6.72e-07	0.000329	-0.29	-0.3	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
COAD	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-5.1	6.72e-07	0.000329	-0.29	-0.3	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
COAD	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	5.1	6.72e-07	0.000329	0.34	0.3	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
COAD	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-5.1	6.72e-07	0.000329	-0.31	-0.3	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
COAD	cis	rs7829975	0.774	rs11775523	ENSG00000253981.4	ALG1L13P	5.1	6.72e-07	0.000329	0.37	0.3	Mood instability;	chr8:8821666	chr8:8236003~8244667:-
COAD	cis	rs58873874	0.737	rs11739062	ENSG00000248544.2	CTB-47B11.3	5.1	6.72e-07	0.000329	0.67	0.3	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157375741~157384950:-
COAD	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-5.1	6.73e-07	0.000329	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
COAD	cis	rs5758511	0.68	rs5758688	ENSG00000237037.8	NDUFA6-AS1	-5.1	6.73e-07	0.000329	-0.36	-0.3	Birth weight;	chr22:42266495	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.633	rs5751258	ENSG00000237037.8	NDUFA6-AS1	-5.1	6.73e-07	0.000329	-0.36	-0.3	Birth weight;	chr22:42267865	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.633	rs5758689	ENSG00000237037.8	NDUFA6-AS1	-5.1	6.73e-07	0.000329	-0.36	-0.3	Birth weight;	chr22:42268966	chr22:42090931~42137742:+
COAD	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	5.1	6.74e-07	0.00033	0.37	0.3	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
COAD	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-5.1	6.74e-07	0.00033	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-5.1	6.74e-07	0.00033	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-5.1	6.74e-07	0.00033	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-5.1	6.74e-07	0.00033	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-5.1	6.74e-07	0.00033	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
COAD	cis	rs440932	0.757	rs330943	ENSG00000253981.4	ALG1L13P	5.1	6.75e-07	0.00033	0.4	0.3	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8236003~8244667:-
COAD	cis	rs7404843	0.789	rs222909	ENSG00000263335.1	AF001548.5	5.1	6.75e-07	0.00033	0.58	0.3	Testicular germ cell tumor;	chr16:15405432	chr16:15726674~15732993:+
COAD	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-5.1	6.76e-07	0.00033	-0.29	-0.3	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
COAD	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	5.09	6.76e-07	0.000331	0.53	0.3	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
COAD	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	5.09	6.76e-07	0.000331	0.53	0.3	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
COAD	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	5.09	6.77e-07	0.000331	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	5.09	6.77e-07	0.000331	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	5.09	6.77e-07	0.000331	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	5.09	6.77e-07	0.000331	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
COAD	cis	rs4761702	0.922	rs7960229	ENSG00000257252.4	RP11-486A14.2	-5.09	6.77e-07	0.000331	-0.37	-0.3	Immature fraction of reticulocytes;	chr12:93323943	chr12:93317135~93377736:-
COAD	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-5.09	6.78e-07	0.000332	-0.3	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
COAD	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	5.09	6.78e-07	0.000332	0.34	0.3	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
COAD	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	5.09	6.78e-07	0.000332	0.34	0.3	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
COAD	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	5.09	6.79e-07	0.000332	0.36	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
COAD	cis	rs1578862	1	rs56358050	ENSG00000259865.1	RP11-488L18.10	-5.09	6.79e-07	0.000332	-0.24	-0.3	Monocyte percentage of white cells;	chr1:247281864	chr1:247187281~247188526:-
COAD	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	5.09	6.8e-07	0.000333	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
COAD	cis	rs13256369	0.755	rs12550057	ENSG00000173295.6	FAM86B3P	5.09	6.82e-07	0.000333	0.43	0.3	Obesity-related traits;	chr8:8704758	chr8:8228595~8244865:+
COAD	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	5.09	6.83e-07	0.000334	0.29	0.3	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
COAD	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	5.09	6.84e-07	0.000334	0.31	0.3	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
COAD	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	5.09	6.84e-07	0.000334	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
COAD	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	5.09	6.84e-07	0.000334	0.36	0.3	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
COAD	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	5.09	6.84e-07	0.000334	0.36	0.3	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
COAD	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-5.09	6.84e-07	0.000334	-0.33	-0.3	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
COAD	cis	rs4568518	0.71	rs6955337	ENSG00000279048.1	RP11-511H23.2	-5.09	6.85e-07	0.000334	-0.21	-0.3	Measles;	chr7:17974951	chr7:17940503~17942922:+
COAD	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-5.09	6.86e-07	0.000335	-0.17	-0.3	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
COAD	cis	rs1578862	1	rs56250713	ENSG00000259865.1	RP11-488L18.10	-5.09	6.87e-07	0.000335	-0.24	-0.3	Monocyte percentage of white cells;	chr1:247281652	chr1:247187281~247188526:-
COAD	cis	rs13256369	0.802	rs2280560	ENSG00000173295.6	FAM86B3P	5.09	6.88e-07	0.000336	0.43	0.3	Obesity-related traits;	chr8:8703092	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	5.09	6.89e-07	0.000336	0.34	0.3	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
COAD	cis	rs58873874	0.737	rs10476052	ENSG00000248544.2	CTB-47B11.3	5.09	6.89e-07	0.000336	0.67	0.3	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157375741~157384950:-
COAD	cis	rs58873874	0.737	rs78832945	ENSG00000248544.2	CTB-47B11.3	5.09	6.89e-07	0.000336	0.67	0.3	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157375741~157384950:-
COAD	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.89e-07	0.000336	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
COAD	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	5.09	6.89e-07	0.000336	0.27	0.3	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
COAD	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-5.09	6.89e-07	0.000336	-0.55	-0.3	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
COAD	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	5.09	6.91e-07	0.000337	0.32	0.3	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
COAD	cis	rs2921036	0.545	rs4840975	ENSG00000253981.4	ALG1L13P	-5.09	6.92e-07	0.000338	-0.37	-0.3	Neuroticism;	chr8:8505748	chr8:8236003~8244667:-
COAD	cis	rs58873874	0.737	rs112160357	ENSG00000251405.2	CTB-109A12.1	5.09	6.92e-07	0.000338	0.72	0.3	Bipolar disorder (body mass index interaction);	chr5:157501696	chr5:157362615~157460078:-
COAD	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	5.09	6.93e-07	0.000338	0.34	0.3	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
COAD	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-5.09	6.94e-07	0.000339	-0.44	-0.3	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
COAD	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-5.09	6.96e-07	0.000339	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
COAD	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	5.09	6.96e-07	0.000339	0.33	0.3	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
COAD	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	5.09	6.96e-07	0.00034	0.66	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
COAD	cis	rs28374715	0.662	rs13329579	ENSG00000247556.5	OIP5-AS1	5.09	6.98e-07	0.00034	0.4	0.3	Ulcerative colitis;	chr15:41175237	chr15:41283990~41309737:+
COAD	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-5.09	6.98e-07	0.00034	-0.42	-0.3	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
COAD	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-5.09	6.98e-07	0.00034	-0.28	-0.3	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
COAD	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	5.09	6.99e-07	0.000341	0.4	0.3	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-5.09	6.99e-07	0.000341	-0.4	-0.3	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
COAD	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-5.09	7e-07	0.000341	-0.33	-0.3	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
COAD	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-5.09	7e-07	0.000341	-0.37	-0.3	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
COAD	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	5.09	7.01e-07	0.000342	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
COAD	cis	rs7656342	0.569	rs7668654	ENSG00000186234.7	FAM86MP	-5.09	7.01e-07	0.000342	-0.38	-0.3	Gut microbiota (bacterial taxa);	chr4:9742967	chr4:9692495~9702954:+
COAD	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-5.09	7.01e-07	0.000342	-0.4	-0.3	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
COAD	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-5.09	7.03e-07	0.000343	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
COAD	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-5.09	7.03e-07	0.000343	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
COAD	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-5.09	7.03e-07	0.000343	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
COAD	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-5.09	7.03e-07	0.000343	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
COAD	cis	rs440932	0.717	rs330944	ENSG00000173295.6	FAM86B3P	5.09	7.03e-07	0.000343	0.4	0.3	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	5.09	7.04e-07	0.000343	0.34	0.3	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
COAD	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	5.09	7.07e-07	0.000344	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
COAD	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-5.09	7.07e-07	0.000344	-0.35	-0.3	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-5.09	7.07e-07	0.000344	-0.35	-0.3	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
COAD	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-5.09	7.07e-07	0.000344	-0.32	-0.3	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
COAD	cis	rs7818688	0.697	rs61591488	ENSG00000253528.2	RP11-347C18.4	-5.09	7.08e-07	0.000345	-0.45	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972727	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs58314911	ENSG00000253528.2	RP11-347C18.4	-5.09	7.08e-07	0.000345	-0.45	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972883	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs58282276	ENSG00000253528.2	RP11-347C18.4	-5.09	7.08e-07	0.000345	-0.45	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94973163	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.654	rs75680386	ENSG00000253528.2	RP11-347C18.4	-5.09	7.08e-07	0.000345	-0.45	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94973920	chr8:94974573~94974853:-
COAD	cis	rs7560272	0.723	rs6729468	ENSG00000163016.8	ALMS1P	5.09	7.08e-07	0.000345	0.37	0.3	Schizophrenia;	chr2:73538126	chr2:73644919~73685576:+
COAD	cis	rs7560272	0.723	rs6744697	ENSG00000163016.8	ALMS1P	5.09	7.08e-07	0.000345	0.37	0.3	Schizophrenia;	chr2:73538311	chr2:73644919~73685576:+
COAD	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	5.08	7.09e-07	0.000345	0.32	0.3	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
COAD	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	5.08	7.1e-07	0.000345	0.32	0.3	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
COAD	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	5.08	7.1e-07	0.000345	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
COAD	cis	rs12935418	0.583	rs2549856	ENSG00000278985.1	RP11-303E16.9	-5.08	7.1e-07	0.000346	-0.32	-0.3	Mean corpuscular volume;	chr16:80993322	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs2549857	ENSG00000278985.1	RP11-303E16.9	5.08	7.1e-07	0.000346	0.32	0.3	Mean corpuscular volume;	chr16:80993353	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.673	rs2602426	ENSG00000278985.1	RP11-303E16.9	-5.08	7.1e-07	0.000346	-0.32	-0.3	Mean corpuscular volume;	chr16:81027632	chr16:80982319~80984094:-
COAD	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	5.08	7.1e-07	0.000346	0.26	0.3	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
COAD	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.1e-07	0.000346	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
COAD	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-5.08	7.11e-07	0.000346	-0.38	-0.3	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
COAD	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-5.08	7.12e-07	0.000346	-0.37	-0.3	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
COAD	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-5.08	7.13e-07	0.000347	-0.32	-0.3	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
COAD	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-5.08	7.13e-07	0.000347	-0.32	-0.3	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
COAD	cis	rs5015933	0.902	rs2841331	ENSG00000232630.1	PRPS1P2	-5.08	7.13e-07	0.000347	-0.31	-0.3	Body mass index;	chr9:125368736	chr9:125150653~125151589:+
COAD	cis	rs2732480	0.577	rs1489109	ENSG00000273765.1	RP11-370I10.11	5.08	7.14e-07	0.000347	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs1489108	ENSG00000273765.1	RP11-370I10.11	5.08	7.14e-07	0.000347	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48360920~48361377:+
COAD	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	5.08	7.14e-07	0.000347	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
COAD	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	5.08	7.14e-07	0.000347	0.35	0.3	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
COAD	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	5.08	7.15e-07	0.000348	0.33	0.3	Height;	chr20:49215517	chr20:49280319~49280409:+
COAD	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-5.08	7.15e-07	0.000348	-0.3	-0.3	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
COAD	cis	rs13217239	0.646	rs12527111	ENSG00000224843.5	LINC00240	-5.08	7.16e-07	0.000348	-0.35	-0.3	Schizophrenia;	chr6:27038696	chr6:26956992~27023924:+
COAD	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.08	7.16e-07	0.000348	-0.53	-0.3	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
COAD	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	5.08	7.16e-07	0.000348	0.53	0.3	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	5.08	7.16e-07	0.000348	0.53	0.3	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
COAD	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	5.08	7.17e-07	0.000349	0.44	0.3	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
COAD	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.08	7.18e-07	0.000349	0.35	0.3	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
COAD	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	5.08	7.18e-07	0.000349	0.31	0.3	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	5.08	7.18e-07	0.000349	0.31	0.3	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
COAD	cis	rs453301	0.686	rs11785819	ENSG00000253981.4	ALG1L13P	-5.08	7.18e-07	0.000349	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9012868	chr8:8236003~8244667:-
COAD	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.08	7.18e-07	0.000349	0.29	0.3	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
COAD	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.08	7.19e-07	0.00035	-0.37	-0.3	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
COAD	cis	rs13256369	0.865	rs13282523	ENSG00000173295.6	FAM86B3P	5.08	7.19e-07	0.00035	0.42	0.3	Obesity-related traits;	chr8:8719783	chr8:8228595~8244865:+
COAD	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.08	7.2e-07	0.00035	0.44	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.08	7.2e-07	0.00035	0.44	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
COAD	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	5.08	7.2e-07	0.00035	0.35	0.3	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
COAD	cis	rs1387259	0.839	rs7486941	ENSG00000273765.1	RP11-370I10.11	-5.08	7.2e-07	0.00035	-0.31	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48360920~48361377:+
COAD	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	5.08	7.21e-07	0.00035	0.42	0.3	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
COAD	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	5.08	7.21e-07	0.00035	0.89	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
COAD	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	5.08	7.21e-07	0.00035	0.38	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
COAD	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-5.08	7.22e-07	0.000351	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-5.08	7.22e-07	0.000351	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-5.08	7.22e-07	0.000351	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-5.08	7.22e-07	0.000351	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
COAD	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
COAD	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-5.08	7.22e-07	0.000351	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
COAD	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-5.08	7.23e-07	0.000351	-0.4	-0.3	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
COAD	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	5.08	7.23e-07	0.000351	0.38	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
COAD	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	5.08	7.23e-07	0.000351	0.33	0.3	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
COAD	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	5.08	7.24e-07	0.000351	0.37	0.3	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
COAD	cis	rs7829975	0.508	rs4841006	ENSG00000253981.4	ALG1L13P	-5.08	7.25e-07	0.000352	-0.36	-0.3	Mood instability;	chr8:8643964	chr8:8236003~8244667:-
COAD	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	5.08	7.26e-07	0.000352	0.32	0.3	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
COAD	cis	rs3752645	1	rs1860805	ENSG00000241764.3	AC002467.7	5.08	7.26e-07	0.000352	0.48	0.3	Bladder cancer (smoking interaction);	chr7:107092918	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs10232542	ENSG00000241764.3	AC002467.7	5.08	7.26e-07	0.000352	0.48	0.3	Bladder cancer (smoking interaction);	chr7:107111101	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs80182231	ENSG00000241764.3	AC002467.7	5.08	7.26e-07	0.000352	0.48	0.3	Bladder cancer (smoking interaction);	chr7:107114286	chr7:107742817~107744581:-
COAD	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	5.08	7.27e-07	0.000353	0.43	0.3	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
COAD	cis	rs58873874	0.737	rs10476050	ENSG00000248544.2	CTB-47B11.3	5.08	7.27e-07	0.000353	0.66	0.3	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157375741~157384950:-
COAD	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	5.08	7.28e-07	0.000353	0.56	0.3	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
COAD	cis	rs7560272	0.723	rs780391	ENSG00000163016.8	ALMS1P	-5.08	7.29e-07	0.000353	-0.36	-0.3	Schizophrenia;	chr2:73476777	chr2:73644919~73685576:+
COAD	cis	rs5758511	0.514	rs5758626	ENSG00000237037.8	NDUFA6-AS1	-5.08	7.31e-07	0.000354	-0.37	-0.3	Birth weight;	chr22:42176357	chr22:42090931~42137742:+
COAD	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	5.08	7.31e-07	0.000354	0.3	0.3	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
COAD	cis	rs748404	0.601	rs502157	ENSG00000205771.5	CATSPER2P1	5.08	7.31e-07	0.000354	0.37	0.3	Lung cancer;	chr15:43236375	chr15:43726918~43747094:-
COAD	cis	rs12935418	0.552	rs2123626	ENSG00000278985.1	RP11-303E16.9	-5.08	7.31e-07	0.000355	-0.32	-0.3	Mean corpuscular volume;	chr16:80988205	chr16:80982319~80984094:-
COAD	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-5.08	7.31e-07	0.000355	-0.31	-0.3	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
COAD	cis	rs7560272	0.588	rs4852959	ENSG00000163016.8	ALMS1P	-5.08	7.32e-07	0.000355	-0.37	-0.3	Schizophrenia;	chr2:73653474	chr2:73644919~73685576:+
COAD	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-5.08	7.32e-07	0.000355	-0.34	-0.3	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
COAD	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	5.08	7.33e-07	0.000355	0.41	0.3	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
COAD	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	5.08	7.33e-07	0.000355	0.41	0.3	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
COAD	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	5.08	7.33e-07	0.000355	0.4	0.3	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
COAD	cis	rs13217239	0.646	rs4403259	ENSG00000224843.5	LINC00240	-5.08	7.33e-07	0.000355	-0.35	-0.3	Schizophrenia;	chr6:27029838	chr6:26956992~27023924:+
COAD	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-5.08	7.34e-07	0.000356	-0.37	-0.3	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
COAD	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	5.08	7.34e-07	0.000356	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
COAD	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-5.08	7.35e-07	0.000356	-0.31	-0.3	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
COAD	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-5.08	7.35e-07	0.000356	-0.47	-0.3	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
COAD	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	5.08	7.35e-07	0.000356	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
COAD	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-5.08	7.35e-07	0.000356	-0.32	-0.3	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
COAD	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	5.08	7.35e-07	0.000356	0.36	0.3	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
COAD	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	5.08	7.36e-07	0.000357	0.34	0.3	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
COAD	cis	rs9393777	0.513	rs7759969	ENSG00000224843.5	LINC00240	5.08	7.36e-07	0.000357	0.47	0.3	Intelligence (multi-trait analysis);	chr6:26662868	chr6:26956992~27023924:+
COAD	cis	rs2665103	0.589	rs3858953	ENSG00000259429.4	UBE2Q2P2	-5.08	7.37e-07	0.000357	-0.26	-0.3	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82355142~82420075:+
COAD	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	5.08	7.37e-07	0.000357	0.27	0.3	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	5.08	7.37e-07	0.000357	0.27	0.3	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
COAD	cis	rs9951698	0.703	rs8097038	ENSG00000266969.1	RP11-773H22.4	5.08	7.38e-07	0.000358	0.39	0.3	Intelligence (multi-trait analysis);	chr18:13037019	chr18:12984694~12991173:-
COAD	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	5.08	7.39e-07	0.000358	0.43	0.3	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
COAD	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	5.08	7.39e-07	0.000358	0.43	0.3	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
COAD	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	5.08	7.39e-07	0.000358	0.37	0.3	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
COAD	cis	rs7647973	0.516	rs4536858	ENSG00000225399.4	RP11-3B7.1	5.08	7.39e-07	0.000358	0.34	0.3	Menarche (age at onset);	chr3:49155648	chr3:49260085~49261316:+
COAD	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.08	7.39e-07	0.000358	-0.27	-0.3	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.08	7.39e-07	0.000358	-0.27	-0.3	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.08	7.39e-07	0.000358	-0.27	-0.3	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.08	7.39e-07	0.000358	-0.27	-0.3	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
COAD	cis	rs12935418	0.672	rs2602424	ENSG00000278985.1	RP11-303E16.9	-5.08	7.4e-07	0.000358	-0.32	-0.3	Mean corpuscular volume;	chr16:81009600	chr16:80982319~80984094:-
COAD	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	5.08	7.4e-07	0.000358	0.4	0.3	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
COAD	cis	rs2255336	0.873	rs7397310	ENSG00000245648.1	RP11-277P12.20	5.08	7.4e-07	0.000358	0.48	0.3	Blood protein levels;	chr12:10368394	chr12:10363769~10398506:+
COAD	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-5.08	7.4e-07	0.000359	-0.37	-0.3	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
COAD	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-5.08	7.41e-07	0.000359	-0.38	-0.3	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
COAD	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	5.08	7.42e-07	0.000359	0.46	0.3	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
COAD	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	5.08	7.43e-07	0.00036	0.46	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
COAD	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	5.08	7.44e-07	0.00036	0.33	0.3	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
COAD	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	5.08	7.44e-07	0.00036	0.33	0.3	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	5.08	7.44e-07	0.00036	0.33	0.3	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
COAD	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-5.07	7.44e-07	0.00036	-0.3	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
COAD	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	5.07	7.45e-07	0.00036	0.33	0.3	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
COAD	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-5.07	7.45e-07	0.00036	-0.52	-0.3	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
COAD	cis	rs1056107	0.931	rs7855376	ENSG00000225513.1	RP11-165N19.2	5.07	7.46e-07	0.000361	0.36	0.3	Colorectal cancer;	chr9:112251851	chr9:112173522~112173971:-
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	5.07	7.46e-07	0.000361	0.3	0.3	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
COAD	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-5.07	7.46e-07	0.000361	-0.3	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
COAD	cis	rs4568518	0.74	rs12699924	ENSG00000279048.1	RP11-511H23.2	5.07	7.46e-07	0.000361	0.22	0.3	Measles;	chr7:17970768	chr7:17940503~17942922:+
COAD	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	5.07	7.46e-07	0.000361	0.45	0.3	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
COAD	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-5.07	7.46e-07	0.000361	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
COAD	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	5.07	7.47e-07	0.000361	0.39	0.3	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
COAD	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	5.07	7.48e-07	0.000362	0.2	0.3	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
COAD	cis	rs73198271	0.96	rs11776546	ENSG00000173295.6	FAM86B3P	-5.07	7.49e-07	0.000362	-0.42	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr8:8228595~8244865:+
COAD	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	5.07	7.49e-07	0.000362	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
COAD	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	5.07	7.49e-07	0.000362	0.18	0.3	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
COAD	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-5.07	7.5e-07	0.000362	-0.34	-0.3	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
COAD	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-5.07	7.5e-07	0.000362	-0.34	-0.3	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
COAD	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-5.07	7.5e-07	0.000362	-0.34	-0.3	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
COAD	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-5.07	7.51e-07	0.000363	-0.36	-0.3	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-5.07	7.51e-07	0.000363	-0.36	-0.3	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
COAD	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	5.07	7.51e-07	0.000363	0.34	0.3	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
COAD	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-5.07	7.51e-07	0.000363	-0.47	-0.3	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
COAD	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	5.07	7.51e-07	0.000363	0.28	0.3	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
COAD	cis	rs9910055	0.529	rs190144	ENSG00000267080.4	ASB16-AS1	5.07	7.52e-07	0.000363	0.29	0.3	Total body bone mineral density;	chr17:44087216	chr17:44175973~44186717:-
COAD	cis	rs13256369	0.951	rs10503394	ENSG00000173295.6	FAM86B3P	5.07	7.52e-07	0.000363	0.43	0.3	Obesity-related traits;	chr8:8708265	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.951	rs13260947	ENSG00000173295.6	FAM86B3P	5.07	7.52e-07	0.000363	0.43	0.3	Obesity-related traits;	chr8:8708373	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.951	rs13259955	ENSG00000173295.6	FAM86B3P	5.07	7.52e-07	0.000363	0.43	0.3	Obesity-related traits;	chr8:8708375	chr8:8228595~8244865:+
COAD	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	5.07	7.52e-07	0.000364	0.36	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
COAD	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	5.07	7.52e-07	0.000364	0.41	0.3	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
COAD	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-5.07	7.54e-07	0.000364	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
COAD	cis	rs9951698	0.703	rs28619103	ENSG00000266969.1	RP11-773H22.4	5.07	7.55e-07	0.000365	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12993196	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs12605638	ENSG00000266969.1	RP11-773H22.4	5.07	7.55e-07	0.000365	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12993544	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.66	rs7229870	ENSG00000266969.1	RP11-773H22.4	5.07	7.55e-07	0.000365	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12994469	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.667	rs28641764	ENSG00000266969.1	RP11-773H22.4	5.07	7.55e-07	0.000365	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12994784	chr18:12984694~12991173:-
COAD	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-5.07	7.55e-07	0.000365	-0.31	-0.3	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
COAD	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	5.07	7.56e-07	0.000365	0.39	0.3	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
COAD	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-5.07	7.56e-07	0.000365	-0.28	-0.3	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
COAD	cis	rs55823223	0.564	rs12103594	ENSG00000267801.1	RP11-552F3.9	5.07	7.56e-07	0.000365	0.42	0.3	Psoriasis;	chr17:75859198	chr17:75876372~75879546:+
COAD	cis	rs55823223	0.59	rs11870142	ENSG00000267801.1	RP11-552F3.9	5.07	7.56e-07	0.000365	0.42	0.3	Psoriasis;	chr17:75862921	chr17:75876372~75879546:+
COAD	cis	rs55823223	0.503	rs55699990	ENSG00000267801.1	RP11-552F3.9	5.07	7.56e-07	0.000365	0.42	0.3	Psoriasis;	chr17:75863105	chr17:75876372~75879546:+
COAD	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	5.07	7.56e-07	0.000365	0.35	0.3	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000273765.1	RP11-370I10.11	5.07	7.56e-07	0.000365	0.32	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48360920~48361377:+
COAD	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	5.07	7.57e-07	0.000365	0.44	0.3	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	5.07	7.58e-07	0.000366	0.34	0.3	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
COAD	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-5.07	7.58e-07	0.000366	-0.52	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
COAD	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-5.07	7.59e-07	0.000366	-0.33	-0.3	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-5.07	7.59e-07	0.000366	-0.33	-0.3	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
COAD	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-5.07	7.59e-07	0.000366	-0.47	-0.3	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
COAD	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	5.07	7.59e-07	0.000366	0.43	0.3	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
COAD	cis	rs58873874	0.737	rs11749762	ENSG00000248544.2	CTB-47B11.3	5.07	7.6e-07	0.000367	0.65	0.3	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157375741~157384950:-
COAD	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	5.07	7.61e-07	0.000367	0.35	0.3	Height;	chr3:53072864	chr3:53064283~53065091:-
COAD	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-5.07	7.62e-07	0.000368	-0.3	-0.3	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
COAD	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-5.07	7.62e-07	0.000368	-0.35	-0.3	Height;	chr20:49257468	chr20:49280319~49280409:+
COAD	cis	rs362272	0.545	rs2749785	ENSG00000248840.2	RP11-357G3.2	-5.07	7.62e-07	0.000368	-0.35	-0.3	Serum sulfate level;	chr4:3323452	chr4:3312512~3313058:+
COAD	cis	rs2732480	0.5	rs7315820	ENSG00000273765.1	RP11-370I10.11	5.07	7.63e-07	0.000368	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48360920~48361377:+
COAD	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-5.07	7.64e-07	0.000369	-0.37	-0.3	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	5.07	7.64e-07	0.000369	0.35	0.3	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
COAD	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-5.07	7.65e-07	0.000369	-0.31	-0.3	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
COAD	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-5.07	7.65e-07	0.000369	-0.35	-0.3	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
COAD	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.07	7.66e-07	0.000369	-0.37	-0.3	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
COAD	cis	rs2732480	0.5	rs7297824	ENSG00000273765.1	RP11-370I10.11	5.07	7.66e-07	0.00037	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48360920~48361377:+
COAD	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-5.07	7.67e-07	0.00037	-0.32	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
COAD	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-5.07	7.67e-07	0.00037	-0.36	-0.3	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
COAD	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	5.07	7.67e-07	0.00037	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
COAD	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	5.07	7.67e-07	0.00037	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
COAD	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	5.07	7.67e-07	0.00037	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
COAD	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	5.07	7.67e-07	0.00037	0.34	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
COAD	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	5.07	7.67e-07	0.00037	0.34	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
COAD	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	5.07	7.68e-07	0.00037	0.4	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	5.07	7.68e-07	0.00037	0.4	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
COAD	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	5.07	7.68e-07	0.00037	0.36	0.3	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
COAD	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	5.07	7.69e-07	0.000371	0.3	0.3	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
COAD	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	5.07	7.69e-07	0.000371	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
COAD	cis	rs9625935	0.536	rs9608819	ENSG00000279159.1	RP3-394A18.1	5.07	7.7e-07	0.000371	0.21	0.3	Tonsillectomy;	chr22:29864820	chr22:29978950~30028236:-
COAD	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-5.07	7.7e-07	0.000371	-0.27	-0.3	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
COAD	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.07	7.71e-07	0.000371	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
COAD	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	5.07	7.71e-07	0.000372	0.47	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
COAD	cis	rs5758511	0.68	rs5758686	ENSG00000237037.8	NDUFA6-AS1	-5.07	7.73e-07	0.000373	-0.36	-0.3	Birth weight;	chr22:42259371	chr22:42090931~42137742:+
COAD	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-5.07	7.74e-07	0.000373	-0.2	-0.3	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
COAD	cis	rs8002861	0.935	rs4101376	ENSG00000274001.1	RP11-5G9.5	-5.07	7.74e-07	0.000373	-0.27	-0.3	Leprosy;	chr13:43895699	chr13:43877715~43878163:-
COAD	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-5.07	7.75e-07	0.000373	-0.17	-0.3	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
COAD	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	5.07	7.75e-07	0.000373	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
COAD	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-5.07	7.76e-07	0.000374	-0.44	-0.3	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
COAD	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	5.07	7.76e-07	0.000374	0.41	0.3	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
COAD	cis	rs603446	0.935	rs180376	ENSG00000254851.1	RP11-109L13.1	-5.07	7.76e-07	0.000374	-0.35	-0.3	Triglycerides;	chr11:116719323	chr11:117135528~117138582:+
COAD	cis	rs8002861	0.81	rs2275252	ENSG00000274001.1	RP11-5G9.5	5.07	7.76e-07	0.000374	0.27	0.3	Leprosy;	chr13:43880238	chr13:43877715~43878163:-
COAD	cis	rs7955901	0.904	rs7956274	ENSG00000258053.1	CTD-2021H9.3	-5.07	7.76e-07	0.000374	-0.36	-0.3	Type 2 diabetes;	chr12:71030622	chr12:71047402~71118247:-
COAD	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-5.07	7.77e-07	0.000374	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
COAD	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-5.07	7.77e-07	0.000374	-0.43	-0.3	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
COAD	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	5.07	7.78e-07	0.000375	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
COAD	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-5.07	7.79e-07	0.000375	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
COAD	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-5.07	7.79e-07	0.000375	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
COAD	cis	rs9847710	1	rs4687697	ENSG00000280417.1	RP11-5O17.1	5.06	7.8e-07	0.000376	0.3	0.3	Ulcerative colitis;	chr3:53056474	chr3:53046166~53048122:+
COAD	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-5.06	7.81e-07	0.000376	-0.44	-0.3	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
COAD	cis	rs7078219	0.743	rs11190128	ENSG00000228778.1	RP11-129J12.1	-5.06	7.82e-07	0.000376	-0.35	-0.3	Dental caries;	chr10:99515392	chr10:99527081~99528261:+
COAD	cis	rs7078219	0.686	rs12412214	ENSG00000228778.1	RP11-129J12.1	-5.06	7.82e-07	0.000376	-0.35	-0.3	Dental caries;	chr10:99516499	chr10:99527081~99528261:+
COAD	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-5.06	7.82e-07	0.000376	-0.33	-0.3	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
COAD	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	5.06	7.82e-07	0.000376	0.4	0.3	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
COAD	cis	rs1790761	0.692	rs614080	ENSG00000231793.4	DOC2GP	5.06	7.83e-07	0.000376	0.34	0.3	Mean corpuscular volume;	chr11:67579816	chr11:67612653~67616257:-
COAD	cis	rs754466	0.958	rs58916802	ENSG00000204049.1	RP11-126H7.4	5.06	7.83e-07	0.000377	0.42	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77936112	chr10:77866875~77869610:+
COAD	cis	rs9951698	0.703	rs7226616	ENSG00000266969.1	RP11-773H22.4	5.06	7.84e-07	0.000377	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13009906	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs7237236	ENSG00000266969.1	RP11-773H22.4	5.06	7.84e-07	0.000377	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13011432	chr18:12984694~12991173:-
COAD	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	5.06	7.85e-07	0.000377	0.32	0.3	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
COAD	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	5.06	7.85e-07	0.000377	0.34	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
COAD	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	5.06	7.86e-07	0.000377	0.42	0.3	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	5.06	7.86e-07	0.000377	0.42	0.3	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	5.06	7.86e-07	0.000377	0.42	0.3	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
COAD	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-5.06	7.87e-07	0.000378	-0.42	-0.3	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
COAD	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-5.06	7.87e-07	0.000378	-0.31	-0.3	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
COAD	cis	rs2439831	0.541	rs12440854	ENSG00000205771.5	CATSPER2P1	-5.06	7.88e-07	0.000378	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43318474	chr15:43726918~43747094:-
COAD	cis	rs7955901	0.904	rs7959965	ENSG00000258053.1	CTD-2021H9.3	-5.06	7.88e-07	0.000378	-0.36	-0.3	Type 2 diabetes;	chr12:71031384	chr12:71047402~71118247:-
COAD	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	5.06	7.88e-07	0.000378	0.39	0.3	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
COAD	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	5.06	7.89e-07	0.000379	0.57	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
COAD	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-5.06	7.9e-07	0.000379	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-5.06	7.9e-07	0.000379	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	5.06	7.91e-07	0.000379	0.34	0.3	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
COAD	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-5.06	7.92e-07	0.00038	-0.3	-0.3	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
COAD	cis	rs5015933	0.902	rs1969045	ENSG00000232630.1	PRPS1P2	-5.06	7.92e-07	0.00038	-0.29	-0.3	Body mass index;	chr9:125368261	chr9:125150653~125151589:+
COAD	cis	rs9291683	0.935	rs1860911	ENSG00000250413.1	RP11-448G15.1	-5.06	7.93e-07	0.000381	-0.37	-0.3	Bone mineral density;	chr4:10273433	chr4:10006482~10009725:+
COAD	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	5.06	7.93e-07	0.000381	0.21	0.3	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
COAD	cis	rs8002861	0.781	rs3816311	ENSG00000274001.1	RP11-5G9.5	5.06	7.95e-07	0.000381	0.27	0.3	Leprosy;	chr13:43879647	chr13:43877715~43878163:-
COAD	cis	rs2115630	0.645	rs1107179	ENSG00000259728.4	LINC00933	5.06	7.95e-07	0.000382	0.36	0.3	P wave terminal force;	chr15:84655131	chr15:84570649~84580175:+
COAD	cis	rs4568518	0.71	rs13230836	ENSG00000279048.1	RP11-511H23.2	5.06	7.96e-07	0.000382	0.22	0.3	Measles;	chr7:17974272	chr7:17940503~17942922:+
COAD	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	5.06	7.96e-07	0.000382	0.34	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
COAD	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-5.06	7.98e-07	0.000383	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
COAD	cis	rs11846409	0.799	rs2583330	ENSG00000274576.2	IGHV2-70	5.06	7.99e-07	0.000383	0.29	0.3	Rheumatic heart disease;	chr14:106621051	chr14:106770577~106771020:-
COAD	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-5.06	7.99e-07	0.000383	-0.39	-0.3	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
COAD	cis	rs6452524	0.562	rs10474080	ENSG00000271862.1	RP11-343L5.2	5.06	8e-07	0.000384	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83049376~83050964:-
COAD	cis	rs7078219	0.714	rs11190137	ENSG00000228778.1	RP11-129J12.1	5.06	8.02e-07	0.000384	0.34	0.3	Dental caries;	chr10:99528187	chr10:99527081~99528261:+
COAD	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5.06	8.03e-07	0.000385	0.33	0.3	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
COAD	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	5.06	8.03e-07	0.000385	0.3	0.3	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
COAD	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.06	8.03e-07	0.000385	0.32	0.3	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
COAD	cis	rs2115630	0.653	rs61394864	ENSG00000259728.4	LINC00933	-5.06	8.03e-07	0.000385	-0.35	-0.3	P wave terminal force;	chr15:84626943	chr15:84570649~84580175:+
COAD	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	5.06	8.03e-07	0.000385	0.35	0.3	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	5.06	8.04e-07	0.000385	0.4	0.3	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
COAD	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-5.06	8.04e-07	0.000385	-0.33	-0.3	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
COAD	cis	rs6452524	0.534	rs10061690	ENSG00000271862.1	RP11-343L5.2	5.06	8.04e-07	0.000385	0.31	0.3	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83049376~83050964:-
COAD	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	5.06	8.05e-07	0.000386	0.39	0.3	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	5.06	8.05e-07	0.000386	0.39	0.3	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
COAD	cis	rs9951698	0.667	rs567031	ENSG00000266969.1	RP11-773H22.4	5.06	8.06e-07	0.000386	0.39	0.3	Intelligence (multi-trait analysis);	chr18:13093775	chr18:12984694~12991173:-
COAD	cis	rs492146	0.765	rs670960	ENSG00000243236.5	GSTA9P	-5.06	8.06e-07	0.000386	-0.33	-0.3	Epilepsy (remission after treatment);	chr6:52978998	chr6:52939726~52957521:-
COAD	cis	rs492146	0.765	rs672281	ENSG00000243236.5	GSTA9P	-5.06	8.06e-07	0.000386	-0.33	-0.3	Epilepsy (remission after treatment);	chr6:52979247	chr6:52939726~52957521:-
COAD	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-5.06	8.07e-07	0.000386	-0.51	-0.3	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
COAD	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	5.06	8.07e-07	0.000387	0.33	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
COAD	cis	rs13256369	0.708	rs11249886	ENSG00000173295.6	FAM86B3P	5.06	8.07e-07	0.000387	0.43	0.3	Obesity-related traits;	chr8:8704511	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs11249887	ENSG00000173295.6	FAM86B3P	5.06	8.07e-07	0.000387	0.43	0.3	Obesity-related traits;	chr8:8704674	chr8:8228595~8244865:+
COAD	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	5.06	8.08e-07	0.000387	0.3	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
COAD	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	5.06	8.08e-07	0.000387	0.46	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
COAD	cis	rs6452524	0.537	rs1583	ENSG00000271862.1	RP11-343L5.2	5.06	8.08e-07	0.000387	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83049376~83050964:-
COAD	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	5.06	8.08e-07	0.000387	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
COAD	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	5.06	8.08e-07	0.000387	0.57	0.3	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	5.06	8.08e-07	0.000387	0.57	0.3	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
COAD	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	5.06	8.08e-07	0.000387	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
COAD	cis	rs7818688	0.591	rs10098025	ENSG00000253528.2	RP11-347C18.4	-5.06	8.09e-07	0.000387	-0.42	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94977355	chr8:94974573~94974853:-
COAD	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.06	8.09e-07	0.000388	0.39	0.3	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
COAD	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	5.06	8.11e-07	0.000388	0.36	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
COAD	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-5.06	8.12e-07	0.000389	-0.34	-0.3	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
COAD	cis	rs9951698	0.703	rs9949589	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12999755	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.693	rs9949682	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:12999822	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs9783903	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13000211	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs7243660	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13002197	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.667	rs7234094	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13007481	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs6505777	ENSG00000266969.1	RP11-773H22.4	5.06	8.12e-07	0.000389	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13008370	chr18:12984694~12991173:-
COAD	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	5.06	8.14e-07	0.000389	0.33	0.3	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
COAD	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-5.06	8.14e-07	0.00039	-0.34	-0.3	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
COAD	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-5.06	8.14e-07	0.00039	-0.42	-0.3	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
COAD	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	5.06	8.15e-07	0.00039	0.2	0.3	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
COAD	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-5.06	8.16e-07	0.00039	-0.52	-0.3	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-5.06	8.16e-07	0.00039	-0.52	-0.3	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-5.06	8.16e-07	0.00039	-0.52	-0.3	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
COAD	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-5.06	8.17e-07	0.000391	-0.3	-0.3	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
COAD	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-5.06	8.17e-07	0.000391	-0.3	-0.3	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
COAD	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-5.06	8.17e-07	0.000391	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-5.06	8.17e-07	0.000391	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-5.06	8.17e-07	0.000391	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
COAD	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-5.05	8.18e-07	0.000391	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
COAD	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	5.05	8.2e-07	0.000392	0.4	0.3	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
COAD	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-5.05	8.2e-07	0.000392	-0.28	-0.3	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
COAD	cis	rs603446	0.967	rs3741300	ENSG00000254851.1	RP11-109L13.1	-5.05	8.21e-07	0.000393	-0.36	-0.3	Triglycerides;	chr11:116760974	chr11:117135528~117138582:+
COAD	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	5.05	8.21e-07	0.000393	0.4	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
COAD	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-5.05	8.22e-07	0.000393	-0.4	-0.3	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
COAD	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	5.05	8.22e-07	0.000393	0.4	0.3	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
COAD	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-5.05	8.22e-07	0.000393	-0.38	-0.3	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
COAD	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-5.05	8.22e-07	0.000393	-0.38	-0.3	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
COAD	cis	rs61160187	0.582	rs17444495	ENSG00000215032.2	GNL3LP1	5.05	8.23e-07	0.000393	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60891935~60893577:-
COAD	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-5.05	8.23e-07	0.000394	-0.39	-0.3	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
COAD	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-5.05	8.23e-07	0.000394	-0.39	-0.3	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
COAD	cis	rs9951698	0.703	rs9964466	ENSG00000266969.1	RP11-773H22.4	5.05	8.27e-07	0.000395	0.37	0.3	Intelligence (multi-trait analysis);	chr18:13030384	chr18:12984694~12991173:-
COAD	cis	rs12935418	0.616	rs2602453	ENSG00000278985.1	RP11-303E16.9	-5.05	8.27e-07	0.000395	-0.32	-0.3	Mean corpuscular volume;	chr16:80994358	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2970086	ENSG00000278985.1	RP11-303E16.9	-5.05	8.27e-07	0.000395	-0.32	-0.3	Mean corpuscular volume;	chr16:80994835	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2970085	ENSG00000278985.1	RP11-303E16.9	-5.05	8.27e-07	0.000395	-0.32	-0.3	Mean corpuscular volume;	chr16:80994842	chr16:80982319~80984094:-
COAD	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.05	8.27e-07	0.000395	-0.42	-0.3	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
COAD	cis	rs2732480	0.5	rs2932093	ENSG00000273765.1	RP11-370I10.11	5.05	8.29e-07	0.000396	0.34	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48360920~48361377:+
COAD	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-5.05	8.29e-07	0.000396	-0.37	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
COAD	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	5.05	8.29e-07	0.000396	0.55	0.3	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
COAD	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	5.05	8.31e-07	0.000397	0.33	0.3	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
COAD	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	5.05	8.32e-07	0.000397	0.32	0.3	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
COAD	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-5.05	8.32e-07	0.000397	-0.28	-0.3	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
COAD	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	5.05	8.33e-07	0.000397	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
COAD	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-5.05	8.34e-07	0.000398	-0.32	-0.3	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
COAD	cis	rs13256369	0.756	rs13282580	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8705393	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs13256404	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8705464	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.756	rs13280759	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8705485	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs13254997	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8706243	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs13255061	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8706324	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs12541477	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8706385	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs13256611	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8706831	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs11786125	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8707060	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.802	rs11249888	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8707424	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs11249889	ENSG00000173295.6	FAM86B3P	5.05	8.35e-07	0.000398	0.43	0.3	Obesity-related traits;	chr8:8707482	chr8:8228595~8244865:+
COAD	cis	rs1578862	0.932	rs11579326	ENSG00000259865.1	RP11-488L18.10	-5.05	8.36e-07	0.000399	-0.24	-0.3	Monocyte percentage of white cells;	chr1:247291089	chr1:247187281~247188526:-
COAD	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	5.05	8.36e-07	0.000399	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	5.05	8.36e-07	0.000399	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	5.05	8.36e-07	0.000399	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	5.05	8.36e-07	0.000399	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
COAD	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-5.05	8.36e-07	0.000399	-0.6	-0.3	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
COAD	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-5.05	8.36e-07	0.000399	-0.6	-0.3	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
COAD	cis	rs9393777	0.513	rs7740197	ENSG00000224843.5	LINC00240	-5.05	8.36e-07	0.000399	-0.47	-0.3	Intelligence (multi-trait analysis);	chr6:26663250	chr6:26956992~27023924:+
COAD	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	5.05	8.37e-07	0.000399	0.27	0.3	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
COAD	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.05	8.37e-07	0.000399	-0.52	-0.3	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
COAD	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-5.05	8.37e-07	0.000399	-0.47	-0.3	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
COAD	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.05	8.37e-07	0.000399	0.36	0.3	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
COAD	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	5.05	8.38e-07	0.000399	0.33	0.3	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
COAD	cis	rs5758511	0.679	rs55867855	ENSG00000237037.8	NDUFA6-AS1	-5.05	8.38e-07	4e-04	-0.36	-0.3	Birth weight;	chr22:42227252	chr22:42090931~42137742:+
COAD	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-5.05	8.38e-07	4e-04	-0.39	-0.3	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
COAD	cis	rs17264034	0.5	rs1508800	ENSG00000250786.1	SNHG18	-5.05	8.39e-07	4e-04	-0.33	-0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556349	chr5:9546200~9550609:+
COAD	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	5.05	8.39e-07	4e-04	0.38	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
COAD	cis	rs13256369	0.851	rs11249890	ENSG00000173295.6	FAM86B3P	5.05	8.4e-07	4e-04	0.43	0.3	Obesity-related traits;	chr8:8707735	chr8:8228595~8244865:+
COAD	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.05	8.41e-07	0.000401	-0.31	-0.3	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
COAD	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.05	8.41e-07	0.000401	-0.31	-0.3	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
COAD	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.05	8.41e-07	0.000401	-0.31	-0.3	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
COAD	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.05	8.41e-07	0.000401	-0.31	-0.3	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
COAD	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-5.05	8.43e-07	0.000401	-0.4	-0.3	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
COAD	cis	rs7560272	0.723	rs2421548	ENSG00000163016.8	ALMS1P	-5.05	8.43e-07	0.000402	-0.36	-0.3	Schizophrenia;	chr2:73414112	chr2:73644919~73685576:+
COAD	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-5.05	8.43e-07	0.000402	-0.31	-0.3	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
COAD	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	5.05	8.43e-07	0.000402	0.35	0.3	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
COAD	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	5.05	8.44e-07	0.000402	0.34	0.3	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
COAD	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-5.05	8.44e-07	0.000402	-0.36	-0.3	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
COAD	cis	rs7404843	0.733	rs153003	ENSG00000263335.1	AF001548.5	5.05	8.44e-07	0.000402	0.54	0.3	Testicular germ cell tumor;	chr16:15397543	chr16:15726674~15732993:+
COAD	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-5.05	8.44e-07	0.000402	-0.3	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
COAD	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.05	8.45e-07	0.000403	0.31	0.3	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
COAD	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-5.05	8.46e-07	0.000403	-0.36	-0.3	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
COAD	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	5.05	8.46e-07	0.000403	0.44	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
COAD	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	5.05	8.49e-07	0.000404	0.4	0.3	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	5.05	8.49e-07	0.000404	0.4	0.3	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
COAD	cis	rs5015933	0.966	rs7870475	ENSG00000232630.1	PRPS1P2	-5.05	8.5e-07	0.000404	-0.3	-0.3	Body mass index;	chr9:125371755	chr9:125150653~125151589:+
COAD	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	5.05	8.5e-07	0.000404	0.33	0.3	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
COAD	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-5.05	8.5e-07	0.000404	-0.35	-0.3	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
COAD	cis	rs12935418	0.672	rs1453327	ENSG00000278985.1	RP11-303E16.9	-5.05	8.5e-07	0.000405	-0.32	-0.3	Mean corpuscular volume;	chr16:81014959	chr16:80982319~80984094:-
COAD	cis	rs9487051	0.714	rs6903695	ENSG00000219700.1	PTCHD3P3	-5.05	8.5e-07	0.000405	-0.32	-0.3	Reticulocyte fraction of red cells;	chr6:109310219	chr6:109288571~109290503:-
COAD	cis	rs10078	0.571	rs2561664	ENSG00000225138.6	CTD-2228K2.7	5.05	8.5e-07	0.000405	0.5	0.3	Fat distribution (HIV);	chr5:459678	chr5:473236~480884:+
COAD	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	5.05	8.51e-07	0.000405	0.31	0.3	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
COAD	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	5.05	8.51e-07	0.000405	0.34	0.3	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
COAD	cis	rs9487051	0.676	rs9398196	ENSG00000219700.1	PTCHD3P3	5.05	8.52e-07	0.000405	0.32	0.3	Reticulocyte fraction of red cells;	chr6:109280351	chr6:109288571~109290503:-
COAD	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.05	8.53e-07	0.000406	-0.39	-0.3	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.05	8.53e-07	0.000406	-0.39	-0.3	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
COAD	cis	rs12928939	0.768	rs71386932	ENSG00000260886.1	TAT-AS1	5.05	8.54e-07	0.000406	0.44	0.3	Post bronchodilator FEV1;	chr16:71782288	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.911	rs8051878	ENSG00000260886.1	TAT-AS1	5.05	8.54e-07	0.000406	0.44	0.3	Post bronchodilator FEV1;	chr16:71784528	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.911	rs11645704	ENSG00000260886.1	TAT-AS1	5.05	8.54e-07	0.000406	0.44	0.3	Post bronchodilator FEV1;	chr16:71792708	chr16:71565789~71578187:+
COAD	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.05	8.54e-07	0.000406	0.37	0.3	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
COAD	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	5.05	8.54e-07	0.000406	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	5.05	8.54e-07	0.000406	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	5.05	8.54e-07	0.000406	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
COAD	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	5.05	8.54e-07	0.000406	0.4	0.3	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
COAD	cis	rs494562	0.667	rs494688	ENSG00000234155.1	RP11-30P6.6	-5.05	8.55e-07	0.000407	-0.57	-0.3	Metabolic traits;Blood metabolite levels;	chr6:85390371	chr6:85387219~85390186:-
COAD	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	5.05	8.56e-07	0.000407	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	5.05	8.56e-07	0.000407	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
COAD	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	5.05	8.57e-07	0.000408	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	5.05	8.57e-07	0.000408	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
COAD	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	5.05	8.57e-07	0.000408	0.36	0.3	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
COAD	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	5.05	8.57e-07	0.000408	0.34	0.3	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
COAD	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-5.04	8.58e-07	0.000408	-0.32	-0.3	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
COAD	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-5.04	8.59e-07	0.000408	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
COAD	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-5.04	8.59e-07	0.000408	-0.55	-0.3	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-5.04	8.62e-07	0.00041	-0.33	-0.3	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
COAD	cis	rs7688540	0.8	rs1578898	ENSG00000211553.1	AC253576.2	-5.04	8.62e-07	0.00041	-0.44	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:136461~136568:+
COAD	cis	rs1056107	0.931	rs1359878	ENSG00000225513.1	RP11-165N19.2	-5.04	8.62e-07	0.00041	-0.36	-0.3	Colorectal cancer;	chr9:112249037	chr9:112173522~112173971:-
COAD	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-5.04	8.63e-07	0.00041	-0.54	-0.3	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
COAD	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	5.04	8.64e-07	0.00041	0.33	0.3	Height;	chr20:49220589	chr20:49280319~49280409:+
COAD	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	5.04	8.64e-07	0.000411	0.37	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
COAD	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-5.04	8.64e-07	0.000411	-0.38	-0.3	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
COAD	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-5.04	8.65e-07	0.000411	-0.31	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
COAD	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-5.04	8.65e-07	0.000411	-0.51	-0.3	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
COAD	cis	rs12935418	0.583	rs2911150	ENSG00000278985.1	RP11-303E16.9	5.04	8.66e-07	0.000411	0.32	0.3	Mean corpuscular volume;	chr16:80995194	chr16:80982319~80984094:-
COAD	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	5.04	8.66e-07	0.000412	0.31	0.3	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
COAD	cis	rs7829975	0.846	rs1879957	ENSG00000253981.4	ALG1L13P	-5.04	8.67e-07	0.000412	-0.35	-0.3	Mood instability;	chr8:8687298	chr8:8236003~8244667:-
COAD	cis	rs5015933	0.902	rs13291306	ENSG00000232630.1	PRPS1P2	-5.04	8.67e-07	0.000412	-0.29	-0.3	Body mass index;	chr9:125362519	chr9:125150653~125151589:+
COAD	cis	rs7829975	0.84	rs555617	ENSG00000253981.4	ALG1L13P	-5.04	8.7e-07	0.000413	-0.36	-0.3	Mood instability;	chr8:8735335	chr8:8236003~8244667:-
COAD	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	5.04	8.7e-07	0.000413	0.58	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
COAD	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-5.04	8.71e-07	0.000414	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-5.04	8.71e-07	0.000414	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-5.04	8.71e-07	0.000414	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-5.04	8.71e-07	0.000414	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-5.04	8.71e-07	0.000414	-0.29	-0.3	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
COAD	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.04	8.72e-07	0.000414	-0.26	-0.3	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
COAD	cis	rs7560272	0.723	rs1083923	ENSG00000163016.8	ALMS1P	-5.04	8.72e-07	0.000414	-0.37	-0.3	Schizophrenia;	chr2:73476247	chr2:73644919~73685576:+
COAD	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	5.04	8.74e-07	0.000415	0.52	0.3	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	5.04	8.74e-07	0.000415	0.52	0.3	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
COAD	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-5.04	8.74e-07	0.000415	-0.38	-0.3	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
COAD	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-5.04	8.75e-07	0.000415	-0.39	-0.3	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
COAD	cis	rs61270009	0.818	rs6452786	ENSG00000247828.6	TMEM161B-AS1	5.04	8.75e-07	0.000415	0.31	0.3	Depressive symptoms;	chr5:88409022	chr5:88268895~88436685:+
COAD	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-5.04	8.76e-07	0.000416	-0.19	-0.3	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
COAD	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	5.04	8.76e-07	0.000416	0.63	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	5.04	8.76e-07	0.000416	0.34	0.3	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	5.04	8.76e-07	0.000416	0.34	0.3	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	5.04	8.76e-07	0.000416	0.34	0.3	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	5.04	8.76e-07	0.000416	0.34	0.3	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	5.04	8.76e-07	0.000416	0.34	0.3	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
COAD	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	5.04	8.76e-07	0.000416	0.3	0.3	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
COAD	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	5.04	8.77e-07	0.000416	0.33	0.3	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
COAD	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	5.04	8.78e-07	0.000416	0.31	0.3	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
COAD	cis	rs7811142	1	rs2897358	ENSG00000078319.8	PMS2P1	-5.04	8.78e-07	0.000417	-0.41	-0.3	Platelet count;	chr7:100491017	chr7:100320992~100341908:-
COAD	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	5.04	8.78e-07	0.000417	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
COAD	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	5.04	8.79e-07	0.000417	0.34	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
COAD	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	5.04	8.79e-07	0.000417	0.46	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
COAD	cis	rs9951698	0.703	rs7241536	ENSG00000266969.1	RP11-773H22.4	5.04	8.79e-07	0.000417	0.37	0.3	Intelligence (multi-trait analysis);	chr18:13033975	chr18:12984694~12991173:-
COAD	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-5.04	8.79e-07	0.000417	-0.17	-0.3	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
COAD	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	5.04	8.79e-07	0.000417	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
COAD	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	5.04	8.8e-07	0.000417	0.41	0.3	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
COAD	cis	rs9487051	0.714	rs9487053	ENSG00000219700.1	PTCHD3P3	5.04	8.81e-07	0.000418	0.32	0.3	Reticulocyte fraction of red cells;	chr6:109298494	chr6:109288571~109290503:-
COAD	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-5.04	8.82e-07	0.000418	-0.3	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
COAD	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	5.04	8.83e-07	0.000419	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	5.04	8.83e-07	0.000419	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
COAD	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.04	8.86e-07	0.00042	-0.37	-0.3	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
COAD	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	5.04	8.87e-07	0.00042	0.4	0.3	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	5.04	8.87e-07	0.00042	0.34	0.3	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
COAD	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-5.04	8.88e-07	0.000421	-0.53	-0.3	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
COAD	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	5.04	8.88e-07	0.000421	0.45	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
COAD	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	5.04	8.9e-07	0.000421	0.38	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
COAD	cis	rs5015933	0.966	rs1965342	ENSG00000232630.1	PRPS1P2	-5.04	8.9e-07	0.000421	-0.29	-0.3	Body mass index;	chr9:125371382	chr9:125150653~125151589:+
COAD	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	5.04	8.91e-07	0.000422	0.4	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
COAD	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-5.04	8.92e-07	0.000422	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-5.04	8.92e-07	0.000422	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
COAD	cis	rs9951698	0.703	rs692964	ENSG00000266969.1	RP11-773H22.4	5.04	8.92e-07	0.000422	0.38	0.3	Intelligence (multi-trait analysis);	chr18:13094133	chr18:12984694~12991173:-
COAD	cis	rs9393777	0.513	rs13210025	ENSG00000224843.5	LINC00240	5.04	8.93e-07	0.000423	0.48	0.3	Intelligence (multi-trait analysis);	chr6:26654589	chr6:26956992~27023924:+
COAD	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	5.04	8.94e-07	0.000423	0.36	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
COAD	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	5.04	8.94e-07	0.000423	0.39	0.3	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
COAD	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-5.04	8.95e-07	0.000424	-0.23	-0.3	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
COAD	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	5.04	8.95e-07	0.000424	0.27	0.3	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
COAD	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	5.04	8.96e-07	0.000424	0.38	0.3	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
COAD	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-5.04	8.96e-07	0.000424	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-5.04	8.96e-07	0.000424	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
COAD	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	5.04	8.96e-07	0.000424	0.34	0.3	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
COAD	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	5.04	8.97e-07	0.000424	0.42	0.3	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	5.04	8.97e-07	0.000424	0.42	0.3	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
COAD	cis	rs1823913	0.503	rs6706578	ENSG00000280083.1	RP11-317J9.1	-5.04	8.97e-07	0.000424	-0.32	-0.3	Obesity-related traits;	chr2:191346992	chr2:191154118~191156070:-
COAD	cis	rs7829975	0.535	rs4841005	ENSG00000253981.4	ALG1L13P	-5.04	8.98e-07	0.000425	-0.36	-0.3	Mood instability;	chr8:8643720	chr8:8236003~8244667:-
COAD	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-5.04	8.98e-07	0.000425	-0.26	-0.3	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
COAD	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-5.04	8.98e-07	0.000425	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-5.04	8.98e-07	0.000425	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
COAD	cis	rs11668609	1	rs10412517	ENSG00000268442.1	CTD-2027I19.2	5.04	8.98e-07	0.000425	0.37	0.3	Response to taxane treatment (docetaxel);	chr19:24119111	chr19:24162370~24163425:-
COAD	cis	rs9450351	0.744	rs7749600	ENSG00000203875.9	SNHG5	-5.04	8.98e-07	0.000425	-0.55	-0.3	Interferon gamma-induced protein 10 levels;	chr6:85624372	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9344538	ENSG00000203875.9	SNHG5	-5.04	8.98e-07	0.000425	-0.55	-0.3	Interferon gamma-induced protein 10 levels;	chr6:85625243	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9450307	ENSG00000203875.9	SNHG5	-5.04	8.98e-07	0.000425	-0.55	-0.3	Interferon gamma-induced protein 10 levels;	chr6:85634633	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9450309	ENSG00000203875.9	SNHG5	-5.04	8.98e-07	0.000425	-0.55	-0.3	Interferon gamma-induced protein 10 levels;	chr6:85639025	chr6:85660950~85678736:-
COAD	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	5.04	8.99e-07	0.000425	0.38	0.3	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
COAD	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-5.04	9e-07	0.000425	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
COAD	cis	rs453301	0.653	rs1562211	ENSG00000233609.3	RP11-62H7.2	-5.04	9e-07	0.000425	-0.32	-0.3	Joint mobility (Beighton score);	chr8:9044914	chr8:8961200~8979025:+
COAD	cis	rs13217239	0.646	rs10946888	ENSG00000224843.5	LINC00240	-5.04	9e-07	0.000425	-0.35	-0.3	Schizophrenia;	chr6:26983899	chr6:26956992~27023924:+
COAD	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	5.04	9e-07	0.000425	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
COAD	cis	rs7647973	0.6	rs35174559	ENSG00000225399.4	RP11-3B7.1	5.04	9e-07	0.000426	0.34	0.3	Menarche (age at onset);	chr3:49250326	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs9880088	ENSG00000225399.4	RP11-3B7.1	-5.03	9e-07	0.000426	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs9862483	ENSG00000225399.4	RP11-3B7.1	-5.03	9e-07	0.000426	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:49260085~49261316:+
COAD	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-5.03	9.02e-07	0.000426	-0.33	-0.3	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
COAD	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.03	9.02e-07	0.000426	0.36	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
COAD	cis	rs385076	0.503	rs212702	ENSG00000272716.1	RP11-563N4.1	5.03	9.03e-07	0.000427	0.36	0.3	Interleukin-18 levels;	chr2:32219181	chr2:32165046~32165757:-
COAD	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	5.03	9.03e-07	0.000427	0.3	0.3	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
COAD	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-5.03	9.04e-07	0.000427	-0.26	-0.3	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
COAD	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	5.03	9.05e-07	0.000428	0.45	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
COAD	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	5.03	9.05e-07	0.000428	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	5.03	9.05e-07	0.000428	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
COAD	cis	rs5742933	0.817	rs6942	ENSG00000253559.1	OSGEPL1-AS1	5.03	9.06e-07	0.000428	0.29	0.3	Ferritin levels;	chr2:189771685	chr2:189762704~189765556:+
COAD	cis	rs8002861	0.87	rs1348671	ENSG00000274001.1	RP11-5G9.5	5.03	9.06e-07	0.000428	0.27	0.3	Leprosy;	chr13:43875369	chr13:43877715~43878163:-
COAD	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-5.03	9.08e-07	0.000429	-0.45	-0.3	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
COAD	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	5.03	9.08e-07	0.000429	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
COAD	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	5.03	9.08e-07	0.000429	0.32	0.3	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
COAD	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-5.03	9.08e-07	0.000429	-0.3	-0.3	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
COAD	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	5.03	9.08e-07	0.000429	0.29	0.3	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	5.03	9.08e-07	0.000429	0.29	0.3	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
COAD	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-5.03	9.09e-07	0.000429	-0.6	-0.3	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
COAD	cis	rs5015933	0.801	rs11999662	ENSG00000232630.1	PRPS1P2	-5.03	9.1e-07	0.00043	-0.3	-0.3	Body mass index;	chr9:125381649	chr9:125150653~125151589:+
COAD	cis	rs440932	0.717	rs330944	ENSG00000253981.4	ALG1L13P	5.03	9.1e-07	0.00043	0.4	0.3	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:8236003~8244667:-
COAD	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	5.03	9.12e-07	0.000431	0.33	0.3	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	5.03	9.12e-07	0.000431	0.33	0.3	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	5.03	9.12e-07	0.000431	0.33	0.3	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
COAD	cis	rs930421	0.689	rs13418278	ENSG00000226491.1	FTOP1	-5.03	9.12e-07	0.000431	-0.41	-0.3	Attention deficit hyperactivity disorder;	chr2:42755035	chr2:42797225~42798712:-
COAD	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-5.03	9.12e-07	0.000431	-0.28	-0.3	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
COAD	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	5.03	9.13e-07	0.000431	0.32	0.3	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
COAD	cis	rs638893	0.541	rs553188	ENSG00000278376.1	RP11-158I9.8	-5.03	9.13e-07	0.000431	-0.49	-0.3	Vitiligo;	chr11:118706053	chr11:118791254~118793137:+
COAD	cis	rs638893	0.541	rs498912	ENSG00000278376.1	RP11-158I9.8	-5.03	9.13e-07	0.000431	-0.49	-0.3	Vitiligo;	chr11:118706288	chr11:118791254~118793137:+
COAD	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	5.03	9.15e-07	0.000432	0.3	0.3	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
COAD	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-5.03	9.15e-07	0.000432	-0.35	-0.3	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-5.03	9.15e-07	0.000432	-0.35	-0.3	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
COAD	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	5.03	9.16e-07	0.000432	0.87	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
COAD	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	5.03	9.17e-07	0.000433	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	5.03	9.17e-07	0.000433	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
COAD	cis	rs453301	0.686	rs28482034	ENSG00000253981.4	ALG1L13P	-5.03	9.17e-07	0.000433	-0.36	-0.3	Joint mobility (Beighton score);	chr8:9012154	chr8:8236003~8244667:-
COAD	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	5.03	9.17e-07	0.000433	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
COAD	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	5.03	9.17e-07	0.000433	0.47	0.3	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
COAD	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	5.03	9.17e-07	0.000433	0.47	0.3	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
COAD	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	5.03	9.17e-07	0.000433	0.47	0.3	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
COAD	cis	rs73376930	0.664	rs4779584	ENSG00000259721.1	RP11-758N13.1	5.03	9.18e-07	0.000433	0.35	0.3	Colorectal cancer;	chr15:32702555	chr15:32717270~32719007:-
COAD	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-5.03	9.18e-07	0.000433	-0.31	-0.3	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
COAD	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	5.03	9.18e-07	0.000433	0.7	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
COAD	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-5.03	9.18e-07	0.000433	-0.38	-0.3	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
COAD	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.03	9.18e-07	0.000433	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
COAD	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.03	9.19e-07	0.000433	-0.36	-0.3	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
COAD	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	5.03	9.19e-07	0.000434	0.47	0.3	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
COAD	cis	rs5015933	0.815	rs12553785	ENSG00000232630.1	PRPS1P2	-5.03	9.21e-07	0.000434	-0.29	-0.3	Body mass index;	chr9:125314262	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.778	rs10819045	ENSG00000232630.1	PRPS1P2	-5.03	9.21e-07	0.000434	-0.29	-0.3	Body mass index;	chr9:125321886	chr9:125150653~125151589:+
COAD	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	5.03	9.23e-07	0.000435	0.31	0.3	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
COAD	cis	rs7209700	0.547	rs16941776	ENSG00000228782.6	CTD-2026D20.3	-5.03	9.25e-07	0.000436	-0.35	-0.3	IgG glycosylation;	chr17:47265775	chr17:47450568~47492492:-
COAD	cis	rs7209700	0.547	rs16941780	ENSG00000228782.6	CTD-2026D20.3	-5.03	9.25e-07	0.000436	-0.35	-0.3	IgG glycosylation;	chr17:47265817	chr17:47450568~47492492:-
COAD	cis	rs8062405	0.964	rs12448902	ENSG00000251417.2	RP11-1348G14.4	-5.03	9.25e-07	0.000436	-0.37	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859870	chr16:28802743~28817828:+
COAD	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	5.03	9.26e-07	0.000436	0.33	0.3	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
COAD	cis	rs9890032	0.618	rs1979507	ENSG00000263531.1	RP13-753N3.1	5.03	9.27e-07	0.000437	0.37	0.3	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30863921~30864940:-
COAD	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-5.03	9.27e-07	0.000437	-0.3	-0.3	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
COAD	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	9.28e-07	0.000437	-0.27	-0.3	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
COAD	cis	rs2732480	0.557	rs2634682	ENSG00000273765.1	RP11-370I10.11	5.03	9.29e-07	0.000438	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48360920~48361377:+
COAD	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	5.03	9.3e-07	0.000438	0.35	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
COAD	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	5.03	9.31e-07	0.000438	0.29	0.3	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	5.03	9.31e-07	0.000438	0.29	0.3	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
COAD	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	5.03	9.31e-07	0.000439	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	5.03	9.31e-07	0.000439	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	5.03	9.31e-07	0.000439	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
COAD	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.03	9.34e-07	0.00044	0.29	0.3	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
COAD	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	5.03	9.34e-07	0.00044	0.32	0.3	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
COAD	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	5.03	9.36e-07	0.00044	0.31	0.3	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	5.03	9.36e-07	0.00044	0.31	0.3	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	5.03	9.36e-07	0.00044	0.31	0.3	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
COAD	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-5.03	9.36e-07	0.000441	-0.57	-0.3	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
COAD	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-5.03	9.37e-07	0.000441	-0.37	-0.3	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
COAD	cis	rs5758511	0.68	rs1107554	ENSG00000237037.8	NDUFA6-AS1	-5.03	9.37e-07	0.000441	-0.36	-0.3	Birth weight;	chr22:42271588	chr22:42090931~42137742:+
COAD	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-5.03	9.38e-07	0.000441	-0.38	-0.3	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
COAD	cis	rs12935418	0.523	rs2549846	ENSG00000278985.1	RP11-303E16.9	-5.03	9.39e-07	0.000442	-0.32	-0.3	Mean corpuscular volume;	chr16:80990522	chr16:80982319~80984094:-
COAD	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	5.03	9.39e-07	0.000442	0.28	0.3	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	5.03	9.39e-07	0.000442	0.28	0.3	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
COAD	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-5.03	9.41e-07	0.000443	-0.31	-0.3	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
COAD	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	5.03	9.41e-07	0.000443	0.28	0.3	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
COAD	cis	rs440932	0.747	rs330946	ENSG00000173295.6	FAM86B3P	5.03	9.42e-07	0.000443	0.4	0.3	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8228595~8244865:+
COAD	cis	rs5015933	0.788	rs13289976	ENSG00000232630.1	PRPS1P2	-5.03	9.42e-07	0.000443	-0.29	-0.3	Body mass index;	chr9:125293178	chr9:125150653~125151589:+
COAD	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	5.03	9.43e-07	0.000444	0.41	0.3	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
COAD	cis	rs5015933	0.815	rs1333055	ENSG00000232630.1	PRPS1P2	-5.03	9.44e-07	0.000444	-0.29	-0.3	Body mass index;	chr9:125307948	chr9:125150653~125151589:+
COAD	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	5.02	9.44e-07	0.000444	0.32	0.3	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
COAD	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-5.02	9.45e-07	0.000444	-0.34	-0.3	Height;	chr20:49310154	chr20:49280319~49280409:+
COAD	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	5.02	9.45e-07	0.000444	0.5	0.3	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
COAD	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-5.02	9.45e-07	0.000444	-0.38	-0.3	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
COAD	cis	rs2281603	0.57	rs3742606	ENSG00000259116.1	RP11-973N13.4	-5.02	9.47e-07	0.000445	-0.29	-0.3	Lymphocyte counts;	chr14:64478371	chr14:64514154~64540368:-
COAD	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.02	9.47e-07	0.000445	0.28	0.3	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
COAD	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	5.02	9.5e-07	0.000447	0.27	0.3	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
COAD	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-5.02	9.5e-07	0.000447	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-5.02	9.5e-07	0.000447	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
COAD	cis	rs2732480	0.538	rs1387259	ENSG00000273765.1	RP11-370I10.11	-5.02	9.51e-07	0.000447	-0.34	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48360920~48361377:+
COAD	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	5.02	9.51e-07	0.000447	0.33	0.3	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
COAD	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	5.02	9.55e-07	0.000449	0.34	0.3	QT interval;	chr12:29310426	chr12:29280418~29317848:-
COAD	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-5.02	9.56e-07	0.000449	-0.35	-0.3	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-5.02	9.56e-07	0.000449	-0.35	-0.3	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
COAD	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	5.02	9.57e-07	0.00045	0.4	0.3	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
COAD	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-5.02	9.58e-07	0.00045	-0.17	-0.3	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
COAD	cis	rs9625935	0.518	rs245008	ENSG00000279159.1	RP3-394A18.1	-5.02	9.58e-07	0.00045	-0.2	-0.3	Tonsillectomy;	chr22:29919747	chr22:29978950~30028236:-
COAD	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	5.02	9.58e-07	0.00045	0.46	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
COAD	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	5.02	9.58e-07	0.00045	0.46	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
COAD	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.02	9.59e-07	0.00045	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
COAD	cis	rs440932	0.887	rs398801	ENSG00000173295.6	FAM86B3P	-5.02	9.59e-07	0.00045	-0.39	-0.3	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8228595~8244865:+
COAD	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	5.02	9.6e-07	0.000451	0.47	0.3	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	5.02	9.6e-07	0.000451	0.47	0.3	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	5.02	9.6e-07	0.000451	0.47	0.3	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
COAD	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-5.02	9.61e-07	0.000451	-0.22	-0.3	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
COAD	cis	rs2665103	0.61	rs56398167	ENSG00000259429.4	UBE2Q2P2	-5.02	9.61e-07	0.000451	-0.25	-0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82355142~82420075:+
COAD	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-5.02	9.62e-07	0.000451	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
COAD	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-5.02	9.62e-07	0.000451	-0.37	-0.3	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
COAD	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	5.02	9.62e-07	0.000452	0.22	0.3	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
COAD	cis	rs9348739	1	rs9348739	ENSG00000224843.5	LINC00240	5.02	9.63e-07	0.000452	0.56	0.3	Autism spectrum disorder or schizophrenia;	chr6:26955320	chr6:26956992~27023924:+
COAD	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.02	9.63e-07	0.000452	-0.52	-0.3	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
COAD	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-5.02	9.64e-07	0.000453	-0.33	-0.3	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
COAD	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	5.02	9.66e-07	0.000454	0.32	0.3	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
COAD	cis	rs728616	0.51	rs61860860	ENSG00000225484.5	NUTM2B-AS1	-5.02	9.69e-07	0.000454	-0.46	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79663088~79826594:-
COAD	cis	rs6993244	1	rs6993244	ENSG00000253981.4	ALG1L13P	5.02	9.69e-07	0.000455	0.37	0.3	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8236003~8244667:-
COAD	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	5.02	9.7e-07	0.000455	0.41	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
COAD	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	5.02	9.72e-07	0.000456	0.3	0.3	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
COAD	cis	rs7598759	0.527	rs12987949	ENSG00000223198.1	RNU2-22P	-5.02	9.73e-07	0.000456	-0.34	-0.3	Noise-induced hearing loss;	chr2:231502800	chr2:231501990~231502201:-
COAD	cis	rs492146	0.935	rs419129	ENSG00000243236.5	GSTA9P	-5.02	9.73e-07	0.000456	-0.31	-0.3	Epilepsy (remission after treatment);	chr6:52977197	chr6:52939726~52957521:-
COAD	cis	rs9487051	0.714	rs1546722	ENSG00000219700.1	PTCHD3P3	5.02	9.73e-07	0.000457	0.32	0.3	Reticulocyte fraction of red cells;	chr6:109304594	chr6:109288571~109290503:-
COAD	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	5.02	9.74e-07	0.000457	0.68	0.3	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
COAD	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	5.02	9.74e-07	0.000457	0.41	0.3	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
COAD	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-5.02	9.75e-07	0.000457	-0.37	-0.3	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
COAD	cis	rs7818688	0.697	rs74553842	ENSG00000253528.2	RP11-347C18.4	-5.02	9.75e-07	0.000457	-0.44	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972164	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs78777150	ENSG00000253528.2	RP11-347C18.4	-5.02	9.75e-07	0.000457	-0.44	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972183	chr8:94974573~94974853:-
COAD	cis	rs75422866	0.85	rs73111226	ENSG00000280054.1	RP1-197B17.7	5.02	9.76e-07	0.000457	0.75	0.3	Pneumonia;	chr12:47582204	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.702	rs12426387	ENSG00000280054.1	RP1-197B17.7	5.02	9.76e-07	0.000457	0.75	0.3	Pneumonia;	chr12:47582915	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.85	rs12423789	ENSG00000280054.1	RP1-197B17.7	5.02	9.76e-07	0.000457	0.75	0.3	Pneumonia;	chr12:47583112	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.702	rs73111229	ENSG00000280054.1	RP1-197B17.7	5.02	9.76e-07	0.000457	0.75	0.3	Pneumonia;	chr12:47583333	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.85	rs73111231	ENSG00000280054.1	RP1-197B17.7	5.02	9.76e-07	0.000457	0.75	0.3	Pneumonia;	chr12:47584539	chr12:47728151~47730598:-
COAD	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	5.02	9.76e-07	0.000458	0.4	0.3	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	5.02	9.77e-07	0.000458	0.34	0.3	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
COAD	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-5.02	9.77e-07	0.000458	-0.35	-0.3	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-5.02	9.77e-07	0.000458	-0.35	-0.3	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-5.02	9.77e-07	0.000458	-0.35	-0.3	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
COAD	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	5.02	9.77e-07	0.000458	0.46	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
COAD	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-5.02	9.78e-07	0.000458	-0.36	-0.3	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
COAD	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-5.02	9.79e-07	0.000459	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
COAD	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-5.02	9.8e-07	0.000459	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
COAD	cis	rs4987094	0.656	rs60373142	ENSG00000270179.1	RP11-159N11.4	5.02	9.82e-07	0.00046	0.52	0.3	Schizophrenia;	chr11:113337811	chr11:113368478~113369117:+
COAD	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-5.02	9.82e-07	0.00046	-0.43	-0.3	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
COAD	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	5.02	9.83e-07	0.00046	0.3	0.3	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
COAD	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	5.02	9.83e-07	0.00046	0.3	0.3	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
COAD	cis	rs13256369	1	rs9329165	ENSG00000173295.6	FAM86B3P	-5.02	9.84e-07	0.000461	-0.41	-0.3	Obesity-related traits;	chr8:8719132	chr8:8228595~8244865:+
COAD	cis	rs5758511	0.68	rs5758657	ENSG00000237037.8	NDUFA6-AS1	-5.02	9.84e-07	0.000461	-0.36	-0.3	Birth weight;	chr22:42222663	chr22:42090931~42137742:+
COAD	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	5.02	9.84e-07	0.000461	0.27	0.3	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	5.02	9.84e-07	0.000461	0.27	0.3	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
COAD	cis	rs73198271	1	rs11776513	ENSG00000173295.6	FAM86B3P	-5.02	9.85e-07	0.000461	-0.4	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8228595~8244865:+
COAD	cis	rs13256369	1	rs13256369	ENSG00000173295.6	FAM86B3P	5.02	9.85e-07	0.000461	0.42	0.3	Obesity-related traits;	chr8:8719869	chr8:8228595~8244865:+
COAD	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	5.02	9.86e-07	0.000461	0.31	0.3	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
COAD	cis	rs8002861	0.935	rs9533678	ENSG00000274001.1	RP11-5G9.5	5.02	9.86e-07	0.000461	0.27	0.3	Leprosy;	chr13:43889273	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.869	rs7989857	ENSG00000274001.1	RP11-5G9.5	5.02	9.86e-07	0.000461	0.27	0.3	Leprosy;	chr13:43889954	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.902	rs1445557	ENSG00000274001.1	RP11-5G9.5	5.02	9.86e-07	0.000461	0.27	0.3	Leprosy;	chr13:43890691	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.905	rs9525869	ENSG00000274001.1	RP11-5G9.5	5.02	9.86e-07	0.000461	0.27	0.3	Leprosy;	chr13:43893074	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.934	rs9533685	ENSG00000274001.1	RP11-5G9.5	5.02	9.86e-07	0.000461	0.27	0.3	Leprosy;	chr13:43894195	chr13:43877715~43878163:-
COAD	cis	rs5015933	1	rs7357647	ENSG00000232630.1	PRPS1P2	-5.02	9.86e-07	0.000462	-0.29	-0.3	Body mass index;	chr9:125374554	chr9:125150653~125151589:+
COAD	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	5.02	9.86e-07	0.000462	0.34	0.3	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
COAD	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-5.02	9.88e-07	0.000462	-0.26	-0.3	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
COAD	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-5.02	9.88e-07	0.000462	-0.31	-0.3	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
COAD	cis	rs5015933	1	rs11998746	ENSG00000232630.1	PRPS1P2	-5.02	9.89e-07	0.000463	-0.29	-0.3	Body mass index;	chr9:125373083	chr9:125150653~125151589:+
COAD	cis	rs5015933	1	rs4289914	ENSG00000232630.1	PRPS1P2	-5.02	9.89e-07	0.000463	-0.29	-0.3	Body mass index;	chr9:125373526	chr9:125150653~125151589:+
COAD	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-5.02	9.89e-07	0.000463	-0.42	-0.3	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
COAD	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-5.02	9.89e-07	0.000463	-0.44	-0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
COAD	cis	rs2732480	0.5	rs2732461	ENSG00000273765.1	RP11-370I10.11	5.01	9.9e-07	0.000463	0.33	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48360920~48361377:+
COAD	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	5.01	9.9e-07	0.000463	0.17	0.3	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
COAD	cis	rs210138	0.706	rs3916279	ENSG00000197251.3	LINC00336	5.01	9.9e-07	0.000463	0.44	0.3	Testicular germ cell tumor;	chr6:33607173	chr6:33586106~33593338:-
COAD	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.01	9.9e-07	0.000463	-0.31	-0.3	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
COAD	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-5.01	9.91e-07	0.000464	-0.32	-0.3	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
COAD	cis	rs5742933	0.817	rs1055091	ENSG00000253559.1	OSGEPL1-AS1	5.01	9.91e-07	0.000464	0.29	0.3	Ferritin levels;	chr2:189770417	chr2:189762704~189765556:+
COAD	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-5.01	9.91e-07	0.000464	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
COAD	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-5.01	9.91e-07	0.000464	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
COAD	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	5.01	9.92e-07	0.000464	0.44	0.3	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	5.01	9.92e-07	0.000464	0.44	0.3	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	5.01	9.92e-07	0.000464	0.44	0.3	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	5.01	9.92e-07	0.000464	0.44	0.3	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
COAD	cis	rs1426063	0.541	rs58959724	ENSG00000249717.1	RP11-44F21.3	5.01	9.94e-07	0.000465	0.68	0.3	QT interval;	chr4:75073543	chr4:74955974~74970362:-
COAD	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	5.01	9.94e-07	0.000465	0.36	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
COAD	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	5.01	9.95e-07	0.000465	0.34	0.3	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
COAD	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	5.01	9.95e-07	0.000465	0.31	0.3	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
COAD	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-5.01	9.95e-07	0.000465	-0.35	-0.3	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
COAD	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-5.01	9.96e-07	0.000466	-0.38	-0.3	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
COAD	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-5.01	9.97e-07	0.000466	-0.46	-0.3	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
COAD	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	5.01	9.97e-07	0.000466	0.31	0.3	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	5.01	9.99e-07	0.000467	0.31	0.3	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	5.01	9.99e-07	0.000467	0.31	0.3	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
COAD	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	5.01	9.99e-07	0.000467	0.39	0.3	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
COAD	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	5.01	1e-06	0.000468	0.36	0.3	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
COAD	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	5.01	1e-06	0.000468	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
COAD	cis	rs12935418	0.616	rs2549855	ENSG00000278985.1	RP11-303E16.9	5.01	1e-06	0.000469	0.32	0.3	Mean corpuscular volume;	chr16:80993247	chr16:80982319~80984094:-
COAD	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-5.01	1e-06	0.000469	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
COAD	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	5.01	1.01e-06	0.000469	0.39	0.3	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
COAD	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-5.01	1.01e-06	0.000469	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-5.01	1.01e-06	0.000469	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
COAD	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-5.01	1.01e-06	0.00047	-0.24	-0.3	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
COAD	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-5.01	1.01e-06	0.00047	-0.36	-0.3	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
COAD	cis	rs13256369	0.802	rs12153	ENSG00000173295.6	FAM86B3P	5.01	1.01e-06	0.000471	0.42	0.3	Obesity-related traits;	chr8:8703399	chr8:8228595~8244865:+
COAD	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49279650	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49282024	chr20:49280319~49280409:+
COAD	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49282748	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49283420	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49286304	chr20:49280319~49280409:+
COAD	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-5.01	1.01e-06	0.000471	-0.34	-0.3	Height;	chr20:49295502	chr20:49280319~49280409:+
COAD	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-5.01	1.01e-06	0.000471	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	5.01	1.01e-06	0.000471	0.51	0.3	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
COAD	cis	rs73198271	0.96	rs12155530	ENSG00000173295.6	FAM86B3P	-5.01	1.01e-06	0.000472	-0.41	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8753454	chr8:8228595~8244865:+
COAD	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-5.01	1.01e-06	0.000472	-0.38	-0.3	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
COAD	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	5.01	1.01e-06	0.000472	0.39	0.3	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
COAD	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.01	1.01e-06	0.000473	-0.38	-0.3	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
COAD	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-5.01	1.01e-06	0.000473	-0.37	-0.3	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
COAD	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-5.01	1.01e-06	0.000473	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
COAD	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	5.01	1.01e-06	0.000473	0.31	0.3	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
COAD	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-5.01	1.02e-06	0.000473	-0.38	-0.3	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
COAD	cis	rs111580313	0.685	rs4843167	ENSG00000270020.1	RP11-463O9.9	5.01	1.02e-06	0.000474	0.74	0.3	Systemic juvenile idiopathic arthritis;	chr16:86573157	chr16:86520383~86523897:-
COAD	cis	rs111580313	0.685	rs79088793	ENSG00000270020.1	RP11-463O9.9	5.01	1.02e-06	0.000474	0.74	0.3	Systemic juvenile idiopathic arthritis;	chr16:86573421	chr16:86520383~86523897:-
COAD	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	5.01	1.02e-06	0.000474	0.39	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
COAD	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-5.01	1.02e-06	0.000474	-0.38	-0.3	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
COAD	cis	rs2732480	0.538	rs1387260	ENSG00000273765.1	RP11-370I10.11	5.01	1.02e-06	0.000475	0.34	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48360920~48361377:+
COAD	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-5.01	1.02e-06	0.000475	-0.44	-0.3	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
COAD	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	5.01	1.02e-06	0.000475	0.32	0.3	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
COAD	cis	rs6452524	0.507	rs28592576	ENSG00000271862.1	RP11-343L5.2	5.01	1.02e-06	0.000476	0.32	0.3	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.534	rs7727691	ENSG00000271862.1	RP11-343L5.2	5.01	1.02e-06	0.000476	0.32	0.3	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83049376~83050964:-
COAD	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-5.01	1.02e-06	0.000476	-0.37	-0.3	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-5.01	1.02e-06	0.000476	-0.37	-0.3	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
COAD	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.01	1.02e-06	0.000476	0.44	0.3	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
COAD	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	5.01	1.02e-06	0.000476	0.44	0.3	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
COAD	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	5.01	1.02e-06	0.000476	0.45	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
COAD	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	5.01	1.02e-06	0.000476	0.32	0.3	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	5.01	1.02e-06	0.000476	0.32	0.3	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
COAD	cis	rs12935418	0.672	rs2549879	ENSG00000278985.1	RP11-303E16.9	-5.01	1.02e-06	0.000477	-0.32	-0.3	Mean corpuscular volume;	chr16:81012496	chr16:80982319~80984094:-
COAD	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	5.01	1.02e-06	0.000477	0.69	0.3	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	5.01	1.02e-06	0.000477	0.69	0.3	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	5.01	1.02e-06	0.000477	0.69	0.3	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	5.01	1.02e-06	0.000477	0.69	0.3	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
COAD	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	5.01	1.02e-06	0.000477	0.36	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
COAD	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	5.01	1.02e-06	0.000477	0.36	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
COAD	cis	rs9368481	0.594	rs7768643	ENSG00000224843.5	LINC00240	-5.01	1.02e-06	0.000477	-0.36	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26956992~27023924:+
COAD	cis	rs9368481	0.594	rs7768814	ENSG00000224843.5	LINC00240	-5.01	1.02e-06	0.000477	-0.36	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26956992~27023924:+
COAD	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	5.01	1.02e-06	0.000477	0.24	0.3	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
COAD	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	5.01	1.02e-06	0.000477	0.24	0.3	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
COAD	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-5.01	1.03e-06	0.000477	-0.36	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	5.01	1.03e-06	0.000477	0.4	0.3	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
COAD	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-5.01	1.03e-06	0.000477	-0.6	-0.3	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-5.01	1.03e-06	0.000477	-0.6	-0.3	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-5.01	1.03e-06	0.000477	-0.6	-0.3	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-5.01	1.03e-06	0.000477	-0.6	-0.3	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-5.01	1.03e-06	0.000477	-0.6	-0.3	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
COAD	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-5.01	1.03e-06	0.000477	-0.32	-0.3	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
COAD	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.01	1.03e-06	0.000478	0.52	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
COAD	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-5.01	1.03e-06	0.000479	-0.24	-0.3	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
COAD	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	5.01	1.03e-06	0.000479	0.56	0.3	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
COAD	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	5.01	1.03e-06	0.000479	0.32	0.3	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
COAD	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	5.01	1.03e-06	0.000479	0.3	0.3	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
COAD	cis	rs7818688	0.614	rs73271148	ENSG00000253528.2	RP11-347C18.4	-5.01	1.03e-06	0.000479	-0.43	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94864317	chr8:94974573~94974853:-
COAD	cis	rs7646881	0.544	rs28856044	ENSG00000272087.1	RP11-379F4.7	5.01	1.03e-06	0.000479	0.46	0.3	Tetralogy of Fallot;	chr3:158584970	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.508	rs6779054	ENSG00000272087.1	RP11-379F4.7	5.01	1.03e-06	0.000479	0.46	0.3	Tetralogy of Fallot;	chr3:158587658	chr3:158693120~158693768:-
COAD	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	5.01	1.03e-06	0.000479	0.42	0.3	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
COAD	cis	rs73198271	1	rs11775821	ENSG00000173295.6	FAM86B3P	-5.01	1.03e-06	0.00048	-0.4	-0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8228595~8244865:+
COAD	cis	rs11079159	0.585	rs8079998	ENSG00000263096.1	RP11-515O17.2	5.01	1.03e-06	0.00048	0.34	0.3	QRS duration;	chr17:55308138	chr17:55271504~55273653:-
COAD	cis	rs253959	0.545	rs6896147	ENSG00000271918.1	CTD-2287O16.5	-5.01	1.03e-06	0.00048	-0.29	-0.3	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116083807~116085416:-
COAD	cis	rs2732480	0.5	rs7966829	ENSG00000257735.1	RP11-370I10.6	5.01	1.03e-06	0.000481	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48350945~48442411:+
COAD	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	5.01	1.03e-06	0.000481	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
COAD	cis	rs12935418	0.552	rs2549842	ENSG00000278985.1	RP11-303E16.9	5.01	1.03e-06	0.000481	0.32	0.3	Mean corpuscular volume;	chr16:80990054	chr16:80982319~80984094:-
COAD	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-5.01	1.03e-06	0.000481	-0.36	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
COAD	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	5.01	1.03e-06	0.000481	0.32	0.3	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-5.01	1.03e-06	0.000481	-0.32	-0.3	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
COAD	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-5.01	1.03e-06	0.000481	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
COAD	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	5.01	1.04e-06	0.000481	0.31	0.3	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
COAD	cis	rs5015933	0.815	rs13294021	ENSG00000232630.1	PRPS1P2	-5.01	1.04e-06	0.000482	-0.29	-0.3	Body mass index;	chr9:125306109	chr9:125150653~125151589:+
COAD	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	5	1.04e-06	0.000483	0.31	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
COAD	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5	1.04e-06	0.000484	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
COAD	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	5	1.04e-06	0.000484	0.6	0.3	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
COAD	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-5	1.04e-06	0.000484	-0.31	-0.3	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
COAD	cis	rs739496	0.653	rs7956676	ENSG00000257595.2	RP3-473L9.4	5	1.04e-06	0.000484	0.44	0.3	Platelet count;	chr12:111753335	chr12:111369282~111403310:+
COAD	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-5	1.05e-06	0.000486	-0.31	-0.3	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
COAD	cis	rs2115630	0.645	rs3825877	ENSG00000259728.4	LINC00933	-5	1.05e-06	0.000486	-0.36	-0.3	P wave terminal force;	chr15:84631400	chr15:84570649~84580175:+
COAD	cis	rs2115630	0.645	rs3825878	ENSG00000259728.4	LINC00933	-5	1.05e-06	0.000486	-0.36	-0.3	P wave terminal force;	chr15:84631524	chr15:84570649~84580175:+
COAD	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	5	1.05e-06	0.000486	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
COAD	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5	1.05e-06	0.000486	-0.52	-0.3	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
COAD	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5	1.05e-06	0.000486	0.37	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
COAD	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-5	1.05e-06	0.000486	-0.41	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
COAD	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	5	1.05e-06	0.000487	0.31	0.3	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
COAD	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	5	1.05e-06	0.000487	0.63	0.3	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
COAD	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-5	1.05e-06	0.000487	-0.51	-0.3	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
COAD	cis	rs7078219	0.743	rs7095953	ENSG00000257582.4	LINC01475	5	1.05e-06	0.000487	0.34	0.3	Dental caries;	chr10:99514668	chr10:99526350~99531177:-
COAD	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	5	1.05e-06	0.000487	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
COAD	cis	rs12935418	0.579	rs2123627	ENSG00000278985.1	RP11-303E16.9	-5	1.05e-06	0.000487	-0.32	-0.3	Mean corpuscular volume;	chr16:80988211	chr16:80982319~80984094:-
COAD	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	5	1.05e-06	0.000488	0.3	0.3	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
COAD	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-5	1.05e-06	0.000489	-0.37	-0.3	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
COAD	cis	rs6452524	0.532	rs26263	ENSG00000271862.1	RP11-343L5.2	5	1.05e-06	0.000489	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83049376~83050964:-
COAD	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	5	1.05e-06	0.000489	0.35	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
COAD	cis	rs5758511	0.68	rs17002902	ENSG00000237037.8	NDUFA6-AS1	-5	1.05e-06	0.000489	-0.35	-0.3	Birth weight;	chr22:42229503	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.68	rs5758662	ENSG00000237037.8	NDUFA6-AS1	-5	1.05e-06	0.000489	-0.35	-0.3	Birth weight;	chr22:42232082	chr22:42090931~42137742:+
COAD	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	5	1.05e-06	0.000489	0.31	0.3	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
COAD	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-5	1.05e-06	0.000489	-0.27	-0.3	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
COAD	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-5	1.05e-06	0.000489	-0.37	-0.3	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
COAD	cis	rs1065852	0.861	rs5758627	ENSG00000237037.8	NDUFA6-AS1	-5	1.05e-06	0.000489	-0.36	-0.3	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42090931~42137742:+
COAD	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-5	1.06e-06	0.000489	-0.36	-0.3	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
COAD	cis	rs9890032	0.532	rs1808257	ENSG00000263531.1	RP13-753N3.1	5	1.06e-06	0.00049	0.36	0.3	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30863921~30864940:-
COAD	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5	1.06e-06	0.00049	-0.31	-0.3	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
COAD	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-5	1.06e-06	0.00049	-0.36	-0.3	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
COAD	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-5	1.06e-06	0.00049	-0.38	-0.3	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
COAD	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-5	1.06e-06	0.00049	-0.25	-0.3	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
COAD	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	5	1.06e-06	0.00049	0.27	0.3	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
COAD	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	5	1.06e-06	0.00049	0.29	0.3	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
COAD	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-5	1.06e-06	0.000491	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
COAD	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	5	1.06e-06	0.000492	0.39	0.3	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
COAD	cis	rs12935418	0.673	rs2549888	ENSG00000278985.1	RP11-303E16.9	-5	1.06e-06	0.000492	-0.32	-0.3	Mean corpuscular volume;	chr16:81028425	chr16:80982319~80984094:-
COAD	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-5	1.06e-06	0.000492	-0.46	-0.3	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
COAD	cis	rs7818688	0.614	rs12056808	ENSG00000253528.2	RP11-347C18.4	-5	1.06e-06	0.000493	-0.42	-0.3	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94864640	chr8:94974573~94974853:-
COAD	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	5	1.06e-06	0.000493	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	5	1.06e-06	0.000493	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
COAD	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-5	1.07e-06	0.000494	-0.31	-0.3	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
COAD	cis	rs75422866	0.764	rs73104177	ENSG00000280054.1	RP1-197B17.7	5	1.07e-06	0.000494	0.73	0.3	Pneumonia;	chr12:47713550	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.764	rs73104184	ENSG00000280054.1	RP1-197B17.7	5	1.07e-06	0.000494	0.73	0.3	Pneumonia;	chr12:47715623	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.764	rs73104188	ENSG00000280054.1	RP1-197B17.7	5	1.07e-06	0.000494	0.73	0.3	Pneumonia;	chr12:47715885	chr12:47728151~47730598:-
COAD	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	5	1.07e-06	0.000494	0.48	0.3	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
COAD	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-5	1.07e-06	0.000494	-0.46	-0.3	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
COAD	cis	rs4704187	0.687	rs9918293	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75219003	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs58067979	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75227730	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1477937	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75229012	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs57646262	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75231647	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4295370	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75233033	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.601	rs77819698	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75234833	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6889372	ENSG00000250889.2	LINC01336	-5	1.07e-06	0.000494	-0.34	-0.3	Response to amphetamines;	chr5:75235325	chr5:75047719~75052843:-
COAD	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	5	1.07e-06	0.000495	0.31	0.3	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
COAD	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	5	1.07e-06	0.000495	0.44	0.3	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
COAD	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5	1.07e-06	0.000495	-0.38	-0.3	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
COAD	cis	rs5015933	0.788	rs359592	ENSG00000232630.1	PRPS1P2	-5	1.07e-06	0.000495	-0.3	-0.3	Body mass index;	chr9:125285007	chr9:125150653~125151589:+
COAD	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-5	1.07e-06	0.000495	-0.4	-0.3	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
COAD	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-5	1.07e-06	0.000495	-0.36	-0.3	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
COAD	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-5	1.07e-06	0.000496	-0.46	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
COAD	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	5	1.07e-06	0.000497	0.35	0.3	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
COAD	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	5	1.07e-06	0.000497	0.41	0.3	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	5	1.07e-06	0.000497	0.41	0.3	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	5	1.07e-06	0.000497	0.41	0.3	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
COAD	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	5	1.08e-06	0.000498	0.37	0.3	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
COAD	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	5	1.08e-06	0.000498	0.23	0.3	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
COAD	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-5	1.08e-06	0.000499	-0.47	-0.3	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
COAD	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-5	1.08e-06	0.000499	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
COAD	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5	1.08e-06	0.000499	-0.52	-0.3	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
COAD	cis	rs12935418	0.583	rs2549836	ENSG00000278985.1	RP11-303E16.9	-5	1.08e-06	5e-04	-0.32	-0.3	Mean corpuscular volume;	chr16:80989476	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2549837	ENSG00000278985.1	RP11-303E16.9	-5	1.08e-06	5e-04	-0.32	-0.3	Mean corpuscular volume;	chr16:80989510	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.552	rs2549838	ENSG00000278985.1	RP11-303E16.9	-5	1.08e-06	5e-04	-0.32	-0.3	Mean corpuscular volume;	chr16:80989605	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2549839	ENSG00000278985.1	RP11-303E16.9	-5	1.08e-06	5e-04	-0.32	-0.3	Mean corpuscular volume;	chr16:80989630	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.583	rs2549843	ENSG00000278985.1	RP11-303E16.9	-5	1.08e-06	5e-04	-0.32	-0.3	Mean corpuscular volume;	chr16:80990140	chr16:80982319~80984094:-
COAD	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-5	1.08e-06	5e-04	-0.35	-0.3	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
COAD	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-5	1.08e-06	5e-04	-0.36	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
COAD	cis	rs7829975	0.774	rs1039915	ENSG00000253981.4	ALG1L13P	5	1.08e-06	5e-04	0.36	0.3	Mood instability;	chr8:8822104	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.774	rs57312668	ENSG00000253981.4	ALG1L13P	5	1.08e-06	5e-04	0.36	0.3	Mood instability;	chr8:8822967	chr8:8236003~8244667:-
COAD	cis	rs754466	1	rs2278218	ENSG00000204049.1	RP11-126H7.4	5	1.08e-06	0.000501	0.41	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77920641	chr10:77866875~77869610:+
COAD	cis	rs754466	1	rs12220311	ENSG00000204049.1	RP11-126H7.4	5	1.08e-06	0.000501	0.41	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77921749	chr10:77866875~77869610:+
COAD	cis	rs754466	1	rs67059283	ENSG00000204049.1	RP11-126H7.4	5	1.08e-06	0.000501	0.41	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77923477	chr10:77866875~77869610:+
COAD	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	5	1.08e-06	0.000501	0.31	0.3	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	5	1.08e-06	0.000501	0.31	0.3	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
COAD	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-5	1.08e-06	0.000501	-0.36	-0.3	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
COAD	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-5	1.09e-06	0.000502	-0.34	-0.3	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
COAD	cis	rs79996792	1	rs79996792	ENSG00000227403.1	AC009299.3	-5	1.09e-06	0.000502	-0.55	-0.3	Neuroticism;	chr2:161587424	chr2:161244739~161249050:+
COAD	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-5	1.09e-06	0.000502	-0.57	-0.3	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-5	1.09e-06	0.000502	-0.57	-0.3	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
COAD	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5	1.09e-06	0.000502	0.41	0.3	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
COAD	cis	rs12497850	0.765	rs12487580	ENSG00000225399.4	RP11-3B7.1	5	1.09e-06	0.000503	0.34	0.3	Parkinson's disease;	chr3:49145499	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.797	rs61583136	ENSG00000225399.4	RP11-3B7.1	5	1.09e-06	0.000503	0.34	0.3	Parkinson's disease;	chr3:49151762	chr3:49260085~49261316:+
COAD	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	4.99	1.09e-06	0.000503	0.36	0.3	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
COAD	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-4.99	1.09e-06	0.000503	-0.36	-0.3	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
COAD	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	4.99	1.09e-06	0.000503	0.28	0.3	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
COAD	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-4.99	1.09e-06	0.000503	-0.42	-0.3	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
COAD	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-4.99	1.09e-06	0.000504	-0.17	-0.3	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
COAD	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	4.99	1.09e-06	0.000504	0.34	0.3	QT interval;	chr12:29304617	chr12:29280418~29317848:-
COAD	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	4.99	1.09e-06	0.000504	0.45	0.3	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
COAD	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	4.99	1.09e-06	0.000504	0.45	0.3	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
COAD	cis	rs453301	0.598	rs1025395	ENSG00000253981.4	ALG1L13P	4.99	1.09e-06	0.000504	0.36	0.3	Joint mobility (Beighton score);	chr8:8979093	chr8:8236003~8244667:-
COAD	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	4.99	1.09e-06	0.000504	0.39	0.3	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
COAD	cis	rs17772222	1	rs3814855	ENSG00000258789.1	RP11-507K2.3	-4.99	1.09e-06	0.000504	-0.42	-0.3	Coronary artery calcification;	chr14:88467016	chr14:88551597~88552493:+
COAD	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-4.99	1.09e-06	0.000504	-0.36	-0.3	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
COAD	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-4.99	1.09e-06	0.000505	-0.37	-0.3	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
COAD	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	4.99	1.09e-06	0.000505	0.34	0.3	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	4.99	1.09e-06	0.000505	0.34	0.3	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
COAD	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	4.99	1.09e-06	0.000505	0.39	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
COAD	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	4.99	1.09e-06	0.000505	0.33	0.3	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	4.99	1.09e-06	0.000505	0.33	0.3	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
COAD	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-4.99	1.1e-06	0.000506	-0.34	-0.3	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
COAD	cis	rs7598759	0.548	rs1584462	ENSG00000223198.1	RNU2-22P	-4.99	1.1e-06	0.000506	-0.34	-0.3	Noise-induced hearing loss;	chr2:231505087	chr2:231501990~231502201:-
COAD	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	4.99	1.1e-06	0.000507	0.31	0.3	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	4.99	1.1e-06	0.000507	0.31	0.3	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
COAD	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	4.99	1.1e-06	0.000507	0.37	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
COAD	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	4.99	1.1e-06	0.000507	0.27	0.3	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
COAD	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.99	1.1e-06	0.000508	0.41	0.3	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
COAD	cis	rs7646881	0.812	rs7624161	ENSG00000272087.1	RP11-379F4.7	4.99	1.1e-06	0.000508	0.44	0.3	Tetralogy of Fallot;	chr3:158742125	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs113166116	ENSG00000272087.1	RP11-379F4.7	4.99	1.1e-06	0.000508	0.44	0.3	Tetralogy of Fallot;	chr3:158742467	chr3:158693120~158693768:-
COAD	cis	rs12928939	0.911	rs7202840	ENSG00000260886.1	TAT-AS1	4.99	1.1e-06	0.000508	0.44	0.3	Post bronchodilator FEV1;	chr16:71790811	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.911	rs11645725	ENSG00000260886.1	TAT-AS1	4.99	1.1e-06	0.000508	0.44	0.3	Post bronchodilator FEV1;	chr16:71792980	chr16:71565789~71578187:+
COAD	cis	rs4704187	0.687	rs7700965	ENSG00000250889.2	LINC01336	-4.99	1.1e-06	0.000508	-0.33	-0.3	Response to amphetamines;	chr5:75061032	chr5:75047719~75052843:-
COAD	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	4.99	1.1e-06	0.000509	0.38	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
COAD	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-4.99	1.1e-06	0.000509	-0.4	-0.3	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
COAD	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-4.99	1.1e-06	0.000509	-0.35	-0.3	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
COAD	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-4.99	1.1e-06	0.00051	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
COAD	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	4.99	1.1e-06	0.00051	0.31	0.3	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
COAD	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	4.99	1.1e-06	0.00051	0.31	0.3	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
COAD	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	4.99	1.1e-06	0.00051	0.31	0.3	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
COAD	cis	rs12497850	0.864	rs3212	ENSG00000225399.4	RP11-3B7.1	4.99	1.1e-06	0.00051	0.34	0.3	Parkinson's disease;	chr3:49108308	chr3:49260085~49261316:+
COAD	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-4.99	1.1e-06	0.00051	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
COAD	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-4.99	1.1e-06	0.00051	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
COAD	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	4.99	1.11e-06	0.00051	0.32	0.3	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
COAD	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	4.99	1.11e-06	0.000511	0.31	0.3	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
COAD	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	4.99	1.11e-06	0.000511	0.31	0.3	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
COAD	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	4.99	1.11e-06	0.000511	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	4.99	1.11e-06	0.000512	0.33	0.3	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	4.99	1.11e-06	0.000512	0.33	0.3	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	4.99	1.11e-06	0.000512	0.33	0.3	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
COAD	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	4.99	1.11e-06	0.000512	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
COAD	cis	rs11846409	0.86	rs1858692	ENSG00000274576.2	IGHV2-70	4.99	1.11e-06	0.000512	0.3	0.3	Rheumatic heart disease;	chr14:106622776	chr14:106770577~106771020:-
COAD	cis	rs1056107	0.898	rs940592	ENSG00000225513.1	RP11-165N19.2	-4.99	1.11e-06	0.000512	-0.36	-0.3	Colorectal cancer;	chr9:112255785	chr9:112173522~112173971:-
COAD	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	4.99	1.11e-06	0.000513	0.36	0.3	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
COAD	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	4.99	1.11e-06	0.000513	0.43	0.3	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
COAD	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	4.99	1.11e-06	0.000513	0.35	0.3	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
COAD	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-4.99	1.11e-06	0.000514	-0.17	-0.3	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
COAD	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	4.99	1.11e-06	0.000514	0.42	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
COAD	cis	rs7560272	0.723	rs1083919	ENSG00000163016.8	ALMS1P	-4.99	1.11e-06	0.000514	-0.37	-0.3	Schizophrenia;	chr2:73486736	chr2:73644919~73685576:+
COAD	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-4.99	1.11e-06	0.000514	-0.33	-0.3	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-4.99	1.11e-06	0.000514	-0.33	-0.3	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
COAD	cis	rs4718428	1	rs4718421	ENSG00000273142.1	RP11-458F8.4	-4.99	1.12e-06	0.000514	-0.23	-0.3	Corneal structure;	chr7:66885313	chr7:66902857~66906297:+
COAD	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000514	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
COAD	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-4.99	1.12e-06	0.000516	-0.34	-0.3	Height;	chr20:49311346	chr20:49280319~49280409:+
COAD	cis	rs12497850	0.864	rs4521268	ENSG00000225399.4	RP11-3B7.1	4.99	1.12e-06	0.000516	0.34	0.3	Parkinson's disease;	chr3:49100471	chr3:49260085~49261316:+
COAD	cis	rs9487051	0.714	rs6927569	ENSG00000219700.1	PTCHD3P3	4.99	1.12e-06	0.000517	0.32	0.3	Reticulocyte fraction of red cells;	chr6:109300291	chr6:109288571~109290503:-
COAD	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	4.99	1.12e-06	0.000518	0.29	0.3	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
COAD	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-4.99	1.12e-06	0.000518	-0.35	-0.3	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
COAD	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	4.99	1.12e-06	0.000518	0.51	0.3	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	4.99	1.12e-06	0.000518	0.51	0.3	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	4.99	1.12e-06	0.000518	0.51	0.3	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-4.99	1.12e-06	0.000518	-0.51	-0.3	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
COAD	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	4.99	1.12e-06	0.000518	0.45	0.3	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
COAD	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	4.99	1.13e-06	0.000518	0.36	0.3	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	4.99	1.13e-06	0.000518	0.36	0.3	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	4.99	1.13e-06	0.000518	0.36	0.3	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	4.99	1.13e-06	0.000518	0.36	0.3	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
COAD	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-4.99	1.13e-06	0.000519	-0.31	-0.3	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-4.99	1.13e-06	0.000519	-0.31	-0.3	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	4.99	1.13e-06	0.000519	0.31	0.3	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	4.99	1.13e-06	0.000519	0.31	0.3	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	4.99	1.13e-06	0.000519	0.31	0.3	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
COAD	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-4.99	1.13e-06	0.000519	-0.35	-0.3	Height;	chr3:53027969	chr3:53064283~53065091:-
COAD	cis	rs7584330	0.554	rs7582964	ENSG00000234949.2	AC104667.3	4.99	1.13e-06	0.000519	0.44	0.3	Prostate cancer;	chr2:237477123	chr2:237591020~237595981:+
COAD	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-4.99	1.13e-06	0.000519	-0.35	-0.3	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
COAD	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	4.99	1.13e-06	0.00052	0.29	0.3	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
COAD	cis	rs2732480	0.5	rs7966829	ENSG00000273765.1	RP11-370I10.11	4.99	1.13e-06	0.00052	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48360920~48361377:+
COAD	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	4.99	1.13e-06	0.00052	0.36	0.3	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
COAD	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	4.99	1.13e-06	0.00052	0.33	0.3	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
COAD	cis	rs36093924	0.646	rs5996092	ENSG00000182057.4	OGFRP1	-4.99	1.13e-06	0.00052	-0.3	-0.3	Intelligence;	chr22:41948404	chr22:42269753~42275196:+
COAD	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	4.99	1.13e-06	0.00052	0.31	0.3	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
COAD	cis	rs1387259	0.899	rs7307566	ENSG00000257735.1	RP11-370I10.6	4.99	1.13e-06	0.000521	0.35	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48350945~48442411:+
COAD	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	4.99	1.13e-06	0.000521	0.53	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	4.99	1.13e-06	0.000521	0.53	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	4.99	1.13e-06	0.000521	0.53	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	4.99	1.13e-06	0.000521	0.53	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
COAD	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	4.99	1.13e-06	0.000521	0.22	0.3	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	4.99	1.13e-06	0.000521	0.22	0.3	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	4.99	1.13e-06	0.000521	0.22	0.3	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	4.99	1.13e-06	0.000521	0.22	0.3	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
COAD	cis	rs58873874	0.737	rs78565801	ENSG00000248544.2	CTB-47B11.3	4.99	1.13e-06	0.000521	0.66	0.3	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157375741~157384950:-
COAD	cis	rs58873874	0.737	rs79951742	ENSG00000248544.2	CTB-47B11.3	4.99	1.13e-06	0.000521	0.66	0.3	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157375741~157384950:-
COAD	cis	rs10971721	0.643	rs10971701	ENSG00000260947.1	RP11-384P7.7	4.99	1.13e-06	0.000521	0.63	0.3	Body mass index;	chr9:33781900	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.643	rs10971702	ENSG00000260947.1	RP11-384P7.7	4.99	1.13e-06	0.000521	0.63	0.3	Body mass index;	chr9:33784104	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.643	rs12375483	ENSG00000260947.1	RP11-384P7.7	4.99	1.13e-06	0.000521	0.63	0.3	Body mass index;	chr9:33784910	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.643	rs72711741	ENSG00000260947.1	RP11-384P7.7	4.99	1.13e-06	0.000521	0.63	0.3	Body mass index;	chr9:33785113	chr9:33697459~33700986:+
COAD	cis	rs5758511	0.524	rs738257	ENSG00000237037.8	NDUFA6-AS1	-4.99	1.14e-06	0.000523	-0.36	-0.3	Birth weight;	chr22:42173292	chr22:42090931~42137742:+
COAD	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-4.99	1.14e-06	0.000523	-0.28	-0.3	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
COAD	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.99	1.14e-06	0.000523	-0.29	-0.3	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
COAD	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	4.99	1.14e-06	0.000523	0.38	0.3	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
COAD	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	4.99	1.14e-06	0.000524	0.39	0.3	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
COAD	cis	rs11668609	0.81	rs9305015	ENSG00000268442.1	CTD-2027I19.2	-4.99	1.14e-06	0.000524	-0.38	-0.3	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24162370~24163425:-
COAD	cis	rs9379945	1	rs9379945	ENSG00000224843.5	LINC00240	4.98	1.14e-06	0.000525	0.56	0.3	Intelligence (multi-trait analysis);	chr6:26940052	chr6:26956992~27023924:+
COAD	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	4.98	1.14e-06	0.000525	0.31	0.3	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	4.98	1.14e-06	0.000525	0.31	0.3	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	4.98	1.14e-06	0.000525	0.31	0.3	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
COAD	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-4.98	1.14e-06	0.000525	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
COAD	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-4.98	1.14e-06	0.000526	-0.27	-0.3	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
COAD	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-4.98	1.14e-06	0.000526	-0.27	-0.3	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
COAD	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	4.98	1.14e-06	0.000526	0.29	0.3	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
COAD	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	4.98	1.15e-06	0.000526	0.44	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
COAD	cis	rs4704187	0.687	rs1345705	ENSG00000250889.2	LINC01336	-4.98	1.15e-06	0.000526	-0.34	-0.3	Response to amphetamines;	chr5:75211182	chr5:75047719~75052843:-
COAD	cis	rs3733585	0.781	rs6449183	ENSG00000250413.1	RP11-448G15.1	4.98	1.15e-06	0.000527	0.37	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10006482~10009725:+
COAD	cis	rs8177876	0.822	rs56198248	ENSG00000261061.1	RP11-303E16.2	-4.98	1.15e-06	0.000527	-0.57	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81030770~81031485:+
COAD	cis	rs7260598	0.685	rs67534545	ENSG00000268442.1	CTD-2027I19.2	4.98	1.15e-06	0.000527	0.43	0.3	Response to taxane treatment (placlitaxel);	chr19:23927339	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs28537609	ENSG00000268442.1	CTD-2027I19.2	4.98	1.15e-06	0.000527	0.43	0.3	Response to taxane treatment (placlitaxel);	chr19:23928662	chr19:24162370~24163425:-
COAD	cis	rs4704187	0.687	rs1544756	ENSG00000250889.2	LINC01336	-4.98	1.15e-06	0.000527	-0.34	-0.3	Response to amphetamines;	chr5:75212587	chr5:75047719~75052843:-
COAD	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-4.98	1.15e-06	0.000529	-0.3	-0.3	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
COAD	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-4.98	1.15e-06	0.000529	-0.54	-0.3	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
COAD	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	4.98	1.15e-06	0.000529	0.45	0.3	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
COAD	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-4.98	1.15e-06	0.000529	-0.47	-0.3	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
COAD	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-4.98	1.15e-06	0.00053	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-4.98	1.15e-06	0.00053	-0.3	-0.3	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
COAD	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	4.98	1.15e-06	0.00053	0.33	0.3	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
COAD	cis	rs7078219	0.714	rs10883359	ENSG00000228778.1	RP11-129J12.1	4.98	1.16e-06	0.000531	0.34	0.3	Dental caries;	chr10:99514276	chr10:99527081~99528261:+
COAD	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	4.98	1.16e-06	0.000531	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
COAD	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	4.98	1.16e-06	0.000532	0.34	0.3	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
COAD	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-4.98	1.16e-06	0.000532	-0.39	-0.3	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
COAD	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.98	1.16e-06	0.000532	0.33	0.3	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
COAD	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-4.98	1.16e-06	0.000532	-0.34	-0.3	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
COAD	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	4.98	1.16e-06	0.000532	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
COAD	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-4.98	1.16e-06	0.000533	-0.4	-0.3	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
COAD	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	4.98	1.16e-06	0.000533	0.63	0.3	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	4.98	1.16e-06	0.000533	0.63	0.3	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
COAD	cis	rs12928939	0.911	rs77823468	ENSG00000260886.1	TAT-AS1	4.98	1.16e-06	0.000533	0.43	0.3	Post bronchodilator FEV1;	chr16:71794713	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.954	rs34998650	ENSG00000260886.1	TAT-AS1	4.98	1.16e-06	0.000533	0.43	0.3	Post bronchodilator FEV1;	chr16:71795426	chr16:71565789~71578187:+
COAD	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-4.98	1.16e-06	0.000534	-0.34	-0.3	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
COAD	cis	rs2115630	0.645	rs6496284	ENSG00000259728.4	LINC00933	-4.98	1.16e-06	0.000534	-0.36	-0.3	P wave terminal force;	chr15:84635039	chr15:84570649~84580175:+
COAD	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	4.98	1.17e-06	0.000535	0.4	0.3	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
COAD	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	4.98	1.17e-06	0.000535	0.48	0.3	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
COAD	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	4.98	1.17e-06	0.000535	0.48	0.3	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
COAD	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-4.98	1.17e-06	0.000535	-0.3	-0.3	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
COAD	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	4.98	1.17e-06	0.000535	0.16	0.3	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
COAD	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	4.98	1.17e-06	0.000535	0.34	0.3	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	4.98	1.17e-06	0.000535	0.34	0.3	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
COAD	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-4.98	1.17e-06	0.000535	-0.34	-0.3	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
COAD	cis	rs7646881	0.812	rs7635704	ENSG00000272087.1	RP11-379F4.7	4.98	1.17e-06	0.000535	0.43	0.3	Tetralogy of Fallot;	chr3:158741931	chr3:158693120~158693768:-
COAD	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	4.98	1.17e-06	0.000536	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
COAD	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	4.98	1.17e-06	0.000536	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
COAD	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	4.98	1.17e-06	0.000536	0.39	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
COAD	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	4.98	1.17e-06	0.000536	0.26	0.3	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
COAD	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	4.98	1.17e-06	0.000536	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
COAD	cis	rs12935418	0.583	rs2167889	ENSG00000278985.1	RP11-303E16.9	-4.98	1.17e-06	0.000536	-0.32	-0.3	Mean corpuscular volume;	chr16:80987867	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.552	rs2911148	ENSG00000278985.1	RP11-303E16.9	-4.98	1.17e-06	0.000536	-0.32	-0.3	Mean corpuscular volume;	chr16:80988289	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.552	rs2549833	ENSG00000278985.1	RP11-303E16.9	-4.98	1.17e-06	0.000536	-0.32	-0.3	Mean corpuscular volume;	chr16:80988627	chr16:80982319~80984094:-
COAD	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-4.98	1.17e-06	0.000536	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-4.98	1.17e-06	0.000536	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
COAD	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-4.98	1.17e-06	0.000536	-0.27	-0.3	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
COAD	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.98	1.17e-06	0.000536	0.34	0.3	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
COAD	cis	rs7811142	1	rs60478351	ENSG00000078319.8	PMS2P1	-4.98	1.17e-06	0.000537	-0.41	-0.3	Platelet count;	chr7:100491394	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs7787620	ENSG00000078319.8	PMS2P1	-4.98	1.17e-06	0.000537	-0.41	-0.3	Platelet count;	chr7:100491611	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11769700	ENSG00000078319.8	PMS2P1	-4.98	1.17e-06	0.000537	-0.41	-0.3	Platelet count;	chr7:100492426	chr7:100320992~100341908:-
COAD	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	4.98	1.17e-06	0.000538	0.32	0.3	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
COAD	cis	rs240993	0.715	rs9400483	ENSG00000230177.1	RP5-1112D6.4	4.98	1.17e-06	0.000538	0.26	0.3	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111277932~111278742:+
COAD	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000539	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000539	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000539	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000539	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000539	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
COAD	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-4.98	1.18e-06	0.000539	-0.32	-0.3	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
COAD	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	4.98	1.18e-06	0.000539	0.4	0.3	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
COAD	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	4.98	1.18e-06	0.000539	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
COAD	cis	rs9910055	0.676	rs11079983	ENSG00000267080.4	ASB16-AS1	-4.98	1.18e-06	0.00054	-0.27	-0.3	Total body bone mineral density;	chr17:44120802	chr17:44175973~44186717:-
COAD	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.00054	0.55	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
COAD	cis	rs5015933	0.902	rs7872015	ENSG00000232630.1	PRPS1P2	-4.98	1.18e-06	0.000541	-0.29	-0.3	Body mass index;	chr9:125368854	chr9:125150653~125151589:+
COAD	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	4.98	1.18e-06	0.000541	0.56	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
COAD	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	4.98	1.18e-06	0.000541	0.34	0.3	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
COAD	cis	rs1056107	0.931	rs7863117	ENSG00000225513.1	RP11-165N19.2	-4.98	1.18e-06	0.000541	-0.35	-0.3	Colorectal cancer;	chr9:112253559	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.931	rs6477903	ENSG00000225513.1	RP11-165N19.2	-4.98	1.18e-06	0.000541	-0.35	-0.3	Colorectal cancer;	chr9:112254581	chr9:112173522~112173971:-
COAD	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	4.98	1.18e-06	0.000541	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
COAD	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	4.98	1.18e-06	0.000542	0.41	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
COAD	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-4.98	1.18e-06	0.000542	-0.4	-0.3	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
COAD	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	4.98	1.19e-06	0.000543	0.27	0.3	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
COAD	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	4.98	1.19e-06	0.000543	0.32	0.3	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
COAD	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-4.98	1.19e-06	0.000543	-0.43	-0.3	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-4.98	1.19e-06	0.000543	-0.43	-0.3	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-4.98	1.19e-06	0.000543	-0.43	-0.3	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
COAD	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-4.98	1.19e-06	0.000543	-0.32	-0.3	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
COAD	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	4.98	1.19e-06	0.000543	0.44	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
COAD	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-4.98	1.19e-06	0.000543	-0.37	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
COAD	cis	rs11603023	1	rs11603023	ENSG00000255422.1	AP002954.4	-4.98	1.19e-06	0.000543	-0.31	-0.3	Cholesterol, total;	chr11:118615352	chr11:118704607~118750263:+
COAD	cis	rs7646881	0.544	rs13315529	ENSG00000272087.1	RP11-379F4.7	4.98	1.19e-06	0.000544	0.45	0.3	Tetralogy of Fallot;	chr3:158610485	chr3:158693120~158693768:-
COAD	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
COAD	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	4.98	1.19e-06	0.000544	0.39	0.3	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
COAD	cis	rs1790761	0.692	rs611663	ENSG00000231793.4	DOC2GP	4.98	1.19e-06	0.000544	0.34	0.3	Mean corpuscular volume;	chr11:67544750	chr11:67612653~67616257:-
COAD	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	4.98	1.19e-06	0.000544	0.28	0.3	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
COAD	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-4.98	1.19e-06	0.000544	-0.37	-0.3	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
COAD	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	4.98	1.19e-06	0.000545	0.4	0.3	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
COAD	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.98	1.19e-06	0.000545	0.34	0.3	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
COAD	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-4.98	1.19e-06	0.000546	-0.33	-0.3	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
COAD	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-4.98	1.19e-06	0.000546	-0.33	-0.3	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
COAD	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-4.98	1.19e-06	0.000546	-0.37	-0.3	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
COAD	cis	rs2732480	0.5	rs7315820	ENSG00000257735.1	RP11-370I10.6	4.98	1.19e-06	0.000546	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48350945~48442411:+
COAD	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-4.97	1.2e-06	0.000547	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-4.97	1.2e-06	0.000547	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
COAD	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	4.97	1.2e-06	0.000547	0.47	0.3	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
COAD	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.97	1.2e-06	0.000547	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
COAD	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.97	1.2e-06	0.000547	-0.32	-0.3	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
COAD	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-4.97	1.2e-06	0.000547	-0.49	-0.3	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
COAD	cis	rs61270009	1	rs61270009	ENSG00000247828.6	TMEM161B-AS1	4.97	1.2e-06	0.000547	0.32	0.3	Depressive symptoms;	chr5:88280322	chr5:88268895~88436685:+
COAD	cis	rs7260598	0.642	rs67799720	ENSG00000268442.1	CTD-2027I19.2	4.97	1.2e-06	0.000547	0.42	0.3	Response to taxane treatment (placlitaxel);	chr19:23981347	chr19:24162370~24163425:-
COAD	cis	rs9951698	0.678	rs557846	ENSG00000266969.1	RP11-773H22.4	4.97	1.2e-06	0.000548	0.36	0.3	Intelligence (multi-trait analysis);	chr18:13133775	chr18:12984694~12991173:-
COAD	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.97	1.2e-06	0.000548	-0.33	-0.3	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
COAD	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	4.97	1.2e-06	0.000548	0.3	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	4.97	1.2e-06	0.000548	0.31	0.3	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
COAD	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	4.97	1.2e-06	0.000549	0.69	0.3	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
COAD	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	4.97	1.2e-06	0.000549	0.69	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
COAD	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-4.97	1.2e-06	0.000549	-0.39	-0.3	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
COAD	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-4.97	1.2e-06	0.000549	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
COAD	cis	rs1056107	0.931	rs940593	ENSG00000225513.1	RP11-165N19.2	-4.97	1.2e-06	0.000549	-0.35	-0.3	Colorectal cancer;	chr9:112255380	chr9:112173522~112173971:-
COAD	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	4.97	1.2e-06	0.00055	0.4	0.3	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	4.97	1.2e-06	0.00055	0.4	0.3	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	4.97	1.2e-06	0.00055	0.4	0.3	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
COAD	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	4.97	1.2e-06	0.00055	0.29	0.3	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
COAD	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	4.97	1.21e-06	0.000551	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
COAD	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	4.97	1.21e-06	0.000551	0.38	0.3	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
COAD	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	4.97	1.21e-06	0.000551	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	4.97	1.21e-06	0.000551	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
COAD	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	4.97	1.21e-06	0.000552	0.33	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
COAD	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-4.97	1.21e-06	0.000552	-0.45	-0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
COAD	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	4.97	1.21e-06	0.000552	0.38	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
COAD	cis	rs2732480	0.5	rs11168468	ENSG00000257735.1	RP11-370I10.6	4.97	1.21e-06	0.000552	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48350945~48442411:+
COAD	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	4.97	1.21e-06	0.000552	0.34	0.3	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
COAD	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	4.97	1.21e-06	0.000552	0.39	0.3	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
COAD	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-4.97	1.21e-06	0.000552	-0.39	-0.3	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
COAD	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	4.97	1.21e-06	0.000553	0.35	0.3	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
COAD	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-4.97	1.21e-06	0.000554	-0.51	-0.3	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
COAD	cis	rs853679	0.527	rs853693	ENSG00000272009.1	RP1-313I6.12	4.97	1.21e-06	0.000554	0.33	0.3	Depression;	chr6:28314871	chr6:28078792~28081130:-
COAD	cis	rs7209700	0.788	rs12949936	ENSG00000228782.6	CTD-2026D20.3	-4.97	1.21e-06	0.000555	-0.33	-0.3	IgG glycosylation;	chr17:47295056	chr17:47450568~47492492:-
COAD	cis	rs9907295	0.591	rs4239252	ENSG00000270977.1	AC015849.16	4.97	1.21e-06	0.000555	0.39	0.3	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35893707~35911023:-
COAD	cis	rs739496	0.563	rs6490294	ENSG00000257595.2	RP3-473L9.4	-4.97	1.21e-06	0.000555	-0.44	-0.3	Platelet count;	chr12:111752634	chr12:111369282~111403310:+
COAD	cis	rs4568518	0.804	rs12699934	ENSG00000279048.1	RP11-511H23.2	4.97	1.22e-06	0.000555	0.22	0.3	Measles;	chr7:17986396	chr7:17940503~17942922:+
COAD	cis	rs17772222	1	rs12589480	ENSG00000258789.1	RP11-507K2.3	-4.97	1.22e-06	0.000555	-0.42	-0.3	Coronary artery calcification;	chr14:88414926	chr14:88551597~88552493:+
COAD	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	4.97	1.22e-06	0.000556	0.35	0.3	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	4.97	1.22e-06	0.000556	0.35	0.3	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
COAD	cis	rs36093924	0.586	rs6002561	ENSG00000182057.4	OGFRP1	-4.97	1.22e-06	0.000556	-0.31	-0.3	Intelligence;	chr22:41963200	chr22:42269753~42275196:+
COAD	cis	rs6840360	0.642	rs7676059	ENSG00000251611.1	RP11-610P16.1	-4.97	1.22e-06	0.000556	-0.28	-0.3	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151407551~151408835:-
COAD	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.97	1.22e-06	0.000557	-0.32	-0.3	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
COAD	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.97	1.22e-06	0.000557	0.34	0.3	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
COAD	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	4.97	1.22e-06	0.000557	0.33	0.3	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
COAD	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	4.97	1.22e-06	0.000557	0.39	0.3	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
COAD	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	4.97	1.22e-06	0.000557	0.36	0.3	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
COAD	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	4.97	1.22e-06	0.000558	0.33	0.3	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
COAD	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-4.97	1.22e-06	0.000558	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-4.97	1.22e-06	0.000558	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-4.97	1.22e-06	0.000558	-0.35	-0.3	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
COAD	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	4.97	1.22e-06	0.000558	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
COAD	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	4.97	1.22e-06	0.000559	0.44	0.3	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
COAD	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	4.97	1.23e-06	0.000559	0.45	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
COAD	cis	rs17772222	1	rs11159856	ENSG00000258789.1	RP11-507K2.3	-4.97	1.23e-06	0.000559	-0.42	-0.3	Coronary artery calcification;	chr14:88417585	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs17124652	ENSG00000258789.1	RP11-507K2.3	-4.97	1.23e-06	0.000559	-0.42	-0.3	Coronary artery calcification;	chr14:88424384	chr14:88551597~88552493:+
COAD	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-4.97	1.23e-06	0.000559	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
COAD	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-4.97	1.23e-06	0.000559	-0.35	-0.3	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
COAD	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	4.97	1.23e-06	0.00056	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	4.97	1.23e-06	0.00056	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	4.97	1.23e-06	0.00056	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	4.97	1.23e-06	0.00056	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	4.97	1.23e-06	0.00056	0.54	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
COAD	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	4.97	1.23e-06	0.00056	0.39	0.3	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	4.97	1.23e-06	0.00056	0.39	0.3	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	4.97	1.23e-06	0.00056	0.39	0.3	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
COAD	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	4.97	1.23e-06	0.00056	0.32	0.3	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
COAD	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	4.97	1.23e-06	0.00056	0.32	0.3	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
COAD	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	4.97	1.23e-06	0.00056	0.39	0.3	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
COAD	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.97	1.23e-06	0.00056	-0.33	-0.3	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
COAD	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-4.97	1.23e-06	0.00056	-0.39	-0.3	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
COAD	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	4.97	1.23e-06	0.00056	0.33	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
COAD	cis	rs2732480	0.5	rs11168464	ENSG00000257735.1	RP11-370I10.6	4.97	1.23e-06	0.00056	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48350945~48442411:+
COAD	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-4.97	1.23e-06	0.00056	-0.34	-0.3	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
COAD	cis	rs2281603	0.57	rs28766386	ENSG00000259116.1	RP11-973N13.4	-4.97	1.23e-06	0.000561	-0.29	-0.3	Lymphocyte counts;	chr14:64479679	chr14:64514154~64540368:-
COAD	cis	rs875971	0.571	rs78668714	ENSG00000224316.1	RP11-479O9.2	4.97	1.23e-06	0.000561	0.38	0.3	Aortic root size;	chr7:66474464	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs73150604	ENSG00000224316.1	RP11-479O9.2	4.97	1.23e-06	0.000561	0.38	0.3	Aortic root size;	chr7:66480545	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs7810213	ENSG00000224316.1	RP11-479O9.2	4.97	1.23e-06	0.000561	0.38	0.3	Aortic root size;	chr7:66481592	chr7:65773620~65802067:+
COAD	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	4.97	1.23e-06	0.000562	0.3	0.3	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
COAD	cis	rs2732480	0.577	rs2634693	ENSG00000273765.1	RP11-370I10.11	4.97	1.23e-06	0.000563	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.577	rs2634691	ENSG00000273765.1	RP11-370I10.11	4.97	1.23e-06	0.000563	0.35	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48360920~48361377:+
COAD	cis	rs7529073	0.815	rs1431984	ENSG00000274895.1	RP11-478J18.2	-4.97	1.23e-06	0.000563	-0.32	-0.3	Schizophrenia;	chr1:213975285	chr1:213983793~213986419:-
COAD	cis	rs12935418	0.552	rs2602448	ENSG00000278985.1	RP11-303E16.9	-4.97	1.24e-06	0.000564	-0.32	-0.3	Mean corpuscular volume;	chr16:80989067	chr16:80982319~80984094:-
COAD	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	4.97	1.24e-06	0.000564	0.32	0.3	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
COAD	cis	rs12928939	0.954	rs8057568	ENSG00000260886.1	TAT-AS1	4.97	1.24e-06	0.000564	0.43	0.3	Post bronchodilator FEV1;	chr16:71778092	chr16:71565789~71578187:+
COAD	cis	rs3120667	0.79	rs11205001	ENSG00000237975.5	FLG-AS1	4.97	1.24e-06	0.000564	0.33	0.3	Eating disorders;	chr1:152423472	chr1:152168125~152445456:+
COAD	cis	rs1578862	0.966	rs61841570	ENSG00000259865.1	RP11-488L18.10	-4.97	1.24e-06	0.000565	-0.23	-0.3	Monocyte percentage of white cells;	chr1:247293871	chr1:247187281~247188526:-
COAD	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	4.97	1.24e-06	0.000565	0.31	0.3	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
COAD	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	4.97	1.24e-06	0.000565	0.88	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
COAD	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-4.97	1.24e-06	0.000566	-0.28	-0.3	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
COAD	cis	rs5742933	0.779	rs1899025	ENSG00000253559.1	OSGEPL1-AS1	4.97	1.24e-06	0.000566	0.29	0.3	Ferritin levels;	chr2:189784856	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.817	rs5742938	ENSG00000253559.1	OSGEPL1-AS1	4.97	1.24e-06	0.000566	0.29	0.3	Ferritin levels;	chr2:189785232	chr2:189762704~189765556:+
COAD	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.97	1.25e-06	0.000567	0.29	0.3	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
COAD	cis	rs896854	0.53	rs10956934	ENSG00000253528.2	RP11-347C18.4	4.97	1.25e-06	0.000567	0.32	0.3	Type 2 diabetes;	chr8:94980245	chr8:94974573~94974853:-
COAD	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-4.97	1.25e-06	0.000567	-0.37	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
COAD	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-4.97	1.25e-06	0.000567	-0.3	-0.3	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
COAD	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-4.97	1.25e-06	0.000567	-0.37	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
COAD	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-4.97	1.25e-06	0.000567	-0.37	-0.3	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
COAD	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-4.97	1.25e-06	0.000567	-0.37	-0.3	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
COAD	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	4.97	1.25e-06	0.000568	0.39	0.3	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
COAD	cis	rs7529073	0.815	rs1431982	ENSG00000274895.1	RP11-478J18.2	-4.97	1.25e-06	0.000568	-0.32	-0.3	Schizophrenia;	chr1:213975718	chr1:213983793~213986419:-
COAD	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	4.97	1.25e-06	0.000568	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
COAD	cis	rs12935418	0.583	rs2549861	ENSG00000278985.1	RP11-303E16.9	-4.97	1.25e-06	0.000569	-0.31	-0.3	Mean corpuscular volume;	chr16:80994699	chr16:80982319~80984094:-
COAD	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-4.97	1.25e-06	0.000569	-0.37	-0.3	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
COAD	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-4.97	1.25e-06	0.000569	-0.37	-0.3	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
COAD	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	4.96	1.25e-06	0.00057	0.37	0.3	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
COAD	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	4.96	1.25e-06	0.00057	0.45	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
COAD	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-4.96	1.25e-06	0.00057	-0.36	-0.3	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
COAD	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	4.96	1.25e-06	0.00057	0.37	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
COAD	cis	rs2732480	0.5	rs11168468	ENSG00000273765.1	RP11-370I10.11	4.96	1.25e-06	0.00057	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48360920~48361377:+
COAD	cis	rs13256369	0.755	rs11776987	ENSG00000173295.6	FAM86B3P	4.96	1.26e-06	0.000571	0.43	0.3	Obesity-related traits;	chr8:8701891	chr8:8228595~8244865:+
COAD	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	4.96	1.26e-06	0.000571	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
COAD	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	4.96	1.26e-06	0.000572	0.33	0.3	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
COAD	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	4.96	1.26e-06	0.000572	0.5	0.3	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
COAD	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	4.96	1.26e-06	0.000573	0.87	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
COAD	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	4.96	1.26e-06	0.000573	0.87	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
COAD	cis	rs1056107	0.931	rs7027240	ENSG00000225513.1	RP11-165N19.2	-4.96	1.26e-06	0.000573	-0.35	-0.3	Colorectal cancer;	chr9:112258733	chr9:112173522~112173971:-
COAD	cis	rs13256369	0.851	rs13258283	ENSG00000173295.6	FAM86B3P	4.96	1.26e-06	0.000573	0.42	0.3	Obesity-related traits;	chr8:8706120	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.851	rs13249700	ENSG00000173295.6	FAM86B3P	4.96	1.26e-06	0.000573	0.42	0.3	Obesity-related traits;	chr8:8706127	chr8:8228595~8244865:+
COAD	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	4.96	1.26e-06	0.000574	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
COAD	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-4.96	1.26e-06	0.000574	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
COAD	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	4.96	1.26e-06	0.000574	0.31	0.3	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
COAD	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	4.96	1.27e-06	0.000574	0.38	0.3	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
COAD	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	4.96	1.27e-06	0.000575	0.29	0.3	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	4.96	1.27e-06	0.000575	0.29	0.3	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
COAD	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	4.96	1.27e-06	0.000575	0.33	0.3	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
COAD	cis	rs17772222	0.958	rs61579615	ENSG00000258789.1	RP11-507K2.3	-4.96	1.27e-06	0.000576	-0.42	-0.3	Coronary artery calcification;	chr14:88400054	chr14:88551597~88552493:+
COAD	cis	rs13256369	0.851	rs13266562	ENSG00000173295.6	FAM86B3P	4.96	1.27e-06	0.000576	0.42	0.3	Obesity-related traits;	chr8:8706555	chr8:8228595~8244865:+
COAD	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-4.96	1.27e-06	0.000576	-0.6	-0.3	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-4.96	1.27e-06	0.000576	-0.6	-0.3	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
COAD	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	4.96	1.27e-06	0.000576	0.51	0.3	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
COAD	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	4.96	1.27e-06	0.000576	0.26	0.3	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
COAD	cis	rs7630852	0.841	rs9325377	ENSG00000272359.1	U4	-4.96	1.27e-06	0.000576	-0.34	-0.3	Eosinophil counts;	chr3:196779282	chr3:196747192~196747324:-
COAD	cis	rs34375054	0.687	rs35540170	ENSG00000279233.1	RP11-158L12.4	4.96	1.27e-06	0.000578	0.36	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125184576	chr12:125138245~125141711:+
COAD	cis	rs7260598	0.642	rs10403746	ENSG00000268442.1	CTD-2027I19.2	4.96	1.27e-06	0.000578	0.43	0.3	Response to taxane treatment (placlitaxel);	chr19:23924452	chr19:24162370~24163425:-
COAD	cis	rs9368481	0.569	rs6907403	ENSG00000224843.5	LINC00240	-4.96	1.27e-06	0.000578	-0.36	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26956992~27023924:+
COAD	cis	rs9368481	0.502	rs3933232	ENSG00000224843.5	LINC00240	-4.96	1.27e-06	0.000578	-0.36	-0.3	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26956992~27023924:+
COAD	cis	rs75422866	0.85	rs73111212	ENSG00000280054.1	RP1-197B17.7	4.96	1.27e-06	0.000578	0.73	0.3	Pneumonia;	chr12:47577638	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.85	rs73111216	ENSG00000280054.1	RP1-197B17.7	4.96	1.27e-06	0.000578	0.73	0.3	Pneumonia;	chr12:47577671	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.85	rs73111217	ENSG00000280054.1	RP1-197B17.7	4.96	1.27e-06	0.000578	0.73	0.3	Pneumonia;	chr12:47577693	chr12:47728151~47730598:-
COAD	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-4.96	1.28e-06	0.000579	-0.44	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
COAD	cis	rs728616	0.867	rs56235549	ENSG00000225484.5	NUTM2B-AS1	-4.96	1.28e-06	0.00058	-0.52	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79663088~79826594:-
COAD	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	4.96	1.28e-06	0.00058	0.31	0.3	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
COAD	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	4.96	1.28e-06	0.00058	0.47	0.3	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
COAD	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	4.96	1.28e-06	0.00058	0.42	0.3	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
COAD	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-4.96	1.28e-06	0.000581	-0.42	-0.3	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
COAD	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	4.96	1.28e-06	0.000581	0.4	0.3	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
COAD	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	4.96	1.28e-06	0.000582	0.29	0.3	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
COAD	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-4.96	1.28e-06	0.000582	-0.4	-0.3	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
COAD	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-4.96	1.28e-06	0.000582	-0.29	-0.3	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
COAD	cis	rs9309473	0.519	rs13017182	ENSG00000163016.8	ALMS1P	-4.96	1.28e-06	0.000582	-0.36	-0.3	Metabolite levels;	chr2:73663877	chr2:73644919~73685576:+
COAD	cis	rs5742933	0.75	rs10197331	ENSG00000253559.1	OSGEPL1-AS1	4.96	1.28e-06	0.000582	0.29	0.3	Ferritin levels;	chr2:189768112	chr2:189762704~189765556:+
COAD	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-4.96	1.29e-06	0.000582	-0.38	-0.3	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
COAD	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	4.96	1.29e-06	0.000583	0.22	0.3	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	4.96	1.29e-06	0.000583	0.22	0.3	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
COAD	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-4.96	1.29e-06	0.000584	-0.39	-0.3	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-4.96	1.29e-06	0.000584	-0.39	-0.3	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-4.96	1.29e-06	0.000584	-0.39	-0.3	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
COAD	cis	rs9487051	0.714	rs7744284	ENSG00000219700.1	PTCHD3P3	4.96	1.29e-06	0.000585	0.31	0.3	Reticulocyte fraction of red cells;	chr6:109295015	chr6:109288571~109290503:-
COAD	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-4.96	1.29e-06	0.000585	-0.39	-0.3	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
COAD	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-4.96	1.29e-06	0.000585	-0.32	-0.3	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
COAD	cis	rs4761702	0.524	rs12581099	ENSG00000257252.4	RP11-486A14.2	-4.96	1.29e-06	0.000585	-0.4	-0.3	Immature fraction of reticulocytes;	chr12:93333720	chr12:93317135~93377736:-
COAD	cis	rs8002861	0.901	rs9525867	ENSG00000274001.1	RP11-5G9.5	4.96	1.29e-06	0.000585	0.27	0.3	Leprosy;	chr13:43889421	chr13:43877715~43878163:-
COAD	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	4.96	1.29e-06	0.000585	0.41	0.3	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
COAD	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-4.96	1.29e-06	0.000585	-0.35	-0.3	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
COAD	cis	rs2115630	1	rs6496441	ENSG00000259728.4	LINC00933	-4.96	1.29e-06	0.000586	-0.35	-0.3	P wave terminal force;	chr15:84820117	chr15:84570649~84580175:+
COAD	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	4.96	1.3e-06	0.000587	0.3	0.3	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
COAD	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-4.96	1.3e-06	0.000588	-0.4	-0.3	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
COAD	cis	rs362272	0.524	rs2857982	ENSG00000248840.2	RP11-357G3.2	-4.96	1.3e-06	0.000588	-0.34	-0.3	Serum sulfate level;	chr4:3356938	chr4:3312512~3313058:+
COAD	cis	rs362272	0.524	rs881816	ENSG00000248840.2	RP11-357G3.2	-4.96	1.3e-06	0.000588	-0.34	-0.3	Serum sulfate level;	chr4:3363639	chr4:3312512~3313058:+
COAD	cis	rs362272	0.524	rs13150241	ENSG00000248840.2	RP11-357G3.2	-4.96	1.3e-06	0.000588	-0.34	-0.3	Serum sulfate level;	chr4:3365554	chr4:3312512~3313058:+
COAD	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	4.96	1.3e-06	0.000588	0.47	0.3	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	4.96	1.3e-06	0.000589	0.47	0.3	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
COAD	cis	rs801193	0.935	rs2659899	ENSG00000272831.1	RP11-792A8.4	4.96	1.3e-06	0.000589	0.31	0.3	Aortic root size;	chr7:66721734	chr7:66739829~66740385:-
COAD	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	4.96	1.3e-06	0.000589	0.34	0.3	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
COAD	cis	rs2281603	0.57	rs10131416	ENSG00000259116.1	RP11-973N13.4	-4.96	1.3e-06	0.00059	-0.28	-0.3	Lymphocyte counts;	chr14:64477555	chr14:64514154~64540368:-
COAD	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-4.96	1.3e-06	0.00059	-0.33	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
COAD	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	4.96	1.3e-06	0.00059	0.31	0.3	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
COAD	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	4.96	1.31e-06	0.00059	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	4.96	1.31e-06	0.00059	0.33	0.3	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	4.96	1.31e-06	0.00059	0.33	0.3	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
COAD	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	4.96	1.31e-06	0.000592	0.39	0.3	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
COAD	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	4.96	1.31e-06	0.000592	0.39	0.3	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
COAD	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	4.96	1.31e-06	0.000592	0.35	0.3	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	4.96	1.31e-06	0.000592	0.35	0.3	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
COAD	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	4.95	1.31e-06	0.000594	0.48	0.3	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
COAD	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-4.95	1.31e-06	0.000594	-0.45	-0.3	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
COAD	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-4.95	1.32e-06	0.000595	-0.31	-0.3	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
COAD	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-4.95	1.32e-06	0.000595	-0.24	-0.3	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
COAD	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-4.95	1.32e-06	0.000596	-0.36	-0.3	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
COAD	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	4.95	1.32e-06	0.000596	0.31	0.3	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
COAD	cis	rs7646881	0.544	rs9872682	ENSG00000272087.1	RP11-379F4.7	4.95	1.32e-06	0.000596	0.45	0.3	Tetralogy of Fallot;	chr3:158592117	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs13318109	ENSG00000272087.1	RP11-379F4.7	4.95	1.32e-06	0.000596	0.45	0.3	Tetralogy of Fallot;	chr3:158595417	chr3:158693120~158693768:-
COAD	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-4.95	1.32e-06	0.000596	-0.35	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
COAD	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	4.95	1.32e-06	0.000596	0.39	0.3	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
COAD	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	4.95	1.32e-06	0.000597	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
COAD	cis	rs5015933	0.788	rs3896096	ENSG00000232630.1	PRPS1P2	-4.95	1.32e-06	0.000598	-0.29	-0.3	Body mass index;	chr9:125265566	chr9:125150653~125151589:+
COAD	cis	rs6543140	0.964	rs6761350	ENSG00000234389.1	AC007278.3	4.95	1.32e-06	0.000598	0.33	0.3	Blood protein levels;	chr2:102414316	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.929	rs7602207	ENSG00000234389.1	AC007278.3	4.95	1.32e-06	0.000598	0.33	0.3	Blood protein levels;	chr2:102415906	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs2160200	ENSG00000234389.1	AC007278.3	4.95	1.32e-06	0.000598	0.33	0.3	Blood protein levels;	chr2:102417503	chr2:102438713~102440475:+
COAD	cis	rs1056107	0.872	rs7865097	ENSG00000225513.1	RP11-165N19.2	-4.95	1.32e-06	0.000598	-0.35	-0.3	Colorectal cancer;	chr9:112272079	chr9:112173522~112173971:-
COAD	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-4.95	1.32e-06	0.000598	-0.31	-0.3	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	4.95	1.32e-06	0.000598	0.31	0.3	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
COAD	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	4.95	1.32e-06	0.000598	0.31	0.3	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	4.95	1.32e-06	0.000598	0.31	0.3	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
COAD	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	4.95	1.32e-06	0.000598	0.35	0.3	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	4.95	1.32e-06	0.000598	0.35	0.3	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
COAD	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	4.95	1.33e-06	0.000598	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
COAD	cis	rs6576086	1	rs6576086	ENSG00000251602.5	RP11-521B24.3	-4.95	1.33e-06	0.000598	-0.56	-0.3	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr14:105406807	chr14:105416884~105419739:-
COAD	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	4.95	1.33e-06	0.000599	0.41	0.3	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
COAD	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	4.95	1.33e-06	0.000599	0.31	0.3	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
COAD	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	4.95	1.33e-06	6e-04	0.52	0.3	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
COAD	cis	rs7260598	0.642	rs8101310	ENSG00000268442.1	CTD-2027I19.2	4.95	1.33e-06	0.000601	0.43	0.3	Response to taxane treatment (placlitaxel);	chr19:23961137	chr19:24162370~24163425:-
COAD	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	4.95	1.33e-06	0.000601	0.3	0.3	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
COAD	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	4.95	1.33e-06	0.000601	0.3	0.3	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
COAD	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	4.95	1.33e-06	0.000601	0.3	0.3	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
COAD	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	4.95	1.33e-06	0.000602	0.3	0.3	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
COAD	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	4.95	1.33e-06	0.000602	0.31	0.3	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
COAD	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	4.95	1.33e-06	0.000602	0.31	0.3	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
COAD	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-4.95	1.33e-06	0.000602	-0.27	-0.3	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
COAD	cis	rs9847710	1	rs12488768	ENSG00000280417.1	RP11-5O17.1	4.95	1.33e-06	0.000602	0.3	0.3	Ulcerative colitis;	chr3:53052218	chr3:53046166~53048122:+
COAD	cis	rs9847710	1	rs13088455	ENSG00000280417.1	RP11-5O17.1	4.95	1.33e-06	0.000602	0.3	0.3	Ulcerative colitis;	chr3:53053466	chr3:53046166~53048122:+
COAD	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	4.95	1.34e-06	0.000602	0.38	0.3	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
COAD	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-4.95	1.34e-06	0.000602	-0.34	-0.3	Height;	chr20:49279608	chr20:49280319~49280409:+
COAD	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	4.95	1.34e-06	0.000603	0.57	0.3	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
COAD	cis	rs7646881	0.544	rs41272617	ENSG00000272087.1	RP11-379F4.7	4.95	1.34e-06	0.000603	0.45	0.3	Tetralogy of Fallot;	chr3:158603103	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs73024790	ENSG00000272087.1	RP11-379F4.7	4.95	1.34e-06	0.000603	0.45	0.3	Tetralogy of Fallot;	chr3:158606615	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs16829135	ENSG00000272087.1	RP11-379F4.7	4.95	1.34e-06	0.000603	0.45	0.3	Tetralogy of Fallot;	chr3:158608049	chr3:158693120~158693768:-
COAD	cis	rs930421	0.586	rs10185815	ENSG00000226491.1	FTOP1	4.95	1.34e-06	0.000603	0.39	0.3	Attention deficit hyperactivity disorder;	chr2:42746299	chr2:42797225~42798712:-
COAD	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	4.95	1.34e-06	0.000603	0.28	0.3	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
COAD	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-4.95	1.34e-06	0.000604	-0.35	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
COAD	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-4.95	1.34e-06	0.000605	-0.17	-0.3	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-4.95	1.34e-06	0.000605	-0.17	-0.3	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
COAD	cis	rs6490294	0.904	rs7304572	ENSG00000257595.2	RP3-473L9.4	4.95	1.34e-06	0.000605	0.42	0.3	Mean platelet volume;	chr12:112087269	chr12:111369282~111403310:+
COAD	cis	rs3120667	0.79	rs726864	ENSG00000237975.5	FLG-AS1	4.95	1.34e-06	0.000605	0.33	0.3	Eating disorders;	chr1:152427817	chr1:152168125~152445456:+
COAD	cis	rs492146	0.935	rs316128	ENSG00000243236.5	GSTA9P	-4.95	1.34e-06	0.000606	-0.31	-0.3	Epilepsy (remission after treatment);	chr6:52984348	chr6:52939726~52957521:-
COAD	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-4.95	1.34e-06	0.000606	-0.2	-0.3	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
COAD	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-4.95	1.34e-06	0.000606	-0.34	-0.3	Height;	chr3:53015087	chr3:53064283~53065091:-
COAD	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-4.95	1.35e-06	0.000607	-0.27	-0.3	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-4.95	1.35e-06	0.000607	-0.27	-0.3	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
COAD	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-4.95	1.35e-06	0.000607	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
COAD	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-4.95	1.35e-06	0.000607	-0.38	-0.3	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
COAD	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	4.95	1.35e-06	0.000607	0.31	0.3	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	4.95	1.35e-06	0.000607	0.31	0.3	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	4.95	1.35e-06	0.000607	0.31	0.3	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	4.95	1.35e-06	0.000607	0.31	0.3	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
COAD	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	4.95	1.35e-06	0.000607	0.27	0.3	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
COAD	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-4.95	1.35e-06	0.000608	-0.5	-0.29	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
COAD	cis	rs58873874	0.737	rs76634949	ENSG00000248544.2	CTB-47B11.3	4.95	1.35e-06	0.000608	0.65	0.29	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157375741~157384950:-
COAD	cis	rs58873874	0.737	rs79339674	ENSG00000248544.2	CTB-47B11.3	4.95	1.35e-06	0.000608	0.65	0.29	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157375741~157384950:-
COAD	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-4.95	1.35e-06	0.000608	-0.31	-0.29	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
COAD	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	4.95	1.35e-06	0.000608	0.22	0.29	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	4.95	1.35e-06	0.000608	0.22	0.29	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
COAD	cis	rs5758511	0.773	rs10154700	ENSG00000237037.8	NDUFA6-AS1	-4.95	1.35e-06	0.000609	-0.32	-0.29	Birth weight;	chr22:41969069	chr22:42090931~42137742:+
COAD	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	4.95	1.35e-06	0.000609	0.34	0.29	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
COAD	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	4.95	1.35e-06	0.000609	0.36	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
COAD	cis	rs5758511	0.68	rs5758682	ENSG00000237037.8	NDUFA6-AS1	-4.95	1.35e-06	0.000609	-0.35	-0.29	Birth weight;	chr22:42249196	chr22:42090931~42137742:+
COAD	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-4.95	1.35e-06	0.000609	-0.36	-0.29	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
COAD	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-4.95	1.35e-06	0.000609	-0.35	-0.29	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
COAD	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	4.95	1.35e-06	0.000609	0.31	0.29	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
COAD	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-4.95	1.36e-06	0.000611	-0.34	-0.29	Height;	chr20:49299758	chr20:49280319~49280409:+
COAD	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-4.95	1.36e-06	0.000612	-0.36	-0.29	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
COAD	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	4.95	1.36e-06	0.000612	0.62	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
COAD	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	4.95	1.36e-06	0.000612	0.3	0.29	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
COAD	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	4.95	1.36e-06	0.000612	0.47	0.29	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
COAD	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	4.95	1.36e-06	0.000613	0.31	0.29	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
COAD	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-4.95	1.36e-06	0.000614	-0.34	-0.29	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
COAD	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	4.95	1.36e-06	0.000614	0.5	0.29	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
COAD	cis	rs12497850	0.864	rs4279134	ENSG00000225399.4	RP11-3B7.1	4.95	1.37e-06	0.000614	0.33	0.29	Parkinson's disease;	chr3:49119243	chr3:49260085~49261316:+
COAD	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	4.95	1.37e-06	0.000615	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
COAD	cis	rs11668609	1	rs7260280	ENSG00000268442.1	CTD-2027I19.2	4.95	1.37e-06	0.000615	0.36	0.29	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:24162370~24163425:-
COAD	cis	rs11668609	1	rs4452076	ENSG00000268442.1	CTD-2027I19.2	4.95	1.37e-06	0.000615	0.36	0.29	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:24162370~24163425:-
COAD	cis	rs11846409	0.86	rs61686131	ENSG00000274576.2	IGHV2-70	-4.95	1.37e-06	0.000615	-0.29	-0.29	Rheumatic heart disease;	chr14:106631568	chr14:106770577~106771020:-
COAD	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-4.95	1.37e-06	0.000615	-0.39	-0.29	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
COAD	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-4.95	1.37e-06	0.000615	-0.36	-0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
COAD	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-4.95	1.37e-06	0.000615	-0.36	-0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
COAD	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	4.95	1.37e-06	0.000615	0.32	0.29	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
COAD	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	4.95	1.37e-06	0.000616	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
COAD	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	4.95	1.37e-06	0.000616	0.38	0.29	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
COAD	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-4.95	1.37e-06	0.000616	-0.37	-0.29	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
COAD	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	4.95	1.37e-06	0.000617	0.43	0.29	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
COAD	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-4.95	1.37e-06	0.000617	-0.34	-0.29	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
COAD	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	4.95	1.37e-06	0.000617	0.29	0.29	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
COAD	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	4.94	1.38e-06	0.000618	0.3	0.29	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
COAD	cis	rs1056107	0.931	rs7875843	ENSG00000225513.1	RP11-165N19.2	-4.94	1.38e-06	0.000619	-0.35	-0.29	Colorectal cancer;	chr9:112256675	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.897	rs4979090	ENSG00000225513.1	RP11-165N19.2	-4.94	1.38e-06	0.000619	-0.35	-0.29	Colorectal cancer;	chr9:112257991	chr9:112173522~112173971:-
COAD	cis	rs1056107	0.866	rs10817305	ENSG00000225513.1	RP11-165N19.2	-4.94	1.38e-06	0.000619	-0.35	-0.29	Colorectal cancer;	chr9:112259120	chr9:112173522~112173971:-
COAD	cis	rs2732480	0.5	rs11168464	ENSG00000273765.1	RP11-370I10.11	4.94	1.38e-06	0.000619	0.32	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48360920~48361377:+
COAD	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	4.94	1.38e-06	0.000619	0.36	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
COAD	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	4.94	1.38e-06	0.00062	0.39	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
COAD	cis	rs2115630	0.645	rs4842978	ENSG00000259728.4	LINC00933	-4.94	1.38e-06	0.00062	-0.36	-0.29	P wave terminal force;	chr15:84654022	chr15:84570649~84580175:+
COAD	cis	rs58873874	0.737	rs11745566	ENSG00000248544.2	CTB-47B11.3	4.94	1.38e-06	0.00062	0.65	0.29	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157375741~157384950:-
COAD	cis	rs35264875	0.846	rs2924534	ENSG00000259799.1	RP11-554A11.9	-4.94	1.38e-06	0.000621	-0.47	-0.29	Blond vs. brown hair color;	chr11:69103048	chr11:69155910~69159752:+
COAD	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	4.94	1.38e-06	0.000621	0.36	0.29	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
COAD	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	4.94	1.38e-06	0.000621	0.37	0.29	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
COAD	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	4.94	1.38e-06	0.000621	0.4	0.29	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
COAD	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-4.94	1.38e-06	0.000621	-0.26	-0.29	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
COAD	cis	rs7955901	0.837	rs10748169	ENSG00000258053.1	CTD-2021H9.3	-4.94	1.38e-06	0.000621	-0.35	-0.29	Type 2 diabetes;	chr12:71023076	chr12:71047402~71118247:-
COAD	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	4.94	1.39e-06	0.000623	0.36	0.29	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
COAD	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-4.94	1.39e-06	0.000623	-0.37	-0.29	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
COAD	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-4.94	1.39e-06	0.000623	-0.37	-0.29	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
COAD	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	4.94	1.39e-06	0.000624	0.36	0.29	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
COAD	cis	rs7615952	0.512	rs4679430	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125639049	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.512	rs34651730	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125639796	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.512	rs2979334	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125639980	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.512	rs11929125	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125640599	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.512	rs11921452	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125640906	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.512	rs2922175	ENSG00000241278.1	ENPP7P4	4.94	1.39e-06	0.000625	0.32	0.29	Blood pressure (smoking interaction);	chr3:125642516	chr3:125848223~125909372:+
COAD	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-4.94	1.4e-06	0.000626	-0.35	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
COAD	cis	rs8002861	0.935	rs4942256	ENSG00000274001.1	RP11-5G9.5	4.94	1.4e-06	0.000626	0.27	0.29	Leprosy;	chr13:43881784	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.935	rs9567299	ENSG00000274001.1	RP11-5G9.5	4.94	1.4e-06	0.000626	0.27	0.29	Leprosy;	chr13:43882833	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.935	rs9525865	ENSG00000274001.1	RP11-5G9.5	4.94	1.4e-06	0.000626	0.27	0.29	Leprosy;	chr13:43885511	chr13:43877715~43878163:-
COAD	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-4.94	1.4e-06	0.000626	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
COAD	cis	rs6719977	0.905	rs2278584	ENSG00000226491.1	FTOP1	-4.94	1.4e-06	0.000626	-0.38	-0.29	Hyperactive-impulsive symptoms;	chr2:42762604	chr2:42797225~42798712:-
COAD	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	4.94	1.4e-06	0.000626	0.43	0.29	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
COAD	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	4.94	1.4e-06	0.000626	0.43	0.29	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
COAD	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-4.94	1.4e-06	0.000627	-0.6	-0.29	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-4.94	1.4e-06	0.000627	-0.6	-0.29	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
COAD	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	4.94	1.4e-06	0.000628	0.3	0.29	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
COAD	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
COAD	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
COAD	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
COAD	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
COAD	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
COAD	cis	rs5758659	0.652	rs133349	ENSG00000182057.4	OGFRP1	4.94	1.4e-06	0.000628	0.31	0.29	Cognitive function;	chr22:42032723	chr22:42269753~42275196:+
COAD	cis	rs5758659	0.652	rs5758553	ENSG00000182057.4	OGFRP1	4.94	1.4e-06	0.000628	0.31	0.29	Cognitive function;	chr22:42035425	chr22:42269753~42275196:+
COAD	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	4.94	1.4e-06	0.000628	0.31	0.29	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
COAD	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-4.94	1.4e-06	0.000628	-0.33	-0.29	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
COAD	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-4.94	1.4e-06	0.000628	-0.27	-0.29	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
COAD	cis	rs9450351	0.744	rs9450295	ENSG00000203875.9	SNHG5	-4.94	1.4e-06	0.000629	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85548156	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs7744309	ENSG00000203875.9	SNHG5	-4.94	1.4e-06	0.000629	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85556764	chr6:85660950~85678736:-
COAD	cis	rs9353324	1	rs7771366	ENSG00000203875.9	SNHG5	-4.94	1.4e-06	0.000629	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85582193	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6902638	ENSG00000203875.9	SNHG5	-4.94	1.4e-06	0.000629	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85608881	chr6:85660950~85678736:-
COAD	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-4.94	1.4e-06	0.000629	-0.51	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
COAD	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	4.94	1.41e-06	0.00063	0.34	0.29	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
COAD	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	4.94	1.41e-06	0.00063	0.34	0.29	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
COAD	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-4.94	1.41e-06	0.00063	-0.25	-0.29	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
COAD	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-4.94	1.41e-06	0.000631	-0.52	-0.29	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
COAD	cis	rs12935418	0.673	rs2549887	ENSG00000278985.1	RP11-303E16.9	-4.94	1.41e-06	0.000631	-0.31	-0.29	Mean corpuscular volume;	chr16:81028222	chr16:80982319~80984094:-
COAD	cis	rs9393777	0.513	rs9368447	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26646446	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9393739	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26646738	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9368448	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26649127	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs3999471	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26650078	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9393741	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26653961	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9379907	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26654090	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9368451	ENSG00000224843.5	LINC00240	4.94	1.41e-06	0.000631	0.46	0.29	Intelligence (multi-trait analysis);	chr6:26654105	chr6:26956992~27023924:+
COAD	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	4.94	1.41e-06	0.000632	0.31	0.29	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
COAD	cis	rs7560272	0.723	rs6722867	ENSG00000163016.8	ALMS1P	4.94	1.41e-06	0.000632	0.35	0.29	Schizophrenia;	chr2:73589158	chr2:73644919~73685576:+
COAD	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-4.94	1.41e-06	0.000632	-0.35	-0.29	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
COAD	cis	rs3126085	0.515	rs12029633	ENSG00000237975.5	FLG-AS1	4.94	1.41e-06	0.000632	0.32	0.29	Atopic dermatitis;	chr1:152374927	chr1:152168125~152445456:+
COAD	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.94	1.41e-06	0.000633	0.55	0.29	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
COAD	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-4.94	1.42e-06	0.000633	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
COAD	cis	rs875971	0.545	rs2420612	ENSG00000224316.1	RP11-479O9.2	4.94	1.42e-06	0.000634	0.38	0.29	Aortic root size;	chr7:66536825	chr7:65773620~65802067:+
COAD	cis	rs17772222	0.958	rs60213984	ENSG00000258789.1	RP11-507K2.3	-4.94	1.42e-06	0.000634	-0.42	-0.29	Coronary artery calcification;	chr14:88401473	chr14:88551597~88552493:+
COAD	cis	rs17772222	1	rs61977058	ENSG00000258789.1	RP11-507K2.3	-4.94	1.42e-06	0.000634	-0.42	-0.29	Coronary artery calcification;	chr14:88415571	chr14:88551597~88552493:+
COAD	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-4.94	1.42e-06	0.000634	-0.16	-0.29	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
COAD	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	4.94	1.42e-06	0.000635	0.34	0.29	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	4.94	1.42e-06	0.000635	0.34	0.29	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	4.94	1.42e-06	0.000635	0.34	0.29	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
COAD	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-4.94	1.42e-06	0.000635	-0.34	-0.29	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
COAD	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-4.94	1.42e-06	0.000635	-0.34	-0.29	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
COAD	cis	rs2732480	0.577	rs2732457	ENSG00000273765.1	RP11-370I10.11	-4.94	1.42e-06	0.000635	-0.34	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48360920~48361377:+
COAD	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-4.94	1.42e-06	0.000635	-0.46	-0.29	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-4.94	1.42e-06	0.000635	-0.46	-0.29	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
COAD	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-4.94	1.42e-06	0.000636	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
COAD	cis	rs9368481	0.547	rs2093303	ENSG00000224843.5	LINC00240	-4.94	1.42e-06	0.000636	-0.35	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26956992~27023924:+
COAD	cis	rs9487051	0.652	rs6568559	ENSG00000219700.1	PTCHD3P3	4.94	1.42e-06	0.000636	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109271548	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6568560	ENSG00000219700.1	PTCHD3P3	4.94	1.42e-06	0.000636	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109271648	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs1521905	ENSG00000219700.1	PTCHD3P3	4.94	1.42e-06	0.000636	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109273312	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs7775206	ENSG00000219700.1	PTCHD3P3	4.94	1.42e-06	0.000636	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109276019	chr6:109288571~109290503:-
COAD	cis	rs11668609	0.81	rs8105851	ENSG00000268442.1	CTD-2027I19.2	4.94	1.42e-06	0.000636	0.36	0.29	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:24162370~24163425:-
COAD	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	4.94	1.42e-06	0.000637	0.66	0.29	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	4.94	1.42e-06	0.000637	0.66	0.29	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
COAD	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	4.94	1.42e-06	0.000637	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	4.94	1.42e-06	0.000637	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
COAD	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-4.94	1.43e-06	0.000637	-0.36	-0.29	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
COAD	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	4.94	1.43e-06	0.000638	0.55	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
COAD	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-4.94	1.43e-06	0.000638	-0.34	-0.29	QT interval;	chr12:29302457	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-4.94	1.43e-06	0.000638	-0.34	-0.29	QT interval;	chr12:29302458	chr12:29280418~29317848:-
COAD	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-4.94	1.43e-06	0.000638	-0.36	-0.29	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
COAD	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-4.94	1.43e-06	0.000639	-0.32	-0.29	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
COAD	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	4.94	1.43e-06	0.000639	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
COAD	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	4.94	1.43e-06	0.000639	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
COAD	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-4.94	1.43e-06	0.000639	-0.6	-0.29	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
COAD	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-4.94	1.43e-06	0.00064	-0.37	-0.29	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
COAD	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	4.94	1.43e-06	0.00064	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	4.94	1.43e-06	0.00064	0.4	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
COAD	cis	rs7260598	0.642	rs10407805	ENSG00000268442.1	CTD-2027I19.2	4.94	1.43e-06	0.00064	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23982903	chr19:24162370~24163425:-
COAD	cis	rs5758511	0.773	rs9623482	ENSG00000237037.8	NDUFA6-AS1	-4.94	1.43e-06	0.000641	-0.32	-0.29	Birth weight;	chr22:41964570	chr22:42090931~42137742:+
COAD	cis	rs6490294	0.904	rs10850003	ENSG00000257595.2	RP3-473L9.4	4.94	1.43e-06	0.000641	0.43	0.29	Mean platelet volume;	chr12:112133365	chr12:111369282~111403310:+
COAD	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-4.94	1.43e-06	0.000641	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
COAD	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-4.94	1.44e-06	0.000641	-0.43	-0.29	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
COAD	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-4.94	1.44e-06	0.000641	-0.43	-0.29	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
COAD	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-4.94	1.44e-06	0.000642	-0.31	-0.29	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
COAD	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-4.94	1.44e-06	0.000643	-0.27	-0.29	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
COAD	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	4.94	1.44e-06	0.000643	0.4	0.29	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
COAD	cis	rs7818688	0.585	rs10102806	ENSG00000253528.2	RP11-347C18.4	4.93	1.44e-06	0.000645	0.38	0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95039463	chr8:94974573~94974853:-
COAD	cis	rs34102591	0.826	rs71458829	ENSG00000269938.1	RP11-214K3.20	-4.93	1.44e-06	0.000645	-0.51	-0.29	Schizophrenia;	chr12:123986200	chr12:123968023~123968579:-
COAD	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-4.93	1.45e-06	0.000647	-0.26	-0.29	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
COAD	cis	rs748404	0.556	rs10851414	ENSG00000249839.1	AC011330.5	4.93	1.45e-06	0.000647	0.36	0.29	Lung cancer;	chr15:43141734	chr15:43663654~43684339:-
COAD	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	4.93	1.45e-06	0.000647	0.33	0.29	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
COAD	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	4.93	1.45e-06	0.000648	0.29	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
COAD	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	4.93	1.45e-06	0.000648	0.45	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
COAD	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-4.93	1.45e-06	0.000648	-0.4	-0.29	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
COAD	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-4.93	1.45e-06	0.000648	-0.4	-0.29	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-4.93	1.45e-06	0.000648	-0.4	-0.29	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-4.93	1.45e-06	0.000648	-0.4	-0.29	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-4.93	1.45e-06	0.000648	-0.4	-0.29	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
COAD	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-4.93	1.45e-06	0.000648	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
COAD	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-4.93	1.45e-06	0.000648	-0.36	-0.29	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
COAD	cis	rs801193	0.967	rs2707841	ENSG00000272831.1	RP11-792A8.4	4.93	1.45e-06	0.000648	0.31	0.29	Aortic root size;	chr7:66692033	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs4717310	ENSG00000272831.1	RP11-792A8.4	4.93	1.45e-06	0.000648	0.31	0.29	Aortic root size;	chr7:66696020	chr7:66739829~66740385:-
COAD	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	4.93	1.45e-06	0.000649	0.31	0.29	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
COAD	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-4.93	1.45e-06	0.000649	-0.32	-0.29	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
COAD	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	4.93	1.45e-06	0.000649	0.38	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
COAD	cis	rs11719291	0.833	rs11713694	ENSG00000225399.4	RP11-3B7.1	-4.93	1.46e-06	0.000649	-0.58	-0.29	Cognitive function;	chr3:48796182	chr3:49260085~49261316:+
COAD	cis	rs11719291	0.833	rs11709246	ENSG00000225399.4	RP11-3B7.1	-4.93	1.46e-06	0.000649	-0.58	-0.29	Cognitive function;	chr3:48822065	chr3:49260085~49261316:+
COAD	cis	rs11719291	0.504	rs71324924	ENSG00000225399.4	RP11-3B7.1	-4.93	1.46e-06	0.000649	-0.58	-0.29	Cognitive function;	chr3:48828011	chr3:49260085~49261316:+
COAD	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-4.93	1.46e-06	0.00065	-0.29	-0.29	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
COAD	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-4.93	1.46e-06	0.00065	-0.36	-0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
COAD	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-4.93	1.46e-06	0.000652	-0.36	-0.29	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-4.93	1.46e-06	0.000652	-0.36	-0.29	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-4.93	1.46e-06	0.000652	-0.36	-0.29	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
COAD	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-4.93	1.46e-06	0.000652	-0.37	-0.29	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
COAD	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-4.93	1.46e-06	0.000652	-0.37	-0.29	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
COAD	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	4.93	1.46e-06	0.000652	0.3	0.29	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
COAD	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-4.93	1.46e-06	0.000653	-0.41	-0.29	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
COAD	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	4.93	1.46e-06	0.000653	0.44	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
COAD	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	4.93	1.46e-06	0.000653	0.32	0.29	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
COAD	cis	rs58873874	0.737	rs75022277	ENSG00000248544.2	CTB-47B11.3	4.93	1.47e-06	0.000654	0.64	0.29	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157375741~157384950:-
COAD	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	4.93	1.47e-06	0.000655	0.34	0.29	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
COAD	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	4.93	1.47e-06	0.000655	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	4.93	1.47e-06	0.000655	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	4.93	1.47e-06	0.000655	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	4.93	1.47e-06	0.000655	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
COAD	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	4.93	1.47e-06	0.000655	0.58	0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
COAD	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	4.93	1.47e-06	0.000655	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
COAD	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	4.93	1.47e-06	0.000656	0.34	0.29	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
COAD	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-4.93	1.47e-06	0.000657	-0.44	-0.29	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
COAD	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-4.93	1.48e-06	0.000657	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
COAD	cis	rs1790761	0.667	rs4147581	ENSG00000231793.4	DOC2GP	4.93	1.48e-06	0.000657	0.33	0.29	Mean corpuscular volume;	chr11:67584114	chr11:67612653~67616257:-
COAD	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-4.93	1.48e-06	0.000658	-0.33	-0.29	Height;	chr3:53080524	chr3:53064283~53065091:-
COAD	cis	rs860818	1	rs858278	ENSG00000226816.2	AC005082.12	4.93	1.48e-06	0.000658	0.72	0.29	Initial pursuit acceleration;	chr7:23212583	chr7:23206013~23208045:+
COAD	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-4.93	1.48e-06	0.000658	-0.54	-0.29	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
COAD	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-4.93	1.48e-06	0.000658	-0.46	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
COAD	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-4.93	1.48e-06	0.000658	-0.3	-0.29	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
COAD	cis	rs6452524	0.534	rs17284134	ENSG00000271862.1	RP11-343L5.2	-4.93	1.48e-06	0.000659	-0.31	-0.29	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83049376~83050964:-
COAD	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	4.93	1.48e-06	0.00066	0.35	0.29	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
COAD	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-4.93	1.48e-06	0.000661	-0.33	-0.29	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
COAD	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-4.93	1.48e-06	0.000661	-0.33	-0.29	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
COAD	cis	rs9309473	0.5	rs11126402	ENSG00000163016.8	ALMS1P	4.93	1.48e-06	0.000661	0.35	0.29	Metabolite levels;	chr2:73549455	chr2:73644919~73685576:+
COAD	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-4.93	1.49e-06	0.000661	-0.35	-0.29	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
COAD	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	4.93	1.49e-06	0.000661	0.53	0.29	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
COAD	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	4.93	1.49e-06	0.000661	0.28	0.29	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
COAD	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	4.93	1.49e-06	0.000662	0.3	0.29	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
COAD	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	4.93	1.49e-06	0.000662	0.39	0.29	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
COAD	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	4.93	1.49e-06	0.000663	0.36	0.29	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
COAD	cis	rs1930961	1	rs6004667	ENSG00000272798.1	CTA-390C10.9	4.93	1.49e-06	0.000664	0.42	0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25436312~25436915:+
COAD	cis	rs41307935	0.915	rs57189461	ENSG00000260063.1	RP5-968P14.2	-4.93	1.49e-06	0.000664	-0.6	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26798054	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12748152	ENSG00000260063.1	RP5-968P14.2	-4.93	1.49e-06	0.000664	-0.6	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26811902	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71636783	ENSG00000260063.1	RP5-968P14.2	-4.93	1.49e-06	0.000664	-0.6	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813370	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.73	rs34716450	ENSG00000260063.1	RP5-968P14.2	-4.93	1.49e-06	0.000664	-0.6	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26817084	chr1:26692132~26694131:-
COAD	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-4.93	1.49e-06	0.000664	-0.37	-0.29	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
COAD	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-4.93	1.49e-06	0.000664	-0.47	-0.29	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
COAD	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-4.93	1.49e-06	0.000664	-0.5	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
COAD	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	4.93	1.49e-06	0.000665	0.3	0.29	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
COAD	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.93	1.5e-06	0.000665	-0.38	-0.29	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
COAD	cis	rs12497850	0.931	rs7616815	ENSG00000225399.4	RP11-3B7.1	4.93	1.5e-06	0.000665	0.33	0.29	Parkinson's disease;	chr3:48742282	chr3:49260085~49261316:+
COAD	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	4.93	1.5e-06	0.000665	0.4	0.29	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
COAD	cis	rs9450351	0.744	rs9450304	ENSG00000203875.9	SNHG5	-4.93	1.5e-06	0.000666	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85620141	chr6:85660950~85678736:-
COAD	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	4.93	1.5e-06	0.000666	0.34	0.29	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
COAD	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	4.93	1.5e-06	0.000666	0.73	0.29	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	4.93	1.5e-06	0.000666	0.73	0.29	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
COAD	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	4.93	1.5e-06	0.000666	0.35	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
COAD	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	4.93	1.5e-06	0.000666	0.32	0.29	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
COAD	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-4.93	1.5e-06	0.000667	-0.35	-0.29	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
COAD	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-4.93	1.5e-06	0.000667	-0.31	-0.29	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
COAD	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-4.93	1.5e-06	0.000667	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
COAD	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	4.93	1.5e-06	0.000668	0.45	0.29	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
COAD	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-4.93	1.5e-06	0.000668	-0.37	-0.29	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
COAD	cis	rs453301	0.658	rs6986044	ENSG00000173295.6	FAM86B3P	-4.93	1.51e-06	0.000669	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9017276	chr8:8228595~8244865:+
COAD	cis	rs7224610	0.931	rs7223342	ENSG00000263096.1	RP11-515O17.2	4.93	1.51e-06	0.000669	0.35	0.29	Urate levels;	chr17:55292233	chr17:55271504~55273653:-
COAD	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	4.93	1.51e-06	0.000669	0.39	0.29	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
COAD	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	4.93	1.51e-06	0.00067	0.33	0.29	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
COAD	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-4.93	1.51e-06	0.00067	-0.47	-0.29	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
COAD	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-4.93	1.51e-06	0.000671	-0.39	-0.29	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
COAD	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-4.93	1.51e-06	0.000671	-0.34	-0.29	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-4.93	1.51e-06	0.000671	-0.34	-0.29	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
COAD	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	4.93	1.51e-06	0.000671	0.31	0.29	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
COAD	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-4.93	1.51e-06	0.000671	-0.4	-0.29	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
COAD	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-4.93	1.51e-06	0.000671	-0.31	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
COAD	cis	rs7818688	0.614	rs16917082	ENSG00000253528.2	RP11-347C18.4	-4.92	1.51e-06	0.000672	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94849597	chr8:94974573~94974853:-
COAD	cis	rs5758511	0.68	rs5758698	ENSG00000237037.8	NDUFA6-AS1	-4.92	1.51e-06	0.000672	-0.35	-0.29	Birth weight;	chr22:42288812	chr22:42090931~42137742:+
COAD	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	4.92	1.51e-06	0.000672	0.38	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
COAD	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	4.92	1.51e-06	0.000672	0.38	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
COAD	cis	rs12935418	0.523	rs2549840	ENSG00000278985.1	RP11-303E16.9	-4.92	1.51e-06	0.000673	-0.31	-0.29	Mean corpuscular volume;	chr16:80989817	chr16:80982319~80984094:-
COAD	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	4.92	1.52e-06	0.000673	0.27	0.29	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	4.92	1.52e-06	0.000673	0.27	0.29	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
COAD	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	4.92	1.52e-06	0.000673	0.28	0.29	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
COAD	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	4.92	1.52e-06	0.000673	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
COAD	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	4.92	1.52e-06	0.000674	0.31	0.29	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000257735.1	RP11-370I10.6	4.92	1.52e-06	0.000675	0.35	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48350945~48442411:+
COAD	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	4.92	1.52e-06	0.000675	0.29	0.29	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
COAD	cis	rs2281603	0.598	rs10151656	ENSG00000259116.1	RP11-973N13.4	-4.92	1.52e-06	0.000675	-0.29	-0.29	Lymphocyte counts;	chr14:64594970	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	4.92	1.52e-06	0.000676	0.32	0.29	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
COAD	cis	rs453301	0.686	rs28665409	ENSG00000253981.4	ALG1L13P	-4.92	1.52e-06	0.000676	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9011767	chr8:8236003~8244667:-
COAD	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.92	1.52e-06	0.000677	-0.39	-0.29	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
COAD	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-4.92	1.53e-06	0.000677	-0.34	-0.29	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
COAD	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	4.92	1.53e-06	0.000678	0.44	0.29	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
COAD	cis	rs754466	0.83	rs61854186	ENSG00000204049.1	RP11-126H7.4	4.92	1.53e-06	0.00068	0.4	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77943497	chr10:77866875~77869610:+
COAD	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	4.92	1.53e-06	0.00068	0.41	0.29	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
COAD	cis	rs11668609	0.515	rs58278214	ENSG00000268442.1	CTD-2027I19.2	4.92	1.53e-06	0.00068	0.47	0.29	Response to taxane treatment (docetaxel);	chr19:23888887	chr19:24162370~24163425:-
COAD	cis	rs801193	1	rs2003301	ENSG00000272831.1	RP11-792A8.4	-4.92	1.54e-06	0.000681	-0.31	-0.29	Aortic root size;	chr7:66682669	chr7:66739829~66740385:-
COAD	cis	rs453301	0.624	rs6987558	ENSG00000253981.4	ALG1L13P	4.92	1.54e-06	0.000681	0.36	0.29	Joint mobility (Beighton score);	chr8:9005011	chr8:8236003~8244667:-
COAD	cis	rs1900504	0.584	rs2915756	ENSG00000266200.5	PNLIPRP2	-4.92	1.54e-06	0.000682	-0.36	-0.29	Tonsillectomy;	chr10:116603428	chr10:116620953~116645143:+
COAD	cis	rs9818758	0.607	rs9990153	ENSG00000225399.4	RP11-3B7.1	-4.92	1.54e-06	0.000682	-0.51	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:49260085~49261316:+
COAD	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-4.92	1.54e-06	0.000682	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-4.92	1.54e-06	0.000682	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-4.92	1.54e-06	0.000682	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
COAD	cis	rs801193	1	rs7785213	ENSG00000272831.1	RP11-792A8.4	-4.92	1.54e-06	0.000682	-0.31	-0.29	Aortic root size;	chr7:66673991	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs11773829	ENSG00000272831.1	RP11-792A8.4	-4.92	1.54e-06	0.000682	-0.31	-0.29	Aortic root size;	chr7:66676087	chr7:66739829~66740385:-
COAD	cis	rs5015933	1	rs10760395	ENSG00000232630.1	PRPS1P2	-4.92	1.54e-06	0.000683	-0.28	-0.29	Body mass index;	chr9:125369582	chr9:125150653~125151589:+
COAD	cis	rs5015933	1	rs10760397	ENSG00000232630.1	PRPS1P2	-4.92	1.54e-06	0.000683	-0.28	-0.29	Body mass index;	chr9:125370928	chr9:125150653~125151589:+
COAD	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-4.92	1.54e-06	0.000684	-0.25	-0.29	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-4.92	1.54e-06	0.000684	-0.25	-0.29	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
COAD	cis	rs453301	0.657	rs36056437	ENSG00000233609.3	RP11-62H7.2	-4.92	1.54e-06	0.000684	-0.32	-0.29	Joint mobility (Beighton score);	chr8:8935355	chr8:8961200~8979025:+
COAD	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-4.92	1.55e-06	0.000685	-0.46	-0.29	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-4.92	1.55e-06	0.000685	-0.46	-0.29	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
COAD	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-4.92	1.55e-06	0.000685	-0.36	-0.29	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
COAD	cis	rs739496	0.579	rs2106697	ENSG00000257595.2	RP3-473L9.4	4.92	1.55e-06	0.000685	0.43	0.29	Platelet count;	chr12:111822261	chr12:111369282~111403310:+
COAD	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-4.92	1.55e-06	0.000685	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-4.92	1.55e-06	0.000686	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
COAD	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	4.92	1.55e-06	0.000686	0.3	0.29	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
COAD	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	4.92	1.55e-06	0.000687	0.35	0.29	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
COAD	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-4.92	1.55e-06	0.000687	-0.36	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
COAD	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	4.92	1.55e-06	0.000688	0.31	0.29	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
COAD	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	4.92	1.55e-06	0.000688	0.35	0.29	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
COAD	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	4.92	1.55e-06	0.000688	0.31	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
COAD	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-4.92	1.56e-06	0.00069	-0.34	-0.29	QT interval;	chr12:29298788	chr12:29280418~29317848:-
COAD	cis	rs453301	0.631	rs17700611	ENSG00000253981.4	ALG1L13P	-4.92	1.56e-06	0.00069	-0.35	-0.29	Joint mobility (Beighton score);	chr8:8936144	chr8:8236003~8244667:-
COAD	cis	rs5758659	0.652	rs133347	ENSG00000182057.4	OGFRP1	4.92	1.56e-06	0.00069	0.31	0.29	Cognitive function;	chr22:42027641	chr22:42269753~42275196:+
COAD	cis	rs7529073	0.815	rs1431983	ENSG00000274895.1	RP11-478J18.2	4.92	1.56e-06	0.000691	0.31	0.29	Schizophrenia;	chr1:213975429	chr1:213983793~213986419:-
COAD	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	4.92	1.56e-06	0.000691	0.27	0.29	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
COAD	cis	rs2732480	0.577	rs2634684	ENSG00000273765.1	RP11-370I10.11	-4.92	1.56e-06	0.000692	-0.33	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48360920~48361377:+
COAD	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-4.92	1.56e-06	0.000692	-0.28	-0.29	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
COAD	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-4.92	1.57e-06	0.000692	-0.34	-0.29	Height;	chr3:52972039	chr3:53064283~53065091:-
COAD	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-4.92	1.57e-06	0.000693	-0.33	-0.29	Height;	chr11:118856460	chr11:118791254~118793137:+
COAD	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-4.92	1.57e-06	0.000693	-0.33	-0.29	Height;	chr11:118856623	chr11:118791254~118793137:+
COAD	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-4.92	1.57e-06	0.000693	-0.33	-0.29	Height;	chr11:118857611	chr11:118791254~118793137:+
COAD	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-4.92	1.57e-06	0.000693	-0.29	-0.29	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
COAD	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-4.92	1.57e-06	0.000693	-0.28	-0.29	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
COAD	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-4.92	1.57e-06	0.000693	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
COAD	cis	rs492146	0.935	rs405729	ENSG00000243236.5	GSTA9P	-4.92	1.57e-06	0.000694	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52977983	chr6:52939726~52957521:-
COAD	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-4.92	1.57e-06	0.000695	-0.35	-0.29	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
COAD	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-4.92	1.57e-06	0.000696	-0.35	-0.29	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	4.92	1.58e-06	0.000696	0.32	0.29	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
COAD	cis	rs13217239	0.646	rs35691005	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27004291	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs10946891	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27005436	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs12201393	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27007911	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs12209886	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27016978	chr6:26956992~27023924:+
COAD	cis	rs6940638	0.531	rs12211984	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs10456351	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27019013	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs10456352	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27022579	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs4583981	ENSG00000224843.5	LINC00240	-4.92	1.58e-06	0.000696	-0.34	-0.29	Schizophrenia;	chr6:27024244	chr6:26956992~27023924:+
COAD	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	4.92	1.58e-06	0.000697	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
COAD	cis	rs2732480	0.538	rs2468943	ENSG00000257735.1	RP11-370I10.6	-4.92	1.58e-06	0.000697	-0.37	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48350945~48442411:+
COAD	cis	rs9951698	0.703	rs8088313	ENSG00000266969.1	RP11-773H22.4	4.92	1.58e-06	0.000697	0.38	0.29	Intelligence (multi-trait analysis);	chr18:12977207	chr18:12984694~12991173:-
COAD	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	4.92	1.58e-06	0.000698	0.3	0.29	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
COAD	cis	rs2732480	0.5	rs7297824	ENSG00000257735.1	RP11-370I10.6	4.92	1.58e-06	0.000698	0.35	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48350945~48442411:+
COAD	cis	rs3126085	0.515	rs10788837	ENSG00000237975.5	FLG-AS1	4.92	1.58e-06	0.000698	0.32	0.29	Atopic dermatitis;	chr1:152379011	chr1:152168125~152445456:+
COAD	cis	rs7818688	0.578	rs11786451	ENSG00000253528.2	RP11-347C18.4	-4.92	1.58e-06	0.000699	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94884803	chr8:94974573~94974853:-
COAD	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.58e-06	0.000699	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
COAD	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-4.92	1.58e-06	0.000699	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
COAD	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-4.91	1.58e-06	0.000699	-0.59	-0.29	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
COAD	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	4.91	1.59e-06	7e-04	0.35	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
COAD	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	4.91	1.59e-06	7e-04	0.37	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
COAD	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-4.91	1.59e-06	7e-04	-0.33	-0.29	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
COAD	cis	rs11124272	0.638	rs4952203	ENSG00000272716.1	RP11-563N4.1	-4.91	1.59e-06	7e-04	-0.36	-0.29	Interleukin-18 levels;	chr2:31878620	chr2:32165046~32165757:-
COAD	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-4.91	1.59e-06	0.000701	-0.33	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
COAD	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-4.91	1.59e-06	0.000701	-0.34	-0.29	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
COAD	cis	rs34792	0.688	rs153785	ENSG00000207425.1	Y_RNA	4.91	1.59e-06	0.000701	0.37	0.29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:14915457~14915556:-
COAD	cis	rs492146	0.729	rs644100	ENSG00000243236.5	GSTA9P	-4.91	1.59e-06	0.000701	-0.33	-0.29	Epilepsy (remission after treatment);	chr6:52977573	chr6:52939726~52957521:-
COAD	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-4.91	1.59e-06	0.000701	-0.34	-0.29	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
COAD	cis	rs2581828	0.646	rs3796351	ENSG00000280417.1	RP11-5O17.1	-4.91	1.59e-06	0.000701	-0.31	-0.29	Crohn's disease;	chr3:53122049	chr3:53046166~53048122:+
COAD	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-4.91	1.59e-06	0.000702	-0.39	-0.29	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-4.91	1.59e-06	0.000702	-0.39	-0.29	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-4.91	1.59e-06	0.000702	-0.39	-0.29	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
COAD	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-4.91	1.59e-06	0.000702	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
COAD	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-4.91	1.59e-06	0.000703	-0.37	-0.29	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
COAD	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	4.91	1.59e-06	0.000703	0.31	0.29	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
COAD	cis	rs7260598	0.539	rs10425192	ENSG00000268442.1	CTD-2027I19.2	4.91	1.59e-06	0.000704	0.47	0.29	Response to taxane treatment (placlitaxel);	chr19:23907909	chr19:24162370~24163425:-
COAD	cis	rs763121	0.889	rs6001209	ENSG00000273076.1	RP3-508I15.22	-4.91	1.59e-06	0.000704	-0.26	-0.29	Menopause (age at onset);	chr22:38725247	chr22:38743495~38743910:+
COAD	cis	rs9847710	1	rs2564956	ENSG00000280417.1	RP11-5O17.1	-4.91	1.6e-06	0.000704	-0.3	-0.29	Ulcerative colitis;	chr3:53036446	chr3:53046166~53048122:+
COAD	cis	rs7119	0.604	rs2271398	ENSG00000259565.2	KRT8P23	4.91	1.6e-06	0.000704	0.32	0.29	Type 2 diabetes;	chr15:77615442	chr15:76979245~76980451:-
COAD	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-4.91	1.6e-06	0.000705	-0.3	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
COAD	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-4.91	1.6e-06	0.000705	-0.31	-0.29	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
COAD	cis	rs11846409	0.86	rs4774167	ENSG00000274576.2	IGHV2-70	-4.91	1.6e-06	0.000705	-0.28	-0.29	Rheumatic heart disease;	chr14:106619987	chr14:106770577~106771020:-
COAD	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	4.91	1.6e-06	0.000705	0.39	0.29	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
COAD	cis	rs2732480	0.967	rs2732469	ENSG00000273765.1	RP11-370I10.11	4.91	1.6e-06	0.000705	0.3	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48360920~48361377:+
COAD	cis	rs2581828	0.618	rs9838517	ENSG00000280417.1	RP11-5O17.1	4.91	1.6e-06	0.000705	0.32	0.29	Crohn's disease;	chr3:53110347	chr3:53046166~53048122:+
COAD	cis	rs6723226	0.721	rs10172510	ENSG00000276334.1	AL133243.1	4.91	1.6e-06	0.000705	0.27	0.29	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32521927~32523547:+
COAD	cis	rs1387259	0.899	rs7307566	ENSG00000273765.1	RP11-370I10.11	4.91	1.6e-06	0.000707	0.31	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48360920~48361377:+
COAD	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	4.91	1.6e-06	0.000707	0.33	0.29	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
COAD	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.91	1.6e-06	0.000707	-0.31	-0.29	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
COAD	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-4.91	1.6e-06	0.000708	-0.36	-0.29	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
COAD	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-4.91	1.6e-06	0.000708	-0.4	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
COAD	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-4.91	1.61e-06	0.000708	-0.26	-0.29	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
COAD	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	4.91	1.61e-06	0.000708	0.42	0.29	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
COAD	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	4.91	1.61e-06	0.000708	0.58	0.29	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
COAD	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	4.91	1.61e-06	0.000708	0.32	0.29	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
COAD	cis	rs11668609	1	rs919813	ENSG00000268442.1	CTD-2027I19.2	4.91	1.61e-06	0.000709	0.36	0.29	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:24162370~24163425:-
COAD	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-4.91	1.61e-06	0.000709	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
COAD	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-4.91	1.61e-06	0.000709	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
COAD	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-4.91	1.61e-06	0.000709	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
COAD	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-4.91	1.61e-06	0.000709	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
COAD	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-4.91	1.61e-06	0.000709	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
COAD	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	4.91	1.61e-06	0.000709	0.36	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
COAD	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-4.91	1.61e-06	0.00071	-0.51	-0.29	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-4.91	1.61e-06	0.00071	-0.51	-0.29	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-4.91	1.61e-06	0.00071	-0.51	-0.29	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
COAD	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	4.91	1.61e-06	0.00071	0.29	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
COAD	cis	rs7615952	0.546	rs2979307	ENSG00000248787.1	RP11-666A20.4	4.91	1.61e-06	0.00071	0.43	0.29	Blood pressure (smoking interaction);	chr3:125590730	chr3:125908005~125910272:-
COAD	cis	rs2732480	0.967	rs2732469	ENSG00000269514.1	RP11-370I10.12	4.91	1.61e-06	0.000711	0.33	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48198387~48202031:+
COAD	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	4.91	1.61e-06	0.000711	0.36	0.29	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
COAD	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	4.91	1.62e-06	0.000711	0.49	0.29	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
COAD	cis	rs17772222	0.674	rs112788894	ENSG00000258789.1	RP11-507K2.3	-4.91	1.62e-06	0.000712	-0.42	-0.29	Coronary artery calcification;	chr14:88442850	chr14:88551597~88552493:+
COAD	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-4.91	1.62e-06	0.000713	-0.27	-0.29	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
COAD	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	4.91	1.62e-06	0.000713	0.36	0.29	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
COAD	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	4.91	1.62e-06	0.000713	0.38	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
COAD	cis	rs739496	0.615	rs886205	ENSG00000257595.2	RP3-473L9.4	4.91	1.62e-06	0.000714	0.43	0.29	Platelet count;	chr12:111766623	chr12:111369282~111403310:+
COAD	cis	rs1900504	0.584	rs3010501	ENSG00000266200.5	PNLIPRP2	-4.91	1.62e-06	0.000715	-0.37	-0.29	Tonsillectomy;	chr10:116604130	chr10:116620953~116645143:+
COAD	cis	rs6840360	0.642	rs2709825	ENSG00000251611.1	RP11-610P16.1	-4.91	1.63e-06	0.000716	-0.28	-0.29	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.607	rs2724547	ENSG00000251611.1	RP11-610P16.1	-4.91	1.63e-06	0.000716	-0.28	-0.29	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151407551~151408835:-
COAD	cis	rs7119	0.604	rs2271396	ENSG00000259565.2	KRT8P23	4.91	1.63e-06	0.000716	0.32	0.29	Type 2 diabetes;	chr15:77615193	chr15:76979245~76980451:-
COAD	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-4.91	1.63e-06	0.000717	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
COAD	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	4.91	1.63e-06	0.000717	0.17	0.29	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
COAD	cis	rs62184315	1	rs62184315	ENSG00000253559.1	OSGEPL1-AS1	-4.91	1.63e-06	0.000718	-0.38	-0.29	Alcohol dependence (age at onset);	chr2:189907219	chr2:189762704~189765556:+
COAD	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-4.91	1.63e-06	0.000719	-0.35	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
COAD	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-4.91	1.63e-06	0.000719	-0.35	-0.29	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
COAD	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	4.91	1.64e-06	0.00072	0.23	0.29	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
COAD	cis	rs9393777	0.513	rs9379893	ENSG00000224843.5	LINC00240	-4.91	1.64e-06	0.00072	-0.47	-0.29	Intelligence (multi-trait analysis);	chr6:26584440	chr6:26956992~27023924:+
COAD	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-4.91	1.64e-06	0.000721	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
COAD	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-4.91	1.64e-06	0.000721	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
COAD	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-4.91	1.64e-06	0.000721	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
COAD	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	4.91	1.64e-06	0.000721	0.32	0.29	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
COAD	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	4.91	1.64e-06	0.000722	0.44	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
COAD	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	4.91	1.64e-06	0.000722	0.47	0.29	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
COAD	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	4.91	1.64e-06	0.000722	0.47	0.29	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
COAD	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	4.91	1.64e-06	0.000722	0.36	0.29	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	4.91	1.64e-06	0.000722	0.36	0.29	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
COAD	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-4.91	1.64e-06	0.000723	-0.45	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
COAD	cis	rs5758511	0.68	rs5758667	ENSG00000237037.8	NDUFA6-AS1	-4.91	1.64e-06	0.000723	-0.35	-0.29	Birth weight;	chr22:42237198	chr22:42090931~42137742:+
COAD	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-4.91	1.65e-06	0.000723	-0.36	-0.29	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-4.91	1.65e-06	0.000723	-0.36	-0.29	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-4.91	1.65e-06	0.000723	-0.36	-0.29	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-4.91	1.65e-06	0.000723	-0.36	-0.29	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-4.91	1.65e-06	0.000723	-0.36	-0.29	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
COAD	cis	rs754466	1	rs12220328	ENSG00000204049.1	RP11-126H7.4	4.91	1.65e-06	0.000723	0.4	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77921724	chr10:77866875~77869610:+
COAD	cis	rs494562	0.667	rs693077	ENSG00000234155.1	RP11-30P6.6	-4.91	1.65e-06	0.000724	-0.55	-0.29	Metabolic traits;Blood metabolite levels;	chr6:85392719	chr6:85387219~85390186:-
COAD	cis	rs11668609	0.748	rs8112938	ENSG00000268442.1	CTD-2027I19.2	4.91	1.65e-06	0.000724	0.36	0.29	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:24162370~24163425:-
COAD	cis	rs9951698	0.667	rs9783859	ENSG00000266969.1	RP11-773H22.4	4.91	1.65e-06	0.000724	0.37	0.29	Intelligence (multi-trait analysis);	chr18:12998930	chr18:12984694~12991173:-
COAD	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	4.91	1.65e-06	0.000724	0.29	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
COAD	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	4.91	1.65e-06	0.000724	0.29	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
COAD	cis	rs5015933	0.872	rs2648328	ENSG00000232630.1	PRPS1P2	-4.91	1.65e-06	0.000725	-0.3	-0.29	Body mass index;	chr9:125361341	chr9:125150653~125151589:+
COAD	cis	rs71636778	0.57	rs12728091	ENSG00000260063.1	RP5-968P14.2	-4.91	1.65e-06	0.000725	-0.6	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26817022	chr1:26692132~26694131:-
COAD	cis	rs3752645	1	rs8180787	ENSG00000241764.3	AC002467.7	4.91	1.65e-06	0.000726	0.47	0.29	Bladder cancer (smoking interaction);	chr7:107132867	chr7:107742817~107744581:-
COAD	cis	rs2638953	0.672	rs10843203	ENSG00000247934.4	RP11-967K21.1	-4.91	1.65e-06	0.000726	-0.3	-0.29	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28563555	chr12:28163298~28190738:-
COAD	cis	rs597539	0.652	rs667989	ENSG00000255741.1	RP11-757G1.5	-4.91	1.65e-06	0.000726	-0.4	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68941503~68942852:-
COAD	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	4.91	1.65e-06	0.000727	0.39	0.29	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
COAD	cis	rs754466	0.874	rs55910200	ENSG00000204049.1	RP11-126H7.4	4.91	1.66e-06	0.000727	0.41	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77905415	chr10:77866875~77869610:+
COAD	cis	rs4568518	0.772	rs12699946	ENSG00000279048.1	RP11-511H23.2	4.91	1.66e-06	0.000727	0.21	0.29	Measles;	chr7:17999436	chr7:17940503~17942922:+
COAD	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	4.91	1.66e-06	0.000728	0.39	0.29	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
COAD	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	4.91	1.66e-06	0.000728	0.39	0.29	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
COAD	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-4.9	1.66e-06	0.000729	-0.3	-0.29	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-4.9	1.66e-06	0.000729	-0.3	-0.29	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-4.9	1.66e-06	0.000729	-0.3	-0.29	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-4.9	1.66e-06	0.000729	-0.3	-0.29	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
COAD	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	4.9	1.66e-06	0.000729	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	4.9	1.66e-06	0.000729	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	4.9	1.66e-06	0.000729	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
COAD	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-4.9	1.66e-06	0.00073	-0.34	-0.29	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
COAD	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	4.9	1.66e-06	0.00073	0.33	0.29	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
COAD	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-4.9	1.66e-06	0.000731	-0.35	-0.29	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
COAD	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-4.9	1.67e-06	0.000731	-0.51	-0.29	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
COAD	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	4.9	1.67e-06	0.000731	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
COAD	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	4.9	1.67e-06	0.000731	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
COAD	cis	rs8002861	0.935	rs1822969	ENSG00000274001.1	RP11-5G9.5	4.9	1.67e-06	0.000732	0.26	0.29	Leprosy;	chr13:43844028	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.935	rs1819595	ENSG00000274001.1	RP11-5G9.5	4.9	1.67e-06	0.000732	0.26	0.29	Leprosy;	chr13:43855580	chr13:43877715~43878163:-
COAD	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-4.9	1.67e-06	0.000732	-0.34	-0.29	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
COAD	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-4.9	1.67e-06	0.000733	-0.39	-0.29	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
COAD	cis	rs739496	0.512	rs6489793	ENSG00000257595.2	RP3-473L9.4	4.9	1.67e-06	0.000733	0.43	0.29	Platelet count;	chr12:111812080	chr12:111369282~111403310:+
COAD	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-4.9	1.67e-06	0.000733	-0.36	-0.29	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
COAD	cis	rs12497850	0.864	rs4955410	ENSG00000225399.4	RP11-3B7.1	4.9	1.67e-06	0.000734	0.34	0.29	Parkinson's disease;	chr3:49143785	chr3:49260085~49261316:+
COAD	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-4.9	1.67e-06	0.000734	-0.3	-0.29	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
COAD	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	4.9	1.67e-06	0.000734	0.37	0.29	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
COAD	cis	rs10466239	0.614	rs56214316	ENSG00000230555.2	RP11-517P14.2	4.9	1.68e-06	0.000735	0.43	0.29	Telomere length;	chr10:43365658	chr10:43420738~43422100:+
COAD	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-4.9	1.68e-06	0.000735	-0.31	-0.29	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
COAD	cis	rs875971	0.502	rs2946580	ENSG00000224316.1	RP11-479O9.2	-4.9	1.68e-06	0.000735	-0.38	-0.29	Aortic root size;	chr7:66066855	chr7:65773620~65802067:+
COAD	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-4.9	1.68e-06	0.000736	-0.26	-0.29	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
COAD	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-4.9	1.68e-06	0.000737	-0.36	-0.29	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
COAD	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	4.9	1.68e-06	0.000737	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
COAD	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	4.9	1.68e-06	0.000737	0.38	0.29	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
COAD	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-4.9	1.68e-06	0.000738	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
COAD	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.68e-06	0.000738	0.28	0.29	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.68e-06	0.000738	0.28	0.29	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.68e-06	0.000738	0.28	0.29	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
COAD	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	4.9	1.69e-06	0.000739	0.32	0.29	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-4.9	1.69e-06	0.000739	-0.51	-0.29	Gout;	chr7:66645053	chr7:66654538~66669855:+
COAD	cis	rs7430456	0.81	rs6443489	ENSG00000228221.4	LINC00578	4.9	1.69e-06	0.00074	0.25	0.29	Breast cancer;	chr3:177737489	chr3:177441921~177752305:+
COAD	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-4.9	1.69e-06	0.00074	-0.46	-0.29	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-4.9	1.69e-06	0.00074	-0.46	-0.29	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
COAD	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-4.9	1.69e-06	0.00074	-0.36	-0.29	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
COAD	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	4.9	1.69e-06	0.000741	0.3	0.29	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
COAD	cis	rs4704187	0.506	rs3935470	ENSG00000250889.2	LINC01336	-4.9	1.69e-06	0.000741	-0.33	-0.29	Response to amphetamines;	chr5:75056355	chr5:75047719~75052843:-
COAD	cis	rs28374715	0.681	rs7168307	ENSG00000247556.5	OIP5-AS1	4.9	1.69e-06	0.000741	0.35	0.29	Ulcerative colitis;	chr15:41328336	chr15:41283990~41309737:+
COAD	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	4.9	1.69e-06	0.000743	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
COAD	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	4.9	1.69e-06	0.000743	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
COAD	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	4.9	1.7e-06	0.000743	0.17	0.29	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
COAD	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-4.9	1.7e-06	0.000744	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-4.9	1.7e-06	0.000744	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
COAD	cis	rs453301	0.686	rs7017868	ENSG00000173295.6	FAM86B3P	-4.9	1.7e-06	0.000744	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9015783	chr8:8228595~8244865:+
COAD	cis	rs2378497	1	rs17011253	ENSG00000232679.1	RP11-400N13.3	4.9	1.7e-06	0.000744	0.38	0.29	Serum thyroid-stimulating hormone levels;	chr1:222040714	chr1:222041705~222064763:-
COAD	cis	rs4448343	1	rs28629854	ENSG00000271155.1	RP11-435O5.5	-4.9	1.7e-06	0.000744	-0.33	-0.29	Height;	chr9:95500551	chr9:95506235~95507636:+
COAD	cis	rs4604234	0.518	rs73463537	ENSG00000272129.1	RP11-250B2.6	-4.9	1.7e-06	0.000745	-0.62	-0.29	Cancer;	chr6:80275314	chr6:80355424~80356859:+
COAD	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	4.9	1.7e-06	0.000745	0.34	0.29	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
COAD	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	4.9	1.7e-06	0.000745	0.34	0.29	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
COAD	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	4.9	1.7e-06	0.000745	0.34	0.29	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
COAD	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-4.9	1.7e-06	0.000745	-0.31	-0.29	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
COAD	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	4.9	1.7e-06	0.000745	0.35	0.29	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
COAD	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-4.9	1.7e-06	0.000745	-0.39	-0.29	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
COAD	cis	rs34792	0.688	rs153782	ENSG00000207425.1	Y_RNA	4.9	1.7e-06	0.000746	0.36	0.29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14915457~14915556:-
COAD	cis	rs2732480	0.577	rs2634681	ENSG00000269514.1	RP11-370I10.12	-4.9	1.7e-06	0.000746	-0.35	-0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48198387~48202031:+
COAD	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	4.9	1.7e-06	0.000746	0.31	0.29	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	4.9	1.7e-06	0.000746	0.31	0.29	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
COAD	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-4.9	1.7e-06	0.000746	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
COAD	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-4.9	1.7e-06	0.000746	-0.37	-0.29	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
COAD	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-4.9	1.71e-06	0.000746	-0.35	-0.29	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
COAD	cis	rs9487051	0.7	rs7773815	ENSG00000219700.1	PTCHD3P3	4.9	1.71e-06	0.000747	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109281140	chr6:109288571~109290503:-
COAD	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-4.9	1.71e-06	0.000747	-0.28	-0.29	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
COAD	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-4.9	1.71e-06	0.000747	-0.28	-0.29	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
COAD	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-4.9	1.71e-06	0.000748	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
COAD	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	4.9	1.71e-06	0.000749	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	4.9	1.71e-06	0.000749	0.39	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
COAD	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-4.9	1.71e-06	0.000749	-0.3	-0.29	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
COAD	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.9	1.72e-06	0.00075	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
COAD	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-4.9	1.72e-06	0.000751	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
COAD	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	4.9	1.72e-06	0.000751	0.3	0.29	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
COAD	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	4.9	1.72e-06	0.000751	0.38	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
COAD	cis	rs7615952	0.512	rs2979336	ENSG00000241278.1	ENPP7P4	4.9	1.72e-06	0.000751	0.31	0.29	Blood pressure (smoking interaction);	chr3:125638626	chr3:125848223~125909372:+
COAD	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-4.9	1.72e-06	0.000752	-0.43	-0.29	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
COAD	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-4.9	1.72e-06	0.000752	-0.17	-0.29	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
COAD	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-4.9	1.72e-06	0.000752	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
COAD	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	4.9	1.72e-06	0.000752	0.37	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
COAD	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-4.9	1.72e-06	0.000753	-0.39	-0.29	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
COAD	cis	rs2281603	0.57	rs28827477	ENSG00000259116.1	RP11-973N13.4	-4.9	1.72e-06	0.000753	-0.29	-0.29	Lymphocyte counts;	chr14:64479792	chr14:64514154~64540368:-
COAD	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-4.9	1.72e-06	0.000754	-0.34	-0.29	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
COAD	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	4.9	1.72e-06	0.000754	0.32	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
COAD	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-4.9	1.72e-06	0.000754	-0.17	-0.29	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
COAD	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.72e-06	0.000754	0.28	0.29	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.72e-06	0.000754	0.28	0.29	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
COAD	cis	rs896854	0.936	rs10108430	ENSG00000253528.2	RP11-347C18.4	4.9	1.72e-06	0.000754	0.3	0.29	Type 2 diabetes;	chr8:94949566	chr8:94974573~94974853:-
COAD	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	4.9	1.73e-06	0.000754	0.39	0.29	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	4.9	1.73e-06	0.000754	0.39	0.29	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
COAD	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	4.9	1.73e-06	0.000754	0.39	0.29	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
COAD	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	4.9	1.73e-06	0.000754	0.39	0.29	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
COAD	cis	rs1790761	0.658	rs684928	ENSG00000231793.4	DOC2GP	4.9	1.73e-06	0.000754	0.33	0.29	Mean corpuscular volume;	chr11:67562271	chr11:67612653~67616257:-
COAD	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	4.9	1.73e-06	0.000754	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	4.9	1.73e-06	0.000754	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	4.9	1.73e-06	0.000754	0.51	0.29	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
COAD	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-4.9	1.73e-06	0.000754	-0.33	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
COAD	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-4.9	1.73e-06	0.000755	-0.33	-0.29	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
COAD	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-4.9	1.73e-06	0.000755	-0.37	-0.29	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
COAD	cis	rs13256369	0.774	rs11777719	ENSG00000253981.4	ALG1L13P	4.9	1.73e-06	0.000755	0.4	0.29	Obesity-related traits;	chr8:8723528	chr8:8236003~8244667:-
COAD	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	4.9	1.73e-06	0.000755	0.32	0.29	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	4.9	1.73e-06	0.000755	0.32	0.29	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	4.9	1.73e-06	0.000755	0.32	0.29	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	4.9	1.73e-06	0.000755	0.32	0.29	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	4.9	1.73e-06	0.000755	0.32	0.29	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
COAD	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-4.9	1.73e-06	0.000755	-0.36	-0.29	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
COAD	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-4.9	1.73e-06	0.000755	-0.36	-0.29	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
COAD	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-4.9	1.73e-06	0.000755	-0.36	-0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
COAD	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-4.9	1.73e-06	0.000755	-0.36	-0.29	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
COAD	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-4.9	1.73e-06	0.000755	-0.36	-0.29	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
COAD	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	4.9	1.73e-06	0.000756	0.37	0.29	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
COAD	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	4.9	1.73e-06	0.000756	0.37	0.29	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
COAD	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	4.9	1.73e-06	0.000757	0.27	0.29	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
COAD	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-4.9	1.73e-06	0.000757	-0.35	-0.29	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
COAD	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	4.9	1.73e-06	0.000757	0.22	0.29	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
COAD	cis	rs2361701	0.929	rs1561810	ENSG00000279259.1	RP11-334C17.3	4.9	1.73e-06	0.000757	0.32	0.29	IgG glycosylation;	chr17:80095525	chr17:80147250~80148596:+
COAD	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-4.9	1.73e-06	0.000757	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
COAD	cis	rs9847710	0.967	rs2244552	ENSG00000280417.1	RP11-5O17.1	-4.9	1.74e-06	0.000757	-0.29	-0.29	Ulcerative colitis;	chr3:53021506	chr3:53046166~53048122:+
COAD	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	4.9	1.74e-06	0.000757	0.3	0.29	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
COAD	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	4.9	1.74e-06	0.000758	0.32	0.29	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
COAD	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	4.9	1.74e-06	0.000758	0.24	0.29	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
COAD	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	4.9	1.74e-06	0.000758	0.36	0.29	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
COAD	cis	rs1387259	0.931	rs11168474	ENSG00000257735.1	RP11-370I10.6	4.89	1.74e-06	0.000758	0.35	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48350945~48442411:+
COAD	cis	rs4568518	0.903	rs12699940	ENSG00000279048.1	RP11-511H23.2	4.89	1.74e-06	0.000759	0.21	0.29	Measles;	chr7:17997414	chr7:17940503~17942922:+
COAD	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-4.89	1.74e-06	0.00076	-0.5	-0.29	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
COAD	cis	rs5758511	0.68	rs5758684	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.74e-06	0.00076	-0.35	-0.29	Birth weight;	chr22:42253503	chr22:42090931~42137742:+
COAD	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	4.89	1.74e-06	0.00076	0.3	0.29	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
COAD	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-4.89	1.74e-06	0.00076	-0.27	-0.29	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
COAD	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-4.89	1.74e-06	0.00076	-0.47	-0.29	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
COAD	cis	rs11719291	0.833	rs34037363	ENSG00000225399.4	RP11-3B7.1	-4.89	1.75e-06	0.000762	-0.57	-0.29	Cognitive function;	chr3:48783603	chr3:49260085~49261316:+
COAD	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.89	1.75e-06	0.000762	-0.36	-0.29	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
COAD	cis	rs896854	0.818	rs896855	ENSG00000253528.2	RP11-347C18.4	4.89	1.75e-06	0.000762	0.3	0.29	Type 2 diabetes;	chr8:94947580	chr8:94974573~94974853:-
COAD	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-4.89	1.75e-06	0.000763	-0.44	-0.29	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
COAD	cis	rs7818688	0.614	rs12056517	ENSG00000253528.2	RP11-347C18.4	-4.89	1.75e-06	0.000763	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94865057	chr8:94974573~94974853:-
COAD	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-4.89	1.75e-06	0.000764	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
COAD	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.89	1.75e-06	0.000764	-0.52	-0.29	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
COAD	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-4.89	1.75e-06	0.000765	-0.35	-0.29	Migraine;	chr4:56850720	chr4:56960927~56961373:-
COAD	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-4.89	1.76e-06	0.000765	-0.41	-0.29	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
COAD	cis	rs5758511	0.514	rs5758622	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.76e-06	0.000766	-0.35	-0.29	Birth weight;	chr22:42167927	chr22:42090931~42137742:+
COAD	cis	rs1065852	0.906	rs5751232	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.76e-06	0.000766	-0.35	-0.29	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.514	rs9607882	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.76e-06	0.000766	-0.35	-0.29	Birth weight;	chr22:42171445	chr22:42090931~42137742:+
COAD	cis	rs9951698	0.601	rs1973779	ENSG00000266969.1	RP11-773H22.4	4.89	1.76e-06	0.000766	0.37	0.29	Intelligence (multi-trait analysis);	chr18:12997774	chr18:12984694~12991173:-
COAD	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	4.89	1.76e-06	0.000766	0.33	0.29	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	4.89	1.76e-06	0.000766	0.33	0.29	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
COAD	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	4.89	1.76e-06	0.000766	0.31	0.29	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
COAD	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	4.89	1.76e-06	0.000766	0.31	0.29	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
COAD	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	4.89	1.76e-06	0.000766	0.31	0.29	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
COAD	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	4.89	1.76e-06	0.000767	0.31	0.29	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
COAD	cis	rs4448343	0.963	rs28457763	ENSG00000271155.1	RP11-435O5.5	-4.89	1.76e-06	0.000767	-0.33	-0.29	Height;	chr9:95498232	chr9:95506235~95507636:+
COAD	cis	rs6840360	0.642	rs2724568	ENSG00000251611.1	RP11-610P16.1	-4.89	1.76e-06	0.000769	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151407551~151408835:-
COAD	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-4.89	1.77e-06	0.000769	-0.38	-0.29	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
COAD	cis	rs801193	1	rs62466793	ENSG00000272831.1	RP11-792A8.4	4.89	1.77e-06	0.000769	0.31	0.29	Aortic root size;	chr7:66726530	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs62466794	ENSG00000272831.1	RP11-792A8.4	4.89	1.77e-06	0.000769	0.31	0.29	Aortic root size;	chr7:66726592	chr7:66739829~66740385:-
COAD	cis	rs6452524	0.532	rs27363	ENSG00000271862.1	RP11-343L5.2	4.89	1.77e-06	0.000769	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83049376~83050964:-
COAD	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-4.89	1.77e-06	0.00077	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
COAD	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-4.89	1.77e-06	0.00077	-0.42	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
COAD	cis	rs597539	0.652	rs627731	ENSG00000255741.1	RP11-757G1.5	-4.89	1.77e-06	0.00077	-0.4	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68941503~68942852:-
COAD	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-4.89	1.77e-06	0.00077	-0.32	-0.29	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
COAD	cis	rs7760535	0.93	rs7742244	ENSG00000271789.1	RP5-1112D6.7	-4.89	1.77e-06	0.00077	-0.28	-0.29	Metabolic traits;	chr6:111531459	chr6:111297126~111298510:+
COAD	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	4.89	1.77e-06	0.00077	0.32	0.29	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
COAD	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-4.89	1.77e-06	0.000771	-0.34	-0.29	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
COAD	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	4.89	1.77e-06	0.000771	0.35	0.29	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
COAD	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	4.89	1.77e-06	0.000771	0.36	0.29	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
COAD	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-4.89	1.77e-06	0.000771	-0.35	-0.29	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
COAD	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	4.89	1.77e-06	0.000772	0.34	0.29	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
COAD	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	4.89	1.77e-06	0.000772	0.36	0.29	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
COAD	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-4.89	1.77e-06	0.000772	-0.34	-0.29	QT interval;	chr12:29297620	chr12:29280418~29317848:-
COAD	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-4.89	1.77e-06	0.000772	-0.38	-0.29	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
COAD	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	4.89	1.77e-06	0.000772	0.36	0.29	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
COAD	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	4.89	1.77e-06	0.000772	0.36	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
COAD	cis	rs55823223	0.68	rs57287238	ENSG00000267801.1	RP11-552F3.9	4.89	1.78e-06	0.000772	0.44	0.29	Psoriasis;	chr17:75854859	chr17:75876372~75879546:+
COAD	cis	rs55823223	0.648	rs936394	ENSG00000267801.1	RP11-552F3.9	4.89	1.78e-06	0.000772	0.44	0.29	Psoriasis;	chr17:75855927	chr17:75876372~75879546:+
COAD	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	4.89	1.78e-06	0.000772	0.34	0.29	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	4.89	1.78e-06	0.000772	0.34	0.29	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
COAD	cis	rs1790761	0.692	rs1148883	ENSG00000231793.4	DOC2GP	4.89	1.78e-06	0.000772	0.33	0.29	Mean corpuscular volume;	chr11:67537215	chr11:67612653~67616257:-
COAD	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-4.89	1.78e-06	0.000773	-0.32	-0.29	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
COAD	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-4.89	1.78e-06	0.000773	-0.32	-0.29	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
COAD	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-4.89	1.78e-06	0.000773	-0.32	-0.29	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
COAD	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	4.89	1.78e-06	0.000774	0.47	0.29	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
COAD	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	4.89	1.78e-06	0.000774	0.39	0.29	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
COAD	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	4.89	1.78e-06	0.000774	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	4.89	1.78e-06	0.000774	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
COAD	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	4.89	1.78e-06	0.000775	0.32	0.29	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	4.89	1.78e-06	0.000775	0.32	0.29	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	4.89	1.78e-06	0.000775	0.32	0.29	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
COAD	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	4.89	1.78e-06	0.000775	0.35	0.29	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	4.89	1.78e-06	0.000775	0.35	0.29	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
COAD	cis	rs2581828	0.646	rs9878875	ENSG00000280417.1	RP11-5O17.1	4.89	1.78e-06	0.000776	0.31	0.29	Crohn's disease;	chr3:53122851	chr3:53046166~53048122:+
COAD	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-4.89	1.79e-06	0.000776	-0.35	-0.29	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
COAD	cis	rs748404	0.601	rs489964	ENSG00000249839.1	AC011330.5	4.89	1.79e-06	0.000776	0.36	0.29	Lung cancer;	chr15:43225356	chr15:43663654~43684339:-
COAD	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	4.89	1.79e-06	0.000776	0.54	0.29	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
COAD	cis	rs55823223	0.648	rs936393	ENSG00000267801.1	RP11-552F3.9	4.89	1.79e-06	0.000776	0.43	0.29	Psoriasis;	chr17:75851532	chr17:75876372~75879546:+
COAD	cis	rs6840360	0.642	rs2709822	ENSG00000251611.1	RP11-610P16.1	-4.89	1.79e-06	0.000777	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151407551~151408835:-
COAD	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-4.89	1.79e-06	0.000778	-0.36	-0.29	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
COAD	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	4.89	1.79e-06	0.000778	0.35	0.29	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
COAD	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-4.89	1.79e-06	0.000778	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
COAD	cis	rs10515750	0.53	rs13358909	ENSG00000248544.2	CTB-47B11.3	4.89	1.79e-06	0.000778	0.58	0.29	Lung function (FEV1/FVC);	chr5:157288824	chr5:157375741~157384950:-
COAD	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	4.89	1.79e-06	0.000779	0.4	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
COAD	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	4.89	1.79e-06	0.00078	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-4.89	1.79e-06	0.00078	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
COAD	cis	rs34779708	0.733	rs16935948	ENSG00000271335.4	RP11-324I22.4	4.89	1.79e-06	0.00078	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35314552~35336401:-
COAD	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	4.89	1.8e-06	0.00078	0.32	0.29	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
COAD	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-4.89	1.8e-06	0.00078	-0.35	-0.29	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-4.89	1.8e-06	0.00078	-0.35	-0.29	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.00078	0.35	0.29	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.00078	0.35	0.29	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.00078	0.35	0.29	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.00078	0.35	0.29	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
COAD	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.00078	0.35	0.29	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
COAD	cis	rs2581828	0.632	rs73088322	ENSG00000280417.1	RP11-5O17.1	4.89	1.8e-06	0.00078	0.31	0.29	Crohn's disease;	chr3:53107500	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.659	rs73088327	ENSG00000280417.1	RP11-5O17.1	4.89	1.8e-06	0.00078	0.31	0.29	Crohn's disease;	chr3:53107533	chr3:53046166~53048122:+
COAD	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-4.89	1.8e-06	0.00078	-0.5	-0.29	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-4.89	1.8e-06	0.00078	-0.5	-0.29	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
COAD	cis	rs55823223	0.702	rs3785437	ENSG00000267801.1	RP11-552F3.9	4.89	1.8e-06	0.000781	0.68	0.29	Psoriasis;	chr17:75910141	chr17:75876372~75879546:+
COAD	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-4.89	1.8e-06	0.000781	-0.5	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
COAD	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	4.89	1.8e-06	0.000781	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
COAD	cis	rs5015933	0.801	rs7848571	ENSG00000232630.1	PRPS1P2	-4.89	1.8e-06	0.000782	-0.28	-0.29	Body mass index;	chr9:125378927	chr9:125150653~125151589:+
COAD	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	4.89	1.8e-06	0.000782	0.34	0.29	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
COAD	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	4.89	1.8e-06	0.000782	0.34	0.29	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
COAD	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	4.89	1.8e-06	0.000782	0.34	0.29	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
COAD	cis	rs2980439	0.525	rs1850511	ENSG00000253981.4	ALG1L13P	4.89	1.8e-06	0.000782	0.35	0.29	Neuroticism;	chr8:8312807	chr8:8236003~8244667:-
COAD	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	4.89	1.8e-06	0.000782	0.35	0.29	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
COAD	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-4.89	1.8e-06	0.000783	-0.42	-0.29	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
COAD	cis	rs5742933	1	rs3791773	ENSG00000253559.1	OSGEPL1-AS1	-4.89	1.8e-06	0.000783	-0.33	-0.29	Ferritin levels;	chr2:189817906	chr2:189762704~189765556:+
COAD	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	4.89	1.8e-06	0.000783	0.32	0.29	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	4.89	1.8e-06	0.000783	0.32	0.29	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	4.89	1.8e-06	0.000783	0.32	0.29	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
COAD	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	4.89	1.8e-06	0.000783	0.47	0.29	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
COAD	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	4.89	1.81e-06	0.000784	0.34	0.29	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
COAD	cis	rs17772222	0.876	rs4375590	ENSG00000258789.1	RP11-507K2.3	-4.89	1.81e-06	0.000784	-0.42	-0.29	Coronary artery calcification;	chr14:88451334	chr14:88551597~88552493:+
COAD	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-4.89	1.81e-06	0.000785	-0.34	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
COAD	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	4.89	1.81e-06	0.000786	0.35	0.29	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
COAD	cis	rs492146	0.902	rs316136	ENSG00000243236.5	GSTA9P	-4.89	1.81e-06	0.000786	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52981971	chr6:52939726~52957521:-
COAD	cis	rs492146	0.935	rs316135	ENSG00000243236.5	GSTA9P	-4.89	1.81e-06	0.000786	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52981979	chr6:52939726~52957521:-
COAD	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-4.89	1.82e-06	0.000787	-0.38	-0.29	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
COAD	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-4.89	1.82e-06	0.000787	-0.32	-0.29	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
COAD	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	4.89	1.82e-06	0.000788	0.51	0.29	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
COAD	cis	rs9818758	0.607	rs66991555	ENSG00000225399.4	RP11-3B7.1	-4.89	1.82e-06	0.000788	-0.5	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs34566463	ENSG00000225399.4	RP11-3B7.1	-4.89	1.82e-06	0.000788	-0.5	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:49260085~49261316:+
COAD	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	4.89	1.82e-06	0.000788	0.22	0.29	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
COAD	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	4.89	1.82e-06	0.000789	0.33	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
COAD	cis	rs6719977	0.935	rs1992286	ENSG00000226491.1	FTOP1	-4.89	1.82e-06	0.000789	-0.38	-0.29	Hyperactive-impulsive symptoms;	chr2:42763196	chr2:42797225~42798712:-
COAD	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-4.89	1.82e-06	0.000789	-0.32	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
COAD	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	4.89	1.82e-06	0.000789	0.37	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	4.89	1.82e-06	0.000789	0.37	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
COAD	cis	rs4448343	0.963	rs10512248	ENSG00000271155.1	RP11-435O5.5	-4.89	1.82e-06	0.000789	-0.32	-0.29	Height;	chr9:95497421	chr9:95506235~95507636:+
COAD	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	4.88	1.82e-06	0.000791	0.33	0.29	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
COAD	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-4.88	1.82e-06	0.000791	-0.34	-0.29	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
COAD	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-4.88	1.82e-06	0.000791	-0.32	-0.29	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
COAD	cis	rs6543140	0.964	rs62154972	ENSG00000234389.1	AC007278.3	4.88	1.83e-06	0.000792	0.32	0.29	Blood protein levels;	chr2:102432278	chr2:102438713~102440475:+
COAD	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	4.88	1.83e-06	0.000792	0.39	0.29	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
COAD	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-4.88	1.83e-06	0.000792	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
COAD	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	4.88	1.83e-06	0.000793	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
COAD	cis	rs3752645	1	rs113285340	ENSG00000241764.3	AC002467.7	4.88	1.83e-06	0.000793	0.45	0.29	Bladder cancer (smoking interaction);	chr7:107102064	chr7:107742817~107744581:-
COAD	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	4.88	1.83e-06	0.000793	0.34	0.29	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
COAD	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-4.88	1.83e-06	0.000795	-0.34	-0.29	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
COAD	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-4.88	1.84e-06	0.000795	-0.16	-0.29	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-4.88	1.84e-06	0.000795	-0.16	-0.29	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
COAD	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-4.88	1.84e-06	0.000795	-0.35	-0.29	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
COAD	cis	rs6490294	0.799	rs61670030	ENSG00000257595.2	RP3-473L9.4	4.88	1.84e-06	0.000795	0.42	0.29	Mean platelet volume;	chr12:111914050	chr12:111369282~111403310:+
COAD	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-4.88	1.84e-06	0.000796	-0.16	-0.29	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
COAD	cis	rs8002861	0.935	rs7320988	ENSG00000274001.1	RP11-5G9.5	4.88	1.84e-06	0.000796	0.26	0.29	Leprosy;	chr13:43839387	chr13:43877715~43878163:-
COAD	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-4.88	1.84e-06	0.000796	-0.16	-0.29	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
COAD	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-4.88	1.84e-06	0.000797	-0.35	-0.29	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
COAD	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-4.88	1.84e-06	0.000797	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
COAD	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-4.88	1.84e-06	0.000797	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
COAD	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	4.88	1.84e-06	0.000798	0.36	0.29	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
COAD	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-4.88	1.85e-06	0.000798	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-4.88	1.85e-06	0.000798	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-4.88	1.85e-06	0.000798	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
COAD	cis	rs7119	0.667	rs907390	ENSG00000259565.2	KRT8P23	4.88	1.85e-06	0.000798	0.32	0.29	Type 2 diabetes;	chr15:77610077	chr15:76979245~76980451:-
COAD	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-4.88	1.85e-06	0.000799	-0.34	-0.29	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
COAD	cis	rs7818688	0.516	rs73269198	ENSG00000253528.2	RP11-347C18.4	-4.88	1.85e-06	0.000799	-0.42	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826817	chr8:94974573~94974853:-
COAD	cis	rs9487051	0.676	rs7773213	ENSG00000219700.1	PTCHD3P3	4.88	1.85e-06	0.000799	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109280682	chr6:109288571~109290503:-
COAD	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-4.88	1.85e-06	0.000799	-0.31	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
COAD	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	4.88	1.85e-06	0.000799	0.3	0.29	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
COAD	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	4.88	1.85e-06	8e-04	0.3	0.29	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
COAD	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-4.88	1.85e-06	0.000801	-0.35	-0.29	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
COAD	cis	rs3813567	0.759	rs12594550	ENSG00000261143.1	ADAMTS7P3	4.88	1.85e-06	0.000801	0.46	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78666695	chr15:77976042~77993057:+
COAD	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	4.88	1.85e-06	0.000802	0.45	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
COAD	cis	rs2115630	1	rs11854291	ENSG00000259728.4	LINC00933	-4.88	1.86e-06	0.000802	-0.34	-0.29	P wave terminal force;	chr15:84820477	chr15:84570649~84580175:+
COAD	cis	rs9907295	0.636	rs4251724	ENSG00000271013.1	AC015849.15	-4.88	1.86e-06	0.000804	-0.36	-0.29	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35912635~35918010:-
COAD	cis	rs12935418	0.616	rs9921448	ENSG00000278985.1	RP11-303E16.9	4.88	1.86e-06	0.000804	0.31	0.29	Mean corpuscular volume;	chr16:80975593	chr16:80982319~80984094:-
COAD	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-4.88	1.86e-06	0.000804	-0.43	-0.29	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
COAD	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-4.88	1.86e-06	0.000804	-0.3	-0.29	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
COAD	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	4.88	1.86e-06	0.000804	0.32	0.29	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
COAD	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-4.88	1.86e-06	0.000804	-0.35	-0.29	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
COAD	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-4.88	1.86e-06	0.000805	-0.41	-0.29	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
COAD	cis	rs4704187	0.687	rs10805893	ENSG00000250889.2	LINC01336	-4.88	1.86e-06	0.000805	-0.33	-0.29	Response to amphetamines;	chr5:75211565	chr5:75047719~75052843:-
COAD	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-4.88	1.86e-06	0.000805	-0.25	-0.29	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
COAD	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-4.88	1.86e-06	0.000805	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
COAD	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	4.88	1.87e-06	0.000805	0.57	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
COAD	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	4.88	1.87e-06	0.000806	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	4.88	1.87e-06	0.000806	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
COAD	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-4.88	1.87e-06	0.000806	-0.35	-0.29	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
COAD	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	4.88	1.87e-06	0.000806	0.39	0.29	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
COAD	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-4.88	1.87e-06	0.000807	-0.31	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
COAD	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-4.88	1.87e-06	0.000807	-0.31	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
COAD	cis	rs17772222	0.92	rs61975260	ENSG00000258789.1	RP11-507K2.3	-4.88	1.87e-06	0.000808	-0.45	-0.29	Coronary artery calcification;	chr14:88429597	chr14:88551597~88552493:+
COAD	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-4.88	1.87e-06	0.000808	-0.53	-0.29	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
COAD	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-4.88	1.87e-06	0.000809	-0.32	-0.29	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
COAD	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-4.88	1.87e-06	0.000809	-0.35	-0.29	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
COAD	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-4.88	1.88e-06	0.00081	-0.33	-0.29	QT interval;	chr12:29300845	chr12:29280418~29317848:-
COAD	cis	rs2439831	1	rs7173487	ENSG00000275601.1	AC011330.13	-4.88	1.88e-06	0.000811	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43458041	chr15:43642389~43643023:-
COAD	cis	rs7818688	0.614	rs11777353	ENSG00000253528.2	RP11-347C18.4	-4.88	1.88e-06	0.000811	-0.42	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94846955	chr8:94974573~94974853:-
COAD	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-4.88	1.88e-06	0.000811	-0.41	-0.29	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
COAD	cis	rs6840360	0.558	rs2709821	ENSG00000270265.1	RP11-731D1.4	-4.88	1.88e-06	0.000811	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151333775~151353224:-
COAD	cis	rs11168351	0.889	rs12817104	ENSG00000240399.1	RP1-228P16.1	4.88	1.88e-06	0.000812	0.3	0.29	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48054813~48055591:-
COAD	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	4.88	1.88e-06	0.000812	0.36	0.29	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
COAD	cis	rs6840360	0.642	rs4235219	ENSG00000251611.1	RP11-610P16.1	-4.88	1.88e-06	0.000812	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs6851814	ENSG00000251611.1	RP11-610P16.1	-4.88	1.88e-06	0.000812	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.606	rs10028035	ENSG00000251611.1	RP11-610P16.1	-4.88	1.88e-06	0.000812	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.667	rs4266275	ENSG00000251611.1	RP11-610P16.1	-4.88	1.88e-06	0.000812	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7684462	ENSG00000251611.1	RP11-610P16.1	-4.88	1.88e-06	0.000812	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151407551~151408835:-
COAD	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-4.88	1.88e-06	0.000812	-0.44	-0.29	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
COAD	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	4.88	1.88e-06	0.000813	0.55	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
COAD	cis	rs9910055	0.762	rs4239142	ENSG00000267080.4	ASB16-AS1	4.88	1.89e-06	0.000813	0.27	0.29	Total body bone mineral density;	chr17:44128508	chr17:44175973~44186717:-
COAD	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	4.88	1.89e-06	0.000813	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
COAD	cis	rs7674212	0.541	rs4699050	ENSG00000230069.3	LRRC37A15P	-4.88	1.89e-06	0.000814	-0.32	-0.29	Type 2 diabetes;	chr4:103193140	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.541	rs17217473	ENSG00000230069.3	LRRC37A15P	-4.88	1.89e-06	0.000814	-0.32	-0.29	Type 2 diabetes;	chr4:103193585	chr4:102727274~102730721:-
COAD	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	4.88	1.89e-06	0.000815	0.43	0.29	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
COAD	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-4.88	1.89e-06	0.000815	-0.34	-0.29	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
COAD	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-4.88	1.89e-06	0.000815	-0.34	-0.29	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
COAD	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-4.88	1.89e-06	0.000815	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
COAD	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	4.88	1.89e-06	0.000815	0.42	0.29	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
COAD	cis	rs2018683	0.834	rs733485	ENSG00000272568.4	CTB-113D17.1	4.88	1.89e-06	0.000815	0.39	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28979967~29013367:+
COAD	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	4.88	1.89e-06	0.000816	0.34	0.29	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
COAD	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-4.88	1.89e-06	0.000816	-0.34	-0.29	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
COAD	cis	rs4568518	0.74	rs11543650	ENSG00000279048.1	RP11-511H23.2	4.88	1.89e-06	0.000816	0.22	0.29	Measles;	chr7:17970257	chr7:17940503~17942922:+
COAD	cis	rs453301	0.598	rs10104303	ENSG00000254340.1	RP11-10A14.3	4.88	1.9e-06	0.000819	0.33	0.29	Joint mobility (Beighton score);	chr8:8977018	chr8:9141424~9145435:+
COAD	cis	rs9951698	0.667	rs9961669	ENSG00000266969.1	RP11-773H22.4	4.88	1.9e-06	0.000819	0.36	0.29	Intelligence (multi-trait analysis);	chr18:13020882	chr18:12984694~12991173:-
COAD	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	4.88	1.9e-06	0.000819	0.32	0.29	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
COAD	cis	rs9487051	0.714	rs6902892	ENSG00000219700.1	PTCHD3P3	4.88	1.9e-06	0.00082	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109306398	chr6:109288571~109290503:-
COAD	cis	rs2581828	0.646	rs6769931	ENSG00000280417.1	RP11-5O17.1	4.88	1.9e-06	0.00082	0.31	0.29	Crohn's disease;	chr3:53126177	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.646	rs6809973	ENSG00000280417.1	RP11-5O17.1	4.88	1.9e-06	0.00082	0.31	0.29	Crohn's disease;	chr3:53126200	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.608	rs6769944	ENSG00000280417.1	RP11-5O17.1	4.88	1.9e-06	0.00082	0.31	0.29	Crohn's disease;	chr3:53126227	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.646	rs9858469	ENSG00000280417.1	RP11-5O17.1	4.88	1.9e-06	0.00082	0.31	0.29	Crohn's disease;	chr3:53128390	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.646	rs9820324	ENSG00000280417.1	RP11-5O17.1	4.88	1.9e-06	0.00082	0.31	0.29	Crohn's disease;	chr3:53128429	chr3:53046166~53048122:+
COAD	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	4.87	1.91e-06	0.000821	0.3	0.29	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
COAD	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-4.87	1.91e-06	0.000822	-0.27	-0.29	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
COAD	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	4.87	1.91e-06	0.000823	0.38	0.29	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
COAD	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-4.87	1.91e-06	0.000823	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
COAD	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	4.87	1.91e-06	0.000823	0.35	0.29	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
COAD	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-4.87	1.91e-06	0.000824	-0.3	-0.29	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
COAD	cis	rs9847710	1	rs2581817	ENSG00000280417.1	RP11-5O17.1	-4.87	1.91e-06	0.000824	-0.3	-0.29	Ulcerative colitis;	chr3:53037781	chr3:53046166~53048122:+
COAD	cis	rs9951698	0.703	rs11663049	ENSG00000266969.1	RP11-773H22.4	4.87	1.91e-06	0.000824	0.36	0.29	Intelligence (multi-trait analysis);	chr18:12991394	chr18:12984694~12991173:-
COAD	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-4.87	1.92e-06	0.000825	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
COAD	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-4.87	1.92e-06	0.000825	-0.31	-0.29	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
COAD	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-4.87	1.92e-06	0.000825	-0.32	-0.29	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
COAD	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-4.87	1.92e-06	0.000826	-0.26	-0.29	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
COAD	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-4.87	1.92e-06	0.000826	-0.45	-0.29	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
COAD	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-4.87	1.92e-06	0.000827	-0.36	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
COAD	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	4.87	1.92e-06	0.000827	0.35	0.29	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
COAD	cis	rs453301	0.658	rs9329175	ENSG00000253981.4	ALG1L13P	-4.87	1.92e-06	0.000827	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9009151	chr8:8236003~8244667:-
COAD	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-4.87	1.92e-06	0.000827	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
COAD	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	4.87	1.92e-06	0.000828	0.35	0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
COAD	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	4.87	1.93e-06	0.000829	0.32	0.29	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
COAD	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	4.87	1.93e-06	0.000829	0.35	0.29	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
COAD	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-4.87	1.93e-06	0.00083	-0.35	-0.29	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
COAD	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	4.87	1.93e-06	0.00083	0.3	0.29	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
COAD	cis	rs7260598	0.539	rs11672512	ENSG00000268442.1	CTD-2027I19.2	4.87	1.93e-06	0.000831	0.46	0.29	Response to taxane treatment (placlitaxel);	chr19:23885948	chr19:24162370~24163425:-
COAD	cis	rs11668609	0.515	rs2195971	ENSG00000268442.1	CTD-2027I19.2	4.87	1.93e-06	0.000831	0.46	0.29	Response to taxane treatment (docetaxel);	chr19:23897191	chr19:24162370~24163425:-
COAD	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-4.87	1.93e-06	0.000831	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
COAD	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	4.87	1.93e-06	0.000832	0.36	0.29	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
COAD	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	4.87	1.94e-06	0.000833	0.36	0.29	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	4.87	1.94e-06	0.000833	0.36	0.29	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
COAD	cis	rs7818688	0.745	rs11779282	ENSG00000253528.2	RP11-347C18.4	-4.87	1.94e-06	0.000833	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94933259	chr8:94974573~94974853:-
COAD	cis	rs6490294	0.904	rs11066099	ENSG00000257595.2	RP3-473L9.4	4.87	1.94e-06	0.000833	0.42	0.29	Mean platelet volume;	chr12:111954232	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.904	rs9630276	ENSG00000257595.2	RP3-473L9.4	4.87	1.94e-06	0.000833	0.42	0.29	Mean platelet volume;	chr12:111967034	chr12:111369282~111403310:+
COAD	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-4.87	1.94e-06	0.000834	-0.27	-0.29	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
COAD	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.87	1.94e-06	0.000834	0.32	0.29	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
COAD	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-4.87	1.94e-06	0.000834	-0.33	-0.29	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
COAD	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	4.87	1.94e-06	0.000834	0.38	0.29	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
COAD	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-4.87	1.95e-06	0.000836	-0.36	-0.29	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
COAD	cis	rs453301	0.658	rs9650616	ENSG00000253981.4	ALG1L13P	-4.87	1.95e-06	0.000837	-0.35	-0.29	Joint mobility (Beighton score);	chr8:9011689	chr8:8236003~8244667:-
COAD	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-4.87	1.95e-06	0.000837	-0.46	-0.29	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
COAD	cis	rs8002861	0.905	rs12853286	ENSG00000274001.1	RP11-5G9.5	-4.87	1.95e-06	0.000838	-0.27	-0.29	Leprosy;	chr13:43872681	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.905	rs12875052	ENSG00000274001.1	RP11-5G9.5	-4.87	1.95e-06	0.000838	-0.27	-0.29	Leprosy;	chr13:43875232	chr13:43877715~43878163:-
COAD	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-4.87	1.96e-06	0.00084	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
COAD	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-4.87	1.96e-06	0.00084	-0.26	-0.29	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
COAD	cis	rs7818688	0.653	rs11775475	ENSG00000253528.2	RP11-347C18.4	-4.87	1.96e-06	0.000841	-0.43	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94893261	chr8:94974573~94974853:-
COAD	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-4.87	1.96e-06	0.000841	-0.31	-0.29	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
COAD	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	4.87	1.96e-06	0.000841	0.4	0.29	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
COAD	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	4.87	1.96e-06	0.000842	0.28	0.29	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
COAD	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-4.87	1.96e-06	0.000842	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
COAD	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	4.87	1.96e-06	0.000842	0.38	0.29	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
COAD	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	4.87	1.96e-06	0.000842	0.31	0.29	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
COAD	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.87	1.96e-06	0.000843	0.29	0.29	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
COAD	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-4.87	1.96e-06	0.000843	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-4.87	1.96e-06	0.000843	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
COAD	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-4.87	1.97e-06	0.000843	-0.29	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
COAD	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-4.87	1.97e-06	0.000844	-0.42	-0.29	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
COAD	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	4.87	1.97e-06	0.000845	0.36	0.29	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
COAD	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	4.87	1.97e-06	0.000845	0.39	0.29	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
COAD	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	4.87	1.97e-06	0.000845	0.39	0.29	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	4.87	1.97e-06	0.000846	0.32	0.29	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
COAD	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	4.87	1.97e-06	0.000846	0.45	0.29	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
COAD	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-4.87	1.97e-06	0.000846	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-4.87	1.97e-06	0.000846	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-4.87	1.97e-06	0.000846	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
COAD	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-4.87	1.98e-06	0.000847	-0.27	-0.29	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
COAD	cis	rs3752645	1	rs12154324	ENSG00000241764.3	AC002467.7	-4.87	1.98e-06	0.000847	-0.49	-0.29	Bladder cancer (smoking interaction);	chr7:107080487	chr7:107742817~107744581:-
COAD	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-4.87	1.98e-06	0.000847	-0.34	-0.29	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
COAD	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-4.87	1.98e-06	0.000847	-0.34	-0.29	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
COAD	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	4.87	1.98e-06	0.000847	0.34	0.29	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
COAD	cis	rs8002861	0.905	rs12874590	ENSG00000274001.1	RP11-5G9.5	-4.87	1.98e-06	0.000848	-0.26	-0.29	Leprosy;	chr13:43859227	chr13:43877715~43878163:-
COAD	cis	rs9450351	0.744	rs6937582	ENSG00000203875.9	SNHG5	-4.87	1.98e-06	0.000848	-0.56	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85855880	chr6:85660950~85678736:-
COAD	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-4.87	1.98e-06	0.000848	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
COAD	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	4.87	1.98e-06	0.000848	0.32	0.29	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
COAD	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-4.87	1.98e-06	0.000849	-0.41	-0.29	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
COAD	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-4.87	1.98e-06	0.000849	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
COAD	cis	rs2581828	0.609	rs73088342	ENSG00000280417.1	RP11-5O17.1	4.87	1.99e-06	0.000851	0.31	0.29	Crohn's disease;	chr3:53117648	chr3:53046166~53048122:+
COAD	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-4.87	1.99e-06	0.000851	-0.3	-0.29	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
COAD	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-4.87	1.99e-06	0.000852	-0.35	-0.29	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
COAD	cis	rs710913	0.966	rs3738676	ENSG00000182109.6	RP11-69E11.4	4.87	1.99e-06	0.000852	0.32	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39522280~39546187:-
COAD	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	4.87	1.99e-06	0.000852	0.22	0.29	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-4.87	1.99e-06	0.000852	-0.17	-0.29	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
COAD	cis	rs6840360	0.642	rs2709817	ENSG00000251611.1	RP11-610P16.1	-4.87	1.99e-06	0.000852	-0.28	-0.29	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709818	ENSG00000251611.1	RP11-610P16.1	-4.87	1.99e-06	0.000852	-0.28	-0.29	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151407551~151408835:-
COAD	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	4.87	1.99e-06	0.000852	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
COAD	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-4.87	1.99e-06	0.000852	-0.44	-0.29	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
COAD	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-4.87	1.99e-06	0.000853	-0.27	-0.29	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
COAD	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-4.87	2e-06	0.000854	-0.27	-0.29	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-4.87	2e-06	0.000854	-0.27	-0.29	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
COAD	cis	rs2732480	0.5	rs1552550	ENSG00000273765.1	RP11-370I10.11	4.87	2e-06	0.000854	0.32	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48360920~48361377:+
COAD	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	4.87	2e-06	0.000854	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
COAD	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	4.87	2e-06	0.000854	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	4.87	2e-06	0.000854	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	4.87	2e-06	0.000854	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	4.87	2e-06	0.000854	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-4.87	2e-06	0.000854	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
COAD	cis	rs7260598	0.642	rs8102034	ENSG00000268442.1	CTD-2027I19.2	4.87	2e-06	0.000854	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23914417	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.605	rs67492250	ENSG00000268442.1	CTD-2027I19.2	4.87	2e-06	0.000854	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23924293	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs7259787	ENSG00000268442.1	CTD-2027I19.2	4.87	2e-06	0.000854	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23935633	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.71	rs10402319	ENSG00000268442.1	CTD-2027I19.2	4.87	2e-06	0.000854	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23945263	chr19:24162370~24163425:-
COAD	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.86	2e-06	0.000855	0.24	0.29	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
COAD	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-4.86	2e-06	0.000855	-0.26	-0.29	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
COAD	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	4.86	2e-06	0.000855	0.32	0.29	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
COAD	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.86	2e-06	0.000856	0.28	0.29	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
COAD	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	4.86	2e-06	0.000856	0.43	0.29	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
COAD	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-4.86	2e-06	0.000856	-0.42	-0.29	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
COAD	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	4.86	2e-06	0.000857	0.37	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
COAD	cis	rs9487051	0.676	rs13195816	ENSG00000219700.1	PTCHD3P3	4.86	2.01e-06	0.000857	0.32	0.29	Reticulocyte fraction of red cells;	chr6:109277421	chr6:109288571~109290503:-
COAD	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	4.86	2.01e-06	0.000857	0.5	0.29	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
COAD	cis	rs4950322	1	rs72694715	ENSG00000278811.3	LINC00624	4.86	2.01e-06	0.000859	0.33	0.29	Protein quantitative trait loci;	chr1:147368468	chr1:147258885~147517875:-
COAD	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.86	2.01e-06	0.000859	-0.28	-0.29	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
COAD	cis	rs9907295	0.591	rs4239252	ENSG00000271013.1	AC015849.15	4.86	2.01e-06	0.000859	0.36	0.29	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35912635~35918010:-
COAD	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-4.86	2.01e-06	0.000859	-0.34	-0.29	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
COAD	cis	rs2732480	0.5	rs1387257	ENSG00000257735.1	RP11-370I10.6	4.86	2.02e-06	0.000861	0.35	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48350945~48442411:+
COAD	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	4.86	2.02e-06	0.000861	0.38	0.29	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
COAD	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	4.86	2.02e-06	0.000861	0.38	0.29	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
COAD	cis	rs3752645	1	rs17153861	ENSG00000241764.3	AC002467.7	4.86	2.02e-06	0.000862	0.46	0.29	Bladder cancer (smoking interaction);	chr7:107129194	chr7:107742817~107744581:-
COAD	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	4.86	2.02e-06	0.000863	0.38	0.29	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
COAD	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	4.86	2.02e-06	0.000863	0.38	0.29	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
COAD	cis	rs9487051	0.752	rs9372209	ENSG00000219700.1	PTCHD3P3	4.86	2.02e-06	0.000863	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109280481	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.652	rs9372210	ENSG00000219700.1	PTCHD3P3	4.86	2.02e-06	0.000863	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109280500	chr6:109288571~109290503:-
COAD	cis	rs9353324	1	rs9351066	ENSG00000203875.9	SNHG5	-4.86	2.02e-06	0.000863	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85689099	chr6:85660950~85678736:-
COAD	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-4.86	2.02e-06	0.000863	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
COAD	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-4.86	2.03e-06	0.000864	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-4.86	2.03e-06	0.000864	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-4.86	2.03e-06	0.000864	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
COAD	cis	rs8002861	0.935	rs1811464	ENSG00000274001.1	RP11-5G9.5	4.86	2.03e-06	0.000864	0.26	0.29	Leprosy;	chr13:43895154	chr13:43877715~43878163:-
COAD	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4.86	2.03e-06	0.000864	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
COAD	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4.86	2.03e-06	0.000864	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
COAD	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-4.86	2.03e-06	0.000865	-0.28	-0.29	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-4.86	2.03e-06	0.000865	-0.28	-0.29	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
COAD	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000865	0.33	0.29	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
COAD	cis	rs11146838	1	rs11146838	ENSG00000275858.1	RP11-291L22.8	4.86	2.03e-06	0.000865	0.3	0.29	Breast cancer;	chr10:38856846	chr10:38450738~38451069:-
COAD	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	4.86	2.03e-06	0.000865	0.34	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	4.86	2.03e-06	0.000865	0.34	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	4.86	2.03e-06	0.000865	0.34	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
COAD	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.86	2.03e-06	0.000866	-0.28	-0.29	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
COAD	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000867	0.33	0.29	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	4.86	2.03e-06	0.000867	0.33	0.29	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
COAD	cis	rs7646881	0.504	rs61080878	ENSG00000272087.1	RP11-379F4.7	4.86	2.04e-06	0.000869	0.4	0.29	Tetralogy of Fallot;	chr3:158745108	chr3:158693120~158693768:-
COAD	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	4.86	2.04e-06	0.000869	0.38	0.29	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
COAD	cis	rs1790761	0.667	rs598811	ENSG00000231793.4	DOC2GP	4.86	2.04e-06	0.00087	0.33	0.29	Mean corpuscular volume;	chr11:67544205	chr11:67612653~67616257:-
COAD	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	4.86	2.04e-06	0.00087	0.34	0.29	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
COAD	cis	rs2115630	0.691	rs8040066	ENSG00000259728.4	LINC00933	-4.86	2.04e-06	0.00087	-0.34	-0.29	P wave terminal force;	chr15:84633234	chr15:84570649~84580175:+
COAD	cis	rs950169	0.526	rs698620	ENSG00000259728.4	LINC00933	-4.86	2.04e-06	0.00087	-0.34	-0.29	Schizophrenia;	chr15:84633977	chr15:84570649~84580175:+
COAD	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-4.86	2.04e-06	0.00087	-0.25	-0.29	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
COAD	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-4.86	2.04e-06	0.00087	-0.25	-0.29	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
COAD	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	4.86	2.04e-06	0.00087	0.27	0.29	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
COAD	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	4.86	2.05e-06	0.000872	0.34	0.29	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
COAD	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	4.86	2.05e-06	0.000872	0.37	0.29	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
COAD	cis	rs2281603	0.57	rs9323451	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64505031	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.52	rs9323452	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64505426	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs28469649	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64505531	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs1453007	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64507485	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs1966865	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64509143	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs11848179	ENSG00000259116.1	RP11-973N13.4	-4.86	2.05e-06	0.000872	-0.29	-0.29	Lymphocyte counts;	chr14:64510335	chr14:64514154~64540368:-
COAD	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	4.86	2.05e-06	0.000873	0.41	0.29	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
COAD	cis	rs71636778	0.73	rs34951175	ENSG00000260063.1	RP5-968P14.2	-4.86	2.05e-06	0.000874	-0.59	-0.29	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778568	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.908	rs60798877	ENSG00000260063.1	RP5-968P14.2	-4.86	2.05e-06	0.000874	-0.59	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781648	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.915	rs12685	ENSG00000260063.1	RP5-968P14.2	-4.86	2.05e-06	0.000874	-0.59	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781754	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.818	rs71636779	ENSG00000260063.1	RP5-968P14.2	-4.86	2.05e-06	0.000874	-0.59	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26787521	chr1:26692132~26694131:-
COAD	cis	rs6452524	0.534	rs10514246	ENSG00000271862.1	RP11-343L5.2	4.86	2.06e-06	0.000874	0.31	0.29	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83049376~83050964:-
COAD	cis	rs7615952	0.512	rs2979351	ENSG00000241278.1	ENPP7P4	4.86	2.06e-06	0.000875	0.31	0.29	Blood pressure (smoking interaction);	chr3:125644755	chr3:125848223~125909372:+
COAD	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	4.86	2.06e-06	0.000875	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
COAD	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66692349	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66693028	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66693433	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66694214	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66701371	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66702658	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66706390	chr7:66654538~66669855:+
COAD	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.86	2.06e-06	0.000875	-0.5	-0.29	Gout;	chr7:66710076	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	4.86	2.06e-06	0.000875	0.34	0.29	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
COAD	cis	rs2380205	0.546	rs636578	ENSG00000232807.2	RP11-536K7.3	-4.86	2.06e-06	0.000875	-0.24	-0.29	Breast cancer;	chr10:5896581	chr10:5934270~5945900:-
COAD	cis	rs17264034	0.861	rs55891419	ENSG00000250786.1	SNHG18	4.86	2.06e-06	0.000876	0.45	0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553468	chr5:9546200~9550609:+
COAD	cis	rs4704187	0.687	rs9293650	ENSG00000250889.2	LINC01336	-4.86	2.06e-06	0.000876	-0.32	-0.29	Response to amphetamines;	chr5:75201259	chr5:75047719~75052843:-
COAD	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-4.86	2.06e-06	0.000876	-0.28	-0.29	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
COAD	cis	rs9847710	0.967	rs4687694	ENSG00000280417.1	RP11-5O17.1	-4.86	2.06e-06	0.000877	-0.29	-0.29	Ulcerative colitis;	chr3:53015031	chr3:53046166~53048122:+
COAD	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	4.86	2.06e-06	0.000877	0.36	0.29	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
COAD	cis	rs111580313	0.792	rs4843171	ENSG00000270020.1	RP11-463O9.9	4.86	2.06e-06	0.000877	0.72	0.29	Systemic juvenile idiopathic arthritis;	chr16:86576879	chr16:86520383~86523897:-
COAD	cis	rs111580313	0.792	rs8064031	ENSG00000270020.1	RP11-463O9.9	4.86	2.06e-06	0.000877	0.72	0.29	Systemic juvenile idiopathic arthritis;	chr16:86576974	chr16:86520383~86523897:-
COAD	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-4.86	2.06e-06	0.000878	-0.41	-0.29	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
COAD	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-4.86	2.06e-06	0.000878	-0.16	-0.29	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
COAD	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-4.86	2.06e-06	0.000878	-0.33	-0.29	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
COAD	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-4.86	2.07e-06	0.000878	-0.4	-0.29	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
COAD	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	4.86	2.07e-06	0.000878	0.3	0.29	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
COAD	cis	rs7260598	0.605	rs78358879	ENSG00000268442.1	CTD-2027I19.2	4.86	2.07e-06	0.000879	0.46	0.29	Response to taxane treatment (placlitaxel);	chr19:23904434	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs10424758	ENSG00000268442.1	CTD-2027I19.2	4.86	2.07e-06	0.000879	0.46	0.29	Response to taxane treatment (placlitaxel);	chr19:23907698	chr19:24162370~24163425:-
COAD	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-4.86	2.07e-06	0.000879	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-4.86	2.07e-06	0.000879	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
COAD	cis	rs2378497	1	rs12117316	ENSG00000232679.1	RP11-400N13.3	4.86	2.07e-06	0.000879	0.37	0.29	Serum thyroid-stimulating hormone levels;	chr1:222012627	chr1:222041705~222064763:-
COAD	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-4.86	2.07e-06	0.000879	-0.35	-0.29	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
COAD	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-4.86	2.07e-06	0.00088	-0.34	-0.29	Height;	chr3:52975027	chr3:53064283~53065091:-
COAD	cis	rs739496	0.615	rs7136874	ENSG00000257595.2	RP3-473L9.4	4.86	2.07e-06	0.00088	0.43	0.29	Platelet count;	chr12:111675854	chr12:111369282~111403310:+
COAD	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	4.86	2.07e-06	0.00088	0.44	0.29	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
COAD	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	4.86	2.07e-06	0.00088	0.36	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
COAD	cis	rs2665103	0.632	rs3902959	ENSG00000259429.4	UBE2Q2P2	-4.86	2.08e-06	0.000882	-0.24	-0.29	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82355142~82420075:+
COAD	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-4.86	2.08e-06	0.000882	-0.3	-0.29	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
COAD	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	4.86	2.08e-06	0.000882	0.57	0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
COAD	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	4.86	2.08e-06	0.000883	0.33	0.29	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	4.86	2.08e-06	0.000883	0.33	0.29	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
COAD	cis	rs5758511	0.633	rs5758690	ENSG00000237037.8	NDUFA6-AS1	-4.86	2.08e-06	0.000883	-0.35	-0.29	Birth weight;	chr22:42272289	chr22:42090931~42137742:+
COAD	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-4.86	2.08e-06	0.000884	-0.32	-0.29	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
COAD	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-4.86	2.08e-06	0.000884	-0.29	-0.29	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
COAD	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
COAD	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	4.86	2.08e-06	0.000884	0.35	0.29	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
COAD	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	4.86	2.08e-06	0.000884	0.35	0.29	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	4.86	2.08e-06	0.000884	0.35	0.29	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
COAD	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	4.86	2.08e-06	0.000884	0.85	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
COAD	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-4.86	2.09e-06	0.000885	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
COAD	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-4.86	2.09e-06	0.000886	-0.41	-0.29	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
COAD	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-4.86	2.09e-06	0.000887	-0.31	-0.29	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
COAD	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	4.86	2.09e-06	0.000887	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
COAD	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-4.86	2.09e-06	0.000887	-0.5	-0.29	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-4.85	2.1e-06	0.000889	-0.5	-0.29	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
COAD	cis	rs1790761	0.559	rs10896190	ENSG00000255318.1	RP11-655M14.13	4.85	2.1e-06	0.000891	0.38	0.29	Mean corpuscular volume;	chr11:67638652	chr11:67618279~67627304:-
COAD	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.85	2.1e-06	0.000892	0.34	0.29	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.85	2.1e-06	0.000892	0.34	0.29	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
COAD	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-4.85	2.1e-06	0.000892	-0.26	-0.29	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
COAD	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	4.85	2.11e-06	0.000893	0.4	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
COAD	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	4.85	2.11e-06	0.000893	0.32	0.29	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
COAD	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-4.85	2.11e-06	0.000893	-0.27	-0.29	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
COAD	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-4.85	2.11e-06	0.000894	-0.31	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
COAD	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	4.85	2.11e-06	0.000894	0.37	0.29	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
COAD	cis	rs6750795	0.87	rs6754952	ENSG00000223198.1	RNU2-22P	4.85	2.11e-06	0.000895	0.33	0.29	Height;	chr2:231516534	chr2:231501990~231502201:-
COAD	cis	rs1964356	0.967	rs2953802	ENSG00000233609.3	RP11-62H7.2	4.85	2.11e-06	0.000895	0.33	0.29	Mean corpuscular volume;	chr8:8994371	chr8:8961200~8979025:+
COAD	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	4.85	2.11e-06	0.000895	0.59	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	4.85	2.11e-06	0.000895	0.59	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	4.85	2.11e-06	0.000895	0.59	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	4.85	2.11e-06	0.000895	0.59	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	4.85	2.11e-06	0.000895	0.59	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
COAD	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	4.85	2.11e-06	0.000895	0.3	0.29	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
COAD	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	4.85	2.11e-06	0.000895	0.33	0.29	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
COAD	cis	rs72827839	0.846	rs72823599	ENSG00000263412.1	RP5-890E16.2	4.85	2.12e-06	0.000896	0.42	0.29	Ease of getting up in the morning;	chr17:48055062	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.846	rs72823601	ENSG00000263412.1	RP5-890E16.2	4.85	2.12e-06	0.000896	0.42	0.29	Ease of getting up in the morning;	chr17:48057846	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.846	rs72825504	ENSG00000263412.1	RP5-890E16.2	4.85	2.12e-06	0.000896	0.42	0.29	Ease of getting up in the morning;	chr17:48062117	chr17:48045141~48048073:-
COAD	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	4.85	2.12e-06	0.000897	0.33	0.29	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
COAD	cis	rs4987094	0.505	rs4938011	ENSG00000270179.1	RP11-159N11.4	4.85	2.12e-06	0.000897	0.48	0.29	Schizophrenia;	chr11:113376510	chr11:113368478~113369117:+
COAD	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-4.85	2.12e-06	0.000898	-0.45	-0.29	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
COAD	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-4.85	2.12e-06	9e-04	-0.41	-0.29	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
COAD	cis	rs6543140	0.964	rs4851578	ENSG00000234389.1	AC007278.3	4.85	2.13e-06	9e-04	0.32	0.29	Blood protein levels;	chr2:102412491	chr2:102438713~102440475:+
COAD	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-4.85	2.13e-06	0.000901	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
COAD	cis	rs9625935	0.518	rs9614086	ENSG00000279159.1	RP3-394A18.1	4.85	2.13e-06	0.000903	0.2	0.29	Tonsillectomy;	chr22:29863619	chr22:29978950~30028236:-
COAD	cis	rs12497850	0.764	rs6784111	ENSG00000225399.4	RP11-3B7.1	4.85	2.13e-06	0.000903	0.33	0.29	Parkinson's disease;	chr3:49141413	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.864	rs12493001	ENSG00000225399.4	RP11-3B7.1	4.85	2.13e-06	0.000903	0.33	0.29	Parkinson's disease;	chr3:49144452	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.829	rs12636030	ENSG00000225399.4	RP11-3B7.1	4.85	2.13e-06	0.000903	0.33	0.29	Parkinson's disease;	chr3:49144804	chr3:49260085~49261316:+
COAD	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.85	2.14e-06	0.000904	-0.5	-0.29	Gout;	chr7:66715944	chr7:66654538~66669855:+
COAD	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	4.85	2.14e-06	0.000904	0.35	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
COAD	cis	rs603446	0.967	rs2849179	ENSG00000254851.1	RP11-109L13.1	-4.85	2.14e-06	0.000905	-0.33	-0.29	Triglycerides;	chr11:116750080	chr11:117135528~117138582:+
COAD	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	4.85	2.14e-06	0.000905	0.17	0.29	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
COAD	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	4.85	2.14e-06	0.000905	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
COAD	cis	rs7647973	0.58	rs7652746	ENSG00000225399.4	RP11-3B7.1	-4.85	2.14e-06	0.000905	-0.33	-0.29	Menarche (age at onset);	chr3:49224874	chr3:49260085~49261316:+
COAD	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	4.85	2.14e-06	0.000906	0.33	0.29	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	4.85	2.14e-06	0.000906	0.33	0.29	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
COAD	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-4.85	2.14e-06	0.000906	-0.33	-0.29	Height;	chr20:49280020	chr20:49280319~49280409:+
COAD	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-4.85	2.14e-06	0.000906	-0.28	-0.29	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
COAD	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-4.85	2.14e-06	0.000906	-0.34	-0.29	Migraine;	chr4:56852029	chr4:56960927~56961373:-
COAD	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-4.85	2.14e-06	0.000906	-0.35	-0.29	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
COAD	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-4.85	2.14e-06	0.000906	-0.35	-0.29	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
COAD	cis	rs6840360	0.617	rs2724563	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.617	rs2724564	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.607	rs2724565	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7677131	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7657670	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709828	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2724551	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.667	rs2709829	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7678823	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.606	rs2709813	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.606	rs2724550	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709815	ENSG00000251611.1	RP11-610P16.1	-4.85	2.14e-06	0.000906	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7698816	ENSG00000251611.1	RP11-610P16.1	-4.85	2.15e-06	0.000908	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151407551~151408835:-
COAD	cis	rs4568518	0.903	rs12155344	ENSG00000279048.1	RP11-511H23.2	4.85	2.15e-06	0.000908	0.21	0.29	Measles;	chr7:17995760	chr7:17940503~17942922:+
COAD	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-4.85	2.15e-06	0.000908	-0.39	-0.29	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
COAD	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-4.85	2.15e-06	0.000908	-0.36	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
COAD	cis	rs36052053	0.908	rs13203020	ENSG00000219700.1	PTCHD3P3	4.85	2.15e-06	0.000908	0.49	0.29	Red cell distribution width;	chr6:109263442	chr6:109288571~109290503:-
COAD	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	4.85	2.15e-06	0.000908	0.38	0.29	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
COAD	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	4.85	2.15e-06	0.000908	0.38	0.29	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
COAD	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	4.85	2.15e-06	0.000908	0.38	0.29	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
COAD	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-4.85	2.15e-06	0.000909	-0.38	-0.29	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
COAD	cis	rs2581828	0.646	rs12630819	ENSG00000280417.1	RP11-5O17.1	4.85	2.15e-06	0.000909	0.31	0.29	Crohn's disease;	chr3:53123286	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.646	rs12638996	ENSG00000280417.1	RP11-5O17.1	4.85	2.15e-06	0.000909	0.31	0.29	Crohn's disease;	chr3:53123530	chr3:53046166~53048122:+
COAD	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-4.85	2.15e-06	0.000909	-0.3	-0.29	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
COAD	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	4.85	2.15e-06	0.00091	0.38	0.29	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
COAD	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-4.85	2.15e-06	0.000911	-0.48	-0.29	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
COAD	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	4.85	2.15e-06	0.000911	0.27	0.29	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	4.85	2.15e-06	0.000911	0.27	0.29	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
COAD	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-4.85	2.16e-06	0.000911	-0.26	-0.29	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
COAD	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-4.85	2.16e-06	0.000911	-0.27	-0.29	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
COAD	cis	rs6840360	0.642	rs7682770	ENSG00000251611.1	RP11-610P16.1	-4.85	2.16e-06	0.000912	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs11729923	ENSG00000251611.1	RP11-610P16.1	-4.85	2.16e-06	0.000912	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7657747	ENSG00000251611.1	RP11-610P16.1	-4.85	2.16e-06	0.000912	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151407551~151408835:-
COAD	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	4.85	2.16e-06	0.000913	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
COAD	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-4.85	2.16e-06	0.000913	-0.34	-0.29	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
COAD	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-4.85	2.16e-06	0.000913	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-4.85	2.16e-06	0.000913	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
COAD	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-4.85	2.16e-06	0.000914	-0.52	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
COAD	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	4.85	2.17e-06	0.000915	0.22	0.29	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
COAD	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-4.85	2.17e-06	0.000915	-0.35	-0.29	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
COAD	cis	rs9450351	0.744	rs9450308	ENSG00000203875.9	SNHG5	-4.85	2.17e-06	0.000915	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85638820	chr6:85660950~85678736:-
COAD	cis	rs6840360	0.642	rs11099815	ENSG00000251611.1	RP11-610P16.1	-4.85	2.17e-06	0.000915	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151407551~151408835:-
COAD	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-4.85	2.17e-06	0.000916	-0.33	-0.29	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
COAD	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.85	2.17e-06	0.000917	-0.5	-0.29	Gout;	chr7:66721259	chr7:66654538~66669855:+
COAD	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	4.85	2.17e-06	0.000917	0.43	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
COAD	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-4.85	2.17e-06	0.000918	-0.33	-0.29	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-4.85	2.17e-06	0.000918	-0.33	-0.29	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
COAD	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-4.85	2.18e-06	0.000919	-0.27	-0.29	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
COAD	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	4.85	2.18e-06	0.00092	0.35	0.29	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
COAD	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-4.85	2.18e-06	0.00092	-0.3	-0.29	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
COAD	cis	rs7826238	0.72	rs12546760	ENSG00000173295.6	FAM86B3P	-4.85	2.18e-06	0.00092	-0.35	-0.29	Systolic blood pressure;	chr8:8517326	chr8:8228595~8244865:+
COAD	cis	rs9291683	1	rs9291683	ENSG00000250413.1	RP11-448G15.1	-4.85	2.18e-06	0.00092	-0.36	-0.29	Bone mineral density;	chr4:10322536	chr4:10006482~10009725:+
COAD	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-4.85	2.18e-06	0.000921	-0.33	-0.29	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-4.85	2.18e-06	0.000921	-0.33	-0.29	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
COAD	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	4.85	2.18e-06	0.000921	0.33	0.29	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
COAD	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-4.85	2.18e-06	0.000921	-0.44	-0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
COAD	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	4.85	2.19e-06	0.000922	0.31	0.29	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
COAD	cis	rs6840360	0.642	rs2724578	ENSG00000251611.1	RP11-610P16.1	-4.85	2.19e-06	0.000923	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.574	rs2709844	ENSG00000251611.1	RP11-610P16.1	-4.85	2.19e-06	0.000923	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.693	rs28622593	ENSG00000251611.1	RP11-610P16.1	-4.85	2.19e-06	0.000923	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2709831	ENSG00000251611.1	RP11-610P16.1	-4.85	2.19e-06	0.000923	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151407551~151408835:-
COAD	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	4.85	2.19e-06	0.000924	0.53	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.84	2.19e-06	0.000925	-0.33	-0.29	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
COAD	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-4.84	2.2e-06	0.000926	-0.39	-0.29	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
COAD	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-4.84	2.2e-06	0.000926	-0.39	-0.29	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
COAD	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	4.84	2.2e-06	0.000926	0.38	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
COAD	cis	rs4704187	0.687	rs10066946	ENSG00000250889.2	LINC01336	-4.84	2.2e-06	0.000927	-0.33	-0.29	Response to amphetamines;	chr5:75212196	chr5:75047719~75052843:-
COAD	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-4.84	2.2e-06	0.000927	-0.35	-0.29	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
COAD	cis	rs7818688	0.745	rs73271178	ENSG00000253528.2	RP11-347C18.4	-4.84	2.2e-06	0.000928	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94895002	chr8:94974573~94974853:-
COAD	cis	rs1055129	0.516	rs7218498	ENSG00000267801.1	RP11-552F3.9	4.84	2.2e-06	0.000928	0.36	0.29	White matter hyperintensity burden;	chr17:75935766	chr17:75876372~75879546:+
COAD	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	4.84	2.2e-06	0.000928	0.3	0.29	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
COAD	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	4.84	2.21e-06	0.00093	0.41	0.29	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
COAD	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.84	2.21e-06	0.00093	-0.46	-0.29	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
COAD	cis	rs7529073	0.545	rs340884	ENSG00000274895.1	RP11-478J18.2	4.84	2.21e-06	0.000932	0.31	0.29	Schizophrenia;	chr1:213972046	chr1:213983793~213986419:-
COAD	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	4.84	2.21e-06	0.000932	0.37	0.29	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	4.84	2.21e-06	0.000932	0.37	0.29	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	4.84	2.21e-06	0.000932	0.37	0.29	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
COAD	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-4.84	2.21e-06	0.000932	-0.31	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
COAD	cis	rs11681884	0.71	rs928940	ENSG00000228251.1	AC012442.6	-4.84	2.21e-06	0.000933	-0.48	-0.29	Stroke;	chr2:113119918	chr2:112590796~112591939:+
COAD	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-4.84	2.21e-06	0.000933	-0.34	-0.29	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
COAD	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-4.84	2.22e-06	0.000933	-0.37	-0.29	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
COAD	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-4.84	2.22e-06	0.000934	-0.34	-0.29	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
COAD	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-4.84	2.22e-06	0.000934	-0.33	-0.29	QT interval;	chr12:29309811	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-4.84	2.22e-06	0.000934	-0.33	-0.29	QT interval;	chr12:29319943	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-4.84	2.22e-06	0.000934	-0.33	-0.29	QT interval;	chr12:29331030	chr12:29280418~29317848:-
COAD	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.22e-06	0.000934	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
COAD	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.22e-06	0.000934	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.22e-06	0.000934	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.22e-06	0.000934	-0.54	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
COAD	cis	rs6840360	0.667	rs9994482	ENSG00000251611.1	RP11-610P16.1	-4.84	2.22e-06	0.000934	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151407551~151408835:-
COAD	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-4.84	2.22e-06	0.000936	-0.34	-0.29	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
COAD	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	4.84	2.22e-06	0.000936	0.33	0.29	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
COAD	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	4.84	2.23e-06	0.000937	0.34	0.29	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
COAD	cis	rs6840360	0.642	rs2724567	ENSG00000251611.1	RP11-610P16.1	4.84	2.23e-06	0.000937	0.27	0.29	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151407551~151408835:-
COAD	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	4.84	2.23e-06	0.000938	0.41	0.29	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	4.84	2.23e-06	0.000938	0.41	0.29	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
COAD	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-4.84	2.23e-06	0.000939	-0.38	-0.29	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
COAD	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	4.84	2.23e-06	0.000939	0.3	0.29	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	4.84	2.23e-06	0.000939	0.3	0.29	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	4.84	2.23e-06	0.000939	0.3	0.29	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	4.84	2.23e-06	0.000939	0.3	0.29	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	4.84	2.23e-06	0.000939	0.3	0.29	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
COAD	cis	rs453301	0.686	rs3895823	ENSG00000173295.6	FAM86B3P	-4.84	2.23e-06	0.000939	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9016136	chr8:8228595~8244865:+
COAD	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-4.84	2.23e-06	0.000939	-0.53	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
COAD	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-4.84	2.23e-06	0.000939	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-4.84	2.23e-06	0.000939	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
COAD	cis	rs801193	1	rs7782320	ENSG00000272831.1	RP11-792A8.4	4.84	2.23e-06	0.00094	0.31	0.29	Aortic root size;	chr7:66712111	chr7:66739829~66740385:-
COAD	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	4.84	2.23e-06	0.00094	0.35	0.29	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
COAD	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-4.84	2.24e-06	0.00094	-0.35	-0.29	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
COAD	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	4.84	2.24e-06	0.00094	0.63	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
COAD	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	4.84	2.24e-06	0.00094	0.33	0.29	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
COAD	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-4.84	2.24e-06	0.000942	-0.39	-0.29	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
COAD	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-4.84	2.24e-06	0.000942	-0.42	-0.29	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
COAD	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	4.84	2.24e-06	0.000942	0.37	0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
COAD	cis	rs6840360	0.642	rs12647555	ENSG00000251611.1	RP11-610P16.1	-4.84	2.24e-06	0.000943	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs1899550	ENSG00000251611.1	RP11-610P16.1	-4.84	2.24e-06	0.000943	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151407551~151408835:-
COAD	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	4.84	2.24e-06	0.000943	0.32	0.29	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
COAD	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	4.84	2.24e-06	0.000943	0.71	0.29	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	4.84	2.24e-06	0.000943	0.71	0.29	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	4.84	2.24e-06	0.000943	0.71	0.29	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
COAD	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	4.84	2.24e-06	0.000943	0.22	0.29	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
COAD	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-4.84	2.24e-06	0.000943	-0.37	-0.29	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
COAD	cis	rs2732480	0.5	rs2450991	ENSG00000273765.1	RP11-370I10.11	4.84	2.25e-06	0.000944	0.32	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48360920~48361377:+
COAD	cis	rs4704187	0.687	rs10058460	ENSG00000250889.2	LINC01336	-4.84	2.25e-06	0.000944	-0.32	-0.29	Response to amphetamines;	chr5:75202890	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6891023	ENSG00000250889.2	LINC01336	-4.84	2.25e-06	0.000944	-0.32	-0.29	Response to amphetamines;	chr5:75204930	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10051040	ENSG00000250889.2	LINC01336	-4.84	2.25e-06	0.000944	-0.32	-0.29	Response to amphetamines;	chr5:75206151	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1592948	ENSG00000250889.2	LINC01336	-4.84	2.25e-06	0.000944	-0.32	-0.29	Response to amphetamines;	chr5:75208327	chr5:75047719~75052843:-
COAD	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	4.84	2.25e-06	0.000944	0.36	0.29	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
COAD	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	4.84	2.25e-06	0.000944	0.43	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
COAD	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-4.84	2.25e-06	0.000945	-0.5	-0.29	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
COAD	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	4.84	2.25e-06	0.000945	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
COAD	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	4.84	2.25e-06	0.000945	0.34	0.29	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
COAD	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-4.84	2.25e-06	0.000945	-0.34	-0.29	Height;	chr3:52971094	chr3:53064283~53065091:-
COAD	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	4.84	2.25e-06	0.000945	0.32	0.29	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
COAD	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-4.84	2.25e-06	0.000946	-0.29	-0.29	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
COAD	cis	rs748404	0.601	rs489964	ENSG00000205771.5	CATSPER2P1	4.84	2.26e-06	0.000947	0.36	0.29	Lung cancer;	chr15:43225356	chr15:43726918~43747094:-
COAD	cis	rs1823913	0.538	rs6732537	ENSG00000227542.1	AC092614.2	4.84	2.26e-06	0.000947	0.32	0.29	Obesity-related traits;	chr2:191346755	chr2:191229165~191246172:-
COAD	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-4.84	2.26e-06	0.000947	-0.43	-0.29	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
COAD	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-4.84	2.26e-06	0.000947	-0.34	-0.29	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
COAD	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-4.84	2.26e-06	0.000948	-0.35	-0.29	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
COAD	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-4.84	2.26e-06	0.000948	-0.3	-0.29	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
COAD	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-4.84	2.26e-06	0.000949	-0.42	-0.29	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
COAD	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-4.84	2.26e-06	0.00095	-0.52	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
COAD	cis	rs111580313	0.792	rs79430710	ENSG00000270020.1	RP11-463O9.9	4.84	2.26e-06	0.00095	0.72	0.29	Systemic juvenile idiopathic arthritis;	chr16:86575505	chr16:86520383~86523897:-
COAD	cis	rs111580313	0.685	rs78285663	ENSG00000270020.1	RP11-463O9.9	4.84	2.26e-06	0.00095	0.72	0.29	Systemic juvenile idiopathic arthritis;	chr16:86575638	chr16:86520383~86523897:-
COAD	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.84	2.27e-06	0.000951	-0.52	-0.29	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
COAD	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-4.84	2.27e-06	0.000951	-0.42	-0.29	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	4.84	2.27e-06	0.000951	0.42	0.29	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
COAD	cis	rs1387259	0.931	rs11168474	ENSG00000273765.1	RP11-370I10.11	4.84	2.27e-06	0.000951	0.31	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48360920~48361377:+
COAD	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	4.84	2.27e-06	0.000951	0.34	0.29	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
COAD	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	4.84	2.27e-06	0.000951	0.43	0.29	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
COAD	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	4.84	2.27e-06	0.000951	0.43	0.29	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
COAD	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	4.84	2.27e-06	0.000951	0.43	0.29	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
COAD	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	4.84	2.27e-06	0.000951	0.43	0.29	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
COAD	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	4.84	2.27e-06	0.000951	0.28	0.29	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
COAD	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	4.84	2.27e-06	0.000951	0.28	0.29	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
COAD	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-4.84	2.27e-06	0.000951	-0.28	-0.29	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
COAD	cis	rs6840360	0.642	rs4696089	ENSG00000251611.1	RP11-610P16.1	-4.84	2.27e-06	0.000952	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs11932398	ENSG00000251611.1	RP11-610P16.1	-4.84	2.27e-06	0.000952	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs4263379	ENSG00000251611.1	RP11-610P16.1	-4.84	2.27e-06	0.000952	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151407551~151408835:-
COAD	cis	rs492146	0.935	rs316137	ENSG00000243236.5	GSTA9P	-4.84	2.27e-06	0.000953	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52981882	chr6:52939726~52957521:-
COAD	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	4.84	2.27e-06	0.000953	0.44	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
COAD	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	4.84	2.27e-06	0.000953	0.44	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
COAD	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	4.84	2.27e-06	0.000953	0.34	0.29	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
COAD	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	4.84	2.27e-06	0.000953	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
COAD	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-4.84	2.27e-06	0.000953	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
COAD	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	4.84	2.28e-06	0.000954	0.29	0.29	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
COAD	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-4.84	2.28e-06	0.000954	-0.35	-0.29	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
COAD	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-4.84	2.28e-06	0.000954	-0.3	-0.29	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
COAD	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-4.84	2.28e-06	0.000956	-0.44	-0.29	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
COAD	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-4.84	2.28e-06	0.000957	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
COAD	cis	rs8002861	0.84	rs7989353	ENSG00000274001.1	RP11-5G9.5	4.84	2.28e-06	0.000957	0.26	0.29	Leprosy;	chr13:43864821	chr13:43877715~43878163:-
COAD	cis	rs75920871	0.588	rs6589580	ENSG00000254851.1	RP11-109L13.1	4.84	2.29e-06	0.000957	0.35	0.29	Subjective well-being;	chr11:116949157	chr11:117135528~117138582:+
COAD	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-4.84	2.29e-06	0.000958	-0.32	-0.29	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
COAD	cis	rs8002861	0.87	rs4942251	ENSG00000274001.1	RP11-5G9.5	4.84	2.29e-06	0.000958	0.26	0.29	Leprosy;	chr13:43865912	chr13:43877715~43878163:-
COAD	cis	rs440932	1	rs378974	ENSG00000253981.4	ALG1L13P	4.84	2.29e-06	0.000958	0.4	0.29	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8236003~8244667:-
COAD	cis	rs7646881	0.504	rs4264773	ENSG00000272087.1	RP11-379F4.7	4.84	2.29e-06	0.000959	0.4	0.29	Tetralogy of Fallot;	chr3:158745436	chr3:158693120~158693768:-
COAD	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-4.84	2.29e-06	0.000959	-0.34	-0.29	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
COAD	cis	rs8002861	0.781	rs7322781	ENSG00000274001.1	RP11-5G9.5	4.84	2.29e-06	0.00096	0.26	0.29	Leprosy;	chr13:43868102	chr13:43877715~43878163:-
COAD	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	4.83	2.3e-06	0.000961	0.36	0.29	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
COAD	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	4.83	2.3e-06	0.000961	0.2	0.29	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
COAD	cis	rs73198271	1	rs73198279	ENSG00000173295.6	FAM86B3P	-4.83	2.3e-06	0.000961	-0.39	-0.29	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8228595~8244865:+
COAD	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	4.83	2.3e-06	0.000962	0.3	0.29	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
COAD	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	4.83	2.3e-06	0.000962	0.32	0.29	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
COAD	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	4.83	2.3e-06	0.000962	0.43	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
COAD	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-4.83	2.3e-06	0.000963	-0.35	-0.29	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
COAD	cis	rs7260598	0.642	rs8104784	ENSG00000268442.1	CTD-2027I19.2	4.83	2.31e-06	0.000965	0.41	0.29	Response to taxane treatment (placlitaxel);	chr19:23961732	chr19:24162370~24163425:-
COAD	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-4.83	2.31e-06	0.000965	-0.35	-0.29	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
COAD	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	4.83	2.31e-06	0.000965	0.31	0.29	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
COAD	cis	rs754466	1	rs12220902	ENSG00000204049.1	RP11-126H7.4	4.83	2.31e-06	0.000966	0.39	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77923160	chr10:77866875~77869610:+
COAD	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-4.83	2.31e-06	0.000967	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
COAD	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	4.83	2.31e-06	0.000967	0.37	0.29	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
COAD	cis	rs2281603	0.57	rs10133696	ENSG00000259116.1	RP11-973N13.4	-4.83	2.31e-06	0.000968	-0.29	-0.29	Lymphocyte counts;	chr14:64504441	chr14:64514154~64540368:-
COAD	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	4.83	2.32e-06	0.000968	0.47	0.29	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
COAD	cis	rs10078	0.51	rs2278248	ENSG00000225138.6	CTD-2228K2.7	4.83	2.32e-06	0.000969	0.44	0.29	Fat distribution (HIV);	chr5:469455	chr5:473236~480884:+
COAD	cis	rs2281603	0.621	rs61985668	ENSG00000259116.1	RP11-973N13.4	-4.83	2.32e-06	0.000969	-0.29	-0.29	Lymphocyte counts;	chr14:64489628	chr14:64514154~64540368:-
COAD	cis	rs9818758	0.607	rs67060340	ENSG00000225399.4	RP11-3B7.1	-4.83	2.32e-06	0.00097	-0.54	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:49260085~49261316:+
COAD	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.83	2.32e-06	0.00097	0.49	0.29	Gout;	chr7:66682070	chr7:66654538~66669855:+
COAD	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.83	2.32e-06	0.00097	0.49	0.29	Gout;	chr7:66682162	chr7:66654538~66669855:+
COAD	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.83	2.32e-06	0.00097	-0.49	-0.29	Gout;	chr7:66679692	chr7:66654538~66669855:+
COAD	cis	rs5758511	0.68	rs56111723	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.32e-06	0.00097	-0.35	-0.29	Birth weight;	chr22:42268877	chr22:42090931~42137742:+
COAD	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-4.83	2.32e-06	0.00097	-0.42	-0.29	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-4.83	2.32e-06	0.00097	-0.42	-0.29	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
COAD	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-4.83	2.32e-06	0.000971	-0.33	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
COAD	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-4.83	2.32e-06	0.000971	-0.35	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	4.83	2.32e-06	0.000971	0.22	0.29	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	4.83	2.32e-06	0.000971	0.22	0.29	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
COAD	cis	rs4568518	0.873	rs4535616	ENSG00000279048.1	RP11-511H23.2	4.83	2.32e-06	0.000971	0.21	0.29	Measles;	chr7:17989040	chr7:17940503~17942922:+
COAD	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	4.83	2.32e-06	0.000971	0.3	0.29	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
COAD	cis	rs9487051	0.676	rs1608044	ENSG00000219700.1	PTCHD3P3	4.83	2.32e-06	0.000972	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109272873	chr6:109288571~109290503:-
COAD	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-4.83	2.32e-06	0.000972	-0.33	-0.29	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs3791770	ENSG00000253559.1	OSGEPL1-AS1	-4.83	2.32e-06	0.000972	-0.33	-0.29	Ferritin levels;	chr2:189809109	chr2:189762704~189765556:+
COAD	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-4.83	2.33e-06	0.000972	-0.17	-0.29	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
COAD	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	4.83	2.33e-06	0.000972	0.51	0.29	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	4.83	2.33e-06	0.000972	0.51	0.29	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	4.83	2.33e-06	0.000972	0.51	0.29	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
COAD	cis	rs7646881	0.5	rs73022762	ENSG00000272087.1	RP11-379F4.7	4.83	2.33e-06	0.000972	0.44	0.29	Tetralogy of Fallot;	chr3:158572516	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs9881679	ENSG00000272087.1	RP11-379F4.7	4.83	2.33e-06	0.000972	0.44	0.29	Tetralogy of Fallot;	chr3:158580643	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs9849437	ENSG00000272087.1	RP11-379F4.7	4.83	2.33e-06	0.000972	0.44	0.29	Tetralogy of Fallot;	chr3:158581612	chr3:158693120~158693768:-
COAD	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	4.83	2.33e-06	0.000972	0.28	0.29	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-4.83	2.33e-06	0.000972	-0.28	-0.29	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-4.83	2.33e-06	0.000972	-0.28	-0.29	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
COAD	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	4.83	2.33e-06	0.000972	0.33	0.29	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
COAD	cis	rs453301	0.686	rs11785819	ENSG00000173295.6	FAM86B3P	-4.83	2.33e-06	0.000974	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9012868	chr8:8228595~8244865:+
COAD	cis	rs7760535	0.763	rs9487666	ENSG00000271789.1	RP5-1112D6.7	-4.83	2.33e-06	0.000974	-0.28	-0.29	Metabolic traits;	chr6:111547821	chr6:111297126~111298510:+
COAD	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.83	2.34e-06	0.000975	0.47	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
COAD	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-4.83	2.34e-06	0.000976	-0.35	-0.29	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-4.83	2.34e-06	0.000976	-0.35	-0.29	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-4.83	2.34e-06	0.000976	-0.35	-0.29	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
COAD	cis	rs1578862	0.833	rs12564303	ENSG00000259865.1	RP11-488L18.10	-4.83	2.34e-06	0.000976	-0.23	-0.29	Monocyte percentage of white cells;	chr1:247326151	chr1:247187281~247188526:-
COAD	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	4.83	2.34e-06	0.000977	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
COAD	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-4.83	2.34e-06	0.000977	-0.29	-0.29	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
COAD	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-4.83	2.34e-06	0.000977	-0.35	-0.29	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-4.83	2.34e-06	0.000977	-0.35	-0.29	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
COAD	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	4.83	2.34e-06	0.000977	0.31	0.29	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
COAD	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-4.83	2.34e-06	0.000977	-0.27	-0.29	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
COAD	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-4.83	2.34e-06	0.000978	-0.32	-0.29	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-4.83	2.34e-06	0.000978	-0.32	-0.29	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
COAD	cis	rs7829975	0.593	rs2979241	ENSG00000254340.1	RP11-10A14.3	4.83	2.34e-06	0.000978	0.34	0.29	Mood instability;	chr8:8445843	chr8:9141424~9145435:+
COAD	cis	rs2733201	1	rs1426658	ENSG00000205771.5	CATSPER2P1	4.83	2.34e-06	0.000979	0.49	0.29	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44046721	chr15:43726918~43747094:-
COAD	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	4.83	2.35e-06	0.000979	0.6	0.29	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
COAD	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-4.83	2.35e-06	0.00098	-0.26	-0.29	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
COAD	cis	rs2115630	0.645	rs2292463	ENSG00000259728.4	LINC00933	-4.83	2.35e-06	0.00098	-0.34	-0.29	P wave terminal force;	chr15:84632519	chr15:84570649~84580175:+
COAD	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-4.83	2.35e-06	0.00098	-0.35	-0.29	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
COAD	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	4.83	2.35e-06	0.00098	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	4.83	2.35e-06	0.00098	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
COAD	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-4.83	2.35e-06	0.00098	-0.31	-0.29	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
COAD	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-4.83	2.35e-06	0.00098	-0.31	-0.29	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
COAD	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-4.83	2.35e-06	0.000981	-0.58	-0.29	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
COAD	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	4.83	2.35e-06	0.000981	0.32	0.29	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
COAD	cis	rs35264875	0.796	rs72930637	ENSG00000259799.1	RP11-554A11.9	4.83	2.35e-06	0.000981	0.47	0.29	Blond vs. brown hair color;	chr11:69102499	chr11:69155910~69159752:+
COAD	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-4.83	2.35e-06	0.000982	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
COAD	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	4.83	2.35e-06	0.000982	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
COAD	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-4.83	2.36e-06	0.000983	-0.38	-0.29	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
COAD	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-4.83	2.36e-06	0.000983	-0.32	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
COAD	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	4.83	2.36e-06	0.000983	0.4	0.29	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
COAD	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-4.83	2.36e-06	0.000984	-0.35	-0.29	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
COAD	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-4.83	2.36e-06	0.000985	-0.26	-0.29	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
COAD	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-4.83	2.36e-06	0.000985	-0.27	-0.29	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
COAD	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-4.83	2.36e-06	0.000986	-0.42	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
COAD	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	4.83	2.36e-06	0.000986	0.36	0.29	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
COAD	cis	rs7598759	0.548	rs11693738	ENSG00000223198.1	RNU2-22P	-4.83	2.36e-06	0.000986	-0.32	-0.29	Noise-induced hearing loss;	chr2:231495773	chr2:231501990~231502201:-
COAD	cis	rs492146	0.935	rs316139	ENSG00000243236.5	GSTA9P	-4.83	2.37e-06	0.000987	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52981574	chr6:52939726~52957521:-
COAD	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	4.83	2.37e-06	0.000987	0.29	0.29	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
COAD	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-4.83	2.37e-06	0.000987	-0.35	-0.29	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-4.83	2.37e-06	0.000987	-0.35	-0.29	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
COAD	cis	rs5758511	0.514	rs5751211	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.37e-06	0.000988	-0.34	-0.29	Birth weight;	chr22:42090052	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.514	rs3985938	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.37e-06	0.000988	-0.34	-0.29	Birth weight;	chr22:42115723	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.514	rs5751221	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.37e-06	0.000988	-0.34	-0.29	Birth weight;	chr22:42120362	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.514	rs5758586	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.37e-06	0.000988	-0.34	-0.29	Birth weight;	chr22:42121467	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.514	rs5751222	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.37e-06	0.000988	-0.34	-0.29	Birth weight;	chr22:42121918	chr22:42090931~42137742:+
COAD	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	4.83	2.37e-06	0.000989	0.16	0.29	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
COAD	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	4.83	2.37e-06	0.000989	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
COAD	cis	rs55823223	0.503	rs9906971	ENSG00000267801.1	RP11-552F3.9	4.83	2.37e-06	0.000989	0.4	0.29	Psoriasis;	chr17:75852396	chr17:75876372~75879546:+
COAD	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-4.83	2.37e-06	0.00099	-0.26	-0.29	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
COAD	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	4.83	2.38e-06	0.00099	0.38	0.29	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
COAD	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-4.83	2.38e-06	0.00099	-0.35	-0.29	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
COAD	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	4.83	2.38e-06	0.00099	0.26	0.29	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
COAD	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-4.83	2.38e-06	0.00099	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
COAD	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	4.83	2.38e-06	0.000991	0.33	0.29	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	4.83	2.38e-06	0.000991	0.33	0.29	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
COAD	cis	rs739496	0.653	rs10744773	ENSG00000257595.2	RP3-473L9.4	4.83	2.38e-06	0.000991	0.43	0.29	Platelet count;	chr12:111649006	chr12:111369282~111403310:+
COAD	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-4.83	2.38e-06	0.000992	-0.34	-0.29	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
COAD	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	4.83	2.38e-06	0.000992	0.31	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
COAD	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	4.83	2.38e-06	0.000992	0.54	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
COAD	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-4.83	2.38e-06	0.000993	-0.35	-0.29	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-4.83	2.38e-06	0.000993	-0.35	-0.29	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-4.83	2.38e-06	0.000993	-0.35	-0.29	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
COAD	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-4.83	2.38e-06	0.000993	-0.43	-0.29	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
COAD	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	4.83	2.39e-06	0.000995	0.39	0.29	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
COAD	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	4.83	2.39e-06	0.000996	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	4.83	2.39e-06	0.000996	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
COAD	cis	rs9847710	0.838	rs2581795	ENSG00000280417.1	RP11-5O17.1	4.83	2.39e-06	0.000996	0.29	0.29	Ulcerative colitis;	chr3:53004770	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.646	rs6783748	ENSG00000280417.1	RP11-5O17.1	4.83	2.39e-06	0.000996	0.31	0.29	Crohn's disease;	chr3:53119415	chr3:53046166~53048122:+
COAD	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	4.83	2.39e-06	0.000997	0.44	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
COAD	cis	rs13256369	1	rs873063	ENSG00000173295.6	FAM86B3P	4.83	2.4e-06	0.000997	0.41	0.29	Obesity-related traits;	chr8:8714937	chr8:8228595~8244865:+
COAD	cis	rs440932	0.747	rs330946	ENSG00000253981.4	ALG1L13P	4.83	2.4e-06	0.000998	0.39	0.29	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8236003~8244667:-
COAD	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	4.83	2.4e-06	0.000998	0.26	0.29	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
COAD	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	4.83	2.4e-06	0.000998	0.37	0.29	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
COAD	cis	rs7260598	0.642	rs56977104	ENSG00000268442.1	CTD-2027I19.2	4.83	2.4e-06	0.000998	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23956560	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.585	rs8112076	ENSG00000268442.1	CTD-2027I19.2	4.83	2.4e-06	0.000998	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23956561	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs8112289	ENSG00000268442.1	CTD-2027I19.2	4.83	2.4e-06	0.000998	0.42	0.29	Response to taxane treatment (placlitaxel);	chr19:23956571	chr19:24162370~24163425:-
COAD	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-4.83	2.4e-06	0.000998	-0.29	-0.29	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
COAD	cis	rs9450351	0.744	rs9362250	ENSG00000203875.9	SNHG5	-4.83	2.4e-06	0.000999	-0.56	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85867970	chr6:85660950~85678736:-
COAD	cis	rs492146	0.935	rs492825	ENSG00000243236.5	GSTA9P	-4.83	2.4e-06	0.001	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52980595	chr6:52939726~52957521:-
COAD	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	4.82	2.4e-06	0.001	0.37	0.29	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
COAD	cis	rs454422	0.767	rs236126	ENSG00000275632.1	RP5-967N21.11	4.82	2.4e-06	0.001	0.35	0.29	HIV-1 viral setpoint;	chr20:5997495	chr20:6000418~6000941:+
COAD	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	4.82	2.41e-06	0.001	0.34	0.29	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
COAD	cis	rs7615952	0.558	rs7641353	ENSG00000241278.1	ENPP7P4	4.82	2.41e-06	0.001	0.31	0.29	Blood pressure (smoking interaction);	chr3:125621035	chr3:125848223~125909372:+
COAD	cis	rs11723261	0.527	rs11731581	ENSG00000211553.1	AC253576.2	-4.82	2.41e-06	0.001	-0.44	-0.29	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:136461~136568:+
COAD	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-4.82	2.41e-06	0.001	-0.26	-0.29	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
COAD	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	4.82	2.41e-06	0.001	0.42	0.29	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
COAD	cis	rs210138	0.591	rs1408711	ENSG00000197251.3	LINC00336	-4.82	2.41e-06	0.001	-0.47	-0.29	Testicular germ cell tumor;	chr6:33652231	chr6:33586106~33593338:-
COAD	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	4.82	2.41e-06	0.001	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	4.82	2.41e-06	0.001	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	4.82	2.41e-06	0.001	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
COAD	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	4.82	2.41e-06	0.001	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
COAD	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-4.82	2.41e-06	0.001	-0.45	-0.29	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
COAD	cis	rs4841097	0.806	rs6992247	ENSG00000173295.6	FAM86B3P	4.82	2.41e-06	0.001	0.36	0.29	Platelet distribution width;	chr8:9090959	chr8:8228595~8244865:+
COAD	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	4.82	2.41e-06	0.001	0.35	0.29	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
COAD	cis	rs3733585	0.683	rs6449140	ENSG00000250413.1	RP11-448G15.1	4.82	2.41e-06	0.001	0.37	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9934813	chr4:10006482~10009725:+
COAD	cis	rs2378497	1	rs2185327	ENSG00000232679.1	RP11-400N13.3	4.82	2.41e-06	0.001	0.39	0.29	Serum thyroid-stimulating hormone levels;	chr1:222014300	chr1:222041705~222064763:-
COAD	cis	rs5758511	0.68	rs34107327	ENSG00000237037.8	NDUFA6-AS1	-4.82	2.42e-06	0.00101	-0.34	-0.29	Birth weight;	chr22:42252347	chr22:42090931~42137742:+
COAD	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	4.82	2.42e-06	0.00101	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
COAD	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-4.82	2.42e-06	0.00101	-0.32	-0.29	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
COAD	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-4.82	2.42e-06	0.00101	-0.27	-0.29	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
COAD	cis	rs17772222	0.636	rs3850390	ENSG00000258789.1	RP11-507K2.3	-4.82	2.42e-06	0.00101	-0.44	-0.29	Coronary artery calcification;	chr14:88829185	chr14:88551597~88552493:+
COAD	cis	rs2281603	0.57	rs10133848	ENSG00000259116.1	RP11-973N13.4	-4.82	2.42e-06	0.00101	-0.28	-0.29	Lymphocyte counts;	chr14:64481771	chr14:64514154~64540368:-
COAD	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-4.82	2.42e-06	0.00101	-0.34	-0.29	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
COAD	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	4.82	2.42e-06	0.00101	0.34	0.29	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
COAD	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-4.82	2.43e-06	0.00101	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
COAD	cis	rs2342406	0.825	rs13000834	ENSG00000259439.2	RP11-89K21.1	4.82	2.43e-06	0.00101	0.49	0.29	Myopia;	chr2:44912668	chr2:44921077~44939199:-
COAD	cis	rs9487051	0.714	rs7774377	ENSG00000219700.1	PTCHD3P3	4.82	2.43e-06	0.00101	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109281240	chr6:109288571~109290503:-
COAD	cis	rs858239	0.509	rs6962213	ENSG00000226816.2	AC005082.12	4.82	2.43e-06	0.00101	0.3	0.29	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23206013~23208045:+
COAD	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-4.82	2.43e-06	0.00101	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
COAD	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-4.82	2.43e-06	0.00101	-0.26	-0.29	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
COAD	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	4.82	2.44e-06	0.00101	0.34	0.29	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
COAD	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	4.82	2.44e-06	0.00101	0.26	0.29	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	4.82	2.44e-06	0.00101	0.26	0.29	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
COAD	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	4.82	2.44e-06	0.00101	0.32	0.29	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
COAD	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	4.82	2.44e-06	0.00101	0.32	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
COAD	cis	rs2617170	0.922	rs2617160	ENSG00000245648.1	RP11-277P12.20	4.82	2.44e-06	0.00101	0.39	0.29	Behcet's disease;	chr12:10392998	chr12:10363769~10398506:+
COAD	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.82	2.44e-06	0.00102	-0.32	-0.29	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
COAD	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-4.82	2.45e-06	0.00102	-0.34	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
COAD	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	4.82	2.45e-06	0.00102	0.36	0.29	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
COAD	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-4.82	2.45e-06	0.00102	-0.3	-0.29	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
COAD	cis	rs453301	0.631	rs28572014	ENSG00000253981.4	ALG1L13P	-4.82	2.45e-06	0.00102	-0.35	-0.29	Joint mobility (Beighton score);	chr8:8936097	chr8:8236003~8244667:-
COAD	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-4.82	2.45e-06	0.00102	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	4.82	2.45e-06	0.00102	0.32	0.29	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
COAD	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-4.82	2.45e-06	0.00102	-0.39	-0.29	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
COAD	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	4.82	2.45e-06	0.00102	0.35	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
COAD	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-4.82	2.45e-06	0.00102	-0.35	-0.29	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
COAD	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-4.82	2.46e-06	0.00102	-0.35	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
COAD	cis	rs6840360	0.642	rs2709820	ENSG00000251611.1	RP11-610P16.1	-4.82	2.46e-06	0.00102	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151407551~151408835:-
COAD	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	4.82	2.46e-06	0.00102	0.39	0.29	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
COAD	cis	rs61270009	0.913	rs396676	ENSG00000247828.6	TMEM161B-AS1	-4.82	2.46e-06	0.00102	-0.3	-0.29	Depressive symptoms;	chr5:88220002	chr5:88268895~88436685:+
COAD	cis	rs875971	0.545	rs2279757	ENSG00000224316.1	RP11-479O9.2	4.82	2.46e-06	0.00102	0.37	0.29	Aortic root size;	chr7:66363676	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs11766183	ENSG00000224316.1	RP11-479O9.2	4.82	2.46e-06	0.00102	0.37	0.29	Aortic root size;	chr7:66374173	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs1065265	ENSG00000224316.1	RP11-479O9.2	4.82	2.46e-06	0.00102	0.37	0.29	Aortic root size;	chr7:66376216	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs7811204	ENSG00000224316.1	RP11-479O9.2	4.82	2.46e-06	0.00102	0.37	0.29	Aortic root size;	chr7:66387213	chr7:65773620~65802067:+
COAD	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	4.82	2.47e-06	0.00102	0.29	0.29	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
COAD	cis	rs12928939	0.911	rs12917983	ENSG00000260886.1	TAT-AS1	4.82	2.47e-06	0.00102	0.42	0.29	Post bronchodilator FEV1;	chr16:71801340	chr16:71565789~71578187:+
COAD	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-4.82	2.47e-06	0.00102	-0.5	-0.29	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
COAD	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-4.82	2.47e-06	0.00103	-0.26	-0.29	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
COAD	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-4.82	2.47e-06	0.00103	-0.33	-0.29	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
COAD	cis	rs5758511	0.68	rs58654759	ENSG00000237037.8	NDUFA6-AS1	-4.82	2.47e-06	0.00103	-0.35	-0.29	Birth weight;	chr22:42246570	chr22:42090931~42137742:+
COAD	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	4.82	2.47e-06	0.00103	0.35	0.29	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
COAD	cis	rs12497850	0.864	rs4513485	ENSG00000225399.4	RP11-3B7.1	4.82	2.47e-06	0.00103	0.33	0.29	Parkinson's disease;	chr3:49102533	chr3:49260085~49261316:+
COAD	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	4.82	2.47e-06	0.00103	0.47	0.29	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
COAD	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-4.82	2.48e-06	0.00103	-0.39	-0.29	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
COAD	cis	rs875971	0.545	rs6979636	ENSG00000224316.1	RP11-479O9.2	4.82	2.48e-06	0.00103	0.33	0.29	Aortic root size;	chr7:66276638	chr7:65773620~65802067:+
COAD	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-4.82	2.48e-06	0.00103	-0.41	-0.29	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
COAD	cis	rs2581828	0.659	rs4282053	ENSG00000280417.1	RP11-5O17.1	4.82	2.48e-06	0.00103	0.31	0.29	Crohn's disease;	chr3:53107949	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.659	rs9845352	ENSG00000280417.1	RP11-5O17.1	4.82	2.48e-06	0.00103	0.31	0.29	Crohn's disease;	chr3:53108205	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.659	rs9845484	ENSG00000280417.1	RP11-5O17.1	4.82	2.48e-06	0.00103	0.31	0.29	Crohn's disease;	chr3:53108240	chr3:53046166~53048122:+
COAD	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	4.82	2.49e-06	0.00103	0.33	0.29	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
COAD	cis	rs74233809	1	rs74233809	ENSG00000213277.3	MARCKSL1P1	4.82	2.49e-06	0.00103	0.59	0.29	Birth weight;	chr10:103154183	chr10:103175554~103176094:+
COAD	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	4.82	2.49e-06	0.00103	0.29	0.29	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	4.82	2.49e-06	0.00103	0.29	0.29	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	4.82	2.49e-06	0.00103	0.29	0.29	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
COAD	cis	rs9818758	0.607	rs35060561	ENSG00000225399.4	RP11-3B7.1	-4.82	2.49e-06	0.00103	-0.5	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:49260085~49261316:+
COAD	cis	rs8177876	0.554	rs56286107	ENSG00000261061.1	RP11-303E16.2	-4.82	2.49e-06	0.00103	-0.56	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81030770~81031485:+
COAD	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-4.82	2.49e-06	0.00103	-0.53	-0.29	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
COAD	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-4.82	2.49e-06	0.00103	-0.54	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
COAD	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-4.82	2.49e-06	0.00103	-0.33	-0.29	QT interval;	chr12:29303562	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-4.82	2.49e-06	0.00103	-0.33	-0.29	QT interval;	chr12:29306799	chr12:29280418~29317848:-
COAD	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	4.82	2.5e-06	0.00104	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
COAD	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	4.82	2.5e-06	0.00104	0.27	0.29	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
COAD	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-4.82	2.5e-06	0.00104	-0.38	-0.29	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
COAD	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	4.82	2.5e-06	0.00104	0.34	0.29	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
COAD	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	4.82	2.51e-06	0.00104	0.31	0.29	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
COAD	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	4.82	2.51e-06	0.00104	0.29	0.29	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	4.82	2.51e-06	0.00104	0.29	0.29	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	4.82	2.51e-06	0.00104	0.29	0.29	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	4.82	2.51e-06	0.00104	0.29	0.29	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
COAD	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	4.82	2.51e-06	0.00104	0.26	0.29	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
COAD	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	4.82	2.51e-06	0.00104	0.34	0.29	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	4.82	2.51e-06	0.00104	0.34	0.29	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
COAD	cis	rs11841001	0.73	rs11148997	ENSG00000261105.4	LMO7-AS1	-4.82	2.51e-06	0.00104	-0.63	-0.29	Corneal astigmatism;	chr13:75663722	chr13:75604700~75635994:-
COAD	cis	rs5742933	1	rs5743032	ENSG00000253559.1	OSGEPL1-AS1	-4.82	2.51e-06	0.00104	-0.33	-0.29	Ferritin levels;	chr2:189814077	chr2:189762704~189765556:+
COAD	cis	rs492146	0.935	rs375887	ENSG00000243236.5	GSTA9P	-4.81	2.52e-06	0.00104	-0.3	-0.29	Epilepsy (remission after treatment);	chr6:52978679	chr6:52939726~52957521:-
COAD	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-4.81	2.52e-06	0.00104	-0.24	-0.29	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
COAD	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-4.81	2.52e-06	0.00104	-0.34	-0.29	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
COAD	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	4.81	2.52e-06	0.00104	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
COAD	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	4.81	2.52e-06	0.00104	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
COAD	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.81	2.53e-06	0.00105	0.3	0.29	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
COAD	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-4.81	2.53e-06	0.00105	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
COAD	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	4.81	2.53e-06	0.00105	0.34	0.29	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
COAD	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-4.81	2.53e-06	0.00105	-0.34	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
COAD	cis	rs597539	0.652	rs513615	ENSG00000255741.1	RP11-757G1.5	-4.81	2.54e-06	0.00105	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68941503~68942852:-
COAD	cis	rs41307935	0.822	rs71636786	ENSG00000260063.1	RP5-968P14.2	-4.81	2.54e-06	0.00105	-0.58	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26851434	chr1:26692132~26694131:-
COAD	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	4.81	2.54e-06	0.00105	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
COAD	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-4.81	2.54e-06	0.00105	-0.3	-0.29	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
COAD	cis	rs6840360	0.642	rs6855845	ENSG00000251611.1	RP11-610P16.1	-4.81	2.54e-06	0.00105	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2034061	ENSG00000251611.1	RP11-610P16.1	-4.81	2.54e-06	0.00105	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151407551~151408835:-
COAD	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	4.81	2.54e-06	0.00105	0.36	0.29	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
COAD	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	4.81	2.54e-06	0.00105	0.38	0.29	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
COAD	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-4.81	2.54e-06	0.00105	-0.5	-0.29	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.81	2.55e-06	0.00105	0.35	0.29	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
COAD	cis	rs6543140	0.964	rs6736135	ENSG00000234389.1	AC007278.3	4.81	2.55e-06	0.00105	0.31	0.29	Blood protein levels;	chr2:102448464	chr2:102438713~102440475:+
COAD	cis	rs5015933	0.788	rs568409	ENSG00000232630.1	PRPS1P2	-4.81	2.55e-06	0.00105	-0.28	-0.29	Body mass index;	chr9:125309994	chr9:125150653~125151589:+
COAD	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-4.81	2.55e-06	0.00105	-0.33	-0.29	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
COAD	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-4.81	2.55e-06	0.00105	-0.51	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
COAD	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	4.81	2.55e-06	0.00105	0.28	0.29	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
COAD	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-4.81	2.55e-06	0.00105	-0.35	-0.29	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
COAD	cis	rs492146	0.967	rs400804	ENSG00000243236.5	GSTA9P	-4.81	2.55e-06	0.00105	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52972292	chr6:52939726~52957521:-
COAD	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-4.81	2.55e-06	0.00105	-0.36	-0.29	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
COAD	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	4.81	2.55e-06	0.00105	0.33	0.29	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
COAD	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-4.81	2.55e-06	0.00105	-0.31	-0.29	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
COAD	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-4.81	2.55e-06	0.00105	-0.31	-0.29	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
COAD	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-4.81	2.56e-06	0.00106	-0.34	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
COAD	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	4.81	2.56e-06	0.00106	0.65	0.29	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	4.81	2.56e-06	0.00106	0.65	0.29	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	4.81	2.56e-06	0.00106	0.65	0.29	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
COAD	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-4.81	2.56e-06	0.00106	-0.33	-0.29	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
COAD	cis	rs6584283	0.656	rs7080361	ENSG00000228778.1	RP11-129J12.1	-4.81	2.56e-06	0.00106	-0.32	-0.29	Ulcerative colitis;	chr10:99518015	chr10:99527081~99528261:+
COAD	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	4.81	2.57e-06	0.00106	0.31	0.29	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
COAD	cis	rs8002861	0.765	rs12868462	ENSG00000274001.1	RP11-5G9.5	-4.81	2.57e-06	0.00106	-0.27	-0.29	Leprosy;	chr13:43879344	chr13:43877715~43878163:-
COAD	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	4.81	2.57e-06	0.00106	0.22	0.29	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
COAD	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	4.81	2.57e-06	0.00106	0.32	0.29	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
COAD	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-4.81	2.57e-06	0.00106	-0.5	-0.29	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-4.81	2.57e-06	0.00106	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-4.81	2.57e-06	0.00106	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
COAD	cis	rs7615952	0.599	rs6438953	ENSG00000248787.1	RP11-666A20.4	-4.81	2.57e-06	0.00106	-0.36	-0.29	Blood pressure (smoking interaction);	chr3:126006108	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.599	rs1044215	ENSG00000248787.1	RP11-666A20.4	-4.81	2.57e-06	0.00106	-0.36	-0.29	Blood pressure (smoking interaction);	chr3:126006716	chr3:125908005~125910272:-
COAD	cis	rs12928939	0.911	rs12919271	ENSG00000260886.1	TAT-AS1	4.81	2.57e-06	0.00106	0.42	0.29	Post bronchodilator FEV1;	chr16:71758793	chr16:71565789~71578187:+
COAD	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	4.81	2.57e-06	0.00106	0.42	0.29	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
COAD	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-4.81	2.57e-06	0.00106	-0.35	-0.29	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
COAD	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-4.81	2.57e-06	0.00106	-0.27	-0.29	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-4.81	2.57e-06	0.00106	-0.27	-0.29	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
COAD	cis	rs61270009	0.955	rs6874182	ENSG00000247828.6	TMEM161B-AS1	4.81	2.57e-06	0.00106	0.3	0.29	Depressive symptoms;	chr5:88407268	chr5:88268895~88436685:+
COAD	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	4.81	2.57e-06	0.00106	0.36	0.29	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
COAD	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	4.81	2.57e-06	0.00106	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	4.81	2.57e-06	0.00106	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	4.81	2.57e-06	0.00106	0.33	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
COAD	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	4.81	2.57e-06	0.00106	0.3	0.29	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
COAD	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	4.81	2.58e-06	0.00106	0.63	0.29	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	4.81	2.58e-06	0.00106	0.63	0.29	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	4.81	2.58e-06	0.00106	0.63	0.29	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	4.81	2.58e-06	0.00106	0.63	0.29	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
COAD	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-4.81	2.58e-06	0.00106	-0.46	-0.29	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
COAD	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	4.81	2.58e-06	0.00106	0.29	0.29	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	4.81	2.58e-06	0.00106	0.29	0.29	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	4.81	2.58e-06	0.00106	0.29	0.29	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	4.81	2.58e-06	0.00106	0.29	0.29	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
COAD	cis	rs891378	0.785	rs6700846	ENSG00000274245.1	RP11-357P18.2	-4.81	2.58e-06	0.00107	-0.38	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228799	chr1:207372559~207373252:+
COAD	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-4.81	2.59e-06	0.00107	-0.35	-0.29	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
COAD	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
COAD	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	4.81	2.59e-06	0.00107	0.31	0.29	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
COAD	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	4.81	2.59e-06	0.00107	0.29	0.29	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
COAD	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.59e-06	0.00107	-0.49	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.59e-06	0.00107	-0.49	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
COAD	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	4.81	2.59e-06	0.00107	0.3	0.29	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	4.81	2.59e-06	0.00107	0.3	0.29	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	4.81	2.59e-06	0.00107	0.3	0.29	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
COAD	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-4.81	2.6e-06	0.00107	-0.51	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
COAD	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	4.81	2.6e-06	0.00107	0.37	0.29	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	4.81	2.6e-06	0.00107	0.37	0.29	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
COAD	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	4.81	2.6e-06	0.00107	0.3	0.29	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
COAD	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.81	2.6e-06	0.00107	0.33	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
COAD	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-4.81	2.6e-06	0.00107	-0.29	-0.29	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
COAD	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.81	2.6e-06	0.00107	0.33	0.29	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
COAD	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-4.81	2.6e-06	0.00107	-0.53	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
COAD	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-4.81	2.6e-06	0.00107	-0.33	-0.29	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
COAD	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	4.81	2.6e-06	0.00107	0.32	0.29	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
COAD	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	4.81	2.61e-06	0.00107	0.46	0.29	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
COAD	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-4.81	2.61e-06	0.00107	-0.26	-0.29	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
COAD	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-4.81	2.61e-06	0.00107	-0.26	-0.29	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
COAD	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	4.81	2.61e-06	0.00107	0.31	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
COAD	cis	rs17772222	1	rs17124700	ENSG00000258789.1	RP11-507K2.3	-4.81	2.61e-06	0.00108	-0.41	-0.29	Coronary artery calcification;	chr14:88439285	chr14:88551597~88552493:+
COAD	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-4.81	2.61e-06	0.00108	-0.37	-0.29	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	4.81	2.61e-06	0.00108	0.38	0.29	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
COAD	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-4.81	2.61e-06	0.00108	-0.39	-0.29	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
COAD	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-4.81	2.61e-06	0.00108	-0.34	-0.29	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
COAD	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-4.81	2.61e-06	0.00108	-0.33	-0.29	Height;	chr3:53034139	chr3:53064283~53065091:-
COAD	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-4.81	2.62e-06	0.00108	-0.51	-0.29	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
COAD	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	4.81	2.62e-06	0.00108	0.33	0.29	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
COAD	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	4.81	2.62e-06	0.00108	0.64	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
COAD	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-4.81	2.62e-06	0.00108	-0.49	-0.29	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
COAD	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-4.81	2.62e-06	0.00108	-0.41	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
COAD	cis	rs5758659	1	rs134882	ENSG00000182057.4	OGFRP1	4.81	2.62e-06	0.00108	0.31	0.29	Cognitive function;	chr22:42274959	chr22:42269753~42275196:+
COAD	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	4.81	2.62e-06	0.00108	0.31	0.29	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
COAD	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4.81	2.62e-06	0.00108	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.62e-06	0.00108	-0.27	-0.29	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
COAD	cis	rs72827839	0.846	rs72825517	ENSG00000263412.1	RP5-890E16.2	4.81	2.62e-06	0.00108	0.42	0.29	Ease of getting up in the morning;	chr17:48094462	chr17:48045141~48048073:-
COAD	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-4.81	2.63e-06	0.00108	-0.26	-0.29	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-4.81	2.63e-06	0.00108	-0.26	-0.29	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-4.81	2.63e-06	0.00108	-0.26	-0.29	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-4.81	2.63e-06	0.00108	-0.26	-0.29	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-4.81	2.63e-06	0.00108	-0.26	-0.29	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
COAD	cis	rs362272	0.524	rs3129334	ENSG00000248840.2	RP11-357G3.2	-4.81	2.63e-06	0.00108	-0.33	-0.29	Serum sulfate level;	chr4:3366799	chr4:3312512~3313058:+
COAD	cis	rs1387259	0.929	rs2634666	ENSG00000273765.1	RP11-370I10.11	4.81	2.63e-06	0.00108	0.32	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.839	rs7486941	ENSG00000226413.2	OR8T1P	-4.81	2.63e-06	0.00108	-0.33	-0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48442030~48442947:-
COAD	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	4.81	2.63e-06	0.00108	0.29	0.29	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
COAD	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	4.81	2.63e-06	0.00108	0.29	0.29	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	4.81	2.63e-06	0.00108	0.29	0.29	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
COAD	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-4.81	2.63e-06	0.00108	-0.3	-0.29	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
COAD	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-4.8	2.64e-06	0.00108	-0.34	-0.29	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
COAD	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-4.8	2.64e-06	0.00108	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
COAD	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	4.8	2.64e-06	0.00109	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	4.8	2.64e-06	0.00109	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	4.8	2.64e-06	0.00109	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	4.8	2.64e-06	0.00109	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
COAD	cis	rs5758511	0.68	rs5758687	ENSG00000237037.8	NDUFA6-AS1	-4.8	2.64e-06	0.00109	-0.34	-0.29	Birth weight;	chr22:42260582	chr22:42090931~42137742:+
COAD	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-4.8	2.64e-06	0.00109	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
COAD	cis	rs73198271	1	rs55971558	ENSG00000173295.6	FAM86B3P	-4.8	2.64e-06	0.00109	-0.4	-0.29	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr8:8228595~8244865:+
COAD	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	4.8	2.64e-06	0.00109	0.55	0.29	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
COAD	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	4.8	2.65e-06	0.00109	0.4	0.29	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
COAD	cis	rs1383484	0.606	rs9329364	ENSG00000259728.4	LINC00933	-4.8	2.65e-06	0.00109	-0.4	-0.29	Height;	chr15:83974490	chr15:84570649~84580175:+
COAD	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-4.8	2.65e-06	0.00109	-0.36	-0.29	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
COAD	cis	rs492146	0.967	rs387853	ENSG00000243236.5	GSTA9P	-4.8	2.65e-06	0.00109	-0.31	-0.29	Epilepsy (remission after treatment);	chr6:52975456	chr6:52939726~52957521:-
COAD	cis	rs73198271	0.653	rs10087633	ENSG00000173295.6	FAM86B3P	-4.8	2.65e-06	0.00109	-0.35	-0.29	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8228595~8244865:+
COAD	cis	rs1578862	0.966	rs17721193	ENSG00000259865.1	RP11-488L18.10	-4.8	2.65e-06	0.00109	-0.23	-0.29	Monocyte percentage of white cells;	chr1:247294552	chr1:247187281~247188526:-
COAD	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	4.8	2.65e-06	0.00109	0.33	0.29	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
COAD	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	4.8	2.65e-06	0.00109	0.3	0.29	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
COAD	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	4.8	2.66e-06	0.00109	0.35	0.29	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
COAD	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-4.8	2.66e-06	0.00109	-0.36	-0.29	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
COAD	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-4.8	2.66e-06	0.00109	-0.5	-0.29	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	4.8	2.66e-06	0.00109	0.5	0.29	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
COAD	cis	rs9393777	0.513	rs9393737	ENSG00000224843.5	LINC00240	-4.8	2.66e-06	0.00109	-0.48	-0.29	Intelligence (multi-trait analysis);	chr6:26617078	chr6:26956992~27023924:+
COAD	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	4.8	2.66e-06	0.00109	0.31	0.29	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
COAD	cis	rs7646881	0.504	rs67305172	ENSG00000272087.1	RP11-379F4.7	4.8	2.66e-06	0.00109	0.39	0.29	Tetralogy of Fallot;	chr3:158746485	chr3:158693120~158693768:-
COAD	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-4.8	2.66e-06	0.00109	-0.43	-0.29	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
COAD	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	4.8	2.66e-06	0.00109	0.38	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
COAD	cis	rs2281603	0.57	rs1470851	ENSG00000259116.1	RP11-973N13.4	-4.8	2.67e-06	0.0011	-0.28	-0.29	Lymphocyte counts;	chr14:64509402	chr14:64514154~64540368:-
COAD	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	4.8	2.67e-06	0.0011	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
COAD	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-4.8	2.67e-06	0.0011	-0.16	-0.29	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
COAD	cis	rs2581828	0.646	rs9867023	ENSG00000280417.1	RP11-5O17.1	-4.8	2.67e-06	0.0011	-0.31	-0.29	Crohn's disease;	chr3:53126116	chr3:53046166~53048122:+
COAD	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	4.8	2.67e-06	0.0011	0.37	0.29	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	4.8	2.67e-06	0.0011	0.37	0.29	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
COAD	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	4.8	2.67e-06	0.0011	0.47	0.29	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
COAD	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-4.8	2.67e-06	0.0011	-0.29	-0.29	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
COAD	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-4.8	2.67e-06	0.0011	-0.29	-0.29	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
COAD	cis	rs9659323	0.73	rs7512189	ENSG00000231365.4	RP11-418J17.1	-4.8	2.67e-06	0.0011	-0.31	-0.29	Body mass index;	chr1:118999909	chr1:119140396~119275973:+
COAD	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	4.8	2.67e-06	0.0011	0.27	0.29	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
COAD	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-4.8	2.67e-06	0.0011	-0.34	-0.29	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
COAD	cis	rs8177876	0.731	rs74878296	ENSG00000261061.1	RP11-303E16.2	-4.8	2.67e-06	0.0011	-0.56	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81030770~81031485:+
COAD	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	4.8	2.67e-06	0.0011	0.26	0.29	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
COAD	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	4.8	2.67e-06	0.0011	0.31	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
COAD	cis	rs7260598	0.642	rs10425299	ENSG00000268442.1	CTD-2027I19.2	4.8	2.67e-06	0.0011	0.41	0.29	Response to taxane treatment (placlitaxel);	chr19:23995757	chr19:24162370~24163425:-
COAD	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-4.8	2.67e-06	0.0011	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-4.8	2.67e-06	0.0011	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
COAD	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-4.8	2.68e-06	0.0011	-0.35	-0.29	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
COAD	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	4.8	2.68e-06	0.0011	0.46	0.29	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
COAD	cis	rs7646881	0.544	rs10154917	ENSG00000272087.1	RP11-379F4.7	4.8	2.68e-06	0.0011	0.45	0.29	Tetralogy of Fallot;	chr3:158614911	chr3:158693120~158693768:-
COAD	cis	rs34792	0.688	rs13339072	ENSG00000207425.1	Y_RNA	-4.8	2.68e-06	0.0011	-0.35	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:14915457~14915556:-
COAD	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	4.8	2.69e-06	0.0011	0.31	0.29	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
COAD	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	4.8	2.69e-06	0.0011	0.29	0.29	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
COAD	cis	rs9910055	0.529	rs228766	ENSG00000267080.4	ASB16-AS1	4.8	2.69e-06	0.0011	0.28	0.29	Total body bone mineral density;	chr17:44109445	chr17:44175973~44186717:-
COAD	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	4.8	2.69e-06	0.0011	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
COAD	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-4.8	2.69e-06	0.0011	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-4.8	2.69e-06	0.0011	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
COAD	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-4.8	2.69e-06	0.0011	-0.35	-0.29	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
COAD	cis	rs801193	1	rs3778909	ENSG00000272831.1	RP11-792A8.4	4.8	2.69e-06	0.0011	0.3	0.29	Aortic root size;	chr7:66790659	chr7:66739829~66740385:-
COAD	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	4.8	2.69e-06	0.0011	0.37	0.29	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
COAD	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	4.8	2.69e-06	0.0011	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	4.8	2.69e-06	0.0011	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	4.8	2.69e-06	0.0011	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	4.8	2.69e-06	0.0011	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
COAD	cis	rs9450351	0.744	rs9362247	ENSG00000203875.9	SNHG5	-4.8	2.69e-06	0.0011	-0.53	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6913958	ENSG00000203875.9	SNHG5	-4.8	2.69e-06	0.0011	-0.53	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85825481	chr6:85660950~85678736:-
COAD	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-4.8	2.69e-06	0.0011	-0.32	-0.29	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
COAD	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-4.8	2.69e-06	0.0011	-0.33	-0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
COAD	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	4.8	2.69e-06	0.0011	0.22	0.29	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
COAD	cis	rs5742933	0.817	rs6738042	ENSG00000253559.1	OSGEPL1-AS1	4.8	2.69e-06	0.0011	0.28	0.29	Ferritin levels;	chr2:189776958	chr2:189762704~189765556:+
COAD	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	4.8	2.7e-06	0.00111	0.46	0.29	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
COAD	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	4.8	2.7e-06	0.00111	0.34	0.29	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	4.8	2.7e-06	0.00111	0.34	0.29	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	4.8	2.7e-06	0.00111	0.34	0.29	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
COAD	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-4.8	2.71e-06	0.00111	-0.34	-0.29	Height;	chr3:52941053	chr3:53064283~53065091:-
COAD	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-4.8	2.71e-06	0.00111	-0.34	-0.29	Height;	chr3:52949886	chr3:53064283~53065091:-
COAD	cis	rs4568518	0.903	rs6957876	ENSG00000279048.1	RP11-511H23.2	-4.8	2.71e-06	0.00111	-0.2	-0.29	Measles;	chr7:18000641	chr7:17940503~17942922:+
COAD	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-4.8	2.71e-06	0.00111	-0.3	-0.29	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-4.8	2.71e-06	0.00111	-0.3	-0.29	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
COAD	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	4.8	2.71e-06	0.00111	0.39	0.29	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
COAD	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-4.8	2.71e-06	0.00111	-0.36	-0.29	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-4.8	2.71e-06	0.00111	-0.36	-0.29	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
COAD	cis	rs5758511	0.514	rs5751240	ENSG00000237037.8	NDUFA6-AS1	-4.8	2.71e-06	0.00111	-0.34	-0.29	Birth weight;	chr22:42199252	chr22:42090931~42137742:+
COAD	cis	rs77972916	0.561	rs13411629	ENSG00000234936.1	AC010883.5	4.8	2.72e-06	0.00111	0.42	0.29	Granulocyte percentage of myeloid white cells;	chr2:43339851	chr2:43229573~43233394:+
COAD	cis	rs6929812	0.577	rs2294309	ENSG00000271755.1	RP1-153G14.4	4.8	2.72e-06	0.00111	0.33	0.29	Neuroticism (multi-trait analysis);	chr6:27516037	chr6:27404010~27406964:-
COAD	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	4.8	2.72e-06	0.00111	0.35	0.29	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
COAD	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-4.8	2.72e-06	0.00111	-0.34	-0.29	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
COAD	cis	rs2581828	0.646	rs13433700	ENSG00000280417.1	RP11-5O17.1	4.8	2.72e-06	0.00111	0.31	0.29	Crohn's disease;	chr3:53113870	chr3:53046166~53048122:+
COAD	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-4.8	2.72e-06	0.00111	-0.36	-0.29	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
COAD	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	4.8	2.72e-06	0.00111	0.34	0.29	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
COAD	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	4.8	2.73e-06	0.00112	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
COAD	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	4.8	2.73e-06	0.00112	0.3	0.29	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
COAD	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	4.8	2.73e-06	0.00112	0.39	0.29	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
COAD	cis	rs7193541	0.965	rs7184423	ENSG00000262904.1	TMPOP2	-4.8	2.73e-06	0.00112	-0.31	-0.29	Multiple myeloma;	chr16:74675839	chr16:74667506~74668706:+
COAD	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-4.8	2.73e-06	0.00112	-0.34	-0.29	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
COAD	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-4.8	2.73e-06	0.00112	-0.34	-0.29	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
COAD	cis	rs11846409	0.86	rs1974470	ENSG00000274576.2	IGHV2-70	-4.8	2.73e-06	0.00112	-0.27	-0.29	Rheumatic heart disease;	chr14:106621300	chr14:106770577~106771020:-
COAD	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-4.8	2.73e-06	0.00112	-0.42	-0.29	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	4.8	2.73e-06	0.00112	0.42	0.29	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
COAD	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	4.8	2.73e-06	0.00112	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	4.8	2.73e-06	0.00112	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	4.8	2.73e-06	0.00112	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	4.8	2.73e-06	0.00112	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
COAD	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-4.8	2.73e-06	0.00112	-0.38	-0.29	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
COAD	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-4.8	2.73e-06	0.00112	-0.3	-0.29	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
COAD	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-4.8	2.73e-06	0.00112	-0.43	-0.29	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
COAD	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4.8	2.74e-06	0.00112	-0.33	-0.29	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
COAD	cis	rs2281603	0.57	rs2198347	ENSG00000259116.1	RP11-973N13.4	4.8	2.74e-06	0.00112	0.3	0.29	Lymphocyte counts;	chr14:64502624	chr14:64514154~64540368:-
COAD	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-4.8	2.74e-06	0.00112	-0.33	-0.29	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
COAD	cis	rs8002861	0.81	rs9533664	ENSG00000274001.1	RP11-5G9.5	4.8	2.74e-06	0.00112	0.25	0.29	Leprosy;	chr13:43866391	chr13:43877715~43878163:-
COAD	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	4.8	2.74e-06	0.00112	0.29	0.29	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
COAD	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-4.8	2.75e-06	0.00112	-0.36	-0.29	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
COAD	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-4.8	2.75e-06	0.00112	-0.36	-0.29	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
COAD	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-4.8	2.75e-06	0.00112	-0.39	-0.29	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
COAD	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	4.8	2.75e-06	0.00112	0.33	0.29	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
COAD	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	4.8	2.75e-06	0.00112	0.33	0.29	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
COAD	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	4.8	2.75e-06	0.00112	0.33	0.29	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
COAD	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	4.8	2.75e-06	0.00112	0.31	0.29	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
COAD	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	4.8	2.75e-06	0.00112	0.35	0.29	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
COAD	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.8	2.75e-06	0.00112	-0.5	-0.29	Gout;	chr7:66732812	chr7:66654538~66669855:+
COAD	cis	rs4950322	0.542	rs1932977	ENSG00000278811.3	LINC00624	4.8	2.75e-06	0.00112	0.28	0.29	Protein quantitative trait loci;	chr1:147217371	chr1:147258885~147517875:-
COAD	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	4.8	2.75e-06	0.00113	0.37	0.29	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
COAD	cis	rs6840360	0.642	rs7680013	ENSG00000251611.1	RP11-610P16.1	-4.8	2.75e-06	0.00113	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs7680236	ENSG00000251611.1	RP11-610P16.1	-4.8	2.75e-06	0.00113	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs4696092	ENSG00000251611.1	RP11-610P16.1	-4.8	2.75e-06	0.00113	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151407551~151408835:-
COAD	cis	rs728616	0.867	rs4633405	ENSG00000234382.2	RP11-40F6.1	-4.8	2.76e-06	0.00113	-0.53	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:80233664~80245367:+
COAD	cis	rs2732480	0.5	rs12828309	ENSG00000273765.1	RP11-370I10.11	4.79	2.76e-06	0.00113	0.31	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48360920~48361377:+
COAD	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-4.79	2.76e-06	0.00113	-0.36	-0.29	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
COAD	cis	rs5758511	0.773	rs7288749	ENSG00000237037.8	NDUFA6-AS1	-4.79	2.76e-06	0.00113	-0.32	-0.29	Birth weight;	chr22:41960426	chr22:42090931~42137742:+
COAD	cis	rs17772222	0.597	rs17700296	ENSG00000258789.1	RP11-507K2.3	-4.79	2.76e-06	0.00113	-0.44	-0.29	Coronary artery calcification;	chr14:88840976	chr14:88551597~88552493:+
COAD	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-4.79	2.76e-06	0.00113	-0.36	-0.29	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-4.79	2.76e-06	0.00113	-0.36	-0.29	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-4.79	2.76e-06	0.00113	-0.36	-0.29	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
COAD	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-4.79	2.76e-06	0.00113	-0.78	-0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
COAD	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	4.79	2.76e-06	0.00113	0.33	0.29	QT interval;	chr12:29292489	chr12:29280418~29317848:-
COAD	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	4.79	2.77e-06	0.00113	0.35	0.29	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
COAD	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-4.79	2.77e-06	0.00113	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
COAD	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-4.79	2.77e-06	0.00113	-0.35	-0.29	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
COAD	cis	rs7646881	0.544	rs7638606	ENSG00000272087.1	RP11-379F4.7	4.79	2.77e-06	0.00113	0.44	0.29	Tetralogy of Fallot;	chr3:158569050	chr3:158693120~158693768:-
COAD	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	4.79	2.77e-06	0.00113	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
COAD	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-4.79	2.77e-06	0.00113	-0.33	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
COAD	cis	rs4718428	0.96	rs6460317	ENSG00000273142.1	RP11-458F8.4	-4.79	2.77e-06	0.00113	-0.22	-0.29	Corneal structure;	chr7:66925268	chr7:66902857~66906297:+
COAD	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	4.79	2.78e-06	0.00113	0.34	0.29	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
COAD	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	4.79	2.78e-06	0.00114	0.22	0.29	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	4.79	2.78e-06	0.00114	0.22	0.29	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
COAD	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	4.79	2.78e-06	0.00114	0.3	0.29	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	4.79	2.78e-06	0.00114	0.3	0.29	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
COAD	cis	rs748404	0.601	rs502157	ENSG00000249839.1	AC011330.5	4.79	2.78e-06	0.00114	0.35	0.29	Lung cancer;	chr15:43236375	chr15:43663654~43684339:-
COAD	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	4.79	2.78e-06	0.00114	0.3	0.29	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
COAD	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-4.79	2.79e-06	0.00114	-0.36	-0.29	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
COAD	cis	rs4718428	0.705	rs4718430	ENSG00000272831.1	RP11-792A8.4	4.79	2.79e-06	0.00114	0.33	0.29	Corneal structure;	chr7:66967037	chr7:66739829~66740385:-
COAD	cis	rs7818688	0.697	rs2904889	ENSG00000253528.2	RP11-347C18.4	-4.79	2.79e-06	0.00114	-0.4	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94928370	chr8:94974573~94974853:-
COAD	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-4.79	2.79e-06	0.00114	-0.58	-0.29	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
COAD	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-4.79	2.8e-06	0.00114	-0.28	-0.29	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
COAD	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-4.79	2.8e-06	0.00114	-0.35	-0.29	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
COAD	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-4.79	2.8e-06	0.00114	-0.3	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
COAD	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	4.79	2.8e-06	0.00114	0.32	0.29	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
COAD	cis	rs754466	1	rs754466	ENSG00000204049.1	RP11-126H7.4	4.79	2.8e-06	0.00114	0.39	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77920676	chr10:77866875~77869610:+
COAD	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	4.79	2.8e-06	0.00114	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
COAD	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-4.79	2.81e-06	0.00114	-0.37	-0.29	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
COAD	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	4.79	2.81e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
COAD	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-4.79	2.81e-06	0.00115	-0.32	-0.29	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
COAD	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	4.79	2.81e-06	0.00115	0.35	0.29	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
COAD	cis	rs7829975	0.593	rs2921077	ENSG00000254340.1	RP11-10A14.3	4.79	2.81e-06	0.00115	0.33	0.29	Mood instability;	chr8:8446992	chr8:9141424~9145435:+
COAD	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-4.79	2.81e-06	0.00115	-0.35	-0.29	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
COAD	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	4.79	2.82e-06	0.00115	0.33	0.29	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
COAD	cis	rs7598759	0.548	rs11686485	ENSG00000223198.1	RNU2-22P	-4.79	2.82e-06	0.00115	-0.32	-0.29	Noise-induced hearing loss;	chr2:231495986	chr2:231501990~231502201:-
COAD	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	4.79	2.82e-06	0.00115	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
COAD	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	4.79	2.82e-06	0.00115	0.21	0.29	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	4.79	2.82e-06	0.00115	0.21	0.29	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
COAD	cis	rs2732480	0.5	rs12828309	ENSG00000257735.1	RP11-370I10.6	4.79	2.82e-06	0.00115	0.35	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48350945~48442411:+
COAD	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	4.79	2.82e-06	0.00115	0.17	0.29	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
COAD	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-4.79	2.82e-06	0.00115	-0.31	-0.29	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
COAD	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-4.79	2.83e-06	0.00115	-0.33	-0.29	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
COAD	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-4.79	2.83e-06	0.00115	-0.29	-0.29	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
COAD	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	4.79	2.83e-06	0.00115	0.29	0.29	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
COAD	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	4.79	2.83e-06	0.00115	0.41	0.29	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
COAD	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-4.79	2.83e-06	0.00115	-0.39	-0.29	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
COAD	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-4.79	2.83e-06	0.00115	-0.3	-0.29	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
COAD	cis	rs6840360	0.642	rs6843639	ENSG00000251611.1	RP11-610P16.1	-4.79	2.84e-06	0.00115	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs28666858	ENSG00000251611.1	RP11-610P16.1	-4.79	2.84e-06	0.00115	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151407551~151408835:-
COAD	cis	rs1383484	0.545	rs9329363	ENSG00000259728.4	LINC00933	-4.79	2.84e-06	0.00116	-0.4	-0.29	Height;	chr15:83974382	chr15:84570649~84580175:+
COAD	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	4.79	2.84e-06	0.00116	0.34	0.29	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
COAD	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-4.79	2.85e-06	0.00116	-0.33	-0.29	Height;	chr3:53064759	chr3:53064283~53065091:-
COAD	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-4.79	2.85e-06	0.00116	-0.33	-0.29	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
COAD	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	4.79	2.86e-06	0.00116	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
COAD	cis	rs5742933	0.948	rs62184286	ENSG00000253559.1	OSGEPL1-AS1	-4.79	2.86e-06	0.00116	-0.33	-0.29	Ferritin levels;	chr2:189812147	chr2:189762704~189765556:+
COAD	cis	rs8002861	0.905	rs12428350	ENSG00000274001.1	RP11-5G9.5	-4.79	2.86e-06	0.00116	-0.27	-0.29	Leprosy;	chr13:43872025	chr13:43877715~43878163:-
COAD	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	4.79	2.86e-06	0.00117	0.37	0.29	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
COAD	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.79	2.86e-06	0.00117	0.29	0.29	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
COAD	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	4.79	2.87e-06	0.00117	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
COAD	cis	rs2919009	0.664	rs2289337	ENSG00000271670.1	RP11-95I16.4	4.79	2.87e-06	0.00117	0.35	0.29	Obesity-related traits;	chr10:120889970	chr10:120879256~120880667:-
COAD	cis	rs801193	0.967	rs2707853	ENSG00000272831.1	RP11-792A8.4	4.79	2.87e-06	0.00117	0.31	0.29	Aortic root size;	chr7:66749023	chr7:66739829~66740385:-
COAD	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	4.79	2.87e-06	0.00117	0.49	0.29	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
COAD	cis	rs9487051	0.676	rs2222392	ENSG00000219700.1	PTCHD3P3	4.79	2.87e-06	0.00117	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109281100	chr6:109288571~109290503:-
COAD	cis	rs6840360	0.642	rs1596290	ENSG00000251611.1	RP11-610P16.1	-4.79	2.87e-06	0.00117	-0.27	-0.29	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151407551~151408835:-
COAD	cis	rs801193	1	rs4279493	ENSG00000272831.1	RP11-792A8.4	4.79	2.87e-06	0.00117	0.3	0.29	Aortic root size;	chr7:66761633	chr7:66739829~66740385:-
COAD	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-4.79	2.87e-06	0.00117	-0.32	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
COAD	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-4.79	2.87e-06	0.00117	-0.32	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
COAD	cis	rs453301	0.686	rs28482034	ENSG00000173295.6	FAM86B3P	-4.79	2.87e-06	0.00117	-0.34	-0.29	Joint mobility (Beighton score);	chr8:9012154	chr8:8228595~8244865:+
COAD	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	4.79	2.87e-06	0.00117	0.21	0.29	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
COAD	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-4.79	2.88e-06	0.00117	-0.37	-0.29	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
COAD	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-4.79	2.88e-06	0.00117	-0.37	-0.29	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
COAD	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	4.79	2.88e-06	0.00117	0.33	0.29	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
COAD	cis	rs801193	0.761	rs2659888	ENSG00000272831.1	RP11-792A8.4	4.79	2.88e-06	0.00117	0.3	0.29	Aortic root size;	chr7:66765184	chr7:66739829~66740385:-
COAD	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-4.79	2.88e-06	0.00117	-0.42	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
COAD	cis	rs3126085	0.515	rs10888484	ENSG00000237975.5	FLG-AS1	4.79	2.88e-06	0.00117	0.31	0.29	Atopic dermatitis;	chr1:152380038	chr1:152168125~152445456:+
COAD	cis	rs896854	0.967	rs1320164	ENSG00000253528.2	RP11-347C18.4	4.79	2.88e-06	0.00117	0.3	0.29	Type 2 diabetes;	chr8:94948539	chr8:94974573~94974853:-
COAD	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	4.79	2.88e-06	0.00117	0.35	0.29	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
COAD	cis	rs801193	1	rs1553609	ENSG00000272831.1	RP11-792A8.4	4.79	2.88e-06	0.00117	0.3	0.29	Aortic root size;	chr7:66732152	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs1553610	ENSG00000272831.1	RP11-792A8.4	4.79	2.88e-06	0.00117	0.3	0.29	Aortic root size;	chr7:66732246	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs2707845	ENSG00000272831.1	RP11-792A8.4	4.79	2.88e-06	0.00117	0.3	0.29	Aortic root size;	chr7:66733811	chr7:66739829~66740385:-
COAD	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	4.79	2.88e-06	0.00117	0.31	0.29	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
COAD	cis	rs2732480	0.5	rs2450986	ENSG00000273765.1	RP11-370I10.11	4.79	2.89e-06	0.00117	0.32	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.929	rs2956703	ENSG00000273765.1	RP11-370I10.11	4.79	2.89e-06	0.00117	0.32	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.931	rs1107654	ENSG00000273765.1	RP11-370I10.11	4.79	2.89e-06	0.00117	0.32	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48360920~48361377:+
COAD	cis	rs2439831	1	rs28628574	ENSG00000275601.1	AC011330.13	-4.78	2.89e-06	0.00117	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43509840	chr15:43642389~43643023:-
COAD	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-4.78	2.89e-06	0.00117	-0.36	-0.29	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
COAD	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	4.78	2.89e-06	0.00117	0.29	0.29	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
COAD	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-4.78	2.89e-06	0.00117	-0.39	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
COAD	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-4.78	2.89e-06	0.00117	-0.39	-0.29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
COAD	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.78	2.89e-06	0.00117	0.32	0.29	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
COAD	cis	rs896854	1	rs896854	ENSG00000253528.2	RP11-347C18.4	4.78	2.89e-06	0.00118	0.3	0.29	Type 2 diabetes;	chr8:94948283	chr8:94974573~94974853:-
COAD	cis	rs896854	0.902	rs896852	ENSG00000253528.2	RP11-347C18.4	4.78	2.89e-06	0.00118	0.3	0.29	Type 2 diabetes;	chr8:94948658	chr8:94974573~94974853:-
COAD	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	4.78	2.89e-06	0.00118	0.3	0.29	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
COAD	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-4.78	2.9e-06	0.00118	-0.29	-0.29	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
COAD	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	4.78	2.9e-06	0.00118	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
COAD	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-4.78	2.9e-06	0.00118	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-4.78	2.9e-06	0.00118	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
COAD	cis	rs55823223	0.564	rs936396	ENSG00000267801.1	RP11-552F3.9	4.78	2.9e-06	0.00118	0.4	0.29	Psoriasis;	chr17:75850748	chr17:75876372~75879546:+
COAD	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-4.78	2.9e-06	0.00118	-0.29	-0.29	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
COAD	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	4.78	2.9e-06	0.00118	0.3	0.29	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
COAD	cis	rs739496	0.615	rs3742001	ENSG00000257595.2	RP3-473L9.4	4.78	2.9e-06	0.00118	0.42	0.29	Platelet count;	chr12:111665344	chr12:111369282~111403310:+
COAD	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	4.78	2.9e-06	0.00118	0.35	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
COAD	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	4.78	2.9e-06	0.00118	0.3	0.29	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	4.78	2.9e-06	0.00118	0.3	0.29	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
COAD	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	4.78	2.9e-06	0.00118	0.3	0.29	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	4.78	2.9e-06	0.00118	0.3	0.29	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
COAD	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	4.78	2.9e-06	0.00118	0.25	0.29	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
COAD	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-4.78	2.9e-06	0.00118	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
COAD	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	4.78	2.9e-06	0.00118	0.42	0.29	Height;	chr4:57019797	chr4:56960927~56961373:-
COAD	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.78	2.91e-06	0.00118	-0.5	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
COAD	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	4.78	2.91e-06	0.00118	0.4	0.29	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
COAD	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-4.78	2.91e-06	0.00118	-0.31	-0.29	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
COAD	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-4.78	2.91e-06	0.00118	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
COAD	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-4.78	2.91e-06	0.00118	-0.32	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
COAD	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	4.78	2.91e-06	0.00118	0.62	0.29	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
COAD	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	4.78	2.92e-06	0.00118	0.39	0.29	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
COAD	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-4.78	2.92e-06	0.00118	-0.36	-0.29	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
COAD	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	4.78	2.92e-06	0.00118	0.35	0.29	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
COAD	cis	rs9487051	0.604	rs9320282	ENSG00000219700.1	PTCHD3P3	4.78	2.92e-06	0.00118	0.31	0.29	Reticulocyte fraction of red cells;	chr6:109298174	chr6:109288571~109290503:-
COAD	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-4.78	2.92e-06	0.00118	-0.36	-0.29	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
COAD	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	4.78	2.92e-06	0.00119	0.35	0.29	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
COAD	cis	rs2281603	0.57	rs11623457	ENSG00000259116.1	RP11-973N13.4	-4.78	2.93e-06	0.00119	-0.29	-0.29	Lymphocyte counts;	chr14:64491388	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs1980520	ENSG00000259116.1	RP11-973N13.4	-4.78	2.93e-06	0.00119	-0.29	-0.29	Lymphocyte counts;	chr14:64493128	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs1980519	ENSG00000259116.1	RP11-973N13.4	-4.78	2.93e-06	0.00119	-0.29	-0.29	Lymphocyte counts;	chr14:64493137	chr14:64514154~64540368:-
COAD	cis	rs597539	0.652	rs553875	ENSG00000255741.1	RP11-757G1.5	-4.78	2.93e-06	0.00119	-0.39	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68941503~68942852:-
COAD	cis	rs72827839	0.74	rs72823594	ENSG00000263412.1	RP5-890E16.2	4.78	2.93e-06	0.00119	0.44	0.29	Ease of getting up in the morning;	chr17:48046914	chr17:48045141~48048073:-
COAD	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-4.78	2.93e-06	0.00119	-0.27	-0.29	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
COAD	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-4.78	2.94e-06	0.00119	-0.53	-0.29	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
COAD	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	4.78	2.94e-06	0.00119	0.26	0.29	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
COAD	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	4.78	2.95e-06	0.00119	0.35	0.29	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	4.78	2.95e-06	0.00119	0.35	0.29	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
COAD	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	4.78	2.95e-06	0.0012	0.2	0.29	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
COAD	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	4.78	2.95e-06	0.0012	0.3	0.29	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	4.78	2.95e-06	0.0012	0.3	0.29	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
COAD	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	4.78	2.95e-06	0.0012	0.32	0.29	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
COAD	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-4.78	2.96e-06	0.0012	-0.34	-0.29	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
COAD	cis	rs801193	1	rs2659889	ENSG00000272831.1	RP11-792A8.4	4.78	2.96e-06	0.0012	0.31	0.29	Aortic root size;	chr7:66752125	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs3800812	ENSG00000272831.1	RP11-792A8.4	4.78	2.96e-06	0.0012	0.31	0.29	Aortic root size;	chr7:66758474	chr7:66739829~66740385:-
COAD	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-4.78	2.96e-06	0.0012	-0.31	-0.29	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
COAD	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-4.78	2.96e-06	0.0012	-0.36	-0.29	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
COAD	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-4.78	2.96e-06	0.0012	-0.54	-0.29	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-4.78	2.96e-06	0.0012	-0.54	-0.29	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-4.78	2.96e-06	0.0012	-0.54	-0.29	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
COAD	cis	rs6490294	0.799	rs2339941	ENSG00000257595.2	RP3-473L9.4	4.78	2.96e-06	0.0012	0.42	0.29	Mean platelet volume;	chr12:112052960	chr12:111369282~111403310:+
COAD	cis	rs73411413	0.608	rs7126170	ENSG00000233930.3	KRTAP5-AS1	-4.78	2.97e-06	0.0012	-0.37	-0.29	Myringotomy;	chr11:1518157	chr11:1571353~1599184:+
COAD	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	4.78	2.97e-06	0.0012	0.42	0.29	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
COAD	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	4.78	2.97e-06	0.0012	0.38	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
COAD	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	4.78	2.97e-06	0.0012	0.35	0.29	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
COAD	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-4.78	2.97e-06	0.0012	-0.35	-0.29	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
COAD	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-4.78	2.98e-06	0.00121	-0.33	-0.29	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-4.78	2.98e-06	0.00121	-0.33	-0.29	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-4.78	2.98e-06	0.00121	-0.33	-0.29	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
COAD	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-4.78	2.98e-06	0.00121	-0.31	-0.29	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
COAD	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-4.78	2.98e-06	0.00121	-0.43	-0.29	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
COAD	cis	rs6095360	0.674	rs7269912	ENSG00000222365.1	SNORD12B	-4.78	2.98e-06	0.00121	-0.3	-0.29	Intelligence (multi-trait analysis);	chr20:49039661	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.7	rs13042443	ENSG00000222365.1	SNORD12B	-4.78	2.98e-06	0.00121	-0.3	-0.29	Intelligence (multi-trait analysis);	chr20:49047217	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-4.78	2.98e-06	0.00121	-0.3	-0.29	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-4.78	2.98e-06	0.00121	-0.3	-0.29	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs2227946	ENSG00000222365.1	SNORD12B	-4.78	2.98e-06	0.00121	-0.3	-0.29	Intelligence (multi-trait analysis);	chr20:49068783	chr20:49280319~49280409:+
COAD	cis	rs492146	0.729	rs426013	ENSG00000243236.5	GSTA9P	-4.78	2.98e-06	0.00121	-0.32	-0.29	Epilepsy (remission after treatment);	chr6:52975947	chr6:52939726~52957521:-
COAD	cis	rs492146	0.756	rs374275	ENSG00000243236.5	GSTA9P	-4.78	2.98e-06	0.00121	-0.32	-0.29	Epilepsy (remission after treatment);	chr6:52975999	chr6:52939726~52957521:-
COAD	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-4.78	2.99e-06	0.00121	-0.32	-0.29	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
COAD	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-4.78	2.99e-06	0.00121	-0.33	-0.29	Height;	chr3:52977358	chr3:53064283~53065091:-
COAD	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-4.78	2.99e-06	0.00121	-0.34	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-4.78	2.99e-06	0.00121	-0.16	-0.29	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-4.78	2.99e-06	0.00121	-0.16	-0.29	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
COAD	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	4.78	2.99e-06	0.00121	0.4	0.29	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
COAD	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-4.78	2.99e-06	0.00121	-0.34	-0.29	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
COAD	cis	rs4704187	0.617	rs12656177	ENSG00000250889.2	LINC01336	-4.78	2.99e-06	0.00121	-0.32	-0.29	Response to amphetamines;	chr5:75058597	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.617	rs7356697	ENSG00000250889.2	LINC01336	-4.78	2.99e-06	0.00121	-0.32	-0.29	Response to amphetamines;	chr5:75058717	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.64	rs7707246	ENSG00000250889.2	LINC01336	-4.78	2.99e-06	0.00121	-0.32	-0.29	Response to amphetamines;	chr5:75059050	chr5:75047719~75052843:-
COAD	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.78	2.99e-06	0.00121	-0.32	-0.29	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
COAD	cis	rs728616	0.717	rs61860016	ENSG00000225484.5	NUTM2B-AS1	-4.78	2.99e-06	0.00121	-0.52	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79663088~79826594:-
COAD	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-4.78	3e-06	0.00121	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
COAD	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	4.78	3e-06	0.00121	0.3	0.29	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	4.78	3e-06	0.00121	0.3	0.29	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
COAD	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-4.78	3e-06	0.00121	-0.33	-0.29	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
COAD	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-4.78	3e-06	0.00121	-0.16	-0.29	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-4.78	3e-06	0.00121	-0.16	-0.29	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-4.78	3e-06	0.00121	-0.16	-0.29	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
COAD	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-4.78	3e-06	0.00121	-0.35	-0.29	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
COAD	cis	rs11668609	0.81	rs17000162	ENSG00000268442.1	CTD-2027I19.2	4.78	3e-06	0.00121	0.39	0.29	Response to taxane treatment (docetaxel);	chr19:24185347	chr19:24162370~24163425:-
COAD	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-4.78	3e-06	0.00121	-0.33	-0.29	QT interval;	chr12:29310155	chr12:29280418~29317848:-
COAD	cis	rs7818688	0.653	rs11783522	ENSG00000253528.2	RP11-347C18.4	-4.78	3e-06	0.00121	-0.41	-0.29	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94874396	chr8:94974573~94974853:-
COAD	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	4.78	3e-06	0.00121	0.28	0.29	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
COAD	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	4.78	3e-06	0.00121	0.32	0.29	Height;	chr4:55363436	chr4:55363971~55395847:-
COAD	cis	rs17772222	1	rs74071851	ENSG00000258789.1	RP11-507K2.3	-4.78	3.01e-06	0.00121	-0.41	-0.29	Coronary artery calcification;	chr14:88415858	chr14:88551597~88552493:+
COAD	cis	rs891378	0.675	rs7543002	ENSG00000274245.1	RP11-357P18.2	-4.78	3.01e-06	0.00122	-0.37	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205496	chr1:207372559~207373252:+
COAD	cis	rs891378	0.785	rs7554219	ENSG00000274245.1	RP11-357P18.2	-4.78	3.01e-06	0.00122	-0.37	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205712	chr1:207372559~207373252:+
COAD	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-4.78	3.01e-06	0.00122	-0.51	-0.29	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
COAD	cis	rs6921919	0.697	rs12180820	ENSG00000272009.1	RP1-313I6.12	-4.78	3.01e-06	0.00122	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28078792~28081130:-
COAD	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-4.78	3.02e-06	0.00122	-0.42	-0.29	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
COAD	cis	rs4704187	0.687	rs1363579	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75214528	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.649	rs1422701	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75214692	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs2216638	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75217162	chr5:75047719~75052843:-
COAD	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.78	3.02e-06	0.00122	0.52	0.29	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
COAD	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	4.78	3.02e-06	0.00122	0.31	0.29	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
COAD	cis	rs2732480	0.5	rs1387257	ENSG00000273765.1	RP11-370I10.11	4.78	3.02e-06	0.00122	0.31	0.29	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48360920~48361377:+
COAD	cis	rs6095360	0.727	rs7274221	ENSG00000222365.1	SNORD12B	-4.78	3.02e-06	0.00122	-0.31	-0.29	Intelligence (multi-trait analysis);	chr20:49006961	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs35752040	ENSG00000222365.1	SNORD12B	-4.78	3.02e-06	0.00122	-0.31	-0.29	Intelligence (multi-trait analysis);	chr20:49008063	chr20:49280319~49280409:+
COAD	cis	rs4704187	0.687	rs6453123	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75223224	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs2112874	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75229340	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10064409	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75231309	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs11957125	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75231814	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4627970	ENSG00000250889.2	LINC01336	-4.78	3.02e-06	0.00122	-0.32	-0.29	Response to amphetamines;	chr5:75232951	chr5:75047719~75052843:-
COAD	cis	rs7138300	0.51	rs4620810	ENSG00000258053.1	CTD-2021H9.3	-4.78	3.02e-06	0.00122	-0.38	-0.29	Type 2 diabetes;	chr12:71095667	chr12:71047402~71118247:-
COAD	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	4.77	3.02e-06	0.00122	0.35	0.29	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	4.77	3.02e-06	0.00122	0.35	0.29	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
COAD	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-4.77	3.02e-06	0.00122	-0.35	-0.29	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-4.77	3.02e-06	0.00122	-0.35	-0.29	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-4.77	3.02e-06	0.00122	-0.35	-0.29	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-4.77	3.02e-06	0.00122	-0.35	-0.29	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
COAD	cis	rs9549328	0.67	rs2873372	ENSG00000267868.1	RP11-120K24.3	4.77	3.02e-06	0.00122	0.36	0.29	Systolic blood pressure;	chr13:112959069	chr13:112964835~112966131:-
COAD	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	4.77	3.02e-06	0.00122	0.35	0.29	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
COAD	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-4.77	3.02e-06	0.00122	-0.35	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
COAD	cis	rs896854	1	rs13255935	ENSG00000253528.2	RP11-347C18.4	4.77	3.03e-06	0.00122	0.3	0.29	Type 2 diabetes;	chr8:94953457	chr8:94974573~94974853:-
COAD	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-4.77	3.03e-06	0.00122	-0.31	-0.29	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
COAD	cis	rs7260598	0.606	rs72483177	ENSG00000268442.1	CTD-2027I19.2	4.77	3.03e-06	0.00122	0.41	0.29	Response to taxane treatment (placlitaxel);	chr19:23970913	chr19:24162370~24163425:-
COAD	cis	rs6095360	0.727	rs17450430	ENSG00000222365.1	SNORD12B	-4.77	3.03e-06	0.00122	-0.31	-0.29	Intelligence (multi-trait analysis);	chr20:49155727	chr20:49280319~49280409:+
COAD	cis	rs72827839	0.793	rs72825512	ENSG00000263412.1	RP5-890E16.2	4.77	3.03e-06	0.00122	0.42	0.29	Ease of getting up in the morning;	chr17:48077707	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.841	rs16952265	ENSG00000263412.1	RP5-890E16.2	4.77	3.03e-06	0.00122	0.42	0.29	Ease of getting up in the morning;	chr17:48107521	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.894	rs112306902	ENSG00000263412.1	RP5-890E16.2	4.77	3.03e-06	0.00122	0.42	0.29	Ease of getting up in the morning;	chr17:48113670	chr17:48045141~48048073:-
COAD	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	4.77	3.03e-06	0.00122	0.31	0.29	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
COAD	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-4.77	3.03e-06	0.00122	-0.49	-0.29	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
COAD	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-4.77	3.03e-06	0.00122	-0.35	-0.29	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
COAD	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-4.77	3.03e-06	0.00122	-0.33	-0.29	Height;	chr3:52967831	chr3:53064283~53065091:-
COAD	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	4.77	3.04e-06	0.00123	0.3	0.29	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	4.77	3.04e-06	0.00123	0.3	0.29	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
COAD	cis	rs1056107	0.806	rs3843823	ENSG00000225513.1	RP11-165N19.2	-4.77	3.04e-06	0.00123	-0.34	-0.29	Colorectal cancer;	chr9:112262691	chr9:112173522~112173971:-
COAD	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	4.77	3.04e-06	0.00123	0.3	0.29	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	4.77	3.04e-06	0.00123	0.3	0.29	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
COAD	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-4.77	3.04e-06	0.00123	-0.36	-0.29	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-4.77	3.04e-06	0.00123	-0.36	-0.29	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-4.77	3.04e-06	0.00123	-0.36	-0.29	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
COAD	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-4.77	3.04e-06	0.00123	-0.24	-0.29	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
COAD	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-4.77	3.04e-06	0.00123	-0.38	-0.29	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	4.77	3.04e-06	0.00123	0.55	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
COAD	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-4.77	3.04e-06	0.00123	-0.32	-0.29	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
COAD	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-4.77	3.05e-06	0.00123	-0.35	-0.29	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-4.77	3.05e-06	0.00123	-0.35	-0.29	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
COAD	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-4.77	3.05e-06	0.00123	-0.4	-0.29	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
COAD	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-4.77	3.05e-06	0.00123	-0.4	-0.29	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
COAD	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-4.77	3.05e-06	0.00123	-0.64	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
COAD	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	4.77	3.05e-06	0.00123	0.29	0.29	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
COAD	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	4.77	3.06e-06	0.00123	0.42	0.29	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
COAD	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-4.77	3.06e-06	0.00123	-0.41	-0.29	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
COAD	cis	rs1900504	0.537	rs4751997	ENSG00000266200.5	PNLIPRP2	4.77	3.07e-06	0.00124	0.43	0.29	Tonsillectomy;	chr10:116641715	chr10:116620953~116645143:+
COAD	cis	rs801193	1	rs2707850	ENSG00000272831.1	RP11-792A8.4	4.77	3.07e-06	0.00124	0.3	0.29	Aortic root size;	chr7:66738883	chr7:66739829~66740385:-
COAD	cis	rs801193	0.967	rs1110414	ENSG00000272831.1	RP11-792A8.4	4.77	3.07e-06	0.00124	0.3	0.29	Aortic root size;	chr7:66740595	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs7783924	ENSG00000272831.1	RP11-792A8.4	4.77	3.07e-06	0.00124	0.3	0.29	Aortic root size;	chr7:66744070	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs7789184	ENSG00000272831.1	RP11-792A8.4	4.77	3.07e-06	0.00124	0.3	0.29	Aortic root size;	chr7:66745208	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs2707854	ENSG00000272831.1	RP11-792A8.4	4.77	3.07e-06	0.00124	0.3	0.29	Aortic root size;	chr7:66747610	chr7:66739829~66740385:-
COAD	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-4.77	3.07e-06	0.00124	-0.34	-0.29	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-4.77	3.07e-06	0.00124	-0.34	-0.29	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-4.77	3.07e-06	0.00124	-0.34	-0.29	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-4.77	3.07e-06	0.00124	-0.34	-0.29	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-4.77	3.07e-06	0.00124	-0.34	-0.29	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
COAD	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	4.77	3.08e-06	0.00124	0.38	0.29	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
COAD	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	4.77	3.08e-06	0.00124	0.28	0.29	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
COAD	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	4.77	3.08e-06	0.00124	0.29	0.29	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
COAD	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	4.77	3.08e-06	0.00124	0.29	0.29	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
COAD	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	4.77	3.08e-06	0.00124	0.29	0.29	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	4.77	3.08e-06	0.00124	0.29	0.29	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
COAD	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	4.77	3.08e-06	0.00124	0.37	0.29	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
COAD	cis	rs733592	0.965	rs1978161	ENSG00000273765.1	RP11-370I10.11	-4.77	3.08e-06	0.00124	-0.29	-0.29	Plateletcrit;	chr12:48073938	chr12:48360920~48361377:+
COAD	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-4.77	3.08e-06	0.00124	-0.41	-0.29	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
COAD	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-4.77	3.08e-06	0.00124	-0.43	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
COAD	cis	rs8002861	0.87	rs9567293	ENSG00000274001.1	RP11-5G9.5	4.77	3.08e-06	0.00124	0.25	0.29	Leprosy;	chr13:43873107	chr13:43877715~43878163:-
COAD	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	4.77	3.09e-06	0.00124	0.6	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
COAD	cis	rs7955901	0.775	rs11178646	ENSG00000258053.1	CTD-2021H9.3	4.77	3.09e-06	0.00124	0.34	0.29	Type 2 diabetes;	chr12:71135116	chr12:71047402~71118247:-
COAD	cis	rs7138300	0.532	rs12833368	ENSG00000258053.1	CTD-2021H9.3	4.77	3.09e-06	0.00124	0.34	0.29	Type 2 diabetes;	chr12:71135221	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs67877703	ENSG00000258053.1	CTD-2021H9.3	4.77	3.09e-06	0.00124	0.34	0.29	Type 2 diabetes;	chr12:71135566	chr12:71047402~71118247:-
COAD	cis	rs7615952	0.599	rs66532274	ENSG00000248787.1	RP11-666A20.4	-4.77	3.09e-06	0.00124	-0.35	-0.29	Blood pressure (smoking interaction);	chr3:126013002	chr3:125908005~125910272:-
COAD	cis	rs13256369	0.826	rs12678414	ENSG00000173295.6	FAM86B3P	4.77	3.09e-06	0.00124	0.39	0.29	Obesity-related traits;	chr8:8728506	chr8:8228595~8244865:+
COAD	cis	rs9910055	0.529	rs368328	ENSG00000267080.4	ASB16-AS1	4.77	3.09e-06	0.00124	0.27	0.29	Total body bone mineral density;	chr17:44092921	chr17:44175973~44186717:-
COAD	cis	rs875971	0.545	rs1796226	ENSG00000224316.1	RP11-479O9.2	4.77	3.09e-06	0.00124	0.35	0.29	Aortic root size;	chr7:66622723	chr7:65773620~65802067:+
COAD	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	4.77	3.09e-06	0.00124	0.29	0.29	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
COAD	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-4.77	3.09e-06	0.00124	-0.32	-0.29	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
COAD	cis	rs853679	0.527	rs853683	ENSG00000272009.1	RP1-313I6.12	4.77	3.09e-06	0.00124	0.33	0.29	Depression;	chr6:28327262	chr6:28078792~28081130:-
COAD	cis	rs739496	0.579	rs6489818	ENSG00000257595.2	RP3-473L9.4	4.77	3.09e-06	0.00124	0.41	0.29	Platelet count;	chr12:111872776	chr12:111369282~111403310:+
COAD	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-4.77	3.1e-06	0.00125	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-4.77	3.1e-06	0.00125	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
COAD	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	4.77	3.1e-06	0.00125	0.32	0.29	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
COAD	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-4.77	3.1e-06	0.00125	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
COAD	cis	rs801193	1	rs2707856	ENSG00000272831.1	RP11-792A8.4	4.77	3.1e-06	0.00125	0.3	0.29	Aortic root size;	chr7:66746023	chr7:66739829~66740385:-
COAD	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	4.77	3.1e-06	0.00125	0.26	0.29	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
COAD	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-4.77	3.1e-06	0.00125	-0.34	-0.29	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
COAD	cis	rs9910055	0.529	rs408282	ENSG00000267080.4	ASB16-AS1	4.77	3.1e-06	0.00125	0.28	0.29	Total body bone mineral density;	chr17:44104899	chr17:44175973~44186717:-
COAD	cis	rs8002861	0.905	rs11617551	ENSG00000274001.1	RP11-5G9.5	-4.77	3.1e-06	0.00125	-0.26	-0.29	Leprosy;	chr13:43869841	chr13:43877715~43878163:-
COAD	cis	rs7560272	0.538	rs17350056	ENSG00000163016.8	ALMS1P	-4.77	3.1e-06	0.00125	-0.34	-0.29	Schizophrenia;	chr2:73695750	chr2:73644919~73685576:+
COAD	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	4.77	3.1e-06	0.00125	0.29	0.29	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
COAD	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	4.77	3.11e-06	0.00125	0.34	0.29	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
COAD	cis	rs7772486	0.558	rs2142980	ENSG00000235652.6	RP11-545I5.3	-4.77	3.11e-06	0.00125	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145759543	chr6:145799409~145886585:+
COAD	cis	rs728616	0.867	rs1054054	ENSG00000225484.5	NUTM2B-AS1	-4.77	3.11e-06	0.00125	-0.52	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61859766	ENSG00000225484.5	NUTM2B-AS1	-4.77	3.11e-06	0.00125	-0.52	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79663088~79826594:-
COAD	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-4.77	3.11e-06	0.00125	-0.3	-0.29	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
COAD	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	4.77	3.11e-06	0.00125	0.32	0.29	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
COAD	cis	rs362272	0.524	rs10937924	ENSG00000248840.2	RP11-357G3.2	-4.77	3.11e-06	0.00125	-0.32	-0.29	Serum sulfate level;	chr4:3373171	chr4:3312512~3313058:+
COAD	cis	rs2378497	1	rs2378497	ENSG00000232679.1	RP11-400N13.3	4.77	3.11e-06	0.00125	0.39	0.29	Serum thyroid-stimulating hormone levels;	chr1:222021660	chr1:222041705~222064763:-
COAD	cis	rs2378497	1	rs55756813	ENSG00000232679.1	RP11-400N13.3	4.77	3.11e-06	0.00125	0.39	0.29	Serum thyroid-stimulating hormone levels;	chr1:222021677	chr1:222041705~222064763:-
COAD	cis	rs9818758	0.556	rs9814987	ENSG00000225399.4	RP11-3B7.1	-4.77	3.12e-06	0.00125	-0.49	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:49260085~49261316:+
COAD	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	4.77	3.12e-06	0.00125	0.39	0.29	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	4.77	3.12e-06	0.00125	0.39	0.29	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
COAD	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-4.77	3.12e-06	0.00125	-0.27	-0.29	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
COAD	cis	rs1914816	0.941	rs2469544	ENSG00000196274.5	Metazoa_SRP	4.77	3.12e-06	0.00125	0.32	0.29	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76230048~76230390:-
COAD	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-4.77	3.12e-06	0.00125	-0.33	-0.29	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-4.77	3.12e-06	0.00125	-0.33	-0.29	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-4.77	3.12e-06	0.00125	-0.33	-0.29	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
COAD	cis	rs9659323	1	rs6680737	ENSG00000231365.4	RP11-418J17.1	-4.77	3.13e-06	0.00126	-0.32	-0.29	Body mass index;	chr1:118979008	chr1:119140396~119275973:+
COAD	cis	rs202072	0.72	rs1550526	ENSG00000272379.1	RP1-257A7.5	4.77	3.13e-06	0.00126	0.47	0.29	HIV-1 viral setpoint;	chr6:13295283	chr6:13290018~13290490:-
COAD	cis	rs9309473	0.5	rs12997018	ENSG00000163016.8	ALMS1P	-4.77	3.13e-06	0.00126	-0.34	-0.29	Metabolite levels;	chr2:73685772	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.5	rs7608328	ENSG00000163016.8	ALMS1P	-4.77	3.13e-06	0.00126	-0.34	-0.29	Metabolite levels;	chr2:73686892	chr2:73644919~73685576:+
COAD	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	4.77	3.13e-06	0.00126	0.33	0.29	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
COAD	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.77	3.13e-06	0.00126	-0.29	-0.29	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
COAD	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-4.77	3.14e-06	0.00126	-0.33	-0.29	QT interval;	chr12:29287150	chr12:29280418~29317848:-
COAD	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-4.77	3.14e-06	0.00126	-0.37	-0.29	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
COAD	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	4.77	3.14e-06	0.00126	0.34	0.28	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
COAD	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	4.77	3.14e-06	0.00126	0.25	0.28	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
COAD	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	4.77	3.14e-06	0.00126	0.32	0.28	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	4.77	3.14e-06	0.00126	0.32	0.28	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	4.77	3.14e-06	0.00126	0.32	0.28	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
COAD	cis	rs3752645	1	rs3752645	ENSG00000241764.3	AC002467.7	4.77	3.14e-06	0.00126	0.44	0.28	Bladder cancer (smoking interaction);	chr7:107142238	chr7:107742817~107744581:-
COAD	cis	rs6840360	0.692	rs1838043	ENSG00000270265.1	RP11-731D1.4	-4.77	3.14e-06	0.00126	-0.35	-0.28	Intelligence (multi-trait analysis);	chr4:151490310	chr4:151333775~151353224:-
COAD	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	4.77	3.14e-06	0.00126	0.31	0.28	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
COAD	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	4.77	3.14e-06	0.00126	0.28	0.28	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
COAD	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-4.77	3.15e-06	0.00126	-0.3	-0.28	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
COAD	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-4.77	3.15e-06	0.00126	-0.58	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-4.77	3.15e-06	0.00126	-0.58	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-4.77	3.15e-06	0.00126	-0.58	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-4.77	3.15e-06	0.00126	-0.58	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-4.77	3.15e-06	0.00126	-0.58	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
COAD	cis	rs492146	0.819	rs677636	ENSG00000243236.5	GSTA9P	-4.77	3.15e-06	0.00126	-0.31	-0.28	Epilepsy (remission after treatment);	chr6:52972509	chr6:52939726~52957521:-
COAD	cis	rs492146	0.819	rs584124	ENSG00000243236.5	GSTA9P	-4.77	3.15e-06	0.00126	-0.31	-0.28	Epilepsy (remission after treatment);	chr6:52973398	chr6:52939726~52957521:-
COAD	cis	rs6543140	0.964	rs10200081	ENSG00000234389.1	AC007278.3	4.77	3.15e-06	0.00126	0.3	0.28	Blood protein levels;	chr2:102475097	chr2:102438713~102440475:+
COAD	cis	rs9450351	0.546	rs9344550	ENSG00000203875.9	SNHG5	-4.77	3.15e-06	0.00126	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85829000	chr6:85660950~85678736:-
COAD	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-4.77	3.15e-06	0.00127	-0.29	-0.28	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
COAD	cis	rs5742933	0.681	rs4525728	ENSG00000253559.1	OSGEPL1-AS1	4.77	3.16e-06	0.00127	0.28	0.28	Ferritin levels;	chr2:189780324	chr2:189762704~189765556:+
COAD	cis	rs9487051	0.714	rs7757347	ENSG00000219700.1	PTCHD3P3	4.77	3.16e-06	0.00127	0.31	0.28	Reticulocyte fraction of red cells;	chr6:109312612	chr6:109288571~109290503:-
COAD	cis	rs8002861	0.905	rs12874535	ENSG00000274001.1	RP11-5G9.5	-4.77	3.16e-06	0.00127	-0.26	-0.28	Leprosy;	chr13:43859429	chr13:43877715~43878163:-
COAD	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	4.77	3.16e-06	0.00127	0.32	0.28	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
COAD	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-4.77	3.16e-06	0.00127	-0.29	-0.28	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
COAD	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-4.76	3.16e-06	0.00127	-0.39	-0.28	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
COAD	cis	rs728616	0.867	rs61860039	ENSG00000234382.2	RP11-40F6.1	-4.76	3.17e-06	0.00127	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860041	ENSG00000234382.2	RP11-40F6.1	-4.76	3.17e-06	0.00127	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860042	ENSG00000234382.2	RP11-40F6.1	-4.76	3.17e-06	0.00127	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs12415870	ENSG00000234382.2	RP11-40F6.1	-4.76	3.17e-06	0.00127	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:80233664~80245367:+
COAD	cis	rs73198271	0.653	rs10087742	ENSG00000173295.6	FAM86B3P	-4.76	3.17e-06	0.00127	-0.35	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8228595~8244865:+
COAD	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	4.76	3.17e-06	0.00127	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	4.76	3.17e-06	0.00127	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
COAD	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	4.76	3.17e-06	0.00127	0.29	0.28	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
COAD	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-4.76	3.17e-06	0.00127	-0.28	-0.28	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
COAD	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-4.76	3.17e-06	0.00127	-0.28	-0.28	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
COAD	cis	rs7584330	0.554	rs880931	ENSG00000234949.2	AC104667.3	-4.76	3.17e-06	0.00127	-0.5	-0.28	Prostate cancer;	chr2:237488098	chr2:237591020~237595981:+
COAD	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-4.76	3.17e-06	0.00127	-0.36	-0.28	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
COAD	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-4.76	3.17e-06	0.00127	-0.32	-0.28	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
COAD	cis	rs12497850	0.931	rs9840050	ENSG00000225399.4	RP11-3B7.1	4.76	3.18e-06	0.00127	0.32	0.28	Parkinson's disease;	chr3:49095877	chr3:49260085~49261316:+
COAD	cis	rs7714670	1	rs13172686	ENSG00000184084.7	CTD-2372A4.1	-4.76	3.18e-06	0.00127	-0.3	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr5:73777599	chr5:73803296~73803599:-
COAD	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.18e-06	0.00127	-0.31	-0.28	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
COAD	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	4.76	3.18e-06	0.00128	0.35	0.28	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
COAD	cis	rs9847710	0.838	rs12635298	ENSG00000242142.1	SERBP1P3	4.76	3.18e-06	0.00128	0.35	0.28	Ulcerative colitis;	chr3:52999780	chr3:53064283~53065091:-
COAD	cis	rs494562	0.667	rs9450263	ENSG00000234155.1	RP11-30P6.6	-4.76	3.19e-06	0.00128	-0.54	-0.28	Metabolic traits;Blood metabolite levels;	chr6:85387984	chr6:85387219~85390186:-
COAD	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-4.76	3.19e-06	0.00128	-0.26	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
COAD	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.19e-06	0.00128	-0.29	-0.28	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.19e-06	0.00128	-0.29	-0.28	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.19e-06	0.00128	-0.29	-0.28	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.19e-06	0.00128	-0.29	-0.28	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-4.76	3.19e-06	0.00128	-0.29	-0.28	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
COAD	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	4.76	3.19e-06	0.00128	0.29	0.28	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-4.76	3.19e-06	0.00128	-0.29	-0.28	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
COAD	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-4.76	3.19e-06	0.00128	-0.31	-0.28	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	4.76	3.19e-06	0.00128	0.31	0.28	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	4.76	3.19e-06	0.00128	0.31	0.28	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	4.76	3.19e-06	0.00128	0.31	0.28	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	4.76	3.19e-06	0.00128	0.31	0.28	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
COAD	cis	rs55823223	0.564	rs9894009	ENSG00000267801.1	RP11-552F3.9	4.76	3.2e-06	0.00128	0.39	0.28	Psoriasis;	chr17:75854333	chr17:75876372~75879546:+
COAD	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-4.76	3.2e-06	0.00128	-0.29	-0.28	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
COAD	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-4.76	3.2e-06	0.00128	-0.29	-0.28	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
COAD	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	4.76	3.2e-06	0.00128	0.33	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
COAD	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-4.76	3.2e-06	0.00128	-0.34	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
COAD	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	4.76	3.2e-06	0.00128	0.26	0.28	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
COAD	cis	rs7209700	0.547	rs61131650	ENSG00000228782.6	CTD-2026D20.3	-4.76	3.2e-06	0.00128	-0.33	-0.28	IgG glycosylation;	chr17:47266961	chr17:47450568~47492492:-
COAD	cis	rs17264034	0.747	rs56411742	ENSG00000250786.1	SNHG18	4.76	3.2e-06	0.00128	0.55	0.28	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544526	chr5:9546200~9550609:+
COAD	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-4.76	3.21e-06	0.00128	-0.5	-0.28	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
COAD	cis	rs11079159	0.606	rs4239192	ENSG00000263096.1	RP11-515O17.2	4.76	3.21e-06	0.00128	0.33	0.28	QRS duration;	chr17:55299143	chr17:55271504~55273653:-
COAD	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	4.76	3.21e-06	0.00128	0.27	0.28	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
COAD	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	4.76	3.21e-06	0.00128	0.27	0.28	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
COAD	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	4.76	3.21e-06	0.00128	0.27	0.28	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
COAD	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	4.76	3.21e-06	0.00129	0.29	0.28	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
COAD	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	4.76	3.21e-06	0.00129	0.29	0.28	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
COAD	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	4.76	3.21e-06	0.00129	0.34	0.28	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
COAD	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	4.76	3.21e-06	0.00129	0.39	0.28	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	4.76	3.21e-06	0.00129	0.39	0.28	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
COAD	cis	rs7584330	0.554	rs6760890	ENSG00000234949.2	AC104667.3	-4.76	3.22e-06	0.00129	-0.48	-0.28	Prostate cancer;	chr2:237492002	chr2:237591020~237595981:+
COAD	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-4.76	3.22e-06	0.00129	-0.29	-0.28	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
COAD	cis	rs8002861	0.875	rs12869697	ENSG00000274001.1	RP11-5G9.5	-4.76	3.22e-06	0.00129	-0.26	-0.28	Leprosy;	chr13:43865033	chr13:43877715~43878163:-
COAD	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-4.76	3.22e-06	0.00129	-0.31	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
COAD	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-4.76	3.22e-06	0.00129	-0.34	-0.28	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000272831.1	RP11-792A8.4	4.76	3.22e-06	0.00129	0.3	0.28	Aortic root size;	chr7:66008701	chr7:66739829~66740385:-
COAD	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-4.76	3.22e-06	0.00129	-0.39	-0.28	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
COAD	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	4.76	3.22e-06	0.00129	0.35	0.28	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
COAD	cis	rs4568518	0.72	rs58338223	ENSG00000279048.1	RP11-511H23.2	4.76	3.23e-06	0.00129	0.2	0.28	Measles;	chr7:18000506	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.803	rs12699947	ENSG00000279048.1	RP11-511H23.2	4.76	3.23e-06	0.00129	0.2	0.28	Measles;	chr7:18000616	chr7:17940503~17942922:+
COAD	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-4.76	3.23e-06	0.00129	-0.33	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
COAD	cis	rs7584330	0.554	rs76408976	ENSG00000234949.2	AC104667.3	-4.76	3.23e-06	0.00129	-0.5	-0.28	Prostate cancer;	chr2:237476141	chr2:237591020~237595981:+
COAD	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	4.76	3.23e-06	0.00129	0.31	0.28	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
COAD	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	4.76	3.23e-06	0.00129	0.31	0.28	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
COAD	cis	rs17264034	1	rs17263917	ENSG00000250786.1	SNHG18	4.76	3.23e-06	0.00129	0.44	0.28	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552226	chr5:9546200~9550609:+
COAD	cis	rs5758511	0.68	rs5751243	ENSG00000237037.8	NDUFA6-AS1	-4.76	3.23e-06	0.00129	-0.34	-0.28	Birth weight;	chr22:42221171	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.637	rs5751244	ENSG00000237037.8	NDUFA6-AS1	-4.76	3.23e-06	0.00129	-0.34	-0.28	Birth weight;	chr22:42221405	chr22:42090931~42137742:+
COAD	cis	rs7584330	0.554	rs6739456	ENSG00000234949.2	AC104667.3	-4.76	3.23e-06	0.00129	-0.44	-0.28	Prostate cancer;	chr2:237476449	chr2:237591020~237595981:+
COAD	cis	rs9487051	0.714	rs7774390	ENSG00000219700.1	PTCHD3P3	-4.76	3.24e-06	0.00129	-0.31	-0.28	Reticulocyte fraction of red cells;	chr6:109281258	chr6:109288571~109290503:-
COAD	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	4.76	3.24e-06	0.0013	0.32	0.28	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
COAD	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	4.76	3.24e-06	0.0013	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
COAD	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	4.76	3.24e-06	0.0013	0.28	0.28	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	4.76	3.24e-06	0.0013	0.28	0.28	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
COAD	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-4.76	3.25e-06	0.0013	-0.32	-0.28	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
COAD	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	4.76	3.25e-06	0.0013	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	4.76	3.25e-06	0.0013	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
COAD	cis	rs17772222	0.636	rs77528165	ENSG00000258789.1	RP11-507K2.3	-4.76	3.25e-06	0.0013	-0.45	-0.28	Coronary artery calcification;	chr14:88794249	chr14:88551597~88552493:+
COAD	cis	rs6543140	0.964	rs10193485	ENSG00000234389.1	AC007278.3	4.76	3.25e-06	0.0013	0.3	0.28	Blood protein levels;	chr2:102473114	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs10196334	ENSG00000234389.1	AC007278.3	4.76	3.25e-06	0.0013	0.3	0.28	Blood protein levels;	chr2:102473582	chr2:102438713~102440475:+
COAD	cis	rs9818758	0.556	rs116432667	ENSG00000225399.4	RP11-3B7.1	-4.76	3.25e-06	0.0013	-0.54	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs13087930	ENSG00000225399.4	RP11-3B7.1	-4.76	3.25e-06	0.0013	-0.54	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:49260085~49261316:+
COAD	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-4.76	3.25e-06	0.0013	-0.32	-0.28	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
COAD	cis	rs9532669	0.963	rs4600338	ENSG00000239827.7	SUGT1P3	-4.76	3.25e-06	0.0013	-0.24	-0.28	Cervical cancer;	chr13:40925175	chr13:40908159~40921774:-
COAD	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-4.76	3.25e-06	0.0013	-0.4	-0.28	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
COAD	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-4.76	3.25e-06	0.0013	-0.4	-0.28	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
COAD	cis	rs6921919	0.697	rs6942030	ENSG00000272009.1	RP1-313I6.12	4.76	3.26e-06	0.0013	0.33	0.28	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28078792~28081130:-
COAD	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	4.76	3.26e-06	0.0013	0.59	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
COAD	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	4.76	3.26e-06	0.0013	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
COAD	cis	rs9818758	0.607	rs34326553	ENSG00000225399.4	RP11-3B7.1	-4.76	3.26e-06	0.0013	-0.54	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:49260085~49261316:+
COAD	cis	rs7260598	0.539	rs7255815	ENSG00000268442.1	CTD-2027I19.2	4.76	3.26e-06	0.0013	0.52	0.28	Response to taxane treatment (placlitaxel);	chr19:23832768	chr19:24162370~24163425:-
COAD	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	4.76	3.26e-06	0.0013	0.7	0.28	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	4.76	3.26e-06	0.0013	0.7	0.28	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	4.76	3.26e-06	0.0013	0.7	0.28	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	4.76	3.26e-06	0.0013	0.7	0.28	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.51	rs73105818	ENSG00000274902.1	RP1-197B17.4	4.76	3.26e-06	0.0013	0.7	0.28	Pneumonia;	chr12:47726538	chr12:47731908~47732351:+
COAD	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.76	3.26e-06	0.0013	0.45	0.28	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
COAD	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	4.76	3.26e-06	0.0013	0.45	0.28	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
COAD	cis	rs12928939	0.862	rs7197104	ENSG00000260886.1	TAT-AS1	4.76	3.26e-06	0.0013	0.41	0.28	Post bronchodilator FEV1;	chr16:71760158	chr16:71565789~71578187:+
COAD	cis	rs748404	0.556	rs10851414	ENSG00000205771.5	CATSPER2P1	4.76	3.26e-06	0.0013	0.35	0.28	Lung cancer;	chr15:43141734	chr15:43726918~43747094:-
COAD	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	4.76	3.26e-06	0.0013	0.42	0.28	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
COAD	cis	rs6452524	0.618	rs6452501	ENSG00000271862.1	RP11-343L5.2	4.76	3.26e-06	0.0013	0.28	0.28	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83049376~83050964:-
COAD	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-4.76	3.27e-06	0.0013	-0.35	-0.28	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
COAD	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-4.76	3.27e-06	0.0013	-0.48	-0.28	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-4.76	3.27e-06	0.0013	-0.48	-0.28	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
COAD	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-4.76	3.27e-06	0.00131	-0.32	-0.28	Height;	chr3:52994359	chr3:53064283~53065091:-
COAD	cis	rs11846409	0.86	rs59055020	ENSG00000274576.2	IGHV2-70	-4.76	3.27e-06	0.00131	-0.28	-0.28	Rheumatic heart disease;	chr14:106631573	chr14:106770577~106771020:-
COAD	cis	rs1578862	1	rs12565357	ENSG00000259865.1	RP11-488L18.10	-4.76	3.28e-06	0.00131	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247264800	chr1:247187281~247188526:-
COAD	cis	rs454422	0.812	rs13041190	ENSG00000275632.1	RP5-967N21.11	4.76	3.28e-06	0.00131	0.34	0.28	HIV-1 viral setpoint;	chr20:5980812	chr20:6000418~6000941:+
COAD	cis	rs7487075	0.754	rs10880962	ENSG00000274723.1	RP11-618L22.1	4.76	3.28e-06	0.00131	0.3	0.28	Itch intensity from mosquito bite;	chr12:46379661	chr12:46970504~46972155:+
COAD	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-4.76	3.28e-06	0.00131	-0.5	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
COAD	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-4.76	3.29e-06	0.00131	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
COAD	cis	rs5742933	1	rs3762545	ENSG00000253559.1	OSGEPL1-AS1	-4.76	3.29e-06	0.00131	-0.32	-0.28	Ferritin levels;	chr2:189790835	chr2:189762704~189765556:+
COAD	cis	rs5742933	1	rs5742998	ENSG00000253559.1	OSGEPL1-AS1	-4.76	3.29e-06	0.00131	-0.32	-0.28	Ferritin levels;	chr2:189799626	chr2:189762704~189765556:+
COAD	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-4.76	3.29e-06	0.00131	-0.38	-0.28	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
COAD	cis	rs9951698	0.678	rs547084	ENSG00000266969.1	RP11-773H22.4	4.76	3.29e-06	0.00131	0.34	0.28	Intelligence (multi-trait analysis);	chr18:13123646	chr18:12984694~12991173:-
COAD	cis	rs8002861	0.905	rs12429722	ENSG00000274001.1	RP11-5G9.5	-4.76	3.29e-06	0.00131	-0.26	-0.28	Leprosy;	chr13:43838330	chr13:43877715~43878163:-
COAD	cis	rs12439619	1	rs12439619	ENSG00000259429.4	UBE2Q2P2	-4.76	3.29e-06	0.00131	-0.26	-0.28	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82355142~82420075:+
COAD	cis	rs875971	0.502	rs2465121	ENSG00000224316.1	RP11-479O9.2	-4.76	3.29e-06	0.00131	-0.37	-0.28	Aortic root size;	chr7:66156017	chr7:65773620~65802067:+
COAD	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	4.76	3.3e-06	0.00131	0.33	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
COAD	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	4.76	3.3e-06	0.00131	0.32	0.28	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	4.76	3.3e-06	0.00131	0.32	0.28	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	4.76	3.3e-06	0.00131	0.32	0.28	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
COAD	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-4.76	3.3e-06	0.00131	-0.29	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
COAD	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-4.76	3.3e-06	0.00132	-0.55	-0.28	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-4.76	3.3e-06	0.00132	-0.55	-0.28	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
COAD	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	4.76	3.3e-06	0.00132	0.3	0.28	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
COAD	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	4.76	3.3e-06	0.00132	0.34	0.28	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
COAD	cis	rs12935418	0.672	rs2602423	ENSG00000278985.1	RP11-303E16.9	-4.76	3.3e-06	0.00132	-0.31	-0.28	Mean corpuscular volume;	chr16:81008423	chr16:80982319~80984094:-
COAD	cis	rs13256369	0.95	rs13270006	ENSG00000173295.6	FAM86B3P	4.76	3.31e-06	0.00132	0.4	0.28	Obesity-related traits;	chr8:8716687	chr8:8228595~8244865:+
COAD	cis	rs10078	0.571	rs2241597	ENSG00000225138.6	CTD-2228K2.7	4.76	3.31e-06	0.00132	0.46	0.28	Fat distribution (HIV);	chr5:480394	chr5:473236~480884:+
COAD	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-4.76	3.31e-06	0.00132	-0.5	-0.28	Gout;	chr7:66642037	chr7:66654538~66669855:+
COAD	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	4.75	3.31e-06	0.00132	0.3	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
COAD	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	4.75	3.31e-06	0.00132	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
COAD	cis	rs12497850	0.931	rs9846123	ENSG00000225399.4	RP11-3B7.1	-4.75	3.31e-06	0.00132	-0.32	-0.28	Parkinson's disease;	chr3:49050679	chr3:49260085~49261316:+
COAD	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	4.75	3.31e-06	0.00132	0.38	0.28	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-4.75	3.31e-06	0.00132	-0.36	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
COAD	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-4.75	3.31e-06	0.00132	-0.35	-0.28	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
COAD	cis	rs7209700	0.662	rs11656865	ENSG00000228782.6	CTD-2026D20.3	-4.75	3.32e-06	0.00132	-0.32	-0.28	IgG glycosylation;	chr17:47269123	chr17:47450568~47492492:-
COAD	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	4.75	3.32e-06	0.00132	0.38	0.28	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
COAD	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	4.75	3.32e-06	0.00132	0.38	0.28	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
COAD	cis	rs603446	0.967	rs180340	ENSG00000254851.1	RP11-109L13.1	-4.75	3.32e-06	0.00132	-0.32	-0.28	Triglycerides;	chr11:116745686	chr11:117135528~117138582:+
COAD	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-4.75	3.32e-06	0.00132	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
COAD	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-4.75	3.32e-06	0.00132	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
COAD	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-4.75	3.32e-06	0.00132	-0.31	-0.28	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.689	rs7274851	ENSG00000222365.1	SNORD12B	-4.75	3.32e-06	0.00132	-0.31	-0.28	Intelligence (multi-trait analysis);	chr20:49177818	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-4.75	3.32e-06	0.00132	-0.31	-0.28	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
COAD	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	4.75	3.33e-06	0.00132	0.32	0.28	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
COAD	cis	rs2337406	1	rs17113331	ENSG00000211974.3	IGHV2-70	-4.75	3.33e-06	0.00132	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106703843	chr14:106723574~106724093:-
COAD	cis	rs7260598	0.792	rs4635459	ENSG00000268442.1	CTD-2027I19.2	4.75	3.33e-06	0.00133	0.41	0.28	Response to taxane treatment (placlitaxel);	chr19:23999020	chr19:24162370~24163425:-
COAD	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-4.75	3.34e-06	0.00133	-0.34	-0.28	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
COAD	cis	rs385076	0.536	rs13017027	ENSG00000272716.1	RP11-563N4.1	-4.75	3.34e-06	0.00133	-0.35	-0.28	Interleukin-18 levels;	chr2:32066834	chr2:32165046~32165757:-
COAD	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-4.75	3.34e-06	0.00133	-0.37	-0.28	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-4.75	3.34e-06	0.00133	-0.37	-0.28	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-4.75	3.34e-06	0.00133	-0.37	-0.28	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
COAD	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-4.75	3.34e-06	0.00133	-0.26	-0.28	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
COAD	cis	rs9450351	0.744	rs9444353	ENSG00000203875.9	SNHG5	-4.75	3.35e-06	0.00133	-0.52	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85566986	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9351063	ENSG00000203875.9	SNHG5	-4.75	3.35e-06	0.00133	-0.52	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85567123	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6923017	ENSG00000203875.9	SNHG5	-4.75	3.35e-06	0.00133	-0.52	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85592619	chr6:85660950~85678736:-
COAD	cis	rs9353324	1	rs7775788	ENSG00000203875.9	SNHG5	-4.75	3.35e-06	0.00133	-0.52	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85595761	chr6:85660950~85678736:-
COAD	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.35e-06	0.00133	-0.52	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
COAD	cis	rs1055129	0.584	rs9895947	ENSG00000267801.1	RP11-552F3.9	4.75	3.35e-06	0.00133	0.36	0.28	White matter hyperintensity burden;	chr17:75912485	chr17:75876372~75879546:+
COAD	cis	rs71636778	0.509	rs35583548	ENSG00000260063.1	RP5-968P14.2	-4.75	3.35e-06	0.00133	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813658	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.73	rs12753968	ENSG00000260063.1	RP5-968P14.2	-4.75	3.36e-06	0.00133	-0.59	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26870872	chr1:26692132~26694131:-
COAD	cis	rs6723226	0.699	rs805830	ENSG00000276334.1	AL133243.1	4.75	3.36e-06	0.00133	0.26	0.28	Intelligence (multi-trait analysis);	chr2:32276406	chr2:32521927~32523547:+
COAD	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	4.75	3.36e-06	0.00133	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	4.75	3.36e-06	0.00133	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	4.75	3.36e-06	0.00133	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
COAD	cis	rs202072	0.652	rs1223393	ENSG00000272379.1	RP1-257A7.5	-4.75	3.36e-06	0.00133	-0.42	-0.28	HIV-1 viral setpoint;	chr6:13265102	chr6:13290018~13290490:-
COAD	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	4.75	3.36e-06	0.00134	0.29	0.28	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
COAD	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	4.75	3.36e-06	0.00134	0.31	0.28	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
COAD	cis	rs7955901	0.775	rs2270589	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.34	0.28	Type 2 diabetes;	chr12:71132507	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs2270588	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.34	0.28	Type 2 diabetes;	chr12:71132634	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs3816942	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.34	0.28	Type 2 diabetes;	chr12:71132929	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.805	rs3851617	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.34	0.28	Type 2 diabetes;	chr12:71133430	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs10784895	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.34	0.28	Type 2 diabetes;	chr12:71134005	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs3914135	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.35	0.28	Type 2 diabetes;	chr12:71130511	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.746	rs3851612	ENSG00000258053.1	CTD-2021H9.3	4.75	3.36e-06	0.00134	0.35	0.28	Type 2 diabetes;	chr12:71131030	chr12:71047402~71118247:-
COAD	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.75	3.37e-06	0.00134	0.29	0.28	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.75	3.37e-06	0.00134	0.29	0.28	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
COAD	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-4.75	3.38e-06	0.00134	-0.35	-0.28	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
COAD	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-4.75	3.39e-06	0.00135	-0.32	-0.28	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
COAD	cis	rs5015933	0.832	rs2841332	ENSG00000232630.1	PRPS1P2	-4.75	3.39e-06	0.00135	-0.27	-0.28	Body mass index;	chr9:125367578	chr9:125150653~125151589:+
COAD	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	4.75	3.39e-06	0.00135	0.42	0.28	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	4.75	3.39e-06	0.00135	0.42	0.28	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
COAD	cis	rs7260598	0.642	rs10405341	ENSG00000268442.1	CTD-2027I19.2	4.75	3.39e-06	0.00135	0.43	0.28	Response to taxane treatment (placlitaxel);	chr19:23924450	chr19:24162370~24163425:-
COAD	cis	rs4718428	1	rs1830070	ENSG00000273142.1	RP11-458F8.4	-4.75	3.4e-06	0.00135	-0.23	-0.28	Corneal structure;	chr7:66884684	chr7:66902857~66906297:+
COAD	cis	rs61270009	0.955	rs17548339	ENSG00000247828.6	TMEM161B-AS1	4.75	3.4e-06	0.00135	0.3	0.28	Depressive symptoms;	chr5:88391761	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs16903122	ENSG00000247828.6	TMEM161B-AS1	4.75	3.4e-06	0.00135	0.3	0.28	Depressive symptoms;	chr5:88397744	chr5:88268895~88436685:+
COAD	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-4.75	3.4e-06	0.00135	-0.26	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
COAD	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-4.75	3.4e-06	0.00135	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-4.75	3.4e-06	0.00135	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-4.75	3.4e-06	0.00135	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-4.75	3.4e-06	0.00135	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-4.75	3.4e-06	0.00135	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
COAD	cis	rs5758511	0.689	rs55906806	ENSG00000237037.8	NDUFA6-AS1	-4.75	3.4e-06	0.00135	-0.4	-0.28	Birth weight;	chr22:42248465	chr22:42090931~42137742:+
COAD	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	4.75	3.4e-06	0.00135	0.38	0.28	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
COAD	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-4.75	3.41e-06	0.00135	-0.34	-0.28	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
COAD	cis	rs13217239	0.608	rs6930508	ENSG00000224843.5	LINC00240	4.75	3.41e-06	0.00135	0.33	0.28	Schizophrenia;	chr6:27085363	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs2142685	ENSG00000224843.5	LINC00240	4.75	3.41e-06	0.00135	0.33	0.28	Schizophrenia;	chr6:27086718	chr6:26956992~27023924:+
COAD	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	4.75	3.41e-06	0.00135	0.3	0.28	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
COAD	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	4.75	3.41e-06	0.00135	0.31	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
COAD	cis	rs710913	0.774	rs2695319	ENSG00000182109.6	RP11-69E11.4	4.75	3.41e-06	0.00135	0.3	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39522280~39546187:-
COAD	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-4.75	3.42e-06	0.00135	-0.29	-0.28	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
COAD	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	4.75	3.42e-06	0.00135	0.82	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
COAD	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	4.75	3.42e-06	0.00136	0.34	0.28	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
COAD	cis	rs8061903	0.917	rs2099106	ENSG00000260071.1	RP11-418I22.2	4.75	3.42e-06	0.00136	0.33	0.28	HIV-1 viral setpoint;	chr16:9286851	chr16:9466655~9517564:+
COAD	cis	rs754466	0.58	rs10762765	ENSG00000204049.1	RP11-126H7.4	4.75	3.42e-06	0.00136	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806649	chr10:77866875~77869610:+
COAD	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-4.75	3.42e-06	0.00136	-0.39	-0.28	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
COAD	cis	rs8061903	0.501	rs2077437	ENSG00000260071.1	RP11-418I22.2	4.75	3.42e-06	0.00136	0.35	0.28	HIV-1 viral setpoint;	chr16:9307313	chr16:9466655~9517564:+
COAD	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	4.75	3.42e-06	0.00136	0.39	0.28	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
COAD	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-4.75	3.42e-06	0.00136	-0.34	-0.28	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
COAD	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-4.75	3.42e-06	0.00136	-0.29	-0.28	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-4.75	3.42e-06	0.00136	-0.29	-0.28	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
COAD	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-4.75	3.43e-06	0.00136	-0.36	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
COAD	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-4.75	3.43e-06	0.00136	-0.27	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
COAD	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	4.75	3.43e-06	0.00136	0.25	0.28	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
COAD	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-4.75	3.43e-06	0.00136	-0.29	-0.28	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-4.75	3.43e-06	0.00136	-0.29	-0.28	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
COAD	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	4.75	3.43e-06	0.00136	0.54	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
COAD	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	4.75	3.43e-06	0.00136	0.54	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
COAD	cis	rs13256369	1	rs10103769	ENSG00000173295.6	FAM86B3P	4.75	3.44e-06	0.00136	0.41	0.28	Obesity-related traits;	chr8:8715526	chr8:8228595~8244865:+
COAD	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	4.75	3.44e-06	0.00136	0.34	0.28	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
COAD	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-4.75	3.44e-06	0.00136	-0.34	-0.28	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
COAD	cis	rs3752645	1	rs10248105	ENSG00000241764.3	AC002467.7	4.75	3.44e-06	0.00136	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107120053	chr7:107742817~107744581:-
COAD	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	4.75	3.44e-06	0.00136	0.38	0.28	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
COAD	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.44e-06	0.00136	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
COAD	cis	rs13256369	1	rs873064	ENSG00000173295.6	FAM86B3P	4.75	3.45e-06	0.00137	0.41	0.28	Obesity-related traits;	chr8:8714870	chr8:8228595~8244865:+
COAD	cis	rs13256369	1	rs4841016	ENSG00000173295.6	FAM86B3P	4.75	3.45e-06	0.00137	0.41	0.28	Obesity-related traits;	chr8:8715051	chr8:8228595~8244865:+
COAD	cis	rs10819861	0.598	rs7041954	ENSG00000238251.2	RP11-172F4.2	-4.75	3.45e-06	0.00137	-0.34	-0.28	Electrocardiographic traits;	chr9:96094119	chr9:96407284~96407797:+
COAD	cis	rs728616	0.681	rs34816332	ENSG00000234382.2	RP11-40F6.1	-4.75	3.45e-06	0.00137	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:80233664~80245367:+
COAD	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-4.75	3.45e-06	0.00137	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
COAD	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	4.75	3.46e-06	0.00137	0.27	0.28	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
COAD	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-4.74	3.46e-06	0.00137	-0.63	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
COAD	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	4.74	3.46e-06	0.00137	0.4	0.28	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
COAD	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-4.74	3.47e-06	0.00137	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
COAD	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-4.74	3.47e-06	0.00137	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
COAD	cis	rs755249	0.565	rs1809697	ENSG00000182109.6	RP11-69E11.4	-4.74	3.47e-06	0.00137	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39522280~39546187:-
COAD	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	4.74	3.47e-06	0.00137	0.47	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
COAD	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	4.74	3.47e-06	0.00137	0.85	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
COAD	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-4.74	3.47e-06	0.00137	-0.33	-0.28	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
COAD	cis	rs853679	0.527	rs9468333	ENSG00000272009.1	RP1-313I6.12	4.74	3.47e-06	0.00137	0.33	0.28	Depression;	chr6:28303421	chr6:28078792~28081130:-
COAD	cis	rs1578862	0.966	rs41268345	ENSG00000259865.1	RP11-488L18.10	-4.74	3.48e-06	0.00138	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247322911	chr1:247187281~247188526:-
COAD	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	4.74	3.48e-06	0.00138	0.33	0.28	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	4.74	3.48e-06	0.00138	0.33	0.28	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
COAD	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-4.74	3.48e-06	0.00138	-0.37	-0.28	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
COAD	cis	rs7615952	0.546	rs11711150	ENSG00000248787.1	RP11-666A20.4	-4.74	3.49e-06	0.00138	-0.44	-0.28	Blood pressure (smoking interaction);	chr3:125596819	chr3:125908005~125910272:-
COAD	cis	rs13256369	0.95	rs13248096	ENSG00000173295.6	FAM86B3P	4.74	3.49e-06	0.00138	0.39	0.28	Obesity-related traits;	chr8:8719966	chr8:8228595~8244865:+
COAD	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	4.74	3.49e-06	0.00138	0.41	0.28	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
COAD	cis	rs4704187	1	rs4704187	ENSG00000250889.2	LINC01336	-4.74	3.49e-06	0.00138	-0.32	-0.28	Response to amphetamines;	chr5:75184463	chr5:75047719~75052843:-
COAD	cis	rs71636778	0.509	rs35615194	ENSG00000260063.1	RP5-968P14.2	-4.74	3.49e-06	0.00138	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26791680	chr1:26692132~26694131:-
COAD	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-4.74	3.49e-06	0.00138	-0.33	-0.28	Height;	chr3:53027361	chr3:53064283~53065091:-
COAD	cis	rs6543140	0.964	rs4851593	ENSG00000234389.1	AC007278.3	-4.74	3.5e-06	0.00138	-0.3	-0.28	Blood protein levels;	chr2:102472767	chr2:102438713~102440475:+
COAD	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	4.74	3.5e-06	0.00138	0.35	0.28	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	4.74	3.5e-06	0.00138	0.35	0.28	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	4.74	3.5e-06	0.00138	0.35	0.28	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
COAD	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	4.74	3.5e-06	0.00138	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
COAD	cis	rs7656342	0.93	rs56205495	ENSG00000186234.7	FAM86MP	-4.74	3.5e-06	0.00138	-0.38	-0.28	Gut microbiota (bacterial taxa);	chr4:9787877	chr4:9692495~9702954:+
COAD	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	4.74	3.5e-06	0.00138	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	4.74	3.5e-06	0.00138	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
COAD	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-4.74	3.5e-06	0.00139	-0.48	-0.28	Gout;	chr7:66671562	chr7:66654538~66669855:+
COAD	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	4.74	3.5e-06	0.00139	0.27	0.28	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
COAD	cis	rs2280018	0.963	rs4985147	ENSG00000270580.4	PKD1P6	4.74	3.51e-06	0.00139	0.29	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104723~15131601:-
COAD	cis	rs7818688	0.697	rs11783878	ENSG00000253528.2	RP11-347C18.4	4.74	3.51e-06	0.00139	0.41	0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967033	chr8:94974573~94974853:-
COAD	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.74	3.51e-06	0.00139	-0.49	-0.28	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
COAD	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	4.74	3.51e-06	0.00139	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
COAD	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	4.74	3.51e-06	0.00139	0.81	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
COAD	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.51e-06	0.00139	-0.45	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
COAD	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-4.74	3.51e-06	0.00139	-0.32	-0.28	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
COAD	cis	rs1387259	0.859	rs2054905	ENSG00000273765.1	RP11-370I10.11	4.74	3.52e-06	0.00139	0.31	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48360920~48361377:+
COAD	cis	rs12935418	0.616	rs9931292	ENSG00000278985.1	RP11-303E16.9	4.74	3.52e-06	0.00139	0.3	0.28	Mean corpuscular volume;	chr16:80975671	chr16:80982319~80984094:-
COAD	cis	rs2599510	0.55	rs2754511	ENSG00000276334.1	AL133243.1	4.74	3.52e-06	0.00139	0.31	0.28	Interleukin-18 levels;	chr2:32545090	chr2:32521927~32523547:+
COAD	cis	rs9450351	0.744	rs9450294	ENSG00000203875.9	SNHG5	-4.74	3.52e-06	0.00139	-0.51	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85540712	chr6:85660950~85678736:-
COAD	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	4.74	3.52e-06	0.00139	0.3	0.28	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
COAD	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	4.74	3.52e-06	0.00139	0.6	0.28	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	4.74	3.52e-06	0.00139	0.6	0.28	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	4.74	3.52e-06	0.00139	0.6	0.28	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
COAD	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	4.74	3.52e-06	0.00139	0.35	0.28	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	4.74	3.52e-06	0.00139	0.35	0.28	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	4.74	3.52e-06	0.00139	0.35	0.28	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
COAD	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	4.74	3.52e-06	0.00139	0.3	0.28	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
COAD	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	4.74	3.52e-06	0.00139	0.3	0.28	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
COAD	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	4.74	3.52e-06	0.00139	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
COAD	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-4.74	3.53e-06	0.00139	-0.49	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-4.74	3.53e-06	0.00139	-0.49	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-4.74	3.53e-06	0.00139	-0.49	-0.28	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
COAD	cis	rs73198271	0.96	rs73198288	ENSG00000173295.6	FAM86B3P	-4.74	3.53e-06	0.00139	-0.4	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.96	rs11778970	ENSG00000173295.6	FAM86B3P	-4.74	3.53e-06	0.00139	-0.4	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:8228595~8244865:+
COAD	cis	rs9532669	0.963	rs4942012	ENSG00000239827.7	SUGT1P3	-4.74	3.53e-06	0.00139	-0.25	-0.28	Cervical cancer;	chr13:40939112	chr13:40908159~40921774:-
COAD	cis	rs2638953	0.64	rs10843211	ENSG00000247934.4	RP11-967K21.1	-4.74	3.53e-06	0.0014	-0.29	-0.28	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28577717	chr12:28163298~28190738:-
COAD	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-4.74	3.54e-06	0.0014	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
COAD	cis	rs9910055	0.529	rs228757	ENSG00000267080.4	ASB16-AS1	4.74	3.54e-06	0.0014	0.28	0.28	Total body bone mineral density;	chr17:44087517	chr17:44175973~44186717:-
COAD	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	4.74	3.54e-06	0.0014	0.4	0.28	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
COAD	cis	rs10895987	1	rs12280510	ENSG00000254614.2	AP003068.23	4.74	3.54e-06	0.0014	0.43	0.28	Blood protein levels;	chr11:65147076	chr11:65177606~65181834:-
COAD	cis	rs801193	1	rs4717319	ENSG00000272831.1	RP11-792A8.4	4.74	3.54e-06	0.0014	0.3	0.28	Aortic root size;	chr7:66777606	chr7:66739829~66740385:-
COAD	cis	rs801193	0.904	rs4718403	ENSG00000272831.1	RP11-792A8.4	4.74	3.54e-06	0.0014	0.3	0.28	Aortic root size;	chr7:66777742	chr7:66739829~66740385:-
COAD	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	4.74	3.54e-06	0.0014	0.45	0.28	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
COAD	cis	rs9659323	1	rs10923714	ENSG00000231365.4	RP11-418J17.1	-4.74	3.54e-06	0.0014	-0.32	-0.28	Body mass index;	chr1:118970290	chr1:119140396~119275973:+
COAD	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	4.74	3.54e-06	0.0014	0.34	0.28	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
COAD	cis	rs7646881	0.951	rs6441222	ENSG00000272087.1	RP11-379F4.7	4.74	3.55e-06	0.0014	0.41	0.28	Tetralogy of Fallot;	chr3:158731978	chr3:158693120~158693768:-
COAD	cis	rs7646881	1	rs73015652	ENSG00000272087.1	RP11-379F4.7	4.74	3.55e-06	0.0014	0.41	0.28	Tetralogy of Fallot;	chr3:158733594	chr3:158693120~158693768:-
COAD	cis	rs930421	0.763	rs62144350	ENSG00000226491.1	FTOP1	-4.74	3.55e-06	0.0014	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr2:42747105	chr2:42797225~42798712:-
COAD	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	4.74	3.55e-06	0.0014	0.39	0.28	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
COAD	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	4.74	3.55e-06	0.0014	0.3	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
COAD	cis	rs4704187	0.687	rs10942729	ENSG00000250889.2	LINC01336	-4.74	3.55e-06	0.0014	-0.32	-0.28	Response to amphetamines;	chr5:75068475	chr5:75047719~75052843:-
COAD	cis	rs1578862	0.966	rs61838689	ENSG00000259865.1	RP11-488L18.10	-4.74	3.56e-06	0.0014	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247321815	chr1:247187281~247188526:-
COAD	cis	rs3752645	0.649	rs10241140	ENSG00000241764.3	AC002467.7	4.74	3.56e-06	0.0014	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107104067	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.649	rs10241141	ENSG00000241764.3	AC002467.7	4.74	3.56e-06	0.0014	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107104069	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs1004570	ENSG00000241764.3	AC002467.7	4.74	3.56e-06	0.0014	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107105076	chr7:107742817~107744581:-
COAD	cis	rs2732480	0.577	rs2634681	ENSG00000273765.1	RP11-370I10.11	-4.74	3.56e-06	0.0014	-0.31	-0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48360920~48361377:+
COAD	cis	rs6095360	0.727	rs8118101	ENSG00000222365.1	SNORD12B	-4.74	3.56e-06	0.0014	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49073301	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs7271812	ENSG00000222365.1	SNORD12B	-4.74	3.56e-06	0.0014	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49076496	chr20:49280319~49280409:+
COAD	cis	rs4568518	0.803	rs4721679	ENSG00000279048.1	RP11-511H23.2	4.74	3.56e-06	0.00141	0.2	0.28	Measles;	chr7:17999629	chr7:17940503~17942922:+
COAD	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs59715866	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26752685	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12737946	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753403	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12742115	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753440	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.57	rs71636776	ENSG00000260063.1	RP5-968P14.2	-4.74	3.56e-06	0.00141	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756557	chr1:26692132~26694131:-
COAD	cis	rs2380205	0.503	rs685852	ENSG00000232807.2	RP11-536K7.3	-4.74	3.56e-06	0.00141	-0.24	-0.28	Breast cancer;	chr10:5892654	chr10:5934270~5945900:-
COAD	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-4.74	3.57e-06	0.00141	-0.31	-0.28	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
COAD	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-4.74	3.57e-06	0.00141	-0.32	-0.28	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
COAD	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-4.74	3.57e-06	0.00141	-0.41	-0.28	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-4.74	3.57e-06	0.00141	-0.41	-0.28	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-4.74	3.57e-06	0.00141	-0.41	-0.28	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
COAD	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-4.74	3.57e-06	0.00141	-0.34	-0.28	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-4.74	3.57e-06	0.00141	-0.34	-0.28	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-4.74	3.57e-06	0.00141	-0.34	-0.28	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
COAD	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	4.74	3.57e-06	0.00141	0.32	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
COAD	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	4.74	3.57e-06	0.00141	0.32	0.28	QT interval;	chr12:29379056	chr12:29280418~29317848:-
COAD	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	4.74	3.57e-06	0.00141	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	4.74	3.57e-06	0.00141	0.32	0.28	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	4.74	3.57e-06	0.00141	0.32	0.28	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	4.74	3.57e-06	0.00141	0.32	0.28	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	4.74	3.57e-06	0.00141	0.32	0.28	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
COAD	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	4.74	3.59e-06	0.00141	0.28	0.28	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
COAD	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-4.74	3.59e-06	0.00141	-0.33	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
COAD	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-4.74	3.59e-06	0.00141	-0.33	-0.28	Height;	chr3:52938846	chr3:53064283~53065091:-
COAD	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-4.74	3.59e-06	0.00141	-0.32	-0.28	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
COAD	cis	rs7829975	0.517	rs12542733	ENSG00000254340.1	RP11-10A14.3	-4.74	3.59e-06	0.00142	-0.32	-0.28	Mood instability;	chr8:8967348	chr8:9141424~9145435:+
COAD	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	4.74	3.6e-06	0.00142	0.33	0.28	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
COAD	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	4.74	3.6e-06	0.00142	0.37	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
COAD	cis	rs12935418	0.616	rs874053	ENSG00000278985.1	RP11-303E16.9	4.74	3.6e-06	0.00142	0.31	0.28	Mean corpuscular volume;	chr16:80972210	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs874054	ENSG00000278985.1	RP11-303E16.9	4.74	3.6e-06	0.00142	0.31	0.28	Mean corpuscular volume;	chr16:80972245	chr16:80982319~80984094:-
COAD	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-4.74	3.6e-06	0.00142	-0.38	-0.28	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
COAD	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-4.74	3.6e-06	0.00142	-0.43	-0.28	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-4.74	3.6e-06	0.00142	-0.43	-0.28	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
COAD	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-4.74	3.6e-06	0.00142	-0.16	-0.28	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
COAD	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	4.74	3.6e-06	0.00142	0.54	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
COAD	cis	rs9450351	0.744	rs111533912	ENSG00000203875.9	SNHG5	-4.74	3.6e-06	0.00142	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85622231	chr6:85660950~85678736:-
COAD	cis	rs9907295	0.591	rs8080959	ENSG00000271013.1	AC015849.15	-4.74	3.6e-06	0.00142	-0.35	-0.28	Fibroblast growth factor basic levels;	chr17:35813450	chr17:35912635~35918010:-
COAD	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	4.74	3.6e-06	0.00142	0.34	0.28	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
COAD	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	4.74	3.61e-06	0.00142	0.44	0.28	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
COAD	cis	rs9990333	0.862	rs6806599	ENSG00000207650.1	MIR570	-4.74	3.61e-06	0.00142	-0.33	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195699401~195699497:+
COAD	cis	rs2638953	0.64	rs11049721	ENSG00000247934.4	RP11-967K21.1	-4.74	3.61e-06	0.00142	-0.29	-0.28	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28163298~28190738:-
COAD	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	4.74	3.61e-06	0.00142	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	4.74	3.61e-06	0.00142	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
COAD	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	4.74	3.61e-06	0.00142	0.27	0.28	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
COAD	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-4.74	3.61e-06	0.00142	-0.44	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
COAD	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-4.74	3.61e-06	0.00142	-0.31	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
COAD	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-4.74	3.61e-06	0.00142	-0.44	-0.28	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
COAD	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-4.74	3.62e-06	0.00142	-0.42	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
COAD	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	4.74	3.62e-06	0.00142	0.37	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
COAD	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-4.74	3.62e-06	0.00143	-0.29	-0.28	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
COAD	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	4.73	3.62e-06	0.00143	0.35	0.28	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
COAD	cis	rs13256369	1	rs1109619	ENSG00000173295.6	FAM86B3P	4.73	3.63e-06	0.00143	0.39	0.28	Obesity-related traits;	chr8:8714106	chr8:8228595~8244865:+
COAD	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	4.73	3.63e-06	0.00143	0.33	0.28	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
COAD	cis	rs9400467	0.508	rs11153283	ENSG00000271789.1	RP5-1112D6.7	-4.73	3.63e-06	0.00143	-0.27	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111297126~111298510:+
COAD	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	4.73	3.63e-06	0.00143	0.44	0.28	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
COAD	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	4.73	3.63e-06	0.00143	0.44	0.28	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
COAD	cis	rs9910055	0.529	rs850851	ENSG00000267080.4	ASB16-AS1	4.73	3.63e-06	0.00143	0.27	0.28	Total body bone mineral density;	chr17:44100306	chr17:44175973~44186717:-
COAD	cis	rs7119	0.604	rs2271397	ENSG00000259565.2	KRT8P23	4.73	3.63e-06	0.00143	0.31	0.28	Type 2 diabetes;	chr15:77615433	chr15:76979245~76980451:-
COAD	cis	rs9818758	0.545	rs11717978	ENSG00000225399.4	RP11-3B7.1	-4.73	3.63e-06	0.00143	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.556	rs13086240	ENSG00000225399.4	RP11-3B7.1	-4.73	3.63e-06	0.00143	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs11706052	ENSG00000225399.4	RP11-3B7.1	-4.73	3.63e-06	0.00143	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:49260085~49261316:+
COAD	cis	rs11719291	0.584	rs13080725	ENSG00000225399.4	RP11-3B7.1	-4.73	3.63e-06	0.00143	-0.53	-0.28	Cognitive function;	chr3:49038659	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs35108630	ENSG00000225399.4	RP11-3B7.1	-4.73	3.63e-06	0.00143	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:49260085~49261316:+
COAD	cis	rs7615952	0.688	rs4422259	ENSG00000248787.1	RP11-666A20.4	-4.73	3.64e-06	0.00143	-0.39	-0.28	Blood pressure (smoking interaction);	chr3:125826988	chr3:125908005~125910272:-
COAD	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	4.73	3.64e-06	0.00143	0.3	0.28	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
COAD	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.73	3.64e-06	0.00143	0.42	0.28	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
COAD	cis	rs58873874	0.579	rs35536103	ENSG00000251405.2	CTB-109A12.1	4.73	3.64e-06	0.00143	0.55	0.28	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157362615~157460078:-
COAD	cis	rs58873874	0.579	rs75099611	ENSG00000251405.2	CTB-109A12.1	4.73	3.64e-06	0.00143	0.55	0.28	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157362615~157460078:-
COAD	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	4.73	3.64e-06	0.00143	0.37	0.28	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	4.73	3.64e-06	0.00143	0.37	0.28	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
COAD	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	4.73	3.64e-06	0.00143	0.37	0.28	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
COAD	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	4.73	3.64e-06	0.00143	0.37	0.28	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
COAD	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	4.73	3.64e-06	0.00143	0.35	0.28	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
COAD	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-4.73	3.65e-06	0.00143	-0.34	-0.28	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
COAD	cis	rs7955901	0.904	rs7298255	ENSG00000258053.1	CTD-2021H9.3	4.73	3.65e-06	0.00143	0.34	0.28	Type 2 diabetes;	chr12:71034289	chr12:71047402~71118247:-
COAD	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-4.73	3.65e-06	0.00143	-0.29	-0.28	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
COAD	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-4.73	3.65e-06	0.00143	-0.31	-0.28	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
COAD	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-4.73	3.65e-06	0.00143	-0.31	-0.28	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
COAD	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-4.73	3.65e-06	0.00143	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
COAD	cis	rs7584330	0.554	rs80151891	ENSG00000234949.2	AC104667.3	-4.73	3.65e-06	0.00143	-0.48	-0.28	Prostate cancer;	chr2:237490183	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs77956735	ENSG00000234949.2	AC104667.3	-4.73	3.65e-06	0.00143	-0.48	-0.28	Prostate cancer;	chr2:237490487	chr2:237591020~237595981:+
COAD	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	4.73	3.65e-06	0.00143	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	4.73	3.65e-06	0.00143	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
COAD	cis	rs875971	0.66	rs801193	ENSG00000272831.1	RP11-792A8.4	-4.73	3.66e-06	0.00144	-0.29	-0.28	Aortic root size;	chr7:66565625	chr7:66739829~66740385:-
COAD	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	4.73	3.66e-06	0.00144	0.47	0.28	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
COAD	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-4.73	3.66e-06	0.00144	-0.24	-0.28	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
COAD	cis	rs853679	0.527	rs853690	ENSG00000272009.1	RP1-313I6.12	4.73	3.66e-06	0.00144	0.33	0.28	Depression;	chr6:28317705	chr6:28078792~28081130:-
COAD	cis	rs853679	0.527	rs707907	ENSG00000272009.1	RP1-313I6.12	4.73	3.66e-06	0.00144	0.33	0.28	Depression;	chr6:28323463	chr6:28078792~28081130:-
COAD	cis	rs8002861	0.875	rs12872943	ENSG00000274001.1	RP11-5G9.5	-4.73	3.66e-06	0.00144	-0.26	-0.28	Leprosy;	chr13:43836417	chr13:43877715~43878163:-
COAD	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-4.73	3.66e-06	0.00144	-0.29	-0.28	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-4.73	3.66e-06	0.00144	-0.29	-0.28	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-4.73	3.66e-06	0.00144	-0.29	-0.28	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
COAD	cis	rs6921919	0.697	rs758398	ENSG00000272009.1	RP1-313I6.12	4.73	3.66e-06	0.00144	0.33	0.28	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28078792~28081130:-
COAD	cis	rs2378497	1	rs2800860	ENSG00000232679.1	RP11-400N13.3	4.73	3.67e-06	0.00144	0.36	0.28	Serum thyroid-stimulating hormone levels;	chr1:222009884	chr1:222041705~222064763:-
COAD	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-4.73	3.67e-06	0.00144	-0.3	-0.28	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
COAD	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-4.73	3.67e-06	0.00144	-0.36	-0.28	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-4.73	3.67e-06	0.00144	-0.36	-0.28	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
COAD	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-4.73	3.68e-06	0.00144	-0.3	-0.28	Axial length;	chr3:53813767	chr3:53797764~53798019:-
COAD	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	4.73	3.68e-06	0.00144	0.3	0.28	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
COAD	cis	rs8141529	0.748	rs5762881	ENSG00000272858.1	CTA-292E10.8	-4.73	3.68e-06	0.00144	-0.35	-0.28	Lymphocyte counts;	chr22:28893358	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.748	rs9620841	ENSG00000272858.1	CTA-292E10.8	-4.73	3.68e-06	0.00144	-0.35	-0.28	Lymphocyte counts;	chr22:28894993	chr22:28814914~28815662:+
COAD	cis	rs1930961	0.702	rs12168476	ENSG00000272977.1	CTA-390C10.10	-4.73	3.68e-06	0.00144	-0.75	-0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25491121	chr22:25476218~25479971:+
COAD	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-4.73	3.68e-06	0.00144	-0.33	-0.28	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-4.73	3.68e-06	0.00144	-0.33	-0.28	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
COAD	cis	rs9818758	0.607	rs3923475	ENSG00000225399.4	RP11-3B7.1	-4.73	3.68e-06	0.00144	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:49260085~49261316:+
COAD	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-4.73	3.68e-06	0.00144	-0.41	-0.28	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
COAD	cis	rs9847710	0.967	rs2581778	ENSG00000280417.1	RP11-5O17.1	-4.73	3.68e-06	0.00144	-0.29	-0.28	Ulcerative colitis;	chr3:53021295	chr3:53046166~53048122:+
COAD	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	4.73	3.68e-06	0.00144	0.52	0.28	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
COAD	cis	rs2638953	0.64	rs11049723	ENSG00000247934.4	RP11-967K21.1	4.73	3.68e-06	0.00144	0.29	0.28	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28575903	chr12:28163298~28190738:-
COAD	cis	rs2281603	0.521	rs3742608	ENSG00000259116.1	RP11-973N13.4	-4.73	3.69e-06	0.00145	-0.27	-0.28	Lymphocyte counts;	chr14:64470315	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs2045024	ENSG00000259116.1	RP11-973N13.4	-4.73	3.69e-06	0.00145	-0.27	-0.28	Lymphocyte counts;	chr14:64470634	chr14:64514154~64540368:-
COAD	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	4.73	3.69e-06	0.00145	0.35	0.28	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
COAD	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-4.73	3.69e-06	0.00145	-0.27	-0.28	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-4.73	3.69e-06	0.00145	-0.27	-0.28	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-4.73	3.69e-06	0.00145	-0.27	-0.28	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
COAD	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	4.73	3.69e-06	0.00145	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
COAD	cis	rs8002861	0.967	rs7994883	ENSG00000274001.1	RP11-5G9.5	-4.73	3.69e-06	0.00145	-0.25	-0.28	Leprosy;	chr13:43904669	chr13:43877715~43878163:-
COAD	cis	rs3752645	1	rs10249866	ENSG00000241764.3	AC002467.7	4.73	3.69e-06	0.00145	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107108380	chr7:107742817~107744581:-
COAD	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.73	3.7e-06	0.00145	0.29	0.28	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
COAD	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	4.73	3.7e-06	0.00145	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
COAD	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.73	3.7e-06	0.00145	-0.35	-0.28	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
COAD	cis	rs41307935	0.915	rs34696599	ENSG00000260063.1	RP5-968P14.2	-4.73	3.7e-06	0.00145	-0.59	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26877237	chr1:26692132~26694131:-
COAD	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	4.73	3.7e-06	0.00145	0.44	0.28	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
COAD	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	4.73	3.7e-06	0.00145	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
COAD	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	4.73	3.7e-06	0.00145	0.44	0.28	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	4.73	3.7e-06	0.00145	0.44	0.28	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	4.73	3.7e-06	0.00145	0.44	0.28	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
COAD	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-4.73	3.71e-06	0.00145	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
COAD	cis	rs597539	0.652	rs646586	ENSG00000255741.1	RP11-757G1.5	4.73	3.71e-06	0.00145	0.37	0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68941503~68942852:-
COAD	cis	rs7637701	0.517	rs66538320	ENSG00000243926.1	TIPARP-AS1	4.73	3.71e-06	0.00145	0.3	0.28	Breast cancer;	chr3:156674346	chr3:156671862~156674378:-
COAD	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	4.73	3.71e-06	0.00145	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	4.73	3.71e-06	0.00145	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
COAD	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	4.73	3.71e-06	0.00145	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
COAD	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	4.73	3.71e-06	0.00145	0.35	0.28	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
COAD	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-4.73	3.71e-06	0.00145	-0.31	-0.28	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
COAD	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-4.73	3.71e-06	0.00145	-0.24	-0.28	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
COAD	cis	rs6903823	0.527	rs4713158	ENSG00000272009.1	RP1-313I6.12	4.73	3.72e-06	0.00146	0.33	0.28	Pulmonary function;	chr6:28309994	chr6:28078792~28081130:-
COAD	cis	rs1578862	1	rs11804760	ENSG00000259865.1	RP11-488L18.10	-4.73	3.72e-06	0.00146	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247262201	chr1:247187281~247188526:-
COAD	cis	rs801193	1	rs10274773	ENSG00000272831.1	RP11-792A8.4	-4.73	3.73e-06	0.00146	-0.3	-0.28	Aortic root size;	chr7:66668591	chr7:66739829~66740385:-
COAD	cis	rs4604732	0.536	rs12049066	ENSG00000227135.1	GCSAML-AS1	-4.73	3.73e-06	0.00146	-0.39	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247479353	chr1:247524679~247526752:-
COAD	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-4.73	3.73e-06	0.00146	-0.3	-0.28	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
COAD	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	4.73	3.73e-06	0.00146	0.43	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
COAD	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-4.73	3.73e-06	0.00146	-0.33	-0.28	Height;	chr3:52936861	chr3:53064283~53065091:-
COAD	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-4.73	3.74e-06	0.00146	-0.44	-0.28	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
COAD	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-4.73	3.74e-06	0.00146	-0.43	-0.28	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
COAD	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	4.73	3.74e-06	0.00146	0.4	0.28	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
COAD	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	4.73	3.74e-06	0.00146	0.35	0.28	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
COAD	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	4.73	3.74e-06	0.00147	0.42	0.28	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
COAD	cis	rs728616	0.867	rs41298231	ENSG00000225484.5	NUTM2B-AS1	-4.73	3.74e-06	0.00147	-0.52	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:79663088~79826594:-
COAD	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	4.73	3.75e-06	0.00147	0.31	0.28	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
COAD	cis	rs739496	0.615	rs688920	ENSG00000257595.2	RP3-473L9.4	4.73	3.75e-06	0.00147	0.42	0.28	Platelet count;	chr12:111719458	chr12:111369282~111403310:+
COAD	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-4.73	3.75e-06	0.00147	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
COAD	cis	rs2337406	1	rs75651733	ENSG00000211974.3	IGHV2-70	-4.73	3.75e-06	0.00147	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106701309	chr14:106723574~106724093:-
COAD	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	4.73	3.76e-06	0.00147	0.38	0.28	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
COAD	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-4.73	3.76e-06	0.00147	-0.3	-0.28	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
COAD	cis	rs7577696	0.752	rs212721	ENSG00000272716.1	RP11-563N4.1	4.73	3.76e-06	0.00147	0.3	0.28	Inflammatory biomarkers;	chr2:32240960	chr2:32165046~32165757:-
COAD	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	4.73	3.76e-06	0.00147	0.37	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
COAD	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	4.73	3.76e-06	0.00147	0.43	0.28	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
COAD	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	4.73	3.76e-06	0.00147	0.27	0.28	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
COAD	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-4.73	3.76e-06	0.00147	-0.34	-0.28	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	4.73	3.76e-06	0.00147	0.34	0.28	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
COAD	cis	rs9910055	0.529	rs575798	ENSG00000267080.4	ASB16-AS1	4.73	3.76e-06	0.00147	0.27	0.28	Total body bone mineral density;	chr17:44104428	chr17:44175973~44186717:-
COAD	cis	rs875971	0.638	rs7793569	ENSG00000272831.1	RP11-792A8.4	-4.73	3.77e-06	0.00147	-0.3	-0.28	Aortic root size;	chr7:66651646	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs6975195	ENSG00000272831.1	RP11-792A8.4	-4.73	3.77e-06	0.00147	-0.3	-0.28	Aortic root size;	chr7:66659787	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs3857688	ENSG00000272831.1	RP11-792A8.4	-4.73	3.77e-06	0.00147	-0.3	-0.28	Aortic root size;	chr7:66662819	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs2286684	ENSG00000272831.1	RP11-792A8.4	-4.73	3.77e-06	0.00147	-0.3	-0.28	Aortic root size;	chr7:66664843	chr7:66739829~66740385:-
COAD	cis	rs801193	0.935	rs2286683	ENSG00000272831.1	RP11-792A8.4	-4.73	3.77e-06	0.00147	-0.3	-0.28	Aortic root size;	chr7:66664856	chr7:66739829~66740385:-
COAD	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	4.73	3.77e-06	0.00147	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
COAD	cis	rs12497850	0.931	rs13064784	ENSG00000225399.4	RP11-3B7.1	4.73	3.77e-06	0.00147	0.31	0.28	Parkinson's disease;	chr3:49098528	chr3:49260085~49261316:+
COAD	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-4.73	3.77e-06	0.00148	-0.58	-0.28	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
COAD	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	4.73	3.77e-06	0.00148	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
COAD	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	4.73	3.78e-06	0.00148	0.36	0.28	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
COAD	cis	rs12935418	0.672	rs7197370	ENSG00000278985.1	RP11-303E16.9	4.73	3.78e-06	0.00148	0.31	0.28	Mean corpuscular volume;	chr16:81017520	chr16:80982319~80984094:-
COAD	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	4.73	3.78e-06	0.00148	0.25	0.28	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
COAD	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-4.73	3.78e-06	0.00148	-0.34	-0.28	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
COAD	cis	rs875971	0.545	rs1796222	ENSG00000224316.1	RP11-479O9.2	-4.73	3.78e-06	0.00148	-0.36	-0.28	Aortic root size;	chr7:66592167	chr7:65773620~65802067:+
COAD	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.73	3.78e-06	0.00148	0.42	0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
COAD	cis	rs3752645	1	rs11760966	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107092082	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.649	rs112171645	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107099220	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs11772245	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107107633	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs11762123	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107107634	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs2250121	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107112803	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs2237653	ENSG00000241764.3	AC002467.7	4.73	3.79e-06	0.00148	0.45	0.28	Bladder cancer (smoking interaction);	chr7:107119603	chr7:107742817~107744581:-
COAD	cis	rs12497850	0.863	rs4974084	ENSG00000225399.4	RP11-3B7.1	4.73	3.79e-06	0.00148	0.32	0.28	Parkinson's disease;	chr3:48901647	chr3:49260085~49261316:+
COAD	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-4.73	3.79e-06	0.00148	-0.35	-0.28	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
COAD	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	4.72	3.8e-06	0.00148	0.35	0.28	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-4.72	3.8e-06	0.00148	-0.35	-0.28	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
COAD	cis	rs8002861	0.87	rs12865116	ENSG00000274001.1	RP11-5G9.5	-4.72	3.8e-06	0.00148	-0.26	-0.28	Leprosy;	chr13:43866305	chr13:43877715~43878163:-
COAD	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-4.72	3.8e-06	0.00149	-0.57	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
COAD	cis	rs893363	1	rs893363	ENSG00000271916.1	RP11-884K10.6	-4.72	3.81e-06	0.00149	-0.28	-0.28	Axial length;	chr3:53813035	chr3:53797764~53798019:-
COAD	cis	rs8141529	0.732	rs5762788	ENSG00000272858.1	CTA-292E10.8	-4.72	3.81e-06	0.00149	-0.33	-0.28	Lymphocyte counts;	chr22:28778782	chr22:28814914~28815662:+
COAD	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-4.72	3.81e-06	0.00149	-0.3	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
COAD	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-4.72	3.82e-06	0.00149	-0.34	-0.28	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
COAD	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-4.72	3.82e-06	0.00149	-0.49	-0.28	Gout;	chr7:66654674	chr7:66654538~66669855:+
COAD	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-4.72	3.82e-06	0.00149	-0.49	-0.28	Gout;	chr7:66661502	chr7:66654538~66669855:+
COAD	cis	rs9307551	0.817	rs13127970	ENSG00000250334.4	LINC00989	-4.72	3.82e-06	0.00149	-0.34	-0.28	Refractive error;	chr4:79581236	chr4:79492416~79576460:+
COAD	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	4.72	3.82e-06	0.00149	0.31	0.28	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	4.72	3.82e-06	0.00149	0.31	0.28	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
COAD	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-4.72	3.82e-06	0.00149	-0.3	-0.28	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
COAD	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-4.72	3.82e-06	0.00149	-0.32	-0.28	QT interval;	chr12:29319476	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-4.72	3.82e-06	0.00149	-0.32	-0.28	QT interval;	chr12:29320175	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-4.72	3.82e-06	0.00149	-0.32	-0.28	QT interval;	chr12:29321177	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-4.72	3.82e-06	0.00149	-0.32	-0.28	QT interval;	chr12:29321323	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-4.72	3.82e-06	0.00149	-0.32	-0.28	QT interval;	chr12:29322770	chr12:29280418~29317848:-
COAD	cis	rs5758511	0.773	rs8140869	ENSG00000237037.8	NDUFA6-AS1	4.72	3.82e-06	0.00149	0.3	0.28	Birth weight;	chr22:41948293	chr22:42090931~42137742:+
COAD	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-4.72	3.82e-06	0.00149	-0.32	-0.28	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
COAD	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	4.72	3.83e-06	0.00149	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
COAD	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	4.72	3.83e-06	0.00149	0.35	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
COAD	cis	rs801193	1	rs2659912	ENSG00000272831.1	RP11-792A8.4	4.72	3.83e-06	0.00149	0.3	0.28	Aortic root size;	chr7:66693012	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs2707836	ENSG00000272831.1	RP11-792A8.4	4.72	3.83e-06	0.00149	0.3	0.28	Aortic root size;	chr7:66695448	chr7:66739829~66740385:-
COAD	cis	rs801193	0.844	rs7779971	ENSG00000272831.1	RP11-792A8.4	4.72	3.83e-06	0.00149	0.3	0.28	Aortic root size;	chr7:66696803	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs2659906	ENSG00000272831.1	RP11-792A8.4	4.72	3.83e-06	0.00149	0.3	0.28	Aortic root size;	chr7:66700323	chr7:66739829~66740385:-
COAD	cis	rs6490294	0.747	rs7978068	ENSG00000257595.2	RP3-473L9.4	4.72	3.83e-06	0.00149	0.41	0.28	Mean platelet volume;	chr12:112063962	chr12:111369282~111403310:+
COAD	cis	rs453301	0.653	rs1045529	ENSG00000254340.1	RP11-10A14.3	-4.72	3.83e-06	0.00149	-0.34	-0.28	Joint mobility (Beighton score);	chr8:9032588	chr8:9141424~9145435:+
COAD	cis	rs8002861	0.87	rs9525855	ENSG00000274001.1	RP11-5G9.5	4.72	3.83e-06	0.0015	0.25	0.28	Leprosy;	chr13:43857524	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.781	rs9525857	ENSG00000274001.1	RP11-5G9.5	4.72	3.83e-06	0.0015	0.25	0.28	Leprosy;	chr13:43862936	chr13:43877715~43878163:-
COAD	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-4.72	3.83e-06	0.0015	-0.31	-0.28	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
COAD	cis	rs7786410	1	rs7786410	ENSG00000273720.1	RP11-613E4.4	4.72	3.83e-06	0.0015	0.47	0.28	Age-related hearing impairment;	chr7:55854630	chr7:55743073~55743457:+
COAD	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	4.72	3.83e-06	0.0015	0.2	0.28	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
COAD	cis	rs8002861	0.84	rs1819597	ENSG00000274001.1	RP11-5G9.5	4.72	3.84e-06	0.0015	0.25	0.28	Leprosy;	chr13:43855417	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.84	rs1819596	ENSG00000274001.1	RP11-5G9.5	4.72	3.84e-06	0.0015	0.25	0.28	Leprosy;	chr13:43855418	chr13:43877715~43878163:-
COAD	cis	rs41307935	0.908	rs34014719	ENSG00000260063.1	RP5-968P14.2	-4.72	3.84e-06	0.0015	-0.57	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26746275	chr1:26692132~26694131:-
COAD	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	4.72	3.84e-06	0.0015	0.32	0.28	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
COAD	cis	rs8002861	0.87	rs2875541	ENSG00000274001.1	RP11-5G9.5	4.72	3.84e-06	0.0015	0.25	0.28	Leprosy;	chr13:43843305	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.754	rs4053664	ENSG00000274001.1	RP11-5G9.5	4.72	3.84e-06	0.0015	0.25	0.28	Leprosy;	chr13:43855036	chr13:43877715~43878163:-
COAD	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	4.72	3.84e-06	0.0015	0.34	0.28	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
COAD	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	4.72	3.84e-06	0.0015	0.47	0.28	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
COAD	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	4.72	3.84e-06	0.0015	0.43	0.28	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
COAD	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	4.72	3.84e-06	0.0015	0.2	0.28	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	4.72	3.84e-06	0.0015	0.2	0.28	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
COAD	cis	rs930421	0.544	rs6719977	ENSG00000226491.1	FTOP1	-4.72	3.85e-06	0.0015	-0.36	-0.28	Attention deficit hyperactivity disorder;	chr2:42758663	chr2:42797225~42798712:-
COAD	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	4.72	3.85e-06	0.0015	0.36	0.28	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
COAD	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-4.72	3.85e-06	0.0015	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
COAD	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-4.72	3.86e-06	0.0015	-0.34	-0.28	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
COAD	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	4.72	3.86e-06	0.0015	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	4.72	3.86e-06	0.0015	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
COAD	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	4.72	3.86e-06	0.0015	0.3	0.28	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
COAD	cis	rs801193	0.967	rs2707849	ENSG00000272831.1	RP11-792A8.4	4.72	3.86e-06	0.0015	0.3	0.28	Aortic root size;	chr7:66687725	chr7:66739829~66740385:-
COAD	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-4.72	3.86e-06	0.00151	-0.16	-0.28	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
COAD	cis	rs6840360	0.642	rs7658169	ENSG00000251611.1	RP11-610P16.1	-4.72	3.86e-06	0.00151	-0.27	-0.28	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151407551~151408835:-
COAD	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	4.72	3.86e-06	0.00151	0.34	0.28	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
COAD	cis	rs7260598	0.539	rs13345286	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23886611	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs73525884	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23886899	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs73525888	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23887039	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs73525890	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23887109	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs73525891	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23887131	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs76305873	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:23887151	chr19:24162370~24163425:-
COAD	cis	rs11668609	0.515	rs73525894	ENSG00000268442.1	CTD-2027I19.2	4.72	3.86e-06	0.00151	0.46	0.28	Response to taxane treatment (docetaxel);	chr19:23887976	chr19:24162370~24163425:-
COAD	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	4.72	3.87e-06	0.00151	0.37	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
COAD	cis	rs8022206	0.773	rs10467735	ENSG00000259502.1	RP11-643G16.3	4.72	3.87e-06	0.00151	0.39	0.28	Platelet count;Mean platelet volume;	chr14:67909764	chr14:67610986~67613864:+
COAD	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	4.72	3.87e-06	0.00151	0.28	0.28	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
COAD	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	4.72	3.87e-06	0.00151	0.39	0.28	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
COAD	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	4.72	3.87e-06	0.00151	0.39	0.28	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
COAD	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-4.72	3.88e-06	0.00151	-0.42	-0.28	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-4.72	3.88e-06	0.00151	-0.42	-0.28	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
COAD	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-4.72	3.88e-06	0.00151	-0.28	-0.28	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
COAD	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-4.72	3.88e-06	0.00151	-0.28	-0.28	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
COAD	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-4.72	3.89e-06	0.00151	-0.48	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
COAD	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-4.72	3.89e-06	0.00151	-0.34	-0.28	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
COAD	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	4.72	3.89e-06	0.00152	0.35	0.28	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
COAD	cis	rs13256369	0.802	rs11249884	ENSG00000173295.6	FAM86B3P	-4.72	3.89e-06	0.00152	-0.4	-0.28	Obesity-related traits;	chr8:8704042	chr8:8228595~8244865:+
COAD	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	4.72	3.9e-06	0.00152	0.32	0.28	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
COAD	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-4.72	3.9e-06	0.00152	-0.31	-0.28	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
COAD	cis	rs9951698	0.655	rs6505774	ENSG00000266969.1	RP11-773H22.4	4.72	3.9e-06	0.00152	0.31	0.28	Intelligence (multi-trait analysis);	chr18:12976468	chr18:12984694~12991173:-
COAD	cis	rs4568518	0.873	rs13309934	ENSG00000279048.1	RP11-511H23.2	-4.72	3.91e-06	0.00152	-0.2	-0.28	Measles;	chr7:17991173	chr7:17940503~17942922:+
COAD	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	4.72	3.91e-06	0.00152	0.51	0.28	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	4.72	3.92e-06	0.00152	0.31	0.28	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
COAD	cis	rs6840360	0.642	rs7682837	ENSG00000251611.1	RP11-610P16.1	-4.72	3.92e-06	0.00153	-0.27	-0.28	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151407551~151408835:-
COAD	cis	rs7826238	0.502	rs10503377	ENSG00000173295.6	FAM86B3P	4.72	3.92e-06	0.00153	0.41	0.28	Systolic blood pressure;	chr8:8520912	chr8:8228595~8244865:+
COAD	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-4.72	3.92e-06	0.00153	-0.16	-0.28	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
COAD	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-4.72	3.93e-06	0.00153	-0.25	-0.28	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
COAD	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	4.72	3.93e-06	0.00153	0.43	0.28	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
COAD	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	4.72	3.93e-06	0.00153	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
COAD	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-4.72	3.94e-06	0.00153	-0.39	-0.28	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
COAD	cis	rs2439831	0.681	rs28594657	ENSG00000205771.5	CATSPER2P1	-4.72	3.94e-06	0.00153	-0.53	-0.28	Lung cancer in ever smokers;	chr15:43296690	chr15:43726918~43747094:-
COAD	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-4.72	3.94e-06	0.00153	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
COAD	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	4.72	3.94e-06	0.00153	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
COAD	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-4.72	3.94e-06	0.00153	-0.35	-0.28	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
COAD	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-4.72	3.94e-06	0.00153	-0.51	-0.28	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-4.72	3.94e-06	0.00153	-0.51	-0.28	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-4.72	3.94e-06	0.00153	-0.51	-0.28	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
COAD	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	4.72	3.95e-06	0.00154	0.35	0.28	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
COAD	cis	rs7818688	0.545	rs11786429	ENSG00000253528.2	RP11-347C18.4	-4.72	3.95e-06	0.00154	-0.43	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94819117	chr8:94974573~94974853:-
COAD	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-4.72	3.95e-06	0.00154	-0.4	-0.28	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
COAD	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	4.72	3.95e-06	0.00154	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
COAD	cis	rs7829975	0.871	rs777709	ENSG00000253981.4	ALG1L13P	-4.72	3.95e-06	0.00154	-0.33	-0.28	Mood instability;	chr8:8726362	chr8:8236003~8244667:-
COAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-4.72	3.96e-06	0.00154	-0.33	-0.28	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
COAD	cis	rs801193	0.935	rs2659916	ENSG00000272831.1	RP11-792A8.4	4.72	3.96e-06	0.00154	0.3	0.28	Aortic root size;	chr7:66686365	chr7:66739829~66740385:-
COAD	cis	rs4841097	0.806	rs6992247	ENSG00000253981.4	ALG1L13P	4.72	3.96e-06	0.00154	0.36	0.28	Platelet distribution width;	chr8:9090959	chr8:8236003~8244667:-
COAD	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	4.72	3.96e-06	0.00154	0.33	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-4.72	3.96e-06	0.00154	-0.3	-0.28	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
COAD	cis	rs2732480	0.5	rs1552550	ENSG00000257735.1	RP11-370I10.6	4.72	3.96e-06	0.00154	0.35	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48350945~48442411:+
COAD	cis	rs11681884	0.642	rs4251991	ENSG00000228251.1	AC012442.6	4.72	3.96e-06	0.00154	0.48	0.28	Stroke;	chr2:113122472	chr2:112590796~112591939:+
COAD	cis	rs3126085	0.56	rs11803108	ENSG00000237975.5	FLG-AS1	4.72	3.97e-06	0.00154	0.33	0.28	Atopic dermatitis;	chr1:152371910	chr1:152168125~152445456:+
COAD	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-4.72	3.97e-06	0.00154	-0.35	-0.28	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
COAD	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-4.72	3.97e-06	0.00154	-0.42	-0.28	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
COAD	cis	rs4657482	0.606	rs4657490	ENSG00000236364.3	RP11-525G13.2	-4.71	3.97e-06	0.00154	-0.24	-0.28	Testicular germ cell tumor;	chr1:165900453	chr1:165890795~165900683:-
COAD	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-4.71	3.97e-06	0.00154	-0.34	-0.28	Migraine;	chr4:56853383	chr4:56960927~56961373:-
COAD	cis	rs7078219	0.743	rs7095953	ENSG00000228778.1	RP11-129J12.1	4.71	3.97e-06	0.00154	0.33	0.28	Dental caries;	chr10:99514668	chr10:99527081~99528261:+
COAD	cis	rs7818688	0.697	rs17665737	ENSG00000253528.2	RP11-347C18.4	-4.71	3.97e-06	0.00154	-0.43	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974078	chr8:94974573~94974853:-
COAD	cis	rs930421	1	rs930421	ENSG00000226491.1	FTOP1	-4.71	3.97e-06	0.00154	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr2:42754099	chr2:42797225~42798712:-
COAD	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-4.71	3.98e-06	0.00154	-0.38	-0.28	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
COAD	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	4.71	3.98e-06	0.00155	0.56	0.28	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
COAD	cis	rs1578862	0.934	rs61838684	ENSG00000259865.1	RP11-488L18.10	-4.71	3.98e-06	0.00155	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247310587	chr1:247187281~247188526:-
COAD	cis	rs1578862	0.966	rs11581163	ENSG00000259865.1	RP11-488L18.10	-4.71	3.98e-06	0.00155	-0.23	-0.28	Monocyte percentage of white cells;	chr1:247312230	chr1:247187281~247188526:-
COAD	cis	rs763121	0.719	rs138699	ENSG00000273076.1	RP3-508I15.22	4.71	3.98e-06	0.00155	0.26	0.28	Menopause (age at onset);	chr22:38733703	chr22:38743495~38743910:+
COAD	cis	rs7615952	0.546	rs16836896	ENSG00000248787.1	RP11-666A20.4	-4.71	3.99e-06	0.00155	-0.45	-0.28	Blood pressure (smoking interaction);	chr3:125592418	chr3:125908005~125910272:-
COAD	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.71	3.99e-06	0.00155	0.35	0.28	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
COAD	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-4.71	3.99e-06	0.00155	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-4.71	3.99e-06	0.00155	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
COAD	cis	rs3752645	1	rs1860804	ENSG00000241764.3	AC002467.7	4.71	3.99e-06	0.00155	0.46	0.28	Bladder cancer (smoking interaction);	chr7:107092831	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs11772066	ENSG00000241764.3	AC002467.7	4.71	3.99e-06	0.00155	0.46	0.28	Bladder cancer (smoking interaction);	chr7:107106996	chr7:107742817~107744581:-
COAD	cis	rs9291683	0.679	rs2278122	ENSG00000250413.1	RP11-448G15.1	4.71	3.99e-06	0.00155	0.34	0.28	Bone mineral density;	chr4:10094617	chr4:10006482~10009725:+
COAD	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	4.71	3.99e-06	0.00155	0.34	0.28	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
COAD	cis	rs4699052	0.787	rs2169508	ENSG00000230069.3	LRRC37A15P	-4.71	3.99e-06	0.00155	-0.3	-0.28	Testicular germ cell tumor;	chr4:103145733	chr4:102727274~102730721:-
COAD	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	4.71	4e-06	0.00155	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
COAD	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-4.71	4e-06	0.00155	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
COAD	cis	rs6940638	0.688	rs2022272	ENSG00000224843.5	LINC00240	4.71	4e-06	0.00155	0.35	0.28	Intelligence (multi-trait analysis);	chr6:27135801	chr6:26956992~27023924:+
COAD	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-4.71	4e-06	0.00155	-0.34	-0.28	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
COAD	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-4.71	4.01e-06	0.00155	-0.35	-0.28	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
COAD	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	4.71	4.01e-06	0.00155	0.33	0.28	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
COAD	cis	rs11124272	0.543	rs11676456	ENSG00000272716.1	RP11-563N4.1	-4.71	4.01e-06	0.00155	-0.34	-0.28	Interleukin-18 levels;	chr2:32106442	chr2:32165046~32165757:-
COAD	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	4.71	4.01e-06	0.00155	0.41	0.28	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
COAD	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-4.71	4.01e-06	0.00155	-0.5	-0.28	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
COAD	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-4.71	4.01e-06	0.00156	-0.34	-0.28	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
COAD	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-4.71	4.01e-06	0.00156	-0.32	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-4.71	4.01e-06	0.00156	-0.32	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-4.71	4.01e-06	0.00156	-0.32	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
COAD	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
COAD	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	4.71	4.02e-06	0.00156	0.38	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
COAD	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	4.71	4.02e-06	0.00156	0.38	0.28	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
COAD	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	4.71	4.02e-06	0.00156	0.27	0.28	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
COAD	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	4.71	4.03e-06	0.00156	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	4.71	4.03e-06	0.00156	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	4.71	4.03e-06	0.00156	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
COAD	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	4.71	4.03e-06	0.00156	0.4	0.28	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
COAD	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	4.71	4.03e-06	0.00156	0.37	0.28	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
COAD	cis	rs801193	1	rs6958520	ENSG00000272831.1	RP11-792A8.4	4.71	4.03e-06	0.00156	0.3	0.28	Aortic root size;	chr7:66686466	chr7:66739829~66740385:-
COAD	cis	rs801193	1	rs7788576	ENSG00000272831.1	RP11-792A8.4	-4.71	4.03e-06	0.00156	-0.3	-0.28	Aortic root size;	chr7:66683315	chr7:66739829~66740385:-
COAD	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-4.71	4.03e-06	0.00156	-0.33	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
COAD	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.03e-06	0.00156	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.03e-06	0.00156	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.03e-06	0.00156	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
COAD	cis	rs3126085	0.515	rs12032854	ENSG00000237975.5	FLG-AS1	4.71	4.04e-06	0.00156	0.32	0.28	Atopic dermatitis;	chr1:152374885	chr1:152168125~152445456:+
COAD	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	4.71	4.04e-06	0.00157	0.42	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
COAD	cis	rs7260598	0.642	rs4313914	ENSG00000268442.1	CTD-2027I19.2	4.71	4.04e-06	0.00157	0.4	0.28	Response to taxane treatment (placlitaxel);	chr19:23994194	chr19:24162370~24163425:-
COAD	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-4.71	4.04e-06	0.00157	-0.4	-0.28	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-4.71	4.04e-06	0.00157	-0.4	-0.28	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
COAD	cis	rs6095360	0.727	rs34841991	ENSG00000222365.1	SNORD12B	-4.71	4.05e-06	0.00157	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49130437	chr20:49280319~49280409:+
COAD	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.05e-06	0.00157	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.05e-06	0.00157	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-4.71	4.05e-06	0.00157	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
COAD	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	4.71	4.05e-06	0.00157	0.47	0.28	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
COAD	cis	rs1387259	0.859	rs2054905	ENSG00000257735.1	RP11-370I10.6	4.71	4.05e-06	0.00157	0.35	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48350945~48442411:+
COAD	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	4.71	4.05e-06	0.00157	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
COAD	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	4.71	4.05e-06	0.00157	0.29	0.28	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
COAD	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	4.71	4.05e-06	0.00157	0.32	0.28	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	4.71	4.05e-06	0.00157	0.32	0.28	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
COAD	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-4.71	4.05e-06	0.00157	-0.48	-0.28	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
COAD	cis	rs440932	1	rs365309	ENSG00000253981.4	ALG1L13P	-4.71	4.06e-06	0.00157	-0.38	-0.28	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8236003~8244667:-
COAD	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-4.71	4.06e-06	0.00157	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
COAD	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	4.71	4.06e-06	0.00157	0.34	0.28	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
COAD	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-4.71	4.06e-06	0.00157	-0.29	-0.28	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	4.71	4.06e-06	0.00157	0.29	0.28	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
COAD	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-4.71	4.06e-06	0.00157	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
COAD	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	4.71	4.07e-06	0.00158	0.35	0.28	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
COAD	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-4.71	4.07e-06	0.00158	-0.35	-0.28	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-4.71	4.07e-06	0.00158	-0.35	-0.28	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-4.71	4.07e-06	0.00158	-0.35	-0.28	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
COAD	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-4.71	4.07e-06	0.00158	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
COAD	cis	rs9818758	0.607	rs35283189	ENSG00000225399.4	RP11-3B7.1	-4.71	4.08e-06	0.00158	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs34580506	ENSG00000225399.4	RP11-3B7.1	-4.71	4.08e-06	0.00158	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:49260085~49261316:+
COAD	cis	rs2581828	0.632	rs891369	ENSG00000280417.1	RP11-5O17.1	4.71	4.08e-06	0.00158	0.31	0.28	Crohn's disease;	chr3:53102535	chr3:53046166~53048122:+
COAD	cis	rs2638953	0.676	rs11049727	ENSG00000247934.4	RP11-967K21.1	-4.71	4.08e-06	0.00158	-0.29	-0.28	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28163298~28190738:-
COAD	cis	rs7577696	0.597	rs13006495	ENSG00000272716.1	RP11-563N4.1	-4.71	4.08e-06	0.00158	-0.32	-0.28	Inflammatory biomarkers;	chr2:32130421	chr2:32165046~32165757:-
COAD	cis	rs4704187	0.687	rs9293643	ENSG00000250889.2	LINC01336	4.71	4.08e-06	0.00158	0.31	0.28	Response to amphetamines;	chr5:75069228	chr5:75047719~75052843:-
COAD	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	4.71	4.09e-06	0.00158	0.28	0.28	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
COAD	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	4.71	4.09e-06	0.00158	0.39	0.28	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
COAD	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	4.71	4.09e-06	0.00158	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
COAD	cis	rs4704187	0.64	rs7721018	ENSG00000250889.2	LINC01336	-4.71	4.09e-06	0.00158	-0.32	-0.28	Response to amphetamines;	chr5:75197153	chr5:75047719~75052843:-
COAD	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-4.71	4.09e-06	0.00158	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
COAD	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-4.71	4.09e-06	0.00158	-0.32	-0.28	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
COAD	cis	rs875971	0.597	rs11763224	ENSG00000224316.1	RP11-479O9.2	4.71	4.1e-06	0.00158	0.36	0.28	Aortic root size;	chr7:66518628	chr7:65773620~65802067:+
COAD	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-4.71	4.1e-06	0.00158	-0.32	-0.28	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
COAD	cis	rs2281603	0.57	rs73265639	ENSG00000259116.1	RP11-973N13.4	-4.71	4.1e-06	0.00158	-0.28	-0.28	Lymphocyte counts;	chr14:64482973	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs73265640	ENSG00000259116.1	RP11-973N13.4	-4.71	4.1e-06	0.00158	-0.28	-0.28	Lymphocyte counts;	chr14:64483083	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs73265641	ENSG00000259116.1	RP11-973N13.4	-4.71	4.1e-06	0.00158	-0.28	-0.28	Lymphocyte counts;	chr14:64483146	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.521	rs35115595	ENSG00000259116.1	RP11-973N13.4	-4.71	4.1e-06	0.00158	-0.28	-0.28	Lymphocyte counts;	chr14:64483206	chr14:64514154~64540368:-
COAD	cis	rs9990333	0.862	rs6806599	ENSG00000242086.7	LINC00969	-4.71	4.1e-06	0.00158	-0.27	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195658062~195739964:+
COAD	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-4.71	4.1e-06	0.00158	-0.34	-0.28	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
COAD	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	4.71	4.1e-06	0.00158	0.43	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
COAD	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	4.71	4.1e-06	0.00158	0.39	0.28	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
COAD	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-4.71	4.1e-06	0.00159	-0.31	-0.28	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
COAD	cis	rs55823223	0.564	rs4572466	ENSG00000267801.1	RP11-552F3.9	4.71	4.1e-06	0.00159	0.4	0.28	Psoriasis;	chr17:75850233	chr17:75876372~75879546:+
COAD	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	4.71	4.1e-06	0.00159	0.31	0.28	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
COAD	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	4.71	4.1e-06	0.00159	0.34	0.28	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
COAD	cis	rs8141529	0.748	rs5752826	ENSG00000272858.1	CTA-292E10.8	-4.71	4.1e-06	0.00159	-0.34	-0.28	Lymphocyte counts;	chr22:28873820	chr22:28814914~28815662:+
COAD	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-4.71	4.1e-06	0.00159	-0.29	-0.28	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
COAD	cis	rs4704187	0.687	rs10050948	ENSG00000250889.2	LINC01336	-4.71	4.11e-06	0.00159	-0.32	-0.28	Response to amphetamines;	chr5:75188450	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1345704	ENSG00000250889.2	LINC01336	-4.71	4.11e-06	0.00159	-0.32	-0.28	Response to amphetamines;	chr5:75194173	chr5:75047719~75052843:-
COAD	cis	rs739496	0.579	rs3742000	ENSG00000257595.2	RP3-473L9.4	4.71	4.11e-06	0.00159	0.42	0.28	Platelet count;	chr12:111900735	chr12:111369282~111403310:+
COAD	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-4.71	4.11e-06	0.00159	-0.36	-0.28	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
COAD	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	4.71	4.11e-06	0.00159	0.45	0.28	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
COAD	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	4.71	4.11e-06	0.00159	0.39	0.28	Height;	chr6:109762861	chr6:109382795~109383666:+
COAD	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	4.71	4.11e-06	0.00159	0.39	0.28	Height;	chr6:109764163	chr6:109382795~109383666:+
COAD	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-4.71	4.11e-06	0.00159	-0.35	-0.28	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
COAD	cis	rs2378497	1	rs996854	ENSG00000232679.1	RP11-400N13.3	4.71	4.11e-06	0.00159	0.35	0.28	Serum thyroid-stimulating hormone levels;	chr1:222027569	chr1:222041705~222064763:-
COAD	cis	rs8022206	0.773	rs8006437	ENSG00000259502.1	RP11-643G16.3	4.71	4.12e-06	0.00159	0.39	0.28	Platelet count;Mean platelet volume;	chr14:67909047	chr14:67610986~67613864:+
COAD	cis	rs739496	0.527	rs2269803	ENSG00000257595.2	RP3-473L9.4	4.71	4.12e-06	0.00159	0.41	0.28	Platelet count;	chr12:111888341	chr12:111369282~111403310:+
COAD	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-4.71	4.12e-06	0.00159	-0.47	-0.28	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
COAD	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-4.71	4.14e-06	0.0016	-0.29	-0.28	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
COAD	cis	rs5015933	0.801	rs2416961	ENSG00000232630.1	PRPS1P2	-4.71	4.14e-06	0.0016	-0.27	-0.28	Body mass index;	chr9:125378078	chr9:125150653~125151589:+
COAD	cis	rs7818688	0.578	rs75025610	ENSG00000253528.2	RP11-347C18.4	-4.71	4.14e-06	0.0016	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826075	chr8:94974573~94974853:-
COAD	cis	rs2581828	0.539	rs114317830	ENSG00000280417.1	RP11-5O17.1	4.71	4.15e-06	0.0016	0.3	0.28	Crohn's disease;	chr3:53126253	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.539	rs114670283	ENSG00000280417.1	RP11-5O17.1	4.71	4.15e-06	0.0016	0.3	0.28	Crohn's disease;	chr3:53126254	chr3:53046166~53048122:+
COAD	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	4.71	4.15e-06	0.0016	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
COAD	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	4.71	4.15e-06	0.0016	0.34	0.28	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
COAD	cis	rs9847710	0.933	rs1529544	ENSG00000280417.1	RP11-5O17.1	4.7	4.15e-06	0.0016	0.28	0.28	Ulcerative colitis;	chr3:53005439	chr3:53046166~53048122:+
COAD	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-4.7	4.15e-06	0.0016	-0.32	-0.28	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
COAD	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	4.7	4.16e-06	0.0016	0.34	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
COAD	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	4.7	4.16e-06	0.00161	0.33	0.28	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
COAD	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	4.7	4.16e-06	0.00161	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
COAD	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	4.7	4.16e-06	0.00161	0.24	0.28	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
COAD	cis	rs6940638	0.513	rs4424065	ENSG00000224843.5	LINC00240	4.7	4.16e-06	0.00161	0.32	0.28	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26956992~27023924:+
COAD	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-4.7	4.17e-06	0.00161	-0.32	-0.28	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
COAD	cis	rs7818688	0.697	rs28399553	ENSG00000253528.2	RP11-347C18.4	-4.7	4.17e-06	0.00161	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94894566	chr8:94974573~94974853:-
COAD	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-4.7	4.17e-06	0.00161	-0.52	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-4.7	4.17e-06	0.00161	-0.52	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
COAD	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	4.7	4.17e-06	0.00161	0.7	0.28	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
COAD	cis	rs739496	0.615	rs12579287	ENSG00000257595.2	RP3-473L9.4	4.7	4.18e-06	0.00161	0.42	0.28	Platelet count;	chr12:111653010	chr12:111369282~111403310:+
COAD	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-4.7	4.18e-06	0.00161	-0.54	-0.28	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
COAD	cis	rs8062405	0.508	rs9929088	ENSG00000251417.2	RP11-1348G14.4	4.7	4.19e-06	0.00161	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28802743~28817828:+
COAD	cis	rs739496	0.694	rs7296651	ENSG00000257595.2	RP3-473L9.4	-4.7	4.19e-06	0.00162	-0.41	-0.28	Platelet count;	chr12:111809150	chr12:111369282~111403310:+
COAD	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-4.7	4.2e-06	0.00162	-0.27	-0.28	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
COAD	cis	rs6750795	0.765	rs6742387	ENSG00000223198.1	RNU2-22P	-4.7	4.2e-06	0.00162	-0.32	-0.28	Height;	chr2:231490121	chr2:231501990~231502201:-
COAD	cis	rs7598759	0.548	rs1823328	ENSG00000223198.1	RNU2-22P	-4.7	4.2e-06	0.00162	-0.32	-0.28	Noise-induced hearing loss;	chr2:231490473	chr2:231501990~231502201:-
COAD	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	4.7	4.2e-06	0.00162	0.38	0.28	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	4.7	4.2e-06	0.00162	0.31	0.28	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
COAD	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	4.7	4.21e-06	0.00162	0.35	0.28	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
COAD	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	4.7	4.21e-06	0.00162	0.54	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
COAD	cis	rs28374715	0.609	rs8043237	ENSG00000247556.5	OIP5-AS1	4.7	4.21e-06	0.00162	0.37	0.28	Ulcerative colitis;	chr15:41222100	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs72737792	ENSG00000247556.5	OIP5-AS1	4.7	4.21e-06	0.00162	0.37	0.28	Ulcerative colitis;	chr15:41223391	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.662	rs72737793	ENSG00000247556.5	OIP5-AS1	4.7	4.21e-06	0.00162	0.37	0.28	Ulcerative colitis;	chr15:41224625	chr15:41283990~41309737:+
COAD	cis	rs9659323	1	rs56897173	ENSG00000231365.4	RP11-418J17.1	-4.7	4.22e-06	0.00162	-0.32	-0.28	Body mass index;	chr1:118973109	chr1:119140396~119275973:+
COAD	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	4.7	4.22e-06	0.00163	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
COAD	cis	rs61270009	0.955	rs34148755	ENSG00000247828.6	TMEM161B-AS1	4.7	4.22e-06	0.00163	0.3	0.28	Depressive symptoms;	chr5:88394130	chr5:88268895~88436685:+
COAD	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-4.7	4.22e-06	0.00163	-0.46	-0.28	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
COAD	cis	rs728616	0.717	rs61860016	ENSG00000234382.2	RP11-40F6.1	-4.7	4.22e-06	0.00163	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:80233664~80245367:+
COAD	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-4.7	4.23e-06	0.00163	-0.34	-0.28	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
COAD	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-4.7	4.23e-06	0.00163	-0.15	-0.28	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
COAD	cis	rs9393777	0.513	rs11967852	ENSG00000224843.5	LINC00240	4.7	4.23e-06	0.00163	0.46	0.28	Intelligence (multi-trait analysis);	chr6:26612642	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs7754159	ENSG00000224843.5	LINC00240	4.7	4.23e-06	0.00163	0.46	0.28	Intelligence (multi-trait analysis);	chr6:26620084	chr6:26956992~27023924:+
COAD	cis	rs9379850	0.73	rs9393738	ENSG00000224843.5	LINC00240	4.7	4.23e-06	0.00163	0.46	0.28	Intelligence (multi-trait analysis);	chr6:26620430	chr6:26956992~27023924:+
COAD	cis	rs492146	1	rs426169	ENSG00000243236.5	GSTA9P	-4.7	4.23e-06	0.00163	-0.3	-0.28	Epilepsy (remission after treatment);	chr6:52975090	chr6:52939726~52957521:-
COAD	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	4.7	4.23e-06	0.00163	0.44	0.28	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
COAD	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	4.7	4.23e-06	0.00163	0.44	0.28	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
COAD	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	4.7	4.24e-06	0.00163	0.16	0.28	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
COAD	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-4.7	4.24e-06	0.00163	-0.38	-0.28	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
COAD	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-4.7	4.24e-06	0.00163	-0.28	-0.28	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
COAD	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	4.7	4.25e-06	0.00164	0.27	0.28	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
COAD	cis	rs2439831	1	rs527921	ENSG00000275601.1	AC011330.13	4.7	4.25e-06	0.00164	0.39	0.28	Lung cancer in ever smokers;	chr15:43478218	chr15:43642389~43643023:-
COAD	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	4.7	4.25e-06	0.00164	0.32	0.28	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
COAD	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-4.7	4.25e-06	0.00164	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
COAD	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	4.7	4.26e-06	0.00164	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
COAD	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	4.7	4.26e-06	0.00164	0.42	0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
COAD	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	4.7	4.26e-06	0.00164	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
COAD	cis	rs7560272	0.538	rs4852975	ENSG00000163016.8	ALMS1P	-4.7	4.26e-06	0.00164	-0.34	-0.28	Schizophrenia;	chr2:73705338	chr2:73644919~73685576:+
COAD	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	4.7	4.26e-06	0.00164	0.45	0.28	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
COAD	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	4.7	4.26e-06	0.00164	0.28	0.28	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
COAD	cis	rs9532669	0.926	rs9532654	ENSG00000239827.7	SUGT1P3	-4.7	4.26e-06	0.00164	-0.24	-0.28	Cervical cancer;	chr13:40909812	chr13:40908159~40921774:-
COAD	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.7	4.26e-06	0.00164	0.29	0.28	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
COAD	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	4.7	4.27e-06	0.00164	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
COAD	cis	rs2732480	0.5	rs2450991	ENSG00000257735.1	RP11-370I10.6	4.7	4.27e-06	0.00164	0.34	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48350945~48442411:+
COAD	cis	rs9307551	0.741	rs7691868	ENSG00000250334.4	LINC00989	-4.7	4.27e-06	0.00164	-0.38	-0.28	Refractive error;	chr4:79495250	chr4:79492416~79576460:+
COAD	cis	rs6490294	0.752	rs608814	ENSG00000257595.2	RP3-473L9.4	4.7	4.27e-06	0.00164	0.42	0.28	Mean platelet volume;	chr12:111688811	chr12:111369282~111403310:+
COAD	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-4.7	4.27e-06	0.00164	-0.35	-0.28	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
COAD	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	4.7	4.28e-06	0.00165	0.35	0.28	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
COAD	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-4.7	4.28e-06	0.00165	-0.3	-0.28	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
COAD	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	4.7	4.28e-06	0.00165	0.22	0.28	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
COAD	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-4.7	4.29e-06	0.00165	-0.35	-0.28	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
COAD	cis	rs7811142	1	rs67040465	ENSG00000078319.8	PMS2P1	-4.7	4.29e-06	0.00165	-0.4	-0.28	Platelet count;	chr7:100485455	chr7:100320992~100341908:-
COAD	cis	rs12935418	0.672	rs3784814	ENSG00000278985.1	RP11-303E16.9	4.7	4.29e-06	0.00165	0.31	0.28	Mean corpuscular volume;	chr16:81007652	chr16:80982319~80984094:-
COAD	cis	rs4604732	0.536	rs4433437	ENSG00000227135.1	GCSAML-AS1	-4.7	4.29e-06	0.00165	-0.4	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473278	chr1:247524679~247526752:-
COAD	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	4.7	4.29e-06	0.00165	0.31	0.28	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
COAD	cis	rs7260598	0.642	rs7256265	ENSG00000268442.1	CTD-2027I19.2	4.7	4.3e-06	0.00165	0.41	0.28	Response to taxane treatment (placlitaxel);	chr19:23950901	chr19:24162370~24163425:-
COAD	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	4.7	4.3e-06	0.00165	0.32	0.28	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	4.7	4.3e-06	0.00165	0.41	0.28	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
COAD	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.7	4.3e-06	0.00165	-0.28	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
COAD	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-4.7	4.3e-06	0.00165	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
COAD	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	4.7	4.3e-06	0.00165	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
COAD	cis	rs4704187	0.687	rs10214239	ENSG00000250889.2	LINC01336	-4.7	4.3e-06	0.00165	-0.32	-0.28	Response to amphetamines;	chr5:75061650	chr5:75047719~75052843:-
COAD	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	4.7	4.3e-06	0.00165	0.34	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
COAD	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-4.7	4.31e-06	0.00166	-0.34	-0.28	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
COAD	cis	rs9818758	0.607	rs35673421	ENSG00000225399.4	RP11-3B7.1	-4.7	4.31e-06	0.00166	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs11552724	ENSG00000225399.4	RP11-3B7.1	-4.7	4.31e-06	0.00166	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:49260085~49261316:+
COAD	cis	rs2732480	0.5	rs2450989	ENSG00000257735.1	RP11-370I10.6	-4.7	4.32e-06	0.00166	-0.34	-0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48350945~48442411:+
COAD	cis	rs930421	0.502	rs2278582	ENSG00000226491.1	FTOP1	-4.7	4.32e-06	0.00166	-0.35	-0.28	Attention deficit hyperactivity disorder;	chr2:42762304	chr2:42797225~42798712:-
COAD	cis	rs7955901	0.837	rs1877527	ENSG00000258053.1	CTD-2021H9.3	-4.7	4.32e-06	0.00166	-0.33	-0.28	Type 2 diabetes;	chr12:71011426	chr12:71047402~71118247:-
COAD	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	4.7	4.32e-06	0.00166	0.31	0.28	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	4.7	4.32e-06	0.00166	0.31	0.28	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	4.7	4.33e-06	0.00166	0.31	0.28	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	4.7	4.33e-06	0.00166	0.31	0.28	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	4.7	4.33e-06	0.00166	0.31	0.28	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
COAD	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-4.7	4.33e-06	0.00166	-0.26	-0.28	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
COAD	cis	rs587080	0.624	rs674485	ENSG00000245532.5	NEAT1	-4.7	4.33e-06	0.00166	-0.24	-0.28	Plateletcrit;	chr11:65429922	chr11:65422774~65445540:+
COAD	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	4.7	4.33e-06	0.00166	0.34	0.28	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
COAD	cis	rs58873874	0.579	rs80253028	ENSG00000251405.2	CTB-109A12.1	4.7	4.34e-06	0.00167	0.55	0.28	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157362615~157460078:-
COAD	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-4.7	4.34e-06	0.00167	-0.34	-0.28	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
COAD	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-4.69	4.34e-06	0.00167	-0.31	-0.28	Height;	chr3:52994045	chr3:53064283~53065091:-
COAD	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-4.69	4.34e-06	0.00167	-0.31	-0.28	Height;	chr3:52994990	chr3:53064283~53065091:-
COAD	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	4.69	4.34e-06	0.00167	0.42	0.28	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
COAD	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	4.69	4.34e-06	0.00167	0.35	0.28	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	4.69	4.34e-06	0.00167	0.35	0.28	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-4.69	4.34e-06	0.00167	-0.35	-0.28	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
COAD	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-4.69	4.34e-06	0.00167	-0.47	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
COAD	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-4.69	4.35e-06	0.00167	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
COAD	cis	rs4713118	0.866	rs9468217	ENSG00000281706.1	LINC01012	-4.69	4.35e-06	0.00167	-0.32	-0.28	Parkinson's disease;	chr6:27758688	chr6:27694035~27710222:+
COAD	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-4.69	4.35e-06	0.00167	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
COAD	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	4.69	4.36e-06	0.00167	0.37	0.28	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
COAD	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	4.69	4.36e-06	0.00167	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
COAD	cis	rs9532669	0.889	rs7333447	ENSG00000277662.1	RP11-74J13.9	-4.69	4.36e-06	0.00167	-0.26	-0.28	Cervical cancer;	chr13:40917586	chr13:41229180~41229676:-
COAD	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-4.69	4.36e-06	0.00167	-0.49	-0.28	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
COAD	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-4.69	4.36e-06	0.00167	-0.34	-0.28	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
COAD	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-4.69	4.36e-06	0.00167	-0.34	-0.28	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
COAD	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-4.69	4.36e-06	0.00167	-0.34	-0.28	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
COAD	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-4.69	4.36e-06	0.00167	-0.33	-0.28	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
COAD	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	4.69	4.36e-06	0.00167	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
COAD	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-4.69	4.37e-06	0.00167	-0.48	-0.28	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-4.69	4.37e-06	0.00167	-0.48	-0.28	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-4.69	4.37e-06	0.00167	-0.48	-0.28	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
COAD	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-4.69	4.37e-06	0.00168	-0.33	-0.28	Height;	chr2:231549981	chr2:231508426~231514339:-
COAD	cis	rs12935418	0.579	rs1477381	ENSG00000278985.1	RP11-303E16.9	-4.69	4.37e-06	0.00168	-0.3	-0.28	Mean corpuscular volume;	chr16:80981095	chr16:80982319~80984094:-
COAD	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	4.69	4.37e-06	0.00168	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	4.69	4.37e-06	0.00168	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
COAD	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-4.69	4.37e-06	0.00168	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-4.69	4.37e-06	0.00168	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-4.69	4.37e-06	0.00168	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-4.69	4.37e-06	0.00168	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
COAD	cis	rs8141529	0.748	rs1318026	ENSG00000272858.1	CTA-292E10.8	-4.69	4.37e-06	0.00168	-0.34	-0.28	Lymphocyte counts;	chr22:28887530	chr22:28814914~28815662:+
COAD	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	4.69	4.37e-06	0.00168	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	4.69	4.37e-06	0.00168	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
COAD	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-4.69	4.38e-06	0.00168	-0.31	-0.28	Height;	chr3:52998472	chr3:53064283~53065091:-
COAD	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.69	4.38e-06	0.00168	0.3	0.28	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
COAD	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-4.69	4.38e-06	0.00168	-0.25	-0.28	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
COAD	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-4.69	4.38e-06	0.00168	-0.31	-0.28	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
COAD	cis	rs9907295	0.591	rs4251749	ENSG00000271013.1	AC015849.15	-4.69	4.38e-06	0.00168	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35823421	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.591	rs4325615	ENSG00000271013.1	AC015849.15	-4.69	4.38e-06	0.00168	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35826379	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.551	rs28595279	ENSG00000271013.1	AC015849.15	-4.69	4.38e-06	0.00168	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35826416	chr17:35912635~35918010:-
COAD	cis	rs9910055	0.529	rs228749	ENSG00000267080.4	ASB16-AS1	4.69	4.39e-06	0.00168	0.27	0.28	Total body bone mineral density;	chr17:44097202	chr17:44175973~44186717:-
COAD	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	4.69	4.39e-06	0.00168	0.32	0.28	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	4.69	4.39e-06	0.00168	0.32	0.28	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	4.69	4.39e-06	0.00168	0.32	0.28	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
COAD	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	4.69	4.39e-06	0.00168	0.28	0.28	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
COAD	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	4.69	4.4e-06	0.00169	0.34	0.28	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
COAD	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-4.69	4.4e-06	0.00169	-0.29	-0.28	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
COAD	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-4.69	4.4e-06	0.00169	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
COAD	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	4.69	4.4e-06	0.00169	0.28	0.28	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
COAD	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	4.69	4.4e-06	0.00169	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
COAD	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	4.69	4.4e-06	0.00169	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	4.69	4.4e-06	0.00169	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	4.69	4.4e-06	0.00169	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
COAD	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	4.69	4.41e-06	0.00169	0.26	0.28	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
COAD	cis	rs11951515	0.508	rs7705166	ENSG00000248554.1	RP11-159F24.6	-4.69	4.41e-06	0.00169	-0.3	-0.28	Metabolite levels  (X-11787);	chr5:43587346	chr5:43511058~43521811:+
COAD	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.69	4.41e-06	0.00169	-0.36	-0.28	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
COAD	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	4.69	4.41e-06	0.00169	0.33	0.28	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
COAD	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	4.69	4.41e-06	0.00169	0.3	0.28	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
COAD	cis	rs899997	0.773	rs7178423	ENSG00000261143.1	ADAMTS7P3	4.69	4.41e-06	0.00169	0.42	0.28	Coronary artery disease or large artery stroke;	chr15:78672619	chr15:77976042~77993057:+
COAD	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	4.69	4.41e-06	0.00169	0.29	0.28	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
COAD	cis	rs733592	0.894	rs886589	ENSG00000273765.1	RP11-370I10.11	-4.69	4.41e-06	0.00169	-0.29	-0.28	Plateletcrit;	chr12:48083414	chr12:48360920~48361377:+
COAD	cis	rs6840360	0.642	rs7676493	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs11735957	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs11099819	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.607	rs6815320	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs11726254	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs2053566	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.607	rs1561918	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs1443089	ENSG00000251611.1	RP11-610P16.1	-4.69	4.41e-06	0.00169	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151407551~151408835:-
COAD	cis	rs4568518	0.869	rs12699939	ENSG00000279048.1	RP11-511H23.2	4.69	4.42e-06	0.00169	0.2	0.28	Measles;	chr7:17997161	chr7:17940503~17942922:+
COAD	cis	rs367615	0.68	rs1103198	ENSG00000249476.1	CTD-2587M2.1	4.69	4.42e-06	0.00169	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109637882	chr5:109237120~109326369:-
COAD	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-4.69	4.42e-06	0.00169	-0.19	-0.28	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
COAD	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-4.69	4.43e-06	0.00169	-0.28	-0.28	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
COAD	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-4.69	4.43e-06	0.0017	-0.52	-0.28	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
COAD	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	4.69	4.44e-06	0.0017	0.39	0.28	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
COAD	cis	rs11951515	0.508	rs6860493	ENSG00000248554.1	RP11-159F24.6	-4.69	4.44e-06	0.0017	-0.3	-0.28	Metabolite levels  (X-11787);	chr5:43602611	chr5:43511058~43521811:+
COAD	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-4.69	4.44e-06	0.0017	-0.3	-0.28	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
COAD	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	4.69	4.44e-06	0.0017	0.36	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
COAD	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-4.69	4.45e-06	0.0017	-0.33	-0.28	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
COAD	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-4.69	4.45e-06	0.0017	-0.33	-0.28	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
COAD	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	4.69	4.45e-06	0.0017	0.35	0.28	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	4.69	4.45e-06	0.0017	0.35	0.28	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	4.69	4.45e-06	0.0017	0.35	0.28	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs4718335	ENSG00000224316.1	RP11-479O9.2	4.69	4.45e-06	0.0017	0.35	0.28	Aortic root size;	chr7:66339619	chr7:65773620~65802067:+
COAD	cis	rs3126085	0.935	rs11204967	ENSG00000237975.5	FLG-AS1	4.69	4.45e-06	0.0017	0.29	0.28	Atopic dermatitis;	chr1:152277244	chr1:152168125~152445456:+
COAD	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-4.69	4.45e-06	0.0017	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
COAD	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-4.69	4.45e-06	0.0017	-0.48	-0.28	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
COAD	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-4.69	4.45e-06	0.0017	-0.34	-0.28	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
COAD	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-4.69	4.46e-06	0.0017	-0.25	-0.28	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
COAD	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	4.69	4.46e-06	0.0017	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	4.69	4.46e-06	0.0017	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
COAD	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	4.69	4.46e-06	0.0017	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
COAD	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	4.69	4.46e-06	0.0017	0.42	0.28	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
COAD	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-4.69	4.46e-06	0.00171	-0.26	-0.28	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
COAD	cis	rs13333054	0.95	rs68143182	ENSG00000269667.1	RP11-542M13.2	-4.69	4.46e-06	0.00171	-0.37	-0.28	Multiple sclerosis;	chr16:85972232	chr16:85981750~85984723:+
COAD	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	4.69	4.47e-06	0.00171	0.29	0.28	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	4.69	4.47e-06	0.00171	0.29	0.28	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
COAD	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	4.69	4.47e-06	0.00171	0.37	0.28	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
COAD	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	4.69	4.47e-06	0.00171	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	4.69	4.47e-06	0.00171	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	4.69	4.47e-06	0.00171	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	4.69	4.47e-06	0.00171	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	4.69	4.47e-06	0.00171	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
COAD	cis	rs5742933	1	rs1898560	ENSG00000253559.1	OSGEPL1-AS1	-4.69	4.47e-06	0.00171	-0.29	-0.28	Ferritin levels;	chr2:189747601	chr2:189762704~189765556:+
COAD	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-4.69	4.47e-06	0.00171	-0.37	-0.28	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
COAD	cis	rs9487051	0.714	rs7755970	ENSG00000219700.1	PTCHD3P3	4.69	4.48e-06	0.00171	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109281156	chr6:109288571~109290503:-
COAD	cis	rs8002861	0.87	rs2121030	ENSG00000274001.1	RP11-5G9.5	-4.69	4.48e-06	0.00171	-0.25	-0.28	Leprosy;	chr13:43870438	chr13:43877715~43878163:-
COAD	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	4.69	4.48e-06	0.00171	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	4.69	4.48e-06	0.00171	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	4.69	4.48e-06	0.00171	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	4.69	4.48e-06	0.00171	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
COAD	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	4.69	4.49e-06	0.00171	0.3	0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
COAD	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	4.69	4.49e-06	0.00171	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
COAD	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	4.69	4.49e-06	0.00171	0.5	0.28	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
COAD	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	4.69	4.49e-06	0.00171	0.33	0.28	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
COAD	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	4.69	4.49e-06	0.00172	0.39	0.28	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
COAD	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.5e-06	0.00172	-0.33	-0.28	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
COAD	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	4.69	4.5e-06	0.00172	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	4.69	4.5e-06	0.00172	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	4.69	4.5e-06	0.00172	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
COAD	cis	rs984222	0.838	rs7553422	ENSG00000231365.4	RP11-418J17.1	-4.69	4.5e-06	0.00172	-0.29	-0.28	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998096	chr1:119140396~119275973:+
COAD	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	4.69	4.5e-06	0.00172	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	4.69	4.5e-06	0.00172	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
COAD	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	4.69	4.51e-06	0.00172	0.35	0.28	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
COAD	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-4.69	4.51e-06	0.00172	-0.32	-0.28	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
COAD	cis	rs2836974	0.568	rs11910906	ENSG00000255568.3	BRWD1-AS2	-4.69	4.51e-06	0.00172	-0.27	-0.28	Cognitive function;	chr21:39313736	chr21:39313935~39314962:+
COAD	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-4.69	4.51e-06	0.00172	-0.36	-0.28	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
COAD	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-4.69	4.51e-06	0.00172	-0.32	-0.28	Height;	chr3:52989412	chr3:53064283~53065091:-
COAD	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	4.69	4.51e-06	0.00172	0.31	0.28	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
COAD	cis	rs9532669	0.926	rs7328139	ENSG00000239827.7	SUGT1P3	-4.69	4.51e-06	0.00172	-0.24	-0.28	Cervical cancer;	chr13:40862295	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7328145	ENSG00000239827.7	SUGT1P3	-4.69	4.51e-06	0.00172	-0.24	-0.28	Cervical cancer;	chr13:40862307	chr13:40908159~40921774:-
COAD	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-4.69	4.51e-06	0.00172	-0.32	-0.28	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
COAD	cis	rs11951515	0.508	rs1366410	ENSG00000248554.1	RP11-159F24.6	-4.69	4.51e-06	0.00172	-0.3	-0.28	Metabolite levels  (X-11787);	chr5:43601508	chr5:43511058~43521811:+
COAD	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	4.69	4.52e-06	0.00172	0.4	0.28	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	4.69	4.52e-06	0.00172	0.4	0.28	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
COAD	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-4.69	4.52e-06	0.00172	-0.28	-0.28	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
COAD	cis	rs17685	0.753	rs4728586	ENSG00000280388.1	RP11-229D13.3	-4.69	4.52e-06	0.00172	-0.29	-0.28	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76043977~76045963:-
COAD	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	4.69	4.52e-06	0.00172	0.29	0.28	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
COAD	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-4.69	4.52e-06	0.00172	-0.41	-0.28	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
COAD	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	4.69	4.52e-06	0.00173	0.32	0.28	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
COAD	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	4.69	4.53e-06	0.00173	0.38	0.28	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
COAD	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-4.69	4.53e-06	0.00173	-0.16	-0.28	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-4.69	4.53e-06	0.00173	-0.16	-0.28	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
COAD	cis	rs603446	0.935	rs918143	ENSG00000254851.1	RP11-109L13.1	-4.69	4.53e-06	0.00173	-0.32	-0.28	Triglycerides;	chr11:116759884	chr11:117135528~117138582:+
COAD	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-4.69	4.54e-06	0.00173	-0.3	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
COAD	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-4.69	4.54e-06	0.00173	-0.35	-0.28	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
COAD	cis	rs385076	0.563	rs12712324	ENSG00000272716.1	RP11-563N4.1	-4.69	4.54e-06	0.00173	-0.3	-0.28	Interleukin-18 levels;	chr2:31833446	chr2:32165046~32165757:-
COAD	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.68	4.54e-06	0.00173	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
COAD	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	4.68	4.55e-06	0.00173	0.34	0.28	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
COAD	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	4.68	4.55e-06	0.00173	0.44	0.28	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
COAD	cis	rs77204473	0.655	rs11216183	ENSG00000280143.1	AP000892.6	-4.68	4.55e-06	0.00173	-0.41	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117204967~117210292:+
COAD	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-4.68	4.55e-06	0.00173	-0.27	-0.28	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
COAD	cis	rs4657482	0.606	rs3790665	ENSG00000236364.3	RP11-525G13.2	-4.68	4.55e-06	0.00173	-0.23	-0.28	Testicular germ cell tumor;	chr1:165900834	chr1:165890795~165900683:-
COAD	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	4.68	4.55e-06	0.00173	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	4.68	4.55e-06	0.00173	0.37	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
COAD	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	4.68	4.55e-06	0.00173	0.38	0.28	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.68	4.55e-06	0.00173	0.29	0.28	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	4.68	4.55e-06	0.00173	0.29	0.28	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	4.68	4.55e-06	0.00173	0.29	0.28	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
COAD	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-4.68	4.55e-06	0.00173	-0.5	-0.28	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
COAD	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	4.68	4.55e-06	0.00173	0.32	0.28	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
COAD	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	4.68	4.55e-06	0.00173	0.24	0.28	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
COAD	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-4.68	4.56e-06	0.00174	-0.3	-0.28	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
COAD	cis	rs755249	0.614	rs10888798	ENSG00000182109.6	RP11-69E11.4	-4.68	4.56e-06	0.00174	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39522280~39546187:-
COAD	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.56e-06	0.00174	-0.33	-0.28	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
COAD	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-4.68	4.56e-06	0.00174	-0.42	-0.28	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
COAD	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	4.68	4.56e-06	0.00174	0.28	0.28	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
COAD	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	4.68	4.57e-06	0.00174	0.31	0.28	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
COAD	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.68	4.57e-06	0.00174	-0.35	-0.28	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
COAD	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-4.68	4.57e-06	0.00174	-0.3	-0.28	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
COAD	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-4.68	4.57e-06	0.00174	-0.32	-0.28	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
COAD	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	4.68	4.57e-06	0.00174	0.29	0.28	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
COAD	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	4.68	4.57e-06	0.00174	0.29	0.28	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	4.68	4.57e-06	0.00174	0.29	0.28	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	4.68	4.57e-06	0.00174	0.29	0.28	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	4.68	4.57e-06	0.00174	0.29	0.28	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
COAD	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-4.68	4.58e-06	0.00174	-0.27	-0.28	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
COAD	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	4.68	4.58e-06	0.00174	0.33	0.28	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
COAD	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	4.68	4.58e-06	0.00174	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
COAD	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	4.68	4.58e-06	0.00174	0.38	0.28	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
COAD	cis	rs13256369	1	rs12547721	ENSG00000173295.6	FAM86B3P	4.68	4.59e-06	0.00175	0.39	0.28	Obesity-related traits;	chr8:8713161	chr8:8228595~8244865:+
COAD	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	4.68	4.59e-06	0.00175	0.35	0.28	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
COAD	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-4.68	4.59e-06	0.00175	-0.33	-0.28	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
COAD	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-4.68	4.59e-06	0.00175	-0.25	-0.28	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
COAD	cis	rs728616	0.867	rs56198874	ENSG00000225484.5	NUTM2B-AS1	-4.68	4.59e-06	0.00175	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79663088~79826594:-
COAD	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.68	4.59e-06	0.00175	0.3	0.28	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
COAD	cis	rs492146	1	rs428957	ENSG00000243236.5	GSTA9P	-4.68	4.6e-06	0.00175	-0.3	-0.28	Epilepsy (remission after treatment);	chr6:52974387	chr6:52939726~52957521:-
COAD	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	4.68	4.61e-06	0.00175	0.29	0.28	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
COAD	cis	rs73198271	0.96	rs10503392	ENSG00000173295.6	FAM86B3P	-4.68	4.61e-06	0.00175	-0.39	-0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:8228595~8244865:+
COAD	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	4.68	4.61e-06	0.00175	0.4	0.28	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
COAD	cis	rs11668609	0.515	rs61308481	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (docetaxel);	chr19:23882545	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs59175483	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23882740	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs61693040	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23883370	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs57061964	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23883476	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs11670271	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23883921	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs11670335	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23884108	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs11672509	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23885967	chr19:24162370~24163425:-
COAD	cis	rs11668609	0.515	rs13346480	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (docetaxel);	chr19:23889271	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs1347177	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23896658	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs10412189	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23897536	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs7254143	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23897735	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs10418417	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23898005	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs10425498	ENSG00000268442.1	CTD-2027I19.2	4.68	4.61e-06	0.00175	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23898869	chr19:24162370~24163425:-
COAD	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-4.68	4.61e-06	0.00175	-0.26	-0.28	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-4.68	4.61e-06	0.00175	-0.26	-0.28	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
COAD	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	4.68	4.62e-06	0.00175	0.31	0.28	Height;	chr4:55370412	chr4:55363971~55395847:-
COAD	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	4.68	4.62e-06	0.00176	0.32	0.28	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
COAD	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-4.68	4.62e-06	0.00176	-0.35	-0.28	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
COAD	cis	rs597539	0.652	rs622082	ENSG00000255741.1	RP11-757G1.5	-4.68	4.62e-06	0.00176	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs546382	ENSG00000255741.1	RP11-757G1.5	-4.68	4.62e-06	0.00176	-0.38	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68941503~68942852:-
COAD	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-4.68	4.63e-06	0.00176	-0.3	-0.28	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-4.68	4.63e-06	0.00176	-0.3	-0.28	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
COAD	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-4.68	4.64e-06	0.00176	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-4.68	4.64e-06	0.00176	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-4.68	4.64e-06	0.00176	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
COAD	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-4.68	4.64e-06	0.00176	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
COAD	cis	rs7829975	0.686	rs907180	ENSG00000173295.6	FAM86B3P	4.68	4.64e-06	0.00176	0.32	0.28	Mood instability;	chr8:8845317	chr8:8228595~8244865:+
COAD	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-4.68	4.64e-06	0.00176	-0.4	-0.28	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
COAD	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-4.68	4.64e-06	0.00176	-0.24	-0.28	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
COAD	cis	rs36093924	0.646	rs5996094	ENSG00000182057.4	OGFRP1	-4.68	4.64e-06	0.00176	-0.28	-0.28	Intelligence;	chr22:41951056	chr22:42269753~42275196:+
COAD	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-4.68	4.65e-06	0.00176	-0.31	-0.28	Height;	chr11:118809363	chr11:118704607~118750263:+
COAD	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-4.68	4.65e-06	0.00176	-0.47	-0.28	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
COAD	cis	rs12908161	0.853	rs12912342	ENSG00000225151.9	GOLGA2P7	-4.68	4.65e-06	0.00176	-0.34	-0.28	Schizophrenia;	chr15:84704985	chr15:84199311~84230136:-
COAD	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	4.68	4.65e-06	0.00177	0.32	0.28	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
COAD	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-4.68	4.65e-06	0.00177	-0.48	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
COAD	cis	rs8002861	0.967	rs2325071	ENSG00000274001.1	RP11-5G9.5	4.68	4.65e-06	0.00177	0.25	0.28	Leprosy;	chr13:43902657	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.967	rs9525871	ENSG00000274001.1	RP11-5G9.5	4.68	4.65e-06	0.00177	0.25	0.28	Leprosy;	chr13:43903576	chr13:43877715~43878163:-
COAD	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-4.68	4.65e-06	0.00177	-0.35	-0.28	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
COAD	cis	rs8002861	0.935	rs1373903	ENSG00000274001.1	RP11-5G9.5	4.68	4.65e-06	0.00177	0.25	0.28	Leprosy;	chr13:43901378	chr13:43877715~43878163:-
COAD	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	4.68	4.66e-06	0.00177	0.53	0.28	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
COAD	cis	rs748404	0.601	rs530118	ENSG00000205771.5	CATSPER2P1	4.68	4.66e-06	0.00177	0.35	0.28	Lung cancer;	chr15:43186313	chr15:43726918~43747094:-
COAD	cis	rs7577696	0.554	rs3769605	ENSG00000272716.1	RP11-563N4.1	-4.68	4.67e-06	0.00177	-0.32	-0.28	Inflammatory biomarkers;	chr2:32097387	chr2:32165046~32165757:-
COAD	cis	rs2777491	0.872	rs7163649	ENSG00000247556.5	OIP5-AS1	4.68	4.67e-06	0.00177	0.3	0.28	Ulcerative colitis;	chr15:41294600	chr15:41283990~41309737:+
COAD	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	4.68	4.67e-06	0.00177	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
COAD	cis	rs9818758	0.607	rs9855123	ENSG00000225399.4	RP11-3B7.1	-4.68	4.67e-06	0.00177	-0.49	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs11719220	ENSG00000225399.4	RP11-3B7.1	-4.68	4.67e-06	0.00177	-0.49	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:49260085~49261316:+
COAD	cis	rs9487051	0.714	rs9487058	ENSG00000219700.1	PTCHD3P3	4.68	4.68e-06	0.00178	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109309857	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.714	rs6930733	ENSG00000219700.1	PTCHD3P3	4.68	4.68e-06	0.00178	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109310384	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.714	rs9386797	ENSG00000219700.1	PTCHD3P3	4.68	4.68e-06	0.00178	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109311317	chr6:109288571~109290503:-
COAD	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	4.68	4.68e-06	0.00178	0.45	0.28	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
COAD	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-4.68	4.69e-06	0.00178	-0.29	-0.28	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.68	4.69e-06	0.00178	-0.29	-0.28	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
COAD	cis	rs9307551	0.741	rs1561640	ENSG00000250334.4	LINC00989	-4.68	4.69e-06	0.00178	-0.37	-0.28	Refractive error;	chr4:79498874	chr4:79492416~79576460:+
COAD	cis	rs8061903	0.535	rs35705628	ENSG00000260071.1	RP11-418I22.2	4.68	4.69e-06	0.00178	0.35	0.28	HIV-1 viral setpoint;	chr16:9309292	chr16:9466655~9517564:+
COAD	cis	rs8061903	0.535	rs3909919	ENSG00000260071.1	RP11-418I22.2	4.68	4.69e-06	0.00178	0.35	0.28	HIV-1 viral setpoint;	chr16:9309725	chr16:9466655~9517564:+
COAD	cis	rs12497850	0.897	rs7373778	ENSG00000225399.4	RP11-3B7.1	4.68	4.69e-06	0.00178	0.31	0.28	Parkinson's disease;	chr3:48798959	chr3:49260085~49261316:+
COAD	cis	rs953301	0.793	rs1394065	ENSG00000229808.1	RP11-456P18.2	4.68	4.7e-06	0.00178	0.5	0.28	Left atrial antero-posterior diameter;	chr1:161861106	chr1:161890833~161892196:+
COAD	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-4.68	4.7e-06	0.00178	-0.29	-0.28	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-4.68	4.7e-06	0.00178	-0.29	-0.28	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-4.68	4.7e-06	0.00178	-0.29	-0.28	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-4.68	4.7e-06	0.00178	-0.29	-0.28	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-4.68	4.7e-06	0.00178	-0.29	-0.28	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
COAD	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-4.68	4.71e-06	0.00178	-0.34	-0.28	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-4.68	4.71e-06	0.00178	-0.34	-0.28	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
COAD	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	4.68	4.71e-06	0.00178	0.35	0.28	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	4.68	4.71e-06	0.00178	0.35	0.28	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
COAD	cis	rs7224610	0.801	rs4793788	ENSG00000263096.1	RP11-515O17.2	-4.68	4.71e-06	0.00178	-0.31	-0.28	Urate levels;	chr17:55304435	chr17:55271504~55273653:-
COAD	cis	rs6840360	0.692	rs4479686	ENSG00000270265.1	RP11-731D1.4	-4.68	4.71e-06	0.00179	-0.34	-0.28	Intelligence (multi-trait analysis);	chr4:151478172	chr4:151333775~151353224:-
COAD	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-4.68	4.71e-06	0.00179	-0.32	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
COAD	cis	rs2337406	0.85	rs11849578	ENSG00000211974.3	IGHV2-70	-4.68	4.71e-06	0.00179	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106670302	chr14:106723574~106724093:-
COAD	cis	rs1790761	0.587	rs7934075	ENSG00000231793.4	DOC2GP	-4.68	4.72e-06	0.00179	-0.31	-0.28	Mean corpuscular volume;	chr11:67528478	chr11:67612653~67616257:-
COAD	cis	rs6490294	0.748	rs7963329	ENSG00000257595.2	RP3-473L9.4	4.68	4.73e-06	0.00179	0.4	0.28	Mean platelet volume;	chr12:111966127	chr12:111369282~111403310:+
COAD	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	4.68	4.73e-06	0.00179	0.31	0.28	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
COAD	cis	rs597539	0.69	rs635529	ENSG00000255741.1	RP11-757G1.5	-4.68	4.73e-06	0.00179	-0.39	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68941503~68942852:-
COAD	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	4.68	4.73e-06	0.00179	0.42	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
COAD	cis	rs875971	0.66	rs10215132	ENSG00000272831.1	RP11-792A8.4	-4.68	4.73e-06	0.00179	-0.29	-0.28	Aortic root size;	chr7:66589419	chr7:66739829~66740385:-
COAD	cis	rs13256369	1	rs13267501	ENSG00000173295.6	FAM86B3P	4.68	4.74e-06	0.00179	0.4	0.28	Obesity-related traits;	chr8:8716548	chr8:8228595~8244865:+
COAD	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-4.68	4.74e-06	0.0018	-0.37	-0.28	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
COAD	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-4.68	4.75e-06	0.0018	-0.37	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
COAD	cis	rs74233809	1	rs12217501	ENSG00000213277.3	MARCKSL1P1	4.68	4.75e-06	0.0018	0.58	0.28	Birth weight;	chr10:103092132	chr10:103175554~103176094:+
COAD	cis	rs5742933	0.51	rs10182631	ENSG00000253559.1	OSGEPL1-AS1	-4.68	4.75e-06	0.0018	-0.33	-0.28	Ferritin levels;	chr2:189635233	chr2:189762704~189765556:+
COAD	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-4.68	4.75e-06	0.0018	-0.46	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
COAD	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	4.68	4.75e-06	0.0018	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
COAD	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	4.67	4.75e-06	0.0018	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
COAD	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-4.67	4.75e-06	0.0018	-0.33	-0.28	Height;	chr2:231551270	chr2:231508426~231514339:-
COAD	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
COAD	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-4.67	4.76e-06	0.0018	-0.34	-0.28	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
COAD	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-4.67	4.76e-06	0.0018	-0.34	-0.28	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
COAD	cis	rs2188554	0.785	rs11772396	ENSG00000237974.1	AC000111.4	-4.67	4.76e-06	0.0018	-0.29	-0.28	Esophageal adenocarcinoma;	chr7:117492865	chr7:117487737~117487929:+
COAD	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-4.67	4.77e-06	0.0018	-0.32	-0.28	QT interval;	chr12:29306357	chr12:29280418~29317848:-
COAD	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	4.67	4.77e-06	0.0018	0.36	0.28	QT interval;	chr4:75104432	chr4:74955974~74970362:-
COAD	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	4.67	4.77e-06	0.00181	0.31	0.28	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	4.67	4.77e-06	0.00181	0.31	0.28	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
COAD	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-4.67	4.77e-06	0.00181	-0.31	-0.28	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
COAD	cis	rs8141529	0.748	rs5762874	ENSG00000272858.1	CTA-292E10.8	-4.67	4.78e-06	0.00181	-0.34	-0.28	Lymphocyte counts;	chr22:28873670	chr22:28814914~28815662:+
COAD	cis	rs9813712	0.574	rs11718032	ENSG00000249846.5	RP11-77P16.4	4.67	4.78e-06	0.00181	0.32	0.28	Response to amphetamines;	chr3:130257749	chr3:130112550~130120579:+
COAD	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	4.67	4.78e-06	0.00181	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
COAD	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	4.67	4.79e-06	0.00181	0.31	0.28	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
COAD	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-4.67	4.79e-06	0.00181	-0.34	-0.28	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-4.67	4.79e-06	0.00181	-0.34	-0.28	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
COAD	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	4.67	4.79e-06	0.00181	0.35	0.28	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
COAD	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-4.67	4.79e-06	0.00181	-0.32	-0.28	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-4.67	4.79e-06	0.00181	-0.32	-0.28	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
COAD	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-4.67	4.8e-06	0.00181	-0.32	-0.28	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-4.67	4.8e-06	0.00181	-0.32	-0.28	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-4.67	4.8e-06	0.00181	-0.32	-0.28	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-4.67	4.8e-06	0.00181	-0.32	-0.28	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
COAD	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-4.67	4.8e-06	0.00181	-0.32	-0.28	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
COAD	cis	rs2281603	0.521	rs6573559	ENSG00000259116.1	RP11-973N13.4	-4.67	4.8e-06	0.00181	-0.27	-0.28	Lymphocyte counts;	chr14:64456448	chr14:64514154~64540368:-
COAD	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	4.67	4.8e-06	0.00182	0.26	0.28	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
COAD	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-4.67	4.81e-06	0.00182	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
COAD	cis	rs4718428	0.924	rs6971897	ENSG00000273142.1	RP11-458F8.4	-4.67	4.81e-06	0.00182	-0.21	-0.28	Corneal structure;	chr7:66947787	chr7:66902857~66906297:+
COAD	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	4.67	4.81e-06	0.00182	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
COAD	cis	rs2777491	0.872	rs61037359	ENSG00000247556.5	OIP5-AS1	4.67	4.81e-06	0.00182	0.3	0.28	Ulcerative colitis;	chr15:41293728	chr15:41283990~41309737:+
COAD	cis	rs492146	1	rs492146	ENSG00000243236.5	GSTA9P	-4.67	4.82e-06	0.00182	-0.3	-0.28	Epilepsy (remission after treatment);	chr6:52971097	chr6:52939726~52957521:-
COAD	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	4.67	4.82e-06	0.00182	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
COAD	cis	rs453301	0.624	rs330049	ENSG00000254340.1	RP11-10A14.3	4.67	4.82e-06	0.00182	0.33	0.28	Joint mobility (Beighton score);	chr8:9229789	chr8:9141424~9145435:+
COAD	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	4.67	4.82e-06	0.00182	0.28	0.28	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
COAD	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	4.67	4.83e-06	0.00182	0.65	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
COAD	cis	rs2732480	0.5	rs2450986	ENSG00000226413.2	OR8T1P	4.67	4.83e-06	0.00182	0.35	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48442030~48442947:-
COAD	cis	rs1387259	0.929	rs2956703	ENSG00000226413.2	OR8T1P	4.67	4.83e-06	0.00182	0.35	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48442030~48442947:-
COAD	cis	rs1387259	0.931	rs1107654	ENSG00000226413.2	OR8T1P	4.67	4.83e-06	0.00182	0.35	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48442030~48442947:-
COAD	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
COAD	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
COAD	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
COAD	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
COAD	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	4.67	4.83e-06	0.00182	0.43	0.28	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
COAD	cis	rs13256369	1	rs7004438	ENSG00000173295.6	FAM86B3P	4.67	4.83e-06	0.00183	0.39	0.28	Obesity-related traits;	chr8:8716869	chr8:8228595~8244865:+
COAD	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	4.67	4.83e-06	0.00183	0.36	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
COAD	cis	rs3126085	0.515	rs6668321	ENSG00000237975.5	FLG-AS1	4.67	4.83e-06	0.00183	0.31	0.28	Atopic dermatitis;	chr1:152381464	chr1:152168125~152445456:+
COAD	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-4.67	4.84e-06	0.00183	-0.29	-0.28	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
COAD	cis	rs492146	1	rs380646	ENSG00000243236.5	GSTA9P	-4.67	4.84e-06	0.00183	-0.3	-0.28	Epilepsy (remission after treatment);	chr6:52972842	chr6:52939726~52957521:-
COAD	cis	rs7560272	0.538	rs12233112	ENSG00000163016.8	ALMS1P	-4.67	4.84e-06	0.00183	-0.34	-0.28	Schizophrenia;	chr2:73704637	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	4.67	4.84e-06	0.00183	0.32	0.28	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	4.67	4.84e-06	0.00183	0.32	0.28	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
COAD	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	4.67	4.85e-06	0.00183	0.31	0.28	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
COAD	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-4.67	4.85e-06	0.00183	-0.38	-0.28	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
COAD	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	4.67	4.85e-06	0.00183	0.32	0.28	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
COAD	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	4.67	4.85e-06	0.00183	0.28	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
COAD	cis	rs36052053	1	rs36052053	ENSG00000219700.1	PTCHD3P3	4.67	4.85e-06	0.00183	0.48	0.28	Red cell distribution width;	chr6:109262596	chr6:109288571~109290503:-
COAD	cis	rs2281603	0.57	rs4632045	ENSG00000259116.1	RP11-973N13.4	-4.67	4.85e-06	0.00183	-0.29	-0.28	Lymphocyte counts;	chr14:64496408	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs12050238	ENSG00000259116.1	RP11-973N13.4	-4.67	4.85e-06	0.00183	-0.29	-0.28	Lymphocyte counts;	chr14:64498157	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.521	rs10142879	ENSG00000259116.1	RP11-973N13.4	-4.67	4.85e-06	0.00183	-0.29	-0.28	Lymphocyte counts;	chr14:64499124	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs12050358	ENSG00000259116.1	RP11-973N13.4	-4.67	4.85e-06	0.00183	-0.29	-0.28	Lymphocyte counts;	chr14:64499986	chr14:64514154~64540368:-
COAD	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	4.67	4.86e-06	0.00183	0.32	0.28	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
COAD	cis	rs2916733	0.607	rs1129706	ENSG00000246089.3	RP11-115C21.2	4.67	4.86e-06	0.00184	0.37	0.28	Epirubicin-induced leukopenia;	chr8:6447293	chr8:6403551~6407142:-
COAD	cis	rs5758511	0.773	rs73165164	ENSG00000237037.8	NDUFA6-AS1	-4.67	4.86e-06	0.00184	-0.31	-0.28	Birth weight;	chr22:41959545	chr22:42090931~42137742:+
COAD	cis	rs6952407	1	rs6952407	ENSG00000272831.1	RP11-792A8.4	-4.67	4.87e-06	0.00184	-0.31	-0.28	Cotinine glucuronidation;	chr7:66580525	chr7:66739829~66740385:-
COAD	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	4.67	4.87e-06	0.00184	0.28	0.28	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
COAD	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-4.67	4.87e-06	0.00184	-0.36	-0.28	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
COAD	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-4.67	4.87e-06	0.00184	-0.41	-0.28	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
COAD	cis	rs4657482	0.572	rs4656466	ENSG00000236364.3	RP11-525G13.2	-4.67	4.88e-06	0.00184	-0.24	-0.28	Testicular germ cell tumor;	chr1:165900130	chr1:165890795~165900683:-
COAD	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	4.67	4.88e-06	0.00184	0.28	0.28	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
COAD	cis	rs4767364	0.645	rs7974383	ENSG00000257595.2	RP3-473L9.4	4.67	4.88e-06	0.00184	0.4	0.28	Oral cavity and pharyngeal cancer;	chr12:112356910	chr12:111369282~111403310:+
COAD	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	4.67	4.89e-06	0.00184	0.3	0.28	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
COAD	cis	rs9307551	0.697	rs7691918	ENSG00000250334.4	LINC00989	-4.67	4.89e-06	0.00184	-0.37	-0.28	Refractive error;	chr4:79495337	chr4:79492416~79576460:+
COAD	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	4.67	4.9e-06	0.00185	0.37	0.28	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
COAD	cis	rs2378497	1	rs2800859	ENSG00000232679.1	RP11-400N13.3	4.67	4.9e-06	0.00185	0.37	0.28	Serum thyroid-stimulating hormone levels;	chr1:222009246	chr1:222041705~222064763:-
COAD	cis	rs74233809	1	rs12412038	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103096405	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	4.67	4.9e-06	0.00185	0.58	0.28	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
COAD	cis	rs7818688	0.697	rs78802294	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965746	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.674	rs74632106	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965804	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs112076731	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965893	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11779698	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967536	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.654	rs11783262	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967588	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11783985	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967658	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs77055525	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968355	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs112411609	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968626	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs76631135	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968760	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs74633621	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968809	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs76815619	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969102	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs74861094	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969157	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs74633235	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969248	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs17665714	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94970314	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs57890591	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94970902	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs10504939	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971126	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs60003497	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971195	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs77805255	ENSG00000253528.2	RP11-347C18.4	-4.67	4.9e-06	0.00185	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971338	chr8:94974573~94974853:-
COAD	cis	rs2732480	0.5	rs2450986	ENSG00000257735.1	RP11-370I10.6	4.67	4.91e-06	0.00185	0.34	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48350945~48442411:+
COAD	cis	rs1387259	0.929	rs2956703	ENSG00000257735.1	RP11-370I10.6	4.67	4.91e-06	0.00185	0.34	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48350945~48442411:+
COAD	cis	rs1387259	0.931	rs1107654	ENSG00000257735.1	RP11-370I10.6	4.67	4.91e-06	0.00185	0.34	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48350945~48442411:+
COAD	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-4.67	4.91e-06	0.00185	-0.25	-0.28	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-4.67	4.91e-06	0.00185	-0.25	-0.28	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
COAD	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	4.67	4.91e-06	0.00185	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
COAD	cis	rs2292884	0.505	rs77856818	ENSG00000234949.2	AC104667.3	-4.67	4.91e-06	0.00185	-0.48	-0.28	Prostate cancer;	chr2:237494187	chr2:237591020~237595981:+
COAD	cis	rs5758511	0.773	rs1894714	ENSG00000237037.8	NDUFA6-AS1	4.67	4.91e-06	0.00185	0.3	0.28	Birth weight;	chr22:41953130	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.731	rs5751186	ENSG00000237037.8	NDUFA6-AS1	4.67	4.91e-06	0.00185	0.3	0.28	Birth weight;	chr22:41953706	chr22:42090931~42137742:+
COAD	cis	rs8002861	0.967	rs9533689	ENSG00000274001.1	RP11-5G9.5	4.67	4.91e-06	0.00185	0.25	0.28	Leprosy;	chr13:43906277	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.967	rs9533690	ENSG00000274001.1	RP11-5G9.5	4.67	4.91e-06	0.00185	0.25	0.28	Leprosy;	chr13:43906462	chr13:43877715~43878163:-
COAD	cis	rs6840360	0.642	rs10857260	ENSG00000251611.1	RP11-610P16.1	-4.67	4.92e-06	0.00185	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151407551~151408835:-
COAD	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-4.67	4.92e-06	0.00185	-0.3	-0.28	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
COAD	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-4.67	4.92e-06	0.00185	-0.3	-0.28	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
COAD	cis	rs9450351	0.744	rs9450299	ENSG00000203875.9	SNHG5	-4.67	4.92e-06	0.00185	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85562103	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6930543	ENSG00000203875.9	SNHG5	-4.67	4.92e-06	0.00185	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85562658	chr6:85660950~85678736:-
COAD	cis	rs7818688	1	rs79396265	ENSG00000253528.2	RP11-347C18.4	-4.67	4.93e-06	0.00186	-0.46	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95059044	chr8:94974573~94974853:-
COAD	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-4.67	4.93e-06	0.00186	-0.26	-0.28	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-4.67	4.93e-06	0.00186	-0.26	-0.28	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
COAD	cis	rs6095360	0.7	rs11908024	ENSG00000222365.1	SNORD12B	-4.67	4.93e-06	0.00186	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49081649	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs2075677	ENSG00000222365.1	SNORD12B	-4.67	4.93e-06	0.00186	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49084487	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-4.67	4.93e-06	0.00186	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
COAD	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	4.67	4.94e-06	0.00186	0.29	0.28	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
COAD	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	4.67	4.94e-06	0.00186	0.29	0.28	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
COAD	cis	rs6723226	0.699	rs376914	ENSG00000276334.1	AL133243.1	4.67	4.94e-06	0.00186	0.26	0.28	Intelligence (multi-trait analysis);	chr2:32283324	chr2:32521927~32523547:+
COAD	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	4.67	4.94e-06	0.00186	0.36	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
COAD	cis	rs953301	0.744	rs35541527	ENSG00000229808.1	RP11-456P18.2	-4.67	4.94e-06	0.00186	-0.62	-0.28	Left atrial antero-posterior diameter;	chr1:161764807	chr1:161890833~161892196:+
COAD	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-4.67	4.95e-06	0.00186	-0.29	-0.28	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
COAD	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-4.67	4.95e-06	0.00186	-0.33	-0.28	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
COAD	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	4.67	4.95e-06	0.00186	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	4.67	4.95e-06	0.00186	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	4.67	4.95e-06	0.00186	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	4.67	4.95e-06	0.00186	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
COAD	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-4.67	4.95e-06	0.00186	-0.34	-0.28	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
COAD	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-4.67	4.96e-06	0.00186	-0.24	-0.28	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
COAD	cis	rs4704187	0.687	rs4447963	ENSG00000250889.2	LINC01336	-4.67	4.96e-06	0.00187	-0.32	-0.28	Response to amphetamines;	chr5:75080484	chr5:75047719~75052843:-
COAD	cis	rs11668609	1	rs919812	ENSG00000268442.1	CTD-2027I19.2	4.67	4.96e-06	0.00187	0.34	0.28	Response to taxane treatment (docetaxel);	chr19:24163425	chr19:24162370~24163425:-
COAD	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-4.66	4.97e-06	0.00187	-0.3	-0.28	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
COAD	cis	rs35264875	0.796	rs72928657	ENSG00000259799.1	RP11-554A11.9	4.66	4.97e-06	0.00187	0.45	0.28	Blond vs. brown hair color;	chr11:69084868	chr11:69155910~69159752:+
COAD	cis	rs35264875	0.95	rs72928659	ENSG00000259799.1	RP11-554A11.9	4.66	4.97e-06	0.00187	0.45	0.28	Blond vs. brown hair color;	chr11:69084890	chr11:69155910~69159752:+
COAD	cis	rs2599510	0.744	rs2254106	ENSG00000276334.1	AL133243.1	4.66	4.98e-06	0.00187	0.25	0.28	Interleukin-18 levels;	chr2:32543730	chr2:32521927~32523547:+
COAD	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	4.66	4.98e-06	0.00187	0.31	0.28	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
COAD	cis	rs2337406	0.866	rs78462736	ENSG00000211974.3	IGHV2-70	-4.66	4.98e-06	0.00187	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106779942	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs8016203	ENSG00000211974.3	IGHV2-70	-4.66	4.98e-06	0.00187	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106780575	chr14:106723574~106724093:-
COAD	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-4.66	4.98e-06	0.00187	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
COAD	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-4.66	4.98e-06	0.00187	-0.43	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
COAD	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.99e-06	0.00188	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
COAD	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-4.66	4.99e-06	0.00188	-0.33	-0.28	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
COAD	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-4.66	4.99e-06	0.00188	-0.34	-0.28	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
COAD	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	4.66	4.99e-06	0.00188	0.42	0.28	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
COAD	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-4.66	4.99e-06	0.00188	-0.3	-0.28	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
COAD	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	4.66	4.99e-06	0.00188	0.31	0.28	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	4.66	4.99e-06	0.00188	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	4.66	4.99e-06	0.00188	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
COAD	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	4.66	5e-06	0.00188	0.34	0.28	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
COAD	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	4.66	5e-06	0.00188	0.31	0.28	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
COAD	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-4.66	5e-06	0.00188	-0.33	-0.28	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
COAD	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	4.66	5e-06	0.00188	0.57	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
COAD	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.66	5.01e-06	0.00188	-0.29	-0.28	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-4.66	5.01e-06	0.00188	-0.29	-0.28	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
COAD	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	4.66	5.01e-06	0.00188	0.22	0.28	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
COAD	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-4.66	5.01e-06	0.00188	-0.4	-0.28	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
COAD	cis	rs13256369	1	rs4840352	ENSG00000173295.6	FAM86B3P	4.66	5.02e-06	0.00189	0.4	0.28	Obesity-related traits;	chr8:8715998	chr8:8228595~8244865:+
COAD	cis	rs9309473	0.519	rs1083922	ENSG00000163016.8	ALMS1P	-4.66	5.02e-06	0.00189	-0.34	-0.28	Metabolite levels;	chr2:73476876	chr2:73644919~73685576:+
COAD	cis	rs7587476	0.599	rs61073893	ENSG00000229267.2	AC072062.1	-4.66	5.02e-06	0.00189	-0.38	-0.28	Neuroblastoma;	chr2:214880090	chr2:214810229~214963274:+
COAD	cis	rs492146	0.819	rs5028437	ENSG00000243236.5	GSTA9P	4.66	5.03e-06	0.00189	0.31	0.28	Epilepsy (remission after treatment);	chr6:52970876	chr6:52939726~52957521:-
COAD	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-4.66	5.03e-06	0.00189	-0.25	-0.28	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
COAD	cis	rs2581828	0.646	rs9861233	ENSG00000280417.1	RP11-5O17.1	4.66	5.04e-06	0.00189	0.3	0.28	Crohn's disease;	chr3:53124815	chr3:53046166~53048122:+
COAD	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-4.66	5.04e-06	0.00189	-0.28	-0.28	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-4.66	5.04e-06	0.00189	-0.28	-0.28	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
COAD	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	4.66	5.04e-06	0.00189	0.35	0.28	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	4.66	5.04e-06	0.00189	0.35	0.28	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	4.66	5.04e-06	0.00189	0.35	0.28	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
COAD	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.66	5.04e-06	0.00189	-0.34	-0.28	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
COAD	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	4.66	5.04e-06	0.00189	0.31	0.28	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
COAD	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	4.66	5.05e-06	0.00189	0.42	0.28	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
COAD	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-4.66	5.05e-06	0.0019	-0.29	-0.28	Axial length;	chr3:53813381	chr3:53797764~53798019:-
COAD	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	4.66	5.05e-06	0.0019	0.31	0.28	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
COAD	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-4.66	5.05e-06	0.0019	-0.35	-0.28	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
COAD	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-4.66	5.05e-06	0.0019	-0.32	-0.28	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
COAD	cis	rs12497850	0.931	rs62262517	ENSG00000225399.4	RP11-3B7.1	4.66	5.07e-06	0.0019	0.31	0.28	Parkinson's disease;	chr3:49097481	chr3:49260085~49261316:+
COAD	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	4.66	5.07e-06	0.0019	0.25	0.28	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
COAD	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-4.66	5.07e-06	0.0019	-0.34	-0.28	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
COAD	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	4.66	5.08e-06	0.0019	0.28	0.28	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
COAD	cis	rs891378	1	rs10864180	ENSG00000274245.1	RP11-357P18.2	-4.66	5.08e-06	0.00191	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272416	chr1:207372559~207373252:+
COAD	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-4.66	5.08e-06	0.00191	-0.32	-0.28	QT interval;	chr12:29314736	chr12:29280418~29317848:-
COAD	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-4.66	5.08e-06	0.00191	-0.37	-0.28	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
COAD	cis	rs1900504	0.584	rs2915754	ENSG00000266200.5	PNLIPRP2	-4.66	5.09e-06	0.00191	-0.35	-0.28	Tonsillectomy;	chr10:116605306	chr10:116620953~116645143:+
COAD	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-4.66	5.09e-06	0.00191	-0.32	-0.28	Height;	chr3:52989619	chr3:53064283~53065091:-
COAD	cis	rs875971	0.66	rs801192	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66566965	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs801190	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66568046	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs3857686	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66571204	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs3898855	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66571411	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs10278816	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66572000	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs10281080	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66577454	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs10950044	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66577989	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs10249404	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66581737	chr7:66739829~66740385:-
COAD	cis	rs875971	0.522	rs1968127	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66591816	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs6460305	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66595421	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs10272357	ENSG00000272831.1	RP11-792A8.4	-4.66	5.09e-06	0.00191	-0.29	-0.28	Aortic root size;	chr7:66598087	chr7:66739829~66740385:-
COAD	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-4.66	5.1e-06	0.00191	-0.32	-0.28	Height;	chr3:53009621	chr3:53064283~53065091:-
COAD	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	4.66	5.1e-06	0.00191	0.33	0.28	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	4.66	5.1e-06	0.00191	0.33	0.28	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
COAD	cis	rs7818688	0.614	rs11784299	ENSG00000253528.2	RP11-347C18.4	-4.66	5.1e-06	0.00191	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94837695	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs10956927	ENSG00000253528.2	RP11-347C18.4	-4.66	5.1e-06	0.00191	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94838715	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs11781429	ENSG00000253528.2	RP11-347C18.4	-4.66	5.1e-06	0.00191	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94843706	chr8:94974573~94974853:-
COAD	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.66	5.1e-06	0.00191	0.32	0.28	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.66	5.1e-06	0.00191	0.32	0.28	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.66	5.1e-06	0.00191	0.32	0.28	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
COAD	cis	rs12935418	0.616	rs1127390	ENSG00000278985.1	RP11-303E16.9	4.66	5.1e-06	0.00191	0.3	0.28	Mean corpuscular volume;	chr16:80976176	chr16:80982319~80984094:-
COAD	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-4.66	5.11e-06	0.00192	-0.16	-0.28	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
COAD	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-4.66	5.11e-06	0.00192	-0.26	-0.28	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
COAD	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-4.66	5.11e-06	0.00192	-0.34	-0.28	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
COAD	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	4.66	5.12e-06	0.00192	0.28	0.28	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
COAD	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-4.66	5.12e-06	0.00192	-0.42	-0.28	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
COAD	cis	rs875971	0.545	rs11770063	ENSG00000224316.1	RP11-479O9.2	4.66	5.12e-06	0.00192	0.35	0.28	Aortic root size;	chr7:66318029	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	4.66	5.12e-06	0.00192	0.35	0.28	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
COAD	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-4.66	5.12e-06	0.00192	-0.32	-0.28	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
COAD	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	4.66	5.12e-06	0.00192	0.39	0.28	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
COAD	cis	rs875971	0.545	rs12670811	ENSG00000224316.1	RP11-479O9.2	4.66	5.13e-06	0.00192	0.34	0.28	Aortic root size;	chr7:66358032	chr7:65773620~65802067:+
COAD	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-4.66	5.13e-06	0.00192	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
COAD	cis	rs2337406	0.778	rs58113768	ENSG00000211974.3	IGHV2-70	-4.66	5.13e-06	0.00192	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106700213	chr14:106723574~106724093:-
COAD	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-4.66	5.13e-06	0.00192	-0.3	-0.28	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
COAD	cis	rs11719291	0.833	rs11715835	ENSG00000225399.4	RP11-3B7.1	-4.66	5.15e-06	0.00193	-0.53	-0.28	Cognitive function;	chr3:48733299	chr3:49260085~49261316:+
COAD	cis	rs12439619	0.739	rs4778988	ENSG00000259429.4	UBE2Q2P2	-4.66	5.15e-06	0.00193	-0.26	-0.28	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82355142~82420075:+
COAD	cis	rs41307935	0.908	rs12739212	ENSG00000260063.1	RP5-968P14.2	-4.66	5.15e-06	0.00193	-0.58	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26724087	chr1:26692132~26694131:-
COAD	cis	rs733592	0.599	rs12819124	ENSG00000273765.1	RP11-370I10.11	4.66	5.15e-06	0.00193	0.28	0.28	Plateletcrit;	chr12:48015271	chr12:48360920~48361377:+
COAD	cis	rs1578862	1	rs55913685	ENSG00000259865.1	RP11-488L18.10	-4.66	5.15e-06	0.00193	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247268416	chr1:247187281~247188526:-
COAD	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-4.66	5.16e-06	0.00193	-0.26	-0.28	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
COAD	cis	rs11719291	0.651	rs1134043	ENSG00000270441.1	RP11-694I15.7	4.66	5.16e-06	0.00193	0.4	0.28	Cognitive function;	chr3:49162704	chr3:49140086~49160851:-
COAD	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-4.66	5.16e-06	0.00193	-0.3	-0.28	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
COAD	cis	rs2115630	0.641	rs11073613	ENSG00000259728.4	LINC00933	-4.66	5.16e-06	0.00193	-0.33	-0.28	P wave terminal force;	chr15:84642662	chr15:84570649~84580175:+
COAD	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	4.66	5.17e-06	0.00193	0.3	0.28	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
COAD	cis	rs13256369	0.951	rs12679360	ENSG00000173295.6	FAM86B3P	-4.66	5.17e-06	0.00193	-0.4	-0.28	Obesity-related traits;	chr8:8708759	chr8:8228595~8244865:+
COAD	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	4.66	5.17e-06	0.00194	0.34	0.28	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	4.66	5.17e-06	0.00194	0.34	0.28	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	4.66	5.17e-06	0.00194	0.34	0.28	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	4.66	5.17e-06	0.00194	0.34	0.28	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	4.66	5.17e-06	0.00194	0.34	0.28	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
COAD	cis	rs9990333	1	rs9990333	ENSG00000242086.7	LINC00969	-4.66	5.18e-06	0.00194	-0.26	-0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195658062~195739964:+
COAD	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-4.66	5.18e-06	0.00194	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
COAD	cis	rs7818688	0.697	rs3802191	ENSG00000253528.2	RP11-347C18.4	4.66	5.18e-06	0.00194	0.39	0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975356	chr8:94974573~94974853:-
COAD	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-4.66	5.18e-06	0.00194	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
COAD	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	4.66	5.19e-06	0.00194	0.33	0.28	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
COAD	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	4.66	5.19e-06	0.00194	0.31	0.28	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
COAD	cis	rs5753037	0.754	rs41158	ENSG00000279159.1	RP3-394A18.1	-4.66	5.19e-06	0.00194	-0.18	-0.28	Type 1 diabetes;	chr22:30009994	chr22:29978950~30028236:-
COAD	cis	rs7818688	0.614	rs16917093	ENSG00000253528.2	RP11-347C18.4	-4.66	5.19e-06	0.00194	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94857892	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs79477990	ENSG00000253528.2	RP11-347C18.4	-4.66	5.19e-06	0.00194	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94859908	chr8:94974573~94974853:-
COAD	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-4.65	5.2e-06	0.00194	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
COAD	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	4.65	5.2e-06	0.00194	0.42	0.28	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	4.65	5.2e-06	0.00194	0.42	0.28	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
COAD	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	4.65	5.2e-06	0.00194	0.34	0.28	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
COAD	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	4.65	5.2e-06	0.00194	0.34	0.28	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
COAD	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-4.65	5.2e-06	0.00194	-0.28	-0.28	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
COAD	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	4.65	5.2e-06	0.00194	0.34	0.28	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
COAD	cis	rs6543140	0.964	rs4851592	ENSG00000234389.1	AC007278.3	4.65	5.2e-06	0.00194	0.29	0.28	Blood protein levels;	chr2:102471181	chr2:102438713~102440475:+
COAD	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	4.65	5.21e-06	0.00194	0.44	0.28	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
COAD	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	4.65	5.21e-06	0.00195	0.34	0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
COAD	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	4.65	5.21e-06	0.00195	0.41	0.28	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	4.65	5.21e-06	0.00195	0.41	0.28	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	4.65	5.21e-06	0.00195	0.41	0.28	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	4.65	5.21e-06	0.00195	0.41	0.28	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	4.65	5.21e-06	0.00195	0.41	0.28	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
COAD	cis	rs6951245	0.786	rs77943789	ENSG00000229043.2	AC091729.9	-4.65	5.21e-06	0.00195	-0.45	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1160374~1165267:+
COAD	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-4.65	5.21e-06	0.00195	-0.34	-0.28	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
COAD	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	4.65	5.22e-06	0.00195	0.35	0.28	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
COAD	cis	rs28374715	0.662	rs11852419	ENSG00000247556.5	OIP5-AS1	-4.65	5.22e-06	0.00195	-0.35	-0.28	Ulcerative colitis;	chr15:41164176	chr15:41283990~41309737:+
COAD	cis	rs728616	0.681	rs35420115	ENSG00000234382.2	RP11-40F6.1	-4.65	5.22e-06	0.00195	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:80233664~80245367:+
COAD	cis	rs1198872	0.892	rs1198864	ENSG00000272275.1	RP11-791G15.2	-4.65	5.22e-06	0.00195	-0.37	-0.28	Cardiac Troponin-T levels;	chr2:10760869	chr2:10767875~10770058:-
COAD	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-4.65	5.24e-06	0.00195	-0.34	-0.28	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
COAD	cis	rs9659323	1	rs6700415	ENSG00000231365.4	RP11-418J17.1	-4.65	5.24e-06	0.00195	-0.31	-0.28	Body mass index;	chr1:118973551	chr1:119140396~119275973:+
COAD	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-4.65	5.24e-06	0.00196	-0.51	-0.28	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
COAD	cis	rs17772222	0.917	rs17260415	ENSG00000258789.1	RP11-507K2.3	-4.65	5.24e-06	0.00196	-0.41	-0.28	Coronary artery calcification;	chr14:88745629	chr14:88551597~88552493:+
COAD	cis	rs2018683	0.834	rs2012754	ENSG00000272568.4	CTB-113D17.1	4.65	5.24e-06	0.00196	0.37	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28979967~29013367:+
COAD	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	4.65	5.25e-06	0.00196	0.3	0.28	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
COAD	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	4.65	5.25e-06	0.00196	0.39	0.28	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
COAD	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.65	5.25e-06	0.00196	-0.29	-0.28	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
COAD	cis	rs9818758	0.607	rs9837625	ENSG00000225399.4	RP11-3B7.1	-4.65	5.25e-06	0.00196	-0.49	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:49260085~49261316:+
COAD	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-4.65	5.25e-06	0.00196	-0.37	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
COAD	cis	rs597539	0.652	rs674654	ENSG00000255741.1	RP11-757G1.5	-4.65	5.26e-06	0.00196	-0.37	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68941503~68942852:-
COAD	cis	rs597539	0.616	rs513476	ENSG00000255741.1	RP11-757G1.5	-4.65	5.26e-06	0.00196	-0.37	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68941503~68942852:-
COAD	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	4.65	5.26e-06	0.00196	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
COAD	cis	rs71636778	0.509	rs41307935	ENSG00000260063.1	RP5-968P14.2	-4.65	5.26e-06	0.00196	-0.56	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26854576	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34556682	ENSG00000260063.1	RP5-968P14.2	-4.65	5.26e-06	0.00196	-0.56	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859658	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34889971	ENSG00000260063.1	RP5-968P14.2	-4.65	5.26e-06	0.00196	-0.56	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26861566	chr1:26692132~26694131:-
COAD	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-4.65	5.27e-06	0.00196	-0.32	-0.28	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
COAD	cis	rs9990333	0.622	rs57783901	ENSG00000242086.7	LINC00969	4.65	5.27e-06	0.00196	0.27	0.28	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195658062~195739964:+
COAD	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.65	5.27e-06	0.00196	-0.49	-0.28	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
COAD	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.65	5.27e-06	0.00196	0.39	0.28	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	4.65	5.27e-06	0.00196	0.39	0.28	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.65	5.27e-06	0.00196	0.39	0.28	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	4.65	5.27e-06	0.00196	0.39	0.28	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
COAD	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.65	5.27e-06	0.00196	0.29	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
COAD	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.65	5.27e-06	0.00196	0.29	0.28	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
COAD	cis	rs12935418	0.616	rs2602446	ENSG00000278985.1	RP11-303E16.9	-4.65	5.27e-06	0.00196	-0.3	-0.28	Mean corpuscular volume;	chr16:80984310	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs2549828	ENSG00000278985.1	RP11-303E16.9	-4.65	5.27e-06	0.00196	-0.3	-0.28	Mean corpuscular volume;	chr16:80985378	chr16:80982319~80984094:-
COAD	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	4.65	5.27e-06	0.00197	0.16	0.28	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
COAD	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	4.65	5.27e-06	0.00197	0.38	0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
COAD	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	4.65	5.27e-06	0.00197	0.29	0.28	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
COAD	cis	rs80346118	0.673	rs6012536	ENSG00000177410.11	ZFAS1	4.65	5.28e-06	0.00197	0.29	0.28	Diastolic blood pressure;	chr20:48807026	chr20:49278178~49295738:+
COAD	cis	rs11089937	0.626	rs10483106	ENSG00000211638.2	IGLV8-61	-4.65	5.28e-06	0.00197	-0.28	-0.28	Periodontitis (PAL4Q3);	chr22:22149240	chr22:22098700~22099212:+
COAD	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-4.65	5.28e-06	0.00197	-0.34	-0.28	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
COAD	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	4.65	5.28e-06	0.00197	0.24	0.28	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
COAD	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-4.65	5.28e-06	0.00197	-0.34	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-4.65	5.28e-06	0.00197	-0.34	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
COAD	cis	rs7674212	0.541	rs2720464	ENSG00000230069.3	LRRC37A15P	-4.65	5.29e-06	0.00197	-0.3	-0.28	Type 2 diabetes;	chr4:103152044	chr4:102727274~102730721:-
COAD	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	4.65	5.29e-06	0.00197	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
COAD	cis	rs801193	0.967	rs34356500	ENSG00000272831.1	RP11-792A8.4	4.65	5.29e-06	0.00197	0.29	0.28	Aortic root size;	chr7:66771620	chr7:66739829~66740385:-
COAD	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	4.65	5.29e-06	0.00197	0.26	0.28	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
COAD	cis	rs9926296	0.509	rs2159113	ENSG00000260259.1	RP11-368I7.4	-4.65	5.29e-06	0.00197	-0.33	-0.28	Vitiligo;	chr16:89765675	chr16:89682620~89686569:-
COAD	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	4.65	5.3e-06	0.00197	0.29	0.28	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
COAD	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-4.65	5.3e-06	0.00198	-0.33	-0.28	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
COAD	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-4.65	5.31e-06	0.00198	-0.3	-0.28	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
COAD	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-4.65	5.31e-06	0.00198	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
COAD	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	4.65	5.33e-06	0.00198	0.39	0.28	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
COAD	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	4.65	5.33e-06	0.00198	0.32	0.28	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
COAD	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	4.65	5.33e-06	0.00198	0.26	0.28	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
COAD	cis	rs728616	0.867	rs61859763	ENSG00000225484.5	NUTM2B-AS1	-4.65	5.33e-06	0.00199	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79663088~79826594:-
COAD	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	4.65	5.34e-06	0.00199	0.24	0.28	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
COAD	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	4.65	5.34e-06	0.00199	0.31	0.28	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
COAD	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	4.65	5.34e-06	0.00199	0.29	0.28	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
COAD	cis	rs10083777	0.551	rs79623059	ENSG00000261061.1	RP11-303E16.2	-4.65	5.34e-06	0.00199	-0.52	-0.28	Metabolite levels (small molecules and protein measures);	chr16:80973348	chr16:81030770~81031485:+
COAD	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-4.65	5.34e-06	0.00199	-0.58	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
COAD	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-4.65	5.35e-06	0.00199	-0.31	-0.28	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-4.65	5.35e-06	0.00199	-0.31	-0.28	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
COAD	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-4.65	5.35e-06	0.00199	-0.33	-0.28	Height;	chr2:231553603	chr2:231508426~231514339:-
COAD	cis	rs875971	0.66	rs79009421	ENSG00000272831.1	RP11-792A8.4	-4.65	5.35e-06	0.00199	-0.29	-0.28	Aortic root size;	chr7:66603522	chr7:66739829~66740385:-
COAD	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-4.65	5.35e-06	0.00199	-0.32	-0.28	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
COAD	cis	rs860295	0.702	rs12067371	ENSG00000160766.13	GBAP1	-4.65	5.36e-06	0.00199	-0.31	-0.28	Body mass index;	chr1:155467878	chr1:155213821~155227422:-
COAD	cis	rs3752645	1	rs79973703	ENSG00000241764.3	AC002467.7	4.65	5.36e-06	0.00199	0.47	0.28	Bladder cancer (smoking interaction);	chr7:107127037	chr7:107742817~107744581:-
COAD	cis	rs8002861	0.905	rs12430629	ENSG00000274001.1	RP11-5G9.5	-4.65	5.37e-06	0.002	-0.26	-0.28	Leprosy;	chr13:43841783	chr13:43877715~43878163:-
COAD	cis	rs9659323	1	rs9659323	ENSG00000231365.4	RP11-418J17.1	-4.65	5.37e-06	0.002	-0.31	-0.28	Body mass index;	chr1:118961738	chr1:119140396~119275973:+
COAD	cis	rs9659323	1	rs9658899	ENSG00000231365.4	RP11-418J17.1	-4.65	5.37e-06	0.002	-0.31	-0.28	Body mass index;	chr1:118961920	chr1:119140396~119275973:+
COAD	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-4.65	5.37e-06	0.002	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-4.65	5.37e-06	0.002	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-4.65	5.37e-06	0.002	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-4.65	5.37e-06	0.002	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-4.65	5.37e-06	0.002	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
COAD	cis	rs2280018	0.963	rs12928424	ENSG00000270580.4	PKD1P6	4.65	5.37e-06	0.002	0.29	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104723~15131601:-
COAD	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-4.65	5.37e-06	0.002	-0.34	-0.28	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-4.65	5.37e-06	0.002	-0.34	-0.28	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	4.65	5.37e-06	0.002	0.34	0.28	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
COAD	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	4.65	5.38e-06	0.002	0.39	0.28	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
COAD	cis	rs9659323	0.73	rs10802070	ENSG00000231365.4	RP11-418J17.1	-4.65	5.38e-06	0.002	-0.3	-0.28	Body mass index;	chr1:118998863	chr1:119140396~119275973:+
COAD	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-4.65	5.38e-06	0.002	-0.16	-0.28	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-4.65	5.38e-06	0.002	-0.16	-0.28	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
COAD	cis	rs7811142	1	rs6979335	ENSG00000078319.8	PMS2P1	-4.65	5.38e-06	0.002	-0.39	-0.28	Platelet count;	chr7:100492237	chr7:100320992~100341908:-
COAD	cis	rs7811142	1	rs73405353	ENSG00000078319.8	PMS2P1	-4.65	5.38e-06	0.002	-0.39	-0.28	Platelet count;	chr7:100493592	chr7:100320992~100341908:-
COAD	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	4.65	5.38e-06	0.002	0.28	0.28	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
COAD	cis	rs733317	0.731	rs6974221	ENSG00000226874.1	AC005154.8	-4.65	5.38e-06	0.002	-0.32	-0.28	Left ventricular obstructive tract defect (inherited effect);	chr7:30999357	chr7:30544053~30544431:+
COAD	cis	rs733317	0.731	rs7792595	ENSG00000226874.1	AC005154.8	-4.65	5.38e-06	0.002	-0.32	-0.28	Left ventricular obstructive tract defect (inherited effect);	chr7:31000122	chr7:30544053~30544431:+
COAD	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	4.65	5.38e-06	0.002	0.34	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-4.65	5.39e-06	0.002	-0.16	-0.28	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
COAD	cis	rs875971	0.502	rs1796227	ENSG00000224316.1	RP11-479O9.2	-4.65	5.39e-06	0.002	-0.35	-0.28	Aortic root size;	chr7:66622032	chr7:65773620~65802067:+
COAD	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	4.65	5.39e-06	0.002	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
COAD	cis	rs9307551	0.817	rs12500146	ENSG00000250334.4	LINC00989	-4.65	5.39e-06	0.002	-0.33	-0.28	Refractive error;	chr4:79580002	chr4:79492416~79576460:+
COAD	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	4.65	5.39e-06	0.002	0.35	0.28	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	4.65	5.39e-06	0.002	0.35	0.28	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
COAD	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-4.65	5.39e-06	0.002	-0.57	-0.28	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
COAD	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-4.65	5.39e-06	0.002	-0.33	-0.28	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
COAD	cis	rs11668609	1	rs2099360	ENSG00000268442.1	CTD-2027I19.2	4.65	5.39e-06	0.002	0.34	0.28	Response to taxane treatment (docetaxel);	chr19:24147361	chr19:24162370~24163425:-
COAD	cis	rs11668609	1	rs2082493	ENSG00000268442.1	CTD-2027I19.2	4.65	5.39e-06	0.002	0.34	0.28	Response to taxane treatment (docetaxel);	chr19:24147554	chr19:24162370~24163425:-
COAD	cis	rs728616	0.867	rs34870056	ENSG00000234382.2	RP11-40F6.1	-4.65	5.4e-06	0.00201	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:80233664~80245367:+
COAD	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-4.65	5.4e-06	0.00201	-0.51	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-4.65	5.4e-06	0.00201	-0.51	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
COAD	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.65	5.4e-06	0.00201	0.42	0.28	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.65	5.4e-06	0.00201	0.42	0.28	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
COAD	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	4.65	5.4e-06	0.00201	0.3	0.28	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
COAD	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	4.65	5.41e-06	0.00201	0.27	0.28	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	4.65	5.41e-06	0.00201	0.27	0.28	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
COAD	cis	rs1578862	1	rs56245379	ENSG00000259865.1	RP11-488L18.10	-4.65	5.41e-06	0.00201	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247276008	chr1:247187281~247188526:-
COAD	cis	rs72700829	0.576	rs6695311	ENSG00000223861.1	RP11-74C1.2	-4.65	5.41e-06	0.00201	-0.55	-0.28	Schizophrenia;	chr1:151030282	chr1:151557446~151557940:+
COAD	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-4.65	5.41e-06	0.00201	-0.55	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
COAD	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	4.65	5.41e-06	0.00201	0.32	0.28	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
COAD	cis	rs7584330	0.554	rs6706729	ENSG00000234949.2	AC104667.3	-4.65	5.42e-06	0.00201	-0.48	-0.28	Prostate cancer;	chr2:237489937	chr2:237591020~237595981:+
COAD	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-4.65	5.42e-06	0.00201	-0.29	-0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
COAD	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	4.65	5.42e-06	0.00201	0.31	0.28	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
COAD	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	4.65	5.42e-06	0.00201	0.28	0.28	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
COAD	cis	rs2337406	0.866	rs2301535	ENSG00000211974.3	IGHV2-70	-4.65	5.43e-06	0.00201	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106790663	chr14:106723574~106724093:-
COAD	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-4.65	5.43e-06	0.00202	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
COAD	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-4.65	5.43e-06	0.00202	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
COAD	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	4.65	5.43e-06	0.00202	0.36	0.28	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
COAD	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-4.65	5.43e-06	0.00202	-0.3	-0.28	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
COAD	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	4.64	5.43e-06	0.00202	0.36	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
COAD	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	4.64	5.44e-06	0.00202	0.54	0.28	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
COAD	cis	rs2581828	0.646	rs9757079	ENSG00000280417.1	RP11-5O17.1	4.64	5.44e-06	0.00202	0.3	0.28	Crohn's disease;	chr3:53121142	chr3:53046166~53048122:+
COAD	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	4.64	5.45e-06	0.00202	0.37	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
COAD	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	4.64	5.45e-06	0.00202	0.33	0.28	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
COAD	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-4.64	5.46e-06	0.00202	-0.34	-0.28	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
COAD	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	4.64	5.46e-06	0.00202	0.42	0.28	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
COAD	cis	rs8002861	0.967	rs7999434	ENSG00000274001.1	RP11-5G9.5	4.64	5.46e-06	0.00203	0.25	0.28	Leprosy;	chr13:43908825	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.967	rs7983109	ENSG00000274001.1	RP11-5G9.5	4.64	5.46e-06	0.00203	0.25	0.28	Leprosy;	chr13:43910215	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.967	rs7984393	ENSG00000274001.1	RP11-5G9.5	4.64	5.46e-06	0.00203	0.25	0.28	Leprosy;	chr13:43910225	chr13:43877715~43878163:-
COAD	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-4.64	5.47e-06	0.00203	-0.35	-0.28	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
COAD	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-4.64	5.47e-06	0.00203	-0.54	-0.28	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
COAD	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-4.64	5.47e-06	0.00203	-0.33	-0.28	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
COAD	cis	rs7615952	0.688	rs12638224	ENSG00000272840.1	RP11-379B18.6	4.64	5.48e-06	0.00203	0.39	0.28	Blood pressure (smoking interaction);	chr3:125822477	chr3:125774714~125797953:+
COAD	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	4.64	5.48e-06	0.00203	0.33	0.28	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
COAD	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	4.64	5.5e-06	0.00204	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
COAD	cis	rs1823913	0.538	rs6732537	ENSG00000280083.1	RP11-317J9.1	-4.64	5.5e-06	0.00204	-0.3	-0.28	Obesity-related traits;	chr2:191346755	chr2:191154118~191156070:-
COAD	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	4.64	5.51e-06	0.00204	0.28	0.28	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
COAD	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	4.64	5.51e-06	0.00204	0.32	0.28	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
COAD	cis	rs728616	0.867	rs77376252	ENSG00000225484.5	NUTM2B-AS1	-4.64	5.51e-06	0.00204	-0.48	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80049626	chr10:79663088~79826594:-
COAD	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-4.64	5.51e-06	0.00204	-0.37	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
COAD	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-4.64	5.51e-06	0.00204	-0.29	-0.28	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
COAD	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	4.64	5.51e-06	0.00204	0.39	0.28	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
COAD	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	4.64	5.51e-06	0.00204	0.29	0.28	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	4.64	5.52e-06	0.00204	0.31	0.28	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	4.64	5.52e-06	0.00204	0.31	0.28	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
COAD	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	4.64	5.52e-06	0.00205	0.35	0.28	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	4.64	5.52e-06	0.00205	0.31	0.28	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
COAD	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	4.64	5.52e-06	0.00205	0.27	0.28	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
COAD	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	4.64	5.53e-06	0.00205	0.29	0.28	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
COAD	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-4.64	5.53e-06	0.00205	-0.36	-0.28	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
COAD	cis	rs12497850	0.931	rs11705888	ENSG00000225399.4	RP11-3B7.1	4.64	5.53e-06	0.00205	0.31	0.28	Parkinson's disease;	chr3:48779856	chr3:49260085~49261316:+
COAD	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	4.64	5.54e-06	0.00205	0.29	0.28	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
COAD	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	4.64	5.54e-06	0.00205	0.29	0.28	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	4.64	5.54e-06	0.00205	0.29	0.28	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	4.64	5.54e-06	0.00205	0.29	0.28	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	4.64	5.54e-06	0.00205	0.29	0.28	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
COAD	cis	rs728616	0.681	rs12412762	ENSG00000234382.2	RP11-40F6.1	4.64	5.54e-06	0.00205	0.48	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147714	chr10:80233664~80245367:+
COAD	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-4.64	5.54e-06	0.00205	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
COAD	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-4.64	5.54e-06	0.00205	-0.33	-0.28	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
COAD	cis	rs7818688	0.697	rs11782590	ENSG00000253528.2	RP11-347C18.4	-4.64	5.54e-06	0.00205	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94957930	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs77402106	ENSG00000253528.2	RP11-347C18.4	-4.64	5.54e-06	0.00205	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94958256	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11776186	ENSG00000253528.2	RP11-347C18.4	-4.64	5.54e-06	0.00205	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94959740	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs78088250	ENSG00000253528.2	RP11-347C18.4	-4.64	5.54e-06	0.00205	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94960490	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11787303	ENSG00000253528.2	RP11-347C18.4	-4.64	5.54e-06	0.00205	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94960636	chr8:94974573~94974853:-
COAD	cis	rs11638352	1	rs4924728	ENSG00000205771.5	CATSPER2P1	4.64	5.55e-06	0.00205	0.51	0.28	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43997755	chr15:43726918~43747094:-
COAD	cis	rs7818688	0.653	rs16893774	ENSG00000253528.2	RP11-347C18.4	4.64	5.55e-06	0.00206	0.39	0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94883748	chr8:94974573~94974853:-
COAD	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	4.64	5.55e-06	0.00206	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	4.64	5.55e-06	0.00206	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	4.64	5.55e-06	0.00206	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
COAD	cis	rs8061903	0.535	rs1366526	ENSG00000260071.1	RP11-418I22.2	4.64	5.55e-06	0.00206	0.34	0.28	HIV-1 viral setpoint;	chr16:9306825	chr16:9466655~9517564:+
COAD	cis	rs10170310	1	rs10170310	ENSG00000228043.4	AC097721.2	4.64	5.56e-06	0.00206	0.34	0.28	Response to antipsychotic treatment;	chr2:138521352	chr2:138418284~138501698:-
COAD	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-4.64	5.56e-06	0.00206	-0.34	-0.28	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
COAD	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-4.64	5.56e-06	0.00206	-0.34	-0.28	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
COAD	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-4.64	5.56e-06	0.00206	-0.56	-0.28	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-4.64	5.56e-06	0.00206	-0.56	-0.28	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
COAD	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	4.64	5.57e-06	0.00206	0.32	0.28	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
COAD	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.64	5.57e-06	0.00206	0.34	0.28	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
COAD	cis	rs34792	0.678	rs153787	ENSG00000207425.1	Y_RNA	4.64	5.57e-06	0.00206	0.35	0.28	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:14915457~14915556:-
COAD	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	4.64	5.58e-06	0.00206	0.32	0.28	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
COAD	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	4.64	5.58e-06	0.00207	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
COAD	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	4.64	5.58e-06	0.00207	0.3	0.28	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
COAD	cis	rs17359493	0.606	rs11776830	ENSG00000253528.2	RP11-347C18.4	-4.64	5.58e-06	0.00207	-0.33	-0.28	Type 2 diabetes;	chr8:94891970	chr8:94974573~94974853:-
COAD	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	4.64	5.59e-06	0.00207	0.4	0.28	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
COAD	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-4.64	5.59e-06	0.00207	-0.56	-0.28	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
COAD	cis	rs9450351	0.744	rs9362248	ENSG00000203875.9	SNHG5	-4.64	5.59e-06	0.00207	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85847249	chr6:85660950~85678736:-
COAD	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-4.64	5.59e-06	0.00207	-0.15	-0.28	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
COAD	cis	rs860295	0.836	rs6684889	ENSG00000223503.1	RP11-29H23.6	4.64	5.59e-06	0.00207	0.36	0.28	Body mass index;	chr1:155457271	chr1:155590601~155591262:-
COAD	cis	rs4568518	0.873	rs4602778	ENSG00000279048.1	RP11-511H23.2	4.64	5.59e-06	0.00207	0.2	0.28	Measles;	chr7:17989131	chr7:17940503~17942922:+
COAD	cis	rs17772222	0.636	rs10484010	ENSG00000258789.1	RP11-507K2.3	-4.64	5.6e-06	0.00207	-0.42	-0.28	Coronary artery calcification;	chr14:88831944	chr14:88551597~88552493:+
COAD	cis	rs1055129	0.56	rs9891076	ENSG00000267801.1	RP11-552F3.9	4.64	5.6e-06	0.00207	0.35	0.28	White matter hyperintensity burden;	chr17:75915634	chr17:75876372~75879546:+
COAD	cis	rs1055129	0.56	rs56248937	ENSG00000267801.1	RP11-552F3.9	4.64	5.6e-06	0.00207	0.35	0.28	White matter hyperintensity burden;	chr17:75919072	chr17:75876372~75879546:+
COAD	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	4.64	5.6e-06	0.00207	0.37	0.28	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
COAD	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	4.64	5.6e-06	0.00207	0.41	0.28	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
COAD	cis	rs6452524	0.618	rs10051445	ENSG00000271862.1	RP11-343L5.2	4.64	5.6e-06	0.00207	0.27	0.28	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83049376~83050964:-
COAD	cis	rs17772222	0.917	rs61977053	ENSG00000258789.1	RP11-507K2.3	-4.64	5.6e-06	0.00207	-0.4	-0.28	Coronary artery calcification;	chr14:88380876	chr14:88551597~88552493:+
COAD	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	4.64	5.61e-06	0.00207	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
COAD	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	4.64	5.61e-06	0.00208	0.43	0.28	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
COAD	cis	rs7224610	0.898	rs4299205	ENSG00000263096.1	RP11-515O17.2	4.64	5.61e-06	0.00208	0.33	0.28	Urate levels;	chr17:55288785	chr17:55271504~55273653:-
COAD	cis	rs597539	0.652	rs559032	ENSG00000255741.1	RP11-757G1.5	-4.64	5.61e-06	0.00208	-0.37	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68941503~68942852:-
COAD	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	4.64	5.61e-06	0.00208	0.37	0.28	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
COAD	cis	rs875971	0.619	rs12533585	ENSG00000272831.1	RP11-792A8.4	4.64	5.62e-06	0.00208	0.29	0.28	Aortic root size;	chr7:66519618	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs28698552	ENSG00000272831.1	RP11-792A8.4	4.64	5.62e-06	0.00208	0.29	0.28	Aortic root size;	chr7:66540031	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs62465434	ENSG00000272831.1	RP11-792A8.4	4.64	5.62e-06	0.00208	0.29	0.28	Aortic root size;	chr7:66540165	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs801216	ENSG00000272831.1	RP11-792A8.4	-4.64	5.62e-06	0.00208	-0.29	-0.28	Aortic root size;	chr7:66546680	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs801211	ENSG00000272831.1	RP11-792A8.4	-4.64	5.62e-06	0.00208	-0.29	-0.28	Aortic root size;	chr7:66550702	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs801205	ENSG00000272831.1	RP11-792A8.4	-4.64	5.62e-06	0.00208	-0.29	-0.28	Aortic root size;	chr7:66557157	chr7:66739829~66740385:-
COAD	cis	rs875971	0.617	rs810400	ENSG00000272831.1	RP11-792A8.4	-4.64	5.62e-06	0.00208	-0.29	-0.28	Aortic root size;	chr7:66557902	chr7:66739829~66740385:-
COAD	cis	rs2638953	0.64	rs11049729	ENSG00000247934.4	RP11-967K21.1	4.64	5.62e-06	0.00208	0.29	0.28	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28163298~28190738:-
COAD	cis	rs13256369	0.774	rs13260303	ENSG00000173295.6	FAM86B3P	4.64	5.62e-06	0.00208	0.38	0.28	Obesity-related traits;	chr8:8729832	chr8:8228595~8244865:+
COAD	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	4.64	5.62e-06	0.00208	0.36	0.28	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
COAD	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-4.64	5.62e-06	0.00208	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-4.64	5.62e-06	0.00208	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-4.64	5.62e-06	0.00208	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	4.64	5.62e-06	0.00208	0.31	0.28	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
COAD	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-4.64	5.63e-06	0.00208	-0.34	-0.28	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.812	rs6788069	ENSG00000272087.1	RP11-379F4.7	-4.64	5.64e-06	0.00208	-0.4	-0.28	Tetralogy of Fallot;	chr3:158741670	chr3:158693120~158693768:-
COAD	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	4.64	5.64e-06	0.00208	0.3	0.28	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
COAD	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-4.64	5.64e-06	0.00208	-0.3	-0.28	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
COAD	cis	rs453301	0.658	rs9329175	ENSG00000173295.6	FAM86B3P	-4.64	5.64e-06	0.00208	-0.32	-0.28	Joint mobility (Beighton score);	chr8:9009151	chr8:8228595~8244865:+
COAD	cis	rs7674212	0.51	rs2720468	ENSG00000230069.3	LRRC37A15P	-4.64	5.64e-06	0.00209	-0.3	-0.28	Type 2 diabetes;	chr4:103163996	chr4:102727274~102730721:-
COAD	cis	rs1510272	0.921	rs2202965	ENSG00000243926.1	TIPARP-AS1	-4.64	5.64e-06	0.00209	-0.31	-0.28	Testicular germ cell tumor;	chr3:156568927	chr3:156671862~156674378:-
COAD	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-4.64	5.65e-06	0.00209	-0.49	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
COAD	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-4.64	5.65e-06	0.00209	-0.29	-0.28	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
COAD	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-4.64	5.66e-06	0.00209	-0.31	-0.28	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
COAD	cis	rs2732480	0.5	rs12829841	ENSG00000273765.1	RP11-370I10.11	4.64	5.66e-06	0.00209	0.31	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48360920~48361377:+
COAD	cis	rs2732480	0.523	rs34286639	ENSG00000273765.1	RP11-370I10.11	4.64	5.66e-06	0.00209	0.31	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.929	rs11168484	ENSG00000273765.1	RP11-370I10.11	4.64	5.66e-06	0.00209	0.31	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48360920~48361377:+
COAD	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-4.64	5.66e-06	0.00209	-0.52	-0.28	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-4.64	5.66e-06	0.00209	-0.52	-0.28	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
COAD	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	4.64	5.66e-06	0.00209	0.3	0.28	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
COAD	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	4.64	5.66e-06	0.00209	0.3	0.28	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
COAD	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-4.64	5.67e-06	0.00209	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-4.64	5.67e-06	0.00209	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-4.64	5.67e-06	0.00209	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-4.64	5.67e-06	0.00209	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
COAD	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	4.64	5.67e-06	0.00209	0.29	0.28	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
COAD	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-4.64	5.67e-06	0.0021	-0.44	-0.28	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
COAD	cis	rs2280018	1	rs2280017	ENSG00000270580.4	PKD1P6	-4.64	5.68e-06	0.0021	-0.28	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104723~15131601:-
COAD	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	4.64	5.68e-06	0.0021	0.39	0.28	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
COAD	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	4.64	5.68e-06	0.0021	0.2	0.28	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
COAD	cis	rs9532669	0.89	rs7333274	ENSG00000239827.7	SUGT1P3	-4.63	5.68e-06	0.0021	-0.24	-0.28	Cervical cancer;	chr13:40862531	chr13:40908159~40921774:-
COAD	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	4.63	5.69e-06	0.0021	0.31	0.28	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	4.63	5.69e-06	0.0021	0.31	0.28	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	4.63	5.69e-06	0.0021	0.31	0.28	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
COAD	cis	rs9847710	0.838	rs2564962	ENSG00000242142.1	SERBP1P3	4.63	5.69e-06	0.0021	0.34	0.28	Ulcerative colitis;	chr3:52997622	chr3:53064283~53065091:-
COAD	cis	rs9847710	0.869	rs2564920	ENSG00000242142.1	SERBP1P3	4.63	5.69e-06	0.0021	0.34	0.28	Ulcerative colitis;	chr3:52999041	chr3:53064283~53065091:-
COAD	cis	rs9847710	0.808	rs2564919	ENSG00000242142.1	SERBP1P3	4.63	5.69e-06	0.0021	0.34	0.28	Ulcerative colitis;	chr3:52999279	chr3:53064283~53065091:-
COAD	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	4.63	5.7e-06	0.0021	0.34	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
COAD	cis	rs2378497	1	rs12136244	ENSG00000232679.1	RP11-400N13.3	4.63	5.7e-06	0.00211	0.38	0.28	Serum thyroid-stimulating hormone levels;	chr1:222016059	chr1:222041705~222064763:-
COAD	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-4.63	5.71e-06	0.00211	-0.29	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
COAD	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	4.63	5.71e-06	0.00211	0.32	0.28	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
COAD	cis	rs2281603	0.57	rs10145013	ENSG00000259116.1	RP11-973N13.4	-4.63	5.71e-06	0.00211	-0.27	-0.28	Lymphocyte counts;	chr14:64474873	chr14:64514154~64540368:-
COAD	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-4.63	5.71e-06	0.00211	-0.33	-0.28	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
COAD	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	4.63	5.72e-06	0.00211	0.29	0.28	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
COAD	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	4.63	5.72e-06	0.00211	0.29	0.28	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
COAD	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	4.63	5.72e-06	0.00211	0.22	0.28	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-4.63	5.72e-06	0.00211	-0.18	-0.28	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
COAD	cis	rs739496	0.615	rs4767939	ENSG00000257595.2	RP3-473L9.4	4.63	5.73e-06	0.00211	0.41	0.28	Platelet count;	chr12:111769091	chr12:111369282~111403310:+
COAD	cis	rs9487051	0.676	rs6910119	ENSG00000219700.1	PTCHD3P3	4.63	5.73e-06	0.00211	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109278060	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs2884013	ENSG00000219700.1	PTCHD3P3	4.63	5.73e-06	0.00211	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109278749	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs9400267	ENSG00000219700.1	PTCHD3P3	4.63	5.73e-06	0.00211	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109278961	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs9374077	ENSG00000219700.1	PTCHD3P3	4.63	5.73e-06	0.00211	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109278991	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs7773775	ENSG00000219700.1	PTCHD3P3	4.63	5.73e-06	0.00211	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109279136	chr6:109288571~109290503:-
COAD	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	4.63	5.73e-06	0.00212	0.29	0.28	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
COAD	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	4.63	5.74e-06	0.00212	0.34	0.28	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
COAD	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	4.63	5.74e-06	0.00212	0.44	0.28	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
COAD	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	4.63	5.74e-06	0.00212	0.4	0.28	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
COAD	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	4.63	5.74e-06	0.00212	0.36	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
COAD	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-4.63	5.74e-06	0.00212	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
COAD	cis	rs453301	0.686	rs13252797	ENSG00000253981.4	ALG1L13P	4.63	5.74e-06	0.00212	0.34	0.28	Joint mobility (Beighton score);	chr8:9003920	chr8:8236003~8244667:-
COAD	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	4.63	5.74e-06	0.00212	0.34	0.28	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
COAD	cis	rs8141529	0.719	rs9625619	ENSG00000272858.1	CTA-292E10.8	-4.63	5.75e-06	0.00212	-0.34	-0.28	Lymphocyte counts;	chr22:28876340	chr22:28814914~28815662:+
COAD	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-4.63	5.75e-06	0.00212	-0.32	-0.28	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
COAD	cis	rs875971	0.545	rs10950027	ENSG00000224316.1	RP11-479O9.2	4.63	5.75e-06	0.00212	0.34	0.28	Aortic root size;	chr7:66169164	chr7:65773620~65802067:+
COAD	cis	rs875971	0.66	rs12698534	ENSG00000272831.1	RP11-792A8.4	4.63	5.76e-06	0.00212	0.29	0.28	Aortic root size;	chr7:66521858	chr7:66739829~66740385:-
COAD	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-4.63	5.76e-06	0.00212	-0.4	-0.28	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-4.63	5.76e-06	0.00212	-0.4	-0.28	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
COAD	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-4.63	5.76e-06	0.00212	-0.4	-0.28	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	4.63	5.76e-06	0.00212	0.2	0.28	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
COAD	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-4.63	5.76e-06	0.00212	-0.39	-0.28	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
COAD	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	4.63	5.76e-06	0.00212	0.32	0.28	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	4.63	5.76e-06	0.00212	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
COAD	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.63	5.77e-06	0.00213	-0.44	-0.28	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.63	5.77e-06	0.00213	-0.44	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
COAD	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-4.63	5.77e-06	0.00213	-0.33	-0.28	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-4.63	5.77e-06	0.00213	-0.33	-0.28	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-4.63	5.77e-06	0.00213	-0.33	-0.28	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-4.63	5.77e-06	0.00213	-0.33	-0.28	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-4.63	5.77e-06	0.00213	-0.33	-0.28	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
COAD	cis	rs9291683	0.655	rs55941493	ENSG00000250413.1	RP11-448G15.1	4.63	5.77e-06	0.00213	0.35	0.28	Bone mineral density;	chr4:10098717	chr4:10006482~10009725:+
COAD	cis	rs4568518	0.869	rs6969961	ENSG00000279048.1	RP11-511H23.2	4.63	5.77e-06	0.00213	0.2	0.28	Measles;	chr7:17990462	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.873	rs6952559	ENSG00000279048.1	RP11-511H23.2	4.63	5.77e-06	0.00213	0.2	0.28	Measles;	chr7:17990547	chr7:17940503~17942922:+
COAD	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-4.63	5.78e-06	0.00213	-0.25	-0.28	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
COAD	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-4.63	5.78e-06	0.00213	-0.57	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
COAD	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-4.63	5.78e-06	0.00213	-0.34	-0.28	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-4.63	5.78e-06	0.00213	-0.34	-0.28	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-4.63	5.78e-06	0.00213	-0.34	-0.28	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-4.63	5.78e-06	0.00213	-0.34	-0.28	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-4.63	5.78e-06	0.00213	-0.34	-0.28	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
COAD	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	4.63	5.78e-06	0.00213	0.29	0.28	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
COAD	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	4.63	5.78e-06	0.00213	0.42	0.28	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
COAD	cis	rs1387259	0.79	rs2732445	ENSG00000273765.1	RP11-370I10.11	4.63	5.79e-06	0.00213	0.31	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48360920~48361377:+
COAD	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	4.63	5.79e-06	0.00213	0.28	0.28	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
COAD	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	4.63	5.79e-06	0.00213	0.25	0.28	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
COAD	cis	rs8002861	0.905	rs80209017	ENSG00000274001.1	RP11-5G9.5	4.63	5.79e-06	0.00213	0.25	0.28	Leprosy;	chr13:43899046	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.967	rs2166301	ENSG00000274001.1	RP11-5G9.5	4.63	5.79e-06	0.00213	0.25	0.28	Leprosy;	chr13:43899819	chr13:43877715~43878163:-
COAD	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	4.63	5.79e-06	0.00213	0.36	0.28	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
COAD	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	4.63	5.79e-06	0.00213	0.35	0.28	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	4.63	5.79e-06	0.00213	0.35	0.28	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
COAD	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	4.63	5.79e-06	0.00213	0.31	0.28	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	4.63	5.79e-06	0.00213	0.31	0.28	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
COAD	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-4.63	5.79e-06	0.00213	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-4.63	5.79e-06	0.00213	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-4.63	5.79e-06	0.00213	-0.29	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
COAD	cis	rs8002861	0.967	rs7321596	ENSG00000274001.1	RP11-5G9.5	4.63	5.8e-06	0.00213	0.25	0.28	Leprosy;	chr13:43898119	chr13:43877715~43878163:-
COAD	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-4.63	5.8e-06	0.00213	-0.37	-0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
COAD	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	4.63	5.8e-06	0.00214	0.34	0.28	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
COAD	cis	rs911119	0.837	rs2208289	ENSG00000270001.1	RP11-218C14.8	4.63	5.8e-06	0.00214	0.33	0.28	Chronic kidney disease;	chr20:23598889	chr20:23631826~23632316:-
COAD	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	4.63	5.8e-06	0.00214	0.33	0.28	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
COAD	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	4.63	5.8e-06	0.00214	0.31	0.28	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
COAD	cis	rs35264875	0.808	rs2305498	ENSG00000259799.1	RP11-554A11.9	4.63	5.8e-06	0.00214	0.39	0.28	Blond vs. brown hair color;	chr11:69099446	chr11:69155910~69159752:+
COAD	cis	rs7772486	0.594	rs6901864	ENSG00000235652.6	RP11-545I5.3	-4.63	5.81e-06	0.00214	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145701914	chr6:145799409~145886585:+
COAD	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	4.63	5.81e-06	0.00214	0.41	0.28	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
COAD	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	4.63	5.81e-06	0.00214	0.31	0.28	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
COAD	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	4.63	5.81e-06	0.00214	0.28	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
COAD	cis	rs9847710	0.869	rs11708675	ENSG00000242142.1	SERBP1P3	4.63	5.81e-06	0.00214	0.34	0.28	Ulcerative colitis;	chr3:52997896	chr3:53064283~53065091:-
COAD	cis	rs7430456	0.87	rs9864169	ENSG00000228221.4	LINC00578	4.63	5.82e-06	0.00214	0.24	0.28	Breast cancer;	chr3:177746841	chr3:177441921~177752305:+
COAD	cis	rs7430456	0.901	rs12696448	ENSG00000228221.4	LINC00578	4.63	5.82e-06	0.00214	0.24	0.28	Breast cancer;	chr3:177746860	chr3:177441921~177752305:+
COAD	cis	rs2439831	0.867	rs935901	ENSG00000249839.1	AC011330.5	-4.63	5.82e-06	0.00214	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43359058	chr15:43663654~43684339:-
COAD	cis	rs17772222	1	rs55722539	ENSG00000258789.1	RP11-507K2.3	-4.63	5.83e-06	0.00214	-0.4	-0.28	Coronary artery calcification;	chr14:88411691	chr14:88551597~88552493:+
COAD	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	4.63	5.83e-06	0.00214	0.34	0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
COAD	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	4.63	5.83e-06	0.00215	0.34	0.28	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
COAD	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	4.63	5.83e-06	0.00215	0.31	0.28	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
COAD	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	4.63	5.84e-06	0.00215	0.38	0.28	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	4.63	5.84e-06	0.00215	0.38	0.28	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
COAD	cis	rs2280018	1	rs2280018	ENSG00000270580.4	PKD1P6	4.63	5.84e-06	0.00215	0.29	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15104723~15131601:-
COAD	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	4.63	5.84e-06	0.00215	0.35	0.28	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
COAD	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-4.63	5.84e-06	0.00215	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
COAD	cis	rs7818688	0.614	rs79487086	ENSG00000253528.2	RP11-347C18.4	-4.63	5.84e-06	0.00215	-0.42	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94863285	chr8:94974573~94974853:-
COAD	cis	rs801193	0.935	rs11772264	ENSG00000272831.1	RP11-792A8.4	4.63	5.84e-06	0.00215	0.3	0.28	Aortic root size;	chr7:66711400	chr7:66739829~66740385:-
COAD	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	4.63	5.85e-06	0.00215	0.35	0.28	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
COAD	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-4.63	5.85e-06	0.00215	-0.3	-0.28	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
COAD	cis	rs7818382	1	rs7818382	ENSG00000253528.2	RP11-347C18.4	4.63	5.85e-06	0.00215	0.31	0.28	Alzheimer's disease (late onset);	chr8:95041772	chr8:94974573~94974853:-
COAD	cis	rs11951515	0.508	rs10059993	ENSG00000248554.1	RP11-159F24.6	-4.63	5.85e-06	0.00215	-0.3	-0.28	Metabolite levels  (X-11787);	chr5:43598250	chr5:43511058~43521811:+
COAD	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-4.63	5.85e-06	0.00215	-0.31	-0.28	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
COAD	cis	rs9951698	0.678	rs554854	ENSG00000266969.1	RP11-773H22.4	4.63	5.85e-06	0.00215	0.35	0.28	Intelligence (multi-trait analysis);	chr18:13101169	chr18:12984694~12991173:-
COAD	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	4.63	5.86e-06	0.00215	0.33	0.28	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
COAD	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	4.63	5.86e-06	0.00215	0.33	0.28	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
COAD	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-4.63	5.87e-06	0.00216	-0.25	-0.28	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
COAD	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-4.63	5.87e-06	0.00216	-0.54	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
COAD	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	4.63	5.88e-06	0.00216	0.38	0.28	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
COAD	cis	rs3126085	0.56	rs2525	ENSG00000237975.5	FLG-AS1	4.63	5.88e-06	0.00216	0.33	0.28	Atopic dermatitis;	chr1:152366588	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs941935	ENSG00000237975.5	FLG-AS1	4.63	5.88e-06	0.00216	0.33	0.28	Atopic dermatitis;	chr1:152367012	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs11204987	ENSG00000237975.5	FLG-AS1	4.63	5.88e-06	0.00216	0.33	0.28	Atopic dermatitis;	chr1:152370393	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs12027445	ENSG00000237975.5	FLG-AS1	4.63	5.88e-06	0.00216	0.33	0.28	Atopic dermatitis;	chr1:152372311	chr1:152168125~152445456:+
COAD	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-4.63	5.88e-06	0.00216	-0.33	-0.28	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
COAD	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	4.63	5.88e-06	0.00216	0.35	0.28	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
COAD	cis	rs2732480	0.5	rs2450991	ENSG00000226413.2	OR8T1P	4.63	5.88e-06	0.00216	0.34	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48442030~48442947:-
COAD	cis	rs9951698	0.678	rs492723	ENSG00000266969.1	RP11-773H22.4	4.63	5.88e-06	0.00216	0.34	0.28	Intelligence (multi-trait analysis);	chr18:13131941	chr18:12984694~12991173:-
COAD	cis	rs1387259	0.929	rs2634666	ENSG00000226413.2	OR8T1P	4.63	5.88e-06	0.00216	0.35	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48442030~48442947:-
COAD	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	4.63	5.88e-06	0.00216	0.31	0.28	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
COAD	cis	rs4779584	0.527	rs1919360	ENSG00000259721.1	RP11-758N13.1	4.63	5.88e-06	0.00216	0.36	0.28	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);	chr15:32751254	chr15:32717270~32719007:-
COAD	cis	rs4604732	0.536	rs10925056	ENSG00000227135.1	GCSAML-AS1	-4.63	5.89e-06	0.00216	-0.41	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247487170	chr1:247524679~247526752:-
COAD	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	4.63	5.89e-06	0.00216	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
COAD	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-4.63	5.89e-06	0.00216	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
COAD	cis	rs7818688	0.697	rs11781397	ENSG00000253528.2	RP11-347C18.4	-4.63	5.89e-06	0.00216	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94962278	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11780130	ENSG00000253528.2	RP11-347C18.4	-4.63	5.89e-06	0.00216	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94963855	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs11784212	ENSG00000253528.2	RP11-347C18.4	-4.63	5.89e-06	0.00216	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94964767	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.697	rs35032356	ENSG00000253528.2	RP11-347C18.4	-4.63	5.89e-06	0.00216	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965256	chr8:94974573~94974853:-
COAD	cis	rs4704187	0.687	rs6860441	ENSG00000250889.2	LINC01336	-4.63	5.9e-06	0.00217	-0.31	-0.28	Response to amphetamines;	chr5:75093974	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6453112	ENSG00000250889.2	LINC01336	-4.63	5.9e-06	0.00217	-0.31	-0.28	Response to amphetamines;	chr5:75094076	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs12653162	ENSG00000250889.2	LINC01336	-4.63	5.9e-06	0.00217	-0.31	-0.28	Response to amphetamines;	chr5:75095841	chr5:75047719~75052843:-
COAD	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-4.63	5.9e-06	0.00217	-0.28	-0.28	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
COAD	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	4.63	5.9e-06	0.00217	0.41	0.28	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
COAD	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-4.63	5.9e-06	0.00217	-0.32	-0.28	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
COAD	cis	rs2836974	0.666	rs4624474	ENSG00000255568.3	BRWD1-AS2	-4.63	5.9e-06	0.00217	-0.26	-0.28	Cognitive function;	chr21:39314401	chr21:39313935~39314962:+
COAD	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	4.63	5.91e-06	0.00217	0.35	0.28	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
COAD	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-4.63	5.91e-06	0.00217	-0.38	-0.28	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
COAD	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	4.63	5.91e-06	0.00217	0.34	0.28	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
COAD	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	4.63	5.91e-06	0.00217	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
COAD	cis	rs7560272	0.695	rs10190002	ENSG00000163016.8	ALMS1P	4.63	5.91e-06	0.00217	0.33	0.28	Schizophrenia;	chr2:73566927	chr2:73644919~73685576:+
COAD	cis	rs507080	0.769	rs12290522	ENSG00000278376.1	RP11-158I9.8	-4.63	5.91e-06	0.00217	-0.29	-0.28	Serum metabolite levels;	chr11:118615610	chr11:118791254~118793137:+
COAD	cis	rs9532669	0.926	rs4454835	ENSG00000239827.7	SUGT1P3	-4.63	5.91e-06	0.00217	-0.24	-0.28	Cervical cancer;	chr13:40928978	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	4.63	5.92e-06	0.00217	0.24	0.28	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
COAD	cis	rs9450351	0.744	rs6906618	ENSG00000203875.9	SNHG5	-4.63	5.92e-06	0.00217	-0.51	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85741719	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs7775016	ENSG00000203875.9	SNHG5	-4.63	5.92e-06	0.00217	-0.51	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85780196	chr6:85660950~85678736:-
COAD	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-4.63	5.92e-06	0.00217	-0.34	-0.28	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
COAD	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-4.63	5.93e-06	0.00218	-0.52	-0.28	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-4.63	5.93e-06	0.00218	-0.52	-0.28	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-4.63	5.93e-06	0.00218	-0.52	-0.28	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
COAD	cis	rs728616	0.867	rs12781912	ENSG00000234382.2	RP11-40F6.1	-4.63	5.93e-06	0.00218	-0.47	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158372	chr10:80233664~80245367:+
COAD	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	4.63	5.93e-06	0.00218	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
COAD	cis	rs1823913	0.538	rs13432697	ENSG00000280083.1	RP11-317J9.1	-4.63	5.93e-06	0.00218	-0.29	-0.28	Obesity-related traits;	chr2:191345944	chr2:191154118~191156070:-
COAD	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-4.63	5.94e-06	0.00218	-0.33	-0.28	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
COAD	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	4.63	5.94e-06	0.00218	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	4.63	5.94e-06	0.00218	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	4.63	5.94e-06	0.00218	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	4.63	5.94e-06	0.00218	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
COAD	cis	rs9659323	1	rs11584380	ENSG00000231365.4	RP11-418J17.1	-4.62	5.94e-06	0.00218	-0.31	-0.28	Body mass index;	chr1:118974797	chr1:119140396~119275973:+
COAD	cis	rs733317	0.731	rs6948808	ENSG00000226874.1	AC005154.8	-4.62	5.94e-06	0.00218	-0.33	-0.28	Left ventricular obstructive tract defect (inherited effect);	chr7:30996546	chr7:30544053~30544431:+
COAD	cis	rs34779708	0.966	rs11010135	ENSG00000271335.4	RP11-324I22.4	4.62	5.94e-06	0.00218	0.31	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35314552~35336401:-
COAD	cis	rs7829975	0.742	rs1533059	ENSG00000233609.3	RP11-62H7.2	-4.62	5.94e-06	0.00218	-0.31	-0.28	Mood instability;	chr8:8827443	chr8:8961200~8979025:+
COAD	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-4.62	5.95e-06	0.00218	-0.36	-0.28	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
COAD	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-4.62	5.95e-06	0.00218	-0.36	-0.28	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
COAD	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.62	5.96e-06	0.00218	-0.29	-0.28	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
COAD	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	4.62	5.96e-06	0.00218	0.3	0.28	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
COAD	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-4.62	5.96e-06	0.00218	-0.3	-0.28	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
COAD	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-4.62	5.96e-06	0.00218	-0.3	-0.28	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
COAD	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-4.62	5.96e-06	0.00218	-0.3	-0.28	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
COAD	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-4.62	5.96e-06	0.00218	-0.33	-0.28	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
COAD	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-4.62	5.96e-06	0.00219	-0.29	-0.28	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
COAD	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	4.62	5.97e-06	0.00219	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
COAD	cis	rs4657482	0.962	rs6703209	ENSG00000236364.3	RP11-525G13.2	-4.62	5.97e-06	0.00219	-0.2	-0.28	Testicular germ cell tumor;	chr1:165870907	chr1:165890795~165900683:-
COAD	cis	rs6929812	0.577	rs2294308	ENSG00000271755.1	RP1-153G14.4	4.62	5.98e-06	0.00219	0.32	0.28	Neuroticism (multi-trait analysis);	chr6:27515481	chr6:27404010~27406964:-
COAD	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	4.62	5.98e-06	0.00219	0.31	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
COAD	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-4.62	5.98e-06	0.00219	-0.41	-0.28	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
COAD	cis	rs728616	0.867	rs17884637	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79663088~79826594:-
COAD	cis	rs728616	1	rs12414891	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79663088~79826594:-
COAD	cis	rs728616	0.717	rs12415523	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79663088~79826594:-
COAD	cis	rs728616	0.764	rs75385771	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs17883671	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs17885031	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs3088308	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs17879726	ENSG00000225484.5	NUTM2B-AS1	-4.62	5.99e-06	0.00219	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79663088~79826594:-
COAD	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	4.62	6e-06	0.0022	0.31	0.28	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
COAD	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-4.62	6e-06	0.0022	-0.27	-0.28	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
COAD	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	4.62	6e-06	0.0022	0.33	0.28	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
COAD	cis	rs4568518	0.869	rs12699943	ENSG00000279048.1	RP11-511H23.2	4.62	6e-06	0.0022	0.2	0.28	Measles;	chr7:17998157	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.869	rs12699944	ENSG00000279048.1	RP11-511H23.2	4.62	6e-06	0.0022	0.2	0.28	Measles;	chr7:17998161	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.869	rs12699945	ENSG00000279048.1	RP11-511H23.2	4.62	6e-06	0.0022	0.2	0.28	Measles;	chr7:17998181	chr7:17940503~17942922:+
COAD	cis	rs8022206	0.773	rs17104764	ENSG00000259502.1	RP11-643G16.3	4.62	6.01e-06	0.0022	0.37	0.28	Platelet count;Mean platelet volume;	chr14:67912314	chr14:67610986~67613864:+
COAD	cis	rs7674212	0.541	rs11727498	ENSG00000230069.3	LRRC37A15P	-4.62	6.01e-06	0.0022	-0.3	-0.28	Type 2 diabetes;	chr4:103179830	chr4:102727274~102730721:-
COAD	cis	rs7955901	0.746	rs4142883	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71130802	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs3844207	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71131078	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.746	rs3844208	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71131157	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs3844209	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71131351	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.746	rs3896814	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71131490	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.775	rs3851613	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71131943	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.746	rs3851614	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71132167	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.746	rs3851615	ENSG00000258053.1	CTD-2021H9.3	4.62	6.01e-06	0.0022	0.34	0.28	Type 2 diabetes;	chr12:71132284	chr12:71047402~71118247:-
COAD	cis	rs2281603	0.57	rs11625265	ENSG00000259116.1	RP11-973N13.4	-4.62	6.01e-06	0.0022	-0.27	-0.28	Lymphocyte counts;	chr14:64510603	chr14:64514154~64540368:-
COAD	cis	rs17685	0.753	rs7788763	ENSG00000280388.1	RP11-229D13.3	4.62	6.01e-06	0.0022	0.28	0.28	Coffee consumption (cups per day);Coffee consumption;	chr7:76022347	chr7:76043977~76045963:-
COAD	cis	rs11700536	1	rs2839636	ENSG00000236663.1	AP001631.9	4.62	6.01e-06	0.0022	0.35	0.28	Interleukin-18 levels;	chr21:43139085	chr21:43140523~43141092:-
COAD	cis	rs1578862	1	rs6698384	ENSG00000259865.1	RP11-488L18.10	-4.62	6.01e-06	0.0022	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247269856	chr1:247187281~247188526:-
COAD	cis	rs2378497	1	rs3121626	ENSG00000232679.1	RP11-400N13.3	4.62	6.02e-06	0.0022	0.38	0.28	Serum thyroid-stimulating hormone levels;	chr1:222017218	chr1:222041705~222064763:-
COAD	cis	rs739496	0.615	rs668774	ENSG00000257595.2	RP3-473L9.4	4.62	6.02e-06	0.0022	0.41	0.28	Platelet count;	chr12:111731848	chr12:111369282~111403310:+
COAD	cis	rs35264875	1	rs72928636	ENSG00000259799.1	RP11-554A11.9	4.62	6.02e-06	0.0022	0.44	0.28	Blond vs. brown hair color;	chr11:69080918	chr11:69155910~69159752:+
COAD	cis	rs35264875	1	rs72928644	ENSG00000259799.1	RP11-554A11.9	4.62	6.02e-06	0.0022	0.44	0.28	Blond vs. brown hair color;	chr11:69082377	chr11:69155910~69159752:+
COAD	cis	rs35264875	1	rs1542334	ENSG00000259799.1	RP11-554A11.9	4.62	6.02e-06	0.0022	0.44	0.28	Blond vs. brown hair color;	chr11:69083305	chr11:69155910~69159752:+
COAD	cis	rs35264875	1	rs72928652	ENSG00000259799.1	RP11-554A11.9	4.62	6.02e-06	0.0022	0.44	0.28	Blond vs. brown hair color;	chr11:69084079	chr11:69155910~69159752:+
COAD	cis	rs2115630	1	rs8037423	ENSG00000259728.4	LINC00933	-4.62	6.02e-06	0.0022	-0.33	-0.28	P wave terminal force;	chr15:84812263	chr15:84570649~84580175:+
COAD	cis	rs9487051	0.872	rs4601178	ENSG00000219700.1	PTCHD3P3	4.62	6.03e-06	0.00221	0.29	0.28	Reticulocyte fraction of red cells;	chr6:109290043	chr6:109288571~109290503:-
COAD	cis	rs12935418	0.616	rs2549853	ENSG00000278985.1	RP11-303E16.9	-4.62	6.03e-06	0.00221	-0.3	-0.28	Mean corpuscular volume;	chr16:80992850	chr16:80982319~80984094:-
COAD	cis	rs28374715	1	rs28374715	ENSG00000247556.5	OIP5-AS1	4.62	6.03e-06	0.00221	0.34	0.28	Ulcerative colitis;	chr15:41271752	chr15:41283990~41309737:+
COAD	cis	rs7119	0.667	rs2867312	ENSG00000259565.2	KRT8P23	-4.62	6.03e-06	0.00221	-0.31	-0.28	Type 2 diabetes;	chr15:77609951	chr15:76979245~76980451:-
COAD	cis	rs12935418	0.616	rs9937731	ENSG00000278985.1	RP11-303E16.9	4.62	6.03e-06	0.00221	0.3	0.28	Mean corpuscular volume;	chr16:80978406	chr16:80982319~80984094:-
COAD	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-4.62	6.03e-06	0.00221	-0.35	-0.28	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
COAD	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-4.62	6.04e-06	0.00221	-0.32	-0.28	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
COAD	cis	rs9392556	0.6	rs664299	ENSG00000230648.1	RP3-406P24.3	4.62	6.04e-06	0.00221	0.32	0.28	Blood metabolite levels;	chr6:4112007	chr6:4018843~4021215:-
COAD	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	4.62	6.04e-06	0.00221	0.31	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
COAD	cis	rs1005224	0.547	rs3784004	ENSG00000258454.1	RP11-361H10.3	-4.62	6.04e-06	0.00221	-0.35	-0.28	Large artery stroke;	chr14:75615321	chr14:76235817~76263474:+
COAD	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-4.62	6.04e-06	0.00221	-0.31	-0.28	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
COAD	cis	rs7656342	0.866	rs13129487	ENSG00000186234.7	FAM86MP	-4.62	6.05e-06	0.00221	-0.37	-0.28	Gut microbiota (bacterial taxa);	chr4:9769384	chr4:9692495~9702954:+
COAD	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	4.62	6.05e-06	0.00221	0.35	0.28	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
COAD	cis	rs2115630	1	rs2879828	ENSG00000259728.4	LINC00933	-4.62	6.05e-06	0.00221	-0.32	-0.28	P wave terminal force;	chr15:84818746	chr15:84570649~84580175:+
COAD	cis	rs728616	0.867	rs17606361	ENSG00000225484.5	NUTM2B-AS1	-4.62	6.05e-06	0.00221	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79663088~79826594:-
COAD	cis	rs728616	0.764	rs61859016	ENSG00000225484.5	NUTM2B-AS1	-4.62	6.05e-06	0.00221	-0.5	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79663088~79826594:-
COAD	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	4.62	6.05e-06	0.00221	0.46	0.28	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
COAD	cis	rs9951698	0.608	rs692833	ENSG00000266969.1	RP11-773H22.4	4.62	6.06e-06	0.00222	0.34	0.28	Intelligence (multi-trait analysis);	chr18:13135434	chr18:12984694~12991173:-
COAD	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	4.62	6.06e-06	0.00222	0.34	0.28	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
COAD	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	4.62	6.06e-06	0.00222	0.34	0.28	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
COAD	cis	rs899997	0.862	rs11072787	ENSG00000261143.1	ADAMTS7P3	-4.62	6.07e-06	0.00222	-0.36	-0.28	Coronary artery disease or large artery stroke;	chr15:78680635	chr15:77976042~77993057:+
COAD	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.62	6.07e-06	0.00222	0.3	0.28	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
COAD	cis	rs4657482	0.962	rs10918303	ENSG00000236364.3	RP11-525G13.2	-4.62	6.07e-06	0.00222	-0.2	-0.28	Testicular germ cell tumor;	chr1:165883992	chr1:165890795~165900683:-
COAD	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	4.62	6.07e-06	0.00222	0.44	0.28	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
COAD	cis	rs1790761	0.587	rs4930430	ENSG00000231793.4	DOC2GP	4.62	6.07e-06	0.00222	0.31	0.28	Mean corpuscular volume;	chr11:67526727	chr11:67612653~67616257:-
COAD	cis	rs2115630	0.967	rs8027779	ENSG00000259728.4	LINC00933	-4.62	6.07e-06	0.00222	-0.33	-0.28	P wave terminal force;	chr15:84712154	chr15:84570649~84580175:+
COAD	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	4.62	6.08e-06	0.00222	0.33	0.28	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
COAD	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	4.62	6.08e-06	0.00222	0.19	0.28	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
COAD	cis	rs801193	1	rs10252765	ENSG00000272831.1	RP11-792A8.4	4.62	6.08e-06	0.00222	0.3	0.28	Aortic root size;	chr7:66763745	chr7:66739829~66740385:-
COAD	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-4.62	6.08e-06	0.00222	-0.4	-0.28	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
COAD	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-4.62	6.09e-06	0.00222	-0.28	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
COAD	cis	rs875971	0.502	rs6460311	ENSG00000224316.1	RP11-479O9.2	-4.62	6.09e-06	0.00223	-0.35	-0.28	Aortic root size;	chr7:66646886	chr7:65773620~65802067:+
COAD	cis	rs6452524	0.618	rs3899556	ENSG00000271862.1	RP11-343L5.2	4.62	6.09e-06	0.00223	0.27	0.28	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83049376~83050964:-
COAD	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	4.62	6.1e-06	0.00223	0.3	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
COAD	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	4.62	6.1e-06	0.00223	0.3	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
COAD	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-4.62	6.11e-06	0.00223	-0.36	-0.28	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
COAD	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	4.62	6.11e-06	0.00223	0.45	0.28	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	4.62	6.11e-06	0.00223	0.45	0.28	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	4.62	6.11e-06	0.00223	0.45	0.28	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
COAD	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-4.62	6.11e-06	0.00223	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-4.62	6.11e-06	0.00223	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-4.62	6.11e-06	0.00223	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
COAD	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	4.62	6.11e-06	0.00223	0.31	0.28	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	4.62	6.11e-06	0.00223	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
COAD	cis	rs1023500	0.505	rs134878	ENSG00000237037.8	NDUFA6-AS1	-4.62	6.11e-06	0.00223	-0.29	-0.28	Schizophrenia;	chr22:42267868	chr22:42090931~42137742:+
COAD	cis	rs2836974	0.644	rs7281853	ENSG00000255568.3	BRWD1-AS2	-4.62	6.12e-06	0.00223	-0.27	-0.28	Cognitive function;	chr21:39321564	chr21:39313935~39314962:+
COAD	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-4.62	6.12e-06	0.00224	-0.33	-0.28	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
COAD	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-4.62	6.12e-06	0.00224	-0.33	-0.28	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
COAD	cis	rs754466	0.58	rs2289311	ENSG00000204049.1	RP11-126H7.4	4.62	6.12e-06	0.00224	0.33	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77805897	chr10:77866875~77869610:+
COAD	cis	rs754466	0.58	rs1058198	ENSG00000204049.1	RP11-126H7.4	4.62	6.12e-06	0.00224	0.33	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806874	chr10:77866875~77869610:+
COAD	cis	rs5015933	0.966	rs10986724	ENSG00000232630.1	PRPS1P2	4.62	6.12e-06	0.00224	0.26	0.28	Body mass index;	chr9:125369240	chr9:125150653~125151589:+
COAD	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	4.62	6.13e-06	0.00224	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	4.62	6.13e-06	0.00224	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
COAD	cis	rs875971	0.545	rs1796219	ENSG00000224316.1	RP11-479O9.2	-4.62	6.14e-06	0.00224	-0.36	-0.28	Aortic root size;	chr7:66645977	chr7:65773620~65802067:+
COAD	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	4.62	6.14e-06	0.00224	0.36	0.28	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	4.62	6.14e-06	0.00224	0.36	0.28	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	4.62	6.14e-06	0.00224	0.36	0.28	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
COAD	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	4.62	6.15e-06	0.00225	0.32	0.28	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
COAD	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	4.62	6.16e-06	0.00225	0.33	0.28	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
COAD	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	4.62	6.16e-06	0.00225	0.31	0.28	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
COAD	cis	rs2337406	0.714	rs8022729	ENSG00000274576.2	IGHV2-70	4.62	6.16e-06	0.00225	0.24	0.28	Alzheimer's disease (late onset);	chr14:106816928	chr14:106770577~106771020:-
COAD	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-4.62	6.17e-06	0.00225	-0.35	-0.28	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
COAD	cis	rs58873874	0.579	rs11738062	ENSG00000251405.2	CTB-109A12.1	4.62	6.17e-06	0.00225	0.49	0.28	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157362615~157460078:-
COAD	cis	rs7656342	0.964	rs2280333	ENSG00000186234.7	FAM86MP	-4.62	6.17e-06	0.00225	-0.36	-0.28	Gut microbiota (bacterial taxa);	chr4:9809509	chr4:9692495~9702954:+
COAD	cis	rs9450351	0.744	rs9362225	ENSG00000203875.9	SNHG5	-4.62	6.17e-06	0.00225	-0.51	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85500713	chr6:85660950~85678736:-
COAD	cis	rs7818688	0.614	rs60171840	ENSG00000253528.2	RP11-347C18.4	-4.62	6.17e-06	0.00225	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94820292	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs59265059	ENSG00000253528.2	RP11-347C18.4	-4.62	6.17e-06	0.00225	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94820588	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.653	rs4075834	ENSG00000253528.2	RP11-347C18.4	-4.62	6.17e-06	0.00225	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94821519	chr8:94974573~94974853:-
COAD	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	4.62	6.17e-06	0.00225	0.31	0.28	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
COAD	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-4.62	6.18e-06	0.00225	-0.34	-0.28	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
COAD	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	4.62	6.18e-06	0.00225	0.41	0.28	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	4.62	6.18e-06	0.00225	0.41	0.28	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
COAD	cis	rs7428	0.545	rs1053561	ENSG00000246575.2	AC093162.5	4.62	6.19e-06	0.00226	0.26	0.28	Ear protrusion;	chr2:85318929	chr2:85315041~85316529:+
COAD	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-4.62	6.19e-06	0.00226	-0.32	-0.28	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
COAD	cis	rs4568518	0.903	rs12699941	ENSG00000279048.1	RP11-511H23.2	4.62	6.19e-06	0.00226	0.2	0.28	Measles;	chr7:17997837	chr7:17940503~17942922:+
COAD	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	4.62	6.2e-06	0.00226	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	4.62	6.2e-06	0.00226	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
COAD	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
COAD	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	4.62	6.2e-06	0.00226	0.24	0.28	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
COAD	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	4.62	6.2e-06	0.00226	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
COAD	cis	rs6840360	0.539	rs1443087	ENSG00000251611.1	RP11-610P16.1	-4.62	6.2e-06	0.00226	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs1443088	ENSG00000251611.1	RP11-610P16.1	-4.62	6.2e-06	0.00226	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151407551~151408835:-
COAD	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-4.62	6.2e-06	0.00226	-0.33	-0.28	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
COAD	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	4.62	6.21e-06	0.00226	0.35	0.28	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
COAD	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	4.62	6.21e-06	0.00226	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
COAD	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	4.62	6.21e-06	0.00226	0.28	0.28	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
COAD	cis	rs227275	0.525	rs4596243	ENSG00000230069.3	LRRC37A15P	-4.62	6.21e-06	0.00226	-0.28	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102727274~102730721:-
COAD	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-4.62	6.21e-06	0.00226	-0.51	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
COAD	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	4.61	6.21e-06	0.00226	0.34	0.28	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
COAD	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-4.61	6.21e-06	0.00226	-0.52	-0.28	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-4.61	6.21e-06	0.00226	-0.52	-0.28	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
COAD	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-4.61	6.21e-06	0.00226	-0.34	-0.28	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
COAD	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-4.61	6.21e-06	0.00226	-0.33	-0.28	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
COAD	cis	rs5742933	0.803	rs1233262	ENSG00000253559.1	OSGEPL1-AS1	-4.61	6.22e-06	0.00227	-0.28	-0.28	Ferritin levels;	chr2:189793107	chr2:189762704~189765556:+
COAD	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	4.61	6.22e-06	0.00227	0.44	0.28	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
COAD	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	4.61	6.22e-06	0.00227	0.68	0.28	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
COAD	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	4.61	6.22e-06	0.00227	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	4.61	6.22e-06	0.00227	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
COAD	cis	rs9400467	0.528	rs10872066	ENSG00000271789.1	RP5-1112D6.7	-4.61	6.23e-06	0.00227	-0.27	-0.28	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111297126~111298510:+
COAD	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-4.61	6.23e-06	0.00227	-0.39	-0.28	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
COAD	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-4.61	6.23e-06	0.00227	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
COAD	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	4.61	6.24e-06	0.00227	0.42	0.28	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
COAD	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-4.61	6.24e-06	0.00227	-0.38	-0.28	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
COAD	cis	rs1832007	0.554	rs7101071	ENSG00000224034.1	RP11-445P17.8	-4.61	6.24e-06	0.00227	-0.42	-0.28	Triglyceride levels;Triglycerides;	chr10:5200674	chr10:5266033~5271236:-
COAD	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-4.61	6.24e-06	0.00227	-0.3	-0.28	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
COAD	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-4.61	6.24e-06	0.00227	-0.48	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-4.61	6.24e-06	0.00227	-0.48	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
COAD	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-4.61	6.24e-06	0.00227	-0.31	-0.28	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
COAD	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-4.61	6.25e-06	0.00228	-0.33	-0.28	Migraine;	chr4:56851192	chr4:56960927~56961373:-
COAD	cis	rs13217239	0.646	rs6456767	ENSG00000224843.5	LINC00240	4.61	6.25e-06	0.00228	0.33	0.28	Schizophrenia;	chr6:27102764	chr6:26956992~27023924:+
COAD	cis	rs3126085	0.515	rs6668764	ENSG00000237975.5	FLG-AS1	-4.61	6.25e-06	0.00228	-0.31	-0.28	Atopic dermatitis;	chr1:152376602	chr1:152168125~152445456:+
COAD	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	4.61	6.26e-06	0.00228	0.32	0.28	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
COAD	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	4.61	6.27e-06	0.00228	0.42	0.28	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
COAD	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	4.61	6.27e-06	0.00228	0.36	0.28	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
COAD	cis	rs9307551	0.817	rs1975399	ENSG00000250334.4	LINC00989	-4.61	6.27e-06	0.00228	-0.32	-0.28	Refractive error;	chr4:79582612	chr4:79492416~79576460:+
COAD	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	4.61	6.28e-06	0.00228	0.34	0.28	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	4.61	6.28e-06	0.00228	0.34	0.28	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
COAD	cis	rs2732480	0.5	rs2450989	ENSG00000273765.1	RP11-370I10.11	-4.61	6.28e-06	0.00229	-0.3	-0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48360920~48361377:+
COAD	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	4.61	6.28e-06	0.00229	0.34	0.28	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
COAD	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	4.61	6.28e-06	0.00229	0.38	0.28	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
COAD	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-4.61	6.29e-06	0.00229	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
COAD	cis	rs2732480	0.5	rs2732461	ENSG00000257735.1	RP11-370I10.6	4.61	6.29e-06	0.00229	0.34	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48350945~48442411:+
COAD	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-4.61	6.3e-06	0.00229	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
COAD	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	4.61	6.3e-06	0.00229	0.17	0.28	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
COAD	cis	rs7818688	0.654	rs896848	ENSG00000253528.2	RP11-347C18.4	-4.61	6.3e-06	0.00229	-0.38	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969582	chr8:94974573~94974853:-
COAD	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-4.61	6.31e-06	0.00229	-0.3	-0.28	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
COAD	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-4.61	6.31e-06	0.00229	-0.31	-0.28	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
COAD	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.61	6.31e-06	0.00229	-0.29	-0.28	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
COAD	cis	rs9907295	0.591	rs3760327	ENSG00000271013.1	AC015849.15	-4.61	6.31e-06	0.0023	-0.34	-0.28	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35912635~35918010:-
COAD	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-4.61	6.31e-06	0.0023	-0.34	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
COAD	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-4.61	6.32e-06	0.0023	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
COAD	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.32e-06	0.0023	-0.32	-0.28	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.32e-06	0.0023	-0.32	-0.28	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.32e-06	0.0023	-0.32	-0.28	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.32e-06	0.0023	-0.32	-0.28	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.32e-06	0.0023	-0.32	-0.28	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
COAD	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-4.61	6.33e-06	0.0023	-0.32	-0.28	Height;	chr3:53007328	chr3:53064283~53065091:-
COAD	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-4.61	6.34e-06	0.0023	-0.33	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
COAD	cis	rs2337406	0.714	rs7145254	ENSG00000274576.2	IGHV2-70	-4.61	6.34e-06	0.00231	-0.24	-0.28	Alzheimer's disease (late onset);	chr14:106817783	chr14:106770577~106771020:-
COAD	cis	rs7961581	0.719	rs10748173	ENSG00000258053.1	CTD-2021H9.3	-4.61	6.35e-06	0.00231	-0.37	-0.28	Type 2 diabetes;	chr12:71259953	chr12:71047402~71118247:-
COAD	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	4.61	6.35e-06	0.00231	0.36	0.28	Depression;	chr6:28199145	chr6:28115628~28116551:+
COAD	cis	rs12497850	0.931	rs4974085	ENSG00000225399.4	RP11-3B7.1	4.61	6.35e-06	0.00231	0.31	0.28	Parkinson's disease;	chr3:48887467	chr3:49260085~49261316:+
COAD	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	4.61	6.35e-06	0.00231	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	4.61	6.35e-06	0.00231	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	4.61	6.35e-06	0.00231	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
COAD	cis	rs58873874	0.579	rs3815829	ENSG00000251405.2	CTB-109A12.1	4.61	6.35e-06	0.00231	0.51	0.28	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157362615~157460078:-
COAD	cis	rs4718428	0.705	rs4718430	ENSG00000232546.1	RP11-458F8.1	-4.61	6.35e-06	0.00231	-0.26	-0.28	Corneal structure;	chr7:66967037	chr7:66848496~66858136:+
COAD	cis	rs6901004	0.565	rs6900341	ENSG00000271789.1	RP5-1112D6.7	-4.61	6.35e-06	0.00231	-0.27	-0.28	Blood metabolite levels;	chr6:111473206	chr6:111297126~111298510:+
COAD	cis	rs2292864	0.764	rs2292867	ENSG00000228782.6	CTD-2026D20.3	-4.61	6.35e-06	0.00231	-0.42	-0.28	Left atrial antero-posterior diameter;	chr17:47280123	chr17:47450568~47492492:-
COAD	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-4.61	6.36e-06	0.00231	-0.34	-0.28	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
COAD	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-4.61	6.36e-06	0.00231	-0.33	-0.28	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-4.61	6.36e-06	0.00231	-0.33	-0.28	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
COAD	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	4.61	6.37e-06	0.00231	0.34	0.28	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
COAD	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	4.61	6.37e-06	0.00231	0.34	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
COAD	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-4.61	6.37e-06	0.00231	-0.47	-0.28	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
COAD	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-4.61	6.38e-06	0.00231	-0.32	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
COAD	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-4.61	6.38e-06	0.00231	-0.34	-0.28	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
COAD	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	4.61	6.38e-06	0.00232	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
COAD	cis	rs4704187	0.687	rs4389672	ENSG00000250889.2	LINC01336	-4.61	6.39e-06	0.00232	-0.31	-0.28	Response to amphetamines;	chr5:75072817	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.712	rs7701262	ENSG00000250889.2	LINC01336	-4.61	6.39e-06	0.00232	-0.31	-0.28	Response to amphetamines;	chr5:75070161	chr5:75047719~75052843:-
COAD	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	4.61	6.39e-06	0.00232	0.34	0.28	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	4.61	6.39e-06	0.00232	0.34	0.28	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
COAD	cis	rs7674212	0.57	rs2711899	ENSG00000230069.3	LRRC37A15P	-4.61	6.39e-06	0.00232	-0.29	-0.28	Type 2 diabetes;	chr4:103141257	chr4:102727274~102730721:-
COAD	cis	rs9847710	0.869	rs2564917	ENSG00000280417.1	RP11-5O17.1	-4.61	6.39e-06	0.00232	-0.28	-0.28	Ulcerative colitis;	chr3:53003679	chr3:53046166~53048122:+
COAD	cis	rs2732480	0.538	rs1387260	ENSG00000257735.1	RP11-370I10.6	4.61	6.39e-06	0.00232	0.35	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48350945~48442411:+
COAD	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	4.61	6.4e-06	0.00232	0.42	0.28	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	4.61	6.4e-06	0.00232	0.42	0.28	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	4.61	6.4e-06	0.00232	0.42	0.28	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	4.61	6.4e-06	0.00232	0.42	0.28	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
COAD	cis	rs2337406	0.866	rs7153964	ENSG00000211974.3	IGHV2-70	-4.61	6.4e-06	0.00232	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106790480	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs2301536	ENSG00000211974.3	IGHV2-70	-4.61	6.4e-06	0.00232	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106790636	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs7144369	ENSG00000211974.3	IGHV2-70	-4.61	6.4e-06	0.00232	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106793065	chr14:106723574~106724093:-
COAD	cis	rs11089937	0.895	rs5756985	ENSG00000211639.2	IGLV4-60	4.61	6.4e-06	0.00232	0.24	0.28	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22162199~22162681:+
COAD	cis	rs13217239	0.572	rs9379958	ENSG00000224843.5	LINC00240	4.61	6.4e-06	0.00232	0.32	0.28	Schizophrenia;	chr6:27098384	chr6:26956992~27023924:+
COAD	cis	rs13217239	0.646	rs9393789	ENSG00000224843.5	LINC00240	4.61	6.4e-06	0.00232	0.32	0.28	Schizophrenia;	chr6:27099249	chr6:26956992~27023924:+
COAD	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-4.61	6.41e-06	0.00233	-0.52	-0.28	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-4.61	6.41e-06	0.00233	-0.52	-0.28	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-4.61	6.41e-06	0.00233	-0.52	-0.28	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-4.61	6.41e-06	0.00233	-0.52	-0.28	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
COAD	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.61	6.42e-06	0.00233	0.29	0.28	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
COAD	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.61	6.42e-06	0.00233	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
COAD	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.61	6.42e-06	0.00233	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
COAD	cis	rs71636778	0.509	rs36053809	ENSG00000260063.1	RP5-968P14.2	-4.61	6.42e-06	0.00233	-0.55	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756602	chr1:26692132~26694131:-
COAD	cis	rs2115630	0.967	rs11073731	ENSG00000259728.4	LINC00933	-4.61	6.42e-06	0.00233	-0.33	-0.28	P wave terminal force;	chr15:84811882	chr15:84570649~84580175:+
COAD	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-4.61	6.42e-06	0.00233	-0.32	-0.28	QT interval;	chr12:29349303	chr12:29280418~29317848:-
COAD	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-4.61	6.43e-06	0.00233	-0.33	-0.28	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
COAD	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
COAD	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-4.61	6.43e-06	0.00233	-0.34	-0.28	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
COAD	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-4.61	6.44e-06	0.00233	-0.55	-0.28	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
COAD	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	4.61	6.44e-06	0.00233	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	4.61	6.44e-06	0.00234	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	4.61	6.44e-06	0.00234	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
COAD	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-4.61	6.44e-06	0.00234	-0.25	-0.28	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	4.61	6.44e-06	0.00234	0.2	0.28	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
COAD	cis	rs7674212	0.541	rs2720458	ENSG00000230069.3	LRRC37A15P	-4.61	6.44e-06	0.00234	-0.3	-0.28	Type 2 diabetes;	chr4:103131806	chr4:102727274~102730721:-
COAD	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-4.61	6.45e-06	0.00234	-0.27	-0.28	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
COAD	cis	rs11846409	0.932	rs74091728	ENSG00000274576.2	IGHV2-70	-4.61	6.45e-06	0.00234	-0.27	-0.28	Rheumatic heart disease;	chr14:106638762	chr14:106770577~106771020:-
COAD	cis	rs7260598	0.539	rs10418377	ENSG00000268442.1	CTD-2027I19.2	4.61	6.47e-06	0.00235	0.44	0.28	Response to taxane treatment (placlitaxel);	chr19:23898542	chr19:24162370~24163425:-
COAD	cis	rs9818758	0.545	rs9853352	ENSG00000225399.4	RP11-3B7.1	4.61	6.47e-06	0.00235	0.54	0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49775825	chr3:49260085~49261316:+
COAD	cis	rs2337406	0.866	rs78525520	ENSG00000211974.3	IGHV2-70	-4.61	6.47e-06	0.00235	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106795643	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs7140974	ENSG00000211974.3	IGHV2-70	-4.61	6.47e-06	0.00235	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106795976	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs76871148	ENSG00000211974.3	IGHV2-70	-4.61	6.47e-06	0.00235	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106799722	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs61521632	ENSG00000211974.3	IGHV2-70	-4.61	6.47e-06	0.00235	-0.31	-0.28	Alzheimer's disease (late onset);	chr14:106801091	chr14:106723574~106724093:-
COAD	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-4.61	6.48e-06	0.00235	-0.25	-0.28	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
COAD	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-4.61	6.48e-06	0.00235	-0.34	-0.28	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
COAD	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-4.61	6.48e-06	0.00235	-0.3	-0.28	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
COAD	cis	rs891378	0.785	rs1346720	ENSG00000274245.1	RP11-357P18.2	4.61	6.49e-06	0.00235	0.36	0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207214421	chr1:207372559~207373252:+
COAD	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-4.61	6.49e-06	0.00235	-0.29	-0.28	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
COAD	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.61	6.49e-06	0.00235	-0.29	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
COAD	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	4.61	6.49e-06	0.00235	0.33	0.28	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	4.61	6.49e-06	0.00235	0.33	0.28	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	4.61	6.49e-06	0.00235	0.33	0.28	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
COAD	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-4.6	6.49e-06	0.00235	-0.31	-0.28	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
COAD	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-4.6	6.5e-06	0.00235	-0.28	-0.28	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
COAD	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	4.6	6.5e-06	0.00236	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
COAD	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	4.6	6.5e-06	0.00236	0.33	0.28	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
COAD	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-4.6	6.5e-06	0.00236	-0.5	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
COAD	cis	rs4568518	0.903	rs10950695	ENSG00000279048.1	RP11-511H23.2	-4.6	6.51e-06	0.00236	-0.2	-0.28	Measles;	chr7:17995592	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.803	rs12699938	ENSG00000279048.1	RP11-511H23.2	4.6	6.51e-06	0.00236	0.19	0.28	Measles;	chr7:17994897	chr7:17940503~17942922:+
COAD	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-4.6	6.52e-06	0.00236	-0.31	-0.28	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
COAD	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	4.6	6.52e-06	0.00236	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
COAD	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-4.6	6.52e-06	0.00236	-0.22	-0.28	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
COAD	cis	rs8002861	0.967	rs9533691	ENSG00000274001.1	RP11-5G9.5	4.6	6.52e-06	0.00236	0.25	0.28	Leprosy;	chr13:43908072	chr13:43877715~43878163:-
COAD	cis	rs74394007	0.541	rs2653817	ENSG00000240875.4	LINC00886	-4.6	6.52e-06	0.00236	-0.3	-0.28	Total body bone mineral density;	chr3:156830057	chr3:156747346~156817062:-
COAD	cis	rs5758511	0.514	rs2899354	ENSG00000237037.8	NDUFA6-AS1	-4.6	6.53e-06	0.00236	-0.34	-0.28	Birth weight;	chr22:42158403	chr22:42090931~42137742:+
COAD	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-4.6	6.53e-06	0.00236	-0.18	-0.28	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
COAD	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-4.6	6.53e-06	0.00236	-0.32	-0.28	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-4.6	6.53e-06	0.00236	-0.32	-0.28	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
COAD	cis	rs4604732	0.536	rs12090434	ENSG00000227135.1	GCSAML-AS1	-4.6	6.53e-06	0.00236	-0.41	-0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247495984	chr1:247524679~247526752:-
COAD	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-4.6	6.53e-06	0.00236	-0.33	-0.28	Migraine;	chr4:56852087	chr4:56960927~56961373:-
COAD	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-4.6	6.53e-06	0.00237	-0.29	-0.28	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-4.6	6.53e-06	0.00237	-0.29	-0.28	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
COAD	cis	rs7818688	0.697	rs11782818	ENSG00000253528.2	RP11-347C18.4	-4.6	6.54e-06	0.00237	-0.4	-0.28	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965993	chr8:94974573~94974853:-
COAD	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-4.6	6.54e-06	0.00237	-0.38	-0.28	Depression;	chr6:28082231	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-4.6	6.54e-06	0.00237	-0.38	-0.28	Depression;	chr6:28082261	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-4.6	6.54e-06	0.00237	-0.38	-0.28	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
COAD	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	4.6	6.54e-06	0.00237	0.34	0.28	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
COAD	cis	rs9393777	0.623	rs2093169	ENSG00000224843.5	LINC00240	4.6	6.54e-06	0.00237	0.46	0.28	Intelligence (multi-trait analysis);	chr6:26494871	chr6:26956992~27023924:+
COAD	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	4.6	6.55e-06	0.00237	0.28	0.28	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
COAD	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	4.6	6.55e-06	0.00237	0.39	0.28	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
COAD	cis	rs4704187	0.687	rs1422696	ENSG00000250889.2	LINC01336	-4.6	6.55e-06	0.00237	-0.31	-0.28	Response to amphetamines;	chr5:75168590	chr5:75047719~75052843:-
COAD	cis	rs6723226	0.842	rs2754522	ENSG00000276334.1	AL133243.1	4.6	6.55e-06	0.00237	0.26	0.28	Intelligence (multi-trait analysis);	chr2:32576190	chr2:32521927~32523547:+
COAD	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-4.6	6.55e-06	0.00237	-0.33	-0.28	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
COAD	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	4.6	6.56e-06	0.00237	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	4.6	6.56e-06	0.00237	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
COAD	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	4.6	6.56e-06	0.00237	0.36	0.28	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
COAD	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-4.6	6.56e-06	0.00237	-0.34	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
COAD	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-4.6	6.56e-06	0.00237	-0.34	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
COAD	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-4.6	6.56e-06	0.00237	-0.31	-0.28	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
COAD	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-4.6	6.56e-06	0.00237	-0.31	-0.28	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
COAD	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	4.6	6.57e-06	0.00238	0.28	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
COAD	cis	rs9951698	0.678	rs1786263	ENSG00000266969.1	RP11-773H22.4	4.6	6.57e-06	0.00238	0.36	0.28	Intelligence (multi-trait analysis);	chr18:13116433	chr18:12984694~12991173:-
COAD	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-4.6	6.57e-06	0.00238	-0.47	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-4.6	6.57e-06	0.00238	-0.47	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
COAD	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	4.6	6.57e-06	0.00238	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	4.6	6.57e-06	0.00238	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
COAD	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	4.6	6.58e-06	0.00238	0.28	0.28	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
COAD	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	4.6	6.58e-06	0.00238	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	4.6	6.58e-06	0.00238	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	4.6	6.58e-06	0.00238	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	4.6	6.58e-06	0.00238	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
COAD	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-4.6	6.59e-06	0.00238	-0.33	-0.28	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
COAD	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-4.6	6.59e-06	0.00238	-0.25	-0.28	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
COAD	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	4.6	6.6e-06	0.00238	0.33	0.28	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
COAD	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	4.6	6.6e-06	0.00238	0.32	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	4.6	6.6e-06	0.00238	0.32	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
COAD	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	4.6	6.6e-06	0.00238	0.28	0.28	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
COAD	cis	rs9450351	0.744	rs1447157	ENSG00000203875.9	SNHG5	-4.6	6.6e-06	0.00238	-0.53	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85879434	chr6:85660950~85678736:-
COAD	cis	rs494562	0.667	rs643591	ENSG00000234155.1	RP11-30P6.6	-4.6	6.6e-06	0.00239	-0.49	-0.28	Metabolic traits;Blood metabolite levels;	chr6:85393838	chr6:85387219~85390186:-
COAD	cis	rs6723226	0.75	rs10182170	ENSG00000276334.1	AL133243.1	4.6	6.61e-06	0.00239	0.25	0.28	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32521927~32523547:+
COAD	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-4.6	6.61e-06	0.00239	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
COAD	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	4.6	6.61e-06	0.00239	0.33	0.28	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	4.6	6.61e-06	0.00239	0.33	0.28	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	4.6	6.61e-06	0.00239	0.33	0.28	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	4.6	6.61e-06	0.00239	0.33	0.28	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	4.6	6.61e-06	0.00239	0.33	0.28	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
COAD	cis	rs4568518	0.903	rs12699937	ENSG00000279048.1	RP11-511H23.2	4.6	6.61e-06	0.00239	0.19	0.28	Measles;	chr7:17994811	chr7:17940503~17942922:+
COAD	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	4.6	6.61e-06	0.00239	0.27	0.28	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
COAD	cis	rs2378497	1	rs2970199	ENSG00000232679.1	RP11-400N13.3	-4.6	6.61e-06	0.00239	-0.35	-0.28	Serum thyroid-stimulating hormone levels;	chr1:222004112	chr1:222041705~222064763:-
COAD	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-4.6	6.61e-06	0.00239	-0.32	-0.28	Height;	chr2:231541633	chr2:231508426~231514339:-
COAD	cis	rs7646881	0.504	rs7617304	ENSG00000272087.1	RP11-379F4.7	4.6	6.62e-06	0.00239	0.39	0.28	Tetralogy of Fallot;	chr3:158745312	chr3:158693120~158693768:-
COAD	cis	rs1930961	0.702	rs11090398	ENSG00000272977.1	CTA-390C10.10	-4.6	6.62e-06	0.00239	-0.74	-0.28	Bipolar disorder with mood-incongruent psychosis;	chr22:25493190	chr22:25476218~25479971:+
COAD	cis	rs6142618	0.52	rs6058669	ENSG00000235217.6	TSPY26P	4.6	6.62e-06	0.00239	0.22	0.28	Inflammatory bowel disease;	chr20:32382622	chr20:32186477~32190527:-
COAD	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	4.6	6.62e-06	0.00239	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	4.6	6.62e-06	0.00239	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	4.6	6.62e-06	0.00239	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
COAD	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	4.6	6.62e-06	0.00239	0.35	0.28	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
COAD	cis	rs5742933	1	rs6719224	ENSG00000253559.1	OSGEPL1-AS1	-4.6	6.62e-06	0.00239	-0.3	-0.28	Ferritin levels;	chr2:189769545	chr2:189762704~189765556:+
COAD	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	4.6	6.62e-06	0.00239	0.28	0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
COAD	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	4.6	6.62e-06	0.00239	0.55	0.28	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
COAD	cis	rs9487051	0.676	rs6913093	ENSG00000219700.1	PTCHD3P3	4.6	6.64e-06	0.0024	0.3	0.28	Reticulocyte fraction of red cells;	chr6:109315002	chr6:109288571~109290503:-
COAD	cis	rs2281603	0.57	rs2123460	ENSG00000259116.1	RP11-973N13.4	-4.6	6.64e-06	0.0024	-0.27	-0.28	Lymphocyte counts;	chr14:64485507	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs2123459	ENSG00000259116.1	RP11-973N13.4	-4.6	6.64e-06	0.0024	-0.27	-0.28	Lymphocyte counts;	chr14:64485585	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs11626222	ENSG00000259116.1	RP11-973N13.4	-4.6	6.64e-06	0.0024	-0.27	-0.28	Lymphocyte counts;	chr14:64486541	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs10132969	ENSG00000259116.1	RP11-973N13.4	-4.6	6.64e-06	0.0024	-0.27	-0.28	Lymphocyte counts;	chr14:64486862	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs10143839	ENSG00000259116.1	RP11-973N13.4	-4.6	6.64e-06	0.0024	-0.27	-0.28	Lymphocyte counts;	chr14:64486873	chr14:64514154~64540368:-
COAD	cis	rs7119	0.7	rs4886519	ENSG00000259565.2	KRT8P23	4.6	6.64e-06	0.0024	0.31	0.28	Type 2 diabetes;	chr15:77601543	chr15:76979245~76980451:-
COAD	cis	rs1578862	1	rs12082983	ENSG00000259865.1	RP11-488L18.10	-4.6	6.64e-06	0.0024	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247265967	chr1:247187281~247188526:-
COAD	cis	rs1578862	1	rs55686936	ENSG00000259865.1	RP11-488L18.10	-4.6	6.64e-06	0.0024	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247266775	chr1:247187281~247188526:-
COAD	cis	rs7260598	0.539	rs11665842	ENSG00000268442.1	CTD-2027I19.2	4.6	6.64e-06	0.0024	0.48	0.28	Response to taxane treatment (placlitaxel);	chr19:23911846	chr19:24162370~24163425:-
COAD	cis	rs12935418	1	rs62054589	ENSG00000261061.1	RP11-303E16.2	-4.6	6.65e-06	0.0024	-0.39	-0.28	Mean corpuscular volume;	chr16:81035143	chr16:81030770~81031485:+
COAD	cis	rs6452524	0.648	rs27364	ENSG00000271862.1	RP11-343L5.2	4.6	6.65e-06	0.0024	0.27	0.28	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83049376~83050964:-
COAD	cis	rs9818758	0.556	rs9835439	ENSG00000225399.4	RP11-3B7.1	-4.6	6.66e-06	0.0024	-0.47	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:49260085~49261316:+
COAD	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-4.6	6.66e-06	0.0024	-0.29	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
COAD	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	4.6	6.66e-06	0.0024	0.31	0.28	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
COAD	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	4.6	6.66e-06	0.0024	0.31	0.28	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
COAD	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	4.6	6.66e-06	0.00241	0.43	0.28	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
COAD	cis	rs1387259	0.929	rs2634666	ENSG00000257735.1	RP11-370I10.6	4.6	6.66e-06	0.00241	0.34	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48350945~48442411:+
COAD	cis	rs492146	0.902	rs385636	ENSG00000243236.5	GSTA9P	-4.6	6.66e-06	0.00241	-0.3	-0.28	Epilepsy (remission after treatment);	chr6:52976139	chr6:52939726~52957521:-
COAD	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	4.6	6.67e-06	0.00241	0.34	0.28	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
COAD	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-4.6	6.67e-06	0.00241	-0.16	-0.28	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
COAD	cis	rs17772222	1	rs2295135	ENSG00000258789.1	RP11-507K2.3	-4.6	6.67e-06	0.00241	-0.4	-0.28	Coronary artery calcification;	chr14:88427866	chr14:88551597~88552493:+
COAD	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-4.6	6.67e-06	0.00241	-0.31	-0.28	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
COAD	cis	rs9393777	0.513	rs9379905	ENSG00000224843.5	LINC00240	4.6	6.68e-06	0.00241	0.44	0.28	Intelligence (multi-trait analysis);	chr6:26630762	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9295702	ENSG00000224843.5	LINC00240	4.6	6.68e-06	0.00241	0.44	0.28	Intelligence (multi-trait analysis);	chr6:26633812	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs9348728	ENSG00000224843.5	LINC00240	4.6	6.68e-06	0.00241	0.44	0.28	Intelligence (multi-trait analysis);	chr6:26634208	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.513	rs6936555	ENSG00000224843.5	LINC00240	4.6	6.68e-06	0.00241	0.44	0.28	Intelligence (multi-trait analysis);	chr6:26640658	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.582	rs6936561	ENSG00000224843.5	LINC00240	4.6	6.68e-06	0.00241	0.44	0.28	Intelligence (multi-trait analysis);	chr6:26640667	chr6:26956992~27023924:+
COAD	cis	rs12497850	0.897	rs6795025	ENSG00000225399.4	RP11-3B7.1	4.6	6.68e-06	0.00241	0.31	0.28	Parkinson's disease;	chr3:49043814	chr3:49260085~49261316:+
COAD	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-4.6	6.68e-06	0.00241	-0.3	-0.28	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
COAD	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-4.6	6.68e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-4.6	6.69e-06	0.00241	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
COAD	cis	rs10466239	0.73	rs2946992	ENSG00000230555.2	RP11-517P14.2	-4.6	6.69e-06	0.00241	-0.4	-0.28	Telomere length;	chr10:43358831	chr10:43420738~43422100:+
COAD	cis	rs1387259	0.859	rs2054905	ENSG00000226413.2	OR8T1P	4.6	6.69e-06	0.00241	0.34	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48442030~48442947:-
COAD	cis	rs5015933	0.767	rs12339434	ENSG00000232630.1	PRPS1P2	-4.6	6.69e-06	0.00241	-0.26	-0.28	Body mass index;	chr9:125376602	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.864	rs10819049	ENSG00000232630.1	PRPS1P2	-4.6	6.69e-06	0.00241	-0.26	-0.28	Body mass index;	chr9:125376805	chr9:125150653~125151589:+
COAD	cis	rs5015933	0.801	rs4240490	ENSG00000232630.1	PRPS1P2	-4.6	6.69e-06	0.00241	-0.26	-0.28	Body mass index;	chr9:125377728	chr9:125150653~125151589:+
COAD	cis	rs884366	1	rs1006081	ENSG00000219700.1	PTCHD3P3	4.6	6.7e-06	0.00242	0.36	0.28	HDL cholesterol;HDL cholesterol levels;	chr6:109304347	chr6:109288571~109290503:-
COAD	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-4.6	6.7e-06	0.00242	-0.33	-0.28	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
COAD	cis	rs1578862	0.901	rs2211273	ENSG00000259865.1	RP11-488L18.10	-4.6	6.7e-06	0.00242	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247270657	chr1:247187281~247188526:-
COAD	cis	rs6490294	0.796	rs7972112	ENSG00000257595.2	RP3-473L9.4	4.6	6.7e-06	0.00242	0.4	0.28	Mean platelet volume;	chr12:112067378	chr12:111369282~111403310:+
COAD	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-4.6	6.7e-06	0.00242	-0.44	-0.28	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
COAD	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-4.6	6.71e-06	0.00242	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
COAD	cis	rs62246343	0.572	rs62246311	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9456459	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.572	rs111979419	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9457372	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.63	rs60771966	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9465573	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.63	rs59302296	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9465630	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.63	rs3774063	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9470052	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.63	rs62246320	ENSG00000254485.4	RP11-380O24.1	4.6	6.71e-06	0.00242	0.41	0.28	Fibrinogen levels;	chr3:9470291	chr3:9292588~9363303:-
COAD	cis	rs12935418	0.672	rs11150334	ENSG00000278985.1	RP11-303E16.9	4.6	6.71e-06	0.00242	0.31	0.28	Mean corpuscular volume;	chr16:81008937	chr16:80982319~80984094:-
COAD	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-4.6	6.71e-06	0.00242	-0.47	-0.28	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
COAD	cis	rs4568518	0.903	rs12699936	ENSG00000279048.1	RP11-511H23.2	4.6	6.72e-06	0.00242	0.19	0.28	Measles;	chr7:17994808	chr7:17940503~17942922:+
COAD	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	4.6	6.72e-06	0.00242	0.36	0.28	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
COAD	cis	rs2378497	0.887	rs12122410	ENSG00000232679.1	RP11-400N13.3	4.6	6.72e-06	0.00242	0.37	0.28	Serum thyroid-stimulating hormone levels;	chr1:222038169	chr1:222041705~222064763:-
COAD	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-4.6	6.72e-06	0.00242	-0.3	-0.28	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
COAD	cis	rs4820539	1	rs2157710	ENSG00000211644.2	IGLV1-51	-4.6	6.73e-06	0.00243	-0.16	-0.28	Bone mineral density;	chr22:23115299	chr22:22322472~22322980:+
COAD	cis	rs7209700	0.632	rs11657963	ENSG00000228782.6	CTD-2026D20.3	-4.6	6.73e-06	0.00243	-0.31	-0.28	IgG glycosylation;	chr17:47270167	chr17:47450568~47492492:-
COAD	cis	rs3743162	0.553	rs4842994	ENSG00000225151.9	GOLGA2P7	4.6	6.73e-06	0.00243	0.35	0.28	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84199311~84230136:-
COAD	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	4.6	6.73e-06	0.00243	0.37	0.28	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
COAD	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-4.6	6.73e-06	0.00243	-0.27	-0.28	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
COAD	cis	rs58873874	0.579	rs10037386	ENSG00000251405.2	CTB-109A12.1	4.6	6.74e-06	0.00243	0.49	0.28	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157362615~157460078:-
COAD	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-4.6	6.74e-06	0.00243	-0.18	-0.28	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
COAD	cis	rs7577696	0.568	rs410469	ENSG00000272716.1	RP11-563N4.1	-4.6	6.75e-06	0.00243	-0.32	-0.28	Inflammatory biomarkers;	chr2:32251923	chr2:32165046~32165757:-
COAD	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	4.6	6.75e-06	0.00243	0.29	0.28	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
COAD	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	4.6	6.75e-06	0.00243	0.49	0.28	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	4.6	6.75e-06	0.00243	0.49	0.28	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	4.6	6.75e-06	0.00243	0.49	0.28	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	4.6	6.75e-06	0.00243	0.49	0.28	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	4.6	6.75e-06	0.00243	0.49	0.28	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
COAD	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	4.6	6.75e-06	0.00243	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
COAD	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	4.6	6.75e-06	0.00243	0.47	0.28	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
COAD	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-4.6	6.76e-06	0.00244	-0.26	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
COAD	cis	rs1578862	1	rs6426236	ENSG00000259865.1	RP11-488L18.10	-4.6	6.76e-06	0.00244	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247271143	chr1:247187281~247188526:-
COAD	cis	rs2378497	0.818	rs61823905	ENSG00000232679.1	RP11-400N13.3	4.6	6.77e-06	0.00244	0.39	0.28	Serum thyroid-stimulating hormone levels;	chr1:222019675	chr1:222041705~222064763:-
COAD	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-4.6	6.78e-06	0.00244	-0.33	-0.28	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
COAD	cis	rs8022206	0.773	rs13329056	ENSG00000259502.1	RP11-643G16.3	4.6	6.78e-06	0.00244	0.37	0.28	Platelet count;Mean platelet volume;	chr14:68003975	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs60201005	ENSG00000259502.1	RP11-643G16.3	4.6	6.78e-06	0.00244	0.37	0.28	Platelet count;Mean platelet volume;	chr14:68005866	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs11622787	ENSG00000259502.1	RP11-643G16.3	4.6	6.78e-06	0.00244	0.37	0.28	Platelet count;Mean platelet volume;	chr14:68006526	chr14:67610986~67613864:+
COAD	cis	rs875971	0.545	rs6950988	ENSG00000224316.1	RP11-479O9.2	4.6	6.78e-06	0.00244	0.34	0.28	Aortic root size;	chr7:66511428	chr7:65773620~65802067:+
COAD	cis	rs7615952	0.546	rs2922194	ENSG00000248787.1	RP11-666A20.4	-4.6	6.78e-06	0.00244	-0.43	-0.28	Blood pressure (smoking interaction);	chr3:125613419	chr3:125908005~125910272:-
COAD	cis	rs7647973	0.58	rs2117938	ENSG00000225399.4	RP11-3B7.1	-4.6	6.78e-06	0.00244	-0.31	-0.28	Menarche (age at onset);	chr3:49226417	chr3:49260085~49261316:+
COAD	cis	rs7674212	1	rs7691873	ENSG00000230069.3	LRRC37A15P	4.59	6.8e-06	0.00245	0.29	0.28	Type 2 diabetes;	chr4:103066742	chr4:102727274~102730721:-
COAD	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-4.59	6.8e-06	0.00245	-0.33	-0.28	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
COAD	cis	rs7659062	0.513	rs68102079	ENSG00000180015.12	RP11-756P10.3	-4.59	6.8e-06	0.00245	-0.51	-0.28	Cognitive performance;	chr4:188714523	chr4:188738373~188739494:+
COAD	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	4.59	6.8e-06	0.00245	0.22	0.28	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
COAD	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	4.59	6.81e-06	0.00245	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	4.59	6.81e-06	0.00245	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	4.59	6.81e-06	0.00245	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
COAD	cis	rs9368481	0.594	rs2636425	ENSG00000224843.5	LINC00240	-4.59	6.82e-06	0.00245	-0.33	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26956992~27023924:+
COAD	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-4.59	6.82e-06	0.00246	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
COAD	cis	rs3752645	1	rs6978486	ENSG00000241764.3	AC002467.7	4.59	6.82e-06	0.00246	0.44	0.28	Bladder cancer (smoking interaction);	chr7:107136600	chr7:107742817~107744581:-
COAD	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	4.59	6.83e-06	0.00246	0.41	0.28	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
COAD	cis	rs13256369	1	rs10095733	ENSG00000173295.6	FAM86B3P	4.59	6.83e-06	0.00246	0.39	0.28	Obesity-related traits;	chr8:8717136	chr8:8228595~8244865:+
COAD	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-4.59	6.85e-06	0.00246	-0.36	-0.28	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
COAD	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-4.59	6.85e-06	0.00246	-0.39	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
COAD	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-4.59	6.85e-06	0.00246	-0.48	-0.28	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
COAD	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-4.59	6.86e-06	0.00247	-0.35	-0.28	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
COAD	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-4.59	6.86e-06	0.00247	-0.28	-0.28	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
COAD	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-4.59	6.86e-06	0.00247	-0.33	-0.28	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
COAD	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.59	6.86e-06	0.00247	0.42	0.28	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.59	6.86e-06	0.00247	0.42	0.28	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.59	6.86e-06	0.00247	0.42	0.28	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
COAD	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-4.59	6.86e-06	0.00247	-0.36	-0.28	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
COAD	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-4.59	6.86e-06	0.00247	-0.29	-0.28	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
COAD	cis	rs9302635	0.745	rs35549608	ENSG00000260886.1	TAT-AS1	4.59	6.86e-06	0.00247	0.53	0.28	Blood protein levels;	chr16:72193499	chr16:71565789~71578187:+
COAD	cis	rs6840360	0.539	rs1443087	ENSG00000270265.1	RP11-731D1.4	-4.59	6.87e-06	0.00247	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs1443088	ENSG00000270265.1	RP11-731D1.4	-4.59	6.87e-06	0.00247	-0.32	-0.28	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151333775~151353224:-
COAD	cis	rs10895987	0.955	rs11227136	ENSG00000254614.2	AP003068.23	4.59	6.88e-06	0.00247	0.43	0.28	Blood protein levels;	chr11:65164493	chr11:65177606~65181834:-
COAD	cis	rs6840360	0.557	rs1143036	ENSG00000251611.1	RP11-610P16.1	-4.59	6.88e-06	0.00247	-0.26	-0.28	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151407551~151408835:-
COAD	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	4.59	6.89e-06	0.00247	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
COAD	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-4.59	6.89e-06	0.00248	-0.33	-0.28	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
COAD	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-4.59	6.89e-06	0.00248	-0.24	-0.28	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
COAD	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	4.59	6.9e-06	0.00248	0.26	0.28	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
COAD	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	-4.59	6.9e-06	0.00248	-0.33	-0.28	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
COAD	cis	rs3120667	0.72	rs1923501	ENSG00000237975.5	FLG-AS1	4.59	6.9e-06	0.00248	0.35	0.28	Eating disorders;	chr1:152438677	chr1:152168125~152445456:+
COAD	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	4.59	6.9e-06	0.00248	0.36	0.28	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
COAD	cis	rs9532669	0.963	rs4600338	ENSG00000277662.1	RP11-74J13.9	-4.59	6.91e-06	0.00248	-0.26	-0.28	Cervical cancer;	chr13:40925175	chr13:41229180~41229676:-
COAD	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	4.59	6.92e-06	0.00248	0.47	0.28	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
COAD	cis	rs4704187	0.687	rs9293642	ENSG00000250889.2	LINC01336	-4.59	6.92e-06	0.00248	-0.31	-0.28	Response to amphetamines;	chr5:75069201	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs7720620	ENSG00000250889.2	LINC01336	-4.59	6.92e-06	0.00248	-0.31	-0.28	Response to amphetamines;	chr5:75070198	chr5:75047719~75052843:-
COAD	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.59	6.92e-06	0.00249	-0.34	-0.28	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
COAD	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-4.59	6.93e-06	0.00249	-0.55	-0.28	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
COAD	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	4.59	6.93e-06	0.00249	0.3	0.28	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
COAD	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-4.59	6.94e-06	0.00249	-0.26	-0.28	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
COAD	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-4.59	6.94e-06	0.00249	-0.39	-0.28	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
COAD	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	4.59	6.94e-06	0.00249	0.37	0.28	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
COAD	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	4.59	6.94e-06	0.00249	0.35	0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
COAD	cis	rs440932	0.798	rs330942	ENSG00000253981.4	ALG1L13P	4.59	6.95e-06	0.00249	0.36	0.28	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8236003~8244667:-
COAD	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	4.59	6.95e-06	0.00249	0.42	0.28	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	4.59	6.95e-06	0.00249	0.42	0.28	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
COAD	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	4.59	6.95e-06	0.0025	0.41	0.28	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	4.59	6.95e-06	0.0025	0.41	0.28	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
COAD	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	4.59	6.95e-06	0.0025	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
COAD	cis	rs6840360	0.642	rs2724574	ENSG00000251611.1	RP11-610P16.1	4.59	6.96e-06	0.0025	0.26	0.28	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151407551~151408835:-
COAD	cis	rs7260598	0.539	rs7250219	ENSG00000268442.1	CTD-2027I19.2	4.59	6.96e-06	0.0025	0.48	0.28	Response to taxane treatment (placlitaxel);	chr19:23912809	chr19:24162370~24163425:-
COAD	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-4.59	6.97e-06	0.0025	-0.33	-0.28	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
COAD	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	4.59	6.97e-06	0.0025	0.32	0.28	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
COAD	cis	rs603446	0.84	rs180329	ENSG00000254851.1	RP11-109L13.1	-4.59	6.97e-06	0.0025	-0.31	-0.28	Triglycerides;	chr11:116752242	chr11:117135528~117138582:+
COAD	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-4.59	6.97e-06	0.0025	-0.27	-0.28	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-4.59	6.97e-06	0.0025	-0.27	-0.28	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
COAD	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	4.59	6.98e-06	0.0025	0.2	0.28	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
COAD	cis	rs9907295	0.688	rs2526327	ENSG00000271013.1	AC015849.15	4.59	6.98e-06	0.0025	0.38	0.28	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35912635~35918010:-
COAD	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	4.59	6.98e-06	0.0025	0.3	0.28	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
COAD	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-4.59	6.98e-06	0.0025	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
COAD	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-4.59	6.98e-06	0.0025	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
COAD	cis	rs875971	0.66	rs2013222	ENSG00000272831.1	RP11-792A8.4	-4.59	6.99e-06	0.00251	-0.28	-0.28	Aortic root size;	chr7:66570949	chr7:66739829~66740385:-
COAD	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	4.59	6.99e-06	0.00251	0.33	0.28	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	4.59	6.99e-06	0.00251	0.33	0.28	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
COAD	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.59	6.99e-06	0.00251	0.45	0.28	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
COAD	cis	rs5758511	0.573	rs1883205	ENSG00000237037.8	NDUFA6-AS1	4.59	6.99e-06	0.00251	0.28	0.28	Birth weight;	chr22:41847016	chr22:42090931~42137742:+
COAD	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	4.59	6.99e-06	0.00251	0.44	0.28	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
COAD	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	4.59	7e-06	0.00251	0.33	0.28	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
COAD	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	4.59	7e-06	0.00251	0.3	0.28	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
COAD	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	4.59	7e-06	0.00251	0.61	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
COAD	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	4.59	7.01e-06	0.00251	0.28	0.28	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
COAD	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-4.59	7.01e-06	0.00251	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
COAD	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-4.59	7.01e-06	0.00251	-0.52	-0.28	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
COAD	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-4.59	7.02e-06	0.00252	-0.33	-0.28	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
COAD	cis	rs5742933	0.817	rs1233299	ENSG00000253559.1	OSGEPL1-AS1	-4.59	7.02e-06	0.00252	-0.28	-0.28	Ferritin levels;	chr2:189799912	chr2:189762704~189765556:+
COAD	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	4.59	7.02e-06	0.00252	0.43	0.28	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
COAD	cis	rs1578862	0.901	rs12072758	ENSG00000259865.1	RP11-488L18.10	-4.59	7.02e-06	0.00252	-0.22	-0.28	Monocyte percentage of white cells;	chr1:247265737	chr1:247187281~247188526:-
COAD	cis	rs13256369	1	rs13271966	ENSG00000173295.6	FAM86B3P	4.59	7.02e-06	0.00252	0.39	0.28	Obesity-related traits;	chr8:8717962	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	4.59	7.03e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
COAD	cis	rs4568518	0.869	rs12699942	ENSG00000279048.1	RP11-511H23.2	4.59	7.04e-06	0.00252	0.2	0.28	Measles;	chr7:17998062	chr7:17940503~17942922:+
COAD	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-4.59	7.04e-06	0.00252	-0.18	-0.28	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
COAD	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-4.59	7.04e-06	0.00252	-0.55	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-4.59	7.04e-06	0.00252	-0.55	-0.28	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
COAD	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-4.59	7.04e-06	0.00252	-0.3	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
COAD	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	4.59	7.04e-06	0.00252	0.37	0.28	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
COAD	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-4.59	7.04e-06	0.00252	-0.52	-0.28	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
COAD	cis	rs733317	0.731	rs7796657	ENSG00000226874.1	AC005154.8	-4.59	7.05e-06	0.00252	-0.32	-0.28	Left ventricular obstructive tract defect (inherited effect);	chr7:30997513	chr7:30544053~30544431:+
COAD	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-4.59	7.05e-06	0.00252	-0.32	-0.28	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
COAD	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-4.59	7.05e-06	0.00253	-0.34	-0.28	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
COAD	cis	rs7955901	0.805	rs1913196	ENSG00000258053.1	CTD-2021H9.3	-4.59	7.06e-06	0.00253	-0.33	-0.28	Type 2 diabetes;	chr12:71024567	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.837	rs1317055	ENSG00000258053.1	CTD-2021H9.3	-4.59	7.06e-06	0.00253	-0.33	-0.28	Type 2 diabetes;	chr12:71025982	chr12:71047402~71118247:-
COAD	cis	rs1510272	0.81	rs907059	ENSG00000243926.1	TIPARP-AS1	-4.59	7.06e-06	0.00253	-0.32	-0.28	Testicular germ cell tumor;	chr3:156574572	chr3:156671862~156674378:-
COAD	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-4.59	7.06e-06	0.00253	-0.31	-0.28	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
COAD	cis	rs73198271	0.653	rs10099808	ENSG00000173295.6	FAM86B3P	4.59	7.07e-06	0.00253	0.33	0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8228595~8244865:+
COAD	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	4.59	7.07e-06	0.00253	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	4.59	7.07e-06	0.00253	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	4.59	7.07e-06	0.00253	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	4.59	7.07e-06	0.00253	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	4.59	7.07e-06	0.00253	0.27	0.28	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
COAD	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	4.59	7.07e-06	0.00253	0.33	0.28	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
COAD	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	4.59	7.08e-06	0.00253	0.28	0.28	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
COAD	cis	rs2617170	1	rs2617170	ENSG00000245648.1	RP11-277P12.20	-4.59	7.08e-06	0.00253	-0.36	-0.28	Behcet's disease;	chr12:10408358	chr12:10363769~10398506:+
COAD	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-4.59	7.08e-06	0.00253	-0.34	-0.28	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
COAD	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-4.59	7.08e-06	0.00253	-0.32	-0.27	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
COAD	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	7.08e-06	0.00253	-0.25	-0.27	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
COAD	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-4.59	7.09e-06	0.00254	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
COAD	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-4.59	7.09e-06	0.00254	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
COAD	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	4.59	7.09e-06	0.00254	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
COAD	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	4.59	7.09e-06	0.00254	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	4.59	7.09e-06	0.00254	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
COAD	cis	rs2916733	0.53	rs2254903	ENSG00000246089.3	RP11-115C21.2	-4.59	7.09e-06	0.00254	-0.36	-0.27	Epirubicin-induced leukopenia;	chr8:6431900	chr8:6403551~6407142:-
COAD	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	4.58	7.1e-06	0.00254	0.3	0.27	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
COAD	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-4.58	7.1e-06	0.00254	-0.32	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
COAD	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-4.58	7.1e-06	0.00254	-0.33	-0.27	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
COAD	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	4.58	7.11e-06	0.00254	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	4.58	7.11e-06	0.00254	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	4.58	7.11e-06	0.00254	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
COAD	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-4.58	7.11e-06	0.00254	-0.34	-0.27	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
COAD	cis	rs6543140	0.964	rs10169192	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102455751	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs11886793	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102455760	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs2310301	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102456475	chr2:102438713~102440475:+
COAD	cis	rs6543140	1	rs6543140	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102457814	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs13390895	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102459039	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.855	rs4851591	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102460963	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs7561351	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102461320	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs13393175	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102462389	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.865	rs6760275	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102463147	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs6734203	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102463606	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs6543142	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102465546	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.929	rs6742530	ENSG00000234389.1	AC007278.3	4.58	7.11e-06	0.00254	0.29	0.27	Blood protein levels;	chr2:102465820	chr2:102438713~102440475:+
COAD	cis	rs7560272	0.538	rs4852976	ENSG00000163016.8	ALMS1P	-4.58	7.12e-06	0.00254	-0.33	-0.27	Schizophrenia;	chr2:73709195	chr2:73644919~73685576:+
COAD	cis	rs728616	0.85	rs3889823	ENSG00000234382.2	RP11-40F6.1	-4.58	7.13e-06	0.00255	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860034	ENSG00000234382.2	RP11-40F6.1	-4.58	7.13e-06	0.00255	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:80233664~80245367:+
COAD	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-4.58	7.13e-06	0.00255	-0.27	-0.27	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
COAD	cis	rs9307551	0.857	rs2196978	ENSG00000250334.4	LINC00989	4.58	7.13e-06	0.00255	0.32	0.27	Refractive error;	chr4:79614815	chr4:79492416~79576460:+
COAD	cis	rs9376098	0.737	rs1320961	ENSG00000232876.1	CTA-212D2.2	-4.58	7.13e-06	0.00255	-0.36	-0.27	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177114	chr6:135055033~135060550:+
COAD	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-4.58	7.13e-06	0.00255	-0.24	-0.27	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
COAD	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-4.58	7.14e-06	0.00255	-0.32	-0.27	Height;	chr2:231543307	chr2:231508426~231514339:-
COAD	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	4.58	7.14e-06	0.00255	0.31	0.27	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
COAD	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	4.58	7.14e-06	0.00255	0.34	0.27	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
COAD	cis	rs7819412	0.522	rs3021495	ENSG00000269918.1	AF131215.9	-4.58	7.14e-06	0.00255	-0.36	-0.27	Triglycerides;	chr8:11137233	chr8:11104691~11106704:-
COAD	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-4.58	7.15e-06	0.00255	-0.3	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
COAD	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	4.58	7.16e-06	0.00256	0.34	0.27	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	4.58	7.16e-06	0.00256	0.34	0.27	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	4.58	7.16e-06	0.00256	0.34	0.27	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
COAD	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	4.58	7.16e-06	0.00256	0.28	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
COAD	cis	rs12906542	0.516	rs76398134	ENSG00000260139.5	CSPG4P13	-4.58	7.16e-06	0.00256	-0.36	-0.27	Breast cancer;	chr15:77996385	chr15:77894684~77904674:+
COAD	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	4.58	7.16e-06	0.00256	0.31	0.27	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
COAD	cis	rs7760535	0.826	rs7753887	ENSG00000271789.1	RP5-1112D6.7	-4.58	7.16e-06	0.00256	-0.27	-0.27	Metabolic traits;	chr6:111533904	chr6:111297126~111298510:+
COAD	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-4.58	7.17e-06	0.00256	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
COAD	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	4.58	7.17e-06	0.00256	0.39	0.27	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
COAD	cis	rs2732480	0.577	rs2732457	ENSG00000257735.1	RP11-370I10.6	-4.58	7.17e-06	0.00256	-0.35	-0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48350945~48442411:+
COAD	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-4.58	7.17e-06	0.00256	-0.25	-0.27	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
COAD	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	4.58	7.17e-06	0.00256	0.33	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
COAD	cis	rs2732480	0.5	rs1552550	ENSG00000226413.2	OR8T1P	4.58	7.17e-06	0.00256	0.34	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48442030~48442947:-
COAD	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	4.58	7.18e-06	0.00256	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
COAD	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	4.58	7.18e-06	0.00256	0.31	0.27	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
COAD	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-4.58	7.18e-06	0.00256	-0.34	-0.27	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	4.58	7.18e-06	0.00256	0.34	0.27	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
COAD	cis	rs6543140	0.964	rs6543144	ENSG00000234389.1	AC007278.3	4.58	7.18e-06	0.00256	0.29	0.27	Blood protein levels;	chr2:102476116	chr2:102438713~102440475:+
COAD	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.58	7.18e-06	0.00256	0.48	0.27	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
COAD	cis	rs2638953	0.64	rs11049726	ENSG00000247934.4	RP11-967K21.1	-4.58	7.18e-06	0.00256	-0.29	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582703	chr12:28163298~28190738:-
COAD	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	4.58	7.19e-06	0.00257	0.43	0.27	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
COAD	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-4.58	7.19e-06	0.00257	-0.33	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
COAD	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-4.58	7.19e-06	0.00257	-0.34	-0.27	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
COAD	cis	rs9450351	0.744	rs9353319	ENSG00000203875.9	SNHG5	-4.58	7.2e-06	0.00257	-0.51	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85522825	chr6:85660950~85678736:-
COAD	cis	rs7674212	0.541	rs2720448	ENSG00000230069.3	LRRC37A15P	-4.58	7.2e-06	0.00257	-0.29	-0.27	Type 2 diabetes;	chr4:103109432	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.541	rs2623064	ENSG00000230069.3	LRRC37A15P	-4.58	7.2e-06	0.00257	-0.29	-0.27	Type 2 diabetes;	chr4:103109635	chr4:102727274~102730721:-
COAD	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-4.58	7.2e-06	0.00257	-0.34	-0.27	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
COAD	cis	rs734999	0.588	rs4648653	ENSG00000225931.3	RP3-395M20.7	4.58	7.21e-06	0.00257	0.31	0.27	Ulcerative colitis;	chr1:2604456	chr1:2566410~2569888:+
COAD	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-4.58	7.21e-06	0.00257	-0.25	-0.27	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
COAD	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-4.58	7.21e-06	0.00257	-0.38	-0.27	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
COAD	cis	rs7260598	0.642	rs11667910	ENSG00000268442.1	CTD-2027I19.2	4.58	7.21e-06	0.00257	0.39	0.27	Response to taxane treatment (placlitaxel);	chr19:23976911	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs10424894	ENSG00000268442.1	CTD-2027I19.2	4.58	7.21e-06	0.00257	0.39	0.27	Response to taxane treatment (placlitaxel);	chr19:23978053	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs10423626	ENSG00000268442.1	CTD-2027I19.2	4.58	7.21e-06	0.00257	0.39	0.27	Response to taxane treatment (placlitaxel);	chr19:23978229	chr19:24162370~24163425:-
COAD	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-4.58	7.22e-06	0.00258	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
COAD	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	4.58	7.23e-06	0.00258	0.32	0.27	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
COAD	cis	rs8022206	0.773	rs11623355	ENSG00000259502.1	RP11-643G16.3	-4.58	7.23e-06	0.00258	-0.37	-0.27	Platelet count;Mean platelet volume;	chr14:68043600	chr14:67610986~67613864:+
COAD	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	4.58	7.23e-06	0.00258	0.34	0.27	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
COAD	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	4.58	7.23e-06	0.00258	0.34	0.27	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
COAD	cis	rs9659323	1	rs12073056	ENSG00000231365.4	RP11-418J17.1	-4.58	7.24e-06	0.00258	-0.31	-0.27	Body mass index;	chr1:118965777	chr1:119140396~119275973:+
COAD	cis	rs896854	0.846	rs2340584	ENSG00000253528.2	RP11-347C18.4	4.58	7.24e-06	0.00258	0.29	0.27	Type 2 diabetes;	chr8:94904583	chr8:94974573~94974853:-
COAD	cis	rs11951515	0.508	rs67261887	ENSG00000248554.1	RP11-159F24.6	-4.58	7.24e-06	0.00258	-0.3	-0.27	Metabolite levels  (X-11787);	chr5:43612339	chr5:43511058~43521811:+
COAD	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-4.58	7.24e-06	0.00258	-0.52	-0.27	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
COAD	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	4.58	7.25e-06	0.00258	0.34	0.27	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
COAD	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-4.58	7.26e-06	0.00259	-0.28	-0.27	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
COAD	cis	rs61270009	0.955	rs450202	ENSG00000247828.6	TMEM161B-AS1	-4.58	7.26e-06	0.00259	-0.29	-0.27	Depressive symptoms;	chr5:88222635	chr5:88268895~88436685:+
COAD	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	4.58	7.26e-06	0.00259	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
COAD	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
COAD	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	4.58	7.26e-06	0.00259	0.41	0.27	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
COAD	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-4.58	7.26e-06	0.00259	-0.26	-0.27	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
COAD	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	4.58	7.27e-06	0.00259	0.25	0.27	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
COAD	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	4.58	7.27e-06	0.00259	0.41	0.27	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
COAD	cis	rs72827839	0.74	rs72825548	ENSG00000263412.1	RP5-890E16.2	4.58	7.27e-06	0.00259	0.4	0.27	Ease of getting up in the morning;	chr17:48153746	chr17:48045141~48048073:-
COAD	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	4.58	7.27e-06	0.00259	0.36	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
COAD	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28082984	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28083994	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28084025	chr6:28115628~28116551:+
COAD	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28085319	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28089816	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28090857	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28091439	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28091659	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28093966	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28094014	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28096077	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28096855	chr6:28115628~28116551:+
COAD	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28099759	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28100648	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28104824	chr6:28115628~28116551:+
COAD	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28107222	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-4.58	7.28e-06	0.00259	-0.39	-0.27	Depression;	chr6:28108492	chr6:28115628~28116551:+
COAD	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-4.58	7.28e-06	0.00259	-0.32	-0.27	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
COAD	cis	rs11846409	0.932	rs28617526	ENSG00000274576.2	IGHV2-70	-4.58	7.28e-06	0.00259	-0.27	-0.27	Rheumatic heart disease;	chr14:106637322	chr14:106770577~106771020:-
COAD	cis	rs7172689	0.955	rs8039027	ENSG00000271725.1	RP11-761I4.4	-4.58	7.29e-06	0.00259	-0.36	-0.27	Inattentive symptoms;	chr15:81263931	chr15:81303215~81309391:-
COAD	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-4.58	7.29e-06	0.0026	-0.29	-0.27	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
COAD	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-4.58	7.29e-06	0.0026	-0.55	-0.27	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
COAD	cis	rs6840360	0.582	rs2709823	ENSG00000251611.1	RP11-610P16.1	-4.58	7.29e-06	0.0026	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151407551~151408835:-
COAD	cis	rs9532669	1	rs9532669	ENSG00000239827.7	SUGT1P3	-4.58	7.3e-06	0.0026	-0.24	-0.27	Cervical cancer;	chr13:40927414	chr13:40908159~40921774:-
COAD	cis	rs6840360	0.642	rs10454251	ENSG00000251611.1	RP11-610P16.1	-4.58	7.31e-06	0.0026	-0.27	-0.27	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151407551~151408835:-
COAD	cis	rs930421	0.544	rs4953645	ENSG00000226491.1	FTOP1	-4.58	7.31e-06	0.0026	-0.35	-0.27	Attention deficit hyperactivity disorder;	chr2:42757896	chr2:42797225~42798712:-
COAD	cis	rs494562	0.73	rs9450269	ENSG00000234155.1	RP11-30P6.6	4.58	7.31e-06	0.0026	0.49	0.27	Metabolic traits;Blood metabolite levels;	chr6:85404966	chr6:85387219~85390186:-
COAD	cis	rs7209700	0.662	rs8074094	ENSG00000228782.6	CTD-2026D20.3	-4.58	7.31e-06	0.0026	-0.31	-0.27	IgG glycosylation;	chr17:47270655	chr17:47450568~47492492:-
COAD	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-4.58	7.32e-06	0.0026	-0.25	-0.27	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
COAD	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-4.58	7.32e-06	0.0026	-0.25	-0.27	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
COAD	cis	rs5758511	0.773	rs62240997	ENSG00000237037.8	NDUFA6-AS1	-4.58	7.32e-06	0.0026	-0.3	-0.27	Birth weight;	chr22:41958563	chr22:42090931~42137742:+
COAD	cis	rs2644899	0.75	rs2249835	ENSG00000233622.1	CYP2T1P	-4.58	7.32e-06	0.0026	-0.31	-0.27	Post bronchodilator FEV1/FVC ratio;	chr19:40763861	chr19:40808525~40811390:-
COAD	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-4.58	7.32e-06	0.00261	-0.48	-0.27	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
COAD	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	4.58	7.33e-06	0.00261	0.28	0.27	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
COAD	cis	rs4713118	0.911	rs9461406	ENSG00000281706.1	LINC01012	4.58	7.33e-06	0.00261	0.31	0.27	Parkinson's disease;	chr6:27751985	chr6:27694035~27710222:+
COAD	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28111382	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28111650	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28112175	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28113851	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28114487	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28114933	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28115743	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Depression;	chr6:28116411	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-4.58	7.33e-06	0.00261	-0.39	-0.27	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
COAD	cis	rs728616	0.681	rs3862518	ENSG00000234382.2	RP11-40F6.1	-4.58	7.33e-06	0.00261	-0.45	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:80233664~80245367:+
COAD	cis	rs875971	0.862	rs6460307	ENSG00000224316.1	RP11-479O9.2	4.58	7.34e-06	0.00261	0.3	0.27	Aortic root size;	chr7:66595884	chr7:65773620~65802067:+
COAD	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.58	7.35e-06	0.00261	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
COAD	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-4.58	7.35e-06	0.00261	-0.32	-0.27	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
COAD	cis	rs2408955	0.5	rs12816820	ENSG00000273765.1	RP11-370I10.11	4.58	7.36e-06	0.00262	0.29	0.27	Glycated hemoglobin levels;	chr12:48164542	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.57	rs12368659	ENSG00000273765.1	RP11-370I10.11	4.58	7.36e-06	0.00262	0.29	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48360920~48361377:+
COAD	cis	rs1578862	1	rs2890342	ENSG00000259865.1	RP11-488L18.10	-4.58	7.36e-06	0.00262	-0.22	-0.27	Monocyte percentage of white cells;	chr1:247272932	chr1:247187281~247188526:-
COAD	cis	rs1578862	1	rs6426238	ENSG00000259865.1	RP11-488L18.10	-4.58	7.36e-06	0.00262	-0.22	-0.27	Monocyte percentage of white cells;	chr1:247273512	chr1:247187281~247188526:-
COAD	cis	rs4704187	0.687	rs1600074	ENSG00000250889.2	LINC01336	-4.58	7.37e-06	0.00262	-0.31	-0.27	Response to amphetamines;	chr5:75140749	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs1422697	ENSG00000250889.2	LINC01336	-4.58	7.37e-06	0.00262	-0.31	-0.27	Response to amphetamines;	chr5:75149992	chr5:75047719~75052843:-
COAD	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-4.58	7.37e-06	0.00262	-0.44	-0.27	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
COAD	cis	rs4704187	0.663	rs9654428	ENSG00000250889.2	LINC01336	-4.58	7.37e-06	0.00262	-0.31	-0.27	Response to amphetamines;	chr5:75171059	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs9654429	ENSG00000250889.2	LINC01336	-4.58	7.37e-06	0.00262	-0.31	-0.27	Response to amphetamines;	chr5:75171100	chr5:75047719~75052843:-
COAD	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-4.58	7.37e-06	0.00262	-0.42	-0.27	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
COAD	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-4.58	7.37e-06	0.00262	-0.32	-0.27	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
COAD	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	4.58	7.38e-06	0.00262	0.29	0.27	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
COAD	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	4.58	7.38e-06	0.00262	0.41	0.27	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
COAD	cis	rs896854	0.516	rs12679044	ENSG00000253528.2	RP11-347C18.4	4.58	7.38e-06	0.00262	0.29	0.27	Type 2 diabetes;	chr8:94879128	chr8:94974573~94974853:-
COAD	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-4.58	7.38e-06	0.00262	-0.25	-0.27	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
COAD	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	4.58	7.39e-06	0.00263	0.36	0.27	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
COAD	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-4.58	7.4e-06	0.00263	-0.33	-0.27	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
COAD	cis	rs12497850	0.931	rs6791542	ENSG00000225399.4	RP11-3B7.1	4.58	7.4e-06	0.00263	0.31	0.27	Parkinson's disease;	chr3:48749786	chr3:49260085~49261316:+
COAD	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-4.58	7.4e-06	0.00263	-0.33	-0.27	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-4.58	7.4e-06	0.00263	-0.33	-0.27	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
COAD	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	4.58	7.41e-06	0.00263	0.3	0.27	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
COAD	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	4.58	7.41e-06	0.00263	0.29	0.27	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-4.58	7.41e-06	0.00263	-0.29	-0.27	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
COAD	cis	rs28374715	0.681	rs77187862	ENSG00000247556.5	OIP5-AS1	4.58	7.41e-06	0.00263	0.34	0.27	Ulcerative colitis;	chr15:41327078	chr15:41283990~41309737:+
COAD	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	4.58	7.41e-06	0.00263	0.37	0.27	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
COAD	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	4.57	7.42e-06	0.00263	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
COAD	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-4.57	7.42e-06	0.00263	-0.32	-0.27	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
COAD	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	4.57	7.42e-06	0.00263	0.36	0.27	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
COAD	cis	rs597539	0.652	rs478647	ENSG00000255741.1	RP11-757G1.5	-4.57	7.42e-06	0.00264	-0.36	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68941503~68942852:-
COAD	cis	rs11841001	0.659	rs35309322	ENSG00000261105.4	LMO7-AS1	-4.57	7.42e-06	0.00264	-0.62	-0.27	Corneal astigmatism;	chr13:75666975	chr13:75604700~75635994:-
COAD	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	4.57	7.42e-06	0.00264	0.31	0.27	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
COAD	cis	rs7260598	0.539	rs11670289	ENSG00000268442.1	CTD-2027I19.2	4.57	7.43e-06	0.00264	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:23884154	chr19:24162370~24163425:-
COAD	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	4.57	7.44e-06	0.00264	0.36	0.27	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
COAD	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-4.57	7.44e-06	0.00264	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-4.57	7.44e-06	0.00264	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
COAD	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	4.57	7.44e-06	0.00264	0.3	0.27	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
COAD	cis	rs9907295	0.591	rs11650668	ENSG00000271013.1	AC015849.15	-4.57	7.44e-06	0.00264	-0.34	-0.27	Fibroblast growth factor basic levels;	chr17:35822045	chr17:35912635~35918010:-
COAD	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	4.57	7.44e-06	0.00264	0.32	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	4.57	7.44e-06	0.00264	0.32	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
COAD	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	4.57	7.44e-06	0.00264	0.32	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	4.57	7.44e-06	0.00264	0.32	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
COAD	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	4.57	7.44e-06	0.00264	0.35	0.27	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	4.57	7.44e-06	0.00264	0.28	0.27	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
COAD	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	4.57	7.45e-06	0.00264	0.29	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
COAD	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	4.57	7.45e-06	0.00264	0.31	0.27	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	4.57	7.45e-06	0.00264	0.31	0.27	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	4.57	7.45e-06	0.00264	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	4.57	7.45e-06	0.00264	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
COAD	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	4.57	7.45e-06	0.00264	0.21	0.27	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
COAD	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-4.57	7.45e-06	0.00264	-0.51	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
COAD	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	4.57	7.45e-06	0.00264	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	4.57	7.45e-06	0.00264	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	4.57	7.45e-06	0.00264	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	4.57	7.45e-06	0.00264	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
COAD	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	4.57	7.45e-06	0.00264	0.3	0.27	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
COAD	cis	rs4704187	0.687	rs6885887	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75202017	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6864485	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75202159	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6879894	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75202339	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10051422	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75206748	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10051572	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75206972	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs6889760	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75207879	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10035303	ENSG00000250889.2	LINC01336	-4.57	7.45e-06	0.00264	-0.31	-0.27	Response to amphetamines;	chr5:75209670	chr5:75047719~75052843:-
COAD	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	4.57	7.46e-06	0.00265	0.34	0.27	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
COAD	cis	rs4704187	0.663	rs28448485	ENSG00000250889.2	LINC01336	-4.57	7.46e-06	0.00265	-0.31	-0.27	Response to amphetamines;	chr5:75129950	chr5:75047719~75052843:-
COAD	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-4.57	7.46e-06	0.00265	-0.4	-0.27	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
COAD	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-4.57	7.46e-06	0.00265	-0.31	-0.27	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
COAD	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-4.57	7.47e-06	0.00265	-0.28	-0.27	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-4.57	7.47e-06	0.00265	-0.28	-0.27	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
COAD	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-4.57	7.47e-06	0.00265	-0.28	-0.27	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
COAD	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-4.57	7.47e-06	0.00265	-0.28	-0.27	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
COAD	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	4.57	7.47e-06	0.00265	0.2	0.27	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
COAD	cis	rs8141529	0.702	rs5762870	ENSG00000272858.1	CTA-292E10.8	-4.57	7.48e-06	0.00265	-0.33	-0.27	Lymphocyte counts;	chr22:28865171	chr22:28814914~28815662:+
COAD	cis	rs13217239	0.574	rs9366680	ENSG00000224843.5	LINC00240	-4.57	7.49e-06	0.00266	-0.32	-0.27	Schizophrenia;	chr6:27038344	chr6:26956992~27023924:+
COAD	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	4.57	7.49e-06	0.00266	0.34	0.27	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
COAD	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-4.57	7.49e-06	0.00266	-0.29	-0.27	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-4.57	7.49e-06	0.00266	-0.29	-0.27	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
COAD	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	4.57	7.49e-06	0.00266	0.38	0.27	Height;	chr6:109775693	chr6:109382795~109383666:+
COAD	cis	rs4927850	1	rs7625570	ENSG00000273009.1	RP11-352G9.1	-4.57	7.5e-06	0.00266	-0.3	-0.27	Pancreatic cancer;	chr3:196020527	chr3:195913078~195913683:-
COAD	cis	rs748404	0.556	rs574856	ENSG00000205771.5	CATSPER2P1	4.57	7.5e-06	0.00266	0.34	0.27	Lung cancer;	chr15:43168636	chr15:43726918~43747094:-
COAD	cis	rs9532669	0.926	rs9532671	ENSG00000239827.7	SUGT1P3	-4.57	7.51e-06	0.00266	-0.24	-0.27	Cervical cancer;	chr13:40927761	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.833	rs9532672	ENSG00000239827.7	SUGT1P3	-4.57	7.51e-06	0.00266	-0.24	-0.27	Cervical cancer;	chr13:40928285	chr13:40908159~40921774:-
COAD	cis	rs10895987	1	rs11227126	ENSG00000254614.2	AP003068.23	4.57	7.51e-06	0.00266	0.42	0.27	Blood protein levels;	chr11:65140591	chr11:65177606~65181834:-
COAD	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-4.57	7.51e-06	0.00266	-0.28	-0.27	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
COAD	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	4.57	7.52e-06	0.00267	0.23	0.27	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
COAD	cis	rs17214007	0.735	rs2075513	ENSG00000263335.1	AF001548.5	-4.57	7.52e-06	0.00267	-0.44	-0.27	Cognitive function;	chr16:15782614	chr16:15726674~15732993:+
COAD	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	4.57	7.53e-06	0.00267	0.34	0.27	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	4.57	7.53e-06	0.00267	0.34	0.27	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	4.57	7.53e-06	0.00267	0.34	0.27	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	4.57	7.53e-06	0.00267	0.34	0.27	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
COAD	cis	rs728616	0.867	rs17886286	ENSG00000225484.5	NUTM2B-AS1	-4.57	7.53e-06	0.00267	-0.5	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:79663088~79826594:-
COAD	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-4.57	7.53e-06	0.00267	-0.15	-0.27	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
COAD	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-4.57	7.53e-06	0.00267	-0.44	-0.27	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
COAD	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-4.57	7.54e-06	0.00267	-0.34	-0.27	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
COAD	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-4.57	7.54e-06	0.00267	-0.27	-0.27	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
COAD	cis	rs4760786	0.865	rs11495637	ENSG00000258053.1	CTD-2021H9.3	-4.57	7.54e-06	0.00267	-0.37	-0.27	Monobrow;	chr12:71090114	chr12:71047402~71118247:-
COAD	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-4.57	7.54e-06	0.00267	-0.34	-0.27	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
COAD	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-4.57	7.55e-06	0.00267	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
COAD	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	4.57	7.55e-06	0.00268	0.41	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
COAD	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-4.57	7.55e-06	0.00268	-0.28	-0.27	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
COAD	cis	rs9532669	0.857	rs9525427	ENSG00000239827.7	SUGT1P3	-4.57	7.56e-06	0.00268	-0.24	-0.27	Cervical cancer;	chr13:40918029	chr13:40908159~40921774:-
COAD	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-4.57	7.56e-06	0.00268	-0.18	-0.27	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
COAD	cis	rs7193541	0.826	rs56143602	ENSG00000262904.1	TMPOP2	-4.57	7.56e-06	0.00268	-0.29	-0.27	Multiple myeloma;	chr16:74660794	chr16:74667506~74668706:+
COAD	cis	rs9450351	0.744	rs9342047	ENSG00000203875.9	SNHG5	-4.57	7.56e-06	0.00268	-0.52	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85869115	chr6:85660950~85678736:-
COAD	cis	rs7598759	0.527	rs4973417	ENSG00000223198.1	RNU2-22P	-4.57	7.57e-06	0.00268	-0.31	-0.27	Noise-induced hearing loss;	chr2:231484925	chr2:231501990~231502201:-
COAD	cis	rs9951698	0.678	rs71353243	ENSG00000266969.1	RP11-773H22.4	4.57	7.57e-06	0.00268	0.33	0.27	Intelligence (multi-trait analysis);	chr18:13134998	chr18:12984694~12991173:-
COAD	cis	rs733592	0.929	rs4760678	ENSG00000273765.1	RP11-370I10.11	-4.57	7.57e-06	0.00268	-0.28	-0.27	Plateletcrit;	chr12:48067798	chr12:48360920~48361377:+
COAD	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-4.57	7.57e-06	0.00268	-0.3	-0.27	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
COAD	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-4.57	7.57e-06	0.00268	-0.33	-0.27	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
COAD	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	4.57	7.57e-06	0.00268	0.3	0.27	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	4.57	7.57e-06	0.00268	0.3	0.27	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	4.57	7.57e-06	0.00268	0.3	0.27	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
COAD	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	4.57	7.58e-06	0.00268	0.32	0.27	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
COAD	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	4.57	7.58e-06	0.00268	0.29	0.27	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
COAD	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	4.57	7.58e-06	0.00268	0.28	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
COAD	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-4.57	7.58e-06	0.00268	-0.29	-0.27	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
COAD	cis	rs2337406	1	rs11850600	ENSG00000211974.3	IGHV2-70	-4.57	7.59e-06	0.00269	-0.32	-0.27	Alzheimer's disease (late onset);	chr14:106670765	chr14:106723574~106724093:-
COAD	cis	rs5742933	0.803	rs1233302	ENSG00000253559.1	OSGEPL1-AS1	-4.57	7.59e-06	0.00269	-0.27	-0.27	Ferritin levels;	chr2:189804154	chr2:189762704~189765556:+
COAD	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-4.57	7.59e-06	0.00269	-0.34	-0.27	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
COAD	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
COAD	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-4.57	7.59e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
COAD	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	4.57	7.59e-06	0.00269	0.28	0.27	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
COAD	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-4.57	7.6e-06	0.00269	-0.32	-0.27	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-4.57	7.6e-06	0.00269	-0.32	-0.27	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
COAD	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-4.57	7.6e-06	0.00269	-0.29	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
COAD	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-4.57	7.6e-06	0.00269	-0.29	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
COAD	cis	rs754466	0.957	rs61854183	ENSG00000204049.1	RP11-126H7.4	4.57	7.6e-06	0.00269	0.37	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77938319	chr10:77866875~77869610:+
COAD	cis	rs210138	1	rs210138	ENSG00000197251.3	LINC00336	-4.57	7.61e-06	0.00269	-0.44	-0.27	Testicular germ cell tumor;	chr6:33574761	chr6:33586106~33593338:-
COAD	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-4.57	7.61e-06	0.00269	-0.32	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-4.57	7.61e-06	0.00269	-0.32	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
COAD	cis	rs5758511	0.68	rs5758681	ENSG00000237037.8	NDUFA6-AS1	-4.57	7.62e-06	0.00269	-0.33	-0.27	Birth weight;	chr22:42249085	chr22:42090931~42137742:+
COAD	cis	rs801193	1	rs2420824	ENSG00000272831.1	RP11-792A8.4	-4.57	7.62e-06	0.00269	-0.29	-0.27	Aortic root size;	chr7:66666129	chr7:66739829~66740385:-
COAD	cis	rs896854	0.818	rs13262110	ENSG00000253528.2	RP11-347C18.4	4.57	7.62e-06	0.0027	0.29	0.27	Type 2 diabetes;	chr8:94914662	chr8:94974573~94974853:-
COAD	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	4.57	7.62e-06	0.0027	0.4	0.27	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
COAD	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-4.57	7.62e-06	0.0027	-0.31	-0.27	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-4.57	7.62e-06	0.0027	-0.31	-0.27	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	4.57	7.62e-06	0.0027	0.31	0.27	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	4.57	7.62e-06	0.0027	0.31	0.27	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	4.57	7.62e-06	0.0027	0.31	0.27	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	4.57	7.62e-06	0.0027	0.31	0.27	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
COAD	cis	rs4713118	0.869	rs4713121	ENSG00000281706.1	LINC01012	-4.57	7.63e-06	0.0027	-0.31	-0.27	Parkinson's disease;	chr6:27754285	chr6:27694035~27710222:+
COAD	cis	rs13256369	1	rs4841017	ENSG00000173295.6	FAM86B3P	4.57	7.63e-06	0.0027	0.37	0.27	Obesity-related traits;	chr8:8719583	chr8:8228595~8244865:+
COAD	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	4.57	7.63e-06	0.0027	0.28	0.27	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
COAD	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	4.57	7.63e-06	0.0027	0.29	0.27	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
COAD	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	4.57	7.63e-06	0.0027	0.32	0.27	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
COAD	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-4.57	7.64e-06	0.0027	-0.35	-0.27	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
COAD	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-4.57	7.64e-06	0.0027	-0.3	-0.27	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-4.57	7.64e-06	0.0027	-0.3	-0.27	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-4.57	7.64e-06	0.0027	-0.3	-0.27	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
COAD	cis	rs9393777	0.623	rs34313099	ENSG00000224843.5	LINC00240	4.57	7.64e-06	0.0027	0.46	0.27	Intelligence (multi-trait analysis);	chr6:26489379	chr6:26956992~27023924:+
COAD	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	4.57	7.64e-06	0.0027	0.37	0.27	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
COAD	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-4.57	7.65e-06	0.0027	-0.36	-0.27	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
COAD	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-4.57	7.65e-06	0.0027	-0.32	-0.27	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
COAD	cis	rs597539	0.652	rs507520	ENSG00000255741.1	RP11-757G1.5	-4.57	7.66e-06	0.00271	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68941503~68942852:-
COAD	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	4.57	7.67e-06	0.00271	0.34	0.27	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	4.57	7.67e-06	0.00271	0.34	0.27	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
COAD	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-4.57	7.67e-06	0.00271	-0.15	-0.27	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
COAD	cis	rs11668609	0.506	rs8113480	ENSG00000268442.1	CTD-2027I19.2	-4.57	7.67e-06	0.00271	-0.43	-0.27	Response to taxane treatment (docetaxel);	chr19:23878217	chr19:24162370~24163425:-
COAD	cis	rs7200543	0.961	rs1741	ENSG00000270580.4	PKD1P6	4.57	7.67e-06	0.00271	0.31	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15104723~15131601:-
COAD	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-4.57	7.67e-06	0.00271	-0.35	-0.27	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
COAD	cis	rs9951698	0.703	rs475139	ENSG00000266969.1	RP11-773H22.4	4.57	7.67e-06	0.00271	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13141397	chr18:12984694~12991173:-
COAD	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-4.57	7.68e-06	0.00271	-0.31	-0.27	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
COAD	cis	rs5758511	0.773	rs62240999	ENSG00000237037.8	NDUFA6-AS1	-4.57	7.68e-06	0.00271	-0.3	-0.27	Birth weight;	chr22:41959559	chr22:42090931~42137742:+
COAD	cis	rs74233809	1	rs11191505	ENSG00000213277.3	MARCKSL1P1	4.57	7.68e-06	0.00271	0.55	0.27	Birth weight;	chr10:103007134	chr10:103175554~103176094:+
COAD	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-4.57	7.68e-06	0.00271	-0.34	-0.27	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-4.57	7.68e-06	0.00271	-0.34	-0.27	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
COAD	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-4.57	7.68e-06	0.00271	-0.4	-0.27	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
COAD	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-4.57	7.69e-06	0.00272	-0.18	-0.27	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
COAD	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-4.57	7.7e-06	0.00272	-0.36	-0.27	Depression;	chr6:28205175	chr6:28115628~28116551:+
COAD	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	4.57	7.7e-06	0.00272	0.29	0.27	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
COAD	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	4.57	7.7e-06	0.00272	0.32	0.27	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
COAD	cis	rs733317	0.672	rs13438114	ENSG00000226874.1	AC005154.8	-4.57	7.7e-06	0.00272	-0.32	-0.27	Left ventricular obstructive tract defect (inherited effect);	chr7:31000367	chr7:30544053~30544431:+
COAD	cis	rs12497850	0.931	rs9311434	ENSG00000225399.4	RP11-3B7.1	4.57	7.7e-06	0.00272	0.3	0.27	Parkinson's disease;	chr3:48846714	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs7623023	ENSG00000225399.4	RP11-3B7.1	4.57	7.7e-06	0.00272	0.3	0.27	Parkinson's disease;	chr3:48876805	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs7431710	ENSG00000225399.4	RP11-3B7.1	4.57	7.7e-06	0.00272	0.3	0.27	Parkinson's disease;	chr3:48898150	chr3:49260085~49261316:+
COAD	cis	rs801193	1	rs2659909	ENSG00000272831.1	RP11-792A8.4	4.57	7.7e-06	0.00272	0.29	0.27	Aortic root size;	chr7:66695292	chr7:66739829~66740385:-
COAD	cis	rs860295	0.702	rs10796945	ENSG00000160766.13	GBAP1	-4.57	7.7e-06	0.00272	-0.3	-0.27	Body mass index;	chr1:155457897	chr1:155213821~155227422:-
COAD	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	4.57	7.72e-06	0.00273	0.18	0.27	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
COAD	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-4.57	7.72e-06	0.00273	-0.31	-0.27	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
COAD	cis	rs6452524	0.868	rs1011981	ENSG00000271862.1	RP11-343L5.2	4.57	7.72e-06	0.00273	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.868	rs17284218	ENSG00000271862.1	RP11-343L5.2	4.57	7.72e-06	0.00273	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83049376~83050964:-
COAD	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	4.57	7.73e-06	0.00273	0.29	0.27	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
COAD	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.57	7.73e-06	0.00273	-0.28	-0.27	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.57	7.73e-06	0.00273	-0.28	-0.27	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.57	7.73e-06	0.00273	-0.28	-0.27	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-4.57	7.73e-06	0.00273	-0.36	-0.27	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
COAD	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.57	7.73e-06	0.00273	0.32	0.27	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
COAD	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-4.57	7.74e-06	0.00273	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
COAD	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-4.57	7.74e-06	0.00273	-0.34	-0.27	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
COAD	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-4.57	7.74e-06	0.00273	-0.32	-0.27	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
COAD	cis	rs4704187	0.687	rs4340901	ENSG00000250889.2	LINC01336	-4.57	7.75e-06	0.00273	-0.31	-0.27	Response to amphetamines;	chr5:75109080	chr5:75047719~75052843:-
COAD	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	4.57	7.75e-06	0.00273	0.33	0.27	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
COAD	cis	rs7260598	0.685	rs78368900	ENSG00000268442.1	CTD-2027I19.2	4.57	7.75e-06	0.00273	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23814332	chr19:24162370~24163425:-
COAD	cis	rs597539	0.617	rs672853	ENSG00000255741.1	RP11-757G1.5	-4.57	7.75e-06	0.00273	-0.38	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68941503~68942852:-
COAD	cis	rs11846409	0.872	rs2516914	ENSG00000274576.2	IGHV2-70	4.56	7.75e-06	0.00274	0.26	0.27	Rheumatic heart disease;	chr14:106629835	chr14:106770577~106771020:-
COAD	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	4.56	7.76e-06	0.00274	0.44	0.27	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	4.56	7.76e-06	0.00274	0.44	0.27	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	4.56	7.76e-06	0.00274	0.44	0.27	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	4.56	7.76e-06	0.00274	0.44	0.27	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
COAD	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	4.56	7.77e-06	0.00274	0.62	0.27	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	4.56	7.77e-06	0.00274	0.62	0.27	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	4.56	7.77e-06	0.00274	0.62	0.27	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	4.56	7.77e-06	0.00274	0.62	0.27	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	4.56	7.77e-06	0.00274	0.62	0.27	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
COAD	cis	rs7200543	1	rs35574015	ENSG00000270580.4	PKD1P6	4.56	7.78e-06	0.00275	0.31	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15104723~15131601:-
COAD	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-4.56	7.78e-06	0.00275	-0.25	-0.27	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
COAD	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-4.56	7.79e-06	0.00275	-0.28	-0.27	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
COAD	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-4.56	7.79e-06	0.00275	-0.31	-0.27	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
COAD	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	4.56	7.79e-06	0.00275	0.32	0.27	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	4.56	7.79e-06	0.00275	0.32	0.27	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
COAD	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	4.56	7.79e-06	0.00275	0.32	0.27	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
COAD	cis	rs9951698	0.678	rs529620	ENSG00000266969.1	RP11-773H22.4	4.56	7.79e-06	0.00275	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13123877	chr18:12984694~12991173:-
COAD	cis	rs74233809	1	rs10509759	ENSG00000213277.3	MARCKSL1P1	4.56	7.8e-06	0.00275	0.57	0.27	Birth weight;	chr10:102929908	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs10883806	ENSG00000213277.3	MARCKSL1P1	4.56	7.8e-06	0.00275	0.57	0.27	Birth weight;	chr10:102953319	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs78260931	ENSG00000213277.3	MARCKSL1P1	4.56	7.8e-06	0.00275	0.57	0.27	Birth weight;	chr10:102962205	chr10:103175554~103176094:+
COAD	cis	rs28374715	0.562	rs8036686	ENSG00000247556.5	OIP5-AS1	4.56	7.8e-06	0.00275	0.27	0.27	Ulcerative colitis;	chr15:41258135	chr15:41283990~41309737:+
COAD	cis	rs4704187	0.687	rs1363578	ENSG00000250889.2	LINC01336	-4.56	7.8e-06	0.00275	-0.31	-0.27	Response to amphetamines;	chr5:75214516	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs2161371	ENSG00000250889.2	LINC01336	-4.56	7.8e-06	0.00275	-0.31	-0.27	Response to amphetamines;	chr5:75224450	chr5:75047719~75052843:-
COAD	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-4.56	7.8e-06	0.00275	-0.32	-0.27	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
COAD	cis	rs79996792	1	rs79996792	ENSG00000235724.7	AC009299.2	-4.56	7.8e-06	0.00275	-0.46	-0.27	Neuroticism;	chr2:161587424	chr2:161222785~161308303:-
COAD	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-4.56	7.81e-06	0.00275	-0.41	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
COAD	cis	rs28374715	0.681	rs59000092	ENSG00000247556.5	OIP5-AS1	4.56	7.81e-06	0.00275	0.33	0.27	Ulcerative colitis;	chr15:41333950	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.681	rs11629979	ENSG00000247556.5	OIP5-AS1	4.56	7.81e-06	0.00275	0.33	0.27	Ulcerative colitis;	chr15:41334381	chr15:41283990~41309737:+
COAD	cis	rs3752645	1	rs7786692	ENSG00000241764.3	AC002467.7	4.56	7.81e-06	0.00275	0.42	0.27	Bladder cancer (smoking interaction);	chr7:107089588	chr7:107742817~107744581:-
COAD	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	4.56	7.81e-06	0.00275	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
COAD	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-4.56	7.81e-06	0.00275	-0.28	-0.27	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
COAD	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-4.56	7.82e-06	0.00275	-0.26	-0.27	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
COAD	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-4.56	7.82e-06	0.00275	-0.34	-0.27	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
COAD	cis	rs7615952	0.932	rs11922218	ENSG00000272840.1	RP11-379B18.6	4.56	7.83e-06	0.00276	0.39	0.27	Blood pressure (smoking interaction);	chr3:125912446	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.866	rs11922276	ENSG00000272840.1	RP11-379B18.6	4.56	7.83e-06	0.00276	0.39	0.27	Blood pressure (smoking interaction);	chr3:125912483	chr3:125774714~125797953:+
COAD	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	4.56	7.84e-06	0.00276	0.42	0.27	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
COAD	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	4.56	7.84e-06	0.00276	0.33	0.27	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
COAD	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	4.56	7.84e-06	0.00276	0.31	0.27	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
COAD	cis	rs35264875	0.851	rs7933746	ENSG00000259799.1	RP11-554A11.9	4.56	7.84e-06	0.00276	0.36	0.27	Blond vs. brown hair color;	chr11:69100254	chr11:69155910~69159752:+
COAD	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	4.56	7.85e-06	0.00276	0.28	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
COAD	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	4.56	7.86e-06	0.00277	0.29	0.27	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	4.56	7.86e-06	0.00277	0.29	0.27	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
COAD	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
COAD	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-4.56	7.86e-06	0.00277	-0.28	-0.27	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
COAD	cis	rs4568518	0.869	rs12699935	ENSG00000279048.1	RP11-511H23.2	-4.56	7.86e-06	0.00277	-0.19	-0.27	Measles;	chr7:17994499	chr7:17940503~17942922:+
COAD	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	4.56	7.86e-06	0.00277	0.33	0.27	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
COAD	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	4.56	7.87e-06	0.00277	0.32	0.27	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
COAD	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-4.56	7.88e-06	0.00277	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
COAD	cis	rs61160187	0.582	rs4700407	ENSG00000215032.2	GNL3LP1	-4.56	7.88e-06	0.00277	-0.34	-0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60891935~60893577:-
COAD	cis	rs62246343	0.63	rs11542009	ENSG00000254485.4	RP11-380O24.1	4.56	7.89e-06	0.00277	0.42	0.27	Fibrinogen levels;	chr3:9475685	chr3:9292588~9363303:-
COAD	cis	rs11719291	0.504	rs34571182	ENSG00000225399.4	RP11-3B7.1	-4.56	7.89e-06	0.00277	-0.48	-0.27	Cognitive function;	chr3:49171624	chr3:49260085~49261316:+
COAD	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	4.56	7.89e-06	0.00277	0.29	0.27	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
COAD	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	4.56	7.89e-06	0.00277	0.31	0.27	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	4.56	7.89e-06	0.00277	0.31	0.27	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
COAD	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-4.56	7.89e-06	0.00277	-0.31	-0.27	Height;	chr3:52991821	chr3:53064283~53065091:-
COAD	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-4.56	7.89e-06	0.00277	-0.31	-0.27	Height;	chr3:52992698	chr3:53064283~53065091:-
COAD	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-4.56	7.89e-06	0.00277	-0.33	-0.27	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
COAD	cis	rs1383484	0.545	rs7171383	ENSG00000259728.4	LINC00933	-4.56	7.89e-06	0.00277	-0.4	-0.27	Height;	chr15:83976087	chr15:84570649~84580175:+
COAD	cis	rs2280018	0.963	rs11075255	ENSG00000270580.4	PKD1P6	4.56	7.9e-06	0.00278	0.28	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15104723~15131601:-
COAD	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	4.56	7.9e-06	0.00278	0.28	0.27	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	4.56	7.9e-06	0.00278	0.28	0.27	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	4.56	7.9e-06	0.00278	0.28	0.27	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-4.56	7.9e-06	0.00278	-0.28	-0.27	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-4.56	7.9e-06	0.00278	-0.28	-0.27	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-4.56	7.9e-06	0.00278	-0.28	-0.27	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
COAD	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-4.56	7.9e-06	0.00278	-0.28	-0.27	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
COAD	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	4.56	7.91e-06	0.00278	0.32	0.27	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
COAD	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	4.56	7.91e-06	0.00278	0.32	0.27	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
COAD	cis	rs9478638	0.507	rs2184406	ENSG00000235381.1	RP11-477D19.2	-4.56	7.91e-06	0.00278	-0.33	-0.27	Electroencephalogram traits;	chr6:155308544	chr6:155253139~155256724:-
COAD	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	4.56	7.91e-06	0.00278	0.29	0.27	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
COAD	cis	rs9487051	0.837	rs4403290	ENSG00000219700.1	PTCHD3P3	4.56	7.92e-06	0.00278	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109290380	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.735	rs882074	ENSG00000219700.1	PTCHD3P3	4.56	7.92e-06	0.00278	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109290517	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs6924815	ENSG00000219700.1	PTCHD3P3	4.56	7.92e-06	0.00278	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109291141	chr6:109288571~109290503:-
COAD	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	4.56	7.92e-06	0.00278	0.32	0.27	QT interval;	chr12:29284120	chr12:29280418~29317848:-
COAD	cis	rs9910055	0.529	rs400460	ENSG00000267080.4	ASB16-AS1	4.56	7.92e-06	0.00278	0.25	0.27	Total body bone mineral density;	chr17:44105402	chr17:44175973~44186717:-
COAD	cis	rs7138300	0.51	rs61932085	ENSG00000258053.1	CTD-2021H9.3	-4.56	7.92e-06	0.00278	-0.37	-0.27	Type 2 diabetes;	chr12:71092882	chr12:71047402~71118247:-
COAD	cis	rs2836974	0.666	rs11910705	ENSG00000255568.3	BRWD1-AS2	-4.56	7.92e-06	0.00278	-0.26	-0.27	Cognitive function;	chr21:39313678	chr21:39313935~39314962:+
COAD	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-4.56	7.93e-06	0.00278	-0.29	-0.27	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
COAD	cis	rs6095360	0.727	rs8119476	ENSG00000222365.1	SNORD12B	-4.56	7.93e-06	0.00279	-0.31	-0.27	Intelligence (multi-trait analysis);	chr20:49073599	chr20:49280319~49280409:+
COAD	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-4.56	7.93e-06	0.00279	-0.33	-0.27	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
COAD	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	4.56	7.94e-06	0.00279	0.31	0.27	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
COAD	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-4.56	7.94e-06	0.00279	-0.3	-0.27	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
COAD	cis	rs7615952	0.605	rs11708269	ENSG00000272840.1	RP11-379B18.6	4.56	7.94e-06	0.00279	0.51	0.27	Blood pressure (smoking interaction);	chr3:125613306	chr3:125774714~125797953:+
COAD	cis	rs748404	0.556	rs7166467	ENSG00000205771.5	CATSPER2P1	4.56	7.94e-06	0.00279	0.34	0.27	Lung cancer;	chr15:43148324	chr15:43726918~43747094:-
COAD	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-4.56	7.94e-06	0.00279	-0.27	-0.27	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
COAD	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-4.56	7.95e-06	0.00279	-0.32	-0.27	QT interval;	chr12:29344573	chr12:29280418~29317848:-
COAD	cis	rs12908161	0.853	rs11633788	ENSG00000225151.9	GOLGA2P7	-4.56	7.95e-06	0.00279	-0.31	-0.27	Schizophrenia;	chr15:84761911	chr15:84199311~84230136:-
COAD	cis	rs5758511	0.773	rs11913631	ENSG00000237037.8	NDUFA6-AS1	-4.56	7.96e-06	0.00279	-0.29	-0.27	Birth weight;	chr22:41951367	chr22:42090931~42137742:+
COAD	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	4.56	7.96e-06	0.0028	0.33	0.27	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
COAD	cis	rs1949733	0.917	rs10461079	ENSG00000205959.3	RP11-689P11.2	4.56	7.96e-06	0.0028	0.34	0.27	Response to antineoplastic agents;	chr4:8390997	chr4:8482270~8512610:+
COAD	cis	rs8022206	0.773	rs10143843	ENSG00000259502.1	RP11-643G16.3	4.56	7.97e-06	0.0028	0.37	0.27	Platelet count;Mean platelet volume;	chr14:67991960	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs10136129	ENSG00000259502.1	RP11-643G16.3	4.56	7.97e-06	0.0028	0.37	0.27	Platelet count;Mean platelet volume;	chr14:67993004	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs28509330	ENSG00000259502.1	RP11-643G16.3	4.56	7.97e-06	0.0028	0.37	0.27	Platelet count;Mean platelet volume;	chr14:67993752	chr14:67610986~67613864:+
COAD	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-4.56	7.97e-06	0.0028	-0.35	-0.27	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
COAD	cis	rs7646881	0.544	rs16847135	ENSG00000272087.1	RP11-379F4.7	4.56	7.97e-06	0.0028	0.46	0.27	Tetralogy of Fallot;	chr3:158706064	chr3:158693120~158693768:-
COAD	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-4.56	7.98e-06	0.0028	-0.32	-0.27	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
COAD	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	4.56	7.98e-06	0.0028	0.34	0.27	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
COAD	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	4.56	7.99e-06	0.0028	0.36	0.27	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
COAD	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-4.56	8e-06	0.00281	-0.3	-0.27	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
COAD	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
COAD	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
COAD	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
COAD	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
COAD	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
COAD	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	4.56	8e-06	0.00281	0.41	0.27	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
COAD	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	4.56	8.01e-06	0.00281	0.23	0.27	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
COAD	cis	rs1023500	0.573	rs1807494	ENSG00000237037.8	NDUFA6-AS1	4.56	8.02e-06	0.00281	0.26	0.27	Schizophrenia;	chr22:42078134	chr22:42090931~42137742:+
COAD	cis	rs1023500	0.573	rs8135801	ENSG00000237037.8	NDUFA6-AS1	4.56	8.02e-06	0.00281	0.26	0.27	Schizophrenia;	chr22:42079564	chr22:42090931~42137742:+
COAD	cis	rs7829975	0.56	rs56094035	ENSG00000253981.4	ALG1L13P	-4.56	8.02e-06	0.00281	-0.33	-0.27	Mood instability;	chr8:8694112	chr8:8236003~8244667:-
COAD	cis	rs7829975	0.539	rs4841012	ENSG00000253981.4	ALG1L13P	-4.56	8.02e-06	0.00281	-0.33	-0.27	Mood instability;	chr8:8694200	chr8:8236003~8244667:-
COAD	cis	rs6840360	0.642	rs1470280	ENSG00000251611.1	RP11-610P16.1	-4.56	8.02e-06	0.00281	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151407551~151408835:-
COAD	cis	rs8141529	0.748	rs715531	ENSG00000272858.1	CTA-292E10.8	-4.56	8.02e-06	0.00281	-0.34	-0.27	Lymphocyte counts;	chr22:28886691	chr22:28814914~28815662:+
COAD	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-4.56	8.03e-06	0.00282	-0.31	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
COAD	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	4.56	8.03e-06	0.00282	0.32	0.27	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
COAD	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-4.56	8.03e-06	0.00282	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-4.56	8.03e-06	0.00282	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-4.56	8.03e-06	0.00282	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
COAD	cis	rs3733585	0.654	rs4447863	ENSG00000250413.1	RP11-448G15.1	4.56	8.04e-06	0.00282	0.35	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9937345	chr4:10006482~10009725:+
COAD	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-4.56	8.04e-06	0.00282	-0.44	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
COAD	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-4.56	8.04e-06	0.00282	-0.41	-0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
COAD	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-4.56	8.04e-06	0.00282	-0.33	-0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
COAD	cis	rs9951698	0.678	rs490853	ENSG00000266969.1	RP11-773H22.4	4.56	8.05e-06	0.00282	0.36	0.27	Intelligence (multi-trait analysis);	chr18:13106338	chr18:12984694~12991173:-
COAD	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-4.56	8.05e-06	0.00282	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
COAD	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	4.56	8.05e-06	0.00282	0.24	0.27	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
COAD	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	4.56	8.05e-06	0.00282	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	4.56	8.05e-06	0.00282	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
COAD	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	4.56	8.05e-06	0.00282	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
COAD	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	4.56	8.05e-06	0.00282	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
COAD	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	4.56	8.06e-06	0.00282	0.34	0.27	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
COAD	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-4.56	8.07e-06	0.00283	-0.32	-0.27	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
COAD	cis	rs2644899	0.715	rs2607415	ENSG00000233622.1	CYP2T1P	-4.56	8.07e-06	0.00283	-0.31	-0.27	Post bronchodilator FEV1/FVC ratio;	chr19:40756782	chr19:40808525~40811390:-
COAD	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	4.56	8.07e-06	0.00283	0.35	0.27	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
COAD	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-4.56	8.07e-06	0.00283	-0.35	-0.27	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
COAD	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	4.56	8.08e-06	0.00283	0.38	0.27	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
COAD	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-4.56	8.08e-06	0.00283	-0.27	-0.27	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
COAD	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	4.56	8.08e-06	0.00283	0.24	0.27	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
COAD	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-4.56	8.08e-06	0.00283	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
COAD	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4.56	8.09e-06	0.00283	0.35	0.27	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
COAD	cis	rs728616	0.867	rs61860043	ENSG00000234382.2	RP11-40F6.1	-4.55	8.1e-06	0.00284	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860044	ENSG00000234382.2	RP11-40F6.1	-4.55	8.1e-06	0.00284	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs12414521	ENSG00000234382.2	RP11-40F6.1	-4.55	8.1e-06	0.00284	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:80233664~80245367:+
COAD	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	4.55	8.1e-06	0.00284	0.33	0.27	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
COAD	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-4.55	8.11e-06	0.00284	-0.28	-0.27	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
COAD	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-4.55	8.12e-06	0.00284	-0.3	-0.27	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
COAD	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-4.55	8.12e-06	0.00284	-0.3	-0.27	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
COAD	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.55	8.12e-06	0.00284	-0.3	-0.27	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
COAD	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.55	8.12e-06	0.00284	-0.3	-0.27	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
COAD	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	4.55	8.12e-06	0.00284	0.28	0.27	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
COAD	cis	rs12497850	0.931	rs6446205	ENSG00000225399.4	RP11-3B7.1	4.55	8.13e-06	0.00284	0.31	0.27	Parkinson's disease;	chr3:48997778	chr3:49260085~49261316:+
COAD	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
COAD	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.13e-06	0.00284	-0.51	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
COAD	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	4.55	8.14e-06	0.00285	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
COAD	cis	rs6723226	0.881	rs10181198	ENSG00000276334.1	AL133243.1	4.55	8.14e-06	0.00285	0.26	0.27	Intelligence (multi-trait analysis);	chr2:32461514	chr2:32521927~32523547:+
COAD	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-4.55	8.14e-06	0.00285	-0.39	-0.27	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
COAD	cis	rs28374715	0.681	rs7163989	ENSG00000247556.5	OIP5-AS1	4.55	8.14e-06	0.00285	0.33	0.27	Ulcerative colitis;	chr15:41322423	chr15:41283990~41309737:+
COAD	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-4.55	8.14e-06	0.00285	-0.52	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
COAD	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	4.55	8.16e-06	0.00285	0.3	0.27	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
COAD	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-4.55	8.17e-06	0.00286	-0.34	-0.27	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
COAD	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	4.55	8.17e-06	0.00286	0.35	0.27	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
COAD	cis	rs7656342	0.897	rs7685396	ENSG00000186234.7	FAM86MP	-4.55	8.17e-06	0.00286	-0.36	-0.27	Gut microbiota (bacterial taxa);	chr4:9793100	chr4:9692495~9702954:+
COAD	cis	rs4704187	0.687	rs4621537	ENSG00000250889.2	LINC01336	-4.55	8.17e-06	0.00286	-0.31	-0.27	Response to amphetamines;	chr5:75066397	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs7709707	ENSG00000250889.2	LINC01336	-4.55	8.17e-06	0.00286	-0.31	-0.27	Response to amphetamines;	chr5:75067750	chr5:75047719~75052843:-
COAD	cis	rs9307551	0.857	rs7662551	ENSG00000250334.4	LINC00989	-4.55	8.19e-06	0.00286	-0.33	-0.27	Refractive error;	chr4:79616484	chr4:79492416~79576460:+
COAD	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-4.55	8.19e-06	0.00286	-0.29	-0.27	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
COAD	cis	rs3752645	1	rs6960708	ENSG00000241764.3	AC002467.7	4.55	8.19e-06	0.00286	0.41	0.27	Bladder cancer (smoking interaction);	chr7:107136758	chr7:107742817~107744581:-
COAD	cis	rs2732480	0.5	rs2732461	ENSG00000226413.2	OR8T1P	4.55	8.2e-06	0.00286	0.35	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48442030~48442947:-
COAD	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	4.55	8.2e-06	0.00287	0.29	0.27	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-4.55	8.2e-06	0.00287	-0.35	-0.27	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
COAD	cis	rs1426063	0.614	rs17199632	ENSG00000249717.1	RP11-44F21.3	4.55	8.2e-06	0.00287	0.59	0.27	QT interval;	chr4:75103663	chr4:74955974~74970362:-
COAD	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	4.55	8.21e-06	0.00287	0.19	0.27	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
COAD	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-4.55	8.21e-06	0.00287	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
COAD	cis	rs559555	0.568	rs569320	ENSG00000272716.1	RP11-563N4.1	4.55	8.21e-06	0.00287	0.31	0.27	Blood metabolite ratios;Blood metabolite levels;	chr2:31642978	chr2:32165046~32165757:-
COAD	cis	rs28374715	0.617	rs16971733	ENSG00000247556.5	OIP5-AS1	4.55	8.21e-06	0.00287	0.27	0.27	Ulcerative colitis;	chr15:41269832	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.617	rs28626792	ENSG00000247556.5	OIP5-AS1	4.55	8.21e-06	0.00287	0.27	0.27	Ulcerative colitis;	chr15:41270020	chr15:41283990~41309737:+
COAD	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-4.55	8.21e-06	0.00287	-0.32	-0.27	Height;	chr2:231539118	chr2:231508426~231514339:-
COAD	cis	rs2408955	0.541	rs11168428	ENSG00000273765.1	RP11-370I10.11	-4.55	8.21e-06	0.00287	-0.29	-0.27	Glycated hemoglobin levels;	chr12:48153345	chr12:48360920~48361377:+
COAD	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-4.55	8.21e-06	0.00287	-0.29	-0.27	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
COAD	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-4.55	8.22e-06	0.00287	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
COAD	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	4.55	8.22e-06	0.00287	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
COAD	cis	rs4568518	0.803	rs13232648	ENSG00000279048.1	RP11-511H23.2	4.55	8.22e-06	0.00287	0.2	0.27	Measles;	chr7:17992618	chr7:17940503~17942922:+
COAD	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	4.55	8.23e-06	0.00287	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
COAD	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.55	8.24e-06	0.00288	0.41	0.27	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.55	8.24e-06	0.00288	0.41	0.27	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.55	8.24e-06	0.00288	0.41	0.27	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
COAD	cis	rs74394007	0.512	rs344074	ENSG00000240875.4	LINC00886	-4.55	8.24e-06	0.00288	-0.3	-0.27	Total body bone mineral density;	chr3:156830868	chr3:156747346~156817062:-
COAD	cis	rs13256369	1	rs9329166	ENSG00000253981.4	ALG1L13P	4.55	8.25e-06	0.00288	0.41	0.27	Obesity-related traits;	chr8:8719145	chr8:8236003~8244667:-
COAD	cis	rs12439619	1	rs35152457	ENSG00000259429.4	UBE2Q2P2	-4.55	8.25e-06	0.00288	-0.26	-0.27	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82355142~82420075:+
COAD	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-4.55	8.25e-06	0.00288	-0.34	-0.27	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
COAD	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	4.55	8.26e-06	0.00288	0.29	0.27	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
COAD	cis	rs2836974	0.568	rs8130795	ENSG00000255568.3	BRWD1-AS2	4.55	8.26e-06	0.00288	0.26	0.27	Cognitive function;	chr21:39178057	chr21:39313935~39314962:+
COAD	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-4.55	8.26e-06	0.00288	-0.32	-0.27	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
COAD	cis	rs9487051	0.872	rs9400269	ENSG00000219700.1	PTCHD3P3	4.55	8.26e-06	0.00288	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109284862	chr6:109288571~109290503:-
COAD	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-4.55	8.26e-06	0.00288	-0.31	-0.27	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
COAD	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	4.55	8.26e-06	0.00288	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
COAD	cis	rs9487051	0.837	rs9480920	ENSG00000219700.1	PTCHD3P3	4.55	8.27e-06	0.00288	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109284119	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9487032	ENSG00000219700.1	PTCHD3P3	4.55	8.27e-06	0.00288	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109284120	chr6:109288571~109290503:-
COAD	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	4.55	8.27e-06	0.00289	0.28	0.27	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
COAD	cis	rs9487051	0.872	rs9372211	ENSG00000219700.1	PTCHD3P3	4.55	8.27e-06	0.00289	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109288445	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9487038	ENSG00000219700.1	PTCHD3P3	4.55	8.27e-06	0.00289	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109288949	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs1111864	ENSG00000219700.1	PTCHD3P3	4.55	8.27e-06	0.00289	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109289935	chr6:109288571~109290503:-
COAD	cis	rs7688540	0.515	rs28415975	ENSG00000211553.1	AC253576.2	-4.55	8.28e-06	0.00289	-0.43	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:136461~136568:+
COAD	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-4.55	8.28e-06	0.00289	-0.25	-0.27	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
COAD	cis	rs9907295	0.636	rs4251703	ENSG00000271013.1	AC015849.15	-4.55	8.29e-06	0.00289	-0.34	-0.27	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35912635~35918010:-
COAD	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-4.55	8.29e-06	0.00289	-0.31	-0.27	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
COAD	cis	rs12497850	0.897	rs7432989	ENSG00000225399.4	RP11-3B7.1	4.55	8.29e-06	0.00289	0.31	0.27	Parkinson's disease;	chr3:49067703	chr3:49260085~49261316:+
COAD	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	4.55	8.29e-06	0.00289	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
COAD	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	4.55	8.29e-06	0.00289	0.43	0.27	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
COAD	cis	rs12497850	0.931	rs11920534	ENSG00000225399.4	RP11-3B7.1	4.55	8.29e-06	0.00289	0.3	0.27	Parkinson's disease;	chr3:48900328	chr3:49260085~49261316:+
COAD	cis	rs2337406	0.925	rs873534	ENSG00000211974.3	IGHV2-70	-4.55	8.3e-06	0.0029	-0.32	-0.27	Alzheimer's disease (late onset);	chr14:106667423	chr14:106723574~106724093:-
COAD	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	4.55	8.3e-06	0.0029	0.35	0.27	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
COAD	cis	rs7465272	1	rs13258638	ENSG00000263660.1	AC087793.1	-4.55	8.31e-06	0.0029	-0.31	-0.27	Bipolar disorder and schizophrenia;	chr8:142602221	chr8:143314921~143315006:+
COAD	cis	rs9951698	0.678	rs570505	ENSG00000266969.1	RP11-773H22.4	4.55	8.31e-06	0.0029	0.35	0.27	Intelligence (multi-trait analysis);	chr18:13047785	chr18:12984694~12991173:-
COAD	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-4.55	8.32e-06	0.0029	-0.24	-0.27	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
COAD	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-4.55	8.32e-06	0.0029	-0.33	-0.27	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
COAD	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-4.55	8.32e-06	0.0029	-0.3	-0.27	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
COAD	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-4.55	8.32e-06	0.0029	-0.3	-0.27	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
COAD	cis	rs8141529	0.748	rs2064261	ENSG00000272858.1	CTA-292E10.8	-4.55	8.32e-06	0.0029	-0.33	-0.27	Lymphocyte counts;	chr22:28891742	chr22:28814914~28815662:+
COAD	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	4.55	8.33e-06	0.0029	0.28	0.27	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
COAD	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-4.55	8.33e-06	0.0029	-0.32	-0.27	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
COAD	cis	rs2408955	0.561	rs9971924	ENSG00000273765.1	RP11-370I10.11	-4.55	8.33e-06	0.0029	-0.28	-0.27	Glycated hemoglobin levels;	chr12:48086049	chr12:48360920~48361377:+
COAD	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-4.55	8.34e-06	0.00291	-0.34	-0.27	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
COAD	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-4.55	8.35e-06	0.00291	-0.35	-0.27	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
COAD	cis	rs10129255	0.646	rs55995061	ENSG00000211974.3	IGHV2-70	-4.55	8.35e-06	0.00291	-0.31	-0.27	Kawasaki disease;	chr14:106799309	chr14:106723574~106724093:-
COAD	cis	rs17772222	0.917	rs11159868	ENSG00000258789.1	RP11-507K2.3	-4.55	8.36e-06	0.00291	-0.4	-0.27	Coronary artery calcification;	chr14:88760528	chr14:88551597~88552493:+
COAD	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	4.55	8.36e-06	0.00291	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
COAD	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	4.55	8.37e-06	0.00292	0.34	0.27	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	4.55	8.37e-06	0.00292	0.34	0.27	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
COAD	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-4.55	8.37e-06	0.00292	-0.27	-0.27	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
COAD	cis	rs7818688	0.578	rs73269188	ENSG00000253528.2	RP11-347C18.4	-4.55	8.37e-06	0.00292	-0.38	-0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94826118	chr8:94974573~94974853:-
COAD	cis	rs1023500	0.505	rs134899	ENSG00000237037.8	NDUFA6-AS1	-4.55	8.37e-06	0.00292	-0.26	-0.27	Schizophrenia;	chr22:42287024	chr22:42090931~42137742:+
COAD	cis	rs1578862	0.966	rs11804773	ENSG00000259865.1	RP11-488L18.10	-4.55	8.38e-06	0.00292	-0.22	-0.27	Monocyte percentage of white cells;	chr1:247262310	chr1:247187281~247188526:-
COAD	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	4.55	8.38e-06	0.00292	0.32	0.27	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
COAD	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	4.55	8.38e-06	0.00292	0.32	0.27	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
COAD	cis	rs739496	0.579	rs9971942	ENSG00000257595.2	RP3-473L9.4	4.55	8.39e-06	0.00292	0.4	0.27	Platelet count;	chr12:111818238	chr12:111369282~111403310:+
COAD	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-4.55	8.39e-06	0.00292	-0.16	-0.27	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
COAD	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	4.55	8.39e-06	0.00292	0.28	0.27	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.55	8.39e-06	0.00292	0.28	0.27	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
COAD	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-4.55	8.4e-06	0.00293	-0.32	-0.27	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
COAD	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-4.55	8.41e-06	0.00293	-0.32	-0.27	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
COAD	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-4.55	8.41e-06	0.00293	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
COAD	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-4.55	8.41e-06	0.00293	-0.56	-0.27	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-4.55	8.41e-06	0.00293	-0.56	-0.27	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
COAD	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-4.55	8.41e-06	0.00293	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
COAD	cis	rs733317	0.731	rs11773820	ENSG00000226874.1	AC005154.8	-4.55	8.41e-06	0.00293	-0.32	-0.27	Left ventricular obstructive tract defect (inherited effect);	chr7:30997756	chr7:30544053~30544431:+
COAD	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-4.55	8.43e-06	0.00293	-0.31	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
COAD	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	4.55	8.43e-06	0.00293	0.35	0.27	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
COAD	cis	rs930421	0.763	rs930420	ENSG00000226491.1	FTOP1	-4.55	8.44e-06	0.00294	-0.35	-0.27	Attention deficit hyperactivity disorder;	chr2:42751296	chr2:42797225~42798712:-
COAD	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	4.55	8.44e-06	0.00294	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
COAD	cis	rs603446	1	rs1145208	ENSG00000254851.1	RP11-109L13.1	-4.55	8.44e-06	0.00294	-0.35	-0.27	Triglycerides;	chr11:116767269	chr11:117135528~117138582:+
COAD	cis	rs6940638	0.688	rs9393791	ENSG00000224843.5	LINC00240	4.55	8.44e-06	0.00294	0.35	0.27	Intelligence (multi-trait analysis);	chr6:27164750	chr6:26956992~27023924:+
COAD	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	4.55	8.45e-06	0.00294	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
COAD	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-4.55	8.45e-06	0.00294	-0.31	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
COAD	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	4.55	8.46e-06	0.00294	0.28	0.27	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
COAD	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-4.55	8.46e-06	0.00294	-0.33	-0.27	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
COAD	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-4.54	8.47e-06	0.00295	-0.36	-0.27	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
COAD	cis	rs3752645	1	rs6971393	ENSG00000241764.3	AC002467.7	4.54	8.47e-06	0.00295	0.45	0.27	Bladder cancer (smoking interaction);	chr7:107140623	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs12055946	ENSG00000241764.3	AC002467.7	4.54	8.47e-06	0.00295	0.45	0.27	Bladder cancer (smoking interaction);	chr7:107141641	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs17341680	ENSG00000241764.3	AC002467.7	4.54	8.47e-06	0.00295	0.45	0.27	Bladder cancer (smoking interaction);	chr7:107141952	chr7:107742817~107744581:-
COAD	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	4.54	8.48e-06	0.00295	0.33	0.27	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
COAD	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.54	8.48e-06	0.00295	-0.28	-0.27	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
COAD	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	4.54	8.48e-06	0.00295	0.34	0.27	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
COAD	cis	rs9487051	0.872	rs7772602	ENSG00000219700.1	PTCHD3P3	-4.54	8.48e-06	0.00295	-0.28	-0.27	Reticulocyte fraction of red cells;	chr6:109287458	chr6:109288571~109290503:-
COAD	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	4.54	8.49e-06	0.00295	0.33	0.27	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
COAD	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	4.54	8.5e-06	0.00296	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
COAD	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-4.54	8.5e-06	0.00296	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
COAD	cis	rs7615952	0.546	rs2979340	ENSG00000248787.1	RP11-666A20.4	-4.54	8.5e-06	0.00296	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125622540	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs2979338	ENSG00000248787.1	RP11-666A20.4	-4.54	8.5e-06	0.00296	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125624282	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs2922171	ENSG00000248787.1	RP11-666A20.4	-4.54	8.5e-06	0.00296	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125624349	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs112919177	ENSG00000248787.1	RP11-666A20.4	-4.54	8.5e-06	0.00296	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125627226	chr3:125908005~125910272:-
COAD	cis	rs9951698	0.678	rs1786279	ENSG00000266969.1	RP11-773H22.4	4.54	8.51e-06	0.00296	0.33	0.27	Intelligence (multi-trait analysis);	chr18:13144973	chr18:12984694~12991173:-
COAD	cis	rs9487051	0.872	rs9386790	ENSG00000219700.1	PTCHD3P3	-4.54	8.51e-06	0.00296	-0.29	-0.27	Reticulocyte fraction of red cells;	chr6:109287257	chr6:109288571~109290503:-
COAD	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-4.54	8.52e-06	0.00296	-0.33	-0.27	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
COAD	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-4.54	8.52e-06	0.00296	-0.32	-0.27	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
COAD	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-4.54	8.52e-06	0.00296	-0.32	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
COAD	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-4.54	8.52e-06	0.00296	-0.51	-0.27	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
COAD	cis	rs8022206	0.773	rs4436722	ENSG00000259502.1	RP11-643G16.3	4.54	8.52e-06	0.00296	0.37	0.27	Platelet count;Mean platelet volume;	chr14:67908898	chr14:67610986~67613864:+
COAD	cis	rs12497850	0.543	rs6446218	ENSG00000225399.4	RP11-3B7.1	4.54	8.52e-06	0.00296	0.31	0.27	Parkinson's disease;	chr3:49038080	chr3:49260085~49261316:+
COAD	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	4.54	8.52e-06	0.00296	0.48	0.27	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
COAD	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	4.54	8.52e-06	0.00296	0.34	0.27	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
COAD	cis	rs2439831	0.867	rs496584	ENSG00000275601.1	AC011330.13	-4.54	8.53e-06	0.00296	-0.39	-0.27	Lung cancer in ever smokers;	chr15:43539725	chr15:43642389~43643023:-
COAD	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-4.54	8.54e-06	0.00297	-0.29	-0.27	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
COAD	cis	rs9487051	0.676	rs4383852	ENSG00000219700.1	PTCHD3P3	4.54	8.54e-06	0.00297	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109273272	chr6:109288571~109290503:-
COAD	cis	rs11079159	0.959	rs17817857	ENSG00000263096.1	RP11-515O17.2	4.54	8.54e-06	0.00297	0.36	0.27	QRS duration;	chr17:55299581	chr17:55271504~55273653:-
COAD	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	4.54	8.54e-06	0.00297	0.35	0.27	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
COAD	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-4.54	8.55e-06	0.00297	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-4.54	8.55e-06	0.00297	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
COAD	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-4.54	8.55e-06	0.00297	-0.29	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-4.54	8.55e-06	0.00297	-0.29	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
COAD	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	4.54	8.55e-06	0.00297	0.5	0.27	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
COAD	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-4.54	8.55e-06	0.00297	-0.33	-0.27	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
COAD	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	4.54	8.56e-06	0.00297	0.33	0.27	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
COAD	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	4.54	8.56e-06	0.00297	0.38	0.27	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
COAD	cis	rs6840360	0.582	rs2724555	ENSG00000251611.1	RP11-610P16.1	-4.54	8.57e-06	0.00297	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151407551~151408835:-
COAD	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-4.54	8.57e-06	0.00297	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
COAD	cis	rs875971	0.66	rs6460308	ENSG00000272831.1	RP11-792A8.4	-4.54	8.57e-06	0.00297	-0.29	-0.27	Aortic root size;	chr7:66619753	chr7:66739829~66740385:-
COAD	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
COAD	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
COAD	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
COAD	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-4.54	8.57e-06	0.00298	-0.51	-0.27	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
COAD	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-4.54	8.57e-06	0.00298	-0.35	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-4.54	8.57e-06	0.00298	-0.35	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
COAD	cis	rs10895987	0.955	rs7113761	ENSG00000254614.2	AP003068.23	4.54	8.58e-06	0.00298	0.41	0.27	Blood protein levels;	chr11:65159251	chr11:65177606~65181834:-
COAD	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-4.54	8.6e-06	0.00298	-0.29	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
COAD	cis	rs9487051	0.652	rs13210424	ENSG00000219700.1	PTCHD3P3	4.54	8.6e-06	0.00298	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109277534	chr6:109288571~109290503:-
COAD	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-4.54	8.6e-06	0.00298	-0.33	-0.27	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-4.54	8.6e-06	0.00298	-0.33	-0.27	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-4.54	8.6e-06	0.00298	-0.33	-0.27	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
COAD	cis	rs7818688	0.614	rs6989591	ENSG00000253528.2	RP11-347C18.4	-4.54	8.6e-06	0.00298	-0.38	-0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94862352	chr8:94974573~94974853:-
COAD	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	4.54	8.61e-06	0.00299	0.37	0.27	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
COAD	cis	rs7615952	0.558	rs17334039	ENSG00000272840.1	RP11-379B18.6	4.54	8.61e-06	0.00299	0.38	0.27	Blood pressure (smoking interaction);	chr3:125821465	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.688	rs12638240	ENSG00000272840.1	RP11-379B18.6	4.54	8.61e-06	0.00299	0.38	0.27	Blood pressure (smoking interaction);	chr3:125822395	chr3:125774714~125797953:+
COAD	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-4.54	8.61e-06	0.00299	-0.27	-0.27	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
COAD	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	4.54	8.61e-06	0.00299	0.33	0.27	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
COAD	cis	rs7260598	0.642	rs11667315	ENSG00000268442.1	CTD-2027I19.2	4.54	8.61e-06	0.00299	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:23932336	chr19:24162370~24163425:-
COAD	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	4.54	8.61e-06	0.00299	0.29	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
COAD	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-4.54	8.61e-06	0.00299	-0.3	-0.27	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
COAD	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	4.54	8.61e-06	0.00299	0.35	0.27	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
COAD	cis	rs4927850	0.957	rs4927851	ENSG00000273009.1	RP11-352G9.1	-4.54	8.62e-06	0.00299	-0.3	-0.27	Pancreatic cancer;	chr3:196024982	chr3:195913078~195913683:-
COAD	cis	rs4927850	0.918	rs4361313	ENSG00000273009.1	RP11-352G9.1	-4.54	8.62e-06	0.00299	-0.3	-0.27	Pancreatic cancer;	chr3:196025389	chr3:195913078~195913683:-
COAD	cis	rs9990333	0.622	rs57783901	ENSG00000207650.1	MIR570	4.54	8.62e-06	0.00299	0.32	0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195699401~195699497:+
COAD	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-4.54	8.62e-06	0.00299	-0.32	-0.27	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
COAD	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-4.54	8.62e-06	0.00299	-0.19	-0.27	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
COAD	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	4.54	8.63e-06	0.00299	0.39	0.27	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
COAD	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-4.54	8.63e-06	0.00299	-0.29	-0.27	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
COAD	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-4.54	8.63e-06	0.00299	-0.29	-0.27	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
COAD	cis	rs8022206	0.773	rs10130829	ENSG00000259502.1	RP11-643G16.3	4.54	8.64e-06	0.003	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67988192	chr14:67610986~67613864:+
COAD	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-4.54	8.64e-06	0.003	-0.29	-0.27	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
COAD	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	4.54	8.65e-06	0.003	0.36	0.27	Depression;	chr6:28205232	chr6:28115628~28116551:+
COAD	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-4.54	8.65e-06	0.003	-0.4	-0.27	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-4.54	8.65e-06	0.003	-0.4	-0.27	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
COAD	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	4.54	8.65e-06	0.003	0.46	0.27	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
COAD	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-4.54	8.66e-06	0.003	-0.3	-0.27	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
COAD	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-4.54	8.66e-06	0.003	-0.38	-0.27	Depression;	chr6:28092227	chr6:28115628~28116551:+
COAD	cis	rs6951245	0.58	rs10257426	ENSG00000229043.2	AC091729.9	-4.54	8.66e-06	0.003	-0.4	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1160374~1165267:+
COAD	cis	rs8061903	0.535	rs12930801	ENSG00000260071.1	RP11-418I22.2	4.54	8.66e-06	0.003	0.34	0.27	HIV-1 viral setpoint;	chr16:9318410	chr16:9466655~9517564:+
COAD	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	4.54	8.66e-06	0.003	0.28	0.27	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
COAD	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	4.54	8.66e-06	0.003	0.16	0.27	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	4.54	8.66e-06	0.003	0.16	0.27	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
COAD	cis	rs2408955	0.504	rs11168441	ENSG00000226413.2	OR8T1P	4.54	8.66e-06	0.003	0.33	0.27	Glycated hemoglobin levels;	chr12:48182271	chr12:48442030~48442947:-
COAD	cis	rs12497850	0.931	rs7647813	ENSG00000225399.4	RP11-3B7.1	4.54	8.67e-06	0.003	0.3	0.27	Parkinson's disease;	chr3:48795915	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs12493289	ENSG00000225399.4	RP11-3B7.1	4.54	8.67e-06	0.003	0.3	0.27	Parkinson's disease;	chr3:48867728	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.865	rs7649458	ENSG00000225399.4	RP11-3B7.1	4.54	8.67e-06	0.003	0.3	0.27	Parkinson's disease;	chr3:48882694	chr3:49260085~49261316:+
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	4.54	8.67e-06	0.003	0.17	0.27	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
COAD	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	4.54	8.67e-06	0.003	0.3	0.27	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
COAD	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	4.54	8.67e-06	0.00301	0.62	0.27	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
COAD	cis	rs7760535	0.826	rs3851229	ENSG00000271789.1	RP5-1112D6.7	-4.54	8.68e-06	0.00301	-0.27	-0.27	Metabolic traits;	chr6:111533457	chr6:111297126~111298510:+
COAD	cis	rs4704187	0.687	rs4447960	ENSG00000250889.2	LINC01336	-4.54	8.68e-06	0.00301	-0.31	-0.27	Response to amphetamines;	chr5:75066032	chr5:75047719~75052843:-
COAD	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-4.54	8.69e-06	0.00301	-0.39	-0.27	Depression;	chr6:28070115	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-4.54	8.69e-06	0.00301	-0.39	-0.27	Depression;	chr6:28071237	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-4.54	8.69e-06	0.00301	-0.39	-0.27	Depression;	chr6:28071808	chr6:28115628~28116551:+
COAD	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-4.54	8.7e-06	0.00301	-0.33	-0.27	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
COAD	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	4.54	8.7e-06	0.00301	0.35	0.27	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
COAD	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-4.54	8.7e-06	0.00301	-0.33	-0.27	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
COAD	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	4.54	8.7e-06	0.00301	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
COAD	cis	rs9910055	0.762	rs184478	ENSG00000267080.4	ASB16-AS1	4.54	8.71e-06	0.00301	0.25	0.27	Total body bone mineral density;	chr17:44132383	chr17:44175973~44186717:-
COAD	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-4.54	8.71e-06	0.00302	-0.34	-0.27	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
COAD	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-4.54	8.71e-06	0.00302	-0.33	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
COAD	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	4.54	8.72e-06	0.00302	0.46	0.27	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
COAD	cis	rs9487051	0.676	rs9400268	ENSG00000219700.1	PTCHD3P3	4.54	8.72e-06	0.00302	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109279347	chr6:109288571~109290503:-
COAD	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-4.54	8.72e-06	0.00302	-0.26	-0.27	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
COAD	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-4.54	8.74e-06	0.00302	-0.32	-0.27	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-4.54	8.74e-06	0.00302	-0.32	-0.27	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-4.54	8.74e-06	0.00302	-0.32	-0.27	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
COAD	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-4.54	8.74e-06	0.00302	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
COAD	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	4.54	8.74e-06	0.00302	0.34	0.27	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
COAD	cis	rs2638953	0.606	rs10843213	ENSG00000247934.4	RP11-967K21.1	-4.54	8.74e-06	0.00303	-0.28	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582853	chr12:28163298~28190738:-
COAD	cis	rs8002861	0.875	rs12428432	ENSG00000274001.1	RP11-5G9.5	-4.54	8.74e-06	0.00303	-0.26	-0.27	Leprosy;	chr13:43889907	chr13:43877715~43878163:-
COAD	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	4.54	8.74e-06	0.00303	0.4	0.27	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
COAD	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	4.54	8.74e-06	0.00303	0.4	0.27	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
COAD	cis	rs9890032	0.934	rs3760318	ENSG00000266490.1	CTD-2349P21.9	4.54	8.75e-06	0.00303	0.27	0.27	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30792372~30792833:+
COAD	cis	rs17685	0.753	rs10233282	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs10251863	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs9691174	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76043977~76045963:-
COAD	cis	rs17685	0.664	rs9801113	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76043977~76045963:-
COAD	cis	rs17685	0.558	rs60787921	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs56965035	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76043977~76045963:-
COAD	cis	rs17685	0.672	rs56343450	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76043977~76045963:-
COAD	cis	rs17685	0.743	rs10277259	ENSG00000280388.1	RP11-229D13.3	-4.54	8.75e-06	0.00303	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76043977~76045963:-
COAD	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-4.54	8.76e-06	0.00303	-0.36	-0.27	Depression;	chr6:28193021	chr6:28115628~28116551:+
COAD	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-4.54	8.76e-06	0.00303	-0.36	-0.27	Depression;	chr6:28197321	chr6:28115628~28116551:+
COAD	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-4.54	8.76e-06	0.00303	-0.36	-0.27	Depression;	chr6:28197412	chr6:28115628~28116551:+
COAD	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-4.54	8.76e-06	0.00303	-0.36	-0.27	Depression;	chr6:28198669	chr6:28115628~28116551:+
COAD	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-4.54	8.77e-06	0.00303	-0.36	-0.27	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
COAD	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-4.54	8.77e-06	0.00303	-0.39	-0.27	Depression;	chr6:28110254	chr6:28115628~28116551:+
COAD	cis	rs240993	0.715	rs7752418	ENSG00000230177.1	RP5-1112D6.4	4.54	8.77e-06	0.00303	0.25	0.27	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111277932~111278742:+
COAD	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-4.54	8.77e-06	0.00304	-0.25	-0.27	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
COAD	cis	rs4938303	0.633	rs12800436	ENSG00000254851.1	RP11-109L13.1	4.54	8.78e-06	0.00304	0.43	0.27	Triglycerides;	chr11:116688086	chr11:117135528~117138582:+
COAD	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-4.54	8.78e-06	0.00304	-0.27	-0.27	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
COAD	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	4.54	8.78e-06	0.00304	0.33	0.27	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	4.54	8.78e-06	0.00304	0.33	0.27	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	4.54	8.78e-06	0.00304	0.33	0.27	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	4.54	8.78e-06	0.00304	0.33	0.27	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
COAD	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	4.54	8.78e-06	0.00304	0.33	0.27	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
COAD	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-4.54	8.78e-06	0.00304	-0.35	-0.27	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
COAD	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-4.54	8.79e-06	0.00304	-0.29	-0.27	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-4.54	8.79e-06	0.00304	-0.29	-0.27	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-4.54	8.79e-06	0.00304	-0.29	-0.27	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
COAD	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-4.54	8.79e-06	0.00304	-0.34	-0.27	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
COAD	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-4.54	8.79e-06	0.00304	-0.49	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
COAD	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-4.54	8.79e-06	0.00304	-0.43	-0.27	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
COAD	cis	rs9813712	0.571	rs6795143	ENSG00000249846.5	RP11-77P16.4	-4.54	8.79e-06	0.00304	-0.3	-0.27	Response to amphetamines;	chr3:130224355	chr3:130112550~130120579:+
COAD	cis	rs9813712	0.571	rs9289366	ENSG00000249846.5	RP11-77P16.4	-4.54	8.79e-06	0.00304	-0.3	-0.27	Response to amphetamines;	chr3:130225267	chr3:130112550~130120579:+
COAD	cis	rs9813712	0.571	rs9289367	ENSG00000249846.5	RP11-77P16.4	-4.54	8.79e-06	0.00304	-0.3	-0.27	Response to amphetamines;	chr3:130225286	chr3:130112550~130120579:+
COAD	cis	rs9813712	0.571	rs9289368	ENSG00000249846.5	RP11-77P16.4	-4.54	8.79e-06	0.00304	-0.3	-0.27	Response to amphetamines;	chr3:130225562	chr3:130112550~130120579:+
COAD	cis	rs9813712	0.571	rs6774141	ENSG00000249846.5	RP11-77P16.4	-4.54	8.79e-06	0.00304	-0.3	-0.27	Response to amphetamines;	chr3:130225599	chr3:130112550~130120579:+
COAD	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	4.54	8.8e-06	0.00304	0.28	0.27	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
COAD	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-4.54	8.81e-06	0.00304	-0.28	-0.27	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
COAD	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-4.54	8.81e-06	0.00305	-0.33	-0.27	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
COAD	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	4.54	8.81e-06	0.00305	0.31	0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
COAD	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	4.54	8.81e-06	0.00305	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
COAD	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-4.54	8.81e-06	0.00305	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-4.54	8.81e-06	0.00305	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
COAD	cis	rs860295	0.639	rs10908469	ENSG00000160766.13	GBAP1	-4.54	8.82e-06	0.00305	-0.31	-0.27	Body mass index;	chr1:155498941	chr1:155213821~155227422:-
COAD	cis	rs2638953	0.853	rs1355473	ENSG00000247934.4	RP11-967K21.1	-4.54	8.83e-06	0.00305	-0.28	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28163298~28190738:-
COAD	cis	rs989978	0.958	rs10458728	ENSG00000257582.4	LINC01475	-4.54	8.83e-06	0.00305	-0.31	-0.27	Red blood cell count;	chr10:99564219	chr10:99526350~99531177:-
COAD	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	4.54	8.83e-06	0.00305	0.32	0.27	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
COAD	cis	rs9818758	0.607	rs11706189	ENSG00000225399.4	RP11-3B7.1	-4.54	8.83e-06	0.00305	-0.48	-0.27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:49260085~49261316:+
COAD	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	4.54	8.83e-06	0.00305	0.31	0.27	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
COAD	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	4.54	8.84e-06	0.00305	0.16	0.27	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
COAD	cis	rs71636778	0.509	rs34216334	ENSG00000260063.1	RP5-968P14.2	-4.54	8.84e-06	0.00306	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26736928	chr1:26692132~26694131:-
COAD	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	4.53	8.85e-06	0.00306	0.37	0.27	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
COAD	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	4.53	8.86e-06	0.00306	0.28	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
COAD	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-4.53	8.87e-06	0.00306	-0.32	-0.27	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
COAD	cis	rs6840360	0.606	rs2709814	ENSG00000251611.1	RP11-610P16.1	-4.53	8.87e-06	0.00306	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151407551~151408835:-
COAD	cis	rs2115630	1	rs58581703	ENSG00000259728.4	LINC00933	-4.53	8.87e-06	0.00306	-0.32	-0.27	P wave terminal force;	chr15:84733704	chr15:84570649~84580175:+
COAD	cis	rs34792	0.637	rs34793	ENSG00000207425.1	Y_RNA	4.53	8.87e-06	0.00306	0.33	0.27	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:14915457~14915556:-
COAD	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-4.53	8.87e-06	0.00306	-0.3	-0.27	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
COAD	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	4.53	8.88e-06	0.00307	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
COAD	cis	rs7615952	0.543	rs4645102	ENSG00000248787.1	RP11-666A20.4	-4.53	8.88e-06	0.00307	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125705597	chr3:125908005~125910272:-
COAD	cis	rs72827839	0.802	rs16953925	ENSG00000263412.1	RP5-890E16.2	4.53	8.88e-06	0.00307	0.4	0.27	Ease of getting up in the morning;	chr17:48217136	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.846	rs16954078	ENSG00000263412.1	RP5-890E16.2	4.53	8.88e-06	0.00307	0.4	0.27	Ease of getting up in the morning;	chr17:48228765	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.846	rs16954204	ENSG00000263412.1	RP5-890E16.2	4.53	8.88e-06	0.00307	0.4	0.27	Ease of getting up in the morning;	chr17:48237836	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.74	rs10514938	ENSG00000263412.1	RP5-890E16.2	4.53	8.88e-06	0.00307	0.4	0.27	Ease of getting up in the morning;	chr17:48245242	chr17:48045141~48048073:-
COAD	cis	rs7615952	0.688	rs9754526	ENSG00000272840.1	RP11-379B18.6	4.53	8.88e-06	0.00307	0.38	0.27	Blood pressure (smoking interaction);	chr3:125824023	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.512	rs34085484	ENSG00000272840.1	RP11-379B18.6	4.53	8.88e-06	0.00307	0.38	0.27	Blood pressure (smoking interaction);	chr3:125825343	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.608	rs35668111	ENSG00000272840.1	RP11-379B18.6	4.53	8.88e-06	0.00307	0.38	0.27	Blood pressure (smoking interaction);	chr3:125825792	chr3:125774714~125797953:+
COAD	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-4.53	8.89e-06	0.00307	-0.29	-0.27	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
COAD	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-4.53	8.89e-06	0.00307	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
COAD	cis	rs9813712	0.571	rs9824426	ENSG00000249846.5	RP11-77P16.4	-4.53	8.9e-06	0.00307	-0.3	-0.27	Response to amphetamines;	chr3:130226115	chr3:130112550~130120579:+
COAD	cis	rs8002861	0.875	rs12867890	ENSG00000274001.1	RP11-5G9.5	-4.53	8.9e-06	0.00307	-0.26	-0.27	Leprosy;	chr13:43848952	chr13:43877715~43878163:-
COAD	cis	rs7487075	0.554	rs7967629	ENSG00000274723.1	RP11-618L22.1	4.53	8.9e-06	0.00307	0.29	0.27	Itch intensity from mosquito bite;	chr12:46234824	chr12:46970504~46972155:+
COAD	cis	rs754466	0.958	rs11002341	ENSG00000204049.1	RP11-126H7.4	4.53	8.9e-06	0.00307	0.36	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941605	chr10:77866875~77869610:+
COAD	cis	rs754466	0.914	rs12218917	ENSG00000204049.1	RP11-126H7.4	4.53	8.9e-06	0.00307	0.36	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941721	chr10:77866875~77869610:+
COAD	cis	rs754466	0.914	rs12219971	ENSG00000204049.1	RP11-126H7.4	4.53	8.9e-06	0.00307	0.36	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941768	chr10:77866875~77869610:+
COAD	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-4.53	8.91e-06	0.00307	-0.33	-0.27	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-4.53	8.91e-06	0.00307	-0.33	-0.27	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
COAD	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-4.53	8.91e-06	0.00307	-0.32	-0.27	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
COAD	cis	rs28374715	0.662	rs1554445	ENSG00000247556.5	OIP5-AS1	4.53	8.91e-06	0.00307	0.37	0.27	Ulcerative colitis;	chr15:41211000	chr15:41283990~41309737:+
COAD	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	4.53	8.92e-06	0.00308	0.33	0.27	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
COAD	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-4.53	8.92e-06	0.00308	-0.42	-0.27	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
COAD	cis	rs6452524	0.56	rs6895174	ENSG00000271862.1	RP11-343L5.2	4.53	8.92e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83049376~83050964:-
COAD	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	4.53	8.92e-06	0.00308	0.35	0.27	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
COAD	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	4.53	8.92e-06	0.00308	0.37	0.27	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
COAD	cis	rs17772222	0.876	rs12586348	ENSG00000258789.1	RP11-507K2.3	-4.53	8.92e-06	0.00308	-0.4	-0.27	Coronary artery calcification;	chr14:88643523	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs12434935	ENSG00000258789.1	RP11-507K2.3	-4.53	8.92e-06	0.00308	-0.4	-0.27	Coronary artery calcification;	chr14:88645449	chr14:88551597~88552493:+
COAD	cis	rs6452524	0.618	rs1871203	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.618	rs6867727	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.618	rs7723639	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.618	rs2306336	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.589	rs6882386	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.618	rs6860752	ENSG00000271862.1	RP11-343L5.2	4.53	8.93e-06	0.00308	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83049376~83050964:-
COAD	cis	rs72827839	0.802	rs72825584	ENSG00000263412.1	RP5-890E16.2	4.53	8.93e-06	0.00308	0.4	0.27	Ease of getting up in the morning;	chr17:48215727	chr17:48045141~48048073:-
COAD	cis	rs989978	0.528	rs7091572	ENSG00000257582.4	LINC01475	4.53	8.93e-06	0.00308	0.31	0.27	Red blood cell count;	chr10:99568094	chr10:99526350~99531177:-
COAD	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	4.53	8.93e-06	0.00308	0.33	0.27	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
COAD	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	4.53	8.93e-06	0.00308	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
COAD	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-4.53	8.94e-06	0.00308	-0.27	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
COAD	cis	rs728616	0.867	rs55666905	ENSG00000234382.2	RP11-40F6.1	-4.53	8.95e-06	0.00309	-0.54	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:80233664~80245367:+
COAD	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-4.53	8.95e-06	0.00309	-0.46	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
COAD	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	4.53	8.96e-06	0.00309	0.58	0.27	QT interval;	chr4:75100963	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	4.53	8.96e-06	0.00309	0.58	0.27	QT interval;	chr4:75101024	chr4:74955974~74970362:-
COAD	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	4.53	8.96e-06	0.00309	0.28	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
COAD	cis	rs3752645	1	rs79589497	ENSG00000241764.3	AC002467.7	4.53	8.96e-06	0.00309	0.46	0.27	Bladder cancer (smoking interaction);	chr7:107088692	chr7:107742817~107744581:-
COAD	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	4.53	8.98e-06	0.00309	0.33	0.27	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
COAD	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-4.53	8.98e-06	0.00309	-0.29	-0.27	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
COAD	cis	rs6723226	0.61	rs458628	ENSG00000276334.1	AL133243.1	4.53	8.98e-06	0.0031	0.25	0.27	Intelligence (multi-trait analysis);	chr2:32290329	chr2:32521927~32523547:+
COAD	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-4.53	8.98e-06	0.0031	-0.41	-0.27	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
COAD	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-4.53	8.99e-06	0.0031	-0.3	-0.27	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
COAD	cis	rs71636778	0.509	rs35617712	ENSG00000260063.1	RP5-968P14.2	-4.53	8.99e-06	0.0031	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724732	chr1:26692132~26694131:-
COAD	cis	rs58873874	1	rs58873874	ENSG00000251405.2	CTB-109A12.1	4.53	8.99e-06	0.0031	0.6	0.27	Bipolar disorder (body mass index interaction);	chr5:157518140	chr5:157362615~157460078:-
COAD	cis	rs739496	0.615	rs7962138	ENSG00000257595.2	RP3-473L9.4	4.53	8.99e-06	0.0031	0.4	0.27	Platelet count;	chr12:111742373	chr12:111369282~111403310:+
COAD	cis	rs801193	0.904	rs4718405	ENSG00000272831.1	RP11-792A8.4	4.53	9e-06	0.0031	0.28	0.27	Aortic root size;	chr7:66789659	chr7:66739829~66740385:-
COAD	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.53	9e-06	0.0031	0.34	0.27	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.53	9e-06	0.0031	0.34	0.27	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.53	9e-06	0.0031	0.34	0.27	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.53	9e-06	0.0031	0.34	0.27	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
COAD	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	4.53	9e-06	0.0031	0.25	0.27	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
COAD	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	4.53	9e-06	0.0031	0.32	0.27	Height;	chr4:55528801	chr4:55540502~55540835:-
COAD	cis	rs3126085	0.56	rs12568784	ENSG00000237975.5	FLG-AS1	4.53	9.01e-06	0.00311	0.33	0.27	Atopic dermatitis;	chr1:152350656	chr1:152168125~152445456:+
COAD	cis	rs9549328	0.8	rs9549616	ENSG00000267868.1	RP11-120K24.3	4.53	9.02e-06	0.00311	0.36	0.27	Systolic blood pressure;	chr13:112973448	chr13:112964835~112966131:-
COAD	cis	rs7260598	0.539	rs75624869	ENSG00000268442.1	CTD-2027I19.2	4.53	9.02e-06	0.00311	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23788844	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.502	rs80285843	ENSG00000268442.1	CTD-2027I19.2	4.53	9.02e-06	0.00311	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23791663	chr19:24162370~24163425:-
COAD	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	4.53	9.03e-06	0.00311	0.37	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
COAD	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
COAD	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
COAD	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
COAD	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
COAD	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
COAD	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-4.53	9.03e-06	0.00311	-0.54	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
COAD	cis	rs6840360	0.642	rs1470281	ENSG00000251611.1	RP11-610P16.1	-4.53	9.04e-06	0.00311	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151407551~151408835:-
COAD	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	4.53	9.04e-06	0.00311	0.31	0.27	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
COAD	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-4.53	9.04e-06	0.00311	-0.32	-0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
COAD	cis	rs3930017	1	rs3930016	ENSG00000225726.1	AC007000.10	-4.53	9.06e-06	0.00312	-0.3	-0.27	Body mass index;	chr7:77091132	chr7:77071751~77072237:-
COAD	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	4.53	9.06e-06	0.00312	0.31	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
COAD	cis	rs56116382	0.604	rs9858428	ENSG00000225399.4	RP11-3B7.1	-4.53	9.06e-06	0.00312	-0.53	-0.27	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49840152	chr3:49260085~49261316:+
COAD	cis	rs7193541	0.825	rs4411525	ENSG00000262904.1	TMPOP2	-4.53	9.06e-06	0.00312	-0.29	-0.27	Multiple myeloma;	chr16:74561604	chr16:74667506~74668706:+
COAD	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-4.53	9.06e-06	0.00312	-0.34	-0.27	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
COAD	cis	rs72827839	0.802	rs16953382	ENSG00000263412.1	RP5-890E16.2	4.53	9.07e-06	0.00312	0.4	0.27	Ease of getting up in the morning;	chr17:48175544	chr17:48045141~48048073:-
COAD	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	4.53	9.07e-06	0.00312	0.39	0.27	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
COAD	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-4.53	9.07e-06	0.00312	-0.28	-0.27	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-4.53	9.07e-06	0.00312	-0.28	-0.27	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-4.53	9.07e-06	0.00312	-0.28	-0.27	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
COAD	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-4.53	9.07e-06	0.00312	-0.28	-0.27	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
COAD	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-4.53	9.07e-06	0.00312	-0.28	-0.27	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
COAD	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-4.53	9.07e-06	0.00312	-0.33	-0.27	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
COAD	cis	rs6840360	0.642	rs7666571	ENSG00000251611.1	RP11-610P16.1	-4.53	9.07e-06	0.00312	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151407551~151408835:-
COAD	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-4.53	9.08e-06	0.00312	-0.32	-0.27	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
COAD	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	4.53	9.08e-06	0.00312	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
COAD	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	4.53	9.08e-06	0.00313	0.31	0.27	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	4.53	9.08e-06	0.00313	0.31	0.27	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
COAD	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-4.53	9.08e-06	0.00313	-0.34	-0.27	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
COAD	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	4.53	9.09e-06	0.00313	0.31	0.27	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
COAD	cis	rs9951698	0.703	rs1786984	ENSG00000266969.1	RP11-773H22.4	4.53	9.09e-06	0.00313	0.33	0.27	Intelligence (multi-trait analysis);	chr18:13154355	chr18:12984694~12991173:-
COAD	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-4.53	9.09e-06	0.00313	-0.37	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
COAD	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	4.53	9.09e-06	0.00313	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	4.53	9.09e-06	0.00313	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-4.53	9.1e-06	0.00313	-0.24	-0.27	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
COAD	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	4.53	9.11e-06	0.00313	0.39	0.27	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
COAD	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	4.53	9.11e-06	0.00313	0.3	0.27	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	4.53	9.11e-06	0.00313	0.3	0.27	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
COAD	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-4.53	9.11e-06	0.00313	-0.29	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
COAD	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	4.53	9.11e-06	0.00313	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
COAD	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.53	9.12e-06	0.00314	-0.43	-0.27	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
COAD	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	4.53	9.12e-06	0.00314	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
COAD	cis	rs9481169	0.717	rs13191781	ENSG00000255389.1	C6orf3	-4.53	9.12e-06	0.00314	-0.55	-0.27	Inflammatory skin disease;	chr6:111620083	chr6:111599875~111602295:+
COAD	cis	rs13256369	0.76	rs7816171	ENSG00000173295.6	FAM86B3P	4.53	9.13e-06	0.00314	0.38	0.27	Obesity-related traits;	chr8:8718325	chr8:8228595~8244865:+
COAD	cis	rs13256369	0.76	rs7839473	ENSG00000173295.6	FAM86B3P	4.53	9.13e-06	0.00314	0.38	0.27	Obesity-related traits;	chr8:8718326	chr8:8228595~8244865:+
COAD	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-4.53	9.13e-06	0.00314	-0.28	-0.27	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
COAD	cis	rs860295	0.665	rs12079134	ENSG00000160766.13	GBAP1	-4.53	9.14e-06	0.00314	-0.31	-0.27	Body mass index;	chr1:155496993	chr1:155213821~155227422:-
COAD	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-4.53	9.15e-06	0.00314	-0.29	-0.27	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
COAD	cis	rs7829975	0.5	rs7841082	ENSG00000253981.4	ALG1L13P	-4.53	9.15e-06	0.00314	-0.34	-0.27	Mood instability;	chr8:8311465	chr8:8236003~8244667:-
COAD	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-4.53	9.15e-06	0.00314	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
COAD	cis	rs17772222	0.917	rs1950806	ENSG00000258789.1	RP11-507K2.3	-4.53	9.15e-06	0.00314	-0.43	-0.27	Coronary artery calcification;	chr14:88774412	chr14:88551597~88552493:+
COAD	cis	rs597539	0.652	rs569777	ENSG00000255741.1	RP11-757G1.5	-4.53	9.16e-06	0.00315	-0.36	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68941503~68942852:-
COAD	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-4.53	9.17e-06	0.00315	-0.28	-0.27	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
COAD	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	4.53	9.18e-06	0.00315	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	4.53	9.18e-06	0.00315	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
COAD	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	4.53	9.19e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
COAD	cis	rs7615952	0.546	rs11717632	ENSG00000248787.1	RP11-666A20.4	-4.53	9.2e-06	0.00316	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125602286	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs2922197	ENSG00000248787.1	RP11-666A20.4	-4.53	9.2e-06	0.00316	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125603188	chr3:125908005~125910272:-
COAD	cis	rs3930017	1	rs7783809	ENSG00000225726.1	AC007000.10	-4.53	9.2e-06	0.00316	-0.3	-0.27	Body mass index;	chr7:77090234	chr7:77071751~77072237:-
COAD	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	4.53	9.2e-06	0.00316	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
COAD	cis	rs1790761	0.501	rs4930210	ENSG00000255318.1	RP11-655M14.13	-4.53	9.2e-06	0.00316	-0.36	-0.27	Mean corpuscular volume;	chr11:67637255	chr11:67618279~67627304:-
COAD	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	4.53	9.21e-06	0.00316	0.29	0.27	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
COAD	cis	rs860295	0.651	rs6692183	ENSG00000160766.13	GBAP1	-4.53	9.21e-06	0.00316	-0.32	-0.27	Body mass index;	chr1:155334536	chr1:155213821~155227422:-
COAD	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	4.53	9.21e-06	0.00316	0.3	0.27	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
COAD	cis	rs4704187	0.687	rs922390	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75105444	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs7735057	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75108032	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4361493	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75109272	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6862740	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75109924	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs9763362	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75110491	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.617	rs2035192	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75111406	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs2335136	ENSG00000250889.2	LINC01336	-4.53	9.22e-06	0.00316	-0.31	-0.27	Response to amphetamines;	chr5:75112169	chr5:75047719~75052843:-
COAD	cis	rs73198271	0.813	rs17697237	ENSG00000173295.6	FAM86B3P	4.53	9.22e-06	0.00316	0.34	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8228595~8244865:+
COAD	cis	rs8022206	0.704	rs11158717	ENSG00000259502.1	RP11-643G16.3	4.53	9.22e-06	0.00316	0.35	0.27	Platelet count;Mean platelet volume;	chr14:68047559	chr14:67610986~67613864:+
COAD	cis	rs1348850	0.831	rs1345139	ENSG00000280374.1	RP11-337N6.3	-4.53	9.22e-06	0.00317	-0.53	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177585063	chr2:177317715~177318471:-
COAD	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.53	9.22e-06	0.00317	-0.46	-0.27	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
COAD	cis	rs61160187	0.75	rs1807017	ENSG00000215032.2	GNL3LP1	4.53	9.23e-06	0.00317	0.36	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60891935~60893577:-
COAD	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	4.53	9.23e-06	0.00317	0.33	0.27	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
COAD	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	4.53	9.24e-06	0.00317	0.28	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
COAD	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-4.53	9.24e-06	0.00317	-0.29	-0.27	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
COAD	cis	rs4704187	0.687	rs4345300	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75080746	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6869345	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75082917	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.595	rs6859176	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75083600	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs12523187	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75083800	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6453111	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75084101	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10462512	ENSG00000250889.2	LINC01336	-4.52	9.24e-06	0.00317	-0.31	-0.27	Response to amphetamines;	chr5:75091492	chr5:75047719~75052843:-
COAD	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-4.52	9.24e-06	0.00317	-0.5	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-4.52	9.25e-06	0.00317	-0.32	-0.27	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-4.52	9.25e-06	0.00317	-0.32	-0.27	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
COAD	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-4.52	9.26e-06	0.00318	-0.32	-0.27	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
COAD	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	4.52	9.26e-06	0.00318	0.36	0.27	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
COAD	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	4.52	9.26e-06	0.00318	0.3	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
COAD	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	4.52	9.26e-06	0.00318	0.35	0.27	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
COAD	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	4.52	9.27e-06	0.00318	0.37	0.27	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
COAD	cis	rs8002861	0.905	rs12873099	ENSG00000274001.1	RP11-5G9.5	-4.52	9.27e-06	0.00318	-0.26	-0.27	Leprosy;	chr13:43822111	chr13:43877715~43878163:-
COAD	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	4.52	9.28e-06	0.00318	0.32	0.27	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
COAD	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	4.52	9.28e-06	0.00318	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
COAD	cis	rs875971	0.545	rs316328	ENSG00000224316.1	RP11-479O9.2	-4.52	9.28e-06	0.00318	-0.32	-0.27	Aortic root size;	chr7:66143851	chr7:65773620~65802067:+
COAD	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	4.52	9.29e-06	0.00318	0.37	0.27	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	4.52	9.29e-06	0.00318	0.37	0.27	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	4.52	9.29e-06	0.00318	0.26	0.27	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
COAD	cis	rs71636778	0.509	rs57217461	ENSG00000260063.1	RP5-968P14.2	-4.52	9.29e-06	0.00319	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701425	chr1:26692132~26694131:-
COAD	cis	rs754466	0.58	rs10824576	ENSG00000204049.1	RP11-126H7.4	4.52	9.3e-06	0.00319	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806282	chr10:77866875~77869610:+
COAD	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	4.52	9.31e-06	0.00319	0.41	0.27	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
COAD	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-4.52	9.31e-06	0.00319	-0.35	-0.27	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
COAD	cis	rs896854	0.846	rs13254283	ENSG00000253528.2	RP11-347C18.4	4.52	9.31e-06	0.00319	0.29	0.27	Type 2 diabetes;	chr8:94901875	chr8:94974573~94974853:-
COAD	cis	rs11976180	1	rs1919951	ENSG00000273234.1	OR2A13P	-4.52	9.31e-06	0.00319	-0.34	-0.27	Obesity-related traits;	chr7:144071798	chr7:144142009~144142938:+
COAD	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	4.52	9.31e-06	0.00319	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	4.52	9.31e-06	0.00319	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
COAD	cis	rs4761470	0.577	rs4761602	ENSG00000258365.1	RP11-1105G2.3	-4.52	9.31e-06	0.00319	-0.33	-0.27	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94277758~94282844:-
COAD	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	4.52	9.32e-06	0.00319	0.31	0.27	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
COAD	cis	rs7818382	0.967	rs7812465	ENSG00000253528.2	RP11-347C18.4	-4.52	9.33e-06	0.0032	-0.29	-0.27	Alzheimer's disease (late onset);	chr8:95038329	chr8:94974573~94974853:-
COAD	cis	rs3752645	1	rs113841792	ENSG00000241764.3	AC002467.7	4.52	9.35e-06	0.0032	0.46	0.27	Bladder cancer (smoking interaction);	chr7:107088139	chr7:107742817~107744581:-
COAD	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	4.52	9.36e-06	0.0032	0.34	0.27	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	4.52	9.36e-06	0.0032	0.34	0.27	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	4.52	9.36e-06	0.0032	0.34	0.27	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
COAD	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-4.52	9.36e-06	0.0032	-0.25	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
COAD	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	4.52	9.36e-06	0.0032	0.5	0.27	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
COAD	cis	rs7119	0.7	rs2867311	ENSG00000259565.2	KRT8P23	4.52	9.37e-06	0.00321	0.3	0.27	Type 2 diabetes;	chr15:77609849	chr15:76979245~76980451:-
COAD	cis	rs7615952	0.609	rs13088451	ENSG00000248787.1	RP11-666A20.4	-4.52	9.38e-06	0.00321	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125834656	chr3:125908005~125910272:-
COAD	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	4.52	9.38e-06	0.00321	0.44	0.27	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	4.52	9.38e-06	0.00321	0.44	0.27	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	4.52	9.38e-06	0.00321	0.44	0.27	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	4.52	9.38e-06	0.00321	0.44	0.27	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	4.52	9.38e-06	0.00321	0.44	0.27	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
COAD	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-4.52	9.38e-06	0.00321	-0.3	-0.27	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
COAD	cis	rs597539	0.616	rs631001	ENSG00000255741.1	RP11-757G1.5	-4.52	9.38e-06	0.00321	-0.38	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68941503~68942852:-
COAD	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	4.52	9.38e-06	0.00321	0.42	0.27	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
COAD	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	4.52	9.39e-06	0.00321	0.52	0.27	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
COAD	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-4.52	9.39e-06	0.00321	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
COAD	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-4.52	9.39e-06	0.00322	-0.43	-0.27	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
COAD	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-4.52	9.4e-06	0.00322	-0.32	-0.27	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
COAD	cis	rs10895987	0.955	rs7114094	ENSG00000254614.2	AP003068.23	4.52	9.4e-06	0.00322	0.42	0.27	Blood protein levels;	chr11:65159740	chr11:65177606~65181834:-
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-4.52	9.4e-06	0.00322	-0.32	-0.27	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
COAD	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	4.52	9.4e-06	0.00322	0.31	0.27	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
COAD	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-4.52	9.41e-06	0.00322	-0.34	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
COAD	cis	rs2581828	0.608	rs9830353	ENSG00000280417.1	RP11-5O17.1	4.52	9.41e-06	0.00322	0.3	0.27	Crohn's disease;	chr3:53129937	chr3:53046166~53048122:+
COAD	cis	rs9951698	0.678	rs11080620	ENSG00000266969.1	RP11-773H22.4	-4.52	9.41e-06	0.00322	-0.32	-0.27	Intelligence (multi-trait analysis);	chr18:13029069	chr18:12984694~12991173:-
COAD	cis	rs2638953	0.64	rs11049718	ENSG00000247934.4	RP11-967K21.1	-4.52	9.41e-06	0.00322	-0.28	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28565739	chr12:28163298~28190738:-
COAD	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	4.52	9.42e-06	0.00322	0.31	0.27	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
COAD	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	4.52	9.42e-06	0.00322	0.37	0.27	Depression;	chr6:28206812	chr6:28943877~28944537:+
COAD	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-4.52	9.42e-06	0.00322	-0.28	-0.27	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
COAD	cis	rs2732480	0.538	rs1387259	ENSG00000257735.1	RP11-370I10.6	-4.52	9.42e-06	0.00322	-0.34	-0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48350945~48442411:+
COAD	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	4.52	9.42e-06	0.00322	0.25	0.27	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
COAD	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-4.52	9.43e-06	0.00322	-0.51	-0.27	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
COAD	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	4.52	9.43e-06	0.00323	0.3	0.27	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	4.52	9.43e-06	0.00323	0.3	0.27	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
COAD	cis	rs7829975	0.714	rs6994038	ENSG00000233609.3	RP11-62H7.2	4.52	9.43e-06	0.00323	0.3	0.27	Mood instability;	chr8:8803028	chr8:8961200~8979025:+
COAD	cis	rs77204473	0.744	rs12420361	ENSG00000254851.1	RP11-109L13.1	4.52	9.43e-06	0.00323	0.65	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117123072	chr11:117135528~117138582:+
COAD	cis	rs9307551	0.741	rs13128134	ENSG00000250334.4	LINC00989	-4.52	9.44e-06	0.00323	-0.37	-0.27	Refractive error;	chr4:79551143	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.741	rs10025630	ENSG00000250334.4	LINC00989	-4.52	9.44e-06	0.00323	-0.37	-0.27	Refractive error;	chr4:79551641	chr4:79492416~79576460:+
COAD	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	4.52	9.45e-06	0.00323	0.33	0.27	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
COAD	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	4.52	9.45e-06	0.00323	0.41	0.27	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	4.52	9.45e-06	0.00323	0.41	0.27	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
COAD	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-4.52	9.46e-06	0.00323	-0.43	-0.27	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
COAD	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-4.52	9.46e-06	0.00323	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
COAD	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-4.52	9.46e-06	0.00323	-0.37	-0.27	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
COAD	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	4.52	9.46e-06	0.00323	0.23	0.27	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
COAD	cis	rs4927850	0.958	rs1975582	ENSG00000273009.1	RP11-352G9.1	-4.52	9.46e-06	0.00323	-0.29	-0.27	Pancreatic cancer;	chr3:196024568	chr3:195913078~195913683:-
COAD	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-4.52	9.46e-06	0.00324	-0.52	-0.27	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-4.52	9.46e-06	0.00324	-0.52	-0.27	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-4.52	9.46e-06	0.00324	-0.52	-0.27	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-4.52	9.46e-06	0.00324	-0.52	-0.27	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-4.52	9.46e-06	0.00324	-0.52	-0.27	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
COAD	cis	rs6095360	0.727	rs755588	ENSG00000222365.1	SNORD12B	-4.52	9.46e-06	0.00324	-0.29	-0.27	Intelligence (multi-trait analysis);	chr20:49104491	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.727	rs13040292	ENSG00000222365.1	SNORD12B	-4.52	9.46e-06	0.00324	-0.29	-0.27	Intelligence (multi-trait analysis);	chr20:49105045	chr20:49280319~49280409:+
COAD	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-4.52	9.46e-06	0.00324	-0.32	-0.27	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
COAD	cis	rs6545883	0.507	rs12617371	ENSG00000273302.1	RP11-493E12.2	-4.52	9.47e-06	0.00324	-0.25	-0.27	Tuberculosis;	chr2:61341999	chr2:61199979~61200769:+
COAD	cis	rs875971	0.66	rs7807944	ENSG00000272831.1	RP11-792A8.4	-4.52	9.47e-06	0.00324	-0.29	-0.27	Aortic root size;	chr7:66622208	chr7:66739829~66740385:-
COAD	cis	rs875971	0.638	rs35986979	ENSG00000272831.1	RP11-792A8.4	-4.52	9.47e-06	0.00324	-0.29	-0.27	Aortic root size;	chr7:66624003	chr7:66739829~66740385:-
COAD	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-4.52	9.47e-06	0.00324	-0.31	-0.27	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
COAD	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	4.52	9.47e-06	0.00324	0.39	0.27	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
COAD	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	4.52	9.47e-06	0.00324	0.35	0.27	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
COAD	cis	rs7646881	0.544	rs17630785	ENSG00000272087.1	RP11-379F4.7	4.52	9.47e-06	0.00324	0.45	0.27	Tetralogy of Fallot;	chr3:158674437	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs12638363	ENSG00000272087.1	RP11-379F4.7	4.52	9.47e-06	0.00324	0.45	0.27	Tetralogy of Fallot;	chr3:158686969	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs59492803	ENSG00000272087.1	RP11-379F4.7	4.52	9.47e-06	0.00324	0.45	0.27	Tetralogy of Fallot;	chr3:158702908	chr3:158693120~158693768:-
COAD	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-4.52	9.47e-06	0.00324	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
COAD	cis	rs2342406	0.825	rs6704663	ENSG00000259439.2	RP11-89K21.1	4.52	9.48e-06	0.00324	0.45	0.27	Myopia;	chr2:44913477	chr2:44921077~44939199:-
COAD	cis	rs2916733	0.607	rs1129704	ENSG00000246089.3	RP11-115C21.2	-4.52	9.48e-06	0.00324	-0.35	-0.27	Epirubicin-induced leukopenia;	chr8:6447209	chr8:6403551~6407142:-
COAD	cis	rs9307551	0.741	rs1971838	ENSG00000250334.4	LINC00989	-4.52	9.48e-06	0.00324	-0.35	-0.27	Refractive error;	chr4:79497477	chr4:79492416~79576460:+
COAD	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	4.52	9.49e-06	0.00324	0.3	0.27	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
COAD	cis	rs989978	1	rs7903634	ENSG00000257582.4	LINC01475	-4.52	9.49e-06	0.00324	-0.31	-0.27	Red blood cell count;	chr10:99562437	chr10:99526350~99531177:-
COAD	cis	rs9467773	0.595	rs12525810	ENSG00000224843.5	LINC00240	4.52	9.5e-06	0.00325	0.46	0.27	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26956992~27023924:+
COAD	cis	rs453301	0.658	rs9329175	ENSG00000233609.3	RP11-62H7.2	-4.52	9.5e-06	0.00325	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9009151	chr8:8961200~8979025:+
COAD	cis	rs8177876	1	rs8177876	ENSG00000261061.1	RP11-303E16.2	-4.52	9.5e-06	0.00325	-0.55	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81030770~81031485:+
COAD	cis	rs7193541	0.965	rs7199068	ENSG00000262904.1	TMPOP2	-4.52	9.51e-06	0.00325	-0.29	-0.27	Multiple myeloma;	chr16:74664365	chr16:74667506~74668706:+
COAD	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-4.52	9.51e-06	0.00325	-0.32	-0.27	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-4.52	9.51e-06	0.00325	-0.32	-0.27	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
COAD	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	4.52	9.51e-06	0.00325	0.33	0.27	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
COAD	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.38	0.27	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.38	0.27	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.38	0.27	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
COAD	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.38	0.27	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs11509187	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.43	0.27	Bladder cancer (smoking interaction);	chr7:107134008	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs113752881	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.43	0.27	Bladder cancer (smoking interaction);	chr7:107134646	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs74382914	ENSG00000241764.3	AC002467.7	4.52	9.52e-06	0.00325	0.43	0.27	Bladder cancer (smoking interaction);	chr7:107134719	chr7:107742817~107744581:-
COAD	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-4.52	9.52e-06	0.00325	-0.32	-0.27	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
COAD	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.52	9.53e-06	0.00325	-0.28	-0.27	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
COAD	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-4.52	9.53e-06	0.00325	-0.27	-0.27	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
COAD	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	4.52	9.53e-06	0.00325	0.27	0.27	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
COAD	cis	rs8022206	0.673	rs9323502	ENSG00000259502.1	RP11-643G16.3	4.52	9.53e-06	0.00325	0.36	0.27	Platelet count;Mean platelet volume;	chr14:68081759	chr14:67610986~67613864:+
COAD	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	4.52	9.54e-06	0.00325	0.42	0.27	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	4.52	9.54e-06	0.00325	0.42	0.27	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
COAD	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	4.52	9.54e-06	0.00325	0.42	0.27	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
COAD	cis	rs2617170	0.922	rs2250877	ENSG00000245648.1	RP11-277P12.20	4.52	9.54e-06	0.00325	0.37	0.27	Behcet's disease;	chr12:10393659	chr12:10363769~10398506:+
COAD	cis	rs11976180	1	rs1540894	ENSG00000273234.1	OR2A13P	-4.52	9.54e-06	0.00326	-0.34	-0.27	Obesity-related traits;	chr7:144070583	chr7:144142009~144142938:+
COAD	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	4.52	9.54e-06	0.00326	0.33	0.27	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
COAD	cis	rs7829975	0.658	rs907181	ENSG00000173295.6	FAM86B3P	4.52	9.54e-06	0.00326	0.32	0.27	Mood instability;	chr8:8845365	chr8:8228595~8244865:+
COAD	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-4.52	9.54e-06	0.00326	-0.18	-0.27	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
COAD	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	4.52	9.55e-06	0.00326	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	4.52	9.55e-06	0.00326	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	4.52	9.55e-06	0.00326	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
COAD	cis	rs3120667	0.72	rs12067942	ENSG00000237975.5	FLG-AS1	4.52	9.56e-06	0.00326	0.34	0.27	Eating disorders;	chr1:152430794	chr1:152168125~152445456:+
COAD	cis	rs72827839	0.79	rs116944299	ENSG00000263412.1	RP5-890E16.2	4.52	9.56e-06	0.00326	0.4	0.27	Ease of getting up in the morning;	chr17:48190403	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.846	rs74992250	ENSG00000263412.1	RP5-890E16.2	4.52	9.56e-06	0.00326	0.4	0.27	Ease of getting up in the morning;	chr17:48195624	chr17:48045141~48048073:-
COAD	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-4.52	9.56e-06	0.00326	-0.32	-0.27	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
COAD	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	4.52	9.56e-06	0.00326	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-4.52	9.56e-06	0.00326	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
COAD	cis	rs9847710	0.869	rs2581793	ENSG00000280417.1	RP11-5O17.1	-4.52	9.57e-06	0.00326	-0.28	-0.27	Ulcerative colitis;	chr3:53001639	chr3:53046166~53048122:+
COAD	cis	rs875971	0.522	rs2949690	ENSG00000272831.1	RP11-792A8.4	-4.52	9.57e-06	0.00326	-0.29	-0.27	Aortic root size;	chr7:66018255	chr7:66739829~66740385:-
COAD	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	4.52	9.57e-06	0.00326	0.33	0.27	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
COAD	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-4.52	9.57e-06	0.00326	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
COAD	cis	rs385076	0.562	rs1119292	ENSG00000272716.1	RP11-563N4.1	-4.52	9.57e-06	0.00326	-0.31	-0.27	Interleukin-18 levels;	chr2:31820704	chr2:32165046~32165757:-
COAD	cis	rs5758511	0.731	rs58302269	ENSG00000237037.8	NDUFA6-AS1	-4.52	9.57e-06	0.00326	-0.3	-0.27	Birth weight;	chr22:41955305	chr22:42090931~42137742:+
COAD	cis	rs9549328	0.837	rs9549618	ENSG00000267868.1	RP11-120K24.3	4.52	9.57e-06	0.00326	0.36	0.27	Systolic blood pressure;	chr13:112974334	chr13:112964835~112966131:-
COAD	cis	rs2378497	1	rs12137305	ENSG00000232679.1	RP11-400N13.3	4.52	9.57e-06	0.00326	0.34	0.27	Serum thyroid-stimulating hormone levels;	chr1:222047359	chr1:222041705~222064763:-
COAD	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	4.52	9.57e-06	0.00326	0.33	0.27	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
COAD	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-4.52	9.57e-06	0.00327	-0.28	-0.27	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
COAD	cis	rs2281603	0.52	rs61985663	ENSG00000259116.1	RP11-973N13.4	-4.52	9.57e-06	0.00327	-0.27	-0.27	Lymphocyte counts;	chr14:64470986	chr14:64514154~64540368:-
COAD	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-4.52	9.57e-06	0.00327	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
COAD	cis	rs9951698	0.678	rs527839	ENSG00000266969.1	RP11-773H22.4	4.52	9.58e-06	0.00327	0.35	0.27	Intelligence (multi-trait analysis);	chr18:13087816	chr18:12984694~12991173:-
COAD	cis	rs7615952	0.688	rs17334074	ENSG00000272840.1	RP11-379B18.6	-4.52	9.58e-06	0.00327	-0.37	-0.27	Blood pressure (smoking interaction);	chr3:125821617	chr3:125774714~125797953:+
COAD	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	4.52	9.59e-06	0.00327	0.44	0.27	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
COAD	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	4.52	9.59e-06	0.00327	0.44	0.27	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
COAD	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	4.52	9.59e-06	0.00327	0.3	0.27	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
COAD	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-4.52	9.59e-06	0.00327	-0.31	-0.27	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-4.52	9.59e-06	0.00327	-0.31	-0.27	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-4.52	9.59e-06	0.00327	-0.31	-0.27	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-4.52	9.59e-06	0.00327	-0.31	-0.27	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-4.52	9.59e-06	0.00327	-0.31	-0.27	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
COAD	cis	rs6921919	0.638	rs1416920	ENSG00000272009.1	RP1-313I6.12	4.52	9.6e-06	0.00327	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28078792~28081130:-
COAD	cis	rs6921919	0.525	rs1361386	ENSG00000272009.1	RP1-313I6.12	4.52	9.6e-06	0.00327	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28078792~28081130:-
COAD	cis	rs6921919	0.638	rs6456815	ENSG00000272009.1	RP1-313I6.12	4.52	9.6e-06	0.00327	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28078792~28081130:-
COAD	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	4.52	9.6e-06	0.00327	0.47	0.27	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
COAD	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-4.52	9.6e-06	0.00327	-0.32	-0.27	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
COAD	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-4.52	9.6e-06	0.00327	-0.32	-0.27	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
COAD	cis	rs7674212	0.541	rs2623070	ENSG00000230069.3	LRRC37A15P	4.52	9.6e-06	0.00327	0.29	0.27	Type 2 diabetes;	chr4:103116231	chr4:102727274~102730721:-
COAD	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-4.52	9.61e-06	0.00327	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
COAD	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	4.52	9.61e-06	0.00328	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	4.52	9.61e-06	0.00328	0.31	0.27	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
COAD	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	4.52	9.61e-06	0.00328	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
COAD	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	4.52	9.61e-06	0.00328	0.33	0.27	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
COAD	cis	rs1044826	0.642	rs2071388	ENSG00000272656.1	RP11-219D15.3	-4.52	9.62e-06	0.00328	-0.32	-0.27	Obesity-related traits;	chr3:139517841	chr3:139349024~139349371:-
COAD	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-4.52	9.62e-06	0.00328	-0.34	-0.27	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
COAD	cis	rs62184315	0.638	rs12475694	ENSG00000253559.1	OSGEPL1-AS1	4.52	9.62e-06	0.00328	0.27	0.27	Alcohol dependence (age at onset);	chr2:189907882	chr2:189762704~189765556:+
COAD	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-4.52	9.62e-06	0.00328	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
COAD	cis	rs7260598	0.502	rs59816383	ENSG00000268442.1	CTD-2027I19.2	4.52	9.62e-06	0.00328	0.5	0.27	Response to taxane treatment (placlitaxel);	chr19:23836786	chr19:24162370~24163425:-
COAD	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	4.52	9.63e-06	0.00328	0.32	0.27	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
COAD	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-4.52	9.63e-06	0.00328	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
COAD	cis	rs6676180	0.514	rs868675	ENSG00000231365.4	RP11-418J17.1	-4.52	9.63e-06	0.00328	-0.29	-0.27	Monobrow;	chr1:119230973	chr1:119140396~119275973:+
COAD	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-4.52	9.64e-06	0.00328	-0.69	-0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
COAD	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	4.52	9.65e-06	0.00329	0.27	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
COAD	cis	rs3126085	0.56	rs2065954	ENSG00000237975.5	FLG-AS1	4.51	9.65e-06	0.00329	0.33	0.27	Atopic dermatitis;	chr1:152348868	chr1:152168125~152445456:+
COAD	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-4.51	9.65e-06	0.00329	-0.26	-0.27	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
COAD	cis	rs9487051	0.844	rs9386792	ENSG00000219700.1	PTCHD3P3	4.51	9.65e-06	0.00329	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109288772	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9398197	ENSG00000219700.1	PTCHD3P3	4.51	9.65e-06	0.00329	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109288785	chr6:109288571~109290503:-
COAD	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	4.51	9.65e-06	0.00329	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
COAD	cis	rs7560272	0.723	rs13386124	ENSG00000163016.8	ALMS1P	4.51	9.66e-06	0.00329	0.34	0.27	Schizophrenia;	chr2:73544568	chr2:73644919~73685576:+
COAD	cis	rs7646881	1	rs59918529	ENSG00000272087.1	RP11-379F4.7	4.51	9.66e-06	0.00329	0.39	0.27	Tetralogy of Fallot;	chr3:158734916	chr3:158693120~158693768:-
COAD	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.51	9.67e-06	0.00329	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
COAD	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-4.51	9.68e-06	0.0033	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-4.51	9.68e-06	0.0033	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-4.51	9.68e-06	0.0033	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-4.51	9.68e-06	0.0033	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
COAD	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	4.51	9.68e-06	0.0033	0.3	0.27	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
COAD	cis	rs3126085	0.56	rs3818831	ENSG00000237975.5	FLG-AS1	4.51	9.69e-06	0.0033	0.31	0.27	Atopic dermatitis;	chr1:152358764	chr1:152168125~152445456:+
COAD	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-4.51	9.69e-06	0.0033	-0.15	-0.27	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
COAD	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	4.51	9.7e-06	0.0033	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
COAD	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-4.51	9.7e-06	0.0033	-0.34	-0.27	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
COAD	cis	rs763121	0.853	rs5750627	ENSG00000273076.1	RP3-508I15.22	4.51	9.71e-06	0.0033	0.23	0.27	Menopause (age at onset);	chr22:38586316	chr22:38743495~38743910:+
COAD	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	4.51	9.72e-06	0.00331	0.25	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
COAD	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.51	9.73e-06	0.00331	-0.34	-0.27	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
COAD	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-4.51	9.73e-06	0.00331	-0.32	-0.27	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
COAD	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	4.51	9.73e-06	0.00331	0.4	0.27	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
COAD	cis	rs10083777	0.551	rs111889995	ENSG00000261061.1	RP11-303E16.2	-4.51	9.73e-06	0.00331	-0.5	-0.27	Metabolite levels (small molecules and protein measures);	chr16:81000166	chr16:81030770~81031485:+
COAD	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	4.51	9.74e-06	0.00331	0.31	0.27	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
COAD	cis	rs2255336	0.657	rs11053765	ENSG00000245648.1	RP11-277P12.20	4.51	9.74e-06	0.00331	0.49	0.27	Blood protein levels;	chr12:10351365	chr12:10363769~10398506:+
COAD	cis	rs4820539	0.966	rs2267000	ENSG00000211644.2	IGLV1-51	-4.51	9.75e-06	0.00332	-0.15	-0.27	Bone mineral density;	chr22:23113179	chr22:22322472~22322980:+
COAD	cis	rs9951698	0.678	rs482577	ENSG00000266969.1	RP11-773H22.4	4.51	9.77e-06	0.00332	0.33	0.27	Intelligence (multi-trait analysis);	chr18:13148618	chr18:12984694~12991173:-
COAD	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	4.51	9.77e-06	0.00332	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
COAD	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-4.51	9.77e-06	0.00332	-0.36	-0.27	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
COAD	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-4.51	9.77e-06	0.00332	-0.32	-0.27	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
COAD	cis	rs2439831	0.618	rs8023508	ENSG00000166763.7	STRCP1	4.51	9.78e-06	0.00333	0.36	0.27	Lung cancer in ever smokers;	chr15:43883905	chr15:43699488~43718184:-
COAD	cis	rs9951698	0.678	rs576963	ENSG00000266969.1	RP11-773H22.4	-4.51	9.79e-06	0.00333	-0.33	-0.27	Intelligence (multi-trait analysis);	chr18:13145265	chr18:12984694~12991173:-
COAD	cis	rs1387259	0.839	rs7487682	ENSG00000273765.1	RP11-370I10.11	-4.51	9.8e-06	0.00333	-0.28	-0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48360920~48361377:+
COAD	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-4.51	9.8e-06	0.00333	-0.43	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
COAD	cis	rs2732480	0.5	rs12829841	ENSG00000257735.1	RP11-370I10.6	4.51	9.81e-06	0.00333	0.34	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.523	rs34286639	ENSG00000257735.1	RP11-370I10.6	4.51	9.81e-06	0.00333	0.34	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48350945~48442411:+
COAD	cis	rs1387259	0.929	rs11168484	ENSG00000257735.1	RP11-370I10.6	4.51	9.81e-06	0.00333	0.34	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48350945~48442411:+
COAD	cis	rs9951698	0.703	rs1787008	ENSG00000266969.1	RP11-773H22.4	4.51	9.82e-06	0.00334	0.35	0.27	Intelligence (multi-trait analysis);	chr18:13058319	chr18:12984694~12991173:-
COAD	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	4.51	9.82e-06	0.00334	0.34	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
COAD	cis	rs2070074	0.591	rs12352811	ENSG00000230074.1	RP11-195F19.9	4.51	9.82e-06	0.00334	0.5	0.27	CTACK levels;	chr9:34614684	chr9:34665665~34681298:+
COAD	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	4.51	9.82e-06	0.00334	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
COAD	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	4.51	9.82e-06	0.00334	0.27	0.27	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
COAD	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-4.51	9.83e-06	0.00334	-0.27	-0.27	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
COAD	cis	rs11700536	0.54	rs8132259	ENSG00000236663.1	AP001631.9	4.51	9.83e-06	0.00334	0.34	0.27	Interleukin-18 levels;	chr21:43129548	chr21:43140523~43141092:-
COAD	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	4.51	9.84e-06	0.00334	0.44	0.27	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	4.51	9.84e-06	0.00334	0.44	0.27	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	4.51	9.84e-06	0.00334	0.44	0.27	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	4.51	9.84e-06	0.00334	0.44	0.27	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
COAD	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	4.51	9.84e-06	0.00334	0.33	0.27	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
COAD	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	4.51	9.85e-06	0.00335	0.31	0.27	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	4.51	9.85e-06	0.00335	0.31	0.27	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
COAD	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-4.51	9.85e-06	0.00335	-0.4	-0.27	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
COAD	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-4.51	9.85e-06	0.00335	-0.32	-0.27	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
COAD	cis	rs1387259	0.839	rs7486941	ENSG00000257735.1	RP11-370I10.6	-4.51	9.85e-06	0.00335	-0.31	-0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48350945~48442411:+
COAD	cis	rs734999	0.588	rs10910099	ENSG00000225931.3	RP3-395M20.7	-4.51	9.85e-06	0.00335	-0.29	-0.27	Ulcerative colitis;	chr1:2602113	chr1:2566410~2569888:+
COAD	cis	rs73198271	0.96	rs73198286	ENSG00000173295.6	FAM86B3P	-4.51	9.86e-06	0.00335	-0.39	-0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr8:8228595~8244865:+
COAD	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	4.51	9.86e-06	0.00335	0.31	0.27	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
COAD	cis	rs7818688	0.745	rs16917117	ENSG00000253528.2	RP11-347C18.4	4.51	9.87e-06	0.00335	0.38	0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94897270	chr8:94974573~94974853:-
COAD	cis	rs11681884	0.71	rs3213448	ENSG00000228251.1	AC012442.6	4.51	9.87e-06	0.00335	0.46	0.27	Stroke;	chr2:113121720	chr2:112590796~112591939:+
COAD	cis	rs1964356	0.967	rs17701675	ENSG00000233609.3	RP11-62H7.2	-4.51	9.88e-06	0.00335	-0.3	-0.27	Mean corpuscular volume;	chr8:8993123	chr8:8961200~8979025:+
COAD	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-4.51	9.88e-06	0.00335	-0.32	-0.27	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
COAD	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-4.51	9.88e-06	0.00335	-0.32	-0.27	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
COAD	cis	rs7615952	0.599	rs2333408	ENSG00000248787.1	RP11-666A20.4	-4.51	9.89e-06	0.00336	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:126013255	chr3:125908005~125910272:-
COAD	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	4.51	9.89e-06	0.00336	0.27	0.27	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
COAD	cis	rs8022206	0.773	rs12100584	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67913058	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs4902535	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67916662	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs4902536	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67918073	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs2877369	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67919892	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs17104776	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67921554	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs11626280	ENSG00000259502.1	RP11-643G16.3	4.51	9.89e-06	0.00336	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67931834	chr14:67610986~67613864:+
COAD	cis	rs71636778	0.509	rs34728853	ENSG00000260063.1	RP5-968P14.2	-4.51	9.89e-06	0.00336	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26674088	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs35989952	ENSG00000260063.1	RP5-968P14.2	-4.51	9.89e-06	0.00336	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26678663	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71640338	ENSG00000260063.1	RP5-968P14.2	-4.51	9.89e-06	0.00336	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26684958	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12754468	ENSG00000260063.1	RP5-968P14.2	-4.51	9.89e-06	0.00336	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26688257	chr1:26692132~26694131:-
COAD	cis	rs494562	0.892	rs632163	ENSG00000234155.1	RP11-30P6.6	-4.51	9.9e-06	0.00336	-0.46	-0.27	Metabolic traits;Blood metabolite levels;	chr6:85412344	chr6:85387219~85390186:-
COAD	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-4.51	9.9e-06	0.00336	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
COAD	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.51	9.91e-06	0.00336	0.28	0.27	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
COAD	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	4.51	9.92e-06	0.00337	0.27	0.27	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
COAD	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-4.51	9.92e-06	0.00337	-0.21	-0.27	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
COAD	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-4.51	9.92e-06	0.00337	-0.28	-0.27	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-4.51	9.92e-06	0.00337	-0.28	-0.27	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-4.51	9.92e-06	0.00337	-0.28	-0.27	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
COAD	cis	rs41307935	0.818	rs80036989	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26721033	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12756074	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26721402	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71636773	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724828	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs60401377	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26725756	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.818	rs35145624	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26726121	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs35256560	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26727525	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs56932185	ENSG00000260063.1	RP5-968P14.2	-4.51	9.93e-06	0.00337	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26730152	chr1:26692132~26694131:-
COAD	cis	rs6840360	0.582	rs1372976	ENSG00000251611.1	RP11-610P16.1	-4.51	9.93e-06	0.00337	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.642	rs1443090	ENSG00000251611.1	RP11-610P16.1	-4.51	9.93e-06	0.00337	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151407551~151408835:-
COAD	cis	rs875971	0.66	rs13224319	ENSG00000272831.1	RP11-792A8.4	4.51	9.93e-06	0.00337	0.28	0.27	Aortic root size;	chr7:66542376	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs801217	ENSG00000272831.1	RP11-792A8.4	-4.51	9.93e-06	0.00337	-0.28	-0.27	Aortic root size;	chr7:66545590	chr7:66739829~66740385:-
COAD	cis	rs6840360	0.642	rs2709819	ENSG00000251611.1	RP11-610P16.1	-4.51	9.94e-06	0.00337	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151407551~151408835:-
COAD	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	4.51	9.94e-06	0.00337	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
COAD	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	4.51	9.95e-06	0.00337	0.35	0.27	Depression;	chr6:28200948	chr6:28115628~28116551:+
COAD	cis	rs4704187	0.687	rs4703657	ENSG00000250889.2	LINC01336	-4.51	9.95e-06	0.00338	-0.31	-0.27	Response to amphetamines;	chr5:75166025	chr5:75047719~75052843:-
COAD	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	4.51	9.95e-06	0.00338	0.43	0.27	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
COAD	cis	rs7209700	0.547	rs11657517	ENSG00000228782.6	CTD-2026D20.3	-4.51	9.96e-06	0.00338	-0.32	-0.27	IgG glycosylation;	chr17:47266347	chr17:47450568~47492492:-
COAD	cis	rs28374715	0.681	rs8037574	ENSG00000247556.5	OIP5-AS1	4.51	9.96e-06	0.00338	0.33	0.27	Ulcerative colitis;	chr15:41338572	chr15:41283990~41309737:+
COAD	cis	rs7032317	0.666	rs11243980	ENSG00000170827.8	CELP	-4.51	9.96e-06	0.00338	-0.23	-0.27	Calcium levels;	chr9:133012559	chr9:133079900~133087355:+
COAD	cis	rs7032317	0.666	rs10119905	ENSG00000170827.8	CELP	-4.51	9.96e-06	0.00338	-0.23	-0.27	Calcium levels;	chr9:133013643	chr9:133079900~133087355:+
COAD	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-4.51	9.97e-06	0.00338	-0.36	-0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
COAD	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-4.51	9.97e-06	0.00338	-0.33	-0.27	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
COAD	cis	rs2732480	0.577	rs2634684	ENSG00000257735.1	RP11-370I10.6	-4.51	9.97e-06	0.00338	-0.34	-0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48350945~48442411:+
COAD	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	4.51	9.98e-06	0.00338	0.35	0.27	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	4.51	9.98e-06	0.00338	0.35	0.27	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	4.51	9.98e-06	0.00338	0.35	0.27	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
COAD	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-4.51	9.98e-06	0.00338	-0.38	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
COAD	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-4.51	9.99e-06	0.00339	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
COAD	cis	rs9487051	0.676	rs9386788	ENSG00000219700.1	PTCHD3P3	-4.51	9.99e-06	0.00339	-0.29	-0.27	Reticulocyte fraction of red cells;	chr6:109279320	chr6:109288571~109290503:-
COAD	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	4.51	9.99e-06	0.00339	0.34	0.27	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
COAD	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-4.51	1e-05	0.00339	-0.43	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
COAD	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	4.51	1e-05	0.00339	0.34	0.27	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	4.51	1e-05	0.00339	0.34	0.27	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	4.51	1e-05	0.00339	0.34	0.27	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	4.51	1e-05	0.00339	0.34	0.27	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
COAD	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	4.51	1e-05	0.00339	0.34	0.27	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
COAD	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	4.51	1e-05	0.00339	0.33	0.27	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
COAD	cis	rs875971	0.642	rs35526611	ENSG00000272831.1	RP11-792A8.4	-4.51	1e-05	0.0034	-0.28	-0.27	Aortic root size;	chr7:66629021	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs3764903	ENSG00000272831.1	RP11-792A8.4	-4.51	1e-05	0.0034	-0.28	-0.27	Aortic root size;	chr7:66633495	chr7:66739829~66740385:-
COAD	cis	rs875971	0.66	rs1860470	ENSG00000272831.1	RP11-792A8.4	-4.51	1e-05	0.0034	-0.28	-0.27	Aortic root size;	chr7:66638707	chr7:66739829~66740385:-
COAD	cis	rs2617170	0.961	rs11053802	ENSG00000245648.1	RP11-277P12.20	4.51	1e-05	0.0034	0.35	0.27	Behcet's disease;	chr12:10444608	chr12:10363769~10398506:+
COAD	cis	rs2337406	0.5	rs7152934	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106778702	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.789	rs12050392	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779073	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092505	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779163	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.789	rs74092507	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779174	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092511	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779234	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092512	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779306	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.789	rs74092514	ENSG00000211967.3	IGHV3-53	-4.51	1e-05	0.0034	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779385	chr14:106592676~106593347:-
COAD	cis	rs1510272	1	rs1510273	ENSG00000243926.1	TIPARP-AS1	-4.51	1e-05	0.0034	-0.3	-0.27	Testicular germ cell tumor;	chr3:156583033	chr3:156671862~156674378:-
COAD	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	4.51	1e-05	0.0034	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
COAD	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-4.51	1e-05	0.0034	-0.26	-0.27	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
COAD	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	4.51	1e-05	0.0034	0.3	0.27	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-4.51	1e-05	0.0034	-0.28	-0.27	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-4.51	1e-05	0.0034	-0.28	-0.27	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-4.51	1e-05	0.0034	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-4.51	1e-05	0.0034	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
COAD	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-4.51	1e-05	0.0034	-0.3	-0.27	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
COAD	cis	rs9532669	0.889	rs6560964	ENSG00000239827.7	SUGT1P3	-4.51	1e-05	0.0034	-0.23	-0.27	Cervical cancer;	chr13:40871132	chr13:40908159~40921774:-
COAD	cis	rs6461992	0.51	rs62454369	ENSG00000253405.1	EVX1-AS	4.51	1e-05	0.0034	0.71	0.27	Systolic blood pressure;	chr7:27059185	chr7:27241429~27247229:-
COAD	cis	rs6461992	0.51	rs62454370	ENSG00000253405.1	EVX1-AS	4.51	1e-05	0.0034	0.71	0.27	Systolic blood pressure;	chr7:27059380	chr7:27241429~27247229:-
COAD	cis	rs7646881	0.812	rs74618709	ENSG00000272087.1	RP11-379F4.7	4.51	1e-05	0.0034	0.39	0.27	Tetralogy of Fallot;	chr3:158737492	chr3:158693120~158693768:-
COAD	cis	rs9291683	0.588	rs4697705	ENSG00000250413.1	RP11-448G15.1	4.51	1e-05	0.0034	0.34	0.27	Bone mineral density;	chr4:10106503	chr4:10006482~10009725:+
COAD	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-4.51	1.01e-05	0.0034	-0.28	-0.27	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
COAD	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-4.51	1.01e-05	0.00341	-0.29	-0.27	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
COAD	cis	rs597539	0.652	rs673821	ENSG00000255741.1	RP11-757G1.5	-4.51	1.01e-05	0.00341	-0.36	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68941503~68942852:-
COAD	cis	rs2337406	0.714	rs117798641	ENSG00000211967.3	IGHV3-53	-4.51	1.01e-05	0.00341	-0.2	-0.27	Alzheimer's disease (late onset);	chr14:106777984	chr14:106592676~106593347:-
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	4.51	1.01e-05	0.00341	0.27	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
COAD	cis	rs7955901	0.539	rs1495381	ENSG00000258053.1	CTD-2021H9.3	-4.51	1.01e-05	0.00341	-0.31	-0.27	Type 2 diabetes;	chr12:71135948	chr12:71047402~71118247:-
COAD	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	4.51	1.01e-05	0.00341	0.34	0.27	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
COAD	cis	rs9400467	0.528	rs11153280	ENSG00000271789.1	RP5-1112D6.7	-4.51	1.01e-05	0.00341	-0.26	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111297126~111298510:+
COAD	cis	rs1900504	0.614	rs2915761	ENSG00000266200.5	PNLIPRP2	-4.5	1.01e-05	0.00342	-0.35	-0.27	Tonsillectomy;	chr10:116601682	chr10:116620953~116645143:+
COAD	cis	rs17772222	0.917	rs61986669	ENSG00000258789.1	RP11-507K2.3	-4.5	1.01e-05	0.00342	-0.42	-0.27	Coronary artery calcification;	chr14:88727121	chr14:88551597~88552493:+
COAD	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	4.5	1.01e-05	0.00342	0.38	0.27	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
COAD	cis	rs6565180	0.926	rs4788413	ENSG00000183604.13	SMG1P5	4.5	1.01e-05	0.00342	0.31	0.27	Tonsillectomy;	chr16:30399124	chr16:30267553~30335374:-
COAD	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.5	1.01e-05	0.00342	0.27	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
COAD	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-4.5	1.01e-05	0.00343	-0.47	-0.27	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
COAD	cis	rs7577696	0.524	rs805831	ENSG00000272716.1	RP11-563N4.1	4.5	1.01e-05	0.00343	0.31	0.27	Inflammatory biomarkers;	chr2:32259159	chr2:32165046~32165757:-
COAD	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	4.5	1.01e-05	0.00343	0.42	0.27	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
COAD	cis	rs728616	0.717	rs17098169	ENSG00000225484.5	NUTM2B-AS1	4.5	1.01e-05	0.00343	0.47	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79663088~79826594:-
COAD	cis	rs9532669	1	rs9532669	ENSG00000277662.1	RP11-74J13.9	-4.5	1.01e-05	0.00343	-0.26	-0.27	Cervical cancer;	chr13:40927414	chr13:41229180~41229676:-
COAD	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-4.5	1.01e-05	0.00343	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-4.5	1.01e-05	0.00343	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
COAD	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-4.5	1.01e-05	0.00343	-0.44	-0.27	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
COAD	cis	rs875971	0.619	rs10278371	ENSG00000272831.1	RP11-792A8.4	-4.5	1.01e-05	0.00343	-0.29	-0.27	Aortic root size;	chr7:66586553	chr7:66739829~66740385:-
COAD	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	4.5	1.01e-05	0.00343	0.16	0.27	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
COAD	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-4.5	1.02e-05	0.00343	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-4.5	1.02e-05	0.00343	-0.32	-0.27	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	4.5	1.02e-05	0.00343	0.35	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
COAD	cis	rs17772222	1	rs17772222	ENSG00000258789.1	RP11-507K2.3	4.5	1.02e-05	0.00344	0.38	0.27	Coronary artery calcification;	chr14:88360138	chr14:88551597~88552493:+
COAD	cis	rs7615952	0.546	rs4428131	ENSG00000248787.1	RP11-666A20.4	-4.5	1.02e-05	0.00344	-0.42	-0.27	Blood pressure (smoking interaction);	chr3:125627635	chr3:125908005~125910272:-
COAD	cis	rs67696533	0.957	rs293567	ENSG00000224452.1	RSL24D1P6	-4.5	1.02e-05	0.00344	-0.33	-0.27	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32510762	chr20:32170390~32170790:-
COAD	cis	rs2408955	0.522	rs7139330	ENSG00000273765.1	RP11-370I10.11	-4.5	1.02e-05	0.00344	-0.28	-0.27	Glycated hemoglobin levels;	chr12:48089701	chr12:48360920~48361377:+
COAD	cis	rs2408955	0.522	rs2051851	ENSG00000273765.1	RP11-370I10.11	-4.5	1.02e-05	0.00344	-0.28	-0.27	Glycated hemoglobin levels;	chr12:48092157	chr12:48360920~48361377:+
COAD	cis	rs2408955	0.522	rs973398	ENSG00000273765.1	RP11-370I10.11	-4.5	1.02e-05	0.00344	-0.28	-0.27	Glycated hemoglobin levels;	chr12:48097265	chr12:48360920~48361377:+
COAD	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-4.5	1.02e-05	0.00344	-0.38	-0.27	Depression;	chr6:28091242	chr6:28115628~28116551:+
COAD	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	4.5	1.02e-05	0.00344	0.44	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
COAD	cis	rs6490294	0.861	rs2106956	ENSG00000257595.2	RP3-473L9.4	4.5	1.02e-05	0.00344	0.4	0.27	Mean platelet volume;	chr12:111981114	chr12:111369282~111403310:+
COAD	cis	rs7577696	0.606	rs212747	ENSG00000272716.1	RP11-563N4.1	4.5	1.02e-05	0.00344	0.32	0.27	Inflammatory biomarkers;	chr2:32189635	chr2:32165046~32165757:-
COAD	cis	rs10857712	0.904	rs7083614	ENSG00000214279.11	SCART1	-4.5	1.02e-05	0.00344	-0.33	-0.27	Systemic lupus erythematosus;	chr10:133412732	chr10:133453928~133523558:+
COAD	cis	rs6840360	0.558	rs2709821	ENSG00000251611.1	RP11-610P16.1	-4.5	1.02e-05	0.00344	-0.26	-0.27	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151407551~151408835:-
COAD	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	4.5	1.02e-05	0.00344	0.27	0.27	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	4.5	1.02e-05	0.00344	0.27	0.27	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	4.5	1.02e-05	0.00344	0.27	0.27	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	4.5	1.02e-05	0.00344	0.27	0.27	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
COAD	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-4.5	1.02e-05	0.00344	-0.28	-0.27	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
COAD	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	4.5	1.02e-05	0.00345	0.3	0.27	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
COAD	cis	rs17772222	0.917	rs61984683	ENSG00000258789.1	RP11-507K2.3	-4.5	1.02e-05	0.00345	-0.39	-0.27	Coronary artery calcification;	chr14:88553162	chr14:88551597~88552493:+
COAD	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-4.5	1.02e-05	0.00345	-0.28	-0.27	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
COAD	cis	rs7961581	0.644	rs1533104	ENSG00000258053.1	CTD-2021H9.3	4.5	1.02e-05	0.00345	0.32	0.27	Type 2 diabetes;	chr12:71262767	chr12:71047402~71118247:-
COAD	cis	rs10083777	0.551	rs79378252	ENSG00000261061.1	RP11-303E16.2	-4.5	1.02e-05	0.00345	-0.5	-0.27	Metabolite levels (small molecules and protein measures);	chr16:81014554	chr16:81030770~81031485:+
COAD	cis	rs8022206	0.704	rs7155840	ENSG00000259502.1	RP11-643G16.3	4.5	1.02e-05	0.00345	0.35	0.27	Platelet count;Mean platelet volume;	chr14:67951112	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.704	rs9323501	ENSG00000259502.1	RP11-643G16.3	4.5	1.02e-05	0.00345	0.35	0.27	Platelet count;Mean platelet volume;	chr14:67958343	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.704	rs28444723	ENSG00000259502.1	RP11-643G16.3	4.5	1.02e-05	0.00345	0.35	0.27	Platelet count;Mean platelet volume;	chr14:67962925	chr14:67610986~67613864:+
COAD	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	4.5	1.02e-05	0.00345	0.28	0.27	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
COAD	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-4.5	1.02e-05	0.00345	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
COAD	cis	rs6452524	0.618	rs6452504	ENSG00000271862.1	RP11-343L5.2	4.5	1.02e-05	0.00346	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83049376~83050964:-
COAD	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	4.5	1.02e-05	0.00346	0.32	0.27	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
COAD	cis	rs6452524	0.618	rs6452506	ENSG00000271862.1	RP11-343L5.2	4.5	1.03e-05	0.00346	0.27	0.27	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83049376~83050964:-
COAD	cis	rs9400467	0.528	rs459403	ENSG00000271789.1	RP5-1112D6.7	-4.5	1.03e-05	0.00346	-0.26	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111297126~111298510:+
COAD	cis	rs2115630	0.967	rs8028490	ENSG00000259728.4	LINC00933	-4.5	1.03e-05	0.00346	-0.32	-0.27	P wave terminal force;	chr15:84734657	chr15:84570649~84580175:+
COAD	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-4.5	1.03e-05	0.00347	-0.37	-0.27	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
COAD	cis	rs5758511	0.773	rs10154700	ENSG00000182057.4	OGFRP1	-4.5	1.03e-05	0.00347	-0.31	-0.27	Birth weight;	chr22:41969069	chr22:42269753~42275196:+
COAD	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	4.5	1.03e-05	0.00347	0.34	0.27	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
COAD	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	4.5	1.03e-05	0.00347	0.19	0.27	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
COAD	cis	rs9847710	0.818	rs6445558	ENSG00000242142.1	SERBP1P3	-4.5	1.03e-05	0.00347	-0.3	-0.27	Ulcerative colitis;	chr3:53063644	chr3:53064283~53065091:-
COAD	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	4.5	1.03e-05	0.00347	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
COAD	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	4.5	1.03e-05	0.00347	0.32	0.27	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
COAD	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	4.5	1.03e-05	0.00347	0.32	0.27	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
COAD	cis	rs9393777	0.623	rs56296968	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26474343	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs3757150	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26476554	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs16891717	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26476915	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs9358946	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26478699	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs9358947	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26478772	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs7756567	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26481414	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs9358948	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00347	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26483578	chr6:26956992~27023924:+
COAD	cis	rs8061903	0.535	rs66934572	ENSG00000260071.1	RP11-418I22.2	4.5	1.03e-05	0.00347	0.34	0.27	HIV-1 viral setpoint;	chr16:9305396	chr16:9466655~9517564:+
COAD	cis	rs8061903	0.535	rs67543368	ENSG00000260071.1	RP11-418I22.2	4.5	1.03e-05	0.00347	0.34	0.27	HIV-1 viral setpoint;	chr16:9305492	chr16:9466655~9517564:+
COAD	cis	rs5758511	0.689	rs11913578	ENSG00000237037.8	NDUFA6-AS1	-4.5	1.03e-05	0.00347	-0.29	-0.27	Birth weight;	chr22:41951387	chr22:42090931~42137742:+
COAD	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-4.5	1.03e-05	0.00348	-0.5	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
COAD	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-4.5	1.03e-05	0.00348	-0.25	-0.27	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
COAD	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.5	1.03e-05	0.00348	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
COAD	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	4.5	1.03e-05	0.00348	0.33	0.27	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
COAD	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-4.5	1.03e-05	0.00348	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-4.5	1.03e-05	0.00348	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
COAD	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	4.5	1.03e-05	0.00348	0.28	0.27	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
COAD	cis	rs4657482	0.962	rs9887956	ENSG00000236364.3	RP11-525G13.2	4.5	1.03e-05	0.00348	0.2	0.27	Testicular germ cell tumor;	chr1:165879976	chr1:165890795~165900683:-
COAD	cis	rs7646881	0.544	rs73028934	ENSG00000272087.1	RP11-379F4.7	4.5	1.03e-05	0.00348	0.43	0.27	Tetralogy of Fallot;	chr3:158655761	chr3:158693120~158693768:-
COAD	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	4.5	1.03e-05	0.00348	0.34	0.27	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
COAD	cis	rs7760535	0.93	rs10872069	ENSG00000271789.1	RP5-1112D6.7	-4.5	1.03e-05	0.00349	-0.26	-0.27	Metabolic traits;	chr6:111540523	chr6:111297126~111298510:+
COAD	cis	rs362272	0.525	rs910568	ENSG00000248840.2	RP11-357G3.2	-4.5	1.03e-05	0.00349	-0.31	-0.27	Serum sulfate level;	chr4:3305646	chr4:3312512~3313058:+
COAD	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-4.5	1.03e-05	0.00349	-0.38	-0.27	Depression;	chr6:28076559	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-4.5	1.03e-05	0.00349	-0.38	-0.27	Depression;	chr6:28078391	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-4.5	1.03e-05	0.00349	-0.38	-0.27	Depression;	chr6:28080757	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-4.5	1.03e-05	0.00349	-0.38	-0.27	Depression;	chr6:28080760	chr6:28115628~28116551:+
COAD	cis	rs860295	0.702	rs11264366	ENSG00000160766.13	GBAP1	-4.5	1.03e-05	0.00349	-0.32	-0.27	Body mass index;	chr1:155365620	chr1:155213821~155227422:-
COAD	cis	rs6940638	0.637	rs13217239	ENSG00000224843.5	LINC00240	4.5	1.03e-05	0.00349	0.33	0.27	Intelligence (multi-trait analysis);	chr6:27287188	chr6:26956992~27023924:+
COAD	cis	rs9487051	0.872	rs1111866	ENSG00000219700.1	PTCHD3P3	-4.5	1.04e-05	0.00349	-0.28	-0.27	Reticulocyte fraction of red cells;	chr6:109289643	chr6:109288571~109290503:-
COAD	cis	rs12497850	0.805	rs11130176	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48806644	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9311430	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48807818	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9311432	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48813010	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9311433	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48826402	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs7430501	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48852686	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs10780033	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48853842	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.864	rs7431857	ENSG00000225399.4	RP11-3B7.1	4.5	1.04e-05	0.00349	0.3	0.27	Parkinson's disease;	chr3:48862914	chr3:49260085~49261316:+
COAD	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	4.5	1.04e-05	0.00349	0.3	0.27	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
COAD	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-4.5	1.04e-05	0.00349	-0.34	-0.27	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
COAD	cis	rs6461992	0.51	rs62457399	ENSG00000253405.1	EVX1-AS	4.5	1.04e-05	0.00349	0.71	0.27	Systolic blood pressure;	chr7:26998544	chr7:27241429~27247229:-
COAD	cis	rs6461992	0.51	rs17436757	ENSG00000253405.1	EVX1-AS	4.5	1.04e-05	0.00349	0.71	0.27	Systolic blood pressure;	chr7:27009910	chr7:27241429~27247229:-
COAD	cis	rs6461992	0.51	rs62457403	ENSG00000253405.1	EVX1-AS	4.5	1.04e-05	0.00349	0.71	0.27	Systolic blood pressure;	chr7:27011148	chr7:27241429~27247229:-
COAD	cis	rs597539	0.616	rs473997	ENSG00000255741.1	RP11-757G1.5	-4.5	1.04e-05	0.00349	-0.38	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68941503~68942852:-
COAD	cis	rs9910055	0.529	rs228765	ENSG00000267080.4	ASB16-AS1	4.5	1.04e-05	0.00349	0.26	0.27	Total body bone mineral density;	chr17:44109054	chr17:44175973~44186717:-
COAD	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-4.5	1.04e-05	0.00349	-0.38	-0.27	Depression;	chr6:28113616	chr6:28115628~28116551:+
COAD	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-4.5	1.04e-05	0.00349	-0.32	-0.27	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
COAD	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-4.5	1.04e-05	0.00349	-0.34	-0.27	Height;	chr20:49218618	chr20:49280319~49280409:+
COAD	cis	rs7209700	0.662	rs8080254	ENSG00000228782.6	CTD-2026D20.3	4.5	1.04e-05	0.0035	0.3	0.27	IgG glycosylation;	chr17:47270526	chr17:47450568~47492492:-
COAD	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-4.5	1.04e-05	0.0035	-0.27	-0.27	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
COAD	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-4.5	1.04e-05	0.0035	-0.27	-0.27	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
COAD	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-4.5	1.04e-05	0.0035	-0.27	-0.27	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
COAD	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-4.5	1.04e-05	0.0035	-0.27	-0.27	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
COAD	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-4.5	1.04e-05	0.0035	-0.33	-0.27	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
COAD	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-4.5	1.04e-05	0.0035	-0.28	-0.27	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
COAD	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-4.5	1.04e-05	0.0035	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
COAD	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.5	1.04e-05	0.0035	0.39	0.27	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
COAD	cis	rs11603023	0.805	rs687190	ENSG00000278376.1	RP11-158I9.8	-4.5	1.04e-05	0.0035	-0.27	-0.27	Cholesterol, total;	chr11:118671674	chr11:118791254~118793137:+
COAD	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	4.5	1.04e-05	0.00351	0.29	0.27	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
COAD	cis	rs6543140	0.964	rs918000	ENSG00000234389.1	AC007278.3	4.5	1.04e-05	0.00351	0.28	0.27	Blood protein levels;	chr2:102451402	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.927	rs917999	ENSG00000234389.1	AC007278.3	4.5	1.04e-05	0.00351	0.28	0.27	Blood protein levels;	chr2:102451409	chr2:102438713~102440475:+
COAD	cis	rs6461992	0.51	rs17437154	ENSG00000253405.1	EVX1-AS	4.5	1.04e-05	0.00351	0.71	0.27	Systolic blood pressure;	chr7:27085432	chr7:27241429~27247229:-
COAD	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.5	1.04e-05	0.00351	-0.34	-0.27	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.5	1.04e-05	0.00351	-0.34	-0.27	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
COAD	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	4.5	1.04e-05	0.00351	0.42	0.27	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
COAD	cis	rs41307935	0.818	rs35738294	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26693642	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71636769	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694100	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71636770	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694624	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs34585496	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26699449	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.57	rs12744003	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701808	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.908	rs77408691	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26707898	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.73	rs12724159	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26709637	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12729444	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26710663	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12726081	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711084	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12730386	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711498	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs79568175	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711725	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12726287	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26712737	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.908	rs12756154	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26714018	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs35407375	ENSG00000260063.1	RP5-968P14.2	-4.5	1.04e-05	0.00351	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26714727	chr1:26692132~26694131:-
COAD	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-4.5	1.04e-05	0.00351	-0.34	-0.27	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
COAD	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	4.5	1.04e-05	0.00351	0.16	0.27	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
COAD	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-4.5	1.04e-05	0.00351	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
COAD	cis	rs4705952	1	rs4705952	ENSG00000233006.5	AC034220.3	-4.5	1.04e-05	0.00351	-0.24	-0.27	C-reactive protein levels;	chr5:132503926	chr5:132311285~132369916:-
COAD	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-4.5	1.04e-05	0.00351	-0.28	-0.27	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
COAD	cis	rs728616	0.867	rs55690691	ENSG00000225484.5	NUTM2B-AS1	-4.5	1.04e-05	0.00351	-0.49	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs1983775	ENSG00000225484.5	NUTM2B-AS1	-4.5	1.04e-05	0.00351	-0.49	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs1983776	ENSG00000225484.5	NUTM2B-AS1	-4.5	1.04e-05	0.00351	-0.49	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79663088~79826594:-
COAD	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	4.5	1.04e-05	0.00351	0.43	0.27	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
COAD	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	4.5	1.04e-05	0.00351	0.33	0.27	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	4.5	1.04e-05	0.00351	0.33	0.27	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
COAD	cis	rs9487051	0.872	rs9386791	ENSG00000219700.1	PTCHD3P3	4.5	1.05e-05	0.00351	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109287294	chr6:109288571~109290503:-
COAD	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	4.5	1.05e-05	0.00352	0.24	0.27	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
COAD	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-4.5	1.05e-05	0.00352	-0.32	-0.27	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
COAD	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	4.5	1.05e-05	0.00352	0.28	0.27	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
COAD	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	4.5	1.05e-05	0.00352	0.41	0.27	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
COAD	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	4.5	1.05e-05	0.00352	0.41	0.27	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
COAD	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	4.5	1.05e-05	0.00352	0.25	0.27	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
COAD	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-4.5	1.05e-05	0.00352	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
COAD	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	4.5	1.05e-05	0.00352	0.3	0.27	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
COAD	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-4.5	1.05e-05	0.00352	-0.33	-0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
COAD	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	4.5	1.05e-05	0.00352	0.28	0.27	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
COAD	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	4.5	1.05e-05	0.00353	0.33	0.27	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
COAD	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-4.5	1.05e-05	0.00353	-0.32	-0.27	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
COAD	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	4.5	1.05e-05	0.00353	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
COAD	cis	rs8022206	0.773	rs7145771	ENSG00000259502.1	RP11-643G16.3	4.5	1.05e-05	0.00353	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67924584	chr14:67610986~67613864:+
COAD	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-4.5	1.05e-05	0.00353	-0.37	-0.27	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
COAD	cis	rs875971	0.545	rs221986	ENSG00000224316.1	RP11-479O9.2	-4.5	1.05e-05	0.00353	-0.34	-0.27	Aortic root size;	chr7:66105323	chr7:65773620~65802067:+
COAD	cis	rs35264875	1	rs35264875	ENSG00000259799.1	RP11-554A11.9	4.5	1.05e-05	0.00353	0.43	0.27	Blond vs. brown hair color;	chr11:69078931	chr11:69155910~69159752:+
COAD	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-4.49	1.05e-05	0.00354	-0.33	-0.27	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
COAD	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	4.49	1.05e-05	0.00354	0.36	0.27	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
COAD	cis	rs2337406	0.866	rs7152809	ENSG00000211967.3	IGHV3-53	-4.49	1.05e-05	0.00354	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106778385	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs7152832	ENSG00000211967.3	IGHV3-53	-4.49	1.05e-05	0.00354	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106778427	chr14:106592676~106593347:-
COAD	cis	rs812925	0.537	rs778153	ENSG00000273302.1	RP11-493E12.2	-4.49	1.05e-05	0.00354	-0.25	-0.27	Immature fraction of reticulocytes;	chr2:61381517	chr2:61199979~61200769:+
COAD	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	4.49	1.05e-05	0.00354	0.31	0.27	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
COAD	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-4.49	1.06e-05	0.00354	-0.34	-0.27	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
COAD	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	4.49	1.06e-05	0.00355	0.35	0.27	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	4.49	1.06e-05	0.00355	0.35	0.27	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	4.49	1.06e-05	0.00355	0.35	0.27	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
COAD	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-4.49	1.06e-05	0.00355	-0.31	-0.27	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
COAD	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	4.49	1.06e-05	0.00355	0.27	0.27	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
COAD	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-4.49	1.06e-05	0.00355	-0.28	-0.27	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
COAD	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-4.49	1.06e-05	0.00355	-0.36	-0.27	Depression;	chr6:28206179	chr6:28115628~28116551:+
COAD	cis	rs7615952	0.599	rs6438955	ENSG00000248787.1	RP11-666A20.4	-4.49	1.06e-05	0.00355	-0.34	-0.27	Blood pressure (smoking interaction);	chr3:126011490	chr3:125908005~125910272:-
COAD	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	4.49	1.06e-05	0.00355	0.45	0.27	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
COAD	cis	rs2946505	0.871	rs2466244	ENSG00000251468.2	RP11-369K16.1	4.49	1.06e-05	0.00355	0.38	0.27	Migraine;	chr8:12964370	chr8:12958387~12962200:+
COAD	cis	rs7615952	0.575	rs35949599	ENSG00000272840.1	RP11-379B18.6	4.49	1.06e-05	0.00355	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825359	chr3:125774714~125797953:+
COAD	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	4.49	1.06e-05	0.00356	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
COAD	cis	rs5758511	0.689	rs62240864	ENSG00000237037.8	NDUFA6-AS1	-4.49	1.06e-05	0.00356	-0.39	-0.27	Birth weight;	chr22:42167883	chr22:42090931~42137742:+
COAD	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.49	1.06e-05	0.00356	-0.32	-0.27	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
COAD	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-4.49	1.06e-05	0.00356	-0.3	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
COAD	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-4.49	1.06e-05	0.00356	-0.3	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
COAD	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-4.49	1.06e-05	0.00356	-0.18	-0.27	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
COAD	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	4.49	1.06e-05	0.00356	0.62	0.27	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
COAD	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	4.49	1.06e-05	0.00356	0.62	0.27	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
COAD	cis	rs2638953	0.888	rs10843189	ENSG00000247934.4	RP11-967K21.1	-4.49	1.06e-05	0.00356	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28163298~28190738:-
COAD	cis	rs9487051	0.837	rs6568561	ENSG00000219700.1	PTCHD3P3	4.49	1.06e-05	0.00357	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109271706	chr6:109288571~109290503:-
COAD	cis	rs9393777	0.623	rs9348719	ENSG00000224843.5	LINC00240	4.49	1.06e-05	0.00357	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26469804	chr6:26956992~27023924:+
COAD	cis	rs4704187	0.687	rs4621540	ENSG00000250889.2	LINC01336	-4.49	1.06e-05	0.00357	-0.3	-0.27	Response to amphetamines;	chr5:75075378	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4324655	ENSG00000250889.2	LINC01336	-4.49	1.06e-05	0.00357	-0.3	-0.27	Response to amphetamines;	chr5:75077535	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.595	rs7717337	ENSG00000250889.2	LINC01336	-4.49	1.06e-05	0.00357	-0.3	-0.27	Response to amphetamines;	chr5:75081176	chr5:75047719~75052843:-
COAD	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.06e-05	0.00357	-0.32	-0.27	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
COAD	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.49	1.06e-05	0.00357	-0.34	-0.27	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
COAD	cis	rs58873874	0.649	rs75791619	ENSG00000251405.2	CTB-109A12.1	4.49	1.06e-05	0.00357	0.52	0.27	Bipolar disorder (body mass index interaction);	chr5:157370204	chr5:157362615~157460078:-
COAD	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	4.49	1.06e-05	0.00357	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
COAD	cis	rs11681884	0.786	rs28928270	ENSG00000228251.1	AC012442.6	4.49	1.06e-05	0.00357	0.61	0.27	Stroke;	chr2:113068646	chr2:112590796~112591939:+
COAD	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
COAD	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	4.49	1.07e-05	0.00357	0.36	0.27	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
COAD	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-4.49	1.07e-05	0.00357	-0.15	-0.27	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
COAD	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	4.49	1.07e-05	0.00357	0.33	0.27	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
COAD	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	4.49	1.07e-05	0.00358	0.27	0.27	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
COAD	cis	rs8061903	0.617	rs12596588	ENSG00000260071.1	RP11-418I22.2	4.49	1.07e-05	0.00358	0.36	0.27	HIV-1 viral setpoint;	chr16:9295008	chr16:9466655~9517564:+
COAD	cis	rs739496	0.615	rs627308	ENSG00000257595.2	RP3-473L9.4	-4.49	1.07e-05	0.00358	-0.4	-0.27	Platelet count;	chr12:111708751	chr12:111369282~111403310:+
COAD	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	4.49	1.07e-05	0.00358	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	4.49	1.07e-05	0.00358	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	4.49	1.07e-05	0.00358	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	4.49	1.07e-05	0.00358	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
COAD	cis	rs1949733	0.958	rs3103069	ENSG00000205959.3	RP11-689P11.2	4.49	1.07e-05	0.00358	0.34	0.27	Response to antineoplastic agents;	chr4:8507724	chr4:8482270~8512610:+
COAD	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-4.49	1.07e-05	0.00358	-0.32	-0.27	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
COAD	cis	rs2337406	0.85	rs10131280	ENSG00000274576.2	IGHV2-70	-4.49	1.07e-05	0.00358	-0.25	-0.27	Alzheimer's disease (late onset);	chr14:106665591	chr14:106770577~106771020:-
COAD	cis	rs7818688	0.614	rs11782617	ENSG00000253528.2	RP11-347C18.4	4.49	1.07e-05	0.00359	0.37	0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94862994	chr8:94974573~94974853:-
COAD	cis	rs8061903	0.958	rs67155775	ENSG00000260071.1	RP11-418I22.2	4.49	1.07e-05	0.00359	0.32	0.27	HIV-1 viral setpoint;	chr16:9290433	chr16:9466655~9517564:+
COAD	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-4.49	1.07e-05	0.00359	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
COAD	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.07e-05	0.0036	-0.32	-0.27	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
COAD	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	4.49	1.07e-05	0.0036	0.22	0.27	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
COAD	cis	rs17772222	0.917	rs17188046	ENSG00000258789.1	RP11-507K2.3	-4.49	1.07e-05	0.0036	-0.39	-0.27	Coronary artery calcification;	chr14:88624417	chr14:88551597~88552493:+
COAD	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	4.49	1.07e-05	0.0036	0.3	0.27	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
COAD	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-4.49	1.07e-05	0.0036	-0.32	-0.27	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
COAD	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-4.49	1.08e-05	0.0036	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
COAD	cis	rs7845219	0.539	rs13271644	ENSG00000253528.2	RP11-347C18.4	4.49	1.08e-05	0.0036	0.27	0.27	Type 2 diabetes;	chr8:94841720	chr8:94974573~94974853:-
COAD	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	4.49	1.08e-05	0.0036	0.31	0.27	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
COAD	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	4.49	1.08e-05	0.00361	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
COAD	cis	rs9487051	0.872	rs9487034	ENSG00000219700.1	PTCHD3P3	4.49	1.08e-05	0.00361	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109284696	chr6:109288571~109290503:-
COAD	cis	rs17772222	0.958	rs17798341	ENSG00000258789.1	RP11-507K2.3	-4.49	1.08e-05	0.00361	-0.39	-0.27	Coronary artery calcification;	chr14:88548201	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.958	rs10134008	ENSG00000258789.1	RP11-507K2.3	-4.49	1.08e-05	0.00361	-0.39	-0.27	Coronary artery calcification;	chr14:88549183	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.958	rs891750	ENSG00000258789.1	RP11-507K2.3	-4.49	1.08e-05	0.00361	-0.39	-0.27	Coronary artery calcification;	chr14:88550856	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.958	rs891749	ENSG00000258789.1	RP11-507K2.3	-4.49	1.08e-05	0.00361	-0.39	-0.27	Coronary artery calcification;	chr14:88550893	chr14:88551597~88552493:+
COAD	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-4.49	1.08e-05	0.00361	-0.42	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
COAD	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.49	1.08e-05	0.00361	-0.34	-0.27	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
COAD	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	4.49	1.08e-05	0.00361	0.17	0.27	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
COAD	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-4.49	1.08e-05	0.00361	-0.33	-0.27	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
COAD	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	4.49	1.08e-05	0.00361	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
COAD	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	4.49	1.08e-05	0.00361	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	4.49	1.08e-05	0.00361	0.47	0.27	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
COAD	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	4.49	1.08e-05	0.00362	0.3	0.27	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
COAD	cis	rs4604732	0.536	rs12058821	ENSG00000227135.1	GCSAML-AS1	-4.49	1.08e-05	0.00362	-0.39	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247486349	chr1:247524679~247526752:-
COAD	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	4.49	1.08e-05	0.00362	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	4.49	1.08e-05	0.00362	0.36	0.27	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
COAD	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	4.49	1.08e-05	0.00362	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-4.49	1.08e-05	0.00362	-0.15	-0.27	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
COAD	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	4.49	1.08e-05	0.00362	0.27	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
COAD	cis	rs728616	0.764	rs56196124	ENSG00000234382.2	RP11-40F6.1	-4.49	1.08e-05	0.00362	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142899	chr10:80233664~80245367:+
COAD	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-4.49	1.08e-05	0.00362	-0.34	-0.27	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-4.49	1.08e-05	0.00362	-0.34	-0.27	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-4.49	1.08e-05	0.00362	-0.34	-0.27	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
COAD	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	4.49	1.08e-05	0.00362	0.33	0.27	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
COAD	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-4.49	1.08e-05	0.00362	-0.31	-0.27	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
COAD	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	4.49	1.08e-05	0.00362	0.35	0.27	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
COAD	cis	rs6921919	0.638	rs2108926	ENSG00000272009.1	RP1-313I6.12	4.49	1.08e-05	0.00362	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28078792~28081130:-
COAD	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	4.49	1.08e-05	0.00362	0.31	0.27	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
COAD	cis	rs4718428	0.672	rs12530806	ENSG00000272831.1	RP11-792A8.4	4.49	1.08e-05	0.00362	0.3	0.27	Corneal structure;	chr7:66925737	chr7:66739829~66740385:-
COAD	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-4.49	1.08e-05	0.00362	-0.55	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
COAD	cis	rs72827839	0.894	rs41336845	ENSG00000263412.1	RP5-890E16.2	-4.49	1.08e-05	0.00362	-0.39	-0.27	Ease of getting up in the morning;	chr17:48137748	chr17:48045141~48048073:-
COAD	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.49	1.08e-05	0.00362	-0.28	-0.27	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
COAD	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.49	1.08e-05	0.00362	-0.28	-0.27	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
COAD	cis	rs6461992	0.51	rs17426751	ENSG00000253405.1	EVX1-AS	4.49	1.08e-05	0.00363	0.71	0.27	Systolic blood pressure;	chr7:26946441	chr7:27241429~27247229:-
COAD	cis	rs7818688	0.546	rs13250762	ENSG00000253528.2	RP11-347C18.4	-4.49	1.08e-05	0.00363	-0.37	-0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975342	chr8:94974573~94974853:-
COAD	cis	rs12935418	0.583	rs7206625	ENSG00000278985.1	RP11-303E16.9	4.49	1.08e-05	0.00363	0.33	0.27	Mean corpuscular volume;	chr16:80930536	chr16:80982319~80984094:-
COAD	cis	rs11681884	0.892	rs11690459	ENSG00000228251.1	AC012442.6	4.49	1.09e-05	0.00363	0.59	0.27	Stroke;	chr2:113075961	chr2:112590796~112591939:+
COAD	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-4.49	1.09e-05	0.00363	-0.33	-0.27	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
COAD	cis	rs9951698	0.653	rs562151	ENSG00000266969.1	RP11-773H22.4	4.49	1.09e-05	0.00363	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13066124	chr18:12984694~12991173:-
COAD	cis	rs8002861	0.905	rs12875768	ENSG00000274001.1	RP11-5G9.5	-4.49	1.09e-05	0.00363	-0.25	-0.27	Leprosy;	chr13:43854169	chr13:43877715~43878163:-
COAD	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	4.49	1.09e-05	0.00363	0.33	0.27	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	4.49	1.09e-05	0.00363	0.33	0.27	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
COAD	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-4.49	1.09e-05	0.00363	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
COAD	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-4.49	1.09e-05	0.00363	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
COAD	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-4.49	1.09e-05	0.00363	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
COAD	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-4.49	1.09e-05	0.00363	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
COAD	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-4.49	1.09e-05	0.00363	-0.33	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
COAD	cis	rs492146	1	rs693733	ENSG00000243236.5	GSTA9P	-4.49	1.09e-05	0.00364	-0.29	-0.27	Epilepsy (remission after treatment);	chr6:52971958	chr6:52939726~52957521:-
COAD	cis	rs492146	1	rs419833	ENSG00000243236.5	GSTA9P	-4.49	1.09e-05	0.00364	-0.29	-0.27	Epilepsy (remission after treatment);	chr6:52973187	chr6:52939726~52957521:-
COAD	cis	rs492146	1	rs449690	ENSG00000243236.5	GSTA9P	-4.49	1.09e-05	0.00364	-0.29	-0.27	Epilepsy (remission after treatment);	chr6:52973360	chr6:52939726~52957521:-
COAD	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-4.49	1.09e-05	0.00364	-0.25	-0.27	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
COAD	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	4.49	1.09e-05	0.00364	0.32	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
COAD	cis	rs7224610	0.966	rs3794748	ENSG00000263096.1	RP11-515O17.2	4.49	1.09e-05	0.00364	0.3	0.27	Urate levels;	chr17:55287811	chr17:55271504~55273653:-
COAD	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	4.49	1.09e-05	0.00364	0.34	0.27	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	4.49	1.09e-05	0.00364	0.34	0.27	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
COAD	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-4.49	1.09e-05	0.00364	-0.37	-0.27	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
COAD	cis	rs72827839	0.846	rs76950846	ENSG00000263412.1	RP5-890E16.2	4.49	1.09e-05	0.00365	0.39	0.27	Ease of getting up in the morning;	chr17:48024787	chr17:48045141~48048073:-
COAD	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	4.49	1.09e-05	0.00365	0.24	0.27	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
COAD	cis	rs9990333	1	rs9990333	ENSG00000207650.1	MIR570	-4.49	1.09e-05	0.00365	-0.31	-0.27	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195699401~195699497:+
COAD	cis	rs12928939	0.517	rs12149307	ENSG00000260886.1	TAT-AS1	4.49	1.09e-05	0.00365	0.4	0.27	Post bronchodilator FEV1;	chr16:71934188	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.517	rs10852507	ENSG00000260886.1	TAT-AS1	4.49	1.09e-05	0.00365	0.4	0.27	Post bronchodilator FEV1;	chr16:71937997	chr16:71565789~71578187:+
COAD	cis	rs9487051	0.872	rs9400271	ENSG00000219700.1	PTCHD3P3	4.49	1.1e-05	0.00366	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109286353	chr6:109288571~109290503:-
COAD	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-4.49	1.1e-05	0.00366	-0.37	-0.27	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
COAD	cis	rs2115630	1	rs4633690	ENSG00000259728.4	LINC00933	-4.49	1.1e-05	0.00366	-0.31	-0.27	P wave terminal force;	chr15:84818729	chr15:84570649~84580175:+
COAD	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.49	1.1e-05	0.00366	0.25	0.27	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
COAD	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-4.49	1.1e-05	0.00366	-0.31	-0.27	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-4.49	1.1e-05	0.00366	-0.31	-0.27	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-4.49	1.1e-05	0.00366	-0.31	-0.27	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
COAD	cis	rs17711722	0.523	rs365896	ENSG00000272831.1	RP11-792A8.4	-4.49	1.1e-05	0.00367	-0.28	-0.27	Calcium levels;	chr7:66045710	chr7:66739829~66740385:-
COAD	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-4.49	1.1e-05	0.00367	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-4.49	1.1e-05	0.00367	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-4.49	1.1e-05	0.00367	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
COAD	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	4.48	1.1e-05	0.00367	0.32	0.27	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
COAD	cis	rs9532669	0.963	rs1571116	ENSG00000239827.7	SUGT1P3	-4.48	1.1e-05	0.00367	-0.23	-0.27	Cervical cancer;	chr13:40929765	chr13:40908159~40921774:-
COAD	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-4.48	1.1e-05	0.00367	-0.29	-0.27	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
COAD	cis	rs7032317	0.666	rs8193012	ENSG00000170827.8	CELP	-4.48	1.1e-05	0.00368	-0.23	-0.27	Calcium levels;	chr9:133008176	chr9:133079900~133087355:+
COAD	cis	rs9450351	0.744	rs9344559	ENSG00000203875.9	SNHG5	-4.48	1.1e-05	0.00368	-0.53	-0.27	Interferon gamma-induced protein 10 levels;	chr6:86012192	chr6:85660950~85678736:-
COAD	cis	rs7829975	0.517	rs12542733	ENSG00000253981.4	ALG1L13P	-4.48	1.1e-05	0.00368	-0.31	-0.27	Mood instability;	chr8:8967348	chr8:8236003~8244667:-
COAD	cis	rs12497850	0.931	rs3774628	ENSG00000225399.4	RP11-3B7.1	4.48	1.1e-05	0.00368	0.3	0.27	Parkinson's disease;	chr3:48764407	chr3:49260085~49261316:+
COAD	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	4.48	1.1e-05	0.00368	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
COAD	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	4.48	1.1e-05	0.00368	0.35	0.27	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	4.48	1.1e-05	0.00368	0.35	0.27	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
COAD	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-4.48	1.1e-05	0.00368	-0.33	-0.27	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
COAD	cis	rs7584330	0.868	rs58057291	ENSG00000234949.2	AC104667.3	-4.48	1.1e-05	0.00368	-0.35	-0.27	Prostate cancer;	chr2:237486836	chr2:237591020~237595981:+
COAD	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-4.48	1.1e-05	0.00368	-0.48	-0.27	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
COAD	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	4.48	1.11e-05	0.00369	0.16	0.27	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	4.48	1.11e-05	0.00369	0.16	0.27	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
COAD	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-4.48	1.11e-05	0.00369	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
COAD	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-4.48	1.11e-05	0.00369	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
COAD	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	4.48	1.11e-05	0.00369	0.32	0.27	Height;	chr4:55527164	chr4:55540502~55540835:-
COAD	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	4.48	1.11e-05	0.00369	0.31	0.27	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
COAD	cis	rs987724	0.593	rs11707914	ENSG00000240875.4	LINC00886	-4.48	1.11e-05	0.00369	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829982	chr3:156747346~156817062:-
COAD	cis	rs2115630	1	rs56074163	ENSG00000259728.4	LINC00933	-4.48	1.11e-05	0.00369	-0.32	-0.27	P wave terminal force;	chr15:84808101	chr15:84570649~84580175:+
COAD	cis	rs2378497	0.938	rs1339869	ENSG00000232679.1	RP11-400N13.3	4.48	1.11e-05	0.00369	0.37	0.27	Serum thyroid-stimulating hormone levels;	chr1:222006591	chr1:222041705~222064763:-
COAD	cis	rs9487051	0.676	rs9398193	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109271931	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs7753697	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109272089	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs7753705	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109272099	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs1829694	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109272657	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6928622	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109273909	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs1608042	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109274428	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs1608041	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109274700	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs9372208	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109274965	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.7	rs9400266	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109274990	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6568566	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109275589	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6568567	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109275790	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6568568	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109275845	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs6903107	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109276508	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.676	rs4406271	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109277010	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.639	rs2884012	ENSG00000219700.1	PTCHD3P3	4.48	1.11e-05	0.00369	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109277018	chr6:109288571~109290503:-
COAD	cis	rs7193541	0.965	rs28616016	ENSG00000262904.1	TMPOP2	-4.48	1.11e-05	0.0037	-0.29	-0.27	Multiple myeloma;	chr16:74643066	chr16:74667506~74668706:+
COAD	cis	rs1662342	0.736	rs4404166	ENSG00000264235.4	RP13-270P17.1	-4.48	1.11e-05	0.0037	-0.39	-0.27	QRS duration;	chr18:3285659	chr18:3255436~3261850:-
COAD	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-4.48	1.11e-05	0.0037	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
COAD	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	4.48	1.11e-05	0.0037	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
COAD	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-4.48	1.11e-05	0.00371	-0.34	-0.27	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
COAD	cis	rs7904519	0.55	rs4073288	ENSG00000227560.1	RP11-139K1.2	-4.48	1.11e-05	0.00371	-0.29	-0.27	Breast cancer (estrogen-receptor negative);Breast cancer;	chr10:112987518	chr10:112987476~112987865:+
COAD	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	4.48	1.11e-05	0.00371	0.35	0.27	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
COAD	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	4.48	1.11e-05	0.00371	0.35	0.27	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
COAD	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-4.48	1.11e-05	0.00371	-0.33	-0.27	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-4.48	1.11e-05	0.00371	-0.33	-0.27	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
COAD	cis	rs2732480	0.5	rs2932093	ENSG00000257735.1	RP11-370I10.6	4.48	1.11e-05	0.00371	0.34	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48350945~48442411:+
COAD	cis	rs2188554	0.785	rs172507	ENSG00000237974.1	AC000111.4	-4.48	1.11e-05	0.00371	-0.31	-0.27	Esophageal adenocarcinoma;	chr7:117522993	chr7:117487737~117487929:+
COAD	cis	rs6543140	0.964	rs1523206	ENSG00000234389.1	AC007278.3	4.48	1.11e-05	0.00371	0.28	0.27	Blood protein levels;	chr2:102453715	chr2:102438713~102440475:+
COAD	cis	rs6543140	0.964	rs1523205	ENSG00000234389.1	AC007278.3	4.48	1.11e-05	0.00371	0.28	0.27	Blood protein levels;	chr2:102453716	chr2:102438713~102440475:+
COAD	cis	rs9393777	0.623	rs9358945	ENSG00000224843.5	LINC00240	-4.48	1.11e-05	0.00371	-0.45	-0.27	Intelligence (multi-trait analysis);	chr6:26471886	chr6:26956992~27023924:+
COAD	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	4.48	1.11e-05	0.00371	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
COAD	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-4.48	1.11e-05	0.00371	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
COAD	cis	rs330048	0.545	rs11774353	ENSG00000233609.3	RP11-62H7.2	4.48	1.11e-05	0.00371	0.34	0.27	Systemic lupus erythematosus;	chr8:9295617	chr8:8961200~8979025:+
COAD	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-4.48	1.12e-05	0.00371	-0.25	-0.27	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
COAD	cis	rs202072	0.72	rs454563	ENSG00000272379.1	RP1-257A7.5	4.48	1.12e-05	0.00371	0.45	0.27	HIV-1 viral setpoint;	chr6:13295304	chr6:13290018~13290490:-
COAD	cis	rs11124272	0.761	rs4952244	ENSG00000272716.1	RP11-563N4.1	-4.48	1.12e-05	0.00371	-0.31	-0.27	Interleukin-18 levels;	chr2:31811556	chr2:32165046~32165757:-
COAD	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-4.48	1.12e-05	0.00372	-0.29	-0.27	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
COAD	cis	rs2836974	0.526	rs1888488	ENSG00000255568.3	BRWD1-AS2	-4.48	1.12e-05	0.00372	-0.26	-0.27	Cognitive function;	chr21:39314595	chr21:39313935~39314962:+
COAD	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	4.48	1.12e-05	0.00372	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
COAD	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	4.48	1.12e-05	0.00372	0.3	0.27	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
COAD	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-4.48	1.12e-05	0.00372	-0.32	-0.27	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
COAD	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	4.48	1.12e-05	0.00372	0.3	0.27	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
COAD	cis	rs11638352	1	rs7176955	ENSG00000205771.5	CATSPER2P1	4.48	1.12e-05	0.00373	0.51	0.27	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44016707	chr15:43726918~43747094:-
COAD	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-4.48	1.12e-05	0.00373	-0.32	-0.27	Height;	chr2:231556448	chr2:231508426~231514339:-
COAD	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	4.48	1.12e-05	0.00373	0.32	0.27	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
COAD	cis	rs10895987	0.955	rs12365171	ENSG00000254614.2	AP003068.23	4.48	1.12e-05	0.00373	0.42	0.27	Blood protein levels;	chr11:65161417	chr11:65177606~65181834:-
COAD	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	4.48	1.12e-05	0.00373	0.35	0.27	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
COAD	cis	rs2832191	0.692	rs2776240	ENSG00000176054.6	RPL23P2	4.48	1.12e-05	0.00373	0.28	0.27	Dental caries;	chr21:28938317	chr21:28997613~28998033:-
COAD	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	4.48	1.12e-05	0.00373	0.37	0.27	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
COAD	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-4.48	1.12e-05	0.00373	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
COAD	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	4.48	1.12e-05	0.00373	0.32	0.27	QT interval;	chr12:29292489	chr12:29277397~29277882:-
COAD	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	4.48	1.12e-05	0.00373	0.28	0.27	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
COAD	cis	rs752010	0.645	rs1109254	ENSG00000230638.4	RP11-486B10.4	-4.48	1.12e-05	0.00373	-0.36	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr1:41626099	chr1:41542069~41544310:+
COAD	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-4.48	1.12e-05	0.00373	-0.33	-0.27	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs316306	ENSG00000224316.1	RP11-479O9.2	-4.48	1.12e-05	0.00373	-0.33	-0.27	Aortic root size;	chr7:66153687	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs2460427	ENSG00000224316.1	RP11-479O9.2	-4.48	1.12e-05	0.00373	-0.33	-0.27	Aortic root size;	chr7:66154218	chr7:65773620~65802067:+
COAD	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-4.48	1.12e-05	0.00374	-0.43	-0.27	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-4.48	1.12e-05	0.00374	-0.43	-0.27	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
COAD	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-4.48	1.12e-05	0.00374	-0.36	-0.27	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
COAD	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-4.48	1.12e-05	0.00374	-0.32	-0.27	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
COAD	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-4.48	1.12e-05	0.00374	-0.34	-0.27	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
COAD	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	4.48	1.13e-05	0.00374	0.27	0.27	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
COAD	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	4.48	1.13e-05	0.00375	0.31	0.27	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
COAD	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-4.48	1.13e-05	0.00375	-0.27	-0.27	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
COAD	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-4.48	1.13e-05	0.00375	-0.27	-0.27	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
COAD	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	4.48	1.13e-05	0.00375	0.35	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
COAD	cis	rs7260598	0.581	rs77986252	ENSG00000268442.1	CTD-2027I19.2	4.48	1.13e-05	0.00375	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23805508	chr19:24162370~24163425:-
COAD	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	4.48	1.13e-05	0.00375	0.3	0.27	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	4.48	1.13e-05	0.00375	0.35	0.27	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	4.48	1.13e-05	0.00375	0.35	0.27	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-4.48	1.13e-05	0.00375	-0.3	-0.27	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
COAD	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	4.48	1.13e-05	0.00375	0.32	0.27	Height;	chr4:55361200	chr4:55363971~55395847:-
COAD	cis	rs6840360	0.582	rs1372976	ENSG00000270265.1	RP11-731D1.4	-4.48	1.13e-05	0.00375	-0.31	-0.27	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.642	rs1443090	ENSG00000270265.1	RP11-731D1.4	-4.48	1.13e-05	0.00375	-0.31	-0.27	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151333775~151353224:-
COAD	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-4.48	1.13e-05	0.00375	-0.43	-0.27	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
COAD	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-4.48	1.13e-05	0.00375	-0.32	-0.27	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
COAD	cis	rs559555	0.512	rs481344	ENSG00000272716.1	RP11-563N4.1	4.48	1.13e-05	0.00376	0.31	0.27	Blood metabolite ratios;Blood metabolite levels;	chr2:31634850	chr2:32165046~32165757:-
COAD	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-4.48	1.13e-05	0.00376	-0.15	-0.27	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-4.48	1.13e-05	0.00376	-0.15	-0.27	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
COAD	cis	rs7646881	0.544	rs73030851	ENSG00000272087.1	RP11-379F4.7	4.48	1.13e-05	0.00376	0.45	0.27	Tetralogy of Fallot;	chr3:158699163	chr3:158693120~158693768:-
COAD	cis	rs7818688	0.614	rs7834966	ENSG00000253528.2	RP11-347C18.4	4.48	1.13e-05	0.00376	0.37	0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94834968	chr8:94974573~94974853:-
COAD	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-4.48	1.13e-05	0.00376	-0.39	-0.27	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
COAD	cis	rs1930961	0.702	rs10483120	ENSG00000272977.1	CTA-390C10.10	4.48	1.13e-05	0.00376	0.66	0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25482396	chr22:25476218~25479971:+
COAD	cis	rs860295	0.775	rs822509	ENSG00000225082.2	DAP3P1	4.48	1.13e-05	0.00376	0.33	0.27	Body mass index;	chr1:155881020	chr1:155586644~155602197:+
COAD	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	4.48	1.13e-05	0.00376	0.47	0.27	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
COAD	cis	rs7615952	0.605	rs34865555	ENSG00000248787.1	RP11-666A20.4	-4.48	1.13e-05	0.00376	-0.52	-0.27	Blood pressure (smoking interaction);	chr3:125585290	chr3:125908005~125910272:-
COAD	cis	rs12497850	0.897	rs9681717	ENSG00000225399.4	RP11-3B7.1	4.48	1.13e-05	0.00376	0.3	0.27	Parkinson's disease;	chr3:48835565	chr3:49260085~49261316:+
COAD	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	4.48	1.13e-05	0.00377	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
COAD	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	4.48	1.13e-05	0.00377	0.36	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
COAD	cis	rs7260598	0.539	rs76001745	ENSG00000268442.1	CTD-2027I19.2	4.48	1.14e-05	0.00377	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23815590	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs80157088	ENSG00000268442.1	CTD-2027I19.2	4.48	1.14e-05	0.00377	0.49	0.27	Response to taxane treatment (placlitaxel);	chr19:23816494	chr19:24162370~24163425:-
COAD	cis	rs11668609	0.63	rs61557819	ENSG00000268442.1	CTD-2027I19.2	4.48	1.14e-05	0.00377	0.49	0.27	Response to taxane treatment (docetaxel);	chr19:23816543	chr19:24162370~24163425:-
COAD	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-4.48	1.14e-05	0.00377	-0.29	-0.27	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
COAD	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-4.48	1.14e-05	0.00377	-0.29	-0.27	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
COAD	cis	rs17772222	0.917	rs61984684	ENSG00000258789.1	RP11-507K2.3	-4.48	1.14e-05	0.00377	-0.39	-0.27	Coronary artery calcification;	chr14:88559104	chr14:88551597~88552493:+
COAD	cis	rs7577696	0.597	rs375050	ENSG00000272716.1	RP11-563N4.1	4.48	1.14e-05	0.00377	0.31	0.27	Inflammatory biomarkers;	chr2:32188696	chr2:32165046~32165757:-
COAD	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.48	1.14e-05	0.00377	-0.3	-0.27	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
COAD	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.48	1.14e-05	0.00377	-0.3	-0.27	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
COAD	cis	rs17711722	0.523	rs313812	ENSG00000272831.1	RP11-792A8.4	-4.48	1.14e-05	0.00378	-0.27	-0.27	Calcium levels;	chr7:66040056	chr7:66739829~66740385:-
COAD	cis	rs4718428	0.705	rs4718424	ENSG00000272831.1	RP11-792A8.4	4.48	1.14e-05	0.00378	0.3	0.27	Corneal structure;	chr7:66911108	chr7:66739829~66740385:-
COAD	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-4.48	1.14e-05	0.00378	-0.35	-0.27	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
COAD	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-4.48	1.14e-05	0.00378	-0.33	-0.27	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-4.48	1.14e-05	0.00378	-0.33	-0.27	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
COAD	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
COAD	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	4.48	1.14e-05	0.00378	0.27	0.27	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
COAD	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-4.48	1.14e-05	0.00378	-0.31	-0.27	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
COAD	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-4.48	1.14e-05	0.00378	-0.27	-0.27	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
COAD	cis	rs875971	0.66	rs10263935	ENSG00000272831.1	RP11-792A8.4	4.48	1.14e-05	0.00378	0.28	0.27	Aortic root size;	chr7:66631041	chr7:66739829~66740385:-
COAD	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.48	1.14e-05	0.00378	-0.3	-0.27	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
COAD	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	4.48	1.14e-05	0.00379	0.37	0.27	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
COAD	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.48	1.14e-05	0.00379	0.32	0.27	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
COAD	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-4.48	1.14e-05	0.00379	-0.48	-0.27	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
COAD	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	4.48	1.14e-05	0.00379	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
COAD	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.48	1.14e-05	0.00379	-0.3	-0.27	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
COAD	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	4.48	1.14e-05	0.00379	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
COAD	cis	rs7584330	0.518	rs7585969	ENSG00000234949.2	AC104667.3	-4.48	1.14e-05	0.00379	-0.45	-0.27	Prostate cancer;	chr2:237530430	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs7585975	ENSG00000234949.2	AC104667.3	-4.48	1.14e-05	0.00379	-0.45	-0.27	Prostate cancer;	chr2:237530446	chr2:237591020~237595981:+
COAD	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	4.48	1.14e-05	0.00379	0.34	0.27	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
COAD	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	4.48	1.14e-05	0.00379	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
COAD	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	4.48	1.14e-05	0.00379	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	4.48	1.14e-05	0.00379	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
COAD	cis	rs2337406	0.866	rs74092520	ENSG00000211967.3	IGHV3-53	-4.48	1.14e-05	0.00379	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106779632	chr14:106592676~106593347:-
COAD	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-4.48	1.14e-05	0.00379	-0.33	-0.27	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
COAD	cis	rs11976020	1	rs11976020	ENSG00000205578.5	POM121B	-4.48	1.14e-05	0.00379	-0.36	-0.27	Educational attainment (years of education);	chr7:72782785	chr7:73293497~73301161:+
COAD	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-4.48	1.14e-05	0.0038	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
COAD	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-4.48	1.14e-05	0.0038	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-4.48	1.14e-05	0.0038	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
COAD	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-4.48	1.14e-05	0.0038	-0.33	-0.27	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-4.48	1.14e-05	0.0038	-0.33	-0.27	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
COAD	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-4.48	1.15e-05	0.0038	-0.35	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
COAD	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-4.48	1.15e-05	0.0038	-0.32	-0.27	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
COAD	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.48	1.15e-05	0.0038	-0.42	-0.27	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
COAD	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-4.48	1.15e-05	0.0038	-0.31	-0.27	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-4.48	1.15e-05	0.0038	-0.31	-0.27	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-4.48	1.15e-05	0.0038	-0.31	-0.27	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
COAD	cis	rs36052053	0.908	rs71558360	ENSG00000219700.1	PTCHD3P3	4.48	1.15e-05	0.0038	0.48	0.27	Red cell distribution width;	chr6:109256780	chr6:109288571~109290503:-
COAD	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-4.48	1.15e-05	0.0038	-0.28	-0.27	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
COAD	cis	rs2281603	0.571	rs59577187	ENSG00000259116.1	RP11-973N13.4	-4.47	1.15e-05	0.00381	-0.27	-0.27	Lymphocyte counts;	chr14:64488953	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs57525201	ENSG00000259116.1	RP11-973N13.4	-4.47	1.15e-05	0.00381	-0.27	-0.27	Lymphocyte counts;	chr14:64488974	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.57	rs10150781	ENSG00000259116.1	RP11-973N13.4	-4.47	1.15e-05	0.00381	-0.27	-0.27	Lymphocyte counts;	chr14:64489141	chr14:64514154~64540368:-
COAD	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-4.47	1.15e-05	0.00381	-0.43	-0.27	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-4.47	1.15e-05	0.00381	-0.43	-0.27	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
COAD	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-4.47	1.15e-05	0.00382	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
COAD	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-4.47	1.15e-05	0.00382	-0.39	-0.27	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-4.47	1.15e-05	0.00382	-0.39	-0.27	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
COAD	cis	rs728616	0.614	rs35395602	ENSG00000234382.2	RP11-40F6.1	-4.47	1.15e-05	0.00382	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:80233664~80245367:+
COAD	cis	rs728616	0.681	rs36023925	ENSG00000234382.2	RP11-40F6.1	-4.47	1.15e-05	0.00382	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:80233664~80245367:+
COAD	cis	rs6545883	0.524	rs2694618	ENSG00000273302.1	RP11-493E12.2	4.47	1.15e-05	0.00382	0.25	0.27	Tuberculosis;	chr2:61309849	chr2:61199979~61200769:+
COAD	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	4.47	1.15e-05	0.00382	0.33	0.27	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	4.47	1.15e-05	0.00382	0.33	0.27	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
COAD	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	4.47	1.15e-05	0.00382	0.27	0.27	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	4.47	1.15e-05	0.00382	0.26	0.27	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
COAD	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	4.47	1.15e-05	0.00382	0.31	0.27	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
COAD	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	4.47	1.15e-05	0.00382	0.27	0.27	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
COAD	cis	rs180730	1	rs343197	ENSG00000251609.2	SETP12	4.47	1.15e-05	0.00382	0.38	0.27	Fasting plasma glucose;	chr4:120877330	chr4:120895494~120897083:-
COAD	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	4.47	1.15e-05	0.00382	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
COAD	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-4.47	1.15e-05	0.00382	-0.38	-0.27	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
COAD	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	4.47	1.15e-05	0.00383	0.23	0.27	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
COAD	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-4.47	1.16e-05	0.00383	-0.27	-0.27	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
COAD	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	4.47	1.16e-05	0.00383	0.32	0.27	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
COAD	cis	rs9532669	0.963	rs7324625	ENSG00000239827.7	SUGT1P3	-4.47	1.16e-05	0.00383	-0.23	-0.27	Cervical cancer;	chr13:40928606	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532654	ENSG00000277662.1	RP11-74J13.9	-4.47	1.16e-05	0.00383	-0.25	-0.27	Cervical cancer;	chr13:40909812	chr13:41229180~41229676:-
COAD	cis	rs875971	0.522	rs6960048	ENSG00000272831.1	RP11-792A8.4	4.47	1.16e-05	0.00383	0.28	0.27	Aortic root size;	chr7:65943052	chr7:66739829~66740385:-
COAD	cis	rs6940638	0.688	rs7764984	ENSG00000224843.5	LINC00240	4.47	1.16e-05	0.00383	0.35	0.27	Intelligence (multi-trait analysis);	chr6:27066402	chr6:26956992~27023924:+
COAD	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	4.47	1.16e-05	0.00383	0.26	0.27	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
COAD	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-4.47	1.16e-05	0.00384	-0.26	-0.27	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
COAD	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	4.47	1.16e-05	0.00384	0.4	0.27	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	4.47	1.16e-05	0.00384	0.4	0.27	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	4.47	1.16e-05	0.00384	0.4	0.27	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
COAD	cis	rs9659323	0.931	rs113197996	ENSG00000231365.4	RP11-418J17.1	-4.47	1.16e-05	0.00384	-0.3	-0.27	Body mass index;	chr1:118979803	chr1:119140396~119275973:+
COAD	cis	rs4657482	0.607	rs3790672	ENSG00000236364.3	RP11-525G13.2	4.47	1.16e-05	0.00384	0.22	0.27	Testicular germ cell tumor;	chr1:165904155	chr1:165890795~165900683:-
COAD	cis	rs1510272	0.889	rs4680291	ENSG00000243926.1	TIPARP-AS1	-4.47	1.16e-05	0.00385	-0.3	-0.27	Testicular germ cell tumor;	chr3:156613411	chr3:156671862~156674378:-
COAD	cis	rs9487051	0.872	rs9386793	ENSG00000219700.1	PTCHD3P3	4.47	1.16e-05	0.00385	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109288799	chr6:109288571~109290503:-
COAD	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-4.47	1.16e-05	0.00385	-0.32	-0.27	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-4.47	1.16e-05	0.00385	-0.32	-0.27	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
COAD	cis	rs9487051	0.676	rs6933326	ENSG00000219700.1	PTCHD3P3	4.47	1.16e-05	0.00385	0.29	0.27	Reticulocyte fraction of red cells;	chr6:109280130	chr6:109288571~109290503:-
COAD	cis	rs6452524	0.618	rs7722924	ENSG00000271862.1	RP11-343L5.2	4.47	1.16e-05	0.00385	0.26	0.27	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83049376~83050964:-
COAD	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-4.47	1.16e-05	0.00385	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
COAD	cis	rs8141529	0.748	rs132528	ENSG00000272858.1	CTA-292E10.8	4.47	1.16e-05	0.00385	0.33	0.27	Lymphocyte counts;	chr22:28899910	chr22:28814914~28815662:+
COAD	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-4.47	1.16e-05	0.00385	-0.31	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
COAD	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-4.47	1.16e-05	0.00385	-0.29	-0.27	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
COAD	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-4.47	1.16e-05	0.00385	-0.29	-0.27	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
COAD	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-4.47	1.16e-05	0.00385	-0.29	-0.27	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
COAD	cis	rs1670533	0.929	rs6599280	ENSG00000273179.1	RP11-20I20.4	4.47	1.17e-05	0.00385	0.35	0.27	Recombination rate (females);	chr4:1070030	chr4:1167778~1168174:+
COAD	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	4.47	1.17e-05	0.00386	0.33	0.27	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
COAD	cis	rs7032317	0.632	rs8193013	ENSG00000170827.8	CELP	-4.47	1.17e-05	0.00386	-0.23	-0.27	Calcium levels;	chr9:133008194	chr9:133079900~133087355:+
COAD	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-4.47	1.17e-05	0.00386	-0.31	-0.27	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
COAD	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	4.47	1.17e-05	0.00386	0.5	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
COAD	cis	rs739496	0.615	rs666951	ENSG00000257595.2	RP3-473L9.4	4.47	1.17e-05	0.00386	0.4	0.27	Platelet count;	chr12:111698779	chr12:111369282~111403310:+
COAD	cis	rs9951698	0.678	rs578208	ENSG00000266969.1	RP11-773H22.4	-4.47	1.17e-05	0.00386	-0.35	-0.27	Intelligence (multi-trait analysis);	chr18:13068133	chr18:12984694~12991173:-
COAD	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-4.47	1.17e-05	0.00386	-0.5	-0.27	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-4.47	1.17e-05	0.00386	-0.51	-0.27	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-4.47	1.17e-05	0.00386	-0.51	-0.27	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-4.47	1.17e-05	0.00386	-0.51	-0.27	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
COAD	cis	rs11079159	0.651	rs2287223	ENSG00000263096.1	RP11-515O17.2	4.47	1.17e-05	0.00386	0.31	0.27	QRS duration;	chr17:55315491	chr17:55271504~55273653:-
COAD	cis	rs9813712	0.597	rs1453255	ENSG00000249846.5	RP11-77P16.4	-4.47	1.17e-05	0.00386	-0.31	-0.27	Response to amphetamines;	chr3:130258815	chr3:130112550~130120579:+
COAD	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-4.47	1.17e-05	0.00386	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
COAD	cis	rs4704187	0.625	rs11947996	ENSG00000250889.2	LINC01336	-4.47	1.17e-05	0.00386	-0.31	-0.27	Response to amphetamines;	chr5:75249723	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.649	rs58999738	ENSG00000250889.2	LINC01336	-4.47	1.17e-05	0.00386	-0.31	-0.27	Response to amphetamines;	chr5:75249973	chr5:75047719~75052843:-
COAD	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-4.47	1.17e-05	0.00387	-0.31	-0.27	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
COAD	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-4.47	1.17e-05	0.00387	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
COAD	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-4.47	1.17e-05	0.00387	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
COAD	cis	rs4657482	0.639	rs12045367	ENSG00000236364.3	RP11-525G13.2	-4.47	1.17e-05	0.00387	-0.23	-0.27	Testicular germ cell tumor;	chr1:165906735	chr1:165890795~165900683:-
COAD	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	4.47	1.17e-05	0.00387	0.32	0.27	Height;	chr4:55529387	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	4.47	1.17e-05	0.00387	0.32	0.27	Height;	chr4:55529786	chr4:55540502~55540835:-
COAD	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	4.47	1.17e-05	0.00387	0.39	0.27	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
COAD	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	4.47	1.17e-05	0.00387	0.26	0.27	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
COAD	cis	rs5758511	0.817	rs133291	ENSG00000237037.8	NDUFA6-AS1	-4.47	1.17e-05	0.00388	-0.29	-0.27	Birth weight;	chr22:41873624	chr22:42090931~42137742:+
COAD	cis	rs9307551	0.697	rs1561638	ENSG00000250334.4	LINC00989	-4.47	1.17e-05	0.00388	-0.36	-0.27	Refractive error;	chr4:79499154	chr4:79492416~79576460:+
COAD	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	4.47	1.17e-05	0.00388	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
COAD	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	4.47	1.17e-05	0.00388	0.4	0.27	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
COAD	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	4.47	1.17e-05	0.00388	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
COAD	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	4.47	1.18e-05	0.00389	0.36	0.27	Depression;	chr6:28110525	chr6:28115628~28116551:+
COAD	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	4.47	1.18e-05	0.00389	0.57	0.27	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	4.47	1.18e-05	0.00389	0.57	0.27	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
COAD	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-4.47	1.18e-05	0.00389	-0.17	-0.27	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-4.47	1.18e-05	0.00389	-0.17	-0.27	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
COAD	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-4.47	1.18e-05	0.00389	-0.27	-0.27	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-4.47	1.18e-05	0.00389	-0.27	-0.27	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
COAD	cis	rs7584330	0.554	rs6760913	ENSG00000234949.2	AC104667.3	-4.47	1.18e-05	0.00389	-0.46	-0.27	Prostate cancer;	chr2:237492059	chr2:237591020~237595981:+
COAD	cis	rs6964833	0.554	rs2527367	ENSG00000277053.3	GTF2IP1	4.47	1.18e-05	0.00389	0.31	0.27	Menarche (age at onset);	chr7:74684804	chr7:75185385~75237696:-
COAD	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-4.47	1.18e-05	0.00389	-0.33	-0.27	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
COAD	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-4.47	1.18e-05	0.00389	-0.32	-0.27	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
COAD	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-4.47	1.18e-05	0.00389	-0.32	-0.27	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
COAD	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-4.47	1.18e-05	0.0039	-0.41	-0.27	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
COAD	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	4.47	1.18e-05	0.0039	0.37	0.27	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
COAD	cis	rs11681884	0.786	rs17042750	ENSG00000228251.1	AC012442.6	4.47	1.18e-05	0.0039	0.6	0.27	Stroke;	chr2:113065574	chr2:112590796~112591939:+
COAD	cis	rs9307551	0.948	rs4389603	ENSG00000250334.4	LINC00989	-4.47	1.18e-05	0.0039	-0.35	-0.27	Refractive error;	chr4:79567720	chr4:79492416~79576460:+
COAD	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-4.47	1.18e-05	0.0039	-0.33	-0.27	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
COAD	cis	rs71636778	0.509	rs34175245	ENSG00000260063.1	RP5-968P14.2	-4.47	1.18e-05	0.0039	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26675220	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12753981	ENSG00000260063.1	RP5-968P14.2	-4.47	1.18e-05	0.0039	-0.55	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26675402	chr1:26692132~26694131:-
COAD	cis	rs597539	0.652	rs11603827	ENSG00000255741.1	RP11-757G1.5	-4.47	1.18e-05	0.0039	-0.36	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68941503~68942852:-
COAD	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-4.47	1.18e-05	0.0039	-0.33	-0.27	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
COAD	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-4.47	1.18e-05	0.00391	-0.38	-0.27	Depression;	chr6:28076704	chr6:28115628~28116551:+
COAD	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	4.47	1.18e-05	0.00391	0.39	0.27	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
COAD	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	4.47	1.18e-05	0.00391	0.27	0.27	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
COAD	cis	rs7615952	0.558	rs7641353	ENSG00000248787.1	RP11-666A20.4	-4.47	1.18e-05	0.00391	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125621035	chr3:125908005~125910272:-
COAD	cis	rs6095360	0.727	rs35989889	ENSG00000222365.1	SNORD12B	-4.47	1.18e-05	0.00391	-0.28	-0.27	Intelligence (multi-trait analysis);	chr20:49100816	chr20:49280319~49280409:+
COAD	cis	rs2836974	0.644	rs11088471	ENSG00000255568.3	BRWD1-AS2	-4.47	1.19e-05	0.00391	-0.26	-0.27	Cognitive function;	chr21:39327387	chr21:39313935~39314962:+
COAD	cis	rs9625935	0.518	rs5752972	ENSG00000279159.1	RP3-394A18.1	4.47	1.19e-05	0.00391	0.18	0.27	Tonsillectomy;	chr22:29854323	chr22:29978950~30028236:-
COAD	cis	rs9392556	0.533	rs619439	ENSG00000230648.1	RP3-406P24.3	4.47	1.19e-05	0.00391	0.31	0.27	Blood metabolite levels;	chr6:4113695	chr6:4018843~4021215:-
COAD	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	4.47	1.19e-05	0.00392	0.39	0.27	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
COAD	cis	rs9625935	0.518	rs713718	ENSG00000279159.1	RP3-394A18.1	4.47	1.19e-05	0.00392	0.18	0.27	Tonsillectomy;	chr22:29918103	chr22:29978950~30028236:-
COAD	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-4.47	1.19e-05	0.00392	-0.49	-0.27	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-4.47	1.19e-05	0.00392	-0.49	-0.27	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
COAD	cis	rs9393813	0.528	rs9468141	ENSG00000271755.1	RP1-153G14.4	4.47	1.19e-05	0.00392	0.31	0.27	Bipolar disorder;	chr6:27506748	chr6:27404010~27406964:-
COAD	cis	rs227275	0.525	rs7660298	ENSG00000230069.3	LRRC37A15P	-4.47	1.19e-05	0.00393	-0.3	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.844	rs7694724	ENSG00000230069.3	LRRC37A15P	-4.47	1.19e-05	0.00393	-0.3	-0.27	Schizophrenia;	chr4:103041375	chr4:102727274~102730721:-
COAD	cis	rs3743162	0.553	rs12900463	ENSG00000259728.4	LINC00933	4.47	1.19e-05	0.00393	0.37	0.27	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84570649~84580175:+
COAD	cis	rs3743162	0.553	rs12915656	ENSG00000259728.4	LINC00933	4.47	1.19e-05	0.00393	0.37	0.27	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84570649~84580175:+
COAD	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	4.47	1.19e-05	0.00393	0.3	0.27	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
COAD	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	4.47	1.19e-05	0.00393	0.3	0.27	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
COAD	cis	rs4704187	0.663	rs1477935	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75152669	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.617	rs1477936	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75152677	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs2059159	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75155353	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs10462354	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75157202	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs28376290	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75158881	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4703655	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75159238	chr5:75047719~75052843:-
COAD	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	4.47	1.19e-05	0.00393	0.3	0.27	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
COAD	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-4.47	1.19e-05	0.00393	-0.41	-0.27	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
COAD	cis	rs12497850	0.931	rs7627404	ENSG00000225399.4	RP11-3B7.1	4.47	1.19e-05	0.00393	0.3	0.27	Parkinson's disease;	chr3:48782235	chr3:49260085~49261316:+
COAD	cis	rs4704187	0.687	rs6894048	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75161013	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4704179	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75161448	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs965735	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75163395	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6885071	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75164220	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs7711762	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75165850	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1363577	ENSG00000250889.2	LINC01336	-4.47	1.19e-05	0.00393	-0.3	-0.27	Response to amphetamines;	chr5:75167360	chr5:75047719~75052843:-
COAD	cis	rs2007126	0.706	rs10739768	ENSG00000204055.4	RP11-247A12.2	4.47	1.19e-05	0.00393	0.54	0.27	LDL peak particle diameter (total fat intake interaction);	chr9:129954605	chr9:129176771~129210548:+
COAD	cis	rs7829975	0.56	rs4841013	ENSG00000253981.4	ALG1L13P	-4.47	1.19e-05	0.00393	-0.33	-0.27	Mood instability;	chr8:8694503	chr8:8236003~8244667:-
COAD	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	4.47	1.19e-05	0.00393	0.35	0.27	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
COAD	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	4.47	1.19e-05	0.00393	0.35	0.27	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
COAD	cis	rs4074961	0.527	rs10908356	ENSG00000233621.1	LINC01137	-4.47	1.19e-05	0.00394	-0.29	-0.27	Axial length;	chr1:37572787	chr1:37454879~37474411:-
COAD	cis	rs9450351	0.744	rs35510369	ENSG00000203875.9	SNHG5	-4.47	1.19e-05	0.00394	-0.51	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85556411	chr6:85660950~85678736:-
COAD	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-4.47	1.2e-05	0.00394	-0.15	-0.27	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
COAD	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-4.47	1.2e-05	0.00394	-0.15	-0.27	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
COAD	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	4.47	1.2e-05	0.00394	0.3	0.27	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
COAD	cis	rs4698036	0.586	rs7672759	ENSG00000250413.1	RP11-448G15.1	-4.47	1.2e-05	0.00394	-0.35	-0.27	Cardiovascular disease risk factors;	chr4:10283391	chr4:10006482~10009725:+
COAD	cis	rs6661961	0.698	rs4845433	ENSG00000237975.5	FLG-AS1	-4.47	1.2e-05	0.00394	-0.28	-0.27	Atopic dermatitis;	chr1:152441963	chr1:152168125~152445456:+
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	4.47	1.2e-05	0.00395	0.16	0.27	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
COAD	cis	rs1510272	0.806	rs4234313	ENSG00000243926.1	TIPARP-AS1	-4.47	1.2e-05	0.00395	-0.3	-0.27	Testicular germ cell tumor;	chr3:156611893	chr3:156671862~156674378:-
COAD	cis	rs1510272	0.889	rs2063349	ENSG00000243926.1	TIPARP-AS1	-4.47	1.2e-05	0.00395	-0.3	-0.27	Testicular germ cell tumor;	chr3:156612356	chr3:156671862~156674378:-
COAD	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	4.47	1.2e-05	0.00395	0.22	0.27	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
COAD	cis	rs453301	0.686	rs28665409	ENSG00000173295.6	FAM86B3P	-4.47	1.2e-05	0.00395	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9011767	chr8:8228595~8244865:+
COAD	cis	rs7577696	0.513	rs212685	ENSG00000272716.1	RP11-563N4.1	4.46	1.2e-05	0.00396	0.32	0.27	Inflammatory biomarkers;	chr2:32209632	chr2:32165046~32165757:-
COAD	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-4.46	1.2e-05	0.00396	-0.5	-0.27	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-4.46	1.2e-05	0.00396	-0.5	-0.27	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
COAD	cis	rs4704187	0.617	rs6898134	ENSG00000250889.2	LINC01336	-4.46	1.2e-05	0.00396	-0.3	-0.27	Response to amphetamines;	chr5:75160906	chr5:75047719~75052843:-
COAD	cis	rs6543140	0.964	rs6543138	ENSG00000234389.1	AC007278.3	4.46	1.2e-05	0.00396	0.28	0.27	Blood protein levels;	chr2:102449672	chr2:102438713~102440475:+
COAD	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	4.46	1.2e-05	0.00396	0.43	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
COAD	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-4.46	1.2e-05	0.00396	-0.28	-0.27	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
COAD	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	4.46	1.2e-05	0.00396	0.48	0.27	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
COAD	cis	rs9532669	0.89	rs11619117	ENSG00000239827.7	SUGT1P3	-4.46	1.2e-05	0.00397	-0.22	-0.27	Cervical cancer;	chr13:40880020	chr13:40908159~40921774:-
COAD	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-4.46	1.2e-05	0.00397	-0.54	-0.27	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
COAD	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	4.46	1.21e-05	0.00397	0.19	0.27	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
COAD	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-4.46	1.21e-05	0.00397	-0.15	-0.27	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
COAD	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-4.46	1.21e-05	0.00397	-0.38	-0.27	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
COAD	cis	rs6951245	0.678	rs4724725	ENSG00000229043.2	AC091729.9	-4.46	1.21e-05	0.00397	-0.42	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1175115	chr7:1160374~1165267:+
COAD	cis	rs17772222	1	rs56987357	ENSG00000258789.1	RP11-507K2.3	-4.46	1.21e-05	0.00398	-0.38	-0.27	Coronary artery calcification;	chr14:88358019	chr14:88551597~88552493:+
COAD	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-4.46	1.21e-05	0.00398	-0.33	-0.27	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
COAD	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	4.46	1.21e-05	0.00398	0.28	0.27	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
COAD	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-4.46	1.21e-05	0.00398	-0.33	-0.27	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
COAD	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-4.46	1.21e-05	0.00398	-0.42	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
COAD	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-4.46	1.21e-05	0.00398	-0.42	-0.27	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
COAD	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-4.46	1.21e-05	0.00398	-0.39	-0.27	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
COAD	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	4.46	1.21e-05	0.00398	0.33	0.27	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
COAD	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-4.46	1.21e-05	0.00398	-0.43	-0.27	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
COAD	cis	rs7615952	0.512	rs4234285	ENSG00000248787.1	RP11-666A20.4	-4.46	1.21e-05	0.00398	-0.35	-0.27	Blood pressure (smoking interaction);	chr3:125685633	chr3:125908005~125910272:-
COAD	cis	rs891378	1	rs971318	ENSG00000274245.1	RP11-357P18.2	4.46	1.21e-05	0.00398	0.37	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302251	chr1:207372559~207373252:+
COAD	cis	rs2617170	0.961	rs2617171	ENSG00000245648.1	RP11-277P12.20	4.46	1.21e-05	0.00399	0.35	0.27	Behcet's disease;	chr12:10408680	chr12:10363769~10398506:+
COAD	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-4.46	1.21e-05	0.00399	-0.34	-0.27	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
COAD	cis	rs7224610	0.932	rs10852974	ENSG00000263096.1	RP11-515O17.2	4.46	1.21e-05	0.004	0.32	0.27	Urate levels;	chr17:55295205	chr17:55271504~55273653:-
COAD	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-4.46	1.21e-05	0.004	-0.33	-0.27	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
COAD	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	4.46	1.22e-05	0.004	0.46	0.27	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
COAD	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	4.46	1.22e-05	0.004	0.26	0.27	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	4.46	1.22e-05	0.004	0.26	0.27	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	4.46	1.22e-05	0.004	0.26	0.27	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
COAD	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-4.46	1.22e-05	0.00401	-0.33	-0.27	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
COAD	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
COAD	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-4.46	1.22e-05	0.00401	-0.5	-0.27	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
COAD	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-4.46	1.22e-05	0.00401	-0.3	-0.27	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
COAD	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	4.46	1.22e-05	0.00401	0.32	0.27	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
COAD	cis	rs9291683	0.546	rs10939672	ENSG00000250413.1	RP11-448G15.1	-4.46	1.22e-05	0.00401	-0.35	-0.27	Bone mineral density;	chr4:10050512	chr4:10006482~10009725:+
COAD	cis	rs7818688	1	rs112529587	ENSG00000253528.2	RP11-347C18.4	-4.46	1.22e-05	0.00401	-0.42	-0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95047807	chr8:94974573~94974853:-
COAD	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-4.46	1.22e-05	0.00401	-0.39	-0.27	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-4.46	1.22e-05	0.00401	-0.39	-0.27	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.876	rs58655091	ENSG00000258789.1	RP11-507K2.3	-4.46	1.22e-05	0.00402	-0.39	-0.27	Coronary artery calcification;	chr14:88748567	chr14:88551597~88552493:+
COAD	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
COAD	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-4.46	1.22e-05	0.00402	-0.51	-0.27	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
COAD	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-4.46	1.22e-05	0.00402	-0.33	-0.27	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
COAD	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	4.46	1.22e-05	0.00402	0.26	0.27	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
COAD	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-4.46	1.22e-05	0.00402	-0.34	-0.27	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
COAD	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-4.46	1.22e-05	0.00402	-0.31	-0.27	Height;	chr3:53093751	chr3:53064283~53065091:-
COAD	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	4.46	1.22e-05	0.00402	0.37	0.27	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
COAD	cis	rs4704187	0.687	rs6858969	ENSG00000250889.2	LINC01336	-4.46	1.23e-05	0.00403	-0.3	-0.27	Response to amphetamines;	chr5:75083456	chr5:75047719~75052843:-
COAD	cis	rs9376098	0.668	rs210962	ENSG00000232876.1	CTA-212D2.2	-4.46	1.23e-05	0.00403	-0.36	-0.27	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135182647	chr6:135055033~135060550:+
COAD	cis	rs597539	0.652	rs516425	ENSG00000255741.1	RP11-757G1.5	-4.46	1.23e-05	0.00403	-0.35	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68941503~68942852:-
COAD	cis	rs7955901	0.837	rs7956771	ENSG00000258053.1	CTD-2021H9.3	-4.46	1.23e-05	0.00403	-0.32	-0.27	Type 2 diabetes;	chr12:71027106	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.774	rs7957932	ENSG00000258053.1	CTD-2021H9.3	-4.46	1.23e-05	0.00403	-0.32	-0.27	Type 2 diabetes;	chr12:71027772	chr12:71047402~71118247:-
COAD	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-4.46	1.23e-05	0.00403	-0.32	-0.27	QT interval;	chr12:29343291	chr12:29280418~29317848:-
COAD	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-4.46	1.23e-05	0.00403	-0.51	-0.27	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
COAD	cis	rs7615952	0.546	rs2976733	ENSG00000248787.1	RP11-666A20.4	-4.46	1.23e-05	0.00403	-0.35	-0.27	Blood pressure (smoking interaction);	chr3:125695294	chr3:125908005~125910272:-
COAD	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-4.46	1.23e-05	0.00403	-0.48	-0.27	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
COAD	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	4.46	1.23e-05	0.00403	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
COAD	cis	rs710913	0.618	rs11206437	ENSG00000182109.6	RP11-69E11.4	4.46	1.23e-05	0.00404	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39522280~39546187:-
COAD	cis	rs4927850	0.881	rs7624638	ENSG00000273009.1	RP11-352G9.1	-4.46	1.23e-05	0.00404	-0.29	-0.27	Pancreatic cancer;	chr3:196021858	chr3:195913078~195913683:-
COAD	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	4.46	1.23e-05	0.00404	0.3	0.27	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
COAD	cis	rs7577696	0.785	rs6723154	ENSG00000272716.1	RP11-563N4.1	-4.46	1.23e-05	0.00404	-0.29	-0.27	Inflammatory biomarkers;	chr2:32140092	chr2:32165046~32165757:-
COAD	cis	rs72827839	0.739	rs16953235	ENSG00000263412.1	RP5-890E16.2	4.46	1.23e-05	0.00404	0.38	0.27	Ease of getting up in the morning;	chr17:48167586	chr17:48045141~48048073:-
COAD	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	4.46	1.23e-05	0.00404	0.34	0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
COAD	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	4.46	1.23e-05	0.00404	0.3	0.27	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
COAD	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	4.46	1.23e-05	0.00404	0.3	0.27	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
COAD	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	4.46	1.23e-05	0.00405	0.27	0.27	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	4.46	1.23e-05	0.00405	0.27	0.27	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	4.46	1.23e-05	0.00405	0.27	0.27	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
COAD	cis	rs13217239	0.646	rs7451149	ENSG00000224843.5	LINC00240	4.46	1.23e-05	0.00405	0.31	0.27	Schizophrenia;	chr6:27089739	chr6:26956992~27023924:+
COAD	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.23e-05	0.00405	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-4.46	1.23e-05	0.00405	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
COAD	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.24e-05	0.00405	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.24e-05	0.00405	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
COAD	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.24e-05	0.00405	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
COAD	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	4.46	1.24e-05	0.00405	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
COAD	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	4.46	1.24e-05	0.00405	0.3	0.27	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
COAD	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	4.46	1.24e-05	0.00405	0.24	0.27	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
COAD	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	4.46	1.24e-05	0.00405	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
COAD	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-4.46	1.24e-05	0.00406	-0.29	-0.27	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
COAD	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	4.46	1.24e-05	0.00406	0.45	0.27	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
COAD	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	4.46	1.24e-05	0.00406	0.33	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
COAD	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	4.46	1.24e-05	0.00406	0.35	0.27	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
COAD	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-4.46	1.24e-05	0.00406	-0.37	-0.27	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
COAD	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	4.46	1.24e-05	0.00406	0.3	0.27	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
COAD	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	4.46	1.24e-05	0.00406	0.3	0.27	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
COAD	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	4.46	1.24e-05	0.00406	0.3	0.27	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
COAD	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	4.46	1.24e-05	0.00406	0.29	0.27	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
COAD	cis	rs7615952	1	rs9289275	ENSG00000241278.1	ENPP7P4	4.46	1.24e-05	0.00406	0.3	0.27	Blood pressure (smoking interaction);	chr3:125929816	chr3:125848223~125909372:+
COAD	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	4.46	1.24e-05	0.00406	0.31	0.27	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	4.46	1.24e-05	0.00406	0.31	0.27	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	4.46	1.24e-05	0.00406	0.31	0.27	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
COAD	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-4.46	1.24e-05	0.00406	-0.35	-0.27	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
COAD	cis	rs17685	0.672	rs55807301	ENSG00000280388.1	RP11-229D13.3	-4.46	1.24e-05	0.00406	-0.28	-0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76043977~76045963:-
COAD	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-4.46	1.24e-05	0.00407	-0.33	-0.27	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
COAD	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-4.46	1.24e-05	0.00407	-0.28	-0.27	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
COAD	cis	rs8022206	0.773	rs2009191	ENSG00000259502.1	RP11-643G16.3	4.46	1.24e-05	0.00407	0.35	0.27	Platelet count;Mean platelet volume;	chr14:67910990	chr14:67610986~67613864:+
COAD	cis	rs362272	0.545	rs2239725	ENSG00000248840.2	RP11-357G3.2	-4.46	1.24e-05	0.00407	-0.31	-0.27	Serum sulfate level;	chr4:3304012	chr4:3312512~3313058:+
COAD	cis	rs8141529	0.748	rs6005936	ENSG00000272858.1	CTA-292E10.8	-4.46	1.24e-05	0.00408	-0.33	-0.27	Lymphocyte counts;	chr22:28893262	chr22:28814914~28815662:+
COAD	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	4.46	1.25e-05	0.00408	0.34	0.27	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
COAD	cis	rs7430456	0.967	rs6780021	ENSG00000228221.4	LINC00578	4.46	1.25e-05	0.00408	0.23	0.27	Breast cancer;	chr3:177739677	chr3:177441921~177752305:+
COAD	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	4.46	1.25e-05	0.00408	0.21	0.27	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
COAD	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	4.46	1.25e-05	0.00408	0.41	0.27	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
COAD	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	4.46	1.25e-05	0.00408	0.36	0.27	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
COAD	cis	rs180730	1	rs3114955	ENSG00000251609.2	SETP12	-4.46	1.25e-05	0.00408	-0.39	-0.27	Fasting plasma glucose;	chr4:120884835	chr4:120895494~120897083:-
COAD	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	4.46	1.25e-05	0.00408	0.16	0.27	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
COAD	cis	rs7646881	0.544	rs16847130	ENSG00000272087.1	RP11-379F4.7	4.46	1.25e-05	0.00408	0.44	0.27	Tetralogy of Fallot;	chr3:158705785	chr3:158693120~158693768:-
COAD	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	4.46	1.25e-05	0.00409	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	4.46	1.25e-05	0.00409	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	4.46	1.25e-05	0.00409	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
COAD	cis	rs9532669	0.926	rs2324737	ENSG00000239827.7	SUGT1P3	-4.46	1.25e-05	0.00409	-0.23	-0.27	Cervical cancer;	chr13:40862808	chr13:40908159~40921774:-
COAD	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	4.46	1.25e-05	0.00409	0.33	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
COAD	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	4.46	1.25e-05	0.00409	0.27	0.27	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
COAD	cis	rs6490294	0.528	rs10850007	ENSG00000257595.2	RP3-473L9.4	4.46	1.25e-05	0.00409	0.43	0.27	Mean platelet volume;	chr12:112178627	chr12:111369282~111403310:+
COAD	cis	rs9532669	0.926	rs6560963	ENSG00000239827.7	SUGT1P3	-4.46	1.25e-05	0.0041	-0.23	-0.27	Cervical cancer;	chr13:40871126	chr13:40908159~40921774:-
COAD	cis	rs7209700	0.662	rs8066295	ENSG00000228782.6	CTD-2026D20.3	4.46	1.25e-05	0.0041	0.3	0.27	IgG glycosylation;	chr17:47270837	chr17:47450568~47492492:-
COAD	cis	rs9400467	0.528	rs462432	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.25e-05	0.0041	-0.26	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111297126~111298510:+
COAD	cis	rs7760535	0.931	rs466923	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.25e-05	0.0041	-0.26	-0.27	Metabolic traits;	chr6:111341774	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs1623806	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.25e-05	0.0041	-0.26	-0.27	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111297126~111298510:+
COAD	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-4.45	1.25e-05	0.0041	-0.32	-0.27	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
COAD	cis	rs6545883	0.56	rs11677775	ENSG00000273302.1	RP11-493E12.2	-4.45	1.25e-05	0.0041	-0.25	-0.27	Tuberculosis;	chr2:61275975	chr2:61199979~61200769:+
COAD	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	4.45	1.25e-05	0.0041	0.34	0.27	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
COAD	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	4.45	1.26e-05	0.00411	0.33	0.27	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
COAD	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	4.45	1.26e-05	0.00411	0.31	0.27	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
COAD	cis	rs2836974	0.623	rs7280326	ENSG00000255568.3	BRWD1-AS2	-4.45	1.26e-05	0.00411	-0.26	-0.27	Cognitive function;	chr21:39328482	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.644	rs2836986	ENSG00000255568.3	BRWD1-AS2	-4.45	1.26e-05	0.00411	-0.26	-0.27	Cognitive function;	chr21:39330210	chr21:39313935~39314962:+
COAD	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-4.45	1.26e-05	0.00411	-0.36	-0.27	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
COAD	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-4.45	1.26e-05	0.00412	-0.47	-0.27	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
COAD	cis	rs12497850	0.931	rs11924597	ENSG00000225399.4	RP11-3B7.1	4.45	1.26e-05	0.00412	0.3	0.27	Parkinson's disease;	chr3:48900357	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.897	rs9850134	ENSG00000225399.4	RP11-3B7.1	4.45	1.26e-05	0.00412	0.3	0.27	Parkinson's disease;	chr3:48919714	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9867373	ENSG00000225399.4	RP11-3B7.1	4.45	1.26e-05	0.00412	0.3	0.27	Parkinson's disease;	chr3:48923505	chr3:49260085~49261316:+
COAD	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-4.45	1.26e-05	0.00412	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-4.45	1.26e-05	0.00412	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-4.45	1.26e-05	0.00412	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-4.45	1.26e-05	0.00412	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-4.45	1.26e-05	0.00412	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
COAD	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-4.45	1.26e-05	0.00412	-0.5	-0.27	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-4.45	1.26e-05	0.00412	-0.5	-0.27	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-4.45	1.26e-05	0.00412	-0.5	-0.27	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
COAD	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-4.45	1.26e-05	0.00412	-0.5	-0.27	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-4.45	1.26e-05	0.00412	-0.5	-0.27	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
COAD	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-4.45	1.26e-05	0.00412	-0.18	-0.27	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
COAD	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-4.45	1.26e-05	0.00412	-0.24	-0.27	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
COAD	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00412	-0.34	-0.27	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00412	-0.34	-0.27	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00412	-0.34	-0.27	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00412	-0.34	-0.27	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00412	-0.34	-0.27	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
COAD	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-4.45	1.26e-05	0.00412	-0.4	-0.27	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
COAD	cis	rs4657482	0.962	rs6703280	ENSG00000236364.3	RP11-525G13.2	-4.45	1.26e-05	0.00412	-0.2	-0.27	Testicular germ cell tumor;	chr1:165871174	chr1:165890795~165900683:-
COAD	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-4.45	1.26e-05	0.00412	-0.23	-0.27	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
COAD	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-4.45	1.26e-05	0.00412	-0.31	-0.27	Height;	chr3:53047596	chr3:53064283~53065091:-
COAD	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-4.45	1.26e-05	0.00412	-0.31	-0.27	Height;	chr3:53052712	chr3:53064283~53065091:-
COAD	cis	rs17772222	0.917	rs1956406	ENSG00000258789.1	RP11-507K2.3	-4.45	1.26e-05	0.00412	-0.39	-0.27	Coronary artery calcification;	chr14:88749711	chr14:88551597~88552493:+
COAD	cis	rs875971	0.545	rs67397473	ENSG00000224316.1	RP11-479O9.2	4.45	1.26e-05	0.00413	0.33	0.27	Aortic root size;	chr7:66168318	chr7:65773620~65802067:+
COAD	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-4.45	1.26e-05	0.00413	-0.34	-0.27	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
COAD	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.26e-05	0.00413	-0.31	-0.27	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
COAD	cis	rs12908161	0.683	rs12903256	ENSG00000259728.4	LINC00933	4.45	1.26e-05	0.00413	0.32	0.27	Schizophrenia;	chr15:84764910	chr15:84570649~84580175:+
COAD	cis	rs7674212	0.541	rs2720460	ENSG00000230069.3	LRRC37A15P	4.45	1.26e-05	0.00413	0.29	0.27	Type 2 diabetes;	chr4:103133529	chr4:102727274~102730721:-
COAD	cis	rs875971	0.522	rs1917563	ENSG00000272831.1	RP11-792A8.4	-4.45	1.26e-05	0.00413	-0.28	-0.27	Aortic root size;	chr7:65950660	chr7:66739829~66740385:-
COAD	cis	rs1578862	1	rs1578862	ENSG00000259865.1	RP11-488L18.10	-4.45	1.26e-05	0.00413	-0.21	-0.27	Monocyte percentage of white cells;	chr1:247264315	chr1:247187281~247188526:-
COAD	cis	rs7656342	0.93	rs1829413	ENSG00000186234.7	FAM86MP	-4.45	1.26e-05	0.00413	-0.35	-0.27	Gut microbiota (bacterial taxa);	chr4:9790715	chr4:9692495~9702954:+
COAD	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.45	1.27e-05	0.00413	0.32	0.27	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
COAD	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-4.45	1.27e-05	0.00413	-0.29	-0.27	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
COAD	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	4.45	1.27e-05	0.00413	0.36	0.27	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
COAD	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-4.45	1.27e-05	0.00413	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
COAD	cis	rs17711722	1	rs17711722	ENSG00000272831.1	RP11-792A8.4	-4.45	1.27e-05	0.00413	-0.28	-0.27	Calcium levels;	chr7:65806210	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000272831.1	RP11-792A8.4	-4.45	1.27e-05	0.00413	-0.28	-0.27	Calcium levels;	chr7:65808508	chr7:66739829~66740385:-
COAD	cis	rs11096990	0.613	rs12643415	ENSG00000249685.1	RP11-360F5.3	-4.45	1.27e-05	0.00414	-0.27	-0.27	Cognitive function;	chr4:39270375	chr4:39133913~39135608:+
COAD	cis	rs367615	0.642	rs439182	ENSG00000249476.1	CTD-2587M2.1	-4.45	1.27e-05	0.00414	-0.33	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109616666	chr5:109237120~109326369:-
COAD	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-4.45	1.27e-05	0.00414	-0.26	-0.27	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
COAD	cis	rs12497850	0.931	rs7621015	ENSG00000225399.4	RP11-3B7.1	4.45	1.27e-05	0.00414	0.3	0.27	Parkinson's disease;	chr3:48978623	chr3:49260085~49261316:+
COAD	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	4.45	1.27e-05	0.00414	0.37	0.27	Depression;	chr6:28086929	chr6:28115628~28116551:+
COAD	cis	rs453301	0.686	rs3895823	ENSG00000254340.1	RP11-10A14.3	-4.45	1.27e-05	0.00414	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9016136	chr8:9141424~9145435:+
COAD	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-4.45	1.27e-05	0.00414	-0.33	-0.27	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
COAD	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-4.45	1.27e-05	0.00414	-0.33	-0.27	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
COAD	cis	rs875971	0.522	rs1880556	ENSG00000272831.1	RP11-792A8.4	4.45	1.27e-05	0.00414	0.28	0.27	Aortic root size;	chr7:65967557	chr7:66739829~66740385:-
COAD	cis	rs8022206	0.773	rs6573801	ENSG00000259502.1	RP11-643G16.3	4.45	1.27e-05	0.00414	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67946658	chr14:67610986~67613864:+
COAD	cis	rs5758511	0.773	rs12167978	ENSG00000237037.8	NDUFA6-AS1	-4.45	1.27e-05	0.00414	-0.29	-0.27	Birth weight;	chr22:41950471	chr22:42090931~42137742:+
COAD	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-4.45	1.27e-05	0.00415	-0.29	-0.27	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
COAD	cis	rs754466	0.914	rs4595491	ENSG00000204049.1	RP11-126H7.4	4.45	1.27e-05	0.00415	0.37	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77926075	chr10:77866875~77869610:+
COAD	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	4.45	1.27e-05	0.00415	0.43	0.27	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
COAD	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	4.45	1.27e-05	0.00415	0.31	0.27	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
COAD	cis	rs6940638	0.744	rs858964	ENSG00000224843.5	LINC00240	-4.45	1.27e-05	0.00416	-0.33	-0.27	Intelligence (multi-trait analysis);	chr6:27174835	chr6:26956992~27023924:+
COAD	cis	rs7688540	0.8	rs11723492	ENSG00000198155.5	ZNF876P	-4.45	1.27e-05	0.00416	-0.41	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:212610~255985:+
COAD	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	4.45	1.28e-05	0.00416	0.32	0.27	Height;	chr4:55532542	chr4:55540502~55540835:-
COAD	cis	rs2638953	0.962	rs10843150	ENSG00000247934.4	RP11-967K21.1	4.45	1.28e-05	0.00416	0.29	0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28304869	chr12:28163298~28190738:-
COAD	cis	rs7193541	0.965	rs4402594	ENSG00000262904.1	TMPOP2	-4.45	1.28e-05	0.00416	-0.28	-0.27	Multiple myeloma;	chr16:74667462	chr16:74667506~74668706:+
COAD	cis	rs2836974	0.568	rs428602	ENSG00000255568.3	BRWD1-AS2	4.45	1.28e-05	0.00416	0.26	0.27	Cognitive function;	chr21:39175078	chr21:39313935~39314962:+
COAD	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	4.45	1.28e-05	0.00417	0.3	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
COAD	cis	rs362272	0.545	rs3135145	ENSG00000248840.2	RP11-357G3.2	-4.45	1.28e-05	0.00417	-0.31	-0.27	Serum sulfate level;	chr4:3297777	chr4:3312512~3313058:+
COAD	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	4.45	1.28e-05	0.00417	0.34	0.27	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
COAD	cis	rs2252521	0.583	rs320088	ENSG00000272568.4	CTB-113D17.1	4.45	1.28e-05	0.00417	0.49	0.27	Cognitive performance;	chr7:29043646	chr7:28979967~29013367:+
COAD	cis	rs2252521	0.614	rs317703	ENSG00000272568.4	CTB-113D17.1	4.45	1.28e-05	0.00417	0.49	0.27	Cognitive performance;	chr7:29047610	chr7:28979967~29013367:+
COAD	cis	rs2252521	0.526	rs317704	ENSG00000272568.4	CTB-113D17.1	4.45	1.28e-05	0.00417	0.49	0.27	Cognitive performance;	chr7:29047727	chr7:28979967~29013367:+
COAD	cis	rs728616	0.867	rs61859977	ENSG00000225484.5	NUTM2B-AS1	-4.45	1.28e-05	0.00417	-0.5	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80123933	chr10:79663088~79826594:-
COAD	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-4.45	1.28e-05	0.00417	-0.32	-0.27	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
COAD	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-4.45	1.28e-05	0.00417	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-4.45	1.28e-05	0.00417	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
COAD	cis	rs7955901	0.563	rs1397566	ENSG00000258053.1	CTD-2021H9.3	-4.45	1.28e-05	0.00418	-0.31	-0.27	Type 2 diabetes;	chr12:71132897	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.563	rs1705261	ENSG00000258053.1	CTD-2021H9.3	-4.45	1.28e-05	0.00418	-0.31	-0.27	Type 2 diabetes;	chr12:71133866	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.563	rs1615252	ENSG00000258053.1	CTD-2021H9.3	-4.45	1.28e-05	0.00418	-0.31	-0.27	Type 2 diabetes;	chr12:71133927	chr12:71047402~71118247:-
COAD	cis	rs763121	0.853	rs4821798	ENSG00000273076.1	RP3-508I15.22	4.45	1.28e-05	0.00418	0.23	0.27	Menopause (age at onset);	chr22:38625160	chr22:38743495~38743910:+
COAD	cis	rs9907295	0.591	rs8069014	ENSG00000271013.1	AC015849.15	-4.45	1.28e-05	0.00418	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35912635~35918010:-
COAD	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	4.45	1.28e-05	0.00418	0.31	0.27	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
COAD	cis	rs2980439	0.87	rs2945230	ENSG00000254340.1	RP11-10A14.3	4.45	1.28e-05	0.00418	0.31	0.27	Neuroticism;	chr8:8252414	chr8:9141424~9145435:+
COAD	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-4.45	1.28e-05	0.00418	-0.34	-0.27	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
COAD	cis	rs7577696	0.597	rs34197800	ENSG00000272716.1	RP11-563N4.1	-4.45	1.28e-05	0.00418	-0.31	-0.27	Inflammatory biomarkers;	chr2:32164577	chr2:32165046~32165757:-
COAD	cis	rs9307551	0.656	rs6818695	ENSG00000250334.4	LINC00989	-4.45	1.28e-05	0.00418	-0.36	-0.27	Refractive error;	chr4:79540680	chr4:79492416~79576460:+
COAD	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	4.45	1.29e-05	0.00419	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
COAD	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	4.45	1.29e-05	0.00419	0.29	0.27	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
COAD	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	4.45	1.29e-05	0.00419	0.46	0.27	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
COAD	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-4.45	1.29e-05	0.00419	-0.45	-0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
COAD	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-4.45	1.29e-05	0.00419	-0.3	-0.27	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
COAD	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	4.45	1.29e-05	0.00419	0.28	0.27	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
COAD	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	4.45	1.29e-05	0.0042	0.23	0.27	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
COAD	cis	rs2243480	1	rs10807702	ENSG00000229886.1	RP5-1132H15.3	4.45	1.29e-05	0.0042	0.46	0.27	Diabetic kidney disease;	chr7:66302856	chr7:66025126~66031544:-
COAD	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-4.45	1.29e-05	0.0042	-0.17	-0.27	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
COAD	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-4.45	1.29e-05	0.0042	-0.3	-0.27	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
COAD	cis	rs2777491	0.915	rs8036498	ENSG00000247556.5	OIP5-AS1	4.45	1.29e-05	0.0042	0.29	0.27	Ulcerative colitis;	chr15:41311078	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs28583065	ENSG00000247556.5	OIP5-AS1	4.45	1.29e-05	0.0042	0.29	0.27	Ulcerative colitis;	chr15:41316272	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.874	rs7161772	ENSG00000247556.5	OIP5-AS1	4.45	1.29e-05	0.0042	0.29	0.27	Ulcerative colitis;	chr15:41318868	chr15:41283990~41309737:+
COAD	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.29e-05	0.0042	-0.25	-0.27	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
COAD	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-4.45	1.29e-05	0.0042	-0.31	-0.27	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
COAD	cis	rs453301	0.686	rs7017868	ENSG00000254340.1	RP11-10A14.3	-4.45	1.29e-05	0.0042	-0.31	-0.27	Joint mobility (Beighton score);	chr8:9015783	chr8:9141424~9145435:+
COAD	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	4.45	1.29e-05	0.0042	0.22	0.27	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
COAD	cis	rs728616	0.681	rs36073865	ENSG00000234382.2	RP11-40F6.1	-4.45	1.29e-05	0.00421	-0.44	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156299	chr10:80233664~80245367:+
COAD	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	4.45	1.29e-05	0.00421	0.28	0.27	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
COAD	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	4.45	1.29e-05	0.00421	0.3	0.27	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
COAD	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-4.45	1.29e-05	0.00421	-0.39	-0.27	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
COAD	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-4.45	1.29e-05	0.00421	-0.32	-0.27	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
COAD	cis	rs84178	0.733	rs163158	ENSG00000230834.1	AC068580.7	4.45	1.29e-05	0.00421	0.47	0.27	Glomerular filtration rate (creatinine);	chr11:2769506	chr11:1776930~1778388:-
COAD	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	4.45	1.3e-05	0.00422	0.32	0.27	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
COAD	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-4.45	1.3e-05	0.00422	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
COAD	cis	rs984222	0.741	rs1886914	ENSG00000231365.4	RP11-418J17.1	-4.45	1.3e-05	0.00423	-0.28	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998829	chr1:119140396~119275973:+
COAD	cis	rs875971	0.54	rs1723268	ENSG00000272831.1	RP11-792A8.4	4.45	1.3e-05	0.00423	0.29	0.27	Aortic root size;	chr7:66008093	chr7:66739829~66740385:-
COAD	cis	rs453301	0.597	rs7001187	ENSG00000233609.3	RP11-62H7.2	-4.45	1.3e-05	0.00423	-0.3	-0.27	Joint mobility (Beighton score);	chr8:8935272	chr8:8961200~8979025:+
COAD	cis	rs1510272	0.889	rs2063350	ENSG00000243926.1	TIPARP-AS1	-4.45	1.3e-05	0.00423	-0.3	-0.27	Testicular germ cell tumor;	chr3:156612398	chr3:156671862~156674378:-
COAD	cis	rs7200543	1	rs2740	ENSG00000270580.4	PKD1P6	4.45	1.3e-05	0.00423	0.3	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15104723~15131601:-
COAD	cis	rs9487051	0.807	rs7748641	ENSG00000219700.1	PTCHD3P3	4.45	1.3e-05	0.00423	0.28	0.27	Reticulocyte fraction of red cells;	chr6:109271178	chr6:109288571~109290503:-
COAD	cis	rs11124272	0.626	rs1978824	ENSG00000272716.1	RP11-563N4.1	-4.45	1.3e-05	0.00423	-0.32	-0.27	Interleukin-18 levels;	chr2:31942772	chr2:32165046~32165757:-
COAD	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	4.45	1.3e-05	0.00423	0.37	0.27	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
COAD	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	4.45	1.3e-05	0.00423	0.61	0.27	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
COAD	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	4.45	1.3e-05	0.00423	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
COAD	cis	rs12935418	0.583	rs7186230	ENSG00000278985.1	RP11-303E16.9	4.45	1.3e-05	0.00424	0.32	0.27	Mean corpuscular volume;	chr16:80930723	chr16:80982319~80984094:-
COAD	cis	rs12935418	0.616	rs7184568	ENSG00000278985.1	RP11-303E16.9	4.45	1.3e-05	0.00424	0.32	0.27	Mean corpuscular volume;	chr16:80930951	chr16:80982319~80984094:-
COAD	cis	rs7760535	0.763	rs10457240	ENSG00000271789.1	RP5-1112D6.7	-4.45	1.3e-05	0.00424	-0.26	-0.27	Metabolic traits;	chr6:111527671	chr6:111297126~111298510:+
COAD	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-4.45	1.3e-05	0.00424	-0.26	-0.27	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
COAD	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	4.45	1.3e-05	0.00424	0.29	0.27	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
COAD	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-4.45	1.3e-05	0.00424	-0.35	-0.27	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
COAD	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	4.45	1.3e-05	0.00424	0.26	0.27	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
COAD	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-4.45	1.3e-05	0.00424	-0.3	-0.27	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
COAD	cis	rs930421	0.731	rs13389948	ENSG00000226491.1	FTOP1	-4.45	1.31e-05	0.00424	-0.36	-0.27	Attention deficit hyperactivity disorder;	chr2:42747436	chr2:42797225~42798712:-
COAD	cis	rs2337406	1	rs10459466	ENSG00000211964.3	IGHV3-48	-4.44	1.31e-05	0.00425	-0.23	-0.27	Alzheimer's disease (late onset);	chr14:106689255	chr14:106537810~106538344:-
COAD	cis	rs2976388	0.524	rs7012804	ENSG00000253741.1	CTD-2292P10.4	-4.44	1.31e-05	0.00425	-0.29	-0.27	Urinary tract infection frequency;	chr8:142763232	chr8:142702252~142726973:-
COAD	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-4.44	1.31e-05	0.00425	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
COAD	cis	rs7818688	0.614	rs73269199	ENSG00000253528.2	RP11-347C18.4	-4.44	1.31e-05	0.00425	-0.37	-0.27	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94829485	chr8:94974573~94974853:-
COAD	cis	rs9532669	0.926	rs4555012	ENSG00000239827.7	SUGT1P3	-4.44	1.31e-05	0.00425	-0.23	-0.27	Cervical cancer;	chr13:40879997	chr13:40908159~40921774:-
COAD	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-4.44	1.31e-05	0.00426	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
COAD	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-4.44	1.31e-05	0.00426	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
COAD	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-4.44	1.31e-05	0.00426	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
COAD	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	4.44	1.31e-05	0.00426	0.37	0.27	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
COAD	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-4.44	1.31e-05	0.00426	-0.25	-0.27	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
COAD	cis	rs4713118	0.911	rs9295746	ENSG00000281706.1	LINC01012	-4.44	1.31e-05	0.00426	-0.31	-0.27	Parkinson's disease;	chr6:27762285	chr6:27694035~27710222:+
COAD	cis	rs7119	0.667	rs1058129	ENSG00000259565.2	KRT8P23	4.44	1.31e-05	0.00426	0.31	0.27	Type 2 diabetes;	chr15:77613319	chr15:76979245~76980451:-
COAD	cis	rs7845219	0.539	rs713113	ENSG00000253528.2	RP11-347C18.4	-4.44	1.31e-05	0.00426	-0.28	-0.27	Type 2 diabetes;	chr8:94865559	chr8:94974573~94974853:-
COAD	cis	rs6840360	0.582	rs2724553	ENSG00000270265.1	RP11-731D1.4	-4.44	1.31e-05	0.00426	-0.33	-0.27	Intelligence (multi-trait analysis);	chr4:151400729	chr4:151333775~151353224:-
COAD	cis	rs11124272	0.717	rs2082185	ENSG00000272716.1	RP11-563N4.1	-4.44	1.31e-05	0.00426	-0.32	-0.27	Interleukin-18 levels;	chr2:31930106	chr2:32165046~32165757:-
COAD	cis	rs875971	0.505	rs2462573	ENSG00000272831.1	RP11-792A8.4	-4.44	1.31e-05	0.00426	-0.28	-0.27	Aortic root size;	chr7:66042405	chr7:66739829~66740385:-
COAD	cis	rs875971	0.505	rs1167385	ENSG00000272831.1	RP11-792A8.4	-4.44	1.31e-05	0.00426	-0.28	-0.27	Aortic root size;	chr7:66048321	chr7:66739829~66740385:-
COAD	cis	rs7674212	0.531	rs4698875	ENSG00000248971.2	KRT8P46	-4.44	1.31e-05	0.00426	-0.28	-0.27	Type 2 diabetes;	chr4:103012211	chr4:102728746~102730171:-
COAD	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-4.44	1.31e-05	0.00426	-0.27	-0.27	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
COAD	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-4.44	1.31e-05	0.00426	-0.36	-0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
COAD	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	4.44	1.31e-05	0.00427	0.27	0.27	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
COAD	cis	rs12497850	0.865	rs13072911	ENSG00000225399.4	RP11-3B7.1	4.44	1.32e-05	0.00427	0.29	0.27	Parkinson's disease;	chr3:48924695	chr3:49260085~49261316:+
COAD	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-4.44	1.32e-05	0.00427	-0.28	-0.27	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
COAD	cis	rs2551802	0.615	rs17395735	ENSG00000226363.3	HAGLROS	-4.44	1.32e-05	0.00427	-0.38	-0.27	Motion sickness;	chr2:176203052	chr2:176177717~176179008:+
COAD	cis	rs875971	0.522	rs2008188	ENSG00000272831.1	RP11-792A8.4	4.44	1.32e-05	0.00428	0.28	0.27	Aortic root size;	chr7:65964026	chr7:66739829~66740385:-
COAD	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.44	1.32e-05	0.00428	-0.34	-0.27	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
COAD	cis	rs2337406	0.866	rs57684263	ENSG00000211967.3	IGHV3-53	-4.44	1.32e-05	0.00428	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106777263	chr14:106592676~106593347:-
COAD	cis	rs8002861	0.875	rs11616803	ENSG00000274001.1	RP11-5G9.5	-4.44	1.32e-05	0.00428	-0.25	-0.27	Leprosy;	chr13:43882973	chr13:43877715~43878163:-
COAD	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	4.44	1.32e-05	0.00428	0.19	0.27	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
COAD	cis	rs2281603	0.57	rs10134530	ENSG00000259116.1	RP11-973N13.4	4.44	1.32e-05	0.00429	0.26	0.27	Lymphocyte counts;	chr14:64484240	chr14:64514154~64540368:-
COAD	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.44	1.32e-05	0.00429	0.35	0.27	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
COAD	cis	rs1578862	0.966	rs56124448	ENSG00000259865.1	RP11-488L18.10	-4.44	1.32e-05	0.00429	-0.22	-0.27	Monocyte percentage of white cells;	chr1:247321616	chr1:247187281~247188526:-
COAD	cis	rs2836974	0.568	rs2142111	ENSG00000255568.3	BRWD1-AS2	4.44	1.32e-05	0.00429	0.26	0.27	Cognitive function;	chr21:39177363	chr21:39313935~39314962:+
COAD	cis	rs72615157	0.634	rs11762932	ENSG00000078319.8	PMS2P1	4.44	1.32e-05	0.00429	0.36	0.27	Lung function (FEV1/FVC);	chr7:100195043	chr7:100320992~100341908:-
COAD	cis	rs10170310	0.608	rs10928657	ENSG00000228043.4	AC097721.2	4.44	1.32e-05	0.00429	0.33	0.27	Response to antipsychotic treatment;	chr2:138534199	chr2:138418284~138501698:-
COAD	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	4.44	1.32e-05	0.00429	0.29	0.27	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
COAD	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-4.44	1.32e-05	0.00429	-0.27	-0.27	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
COAD	cis	rs9532669	0.926	rs9532657	ENSG00000277662.1	RP11-74J13.9	4.44	1.33e-05	0.0043	0.25	0.27	Cervical cancer;	chr13:40918208	chr13:41229180~41229676:-
COAD	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
COAD	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-4.44	1.33e-05	0.0043	-0.51	-0.27	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
COAD	cis	rs4704187	0.687	rs1582504	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.0043	-0.3	-0.27	Response to amphetamines;	chr5:75183720	chr5:75047719~75052843:-
COAD	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	4.44	1.33e-05	0.0043	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
COAD	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	4.44	1.33e-05	0.0043	0.38	0.27	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
COAD	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
COAD	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.0043	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
COAD	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	4.44	1.33e-05	0.0043	0.21	0.27	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
COAD	cis	rs9307551	0.697	rs1992367	ENSG00000250334.4	LINC00989	-4.44	1.33e-05	0.0043	-0.35	-0.27	Refractive error;	chr4:79528495	chr4:79492416~79576460:+
COAD	cis	rs8022206	0.592	rs11158715	ENSG00000259502.1	RP11-643G16.3	4.44	1.33e-05	0.0043	0.35	0.27	Platelet count;Mean platelet volume;	chr14:68022669	chr14:67610986~67613864:+
COAD	cis	rs17772222	0.917	rs57889459	ENSG00000258789.1	RP11-507K2.3	-4.44	1.33e-05	0.0043	-0.39	-0.27	Coronary artery calcification;	chr14:88770820	chr14:88551597~88552493:+
COAD	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-4.44	1.33e-05	0.0043	-0.34	-0.27	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
COAD	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	4.44	1.33e-05	0.00431	0.31	0.27	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
COAD	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-4.44	1.33e-05	0.00431	-0.33	-0.27	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
COAD	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-4.44	1.33e-05	0.00431	-0.27	-0.27	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
COAD	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.00431	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
COAD	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-4.44	1.33e-05	0.00431	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
COAD	cis	rs17685	0.753	rs13240967	ENSG00000280388.1	RP11-229D13.3	4.44	1.33e-05	0.00431	0.27	0.27	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76043977~76045963:-
COAD	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	4.44	1.33e-05	0.00431	0.33	0.27	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
COAD	cis	rs6723226	0.803	rs387780	ENSG00000276334.1	AL133243.1	4.44	1.33e-05	0.00431	0.25	0.27	Intelligence (multi-trait analysis);	chr2:32277426	chr2:32521927~32523547:+
COAD	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	4.44	1.33e-05	0.00431	0.29	0.27	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
COAD	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-4.44	1.33e-05	0.00431	-0.31	-0.27	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
COAD	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-4.44	1.33e-05	0.00431	-0.32	-0.27	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
COAD	cis	rs11976180	1	rs2961144	ENSG00000204959.4	ARHGEF34P	-4.44	1.33e-05	0.00431	-0.32	-0.27	Obesity-related traits;	chr7:144050777	chr7:144272445~144286966:-
COAD	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-4.44	1.33e-05	0.00431	-0.28	-0.27	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
COAD	cis	rs61270009	0.913	rs3733809	ENSG00000247828.6	TMEM161B-AS1	4.44	1.33e-05	0.00431	0.29	0.27	Depressive symptoms;	chr5:88410112	chr5:88268895~88436685:+
COAD	cis	rs6095360	0.727	rs13044004	ENSG00000222365.1	SNORD12B	-4.44	1.33e-05	0.00432	-0.28	-0.27	Intelligence (multi-trait analysis);	chr20:49101834	chr20:49280319~49280409:+
COAD	cis	rs7577696	0.597	rs212751	ENSG00000272716.1	RP11-563N4.1	4.44	1.33e-05	0.00432	0.31	0.27	Inflammatory biomarkers;	chr2:32193739	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.626	rs212754	ENSG00000272716.1	RP11-563N4.1	4.44	1.33e-05	0.00432	0.31	0.27	Inflammatory biomarkers;	chr2:32196559	chr2:32165046~32165757:-
COAD	cis	rs4704187	0.687	rs10036527	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.00432	-0.3	-0.27	Response to amphetamines;	chr5:75186012	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6889429	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.00432	-0.3	-0.27	Response to amphetamines;	chr5:75186358	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.64	rs4704188	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.00432	-0.3	-0.27	Response to amphetamines;	chr5:75186850	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6898116	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.00432	-0.3	-0.27	Response to amphetamines;	chr5:75190953	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs4704189	ENSG00000250889.2	LINC01336	-4.44	1.33e-05	0.00432	-0.3	-0.27	Response to amphetamines;	chr5:75191550	chr5:75047719~75052843:-
COAD	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	4.44	1.33e-05	0.00432	0.32	0.27	Height;	chr4:55542243	chr4:55540502~55540835:-
COAD	cis	rs202072	0.72	rs4602719	ENSG00000272379.1	RP1-257A7.5	4.44	1.33e-05	0.00432	0.45	0.27	HIV-1 viral setpoint;	chr6:13295270	chr6:13290018~13290490:-
COAD	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-4.44	1.34e-05	0.00432	-0.33	-0.27	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4.44	1.34e-05	0.00432	-0.34	-0.27	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
COAD	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-4.44	1.34e-05	0.00432	-0.41	-0.27	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-4.44	1.34e-05	0.00432	-0.41	-0.27	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
COAD	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	4.44	1.34e-05	0.00432	0.35	0.27	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	4.44	1.34e-05	0.00432	0.35	0.27	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	4.44	1.34e-05	0.00432	0.35	0.27	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
COAD	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	4.44	1.34e-05	0.00432	0.43	0.27	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
COAD	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-4.44	1.34e-05	0.00433	-0.32	-0.27	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
COAD	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-4.44	1.34e-05	0.00433	-0.33	-0.27	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
COAD	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-4.44	1.34e-05	0.00433	-0.22	-0.27	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
COAD	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-4.44	1.34e-05	0.00433	-0.28	-0.27	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
COAD	cis	rs8022206	0.773	rs6573800	ENSG00000259502.1	RP11-643G16.3	4.44	1.34e-05	0.00433	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67930343	chr14:67610986~67613864:+
COAD	cis	rs17772222	0.917	rs17188228	ENSG00000258789.1	RP11-507K2.3	-4.44	1.34e-05	0.00433	-0.39	-0.27	Coronary artery calcification;	chr14:88738921	chr14:88551597~88552493:+
COAD	cis	rs2337406	0.866	rs988130	ENSG00000211967.3	IGHV3-53	-4.44	1.34e-05	0.00433	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106777154	chr14:106592676~106593347:-
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000272831.1	RP11-792A8.4	4.44	1.34e-05	0.00433	0.29	0.27	Calcium levels;	chr7:65967580	chr7:66739829~66740385:-
COAD	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	4.44	1.34e-05	0.00433	0.4	0.27	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
COAD	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-4.44	1.34e-05	0.00433	-0.14	-0.27	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
COAD	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-4.44	1.34e-05	0.00434	-0.28	-0.27	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
COAD	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-4.44	1.34e-05	0.00434	-0.35	-0.27	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
COAD	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-4.44	1.34e-05	0.00434	-0.35	-0.27	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
COAD	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-4.44	1.34e-05	0.00434	-0.35	-0.27	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
COAD	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-4.44	1.34e-05	0.00434	-0.28	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
COAD	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	4.44	1.34e-05	0.00434	0.32	0.27	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
COAD	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-4.44	1.34e-05	0.00434	-0.15	-0.27	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
COAD	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	4.44	1.34e-05	0.00434	0.3	0.27	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
COAD	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-4.44	1.34e-05	0.00435	-0.34	-0.27	QT interval;	chr4:75107103	chr4:74955974~74970362:-
COAD	cis	rs4704187	0.687	rs13359143	ENSG00000250889.2	LINC01336	-4.44	1.34e-05	0.00435	-0.3	-0.27	Response to amphetamines;	chr5:75137535	chr5:75047719~75052843:-
COAD	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	4.44	1.34e-05	0.00435	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
COAD	cis	rs7584330	0.666	rs60671275	ENSG00000234949.2	AC104667.3	-4.44	1.35e-05	0.00435	-0.36	-0.27	Prostate cancer;	chr2:237465675	chr2:237591020~237595981:+
COAD	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-4.44	1.35e-05	0.00435	-0.29	-0.27	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
COAD	cis	rs9818758	0.607	rs9837237	ENSG00000225399.4	RP11-3B7.1	-4.44	1.35e-05	0.00435	-0.46	-0.27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:49260085~49261316:+
COAD	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	4.44	1.35e-05	0.00435	0.35	0.27	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
COAD	cis	rs3788317	0.535	rs5993856	ENSG00000232926.1	AC000078.5	-4.44	1.35e-05	0.00436	-0.29	-0.27	Glaucoma (primary angle closure);	chr22:19895107	chr22:19887289~19887970:+
COAD	cis	rs17772222	0.651	rs865285	ENSG00000258789.1	RP11-507K2.3	4.44	1.35e-05	0.00436	0.32	0.27	Coronary artery calcification;	chr14:88391138	chr14:88551597~88552493:+
COAD	cis	rs891378	1	rs925131	ENSG00000274245.1	RP11-357P18.2	-4.44	1.35e-05	0.00436	-0.37	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207330376	chr1:207372559~207373252:+
COAD	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	4.44	1.35e-05	0.00436	0.34	0.27	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
COAD	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	4.44	1.35e-05	0.00436	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
COAD	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	4.44	1.35e-05	0.00436	0.33	0.27	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
COAD	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	4.44	1.35e-05	0.00436	0.33	0.27	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
COAD	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	4.44	1.35e-05	0.00436	0.61	0.27	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
COAD	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	4.44	1.35e-05	0.00436	0.4	0.27	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
COAD	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-4.44	1.35e-05	0.00437	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
COAD	cis	rs73198271	0.96	rs73198290	ENSG00000173295.6	FAM86B3P	-4.44	1.35e-05	0.00437	-0.37	-0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758499	chr8:8228595~8244865:+
COAD	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	4.44	1.35e-05	0.00437	0.31	0.27	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
COAD	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	4.44	1.35e-05	0.00437	0.31	0.27	Height;	chr4:55440988	chr4:55540502~55540835:-
COAD	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-4.44	1.35e-05	0.00437	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
COAD	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-4.44	1.35e-05	0.00437	-0.24	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
COAD	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-4.44	1.35e-05	0.00437	-0.31	-0.27	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
COAD	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	4.44	1.35e-05	0.00438	0.34	0.27	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
COAD	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-4.44	1.35e-05	0.00438	-0.33	-0.27	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
COAD	cis	rs1044826	0.642	rs167187	ENSG00000272656.1	RP11-219D15.3	-4.44	1.35e-05	0.00438	-0.31	-0.27	Obesity-related traits;	chr3:139518166	chr3:139349024~139349371:-
COAD	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	4.44	1.36e-05	0.00438	0.31	0.27	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
COAD	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	4.44	1.36e-05	0.00438	0.31	0.27	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
COAD	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	4.44	1.36e-05	0.00438	0.16	0.27	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
COAD	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	4.44	1.36e-05	0.00439	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	4.44	1.36e-05	0.00439	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	4.44	1.36e-05	0.00439	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
COAD	cis	rs2281603	0.57	rs11158542	ENSG00000259116.1	RP11-973N13.4	4.44	1.36e-05	0.00439	0.26	0.27	Lymphocyte counts;	chr14:64462940	chr14:64514154~64540368:-
COAD	cis	rs2732480	0.577	rs2634693	ENSG00000257735.1	RP11-370I10.6	4.44	1.36e-05	0.00439	0.35	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2634691	ENSG00000257735.1	RP11-370I10.6	4.44	1.36e-05	0.00439	0.35	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48350945~48442411:+
COAD	cis	rs4927850	1	rs10881564	ENSG00000273009.1	RP11-352G9.1	-4.44	1.36e-05	0.0044	-0.29	-0.27	Pancreatic cancer;	chr3:196023455	chr3:195913078~195913683:-
COAD	cis	rs71636778	0.509	rs34460334	ENSG00000260063.1	RP5-968P14.2	-4.44	1.36e-05	0.0044	-0.54	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26888588	chr1:26692132~26694131:-
COAD	cis	rs860295	0.702	rs11264380	ENSG00000160766.13	GBAP1	-4.44	1.36e-05	0.0044	-0.31	-0.27	Body mass index;	chr1:155550353	chr1:155213821~155227422:-
COAD	cis	rs9478638	0.507	rs9371882	ENSG00000235381.1	RP11-477D19.2	-4.44	1.36e-05	0.0044	-0.32	-0.27	Electroencephalogram traits;	chr6:155317607	chr6:155253139~155256724:-
COAD	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-4.44	1.36e-05	0.0044	-0.5	-0.27	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
COAD	cis	rs603446	0.967	rs180370	ENSG00000254851.1	RP11-109L13.1	-4.44	1.36e-05	0.0044	-0.3	-0.27	Triglycerides;	chr11:116721649	chr11:117135528~117138582:+
COAD	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	4.44	1.36e-05	0.0044	0.34	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
COAD	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.43	1.37e-05	0.00441	-0.29	-0.27	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
COAD	cis	rs9393777	0.623	rs9366658	ENSG00000224843.5	LINC00240	4.43	1.37e-05	0.00441	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26469638	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.623	rs9358944	ENSG00000224843.5	LINC00240	4.43	1.37e-05	0.00441	0.45	0.27	Intelligence (multi-trait analysis);	chr6:26469647	chr6:26956992~27023924:+
COAD	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	4.43	1.37e-05	0.00441	0.49	0.27	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
COAD	cis	rs1044826	0.642	rs6799312	ENSG00000272656.1	RP11-219D15.3	4.43	1.37e-05	0.00441	0.31	0.27	Obesity-related traits;	chr3:139493090	chr3:139349024~139349371:-
COAD	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	4.43	1.37e-05	0.00441	0.42	0.27	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
COAD	cis	rs763121	0.819	rs5757237	ENSG00000273076.1	RP3-508I15.22	4.43	1.37e-05	0.00441	0.24	0.27	Menopause (age at onset);	chr22:38677830	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs11704021	ENSG00000273076.1	RP3-508I15.22	4.43	1.37e-05	0.00441	0.24	0.27	Menopause (age at onset);	chr22:38678711	chr22:38743495~38743910:+
COAD	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-4.43	1.37e-05	0.00441	-0.33	-0.27	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
COAD	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	4.43	1.37e-05	0.00441	0.32	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
COAD	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	4.43	1.37e-05	0.00441	0.31	0.27	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
COAD	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	4.43	1.37e-05	0.00441	0.31	0.27	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
COAD	cis	rs860295	0.702	rs475550	ENSG00000203761.5	MSTO2P	-4.43	1.37e-05	0.00441	-0.25	-0.27	Body mass index;	chr1:155682290	chr1:155745829~155750137:+
COAD	cis	rs875971	0.522	rs4502988	ENSG00000272831.1	RP11-792A8.4	4.43	1.37e-05	0.00441	0.28	0.27	Aortic root size;	chr7:65832759	chr7:66739829~66740385:-
COAD	cis	rs739496	0.527	rs10774639	ENSG00000257595.2	RP3-473L9.4	4.43	1.37e-05	0.00442	0.39	0.27	Platelet count;	chr12:111820641	chr12:111369282~111403310:+
COAD	cis	rs2836974	0.602	rs2836987	ENSG00000255568.3	BRWD1-AS2	-4.43	1.37e-05	0.00442	-0.26	-0.27	Cognitive function;	chr21:39334668	chr21:39313935~39314962:+
COAD	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-4.43	1.37e-05	0.00442	-0.32	-0.27	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-4.43	1.37e-05	0.00442	-0.32	-0.27	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
COAD	cis	rs2581828	0.646	rs28501212	ENSG00000280417.1	RP11-5O17.1	4.43	1.37e-05	0.00442	0.29	0.27	Crohn's disease;	chr3:53129041	chr3:53046166~53048122:+
COAD	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-4.43	1.37e-05	0.00442	-0.32	-0.27	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
COAD	cis	rs9902453	0.709	rs6505162	ENSG00000266876.1	RP11-1148O4.1	4.43	1.37e-05	0.00442	0.3	0.27	Coffee consumption (cups per day);	chr17:30117165	chr17:30068632~30069631:+
COAD	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-4.43	1.37e-05	0.00442	-0.29	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
COAD	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-4.43	1.37e-05	0.00442	-0.29	-0.27	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
COAD	cis	rs8061903	0.535	rs17681488	ENSG00000260071.1	RP11-418I22.2	-4.43	1.37e-05	0.00442	-0.33	-0.27	HIV-1 viral setpoint;	chr16:9309236	chr16:9466655~9517564:+
COAD	cis	rs36052053	0.908	rs34352435	ENSG00000219700.1	PTCHD3P3	4.43	1.37e-05	0.00443	0.47	0.27	Red cell distribution width;	chr6:109272401	chr6:109288571~109290503:-
COAD	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-4.43	1.37e-05	0.00443	-0.39	-0.27	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
COAD	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	4.43	1.37e-05	0.00443	0.34	0.27	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-4.43	1.37e-05	0.00443	-0.25	-0.27	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
COAD	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.43	1.38e-05	0.00443	-0.27	-0.27	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
COAD	cis	rs9309473	0.607	rs58962779	ENSG00000163016.8	ALMS1P	4.43	1.38e-05	0.00443	0.33	0.27	Metabolite levels;	chr2:73328673	chr2:73644919~73685576:+
COAD	cis	rs2732480	0.5	rs2932093	ENSG00000226413.2	OR8T1P	4.43	1.38e-05	0.00443	0.34	0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48442030~48442947:-
COAD	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	4.43	1.38e-05	0.00443	0.33	0.27	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
COAD	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	4.43	1.38e-05	0.00443	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
COAD	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	4.43	1.38e-05	0.00443	0.31	0.27	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
COAD	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	4.43	1.38e-05	0.00443	0.32	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
COAD	cis	rs1223397	0.938	rs20499	ENSG00000215022.6	RP1-257A7.4	-4.43	1.38e-05	0.00444	-0.35	-0.27	Blood pressure;	chr6:13294772	chr6:13264861~13295586:-
COAD	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	4.43	1.38e-05	0.00444	0.29	0.27	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
COAD	cis	rs8039808	1	rs79370979	ENSG00000259531.2	RP11-295H24.3	4.43	1.38e-05	0.00444	0.64	0.27	Response to anti-depressant treatment in major depressive disorder;	chr15:49200004	chr15:49365124~49366685:-
COAD	cis	rs8039808	1	rs112705362	ENSG00000259531.2	RP11-295H24.3	4.43	1.38e-05	0.00444	0.64	0.27	Response to anti-depressant treatment in major depressive disorder;	chr15:49208982	chr15:49365124~49366685:-
COAD	cis	rs9910055	0.529	rs228746	ENSG00000267080.4	ASB16-AS1	4.43	1.38e-05	0.00444	0.26	0.27	Total body bone mineral density;	chr17:44096384	chr17:44175973~44186717:-
COAD	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-4.43	1.38e-05	0.00444	-0.27	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
COAD	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-4.43	1.38e-05	0.00444	-0.31	-0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
COAD	cis	rs75422866	0.85	rs73111210	ENSG00000280054.1	RP1-197B17.7	4.43	1.38e-05	0.00444	0.7	0.27	Pneumonia;	chr12:47576949	chr12:47728151~47730598:-
COAD	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	4.43	1.38e-05	0.00444	0.37	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
COAD	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	4.43	1.38e-05	0.00444	0.32	0.27	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
COAD	cis	rs55962025	0.804	rs2071703	ENSG00000248840.2	RP11-357G3.2	4.43	1.38e-05	0.00445	0.31	0.27	Parental longevity (mother's age at death);	chr4:3239686	chr4:3312512~3313058:+
COAD	cis	rs1023500	1	rs9620001	ENSG00000237037.8	NDUFA6-AS1	4.43	1.38e-05	0.00445	0.29	0.27	Schizophrenia;	chr22:41934225	chr22:42090931~42137742:+
COAD	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	4.43	1.38e-05	0.00445	0.27	0.27	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
COAD	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	4.43	1.38e-05	0.00445	0.27	0.27	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
COAD	cis	rs7829975	0.742	rs12547493	ENSG00000233609.3	RP11-62H7.2	-4.43	1.38e-05	0.00445	-0.31	-0.27	Mood instability;	chr8:8804024	chr8:8961200~8979025:+
COAD	cis	rs860295	0.775	rs729022	ENSG00000225082.2	DAP3P1	4.43	1.38e-05	0.00445	0.33	0.27	Body mass index;	chr1:155882332	chr1:155586644~155602197:+
COAD	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-4.43	1.39e-05	0.00446	-0.32	-0.27	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
COAD	cis	rs9450351	0.744	rs6902904	ENSG00000203875.9	SNHG5	-4.43	1.39e-05	0.00446	-0.5	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85660950~85678736:-
COAD	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	4.43	1.39e-05	0.00446	0.27	0.27	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	4.43	1.39e-05	0.00446	0.27	0.27	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	4.43	1.39e-05	0.00446	0.27	0.27	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
COAD	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-4.43	1.39e-05	0.00446	-0.32	-0.27	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-4.43	1.39e-05	0.00446	-0.32	-0.27	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
COAD	cis	rs7714670	1	rs4413512	ENSG00000184084.7	CTD-2372A4.1	4.43	1.39e-05	0.00446	0.29	0.27	Venous thromboembolism (SNP x SNP interaction);	chr5:73781524	chr5:73803296~73803599:-
COAD	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-4.43	1.39e-05	0.00446	-0.3	-0.27	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
COAD	cis	rs728616	0.681	rs35014047	ENSG00000234382.2	RP11-40F6.1	-4.43	1.39e-05	0.00446	-0.44	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80152641	chr10:80233664~80245367:+
COAD	cis	rs728616	0.681	rs17100316	ENSG00000234382.2	RP11-40F6.1	-4.43	1.39e-05	0.00446	-0.44	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80153581	chr10:80233664~80245367:+
COAD	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	4.43	1.39e-05	0.00446	0.33	0.27	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	4.43	1.39e-05	0.00446	0.33	0.27	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
COAD	cis	rs860295	0.775	rs822508	ENSG00000225082.2	DAP3P1	-4.43	1.39e-05	0.00447	-0.32	-0.27	Body mass index;	chr1:155880767	chr1:155586644~155602197:+
COAD	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	4.43	1.39e-05	0.00447	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
COAD	cis	rs180730	1	rs171069	ENSG00000251609.2	SETP12	-4.43	1.39e-05	0.00447	-0.38	-0.27	Fasting plasma glucose;	chr4:120880210	chr4:120895494~120897083:-
COAD	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-4.43	1.39e-05	0.00447	-0.27	-0.27	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
COAD	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-4.43	1.39e-05	0.00447	-0.33	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
COAD	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	4.43	1.39e-05	0.00447	0.47	0.27	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
COAD	cis	rs6723226	0.961	rs13010404	ENSG00000276334.1	AL133243.1	-4.43	1.39e-05	0.00447	-0.25	-0.27	Intelligence (multi-trait analysis);	chr2:32623787	chr2:32521927~32523547:+
COAD	cis	rs2617170	0.732	rs2734423	ENSG00000245648.1	RP11-277P12.20	4.43	1.39e-05	0.00448	0.34	0.27	Behcet's disease;	chr12:10429008	chr12:10363769~10398506:+
COAD	cis	rs2638953	0.853	rs10843180	ENSG00000247934.4	RP11-967K21.1	-4.43	1.39e-05	0.00448	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28163298~28190738:-
COAD	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	4.43	1.39e-05	0.00448	0.27	0.27	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
COAD	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	4.43	1.39e-05	0.00448	0.26	0.27	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
COAD	cis	rs55665837	0.502	rs12795794	ENSG00000251991.1	RNU7-49P	4.43	1.39e-05	0.00448	0.33	0.27	Vitamin D levels;	chr11:14825327	chr11:14478892~14478953:+
COAD	cis	rs754466	1	rs56256440	ENSG00000204049.1	RP11-126H7.4	4.43	1.4e-05	0.00448	0.35	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77938449	chr10:77866875~77869610:+
COAD	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	4.43	1.4e-05	0.00448	0.31	0.27	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
COAD	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	4.43	1.4e-05	0.00449	0.43	0.27	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	4.43	1.4e-05	0.00449	0.43	0.27	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	4.43	1.4e-05	0.00449	0.43	0.27	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
COAD	cis	rs73198271	0.96	rs73198287	ENSG00000173295.6	FAM86B3P	-4.43	1.4e-05	0.00449	-0.38	-0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr8:8228595~8244865:+
COAD	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-4.43	1.4e-05	0.00449	-0.42	-0.27	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
COAD	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-4.43	1.4e-05	0.00449	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
COAD	cis	rs28374715	0.662	rs16971558	ENSG00000247556.5	OIP5-AS1	4.43	1.4e-05	0.00449	0.34	0.27	Ulcerative colitis;	chr15:41166421	chr15:41283990~41309737:+
COAD	cis	rs74233809	1	rs17115213	ENSG00000213277.3	MARCKSL1P1	4.43	1.4e-05	0.00449	0.57	0.27	Birth weight;	chr10:102921386	chr10:103175554~103176094:+
COAD	cis	rs6840360	0.608	rs2724556	ENSG00000270265.1	RP11-731D1.4	-4.43	1.4e-05	0.00449	-0.33	-0.27	Intelligence (multi-trait analysis);	chr4:151420565	chr4:151333775~151353224:-
COAD	cis	rs9532669	0.926	rs4600337	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40879564	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs12871420	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880034	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs12871735	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880169	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs12871895	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880189	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs12872288	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880268	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532640	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880628	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs9532641	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880648	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532643	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880800	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.963	rs9532644	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880860	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532645	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880898	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532646	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40880989	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9525419	ENSG00000239827.7	SUGT1P3	-4.43	1.4e-05	0.0045	-0.23	-0.27	Cervical cancer;	chr13:40881047	chr13:40908159~40921774:-
COAD	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.43	1.4e-05	0.0045	0.32	0.27	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
COAD	cis	rs5015933	0.801	rs3104546	ENSG00000232630.1	PRPS1P2	-4.43	1.4e-05	0.0045	-0.26	-0.27	Body mass index;	chr9:125375390	chr9:125150653~125151589:+
COAD	cis	rs7465272	1	rs35868630	ENSG00000263660.1	AC087793.1	-4.43	1.4e-05	0.0045	-0.3	-0.27	Bipolar disorder and schizophrenia;	chr8:142604572	chr8:143314921~143315006:+
COAD	cis	rs2638953	0.853	rs11049632	ENSG00000247934.4	RP11-967K21.1	-4.43	1.4e-05	0.0045	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10843191	ENSG00000247934.4	RP11-967K21.1	-4.43	1.4e-05	0.0045	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:28163298~28190738:-
COAD	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	4.43	1.4e-05	0.0045	0.53	0.27	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
COAD	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	4.43	1.4e-05	0.0045	0.3	0.27	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
COAD	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
COAD	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
COAD	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
COAD	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-4.43	1.4e-05	0.0045	-0.32	-0.27	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
COAD	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-4.43	1.4e-05	0.0045	-0.26	-0.27	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-4.43	1.4e-05	0.0045	-0.26	-0.27	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
COAD	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	4.43	1.4e-05	0.0045	0.33	0.27	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
COAD	cis	rs8022206	0.704	rs10144995	ENSG00000259502.1	RP11-643G16.3	4.43	1.4e-05	0.00451	0.34	0.27	Platelet count;Mean platelet volume;	chr14:67980237	chr14:67610986~67613864:+
COAD	cis	rs9813712	0.597	rs62281648	ENSG00000249846.5	RP11-77P16.4	-4.43	1.4e-05	0.00451	-0.3	-0.27	Response to amphetamines;	chr3:130244794	chr3:130112550~130120579:+
COAD	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-4.43	1.4e-05	0.00451	-0.33	-0.27	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-4.43	1.4e-05	0.00451	-0.33	-0.27	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
COAD	cis	rs5742933	1	rs62184283	ENSG00000253559.1	OSGEPL1-AS1	-4.43	1.41e-05	0.00451	-0.28	-0.27	Ferritin levels;	chr2:189801179	chr2:189762704~189765556:+
COAD	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	4.43	1.41e-05	0.00451	0.29	0.27	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
COAD	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	4.43	1.41e-05	0.00451	0.38	0.27	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	4.43	1.41e-05	0.00452	0.25	0.27	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
COAD	cis	rs9907295	0.591	rs2107538	ENSG00000271013.1	AC015849.15	-4.43	1.41e-05	0.00452	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35912635~35918010:-
COAD	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	4.43	1.41e-05	0.00452	0.32	0.27	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
COAD	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-4.43	1.41e-05	0.00452	-0.26	-0.27	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
COAD	cis	rs913655	0.536	rs10764729	ENSG00000240291.1	RP11-499P20.2	4.43	1.41e-05	0.00452	0.3	0.27	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18733911	chr10:18513115~18545651:-
COAD	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-4.43	1.41e-05	0.00452	-0.39	-0.27	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
COAD	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	4.43	1.41e-05	0.00452	0.33	0.27	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
COAD	cis	rs1023500	1	rs1047997	ENSG00000237037.8	NDUFA6-AS1	4.43	1.41e-05	0.00452	0.29	0.27	Schizophrenia;	chr22:41938949	chr22:42090931~42137742:+
COAD	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	4.43	1.41e-05	0.00452	0.33	0.27	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
COAD	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
COAD	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-4.43	1.41e-05	0.00452	-0.45	-0.27	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
COAD	cis	rs362296	0.511	rs2857861	ENSG00000248840.2	RP11-357G3.2	-4.43	1.41e-05	0.00452	-0.27	-0.27	Parental longevity (mother's age at death);	chr4:3322040	chr4:3312512~3313058:+
COAD	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	4.43	1.41e-05	0.00452	0.35	0.27	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
COAD	cis	rs742132	0.858	rs16890900	ENSG00000220875.1	HIST1H3PS1	4.43	1.41e-05	0.00452	0.34	0.27	Uric acid levels;	chr6:25655611	chr6:26321876~26322292:-
COAD	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	4.43	1.41e-05	0.00452	0.32	0.27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
COAD	cis	rs2638953	0.853	rs1355474	ENSG00000247934.4	RP11-967K21.1	-4.43	1.41e-05	0.00452	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28163298~28190738:-
COAD	cis	rs6545883	0.524	rs7561697	ENSG00000273302.1	RP11-493E12.2	-4.43	1.41e-05	0.00453	-0.25	-0.27	Tuberculosis;	chr2:61292030	chr2:61199979~61200769:+
COAD	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-4.43	1.41e-05	0.00453	-0.28	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
COAD	cis	rs36052053	0.908	rs34599673	ENSG00000219700.1	PTCHD3P3	4.43	1.41e-05	0.00453	0.47	0.27	Red cell distribution width;	chr6:109251799	chr6:109288571~109290503:-
COAD	cis	rs36052053	0.908	rs13209450	ENSG00000219700.1	PTCHD3P3	4.43	1.41e-05	0.00453	0.47	0.27	Red cell distribution width;	chr6:109252804	chr6:109288571~109290503:-
COAD	cis	rs36052053	0.908	rs75793323	ENSG00000219700.1	PTCHD3P3	4.43	1.41e-05	0.00453	0.47	0.27	Red cell distribution width;	chr6:109253508	chr6:109288571~109290503:-
COAD	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	4.43	1.41e-05	0.00453	0.3	0.27	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
COAD	cis	rs77972916	0.561	rs13411485	ENSG00000234936.1	AC010883.5	-4.43	1.41e-05	0.00453	-0.4	-0.27	Granulocyte percentage of myeloid white cells;	chr2:43348845	chr2:43229573~43233394:+
COAD	cis	rs6723226	0.739	rs2069213	ENSG00000276334.1	AL133243.1	4.43	1.41e-05	0.00453	0.25	0.27	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32521927~32523547:+
COAD	cis	rs476633	0.691	rs2164996	ENSG00000247556.5	OIP5-AS1	4.43	1.42e-05	0.00453	0.26	0.27	Glomerular filtration rate (creatinine);	chr15:41244426	chr15:41283990~41309737:+
COAD	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-4.43	1.42e-05	0.00453	-0.31	-0.27	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
COAD	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-4.43	1.42e-05	0.00454	-0.27	-0.27	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
COAD	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-4.43	1.42e-05	0.00454	-0.33	-0.27	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
COAD	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-4.43	1.42e-05	0.00454	-0.32	-0.27	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
COAD	cis	rs1624802	1	rs1624802	ENSG00000280002.1	RP11-76C10.6	4.43	1.42e-05	0.00454	0.3	0.27	Obesity-related traits;	chr12:130012927	chr12:130988312~130990028:-
COAD	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-4.43	1.42e-05	0.00454	-0.41	-0.27	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
COAD	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	4.43	1.42e-05	0.00455	0.34	0.27	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
COAD	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	4.43	1.42e-05	0.00455	0.3	0.27	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
COAD	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	4.43	1.42e-05	0.00455	0.4	0.27	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
COAD	cis	rs9532669	0.963	rs1056824	ENSG00000239827.7	SUGT1P3	-4.43	1.42e-05	0.00455	-0.23	-0.27	Cervical cancer;	chr13:40932748	chr13:40908159~40921774:-
COAD	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-4.43	1.42e-05	0.00455	-0.48	-0.27	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
COAD	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-4.43	1.42e-05	0.00455	-0.48	-0.27	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
COAD	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	4.43	1.42e-05	0.00455	0.27	0.27	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
COAD	cis	rs3126085	0.56	rs11204985	ENSG00000237975.5	FLG-AS1	-4.43	1.42e-05	0.00455	-0.31	-0.27	Atopic dermatitis;	chr1:152361121	chr1:152168125~152445456:+
COAD	cis	rs72827839	0.846	rs72823530	ENSG00000263412.1	RP5-890E16.2	4.43	1.42e-05	0.00455	0.38	0.27	Ease of getting up in the morning;	chr17:48032005	chr17:48045141~48048073:-
COAD	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-4.43	1.42e-05	0.00455	-0.32	-0.27	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
COAD	cis	rs3752645	1	rs11764389	ENSG00000241764.3	AC002467.7	4.43	1.42e-05	0.00455	0.44	0.27	Bladder cancer (smoking interaction);	chr7:107083433	chr7:107742817~107744581:-
COAD	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	4.43	1.42e-05	0.00455	0.33	0.27	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
COAD	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-4.43	1.42e-05	0.00455	-0.5	-0.27	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
COAD	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	4.43	1.42e-05	0.00455	0.32	0.27	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
COAD	cis	rs2337406	0.85	rs4774179	ENSG00000211974.3	IGHV2-70	-4.43	1.42e-05	0.00456	-0.29	-0.27	Alzheimer's disease (late onset);	chr14:106700837	chr14:106723574~106724093:-
COAD	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	4.43	1.42e-05	0.00456	0.35	0.27	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
COAD	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	4.43	1.43e-05	0.00456	0.38	0.27	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
COAD	cis	rs6840360	0.582	rs11732918	ENSG00000251611.1	RP11-610P16.1	-4.43	1.43e-05	0.00456	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.557	rs4696261	ENSG00000251611.1	RP11-610P16.1	-4.43	1.43e-05	0.00456	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151407551~151408835:-
COAD	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-4.43	1.43e-05	0.00456	-0.51	-0.27	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
COAD	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	4.43	1.43e-05	0.00456	0.3	0.27	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
COAD	cis	rs733317	0.672	rs11760522	ENSG00000226874.1	AC005154.8	-4.42	1.43e-05	0.00456	-0.31	-0.27	Left ventricular obstructive tract defect (inherited effect);	chr7:30989018	chr7:30544053~30544431:+
COAD	cis	rs4704187	0.687	rs6864324	ENSG00000250889.2	LINC01336	4.42	1.43e-05	0.00456	0.3	0.27	Response to amphetamines;	chr5:75202060	chr5:75047719~75052843:-
COAD	cis	rs7650267	0.765	rs7646966	ENSG00000232354.6	VIPR1-AS1	-4.42	1.43e-05	0.00456	-0.28	-0.27	Obesity-related traits;	chr3:43259379	chr3:42506465~42533258:-
COAD	cis	rs2564921	0.513	rs12638195	ENSG00000242142.1	SERBP1P3	-4.42	1.43e-05	0.00456	-0.31	-0.27	Height;	chr3:52842623	chr3:53064283~53065091:-
COAD	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-4.42	1.43e-05	0.00456	-0.32	-0.27	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
COAD	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-4.42	1.43e-05	0.00457	-0.38	-0.27	Depression;	chr6:28074687	chr6:28115628~28116551:+
COAD	cis	rs6545883	0.524	rs12713435	ENSG00000273302.1	RP11-493E12.2	-4.42	1.43e-05	0.00457	-0.25	-0.27	Tuberculosis;	chr2:61272654	chr2:61199979~61200769:+
COAD	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	4.42	1.43e-05	0.00457	0.31	0.27	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
COAD	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	4.42	1.43e-05	0.00457	0.31	0.27	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
COAD	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	4.42	1.43e-05	0.00457	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
COAD	cis	rs1832007	0.529	rs7100517	ENSG00000224034.1	RP11-445P17.8	-4.42	1.43e-05	0.00457	-0.4	-0.27	Triglyceride levels;Triglycerides;	chr10:5201007	chr10:5266033~5271236:-
COAD	cis	rs1832007	0.529	rs7085249	ENSG00000224034.1	RP11-445P17.8	-4.42	1.43e-05	0.00457	-0.4	-0.27	Triglyceride levels;Triglycerides;	chr10:5201054	chr10:5266033~5271236:-
COAD	cis	rs1832007	0.529	rs7088788	ENSG00000224034.1	RP11-445P17.8	-4.42	1.43e-05	0.00457	-0.4	-0.27	Triglyceride levels;Triglycerides;	chr10:5201130	chr10:5266033~5271236:-
COAD	cis	rs9652601	0.691	rs7186145	ENSG00000274038.1	RP11-66H6.4	-4.42	1.43e-05	0.00457	-0.31	-0.27	Systemic lupus erythematosus;	chr16:11117021	chr16:11056556~11057034:+
COAD	cis	rs9532669	0.926	rs9532647	ENSG00000239827.7	SUGT1P3	-4.42	1.43e-05	0.00457	-0.23	-0.27	Cervical cancer;	chr13:40881799	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs9525420	ENSG00000239827.7	SUGT1P3	-4.42	1.43e-05	0.00457	-0.23	-0.27	Cervical cancer;	chr13:40882628	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7324383	ENSG00000239827.7	SUGT1P3	-4.42	1.43e-05	0.00457	-0.23	-0.27	Cervical cancer;	chr13:40882754	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532648	ENSG00000239827.7	SUGT1P3	-4.42	1.43e-05	0.00457	-0.23	-0.27	Cervical cancer;	chr13:40882795	chr13:40908159~40921774:-
COAD	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-4.42	1.43e-05	0.00457	-0.37	-0.27	Depression;	chr6:28079011	chr6:28115628~28116551:+
COAD	cis	rs8022206	0.773	rs8013677	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00457	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67932479	chr14:67610986~67613864:+
COAD	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-4.42	1.43e-05	0.00457	-0.3	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
COAD	cis	rs875971	0.522	rs10807697	ENSG00000272831.1	RP11-792A8.4	4.42	1.43e-05	0.00458	0.28	0.27	Aortic root size;	chr7:65951183	chr7:66739829~66740385:-
COAD	cis	rs7615952	0.515	rs7630575	ENSG00000241288.6	RP11-379B18.5	-4.42	1.43e-05	0.00458	-0.26	-0.27	Blood pressure (smoking interaction);	chr3:125963487	chr3:125827238~125916384:-
COAD	cis	rs9532669	0.824	rs4941998	ENSG00000239827.7	SUGT1P3	-4.42	1.43e-05	0.00458	-0.23	-0.27	Cervical cancer;	chr13:40859901	chr13:40908159~40921774:-
COAD	cis	rs739496	0.579	rs10774640	ENSG00000257595.2	RP3-473L9.4	4.42	1.43e-05	0.00458	0.39	0.27	Platelet count;	chr12:111857386	chr12:111369282~111403310:+
COAD	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	4.42	1.43e-05	0.00458	0.35	0.27	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
COAD	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	4.42	1.43e-05	0.00458	0.43	0.27	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
COAD	cis	rs2638953	0.925	rs11049520	ENSG00000247934.4	RP11-967K21.1	-4.42	1.43e-05	0.00458	-0.28	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310656	chr12:28163298~28190738:-
COAD	cis	rs8022206	0.773	rs8016525	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00458	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67950356	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs4902538	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00458	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67958092	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs4902540	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00458	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67964578	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs7160115	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00458	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67965538	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs11852180	ENSG00000259502.1	RP11-643G16.3	4.42	1.43e-05	0.00458	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67969484	chr14:67610986~67613864:+
COAD	cis	rs4950322	1	rs4950322	ENSG00000278811.3	LINC00624	-4.42	1.43e-05	0.00458	-0.29	-0.27	Protein quantitative trait loci;	chr1:147383114	chr1:147258885~147517875:-
COAD	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-4.42	1.44e-05	0.00459	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
COAD	cis	rs875971	0.545	rs10950025	ENSG00000224316.1	RP11-479O9.2	4.42	1.44e-05	0.00459	0.33	0.27	Aortic root size;	chr7:66158946	chr7:65773620~65802067:+
COAD	cis	rs875971	0.52	rs12666485	ENSG00000224316.1	RP11-479O9.2	4.42	1.44e-05	0.00459	0.33	0.27	Aortic root size;	chr7:66160135	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs67688847	ENSG00000224316.1	RP11-479O9.2	4.42	1.44e-05	0.00459	0.33	0.27	Aortic root size;	chr7:66161064	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs7787063	ENSG00000224316.1	RP11-479O9.2	4.42	1.44e-05	0.00459	0.33	0.27	Aortic root size;	chr7:66164012	chr7:65773620~65802067:+
COAD	cis	rs875971	0.545	rs12673308	ENSG00000224316.1	RP11-479O9.2	4.42	1.44e-05	0.00459	0.33	0.27	Aortic root size;	chr7:66166374	chr7:65773620~65802067:+
COAD	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-4.42	1.44e-05	0.00459	-0.31	-0.27	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
COAD	cis	rs6840360	0.582	rs11733820	ENSG00000251611.1	RP11-610P16.1	-4.42	1.44e-05	0.00459	-0.25	-0.27	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151407551~151408835:-
COAD	cis	rs739496	0.615	rs7977828	ENSG00000257595.2	RP3-473L9.4	4.42	1.44e-05	0.00459	0.39	0.27	Platelet count;	chr12:111656962	chr12:111369282~111403310:+
COAD	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-4.42	1.44e-05	0.00459	-0.31	-0.27	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
COAD	cis	rs734999	0.566	rs10797435	ENSG00000225931.3	RP3-395M20.7	4.42	1.44e-05	0.0046	0.29	0.27	Ulcerative colitis;	chr1:2603362	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs4648562	ENSG00000225931.3	RP3-395M20.7	4.42	1.44e-05	0.0046	0.29	0.27	Ulcerative colitis;	chr1:2604174	chr1:2566410~2569888:+
COAD	cis	rs734999	0.566	rs4648563	ENSG00000225931.3	RP3-395M20.7	4.42	1.44e-05	0.0046	0.29	0.27	Ulcerative colitis;	chr1:2604563	chr1:2566410~2569888:+
COAD	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-4.42	1.44e-05	0.0046	-0.27	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
COAD	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	4.42	1.44e-05	0.0046	0.43	0.27	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
COAD	cis	rs10461617	0.617	rs1423623	ENSG00000271828.1	CTD-2310F14.1	-4.42	1.44e-05	0.0046	-0.32	-0.27	Type 2 diabetes;	chr5:56769748	chr5:56927874~56929573:+
COAD	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-4.42	1.44e-05	0.0046	-0.31	-0.27	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
COAD	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-4.42	1.44e-05	0.0046	-0.43	-0.27	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-4.42	1.44e-05	0.0046	-0.15	-0.27	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
COAD	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	4.42	1.44e-05	0.0046	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
COAD	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	4.42	1.44e-05	0.0046	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
COAD	cis	rs12497850	0.897	rs6781790	ENSG00000225399.4	RP11-3B7.1	4.42	1.44e-05	0.0046	0.3	0.27	Parkinson's disease;	chr3:49007334	chr3:49260085~49261316:+
COAD	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	4.42	1.44e-05	0.0046	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
COAD	cis	rs11079159	1	rs10445344	ENSG00000263096.1	RP11-515O17.2	4.42	1.44e-05	0.0046	0.33	0.27	QRS duration;	chr17:55290427	chr17:55271504~55273653:-
COAD	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-4.42	1.44e-05	0.0046	-0.36	-0.27	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
COAD	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-4.42	1.44e-05	0.00461	-0.48	-0.27	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
COAD	cis	rs4704187	0.624	rs35719345	ENSG00000250889.2	LINC01336	-4.42	1.44e-05	0.00461	-0.3	-0.27	Response to amphetamines;	chr5:75256137	chr5:75047719~75052843:-
COAD	cis	rs5758511	0.573	rs5996074	ENSG00000237037.8	NDUFA6-AS1	4.42	1.44e-05	0.00461	0.28	0.27	Birth weight;	chr22:41840333	chr22:42090931~42137742:+
COAD	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-4.42	1.44e-05	0.00461	-0.32	-0.27	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
COAD	cis	rs4704187	0.663	rs56012051	ENSG00000250889.2	LINC01336	-4.42	1.45e-05	0.00461	-0.3	-0.27	Response to amphetamines;	chr5:75256003	chr5:75047719~75052843:-
COAD	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-4.42	1.45e-05	0.00461	-0.32	-0.27	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
COAD	cis	rs4704187	0.649	rs7717415	ENSG00000250889.2	LINC01336	-4.42	1.45e-05	0.00461	-0.3	-0.27	Response to amphetamines;	chr5:75263068	chr5:75047719~75052843:-
COAD	cis	rs2408955	0.504	rs11168441	ENSG00000273765.1	RP11-370I10.11	4.42	1.45e-05	0.00462	0.29	0.27	Glycated hemoglobin levels;	chr12:48182271	chr12:48360920~48361377:+
COAD	cis	rs6964833	0.554	rs2527380	ENSG00000277053.3	GTF2IP1	4.42	1.45e-05	0.00462	0.3	0.27	Menarche (age at onset);	chr7:74690372	chr7:75185385~75237696:-
COAD	cis	rs1510272	1	rs4679778	ENSG00000243926.1	TIPARP-AS1	-4.42	1.45e-05	0.00462	-0.3	-0.27	Testicular germ cell tumor;	chr3:156578150	chr3:156671862~156674378:-
COAD	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-4.42	1.45e-05	0.00463	-0.35	-0.27	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
COAD	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	4.42	1.45e-05	0.00463	0.37	0.27	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
COAD	cis	rs2559856	0.935	rs7957666	ENSG00000199933.1	RNY1P16	4.42	1.45e-05	0.00463	0.29	0.27	Blood protein levels;	chr12:101687773	chr12:101719808~101719918:+
COAD	cis	rs2559856	0.967	rs7970837	ENSG00000199933.1	RNY1P16	4.42	1.45e-05	0.00463	0.29	0.27	Blood protein levels;	chr12:101687798	chr12:101719808~101719918:+
COAD	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	4.42	1.45e-05	0.00463	0.29	0.27	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
COAD	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	4.42	1.45e-05	0.00463	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-4.42	1.45e-05	0.00463	-0.26	-0.27	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
COAD	cis	rs237743	1	rs1567865	ENSG00000222365.1	SNORD12B	-4.42	1.45e-05	0.00463	-0.32	-0.27	Height;	chr20:49265430	chr20:49280319~49280409:+
COAD	cis	rs12497850	0.931	rs7628719	ENSG00000225399.4	RP11-3B7.1	4.42	1.45e-05	0.00463	0.3	0.27	Parkinson's disease;	chr3:48958054	chr3:49260085~49261316:+
COAD	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-4.42	1.45e-05	0.00464	-0.3	-0.27	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
COAD	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-4.42	1.45e-05	0.00464	-0.51	-0.27	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-4.42	1.45e-05	0.00464	-0.51	-0.27	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
COAD	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	4.42	1.46e-05	0.00464	0.43	0.27	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
COAD	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-4.42	1.46e-05	0.00464	-0.31	-0.27	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	4.42	1.46e-05	0.00464	0.31	0.27	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
COAD	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	4.42	1.46e-05	0.00464	0.27	0.27	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
COAD	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-4.42	1.46e-05	0.00464	-0.37	-0.27	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
COAD	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	4.42	1.46e-05	0.00464	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	4.42	1.46e-05	0.00464	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	4.42	1.46e-05	0.00464	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
COAD	cis	rs7430456	0.901	rs9824206	ENSG00000228221.4	LINC00578	4.42	1.46e-05	0.00464	0.24	0.27	Breast cancer;	chr3:177742093	chr3:177441921~177752305:+
COAD	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.42	1.46e-05	0.00465	-0.41	-0.27	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
COAD	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	4.42	1.46e-05	0.00465	0.32	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
COAD	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-4.42	1.46e-05	0.00465	-0.28	-0.27	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
COAD	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-4.42	1.46e-05	0.00465	-0.28	-0.27	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
COAD	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-4.42	1.46e-05	0.00466	-0.3	-0.27	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
COAD	cis	rs9353324	1	rs9450372	ENSG00000203875.9	SNHG5	-4.42	1.46e-05	0.00466	-0.53	-0.27	Interferon gamma-induced protein 10 levels;	chr6:86027230	chr6:85660950~85678736:-
COAD	cis	rs17772222	0.917	rs12588535	ENSG00000258789.1	RP11-507K2.3	-4.42	1.46e-05	0.00466	-0.39	-0.27	Coronary artery calcification;	chr14:88781900	chr14:88551597~88552493:+
COAD	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	4.42	1.46e-05	0.00466	0.24	0.27	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
COAD	cis	rs728616	0.867	rs7080405	ENSG00000225484.5	NUTM2B-AS1	-4.42	1.46e-05	0.00466	-0.49	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:79663088~79826594:-
COAD	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-4.42	1.47e-05	0.00467	-0.29	-0.27	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-4.42	1.47e-05	0.00467	-0.29	-0.27	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-4.42	1.47e-05	0.00467	-0.29	-0.27	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
COAD	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-4.42	1.47e-05	0.00467	-0.32	-0.27	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
COAD	cis	rs12497850	0.931	rs4974082	ENSG00000225399.4	RP11-3B7.1	4.42	1.47e-05	0.00468	0.3	0.27	Parkinson's disease;	chr3:48961890	chr3:49260085~49261316:+
COAD	cis	rs6452524	0.618	rs1478487	ENSG00000271862.1	RP11-343L5.2	4.42	1.47e-05	0.00468	0.26	0.27	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83049376~83050964:-
COAD	cis	rs603446	0.56	rs1240781	ENSG00000254851.1	RP11-109L13.1	4.42	1.47e-05	0.00468	0.31	0.27	Triglycerides;	chr11:116704101	chr11:117135528~117138582:+
COAD	cis	rs6903823	0.508	rs1150726	ENSG00000272009.1	RP1-313I6.12	4.42	1.47e-05	0.00469	0.29	0.27	Pulmonary function;	chr6:28275265	chr6:28078792~28081130:-
COAD	cis	rs12682352	0.602	rs6988939	ENSG00000173295.6	FAM86B3P	4.42	1.47e-05	0.00469	0.3	0.27	Neuroticism;	chr8:8809406	chr8:8228595~8244865:+
COAD	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	4.42	1.47e-05	0.00469	0.33	0.27	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
COAD	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	4.42	1.47e-05	0.00469	0.33	0.27	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
COAD	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	4.42	1.47e-05	0.00469	0.33	0.27	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
COAD	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-4.42	1.47e-05	0.00469	-0.32	-0.27	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-4.42	1.47e-05	0.00469	-0.32	-0.27	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
COAD	cis	rs2638953	0.853	rs11049636	ENSG00000247934.4	RP11-967K21.1	-4.42	1.47e-05	0.00469	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28163298~28190738:-
COAD	cis	rs10466239	0.73	rs2245413	ENSG00000230555.2	RP11-517P14.2	-4.42	1.47e-05	0.00469	-0.38	-0.27	Telomere length;	chr10:43355120	chr10:43420738~43422100:+
COAD	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	4.42	1.47e-05	0.00469	0.38	0.27	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000272831.1	RP11-792A8.4	4.42	1.47e-05	0.00469	0.28	0.27	Calcium levels;	chr7:65941231	chr7:66739829~66740385:-
COAD	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-4.42	1.48e-05	0.0047	-0.41	-0.27	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
COAD	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	4.42	1.48e-05	0.0047	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
COAD	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-4.42	1.48e-05	0.0047	-0.51	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
COAD	cis	rs561341	1	rs508192	ENSG00000265798.5	RP11-271K11.5	-4.42	1.48e-05	0.0047	-0.43	-0.27	Hip circumference adjusted for BMI;	chr17:31988128	chr17:31038575~31059121:-
COAD	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-4.42	1.48e-05	0.00471	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
COAD	cis	rs3752645	1	rs2191917	ENSG00000241764.3	AC002467.7	4.42	1.48e-05	0.00471	0.42	0.27	Bladder cancer (smoking interaction);	chr7:107133263	chr7:107742817~107744581:-
COAD	cis	rs858239	0.601	rs6966776	ENSG00000226816.2	AC005082.12	4.42	1.48e-05	0.00471	0.28	0.27	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23206013~23208045:+
COAD	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	4.42	1.48e-05	0.00471	0.43	0.27	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
COAD	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-4.42	1.48e-05	0.00471	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
COAD	cis	rs79996792	0.736	rs79299044	ENSG00000227403.1	AC009299.3	-4.42	1.48e-05	0.00471	-0.47	-0.27	Neuroticism;	chr2:161637672	chr2:161244739~161249050:+
COAD	cis	rs9907295	0.584	rs7215845	ENSG00000271013.1	AC015849.15	-4.42	1.48e-05	0.00471	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.591	rs4796128	ENSG00000271013.1	AC015849.15	-4.42	1.48e-05	0.00471	-0.32	-0.27	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35912635~35918010:-
COAD	cis	rs9951698	0.678	rs474337	ENSG00000266969.1	RP11-773H22.4	4.42	1.48e-05	0.00472	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13095610	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.678	rs556371	ENSG00000266969.1	RP11-773H22.4	4.42	1.48e-05	0.00472	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13096437	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.703	rs1787003	ENSG00000266969.1	RP11-773H22.4	4.42	1.48e-05	0.00472	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13104252	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.678	rs1786270	ENSG00000266969.1	RP11-773H22.4	4.42	1.48e-05	0.00472	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13109880	chr18:12984694~12991173:-
COAD	cis	rs9951698	0.678	rs1787000	ENSG00000266969.1	RP11-773H22.4	4.42	1.48e-05	0.00472	0.34	0.27	Intelligence (multi-trait analysis);	chr18:13113198	chr18:12984694~12991173:-
COAD	cis	rs597539	0.652	rs686390	ENSG00000255741.1	RP11-757G1.5	-4.42	1.48e-05	0.00472	-0.37	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68941503~68942852:-
COAD	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	4.42	1.48e-05	0.00472	0.37	0.27	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
COAD	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	4.42	1.49e-05	0.00472	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
COAD	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-4.42	1.49e-05	0.00472	-0.38	-0.27	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
COAD	cis	rs7193541	0.929	rs12933037	ENSG00000262904.1	TMPOP2	-4.42	1.49e-05	0.00472	-0.28	-0.27	Multiple myeloma;	chr16:74626276	chr16:74667506~74668706:+
COAD	cis	rs6964833	0.554	rs2527366	ENSG00000277053.3	GTF2IP1	4.42	1.49e-05	0.00473	0.3	0.27	Menarche (age at onset);	chr7:74684615	chr7:75185385~75237696:-
COAD	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	4.42	1.49e-05	0.00473	0.27	0.27	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	4.42	1.49e-05	0.00473	0.27	0.27	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
COAD	cis	rs9307551	0.779	rs1440854	ENSG00000250334.4	LINC00989	-4.42	1.49e-05	0.00473	-0.31	-0.27	Refractive error;	chr4:79585580	chr4:79492416~79576460:+
COAD	cis	rs13129838	1	rs13129838	ENSG00000250334.4	LINC00989	-4.42	1.49e-05	0.00473	-0.31	-0.27	Myopia;	chr4:79587634	chr4:79492416~79576460:+
COAD	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	4.42	1.49e-05	0.00473	0.42	0.27	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
COAD	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	4.42	1.49e-05	0.00473	0.42	0.27	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
COAD	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	4.41	1.49e-05	0.00473	0.32	0.27	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
COAD	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-4.41	1.49e-05	0.00473	-0.29	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
COAD	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.49e-05	0.00474	-0.26	-0.27	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
COAD	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	4.41	1.49e-05	0.00474	0.21	0.27	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	4.41	1.49e-05	0.00474	0.21	0.27	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
COAD	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	4.41	1.49e-05	0.00474	0.3	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
COAD	cis	rs12497850	0.864	rs6779394	ENSG00000225399.4	RP11-3B7.1	4.41	1.49e-05	0.00474	0.31	0.27	Parkinson's disease;	chr3:49120338	chr3:49260085~49261316:+
COAD	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	4.41	1.5e-05	0.00475	0.29	0.27	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
COAD	cis	rs11124272	0.857	rs7587666	ENSG00000272716.1	RP11-563N4.1	-4.41	1.5e-05	0.00475	-0.3	-0.27	Interleukin-18 levels;	chr2:31830821	chr2:32165046~32165757:-
COAD	cis	rs180730	1	rs343166	ENSG00000251609.2	SETP12	-4.41	1.5e-05	0.00475	-0.38	-0.27	Fasting plasma glucose;	chr4:120897567	chr4:120895494~120897083:-
COAD	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	4.41	1.5e-05	0.00475	0.31	0.27	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
COAD	cis	rs1044826	0.642	rs2118981	ENSG00000272656.1	RP11-219D15.3	4.41	1.5e-05	0.00475	0.31	0.27	Obesity-related traits;	chr3:139460011	chr3:139349024~139349371:-
COAD	cis	rs5758511	0.68	rs1107553	ENSG00000237037.8	NDUFA6-AS1	-4.41	1.5e-05	0.00475	-0.31	-0.27	Birth weight;	chr22:42271467	chr22:42090931~42137742:+
COAD	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	4.41	1.5e-05	0.00475	0.26	0.27	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
COAD	cis	rs875971	0.522	rs709604	ENSG00000272831.1	RP11-792A8.4	-4.41	1.5e-05	0.00476	-0.28	-0.27	Aortic root size;	chr7:66032447	chr7:66739829~66740385:-
COAD	cis	rs7630852	1	rs7626440	ENSG00000272359.1	U4	-4.41	1.5e-05	0.00476	-0.31	-0.27	Eosinophil counts;	chr3:196778019	chr3:196747192~196747324:-
COAD	cis	rs5753037	0.754	rs4820824	ENSG00000279159.1	RP3-394A18.1	-4.41	1.5e-05	0.00476	-0.18	-0.27	Type 1 diabetes;	chr22:29964926	chr22:29978950~30028236:-
COAD	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	4.41	1.5e-05	0.00476	0.34	0.27	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
COAD	cis	rs13256369	1	rs13282915	ENSG00000173295.6	FAM86B3P	4.41	1.5e-05	0.00476	0.37	0.27	Obesity-related traits;	chr8:8713381	chr8:8228595~8244865:+
COAD	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	4.41	1.5e-05	0.00476	0.34	0.27	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
COAD	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
COAD	cis	rs7584330	0.628	rs7591065	ENSG00000234949.2	AC104667.3	-4.41	1.5e-05	0.00477	-0.38	-0.27	Prostate cancer;	chr2:237482096	chr2:237591020~237595981:+
COAD	cis	rs2638953	0.853	rs11049641	ENSG00000247934.4	RP11-967K21.1	-4.41	1.5e-05	0.00477	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28163298~28190738:-
COAD	cis	rs4392868	0.514	rs4329243	ENSG00000254248.1	RP11-320N21.2	-4.41	1.5e-05	0.00477	-0.32	-0.27	Radiation response;	chr8:95093463	chr8:95071732~95087924:-
COAD	cis	rs2439831	0.702	rs28699233	ENSG00000275601.1	AC011330.13	-4.41	1.5e-05	0.00477	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43830668	chr15:43642389~43643023:-
COAD	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
COAD	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
COAD	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
COAD	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
COAD	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-4.41	1.5e-05	0.00477	-0.28	-0.27	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
COAD	cis	rs17772222	0.917	rs10143767	ENSG00000258789.1	RP11-507K2.3	-4.41	1.5e-05	0.00477	-0.38	-0.27	Coronary artery calcification;	chr14:88514867	chr14:88551597~88552493:+
COAD	cis	rs7200543	1	rs4985154	ENSG00000270580.4	PKD1P6	4.41	1.51e-05	0.00478	0.3	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15104723~15131601:-
COAD	cis	rs1914816	0.941	rs2957037	ENSG00000196274.5	Metazoa_SRP	4.41	1.51e-05	0.00478	0.29	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76193195	chr15:76230048~76230390:-
COAD	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	4.41	1.51e-05	0.00478	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	4.41	1.51e-05	0.00478	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
COAD	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-4.41	1.51e-05	0.00479	-0.39	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
COAD	cis	rs453301	0.658	rs9650616	ENSG00000173295.6	FAM86B3P	-4.41	1.51e-05	0.00479	-0.32	-0.27	Joint mobility (Beighton score);	chr8:9011689	chr8:8228595~8244865:+
COAD	cis	rs7560272	0.669	rs7598660	ENSG00000163016.8	ALMS1P	4.41	1.51e-05	0.00479	0.31	0.27	Schizophrenia;	chr2:73513298	chr2:73644919~73685576:+
COAD	cis	rs7955901	0.774	rs7308528	ENSG00000258053.1	CTD-2021H9.3	-4.41	1.51e-05	0.00479	-0.32	-0.27	Type 2 diabetes;	chr12:71024220	chr12:71047402~71118247:-
COAD	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-4.41	1.51e-05	0.00479	-0.29	-0.27	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
COAD	cis	rs875971	0.54	rs4717275	ENSG00000272831.1	RP11-792A8.4	-4.41	1.51e-05	0.00479	-0.28	-0.27	Aortic root size;	chr7:65800193	chr7:66739829~66740385:-
COAD	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	4.41	1.51e-05	0.0048	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
COAD	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	4.41	1.51e-05	0.0048	0.41	0.27	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
COAD	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-4.41	1.52e-05	0.00481	-0.3	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
COAD	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	4.41	1.52e-05	0.00481	0.32	0.27	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
COAD	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	4.41	1.52e-05	0.00481	0.32	0.27	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
COAD	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-4.41	1.52e-05	0.00482	-0.32	-0.27	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
COAD	cis	rs8022206	0.773	rs28488544	ENSG00000259502.1	RP11-643G16.3	4.41	1.52e-05	0.00482	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67954278	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs7146354	ENSG00000259502.1	RP11-643G16.3	4.41	1.52e-05	0.00482	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67955069	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs7142112	ENSG00000259502.1	RP11-643G16.3	4.41	1.52e-05	0.00482	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67957255	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs7142210	ENSG00000259502.1	RP11-643G16.3	4.41	1.52e-05	0.00482	0.36	0.27	Platelet count;Mean platelet volume;	chr14:67957546	chr14:67610986~67613864:+
COAD	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	4.41	1.52e-05	0.00482	0.29	0.27	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
COAD	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-4.41	1.52e-05	0.00482	-0.32	-0.27	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
COAD	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	4.41	1.52e-05	0.00482	0.33	0.27	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
COAD	cis	rs12928939	0.768	rs11861296	ENSG00000260886.1	TAT-AS1	4.41	1.52e-05	0.00482	0.38	0.27	Post bronchodilator FEV1;	chr16:71816729	chr16:71565789~71578187:+
COAD	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-4.41	1.52e-05	0.00482	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
COAD	cis	rs7656342	0.866	rs11731100	ENSG00000186234.7	FAM86MP	4.41	1.52e-05	0.00482	0.33	0.27	Gut microbiota (bacterial taxa);	chr4:9765556	chr4:9692495~9702954:+
COAD	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	4.41	1.52e-05	0.00482	0.32	0.27	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
COAD	cis	rs6452524	0.618	rs2075685	ENSG00000271862.1	RP11-343L5.2	4.41	1.52e-05	0.00482	0.26	0.27	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83049376~83050964:-
COAD	cis	rs9400317	0.901	rs78941670	ENSG00000260273.1	RP11-425D10.10	-4.41	1.52e-05	0.00482	-0.46	-0.27	Response to hepatitis C treatment;	chr6:109634646	chr6:109382795~109383666:+
COAD	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-4.41	1.52e-05	0.00483	-0.29	-0.27	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
COAD	cis	rs2732480	0.5	rs2450989	ENSG00000226413.2	OR8T1P	-4.41	1.53e-05	0.00483	-0.33	-0.27	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48442030~48442947:-
COAD	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-4.41	1.53e-05	0.00483	-0.55	-0.27	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-4.41	1.53e-05	0.00483	-0.55	-0.27	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-4.41	1.53e-05	0.00483	-0.55	-0.27	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
COAD	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-4.41	1.53e-05	0.00483	-0.31	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
COAD	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-4.41	1.53e-05	0.00483	-0.28	-0.27	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-4.41	1.53e-05	0.00483	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
COAD	cis	rs752010	1	rs752010	ENSG00000230638.4	RP11-486B10.4	-4.41	1.53e-05	0.00483	-0.31	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr1:41627344	chr1:41542069~41544310:+
COAD	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	4.41	1.53e-05	0.00483	0.32	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	4.41	1.53e-05	0.00483	0.32	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	4.41	1.53e-05	0.00483	0.32	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
COAD	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	4.41	1.53e-05	0.00483	0.4	0.27	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	4.41	1.53e-05	0.00483	0.4	0.27	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	4.41	1.53e-05	0.00483	0.4	0.27	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	4.41	1.53e-05	0.00483	0.4	0.27	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	4.41	1.53e-05	0.00483	0.4	0.27	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
COAD	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-4.41	1.53e-05	0.00483	-0.23	-0.27	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
COAD	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	4.41	1.53e-05	0.00484	0.32	0.27	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
COAD	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	4.41	1.53e-05	0.00484	0.32	0.27	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
COAD	cis	rs8022206	0.773	rs10143455	ENSG00000259502.1	RP11-643G16.3	4.41	1.53e-05	0.00484	0.36	0.27	Platelet count;Mean platelet volume;	chr14:68012734	chr14:67610986~67613864:+
COAD	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	4.41	1.53e-05	0.00484	0.31	0.27	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
COAD	cis	rs9549328	0.8	rs9549617	ENSG00000267868.1	RP11-120K24.3	4.41	1.53e-05	0.00484	0.35	0.27	Systolic blood pressure;	chr13:112973756	chr13:112964835~112966131:-
COAD	cis	rs9532669	0.926	rs12428966	ENSG00000239827.7	SUGT1P3	-4.41	1.53e-05	0.00484	-0.23	-0.27	Cervical cancer;	chr13:40876552	chr13:40908159~40921774:-
COAD	cis	rs2638953	0.853	rs3911810	ENSG00000247934.4	RP11-967K21.1	-4.41	1.53e-05	0.00485	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461669	chr12:28163298~28190738:-
COAD	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	4.41	1.53e-05	0.00485	0.34	0.27	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
COAD	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.41	1.53e-05	0.00485	0.32	0.27	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.41	1.53e-05	0.00485	0.32	0.27	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
COAD	cis	rs494562	0.73	rs9362209	ENSG00000234155.1	RP11-30P6.6	-4.41	1.53e-05	0.00485	-0.48	-0.27	Metabolic traits;Blood metabolite levels;	chr6:85404773	chr6:85387219~85390186:-
COAD	cis	rs7260598	0.642	rs66750293	ENSG00000268442.1	CTD-2027I19.2	4.41	1.53e-05	0.00485	0.41	0.27	Response to taxane treatment (placlitaxel);	chr19:23997819	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.642	rs67908565	ENSG00000268442.1	CTD-2027I19.2	4.41	1.53e-05	0.00485	0.41	0.27	Response to taxane treatment (placlitaxel);	chr19:23998579	chr19:24162370~24163425:-
COAD	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-4.41	1.53e-05	0.00485	-0.42	-0.27	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
COAD	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-4.41	1.53e-05	0.00485	-0.42	-0.27	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
COAD	cis	rs13256369	1	rs13266699	ENSG00000253981.4	ALG1L13P	-4.41	1.53e-05	0.00485	-0.38	-0.27	Obesity-related traits;	chr8:8712803	chr8:8236003~8244667:-
COAD	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	4.41	1.53e-05	0.00485	0.35	0.27	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
COAD	cis	rs9500256	0.934	rs1343391	ENSG00000215190.7	LINC00680	-4.41	1.53e-05	0.00485	-0.33	-0.27	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57946074~57961501:-
COAD	cis	rs2638953	0.853	rs11049635	ENSG00000247934.4	RP11-967K21.1	-4.41	1.53e-05	0.00485	-0.27	-0.27	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28163298~28190738:-
COAD	cis	rs989978	1	rs989978	ENSG00000257582.4	LINC01475	4.41	1.53e-05	0.00485	0.3	0.27	Red blood cell count;	chr10:99562798	chr10:99526350~99531177:-
COAD	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-4.41	1.54e-05	0.00486	-0.32	-0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
COAD	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	4.41	1.54e-05	0.00486	0.35	0.27	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
COAD	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	4.41	1.54e-05	0.00486	0.34	0.27	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
COAD	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-4.41	1.54e-05	0.00486	-0.27	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
COAD	cis	rs3733585	0.683	rs13112015	ENSG00000250413.1	RP11-448G15.1	4.41	1.54e-05	0.00486	0.34	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9932172	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	4.41	1.54e-05	0.00486	0.34	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
COAD	cis	rs2337406	0.866	rs4583128	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106780669	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.929	rs12050200	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106780983	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.929	rs12050233	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781123	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.852	rs12050466	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781131	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.929	rs59263250	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781183	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs58083017	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781256	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.789	rs60390024	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781327	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092532	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781363	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092534	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781364	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74092537	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781883	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.81	rs74092538	ENSG00000211967.3	IGHV3-53	-4.41	1.54e-05	0.00486	-0.19	-0.27	Alzheimer's disease (late onset);	chr14:106781942	chr14:106592676~106593347:-
COAD	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	4.41	1.54e-05	0.00486	0.31	0.27	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
COAD	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	4.41	1.54e-05	0.00486	0.35	0.27	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
COAD	cis	rs17772222	0.917	rs58550317	ENSG00000258789.1	RP11-507K2.3	-4.41	1.54e-05	0.00487	-0.39	-0.27	Coronary artery calcification;	chr14:88775243	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs61982733	ENSG00000258789.1	RP11-507K2.3	-4.41	1.54e-05	0.00487	-0.39	-0.27	Coronary artery calcification;	chr14:88776244	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs2145120	ENSG00000258789.1	RP11-507K2.3	-4.41	1.54e-05	0.00487	-0.39	-0.27	Coronary artery calcification;	chr14:88777699	chr14:88551597~88552493:+
COAD	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	4.41	1.54e-05	0.00487	0.34	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
COAD	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	4.41	1.54e-05	0.00487	0.34	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
COAD	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	4.41	1.54e-05	0.00487	0.4	0.27	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
COAD	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	4.41	1.54e-05	0.00488	0.29	0.27	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
COAD	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	4.41	1.54e-05	0.00488	0.42	0.27	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
COAD	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	4.41	1.54e-05	0.00488	0.16	0.27	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
COAD	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-4.41	1.55e-05	0.00488	-0.3	-0.27	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
COAD	cis	rs7577696	0.693	rs466126	ENSG00000272716.1	RP11-563N4.1	4.41	1.55e-05	0.00488	0.28	0.27	Inflammatory biomarkers;	chr2:32237025	chr2:32165046~32165757:-
COAD	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-4.41	1.55e-05	0.00488	-0.3	-0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
COAD	cis	rs13256369	1	rs12550762	ENSG00000173295.6	FAM86B3P	4.41	1.55e-05	0.00488	0.36	0.27	Obesity-related traits;	chr8:8719025	chr8:8228595~8244865:+
COAD	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-4.41	1.55e-05	0.00489	-0.31	-0.27	Height;	chr3:52819385	chr3:53064283~53065091:-
COAD	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-4.41	1.55e-05	0.00489	-0.28	-0.27	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
COAD	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	4.41	1.55e-05	0.00489	0.49	0.27	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	4.41	1.55e-05	0.00489	0.49	0.27	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
COAD	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	4.41	1.55e-05	0.00489	0.37	0.27	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
COAD	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	4.41	1.55e-05	0.00489	0.51	0.27	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
COAD	cis	rs4604732	0.578	rs12040725	ENSG00000227135.1	GCSAML-AS1	-4.41	1.55e-05	0.00489	-0.38	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247481395	chr1:247524679~247526752:-
COAD	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	4.41	1.55e-05	0.00489	0.36	0.26	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
COAD	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	4.41	1.55e-05	0.00489	0.31	0.26	Height;	chr4:55544621	chr4:55540502~55540835:-
COAD	cis	rs2976388	0.632	rs2585139	ENSG00000253741.1	CTD-2292P10.4	-4.41	1.55e-05	0.00489	-0.29	-0.26	Urinary tract infection frequency;	chr8:142726757	chr8:142702252~142726973:-
COAD	cis	rs17772222	0.917	rs12431548	ENSG00000258789.1	RP11-507K2.3	-4.41	1.55e-05	0.00489	-0.38	-0.26	Coronary artery calcification;	chr14:88635826	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs61984737	ENSG00000258789.1	RP11-507K2.3	-4.41	1.55e-05	0.00489	-0.38	-0.26	Coronary artery calcification;	chr14:88637028	chr14:88551597~88552493:+
COAD	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	4.41	1.55e-05	0.0049	0.27	0.26	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
COAD	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	4.41	1.55e-05	0.0049	0.31	0.26	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
COAD	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	4.41	1.55e-05	0.0049	0.34	0.26	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
COAD	cis	rs17685	0.672	rs6465011	ENSG00000280388.1	RP11-229D13.3	-4.41	1.55e-05	0.0049	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76181979	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs11764119	ENSG00000280388.1	RP11-229D13.3	-4.41	1.55e-05	0.0049	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76183040	chr7:76043977~76045963:-
COAD	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	4.4	1.55e-05	0.00491	0.3	0.26	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
COAD	cis	rs1510272	0.961	rs13319258	ENSG00000243926.1	TIPARP-AS1	-4.4	1.56e-05	0.00491	-0.3	-0.26	Testicular germ cell tumor;	chr3:156586782	chr3:156671862~156674378:-
COAD	cis	rs1510272	0.961	rs12696040	ENSG00000243926.1	TIPARP-AS1	-4.4	1.56e-05	0.00491	-0.3	-0.26	Testicular germ cell tumor;	chr3:156587022	chr3:156671862~156674378:-
COAD	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.4	1.56e-05	0.00492	0.31	0.26	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
COAD	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	4.4	1.56e-05	0.00492	0.33	0.26	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
COAD	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	4.4	1.56e-05	0.00492	0.35	0.26	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	4.4	1.56e-05	0.00492	0.35	0.26	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	4.4	1.56e-05	0.00492	0.35	0.26	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	4.4	1.56e-05	0.00492	0.35	0.26	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
COAD	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.4	1.56e-05	0.00492	-0.27	-0.26	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
COAD	cis	rs11638352	1	rs2412854	ENSG00000205771.5	CATSPER2P1	4.4	1.56e-05	0.00493	0.51	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43726918~43747094:-
COAD	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-4.4	1.56e-05	0.00493	-0.28	-0.26	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
COAD	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-4.4	1.56e-05	0.00493	-0.27	-0.26	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
COAD	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.56e-05	0.00493	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.56e-05	0.00493	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.56e-05	0.00493	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.56e-05	0.00493	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
COAD	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-4.4	1.56e-05	0.00493	-0.36	-0.26	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
COAD	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	4.4	1.56e-05	0.00493	0.31	0.26	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
COAD	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	4.4	1.56e-05	0.00493	0.39	0.26	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
COAD	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	4.4	1.56e-05	0.00493	0.34	0.26	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
COAD	cis	rs9307551	0.741	rs1440866	ENSG00000250334.4	LINC00989	-4.4	1.56e-05	0.00493	-0.36	-0.26	Refractive error;	chr4:79545005	chr4:79492416~79576460:+
COAD	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	4.4	1.56e-05	0.00493	0.35	0.26	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
COAD	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-4.4	1.57e-05	0.00494	-0.23	-0.26	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
COAD	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-4.4	1.57e-05	0.00494	-0.33	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
COAD	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-4.4	1.57e-05	0.00494	-0.31	-0.26	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
COAD	cis	rs3120667	0.79	rs726863	ENSG00000237975.5	FLG-AS1	-4.4	1.57e-05	0.00494	-0.3	-0.26	Eating disorders;	chr1:152427885	chr1:152168125~152445456:+
COAD	cis	rs1023500	0.573	rs2269524	ENSG00000237037.8	NDUFA6-AS1	4.4	1.57e-05	0.00494	0.26	0.26	Schizophrenia;	chr22:42079699	chr22:42090931~42137742:+
COAD	cis	rs1023500	0.573	rs6002592	ENSG00000237037.8	NDUFA6-AS1	4.4	1.57e-05	0.00494	0.26	0.26	Schizophrenia;	chr22:42080750	chr22:42090931~42137742:+
COAD	cis	rs11951515	0.508	rs6898866	ENSG00000248554.1	RP11-159F24.6	-4.4	1.57e-05	0.00495	-0.28	-0.26	Metabolite levels  (X-11787);	chr5:43586273	chr5:43511058~43521811:+
COAD	cis	rs2638953	0.924	rs11049610	ENSG00000247934.4	RP11-967K21.1	-4.4	1.57e-05	0.00495	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28446674	chr12:28163298~28190738:-
COAD	cis	rs7465272	1	rs35476574	ENSG00000263660.1	AC087793.1	-4.4	1.57e-05	0.00495	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr8:142602423	chr8:143314921~143315006:+
COAD	cis	rs752010	0.806	rs6696511	ENSG00000230638.4	RP11-486B10.4	-4.4	1.57e-05	0.00495	-0.32	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41645217	chr1:41542069~41544310:+
COAD	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	4.4	1.57e-05	0.00495	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
COAD	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.4	1.57e-05	0.00495	0.26	0.26	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
COAD	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-4.4	1.57e-05	0.00496	-0.39	-0.26	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
COAD	cis	rs6982240	0.514	rs892362	ENSG00000253307.1	RP11-10J21.4	-4.4	1.57e-05	0.00496	-0.34	-0.26	Tonsillectomy;	chr8:141259115	chr8:141252286~141253292:-
COAD	cis	rs2378497	1	rs12137800	ENSG00000232679.1	RP11-400N13.3	4.4	1.57e-05	0.00496	0.37	0.26	Serum thyroid-stimulating hormone levels;	chr1:222005713	chr1:222041705~222064763:-
COAD	cis	rs2638953	0.815	rs11049680	ENSG00000247934.4	RP11-967K21.1	-4.4	1.57e-05	0.00496	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508436	chr12:28163298~28190738:-
COAD	cis	rs752010	1	rs2077172	ENSG00000230638.4	RP11-486B10.4	-4.4	1.57e-05	0.00496	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41627669	chr1:41542069~41544310:+
COAD	cis	rs752010	1	rs4999015	ENSG00000230638.4	RP11-486B10.4	-4.4	1.57e-05	0.00496	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41627876	chr1:41542069~41544310:+
COAD	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-4.4	1.57e-05	0.00496	-0.37	-0.26	Depression;	chr6:28135913	chr6:28115628~28116551:+
COAD	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-4.4	1.57e-05	0.00496	-0.31	-0.26	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
COAD	cis	rs2836974	0.627	rs9981301	ENSG00000255568.3	BRWD1-AS2	-4.4	1.57e-05	0.00496	-0.25	-0.26	Cognitive function;	chr21:39314152	chr21:39313935~39314962:+
COAD	cis	rs12497850	0.897	rs9884022	ENSG00000225399.4	RP11-3B7.1	4.4	1.58e-05	0.00497	0.29	0.26	Parkinson's disease;	chr3:48919429	chr3:49260085~49261316:+
COAD	cis	rs1578862	1	rs6426233	ENSG00000259865.1	RP11-488L18.10	-4.4	1.58e-05	0.00497	-0.21	-0.26	Monocyte percentage of white cells;	chr1:247263679	chr1:247187281~247188526:-
COAD	cis	rs17711722	0.701	rs781145	ENSG00000272831.1	RP11-792A8.4	4.4	1.58e-05	0.00497	0.28	0.26	Calcium levels;	chr7:65975383	chr7:66739829~66740385:-
COAD	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-4.4	1.58e-05	0.00497	-0.31	-0.26	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
COAD	cis	rs6921919	0.638	rs9468344	ENSG00000272009.1	RP1-313I6.12	4.4	1.58e-05	0.00498	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28078792~28081130:-
COAD	cis	rs9487051	0.872	rs1111863	ENSG00000219700.1	PTCHD3P3	-4.4	1.58e-05	0.00498	-0.28	-0.26	Reticulocyte fraction of red cells;	chr6:109290003	chr6:109288571~109290503:-
COAD	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-4.4	1.58e-05	0.00498	-0.32	-0.26	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
COAD	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.4	1.58e-05	0.00498	-0.41	-0.26	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.4	1.58e-05	0.00498	-0.41	-0.26	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.4	1.58e-05	0.00498	-0.41	-0.26	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	4.4	1.58e-05	0.00498	0.41	0.26	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	4.4	1.58e-05	0.00498	0.41	0.26	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
COAD	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-4.4	1.58e-05	0.00498	-0.27	-0.26	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
COAD	cis	rs7829975	0.56	rs6994131	ENSG00000253981.4	ALG1L13P	-4.4	1.58e-05	0.00498	-0.32	-0.26	Mood instability;	chr8:8693448	chr8:8236003~8244667:-
COAD	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-4.4	1.58e-05	0.00498	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
COAD	cis	rs875971	0.522	rs4718285	ENSG00000272831.1	RP11-792A8.4	4.4	1.58e-05	0.00498	0.28	0.26	Aortic root size;	chr7:65827018	chr7:66739829~66740385:-
COAD	cis	rs875971	0.522	rs4718286	ENSG00000272831.1	RP11-792A8.4	4.4	1.58e-05	0.00498	0.28	0.26	Aortic root size;	chr7:65827777	chr7:66739829~66740385:-
COAD	cis	rs41307935	0.818	rs35161452	ENSG00000260063.1	RP5-968P14.2	-4.4	1.58e-05	0.00498	-0.55	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26691718	chr1:26692132~26694131:-
COAD	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	4.4	1.58e-05	0.00499	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
COAD	cis	rs62184315	0.575	rs256546	ENSG00000253559.1	OSGEPL1-AS1	-4.4	1.58e-05	0.00499	-0.27	-0.26	Alcohol dependence (age at onset);	chr2:189886437	chr2:189762704~189765556:+
COAD	cis	rs12497850	0.931	rs13315711	ENSG00000225399.4	RP11-3B7.1	4.4	1.58e-05	0.00499	0.29	0.26	Parkinson's disease;	chr3:48948966	chr3:49260085~49261316:+
COAD	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	4.4	1.59e-05	0.00499	0.38	0.26	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	4.4	1.59e-05	0.00499	0.38	0.26	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	4.4	1.59e-05	0.00499	0.38	0.26	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
COAD	cis	rs603446	0.61	rs1263058	ENSG00000254851.1	RP11-109L13.1	-4.4	1.59e-05	0.00499	-0.3	-0.26	Triglycerides;	chr11:116704839	chr11:117135528~117138582:+
COAD	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-4.4	1.59e-05	0.005	-0.29	-0.26	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
COAD	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-4.4	1.59e-05	0.005	-0.32	-0.26	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
COAD	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	4.4	1.59e-05	0.005	0.29	0.26	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	4.4	1.59e-05	0.005	0.29	0.26	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
COAD	cis	rs763121	0.853	rs5757193	ENSG00000273076.1	RP3-508I15.22	-4.4	1.59e-05	0.005	-0.25	-0.26	Menopause (age at onset);	chr22:38638862	chr22:38743495~38743910:+
COAD	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	4.4	1.59e-05	0.005	0.29	0.26	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
COAD	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-4.4	1.59e-05	0.005	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
COAD	cis	rs2337406	0.866	rs7152038	ENSG00000211967.3	IGHV3-53	-4.4	1.59e-05	0.005	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106778230	chr14:106592676~106593347:-
COAD	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-4.4	1.59e-05	0.00501	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
COAD	cis	rs8141529	0.732	rs5762815	ENSG00000272858.1	CTA-292E10.8	-4.4	1.59e-05	0.00501	-0.31	-0.26	Lymphocyte counts;	chr22:28809088	chr22:28814914~28815662:+
COAD	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-4.4	1.59e-05	0.00501	-0.32	-0.26	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
COAD	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-4.4	1.59e-05	0.00501	-0.32	-0.26	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
COAD	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-4.4	1.59e-05	0.00501	-0.18	-0.26	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-4.4	1.59e-05	0.00501	-0.18	-0.26	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
COAD	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-4.4	1.6e-05	0.00502	-0.34	-0.26	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
COAD	cis	rs492146	1	rs375872	ENSG00000243236.5	GSTA9P	-4.4	1.6e-05	0.00502	-0.29	-0.26	Epilepsy (remission after treatment);	chr6:52970119	chr6:52939726~52957521:-
COAD	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-4.4	1.6e-05	0.00502	-0.32	-0.26	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
COAD	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	4.4	1.6e-05	0.00502	0.29	0.26	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
COAD	cis	rs6723226	0.882	rs13035097	ENSG00000276334.1	AL133243.1	-4.4	1.6e-05	0.00502	-0.25	-0.26	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32521927~32523547:+
COAD	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-4.4	1.6e-05	0.00502	-0.38	-0.26	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
COAD	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	4.4	1.6e-05	0.00502	0.43	0.26	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
COAD	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	4.4	1.6e-05	0.00502	0.32	0.26	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
COAD	cis	rs2337406	0.866	rs8003852	ENSG00000211967.3	IGHV3-53	-4.4	1.6e-05	0.00502	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106776648	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs988131	ENSG00000211967.3	IGHV3-53	-4.4	1.6e-05	0.00502	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106776833	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs8005518	ENSG00000211967.3	IGHV3-53	-4.4	1.6e-05	0.00502	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106777009	chr14:106592676~106593347:-
COAD	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-4.4	1.6e-05	0.00502	-0.33	-0.26	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
COAD	cis	rs739496	0.615	rs624716	ENSG00000257595.2	RP3-473L9.4	4.4	1.6e-05	0.00502	0.39	0.26	Platelet count;	chr12:111728892	chr12:111369282~111403310:+
COAD	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	4.4	1.6e-05	0.00503	0.32	0.26	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
COAD	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-4.4	1.6e-05	0.00503	-0.34	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
COAD	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-4.4	1.6e-05	0.00503	-0.26	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
COAD	cis	rs860295	0.967	rs6665227	ENSG00000203761.5	MSTO2P	-4.4	1.6e-05	0.00503	-0.24	-0.26	Body mass index;	chr1:155740669	chr1:155745829~155750137:+
COAD	cis	rs7615952	0.688	rs4422259	ENSG00000272840.1	RP11-379B18.6	4.4	1.6e-05	0.00503	0.36	0.26	Blood pressure (smoking interaction);	chr3:125826988	chr3:125774714~125797953:+
COAD	cis	rs4950322	0.947	rs72694723	ENSG00000278811.3	LINC00624	4.4	1.6e-05	0.00503	0.29	0.26	Protein quantitative trait loci;	chr1:147373174	chr1:147258885~147517875:-
COAD	cis	rs11951515	0.508	rs10065689	ENSG00000248554.1	RP11-159F24.6	-4.4	1.6e-05	0.00503	-0.28	-0.26	Metabolite levels  (X-11787);	chr5:43604156	chr5:43511058~43521811:+
COAD	cis	rs12497850	0.931	rs6414613	ENSG00000225399.4	RP11-3B7.1	4.4	1.6e-05	0.00503	0.29	0.26	Parkinson's disease;	chr3:48998452	chr3:49260085~49261316:+
COAD	cis	rs860295	0.836	rs1360554	ENSG00000223503.1	RP11-29H23.6	4.4	1.6e-05	0.00504	0.34	0.26	Body mass index;	chr1:155503565	chr1:155590601~155591262:-
COAD	cis	rs875971	0.545	rs6969224	ENSG00000224316.1	RP11-479O9.2	4.4	1.6e-05	0.00504	0.34	0.26	Aortic root size;	chr7:66370011	chr7:65773620~65802067:+
COAD	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-4.4	1.6e-05	0.00504	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
COAD	cis	rs9487051	0.676	rs6925716	ENSG00000219700.1	PTCHD3P3	4.4	1.6e-05	0.00504	0.28	0.26	Reticulocyte fraction of red cells;	chr6:109276438	chr6:109288571~109290503:-
COAD	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	4.4	1.6e-05	0.00504	0.32	0.26	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
COAD	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	4.4	1.6e-05	0.00504	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
COAD	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-4.4	1.61e-05	0.00504	-0.5	-0.26	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-4.4	1.61e-05	0.00504	-0.5	-0.26	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
COAD	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-4.4	1.61e-05	0.00504	-0.5	-0.26	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-4.4	1.61e-05	0.00504	-0.5	-0.26	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
COAD	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4.4	1.61e-05	0.00505	0.47	0.26	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4.4	1.61e-05	0.00505	0.47	0.26	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
COAD	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-4.4	1.61e-05	0.00505	-0.47	-0.26	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
COAD	cis	rs6452524	0.618	rs1993948	ENSG00000271862.1	RP11-343L5.2	4.4	1.61e-05	0.00505	0.26	0.26	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83049376~83050964:-
COAD	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	4.4	1.61e-05	0.00505	0.3	0.26	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
COAD	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-4.4	1.61e-05	0.00505	-0.24	-0.26	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
COAD	cis	rs6452524	0.618	rs6452502	ENSG00000271862.1	RP11-343L5.2	4.4	1.61e-05	0.00505	0.26	0.26	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.618	rs6452503	ENSG00000271862.1	RP11-343L5.2	4.4	1.61e-05	0.00505	0.26	0.26	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83049376~83050964:-
COAD	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-4.4	1.61e-05	0.00505	-0.3	-0.26	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
COAD	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	4.4	1.61e-05	0.00506	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
COAD	cis	rs4718428	0.705	rs4717328	ENSG00000272831.1	RP11-792A8.4	4.4	1.61e-05	0.00506	0.3	0.26	Corneal structure;	chr7:66887678	chr7:66739829~66740385:-
COAD	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	4.4	1.61e-05	0.00506	0.3	0.26	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	4.4	1.61e-05	0.00506	0.3	0.26	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	4.4	1.61e-05	0.00506	0.3	0.26	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
COAD	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	4.4	1.61e-05	0.00506	0.3	0.26	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
COAD	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-4.4	1.61e-05	0.00506	-0.27	-0.26	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
COAD	cis	rs1510272	0.889	rs2048336	ENSG00000243926.1	TIPARP-AS1	-4.4	1.61e-05	0.00507	-0.3	-0.26	Testicular germ cell tumor;	chr3:156610464	chr3:156671862~156674378:-
COAD	cis	rs1106529	0.51	rs7526102	ENSG00000231365.4	RP11-418J17.1	-4.4	1.61e-05	0.00507	-0.34	-0.26	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119140396~119275973:+
COAD	cis	rs4704187	0.687	rs4235683	ENSG00000250889.2	LINC01336	-4.4	1.61e-05	0.00507	-0.3	-0.26	Response to amphetamines;	chr5:75119263	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.64	rs1600075	ENSG00000250889.2	LINC01336	-4.4	1.61e-05	0.00507	-0.3	-0.26	Response to amphetamines;	chr5:75122479	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6872475	ENSG00000250889.2	LINC01336	-4.4	1.61e-05	0.00507	-0.3	-0.26	Response to amphetamines;	chr5:75123968	chr5:75047719~75052843:-
COAD	cis	rs71636778	0.509	rs34576193	ENSG00000260063.1	RP5-968P14.2	-4.4	1.62e-05	0.00507	-0.55	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26728289	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs41303629	ENSG00000260063.1	RP5-968P14.2	-4.4	1.62e-05	0.00507	-0.55	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26731130	chr1:26692132~26694131:-
COAD	cis	rs9450351	0.744	rs6910543	ENSG00000203875.9	SNHG5	-4.4	1.62e-05	0.00507	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85519023	chr6:85660950~85678736:-
COAD	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	4.4	1.62e-05	0.00507	0.49	0.26	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
COAD	cis	rs13256369	0.865	rs13282523	ENSG00000253981.4	ALG1L13P	4.4	1.62e-05	0.00507	0.37	0.26	Obesity-related traits;	chr8:8719783	chr8:8236003~8244667:-
COAD	cis	rs2337406	0.866	rs74092535	ENSG00000211967.3	IGHV3-53	-4.4	1.62e-05	0.00507	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106781722	chr14:106592676~106593347:-
COAD	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-4.4	1.62e-05	0.00508	-0.34	-0.26	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
COAD	cis	rs10895987	1	rs9971407	ENSG00000254614.2	AP003068.23	4.4	1.62e-05	0.00509	0.41	0.26	Blood protein levels;	chr11:65130754	chr11:65177606~65181834:-
COAD	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	4.4	1.62e-05	0.00509	0.37	0.26	Depression;	chr6:28142370	chr6:28115628~28116551:+
COAD	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	4.39	1.62e-05	0.00509	0.39	0.26	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	4.39	1.62e-05	0.00509	0.39	0.26	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
COAD	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	4.39	1.62e-05	0.00509	0.39	0.26	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
COAD	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	4.39	1.62e-05	0.00509	0.39	0.26	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
COAD	cis	rs9532669	0.926	rs9532632	ENSG00000239827.7	SUGT1P3	-4.39	1.62e-05	0.00509	-0.23	-0.26	Cervical cancer;	chr13:40876309	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532633	ENSG00000239827.7	SUGT1P3	-4.39	1.62e-05	0.00509	-0.23	-0.26	Cervical cancer;	chr13:40876332	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532634	ENSG00000239827.7	SUGT1P3	-4.39	1.62e-05	0.00509	-0.23	-0.26	Cervical cancer;	chr13:40876369	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532635	ENSG00000239827.7	SUGT1P3	-4.39	1.62e-05	0.00509	-0.23	-0.26	Cervical cancer;	chr13:40876397	chr13:40908159~40921774:-
COAD	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	4.39	1.62e-05	0.00509	0.3	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
COAD	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.39	1.63e-05	0.0051	-0.33	-0.26	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.39	1.63e-05	0.0051	-0.33	-0.26	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
COAD	cis	rs476633	0.573	rs2099652	ENSG00000247556.5	OIP5-AS1	4.39	1.63e-05	0.0051	0.27	0.26	Glomerular filtration rate (creatinine);	chr15:41236547	chr15:41283990~41309737:+
COAD	cis	rs1670533	1	rs2045065	ENSG00000273179.1	RP11-20I20.4	4.39	1.63e-05	0.0051	0.35	0.26	Recombination rate (females);	chr4:1058700	chr4:1167778~1168174:+
COAD	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	4.39	1.63e-05	0.0051	0.33	0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
COAD	cis	rs12497850	0.931	rs9876848	ENSG00000225399.4	RP11-3B7.1	4.39	1.63e-05	0.00511	0.29	0.26	Parkinson's disease;	chr3:48806626	chr3:49260085~49261316:+
COAD	cis	rs453301	0.562	rs1038248	ENSG00000253981.4	ALG1L13P	-4.39	1.63e-05	0.00511	-0.32	-0.26	Joint mobility (Beighton score);	chr8:9183348	chr8:8236003~8244667:-
COAD	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	4.39	1.63e-05	0.00511	0.39	0.26	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
COAD	cis	rs6545883	0.524	rs778159	ENSG00000273302.1	RP11-493E12.2	-4.39	1.63e-05	0.00511	-0.24	-0.26	Tuberculosis;	chr2:61329609	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.507	rs34668697	ENSG00000273302.1	RP11-493E12.2	-4.39	1.63e-05	0.00511	-0.24	-0.26	Tuberculosis;	chr2:61341214	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.507	rs2442025	ENSG00000273302.1	RP11-493E12.2	-4.39	1.63e-05	0.00511	-0.24	-0.26	Tuberculosis;	chr2:61344310	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.524	rs2593631	ENSG00000273302.1	RP11-493E12.2	-4.39	1.63e-05	0.00511	-0.24	-0.26	Tuberculosis;	chr2:61345151	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.542	rs2593628	ENSG00000273302.1	RP11-493E12.2	-4.39	1.63e-05	0.00511	-0.24	-0.26	Tuberculosis;	chr2:61346152	chr2:61199979~61200769:+
COAD	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.39	1.63e-05	0.00512	0.42	0.26	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
COAD	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-4.39	1.63e-05	0.00512	-0.3	-0.26	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-4.39	1.63e-05	0.00512	-0.3	-0.26	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
COAD	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	4.39	1.63e-05	0.00512	0.31	0.26	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
COAD	cis	rs847577	0.677	rs4729403	ENSG00000272950.1	RP11-307C18.1	-4.39	1.63e-05	0.00512	-0.29	-0.26	Breast cancer;	chr7:98078529	chr7:98322853~98323430:+
COAD	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	4.39	1.64e-05	0.00512	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
COAD	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-4.39	1.64e-05	0.00513	-0.31	-0.26	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-4.39	1.64e-05	0.00513	-0.31	-0.26	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
COAD	cis	rs8022206	0.68	rs7142860	ENSG00000259502.1	RP11-643G16.3	4.39	1.64e-05	0.00513	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67927581	chr14:67610986~67613864:+
COAD	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	4.39	1.64e-05	0.00513	0.4	0.26	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
COAD	cis	rs2337406	0.789	rs112027230	ENSG00000211974.3	IGHV2-70	-4.39	1.64e-05	0.00513	-0.3	-0.26	Alzheimer's disease (late onset);	chr14:106810329	chr14:106723574~106724093:-
COAD	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	4.39	1.64e-05	0.00513	0.34	0.26	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
COAD	cis	rs9532669	0.857	rs9525427	ENSG00000277662.1	RP11-74J13.9	-4.39	1.64e-05	0.00513	-0.25	-0.26	Cervical cancer;	chr13:40918029	chr13:41229180~41229676:-
COAD	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-4.39	1.64e-05	0.00514	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-4.39	1.64e-05	0.00514	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
COAD	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	4.39	1.64e-05	0.00514	0.42	0.26	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
COAD	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-4.39	1.64e-05	0.00514	-0.3	-0.26	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
COAD	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	4.39	1.64e-05	0.00514	0.34	0.26	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
COAD	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-4.39	1.64e-05	0.00514	-0.24	-0.26	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
COAD	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-4.39	1.64e-05	0.00514	-0.27	-0.26	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
COAD	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-4.39	1.64e-05	0.00514	-0.27	-0.26	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
COAD	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-4.39	1.64e-05	0.00514	-0.24	-0.26	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
COAD	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	4.39	1.64e-05	0.00515	0.28	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
COAD	cis	rs7630852	1	rs7630852	ENSG00000272359.1	U4	-4.39	1.64e-05	0.00515	-0.31	-0.26	Eosinophil counts;	chr3:196781680	chr3:196747192~196747324:-
COAD	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-4.39	1.64e-05	0.00515	-0.28	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
COAD	cis	rs9910055	0.529	rs228764	ENSG00000267080.4	ASB16-AS1	4.39	1.65e-05	0.00515	0.25	0.26	Total body bone mineral density;	chr17:44108101	chr17:44175973~44186717:-
COAD	cis	rs228769	0.673	rs375677	ENSG00000267080.4	ASB16-AS1	4.39	1.65e-05	0.00515	0.28	0.26	Bone mineral density (hip);Bone mineral density (spine);	chr17:44031606	chr17:44175973~44186717:-
COAD	cis	rs9400467	0.528	rs6913769	ENSG00000271789.1	RP5-1112D6.7	-4.39	1.65e-05	0.00516	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111297126~111298510:+
COAD	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-4.39	1.65e-05	0.00516	-0.24	-0.26	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
COAD	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-4.39	1.65e-05	0.00516	-0.33	-0.26	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
COAD	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-4.39	1.65e-05	0.00516	-0.38	-0.26	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
COAD	cis	rs9393777	0.623	rs7773938	ENSG00000224843.5	LINC00240	4.39	1.65e-05	0.00516	0.44	0.26	Intelligence (multi-trait analysis);	chr6:26473816	chr6:26956992~27023924:+
COAD	cis	rs7656342	0.808	rs6815039	ENSG00000186234.7	FAM86MP	-4.39	1.65e-05	0.00516	-0.35	-0.26	Gut microbiota (bacterial taxa);	chr4:9776185	chr4:9692495~9702954:+
COAD	cis	rs453301	0.653	rs7853	ENSG00000254340.1	RP11-10A14.3	4.39	1.65e-05	0.00516	0.32	0.26	Joint mobility (Beighton score);	chr8:9033304	chr8:9141424~9145435:+
COAD	cis	rs13256369	1	rs13256369	ENSG00000253981.4	ALG1L13P	4.39	1.65e-05	0.00516	0.38	0.26	Obesity-related traits;	chr8:8719869	chr8:8236003~8244667:-
COAD	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	4.39	1.65e-05	0.00516	0.34	0.26	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	4.39	1.65e-05	0.00516	0.34	0.26	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
COAD	cis	rs4555772	0.573	rs7714420	ENSG00000250889.2	LINC01336	-4.39	1.65e-05	0.00517	-0.3	-0.26	Stearic acid (18:0) levels;	chr5:75044502	chr5:75047719~75052843:-
COAD	cis	rs11681884	0.71	rs4252001	ENSG00000228251.1	AC012442.6	-4.39	1.65e-05	0.00517	-0.43	-0.26	Stroke;	chr2:113126106	chr2:112590796~112591939:+
COAD	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-4.39	1.65e-05	0.00517	-0.33	-0.26	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
COAD	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-4.39	1.65e-05	0.00517	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
COAD	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	4.39	1.65e-05	0.00517	0.34	0.26	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
COAD	cis	rs1387259	0.79	rs2732445	ENSG00000257735.1	RP11-370I10.6	4.39	1.65e-05	0.00517	0.33	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48350945~48442411:+
COAD	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	4.39	1.65e-05	0.00518	0.31	0.26	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
COAD	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-4.39	1.65e-05	0.00518	-0.34	-0.26	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
COAD	cis	rs440932	0.565	rs19334	ENSG00000173295.6	FAM86B3P	4.39	1.66e-05	0.00518	0.33	0.26	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8228595~8244865:+
COAD	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.39	1.66e-05	0.00518	0.35	0.26	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
COAD	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	4.39	1.66e-05	0.00519	0.37	0.26	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
COAD	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	4.39	1.66e-05	0.00519	0.24	0.26	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
COAD	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	4.39	1.66e-05	0.00519	0.24	0.26	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
COAD	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	4.39	1.66e-05	0.00519	0.24	0.26	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
COAD	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	4.39	1.66e-05	0.00519	0.24	0.26	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
COAD	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	4.39	1.66e-05	0.00519	0.24	0.26	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
COAD	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-4.39	1.66e-05	0.00519	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-4.39	1.66e-05	0.00519	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-4.39	1.66e-05	0.00519	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
COAD	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.39	1.66e-05	0.00519	0.42	0.26	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
COAD	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-4.39	1.66e-05	0.00519	-0.34	-0.26	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
COAD	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	4.39	1.66e-05	0.0052	0.34	0.26	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	4.39	1.66e-05	0.0052	0.34	0.26	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
COAD	cis	rs1559040	1	rs11677951	ENSG00000233266.1	HMGB1P31	-4.39	1.66e-05	0.0052	-0.42	-0.26	Sudden cardiac arrest;	chr2:54075538	chr2:54051334~54051760:+
COAD	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	4.39	1.66e-05	0.0052	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	4.39	1.66e-05	0.0052	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	4.39	1.66e-05	0.0052	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
COAD	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	4.39	1.66e-05	0.0052	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
COAD	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	4.39	1.66e-05	0.0052	0.61	0.26	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	4.39	1.66e-05	0.0052	0.61	0.26	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
COAD	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	4.39	1.66e-05	0.0052	0.61	0.26	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
COAD	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	4.39	1.66e-05	0.0052	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
COAD	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	4.39	1.66e-05	0.0052	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
COAD	cis	rs8002861	0.905	rs6561149	ENSG00000274001.1	RP11-5G9.5	-4.39	1.67e-05	0.00521	-0.25	-0.26	Leprosy;	chr13:43882646	chr13:43877715~43878163:-
COAD	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-4.39	1.67e-05	0.00521	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
COAD	cis	rs7674212	1	rs7674212	ENSG00000230069.3	LRRC37A15P	-4.39	1.67e-05	0.00521	-0.28	-0.26	Type 2 diabetes;	chr4:103067742	chr4:102727274~102730721:-
COAD	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-4.39	1.67e-05	0.00521	-0.33	-0.26	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
COAD	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-4.39	1.67e-05	0.00521	-0.33	-0.26	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
COAD	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-4.39	1.67e-05	0.00521	-0.28	-0.26	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
COAD	cis	rs7577696	0.752	rs212714	ENSG00000272716.1	RP11-563N4.1	4.39	1.67e-05	0.00521	0.27	0.26	Inflammatory biomarkers;	chr2:32235279	chr2:32165046~32165757:-
COAD	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-4.39	1.67e-05	0.00522	-0.28	-0.26	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
COAD	cis	rs4718428	0.705	rs10267335	ENSG00000272831.1	RP11-792A8.4	4.39	1.67e-05	0.00522	0.3	0.26	Corneal structure;	chr7:66938233	chr7:66739829~66740385:-
COAD	cis	rs58873874	1	rs11740562	ENSG00000251405.2	CTB-109A12.1	-4.39	1.67e-05	0.00522	-0.55	-0.26	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157362615~157460078:-
COAD	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	4.39	1.67e-05	0.00522	0.35	0.26	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
COAD	cis	rs875971	0.638	rs6960778	ENSG00000272831.1	RP11-792A8.4	-4.39	1.67e-05	0.00522	-0.28	-0.26	Aortic root size;	chr7:66606610	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.701	rs781143	ENSG00000272831.1	RP11-792A8.4	4.39	1.67e-05	0.00522	0.28	0.26	Calcium levels;	chr7:65974892	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000272831.1	RP11-792A8.4	4.39	1.67e-05	0.00522	0.28	0.26	Calcium levels;	chr7:65996954	chr7:66739829~66740385:-
COAD	cis	rs597539	0.652	rs1249474	ENSG00000255741.1	RP11-757G1.5	-4.39	1.67e-05	0.00522	-0.34	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68941503~68942852:-
COAD	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.39	1.67e-05	0.00522	-0.42	-0.26	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
COAD	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	4.39	1.67e-05	0.00522	0.34	0.26	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
COAD	cis	rs4704187	0.687	rs2335134	ENSG00000250889.2	LINC01336	-4.39	1.67e-05	0.00523	-0.3	-0.26	Response to amphetamines;	chr5:75183018	chr5:75047719~75052843:-
COAD	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	4.39	1.67e-05	0.00523	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
COAD	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.39	1.67e-05	0.00523	0.23	0.26	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
COAD	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	4.39	1.67e-05	0.00523	0.35	0.26	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	4.39	1.67e-05	0.00523	0.35	0.26	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
COAD	cis	rs812925	0.537	rs778146	ENSG00000273302.1	RP11-493E12.2	-4.39	1.67e-05	0.00523	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61379340	chr2:61199979~61200769:+
COAD	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	4.39	1.67e-05	0.00523	0.32	0.26	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
COAD	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-4.39	1.67e-05	0.00523	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
COAD	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	4.39	1.68e-05	0.00523	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
COAD	cis	rs36052053	0.908	rs34854922	ENSG00000219700.1	PTCHD3P3	4.39	1.68e-05	0.00524	0.47	0.26	Red cell distribution width;	chr6:109272953	chr6:109288571~109290503:-
COAD	cis	rs7577696	0.962	rs2365555	ENSG00000272716.1	RP11-563N4.1	4.39	1.68e-05	0.00524	0.27	0.26	Inflammatory biomarkers;	chr2:32055630	chr2:32165046~32165757:-
COAD	cis	rs9951698	0.667	rs518145	ENSG00000266969.1	RP11-773H22.4	4.39	1.68e-05	0.00524	0.33	0.26	Intelligence (multi-trait analysis);	chr18:13091662	chr18:12984694~12991173:-
COAD	cis	rs2638953	0.849	rs10843172	ENSG00000247934.4	RP11-967K21.1	-4.39	1.68e-05	0.00524	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452300	chr12:28163298~28190738:-
COAD	cis	rs875971	0.522	rs7784623	ENSG00000272831.1	RP11-792A8.4	4.39	1.68e-05	0.00524	0.27	0.26	Aortic root size;	chr7:65930047	chr7:66739829~66740385:-
COAD	cis	rs875971	0.522	rs34973832	ENSG00000272831.1	RP11-792A8.4	4.39	1.68e-05	0.00524	0.27	0.26	Aortic root size;	chr7:65931217	chr7:66739829~66740385:-
COAD	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-4.39	1.68e-05	0.00524	-0.27	-0.26	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
COAD	cis	rs12497850	0.931	rs28642807	ENSG00000225399.4	RP11-3B7.1	4.39	1.68e-05	0.00525	0.29	0.26	Parkinson's disease;	chr3:48889383	chr3:49260085~49261316:+
COAD	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-4.39	1.68e-05	0.00525	-0.34	-0.26	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
COAD	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	4.39	1.68e-05	0.00525	0.3	0.26	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
COAD	cis	rs2337406	0.704	rs1858679	ENSG00000211974.3	IGHV2-70	-4.39	1.68e-05	0.00525	-0.3	-0.26	Alzheimer's disease (late onset);	chr14:106706726	chr14:106723574~106724093:-
COAD	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-4.39	1.69e-05	0.00525	-0.31	-0.26	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
COAD	cis	rs7904519	0.55	rs11196180	ENSG00000227560.1	RP11-139K1.2	-4.39	1.69e-05	0.00525	-0.29	-0.26	Breast cancer (estrogen-receptor negative);Breast cancer;	chr10:112988270	chr10:112987476~112987865:+
COAD	cis	rs12049351	0.665	rs3753884	ENSG00000229367.1	HMGN2P19	4.39	1.69e-05	0.00525	0.38	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229436507	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.613	rs10458374	ENSG00000229367.1	HMGN2P19	4.39	1.69e-05	0.00525	0.38	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229440389	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.665	rs12142272	ENSG00000229367.1	HMGN2P19	4.39	1.69e-05	0.00525	0.38	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229443068	chr1:229570532~229570796:+
COAD	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.39	1.69e-05	0.00525	0.32	0.26	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
COAD	cis	rs11668609	0.505	rs60888272	ENSG00000268442.1	CTD-2027I19.2	4.39	1.69e-05	0.00525	0.41	0.26	Response to taxane treatment (docetaxel);	chr19:23968491	chr19:24162370~24163425:-
COAD	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-4.39	1.69e-05	0.00526	-0.32	-0.26	QT interval;	chr12:29298788	chr12:29277397~29277882:-
COAD	cis	rs742132	0.858	rs10946787	ENSG00000220875.1	HIST1H3PS1	4.39	1.69e-05	0.00526	0.34	0.26	Uric acid levels;	chr6:25646611	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs1040419	ENSG00000220875.1	HIST1H3PS1	4.39	1.69e-05	0.00526	0.34	0.26	Uric acid levels;	chr6:25652862	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs1406927	ENSG00000220875.1	HIST1H3PS1	4.39	1.69e-05	0.00526	0.34	0.26	Uric acid levels;	chr6:25653614	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs2072846	ENSG00000220875.1	HIST1H3PS1	4.39	1.69e-05	0.00526	0.34	0.26	Uric acid levels;	chr6:25654876	chr6:26321876~26322292:-
COAD	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	4.39	1.69e-05	0.00526	0.31	0.26	Height;	chr4:55540928	chr4:55540502~55540835:-
COAD	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-4.39	1.69e-05	0.00526	-0.27	-0.26	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-4.39	1.69e-05	0.00526	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-4.39	1.69e-05	0.00526	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
COAD	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-4.39	1.69e-05	0.00526	-0.28	-0.26	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
COAD	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	4.39	1.69e-05	0.00526	0.33	0.26	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
COAD	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-4.39	1.69e-05	0.00526	-0.38	-0.26	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-4.39	1.69e-05	0.00526	-0.38	-0.26	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-4.39	1.69e-05	0.00526	-0.38	-0.26	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
COAD	cis	rs875971	0.798	rs12698522	ENSG00000224316.1	RP11-479O9.2	4.39	1.69e-05	0.00526	0.28	0.26	Aortic root size;	chr7:66502354	chr7:65773620~65802067:+
COAD	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	4.39	1.69e-05	0.00527	0.32	0.26	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
COAD	cis	rs9291683	0.668	rs2241474	ENSG00000250413.1	RP11-448G15.1	-4.39	1.69e-05	0.00527	-0.34	-0.26	Bone mineral density;	chr4:10084391	chr4:10006482~10009725:+
COAD	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	4.39	1.69e-05	0.00527	0.48	0.26	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
COAD	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
COAD	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-4.39	1.69e-05	0.00527	-0.48	-0.26	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
COAD	cis	rs71636778	0.509	rs35917448	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26690834	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12738345	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26693253	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.908	rs4579782	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26700496	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs71514277	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26707937	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.57	rs12737407	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26709671	chr1:26692132~26694131:-
COAD	cis	rs41307935	0.778	rs78533482	ENSG00000260063.1	RP5-968P14.2	-4.38	1.69e-05	0.00527	-0.54	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26715851	chr1:26692132~26694131:-
COAD	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-4.38	1.69e-05	0.00527	-0.32	-0.26	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
COAD	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-4.38	1.69e-05	0.00527	-0.32	-0.26	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
COAD	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-4.38	1.69e-05	0.00527	-0.34	-0.26	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
COAD	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-4.38	1.69e-05	0.00527	-0.32	-0.26	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
COAD	cis	rs17685	0.753	rs6951808	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs6951943	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs10952840	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76043977~76045963:-
COAD	cis	rs17685	0.672	rs10952841	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1806885	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1859791	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs6464999	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs6465000	ENSG00000280388.1	RP11-229D13.3	-4.38	1.69e-05	0.00527	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76043977~76045963:-
COAD	cis	rs2188554	0.711	rs213947	ENSG00000237974.1	AC000111.4	4.38	1.69e-05	0.00527	0.28	0.26	Esophageal adenocarcinoma;	chr7:117552554	chr7:117487737~117487929:+
COAD	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-4.38	1.69e-05	0.00527	-0.31	-0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
COAD	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	4.38	1.69e-05	0.00527	0.29	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
COAD	cis	rs2732480	0.577	rs2634693	ENSG00000269514.1	RP11-370I10.12	4.38	1.7e-05	0.00527	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2634691	ENSG00000269514.1	RP11-370I10.12	4.38	1.7e-05	0.00527	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48198387~48202031:+
COAD	cis	rs1832007	0.529	rs4612705	ENSG00000224034.1	RP11-445P17.8	-4.38	1.7e-05	0.00528	-0.4	-0.26	Triglyceride levels;Triglycerides;	chr10:5201635	chr10:5266033~5271236:-
COAD	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	4.38	1.7e-05	0.00528	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
COAD	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	4.38	1.7e-05	0.00528	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
COAD	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	4.38	1.7e-05	0.00528	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
COAD	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	4.38	1.7e-05	0.00528	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
COAD	cis	rs10078	0.559	rs2672725	ENSG00000225138.6	CTD-2228K2.7	4.38	1.7e-05	0.00528	0.4	0.26	Fat distribution (HIV);	chr5:434866	chr5:473236~480884:+
COAD	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-4.38	1.7e-05	0.00529	-0.27	-0.26	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
COAD	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-4.38	1.7e-05	0.00529	-0.49	-0.26	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
COAD	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-4.38	1.7e-05	0.00529	-0.28	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
COAD	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.38	1.7e-05	0.00529	0.45	0.26	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
COAD	cis	rs763121	0.853	rs1013338	ENSG00000273076.1	RP3-508I15.22	4.38	1.7e-05	0.00529	0.23	0.26	Menopause (age at onset);	chr22:38578149	chr22:38743495~38743910:+
COAD	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	4.38	1.7e-05	0.0053	0.31	0.26	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
COAD	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	4.38	1.7e-05	0.0053	0.36	0.26	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
COAD	cis	rs7829975	0.714	rs4840362	ENSG00000233609.3	RP11-62H7.2	-4.38	1.7e-05	0.0053	-0.3	-0.26	Mood instability;	chr8:8812572	chr8:8961200~8979025:+
COAD	cis	rs2380205	0.546	rs626344	ENSG00000232807.2	RP11-536K7.3	-4.38	1.71e-05	0.0053	-0.22	-0.26	Breast cancer;	chr10:5908272	chr10:5934270~5945900:-
COAD	cis	rs453301	0.686	rs6748	ENSG00000254340.1	RP11-10A14.3	-4.38	1.71e-05	0.0053	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9033292	chr8:9141424~9145435:+
COAD	cis	rs1045529	0.524	rs34251783	ENSG00000254340.1	RP11-10A14.3	-4.38	1.71e-05	0.0053	-0.3	-0.26	Myopia (pathological);Myopia;	chr8:9033866	chr8:9141424~9145435:+
COAD	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	4.38	1.71e-05	0.0053	0.3	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
COAD	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-4.38	1.71e-05	0.00531	-0.18	-0.26	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
COAD	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	4.38	1.71e-05	0.00531	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
COAD	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-4.38	1.71e-05	0.00531	-0.36	-0.26	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-4.38	1.71e-05	0.00531	-0.36	-0.26	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-4.38	1.71e-05	0.00531	-0.36	-0.26	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
COAD	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-4.38	1.71e-05	0.00531	-0.28	-0.26	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-4.38	1.71e-05	0.00531	-0.28	-0.26	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
COAD	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-4.38	1.71e-05	0.00531	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
COAD	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-4.38	1.71e-05	0.00531	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
COAD	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	4.38	1.71e-05	0.00531	0.3	0.26	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
COAD	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	4.38	1.71e-05	0.00531	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
COAD	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	4.38	1.71e-05	0.00531	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
COAD	cis	rs2361718	0.501	rs8065486	ENSG00000279259.1	RP11-334C17.3	-4.38	1.71e-05	0.00531	-0.3	-0.26	Yeast infection;	chr17:80164397	chr17:80147250~80148596:+
COAD	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	4.38	1.71e-05	0.00531	0.33	0.26	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
COAD	cis	rs228769	0.635	rs228754	ENSG00000267080.4	ASB16-AS1	4.38	1.71e-05	0.00531	0.28	0.26	Bone mineral density (hip);Bone mineral density (spine);	chr17:44038688	chr17:44175973~44186717:-
COAD	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	4.38	1.71e-05	0.00531	0.38	0.26	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
COAD	cis	rs7829975	0.846	rs7005216	ENSG00000253981.4	ALG1L13P	-4.38	1.71e-05	0.00532	-0.3	-0.26	Mood instability;	chr8:8689600	chr8:8236003~8244667:-
COAD	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	4.38	1.71e-05	0.00532	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	4.38	1.71e-05	0.00532	0.27	0.26	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
COAD	cis	rs6452524	0.618	rs10462394	ENSG00000271862.1	RP11-343L5.2	4.38	1.71e-05	0.00532	0.26	0.26	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83049376~83050964:-
COAD	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-4.38	1.71e-05	0.00532	-0.32	-0.26	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
COAD	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	4.38	1.71e-05	0.00533	0.39	0.26	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
COAD	cis	rs6840360	0.582	rs4473638	ENSG00000251611.1	RP11-610P16.1	-4.38	1.72e-05	0.00533	-0.25	-0.26	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.548	rs4254751	ENSG00000251611.1	RP11-610P16.1	-4.38	1.72e-05	0.00533	-0.25	-0.26	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151407551~151408835:-
COAD	cis	rs7646881	0.544	rs16829273	ENSG00000272087.1	RP11-379F4.7	-4.38	1.72e-05	0.00533	-0.41	-0.26	Tetralogy of Fallot;	chr3:158664831	chr3:158693120~158693768:-
COAD	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-4.38	1.72e-05	0.00533	-0.18	-0.26	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
COAD	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	4.38	1.72e-05	0.00533	0.29	0.26	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
COAD	cis	rs1930961	0.702	rs60835827	ENSG00000271138.1	IGLVIVOR22-1	-4.38	1.72e-05	0.00533	-0.62	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25473570	chr22:25437306~25437823:-
COAD	cis	rs1930961	0.702	rs73410917	ENSG00000271138.1	IGLVIVOR22-1	-4.38	1.72e-05	0.00533	-0.62	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25476723	chr22:25437306~25437823:-
COAD	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.38	1.72e-05	0.00534	0.32	0.26	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
COAD	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	4.38	1.72e-05	0.00534	0.35	0.26	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
COAD	cis	rs6929812	0.613	rs13215560	ENSG00000271755.1	RP1-153G14.4	4.38	1.72e-05	0.00534	0.31	0.26	Neuroticism (multi-trait analysis);	chr6:27514160	chr6:27404010~27406964:-
COAD	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	4.38	1.72e-05	0.00534	0.33	0.26	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
COAD	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-4.38	1.72e-05	0.00535	-0.38	-0.26	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-4.38	1.72e-05	0.00535	-0.38	-0.26	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
COAD	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-4.38	1.72e-05	0.00535	-0.26	-0.26	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
COAD	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	4.38	1.72e-05	0.00535	0.31	0.26	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
COAD	cis	rs812925	0.537	rs2463097	ENSG00000273302.1	RP11-493E12.2	-4.38	1.72e-05	0.00535	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61387166	chr2:61199979~61200769:+
COAD	cis	rs2638953	0.962	rs10506029	ENSG00000247934.4	RP11-967K21.1	-4.38	1.72e-05	0.00535	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28163298~28190738:-
COAD	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-4.38	1.73e-05	0.00536	-0.28	-0.26	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
COAD	cis	rs763121	0.853	rs5750630	ENSG00000273076.1	RP3-508I15.22	4.38	1.73e-05	0.00537	0.25	0.26	Menopause (age at onset);	chr22:38589813	chr22:38743495~38743910:+
COAD	cis	rs2638953	0.672	rs11609619	ENSG00000247934.4	RP11-967K21.1	-4.38	1.73e-05	0.00537	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28557876	chr12:28163298~28190738:-
COAD	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-4.38	1.73e-05	0.00537	-0.34	-0.26	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
COAD	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	4.38	1.73e-05	0.00537	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
COAD	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	4.38	1.73e-05	0.00537	0.31	0.26	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
COAD	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	4.38	1.73e-05	0.00537	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
COAD	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-4.38	1.73e-05	0.00538	-0.42	-0.26	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
COAD	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-4.38	1.73e-05	0.00538	-0.32	-0.26	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
COAD	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	4.38	1.73e-05	0.00538	0.33	0.26	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
COAD	cis	rs2732480	0.577	rs2732466	ENSG00000257735.1	RP11-370I10.6	4.38	1.73e-05	0.00538	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48350945~48442411:+
COAD	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	4.38	1.73e-05	0.00538	0.4	0.26	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
COAD	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-4.38	1.74e-05	0.00538	-0.51	-0.26	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
COAD	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	4.38	1.74e-05	0.00538	0.49	0.26	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
COAD	cis	rs1275411	0.511	rs2012752	ENSG00000259062.2	ACTN1-AS1	4.38	1.74e-05	0.00539	0.35	0.26	Neuroticism;	chr14:68973553	chr14:68979682~68987463:+
COAD	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	4.38	1.74e-05	0.00539	0.32	0.26	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
COAD	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-4.38	1.74e-05	0.00539	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
COAD	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-4.38	1.74e-05	0.00539	-0.27	-0.26	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
COAD	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	4.38	1.74e-05	0.0054	0.43	0.26	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
COAD	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	4.38	1.74e-05	0.0054	0.4	0.26	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
COAD	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-4.38	1.74e-05	0.0054	-0.25	-0.26	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
COAD	cis	rs2638953	0.815	rs11049658	ENSG00000247934.4	RP11-967K21.1	-4.38	1.74e-05	0.0054	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481930	chr12:28163298~28190738:-
COAD	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-4.38	1.74e-05	0.0054	-0.32	-0.26	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
COAD	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	4.38	1.75e-05	0.00541	0.19	0.26	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
COAD	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-4.38	1.75e-05	0.00541	-0.32	-0.26	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
COAD	cis	rs362296	0.511	rs2051558	ENSG00000248840.2	RP11-357G3.2	-4.38	1.75e-05	0.00542	-0.27	-0.26	Parental longevity (mother's age at death);	chr4:3323159	chr4:3312512~3313058:+
COAD	cis	rs4718428	0.705	rs4718422	ENSG00000272831.1	RP11-792A8.4	4.38	1.75e-05	0.00542	0.3	0.26	Corneal structure;	chr7:66894282	chr7:66739829~66740385:-
COAD	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	4.38	1.75e-05	0.00542	0.23	0.26	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
COAD	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-4.38	1.75e-05	0.00542	-0.28	-0.26	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
COAD	cis	rs1023500	0.573	rs133370	ENSG00000237037.8	NDUFA6-AS1	-4.38	1.75e-05	0.00543	-0.25	-0.26	Schizophrenia;	chr22:42069256	chr22:42090931~42137742:+
COAD	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-4.38	1.75e-05	0.00543	-0.18	-0.26	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
COAD	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-4.38	1.75e-05	0.00543	-0.18	-0.26	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
COAD	cis	rs6095360	0.727	rs1983528	ENSG00000222365.1	SNORD12B	4.38	1.75e-05	0.00543	0.28	0.26	Intelligence (multi-trait analysis);	chr20:49069753	chr20:49280319~49280409:+
COAD	cis	rs7826238	0.509	rs2948288	ENSG00000254340.1	RP11-10A14.3	4.38	1.76e-05	0.00544	0.31	0.26	Systolic blood pressure;	chr8:8257782	chr8:9141424~9145435:+
COAD	cis	rs2439831	0.85	rs68079546	ENSG00000166763.7	STRCP1	-4.38	1.76e-05	0.00544	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43844759	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs56909447	ENSG00000166763.7	STRCP1	-4.38	1.76e-05	0.00544	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43845420	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs28476182	ENSG00000166763.7	STRCP1	-4.38	1.76e-05	0.00544	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43847445	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs28696802	ENSG00000166763.7	STRCP1	-4.38	1.76e-05	0.00544	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43848197	chr15:43699488~43718184:-
COAD	cis	rs6723226	0.772	rs2366894	ENSG00000276334.1	AL133243.1	4.38	1.76e-05	0.00544	0.24	0.26	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32521927~32523547:+
COAD	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	4.38	1.76e-05	0.00544	0.44	0.26	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
COAD	cis	rs9392556	0.734	rs648900	ENSG00000230648.1	RP3-406P24.3	4.38	1.76e-05	0.00545	0.3	0.26	Blood metabolite levels;	chr6:4109188	chr6:4018843~4021215:-
COAD	cis	rs1029738	0.615	rs717624	ENSG00000228649.7	AC005682.5	4.38	1.76e-05	0.00545	0.3	0.26	Fibrinogen levels;	chr7:22854868	chr7:22854178~22861579:+
COAD	cis	rs61270009	0.955	rs10514300	ENSG00000247828.6	TMEM161B-AS1	4.38	1.76e-05	0.00545	0.29	0.26	Depressive symptoms;	chr5:88409465	chr5:88268895~88436685:+
COAD	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	4.38	1.76e-05	0.00545	0.35	0.26	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	4.38	1.76e-05	0.00545	0.35	0.26	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
COAD	cis	rs891378	1	rs6703857	ENSG00000274245.1	RP11-357P18.2	-4.38	1.76e-05	0.00545	-0.33	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270208	chr1:207372559~207373252:+
COAD	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-4.38	1.76e-05	0.00545	-0.33	-0.26	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
COAD	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-4.38	1.76e-05	0.00545	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
COAD	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-4.38	1.76e-05	0.00545	-0.26	-0.26	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
COAD	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.38	1.76e-05	0.00546	-0.32	-0.26	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
COAD	cis	rs2252521	0.553	rs2648659	ENSG00000272568.4	CTB-113D17.1	4.38	1.76e-05	0.00546	0.5	0.26	Cognitive performance;	chr7:29001336	chr7:28979967~29013367:+
COAD	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-4.38	1.76e-05	0.00546	-0.28	-0.26	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
COAD	cis	rs9450351	0.744	rs7752222	ENSG00000203875.9	SNHG5	-4.38	1.77e-05	0.00546	-0.51	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85913874	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-4.38	1.77e-05	0.00546	-0.51	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-4.38	1.77e-05	0.00546	-0.51	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
COAD	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-4.38	1.77e-05	0.00546	-0.41	-0.26	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.38	1.77e-05	0.00546	-0.41	-0.26	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.38	1.77e-05	0.00546	-0.41	-0.26	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.38	1.77e-05	0.00546	-0.41	-0.26	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
COAD	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	4.38	1.77e-05	0.00547	0.29	0.26	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
COAD	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	4.37	1.77e-05	0.00547	0.35	0.26	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
COAD	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	4.37	1.77e-05	0.00547	0.4	0.26	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
COAD	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-4.37	1.77e-05	0.00547	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
COAD	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	4.37	1.77e-05	0.00547	0.31	0.26	QT interval;	chr12:29304617	chr12:29277397~29277882:-
COAD	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-4.37	1.77e-05	0.00548	-0.49	-0.26	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
COAD	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-4.37	1.77e-05	0.00548	-0.48	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
COAD	cis	rs9393777	0.545	rs56303243	ENSG00000224843.5	LINC00240	4.37	1.77e-05	0.00548	0.44	0.26	Intelligence (multi-trait analysis);	chr6:26485499	chr6:26956992~27023924:+
COAD	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-4.37	1.77e-05	0.00548	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
COAD	cis	rs17772222	1	rs12589467	ENSG00000258789.1	RP11-507K2.3	-4.37	1.77e-05	0.00548	-0.36	-0.26	Coronary artery calcification;	chr14:88357239	chr14:88551597~88552493:+
COAD	cis	rs1055129	0.56	rs2608880	ENSG00000267801.1	RP11-552F3.9	4.37	1.77e-05	0.00548	0.33	0.26	White matter hyperintensity burden;	chr17:75942876	chr17:75876372~75879546:+
COAD	cis	rs1055129	0.56	rs2666003	ENSG00000267801.1	RP11-552F3.9	4.37	1.77e-05	0.00548	0.33	0.26	White matter hyperintensity burden;	chr17:75946895	chr17:75876372~75879546:+
COAD	cis	rs10819861	0.645	rs10819835	ENSG00000238251.2	RP11-172F4.2	-4.37	1.77e-05	0.00548	-0.33	-0.26	Electrocardiographic traits;	chr9:96096383	chr9:96407284~96407797:+
COAD	cis	rs11668609	0.505	rs60605343	ENSG00000268442.1	CTD-2027I19.2	4.37	1.77e-05	0.00548	0.41	0.26	Response to taxane treatment (docetaxel);	chr19:23968486	chr19:24162370~24163425:-
COAD	cis	rs2916733	0.818	rs2922818	ENSG00000246089.3	RP11-115C21.2	4.37	1.77e-05	0.00548	0.36	0.26	Epirubicin-induced leukopenia;	chr8:6462001	chr8:6403551~6407142:-
COAD	cis	rs2188554	0.771	rs213951	ENSG00000237974.1	AC000111.4	4.37	1.77e-05	0.00548	0.28	0.26	Esophageal adenocarcinoma;	chr7:117562380	chr7:117487737~117487929:+
COAD	cis	rs2581828	0.618	rs9868406	ENSG00000280417.1	RP11-5O17.1	4.37	1.77e-05	0.00549	0.29	0.26	Crohn's disease;	chr3:53130177	chr3:53046166~53048122:+
COAD	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	4.37	1.77e-05	0.00549	0.4	0.26	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
COAD	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	4.37	1.77e-05	0.00549	0.31	0.26	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
COAD	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-4.37	1.78e-05	0.00549	-0.26	-0.26	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
COAD	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-4.37	1.78e-05	0.00549	-0.31	-0.26	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
COAD	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	4.37	1.78e-05	0.00549	0.35	0.26	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
COAD	cis	rs6940638	0.688	rs9393790	ENSG00000224843.5	LINC00240	-4.37	1.78e-05	0.00549	-0.35	-0.26	Intelligence (multi-trait analysis);	chr6:27146273	chr6:26956992~27023924:+
COAD	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	4.37	1.78e-05	0.00549	0.28	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
COAD	cis	rs8141529	0.719	rs2097461	ENSG00000272858.1	CTA-292E10.8	-4.37	1.78e-05	0.0055	-0.31	-0.26	Lymphocyte counts;	chr22:28795891	chr22:28814914~28815662:+
COAD	cis	rs2777491	0.872	rs7176588	ENSG00000247556.5	OIP5-AS1	4.37	1.78e-05	0.0055	0.27	0.26	Ulcerative colitis;	chr15:41296674	chr15:41283990~41309737:+
COAD	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	4.37	1.78e-05	0.0055	0.28	0.26	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
COAD	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-4.37	1.78e-05	0.0055	-0.37	-0.26	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
COAD	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	4.37	1.78e-05	0.0055	0.36	0.26	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
COAD	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	4.37	1.78e-05	0.0055	0.36	0.26	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
COAD	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	4.37	1.78e-05	0.0055	0.36	0.26	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
COAD	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	4.37	1.78e-05	0.0055	0.3	0.26	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	4.37	1.78e-05	0.0055	0.3	0.26	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	4.37	1.78e-05	0.0055	0.3	0.26	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
COAD	cis	rs7032317	0.666	rs11243978	ENSG00000170827.8	CELP	-4.37	1.78e-05	0.0055	-0.23	-0.26	Calcium levels;	chr9:133006297	chr9:133079900~133087355:+
COAD	cis	rs11668609	0.515	rs11668661	ENSG00000268442.1	CTD-2027I19.2	4.37	1.78e-05	0.0055	0.49	0.26	Response to taxane treatment (docetaxel);	chr19:23825708	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs77931611	ENSG00000268442.1	CTD-2027I19.2	4.37	1.78e-05	0.0055	0.49	0.26	Response to taxane treatment (placlitaxel);	chr19:23834800	chr19:24162370~24163425:-
COAD	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-4.37	1.78e-05	0.0055	-0.42	-0.26	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
COAD	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.78e-05	0.0055	-0.31	-0.26	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
COAD	cis	rs4718428	0.705	rs68168107	ENSG00000272831.1	RP11-792A8.4	4.37	1.78e-05	0.00551	0.3	0.26	Corneal structure;	chr7:66790251	chr7:66739829~66740385:-
COAD	cis	rs36052053	0.908	rs36094641	ENSG00000219700.1	PTCHD3P3	4.37	1.78e-05	0.00551	0.47	0.26	Red cell distribution width;	chr6:109282652	chr6:109288571~109290503:-
COAD	cis	rs36052053	0.908	rs71558363	ENSG00000219700.1	PTCHD3P3	4.37	1.78e-05	0.00551	0.47	0.26	Red cell distribution width;	chr6:109283778	chr6:109288571~109290503:-
COAD	cis	rs61160187	0.582	rs17332824	ENSG00000215032.2	GNL3LP1	-4.37	1.78e-05	0.00551	-0.35	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60891935~60893577:-
COAD	cis	rs2378497	0.938	rs2153352	ENSG00000232679.1	RP11-400N13.3	4.37	1.78e-05	0.00551	0.38	0.26	Serum thyroid-stimulating hormone levels;	chr1:221984008	chr1:222041705~222064763:-
COAD	cis	rs7428	0.502	rs3184781	ENSG00000246575.2	AC093162.5	4.37	1.78e-05	0.00551	0.24	0.26	Ear protrusion;	chr2:85322404	chr2:85315041~85316529:+
COAD	cis	rs7428	0.527	rs3184780	ENSG00000246575.2	AC093162.5	4.37	1.78e-05	0.00551	0.24	0.26	Ear protrusion;	chr2:85322424	chr2:85315041~85316529:+
COAD	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	4.37	1.78e-05	0.00551	0.35	0.26	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
COAD	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-4.37	1.78e-05	0.00551	-0.26	-0.26	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
COAD	cis	rs1387259	0.839	rs7487682	ENSG00000257735.1	RP11-370I10.6	-4.37	1.78e-05	0.00551	-0.31	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48350945~48442411:+
COAD	cis	rs875971	0.522	rs781144	ENSG00000272831.1	RP11-792A8.4	4.37	1.78e-05	0.00551	0.27	0.26	Aortic root size;	chr7:65975357	chr7:66739829~66740385:-
COAD	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-4.37	1.78e-05	0.00551	-0.31	-0.26	QT interval;	chr12:29309811	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-4.37	1.78e-05	0.00551	-0.31	-0.26	QT interval;	chr12:29319943	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-4.37	1.78e-05	0.00551	-0.31	-0.26	QT interval;	chr12:29331030	chr12:29277397~29277882:-
COAD	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	4.37	1.79e-05	0.00552	0.3	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
COAD	cis	rs41294858	1	rs41294860	ENSG00000232876.1	CTA-212D2.2	-4.37	1.79e-05	0.00552	-0.49	-0.26	Red blood cell count;	chr6:135092931	chr6:135055033~135060550:+
COAD	cis	rs41294858	1	rs56076748	ENSG00000232876.1	CTA-212D2.2	-4.37	1.79e-05	0.00552	-0.49	-0.26	Red blood cell count;	chr6:135093071	chr6:135055033~135060550:+
COAD	cis	rs180730	1	rs3115314	ENSG00000251609.2	SETP12	-4.37	1.79e-05	0.00552	-0.38	-0.26	Fasting plasma glucose;	chr4:120888621	chr4:120895494~120897083:-
COAD	cis	rs180730	1	rs184668	ENSG00000251609.2	SETP12	-4.37	1.79e-05	0.00552	-0.38	-0.26	Fasting plasma glucose;	chr4:120888812	chr4:120895494~120897083:-
COAD	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-4.37	1.79e-05	0.00552	-0.27	-0.26	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
COAD	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	4.37	1.79e-05	0.00553	0.29	0.26	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
COAD	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-4.37	1.79e-05	0.00553	-0.31	-0.26	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
COAD	cis	rs2337406	0.866	rs4774019	ENSG00000211974.3	IGHV2-70	-4.37	1.79e-05	0.00553	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106805386	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs58850145	ENSG00000211974.3	IGHV2-70	-4.37	1.79e-05	0.00553	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106806185	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.866	rs2027901	ENSG00000211974.3	IGHV2-70	-4.37	1.79e-05	0.00553	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106807164	chr14:106723574~106724093:-
COAD	cis	rs7119	0.667	rs4886889	ENSG00000259565.2	KRT8P23	4.37	1.79e-05	0.00553	0.3	0.26	Type 2 diabetes;	chr15:77610005	chr15:76979245~76980451:-
COAD	cis	rs8022206	0.704	rs10132022	ENSG00000259502.1	RP11-643G16.3	4.37	1.79e-05	0.00553	0.34	0.26	Platelet count;Mean platelet volume;	chr14:68034034	chr14:67610986~67613864:+
COAD	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	4.37	1.79e-05	0.00553	0.44	0.26	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
COAD	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-4.37	1.79e-05	0.00554	-0.53	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
COAD	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-4.37	1.79e-05	0.00554	-0.31	-0.26	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
COAD	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-4.37	1.79e-05	0.00554	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
COAD	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	4.37	1.79e-05	0.00554	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
COAD	cis	rs2638953	0.672	rs11049715	ENSG00000247934.4	RP11-967K21.1	-4.37	1.79e-05	0.00554	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28561520	chr12:28163298~28190738:-
COAD	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	4.37	1.79e-05	0.00554	0.3	0.26	Temperament;	chr17:13996939	chr17:13756478~14069495:-
COAD	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-4.37	1.8e-05	0.00555	-0.32	-0.26	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
COAD	cis	rs4820539	0.966	rs2157709	ENSG00000211644.2	IGLV1-51	-4.37	1.8e-05	0.00555	-0.15	-0.26	Bone mineral density;	chr22:23115233	chr22:22322472~22322980:+
COAD	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-4.37	1.8e-05	0.00555	-0.5	-0.26	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
COAD	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	4.37	1.8e-05	0.00555	0.32	0.26	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-4.37	1.8e-05	0.00555	-0.32	-0.26	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-4.37	1.8e-05	0.00555	-0.32	-0.26	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
COAD	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	4.37	1.8e-05	0.00555	0.4	0.26	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
COAD	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	4.37	1.8e-05	0.00556	0.3	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
COAD	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	4.37	1.8e-05	0.00556	0.32	0.26	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
COAD	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-4.37	1.8e-05	0.00556	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
COAD	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	4.37	1.8e-05	0.00556	0.34	0.26	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
COAD	cis	rs9532669	0.926	rs9315789	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40852898	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.857	rs7327018	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40856376	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7327315	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40856383	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7327059	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40856458	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9594433	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40856935	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9525403	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40858292	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7318768	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40859140	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942000	ENSG00000239827.7	SUGT1P3	-4.37	1.8e-05	0.00556	-0.22	-0.26	Cervical cancer;	chr13:40859979	chr13:40908159~40921774:-
COAD	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	4.37	1.8e-05	0.00556	0.34	0.26	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	4.37	1.8e-05	0.00556	0.34	0.26	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
COAD	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-4.37	1.8e-05	0.00556	-0.33	-0.26	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
COAD	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-4.37	1.8e-05	0.00556	-0.33	-0.26	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
COAD	cis	rs812925	0.537	rs10196146	ENSG00000273302.1	RP11-493E12.2	-4.37	1.8e-05	0.00556	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61378244	chr2:61199979~61200769:+
COAD	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-4.37	1.8e-05	0.00557	-0.32	-0.26	QT interval;	chr12:29344573	chr12:29277397~29277882:-
COAD	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	4.37	1.81e-05	0.00557	0.36	0.26	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
COAD	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-4.37	1.81e-05	0.00558	-0.3	-0.26	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
COAD	cis	rs9307551	0.948	rs2165386	ENSG00000250334.4	LINC00989	-4.37	1.81e-05	0.00558	-0.34	-0.26	Refractive error;	chr4:79582248	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.948	rs1440853	ENSG00000250334.4	LINC00989	-4.37	1.81e-05	0.00558	-0.34	-0.26	Refractive error;	chr4:79585493	chr4:79492416~79576460:+
COAD	cis	rs7176527	0.784	rs62021162	ENSG00000225151.9	GOLGA2P7	4.37	1.81e-05	0.00558	0.37	0.26	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84199311~84230136:-
COAD	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	4.37	1.81e-05	0.00558	0.22	0.26	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
COAD	cis	rs9532669	0.963	rs9532673	ENSG00000239827.7	SUGT1P3	-4.37	1.81e-05	0.00559	-0.23	-0.26	Cervical cancer;	chr13:40930412	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs9532676	ENSG00000239827.7	SUGT1P3	-4.37	1.81e-05	0.00559	-0.23	-0.26	Cervical cancer;	chr13:40935626	chr13:40908159~40921774:-
COAD	cis	rs12497850	0.931	rs9682444	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48815206	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9835307	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48820372	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9755490	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48834231	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs9840684	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48856347	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs4974079	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48869036	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.897	rs6446252	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48873692	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs4974087	ENSG00000225399.4	RP11-3B7.1	4.37	1.81e-05	0.00559	0.29	0.26	Parkinson's disease;	chr3:48881799	chr3:49260085~49261316:+
COAD	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	4.37	1.81e-05	0.00559	0.24	0.26	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
COAD	cis	rs9307551	0.619	rs1899232	ENSG00000250334.4	LINC00989	-4.37	1.81e-05	0.00559	-0.31	-0.26	Refractive error;	chr4:79501789	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.619	rs7684683	ENSG00000250334.4	LINC00989	-4.37	1.81e-05	0.00559	-0.31	-0.26	Refractive error;	chr4:79501867	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.584	rs7663844	ENSG00000250334.4	LINC00989	-4.37	1.81e-05	0.00559	-0.31	-0.26	Refractive error;	chr4:79502053	chr4:79492416~79576460:+
COAD	cis	rs2292884	0.505	rs11889660	ENSG00000234949.2	AC104667.3	-4.37	1.81e-05	0.00559	-0.44	-0.26	Prostate cancer;	chr2:237529752	chr2:237591020~237595981:+
COAD	cis	rs8061903	0.958	rs4780304	ENSG00000260071.1	RP11-418I22.2	4.37	1.81e-05	0.00559	0.31	0.26	HIV-1 viral setpoint;	chr16:9287914	chr16:9466655~9517564:+
COAD	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	4.37	1.82e-05	0.0056	0.32	0.26	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	4.37	1.82e-05	0.0056	0.32	0.26	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	4.37	1.82e-05	0.0056	0.32	0.26	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
COAD	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	4.37	1.82e-05	0.0056	0.34	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
COAD	cis	rs742132	0.858	rs10484591	ENSG00000220875.1	HIST1H3PS1	4.37	1.82e-05	0.0056	0.35	0.26	Uric acid levels;	chr6:25656433	chr6:26321876~26322292:-
COAD	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-4.37	1.82e-05	0.00561	-0.28	-0.26	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
COAD	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-4.37	1.82e-05	0.00561	-0.29	-0.26	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
COAD	cis	rs728616	0.867	rs12414877	ENSG00000225484.5	NUTM2B-AS1	-4.37	1.82e-05	0.00561	-0.49	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79663088~79826594:-
COAD	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-4.37	1.82e-05	0.00561	-0.27	-0.26	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
COAD	cis	rs11668609	0.515	rs74443274	ENSG00000268442.1	CTD-2027I19.2	4.37	1.82e-05	0.00561	0.49	0.26	Response to taxane treatment (docetaxel);	chr19:23838810	chr19:24162370~24163425:-
COAD	cis	rs4718428	0.705	rs12698547	ENSG00000272831.1	RP11-792A8.4	4.37	1.82e-05	0.00561	0.3	0.26	Corneal structure;	chr7:66813271	chr7:66739829~66740385:-
COAD	cis	rs8141529	0.748	rs5997412	ENSG00000272858.1	CTA-292E10.8	-4.37	1.82e-05	0.00561	-0.32	-0.26	Lymphocyte counts;	chr22:28880759	chr22:28814914~28815662:+
COAD	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-4.37	1.82e-05	0.00561	-0.3	-0.26	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
COAD	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	4.37	1.82e-05	0.00561	0.35	0.26	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
COAD	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-4.37	1.82e-05	0.00561	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
COAD	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	4.37	1.82e-05	0.00562	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
COAD	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-4.37	1.83e-05	0.00562	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-4.37	1.83e-05	0.00562	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
COAD	cis	rs34375054	0.573	rs12823172	ENSG00000279233.1	RP11-158L12.4	4.37	1.83e-05	0.00562	0.32	0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125161737	chr12:125138245~125141711:+
COAD	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.37	1.83e-05	0.00562	0.47	0.26	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
COAD	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-4.37	1.83e-05	0.00562	-0.35	-0.26	Depression;	chr6:28201380	chr6:28115628~28116551:+
COAD	cis	rs17772222	0.876	rs12587528	ENSG00000258789.1	RP11-507K2.3	-4.37	1.83e-05	0.00562	-0.38	-0.26	Coronary artery calcification;	chr14:88487652	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.837	rs1864748	ENSG00000258789.1	RP11-507K2.3	-4.37	1.83e-05	0.00562	-0.38	-0.26	Coronary artery calcification;	chr14:88488847	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.916	rs77306894	ENSG00000258789.1	RP11-507K2.3	-4.37	1.83e-05	0.00562	-0.38	-0.26	Coronary artery calcification;	chr14:88494507	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.958	rs17203789	ENSG00000258789.1	RP11-507K2.3	-4.37	1.83e-05	0.00563	-0.38	-0.26	Coronary artery calcification;	chr14:88541362	chr14:88551597~88552493:+
COAD	cis	rs9307551	0.817	rs12643976	ENSG00000250334.4	LINC00989	-4.37	1.83e-05	0.00563	-0.3	-0.26	Refractive error;	chr4:79589616	chr4:79492416~79576460:+
COAD	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	4.37	1.83e-05	0.00563	0.32	0.26	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
COAD	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-4.37	1.83e-05	0.00563	-0.23	-0.26	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
COAD	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-4.37	1.83e-05	0.00563	-0.23	-0.26	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
COAD	cis	rs72827839	0.793	rs112296021	ENSG00000263412.1	RP5-890E16.2	4.37	1.83e-05	0.00563	0.38	0.26	Ease of getting up in the morning;	chr17:48024094	chr17:48045141~48048073:-
COAD	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-4.37	1.83e-05	0.00564	-0.5	-0.26	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-4.37	1.83e-05	0.00564	-0.5	-0.26	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
COAD	cis	rs4704187	0.532	rs75392670	ENSG00000250889.2	LINC01336	-4.37	1.83e-05	0.00564	-0.3	-0.26	Response to amphetamines;	chr5:75099143	chr5:75047719~75052843:-
COAD	cis	rs812925	0.537	rs2593620	ENSG00000273302.1	RP11-493E12.2	-4.37	1.83e-05	0.00564	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61386126	chr2:61199979~61200769:+
COAD	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	4.37	1.83e-05	0.00564	0.41	0.26	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
COAD	cis	rs2836974	0.644	rs2836981	ENSG00000255568.3	BRWD1-AS2	-4.37	1.83e-05	0.00564	-0.25	-0.26	Cognitive function;	chr21:39316439	chr21:39313935~39314962:+
COAD	cis	rs17772222	1	rs60310240	ENSG00000258789.1	RP11-507K2.3	-4.37	1.83e-05	0.00564	-0.36	-0.26	Coronary artery calcification;	chr14:88356365	chr14:88551597~88552493:+
COAD	cis	rs36052053	0.908	rs1812230	ENSG00000219700.1	PTCHD3P3	4.37	1.83e-05	0.00564	0.46	0.26	Red cell distribution width;	chr6:109268132	chr6:109288571~109290503:-
COAD	cis	rs6545883	0.507	rs2123111	ENSG00000273302.1	RP11-493E12.2	-4.37	1.83e-05	0.00564	-0.24	-0.26	Tuberculosis;	chr2:61223319	chr2:61199979~61200769:+
COAD	cis	rs4704187	0.687	rs4704196	ENSG00000250889.2	LINC01336	-4.37	1.83e-05	0.00564	-0.3	-0.26	Response to amphetamines;	chr5:75241781	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4704197	ENSG00000250889.2	LINC01336	-4.37	1.83e-05	0.00564	-0.3	-0.26	Response to amphetamines;	chr5:75241926	chr5:75047719~75052843:-
COAD	cis	rs9951698	0.678	rs556536	ENSG00000266969.1	RP11-773H22.4	4.37	1.84e-05	0.00564	0.34	0.26	Intelligence (multi-trait analysis);	chr18:13065485	chr18:12984694~12991173:-
COAD	cis	rs4704187	0.663	rs17738989	ENSG00000250889.2	LINC01336	-4.37	1.84e-05	0.00565	-0.3	-0.26	Response to amphetamines;	chr5:75237905	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs28539749	ENSG00000250889.2	LINC01336	-4.37	1.84e-05	0.00565	-0.3	-0.26	Response to amphetamines;	chr5:75238077	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs67065524	ENSG00000250889.2	LINC01336	-4.37	1.84e-05	0.00565	-0.3	-0.26	Response to amphetamines;	chr5:75238484	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6866661	ENSG00000250889.2	LINC01336	-4.37	1.84e-05	0.00565	-0.3	-0.26	Response to amphetamines;	chr5:75238547	chr5:75047719~75052843:-
COAD	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	4.37	1.84e-05	0.00565	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	4.37	1.84e-05	0.00565	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
COAD	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	4.37	1.84e-05	0.00565	0.26	0.26	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
COAD	cis	rs7577696	0.785	rs3851310	ENSG00000272716.1	RP11-563N4.1	-4.37	1.84e-05	0.00565	-0.28	-0.26	Inflammatory biomarkers;	chr2:32142917	chr2:32165046~32165757:-
COAD	cis	rs891378	1	rs971317	ENSG00000274245.1	RP11-357P18.2	-4.37	1.84e-05	0.00565	-0.36	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302695	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs2802238	ENSG00000274245.1	RP11-357P18.2	-4.37	1.84e-05	0.00565	-0.36	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302796	chr1:207372559~207373252:+
COAD	cis	rs9400467	0.508	rs1676863	ENSG00000271789.1	RP5-1112D6.7	-4.37	1.84e-05	0.00565	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111297126~111298510:+
COAD	cis	rs2188554	0.667	rs213949	ENSG00000237974.1	AC000111.4	4.37	1.84e-05	0.00565	0.28	0.26	Esophageal adenocarcinoma;	chr7:117556977	chr7:117487737~117487929:+
COAD	cis	rs6095360	0.727	rs13040426	ENSG00000222365.1	SNORD12B	-4.37	1.84e-05	0.00565	-0.28	-0.26	Intelligence (multi-trait analysis);	chr20:49097916	chr20:49280319~49280409:+
COAD	cis	rs9532669	0.926	rs2183144	ENSG00000239827.7	SUGT1P3	4.37	1.84e-05	0.00565	0.22	0.26	Cervical cancer;	chr13:40862129	chr13:40908159~40921774:-
COAD	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	4.37	1.84e-05	0.00566	0.3	0.26	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
COAD	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-4.37	1.84e-05	0.00566	-0.26	-0.26	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
COAD	cis	rs891378	0.874	rs59036171	ENSG00000274245.1	RP11-357P18.2	-4.37	1.84e-05	0.00566	-0.33	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207271583	chr1:207372559~207373252:+
COAD	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-4.37	1.84e-05	0.00566	-0.32	-0.26	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-4.37	1.84e-05	0.00566	-0.32	-0.26	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-4.37	1.84e-05	0.00566	-0.32	-0.26	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
COAD	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-4.36	1.84e-05	0.00567	-0.29	-0.26	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
COAD	cis	rs7688540	0.61	rs6830496	ENSG00000211553.1	AC253576.2	-4.36	1.84e-05	0.00567	-0.47	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:136461~136568:+
COAD	cis	rs7615952	0.512	rs2979351	ENSG00000248787.1	RP11-666A20.4	-4.36	1.84e-05	0.00567	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125644755	chr3:125908005~125910272:-
COAD	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-4.36	1.84e-05	0.00567	-0.28	-0.26	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-4.36	1.84e-05	0.00567	-0.28	-0.26	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
COAD	cis	rs742132	0.858	rs12527646	ENSG00000220875.1	HIST1H3PS1	4.36	1.85e-05	0.00567	0.34	0.26	Uric acid levels;	chr6:25655447	chr6:26321876~26322292:-
COAD	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-4.36	1.85e-05	0.00568	-0.27	-0.26	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
COAD	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-4.36	1.85e-05	0.00568	-0.27	-0.26	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
COAD	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-4.36	1.85e-05	0.00568	-0.27	-0.26	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
COAD	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-4.36	1.85e-05	0.00568	-0.46	-0.26	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
COAD	cis	rs9532669	0.926	rs4941995	ENSG00000239827.7	SUGT1P3	-4.36	1.85e-05	0.00568	-0.22	-0.26	Cervical cancer;	chr13:40850117	chr13:40908159~40921774:-
COAD	cis	rs9907295	0.551	rs4795090	ENSG00000271013.1	AC015849.15	-4.36	1.85e-05	0.00568	-0.33	-0.26	Fibroblast growth factor basic levels;	chr17:35796593	chr17:35912635~35918010:-
COAD	cis	rs4760786	0.671	rs2870844	ENSG00000258053.1	CTD-2021H9.3	-4.36	1.85e-05	0.00568	-0.36	-0.26	Monobrow;	chr12:71057396	chr12:71047402~71118247:-
COAD	cis	rs4760786	0.698	rs2870843	ENSG00000258053.1	CTD-2021H9.3	-4.36	1.85e-05	0.00568	-0.36	-0.26	Monobrow;	chr12:71057397	chr12:71047402~71118247:-
COAD	cis	rs4760786	0.752	rs2870842	ENSG00000258053.1	CTD-2021H9.3	-4.36	1.85e-05	0.00568	-0.36	-0.26	Monobrow;	chr12:71057399	chr12:71047402~71118247:-
COAD	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	4.36	1.85e-05	0.00568	0.24	0.26	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	4.36	1.85e-05	0.00568	0.24	0.26	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	4.36	1.85e-05	0.00568	0.24	0.26	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
COAD	cis	rs12497850	0.829	rs8926	ENSG00000225399.4	RP11-3B7.1	4.36	1.85e-05	0.00569	0.3	0.26	Parkinson's disease;	chr3:49015352	chr3:49260085~49261316:+
COAD	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	4.36	1.85e-05	0.00569	0.43	0.26	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	4.36	1.85e-05	0.00569	0.43	0.26	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
COAD	cis	rs1670533	1	rs7660779	ENSG00000273179.1	RP11-20I20.4	4.36	1.85e-05	0.00569	0.34	0.26	Recombination rate (females);	chr4:1082152	chr4:1167778~1168174:+
COAD	cis	rs62184315	0.536	rs5742926	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.85e-05	0.00569	-0.32	-0.26	Alcohol dependence (age at onset);	chr2:189784079	chr2:189762704~189765556:+
COAD	cis	rs7829975	0.774	rs1039915	ENSG00000233609.3	RP11-62H7.2	4.36	1.85e-05	0.00569	0.3	0.26	Mood instability;	chr8:8822104	chr8:8961200~8979025:+
COAD	cis	rs7829975	0.774	rs57312668	ENSG00000233609.3	RP11-62H7.2	4.36	1.85e-05	0.00569	0.3	0.26	Mood instability;	chr8:8822967	chr8:8961200~8979025:+
COAD	cis	rs2638953	0.886	rs11049615	ENSG00000247934.4	RP11-967K21.1	-4.36	1.85e-05	0.00569	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28163298~28190738:-
COAD	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	4.36	1.86e-05	0.0057	0.32	0.26	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
COAD	cis	rs4819052	0.851	rs2838865	ENSG00000227039.5	ITGB2-AS1	-4.36	1.86e-05	0.0057	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:44921051~44929678:+
COAD	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-4.36	1.86e-05	0.0057	-0.32	-0.26	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
COAD	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-4.36	1.86e-05	0.0057	-0.54	-0.26	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-4.36	1.86e-05	0.0057	-0.54	-0.26	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-4.36	1.86e-05	0.0057	-0.54	-0.26	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
COAD	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-4.36	1.86e-05	0.0057	-0.38	-0.26	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-4.36	1.86e-05	0.0057	-0.38	-0.26	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-4.36	1.86e-05	0.0057	-0.38	-0.26	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
COAD	cis	rs2638953	0.962	rs11049518	ENSG00000247934.4	RP11-967K21.1	-4.36	1.86e-05	0.0057	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28163298~28190738:-
COAD	cis	rs2765539	1	rs2765539	ENSG00000231365.4	RP11-418J17.1	-4.36	1.86e-05	0.0057	-0.31	-0.26	Waist-hip ratio;	chr1:119006795	chr1:119140396~119275973:+
COAD	cis	rs2836974	0.8	rs73221174	ENSG00000255568.3	BRWD1-AS2	4.36	1.86e-05	0.0057	0.28	0.26	Cognitive function;	chr21:39169013	chr21:39313935~39314962:+
COAD	cis	rs860295	0.557	rs348196	ENSG00000203761.5	MSTO2P	-4.36	1.86e-05	0.0057	-0.25	-0.26	Body mass index;	chr1:155697170	chr1:155745829~155750137:+
COAD	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-4.36	1.86e-05	0.0057	-0.32	-0.26	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-4.36	1.86e-05	0.0057	-0.32	-0.26	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
COAD	cis	rs440932	0.757	rs330943	ENSG00000254340.1	RP11-10A14.3	4.36	1.86e-05	0.00571	0.34	0.26	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9141424~9145435:+
COAD	cis	rs3126085	0.56	rs3120665	ENSG00000237975.5	FLG-AS1	4.36	1.86e-05	0.00571	0.3	0.26	Atopic dermatitis;	chr1:152344114	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs3120667	ENSG00000237975.5	FLG-AS1	4.36	1.86e-05	0.00571	0.3	0.26	Atopic dermatitis;	chr1:152345685	chr1:152168125~152445456:+
COAD	cis	rs11239930	0.517	rs535827	ENSG00000278811.3	LINC00624	4.36	1.86e-05	0.00571	0.26	0.26	AIDS progression;	chr1:147076642	chr1:147258885~147517875:-
COAD	cis	rs7560272	0.501	rs13003035	ENSG00000163016.8	ALMS1P	-4.36	1.86e-05	0.00571	-0.32	-0.26	Schizophrenia;	chr2:73730100	chr2:73644919~73685576:+
COAD	cis	rs7560272	0.501	rs12992607	ENSG00000163016.8	ALMS1P	-4.36	1.86e-05	0.00571	-0.32	-0.26	Schizophrenia;	chr2:73732833	chr2:73644919~73685576:+
COAD	cis	rs1275468	1	rs1148000	ENSG00000257497.2	RP11-585P4.5	-4.36	1.86e-05	0.00571	-0.34	-0.26	Polycystic ovary syndrome;	chr12:75542521	chr12:75483454~75489820:-
COAD	cis	rs2337406	0.85	rs75196489	ENSG00000211974.3	IGHV2-70	-4.36	1.86e-05	0.00571	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106699438	chr14:106723574~106724093:-
COAD	cis	rs2638953	0.962	rs10843151	ENSG00000247934.4	RP11-967K21.1	-4.36	1.86e-05	0.00571	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28163298~28190738:-
COAD	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-4.36	1.87e-05	0.00572	-0.27	-0.26	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
COAD	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	4.36	1.87e-05	0.00573	0.31	0.26	Height;	chr4:55451489	chr4:55540502~55540835:-
COAD	cis	rs728616	0.558	rs72817596	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.87e-05	0.00573	-0.43	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79663088~79826594:-
COAD	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-4.36	1.87e-05	0.00573	-0.32	-0.26	QT interval;	chr12:29297620	chr12:29277397~29277882:-
COAD	cis	rs71636778	0.509	rs35041418	ENSG00000260063.1	RP5-968P14.2	-4.36	1.87e-05	0.00573	-0.53	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26722492	chr1:26692132~26694131:-
COAD	cis	rs1387259	0.839	rs7486941	ENSG00000269514.1	RP11-370I10.12	-4.36	1.87e-05	0.00574	-0.3	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48198387~48202031:+
COAD	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-4.36	1.87e-05	0.00574	-0.32	-0.26	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
COAD	cis	rs253959	0.672	rs4920903	ENSG00000271918.1	CTD-2287O16.5	4.36	1.87e-05	0.00574	0.22	0.26	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116083807~116085416:-
COAD	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-4.36	1.87e-05	0.00574	-0.25	-0.26	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
COAD	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-4.36	1.87e-05	0.00574	-0.31	-0.26	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
COAD	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	4.36	1.87e-05	0.00575	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
COAD	cis	rs17772222	1	rs7145588	ENSG00000258789.1	RP11-507K2.3	-4.36	1.87e-05	0.00575	-0.36	-0.26	Coronary artery calcification;	chr14:88360452	chr14:88551597~88552493:+
COAD	cis	rs17772222	1	rs61977049	ENSG00000258789.1	RP11-507K2.3	-4.36	1.87e-05	0.00575	-0.36	-0.26	Coronary artery calcification;	chr14:88360656	chr14:88551597~88552493:+
COAD	cis	rs17772222	1	rs12587386	ENSG00000258789.1	RP11-507K2.3	-4.36	1.87e-05	0.00575	-0.36	-0.26	Coronary artery calcification;	chr14:88361420	chr14:88551597~88552493:+
COAD	cis	rs7829975	0.774	rs11775523	ENSG00000233609.3	RP11-62H7.2	4.36	1.87e-05	0.00575	0.3	0.26	Mood instability;	chr8:8821666	chr8:8961200~8979025:+
COAD	cis	rs2252521	0.583	rs1846490	ENSG00000272568.4	CTB-113D17.1	4.36	1.87e-05	0.00575	0.5	0.26	Cognitive performance;	chr7:29041211	chr7:28979967~29013367:+
COAD	cis	rs6565653	0.967	rs9891253	ENSG00000262580.4	RP11-334C17.5	4.36	1.88e-05	0.00575	0.25	0.26	Ischemic stroke;	chr17:80226377	chr17:80200673~80205949:-
COAD	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.88e-05	0.00575	-0.33	-0.26	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
COAD	cis	rs58873874	0.579	rs11551374	ENSG00000251405.2	CTB-109A12.1	4.36	1.88e-05	0.00575	0.5	0.26	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157362615~157460078:-
COAD	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	4.36	1.88e-05	0.00575	0.29	0.26	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
COAD	cis	rs8061903	0.958	rs35016073	ENSG00000260071.1	RP11-418I22.2	4.36	1.88e-05	0.00575	0.31	0.26	HIV-1 viral setpoint;	chr16:9287387	chr16:9466655~9517564:+
COAD	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-4.36	1.88e-05	0.00575	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
COAD	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-4.36	1.88e-05	0.00575	-0.31	-0.26	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-4.36	1.88e-05	0.00575	-0.31	-0.26	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
COAD	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-4.36	1.88e-05	0.00576	-0.29	-0.26	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
COAD	cis	rs2337406	0.852	rs12050239	ENSG00000211967.3	IGHV3-53	-4.36	1.88e-05	0.00576	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106781132	chr14:106592676~106593347:-
COAD	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	4.36	1.88e-05	0.00576	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
COAD	cis	rs3809912	0.693	rs12605081	ENSG00000266969.1	RP11-773H22.4	4.36	1.88e-05	0.00576	0.32	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:12999965	chr18:12984694~12991173:-
COAD	cis	rs180730	0.898	rs343200	ENSG00000251609.2	SETP12	-4.36	1.88e-05	0.00577	-0.37	-0.26	Fasting plasma glucose;	chr4:120876657	chr4:120895494~120897083:-
COAD	cis	rs8022206	0.738	rs6573805	ENSG00000259502.1	RP11-643G16.3	4.36	1.88e-05	0.00577	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68011422	chr14:67610986~67613864:+
COAD	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-4.36	1.88e-05	0.00577	-0.27	-0.26	Cancer;	chr16:4805278	chr16:4795265~4796532:-
COAD	cis	rs2342406	0.825	rs1026061	ENSG00000259439.2	RP11-89K21.1	4.36	1.88e-05	0.00577	0.45	0.26	Myopia;	chr2:44914872	chr2:44921077~44939199:-
COAD	cis	rs2342406	0.825	rs1026062	ENSG00000259439.2	RP11-89K21.1	4.36	1.88e-05	0.00577	0.45	0.26	Myopia;	chr2:44914939	chr2:44921077~44939199:-
COAD	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-4.36	1.88e-05	0.00577	-0.33	-0.26	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
COAD	cis	rs6545883	0.524	rs811871	ENSG00000273302.1	RP11-493E12.2	-4.36	1.89e-05	0.00577	-0.24	-0.26	Tuberculosis;	chr2:61350814	chr2:61199979~61200769:+
COAD	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	4.36	1.89e-05	0.00578	0.33	0.26	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
COAD	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	4.36	1.89e-05	0.00578	0.42	0.26	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
COAD	cis	rs1387259	0.839	rs7487682	ENSG00000269514.1	RP11-370I10.12	-4.36	1.89e-05	0.00578	-0.31	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48198387~48202031:+
COAD	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	4.36	1.89e-05	0.00578	0.31	0.26	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
COAD	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	4.36	1.89e-05	0.00578	0.29	0.26	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
COAD	cis	rs853679	0.607	rs33932084	ENSG00000204709.4	LINC01556	4.36	1.89e-05	0.00578	0.71	0.26	Depression;	chr6:28301047	chr6:28943877~28944537:+
COAD	cis	rs8022206	0.738	rs424032	ENSG00000259502.1	RP11-643G16.3	4.36	1.89e-05	0.00578	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68106001	chr14:67610986~67613864:+
COAD	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-4.36	1.89e-05	0.00578	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
COAD	cis	rs3930017	1	rs3930017	ENSG00000225726.1	AC007000.10	-4.36	1.89e-05	0.00578	-0.29	-0.26	Body mass index;	chr7:77091265	chr7:77071751~77072237:-
COAD	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-4.36	1.89e-05	0.00578	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-4.36	1.89e-05	0.00578	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
COAD	cis	rs4718428	0.705	rs28648401	ENSG00000272831.1	RP11-792A8.4	4.36	1.89e-05	0.00579	0.29	0.26	Corneal structure;	chr7:66902145	chr7:66739829~66740385:-
COAD	cis	rs4718428	0.607	rs66954441	ENSG00000272831.1	RP11-792A8.4	4.36	1.89e-05	0.00579	0.29	0.26	Corneal structure;	chr7:66904222	chr7:66739829~66740385:-
COAD	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	4.36	1.89e-05	0.00579	0.34	0.26	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
COAD	cis	rs12506228	0.502	rs11735398	ENSG00000279943.1	FLJ38576	4.36	1.89e-05	0.00579	0.36	0.26	Job-related exhaustion in shift workers;	chr4:186410372	chr4:186189032~186191490:-
COAD	cis	rs12699921	0.632	rs2691621	ENSG00000279048.1	RP11-511H23.2	-4.36	1.89e-05	0.00579	-0.19	-0.26	Fibrinogen levels;	chr7:17782826	chr7:17940503~17942922:+
COAD	cis	rs7646881	0.904	rs112493023	ENSG00000272087.1	RP11-379F4.7	4.36	1.89e-05	0.00579	0.38	0.26	Tetralogy of Fallot;	chr3:158730487	chr3:158693120~158693768:-
COAD	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-4.36	1.89e-05	0.0058	-0.28	-0.26	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-4.36	1.89e-05	0.0058	-0.28	-0.26	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
COAD	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-4.36	1.89e-05	0.0058	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
COAD	cis	rs7646881	1	rs73015655	ENSG00000272087.1	RP11-379F4.7	4.36	1.89e-05	0.0058	0.38	0.26	Tetralogy of Fallot;	chr3:158734093	chr3:158693120~158693768:-
COAD	cis	rs10043775	1	rs9325095	ENSG00000251330.3	CTD-2283N19.1	-4.36	1.9e-05	0.0058	-0.32	-0.26	Periodontal microbiota;	chr5:148405595	chr5:148430159~148430807:-
COAD	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	4.36	1.9e-05	0.0058	0.33	0.26	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	4.36	1.9e-05	0.0058	0.33	0.26	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
COAD	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	4.36	1.9e-05	0.0058	0.23	0.26	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	4.36	1.9e-05	0.0058	0.23	0.26	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	4.36	1.9e-05	0.0058	0.23	0.26	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
COAD	cis	rs1930961	0.702	rs9624842	ENSG00000272977.1	CTA-390C10.10	-4.36	1.9e-05	0.00581	-0.71	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25497117	chr22:25476218~25479971:+
COAD	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	4.36	1.9e-05	0.00581	0.29	0.26	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
COAD	cis	rs11098499	0.866	rs13105020	ENSG00000249244.1	RP11-548H18.2	4.36	1.9e-05	0.00581	0.34	0.26	Corneal astigmatism;	chr4:119364533	chr4:119391831~119395335:-
COAD	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-4.36	1.9e-05	0.00581	-0.32	-0.26	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
COAD	cis	rs3813567	0.759	rs7163204	ENSG00000261143.1	ADAMTS7P3	-4.36	1.9e-05	0.00581	-0.42	-0.26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661398	chr15:77976042~77993057:+
COAD	cis	rs3813567	0.702	rs7164665	ENSG00000261143.1	ADAMTS7P3	-4.36	1.9e-05	0.00581	-0.42	-0.26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661577	chr15:77976042~77993057:+
COAD	cis	rs2836974	0.623	rs34240248	ENSG00000255568.3	BRWD1-AS2	-4.36	1.9e-05	0.00581	-0.25	-0.26	Cognitive function;	chr21:39313313	chr21:39313935~39314962:+
COAD	cis	rs6661961	0.752	rs4845767	ENSG00000237975.5	FLG-AS1	-4.36	1.9e-05	0.00581	-0.27	-0.26	Atopic dermatitis;	chr1:152442832	chr1:152168125~152445456:+
COAD	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-4.36	1.9e-05	0.00582	-0.49	-0.26	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-4.36	1.9e-05	0.00582	-0.49	-0.26	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-4.36	1.9e-05	0.00582	-0.49	-0.26	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
COAD	cis	rs9907295	0.688	rs2251660	ENSG00000271013.1	AC015849.15	-4.36	1.9e-05	0.00582	-0.36	-0.26	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35912635~35918010:-
COAD	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-4.36	1.9e-05	0.00582	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
COAD	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-4.36	1.9e-05	0.00582	-0.54	-0.26	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-4.36	1.9e-05	0.00582	-0.54	-0.26	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
COAD	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-4.36	1.91e-05	0.00583	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
COAD	cis	rs8022206	0.773	rs10136790	ENSG00000259502.1	RP11-643G16.3	4.36	1.91e-05	0.00583	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67935228	chr14:67610986~67613864:+
COAD	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	4.36	1.91e-05	0.00583	0.28	0.26	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
COAD	cis	rs9532669	0.889	rs7333447	ENSG00000239827.7	SUGT1P3	-4.36	1.91e-05	0.00583	-0.22	-0.26	Cervical cancer;	chr13:40917586	chr13:40908159~40921774:-
COAD	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	4.36	1.91e-05	0.00583	0.39	0.26	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
COAD	cis	rs56052703	0.536	rs2292037	ENSG00000267633.1	CTB-5E10.3	-4.36	1.91e-05	0.00583	-0.3	-0.26	Proteinuria and chronic kidney disease;	chr19:13316991	chr19:13772118~13774118:-
COAD	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-4.36	1.91e-05	0.00583	-0.34	-0.26	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
COAD	cis	rs2836974	0.897	rs2836923	ENSG00000255568.3	BRWD1-AS2	4.36	1.91e-05	0.00583	0.27	0.26	Cognitive function;	chr21:39152310	chr21:39313935~39314962:+
COAD	cis	rs7760535	0.811	rs1002475	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Metabolic traits;	chr6:111388386	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs11153288	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs11153290	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs11153291	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs11153292	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs12190634	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs1989574	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.508	rs11153294	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs7451051	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.91e-05	0.00583	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111297126~111298510:+
COAD	cis	rs2408955	0.522	rs4760679	ENSG00000273765.1	RP11-370I10.11	-4.36	1.91e-05	0.00583	-0.27	-0.26	Glycated hemoglobin levels;	chr12:48067852	chr12:48360920~48361377:+
COAD	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	4.36	1.91e-05	0.00583	0.34	0.26	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	4.36	1.91e-05	0.00583	0.34	0.26	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
COAD	cis	rs3752645	0.764	rs112203311	ENSG00000241764.3	AC002467.7	4.36	1.91e-05	0.00584	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107054146	chr7:107742817~107744581:-
COAD	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	4.36	1.91e-05	0.00584	0.44	0.26	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
COAD	cis	rs2638953	0.853	rs11049622	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457637	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.888	rs10843177	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457737	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10771428	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458070	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10506035	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458159	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs11049627	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459389	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049628	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459781	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049629	ENSG00000247934.4	RP11-967K21.1	-4.36	1.91e-05	0.00584	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459856	chr12:28163298~28190738:-
COAD	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	4.36	1.91e-05	0.00584	0.32	0.26	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
COAD	cis	rs71636778	0.509	rs12746810	ENSG00000260063.1	RP5-968P14.2	-4.36	1.91e-05	0.00584	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26686642	chr1:26692132~26694131:-
COAD	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-4.36	1.91e-05	0.00584	-0.3	-0.26	Height;	chr3:53097932	chr3:53064283~53065091:-
COAD	cis	rs2115630	1	rs55646601	ENSG00000259728.4	LINC00933	-4.36	1.91e-05	0.00584	-0.31	-0.26	P wave terminal force;	chr15:84780337	chr15:84570649~84580175:+
COAD	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	4.36	1.92e-05	0.00585	0.46	0.26	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
COAD	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	4.36	1.92e-05	0.00585	0.39	0.26	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
COAD	cis	rs2638953	0.853	rs11049679	ENSG00000247934.4	RP11-967K21.1	-4.36	1.92e-05	0.00585	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28163298~28190738:-
COAD	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	4.36	1.92e-05	0.00585	0.29	0.26	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
COAD	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	4.36	1.92e-05	0.00586	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	4.36	1.92e-05	0.00586	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
COAD	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-4.36	1.92e-05	0.00586	-0.32	-0.26	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
COAD	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-4.36	1.92e-05	0.00587	-0.28	-0.26	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
COAD	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	4.36	1.92e-05	0.00587	0.27	0.26	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
COAD	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-4.36	1.92e-05	0.00587	-0.17	-0.26	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
COAD	cis	rs115769866	0.609	rs2191037	ENSG00000204709.4	LINC01556	4.35	1.92e-05	0.00587	0.37	0.26	Bipolar disorder;	chr6:28499211	chr6:28943877~28944537:+
COAD	cis	rs115769866	0.569	rs2859358	ENSG00000204709.4	LINC01556	4.35	1.92e-05	0.00587	0.37	0.26	Bipolar disorder;	chr6:28505044	chr6:28943877~28944537:+
COAD	cis	rs9532669	0.89	rs12865032	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40873801	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs34123829	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40873808	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4488324	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40873864	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4288867	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40873880	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4415896	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874001	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs4415897	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874035	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4389021	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874209	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.824	rs4628828	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874369	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.737	rs34354179	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874424	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9594445	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874859	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9594446	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40874863	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4402423	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875010	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.963	rs9532628	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875172	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532629	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875193	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7491149	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875216	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532630	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875472	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs4306385	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40875641	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4406939	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40876108	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4628824	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40876217	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs12428959	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40876638	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.895	rs4942009	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40877243	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4334153	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40877737	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4309270	ENSG00000239827.7	SUGT1P3	-4.35	1.92e-05	0.00587	-0.23	-0.26	Cervical cancer;	chr13:40877827	chr13:40908159~40921774:-
COAD	cis	rs875971	0.862	rs1968126	ENSG00000224316.1	RP11-479O9.2	-4.35	1.92e-05	0.00587	-0.28	-0.26	Aortic root size;	chr7:66592017	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6460306	ENSG00000224316.1	RP11-479O9.2	-4.35	1.92e-05	0.00587	-0.28	-0.26	Aortic root size;	chr7:66595806	chr7:65773620~65802067:+
COAD	cis	rs9353324	1	rs58334368	ENSG00000203875.9	SNHG5	-4.35	1.92e-05	0.00587	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85971591	chr6:85660950~85678736:-
COAD	cis	rs2976388	0.507	rs7813604	ENSG00000253741.1	CTD-2292P10.4	-4.35	1.93e-05	0.00587	-0.3	-0.26	Urinary tract infection frequency;	chr8:142756644	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.507	rs13259549	ENSG00000253741.1	CTD-2292P10.4	-4.35	1.93e-05	0.00587	-0.3	-0.26	Urinary tract infection frequency;	chr8:142757101	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.525	rs2016749	ENSG00000253741.1	CTD-2292P10.4	4.35	1.93e-05	0.00587	0.3	0.26	Urinary tract infection frequency;	chr8:142754700	chr8:142702252~142726973:-
COAD	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-4.35	1.93e-05	0.00587	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
COAD	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.35	1.93e-05	0.00587	-0.41	-0.26	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
COAD	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-4.35	1.93e-05	0.00588	-0.33	-0.26	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
COAD	cis	rs1023500	0.505	rs134874	ENSG00000237037.8	NDUFA6-AS1	-4.35	1.93e-05	0.00588	-0.27	-0.26	Schizophrenia;	chr22:42265138	chr22:42090931~42137742:+
COAD	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-4.35	1.93e-05	0.00588	-0.25	-0.26	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
COAD	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	4.35	1.93e-05	0.00588	0.39	0.26	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	4.35	1.93e-05	0.00588	0.39	0.26	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	4.35	1.93e-05	0.00588	0.39	0.26	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	4.35	1.93e-05	0.00588	0.39	0.26	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
COAD	cis	rs8141529	0.584	rs58004020	ENSG00000272858.1	CTA-292E10.8	-4.35	1.93e-05	0.00589	-0.31	-0.26	Lymphocyte counts;	chr22:28861062	chr22:28814914~28815662:+
COAD	cis	rs2682471	0.585	rs4763533	ENSG00000245648.1	RP11-277P12.20	4.35	1.93e-05	0.00589	0.33	0.26	Macrophage inflammatory protein 1a levels;	chr12:10446828	chr12:10363769~10398506:+
COAD	cis	rs773506	0.933	rs773514	ENSG00000228069.1	RP11-100G15.3	-4.35	1.93e-05	0.00589	-0.29	-0.26	Type 2 diabetes nephropathy;	chr9:91219367	chr9:92109013~92110095:+
COAD	cis	rs7656342	0.93	rs13106539	ENSG00000186234.7	FAM86MP	-4.35	1.93e-05	0.00589	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9796079	chr4:9692495~9702954:+
COAD	cis	rs875971	0.965	rs697968	ENSG00000230189.5	GS1-124K5.2	-4.35	1.93e-05	0.00589	-0.22	-0.26	Aortic root size;	chr7:66070046	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1183245	ENSG00000230189.5	GS1-124K5.2	-4.35	1.93e-05	0.00589	-0.22	-0.26	Aortic root size;	chr7:66076198	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1144895	ENSG00000230189.5	GS1-124K5.2	-4.35	1.93e-05	0.00589	-0.22	-0.26	Aortic root size;	chr7:66076320	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1144894	ENSG00000230189.5	GS1-124K5.2	-4.35	1.93e-05	0.00589	-0.22	-0.26	Aortic root size;	chr7:66077907	chr7:66409143~66490059:-
COAD	cis	rs7200543	1	rs1135999	ENSG00000270580.4	PKD1P6	4.35	1.93e-05	0.00589	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15104723~15131601:-
COAD	cis	rs7200543	1	rs34614532	ENSG00000270580.4	PKD1P6	4.35	1.93e-05	0.00589	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15104723~15131601:-
COAD	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	4.35	1.93e-05	0.00589	0.3	0.26	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
COAD	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	4.35	1.94e-05	0.0059	0.35	0.26	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
COAD	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-4.35	1.94e-05	0.0059	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-4.35	1.94e-05	0.0059	-0.29	-0.26	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
COAD	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-4.35	1.94e-05	0.0059	-0.36	-0.26	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
COAD	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-4.35	1.94e-05	0.0059	-0.36	-0.26	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
COAD	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-4.35	1.94e-05	0.0059	-0.36	-0.26	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
COAD	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-4.35	1.94e-05	0.0059	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-4.35	1.94e-05	0.0059	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-4.35	1.94e-05	0.0059	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-4.35	1.94e-05	0.0059	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
COAD	cis	rs2832191	0.729	rs2832201	ENSG00000176054.6	RPL23P2	-4.35	1.94e-05	0.00591	-0.27	-0.26	Dental caries;	chr21:29127520	chr21:28997613~28998033:-
COAD	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-4.35	1.94e-05	0.00591	-0.33	-0.26	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
COAD	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-4.35	1.94e-05	0.00591	-0.31	-0.26	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
COAD	cis	rs9907295	0.688	rs8066406	ENSG00000270977.1	AC015849.16	-4.35	1.94e-05	0.00591	-0.34	-0.26	Fibroblast growth factor basic levels;	chr17:35905550	chr17:35893707~35911023:-
COAD	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	4.35	1.94e-05	0.00591	0.33	0.26	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	4.35	1.94e-05	0.00591	0.33	0.26	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
COAD	cis	rs3733585	0.699	rs4621431	ENSG00000250413.1	RP11-448G15.1	4.35	1.94e-05	0.00591	0.35	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9945966	chr4:10006482~10009725:+
COAD	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	4.35	1.94e-05	0.00591	0.32	0.26	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	4.35	1.94e-05	0.00592	0.31	0.26	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
COAD	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	4.35	1.94e-05	0.00592	0.32	0.26	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
COAD	cis	rs3864261	0.515	rs55769858	ENSG00000272081.1	CTD-2376I4.2	4.35	1.95e-05	0.00592	0.31	0.26	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72955206~72955699:-
COAD	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	4.35	1.95e-05	0.00593	0.29	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
COAD	cis	rs6840360	0.582	rs4696260	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.515	rs11099811	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.582	rs7691601	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.582	rs59714108	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.582	rs6813735	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151407551~151408835:-
COAD	cis	rs6840360	0.582	rs57585665	ENSG00000251611.1	RP11-610P16.1	-4.35	1.95e-05	0.00593	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151407551~151408835:-
COAD	cis	rs36052053	0.908	rs34780834	ENSG00000219700.1	PTCHD3P3	4.35	1.95e-05	0.00593	0.46	0.26	Red cell distribution width;	chr6:109303563	chr6:109288571~109290503:-
COAD	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-4.35	1.95e-05	0.00593	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-4.35	1.95e-05	0.00593	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
COAD	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-4.35	1.95e-05	0.00593	-0.33	-0.26	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
COAD	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	4.35	1.95e-05	0.00593	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
COAD	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	4.35	1.95e-05	0.00594	0.43	0.26	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
COAD	cis	rs71636778	0.509	rs12743862	ENSG00000260063.1	RP5-968P14.2	-4.35	1.95e-05	0.00594	-0.53	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701730	chr1:26692132~26694131:-
COAD	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	4.35	1.95e-05	0.00594	0.33	0.26	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	4.35	1.95e-05	0.00594	0.33	0.26	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
COAD	cis	rs9532669	0.89	rs35396630	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863135	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942001	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863176	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942003	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863270	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs4942004	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863598	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs9315791	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863931	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.824	rs9315792	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40863951	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.684	rs7139788	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40864264	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7338617	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40870787	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.857	rs6560961	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40870878	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs6560962	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40870948	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs3610	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40871334	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942005	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40871636	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942006	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40871862	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4942008	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40871989	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs2039118	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40872260	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4356347	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40872516	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7982346	ENSG00000239827.7	SUGT1P3	-4.35	1.95e-05	0.00594	-0.23	-0.26	Cervical cancer;	chr13:40873273	chr13:40908159~40921774:-
COAD	cis	rs2337406	0.866	rs79901786	ENSG00000211967.3	IGHV3-53	-4.35	1.95e-05	0.00594	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106777623	chr14:106592676~106593347:-
COAD	cis	rs8022206	0.773	rs12432681	ENSG00000259502.1	RP11-643G16.3	4.35	1.95e-05	0.00594	0.36	0.26	Platelet count;Mean platelet volume;	chr14:68037648	chr14:67610986~67613864:+
COAD	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	4.35	1.95e-05	0.00594	0.33	0.26	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
COAD	cis	rs2115630	0.936	rs11073663	ENSG00000259728.4	LINC00933	-4.35	1.96e-05	0.00595	-0.31	-0.26	P wave terminal force;	chr15:84717037	chr15:84570649~84580175:+
COAD	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	4.35	1.96e-05	0.00595	0.34	0.26	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
COAD	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-4.35	1.96e-05	0.00595	-0.3	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
COAD	cis	rs7955901	0.837	rs10748168	ENSG00000258053.1	CTD-2021H9.3	-4.35	1.96e-05	0.00595	-0.31	-0.26	Type 2 diabetes;	chr12:71015072	chr12:71047402~71118247:-
COAD	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	4.35	1.96e-05	0.00595	0.35	0.26	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
COAD	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	4.35	1.96e-05	0.00595	0.3	0.26	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	4.35	1.96e-05	0.00595	0.34	0.26	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	4.35	1.96e-05	0.00595	0.34	0.26	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
COAD	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-4.35	1.96e-05	0.00595	-0.37	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
COAD	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	4.35	1.96e-05	0.00595	0.36	0.26	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
COAD	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	4.35	1.96e-05	0.00595	0.32	0.26	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
COAD	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	4.35	1.96e-05	0.00596	0.29	0.26	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
COAD	cis	rs860295	0.775	rs822505	ENSG00000225082.2	DAP3P1	4.35	1.96e-05	0.00596	0.32	0.26	Body mass index;	chr1:155876737	chr1:155586644~155602197:+
COAD	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-4.35	1.96e-05	0.00596	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
COAD	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-4.35	1.96e-05	0.00597	-0.3	-0.26	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-4.35	1.96e-05	0.00597	-0.3	-0.26	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
COAD	cis	rs7656342	0.866	rs13124141	ENSG00000186234.7	FAM86MP	-4.35	1.96e-05	0.00597	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9771613	chr4:9692495~9702954:+
COAD	cis	rs7656342	0.836	rs10022923	ENSG00000186234.7	FAM86MP	-4.35	1.96e-05	0.00597	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9771814	chr4:9692495~9702954:+
COAD	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-4.35	1.97e-05	0.00597	-0.29	-0.26	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
COAD	cis	rs3733585	0.753	rs12500805	ENSG00000250413.1	RP11-448G15.1	-4.35	1.97e-05	0.00598	-0.34	-0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10006482~10009725:+
COAD	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	4.35	1.97e-05	0.00598	0.41	0.26	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
COAD	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	4.35	1.97e-05	0.00598	0.35	0.26	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
COAD	cis	rs12497850	0.931	rs7636057	ENSG00000225399.4	RP11-3B7.1	4.35	1.97e-05	0.00598	0.29	0.26	Parkinson's disease;	chr3:48955149	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs7643368	ENSG00000225399.4	RP11-3B7.1	4.35	1.97e-05	0.00598	0.29	0.26	Parkinson's disease;	chr3:48955422	chr3:49260085~49261316:+
COAD	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	4.35	1.97e-05	0.00598	0.31	0.26	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
COAD	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	4.35	1.97e-05	0.00598	0.33	0.26	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
COAD	cis	rs6993244	1	rs6993244	ENSG00000254340.1	RP11-10A14.3	4.35	1.97e-05	0.00598	0.32	0.26	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9141424~9145435:+
COAD	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	4.35	1.97e-05	0.00598	0.36	0.26	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
COAD	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	4.35	1.97e-05	0.00598	0.36	0.26	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
COAD	cis	rs12497850	0.931	rs4974080	ENSG00000225399.4	RP11-3B7.1	4.35	1.97e-05	0.00598	0.29	0.26	Parkinson's disease;	chr3:48993395	chr3:49260085~49261316:+
COAD	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	4.35	1.97e-05	0.00598	0.26	0.26	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
COAD	cis	rs7487075	0.78	rs12296120	ENSG00000274723.1	RP11-618L22.1	4.35	1.97e-05	0.00599	0.28	0.26	Itch intensity from mosquito bite;	chr12:46343808	chr12:46970504~46972155:+
COAD	cis	rs812925	0.502	rs778150	ENSG00000273302.1	RP11-493E12.2	-4.35	1.97e-05	0.00599	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61381237	chr2:61199979~61200769:+
COAD	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-4.35	1.97e-05	0.00599	-0.36	-0.26	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
COAD	cis	rs9393813	0.967	rs764284	ENSG00000224843.5	LINC00240	-4.35	1.97e-05	0.00599	-0.3	-0.26	Bipolar disorder;	chr6:27344299	chr6:26956992~27023924:+
COAD	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	4.35	1.97e-05	0.00599	0.42	0.26	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
COAD	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	4.35	1.97e-05	0.00599	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	4.35	1.97e-05	0.00599	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	4.35	1.97e-05	0.00599	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
COAD	cis	rs41294858	1	rs41294858	ENSG00000232876.1	CTA-212D2.2	-4.35	1.97e-05	0.00599	-0.49	-0.26	Red blood cell count;	chr6:135091498	chr6:135055033~135060550:+
COAD	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-4.35	1.98e-05	0.006	-0.33	-0.26	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
COAD	cis	rs964611	0.654	rs968852	ENSG00000259656.1	RP11-325E5.1	-4.35	1.98e-05	0.006	-0.34	-0.26	Metabolite levels (Pyroglutamine);	chr15:48375604	chr15:49101791~49103264:+
COAD	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	4.35	1.98e-05	0.006	0.38	0.26	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
COAD	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-4.35	1.98e-05	0.006	-0.49	-0.26	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
COAD	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	4.35	1.98e-05	0.006	0.31	0.26	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
COAD	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	4.35	1.98e-05	0.006	0.31	0.26	Height;	chr4:55489895	chr4:55540502~55540835:-
COAD	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.35	1.98e-05	0.00601	0.42	0.26	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
COAD	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-4.35	1.98e-05	0.00601	-0.3	-0.26	Height;	chr3:53084188	chr3:53064283~53065091:-
COAD	cis	rs11089937	0.616	rs928896	ENSG00000211638.2	IGLV8-61	-4.35	1.98e-05	0.00601	-0.25	-0.26	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22098700~22099212:+
COAD	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	4.35	1.98e-05	0.00601	0.36	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
COAD	cis	rs7572733	0.84	rs7340470	ENSG00000222017.1	AC011997.1	-4.35	1.98e-05	0.00601	-0.29	-0.26	Dermatomyositis;	chr2:197680738	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs12622674	ENSG00000222017.1	AC011997.1	-4.35	1.98e-05	0.00601	-0.29	-0.26	Dermatomyositis;	chr2:197687088	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs2341510	ENSG00000222017.1	AC011997.1	-4.35	1.98e-05	0.00601	-0.29	-0.26	Dermatomyositis;	chr2:197693955	chr2:197693106~197774823:+
COAD	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-4.35	1.98e-05	0.00601	-0.27	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
COAD	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-4.35	1.98e-05	0.00602	-0.3	-0.26	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
COAD	cis	rs7138300	0.51	rs2870845	ENSG00000258053.1	CTD-2021H9.3	-4.35	1.98e-05	0.00602	-0.38	-0.26	Type 2 diabetes;	chr12:71052656	chr12:71047402~71118247:-
COAD	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	4.35	1.98e-05	0.00602	0.35	0.26	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	4.35	1.98e-05	0.00602	0.35	0.26	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	4.35	1.98e-05	0.00602	0.35	0.26	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	4.35	1.98e-05	0.00602	0.35	0.26	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	4.35	1.98e-05	0.00602	0.35	0.26	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
COAD	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	4.35	1.98e-05	0.00602	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	4.35	1.98e-05	0.00602	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	4.35	1.98e-05	0.00602	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	4.35	1.98e-05	0.00602	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	4.35	1.98e-05	0.00602	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
COAD	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	4.35	1.99e-05	0.00602	0.34	0.26	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
COAD	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-4.35	1.99e-05	0.00602	-0.29	-0.26	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
COAD	cis	rs72827839	0.793	rs72823527	ENSG00000263412.1	RP5-890E16.2	4.35	1.99e-05	0.00602	0.38	0.26	Ease of getting up in the morning;	chr17:48021444	chr17:48045141~48048073:-
COAD	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	4.35	1.99e-05	0.00602	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
COAD	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-4.35	1.99e-05	0.00603	-0.28	-0.26	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
COAD	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-4.35	1.99e-05	0.00603	-0.28	-0.26	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
COAD	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	4.35	1.99e-05	0.00603	0.19	0.26	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
COAD	cis	rs6740322	0.748	rs6544636	ENSG00000234936.1	AC010883.5	4.35	1.99e-05	0.00603	0.33	0.26	Coronary artery disease;	chr2:43260347	chr2:43229573~43233394:+
COAD	cis	rs7119	0.667	rs907393	ENSG00000259565.2	KRT8P23	4.35	1.99e-05	0.00604	0.3	0.26	Type 2 diabetes;	chr15:77611105	chr15:76979245~76980451:-
COAD	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	4.35	1.99e-05	0.00604	0.31	0.26	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
COAD	cis	rs13256369	0.708	rs10903310	ENSG00000173295.6	FAM86B3P	-4.35	1.99e-05	0.00604	-0.37	-0.26	Obesity-related traits;	chr8:8732177	chr8:8228595~8244865:+
COAD	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.35	1.99e-05	0.00604	-0.53	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
COAD	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	4.35	1.99e-05	0.00604	0.46	0.26	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
COAD	cis	rs875971	0.861	rs801215	ENSG00000224316.1	RP11-479O9.2	-4.35	1.99e-05	0.00604	-0.28	-0.26	Aortic root size;	chr7:66546951	chr7:65773620~65802067:+
COAD	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-4.35	2e-05	0.00604	-0.31	-0.26	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
COAD	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	4.35	2e-05	0.00605	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
COAD	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	4.35	2e-05	0.00605	0.26	0.26	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
COAD	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	4.35	2e-05	0.00605	0.31	0.26	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
COAD	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	4.35	2e-05	0.00605	0.31	0.26	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
COAD	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	4.35	2e-05	0.00605	0.31	0.26	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
COAD	cis	rs12928939	0.517	rs17358402	ENSG00000260886.1	TAT-AS1	4.35	2e-05	0.00605	0.39	0.26	Post bronchodilator FEV1;	chr16:71934024	chr16:71565789~71578187:+
COAD	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-4.35	2e-05	0.00605	-0.23	-0.26	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
COAD	cis	rs739496	0.527	rs11066079	ENSG00000257595.2	RP3-473L9.4	4.35	2e-05	0.00605	0.39	0.26	Platelet count;	chr12:111912599	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.799	rs11066080	ENSG00000257595.2	RP3-473L9.4	4.35	2e-05	0.00605	0.39	0.26	Mean platelet volume;	chr12:111912600	chr12:111369282~111403310:+
COAD	cis	rs752010	0.715	rs4083592	ENSG00000230638.4	RP11-486B10.4	-4.35	2e-05	0.00605	-0.35	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41633851	chr1:41542069~41544310:+
COAD	cis	rs752010	0.715	rs4660551	ENSG00000230638.4	RP11-486B10.4	-4.35	2e-05	0.00605	-0.35	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41634308	chr1:41542069~41544310:+
COAD	cis	rs752010	0.715	rs11807117	ENSG00000230638.4	RP11-486B10.4	-4.35	2e-05	0.00605	-0.35	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41635535	chr1:41542069~41544310:+
COAD	cis	rs1044826	0.647	rs4683463	ENSG00000272656.1	RP11-219D15.3	4.35	2e-05	0.00606	0.31	0.26	Obesity-related traits;	chr3:139478104	chr3:139349024~139349371:-
COAD	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-4.35	2e-05	0.00606	-0.3	-0.26	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
COAD	cis	rs7656342	0.866	rs2280206	ENSG00000186234.7	FAM86MP	-4.35	2e-05	0.00606	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9797613	chr4:9692495~9702954:+
COAD	cis	rs10760158	0.832	rs4837832	ENSG00000226752.6	PSMD5-AS1	4.35	2e-05	0.00606	0.28	0.26	Pulse pressure;	chr9:121294150	chr9:120824828~120854385:+
COAD	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	4.35	2e-05	0.00606	0.51	0.26	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
COAD	cis	rs3752645	1	rs7778076	ENSG00000241764.3	AC002467.7	4.35	2e-05	0.00606	0.42	0.26	Bladder cancer (smoking interaction);	chr7:107082563	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs11767753	ENSG00000241764.3	AC002467.7	4.35	2e-05	0.00606	0.42	0.26	Bladder cancer (smoking interaction);	chr7:107083022	chr7:107742817~107744581:-
COAD	cis	rs9376098	1	rs9376098	ENSG00000232876.1	CTA-212D2.2	-4.35	2e-05	0.00606	-0.32	-0.26	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135178322	chr6:135055033~135060550:+
COAD	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	4.35	2e-05	0.00606	0.31	0.26	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
COAD	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-4.35	2e-05	0.00606	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-4.35	2e-05	0.00606	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
COAD	cis	rs9309473	0.528	rs10191517	ENSG00000163016.8	ALMS1P	4.35	2e-05	0.00606	0.33	0.26	Metabolite levels;	chr2:73331275	chr2:73644919~73685576:+
COAD	cis	rs9487051	0.872	rs9386794	ENSG00000219700.1	PTCHD3P3	4.35	2e-05	0.00607	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109290318	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs6924776	ENSG00000219700.1	PTCHD3P3	4.35	2e-05	0.00607	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109291073	chr6:109288571~109290503:-
COAD	cis	rs4950322	1	rs72694720	ENSG00000278811.3	LINC00624	4.35	2.01e-05	0.00607	0.29	0.26	Protein quantitative trait loci;	chr1:147371939	chr1:147258885~147517875:-
COAD	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	4.35	2.01e-05	0.00607	0.32	0.26	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
COAD	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-4.35	2.01e-05	0.00607	-0.5	-0.26	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
COAD	cis	rs875971	1	rs1167411	ENSG00000230189.5	GS1-124K5.2	-4.35	2.01e-05	0.00607	-0.22	-0.26	Aortic root size;	chr7:66074277	chr7:66409143~66490059:-
COAD	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-4.35	2.01e-05	0.00607	-0.36	-0.26	Depression;	chr6:28192182	chr6:28170845~28172521:+
COAD	cis	rs728616	0.764	rs56122289	ENSG00000225484.5	NUTM2B-AS1	-4.35	2.01e-05	0.00607	-0.49	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79986271	chr10:79663088~79826594:-
COAD	cis	rs2836974	0.584	rs34436313	ENSG00000255568.3	BRWD1-AS2	-4.34	2.01e-05	0.00607	-0.25	-0.26	Cognitive function;	chr21:39313320	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.666	rs35182074	ENSG00000255568.3	BRWD1-AS2	-4.34	2.01e-05	0.00607	-0.25	-0.26	Cognitive function;	chr21:39313358	chr21:39313935~39314962:+
COAD	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-4.34	2.01e-05	0.00607	-0.3	-0.26	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
COAD	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	4.34	2.01e-05	0.00608	0.28	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
COAD	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-4.34	2.01e-05	0.00608	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
COAD	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-4.34	2.01e-05	0.00608	-0.28	-0.26	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
COAD	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	4.34	2.01e-05	0.00608	0.31	0.26	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
COAD	cis	rs7961581	0.957	rs6581998	ENSG00000258053.1	CTD-2021H9.3	-4.34	2.01e-05	0.00608	-0.35	-0.26	Type 2 diabetes;	chr12:71262943	chr12:71047402~71118247:-
COAD	cis	rs494562	0.803	rs727870	ENSG00000234155.1	RP11-30P6.6	-4.34	2.01e-05	0.00608	-0.43	-0.26	Metabolic traits;Blood metabolite levels;	chr6:85421438	chr6:85387219~85390186:-
COAD	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	4.34	2.01e-05	0.00608	0.38	0.26	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	4.34	2.01e-05	0.00608	0.38	0.26	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
COAD	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	4.34	2.01e-05	0.00608	0.47	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
COAD	cis	rs9322193	0.923	rs958953	ENSG00000268592.3	RAET1E-AS1	4.34	2.01e-05	0.00608	0.3	0.26	Lung cancer;	chr6:149840735	chr6:149863494~149919507:+
COAD	cis	rs62184315	0.938	rs17806132	ENSG00000253559.1	OSGEPL1-AS1	4.34	2.01e-05	0.00608	0.35	0.26	Alcohol dependence (age at onset);	chr2:189843561	chr2:189762704~189765556:+
COAD	cis	rs7200543	0.883	rs4985148	ENSG00000270580.4	PKD1P6	4.34	2.01e-05	0.00609	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15104723~15131601:-
COAD	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	4.34	2.01e-05	0.00609	0.31	0.26	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
COAD	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	4.34	2.01e-05	0.00609	0.23	0.26	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
COAD	cis	rs9487051	0.714	rs6932503	ENSG00000219700.1	PTCHD3P3	4.34	2.02e-05	0.0061	0.28	0.26	Reticulocyte fraction of red cells;	chr6:109286755	chr6:109288571~109290503:-
COAD	cis	rs71636778	0.509	rs78581866	ENSG00000260063.1	RP5-968P14.2	-4.34	2.02e-05	0.0061	-0.56	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921075	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs11538549	ENSG00000260063.1	RP5-968P14.2	-4.34	2.02e-05	0.0061	-0.56	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921792	chr1:26692132~26694131:-
COAD	cis	rs683257	0.673	rs72990126	ENSG00000234147.1	RP3-460G2.2	-4.34	2.02e-05	0.0061	-0.44	-0.26	Facial emotion recognition (angry faces);	chr6:140850534	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs6934165	ENSG00000234147.1	RP3-460G2.2	-4.34	2.02e-05	0.0061	-0.44	-0.26	Facial emotion recognition (angry faces);	chr6:140851191	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs56295525	ENSG00000234147.1	RP3-460G2.2	-4.34	2.02e-05	0.0061	-0.44	-0.26	Facial emotion recognition (angry faces);	chr6:140853380	chr6:140845958~140852924:-
COAD	cis	rs4657482	0.962	rs10800164	ENSG00000236364.3	RP11-525G13.2	4.34	2.02e-05	0.0061	0.2	0.26	Testicular germ cell tumor;	chr1:165889117	chr1:165890795~165900683:-
COAD	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-4.34	2.02e-05	0.0061	-0.38	-0.26	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
COAD	cis	rs1670533	0.685	rs56019586	ENSG00000273179.1	RP11-20I20.4	4.34	2.02e-05	0.0061	0.34	0.26	Recombination rate (females);	chr4:1066054	chr4:1167778~1168174:+
COAD	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-4.34	2.02e-05	0.0061	-0.26	-0.26	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
COAD	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	4.34	2.02e-05	0.00611	0.32	0.26	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
COAD	cis	rs899997	0.773	rs8032156	ENSG00000261143.1	ADAMTS7P3	4.34	2.02e-05	0.00611	0.37	0.26	Coronary artery disease or large artery stroke;	chr15:78672156	chr15:77976042~77993057:+
COAD	cis	rs1029738	0.615	rs3757447	ENSG00000228649.7	AC005682.5	4.34	2.02e-05	0.00611	0.3	0.26	Fibrinogen levels;	chr7:22855116	chr7:22854178~22861579:+
COAD	cis	rs7818688	0.697	rs11778553	ENSG00000253528.2	RP11-347C18.4	-4.34	2.02e-05	0.00611	-0.37	-0.26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94966032	chr8:94974573~94974853:-
COAD	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-4.34	2.02e-05	0.00612	-0.35	-0.26	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
COAD	cis	rs2439831	0.681	rs3742971	ENSG00000249839.1	AC011330.5	4.34	2.03e-05	0.00612	0.35	0.26	Lung cancer in ever smokers;	chr15:43330718	chr15:43663654~43684339:-
COAD	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	4.34	2.03e-05	0.00612	0.29	0.26	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
COAD	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	4.34	2.03e-05	0.00612	0.32	0.26	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
COAD	cis	rs180730	0.5	rs6810734	ENSG00000251609.2	SETP12	4.34	2.03e-05	0.00613	0.34	0.26	Fasting plasma glucose;	chr4:120935625	chr4:120895494~120897083:-
COAD	cis	rs180730	0.519	rs6848268	ENSG00000251609.2	SETP12	4.34	2.03e-05	0.00613	0.34	0.26	Fasting plasma glucose;	chr4:120936802	chr4:120895494~120897083:-
COAD	cis	rs1790761	0.802	rs2276118	ENSG00000231793.4	DOC2GP	-4.34	2.03e-05	0.00613	-0.29	-0.26	Mean corpuscular volume;	chr11:67521123	chr11:67612653~67616257:-
COAD	cis	rs7224610	1	rs7224610	ENSG00000263096.1	RP11-515O17.2	4.34	2.03e-05	0.00613	0.29	0.26	Urate levels;	chr17:55287427	chr17:55271504~55273653:-
COAD	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	4.34	2.03e-05	0.00613	0.42	0.26	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	4.34	2.03e-05	0.00613	0.42	0.26	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	4.34	2.03e-05	0.00613	0.42	0.26	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
COAD	cis	rs2862774	1	rs2862774	ENSG00000228251.1	AC012442.6	4.34	2.03e-05	0.00613	0.42	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr2:113040100	chr2:112590796~112591939:+
COAD	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-4.34	2.03e-05	0.00613	-0.31	-0.26	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-4.34	2.03e-05	0.00613	-0.31	-0.26	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
COAD	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	4.34	2.03e-05	0.00613	0.24	0.26	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
COAD	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-4.34	2.03e-05	0.00613	-0.33	-0.26	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
COAD	cis	rs11638352	0.661	rs2706488	ENSG00000205771.5	CATSPER2P1	4.34	2.03e-05	0.00613	0.44	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097699	chr15:43726918~43747094:-
COAD	cis	rs6840360	0.642	rs2724577	ENSG00000251611.1	RP11-610P16.1	-4.34	2.03e-05	0.00613	-0.27	-0.26	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151407551~151408835:-
COAD	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-4.34	2.03e-05	0.00613	-0.24	-0.26	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
COAD	cis	rs9532669	0.926	rs8002809	ENSG00000239827.7	SUGT1P3	-4.34	2.03e-05	0.00613	-0.23	-0.26	Cervical cancer;	chr13:40872769	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.929	rs7982421	ENSG00000239827.7	SUGT1P3	-4.34	2.03e-05	0.00613	-0.23	-0.26	Cervical cancer;	chr13:40872776	chr13:40908159~40921774:-
COAD	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-4.34	2.03e-05	0.00613	-0.24	-0.26	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
COAD	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-4.34	2.03e-05	0.00613	-0.27	-0.26	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
COAD	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-4.34	2.03e-05	0.00613	-0.34	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
COAD	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-4.34	2.03e-05	0.00614	-0.49	-0.26	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
COAD	cis	rs875971	1	rs10244498	ENSG00000179406.6	LINC00174	4.34	2.03e-05	0.00614	0.19	0.26	Aortic root size;	chr7:66651069	chr7:66376044~66401338:-
COAD	cis	rs2638953	0.853	rs3782515	ENSG00000247934.4	RP11-967K21.1	-4.34	2.03e-05	0.00614	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049521	ENSG00000247934.4	RP11-967K21.1	-4.34	2.03e-05	0.00614	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310976	chr12:28163298~28190738:-
COAD	cis	rs9392556	0.6	rs611500	ENSG00000230648.1	RP3-406P24.3	4.34	2.03e-05	0.00614	0.3	0.26	Blood metabolite levels;	chr6:4126529	chr6:4018843~4021215:-
COAD	cis	rs35264875	1	rs7110274	ENSG00000259799.1	RP11-554A11.9	4.34	2.04e-05	0.00614	0.42	0.26	Blond vs. brown hair color;	chr11:69075236	chr11:69155910~69159752:+
COAD	cis	rs3752645	0.764	rs74620117	ENSG00000241764.3	AC002467.7	4.34	2.04e-05	0.00614	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107064285	chr7:107742817~107744581:-
COAD	cis	rs4820539	1	rs2267003	ENSG00000211644.2	IGLV1-51	-4.34	2.04e-05	0.00615	-0.15	-0.26	Bone mineral density;	chr22:23114911	chr22:22322472~22322980:+
COAD	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	4.34	2.04e-05	0.00615	0.31	0.26	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
COAD	cis	rs8002861	0.935	rs7318147	ENSG00000274001.1	RP11-5G9.5	-4.34	2.04e-05	0.00615	-0.23	-0.26	Leprosy;	chr13:43871017	chr13:43877715~43878163:-
COAD	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	4.34	2.04e-05	0.00615	0.3	0.26	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
COAD	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-4.34	2.04e-05	0.00615	-0.29	-0.26	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-4.34	2.04e-05	0.00615	-0.29	-0.26	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-4.34	2.04e-05	0.00615	-0.29	-0.26	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
COAD	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-4.34	2.04e-05	0.00615	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
COAD	cis	rs2765539	0.545	rs1623409	ENSG00000231365.4	RP11-418J17.1	-4.34	2.04e-05	0.00615	-0.34	-0.26	Waist-hip ratio;	chr1:118962218	chr1:119140396~119275973:+
COAD	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	4.34	2.04e-05	0.00616	0.32	0.26	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
COAD	cis	rs12049351	0.613	rs10799530	ENSG00000229367.1	HMGN2P19	4.34	2.04e-05	0.00616	0.38	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229439986	chr1:229570532~229570796:+
COAD	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	4.34	2.04e-05	0.00616	0.33	0.26	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	4.34	2.04e-05	0.00616	0.33	0.26	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
COAD	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	4.34	2.04e-05	0.00616	0.29	0.26	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
COAD	cis	rs3126085	0.56	rs1858485	ENSG00000237975.5	FLG-AS1	4.34	2.04e-05	0.00616	0.3	0.26	Atopic dermatitis;	chr1:152362054	chr1:152168125~152445456:+
COAD	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	4.34	2.04e-05	0.00616	0.32	0.26	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
COAD	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.04e-05	0.00616	-0.33	-0.26	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.04e-05	0.00616	-0.33	-0.26	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.04e-05	0.00616	-0.33	-0.26	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
COAD	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-4.34	2.05e-05	0.00617	-0.42	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-4.34	2.05e-05	0.00617	-0.42	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
COAD	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-4.34	2.05e-05	0.00617	-0.52	-0.26	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
COAD	cis	rs812925	0.537	rs10865324	ENSG00000273302.1	RP11-493E12.2	-4.34	2.05e-05	0.00617	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61394172	chr2:61199979~61200769:+
COAD	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	4.34	2.05e-05	0.00618	0.37	0.26	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
COAD	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	4.34	2.05e-05	0.00618	0.31	0.26	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
COAD	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	4.34	2.05e-05	0.00618	0.59	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
COAD	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	4.34	2.05e-05	0.00618	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	4.34	2.05e-05	0.00618	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
COAD	cis	rs36052053	0.808	rs78799897	ENSG00000219700.1	PTCHD3P3	4.34	2.05e-05	0.00618	0.46	0.26	Red cell distribution width;	chr6:109285941	chr6:109288571~109290503:-
COAD	cis	rs8030379	0.811	rs7162542	ENSG00000176700.18	SCAND2P	-4.34	2.05e-05	0.00618	-0.22	-0.26	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84631451~84647478:+
COAD	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-4.34	2.05e-05	0.00618	-0.31	-0.26	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
COAD	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-4.34	2.06e-05	0.00619	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
COAD	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	4.34	2.06e-05	0.0062	0.29	0.26	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
COAD	cis	rs8022206	0.773	rs11844529	ENSG00000259502.1	RP11-643G16.3	4.34	2.06e-05	0.0062	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67978835	chr14:67610986~67613864:+
COAD	cis	rs17772222	0.917	rs61986671	ENSG00000258789.1	RP11-507K2.3	-4.34	2.06e-05	0.0062	-0.38	-0.26	Coronary artery calcification;	chr14:88732917	chr14:88551597~88552493:+
COAD	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-4.34	2.06e-05	0.0062	-0.53	-0.26	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-4.34	2.06e-05	0.0062	-0.53	-0.26	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
COAD	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-4.34	2.06e-05	0.0062	-0.28	-0.26	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
COAD	cis	rs6565653	0.967	rs6565652	ENSG00000262580.4	RP11-334C17.5	4.34	2.06e-05	0.0062	0.25	0.26	Ischemic stroke;	chr17:80227755	chr17:80200673~80205949:-
COAD	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-4.34	2.06e-05	0.00621	-0.42	-0.26	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
COAD	cis	rs2018683	0.677	rs2057956	ENSG00000272568.4	CTB-113D17.1	4.34	2.06e-05	0.00621	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28979967~29013367:+
COAD	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	4.34	2.06e-05	0.00621	0.34	0.26	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
COAD	cis	rs71636778	0.509	rs71640337	ENSG00000260063.1	RP5-968P14.2	-4.34	2.06e-05	0.00621	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26677897	chr1:26692132~26694131:-
COAD	cis	rs7200543	1	rs4500751	ENSG00000270580.4	PKD1P6	4.34	2.06e-05	0.00621	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15104723~15131601:-
COAD	cis	rs896854	0.812	rs12546365	ENSG00000253528.2	RP11-347C18.4	4.34	2.06e-05	0.00621	0.28	0.26	Type 2 diabetes;	chr8:94899249	chr8:94974573~94974853:-
COAD	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	4.34	2.06e-05	0.00621	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
COAD	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	4.34	2.06e-05	0.00621	0.34	0.26	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
COAD	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	4.34	2.06e-05	0.00621	0.4	0.26	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
COAD	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	4.34	2.06e-05	0.00621	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
COAD	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-4.34	2.06e-05	0.00621	-0.33	-0.26	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
COAD	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	4.34	2.06e-05	0.00622	0.29	0.26	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
COAD	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.34	2.06e-05	0.00622	0.26	0.26	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
COAD	cis	rs7487075	0.78	rs12307969	ENSG00000274723.1	RP11-618L22.1	4.34	2.07e-05	0.00622	0.28	0.26	Itch intensity from mosquito bite;	chr12:46365274	chr12:46970504~46972155:+
COAD	cis	rs1023500	1	rs7293091	ENSG00000237037.8	NDUFA6-AS1	4.34	2.07e-05	0.00622	0.28	0.26	Schizophrenia;	chr22:41945304	chr22:42090931~42137742:+
COAD	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	4.34	2.07e-05	0.00622	0.32	0.26	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	4.34	2.07e-05	0.00622	0.32	0.26	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
COAD	cis	rs3752645	1	rs17153823	ENSG00000241764.3	AC002467.7	4.34	2.07e-05	0.00622	0.43	0.26	Bladder cancer (smoking interaction);	chr7:107089766	chr7:107742817~107744581:-
COAD	cis	rs2337406	0.539	rs2583292	ENSG00000211964.3	IGHV3-48	-4.34	2.07e-05	0.00622	-0.22	-0.26	Alzheimer's disease (late onset);	chr14:106649040	chr14:106537810~106538344:-
COAD	cis	rs453301	0.686	rs13252797	ENSG00000173295.6	FAM86B3P	4.34	2.07e-05	0.00623	0.31	0.26	Joint mobility (Beighton score);	chr8:9003920	chr8:8228595~8244865:+
COAD	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-4.34	2.07e-05	0.00623	-0.36	-0.26	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
COAD	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	4.34	2.07e-05	0.00623	0.35	0.26	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
COAD	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	4.34	2.07e-05	0.00623	0.33	0.26	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
COAD	cis	rs17772222	0.958	rs59136503	ENSG00000258789.1	RP11-507K2.3	-4.34	2.07e-05	0.00623	-0.37	-0.26	Coronary artery calcification;	chr14:88501921	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.958	rs1816372	ENSG00000258789.1	RP11-507K2.3	-4.34	2.07e-05	0.00623	-0.37	-0.26	Coronary artery calcification;	chr14:88507033	chr14:88551597~88552493:+
COAD	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	4.34	2.07e-05	0.00623	0.28	0.26	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
COAD	cis	rs9400467	0.528	rs455247	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111297126~111298510:+
COAD	cis	rs7760535	0.811	rs464401	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Metabolic traits;	chr6:111347804	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.509	rs463854	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.509	rs463853	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs456569	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs455335	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs465795	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs110732	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.592	rs462493	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.508	rs456871	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111297126~111298510:+
COAD	cis	rs7760535	0.811	rs455732	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Metabolic traits;	chr6:111374065	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs458486	ENSG00000271789.1	RP5-1112D6.7	-4.34	2.07e-05	0.00623	-0.26	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111297126~111298510:+
COAD	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	4.34	2.07e-05	0.00624	0.31	0.26	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
COAD	cis	rs9487051	0.872	rs7773331	ENSG00000219700.1	PTCHD3P3	4.34	2.07e-05	0.00624	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109288005	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9374079	ENSG00000219700.1	PTCHD3P3	4.34	2.07e-05	0.00624	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109288416	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.802	rs9487039	ENSG00000219700.1	PTCHD3P3	4.34	2.07e-05	0.00624	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109288960	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9487042	ENSG00000219700.1	PTCHD3P3	4.34	2.07e-05	0.00624	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109289240	chr6:109288571~109290503:-
COAD	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-4.34	2.07e-05	0.00624	-0.37	-0.26	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
COAD	cis	rs7577696	0.853	rs212758	ENSG00000272716.1	RP11-563N4.1	-4.34	2.07e-05	0.00624	-0.28	-0.26	Inflammatory biomarkers;	chr2:32200913	chr2:32165046~32165757:-
COAD	cis	rs2504916	0.83	rs2504934	ENSG00000230234.1	RP1-276N6.2	4.34	2.07e-05	0.00624	0.34	0.26	Response to hepatitis C treatment;	chr6:160360634	chr6:160272617~160276130:+
COAD	cis	rs3752645	1	rs17425839	ENSG00000241764.3	AC002467.7	-4.34	2.08e-05	0.00625	-0.47	-0.26	Bladder cancer (smoking interaction);	chr7:107122833	chr7:107742817~107744581:-
COAD	cis	rs7017212	0.825	rs2046397	ENSG00000272267.2	RP11-375N15.2	4.34	2.08e-05	0.00625	0.33	0.26	Schizophrenia;	chr8:10168621	chr8:9555144~9556520:-
COAD	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-4.34	2.08e-05	0.00625	-0.33	-0.26	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-4.34	2.08e-05	0.00625	-0.33	-0.26	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
COAD	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-4.34	2.08e-05	0.00625	-0.41	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
COAD	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.34	2.08e-05	0.00626	-0.3	-0.26	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
COAD	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-4.34	2.08e-05	0.00626	-0.45	-0.26	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
COAD	cis	rs7246657	0.943	rs6508711	ENSG00000226686.6	LINC01535	-4.34	2.08e-05	0.00626	-0.37	-0.26	Coronary artery calcification;	chr19:37324232	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs6508716	ENSG00000226686.6	LINC01535	-4.34	2.08e-05	0.00626	-0.37	-0.26	Coronary artery calcification;	chr19:37328108	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7257672	ENSG00000226686.6	LINC01535	-4.34	2.08e-05	0.00626	-0.37	-0.26	Coronary artery calcification;	chr19:37332957	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.891	rs7257495	ENSG00000226686.6	LINC01535	-4.34	2.08e-05	0.00626	-0.37	-0.26	Coronary artery calcification;	chr19:37332974	chr19:37251912~37265535:+
COAD	cis	rs34102591	0.784	rs7964945	ENSG00000269938.1	RP11-214K3.20	-4.34	2.08e-05	0.00626	-0.41	-0.26	Schizophrenia;	chr12:123953121	chr12:123968023~123968579:-
COAD	cis	rs11969893	0.85	rs9791284	ENSG00000270987.1	RP3-467N11.2	4.34	2.08e-05	0.00626	0.59	0.26	Economic and political preferences (immigration/crime);	chr6:100906010	chr6:100889603~100890338:+
COAD	cis	rs11681884	0.892	rs56060225	ENSG00000228251.1	AC012442.6	4.34	2.08e-05	0.00627	0.57	0.26	Stroke;	chr2:113080493	chr2:112590796~112591939:+
COAD	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	4.34	2.08e-05	0.00627	0.34	0.26	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
COAD	cis	rs34102591	0.577	rs3762102	ENSG00000269938.1	RP11-214K3.20	-4.34	2.08e-05	0.00627	-0.41	-0.26	Schizophrenia;	chr12:123962861	chr12:123968023~123968579:-
COAD	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	4.34	2.09e-05	0.00627	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
COAD	cis	rs860295	0.702	rs4971095	ENSG00000223503.1	RP11-29H23.6	4.34	2.09e-05	0.00628	0.34	0.26	Body mass index;	chr1:155636433	chr1:155590601~155591262:-
COAD	cis	rs1182436	1	rs1182436	ENSG00000229660.1	RP5-1142J19.1	4.34	2.09e-05	0.00628	0.31	0.26	Type 2 diabetes;	chr7:157235059	chr7:157281536~157282686:-
COAD	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	4.34	2.09e-05	0.00628	0.25	0.26	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
COAD	cis	rs2732480	0.557	rs2732441	ENSG00000257735.1	RP11-370I10.6	4.34	2.09e-05	0.00628	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2732448	ENSG00000257735.1	RP11-370I10.6	4.34	2.09e-05	0.00628	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48350945~48442411:+
COAD	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	4.34	2.09e-05	0.00628	0.28	0.26	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
COAD	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-4.34	2.09e-05	0.00628	-0.27	-0.26	Axial length;	chr3:53814645	chr3:53797764~53798019:-
COAD	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	4.34	2.09e-05	0.00628	0.45	0.26	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	4.34	2.09e-05	0.00628	0.45	0.26	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	4.34	2.09e-05	0.00628	0.45	0.26	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
COAD	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-4.34	2.09e-05	0.00628	-0.29	-0.26	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
COAD	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	4.34	2.09e-05	0.00628	0.3	0.26	Height;	chr4:55409063	chr4:55540502~55540835:-
COAD	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-4.34	2.09e-05	0.00629	-0.34	-0.26	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
COAD	cis	rs7428	0.545	rs17026212	ENSG00000246575.2	AC093162.5	4.34	2.09e-05	0.00629	0.24	0.26	Ear protrusion;	chr2:85324573	chr2:85315041~85316529:+
COAD	cis	rs9487051	0.676	rs9386780	ENSG00000219700.1	PTCHD3P3	4.34	2.09e-05	0.00629	0.29	0.26	Reticulocyte fraction of red cells;	chr6:109263207	chr6:109288571~109290503:-
COAD	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	4.34	2.09e-05	0.00629	0.34	0.26	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
COAD	cis	rs36052053	0.908	rs13203987	ENSG00000219700.1	PTCHD3P3	4.34	2.09e-05	0.00629	0.46	0.26	Red cell distribution width;	chr6:109264037	chr6:109288571~109290503:-
COAD	cis	rs9951698	0.678	rs565832	ENSG00000266969.1	RP11-773H22.4	4.33	2.09e-05	0.00629	0.33	0.26	Intelligence (multi-trait analysis);	chr18:13070931	chr18:12984694~12991173:-
COAD	cis	rs9532669	0.929	rs9532601	ENSG00000239827.7	SUGT1P3	-4.33	2.09e-05	0.00629	-0.22	-0.26	Cervical cancer;	chr13:40861086	chr13:40908159~40921774:-
COAD	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-4.33	2.09e-05	0.00629	-0.43	-0.26	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
COAD	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-4.33	2.1e-05	0.0063	-0.28	-0.26	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
COAD	cis	rs733317	1	rs7794503	ENSG00000226874.1	AC005154.8	-4.33	2.1e-05	0.0063	-0.31	-0.26	Left ventricular obstructive tract defect (inherited effect);	chr7:31009283	chr7:30544053~30544431:+
COAD	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	4.33	2.1e-05	0.0063	0.33	0.26	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
COAD	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	4.33	2.1e-05	0.0063	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
COAD	cis	rs597539	0.616	rs10896386	ENSG00000255741.1	RP11-757G1.5	-4.33	2.1e-05	0.0063	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68941503~68942852:-
COAD	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-4.33	2.1e-05	0.0063	-0.36	-0.26	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
COAD	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	4.33	2.1e-05	0.00631	0.24	0.26	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
COAD	cis	rs9307551	0.744	rs10004226	ENSG00000250334.4	LINC00989	-4.33	2.1e-05	0.00631	-0.3	-0.26	Refractive error;	chr4:79569654	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.817	rs12507160	ENSG00000250334.4	LINC00989	-4.33	2.1e-05	0.00631	-0.3	-0.26	Refractive error;	chr4:79573647	chr4:79492416~79576460:+
COAD	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-4.33	2.1e-05	0.00631	-0.42	-0.26	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
COAD	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-4.33	2.1e-05	0.00632	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
COAD	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-4.33	2.1e-05	0.00632	-0.31	-0.26	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
COAD	cis	rs7555523	0.779	rs2790049	ENSG00000224358.1	RP11-466F5.8	-4.33	2.1e-05	0.00632	-0.53	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165774286	chr1:165768929~165775176:+
COAD	cis	rs2337406	0.539	rs2583290	ENSG00000274576.2	IGHV2-70	4.33	2.11e-05	0.00632	0.23	0.26	Alzheimer's disease (late onset);	chr14:106650277	chr14:106770577~106771020:-
COAD	cis	rs10129255	0.5	rs2105991	ENSG00000211967.3	IGHV3-53	-4.33	2.11e-05	0.00632	-0.15	-0.26	Kawasaki disease;	chr14:106682022	chr14:106592676~106593347:-
COAD	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-4.33	2.11e-05	0.00632	-0.3	-0.26	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
COAD	cis	rs330048	0.545	rs11249913	ENSG00000233609.3	RP11-62H7.2	-4.33	2.11e-05	0.00632	-0.32	-0.26	Systemic lupus erythematosus;	chr8:9286011	chr8:8961200~8979025:+
COAD	cis	rs733317	0.731	rs10251425	ENSG00000226874.1	AC005154.8	-4.33	2.11e-05	0.00632	-0.3	-0.26	Left ventricular obstructive tract defect (inherited effect);	chr7:30988648	chr7:30544053~30544431:+
COAD	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	4.33	2.11e-05	0.00632	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	4.33	2.11e-05	0.00632	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
COAD	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	4.33	2.11e-05	0.00633	0.3	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
COAD	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-4.33	2.11e-05	0.00633	-0.29	-0.26	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
COAD	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-4.33	2.11e-05	0.00633	-0.31	-0.26	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
COAD	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	4.33	2.11e-05	0.00633	0.45	0.26	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
COAD	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	4.33	2.11e-05	0.00633	0.28	0.26	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
COAD	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-4.33	2.11e-05	0.00634	-0.24	-0.26	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
COAD	cis	rs2337406	1	rs79452530	ENSG00000211974.3	IGHV2-70	-4.33	2.11e-05	0.00634	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106699992	chr14:106723574~106724093:-
COAD	cis	rs7818688	0.614	rs59521030	ENSG00000253528.2	RP11-347C18.4	-4.33	2.11e-05	0.00634	-0.35	-0.26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94848075	chr8:94974573~94974853:-
COAD	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	4.33	2.11e-05	0.00634	0.29	0.26	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	4.33	2.11e-05	0.00634	0.29	0.26	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
COAD	cis	rs4767364	0.569	rs1468253	ENSG00000257595.2	RP3-473L9.4	-4.33	2.11e-05	0.00634	-0.38	-0.26	Oral cavity and pharyngeal cancer;	chr12:112338238	chr12:111369282~111403310:+
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-4.33	2.11e-05	0.00634	-0.32	-0.26	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
COAD	cis	rs7674212	0.581	rs11946020	ENSG00000248971.2	KRT8P46	-4.33	2.11e-05	0.00634	-0.27	-0.26	Type 2 diabetes;	chr4:103023585	chr4:102728746~102730171:-
COAD	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	4.33	2.12e-05	0.00635	0.21	0.26	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
COAD	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-4.33	2.12e-05	0.00635	-0.28	-0.26	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
COAD	cis	rs4704187	0.687	rs10079346	ENSG00000250889.2	LINC01336	-4.33	2.12e-05	0.00635	-0.3	-0.26	Response to amphetamines;	chr5:75240830	chr5:75047719~75052843:-
COAD	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	4.33	2.12e-05	0.00635	0.31	0.26	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
COAD	cis	rs453301	0.653	rs2956244	ENSG00000254340.1	RP11-10A14.3	4.33	2.12e-05	0.00635	0.31	0.26	Joint mobility (Beighton score);	chr8:9027656	chr8:9141424~9145435:+
COAD	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	4.33	2.12e-05	0.00636	0.26	0.26	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
COAD	cis	rs6840360	0.692	rs1838043	ENSG00000251611.1	RP11-610P16.1	-4.33	2.12e-05	0.00636	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151490310	chr4:151407551~151408835:-
COAD	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-4.33	2.12e-05	0.00636	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
COAD	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-4.33	2.12e-05	0.00636	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
COAD	cis	rs9951698	0.678	rs473580	ENSG00000266969.1	RP11-773H22.4	4.33	2.12e-05	0.00636	0.33	0.26	Intelligence (multi-trait analysis);	chr18:13059495	chr18:12984694~12991173:-
COAD	cis	rs4820539	1	rs2267002	ENSG00000211644.2	IGLV1-51	-4.33	2.12e-05	0.00636	-0.15	-0.26	Bone mineral density;	chr22:23114515	chr22:22322472~22322980:+
COAD	cis	rs9487051	0.872	rs9487033	ENSG00000219700.1	PTCHD3P3	-4.33	2.12e-05	0.00636	-0.28	-0.26	Reticulocyte fraction of red cells;	chr6:109284185	chr6:109288571~109290503:-
COAD	cis	rs4819052	0.851	rs2838867	ENSG00000227039.5	ITGB2-AS1	-4.33	2.12e-05	0.00637	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:44921051~44929678:+
COAD	cis	rs2378497	0.877	rs12129517	ENSG00000232679.1	RP11-400N13.3	4.33	2.12e-05	0.00637	0.37	0.26	Serum thyroid-stimulating hormone levels;	chr1:221984959	chr1:222041705~222064763:-
COAD	cis	rs2378497	1	rs56054113	ENSG00000232679.1	RP11-400N13.3	4.33	2.12e-05	0.00637	0.37	0.26	Serum thyroid-stimulating hormone levels;	chr1:221987052	chr1:222041705~222064763:-
COAD	cis	rs728616	0.867	rs56008106	ENSG00000225484.5	NUTM2B-AS1	-4.33	2.12e-05	0.00637	-0.52	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79663088~79826594:-
COAD	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-4.33	2.13e-05	0.00638	-0.32	-0.26	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
COAD	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-4.33	2.13e-05	0.00638	-0.28	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
COAD	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-4.33	2.13e-05	0.00638	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-4.33	2.13e-05	0.00638	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
COAD	cis	rs17772222	0.958	rs74074098	ENSG00000258789.1	RP11-507K2.3	-4.33	2.13e-05	0.00638	-0.38	-0.26	Coronary artery calcification;	chr14:88484213	chr14:88551597~88552493:+
COAD	cis	rs8177876	0.822	rs9923732	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9925940	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9925943	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9933184	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9926174	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.642	rs8052490	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00638	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81030770~81031485:+
COAD	cis	rs180730	1	rs1450479	ENSG00000251609.2	SETP12	4.33	2.13e-05	0.00639	0.39	0.26	Fasting plasma glucose;	chr4:120916718	chr4:120895494~120897083:-
COAD	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	4.33	2.13e-05	0.00639	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	4.33	2.13e-05	0.00639	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	4.33	2.13e-05	0.00639	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
COAD	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00639	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs79926943	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00639	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-4.33	2.13e-05	0.00639	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
COAD	cis	rs2559856	0.967	rs2695290	ENSG00000199933.1	RNY1P16	-4.33	2.13e-05	0.00639	-0.28	-0.26	Blood protein levels;	chr12:101694066	chr12:101719808~101719918:+
COAD	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.33	2.14e-05	0.00639	0.42	0.26	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.33	2.14e-05	0.00639	0.42	0.26	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.33	2.14e-05	0.00639	0.42	0.26	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.33	2.14e-05	0.00639	0.42	0.26	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
COAD	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	4.33	2.14e-05	0.0064	0.49	0.26	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
COAD	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	4.33	2.14e-05	0.00641	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
COAD	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	4.33	2.14e-05	0.00641	0.28	0.26	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-4.33	2.14e-05	0.00641	-0.31	-0.26	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
COAD	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	4.33	2.14e-05	0.00641	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
COAD	cis	rs2732480	0.577	rs2634680	ENSG00000257735.1	RP11-370I10.6	4.33	2.14e-05	0.00641	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2634678	ENSG00000257735.1	RP11-370I10.6	4.33	2.14e-05	0.00641	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2732479	ENSG00000257735.1	RP11-370I10.6	4.33	2.14e-05	0.00641	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.537	rs1061986	ENSG00000257735.1	RP11-370I10.6	4.33	2.14e-05	0.00641	0.34	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2634684	ENSG00000226413.2	OR8T1P	-4.33	2.14e-05	0.00642	-0.33	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48442030~48442947:-
COAD	cis	rs1150668	0.799	rs9301	ENSG00000272009.1	RP1-313I6.12	4.33	2.14e-05	0.00642	0.29	0.26	Pubertal anthropometrics;	chr6:28324929	chr6:28078792~28081130:-
COAD	cis	rs1150668	0.799	rs853684	ENSG00000272009.1	RP1-313I6.12	4.33	2.14e-05	0.00642	0.29	0.26	Pubertal anthropometrics;	chr6:28326773	chr6:28078792~28081130:-
COAD	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	4.33	2.14e-05	0.00642	0.3	0.26	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
COAD	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-4.33	2.14e-05	0.00642	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
COAD	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	4.33	2.15e-05	0.00642	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
COAD	cis	rs6840360	0.692	rs4479686	ENSG00000251611.1	RP11-610P16.1	-4.33	2.15e-05	0.00642	-0.26	-0.26	Intelligence (multi-trait analysis);	chr4:151478172	chr4:151407551~151408835:-
COAD	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-4.33	2.15e-05	0.00642	-0.41	-0.26	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
COAD	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-4.33	2.15e-05	0.00642	-0.41	-0.26	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
COAD	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-4.33	2.15e-05	0.00642	-0.41	-0.26	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
COAD	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-4.33	2.15e-05	0.00643	-0.48	-0.26	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
COAD	cis	rs879620	0.929	rs2238435	ENSG00000262185.1	RP11-462G12.1	-4.33	2.15e-05	0.00643	-0.32	-0.26	Hip circumference;Body mass index;	chr16:3964281	chr16:3947609~3950444:-
COAD	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-4.33	2.15e-05	0.00643	-0.32	-0.26	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
COAD	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-4.33	2.15e-05	0.00643	-0.32	-0.26	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
COAD	cis	rs62362510	0.535	rs3797642	ENSG00000264391.2	RN7SL208P	4.33	2.15e-05	0.00643	0.46	0.26	Morning vs. evening chronotype;	chr5:77453101	chr5:76836900~76837195:-
COAD	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	4.33	2.15e-05	0.00643	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
COAD	cis	rs9813712	0.526	rs62281641	ENSG00000249846.5	RP11-77P16.4	-4.33	2.15e-05	0.00643	-0.3	-0.26	Response to amphetamines;	chr3:130235668	chr3:130112550~130120579:+
COAD	cis	rs8141529	0.732	rs3788409	ENSG00000272858.1	CTA-292E10.8	-4.33	2.15e-05	0.00643	-0.3	-0.26	Lymphocyte counts;	chr22:28802163	chr22:28814914~28815662:+
COAD	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	4.33	2.15e-05	0.00643	0.33	0.26	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
COAD	cis	rs12530	0.938	rs9606952	ENSG00000232218.1	RP1-149A16.16	-4.33	2.15e-05	0.00644	-0.48	-0.26	IgG glycosylation;	chr22:32425290	chr22:32386668~32386868:+
COAD	cis	rs12530	0.938	rs9606953	ENSG00000232218.1	RP1-149A16.16	-4.33	2.15e-05	0.00644	-0.48	-0.26	IgG glycosylation;	chr22:32425291	chr22:32386668~32386868:+
COAD	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.33	2.15e-05	0.00644	-0.33	-0.26	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
COAD	cis	rs6088813	0.677	rs224322	ENSG00000269202.1	RP4-614O4.12	4.33	2.15e-05	0.00644	0.26	0.26	Height;	chr20:35423251	chr20:35201747~35203288:-
COAD	cis	rs17772222	0.917	rs61986664	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88711251	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.876	rs61986665	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88711354	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs8018755	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88714249	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs8018630	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88714250	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs8020072	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88714332	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs17260408	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88715464	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs12589982	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88716861	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs8021690	ENSG00000258789.1	RP11-507K2.3	-4.33	2.15e-05	0.00644	-0.38	-0.26	Coronary artery calcification;	chr14:88717806	chr14:88551597~88552493:+
COAD	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-4.33	2.15e-05	0.00644	-0.32	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
COAD	cis	rs17772222	0.958	rs60878614	ENSG00000258789.1	RP11-507K2.3	-4.33	2.16e-05	0.00645	-0.38	-0.26	Coronary artery calcification;	chr14:88513871	chr14:88551597~88552493:+
COAD	cis	rs2564921	0.704	rs55950520	ENSG00000280417.1	RP11-5O17.1	4.33	2.16e-05	0.00645	0.28	0.26	Height;	chr3:53094335	chr3:53046166~53048122:+
COAD	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-4.33	2.16e-05	0.00645	-0.32	-0.26	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
COAD	cis	rs4657482	0.607	rs3790671	ENSG00000236364.3	RP11-525G13.2	-4.33	2.16e-05	0.00646	-0.22	-0.26	Testicular germ cell tumor;	chr1:165904085	chr1:165890795~165900683:-
COAD	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-4.33	2.16e-05	0.00646	-0.24	-0.26	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
COAD	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-4.33	2.16e-05	0.00646	-0.24	-0.26	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
COAD	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	4.33	2.16e-05	0.00646	0.28	0.26	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
COAD	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-4.33	2.16e-05	0.00646	-0.47	-0.26	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
COAD	cis	rs36052053	0.908	rs13205489	ENSG00000219700.1	PTCHD3P3	-4.33	2.16e-05	0.00646	-0.45	-0.26	Red cell distribution width;	chr6:109282207	chr6:109288571~109290503:-
COAD	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-4.33	2.16e-05	0.00647	-0.25	-0.26	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
COAD	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	4.33	2.16e-05	0.00647	0.31	0.26	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
COAD	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	4.33	2.16e-05	0.00647	0.43	0.26	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
COAD	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	4.33	2.16e-05	0.00647	0.43	0.26	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
COAD	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	4.33	2.16e-05	0.00647	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
COAD	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-4.33	2.17e-05	0.00647	-0.32	-0.26	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
COAD	cis	rs7577696	0.925	rs12474443	ENSG00000272716.1	RP11-563N4.1	-4.33	2.17e-05	0.00647	-0.27	-0.26	Inflammatory biomarkers;	chr2:32112803	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs4952249	ENSG00000272716.1	RP11-563N4.1	-4.33	2.17e-05	0.00647	-0.27	-0.26	Inflammatory biomarkers;	chr2:32118604	chr2:32165046~32165757:-
COAD	cis	rs2638953	0.777	rs11049689	ENSG00000247934.4	RP11-967K21.1	-4.33	2.17e-05	0.00647	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs61922546	ENSG00000247934.4	RP11-967K21.1	-4.33	2.17e-05	0.00647	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28163298~28190738:-
COAD	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	4.33	2.17e-05	0.00647	0.35	0.26	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
COAD	cis	rs72700829	0.531	rs12070288	ENSG00000223861.1	RP11-74C1.2	-4.33	2.17e-05	0.00648	-0.49	-0.26	Schizophrenia;	chr1:151037508	chr1:151557446~151557940:+
COAD	cis	rs13256369	1	rs10098234	ENSG00000253981.4	ALG1L13P	4.33	2.17e-05	0.00648	0.38	0.26	Obesity-related traits;	chr8:8719182	chr8:8236003~8244667:-
COAD	cis	rs13256369	1	rs10088439	ENSG00000253981.4	ALG1L13P	4.33	2.17e-05	0.00648	0.38	0.26	Obesity-related traits;	chr8:8719189	chr8:8236003~8244667:-
COAD	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	4.33	2.17e-05	0.00648	0.31	0.26	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
COAD	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-4.33	2.17e-05	0.00648	-0.29	-0.26	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
COAD	cis	rs36052053	0.908	rs71558364	ENSG00000219700.1	PTCHD3P3	4.33	2.17e-05	0.00648	0.46	0.26	Red cell distribution width;	chr6:109295036	chr6:109288571~109290503:-
COAD	cis	rs36052053	0.908	rs28360564	ENSG00000219700.1	PTCHD3P3	4.33	2.17e-05	0.00648	0.46	0.26	Red cell distribution width;	chr6:109297186	chr6:109288571~109290503:-
COAD	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.33	2.17e-05	0.00649	-0.26	-0.26	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
COAD	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-4.33	2.17e-05	0.00649	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
COAD	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-4.33	2.17e-05	0.00649	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
COAD	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-4.33	2.17e-05	0.00649	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
COAD	cis	rs12497850	0.805	rs6446198	ENSG00000225399.4	RP11-3B7.1	4.33	2.17e-05	0.00649	0.29	0.26	Parkinson's disease;	chr3:48970205	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.931	rs4072859	ENSG00000225399.4	RP11-3B7.1	4.33	2.17e-05	0.00649	0.29	0.26	Parkinson's disease;	chr3:48994772	chr3:49260085~49261316:+
COAD	cis	rs2638953	0.853	rs10506038	ENSG00000247934.4	RP11-967K21.1	4.33	2.17e-05	0.00649	0.27	0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28163298~28190738:-
COAD	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-4.33	2.17e-05	0.0065	-0.32	-0.26	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
COAD	cis	rs1670533	1	rs2290408	ENSG00000273179.1	RP11-20I20.4	-4.33	2.17e-05	0.0065	-0.33	-0.26	Recombination rate (females);	chr4:1073479	chr4:1167778~1168174:+
COAD	cis	rs8022206	0.773	rs7157185	ENSG00000259502.1	RP11-643G16.3	4.33	2.18e-05	0.0065	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67986337	chr14:67610986~67613864:+
COAD	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	4.33	2.18e-05	0.0065	0.31	0.26	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	4.33	2.18e-05	0.0065	0.31	0.26	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
COAD	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	4.33	2.18e-05	0.0065	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
COAD	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-4.33	2.18e-05	0.00651	-0.26	-0.26	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
COAD	cis	rs4819052	0.807	rs1075788	ENSG00000227039.5	ITGB2-AS1	-4.33	2.18e-05	0.00651	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:44921051~44929678:+
COAD	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-4.33	2.18e-05	0.00651	-0.31	-0.26	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
COAD	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-4.33	2.18e-05	0.00652	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
COAD	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-4.32	2.19e-05	0.00652	-0.32	-0.26	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
COAD	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	4.32	2.19e-05	0.00653	0.32	0.26	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
COAD	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-4.32	2.19e-05	0.00653	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
COAD	cis	rs9487051	0.676	rs6929438	ENSG00000219700.1	PTCHD3P3	4.32	2.19e-05	0.00653	0.28	0.26	Reticulocyte fraction of red cells;	chr6:109274303	chr6:109288571~109290503:-
COAD	cis	rs7200543	1	rs16966952	ENSG00000270580.4	PKD1P6	4.32	2.19e-05	0.00653	0.3	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15104723~15131601:-
COAD	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	4.32	2.19e-05	0.00654	0.31	0.26	Height;	chr4:55559957	chr4:55547112~55547889:+
COAD	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	4.32	2.19e-05	0.00654	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	4.32	2.19e-05	0.00654	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
COAD	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-4.32	2.19e-05	0.00654	-0.45	-0.26	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
COAD	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-4.32	2.2e-05	0.00655	-0.33	-0.26	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
COAD	cis	rs2638953	0.962	rs11049525	ENSG00000247934.4	RP11-967K21.1	-4.32	2.2e-05	0.00655	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28163298~28190738:-
COAD	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.2e-05	0.00655	-0.3	-0.26	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.2e-05	0.00655	-0.3	-0.26	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.2e-05	0.00655	-0.3	-0.26	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.2e-05	0.00655	-0.3	-0.26	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
COAD	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	4.32	2.2e-05	0.00656	0.29	0.26	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
COAD	cis	rs9393813	0.528	rs6911865	ENSG00000271755.1	RP1-153G14.4	4.32	2.2e-05	0.00656	0.3	0.26	Bipolar disorder;	chr6:27502999	chr6:27404010~27406964:-
COAD	cis	rs9907295	0.591	rs6505498	ENSG00000271013.1	AC015849.15	-4.32	2.2e-05	0.00656	-0.32	-0.26	Fibroblast growth factor basic levels;	chr17:35803047	chr17:35912635~35918010:-
COAD	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	4.32	2.2e-05	0.00656	0.33	0.26	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
COAD	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-4.32	2.2e-05	0.00657	-0.27	-0.26	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
COAD	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-4.32	2.2e-05	0.00657	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
COAD	cis	rs7138300	0.528	rs2077702	ENSG00000258053.1	CTD-2021H9.3	-4.32	2.2e-05	0.00657	-0.37	-0.26	Type 2 diabetes;	chr12:71054925	chr12:71047402~71118247:-
COAD	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	4.32	2.21e-05	0.00657	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
COAD	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	4.32	2.21e-05	0.00657	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
COAD	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-4.32	2.21e-05	0.00657	-0.27	-0.26	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
COAD	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	4.32	2.21e-05	0.00657	0.16	0.26	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
COAD	cis	rs6088813	0.635	rs6088792	ENSG00000269202.1	RP4-614O4.12	4.32	2.21e-05	0.00658	0.26	0.26	Height;	chr20:35321981	chr20:35201747~35203288:-
COAD	cis	rs34792	0.637	rs1684547	ENSG00000207425.1	Y_RNA	-4.32	2.21e-05	0.00658	-0.32	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:14915457~14915556:-
COAD	cis	rs742132	0.858	rs909665	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25645917	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs976958	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25649868	chr6:26321876~26322292:-
COAD	cis	rs742132	0.824	rs12528182	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25650969	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs12524760	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25651035	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs4140640	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25651422	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs2281075	ENSG00000220875.1	HIST1H3PS1	4.32	2.21e-05	0.00658	0.33	0.26	Uric acid levels;	chr6:25654759	chr6:26321876~26322292:-
COAD	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	4.32	2.21e-05	0.00658	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
COAD	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.32	2.21e-05	0.00658	0.31	0.26	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.32	2.21e-05	0.00658	0.31	0.26	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.32	2.21e-05	0.00658	0.31	0.26	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
COAD	cis	rs2638953	0.853	rs10843195	ENSG00000247934.4	RP11-967K21.1	-4.32	2.21e-05	0.00658	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10843196	ENSG00000247934.4	RP11-967K21.1	-4.32	2.21e-05	0.00658	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28163298~28190738:-
COAD	cis	rs12497850	0.931	rs13064911	ENSG00000225399.4	RP11-3B7.1	4.32	2.21e-05	0.00658	0.29	0.26	Parkinson's disease;	chr3:48914952	chr3:49260085~49261316:+
COAD	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	4.32	2.21e-05	0.00659	0.37	0.26	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
COAD	cis	rs7200543	1	rs14347	ENSG00000270580.4	PKD1P6	4.32	2.21e-05	0.00659	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15104723~15131601:-
COAD	cis	rs2337406	1	rs61268362	ENSG00000211974.3	IGHV2-70	-4.32	2.21e-05	0.0066	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106697010	chr14:106723574~106724093:-
COAD	cis	rs4761470	0.577	rs3803070	ENSG00000258365.1	RP11-1105G2.3	-4.32	2.22e-05	0.0066	-0.32	-0.26	Estradiol plasma levels (breast cancer);	chr12:94294912	chr12:94277758~94282844:-
COAD	cis	rs5753037	0.585	rs5752962	ENSG00000279159.1	RP3-394A18.1	-4.32	2.22e-05	0.0066	-0.17	-0.26	Type 1 diabetes;	chr22:29792256	chr22:29978950~30028236:-
COAD	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	4.32	2.22e-05	0.0066	0.29	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
COAD	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	4.32	2.22e-05	0.0066	0.29	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
COAD	cis	rs8002861	1	rs8002861	ENSG00000274001.1	RP11-5G9.5	4.32	2.22e-05	0.0066	0.23	0.26	Leprosy;	chr13:43900381	chr13:43877715~43878163:-
COAD	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	4.32	2.22e-05	0.0066	0.42	0.26	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
COAD	cis	rs3752645	1	rs28610544	ENSG00000241764.3	AC002467.7	4.32	2.22e-05	0.00661	0.42	0.26	Bladder cancer (smoking interaction);	chr7:107131258	chr7:107742817~107744581:-
COAD	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	4.32	2.22e-05	0.00661	0.36	0.26	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
COAD	cis	rs7688540	0.76	rs4510422	ENSG00000211553.1	AC253576.2	-4.32	2.22e-05	0.00661	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:136461~136568:+
COAD	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-4.32	2.22e-05	0.00661	-0.2	-0.26	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
COAD	cis	rs739496	0.615	rs649406	ENSG00000257595.2	RP3-473L9.4	4.32	2.22e-05	0.00661	0.38	0.26	Platelet count;	chr12:111688261	chr12:111369282~111403310:+
COAD	cis	rs12928939	0.518	rs12445564	ENSG00000260886.1	TAT-AS1	4.32	2.22e-05	0.00661	0.39	0.26	Post bronchodilator FEV1;	chr16:71909406	chr16:71565789~71578187:+
COAD	cis	rs6723226	0.732	rs390480	ENSG00000276334.1	AL133243.1	-4.32	2.22e-05	0.00661	-0.24	-0.26	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32521927~32523547:+
COAD	cis	rs9532669	0.89	rs9525417	ENSG00000239827.7	SUGT1P3	-4.32	2.22e-05	0.00662	-0.23	-0.26	Cervical cancer;	chr13:40878431	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.89	rs9532638	ENSG00000239827.7	SUGT1P3	-4.32	2.22e-05	0.00662	-0.23	-0.26	Cervical cancer;	chr13:40878471	chr13:40908159~40921774:-
COAD	cis	rs253959	0.629	rs10054121	ENSG00000271918.1	CTD-2287O16.5	4.32	2.22e-05	0.00662	0.22	0.26	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116083807~116085416:-
COAD	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	4.32	2.23e-05	0.00663	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
COAD	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.32	2.23e-05	0.00663	-0.32	-0.26	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
COAD	cis	rs2337406	0.706	rs74090742	ENSG00000211974.3	IGHV2-70	-4.32	2.23e-05	0.00663	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106696601	chr14:106723574~106724093:-
COAD	cis	rs2638953	0.962	rs11049517	ENSG00000247934.4	RP11-967K21.1	-4.32	2.23e-05	0.00663	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28163298~28190738:-
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	4.32	2.23e-05	0.00663	0.24	0.26	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
COAD	cis	rs2581828	0.608	rs9868263	ENSG00000280417.1	RP11-5O17.1	4.32	2.23e-05	0.00663	0.28	0.26	Crohn's disease;	chr3:53130078	chr3:53046166~53048122:+
COAD	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4.32	2.23e-05	0.00663	-0.37	-0.26	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
COAD	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-4.32	2.23e-05	0.00663	-0.31	-0.26	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
COAD	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	4.32	2.23e-05	0.00663	0.3	0.26	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
COAD	cis	rs989978	0.958	rs1332102	ENSG00000257582.4	LINC01475	-4.32	2.23e-05	0.00664	-0.3	-0.26	Red blood cell count;	chr10:99564679	chr10:99526350~99531177:-
COAD	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	4.32	2.23e-05	0.00664	0.34	0.26	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
COAD	cis	rs860295	1	rs708611	ENSG00000203761.5	MSTO2P	4.32	2.23e-05	0.00664	0.23	0.26	Body mass index;	chr1:155773519	chr1:155745829~155750137:+
COAD	cis	rs7630852	0.965	rs6774504	ENSG00000272359.1	U4	4.32	2.23e-05	0.00664	0.3	0.26	Eosinophil counts;	chr3:196784021	chr3:196747192~196747324:-
COAD	cis	rs860295	1	rs822527	ENSG00000203761.5	MSTO2P	4.32	2.23e-05	0.00664	0.23	0.26	Body mass index;	chr1:155768262	chr1:155745829~155750137:+
COAD	cis	rs597539	0.652	rs496616	ENSG00000255741.1	RP11-757G1.5	-4.32	2.24e-05	0.00665	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68941503~68942852:-
COAD	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-4.32	2.24e-05	0.00665	-0.33	-0.26	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
COAD	cis	rs1949733	1	rs3103099	ENSG00000205959.3	RP11-689P11.2	4.32	2.24e-05	0.00665	0.32	0.26	Response to antineoplastic agents;	chr4:8509840	chr4:8482270~8512610:+
COAD	cis	rs9487051	0.676	rs13210693	ENSG00000219700.1	PTCHD3P3	-4.32	2.24e-05	0.00666	-0.28	-0.26	Reticulocyte fraction of red cells;	chr6:109277761	chr6:109288571~109290503:-
COAD	cis	rs2281603	0.762	rs10130241	ENSG00000259116.1	RP11-973N13.4	-4.32	2.24e-05	0.00666	-0.28	-0.26	Lymphocyte counts;	chr14:64577402	chr14:64514154~64540368:-
COAD	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	4.32	2.24e-05	0.00666	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
COAD	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	4.32	2.24e-05	0.00666	0.3	0.26	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
COAD	cis	rs2337406	0.778	rs56965016	ENSG00000211964.3	IGHV3-48	-4.32	2.24e-05	0.00666	-0.22	-0.26	Alzheimer's disease (late onset);	chr14:106656649	chr14:106537810~106538344:-
COAD	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-4.32	2.24e-05	0.00666	-0.3	-0.26	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
COAD	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	4.32	2.24e-05	0.00666	0.29	0.26	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	4.32	2.24e-05	0.00666	0.29	0.26	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	4.32	2.24e-05	0.00666	0.29	0.26	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	4.32	2.24e-05	0.00666	0.29	0.26	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
COAD	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	4.32	2.24e-05	0.00666	0.16	0.26	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
COAD	cis	rs812925	0.519	rs2922089	ENSG00000273302.1	RP11-493E12.2	-4.32	2.24e-05	0.00666	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61397994	chr2:61199979~61200769:+
COAD	cis	rs812925	0.519	rs2694627	ENSG00000273302.1	RP11-493E12.2	-4.32	2.24e-05	0.00666	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61398371	chr2:61199979~61200769:+
COAD	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-4.32	2.24e-05	0.00666	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
COAD	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	4.32	2.24e-05	0.00667	0.29	0.26	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	4.32	2.24e-05	0.00667	0.29	0.26	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	4.32	2.24e-05	0.00667	0.29	0.26	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
COAD	cis	rs8022206	0.773	rs28403941	ENSG00000259502.1	RP11-643G16.3	4.32	2.24e-05	0.00667	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68009025	chr14:67610986~67613864:+
COAD	cis	rs7615952	0.546	rs2979333	ENSG00000248787.1	RP11-666A20.4	-4.32	2.24e-05	0.00667	-0.4	-0.26	Blood pressure (smoking interaction);	chr3:125641499	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs111812401	ENSG00000248787.1	RP11-666A20.4	-4.32	2.24e-05	0.00667	-0.4	-0.26	Blood pressure (smoking interaction);	chr3:125642651	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.546	rs2979350	ENSG00000248787.1	RP11-666A20.4	-4.32	2.24e-05	0.00667	-0.4	-0.26	Blood pressure (smoking interaction);	chr3:125643371	chr3:125908005~125910272:-
COAD	cis	rs2337406	0.85	rs8014460	ENSG00000211974.3	IGHV2-70	-4.32	2.24e-05	0.00667	-0.29	-0.26	Alzheimer's disease (late onset);	chr14:106697140	chr14:106723574~106724093:-
COAD	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-4.32	2.24e-05	0.00667	-0.23	-0.26	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
COAD	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-4.32	2.24e-05	0.00667	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
COAD	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	4.32	2.25e-05	0.00667	0.47	0.26	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
COAD	cis	rs893363	0.522	rs2241808	ENSG00000271916.1	RP11-884K10.6	-4.32	2.25e-05	0.00667	-0.25	-0.26	Axial length;	chr3:53822626	chr3:53797764~53798019:-
COAD	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-4.32	2.25e-05	0.00667	-0.38	-0.26	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
COAD	cis	rs6903823	0.508	rs1778484	ENSG00000272009.1	RP1-313I6.12	4.32	2.25e-05	0.00668	0.29	0.26	Pulmonary function;	chr6:28273021	chr6:28078792~28081130:-
COAD	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-4.32	2.25e-05	0.00668	-0.49	-0.26	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-4.32	2.25e-05	0.00668	-0.49	-0.26	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
COAD	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-4.32	2.25e-05	0.00668	-0.49	-0.26	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-4.32	2.25e-05	0.00668	-0.49	-0.26	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
COAD	cis	rs9291683	0.509	rs10939671	ENSG00000250413.1	RP11-448G15.1	-4.32	2.25e-05	0.00668	-0.34	-0.26	Bone mineral density;	chr4:10049191	chr4:10006482~10009725:+
COAD	cis	rs11841001	0.556	rs1470273	ENSG00000261105.4	LMO7-AS1	-4.32	2.25e-05	0.00668	-0.47	-0.26	Corneal astigmatism;	chr13:75768241	chr13:75604700~75635994:-
COAD	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-4.32	2.25e-05	0.00668	-0.47	-0.26	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
COAD	cis	rs7760535	0.763	rs10457241	ENSG00000271789.1	RP5-1112D6.7	-4.32	2.25e-05	0.00668	-0.26	-0.26	Metabolic traits;	chr6:111527831	chr6:111297126~111298510:+
COAD	cis	rs2333021	0.934	rs12879195	ENSG00000259015.1	RP11-109N23.6	4.32	2.25e-05	0.00669	0.24	0.26	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:72960595~72961993:+
COAD	cis	rs1044826	0.642	rs407958	ENSG00000272656.1	RP11-219D15.3	4.32	2.25e-05	0.00669	0.31	0.26	Obesity-related traits;	chr3:139494790	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs176983	ENSG00000272656.1	RP11-219D15.3	4.32	2.25e-05	0.00669	0.31	0.26	Obesity-related traits;	chr3:139494913	chr3:139349024~139349371:-
COAD	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-4.32	2.25e-05	0.00669	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
COAD	cis	rs453301	0.658	rs6986044	ENSG00000254340.1	RP11-10A14.3	-4.32	2.25e-05	0.00669	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9017276	chr8:9141424~9145435:+
COAD	cis	rs1670533	0.585	rs6827206	ENSG00000273179.1	RP11-20I20.4	4.32	2.25e-05	0.00669	0.33	0.26	Recombination rate (females);	chr4:1071283	chr4:1167778~1168174:+
COAD	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-4.32	2.25e-05	0.00669	-0.19	-0.26	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
COAD	cis	rs2732480	0.538	rs2732462	ENSG00000273765.1	RP11-370I10.11	4.32	2.25e-05	0.00669	0.3	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48360920~48361377:+
COAD	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-4.32	2.25e-05	0.00669	-0.17	-0.26	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
COAD	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	4.32	2.25e-05	0.00669	0.27	0.26	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
COAD	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	4.32	2.26e-05	0.00669	0.3	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
COAD	cis	rs1044826	0.642	rs295470	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139495061	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.667	rs295471	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139495080	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs295473	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139496743	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs7624321	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139501317	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs295478	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139504293	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs295479	ENSG00000272656.1	RP11-219D15.3	4.32	2.26e-05	0.0067	0.31	0.26	Obesity-related traits;	chr3:139505023	chr3:139349024~139349371:-
COAD	cis	rs2638953	0.962	rs11049530	ENSG00000247934.4	RP11-967K21.1	-4.32	2.26e-05	0.0067	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049531	ENSG00000247934.4	RP11-967K21.1	-4.32	2.26e-05	0.0067	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28163298~28190738:-
COAD	cis	rs9532669	0.926	rs7997560	ENSG00000239827.7	SUGT1P3	-4.32	2.26e-05	0.0067	-0.23	-0.26	Cervical cancer;	chr13:40878723	chr13:40908159~40921774:-
COAD	cis	rs1510272	0.847	rs6441085	ENSG00000243926.1	TIPARP-AS1	-4.32	2.26e-05	0.0067	-0.3	-0.26	Testicular germ cell tumor;	chr3:156607673	chr3:156671862~156674378:-
COAD	cis	rs1510272	0.847	rs12492935	ENSG00000243926.1	TIPARP-AS1	-4.32	2.26e-05	0.0067	-0.3	-0.26	Testicular germ cell tumor;	chr3:156610164	chr3:156671862~156674378:-
COAD	cis	rs1510272	0.842	rs2048337	ENSG00000243926.1	TIPARP-AS1	-4.32	2.26e-05	0.0067	-0.3	-0.26	Testicular germ cell tumor;	chr3:156610306	chr3:156671862~156674378:-
COAD	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	4.32	2.26e-05	0.0067	0.38	0.26	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
COAD	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.32	2.26e-05	0.0067	0.32	0.26	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
COAD	cis	rs11168351	0.833	rs6580652	ENSG00000273765.1	RP11-370I10.11	-4.32	2.26e-05	0.0067	-0.27	-0.26	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48360920~48361377:+
COAD	cis	rs8022206	0.738	rs10151115	ENSG00000259502.1	RP11-643G16.3	4.32	2.26e-05	0.0067	0.36	0.26	Platelet count;Mean platelet volume;	chr14:68069355	chr14:67610986~67613864:+
COAD	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-4.32	2.26e-05	0.0067	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
COAD	cis	rs4718428	0.705	rs4717331	ENSG00000272831.1	RP11-792A8.4	4.32	2.26e-05	0.00671	0.29	0.26	Corneal structure;	chr7:66913899	chr7:66739829~66740385:-
COAD	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-4.32	2.26e-05	0.00671	-0.26	-0.26	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
COAD	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-4.32	2.26e-05	0.00671	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
COAD	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-4.32	2.26e-05	0.00671	-0.27	-0.26	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
COAD	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.32	2.26e-05	0.00671	0.34	0.26	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
COAD	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-4.32	2.26e-05	0.00672	-0.23	-0.26	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
COAD	cis	rs2732480	0.967	rs2732469	ENSG00000240399.1	RP1-228P16.1	4.32	2.26e-05	0.00672	0.25	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48054813~48055591:-
COAD	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-4.32	2.27e-05	0.00672	-0.29	-0.26	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
COAD	cis	rs36052053	0.522	rs74997551	ENSG00000219700.1	PTCHD3P3	4.32	2.27e-05	0.00672	0.53	0.26	Red cell distribution width;	chr6:109308440	chr6:109288571~109290503:-
COAD	cis	rs875971	0.66	rs7807930	ENSG00000272831.1	RP11-792A8.4	-4.32	2.27e-05	0.00672	-0.28	-0.26	Aortic root size;	chr7:66622178	chr7:66739829~66740385:-
COAD	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-4.32	2.27e-05	0.00672	-0.32	-0.26	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-4.32	2.27e-05	0.00672	-0.32	-0.26	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
COAD	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	4.32	2.27e-05	0.00672	0.27	0.26	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
COAD	cis	rs812925	0.519	rs2463099	ENSG00000273302.1	RP11-493E12.2	-4.32	2.27e-05	0.00672	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61391176	chr2:61199979~61200769:+
COAD	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	4.32	2.27e-05	0.00673	0.33	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
COAD	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	4.32	2.27e-05	0.00673	0.32	0.26	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
COAD	cis	rs2281603	0.674	rs74883409	ENSG00000259116.1	RP11-973N13.4	-4.32	2.27e-05	0.00673	-0.28	-0.26	Lymphocyte counts;	chr14:64594361	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	4.32	2.27e-05	0.00673	0.29	0.26	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
COAD	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-4.32	2.27e-05	0.00673	-0.27	-0.26	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
COAD	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	4.32	2.27e-05	0.00673	0.27	0.26	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
COAD	cis	rs41294858	1	rs41294854	ENSG00000232876.1	CTA-212D2.2	-4.32	2.27e-05	0.00673	-0.49	-0.26	Red blood cell count;	chr6:135080233	chr6:135055033~135060550:+
COAD	cis	rs41294858	1	rs75375208	ENSG00000232876.1	CTA-212D2.2	-4.32	2.27e-05	0.00673	-0.49	-0.26	Red blood cell count;	chr6:135081951	chr6:135055033~135060550:+
COAD	cis	rs41294858	1	rs113033196	ENSG00000232876.1	CTA-212D2.2	-4.32	2.27e-05	0.00673	-0.49	-0.26	Red blood cell count;	chr6:135082789	chr6:135055033~135060550:+
COAD	cis	rs41294858	0.908	rs79562575	ENSG00000232876.1	CTA-212D2.2	-4.32	2.27e-05	0.00673	-0.49	-0.26	Red blood cell count;	chr6:135082974	chr6:135055033~135060550:+
COAD	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	4.32	2.27e-05	0.00673	0.42	0.26	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	4.32	2.27e-05	0.00673	0.42	0.26	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
COAD	cis	rs7307902	0.504	rs11168124	ENSG00000268069.2	RP5-1057I20.4	4.32	2.27e-05	0.00673	0.3	0.26	Obesity-related traits;	chr12:47507771	chr12:47784923~47786002:+
COAD	cis	rs7577696	0.853	rs212734	ENSG00000272716.1	RP11-563N4.1	4.32	2.27e-05	0.00673	0.27	0.26	Inflammatory biomarkers;	chr2:32247684	chr2:32165046~32165757:-
COAD	cis	rs1670533	1	rs6839931	ENSG00000273179.1	RP11-20I20.4	4.32	2.27e-05	0.00673	0.34	0.26	Recombination rate (females);	chr4:1059384	chr4:1167778~1168174:+
COAD	cis	rs56052703	0.536	rs2292035	ENSG00000267633.1	CTB-5E10.3	4.32	2.27e-05	0.00674	0.29	0.26	Proteinuria and chronic kidney disease;	chr19:13316929	chr19:13772118~13774118:-
COAD	cis	rs56052703	0.536	rs2292036	ENSG00000267633.1	CTB-5E10.3	4.32	2.27e-05	0.00674	0.29	0.26	Proteinuria and chronic kidney disease;	chr19:13316950	chr19:13772118~13774118:-
COAD	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-4.32	2.27e-05	0.00674	-0.37	-0.26	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
COAD	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-4.32	2.27e-05	0.00674	-0.3	-0.26	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
COAD	cis	rs4927850	1	rs10881563	ENSG00000273009.1	RP11-352G9.1	-4.32	2.27e-05	0.00674	-0.3	-0.26	Pancreatic cancer;	chr3:196023354	chr3:195913078~195913683:-
COAD	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	4.32	2.27e-05	0.00674	0.36	0.26	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-4.32	2.28e-05	0.00675	-0.3	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
COAD	cis	rs748404	0.556	rs574856	ENSG00000249839.1	AC011330.5	4.32	2.28e-05	0.00675	0.32	0.26	Lung cancer;	chr15:43168636	chr15:43663654~43684339:-
COAD	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-4.32	2.28e-05	0.00675	-0.4	-0.26	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
COAD	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-4.31	2.28e-05	0.00676	-0.33	-0.26	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
COAD	cis	rs6545883	0.56	rs11677776	ENSG00000273302.1	RP11-493E12.2	-4.31	2.28e-05	0.00676	-0.24	-0.26	Tuberculosis;	chr2:61275978	chr2:61199979~61200769:+
COAD	cis	rs11079159	0.848	rs17817923	ENSG00000263096.1	RP11-515O17.2	4.31	2.28e-05	0.00676	0.34	0.26	QRS duration;	chr17:55310516	chr17:55271504~55273653:-
COAD	cis	rs2378497	1	rs56236427	ENSG00000232679.1	RP11-400N13.3	4.31	2.28e-05	0.00676	0.37	0.26	Serum thyroid-stimulating hormone levels;	chr1:221988852	chr1:222041705~222064763:-
COAD	cis	rs7615952	0.512	rs4679430	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125639049	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs34651730	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125639796	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs2979334	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125639980	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs11929125	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125640599	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs11921452	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125640906	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs2922175	ENSG00000248787.1	RP11-666A20.4	-4.31	2.28e-05	0.00676	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125642516	chr3:125908005~125910272:-
COAD	cis	rs7818688	0.614	rs11783589	ENSG00000253528.2	RP11-347C18.4	-4.31	2.28e-05	0.00676	-0.36	-0.26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94833736	chr8:94974573~94974853:-
COAD	cis	rs17359493	0.708	rs11783941	ENSG00000253528.2	RP11-347C18.4	-4.31	2.28e-05	0.00676	-0.34	-0.26	Type 2 diabetes;	chr8:94891967	chr8:94974573~94974853:-
COAD	cis	rs10895987	0.83	rs12292693	ENSG00000254614.2	AP003068.23	-4.31	2.28e-05	0.00676	-0.39	-0.26	Blood protein levels;	chr11:65169248	chr11:65177606~65181834:-
COAD	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	4.31	2.28e-05	0.00677	0.32	0.26	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
COAD	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-4.31	2.29e-05	0.00677	-0.26	-0.26	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
COAD	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	4.31	2.29e-05	0.00677	0.3	0.26	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
COAD	cis	rs2581828	0.618	rs6792345	ENSG00000280417.1	RP11-5O17.1	4.31	2.29e-05	0.00677	0.29	0.26	Crohn's disease;	chr3:53131178	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.618	rs6792363	ENSG00000280417.1	RP11-5O17.1	4.31	2.29e-05	0.00677	0.29	0.26	Crohn's disease;	chr3:53131247	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.618	rs6445565	ENSG00000280417.1	RP11-5O17.1	4.31	2.29e-05	0.00677	0.29	0.26	Crohn's disease;	chr3:53131448	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.618	rs6784207	ENSG00000280417.1	RP11-5O17.1	4.31	2.29e-05	0.00677	0.29	0.26	Crohn's disease;	chr3:53133458	chr3:53046166~53048122:+
COAD	cis	rs11098499	0.738	rs28687057	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119359657	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.775	rs67281037	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119360002	chr4:119391831~119395335:-
COAD	cis	rs10028773	0.506	rs12374346	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Educational attainment;	chr4:119360550	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs12374244	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119360817	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs12374352	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119360822	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs6857892	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119361541	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28581362	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119362393	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.82	rs12503082	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119363162	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs12499602	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119363232	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.774	rs11098505	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119363472	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs6824111	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119364813	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.775	rs10029303	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119365600	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs9995136	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119365690	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs13125526	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119366864	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs12513310	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119366884	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.564	rs11098507	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119367131	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs12510451	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119367988	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.774	rs73842616	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119369528	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.645	rs72676059	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119369673	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.569	rs55845118	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119369758	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs7677068	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119370549	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.866	rs9991221	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00677	0.34	0.26	Corneal astigmatism;	chr4:119370952	chr4:119391831~119395335:-
COAD	cis	rs2732480	0.577	rs2732481	ENSG00000257735.1	RP11-370I10.6	4.31	2.29e-05	0.00677	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.557	rs2732484	ENSG00000257735.1	RP11-370I10.6	4.31	2.29e-05	0.00677	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2732486	ENSG00000257735.1	RP11-370I10.6	4.31	2.29e-05	0.00677	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.517	rs2634676	ENSG00000257735.1	RP11-370I10.6	4.31	2.29e-05	0.00677	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48350945~48442411:+
COAD	cis	rs3752645	0.764	rs76270442	ENSG00000241764.3	AC002467.7	4.31	2.29e-05	0.00677	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107048809	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs76214791	ENSG00000241764.3	AC002467.7	4.31	2.29e-05	0.00677	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107048976	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs9641372	ENSG00000241764.3	AC002467.7	4.31	2.29e-05	0.00677	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107051041	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs79184476	ENSG00000241764.3	AC002467.7	4.31	2.29e-05	0.00677	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107053225	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs58386564	ENSG00000241764.3	AC002467.7	4.31	2.29e-05	0.00677	0.53	0.26	Bladder cancer (smoking interaction);	chr7:107053829	chr7:107742817~107744581:-
COAD	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-4.31	2.29e-05	0.00677	-0.39	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
COAD	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	4.31	2.29e-05	0.00677	0.27	0.26	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
COAD	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	4.31	2.29e-05	0.00678	0.35	0.26	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
COAD	cis	rs763121	0.853	rs5750626	ENSG00000273076.1	RP3-508I15.22	4.31	2.29e-05	0.00678	0.24	0.26	Menopause (age at onset);	chr22:38581885	chr22:38743495~38743910:+
COAD	cis	rs673078	0.562	rs61944672	ENSG00000275409.1	RP11-131L12.4	-4.31	2.29e-05	0.00678	-0.52	-0.26	Glucose homeostasis traits;	chr12:118450123	chr12:118430147~118430699:+
COAD	cis	rs180730	1	rs180730	ENSG00000251609.2	SETP12	-4.31	2.29e-05	0.00678	-0.38	-0.26	Fasting plasma glucose;	chr4:120880635	chr4:120895494~120897083:-
COAD	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-4.31	2.29e-05	0.00678	-0.27	-0.26	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
COAD	cis	rs7138300	0.528	rs12366662	ENSG00000258053.1	CTD-2021H9.3	-4.31	2.29e-05	0.00678	-0.36	-0.26	Type 2 diabetes;	chr12:71067597	chr12:71047402~71118247:-
COAD	cis	rs7138300	0.51	rs10506624	ENSG00000258053.1	CTD-2021H9.3	-4.31	2.29e-05	0.00678	-0.36	-0.26	Type 2 diabetes;	chr12:71076591	chr12:71047402~71118247:-
COAD	cis	rs2836974	0.644	rs2410123	ENSG00000255568.3	BRWD1-AS2	-4.31	2.29e-05	0.00678	-0.25	-0.26	Cognitive function;	chr21:39328167	chr21:39313935~39314962:+
COAD	cis	rs9450351	1	rs7774219	ENSG00000203875.9	SNHG5	-4.31	2.29e-05	0.00678	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85908837	chr6:85660950~85678736:-
COAD	cis	rs8046148	0.666	rs10852606	ENSG00000260381.2	RP11-429P3.5	-4.31	2.29e-05	0.00679	-0.34	-0.26	Testicular germ cell tumor;	chr16:50094961	chr16:50100339~50121943:-
COAD	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-4.31	2.29e-05	0.00679	-0.27	-0.26	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
COAD	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-4.31	2.3e-05	0.0068	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
COAD	cis	rs58873874	0.579	rs10040318	ENSG00000251405.2	CTB-109A12.1	4.31	2.3e-05	0.0068	0.47	0.26	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157362615~157460078:-
COAD	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-4.31	2.3e-05	0.0068	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-4.31	2.3e-05	0.0068	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-4.31	2.3e-05	0.0068	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
COAD	cis	rs41307935	0.818	rs34339345	ENSG00000260063.1	RP5-968P14.2	-4.31	2.3e-05	0.0068	-0.56	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26899598	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.509	rs12739698	ENSG00000260063.1	RP5-968P14.2	-4.31	2.3e-05	0.0068	-0.56	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903542	chr1:26692132~26694131:-
COAD	cis	rs6461992	0.51	rs2301719	ENSG00000253405.1	EVX1-AS	4.31	2.3e-05	0.00681	0.59	0.26	Systolic blood pressure;	chr7:27030978	chr7:27241429~27247229:-
COAD	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-4.31	2.3e-05	0.00681	-0.17	-0.26	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-4.31	2.3e-05	0.00681	-0.17	-0.26	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
COAD	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-4.31	2.3e-05	0.00681	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
COAD	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-4.31	2.3e-05	0.00681	-0.28	-0.26	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
COAD	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	4.31	2.3e-05	0.00681	0.34	0.26	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	4.31	2.3e-05	0.00681	0.34	0.26	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
COAD	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	4.31	2.3e-05	0.00681	0.41	0.26	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
COAD	cis	rs7646881	0.544	rs1864502	ENSG00000272087.1	RP11-379F4.7	4.31	2.3e-05	0.00681	0.41	0.26	Tetralogy of Fallot;	chr3:158648625	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs61107068	ENSG00000272087.1	RP11-379F4.7	4.31	2.3e-05	0.00681	0.41	0.26	Tetralogy of Fallot;	chr3:158665915	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.509	rs56321207	ENSG00000272087.1	RP11-379F4.7	4.31	2.3e-05	0.00681	0.41	0.26	Tetralogy of Fallot;	chr3:158666944	chr3:158693120~158693768:-
COAD	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.31e-05	0.00682	-0.24	-0.26	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
COAD	cis	rs6095360	0.727	rs1556876	ENSG00000222365.1	SNORD12B	-4.31	2.31e-05	0.00682	-0.28	-0.26	Intelligence (multi-trait analysis);	chr20:49099914	chr20:49280319~49280409:+
COAD	cis	rs748404	0.556	rs7166467	ENSG00000249839.1	AC011330.5	4.31	2.31e-05	0.00682	0.32	0.26	Lung cancer;	chr15:43148324	chr15:43663654~43684339:-
COAD	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	4.31	2.31e-05	0.00682	0.33	0.26	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
COAD	cis	rs9307551	0.817	rs12511646	ENSG00000250334.4	LINC00989	-4.31	2.31e-05	0.00682	-0.29	-0.26	Refractive error;	chr4:79578700	chr4:79492416~79576460:+
COAD	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-4.31	2.31e-05	0.00682	-0.27	-0.26	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
COAD	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-4.31	2.31e-05	0.00682	-0.27	-0.26	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
COAD	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	4.31	2.31e-05	0.00682	0.33	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
COAD	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	4.31	2.31e-05	0.00682	0.4	0.26	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	4.31	2.31e-05	0.00682	0.4	0.26	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
COAD	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	4.31	2.31e-05	0.00682	0.5	0.26	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
COAD	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.31e-05	0.00682	-0.22	-0.26	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
COAD	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	4.31	2.31e-05	0.00682	0.4	0.26	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	4.31	2.31e-05	0.00683	0.34	0.26	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	4.31	2.31e-05	0.00683	0.34	0.26	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	4.31	2.31e-05	0.00683	0.34	0.26	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
COAD	cis	rs8046148	0.614	rs8047504	ENSG00000260381.2	RP11-429P3.5	-4.31	2.31e-05	0.00683	-0.34	-0.26	Testicular germ cell tumor;	chr16:50073724	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.54	rs59059423	ENSG00000260381.2	RP11-429P3.5	-4.31	2.31e-05	0.00683	-0.34	-0.26	Testicular germ cell tumor;	chr16:50074191	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs9939688	ENSG00000260381.2	RP11-429P3.5	-4.31	2.31e-05	0.00683	-0.34	-0.26	Testicular germ cell tumor;	chr16:50075189	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs12931497	ENSG00000260381.2	RP11-429P3.5	-4.31	2.31e-05	0.00683	-0.34	-0.26	Testicular germ cell tumor;	chr16:50075567	chr16:50100339~50121943:-
COAD	cis	rs739496	0.615	rs57072497	ENSG00000257595.2	RP3-473L9.4	4.31	2.31e-05	0.00683	0.38	0.26	Platelet count;	chr12:111707413	chr12:111369282~111403310:+
COAD	cis	rs7829975	0.714	rs60315134	ENSG00000233609.3	RP11-62H7.2	4.31	2.31e-05	0.00684	0.29	0.26	Mood instability;	chr8:8813089	chr8:8961200~8979025:+
COAD	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.32e-05	0.00684	-0.24	-0.26	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
COAD	cis	rs4704187	0.687	rs13360638	ENSG00000250889.2	LINC01336	-4.31	2.32e-05	0.00684	-0.29	-0.26	Response to amphetamines;	chr5:75137433	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1477933	ENSG00000250889.2	LINC01336	-4.31	2.32e-05	0.00684	-0.29	-0.26	Response to amphetamines;	chr5:75141328	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1422699	ENSG00000250889.2	LINC01336	-4.31	2.32e-05	0.00684	-0.29	-0.26	Response to amphetamines;	chr5:75146585	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6888707	ENSG00000250889.2	LINC01336	-4.31	2.32e-05	0.00684	-0.29	-0.26	Response to amphetamines;	chr5:75147095	chr5:75047719~75052843:-
COAD	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	4.31	2.32e-05	0.00685	0.35	0.26	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
COAD	cis	rs969413	0.624	rs7213540	ENSG00000263069.4	CTD-2047H16.4	4.31	2.32e-05	0.00685	0.22	0.26	Frontotemporal dementia;	chr17:81282112	chr17:80351828~80415168:-
COAD	cis	rs17685	0.736	rs4732594	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76043977~76045963:-
COAD	cis	rs17685	0.671	rs60303271	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76043977~76045963:-
COAD	cis	rs17685	0.735	rs11763339	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76043977~76045963:-
COAD	cis	rs17685	0.775	rs11761172	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs11764129	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76043977~76045963:-
COAD	cis	rs17685	0.816	rs11763076	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76043977~76045963:-
COAD	cis	rs17685	0.623	rs7782808	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs6953665	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs7778735	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs10275521	ENSG00000280388.1	RP11-229D13.3	-4.31	2.32e-05	0.00685	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76043977~76045963:-
COAD	cis	rs4819052	0.819	rs7279136	ENSG00000227039.5	ITGB2-AS1	-4.31	2.32e-05	0.00685	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs7276828	ENSG00000227039.5	ITGB2-AS1	-4.31	2.32e-05	0.00685	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:44921051~44929678:+
COAD	cis	rs2638953	0.962	rs3782517	ENSG00000247934.4	RP11-967K21.1	-4.31	2.32e-05	0.00685	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28163298~28190738:-
COAD	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	4.31	2.32e-05	0.00686	0.33	0.26	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
COAD	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	4.31	2.32e-05	0.00686	0.28	0.26	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
COAD	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	4.31	2.32e-05	0.00686	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
COAD	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-4.31	2.32e-05	0.00686	-0.35	-0.26	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
COAD	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	4.31	2.33e-05	0.00686	0.29	0.26	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
COAD	cis	rs2638953	0.853	rs10843179	ENSG00000247934.4	RP11-967K21.1	4.31	2.33e-05	0.00686	0.27	0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28163298~28190738:-
COAD	cis	rs9450351	0.744	rs7772723	ENSG00000203875.9	SNHG5	-4.31	2.33e-05	0.00687	-0.47	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85913980	chr6:85660950~85678736:-
COAD	cis	rs4704187	0.687	rs1477934	ENSG00000250889.2	LINC01336	-4.31	2.33e-05	0.00687	-0.29	-0.26	Response to amphetamines;	chr5:75127418	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs6897274	ENSG00000250889.2	LINC01336	-4.31	2.33e-05	0.00687	-0.29	-0.26	Response to amphetamines;	chr5:75130278	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs6862754	ENSG00000250889.2	LINC01336	-4.31	2.33e-05	0.00687	-0.29	-0.26	Response to amphetamines;	chr5:75131368	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.64	rs74719230	ENSG00000250889.2	LINC01336	-4.31	2.33e-05	0.00687	-0.29	-0.26	Response to amphetamines;	chr5:75136063	chr5:75047719~75052843:-
COAD	cis	rs36052053	0.522	rs56150455	ENSG00000219700.1	PTCHD3P3	4.31	2.33e-05	0.00687	0.53	0.26	Red cell distribution width;	chr6:109307939	chr6:109288571~109290503:-
COAD	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	4.31	2.33e-05	0.00687	0.28	0.26	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
COAD	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	4.31	2.33e-05	0.00687	0.3	0.26	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
COAD	cis	rs597539	0.615	rs629426	ENSG00000255741.1	RP11-757G1.5	-4.31	2.33e-05	0.00688	-0.35	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68941503~68942852:-
COAD	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	4.31	2.33e-05	0.00688	0.4	0.26	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
COAD	cis	rs72700829	0.531	rs955955	ENSG00000223861.1	RP11-74C1.2	-4.31	2.33e-05	0.00688	-0.51	-0.26	Schizophrenia;	chr1:151039067	chr1:151557446~151557940:+
COAD	cis	rs41271951	0.512	rs12068365	ENSG00000223861.1	RP11-74C1.2	-4.31	2.33e-05	0.00688	-0.51	-0.26	Blood protein levels;	chr1:151043392	chr1:151557446~151557940:+
COAD	cis	rs41271951	0.512	rs11204765	ENSG00000223861.1	RP11-74C1.2	-4.31	2.33e-05	0.00688	-0.51	-0.26	Blood protein levels;	chr1:151044281	chr1:151557446~151557940:+
COAD	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-4.31	2.33e-05	0.00688	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-4.31	2.33e-05	0.00688	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
COAD	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-4.31	2.33e-05	0.00688	-0.31	-0.26	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
COAD	cis	rs2638953	0.962	rs11049537	ENSG00000247934.4	RP11-967K21.1	-4.31	2.33e-05	0.00688	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28163298~28190738:-
COAD	cis	rs4927850	1	rs7627706	ENSG00000273009.1	RP11-352G9.1	-4.31	2.34e-05	0.00689	-0.28	-0.26	Pancreatic cancer;	chr3:196026482	chr3:195913078~195913683:-
COAD	cis	rs4927850	0.881	rs7630489	ENSG00000273009.1	RP11-352G9.1	-4.31	2.34e-05	0.00689	-0.28	-0.26	Pancreatic cancer;	chr3:196026530	chr3:195913078~195913683:-
COAD	cis	rs4927850	1	rs7627868	ENSG00000273009.1	RP11-352G9.1	-4.31	2.34e-05	0.00689	-0.28	-0.26	Pancreatic cancer;	chr3:196026602	chr3:195913078~195913683:-
COAD	cis	rs1972460	0.506	rs62012050	ENSG00000259429.4	UBE2Q2P2	-4.31	2.34e-05	0.00689	-0.24	-0.26	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82355142~82420075:+
COAD	cis	rs6545883	0.524	rs4599092	ENSG00000273302.1	RP11-493E12.2	-4.31	2.34e-05	0.00689	-0.24	-0.26	Tuberculosis;	chr2:61271833	chr2:61199979~61200769:+
COAD	cis	rs17685	0.712	rs60232511	ENSG00000280388.1	RP11-229D13.3	-4.31	2.34e-05	0.00689	-0.27	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76043977~76045963:-
COAD	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-4.31	2.34e-05	0.00689	-0.28	-0.26	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
COAD	cis	rs1832007	0.554	rs34179396	ENSG00000224034.1	RP11-445P17.8	-4.31	2.34e-05	0.0069	-0.39	-0.26	Triglyceride levels;Triglycerides;	chr10:5278817	chr10:5266033~5271236:-
COAD	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	4.31	2.34e-05	0.0069	0.34	0.26	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
COAD	cis	rs6545883	0.507	rs10169662	ENSG00000273302.1	RP11-493E12.2	-4.31	2.34e-05	0.0069	-0.24	-0.26	Tuberculosis;	chr2:61280801	chr2:61199979~61200769:+
COAD	cis	rs11638352	1	rs4924731	ENSG00000205771.5	CATSPER2P1	4.31	2.34e-05	0.0069	0.53	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44004526	chr15:43726918~43747094:-
COAD	cis	rs9951698	0.728	rs35790309	ENSG00000266969.1	RP11-773H22.4	4.31	2.34e-05	0.0069	0.33	0.26	Intelligence (multi-trait analysis);	chr18:13026121	chr18:12984694~12991173:-
COAD	cis	rs2638953	0.853	rs10506037	ENSG00000247934.4	RP11-967K21.1	-4.31	2.34e-05	0.0069	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28163298~28190738:-
COAD	cis	rs6452524	0.618	rs4266384	ENSG00000271862.1	RP11-343L5.2	4.31	2.34e-05	0.0069	0.26	0.26	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83049376~83050964:-
COAD	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	4.31	2.34e-05	0.0069	0.32	0.26	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
COAD	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-4.31	2.34e-05	0.0069	-0.3	-0.26	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
COAD	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-4.31	2.35e-05	0.00691	-0.36	-0.26	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
COAD	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.35e-05	0.00691	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.35e-05	0.00691	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.35e-05	0.00691	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
COAD	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.35e-05	0.00691	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
COAD	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	4.31	2.35e-05	0.00691	0.41	0.26	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	4.31	2.35e-05	0.00691	0.41	0.26	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	4.31	2.35e-05	0.00691	0.41	0.26	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	4.31	2.35e-05	0.00691	0.41	0.26	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
COAD	cis	rs9400467	0.528	rs10872066	ENSG00000230177.1	RP5-1112D6.4	-4.31	2.35e-05	0.00691	-0.22	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111277932~111278742:+
COAD	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.35e-05	0.00691	-0.25	-0.26	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
COAD	cis	rs4144743	0.641	rs67696888	ENSG00000228782.6	CTD-2026D20.3	-4.31	2.35e-05	0.00691	-0.37	-0.26	Body mass index;	chr17:47277750	chr17:47450568~47492492:-
COAD	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	4.31	2.35e-05	0.00692	0.42	0.26	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.31	2.35e-05	0.00692	0.42	0.26	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
COAD	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-4.31	2.35e-05	0.00692	-0.32	-0.26	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
COAD	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-4.31	2.35e-05	0.00692	-0.32	-0.26	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
COAD	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-4.31	2.35e-05	0.00692	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
COAD	cis	rs8022206	0.812	rs11622243	ENSG00000259502.1	RP11-643G16.3	4.31	2.35e-05	0.00692	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67988454	chr14:67610986~67613864:+
COAD	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-4.31	2.35e-05	0.00693	-0.23	-0.26	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
COAD	cis	rs9532669	0.926	rs4270044	ENSG00000239827.7	SUGT1P3	-4.31	2.35e-05	0.00693	-0.22	-0.26	Cervical cancer;	chr13:40877923	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs11147824	ENSG00000239827.7	SUGT1P3	-4.31	2.35e-05	0.00693	-0.22	-0.26	Cervical cancer;	chr13:40878183	chr13:40908159~40921774:-
COAD	cis	rs11089937	0.616	rs4145537	ENSG00000211638.2	IGLV8-61	4.31	2.35e-05	0.00693	0.25	0.26	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22098700~22099212:+
COAD	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	4.31	2.35e-05	0.00693	0.3	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
COAD	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	4.31	2.35e-05	0.00693	0.28	0.26	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
COAD	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-4.31	2.36e-05	0.00693	-0.18	-0.26	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
COAD	cis	rs5758511	0.573	rs2267438	ENSG00000237037.8	NDUFA6-AS1	4.31	2.36e-05	0.00693	0.27	0.26	Birth weight;	chr22:41841561	chr22:42090931~42137742:+
COAD	cis	rs5758511	0.573	rs2267439	ENSG00000237037.8	NDUFA6-AS1	4.31	2.36e-05	0.00693	0.27	0.26	Birth weight;	chr22:41841765	chr22:42090931~42137742:+
COAD	cis	rs12699921	0.632	rs2691627	ENSG00000279048.1	RP11-511H23.2	-4.31	2.36e-05	0.00693	-0.19	-0.26	Fibrinogen levels;	chr7:17784627	chr7:17940503~17942922:+
COAD	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	4.31	2.36e-05	0.00693	0.39	0.26	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
COAD	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-4.31	2.36e-05	0.00694	-0.27	-0.26	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
COAD	cis	rs180730	1	rs343198	ENSG00000251609.2	SETP12	-4.31	2.36e-05	0.00694	-0.37	-0.26	Fasting plasma glucose;	chr4:120877031	chr4:120895494~120897083:-
COAD	cis	rs2732480	0.538	rs1387260	ENSG00000226413.2	OR8T1P	4.31	2.36e-05	0.00695	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48442030~48442947:-
COAD	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-4.31	2.36e-05	0.00695	-0.27	-0.26	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
COAD	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	4.31	2.36e-05	0.00695	0.3	0.26	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
COAD	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	4.31	2.36e-05	0.00695	0.51	0.26	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
COAD	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-4.31	2.36e-05	0.00695	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-4.31	2.36e-05	0.00695	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-4.31	2.36e-05	0.00695	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
COAD	cis	rs4819052	0.851	rs2838866	ENSG00000215447.6	BX322557.10	-4.31	2.36e-05	0.00695	-0.26	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45288052~45291738:+
COAD	cis	rs12497850	0.931	rs13316620	ENSG00000225399.4	RP11-3B7.1	4.31	2.36e-05	0.00695	0.29	0.26	Parkinson's disease;	chr3:49007922	chr3:49260085~49261316:+
COAD	cis	rs1510272	0.924	rs6783873	ENSG00000243926.1	TIPARP-AS1	-4.31	2.36e-05	0.00695	-0.29	-0.26	Testicular germ cell tumor;	chr3:156594525	chr3:156671862~156674378:-
COAD	cis	rs453301	0.686	rs11787026	ENSG00000233609.3	RP11-62H7.2	4.31	2.36e-05	0.00695	0.26	0.26	Joint mobility (Beighton score);	chr8:9044861	chr8:8961200~8979025:+
COAD	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	4.31	2.37e-05	0.00696	0.49	0.26	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
COAD	cis	rs899997	0.773	rs11072784	ENSG00000261143.1	ADAMTS7P3	4.31	2.37e-05	0.00696	0.36	0.26	Coronary artery disease or large artery stroke;	chr15:78673716	chr15:77976042~77993057:+
COAD	cis	rs4843747	0.749	rs13333619	ENSG00000205037.2	RP11-863P13.4	4.31	2.37e-05	0.00696	0.33	0.26	Menopause (age at onset);	chr16:88038470	chr16:88088041~88100985:-
COAD	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.31	2.37e-05	0.00697	-0.25	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
COAD	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-4.31	2.37e-05	0.00697	-0.31	-0.26	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
COAD	cis	rs1670533	1	rs34956924	ENSG00000273179.1	RP11-20I20.4	4.31	2.37e-05	0.00698	0.35	0.26	Recombination rate (females);	chr4:1053482	chr4:1167778~1168174:+
COAD	cis	rs2638953	0.962	rs11049524	ENSG00000247934.4	RP11-967K21.1	-4.31	2.37e-05	0.00698	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs12371974	ENSG00000247934.4	RP11-967K21.1	-4.31	2.37e-05	0.00698	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049526	ENSG00000247934.4	RP11-967K21.1	-4.31	2.37e-05	0.00698	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28163298~28190738:-
COAD	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	4.31	2.37e-05	0.00698	0.15	0.26	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	4.31	2.37e-05	0.00698	0.15	0.26	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
COAD	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-4.31	2.38e-05	0.00698	-0.25	-0.26	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
COAD	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-4.3	2.38e-05	0.00699	-0.48	-0.26	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-4.3	2.38e-05	0.00699	-0.48	-0.26	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
COAD	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	4.3	2.38e-05	0.00699	0.34	0.26	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
COAD	cis	rs1275468	1	rs1679381	ENSG00000257497.2	RP11-585P4.5	-4.3	2.38e-05	0.00699	-0.34	-0.26	Polycystic ovary syndrome;	chr12:75552344	chr12:75483454~75489820:-
COAD	cis	rs17359493	0.731	rs7009940	ENSG00000253528.2	RP11-347C18.4	-4.3	2.38e-05	0.007	-0.34	-0.26	Type 2 diabetes;	chr8:94882572	chr8:94974573~94974853:-
COAD	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-4.3	2.39e-05	0.00701	-0.36	-0.26	Depression;	chr6:28184805	chr6:28115628~28116551:+
COAD	cis	rs11098499	0.779	rs10857066	ENSG00000249244.1	RP11-548H18.2	4.3	2.39e-05	0.00702	0.34	0.26	Corneal astigmatism;	chr4:119365441	chr4:119391831~119395335:-
COAD	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-4.3	2.39e-05	0.00702	-0.28	-0.26	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
COAD	cis	rs7119	0.671	rs10152850	ENSG00000259565.2	KRT8P23	4.3	2.39e-05	0.00702	0.3	0.26	Type 2 diabetes;	chr15:77612084	chr15:76979245~76980451:-
COAD	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-4.3	2.39e-05	0.00702	-0.26	-0.26	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
COAD	cis	rs9532669	0.926	rs7997536	ENSG00000239827.7	SUGT1P3	-4.3	2.39e-05	0.00703	-0.23	-0.26	Cervical cancer;	chr13:40878685	chr13:40908159~40921774:-
COAD	cis	rs72827839	0.846	rs16953461	ENSG00000263412.1	RP5-890E16.2	-4.3	2.39e-05	0.00703	-0.37	-0.26	Ease of getting up in the morning;	chr17:48184374	chr17:48045141~48048073:-
COAD	cis	rs2408955	0.521	rs10875753	ENSG00000273765.1	RP11-370I10.11	4.3	2.39e-05	0.00703	0.27	0.26	Glycated hemoglobin levels;	chr12:48163358	chr12:48360920~48361377:+
COAD	cis	rs7260598	0.539	rs57417281	ENSG00000268442.1	CTD-2027I19.2	4.3	2.39e-05	0.00703	0.48	0.26	Response to taxane treatment (placlitaxel);	chr19:23877968	chr19:24162370~24163425:-
COAD	cis	rs11951515	0.508	rs7706431	ENSG00000248554.1	RP11-159F24.6	-4.3	2.39e-05	0.00703	-0.28	-0.26	Metabolite levels  (X-11787);	chr5:43582321	chr5:43511058~43521811:+
COAD	cis	rs1044826	0.642	rs186103	ENSG00000272656.1	RP11-219D15.3	4.3	2.39e-05	0.00703	0.3	0.26	Obesity-related traits;	chr3:139493100	chr3:139349024~139349371:-
COAD	cis	rs6723226	0.598	rs2710629	ENSG00000276334.1	AL133243.1	4.3	2.39e-05	0.00703	0.23	0.26	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32521927~32523547:+
COAD	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-4.3	2.4e-05	0.00704	-0.28	-0.26	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
COAD	cis	rs728616	0.867	rs56008106	ENSG00000234382.2	RP11-40F6.1	-4.3	2.4e-05	0.00704	-0.52	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:80233664~80245367:+
COAD	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.4e-05	0.00704	-0.34	-0.26	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.4e-05	0.00704	-0.34	-0.26	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
COAD	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	4.3	2.4e-05	0.00704	0.33	0.26	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
COAD	cis	rs1044826	0.692	rs169824	ENSG00000272656.1	RP11-219D15.3	-4.3	2.4e-05	0.00704	-0.31	-0.26	Obesity-related traits;	chr3:139516164	chr3:139349024~139349371:-
COAD	cis	rs17685	0.753	rs1637039	ENSG00000280388.1	RP11-229D13.3	-4.3	2.4e-05	0.00704	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76043977~76045963:-
COAD	cis	rs1023500	1	rs1023499	ENSG00000237037.8	NDUFA6-AS1	4.3	2.4e-05	0.00705	0.27	0.26	Schizophrenia;	chr22:41944578	chr22:42090931~42137742:+
COAD	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	4.3	2.4e-05	0.00705	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
COAD	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-4.3	2.4e-05	0.00705	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
COAD	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-4.3	2.41e-05	0.00706	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
COAD	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	4.3	2.41e-05	0.00706	0.31	0.26	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
COAD	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	4.3	2.41e-05	0.00706	0.4	0.26	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
COAD	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-4.3	2.41e-05	0.00706	-0.33	-0.26	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
COAD	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	4.3	2.41e-05	0.00706	0.31	0.26	Height;	chr4:55577294	chr4:55540502~55540835:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	4.3	2.41e-05	0.00706	0.26	0.26	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
COAD	cis	rs733592	0.504	rs2261608	ENSG00000273765.1	RP11-370I10.11	4.3	2.41e-05	0.00707	0.26	0.26	Plateletcrit;	chr12:48327851	chr12:48360920~48361377:+
COAD	cis	rs860295	0.702	rs475550	ENSG00000160766.13	GBAP1	-4.3	2.41e-05	0.00707	-0.3	-0.26	Body mass index;	chr1:155682290	chr1:155213821~155227422:-
COAD	cis	rs6088813	0.645	rs6087709	ENSG00000269202.1	RP4-614O4.12	4.3	2.41e-05	0.00707	0.27	0.26	Height;	chr20:35430145	chr20:35201747~35203288:-
COAD	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-4.3	2.41e-05	0.00707	-0.31	-0.26	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
COAD	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	4.3	2.41e-05	0.00708	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
COAD	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.3	2.42e-05	0.00708	0.42	0.26	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.3	2.42e-05	0.00708	0.42	0.26	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.3	2.42e-05	0.00708	0.42	0.26	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
COAD	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	4.3	2.42e-05	0.00709	0.33	0.26	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
COAD	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	4.3	2.42e-05	0.00709	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
COAD	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	4.3	2.42e-05	0.00709	0.42	0.26	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
COAD	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	4.3	2.42e-05	0.00709	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
COAD	cis	rs1044826	0.692	rs295484	ENSG00000272656.1	RP11-219D15.3	-4.3	2.42e-05	0.00709	-0.31	-0.26	Obesity-related traits;	chr3:139512940	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs432387	ENSG00000272656.1	RP11-219D15.3	-4.3	2.42e-05	0.00709	-0.31	-0.26	Obesity-related traits;	chr3:139513011	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.692	rs176987	ENSG00000272656.1	RP11-219D15.3	-4.3	2.42e-05	0.00709	-0.31	-0.26	Obesity-related traits;	chr3:139514159	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.692	rs188420	ENSG00000272656.1	RP11-219D15.3	-4.3	2.42e-05	0.00709	-0.31	-0.26	Obesity-related traits;	chr3:139515023	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.692	rs188421	ENSG00000272656.1	RP11-219D15.3	-4.3	2.42e-05	0.00709	-0.31	-0.26	Obesity-related traits;	chr3:139515224	chr3:139349024~139349371:-
COAD	cis	rs2408955	0.542	rs7975632	ENSG00000273765.1	RP11-370I10.11	4.3	2.42e-05	0.0071	0.27	0.26	Glycated hemoglobin levels;	chr12:48049265	chr12:48360920~48361377:+
COAD	cis	rs2337406	1	rs7145172	ENSG00000211974.3	IGHV2-70	-4.3	2.42e-05	0.0071	-0.28	-0.26	Alzheimer's disease (late onset);	chr14:106704924	chr14:106723574~106724093:-
COAD	cis	rs2408955	0.521	rs10875749	ENSG00000273765.1	RP11-370I10.11	-4.3	2.42e-05	0.0071	-0.27	-0.26	Glycated hemoglobin levels;	chr12:48138134	chr12:48360920~48361377:+
COAD	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-4.3	2.42e-05	0.0071	-0.31	-0.26	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
COAD	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.42e-05	0.0071	-0.3	-0.26	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.42e-05	0.0071	-0.3	-0.26	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
COAD	cis	rs1044826	0.642	rs7652860	ENSG00000272656.1	RP11-219D15.3	4.3	2.42e-05	0.0071	0.31	0.26	Obesity-related traits;	chr3:139486976	chr3:139349024~139349371:-
COAD	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	4.3	2.43e-05	0.0071	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	4.3	2.43e-05	0.0071	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
COAD	cis	rs2581828	0.58	rs9872260	ENSG00000280417.1	RP11-5O17.1	4.3	2.43e-05	0.00711	0.29	0.26	Crohn's disease;	chr3:53136158	chr3:53046166~53048122:+
COAD	cis	rs10170310	1	rs10803568	ENSG00000228043.4	AC097721.2	4.3	2.43e-05	0.00711	0.32	0.26	Response to antipsychotic treatment;	chr2:138533344	chr2:138418284~138501698:-
COAD	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	4.3	2.43e-05	0.00711	0.46	0.26	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
COAD	cis	rs2638953	0.925	rs17432330	ENSG00000247934.4	RP11-967K21.1	-4.3	2.43e-05	0.00712	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28163298~28190738:-
COAD	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	4.3	2.43e-05	0.00712	0.15	0.26	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	4.3	2.43e-05	0.00712	0.15	0.26	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
COAD	cis	rs17772222	1	rs17772064	ENSG00000258789.1	RP11-507K2.3	-4.3	2.43e-05	0.00712	-0.35	-0.26	Coronary artery calcification;	chr14:88356527	chr14:88551597~88552493:+
COAD	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-4.3	2.43e-05	0.00712	-0.31	-0.26	QT interval;	chr12:29300845	chr12:29277397~29277882:-
COAD	cis	rs7826238	0.623	rs2976893	ENSG00000254153.1	CTA-398F10.2	-4.3	2.43e-05	0.00712	-0.29	-0.26	Systolic blood pressure;	chr8:8480709	chr8:8456909~8461337:-
COAD	cis	rs7487075	0.93	rs4076248	ENSG00000257261.4	RP11-96H19.1	4.3	2.43e-05	0.00712	0.27	0.26	Itch intensity from mosquito bite;	chr12:46439822	chr12:46383679~46876159:+
COAD	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	4.3	2.43e-05	0.00713	0.15	0.26	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	4.3	2.43e-05	0.00713	0.15	0.26	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	4.3	2.43e-05	0.00713	0.15	0.26	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
COAD	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	4.3	2.43e-05	0.00713	0.29	0.26	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
COAD	cis	rs1670533	0.872	rs935969	ENSG00000273179.1	RP11-20I20.4	4.3	2.43e-05	0.00713	0.34	0.26	Recombination rate (females);	chr4:1068800	chr4:1167778~1168174:+
COAD	cis	rs2018683	0.707	rs1874974	ENSG00000272568.4	CTB-113D17.1	4.3	2.43e-05	0.00713	0.37	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928030	chr7:28979967~29013367:+
COAD	cis	rs5015933	0.801	rs6478703	ENSG00000232630.1	PRPS1P2	4.3	2.43e-05	0.00713	0.25	0.26	Body mass index;	chr9:125379069	chr9:125150653~125151589:+
COAD	cis	rs17685	0.753	rs4728550	ENSG00000280388.1	RP11-229D13.3	4.3	2.44e-05	0.00713	0.26	0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs13240404	ENSG00000280388.1	RP11-229D13.3	4.3	2.44e-05	0.00713	0.26	0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76043977~76045963:-
COAD	cis	rs17685	0.697	rs2302437	ENSG00000280388.1	RP11-229D13.3	4.3	2.44e-05	0.00713	0.26	0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs3757593	ENSG00000280388.1	RP11-229D13.3	4.3	2.44e-05	0.00713	0.26	0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76043977~76045963:-
COAD	cis	rs7656342	0.866	rs6841397	ENSG00000186234.7	FAM86MP	-4.3	2.44e-05	0.00713	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9813778	chr4:9692495~9702954:+
COAD	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.3	2.44e-05	0.00713	0.31	0.26	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
COAD	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.3	2.44e-05	0.00713	0.31	0.26	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
COAD	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-4.3	2.44e-05	0.00713	-0.3	-0.26	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
COAD	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-4.3	2.44e-05	0.00713	-0.3	-0.26	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
COAD	cis	rs2408955	0.522	rs10875721	ENSG00000273765.1	RP11-370I10.11	-4.3	2.44e-05	0.00714	-0.28	-0.26	Glycated hemoglobin levels;	chr12:48019810	chr12:48360920~48361377:+
COAD	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-4.3	2.44e-05	0.00714	-0.27	-0.26	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
COAD	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-4.3	2.44e-05	0.00714	-0.36	-0.26	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
COAD	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-4.3	2.44e-05	0.00714	-0.5	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
COAD	cis	rs6565180	0.632	rs8050812	ENSG00000261367.1	RP11-455F5.4	4.3	2.44e-05	0.00714	0.32	0.26	Tonsillectomy;	chr16:30374516	chr16:30107675~30110541:+
COAD	cis	rs5758511	0.573	rs2284082	ENSG00000237037.8	NDUFA6-AS1	4.3	2.44e-05	0.00714	0.27	0.26	Birth weight;	chr22:41844793	chr22:42090931~42137742:+
COAD	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-4.3	2.44e-05	0.00714	-0.49	-0.26	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
COAD	cis	rs12928939	0.517	rs71384782	ENSG00000260886.1	TAT-AS1	4.3	2.44e-05	0.00715	0.39	0.26	Post bronchodilator FEV1;	chr16:71944688	chr16:71565789~71578187:+
COAD	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	4.3	2.44e-05	0.00715	0.32	0.26	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
COAD	cis	rs2408955	0.521	rs7301003	ENSG00000273765.1	RP11-370I10.11	4.3	2.44e-05	0.00715	0.27	0.26	Glycated hemoglobin levels;	chr12:48156444	chr12:48360920~48361377:+
COAD	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	4.3	2.44e-05	0.00715	0.42	0.26	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	4.3	2.44e-05	0.00715	0.42	0.26	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
COAD	cis	rs987724	0.593	rs9844054	ENSG00000240875.4	LINC00886	4.3	2.44e-05	0.00715	0.24	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156957527	chr3:156747346~156817062:-
COAD	cis	rs2337406	0.587	rs916547	ENSG00000211964.3	IGHV3-48	-4.3	2.44e-05	0.00715	-0.22	-0.26	Alzheimer's disease (late onset);	chr14:106646735	chr14:106537810~106538344:-
COAD	cis	rs8022206	0.773	rs4902544	ENSG00000259502.1	RP11-643G16.3	4.3	2.45e-05	0.00715	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68016163	chr14:67610986~67613864:+
COAD	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	4.3	2.45e-05	0.00715	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
COAD	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	4.3	2.45e-05	0.00715	0.46	0.26	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
COAD	cis	rs12928939	0.517	rs12934512	ENSG00000260886.1	TAT-AS1	4.3	2.45e-05	0.00716	0.39	0.26	Post bronchodilator FEV1;	chr16:71931327	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.517	rs12445641	ENSG00000260886.1	TAT-AS1	4.3	2.45e-05	0.00716	0.39	0.26	Post bronchodilator FEV1;	chr16:71933880	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.517	rs12149325	ENSG00000260886.1	TAT-AS1	4.3	2.45e-05	0.00716	0.39	0.26	Post bronchodilator FEV1;	chr16:71934244	chr16:71565789~71578187:+
COAD	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-4.3	2.45e-05	0.00716	-0.24	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
COAD	cis	rs8022206	0.945	rs57069083	ENSG00000259502.1	RP11-643G16.3	4.3	2.45e-05	0.00716	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68072158	chr14:67610986~67613864:+
COAD	cis	rs7819412	0.765	rs7000132	ENSG00000269918.1	AF131215.9	-4.3	2.45e-05	0.00716	-0.33	-0.26	Triglycerides;	chr8:11173426	chr8:11104691~11106704:-
COAD	cis	rs2123926	0.52	rs1808723	ENSG00000182397.13	DNM1P46	4.3	2.45e-05	0.00717	0.26	0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99722623	chr15:99790156~99806927:-
COAD	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	4.3	2.45e-05	0.00717	0.54	0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
COAD	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	4.3	2.45e-05	0.00717	0.33	0.26	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
COAD	cis	rs74233809	1	rs11191551	ENSG00000213277.3	MARCKSL1P1	4.3	2.45e-05	0.00717	0.5	0.26	Birth weight;	chr10:103091078	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs17094683	ENSG00000213277.3	MARCKSL1P1	4.3	2.45e-05	0.00717	0.5	0.26	Birth weight;	chr10:103091544	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	4.3	2.45e-05	0.00717	0.5	0.26	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
COAD	cis	rs7845219	0.539	rs10441538	ENSG00000253528.2	RP11-347C18.4	4.3	2.45e-05	0.00717	0.27	0.26	Type 2 diabetes;	chr8:94856380	chr8:94974573~94974853:-
COAD	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	4.3	2.45e-05	0.00717	0.28	0.26	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
COAD	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-4.3	2.45e-05	0.00717	-0.38	-0.26	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
COAD	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-4.3	2.45e-05	0.00717	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-4.3	2.45e-05	0.00717	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-4.3	2.45e-05	0.00717	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
COAD	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	4.3	2.46e-05	0.00718	0.31	0.26	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
COAD	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-4.3	2.46e-05	0.00718	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
COAD	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-4.3	2.46e-05	0.00719	-0.46	-0.26	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
COAD	cis	rs1930961	0.702	rs7284654	ENSG00000272977.1	CTA-390C10.10	-4.3	2.46e-05	0.00719	-0.59	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25521181	chr22:25476218~25479971:+
COAD	cis	rs10936632	0.565	rs7610584	ENSG00000242578.1	RP11-469J4.3	-4.3	2.46e-05	0.00719	-0.29	-0.26	Prostate cancer;	chr3:170435395	chr3:170410512~170418615:+
COAD	cis	rs2638953	0.815	rs11049682	ENSG00000247934.4	RP11-967K21.1	-4.3	2.46e-05	0.00719	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28163298~28190738:-
COAD	cis	rs875971	0.505	rs1723275	ENSG00000272831.1	RP11-792A8.4	-4.3	2.46e-05	0.00719	-0.27	-0.26	Aortic root size;	chr7:66039646	chr7:66739829~66740385:-
COAD	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	4.3	2.46e-05	0.00719	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
COAD	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
COAD	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	4.3	2.46e-05	0.00719	0.29	0.26	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
COAD	cis	rs9307551	0.817	rs7667469	ENSG00000250334.4	LINC00989	-4.3	2.46e-05	0.00719	-0.3	-0.26	Refractive error;	chr4:79576538	chr4:79492416~79576460:+
COAD	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	4.3	2.46e-05	0.0072	0.32	0.26	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
COAD	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	4.3	2.47e-05	0.0072	0.32	0.26	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
COAD	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-4.3	2.47e-05	0.0072	-0.49	-0.26	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
COAD	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-4.3	2.47e-05	0.0072	-0.27	-0.26	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
COAD	cis	rs2439831	1	rs28628574	ENSG00000166763.7	STRCP1	-4.3	2.47e-05	0.0072	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43509840	chr15:43699488~43718184:-
COAD	cis	rs7584330	0.518	rs74003104	ENSG00000234949.2	AC104667.3	-4.3	2.47e-05	0.0072	-0.43	-0.26	Prostate cancer;	chr2:237538180	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs74003105	ENSG00000234949.2	AC104667.3	-4.3	2.47e-05	0.0072	-0.43	-0.26	Prostate cancer;	chr2:237538208	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs74003106	ENSG00000234949.2	AC104667.3	-4.3	2.47e-05	0.0072	-0.43	-0.26	Prostate cancer;	chr2:237538361	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs80282956	ENSG00000234949.2	AC104667.3	-4.3	2.47e-05	0.0072	-0.43	-0.26	Prostate cancer;	chr2:237539286	chr2:237591020~237595981:+
COAD	cis	rs7646881	0.544	rs16829283	ENSG00000272087.1	RP11-379F4.7	4.3	2.47e-05	0.0072	0.41	0.26	Tetralogy of Fallot;	chr3:158671339	chr3:158693120~158693768:-
COAD	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-4.3	2.47e-05	0.0072	-0.3	-0.26	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
COAD	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	4.3	2.47e-05	0.0072	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
COAD	cis	rs7212590	0.655	rs8070039	ENSG00000264049.1	MIR4737	-4.3	2.47e-05	0.00721	-0.4	-0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59896224	chr17:60043025~60043105:-
COAD	cis	rs7212590	0.655	rs56198517	ENSG00000264049.1	MIR4737	-4.3	2.47e-05	0.00721	-0.4	-0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59899221	chr17:60043025~60043105:-
COAD	cis	rs4704187	0.687	rs4704176	ENSG00000250889.2	LINC01336	-4.3	2.47e-05	0.00721	-0.29	-0.26	Response to amphetamines;	chr5:75124771	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs1903839	ENSG00000250889.2	LINC01336	-4.3	2.47e-05	0.00721	-0.29	-0.26	Response to amphetamines;	chr5:75125572	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4360021	ENSG00000250889.2	LINC01336	-4.3	2.47e-05	0.00721	-0.29	-0.26	Response to amphetamines;	chr5:75126137	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.663	rs4404659	ENSG00000250889.2	LINC01336	-4.3	2.47e-05	0.00721	-0.29	-0.26	Response to amphetamines;	chr5:75126294	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs4404660	ENSG00000250889.2	LINC01336	-4.3	2.47e-05	0.00721	-0.29	-0.26	Response to amphetamines;	chr5:75126385	chr5:75047719~75052843:-
COAD	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	4.3	2.47e-05	0.00721	0.34	0.26	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	4.3	2.47e-05	0.00721	0.34	0.26	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
COAD	cis	rs11089937	0.616	rs7286793	ENSG00000211638.2	IGLV8-61	-4.3	2.47e-05	0.00721	-0.25	-0.26	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22098700~22099212:+
COAD	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-4.3	2.47e-05	0.00721	-0.32	-0.26	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
COAD	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	4.3	2.47e-05	0.00721	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	4.3	2.47e-05	0.00721	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
COAD	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	4.3	2.47e-05	0.00721	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
COAD	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-4.3	2.47e-05	0.00721	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
COAD	cis	rs1044826	0.667	rs2083336	ENSG00000272656.1	RP11-219D15.3	4.3	2.47e-05	0.00722	0.3	0.26	Obesity-related traits;	chr3:139482430	chr3:139349024~139349371:-
COAD	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-4.3	2.47e-05	0.00722	-0.41	-0.26	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
COAD	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-4.3	2.47e-05	0.00722	-0.28	-0.26	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
COAD	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	4.3	2.48e-05	0.00722	0.29	0.26	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
COAD	cis	rs2836974	0.897	rs34394827	ENSG00000255568.3	BRWD1-AS2	4.3	2.48e-05	0.00723	0.26	0.26	Cognitive function;	chr21:39156161	chr21:39313935~39314962:+
COAD	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-4.29	2.48e-05	0.00723	-0.31	-0.26	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
COAD	cis	rs860295	0.557	rs11264371	ENSG00000160766.13	GBAP1	-4.29	2.48e-05	0.00723	-0.3	-0.26	Body mass index;	chr1:155442246	chr1:155213821~155227422:-
COAD	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-4.29	2.48e-05	0.00723	-0.33	-0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
COAD	cis	rs6903823	0.508	rs1150724	ENSG00000272009.1	RP1-313I6.12	4.29	2.48e-05	0.00724	0.29	0.26	Pulmonary function;	chr6:28282459	chr6:28078792~28081130:-
COAD	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	4.29	2.48e-05	0.00724	0.29	0.26	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
COAD	cis	rs4834770	1	rs4336213	ENSG00000250412.1	KLHL2P1	4.29	2.48e-05	0.00724	0.32	0.26	Blood protein levels;	chr4:119315314	chr4:119334329~119378233:+
COAD	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-4.29	2.48e-05	0.00724	-0.27	-0.26	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
COAD	cis	rs752010	0.905	rs2038977	ENSG00000230638.4	RP11-486B10.4	-4.29	2.48e-05	0.00724	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41628988	chr1:41542069~41544310:+
COAD	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	4.29	2.48e-05	0.00724	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
COAD	cis	rs984222	0.838	rs10923724	ENSG00000231365.4	RP11-418J17.1	-4.29	2.49e-05	0.00725	-0.28	-0.26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119140396~119275973:+
COAD	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28123153	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28124529	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28127577	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28131566	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28133900	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28136698	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28136856	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28137418	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28138363	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28138981	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28139012	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28139049	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28139876	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-4.29	2.49e-05	0.00725	-0.37	-0.26	Depression;	chr6:28139998	chr6:28115628~28116551:+
COAD	cis	rs240993	0.715	rs4947122	ENSG00000230177.1	RP5-1112D6.4	-4.29	2.49e-05	0.00725	-0.22	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111277932~111278742:+
COAD	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-4.29	2.49e-05	0.00726	-0.3	-0.26	Height;	chr3:53094335	chr3:53064283~53065091:-
COAD	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-4.29	2.49e-05	0.00726	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
COAD	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-4.29	2.49e-05	0.00726	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
COAD	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-4.29	2.5e-05	0.00727	-0.53	-0.26	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
COAD	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-4.29	2.5e-05	0.00727	-0.43	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
COAD	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	4.29	2.5e-05	0.00728	0.34	0.26	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
COAD	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.29	2.5e-05	0.00728	0.22	0.26	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
COAD	cis	rs17214007	0.518	rs56374730	ENSG00000263335.1	AF001548.5	-4.29	2.5e-05	0.00728	-0.4	-0.26	Cognitive function;	chr16:15773795	chr16:15726674~15732993:+
COAD	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-4.29	2.5e-05	0.00728	-0.25	-0.26	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
COAD	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	4.29	2.5e-05	0.00728	0.38	0.26	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
COAD	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	4.29	2.5e-05	0.00729	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-4.29	2.5e-05	0.00729	-0.25	-0.26	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
COAD	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	4.29	2.5e-05	0.00729	0.33	0.26	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
COAD	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	4.29	2.5e-05	0.00729	0.3	0.26	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
COAD	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-4.29	2.5e-05	0.00729	-0.48	-0.26	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
COAD	cis	rs1044826	0.642	rs1080371	ENSG00000272656.1	RP11-219D15.3	4.29	2.5e-05	0.00729	0.3	0.26	Obesity-related traits;	chr3:139492052	chr3:139349024~139349371:-
COAD	cis	rs2638953	0.741	rs10843199	ENSG00000247934.4	RP11-967K21.1	4.29	2.5e-05	0.00729	0.27	0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535711	chr12:28163298~28190738:-
COAD	cis	rs739496	0.579	rs10849983	ENSG00000257595.2	RP3-473L9.4	4.29	2.51e-05	0.00729	0.38	0.26	Platelet count;	chr12:111902605	chr12:111369282~111403310:+
COAD	cis	rs739496	0.527	rs11066090	ENSG00000257595.2	RP3-473L9.4	4.29	2.51e-05	0.00729	0.38	0.26	Platelet count;	chr12:111927719	chr12:111369282~111403310:+
COAD	cis	rs7647973	0.506	rs11920251	ENSG00000225399.4	RP11-3B7.1	4.29	2.51e-05	0.0073	0.28	0.26	Menarche (age at onset);	chr3:49319238	chr3:49260085~49261316:+
COAD	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	4.29	2.51e-05	0.0073	0.3	0.26	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
COAD	cis	rs11681884	0.892	rs17042810	ENSG00000228251.1	AC012442.6	4.29	2.51e-05	0.0073	0.56	0.26	Stroke;	chr2:113080992	chr2:112590796~112591939:+
COAD	cis	rs9652601	0.691	rs9941107	ENSG00000274038.1	RP11-66H6.4	-4.29	2.51e-05	0.0073	-0.3	-0.26	Systemic lupus erythematosus;	chr16:11102184	chr16:11056556~11057034:+
COAD	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	4.29	2.51e-05	0.0073	0.3	0.26	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
COAD	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	4.29	2.51e-05	0.0073	0.31	0.26	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	4.29	2.51e-05	0.0073	0.31	0.26	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	4.29	2.51e-05	0.0073	0.31	0.26	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
COAD	cis	rs11098499	0.73	rs78971550	ENSG00000249244.1	RP11-548H18.2	4.29	2.51e-05	0.0073	0.35	0.26	Corneal astigmatism;	chr4:119359886	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.645	rs78422072	ENSG00000249244.1	RP11-548H18.2	4.29	2.51e-05	0.0073	0.35	0.26	Corneal astigmatism;	chr4:119359887	chr4:119391831~119395335:-
COAD	cis	rs9307551	0.741	rs11098735	ENSG00000250334.4	LINC00989	-4.29	2.51e-05	0.0073	-0.34	-0.26	Refractive error;	chr4:79537259	chr4:79492416~79576460:+
COAD	cis	rs2638953	0.962	rs3825246	ENSG00000247934.4	RP11-967K21.1	-4.29	2.51e-05	0.0073	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310186	chr12:28163298~28190738:-
COAD	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	4.29	2.51e-05	0.00731	0.47	0.26	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
COAD	cis	rs12682352	0.602	rs28399241	ENSG00000173295.6	FAM86B3P	4.29	2.51e-05	0.00731	0.29	0.26	Neuroticism;	chr8:8805705	chr8:8228595~8244865:+
COAD	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-4.29	2.51e-05	0.00731	-0.33	-0.26	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
COAD	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-4.29	2.51e-05	0.00731	-0.36	-0.26	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
COAD	cis	rs896854	0.552	rs2515236	ENSG00000253528.2	RP11-347C18.4	-4.29	2.51e-05	0.00731	-0.29	-0.26	Type 2 diabetes;	chr8:94922679	chr8:94974573~94974853:-
COAD	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	4.29	2.51e-05	0.00731	0.26	0.26	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
COAD	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	4.29	2.51e-05	0.00731	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
COAD	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.29	2.51e-05	0.00732	0.23	0.26	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
COAD	cis	rs11133665	1	rs11133665	ENSG00000260774.1	CTD-2083E4.4	4.29	2.52e-05	0.00732	0.34	0.26	Urinary metabolites;	chr5:1188170	chr5:213898~217279:-
COAD	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-4.29	2.52e-05	0.00732	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
COAD	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	4.29	2.52e-05	0.00733	0.23	0.26	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
COAD	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	4.29	2.52e-05	0.00733	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
COAD	cis	rs453301	0.631	rs13250781	ENSG00000233609.3	RP11-62H7.2	-4.29	2.52e-05	0.00733	-0.29	-0.26	Joint mobility (Beighton score);	chr8:8935833	chr8:8961200~8979025:+
COAD	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-4.29	2.52e-05	0.00733	-0.43	-0.26	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
COAD	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	4.29	2.52e-05	0.00733	0.32	0.26	Height;	chr4:55457922	chr4:55540502~55540835:-
COAD	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	4.29	2.52e-05	0.00734	0.34	0.26	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	4.29	2.52e-05	0.00734	0.34	0.26	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
COAD	cis	rs1044826	0.642	rs6784684	ENSG00000272656.1	RP11-219D15.3	4.29	2.52e-05	0.00734	0.3	0.26	Obesity-related traits;	chr3:139458792	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.597	rs6772199	ENSG00000272656.1	RP11-219D15.3	4.29	2.52e-05	0.00734	0.3	0.26	Obesity-related traits;	chr3:139459291	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs9833307	ENSG00000272656.1	RP11-219D15.3	4.29	2.52e-05	0.00734	0.3	0.26	Obesity-related traits;	chr3:139462528	chr3:139349024~139349371:-
COAD	cis	rs5758659	0.504	rs133367	ENSG00000227370.1	RP4-669P10.19	4.29	2.52e-05	0.00734	0.25	0.26	Cognitive function;	chr22:42067362	chr22:42132543~42132998:+
COAD	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-4.29	2.52e-05	0.00734	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
COAD	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-4.29	2.52e-05	0.00734	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
COAD	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	4.29	2.53e-05	0.00736	0.26	0.26	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
COAD	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	4.29	2.53e-05	0.00736	0.5	0.26	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
COAD	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	4.29	2.53e-05	0.00736	0.5	0.26	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	4.29	2.53e-05	0.00736	0.5	0.26	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	4.29	2.53e-05	0.00736	0.5	0.26	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	4.29	2.53e-05	0.00736	0.5	0.26	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
COAD	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	4.29	2.53e-05	0.00736	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
COAD	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	4.29	2.53e-05	0.00737	0.32	0.26	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
COAD	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	4.29	2.54e-05	0.00737	0.29	0.26	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	4.29	2.54e-05	0.00737	0.29	0.26	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
COAD	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	4.29	2.54e-05	0.00737	0.29	0.26	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
COAD	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	4.29	2.54e-05	0.00737	0.29	0.26	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
COAD	cis	rs2638953	0.777	rs11049681	ENSG00000247934.4	RP11-967K21.1	-4.29	2.54e-05	0.00737	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28163298~28190738:-
COAD	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-4.29	2.54e-05	0.00737	-0.26	-0.26	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
COAD	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-4.29	2.54e-05	0.00737	-0.14	-0.26	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
COAD	cis	rs7615952	0.605	rs11708269	ENSG00000248787.1	RP11-666A20.4	-4.29	2.54e-05	0.00737	-0.48	-0.26	Blood pressure (smoking interaction);	chr3:125613306	chr3:125908005~125910272:-
COAD	cis	rs728616	0.867	rs41298231	ENSG00000234382.2	RP11-40F6.1	-4.29	2.54e-05	0.00737	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:80233664~80245367:+
COAD	cis	rs1044826	0.597	rs6803593	ENSG00000272656.1	RP11-219D15.3	4.29	2.54e-05	0.00737	0.3	0.26	Obesity-related traits;	chr3:139475145	chr3:139349024~139349371:-
COAD	cis	rs7577696	0.752	rs12618002	ENSG00000272716.1	RP11-563N4.1	-4.29	2.54e-05	0.00737	-0.27	-0.26	Inflammatory biomarkers;	chr2:32122646	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.752	rs12995952	ENSG00000272716.1	RP11-563N4.1	-4.29	2.54e-05	0.00737	-0.27	-0.26	Inflammatory biomarkers;	chr2:32148229	chr2:32165046~32165757:-
COAD	cis	rs2733201	1	rs11070419	ENSG00000205771.5	CATSPER2P1	4.29	2.54e-05	0.00737	0.54	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44034981	chr15:43726918~43747094:-
COAD	cis	rs11638352	1	rs4924734	ENSG00000205771.5	CATSPER2P1	4.29	2.54e-05	0.00737	0.54	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44035872	chr15:43726918~43747094:-
COAD	cis	rs2281603	0.762	rs12588437	ENSG00000259116.1	RP11-973N13.4	-4.29	2.54e-05	0.00737	-0.28	-0.26	Lymphocyte counts;	chr14:64580366	chr14:64514154~64540368:-
COAD	cis	rs2281603	0.762	rs11850291	ENSG00000259116.1	RP11-973N13.4	-4.29	2.54e-05	0.00737	-0.28	-0.26	Lymphocyte counts;	chr14:64582676	chr14:64514154~64540368:-
COAD	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	4.29	2.54e-05	0.00738	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	4.29	2.54e-05	0.00738	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
COAD	cis	rs6723226	0.806	rs6543658	ENSG00000276334.1	AL133243.1	4.29	2.54e-05	0.00738	0.24	0.26	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32521927~32523547:+
COAD	cis	rs752010	0.871	rs2038976	ENSG00000230638.4	RP11-486B10.4	-4.29	2.54e-05	0.00738	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41628827	chr1:41542069~41544310:+
COAD	cis	rs7688540	0.8	rs10003142	ENSG00000198155.5	ZNF876P	-4.29	2.54e-05	0.00738	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:212610~255985:+
COAD	cis	rs7688540	0.771	rs11723803	ENSG00000198155.5	ZNF876P	-4.29	2.54e-05	0.00738	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:212610~255985:+
COAD	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-4.29	2.54e-05	0.00739	-0.23	-0.26	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
COAD	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-4.29	2.55e-05	0.00739	-0.5	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
COAD	cis	rs8046148	0.694	rs877639	ENSG00000260381.2	RP11-429P3.5	4.29	2.55e-05	0.0074	0.34	0.26	Testicular germ cell tumor;	chr16:50084334	chr16:50100339~50121943:-
COAD	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-4.29	2.55e-05	0.0074	-0.32	-0.26	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
COAD	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-4.29	2.55e-05	0.0074	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
COAD	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	4.29	2.55e-05	0.0074	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	4.29	2.55e-05	0.0074	0.26	0.26	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
COAD	cis	rs2255336	0.684	rs6416265	ENSG00000245648.1	RP11-277P12.20	4.29	2.55e-05	0.0074	0.47	0.26	Blood protein levels;	chr12:10344268	chr12:10363769~10398506:+
COAD	cis	rs2337406	0.789	rs60000589	ENSG00000211967.3	IGHV3-53	-4.29	2.55e-05	0.00741	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106782459	chr14:106592676~106593347:-
COAD	cis	rs72827839	0.74	rs72823509	ENSG00000263412.1	RP5-890E16.2	4.29	2.55e-05	0.00741	0.37	0.26	Ease of getting up in the morning;	chr17:47967223	chr17:48045141~48048073:-
COAD	cis	rs72827839	0.793	rs72823513	ENSG00000263412.1	RP5-890E16.2	4.29	2.55e-05	0.00741	0.37	0.26	Ease of getting up in the morning;	chr17:47971554	chr17:48045141~48048073:-
COAD	cis	rs4834770	1	rs878374	ENSG00000250412.1	KLHL2P1	4.29	2.55e-05	0.00741	0.31	0.26	Blood protein levels;	chr4:119316409	chr4:119334329~119378233:+
COAD	cis	rs9532669	0.927	rs9532670	ENSG00000239827.7	SUGT1P3	4.29	2.55e-05	0.00741	0.22	0.26	Cervical cancer;	chr13:40927691	chr13:40908159~40921774:-
COAD	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	4.29	2.55e-05	0.00741	0.31	0.26	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
COAD	cis	rs6723226	0.708	rs2754513	ENSG00000276334.1	AL133243.1	4.29	2.55e-05	0.00741	0.24	0.26	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32521927~32523547:+
COAD	cis	rs8022206	0.704	rs8006492	ENSG00000259502.1	RP11-643G16.3	4.29	2.56e-05	0.00742	0.35	0.26	Platelet count;Mean platelet volume;	chr14:68046008	chr14:67610986~67613864:+
COAD	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	4.29	2.56e-05	0.00742	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
COAD	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-4.29	2.56e-05	0.00742	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
COAD	cis	rs6940638	0.688	rs9348750	ENSG00000224843.5	LINC00240	4.29	2.56e-05	0.00742	0.33	0.26	Intelligence (multi-trait analysis);	chr6:27090166	chr6:26956992~27023924:+
COAD	cis	rs2243480	1	rs160655	ENSG00000229886.1	RP5-1132H15.3	4.29	2.56e-05	0.00742	0.43	0.26	Diabetic kidney disease;	chr7:66068227	chr7:66025126~66031544:-
COAD	cis	rs2188554	0.785	rs213938	ENSG00000237974.1	AC000111.4	4.29	2.56e-05	0.00742	0.26	0.26	Esophageal adenocarcinoma;	chr7:117524385	chr7:117487737~117487929:+
COAD	cis	rs9291683	0.546	rs13120348	ENSG00000250413.1	RP11-448G15.1	4.29	2.56e-05	0.00742	0.34	0.26	Bone mineral density;	chr4:10051531	chr4:10006482~10009725:+
COAD	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	4.29	2.56e-05	0.00742	0.36	0.26	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
COAD	cis	rs9796	0.621	rs2578655	ENSG00000247556.5	OIP5-AS1	4.29	2.56e-05	0.00742	0.26	0.26	Menopause (age at onset);	chr15:41170611	chr15:41283990~41309737:+
COAD	cis	rs7688540	0.76	rs12506250	ENSG00000211553.1	AC253576.2	-4.29	2.56e-05	0.00742	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:136461~136568:+
COAD	cis	rs7688540	0.76	rs2883229	ENSG00000211553.1	AC253576.2	-4.29	2.56e-05	0.00742	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:136461~136568:+
COAD	cis	rs2638953	0.782	rs11049710	ENSG00000247934.4	RP11-967K21.1	-4.29	2.56e-05	0.00742	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28163298~28190738:-
COAD	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-4.29	2.56e-05	0.00742	-0.28	-0.26	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
COAD	cis	rs11098499	0.866	rs12501602	ENSG00000249244.1	RP11-548H18.2	4.29	2.56e-05	0.00742	0.34	0.26	Corneal astigmatism;	chr4:119366780	chr4:119391831~119395335:-
COAD	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	4.29	2.56e-05	0.00743	0.16	0.26	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
COAD	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-4.29	2.56e-05	0.00743	-0.33	-0.26	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
COAD	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.29	2.56e-05	0.00743	0.25	0.26	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
COAD	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	4.29	2.56e-05	0.00743	0.29	0.26	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
COAD	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	4.29	2.56e-05	0.00744	0.31	0.26	Height;	chr4:55460485	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	4.29	2.56e-05	0.00744	0.31	0.26	Height;	chr4:55465165	chr4:55540502~55540835:-
COAD	cis	rs875971	0.54	rs736270	ENSG00000272831.1	RP11-792A8.4	4.29	2.57e-05	0.00744	0.28	0.26	Aortic root size;	chr7:65963835	chr7:66739829~66740385:-
COAD	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.29	2.57e-05	0.00744	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
COAD	cis	rs8022206	0.773	rs7155097	ENSG00000259502.1	RP11-643G16.3	4.29	2.57e-05	0.00745	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67989797	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs10140282	ENSG00000259502.1	RP11-643G16.3	4.29	2.57e-05	0.00745	0.35	0.26	Platelet count;Mean platelet volume;	chr14:67990695	chr14:67610986~67613864:+
COAD	cis	rs2732480	0.538	rs1387259	ENSG00000226413.2	OR8T1P	-4.29	2.57e-05	0.00745	-0.33	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48442030~48442947:-
COAD	cis	rs5758511	0.689	rs17478227	ENSG00000237037.8	NDUFA6-AS1	4.29	2.57e-05	0.00745	0.39	0.26	Birth weight;	chr22:42258321	chr22:42090931~42137742:+
COAD	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	4.29	2.57e-05	0.00745	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
COAD	cis	rs17407555	0.657	rs10489076	ENSG00000250413.1	RP11-448G15.1	-4.29	2.57e-05	0.00745	-0.34	-0.26	Schizophrenia (age at onset);	chr4:10269224	chr4:10006482~10009725:+
COAD	cis	rs17407555	0.657	rs12508233	ENSG00000250413.1	RP11-448G15.1	-4.29	2.57e-05	0.00745	-0.34	-0.26	Schizophrenia (age at onset);	chr4:10269413	chr4:10006482~10009725:+
COAD	cis	rs17407555	0.632	rs12510726	ENSG00000250413.1	RP11-448G15.1	-4.29	2.57e-05	0.00745	-0.34	-0.26	Schizophrenia (age at onset);	chr4:10269443	chr4:10006482~10009725:+
COAD	cis	rs17407555	0.632	rs12510727	ENSG00000250413.1	RP11-448G15.1	-4.29	2.57e-05	0.00745	-0.34	-0.26	Schizophrenia (age at onset);	chr4:10269446	chr4:10006482~10009725:+
COAD	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	4.29	2.57e-05	0.00745	0.35	0.26	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
COAD	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	4.29	2.57e-05	0.00745	0.35	0.26	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
COAD	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-4.29	2.57e-05	0.00745	-0.23	-0.26	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
COAD	cis	rs9487051	0.872	rs1111865	ENSG00000219700.1	PTCHD3P3	-4.29	2.57e-05	0.00745	-0.27	-0.26	Reticulocyte fraction of red cells;	chr6:109289660	chr6:109288571~109290503:-
COAD	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-4.29	2.57e-05	0.00746	-0.35	-0.26	Depression;	chr6:28192182	chr6:28115628~28116551:+
COAD	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-4.29	2.57e-05	0.00746	-0.3	-0.26	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
COAD	cis	rs3752645	1	rs10272371	ENSG00000241764.3	AC002467.7	-4.29	2.58e-05	0.00747	-0.39	-0.26	Bladder cancer (smoking interaction);	chr7:107122402	chr7:107742817~107744581:-
COAD	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-4.29	2.58e-05	0.00747	-0.3	-0.26	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
COAD	cis	rs875971	0.505	rs6955582	ENSG00000272831.1	RP11-792A8.4	4.29	2.58e-05	0.00747	0.27	0.26	Aortic root size;	chr7:65966699	chr7:66739829~66740385:-
COAD	cis	rs3120667	0.72	rs11579266	ENSG00000237975.5	FLG-AS1	4.29	2.58e-05	0.00747	0.37	0.26	Eating disorders;	chr1:152439337	chr1:152168125~152445456:+
COAD	cis	rs1044826	0.642	rs295481	ENSG00000272656.1	RP11-219D15.3	4.29	2.58e-05	0.00747	0.31	0.26	Obesity-related traits;	chr3:139509969	chr3:139349024~139349371:-
COAD	cis	rs7246657	0.943	rs7259968	ENSG00000226686.6	LINC01535	-4.29	2.58e-05	0.00747	-0.37	-0.26	Coronary artery calcification;	chr19:37320952	chr19:37251912~37265535:+
COAD	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	4.29	2.58e-05	0.00748	0.31	0.26	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
COAD	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-4.29	2.58e-05	0.00748	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
COAD	cis	rs6732160	0.613	rs57208378	ENSG00000163016.8	ALMS1P	4.29	2.58e-05	0.00748	0.33	0.26	Intelligence (multi-trait analysis);	chr2:73162871	chr2:73644919~73685576:+
COAD	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-4.29	2.58e-05	0.00748	-0.34	-0.26	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
COAD	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-4.29	2.58e-05	0.00748	-0.23	-0.26	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
COAD	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	4.29	2.58e-05	0.00748	0.35	0.26	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
COAD	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	4.29	2.58e-05	0.00748	0.38	0.26	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
COAD	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	4.29	2.58e-05	0.00748	0.38	0.26	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
COAD	cis	rs4704187	0.687	rs6896474	ENSG00000250889.2	LINC01336	4.29	2.58e-05	0.00748	0.29	0.26	Response to amphetamines;	chr5:75157993	chr5:75047719~75052843:-
COAD	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-4.29	2.59e-05	0.00749	-0.28	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
COAD	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	4.29	2.59e-05	0.00749	0.32	0.26	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
COAD	cis	rs8141529	0.732	rs2269577	ENSG00000272858.1	CTA-292E10.8	-4.28	2.59e-05	0.00749	-0.3	-0.26	Lymphocyte counts;	chr22:28800769	chr22:28814914~28815662:+
COAD	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	4.28	2.59e-05	0.00749	0.32	0.26	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
COAD	cis	rs9450351	0.744	rs6919244	ENSG00000203875.9	SNHG5	-4.28	2.59e-05	0.00749	-0.52	-0.26	Interferon gamma-induced protein 10 levels;	chr6:86045035	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs73751283	ENSG00000203875.9	SNHG5	-4.28	2.59e-05	0.00749	-0.52	-0.26	Interferon gamma-induced protein 10 levels;	chr6:86072398	chr6:85660950~85678736:-
COAD	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-4.28	2.59e-05	0.0075	-0.28	-0.26	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
COAD	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	4.28	2.59e-05	0.0075	0.26	0.26	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
COAD	cis	rs7246657	1	rs12709812	ENSG00000226686.6	LINC01535	4.28	2.59e-05	0.0075	0.38	0.26	Coronary artery calcification;	chr19:37303948	chr19:37251912~37265535:+
COAD	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	4.28	2.59e-05	0.0075	0.28	0.26	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
COAD	cis	rs9813712	0.597	rs11711883	ENSG00000249846.5	RP11-77P16.4	-4.28	2.59e-05	0.0075	-0.29	-0.26	Response to amphetamines;	chr3:130241367	chr3:130112550~130120579:+
COAD	cis	rs9813712	0.574	rs62281647	ENSG00000249846.5	RP11-77P16.4	-4.28	2.59e-05	0.0075	-0.29	-0.26	Response to amphetamines;	chr3:130242670	chr3:130112550~130120579:+
COAD	cis	rs3752645	1	rs76434589	ENSG00000241764.3	AC002467.7	4.28	2.59e-05	0.0075	0.49	0.26	Bladder cancer (smoking interaction);	chr7:107076772	chr7:107742817~107744581:-
COAD	cis	rs3752645	1	rs112953061	ENSG00000241764.3	AC002467.7	4.28	2.59e-05	0.0075	0.49	0.26	Bladder cancer (smoking interaction);	chr7:107078063	chr7:107742817~107744581:-
COAD	cis	rs12497850	0.931	rs6446196	ENSG00000225399.4	RP11-3B7.1	4.28	2.59e-05	0.00751	0.29	0.26	Parkinson's disease;	chr3:48967290	chr3:49260085~49261316:+
COAD	cis	rs683257	0.636	rs17070386	ENSG00000234147.1	RP3-460G2.2	4.28	2.59e-05	0.00751	0.46	0.26	Facial emotion recognition (angry faces);	chr6:140850424	chr6:140845958~140852924:-
COAD	cis	rs2644899	0.75	rs2607424	ENSG00000233622.1	CYP2T1P	-4.28	2.6e-05	0.00751	-0.29	-0.26	Post bronchodilator FEV1/FVC ratio;	chr19:40769242	chr19:40808525~40811390:-
COAD	cis	rs11098499	0.775	rs10021601	ENSG00000249244.1	RP11-548H18.2	4.28	2.6e-05	0.00751	0.34	0.26	Corneal astigmatism;	chr4:119361408	chr4:119391831~119395335:-
COAD	cis	rs1044826	0.642	rs295482	ENSG00000272656.1	RP11-219D15.3	-4.28	2.6e-05	0.00751	-0.31	-0.26	Obesity-related traits;	chr3:139510422	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.692	rs184155	ENSG00000272656.1	RP11-219D15.3	-4.28	2.6e-05	0.00751	-0.31	-0.26	Obesity-related traits;	chr3:139510930	chr3:139349024~139349371:-
COAD	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	4.28	2.6e-05	0.00752	0.39	0.26	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
COAD	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	4.28	2.6e-05	0.00752	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
COAD	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	4.28	2.6e-05	0.00752	0.3	0.26	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
COAD	cis	rs12699921	0.632	rs2691628	ENSG00000279048.1	RP11-511H23.2	-4.28	2.6e-05	0.00753	-0.19	-0.26	Fibrinogen levels;	chr7:17784732	chr7:17940503~17942922:+
COAD	cis	rs7829975	0.742	rs1533058	ENSG00000254340.1	RP11-10A14.3	4.28	2.6e-05	0.00753	0.31	0.26	Mood instability;	chr8:8827680	chr8:9141424~9145435:+
COAD	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	4.28	2.6e-05	0.00753	0.32	0.26	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
COAD	cis	rs4704187	0.649	rs9942407	ENSG00000250889.2	LINC01336	-4.28	2.6e-05	0.00753	-0.29	-0.26	Response to amphetamines;	chr5:75244362	chr5:75047719~75052843:-
COAD	cis	rs2732480	0.557	rs2409004	ENSG00000226413.2	OR8T1P	4.28	2.6e-05	0.00753	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2450994	ENSG00000226413.2	OR8T1P	4.28	2.6e-05	0.00753	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48442030~48442947:-
COAD	cis	rs1005224	0.782	rs34882722	ENSG00000258454.1	RP11-361H10.3	4.28	2.6e-05	0.00753	0.32	0.26	Large artery stroke;	chr14:75687553	chr14:76235817~76263474:+
COAD	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	4.28	2.6e-05	0.00753	0.3	0.26	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
COAD	cis	rs11603023	0.967	rs4245184	ENSG00000278376.1	RP11-158I9.8	4.28	2.6e-05	0.00753	0.26	0.26	Cholesterol, total;	chr11:118639844	chr11:118791254~118793137:+
COAD	cis	rs11603023	0.967	rs644273	ENSG00000278376.1	RP11-158I9.8	4.28	2.6e-05	0.00753	0.26	0.26	Cholesterol, total;	chr11:118640634	chr11:118791254~118793137:+
COAD	cis	rs11603023	0.967	rs654423	ENSG00000278376.1	RP11-158I9.8	4.28	2.6e-05	0.00753	0.26	0.26	Cholesterol, total;	chr11:118641039	chr11:118791254~118793137:+
COAD	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-4.28	2.61e-05	0.00754	-0.32	-0.26	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
COAD	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	4.28	2.61e-05	0.00754	0.16	0.26	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
COAD	cis	rs9532669	0.926	rs1055588	ENSG00000239827.7	SUGT1P3	-4.28	2.61e-05	0.00754	-0.22	-0.26	Cervical cancer;	chr13:40871306	chr13:40908159~40921774:-
COAD	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-4.28	2.61e-05	0.00754	-0.26	-0.26	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
COAD	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-4.28	2.61e-05	0.00755	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
COAD	cis	rs2018683	0.683	rs12538606	ENSG00000272568.4	CTB-113D17.1	4.28	2.61e-05	0.00755	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28979967~29013367:+
COAD	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-4.28	2.61e-05	0.00755	-0.36	-0.26	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
COAD	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-4.28	2.61e-05	0.00755	-0.36	-0.26	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
COAD	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	4.28	2.61e-05	0.00755	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
COAD	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	4.28	2.61e-05	0.00755	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
COAD	cis	rs9907295	0.591	rs6505496	ENSG00000271013.1	AC015849.15	-4.28	2.61e-05	0.00755	-0.32	-0.26	Fibroblast growth factor basic levels;	chr17:35802063	chr17:35912635~35918010:-
COAD	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-4.28	2.61e-05	0.00755	-0.3	-0.26	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
COAD	cis	rs7224610	0.57	rs963955	ENSG00000263096.1	RP11-515O17.2	-4.28	2.61e-05	0.00755	-0.28	-0.26	Urate levels;	chr17:55309465	chr17:55271504~55273653:-
COAD	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-4.28	2.61e-05	0.00756	-0.35	-0.26	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
COAD	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-4.28	2.61e-05	0.00756	-0.41	-0.26	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
COAD	cis	rs1023500	0.552	rs133368	ENSG00000237037.8	NDUFA6-AS1	-4.28	2.61e-05	0.00756	-0.25	-0.26	Schizophrenia;	chr22:42067685	chr22:42090931~42137742:+
COAD	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	4.28	2.62e-05	0.00756	0.34	0.26	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	4.28	2.62e-05	0.00756	0.34	0.26	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	4.28	2.62e-05	0.00756	0.34	0.26	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
COAD	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	4.28	2.62e-05	0.00756	0.16	0.26	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	4.28	2.62e-05	0.00756	0.16	0.26	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
COAD	cis	rs453301	0.686	rs28482034	ENSG00000254340.1	RP11-10A14.3	-4.28	2.62e-05	0.00756	-0.31	-0.26	Joint mobility (Beighton score);	chr8:9012154	chr8:9141424~9145435:+
COAD	cis	rs597539	0.652	rs513359	ENSG00000255741.1	RP11-757G1.5	4.28	2.62e-05	0.00756	0.34	0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68941503~68942852:-
COAD	cis	rs1928295	0.786	rs7032255	ENSG00000233569.1	RP11-500B12.1	4.28	2.62e-05	0.00757	0.31	0.26	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117637809	chr9:117648606~117657027:+
COAD	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	4.28	2.62e-05	0.00757	0.15	0.26	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
COAD	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	4.28	2.62e-05	0.00757	0.28	0.26	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
COAD	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	4.28	2.62e-05	0.00757	0.31	0.26	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
COAD	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	4.28	2.62e-05	0.00757	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	4.28	2.62e-05	0.00757	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
COAD	cis	rs1670533	1	rs604597	ENSG00000273179.1	RP11-20I20.4	-4.28	2.62e-05	0.00758	-0.34	-0.26	Recombination rate (females);	chr4:1100363	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6857085	ENSG00000273179.1	RP11-20I20.4	-4.28	2.62e-05	0.00758	-0.34	-0.26	Recombination rate (females);	chr4:1102132	chr4:1167778~1168174:+
COAD	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	4.28	2.63e-05	0.00759	0.15	0.26	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	4.28	2.63e-05	0.00759	0.15	0.26	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
COAD	cis	rs34286592	1	rs34286592	ENSG00000214725.6	CDIPT-AS1	-4.28	2.63e-05	0.00759	-0.48	-0.26	Multiple sclerosis;	chr16:29809159	chr16:29863593~29868053:+
COAD	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	4.28	2.63e-05	0.00759	0.15	0.26	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
COAD	cis	rs55962025	0.804	rs362268	ENSG00000248840.2	RP11-357G3.2	4.28	2.63e-05	0.00759	0.31	0.26	Parental longevity (mother's age at death);	chr4:3240421	chr4:3312512~3313058:+
COAD	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-4.28	2.63e-05	0.00759	-0.31	-0.26	QT interval;	chr12:29302457	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-4.28	2.63e-05	0.00759	-0.31	-0.26	QT interval;	chr12:29302458	chr12:29277397~29277882:-
COAD	cis	rs2638953	0.962	rs11049527	ENSG00000247934.4	RP11-967K21.1	-4.28	2.63e-05	0.00759	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.925	rs11049528	ENSG00000247934.4	RP11-967K21.1	-4.28	2.63e-05	0.00759	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs10843152	ENSG00000247934.4	RP11-967K21.1	-4.28	2.63e-05	0.00759	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs10843153	ENSG00000247934.4	RP11-967K21.1	-4.28	2.63e-05	0.00759	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28163298~28190738:-
COAD	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-4.28	2.63e-05	0.00759	-0.3	-0.26	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
COAD	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	4.28	2.63e-05	0.00759	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
COAD	cis	rs2638953	0.962	rs61922979	ENSG00000247934.4	RP11-967K21.1	-4.28	2.63e-05	0.0076	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28163298~28190738:-
COAD	cis	rs3752645	1	rs10261881	ENSG00000241764.3	AC002467.7	4.28	2.63e-05	0.0076	0.41	0.26	Bladder cancer (smoking interaction);	chr7:107141205	chr7:107742817~107744581:-
COAD	cis	rs2581828	0.591	rs6445566	ENSG00000280417.1	RP11-5O17.1	4.28	2.63e-05	0.0076	0.29	0.26	Crohn's disease;	chr3:53131611	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.618	rs13319872	ENSG00000280417.1	RP11-5O17.1	4.28	2.63e-05	0.0076	0.29	0.26	Crohn's disease;	chr3:53132082	chr3:53046166~53048122:+
COAD	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	4.28	2.63e-05	0.0076	0.31	0.26	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	4.28	2.63e-05	0.0076	0.31	0.26	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	4.28	2.63e-05	0.0076	0.31	0.26	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
COAD	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	4.28	2.63e-05	0.0076	0.21	0.26	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
COAD	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	4.28	2.63e-05	0.0076	0.21	0.26	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
COAD	cis	rs9652601	0.691	rs3862468	ENSG00000274038.1	RP11-66H6.4	4.28	2.63e-05	0.0076	0.31	0.26	Systemic lupus erythematosus;	chr16:11100161	chr16:11056556~11057034:+
COAD	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-4.28	2.63e-05	0.0076	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
COAD	cis	rs367615	0.68	rs31595	ENSG00000249476.1	CTD-2587M2.1	4.28	2.63e-05	0.0076	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109643617	chr5:109237120~109326369:-
COAD	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-4.28	2.64e-05	0.0076	-0.26	-0.26	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
COAD	cis	rs11638352	1	rs2412853	ENSG00000205771.5	CATSPER2P1	4.28	2.64e-05	0.00761	0.51	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44003059	chr15:43726918~43747094:-
COAD	cis	rs1510272	0.883	rs9819534	ENSG00000243926.1	TIPARP-AS1	-4.28	2.64e-05	0.00761	-0.29	-0.26	Testicular germ cell tumor;	chr3:156593254	chr3:156671862~156674378:-
COAD	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-4.28	2.64e-05	0.00761	-0.29	-0.26	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
COAD	cis	rs7630852	1	rs9852432	ENSG00000272359.1	U4	-4.28	2.64e-05	0.00761	-0.3	-0.26	Eosinophil counts;	chr3:196780210	chr3:196747192~196747324:-
COAD	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-4.28	2.64e-05	0.00761	-0.28	-0.26	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
COAD	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	4.28	2.64e-05	0.00761	0.33	0.26	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
COAD	cis	rs41294858	1	rs76732255	ENSG00000232876.1	CTA-212D2.2	-4.28	2.64e-05	0.00761	-0.48	-0.26	Red blood cell count;	chr6:135087334	chr6:135055033~135060550:+
COAD	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	4.28	2.64e-05	0.00762	0.15	0.26	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
COAD	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
COAD	cis	rs9532669	0.963	rs4941391	ENSG00000239827.7	SUGT1P3	-4.28	2.64e-05	0.00762	-0.22	-0.26	Cervical cancer;	chr13:40939787	chr13:40908159~40921774:-
COAD	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-4.28	2.64e-05	0.00762	-0.32	-0.26	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
COAD	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	4.28	2.64e-05	0.00762	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
COAD	cis	rs875971	0.756	rs2901210	ENSG00000224316.1	RP11-479O9.2	-4.28	2.64e-05	0.00762	-0.28	-0.26	Aortic root size;	chr7:66552518	chr7:65773620~65802067:+
COAD	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-4.28	2.64e-05	0.00762	-0.27	-0.26	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
COAD	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	4.28	2.64e-05	0.00762	0.27	0.26	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
COAD	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-4.28	2.64e-05	0.00762	-0.28	-0.26	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
COAD	cis	rs10895987	1	rs10895987	ENSG00000254614.2	AP003068.23	-4.28	2.64e-05	0.00762	-0.38	-0.26	Blood protein levels;	chr11:65137437	chr11:65177606~65181834:-
COAD	cis	rs2765539	0.851	rs1409159	ENSG00000231365.4	RP11-418J17.1	-4.28	2.64e-05	0.00762	-0.32	-0.26	Waist-hip ratio;	chr1:118995810	chr1:119140396~119275973:+
COAD	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	4.28	2.65e-05	0.00763	0.38	0.26	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
COAD	cis	rs4243971	0.557	rs58921650	ENSG00000101898.5	MCTS2P	4.28	2.65e-05	0.00763	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32306100	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs35290636	ENSG00000101898.5	MCTS2P	4.28	2.65e-05	0.00763	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32285000	chr20:31547504~31548049:+
COAD	cis	rs1555133	0.694	rs3787373	ENSG00000101898.5	MCTS2P	4.28	2.65e-05	0.00763	0.28	0.26	Monocyte count;	chr20:32285519	chr20:31547504~31548049:+
COAD	cis	rs860295	0.812	rs12131079	ENSG00000223503.1	RP11-29H23.6	4.28	2.65e-05	0.00763	0.33	0.26	Body mass index;	chr1:155349877	chr1:155590601~155591262:-
COAD	cis	rs17772222	0.958	rs12436326	ENSG00000258789.1	RP11-507K2.3	-4.28	2.65e-05	0.00763	-0.37	-0.26	Coronary artery calcification;	chr14:88533632	chr14:88551597~88552493:+
COAD	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-4.28	2.65e-05	0.00763	-0.26	-0.26	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
COAD	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-4.28	2.65e-05	0.00763	-0.26	-0.26	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
COAD	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	4.28	2.65e-05	0.00764	0.27	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
COAD	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	4.28	2.65e-05	0.00765	0.3	0.26	Height;	chr4:55407965	chr4:55540502~55540835:-
COAD	cis	rs9532669	0.926	rs2324742	ENSG00000239827.7	SUGT1P3	-4.28	2.65e-05	0.00765	-0.22	-0.26	Cervical cancer;	chr13:40919059	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.857	rs9594455	ENSG00000239827.7	SUGT1P3	-4.28	2.65e-05	0.00765	-0.22	-0.26	Cervical cancer;	chr13:40919452	chr13:40908159~40921774:-
COAD	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	4.28	2.65e-05	0.00765	0.29	0.26	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
COAD	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.28	2.65e-05	0.00765	-0.32	-0.26	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
COAD	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.28	2.65e-05	0.00765	-0.38	-0.26	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
COAD	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-4.28	2.65e-05	0.00765	-0.37	-0.26	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
COAD	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-4.28	2.65e-05	0.00765	-0.3	-0.26	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
COAD	cis	rs71636778	0.509	rs11555809	ENSG00000260063.1	RP5-968P14.2	-4.28	2.66e-05	0.00765	-0.54	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26890178	chr1:26692132~26694131:-
COAD	cis	rs13256369	0.774	rs13260303	ENSG00000253981.4	ALG1L13P	4.28	2.66e-05	0.00766	0.36	0.26	Obesity-related traits;	chr8:8729832	chr8:8236003~8244667:-
COAD	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	4.28	2.66e-05	0.00766	0.29	0.26	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	4.28	2.66e-05	0.00766	0.34	0.26	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
COAD	cis	rs2337406	0.866	rs11488879	ENSG00000211967.3	IGHV3-53	-4.28	2.66e-05	0.00766	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106786097	chr14:106592676~106593347:-
COAD	cis	rs3824347	0.741	rs10869476	ENSG00000229587.2	RP11-197P3.5	4.28	2.66e-05	0.00766	0.29	0.26	Urinary magnesium-to-creatinine ratio;	chr9:75037539	chr9:75009828~75016036:-
COAD	cis	rs9307551	0.901	rs6850999	ENSG00000250334.4	LINC00989	-4.28	2.66e-05	0.00766	-0.34	-0.26	Refractive error;	chr4:79580784	chr4:79492416~79576460:+
COAD	cis	rs7819412	0.521	rs10100660	ENSG00000269918.1	AF131215.9	-4.28	2.66e-05	0.00766	-0.32	-0.26	Triglycerides;	chr8:11181376	chr8:11104691~11106704:-
COAD	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	4.28	2.66e-05	0.00766	0.3	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
COAD	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-4.28	2.66e-05	0.00767	-0.26	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
COAD	cis	rs1510272	0.69	rs10513491	ENSG00000243926.1	TIPARP-AS1	-4.28	2.66e-05	0.00767	-0.29	-0.26	Testicular germ cell tumor;	chr3:156602441	chr3:156671862~156674378:-
COAD	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	4.28	2.66e-05	0.00767	0.43	0.26	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	4.28	2.67e-05	0.00767	0.24	0.26	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
COAD	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	4.28	2.67e-05	0.00768	0.31	0.26	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
COAD	cis	rs2337406	0.636	rs74090069	ENSG00000211967.3	IGHV3-53	-4.28	2.67e-05	0.00768	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106777532	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74090071	ENSG00000211967.3	IGHV3-53	-4.28	2.67e-05	0.00768	-0.19	-0.26	Alzheimer's disease (late onset);	chr14:106777533	chr14:106592676~106593347:-
COAD	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	4.28	2.67e-05	0.00768	0.35	0.26	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
COAD	cis	rs36051354	0.573	rs2581792	ENSG00000242142.1	SERBP1P3	4.28	2.67e-05	0.00768	0.34	0.26	Intelligence (multi-trait analysis);	chr3:53001028	chr3:53064283~53065091:-
COAD	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	4.28	2.67e-05	0.00769	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	4.28	2.67e-05	0.00769	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	4.28	2.67e-05	0.00769	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	4.28	2.67e-05	0.00769	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	4.28	2.67e-05	0.00769	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
COAD	cis	rs440932	0.887	rs398801	ENSG00000253981.4	ALG1L13P	-4.28	2.67e-05	0.00769	-0.34	-0.26	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8236003~8244667:-
COAD	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	4.28	2.67e-05	0.00769	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
COAD	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.28	2.67e-05	0.00769	0.26	0.26	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
COAD	cis	rs1044826	0.642	rs4683464	ENSG00000272656.1	RP11-219D15.3	4.28	2.68e-05	0.0077	0.3	0.26	Obesity-related traits;	chr3:139478119	chr3:139349024~139349371:-
COAD	cis	rs72793342	0.651	rs8050463	ENSG00000235560.3	AC002310.12	4.28	2.68e-05	0.0077	0.37	0.26	RANTES levels;	chr16:30542838	chr16:30534752~30537144:+
COAD	cis	rs2018683	0.707	rs4722875	ENSG00000272568.4	CTB-113D17.1	4.28	2.68e-05	0.00771	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28979967~29013367:+
COAD	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-4.28	2.68e-05	0.00771	-0.32	-0.26	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
COAD	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	4.28	2.68e-05	0.00771	0.29	0.26	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	4.28	2.68e-05	0.00771	0.29	0.26	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
COAD	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	4.28	2.68e-05	0.00771	0.32	0.26	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
COAD	cis	rs739496	0.579	rs2285695	ENSG00000257595.2	RP3-473L9.4	4.28	2.69e-05	0.00772	0.38	0.26	Platelet count;	chr12:111937504	chr12:111369282~111403310:+
COAD	cis	rs739496	0.527	rs3752632	ENSG00000257595.2	RP3-473L9.4	4.28	2.69e-05	0.00772	0.38	0.26	Platelet count;	chr12:111938493	chr12:111369282~111403310:+
COAD	cis	rs739496	0.614	rs9788231	ENSG00000257595.2	RP3-473L9.4	4.28	2.69e-05	0.00772	0.38	0.26	Platelet count;	chr12:111947861	chr12:111369282~111403310:+
COAD	cis	rs1510272	0.961	rs9861440	ENSG00000243926.1	TIPARP-AS1	-4.28	2.69e-05	0.00772	-0.3	-0.26	Testicular germ cell tumor;	chr3:156599590	chr3:156671862~156674378:-
COAD	cis	rs2638953	0.741	rs10843194	ENSG00000247934.4	RP11-967K21.1	-4.28	2.69e-05	0.00772	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28163298~28190738:-
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	4.28	2.69e-05	0.00773	0.27	0.26	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
COAD	cis	rs17359493	0.887	rs11786389	ENSG00000253528.2	RP11-347C18.4	-4.28	2.69e-05	0.00773	-0.35	-0.26	Type 2 diabetes;	chr8:94842592	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs17359493	ENSG00000253528.2	RP11-347C18.4	-4.28	2.69e-05	0.00773	-0.35	-0.26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94844683	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.614	rs16917079	ENSG00000253528.2	RP11-347C18.4	-4.28	2.69e-05	0.00773	-0.35	-0.26	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94847943	chr8:94974573~94974853:-
COAD	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-4.28	2.69e-05	0.00773	-0.46	-0.26	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
COAD	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	4.28	2.69e-05	0.00773	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
COAD	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	4.28	2.69e-05	0.00773	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
COAD	cis	rs180730	1	rs3106313	ENSG00000251609.2	SETP12	-4.28	2.69e-05	0.00774	-0.38	-0.26	Fasting plasma glucose;	chr4:120882815	chr4:120895494~120897083:-
COAD	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.28	2.69e-05	0.00774	0.25	0.26	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000254340.1	RP11-10A14.3	4.28	2.7e-05	0.00774	0.29	0.26	Mood instability;	chr8:8522961	chr8:9141424~9145435:+
COAD	cis	rs7584330	0.744	rs10929235	ENSG00000234949.2	AC104667.3	-4.28	2.7e-05	0.00774	-0.35	-0.26	Prostate cancer;	chr2:237471629	chr2:237591020~237595981:+
COAD	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	4.27	2.7e-05	0.00775	0.3	0.26	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
COAD	cis	rs11603023	0.772	rs540800	ENSG00000278376.1	RP11-158I9.8	-4.27	2.7e-05	0.00775	-0.26	-0.26	Cholesterol, total;	chr11:118694942	chr11:118791254~118793137:+
COAD	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-4.27	2.7e-05	0.00775	-0.31	-0.26	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
COAD	cis	rs17772222	1	rs1955599	ENSG00000258789.1	RP11-507K2.3	-4.27	2.7e-05	0.00775	-0.36	-0.26	Coronary artery calcification;	chr14:88358788	chr14:88551597~88552493:+
COAD	cis	rs17772222	1	rs1955600	ENSG00000258789.1	RP11-507K2.3	-4.27	2.7e-05	0.00775	-0.36	-0.26	Coronary artery calcification;	chr14:88359040	chr14:88551597~88552493:+
COAD	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	4.27	2.7e-05	0.00775	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
COAD	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	4.27	2.7e-05	0.00775	0.25	0.26	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
COAD	cis	rs7955901	0.837	rs2063591	ENSG00000258053.1	CTD-2021H9.3	-4.27	2.7e-05	0.00776	-0.31	-0.26	Type 2 diabetes;	chr12:71018075	chr12:71047402~71118247:-
COAD	cis	rs7200543	1	rs16966947	ENSG00000270580.4	PKD1P6	4.27	2.7e-05	0.00776	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15104723~15131601:-
COAD	cis	rs739496	0.615	rs634389	ENSG00000257595.2	RP3-473L9.4	4.27	2.7e-05	0.00776	0.38	0.26	Platelet count;	chr12:111726911	chr12:111369282~111403310:+
COAD	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.27	2.7e-05	0.00776	0.32	0.26	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
COAD	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.27	2.7e-05	0.00777	0.31	0.26	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
COAD	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	4.27	2.71e-05	0.00777	0.33	0.26	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
COAD	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	4.27	2.71e-05	0.00777	0.46	0.26	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
COAD	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	4.27	2.71e-05	0.00777	0.26	0.26	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
COAD	cis	rs2638953	0.853	rs12370338	ENSG00000247934.4	RP11-967K21.1	-4.27	2.71e-05	0.00777	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28163298~28190738:-
COAD	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-4.27	2.71e-05	0.00777	-0.5	-0.26	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-4.27	2.71e-05	0.00777	-0.5	-0.26	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
COAD	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-4.27	2.71e-05	0.00777	-0.27	-0.26	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
COAD	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-4.27	2.71e-05	0.00777	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
COAD	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	4.27	2.71e-05	0.00778	0.37	0.26	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
COAD	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-4.27	2.71e-05	0.00778	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
COAD	cis	rs11935103	0.654	rs1868897	ENSG00000279943.1	FLJ38576	-4.27	2.71e-05	0.00778	-0.32	-0.26	Response to citalopram treatment;	chr4:186428942	chr4:186189032~186191490:-
COAD	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	4.27	2.71e-05	0.00778	0.36	0.26	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
COAD	cis	rs9400467	0.508	rs12211763	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.71e-05	0.00779	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs10872067	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.71e-05	0.00779	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111297126~111298510:+
COAD	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	4.27	2.72e-05	0.00779	0.38	0.26	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
COAD	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.27	2.72e-05	0.00779	-0.25	-0.26	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
COAD	cis	rs2638953	1	rs11049532	ENSG00000247934.4	RP11-967K21.1	-4.27	2.72e-05	0.00779	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.925	rs10843154	ENSG00000247934.4	RP11-967K21.1	-4.27	2.72e-05	0.00779	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.889	rs10843155	ENSG00000247934.4	RP11-967K21.1	-4.27	2.72e-05	0.00779	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.889	rs11049538	ENSG00000247934.4	RP11-967K21.1	-4.27	2.72e-05	0.00779	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28163298~28190738:-
COAD	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	4.27	2.72e-05	0.00779	0.3	0.26	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
COAD	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-4.27	2.72e-05	0.0078	-0.28	-0.26	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
COAD	cis	rs930421	0.544	rs4953653	ENSG00000226491.1	FTOP1	-4.27	2.72e-05	0.0078	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr2:42762019	chr2:42797225~42798712:-
COAD	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.27	2.72e-05	0.0078	0.33	0.26	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
COAD	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-4.27	2.72e-05	0.00781	-0.27	-0.26	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
COAD	cis	rs7615952	0.512	rs2979336	ENSG00000248787.1	RP11-666A20.4	-4.27	2.72e-05	0.00781	-0.35	-0.26	Blood pressure (smoking interaction);	chr3:125638626	chr3:125908005~125910272:-
COAD	cis	rs2732480	0.557	rs2732454	ENSG00000226413.2	OR8T1P	4.27	2.72e-05	0.00781	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48442030~48442947:-
COAD	cis	rs7260598	0.605	rs61053953	ENSG00000268442.1	CTD-2027I19.2	4.27	2.72e-05	0.00781	0.46	0.26	Response to taxane treatment (placlitaxel);	chr19:23773846	chr19:24162370~24163425:-
COAD	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-4.27	2.72e-05	0.00781	-0.22	-0.26	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
COAD	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-4.27	2.72e-05	0.00781	-0.27	-0.26	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
COAD	cis	rs1048886	0.938	rs9294868	ENSG00000271967.1	RP11-134K13.4	-4.27	2.73e-05	0.00781	-0.35	-0.26	Type 2 diabetes;	chr6:70415806	chr6:70596438~70596980:+
COAD	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	4.27	2.73e-05	0.00782	0.24	0.26	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
COAD	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-4.27	2.73e-05	0.00782	-0.37	-0.26	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
COAD	cis	rs3135063	0.847	rs1138690	ENSG00000248840.2	RP11-357G3.2	-4.27	2.73e-05	0.00782	-0.27	-0.26	Blood protein levels;	chr4:3289674	chr4:3312512~3313058:+
COAD	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	4.27	2.73e-05	0.00782	0.51	0.26	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
COAD	cis	rs2408955	0.568	rs12099462	ENSG00000273765.1	RP11-370I10.11	-4.27	2.73e-05	0.00782	-0.27	-0.26	Glycated hemoglobin levels;	chr12:48109321	chr12:48360920~48361377:+
COAD	cis	rs7260598	0.892	rs2116956	ENSG00000268442.1	CTD-2027I19.2	4.27	2.73e-05	0.00782	0.41	0.26	Response to taxane treatment (placlitaxel);	chr19:24005987	chr19:24162370~24163425:-
COAD	cis	rs12807809	1	rs36053597	ENSG00000245498.5	RP11-677M14.7	4.27	2.73e-05	0.00782	0.32	0.26	Schizophrenia;	chr11:124736588	chr11:124800450~124834487:+
COAD	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.27	2.73e-05	0.00782	0.22	0.26	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
COAD	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	4.27	2.73e-05	0.00782	0.24	0.26	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
COAD	cis	rs6687821	0.515	rs2764425	ENSG00000261737.1	RP4-612B15.3	4.27	2.73e-05	0.00782	0.34	0.26	Yeast infection;	chr1:87083076	chr1:86703502~86704462:-
COAD	cis	rs2378497	0.938	rs12140406	ENSG00000232679.1	RP11-400N13.3	4.27	2.73e-05	0.00783	0.37	0.26	Serum thyroid-stimulating hormone levels;	chr1:221985191	chr1:222041705~222064763:-
COAD	cis	rs34792	0.554	rs4597346	ENSG00000207425.1	Y_RNA	-4.27	2.73e-05	0.00783	-0.32	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14915457~14915556:-
COAD	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-4.27	2.73e-05	0.00783	-0.32	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
COAD	cis	rs34792	0.525	rs12708795	ENSG00000207425.1	Y_RNA	-4.27	2.73e-05	0.00783	-0.32	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14915457~14915556:-
COAD	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	4.27	2.73e-05	0.00783	0.24	0.26	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
COAD	cis	rs58873874	0.737	rs11466784	ENSG00000248544.2	CTB-47B11.3	4.27	2.73e-05	0.00783	0.59	0.26	Bipolar disorder (body mass index interaction);	chr5:157494643	chr5:157375741~157384950:-
COAD	cis	rs1510272	0.961	rs1510275	ENSG00000243926.1	TIPARP-AS1	-4.27	2.73e-05	0.00783	-0.29	-0.26	Testicular germ cell tumor;	chr3:156586611	chr3:156671862~156674378:-
COAD	cis	rs9907295	0.636	rs4251724	ENSG00000270977.1	AC015849.16	-4.27	2.73e-05	0.00783	-0.34	-0.26	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35893707~35911023:-
COAD	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-4.27	2.73e-05	0.00783	-0.26	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
COAD	cis	rs9532669	0.926	rs2324742	ENSG00000277662.1	RP11-74J13.9	-4.27	2.73e-05	0.00783	-0.25	-0.26	Cervical cancer;	chr13:40919059	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.857	rs9594455	ENSG00000277662.1	RP11-74J13.9	-4.27	2.73e-05	0.00783	-0.25	-0.26	Cervical cancer;	chr13:40919452	chr13:41229180~41229676:-
COAD	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	4.27	2.73e-05	0.00783	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
COAD	cis	rs1044826	0.642	rs6787649	ENSG00000272656.1	RP11-219D15.3	4.27	2.73e-05	0.00784	0.3	0.26	Obesity-related traits;	chr3:139474479	chr3:139349024~139349371:-
COAD	cis	rs36052053	0.908	rs34739891	ENSG00000219700.1	PTCHD3P3	4.27	2.73e-05	0.00784	0.45	0.26	Red cell distribution width;	chr6:109290264	chr6:109288571~109290503:-
COAD	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-4.27	2.74e-05	0.00784	-0.29	-0.26	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
COAD	cis	rs801193	1	rs10234018	ENSG00000272831.1	RP11-792A8.4	-4.27	2.74e-05	0.00784	-0.27	-0.26	Aortic root size;	chr7:66681297	chr7:66739829~66740385:-
COAD	cis	rs9532669	0.963	rs4343141	ENSG00000239827.7	SUGT1P3	-4.27	2.74e-05	0.00784	-0.22	-0.26	Cervical cancer;	chr13:40940497	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.963	rs3887418	ENSG00000239827.7	SUGT1P3	-4.27	2.74e-05	0.00784	-0.22	-0.26	Cervical cancer;	chr13:40940560	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs1056820	ENSG00000239827.7	SUGT1P3	-4.27	2.74e-05	0.00784	-0.22	-0.26	Cervical cancer;	chr13:40941150	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9532678	ENSG00000239827.7	SUGT1P3	-4.27	2.74e-05	0.00784	-0.22	-0.26	Cervical cancer;	chr13:40941862	chr13:40908159~40921774:-
COAD	cis	rs3788317	0.526	rs5992495	ENSG00000232926.1	AC000078.5	-4.27	2.74e-05	0.00784	-0.28	-0.26	Glaucoma (primary angle closure);	chr22:19895461	chr22:19887289~19887970:+
COAD	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-4.27	2.74e-05	0.00784	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
COAD	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	4.27	2.74e-05	0.00785	0.31	0.26	Height;	chr4:55508982	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	4.27	2.74e-05	0.00785	0.31	0.26	Height;	chr4:55509442	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	4.27	2.74e-05	0.00785	0.31	0.26	Height;	chr4:55510177	chr4:55540502~55540835:-
COAD	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	4.27	2.74e-05	0.00785	0.31	0.26	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
COAD	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-4.27	2.74e-05	0.00785	-0.26	-0.26	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
COAD	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-4.27	2.74e-05	0.00785	-0.26	-0.26	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
COAD	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	4.27	2.74e-05	0.00786	0.34	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
COAD	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.74e-05	0.00786	-0.24	-0.26	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.74e-05	0.00786	-0.24	-0.26	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
COAD	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	4.27	2.74e-05	0.00786	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	4.27	2.74e-05	0.00786	0.34	0.26	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
COAD	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	4.27	2.75e-05	0.00786	0.46	0.26	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
COAD	cis	rs9487051	0.836	rs9487036	ENSG00000219700.1	PTCHD3P3	4.27	2.75e-05	0.00786	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109286246	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.836	rs9400270	ENSG00000219700.1	PTCHD3P3	4.27	2.75e-05	0.00786	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109286285	chr6:109288571~109290503:-
COAD	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-4.27	2.75e-05	0.00786	-0.28	-0.26	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
COAD	cis	rs8022206	0.738	rs68139749	ENSG00000259502.1	RP11-643G16.3	4.27	2.75e-05	0.00787	0.36	0.26	Platelet count;Mean platelet volume;	chr14:68073038	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs17104889	ENSG00000259502.1	RP11-643G16.3	4.27	2.75e-05	0.00787	0.36	0.26	Platelet count;Mean platelet volume;	chr14:68076939	chr14:67610986~67613864:+
COAD	cis	rs875971	0.66	rs1860468	ENSG00000272831.1	RP11-792A8.4	-4.27	2.75e-05	0.00787	-0.27	-0.26	Aortic root size;	chr7:66642265	chr7:66739829~66740385:-
COAD	cis	rs1044826	0.642	rs9859864	ENSG00000272656.1	RP11-219D15.3	-4.27	2.75e-05	0.00787	-0.3	-0.26	Obesity-related traits;	chr3:139372377	chr3:139349024~139349371:-
COAD	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	4.27	2.75e-05	0.00787	0.31	0.26	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
COAD	cis	rs2638953	0.853	rs10843185	ENSG00000247934.4	RP11-967K21.1	-4.27	2.75e-05	0.00787	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473778	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs12367657	ENSG00000247934.4	RP11-967K21.1	-4.27	2.75e-05	0.00787	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28163298~28190738:-
COAD	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	4.27	2.75e-05	0.00788	0.3	0.26	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
COAD	cis	rs7200543	1	rs55727637	ENSG00000270580.4	PKD1P6	4.27	2.75e-05	0.00788	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15104723~15131601:-
COAD	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	4.27	2.75e-05	0.00788	0.35	0.26	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
COAD	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	4.27	2.75e-05	0.00788	0.35	0.26	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
COAD	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	4.27	2.75e-05	0.00788	0.35	0.26	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
COAD	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-4.27	2.75e-05	0.00788	-0.31	-0.26	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
COAD	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-4.27	2.75e-05	0.00788	-0.3	-0.26	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-4.27	2.75e-05	0.00788	-0.3	-0.26	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
COAD	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-4.27	2.76e-05	0.00789	-0.41	-0.26	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-4.27	2.76e-05	0.00789	-0.41	-0.26	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-4.27	2.76e-05	0.00789	-0.41	-0.26	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-4.27	2.76e-05	0.00789	-0.41	-0.26	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
COAD	cis	rs9990333	1	rs9990333	ENSG00000185485.13	SDHAP1	-4.27	2.76e-05	0.00789	-0.22	-0.26	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195959748~195990318:-
COAD	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	4.27	2.76e-05	0.00789	0.3	0.26	Height;	chr4:55561218	chr4:55540502~55540835:-
COAD	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	4.27	2.76e-05	0.0079	0.33	0.26	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
COAD	cis	rs6661961	0.644	rs11205002	ENSG00000237975.5	FLG-AS1	-4.27	2.76e-05	0.0079	-0.27	-0.26	Atopic dermatitis;	chr1:152430863	chr1:152168125~152445456:+
COAD	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	4.27	2.76e-05	0.0079	0.29	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
COAD	cis	rs875971	0.862	rs2024192	ENSG00000224316.1	RP11-479O9.2	-4.27	2.76e-05	0.00791	-0.28	-0.26	Aortic root size;	chr7:66576460	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6955837	ENSG00000224316.1	RP11-479O9.2	-4.27	2.76e-05	0.00791	-0.28	-0.26	Aortic root size;	chr7:66578155	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs10281499	ENSG00000224316.1	RP11-479O9.2	-4.27	2.76e-05	0.00791	-0.28	-0.26	Aortic root size;	chr7:66583979	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs4718377	ENSG00000224316.1	RP11-479O9.2	-4.27	2.76e-05	0.00791	-0.28	-0.26	Aortic root size;	chr7:66584691	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs10278014	ENSG00000224316.1	RP11-479O9.2	-4.27	2.76e-05	0.00791	-0.28	-0.26	Aortic root size;	chr7:66586277	chr7:65773620~65802067:+
COAD	cis	rs7260598	0.539	rs79838949	ENSG00000268442.1	CTD-2027I19.2	4.27	2.76e-05	0.00791	0.45	0.26	Response to taxane treatment (placlitaxel);	chr19:23866311	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs76237579	ENSG00000268442.1	CTD-2027I19.2	4.27	2.76e-05	0.00791	0.45	0.26	Response to taxane treatment (placlitaxel);	chr19:23869921	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs10518280	ENSG00000268442.1	CTD-2027I19.2	4.27	2.76e-05	0.00791	0.45	0.26	Response to taxane treatment (placlitaxel);	chr19:23872279	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs75695352	ENSG00000268442.1	CTD-2027I19.2	4.27	2.76e-05	0.00791	0.45	0.26	Response to taxane treatment (placlitaxel);	chr19:23872302	chr19:24162370~24163425:-
COAD	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	4.27	2.76e-05	0.00791	0.31	0.26	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
COAD	cis	rs11098499	0.78	rs10013652	ENSG00000249244.1	RP11-548H18.2	4.27	2.77e-05	0.00791	0.34	0.26	Corneal astigmatism;	chr4:119371101	chr4:119391831~119395335:-
COAD	cis	rs11603023	0.967	rs7936556	ENSG00000278376.1	RP11-158I9.8	4.27	2.77e-05	0.00792	0.26	0.26	Cholesterol, total;	chr11:118630582	chr11:118791254~118793137:+
COAD	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	4.27	2.77e-05	0.00792	0.29	0.26	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
COAD	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-4.27	2.77e-05	0.00792	-0.3	-0.26	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
COAD	cis	rs728616	0.867	rs1054054	ENSG00000234382.2	RP11-40F6.1	-4.27	2.77e-05	0.00792	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61859766	ENSG00000234382.2	RP11-40F6.1	-4.27	2.77e-05	0.00792	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:80233664~80245367:+
COAD	cis	rs74781061	0.929	rs6495108	ENSG00000260103.2	RP11-10O17.1	-4.27	2.77e-05	0.00792	-0.32	-0.26	Endometriosis;	chr15:74502186	chr15:74478070~74490286:-
COAD	cis	rs2777491	0.789	rs316617	ENSG00000247556.5	OIP5-AS1	-4.27	2.77e-05	0.00792	-0.28	-0.26	Ulcerative colitis;	chr15:41503702	chr15:41283990~41309737:+
COAD	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-4.27	2.77e-05	0.00792	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-4.27	2.77e-05	0.00792	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-4.27	2.77e-05	0.00792	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-4.27	2.77e-05	0.00792	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
COAD	cis	rs7260598	0.581	rs17311328	ENSG00000268442.1	CTD-2027I19.2	4.27	2.77e-05	0.00792	0.41	0.26	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:24162370~24163425:-
COAD	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	4.27	2.77e-05	0.00792	0.35	0.26	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
COAD	cis	rs860295	0.776	rs11264362	ENSG00000223503.1	RP11-29H23.6	4.27	2.77e-05	0.00792	0.33	0.26	Body mass index;	chr1:155345824	chr1:155590601~155591262:-
COAD	cis	rs6661961	0.714	rs986903	ENSG00000237975.5	FLG-AS1	-4.27	2.77e-05	0.00793	-0.27	-0.26	Atopic dermatitis;	chr1:152438093	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-4.27	2.77e-05	0.00793	-0.33	-0.26	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
COAD	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-4.27	2.77e-05	0.00793	-0.24	-0.26	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
COAD	cis	rs9813712	0.526	rs13065659	ENSG00000249846.5	RP11-77P16.4	-4.27	2.77e-05	0.00793	-0.29	-0.26	Response to amphetamines;	chr3:130231945	chr3:130112550~130120579:+
COAD	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	4.27	2.77e-05	0.00793	0.23	0.26	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
COAD	cis	rs11668609	0.515	rs11670600	ENSG00000268442.1	CTD-2027I19.2	4.27	2.77e-05	0.00793	0.46	0.26	Response to taxane treatment (docetaxel);	chr19:23782120	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.539	rs74612410	ENSG00000268442.1	CTD-2027I19.2	4.27	2.77e-05	0.00793	0.46	0.26	Response to taxane treatment (placlitaxel);	chr19:23785148	chr19:24162370~24163425:-
COAD	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-4.27	2.77e-05	0.00793	-0.3	-0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
COAD	cis	rs17407555	0.657	rs12505144	ENSG00000250413.1	RP11-448G15.1	-4.27	2.77e-05	0.00793	-0.34	-0.26	Schizophrenia (age at onset);	chr4:10269295	chr4:10006482~10009725:+
COAD	cis	rs453301	0.686	rs4840389	ENSG00000254340.1	RP11-10A14.3	-4.27	2.78e-05	0.00794	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9026993	chr8:9141424~9145435:+
COAD	cis	rs4239252	0.929	rs4796116	ENSG00000271013.1	AC015849.15	-4.27	2.78e-05	0.00794	-0.31	-0.26	Blood protein levels;	chr17:35841496	chr17:35912635~35918010:-
COAD	cis	rs4239252	0.929	rs4251791	ENSG00000271013.1	AC015849.15	-4.27	2.78e-05	0.00794	-0.31	-0.26	Blood protein levels;	chr17:35845711	chr17:35912635~35918010:-
COAD	cis	rs2777491	0.915	rs8032838	ENSG00000247556.5	OIP5-AS1	4.27	2.78e-05	0.00795	0.28	0.26	Ulcerative colitis;	chr15:41313434	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs9302109	ENSG00000247556.5	OIP5-AS1	4.27	2.78e-05	0.00795	0.28	0.26	Ulcerative colitis;	chr15:41319982	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs7165675	ENSG00000247556.5	OIP5-AS1	4.27	2.78e-05	0.00795	0.28	0.26	Ulcerative colitis;	chr15:41322506	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs28526381	ENSG00000247556.5	OIP5-AS1	4.27	2.78e-05	0.00795	0.28	0.26	Ulcerative colitis;	chr15:41329644	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs28578057	ENSG00000247556.5	OIP5-AS1	4.27	2.78e-05	0.00795	0.28	0.26	Ulcerative colitis;	chr15:41329723	chr15:41283990~41309737:+
COAD	cis	rs7829975	0.714	rs59046059	ENSG00000233609.3	RP11-62H7.2	4.27	2.78e-05	0.00795	0.29	0.26	Mood instability;	chr8:8813226	chr8:8961200~8979025:+
COAD	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	4.27	2.78e-05	0.00795	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
COAD	cis	rs17685	0.753	rs2868203	ENSG00000280388.1	RP11-229D13.3	4.27	2.78e-05	0.00795	0.26	0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1104878	ENSG00000280388.1	RP11-229D13.3	-4.27	2.78e-05	0.00795	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs869805	ENSG00000280388.1	RP11-229D13.3	-4.27	2.78e-05	0.00795	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76043977~76045963:-
COAD	cis	rs12497850	0.931	rs7430198	ENSG00000225399.4	RP11-3B7.1	4.27	2.78e-05	0.00795	0.28	0.26	Parkinson's disease;	chr3:48951327	chr3:49260085~49261316:+
COAD	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	4.27	2.78e-05	0.00796	0.29	0.26	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
COAD	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	4.27	2.79e-05	0.00796	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
COAD	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	4.27	2.79e-05	0.00796	0.42	0.26	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
COAD	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-4.27	2.79e-05	0.00796	-0.29	-0.26	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
COAD	cis	rs860295	1	rs10908482	ENSG00000203761.5	MSTO2P	-4.27	2.79e-05	0.00796	-0.23	-0.26	Body mass index;	chr1:155744082	chr1:155745829~155750137:+
COAD	cis	rs5758511	0.773	rs62241023	ENSG00000237037.8	NDUFA6-AS1	-4.27	2.79e-05	0.00796	-0.3	-0.26	Birth weight;	chr22:41989425	chr22:42090931~42137742:+
COAD	cis	rs9532669	0.853	rs9315795	ENSG00000239827.7	SUGT1P3	-4.27	2.79e-05	0.00796	-0.22	-0.26	Cervical cancer;	chr13:40943382	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.963	rs3764056	ENSG00000239827.7	SUGT1P3	-4.27	2.79e-05	0.00796	-0.22	-0.26	Cervical cancer;	chr13:40943849	chr13:40908159~40921774:-
COAD	cis	rs2732480	0.538	rs2468943	ENSG00000226413.2	OR8T1P	-4.27	2.79e-05	0.00797	-0.33	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48442030~48442947:-
COAD	cis	rs6452524	0.618	rs255561	ENSG00000271862.1	RP11-343L5.2	4.27	2.79e-05	0.00797	0.25	0.26	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83049376~83050964:-
COAD	cis	rs7465272	1	rs13259747	ENSG00000263660.1	AC087793.1	-4.27	2.79e-05	0.00797	-0.29	-0.26	Bipolar disorder and schizophrenia;	chr8:142602206	chr8:143314921~143315006:+
COAD	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	4.27	2.79e-05	0.00797	0.26	0.26	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
COAD	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.27	2.79e-05	0.00797	-0.32	-0.26	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.27	2.79e-05	0.00797	-0.32	-0.26	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
COAD	cis	rs6490294	0.659	rs11066028	ENSG00000257595.2	RP3-473L9.4	4.27	2.79e-05	0.00798	0.33	0.26	Mean platelet volume;	chr12:111807366	chr12:111369282~111403310:+
COAD	cis	rs6452524	0.508	rs256795	ENSG00000271862.1	RP11-343L5.2	-4.27	2.79e-05	0.00798	-0.25	-0.26	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83049376~83050964:-
COAD	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
COAD	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	4.27	2.8e-05	0.00798	0.42	0.26	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
COAD	cis	rs7577696	0.785	rs11683760	ENSG00000272716.1	RP11-563N4.1	-4.27	2.8e-05	0.00798	-0.27	-0.26	Inflammatory biomarkers;	chr2:32139024	chr2:32165046~32165757:-
COAD	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-4.27	2.8e-05	0.00798	-0.33	-0.26	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
COAD	cis	rs7200543	0.961	rs3803573	ENSG00000270580.4	PKD1P6	4.27	2.8e-05	0.00798	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15104723~15131601:-
COAD	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	4.27	2.8e-05	0.00798	0.27	0.26	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
COAD	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.27	2.8e-05	0.00798	0.31	0.26	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
COAD	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	4.27	2.8e-05	0.00799	0.38	0.26	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
COAD	cis	rs739496	0.579	rs6489810	ENSG00000257595.2	RP3-473L9.4	4.27	2.8e-05	0.00799	0.38	0.26	Platelet count;	chr12:111839602	chr12:111369282~111403310:+
COAD	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-4.27	2.8e-05	0.00799	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-4.27	2.8e-05	0.00799	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
COAD	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	4.27	2.8e-05	0.00799	0.19	0.26	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
COAD	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	4.27	2.8e-05	0.00799	0.33	0.26	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
COAD	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	4.27	2.8e-05	0.00799	0.58	0.26	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
COAD	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-4.27	2.8e-05	0.00799	-0.49	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
COAD	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	4.27	2.8e-05	0.00799	0.24	0.26	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
COAD	cis	rs4760786	0.735	rs17226863	ENSG00000258053.1	CTD-2021H9.3	-4.27	2.8e-05	0.00799	-0.32	-0.26	Monobrow;	chr12:71164668	chr12:71047402~71118247:-
COAD	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-4.27	2.8e-05	0.008	-0.33	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
COAD	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-4.27	2.8e-05	0.008	-0.33	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
COAD	cis	rs385076	0.527	rs10779914	ENSG00000272716.1	RP11-563N4.1	-4.27	2.8e-05	0.008	-0.3	-0.26	Interleukin-18 levels;	chr2:31880971	chr2:32165046~32165757:-
COAD	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	4.27	2.8e-05	0.008	0.34	0.26	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	4.27	2.8e-05	0.008	0.33	0.26	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	4.27	2.8e-05	0.008	0.33	0.26	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	4.27	2.8e-05	0.008	0.33	0.26	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
COAD	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-4.27	2.8e-05	0.008	-0.26	-0.26	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
COAD	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-4.27	2.81e-05	0.008	-0.31	-0.26	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
COAD	cis	rs6661961	0.714	rs10888488	ENSG00000237975.5	FLG-AS1	-4.27	2.81e-05	0.008	-0.27	-0.26	Atopic dermatitis;	chr1:152438614	chr1:152168125~152445456:+
COAD	cis	rs2732480	0.557	rs2732454	ENSG00000240399.1	RP1-228P16.1	4.27	2.81e-05	0.008	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48054813~48055591:-
COAD	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	4.27	2.81e-05	0.008	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	4.27	2.81e-05	0.008	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	4.27	2.81e-05	0.008	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
COAD	cis	rs1670533	1	rs11247971	ENSG00000273179.1	RP11-20I20.4	4.27	2.81e-05	0.00801	0.34	0.26	Recombination rate (females);	chr4:1059792	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10084849	ENSG00000273179.1	RP11-20I20.4	4.27	2.81e-05	0.00801	0.34	0.26	Recombination rate (females);	chr4:1059798	chr4:1167778~1168174:+
COAD	cis	rs180730	1	rs1901136	ENSG00000251609.2	SETP12	-4.27	2.81e-05	0.00801	-0.38	-0.26	Fasting plasma glucose;	chr4:120881574	chr4:120895494~120897083:-
COAD	cis	rs180730	1	rs2667175	ENSG00000251609.2	SETP12	-4.27	2.81e-05	0.00801	-0.38	-0.26	Fasting plasma glucose;	chr4:120882099	chr4:120895494~120897083:-
COAD	cis	rs180730	0.948	rs3115312	ENSG00000251609.2	SETP12	-4.27	2.81e-05	0.00801	-0.38	-0.26	Fasting plasma glucose;	chr4:120882651	chr4:120895494~120897083:-
COAD	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-4.27	2.81e-05	0.00801	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
COAD	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.27	2.81e-05	0.00801	0.23	0.26	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.27	2.81e-05	0.00801	0.23	0.26	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
COAD	cis	rs2638953	0.815	rs11049683	ENSG00000247934.4	RP11-967K21.1	-4.27	2.81e-05	0.00801	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs10843193	ENSG00000247934.4	RP11-967K21.1	-4.27	2.81e-05	0.00801	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28163298~28190738:-
COAD	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	4.26	2.81e-05	0.00802	0.29	0.26	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
COAD	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	4.26	2.81e-05	0.00803	0.34	0.26	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	4.26	2.82e-05	0.00803	0.33	0.26	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	4.26	2.82e-05	0.00803	0.33	0.26	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
COAD	cis	rs4704187	0.687	rs1903838	ENSG00000250889.2	LINC01336	-4.26	2.82e-05	0.00803	-0.29	-0.26	Response to amphetamines;	chr5:75184174	chr5:75047719~75052843:-
COAD	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	4.26	2.82e-05	0.00803	0.33	0.26	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
COAD	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-4.26	2.82e-05	0.00803	-0.26	-0.26	Axial length;	chr3:53806638	chr3:53797764~53798019:-
COAD	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-4.26	2.82e-05	0.00803	-0.41	-0.26	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-4.26	2.82e-05	0.00803	-0.41	-0.26	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-4.26	2.82e-05	0.00803	-0.41	-0.26	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
COAD	cis	rs2638953	0.815	rs11049696	ENSG00000247934.4	RP11-967K21.1	-4.26	2.82e-05	0.00803	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28528922	chr12:28163298~28190738:-
COAD	cis	rs172166	0.516	rs1225710	ENSG00000272009.1	RP1-313I6.12	-4.26	2.82e-05	0.00804	-0.28	-0.26	Cardiac Troponin-T levels;	chr6:28132862	chr6:28078792~28081130:-
COAD	cis	rs7656342	0.808	rs6835741	ENSG00000186234.7	FAM86MP	-4.26	2.82e-05	0.00804	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9777287	chr4:9692495~9702954:+
COAD	cis	rs2832191	0.716	rs1888439	ENSG00000176054.6	RPL23P2	4.26	2.82e-05	0.00804	0.27	0.26	Dental caries;	chr21:29082136	chr21:28997613~28998033:-
COAD	cis	rs2115630	1	rs7183401	ENSG00000259728.4	LINC00933	-4.26	2.82e-05	0.00804	-0.29	-0.26	P wave terminal force;	chr15:84828713	chr15:84570649~84580175:+
COAD	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	4.26	2.82e-05	0.00804	0.28	0.26	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
COAD	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	4.26	2.82e-05	0.00804	0.28	0.26	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
COAD	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-4.26	2.82e-05	0.00804	-0.28	-0.26	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
COAD	cis	rs9910055	0.502	rs1684662	ENSG00000267080.4	ASB16-AS1	4.26	2.82e-05	0.00804	0.25	0.26	Total body bone mineral density;	chr17:44103454	chr17:44175973~44186717:-
COAD	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-4.26	2.82e-05	0.00805	-0.34	-0.26	Depression;	chr6:28206812	chr6:28115628~28116551:+
COAD	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	4.26	2.82e-05	0.00805	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
COAD	cis	rs2732480	0.557	rs923397	ENSG00000226413.2	OR8T1P	4.26	2.83e-05	0.00805	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48442030~48442947:-
COAD	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-4.26	2.83e-05	0.00805	-0.35	-0.26	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
COAD	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	4.26	2.83e-05	0.00805	0.3	0.26	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
COAD	cis	rs9291683	0.62	rs4383618	ENSG00000250413.1	RP11-448G15.1	4.26	2.83e-05	0.00805	0.33	0.26	Bone mineral density;	chr4:10123527	chr4:10006482~10009725:+
COAD	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-4.26	2.83e-05	0.00805	-0.41	-0.26	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
COAD	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-4.26	2.83e-05	0.00806	-0.31	-0.26	QT interval;	chr12:29287150	chr12:29277397~29277882:-
COAD	cis	rs9532669	0.926	rs9532671	ENSG00000277662.1	RP11-74J13.9	-4.26	2.83e-05	0.00806	-0.25	-0.26	Cervical cancer;	chr13:40927761	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.833	rs9532672	ENSG00000277662.1	RP11-74J13.9	-4.26	2.83e-05	0.00806	-0.25	-0.26	Cervical cancer;	chr13:40928285	chr13:41229180~41229676:-
COAD	cis	rs7650267	0.637	rs2372360	ENSG00000232354.6	VIPR1-AS1	4.26	2.83e-05	0.00806	0.28	0.26	Obesity-related traits;	chr3:43259962	chr3:42506465~42533258:-
COAD	cis	rs8046148	0.756	rs8047742	ENSG00000260381.2	RP11-429P3.5	-4.26	2.83e-05	0.00806	-0.33	-0.26	Testicular germ cell tumor;	chr16:50083405	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs2080504	ENSG00000260381.2	RP11-429P3.5	-4.26	2.83e-05	0.00806	-0.33	-0.26	Testicular germ cell tumor;	chr16:50085259	chr16:50100339~50121943:-
COAD	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-4.26	2.83e-05	0.00806	-0.27	-0.26	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
COAD	cis	rs9818758	0.556	rs73077200	ENSG00000225399.4	RP11-3B7.1	-4.26	2.83e-05	0.00806	-0.58	-0.26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49789554	chr3:49260085~49261316:+
COAD	cis	rs9847710	0.696	rs62253605	ENSG00000242142.1	SERBP1P3	4.26	2.83e-05	0.00807	0.34	0.26	Ulcerative colitis;	chr3:52944402	chr3:53064283~53065091:-
COAD	cis	rs4718428	0.662	rs34577323	ENSG00000272831.1	RP11-792A8.4	4.26	2.83e-05	0.00807	0.29	0.26	Corneal structure;	chr7:66845054	chr7:66739829~66740385:-
COAD	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-4.26	2.83e-05	0.00807	-0.2	-0.26	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
COAD	cis	rs17772222	0.917	rs4635267	ENSG00000258789.1	RP11-507K2.3	-4.26	2.84e-05	0.00808	-0.37	-0.26	Coronary artery calcification;	chr14:88621922	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.876	rs56144430	ENSG00000258789.1	RP11-507K2.3	-4.26	2.84e-05	0.00808	-0.37	-0.26	Coronary artery calcification;	chr14:88622013	chr14:88551597~88552493:+
COAD	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	4.26	2.84e-05	0.00808	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
COAD	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55486718	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55490176	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55490228	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55491150	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55493557	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55495262	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	4.26	2.84e-05	0.00808	0.31	0.26	Height;	chr4:55502504	chr4:55540502~55540835:-
COAD	cis	rs9487051	0.872	rs9480922	ENSG00000219700.1	PTCHD3P3	4.26	2.84e-05	0.00808	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109286008	chr6:109288571~109290503:-
COAD	cis	rs9487051	0.872	rs9480923	ENSG00000219700.1	PTCHD3P3	4.26	2.84e-05	0.00808	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109286166	chr6:109288571~109290503:-
COAD	cis	rs8076220	0.555	rs12453145	ENSG00000244753.2	RPL15P21	4.26	2.84e-05	0.00808	0.43	0.26	Obesity-related traits;	chr17:11170128	chr17:10860535~10861462:-
COAD	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	4.26	2.84e-05	0.00809	0.31	0.26	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
COAD	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	4.26	2.84e-05	0.00809	0.31	0.26	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
COAD	cis	rs875971	0.505	rs1167386	ENSG00000272831.1	RP11-792A8.4	-4.26	2.84e-05	0.00809	-0.27	-0.26	Aortic root size;	chr7:66048109	chr7:66739829~66740385:-
COAD	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	4.26	2.84e-05	0.00809	0.23	0.26	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
COAD	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	4.26	2.84e-05	0.00809	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
COAD	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	4.26	2.84e-05	0.00809	0.34	0.26	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	4.26	2.84e-05	0.00809	0.34	0.26	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	4.26	2.84e-05	0.00809	0.34	0.26	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
COAD	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	4.26	2.85e-05	0.0081	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
COAD	cis	rs2018683	0.768	rs10282015	ENSG00000272568.4	CTB-113D17.1	4.26	2.85e-05	0.0081	0.37	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28979967~29013367:+
COAD	cis	rs1555133	0.694	rs6141289	ENSG00000101898.5	MCTS2P	4.26	2.85e-05	0.0081	0.28	0.26	Monocyte count;	chr20:32324757	chr20:31547504~31548049:+
COAD	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.26	2.85e-05	0.00811	0.27	0.26	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
COAD	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	4.26	2.85e-05	0.00811	0.24	0.26	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
COAD	cis	rs2115630	0.764	rs11073716	ENSG00000225151.9	GOLGA2P7	4.26	2.85e-05	0.00811	0.29	0.26	P wave terminal force;	chr15:84792543	chr15:84199311~84230136:-
COAD	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	4.26	2.85e-05	0.00811	0.31	0.26	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	4.26	2.85e-05	0.00811	0.31	0.26	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	4.26	2.85e-05	0.00811	0.31	0.26	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
COAD	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-4.26	2.85e-05	0.00812	-0.17	-0.26	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
COAD	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-4.26	2.85e-05	0.00812	-0.49	-0.26	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
COAD	cis	rs2243480	1	rs160633	ENSG00000229886.1	RP5-1132H15.3	4.26	2.85e-05	0.00812	0.44	0.26	Diabetic kidney disease;	chr7:66063241	chr7:66025126~66031544:-
COAD	cis	rs8177876	0.822	rs1563075	ENSG00000261061.1	RP11-303E16.2	-4.26	2.86e-05	0.00812	-0.41	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81030770~81031485:+
COAD	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	4.26	2.86e-05	0.00812	0.42	0.26	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
COAD	cis	rs752010	0.967	rs752011	ENSG00000230638.4	RP11-486B10.4	-4.26	2.86e-05	0.00813	-0.3	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41627258	chr1:41542069~41544310:+
COAD	cis	rs9393813	0.528	rs4713109	ENSG00000271755.1	RP1-153G14.4	4.26	2.86e-05	0.00813	0.3	0.26	Bipolar disorder;	chr6:27508489	chr6:27404010~27406964:-
COAD	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-4.26	2.86e-05	0.00813	-0.3	-0.26	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
COAD	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-4.26	2.86e-05	0.00813	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
COAD	cis	rs11681884	0.71	rs3087262	ENSG00000228251.1	AC012442.6	4.26	2.86e-05	0.00813	0.45	0.26	Stroke;	chr2:113126625	chr2:112590796~112591939:+
COAD	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	4.26	2.86e-05	0.00813	0.43	0.26	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
COAD	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	4.26	2.86e-05	0.00813	0.57	0.26	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
COAD	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-4.26	2.86e-05	0.00813	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
COAD	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-4.26	2.86e-05	0.00813	-0.46	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
COAD	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-4.26	2.86e-05	0.00814	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
COAD	cis	rs9400467	0.528	rs6933627	ENSG00000271789.1	RP5-1112D6.7	-4.26	2.86e-05	0.00814	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111297126~111298510:+
COAD	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	4.26	2.86e-05	0.00814	0.28	0.26	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
COAD	cis	rs370915	0.549	rs1367933	ENSG00000250971.1	RP11-696F12.1	4.26	2.86e-05	0.00814	0.31	0.26	Gout;	chr4:186855437	chr4:187060099~187060930:+
COAD	cis	rs370915	0.578	rs1367932	ENSG00000250971.1	RP11-696F12.1	4.26	2.86e-05	0.00814	0.31	0.26	Gout;	chr4:186855500	chr4:187060099~187060930:+
COAD	cis	rs180730	1	rs343195	ENSG00000251609.2	SETP12	-4.26	2.86e-05	0.00814	-0.38	-0.26	Fasting plasma glucose;	chr4:120879311	chr4:120895494~120897083:-
COAD	cis	rs4718428	0.705	rs2901311	ENSG00000272831.1	RP11-792A8.4	4.26	2.87e-05	0.00814	0.29	0.26	Corneal structure;	chr7:66950082	chr7:66739829~66740385:-
COAD	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	4.26	2.87e-05	0.00815	0.33	0.26	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
COAD	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	4.26	2.87e-05	0.00815	0.33	0.26	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
COAD	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	4.26	2.87e-05	0.00815	0.33	0.26	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
COAD	cis	rs891378	1	rs10864175	ENSG00000274245.1	RP11-357P18.2	-4.26	2.87e-05	0.00815	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207260004	chr1:207372559~207373252:+
COAD	cis	rs891378	0.92	rs4611012	ENSG00000274245.1	RP11-357P18.2	-4.26	2.87e-05	0.00815	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207263470	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs6540896	ENSG00000274245.1	RP11-357P18.2	-4.26	2.87e-05	0.00815	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207267506	chr1:207372559~207373252:+
COAD	cis	rs891378	0.959	rs6703860	ENSG00000274245.1	RP11-357P18.2	-4.26	2.87e-05	0.00815	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270226	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs10864178	ENSG00000274245.1	RP11-357P18.2	-4.26	2.87e-05	0.00815	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272333	chr1:207372559~207373252:+
COAD	cis	rs734999	0.566	rs6424092	ENSG00000225931.3	RP3-395M20.7	-4.26	2.87e-05	0.00815	-0.28	-0.26	Ulcerative colitis;	chr1:2601460	chr1:2566410~2569888:+
COAD	cis	rs6052484	0.883	rs12481620	ENSG00000275491.1	RP5-1009E24.8	4.26	2.87e-05	0.00815	0.39	0.26	Sense of smell;	chr20:4297499	chr20:3808357~3812434:+
COAD	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	4.26	2.87e-05	0.00815	0.28	0.26	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
COAD	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-4.26	2.87e-05	0.00816	-0.63	-0.26	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
COAD	cis	rs11976180	1	rs13226728	ENSG00000204959.4	ARHGEF34P	4.26	2.87e-05	0.00816	0.31	0.26	Obesity-related traits;	chr7:144049485	chr7:144272445~144286966:-
COAD	cis	rs2732480	0.557	rs2634682	ENSG00000257735.1	RP11-370I10.6	4.26	2.87e-05	0.00816	0.33	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48350945~48442411:+
COAD	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-4.26	2.87e-05	0.00816	-0.48	-0.26	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
COAD	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	4.26	2.88e-05	0.00817	0.46	0.26	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	4.26	2.88e-05	0.00817	0.46	0.26	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
COAD	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	4.26	2.88e-05	0.00817	0.33	0.26	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
COAD	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	4.26	2.88e-05	0.00817	0.23	0.26	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
COAD	cis	rs11079159	0.959	rs3794752	ENSG00000263096.1	RP11-515O17.2	4.26	2.88e-05	0.00817	0.32	0.26	QRS duration;	chr17:55305468	chr17:55271504~55273653:-
COAD	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	4.26	2.88e-05	0.00818	0.28	0.26	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	4.26	2.88e-05	0.00818	0.28	0.26	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	4.26	2.88e-05	0.00818	0.28	0.26	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-4.26	2.88e-05	0.00818	-0.27	-0.26	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
COAD	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-4.26	2.88e-05	0.00818	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
COAD	cis	rs739496	0.615	rs2285727	ENSG00000257595.2	RP3-473L9.4	4.26	2.88e-05	0.00819	0.38	0.26	Platelet count;	chr12:111655274	chr12:111369282~111403310:+
COAD	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	4.26	2.89e-05	0.00819	0.36	0.26	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
COAD	cis	rs7200543	1	rs3803575	ENSG00000270580.4	PKD1P6	4.26	2.89e-05	0.00819	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15104723~15131601:-
COAD	cis	rs12906542	0.516	rs10444863	ENSG00000260139.5	CSPG4P13	-4.26	2.89e-05	0.00819	-0.36	-0.26	Breast cancer;	chr15:78066495	chr15:77894684~77904674:+
COAD	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-4.26	2.89e-05	0.0082	-0.3	-0.26	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
COAD	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	4.26	2.89e-05	0.0082	0.3	0.26	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
COAD	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-4.26	2.89e-05	0.0082	-0.32	-0.26	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
COAD	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.26	2.89e-05	0.0082	0.42	0.26	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
COAD	cis	rs2408955	0.501	rs8716	ENSG00000273765.1	RP11-370I10.11	4.26	2.89e-05	0.0082	0.27	0.26	Glycated hemoglobin levels;	chr12:48145699	chr12:48360920~48361377:+
COAD	cis	rs6723226	0.806	rs2249109	ENSG00000276334.1	AL133243.1	4.26	2.89e-05	0.0082	0.24	0.26	Intelligence (multi-trait analysis);	chr2:32525812	chr2:32521927~32523547:+
COAD	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-4.26	2.89e-05	0.0082	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
COAD	cis	rs7260598	0.642	rs73023276	ENSG00000268442.1	CTD-2027I19.2	4.26	2.89e-05	0.0082	0.4	0.26	Response to taxane treatment (placlitaxel);	chr19:23976045	chr19:24162370~24163425:-
COAD	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-4.26	2.89e-05	0.00821	-0.33	-0.26	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
COAD	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	4.26	2.89e-05	0.00821	0.34	0.26	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
COAD	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	4.26	2.89e-05	0.00821	0.27	0.26	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
COAD	cis	rs494562	0.892	rs9353310	ENSG00000234155.1	RP11-30P6.6	-4.26	2.89e-05	0.00821	-0.47	-0.26	Metabolic traits;Blood metabolite levels;	chr6:85416481	chr6:85387219~85390186:-
COAD	cis	rs494562	0.773	rs6919207	ENSG00000234155.1	RP11-30P6.6	-4.26	2.89e-05	0.00821	-0.47	-0.26	Metabolic traits;Blood metabolite levels;	chr6:85419553	chr6:85387219~85390186:-
COAD	cis	rs9307551	0.741	rs6840265	ENSG00000250334.4	LINC00989	-4.26	2.89e-05	0.00821	-0.34	-0.26	Refractive error;	chr4:79521327	chr4:79492416~79576460:+
COAD	cis	rs875971	0.862	rs13232191	ENSG00000224316.1	RP11-479O9.2	4.26	2.89e-05	0.00821	0.28	0.26	Aortic root size;	chr7:66521661	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs35378740	ENSG00000224316.1	RP11-479O9.2	4.26	2.89e-05	0.00821	0.28	0.26	Aortic root size;	chr7:66522725	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs10950043	ENSG00000224316.1	RP11-479O9.2	4.26	2.89e-05	0.00821	0.28	0.26	Aortic root size;	chr7:66523623	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs17747530	ENSG00000224316.1	RP11-479O9.2	4.26	2.89e-05	0.00821	0.28	0.26	Aortic root size;	chr7:66529742	chr7:65773620~65802067:+
COAD	cis	rs875971	0.767	rs61348003	ENSG00000224316.1	RP11-479O9.2	4.26	2.89e-05	0.00821	0.28	0.26	Aortic root size;	chr7:66540947	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs13536	ENSG00000224316.1	RP11-479O9.2	-4.26	2.89e-05	0.00821	-0.28	-0.26	Aortic root size;	chr7:66554203	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs801209	ENSG00000224316.1	RP11-479O9.2	-4.26	2.89e-05	0.00821	-0.28	-0.26	Aortic root size;	chr7:66554403	chr7:65773620~65802067:+
COAD	cis	rs2638953	0.924	rs11049569	ENSG00000247934.4	RP11-967K21.1	-4.26	2.89e-05	0.00821	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28386823	chr12:28163298~28190738:-
COAD	cis	rs875971	0.545	rs4718348	ENSG00000224316.1	RP11-479O9.2	4.26	2.9e-05	0.00821	0.33	0.26	Aortic root size;	chr7:66441589	chr7:65773620~65802067:+
COAD	cis	rs9307551	0.741	rs1440863	ENSG00000250334.4	LINC00989	-4.26	2.9e-05	0.00821	-0.34	-0.26	Refractive error;	chr4:79503061	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.697	rs4975052	ENSG00000250334.4	LINC00989	-4.26	2.9e-05	0.00821	-0.34	-0.26	Refractive error;	chr4:79505054	chr4:79492416~79576460:+
COAD	cis	rs4834770	1	rs4834770	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119320694	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs6823963	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119321009	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs4834771	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119321617	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs1397613	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119321774	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs6857641	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119322356	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs2282688	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119322567	chr4:119334329~119378233:+
COAD	cis	rs4834770	1	rs10034579	ENSG00000250412.1	KLHL2P1	4.26	2.9e-05	0.00822	0.31	0.26	Blood protein levels;	chr4:119322874	chr4:119334329~119378233:+
COAD	cis	rs78472555	0.507	rs2061007	ENSG00000182397.13	DNM1P46	-4.26	2.9e-05	0.00822	-0.26	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99729475	chr15:99790156~99806927:-
COAD	cis	rs75920871	0.502	rs10790166	ENSG00000254851.1	RP11-109L13.1	4.26	2.9e-05	0.00822	0.32	0.26	Subjective well-being;	chr11:116908783	chr11:117135528~117138582:+
COAD	cis	rs2337406	1	rs10459466	ENSG00000280411.1	IGHV1-69-2	-4.26	2.9e-05	0.00822	-0.2	-0.26	Alzheimer's disease (late onset);	chr14:106689255	chr14:106762092~106762588:-
COAD	cis	rs7637701	0.967	rs12638253	ENSG00000240875.4	LINC00886	4.26	2.9e-05	0.00823	0.24	0.26	Breast cancer;	chr3:156908302	chr3:156747346~156817062:-
COAD	cis	rs9307551	0.817	rs4975057	ENSG00000250334.4	LINC00989	-4.26	2.9e-05	0.00823	-0.3	-0.26	Refractive error;	chr4:79567191	chr4:79492416~79576460:+
COAD	cis	rs1005224	0.864	rs11625011	ENSG00000258454.1	RP11-361H10.3	4.26	2.9e-05	0.00823	0.31	0.26	Large artery stroke;	chr14:75678485	chr14:76235817~76263474:+
COAD	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-4.26	2.9e-05	0.00823	-0.32	-0.26	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
COAD	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-4.26	2.91e-05	0.00823	-0.35	-0.26	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
COAD	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	4.26	2.91e-05	0.00823	0.45	0.26	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
COAD	cis	rs2559856	1	rs2695284	ENSG00000199933.1	RNY1P16	-4.26	2.91e-05	0.00824	-0.27	-0.26	Blood protein levels;	chr12:101695540	chr12:101719808~101719918:+
COAD	cis	rs9907295	0.688	rs8066406	ENSG00000271013.1	AC015849.15	-4.26	2.91e-05	0.00824	-0.32	-0.26	Fibroblast growth factor basic levels;	chr17:35905550	chr17:35912635~35918010:-
COAD	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	4.26	2.91e-05	0.00824	0.42	0.26	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
COAD	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-4.26	2.91e-05	0.00824	-0.49	-0.26	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
COAD	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-4.26	2.91e-05	0.00824	-0.31	-0.26	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-4.26	2.91e-05	0.00824	-0.31	-0.26	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
COAD	cis	rs7260598	0.539	rs11878343	ENSG00000268442.1	CTD-2027I19.2	4.26	2.91e-05	0.00824	0.45	0.26	Response to taxane treatment (placlitaxel);	chr19:23874804	chr19:24162370~24163425:-
COAD	cis	rs9951698	0.618	rs472992	ENSG00000266969.1	RP11-773H22.4	4.26	2.91e-05	0.00824	0.33	0.26	Intelligence (multi-trait analysis);	chr18:13087790	chr18:12984694~12991173:-
COAD	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	4.26	2.91e-05	0.00824	0.48	0.26	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	4.26	2.91e-05	0.00824	0.48	0.26	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191454	ENSG00000213277.3	MARCKSL1P1	4.26	2.91e-05	0.00825	0.52	0.26	Birth weight;	chr10:102900247	chr10:103175554~103176094:+
COAD	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	4.26	2.91e-05	0.00825	0.32	0.26	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
COAD	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-4.26	2.91e-05	0.00825	-0.37	-0.26	Depression;	chr6:28096845	chr6:28115628~28116551:+
COAD	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-4.26	2.91e-05	0.00825	-0.26	-0.26	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
COAD	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	4.26	2.91e-05	0.00825	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
COAD	cis	rs7760535	0.757	rs10456875	ENSG00000271789.1	RP5-1112D6.7	-4.26	2.92e-05	0.00826	-0.25	-0.26	Metabolic traits;	chr6:111428522	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs4276544	ENSG00000271789.1	RP5-1112D6.7	-4.26	2.92e-05	0.00826	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111297126~111298510:+
COAD	cis	rs4704187	0.687	rs9654426	ENSG00000250889.2	LINC01336	-4.26	2.92e-05	0.00826	-0.29	-0.26	Response to amphetamines;	chr5:75170912	chr5:75047719~75052843:-
COAD	cis	rs2638953	0.853	rs11614463	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10843183	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11494781	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049638	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049639	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049642	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049643	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.777	rs11049644	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049645	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs10843184	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs61920658	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049646	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs11049654	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049657	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049659	ENSG00000247934.4	RP11-967K21.1	-4.26	2.92e-05	0.00826	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28163298~28190738:-
COAD	cis	rs2243480	0.803	rs160649	ENSG00000229886.1	RP5-1132H15.3	4.26	2.92e-05	0.00826	0.43	0.26	Diabetic kidney disease;	chr7:66078212	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs160648	ENSG00000229886.1	RP5-1132H15.3	4.26	2.92e-05	0.00826	0.43	0.26	Diabetic kidney disease;	chr7:66078397	chr7:66025126~66031544:-
COAD	cis	rs2280018	0.538	rs7404526	ENSG00000270580.4	PKD1P6	4.26	2.92e-05	0.00827	0.28	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15104723~15131601:-
COAD	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	4.26	2.92e-05	0.00827	0.33	0.26	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
COAD	cis	rs7172689	1	rs11638444	ENSG00000271725.1	RP11-761I4.4	4.26	2.92e-05	0.00828	0.34	0.26	Inattentive symptoms;	chr15:81242479	chr15:81303215~81309391:-
COAD	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.26	2.92e-05	0.00828	0.31	0.26	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
COAD	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	4.26	2.92e-05	0.00828	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	4.26	2.92e-05	0.00828	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
COAD	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-4.26	2.93e-05	0.00828	-0.29	-0.26	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
COAD	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	4.26	2.93e-05	0.00829	0.31	0.26	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
COAD	cis	rs2638953	0.79	rs11049653	ENSG00000247934.4	RP11-967K21.1	-4.26	2.93e-05	0.00829	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28163298~28190738:-
COAD	cis	rs507080	0.922	rs654792	ENSG00000278376.1	RP11-158I9.8	4.26	2.93e-05	0.00829	0.27	0.26	Serum metabolite levels;	chr11:118682287	chr11:118791254~118793137:+
COAD	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-4.25	2.93e-05	0.0083	-0.29	-0.26	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
COAD	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-4.25	2.93e-05	0.0083	-0.37	-0.26	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
COAD	cis	rs2188554	0.74	rs213948	ENSG00000237974.1	AC000111.4	4.25	2.94e-05	0.0083	0.28	0.26	Esophageal adenocarcinoma;	chr7:117554416	chr7:117487737~117487929:+
COAD	cis	rs2018683	0.649	rs12536605	ENSG00000272568.4	CTB-113D17.1	4.25	2.94e-05	0.0083	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28979967~29013367:+
COAD	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	4.25	2.94e-05	0.0083	0.26	0.26	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
COAD	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	4.25	2.94e-05	0.0083	0.26	0.26	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
COAD	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-4.25	2.94e-05	0.00831	-0.3	-0.26	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
COAD	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	4.25	2.94e-05	0.00831	0.3	0.26	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
COAD	cis	rs2243480	1	rs464895	ENSG00000229886.1	RP5-1132H15.3	4.25	2.94e-05	0.00832	0.46	0.26	Diabetic kidney disease;	chr7:66062119	chr7:66025126~66031544:-
COAD	cis	rs7674212	0.507	rs6843738	ENSG00000248971.2	KRT8P46	-4.25	2.94e-05	0.00832	-0.27	-0.26	Type 2 diabetes;	chr4:103014844	chr4:102728746~102730171:-
COAD	cis	rs453301	0.686	rs11785819	ENSG00000254340.1	RP11-10A14.3	-4.25	2.94e-05	0.00832	-0.3	-0.26	Joint mobility (Beighton score);	chr8:9012868	chr8:9141424~9145435:+
COAD	cis	rs752010	0.619	rs10736421	ENSG00000230638.4	RP11-486B10.4	-4.25	2.94e-05	0.00832	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41640559	chr1:41542069~41544310:+
COAD	cis	rs13256369	1	rs885000	ENSG00000253981.4	ALG1L13P	4.25	2.95e-05	0.00833	0.37	0.26	Obesity-related traits;	chr8:8711365	chr8:8236003~8244667:-
COAD	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-4.25	2.95e-05	0.00833	-0.36	-0.26	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
COAD	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.25	2.95e-05	0.00833	-0.26	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.25	2.95e-05	0.00833	-0.26	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
COAD	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	4.25	2.95e-05	0.00833	0.48	0.26	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
COAD	cis	rs2252521	0.524	rs317744	ENSG00000272568.4	CTB-113D17.1	4.25	2.95e-05	0.00834	0.49	0.26	Cognitive performance;	chr7:29027677	chr7:28979967~29013367:+
COAD	cis	rs2252521	0.524	rs317745	ENSG00000272568.4	CTB-113D17.1	4.25	2.95e-05	0.00834	0.49	0.26	Cognitive performance;	chr7:29028498	chr7:28979967~29013367:+
COAD	cis	rs2252521	0.524	rs2074782	ENSG00000272568.4	CTB-113D17.1	4.25	2.95e-05	0.00834	0.49	0.26	Cognitive performance;	chr7:29031037	chr7:28979967~29013367:+
COAD	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	4.25	2.95e-05	0.00834	0.27	0.26	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
COAD	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	4.25	2.95e-05	0.00834	0.27	0.26	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
COAD	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-4.25	2.95e-05	0.00834	-0.36	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
COAD	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-4.25	2.95e-05	0.00835	-0.29	-0.26	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
COAD	cis	rs2732480	0.5	rs1387257	ENSG00000226413.2	OR8T1P	4.25	2.95e-05	0.00835	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48442030~48442947:-
COAD	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	4.25	2.96e-05	0.00835	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
COAD	cis	rs61270009	0.913	rs357512	ENSG00000247828.6	TMEM161B-AS1	-4.25	2.96e-05	0.00835	-0.27	-0.26	Depressive symptoms;	chr5:88222061	chr5:88268895~88436685:+
COAD	cis	rs9487051	0.802	rs6910696	ENSG00000219700.1	PTCHD3P3	4.25	2.96e-05	0.00835	0.27	0.26	Reticulocyte fraction of red cells;	chr6:109271126	chr6:109288571~109290503:-
COAD	cis	rs875971	0.895	rs6460278	ENSG00000224316.1	RP11-479O9.2	-4.25	2.96e-05	0.00836	-0.28	-0.26	Aortic root size;	chr7:66197749	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6460279	ENSG00000224316.1	RP11-479O9.2	-4.25	2.96e-05	0.00836	-0.28	-0.26	Aortic root size;	chr7:66197774	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs28491091	ENSG00000224316.1	RP11-479O9.2	-4.25	2.96e-05	0.00836	-0.28	-0.26	Aortic root size;	chr7:66204077	chr7:65773620~65802067:+
COAD	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	4.25	2.96e-05	0.00836	0.27	0.26	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
COAD	cis	rs8141529	0.764	rs5762854	ENSG00000272858.1	CTA-292E10.8	-4.25	2.96e-05	0.00837	-0.3	-0.26	Lymphocyte counts;	chr22:28850290	chr22:28814914~28815662:+
COAD	cis	rs1949733	0.636	rs16842498	ENSG00000205959.3	RP11-689P11.2	4.25	2.96e-05	0.00837	0.32	0.26	Response to antineoplastic agents;	chr4:8537802	chr4:8482270~8512610:+
COAD	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	4.25	2.96e-05	0.00837	0.31	0.26	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
COAD	cis	rs791888	1	rs791882	ENSG00000225913.2	RP11-57C13.6	4.25	2.96e-05	0.00837	0.33	0.26	Magnesium levels;	chr10:87648501	chr10:87607985~87659279:+
COAD	cis	rs7131987	0.903	rs2194519	ENSG00000257176.2	RP11-996F15.2	4.25	2.96e-05	0.00837	0.29	0.26	QT interval;	chr12:29270650	chr12:29280418~29317848:-
COAD	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	4.25	2.97e-05	0.00837	0.36	0.26	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
COAD	cis	rs7584330	0.518	rs74003103	ENSG00000234949.2	AC104667.3	-4.25	2.97e-05	0.00838	-0.43	-0.26	Prostate cancer;	chr2:237538056	chr2:237591020~237595981:+
COAD	cis	rs8047014	1	rs8047014	ENSG00000260459.2	FTLP14	4.25	2.97e-05	0.00838	0.34	0.26	Attention deficit hyperactivity disorder;	chr16:69101146	chr16:68822587~68823070:+
COAD	cis	rs7829975	0.688	rs7817376	ENSG00000254340.1	RP11-10A14.3	-4.25	2.97e-05	0.00838	-0.29	-0.26	Mood instability;	chr8:8523020	chr8:9141424~9145435:+
COAD	cis	rs2337406	0.866	rs112089985	ENSG00000211967.3	IGHV3-53	-4.25	2.97e-05	0.00839	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106780074	chr14:106592676~106593347:-
COAD	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-4.25	2.97e-05	0.00839	-0.26	-0.26	Height;	chr11:118703185	chr11:118791254~118793137:+
COAD	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-4.25	2.97e-05	0.00839	-0.26	-0.26	Height;	chr11:118703207	chr11:118791254~118793137:+
COAD	cis	rs1670533	0.932	rs3796620	ENSG00000273179.1	RP11-20I20.4	-4.25	2.97e-05	0.00839	-0.33	-0.26	Recombination rate (females);	chr4:1101291	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs62294756	ENSG00000273179.1	RP11-20I20.4	-4.25	2.97e-05	0.00839	-0.33	-0.26	Recombination rate (females);	chr4:1103888	chr4:1167778~1168174:+
COAD	cis	rs116139393	0.561	rs62439737	ENSG00000187953.9	PMS2CL	-4.25	2.97e-05	0.00839	-0.29	-0.26	Alzheimer's disease (APOE e4 interaction);	chr7:6740179	chr7:6710128~6753862:+
COAD	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	4.25	2.97e-05	0.00839	0.57	0.26	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
COAD	cis	rs2638953	0.962	rs11494780	ENSG00000247934.4	RP11-967K21.1	-4.25	2.97e-05	0.00839	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049574	ENSG00000247934.4	RP11-967K21.1	-4.25	2.97e-05	0.00839	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28163298~28190738:-
COAD	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	4.25	2.97e-05	0.0084	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
COAD	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-4.25	2.97e-05	0.0084	-0.27	-0.26	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
COAD	cis	rs597539	0.552	rs6591361	ENSG00000255741.1	RP11-757G1.5	-4.25	2.98e-05	0.0084	-0.33	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68941503~68942852:-
COAD	cis	rs17685	0.753	rs1639609	ENSG00000280388.1	RP11-229D13.3	-4.25	2.98e-05	0.00841	-0.26	-0.26	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76043977~76045963:-
COAD	cis	rs2765539	0.851	rs1409158	ENSG00000231365.4	RP11-418J17.1	4.25	2.98e-05	0.00841	0.32	0.26	Waist-hip ratio;	chr1:118996267	chr1:119140396~119275973:+
COAD	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-4.25	2.98e-05	0.00841	-0.3	-0.26	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
COAD	cis	rs7829975	0.714	rs12544992	ENSG00000233609.3	RP11-62H7.2	4.25	2.98e-05	0.00842	0.28	0.26	Mood instability;	chr8:8804171	chr8:8961200~8979025:+
COAD	cis	rs2777491	0.915	rs16971767	ENSG00000247556.5	OIP5-AS1	4.25	2.98e-05	0.00842	0.28	0.26	Ulcerative colitis;	chr15:41331110	chr15:41283990~41309737:+
COAD	cis	rs58873874	0.579	rs962459	ENSG00000248544.2	CTB-47B11.3	4.25	2.99e-05	0.00843	0.38	0.26	Bipolar disorder (body mass index interaction);	chr5:157346777	chr5:157375741~157384950:-
COAD	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	4.25	2.99e-05	0.00843	0.33	0.26	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
COAD	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	4.25	2.99e-05	0.00843	0.31	0.26	Height;	chr4:55401306	chr4:55363971~55395847:-
COAD	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-4.25	2.99e-05	0.00843	-0.34	-0.26	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-4.25	2.99e-05	0.00843	-0.34	-0.26	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
COAD	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	4.25	2.99e-05	0.00843	0.41	0.26	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	4.25	2.99e-05	0.00843	0.41	0.26	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	4.25	2.99e-05	0.00843	0.41	0.26	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
COAD	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	4.25	2.99e-05	0.00843	0.33	0.26	QT interval;	chr4:75106366	chr4:74955974~74970362:-
COAD	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-4.25	2.99e-05	0.00843	-0.31	-0.26	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-4.25	2.99e-05	0.00843	-0.31	-0.26	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
COAD	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	4.25	2.99e-05	0.00843	0.33	0.26	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
COAD	cis	rs752010	1	rs6656183	ENSG00000230638.4	RP11-486B10.4	-4.25	2.99e-05	0.00843	-0.3	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41628354	chr1:41542069~41544310:+
COAD	cis	rs4819052	0.808	rs2246697	ENSG00000227039.5	ITGB2-AS1	-4.25	2.99e-05	0.00844	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.788	rs4819051	ENSG00000227039.5	ITGB2-AS1	-4.25	2.99e-05	0.00844	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.819	rs8134084	ENSG00000227039.5	ITGB2-AS1	-4.25	2.99e-05	0.00844	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs7281263	ENSG00000227039.5	ITGB2-AS1	-4.25	2.99e-05	0.00844	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs914214	ENSG00000227039.5	ITGB2-AS1	-4.25	2.99e-05	0.00844	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:44921051~44929678:+
COAD	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	4.25	2.99e-05	0.00844	0.29	0.26	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
COAD	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	-4.25	3e-05	0.00844	-0.28	-0.26	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
COAD	cis	rs490608	0.628	rs678157	ENSG00000203761.5	MSTO2P	-4.25	3e-05	0.00844	-0.24	-0.26	Inflammatory bowel disease;	chr1:155688550	chr1:155745829~155750137:+
COAD	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.25	3e-05	0.00844	0.41	0.26	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
COAD	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-4.25	3e-05	0.00845	-0.32	-0.26	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
COAD	cis	rs11719291	0.833	rs13074318	ENSG00000225399.4	RP11-3B7.1	-4.25	3e-05	0.00845	-0.52	-0.26	Cognitive function;	chr3:48779292	chr3:49260085~49261316:+
COAD	cis	rs891378	1	rs7522701	ENSG00000274245.1	RP11-357P18.2	-4.25	3e-05	0.00845	-0.32	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207237620	chr1:207372559~207373252:+
COAD	cis	rs2439831	0.85	rs7183809	ENSG00000166763.7	STRCP1	-4.25	3e-05	0.00845	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43828670	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs3759790	ENSG00000166763.7	STRCP1	-4.25	3e-05	0.00845	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43828832	chr15:43699488~43718184:-
COAD	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-4.25	3e-05	0.00845	-0.34	-0.26	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
COAD	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-4.25	3e-05	0.00845	-0.31	-0.26	QT interval;	chr12:29357436	chr12:29280418~29317848:-
COAD	cis	rs7646881	0.812	rs75267618	ENSG00000240207.5	RP11-379F4.4	-4.25	3e-05	0.00845	-0.33	-0.26	Tetralogy of Fallot;	chr3:158726027	chr3:158732263~158784070:+
COAD	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-4.25	3e-05	0.00845	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
COAD	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	4.25	3e-05	0.00846	0.27	0.26	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	4.25	3e-05	0.00846	0.27	0.26	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
COAD	cis	rs4938303	0.718	rs4938300	ENSG00000254851.1	RP11-109L13.1	4.25	3e-05	0.00846	0.4	0.26	Triglycerides;	chr11:116696903	chr11:117135528~117138582:+
COAD	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-4.25	3.01e-05	0.00847	-0.4	-0.26	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
COAD	cis	rs6545883	0.524	rs2463101	ENSG00000273302.1	RP11-493E12.2	-4.25	3.01e-05	0.00847	-0.24	-0.26	Tuberculosis;	chr2:61347287	chr2:61199979~61200769:+
COAD	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-4.25	3.01e-05	0.00847	-0.36	-0.26	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
COAD	cis	rs597539	0.652	rs668576	ENSG00000255741.1	RP11-757G1.5	-4.25	3.01e-05	0.00847	-0.34	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs482172	ENSG00000255741.1	RP11-757G1.5	-4.25	3.01e-05	0.00847	-0.34	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68941503~68942852:-
COAD	cis	rs2018683	0.707	rs7799357	ENSG00000272568.4	CTB-113D17.1	4.25	3.01e-05	0.00847	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930501	chr7:28979967~29013367:+
COAD	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	4.25	3.01e-05	0.00848	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
COAD	cis	rs2638953	0.815	rs11049709	ENSG00000247934.4	RP11-967K21.1	-4.25	3.01e-05	0.00848	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28163298~28190738:-
COAD	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	4.25	3.01e-05	0.00848	0.34	0.26	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	4.25	3.01e-05	0.00848	0.34	0.26	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
COAD	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	4.25	3.01e-05	0.00848	0.28	0.26	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
COAD	cis	rs812925	0.502	rs2053750	ENSG00000273302.1	RP11-493E12.2	-4.25	3.01e-05	0.00848	-0.24	-0.26	Immature fraction of reticulocytes;	chr2:61429138	chr2:61199979~61200769:+
COAD	cis	rs2732480	0.557	rs2732454	ENSG00000269514.1	RP11-370I10.12	4.25	3.01e-05	0.00849	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48198387~48202031:+
COAD	cis	rs113835537	0.529	rs11227515	ENSG00000258297.1	RP11-658F2.8	-4.25	3.01e-05	0.00849	-0.25	-0.26	Airway imaging phenotypes;	chr11:66519912	chr11:66666036~66668374:+
COAD	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-4.25	3.02e-05	0.00849	-0.27	-0.26	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
COAD	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.25	3.02e-05	0.00849	0.39	0.26	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
COAD	cis	rs72615157	0.697	rs2056726	ENSG00000078319.8	PMS2P1	-4.25	3.02e-05	0.00849	-0.35	-0.26	Lung function (FEV1/FVC);	chr7:100182660	chr7:100320992~100341908:-
COAD	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	4.25	3.02e-05	0.00849	0.41	0.26	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
COAD	cis	rs742132	0.858	rs876239	ENSG00000220875.1	HIST1H3PS1	4.25	3.02e-05	0.0085	0.33	0.26	Uric acid levels;	chr6:25645134	chr6:26321876~26322292:-
COAD	cis	rs4819052	0.851	rs58644915	ENSG00000227039.5	ITGB2-AS1	-4.25	3.02e-05	0.0085	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:44921051~44929678:+
COAD	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-4.25	3.02e-05	0.0085	-0.36	-0.26	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
COAD	cis	rs11641365	0.517	rs73262667	ENSG00000278341.1	RP5-1142A6.10	-4.25	3.02e-05	0.0085	-0.49	-0.26	Autism spectrum disorder-related traits;	chr16:88713345	chr16:88708956~88710437:-
COAD	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	4.25	3.02e-05	0.0085	0.26	0.26	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
COAD	cis	rs7656342	0.754	rs12509511	ENSG00000186234.7	FAM86MP	-4.25	3.02e-05	0.0085	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr4:9767939	chr4:9692495~9702954:+
COAD	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	4.25	3.02e-05	0.00851	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	4.25	3.02e-05	0.00851	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
COAD	cis	rs72827839	0.779	rs72823592	ENSG00000263412.1	RP5-890E16.2	4.25	3.02e-05	0.00851	0.33	0.26	Ease of getting up in the morning;	chr17:48045642	chr17:48045141~48048073:-
COAD	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-4.25	3.02e-05	0.00851	-0.48	-0.26	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
COAD	cis	rs1552244	0.832	rs61056817	ENSG00000186162.9	CIDECP	4.25	3.03e-05	0.00852	0.39	0.26	Alzheimer's disease;	chr3:9985957	chr3:10014238~10026365:-
COAD	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	4.25	3.03e-05	0.00852	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
COAD	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-4.25	3.03e-05	0.00852	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
COAD	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-4.25	3.04e-05	0.00854	-0.29	-0.26	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
COAD	cis	rs2638953	0.815	rs11049684	ENSG00000247934.4	RP11-967K21.1	-4.25	3.04e-05	0.00854	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28163298~28190738:-
COAD	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	4.25	3.04e-05	0.00854	0.34	0.26	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
COAD	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-4.25	3.04e-05	0.00854	-0.26	-0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
COAD	cis	rs11079159	0.959	rs4794562	ENSG00000263096.1	RP11-515O17.2	4.25	3.04e-05	0.00854	0.33	0.26	QRS duration;	chr17:55302450	chr17:55271504~55273653:-
COAD	cis	rs12928939	1	rs12928939	ENSG00000260886.1	TAT-AS1	4.25	3.04e-05	0.00855	0.39	0.26	Post bronchodilator FEV1;	chr16:71766142	chr16:71565789~71578187:+
COAD	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-4.25	3.04e-05	0.00855	-0.3	-0.26	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
COAD	cis	rs2765539	0.887	rs1325933	ENSG00000231365.4	RP11-418J17.1	-4.25	3.04e-05	0.00855	-0.31	-0.26	Waist-hip ratio;	chr1:119013136	chr1:119140396~119275973:+
COAD	cis	rs2638953	0.853	rs7485676	ENSG00000247934.4	RP11-967K21.1	-4.25	3.04e-05	0.00855	-0.26	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28163298~28190738:-
COAD	cis	rs1930961	0.702	rs28421243	ENSG00000272977.1	CTA-390C10.10	-4.25	3.04e-05	0.00855	-0.6	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25522823	chr22:25476218~25479971:+
COAD	cis	rs4243971	0.516	rs1028563	ENSG00000101898.5	MCTS2P	-4.25	3.04e-05	0.00856	-0.27	-0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32330729	chr20:31547504~31548049:+
COAD	cis	rs6982240	0.514	rs10095322	ENSG00000253307.1	RP11-10J21.4	4.25	3.05e-05	0.00856	0.34	0.26	Tonsillectomy;	chr8:141252228	chr8:141252286~141253292:-
COAD	cis	rs7577696	0.524	rs212696	ENSG00000272716.1	RP11-563N4.1	4.25	3.05e-05	0.00856	0.3	0.26	Inflammatory biomarkers;	chr2:32216616	chr2:32165046~32165757:-
COAD	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.25	3.05e-05	0.00856	0.31	0.26	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
COAD	cis	rs6732160	0.613	rs62151837	ENSG00000163016.8	ALMS1P	4.25	3.05e-05	0.00857	0.33	0.26	Intelligence (multi-trait analysis);	chr2:73163268	chr2:73644919~73685576:+
COAD	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	4.25	3.05e-05	0.00857	0.46	0.26	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
COAD	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	4.25	3.05e-05	0.00857	0.27	0.26	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
COAD	cis	rs9400467	0.528	rs445349	ENSG00000271789.1	RP5-1112D6.7	4.25	3.05e-05	0.00857	0.25	0.26	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111297126~111298510:+
COAD	cis	rs6940638	0.688	rs9295730	ENSG00000224843.5	LINC00240	4.25	3.05e-05	0.00857	0.33	0.26	Intelligence (multi-trait analysis);	chr6:27161027	chr6:26956992~27023924:+
COAD	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.25	3.05e-05	0.00858	0.25	0.26	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
COAD	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-4.25	3.05e-05	0.00858	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
COAD	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	4.25	3.05e-05	0.00858	0.41	0.26	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	4.25	3.05e-05	0.00858	0.41	0.26	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
COAD	cis	rs4648045	0.535	rs4698861	ENSG00000230069.3	LRRC37A15P	4.25	3.05e-05	0.00858	0.31	0.26	Lymphocyte percentage of white cells;	chr4:102624330	chr4:102727274~102730721:-
COAD	cis	rs9652601	0.691	rs3893661	ENSG00000274038.1	RP11-66H6.4	-4.24	3.06e-05	0.00859	-0.3	-0.26	Systemic lupus erythematosus;	chr16:11100023	chr16:11056556~11057034:+
COAD	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-4.24	3.06e-05	0.00859	-0.29	-0.26	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
COAD	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	4.24	3.06e-05	0.00859	0.29	0.26	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
COAD	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	4.24	3.06e-05	0.00859	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
COAD	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-4.24	3.06e-05	0.00859	-0.26	-0.26	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
COAD	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	4.24	3.06e-05	0.00859	0.29	0.26	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
COAD	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.24	3.06e-05	0.00859	0.25	0.26	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
COAD	cis	rs7246657	0.882	rs13345148	ENSG00000226686.6	LINC01535	-4.24	3.06e-05	0.0086	-0.36	-0.26	Coronary artery calcification;	chr19:37328729	chr19:37251912~37265535:+
COAD	cis	rs55823223	0.564	rs936391	ENSG00000267801.1	RP11-552F3.9	-4.24	3.06e-05	0.0086	-0.36	-0.26	Psoriasis;	chr17:75851718	chr17:75876372~75879546:+
COAD	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.24	3.06e-05	0.0086	-0.31	-0.26	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
COAD	cis	rs2559856	0.903	rs10128996	ENSG00000199933.1	RNY1P16	4.24	3.06e-05	0.0086	0.28	0.26	Blood protein levels;	chr12:101687720	chr12:101719808~101719918:+
COAD	cis	rs2559856	0.935	rs7970952	ENSG00000199933.1	RNY1P16	4.24	3.06e-05	0.0086	0.28	0.26	Blood protein levels;	chr12:101687799	chr12:101719808~101719918:+
COAD	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	4.24	3.06e-05	0.0086	0.34	0.26	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
COAD	cis	rs1930961	0.702	rs7286366	ENSG00000271138.1	IGLVIVOR22-1	-4.24	3.06e-05	0.0086	-0.6	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25514348	chr22:25437306~25437823:-
COAD	cis	rs6840360	0.582	rs2709827	ENSG00000251611.1	RP11-610P16.1	-4.24	3.06e-05	0.00861	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151407551~151408835:-
COAD	cis	rs10916814	0.569	rs10799639	ENSG00000117242.7	PINK1-AS	-4.24	3.07e-05	0.00861	-0.29	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:20560287	chr1:20642657~20652193:-
COAD	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	4.24	3.07e-05	0.00861	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
COAD	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	4.24	3.07e-05	0.00861	0.3	0.26	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
COAD	cis	rs2018683	0.707	rs4722878	ENSG00000272568.4	CTB-113D17.1	4.24	3.07e-05	0.00862	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28979967~29013367:+
COAD	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	4.24	3.07e-05	0.00862	0.41	0.26	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
COAD	cis	rs7032317	0.666	rs7021235	ENSG00000170827.8	CELP	-4.24	3.07e-05	0.00862	-0.22	-0.26	Calcium levels;	chr9:133014192	chr9:133079900~133087355:+
COAD	cis	rs6951245	1	rs2363286	ENSG00000229043.2	AC091729.9	-4.24	3.07e-05	0.00863	-0.41	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1160374~1165267:+
COAD	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-4.24	3.07e-05	0.00863	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
COAD	cis	rs8002861	0.846	rs56408817	ENSG00000274001.1	RP11-5G9.5	-4.24	3.07e-05	0.00863	-0.24	-0.26	Leprosy;	chr13:43897847	chr13:43877715~43878163:-
COAD	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-4.24	3.08e-05	0.00863	-0.35	-0.26	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
COAD	cis	rs2929278	0.588	rs688009	ENSG00000275601.1	AC011330.13	-4.24	3.08e-05	0.00863	-0.31	-0.26	Schizophrenia;	chr15:43864104	chr15:43642389~43643023:-
COAD	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-4.24	3.08e-05	0.00863	-0.31	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
COAD	cis	rs2018683	0.707	rs4722877	ENSG00000272568.4	CTB-113D17.1	4.24	3.08e-05	0.00864	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28979967~29013367:+
COAD	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-4.24	3.08e-05	0.00864	-0.37	-0.26	Depression;	chr6:28168434	chr6:28115628~28116551:+
COAD	cis	rs11023332	0.706	rs10766197	ENSG00000251991.1	RNU7-49P	4.24	3.08e-05	0.00864	0.31	0.26	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr11:14478892~14478953:+
COAD	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	4.24	3.08e-05	0.00864	0.42	0.26	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
COAD	cis	rs2017305	0.834	rs12242235	ENSG00000233590.1	RP11-153K11.3	4.24	3.08e-05	0.00864	0.45	0.26	Depression (quantitative trait);	chr10:69022800	chr10:68233251~68242379:-
COAD	cis	rs2017305	0.834	rs12266901	ENSG00000233590.1	RP11-153K11.3	4.24	3.08e-05	0.00864	0.45	0.26	Depression (quantitative trait);	chr10:69023766	chr10:68233251~68242379:-
COAD	cis	rs41294858	1	rs41294856	ENSG00000232876.1	CTA-212D2.2	-4.24	3.08e-05	0.00864	-0.48	-0.26	Red blood cell count;	chr6:135091244	chr6:135055033~135060550:+
COAD	cis	rs11638352	1	rs2899103	ENSG00000205771.5	CATSPER2P1	4.24	3.08e-05	0.00864	0.51	0.26	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44048357	chr15:43726918~43747094:-
COAD	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	4.24	3.08e-05	0.00864	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	4.24	3.08e-05	0.00864	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
COAD	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	4.24	3.08e-05	0.00865	0.3	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
COAD	cis	rs4820539	0.966	rs2267001	ENSG00000211644.2	IGLV1-51	-4.24	3.08e-05	0.00865	-0.15	-0.26	Bone mineral density;	chr22:23114509	chr22:22322472~22322980:+
COAD	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-4.24	3.08e-05	0.00865	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-4.24	3.08e-05	0.00865	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-4.24	3.08e-05	0.00865	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
COAD	cis	rs2018683	0.707	rs10279870	ENSG00000272568.4	CTB-113D17.1	4.24	3.08e-05	0.00865	0.36	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929318	chr7:28979967~29013367:+
COAD	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	4.24	3.08e-05	0.00865	0.37	0.26	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
COAD	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-4.24	3.09e-05	0.00865	-0.37	-0.26	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
COAD	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	4.24	3.09e-05	0.00865	0.32	0.26	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
COAD	cis	rs11846409	0.587	rs1806881	ENSG00000211964.3	IGHV3-48	4.24	3.09e-05	0.00865	0.22	0.26	Rheumatic heart disease;	chr14:106650770	chr14:106537810~106538344:-
COAD	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	4.24	3.09e-05	0.00866	0.2	0.26	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
COAD	cis	rs734999	0.588	rs2985859	ENSG00000225931.3	RP3-395M20.7	-4.24	3.09e-05	0.00866	-0.28	-0.26	Ulcerative colitis;	chr1:2600977	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs3001837	ENSG00000225931.3	RP3-395M20.7	-4.24	3.09e-05	0.00866	-0.28	-0.26	Ulcerative colitis;	chr1:2601067	chr1:2566410~2569888:+
COAD	cis	rs7656342	0.964	rs13148356	ENSG00000186234.7	FAM86MP	-4.24	3.09e-05	0.00866	-0.33	-0.26	Gut microbiota (bacterial taxa);	chr4:9815446	chr4:9692495~9702954:+
COAD	cis	rs80346118	0.673	rs7360629	ENSG00000177410.11	ZFAS1	-4.24	3.09e-05	0.00867	-0.29	-0.26	Diastolic blood pressure;	chr20:48800635	chr20:49278178~49295738:+
COAD	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	4.24	3.1e-05	0.00868	0.31	0.26	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
COAD	cis	rs2337406	0.866	rs61164979	ENSG00000211967.3	IGHV3-53	-4.24	3.1e-05	0.00869	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106783133	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs61419485	ENSG00000211967.3	IGHV3-53	-4.24	3.1e-05	0.00869	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106783374	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs8015361	ENSG00000211967.3	IGHV3-53	-4.24	3.1e-05	0.00869	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106783991	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs74090151	ENSG00000211967.3	IGHV3-53	-4.24	3.1e-05	0.00869	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106785377	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs8012619	ENSG00000211967.3	IGHV3-53	-4.24	3.1e-05	0.00869	-0.18	-0.26	Alzheimer's disease (late onset);	chr14:106793907	chr14:106592676~106593347:-
COAD	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.24	3.1e-05	0.00869	-0.49	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
COAD	cis	rs10515750	0.5	rs6890694	ENSG00000248544.2	CTB-47B11.3	4.24	3.1e-05	0.00869	0.35	0.26	Lung function (FEV1/FVC);	chr5:157283735	chr5:157375741~157384950:-
COAD	cis	rs2732480	0.557	rs923397	ENSG00000269514.1	RP11-370I10.12	4.24	3.1e-05	0.00869	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48198387~48202031:+
COAD	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-4.24	3.1e-05	0.00869	-0.27	-0.26	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
COAD	cis	rs8022206	0.704	rs10873209	ENSG00000259502.1	RP11-643G16.3	4.24	3.1e-05	0.00869	0.33	0.26	Platelet count;Mean platelet volume;	chr14:67933747	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.704	rs10873210	ENSG00000259502.1	RP11-643G16.3	4.24	3.1e-05	0.00869	0.33	0.26	Platelet count;Mean platelet volume;	chr14:67933748	chr14:67610986~67613864:+
COAD	cis	rs1577917	0.696	rs10806334	ENSG00000220563.1	PKMP3	-4.24	3.1e-05	0.0087	-0.28	-0.26	Response to antipsychotic treatment;	chr6:85729611	chr6:85659892~85660606:-
COAD	cis	rs875971	0.545	rs2707851	ENSG00000224316.1	RP11-479O9.2	-4.24	3.1e-05	0.0087	-0.32	-0.26	Aortic root size;	chr7:66624178	chr7:65773620~65802067:+
COAD	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-4.24	3.11e-05	0.0087	-0.29	-0.26	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
COAD	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	4.24	3.11e-05	0.0087	0.3	0.26	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
COAD	cis	rs7760535	0.826	rs10872068	ENSG00000271789.1	RP5-1112D6.7	4.24	3.11e-05	0.0087	0.25	0.26	Metabolic traits;	chr6:111528657	chr6:111297126~111298510:+
COAD	cis	rs2836974	0.897	rs35386515	ENSG00000255568.3	BRWD1-AS2	4.24	3.11e-05	0.0087	0.26	0.26	Cognitive function;	chr21:39160121	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs2836925	ENSG00000255568.3	BRWD1-AS2	4.24	3.11e-05	0.0087	0.26	0.26	Cognitive function;	chr21:39160427	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.863	rs8128026	ENSG00000255568.3	BRWD1-AS2	4.24	3.11e-05	0.0087	0.26	0.26	Cognitive function;	chr21:39161776	chr21:39313935~39314962:+
COAD	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-4.24	3.11e-05	0.00871	-0.52	-0.26	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
COAD	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-4.24	3.11e-05	0.00871	-0.52	-0.26	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
COAD	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	4.24	3.11e-05	0.00871	0.48	0.26	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
COAD	cis	rs7584330	0.666	rs1574530	ENSG00000234949.2	AC104667.3	-4.24	3.11e-05	0.00871	-0.4	-0.26	Prostate cancer;	chr2:237487065	chr2:237591020~237595981:+
COAD	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	4.24	3.11e-05	0.00871	0.23	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
COAD	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	4.24	3.11e-05	0.00871	0.23	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
COAD	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	4.24	3.11e-05	0.00872	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
COAD	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-4.24	3.12e-05	0.00872	-0.33	-0.26	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
COAD	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	4.24	3.12e-05	0.00873	0.43	0.26	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	4.24	3.12e-05	0.00873	0.43	0.26	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
COAD	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	4.24	3.12e-05	0.00873	0.43	0.26	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
COAD	cis	rs7829975	0.667	rs1877119	ENSG00000173295.6	FAM86B3P	4.24	3.12e-05	0.00873	0.31	0.26	Mood instability;	chr8:8849687	chr8:8228595~8244865:+
COAD	cis	rs9942416	0.928	rs6453143	ENSG00000271815.1	CTD-2235C13.3	-4.24	3.12e-05	0.00873	-0.32	-0.26	Age-related disease endophenotypes;	chr5:75727385	chr5:75363760~75364242:+
COAD	cis	rs2188554	0.785	rs2518881	ENSG00000237974.1	AC000111.4	4.24	3.12e-05	0.00873	0.26	0.26	Esophageal adenocarcinoma;	chr7:117532677	chr7:117487737~117487929:+
COAD	cis	rs72647484	0.558	rs2807366	ENSG00000271840.1	RP1-224A6.9	4.24	3.12e-05	0.00873	0.57	0.26	Colorectal cancer;	chr1:22157419	chr1:22100613~22101360:+
COAD	cis	rs2638953	0.962	rs11049611	ENSG00000247934.4	RP11-967K21.1	-4.24	3.12e-05	0.00873	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28163298~28190738:-
COAD	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	4.24	3.12e-05	0.00873	0.28	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
COAD	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-4.24	3.12e-05	0.00874	-0.31	-0.26	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
COAD	cis	rs3764400	0.567	rs208012	ENSG00000278765.1	RP5-890E16.5	-4.24	3.12e-05	0.00874	-0.48	-0.26	Body mass index;	chr17:48180655	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs208011	ENSG00000278765.1	RP5-890E16.5	-4.24	3.12e-05	0.00874	-0.48	-0.26	Body mass index;	chr17:48180983	chr17:48066704~48067293:-
COAD	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	4.24	3.12e-05	0.00874	0.29	0.26	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
COAD	cis	rs6490294	0.799	rs6489819	ENSG00000257595.2	RP3-473L9.4	4.24	3.13e-05	0.00875	0.37	0.26	Mean platelet volume;	chr12:111890426	chr12:111369282~111403310:+
COAD	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	4.24	3.13e-05	0.00876	0.29	0.26	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	4.24	3.13e-05	0.00876	0.29	0.26	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	4.24	3.13e-05	0.00876	0.29	0.26	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	4.24	3.13e-05	0.00876	0.29	0.26	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
COAD	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	4.24	3.13e-05	0.00876	0.23	0.26	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
COAD	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-4.24	3.13e-05	0.00876	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
COAD	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	4.24	3.13e-05	0.00876	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
COAD	cis	rs1949733	0.628	rs2688231	ENSG00000205959.3	RP11-689P11.2	-4.24	3.13e-05	0.00877	-0.31	-0.26	Response to antineoplastic agents;	chr4:8489254	chr4:8482270~8512610:+
COAD	cis	rs7246657	0.943	rs4803347	ENSG00000226686.6	LINC01535	-4.24	3.13e-05	0.00877	-0.36	-0.26	Coronary artery calcification;	chr19:37357115	chr19:37251912~37265535:+
COAD	cis	rs73607972	0.696	rs7197014	ENSG00000275191.1	RP11-36I17.2	-4.24	3.14e-05	0.00877	-0.36	-0.26	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53628256~53628816:-
COAD	cis	rs1275468	1	rs1148004	ENSG00000257497.2	RP11-585P4.5	-4.24	3.14e-05	0.00878	-0.34	-0.26	Polycystic ovary syndrome;	chr12:75584897	chr12:75483454~75489820:-
COAD	cis	rs7200543	1	rs16966953	ENSG00000270580.4	PKD1P6	4.24	3.14e-05	0.00878	0.29	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15104723~15131601:-
COAD	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-4.24	3.14e-05	0.00878	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
COAD	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-4.24	3.14e-05	0.00878	-0.25	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
COAD	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	4.24	3.14e-05	0.00879	0.29	0.26	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	4.24	3.14e-05	0.00879	0.24	0.26	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
COAD	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-4.24	3.14e-05	0.00879	-0.4	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
COAD	cis	rs6929812	0.613	rs9468140	ENSG00000271755.1	RP1-153G14.4	4.24	3.14e-05	0.00879	0.29	0.26	Neuroticism (multi-trait analysis);	chr6:27503736	chr6:27404010~27406964:-
COAD	cis	rs7955901	0.837	rs11178531	ENSG00000258053.1	CTD-2021H9.3	-4.24	3.14e-05	0.00879	-0.3	-0.26	Type 2 diabetes;	chr12:71014910	chr12:71047402~71118247:-
COAD	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	4.24	3.14e-05	0.00879	0.34	0.26	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
COAD	cis	rs4819052	0.684	rs914216	ENSG00000227039.5	ITGB2-AS1	-4.24	3.15e-05	0.00879	-0.22	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:44921051~44929678:+
COAD	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	4.24	3.15e-05	0.0088	0.39	0.26	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
COAD	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-4.24	3.15e-05	0.0088	-0.58	-0.26	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
COAD	cis	rs1949733	0.635	rs4358384	ENSG00000205959.3	RP11-689P11.2	4.24	3.15e-05	0.0088	0.32	0.26	Response to antineoplastic agents;	chr4:8535186	chr4:8482270~8512610:+
COAD	cis	rs13256369	1	rs883648	ENSG00000253981.4	ALG1L13P	4.24	3.15e-05	0.0088	0.37	0.26	Obesity-related traits;	chr8:8712011	chr8:8236003~8244667:-
COAD	cis	rs5742933	0.696	rs17271246	ENSG00000253559.1	OSGEPL1-AS1	-4.24	3.15e-05	0.0088	-0.32	-0.26	Ferritin levels;	chr2:189781481	chr2:189762704~189765556:+
COAD	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	4.24	3.15e-05	0.00881	0.32	0.26	Height;	chr6:109773423	chr6:109382795~109383666:+
COAD	cis	rs2732480	0.557	rs2409004	ENSG00000240399.1	RP1-228P16.1	4.24	3.15e-05	0.00881	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48054813~48055591:-
COAD	cis	rs2732480	0.577	rs2450994	ENSG00000240399.1	RP1-228P16.1	4.24	3.15e-05	0.00881	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48054813~48055591:-
COAD	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00881	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00881	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00881	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
COAD	cis	rs9307551	0.817	rs1440864	ENSG00000250334.4	LINC00989	-4.24	3.15e-05	0.00881	-0.29	-0.26	Refractive error;	chr4:79571830	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.817	rs12507375	ENSG00000250334.4	LINC00989	-4.24	3.15e-05	0.00881	-0.29	-0.26	Refractive error;	chr4:79575206	chr4:79492416~79576460:+
COAD	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	4.24	3.15e-05	0.00881	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
COAD	cis	rs6840360	0.582	rs2709826	ENSG00000251611.1	RP11-610P16.1	-4.24	3.15e-05	0.00881	-0.24	-0.26	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151407551~151408835:-
COAD	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	4.24	3.15e-05	0.00881	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
COAD	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	4.24	3.15e-05	0.00881	0.44	0.26	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
COAD	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	4.24	3.15e-05	0.00881	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	4.24	3.15e-05	0.00881	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	4.24	3.15e-05	0.00881	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	4.24	3.15e-05	0.00881	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
COAD	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-4.24	3.15e-05	0.00881	-0.3	-0.26	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-4.24	3.15e-05	0.00881	-0.3	-0.26	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
COAD	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-4.24	3.15e-05	0.00881	-0.3	-0.26	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
COAD	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	4.24	3.15e-05	0.00881	0.46	0.26	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
COAD	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00882	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00882	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00882	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-4.24	3.15e-05	0.00882	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
COAD	cis	rs73198271	0.74	rs67766414	ENSG00000173295.6	FAM86B3P	-4.24	3.16e-05	0.00882	-0.34	-0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8228595~8244865:+
COAD	cis	rs2638953	0.853	rs10506036	ENSG00000247934.4	RP11-967K21.1	4.24	3.16e-05	0.00882	0.26	0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28163298~28190738:-
COAD	cis	rs752010	0.668	rs10890147	ENSG00000230638.4	RP11-486B10.4	-4.24	3.16e-05	0.00883	-0.33	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41624054	chr1:41542069~41544310:+
COAD	cis	rs2638953	0.853	rs17433981	ENSG00000247934.4	RP11-967K21.1	-4.24	3.16e-05	0.00883	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs12366617	ENSG00000247934.4	RP11-967K21.1	-4.24	3.16e-05	0.00883	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28163298~28190738:-
COAD	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	4.24	3.16e-05	0.00883	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
COAD	cis	rs4819052	0.851	rs914218	ENSG00000227039.5	ITGB2-AS1	-4.24	3.16e-05	0.00883	-0.23	-0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:44921051~44929678:+
COAD	cis	rs9291683	0.62	rs4444830	ENSG00000250413.1	RP11-448G15.1	4.24	3.16e-05	0.00883	0.35	0.26	Bone mineral density;	chr4:10123195	chr4:10006482~10009725:+
COAD	cis	rs6940638	0.688	rs6921388	ENSG00000224843.5	LINC00240	4.24	3.16e-05	0.00883	0.33	0.26	Intelligence (multi-trait analysis);	chr6:27112426	chr6:26956992~27023924:+
COAD	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	4.24	3.16e-05	0.00884	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
COAD	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	4.24	3.17e-05	0.00884	0.31	0.26	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
COAD	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	4.24	3.17e-05	0.00884	0.31	0.26	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
COAD	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-4.24	3.17e-05	0.00884	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-4.24	3.17e-05	0.00884	-0.27	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
COAD	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	4.24	3.17e-05	0.00884	0.36	0.26	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
COAD	cis	rs56052703	0.536	rs7250570	ENSG00000267633.1	CTB-5E10.3	4.24	3.17e-05	0.00885	0.29	0.26	Proteinuria and chronic kidney disease;	chr19:13318520	chr19:13772118~13774118:-
COAD	cis	rs791888	0.858	rs2180968	ENSG00000225913.2	RP11-57C13.6	-4.24	3.17e-05	0.00885	-0.32	-0.26	Magnesium levels;	chr10:87658973	chr10:87607985~87659279:+
COAD	cis	rs2408955	0.504	rs11168441	ENSG00000257735.1	RP11-370I10.6	4.24	3.17e-05	0.00885	0.31	0.26	Glycated hemoglobin levels;	chr12:48182271	chr12:48350945~48442411:+
COAD	cis	rs752010	0.619	rs6703992	ENSG00000230638.4	RP11-486B10.4	-4.24	3.17e-05	0.00885	-0.31	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr1:41650217	chr1:41542069~41544310:+
COAD	cis	rs9532669	0.926	rs9532659	ENSG00000239827.7	SUGT1P3	-4.24	3.17e-05	0.00885	-0.22	-0.26	Cervical cancer;	chr13:40920380	chr13:40908159~40921774:-
COAD	cis	rs860295	0.651	rs6677385	ENSG00000160766.13	GBAP1	-4.24	3.17e-05	0.00886	-0.3	-0.26	Body mass index;	chr1:155334790	chr1:155213821~155227422:-
COAD	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-4.24	3.18e-05	0.00887	-0.26	-0.26	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
COAD	cis	rs7760535	0.831	rs62420437	ENSG00000271789.1	RP5-1112D6.7	-4.24	3.18e-05	0.00887	-0.25	-0.26	Metabolic traits;	chr6:111427577	chr6:111297126~111298510:+
COAD	cis	rs2732480	0.557	rs2409004	ENSG00000257735.1	RP11-370I10.6	4.24	3.18e-05	0.00887	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs2450994	ENSG00000257735.1	RP11-370I10.6	4.24	3.18e-05	0.00887	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48350945~48442411:+
COAD	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
COAD	cis	rs875971	0.862	rs6947339	ENSG00000224316.1	RP11-479O9.2	4.24	3.18e-05	0.00887	0.28	0.26	Aortic root size;	chr7:66423483	chr7:65773620~65802067:+
COAD	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-4.24	3.18e-05	0.00887	-0.49	-0.26	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
COAD	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	4.24	3.18e-05	0.00888	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	4.24	3.18e-05	0.00888	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
COAD	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	4.24	3.18e-05	0.00888	0.31	0.26	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	4.24	3.18e-05	0.00888	0.31	0.26	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	4.24	3.18e-05	0.00888	0.31	0.26	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	4.24	3.18e-05	0.00888	0.31	0.26	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
COAD	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	4.24	3.18e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
COAD	cis	rs7193541	1	rs7193541	ENSG00000262904.1	TMPOP2	4.24	3.18e-05	0.00888	0.27	0.26	Multiple myeloma;	chr16:74630845	chr16:74667506~74668706:+
COAD	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-4.24	3.18e-05	0.00888	-0.28	-0.26	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
COAD	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	4.24	3.18e-05	0.00888	0.28	0.26	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
COAD	cis	rs17772222	0.958	rs76559451	ENSG00000258789.1	RP11-507K2.3	-4.24	3.18e-05	0.00888	-0.37	-0.26	Coronary artery calcification;	chr14:88523193	chr14:88551597~88552493:+
COAD	cis	rs1387259	0.839	rs7487682	ENSG00000226413.2	OR8T1P	-4.24	3.19e-05	0.00888	-0.3	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48442030~48442947:-
COAD	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-4.24	3.19e-05	0.00888	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
COAD	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-4.24	3.19e-05	0.00888	-0.31	-0.26	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-4.24	3.19e-05	0.00888	-0.31	-0.26	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
COAD	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	4.23	3.19e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	4.23	3.19e-05	0.00888	0.34	0.26	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
COAD	cis	rs2638953	0.924	rs11049575	ENSG00000247934.4	RP11-967K21.1	-4.23	3.19e-05	0.00889	-0.27	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28411328	chr12:28163298~28190738:-
COAD	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-4.23	3.19e-05	0.00889	-0.27	-0.26	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
COAD	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-4.23	3.19e-05	0.00889	-0.34	-0.26	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
COAD	cis	rs74233809	1	rs11191514	ENSG00000213277.3	MARCKSL1P1	4.23	3.19e-05	0.00889	0.48	0.26	Birth weight;	chr10:103013607	chr10:103175554~103176094:+
COAD	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	4.23	3.19e-05	0.00889	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
COAD	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.23	3.19e-05	0.0089	-0.25	-0.26	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
COAD	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	4.23	3.19e-05	0.0089	0.29	0.26	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	4.23	3.19e-05	0.0089	0.29	0.26	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
COAD	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	4.23	3.19e-05	0.0089	0.29	0.26	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
COAD	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	4.23	3.19e-05	0.0089	0.29	0.26	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
COAD	cis	rs6903823	0.508	rs1150721	ENSG00000272009.1	RP1-313I6.12	4.23	3.19e-05	0.0089	0.28	0.26	Pulmonary function;	chr6:28287263	chr6:28078792~28081130:-
COAD	cis	rs6585424	1	rs35180576	ENSG00000234382.2	RP11-40F6.1	-4.23	3.19e-05	0.0089	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs34148644	ENSG00000234382.2	RP11-40F6.1	-4.23	3.19e-05	0.0089	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:80233664~80245367:+
COAD	cis	rs734999	0.588	rs10910098	ENSG00000225931.3	RP3-395M20.7	4.23	3.19e-05	0.0089	0.28	0.26	Ulcerative colitis;	chr1:2601811	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs60520190	ENSG00000225931.3	RP3-395M20.7	4.23	3.19e-05	0.0089	0.28	0.26	Ulcerative colitis;	chr1:2602267	chr1:2566410~2569888:+
COAD	cis	rs884366	1	rs884366	ENSG00000219700.1	PTCHD3P3	-4.23	3.19e-05	0.0089	-0.33	-0.26	HDL cholesterol;HDL cholesterol levels;	chr6:109252892	chr6:109288571~109290503:-
COAD	cis	rs2921036	0.545	rs4840975	ENSG00000254340.1	RP11-10A14.3	-4.23	3.2e-05	0.00891	-0.31	-0.26	Neuroticism;	chr8:8505748	chr8:9141424~9145435:+
COAD	cis	rs7646881	0.544	rs73024783	ENSG00000272087.1	RP11-379F4.7	4.23	3.2e-05	0.00891	0.41	0.26	Tetralogy of Fallot;	chr3:158604426	chr3:158693120~158693768:-
COAD	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	4.23	3.2e-05	0.00892	0.34	0.26	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	4.23	3.2e-05	0.00892	0.34	0.26	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
COAD	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.23	3.2e-05	0.00892	0.43	0.26	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
COAD	cis	rs67072384	0.818	rs7926287	ENSG00000202522.1	Y_RNA	-4.23	3.2e-05	0.00893	-0.36	-0.26	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72753480	chr11:72766004~72766116:+
COAD	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	4.23	3.2e-05	0.00893	0.3	0.26	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
COAD	cis	rs9450351	0.744	rs56344601	ENSG00000203875.9	SNHG5	-4.23	3.2e-05	0.00893	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:86057967	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6901489	ENSG00000203875.9	SNHG5	-4.23	3.2e-05	0.00893	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:86066343	chr6:85660950~85678736:-
COAD	cis	rs9450351	0.744	rs6913399	ENSG00000203875.9	SNHG5	-4.23	3.2e-05	0.00893	-0.5	-0.26	Interferon gamma-induced protein 10 levels;	chr6:86068202	chr6:85660950~85678736:-
COAD	cis	rs7646881	0.812	rs7624408	ENSG00000272087.1	RP11-379F4.7	4.23	3.21e-05	0.00893	0.39	0.26	Tetralogy of Fallot;	chr3:158742269	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs7636023	ENSG00000272087.1	RP11-379F4.7	4.23	3.21e-05	0.00893	0.39	0.26	Tetralogy of Fallot;	chr3:158742270	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs73017536	ENSG00000272087.1	RP11-379F4.7	4.23	3.21e-05	0.00893	0.39	0.26	Tetralogy of Fallot;	chr3:158742813	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs73017540	ENSG00000272087.1	RP11-379F4.7	4.23	3.21e-05	0.00893	0.39	0.26	Tetralogy of Fallot;	chr3:158742999	chr3:158693120~158693768:-
COAD	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.23	3.21e-05	0.00894	0.27	0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
COAD	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-4.23	3.21e-05	0.00894	-0.26	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
COAD	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-4.23	3.21e-05	0.00894	-0.41	-0.26	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
COAD	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-4.23	3.21e-05	0.00894	-0.37	-0.26	Depression;	chr6:28161802	chr6:28115628~28116551:+
COAD	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-4.23	3.21e-05	0.00895	-0.27	-0.26	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
COAD	cis	rs6840360	0.582	rs11733820	ENSG00000270265.1	RP11-731D1.4	-4.23	3.21e-05	0.00895	-0.3	-0.26	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151333775~151353224:-
COAD	cis	rs683257	0.636	rs72988149	ENSG00000234147.1	RP3-460G2.2	-4.23	3.21e-05	0.00895	-0.45	-0.26	Facial emotion recognition (angry faces);	chr6:140829500	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs58922657	ENSG00000234147.1	RP3-460G2.2	-4.23	3.21e-05	0.00895	-0.45	-0.26	Facial emotion recognition (angry faces);	chr6:140831739	chr6:140845958~140852924:-
COAD	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-4.23	3.22e-05	0.00895	-0.31	-0.26	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-4.23	3.22e-05	0.00895	-0.31	-0.26	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-4.23	3.22e-05	0.00895	-0.31	-0.26	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-4.23	3.22e-05	0.00895	-0.31	-0.26	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-4.23	3.22e-05	0.00895	-0.31	-0.26	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
COAD	cis	rs2644899	0.75	rs2607414	ENSG00000233622.1	CYP2T1P	4.23	3.22e-05	0.00895	0.29	0.26	Post bronchodilator FEV1/FVC ratio;	chr19:40761224	chr19:40808525~40811390:-
COAD	cis	rs9868809	0.505	rs11719291	ENSG00000225399.4	RP11-3B7.1	-4.23	3.22e-05	0.00895	-0.39	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698273	chr3:49260085~49261316:+
COAD	cis	rs9400467	0.528	rs6568680	ENSG00000271789.1	RP5-1112D6.7	-4.23	3.22e-05	0.00896	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111297126~111298510:+
COAD	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-4.23	3.22e-05	0.00896	-0.41	-0.26	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-4.23	3.22e-05	0.00896	-0.41	-0.26	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-4.23	3.22e-05	0.00896	-0.41	-0.26	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-4.23	3.22e-05	0.00896	-0.41	-0.26	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
COAD	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-4.23	3.22e-05	0.00897	-0.3	-0.26	QT interval;	chr12:29310155	chr12:29277397~29277882:-
COAD	cis	rs7688540	0.8	rs28531997	ENSG00000198155.5	ZNF876P	-4.23	3.22e-05	0.00897	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:212610~255985:+
COAD	cis	rs875971	0.862	rs801206	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66556979	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs801204	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66557934	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs801203	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66558025	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs801202	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66558942	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs801195	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66561128	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs801194	ENSG00000224316.1	RP11-479O9.2	-4.23	3.22e-05	0.00897	-0.28	-0.26	Aortic root size;	chr7:66563508	chr7:65773620~65802067:+
COAD	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	4.23	3.22e-05	0.00897	0.29	0.26	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	4.23	3.22e-05	0.00897	0.29	0.26	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
COAD	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-4.23	3.22e-05	0.00897	-0.32	-0.26	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
COAD	cis	rs11229555	0.645	rs11229445	ENSG00000254602.1	AP000662.4	-4.23	3.22e-05	0.00897	-0.3	-0.26	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58431985	chr11:57638024~57652790:+
COAD	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	4.23	3.23e-05	0.00897	0.36	0.26	Depression;	chr6:28184805	chr6:28943877~28944537:+
COAD	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-4.23	3.23e-05	0.00897	-0.31	-0.26	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
COAD	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-4.23	3.23e-05	0.00897	-0.31	-0.26	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
COAD	cis	rs13113518	0.678	rs7663650	ENSG00000223305.1	RN7SKP30	-4.23	3.23e-05	0.00898	-0.29	-0.26	Height;	chr4:55364952	chr4:55540502~55540835:-
COAD	cis	rs7584330	0.826	rs72620825	ENSG00000234949.2	AC104667.3	-4.23	3.23e-05	0.00898	-0.35	-0.26	Prostate cancer;	chr2:237472600	chr2:237591020~237595981:+
COAD	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-4.23	3.23e-05	0.00899	-0.26	-0.26	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
COAD	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	4.23	3.23e-05	0.00899	0.19	0.26	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
COAD	cis	rs2732480	0.557	rs2409004	ENSG00000269514.1	RP11-370I10.12	4.23	3.23e-05	0.00899	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2450994	ENSG00000269514.1	RP11-370I10.12	4.23	3.23e-05	0.00899	0.32	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48198387~48202031:+
COAD	cis	rs2516839	0.652	rs2516841	ENSG00000232879.2	RP11-544M22.3	-4.23	3.24e-05	0.009	-0.35	-0.26	Granulocyte percentage of myeloid white cells;	chr1:161040984	chr1:161034834~161035006:+
COAD	cis	rs2516839	0.652	rs2774276	ENSG00000232879.2	RP11-544M22.3	-4.23	3.24e-05	0.009	-0.35	-0.26	Granulocyte percentage of myeloid white cells;	chr1:161041926	chr1:161034834~161035006:+
COAD	cis	rs72827839	0.846	rs72823591	ENSG00000263412.1	RP5-890E16.2	4.23	3.24e-05	0.009	0.35	0.26	Ease of getting up in the morning;	chr17:48045266	chr17:48045141~48048073:-
COAD	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	4.23	3.24e-05	0.009	0.34	0.26	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
COAD	cis	rs3752645	0.881	rs17340479	ENSG00000241764.3	AC002467.7	4.23	3.24e-05	0.009	0.5	0.26	Bladder cancer (smoking interaction);	chr7:107073551	chr7:107742817~107744581:-
COAD	cis	rs1062753	0.527	rs6002560	ENSG00000182057.4	OGFRP1	4.23	3.24e-05	0.009	0.25	0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41960882	chr22:42269753~42275196:+
COAD	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	4.23	3.24e-05	0.00901	0.3	0.26	Height;	chr4:55501955	chr4:55363971~55395847:-
COAD	cis	rs1023500	0.552	rs133368	ENSG00000227370.1	RP4-669P10.19	-4.23	3.24e-05	0.00901	-0.26	-0.26	Schizophrenia;	chr22:42067685	chr22:42132543~42132998:+
COAD	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-4.23	3.24e-05	0.00901	-0.48	-0.26	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
COAD	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	4.23	3.24e-05	0.00901	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
COAD	cis	rs7955901	0.563	rs1798093	ENSG00000258053.1	CTD-2021H9.3	-4.23	3.24e-05	0.00902	-0.29	-0.26	Type 2 diabetes;	chr12:71138109	chr12:71047402~71118247:-
COAD	cis	rs595244	1	rs363820	ENSG00000259705.1	RP11-227D13.1	-4.23	3.24e-05	0.00902	-0.41	-0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48436833	chr15:48645951~48652016:+
COAD	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	4.23	3.25e-05	0.00902	0.31	0.26	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
COAD	cis	rs7656342	0.897	rs1967551	ENSG00000186234.7	FAM86MP	-4.23	3.25e-05	0.00902	-0.34	-0.26	Gut microbiota (bacterial taxa);	chr4:9783510	chr4:9692495~9702954:+
COAD	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-4.23	3.25e-05	0.00902	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-4.23	3.25e-05	0.00902	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
COAD	cis	rs2732480	0.557	rs923397	ENSG00000240399.1	RP1-228P16.1	4.23	3.25e-05	0.00903	0.27	0.26	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48054813~48055591:-
COAD	cis	rs4819052	0.851	rs8131143	ENSG00000227039.5	ITGB2-AS1	4.23	3.25e-05	0.00903	0.22	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:44921051~44929678:+
COAD	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-4.23	3.25e-05	0.00903	-0.32	-0.26	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
COAD	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-4.23	3.25e-05	0.00903	-0.25	-0.26	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
COAD	cis	rs9863	0.536	rs4765568	ENSG00000269938.1	RP11-214K3.20	4.23	3.25e-05	0.00903	0.32	0.26	White blood cell count;	chr12:123994614	chr12:123968023~123968579:-
COAD	cis	rs4243971	0.516	rs6141282	ENSG00000101898.5	MCTS2P	4.23	3.25e-05	0.00904	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32289514	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs6141662	ENSG00000101898.5	MCTS2P	4.23	3.25e-05	0.00904	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32294357	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs6141664	ENSG00000101898.5	MCTS2P	4.23	3.25e-05	0.00904	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr20:32300565	chr20:31547504~31548049:+
COAD	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	4.23	3.25e-05	0.00904	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
COAD	cis	rs61270009	0.955	rs780397	ENSG00000247828.6	TMEM161B-AS1	-4.23	3.26e-05	0.00904	-0.28	-0.26	Depressive symptoms;	chr5:88233841	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.874	rs780403	ENSG00000247828.6	TMEM161B-AS1	-4.23	3.26e-05	0.00904	-0.28	-0.26	Depressive symptoms;	chr5:88244989	chr5:88268895~88436685:+
COAD	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	4.23	3.26e-05	0.00905	0.33	0.26	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	4.23	3.26e-05	0.00905	0.33	0.26	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
COAD	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	4.23	3.26e-05	0.00905	0.27	0.26	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
COAD	cis	rs2018683	0.707	rs2391718	ENSG00000272568.4	CTB-113D17.1	4.23	3.26e-05	0.00905	0.35	0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28979967~29013367:+
COAD	cis	rs3733585	0.682	rs13124563	ENSG00000250413.1	RP11-448G15.1	-4.23	3.26e-05	0.00906	-0.32	-0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9925929	chr4:10006482~10009725:+
COAD	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-4.23	3.26e-05	0.00906	-0.34	-0.26	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
COAD	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-4.23	3.26e-05	0.00906	-0.31	-0.26	QT interval;	chr12:29343291	chr12:29277397~29277882:-
COAD	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	4.23	3.26e-05	0.00906	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
COAD	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	4.23	3.26e-05	0.00906	0.27	0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
COAD	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-4.23	3.26e-05	0.00906	-0.44	-0.26	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
COAD	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	4.23	3.26e-05	0.00906	0.45	0.26	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
COAD	cis	rs9291683	0.566	rs13115776	ENSG00000250413.1	RP11-448G15.1	-4.23	3.26e-05	0.00906	-0.33	-0.26	Bone mineral density;	chr4:10038565	chr4:10006482~10009725:+
COAD	cis	rs17772222	0.917	rs1998670	ENSG00000258789.1	RP11-507K2.3	-4.23	3.26e-05	0.00907	-0.37	-0.26	Coronary artery calcification;	chr14:88504581	chr14:88551597~88552493:+
COAD	cis	rs11976180	1	rs2961117	ENSG00000273234.1	OR2A13P	-4.23	3.27e-05	0.00907	-0.32	-0.26	Obesity-related traits;	chr7:144058160	chr7:144142009~144142938:+
COAD	cis	rs34792	0.525	rs12923446	ENSG00000207425.1	Y_RNA	4.23	3.27e-05	0.00907	0.31	0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15509723	chr16:14915457~14915556:-
COAD	cis	rs6940638	0.715	rs9348751	ENSG00000224843.5	LINC00240	4.23	3.27e-05	0.00907	0.33	0.26	Intelligence (multi-trait analysis);	chr6:27099411	chr6:26956992~27023924:+
COAD	cis	rs2638953	0.925	rs11049510	ENSG00000247934.4	RP11-967K21.1	-4.23	3.27e-05	0.00907	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049515	ENSG00000247934.4	RP11-967K21.1	-4.23	3.27e-05	0.00907	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299564	chr12:28163298~28190738:-
COAD	cis	rs2638953	1	rs11049516	ENSG00000247934.4	RP11-967K21.1	-4.23	3.27e-05	0.00907	-0.28	-0.26	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299649	chr12:28163298~28190738:-
COAD	cis	rs13256369	0.708	rs9644772	ENSG00000253981.4	ALG1L13P	4.23	3.27e-05	0.00907	0.39	0.26	Obesity-related traits;	chr8:8700175	chr8:8236003~8244667:-
COAD	cis	rs2252521	0.583	rs317763	ENSG00000272568.4	CTB-113D17.1	4.23	3.27e-05	0.00907	0.49	0.26	Cognitive performance;	chr7:29042687	chr7:28979967~29013367:+
COAD	cis	rs7200543	1	rs72774845	ENSG00000270580.4	PKD1P6	4.23	3.27e-05	0.00907	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15104723~15131601:-
COAD	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	4.23	3.27e-05	0.00907	0.27	0.26	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
COAD	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-4.23	3.27e-05	0.00907	-0.49	-0.26	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
COAD	cis	rs7138300	0.528	rs11178578	ENSG00000258053.1	CTD-2021H9.3	-4.23	3.27e-05	0.00907	-0.35	-0.26	Type 2 diabetes;	chr12:71062330	chr12:71047402~71118247:-
COAD	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	4.23	3.27e-05	0.00907	0.3	0.26	Height;	chr4:55570843	chr4:55540502~55540835:-
COAD	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	4.23	3.27e-05	0.00908	0.28	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
COAD	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	4.23	3.27e-05	0.00908	0.3	0.26	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
COAD	cis	rs6565653	1	rs6565653	ENSG00000262580.4	RP11-334C17.5	4.23	3.27e-05	0.00908	0.24	0.26	Ischemic stroke;	chr17:80227984	chr17:80200673~80205949:-
COAD	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-4.23	3.27e-05	0.00908	-0.31	-0.26	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-4.23	3.27e-05	0.00908	-0.31	-0.26	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
COAD	cis	rs7688540	0.76	rs28460123	ENSG00000198155.5	ZNF876P	-4.23	3.27e-05	0.00908	-0.38	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:212610~255985:+
COAD	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	4.23	3.27e-05	0.00908	0.33	0.26	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
COAD	cis	rs734999	0.967	rs10752745	ENSG00000225931.3	RP3-395M20.7	4.23	3.27e-05	0.00908	0.28	0.26	Ulcerative colitis;	chr1:2576499	chr1:2566410~2569888:+
COAD	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	4.23	3.27e-05	0.00908	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
COAD	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	4.23	3.27e-05	0.00908	0.38	0.26	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
COAD	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-4.23	3.27e-05	0.00908	-0.26	-0.26	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
COAD	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	4.23	3.28e-05	0.00909	0.33	0.26	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
COAD	cis	rs11969893	0.85	rs9390713	ENSG00000270987.1	RP3-467N11.2	4.23	3.28e-05	0.00909	0.61	0.26	Economic and political preferences (immigration/crime);	chr6:100976386	chr6:100889603~100890338:+
COAD	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	4.23	3.28e-05	0.00909	0.32	0.26	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
COAD	cis	rs4392868	0.514	rs4323439	ENSG00000254248.1	RP11-320N21.2	-4.23	3.28e-05	0.00909	-0.3	-0.26	Radiation response;	chr8:95093533	chr8:95071732~95087924:-
COAD	cis	rs4392868	0.514	rs4236831	ENSG00000254248.1	RP11-320N21.2	-4.23	3.28e-05	0.00909	-0.3	-0.26	Radiation response;	chr8:95093705	chr8:95071732~95087924:-
COAD	cis	rs9910055	0.664	rs433610	ENSG00000267080.4	ASB16-AS1	4.23	3.28e-05	0.0091	0.24	0.26	Total body bone mineral density;	chr17:44119913	chr17:44175973~44186717:-
COAD	cis	rs7688540	0.8	rs61792060	ENSG00000198155.5	ZNF876P	-4.23	3.28e-05	0.0091	-0.39	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:212610~255985:+
COAD	cis	rs9813712	0.596	rs2587988	ENSG00000249846.5	RP11-77P16.4	-4.23	3.28e-05	0.0091	-0.3	-0.26	Response to amphetamines;	chr3:130201415	chr3:130112550~130120579:+
COAD	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	4.23	3.28e-05	0.0091	0.45	0.26	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
COAD	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-4.23	3.28e-05	0.0091	-0.26	-0.26	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
COAD	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	4.23	3.28e-05	0.0091	0.33	0.26	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
COAD	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-4.23	3.28e-05	0.00911	-0.26	-0.25	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-4.23	3.28e-05	0.00911	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
COAD	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-4.23	3.29e-05	0.00911	-0.32	-0.25	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-4.23	3.29e-05	0.00911	-0.32	-0.25	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-4.23	3.29e-05	0.00911	-0.32	-0.25	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
COAD	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	4.23	3.29e-05	0.00911	0.32	0.25	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
COAD	cis	rs7584330	0.554	rs77648388	ENSG00000234949.2	AC104667.3	-4.23	3.29e-05	0.00911	-0.45	-0.25	Prostate cancer;	chr2:237523189	chr2:237591020~237595981:+
COAD	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-4.23	3.29e-05	0.00911	-0.32	-0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
COAD	cis	rs28374715	0.681	rs28712264	ENSG00000247556.5	OIP5-AS1	4.23	3.29e-05	0.00912	0.37	0.25	Ulcerative colitis;	chr15:41296599	chr15:41283990~41309737:+
COAD	cis	rs7260598	0.535	rs13343732	ENSG00000268442.1	CTD-2027I19.2	4.23	3.29e-05	0.00912	0.35	0.25	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:24162370~24163425:-
COAD	cis	rs11763147	1	rs11763147	ENSG00000272831.1	RP11-792A8.4	-4.23	3.29e-05	0.00912	-0.26	-0.25	Corneal structure;	chr7:65861834	chr7:66739829~66740385:-
COAD	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	4.23	3.29e-05	0.00912	0.4	0.25	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
COAD	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	4.23	3.29e-05	0.00912	0.19	0.25	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
COAD	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	4.23	3.29e-05	0.00912	0.28	0.25	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
COAD	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	4.23	3.29e-05	0.00913	0.29	0.25	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
COAD	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-4.23	3.29e-05	0.00913	-0.17	-0.25	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
COAD	cis	rs2732480	0.557	rs923397	ENSG00000257735.1	RP11-370I10.6	4.23	3.29e-05	0.00913	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48350945~48442411:+
COAD	cis	rs6661961	0.714	rs6695950	ENSG00000237975.5	FLG-AS1	-4.23	3.3e-05	0.00913	-0.26	-0.25	Atopic dermatitis;	chr1:152440211	chr1:152168125~152445456:+
COAD	cis	rs875971	0.83	rs778711	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66386670	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs1083554	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66387354	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs778707	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66392040	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs778705	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66396128	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs778697	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66405439	chr7:65773620~65802067:+
COAD	cis	rs875971	0.798	rs7789615	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66413674	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6978028	ENSG00000224316.1	RP11-479O9.2	4.23	3.3e-05	0.00913	0.28	0.25	Aortic root size;	chr7:66421313	chr7:65773620~65802067:+
COAD	cis	rs75422866	0.51	rs73105845	ENSG00000280054.1	RP1-197B17.7	4.23	3.3e-05	0.00913	0.58	0.25	Pneumonia;	chr12:47741824	chr12:47728151~47730598:-
COAD	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-4.23	3.3e-05	0.00913	-0.33	-0.25	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
COAD	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-4.23	3.3e-05	0.00913	-0.28	-0.25	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
COAD	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-4.23	3.3e-05	0.00913	-0.32	-0.25	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
COAD	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-4.23	3.3e-05	0.00913	-0.36	-0.25	Depression;	chr6:28159843	chr6:28115628~28116551:+
COAD	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	4.23	3.3e-05	0.00913	0.27	0.25	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-4.23	3.3e-05	0.00913	-0.3	-0.25	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
COAD	cis	rs74233809	1	rs11191502	ENSG00000213277.3	MARCKSL1P1	4.23	3.3e-05	0.00913	0.48	0.25	Birth weight;	chr10:103005737	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs74444347	ENSG00000213277.3	MARCKSL1P1	4.23	3.3e-05	0.00913	0.48	0.25	Birth weight;	chr10:103009518	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs12221335	ENSG00000213277.3	MARCKSL1P1	4.23	3.3e-05	0.00913	0.48	0.25	Birth weight;	chr10:103009635	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	4.23	3.3e-05	0.00913	0.48	0.25	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	4.23	3.3e-05	0.00913	0.48	0.25	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
COAD	cis	rs4604732	0.536	rs61184655	ENSG00000227135.1	GCSAML-AS1	-4.23	3.3e-05	0.00913	-0.36	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247488040	chr1:247524679~247526752:-
COAD	cis	rs9291683	0.546	rs4529049	ENSG00000250413.1	RP11-448G15.1	-4.23	3.3e-05	0.00914	-0.33	-0.25	Bone mineral density;	chr4:10043765	chr4:10006482~10009725:+
COAD	cis	rs8141529	0.644	rs5752795	ENSG00000272858.1	CTA-292E10.8	-4.23	3.3e-05	0.00914	-0.3	-0.25	Lymphocyte counts;	chr22:28782832	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.732	rs2347447	ENSG00000272858.1	CTA-292E10.8	-4.23	3.3e-05	0.00914	-0.3	-0.25	Lymphocyte counts;	chr22:28783751	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.732	rs5752798	ENSG00000272858.1	CTA-292E10.8	-4.23	3.3e-05	0.00914	-0.3	-0.25	Lymphocyte counts;	chr22:28785880	chr22:28814914~28815662:+
COAD	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-4.23	3.3e-05	0.00914	-0.46	-0.25	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
COAD	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	4.23	3.3e-05	0.00914	0.25	0.25	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
COAD	cis	rs7615952	0.515	rs4441610	ENSG00000241288.6	RP11-379B18.5	-4.23	3.31e-05	0.00915	-0.25	-0.25	Blood pressure (smoking interaction);	chr3:125962464	chr3:125827238~125916384:-
COAD	cis	rs9818758	0.607	rs4855860	ENSG00000225399.4	RP11-3B7.1	4.23	3.31e-05	0.00915	0.48	0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49488611	chr3:49260085~49261316:+
COAD	cis	rs930421	0.544	rs7566714	ENSG00000226491.1	FTOP1	4.23	3.31e-05	0.00916	0.33	0.25	Attention deficit hyperactivity disorder;	chr2:42757567	chr2:42797225~42798712:-
COAD	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-4.23	3.31e-05	0.00916	-0.27	-0.25	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
COAD	cis	rs6743226	0.548	rs886811	ENSG00000224232.1	AC110299.5	4.23	3.31e-05	0.00916	0.26	0.25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241457877	chr2:241478316~241478993:+
COAD	cis	rs8141529	0.732	rs2239815	ENSG00000272858.1	CTA-292E10.8	4.23	3.31e-05	0.00916	0.3	0.25	Lymphocyte counts;	chr22:28796682	chr22:28814914~28815662:+
COAD	cis	rs10465746	0.57	rs1886769	ENSG00000249237.4	RP11-376N17.4	-4.23	3.31e-05	0.00916	-0.28	-0.25	Obesity-related traits;	chr1:84005451	chr1:84344678~84349939:+
COAD	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-4.23	3.31e-05	0.00916	-0.31	-0.25	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
COAD	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.23	3.31e-05	0.00917	-0.32	-0.25	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
COAD	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-4.23	3.31e-05	0.00917	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
COAD	cis	rs875971	0.545	rs313830	ENSG00000224316.1	RP11-479O9.2	-4.23	3.31e-05	0.00917	-0.33	-0.25	Aortic root size;	chr7:66086944	chr7:65773620~65802067:+
COAD	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	4.23	3.31e-05	0.00917	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	4.23	3.31e-05	0.00917	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	4.23	3.31e-05	0.00917	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	4.23	3.31e-05	0.00917	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
COAD	cis	rs17685	0.712	rs2158867	ENSG00000280388.1	RP11-229D13.3	-4.23	3.32e-05	0.00918	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs1859794	ENSG00000280388.1	RP11-229D13.3	-4.23	3.32e-05	0.00918	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76043977~76045963:-
COAD	cis	rs6719977	0.805	rs7578904	ENSG00000226491.1	FTOP1	-4.23	3.32e-05	0.00918	-0.32	-0.25	Hyperactive-impulsive symptoms;	chr2:42757350	chr2:42797225~42798712:-
COAD	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-4.23	3.32e-05	0.00918	-0.3	-0.25	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
COAD	cis	rs1707322	0.827	rs6683274	ENSG00000230896.1	RP11-767N6.7	-4.23	3.32e-05	0.00918	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45694684~45697075:-
COAD	cis	rs2018683	0.707	rs917216	ENSG00000272568.4	CTB-113D17.1	4.23	3.32e-05	0.00918	0.36	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931855	chr7:28979967~29013367:+
COAD	cis	rs1949733	0.656	rs2631762	ENSG00000205959.3	RP11-689P11.2	-4.23	3.32e-05	0.00919	-0.31	-0.25	Response to antineoplastic agents;	chr4:8421395	chr4:8482270~8512610:+
COAD	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-4.23	3.32e-05	0.00919	-0.24	-0.25	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
COAD	cis	rs2836974	0.897	rs2836944	ENSG00000255568.3	BRWD1-AS2	4.22	3.32e-05	0.00919	0.26	0.25	Cognitive function;	chr21:39221613	chr21:39313935~39314962:+
COAD	cis	rs2638953	0.853	rs11049668	ENSG00000247934.4	RP11-967K21.1	-4.22	3.32e-05	0.0092	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28163298~28190738:-
COAD	cis	rs10129255	1	rs8010605	ENSG00000224373.3	IGHV4-59	4.22	3.33e-05	0.0092	0.16	0.25	Kawasaki disease;	chr14:106678742	chr14:106627249~106627825:-
COAD	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-4.22	3.33e-05	0.0092	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
COAD	cis	rs113835537	0.529	rs11227499	ENSG00000258297.1	RP11-658F2.8	-4.22	3.33e-05	0.0092	-0.26	-0.25	Airway imaging phenotypes;	chr11:66505353	chr11:66666036~66668374:+
COAD	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-4.22	3.33e-05	0.0092	-0.3	-0.25	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-4.22	3.33e-05	0.0092	-0.3	-0.25	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-4.22	3.33e-05	0.0092	-0.3	-0.25	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
COAD	cis	rs1949733	1	rs868105	ENSG00000205959.3	RP11-689P11.2	4.22	3.33e-05	0.0092	0.31	0.25	Response to antineoplastic agents;	chr4:8499303	chr4:8482270~8512610:+
COAD	cis	rs2581828	0.58	rs9845021	ENSG00000280417.1	RP11-5O17.1	4.22	3.33e-05	0.00921	0.29	0.25	Crohn's disease;	chr3:53138096	chr3:53046166~53048122:+
COAD	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-4.22	3.33e-05	0.00921	-0.52	-0.25	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
COAD	cis	rs7009110	0.616	rs13276142	ENSG00000213791.4	RP11-941H19.2	4.22	3.33e-05	0.00921	0.25	0.25	Asthma and hay fever;	chr8:80344336	chr8:80300869~80301481:+
COAD	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	4.22	3.33e-05	0.00921	0.3	0.25	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
COAD	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	4.22	3.33e-05	0.00921	0.3	0.25	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
COAD	cis	rs7200543	1	rs1121	ENSG00000270580.4	PKD1P6	4.22	3.33e-05	0.00921	0.29	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15104723~15131601:-
COAD	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-4.22	3.33e-05	0.00921	-0.37	-0.25	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
COAD	cis	rs9990333	0.622	rs57783901	ENSG00000185485.13	SDHAP1	4.22	3.33e-05	0.00921	0.22	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195959748~195990318:-
COAD	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	4.22	3.34e-05	0.00922	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
COAD	cis	rs7665090	0.87	rs228613	ENSG00000230069.3	LRRC37A15P	4.22	3.34e-05	0.00922	0.27	0.25	Primary biliary cholangitis;	chr4:102656308	chr4:102727274~102730721:-
COAD	cis	rs62362510	0.535	rs12188735	ENSG00000264391.2	RN7SL208P	-4.22	3.34e-05	0.00923	-0.47	-0.25	Morning vs. evening chronotype;	chr5:77441059	chr5:76836900~76837195:-
COAD	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	4.22	3.34e-05	0.00923	0.28	0.25	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
COAD	cis	rs2638953	0.924	rs11049608	ENSG00000247934.4	RP11-967K21.1	-4.22	3.34e-05	0.00924	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445528	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049609	ENSG00000247934.4	RP11-967K21.1	-4.22	3.34e-05	0.00924	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445732	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049612	ENSG00000247934.4	RP11-967K21.1	-4.22	3.34e-05	0.00924	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449160	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049613	ENSG00000247934.4	RP11-967K21.1	-4.22	3.34e-05	0.00924	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449859	chr12:28163298~28190738:-
COAD	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.22	3.34e-05	0.00924	0.26	0.25	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
COAD	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-4.22	3.34e-05	0.00924	-0.3	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
COAD	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	4.22	3.35e-05	0.00924	0.28	0.25	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
COAD	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	4.22	3.35e-05	0.00925	0.37	0.25	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
COAD	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	4.22	3.35e-05	0.00925	0.34	0.25	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	4.22	3.35e-05	0.00925	0.34	0.25	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	4.22	3.35e-05	0.00925	0.34	0.25	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
COAD	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-4.22	3.35e-05	0.00925	-0.26	-0.25	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
COAD	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	4.22	3.35e-05	0.00925	0.25	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	4.22	3.35e-05	0.00925	0.25	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
COAD	cis	rs9813712	0.574	rs35856399	ENSG00000249846.5	RP11-77P16.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Response to amphetamines;	chr3:130241961	chr3:130112550~130120579:+
COAD	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-4.22	3.35e-05	0.00925	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
COAD	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-4.22	3.35e-05	0.00925	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
COAD	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-4.22	3.35e-05	0.00925	-0.29	-0.25	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
COAD	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	4.22	3.35e-05	0.00926	0.31	0.25	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	4.22	3.35e-05	0.00926	0.31	0.25	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
COAD	cis	rs2790457	0.958	rs2532741	ENSG00000254635.4	WAC-AS1	-4.22	3.35e-05	0.00926	-0.28	-0.25	Multiple myeloma;	chr10:28574879	chr10:28522652~28532743:-
COAD	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	4.22	3.35e-05	0.00926	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
COAD	cis	rs1670533	1	rs6850784	ENSG00000273179.1	RP11-20I20.4	4.22	3.35e-05	0.00926	0.33	0.25	Recombination rate (females);	chr4:1066021	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6852558	ENSG00000273179.1	RP11-20I20.4	4.22	3.35e-05	0.00926	0.33	0.25	Recombination rate (females);	chr4:1066156	chr4:1167778~1168174:+
COAD	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-4.22	3.36e-05	0.00927	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
COAD	cis	rs8177876	0.658	rs16954505	ENSG00000261061.1	RP11-303E16.2	-4.22	3.36e-05	0.00927	-0.42	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81030770~81031485:+
COAD	cis	rs12497850	0.931	rs7626445	ENSG00000225399.4	RP11-3B7.1	4.22	3.36e-05	0.00927	0.29	0.25	Parkinson's disease;	chr3:49077111	chr3:49260085~49261316:+
COAD	cis	rs13113518	0.812	rs12500456	ENSG00000223305.1	RN7SKP30	4.22	3.36e-05	0.00927	0.3	0.25	Height;	chr4:55561053	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.783	rs2171618	ENSG00000223305.1	RN7SKP30	4.22	3.36e-05	0.00927	0.3	0.25	Height;	chr4:55564241	chr4:55540502~55540835:-
COAD	cis	rs9951698	0.678	rs482360	ENSG00000266969.1	RP11-773H22.4	4.22	3.36e-05	0.00928	0.32	0.25	Intelligence (multi-trait analysis);	chr18:13137993	chr18:12984694~12991173:-
COAD	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-4.22	3.36e-05	0.00929	-0.41	-0.25	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
COAD	cis	rs4819052	0.851	rs2838842	ENSG00000227039.5	ITGB2-AS1	-4.22	3.36e-05	0.00929	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:44921051~44929678:+
COAD	cis	rs7584330	0.554	rs77380873	ENSG00000234949.2	AC104667.3	-4.22	3.37e-05	0.00929	-0.44	-0.25	Prostate cancer;	chr2:237517908	chr2:237591020~237595981:+
COAD	cis	rs9992966	0.85	rs10034736	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187693754	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs10034852	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187693888	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs10012750	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187693959	chr4:186890969~186892366:+
COAD	cis	rs9992966	1	rs9992966	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187694453	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs9993712	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187695266	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs28478837	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187695761	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs7694110	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696170	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs7672520	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696204	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs7699328	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696470	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs9683998	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696689	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs9714717	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696715	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs34710225	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696733	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs28800609	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696817	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs13149971	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187696882	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs28807423	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187697048	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs28760109	ENSG00000250829.2	RP11-11N5.1	-4.22	3.37e-05	0.00929	-0.4	-0.25	Trans fatty acid levels;	chr4:187697249	chr4:186890969~186892366:+
COAD	cis	rs11638352	1	rs12324261	ENSG00000205771.5	CATSPER2P1	4.22	3.37e-05	0.00929	0.53	0.25	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44026273	chr15:43726918~43747094:-
COAD	cis	rs2733201	1	rs8036541	ENSG00000205771.5	CATSPER2P1	4.22	3.37e-05	0.00929	0.53	0.25	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44027179	chr15:43726918~43747094:-
COAD	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-4.22	3.37e-05	0.00929	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
COAD	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	4.22	3.37e-05	0.0093	0.32	0.25	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
COAD	cis	rs1949733	0.675	rs2688219	ENSG00000205959.3	RP11-689P11.2	-4.22	3.37e-05	0.0093	-0.31	-0.25	Response to antineoplastic agents;	chr4:8442904	chr4:8482270~8512610:+
COAD	cis	rs1949733	0.701	rs2631754	ENSG00000205959.3	RP11-689P11.2	-4.22	3.37e-05	0.0093	-0.31	-0.25	Response to antineoplastic agents;	chr4:8447506	chr4:8482270~8512610:+
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000272831.1	RP11-792A8.4	4.22	3.37e-05	0.0093	0.26	0.25	Calcium levels;	chr7:65837419	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000272831.1	RP11-792A8.4	4.22	3.37e-05	0.0093	0.26	0.25	Calcium levels;	chr7:65853042	chr7:66739829~66740385:-
COAD	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-4.22	3.37e-05	0.0093	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
COAD	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	4.22	3.37e-05	0.0093	0.37	0.25	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
COAD	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.22	3.37e-05	0.0093	0.34	0.25	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
COAD	cis	rs11663316	0.851	rs9973176	ENSG00000264644.1	KRT18P8	4.22	3.37e-05	0.0093	0.31	0.25	Epilepsy and lamotrigine-induced maculopapular eruptions;Blood osmolality (transformed sodium);	chr18:9029560	chr18:9678248~9679493:-
COAD	cis	rs6066835	0.702	rs6095228	ENSG00000227431.4	CSE1L-AS1	-4.22	3.37e-05	0.00931	-0.49	-0.25	Multiple myeloma;	chr20:48663338	chr20:49040463~49046044:-
COAD	cis	rs752010	1	rs6664724	ENSG00000230638.4	RP11-486B10.4	-4.22	3.37e-05	0.00931	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41628150	chr1:41542069~41544310:+
COAD	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	4.22	3.37e-05	0.00931	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
COAD	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	4.22	3.37e-05	0.00931	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
COAD	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	4.22	3.37e-05	0.00931	0.26	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
COAD	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	4.22	3.38e-05	0.00931	0.28	0.25	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
COAD	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	4.22	3.38e-05	0.00932	0.29	0.25	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	4.22	3.38e-05	0.00932	0.29	0.25	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
COAD	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-4.22	3.38e-05	0.00932	-0.31	-0.25	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
COAD	cis	rs1670533	1	rs652063	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1090349	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.818	rs643484	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1092038	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs629261	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1092975	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs629260	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1092976	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs1670534	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1093477	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs11725984	ENSG00000273179.1	RP11-20I20.4	4.22	3.38e-05	0.00932	0.33	0.25	Recombination rate (females);	chr4:1093550	chr4:1167778~1168174:+
COAD	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-4.22	3.38e-05	0.00932	-0.27	-0.25	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
COAD	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.22	3.38e-05	0.00932	0.41	0.25	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
COAD	cis	rs875971	0.83	rs28714531	ENSG00000224316.1	RP11-479O9.2	4.22	3.38e-05	0.00932	0.27	0.25	Aortic root size;	chr7:66503250	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs12698526	ENSG00000224316.1	RP11-479O9.2	4.22	3.38e-05	0.00932	0.27	0.25	Aortic root size;	chr7:66504118	chr7:65773620~65802067:+
COAD	cis	rs34102591	0.826	rs12322694	ENSG00000269938.1	RP11-214K3.20	-4.22	3.38e-05	0.00932	-0.4	-0.25	Schizophrenia;	chr12:123922745	chr12:123968023~123968579:-
COAD	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	4.22	3.38e-05	0.00933	0.29	0.25	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
COAD	cis	rs2638953	0.924	rs12368745	ENSG00000247934.4	RP11-967K21.1	-4.22	3.39e-05	0.00933	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28396198	chr12:28163298~28190738:-
COAD	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	4.22	3.39e-05	0.00933	0.45	0.25	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
COAD	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-4.22	3.39e-05	0.00933	-0.4	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
COAD	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-4.22	3.39e-05	0.00933	-0.26	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
COAD	cis	rs73191547	0.706	rs1905634	ENSG00000254936.4	AF131215.3	-4.22	3.39e-05	0.00933	-0.26	-0.25	Schizophrenia;	chr8:10194238	chr8:11123381~11126064:-
COAD	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	4.22	3.39e-05	0.00934	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	4.22	3.39e-05	0.00934	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
COAD	cis	rs2378497	1	rs5013041	ENSG00000232679.1	RP11-400N13.3	4.22	3.39e-05	0.00934	0.36	0.25	Serum thyroid-stimulating hormone levels;	chr1:221983648	chr1:222041705~222064763:-
COAD	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	4.22	3.39e-05	0.00934	0.37	0.25	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
COAD	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	4.22	3.39e-05	0.00934	0.3	0.25	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
COAD	cis	rs875971	0.862	rs6944374	ENSG00000224316.1	RP11-479O9.2	-4.22	3.39e-05	0.00934	-0.28	-0.25	Aortic root size;	chr7:66221942	chr7:65773620~65802067:+
COAD	cis	rs28374715	0.51	rs8034073	ENSG00000247556.5	OIP5-AS1	4.22	3.39e-05	0.00934	0.25	0.25	Ulcerative colitis;	chr15:41253415	chr15:41283990~41309737:+
COAD	cis	rs2638953	0.962	rs11049539	ENSG00000247934.4	RP11-967K21.1	-4.22	3.39e-05	0.00934	-0.28	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28163298~28190738:-
COAD	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	4.22	3.39e-05	0.00934	0.33	0.25	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
COAD	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-4.22	3.39e-05	0.00934	-0.27	-0.25	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
COAD	cis	rs2018683	0.707	rs1021690	ENSG00000272568.4	CTB-113D17.1	4.22	3.39e-05	0.00935	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28979967~29013367:+
COAD	cis	rs2018683	0.707	rs1021691	ENSG00000272568.4	CTB-113D17.1	4.22	3.39e-05	0.00935	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28979967~29013367:+
COAD	cis	rs7200543	1	rs6498541	ENSG00000270580.4	PKD1P6	4.22	3.39e-05	0.00935	0.28	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15104723~15131601:-
COAD	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4.22	3.39e-05	0.00935	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	4.22	3.39e-05	0.00935	0.34	0.25	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
COAD	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	4.22	3.39e-05	0.00935	0.22	0.25	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	4.22	3.39e-05	0.00935	0.22	0.25	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
COAD	cis	rs7656342	0.897	rs12507861	ENSG00000186234.7	FAM86MP	-4.22	3.4e-05	0.00936	-0.34	-0.25	Gut microbiota (bacterial taxa);	chr4:9775966	chr4:9692495~9702954:+
COAD	cis	rs11168351	0.864	rs12228750	ENSG00000273765.1	RP11-370I10.11	-4.22	3.4e-05	0.00936	-0.27	-0.25	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48360920~48361377:+
COAD	cis	rs11168351	0.864	rs10875743	ENSG00000273765.1	RP11-370I10.11	-4.22	3.4e-05	0.00936	-0.27	-0.25	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48360920~48361377:+
COAD	cis	rs4243971	0.557	rs1984792	ENSG00000101898.5	MCTS2P	4.22	3.4e-05	0.00936	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32279465	chr20:31547504~31548049:+
COAD	cis	rs891378	1	rs2564978	ENSG00000274245.1	RP11-357P18.2	-4.22	3.4e-05	0.00936	-0.36	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207321071	chr1:207372559~207373252:+
COAD	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	4.22	3.4e-05	0.00936	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	4.22	3.4e-05	0.00936	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	4.22	3.4e-05	0.00936	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
COAD	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-4.22	3.4e-05	0.00936	-0.28	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
COAD	cis	rs476633	0.691	rs28568756	ENSG00000247556.5	OIP5-AS1	4.22	3.4e-05	0.00937	0.25	0.25	Glomerular filtration rate (creatinine);	chr15:41247173	chr15:41283990~41309737:+
COAD	cis	rs476633	0.691	rs11858115	ENSG00000247556.5	OIP5-AS1	4.22	3.4e-05	0.00937	0.25	0.25	Glomerular filtration rate (creatinine);	chr15:41250393	chr15:41283990~41309737:+
COAD	cis	rs9400467	0.528	rs9689727	ENSG00000271789.1	RP5-1112D6.7	-4.22	3.4e-05	0.00937	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs12214380	ENSG00000271789.1	RP5-1112D6.7	-4.22	3.4e-05	0.00937	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111297126~111298510:+
COAD	cis	rs6545883	0.507	rs12478192	ENSG00000273302.1	RP11-493E12.2	-4.22	3.4e-05	0.00937	-0.23	-0.25	Tuberculosis;	chr2:61364040	chr2:61199979~61200769:+
COAD	cis	rs763121	0.853	rs4820345	ENSG00000273076.1	RP3-508I15.22	4.22	3.4e-05	0.00937	0.24	0.25	Menopause (age at onset);	chr22:38695146	chr22:38743495~38743910:+
COAD	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	4.22	3.41e-05	0.00938	0.29	0.25	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
COAD	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	4.22	3.41e-05	0.00938	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	4.22	3.41e-05	0.00938	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
COAD	cis	rs7818688	1	rs11774085	ENSG00000253528.2	RP11-347C18.4	-4.22	3.41e-05	0.00938	-0.39	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95008649	chr8:94974573~94974853:-
COAD	cis	rs875971	0.52	rs160645	ENSG00000164669.11	INTS4P1	4.22	3.41e-05	0.00938	0.37	0.25	Aortic root size;	chr7:66091320	chr7:65141225~65234216:+
COAD	cis	rs875971	0.789	rs28815324	ENSG00000164669.11	INTS4P1	4.22	3.41e-05	0.00938	0.37	0.25	Aortic root size;	chr7:66100789	chr7:65141225~65234216:+
COAD	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	4.22	3.41e-05	0.00938	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
COAD	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	4.22	3.41e-05	0.00938	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
COAD	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.22	3.41e-05	0.00938	-0.32	-0.25	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
COAD	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-4.22	3.41e-05	0.00939	-0.28	-0.25	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-4.22	3.41e-05	0.00939	-0.28	-0.25	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
COAD	cis	rs7572733	0.84	rs6743671	ENSG00000222017.1	AC011997.1	-4.22	3.41e-05	0.0094	-0.28	-0.25	Dermatomyositis;	chr2:197698918	chr2:197693106~197774823:+
COAD	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	4.22	3.42e-05	0.0094	0.32	0.25	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	4.22	3.42e-05	0.0094	0.32	0.25	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	4.22	3.42e-05	0.0094	0.32	0.25	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	4.22	3.42e-05	0.0094	0.32	0.25	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
COAD	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	4.22	3.42e-05	0.0094	0.27	0.25	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
COAD	cis	rs113835537	0.529	rs2305535	ENSG00000258297.1	RP11-658F2.8	4.22	3.42e-05	0.0094	0.26	0.25	Airway imaging phenotypes;	chr11:66504766	chr11:66666036~66668374:+
COAD	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-4.22	3.42e-05	0.0094	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
COAD	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	4.22	3.42e-05	0.0094	0.26	0.25	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
COAD	cis	rs7572733	0.84	rs13034353	ENSG00000222017.1	AC011997.1	-4.22	3.42e-05	0.00941	-0.28	-0.25	Dermatomyositis;	chr2:197701039	chr2:197693106~197774823:+
COAD	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-4.22	3.42e-05	0.00941	-0.27	-0.25	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
COAD	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	4.22	3.42e-05	0.00941	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
COAD	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	4.22	3.42e-05	0.00941	0.4	0.25	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
COAD	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-4.22	3.42e-05	0.00941	-0.5	-0.25	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
COAD	cis	rs6951245	0.935	rs79143504	ENSG00000229043.2	AC091729.9	-4.22	3.42e-05	0.00942	-0.43	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1160374~1165267:+
COAD	cis	rs7818688	0.585	rs2599714	ENSG00000253528.2	RP11-347C18.4	4.22	3.43e-05	0.00942	0.32	0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95039822	chr8:94974573~94974853:-
COAD	cis	rs41294858	1	rs76267242	ENSG00000232876.1	CTA-212D2.2	-4.22	3.43e-05	0.00943	-0.48	-0.25	Red blood cell count;	chr6:135096322	chr6:135055033~135060550:+
COAD	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	4.22	3.43e-05	0.00943	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
COAD	cis	rs763121	0.853	rs2072794	ENSG00000273076.1	RP3-508I15.22	4.22	3.43e-05	0.00943	0.24	0.25	Menopause (age at onset);	chr22:38754538	chr22:38743495~38743910:+
COAD	cis	rs752010	0.619	rs4393146	ENSG00000230638.4	RP11-486B10.4	-4.22	3.43e-05	0.00943	-0.33	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41653095	chr1:41542069~41544310:+
COAD	cis	rs8022206	0.773	rs11846344	ENSG00000259502.1	RP11-643G16.3	-4.22	3.43e-05	0.00943	-0.34	-0.25	Platelet count;Mean platelet volume;	chr14:67985302	chr14:67610986~67613864:+
COAD	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	4.22	3.43e-05	0.00943	0.28	0.25	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
COAD	cis	rs1914816	0.941	rs2460151	ENSG00000196274.5	Metazoa_SRP	4.22	3.43e-05	0.00943	0.28	0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76230048~76230390:-
COAD	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28140454	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28141189	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28141484	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28143758	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28144784	chr6:28115628~28116551:+
COAD	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28145952	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28147378	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28147406	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28148143	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28149979	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28151096	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28152885	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28153120	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28154567	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28156691	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28158424	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28159056	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28162053	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28163375	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28163759	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28164580	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28164825	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28164948	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28165025	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28165528	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28169019	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28169249	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28169676	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28169755	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28169791	chr6:28115628~28116551:+
COAD	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-4.22	3.43e-05	0.00943	-0.36	-0.25	Depression;	chr6:28170075	chr6:28115628~28116551:+
COAD	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	4.22	3.43e-05	0.00943	0.3	0.25	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
COAD	cis	rs6585424	1	rs34162901	ENSG00000234382.2	RP11-40F6.1	-4.22	3.43e-05	0.00943	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs61860045	ENSG00000234382.2	RP11-40F6.1	-4.22	3.43e-05	0.00943	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:80233664~80245367:+
COAD	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	4.22	3.43e-05	0.00944	0.28	0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
COAD	cis	rs12530	0.715	rs2294313	ENSG00000230736.2	RP1-149A16.3	-4.22	3.43e-05	0.00944	-0.31	-0.25	IgG glycosylation;	chr22:32398452	chr22:32376664~32384343:+
COAD	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-4.22	3.43e-05	0.00944	-0.41	-0.25	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
COAD	cis	rs10027350	0.857	rs3796793	ENSG00000281501.1	SEPSECS-AS1	4.22	3.43e-05	0.00944	0.31	0.25	Childhood ear infection;	chr4:25142945	chr4:25160641~25201440:+
COAD	cis	rs10916814	0.589	rs72649157	ENSG00000117242.7	PINK1-AS	-4.22	3.43e-05	0.00944	-0.3	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:20566291	chr1:20642657~20652193:-
COAD	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-4.22	3.44e-05	0.00944	-0.31	-0.25	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
COAD	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	4.22	3.44e-05	0.00944	0.33	0.25	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	4.22	3.44e-05	0.00944	0.33	0.25	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	4.22	3.44e-05	0.00944	0.33	0.25	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	4.22	3.44e-05	0.00944	0.33	0.25	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
COAD	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	4.22	3.44e-05	0.00944	0.3	0.25	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	4.22	3.44e-05	0.00944	0.3	0.25	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	4.22	3.44e-05	0.00944	0.3	0.25	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
COAD	cis	rs3733829	1	rs4802090	ENSG00000279759.1	CTC-425O23.5	-4.22	3.44e-05	0.00945	-0.22	-0.25	Smoking behavior;	chr19:40809329	chr19:40355842~40360606:+
COAD	cis	rs34286592	0.929	rs1057452	ENSG00000214725.6	CDIPT-AS1	4.22	3.44e-05	0.00945	0.48	0.25	Multiple sclerosis;	chr16:29822393	chr16:29863593~29868053:+
COAD	cis	rs734999	0.967	rs10797434	ENSG00000225931.3	RP3-395M20.7	4.22	3.44e-05	0.00945	0.28	0.25	Ulcerative colitis;	chr1:2579841	chr1:2566410~2569888:+
COAD	cis	rs11089937	0.597	rs4145535	ENSG00000211638.2	IGLV8-61	-4.22	3.44e-05	0.00946	-0.25	-0.25	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22098700~22099212:+
COAD	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-4.22	3.45e-05	0.00946	-0.35	-0.25	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
COAD	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	4.22	3.45e-05	0.00947	0.3	0.25	Height;	chr4:55514802	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	4.22	3.45e-05	0.00947	0.3	0.25	Height;	chr4:55516548	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	4.22	3.45e-05	0.00947	0.3	0.25	Height;	chr4:55516744	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	4.22	3.45e-05	0.00947	0.3	0.25	Height;	chr4:55517185	chr4:55540502~55540835:-
COAD	cis	rs2408955	0.521	rs1476607	ENSG00000273765.1	RP11-370I10.11	-4.22	3.45e-05	0.00947	-0.28	-0.25	Glycated hemoglobin levels;	chr12:48131021	chr12:48360920~48361377:+
COAD	cis	rs11089937	0.616	rs928895	ENSG00000211638.2	IGLV8-61	-4.22	3.45e-05	0.00947	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs6001224	ENSG00000211638.2	IGLV8-61	-4.22	3.45e-05	0.00947	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22098700~22099212:+
COAD	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	4.22	3.45e-05	0.00947	0.3	0.25	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
COAD	cis	rs6585424	1	rs35025775	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs34749786	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs61860024	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs61860025	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs12411386	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs2228427	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs34332933	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs61860035	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:80233664~80245367:+
COAD	cis	rs6585424	0.85	rs75804987	ENSG00000234382.2	RP11-40F6.1	-4.22	3.45e-05	0.00947	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:80233664~80245367:+
COAD	cis	rs7577696	0.597	rs56322034	ENSG00000272716.1	RP11-563N4.1	-4.22	3.45e-05	0.00947	-0.29	-0.25	Inflammatory biomarkers;	chr2:32127944	chr2:32165046~32165757:-
COAD	cis	rs8141529	0.843	rs1065497	ENSG00000272858.1	CTA-292E10.8	-4.22	3.45e-05	0.00947	-0.32	-0.25	Lymphocyte counts;	chr22:28884003	chr22:28814914~28815662:+
COAD	cis	rs1670533	1	rs7669622	ENSG00000273179.1	RP11-20I20.4	4.22	3.45e-05	0.00948	0.33	0.25	Recombination rate (females);	chr4:1064871	chr4:1167778~1168174:+
COAD	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	4.22	3.45e-05	0.00948	0.28	0.25	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
COAD	cis	rs17685	0.753	rs1637037	ENSG00000280388.1	RP11-229D13.3	-4.22	3.45e-05	0.00948	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76043977~76045963:-
COAD	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.22	3.46e-05	0.00949	0.27	0.25	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
COAD	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	4.22	3.46e-05	0.00949	0.36	0.25	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
COAD	cis	rs2018683	0.677	rs12531456	ENSG00000272568.4	CTB-113D17.1	4.22	3.46e-05	0.00949	0.36	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930994	chr7:28979967~29013367:+
COAD	cis	rs2018683	0.707	rs2391717	ENSG00000272568.4	CTB-113D17.1	4.22	3.46e-05	0.00949	0.36	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931545	chr7:28979967~29013367:+
COAD	cis	rs2018683	0.707	rs917215	ENSG00000272568.4	CTB-113D17.1	4.22	3.46e-05	0.00949	0.36	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931750	chr7:28979967~29013367:+
COAD	cis	rs2337406	0.778	rs56658355	ENSG00000211964.3	IGHV3-48	-4.22	3.46e-05	0.0095	-0.22	-0.25	Alzheimer's disease (late onset);	chr14:106662151	chr14:106537810~106538344:-
COAD	cis	rs2337406	1	rs7145100	ENSG00000211974.3	IGHV2-70	-4.21	3.46e-05	0.0095	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106704673	chr14:106723574~106724093:-
COAD	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	4.21	3.46e-05	0.0095	0.32	0.25	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
COAD	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	4.21	3.46e-05	0.0095	0.3	0.25	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
COAD	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	4.21	3.46e-05	0.0095	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
COAD	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	4.21	3.46e-05	0.00951	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
COAD	cis	rs6519955	0.796	rs4072455	ENSG00000231711.2	LINC00899	4.21	3.47e-05	0.00951	0.25	0.25	Dupuytren's disease;	chr22:46027058	chr22:46039907~46044853:-
COAD	cis	rs73607972	0.696	rs7201237	ENSG00000275191.1	RP11-36I17.2	-4.21	3.47e-05	0.00951	-0.35	-0.25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53628256~53628816:-
COAD	cis	rs7646881	1	rs73015649	ENSG00000272087.1	RP11-379F4.7	4.21	3.47e-05	0.00951	0.37	0.25	Tetralogy of Fallot;	chr3:158732509	chr3:158693120~158693768:-
COAD	cis	rs7646881	1	rs73015654	ENSG00000272087.1	RP11-379F4.7	4.21	3.47e-05	0.00951	0.37	0.25	Tetralogy of Fallot;	chr3:158733865	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.953	rs73015657	ENSG00000272087.1	RP11-379F4.7	4.21	3.47e-05	0.00951	0.37	0.25	Tetralogy of Fallot;	chr3:158734143	chr3:158693120~158693768:-
COAD	cis	rs7646881	1	rs59313096	ENSG00000272087.1	RP11-379F4.7	4.21	3.47e-05	0.00951	0.37	0.25	Tetralogy of Fallot;	chr3:158734453	chr3:158693120~158693768:-
COAD	cis	rs7646881	1	rs59217052	ENSG00000272087.1	RP11-379F4.7	4.21	3.47e-05	0.00951	0.37	0.25	Tetralogy of Fallot;	chr3:158734667	chr3:158693120~158693768:-
COAD	cis	rs1670533	1	rs688785	ENSG00000273179.1	RP11-20I20.4	4.21	3.47e-05	0.00951	0.33	0.25	Recombination rate (females);	chr4:1088919	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.746	rs688008	ENSG00000273179.1	RP11-20I20.4	4.21	3.47e-05	0.00951	0.33	0.25	Recombination rate (females);	chr4:1089041	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs676561	ENSG00000273179.1	RP11-20I20.4	4.21	3.47e-05	0.00951	0.33	0.25	Recombination rate (females);	chr4:1089324	chr4:1167778~1168174:+
COAD	cis	rs17359493	0.671	rs16917106	ENSG00000253528.2	RP11-347C18.4	-4.21	3.47e-05	0.00951	-0.33	-0.25	Type 2 diabetes;	chr8:94882018	chr8:94974573~94974853:-
COAD	cis	rs1009647	1	rs1890256	ENSG00000258413.1	RP11-665C16.6	-4.21	3.47e-05	0.00951	-0.33	-0.25	Testicular germ cell tumor;	chr14:55414558	chr14:55262767~55272075:-
COAD	cis	rs9942416	0.55	rs253412	ENSG00000271815.1	CTD-2235C13.3	4.21	3.47e-05	0.00952	0.31	0.25	Age-related disease endophenotypes;	chr5:75660016	chr5:75363760~75364242:+
COAD	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-4.21	3.47e-05	0.00952	-0.37	-0.25	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
COAD	cis	rs17783634	0.509	rs11775489	ENSG00000269918.1	AF131215.9	-4.21	3.47e-05	0.00952	-0.32	-0.25	Subjective well-being;	chr8:11179334	chr8:11104691~11106704:-
COAD	cis	rs6545883	0.562	rs777588	ENSG00000273302.1	RP11-493E12.2	4.21	3.47e-05	0.00952	0.25	0.25	Tuberculosis;	chr2:61199685	chr2:61199979~61200769:+
COAD	cis	rs180730	1	rs1376109	ENSG00000251609.2	SETP12	-4.21	3.47e-05	0.00952	-0.38	-0.25	Fasting plasma glucose;	chr4:120917160	chr4:120895494~120897083:-
COAD	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-4.21	3.47e-05	0.00952	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
COAD	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-4.21	3.47e-05	0.00952	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
COAD	cis	rs12497850	0.866	rs6791234	ENSG00000225399.4	RP11-3B7.1	4.21	3.47e-05	0.00952	0.28	0.25	Parkinson's disease;	chr3:48958704	chr3:49260085~49261316:+
COAD	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	4.21	3.47e-05	0.00953	0.31	0.25	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
COAD	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	4.21	3.47e-05	0.00953	0.31	0.25	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
COAD	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	4.21	3.48e-05	0.00953	0.27	0.25	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
COAD	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-4.21	3.48e-05	0.00953	-0.27	-0.25	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
COAD	cis	rs2017305	0.764	rs2805918	ENSG00000233590.1	RP11-153K11.3	4.21	3.48e-05	0.00953	0.43	0.25	Depression (quantitative trait);	chr10:69022758	chr10:68233251~68242379:-
COAD	cis	rs2017305	0.834	rs2246952	ENSG00000233590.1	RP11-153K11.3	4.21	3.48e-05	0.00953	0.43	0.25	Depression (quantitative trait);	chr10:69022836	chr10:68233251~68242379:-
COAD	cis	rs2017305	0.834	rs2246974	ENSG00000233590.1	RP11-153K11.3	4.21	3.48e-05	0.00953	0.43	0.25	Depression (quantitative trait);	chr10:69023568	chr10:68233251~68242379:-
COAD	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	4.21	3.48e-05	0.00953	0.28	0.25	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
COAD	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	4.21	3.48e-05	0.00954	0.28	0.25	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
COAD	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	4.21	3.48e-05	0.00954	0.14	0.25	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
COAD	cis	rs739496	0.579	rs4766705	ENSG00000257595.2	RP3-473L9.4	4.21	3.48e-05	0.00954	0.37	0.25	Platelet count;	chr12:111895856	chr12:111369282~111403310:+
COAD	cis	rs8022206	0.773	rs10136868	ENSG00000259502.1	RP11-643G16.3	4.21	3.48e-05	0.00954	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68047521	chr14:67610986~67613864:+
COAD	cis	rs6545883	0.524	rs12992614	ENSG00000273302.1	RP11-493E12.2	-4.21	3.48e-05	0.00954	-0.23	-0.25	Tuberculosis;	chr2:61365941	chr2:61199979~61200769:+
COAD	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-4.21	3.48e-05	0.00954	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
COAD	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-4.21	3.48e-05	0.00955	-0.28	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
COAD	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-4.21	3.48e-05	0.00955	-0.27	-0.25	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
COAD	cis	rs228614	0.502	rs78573682	ENSG00000246560.2	RP11-10L12.4	-4.21	3.48e-05	0.00955	-0.34	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102502510	chr4:102828055~102844075:+
COAD	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	4.21	3.48e-05	0.00955	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
COAD	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	4.21	3.48e-05	0.00955	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
COAD	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-4.21	3.49e-05	0.00955	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
COAD	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	4.21	3.49e-05	0.00955	0.41	0.25	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
COAD	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-4.21	3.49e-05	0.00956	-0.25	-0.25	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
COAD	cis	rs1023500	0.551	rs2859438	ENSG00000237037.8	NDUFA6-AS1	-4.21	3.49e-05	0.00956	-0.25	-0.25	Schizophrenia;	chr22:42070976	chr22:42090931~42137742:+
COAD	cis	rs1023500	0.573	rs4822088	ENSG00000237037.8	NDUFA6-AS1	-4.21	3.49e-05	0.00956	-0.25	-0.25	Schizophrenia;	chr22:42074585	chr22:42090931~42137742:+
COAD	cis	rs7646881	0.508	rs12106885	ENSG00000272087.1	RP11-379F4.7	4.21	3.49e-05	0.00956	0.41	0.25	Tetralogy of Fallot;	chr3:158598854	chr3:158693120~158693768:-
COAD	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	4.21	3.5e-05	0.00958	0.21	0.25	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
COAD	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-4.21	3.5e-05	0.00958	-0.24	-0.25	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
COAD	cis	rs728616	0.764	rs61545595	ENSG00000225484.5	NUTM2B-AS1	-4.21	3.5e-05	0.00958	-0.44	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094013	chr10:79663088~79826594:-
COAD	cis	rs9532669	0.926	rs9566582	ENSG00000239827.7	SUGT1P3	-4.21	3.5e-05	0.00958	-0.22	-0.25	Cervical cancer;	chr13:40852121	chr13:40908159~40921774:-
COAD	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-4.21	3.5e-05	0.00958	-0.27	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
COAD	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-4.21	3.5e-05	0.00958	-0.33	-0.25	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
COAD	cis	rs7615952	0.546	rs11718647	ENSG00000248787.1	RP11-666A20.4	-4.21	3.5e-05	0.00958	-0.38	-0.25	Blood pressure (smoking interaction);	chr3:125633178	chr3:125908005~125910272:-
COAD	cis	rs597539	0.652	rs602805	ENSG00000255741.1	RP11-757G1.5	-4.21	3.5e-05	0.00958	-0.34	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs602364	ENSG00000255741.1	RP11-757G1.5	-4.21	3.5e-05	0.00958	-0.34	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68941503~68942852:-
COAD	cis	rs812925	0.502	rs13028833	ENSG00000273302.1	RP11-493E12.2	-4.21	3.5e-05	0.00959	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61417194	chr2:61199979~61200769:+
COAD	cis	rs4239252	0.929	rs4251787	ENSG00000271013.1	AC015849.15	-4.21	3.5e-05	0.00959	-0.31	-0.25	Blood protein levels;	chr17:35845577	chr17:35912635~35918010:-
COAD	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.21	3.5e-05	0.00959	0.26	0.25	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
COAD	cis	rs17359493	0.671	rs716733	ENSG00000253528.2	RP11-347C18.4	-4.21	3.5e-05	0.00959	-0.34	-0.25	Type 2 diabetes;	chr8:94876753	chr8:94974573~94974853:-
COAD	cis	rs12699921	0.632	rs2691625	ENSG00000279048.1	RP11-511H23.2	-4.21	3.5e-05	0.00959	-0.18	-0.25	Fibrinogen levels;	chr7:17784000	chr7:17940503~17942922:+
COAD	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-4.21	3.5e-05	0.00959	-0.36	-0.25	Depression;	chr6:28180209	chr6:28115628~28116551:+
COAD	cis	rs7487075	0.554	rs7960819	ENSG00000274723.1	RP11-618L22.1	4.21	3.5e-05	0.00959	0.27	0.25	Itch intensity from mosquito bite;	chr12:46234999	chr12:46970504~46972155:+
COAD	cis	rs7487075	0.554	rs7957777	ENSG00000274723.1	RP11-618L22.1	4.21	3.5e-05	0.00959	0.27	0.25	Itch intensity from mosquito bite;	chr12:46235006	chr12:46970504~46972155:+
COAD	cis	rs7307902	0.504	rs10875648	ENSG00000268069.2	RP5-1057I20.4	4.21	3.5e-05	0.00959	0.3	0.25	Obesity-related traits;	chr12:47498268	chr12:47784923~47786002:+
COAD	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-4.21	3.51e-05	0.0096	-0.26	-0.25	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
COAD	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	4.21	3.51e-05	0.0096	0.31	0.25	Depression;	chr6:28273214	chr6:28943877~28944537:+
COAD	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	4.21	3.51e-05	0.0096	0.31	0.25	Depression;	chr6:28273215	chr6:28943877~28944537:+
COAD	cis	rs4834770	0.746	rs2389747	ENSG00000250412.1	KLHL2P1	4.21	3.51e-05	0.0096	0.3	0.25	Blood protein levels;	chr4:119314947	chr4:119334329~119378233:+
COAD	cis	rs4834770	0.717	rs1022146	ENSG00000250412.1	KLHL2P1	4.21	3.51e-05	0.0096	0.3	0.25	Blood protein levels;	chr4:119314948	chr4:119334329~119378233:+
COAD	cis	rs72615157	0.634	rs2272343	ENSG00000078319.8	PMS2P1	-4.21	3.51e-05	0.0096	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100180662	chr7:100320992~100341908:-
COAD	cis	rs72615157	0.634	rs74742883	ENSG00000078319.8	PMS2P1	-4.21	3.51e-05	0.0096	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100188142	chr7:100320992~100341908:-
COAD	cis	rs72615157	0.634	rs7789890	ENSG00000078319.8	PMS2P1	-4.21	3.51e-05	0.0096	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100202936	chr7:100320992~100341908:-
COAD	cis	rs72615157	0.634	rs79986079	ENSG00000078319.8	PMS2P1	-4.21	3.51e-05	0.0096	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100204421	chr7:100320992~100341908:-
COAD	cis	rs1670533	0.932	rs2045067	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1058567	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6852850	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1059069	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10084888	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060026	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10084889	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060027	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs13134921	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060389	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs13106586	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060394	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.872	rs13108222	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060468	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs13140571	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060570	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs13135215	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060576	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs13107058	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060591	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs4690215	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060831	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs4690214	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1060848	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs4690212	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1061110	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs28562028	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1061327	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10902752	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1062411	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs7673898	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1062781	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs6599276	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1063039	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs4690347	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1063540	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs11731289	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1063985	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs11731320	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1064128	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs7685541	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.0096	0.33	0.25	Recombination rate (females);	chr4:1064713	chr4:1167778~1168174:+
COAD	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	4.21	3.51e-05	0.0096	0.3	0.25	Height;	chr4:55483718	chr4:55540502~55540835:-
COAD	cis	rs2408955	0.5	rs12816820	ENSG00000257735.1	RP11-370I10.6	4.21	3.51e-05	0.0096	0.29	0.25	Glycated hemoglobin levels;	chr12:48164542	chr12:48350945~48442411:+
COAD	cis	rs1387259	0.57	rs12368659	ENSG00000257735.1	RP11-370I10.6	4.21	3.51e-05	0.0096	0.29	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48350945~48442411:+
COAD	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-4.21	3.51e-05	0.00961	-0.4	-0.25	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
COAD	cis	rs2018683	0.707	rs1021689	ENSG00000272568.4	CTB-113D17.1	4.21	3.51e-05	0.00961	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28979967~29013367:+
COAD	cis	rs1670533	1	rs2100411	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.00961	0.32	0.25	Recombination rate (females);	chr4:1080624	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs641987	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.00961	0.32	0.25	Recombination rate (females);	chr4:1083754	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs1670533	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.00961	0.32	0.25	Recombination rate (females);	chr4:1084399	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs610218	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.00961	0.32	0.25	Recombination rate (females);	chr4:1086295	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.818	rs585735	ENSG00000273179.1	RP11-20I20.4	4.21	3.51e-05	0.00961	0.32	0.25	Recombination rate (females);	chr4:1086603	chr4:1167778~1168174:+
COAD	cis	rs9487051	0.837	rs932223	ENSG00000219700.1	PTCHD3P3	4.21	3.51e-05	0.00962	0.27	0.25	Reticulocyte fraction of red cells;	chr6:109265453	chr6:109288571~109290503:-
COAD	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-4.21	3.51e-05	0.00962	-0.27	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
COAD	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	4.21	3.52e-05	0.00963	0.27	0.25	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
COAD	cis	rs9990333	0.521	rs3862281	ENSG00000207650.1	MIR570	4.21	3.52e-05	0.00963	0.32	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195699401~195699497:+
COAD	cis	rs10146615	0.744	rs17099628	ENSG00000232774.6	FLJ22447	4.21	3.52e-05	0.00963	0.34	0.25	Economic and political preferences (immigration/crime);	chr14:62260282	chr14:61570540~61658696:+
COAD	cis	rs2617170	0.883	rs1351111	ENSG00000245648.1	RP11-277P12.20	4.21	3.52e-05	0.00963	0.34	0.25	Behcet's disease;	chr12:10402849	chr12:10363769~10398506:+
COAD	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-4.21	3.52e-05	0.00963	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
COAD	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-4.21	3.52e-05	0.00963	-0.22	-0.25	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
COAD	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	4.21	3.52e-05	0.00963	0.33	0.25	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
COAD	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-4.21	3.52e-05	0.00963	-0.56	-0.25	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
COAD	cis	rs8046148	0.724	rs8051216	ENSG00000260381.2	RP11-429P3.5	-4.21	3.52e-05	0.00963	-0.33	-0.25	Testicular germ cell tumor;	chr16:50079862	chr16:50100339~50121943:-
COAD	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-4.21	3.52e-05	0.00964	-0.28	-0.25	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
COAD	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-4.21	3.52e-05	0.00964	-0.28	-0.25	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
COAD	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	4.21	3.52e-05	0.00964	0.43	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
COAD	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-4.21	3.52e-05	0.00964	-0.17	-0.25	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
COAD	cis	rs6940638	0.688	rs9461335	ENSG00000224843.5	LINC00240	4.21	3.53e-05	0.00964	0.32	0.25	Intelligence (multi-trait analysis);	chr6:27170750	chr6:26956992~27023924:+
COAD	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	4.21	3.53e-05	0.00964	0.32	0.25	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
COAD	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-4.21	3.53e-05	0.00965	-0.26	-0.25	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
COAD	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-4.21	3.53e-05	0.00965	-0.26	-0.25	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
COAD	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-4.21	3.53e-05	0.00965	-0.26	-0.25	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
COAD	cis	rs2836974	0.644	rs2836982	ENSG00000255568.3	BRWD1-AS2	-4.21	3.53e-05	0.00965	-0.24	-0.25	Cognitive function;	chr21:39317245	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.644	rs4818017	ENSG00000255568.3	BRWD1-AS2	-4.21	3.53e-05	0.00965	-0.24	-0.25	Cognitive function;	chr21:39318635	chr21:39313935~39314962:+
COAD	cis	rs12906542	0.516	rs12593545	ENSG00000260139.5	CSPG4P13	-4.21	3.53e-05	0.00965	-0.35	-0.25	Breast cancer;	chr15:78045597	chr15:77894684~77904674:+
COAD	cis	rs1055129	0.537	rs1135640	ENSG00000267801.1	RP11-552F3.9	-4.21	3.53e-05	0.00965	-0.32	-0.25	White matter hyperintensity burden;	chr17:75953459	chr17:75876372~75879546:+
COAD	cis	rs7615952	0.609	rs13088451	ENSG00000272840.1	RP11-379B18.6	4.21	3.53e-05	0.00966	0.36	0.25	Blood pressure (smoking interaction);	chr3:125834656	chr3:125774714~125797953:+
COAD	cis	rs1670533	1	rs7669399	ENSG00000273179.1	RP11-20I20.4	4.21	3.53e-05	0.00966	0.33	0.25	Recombination rate (females);	chr4:1064690	chr4:1167778~1168174:+
COAD	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	4.21	3.53e-05	0.00966	0.33	0.25	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
COAD	cis	rs4704187	0.574	rs4704184	ENSG00000250889.2	LINC01336	-4.21	3.53e-05	0.00966	-0.29	-0.25	Response to amphetamines;	chr5:75175852	chr5:75047719~75052843:-
COAD	cis	rs84178	0.733	rs63934	ENSG00000230834.1	AC068580.7	4.21	3.54e-05	0.00966	0.4	0.25	Glomerular filtration rate (creatinine);	chr11:2767832	chr11:1776930~1778388:-
COAD	cis	rs2638953	0.962	rs9645730	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00966	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317151	chr12:28163298~28190738:-
COAD	cis	rs913655	0.508	rs11006743	ENSG00000240291.1	RP11-499P20.2	4.21	3.54e-05	0.00967	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18747357	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs7910310	ENSG00000240291.1	RP11-499P20.2	4.21	3.54e-05	0.00967	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18748414	chr10:18513115~18545651:-
COAD	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	4.21	3.54e-05	0.00967	0.28	0.25	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
COAD	cis	rs2638953	0.962	rs10506033	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00967	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049586	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00967	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049588	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00967	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.925	rs10843166	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00967	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28163298~28190738:-
COAD	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	4.21	3.54e-05	0.00967	0.27	0.25	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
COAD	cis	rs11079159	1	rs876719	ENSG00000263096.1	RP11-515O17.2	4.21	3.54e-05	0.00967	0.34	0.25	QRS duration;	chr17:55289205	chr17:55271504~55273653:-
COAD	cis	rs2638953	0.886	rs11049617	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00968	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453344	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049618	ENSG00000247934.4	RP11-967K21.1	-4.21	3.54e-05	0.00968	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453371	chr12:28163298~28190738:-
COAD	cis	rs9907295	0.591	rs78655848	ENSG00000271013.1	AC015849.15	-4.21	3.54e-05	0.00968	-0.31	-0.25	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.591	rs9908928	ENSG00000271013.1	AC015849.15	-4.21	3.54e-05	0.00968	-0.31	-0.25	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35912635~35918010:-
COAD	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-4.21	3.54e-05	0.00968	-0.29	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
COAD	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-4.21	3.54e-05	0.00968	-0.35	-0.25	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
COAD	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	4.21	3.54e-05	0.00968	0.34	0.25	Depression;	chr6:28206179	chr6:28943877~28944537:+
COAD	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	4.21	3.54e-05	0.00968	0.42	0.25	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
COAD	cis	rs875971	0.862	rs2088655	ENSG00000224316.1	RP11-479O9.2	-4.21	3.55e-05	0.00968	-0.28	-0.25	Aortic root size;	chr7:66330724	chr7:65773620~65802067:+
COAD	cis	rs875971	0.895	rs10447522	ENSG00000224316.1	RP11-479O9.2	-4.21	3.55e-05	0.00968	-0.28	-0.25	Aortic root size;	chr7:66331087	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs778736	ENSG00000224316.1	RP11-479O9.2	4.21	3.55e-05	0.00968	0.28	0.25	Aortic root size;	chr7:66348861	chr7:65773620~65802067:+
COAD	cis	rs71636778	0.509	rs35108146	ENSG00000260063.1	RP5-968P14.2	-4.21	3.55e-05	0.00968	-0.52	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921949	chr1:26692132~26694131:-
COAD	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-4.21	3.55e-05	0.00969	-0.36	-0.25	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
COAD	cis	rs5751168	0.915	rs6002485	ENSG00000211660.3	IGLV2-23	-4.21	3.55e-05	0.00969	-0.19	-0.25	Prostate cancer (SNP x SNP interaction);	chr22:22486707	chr22:22697789~22698407:+
COAD	cis	rs8039808	1	rs76590369	ENSG00000259531.2	RP11-295H24.3	4.21	3.55e-05	0.00969	0.61	0.25	Response to anti-depressant treatment in major depressive disorder;	chr15:49266044	chr15:49365124~49366685:-
COAD	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-4.21	3.55e-05	0.00969	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
COAD	cis	rs7577696	0.524	rs12991444	ENSG00000272716.1	RP11-563N4.1	-4.21	3.55e-05	0.00969	-0.29	-0.25	Inflammatory biomarkers;	chr2:32040056	chr2:32165046~32165757:-
COAD	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-4.21	3.55e-05	0.00969	-0.31	-0.25	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
COAD	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-4.21	3.55e-05	0.00969	-0.43	-0.25	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
COAD	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	4.21	3.55e-05	0.00969	0.32	0.25	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
COAD	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	4.21	3.55e-05	0.0097	0.46	0.25	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
COAD	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	4.21	3.55e-05	0.0097	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
COAD	cis	rs6951245	0.706	rs28522260	ENSG00000229043.2	AC091729.9	-4.21	3.55e-05	0.0097	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1160374~1165267:+
COAD	cis	rs2765539	0.59	rs4659137	ENSG00000231365.4	RP11-418J17.1	-4.21	3.56e-05	0.00971	-0.34	-0.25	Waist-hip ratio;	chr1:118978171	chr1:119140396~119275973:+
COAD	cis	rs7646881	0.812	rs73017539	ENSG00000272087.1	RP11-379F4.7	4.21	3.56e-05	0.00971	0.38	0.25	Tetralogy of Fallot;	chr3:158742954	chr3:158693120~158693768:-
COAD	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	4.21	3.56e-05	0.00971	0.29	0.25	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
COAD	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.21	3.56e-05	0.00971	0.41	0.25	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
COAD	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.21	3.56e-05	0.00971	0.41	0.25	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
COAD	cis	rs9868809	0.505	rs73080312	ENSG00000225399.4	RP11-3B7.1	-4.21	3.56e-05	0.00972	-0.55	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:49260085~49261316:+
COAD	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	4.21	3.56e-05	0.00972	0.28	0.25	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	4.21	3.56e-05	0.00972	0.28	0.25	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
COAD	cis	rs9868809	0.881	rs9878063	ENSG00000225399.4	RP11-3B7.1	-4.21	3.56e-05	0.00972	-0.38	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48641538	chr3:49260085~49261316:+
COAD	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-4.21	3.56e-05	0.00972	-0.32	-0.25	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
COAD	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-4.21	3.56e-05	0.00972	-0.28	-0.25	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
COAD	cis	rs2732480	0.577	rs1489109	ENSG00000257735.1	RP11-370I10.6	4.21	3.56e-05	0.00972	0.33	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48350945~48442411:+
COAD	cis	rs2732480	0.577	rs1489108	ENSG00000257735.1	RP11-370I10.6	4.21	3.56e-05	0.00972	0.33	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48350945~48442411:+
COAD	cis	rs7172689	0.908	rs7181247	ENSG00000271725.1	RP11-761I4.4	4.21	3.56e-05	0.00973	0.32	0.25	Inattentive symptoms;	chr15:81267736	chr15:81303215~81309391:-
COAD	cis	rs2638953	0.814	rs60960895	ENSG00000247934.4	RP11-967K21.1	-4.21	3.56e-05	0.00973	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454499	chr12:28163298~28190738:-
COAD	cis	rs7818688	1	rs7832570	ENSG00000253528.2	RP11-347C18.4	-4.21	3.56e-05	0.00973	-0.37	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011567	chr8:94974573~94974853:-
COAD	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-4.21	3.56e-05	0.00973	-0.37	-0.25	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
COAD	cis	rs2638953	0.853	rs1355475	ENSG00000247934.4	RP11-967K21.1	-4.21	3.57e-05	0.00973	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28163298~28190738:-
COAD	cis	rs7200543	0.583	rs4985149	ENSG00000270580.4	PKD1P6	4.21	3.57e-05	0.00974	0.28	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15104723~15131601:-
COAD	cis	rs6545883	0.507	rs59981505	ENSG00000273302.1	RP11-493E12.2	-4.21	3.57e-05	0.00975	-0.23	-0.25	Tuberculosis;	chr2:61353394	chr2:61199979~61200769:+
COAD	cis	rs74233809	0.901	rs3824754	ENSG00000213277.3	MARCKSL1P1	4.21	3.58e-05	0.00975	0.52	0.25	Birth weight;	chr10:102854593	chr10:103175554~103176094:+
COAD	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	4.21	3.58e-05	0.00977	0.33	0.25	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	4.21	3.58e-05	0.00977	0.33	0.25	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	4.21	3.58e-05	0.00977	0.33	0.25	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	4.21	3.58e-05	0.00977	0.33	0.25	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	4.21	3.58e-05	0.00977	0.33	0.25	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
COAD	cis	rs7577696	0.512	rs9789593	ENSG00000272716.1	RP11-563N4.1	-4.21	3.58e-05	0.00977	-0.3	-0.25	Inflammatory biomarkers;	chr2:32156041	chr2:32165046~32165757:-
COAD	cis	rs2638953	0.821	rs76265865	ENSG00000247934.4	RP11-967K21.1	-4.21	3.58e-05	0.00977	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504107	chr12:28163298~28190738:-
COAD	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-4.21	3.58e-05	0.00977	-0.32	-0.25	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
COAD	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-4.21	3.58e-05	0.00977	-0.32	-0.25	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
COAD	cis	rs1023500	0.529	rs133375	ENSG00000237037.8	NDUFA6-AS1	-4.21	3.59e-05	0.00978	-0.25	-0.25	Schizophrenia;	chr22:42070505	chr22:42090931~42137742:+
COAD	cis	rs6687821	0.515	rs523679	ENSG00000261737.1	RP4-612B15.3	-4.21	3.59e-05	0.00978	-0.34	-0.25	Yeast infection;	chr1:86902412	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs525519	ENSG00000261737.1	RP4-612B15.3	-4.21	3.59e-05	0.00978	-0.34	-0.25	Yeast infection;	chr1:86902611	chr1:86703502~86704462:-
COAD	cis	rs3764400	0.567	rs2240120	ENSG00000278765.1	RP5-890E16.5	4.21	3.59e-05	0.00978	0.49	0.25	Body mass index;	chr17:48064782	chr17:48066704~48067293:-
COAD	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-4.21	3.59e-05	0.00978	-0.3	-0.25	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
COAD	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	4.21	3.59e-05	0.00978	0.32	0.25	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
COAD	cis	rs9392556	0.6	rs661404	ENSG00000230648.1	RP3-406P24.3	4.21	3.59e-05	0.00979	0.29	0.25	Blood metabolite levels;	chr6:4125863	chr6:4018843~4021215:-
COAD	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-4.21	3.59e-05	0.00979	-0.42	-0.25	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
COAD	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-4.21	3.59e-05	0.00979	-0.33	-0.25	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
COAD	cis	rs11603023	1	rs11603023	ENSG00000278376.1	RP11-158I9.8	-4.21	3.59e-05	0.00979	-0.26	-0.25	Cholesterol, total;	chr11:118615352	chr11:118791254~118793137:+
COAD	cis	rs9532669	0.963	rs2324739	ENSG00000277662.1	RP11-74J13.9	-4.21	3.59e-05	0.00979	-0.24	-0.25	Cervical cancer;	chr13:40925479	chr13:41229180~41229676:-
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000272831.1	RP11-792A8.4	4.21	3.59e-05	0.00979	0.26	0.25	Calcium levels;	chr7:65903721	chr7:66739829~66740385:-
COAD	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	4.21	3.59e-05	0.00979	0.31	0.25	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
COAD	cis	rs9400467	0.528	rs456865	ENSG00000271789.1	RP5-1112D6.7	-4.21	3.59e-05	0.0098	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111297126~111298510:+
COAD	cis	rs2361718	0.564	rs2304844	ENSG00000279259.1	RP11-334C17.3	4.21	3.59e-05	0.0098	0.27	0.25	Yeast infection;	chr17:80110708	chr17:80147250~80148596:+
COAD	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	4.21	3.6e-05	0.0098	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
COAD	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	4.21	3.6e-05	0.0098	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
COAD	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-4.21	3.6e-05	0.0098	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	4.21	3.6e-05	0.00981	0.33	0.25	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
COAD	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-4.21	3.6e-05	0.00981	-0.32	-0.25	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
COAD	cis	rs1914816	1	rs2456072	ENSG00000196274.5	Metazoa_SRP	4.21	3.6e-05	0.00981	0.27	0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76253503	chr15:76230048~76230390:-
COAD	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	4.21	3.6e-05	0.00982	0.32	0.25	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
COAD	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	4.21	3.6e-05	0.00982	0.41	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
COAD	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-4.21	3.6e-05	0.00982	-0.31	-0.25	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
COAD	cis	rs875971	0.862	rs13226170	ENSG00000224316.1	RP11-479O9.2	4.21	3.6e-05	0.00982	0.27	0.25	Aortic root size;	chr7:66534311	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs2420611	ENSG00000224316.1	RP11-479O9.2	4.21	3.6e-05	0.00982	0.27	0.25	Aortic root size;	chr7:66534333	chr7:65773620~65802067:+
COAD	cis	rs7819412	0.502	rs4841499	ENSG00000269918.1	AF131215.9	-4.21	3.61e-05	0.00982	-0.33	-0.25	Triglycerides;	chr8:11130628	chr8:11104691~11106704:-
COAD	cis	rs4704187	0.687	rs10462513	ENSG00000250889.2	LINC01336	-4.21	3.61e-05	0.00982	-0.29	-0.25	Response to amphetamines;	chr5:75126782	chr5:75047719~75052843:-
COAD	cis	rs3764400	0.508	rs2240121	ENSG00000278765.1	RP5-890E16.5	4.21	3.61e-05	0.00982	0.48	0.25	Body mass index;	chr17:48074960	chr17:48066704~48067293:-
COAD	cis	rs7307902	0.504	rs10875649	ENSG00000268069.2	RP5-1057I20.4	4.21	3.61e-05	0.00983	0.29	0.25	Obesity-related traits;	chr12:47510214	chr12:47784923~47786002:+
COAD	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-4.2	3.61e-05	0.00983	-0.33	-0.25	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
COAD	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-4.2	3.61e-05	0.00983	-0.33	-0.25	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
COAD	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	4.2	3.61e-05	0.00983	0.26	0.25	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
COAD	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	4.2	3.61e-05	0.00983	0.4	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
COAD	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-4.2	3.61e-05	0.00983	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
COAD	cis	rs4657482	0.607	rs10918309	ENSG00000236364.3	RP11-525G13.2	-4.2	3.61e-05	0.00983	-0.22	-0.25	Testicular germ cell tumor;	chr1:165904791	chr1:165890795~165900683:-
COAD	cis	rs4718428	0.672	rs13241598	ENSG00000272831.1	RP11-792A8.4	4.2	3.61e-05	0.00983	0.28	0.25	Corneal structure;	chr7:66835665	chr7:66739829~66740385:-
COAD	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	4.2	3.61e-05	0.00983	0.28	0.25	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
COAD	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	4.2	3.61e-05	0.00984	0.28	0.25	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
COAD	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	4.2	3.61e-05	0.00984	0.3	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
COAD	cis	rs763121	0.853	rs4821808	ENSG00000273076.1	RP3-508I15.22	4.2	3.61e-05	0.00984	0.22	0.25	Menopause (age at onset);	chr22:38669734	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs4821809	ENSG00000273076.1	RP3-508I15.22	4.2	3.61e-05	0.00984	0.22	0.25	Menopause (age at onset);	chr22:38669738	chr22:38743495~38743910:+
COAD	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	4.2	3.62e-05	0.00984	0.2	0.25	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	4.2	3.62e-05	0.00984	0.2	0.25	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
COAD	cis	rs4718428	0.705	rs12536410	ENSG00000272831.1	RP11-792A8.4	4.2	3.62e-05	0.00985	0.29	0.25	Corneal structure;	chr7:66789303	chr7:66739829~66740385:-
COAD	cis	rs11681884	0.786	rs17042721	ENSG00000228251.1	AC012442.6	4.2	3.62e-05	0.00985	0.56	0.25	Stroke;	chr2:113032550	chr2:112590796~112591939:+
COAD	cis	rs11681884	0.786	rs34200521	ENSG00000228251.1	AC012442.6	4.2	3.62e-05	0.00985	0.56	0.25	Stroke;	chr2:113033301	chr2:112590796~112591939:+
COAD	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-4.2	3.62e-05	0.00985	-0.29	-0.25	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-4.2	3.62e-05	0.00986	-0.3	-0.25	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
COAD	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	4.2	3.62e-05	0.00986	0.3	0.25	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
COAD	cis	rs9450351	0.744	rs7738777	ENSG00000203875.9	SNHG5	-4.2	3.62e-05	0.00986	-0.49	-0.25	Interferon gamma-induced protein 10 levels;	chr6:85923468	chr6:85660950~85678736:-
COAD	cis	rs2733201	1	rs4923972	ENSG00000205771.5	CATSPER2P1	4.2	3.62e-05	0.00986	0.53	0.25	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44037058	chr15:43726918~43747094:-
COAD	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.2	3.62e-05	0.00987	-0.25	-0.25	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
COAD	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	4.2	3.63e-05	0.00988	0.27	0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
COAD	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	4.2	3.63e-05	0.00988	0.64	0.25	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
COAD	cis	rs6052484	1	rs6052484	ENSG00000275491.1	RP5-1009E24.8	4.2	3.63e-05	0.00988	0.33	0.25	Sense of smell;	chr20:4279963	chr20:3808357~3812434:+
COAD	cis	rs7577696	0.554	rs34835885	ENSG00000272716.1	RP11-563N4.1	-4.2	3.63e-05	0.00988	-0.29	-0.25	Inflammatory biomarkers;	chr2:32100345	chr2:32165046~32165757:-
COAD	cis	rs12165098	0.64	rs12959321	ENSG00000267374.1	RP11-244M2.1	-4.2	3.63e-05	0.00989	-0.48	-0.25	Sleep duration;	chr18:39246652	chr18:39206924~39800318:-
COAD	cis	rs12165098	0.714	rs12958110	ENSG00000267374.1	RP11-244M2.1	-4.2	3.63e-05	0.00989	-0.48	-0.25	Sleep duration;	chr18:39246653	chr18:39206924~39800318:-
COAD	cis	rs7829975	0.711	rs4841051	ENSG00000233609.3	RP11-62H7.2	-4.2	3.64e-05	0.00989	-0.27	-0.25	Mood instability;	chr8:8828136	chr8:8961200~8979025:+
COAD	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	4.2	3.64e-05	0.00989	0.26	0.25	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
COAD	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	4.2	3.64e-05	0.00989	0.26	0.25	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
COAD	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	4.2	3.64e-05	0.00989	0.26	0.25	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
COAD	cis	rs6740322	0.895	rs11684601	ENSG00000234936.1	AC010883.5	4.2	3.64e-05	0.00991	0.3	0.25	Coronary artery disease;	chr2:43347103	chr2:43229573~43233394:+
COAD	cis	rs11138902	0.673	rs2777864	ENSG00000229312.2	RP11-470P21.2	-4.2	3.64e-05	0.00991	-0.29	-0.25	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69476497	chr9:69472466~69494513:+
COAD	cis	rs2280018	0.581	rs7404524	ENSG00000270580.4	PKD1P6	4.2	3.64e-05	0.00991	0.28	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15104723~15131601:-
COAD	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-4.2	3.64e-05	0.00991	-0.31	-0.25	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
COAD	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-4.2	3.65e-05	0.00991	-0.3	-0.25	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
COAD	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	4.2	3.65e-05	0.00991	0.34	0.25	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
COAD	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	4.2	3.65e-05	0.00991	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
COAD	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-4.2	3.65e-05	0.00992	-0.31	-0.25	Height;	chr4:55477866	chr4:55547112~55547889:+
COAD	cis	rs3120667	0.929	rs3126099	ENSG00000237975.5	FLG-AS1	4.2	3.65e-05	0.00992	0.29	0.25	Eating disorders;	chr1:152341743	chr1:152168125~152445456:+
COAD	cis	rs6017291	0.793	rs12624924	ENSG00000223891.4	OSER1-AS1	4.2	3.65e-05	0.00992	0.32	0.25	Cognitive performance;	chr20:44216629	chr20:44210960~44226027:+
COAD	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-4.2	3.65e-05	0.00992	-0.6	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
COAD	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-4.2	3.65e-05	0.00992	-0.6	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
COAD	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	4.2	3.65e-05	0.00992	0.34	0.25	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	4.2	3.65e-05	0.00992	0.34	0.25	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
COAD	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	4.2	3.65e-05	0.00992	0.34	0.25	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	4.2	3.65e-05	0.00992	0.34	0.25	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
COAD	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	4.2	3.65e-05	0.00992	0.3	0.25	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
COAD	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	4.2	3.65e-05	0.00992	0.25	0.25	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
COAD	cis	rs875971	0.545	rs1796217	ENSG00000224316.1	RP11-479O9.2	-4.2	3.65e-05	0.00993	-0.32	-0.25	Aortic root size;	chr7:66620931	chr7:65773620~65802067:+
COAD	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	4.2	3.65e-05	0.00993	0.31	0.25	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
COAD	cis	rs711830	0.576	rs72916141	ENSG00000226363.3	HAGLROS	4.2	3.65e-05	0.00993	0.43	0.25	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176204636	chr2:176177717~176179008:+
COAD	cis	rs11229555	0.645	rs7117080	ENSG00000254602.1	AP000662.4	-4.2	3.65e-05	0.00993	-0.28	-0.25	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58411204	chr11:57638024~57652790:+
COAD	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.2	3.65e-05	0.00993	0.22	0.25	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
COAD	cis	rs1023500	0.596	rs133369	ENSG00000237037.8	NDUFA6-AS1	-4.2	3.66e-05	0.00993	-0.25	-0.25	Schizophrenia;	chr22:42067810	chr22:42090931~42137742:+
COAD	cis	rs875971	0.619	rs2302918	ENSG00000272831.1	RP11-792A8.4	4.2	3.66e-05	0.00994	0.27	0.25	Aortic root size;	chr7:66535945	chr7:66739829~66740385:-
COAD	cis	rs2638953	0.853	rs11049670	ENSG00000247934.4	RP11-967K21.1	4.2	3.66e-05	0.00994	0.26	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28163298~28190738:-
COAD	cis	rs6687821	0.515	rs512912	ENSG00000261737.1	RP4-612B15.3	-4.2	3.66e-05	0.00994	-0.33	-0.25	Yeast infection;	chr1:86898359	chr1:86703502~86704462:-
COAD	cis	rs2638953	0.853	rs1918418	ENSG00000247934.4	RP11-967K21.1	-4.2	3.66e-05	0.00994	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs1511550	ENSG00000247934.4	RP11-967K21.1	-4.2	3.66e-05	0.00994	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28163298~28190738:-
COAD	cis	rs9400467	0.509	rs11153287	ENSG00000271789.1	RP5-1112D6.7	-4.2	3.66e-05	0.00994	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111297126~111298510:+
COAD	cis	rs41464545	1	rs11932556	ENSG00000249413.2	RP11-25H12.1	4.2	3.66e-05	0.00994	0.34	0.25	Schizophrenia;	chr4:65017518	chr4:65998846~66150012:+
COAD	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	4.2	3.66e-05	0.00994	0.31	0.25	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
COAD	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	4.2	3.66e-05	0.00994	0.28	0.25	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
COAD	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-4.2	3.66e-05	0.00995	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
COAD	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	4.2	3.66e-05	0.00995	0.51	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
COAD	cis	rs763121	0.853	rs2413545	ENSG00000273076.1	RP3-508I15.22	4.2	3.66e-05	0.00995	0.24	0.25	Menopause (age at onset);	chr22:38696519	chr22:38743495~38743910:+
COAD	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	4.2	3.66e-05	0.00995	0.31	0.25	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
COAD	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	4.2	3.66e-05	0.00995	0.32	0.25	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
COAD	cis	rs2638953	0.853	rs3926041	ENSG00000247934.4	RP11-967K21.1	-4.2	3.67e-05	0.00995	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs2141203	ENSG00000247934.4	RP11-967K21.1	-4.2	3.67e-05	0.00995	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28163298~28190738:-
COAD	cis	rs1670533	1	rs935970	ENSG00000273179.1	RP11-20I20.4	-4.2	3.67e-05	0.00995	-0.34	-0.25	Recombination rate (females);	chr4:1051535	chr4:1167778~1168174:+
COAD	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	4.2	3.67e-05	0.00996	0.25	0.25	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
COAD	cis	rs6740322	0.748	rs6756625	ENSG00000234936.1	AC010883.5	-4.2	3.67e-05	0.00996	-0.32	-0.25	Coronary artery disease;	chr2:43262174	chr2:43229573~43233394:+
COAD	cis	rs1275411	0.511	rs4902683	ENSG00000259062.2	ACTN1-AS1	4.2	3.67e-05	0.00996	0.33	0.25	Neuroticism;	chr14:68976131	chr14:68979682~68987463:+
COAD	cis	rs875971	0.516	rs6945322	ENSG00000272831.1	RP11-792A8.4	4.2	3.67e-05	0.00996	0.26	0.25	Aortic root size;	chr7:65871069	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000272831.1	RP11-792A8.4	4.2	3.67e-05	0.00996	0.26	0.25	Calcium levels;	chr7:65872915	chr7:66739829~66740385:-
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000272831.1	RP11-792A8.4	4.2	3.67e-05	0.00996	0.26	0.25	Calcium levels;	chr7:65892789	chr7:66739829~66740385:-
COAD	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	4.2	3.67e-05	0.00996	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
COAD	cis	rs1387259	0.931	rs11168474	ENSG00000226413.2	OR8T1P	4.2	3.67e-05	0.00997	0.31	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48442030~48442947:-
COAD	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
COAD	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-4.2	3.67e-05	0.00997	-0.23	-0.25	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
COAD	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-4.2	3.67e-05	0.00997	-0.32	-0.25	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
COAD	cis	rs9393813	0.528	rs6903282	ENSG00000271755.1	RP1-153G14.4	4.2	3.67e-05	0.00997	0.29	0.25	Bipolar disorder;	chr6:27498933	chr6:27404010~27406964:-
COAD	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-4.2	3.67e-05	0.00997	-0.27	-0.25	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-4.2	3.67e-05	0.00997	-0.27	-0.25	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-4.2	3.67e-05	0.00997	-0.27	-0.25	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
COAD	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	4.2	3.67e-05	0.00997	0.38	0.25	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
COAD	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-4.2	3.67e-05	0.00997	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-4.2	3.67e-05	0.00997	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
COAD	cis	rs12906542	0.516	rs894301	ENSG00000260139.5	CSPG4P13	-4.2	3.67e-05	0.00997	-0.35	-0.25	Breast cancer;	chr15:78005183	chr15:77894684~77904674:+
COAD	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-4.2	3.67e-05	0.00997	-0.27	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
COAD	cis	rs4761470	0.577	rs55836966	ENSG00000258365.1	RP11-1105G2.3	-4.2	3.67e-05	0.00997	-0.31	-0.25	Estradiol plasma levels (breast cancer);	chr12:94287384	chr12:94277758~94282844:-
COAD	cis	rs77972916	0.611	rs61552842	ENSG00000234936.1	AC010883.5	4.2	3.68e-05	0.00998	0.3	0.25	Granulocyte percentage of myeloid white cells;	chr2:43356897	chr2:43229573~43233394:+
COAD	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	4.2	3.68e-05	0.00998	0.34	0.25	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
COAD	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-4.2	3.68e-05	0.00998	-0.32	-0.25	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
COAD	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-4.2	3.68e-05	0.00998	-0.45	-0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
COAD	cis	rs7646881	0.812	rs59957986	ENSG00000272087.1	RP11-379F4.7	4.2	3.68e-05	0.00998	0.38	0.25	Tetralogy of Fallot;	chr3:158741124	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs59192661	ENSG00000272087.1	RP11-379F4.7	4.2	3.68e-05	0.00998	0.38	0.25	Tetralogy of Fallot;	chr3:158741238	chr3:158693120~158693768:-
COAD	cis	rs7818688	1	rs28616734	ENSG00000253528.2	RP11-347C18.4	-4.2	3.68e-05	0.00999	-0.37	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009215	chr8:94974573~94974853:-
COAD	cis	rs7818688	1	rs7818688	ENSG00000253528.2	RP11-347C18.4	-4.2	3.68e-05	0.00999	-0.37	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011854	chr8:94974573~94974853:-
COAD	cis	rs9818758	0.607	rs73074866	ENSG00000225399.4	RP11-3B7.1	-4.2	3.68e-05	0.00999	-0.54	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49589233	chr3:49260085~49261316:+
COAD	cis	rs2018683	0.677	rs55718000	ENSG00000272568.4	CTB-113D17.1	4.2	3.68e-05	0.00999	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28979967~29013367:+
COAD	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-4.2	3.68e-05	0.00999	-0.29	-0.25	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
COAD	cis	rs597539	0.652	rs611046	ENSG00000255741.1	RP11-757G1.5	-4.2	3.69e-05	0.01	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68941503~68942852:-
COAD	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-4.2	3.69e-05	0.01	-0.31	-0.25	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
COAD	cis	rs6719977	0.935	rs2289355	ENSG00000226491.1	FTOP1	-4.2	3.69e-05	0.01	-0.32	-0.25	Hyperactive-impulsive symptoms;	chr2:42754850	chr2:42797225~42798712:-
COAD	cis	rs1005224	0.926	rs12892551	ENSG00000258454.1	RP11-361H10.3	4.2	3.69e-05	0.01	0.31	0.25	Large artery stroke;	chr14:75693559	chr14:76235817~76263474:+
COAD	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-4.2	3.69e-05	0.01	-0.25	-0.25	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
COAD	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	4.2	3.69e-05	0.01	0.35	0.25	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	4.2	3.69e-05	0.01	0.35	0.25	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
COAD	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-4.2	3.69e-05	0.01	-0.3	-0.25	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
COAD	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	4.2	3.69e-05	0.01	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
COAD	cis	rs875971	0.545	rs13311962	ENSG00000224316.1	RP11-479O9.2	-4.2	3.69e-05	0.01	-0.32	-0.25	Aortic root size;	chr7:66603142	chr7:65773620~65802067:+
COAD	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	4.2	3.69e-05	0.01	0.28	0.25	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
COAD	cis	rs2333021	0.78	rs12886469	ENSG00000259015.1	RP11-109N23.6	4.2	3.69e-05	0.01	0.23	0.25	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72985979	chr14:72960595~72961993:+
COAD	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-4.2	3.69e-05	0.01	-0.27	-0.25	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
COAD	cis	rs8022206	0.773	rs7158544	ENSG00000259502.1	RP11-643G16.3	4.2	3.69e-05	0.01	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68014665	chr14:67610986~67613864:+
COAD	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	4.2	3.69e-05	0.01	0.32	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
COAD	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	4.2	3.7e-05	0.01	0.32	0.25	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
COAD	cis	rs1023500	1	rs3752591	ENSG00000237037.8	NDUFA6-AS1	4.2	3.7e-05	0.01	0.28	0.25	Schizophrenia;	chr22:41943512	chr22:42090931~42137742:+
COAD	cis	rs8002861	0.846	rs12428112	ENSG00000274001.1	RP11-5G9.5	-4.2	3.7e-05	0.01	-0.24	-0.25	Leprosy;	chr13:43901685	chr13:43877715~43878163:-
COAD	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	4.2	3.7e-05	0.01	0.33	0.25	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
COAD	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-4.2	3.7e-05	0.01	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
COAD	cis	rs2337406	0.587	rs11624678	ENSG00000211974.3	IGHV2-70	4.2	3.7e-05	0.01	0.29	0.25	Alzheimer's disease (late onset);	chr14:106650408	chr14:106723574~106724093:-
COAD	cis	rs763121	0.853	rs8140617	ENSG00000273076.1	RP3-508I15.22	-4.2	3.7e-05	0.01	-0.24	-0.25	Menopause (age at onset);	chr22:38574434	chr22:38743495~38743910:+
COAD	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	4.2	3.7e-05	0.01	0.32	0.25	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
COAD	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.2	3.7e-05	0.01	-0.27	-0.25	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
COAD	cis	rs7572733	0.773	rs6748788	ENSG00000222017.1	AC011997.1	-4.2	3.7e-05	0.01	-0.27	-0.25	Dermatomyositis;	chr2:197668882	chr2:197693106~197774823:+
COAD	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
COAD	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-4.2	3.7e-05	0.01	-0.27	-0.25	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
COAD	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-4.2	3.7e-05	0.01	-0.36	-0.25	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
COAD	cis	rs12554020	0.551	rs4744257	ENSG00000227603.1	RP11-165J3.6	-4.2	3.7e-05	0.01	-0.34	-0.25	Schizophrenia;	chr9:93599204	chr9:93435332~93437121:-
COAD	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	4.2	3.71e-05	0.01	0.3	0.25	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
COAD	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	4.2	3.71e-05	0.01	0.32	0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
COAD	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	4.2	3.71e-05	0.01	0.32	0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
COAD	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	4.2	3.71e-05	0.01	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
COAD	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-4.2	3.71e-05	0.0101	-0.26	-0.25	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
COAD	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-4.2	3.71e-05	0.0101	-0.26	-0.25	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
COAD	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	4.2	3.71e-05	0.0101	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
COAD	cis	rs17772222	0.958	rs2297128	ENSG00000258789.1	RP11-507K2.3	-4.2	3.71e-05	0.0101	-0.37	-0.25	Coronary artery calcification;	chr14:88469910	chr14:88551597~88552493:+
COAD	cis	rs2018683	0.677	rs12540529	ENSG00000272568.4	CTB-113D17.1	4.2	3.71e-05	0.0101	0.36	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929767	chr7:28979967~29013367:+
COAD	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-4.2	3.71e-05	0.0101	-0.24	-0.25	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
COAD	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	4.2	3.71e-05	0.0101	0.36	0.25	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
COAD	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	4.2	3.72e-05	0.0101	0.37	0.25	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	4.2	3.72e-05	0.0101	0.37	0.25	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	4.2	3.72e-05	0.0101	0.37	0.25	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
COAD	cis	rs2732480	0.5	rs7315820	ENSG00000226413.2	OR8T1P	4.2	3.72e-05	0.0101	0.31	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48442030~48442947:-
COAD	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-4.2	3.72e-05	0.0101	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
COAD	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-4.2	3.72e-05	0.0101	-0.23	-0.25	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-4.2	3.72e-05	0.0101	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
COAD	cis	rs2638953	0.853	rs11049519	ENSG00000247934.4	RP11-967K21.1	-4.2	3.72e-05	0.0101	-0.28	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28307285	chr12:28163298~28190738:-
COAD	cis	rs1578862	0.55	rs57653401	ENSG00000259865.1	RP11-488L18.10	-4.2	3.72e-05	0.0101	-0.23	-0.25	Monocyte percentage of white cells;	chr1:247294145	chr1:247187281~247188526:-
COAD	cis	rs1023500	0.551	rs133371	ENSG00000237037.8	NDUFA6-AS1	-4.2	3.72e-05	0.0101	-0.25	-0.25	Schizophrenia;	chr22:42069570	chr22:42090931~42137742:+
COAD	cis	rs1023500	0.573	rs133374	ENSG00000237037.8	NDUFA6-AS1	-4.2	3.72e-05	0.0101	-0.25	-0.25	Schizophrenia;	chr22:42069937	chr22:42090931~42137742:+
COAD	cis	rs1670533	1	rs10084890	ENSG00000273179.1	RP11-20I20.4	-4.2	3.72e-05	0.0101	-0.32	-0.25	Recombination rate (females);	chr4:1060146	chr4:1167778~1168174:+
COAD	cis	rs891378	1	rs7545125	ENSG00000274245.1	RP11-357P18.2	-4.2	3.72e-05	0.0101	-0.35	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251382	chr1:207372559~207373252:+
COAD	cis	rs74781061	0.932	rs11629749	ENSG00000260103.2	RP11-10O17.1	-4.2	3.73e-05	0.0101	-0.27	-0.25	Endometriosis;	chr15:74627252	chr15:74478070~74490286:-
COAD	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	4.2	3.73e-05	0.0101	0.31	0.25	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
COAD	cis	rs6452524	0.901	rs1600362	ENSG00000271862.1	RP11-343L5.2	4.2	3.73e-05	0.0101	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs1580310	ENSG00000271862.1	RP11-343L5.2	4.2	3.73e-05	0.0101	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs1011979	ENSG00000271862.1	RP11-343L5.2	4.2	3.73e-05	0.0101	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83049376~83050964:-
COAD	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-4.2	3.73e-05	0.0101	-0.32	-0.25	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
COAD	cis	rs12530	0.715	rs2294311	ENSG00000230736.2	RP1-149A16.3	-4.2	3.73e-05	0.0101	-0.31	-0.25	IgG glycosylation;	chr22:32397282	chr22:32376664~32384343:+
COAD	cis	rs1670533	0.769	rs6814833	ENSG00000273179.1	RP11-20I20.4	4.2	3.73e-05	0.0101	0.33	0.25	Recombination rate (females);	chr4:1063891	chr4:1167778~1168174:+
COAD	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	4.2	3.73e-05	0.0101	0.3	0.25	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
COAD	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	4.2	3.74e-05	0.0101	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	4.2	3.74e-05	0.0101	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	4.2	3.74e-05	0.0101	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	4.2	3.74e-05	0.0101	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	4.2	3.74e-05	0.0101	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
COAD	cis	rs1670533	1	rs6821725	ENSG00000273179.1	RP11-20I20.4	4.2	3.74e-05	0.0101	0.32	0.25	Recombination rate (females);	chr4:1066572	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs11247972	ENSG00000273179.1	RP11-20I20.4	4.2	3.74e-05	0.0101	0.32	0.25	Recombination rate (females);	chr4:1066762	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10007978	ENSG00000273179.1	RP11-20I20.4	4.2	3.74e-05	0.0101	0.32	0.25	Recombination rate (females);	chr4:1067196	chr4:1167778~1168174:+
COAD	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-4.2	3.74e-05	0.0101	-0.28	-0.25	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
COAD	cis	rs9532669	0.963	rs1056824	ENSG00000277662.1	RP11-74J13.9	-4.2	3.74e-05	0.0101	-0.25	-0.25	Cervical cancer;	chr13:40932748	chr13:41229180~41229676:-
COAD	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-4.2	3.74e-05	0.0101	-0.35	-0.25	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
COAD	cis	rs763121	0.651	rs738249	ENSG00000273076.1	RP3-508I15.22	4.2	3.74e-05	0.0101	0.23	0.25	Menopause (age at onset);	chr22:38641974	chr22:38743495~38743910:+
COAD	cis	rs7818688	1	rs11786878	ENSG00000253528.2	RP11-347C18.4	-4.2	3.74e-05	0.0101	-0.38	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021064	chr8:94974573~94974853:-
COAD	cis	rs2408955	0.504	rs11168441	ENSG00000269514.1	RP11-370I10.12	4.2	3.74e-05	0.0101	0.31	0.25	Glycated hemoglobin levels;	chr12:48182271	chr12:48198387~48202031:+
COAD	cis	rs2439831	1	rs9920763	ENSG00000166763.7	STRCP1	-4.2	3.74e-05	0.0101	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43468310	chr15:43699488~43718184:-
COAD	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	4.2	3.74e-05	0.0101	0.22	0.25	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
COAD	cis	rs9816784	0.901	rs56253832	ENSG00000242086.7	LINC00969	4.2	3.75e-05	0.0101	0.24	0.25	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195658062~195739964:+
COAD	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	4.2	3.75e-05	0.0101	0.43	0.25	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
COAD	cis	rs1510272	0.889	rs4680286	ENSG00000243926.1	TIPARP-AS1	-4.2	3.75e-05	0.0101	-0.28	-0.25	Testicular germ cell tumor;	chr3:156601298	chr3:156671862~156674378:-
COAD	cis	rs12530	1	rs9606944	ENSG00000232218.1	RP1-149A16.16	-4.2	3.75e-05	0.0102	-0.45	-0.25	IgG glycosylation;	chr22:32384139	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs9606945	ENSG00000232218.1	RP1-149A16.16	-4.2	3.75e-05	0.0102	-0.45	-0.25	IgG glycosylation;	chr22:32384409	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs9609523	ENSG00000232218.1	RP1-149A16.16	-4.2	3.75e-05	0.0102	-0.45	-0.25	IgG glycosylation;	chr22:32385944	chr22:32386668~32386868:+
COAD	cis	rs9910055	0.607	rs13726	ENSG00000267080.4	ASB16-AS1	-4.2	3.75e-05	0.0102	-0.23	-0.25	Total body bone mineral density;	chr17:44162193	chr17:44175973~44186717:-
COAD	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	4.2	3.76e-05	0.0102	0.31	0.25	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
COAD	cis	rs11976180	1	rs13243677	ENSG00000204959.4	ARHGEF34P	4.2	3.76e-05	0.0102	0.31	0.25	Obesity-related traits;	chr7:144049479	chr7:144272445~144286966:-
COAD	cis	rs58873874	0.737	rs112160357	ENSG00000248544.2	CTB-47B11.3	4.2	3.76e-05	0.0102	0.59	0.25	Bipolar disorder (body mass index interaction);	chr5:157501696	chr5:157375741~157384950:-
COAD	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	4.2	3.76e-05	0.0102	0.26	0.25	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
COAD	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	4.2	3.76e-05	0.0102	0.26	0.25	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
COAD	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-4.19	3.76e-05	0.0102	-0.43	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
COAD	cis	rs8022206	0.704	rs17104800	ENSG00000259502.1	RP11-643G16.3	4.19	3.76e-05	0.0102	0.32	0.25	Platelet count;Mean platelet volume;	chr14:67954062	chr14:67610986~67613864:+
COAD	cis	rs8177876	0.822	rs4324141	ENSG00000261061.1	RP11-303E16.2	4.19	3.76e-05	0.0102	0.38	0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81030770~81031485:+
COAD	cis	rs875971	0.862	rs3893216	ENSG00000224316.1	RP11-479O9.2	-4.19	3.76e-05	0.0102	-0.28	-0.25	Aortic root size;	chr7:66325720	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6958294	ENSG00000224316.1	RP11-479O9.2	-4.19	3.76e-05	0.0102	-0.28	-0.25	Aortic root size;	chr7:66329809	chr7:65773620~65802067:+
COAD	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	4.19	3.76e-05	0.0102	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
COAD	cis	rs2638953	0.924	rs11049619	ENSG00000247934.4	RP11-967K21.1	-4.19	3.77e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453495	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs60703205	ENSG00000247934.4	RP11-967K21.1	-4.19	3.77e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454371	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.85	rs59879751	ENSG00000247934.4	RP11-967K21.1	-4.19	3.77e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454490	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs59193275	ENSG00000247934.4	RP11-967K21.1	-4.19	3.77e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454560	chr12:28163298~28190738:-
COAD	cis	rs1670533	1	rs6599278	ENSG00000273179.1	RP11-20I20.4	4.19	3.77e-05	0.0102	0.33	0.25	Recombination rate (females);	chr4:1065010	chr4:1167778~1168174:+
COAD	cis	rs13333054	1	rs13333054	ENSG00000269667.1	RP11-542M13.2	-4.19	3.77e-05	0.0102	-0.34	-0.25	Multiple sclerosis;	chr16:85977427	chr16:85981750~85984723:+
COAD	cis	rs893363	0.559	rs893365	ENSG00000271916.1	RP11-884K10.6	-4.19	3.77e-05	0.0102	-0.25	-0.25	Axial length;	chr3:53807119	chr3:53797764~53798019:-
COAD	cis	rs6719977	0.513	rs7591304	ENSG00000226491.1	FTOP1	-4.19	3.77e-05	0.0102	-0.34	-0.25	Hyperactive-impulsive symptoms;	chr2:42750659	chr2:42797225~42798712:-
COAD	cis	rs6719977	0.543	rs6544595	ENSG00000226491.1	FTOP1	-4.19	3.77e-05	0.0102	-0.34	-0.25	Hyperactive-impulsive symptoms;	chr2:42750730	chr2:42797225~42798712:-
COAD	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.19	3.77e-05	0.0102	0.44	0.25	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
COAD	cis	rs911119	0.913	rs2405392	ENSG00000270001.1	RP11-218C14.8	-4.19	3.77e-05	0.0102	-0.32	-0.25	Chronic kidney disease;	chr20:23588549	chr20:23631826~23632316:-
COAD	cis	rs860295	0.871	rs6688636	ENSG00000223503.1	RP11-29H23.6	4.19	3.77e-05	0.0102	0.33	0.25	Body mass index;	chr1:155509106	chr1:155590601~155591262:-
COAD	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	4.19	3.77e-05	0.0102	0.3	0.25	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
COAD	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-4.19	3.77e-05	0.0102	-0.27	-0.25	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
COAD	cis	rs2638953	0.924	rs2348235	ENSG00000247934.4	RP11-967K21.1	-4.19	3.78e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414019	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049577	ENSG00000247934.4	RP11-967K21.1	-4.19	3.78e-05	0.0102	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414437	chr12:28163298~28190738:-
COAD	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-4.19	3.78e-05	0.0102	-0.29	-0.25	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
COAD	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	4.19	3.78e-05	0.0102	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
COAD	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	4.19	3.78e-05	0.0102	0.31	0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
COAD	cis	rs13113518	0.683	rs9761521	ENSG00000223305.1	RN7SKP30	4.19	3.78e-05	0.0102	0.3	0.25	Height;	chr4:55363436	chr4:55540502~55540835:-
COAD	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	4.19	3.78e-05	0.0102	0.32	0.25	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
COAD	cis	rs7829975	0.508	rs4841006	ENSG00000254340.1	RP11-10A14.3	-4.19	3.78e-05	0.0102	-0.3	-0.25	Mood instability;	chr8:8643964	chr8:9141424~9145435:+
COAD	cis	rs2732480	0.577	rs2634693	ENSG00000226413.2	OR8T1P	4.19	3.78e-05	0.0102	0.33	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2634691	ENSG00000226413.2	OR8T1P	4.19	3.78e-05	0.0102	0.33	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48442030~48442947:-
COAD	cis	rs71636778	0.509	rs34217609	ENSG00000260063.1	RP5-968P14.2	-4.19	3.78e-05	0.0102	-0.52	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26681776	chr1:26692132~26694131:-
COAD	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	4.19	3.78e-05	0.0102	0.3	0.25	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
COAD	cis	rs1670533	1	rs6858612	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1059565	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs13108207	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1060430	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs4690213	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1061080	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6822863	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1061818	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.872	rs6854793	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1061980	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs10902753	ENSG00000273179.1	RP11-20I20.4	4.19	3.78e-05	0.0102	0.32	0.25	Recombination rate (females);	chr4:1062435	chr4:1167778~1168174:+
COAD	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-4.19	3.78e-05	0.0102	-0.25	-0.25	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
COAD	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.19	3.78e-05	0.0102	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
COAD	cis	rs875971	0.545	rs313828	ENSG00000224316.1	RP11-479O9.2	-4.19	3.78e-05	0.0102	-0.32	-0.25	Aortic root size;	chr7:66087627	chr7:65773620~65802067:+
COAD	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-4.19	3.79e-05	0.0102	-0.41	-0.25	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-4.19	3.79e-05	0.0102	-0.41	-0.25	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
COAD	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-4.19	3.79e-05	0.0102	-0.41	-0.25	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
COAD	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	4.19	3.79e-05	0.0102	0.29	0.25	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
COAD	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-4.19	3.79e-05	0.0102	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-4.19	3.79e-05	0.0102	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-4.19	3.79e-05	0.0102	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-4.19	3.79e-05	0.0102	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
COAD	cis	rs739496	0.579	rs11066051	ENSG00000257595.2	RP3-473L9.4	4.19	3.79e-05	0.0102	0.37	0.25	Platelet count;	chr12:111863956	chr12:111369282~111403310:+
COAD	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	4.19	3.79e-05	0.0102	0.33	0.25	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
COAD	cis	rs7674212	0.531	rs10006474	ENSG00000248971.2	KRT8P46	-4.19	3.79e-05	0.0102	-0.25	-0.25	Type 2 diabetes;	chr4:103006890	chr4:102728746~102730171:-
COAD	cis	rs11089937	0.616	rs7291684	ENSG00000211638.2	IGLV8-61	-4.19	3.79e-05	0.0102	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs6001219	ENSG00000211638.2	IGLV8-61	-4.19	3.79e-05	0.0102	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22098700~22099212:+
COAD	cis	rs739496	0.527	rs4767074	ENSG00000257595.2	RP3-473L9.4	4.19	3.79e-05	0.0102	0.37	0.25	Platelet count;	chr12:111855158	chr12:111369282~111403310:+
COAD	cis	rs913655	0.508	rs10829297	ENSG00000240291.1	RP11-499P20.2	4.19	3.79e-05	0.0102	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18725041	chr10:18513115~18545651:-
COAD	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	4.19	3.79e-05	0.0102	0.2	0.25	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
COAD	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	4.19	3.79e-05	0.0102	0.27	0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
COAD	cis	rs9517302	0.615	rs9517306	ENSG00000231194.1	FARP1-AS1	4.19	3.79e-05	0.0102	0.33	0.25	Obesity-related traits;	chr13:98445708	chr13:98435405~98435840:-
COAD	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	4.19	3.79e-05	0.0102	0.32	0.25	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
COAD	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-4.19	3.79e-05	0.0102	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
COAD	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	4.19	3.79e-05	0.0102	0.3	0.25	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
COAD	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-4.19	3.79e-05	0.0102	-0.24	-0.25	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
COAD	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-4.19	3.79e-05	0.0102	-0.31	-0.25	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
COAD	cis	rs2307394	0.896	rs12992412	ENSG00000281469.1	RP11-567F11.1	4.19	3.79e-05	0.0102	0.3	0.25	Urate levels;	chr2:148035096	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.896	rs12992231	ENSG00000281469.1	RP11-567F11.1	4.19	3.79e-05	0.0102	0.3	0.25	Urate levels;	chr2:148042141	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.858	rs6430285	ENSG00000281469.1	RP11-567F11.1	4.19	3.79e-05	0.0102	0.3	0.25	Urate levels;	chr2:148042519	chr2:148044380~148044894:+
COAD	cis	rs875971	0.545	rs73136346	ENSG00000224316.1	RP11-479O9.2	-4.19	3.8e-05	0.0102	-0.32	-0.25	Aortic root size;	chr7:66101095	chr7:65773620~65802067:+
COAD	cis	rs763121	0.853	rs4821811	ENSG00000273076.1	RP3-508I15.22	4.19	3.8e-05	0.0103	0.23	0.25	Menopause (age at onset);	chr22:38679140	chr22:38743495~38743910:+
COAD	cis	rs1670533	1	rs6812586	ENSG00000273179.1	RP11-20I20.4	4.19	3.8e-05	0.0103	0.32	0.25	Recombination rate (females);	chr4:1076063	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6812596	ENSG00000273179.1	RP11-20I20.4	4.19	3.8e-05	0.0103	0.32	0.25	Recombination rate (females);	chr4:1076078	chr4:1167778~1168174:+
COAD	cis	rs6585424	1	rs35483545	ENSG00000234382.2	RP11-40F6.1	-4.19	3.8e-05	0.0103	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs34386571	ENSG00000234382.2	RP11-40F6.1	-4.19	3.8e-05	0.0103	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:80233664~80245367:+
COAD	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	4.19	3.8e-05	0.0103	0.27	0.25	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
COAD	cis	rs8022206	0.738	rs11623467	ENSG00000259502.1	RP11-643G16.3	4.19	3.8e-05	0.0103	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68074029	chr14:67610986~67613864:+
COAD	cis	rs7760535	1	rs7760535	ENSG00000271789.1	RP5-1112D6.7	4.19	3.8e-05	0.0103	0.25	0.25	Metabolic traits;	chr6:111425880	chr6:111297126~111298510:+
COAD	cis	rs1799949	0.683	rs55737636	ENSG00000279602.1	CTD-3014M21.1	4.19	3.8e-05	0.0103	0.28	0.25	Menopause (age at onset);	chr17:43112722	chr17:43360041~43361361:-
COAD	cis	rs10971721	0.543	rs68113313	ENSG00000260947.1	RP11-384P7.7	4.19	3.8e-05	0.0103	0.44	0.25	Body mass index;	chr9:34059988	chr9:33697459~33700986:+
COAD	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-4.19	3.8e-05	0.0103	-0.28	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-4.19	3.8e-05	0.0103	-0.28	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-4.19	3.8e-05	0.0103	-0.28	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
COAD	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	4.19	3.8e-05	0.0103	0.28	0.25	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
COAD	cis	rs9450351	0.744	rs12528808	ENSG00000203875.9	SNHG5	-4.19	3.8e-05	0.0103	-0.46	-0.25	Interferon gamma-induced protein 10 levels;	chr6:85495926	chr6:85660950~85678736:-
COAD	cis	rs9341808	0.754	rs6918172	ENSG00000272129.1	RP11-250B2.6	4.19	3.81e-05	0.0103	0.33	0.25	Sitting height ratio;	chr6:80309525	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	4.19	3.81e-05	0.0103	0.33	0.25	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
COAD	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	4.19	3.81e-05	0.0103	0.28	0.25	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
COAD	cis	rs172166	0.538	rs1150686	ENSG00000272009.1	RP1-313I6.12	4.19	3.81e-05	0.0103	0.28	0.25	Cardiac Troponin-T levels;	chr6:28193493	chr6:28078792~28081130:-
COAD	cis	rs1150688	1	rs1150688	ENSG00000272009.1	RP1-313I6.12	4.19	3.81e-05	0.0103	0.28	0.25	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28078792~28081130:-
COAD	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-4.19	3.81e-05	0.0103	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
COAD	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-4.19	3.81e-05	0.0103	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
COAD	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-4.19	3.81e-05	0.0103	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
COAD	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-4.19	3.81e-05	0.0103	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
COAD	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	4.19	3.81e-05	0.0103	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	4.19	3.81e-05	0.0103	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
COAD	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-4.19	3.81e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-4.19	3.81e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-4.19	3.81e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
COAD	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	4.19	3.81e-05	0.0103	0.4	0.25	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
COAD	cis	rs6452524	0.935	rs6880566	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.905	rs6884981	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.905	rs6896548	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs1580311	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.901	rs17284211	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs1382374	ENSG00000271862.1	RP11-343L5.2	4.19	3.81e-05	0.0103	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83049376~83050964:-
COAD	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-4.19	3.81e-05	0.0103	-0.26	-0.25	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
COAD	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-4.19	3.82e-05	0.0103	-0.23	-0.25	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
COAD	cis	rs763121	0.853	rs5757204	ENSG00000273076.1	RP3-508I15.22	4.19	3.82e-05	0.0103	0.22	0.25	Menopause (age at onset);	chr22:38650695	chr22:38743495~38743910:+
COAD	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-4.19	3.82e-05	0.0103	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
COAD	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.19	3.82e-05	0.0103	0.4	0.25	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
COAD	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	4.19	3.82e-05	0.0103	0.3	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	4.19	3.82e-05	0.0103	0.3	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
COAD	cis	rs6903823	0.508	rs1150718	ENSG00000272009.1	RP1-313I6.12	4.19	3.82e-05	0.0103	0.28	0.25	Pulmonary function;	chr6:28289170	chr6:28078792~28081130:-
COAD	cis	rs6903823	0.508	rs1233660	ENSG00000272009.1	RP1-313I6.12	4.19	3.82e-05	0.0103	0.28	0.25	Pulmonary function;	chr6:28292472	chr6:28078792~28081130:-
COAD	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-4.19	3.82e-05	0.0103	-0.37	-0.25	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
COAD	cis	rs7656342	0.866	rs13124305	ENSG00000186234.7	FAM86MP	-4.19	3.82e-05	0.0103	-0.33	-0.25	Gut microbiota (bacterial taxa);	chr4:9771649	chr4:9692495~9702954:+
COAD	cis	rs13113518	1	rs13132420	ENSG00000223305.1	RN7SKP30	-4.19	3.82e-05	0.0103	-0.29	-0.25	Height;	chr4:55526646	chr4:55540502~55540835:-
COAD	cis	rs987724	0.593	rs9867621	ENSG00000240875.4	LINC00886	-4.19	3.82e-05	0.0103	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156896774	chr3:156747346~156817062:-
COAD	cis	rs987724	0.555	rs12629380	ENSG00000240875.4	LINC00886	-4.19	3.82e-05	0.0103	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898291	chr3:156747346~156817062:-
COAD	cis	rs987724	0.519	rs1875622	ENSG00000240875.4	LINC00886	-4.19	3.82e-05	0.0103	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901217	chr3:156747346~156817062:-
COAD	cis	rs987724	0.555	rs9866373	ENSG00000240875.4	LINC00886	-4.19	3.82e-05	0.0103	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901961	chr3:156747346~156817062:-
COAD	cis	rs6840360	0.582	rs4696260	ENSG00000270265.1	RP11-731D1.4	-4.19	3.82e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.515	rs11099811	ENSG00000270265.1	RP11-731D1.4	-4.19	3.82e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.582	rs7691601	ENSG00000270265.1	RP11-731D1.4	-4.19	3.82e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.582	rs59714108	ENSG00000270265.1	RP11-731D1.4	-4.19	3.82e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.582	rs6813735	ENSG00000270265.1	RP11-731D1.4	-4.19	3.83e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.582	rs57585665	ENSG00000270265.1	RP11-731D1.4	-4.19	3.83e-05	0.0103	-0.31	-0.25	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151333775~151353224:-
COAD	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	4.19	3.83e-05	0.0103	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
COAD	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	4.19	3.83e-05	0.0103	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	4.19	3.83e-05	0.0103	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	4.19	3.83e-05	0.0103	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	4.19	3.83e-05	0.0103	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	4.19	3.83e-05	0.0103	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
COAD	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-4.19	3.83e-05	0.0103	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
COAD	cis	rs9487051	0.872	rs1320612	ENSG00000219700.1	PTCHD3P3	4.19	3.83e-05	0.0103	0.26	0.25	Reticulocyte fraction of red cells;	chr6:109290787	chr6:109288571~109290503:-
COAD	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-4.19	3.83e-05	0.0103	-0.49	-0.25	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-4.19	3.83e-05	0.0103	-0.49	-0.25	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
COAD	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-4.19	3.83e-05	0.0103	-0.28	-0.25	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
COAD	cis	rs2638953	0.925	rs11049567	ENSG00000247934.4	RP11-967K21.1	4.19	3.83e-05	0.0103	0.27	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28163298~28190738:-
COAD	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	4.19	3.83e-05	0.0103	0.26	0.25	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
COAD	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	4.19	3.83e-05	0.0103	0.3	0.25	Height;	chr4:55522229	chr4:55540502~55540835:-
COAD	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-4.19	3.83e-05	0.0103	-0.25	-0.25	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
COAD	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	4.19	3.84e-05	0.0103	0.31	0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
COAD	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	4.19	3.84e-05	0.0103	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
COAD	cis	rs10876993	0.928	rs1689594	ENSG00000270039.1	RP11-571M6.17	4.19	3.84e-05	0.0103	0.28	0.25	Celiac disease or Rheumatoid arthritis;	chr12:57663373	chr12:57803838~57804415:+
COAD	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	4.19	3.84e-05	0.0103	0.3	0.25	Height;	chr4:55452295	chr4:55540502~55540835:-
COAD	cis	rs2638953	0.962	rs61922978	ENSG00000247934.4	RP11-967K21.1	-4.19	3.84e-05	0.0103	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs12372448	ENSG00000247934.4	RP11-967K21.1	-4.19	3.84e-05	0.0103	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.925	rs11049511	ENSG00000247934.4	RP11-967K21.1	-4.19	3.84e-05	0.0103	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28163298~28190738:-
COAD	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	4.19	3.84e-05	0.0103	0.38	0.25	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
COAD	cis	rs9450351	0.744	rs9450383	ENSG00000203875.9	SNHG5	-4.19	3.84e-05	0.0103	-0.5	-0.25	Interferon gamma-induced protein 10 levels;	chr6:86073540	chr6:85660950~85678736:-
COAD	cis	rs13256369	0.901	rs13251887	ENSG00000253981.4	ALG1L13P	4.19	3.85e-05	0.0104	0.36	0.25	Obesity-related traits;	chr8:8711168	chr8:8236003~8244667:-
COAD	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	4.19	3.85e-05	0.0104	0.19	0.25	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
COAD	cis	rs228614	0.536	rs223475	ENSG00000230069.3	LRRC37A15P	-4.19	3.85e-05	0.0104	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223474	ENSG00000230069.3	LRRC37A15P	-4.19	3.85e-05	0.0104	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102727274~102730721:-
COAD	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-4.19	3.85e-05	0.0104	-0.28	-0.25	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
COAD	cis	rs6723226	0.767	rs10172308	ENSG00000276334.1	AL133243.1	-4.19	3.85e-05	0.0104	-0.24	-0.25	Intelligence (multi-trait analysis);	chr2:32330691	chr2:32521927~32523547:+
COAD	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
COAD	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	4.19	3.85e-05	0.0104	0.32	0.25	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
COAD	cis	rs1930961	0.702	rs60835827	ENSG00000272942.1	CTA-246H3.12	-4.19	3.85e-05	0.0104	-0.59	-0.25	Bipolar disorder with mood-incongruent psychosis;	chr22:25473570	chr22:25434324~25435070:-
COAD	cis	rs1930961	0.702	rs73410917	ENSG00000272942.1	CTA-246H3.12	-4.19	3.85e-05	0.0104	-0.59	-0.25	Bipolar disorder with mood-incongruent psychosis;	chr22:25476723	chr22:25434324~25435070:-
COAD	cis	rs860295	0.836	rs35615695	ENSG00000223503.1	RP11-29H23.6	4.19	3.85e-05	0.0104	0.33	0.25	Body mass index;	chr1:155531223	chr1:155590601~155591262:-
COAD	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-4.19	3.85e-05	0.0104	-0.31	-0.25	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
COAD	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-4.19	3.85e-05	0.0104	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-4.19	3.85e-05	0.0104	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-4.19	3.85e-05	0.0104	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
COAD	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-4.19	3.85e-05	0.0104	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
COAD	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	4.19	3.85e-05	0.0104	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
COAD	cis	rs57561814	0.51	rs2066992	ENSG00000179428.2	AC073072.5	-4.19	3.86e-05	0.0104	-0.52	-0.25	Tonsillectomy;	chr7:22728630	chr7:22725395~22727620:-
COAD	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.19	3.86e-05	0.0104	0.32	0.25	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
COAD	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	4.19	3.86e-05	0.0104	0.3	0.25	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
COAD	cis	rs35264875	0.731	rs2924533	ENSG00000259799.1	RP11-554A11.9	-4.19	3.86e-05	0.0104	-0.35	-0.25	Blond vs. brown hair color;	chr11:69103533	chr11:69155910~69159752:+
COAD	cis	rs875971	0.862	rs6460282	ENSG00000224316.1	RP11-479O9.2	-4.19	3.86e-05	0.0104	-0.28	-0.25	Aortic root size;	chr7:66226259	chr7:65773620~65802067:+
COAD	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.19	3.86e-05	0.0104	0.35	0.25	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
COAD	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-4.19	3.86e-05	0.0104	-0.6	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
COAD	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-4.19	3.86e-05	0.0104	-0.6	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
COAD	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-4.19	3.86e-05	0.0104	-0.2	-0.25	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
COAD	cis	rs13333054	1	rs12232384	ENSG00000269667.1	RP11-542M13.2	4.19	3.86e-05	0.0104	0.33	0.25	Multiple sclerosis;	chr16:85976154	chr16:85981750~85984723:+
COAD	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	4.19	3.86e-05	0.0104	0.32	0.25	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
COAD	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	4.19	3.87e-05	0.0104	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
COAD	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-4.19	3.87e-05	0.0104	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
COAD	cis	rs7584330	0.518	rs11888077	ENSG00000234949.2	AC104667.3	-4.19	3.87e-05	0.0104	-0.44	-0.25	Prostate cancer;	chr2:237516120	chr2:237591020~237595981:+
COAD	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	4.19	3.87e-05	0.0104	0.34	0.25	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
COAD	cis	rs12908161	0.515	rs12907646	ENSG00000259728.4	LINC00933	4.19	3.88e-05	0.0104	0.36	0.25	Schizophrenia;	chr15:84860265	chr15:84570649~84580175:+
COAD	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	4.19	3.88e-05	0.0104	0.34	0.25	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
COAD	cis	rs11124272	0.857	rs11683744	ENSG00000272716.1	RP11-563N4.1	-4.19	3.88e-05	0.0104	-0.29	-0.25	Interleukin-18 levels;	chr2:31760239	chr2:32165046~32165757:-
COAD	cis	rs1670533	1	rs11724371	ENSG00000273179.1	RP11-20I20.4	4.19	3.88e-05	0.0104	0.34	0.25	Recombination rate (females);	chr4:1058337	chr4:1167778~1168174:+
COAD	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-4.19	3.88e-05	0.0104	-0.25	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
COAD	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-4.19	3.88e-05	0.0104	-0.24	-0.25	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
COAD	cis	rs11650494	0.71	rs74619404	ENSG00000257178.3	RP11-357H14.16	4.19	3.88e-05	0.0104	0.51	0.25	Prostate cancer;	chr17:49407083	chr17:48579630~48582259:-
COAD	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-4.19	3.88e-05	0.0104	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
COAD	cis	rs56052703	0.536	rs2292034	ENSG00000267633.1	CTB-5E10.3	4.19	3.88e-05	0.0104	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13316853	chr19:13772118~13774118:-
COAD	cis	rs11124272	0.859	rs11678843	ENSG00000272716.1	RP11-563N4.1	-4.19	3.89e-05	0.0104	-0.29	-0.25	Interleukin-18 levels;	chr2:31736113	chr2:32165046~32165757:-
COAD	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	4.19	3.89e-05	0.0104	0.28	0.25	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
COAD	cis	rs250677	0.687	rs250679	ENSG00000250072.4	CTC-529P8.1	4.19	3.89e-05	0.0104	0.36	0.25	Breast cancer;	chr5:149055389	chr5:149063317~149109787:+
COAD	cis	rs6545883	0.507	rs4672427	ENSG00000273302.1	RP11-493E12.2	-4.19	3.89e-05	0.0105	-0.23	-0.25	Tuberculosis;	chr2:61242115	chr2:61199979~61200769:+
COAD	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	4.19	3.89e-05	0.0105	0.19	0.25	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	4.19	3.89e-05	0.0105	0.19	0.25	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
COAD	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-4.19	3.89e-05	0.0105	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
COAD	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	4.19	3.89e-05	0.0105	0.37	0.25	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
COAD	cis	rs8022206	0.898	rs72725159	ENSG00000259502.1	RP11-643G16.3	4.19	3.89e-05	0.0105	0.41	0.25	Platelet count;Mean platelet volume;	chr14:68010546	chr14:67610986~67613864:+
COAD	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-4.19	3.89e-05	0.0105	-0.27	-0.25	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
COAD	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-4.19	3.89e-05	0.0105	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
COAD	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-4.19	3.89e-05	0.0105	-0.34	-0.25	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
COAD	cis	rs7845219	0.597	rs7002058	ENSG00000253528.2	RP11-347C18.4	4.19	3.89e-05	0.0105	0.26	0.25	Type 2 diabetes;	chr8:94861765	chr8:94974573~94974853:-
COAD	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	4.19	3.9e-05	0.0105	0.32	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
COAD	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-4.19	3.9e-05	0.0105	-0.27	-0.25	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
COAD	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-4.19	3.9e-05	0.0105	-0.36	-0.25	Depression;	chr6:28159925	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-4.19	3.9e-05	0.0105	-0.36	-0.25	Depression;	chr6:28159932	chr6:28115628~28116551:+
COAD	cis	rs1630500	0.793	rs1218583	ENSG00000271380.1	RP11-307C12.12	4.19	3.9e-05	0.0105	0.49	0.25	Parkinson's disease;	chr1:154861502	chr1:154961825~154962623:+
COAD	cis	rs7138300	0.528	rs11178575	ENSG00000258053.1	CTD-2021H9.3	-4.19	3.9e-05	0.0105	-0.35	-0.25	Type 2 diabetes;	chr12:71058501	chr12:71047402~71118247:-
COAD	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	4.19	3.9e-05	0.0105	0.34	0.25	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
COAD	cis	rs9652601	0.691	rs12708717	ENSG00000274038.1	RP11-66H6.4	-4.19	3.9e-05	0.0105	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11098522	chr16:11056556~11057034:+
COAD	cis	rs9652601	0.608	rs8061826	ENSG00000274038.1	RP11-66H6.4	-4.19	3.9e-05	0.0105	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11098930	chr16:11056556~11057034:+
COAD	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.19	3.9e-05	0.0105	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
COAD	cis	rs913655	0.508	rs10763624	ENSG00000240291.1	RP11-499P20.2	4.19	3.9e-05	0.0105	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18744832	chr10:18513115~18545651:-
COAD	cis	rs7487075	0.78	rs1873793	ENSG00000274723.1	RP11-618L22.1	-4.19	3.91e-05	0.0105	-0.27	-0.25	Itch intensity from mosquito bite;	chr12:46367541	chr12:46970504~46972155:+
COAD	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-4.19	3.91e-05	0.0105	-0.26	-0.25	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
COAD	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-4.19	3.91e-05	0.0105	-0.33	-0.25	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
COAD	cis	rs875971	0.767	rs12668005	ENSG00000224316.1	RP11-479O9.2	4.19	3.91e-05	0.0105	0.27	0.25	Aortic root size;	chr7:66444034	chr7:65773620~65802067:+
COAD	cis	rs11681884	0.71	rs2071459	ENSG00000228251.1	AC012442.6	4.19	3.91e-05	0.0105	0.44	0.25	Stroke;	chr2:113129906	chr2:112590796~112591939:+
COAD	cis	rs72615157	0.634	rs74774557	ENSG00000078319.8	PMS2P1	-4.19	3.91e-05	0.0105	-0.35	-0.25	Lung function (FEV1/FVC);	chr7:100212802	chr7:100320992~100341908:-
COAD	cis	rs6982240	0.514	rs10093988	ENSG00000253307.1	RP11-10J21.4	4.19	3.91e-05	0.0105	0.34	0.25	Tonsillectomy;	chr8:141250896	chr8:141252286~141253292:-
COAD	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-4.19	3.91e-05	0.0105	-0.27	-0.25	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
COAD	cis	rs5753037	0.543	rs140119	ENSG00000279159.1	RP3-394A18.1	-4.19	3.91e-05	0.0105	-0.17	-0.25	Type 1 diabetes;	chr22:29742160	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.543	rs140122	ENSG00000279159.1	RP3-394A18.1	-4.19	3.91e-05	0.0105	-0.17	-0.25	Type 1 diabetes;	chr22:29742919	chr22:29978950~30028236:-
COAD	cis	rs7829975	0.774	rs13259216	ENSG00000233609.3	RP11-62H7.2	4.19	3.91e-05	0.0105	0.28	0.25	Mood instability;	chr8:8816091	chr8:8961200~8979025:+
COAD	cis	rs17685	0.712	rs28456330	ENSG00000280388.1	RP11-229D13.3	-4.19	3.91e-05	0.0105	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76181224	chr7:76043977~76045963:-
COAD	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-4.19	3.92e-05	0.0105	-0.26	-0.25	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
COAD	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-4.19	3.92e-05	0.0105	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
COAD	cis	rs875971	0.545	rs1638735	ENSG00000232546.1	RP11-458F8.1	4.19	3.92e-05	0.0105	0.25	0.25	Aortic root size;	chr7:66630751	chr7:66848496~66858136:+
COAD	cis	rs8046148	0.724	rs7190890	ENSG00000260381.2	RP11-429P3.5	-4.18	3.92e-05	0.0105	-0.33	-0.25	Testicular germ cell tumor;	chr16:50091945	chr16:50100339~50121943:-
COAD	cis	rs875971	0.66	rs2191268	ENSG00000224316.1	RP11-479O9.2	4.18	3.92e-05	0.0105	0.25	0.25	Aortic root size;	chr7:66645237	chr7:65773620~65802067:+
COAD	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	4.18	3.93e-05	0.0105	0.32	0.25	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
COAD	cis	rs12682352	0.602	rs11783966	ENSG00000173295.6	FAM86B3P	-4.18	3.93e-05	0.0105	-0.28	-0.25	Neuroticism;	chr8:8807637	chr8:8228595~8244865:+
COAD	cis	rs2115630	0.967	rs12595786	ENSG00000259728.4	LINC00933	-4.18	3.93e-05	0.0105	-0.3	-0.25	P wave terminal force;	chr15:84793439	chr15:84570649~84580175:+
COAD	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	4.18	3.93e-05	0.0105	0.34	0.25	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
COAD	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	4.18	3.93e-05	0.0105	0.34	0.25	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
COAD	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	4.18	3.93e-05	0.0105	0.34	0.25	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	4.18	3.93e-05	0.0105	0.34	0.25	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
COAD	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	4.18	3.93e-05	0.0105	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
COAD	cis	rs84178	0.683	rs231875	ENSG00000230834.1	AC068580.7	-4.18	3.94e-05	0.0106	-0.42	-0.25	Glomerular filtration rate (creatinine);	chr11:2763601	chr11:1776930~1778388:-
COAD	cis	rs2559856	1	rs2695282	ENSG00000199933.1	RNY1P16	-4.18	3.94e-05	0.0106	-0.27	-0.25	Blood protein levels;	chr12:101695724	chr12:101719808~101719918:+
COAD	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-4.18	3.94e-05	0.0106	-0.35	-0.25	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
COAD	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-4.18	3.95e-05	0.0106	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
COAD	cis	rs7129556	0.621	rs663674	ENSG00000254691.1	RP11-91P24.5	4.18	3.95e-05	0.0106	0.3	0.25	Weight loss (gastric bypass surgery);	chr11:77881476	chr11:77850604~77851511:+
COAD	cis	rs875971	0.83	rs427575	ENSG00000224316.1	RP11-479O9.2	4.18	3.95e-05	0.0106	0.27	0.25	Aortic root size;	chr7:66054232	chr7:65773620~65802067:+
COAD	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	4.18	3.95e-05	0.0106	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
COAD	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	4.18	3.95e-05	0.0106	0.16	0.25	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
COAD	cis	rs7572733	0.84	rs10497807	ENSG00000222017.1	AC011997.1	-4.18	3.95e-05	0.0106	-0.28	-0.25	Dermatomyositis;	chr2:197720363	chr2:197693106~197774823:+
COAD	cis	rs9880211	0.898	rs6770476	ENSG00000273486.1	RP11-731C17.2	4.18	3.96e-05	0.0106	0.28	0.25	Height;Body mass index;	chr3:136355078	chr3:136837338~136839021:-
COAD	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	4.18	3.96e-05	0.0106	0.34	0.25	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
COAD	cis	rs12530	0.715	rs5749416	ENSG00000241954.1	RP1-149A16.17	4.18	3.96e-05	0.0106	0.32	0.25	IgG glycosylation;	chr22:32381136	chr22:32383786~32385631:+
COAD	cis	rs2732480	0.5	rs12828309	ENSG00000226413.2	OR8T1P	4.18	3.96e-05	0.0106	0.31	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48442030~48442947:-
COAD	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	4.18	3.96e-05	0.0106	0.42	0.25	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
COAD	cis	rs1381660	0.595	rs830459	ENSG00000249395.2	CASC9	-4.18	3.96e-05	0.0106	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;	chr8:76056824	chr8:75223404~75324741:-
COAD	cis	rs2564921	0.704	rs56058643	ENSG00000280417.1	RP11-5O17.1	4.18	3.96e-05	0.0106	0.27	0.25	Height;	chr3:53093751	chr3:53046166~53048122:+
COAD	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	4.18	3.96e-05	0.0106	0.26	0.25	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
COAD	cis	rs17407555	0.657	rs12505222	ENSG00000250413.1	RP11-448G15.1	-4.18	3.96e-05	0.0106	-0.34	-0.25	Schizophrenia (age at onset);	chr4:10269512	chr4:10006482~10009725:+
COAD	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-4.18	3.96e-05	0.0106	-0.34	-0.25	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
COAD	cis	rs4973517	0.727	rs3116229	ENSG00000237126.7	AC073254.1	-4.18	3.96e-05	0.0106	-0.36	-0.25	Hip circumference adjusted for BMI;	chr2:232026538	chr2:232580948~232611971:-
COAD	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	4.18	3.96e-05	0.0106	0.36	0.25	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
COAD	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-4.18	3.97e-05	0.0106	-0.25	-0.25	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-4.18	3.97e-05	0.0106	-0.25	-0.25	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
COAD	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.18	3.97e-05	0.0106	0.38	0.25	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
COAD	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-4.18	3.97e-05	0.0106	-0.51	-0.25	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-4.18	3.97e-05	0.0106	-0.51	-0.25	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-4.18	3.97e-05	0.0106	-0.51	-0.25	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-4.18	3.97e-05	0.0106	-0.51	-0.25	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-4.18	3.97e-05	0.0106	-0.51	-0.25	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
COAD	cis	rs8002861	0.846	rs12428314	ENSG00000274001.1	RP11-5G9.5	-4.18	3.97e-05	0.0106	-0.24	-0.25	Leprosy;	chr13:43901875	chr13:43877715~43878163:-
COAD	cis	rs6840360	0.582	rs2724553	ENSG00000251611.1	RP11-610P16.1	-4.18	3.97e-05	0.0106	-0.25	-0.25	Intelligence (multi-trait analysis);	chr4:151400729	chr4:151407551~151408835:-
COAD	cis	rs8061903	0.535	rs1001897	ENSG00000261617.1	RP11-243A14.1	4.18	3.97e-05	0.0106	0.31	0.25	HIV-1 viral setpoint;	chr16:9315247	chr16:9355588~9408093:+
COAD	cis	rs8022206	0.773	rs2208596	ENSG00000259502.1	RP11-643G16.3	4.18	3.97e-05	0.0106	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68033447	chr14:67610986~67613864:+
COAD	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-4.18	3.97e-05	0.0106	-0.35	-0.25	Depression;	chr6:28126588	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-4.18	3.97e-05	0.0106	-0.35	-0.25	Depression;	chr6:28126953	chr6:28115628~28116551:+
COAD	cis	rs1275468	1	rs1275469	ENSG00000257497.2	RP11-585P4.5	-4.18	3.97e-05	0.0106	-0.33	-0.25	Polycystic ovary syndrome;	chr12:75541450	chr12:75483454~75489820:-
COAD	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	4.18	3.97e-05	0.0106	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
COAD	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-4.18	3.98e-05	0.0107	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-4.18	3.98e-05	0.0107	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
COAD	cis	rs4843747	0.619	rs66508972	ENSG00000205037.2	RP11-863P13.4	4.18	3.98e-05	0.0107	0.32	0.25	Menopause (age at onset);	chr16:88052779	chr16:88088041~88100985:-
COAD	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	4.18	3.98e-05	0.0107	0.4	0.25	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
COAD	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	4.18	3.98e-05	0.0107	0.32	0.25	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
COAD	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-4.18	3.98e-05	0.0107	-0.4	-0.25	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
COAD	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	4.18	3.98e-05	0.0107	0.34	0.25	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
COAD	cis	rs763121	0.744	rs5757140	ENSG00000273076.1	RP3-508I15.22	4.18	3.98e-05	0.0107	0.24	0.25	Menopause (age at onset);	chr22:38561008	chr22:38743495~38743910:+
COAD	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	4.18	3.98e-05	0.0107	0.47	0.25	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
COAD	cis	rs763121	0.853	rs3761454	ENSG00000273076.1	RP3-508I15.22	4.18	3.98e-05	0.0107	0.22	0.25	Menopause (age at onset);	chr22:38670815	chr22:38743495~38743910:+
COAD	cis	rs494562	0.892	rs683218	ENSG00000234155.1	RP11-30P6.6	-4.18	3.99e-05	0.0107	-0.44	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85408866	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs7750970	ENSG00000234155.1	RP11-30P6.6	-4.18	3.99e-05	0.0107	-0.44	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85418852	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs4624841	ENSG00000234155.1	RP11-30P6.6	-4.18	3.99e-05	0.0107	-0.44	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85420533	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs7771860	ENSG00000234155.1	RP11-30P6.6	-4.18	3.99e-05	0.0107	-0.44	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85421011	chr6:85387219~85390186:-
COAD	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	4.18	3.99e-05	0.0107	0.3	0.25	Height;	chr4:55436423	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	4.18	3.99e-05	0.0107	0.3	0.25	Height;	chr4:55437438	chr4:55540502~55540835:-
COAD	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	4.18	3.99e-05	0.0107	0.49	0.25	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
COAD	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	4.18	3.99e-05	0.0107	0.32	0.25	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
COAD	cis	rs2361718	0.501	rs11869566	ENSG00000279259.1	RP11-334C17.3	4.18	3.99e-05	0.0107	0.29	0.25	Yeast infection;	chr17:80169449	chr17:80147250~80148596:+
COAD	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-4.18	3.99e-05	0.0107	-0.31	-0.25	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
COAD	cis	rs812925	0.519	rs967968	ENSG00000273302.1	RP11-493E12.2	-4.18	3.99e-05	0.0107	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61428921	chr2:61199979~61200769:+
COAD	cis	rs9400467	0.508	rs11153293	ENSG00000271789.1	RP5-1112D6.7	-4.18	4e-05	0.0107	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.508	rs11756643	ENSG00000271789.1	RP5-1112D6.7	-4.18	4e-05	0.0107	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111297126~111298510:+
COAD	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-4.18	4e-05	0.0107	-0.3	-0.25	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
COAD	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	4.18	4e-05	0.0107	0.35	0.25	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
COAD	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-4.18	4e-05	0.0107	-0.32	-0.25	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
COAD	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-4.18	4e-05	0.0107	-0.31	-0.25	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
COAD	cis	rs812925	0.519	rs1186696	ENSG00000273302.1	RP11-493E12.2	4.18	4e-05	0.0107	0.23	0.25	Immature fraction of reticulocytes;	chr2:61433348	chr2:61199979~61200769:+
COAD	cis	rs812925	0.502	rs6545868	ENSG00000273302.1	RP11-493E12.2	-4.18	4e-05	0.0107	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61428230	chr2:61199979~61200769:+
COAD	cis	rs2243480	0.901	rs35256305	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65841418	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs35825738	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65853040	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs34702770	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65879836	chr7:66554588~66576923:-
COAD	cis	rs2243480	0.803	rs35480979	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65892097	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs34637256	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65895144	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs35391607	ENSG00000232559.3	GS1-124K5.12	4.18	4e-05	0.0107	0.44	0.25	Diabetic kidney disease;	chr7:65895842	chr7:66554588~66576923:-
COAD	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	4.18	4e-05	0.0107	0.34	0.25	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
COAD	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	4.18	4e-05	0.0107	0.32	0.25	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
COAD	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-4.18	4e-05	0.0107	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
COAD	cis	rs12699921	0.632	rs2691609	ENSG00000279048.1	RP11-511H23.2	-4.18	4e-05	0.0107	-0.18	-0.25	Fibrinogen levels;	chr7:17841539	chr7:17940503~17942922:+
COAD	cis	rs2115630	0.905	rs1975277	ENSG00000259728.4	LINC00933	-4.18	4e-05	0.0107	-0.3	-0.25	P wave terminal force;	chr15:84786327	chr15:84570649~84580175:+
COAD	cis	rs9393813	0.566	rs12662076	ENSG00000271755.1	RP1-153G14.4	4.18	4e-05	0.0107	0.3	0.25	Bipolar disorder;	chr6:27395358	chr6:27404010~27406964:-
COAD	cis	rs80346118	0.929	rs6095299	ENSG00000177410.11	ZFAS1	-4.18	4e-05	0.0107	-0.31	-0.25	Diastolic blood pressure;	chr20:48798488	chr20:49278178~49295738:+
COAD	cis	rs7829975	0.774	rs35431455	ENSG00000233609.3	RP11-62H7.2	4.18	4.01e-05	0.0107	0.29	0.25	Mood instability;	chr8:8816226	chr8:8961200~8979025:+
COAD	cis	rs253959	0.607	rs1396497	ENSG00000271918.1	CTD-2287O16.5	4.18	4.01e-05	0.0107	0.24	0.25	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116083807~116085416:-
COAD	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-4.18	4.01e-05	0.0107	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
COAD	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	4.18	4.01e-05	0.0107	0.45	0.25	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	4.18	4.01e-05	0.0107	0.45	0.25	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	4.18	4.01e-05	0.0107	0.45	0.25	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
COAD	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-4.18	4.01e-05	0.0107	-0.29	-0.25	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
COAD	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-4.18	4.02e-05	0.0107	-0.35	-0.25	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
COAD	cis	rs2337406	0.925	rs10131226	ENSG00000211964.3	IGHV3-48	-4.18	4.02e-05	0.0107	-0.21	-0.25	Alzheimer's disease (late onset);	chr14:106665764	chr14:106537810~106538344:-
COAD	cis	rs12682352	0.715	rs332039	ENSG00000173295.6	FAM86B3P	4.18	4.02e-05	0.0107	0.31	0.25	Neuroticism;	chr8:8866141	chr8:8228595~8244865:+
COAD	cis	rs3120667	0.72	rs72698947	ENSG00000237975.5	FLG-AS1	4.18	4.02e-05	0.0107	0.35	0.25	Eating disorders;	chr1:152429861	chr1:152168125~152445456:+
COAD	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	4.18	4.02e-05	0.0107	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
COAD	cis	rs7572733	0.84	rs4850437	ENSG00000222017.1	AC011997.1	-4.18	4.02e-05	0.0107	-0.29	-0.25	Dermatomyositis;	chr2:197704327	chr2:197693106~197774823:+
COAD	cis	rs6982240	0.514	rs11778579	ENSG00000253307.1	RP11-10J21.4	4.18	4.02e-05	0.0107	0.34	0.25	Tonsillectomy;	chr8:141251522	chr8:141252286~141253292:-
COAD	cis	rs17685	0.753	rs869806	ENSG00000280388.1	RP11-229D13.3	-4.18	4.02e-05	0.0107	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76043977~76045963:-
COAD	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	4.18	4.02e-05	0.0107	0.57	0.25	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	4.18	4.02e-05	0.0107	0.57	0.25	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	4.18	4.02e-05	0.0107	0.57	0.25	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
COAD	cis	rs6687821	0.506	rs559491	ENSG00000261737.1	RP4-612B15.3	-4.18	4.03e-05	0.0108	-0.41	-0.25	Yeast infection;	chr1:86853136	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.548	rs492624	ENSG00000261737.1	RP4-612B15.3	-4.18	4.03e-05	0.0108	-0.41	-0.25	Yeast infection;	chr1:86854981	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.548	rs539915	ENSG00000261737.1	RP4-612B15.3	-4.18	4.03e-05	0.0108	-0.41	-0.25	Yeast infection;	chr1:86856101	chr1:86703502~86704462:-
COAD	cis	rs9532669	0.963	rs1056835	ENSG00000239827.7	SUGT1P3	-4.18	4.03e-05	0.0108	-0.22	-0.25	Cervical cancer;	chr13:40932585	chr13:40908159~40921774:-
COAD	cis	rs597539	0.552	rs6591360	ENSG00000255741.1	RP11-757G1.5	-4.18	4.03e-05	0.0108	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68941503~68942852:-
COAD	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-4.18	4.03e-05	0.0108	-0.28	-0.25	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
COAD	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-4.18	4.03e-05	0.0108	-0.25	-0.25	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
COAD	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-4.18	4.03e-05	0.0108	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
COAD	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-4.18	4.03e-05	0.0108	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
COAD	cis	rs875971	0.862	rs6952182	ENSG00000224316.1	RP11-479O9.2	-4.18	4.03e-05	0.0108	-0.28	-0.25	Aortic root size;	chr7:66218330	chr7:65773620~65802067:+
COAD	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-4.18	4.04e-05	0.0108	-0.26	-0.25	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
COAD	cis	rs6543140	0.964	rs4851589	ENSG00000234389.1	AC007278.3	4.18	4.04e-05	0.0108	0.26	0.25	Blood protein levels;	chr2:102460685	chr2:102438713~102440475:+
COAD	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	4.18	4.04e-05	0.0108	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
COAD	cis	rs728616	0.867	rs56198874	ENSG00000234382.2	RP11-40F6.1	-4.18	4.04e-05	0.0108	-0.47	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:80233664~80245367:+
COAD	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	4.18	4.04e-05	0.0108	0.36	0.25	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
COAD	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	4.18	4.04e-05	0.0108	0.28	0.25	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
COAD	cis	rs6585424	0.929	rs12256429	ENSG00000234382.2	RP11-40F6.1	-4.18	4.04e-05	0.0108	-0.4	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:80233664~80245367:+
COAD	cis	rs6095360	0.727	rs35393280	ENSG00000222365.1	SNORD12B	-4.18	4.04e-05	0.0108	-0.27	-0.25	Intelligence (multi-trait analysis);	chr20:48927097	chr20:49280319~49280409:+
COAD	cis	rs453301	0.686	rs7814328	ENSG00000233609.3	RP11-62H7.2	-4.18	4.04e-05	0.0108	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9018719	chr8:8961200~8979025:+
COAD	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	4.18	4.04e-05	0.0108	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	4.18	4.04e-05	0.0108	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	4.18	4.04e-05	0.0108	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
COAD	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	4.18	4.04e-05	0.0108	0.33	0.25	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
COAD	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	4.18	4.04e-05	0.0108	0.44	0.25	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
COAD	cis	rs763121	0.853	rs5750621	ENSG00000273076.1	RP3-508I15.22	4.18	4.04e-05	0.0108	0.24	0.25	Menopause (age at onset);	chr22:38560161	chr22:38743495~38743910:+
COAD	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	4.18	4.04e-05	0.0108	0.28	0.25	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
COAD	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	4.18	4.04e-05	0.0108	0.34	0.25	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
COAD	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-4.18	4.04e-05	0.0108	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
COAD	cis	rs7818688	0.585	rs2678829	ENSG00000253528.2	RP11-347C18.4	4.18	4.05e-05	0.0108	0.32	0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015952	chr8:94974573~94974853:-
COAD	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-4.18	4.05e-05	0.0108	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-4.18	4.05e-05	0.0108	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
COAD	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	4.18	4.05e-05	0.0108	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
COAD	cis	rs3752645	0.881	rs77363449	ENSG00000241764.3	AC002467.7	4.18	4.05e-05	0.0108	0.44	0.25	Bladder cancer (smoking interaction);	chr7:107076333	chr7:107742817~107744581:-
COAD	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-4.18	4.05e-05	0.0108	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
COAD	cis	rs860295	0.729	rs11264369	ENSG00000223503.1	RP11-29H23.6	4.18	4.05e-05	0.0108	0.34	0.25	Body mass index;	chr1:155390039	chr1:155590601~155591262:-
COAD	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-4.18	4.05e-05	0.0108	-0.33	-0.25	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
COAD	cis	rs603446	0.61	rs1268832	ENSG00000254851.1	RP11-109L13.1	4.18	4.05e-05	0.0108	0.29	0.25	Triglycerides;	chr11:116704513	chr11:117135528~117138582:+
COAD	cis	rs11681884	0.892	rs73955151	ENSG00000228251.1	AC012442.6	4.18	4.05e-05	0.0108	0.54	0.25	Stroke;	chr2:113103648	chr2:112590796~112591939:+
COAD	cis	rs8020095	0.571	rs7156655	ENSG00000196553.12	LINC00238	-4.18	4.05e-05	0.0108	-0.34	-0.25	Depression (quantitative trait);	chr14:66889344	chr14:66486354~66498553:+
COAD	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-4.18	4.06e-05	0.0108	-0.32	-0.25	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
COAD	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-4.18	4.06e-05	0.0108	-0.22	-0.25	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
COAD	cis	rs11089937	0.616	rs5995615	ENSG00000211638.2	IGLV8-61	-4.18	4.06e-05	0.0108	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs6001223	ENSG00000211638.2	IGLV8-61	-4.18	4.06e-05	0.0108	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22098700~22099212:+
COAD	cis	rs2243480	1	rs1404147	ENSG00000229886.1	RP5-1132H15.3	4.18	4.06e-05	0.0108	0.38	0.25	Diabetic kidney disease;	chr7:65799537	chr7:66025126~66031544:-
COAD	cis	rs6687821	0.515	rs5859	ENSG00000261737.1	RP4-612B15.3	-4.18	4.06e-05	0.0108	-0.33	-0.25	Yeast infection;	chr1:86862842	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs554213	ENSG00000261737.1	RP4-612B15.3	-4.18	4.06e-05	0.0108	-0.33	-0.25	Yeast infection;	chr1:86876474	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs576955	ENSG00000261737.1	RP4-612B15.3	-4.18	4.06e-05	0.0108	-0.33	-0.25	Yeast infection;	chr1:86876627	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs502404	ENSG00000261737.1	RP4-612B15.3	-4.18	4.06e-05	0.0108	-0.33	-0.25	Yeast infection;	chr1:86878204	chr1:86703502~86704462:-
COAD	cis	rs10819861	0.62	rs10989244	ENSG00000238251.2	RP11-172F4.2	-4.18	4.06e-05	0.0108	-0.31	-0.25	Electrocardiographic traits;	chr9:96094490	chr9:96407284~96407797:+
COAD	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	4.18	4.06e-05	0.0108	0.3	0.25	Height;	chr4:55457922	chr4:55363971~55395847:-
COAD	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-4.18	4.06e-05	0.0108	-0.27	-0.25	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
COAD	cis	rs734999	1	rs10797432	ENSG00000225931.3	RP3-395M20.7	4.18	4.07e-05	0.0108	0.27	0.25	Ulcerative colitis;	chr1:2569899	chr1:2566410~2569888:+
COAD	cis	rs7138300	0.528	rs1398562	ENSG00000258053.1	CTD-2021H9.3	-4.18	4.07e-05	0.0108	-0.34	-0.25	Type 2 diabetes;	chr12:71052213	chr12:71047402~71118247:-
COAD	cis	rs9847710	1	rs6770152	ENSG00000242142.1	SERBP1P3	4.18	4.07e-05	0.0108	0.28	0.25	Ulcerative colitis;	chr3:53066198	chr3:53064283~53065091:-
COAD	cis	rs2281603	0.762	rs10132794	ENSG00000259116.1	RP11-973N13.4	-4.18	4.07e-05	0.0108	-0.28	-0.25	Lymphocyte counts;	chr14:64581793	chr14:64514154~64540368:-
COAD	cis	rs9818758	0.607	rs11716445	ENSG00000225399.4	RP11-3B7.1	-4.18	4.07e-05	0.0108	-0.54	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49368662	chr3:49260085~49261316:+
COAD	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0108	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
COAD	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-4.18	4.07e-05	0.0109	-0.26	-0.25	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
COAD	cis	rs9450351	0.744	rs9362225	ENSG00000234155.1	RP11-30P6.6	-4.18	4.07e-05	0.0109	-0.52	-0.25	Interferon gamma-induced protein 10 levels;	chr6:85500713	chr6:85387219~85390186:-
COAD	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-4.18	4.07e-05	0.0109	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
COAD	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0109	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0109	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0109	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0109	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-4.18	4.07e-05	0.0109	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
COAD	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	4.18	4.07e-05	0.0109	0.32	0.25	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	4.18	4.07e-05	0.0109	0.32	0.25	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	4.18	4.07e-05	0.0109	0.32	0.25	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
COAD	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	4.18	4.07e-05	0.0109	0.21	0.25	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
COAD	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28159666	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28162598	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28173770	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28174809	chr6:28115628~28116551:+
COAD	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28175233	chr6:28115628~28116551:+
COAD	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-4.18	4.08e-05	0.0109	-0.36	-0.25	Depression;	chr6:28176973	chr6:28115628~28116551:+
COAD	cis	rs801193	0.548	rs7805152	ENSG00000224316.1	RP11-479O9.2	4.18	4.08e-05	0.0109	0.27	0.25	Aortic root size;	chr7:66744266	chr7:65773620~65802067:+
COAD	cis	rs71636778	0.509	rs12741472	ENSG00000260063.1	RP5-968P14.2	-4.18	4.08e-05	0.0109	-0.52	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895118	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.57	rs34026565	ENSG00000260063.1	RP5-968P14.2	-4.18	4.08e-05	0.0109	-0.52	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903485	chr1:26692132~26694131:-
COAD	cis	rs2836974	0.831	rs4375956	ENSG00000255568.3	BRWD1-AS2	4.18	4.08e-05	0.0109	0.26	0.25	Cognitive function;	chr21:39149862	chr21:39313935~39314962:+
COAD	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	4.17	4.08e-05	0.0109	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
COAD	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	4.17	4.08e-05	0.0109	0.42	0.25	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
COAD	cis	rs9400467	0.528	rs6933627	ENSG00000230177.1	RP5-1112D6.4	-4.17	4.08e-05	0.0109	-0.22	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111277932~111278742:+
COAD	cis	rs2281603	0.517	rs10134770	ENSG00000259116.1	RP11-973N13.4	-4.17	4.09e-05	0.0109	-0.26	-0.25	Lymphocyte counts;	chr14:64596597	chr14:64514154~64540368:-
COAD	cis	rs3764400	0.567	rs741058	ENSG00000278765.1	RP5-890E16.5	-4.17	4.09e-05	0.0109	-0.48	-0.25	Body mass index;	chr17:48127991	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs2109983	ENSG00000278765.1	RP5-890E16.5	-4.17	4.09e-05	0.0109	-0.48	-0.25	Body mass index;	chr17:48129786	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.517	rs7209042	ENSG00000278765.1	RP5-890E16.5	-4.17	4.09e-05	0.0109	-0.48	-0.25	Body mass index;	chr17:48130430	chr17:48066704~48067293:-
COAD	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-4.17	4.09e-05	0.0109	-0.39	-0.25	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
COAD	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-4.17	4.09e-05	0.0109	-0.27	-0.25	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
COAD	cis	rs2732480	0.557	rs2732454	ENSG00000257735.1	RP11-370I10.6	4.17	4.09e-05	0.0109	0.31	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48350945~48442411:+
COAD	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.17	4.09e-05	0.0109	-0.31	-0.25	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
COAD	cis	rs11098499	0.909	rs10017335	ENSG00000250412.1	KLHL2P1	-4.17	4.1e-05	0.0109	-0.34	-0.25	Corneal astigmatism;	chr4:119460368	chr4:119334329~119378233:+
COAD	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-4.17	4.1e-05	0.0109	-0.48	-0.25	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
COAD	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	4.17	4.1e-05	0.0109	0.23	0.25	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
COAD	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-4.17	4.1e-05	0.0109	-0.29	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
COAD	cis	rs2638953	0.815	rs11049634	ENSG00000247934.4	RP11-967K21.1	4.17	4.1e-05	0.0109	0.26	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461296	chr12:28163298~28190738:-
COAD	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
COAD	cis	rs2638953	0.924	rs11049607	ENSG00000247934.4	RP11-967K21.1	-4.17	4.1e-05	0.0109	-0.25	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444574	chr12:28163298~28190738:-
COAD	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	4.17	4.1e-05	0.0109	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
COAD	cis	rs9307551	0.779	rs12501981	ENSG00000250334.4	LINC00989	-4.17	4.1e-05	0.0109	-0.3	-0.25	Refractive error;	chr4:79591850	chr4:79492416~79576460:+
COAD	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-4.17	4.1e-05	0.0109	-0.4	-0.25	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
COAD	cis	rs11603023	0.804	rs527619	ENSG00000278376.1	RP11-158I9.8	4.17	4.1e-05	0.0109	0.25	0.25	Cholesterol, total;	chr11:118692577	chr11:118791254~118793137:+
COAD	cis	rs763121	0.853	rs5757187	ENSG00000273076.1	RP3-508I15.22	-4.17	4.11e-05	0.0109	-0.22	-0.25	Menopause (age at onset);	chr22:38625517	chr22:38743495~38743910:+
COAD	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	4.17	4.11e-05	0.0109	0.45	0.25	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
COAD	cis	rs1005224	0.963	rs11623813	ENSG00000258454.1	RP11-361H10.3	4.17	4.11e-05	0.0109	0.31	0.25	Large artery stroke;	chr14:75671851	chr14:76235817~76263474:+
COAD	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-4.17	4.11e-05	0.0109	-0.3	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
COAD	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-4.17	4.11e-05	0.0109	-0.3	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
COAD	cis	rs2243480	1	rs73142121	ENSG00000232559.3	GS1-124K5.12	4.17	4.11e-05	0.0109	0.44	0.25	Diabetic kidney disease;	chr7:65846219	chr7:66554588~66576923:-
COAD	cis	rs2243480	0.803	rs34004500	ENSG00000232559.3	GS1-124K5.12	4.17	4.11e-05	0.0109	0.44	0.25	Diabetic kidney disease;	chr7:65847191	chr7:66554588~66576923:-
COAD	cis	rs11719291	0.915	rs11557629	ENSG00000225399.4	RP11-3B7.1	-4.17	4.11e-05	0.0109	-0.39	-0.25	Cognitive function;	chr3:48694790	chr3:49260085~49261316:+
COAD	cis	rs7246657	0.714	rs12972195	ENSG00000226686.6	LINC01535	-4.17	4.11e-05	0.0109	-0.36	-0.25	Coronary artery calcification;	chr19:37261603	chr19:37251912~37265535:+
COAD	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-4.17	4.11e-05	0.0109	-0.36	-0.25	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
COAD	cis	rs8177876	0.841	rs8177851	ENSG00000261061.1	RP11-303E16.2	-4.17	4.11e-05	0.0109	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81030770~81031485:+
COAD	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-4.17	4.12e-05	0.0109	-0.22	-0.25	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
COAD	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	4.17	4.12e-05	0.0109	0.32	0.25	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
COAD	cis	rs8022206	0.738	rs8011621	ENSG00000259502.1	RP11-643G16.3	4.17	4.12e-05	0.011	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68062300	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs67566613	ENSG00000259502.1	RP11-643G16.3	4.17	4.12e-05	0.011	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68071020	chr14:67610986~67613864:+
COAD	cis	rs7656342	0.755	rs1519098	ENSG00000186234.7	FAM86MP	4.17	4.12e-05	0.011	0.31	0.25	Gut microbiota (bacterial taxa);	chr4:9879534	chr4:9692495~9702954:+
COAD	cis	rs12165098	0.852	rs12456581	ENSG00000267374.1	RP11-244M2.1	-4.17	4.12e-05	0.011	-0.48	-0.25	Sleep duration;	chr18:39240119	chr18:39206924~39800318:-
COAD	cis	rs12165098	0.852	rs12608109	ENSG00000267374.1	RP11-244M2.1	-4.17	4.12e-05	0.011	-0.48	-0.25	Sleep duration;	chr18:39241149	chr18:39206924~39800318:-
COAD	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-4.17	4.12e-05	0.011	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
COAD	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-4.17	4.12e-05	0.011	-0.29	-0.25	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
COAD	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-4.17	4.12e-05	0.011	-0.34	-0.25	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
COAD	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-4.17	4.12e-05	0.011	-0.34	-0.25	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
COAD	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-4.17	4.13e-05	0.011	-0.41	-0.25	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-4.17	4.13e-05	0.011	-0.41	-0.25	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
COAD	cis	rs12188164	0.686	rs72711369	ENSG00000221990.4	EXOC3-AS1	4.17	4.13e-05	0.011	0.26	0.25	Cystic fibrosis severity;	chr5:420402	chr5:441498~443160:-
COAD	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	4.17	4.13e-05	0.011	0.3	0.25	Height;	chr4:55540912	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	4.17	4.13e-05	0.011	0.3	0.25	Height;	chr4:55540972	chr4:55547112~55547889:+
COAD	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	4.17	4.13e-05	0.011	0.26	0.25	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
COAD	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-4.17	4.13e-05	0.011	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
COAD	cis	rs9400467	0.528	rs11153280	ENSG00000230177.1	RP5-1112D6.4	-4.17	4.13e-05	0.011	-0.22	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111277932~111278742:+
COAD	cis	rs683257	0.636	rs55942214	ENSG00000234147.1	RP3-460G2.2	-4.17	4.13e-05	0.011	-0.43	-0.25	Facial emotion recognition (angry faces);	chr6:140827313	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs56266921	ENSG00000234147.1	RP3-460G2.2	-4.17	4.13e-05	0.011	-0.43	-0.25	Facial emotion recognition (angry faces);	chr6:140827339	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs72988142	ENSG00000234147.1	RP3-460G2.2	-4.17	4.13e-05	0.011	-0.43	-0.25	Facial emotion recognition (angry faces);	chr6:140827387	chr6:140845958~140852924:-
COAD	cis	rs683257	0.563	rs9495842	ENSG00000234147.1	RP3-460G2.2	-4.17	4.13e-05	0.011	-0.43	-0.25	Facial emotion recognition (angry faces);	chr6:140828411	chr6:140845958~140852924:-
COAD	cis	rs683257	0.636	rs9495843	ENSG00000234147.1	RP3-460G2.2	-4.17	4.13e-05	0.011	-0.43	-0.25	Facial emotion recognition (angry faces);	chr6:140829354	chr6:140845958~140852924:-
COAD	cis	rs7615952	0.932	rs13086087	ENSG00000241278.1	ENPP7P4	4.17	4.13e-05	0.011	0.28	0.25	Blood pressure (smoking interaction);	chr3:125927438	chr3:125848223~125909372:+
COAD	cis	rs7584330	0.744	rs58223447	ENSG00000234949.2	AC104667.3	-4.17	4.13e-05	0.011	-0.34	-0.25	Prostate cancer;	chr2:237470001	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.744	rs72620822	ENSG00000234949.2	AC104667.3	-4.17	4.13e-05	0.011	-0.34	-0.25	Prostate cancer;	chr2:237470939	chr2:237591020~237595981:+
COAD	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	4.17	4.13e-05	0.011	0.37	0.25	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	4.17	4.13e-05	0.011	0.37	0.25	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	4.17	4.13e-05	0.011	0.37	0.25	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	4.17	4.13e-05	0.011	0.37	0.25	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
COAD	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	4.17	4.13e-05	0.011	0.3	0.25	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	4.17	4.13e-05	0.011	0.3	0.25	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
COAD	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-4.17	4.14e-05	0.011	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
COAD	cis	rs12699921	0.632	rs2691581	ENSG00000279048.1	RP11-511H23.2	-4.17	4.14e-05	0.011	-0.19	-0.25	Fibrinogen levels;	chr7:17789568	chr7:17940503~17942922:+
COAD	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	4.17	4.14e-05	0.011	0.26	0.25	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
COAD	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-4.17	4.14e-05	0.011	-0.29	-0.25	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
COAD	cis	rs2439831	0.702	rs3784275	ENSG00000275601.1	AC011330.13	-4.17	4.14e-05	0.011	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43799188	chr15:43642389~43643023:-
COAD	cis	rs9400467	0.528	rs7752361	ENSG00000271789.1	RP5-1112D6.7	-4.17	4.14e-05	0.011	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111297126~111298510:+
COAD	cis	rs7760535	0.811	rs7764591	ENSG00000271789.1	RP5-1112D6.7	-4.17	4.14e-05	0.011	-0.25	-0.25	Metabolic traits;	chr6:111462211	chr6:111297126~111298510:+
COAD	cis	rs9400467	0.528	rs7750792	ENSG00000271789.1	RP5-1112D6.7	-4.17	4.14e-05	0.011	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111297126~111298510:+
COAD	cis	rs1949733	0.701	rs4696828	ENSG00000205959.3	RP11-689P11.2	4.17	4.14e-05	0.011	0.3	0.25	Response to antineoplastic agents;	chr4:8453877	chr4:8482270~8512610:+
COAD	cis	rs763121	0.853	rs9610986	ENSG00000273076.1	RP3-508I15.22	4.17	4.14e-05	0.011	0.22	0.25	Menopause (age at onset);	chr22:38629272	chr22:38743495~38743910:+
COAD	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	4.17	4.14e-05	0.011	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	4.17	4.14e-05	0.011	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
COAD	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	4.17	4.14e-05	0.011	0.27	0.25	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
COAD	cis	rs728616	0.867	rs7080405	ENSG00000234382.2	RP11-40F6.1	-4.17	4.14e-05	0.011	-0.47	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:80233664~80245367:+
COAD	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	4.17	4.15e-05	0.011	0.32	0.25	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	4.17	4.15e-05	0.011	0.32	0.25	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
COAD	cis	rs11719291	0.915	rs1048940	ENSG00000225399.4	RP11-3B7.1	-4.17	4.15e-05	0.011	-0.54	-0.25	Cognitive function;	chr3:48688274	chr3:49260085~49261316:+
COAD	cis	rs9291683	0.546	rs6820188	ENSG00000250413.1	RP11-448G15.1	-4.17	4.15e-05	0.011	-0.33	-0.25	Bone mineral density;	chr4:10050031	chr4:10006482~10009725:+
COAD	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-4.17	4.15e-05	0.011	-0.25	-0.25	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-4.17	4.15e-05	0.011	-0.25	-0.25	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-4.17	4.15e-05	0.011	-0.25	-0.25	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-4.17	4.15e-05	0.011	-0.25	-0.25	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
COAD	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-4.17	4.15e-05	0.011	-0.26	-0.25	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
COAD	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-4.17	4.15e-05	0.011	-0.25	-0.25	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
COAD	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-4.17	4.16e-05	0.011	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
COAD	cis	rs860295	0.812	rs7556519	ENSG00000160766.13	GBAP1	-4.17	4.16e-05	0.011	-0.29	-0.25	Body mass index;	chr1:155857755	chr1:155213821~155227422:-
COAD	cis	rs7584330	0.826	rs72620824	ENSG00000234949.2	AC104667.3	-4.17	4.16e-05	0.011	-0.34	-0.25	Prostate cancer;	chr2:237472440	chr2:237591020~237595981:+
COAD	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	4.17	4.16e-05	0.0111	0.3	0.25	Height;	chr4:55578154	chr4:55540502~55540835:-
COAD	cis	rs10779751	1	rs11121711	ENSG00000215785.2	CFL1P6	-4.17	4.16e-05	0.0111	-0.29	-0.25	Body mass index;	chr1:11257604	chr1:10990978~10991797:-
COAD	cis	rs10779751	1	rs7525957	ENSG00000215785.2	CFL1P6	-4.17	4.16e-05	0.0111	-0.29	-0.25	Body mass index;	chr1:11258179	chr1:10990978~10991797:-
COAD	cis	rs742132	0.858	rs16890878	ENSG00000220875.1	HIST1H3PS1	4.17	4.16e-05	0.0111	0.34	0.25	Uric acid levels;	chr6:25636687	chr6:26321876~26322292:-
COAD	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	4.17	4.17e-05	0.0111	0.27	0.25	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
COAD	cis	rs2732480	0.577	rs2732457	ENSG00000226413.2	OR8T1P	-4.17	4.17e-05	0.0111	-0.33	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48442030~48442947:-
COAD	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	4.17	4.17e-05	0.0111	0.19	0.25	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
COAD	cis	rs9532669	0.853	rs9315795	ENSG00000277662.1	RP11-74J13.9	-4.17	4.17e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40943382	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.963	rs3764056	ENSG00000277662.1	RP11-74J13.9	-4.17	4.17e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40943849	chr13:41229180~41229676:-
COAD	cis	rs1790761	0.587	rs4930431	ENSG00000231793.4	DOC2GP	-4.17	4.17e-05	0.0111	-0.28	-0.25	Mean corpuscular volume;	chr11:67526837	chr11:67612653~67616257:-
COAD	cis	rs7584330	0.737	rs7568588	ENSG00000234949.2	AC104667.3	-4.17	4.17e-05	0.0111	-0.29	-0.25	Prostate cancer;	chr2:237455699	chr2:237591020~237595981:+
COAD	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	4.17	4.17e-05	0.0111	0.32	0.25	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
COAD	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	4.17	4.17e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
COAD	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-4.17	4.17e-05	0.0111	-0.31	-0.25	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
COAD	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	4.17	4.18e-05	0.0111	0.4	0.25	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
COAD	cis	rs2732480	0.538	rs2732462	ENSG00000226413.2	OR8T1P	4.17	4.18e-05	0.0111	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48442030~48442947:-
COAD	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-4.17	4.18e-05	0.0111	-0.29	-0.25	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
COAD	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	4.17	4.18e-05	0.0111	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
COAD	cis	rs17772222	0.917	rs61984736	ENSG00000258789.1	RP11-507K2.3	-4.17	4.18e-05	0.0111	-0.4	-0.25	Coronary artery calcification;	chr14:88626359	chr14:88551597~88552493:+
COAD	cis	rs8022206	0.773	rs10140097	ENSG00000259502.1	RP11-643G16.3	4.17	4.18e-05	0.0111	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68018284	chr14:67610986~67613864:+
COAD	cis	rs3824347	0.738	rs7465903	ENSG00000229587.2	RP11-197P3.5	4.17	4.19e-05	0.0111	0.28	0.25	Urinary magnesium-to-creatinine ratio;	chr9:75034643	chr9:75009828~75016036:-
COAD	cis	rs3824347	0.802	rs1003119	ENSG00000229587.2	RP11-197P3.5	4.17	4.19e-05	0.0111	0.28	0.25	Urinary magnesium-to-creatinine ratio;	chr9:75035151	chr9:75009828~75016036:-
COAD	cis	rs972578	0.715	rs2024645	ENSG00000230107.1	CTA-126B4.7	-4.17	4.19e-05	0.0111	-0.32	-0.25	Mean platelet volume;	chr22:42816775	chr22:42438023~42446195:+
COAD	cis	rs2439831	0.85	rs7179388	ENSG00000166763.7	STRCP1	-4.17	4.19e-05	0.0111	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43831747	chr15:43699488~43718184:-
COAD	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	4.17	4.19e-05	0.0111	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	4.17	4.19e-05	0.0111	0.27	0.25	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
COAD	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-4.17	4.19e-05	0.0111	-0.36	-0.25	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
COAD	cis	rs10461617	0.617	rs6874733	ENSG00000271828.1	CTD-2310F14.1	4.17	4.19e-05	0.0111	0.33	0.25	Type 2 diabetes;	chr5:56773773	chr5:56927874~56929573:+
COAD	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.52	-0.25	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
COAD	cis	rs2439831	0.85	rs28590651	ENSG00000166763.7	STRCP1	-4.17	4.19e-05	0.0111	-0.35	-0.25	Lung cancer in ever smokers;	chr15:43820818	chr15:43699488~43718184:-
COAD	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-4.17	4.19e-05	0.0111	-0.26	-0.25	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	4.17	4.19e-05	0.0111	0.35	0.25	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
COAD	cis	rs1426063	1	rs9993589	ENSG00000249717.1	RP11-44F21.3	4.17	4.19e-05	0.0111	0.37	0.25	QT interval;	chr4:75099556	chr4:74955974~74970362:-
COAD	cis	rs683257	0.636	rs6918856	ENSG00000234147.1	RP3-460G2.2	-4.17	4.19e-05	0.0111	-0.45	-0.25	Facial emotion recognition (angry faces);	chr6:140851609	chr6:140845958~140852924:-
COAD	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-4.17	4.19e-05	0.0111	-0.27	-0.25	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
COAD	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
COAD	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
COAD	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
COAD	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-4.17	4.19e-05	0.0111	-0.48	-0.25	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
COAD	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	4.17	4.19e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	4.17	4.19e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	4.17	4.19e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	4.17	4.19e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	4.17	4.19e-05	0.0111	0.33	0.25	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
COAD	cis	rs2115630	1	rs6496452	ENSG00000259728.4	LINC00933	-4.17	4.19e-05	0.0111	-0.29	-0.25	P wave terminal force;	chr15:84829414	chr15:84570649~84580175:+
COAD	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	4.17	4.19e-05	0.0111	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
COAD	cis	rs742132	0.858	rs1406926	ENSG00000220875.1	HIST1H3PS1	4.17	4.2e-05	0.0111	0.32	0.25	Uric acid levels;	chr6:25636889	chr6:26321876~26322292:-
COAD	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-4.17	4.2e-05	0.0111	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
COAD	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-4.17	4.2e-05	0.0111	-0.27	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
COAD	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-4.17	4.2e-05	0.0111	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
COAD	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-4.17	4.2e-05	0.0111	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
COAD	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-4.17	4.2e-05	0.0111	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
COAD	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-4.17	4.2e-05	0.0111	-0.41	-0.25	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
COAD	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-4.17	4.2e-05	0.0111	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
COAD	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-4.17	4.2e-05	0.0111	-0.3	-0.25	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-4.17	4.2e-05	0.0111	-0.3	-0.25	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-4.17	4.2e-05	0.0111	-0.3	-0.25	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
COAD	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.17	4.2e-05	0.0111	-0.31	-0.25	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
COAD	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-4.17	4.2e-05	0.0111	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
COAD	cis	rs9532669	0.963	rs4343141	ENSG00000277662.1	RP11-74J13.9	-4.17	4.21e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40940497	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.963	rs3887418	ENSG00000277662.1	RP11-74J13.9	-4.17	4.21e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40940560	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs1056820	ENSG00000277662.1	RP11-74J13.9	-4.17	4.21e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40941150	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532678	ENSG00000277662.1	RP11-74J13.9	-4.17	4.21e-05	0.0111	-0.24	-0.25	Cervical cancer;	chr13:40941862	chr13:41229180~41229676:-
COAD	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-4.17	4.21e-05	0.0111	-0.27	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
COAD	cis	rs9307551	0.645	rs7655446	ENSG00000250334.4	LINC00989	-4.17	4.21e-05	0.0111	-0.33	-0.25	Refractive error;	chr4:79499947	chr4:79492416~79576460:+
COAD	cis	rs79996792	0.736	rs79299044	ENSG00000235724.7	AC009299.2	-4.17	4.21e-05	0.0112	-0.4	-0.25	Neuroticism;	chr2:161637672	chr2:161222785~161308303:-
COAD	cis	rs2378497	1	rs61823902	ENSG00000232679.1	RP11-400N13.3	4.17	4.21e-05	0.0112	0.35	0.25	Serum thyroid-stimulating hormone levels;	chr1:221990788	chr1:222041705~222064763:-
COAD	cis	rs2378497	1	rs61823903	ENSG00000232679.1	RP11-400N13.3	4.17	4.21e-05	0.0112	0.35	0.25	Serum thyroid-stimulating hormone levels;	chr1:221991095	chr1:222041705~222064763:-
COAD	cis	rs2378497	1	rs75451751	ENSG00000232679.1	RP11-400N13.3	4.17	4.21e-05	0.0112	0.35	0.25	Serum thyroid-stimulating hormone levels;	chr1:221994454	chr1:222041705~222064763:-
COAD	cis	rs8141529	0.764	rs5762824	ENSG00000272858.1	CTA-292E10.8	-4.17	4.21e-05	0.0112	-0.3	-0.25	Lymphocyte counts;	chr22:28826942	chr22:28814914~28815662:+
COAD	cis	rs8141529	0.764	rs5752807	ENSG00000272858.1	CTA-292E10.8	-4.17	4.21e-05	0.0112	-0.3	-0.25	Lymphocyte counts;	chr22:28827181	chr22:28814914~28815662:+
COAD	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	4.17	4.21e-05	0.0112	0.32	0.25	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
COAD	cis	rs1426063	1	rs10030850	ENSG00000249717.1	RP11-44F21.3	4.17	4.21e-05	0.0112	0.37	0.25	QT interval;	chr4:75099199	chr4:74955974~74970362:-
COAD	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-4.17	4.22e-05	0.0112	-0.3	-0.25	QT interval;	chr12:29349303	chr12:29277397~29277882:-
COAD	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.17	4.22e-05	0.0112	0.22	0.25	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
COAD	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	4.17	4.22e-05	0.0112	0.32	0.25	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
COAD	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-4.17	4.22e-05	0.0112	-0.31	-0.25	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-4.17	4.22e-05	0.0112	-0.31	-0.25	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
COAD	cis	rs35668226	0.714	rs11199753	ENSG00000278484.1	RP11-95I16.6	4.17	4.22e-05	0.0112	0.41	0.25	Type 2 diabetes;	chr10:121075059	chr10:120984966~120985596:-
COAD	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-4.17	4.22e-05	0.0112	-0.26	-0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
COAD	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-4.17	4.22e-05	0.0112	-0.29	-0.25	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
COAD	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-4.17	4.22e-05	0.0112	-0.37	-0.25	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
COAD	cis	rs4657482	0.607	rs473222	ENSG00000236364.3	RP11-525G13.2	4.17	4.22e-05	0.0112	0.21	0.25	Testicular germ cell tumor;	chr1:165907341	chr1:165890795~165900683:-
COAD	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-4.17	4.23e-05	0.0112	-0.28	-0.25	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
COAD	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-4.17	4.23e-05	0.0112	-0.28	-0.25	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
COAD	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-4.17	4.23e-05	0.0112	-0.28	-0.25	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
COAD	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-4.17	4.23e-05	0.0112	-0.28	-0.25	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
COAD	cis	rs9880211	0.898	rs73231903	ENSG00000273486.1	RP11-731C17.2	4.17	4.23e-05	0.0112	0.3	0.25	Height;Body mass index;	chr3:136842783	chr3:136837338~136839021:-
COAD	cis	rs9532669	0.889	rs1989252	ENSG00000277662.1	RP11-74J13.9	4.17	4.23e-05	0.0112	0.24	0.25	Cervical cancer;	chr13:40911532	chr13:41229180~41229676:-
COAD	cis	rs4074961	0.565	rs4415526	ENSG00000233621.1	LINC01137	-4.17	4.23e-05	0.0112	-0.28	-0.25	Axial length;	chr1:37606127	chr1:37454879~37474411:-
COAD	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-4.17	4.23e-05	0.0112	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-4.17	4.23e-05	0.0112	-0.48	-0.25	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-4.17	4.23e-05	0.0112	-0.48	-0.25	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
COAD	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-4.17	4.23e-05	0.0112	-0.48	-0.25	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
COAD	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-4.17	4.23e-05	0.0112	-0.31	-0.25	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
COAD	cis	rs6545883	0.524	rs2694619	ENSG00000273302.1	RP11-493E12.2	-4.17	4.23e-05	0.0112	-0.23	-0.25	Tuberculosis;	chr2:61309766	chr2:61199979~61200769:+
COAD	cis	rs9532669	0.963	rs7324625	ENSG00000277662.1	RP11-74J13.9	-4.17	4.23e-05	0.0112	-0.24	-0.25	Cervical cancer;	chr13:40928606	chr13:41229180~41229676:-
COAD	cis	rs1949733	0.598	rs4696838	ENSG00000205959.3	RP11-689P11.2	4.17	4.24e-05	0.0112	0.31	0.25	Response to antineoplastic agents;	chr4:8538622	chr4:8482270~8512610:+
COAD	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.17	4.24e-05	0.0112	-0.25	-0.25	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
COAD	cis	rs74233809	1	rs11191472	ENSG00000213277.3	MARCKSL1P1	4.17	4.24e-05	0.0112	0.54	0.25	Birth weight;	chr10:102947259	chr10:103175554~103176094:+
COAD	cis	rs4704187	0.687	rs1422698	ENSG00000250889.2	LINC01336	-4.17	4.24e-05	0.0112	-0.29	-0.25	Response to amphetamines;	chr5:75147307	chr5:75047719~75052843:-
COAD	cis	rs56052703	0.536	rs10407951	ENSG00000267633.1	CTB-5E10.3	4.17	4.24e-05	0.0112	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13312874	chr19:13772118~13774118:-
COAD	cis	rs56052703	0.536	rs7257258	ENSG00000267633.1	CTB-5E10.3	4.17	4.24e-05	0.0112	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13314019	chr19:13772118~13774118:-
COAD	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-4.17	4.24e-05	0.0112	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
COAD	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.17	4.24e-05	0.0112	0.4	0.25	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
COAD	cis	rs12807809	1	rs12807809	ENSG00000245498.5	RP11-677M14.7	-4.17	4.25e-05	0.0112	-0.29	-0.25	Schizophrenia;	chr11:124736389	chr11:124800450~124834487:+
COAD	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-4.17	4.25e-05	0.0112	-0.27	-0.25	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	4.17	4.25e-05	0.0112	0.33	0.25	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
COAD	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-4.17	4.25e-05	0.0112	-0.3	-0.25	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
COAD	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	4.17	4.25e-05	0.0112	0.27	0.25	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
COAD	cis	rs3764400	0.567	rs8071879	ENSG00000278765.1	RP5-890E16.5	-4.17	4.25e-05	0.0112	-0.48	-0.25	Body mass index;	chr17:48140095	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs2325804	ENSG00000278765.1	RP5-890E16.5	-4.17	4.25e-05	0.0112	-0.48	-0.25	Body mass index;	chr17:48141183	chr17:48066704~48067293:-
COAD	cis	rs9903692	0.505	rs208009	ENSG00000278765.1	RP5-890E16.5	-4.17	4.25e-05	0.0112	-0.48	-0.25	Pulse pressure;	chr17:48152329	chr17:48066704~48067293:-
COAD	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-4.16	4.25e-05	0.0112	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
COAD	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-4.16	4.25e-05	0.0112	-0.3	-0.25	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
COAD	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-4.16	4.26e-05	0.0113	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
COAD	cis	rs1624802	0.967	rs1696432	ENSG00000280002.1	RP11-76C10.6	-4.16	4.26e-05	0.0113	-0.29	-0.25	Obesity-related traits;	chr12:130012431	chr12:130988312~130990028:-
COAD	cis	rs9880211	1	rs67949818	ENSG00000273486.1	RP11-731C17.2	4.16	4.26e-05	0.0113	0.3	0.25	Height;Body mass index;	chr3:136494136	chr3:136837338~136839021:-
COAD	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-4.16	4.26e-05	0.0113	-0.27	-0.25	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
COAD	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-4.16	4.26e-05	0.0113	-0.27	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
COAD	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-4.16	4.26e-05	0.0113	-0.32	-0.25	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
COAD	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-4.16	4.26e-05	0.0113	-0.32	-0.25	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
COAD	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-4.16	4.26e-05	0.0113	-0.32	-0.25	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
COAD	cis	rs12682352	0.535	rs12677550	ENSG00000173295.6	FAM86B3P	-4.16	4.26e-05	0.0113	-0.29	-0.25	Neuroticism;	chr8:8786812	chr8:8228595~8244865:+
COAD	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-4.16	4.26e-05	0.0113	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
COAD	cis	rs17407555	0.683	rs6852641	ENSG00000250413.1	RP11-448G15.1	-4.16	4.26e-05	0.0113	-0.35	-0.25	Schizophrenia (age at onset);	chr4:10274122	chr4:10006482~10009725:+
COAD	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	4.16	4.26e-05	0.0113	0.3	0.25	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
COAD	cis	rs8022206	0.704	rs10129612	ENSG00000259502.1	RP11-643G16.3	4.16	4.26e-05	0.0113	0.32	0.25	Platelet count;Mean platelet volume;	chr14:68027753	chr14:67610986~67613864:+
COAD	cis	rs742132	0.858	rs9467552	ENSG00000220875.1	HIST1H3PS1	4.16	4.26e-05	0.0113	0.32	0.25	Uric acid levels;	chr6:25658991	chr6:26321876~26322292:-
COAD	cis	rs1949733	0.656	rs6845969	ENSG00000205959.3	RP11-689P11.2	-4.16	4.27e-05	0.0113	-0.3	-0.25	Response to antineoplastic agents;	chr4:8400738	chr4:8482270~8512610:+
COAD	cis	rs17772222	1	rs79579293	ENSG00000258789.1	RP11-507K2.3	-4.16	4.27e-05	0.0113	-0.35	-0.25	Coronary artery calcification;	chr14:88355724	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs77382318	ENSG00000258789.1	RP11-507K2.3	-4.16	4.27e-05	0.0113	-0.35	-0.25	Coronary artery calcification;	chr14:88355785	chr14:88551597~88552493:+
COAD	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	4.16	4.27e-05	0.0113	0.43	0.25	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
COAD	cis	rs7193541	0.859	rs12598791	ENSG00000262904.1	TMPOP2	-4.16	4.27e-05	0.0113	-0.27	-0.25	Multiple myeloma;	chr16:74466847	chr16:74667506~74668706:+
COAD	cis	rs17772222	1	rs17698817	ENSG00000258789.1	RP11-507K2.3	-4.16	4.27e-05	0.0113	-0.34	-0.25	Coronary artery calcification;	chr14:88356632	chr14:88551597~88552493:+
COAD	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-4.16	4.27e-05	0.0113	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
COAD	cis	rs2749097	0.825	rs10889436	ENSG00000244256.3	RN7SL130P	-4.16	4.27e-05	0.0113	-0.31	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63658226	chr1:63655743~63656047:+
COAD	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	4.16	4.27e-05	0.0113	0.3	0.25	Height;	chr4:55413708	chr4:55363971~55395847:-
COAD	cis	rs12530	1	rs9606947	ENSG00000232218.1	RP1-149A16.16	-4.16	4.27e-05	0.0113	-0.44	-0.25	IgG glycosylation;	chr22:32399298	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs73168729	ENSG00000232218.1	RP1-149A16.16	-4.16	4.27e-05	0.0113	-0.44	-0.25	IgG glycosylation;	chr22:32400731	chr22:32386668~32386868:+
COAD	cis	rs7131987	0.903	rs67517901	ENSG00000257176.2	RP11-996F15.2	-4.16	4.27e-05	0.0113	-0.29	-0.25	QT interval;	chr12:29268413	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.903	rs6487796	ENSG00000257176.2	RP11-996F15.2	-4.16	4.27e-05	0.0113	-0.29	-0.25	QT interval;	chr12:29269831	chr12:29280418~29317848:-
COAD	cis	rs3733829	0.732	rs41530251	ENSG00000233622.1	CYP2T1P	4.16	4.28e-05	0.0113	0.28	0.25	Smoking behavior;	chr19:40810450	chr19:40808525~40811390:-
COAD	cis	rs8141529	0.732	rs6005881	ENSG00000272858.1	CTA-292E10.8	-4.16	4.28e-05	0.0113	-0.3	-0.25	Lymphocyte counts;	chr22:28787145	chr22:28814914~28815662:+
COAD	cis	rs9309473	0.607	rs1522927	ENSG00000163016.8	ALMS1P	4.16	4.28e-05	0.0113	0.31	0.25	Metabolite levels;	chr2:73329027	chr2:73644919~73685576:+
COAD	cis	rs9376098	1	rs1320960	ENSG00000232876.1	CTA-212D2.2	-4.16	4.28e-05	0.0113	-0.3	-0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177063	chr6:135055033~135060550:+
COAD	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-4.16	4.28e-05	0.0113	-0.3	-0.25	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
COAD	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-4.16	4.28e-05	0.0113	-0.25	-0.25	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
COAD	cis	rs2638953	0.815	rs1534340	ENSG00000247934.4	RP11-967K21.1	-4.16	4.28e-05	0.0113	-0.25	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28163298~28190738:-
COAD	cis	rs7674212	0.57	rs6813563	ENSG00000230069.3	LRRC37A15P	-4.16	4.28e-05	0.0113	-0.27	-0.25	Type 2 diabetes;	chr4:103177953	chr4:102727274~102730721:-
COAD	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	4.16	4.28e-05	0.0113	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
COAD	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-4.16	4.28e-05	0.0113	-0.27	-0.25	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
COAD	cis	rs6452524	0.935	rs1382376	ENSG00000271862.1	RP11-343L5.2	4.16	4.28e-05	0.0113	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs12109517	ENSG00000271862.1	RP11-343L5.2	4.16	4.28e-05	0.0113	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs12109514	ENSG00000271862.1	RP11-343L5.2	4.16	4.28e-05	0.0113	0.24	0.25	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83049376~83050964:-
COAD	cis	rs9880211	0.948	rs9813691	ENSG00000273486.1	RP11-731C17.2	4.16	4.28e-05	0.0113	0.29	0.25	Height;Body mass index;	chr3:136541880	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs9883189	ENSG00000273486.1	RP11-731C17.2	4.16	4.28e-05	0.0113	0.29	0.25	Height;Body mass index;	chr3:136570624	chr3:136837338~136839021:-
COAD	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-4.16	4.29e-05	0.0113	-0.31	-0.25	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
COAD	cis	rs728616	0.717	rs17098169	ENSG00000234382.2	RP11-40F6.1	4.16	4.29e-05	0.0113	0.44	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:80233664~80245367:+
COAD	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-4.16	4.29e-05	0.0113	-0.31	-0.25	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
COAD	cis	rs9990333	0.6	rs6793116	ENSG00000207650.1	MIR570	-4.16	4.29e-05	0.0113	-0.29	-0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085217	chr3:195699401~195699497:+
COAD	cis	rs9990333	0.762	rs6810239	ENSG00000207650.1	MIR570	-4.16	4.29e-05	0.0113	-0.29	-0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196085292	chr3:195699401~195699497:+
COAD	cis	rs8141529	0.719	rs6005916	ENSG00000272858.1	CTA-292E10.8	-4.16	4.29e-05	0.0113	-0.29	-0.25	Lymphocyte counts;	chr22:28837354	chr22:28814914~28815662:+
COAD	cis	rs9532669	0.926	rs4454835	ENSG00000277662.1	RP11-74J13.9	-4.16	4.29e-05	0.0113	-0.24	-0.25	Cervical cancer;	chr13:40928978	chr13:41229180~41229676:-
COAD	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	4.16	4.29e-05	0.0113	0.4	0.25	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	4.16	4.29e-05	0.0113	0.4	0.25	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	4.16	4.29e-05	0.0113	0.4	0.25	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	4.16	4.29e-05	0.0113	0.4	0.25	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	4.16	4.29e-05	0.0113	0.4	0.25	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
COAD	cis	rs34779708	0.966	rs12775548	ENSG00000271335.4	RP11-324I22.4	4.16	4.29e-05	0.0113	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35314552~35336401:-
COAD	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-4.16	4.29e-05	0.0113	-0.31	-0.25	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
COAD	cis	rs17685	0.753	rs2108274	ENSG00000280388.1	RP11-229D13.3	-4.16	4.3e-05	0.0113	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76152318	chr7:76043977~76045963:-
COAD	cis	rs6687821	0.515	rs10493794	ENSG00000261737.1	RP4-612B15.3	4.16	4.3e-05	0.0113	0.32	0.25	Yeast infection;	chr1:87004946	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs10747335	ENSG00000261737.1	RP4-612B15.3	4.16	4.3e-05	0.0113	0.32	0.25	Yeast infection;	chr1:87006739	chr1:86703502~86704462:-
COAD	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	4.16	4.3e-05	0.0113	0.32	0.25	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
COAD	cis	rs9532669	0.963	rs4941391	ENSG00000277662.1	RP11-74J13.9	-4.16	4.3e-05	0.0113	-0.24	-0.25	Cervical cancer;	chr13:40939787	chr13:41229180~41229676:-
COAD	cis	rs6017291	0.59	rs16988852	ENSG00000223891.4	OSER1-AS1	4.16	4.3e-05	0.0113	0.3	0.25	Cognitive performance;	chr20:44212989	chr20:44210960~44226027:+
COAD	cis	rs11603023	0.967	rs494560	ENSG00000278376.1	RP11-158I9.8	4.16	4.3e-05	0.0113	0.25	0.25	Cholesterol, total;	chr11:118650844	chr11:118791254~118793137:+
COAD	cis	rs2638953	0.815	rs117066882	ENSG00000247934.4	RP11-967K21.1	-4.16	4.3e-05	0.0113	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28477287	chr12:28163298~28190738:-
COAD	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-4.16	4.3e-05	0.0114	-0.3	-0.25	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
COAD	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	4.16	4.3e-05	0.0114	0.3	0.25	Migraine;	chr4:56861145	chr4:56960927~56961373:-
COAD	cis	rs56052703	0.536	rs10406620	ENSG00000267633.1	CTB-5E10.3	4.16	4.31e-05	0.0114	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13318203	chr19:13772118~13774118:-
COAD	cis	rs56052703	0.536	rs10406665	ENSG00000267633.1	CTB-5E10.3	4.16	4.31e-05	0.0114	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13318269	chr19:13772118~13774118:-
COAD	cis	rs56052703	0.536	rs67507307	ENSG00000267633.1	CTB-5E10.3	4.16	4.31e-05	0.0114	0.29	0.25	Proteinuria and chronic kidney disease;	chr19:13318300	chr19:13772118~13774118:-
COAD	cis	rs6951245	1	rs78185558	ENSG00000229043.2	AC091729.9	-4.16	4.31e-05	0.0114	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1160374~1165267:+
COAD	cis	rs879620	1	rs2531995	ENSG00000262185.1	RP11-462G12.1	-4.16	4.31e-05	0.0114	-0.31	-0.25	Hip circumference;Body mass index;	chr16:3963466	chr16:3947609~3950444:-
COAD	cis	rs6719977	0.543	rs6713059	ENSG00000226491.1	FTOP1	-4.16	4.31e-05	0.0114	-0.34	-0.25	Hyperactive-impulsive symptoms;	chr2:42750140	chr2:42797225~42798712:-
COAD	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.16	4.31e-05	0.0114	0.32	0.25	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
COAD	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-4.16	4.31e-05	0.0114	-0.3	-0.25	QT interval;	chr12:29319476	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-4.16	4.31e-05	0.0114	-0.3	-0.25	QT interval;	chr12:29320175	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-4.16	4.31e-05	0.0114	-0.3	-0.25	QT interval;	chr12:29321177	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-4.16	4.31e-05	0.0114	-0.3	-0.25	QT interval;	chr12:29321323	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-4.16	4.31e-05	0.0114	-0.3	-0.25	QT interval;	chr12:29322770	chr12:29277397~29277882:-
COAD	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	4.16	4.31e-05	0.0114	0.36	0.25	Depression;	chr6:28109824	chr6:28115628~28116551:+
COAD	cis	rs6543140	0.964	rs6543136	ENSG00000234389.1	AC007278.3	4.16	4.31e-05	0.0114	0.27	0.25	Blood protein levels;	chr2:102449087	chr2:102438713~102440475:+
COAD	cis	rs2638953	0.962	rs61922975	ENSG00000247934.4	RP11-967K21.1	-4.16	4.31e-05	0.0114	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs61922976	ENSG00000247934.4	RP11-967K21.1	-4.16	4.31e-05	0.0114	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28163298~28190738:-
COAD	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-4.16	4.32e-05	0.0114	-0.34	-0.25	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
COAD	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	4.16	4.32e-05	0.0114	0.33	0.25	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	4.16	4.32e-05	0.0114	0.33	0.25	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	4.16	4.32e-05	0.0114	0.33	0.25	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
COAD	cis	rs860295	0.836	rs1360554	ENSG00000225082.2	DAP3P1	4.16	4.32e-05	0.0114	0.31	0.25	Body mass index;	chr1:155503565	chr1:155586644~155602197:+
COAD	cis	rs6687821	0.515	rs2764427	ENSG00000261737.1	RP4-612B15.3	4.16	4.32e-05	0.0114	0.33	0.25	Yeast infection;	chr1:87076636	chr1:86703502~86704462:-
COAD	cis	rs1624802	1	rs1707934	ENSG00000280002.1	RP11-76C10.6	4.16	4.32e-05	0.0114	0.29	0.25	Obesity-related traits;	chr12:130013066	chr12:130988312~130990028:-
COAD	cis	rs7829975	0.688	rs7837587	ENSG00000254340.1	RP11-10A14.3	4.16	4.32e-05	0.0114	0.29	0.25	Mood instability;	chr8:8521482	chr8:9141424~9145435:+
COAD	cis	rs7829975	0.688	rs7826654	ENSG00000254340.1	RP11-10A14.3	4.16	4.32e-05	0.0114	0.29	0.25	Mood instability;	chr8:8521596	chr8:9141424~9145435:+
COAD	cis	rs7829975	0.688	rs7826660	ENSG00000254340.1	RP11-10A14.3	4.16	4.32e-05	0.0114	0.29	0.25	Mood instability;	chr8:8521597	chr8:9141424~9145435:+
COAD	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-4.16	4.32e-05	0.0114	-0.3	-0.25	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
COAD	cis	rs9910055	1	rs9895423	ENSG00000267080.4	ASB16-AS1	-4.16	4.32e-05	0.0114	-0.24	-0.25	Total body bone mineral density;	chr17:44208372	chr17:44175973~44186717:-
COAD	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	4.16	4.32e-05	0.0114	0.29	0.25	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
COAD	cis	rs495337	1	rs4810997	ENSG00000229222.1	KRT18P4	-4.16	4.32e-05	0.0114	-0.26	-0.25	Psoriasis;	chr20:49962811	chr20:49956745~49958032:+
COAD	cis	rs4841097	0.876	rs6601288	ENSG00000233609.3	RP11-62H7.2	4.16	4.32e-05	0.0114	0.3	0.25	Platelet distribution width;	chr8:9085920	chr8:8961200~8979025:+
COAD	cis	rs17772222	0.917	rs8006652	ENSG00000258789.1	RP11-507K2.3	-4.16	4.33e-05	0.0114	-0.37	-0.25	Coronary artery calcification;	chr14:88631290	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.917	rs12587200	ENSG00000258789.1	RP11-507K2.3	-4.16	4.33e-05	0.0114	-0.37	-0.25	Coronary artery calcification;	chr14:88632060	chr14:88551597~88552493:+
COAD	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-4.16	4.33e-05	0.0114	-0.34	-0.25	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
COAD	cis	rs2638953	0.64	rs10843204	ENSG00000247934.4	RP11-967K21.1	-4.16	4.33e-05	0.0114	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568028	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.64	rs10843205	ENSG00000247934.4	RP11-967K21.1	-4.16	4.33e-05	0.0114	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568220	chr12:28163298~28190738:-
COAD	cis	rs734999	0.588	rs2764848	ENSG00000225931.3	RP3-395M20.7	-4.16	4.33e-05	0.0114	-0.28	-0.25	Ulcerative colitis;	chr1:2599255	chr1:2566410~2569888:+
COAD	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-4.16	4.33e-05	0.0114	-0.42	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
COAD	cis	rs1400745	0.756	rs761924	ENSG00000258738.1	RP11-73E17.2	-4.16	4.33e-05	0.0114	-0.29	-0.25	Monocyte count;	chr14:34864077	chr14:34874343~34876459:+
COAD	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	4.16	4.33e-05	0.0114	0.28	0.25	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	4.16	4.33e-05	0.0114	0.28	0.25	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	4.16	4.33e-05	0.0114	0.28	0.25	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
COAD	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	4.16	4.33e-05	0.0114	0.43	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
COAD	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-4.16	4.33e-05	0.0114	-0.27	-0.25	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
COAD	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	4.16	4.33e-05	0.0114	0.25	0.25	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	4.16	4.33e-05	0.0114	0.25	0.25	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
COAD	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-4.16	4.33e-05	0.0114	-0.43	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
COAD	cis	rs7584330	0.518	rs113812061	ENSG00000234949.2	AC104667.3	-4.16	4.33e-05	0.0114	-0.41	-0.25	Prostate cancer;	chr2:237539291	chr2:237591020~237595981:+
COAD	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-4.16	4.33e-05	0.0114	-0.36	-0.25	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
COAD	cis	rs2337406	0.866	rs111881598	ENSG00000211967.3	IGHV3-53	-4.16	4.33e-05	0.0114	-0.18	-0.25	Alzheimer's disease (late onset);	chr14:106783113	chr14:106592676~106593347:-
COAD	cis	rs423955	1	rs296847	ENSG00000225893.1	RP11-6J24.3	-4.16	4.33e-05	0.0114	-0.26	-0.25	Platelet count;	chr9:4793798	chr9:4633027~4633756:+
COAD	cis	rs8061903	0.916	rs12599300	ENSG00000260071.1	RP11-418I22.2	4.16	4.34e-05	0.0114	0.3	0.25	HIV-1 viral setpoint;	chr16:9296795	chr16:9466655~9517564:+
COAD	cis	rs12497850	1	rs1352420	ENSG00000225399.4	RP11-3B7.1	4.16	4.34e-05	0.0114	0.28	0.25	Parkinson's disease;	chr3:48719858	chr3:49260085~49261316:+
COAD	cis	rs7646881	1	rs73015651	ENSG00000272087.1	RP11-379F4.7	4.16	4.34e-05	0.0114	0.37	0.25	Tetralogy of Fallot;	chr3:158733133	chr3:158693120~158693768:-
COAD	cis	rs12497850	0.931	rs6442130	ENSG00000225399.4	RP11-3B7.1	4.16	4.34e-05	0.0114	0.28	0.25	Parkinson's disease;	chr3:48740594	chr3:49260085~49261316:+
COAD	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	4.16	4.34e-05	0.0114	0.35	0.25	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
COAD	cis	rs55962025	0.842	rs362267	ENSG00000248840.2	RP11-357G3.2	4.16	4.34e-05	0.0114	0.3	0.25	Parental longevity (mother's age at death);	chr4:3241491	chr4:3312512~3313058:+
COAD	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-4.16	4.34e-05	0.0114	-0.27	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
COAD	cis	rs6095360	0.934	rs6019581	ENSG00000222365.1	SNORD12B	4.16	4.34e-05	0.0114	0.21	0.25	Intelligence (multi-trait analysis);	chr20:49011035	chr20:49280319~49280409:+
COAD	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.16	4.34e-05	0.0114	-0.25	-0.25	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.16	4.34e-05	0.0114	-0.25	-0.25	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.16	4.34e-05	0.0114	-0.25	-0.25	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
COAD	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-4.16	4.35e-05	0.0114	-0.41	-0.25	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
COAD	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-4.16	4.35e-05	0.0114	-0.41	-0.25	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
COAD	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-4.16	4.35e-05	0.0114	-0.24	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
COAD	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-4.16	4.35e-05	0.0114	-0.26	-0.25	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
COAD	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	4.16	4.35e-05	0.0115	0.34	0.25	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
COAD	cis	rs6585424	1	rs12779955	ENSG00000234382.2	RP11-40F6.1	4.16	4.35e-05	0.0115	0.4	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80181108	chr10:80233664~80245367:+
COAD	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	4.16	4.35e-05	0.0115	0.41	0.25	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
COAD	cis	rs12530	1	rs73168721	ENSG00000232218.1	RP1-149A16.16	-4.16	4.35e-05	0.0115	-0.44	-0.25	IgG glycosylation;	chr22:32397654	chr22:32386668~32386868:+
COAD	cis	rs453301	0.658	rs9329175	ENSG00000254340.1	RP11-10A14.3	-4.16	4.35e-05	0.0115	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9009151	chr8:9141424~9145435:+
COAD	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-4.16	4.36e-05	0.0115	-0.43	-0.25	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
COAD	cis	rs36052053	0.908	rs71558361	ENSG00000219700.1	PTCHD3P3	4.16	4.36e-05	0.0115	0.45	0.25	Red cell distribution width;	chr6:109260045	chr6:109288571~109290503:-
COAD	cis	rs36052053	0.908	rs13190802	ENSG00000219700.1	PTCHD3P3	4.16	4.36e-05	0.0115	0.45	0.25	Red cell distribution width;	chr6:109260601	chr6:109288571~109290503:-
COAD	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	4.16	4.36e-05	0.0115	0.31	0.25	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
COAD	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	4.16	4.36e-05	0.0115	0.15	0.25	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
COAD	cis	rs1044826	0.642	rs6439860	ENSG00000272656.1	RP11-219D15.3	4.16	4.36e-05	0.0115	0.29	0.25	Obesity-related traits;	chr3:139456955	chr3:139349024~139349371:-
COAD	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-4.16	4.36e-05	0.0115	-0.3	-0.25	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
COAD	cis	rs11098499	0.661	rs10015965	ENSG00000249244.1	RP11-548H18.2	4.16	4.36e-05	0.0115	0.32	0.25	Corneal astigmatism;	chr4:119347082	chr4:119391831~119395335:-
COAD	cis	rs9532669	0.963	rs1571116	ENSG00000277662.1	RP11-74J13.9	-4.16	4.36e-05	0.0115	-0.24	-0.25	Cervical cancer;	chr13:40929765	chr13:41229180~41229676:-
COAD	cis	rs7577696	0.785	rs7592239	ENSG00000272716.1	RP11-563N4.1	-4.16	4.37e-05	0.0115	-0.26	-0.25	Inflammatory biomarkers;	chr2:32145189	chr2:32165046~32165757:-
COAD	cis	rs8061903	0.501	rs2077437	ENSG00000261617.1	RP11-243A14.1	4.16	4.37e-05	0.0115	0.32	0.25	HIV-1 viral setpoint;	chr16:9307313	chr16:9355588~9408093:+
COAD	cis	rs9487051	0.807	rs1915835	ENSG00000219700.1	PTCHD3P3	4.16	4.37e-05	0.0115	0.27	0.25	Reticulocyte fraction of red cells;	chr6:109276280	chr6:109288571~109290503:-
COAD	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	4.16	4.38e-05	0.0115	0.32	0.25	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
COAD	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-4.16	4.38e-05	0.0115	-0.31	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
COAD	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.16	4.38e-05	0.0115	0.29	0.25	Height;	chr4:55537960	chr4:55547112~55547889:+
COAD	cis	rs2188554	0.785	rs6943105	ENSG00000237974.1	AC000111.4	4.16	4.38e-05	0.0115	0.25	0.25	Esophageal adenocarcinoma;	chr7:117516287	chr7:117487737~117487929:+
COAD	cis	rs2929278	0.561	rs3099045	ENSG00000275601.1	AC011330.13	-4.16	4.38e-05	0.0115	-0.3	-0.25	Schizophrenia;	chr15:43631757	chr15:43642389~43643023:-
COAD	cis	rs2115630	0.936	rs8033459	ENSG00000259728.4	LINC00933	-4.16	4.38e-05	0.0115	-0.3	-0.25	P wave terminal force;	chr15:84710027	chr15:84570649~84580175:+
COAD	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-4.16	4.38e-05	0.0115	-0.26	-0.25	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
COAD	cis	rs7577696	0.597	rs2280968	ENSG00000272716.1	RP11-563N4.1	-4.16	4.38e-05	0.0115	-0.29	-0.25	Inflammatory biomarkers;	chr2:32064971	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.597	rs7556942	ENSG00000272716.1	RP11-563N4.1	-4.16	4.38e-05	0.0115	-0.29	-0.25	Inflammatory biomarkers;	chr2:32070625	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.597	rs17011801	ENSG00000272716.1	RP11-563N4.1	-4.16	4.38e-05	0.0115	-0.29	-0.25	Inflammatory biomarkers;	chr2:32073003	chr2:32165046~32165757:-
COAD	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-4.16	4.38e-05	0.0115	-0.4	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
COAD	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	4.16	4.39e-05	0.0115	0.27	0.25	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	4.16	4.39e-05	0.0115	0.27	0.25	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
COAD	cis	rs4927850	1	rs4927850	ENSG00000273009.1	RP11-352G9.1	4.16	4.39e-05	0.0115	0.27	0.25	Pancreatic cancer;	chr3:196024759	chr3:195913078~195913683:-
COAD	cis	rs2188554	0.785	rs17139943	ENSG00000237974.1	AC000111.4	-4.16	4.39e-05	0.0115	-0.25	-0.25	Esophageal adenocarcinoma;	chr7:117489437	chr7:117487737~117487929:+
COAD	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	4.16	4.39e-05	0.0115	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	4.16	4.39e-05	0.0115	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
COAD	cis	rs3743162	0.553	rs4842994	ENSG00000259728.4	LINC00933	-4.16	4.39e-05	0.0115	-0.34	-0.25	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84570649~84580175:+
COAD	cis	rs11168618	0.567	rs12372687	ENSG00000273765.1	RP11-370I10.11	4.16	4.39e-05	0.0115	0.27	0.25	Adiponectin levels;	chr12:48418016	chr12:48360920~48361377:+
COAD	cis	rs7955901	0.691	rs36071486	ENSG00000258053.1	CTD-2021H9.3	4.16	4.39e-05	0.0115	0.31	0.25	Type 2 diabetes;	chr12:71094051	chr12:71047402~71118247:-
COAD	cis	rs2243480	1	rs34815098	ENSG00000232559.3	GS1-124K5.12	4.16	4.4e-05	0.0115	0.44	0.25	Diabetic kidney disease;	chr7:65827267	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs7456042	ENSG00000232559.3	GS1-124K5.12	4.16	4.4e-05	0.0115	0.44	0.25	Diabetic kidney disease;	chr7:65834791	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs34703416	ENSG00000232559.3	GS1-124K5.12	4.16	4.4e-05	0.0115	0.44	0.25	Diabetic kidney disease;	chr7:65835655	chr7:66554588~66576923:-
COAD	cis	rs860295	0.676	rs2666826	ENSG00000203761.5	MSTO2P	-4.16	4.4e-05	0.0116	-0.23	-0.25	Body mass index;	chr1:155688294	chr1:155745829~155750137:+
COAD	cis	rs4657482	0.962	rs4657483	ENSG00000236364.3	RP11-525G13.2	4.16	4.4e-05	0.0116	0.19	0.25	Testicular germ cell tumor;	chr1:165864880	chr1:165890795~165900683:-
COAD	cis	rs9532669	0.963	rs7989303	ENSG00000277662.1	RP11-74J13.9	-4.16	4.4e-05	0.0116	-0.25	-0.25	Cervical cancer;	chr13:40950087	chr13:41229180~41229676:-
COAD	cis	rs4072705	1	rs7874367	ENSG00000236643.1	RP11-175D17.3	-4.16	4.4e-05	0.0116	-0.27	-0.25	Menarche (age at onset);	chr9:124615501	chr9:124770123~124772927:+
COAD	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	4.16	4.4e-05	0.0116	0.3	0.25	Height;	chr4:55452921	chr4:55540502~55540835:-
COAD	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-4.16	4.4e-05	0.0116	-0.31	-0.25	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
COAD	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-4.16	4.4e-05	0.0116	-0.31	-0.25	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
COAD	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	4.16	4.4e-05	0.0116	0.26	0.25	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
COAD	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	4.16	4.4e-05	0.0116	0.56	0.25	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	4.16	4.4e-05	0.0116	0.56	0.25	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
COAD	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-4.16	4.4e-05	0.0116	-0.29	-0.25	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
COAD	cis	rs7077164	0.607	rs1227771	ENSG00000231748.1	RP11-227H15.5	4.16	4.4e-05	0.0116	0.26	0.25	Non-alcoholic fatty liver disease histology (lobular);	chr10:69818146	chr10:69265342~69268148:-
COAD	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.16	4.4e-05	0.0116	-0.25	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
COAD	cis	rs953301	1	rs74125007	ENSG00000229808.1	RP11-456P18.2	-4.16	4.4e-05	0.0116	-0.58	-0.25	Left atrial antero-posterior diameter;	chr1:161743340	chr1:161890833~161892196:+
COAD	cis	rs953301	1	rs905593	ENSG00000229808.1	RP11-456P18.2	-4.16	4.4e-05	0.0116	-0.58	-0.25	Left atrial antero-posterior diameter;	chr1:161747949	chr1:161890833~161892196:+
COAD	cis	rs953301	1	rs953301	ENSG00000229808.1	RP11-456P18.2	-4.16	4.4e-05	0.0116	-0.58	-0.25	Left atrial antero-posterior diameter;	chr1:161749589	chr1:161890833~161892196:+
COAD	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-4.16	4.41e-05	0.0116	-0.26	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
COAD	cis	rs9907295	0.591	rs2291299	ENSG00000271013.1	AC015849.15	-4.16	4.41e-05	0.0116	-0.31	-0.25	Fibroblast growth factor basic levels;	chr17:35864402	chr17:35912635~35918010:-
COAD	cis	rs1510272	0.924	rs4680284	ENSG00000243926.1	TIPARP-AS1	-4.16	4.41e-05	0.0116	-0.28	-0.25	Testicular germ cell tumor;	chr3:156587852	chr3:156671862~156674378:-
COAD	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-4.16	4.41e-05	0.0116	-0.48	-0.25	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-4.16	4.41e-05	0.0116	-0.48	-0.25	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-4.16	4.41e-05	0.0116	-0.48	-0.25	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
COAD	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-4.16	4.41e-05	0.0116	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-4.16	4.41e-05	0.0116	-0.48	-0.25	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
COAD	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	4.16	4.41e-05	0.0116	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
COAD	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-4.16	4.41e-05	0.0116	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
COAD	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-4.16	4.41e-05	0.0116	-0.25	-0.25	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
COAD	cis	rs7615952	0.605	rs34865555	ENSG00000272840.1	RP11-379B18.6	4.16	4.41e-05	0.0116	0.49	0.25	Blood pressure (smoking interaction);	chr3:125585290	chr3:125774714~125797953:+
COAD	cis	rs1044826	0.642	rs9826544	ENSG00000272656.1	RP11-219D15.3	4.16	4.41e-05	0.0116	0.3	0.25	Obesity-related traits;	chr3:139443989	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.642	rs4607068	ENSG00000272656.1	RP11-219D15.3	4.16	4.41e-05	0.0116	0.3	0.25	Obesity-related traits;	chr3:139444152	chr3:139349024~139349371:-
COAD	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-4.16	4.42e-05	0.0116	-0.25	-0.25	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
COAD	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-4.16	4.42e-05	0.0116	-0.34	-0.25	Pain;	chr19:21568988	chr19:21554640~21569237:-
COAD	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	4.16	4.42e-05	0.0116	0.23	0.25	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
COAD	cis	rs2638953	0.815	rs58416107	ENSG00000247934.4	RP11-967K21.1	-4.16	4.42e-05	0.0116	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28543645	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs11049708	ENSG00000247934.4	RP11-967K21.1	-4.16	4.42e-05	0.0116	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28544881	chr12:28163298~28190738:-
COAD	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-4.16	4.42e-05	0.0116	-0.23	-0.25	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
COAD	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-4.16	4.42e-05	0.0116	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-4.16	4.42e-05	0.0116	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-4.16	4.42e-05	0.0116	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-4.16	4.42e-05	0.0116	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
COAD	cis	rs7819412	0.521	rs10110684	ENSG00000269918.1	AF131215.9	-4.16	4.42e-05	0.0116	-0.31	-0.25	Triglycerides;	chr8:11181650	chr8:11104691~11106704:-
COAD	cis	rs8141529	0.764	rs8137969	ENSG00000272858.1	CTA-292E10.8	-4.16	4.42e-05	0.0116	-0.3	-0.25	Lymphocyte counts;	chr22:28832496	chr22:28814914~28815662:+
COAD	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-4.16	4.42e-05	0.0116	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
COAD	cis	rs2732480	0.967	rs2732469	ENSG00000257735.1	RP11-370I10.6	4.16	4.43e-05	0.0116	0.29	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48350945~48442411:+
COAD	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	4.16	4.43e-05	0.0116	0.3	0.25	Height;	chr4:55548666	chr4:55540502~55540835:-
COAD	cis	rs1670533	1	rs12645644	ENSG00000273179.1	RP11-20I20.4	4.16	4.43e-05	0.0116	0.31	0.25	Recombination rate (females);	chr4:1060371	chr4:1167778~1168174:+
COAD	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	4.16	4.43e-05	0.0116	0.3	0.25	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
COAD	cis	rs801193	0.569	rs7782587	ENSG00000224316.1	RP11-479O9.2	4.15	4.43e-05	0.0116	0.27	0.25	Aortic root size;	chr7:66701485	chr7:65773620~65802067:+
COAD	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	4.15	4.43e-05	0.0116	0.3	0.25	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
COAD	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	4.15	4.44e-05	0.0116	0.26	0.25	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
COAD	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-4.15	4.44e-05	0.0116	-0.28	-0.25	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
COAD	cis	rs8002861	0.664	rs2184882	ENSG00000274001.1	RP11-5G9.5	4.15	4.44e-05	0.0116	0.22	0.25	Leprosy;	chr13:43876210	chr13:43877715~43878163:-
COAD	cis	rs739496	0.615	rs12582964	ENSG00000257595.2	RP3-473L9.4	4.15	4.44e-05	0.0117	0.37	0.25	Platelet count;	chr12:111652975	chr12:111369282~111403310:+
COAD	cis	rs11089937	0.555	rs6001226	ENSG00000211638.2	IGLV8-61	-4.15	4.44e-05	0.0117	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22098700~22099212:+
COAD	cis	rs734999	0.566	rs6664969	ENSG00000225931.3	RP3-395M20.7	4.15	4.45e-05	0.0117	0.28	0.25	Ulcerative colitis;	chr1:2603539	chr1:2566410~2569888:+
COAD	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-4.15	4.45e-05	0.0117	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
COAD	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-4.15	4.45e-05	0.0117	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
COAD	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-4.15	4.45e-05	0.0117	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-4.15	4.45e-05	0.0117	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
COAD	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.15	4.45e-05	0.0117	-0.22	-0.25	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
COAD	cis	rs10819861	0.62	rs10819834	ENSG00000238251.2	RP11-172F4.2	-4.15	4.45e-05	0.0117	-0.31	-0.25	Electrocardiographic traits;	chr9:96095191	chr9:96407284~96407797:+
COAD	cis	rs10819861	0.621	rs4743536	ENSG00000238251.2	RP11-172F4.2	-4.15	4.45e-05	0.0117	-0.31	-0.25	Electrocardiographic traits;	chr9:96095704	chr9:96407284~96407797:+
COAD	cis	rs73198271	0.74	rs10105920	ENSG00000173295.6	FAM86B3P	4.15	4.45e-05	0.0117	0.32	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8228595~8244865:+
COAD	cis	rs1914816	1	rs2255408	ENSG00000196274.5	Metazoa_SRP	-4.15	4.45e-05	0.0117	-0.26	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76230048~76230390:-
COAD	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-4.15	4.45e-05	0.0117	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-4.15	4.45e-05	0.0117	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-4.15	4.45e-05	0.0117	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
COAD	cis	rs6687821	0.515	rs2390220	ENSG00000261737.1	RP4-612B15.3	4.15	4.45e-05	0.0117	0.32	0.25	Yeast infection;	chr1:86989235	chr1:86703502~86704462:-
COAD	cis	rs74781061	0.932	rs7161903	ENSG00000260103.2	RP11-10O17.1	-4.15	4.46e-05	0.0117	-0.28	-0.25	Endometriosis;	chr15:74647929	chr15:74478070~74490286:-
COAD	cis	rs2980439	0.818	rs2948294	ENSG00000254340.1	RP11-10A14.3	4.15	4.46e-05	0.0117	0.31	0.25	Neuroticism;	chr8:8237439	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	4.15	4.46e-05	0.0117	0.33	0.25	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
COAD	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-4.15	4.46e-05	0.0117	-0.52	-0.25	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
COAD	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	4.15	4.46e-05	0.0117	0.22	0.25	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
COAD	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-4.15	4.46e-05	0.0117	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
COAD	cis	rs3096299	0.967	rs2965935	ENSG00000260259.1	RP11-368I7.4	-4.15	4.46e-05	0.0117	-0.29	-0.25	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89682620~89686569:-
COAD	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-4.15	4.46e-05	0.0117	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
COAD	cis	rs4142995	0.586	rs2389858	ENSG00000279048.1	RP11-511H23.2	-4.15	4.46e-05	0.0117	-0.18	-0.25	HDL cholesterol;HDL cholesterol levels;	chr7:17868507	chr7:17940503~17942922:+
COAD	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-4.15	4.46e-05	0.0117	-0.27	-0.25	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
COAD	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	4.15	4.47e-05	0.0117	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
COAD	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	4.15	4.47e-05	0.0117	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
COAD	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	4.15	4.47e-05	0.0117	0.34	0.25	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
COAD	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	4.15	4.47e-05	0.0117	0.35	0.25	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
COAD	cis	rs9903692	0.505	rs208005	ENSG00000278765.1	RP5-890E16.5	-4.15	4.47e-05	0.0117	-0.47	-0.25	Pulse pressure;	chr17:48162623	chr17:48066704~48067293:-
COAD	cis	rs3120667	0.79	rs11590822	ENSG00000237975.5	FLG-AS1	4.15	4.47e-05	0.0117	0.29	0.25	Eating disorders;	chr1:152420483	chr1:152168125~152445456:+
COAD	cis	rs2638953	0.741	rs12184491	ENSG00000247934.4	RP11-967K21.1	-4.15	4.47e-05	0.0117	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535619	chr12:28163298~28190738:-
COAD	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	4.15	4.47e-05	0.0117	0.29	0.25	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
COAD	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-4.15	4.48e-05	0.0117	-0.29	-0.25	Height;	chr11:118856460	chr11:118704607~118750263:+
COAD	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-4.15	4.48e-05	0.0117	-0.29	-0.25	Height;	chr11:118856623	chr11:118704607~118750263:+
COAD	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-4.15	4.48e-05	0.0117	-0.29	-0.25	Height;	chr11:118857611	chr11:118704607~118750263:+
COAD	cis	rs58873874	1	rs75720504	ENSG00000248544.2	CTB-47B11.3	4.15	4.48e-05	0.0117	0.59	0.25	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157375741~157384950:-
COAD	cis	rs9400467	0.508	rs61269242	ENSG00000271789.1	RP5-1112D6.7	-4.15	4.48e-05	0.0117	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111297126~111298510:+
COAD	cis	rs2638953	0.962	rs61922977	ENSG00000247934.4	RP11-967K21.1	-4.15	4.48e-05	0.0117	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049505	ENSG00000247934.4	RP11-967K21.1	-4.15	4.48e-05	0.0117	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049509	ENSG00000247934.4	RP11-967K21.1	-4.15	4.48e-05	0.0117	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28163298~28190738:-
COAD	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	4.15	4.48e-05	0.0117	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
COAD	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	4.15	4.48e-05	0.0117	0.33	0.25	Depression;	chr6:28205232	chr6:28170845~28172521:+
COAD	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	4.15	4.48e-05	0.0117	0.32	0.25	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
COAD	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.15	4.48e-05	0.0117	-0.25	-0.25	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
COAD	cis	rs3126085	0.56	rs3120666	ENSG00000237975.5	FLG-AS1	4.15	4.48e-05	0.0117	0.29	0.25	Atopic dermatitis;	chr1:152344505	chr1:152168125~152445456:+
COAD	cis	rs7131987	0.903	rs11050161	ENSG00000257176.2	RP11-996F15.2	-4.15	4.48e-05	0.0117	-0.29	-0.25	QT interval;	chr12:29267116	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.903	rs11050162	ENSG00000257176.2	RP11-996F15.2	-4.15	4.48e-05	0.0117	-0.29	-0.25	QT interval;	chr12:29267121	chr12:29280418~29317848:-
COAD	cis	rs17772222	0.793	rs7143853	ENSG00000258789.1	RP11-507K2.3	-4.15	4.48e-05	0.0117	-0.37	-0.25	Coronary artery calcification;	chr14:88578477	chr14:88551597~88552493:+
COAD	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-4.15	4.49e-05	0.0117	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
COAD	cis	rs453301	0.631	rs28572014	ENSG00000233609.3	RP11-62H7.2	-4.15	4.49e-05	0.0117	-0.28	-0.25	Joint mobility (Beighton score);	chr8:8936097	chr8:8961200~8979025:+
COAD	cis	rs7615952	0.688	rs4422259	ENSG00000241288.6	RP11-379B18.5	-4.15	4.49e-05	0.0117	-0.25	-0.25	Blood pressure (smoking interaction);	chr3:125826988	chr3:125827238~125916384:-
COAD	cis	rs17036350	1	rs17036350	ENSG00000230337.1	RP4-635E18.6	-4.15	4.49e-05	0.0118	-0.54	-0.25	Corneal curvature;	chr1:11111169	chr1:11099675~11102100:+
COAD	cis	rs2408955	0.521	rs11168437	ENSG00000273765.1	RP11-370I10.11	4.15	4.49e-05	0.0118	0.27	0.25	Glycated hemoglobin levels;	chr12:48172373	chr12:48360920~48361377:+
COAD	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	4.15	4.49e-05	0.0118	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
COAD	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-4.15	4.49e-05	0.0118	-0.17	-0.25	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
COAD	cis	rs4704187	0.687	rs11950665	ENSG00000250889.2	LINC01336	-4.15	4.49e-05	0.0118	-0.28	-0.25	Response to amphetamines;	chr5:75127514	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.687	rs7735937	ENSG00000250889.2	LINC01336	-4.15	4.49e-05	0.0118	-0.28	-0.25	Response to amphetamines;	chr5:75145875	chr5:75047719~75052843:-
COAD	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-4.15	4.5e-05	0.0118	-0.23	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
COAD	cis	rs1275468	0.954	rs6582292	ENSG00000257497.2	RP11-585P4.5	4.15	4.5e-05	0.0118	0.32	0.25	Polycystic ovary syndrome;	chr12:75539175	chr12:75483454~75489820:-
COAD	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-4.15	4.5e-05	0.0118	-0.33	-0.25	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
COAD	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	4.15	4.5e-05	0.0118	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
COAD	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-4.15	4.5e-05	0.0118	-0.3	-0.25	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
COAD	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	4.15	4.5e-05	0.0118	0.26	0.25	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	4.15	4.5e-05	0.0118	0.26	0.25	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
COAD	cis	rs9532669	0.7	rs9525406	ENSG00000239827.7	SUGT1P3	-4.15	4.5e-05	0.0118	-0.21	-0.25	Cervical cancer;	chr13:40860812	chr13:40908159~40921774:-
COAD	cis	rs7829975	0.714	rs7823757	ENSG00000233609.3	RP11-62H7.2	4.15	4.5e-05	0.0118	0.28	0.25	Mood instability;	chr8:8812667	chr8:8961200~8979025:+
COAD	cis	rs1949733	0.959	rs2688242	ENSG00000205959.3	RP11-689P11.2	-4.15	4.5e-05	0.0118	-0.31	-0.25	Response to antineoplastic agents;	chr4:8428216	chr4:8482270~8512610:+
COAD	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-4.15	4.5e-05	0.0118	-0.3	-0.25	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
COAD	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.15	4.5e-05	0.0118	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	4.15	4.51e-05	0.0118	0.32	0.25	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
COAD	cis	rs4879656	0.866	rs10971316	ENSG00000225693.1	LAGE3P1	-4.15	4.51e-05	0.0118	-0.29	-0.25	Menopause (age at onset);	chr9:33013964	chr9:33019682~33020165:-
COAD	cis	rs4879656	0.872	rs12375624	ENSG00000225693.1	LAGE3P1	-4.15	4.51e-05	0.0118	-0.29	-0.25	Menopause (age at onset);	chr9:33017140	chr9:33019682~33020165:-
COAD	cis	rs7200543	1	rs1136001	ENSG00000270580.4	PKD1P6	4.15	4.51e-05	0.0118	0.28	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15104723~15131601:-
COAD	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	4.15	4.51e-05	0.0118	0.2	0.25	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	4.15	4.51e-05	0.0118	0.2	0.25	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
COAD	cis	rs58873874	0.737	rs11744671	ENSG00000248544.2	CTB-47B11.3	4.15	4.51e-05	0.0118	0.59	0.25	Bipolar disorder (body mass index interaction);	chr5:157494223	chr5:157375741~157384950:-
COAD	cis	rs2243480	1	rs35735127	ENSG00000232559.3	GS1-124K5.12	4.15	4.51e-05	0.0118	0.44	0.25	Diabetic kidney disease;	chr7:65835436	chr7:66554588~66576923:-
COAD	cis	rs4834770	1	rs878375	ENSG00000250412.1	KLHL2P1	4.15	4.51e-05	0.0118	0.3	0.25	Blood protein levels;	chr4:119316419	chr4:119334329~119378233:+
COAD	cis	rs1023500	1	rs6002554	ENSG00000237037.8	NDUFA6-AS1	4.15	4.51e-05	0.0118	0.26	0.25	Schizophrenia;	chr22:41943091	chr22:42090931~42137742:+
COAD	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	4.15	4.51e-05	0.0118	0.28	0.25	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
COAD	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-4.15	4.51e-05	0.0118	-0.31	-0.25	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
COAD	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-4.15	4.51e-05	0.0118	-0.31	-0.25	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
COAD	cis	rs13256369	0.901	rs4841015	ENSG00000173295.6	FAM86B3P	4.15	4.51e-05	0.0118	0.35	0.25	Obesity-related traits;	chr8:8709630	chr8:8228595~8244865:+
COAD	cis	rs6088813	0.645	rs6088836	ENSG00000269202.1	RP4-614O4.12	-4.15	4.51e-05	0.0118	-0.26	-0.25	Height;	chr20:35428410	chr20:35201747~35203288:-
COAD	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-4.15	4.51e-05	0.0118	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
COAD	cis	rs1949733	0.598	rs869602	ENSG00000205959.3	RP11-689P11.2	4.15	4.52e-05	0.0118	0.31	0.25	Response to antineoplastic agents;	chr4:8533644	chr4:8482270~8512610:+
COAD	cis	rs1949733	0.598	rs16842480	ENSG00000205959.3	RP11-689P11.2	4.15	4.52e-05	0.0118	0.31	0.25	Response to antineoplastic agents;	chr4:8533894	chr4:8482270~8512610:+
COAD	cis	rs7577696	0.924	rs72862234	ENSG00000272716.1	RP11-563N4.1	-4.15	4.52e-05	0.0118	-0.26	-0.25	Inflammatory biomarkers;	chr2:32045077	chr2:32165046~32165757:-
COAD	cis	rs28374715	0.617	rs16971735	ENSG00000247556.5	OIP5-AS1	4.15	4.52e-05	0.0118	0.25	0.25	Ulcerative colitis;	chr15:41271772	chr15:41283990~41309737:+
COAD	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-4.15	4.52e-05	0.0118	-0.27	-0.25	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
COAD	cis	rs2581828	0.58	rs57514626	ENSG00000280417.1	RP11-5O17.1	4.15	4.52e-05	0.0118	0.28	0.25	Crohn's disease;	chr3:53135286	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.58	rs61296683	ENSG00000280417.1	RP11-5O17.1	4.15	4.52e-05	0.0118	0.28	0.25	Crohn's disease;	chr3:53135307	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.58	rs9867590	ENSG00000280417.1	RP11-5O17.1	4.15	4.52e-05	0.0118	0.28	0.25	Crohn's disease;	chr3:53135635	chr3:53046166~53048122:+
COAD	cis	rs9816784	0.576	rs12631246	ENSG00000207650.1	MIR570	4.15	4.52e-05	0.0118	0.32	0.25	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195699401~195699497:+
COAD	cis	rs7577696	0.962	rs13017189	ENSG00000272716.1	RP11-563N4.1	-4.15	4.52e-05	0.0118	-0.26	-0.25	Inflammatory biomarkers;	chr2:32056211	chr2:32165046~32165757:-
COAD	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	4.15	4.52e-05	0.0118	0.41	0.25	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
COAD	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-4.15	4.53e-05	0.0118	-0.31	-0.25	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
COAD	cis	rs7487075	0.93	rs11183468	ENSG00000257261.4	RP11-96H19.1	4.15	4.53e-05	0.0118	0.26	0.25	Itch intensity from mosquito bite;	chr12:46412478	chr12:46383679~46876159:+
COAD	cis	rs6719977	0.543	rs6544594	ENSG00000226491.1	FTOP1	-4.15	4.53e-05	0.0118	-0.34	-0.25	Hyperactive-impulsive symptoms;	chr2:42750439	chr2:42797225~42798712:-
COAD	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	4.15	4.53e-05	0.0118	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	4.15	4.53e-05	0.0118	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	4.15	4.53e-05	0.0118	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
COAD	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-4.15	4.53e-05	0.0118	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
COAD	cis	rs2307394	0.896	rs12995413	ENSG00000281469.1	RP11-567F11.1	4.15	4.53e-05	0.0118	0.3	0.25	Urate levels;	chr2:148044083	chr2:148044380~148044894:+
COAD	cis	rs6452524	0.935	rs6896953	ENSG00000271862.1	RP11-343L5.2	-4.15	4.54e-05	0.0119	-0.24	-0.25	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83049376~83050964:-
COAD	cis	rs2638953	0.85	rs10843167	ENSG00000247934.4	RP11-967K21.1	-4.15	4.54e-05	0.0119	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:28163298~28190738:-
COAD	cis	rs1624802	0.966	rs1707933	ENSG00000280002.1	RP11-76C10.6	-4.15	4.54e-05	0.0119	-0.29	-0.25	Obesity-related traits;	chr12:130013268	chr12:130988312~130990028:-
COAD	cis	rs8091660	0.624	rs9948328	ENSG00000278983.1	RP11-426J5.3	4.15	4.54e-05	0.0119	0.29	0.25	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569613	chr18:48564795~48568342:+
COAD	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-4.15	4.54e-05	0.0119	-0.44	-0.25	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
COAD	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-4.15	4.55e-05	0.0119	-0.23	-0.25	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
COAD	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-4.15	4.55e-05	0.0119	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
COAD	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.15	4.55e-05	0.0119	-0.31	-0.25	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
COAD	cis	rs41294858	0.841	rs55731938	ENSG00000232876.1	CTA-212D2.2	-4.15	4.55e-05	0.0119	-0.46	-0.25	Red blood cell count;	chr6:135093712	chr6:135055033~135060550:+
COAD	cis	rs1555133	0.625	rs6141665	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Monocyte count;	chr20:32303438	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs6141666	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32307959	chr20:31547504~31548049:+
COAD	cis	rs1555133	0.625	rs6141671	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Monocyte count;	chr20:32317768	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs4911216	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32322107	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs4911217	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32322148	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs56012551	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32323312	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs56366536	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32323462	chr20:31547504~31548049:+
COAD	cis	rs1555133	0.624	rs55647947	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Monocyte count;	chr20:32323583	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs13043343	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32324404	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs2024952	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32326149	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs3746606	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32326903	chr20:31547504~31548049:+
COAD	cis	rs4243971	0.516	rs933004	ENSG00000101898.5	MCTS2P	4.15	4.55e-05	0.0119	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32329704	chr20:31547504~31548049:+
COAD	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	4.15	4.55e-05	0.0119	0.3	0.25	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
COAD	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-4.15	4.55e-05	0.0119	-0.3	-0.25	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-4.15	4.55e-05	0.0119	-0.3	-0.25	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
COAD	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	4.15	4.55e-05	0.0119	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
COAD	cis	rs11603023	0.874	rs483598	ENSG00000278376.1	RP11-158I9.8	-4.15	4.55e-05	0.0119	-0.25	-0.25	Cholesterol, total;	chr11:118638950	chr11:118791254~118793137:+
COAD	cis	rs74394007	0.541	rs542934	ENSG00000240875.4	LINC00886	4.15	4.55e-05	0.0119	0.27	0.25	Total body bone mineral density;	chr3:156854443	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs2633815	ENSG00000240875.4	LINC00886	4.15	4.55e-05	0.0119	0.27	0.25	Total body bone mineral density;	chr3:156855425	chr3:156747346~156817062:-
COAD	cis	rs2799081	1	rs2799081	ENSG00000272009.1	RP1-313I6.12	4.15	4.55e-05	0.0119	0.3	0.25	Myopia;	chr6:28302807	chr6:28078792~28081130:-
COAD	cis	rs597539	0.652	rs514833	ENSG00000255741.1	RP11-757G1.5	-4.15	4.55e-05	0.0119	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs488363	ENSG00000255741.1	RP11-757G1.5	-4.15	4.55e-05	0.0119	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs660614	ENSG00000255741.1	RP11-757G1.5	-4.15	4.55e-05	0.0119	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68941503~68942852:-
COAD	cis	rs728616	0.51	rs12411989	ENSG00000234382.2	RP11-40F6.1	-4.15	4.55e-05	0.0119	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:80233664~80245367:+
COAD	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-4.15	4.55e-05	0.0119	-0.32	-0.25	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
COAD	cis	rs2682471	0.605	rs10772275	ENSG00000245648.1	RP11-277P12.20	4.15	4.56e-05	0.0119	0.32	0.25	Macrophage inflammatory protein 1a levels;	chr12:10410993	chr12:10363769~10398506:+
COAD	cis	rs6088813	0.645	rs8123889	ENSG00000269202.1	RP4-614O4.12	-4.15	4.56e-05	0.0119	-0.26	-0.25	Height;	chr20:35425455	chr20:35201747~35203288:-
COAD	cis	rs8022206	0.853	rs72725186	ENSG00000259502.1	RP11-643G16.3	4.15	4.56e-05	0.0119	0.41	0.25	Platelet count;Mean platelet volume;	chr14:68073539	chr14:67610986~67613864:+
COAD	cis	rs2638953	0.925	rs11049598	ENSG00000247934.4	RP11-967K21.1	-4.15	4.56e-05	0.0119	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28163298~28190738:-
COAD	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	4.15	4.56e-05	0.0119	0.22	0.25	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
COAD	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	4.15	4.56e-05	0.0119	0.32	0.25	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
COAD	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	4.15	4.56e-05	0.0119	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
COAD	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	4.15	4.57e-05	0.0119	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
COAD	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-4.15	4.57e-05	0.0119	-0.27	-0.25	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
COAD	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-4.15	4.57e-05	0.0119	-0.26	-0.25	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
COAD	cis	rs2836974	0.897	rs8128102	ENSG00000255568.3	BRWD1-AS2	4.15	4.57e-05	0.0119	0.26	0.25	Cognitive function;	chr21:39234488	chr21:39313935~39314962:+
COAD	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	4.15	4.57e-05	0.0119	0.3	0.25	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
COAD	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	4.15	4.58e-05	0.0119	0.25	0.25	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
COAD	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	4.15	4.58e-05	0.0119	0.25	0.25	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
COAD	cis	rs2836974	0.965	rs2836965	ENSG00000255568.3	BRWD1-AS2	-4.15	4.58e-05	0.0119	-0.26	-0.25	Cognitive function;	chr21:39261705	chr21:39313935~39314962:+
COAD	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	4.15	4.58e-05	0.0119	0.41	0.25	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
COAD	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	4.15	4.58e-05	0.012	0.15	0.25	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
COAD	cis	rs3126085	1	rs3126098	ENSG00000237975.5	FLG-AS1	4.15	4.58e-05	0.012	0.29	0.25	Atopic dermatitis;	chr1:152339447	chr1:152168125~152445456:+
COAD	cis	rs3733585	0.673	rs10000983	ENSG00000250413.1	RP11-448G15.1	4.15	4.58e-05	0.012	0.32	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9949982	chr4:10006482~10009725:+
COAD	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-4.15	4.58e-05	0.012	-0.33	-0.25	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
COAD	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	4.15	4.59e-05	0.012	0.48	0.25	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	4.15	4.59e-05	0.012	0.48	0.25	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	4.15	4.59e-05	0.012	0.48	0.25	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
COAD	cis	rs860295	0.871	rs6696888	ENSG00000225082.2	DAP3P1	4.15	4.59e-05	0.012	0.31	0.25	Body mass index;	chr1:155539091	chr1:155586644~155602197:+
COAD	cis	rs2115630	1	rs10220733	ENSG00000259728.4	LINC00933	-4.15	4.59e-05	0.012	-0.29	-0.25	P wave terminal force;	chr15:84737633	chr15:84570649~84580175:+
COAD	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	4.15	4.59e-05	0.012	0.26	0.25	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
COAD	cis	rs17685	0.753	rs10245584	ENSG00000280388.1	RP11-229D13.3	-4.15	4.59e-05	0.012	-0.26	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76043977~76045963:-
COAD	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	4.15	4.59e-05	0.012	0.32	0.25	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
COAD	cis	rs812925	0.502	rs2084318	ENSG00000273302.1	RP11-493E12.2	-4.15	4.59e-05	0.012	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61425466	chr2:61199979~61200769:+
COAD	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-4.15	4.59e-05	0.012	-0.33	-0.25	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
COAD	cis	rs9307551	0.553	rs12639996	ENSG00000250334.4	LINC00989	-4.15	4.6e-05	0.012	-0.3	-0.25	Refractive error;	chr4:79551326	chr4:79492416~79576460:+
COAD	cis	rs7646881	0.812	rs73015665	ENSG00000272087.1	RP11-379F4.7	4.15	4.6e-05	0.012	0.38	0.25	Tetralogy of Fallot;	chr3:158736145	chr3:158693120~158693768:-
COAD	cis	rs3120667	0.79	rs3753444	ENSG00000237975.5	FLG-AS1	4.15	4.6e-05	0.012	0.3	0.25	Eating disorders;	chr1:152415391	chr1:152168125~152445456:+
COAD	cis	rs12188164	0.686	rs72711370	ENSG00000221990.4	EXOC3-AS1	4.15	4.6e-05	0.012	0.26	0.25	Cystic fibrosis severity;	chr5:420942	chr5:441498~443160:-
COAD	cis	rs12188164	0.714	rs11741954	ENSG00000221990.4	EXOC3-AS1	4.15	4.6e-05	0.012	0.26	0.25	Cystic fibrosis severity;	chr5:421340	chr5:441498~443160:-
COAD	cis	rs4819052	0.851	rs2255766	ENSG00000227039.5	ITGB2-AS1	-4.15	4.6e-05	0.012	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:44921051~44929678:+
COAD	cis	rs2836974	0.897	rs34035316	ENSG00000255568.3	BRWD1-AS2	4.15	4.6e-05	0.012	0.25	0.25	Cognitive function;	chr21:39222097	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs2026265	ENSG00000255568.3	BRWD1-AS2	4.15	4.6e-05	0.012	0.25	0.25	Cognitive function;	chr21:39223591	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs1984022	ENSG00000255568.3	BRWD1-AS2	4.15	4.6e-05	0.012	0.25	0.25	Cognitive function;	chr21:39224159	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs56306759	ENSG00000255568.3	BRWD1-AS2	4.15	4.6e-05	0.012	0.25	0.25	Cognitive function;	chr21:39236180	chr21:39313935~39314962:+
COAD	cis	rs2929278	0.617	rs2955969	ENSG00000275601.1	AC011330.13	4.15	4.61e-05	0.012	0.3	0.25	Schizophrenia;	chr15:43822329	chr15:43642389~43643023:-
COAD	cis	rs875971	0.862	rs9791712	ENSG00000224316.1	RP11-479O9.2	-4.15	4.61e-05	0.012	-0.27	-0.25	Aortic root size;	chr7:66640176	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs9791713	ENSG00000224316.1	RP11-479O9.2	-4.15	4.61e-05	0.012	-0.27	-0.25	Aortic root size;	chr7:66640211	chr7:65773620~65802067:+
COAD	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-4.15	4.61e-05	0.012	-0.35	-0.25	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-4.15	4.61e-05	0.012	-0.35	-0.25	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
COAD	cis	rs12699921	0.607	rs35819944	ENSG00000279048.1	RP11-511H23.2	4.15	4.61e-05	0.012	0.18	0.25	Fibrinogen levels;	chr7:17928168	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs12699918	ENSG00000279048.1	RP11-511H23.2	4.15	4.61e-05	0.012	0.18	0.25	Fibrinogen levels;	chr7:17930277	chr7:17940503~17942922:+
COAD	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	4.15	4.61e-05	0.012	0.31	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
COAD	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-4.15	4.61e-05	0.012	-0.32	-0.25	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
COAD	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-4.15	4.61e-05	0.012	-0.26	-0.25	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-4.15	4.61e-05	0.012	-0.26	-0.25	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
COAD	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-4.15	4.61e-05	0.012	-0.43	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
COAD	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
COAD	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-4.15	4.62e-05	0.012	-0.3	-0.25	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
COAD	cis	rs5742933	0.817	rs1233265	ENSG00000253559.1	OSGEPL1-AS1	-4.15	4.62e-05	0.012	-0.25	-0.25	Ferritin levels;	chr2:189796390	chr2:189762704~189765556:+
COAD	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-4.14	4.62e-05	0.012	-0.31	-0.25	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
COAD	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-4.14	4.62e-05	0.012	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-4.14	4.62e-05	0.012	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
COAD	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-4.14	4.62e-05	0.012	-0.3	-0.25	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-4.14	4.62e-05	0.012	-0.3	-0.25	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-4.14	4.62e-05	0.012	-0.3	-0.25	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
COAD	cis	rs875971	1	rs1565531	ENSG00000230189.5	GS1-124K5.2	-4.14	4.62e-05	0.012	-0.21	-0.25	Aortic root size;	chr7:66198126	chr7:66409143~66490059:-
COAD	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-4.14	4.62e-05	0.012	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-4.14	4.62e-05	0.012	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-4.14	4.62e-05	0.012	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-4.14	4.62e-05	0.012	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
COAD	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-4.14	4.62e-05	0.012	-0.48	-0.25	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
COAD	cis	rs7204230	1	rs17302707	ENSG00000261056.2	RP11-454F8.2	-4.14	4.62e-05	0.012	-0.3	-0.25	Fibrinogen;	chr16:53177940	chr16:53298224~53299792:+
COAD	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	4.14	4.62e-05	0.012	0.35	0.25	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
COAD	cis	rs9532669	0.89	rs2324738	ENSG00000277662.1	RP11-74J13.9	-4.14	4.62e-05	0.012	-0.24	-0.25	Cervical cancer;	chr13:40925242	chr13:41229180~41229676:-
COAD	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	4.14	4.62e-05	0.012	0.32	0.25	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
COAD	cis	rs8022206	0.773	rs6573814	ENSG00000259502.1	RP11-643G16.3	4.14	4.62e-05	0.012	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68051046	chr14:67610986~67613864:+
COAD	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-4.14	4.63e-05	0.012	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-4.14	4.63e-05	0.012	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
COAD	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	4.14	4.63e-05	0.012	0.51	0.25	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
COAD	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-4.14	4.63e-05	0.012	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
COAD	cis	rs4006360	0.575	rs436266	ENSG00000267221.1	CTD-2132N18.2	4.14	4.63e-05	0.0121	0.27	0.25	Bipolar disorder and schizophrenia;	chr17:41157546	chr17:42040713~42043117:-
COAD	cis	rs494562	0.892	rs9353309	ENSG00000234155.1	RP11-30P6.6	-4.14	4.63e-05	0.0121	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85416427	chr6:85387219~85390186:-
COAD	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	4.14	4.63e-05	0.0121	0.34	0.25	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
COAD	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	4.14	4.63e-05	0.0121	0.36	0.25	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
COAD	cis	rs74394007	0.541	rs7650127	ENSG00000240875.4	LINC00886	4.14	4.63e-05	0.0121	0.28	0.25	Total body bone mineral density;	chr3:156924845	chr3:156747346~156817062:-
COAD	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-4.14	4.64e-05	0.0121	-0.35	-0.25	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
COAD	cis	rs10087240	0.509	rs1909457	ENSG00000207110.1	RNU1-106P	4.14	4.64e-05	0.0121	0.32	0.25	Lymphocyte counts;White blood cell count;	chr8:128019371	chr8:127999131~127999294:+
COAD	cis	rs12530	0.715	rs5998475	ENSG00000230736.2	RP1-149A16.3	-4.14	4.64e-05	0.0121	-0.31	-0.25	IgG glycosylation;	chr22:32405345	chr22:32376664~32384343:+
COAD	cis	rs4843747	0.709	rs72818521	ENSG00000205037.2	RP11-863P13.4	4.14	4.64e-05	0.0121	0.33	0.25	Menopause (age at onset);	chr16:88025145	chr16:88088041~88100985:-
COAD	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-4.14	4.64e-05	0.0121	-0.27	-0.25	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
COAD	cis	rs5758659	0.504	rs133367	ENSG00000182057.4	OGFRP1	-4.14	4.64e-05	0.0121	-0.25	-0.25	Cognitive function;	chr22:42067362	chr22:42269753~42275196:+
COAD	cis	rs253959	0.672	rs4921056	ENSG00000271918.1	CTD-2287O16.5	4.14	4.64e-05	0.0121	0.21	0.25	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116083807~116085416:-
COAD	cis	rs2638953	0.925	rs11049545	ENSG00000247934.4	RP11-967K21.1	-4.14	4.64e-05	0.0121	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28344965	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049547	ENSG00000247934.4	RP11-967K21.1	-4.14	4.64e-05	0.0121	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346945	chr12:28163298~28190738:-
COAD	cis	rs8022206	0.738	rs4899231	ENSG00000259502.1	RP11-643G16.3	4.14	4.64e-05	0.0121	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68063464	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.624	rs1080958	ENSG00000259502.1	RP11-643G16.3	4.14	4.64e-05	0.0121	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68064454	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.68	rs1080957	ENSG00000259502.1	RP11-643G16.3	4.14	4.64e-05	0.0121	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68064484	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.754	rs1080956	ENSG00000259502.1	RP11-643G16.3	4.14	4.64e-05	0.0121	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68064581	chr14:67610986~67613864:+
COAD	cis	rs9307551	0.857	rs2165387	ENSG00000250334.4	LINC00989	-4.14	4.65e-05	0.0121	-0.29	-0.25	Refractive error;	chr4:79570666	chr4:79492416~79576460:+
COAD	cis	rs7577696	0.539	rs13010405	ENSG00000272716.1	RP11-563N4.1	-4.14	4.65e-05	0.0121	-0.29	-0.25	Inflammatory biomarkers;	chr2:32113135	chr2:32165046~32165757:-
COAD	cis	rs860295	0.871	rs6696888	ENSG00000223503.1	RP11-29H23.6	4.14	4.65e-05	0.0121	0.33	0.25	Body mass index;	chr1:155539091	chr1:155590601~155591262:-
COAD	cis	rs2836974	0.666	rs4818015	ENSG00000255568.3	BRWD1-AS2	4.14	4.65e-05	0.0121	0.23	0.25	Cognitive function;	chr21:39303567	chr21:39313935~39314962:+
COAD	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-4.14	4.65e-05	0.0121	-0.15	-0.25	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
COAD	cis	rs1056107	0.656	rs10759537	ENSG00000225513.1	RP11-165N19.2	-4.14	4.65e-05	0.0121	-0.3	-0.25	Colorectal cancer;	chr9:112229799	chr9:112173522~112173971:-
COAD	cis	rs875971	0.862	rs6964437	ENSG00000224316.1	RP11-479O9.2	-4.14	4.66e-05	0.0121	-0.27	-0.25	Aortic root size;	chr7:66221457	chr7:65773620~65802067:+
COAD	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	4.14	4.66e-05	0.0121	0.26	0.25	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
COAD	cis	rs4688759	0.719	rs73079018	ENSG00000225399.4	RP11-3B7.1	-4.14	4.66e-05	0.0121	-0.51	-0.25	Blood protein levels;	chr3:49837894	chr3:49260085~49261316:+
COAD	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-4.14	4.66e-05	0.0121	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
COAD	cis	rs8061903	0.535	rs16965133	ENSG00000261617.1	RP11-243A14.1	4.14	4.66e-05	0.0121	0.31	0.25	HIV-1 viral setpoint;	chr16:9315608	chr16:9355588~9408093:+
COAD	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	4.14	4.66e-05	0.0121	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
COAD	cis	rs812925	0.537	rs10208769	ENSG00000273302.1	RP11-493E12.2	-4.14	4.66e-05	0.0121	-0.22	-0.25	Immature fraction of reticulocytes;	chr2:61378479	chr2:61199979~61200769:+
COAD	cis	rs4657482	0.962	rs4657484	ENSG00000236364.3	RP11-525G13.2	4.14	4.67e-05	0.0121	0.19	0.25	Testicular germ cell tumor;	chr1:165864886	chr1:165890795~165900683:-
COAD	cis	rs4657482	0.962	rs4657485	ENSG00000236364.3	RP11-525G13.2	4.14	4.67e-05	0.0121	0.19	0.25	Testicular germ cell tumor;	chr1:165865015	chr1:165890795~165900683:-
COAD	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-4.14	4.67e-05	0.0121	-0.33	-0.25	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
COAD	cis	rs9880211	0.613	rs28535121	ENSG00000273486.1	RP11-731C17.2	4.14	4.67e-05	0.0121	0.29	0.25	Height;Body mass index;	chr3:136173956	chr3:136837338~136839021:-
COAD	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	4.14	4.67e-05	0.0121	0.33	0.25	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
COAD	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	4.14	4.67e-05	0.0121	0.36	0.25	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	4.14	4.67e-05	0.0121	0.36	0.25	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	4.14	4.67e-05	0.0121	0.36	0.25	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
COAD	cis	rs55661361	1	rs55661361	ENSG00000245498.5	RP11-677M14.7	4.14	4.67e-05	0.0121	0.22	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124744061	chr11:124800450~124834487:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	4.14	4.67e-05	0.0121	0.25	0.25	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
COAD	cis	rs1949733	0.543	rs62287446	ENSG00000205959.3	RP11-689P11.2	4.14	4.67e-05	0.0121	0.29	0.25	Response to antineoplastic agents;	chr4:8534261	chr4:8482270~8512610:+
COAD	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-4.14	4.67e-05	0.0121	-0.3	-0.25	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
COAD	cis	rs2732480	0.5	rs7966829	ENSG00000226413.2	OR8T1P	4.14	4.67e-05	0.0121	0.3	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48442030~48442947:-
COAD	cis	rs11098499	0.731	rs6846966	ENSG00000249244.1	RP11-548H18.2	4.14	4.67e-05	0.0122	0.33	0.25	Corneal astigmatism;	chr4:119372053	chr4:119391831~119395335:-
COAD	cis	rs2307394	0.964	rs4972318	ENSG00000281469.1	RP11-567F11.1	4.14	4.67e-05	0.0122	0.29	0.25	Urate levels;	chr2:147983018	chr2:148044380~148044894:+
COAD	cis	rs7818688	0.585	rs1031388	ENSG00000253528.2	RP11-347C18.4	4.14	4.68e-05	0.0122	0.31	0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95037456	chr8:94974573~94974853:-
COAD	cis	rs6840360	0.608	rs2724556	ENSG00000251611.1	RP11-610P16.1	-4.14	4.68e-05	0.0122	-0.25	-0.25	Intelligence (multi-trait analysis);	chr4:151420565	chr4:151407551~151408835:-
COAD	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.68e-05	0.0122	-0.23	-0.25	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
COAD	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.68e-05	0.0122	-0.23	-0.25	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
COAD	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-4.14	4.68e-05	0.0122	-0.25	-0.25	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
COAD	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-4.14	4.68e-05	0.0122	-0.25	-0.25	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
COAD	cis	rs2243480	0.831	rs57294491	ENSG00000229886.1	RP5-1132H15.3	-4.14	4.68e-05	0.0122	-0.43	-0.25	Diabetic kidney disease;	chr7:66219914	chr7:66025126~66031544:-
COAD	cis	rs6163	0.727	rs284862	ENSG00000228657.1	RP11-170J3.2	4.14	4.68e-05	0.0122	0.27	0.25	Waist circumference;Hip circumference;	chr10:102812324	chr10:102572757~102573225:-
COAD	cis	rs2337406	1	rs78631692	ENSG00000211974.3	IGHV2-70	-4.14	4.68e-05	0.0122	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106709371	chr14:106723574~106724093:-
COAD	cis	rs7726414	1	rs115808154	ENSG00000279469.1	RP11-215P8.2	4.14	4.69e-05	0.0122	0.4	0.25	Systemic lupus erythematosus;	chr5:134128584	chr5:134394360~134395008:-
COAD	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	4.14	4.69e-05	0.0122	0.33	0.25	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
COAD	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	4.14	4.69e-05	0.0122	0.48	0.25	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
COAD	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-4.14	4.69e-05	0.0122	-0.25	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-4.14	4.69e-05	0.0122	-0.25	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-4.14	4.69e-05	0.0122	-0.25	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
COAD	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-4.14	4.69e-05	0.0122	-0.26	-0.25	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
COAD	cis	rs6687821	0.515	rs507966	ENSG00000261737.1	RP4-612B15.3	-4.14	4.69e-05	0.0122	-0.33	-0.25	Yeast infection;	chr1:86904391	chr1:86703502~86704462:-
COAD	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	4.14	4.7e-05	0.0122	0.31	0.25	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
COAD	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	4.14	4.7e-05	0.0122	0.33	0.25	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
COAD	cis	rs495337	0.76	rs2769982	ENSG00000229222.1	KRT18P4	4.14	4.7e-05	0.0122	0.25	0.25	Psoriasis;	chr20:49908290	chr20:49956745~49958032:+
COAD	cis	rs2916733	0.53	rs1054074	ENSG00000246089.3	RP11-115C21.2	-4.14	4.7e-05	0.0122	-0.33	-0.25	Epirubicin-induced leukopenia;	chr8:6446093	chr8:6403551~6407142:-
COAD	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-4.14	4.7e-05	0.0122	-0.28	-0.25	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
COAD	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	4.14	4.7e-05	0.0122	0.35	0.25	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
COAD	cis	rs3788317	0.526	rs5993855	ENSG00000232926.1	AC000078.5	-4.14	4.7e-05	0.0122	-0.27	-0.25	Glaucoma (primary angle closure);	chr22:19894592	chr22:19887289~19887970:+
COAD	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-4.14	4.71e-05	0.0122	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-4.14	4.71e-05	0.0122	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
COAD	cis	rs7646881	0.544	rs57522494	ENSG00000272087.1	RP11-379F4.7	4.14	4.71e-05	0.0122	0.4	0.25	Tetralogy of Fallot;	chr3:158620701	chr3:158693120~158693768:-
COAD	cis	rs8061903	0.958	rs17748873	ENSG00000260071.1	RP11-418I22.2	4.14	4.71e-05	0.0122	0.29	0.25	HIV-1 viral setpoint;	chr16:9290934	chr16:9466655~9517564:+
COAD	cis	rs739496	0.615	rs847898	ENSG00000257595.2	RP3-473L9.4	4.14	4.71e-05	0.0122	0.38	0.25	Platelet count;	chr12:111725842	chr12:111369282~111403310:+
COAD	cis	rs9393777	0.588	rs6456728	ENSG00000224843.5	LINC00240	4.14	4.71e-05	0.0122	0.36	0.25	Intelligence (multi-trait analysis);	chr6:26477551	chr6:26956992~27023924:+
COAD	cis	rs987724	0.613	rs1384538	ENSG00000240875.4	LINC00886	-4.14	4.71e-05	0.0122	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156977820	chr3:156747346~156817062:-
COAD	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	4.14	4.72e-05	0.0122	0.25	0.25	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
COAD	cis	rs9307551	0.817	rs11098766	ENSG00000250334.4	LINC00989	-4.14	4.72e-05	0.0122	-0.28	-0.25	Refractive error;	chr4:79579266	chr4:79492416~79576460:+
COAD	cis	rs8022206	0.738	rs11628745	ENSG00000259502.1	RP11-643G16.3	4.14	4.72e-05	0.0122	0.35	0.25	Platelet count;Mean platelet volume;	chr14:68072796	chr14:67610986~67613864:+
COAD	cis	rs2617170	0.961	rs1841957	ENSG00000245648.1	RP11-277P12.20	4.14	4.72e-05	0.0122	0.32	0.25	Behcet's disease;	chr12:10409426	chr12:10363769~10398506:+
COAD	cis	rs73222236	1	rs73222236	ENSG00000273486.1	RP11-731C17.2	4.14	4.72e-05	0.0122	0.26	0.25	Coronary artery disease;	chr3:136169800	chr3:136837338~136839021:-
COAD	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	4.14	4.72e-05	0.0122	0.3	0.25	Height;	chr4:55551447	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	4.14	4.72e-05	0.0122	0.3	0.25	Height;	chr4:55551845	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	4.14	4.72e-05	0.0122	0.3	0.25	Height;	chr4:55553396	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	4.14	4.72e-05	0.0122	0.3	0.25	Height;	chr4:55554025	chr4:55547112~55547889:+
COAD	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	4.14	4.72e-05	0.0123	0.23	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
COAD	cis	rs7674212	0.512	rs2720462	ENSG00000246560.2	RP11-10L12.4	4.14	4.72e-05	0.0123	0.29	0.25	Type 2 diabetes;	chr4:103135053	chr4:102828055~102844075:+
COAD	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-4.14	4.72e-05	0.0123	-0.25	-0.25	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
COAD	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	4.14	4.72e-05	0.0123	0.28	0.25	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
COAD	cis	rs7646881	0.544	rs6792976	ENSG00000272087.1	RP11-379F4.7	4.14	4.73e-05	0.0123	0.4	0.25	Tetralogy of Fallot;	chr3:158608781	chr3:158693120~158693768:-
COAD	cis	rs2378497	1	rs2790762	ENSG00000232679.1	RP11-400N13.3	-4.14	4.73e-05	0.0123	-0.33	-0.25	Serum thyroid-stimulating hormone levels;	chr1:222023668	chr1:222041705~222064763:-
COAD	cis	rs9942416	0.615	rs253414	ENSG00000271815.1	CTD-2235C13.3	4.14	4.73e-05	0.0123	0.3	0.25	Age-related disease endophenotypes;	chr5:75660692	chr5:75363760~75364242:+
COAD	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-4.14	4.73e-05	0.0123	-0.29	-0.25	Height;	chr4:55537550	chr4:55547112~55547889:+
COAD	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	4.14	4.73e-05	0.0123	0.3	0.25	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
COAD	cis	rs735539	0.645	rs1329518	ENSG00000222726.1	RNU2-7P	-4.14	4.73e-05	0.0123	-0.33	-0.25	Dental caries;	chr13:20629472	chr13:20612161~20612338:+
COAD	cis	rs9880211	0.948	rs17298525	ENSG00000273486.1	RP11-731C17.2	4.14	4.73e-05	0.0123	0.29	0.25	Height;Body mass index;	chr3:136474183	chr3:136837338~136839021:-
COAD	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	4.14	4.73e-05	0.0123	0.24	0.25	Axial length;	chr3:53812897	chr3:53797764~53798019:-
COAD	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	4.14	4.73e-05	0.0123	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
COAD	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-4.14	4.73e-05	0.0123	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
COAD	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-4.14	4.73e-05	0.0123	-0.3	-0.25	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	4.14	4.73e-05	0.0123	0.25	0.25	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
COAD	cis	rs2489715	1	rs2505842	ENSG00000185904.10	LINC00839	-4.14	4.74e-05	0.0123	-0.4	-0.25	Helix rolling;	chr10:42392112	chr10:42475543~42495336:+
COAD	cis	rs2489715	0.951	rs2489703	ENSG00000185904.10	LINC00839	-4.14	4.74e-05	0.0123	-0.4	-0.25	Helix rolling;	chr10:42397264	chr10:42475543~42495336:+
COAD	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	4.14	4.74e-05	0.0123	0.2	0.25	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
COAD	cis	rs1552244	0.882	rs3755783	ENSG00000186162.9	CIDECP	4.14	4.74e-05	0.0123	0.38	0.25	Alzheimer's disease;	chr3:9987605	chr3:10014238~10026365:-
COAD	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-4.14	4.74e-05	0.0123	-0.45	-0.25	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-4.14	4.74e-05	0.0123	-0.45	-0.25	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
COAD	cis	rs9307551	0.817	rs6852514	ENSG00000250334.4	LINC00989	-4.14	4.74e-05	0.0123	-0.29	-0.25	Refractive error;	chr4:79580759	chr4:79492416~79576460:+
COAD	cis	rs2617170	0.922	rs1600128	ENSG00000245648.1	RP11-277P12.20	4.14	4.74e-05	0.0123	0.33	0.25	Behcet's disease;	chr12:10383559	chr12:10363769~10398506:+
COAD	cis	rs1005224	0.895	rs6574252	ENSG00000258454.1	RP11-361H10.3	4.14	4.74e-05	0.0123	0.31	0.25	Large artery stroke;	chr14:75675491	chr14:76235817~76263474:+
COAD	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	4.14	4.74e-05	0.0123	0.28	0.25	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
COAD	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	4.14	4.74e-05	0.0123	0.28	0.25	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
COAD	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-4.14	4.74e-05	0.0123	-0.3	-0.25	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
COAD	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	4.14	4.74e-05	0.0123	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
COAD	cis	rs12699921	0.632	rs2723497	ENSG00000279048.1	RP11-511H23.2	-4.14	4.74e-05	0.0123	-0.18	-0.25	Fibrinogen levels;	chr7:17786204	chr7:17940503~17942922:+
COAD	cis	rs11603023	0.874	rs577396	ENSG00000278376.1	RP11-158I9.8	-4.14	4.74e-05	0.0123	-0.25	-0.25	Cholesterol, total;	chr11:118628753	chr11:118791254~118793137:+
COAD	cis	rs11603023	0.874	rs11216934	ENSG00000278376.1	RP11-158I9.8	-4.14	4.74e-05	0.0123	-0.25	-0.25	Cholesterol, total;	chr11:118630742	chr11:118791254~118793137:+
COAD	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-4.14	4.74e-05	0.0123	-0.31	-0.25	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
COAD	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	4.14	4.75e-05	0.0123	0.29	0.25	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
COAD	cis	rs6840360	0.582	rs2709827	ENSG00000270265.1	RP11-731D1.4	-4.14	4.75e-05	0.0123	-0.29	-0.25	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151333775~151353224:-
COAD	cis	rs17685	0.712	rs9800948	ENSG00000280388.1	RP11-229D13.3	-4.14	4.75e-05	0.0123	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76181155	chr7:76043977~76045963:-
COAD	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	4.14	4.75e-05	0.0123	0.29	0.25	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
COAD	cis	rs8022206	0.898	rs72725156	ENSG00000259502.1	RP11-643G16.3	4.14	4.75e-05	0.0123	0.4	0.25	Platelet count;Mean platelet volume;	chr14:68008161	chr14:67610986~67613864:+
COAD	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	4.14	4.75e-05	0.0123	0.3	0.25	Height;	chr4:55454900	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	4.14	4.75e-05	0.0123	0.3	0.25	Height;	chr4:55454938	chr4:55540502~55540835:-
COAD	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	4.14	4.75e-05	0.0123	0.3	0.25	Height;	chr4:55455102	chr4:55540502~55540835:-
COAD	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-4.14	4.75e-05	0.0123	-0.31	-0.25	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-4.14	4.75e-05	0.0123	-0.31	-0.25	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-4.14	4.75e-05	0.0123	-0.31	-0.25	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
COAD	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	4.14	4.75e-05	0.0123	0.31	0.25	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
COAD	cis	rs7646881	0.544	rs6788046	ENSG00000272087.1	RP11-379F4.7	4.14	4.76e-05	0.0123	0.41	0.25	Tetralogy of Fallot;	chr3:158616465	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs6799605	ENSG00000272087.1	RP11-379F4.7	4.14	4.76e-05	0.0123	0.41	0.25	Tetralogy of Fallot;	chr3:158616551	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs59601316	ENSG00000272087.1	RP11-379F4.7	4.14	4.76e-05	0.0123	0.41	0.25	Tetralogy of Fallot;	chr3:158618847	chr3:158693120~158693768:-
COAD	cis	rs6840360	0.582	rs11732918	ENSG00000270265.1	RP11-731D1.4	-4.14	4.76e-05	0.0123	-0.3	-0.25	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.557	rs4696261	ENSG00000270265.1	RP11-731D1.4	-4.14	4.76e-05	0.0123	-0.3	-0.25	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151333775~151353224:-
COAD	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-4.14	4.76e-05	0.0123	-0.24	-0.25	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
COAD	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	4.14	4.76e-05	0.0123	0.3	0.25	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
COAD	cis	rs3126085	0.56	rs12408401	ENSG00000237975.5	FLG-AS1	4.14	4.76e-05	0.0123	0.33	0.25	Atopic dermatitis;	chr1:152399325	chr1:152168125~152445456:+
COAD	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	4.14	4.76e-05	0.0123	0.4	0.25	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
COAD	cis	rs2489715	0.859	rs2489701	ENSG00000185904.10	LINC00839	-4.14	4.76e-05	0.0123	-0.4	-0.25	Helix rolling;	chr10:42400735	chr10:42475543~42495336:+
COAD	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	4.14	4.76e-05	0.0123	0.29	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	4.14	4.76e-05	0.0123	0.29	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	4.14	4.76e-05	0.0123	0.29	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
COAD	cis	rs2252521	0.583	rs317732	ENSG00000272568.4	CTB-113D17.1	4.14	4.76e-05	0.0123	0.46	0.25	Cognitive performance;	chr7:29049567	chr7:28979967~29013367:+
COAD	cis	rs2307394	0.964	rs13033589	ENSG00000281469.1	RP11-567F11.1	4.14	4.76e-05	0.0123	0.29	0.25	Urate levels;	chr2:147945430	chr2:148044380~148044894:+
COAD	cis	rs9907295	0.818	rs7211393	ENSG00000271013.1	AC015849.15	-4.14	4.77e-05	0.0123	-0.31	-0.25	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35912635~35918010:-
COAD	cis	rs7646881	1	rs61558956	ENSG00000272087.1	RP11-379F4.7	4.14	4.77e-05	0.0124	0.36	0.25	Tetralogy of Fallot;	chr3:158734866	chr3:158693120~158693768:-
COAD	cis	rs80346118	0.673	rs6095300	ENSG00000177410.11	ZFAS1	-4.14	4.77e-05	0.0124	-0.27	-0.25	Diastolic blood pressure;	chr20:48805851	chr20:49278178~49295738:+
COAD	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	4.14	4.77e-05	0.0124	0.35	0.25	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
COAD	cis	rs1630500	0.793	rs1218581	ENSG00000271380.1	RP11-307C12.12	4.14	4.77e-05	0.0124	0.48	0.25	Parkinson's disease;	chr1:154862220	chr1:154961825~154962623:+
COAD	cis	rs763121	0.853	rs5757162	ENSG00000273076.1	RP3-508I15.22	4.14	4.77e-05	0.0124	0.24	0.25	Menopause (age at onset);	chr22:38597365	chr22:38743495~38743910:+
COAD	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-4.14	4.77e-05	0.0124	-0.25	-0.25	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
COAD	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-4.14	4.78e-05	0.0124	-0.35	-0.25	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-4.14	4.78e-05	0.0124	-0.35	-0.25	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
COAD	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	4.14	4.78e-05	0.0124	0.3	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
COAD	cis	rs7138300	0.51	rs11178591	ENSG00000258053.1	CTD-2021H9.3	-4.14	4.78e-05	0.0124	-0.34	-0.25	Type 2 diabetes;	chr12:71082587	chr12:71047402~71118247:-
COAD	cis	rs8002861	0.846	rs12869521	ENSG00000274001.1	RP11-5G9.5	-4.14	4.78e-05	0.0124	-0.23	-0.25	Leprosy;	chr13:43904210	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.846	rs12867732	ENSG00000274001.1	RP11-5G9.5	-4.14	4.78e-05	0.0124	-0.23	-0.25	Leprosy;	chr13:43908948	chr13:43877715~43878163:-
COAD	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	4.14	4.78e-05	0.0124	0.27	0.25	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	4.14	4.78e-05	0.0124	0.27	0.25	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	4.14	4.78e-05	0.0124	0.28	0.25	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
COAD	cis	rs35264875	1	rs6591370	ENSG00000259799.1	RP11-554A11.9	4.14	4.78e-05	0.0124	0.4	0.25	Blond vs. brown hair color;	chr11:69075535	chr11:69155910~69159752:+
COAD	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	4.14	4.78e-05	0.0124	0.28	0.25	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
COAD	cis	rs8046148	0.789	rs2005402	ENSG00000260381.2	RP11-429P3.5	-4.14	4.78e-05	0.0124	-0.33	-0.25	Testicular germ cell tumor;	chr16:50086757	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs2356835	ENSG00000260381.2	RP11-429P3.5	-4.14	4.78e-05	0.0124	-0.33	-0.25	Testicular germ cell tumor;	chr16:50086956	chr16:50100339~50121943:-
COAD	cis	rs10852606	0.685	rs2356838	ENSG00000260381.2	RP11-429P3.5	-4.14	4.78e-05	0.0124	-0.33	-0.25	Glioma;Glioblastoma;	chr16:50087072	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs8057524	ENSG00000260381.2	RP11-429P3.5	-4.14	4.78e-05	0.0124	-0.33	-0.25	Testicular germ cell tumor;	chr16:50089035	chr16:50100339~50121943:-
COAD	cis	rs8076220	1	rs17594365	ENSG00000244753.2	RPL15P21	-4.14	4.78e-05	0.0124	-0.36	-0.25	Obesity-related traits;	chr17:11185228	chr17:10860535~10861462:-
COAD	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	4.14	4.78e-05	0.0124	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	4.14	4.78e-05	0.0124	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	4.14	4.78e-05	0.0124	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	4.14	4.78e-05	0.0124	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	4.14	4.78e-05	0.0124	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
COAD	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	4.14	4.78e-05	0.0124	0.43	0.25	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
COAD	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	4.14	4.79e-05	0.0124	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
COAD	cis	rs3120667	0.79	rs12049036	ENSG00000237975.5	FLG-AS1	4.14	4.79e-05	0.0124	0.3	0.25	Eating disorders;	chr1:152417364	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	4.14	4.79e-05	0.0124	0.34	0.25	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
COAD	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-4.14	4.79e-05	0.0124	-0.29	-0.25	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
COAD	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-4.14	4.79e-05	0.0124	-0.25	-0.25	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
COAD	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	4.14	4.79e-05	0.0124	0.37	0.25	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
COAD	cis	rs2061333	0.5	rs8113750	ENSG00000278492.1	RP11-15A1.9	-4.14	4.79e-05	0.0124	-0.32	-0.25	Alzheimer's disease;	chr19:44104636	chr19:43978376~43978663:+
COAD	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	4.14	4.8e-05	0.0124	0.26	0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
COAD	cis	rs4820539	0.966	rs2267005	ENSG00000211644.2	IGLV1-51	-4.14	4.8e-05	0.0124	-0.14	-0.25	Bone mineral density;	chr22:23119536	chr22:22322472~22322980:+
COAD	cis	rs4843747	0.641	rs11117353	ENSG00000205037.2	RP11-863P13.4	4.14	4.8e-05	0.0124	0.32	0.25	Menopause (age at onset);	chr16:88057289	chr16:88088041~88100985:-
COAD	cis	rs9291683	0.645	rs11557743	ENSG00000250413.1	RP11-448G15.1	4.14	4.8e-05	0.0124	0.32	0.25	Bone mineral density;	chr4:10116753	chr4:10006482~10009725:+
COAD	cis	rs7260598	0.892	rs67180860	ENSG00000268442.1	CTD-2027I19.2	4.14	4.8e-05	0.0124	0.39	0.25	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:24162370~24163425:-
COAD	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-4.14	4.8e-05	0.0124	-0.37	-0.25	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
COAD	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-4.14	4.8e-05	0.0124	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
COAD	cis	rs138249	0.505	rs138218	ENSG00000273253.2	RP3-402G11.26	-4.14	4.81e-05	0.0124	-0.29	-0.25	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50109129	chr22:50199090~50200837:-
COAD	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-4.14	4.81e-05	0.0124	-0.31	-0.25	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
COAD	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-4.14	4.81e-05	0.0124	-0.31	-0.25	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
COAD	cis	rs9990333	0.862	rs6806599	ENSG00000185485.13	SDHAP1	-4.14	4.81e-05	0.0124	-0.21	-0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195959748~195990318:-
COAD	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	4.14	4.81e-05	0.0124	0.29	0.25	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
COAD	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-4.14	4.81e-05	0.0124	-0.26	-0.25	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
COAD	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	4.13	4.81e-05	0.0124	0.37	0.25	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
COAD	cis	rs712039	0.652	rs67879888	ENSG00000276054.1	RP11-378E13.3	4.13	4.81e-05	0.0124	0.37	0.25	Tuberculosis;	chr17:37435211	chr17:37386886~37387926:+
COAD	cis	rs4842666	0.834	rs2681492	ENSG00000258302.2	RP11-981P6.1	4.13	4.81e-05	0.0124	0.34	0.25	Blood pressure;	chr12:89619312	chr12:89561129~89594878:+
COAD	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-4.13	4.81e-05	0.0124	-0.32	-0.25	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
COAD	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	4.13	4.82e-05	0.0125	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
COAD	cis	rs7637701	1	rs7637701	ENSG00000240875.4	LINC00886	-4.13	4.82e-05	0.0125	-0.24	-0.25	Breast cancer;	chr3:156927968	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.967	rs9865905	ENSG00000240875.4	LINC00886	-4.13	4.82e-05	0.0125	-0.24	-0.25	Breast cancer;	chr3:156931805	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.967	rs6784421	ENSG00000240875.4	LINC00886	-4.13	4.82e-05	0.0125	-0.24	-0.25	Breast cancer;	chr3:156937705	chr3:156747346~156817062:-
COAD	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	4.13	4.82e-05	0.0125	0.32	0.25	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
COAD	cis	rs2617170	0.922	rs1904123	ENSG00000245648.1	RP11-277P12.20	4.13	4.82e-05	0.0125	0.33	0.25	Behcet's disease;	chr12:10385181	chr12:10363769~10398506:+
COAD	cis	rs9818758	0.505	rs11716159	ENSG00000225399.4	RP11-3B7.1	-4.13	4.82e-05	0.0125	-0.52	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49594152	chr3:49260085~49261316:+
COAD	cis	rs4950322	0.542	rs4950382	ENSG00000278811.3	LINC00624	4.13	4.82e-05	0.0125	0.24	0.25	Protein quantitative trait loci;	chr1:147176645	chr1:147258885~147517875:-
COAD	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	4.13	4.83e-05	0.0125	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	4.13	4.83e-05	0.0125	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
COAD	cis	rs9487023	1	rs9487023	ENSG00000219700.1	PTCHD3P3	4.13	4.83e-05	0.0125	0.27	0.25	Mean corpuscular volume;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin concentration;Mean corpuscular hemoglobin;Red blood cell count;High light scatter reticulocyte percentage of red cells;Neutrophil percentage of white cells;	chr6:109268801	chr6:109288571~109290503:-
COAD	cis	rs763121	0.853	rs4821812	ENSG00000273076.1	RP3-508I15.22	4.13	4.83e-05	0.0125	0.22	0.25	Menopause (age at onset);	chr22:38679230	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs9607566	ENSG00000273076.1	RP3-508I15.22	4.13	4.83e-05	0.0125	0.22	0.25	Menopause (age at onset);	chr22:38679429	chr22:38743495~38743910:+
COAD	cis	rs2268667	0.565	rs6657732	ENSG00000223653.4	RP11-131L23.1	-4.13	4.83e-05	0.0125	-0.28	-0.25	Asymmetrical dimethylarginine levels;	chr1:85408812	chr1:85276715~85448124:+
COAD	cis	rs2638953	0.889	rs11049543	ENSG00000247934.4	RP11-967K21.1	-4.13	4.83e-05	0.0125	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342124	chr12:28163298~28190738:-
COAD	cis	rs7665090	0.87	rs228616	ENSG00000230069.3	LRRC37A15P	4.13	4.83e-05	0.0125	0.27	0.25	Primary biliary cholangitis;	chr4:102658534	chr4:102727274~102730721:-
COAD	cis	rs4820539	0.933	rs2267004	ENSG00000211644.2	IGLV1-51	-4.13	4.83e-05	0.0125	-0.14	-0.25	Bone mineral density;	chr22:23117676	chr22:22322472~22322980:+
COAD	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	4.13	4.83e-05	0.0125	0.3	0.25	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
COAD	cis	rs11976180	1	rs2961132	ENSG00000273234.1	OR2A13P	-4.13	4.84e-05	0.0125	-0.31	-0.25	Obesity-related traits;	chr7:144071035	chr7:144142009~144142938:+
COAD	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	4.13	4.84e-05	0.0125	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
COAD	cis	rs860295	0.871	rs12724079	ENSG00000160766.13	GBAP1	4.13	4.84e-05	0.0125	0.27	0.25	Body mass index;	chr1:155464151	chr1:155213821~155227422:-
COAD	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-4.13	4.84e-05	0.0125	-0.4	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
COAD	cis	rs2018683	0.711	rs2158788	ENSG00000272568.4	CTB-113D17.1	4.13	4.84e-05	0.0125	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28979967~29013367:+
COAD	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-4.13	4.84e-05	0.0125	-0.37	-0.25	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
COAD	cis	rs12497850	1	rs4858828	ENSG00000225399.4	RP11-3B7.1	4.13	4.85e-05	0.0125	0.27	0.25	Parkinson's disease;	chr3:48687378	chr3:49260085~49261316:+
COAD	cis	rs2638953	0.853	rs11049666	ENSG00000247934.4	RP11-967K21.1	-4.13	4.85e-05	0.0125	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496138	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049667	ENSG00000247934.4	RP11-967K21.1	-4.13	4.85e-05	0.0125	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496942	chr12:28163298~28190738:-
COAD	cis	rs6545883	0.558	rs7587389	ENSG00000273302.1	RP11-493E12.2	-4.13	4.85e-05	0.0125	-0.23	-0.25	Tuberculosis;	chr2:61422656	chr2:61199979~61200769:+
COAD	cis	rs7715806	0.517	rs34340	ENSG00000271815.1	CTD-2235C13.3	-4.13	4.85e-05	0.0125	-0.31	-0.25	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:75636274	chr5:75363760~75364242:+
COAD	cis	rs7818688	1	rs73276406	ENSG00000253528.2	RP11-347C18.4	-4.13	4.85e-05	0.0125	-0.36	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009532	chr8:94974573~94974853:-
COAD	cis	rs7818688	1	rs9297950	ENSG00000253528.2	RP11-347C18.4	-4.13	4.85e-05	0.0125	-0.36	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013431	chr8:94974573~94974853:-
COAD	cis	rs7818688	1	rs28651964	ENSG00000253528.2	RP11-347C18.4	-4.13	4.85e-05	0.0125	-0.36	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014553	chr8:94974573~94974853:-
COAD	cis	rs11694172	1	rs11694172	ENSG00000273456.1	RP11-686O6.2	-4.13	4.85e-05	0.0125	-0.29	-0.25	Cholesterol, total;	chr2:202667581	chr2:202374932~202375604:-
COAD	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	4.13	4.85e-05	0.0125	0.32	0.25	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
COAD	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	4.13	4.85e-05	0.0125	0.24	0.25	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
COAD	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-4.13	4.85e-05	0.0125	-0.34	-0.25	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-4.13	4.85e-05	0.0125	-0.34	-0.25	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-4.13	4.85e-05	0.0125	-0.34	-0.25	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
COAD	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-4.13	4.85e-05	0.0125	-0.32	-0.25	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
COAD	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	4.13	4.86e-05	0.0125	0.29	0.25	Height;	chr4:55573424	chr4:55540502~55540835:-
COAD	cis	rs7032317	0.934	rs9942933	ENSG00000170827.8	CELP	-4.13	4.86e-05	0.0125	-0.23	-0.25	Calcium levels;	chr9:133003633	chr9:133079900~133087355:+
COAD	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	4.13	4.86e-05	0.0125	0.27	0.25	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
COAD	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	4.13	4.86e-05	0.0125	0.26	0.25	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
COAD	cis	rs7487075	0.93	rs4076484	ENSG00000257261.4	RP11-96H19.1	4.13	4.86e-05	0.0125	0.26	0.25	Itch intensity from mosquito bite;	chr12:46440129	chr12:46383679~46876159:+
COAD	cis	rs7487075	0.823	rs34472481	ENSG00000257261.4	RP11-96H19.1	4.13	4.86e-05	0.0125	0.26	0.25	Itch intensity from mosquito bite;	chr12:46442565	chr12:46383679~46876159:+
COAD	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-4.13	4.86e-05	0.0125	-0.29	-0.25	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
COAD	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	4.13	4.86e-05	0.0125	0.28	0.25	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	4.13	4.86e-05	0.0125	0.28	0.25	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
COAD	cis	rs73219805	0.554	rs3808569	ENSG00000228451.3	SDAD1P1	-4.13	4.86e-05	0.0125	-0.44	-0.25	Schizophrenia;	chr8:26356252	chr8:26379259~26382953:-
COAD	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-4.13	4.86e-05	0.0125	-0.46	-0.25	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
COAD	cis	rs9513627	0.573	rs4771336	ENSG00000280710.1	RP11-214F16.8	4.13	4.86e-05	0.0125	0.32	0.25	Obesity-related traits;	chr13:99558356	chr13:99498524~99501315:+
COAD	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-4.13	4.86e-05	0.0125	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
COAD	cis	rs3764400	0.567	rs8071199	ENSG00000278765.1	RP5-890E16.5	-4.13	4.86e-05	0.0125	-0.47	-0.25	Body mass index;	chr17:48117973	chr17:48066704~48067293:-
COAD	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.13	4.86e-05	0.0125	0.24	0.25	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
COAD	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.86e-05	0.0126	-0.24	-0.25	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
COAD	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	4.13	4.86e-05	0.0126	0.3	0.25	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
COAD	cis	rs2638953	0.815	rs11049677	ENSG00000247934.4	RP11-967K21.1	4.13	4.87e-05	0.0126	0.26	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28163298~28190738:-
COAD	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-4.13	4.87e-05	0.0126	-0.35	-0.25	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
COAD	cis	rs4879656	0.872	rs2274767	ENSG00000225693.1	LAGE3P1	-4.13	4.87e-05	0.0126	-0.29	-0.25	Menopause (age at onset);	chr9:33047400	chr9:33019682~33020165:-
COAD	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-4.13	4.87e-05	0.0126	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-4.13	4.87e-05	0.0126	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-4.13	4.87e-05	0.0126	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
COAD	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	4.13	4.87e-05	0.0126	0.26	0.25	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
COAD	cis	rs9532669	0.89	rs11619117	ENSG00000277662.1	RP11-74J13.9	-4.13	4.87e-05	0.0126	-0.23	-0.25	Cervical cancer;	chr13:40880020	chr13:41229180~41229676:-
COAD	cis	rs9880211	0.948	rs9857966	ENSG00000273486.1	RP11-731C17.2	4.13	4.87e-05	0.0126	0.29	0.25	Height;Body mass index;	chr3:136560548	chr3:136837338~136839021:-
COAD	cis	rs7577696	0.568	rs7562653	ENSG00000272716.1	RP11-563N4.1	4.13	4.87e-05	0.0126	0.28	0.25	Inflammatory biomarkers;	chr2:32253560	chr2:32165046~32165757:-
COAD	cis	rs860295	0.812	rs4278368	ENSG00000160766.13	GBAP1	-4.13	4.87e-05	0.0126	-0.29	-0.25	Body mass index;	chr1:155752766	chr1:155213821~155227422:-
COAD	cis	rs860295	0.812	rs12081192	ENSG00000160766.13	GBAP1	-4.13	4.87e-05	0.0126	-0.29	-0.25	Body mass index;	chr1:155768253	chr1:155213821~155227422:-
COAD	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-4.13	4.88e-05	0.0126	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
COAD	cis	rs2638953	0.924	rs10843170	ENSG00000247934.4	RP11-967K21.1	-4.13	4.88e-05	0.0126	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430118	chr12:28163298~28190738:-
COAD	cis	rs2732480	0.538	rs1387259	ENSG00000269514.1	RP11-370I10.12	-4.13	4.88e-05	0.0126	-0.32	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48198387~48202031:+
COAD	cis	rs4819052	0.851	rs1999333	ENSG00000227039.5	ITGB2-AS1	-4.13	4.88e-05	0.0126	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:44921051~44929678:+
COAD	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	4.13	4.88e-05	0.0126	0.26	0.25	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
COAD	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-4.13	4.88e-05	0.0126	-0.28	-0.25	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
COAD	cis	rs7131987	0.903	rs7308125	ENSG00000257176.2	RP11-996F15.2	-4.13	4.88e-05	0.0126	-0.29	-0.25	QT interval;	chr12:29272278	chr12:29280418~29317848:-
COAD	cis	rs35264875	0.808	rs921675	ENSG00000259799.1	RP11-554A11.9	-4.13	4.88e-05	0.0126	-0.32	-0.25	Blond vs. brown hair color;	chr11:69101566	chr11:69155910~69159752:+
COAD	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-4.13	4.89e-05	0.0126	-0.31	-0.25	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
COAD	cis	rs11098499	0.754	rs1814813	ENSG00000249244.1	RP11-548H18.2	-4.13	4.89e-05	0.0126	-0.32	-0.25	Corneal astigmatism;	chr4:119337052	chr4:119391831~119395335:-
COAD	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	4.13	4.89e-05	0.0126	0.27	0.25	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
COAD	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	4.13	4.89e-05	0.0126	0.34	0.25	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
COAD	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-4.13	4.89e-05	0.0126	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
COAD	cis	rs2711721	0.557	rs2711715	ENSG00000280054.1	RP1-197B17.7	-4.13	4.89e-05	0.0126	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr12:47020031	chr12:47728151~47730598:-
COAD	cis	rs7009110	0.652	rs13266153	ENSG00000213791.4	RP11-941H19.2	4.13	4.89e-05	0.0126	0.24	0.25	Asthma and hay fever;	chr8:80344144	chr8:80300869~80301481:+
COAD	cis	rs4704187	0.687	rs2112871	ENSG00000250889.2	LINC01336	-4.13	4.89e-05	0.0126	-0.28	-0.25	Response to amphetamines;	chr5:75174028	chr5:75047719~75052843:-
COAD	cis	rs4704187	0.64	rs4704183	ENSG00000250889.2	LINC01336	-4.13	4.89e-05	0.0126	-0.28	-0.25	Response to amphetamines;	chr5:75175223	chr5:75047719~75052843:-
COAD	cis	rs10779751	1	rs7544489	ENSG00000215785.2	CFL1P6	4.13	4.89e-05	0.0126	0.28	0.25	Body mass index;	chr1:11239454	chr1:10990978~10991797:-
COAD	cis	rs9813712	0.571	rs9855777	ENSG00000249846.5	RP11-77P16.4	4.13	4.89e-05	0.0126	0.28	0.25	Response to amphetamines;	chr3:130214805	chr3:130112550~130120579:+
COAD	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-4.13	4.89e-05	0.0126	-0.41	-0.25	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
COAD	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-4.13	4.89e-05	0.0126	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
COAD	cis	rs1949733	0.958	rs2631731	ENSG00000205959.3	RP11-689P11.2	-4.13	4.89e-05	0.0126	-0.31	-0.25	Response to antineoplastic agents;	chr4:8428090	chr4:8482270~8512610:+
COAD	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	4.13	4.89e-05	0.0126	0.31	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
COAD	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-4.13	4.89e-05	0.0126	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.89e-05	0.0126	-0.25	-0.25	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.89e-05	0.0126	-0.25	-0.25	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
COAD	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-4.13	4.9e-05	0.0126	-0.28	-0.25	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
COAD	cis	rs2581828	0.618	rs1560332	ENSG00000280417.1	RP11-5O17.1	-4.13	4.9e-05	0.0126	-0.28	-0.25	Crohn's disease;	chr3:53130787	chr3:53046166~53048122:+
COAD	cis	rs4819052	0.851	rs2838829	ENSG00000227039.5	ITGB2-AS1	-4.13	4.9e-05	0.0126	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:44921051~44929678:+
COAD	cis	rs73198271	0.74	rs10092600	ENSG00000173295.6	FAM86B3P	-4.13	4.9e-05	0.0126	-0.33	-0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8228595~8244865:+
COAD	cis	rs875971	0.825	rs28480509	ENSG00000224316.1	RP11-479O9.2	-4.13	4.9e-05	0.0126	-0.27	-0.25	Aortic root size;	chr7:66634237	chr7:65773620~65802067:+
COAD	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-4.13	4.9e-05	0.0126	-0.27	-0.25	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
COAD	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	4.13	4.9e-05	0.0126	0.27	0.25	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
COAD	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	4.13	4.9e-05	0.0126	0.27	0.25	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
COAD	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-4.13	4.9e-05	0.0126	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-4.13	4.9e-05	0.0126	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
COAD	cis	rs4074961	0.527	rs2294875	ENSG00000233621.1	LINC01137	-4.13	4.9e-05	0.0126	-0.28	-0.25	Axial length;	chr1:37586844	chr1:37454879~37474411:-
COAD	cis	rs9532669	0.926	rs9532657	ENSG00000239827.7	SUGT1P3	4.13	4.9e-05	0.0126	0.21	0.25	Cervical cancer;	chr13:40918208	chr13:40908159~40921774:-
COAD	cis	rs476633	0.573	rs6492995	ENSG00000247556.5	OIP5-AS1	4.13	4.9e-05	0.0126	0.26	0.25	Glomerular filtration rate (creatinine);	chr15:41237514	chr15:41283990~41309737:+
COAD	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	4.13	4.91e-05	0.0126	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
COAD	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-4.13	4.91e-05	0.0126	-0.31	-0.25	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
COAD	cis	rs12554020	0.515	rs2254389	ENSG00000227603.1	RP11-165J3.6	-4.13	4.91e-05	0.0126	-0.33	-0.25	Schizophrenia;	chr9:93604133	chr9:93435332~93437121:-
COAD	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	4.13	4.91e-05	0.0126	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
COAD	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-4.13	4.91e-05	0.0126	-0.26	-0.25	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
COAD	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	4.13	4.91e-05	0.0127	0.29	0.25	Height;	chr4:55587104	chr4:55540502~55540835:-
COAD	cis	rs8022206	0.773	rs11850191	ENSG00000259502.1	RP11-643G16.3	-4.13	4.91e-05	0.0127	-0.32	-0.25	Platelet count;Mean platelet volume;	chr14:67985341	chr14:67610986~67613864:+
COAD	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	4.13	4.91e-05	0.0127	0.28	0.25	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
COAD	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	4.13	4.92e-05	0.0127	0.5	0.25	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
COAD	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-4.13	4.92e-05	0.0127	-0.29	-0.25	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
COAD	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	4.13	4.92e-05	0.0127	0.33	0.25	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	4.13	4.92e-05	0.0127	0.33	0.25	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
COAD	cis	rs4820539	1	rs5759596	ENSG00000211644.2	IGLV1-51	-4.13	4.92e-05	0.0127	-0.14	-0.25	Bone mineral density;	chr22:23133563	chr22:22322472~22322980:+
COAD	cis	rs7000734	0.687	rs6471516	ENSG00000245080.5	RP11-320N21.1	4.13	4.92e-05	0.0127	0.4	0.25	Radiation response;	chr8:95088249	chr8:95066808~95073182:-
COAD	cis	rs7208859	0.673	rs9889755	ENSG00000280069.1	CTD-2349P21.3	4.13	4.93e-05	0.0127	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30738182~30740275:+
COAD	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-4.13	4.93e-05	0.0127	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
COAD	cis	rs875971	0.79	rs10257911	ENSG00000224316.1	RP11-479O9.2	-4.13	4.93e-05	0.0127	-0.28	-0.25	Aortic root size;	chr7:66278783	chr7:65773620~65802067:+
COAD	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-4.13	4.93e-05	0.0127	-0.29	-0.25	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
COAD	cis	rs2574985	0.512	rs7075289	ENSG00000231345.3	BEND3P1	-4.13	4.93e-05	0.0127	-0.31	-0.25	Subjective well-being;	chr10:50503972	chr10:50655967~50660472:+
COAD	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	4.13	4.93e-05	0.0127	0.33	0.25	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
COAD	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	4.13	4.93e-05	0.0127	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
COAD	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	4.13	4.93e-05	0.0127	0.3	0.25	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
COAD	cis	rs6585424	1	rs12769115	ENSG00000234382.2	RP11-40F6.1	-4.13	4.93e-05	0.0127	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:80233664~80245367:+
COAD	cis	rs6585424	0.85	rs61860036	ENSG00000234382.2	RP11-40F6.1	-4.13	4.93e-05	0.0127	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs12777867	ENSG00000234382.2	RP11-40F6.1	-4.13	4.93e-05	0.0127	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:80233664~80245367:+
COAD	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	4.13	4.93e-05	0.0127	0.29	0.25	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
COAD	cis	rs9652601	0.748	rs9927527	ENSG00000274038.1	RP11-66H6.4	-4.13	4.93e-05	0.0127	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11118824	chr16:11056556~11057034:+
COAD	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-4.13	4.94e-05	0.0127	-0.44	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
COAD	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	4.13	4.94e-05	0.0127	0.23	0.25	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
COAD	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	4.13	4.94e-05	0.0127	0.32	0.25	QT interval;	chr4:75108281	chr4:74955974~74970362:-
COAD	cis	rs2749097	0.825	rs2658432	ENSG00000244256.3	RN7SL130P	-4.13	4.94e-05	0.0127	-0.31	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659153	chr1:63655743~63656047:+
COAD	cis	rs987724	0.574	rs9812895	ENSG00000240875.4	LINC00886	-4.13	4.94e-05	0.0127	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156886370	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs17382070	ENSG00000240875.4	LINC00886	-4.13	4.94e-05	0.0127	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156890754	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs9871817	ENSG00000240875.4	LINC00886	-4.13	4.94e-05	0.0127	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156893887	chr3:156747346~156817062:-
COAD	cis	rs9400467	0.528	rs455726	ENSG00000271789.1	RP5-1112D6.7	-4.13	4.94e-05	0.0127	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111297126~111298510:+
COAD	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-4.13	4.94e-05	0.0127	-0.41	-0.25	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
COAD	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-4.13	4.94e-05	0.0127	-0.41	-0.25	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
COAD	cis	rs10819861	0.655	rs55821317	ENSG00000238251.2	RP11-172F4.2	-4.13	4.94e-05	0.0127	-0.31	-0.25	Electrocardiographic traits;	chr9:96106090	chr9:96407284~96407797:+
COAD	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	4.13	4.94e-05	0.0127	0.22	0.25	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
COAD	cis	rs875971	0.862	rs1860469	ENSG00000224316.1	RP11-479O9.2	-4.13	4.94e-05	0.0127	-0.27	-0.25	Aortic root size;	chr7:66641888	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs4718383	ENSG00000224316.1	RP11-479O9.2	-4.13	4.94e-05	0.0127	-0.27	-0.25	Aortic root size;	chr7:66643422	chr7:65773620~65802067:+
COAD	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	4.13	4.94e-05	0.0127	0.33	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
COAD	cis	rs492146	0.817	rs384505	ENSG00000243236.5	GSTA9P	-4.13	4.94e-05	0.0127	-0.28	-0.25	Epilepsy (remission after treatment);	chr6:52970774	chr6:52939726~52957521:-
COAD	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-4.13	4.95e-05	0.0127	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
COAD	cis	rs9990333	0.562	rs56038600	ENSG00000207650.1	MIR570	4.13	4.95e-05	0.0127	0.31	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195699401~195699497:+
COAD	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.13	4.95e-05	0.0127	0.24	0.25	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
COAD	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	4.13	4.95e-05	0.0127	0.27	0.25	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
COAD	cis	rs9796	0.558	rs11855102	ENSG00000247556.5	OIP5-AS1	4.13	4.96e-05	0.0127	0.25	0.25	Menopause (age at onset);	chr15:41221059	chr15:41283990~41309737:+
COAD	cis	rs9468199	0.523	rs9468152	ENSG00000281706.1	LINC01012	-4.13	4.96e-05	0.0127	-0.32	-0.25	Parkinson's disease;	chr6:27525127	chr6:27694035~27710222:+
COAD	cis	rs742132	0.858	rs909663	ENSG00000220875.1	HIST1H3PS1	-4.13	4.96e-05	0.0127	-0.32	-0.25	Uric acid levels;	chr6:25645086	chr6:26321876~26322292:-
COAD	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-4.13	4.96e-05	0.0128	-0.26	-0.25	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
COAD	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-4.13	4.96e-05	0.0128	-0.48	-0.25	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-4.13	4.96e-05	0.0128	-0.48	-0.25	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-4.13	4.96e-05	0.0128	-0.48	-0.25	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-4.13	4.96e-05	0.0128	-0.48	-0.25	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
COAD	cis	rs2732480	0.5	rs7297824	ENSG00000226413.2	OR8T1P	4.13	4.96e-05	0.0128	0.3	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48442030~48442947:-
COAD	cis	rs987724	0.537	rs9847187	ENSG00000240875.4	LINC00886	-4.13	4.96e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873356	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs2321290	ENSG00000240875.4	LINC00886	-4.13	4.96e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873765	chr3:156747346~156817062:-
COAD	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-4.13	4.96e-05	0.0128	-0.32	-0.25	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
COAD	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	4.13	4.96e-05	0.0128	0.38	0.25	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
COAD	cis	rs860295	1	rs822478	ENSG00000225082.2	DAP3P1	4.13	4.96e-05	0.0128	0.31	0.25	Body mass index;	chr1:155824178	chr1:155586644~155602197:+
COAD	cis	rs253959	0.545	rs7734133	ENSG00000271918.1	CTD-2287O16.5	4.13	4.97e-05	0.0128	0.24	0.25	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116083807~116085416:-
COAD	cis	rs253959	0.545	rs10072417	ENSG00000271918.1	CTD-2287O16.5	4.13	4.97e-05	0.0128	0.24	0.25	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116083807~116085416:-
COAD	cis	rs253959	0.576	rs1588268	ENSG00000271918.1	CTD-2287O16.5	4.13	4.97e-05	0.0128	0.24	0.25	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116083807~116085416:-
COAD	cis	rs253959	0.545	rs2416425	ENSG00000271918.1	CTD-2287O16.5	4.13	4.97e-05	0.0128	0.24	0.25	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116083807~116085416:-
COAD	cis	rs1023500	1	rs1023500	ENSG00000237037.8	NDUFA6-AS1	-4.13	4.97e-05	0.0128	-0.26	-0.25	Schizophrenia;	chr22:41944840	chr22:42090931~42137742:+
COAD	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.97e-05	0.0128	-0.23	-0.25	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
COAD	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	4.13	4.97e-05	0.0128	0.31	0.25	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
COAD	cis	rs9840812	0.953	rs34330586	ENSG00000239213.4	NCK1-AS1	-4.13	4.97e-05	0.0128	-0.34	-0.25	Fibrinogen levels;	chr3:136081567	chr3:136841726~136862054:-
COAD	cis	rs5753037	0.653	rs140121	ENSG00000279159.1	RP3-394A18.1	-4.13	4.97e-05	0.0128	-0.17	-0.25	Type 1 diabetes;	chr22:29742700	chr22:29978950~30028236:-
COAD	cis	rs2836974	0.644	rs1882779	ENSG00000255568.3	BRWD1-AS2	-4.13	4.97e-05	0.0128	-0.24	-0.25	Cognitive function;	chr21:39319012	chr21:39313935~39314962:+
COAD	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-4.13	4.97e-05	0.0128	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
COAD	cis	rs5758511	0.573	rs4501042	ENSG00000237037.8	NDUFA6-AS1	4.13	4.97e-05	0.0128	0.26	0.25	Birth weight;	chr22:41849759	chr22:42090931~42137742:+
COAD	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-4.13	4.97e-05	0.0128	-0.27	-0.25	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
COAD	cis	rs4819052	0.851	rs2838845	ENSG00000227039.5	ITGB2-AS1	-4.13	4.97e-05	0.0128	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:44921051~44929678:+
COAD	cis	rs7577696	0.568	rs7574000	ENSG00000272716.1	RP11-563N4.1	-4.13	4.97e-05	0.0128	-0.29	-0.25	Inflammatory biomarkers;	chr2:32117819	chr2:32165046~32165757:-
COAD	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-4.13	4.97e-05	0.0128	-0.3	-0.25	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
COAD	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.98e-05	0.0128	-0.25	-0.25	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.98e-05	0.0128	-0.25	-0.25	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
COAD	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	4.13	4.98e-05	0.0128	0.43	0.25	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	4.13	4.98e-05	0.0128	0.43	0.25	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
COAD	cis	rs11935103	0.654	rs28574667	ENSG00000279943.1	FLJ38576	4.13	4.98e-05	0.0128	0.32	0.25	Response to citalopram treatment;	chr4:186429748	chr4:186189032~186191490:-
COAD	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	4.13	4.98e-05	0.0128	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	4.13	4.98e-05	0.0128	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-4.13	4.98e-05	0.0128	-0.22	-0.25	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
COAD	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	4.13	4.98e-05	0.0128	0.4	0.25	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
COAD	cis	rs1670533	1	rs10031302	ENSG00000273179.1	RP11-20I20.4	4.13	4.98e-05	0.0128	0.32	0.25	Recombination rate (females);	chr4:1065876	chr4:1167778~1168174:+
COAD	cis	rs9487051	0.837	rs2356817	ENSG00000219700.1	PTCHD3P3	4.13	4.99e-05	0.0128	0.27	0.25	Reticulocyte fraction of red cells;	chr6:109321472	chr6:109288571~109290503:-
COAD	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	4.13	4.99e-05	0.0128	0.28	0.25	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	4.13	4.99e-05	0.0128	0.28	0.25	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	4.13	4.99e-05	0.0128	0.28	0.25	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
COAD	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	4.13	4.99e-05	0.0128	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
COAD	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-4.13	4.99e-05	0.0128	-0.43	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
COAD	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	4.13	4.99e-05	0.0128	0.26	0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
COAD	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-4.13	4.99e-05	0.0128	-0.26	-0.25	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
COAD	cis	rs987724	0.593	rs3910072	ENSG00000240875.4	LINC00886	-4.13	4.99e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156843137	chr3:156747346~156817062:-
COAD	cis	rs987724	0.551	rs9876010	ENSG00000240875.4	LINC00886	-4.13	4.99e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156845715	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs7652112	ENSG00000240875.4	LINC00886	-4.13	4.99e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156854774	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs2060015	ENSG00000240875.4	LINC00886	-4.13	4.99e-05	0.0128	-0.23	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856141	chr3:156747346~156817062:-
COAD	cis	rs7818688	0.929	rs7812312	ENSG00000253528.2	RP11-347C18.4	-4.13	4.99e-05	0.0128	-0.36	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95008172	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.929	rs28419772	ENSG00000253528.2	RP11-347C18.4	-4.13	4.99e-05	0.0128	-0.36	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009208	chr8:94974573~94974853:-
COAD	cis	rs1713985	0.508	rs1277286	ENSG00000269949.1	RP11-738E22.3	-4.13	4.99e-05	0.0128	-0.47	-0.25	Age-related macular degeneration;	chr4:56988132	chr4:56960927~56961373:-
COAD	cis	rs453301	0.719	rs34004903	ENSG00000254340.1	RP11-10A14.3	-4.13	4.99e-05	0.0128	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9035094	chr8:9141424~9145435:+
COAD	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-4.13	4.99e-05	0.0128	-0.17	-0.25	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
COAD	cis	rs8044868	1	rs10400963	ENSG00000279206.1	RP5-991G20.6	-4.13	4.99e-05	0.0128	-0.3	-0.25	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72151084	chr16:72772673~72773272:+
COAD	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	4.13	5e-05	0.0128	0.29	0.25	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
COAD	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	4.13	5e-05	0.0128	0.31	0.25	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
COAD	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-4.13	5e-05	0.0128	-0.31	-0.25	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-4.13	5e-05	0.0128	-0.31	-0.25	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
COAD	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	4.13	5e-05	0.0128	0.4	0.25	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
COAD	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	4.13	5.01e-05	0.0129	0.32	0.25	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
COAD	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	4.13	5.01e-05	0.0129	0.32	0.25	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
COAD	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-4.13	5.01e-05	0.0129	-0.26	-0.25	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
COAD	cis	rs2281603	0.762	rs10150987	ENSG00000259116.1	RP11-973N13.4	-4.12	5.01e-05	0.0129	-0.27	-0.25	Lymphocyte counts;	chr14:64571472	chr14:64514154~64540368:-
COAD	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-4.12	5.01e-05	0.0129	-0.3	-0.25	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
COAD	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-4.12	5.02e-05	0.0129	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
COAD	cis	rs2235642	0.653	rs7197288	ENSG00000280231.1	LA16c-380F5.3	-4.12	5.02e-05	0.0129	-0.32	-0.25	Coronary artery disease;	chr16:1604752	chr16:1553655~1554130:-
COAD	cis	rs2765539	0.701	rs6671822	ENSG00000231365.4	RP11-418J17.1	-4.12	5.02e-05	0.0129	-0.3	-0.25	Waist-hip ratio;	chr1:119118898	chr1:119140396~119275973:+
COAD	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-4.12	5.02e-05	0.0129	-0.37	-0.25	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
COAD	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.12	5.02e-05	0.0129	-0.25	-0.25	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
COAD	cis	rs875971	1	rs10244498	ENSG00000224316.1	RP11-479O9.2	4.12	5.02e-05	0.0129	0.27	0.25	Aortic root size;	chr7:66651069	chr7:65773620~65802067:+
COAD	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	4.12	5.02e-05	0.0129	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
COAD	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-4.12	5.02e-05	0.0129	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
COAD	cis	rs3120667	0.79	rs7521839	ENSG00000237975.5	FLG-AS1	4.12	5.03e-05	0.0129	0.3	0.25	Eating disorders;	chr1:152412283	chr1:152168125~152445456:+
COAD	cis	rs2018683	0.77	rs10951208	ENSG00000272568.4	CTB-113D17.1	4.12	5.03e-05	0.0129	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28979967~29013367:+
COAD	cis	rs7674212	0.541	rs11727498	ENSG00000246560.2	RP11-10L12.4	4.12	5.03e-05	0.0129	0.29	0.25	Type 2 diabetes;	chr4:103179830	chr4:102828055~102844075:+
COAD	cis	rs34792	0.554	rs28393495	ENSG00000207425.1	Y_RNA	-4.12	5.03e-05	0.0129	-0.31	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:14915457~14915556:-
COAD	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	4.12	5.03e-05	0.0129	0.37	0.25	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
COAD	cis	rs34779708	0.966	rs35079558	ENSG00000271335.4	RP11-324I22.4	4.12	5.03e-05	0.0129	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35314552~35336401:-
COAD	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	4.12	5.04e-05	0.0129	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	4.12	5.04e-05	0.0129	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
COAD	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.12	5.04e-05	0.0129	0.42	0.25	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
COAD	cis	rs2307394	0.964	rs1030317	ENSG00000281469.1	RP11-567F11.1	4.12	5.04e-05	0.0129	0.29	0.25	Urate levels;	chr2:147947363	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs12463798	ENSG00000281469.1	RP11-567F11.1	4.12	5.04e-05	0.0129	0.29	0.25	Urate levels;	chr2:147958530	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs4972317	ENSG00000281469.1	RP11-567F11.1	4.12	5.04e-05	0.0129	0.29	0.25	Urate levels;	chr2:147961351	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.927	rs11901963	ENSG00000281469.1	RP11-567F11.1	4.12	5.04e-05	0.0129	0.29	0.25	Urate levels;	chr2:147969202	chr2:148044380~148044894:+
COAD	cis	rs796825	0.543	rs805080	ENSG00000240661.1	RP11-174O3.3	-4.12	5.04e-05	0.0129	-0.37	-0.25	HIV-1 susceptibility;	chr3:120299954	chr3:120349510~120367998:+
COAD	cis	rs72827839	0.846	rs113187178	ENSG00000263412.1	RP5-890E16.2	4.12	5.04e-05	0.0129	0.34	0.25	Ease of getting up in the morning;	chr17:48040109	chr17:48045141~48048073:-
COAD	cis	rs1318937	0.915	rs3732728	ENSG00000224660.1	SH3BP5-AS1	-4.12	5.04e-05	0.0129	-0.25	-0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15256447	chr3:15254184~15264493:+
COAD	cis	rs1930961	0.702	rs10483120	ENSG00000271138.1	IGLVIVOR22-1	4.12	5.04e-05	0.0129	0.58	0.25	Bipolar disorder with mood-incongruent psychosis;	chr22:25482396	chr22:25437306~25437823:-
COAD	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	4.12	5.05e-05	0.0129	0.28	0.25	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
COAD	cis	rs7577696	0.525	rs11124272	ENSG00000272716.1	RP11-563N4.1	4.12	5.05e-05	0.0129	0.27	0.25	Inflammatory biomarkers;	chr2:31917451	chr2:32165046~32165757:-
COAD	cis	rs752010	0.631	rs1073197	ENSG00000230638.4	RP11-486B10.4	4.12	5.05e-05	0.0129	0.31	0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41594151	chr1:41542069~41544310:+
COAD	cis	rs9307551	0.817	rs13146986	ENSG00000250334.4	LINC00989	-4.12	5.05e-05	0.0129	-0.29	-0.25	Refractive error;	chr4:79591074	chr4:79492416~79576460:+
COAD	cis	rs4819052	0.765	rs2838852	ENSG00000227039.5	ITGB2-AS1	-4.12	5.05e-05	0.0129	-0.23	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:44921051~44929678:+
COAD	cis	rs2018683	0.707	rs2057957	ENSG00000272568.4	CTB-113D17.1	-4.12	5.05e-05	0.0129	-0.34	-0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28979967~29013367:+
COAD	cis	rs2638953	0.962	rs2172299	ENSG00000247934.4	RP11-967K21.1	-4.12	5.05e-05	0.0129	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049503	ENSG00000247934.4	RP11-967K21.1	-4.12	5.05e-05	0.0129	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs61922974	ENSG00000247934.4	RP11-967K21.1	-4.12	5.05e-05	0.0129	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28163298~28190738:-
COAD	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-4.12	5.05e-05	0.0129	-0.28	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
COAD	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.12	5.05e-05	0.0129	-0.35	-0.25	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
COAD	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-4.12	5.05e-05	0.013	-0.43	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
COAD	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-4.12	5.05e-05	0.013	-0.49	-0.25	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
COAD	cis	rs8192917	0.511	rs7150231	ENSG00000225766.7	DHRS4L1	4.12	5.05e-05	0.013	0.5	0.25	Vitiligo;	chr14:24592407	chr14:24036453~24051028:+
COAD	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	4.12	5.05e-05	0.013	0.32	0.25	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
COAD	cis	rs2123926	0.52	rs921704	ENSG00000182397.13	DNM1P46	-4.12	5.05e-05	0.013	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99725802	chr15:99790156~99806927:-
COAD	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	4.12	5.06e-05	0.013	0.3	0.25	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
COAD	cis	rs1552244	0.766	rs34232505	ENSG00000186162.9	CIDECP	4.12	5.06e-05	0.013	0.37	0.25	Alzheimer's disease;	chr3:10144532	chr3:10014238~10026365:-
COAD	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	4.12	5.06e-05	0.013	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
COAD	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	4.12	5.06e-05	0.013	0.29	0.25	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	4.12	5.06e-05	0.013	0.29	0.25	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
COAD	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-4.12	5.06e-05	0.013	-0.32	-0.25	QT interval;	chr12:29357436	chr12:29277397~29277882:-
COAD	cis	rs9910055	0.96	rs9911991	ENSG00000267080.4	ASB16-AS1	-4.12	5.06e-05	0.013	-0.24	-0.25	Total body bone mineral density;	chr17:44201548	chr17:44175973~44186717:-
COAD	cis	rs4660214	0.789	rs1180375	ENSG00000182109.6	RP11-69E11.4	4.12	5.06e-05	0.013	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs663892	ENSG00000182109.6	RP11-69E11.4	4.12	5.06e-05	0.013	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs1180384	ENSG00000182109.6	RP11-69E11.4	4.12	5.06e-05	0.013	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs683135	ENSG00000182109.6	RP11-69E11.4	4.12	5.06e-05	0.013	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39522280~39546187:-
COAD	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-4.12	5.07e-05	0.013	-0.26	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
COAD	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	4.12	5.07e-05	0.013	0.25	0.25	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
COAD	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	4.12	5.07e-05	0.013	0.45	0.25	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
COAD	cis	rs10779751	0.887	rs6686835	ENSG00000215785.2	CFL1P6	-4.12	5.07e-05	0.013	-0.29	-0.25	Body mass index;	chr1:11245259	chr1:10990978~10991797:-
COAD	cis	rs801193	0.569	rs2659893	ENSG00000224316.1	RP11-479O9.2	4.12	5.07e-05	0.013	0.27	0.25	Aortic root size;	chr7:66735006	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs2659892	ENSG00000224316.1	RP11-479O9.2	4.12	5.07e-05	0.013	0.27	0.25	Aortic root size;	chr7:66735318	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs2707847	ENSG00000224316.1	RP11-479O9.2	4.12	5.07e-05	0.013	0.27	0.25	Aortic root size;	chr7:66737884	chr7:65773620~65802067:+
COAD	cis	rs728616	0.51	rs12768957	ENSG00000225484.5	NUTM2B-AS1	-4.12	5.07e-05	0.013	-0.4	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80427537	chr10:79663088~79826594:-
COAD	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-4.12	5.08e-05	0.013	-0.35	-0.25	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
COAD	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	4.12	5.08e-05	0.013	0.28	0.25	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
COAD	cis	rs11722779	0.933	rs7695096	ENSG00000230069.3	LRRC37A15P	-4.12	5.08e-05	0.013	-0.26	-0.25	Schizophrenia;	chr4:103011399	chr4:102727274~102730721:-
COAD	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	4.12	5.08e-05	0.013	0.44	0.25	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	4.12	5.08e-05	0.013	0.44	0.25	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	4.12	5.08e-05	0.013	0.44	0.25	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
COAD	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-4.12	5.08e-05	0.013	-0.38	-0.25	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
COAD	cis	rs3120667	0.72	rs72698953	ENSG00000237975.5	FLG-AS1	4.12	5.08e-05	0.013	0.35	0.25	Eating disorders;	chr1:152437918	chr1:152168125~152445456:+
COAD	cis	rs6461992	0.51	rs62454368	ENSG00000253405.1	EVX1-AS	4.12	5.08e-05	0.013	0.66	0.25	Systolic blood pressure;	chr7:27058051	chr7:27241429~27247229:-
COAD	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-4.12	5.09e-05	0.013	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
COAD	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	4.12	5.09e-05	0.013	0.27	0.25	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	4.12	5.09e-05	0.013	0.27	0.25	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	4.12	5.09e-05	0.013	0.27	0.25	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.12	5.09e-05	0.013	-0.25	-0.25	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
COAD	cis	rs57221529	0.766	rs17563576	ENSG00000250385.1	RP11-310P5.2	4.12	5.09e-05	0.013	0.4	0.25	Lung disease severity in cystic fibrosis;	chr5:560361	chr5:524705~526594:+
COAD	cis	rs78487399	0.614	rs10166376	ENSG00000234936.1	AC010883.5	4.12	5.09e-05	0.013	0.34	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43395333	chr2:43229573~43233394:+
COAD	cis	rs3764400	0.567	rs67345313	ENSG00000278765.1	RP5-890E16.5	4.12	5.09e-05	0.013	0.47	0.25	Body mass index;	chr17:48224839	chr17:48066704~48067293:-
COAD	cis	rs4938303	0.587	rs10892017	ENSG00000254851.1	RP11-109L13.1	4.12	5.09e-05	0.013	0.33	0.25	Triglycerides;	chr11:116697165	chr11:117135528~117138582:+
COAD	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	4.12	5.09e-05	0.013	0.3	0.25	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
COAD	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	4.12	5.1e-05	0.013	0.36	0.25	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
COAD	cis	rs9992966	0.677	rs1394867	ENSG00000250829.2	RP11-11N5.1	-4.12	5.1e-05	0.0131	-0.39	-0.25	Trans fatty acid levels;	chr4:187693587	chr4:186890969~186892366:+
COAD	cis	rs9393777	0.623	rs3734544	ENSG00000224843.5	LINC00240	4.12	5.1e-05	0.0131	0.42	0.25	Intelligence (multi-trait analysis);	chr6:26468432	chr6:26956992~27023924:+
COAD	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	4.12	5.1e-05	0.0131	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
COAD	cis	rs188759467	1	rs188759467	ENSG00000184084.7	CTD-2372A4.1	4.12	5.1e-05	0.0131	0.6	0.25	Interferon gamma-induced protein 10 levels;	chr5:73807422	chr5:73803296~73803599:-
COAD	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-4.12	5.1e-05	0.0131	-0.24	-0.25	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-4.12	5.1e-05	0.0131	-0.24	-0.25	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
COAD	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-4.12	5.1e-05	0.0131	-0.35	-0.25	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
COAD	cis	rs6723226	1	rs6723226	ENSG00000276334.1	AL133243.1	4.12	5.11e-05	0.0131	0.23	0.25	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32521927~32523547:+
COAD	cis	rs8141529	0.871	rs5762877	ENSG00000272858.1	CTA-292E10.8	-4.12	5.11e-05	0.0131	-0.31	-0.25	Lymphocyte counts;	chr22:28881567	chr22:28814914~28815662:+
COAD	cis	rs11089937	0.651	rs2877023	ENSG00000211638.2	IGLV8-61	-4.12	5.11e-05	0.0131	-0.25	-0.25	Periodontitis (PAL4Q3);	chr22:22182414	chr22:22098700~22099212:+
COAD	cis	rs8046148	0.666	rs2287196	ENSG00000260381.2	RP11-429P3.5	-4.12	5.11e-05	0.0131	-0.33	-0.25	Testicular germ cell tumor;	chr16:50086211	chr16:50100339~50121943:-
COAD	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	4.12	5.11e-05	0.0131	0.27	0.25	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
COAD	cis	rs2333021	0.934	rs4903092	ENSG00000259015.1	RP11-109N23.6	4.12	5.11e-05	0.0131	0.23	0.25	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:72960595~72961993:+
COAD	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.12	5.11e-05	0.0131	-0.25	-0.25	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.12	5.11e-05	0.0131	-0.25	-0.25	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.12	5.11e-05	0.0131	-0.25	-0.25	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
COAD	cis	rs12928939	0.723	rs34053338	ENSG00000260886.1	TAT-AS1	4.12	5.11e-05	0.0131	0.36	0.25	Post bronchodilator FEV1;	chr16:71816071	chr16:71565789~71578187:+
COAD	cis	rs2333021	1	rs2333021	ENSG00000259015.1	RP11-109N23.6	4.12	5.12e-05	0.0131	0.23	0.25	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:72960595~72961993:+
COAD	cis	rs1670533	1	rs2014318	ENSG00000273179.1	RP11-20I20.4	-4.12	5.12e-05	0.0131	-0.32	-0.25	Recombination rate (females);	chr4:1074990	chr4:1167778~1168174:+
COAD	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	4.12	5.12e-05	0.0131	0.29	0.25	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	4.12	5.12e-05	0.0131	0.29	0.25	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
COAD	cis	rs2489715	0.951	rs2489718	ENSG00000185904.10	LINC00839	-4.12	5.12e-05	0.0131	-0.4	-0.25	Helix rolling;	chr10:42423490	chr10:42475543~42495336:+
COAD	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	4.12	5.12e-05	0.0131	0.32	0.25	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
COAD	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	4.12	5.12e-05	0.0131	0.32	0.25	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
COAD	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	4.12	5.12e-05	0.0131	0.2	0.25	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
COAD	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	4.12	5.12e-05	0.0131	0.29	0.25	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
COAD	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-4.12	5.13e-05	0.0131	-0.47	-0.25	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
COAD	cis	rs1005224	0.853	rs12898082	ENSG00000258454.1	RP11-361H10.3	-4.12	5.13e-05	0.0131	-0.31	-0.25	Large artery stroke;	chr14:75840016	chr14:76235817~76263474:+
COAD	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	4.12	5.13e-05	0.0131	0.23	0.25	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
COAD	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-4.12	5.14e-05	0.0131	-0.27	-0.25	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
COAD	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	4.12	5.14e-05	0.0131	0.28	0.25	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
COAD	cis	rs3120667	0.72	rs11577946	ENSG00000237975.5	FLG-AS1	4.12	5.15e-05	0.0131	0.35	0.25	Eating disorders;	chr1:152439667	chr1:152168125~152445456:+
COAD	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	4.12	5.15e-05	0.0132	0.33	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
COAD	cis	rs3748656	0.573	rs3790598	ENSG00000231246.1	RP5-965F6.2	-4.12	5.15e-05	0.0132	-0.37	-0.25	Hip circumference adjusted for BMI;	chr1:112654274	chr1:112177234~112360528:-
COAD	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-4.12	5.15e-05	0.0132	-0.35	-0.25	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-4.12	5.15e-05	0.0132	-0.35	-0.25	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-4.12	5.15e-05	0.0132	-0.35	-0.25	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
COAD	cis	rs9863	0.513	rs34102591	ENSG00000269938.1	RP11-214K3.20	-4.12	5.15e-05	0.0132	-0.33	-0.25	White blood cell count;	chr12:123996254	chr12:123968023~123968579:-
COAD	cis	rs7829975	0.714	rs11777085	ENSG00000233609.3	RP11-62H7.2	4.12	5.15e-05	0.0132	0.28	0.25	Mood instability;	chr8:8814919	chr8:8961200~8979025:+
COAD	cis	rs3126085	1	rs1858482	ENSG00000237975.5	FLG-AS1	-4.12	5.15e-05	0.0132	-0.29	-0.25	Atopic dermatitis;	chr1:152334445	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	4.12	5.16e-05	0.0132	0.29	0.25	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
COAD	cis	rs9813712	0.571	rs9836814	ENSG00000249846.5	RP11-77P16.4	4.12	5.16e-05	0.0132	0.27	0.25	Response to amphetamines;	chr3:130216054	chr3:130112550~130120579:+
COAD	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	4.12	5.16e-05	0.0132	0.33	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
COAD	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-4.12	5.16e-05	0.0132	-0.37	-0.25	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
COAD	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-4.12	5.16e-05	0.0132	-0.28	-0.25	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
COAD	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-4.12	5.16e-05	0.0132	-0.25	-0.25	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
COAD	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-4.12	5.17e-05	0.0132	-0.28	-0.25	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
COAD	cis	rs4718428	0.672	rs36038499	ENSG00000272831.1	RP11-792A8.4	4.12	5.17e-05	0.0132	0.28	0.25	Corneal structure;	chr7:66824628	chr7:66739829~66740385:-
COAD	cis	rs4718428	0.705	rs62465692	ENSG00000272831.1	RP11-792A8.4	4.12	5.17e-05	0.0132	0.28	0.25	Corneal structure;	chr7:66830758	chr7:66739829~66740385:-
COAD	cis	rs2307394	0.964	rs2303392	ENSG00000281469.1	RP11-567F11.1	4.12	5.17e-05	0.0132	0.29	0.25	Urate levels;	chr2:147922858	chr2:148044380~148044894:+
COAD	cis	rs7674212	0.531	rs6816370	ENSG00000248971.2	KRT8P46	-4.12	5.17e-05	0.0132	-0.26	-0.25	Type 2 diabetes;	chr4:103018276	chr4:102728746~102730171:-
COAD	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-4.12	5.17e-05	0.0132	-0.31	-0.25	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
COAD	cis	rs1023500	0.573	rs133380	ENSG00000237037.8	NDUFA6-AS1	-4.12	5.17e-05	0.0132	-0.24	-0.25	Schizophrenia;	chr22:42072906	chr22:42090931~42137742:+
COAD	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-4.12	5.18e-05	0.0132	-0.31	-0.25	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
COAD	cis	rs7487075	0.78	rs10785624	ENSG00000274723.1	RP11-618L22.1	4.12	5.18e-05	0.0132	0.26	0.25	Itch intensity from mosquito bite;	chr12:46373004	chr12:46970504~46972155:+
COAD	cis	rs7487075	0.78	rs2279559	ENSG00000274723.1	RP11-618L22.1	4.12	5.18e-05	0.0132	0.26	0.25	Itch intensity from mosquito bite;	chr12:46373392	chr12:46970504~46972155:+
COAD	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	4.12	5.18e-05	0.0132	0.34	0.25	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
COAD	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	4.12	5.18e-05	0.0132	0.34	0.25	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	4.12	5.18e-05	0.0132	0.34	0.25	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	4.12	5.18e-05	0.0132	0.34	0.25	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
COAD	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	4.12	5.18e-05	0.0132	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
COAD	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	4.12	5.18e-05	0.0132	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
COAD	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	4.12	5.18e-05	0.0132	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
COAD	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	4.12	5.18e-05	0.0132	0.29	0.25	Height;	chr4:55575856	chr4:55540502~55540835:-
COAD	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-4.12	5.19e-05	0.0132	-0.23	-0.25	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
COAD	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-4.12	5.19e-05	0.0132	-0.3	-0.25	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
COAD	cis	rs9400317	1	rs9400317	ENSG00000260273.1	RP11-425D10.10	4.12	5.19e-05	0.0132	0.43	0.25	Response to hepatitis C treatment;	chr6:109686444	chr6:109382795~109383666:+
COAD	cis	rs4879656	0.843	rs10813918	ENSG00000225693.1	LAGE3P1	4.12	5.19e-05	0.0132	0.29	0.25	Menopause (age at onset);	chr9:32996372	chr9:33019682~33020165:-
COAD	cis	rs6951245	0.935	rs113365567	ENSG00000229043.2	AC091729.9	-4.12	5.19e-05	0.0132	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1160374~1165267:+
COAD	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	4.12	5.19e-05	0.0132	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
COAD	cis	rs875971	0.964	rs160635	ENSG00000230189.5	GS1-124K5.2	4.12	5.19e-05	0.0132	0.2	0.25	Aortic root size;	chr7:66063931	chr7:66409143~66490059:-
COAD	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	4.12	5.19e-05	0.0132	0.4	0.25	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
COAD	cis	rs9487051	0.837	rs1915834	ENSG00000219700.1	PTCHD3P3	4.12	5.19e-05	0.0133	0.26	0.25	Reticulocyte fraction of red cells;	chr6:109276421	chr6:109288571~109290503:-
COAD	cis	rs1044826	0.619	rs7375091	ENSG00000272656.1	RP11-219D15.3	-4.12	5.19e-05	0.0133	-0.3	-0.25	Obesity-related traits;	chr3:139371547	chr3:139349024~139349371:-
COAD	cis	rs1044826	0.619	rs57357132	ENSG00000272656.1	RP11-219D15.3	-4.12	5.19e-05	0.0133	-0.3	-0.25	Obesity-related traits;	chr3:139399516	chr3:139349024~139349371:-
COAD	cis	rs8141529	1	rs132534	ENSG00000272858.1	CTA-292E10.8	4.12	5.19e-05	0.0133	0.31	0.25	Lymphocyte counts;	chr22:28903818	chr22:28814914~28815662:+
COAD	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.12	5.19e-05	0.0133	0.42	0.25	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
COAD	cis	rs9307551	0.741	rs11936123	ENSG00000250334.4	LINC00989	-4.12	5.2e-05	0.0133	-0.33	-0.25	Refractive error;	chr4:79506113	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.741	rs1440860	ENSG00000250334.4	LINC00989	-4.12	5.2e-05	0.0133	-0.33	-0.25	Refractive error;	chr4:79509083	chr4:79492416~79576460:+
COAD	cis	rs763121	0.853	rs6001188	ENSG00000273076.1	RP3-508I15.22	4.12	5.2e-05	0.0133	0.22	0.25	Menopause (age at onset);	chr22:38666189	chr22:38743495~38743910:+
COAD	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	4.12	5.2e-05	0.0133	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
COAD	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	4.12	5.2e-05	0.0133	0.2	0.25	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
COAD	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	4.12	5.2e-05	0.0133	0.2	0.25	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
COAD	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-4.12	5.2e-05	0.0133	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
COAD	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-4.12	5.2e-05	0.0133	-0.44	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
COAD	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	4.12	5.2e-05	0.0133	0.35	0.25	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
COAD	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-4.12	5.21e-05	0.0133	-0.29	-0.25	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
COAD	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	4.12	5.21e-05	0.0133	0.29	0.25	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
COAD	cis	rs34792	0.626	rs153784	ENSG00000207425.1	Y_RNA	-4.12	5.21e-05	0.0133	-0.34	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508734	chr16:14915457~14915556:-
COAD	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-4.12	5.21e-05	0.0133	-0.32	-0.25	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
COAD	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-4.12	5.21e-05	0.0133	-0.34	-0.25	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
COAD	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-4.12	5.21e-05	0.0133	-0.34	-0.25	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
COAD	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	4.12	5.22e-05	0.0133	0.32	0.25	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
COAD	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	4.12	5.22e-05	0.0133	0.32	0.25	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
COAD	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	4.12	5.22e-05	0.0133	0.32	0.25	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
COAD	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-4.12	5.22e-05	0.0133	-0.22	-0.25	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
COAD	cis	rs2733201	1	rs2042741	ENSG00000205771.5	CATSPER2P1	4.12	5.22e-05	0.0133	0.42	0.25	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44098088	chr15:43726918~43747094:-
COAD	cis	rs9291683	0.526	rs6827785	ENSG00000250413.1	RP11-448G15.1	-4.11	5.22e-05	0.0133	-0.32	-0.25	Bone mineral density;	chr4:10016581	chr4:10006482~10009725:+
COAD	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	4.11	5.22e-05	0.0133	0.32	0.25	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
COAD	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-4.11	5.22e-05	0.0133	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
COAD	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-4.11	5.22e-05	0.0133	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
COAD	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	4.11	5.22e-05	0.0133	0.26	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
COAD	cis	rs1044826	0.619	rs6439856	ENSG00000272656.1	RP11-219D15.3	-4.11	5.22e-05	0.0133	-0.3	-0.25	Obesity-related traits;	chr3:139416026	chr3:139349024~139349371:-
COAD	cis	rs9300255	0.602	rs1569068	ENSG00000280120.1	RP11-546D6.3	-4.11	5.22e-05	0.0133	-0.25	-0.25	Neutrophil percentage of white cells;	chr12:123147729	chr12:123152324~123153377:-
COAD	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	4.11	5.22e-05	0.0133	0.3	0.25	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
COAD	cis	rs7119	0.7	rs4886883	ENSG00000259565.2	KRT8P23	-4.11	5.22e-05	0.0133	-0.29	-0.25	Type 2 diabetes;	chr15:77596582	chr15:76979245~76980451:-
COAD	cis	rs891378	1	rs891378	ENSG00000274245.1	RP11-357P18.2	-4.11	5.22e-05	0.0133	-0.35	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316974	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs2782828	ENSG00000274245.1	RP11-357P18.2	-4.11	5.22e-05	0.0133	-0.35	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207323654	chr1:207372559~207373252:+
COAD	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	4.11	5.22e-05	0.0133	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
COAD	cis	rs1949733	0.598	rs55765509	ENSG00000205959.3	RP11-689P11.2	4.11	5.22e-05	0.0133	0.31	0.25	Response to antineoplastic agents;	chr4:8531005	chr4:8482270~8512610:+
COAD	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	4.11	5.23e-05	0.0133	0.29	0.25	Height;	chr4:55533481	chr4:55547112~55547889:+
COAD	cis	rs748404	0.588	rs2255410	ENSG00000275601.1	AC011330.13	-4.11	5.23e-05	0.0133	-0.28	-0.25	Lung cancer;	chr15:43538899	chr15:43642389~43643023:-
COAD	cis	rs11018904	0.906	rs61903722	ENSG00000280385.1	AP000648.5	-4.11	5.23e-05	0.0133	-0.34	-0.25	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90193614~90198120:+
COAD	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	4.11	5.23e-05	0.0133	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
COAD	cis	rs9291683	0.51	rs4318649	ENSG00000250413.1	RP11-448G15.1	-4.11	5.23e-05	0.0133	-0.32	-0.25	Bone mineral density;	chr4:10015191	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.746	rs4318650	ENSG00000250413.1	RP11-448G15.1	-4.11	5.23e-05	0.0133	-0.32	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10015244	chr4:10006482~10009725:+
COAD	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	4.11	5.23e-05	0.0133	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
COAD	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	4.11	5.23e-05	0.0133	0.32	0.25	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
COAD	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-4.11	5.23e-05	0.0133	-0.29	-0.25	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
COAD	cis	rs453301	0.562	rs1038248	ENSG00000254340.1	RP11-10A14.3	-4.11	5.23e-05	0.0133	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9183348	chr8:9141424~9145435:+
COAD	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-4.11	5.23e-05	0.0133	-0.25	-0.25	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
COAD	cis	rs6730558	0.966	rs4669306	ENSG00000235092.4	ID2-AS1	-4.11	5.23e-05	0.0133	-0.32	-0.25	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8614076	chr2:8666636~8681863:-
COAD	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	4.11	5.23e-05	0.0133	0.29	0.25	Height;	chr4:55526514	chr4:55547112~55547889:+
COAD	cis	rs7584330	0.666	rs72620819	ENSG00000234949.2	AC104667.3	-4.11	5.24e-05	0.0133	-0.34	-0.25	Prostate cancer;	chr2:237446339	chr2:237591020~237595981:+
COAD	cis	rs9907295	0.591	rs4251749	ENSG00000270977.1	AC015849.16	-4.11	5.24e-05	0.0133	-0.32	-0.25	Fibroblast growth factor basic levels;	chr17:35823421	chr17:35893707~35911023:-
COAD	cis	rs9907295	0.591	rs4325615	ENSG00000270977.1	AC015849.16	-4.11	5.24e-05	0.0133	-0.32	-0.25	Fibroblast growth factor basic levels;	chr17:35826379	chr17:35893707~35911023:-
COAD	cis	rs9907295	0.551	rs28595279	ENSG00000270977.1	AC015849.16	-4.11	5.24e-05	0.0133	-0.32	-0.25	Fibroblast growth factor basic levels;	chr17:35826416	chr17:35893707~35911023:-
COAD	cis	rs2564921	0.704	rs62255931	ENSG00000280417.1	RP11-5O17.1	4.11	5.24e-05	0.0133	0.27	0.25	Height;	chr3:53097932	chr3:53046166~53048122:+
COAD	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	4.11	5.24e-05	0.0134	0.4	0.25	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
COAD	cis	rs6490294	0.748	rs6489820	ENSG00000257595.2	RP3-473L9.4	4.11	5.24e-05	0.0134	0.36	0.25	Mean platelet volume;	chr12:111890699	chr12:111369282~111403310:+
COAD	cis	rs875971	0.502	rs2946580	ENSG00000164669.11	INTS4P1	4.11	5.24e-05	0.0134	0.36	0.25	Aortic root size;	chr7:66066855	chr7:65141225~65234216:+
COAD	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-4.11	5.24e-05	0.0134	-0.27	-0.25	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
COAD	cis	rs7646881	0.583	rs2115942	ENSG00000272087.1	RP11-379F4.7	4.11	5.24e-05	0.0134	0.4	0.25	Tetralogy of Fallot;	chr3:158588841	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs73022798	ENSG00000272087.1	RP11-379F4.7	4.11	5.24e-05	0.0134	0.4	0.25	Tetralogy of Fallot;	chr3:158590099	chr3:158693120~158693768:-
COAD	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-4.11	5.25e-05	0.0134	-0.3	-0.25	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
COAD	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-4.11	5.25e-05	0.0134	-0.29	-0.25	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
COAD	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-4.11	5.25e-05	0.0134	-0.47	-0.25	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
COAD	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	4.11	5.25e-05	0.0134	0.32	0.25	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
COAD	cis	rs8022206	1	rs72725160	ENSG00000259502.1	RP11-643G16.3	4.11	5.25e-05	0.0134	0.42	0.25	Platelet count;Mean platelet volume;	chr14:68010672	chr14:67610986~67613864:+
COAD	cis	rs2581828	0.58	rs9834111	ENSG00000280417.1	RP11-5O17.1	4.11	5.26e-05	0.0134	0.28	0.25	Crohn's disease;	chr3:53136028	chr3:53046166~53048122:+
COAD	cis	rs2581828	0.58	rs9817467	ENSG00000280417.1	RP11-5O17.1	4.11	5.26e-05	0.0134	0.28	0.25	Crohn's disease;	chr3:53136609	chr3:53046166~53048122:+
COAD	cis	rs9992667	0.577	rs10021686	ENSG00000231160.8	KLF3-AS1	4.11	5.26e-05	0.0134	0.36	0.25	Eosinophil percentage of granulocytes;	chr4:38703636	chr4:38612701~38664883:-
COAD	cis	rs7584330	0.737	rs7595979	ENSG00000234949.2	AC104667.3	-4.11	5.26e-05	0.0134	-0.29	-0.25	Prostate cancer;	chr2:237455849	chr2:237591020~237595981:+
COAD	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	4.11	5.26e-05	0.0134	0.61	0.25	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
COAD	cis	rs2439831	0.702	rs16977724	ENSG00000166763.7	STRCP1	-4.11	5.26e-05	0.0134	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43859101	chr15:43699488~43718184:-
COAD	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-4.11	5.26e-05	0.0134	-0.33	-0.25	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
COAD	cis	rs9867325	0.895	rs9879531	ENSG00000273486.1	RP11-731C17.2	4.11	5.26e-05	0.0134	0.29	0.25	Body mass index;	chr3:136920133	chr3:136837338~136839021:-
COAD	cis	rs3752645	0.764	rs2041525	ENSG00000241764.3	AC002467.7	4.11	5.26e-05	0.0134	0.51	0.25	Bladder cancer (smoking interaction);	chr7:107052146	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs2041526	ENSG00000241764.3	AC002467.7	4.11	5.26e-05	0.0134	0.51	0.25	Bladder cancer (smoking interaction);	chr7:107052184	chr7:107742817~107744581:-
COAD	cis	rs17685	0.753	rs2286830	ENSG00000280388.1	RP11-229D13.3	4.11	5.26e-05	0.0134	0.25	0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76043977~76045963:-
COAD	cis	rs4820539	1	rs916583	ENSG00000211644.2	IGLV1-51	-4.11	5.26e-05	0.0134	-0.14	-0.25	Bone mineral density;	chr22:23127080	chr22:22322472~22322980:+
COAD	cis	rs2581828	0.58	rs6799837	ENSG00000280417.1	RP11-5O17.1	4.11	5.26e-05	0.0134	0.28	0.25	Crohn's disease;	chr3:53133838	chr3:53046166~53048122:+
COAD	cis	rs875971	1	rs2220626	ENSG00000230189.5	GS1-124K5.2	-4.11	5.27e-05	0.0134	-0.2	-0.25	Aortic root size;	chr7:66081075	chr7:66409143~66490059:-
COAD	cis	rs2765539	0.701	rs12068932	ENSG00000231365.4	RP11-418J17.1	-4.11	5.27e-05	0.0134	-0.3	-0.25	Waist-hip ratio;	chr1:119113057	chr1:119140396~119275973:+
COAD	cis	rs7829975	0.714	rs11784052	ENSG00000233609.3	RP11-62H7.2	4.11	5.27e-05	0.0134	0.28	0.25	Mood instability;	chr8:8814452	chr8:8961200~8979025:+
COAD	cis	rs9402682	0.663	rs1074849	ENSG00000232876.1	CTA-212D2.2	-4.11	5.27e-05	0.0134	-0.36	-0.25	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135102274	chr6:135055033~135060550:+
COAD	cis	rs7688540	0.8	rs28429717	ENSG00000211553.1	AC253576.2	-4.11	5.27e-05	0.0134	-0.42	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:136461~136568:+
COAD	cis	rs5753037	0.504	rs140114	ENSG00000279159.1	RP3-394A18.1	-4.11	5.27e-05	0.0134	-0.17	-0.25	Type 1 diabetes;	chr22:29737892	chr22:29978950~30028236:-
COAD	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-4.11	5.27e-05	0.0134	-0.43	-0.25	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
COAD	cis	rs3764400	0.567	rs4995899	ENSG00000278765.1	RP5-890E16.5	4.11	5.27e-05	0.0134	0.47	0.25	Body mass index;	chr17:48073368	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs16951519	ENSG00000278765.1	RP5-890E16.5	4.11	5.27e-05	0.0134	0.47	0.25	Body mass index;	chr17:48074929	chr17:48066704~48067293:-
COAD	cis	rs2439831	0.541	rs12440854	ENSG00000249839.1	AC011330.5	-4.11	5.27e-05	0.0134	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43318474	chr15:43663654~43684339:-
COAD	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-4.11	5.27e-05	0.0134	-0.25	-0.25	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
COAD	cis	rs12677618	0.623	rs28506950	ENSG00000253307.1	RP11-10J21.4	4.11	5.27e-05	0.0134	0.33	0.25	Plateletcrit;	chr8:141251868	chr8:141252286~141253292:-
COAD	cis	rs62184315	0.938	rs7563391	ENSG00000253559.1	OSGEPL1-AS1	-4.11	5.27e-05	0.0134	-0.3	-0.25	Alcohol dependence (age at onset);	chr2:189915077	chr2:189762704~189765556:+
COAD	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	4.11	5.27e-05	0.0134	0.15	0.25	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
COAD	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.11	5.28e-05	0.0134	0.26	0.25	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
COAD	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.11	5.28e-05	0.0134	0.26	0.25	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
COAD	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-4.11	5.28e-05	0.0134	-0.26	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
COAD	cis	rs7577696	0.962	rs212739	ENSG00000272716.1	RP11-563N4.1	4.11	5.28e-05	0.0134	0.26	0.25	Inflammatory biomarkers;	chr2:32179634	chr2:32165046~32165757:-
COAD	cis	rs9376098	0.737	rs9402694	ENSG00000232876.1	CTA-212D2.2	-4.11	5.28e-05	0.0134	-0.32	-0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177595	chr6:135055033~135060550:+
COAD	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-4.11	5.28e-05	0.0134	-0.37	-0.25	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
COAD	cis	rs2252521	0.524	rs1719570	ENSG00000272568.4	CTB-113D17.1	4.11	5.28e-05	0.0134	0.48	0.25	Cognitive performance;	chr7:29003747	chr7:28979967~29013367:+
COAD	cis	rs2281603	0.762	rs12588509	ENSG00000259116.1	RP11-973N13.4	4.11	5.29e-05	0.0134	0.27	0.25	Lymphocyte counts;	chr14:64580554	chr14:64514154~64540368:-
COAD	cis	rs4820539	1	rs13054985	ENSG00000211644.2	IGLV1-51	-4.11	5.29e-05	0.0134	-0.14	-0.25	Bone mineral density;	chr22:23116390	chr22:22322472~22322980:+
COAD	cis	rs911263	0.603	rs7147852	ENSG00000259502.1	RP11-643G16.3	-4.11	5.29e-05	0.0134	-0.3	-0.25	Primary biliary cholangitis;	chr14:68330082	chr14:67610986~67613864:+
COAD	cis	rs875971	0.545	rs313830	ENSG00000164669.11	INTS4P1	4.11	5.29e-05	0.0135	0.36	0.25	Aortic root size;	chr7:66086944	chr7:65141225~65234216:+
COAD	cis	rs9847710	0.818	rs6445558	ENSG00000280417.1	RP11-5O17.1	4.11	5.29e-05	0.0135	0.26	0.25	Ulcerative colitis;	chr3:53063644	chr3:53046166~53048122:+
COAD	cis	rs13188386	0.763	rs4368736	ENSG00000249779.1	RP11-447H19.3	4.11	5.29e-05	0.0135	0.3	0.25	Iron status biomarkers;	chr5:42553799	chr5:43206709~43207811:+
COAD	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	4.11	5.29e-05	0.0135	0.33	0.25	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
COAD	cis	rs7911712	0.873	rs17157056	ENSG00000165511.6	C10orf25	4.11	5.29e-05	0.0135	0.43	0.25	Emphysema-related traits;	chr10:44819969	chr10:44997698~45000888:-
COAD	cis	rs9393813	0.528	rs6901629	ENSG00000271755.1	RP1-153G14.4	4.11	5.29e-05	0.0135	0.29	0.25	Bipolar disorder;	chr6:27380029	chr6:27404010~27406964:-
COAD	cis	rs7584330	0.666	rs72620816	ENSG00000234949.2	AC104667.3	-4.11	5.3e-05	0.0135	-0.34	-0.25	Prostate cancer;	chr2:237444961	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.666	rs72620817	ENSG00000234949.2	AC104667.3	-4.11	5.3e-05	0.0135	-0.34	-0.25	Prostate cancer;	chr2:237445018	chr2:237591020~237595981:+
COAD	cis	rs5753037	0.869	rs5752992	ENSG00000279159.1	RP3-394A18.1	-4.11	5.3e-05	0.0135	-0.17	-0.25	Type 1 diabetes;	chr22:29988055	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.835	rs2007458	ENSG00000279159.1	RP3-394A18.1	-4.11	5.3e-05	0.0135	-0.17	-0.25	Type 1 diabetes;	chr22:29992717	chr22:29978950~30028236:-
COAD	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.11	5.3e-05	0.0135	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
COAD	cis	rs1707322	0.789	rs7540578	ENSG00000230896.1	RP11-767N6.7	-4.11	5.3e-05	0.0135	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45694684~45697075:-
COAD	cis	rs1949733	0.656	rs2688224	ENSG00000205959.3	RP11-689P11.2	-4.11	5.3e-05	0.0135	-0.3	-0.25	Response to antineoplastic agents;	chr4:8402973	chr4:8482270~8512610:+
COAD	cis	rs9393813	0.506	rs13201985	ENSG00000271755.1	RP1-153G14.4	4.11	5.3e-05	0.0135	0.29	0.25	Bipolar disorder;	chr6:27465854	chr6:27404010~27406964:-
COAD	cis	rs9393813	0.528	rs13207497	ENSG00000271755.1	RP1-153G14.4	4.11	5.3e-05	0.0135	0.29	0.25	Bipolar disorder;	chr6:27489601	chr6:27404010~27406964:-
COAD	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-4.11	5.3e-05	0.0135	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
COAD	cis	rs7529073	0.545	rs1431985	ENSG00000274895.1	RP11-478J18.2	-4.11	5.3e-05	0.0135	-0.26	-0.25	Schizophrenia;	chr1:213974903	chr1:213983793~213986419:-
COAD	cis	rs4819052	0.851	rs2838855	ENSG00000227039.5	ITGB2-AS1	4.11	5.3e-05	0.0135	0.21	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:44921051~44929678:+
COAD	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	4.11	5.3e-05	0.0135	0.26	0.25	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
COAD	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	4.11	5.3e-05	0.0135	0.35	0.25	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
COAD	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-4.11	5.3e-05	0.0135	-0.25	-0.25	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-4.11	5.3e-05	0.0135	-0.25	-0.25	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
COAD	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	4.11	5.3e-05	0.0135	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
COAD	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-4.11	5.3e-05	0.0135	-0.26	-0.25	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
COAD	cis	rs2337406	0.85	rs10131280	ENSG00000211964.3	IGHV3-48	-4.11	5.31e-05	0.0135	-0.2	-0.25	Alzheimer's disease (late onset);	chr14:106665591	chr14:106537810~106538344:-
COAD	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	4.11	5.31e-05	0.0135	0.3	0.25	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
COAD	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	4.11	5.31e-05	0.0135	0.33	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
COAD	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-4.11	5.32e-05	0.0135	-0.3	-0.25	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
COAD	cis	rs172166	0.516	rs2791333	ENSG00000272009.1	RP1-313I6.12	4.11	5.32e-05	0.0135	0.27	0.25	Cardiac Troponin-T levels;	chr6:28143336	chr6:28078792~28081130:-
COAD	cis	rs172166	0.516	rs2622322	ENSG00000272009.1	RP1-313I6.12	4.11	5.32e-05	0.0135	0.27	0.25	Cardiac Troponin-T levels;	chr6:28149665	chr6:28078792~28081130:-
COAD	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	4.11	5.32e-05	0.0135	0.28	0.25	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	4.11	5.32e-05	0.0135	0.28	0.25	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
COAD	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	4.11	5.32e-05	0.0135	0.49	0.25	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	4.11	5.32e-05	0.0135	0.49	0.25	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
COAD	cis	rs11168618	0.626	rs11609074	ENSG00000273765.1	RP11-370I10.11	4.11	5.32e-05	0.0135	0.27	0.25	Adiponectin levels;	chr12:48425552	chr12:48360920~48361377:+
COAD	cis	rs11168618	0.626	rs11514105	ENSG00000273765.1	RP11-370I10.11	4.11	5.32e-05	0.0135	0.27	0.25	Adiponectin levels;	chr12:48427151	chr12:48360920~48361377:+
COAD	cis	rs2732480	1	rs2732480	ENSG00000240399.1	RP1-228P16.1	-4.11	5.33e-05	0.0135	-0.23	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48054813~48055591:-
COAD	cis	rs180730	1	rs2667176	ENSG00000251609.2	SETP12	-4.11	5.33e-05	0.0135	-0.37	-0.25	Fasting plasma glucose;	chr4:120881498	chr4:120895494~120897083:-
COAD	cis	rs6687821	0.515	rs1112998	ENSG00000261737.1	RP4-612B15.3	4.11	5.33e-05	0.0135	0.32	0.25	Yeast infection;	chr1:86983198	chr1:86703502~86704462:-
COAD	cis	rs476633	0.691	rs6492997	ENSG00000247556.5	OIP5-AS1	4.11	5.33e-05	0.0135	0.24	0.25	Glomerular filtration rate (creatinine);	chr15:41248973	chr15:41283990~41309737:+
COAD	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-4.11	5.33e-05	0.0135	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
COAD	cis	rs2836974	0.59	rs9974757	ENSG00000255568.3	BRWD1-AS2	-4.11	5.33e-05	0.0135	-0.23	-0.25	Cognitive function;	chr21:39245318	chr21:39313935~39314962:+
COAD	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-4.11	5.33e-05	0.0135	-0.25	-0.25	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
COAD	cis	rs1559040	1	rs56374740	ENSG00000233266.1	HMGB1P31	-4.11	5.33e-05	0.0135	-0.4	-0.25	Sudden cardiac arrest;	chr2:54092380	chr2:54051334~54051760:+
COAD	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	4.11	5.33e-05	0.0135	0.3	0.25	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
COAD	cis	rs10043775	0.957	rs10042369	ENSG00000251330.3	CTD-2283N19.1	-4.11	5.33e-05	0.0135	-0.29	-0.25	Periodontal microbiota;	chr5:148424507	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs10043775	ENSG00000251330.3	CTD-2283N19.1	-4.11	5.33e-05	0.0135	-0.29	-0.25	Periodontal microbiota;	chr5:148425557	chr5:148430159~148430807:-
COAD	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-4.11	5.33e-05	0.0135	-0.39	-0.25	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
COAD	cis	rs10170310	1	rs12691947	ENSG00000228043.4	AC097721.2	4.11	5.34e-05	0.0136	0.31	0.25	Response to antipsychotic treatment;	chr2:138506901	chr2:138418284~138501698:-
COAD	cis	rs10170310	1	rs6720716	ENSG00000228043.4	AC097721.2	4.11	5.34e-05	0.0136	0.31	0.25	Response to antipsychotic treatment;	chr2:138511232	chr2:138418284~138501698:-
COAD	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	4.11	5.34e-05	0.0136	0.28	0.25	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
COAD	cis	rs8002861	0.515	rs9525846	ENSG00000274001.1	RP11-5G9.5	-4.11	5.34e-05	0.0136	-0.22	-0.25	Leprosy;	chr13:43816721	chr13:43877715~43878163:-
COAD	cis	rs791590	0.54	rs10905599	ENSG00000215267.7	AKR1C7P	4.11	5.35e-05	0.0136	0.35	0.25	Soluble interleukin-2 receptor subunit alpha;	chr10:5999960	chr10:5275173~5288470:-
COAD	cis	rs9307551	0.817	rs11098764	ENSG00000250334.4	LINC00989	-4.11	5.35e-05	0.0136	-0.29	-0.25	Refractive error;	chr4:79578860	chr4:79492416~79576460:+
COAD	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	4.11	5.35e-05	0.0136	0.29	0.25	Height;	chr4:55538228	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	4.11	5.35e-05	0.0136	0.29	0.25	Height;	chr4:55541259	chr4:55547112~55547889:+
COAD	cis	rs1485395	0.836	rs10876471	ENSG00000250133.2	HOXC-AS2	4.11	5.35e-05	0.0136	0.28	0.25	Migraine without aura;	chr12:53630760	chr12:53993810~53996785:-
COAD	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	4.11	5.35e-05	0.0136	0.3	0.25	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	4.11	5.35e-05	0.0136	0.3	0.25	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
COAD	cis	rs67072384	0.818	rs2291291	ENSG00000202522.1	Y_RNA	-4.11	5.35e-05	0.0136	-0.36	-0.25	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72755852	chr11:72766004~72766116:+
COAD	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-4.11	5.35e-05	0.0136	-0.49	-0.25	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
COAD	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-4.11	5.35e-05	0.0136	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
COAD	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	4.11	5.35e-05	0.0136	0.21	0.25	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
COAD	cis	rs12549025	0.53	rs11135740	ENSG00000253390.1	CTC-756D1.2	4.11	5.36e-05	0.0136	0.33	0.25	Reticulocyte fraction of red cells;	chr8:23510244	chr8:23458601~23484971:+
COAD	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-4.11	5.36e-05	0.0136	-0.48	-0.25	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
COAD	cis	rs9307551	0.744	rs968176	ENSG00000250334.4	LINC00989	-4.11	5.36e-05	0.0136	-0.29	-0.25	Refractive error;	chr4:79585080	chr4:79492416~79576460:+
COAD	cis	rs6088813	0.645	rs7267783	ENSG00000269202.1	RP4-614O4.12	-4.11	5.36e-05	0.0136	-0.27	-0.25	Height;	chr20:35435421	chr20:35201747~35203288:-
COAD	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	4.11	5.36e-05	0.0136	0.44	0.25	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
COAD	cis	rs453301	0.686	rs28665409	ENSG00000254340.1	RP11-10A14.3	-4.11	5.36e-05	0.0136	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9011767	chr8:9141424~9145435:+
COAD	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-4.11	5.36e-05	0.0136	-0.34	-0.25	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
COAD	cis	rs7577696	0.889	rs212733	ENSG00000272716.1	RP11-563N4.1	4.11	5.36e-05	0.0136	0.25	0.25	Inflammatory biomarkers;	chr2:32247571	chr2:32165046~32165757:-
COAD	cis	rs3126085	0.56	rs67661262	ENSG00000237975.5	FLG-AS1	4.11	5.36e-05	0.0136	0.33	0.25	Atopic dermatitis;	chr1:152395540	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs4378206	ENSG00000237975.5	FLG-AS1	-4.11	5.36e-05	0.0136	-0.33	-0.25	Atopic dermatitis;	chr1:152397437	chr1:152168125~152445456:+
COAD	cis	rs7646881	0.544	rs3817373	ENSG00000272087.1	RP11-379F4.7	4.11	5.37e-05	0.0136	0.39	0.25	Tetralogy of Fallot;	chr3:158571246	chr3:158693120~158693768:-
COAD	cis	rs8022206	0.738	rs1548264	ENSG00000259502.1	RP11-643G16.3	4.11	5.37e-05	0.0136	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68079621	chr14:67610986~67613864:+
COAD	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-4.11	5.37e-05	0.0136	-0.28	-0.25	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
COAD	cis	rs8141529	0.732	rs6005872	ENSG00000272858.1	CTA-292E10.8	-4.11	5.37e-05	0.0136	-0.29	-0.25	Lymphocyte counts;	chr22:28776910	chr22:28814914~28815662:+
COAD	cis	rs1887320	1	rs1327235	ENSG00000270777.1	RP11-103J8.2	4.11	5.37e-05	0.0136	0.26	0.25	Diastolic blood pressure;Systolic blood pressure;	chr20:10988382	chr20:11001304~11001763:+
COAD	cis	rs9487051	0.802	rs6568558	ENSG00000219700.1	PTCHD3P3	4.11	5.37e-05	0.0136	0.26	0.25	Reticulocyte fraction of red cells;	chr6:109271498	chr6:109288571~109290503:-
COAD	cis	rs28374715	0.51	rs28468975	ENSG00000247556.5	OIP5-AS1	4.11	5.37e-05	0.0136	0.26	0.25	Ulcerative colitis;	chr15:41272394	chr15:41283990~41309737:+
COAD	cis	rs12928939	0.815	rs8049163	ENSG00000260886.1	TAT-AS1	4.11	5.37e-05	0.0136	0.35	0.25	Post bronchodilator FEV1;	chr16:71685450	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.769	rs12445161	ENSG00000260886.1	TAT-AS1	4.11	5.37e-05	0.0136	0.35	0.25	Post bronchodilator FEV1;	chr16:71708025	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.815	rs34731378	ENSG00000260886.1	TAT-AS1	4.11	5.37e-05	0.0136	0.35	0.25	Post bronchodilator FEV1;	chr16:71711845	chr16:71565789~71578187:+
COAD	cis	rs801193	0.569	rs11761542	ENSG00000224316.1	RP11-479O9.2	4.11	5.37e-05	0.0136	0.27	0.25	Aortic root size;	chr7:66753209	chr7:65773620~65802067:+
COAD	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
COAD	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	4.11	5.37e-05	0.0136	0.29	0.25	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
COAD	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	4.11	5.38e-05	0.0136	0.17	0.25	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
COAD	cis	rs7615952	0.8	rs13086460	ENSG00000241278.1	ENPP7P4	4.11	5.38e-05	0.0136	0.28	0.25	Blood pressure (smoking interaction);	chr3:125927574	chr3:125848223~125909372:+
COAD	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	4.11	5.38e-05	0.0136	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
COAD	cis	rs80346118	0.929	rs754064	ENSG00000177410.11	ZFAS1	-4.11	5.38e-05	0.0136	-0.31	-0.25	Diastolic blood pressure;	chr20:48798909	chr20:49278178~49295738:+
COAD	cis	rs875971	1	rs6963646	ENSG00000230189.5	GS1-124K5.2	-4.11	5.38e-05	0.0136	-0.2	-0.25	Aortic root size;	chr7:66220780	chr7:66409143~66490059:-
COAD	cis	rs875971	0.965	rs28682868	ENSG00000230189.5	GS1-124K5.2	-4.11	5.38e-05	0.0136	-0.2	-0.25	Aortic root size;	chr7:66224822	chr7:66409143~66490059:-
COAD	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-4.11	5.38e-05	0.0136	-0.25	-0.25	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
COAD	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-4.11	5.38e-05	0.0136	-0.26	-0.25	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
COAD	cis	rs742134	1	rs742134	ENSG00000229891.1	LINC01315	-4.11	5.38e-05	0.0136	-0.33	-0.25	Prostate cancer;	chr22:43122269	chr22:42364400~42369236:-
COAD	cis	rs9818758	0.607	rs34823813	ENSG00000225399.4	RP11-3B7.1	-4.11	5.38e-05	0.0136	-0.53	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49712543	chr3:49260085~49261316:+
COAD	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	4.11	5.38e-05	0.0137	0.34	0.25	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
COAD	cis	rs2732480	0.5	rs11168468	ENSG00000226413.2	OR8T1P	4.11	5.39e-05	0.0137	0.3	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48442030~48442947:-
COAD	cis	rs875971	0.545	rs73136346	ENSG00000164669.11	INTS4P1	4.11	5.39e-05	0.0137	0.36	0.25	Aortic root size;	chr7:66101095	chr7:65141225~65234216:+
COAD	cis	rs2115630	1	rs1030863	ENSG00000259728.4	LINC00933	-4.11	5.39e-05	0.0137	-0.29	-0.25	P wave terminal force;	chr15:84739404	chr15:84570649~84580175:+
COAD	cis	rs12682352	0.602	rs4841044	ENSG00000173295.6	FAM86B3P	-4.11	5.39e-05	0.0137	-0.28	-0.25	Neuroticism;	chr8:8807430	chr8:8228595~8244865:+
COAD	cis	rs9818758	0.607	rs12185979	ENSG00000225399.4	RP11-3B7.1	-4.11	5.39e-05	0.0137	-0.56	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49614537	chr3:49260085~49261316:+
COAD	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-4.11	5.39e-05	0.0137	-0.27	-0.25	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
COAD	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-4.11	5.39e-05	0.0137	-0.27	-0.25	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
COAD	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-4.11	5.39e-05	0.0137	-0.27	-0.25	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-4.11	5.39e-05	0.0137	-0.27	-0.25	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
COAD	cis	rs2663905	1	rs2663905	ENSG00000277782.1	RP11-775C24.5	-4.11	5.39e-05	0.0137	-0.3	-0.25	QT interval (drug interaction);	chr15:81066796	chr15:80999593~80999981:-
COAD	cis	rs763121	0.853	rs3747170	ENSG00000273076.1	RP3-508I15.22	4.11	5.39e-05	0.0137	0.22	0.25	Menopause (age at onset);	chr22:38671326	chr22:38743495~38743910:+
COAD	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	4.11	5.4e-05	0.0137	0.34	0.25	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
COAD	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	4.11	5.4e-05	0.0137	0.27	0.25	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
COAD	cis	rs9291683	0.507	rs6845554	ENSG00000250413.1	RP11-448G15.1	-4.11	5.4e-05	0.0137	-0.32	-0.25	Bone mineral density;	chr4:10011549	chr4:10006482~10009725:+
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	4.11	5.4e-05	0.0137	0.23	0.25	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
COAD	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-4.11	5.41e-05	0.0137	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
COAD	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-4.11	5.41e-05	0.0137	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
COAD	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-4.11	5.41e-05	0.0137	-0.48	-0.25	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-4.11	5.41e-05	0.0137	-0.48	-0.25	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
COAD	cis	rs2252521	0.583	rs317707	ENSG00000272568.4	CTB-113D17.1	4.11	5.41e-05	0.0137	0.46	0.25	Cognitive performance;	chr7:29058720	chr7:28979967~29013367:+
COAD	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	4.11	5.41e-05	0.0137	0.29	0.25	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
COAD	cis	rs2638953	0.853	rs11049678	ENSG00000247934.4	RP11-967K21.1	-4.11	5.41e-05	0.0137	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505546	chr12:28163298~28190738:-
COAD	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	4.11	5.41e-05	0.0137	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
COAD	cis	rs2562784	1	rs2562784	ENSG00000230373.7	GOLGA6L5P	4.11	5.41e-05	0.0137	0.29	0.25	Height;	chr15:83617740	chr15:84507885~84516814:-
COAD	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-4.11	5.41e-05	0.0137	-0.25	-0.25	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
COAD	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-4.11	5.41e-05	0.0137	-0.26	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
COAD	cis	rs2638953	0.924	rs11049416	ENSG00000247934.4	RP11-967K21.1	4.11	5.41e-05	0.0137	0.26	0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28163298~28190738:-
COAD	cis	rs494562	0.892	rs575477	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85408346	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs573892	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85408471	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs573737	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85408515	chr6:85387219~85390186:-
COAD	cis	rs494562	1	rs7763191	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85408599	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs547963	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85409025	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs547052	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85409122	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs544408	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85409392	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs544403	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85409398	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs515980	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85410199	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs618448	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85411606	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs619299	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85411764	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs567686	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85414446	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs7767626	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85414676	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs7767800	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85414808	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs9344518	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85415426	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs9294335	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85416962	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs1322404	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85417194	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs1322403	ENSG00000234155.1	RP11-30P6.6	-4.11	5.41e-05	0.0137	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85417444	chr6:85387219~85390186:-
COAD	cis	rs2070488	0.662	rs6599202	ENSG00000229589.1	ACVR2B-AS1	4.11	5.42e-05	0.0137	0.25	0.25	Electrocardiographic conduction measures;	chr3:38439160	chr3:38451027~38454820:-
COAD	cis	rs763121	0.853	rs2294296	ENSG00000273076.1	RP3-508I15.22	4.11	5.42e-05	0.0137	0.22	0.25	Menopause (age at onset);	chr22:38657044	chr22:38743495~38743910:+
COAD	cis	rs7009110	0.652	rs13275909	ENSG00000213791.4	RP11-941H19.2	4.11	5.42e-05	0.0137	0.24	0.25	Asthma and hay fever;	chr8:80344307	chr8:80300869~80301481:+
COAD	cis	rs561341	1	rs55962687	ENSG00000265798.5	RP11-271K11.5	4.11	5.42e-05	0.0137	0.4	0.25	Hip circumference adjusted for BMI;	chr17:31933350	chr17:31038575~31059121:-
COAD	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	4.11	5.43e-05	0.0137	0.4	0.25	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
COAD	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	4.11	5.43e-05	0.0137	0.31	0.25	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
COAD	cis	rs2836974	0.897	rs8133146	ENSG00000255568.3	BRWD1-AS2	4.11	5.43e-05	0.0137	0.25	0.25	Cognitive function;	chr21:39242372	chr21:39313935~39314962:+
COAD	cis	rs9291683	0.62	rs11722946	ENSG00000250413.1	RP11-448G15.1	4.11	5.43e-05	0.0137	0.31	0.25	Bone mineral density;	chr4:10124366	chr4:10006482~10009725:+
COAD	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-4.11	5.43e-05	0.0137	-0.27	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
COAD	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-4.1	5.44e-05	0.0138	-0.3	-0.25	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
COAD	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-4.1	5.44e-05	0.0138	-0.26	-0.25	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
COAD	cis	rs2732480	0.577	rs2634680	ENSG00000226413.2	OR8T1P	4.1	5.44e-05	0.0138	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2634678	ENSG00000226413.2	OR8T1P	4.1	5.44e-05	0.0138	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2732479	ENSG00000226413.2	OR8T1P	4.1	5.44e-05	0.0138	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.537	rs1061986	ENSG00000226413.2	OR8T1P	4.1	5.44e-05	0.0138	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48442030~48442947:-
COAD	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	4.1	5.44e-05	0.0138	0.22	0.25	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
COAD	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	4.1	5.44e-05	0.0138	0.22	0.25	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
COAD	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	4.1	5.44e-05	0.0138	0.22	0.25	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
COAD	cis	rs860295	0.702	rs11264386	ENSG00000225855.5	RUSC1-AS1	4.1	5.44e-05	0.0138	0.22	0.25	Body mass index;	chr1:155589379	chr1:155316863~155324176:-
COAD	cis	rs494562	0.892	rs521005	ENSG00000234155.1	RP11-30P6.6	-4.1	5.44e-05	0.0138	-0.47	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85406824	chr6:85387219~85390186:-
COAD	cis	rs4819052	0.851	rs9977178	ENSG00000227039.5	ITGB2-AS1	-4.1	5.44e-05	0.0138	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:44921051~44929678:+
COAD	cis	rs9532669	0.926	rs9532659	ENSG00000277662.1	RP11-74J13.9	-4.1	5.44e-05	0.0138	-0.24	-0.25	Cervical cancer;	chr13:40920380	chr13:41229180~41229676:-
COAD	cis	rs7955901	0.691	rs12831292	ENSG00000258053.1	CTD-2021H9.3	4.1	5.45e-05	0.0138	0.31	0.25	Type 2 diabetes;	chr12:71096376	chr12:71047402~71118247:-
COAD	cis	rs4074961	0.505	rs4653306	ENSG00000233621.1	LINC01137	-4.1	5.45e-05	0.0138	-0.28	-0.25	Axial length;	chr1:37599789	chr1:37454879~37474411:-
COAD	cis	rs2564921	0.704	rs12053904	ENSG00000280417.1	RP11-5O17.1	4.1	5.45e-05	0.0138	0.27	0.25	Height;	chr3:52991821	chr3:53046166~53048122:+
COAD	cis	rs2564921	0.679	rs2115779	ENSG00000280417.1	RP11-5O17.1	4.1	5.45e-05	0.0138	0.27	0.25	Height;	chr3:52992698	chr3:53046166~53048122:+
COAD	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	4.1	5.45e-05	0.0138	0.29	0.25	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
COAD	cis	rs2638953	0.962	rs11049544	ENSG00000247934.4	RP11-967K21.1	-4.1	5.45e-05	0.0138	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342348	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.889	rs10843157	ENSG00000247934.4	RP11-967K21.1	-4.1	5.45e-05	0.0138	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346417	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049548	ENSG00000247934.4	RP11-967K21.1	-4.1	5.45e-05	0.0138	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28350789	chr12:28163298~28190738:-
COAD	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	4.1	5.45e-05	0.0138	0.32	0.25	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
COAD	cis	rs2307394	0.964	rs2161983	ENSG00000281469.1	RP11-567F11.1	4.1	5.45e-05	0.0138	0.3	0.25	Urate levels;	chr2:147891817	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13019809	ENSG00000281469.1	RP11-567F11.1	4.1	5.45e-05	0.0138	0.3	0.25	Urate levels;	chr2:147892904	chr2:148044380~148044894:+
COAD	cis	rs4243971	0.516	rs62208761	ENSG00000101898.5	MCTS2P	4.1	5.46e-05	0.0138	0.27	0.25	Inflammatory bowel disease;Crohn's disease;	chr20:32275071	chr20:31547504~31548049:+
COAD	cis	rs7260598	0.892	rs58931976	ENSG00000268442.1	CTD-2027I19.2	4.1	5.46e-05	0.0138	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.892	rs59831281	ENSG00000268442.1	CTD-2027I19.2	4.1	5.46e-05	0.0138	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.786	rs59387271	ENSG00000268442.1	CTD-2027I19.2	4.1	5.46e-05	0.0138	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:24162370~24163425:-
COAD	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-4.1	5.46e-05	0.0138	-0.35	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
COAD	cis	rs1914816	0.887	rs2460155	ENSG00000196274.5	Metazoa_SRP	4.1	5.46e-05	0.0138	0.28	0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76230048~76230390:-
COAD	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-4.1	5.46e-05	0.0138	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
COAD	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-4.1	5.46e-05	0.0138	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
COAD	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	4.1	5.47e-05	0.0138	0.49	0.25	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
COAD	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	4.1	5.47e-05	0.0138	0.49	0.25	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
COAD	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	4.1	5.47e-05	0.0138	0.49	0.25	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	4.1	5.47e-05	0.0138	0.49	0.25	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
COAD	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	4.1	5.47e-05	0.0138	0.49	0.25	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
COAD	cis	rs11976180	1	rs1919950	ENSG00000273234.1	OR2A13P	-4.1	5.47e-05	0.0138	-0.3	-0.25	Obesity-related traits;	chr7:144070805	chr7:144142009~144142938:+
COAD	cis	rs10819861	0.645	rs7862829	ENSG00000238251.2	RP11-172F4.2	-4.1	5.47e-05	0.0138	-0.29	-0.25	Electrocardiographic traits;	chr9:96094462	chr9:96407284~96407797:+
COAD	cis	rs4950322	1	rs1806618	ENSG00000278811.3	LINC00624	4.1	5.47e-05	0.0138	0.27	0.25	Protein quantitative trait loci;	chr1:147377075	chr1:147258885~147517875:-
COAD	cis	rs4950322	1	rs4448568	ENSG00000278811.3	LINC00624	4.1	5.47e-05	0.0138	0.27	0.25	Protein quantitative trait loci;	chr1:147377296	chr1:147258885~147517875:-
COAD	cis	rs4950322	0.895	rs17356735	ENSG00000278811.3	LINC00624	4.1	5.47e-05	0.0138	0.27	0.25	Protein quantitative trait loci;	chr1:147378328	chr1:147258885~147517875:-
COAD	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-4.1	5.47e-05	0.0138	-0.48	-0.25	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
COAD	cis	rs250677	0.687	rs2963485	ENSG00000250072.4	CTC-529P8.1	4.1	5.47e-05	0.0138	0.35	0.25	Breast cancer;	chr5:149072480	chr5:149063317~149109787:+
COAD	cis	rs61864810	1	rs61864810	ENSG00000274723.1	RP11-618L22.1	4.1	5.47e-05	0.0138	0.27	0.25	Itch intensity from mosquito bite;	chr12:46288226	chr12:46970504~46972155:+
COAD	cis	rs7637701	0.78	rs9858158	ENSG00000240875.4	LINC00886	-4.1	5.47e-05	0.0138	-0.24	-0.25	Breast cancer;	chr3:156845538	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.901	rs13071598	ENSG00000240875.4	LINC00886	-4.1	5.47e-05	0.0138	-0.24	-0.25	Breast cancer;	chr3:156854426	chr3:156747346~156817062:-
COAD	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	4.1	5.47e-05	0.0138	0.47	0.25	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
COAD	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-4.1	5.47e-05	0.0138	-0.35	-0.25	Depression;	chr6:28140307	chr6:28115628~28116551:+
COAD	cis	rs812925	0.519	rs10199672	ENSG00000273302.1	RP11-493E12.2	-4.1	5.47e-05	0.0138	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61400499	chr2:61199979~61200769:+
COAD	cis	rs9291683	0.554	rs7668175	ENSG00000250413.1	RP11-448G15.1	4.1	5.48e-05	0.0138	0.32	0.25	Bone mineral density;	chr4:10124158	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.62	rs7699512	ENSG00000250413.1	RP11-448G15.1	4.1	5.48e-05	0.0138	0.32	0.25	Bone mineral density;	chr4:10124184	chr4:10006482~10009725:+
COAD	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-4.1	5.48e-05	0.0138	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
COAD	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	4.1	5.48e-05	0.0138	0.35	0.25	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
COAD	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	4.1	5.48e-05	0.0138	0.43	0.25	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
COAD	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-4.1	5.49e-05	0.0138	-0.31	-0.25	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
COAD	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-4.1	5.49e-05	0.0139	-0.34	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
COAD	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-4.1	5.49e-05	0.0139	-0.34	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
COAD	cis	rs3126085	0.935	rs11204941	ENSG00000237975.5	FLG-AS1	-4.1	5.49e-05	0.0139	-0.27	-0.25	Atopic dermatitis;	chr1:152230867	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.825	rs10788830	ENSG00000237975.5	FLG-AS1	-4.1	5.49e-05	0.0139	-0.27	-0.25	Atopic dermatitis;	chr1:152234422	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs1466757	ENSG00000237975.5	FLG-AS1	-4.1	5.49e-05	0.0139	-0.27	-0.25	Atopic dermatitis;	chr1:152239993	chr1:152168125~152445456:+
COAD	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	4.1	5.49e-05	0.0139	0.3	0.25	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
COAD	cis	rs2638953	0.925	rs7967281	ENSG00000247934.4	RP11-967K21.1	-4.1	5.49e-05	0.0139	-0.25	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:28163298~28190738:-
COAD	cis	rs9990333	0.562	rs55970879	ENSG00000207650.1	MIR570	4.1	5.49e-05	0.0139	0.31	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195699401~195699497:+
COAD	cis	rs9990333	0.562	rs75681503	ENSG00000207650.1	MIR570	4.1	5.49e-05	0.0139	0.31	0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195699401~195699497:+
COAD	cis	rs55962025	0.804	rs3775061	ENSG00000248840.2	RP11-357G3.2	4.1	5.49e-05	0.0139	0.3	0.25	Parental longevity (mother's age at death);	chr4:3237027	chr4:3312512~3313058:+
COAD	cis	rs10129255	0.5	rs1024350	ENSG00000211967.3	IGHV3-53	-4.1	5.5e-05	0.0139	-0.14	-0.25	Kawasaki disease;	chr14:106685105	chr14:106592676~106593347:-
COAD	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-4.1	5.5e-05	0.0139	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
COAD	cis	rs3126085	0.935	rs10749670	ENSG00000237975.5	FLG-AS1	-4.1	5.5e-05	0.0139	-0.28	-0.25	Atopic dermatitis;	chr1:152247991	chr1:152168125~152445456:+
COAD	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-4.1	5.5e-05	0.0139	-0.25	-0.25	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
COAD	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	4.1	5.5e-05	0.0139	0.3	0.25	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
COAD	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-4.1	5.5e-05	0.0139	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	4.1	5.5e-05	0.0139	0.33	0.25	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	4.1	5.5e-05	0.0139	0.33	0.25	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
COAD	cis	rs172166	0.516	rs1225618	ENSG00000272009.1	RP1-313I6.12	4.1	5.51e-05	0.0139	0.27	0.25	Cardiac Troponin-T levels;	chr6:28161935	chr6:28078792~28081130:-
COAD	cis	rs172166	0.516	rs1150670	ENSG00000272009.1	RP1-313I6.12	4.1	5.51e-05	0.0139	0.27	0.25	Cardiac Troponin-T levels;	chr6:28162781	chr6:28078792~28081130:-
COAD	cis	rs172166	0.516	rs2021826	ENSG00000272009.1	RP1-313I6.12	4.1	5.51e-05	0.0139	0.27	0.25	Cardiac Troponin-T levels;	chr6:28164978	chr6:28078792~28081130:-
COAD	cis	rs1150668	0.835	rs1233696	ENSG00000272009.1	RP1-313I6.12	4.1	5.51e-05	0.0139	0.27	0.25	Pubertal anthropometrics;	chr6:28175232	chr6:28078792~28081130:-
COAD	cis	rs7246657	1	rs6508710	ENSG00000226686.6	LINC01535	-4.1	5.51e-05	0.0139	-0.35	-0.25	Coronary artery calcification;	chr19:37258984	chr19:37251912~37265535:+
COAD	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-4.1	5.51e-05	0.0139	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
COAD	cis	rs228769	0.562	rs228779	ENSG00000267080.4	ASB16-AS1	4.1	5.51e-05	0.0139	0.28	0.25	Bone mineral density (hip);Bone mineral density (spine);	chr17:44013845	chr17:44175973~44186717:-
COAD	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-4.1	5.51e-05	0.0139	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
COAD	cis	rs495337	1	rs2281216	ENSG00000229222.1	KRT18P4	-4.1	5.51e-05	0.0139	-0.26	-0.25	Psoriasis;	chr20:49951966	chr20:49956745~49958032:+
COAD	cis	rs2307394	0.929	rs1020653	ENSG00000281469.1	RP11-567F11.1	4.1	5.51e-05	0.0139	0.29	0.25	Urate levels;	chr2:147974841	chr2:148044380~148044894:+
COAD	cis	rs7567389	0.576	rs2069902	ENSG00000236682.1	AC068282.3	-4.1	5.51e-05	0.0139	-0.32	-0.25	Self-rated health;	chr2:127417287	chr2:127389130~127400580:+
COAD	cis	rs4072705	0.967	rs10120039	ENSG00000224020.1	MIR181A2HG	-4.1	5.51e-05	0.0139	-0.3	-0.25	Menarche (age at onset);	chr9:124644682	chr9:124658467~124698631:+
COAD	cis	rs12681963	0.686	rs16876445	ENSG00000279041.1	CTD-2373N4.3	4.1	5.51e-05	0.0139	0.36	0.25	Migraine;	chr8:30100148	chr8:30552345~30553766:+
COAD	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	4.1	5.51e-05	0.0139	0.3	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
COAD	cis	rs5758511	0.689	rs17002947	ENSG00000237037.8	NDUFA6-AS1	4.1	5.52e-05	0.0139	0.29	0.25	Birth weight;	chr22:42292526	chr22:42090931~42137742:+
COAD	cis	rs3120667	0.79	rs1923493	ENSG00000237975.5	FLG-AS1	4.1	5.52e-05	0.0139	0.3	0.25	Eating disorders;	chr1:152411727	chr1:152168125~152445456:+
COAD	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.1	5.52e-05	0.0139	0.38	0.25	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
COAD	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.1	5.52e-05	0.0139	0.38	0.25	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
COAD	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-4.1	5.52e-05	0.0139	-0.34	-0.25	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
COAD	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	4.1	5.52e-05	0.0139	0.33	0.25	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
COAD	cis	rs1510272	0.728	rs4680287	ENSG00000243926.1	TIPARP-AS1	-4.1	5.52e-05	0.0139	-0.28	-0.25	Testicular germ cell tumor;	chr3:156611391	chr3:156671862~156674378:-
COAD	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	4.1	5.52e-05	0.0139	0.36	0.25	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	4.1	5.52e-05	0.0139	0.36	0.25	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	4.1	5.52e-05	0.0139	0.36	0.25	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
COAD	cis	rs2188554	0.533	rs213981	ENSG00000237974.1	AC000111.4	-4.1	5.53e-05	0.0139	-0.27	-0.25	Esophageal adenocarcinoma;	chr7:117614473	chr7:117487737~117487929:+
COAD	cis	rs9307551	1	rs3943669	ENSG00000250334.4	LINC00989	-4.1	5.53e-05	0.0139	-0.33	-0.25	Refractive error;	chr4:79595389	chr4:79492416~79576460:+
COAD	cis	rs7577696	0.962	rs11124275	ENSG00000272716.1	RP11-563N4.1	-4.1	5.53e-05	0.0139	-0.26	-0.25	Inflammatory biomarkers;	chr2:32078693	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.925	rs11683931	ENSG00000272716.1	RP11-563N4.1	-4.1	5.53e-05	0.0139	-0.26	-0.25	Inflammatory biomarkers;	chr2:32078999	chr2:32165046~32165757:-
COAD	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	4.1	5.53e-05	0.0139	0.27	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
COAD	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	4.1	5.53e-05	0.0139	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
COAD	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-4.1	5.54e-05	0.014	-0.34	-0.25	Pain;	chr19:21495996	chr19:21554640~21569237:-
COAD	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-4.1	5.54e-05	0.014	-0.26	-0.25	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
COAD	cis	rs4938303	0.633	rs567209	ENSG00000254851.1	RP11-109L13.1	4.1	5.54e-05	0.014	0.37	0.25	Triglycerides;	chr11:116664111	chr11:117135528~117138582:+
COAD	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-4.1	5.54e-05	0.014	-0.5	-0.25	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
COAD	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	4.1	5.54e-05	0.014	0.34	0.25	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
COAD	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	4.1	5.54e-05	0.014	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
COAD	cis	rs5753037	0.835	rs737908	ENSG00000279159.1	RP3-394A18.1	-4.1	5.54e-05	0.014	-0.17	-0.25	Type 1 diabetes;	chr22:29992313	chr22:29978950~30028236:-
COAD	cis	rs6723226	0.764	rs176403	ENSG00000276334.1	AL133243.1	-4.1	5.54e-05	0.014	-0.23	-0.25	Intelligence (multi-trait analysis);	chr2:32412796	chr2:32521927~32523547:+
COAD	cis	rs9796	0.621	rs2918462	ENSG00000247556.5	OIP5-AS1	-4.1	5.55e-05	0.014	-0.24	-0.25	Menopause (age at onset);	chr15:41189056	chr15:41283990~41309737:+
COAD	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-4.1	5.55e-05	0.014	-0.3	-0.25	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
COAD	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.1	5.55e-05	0.014	-0.32	-0.25	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
COAD	cis	rs6687821	0.515	rs2390219	ENSG00000261737.1	RP4-612B15.3	4.1	5.55e-05	0.014	0.32	0.25	Yeast infection;	chr1:86988738	chr1:86703502~86704462:-
COAD	cis	rs17685	0.725	rs6947068	ENSG00000280388.1	RP11-229D13.3	4.1	5.55e-05	0.014	0.25	0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76043977~76045963:-
COAD	cis	rs875971	1	rs2220626	ENSG00000232559.3	GS1-124K5.12	-4.1	5.55e-05	0.014	-0.29	-0.25	Aortic root size;	chr7:66081075	chr7:66554588~66576923:-
COAD	cis	rs6732160	0.588	rs62151795	ENSG00000163016.8	ALMS1P	4.1	5.55e-05	0.014	0.32	0.25	Intelligence (multi-trait analysis);	chr2:73149712	chr2:73644919~73685576:+
COAD	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	4.1	5.55e-05	0.014	0.42	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
COAD	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	4.1	5.55e-05	0.014	0.42	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
COAD	cis	rs453301	0.682	rs2929451	ENSG00000254340.1	RP11-10A14.3	4.1	5.56e-05	0.014	0.28	0.25	Joint mobility (Beighton score);	chr8:9227785	chr8:9141424~9145435:+
COAD	cis	rs875971	0.862	rs1875057	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66266868	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6960446	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66268272	chr7:65773620~65802067:+
COAD	cis	rs875971	0.789	rs10260426	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66271055	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs7796162	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66280771	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs2901152	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66300017	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs10263690	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66301466	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs10250544	ENSG00000224316.1	RP11-479O9.2	-4.1	5.56e-05	0.014	-0.27	-0.25	Aortic root size;	chr7:66301574	chr7:65773620~65802067:+
COAD	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-4.1	5.56e-05	0.014	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
COAD	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-4.1	5.56e-05	0.014	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-4.1	5.56e-05	0.014	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
COAD	cis	rs8177876	0.642	rs56375210	ENSG00000261061.1	RP11-303E16.2	-4.1	5.56e-05	0.014	-0.53	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81110070	chr16:81030770~81031485:+
COAD	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-4.1	5.56e-05	0.014	-0.23	-0.25	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
COAD	cis	rs4074961	0.565	rs10908362	ENSG00000233621.1	LINC01137	-4.1	5.56e-05	0.014	-0.28	-0.25	Axial length;	chr1:37596105	chr1:37454879~37474411:-
COAD	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-4.1	5.56e-05	0.014	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
COAD	cis	rs875971	0.898	rs6977501	ENSG00000230189.5	GS1-124K5.2	-4.1	5.57e-05	0.014	-0.21	-0.25	Aortic root size;	chr7:66228355	chr7:66409143~66490059:-
COAD	cis	rs7819412	0.595	rs10503416	ENSG00000269918.1	AF131215.9	4.1	5.57e-05	0.014	0.3	0.25	Triglycerides;	chr8:11130043	chr8:11104691~11106704:-
COAD	cis	rs4950322	0.542	rs12046706	ENSG00000278811.3	LINC00624	4.1	5.57e-05	0.014	0.24	0.25	Protein quantitative trait loci;	chr1:147189758	chr1:147258885~147517875:-
COAD	cis	rs11138902	0.649	rs11139224	ENSG00000229312.2	RP11-470P21.2	4.1	5.57e-05	0.014	0.28	0.25	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69540279	chr9:69472466~69494513:+
COAD	cis	rs12908161	0.96	rs11633450	ENSG00000225151.9	GOLGA2P7	-4.1	5.57e-05	0.014	-0.32	-0.25	Schizophrenia;	chr15:84764056	chr15:84199311~84230136:-
COAD	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-4.1	5.57e-05	0.014	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
COAD	cis	rs884366	1	rs6903519	ENSG00000219700.1	PTCHD3P3	4.1	5.58e-05	0.014	0.32	0.25	HDL cholesterol;HDL cholesterol levels;	chr6:109310112	chr6:109288571~109290503:-
COAD	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	4.1	5.58e-05	0.014	0.29	0.25	Height;	chr4:55534166	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	4.1	5.58e-05	0.014	0.29	0.25	Height;	chr4:55534180	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	4.1	5.58e-05	0.014	0.29	0.25	Height;	chr4:55534788	chr4:55547112~55547889:+
COAD	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-4.1	5.58e-05	0.014	-0.3	-0.25	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
COAD	cis	rs9532669	0.963	rs9532673	ENSG00000277662.1	RP11-74J13.9	-4.1	5.58e-05	0.014	-0.24	-0.25	Cervical cancer;	chr13:40930412	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.89	rs9532676	ENSG00000277662.1	RP11-74J13.9	-4.1	5.58e-05	0.014	-0.24	-0.25	Cervical cancer;	chr13:40935626	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.89	rs9594457	ENSG00000239827.7	SUGT1P3	-4.1	5.58e-05	0.014	-0.22	-0.25	Cervical cancer;	chr13:40920439	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9594458	ENSG00000239827.7	SUGT1P3	-4.1	5.58e-05	0.014	-0.22	-0.25	Cervical cancer;	chr13:40920448	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs9590562	ENSG00000239827.7	SUGT1P3	-4.1	5.58e-05	0.014	-0.22	-0.25	Cervical cancer;	chr13:40920503	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.963	rs12857052	ENSG00000239827.7	SUGT1P3	-4.1	5.58e-05	0.014	-0.22	-0.25	Cervical cancer;	chr13:40920831	chr13:40908159~40921774:-
COAD	cis	rs7829975	0.688	rs6601703	ENSG00000254340.1	RP11-10A14.3	4.1	5.58e-05	0.0141	0.28	0.25	Mood instability;	chr8:8522714	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-4.1	5.58e-05	0.0141	-0.31	-0.25	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
COAD	cis	rs7829975	0.688	rs13270194	ENSG00000254340.1	RP11-10A14.3	4.1	5.58e-05	0.0141	0.28	0.25	Mood instability;	chr8:8520592	chr8:9141424~9145435:+
COAD	cis	rs7714670	1	rs34929759	ENSG00000184084.7	CTD-2372A4.1	-4.1	5.59e-05	0.0141	-0.26	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr5:73777250	chr5:73803296~73803599:-
COAD	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	4.1	5.59e-05	0.0141	0.29	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
COAD	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	4.1	5.59e-05	0.0141	0.25	0.25	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
COAD	cis	rs7577696	0.962	rs7581340	ENSG00000272716.1	RP11-563N4.1	-4.1	5.59e-05	0.0141	-0.26	-0.25	Inflammatory biomarkers;	chr2:32112322	chr2:32165046~32165757:-
COAD	cis	rs7955901	0.837	rs7132840	ENSG00000258053.1	CTD-2021H9.3	-4.1	5.59e-05	0.0141	-0.29	-0.25	Type 2 diabetes;	chr12:71017781	chr12:71047402~71118247:-
COAD	cis	rs801193	0.569	rs2659907	ENSG00000224316.1	RP11-479O9.2	4.1	5.59e-05	0.0141	0.27	0.25	Aortic root size;	chr7:66699045	chr7:65773620~65802067:+
COAD	cis	rs801193	0.527	rs2707837	ENSG00000224316.1	RP11-479O9.2	4.1	5.59e-05	0.0141	0.27	0.25	Aortic root size;	chr7:66716086	chr7:65773620~65802067:+
COAD	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-4.1	5.59e-05	0.0141	-0.41	-0.25	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
COAD	cis	rs930421	0.965	rs11681208	ENSG00000226491.1	FTOP1	-4.1	5.59e-05	0.0141	-0.34	-0.25	Attention deficit hyperactivity disorder;	chr2:42760128	chr2:42797225~42798712:-
COAD	cis	rs6088813	0.645	rs7263431	ENSG00000269202.1	RP4-614O4.12	-4.1	5.59e-05	0.0141	-0.26	-0.25	Height;	chr20:35426395	chr20:35201747~35203288:-
COAD	cis	rs189798	0.807	rs12785	ENSG00000173295.6	FAM86B3P	4.1	5.59e-05	0.0141	0.35	0.25	Myopia (pathological);	chr8:9137426	chr8:8228595~8244865:+
COAD	cis	rs9868809	0.505	rs28657585	ENSG00000225399.4	RP11-3B7.1	-4.1	5.59e-05	0.0141	-0.38	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698783	chr3:49260085~49261316:+
COAD	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-4.1	5.6e-05	0.0141	-0.33	-0.25	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
COAD	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	4.1	5.6e-05	0.0141	0.31	0.25	Height;	chr6:109769861	chr6:109382795~109383666:+
COAD	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-4.1	5.61e-05	0.0141	-0.3	-0.25	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
COAD	cis	rs2281603	0.762	rs61987035	ENSG00000259116.1	RP11-973N13.4	-4.1	5.61e-05	0.0141	-0.26	-0.25	Lymphocyte counts;	chr14:64571149	chr14:64514154~64540368:-
COAD	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-4.1	5.61e-05	0.0141	-0.36	-0.25	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
COAD	cis	rs4767364	0.922	rs7300252	ENSG00000257595.2	RP3-473L9.4	4.1	5.61e-05	0.0141	0.31	0.25	Oral cavity and pharyngeal cancer;	chr12:111992542	chr12:111369282~111403310:+
COAD	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-4.1	5.61e-05	0.0141	-0.33	-0.25	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
COAD	cis	rs7615952	0.546	rs2979307	ENSG00000241278.1	ENPP7P4	-4.1	5.61e-05	0.0141	-0.29	-0.25	Blood pressure (smoking interaction);	chr3:125590730	chr3:125848223~125909372:+
COAD	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	4.1	5.61e-05	0.0141	0.25	0.25	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
COAD	cis	rs12506228	0.598	rs11726393	ENSG00000279943.1	FLJ38576	4.1	5.61e-05	0.0141	0.34	0.25	Job-related exhaustion in shift workers;	chr4:186427330	chr4:186189032~186191490:-
COAD	cis	rs2281603	0.762	rs10144661	ENSG00000259116.1	RP11-973N13.4	-4.1	5.61e-05	0.0141	-0.26	-0.25	Lymphocyte counts;	chr14:64569651	chr14:64514154~64540368:-
COAD	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	4.1	5.61e-05	0.0141	0.32	0.25	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
COAD	cis	rs9291683	0.546	rs13139055	ENSG00000250413.1	RP11-448G15.1	-4.1	5.61e-05	0.0141	-0.33	-0.25	Bone mineral density;	chr4:10037300	chr4:10006482~10009725:+
COAD	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	4.1	5.62e-05	0.0141	0.26	0.25	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
COAD	cis	rs12699921	0.599	rs998342	ENSG00000279048.1	RP11-511H23.2	-4.1	5.62e-05	0.0141	-0.18	-0.25	Fibrinogen levels;	chr7:17785965	chr7:17940503~17942922:+
COAD	cis	rs9858542	0.537	rs2304442	ENSG00000225399.4	RP11-3B7.1	4.1	5.62e-05	0.0141	0.36	0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49284594	chr3:49260085~49261316:+
COAD	cis	rs4820539	1	rs5759598	ENSG00000211644.2	IGLV1-51	-4.1	5.62e-05	0.0141	-0.14	-0.25	Bone mineral density;	chr22:23138775	chr22:22322472~22322980:+
COAD	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-4.1	5.62e-05	0.0141	-0.25	-0.25	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
COAD	cis	rs3824347	0.771	rs10781263	ENSG00000229587.2	RP11-197P3.5	4.1	5.62e-05	0.0141	0.28	0.25	Urinary magnesium-to-creatinine ratio;	chr9:75038244	chr9:75009828~75016036:-
COAD	cis	rs2777491	0.915	rs7180418	ENSG00000247556.5	OIP5-AS1	4.1	5.62e-05	0.0141	0.27	0.25	Ulcerative colitis;	chr15:41337304	chr15:41283990~41309737:+
COAD	cis	rs2836974	0.897	rs12481860	ENSG00000255568.3	BRWD1-AS2	4.1	5.62e-05	0.0141	0.25	0.25	Cognitive function;	chr21:39165910	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.863	rs12483216	ENSG00000255568.3	BRWD1-AS2	4.1	5.62e-05	0.0141	0.25	0.25	Cognitive function;	chr21:39167688	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.863	rs6517519	ENSG00000255568.3	BRWD1-AS2	4.1	5.62e-05	0.0141	0.25	0.25	Cognitive function;	chr21:39168319	chr21:39313935~39314962:+
COAD	cis	rs1670533	1	rs6599279	ENSG00000273179.1	RP11-20I20.4	4.1	5.62e-05	0.0141	0.32	0.25	Recombination rate (females);	chr4:1065045	chr4:1167778~1168174:+
COAD	cis	rs9307551	0.817	rs1440852	ENSG00000250334.4	LINC00989	-4.1	5.62e-05	0.0141	-0.29	-0.25	Refractive error;	chr4:79585435	chr4:79492416~79576460:+
COAD	cis	rs11588062	0.687	rs3991796	ENSG00000230896.1	RP11-767N6.7	4.1	5.62e-05	0.0141	0.29	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:46336936	chr1:45694684~45697075:-
COAD	cis	rs2765539	0.851	rs8928	ENSG00000231365.4	RP11-418J17.1	-4.1	5.62e-05	0.0141	-0.3	-0.25	Waist-hip ratio;	chr1:119031451	chr1:119140396~119275973:+
COAD	cis	rs752010	0.875	rs11210502	ENSG00000230638.4	RP11-486B10.4	-4.1	5.63e-05	0.0141	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41628041	chr1:41542069~41544310:+
COAD	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	4.1	5.63e-05	0.0141	0.33	0.25	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
COAD	cis	rs74233809	1	rs5011520	ENSG00000213277.3	MARCKSL1P1	4.1	5.63e-05	0.0141	0.51	0.25	Birth weight;	chr10:102937759	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs10883808	ENSG00000213277.3	MARCKSL1P1	4.1	5.63e-05	0.0141	0.51	0.25	Birth weight;	chr10:102961369	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs11191479	ENSG00000213277.3	MARCKSL1P1	4.1	5.63e-05	0.0141	0.51	0.25	Birth weight;	chr10:102963863	chr10:103175554~103176094:+
COAD	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	4.1	5.63e-05	0.0141	0.4	0.25	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
COAD	cis	rs8141529	0.764	rs5752809	ENSG00000272858.1	CTA-292E10.8	-4.1	5.64e-05	0.0142	-0.29	-0.25	Lymphocyte counts;	chr22:28829512	chr22:28814914~28815662:+
COAD	cis	rs7760535	0.794	rs3851225	ENSG00000271789.1	RP5-1112D6.7	-4.1	5.64e-05	0.0142	-0.24	-0.25	Metabolic traits;	chr6:111503929	chr6:111297126~111298510:+
COAD	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	4.1	5.64e-05	0.0142	0.32	0.25	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	4.1	5.64e-05	0.0142	0.32	0.25	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	4.1	5.64e-05	0.0142	0.32	0.25	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
COAD	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	4.1	5.64e-05	0.0142	0.26	0.25	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
COAD	cis	rs3733585	0.775	rs13124007	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.566	rs13144709	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10042558	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.546	rs13110307	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10042740	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.566	rs13122689	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10043024	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.546	rs13129453	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10043160	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.546	rs12504565	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10043521	chr4:10006482~10009725:+
COAD	cis	rs9291683	0.546	rs7442336	ENSG00000250413.1	RP11-448G15.1	-4.1	5.64e-05	0.0142	-0.33	-0.25	Bone mineral density;	chr4:10044159	chr4:10006482~10009725:+
COAD	cis	rs8081187	0.505	rs9904033	ENSG00000264538.5	SUZ12P1	4.1	5.64e-05	0.0142	0.21	0.25	Breast cancer;	chr17:30673001	chr17:30709299~30790908:+
COAD	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	4.1	5.64e-05	0.0142	0.28	0.25	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
COAD	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-4.1	5.64e-05	0.0142	-0.27	-0.25	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
COAD	cis	rs9532669	0.89	rs9594457	ENSG00000277662.1	RP11-74J13.9	-4.1	5.64e-05	0.0142	-0.24	-0.25	Cervical cancer;	chr13:40920439	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9594458	ENSG00000277662.1	RP11-74J13.9	-4.1	5.64e-05	0.0142	-0.24	-0.25	Cervical cancer;	chr13:40920448	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9590562	ENSG00000277662.1	RP11-74J13.9	-4.1	5.64e-05	0.0142	-0.24	-0.25	Cervical cancer;	chr13:40920503	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.963	rs12857052	ENSG00000277662.1	RP11-74J13.9	-4.1	5.64e-05	0.0142	-0.24	-0.25	Cervical cancer;	chr13:40920831	chr13:41229180~41229676:-
COAD	cis	rs2682471	0.589	rs11053781	ENSG00000245648.1	RP11-277P12.20	4.1	5.65e-05	0.0142	0.31	0.25	Macrophage inflammatory protein 1a levels;	chr12:10384670	chr12:10363769~10398506:+
COAD	cis	rs2916733	0.607	rs2979647	ENSG00000246089.3	RP11-115C21.2	4.1	5.65e-05	0.0142	0.33	0.25	Epirubicin-induced leukopenia;	chr8:6457826	chr8:6403551~6407142:-
COAD	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	4.1	5.65e-05	0.0142	0.38	0.25	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
COAD	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	4.1	5.65e-05	0.0142	0.38	0.25	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
COAD	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	4.1	5.65e-05	0.0142	0.38	0.25	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
COAD	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	4.1	5.65e-05	0.0142	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
COAD	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	4.1	5.65e-05	0.0142	0.44	0.25	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
COAD	cis	rs2711721	0.56	rs2522256	ENSG00000280054.1	RP1-197B17.7	-4.1	5.65e-05	0.0142	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr12:46980940	chr12:47728151~47730598:-
COAD	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	4.1	5.65e-05	0.0142	0.3	0.25	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
COAD	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	4.1	5.65e-05	0.0142	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
COAD	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-4.1	5.65e-05	0.0142	-0.29	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
COAD	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	4.1	5.66e-05	0.0142	0.27	0.25	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
COAD	cis	rs4879656	0.797	rs7872744	ENSG00000225693.1	LAGE3P1	-4.09	5.66e-05	0.0142	-0.28	-0.25	Menopause (age at onset);	chr9:33054164	chr9:33019682~33020165:-
COAD	cis	rs11588062	0.628	rs3737744	ENSG00000230896.1	RP11-767N6.7	-4.09	5.66e-05	0.0142	-0.29	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:46344858	chr1:45694684~45697075:-
COAD	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-4.09	5.66e-05	0.0142	-0.4	-0.25	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
COAD	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-4.09	5.67e-05	0.0142	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
COAD	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-4.09	5.67e-05	0.0142	-0.26	-0.25	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
COAD	cis	rs950893	0.557	rs2942194	ENSG00000253930.1	RP11-1149O23.2	4.09	5.67e-05	0.0142	0.31	0.25	Mean corpuscular hemoglobin;	chr8:23566156	chr8:23189279~23190675:+
COAD	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	4.09	5.68e-05	0.0142	0.24	0.25	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
COAD	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	4.09	5.68e-05	0.0142	0.28	0.25	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
COAD	cis	rs4819052	0.851	rs28616694	ENSG00000227039.5	ITGB2-AS1	-4.09	5.68e-05	0.0142	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:44921051~44929678:+
COAD	cis	rs8022206	0.617	rs2588831	ENSG00000259502.1	RP11-643G16.3	-4.09	5.68e-05	0.0142	-0.32	-0.25	Platelet count;Mean platelet volume;	chr14:68139505	chr14:67610986~67613864:+
COAD	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	4.09	5.68e-05	0.0143	0.33	0.25	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
COAD	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	4.09	5.69e-05	0.0143	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
COAD	cis	rs1670533	1	rs2290410	ENSG00000273179.1	RP11-20I20.4	4.09	5.69e-05	0.0143	0.33	0.25	Recombination rate (females);	chr4:1058290	chr4:1167778~1168174:+
COAD	cis	rs5015933	0.736	rs10125995	ENSG00000232630.1	PRPS1P2	-4.09	5.69e-05	0.0143	-0.24	-0.25	Body mass index;	chr9:125383663	chr9:125150653~125151589:+
COAD	cis	rs7580658	0.68	rs6710535	ENSG00000236682.1	AC068282.3	4.09	5.69e-05	0.0143	0.32	0.25	Protein C levels;	chr2:127433384	chr2:127389130~127400580:+
COAD	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-4.09	5.69e-05	0.0143	-0.23	-0.25	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
COAD	cis	rs9400467	0.528	rs240954	ENSG00000271789.1	RP5-1112D6.7	-4.09	5.69e-05	0.0143	-0.24	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111297126~111298510:+
COAD	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	4.09	5.69e-05	0.0143	0.33	0.25	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
COAD	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	4.09	5.69e-05	0.0143	0.44	0.25	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
COAD	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	4.09	5.7e-05	0.0143	0.31	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
COAD	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	4.09	5.7e-05	0.0143	0.31	0.25	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
COAD	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-4.09	5.7e-05	0.0143	-0.3	-0.25	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-4.09	5.7e-05	0.0143	-0.3	-0.25	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-4.09	5.7e-05	0.0143	-0.3	-0.25	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
COAD	cis	rs2018293	1	rs5997067	ENSG00000272798.1	CTA-390C10.9	4.09	5.7e-05	0.0143	0.3	0.25	Vascular brain injury;	chr22:26312286	chr22:25436312~25436915:+
COAD	cis	rs17685	0.753	rs869804	ENSG00000280388.1	RP11-229D13.3	-4.09	5.7e-05	0.0143	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76043977~76045963:-
COAD	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-4.09	5.7e-05	0.0143	-0.36	-0.25	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
COAD	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	4.09	5.7e-05	0.0143	0.3	0.25	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
COAD	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	4.09	5.71e-05	0.0143	0.3	0.25	Height;	chr4:55554380	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	4.09	5.71e-05	0.0143	0.3	0.25	Height;	chr4:55554456	chr4:55547112~55547889:+
COAD	cis	rs7637701	0.901	rs4680312	ENSG00000240875.4	LINC00886	-4.09	5.71e-05	0.0143	-0.24	-0.25	Breast cancer;	chr3:156888140	chr3:156747346~156817062:-
COAD	cis	rs7637701	0.967	rs11712111	ENSG00000240875.4	LINC00886	-4.09	5.71e-05	0.0143	-0.24	-0.25	Breast cancer;	chr3:156891151	chr3:156747346~156817062:-
COAD	cis	rs2836974	0.932	rs8129416	ENSG00000255568.3	BRWD1-AS2	4.09	5.71e-05	0.0143	0.25	0.25	Cognitive function;	chr21:39245219	chr21:39313935~39314962:+
COAD	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	4.09	5.71e-05	0.0143	0.3	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
COAD	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	4.09	5.71e-05	0.0143	0.3	0.25	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
COAD	cis	rs7695597	0.708	rs7680050	ENSG00000244512.3	RN7SL28P	4.09	5.71e-05	0.0143	0.27	0.25	Night sleep phenotypes;	chr4:184260123	chr4:184278936~184279233:+
COAD	cis	rs10129255	0.536	rs17113249	ENSG00000211967.3	IGHV3-53	-4.09	5.71e-05	0.0143	-0.14	-0.25	Kawasaki disease;	chr14:106678273	chr14:106592676~106593347:-
COAD	cis	rs9532669	0.926	rs2875421	ENSG00000277662.1	RP11-74J13.9	-4.09	5.71e-05	0.0143	-0.24	-0.25	Cervical cancer;	chr13:40936536	chr13:41229180~41229676:-
COAD	cis	rs2408955	0.561	rs9971924	ENSG00000226413.2	OR8T1P	-4.09	5.71e-05	0.0143	-0.29	-0.25	Glycated hemoglobin levels;	chr12:48086049	chr12:48442030~48442947:-
COAD	cis	rs8022206	0.898	rs34723132	ENSG00000259502.1	RP11-643G16.3	4.09	5.72e-05	0.0143	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67916918	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs7145044	ENSG00000259502.1	RP11-643G16.3	4.09	5.72e-05	0.0143	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67922326	chr14:67610986~67613864:+
COAD	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-4.09	5.72e-05	0.0143	-0.32	-0.25	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
COAD	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	4.09	5.72e-05	0.0143	0.33	0.25	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
COAD	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-4.09	5.72e-05	0.0143	-0.25	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
COAD	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-4.09	5.72e-05	0.0143	-0.3	-0.25	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
COAD	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	4.09	5.72e-05	0.0143	0.55	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
COAD	cis	rs7646881	0.767	rs58152433	ENSG00000272087.1	RP11-379F4.7	4.09	5.72e-05	0.0143	0.36	0.25	Tetralogy of Fallot;	chr3:158738851	chr3:158693120~158693768:-
COAD	cis	rs8022206	0.716	rs57990032	ENSG00000259502.1	RP11-643G16.3	4.09	5.72e-05	0.0143	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68032207	chr14:67610986~67613864:+
COAD	cis	rs17685	0.712	rs28506984	ENSG00000280388.1	RP11-229D13.3	-4.09	5.72e-05	0.0143	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76134166	chr7:76043977~76045963:-
COAD	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	4.09	5.72e-05	0.0143	0.31	0.25	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
COAD	cis	rs180730	0.861	rs4833694	ENSG00000251609.2	SETP12	4.09	5.72e-05	0.0143	0.36	0.25	Fasting plasma glucose;	chr4:120928563	chr4:120895494~120897083:-
COAD	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.09	5.73e-05	0.0143	-0.32	-0.25	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
COAD	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	4.09	5.73e-05	0.0143	0.34	0.25	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	4.09	5.73e-05	0.0143	0.34	0.25	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	4.09	5.73e-05	0.0143	0.34	0.25	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
COAD	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	4.09	5.73e-05	0.0143	0.3	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
COAD	cis	rs3126085	0.56	rs1923505	ENSG00000237975.5	FLG-AS1	4.09	5.73e-05	0.0143	0.33	0.25	Atopic dermatitis;	chr1:152387361	chr1:152168125~152445456:+
COAD	cis	rs9532669	0.963	rs3736953	ENSG00000277662.1	RP11-74J13.9	-4.09	5.73e-05	0.0143	-0.24	-0.25	Cervical cancer;	chr13:40951450	chr13:41229180~41229676:-
COAD	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	4.09	5.73e-05	0.0143	0.25	0.25	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	4.09	5.73e-05	0.0143	0.25	0.25	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	4.09	5.73e-05	0.0143	0.25	0.25	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
COAD	cis	rs597539	0.652	rs592697	ENSG00000255741.1	RP11-757G1.5	-4.09	5.73e-05	0.0143	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs654071	ENSG00000255741.1	RP11-757G1.5	-4.09	5.73e-05	0.0143	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68941503~68942852:-
COAD	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-4.09	5.74e-05	0.0144	-0.28	-0.25	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
COAD	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	4.09	5.74e-05	0.0144	0.31	0.25	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
COAD	cis	rs10129255	0.872	rs1858683	ENSG00000224373.3	IGHV4-59	4.09	5.74e-05	0.0144	0.15	0.25	Kawasaki disease;	chr14:106670217	chr14:106627249~106627825:-
COAD	cis	rs9992667	0.725	rs1466414	ENSG00000231160.8	KLF3-AS1	4.09	5.74e-05	0.0144	0.25	0.25	Eosinophil percentage of granulocytes;	chr4:38662703	chr4:38612701~38664883:-
COAD	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-4.09	5.74e-05	0.0144	-0.22	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
COAD	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-4.09	5.74e-05	0.0144	-0.34	-0.25	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
COAD	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.09	5.74e-05	0.0144	-0.23	-0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
COAD	cis	rs4843747	0.803	rs72818526	ENSG00000205037.2	RP11-863P13.4	4.09	5.74e-05	0.0144	0.33	0.25	Menopause (age at onset);	chr16:88034918	chr16:88088041~88100985:-
COAD	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	4.09	5.74e-05	0.0144	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
COAD	cis	rs896854	0.738	rs1713669	ENSG00000253528.2	RP11-347C18.4	4.09	5.74e-05	0.0144	0.28	0.25	Type 2 diabetes;	chr8:94946409	chr8:94974573~94974853:-
COAD	cis	rs875971	0.862	rs11765791	ENSG00000224316.1	RP11-479O9.2	4.09	5.74e-05	0.0144	0.27	0.25	Aortic root size;	chr7:66471587	chr7:65773620~65802067:+
COAD	cis	rs1387259	0.899	rs7307566	ENSG00000226413.2	OR8T1P	4.09	5.75e-05	0.0144	0.3	0.25	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48442030~48442947:-
COAD	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-4.09	5.75e-05	0.0144	-0.26	-0.25	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
COAD	cis	rs989978	0.958	rs1332102	ENSG00000228778.1	RP11-129J12.1	-4.09	5.75e-05	0.0144	-0.29	-0.25	Red blood cell count;	chr10:99564679	chr10:99527081~99528261:+
COAD	cis	rs8022206	1	rs72725163	ENSG00000259502.1	RP11-643G16.3	4.09	5.75e-05	0.0144	0.41	0.25	Platelet count;Mean platelet volume;	chr14:68018058	chr14:67610986~67613864:+
COAD	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.09	5.75e-05	0.0144	0.31	0.25	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
COAD	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-4.09	5.75e-05	0.0144	-0.3	-0.25	Height;	chr4:55547636	chr4:55547112~55547889:+
COAD	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	4.09	5.75e-05	0.0144	0.44	0.25	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
COAD	cis	rs1023500	1	rs3752591	ENSG00000227370.1	RP4-669P10.19	4.09	5.75e-05	0.0144	0.29	0.25	Schizophrenia;	chr22:41943512	chr22:42132543~42132998:+
COAD	cis	rs12530	0.54	rs2294312	ENSG00000279338.1	RP1-309I22.2	4.09	5.76e-05	0.0144	0.22	0.25	IgG glycosylation;	chr22:32397397	chr22:32836706~32865634:+
COAD	cis	rs9307551	0.619	rs1561639	ENSG00000250334.4	LINC00989	-4.09	5.76e-05	0.0144	-0.29	-0.25	Refractive error;	chr4:79498986	chr4:79492416~79576460:+
COAD	cis	rs77686669	1	rs77686669	ENSG00000242294.5	STAG3L5P	4.09	5.76e-05	0.0144	0.16	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:100336079~100351900:+
COAD	cis	rs1150668	0.796	rs1124132	ENSG00000272009.1	RP1-313I6.12	4.09	5.76e-05	0.0144	0.28	0.25	Pubertal anthropometrics;	chr6:28412544	chr6:28078792~28081130:-
COAD	cis	rs9926296	0.585	rs4785595	ENSG00000260259.1	RP11-368I7.4	4.09	5.76e-05	0.0144	0.29	0.25	Vitiligo;	chr16:89769113	chr16:89682620~89686569:-
COAD	cis	rs763121	0.853	rs5757196	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38643850	chr22:38743495~38743910:+
COAD	cis	rs763121	0.785	rs5757199	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38644612	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs7289577	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38646209	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs9610993	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38646813	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757200	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38647486	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757203	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38648147	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2205802	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38650322	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs8138996	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38651430	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs6001182	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38651438	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757208	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38653225	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757211	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38655700	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs6001184	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38656111	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs6001185	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38656150	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2064088	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38657377	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757213	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38657883	chr22:38743495~38743910:+
COAD	cis	rs763121	0.719	rs9610995	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38661758	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs8142098	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38662752	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2413544	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38663399	chr22:38743495~38743910:+
COAD	cis	rs763121	0.752	rs5757222	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38664468	chr22:38743495~38743910:+
COAD	cis	rs763121	0.819	rs5750658	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38664912	chr22:38743495~38743910:+
COAD	cis	rs763121	0.819	rs8137829	ENSG00000273076.1	RP3-508I15.22	4.09	5.76e-05	0.0144	0.22	0.25	Menopause (age at onset);	chr22:38665025	chr22:38743495~38743910:+
COAD	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	4.09	5.76e-05	0.0144	0.29	0.25	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
COAD	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-4.09	5.77e-05	0.0144	-0.34	-0.25	Depression;	chr6:28187640	chr6:28943877~28944537:+
COAD	cis	rs2638953	0.924	rs11049410	ENSG00000247934.4	RP11-967K21.1	-4.09	5.77e-05	0.0144	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28163298~28190738:-
COAD	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	4.09	5.77e-05	0.0144	0.29	0.25	Height;	chr4:55535489	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	4.09	5.77e-05	0.0144	0.29	0.25	Height;	chr4:55536421	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	4.09	5.77e-05	0.0144	0.29	0.25	Height;	chr4:55537080	chr4:55547112~55547889:+
COAD	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	4.09	5.77e-05	0.0144	0.35	0.25	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
COAD	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs72727392	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:33988921	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	4.09	5.77e-05	0.0144	0.46	0.25	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
COAD	cis	rs597539	0.552	rs10896384	ENSG00000255741.1	RP11-757G1.5	4.09	5.78e-05	0.0144	0.32	0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68941503~68942852:-
COAD	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.09	5.78e-05	0.0144	0.39	0.25	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
COAD	cis	rs72730918	0.648	rs10519317	ENSG00000242327.1	CTD-2184D3.1	-4.09	5.78e-05	0.0144	-0.39	-0.25	Intelligence (multi-trait analysis);	chr15:51685396	chr15:52095295~52095747:+
COAD	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	4.09	5.79e-05	0.0144	0.3	0.25	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
COAD	cis	rs6921919	0.789	rs1119211	ENSG00000272009.1	RP1-313I6.12	-4.09	5.79e-05	0.0145	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28078792~28081130:-
COAD	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	4.09	5.79e-05	0.0145	0.32	0.25	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	4.09	5.79e-05	0.0145	0.32	0.25	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
COAD	cis	rs860295	0.966	rs821551	ENSG00000203761.5	MSTO2P	-4.09	5.79e-05	0.0145	-0.22	-0.25	Body mass index;	chr1:155718789	chr1:155745829~155750137:+
COAD	cis	rs1275411	0.54	rs1983700	ENSG00000259062.2	ACTN1-AS1	4.09	5.79e-05	0.0145	0.32	0.25	Neuroticism;	chr14:68978401	chr14:68979682~68987463:+
COAD	cis	rs28475163	0.958	rs7395116	ENSG00000255328.1	RP11-326C3.12	-4.09	5.79e-05	0.0145	-0.34	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:327171~330122:+
COAD	cis	rs17685	0.753	rs4732595	ENSG00000280388.1	RP11-229D13.3	-4.09	5.79e-05	0.0145	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76043977~76045963:-
COAD	cis	rs2346160	0.867	rs2989556	ENSG00000228648.1	RP11-568A7.2	4.09	5.79e-05	0.0145	0.28	0.25	Parental extreme longevity (95 years and older);	chr6:167290916	chr6:167241891~167245916:+
COAD	cis	rs2836974	0.644	rs719230	ENSG00000255568.3	BRWD1-AS2	-4.09	5.79e-05	0.0145	-0.23	-0.25	Cognitive function;	chr21:39304381	chr21:39313935~39314962:+
COAD	cis	rs8022206	1	rs34558039	ENSG00000259502.1	RP11-643G16.3	4.09	5.8e-05	0.0145	0.42	0.25	Platelet count;Mean platelet volume;	chr14:68075078	chr14:67610986~67613864:+
COAD	cis	rs7630852	0.965	rs4256169	ENSG00000272359.1	U4	-4.09	5.8e-05	0.0145	-0.3	-0.25	Eosinophil counts;	chr3:196785852	chr3:196747192~196747324:-
COAD	cis	rs8141529	0.719	rs5762825	ENSG00000272858.1	CTA-292E10.8	-4.09	5.8e-05	0.0145	-0.29	-0.25	Lymphocyte counts;	chr22:28827654	chr22:28814914~28815662:+
COAD	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs56160720	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33899827	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	4.09	5.8e-05	0.0145	0.44	0.25	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
COAD	cis	rs896854	0.573	rs13271375	ENSG00000253528.2	RP11-347C18.4	4.09	5.8e-05	0.0145	0.26	0.25	Type 2 diabetes;	chr8:94841679	chr8:94974573~94974853:-
COAD	cis	rs8022206	0.838	rs72725154	ENSG00000259502.1	RP11-643G16.3	4.09	5.8e-05	0.0145	0.41	0.25	Platelet count;Mean platelet volume;	chr14:68007530	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.891	rs72725158	ENSG00000259502.1	RP11-643G16.3	4.09	5.8e-05	0.0145	0.41	0.25	Platelet count;Mean platelet volume;	chr14:68010163	chr14:67610986~67613864:+
COAD	cis	rs7577696	0.695	rs6716179	ENSG00000272716.1	RP11-563N4.1	-4.09	5.8e-05	0.0145	-0.25	-0.25	Inflammatory biomarkers;	chr2:32168007	chr2:32165046~32165757:-
COAD	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	4.09	5.81e-05	0.0145	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
COAD	cis	rs7577696	0.962	rs13000753	ENSG00000272716.1	RP11-563N4.1	-4.09	5.81e-05	0.0145	-0.26	-0.25	Inflammatory biomarkers;	chr2:32057228	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs13024004	ENSG00000272716.1	RP11-563N4.1	-4.09	5.81e-05	0.0145	-0.26	-0.25	Inflammatory biomarkers;	chr2:32057293	chr2:32165046~32165757:-
COAD	cis	rs2018683	0.739	rs10233884	ENSG00000272568.4	CTB-113D17.1	4.09	5.81e-05	0.0145	0.34	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28979967~29013367:+
COAD	cis	rs1832007	0.554	rs75353459	ENSG00000224034.1	RP11-445P17.8	-4.09	5.81e-05	0.0145	-0.36	-0.25	Triglyceride levels;Triglycerides;	chr10:5202899	chr10:5266033~5271236:-
COAD	cis	rs1832007	0.554	rs77506074	ENSG00000224034.1	RP11-445P17.8	-4.09	5.81e-05	0.0145	-0.36	-0.25	Triglyceride levels;Triglycerides;	chr10:5202905	chr10:5266033~5271236:-
COAD	cis	rs1832007	0.554	rs11594428	ENSG00000224034.1	RP11-445P17.8	-4.09	5.81e-05	0.0145	-0.36	-0.25	Triglyceride levels;Triglycerides;	chr10:5203006	chr10:5266033~5271236:-
COAD	cis	rs2919009	0.62	rs17501806	ENSG00000271670.1	RP11-95I16.4	4.09	5.81e-05	0.0145	0.3	0.25	Obesity-related traits;	chr10:120868905	chr10:120879256~120880667:-
COAD	cis	rs67072384	0.818	rs2291292	ENSG00000202522.1	Y_RNA	-4.09	5.81e-05	0.0145	-0.36	-0.25	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72755968	chr11:72766004~72766116:+
COAD	cis	rs7714670	1	rs11949860	ENSG00000184084.7	CTD-2372A4.1	-4.09	5.81e-05	0.0145	-0.26	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr5:73780632	chr5:73803296~73803599:-
COAD	cis	rs2361718	0.5	rs12451697	ENSG00000279259.1	RP11-334C17.3	4.09	5.81e-05	0.0145	0.26	0.25	Yeast infection;	chr17:80126891	chr17:80147250~80148596:+
COAD	cis	rs17685	0.725	rs4476928	ENSG00000280388.1	RP11-229D13.3	4.09	5.81e-05	0.0145	0.25	0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76043977~76045963:-
COAD	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	4.09	5.81e-05	0.0145	0.27	0.25	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
COAD	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	4.09	5.81e-05	0.0145	0.4	0.25	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	4.09	5.81e-05	0.0145	0.4	0.25	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
COAD	cis	rs11168351	1	rs11168351	ENSG00000273765.1	RP11-370I10.11	4.09	5.81e-05	0.0145	0.26	0.25	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48360920~48361377:+
COAD	cis	rs1670533	0.697	rs658846	ENSG00000273179.1	RP11-20I20.4	4.09	5.81e-05	0.0145	0.33	0.25	Recombination rate (females);	chr4:1090935	chr4:1167778~1168174:+
COAD	cis	rs12165098	0.852	rs10502721	ENSG00000267374.1	RP11-244M2.1	-4.09	5.82e-05	0.0145	-0.45	-0.25	Sleep duration;	chr18:39280692	chr18:39206924~39800318:-
COAD	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-4.09	5.82e-05	0.0145	-0.3	-0.25	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
COAD	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-4.09	5.82e-05	0.0145	-0.27	-0.25	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
COAD	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-4.09	5.82e-05	0.0145	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
COAD	cis	rs9487051	0.714	rs13209277	ENSG00000219700.1	PTCHD3P3	4.09	5.82e-05	0.0145	0.26	0.25	Reticulocyte fraction of red cells;	chr6:109303760	chr6:109288571~109290503:-
COAD	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
COAD	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	4.09	5.83e-05	0.0145	0.28	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
COAD	cis	rs3752645	0.536	rs56704102	ENSG00000241764.3	AC002467.7	4.09	5.83e-05	0.0145	0.47	0.25	Bladder cancer (smoking interaction);	chr7:107074837	chr7:107742817~107744581:-
COAD	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-4.09	5.83e-05	0.0145	-0.27	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
COAD	cis	rs2018683	0.523	rs1499224	ENSG00000272568.4	CTB-113D17.1	4.09	5.83e-05	0.0145	0.38	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28979967~29013367:+
COAD	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-4.09	5.83e-05	0.0145	-0.29	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
COAD	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	4.09	5.83e-05	0.0145	0.33	0.25	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	4.09	5.83e-05	0.0145	0.33	0.25	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
COAD	cis	rs748404	0.56	rs689797	ENSG00000275601.1	AC011330.13	-4.09	5.83e-05	0.0145	-0.28	-0.25	Lung cancer;	chr15:43534359	chr15:43642389~43643023:-
COAD	cis	rs72615157	0.612	rs7786505	ENSG00000078319.8	PMS2P1	-4.09	5.83e-05	0.0145	-0.33	-0.25	Lung function (FEV1/FVC);	chr7:100219962	chr7:100320992~100341908:-
COAD	cis	rs72615157	0.613	rs56089143	ENSG00000078319.8	PMS2P1	-4.09	5.83e-05	0.0145	-0.33	-0.25	Lung function (FEV1/FVC);	chr7:100222221	chr7:100320992~100341908:-
COAD	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-4.09	5.83e-05	0.0145	-0.26	-0.25	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
COAD	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-4.09	5.83e-05	0.0145	-0.26	-0.25	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
COAD	cis	rs3764400	0.567	rs1452662	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48215948	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.564	rs1452663	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48216024	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs16953941	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48218842	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs12939334	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48225307	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs1979897	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48232184	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs12946208	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48234767	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs3897789	ENSG00000278765.1	RP5-890E16.5	4.09	5.84e-05	0.0145	0.47	0.25	Body mass index;	chr17:48235415	chr17:48066704~48067293:-
COAD	cis	rs6951245	1	rs79617366	ENSG00000229043.2	AC091729.9	-4.09	5.84e-05	0.0145	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs111899361	ENSG00000229043.2	AC091729.9	-4.09	5.84e-05	0.0145	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1160374~1165267:+
COAD	cis	rs2732480	0.577	rs2634684	ENSG00000269514.1	RP11-370I10.12	-4.09	5.84e-05	0.0145	-0.31	-0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48198387~48202031:+
COAD	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-4.09	5.84e-05	0.0146	-0.26	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
COAD	cis	rs6545883	0.655	rs11893880	ENSG00000273302.1	RP11-493E12.2	4.09	5.84e-05	0.0146	0.24	0.25	Tuberculosis;	chr2:61194884	chr2:61199979~61200769:+
COAD	cis	rs4820539	1	rs916585	ENSG00000211644.2	IGLV1-51	-4.09	5.85e-05	0.0146	-0.14	-0.25	Bone mineral density;	chr22:23127251	chr22:22322472~22322980:+
COAD	cis	rs4820539	0.966	rs5751587	ENSG00000211644.2	IGLV1-51	-4.09	5.85e-05	0.0146	-0.14	-0.25	Bone mineral density;	chr22:23127903	chr22:22322472~22322980:+
COAD	cis	rs4820539	0.966	rs5759594	ENSG00000211644.2	IGLV1-51	-4.09	5.85e-05	0.0146	-0.14	-0.25	Bone mineral density;	chr22:23128473	chr22:22322472~22322980:+
COAD	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	4.09	5.85e-05	0.0146	0.44	0.25	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	4.09	5.85e-05	0.0146	0.44	0.25	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
COAD	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-4.09	5.85e-05	0.0146	-0.29	-0.25	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-4.09	5.85e-05	0.0146	-0.29	-0.25	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
COAD	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-4.09	5.85e-05	0.0146	-0.51	-0.25	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
COAD	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-4.09	5.85e-05	0.0146	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
COAD	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-4.09	5.85e-05	0.0146	-0.33	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
COAD	cis	rs393155	0.517	rs330050	ENSG00000254340.1	RP11-10A14.3	-4.09	5.85e-05	0.0146	-0.28	-0.25	Neuroticism;	chr8:9230169	chr8:9141424~9145435:+
COAD	cis	rs453301	0.571	rs330054	ENSG00000254340.1	RP11-10A14.3	-4.09	5.85e-05	0.0146	-0.28	-0.25	Joint mobility (Beighton score);	chr8:9230781	chr8:9141424~9145435:+
COAD	cis	rs1670533	1	rs6827357	ENSG00000273179.1	RP11-20I20.4	4.09	5.85e-05	0.0146	0.31	0.25	Recombination rate (females);	chr4:1065414	chr4:1167778~1168174:+
COAD	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-4.09	5.86e-05	0.0146	-0.29	-0.25	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
COAD	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-4.09	5.86e-05	0.0146	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
COAD	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-4.09	5.86e-05	0.0146	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
COAD	cis	rs5751614	0.537	rs7288846	ENSG00000264629.1	AC244250.4	-4.09	5.86e-05	0.0146	-0.23	-0.25	Height;	chr22:23281097	chr22:22734575~22734669:+
COAD	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-4.09	5.86e-05	0.0146	-0.26	-0.25	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
COAD	cis	rs2638953	0.962	rs11049533	ENSG00000247934.4	RP11-967K21.1	-4.09	5.86e-05	0.0146	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28327471	chr12:28163298~28190738:-
COAD	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	4.09	5.86e-05	0.0146	0.28	0.25	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
COAD	cis	rs6728302	0.655	rs882098	ENSG00000237641.1	RP11-690I21.1	-4.09	5.86e-05	0.0146	-0.31	-0.25	Height;	chr2:232244147	chr2:231789481~231789887:-
COAD	cis	rs59586681	0.902	rs6113390	ENSG00000276649.1	RP5-858L17.1	-4.09	5.86e-05	0.0146	-0.25	-0.25	Basal cell carcinoma;	chr20:2253130	chr20:1888128~1894374:-
COAD	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-4.09	5.86e-05	0.0146	-0.27	-0.25	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
COAD	cis	rs875971	0.52	rs160645	ENSG00000224316.1	RP11-479O9.2	-4.09	5.86e-05	0.0146	-0.32	-0.25	Aortic root size;	chr7:66091320	chr7:65773620~65802067:+
COAD	cis	rs875971	0.789	rs28815324	ENSG00000224316.1	RP11-479O9.2	-4.09	5.86e-05	0.0146	-0.32	-0.25	Aortic root size;	chr7:66100789	chr7:65773620~65802067:+
COAD	cis	rs734999	0.967	rs10797433	ENSG00000225931.3	RP3-395M20.7	4.09	5.86e-05	0.0146	0.27	0.25	Ulcerative colitis;	chr1:2570571	chr1:2566410~2569888:+
COAD	cis	rs4006360	0.553	rs71383383	ENSG00000267221.1	CTD-2132N18.2	-4.09	5.86e-05	0.0146	-0.26	-0.25	Bipolar disorder and schizophrenia;	chr17:41161920	chr17:42040713~42043117:-
COAD	cis	rs4819052	0.851	rs28622522	ENSG00000227039.5	ITGB2-AS1	-4.09	5.87e-05	0.0146	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:44921051~44929678:+
COAD	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	4.09	5.87e-05	0.0146	0.3	0.25	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
COAD	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.09	5.87e-05	0.0146	0.21	0.25	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.09	5.87e-05	0.0146	0.21	0.25	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
COAD	cis	rs2929278	0.561	rs2927071	ENSG00000275601.1	AC011330.13	-4.09	5.87e-05	0.0146	-0.3	-0.25	Schizophrenia;	chr15:43626883	chr15:43642389~43643023:-
COAD	cis	rs911263	0.581	rs12890110	ENSG00000259502.1	RP11-643G16.3	-4.09	5.87e-05	0.0146	-0.3	-0.25	Primary biliary cholangitis;	chr14:68314878	chr14:67610986~67613864:+
COAD	cis	rs2348418	0.647	rs10843210	ENSG00000247934.4	RP11-967K21.1	4.09	5.87e-05	0.0146	0.22	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28575800	chr12:28163298~28190738:-
COAD	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-4.09	5.87e-05	0.0146	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
COAD	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	4.09	5.87e-05	0.0146	0.37	0.25	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
COAD	cis	rs752010	0.619	rs6702659	ENSG00000230638.4	RP11-486B10.4	-4.09	5.87e-05	0.0146	-0.3	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41646565	chr1:41542069~41544310:+
COAD	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	4.09	5.88e-05	0.0146	0.23	0.25	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
COAD	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-4.09	5.88e-05	0.0146	-0.48	-0.25	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
COAD	cis	rs763121	0.853	rs5757141	ENSG00000273076.1	RP3-508I15.22	4.09	5.88e-05	0.0146	0.23	0.25	Menopause (age at onset);	chr22:38561478	chr22:38743495~38743910:+
COAD	cis	rs6490294	0.5	rs4767284	ENSG00000257595.2	RP3-473L9.4	4.09	5.88e-05	0.0146	0.32	0.25	Mean platelet volume;	chr12:112002927	chr12:111369282~111403310:+
COAD	cis	rs896854	0.738	rs527234	ENSG00000253528.2	RP11-347C18.4	-4.09	5.88e-05	0.0146	-0.28	-0.25	Type 2 diabetes;	chr8:94951570	chr8:94974573~94974853:-
COAD	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	4.09	5.88e-05	0.0146	0.29	0.25	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
COAD	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	4.09	5.88e-05	0.0146	0.2	0.25	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
COAD	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-4.09	5.89e-05	0.0146	-0.34	-0.25	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
COAD	cis	rs240993	0.812	rs9487668	ENSG00000230177.1	RP5-1112D6.4	4.09	5.89e-05	0.0146	0.23	0.25	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111277932~111278742:+
COAD	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-4.09	5.89e-05	0.0146	-0.34	-0.25	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
COAD	cis	rs1009647	1	rs1009647	ENSG00000258413.1	RP11-665C16.6	-4.09	5.89e-05	0.0147	-0.33	-0.25	Testicular germ cell tumor;	chr14:55413329	chr14:55262767~55272075:-
COAD	cis	rs2638953	0.962	rs11049541	ENSG00000247934.4	RP11-967K21.1	-4.08	5.89e-05	0.0147	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341781	chr12:28163298~28190738:-
COAD	cis	rs860295	0.812	rs12407800	ENSG00000160766.13	GBAP1	-4.08	5.9e-05	0.0147	-0.29	-0.25	Body mass index;	chr1:155790951	chr1:155213821~155227422:-
COAD	cis	rs791590	0.54	rs11596136	ENSG00000215267.7	AKR1C7P	-4.08	5.9e-05	0.0147	-0.34	-0.25	Soluble interleukin-2 receptor subunit alpha;	chr10:5999910	chr10:5275173~5288470:-
COAD	cis	rs228614	0.502	rs4648004	ENSG00000246560.2	RP11-10L12.4	-4.08	5.9e-05	0.0147	-0.33	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102539950	chr4:102828055~102844075:+
COAD	cis	rs7818688	0.653	rs11786088	ENSG00000253528.2	RP11-347C18.4	-4.08	5.9e-05	0.0147	-0.34	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94823912	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.653	rs11776687	ENSG00000253528.2	RP11-347C18.4	-4.08	5.9e-05	0.0147	-0.34	-0.25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94824079	chr8:94974573~94974853:-
COAD	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-4.08	5.91e-05	0.0147	-0.24	-0.25	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
COAD	cis	rs8022206	0.773	rs7150168	ENSG00000259502.1	RP11-643G16.3	4.08	5.91e-05	0.0147	0.34	0.25	Platelet count;Mean platelet volume;	chr14:68071518	chr14:67610986~67613864:+
COAD	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-4.08	5.91e-05	0.0147	-0.26	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
COAD	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	4.08	5.91e-05	0.0147	0.35	0.25	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
COAD	cis	rs2732480	0.577	rs2732466	ENSG00000226413.2	OR8T1P	4.08	5.91e-05	0.0147	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48442030~48442947:-
COAD	cis	rs3126085	0.515	rs9633409	ENSG00000237975.5	FLG-AS1	4.08	5.92e-05	0.0147	0.33	0.25	Atopic dermatitis;	chr1:152389853	chr1:152168125~152445456:+
COAD	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	4.08	5.92e-05	0.0147	0.31	0.25	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
COAD	cis	rs7584330	0.666	rs72620818	ENSG00000234949.2	AC104667.3	-4.08	5.92e-05	0.0147	-0.34	-0.25	Prostate cancer;	chr2:237446009	chr2:237591020~237595981:+
COAD	cis	rs9910055	0.573	rs228768	ENSG00000267080.4	ASB16-AS1	-4.08	5.92e-05	0.0147	-0.23	-0.25	Total body bone mineral density;	chr17:44114525	chr17:44175973~44186717:-
COAD	cis	rs561341	1	rs497479	ENSG00000265798.5	RP11-271K11.5	4.08	5.92e-05	0.0147	0.39	0.25	Hip circumference adjusted for BMI;	chr17:32001586	chr17:31038575~31059121:-
COAD	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	4.08	5.92e-05	0.0147	0.45	0.25	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
COAD	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-4.08	5.92e-05	0.0147	-0.48	-0.25	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
COAD	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-4.08	5.92e-05	0.0147	-0.23	-0.25	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
COAD	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-4.08	5.92e-05	0.0147	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
COAD	cis	rs2638953	0.924	rs11049620	ENSG00000247934.4	RP11-967K21.1	-4.08	5.92e-05	0.0147	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454698	chr12:28163298~28190738:-
COAD	cis	rs742132	0.858	rs1003967	ENSG00000220875.1	HIST1H3PS1	4.08	5.93e-05	0.0147	0.32	0.25	Uric acid levels;	chr6:25658679	chr6:26321876~26322292:-
COAD	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-4.08	5.93e-05	0.0147	-0.25	-0.25	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
COAD	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	4.08	5.93e-05	0.0147	0.36	0.25	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	4.08	5.93e-05	0.0147	0.36	0.25	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	4.08	5.93e-05	0.0147	0.36	0.25	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
COAD	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	4.08	5.93e-05	0.0147	0.35	0.25	Depression;	chr6:28226851	chr6:28943877~28944537:+
COAD	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-4.08	5.93e-05	0.0147	-0.25	-0.25	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
COAD	cis	rs812925	0.537	rs778139	ENSG00000273302.1	RP11-493E12.2	-4.08	5.93e-05	0.0147	-0.23	-0.25	Immature fraction of reticulocytes;	chr2:61457429	chr2:61199979~61200769:+
COAD	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.08	5.94e-05	0.0148	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
COAD	cis	rs1023500	1	rs10154646	ENSG00000237037.8	NDUFA6-AS1	4.08	5.94e-05	0.0148	0.27	0.25	Schizophrenia;	chr22:41935405	chr22:42090931~42137742:+
COAD	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	4.08	5.94e-05	0.0148	0.33	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
COAD	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-4.08	5.94e-05	0.0148	-0.32	-0.25	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
COAD	cis	rs919433	1	rs1560277	ENSG00000222017.1	AC011997.1	4.08	5.94e-05	0.0148	0.29	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197693106~197774823:+
COAD	cis	rs78487399	0.908	rs11889803	ENSG00000234936.1	AC010883.5	4.08	5.94e-05	0.0148	0.34	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43622892	chr2:43229573~43233394:+
COAD	cis	rs752010	0.619	rs1123483	ENSG00000230638.4	RP11-486B10.4	4.08	5.94e-05	0.0148	0.3	0.25	Lupus nephritis in systemic lupus erythematosus;	chr1:41648527	chr1:41542069~41544310:+
COAD	cis	rs11700536	1	rs4919965	ENSG00000236663.1	AP001631.9	-4.08	5.94e-05	0.0148	-0.31	-0.25	Interleukin-18 levels;	chr21:43137961	chr21:43140523~43141092:-
COAD	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	4.08	5.95e-05	0.0148	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
COAD	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	4.08	5.95e-05	0.0148	0.3	0.25	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
COAD	cis	rs8046148	0.724	rs2356836	ENSG00000260381.2	RP11-429P3.5	-4.08	5.95e-05	0.0148	-0.32	-0.25	Testicular germ cell tumor;	chr16:50086958	chr16:50100339~50121943:-
COAD	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-4.08	5.95e-05	0.0148	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
COAD	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-4.08	5.95e-05	0.0148	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
COAD	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	4.08	5.95e-05	0.0148	0.41	0.25	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
COAD	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-4.08	5.95e-05	0.0148	-0.31	-0.25	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
COAD	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	4.08	5.95e-05	0.0148	0.19	0.25	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
COAD	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	4.08	5.95e-05	0.0148	0.35	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
COAD	cis	rs7339483	0.85	rs2463067	ENSG00000268442.1	CTD-2027I19.2	4.08	5.96e-05	0.0148	0.39	0.25	Discordance in emotional problems in monozygotic twins;	chr19:24276052	chr19:24162370~24163425:-
COAD	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	4.08	5.96e-05	0.0148	0.29	0.25	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
COAD	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	4.08	5.96e-05	0.0148	0.29	0.25	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
COAD	cis	rs71636778	0.584	rs17162316	ENSG00000260063.1	RP5-968P14.2	-4.08	5.96e-05	0.0148	-0.33	-0.25	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26851416	chr1:26692132~26694131:-
COAD	cis	rs6840360	0.582	rs4473638	ENSG00000270265.1	RP11-731D1.4	-4.08	5.96e-05	0.0148	-0.29	-0.25	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151333775~151353224:-
COAD	cis	rs6840360	0.548	rs4254751	ENSG00000270265.1	RP11-731D1.4	-4.08	5.96e-05	0.0148	-0.29	-0.25	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151333775~151353224:-
COAD	cis	rs7674212	0.57	rs2126470	ENSG00000230069.3	LRRC37A15P	-4.08	5.96e-05	0.0148	-0.26	-0.25	Type 2 diabetes;	chr4:103140605	chr4:102727274~102730721:-
COAD	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-4.08	5.96e-05	0.0148	-0.3	-0.25	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
COAD	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	4.08	5.96e-05	0.0148	0.33	0.25	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
COAD	cis	rs2018683	0.707	rs4719961	ENSG00000272568.4	CTB-113D17.1	4.08	5.97e-05	0.0148	0.35	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28979967~29013367:+
COAD	cis	rs7918232	1	rs6482595	ENSG00000262412.1	RP11-85G18.6	-4.08	5.97e-05	0.0148	-0.32	-0.25	Breast cancer;	chr10:27091332	chr10:27243130~27250804:+
COAD	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-4.08	5.97e-05	0.0148	-0.31	-0.25	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
COAD	cis	rs1023500	1	rs6002552	ENSG00000237037.8	NDUFA6-AS1	4.08	5.97e-05	0.0148	0.27	0.25	Schizophrenia;	chr22:41942347	chr22:42090931~42137742:+
COAD	cis	rs4843747	0.697	rs72818533	ENSG00000205037.2	RP11-863P13.4	4.08	5.98e-05	0.0148	0.31	0.25	Menopause (age at onset);	chr16:88040235	chr16:88088041~88100985:-
COAD	cis	rs4843747	0.749	rs72818535	ENSG00000205037.2	RP11-863P13.4	4.08	5.98e-05	0.0148	0.31	0.25	Menopause (age at onset);	chr16:88040433	chr16:88088041~88100985:-
COAD	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	4.08	5.98e-05	0.0148	0.4	0.25	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
COAD	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-4.08	5.98e-05	0.0148	-0.14	-0.25	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
COAD	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	4.08	5.98e-05	0.0148	0.23	0.25	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
COAD	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-4.08	5.98e-05	0.0148	-0.3	-0.25	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
COAD	cis	rs2489715	0.723	rs2801942	ENSG00000185904.10	LINC00839	-4.08	5.98e-05	0.0148	-0.39	-0.25	Helix rolling;	chr10:42443920	chr10:42475543~42495336:+
COAD	cis	rs12906542	0.516	rs56357772	ENSG00000260139.5	CSPG4P13	-4.08	5.98e-05	0.0148	-0.34	-0.25	Breast cancer;	chr15:78020699	chr15:77894684~77904674:+
COAD	cis	rs12906542	0.516	rs16969422	ENSG00000260139.5	CSPG4P13	-4.08	5.98e-05	0.0148	-0.34	-0.25	Breast cancer;	chr15:78033857	chr15:77894684~77904674:+
COAD	cis	rs9652601	0.691	rs12922303	ENSG00000274038.1	RP11-66H6.4	-4.08	5.99e-05	0.0148	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11099608	chr16:11056556~11057034:+
COAD	cis	rs7656342	0.964	rs56139970	ENSG00000186234.7	FAM86MP	-4.08	5.99e-05	0.0148	-0.32	-0.25	Gut microbiota (bacterial taxa);	chr4:9800648	chr4:9692495~9702954:+
COAD	cis	rs9818758	0.556	rs9813813	ENSG00000225399.4	RP11-3B7.1	-4.08	5.99e-05	0.0149	-0.51	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:49260085~49261316:+
COAD	cis	rs7572733	0.84	rs700640	ENSG00000222017.1	AC011997.1	4.08	5.99e-05	0.0149	0.28	0.25	Dermatomyositis;	chr2:197726162	chr2:197693106~197774823:+
COAD	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-4.08	5.99e-05	0.0149	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-4.08	5.99e-05	0.0149	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
COAD	cis	rs9880211	1	rs9809988	ENSG00000273486.1	RP11-731C17.2	4.08	5.99e-05	0.0149	0.29	0.25	Height;Body mass index;	chr3:136803379	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs9828976	ENSG00000273486.1	RP11-731C17.2	4.08	5.99e-05	0.0149	0.29	0.25	Height;Body mass index;	chr3:136817993	chr3:136837338~136839021:-
COAD	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	4.08	6e-05	0.0149	0.44	0.25	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
COAD	cis	rs240993	0.812	rs7766610	ENSG00000271789.1	RP5-1112D6.7	-4.08	6e-05	0.0149	-0.26	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111297126~111298510:+
COAD	cis	rs10043775	1	rs3734120	ENSG00000251330.3	CTD-2283N19.1	-4.08	6e-05	0.0149	-0.29	-0.25	Periodontal microbiota;	chr5:148441906	chr5:148430159~148430807:-
COAD	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	4.08	6.01e-05	0.0149	0.4	0.25	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
COAD	cis	rs957448	0.554	rs12541408	ENSG00000261437.1	RP11-22C11.2	4.08	6.01e-05	0.0149	0.19	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94637285~94639467:-
COAD	cis	rs6940638	0.688	rs9379960	ENSG00000224843.5	LINC00240	4.08	6.01e-05	0.0149	0.31	0.25	Intelligence (multi-trait analysis);	chr6:27153546	chr6:26956992~27023924:+
COAD	cis	rs7142002	0.881	rs1904298	ENSG00000271780.1	RP11-1017G21.5	4.08	6.01e-05	0.0149	0.33	0.25	Autism;	chr14:101890138	chr14:101948347~101949425:+
COAD	cis	rs7617773	1	rs7617773	ENSG00000228638.1	FCF1P2	4.08	6.01e-05	0.0149	0.3	0.25	Coronary artery disease;	chr3:48152025	chr3:48290793~48291375:-
COAD	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	4.08	6.01e-05	0.0149	0.37	0.25	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	4.08	6.01e-05	0.0149	0.37	0.25	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	4.08	6.01e-05	0.0149	0.37	0.25	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	4.08	6.01e-05	0.0149	0.37	0.25	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	4.08	6.01e-05	0.0149	0.37	0.25	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
COAD	cis	rs56052703	0.584	rs2419246	ENSG00000267633.1	CTB-5E10.3	4.08	6.01e-05	0.0149	0.28	0.25	Proteinuria and chronic kidney disease;	chr19:13312171	chr19:13772118~13774118:-
COAD	cis	rs56052703	0.536	rs2419244	ENSG00000267633.1	CTB-5E10.3	-4.08	6.01e-05	0.0149	-0.28	-0.25	Proteinuria and chronic kidney disease;	chr19:13311910	chr19:13772118~13774118:-
COAD	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-4.08	6.02e-05	0.0149	-0.28	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
COAD	cis	rs6687821	0.515	rs496675	ENSG00000261737.1	RP4-612B15.3	-4.08	6.02e-05	0.0149	-0.33	-0.25	Yeast infection;	chr1:86858756	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs552483	ENSG00000261737.1	RP4-612B15.3	-4.08	6.02e-05	0.0149	-0.33	-0.25	Yeast infection;	chr1:86860335	chr1:86703502~86704462:-
COAD	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-4.08	6.02e-05	0.0149	-0.33	-0.25	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
COAD	cis	rs1480597	1	rs17488358	ENSG00000165511.6	C10orf25	4.08	6.02e-05	0.0149	0.44	0.25	Parkinson's disease;	chr10:44657931	chr10:44997698~45000888:-
COAD	cis	rs1480597	1	rs17410010	ENSG00000165511.6	C10orf25	4.08	6.02e-05	0.0149	0.44	0.25	Parkinson's disease;	chr10:44658314	chr10:44997698~45000888:-
COAD	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	4.08	6.02e-05	0.0149	0.27	0.25	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
COAD	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	4.08	6.02e-05	0.0149	0.27	0.25	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
COAD	cis	rs801193	0.548	rs2659891	ENSG00000224316.1	RP11-479O9.2	4.08	6.02e-05	0.0149	0.27	0.25	Aortic root size;	chr7:66736127	chr7:65773620~65802067:+
COAD	cis	rs2929278	0.617	rs11070410	ENSG00000275601.1	AC011330.13	4.08	6.02e-05	0.0149	0.3	0.25	Schizophrenia;	chr15:43764847	chr15:43642389~43643023:-
COAD	cis	rs860295	1	rs860295	ENSG00000203761.5	MSTO2P	4.08	6.02e-05	0.0149	0.22	0.25	Body mass index;	chr1:155797917	chr1:155745829~155750137:+
COAD	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	4.08	6.02e-05	0.0149	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
COAD	cis	rs370915	0.578	rs1431929	ENSG00000250971.1	RP11-696F12.1	4.08	6.02e-05	0.0149	0.3	0.25	Gout;	chr4:186854170	chr4:187060099~187060930:+
COAD	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-4.08	6.02e-05	0.0149	-0.38	-0.25	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
COAD	cis	rs8044868	1	rs4238964	ENSG00000279206.1	RP5-991G20.6	-4.08	6.03e-05	0.0149	-0.29	-0.25	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72141257	chr16:72772673~72773272:+
COAD	cis	rs3025343	1	rs739447	ENSG00000235138.1	RP11-374P20.4	4.08	6.03e-05	0.0149	0.4	0.25	Smoking behavior;	chr9:133612389	chr9:134054290~134058805:+
COAD	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-4.08	6.03e-05	0.0149	-0.26	-0.25	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-4.08	6.03e-05	0.0149	-0.26	-0.25	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
COAD	cis	rs7105056	1	rs7951263	ENSG00000270179.1	RP11-159N11.4	4.08	6.03e-05	0.0149	0.57	0.25	Immune reponse to smallpox (secreted IL-12p40);	chr11:112390072	chr11:113368478~113369117:+
COAD	cis	rs11951515	0.508	rs11958046	ENSG00000248554.1	RP11-159F24.6	-4.08	6.03e-05	0.0149	-0.26	-0.25	Metabolite levels  (X-11787);	chr5:43583287	chr5:43511058~43521811:+
COAD	cis	rs748404	0.56	rs2255663	ENSG00000275601.1	AC011330.13	4.08	6.03e-05	0.0149	0.28	0.25	Lung cancer;	chr15:43536810	chr15:43642389~43643023:-
COAD	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	4.08	6.03e-05	0.0149	0.38	0.25	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
COAD	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	4.08	6.04e-05	0.0149	0.29	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
COAD	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-4.08	6.04e-05	0.015	-0.29	-0.25	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
COAD	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	4.08	6.04e-05	0.015	0.32	0.25	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
COAD	cis	rs12554020	0.579	rs59326991	ENSG00000227603.1	RP11-165J3.6	4.08	6.04e-05	0.015	0.44	0.25	Schizophrenia;	chr9:93473603	chr9:93435332~93437121:-
COAD	cis	rs2243480	1	rs4548056	ENSG00000232559.3	GS1-124K5.12	4.08	6.04e-05	0.015	0.43	0.25	Diabetic kidney disease;	chr7:65833886	chr7:66554588~66576923:-
COAD	cis	rs9813712	0.596	rs2587988	ENSG00000253540.4	FAM86HP	-4.08	6.05e-05	0.015	-0.27	-0.25	Response to amphetamines;	chr3:130201415	chr3:130099092~130111472:-
COAD	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	4.08	6.05e-05	0.015	0.34	0.25	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
COAD	cis	rs739496	0.615	rs640783	ENSG00000257595.2	RP3-473L9.4	4.08	6.05e-05	0.015	0.36	0.25	Platelet count;	chr12:111730246	chr12:111369282~111403310:+
COAD	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.08	6.05e-05	0.015	0.25	0.25	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
COAD	cis	rs73198271	0.74	rs10105690	ENSG00000173295.6	FAM86B3P	-4.08	6.05e-05	0.015	-0.32	-0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8228595~8244865:+
COAD	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-4.08	6.05e-05	0.015	-0.28	-0.25	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
COAD	cis	rs7577696	0.924	rs212760	ENSG00000272716.1	RP11-563N4.1	4.08	6.05e-05	0.015	0.26	0.25	Inflammatory biomarkers;	chr2:32204153	chr2:32165046~32165757:-
COAD	cis	rs1949733	0.523	rs55977448	ENSG00000205959.3	RP11-689P11.2	4.08	6.06e-05	0.015	0.31	0.25	Response to antineoplastic agents;	chr4:8541191	chr4:8482270~8512610:+
COAD	cis	rs78487399	0.71	rs114510001	ENSG00000234936.1	AC010883.5	4.08	6.06e-05	0.015	0.43	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43289949	chr2:43229573~43233394:+
COAD	cis	rs7009110	0.632	rs7822785	ENSG00000213791.4	RP11-941H19.2	4.08	6.06e-05	0.015	0.25	0.25	Asthma and hay fever;	chr8:80334777	chr8:80300869~80301481:+
COAD	cis	rs9888739	0.591	rs4632147	ENSG00000260304.1	RP11-388M20.6	4.08	6.06e-05	0.015	0.32	0.25	Systemic lupus erythematosus;	chr16:31352060	chr16:31182511~31183285:-
COAD	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	4.08	6.06e-05	0.015	0.26	0.25	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
COAD	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	4.08	6.07e-05	0.015	0.36	0.25	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	4.08	6.07e-05	0.015	0.36	0.25	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
COAD	cis	rs4718428	0.705	rs13231140	ENSG00000272831.1	RP11-792A8.4	4.08	6.07e-05	0.015	0.28	0.25	Corneal structure;	chr7:66896631	chr7:66739829~66740385:-
COAD	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	4.08	6.07e-05	0.015	0.22	0.25	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
COAD	cis	rs875971	0.965	rs697968	ENSG00000232559.3	GS1-124K5.12	-4.08	6.07e-05	0.015	-0.29	-0.25	Aortic root size;	chr7:66070046	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1183245	ENSG00000232559.3	GS1-124K5.12	-4.08	6.07e-05	0.015	-0.29	-0.25	Aortic root size;	chr7:66076198	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1144895	ENSG00000232559.3	GS1-124K5.12	-4.08	6.07e-05	0.015	-0.29	-0.25	Aortic root size;	chr7:66076320	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1144894	ENSG00000232559.3	GS1-124K5.12	-4.08	6.07e-05	0.015	-0.29	-0.25	Aortic root size;	chr7:66077907	chr7:66554588~66576923:-
COAD	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-4.08	6.07e-05	0.015	-0.31	-0.25	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
COAD	cis	rs875971	0.545	rs313828	ENSG00000164669.11	INTS4P1	4.08	6.07e-05	0.015	0.36	0.25	Aortic root size;	chr7:66087627	chr7:65141225~65234216:+
COAD	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	4.08	6.07e-05	0.015	0.19	0.25	Breast size;	chr12:9232939	chr12:9277235~9313241:+
COAD	cis	rs8022206	0.773	rs10133262	ENSG00000259502.1	RP11-643G16.3	4.08	6.07e-05	0.015	0.32	0.25	Platelet count;Mean platelet volume;	chr14:67941221	chr14:67610986~67613864:+
COAD	cis	rs73198271	0.681	rs35457364	ENSG00000173295.6	FAM86B3P	-4.08	6.08e-05	0.015	-0.32	-0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.681	rs11987924	ENSG00000173295.6	FAM86B3P	-4.08	6.08e-05	0.015	-0.32	-0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8228595~8244865:+
COAD	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	4.08	6.08e-05	0.015	0.25	0.25	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
COAD	cis	rs73198271	0.74	rs964771	ENSG00000173295.6	FAM86B3P	4.08	6.08e-05	0.015	0.31	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8228595~8244865:+
COAD	cis	rs2765539	0.772	rs2148150	ENSG00000231365.4	RP11-418J17.1	-4.08	6.08e-05	0.015	-0.28	-0.25	Waist-hip ratio;	chr1:119029434	chr1:119140396~119275973:+
COAD	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	4.08	6.08e-05	0.015	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	4.08	6.08e-05	0.015	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	4.08	6.08e-05	0.015	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
COAD	cis	rs801193	0.569	rs2707824	ENSG00000224316.1	RP11-479O9.2	4.08	6.08e-05	0.015	0.27	0.25	Aortic root size;	chr7:66724256	chr7:65773620~65802067:+
COAD	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	4.08	6.08e-05	0.0151	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
COAD	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	4.08	6.08e-05	0.0151	0.34	0.25	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
COAD	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-4.08	6.08e-05	0.0151	-0.26	-0.25	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
COAD	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	4.08	6.08e-05	0.0151	0.32	0.25	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
COAD	cis	rs9307551	0.817	rs11098762	ENSG00000250334.4	LINC00989	-4.08	6.09e-05	0.0151	-0.28	-0.25	Refractive error;	chr4:79575097	chr4:79492416~79576460:+
COAD	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-4.08	6.09e-05	0.0151	-0.34	-0.25	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.941	rs7256130	ENSG00000226686.6	LINC01535	-4.08	6.09e-05	0.0151	-0.34	-0.25	Coronary artery calcification;	chr19:37443079	chr19:37251912~37265535:+
COAD	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-4.08	6.09e-05	0.0151	-0.39	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
COAD	cis	rs987724	0.593	rs4680317	ENSG00000240875.4	LINC00886	4.08	6.09e-05	0.0151	0.22	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156938964	chr3:156747346~156817062:-
COAD	cis	rs10515750	0.53	rs13358909	ENSG00000251405.2	CTB-109A12.1	4.08	6.09e-05	0.0151	0.5	0.25	Lung function (FEV1/FVC);	chr5:157288824	chr5:157362615~157460078:-
COAD	cis	rs2732480	0.577	rs2732481	ENSG00000226413.2	OR8T1P	4.08	6.09e-05	0.0151	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.557	rs2732484	ENSG00000226413.2	OR8T1P	4.08	6.09e-05	0.0151	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2732486	ENSG00000226413.2	OR8T1P	4.08	6.09e-05	0.0151	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.517	rs2634676	ENSG00000226413.2	OR8T1P	4.08	6.09e-05	0.0151	0.32	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48442030~48442947:-
COAD	cis	rs12188164	0.686	rs56279338	ENSG00000221990.4	EXOC3-AS1	4.08	6.09e-05	0.0151	0.25	0.25	Cystic fibrosis severity;	chr5:416003	chr5:441498~443160:-
COAD	cis	rs12188164	0.686	rs72711365	ENSG00000221990.4	EXOC3-AS1	4.08	6.09e-05	0.0151	0.25	0.25	Cystic fibrosis severity;	chr5:416557	chr5:441498~443160:-
COAD	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	4.08	6.09e-05	0.0151	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
COAD	cis	rs930421	0.763	rs10205149	ENSG00000226491.1	FTOP1	-4.08	6.09e-05	0.0151	-0.32	-0.25	Attention deficit hyperactivity disorder;	chr2:42750593	chr2:42797225~42798712:-
COAD	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-4.08	6.09e-05	0.0151	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-4.08	6.09e-05	0.0151	-0.26	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-4.08	6.09e-05	0.0151	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
COAD	cis	rs9907295	1	rs11653282	ENSG00000271013.1	AC015849.15	-4.08	6.1e-05	0.0151	-0.36	-0.25	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35912635~35918010:-
COAD	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.08	6.1e-05	0.0151	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
COAD	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	4.08	6.1e-05	0.0151	0.29	0.25	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
COAD	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-4.08	6.1e-05	0.0151	-0.29	-0.25	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
COAD	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-4.08	6.1e-05	0.0151	-0.29	-0.25	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
COAD	cis	rs860295	0.836	rs35615695	ENSG00000225082.2	DAP3P1	4.08	6.1e-05	0.0151	0.31	0.25	Body mass index;	chr1:155531223	chr1:155586644~155602197:+
COAD	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	4.08	6.11e-05	0.0151	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
COAD	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	4.08	6.11e-05	0.0151	0.29	0.25	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
COAD	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	4.08	6.11e-05	0.0151	0.33	0.25	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
COAD	cis	rs4819052	0.851	rs4819049	ENSG00000227039.5	ITGB2-AS1	-4.08	6.11e-05	0.0151	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:44921051~44929678:+
COAD	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-4.08	6.11e-05	0.0151	-0.22	-0.25	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
COAD	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-4.08	6.11e-05	0.0151	-0.26	-0.25	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
COAD	cis	rs8022206	0.812	rs372143	ENSG00000259502.1	RP11-643G16.3	4.08	6.11e-05	0.0151	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68120621	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.812	rs435620	ENSG00000259502.1	RP11-643G16.3	4.08	6.11e-05	0.0151	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68121086	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.812	rs401021	ENSG00000259502.1	RP11-643G16.3	4.08	6.11e-05	0.0151	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68121244	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.812	rs411547	ENSG00000259502.1	RP11-643G16.3	4.08	6.11e-05	0.0151	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68121593	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.812	rs365934	ENSG00000259502.1	RP11-643G16.3	4.08	6.11e-05	0.0151	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68123035	chr14:67610986~67613864:+
COAD	cis	rs2638953	0.777	rs10843181	ENSG00000247934.4	RP11-967K21.1	-4.08	6.11e-05	0.0151	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28163298~28190738:-
COAD	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-4.08	6.12e-05	0.0151	-0.33	-0.25	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
COAD	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-4.08	6.12e-05	0.0151	-0.25	-0.25	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
COAD	cis	rs189798	0.807	rs330905	ENSG00000173295.6	FAM86B3P	4.08	6.12e-05	0.0151	0.34	0.25	Myopia (pathological);	chr8:9136041	chr8:8228595~8244865:+
COAD	cis	rs1552244	0.882	rs17050672	ENSG00000186162.9	CIDECP	4.08	6.12e-05	0.0151	0.37	0.25	Alzheimer's disease;	chr3:9983779	chr3:10014238~10026365:-
COAD	cis	rs8141529	0.778	rs7287806	ENSG00000272858.1	CTA-292E10.8	-4.08	6.12e-05	0.0151	-0.29	-0.25	Lymphocyte counts;	chr22:28817023	chr22:28814914~28815662:+
COAD	cis	rs1914816	0.941	rs2460146	ENSG00000196274.5	Metazoa_SRP	4.08	6.12e-05	0.0151	0.26	0.25	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76230048~76230390:-
COAD	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-4.08	6.12e-05	0.0151	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-4.08	6.12e-05	0.0151	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
COAD	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	4.08	6.12e-05	0.0151	0.35	0.25	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
COAD	cis	rs1670533	1	rs2045069	ENSG00000273179.1	RP11-20I20.4	4.08	6.13e-05	0.0151	0.32	0.25	Recombination rate (females);	chr4:1058418	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs2045068	ENSG00000273179.1	RP11-20I20.4	4.08	6.13e-05	0.0151	0.32	0.25	Recombination rate (females);	chr4:1058424	chr4:1167778~1168174:+
COAD	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.08	6.13e-05	0.0151	0.39	0.25	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
COAD	cis	rs2307394	0.964	rs13012311	ENSG00000281469.1	RP11-567F11.1	4.08	6.13e-05	0.0151	0.29	0.25	Urate levels;	chr2:147949463	chr2:148044380~148044894:+
COAD	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-4.08	6.13e-05	0.0152	-0.28	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
COAD	cis	rs6687821	0.515	rs2798677	ENSG00000261737.1	RP4-612B15.3	4.08	6.13e-05	0.0152	0.32	0.25	Yeast infection;	chr1:87086740	chr1:86703502~86704462:-
COAD	cis	rs2337406	0.925	rs34064152	ENSG00000211974.3	IGHV2-70	-4.08	6.14e-05	0.0152	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106700364	chr14:106723574~106724093:-
COAD	cis	rs4820539	1	rs4822358	ENSG00000211644.2	IGLV1-51	-4.07	6.14e-05	0.0152	-0.14	-0.25	Bone mineral density;	chr22:23132608	chr22:22322472~22322980:+
COAD	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	4.07	6.14e-05	0.0152	0.33	0.25	Pain;	chr19:21569087	chr19:21554640~21569237:-
COAD	cis	rs240993	0.812	rs9400481	ENSG00000271789.1	RP5-1112D6.7	4.07	6.14e-05	0.0152	0.27	0.25	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111297126~111298510:+
COAD	cis	rs5753037	0.869	rs5752973	ENSG00000279159.1	RP3-394A18.1	-4.07	6.14e-05	0.0152	-0.17	-0.25	Type 1 diabetes;	chr22:29868285	chr22:29978950~30028236:-
COAD	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	4.07	6.14e-05	0.0152	0.4	0.25	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	4.07	6.14e-05	0.0152	0.4	0.25	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
COAD	cis	rs172166	0.637	rs1225597	ENSG00000280107.1	AL022393.9	-4.07	6.15e-05	0.0152	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28170845~28172521:+
COAD	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-4.07	6.15e-05	0.0152	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
COAD	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-4.07	6.15e-05	0.0152	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
COAD	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.07	6.15e-05	0.0152	0.39	0.25	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
COAD	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	4.07	6.16e-05	0.0152	0.26	0.25	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
COAD	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	4.07	6.16e-05	0.0152	0.28	0.25	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
COAD	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	4.07	6.16e-05	0.0152	0.28	0.25	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
COAD	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	4.07	6.16e-05	0.0152	0.28	0.25	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
COAD	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-4.07	6.16e-05	0.0152	-0.26	-0.25	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
COAD	cis	rs875971	0.571	rs160647	ENSG00000164669.11	INTS4P1	4.07	6.16e-05	0.0152	0.35	0.25	Aortic root size;	chr7:66089365	chr7:65141225~65234216:+
COAD	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-4.07	6.16e-05	0.0152	-0.35	-0.25	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
COAD	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-4.07	6.16e-05	0.0152	-0.29	-0.25	QT interval;	chr12:29303562	chr12:29277397~29277882:-
COAD	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-4.07	6.16e-05	0.0152	-0.29	-0.25	QT interval;	chr12:29306799	chr12:29277397~29277882:-
COAD	cis	rs728616	0.558	rs35698456	ENSG00000225484.5	NUTM2B-AS1	-4.07	6.16e-05	0.0152	-0.38	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80381806	chr10:79663088~79826594:-
COAD	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	4.07	6.17e-05	0.0152	0.33	0.25	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
COAD	cis	rs2638953	0.925	rs61920563	ENSG00000247934.4	RP11-967K21.1	-4.07	6.17e-05	0.0152	-0.28	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28332760	chr12:28163298~28190738:-
COAD	cis	rs2832191	0.632	rs2246777	ENSG00000176054.6	RPL23P2	-4.07	6.17e-05	0.0152	-0.26	-0.25	Dental caries;	chr21:28937264	chr21:28997613~28998033:-
COAD	cis	rs9990333	0.87	rs58758084	ENSG00000207650.1	MIR570	-4.07	6.17e-05	0.0152	-0.28	-0.25	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195699401~195699497:+
COAD	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	4.07	6.18e-05	0.0152	0.24	0.25	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
COAD	cis	rs8141529	0.748	rs132531	ENSG00000272858.1	CTA-292E10.8	4.07	6.18e-05	0.0152	0.31	0.25	Lymphocyte counts;	chr22:28901377	chr22:28814914~28815662:+
COAD	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	4.07	6.18e-05	0.0152	0.33	0.25	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
COAD	cis	rs494562	0.892	rs617483	ENSG00000234155.1	RP11-30P6.6	-4.07	6.18e-05	0.0152	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85414290	chr6:85387219~85390186:-
COAD	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	4.07	6.18e-05	0.0152	0.24	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
COAD	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-4.07	6.18e-05	0.0153	-0.3	-0.25	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
COAD	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-4.07	6.19e-05	0.0153	-0.28	-0.25	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
COAD	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	4.07	6.19e-05	0.0153	0.22	0.25	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
COAD	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	4.07	6.19e-05	0.0153	0.31	0.25	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
COAD	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-4.07	6.19e-05	0.0153	-0.41	-0.25	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
COAD	cis	rs9307551	0.619	rs11736348	ENSG00000250334.4	LINC00989	-4.07	6.19e-05	0.0153	-0.29	-0.25	Refractive error;	chr4:79498711	chr4:79492416~79576460:+
COAD	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-4.07	6.19e-05	0.0153	-0.39	-0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
COAD	cis	rs1949733	0.701	rs1880024	ENSG00000205959.3	RP11-689P11.2	-4.07	6.19e-05	0.0153	-0.3	-0.25	Response to antineoplastic agents;	chr4:8452912	chr4:8482270~8512610:+
COAD	cis	rs8022206	0.898	rs72725141	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67938527	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs7151917	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67947052	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs12435554	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67949713	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs7155985	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67951165	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725149	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67983560	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs17783304	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67984531	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs17192586	ENSG00000259502.1	RP11-643G16.3	4.07	6.19e-05	0.0153	0.36	0.25	Platelet count;Mean platelet volume;	chr14:67987788	chr14:67610986~67613864:+
COAD	cis	rs72823319	0.68	rs9904756	ENSG00000263818.4	CTD-2206N4.4	4.07	6.2e-05	0.0153	0.35	0.25	Verbal memory performance (residualized delayed recall change);	chr17:39067540	chr17:39057019~39113190:+
COAD	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	4.07	6.2e-05	0.0153	0.32	0.25	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
COAD	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	4.07	6.2e-05	0.0153	0.27	0.25	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
COAD	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	4.07	6.2e-05	0.0153	0.2	0.25	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
COAD	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-4.07	6.2e-05	0.0153	-0.34	-0.25	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
COAD	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-4.07	6.2e-05	0.0153	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
COAD	cis	rs3015497	0.616	rs11157759	ENSG00000258857.1	RP11-247L20.3	4.07	6.21e-05	0.0153	0.27	0.25	Mean platelet volume;	chr14:50620545	chr14:50397013~50398345:+
COAD	cis	rs2919009	0.551	rs61872771	ENSG00000271670.1	RP11-95I16.4	4.07	6.21e-05	0.0153	0.33	0.25	Obesity-related traits;	chr10:120939465	chr10:120879256~120880667:-
COAD	cis	rs7009110	0.606	rs7006626	ENSG00000213791.4	RP11-941H19.2	4.07	6.21e-05	0.0153	0.25	0.25	Asthma and hay fever;	chr8:80335441	chr8:80300869~80301481:+
COAD	cis	rs1059312	0.5	rs10734964	ENSG00000279500.1	RP11-21K12.2	-4.07	6.21e-05	0.0153	-0.22	-0.25	Systemic lupus erythematosus;	chr12:128801941	chr12:128813186~128814750:-
COAD	cis	rs12549025	0.53	rs34297248	ENSG00000253390.1	CTC-756D1.2	-4.07	6.21e-05	0.0153	-0.33	-0.25	Reticulocyte fraction of red cells;	chr8:23506865	chr8:23458601~23484971:+
COAD	cis	rs1055129	0.537	rs10852766	ENSG00000267801.1	RP11-552F3.9	-4.07	6.21e-05	0.0153	-0.3	-0.25	White matter hyperintensity burden;	chr17:75955783	chr17:75876372~75879546:+
COAD	cis	rs2018683	0.707	rs10279610	ENSG00000272568.4	CTB-113D17.1	-4.07	6.21e-05	0.0153	-0.34	-0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28979967~29013367:+
COAD	cis	rs875971	0.964	rs160635	ENSG00000224316.1	RP11-479O9.2	4.07	6.22e-05	0.0153	0.26	0.25	Aortic root size;	chr7:66063931	chr7:65773620~65802067:+
COAD	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	4.07	6.22e-05	0.0153	0.39	0.25	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
COAD	cis	rs911263	0.603	rs11628954	ENSG00000259502.1	RP11-643G16.3	-4.07	6.22e-05	0.0153	-0.3	-0.25	Primary biliary cholangitis;	chr14:68315887	chr14:67610986~67613864:+
COAD	cis	rs1832007	0.58	rs72772226	ENSG00000224034.1	RP11-445P17.8	-4.07	6.22e-05	0.0153	-0.36	-0.25	Triglyceride levels;Triglycerides;	chr10:5203048	chr10:5266033~5271236:-
COAD	cis	rs2732480	0.538	rs1387260	ENSG00000269514.1	RP11-370I10.12	4.07	6.23e-05	0.0153	0.31	0.25	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48198387~48202031:+
COAD	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-4.07	6.23e-05	0.0153	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
COAD	cis	rs742132	0.858	rs1406925	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25637240	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs58499973	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25637404	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs58262709	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25637480	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs7774036	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25637983	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs714563	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25639938	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs10447385	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25640446	chr6:26321876~26322292:-
COAD	cis	rs742132	0.824	rs10447386	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25640499	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs6456687	ENSG00000220875.1	HIST1H3PS1	4.07	6.23e-05	0.0153	0.32	0.25	Uric acid levels;	chr6:25641408	chr6:26321876~26322292:-
COAD	cis	rs860295	0.702	rs10908479	ENSG00000223503.1	RP11-29H23.6	-4.07	6.23e-05	0.0154	-0.33	-0.25	Body mass index;	chr1:155673612	chr1:155590601~155591262:-
COAD	cis	rs654950	0.934	rs662999	ENSG00000230638.4	RP11-486B10.4	-4.07	6.23e-05	0.0154	-0.28	-0.25	Airway imaging phenotypes;	chr1:41535489	chr1:41542069~41544310:+
COAD	cis	rs6661961	0.65	rs726865	ENSG00000237975.5	FLG-AS1	-4.07	6.23e-05	0.0154	-0.25	-0.25	Atopic dermatitis;	chr1:152427579	chr1:152168125~152445456:+
COAD	cis	rs10129255	0.5	rs10143242	ENSG00000211967.3	IGHV3-53	-4.07	6.23e-05	0.0154	-0.14	-0.25	Kawasaki disease;	chr14:106681814	chr14:106592676~106593347:-
COAD	cis	rs72827839	1	rs17696392	ENSG00000263412.1	RP5-890E16.2	-4.07	6.23e-05	0.0154	-0.36	-0.25	Ease of getting up in the morning;	chr17:48349798	chr17:48045141~48048073:-
COAD	cis	rs72827839	1	rs72827834	ENSG00000263412.1	RP5-890E16.2	4.07	6.23e-05	0.0154	0.36	0.25	Ease of getting up in the morning;	chr17:48336457	chr17:48045141~48048073:-
COAD	cis	rs72827839	1	rs1472966	ENSG00000263412.1	RP5-890E16.2	4.07	6.23e-05	0.0154	0.36	0.25	Ease of getting up in the morning;	chr17:48352783	chr17:48045141~48048073:-
COAD	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-4.07	6.24e-05	0.0154	-0.29	-0.25	Height;	chr4:55514317	chr4:55540502~55540835:-
COAD	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	4.07	6.24e-05	0.0154	0.25	0.25	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	4.07	6.24e-05	0.0154	0.32	0.25	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
COAD	cis	rs1949733	0.523	rs56053534	ENSG00000205959.3	RP11-689P11.2	4.07	6.24e-05	0.0154	0.31	0.25	Response to antineoplastic agents;	chr4:8541149	chr4:8482270~8512610:+
COAD	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
COAD	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-4.07	6.24e-05	0.0154	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
COAD	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	4.07	6.25e-05	0.0154	0.37	0.25	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
COAD	cis	rs6095360	0.727	rs7274612	ENSG00000222365.1	SNORD12B	4.07	6.25e-05	0.0154	0.24	0.25	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49280319~49280409:+
COAD	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	4.07	6.25e-05	0.0154	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
COAD	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-4.07	6.25e-05	0.0154	-0.42	-0.25	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
COAD	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	4.07	6.25e-05	0.0154	0.34	0.25	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
COAD	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	4.07	6.25e-05	0.0154	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
COAD	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	4.07	6.26e-05	0.0154	0.3	0.25	Height;	chr4:55548261	chr4:55547112~55547889:+
COAD	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-4.07	6.26e-05	0.0154	-0.27	-0.25	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
COAD	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-4.07	6.26e-05	0.0154	-0.47	-0.25	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
COAD	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	4.07	6.26e-05	0.0154	0.29	0.25	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
COAD	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	4.07	6.26e-05	0.0154	0.27	0.25	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
COAD	cis	rs8022206	0.773	rs11623984	ENSG00000259502.1	RP11-643G16.3	4.07	6.26e-05	0.0154	0.33	0.25	Platelet count;Mean platelet volume;	chr14:68048156	chr14:67610986~67613864:+
COAD	cis	rs9900062	1	rs9900062	ENSG00000270714.1	MINOS1P2	-4.07	6.27e-05	0.0154	-0.32	-0.25	QT interval;	chr17:64743456	chr17:64747264~64747492:-
COAD	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	4.07	6.27e-05	0.0154	0.29	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
COAD	cis	rs11089937	0.585	rs6001229	ENSG00000211638.2	IGLV8-61	4.07	6.27e-05	0.0154	0.24	0.25	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22098700~22099212:+
COAD	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-4.07	6.27e-05	0.0154	-0.34	-0.25	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
COAD	cis	rs5753037	0.869	rs5763646	ENSG00000279159.1	RP3-394A18.1	-4.07	6.27e-05	0.0154	-0.17	-0.25	Type 1 diabetes;	chr22:29963421	chr22:29978950~30028236:-
COAD	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.07	6.28e-05	0.0154	0.34	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
COAD	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	4.07	6.28e-05	0.0154	0.29	0.25	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
COAD	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-4.07	6.28e-05	0.0155	-0.29	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
COAD	cis	rs78487399	0.71	rs74382177	ENSG00000234936.1	AC010883.5	4.07	6.29e-05	0.0155	0.43	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43300918	chr2:43229573~43233394:+
COAD	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-4.07	6.29e-05	0.0155	-0.28	-0.25	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
COAD	cis	rs9910055	0.529	rs183462	ENSG00000267080.4	ASB16-AS1	4.07	6.3e-05	0.0155	0.24	0.25	Total body bone mineral density;	chr17:44106008	chr17:44175973~44186717:-
COAD	cis	rs9291683	0.507	rs3775940	ENSG00000250413.1	RP11-448G15.1	-4.07	6.3e-05	0.0155	-0.32	-0.25	Bone mineral density;	chr4:10023539	chr4:10006482~10009725:+
COAD	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	4.07	6.3e-05	0.0155	0.31	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
COAD	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-4.07	6.3e-05	0.0155	-0.28	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
COAD	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-4.07	6.31e-05	0.0155	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-4.07	6.31e-05	0.0155	-0.26	-0.25	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-4.07	6.31e-05	0.0155	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
COAD	cis	rs12699921	0.526	rs12699916	ENSG00000279048.1	RP11-511H23.2	-4.07	6.31e-05	0.0155	-0.21	-0.25	Fibrinogen levels;	chr7:17868923	chr7:17940503~17942922:+
COAD	cis	rs72827839	0.947	rs72827814	ENSG00000263412.1	RP5-890E16.2	4.07	6.31e-05	0.0155	0.36	0.25	Ease of getting up in the morning;	chr17:48289598	chr17:48045141~48048073:-
COAD	cis	rs72827839	1	rs17695373	ENSG00000263412.1	RP5-890E16.2	4.07	6.31e-05	0.0155	0.36	0.25	Ease of getting up in the morning;	chr17:48298105	chr17:48045141~48048073:-
COAD	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-4.07	6.31e-05	0.0155	-0.31	-0.25	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
COAD	cis	rs10043775	1	rs12513547	ENSG00000251330.3	CTD-2283N19.1	-4.07	6.31e-05	0.0155	-0.29	-0.25	Periodontal microbiota;	chr5:148431902	chr5:148430159~148430807:-
COAD	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-4.07	6.32e-05	0.0155	-0.34	-0.25	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-4.07	6.32e-05	0.0155	-0.34	-0.25	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
COAD	cis	rs12807809	0.945	rs1939214	ENSG00000245498.5	RP11-677M14.7	4.07	6.32e-05	0.0155	0.3	0.25	Schizophrenia;	chr11:124735394	chr11:124800450~124834487:+
COAD	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-4.07	6.32e-05	0.0155	-0.26	-0.25	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
COAD	cis	rs56052703	0.536	rs10423830	ENSG00000267633.1	CTB-5E10.3	4.07	6.32e-05	0.0155	0.28	0.25	Proteinuria and chronic kidney disease;	chr19:13315362	chr19:13772118~13774118:-
COAD	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-4.07	6.32e-05	0.0155	-0.25	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
COAD	cis	rs13256369	1	rs873063	ENSG00000253981.4	ALG1L13P	4.07	6.32e-05	0.0155	0.36	0.25	Obesity-related traits;	chr8:8714937	chr8:8236003~8244667:-
COAD	cis	rs4918072	0.917	rs35041090	ENSG00000273108.1	RP11-416N2.4	4.07	6.32e-05	0.0155	0.3	0.25	Coronary artery disease;	chr10:103888928	chr10:103608619~103610050:+
COAD	cis	rs8177876	0.822	rs1410	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs1412	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs1414	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs8177950	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs8177948	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs8177940	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.73	rs76656387	ENSG00000261061.1	RP11-303E16.2	-4.07	6.32e-05	0.0155	-0.37	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81030770~81031485:+
COAD	cis	rs875971	1	rs1167411	ENSG00000232559.3	GS1-124K5.12	-4.07	6.33e-05	0.0155	-0.29	-0.25	Aortic root size;	chr7:66074277	chr7:66554588~66576923:-
COAD	cis	rs3764400	0.567	rs12936369	ENSG00000278765.1	RP5-890E16.5	4.07	6.33e-05	0.0155	0.46	0.25	Body mass index;	chr17:48193334	chr17:48066704~48067293:-
COAD	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	4.07	6.33e-05	0.0155	0.3	0.25	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
COAD	cis	rs2638953	0.886	rs10843168	ENSG00000247934.4	RP11-967K21.1	-4.07	6.33e-05	0.0155	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430038	chr12:28163298~28190738:-
COAD	cis	rs1426063	0.614	rs76931926	ENSG00000249717.1	RP11-44F21.3	4.07	6.33e-05	0.0155	0.52	0.25	QT interval;	chr4:75106902	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.614	rs114761716	ENSG00000249717.1	RP11-44F21.3	4.07	6.33e-05	0.0155	0.52	0.25	QT interval;	chr4:75107209	chr4:74955974~74970362:-
COAD	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-4.07	6.33e-05	0.0155	-0.34	-0.25	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
COAD	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	4.07	6.33e-05	0.0156	0.3	0.25	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
COAD	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-4.07	6.33e-05	0.0156	-0.3	-0.25	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
COAD	cis	rs4819052	0.851	rs8133045	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2877018	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2330012	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2877020	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs10470245	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs10470258	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4819038	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4819039	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4818768	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4819042	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.8	rs4819045	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs13048789	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs13047598	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.724	rs9753962	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.724	rs9753987	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs9753963	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs9754134	ENSG00000227039.5	ITGB2-AS1	-4.07	6.34e-05	0.0156	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:44921051~44929678:+
COAD	cis	rs6661961	0.651	rs3753446	ENSG00000237975.5	FLG-AS1	-4.07	6.34e-05	0.0156	-0.25	-0.25	Atopic dermatitis;	chr1:152415999	chr1:152168125~152445456:+
COAD	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-4.07	6.34e-05	0.0156	-0.26	-0.25	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
COAD	cis	rs728616	0.51	rs35671072	ENSG00000225484.5	NUTM2B-AS1	-4.07	6.34e-05	0.0156	-0.4	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79663088~79826594:-
COAD	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-4.07	6.34e-05	0.0156	-0.35	-0.25	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
COAD	cis	rs494562	0.892	rs7753711	ENSG00000234155.1	RP11-30P6.6	4.07	6.34e-05	0.0156	0.43	0.25	Metabolic traits;Blood metabolite levels;	chr6:85420981	chr6:85387219~85390186:-
COAD	cis	rs2380205	0.546	rs649537	ENSG00000232807.2	RP11-536K7.3	-4.07	6.34e-05	0.0156	-0.2	-0.25	Breast cancer;	chr10:5903709	chr10:5934270~5945900:-
COAD	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-4.07	6.34e-05	0.0156	-0.36	-0.25	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
COAD	cis	rs8061903	0.535	rs1001897	ENSG00000260071.1	RP11-418I22.2	4.07	6.35e-05	0.0156	0.3	0.25	HIV-1 viral setpoint;	chr16:9315247	chr16:9466655~9517564:+
COAD	cis	rs2496589	0.963	rs9496638	ENSG00000218896.1	TUBB8P2	4.07	6.35e-05	0.0156	0.28	0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143446420	chr6:143436216~143436710:+
COAD	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	4.07	6.35e-05	0.0156	0.27	0.25	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
COAD	cis	rs2638953	0.853	rs10843178	ENSG00000247934.4	RP11-967K21.1	-4.07	6.35e-05	0.0156	-0.24	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28163298~28190738:-
COAD	cis	rs2929278	0.546	rs686666	ENSG00000275601.1	AC011330.13	-4.07	6.35e-05	0.0156	-0.29	-0.25	Schizophrenia;	chr15:43869352	chr15:43642389~43643023:-
COAD	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	4.07	6.35e-05	0.0156	0.31	0.25	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
COAD	cis	rs911555	0.755	rs975892	ENSG00000251533.2	LINC00605	-4.07	6.36e-05	0.0156	-0.32	-0.25	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103187221~103189028:-
COAD	cis	rs4253772	0.55	rs6008601	ENSG00000280424.1	CITF22-92A6.2	4.07	6.36e-05	0.0156	0.41	0.25	Cholesterol, total;LDL cholesterol;	chr22:46309429	chr22:46006616~46010777:+
COAD	cis	rs2836974	0.568	rs419469	ENSG00000255568.3	BRWD1-AS2	4.07	6.36e-05	0.0156	0.23	0.25	Cognitive function;	chr21:39165308	chr21:39313935~39314962:+
COAD	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-4.07	6.36e-05	0.0156	-0.25	-0.25	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-4.07	6.36e-05	0.0156	-0.25	-0.25	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-4.07	6.36e-05	0.0156	-0.25	-0.25	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-4.07	6.36e-05	0.0156	-0.25	-0.25	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
COAD	cis	rs12935418	0.616	rs12446053	ENSG00000278985.1	RP11-303E16.9	-4.07	6.36e-05	0.0156	-0.28	-0.25	Mean corpuscular volume;	chr16:80930234	chr16:80982319~80984094:-
COAD	cis	rs875971	0.862	rs7783779	ENSG00000224316.1	RP11-479O9.2	-4.07	6.36e-05	0.0156	-0.27	-0.25	Aortic root size;	chr7:66331639	chr7:65773620~65802067:+
COAD	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-4.07	6.36e-05	0.0156	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
COAD	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-4.07	6.36e-05	0.0156	-0.34	-0.25	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
COAD	cis	rs10971721	1	rs10971721	ENSG00000260947.1	RP11-384P7.7	4.07	6.36e-05	0.0156	0.43	0.25	Body mass index;	chr9:33827696	chr9:33697459~33700986:+
COAD	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-4.07	6.36e-05	0.0156	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
COAD	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-4.07	6.37e-05	0.0156	-0.26	-0.25	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
COAD	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	4.07	6.37e-05	0.0156	0.29	0.25	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
COAD	cis	rs6822297	1	rs6822297	ENSG00000240005.4	RP11-293A21.1	-4.07	6.37e-05	0.0156	-0.32	-0.25	Obesity-related traits;	chr4:26999373	chr4:26859806~26860599:-
COAD	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-4.07	6.37e-05	0.0156	-0.47	-0.25	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
COAD	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-4.07	6.37e-05	0.0156	-0.28	-0.25	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
COAD	cis	rs801193	0.569	rs13226966	ENSG00000224316.1	RP11-479O9.2	4.07	6.37e-05	0.0156	0.27	0.25	Aortic root size;	chr7:66768636	chr7:65773620~65802067:+
COAD	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.07	6.37e-05	0.0156	-0.5	-0.25	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
COAD	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	4.07	6.38e-05	0.0156	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
COAD	cis	rs853679	0.546	rs13214023	ENSG00000204709.4	LINC01556	-4.07	6.38e-05	0.0156	-0.64	-0.25	Depression;	chr6:28364364	chr6:28943877~28944537:+
COAD	cis	rs8141529	1	rs8141529	ENSG00000272858.1	CTA-292E10.8	-4.07	6.38e-05	0.0156	-0.3	-0.25	Lymphocyte counts;	chr22:28873704	chr22:28814914~28815662:+
COAD	cis	rs9393777	0.588	rs3799380	ENSG00000224843.5	LINC00240	-4.07	6.38e-05	0.0157	-0.35	-0.25	Intelligence (multi-trait analysis);	chr6:26466954	chr6:26956992~27023924:+
COAD	cis	rs12906542	0.516	rs4886992	ENSG00000260139.5	CSPG4P13	-4.06	6.39e-05	0.0157	-0.34	-0.25	Breast cancer;	chr15:78032887	chr15:77894684~77904674:+
COAD	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	4.06	6.39e-05	0.0157	0.23	0.25	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
COAD	cis	rs5753037	0.585	rs7954	ENSG00000279159.1	RP3-394A18.1	-4.06	6.39e-05	0.0157	-0.16	-0.25	Type 1 diabetes;	chr22:29788961	chr22:29978950~30028236:-
COAD	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.06	6.4e-05	0.0157	0.3	0.25	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
COAD	cis	rs9393813	0.528	rs6899950	ENSG00000271755.1	RP1-153G14.4	4.06	6.4e-05	0.0157	0.29	0.25	Bipolar disorder;	chr6:27466216	chr6:27404010~27406964:-
COAD	cis	rs6929812	0.639	rs7754724	ENSG00000271755.1	RP1-153G14.4	4.06	6.4e-05	0.0157	0.29	0.25	Neuroticism (multi-trait analysis);	chr6:27483018	chr6:27404010~27406964:-
COAD	cis	rs7646881	0.544	rs16829118	ENSG00000272087.1	RP11-379F4.7	4.06	6.4e-05	0.0157	0.39	0.25	Tetralogy of Fallot;	chr3:158571033	chr3:158693120~158693768:-
COAD	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-4.06	6.4e-05	0.0157	-0.29	-0.25	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
COAD	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-4.06	6.4e-05	0.0157	-0.29	-0.25	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
COAD	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-4.06	6.4e-05	0.0157	-0.29	-0.25	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-4.06	6.4e-05	0.0157	-0.29	-0.25	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
COAD	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-4.06	6.4e-05	0.0157	-0.24	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
COAD	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-4.06	6.4e-05	0.0157	-0.3	-0.25	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
COAD	cis	rs7577696	0.924	rs3769604	ENSG00000272716.1	RP11-563N4.1	-4.06	6.4e-05	0.0157	-0.26	-0.25	Inflammatory biomarkers;	chr2:32097426	chr2:32165046~32165757:-
COAD	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	4.06	6.4e-05	0.0157	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	4.06	6.4e-05	0.0157	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	4.06	6.4e-05	0.0157	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
COAD	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.06	6.4e-05	0.0157	0.34	0.25	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
COAD	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-4.06	6.41e-05	0.0157	-0.2	-0.25	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
COAD	cis	rs987724	0.593	rs9878585	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156952028	chr3:156747346~156817062:-
COAD	cis	rs987724	0.574	rs2874492	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953387	chr3:156747346~156817062:-
COAD	cis	rs987724	0.574	rs9856725	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156954781	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs10936040	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156959236	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs9289973	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156960726	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs9875585	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156963334	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs9853479	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156966135	chr3:156747346~156817062:-
COAD	cis	rs987724	0.593	rs10212230	ENSG00000240875.4	LINC00886	-4.06	6.41e-05	0.0157	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973164	chr3:156747346~156817062:-
COAD	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	4.06	6.41e-05	0.0157	0.35	0.25	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	4.06	6.41e-05	0.0157	0.35	0.25	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
COAD	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	4.06	6.41e-05	0.0157	0.3	0.25	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
COAD	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	4.06	6.41e-05	0.0157	0.25	0.25	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
COAD	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	4.06	6.41e-05	0.0157	0.25	0.25	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
COAD	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	4.06	6.41e-05	0.0157	0.33	0.25	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
COAD	cis	rs2836974	0.644	rs61300849	ENSG00000255568.3	BRWD1-AS2	-4.06	6.41e-05	0.0157	-0.23	-0.25	Cognitive function;	chr21:39308268	chr21:39313935~39314962:+
COAD	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	4.06	6.42e-05	0.0157	0.27	0.25	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	4.06	6.42e-05	0.0157	0.27	0.25	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
COAD	cis	rs494562	1	rs495472	ENSG00000234155.1	RP11-30P6.6	-4.06	6.42e-05	0.0157	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85407303	chr6:85387219~85390186:-
COAD	cis	rs494562	1	rs495469	ENSG00000234155.1	RP11-30P6.6	-4.06	6.42e-05	0.0157	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85407307	chr6:85387219~85390186:-
COAD	cis	rs494562	1	rs494562	ENSG00000234155.1	RP11-30P6.6	-4.06	6.42e-05	0.0157	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85407411	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs490079	ENSG00000234155.1	RP11-30P6.6	-4.06	6.42e-05	0.0157	-0.43	-0.25	Metabolic traits;Blood metabolite levels;	chr6:85407881	chr6:85387219~85390186:-
COAD	cis	rs801193	0.569	rs11772819	ENSG00000224316.1	RP11-479O9.2	4.06	6.42e-05	0.0157	0.27	0.25	Aortic root size;	chr7:66752983	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs7800620	ENSG00000224316.1	RP11-479O9.2	4.06	6.42e-05	0.0157	0.27	0.25	Aortic root size;	chr7:66758701	chr7:65773620~65802067:+
COAD	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	4.06	6.42e-05	0.0157	0.32	0.25	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
COAD	cis	rs72627123	1	rs2302139	ENSG00000259065.1	RP5-1021I20.1	-4.06	6.42e-05	0.0157	-0.4	-0.25	Morning vs. evening chronotype;	chr14:73896232	chr14:73787360~73803270:+
COAD	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	4.06	6.42e-05	0.0157	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
COAD	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	4.06	6.42e-05	0.0157	0.34	0.25	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
COAD	cis	rs6565180	0.851	rs3574	ENSG00000183604.13	SMG1P5	4.06	6.43e-05	0.0157	0.26	0.25	Tonsillectomy;	chr16:30400061	chr16:30267553~30335374:-
COAD	cis	rs210138	0.591	rs9394158	ENSG00000197251.3	LINC00336	4.06	6.43e-05	0.0157	0.37	0.25	Testicular germ cell tumor;	chr6:33645590	chr6:33586106~33593338:-
COAD	cis	rs17772222	0.958	rs2274737	ENSG00000258789.1	RP11-507K2.3	-4.06	6.43e-05	0.0157	-0.36	-0.25	Coronary artery calcification;	chr14:88469307	chr14:88551597~88552493:+
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	4.06	6.43e-05	0.0158	0.23	0.25	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
COAD	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-4.06	6.43e-05	0.0158	-0.34	-0.25	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
COAD	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	4.06	6.43e-05	0.0158	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
COAD	cis	rs12699921	0.632	rs2691629	ENSG00000279048.1	RP11-511H23.2	-4.06	6.44e-05	0.0158	-0.18	-0.25	Fibrinogen levels;	chr7:17785007	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723500	ENSG00000279048.1	RP11-511H23.2	-4.06	6.44e-05	0.0158	-0.18	-0.25	Fibrinogen levels;	chr7:17785111	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2691630	ENSG00000279048.1	RP11-511H23.2	-4.06	6.44e-05	0.0158	-0.18	-0.25	Fibrinogen levels;	chr7:17785163	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723499	ENSG00000279048.1	RP11-511H23.2	-4.06	6.44e-05	0.0158	-0.18	-0.25	Fibrinogen levels;	chr7:17785261	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723498	ENSG00000279048.1	RP11-511H23.2	-4.06	6.44e-05	0.0158	-0.18	-0.25	Fibrinogen levels;	chr7:17785362	chr7:17940503~17942922:+
COAD	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-4.06	6.44e-05	0.0158	-0.26	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
COAD	cis	rs9307551	0.741	rs9307532	ENSG00000250334.4	LINC00989	-4.06	6.44e-05	0.0158	-0.33	-0.25	Refractive error;	chr4:79510067	chr4:79492416~79576460:+
COAD	cis	rs987724	0.502	rs4680320	ENSG00000240875.4	LINC00886	-4.06	6.45e-05	0.0158	-0.22	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955813	chr3:156747346~156817062:-
COAD	cis	rs2877649	0.51	rs10083382	ENSG00000215256.3	DHRS4-AS1	4.06	6.45e-05	0.0158	0.38	0.25	Smooth-surface caries;	chr14:24438911	chr14:23938731~23988839:-
COAD	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	4.06	6.45e-05	0.0158	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
COAD	cis	rs2408955	0.561	rs11168365	ENSG00000269514.1	RP11-370I10.12	-4.06	6.45e-05	0.0158	-0.29	-0.25	Glycated hemoglobin levels;	chr12:48027989	chr12:48198387~48202031:+
COAD	cis	rs9307551	0.779	rs13124357	ENSG00000250334.4	LINC00989	-4.06	6.45e-05	0.0158	-0.28	-0.25	Refractive error;	chr4:79591148	chr4:79492416~79576460:+
COAD	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	4.06	6.45e-05	0.0158	0.29	0.25	Height;	chr4:55566291	chr4:55363971~55395847:-
COAD	cis	rs1510510	0.69	rs13028301	ENSG00000225057.2	AC096574.4	4.06	6.45e-05	0.0158	0.33	0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640718	chr2:238231684~238255633:+
COAD	cis	rs4006360	0.575	rs67524820	ENSG00000267221.1	CTD-2132N18.2	-4.06	6.45e-05	0.0158	-0.26	-0.25	Bipolar disorder and schizophrenia;	chr17:41161956	chr17:42040713~42043117:-
COAD	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.06	6.45e-05	0.0158	-0.25	-0.25	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
COAD	cis	rs17685	0.753	rs2302435	ENSG00000280388.1	RP11-229D13.3	4.06	6.45e-05	0.0158	0.25	0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76043977~76045963:-
COAD	cis	rs17685	0.725	rs2302436	ENSG00000280388.1	RP11-229D13.3	4.06	6.45e-05	0.0158	0.25	0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76043977~76045963:-
COAD	cis	rs2243480	0.901	rs3813708	ENSG00000232559.3	GS1-124K5.12	4.06	6.45e-05	0.0158	0.46	0.25	Diabetic kidney disease;	chr7:65840645	chr7:66554588~66576923:-
COAD	cis	rs11124272	0.716	rs527112	ENSG00000272716.1	RP11-563N4.1	4.06	6.46e-05	0.0158	0.27	0.25	Interleukin-18 levels;	chr2:31640549	chr2:32165046~32165757:-
COAD	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	4.06	6.46e-05	0.0158	0.31	0.25	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
COAD	cis	rs2333021	0.833	rs10141389	ENSG00000259015.1	RP11-109N23.6	4.06	6.46e-05	0.0158	0.23	0.25	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:72960595~72961993:+
COAD	cis	rs6732160	0.613	rs10179063	ENSG00000163016.8	ALMS1P	4.06	6.46e-05	0.0158	0.31	0.25	Intelligence (multi-trait analysis);	chr2:73157983	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.613	rs6546804	ENSG00000163016.8	ALMS1P	4.06	6.46e-05	0.0158	0.31	0.25	Intelligence (multi-trait analysis);	chr2:73158791	chr2:73644919~73685576:+
COAD	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	4.06	6.46e-05	0.0158	0.22	0.25	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
COAD	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	4.06	6.46e-05	0.0158	0.29	0.25	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
COAD	cis	rs34779708	0.966	rs4934538	ENSG00000271335.4	RP11-324I22.4	4.06	6.46e-05	0.0158	0.28	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35314552~35336401:-
COAD	cis	rs34638657	0.536	rs2967327	ENSG00000261235.1	RP11-510J16.5	4.06	6.46e-05	0.0158	0.31	0.25	Lung adenocarcinoma;	chr16:82155052	chr16:82044336~82139631:-
COAD	cis	rs12928939	0.815	rs12448022	ENSG00000260886.1	TAT-AS1	4.06	6.46e-05	0.0158	0.34	0.25	Post bronchodilator FEV1;	chr16:71690466	chr16:71565789~71578187:+
COAD	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	4.06	6.47e-05	0.0158	0.28	0.25	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
COAD	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	4.06	6.47e-05	0.0158	0.32	0.25	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
COAD	cis	rs742132	0.858	rs9461188	ENSG00000220875.1	HIST1H3PS1	4.06	6.47e-05	0.0158	0.32	0.25	Uric acid levels;	chr6:25660744	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs9461189	ENSG00000220875.1	HIST1H3PS1	4.06	6.47e-05	0.0158	0.32	0.25	Uric acid levels;	chr6:25660836	chr6:26321876~26322292:-
COAD	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-4.06	6.48e-05	0.0158	-0.27	-0.25	Gout;	chr7:66721259	chr7:66902857~66906297:+
COAD	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	4.06	6.48e-05	0.0158	0.3	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
COAD	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	4.06	6.48e-05	0.0158	0.3	0.25	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
COAD	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	4.06	6.48e-05	0.0158	0.3	0.25	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
COAD	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.06	6.48e-05	0.0158	0.31	0.25	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.06	6.48e-05	0.0158	0.31	0.25	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
COAD	cis	rs7819412	0.54	rs2409725	ENSG00000269918.1	AF131215.9	-4.06	6.48e-05	0.0158	-0.31	-0.25	Triglycerides;	chr8:11184152	chr8:11104691~11106704:-
COAD	cis	rs7819412	0.54	rs2409726	ENSG00000269918.1	AF131215.9	-4.06	6.48e-05	0.0158	-0.31	-0.25	Triglycerides;	chr8:11185629	chr8:11104691~11106704:-
COAD	cis	rs7819412	0.54	rs11777355	ENSG00000269918.1	AF131215.9	-4.06	6.48e-05	0.0158	-0.31	-0.25	Triglycerides;	chr8:11187180	chr8:11104691~11106704:-
COAD	cis	rs5758511	0.68	rs739146	ENSG00000237037.8	NDUFA6-AS1	-4.06	6.48e-05	0.0158	-0.29	-0.25	Birth weight;	chr22:42264408	chr22:42090931~42137742:+
COAD	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.06	6.48e-05	0.0159	-0.38	-0.25	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
COAD	cis	rs4819052	0.851	rs2838839	ENSG00000227039.5	ITGB2-AS1	4.06	6.49e-05	0.0159	0.22	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:44921051~44929678:+
COAD	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-4.06	6.49e-05	0.0159	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-4.06	6.49e-05	0.0159	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-4.06	6.49e-05	0.0159	-0.33	-0.25	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
COAD	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-4.06	6.49e-05	0.0159	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
COAD	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-4.06	6.49e-05	0.0159	-0.24	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
COAD	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	4.06	6.49e-05	0.0159	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
COAD	cis	rs7760535	0.763	rs10457240	ENSG00000230177.1	RP5-1112D6.4	-4.06	6.49e-05	0.0159	-0.22	-0.25	Metabolic traits;	chr6:111527671	chr6:111277932~111278742:+
COAD	cis	rs1426063	0.614	rs115279737	ENSG00000249717.1	RP11-44F21.3	4.06	6.49e-05	0.0159	0.52	0.25	QT interval;	chr4:75107557	chr4:74955974~74970362:-
COAD	cis	rs734999	0.588	rs2843401	ENSG00000225931.3	RP3-395M20.7	-4.06	6.5e-05	0.0159	-0.27	-0.25	Ulcerative colitis;	chr1:2596694	chr1:2566410~2569888:+
COAD	cis	rs6951245	0.938	rs113642700	ENSG00000229043.2	AC091729.9	-4.06	6.5e-05	0.0159	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1160374~1165267:+
COAD	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
COAD	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-4.06	6.5e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
COAD	cis	rs12554020	0.591	rs2989754	ENSG00000227603.1	RP11-165J3.6	-4.06	6.5e-05	0.0159	-0.33	-0.25	Schizophrenia;	chr9:93613875	chr9:93435332~93437121:-
COAD	cis	rs875971	0.862	rs2909688	ENSG00000224316.1	RP11-479O9.2	4.06	6.5e-05	0.0159	0.27	0.25	Aortic root size;	chr7:66376625	chr7:65773620~65802067:+
COAD	cis	rs7584330	0.704	rs72620821	ENSG00000234949.2	AC104667.3	-4.06	6.5e-05	0.0159	-0.33	-0.25	Prostate cancer;	chr2:237453972	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.704	rs7598954	ENSG00000234949.2	AC104667.3	-4.06	6.5e-05	0.0159	-0.33	-0.25	Prostate cancer;	chr2:237456133	chr2:237591020~237595981:+
COAD	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-4.06	6.5e-05	0.0159	-0.23	-0.25	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
COAD	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-4.06	6.5e-05	0.0159	-0.23	-0.25	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
COAD	cis	rs453301	0.686	rs13252797	ENSG00000233609.3	RP11-62H7.2	4.06	6.5e-05	0.0159	0.28	0.25	Joint mobility (Beighton score);	chr8:9003920	chr8:8961200~8979025:+
COAD	cis	rs891378	1	rs2802217	ENSG00000274245.1	RP11-357P18.2	-4.06	6.51e-05	0.0159	-0.34	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207309625	chr1:207372559~207373252:+
COAD	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-4.06	6.51e-05	0.0159	-0.48	-0.25	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
COAD	cis	rs875971	0.862	rs2460432	ENSG00000232559.3	GS1-124K5.12	-4.06	6.51e-05	0.0159	-0.29	-0.25	Aortic root size;	chr7:66089398	chr7:66554588~66576923:-
COAD	cis	rs12049351	0.665	rs10916477	ENSG00000229367.1	HMGN2P19	4.06	6.52e-05	0.0159	0.33	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229441218	chr1:229570532~229570796:+
COAD	cis	rs875971	0.964	rs697969	ENSG00000230189.5	GS1-124K5.2	-4.06	6.52e-05	0.0159	-0.2	-0.25	Aortic root size;	chr7:66093491	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1182882	ENSG00000230189.5	GS1-124K5.2	-4.06	6.52e-05	0.0159	-0.2	-0.25	Aortic root size;	chr7:66097076	chr7:66409143~66490059:-
COAD	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.06	6.52e-05	0.0159	0.41	0.25	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
COAD	cis	rs7615952	0.741	rs13314845	ENSG00000241278.1	ENPP7P4	4.06	6.52e-05	0.0159	0.28	0.25	Blood pressure (smoking interaction);	chr3:125925939	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.733	rs13314847	ENSG00000241278.1	ENPP7P4	4.06	6.52e-05	0.0159	0.28	0.25	Blood pressure (smoking interaction);	chr3:125925945	chr3:125848223~125909372:+
COAD	cis	rs2297363	0.502	rs4709393	ENSG00000213073.4	RP11-288H12.3	-4.06	6.52e-05	0.0159	-0.24	-0.25	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:160093082~160096212:+
COAD	cis	rs10043775	0.958	rs60625004	ENSG00000251330.3	CTD-2283N19.1	-4.06	6.53e-05	0.0159	-0.29	-0.25	Periodontal microbiota;	chr5:148435394	chr5:148430159~148430807:-
COAD	cis	rs10043775	0.718	rs10056586	ENSG00000251330.3	CTD-2283N19.1	-4.06	6.53e-05	0.0159	-0.29	-0.25	Periodontal microbiota;	chr5:148440140	chr5:148430159~148430807:-
COAD	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-4.06	6.54e-05	0.016	-0.32	-0.25	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
COAD	cis	rs603446	0.678	rs664059	ENSG00000254851.1	RP11-109L13.1	-4.06	6.54e-05	0.016	-0.28	-0.25	Triglycerides;	chr11:116771421	chr11:117135528~117138582:+
COAD	cis	rs7200543	0.884	rs72789542	ENSG00000270580.4	PKD1P6	4.06	6.54e-05	0.016	0.28	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15033678	chr16:15104723~15131601:-
COAD	cis	rs2108622	0.628	rs11086005	ENSG00000267056.2	AC005336.4	4.06	6.54e-05	0.016	0.34	0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15910582~15911824:-
COAD	cis	rs72827839	0.846	rs41280120	ENSG00000263412.1	RP5-890E16.2	4.06	6.54e-05	0.016	0.33	0.25	Ease of getting up in the morning;	chr17:48037326	chr17:48045141~48048073:-
COAD	cis	rs9532669	0.926	rs7322399	ENSG00000277662.1	RP11-74J13.9	-4.06	6.54e-05	0.016	-0.24	-0.25	Cervical cancer;	chr13:40952511	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs7322097	ENSG00000277662.1	RP11-74J13.9	-4.06	6.54e-05	0.016	-0.24	-0.25	Cervical cancer;	chr13:40952513	chr13:41229180~41229676:-
COAD	cis	rs56052703	0.536	rs7247782	ENSG00000267633.1	CTB-5E10.3	4.06	6.54e-05	0.016	0.28	0.25	Proteinuria and chronic kidney disease;	chr19:13317901	chr19:13772118~13774118:-
COAD	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	4.06	6.55e-05	0.016	0.46	0.25	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
COAD	cis	rs2070488	0.662	rs7375040	ENSG00000229589.1	ACVR2B-AS1	4.06	6.55e-05	0.016	0.25	0.25	Electrocardiographic conduction measures;	chr3:38427625	chr3:38451027~38454820:-
COAD	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	4.06	6.55e-05	0.016	0.27	0.25	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
COAD	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	4.06	6.55e-05	0.016	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
COAD	cis	rs4819052	0.851	rs34101026	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs13052312	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2838828	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs13049337	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.885	rs9980676	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2838836	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2838837	ENSG00000227039.5	ITGB2-AS1	-4.06	6.55e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:44921051~44929678:+
COAD	cis	rs801193	0.569	rs2659908	ENSG00000224316.1	RP11-479O9.2	4.06	6.55e-05	0.016	0.26	0.25	Aortic root size;	chr7:66695835	chr7:65773620~65802067:+
COAD	cis	rs4819052	0.851	rs35064782	ENSG00000227039.5	ITGB2-AS1	-4.06	6.56e-05	0.016	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:44921051~44929678:+
COAD	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	4.06	6.56e-05	0.016	0.32	0.25	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
COAD	cis	rs801193	0.66	rs2659914	ENSG00000179406.6	LINC00174	4.06	6.57e-05	0.016	0.18	0.25	Aortic root size;	chr7:66691927	chr7:66376044~66401338:-
COAD	cis	rs860295	1	rs822478	ENSG00000203761.5	MSTO2P	4.06	6.57e-05	0.016	0.22	0.25	Body mass index;	chr1:155824178	chr1:155745829~155750137:+
COAD	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.06	6.57e-05	0.016	-0.24	-0.25	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
COAD	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-4.06	6.57e-05	0.016	-0.26	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
COAD	cis	rs17711722	0.565	rs73372653	ENSG00000272831.1	RP11-792A8.4	4.06	6.57e-05	0.016	0.25	0.25	Calcium levels;	chr7:65977808	chr7:66739829~66740385:-
COAD	cis	rs913655	0.508	rs1552609	ENSG00000240291.1	RP11-499P20.2	4.06	6.57e-05	0.016	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18723230	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs12413511	ENSG00000240291.1	RP11-499P20.2	4.06	6.57e-05	0.016	0.29	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18723961	chr10:18513115~18545651:-
COAD	cis	rs1949733	0.582	rs61258495	ENSG00000205959.3	RP11-689P11.2	4.06	6.58e-05	0.0161	0.28	0.25	Response to antineoplastic agents;	chr4:8532290	chr4:8482270~8512610:+
COAD	cis	rs8044868	0.586	rs6499564	ENSG00000279206.1	RP5-991G20.6	-4.06	6.58e-05	0.0161	-0.3	-0.25	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72155756	chr16:72772673~72773272:+
COAD	cis	rs180730	1	rs1450472	ENSG00000251609.2	SETP12	4.06	6.58e-05	0.0161	0.36	0.25	Fasting plasma glucose;	chr4:120882137	chr4:120895494~120897083:-
COAD	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-4.06	6.59e-05	0.0161	-0.25	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
COAD	cis	rs4819052	0.851	rs2877019	ENSG00000227039.5	ITGB2-AS1	-4.06	6.59e-05	0.0161	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:44921051~44929678:+
COAD	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-4.06	6.59e-05	0.0161	-0.29	-0.25	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
COAD	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-4.06	6.59e-05	0.0161	-0.29	-0.25	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
COAD	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-4.06	6.59e-05	0.0161	-0.29	-0.25	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
COAD	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-4.06	6.6e-05	0.0161	-0.26	-0.25	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
COAD	cis	rs1135642	0.509	rs78111759	ENSG00000270244.1	RP11-123J14.4	4.06	6.6e-05	0.0161	0.57	0.25	Food addiction;	chr4:76886473	chr4:76886029~76886370:-
COAD	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	4.06	6.6e-05	0.0161	0.35	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
COAD	cis	rs4834770	0.718	rs4833618	ENSG00000250412.1	KLHL2P1	-4.06	6.6e-05	0.0161	-0.31	-0.25	Blood protein levels;	chr4:119388345	chr4:119334329~119378233:+
COAD	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-4.06	6.6e-05	0.0161	-0.28	-0.25	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
COAD	cis	rs4392868	0.514	rs2341400	ENSG00000254248.1	RP11-320N21.2	-4.06	6.6e-05	0.0161	-0.28	-0.25	Radiation response;	chr8:95091310	chr8:95071732~95087924:-
COAD	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	4.06	6.6e-05	0.0161	0.29	0.25	Height;	chr4:55482360	chr4:55363971~55395847:-
COAD	cis	rs12554020	0.551	rs2989751	ENSG00000227603.1	RP11-165J3.6	-4.06	6.6e-05	0.0161	-0.33	-0.25	Schizophrenia;	chr9:93604365	chr9:93435332~93437121:-
COAD	cis	rs7584330	0.657	rs10211024	ENSG00000234949.2	AC104667.3	-4.06	6.6e-05	0.0161	-0.3	-0.25	Prostate cancer;	chr2:237445133	chr2:237591020~237595981:+
COAD	cis	rs13256369	0.802	rs12541520	ENSG00000173295.6	FAM86B3P	4.06	6.6e-05	0.0161	0.35	0.25	Obesity-related traits;	chr8:8706636	chr8:8228595~8244865:+
COAD	cis	rs9487051	0.872	rs1521908	ENSG00000219700.1	PTCHD3P3	4.06	6.6e-05	0.0161	0.26	0.25	Reticulocyte fraction of red cells;	chr6:109292783	chr6:109288571~109290503:-
COAD	cis	rs7903146	0.651	rs4267006	ENSG00000227560.1	RP11-139K1.2	-4.06	6.6e-05	0.0161	-0.31	-0.25	Hip circumference;Clinical laboratory measurements;BMI in non-smokers;Fasting blood insulin (BMI interaction);BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Fasting blood glucose (BMI interaction);Glycated hemoglobin levels;Type 2 diabetes;Waist circumference;Proinsulin levels;Body mass index (joint analysis main effects and smoking interaction);Metabolic syndrome;Peak insulin response;Fasting blood glucose;Body mass index;Fasting blood insulin;Type 2 diabetes and other traits;	chr10:112999020	chr10:112987476~112987865:+
COAD	cis	rs801193	0.569	rs4717315	ENSG00000224316.1	RP11-479O9.2	4.06	6.61e-05	0.0161	0.27	0.25	Aortic root size;	chr7:66713338	chr7:65773620~65802067:+
COAD	cis	rs4392868	0.514	rs12548426	ENSG00000254248.1	RP11-320N21.2	-4.06	6.61e-05	0.0161	-0.28	-0.25	Radiation response;	chr8:95092958	chr8:95071732~95087924:-
COAD	cis	rs17685	0.753	rs1574107	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76043977~76045963:-
COAD	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-4.06	6.61e-05	0.0161	-0.28	-0.25	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
COAD	cis	rs7674212	0.833	rs61075040	ENSG00000230069.3	LRRC37A15P	-4.06	6.61e-05	0.0161	-0.27	-0.25	Type 2 diabetes;	chr4:103052804	chr4:102727274~102730721:-
COAD	cis	rs17685	0.672	rs1639618	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1637044	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs1639620	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76043977~76045963:-
COAD	cis	rs17685	0.672	rs1639623	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs4552844	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs4732578	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76043977~76045963:-
COAD	cis	rs17685	0.625	rs1639630	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76043977~76045963:-
COAD	cis	rs17685	0.784	rs1613890	ENSG00000280388.1	RP11-229D13.3	-4.06	6.61e-05	0.0161	-0.25	-0.25	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76043977~76045963:-
COAD	cis	rs2638953	0.925	rs11049604	ENSG00000247934.4	RP11-967K21.1	-4.06	6.61e-05	0.0161	-0.26	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443092	chr12:28163298~28190738:-
COAD	cis	rs13256369	0.95	rs13248096	ENSG00000253981.4	ALG1L13P	4.06	6.61e-05	0.0161	0.35	0.25	Obesity-related traits;	chr8:8719966	chr8:8236003~8244667:-
COAD	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-4.06	6.61e-05	0.0161	-0.47	-0.25	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-4.06	6.61e-05	0.0161	-0.47	-0.25	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-4.06	6.61e-05	0.0161	-0.47	-0.25	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
COAD	cis	rs7615952	1	rs7615952	ENSG00000241278.1	ENPP7P4	-4.06	6.62e-05	0.0161	-0.27	-0.25	Blood pressure (smoking interaction);	chr3:125930560	chr3:125848223~125909372:+
COAD	cis	rs9329221	0.537	rs6983332	ENSG00000254340.1	RP11-10A14.3	-4.06	6.62e-05	0.0161	-0.29	-0.25	Neuroticism;	chr8:10120408	chr8:9141424~9145435:+
COAD	cis	rs10779751	1	rs4845859	ENSG00000215785.2	CFL1P6	-4.06	6.62e-05	0.0161	-0.28	-0.25	Body mass index;	chr1:11244816	chr1:10990978~10991797:-
COAD	cis	rs10779751	0.922	rs11121708	ENSG00000215785.2	CFL1P6	-4.06	6.62e-05	0.0161	-0.28	-0.25	Body mass index;	chr1:11247196	chr1:10990978~10991797:-
COAD	cis	rs10779751	1	rs6670821	ENSG00000215785.2	CFL1P6	-4.06	6.62e-05	0.0161	-0.28	-0.25	Body mass index;	chr1:11248705	chr1:10990978~10991797:-
COAD	cis	rs7772486	0.654	rs9376958	ENSG00000235652.6	RP11-545I5.3	-4.06	6.62e-05	0.0161	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145799409~145886585:+
COAD	cis	rs11681884	0.892	rs2121327	ENSG00000228251.1	AC012442.6	4.06	6.62e-05	0.0161	0.53	0.25	Stroke;	chr2:113094616	chr2:112590796~112591939:+
COAD	cis	rs2115630	0.967	rs10438428	ENSG00000259728.4	LINC00933	-4.06	6.63e-05	0.0161	-0.28	-0.25	P wave terminal force;	chr15:84787514	chr15:84570649~84580175:+
COAD	cis	rs6687821	0.515	rs2096286	ENSG00000261737.1	RP4-612B15.3	4.06	6.63e-05	0.0161	0.32	0.25	Yeast infection;	chr1:87075298	chr1:86703502~86704462:-
COAD	cis	rs9888736	0.871	rs869731	ENSG00000259488.2	RP11-154J22.1	4.06	6.63e-05	0.0161	0.26	0.25	Body mass index;	chr15:47674453	chr15:48312353~48331856:-
COAD	cis	rs9888736	0.871	rs869730	ENSG00000259488.2	RP11-154J22.1	4.06	6.63e-05	0.0161	0.26	0.25	Body mass index;	chr15:47674555	chr15:48312353~48331856:-
COAD	cis	rs4819052	0.851	rs2838833	ENSG00000227039.5	ITGB2-AS1	-4.06	6.63e-05	0.0161	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:44921051~44929678:+
COAD	cis	rs730566	1	rs4858819	ENSG00000228638.1	FCF1P2	4.06	6.63e-05	0.0162	0.35	0.25	Prion diseases;	chr3:48436678	chr3:48290793~48291375:-
COAD	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	4.06	6.63e-05	0.0162	0.33	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
COAD	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	4.06	6.63e-05	0.0162	0.33	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
COAD	cis	rs115769866	0.609	rs2859356	ENSG00000204709.4	LINC01556	4.06	6.63e-05	0.0162	0.35	0.25	Bipolar disorder;	chr6:28497578	chr6:28943877~28944537:+
COAD	cis	rs12549025	0.782	rs11781222	ENSG00000253390.1	CTC-756D1.2	-4.06	6.63e-05	0.0162	-0.39	-0.25	Reticulocyte fraction of red cells;	chr8:23532058	chr8:23458601~23484971:+
COAD	cis	rs5753037	0.838	rs5752975	ENSG00000279159.1	RP3-394A18.1	-4.06	6.64e-05	0.0162	-0.17	-0.25	Type 1 diabetes;	chr22:29878346	chr22:29978950~30028236:-
COAD	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	4.06	6.64e-05	0.0162	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
COAD	cis	rs1510510	0.69	rs7590443	ENSG00000225057.2	AC096574.4	4.06	6.64e-05	0.0162	0.33	0.25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641268	chr2:238231684~238255633:+
COAD	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	4.06	6.64e-05	0.0162	0.23	0.25	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
COAD	cis	rs2836974	0.644	rs9978775	ENSG00000255568.3	BRWD1-AS2	-4.06	6.64e-05	0.0162	-0.24	-0.25	Cognitive function;	chr21:39322600	chr21:39313935~39314962:+
COAD	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-4.06	6.65e-05	0.0162	-0.28	-0.25	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
COAD	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.06	6.65e-05	0.0162	-0.25	-0.25	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
COAD	cis	rs875971	0.895	rs12531677	ENSG00000224316.1	RP11-479O9.2	-4.06	6.65e-05	0.0162	-0.27	-0.25	Aortic root size;	chr7:66304099	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs7798630	ENSG00000224316.1	RP11-479O9.2	-4.06	6.65e-05	0.0162	-0.27	-0.25	Aortic root size;	chr7:66306492	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs11984115	ENSG00000224316.1	RP11-479O9.2	-4.06	6.65e-05	0.0162	-0.27	-0.25	Aortic root size;	chr7:66308872	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs2088653	ENSG00000224316.1	RP11-479O9.2	-4.06	6.65e-05	0.0162	-0.27	-0.25	Aortic root size;	chr7:66343621	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6460293	ENSG00000224316.1	RP11-479O9.2	-4.06	6.65e-05	0.0162	-0.27	-0.25	Aortic root size;	chr7:66345205	chr7:65773620~65802067:+
COAD	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-4.06	6.65e-05	0.0162	-0.25	-0.25	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
COAD	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-4.06	6.65e-05	0.0162	-0.25	-0.25	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
COAD	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-4.06	6.65e-05	0.0162	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
COAD	cis	rs1832007	0.529	rs72772224	ENSG00000224034.1	RP11-445P17.8	-4.05	6.65e-05	0.0162	-0.36	-0.25	Triglyceride levels;Triglycerides;	chr10:5202739	chr10:5266033~5271236:-
COAD	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	4.05	6.65e-05	0.0162	0.28	0.25	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
COAD	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	4.05	6.65e-05	0.0162	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
COAD	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	4.05	6.66e-05	0.0162	0.26	0.25	Axial length;	chr3:53815483	chr3:53797764~53798019:-
COAD	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	4.05	6.66e-05	0.0162	0.26	0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
COAD	cis	rs597539	0.69	rs497149	ENSG00000255741.1	RP11-757G1.5	-4.05	6.66e-05	0.0162	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68941503~68942852:-
COAD	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.32	0.25	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.32	0.25	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
COAD	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	4.05	6.66e-05	0.0162	0.32	0.25	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
COAD	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	4.05	6.66e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
COAD	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	4.05	6.67e-05	0.0162	0.28	0.25	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	4.05	6.67e-05	0.0162	0.28	0.25	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
COAD	cis	rs4006360	0.575	rs447608	ENSG00000267221.1	CTD-2132N18.2	4.05	6.67e-05	0.0162	0.26	0.25	Bipolar disorder and schizophrenia;	chr17:41152245	chr17:42040713~42043117:-
COAD	cis	rs4006360	0.575	rs404154	ENSG00000267221.1	CTD-2132N18.2	4.05	6.67e-05	0.0162	0.26	0.25	Bipolar disorder and schizophrenia;	chr17:41159089	chr17:42040713~42043117:-
COAD	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	4.05	6.67e-05	0.0162	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
COAD	cis	rs11588062	0.601	rs4660344	ENSG00000230896.1	RP11-767N6.7	4.05	6.67e-05	0.0162	0.29	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr1:46339550	chr1:45694684~45697075:-
COAD	cis	rs597539	0.518	rs35093305	ENSG00000255741.1	RP11-757G1.5	-4.05	6.67e-05	0.0162	-0.33	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68941503~68942852:-
COAD	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-4.05	6.67e-05	0.0162	-0.21	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
COAD	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	4.05	6.68e-05	0.0162	0.33	0.25	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
COAD	cis	rs8141529	0.764	rs5752812	ENSG00000272858.1	CTA-292E10.8	-4.05	6.68e-05	0.0162	-0.29	-0.25	Lymphocyte counts;	chr22:28829615	chr22:28814914~28815662:+
COAD	cis	rs2638953	0.924	rs11049507	ENSG00000247934.4	RP11-967K21.1	-4.05	6.68e-05	0.0162	-0.27	-0.25	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28163298~28190738:-
COAD	cis	rs2061333	0.557	rs8104573	ENSG00000278492.1	RP11-15A1.9	-4.05	6.68e-05	0.0162	-0.34	-0.25	Alzheimer's disease;	chr19:44099232	chr19:43978376~43978663:+
COAD	cis	rs7015630	0.647	rs12679902	ENSG00000251136.7	RP11-37B2.1	-4.05	6.68e-05	0.0162	-0.26	-0.25	Inflammatory bowel disease;Crohn's disease;	chr8:89845761	chr8:89609409~89757727:-
COAD	cis	rs6687821	0.515	rs7531296	ENSG00000261737.1	RP4-612B15.3	4.05	6.68e-05	0.0163	0.32	0.25	Yeast infection;	chr1:87005691	chr1:86703502~86704462:-
COAD	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-4.05	6.69e-05	0.0163	-0.25	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
COAD	cis	rs4074961	0.585	rs10752600	ENSG00000233621.1	LINC01137	-4.05	6.69e-05	0.0163	-0.28	-0.25	Axial length;	chr1:37601951	chr1:37454879~37474411:-
COAD	cis	rs6951245	1	rs80094748	ENSG00000229043.2	AC091729.9	-4.05	6.69e-05	0.0163	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1160374~1165267:+
COAD	cis	rs11969893	0.85	rs12664068	ENSG00000270987.1	RP3-467N11.2	4.05	6.69e-05	0.0163	0.56	0.25	Economic and political preferences (immigration/crime);	chr6:100914222	chr6:100889603~100890338:+
COAD	cis	rs1559040	0.858	rs11695936	ENSG00000233266.1	HMGB1P31	-4.05	6.69e-05	0.0163	-0.37	-0.25	Sudden cardiac arrest;	chr2:54090135	chr2:54051334~54051760:+
COAD	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	4.05	6.69e-05	0.0163	0.33	0.25	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
COAD	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	4.05	6.69e-05	0.0163	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
COAD	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-4.05	6.69e-05	0.0163	-0.26	-0.25	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-4.05	6.69e-05	0.0163	-0.26	-0.25	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
COAD	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	4.05	6.69e-05	0.0163	0.28	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
COAD	cis	rs12908161	0.683	rs12903256	ENSG00000225151.9	GOLGA2P7	-4.05	6.69e-05	0.0163	-0.28	-0.25	Schizophrenia;	chr15:84764910	chr15:84199311~84230136:-
COAD	cis	rs79349575	0.715	rs11657238	ENSG00000248278.1	SUMO2P17	4.05	6.7e-05	0.0163	0.26	0.25	Type 2 diabetes;	chr17:48908272	chr17:48874860~48908983:-
COAD	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	4.05	6.7e-05	0.0163	0.32	0.25	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
COAD	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-4.05	6.7e-05	0.0163	-0.25	-0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
COAD	cis	rs1023500	1	rs6002548	ENSG00000237037.8	NDUFA6-AS1	4.05	6.71e-05	0.0163	0.27	0.25	Schizophrenia;	chr22:41941036	chr22:42090931~42137742:+
COAD	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	4.05	6.71e-05	0.0163	0.32	0.25	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	4.05	6.71e-05	0.0163	0.32	0.25	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
COAD	cis	rs253959	0.545	rs4921057	ENSG00000271918.1	CTD-2287O16.5	4.05	6.71e-05	0.0163	0.23	0.25	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116083807~116085416:-
COAD	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.05	6.71e-05	0.0163	-0.4	-0.25	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
COAD	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.05	6.71e-05	0.0163	-0.4	-0.25	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
COAD	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-4.05	6.71e-05	0.0163	-0.23	-0.25	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
COAD	cis	rs7615952	0.8	rs12489350	ENSG00000241278.1	ENPP7P4	4.05	6.71e-05	0.0163	0.27	0.25	Blood pressure (smoking interaction);	chr3:125925273	chr3:125848223~125909372:+
COAD	cis	rs9307551	0.857	rs2218212	ENSG00000250334.4	LINC00989	-4.05	6.72e-05	0.0163	-0.28	-0.25	Refractive error;	chr4:79614887	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.857	rs2218213	ENSG00000250334.4	LINC00989	-4.05	6.72e-05	0.0163	-0.28	-0.25	Refractive error;	chr4:79614890	chr4:79492416~79576460:+
COAD	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.05	6.73e-05	0.0163	0.38	0.25	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
COAD	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-4.05	6.73e-05	0.0163	-0.33	-0.25	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
COAD	cis	rs9532669	0.963	rs3736953	ENSG00000239827.7	SUGT1P3	-4.05	6.73e-05	0.0163	-0.21	-0.25	Cervical cancer;	chr13:40951450	chr13:40908159~40921774:-
COAD	cis	rs9813712	0.571	rs9855426	ENSG00000249846.5	RP11-77P16.4	4.05	6.73e-05	0.0163	0.28	0.25	Response to amphetamines;	chr3:130214475	chr3:130112550~130120579:+
COAD	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	4.05	6.73e-05	0.0163	0.29	0.25	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	4.05	6.73e-05	0.0163	0.29	0.25	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	4.05	6.73e-05	0.0163	0.29	0.25	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
COAD	cis	rs4819052	0.851	rs2838840	ENSG00000227039.5	ITGB2-AS1	-4.05	6.73e-05	0.0164	-0.22	-0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:44921051~44929678:+
COAD	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	4.05	6.73e-05	0.0164	0.29	0.25	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
COAD	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.05	6.73e-05	0.0164	0.21	0.25	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
COAD	cis	rs10876993	0.928	rs1689595	ENSG00000270039.1	RP11-571M6.17	4.05	6.74e-05	0.0164	0.27	0.25	Celiac disease or Rheumatoid arthritis;	chr12:57662980	chr12:57803838~57804415:+
COAD	cis	rs7646881	1	rs7646987	ENSG00000272087.1	RP11-379F4.7	-4.05	6.74e-05	0.0164	-0.35	-0.25	Tetralogy of Fallot;	chr3:158735653	chr3:158693120~158693768:-
COAD	cis	rs941898	0.846	rs3783334	ENSG00000258982.1	RP11-638I2.4	4.05	6.74e-05	0.0164	0.33	0.25	White matter hyperintensity burden;	chr14:100121942	chr14:100207407~100238555:-
COAD	cis	rs12497850	0.863	rs4858799	ENSG00000225399.4	RP11-3B7.1	4.05	6.75e-05	0.0164	0.27	0.25	Parkinson's disease;	chr3:48690771	chr3:49260085~49261316:+
COAD	cis	rs7577696	0.925	rs12617290	ENSG00000272716.1	RP11-563N4.1	-4.05	6.75e-05	0.0164	-0.26	-0.25	Inflammatory biomarkers;	chr2:32116339	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.925	rs7573543	ENSG00000272716.1	RP11-563N4.1	-4.05	6.75e-05	0.0164	-0.26	-0.25	Inflammatory biomarkers;	chr2:32117439	chr2:32165046~32165757:-
COAD	cis	rs1662342	0.673	rs4325658	ENSG00000264235.4	RP13-270P17.1	-4.05	6.75e-05	0.0164	-0.37	-0.25	QRS duration;	chr18:3286925	chr18:3255436~3261850:-
COAD	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	4.05	6.75e-05	0.0164	0.27	0.25	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
COAD	cis	rs72615157	0.664	rs6953580	ENSG00000078319.8	PMS2P1	-4.05	6.75e-05	0.0164	-0.32	-0.25	Lung function (FEV1/FVC);	chr7:100227652	chr7:100320992~100341908:-
COAD	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-4.05	6.76e-05	0.0164	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-4.05	6.76e-05	0.0164	-0.3	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
COAD	cis	rs2638953	0.962	rs10843159	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs61920564	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357000	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049550	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28358591	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049552	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361466	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049553	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361611	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049554	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28362819	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs12371222	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28363245	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049555	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28364919	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049556	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28365626	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049558	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.925	rs11049563	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs61920565	ENSG00000247934.4	RP11-967K21.1	-4.05	6.76e-05	0.0164	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28163298~28190738:-
COAD	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	4.05	6.76e-05	0.0164	0.32	0.24	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
COAD	cis	rs1559040	1	rs72800725	ENSG00000233266.1	HMGB1P31	-4.05	6.76e-05	0.0164	-0.38	-0.24	Sudden cardiac arrest;	chr2:54074000	chr2:54051334~54051760:+
COAD	cis	rs72827839	1	rs72827832	ENSG00000263412.1	RP5-890E16.2	4.05	6.76e-05	0.0164	0.36	0.24	Ease of getting up in the morning;	chr17:48329746	chr17:48045141~48048073:-
COAD	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	4.05	6.76e-05	0.0164	0.32	0.24	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
COAD	cis	rs4718428	0.705	rs3800817	ENSG00000272831.1	RP11-792A8.4	4.05	6.76e-05	0.0164	0.27	0.24	Corneal structure;	chr7:66798563	chr7:66739829~66740385:-
COAD	cis	rs6095360	0.966	rs13037557	ENSG00000222365.1	SNORD12B	-4.05	6.76e-05	0.0164	-0.23	-0.24	Intelligence (multi-trait analysis);	chr20:48918053	chr20:49280319~49280409:+
COAD	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	4.05	6.77e-05	0.0164	0.29	0.24	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
COAD	cis	rs9900062	1	rs2521879	ENSG00000270714.1	MINOS1P2	-4.05	6.77e-05	0.0164	-0.32	-0.24	QT interval;	chr17:64746560	chr17:64747264~64747492:-
COAD	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-4.05	6.77e-05	0.0164	-0.3	-0.24	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
COAD	cis	rs1137	0.857	rs150135	ENSG00000225439.2	BOLA3-AS1	-4.05	6.77e-05	0.0164	-0.26	-0.24	Myopia (pathological);	chr2:74721477	chr2:74148009~74150061:+
COAD	cis	rs73219805	0.759	rs3758098	ENSG00000228451.3	SDAD1P1	-4.05	6.77e-05	0.0164	-0.41	-0.24	Schizophrenia;	chr8:26381867	chr8:26379259~26382953:-
COAD	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-4.05	6.77e-05	0.0164	-0.41	-0.24	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
COAD	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	4.05	6.78e-05	0.0165	0.39	0.24	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
COAD	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-4.05	6.78e-05	0.0165	-0.22	-0.24	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-4.05	6.78e-05	0.0165	-0.22	-0.24	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
COAD	cis	rs2337406	0.587	rs11624678	ENSG00000211964.3	IGHV3-48	4.05	6.79e-05	0.0165	0.21	0.24	Alzheimer's disease (late onset);	chr14:106650408	chr14:106537810~106538344:-
COAD	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	4.05	6.79e-05	0.0165	0.27	0.24	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
COAD	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	4.05	6.79e-05	0.0165	0.14	0.24	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
COAD	cis	rs250677	0.798	rs11168080	ENSG00000250072.4	CTC-529P8.1	-4.05	6.79e-05	0.0165	-0.37	-0.24	Breast cancer;	chr5:149030258	chr5:149063317~149109787:+
COAD	cis	rs11588062	0.601	rs11579255	ENSG00000230896.1	RP11-767N6.7	4.05	6.79e-05	0.0165	0.29	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:46341287	chr1:45694684~45697075:-
COAD	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-4.05	6.79e-05	0.0165	-0.47	-0.24	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
COAD	cis	rs4820539	1	rs3788347	ENSG00000211644.2	IGLV1-51	-4.05	6.79e-05	0.0165	-0.14	-0.24	Bone mineral density;	chr22:23125617	chr22:22322472~22322980:+
COAD	cis	rs867186	1	rs8117847	ENSG00000201151.1	SNORD56	4.05	6.8e-05	0.0165	0.34	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35054677	chr20:35117136~35117207:-
COAD	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-4.05	6.8e-05	0.0165	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
COAD	cis	rs394563	0.717	rs548848	ENSG00000231760.4	RP11-350J20.5	4.05	6.81e-05	0.0165	0.31	0.24	Dupuytren's disease;	chr6:149460873	chr6:149796151~149826294:-
COAD	cis	rs394563	0.775	rs399673	ENSG00000231760.4	RP11-350J20.5	4.05	6.81e-05	0.0165	0.31	0.24	Dupuytren's disease;	chr6:149462085	chr6:149796151~149826294:-
COAD	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	4.05	6.81e-05	0.0165	0.31	0.24	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
COAD	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	4.05	6.81e-05	0.0165	0.31	0.24	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
COAD	cis	rs74233809	0.892	rs11191447	ENSG00000213277.3	MARCKSL1P1	4.05	6.81e-05	0.0165	0.51	0.24	Birth weight;	chr10:102892566	chr10:103175554~103176094:+
COAD	cis	rs11638352	1	rs2733221	ENSG00000205771.5	CATSPER2P1	4.05	6.81e-05	0.0165	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44097672	chr15:43726918~43747094:-
COAD	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	4.05	6.81e-05	0.0165	0.29	0.24	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
COAD	cis	rs11976180	1	rs2951308	ENSG00000273234.1	OR2A13P	4.05	6.81e-05	0.0165	0.3	0.24	Obesity-related traits;	chr7:144070056	chr7:144142009~144142938:+
COAD	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-4.05	6.82e-05	0.0165	-0.38	-0.24	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
COAD	cis	rs12928939	0.815	rs11648483	ENSG00000260886.1	TAT-AS1	4.05	6.82e-05	0.0165	0.34	0.24	Post bronchodilator FEV1;	chr16:71673495	chr16:71565789~71578187:+
COAD	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-4.05	6.82e-05	0.0165	-0.28	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
COAD	cis	rs3752645	0.764	rs17424512	ENSG00000241764.3	AC002467.7	4.05	6.82e-05	0.0165	0.49	0.24	Bladder cancer (smoking interaction);	chr7:107026785	chr7:107742817~107744581:-
COAD	cis	rs3752645	0.764	rs79940347	ENSG00000241764.3	AC002467.7	4.05	6.82e-05	0.0165	0.49	0.24	Bladder cancer (smoking interaction);	chr7:107039312	chr7:107742817~107744581:-
COAD	cis	rs2638953	0.962	rs12370271	ENSG00000247934.4	RP11-967K21.1	-4.05	6.82e-05	0.0165	-0.27	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313840	chr12:28163298~28190738:-
COAD	cis	rs453301	0.658	rs13271797	ENSG00000254340.1	RP11-10A14.3	-4.05	6.83e-05	0.0165	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9028444	chr8:9141424~9145435:+
COAD	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-4.05	6.83e-05	0.0165	-0.3	-0.24	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
COAD	cis	rs7829975	0.564	rs2976855	ENSG00000254340.1	RP11-10A14.3	4.05	6.83e-05	0.0165	0.27	0.24	Mood instability;	chr8:8444284	chr8:9141424~9145435:+
COAD	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	4.05	6.83e-05	0.0166	0.31	0.24	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
COAD	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	4.05	6.83e-05	0.0166	0.28	0.24	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
COAD	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	4.05	6.83e-05	0.0166	0.5	0.24	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
COAD	cis	rs253959	0.672	rs1133186	ENSG00000271918.1	CTD-2287O16.5	4.05	6.84e-05	0.0166	0.21	0.24	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116083807~116085416:-
COAD	cis	rs858239	0.509	rs57611130	ENSG00000226816.2	AC005082.12	4.05	6.84e-05	0.0166	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23206013~23208045:+
COAD	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	4.05	6.84e-05	0.0166	0.29	0.24	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
COAD	cis	rs12699921	0.632	rs2254176	ENSG00000279048.1	RP11-511H23.2	-4.05	6.85e-05	0.0166	-0.18	-0.24	Fibrinogen levels;	chr7:17785981	chr7:17940503~17942922:+
COAD	cis	rs2564921	0.704	rs2336720	ENSG00000280417.1	RP11-5O17.1	4.05	6.85e-05	0.0166	0.26	0.24	Height;	chr3:52994045	chr3:53046166~53048122:+
COAD	cis	rs2564921	0.73	rs56384586	ENSG00000280417.1	RP11-5O17.1	4.05	6.85e-05	0.0166	0.26	0.24	Height;	chr3:52994990	chr3:53046166~53048122:+
COAD	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	4.05	6.85e-05	0.0166	0.29	0.24	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
COAD	cis	rs4819052	0.765	rs2838854	ENSG00000227039.5	ITGB2-AS1	-4.05	6.85e-05	0.0166	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:44921051~44929678:+
COAD	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	4.05	6.85e-05	0.0166	0.28	0.24	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
COAD	cis	rs10170310	0.872	rs62161711	ENSG00000228043.4	AC097721.2	4.05	6.85e-05	0.0166	0.3	0.24	Response to antipsychotic treatment;	chr2:138501652	chr2:138418284~138501698:-
COAD	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	4.05	6.86e-05	0.0166	0.31	0.24	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
COAD	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	4.05	6.86e-05	0.0166	0.25	0.24	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
COAD	cis	rs2559856	1	rs2695285	ENSG00000199933.1	RNY1P16	4.05	6.86e-05	0.0166	0.26	0.24	Blood protein levels;	chr12:101695265	chr12:101719808~101719918:+
COAD	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	4.05	6.86e-05	0.0166	0.29	0.24	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
COAD	cis	rs8061903	0.535	rs17681488	ENSG00000261617.1	RP11-243A14.1	-4.05	6.86e-05	0.0166	-0.31	-0.24	HIV-1 viral setpoint;	chr16:9309236	chr16:9355588~9408093:+
COAD	cis	rs860295	0.702	rs475550	ENSG00000223503.1	RP11-29H23.6	-4.05	6.86e-05	0.0166	-0.33	-0.24	Body mass index;	chr1:155682290	chr1:155590601~155591262:-
COAD	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-4.05	6.87e-05	0.0166	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
COAD	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	4.05	6.87e-05	0.0166	0.27	0.24	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
COAD	cis	rs2243480	0.666	rs1880311	ENSG00000232559.3	GS1-124K5.12	-4.05	6.87e-05	0.0166	-0.46	-0.24	Diabetic kidney disease;	chr7:65811765	chr7:66554588~66576923:-
COAD	cis	rs875971	0.545	rs12671152	ENSG00000224316.1	RP11-479O9.2	4.05	6.87e-05	0.0166	0.31	0.24	Aortic root size;	chr7:66311140	chr7:65773620~65802067:+
COAD	cis	rs8141529	0.732	rs5997408	ENSG00000272858.1	CTA-292E10.8	-4.05	6.87e-05	0.0166	-0.29	-0.24	Lymphocyte counts;	chr22:28811927	chr22:28814914~28815662:+
COAD	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-4.05	6.88e-05	0.0166	-0.3	-0.24	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
COAD	cis	rs6715284	1	rs2019097	ENSG00000232133.1	IMPDH1P10	-4.05	6.88e-05	0.0166	-0.39	-0.24	Rheumatoid arthritis;	chr2:201328740	chr2:201137516~201140027:-
COAD	cis	rs7615952	0.736	rs13063122	ENSG00000272840.1	RP11-379B18.6	4.05	6.88e-05	0.0166	0.34	0.24	Blood pressure (smoking interaction);	chr3:125925017	chr3:125774714~125797953:+
COAD	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	4.05	6.89e-05	0.0167	0.32	0.24	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
COAD	cis	rs17685	0.712	rs11770149	ENSG00000280388.1	RP11-229D13.3	-4.05	6.89e-05	0.0167	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76043977~76045963:-
COAD	cis	rs17685	0.593	rs56265719	ENSG00000280388.1	RP11-229D13.3	-4.05	6.89e-05	0.0167	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76043977~76045963:-
COAD	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-4.05	6.89e-05	0.0167	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
COAD	cis	rs987724	0.574	rs2321292	ENSG00000240875.4	LINC00886	-4.05	6.89e-05	0.0167	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156925970	chr3:156747346~156817062:-
COAD	cis	rs2919009	0.607	rs61088531	ENSG00000271670.1	RP11-95I16.4	4.05	6.89e-05	0.0167	0.34	0.24	Obesity-related traits;	chr10:120946696	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.607	rs61872773	ENSG00000271670.1	RP11-95I16.4	4.05	6.89e-05	0.0167	0.34	0.24	Obesity-related traits;	chr10:120946998	chr10:120879256~120880667:-
COAD	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-4.05	6.89e-05	0.0167	-0.24	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
COAD	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-4.05	6.89e-05	0.0167	-0.37	-0.24	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
COAD	cis	rs13256369	0.95	rs13270006	ENSG00000253981.4	ALG1L13P	4.05	6.89e-05	0.0167	0.35	0.24	Obesity-related traits;	chr8:8716687	chr8:8236003~8244667:-
COAD	cis	rs17685	0.712	rs1859792	ENSG00000280388.1	RP11-229D13.3	-4.05	6.89e-05	0.0167	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76043977~76045963:-
COAD	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-4.05	6.89e-05	0.0167	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
COAD	cis	rs2765539	1	rs7525637	ENSG00000231365.4	RP11-418J17.1	-4.05	6.9e-05	0.0167	-0.29	-0.24	Waist-hip ratio;	chr1:119000848	chr1:119140396~119275973:+
COAD	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	4.05	6.9e-05	0.0167	0.35	0.24	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
COAD	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	4.05	6.9e-05	0.0167	0.28	0.24	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
COAD	cis	rs860295	0.812	rs10908481	ENSG00000160766.13	GBAP1	-4.05	6.9e-05	0.0167	-0.28	-0.24	Body mass index;	chr1:155743859	chr1:155213821~155227422:-
COAD	cis	rs12530	0.715	rs5749428	ENSG00000230736.2	RP1-149A16.3	-4.05	6.9e-05	0.0167	-0.3	-0.24	IgG glycosylation;	chr22:32403709	chr22:32376664~32384343:+
COAD	cis	rs9532669	0.963	rs9532662	ENSG00000277662.1	RP11-74J13.9	-4.05	6.9e-05	0.0167	-0.22	-0.24	Cervical cancer;	chr13:40926215	chr13:41229180~41229676:-
COAD	cis	rs1510272	0.961	rs7644461	ENSG00000243926.1	TIPARP-AS1	-4.05	6.9e-05	0.0167	-0.28	-0.24	Testicular germ cell tumor;	chr3:156598903	chr3:156671862~156674378:-
COAD	cis	rs2408955	0.522	rs3997	ENSG00000273765.1	RP11-370I10.11	-4.05	6.9e-05	0.0167	-0.26	-0.24	Glycated hemoglobin levels;	chr12:48087804	chr12:48360920~48361377:+
COAD	cis	rs2408955	0.522	rs11168408	ENSG00000273765.1	RP11-370I10.11	-4.05	6.9e-05	0.0167	-0.26	-0.24	Glycated hemoglobin levels;	chr12:48104544	chr12:48360920~48361377:+
COAD	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-4.05	6.9e-05	0.0167	-0.24	-0.24	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
COAD	cis	rs11138902	0.673	rs2297420	ENSG00000229312.2	RP11-470P21.2	4.05	6.9e-05	0.0167	0.28	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69494122	chr9:69472466~69494513:+
COAD	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-4.05	6.91e-05	0.0167	-0.3	-0.24	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
COAD	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-4.05	6.91e-05	0.0167	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
COAD	cis	rs113835537	0.529	rs78999944	ENSG00000258297.1	RP11-658F2.8	-4.05	6.91e-05	0.0167	-0.25	-0.24	Airway imaging phenotypes;	chr11:66483757	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs11550299	ENSG00000258297.1	RP11-658F2.8	-4.05	6.91e-05	0.0167	-0.25	-0.24	Airway imaging phenotypes;	chr11:66486614	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs4930379	ENSG00000258297.1	RP11-658F2.8	-4.05	6.91e-05	0.0167	-0.25	-0.24	Airway imaging phenotypes;	chr11:66488203	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs4930183	ENSG00000258297.1	RP11-658F2.8	-4.05	6.91e-05	0.0167	-0.25	-0.24	Airway imaging phenotypes;	chr11:66488261	chr11:66666036~66668374:+
COAD	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	4.05	6.91e-05	0.0167	0.53	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
COAD	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	4.05	6.91e-05	0.0167	0.46	0.24	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	4.05	6.91e-05	0.0167	0.46	0.24	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	4.05	6.91e-05	0.0167	0.46	0.24	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
COAD	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	4.05	6.91e-05	0.0167	0.29	0.24	Height;	chr4:55531150	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	4.05	6.91e-05	0.0167	0.29	0.24	Height;	chr4:55531218	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	4.05	6.91e-05	0.0167	0.29	0.24	Height;	chr4:55531811	chr4:55547112~55547889:+
COAD	cis	rs752010	0.806	rs1109255	ENSG00000230638.4	RP11-486B10.4	-4.05	6.91e-05	0.0167	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41626037	chr1:41542069~41544310:+
COAD	cis	rs4763879	0.729	rs10844472	ENSG00000278635.1	CTD-2318O12.1	4.05	6.92e-05	0.0167	0.23	0.24	Type 1 diabetes;	chr12:9691137	chr12:9415641~9416718:+
COAD	cis	rs78487399	0.71	rs13408002	ENSG00000234936.1	AC010883.5	4.05	6.92e-05	0.0167	0.37	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43382888	chr2:43229573~43233394:+
COAD	cis	rs2638953	0.886	rs11049594	ENSG00000247934.4	RP11-967K21.1	4.05	6.92e-05	0.0167	0.26	0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28163298~28190738:-
COAD	cis	rs7584330	0.704	rs72620820	ENSG00000234949.2	AC104667.3	-4.05	6.92e-05	0.0167	-0.33	-0.24	Prostate cancer;	chr2:237450201	chr2:237591020~237595981:+
COAD	cis	rs71636778	0.509	rs12752711	ENSG00000260063.1	RP5-968P14.2	-4.05	6.92e-05	0.0167	-0.51	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26923767	chr1:26692132~26694131:-
COAD	cis	rs4973517	0.719	rs3116231	ENSG00000237126.7	AC073254.1	-4.04	6.93e-05	0.0167	-0.35	-0.24	Hip circumference adjusted for BMI;	chr2:232027573	chr2:232580948~232611971:-
COAD	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-4.04	6.93e-05	0.0167	-0.38	-0.24	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
COAD	cis	rs11681884	0.892	rs73955148	ENSG00000228251.1	AC012442.6	4.04	6.93e-05	0.0167	0.53	0.24	Stroke;	chr2:113101200	chr2:112590796~112591939:+
COAD	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	4.04	6.93e-05	0.0167	0.28	0.24	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
COAD	cis	rs2581828	0.618	rs9828221	ENSG00000280417.1	RP11-5O17.1	4.04	6.93e-05	0.0167	0.27	0.24	Crohn's disease;	chr3:53132643	chr3:53046166~53048122:+
COAD	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-4.04	6.94e-05	0.0168	-0.35	-0.24	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
COAD	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-4.04	6.94e-05	0.0168	-0.35	-0.24	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
COAD	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-4.04	6.94e-05	0.0168	-0.35	-0.24	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
COAD	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	4.04	6.94e-05	0.0168	0.26	0.24	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
COAD	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-4.04	6.94e-05	0.0168	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
COAD	cis	rs4660214	0.666	rs4617393	ENSG00000182109.6	RP11-69E11.4	-4.04	6.95e-05	0.0168	-0.27	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39522280~39546187:-
COAD	cis	rs3733585	0.699	rs1122142	ENSG00000250413.1	RP11-448G15.1	4.04	6.95e-05	0.0168	0.32	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9945924	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs4339211	ENSG00000250413.1	RP11-448G15.1	4.04	6.95e-05	0.0168	0.32	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9946034	chr4:10006482~10009725:+
COAD	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-4.04	6.95e-05	0.0168	-0.3	-0.24	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
COAD	cis	rs7646881	0.812	rs75267618	ENSG00000272087.1	RP11-379F4.7	4.04	6.95e-05	0.0168	0.37	0.24	Tetralogy of Fallot;	chr3:158726027	chr3:158693120~158693768:-
COAD	cis	rs1387259	0.79	rs2732445	ENSG00000226413.2	OR8T1P	4.04	6.95e-05	0.0168	0.31	0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48442030~48442947:-
COAD	cis	rs74233809	1	rs35125602	ENSG00000213277.3	MARCKSL1P1	4.04	6.95e-05	0.0168	0.48	0.24	Birth weight;	chr10:102896282	chr10:103175554~103176094:+
COAD	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	4.04	6.95e-05	0.0168	0.28	0.24	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
COAD	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	4.04	6.95e-05	0.0168	0.29	0.24	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
COAD	cis	rs67180937	0.542	rs61824282	ENSG00000225265.1	TAF1A-AS1	4.04	6.95e-05	0.0168	0.26	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222589825~222593032:+
COAD	cis	rs10779751	0.879	rs7543400	ENSG00000215785.2	CFL1P6	-4.04	6.95e-05	0.0168	-0.27	-0.24	Body mass index;	chr1:11223907	chr1:10990978~10991797:-
COAD	cis	rs10779751	1	rs12730522	ENSG00000215785.2	CFL1P6	-4.04	6.95e-05	0.0168	-0.27	-0.24	Body mass index;	chr1:11224034	chr1:10990978~10991797:-
COAD	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	4.04	6.96e-05	0.0168	0.33	0.24	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	4.04	6.96e-05	0.0168	0.33	0.24	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
COAD	cis	rs480407	0.667	rs62195648	ENSG00000232320.6	AC009299.5	4.04	6.96e-05	0.0168	0.33	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160780809	chr2:161340816~161341326:-
COAD	cis	rs3764400	0.567	rs36071506	ENSG00000278765.1	RP5-890E16.5	4.04	6.96e-05	0.0168	0.46	0.24	Body mass index;	chr17:48202410	chr17:48066704~48067293:-
COAD	cis	rs3126085	0.935	rs3126088	ENSG00000237975.5	FLG-AS1	4.04	6.96e-05	0.0168	0.28	0.24	Atopic dermatitis;	chr1:152333309	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs2338555	ENSG00000237975.5	FLG-AS1	4.04	6.96e-05	0.0168	0.28	0.24	Atopic dermatitis;	chr1:152336904	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs2338556	ENSG00000237975.5	FLG-AS1	4.04	6.96e-05	0.0168	0.28	0.24	Atopic dermatitis;	chr1:152336951	chr1:152168125~152445456:+
COAD	cis	rs7577696	0.962	rs4952248	ENSG00000272716.1	RP11-563N4.1	-4.04	6.96e-05	0.0168	-0.26	-0.24	Inflammatory biomarkers;	chr2:32118600	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs4952250	ENSG00000272716.1	RP11-563N4.1	-4.04	6.96e-05	0.0168	-0.26	-0.24	Inflammatory biomarkers;	chr2:32118630	chr2:32165046~32165757:-
COAD	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-4.04	6.96e-05	0.0168	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
COAD	cis	rs73198271	0.641	rs34473848	ENSG00000173295.6	FAM86B3P	-4.04	6.96e-05	0.0168	-0.32	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.601	rs11997731	ENSG00000173295.6	FAM86B3P	-4.04	6.96e-05	0.0168	-0.32	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8228595~8244865:+
COAD	cis	rs55661361	0.965	rs12293670	ENSG00000245498.5	RP11-677M14.7	4.04	6.96e-05	0.0168	0.22	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124743036	chr11:124800450~124834487:+
COAD	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-4.04	6.96e-05	0.0168	-0.28	-0.24	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
COAD	cis	rs3764400	0.567	rs9890691	ENSG00000278765.1	RP5-890E16.5	-4.04	6.97e-05	0.0168	-0.46	-0.24	Body mass index;	chr17:48115574	chr17:48066704~48067293:-
COAD	cis	rs72827839	1	rs72827830	ENSG00000263412.1	RP5-890E16.2	4.04	6.97e-05	0.0168	0.36	0.24	Ease of getting up in the morning;	chr17:48320140	chr17:48045141~48048073:-
COAD	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	4.04	6.97e-05	0.0168	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
COAD	cis	rs1275468	1	rs17115231	ENSG00000257497.2	RP11-585P4.5	-4.04	6.97e-05	0.0168	-0.31	-0.24	Polycystic ovary syndrome;	chr12:75539895	chr12:75483454~75489820:-
COAD	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-4.04	6.97e-05	0.0168	-0.47	-0.24	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
COAD	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	4.04	6.97e-05	0.0168	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
COAD	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	4.04	6.97e-05	0.0168	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
COAD	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	4.04	6.98e-05	0.0168	0.33	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
COAD	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-4.04	6.98e-05	0.0168	-0.21	-0.24	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
COAD	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-4.04	6.98e-05	0.0168	-0.3	-0.24	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-4.04	6.98e-05	0.0168	-0.3	-0.24	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
COAD	cis	rs1048886	0.872	rs7741265	ENSG00000271967.1	RP11-134K13.4	-4.04	6.98e-05	0.0168	-0.35	-0.24	Type 2 diabetes;	chr6:70575675	chr6:70596438~70596980:+
COAD	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	4.04	6.98e-05	0.0168	0.31	0.24	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
COAD	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-4.04	6.98e-05	0.0168	-0.26	-0.24	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
COAD	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-4.04	6.98e-05	0.0168	-0.26	-0.24	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
COAD	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-4.04	6.98e-05	0.0168	-0.26	-0.24	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
COAD	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-4.04	6.98e-05	0.0168	-0.41	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
COAD	cis	rs2919009	0.581	rs2118962	ENSG00000271670.1	RP11-95I16.4	4.04	6.98e-05	0.0168	0.32	0.24	Obesity-related traits;	chr10:120937721	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.581	rs56118695	ENSG00000271670.1	RP11-95I16.4	4.04	6.98e-05	0.0168	0.32	0.24	Obesity-related traits;	chr10:120938383	chr10:120879256~120880667:-
COAD	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-4.04	6.98e-05	0.0168	-0.36	-0.24	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
COAD	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	4.04	6.98e-05	0.0168	0.26	0.24	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
COAD	cis	rs4698412	0.874	rs3213710	ENSG00000214846.4	RP11-115L11.1	-4.04	6.98e-05	0.0168	-0.3	-0.24	Parkinson's disease;	chr4:15715698	chr4:15730962~15731627:-
COAD	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-4.04	6.98e-05	0.0168	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
COAD	cis	rs72700829	0.593	rs80350997	ENSG00000223861.1	RP11-74C1.2	-4.04	6.98e-05	0.0168	-0.47	-0.24	Schizophrenia;	chr1:151019534	chr1:151557446~151557940:+
COAD	cis	rs72700829	0.593	rs77209899	ENSG00000223861.1	RP11-74C1.2	-4.04	6.98e-05	0.0168	-0.47	-0.24	Schizophrenia;	chr1:151019543	chr1:151557446~151557940:+
COAD	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	4.04	6.98e-05	0.0168	0.36	0.24	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
COAD	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-4.04	6.99e-05	0.0168	-0.29	-0.24	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
COAD	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	4.04	6.99e-05	0.0168	0.32	0.24	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	4.04	6.99e-05	0.0168	0.32	0.24	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	4.04	6.99e-05	0.0168	0.32	0.24	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
COAD	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
COAD	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
COAD	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	4.04	6.99e-05	0.0168	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
COAD	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-4.04	6.99e-05	0.0169	-0.29	-0.24	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-4.04	6.99e-05	0.0169	-0.29	-0.24	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-4.04	6.99e-05	0.0169	-0.29	-0.24	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
COAD	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-4.04	6.99e-05	0.0169	-0.29	-0.24	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
COAD	cis	rs74394007	0.541	rs6441103	ENSG00000240875.4	LINC00886	4.04	6.99e-05	0.0169	0.26	0.24	Total body bone mineral density;	chr3:156925596	chr3:156747346~156817062:-
COAD	cis	rs4820539	1	rs885965	ENSG00000211644.2	IGLV1-51	-4.04	6.99e-05	0.0169	-0.14	-0.24	Bone mineral density;	chr22:23119238	chr22:22322472~22322980:+
COAD	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	4.04	7e-05	0.0169	0.32	0.24	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
COAD	cis	rs853679	0.723	rs1736904	ENSG00000204709.4	LINC01556	4.04	7e-05	0.0169	0.36	0.24	Depression;	chr6:28251492	chr6:28943877~28944537:+
COAD	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	4.04	7e-05	0.0169	0.43	0.24	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
COAD	cis	rs454422	1	rs6053816	ENSG00000275632.1	RP5-967N21.11	4.04	7e-05	0.0169	0.28	0.24	HIV-1 viral setpoint;	chr20:5990104	chr20:6000418~6000941:+
COAD	cis	rs5758511	0.596	rs55644935	ENSG00000237037.8	NDUFA6-AS1	-4.04	7e-05	0.0169	-0.29	-0.24	Birth weight;	chr22:42270063	chr22:42090931~42137742:+
COAD	cis	rs7577696	0.597	rs6756085	ENSG00000272716.1	RP11-563N4.1	-4.04	7e-05	0.0169	-0.28	-0.24	Inflammatory biomarkers;	chr2:32111453	chr2:32165046~32165757:-
COAD	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	4.04	7e-05	0.0169	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
COAD	cis	rs964184	0.63	rs9326246	ENSG00000254851.1	RP11-109L13.1	-4.04	7.01e-05	0.0169	-0.49	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116741017	chr11:117135528~117138582:+
COAD	cis	rs8035957	0.544	rs28438860	ENSG00000259225.5	RP11-1008C21.1	-4.04	7.01e-05	0.0169	-0.38	-0.24	Type 1 diabetes;	chr15:38565861	chr15:37984766~38062340:+
COAD	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-4.04	7.01e-05	0.0169	-0.26	-0.24	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
COAD	cis	rs6840360	0.582	rs2709812	ENSG00000251611.1	RP11-610P16.1	4.04	7.01e-05	0.0169	0.23	0.24	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151407551~151408835:-
COAD	cis	rs7818688	1	rs6651272	ENSG00000253528.2	RP11-347C18.4	4.04	7.01e-05	0.0169	0.37	0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035705	chr8:94974573~94974853:-
COAD	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	4.04	7.01e-05	0.0169	0.39	0.24	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
COAD	cis	rs28374715	0.635	rs28557159	ENSG00000247556.5	OIP5-AS1	4.04	7.01e-05	0.0169	0.3	0.24	Ulcerative colitis;	chr15:41365155	chr15:41283990~41309737:+
COAD	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-4.04	7.01e-05	0.0169	-0.27	-0.24	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
COAD	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-4.04	7.02e-05	0.0169	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
COAD	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-4.04	7.02e-05	0.0169	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
COAD	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-4.04	7.02e-05	0.0169	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
COAD	cis	rs2976388	0.556	rs10956985	ENSG00000247317.3	RP11-273G15.2	4.04	7.02e-05	0.0169	0.29	0.24	Urinary tract infection frequency;	chr8:142737332	chr8:142981738~143018437:-
COAD	cis	rs11098499	0.722	rs1814814	ENSG00000249244.1	RP11-548H18.2	4.04	7.02e-05	0.0169	0.32	0.24	Corneal astigmatism;	chr4:119336969	chr4:119391831~119395335:-
COAD	cis	rs8046148	0.724	rs7203348	ENSG00000260381.2	RP11-429P3.5	-4.04	7.02e-05	0.0169	-0.32	-0.24	Testicular germ cell tumor;	chr16:50078356	chr16:50100339~50121943:-
COAD	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	4.04	7.03e-05	0.0169	0.4	0.24	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
COAD	cis	rs9880211	1	rs28641809	ENSG00000273486.1	RP11-731C17.2	4.04	7.03e-05	0.0169	0.28	0.24	Height;Body mass index;	chr3:136571647	chr3:136837338~136839021:-
COAD	cis	rs2638953	0.925	rs11049584	ENSG00000247934.4	RP11-967K21.1	-4.04	7.03e-05	0.0169	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417879	chr12:28163298~28190738:-
COAD	cis	rs57221529	0.713	rs12521091	ENSG00000250385.1	RP11-310P5.2	4.04	7.03e-05	0.0169	0.42	0.24	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:524705~526594:+
COAD	cis	rs480407	0.667	rs55909859	ENSG00000232320.6	AC009299.5	4.04	7.03e-05	0.0169	0.33	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160778168	chr2:161340816~161341326:-
COAD	cis	rs875971	0.755	rs10228885	ENSG00000224316.1	RP11-479O9.2	-4.04	7.04e-05	0.0169	-0.27	-0.24	Aortic root size;	chr7:66315542	chr7:65773620~65802067:+
COAD	cis	rs7584330	0.504	rs11890255	ENSG00000234949.2	AC104667.3	-4.04	7.04e-05	0.0169	-0.36	-0.24	Prostate cancer;	chr2:237525962	chr2:237591020~237595981:+
COAD	cis	rs74233809	1	rs74233296	ENSG00000213277.3	MARCKSL1P1	4.04	7.04e-05	0.0169	0.51	0.24	Birth weight;	chr10:102895593	chr10:103175554~103176094:+
COAD	cis	rs28374715	0.733	rs7167706	ENSG00000247556.5	OIP5-AS1	4.04	7.04e-05	0.0169	0.34	0.24	Ulcerative colitis;	chr15:41277446	chr15:41283990~41309737:+
COAD	cis	rs10043775	1	rs34269182	ENSG00000251330.3	CTD-2283N19.1	-4.04	7.04e-05	0.0169	-0.28	-0.24	Periodontal microbiota;	chr5:148444850	chr5:148430159~148430807:-
COAD	cis	rs10043775	0.874	rs4574533	ENSG00000251330.3	CTD-2283N19.1	-4.04	7.04e-05	0.0169	-0.28	-0.24	Periodontal microbiota;	chr5:148445782	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs4274967	ENSG00000251330.3	CTD-2283N19.1	-4.04	7.04e-05	0.0169	-0.28	-0.24	Periodontal microbiota;	chr5:148445876	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs9325098	ENSG00000251330.3	CTD-2283N19.1	-4.04	7.04e-05	0.0169	-0.28	-0.24	Periodontal microbiota;	chr5:148447875	chr5:148430159~148430807:-
COAD	cis	rs9907295	0.584	rs7215845	ENSG00000270977.1	AC015849.16	-4.04	7.04e-05	0.0169	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35893707~35911023:-
COAD	cis	rs9907295	0.591	rs4796128	ENSG00000270977.1	AC015849.16	-4.04	7.04e-05	0.0169	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35893707~35911023:-
COAD	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-4.04	7.04e-05	0.017	-0.3	-0.24	Height;	chr4:55487920	chr4:55547112~55547889:+
COAD	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	4.04	7.04e-05	0.017	0.29	0.24	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
COAD	cis	rs7009110	0.652	rs13267071	ENSG00000213791.4	RP11-941H19.2	4.04	7.05e-05	0.017	0.23	0.24	Asthma and hay fever;	chr8:80343712	chr8:80300869~80301481:+
COAD	cis	rs7009110	0.652	rs13265296	ENSG00000213791.4	RP11-941H19.2	4.04	7.05e-05	0.017	0.23	0.24	Asthma and hay fever;	chr8:80343806	chr8:80300869~80301481:+
COAD	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	4.04	7.05e-05	0.017	0.23	0.24	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
COAD	cis	rs8022206	0.68	rs4902545	ENSG00000259502.1	RP11-643G16.3	4.04	7.05e-05	0.017	0.34	0.24	Platelet count;Mean platelet volume;	chr14:68061161	chr14:67610986~67613864:+
COAD	cis	rs2919009	0.664	rs10510083	ENSG00000271670.1	RP11-95I16.4	4.04	7.05e-05	0.017	0.3	0.24	Obesity-related traits;	chr10:120925013	chr10:120879256~120880667:-
COAD	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	4.04	7.06e-05	0.017	0.31	0.24	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
COAD	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-4.04	7.06e-05	0.017	-0.29	-0.24	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
COAD	cis	rs2496589	0.889	rs9321908	ENSG00000218896.1	TUBB8P2	4.04	7.06e-05	0.017	0.28	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430477	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.791	rs9496623	ENSG00000218896.1	TUBB8P2	4.04	7.06e-05	0.017	0.28	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430488	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.791	rs9496624	ENSG00000218896.1	TUBB8P2	4.04	7.06e-05	0.017	0.28	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430490	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.824	rs9496625	ENSG00000218896.1	TUBB8P2	4.04	7.06e-05	0.017	0.28	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430496	chr6:143436216~143436710:+
COAD	cis	rs507080	0.922	rs4936433	ENSG00000278376.1	RP11-158I9.8	4.04	7.06e-05	0.017	0.25	0.24	Serum metabolite levels;	chr11:118681711	chr11:118791254~118793137:+
COAD	cis	rs2408955	0.522	rs7139330	ENSG00000226413.2	OR8T1P	-4.04	7.07e-05	0.017	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48089701	chr12:48442030~48442947:-
COAD	cis	rs2408955	0.522	rs2051851	ENSG00000226413.2	OR8T1P	-4.04	7.07e-05	0.017	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48092157	chr12:48442030~48442947:-
COAD	cis	rs2408955	0.522	rs973398	ENSG00000226413.2	OR8T1P	-4.04	7.07e-05	0.017	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48097265	chr12:48442030~48442947:-
COAD	cis	rs62246343	0.786	rs62246267	ENSG00000254485.4	RP11-380O24.1	4.04	7.07e-05	0.017	0.32	0.24	Fibrinogen levels;	chr3:9361477	chr3:9292588~9363303:-
COAD	cis	rs763121	0.853	rs5750672	ENSG00000273076.1	RP3-508I15.22	-4.04	7.07e-05	0.017	-0.22	-0.24	Menopause (age at onset);	chr22:38708163	chr22:38743495~38743910:+
COAD	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-4.04	7.07e-05	0.017	-0.33	-0.24	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
COAD	cis	rs7131987	0.834	rs1989478	ENSG00000257176.2	RP11-996F15.2	-4.04	7.07e-05	0.017	-0.29	-0.24	QT interval;	chr12:29289296	chr12:29280418~29317848:-
COAD	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	4.04	7.08e-05	0.017	0.26	0.24	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
COAD	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	4.04	7.08e-05	0.017	0.43	0.24	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
COAD	cis	rs9796	0.558	rs7166205	ENSG00000247556.5	OIP5-AS1	4.04	7.08e-05	0.017	0.24	0.24	Menopause (age at onset);	chr15:41222535	chr15:41283990~41309737:+
COAD	cis	rs9796	0.558	rs7166905	ENSG00000247556.5	OIP5-AS1	4.04	7.08e-05	0.017	0.24	0.24	Menopause (age at onset);	chr15:41222678	chr15:41283990~41309737:+
COAD	cis	rs74233809	1	rs11191453	ENSG00000213277.3	MARCKSL1P1	4.04	7.08e-05	0.017	0.48	0.24	Birth weight;	chr10:102900095	chr10:103175554~103176094:+
COAD	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-4.04	7.08e-05	0.017	-0.47	-0.24	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-4.04	7.08e-05	0.017	-0.47	-0.24	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-4.04	7.08e-05	0.017	-0.47	-0.24	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-4.04	7.08e-05	0.017	-0.47	-0.24	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
COAD	cis	rs4819052	0.851	rs2838843	ENSG00000227039.5	ITGB2-AS1	-4.04	7.08e-05	0.017	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:44921051~44929678:+
COAD	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	4.04	7.08e-05	0.017	0.3	0.24	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
COAD	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	4.04	7.08e-05	0.017	0.34	0.24	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
COAD	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	4.04	7.08e-05	0.017	0.34	0.24	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
COAD	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-4.04	7.09e-05	0.017	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
COAD	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	4.04	7.09e-05	0.017	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
COAD	cis	rs9818758	0.607	rs5030795	ENSG00000225399.4	RP11-3B7.1	-4.04	7.09e-05	0.017	-0.43	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:49260085~49261316:+
COAD	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	4.04	7.09e-05	0.017	0.29	0.24	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
COAD	cis	rs55962025	0.804	rs2269499	ENSG00000248840.2	RP11-357G3.2	4.04	7.09e-05	0.017	0.29	0.24	Parental longevity (mother's age at death);	chr4:3237975	chr4:3312512~3313058:+
COAD	cis	rs9400467	0.528	rs6913769	ENSG00000230177.1	RP5-1112D6.4	-4.04	7.09e-05	0.0171	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111277932~111278742:+
COAD	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
COAD	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
COAD	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	4.04	7.09e-05	0.0171	0.29	0.24	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
COAD	cis	rs6479891	0.63	rs10995447	ENSG00000232075.1	MRPL35P2	4.04	7.1e-05	0.0171	0.39	0.24	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63634317~63634827:-
COAD	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-4.04	7.1e-05	0.0171	-0.46	-0.24	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-4.04	7.1e-05	0.0171	-0.46	-0.24	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-4.04	7.1e-05	0.0171	-0.46	-0.24	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
COAD	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-4.04	7.1e-05	0.0171	-0.33	-0.24	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
COAD	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-4.04	7.1e-05	0.0171	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
COAD	cis	rs2243480	0.901	rs34807232	ENSG00000232559.3	GS1-124K5.12	4.04	7.1e-05	0.0171	0.43	0.24	Diabetic kidney disease;	chr7:66500146	chr7:66554588~66576923:-
COAD	cis	rs7172689	1	rs28648707	ENSG00000271725.1	RP11-761I4.4	4.04	7.1e-05	0.0171	0.31	0.24	Inattentive symptoms;	chr15:81241693	chr15:81303215~81309391:-
COAD	cis	rs10876993	0.89	rs1585781	ENSG00000270039.1	RP11-571M6.17	4.04	7.1e-05	0.0171	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57662918	chr12:57803838~57804415:+
COAD	cis	rs8177876	0.822	rs8056972	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs74437879	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs76948085	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs80315956	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.642	rs16954572	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9929586	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs9938965	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs7204040	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs7188508	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs28672349	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs4306521	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs4324142	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.642	rs4324143	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.818	rs59177227	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs59685942	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.822	rs10514515	ENSG00000261061.1	RP11-303E16.2	-4.04	7.11e-05	0.0171	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81030770~81031485:+
COAD	cis	rs7572733	0.773	rs970552	ENSG00000222017.1	AC011997.1	-4.04	7.11e-05	0.0171	-0.26	-0.24	Dermatomyositis;	chr2:197632788	chr2:197693106~197774823:+
COAD	cis	rs6951245	1	rs11763835	ENSG00000229043.2	AC091729.9	-4.04	7.11e-05	0.0171	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1160374~1165267:+
COAD	cis	rs73198271	0.653	rs3827811	ENSG00000173295.6	FAM86B3P	-4.04	7.11e-05	0.0171	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8228595~8244865:+
COAD	cis	rs10819861	0.547	rs10760781	ENSG00000238251.2	RP11-172F4.2	-4.04	7.11e-05	0.0171	-0.3	-0.24	Electrocardiographic traits;	chr9:96110549	chr9:96407284~96407797:+
COAD	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-4.04	7.11e-05	0.0171	-0.29	-0.24	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
COAD	cis	rs9880211	0.563	rs6792630	ENSG00000273486.1	RP11-731C17.2	4.04	7.11e-05	0.0171	0.28	0.24	Height;Body mass index;	chr3:136106059	chr3:136837338~136839021:-
COAD	cis	rs2018683	1	rs2018683	ENSG00000272568.4	CTB-113D17.1	4.04	7.12e-05	0.0171	0.32	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28979967~29013367:+
COAD	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-4.04	7.12e-05	0.0171	-0.36	-0.24	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
COAD	cis	rs1670533	1	rs6852155	ENSG00000273179.1	RP11-20I20.4	4.04	7.12e-05	0.0171	0.31	0.24	Recombination rate (females);	chr4:1073850	chr4:1167778~1168174:+
COAD	cis	rs1480597	1	rs11817455	ENSG00000165511.6	C10orf25	4.04	7.12e-05	0.0171	0.43	0.24	Parkinson's disease;	chr10:44662408	chr10:44997698~45000888:-
COAD	cis	rs1480597	1	rs11815663	ENSG00000165511.6	C10orf25	4.04	7.12e-05	0.0171	0.43	0.24	Parkinson's disease;	chr10:44662420	chr10:44997698~45000888:-
COAD	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	4.04	7.12e-05	0.0171	0.25	0.24	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
COAD	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	4.04	7.12e-05	0.0171	0.33	0.24	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
COAD	cis	rs7584330	0.518	rs78856668	ENSG00000234949.2	AC104667.3	-4.04	7.12e-05	0.0171	-0.42	-0.24	Prostate cancer;	chr2:237529412	chr2:237591020~237595981:+
COAD	cis	rs7674212	0.541	rs2251322	ENSG00000230069.3	LRRC37A15P	-4.04	7.12e-05	0.0171	-0.26	-0.24	Type 2 diabetes;	chr4:103158267	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.541	rs2615539	ENSG00000230069.3	LRRC37A15P	-4.04	7.12e-05	0.0171	-0.26	-0.24	Type 2 diabetes;	chr4:103159949	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.57	rs2251634	ENSG00000230069.3	LRRC37A15P	-4.04	7.12e-05	0.0171	-0.26	-0.24	Type 2 diabetes;	chr4:103161192	chr4:102727274~102730721:-
COAD	cis	rs10876993	0.826	rs1678534	ENSG00000270039.1	RP11-571M6.17	4.04	7.12e-05	0.0171	0.28	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57663652	chr12:57803838~57804415:+
COAD	cis	rs453301	0.658	rs9650616	ENSG00000254340.1	RP11-10A14.3	-4.04	7.13e-05	0.0171	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9011689	chr8:9141424~9145435:+
COAD	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-4.04	7.13e-05	0.0171	-0.18	-0.24	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.04	7.13e-05	0.0171	-0.18	-0.24	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
COAD	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-4.04	7.13e-05	0.0171	-0.29	-0.24	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
COAD	cis	rs74233809	1	rs12411886	ENSG00000213277.3	MARCKSL1P1	4.04	7.13e-05	0.0171	0.53	0.24	Birth weight;	chr10:102925542	chr10:103175554~103176094:+
COAD	cis	rs6951245	1	rs77868187	ENSG00000229043.2	AC091729.9	-4.04	7.14e-05	0.0171	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs75016635	ENSG00000229043.2	AC091729.9	-4.04	7.14e-05	0.0171	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs113066613	ENSG00000229043.2	AC091729.9	-4.04	7.14e-05	0.0171	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs11763793	ENSG00000229043.2	AC091729.9	-4.04	7.14e-05	0.0171	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1160374~1165267:+
COAD	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	4.04	7.14e-05	0.0171	0.27	0.24	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
COAD	cis	rs8022206	0.773	rs7154646	ENSG00000259502.1	RP11-643G16.3	4.04	7.14e-05	0.0171	0.33	0.24	Platelet count;Mean platelet volume;	chr14:67989736	chr14:67610986~67613864:+
COAD	cis	rs2929278	0.561	rs62018952	ENSG00000275601.1	AC011330.13	4.04	7.14e-05	0.0171	0.3	0.24	Schizophrenia;	chr15:43788539	chr15:43642389~43643023:-
COAD	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-4.04	7.14e-05	0.0171	-0.27	-0.24	Gout;	chr7:66715944	chr7:66902857~66906297:+
COAD	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	4.04	7.14e-05	0.0171	0.3	0.24	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
COAD	cis	rs1670533	1	rs1010342	ENSG00000273179.1	RP11-20I20.4	4.04	7.14e-05	0.0171	0.31	0.24	Recombination rate (females);	chr4:1075031	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs6836350	ENSG00000273179.1	RP11-20I20.4	4.04	7.14e-05	0.0171	0.31	0.24	Recombination rate (females);	chr4:1076185	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.818	rs6835141	ENSG00000273179.1	RP11-20I20.4	4.04	7.14e-05	0.0171	0.31	0.24	Recombination rate (females);	chr4:1076352	chr4:1167778~1168174:+
COAD	cis	rs17570583	1	rs17570583	ENSG00000253785.1	CTC-308K20.3	4.04	7.14e-05	0.0171	0.32	0.24	Migraine - clinic-based;	chr5:172132527	chr5:172975511~172976374:+
COAD	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-4.04	7.14e-05	0.0171	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
COAD	cis	rs495337	0.965	rs12151879	ENSG00000229222.1	KRT18P4	-4.04	7.14e-05	0.0171	-0.26	-0.24	Psoriasis;	chr20:49932705	chr20:49956745~49958032:+
COAD	cis	rs4243971	0.516	rs14353	ENSG00000101898.5	MCTS2P	4.04	7.15e-05	0.0172	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr20:32334595	chr20:31547504~31548049:+
COAD	cis	rs9796	0.649	rs8035828	ENSG00000247556.5	OIP5-AS1	4.04	7.15e-05	0.0172	0.25	0.24	Menopause (age at onset);	chr15:41175089	chr15:41283990~41309737:+
COAD	cis	rs7829975	0.535	rs4841005	ENSG00000254340.1	RP11-10A14.3	-4.04	7.15e-05	0.0172	-0.29	-0.24	Mood instability;	chr8:8643720	chr8:9141424~9145435:+
COAD	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-4.04	7.15e-05	0.0172	-0.32	-0.24	Depression;	chr6:28193021	chr6:28170845~28172521:+
COAD	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-4.04	7.15e-05	0.0172	-0.32	-0.24	Depression;	chr6:28197321	chr6:28170845~28172521:+
COAD	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-4.04	7.15e-05	0.0172	-0.32	-0.24	Depression;	chr6:28197412	chr6:28170845~28172521:+
COAD	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-4.04	7.15e-05	0.0172	-0.32	-0.24	Depression;	chr6:28198669	chr6:28170845~28172521:+
COAD	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-4.04	7.15e-05	0.0172	-0.38	-0.24	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
COAD	cis	rs603446	0.586	rs1787690	ENSG00000254851.1	RP11-109L13.1	4.04	7.15e-05	0.0172	0.29	0.24	Triglycerides;	chr11:116697800	chr11:117135528~117138582:+
COAD	cis	rs603446	0.586	rs947986	ENSG00000254851.1	RP11-109L13.1	4.04	7.15e-05	0.0172	0.29	0.24	Triglycerides;	chr11:116698488	chr11:117135528~117138582:+
COAD	cis	rs11976180	1	rs1320893	ENSG00000204959.4	ARHGEF34P	4.04	7.15e-05	0.0172	0.31	0.24	Obesity-related traits;	chr7:144055019	chr7:144272445~144286966:-
COAD	cis	rs4704187	0.617	rs4704185	ENSG00000250889.2	LINC01336	-4.04	7.16e-05	0.0172	-0.27	-0.24	Response to amphetamines;	chr5:75175865	chr5:75047719~75052843:-
COAD	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	4.04	7.16e-05	0.0172	0.31	0.24	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
COAD	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-4.04	7.16e-05	0.0172	-0.3	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
COAD	cis	rs11638352	1	rs1365456	ENSG00000205771.5	CATSPER2P1	4.04	7.16e-05	0.0172	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44086645	chr15:43726918~43747094:-
COAD	cis	rs10865397	0.506	rs6546810	ENSG00000163016.8	ALMS1P	4.04	7.17e-05	0.0172	0.29	0.24	Intelligence (multi-trait analysis);	chr2:73162588	chr2:73644919~73685576:+
COAD	cis	rs2333021	0.866	rs10133784	ENSG00000259015.1	RP11-109N23.6	4.04	7.17e-05	0.0172	0.23	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:72960595~72961993:+
COAD	cis	rs3960554	0.66	rs55671363	ENSG00000280388.1	RP11-229D13.3	-4.04	7.18e-05	0.0172	-0.26	-0.24	Eotaxin levels;	chr7:76164087	chr7:76043977~76045963:-
COAD	cis	rs875971	1	rs697970	ENSG00000230189.5	GS1-124K5.2	-4.04	7.18e-05	0.0172	-0.2	-0.24	Aortic root size;	chr7:66095065	chr7:66409143~66490059:-
COAD	cis	rs9532669	0.926	rs4942007	ENSG00000239827.7	SUGT1P3	-4.04	7.18e-05	0.0172	-0.21	-0.24	Cervical cancer;	chr13:40871887	chr13:40908159~40921774:-
COAD	cis	rs2115630	0.905	rs6496401	ENSG00000259728.4	LINC00933	-4.04	7.18e-05	0.0172	-0.29	-0.24	P wave terminal force;	chr15:84754562	chr15:84570649~84580175:+
COAD	cis	rs6088813	0.635	rs17323916	ENSG00000269202.1	RP4-614O4.12	-4.04	7.18e-05	0.0172	-0.25	-0.24	Height;	chr20:35322778	chr20:35201747~35203288:-
COAD	cis	rs1510510	0.625	rs13012877	ENSG00000225057.2	AC096574.4	4.04	7.18e-05	0.0172	0.32	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238638652	chr2:238231684~238255633:+
COAD	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-4.04	7.19e-05	0.0172	-0.26	-0.24	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
COAD	cis	rs1510510	0.742	rs7582920	ENSG00000225057.2	AC096574.4	4.04	7.19e-05	0.0172	0.32	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238656148	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.742	rs907106	ENSG00000225057.2	AC096574.4	4.04	7.19e-05	0.0172	0.32	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238656615	chr2:238231684~238255633:+
COAD	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-4.04	7.19e-05	0.0172	-0.29	-0.24	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
COAD	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-4.04	7.19e-05	0.0172	-0.29	-0.24	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
COAD	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	4.04	7.19e-05	0.0172	0.32	0.24	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	4.04	7.19e-05	0.0172	0.32	0.24	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	4.04	7.19e-05	0.0172	0.32	0.24	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	4.04	7.19e-05	0.0172	0.32	0.24	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
COAD	cis	rs763121	0.853	rs35565791	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38667006	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs35522482	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38667010	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2072796	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38668225	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2281019	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38668373	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2281020	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38668401	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2281021	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38668662	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5995610	ENSG00000273076.1	RP3-508I15.22	4.04	7.2e-05	0.0173	0.22	0.24	Menopause (age at onset);	chr22:38668676	chr22:38743495~38743910:+
COAD	cis	rs7674212	0.57	rs12501621	ENSG00000230069.3	LRRC37A15P	-4.04	7.2e-05	0.0173	-0.26	-0.24	Type 2 diabetes;	chr4:103174348	chr4:102727274~102730721:-
COAD	cis	rs8141529	0.778	rs5762795	ENSG00000272858.1	CTA-292E10.8	-4.04	7.2e-05	0.0173	-0.29	-0.24	Lymphocyte counts;	chr22:28786512	chr22:28814914~28815662:+
COAD	cis	rs2732480	0.5	rs11168464	ENSG00000226413.2	OR8T1P	4.04	7.2e-05	0.0173	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48442030~48442947:-
COAD	cis	rs860295	1	rs822527	ENSG00000225082.2	DAP3P1	4.04	7.2e-05	0.0173	0.29	0.24	Body mass index;	chr1:155768262	chr1:155586644~155602197:+
COAD	cis	rs7584330	0.518	rs74003108	ENSG00000234949.2	AC104667.3	-4.04	7.2e-05	0.0173	-0.41	-0.24	Prostate cancer;	chr2:237539357	chr2:237591020~237595981:+
COAD	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.04	7.2e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.04	7.2e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
COAD	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-4.03	7.21e-05	0.0173	-0.27	-0.24	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
COAD	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.03	7.21e-05	0.0173	0.29	0.24	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
COAD	cis	rs12530	1	rs734809	ENSG00000232218.1	RP1-149A16.16	-4.03	7.21e-05	0.0173	-0.43	-0.24	IgG glycosylation;	chr22:32413011	chr22:32386668~32386868:+
COAD	cis	rs2638953	0.886	rs11049572	ENSG00000247934.4	RP11-967K21.1	-4.03	7.22e-05	0.0173	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28163298~28190738:-
COAD	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-4.03	7.22e-05	0.0173	-0.29	-0.24	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
COAD	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	4.03	7.22e-05	0.0173	0.28	0.24	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
COAD	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	4.03	7.22e-05	0.0173	0.28	0.24	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
COAD	cis	rs4243971	0.516	rs56930149	ENSG00000101898.5	MCTS2P	4.03	7.22e-05	0.0173	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr20:32288383	chr20:31547504~31548049:+
COAD	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-4.03	7.22e-05	0.0173	-0.23	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-4.03	7.22e-05	0.0173	-0.23	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-4.03	7.22e-05	0.0173	-0.23	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
COAD	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66692349	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66693028	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66693433	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66694214	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66701371	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66702658	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66706390	chr7:66902857~66906297:+
COAD	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-4.03	7.22e-05	0.0173	-0.27	-0.24	Gout;	chr7:66710076	chr7:66902857~66906297:+
COAD	cis	rs2188554	0.74	rs213945	ENSG00000237974.1	AC000111.4	-4.03	7.23e-05	0.0173	-0.26	-0.24	Esophageal adenocarcinoma;	chr7:117550649	chr7:117487737~117487929:+
COAD	cis	rs10492201	0.529	rs740420	ENSG00000255733.4	IFNG-AS1	-4.03	7.23e-05	0.0173	-0.29	-0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:67989445~68234686:+
COAD	cis	rs728616	0.681	rs12769764	ENSG00000234382.2	RP11-40F6.1	-4.03	7.23e-05	0.0173	-0.34	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:80233664~80245367:+
COAD	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	4.03	7.23e-05	0.0173	0.23	0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
COAD	cis	rs2836974	1	rs2836974	ENSG00000255568.3	BRWD1-AS2	-4.03	7.23e-05	0.0173	-0.25	-0.24	Cognitive function;	chr21:39291255	chr21:39313935~39314962:+
COAD	cis	rs61542988	0.532	rs10240168	ENSG00000226816.2	AC005082.12	-4.03	7.24e-05	0.0173	-0.28	-0.24	Fibrinogen levels;	chr7:22779715	chr7:23206013~23208045:+
COAD	cis	rs6951245	1	rs113146460	ENSG00000229043.2	AC091729.9	-4.03	7.24e-05	0.0173	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.935	rs61753396	ENSG00000229043.2	AC091729.9	-4.03	7.24e-05	0.0173	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs79327308	ENSG00000229043.2	AC091729.9	-4.03	7.24e-05	0.0173	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.938	rs117729148	ENSG00000229043.2	AC091729.9	-4.03	7.24e-05	0.0173	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1160374~1165267:+
COAD	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.03	7.24e-05	0.0173	0.31	0.24	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
COAD	cis	rs8141529	0.748	rs6519766	ENSG00000272858.1	CTA-292E10.8	4.03	7.24e-05	0.0173	0.3	0.24	Lymphocyte counts;	chr22:28874003	chr22:28814914~28815662:+
COAD	cis	rs17685	0.753	rs10262501	ENSG00000280388.1	RP11-229D13.3	4.03	7.25e-05	0.0174	0.25	0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76043977~76045963:-
COAD	cis	rs9307551	0.894	rs6812760	ENSG00000250334.4	LINC00989	-4.03	7.25e-05	0.0174	-0.32	-0.24	Refractive error;	chr4:79560702	chr4:79492416~79576460:+
COAD	cis	rs728616	0.867	rs723191	ENSG00000234382.2	RP11-40F6.1	-4.03	7.25e-05	0.0174	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:80233664~80245367:+
COAD	cis	rs8022206	0.773	rs1980655	ENSG00000259502.1	RP11-643G16.3	4.03	7.25e-05	0.0174	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68058380	chr14:67610986~67613864:+
COAD	cis	rs9880211	0.679	rs9818740	ENSG00000239213.4	NCK1-AS1	4.03	7.26e-05	0.0174	0.33	0.24	Height;Body mass index;	chr3:136220744	chr3:136841726~136862054:-
COAD	cis	rs17373728	0.71	rs12544686	ENSG00000249395.2	CASC9	4.03	7.26e-05	0.0174	0.29	0.24	Diabetic kidney disease;	chr8:75305839	chr8:75223404~75324741:-
COAD	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	4.03	7.26e-05	0.0174	0.26	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
COAD	cis	rs860295	0.702	rs1325908	ENSG00000223503.1	RP11-29H23.6	-4.03	7.26e-05	0.0174	-0.3	-0.24	Body mass index;	chr1:155443513	chr1:155590601~155591262:-
COAD	cis	rs913655	0.508	rs2495839	ENSG00000240291.1	RP11-499P20.2	4.03	7.26e-05	0.0174	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18765647	chr10:18513115~18545651:-
COAD	cis	rs4950322	0.542	rs2883434	ENSG00000278811.3	LINC00624	4.03	7.26e-05	0.0174	0.23	0.24	Protein quantitative trait loci;	chr1:147177505	chr1:147258885~147517875:-
COAD	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-4.03	7.26e-05	0.0174	-0.48	-0.24	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-4.03	7.26e-05	0.0174	-0.48	-0.24	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
COAD	cis	rs2439831	0.867	rs935901	ENSG00000275601.1	AC011330.13	-4.03	7.26e-05	0.0174	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43359058	chr15:43642389~43643023:-
COAD	cis	rs9307551	0.553	rs7673033	ENSG00000250334.4	LINC00989	-4.03	7.26e-05	0.0174	-0.29	-0.24	Refractive error;	chr4:79537914	chr4:79492416~79576460:+
COAD	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-4.03	7.26e-05	0.0174	-0.17	-0.24	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
COAD	cis	rs317865	0.737	rs16893097	ENSG00000263327.5	TAPT1-AS1	-4.03	7.26e-05	0.0174	-0.35	-0.24	Kidney disease (early stage) in type 1 diabetes;	chr4:16155341	chr4:16226685~16320140:+
COAD	cis	rs11681884	0.892	rs112189581	ENSG00000228251.1	AC012442.6	4.03	7.27e-05	0.0174	0.64	0.24	Stroke;	chr2:113095336	chr2:112590796~112591939:+
COAD	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-4.03	7.27e-05	0.0174	-0.51	-0.24	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
COAD	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	4.03	7.27e-05	0.0174	0.3	0.24	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
COAD	cis	rs12935418	0.504	rs1549288	ENSG00000278985.1	RP11-303E16.9	4.03	7.27e-05	0.0174	0.24	0.24	Mean corpuscular volume;	chr16:81027156	chr16:80982319~80984094:-
COAD	cis	rs9291683	0.597	rs11723016	ENSG00000250413.1	RP11-448G15.1	4.03	7.27e-05	0.0174	0.31	0.24	Bone mineral density;	chr4:10124565	chr4:10006482~10009725:+
COAD	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	4.03	7.28e-05	0.0174	0.29	0.24	Height;	chr4:55546002	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	4.03	7.28e-05	0.0174	0.29	0.24	Height;	chr4:55546378	chr4:55547112~55547889:+
COAD	cis	rs7795541	0.691	rs272695	ENSG00000232553.3	AC006026.10	-4.03	7.28e-05	0.0174	-0.28	-0.24	Morning vs. evening chronotype;	chr7:24052553	chr7:23585062~23586355:-
COAD	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	4.03	7.28e-05	0.0174	0.28	0.24	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
COAD	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	4.03	7.28e-05	0.0174	0.21	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
COAD	cis	rs4718428	1	rs4718428	ENSG00000272831.1	RP11-792A8.4	4.03	7.29e-05	0.0174	0.27	0.24	Corneal structure;	chr7:66956459	chr7:66739829~66740385:-
COAD	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-4.03	7.29e-05	0.0174	-0.26	-0.24	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
COAD	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-4.03	7.29e-05	0.0174	-0.32	-0.24	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
COAD	cis	rs860295	0.702	rs12041534	ENSG00000160766.13	GBAP1	4.03	7.29e-05	0.0174	0.28	0.24	Body mass index;	chr1:155437305	chr1:155213821~155227422:-
COAD	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	4.03	7.29e-05	0.0174	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	4.03	7.29e-05	0.0174	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
COAD	cis	rs2723064	0.516	rs2901749	ENSG00000214533.3	KRT18P33	4.03	7.29e-05	0.0174	0.29	0.24	Atrial fibrillation;	chr2:65065436	chr2:65666695~65667737:+
COAD	cis	rs2564921	0.73	rs73082047	ENSG00000280417.1	RP11-5O17.1	4.03	7.29e-05	0.0174	0.26	0.24	Height;	chr3:53070344	chr3:53046166~53048122:+
COAD	cis	rs12530	0.938	rs73170329	ENSG00000232218.1	RP1-149A16.16	-4.03	7.29e-05	0.0174	-0.44	-0.24	IgG glycosylation;	chr22:32425554	chr22:32386668~32386868:+
COAD	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-4.03	7.3e-05	0.0175	-0.28	-0.24	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
COAD	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-4.03	7.3e-05	0.0175	-0.29	-0.24	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
COAD	cis	rs10876993	1	rs10876993	ENSG00000270039.1	RP11-571M6.17	4.03	7.3e-05	0.0175	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57668884	chr12:57803838~57804415:+
COAD	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-4.03	7.31e-05	0.0175	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
COAD	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	4.03	7.31e-05	0.0175	0.25	0.24	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	4.03	7.31e-05	0.0175	0.25	0.24	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.599	rs7652883	ENSG00000248787.1	RP11-666A20.4	-4.03	7.31e-05	0.0175	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125989134	chr3:125908005~125910272:-
COAD	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	4.03	7.31e-05	0.0175	0.33	0.24	Depression;	chr6:28187640	chr6:28115628~28116551:+
COAD	cis	rs2337406	0.929	rs11847182	ENSG00000280411.1	IGHV1-69-2	-4.03	7.31e-05	0.0175	-0.2	-0.24	Alzheimer's disease (late onset);	chr14:106697724	chr14:106762092~106762588:-
COAD	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	4.03	7.31e-05	0.0175	0.29	0.24	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
COAD	cis	rs1150668	0.796	rs1005125	ENSG00000272009.1	RP1-313I6.12	4.03	7.32e-05	0.0175	0.27	0.24	Pubertal anthropometrics;	chr6:28399578	chr6:28078792~28081130:-
COAD	cis	rs9907295	0.591	rs2107538	ENSG00000270977.1	AC015849.16	-4.03	7.32e-05	0.0175	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35893707~35911023:-
COAD	cis	rs9450351	0.744	rs7741914	ENSG00000203875.9	SNHG5	-4.03	7.32e-05	0.0175	-0.49	-0.24	Interferon gamma-induced protein 10 levels;	chr6:86095057	chr6:85660950~85678736:-
COAD	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-4.03	7.32e-05	0.0175	-0.3	-0.24	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
COAD	cis	rs7577696	0.597	rs11691939	ENSG00000272716.1	RP11-563N4.1	4.03	7.32e-05	0.0175	0.28	0.24	Inflammatory biomarkers;	chr2:32114492	chr2:32165046~32165757:-
COAD	cis	rs2243480	1	rs781156	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66014154	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs781149	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66016297	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs451396	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66019087	chr7:66554588~66576923:-
COAD	cis	rs2243480	0.901	rs58207111	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66021736	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs1167613	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66022452	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs1715235	ENSG00000232559.3	GS1-124K5.12	4.03	7.32e-05	0.0175	0.42	0.24	Diabetic kidney disease;	chr7:66023407	chr7:66554588~66576923:-
COAD	cis	rs4819052	0.851	rs8134392	ENSG00000227039.5	ITGB2-AS1	4.03	7.32e-05	0.0175	0.22	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:44921051~44929678:+
COAD	cis	rs6951245	1	rs11761941	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs11767527	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.935	rs61910751	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs77434655	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs75398423	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs112309216	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs76161580	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs76388414	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs77305932	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs11768486	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs11766526	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs76214082	ENSG00000229043.2	AC091729.9	-4.03	7.32e-05	0.0175	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1160374~1165267:+
COAD	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	4.03	7.33e-05	0.0175	0.31	0.24	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
COAD	cis	rs925255	0.967	rs10199829	ENSG00000270210.1	RP11-373D23.3	4.03	7.33e-05	0.0175	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28380044	chr2:28425945~28426719:+
COAD	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-4.03	7.33e-05	0.0175	-0.26	-0.24	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
COAD	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	4.03	7.33e-05	0.0175	0.29	0.24	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
COAD	cis	rs2179367	0.632	rs11155642	ENSG00000216906.2	RP11-350J20.9	4.03	7.33e-05	0.0175	0.36	0.24	Dupuytren's disease;	chr6:149332984	chr6:149904243~149906418:+
COAD	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	4.03	7.33e-05	0.0175	0.26	0.24	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
COAD	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-4.03	7.33e-05	0.0175	-0.22	-0.24	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
COAD	cis	rs4604234	0.614	rs11963923	ENSG00000272129.1	RP11-250B2.6	-4.03	7.33e-05	0.0175	-0.7	-0.24	Cancer;	chr6:80355099	chr6:80355424~80356859:+
COAD	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	4.03	7.33e-05	0.0175	0.18	0.24	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
COAD	cis	rs480407	0.667	rs56138008	ENSG00000232320.6	AC009299.5	4.03	7.33e-05	0.0175	0.33	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160775987	chr2:161340816~161341326:-
COAD	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	4.03	7.34e-05	0.0175	0.28	0.24	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
COAD	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	4.03	7.34e-05	0.0175	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
COAD	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	4.03	7.34e-05	0.0175	0.25	0.24	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
COAD	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	4.03	7.34e-05	0.0175	0.27	0.24	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
COAD	cis	rs7646881	0.812	rs73015644	ENSG00000272087.1	RP11-379F4.7	4.03	7.34e-05	0.0175	0.38	0.24	Tetralogy of Fallot;	chr3:158729955	chr3:158693120~158693768:-
COAD	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	4.03	7.35e-05	0.0175	0.44	0.24	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
COAD	cis	rs17598306	1	rs17598306	ENSG00000238228.1	OR7E7P	-4.03	7.35e-05	0.0176	-0.43	-0.24	Radiation response;	chr7:96952499	chr7:97946987~97947998:-
COAD	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-4.03	7.36e-05	0.0176	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-4.03	7.36e-05	0.0176	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
COAD	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-4.03	7.36e-05	0.0176	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
COAD	cis	rs2638953	0.962	rs11049514	ENSG00000247934.4	RP11-967K21.1	-4.03	7.36e-05	0.0176	-0.27	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299461	chr12:28163298~28190738:-
COAD	cis	rs10028773	0.6	rs4001390	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Educational attainment;	chr4:119344628	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs2136911	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119344704	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.554	rs2175381	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119344812	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.599	rs3864142	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119345036	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.605	rs6833140	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119345667	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.779	rs6815934	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119346155	chr4:119391831~119395335:-
COAD	cis	rs10028773	0.568	rs6838457	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Educational attainment;	chr4:119346212	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.535	rs10005542	ENSG00000249244.1	RP11-548H18.2	4.03	7.36e-05	0.0176	0.31	0.24	Corneal astigmatism;	chr4:119347147	chr4:119391831~119395335:-
COAD	cis	rs9926296	0.632	rs72807526	ENSG00000260259.1	RP11-368I7.4	4.03	7.36e-05	0.0176	0.29	0.24	Vitiligo;	chr16:89709538	chr16:89682620~89686569:-
COAD	cis	rs9532669	0.963	rs9315794	ENSG00000239827.7	SUGT1P3	-4.03	7.36e-05	0.0176	-0.21	-0.24	Cervical cancer;	chr13:40939489	chr13:40908159~40921774:-
COAD	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-4.03	7.37e-05	0.0176	-0.33	-0.24	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
COAD	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-4.03	7.37e-05	0.0176	-0.32	-0.24	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
COAD	cis	rs12699921	0.632	rs2723496	ENSG00000279048.1	RP11-511H23.2	-4.03	7.37e-05	0.0176	-0.18	-0.24	Fibrinogen levels;	chr7:17786367	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2691553	ENSG00000279048.1	RP11-511H23.2	-4.03	7.37e-05	0.0176	-0.18	-0.24	Fibrinogen levels;	chr7:17786658	chr7:17940503~17942922:+
COAD	cis	rs2188554	0.74	rs213944	ENSG00000237974.1	AC000111.4	4.03	7.37e-05	0.0176	0.24	0.24	Esophageal adenocarcinoma;	chr7:117550012	chr7:117487737~117487929:+
COAD	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.03	7.37e-05	0.0176	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
COAD	cis	rs875971	1	rs10244498	ENSG00000236529.1	RP13-254B10.1	4.03	7.37e-05	0.0176	0.28	0.24	Aortic root size;	chr7:66651069	chr7:65840212~65840596:+
COAD	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.03	7.37e-05	0.0176	-0.25	-0.24	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
COAD	cis	rs728616	0.867	rs28365998	ENSG00000234382.2	RP11-40F6.1	-4.03	7.37e-05	0.0176	-0.5	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:80233664~80245367:+
COAD	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.03	7.37e-05	0.0176	-0.43	-0.24	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
COAD	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	4.03	7.37e-05	0.0176	0.32	0.24	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
COAD	cis	rs3733829	0.925	rs7245595	ENSG00000233622.1	CYP2T1P	-4.03	7.38e-05	0.0176	-0.3	-0.24	Smoking behavior;	chr19:40789954	chr19:40808525~40811390:-
COAD	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	4.03	7.38e-05	0.0176	0.39	0.24	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
COAD	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	4.03	7.38e-05	0.0176	0.33	0.24	Depression;	chr6:28391932	chr6:28943877~28944537:+
COAD	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	4.03	7.38e-05	0.0176	0.28	0.24	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
COAD	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	4.03	7.38e-05	0.0176	0.28	0.24	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
COAD	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	4.03	7.38e-05	0.0176	0.28	0.24	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
COAD	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	4.03	7.38e-05	0.0176	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
COAD	cis	rs2179367	0.632	rs11155645	ENSG00000216906.2	RP11-350J20.9	4.03	7.38e-05	0.0176	0.35	0.24	Dupuytren's disease;	chr6:149360056	chr6:149904243~149906418:+
COAD	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-4.03	7.38e-05	0.0176	-0.36	-0.24	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
COAD	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-4.03	7.38e-05	0.0176	-0.36	-0.24	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
COAD	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-4.03	7.38e-05	0.0176	-0.36	-0.24	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-4.03	7.38e-05	0.0176	-0.36	-0.24	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
COAD	cis	rs858267	0.661	rs199349	ENSG00000226816.2	AC005082.12	4.03	7.38e-05	0.0176	0.59	0.24	Blood protein levels;	chr7:23262969	chr7:23206013~23208045:+
COAD	cis	rs12188164	0.686	rs72711367	ENSG00000221990.4	EXOC3-AS1	4.03	7.39e-05	0.0176	0.25	0.24	Cystic fibrosis severity;	chr5:418379	chr5:441498~443160:-
COAD	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-4.03	7.39e-05	0.0176	-0.23	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
COAD	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-4.03	7.39e-05	0.0176	-0.23	-0.24	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
COAD	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	4.03	7.39e-05	0.0176	0.28	0.24	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
COAD	cis	rs9796	0.621	rs1659228	ENSG00000247556.5	OIP5-AS1	4.03	7.39e-05	0.0176	0.24	0.24	Menopause (age at onset);	chr15:41179780	chr15:41283990~41309737:+
COAD	cis	rs9796	0.621	rs691702	ENSG00000247556.5	OIP5-AS1	4.03	7.39e-05	0.0176	0.24	0.24	Menopause (age at onset);	chr15:41182201	chr15:41283990~41309737:+
COAD	cis	rs9796	0.621	rs690733	ENSG00000247556.5	OIP5-AS1	4.03	7.39e-05	0.0176	0.24	0.24	Menopause (age at onset);	chr15:41184267	chr15:41283990~41309737:+
COAD	cis	rs718433	0.584	rs2874142	ENSG00000211778.2	TRAV4	-4.03	7.39e-05	0.0176	-0.2	-0.24	Intraocular pressure;	chr14:21750036	chr14:21736152~21736982:+
COAD	cis	rs2564921	0.615	rs56129941	ENSG00000280417.1	RP11-5O17.1	4.03	7.39e-05	0.0176	0.26	0.24	Height;	chr3:53007328	chr3:53046166~53048122:+
COAD	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-4.03	7.4e-05	0.0176	-0.31	-0.24	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
COAD	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-4.03	7.4e-05	0.0176	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
COAD	cis	rs860295	1	rs708611	ENSG00000225082.2	DAP3P1	4.03	7.4e-05	0.0176	0.29	0.24	Body mass index;	chr1:155773519	chr1:155586644~155602197:+
COAD	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-4.03	7.4e-05	0.0176	-0.46	-0.24	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
COAD	cis	rs860295	1	rs822527	ENSG00000223503.1	RP11-29H23.6	4.03	7.4e-05	0.0176	0.31	0.24	Body mass index;	chr1:155768262	chr1:155590601~155591262:-
COAD	cis	rs4819052	0.851	rs8127834	ENSG00000227039.5	ITGB2-AS1	-4.03	7.4e-05	0.0176	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:44921051~44929678:+
COAD	cis	rs7674212	0.507	rs223471	ENSG00000248971.2	KRT8P46	-4.03	7.4e-05	0.0177	-0.25	-0.24	Type 2 diabetes;	chr4:102777629	chr4:102728746~102730171:-
COAD	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	4.03	7.41e-05	0.0177	0.31	0.24	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
COAD	cis	rs2243480	0.901	rs35823062	ENSG00000232559.3	GS1-124K5.12	4.03	7.41e-05	0.0177	0.43	0.24	Diabetic kidney disease;	chr7:66500834	chr7:66554588~66576923:-
COAD	cis	rs1048886	0.872	rs12525538	ENSG00000271967.1	RP11-134K13.4	-4.03	7.41e-05	0.0177	-0.38	-0.24	Type 2 diabetes;	chr6:70575198	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs34246525	ENSG00000271967.1	RP11-134K13.4	-4.03	7.41e-05	0.0177	-0.38	-0.24	Type 2 diabetes;	chr6:70575239	chr6:70596438~70596980:+
COAD	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-4.03	7.41e-05	0.0177	-0.31	-0.24	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
COAD	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	4.03	7.41e-05	0.0177	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	4.03	7.41e-05	0.0177	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
COAD	cis	rs9942416	0.963	rs7715806	ENSG00000271815.1	CTD-2235C13.3	4.03	7.42e-05	0.0177	0.3	0.24	Age-related disease endophenotypes;	chr5:75738562	chr5:75363760~75364242:+
COAD	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	4.03	7.42e-05	0.0177	0.41	0.24	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
COAD	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-4.03	7.42e-05	0.0177	-0.28	-0.24	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
COAD	cis	rs6504622	0.693	rs12950276	ENSG00000263142.4	LRRC37A17P	-4.03	7.42e-05	0.0177	-0.18	-0.24	Orofacial clefts;	chr17:47095819	chr17:46978481~47054569:+
COAD	cis	rs6504622	0.755	rs12950699	ENSG00000263142.4	LRRC37A17P	-4.03	7.42e-05	0.0177	-0.18	-0.24	Orofacial clefts;	chr17:47096296	chr17:46978481~47054569:+
COAD	cis	rs2638953	0.886	rs11049576	ENSG00000247934.4	RP11-967K21.1	-4.03	7.42e-05	0.0177	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28412347	chr12:28163298~28190738:-
COAD	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	4.03	7.42e-05	0.0177	0.18	0.24	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	4.03	7.42e-05	0.0177	0.18	0.24	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
COAD	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-4.03	7.42e-05	0.0177	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
COAD	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-4.03	7.42e-05	0.0177	-0.39	-0.24	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
COAD	cis	rs2749097	0.825	rs2749100	ENSG00000244256.3	RN7SL130P	4.03	7.42e-05	0.0177	0.3	0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659308	chr1:63655743~63656047:+
COAD	cis	rs2638953	0.924	rs11049606	ENSG00000247934.4	RP11-967K21.1	-4.03	7.42e-05	0.0177	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444213	chr12:28163298~28190738:-
COAD	cis	rs62246343	0.719	rs1152314	ENSG00000254485.4	RP11-380O24.1	4.03	7.43e-05	0.0177	0.33	0.24	Fibrinogen levels;	chr3:9450656	chr3:9292588~9363303:-
COAD	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-4.03	7.43e-05	0.0177	-0.38	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
COAD	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	4.03	7.44e-05	0.0177	0.31	0.24	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
COAD	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	4.03	7.44e-05	0.0177	0.29	0.24	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
COAD	cis	rs11089937	0.626	rs9622968	ENSG00000211638.2	IGLV8-61	-4.03	7.44e-05	0.0177	-0.24	-0.24	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.667	rs5757081	ENSG00000211638.2	IGLV8-61	-4.03	7.44e-05	0.0177	-0.24	-0.24	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22098700~22099212:+
COAD	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-4.03	7.44e-05	0.0177	-0.28	-0.24	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
COAD	cis	rs860295	0.702	rs1325908	ENSG00000225082.2	DAP3P1	-4.03	7.45e-05	0.0177	-0.29	-0.24	Body mass index;	chr1:155443513	chr1:155586644~155602197:+
COAD	cis	rs728616	0.558	rs35547640	ENSG00000225484.5	NUTM2B-AS1	-4.03	7.45e-05	0.0177	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79663088~79826594:-
COAD	cis	rs9291683	0.655	rs2278121	ENSG00000250413.1	RP11-448G15.1	4.03	7.45e-05	0.0177	0.31	0.24	Bone mineral density;	chr4:10094510	chr4:10006482~10009725:+
COAD	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
COAD	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
COAD	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
COAD	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-4.03	7.45e-05	0.0177	-0.26	-0.24	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
COAD	cis	rs1048886	0.872	rs55795712	ENSG00000271967.1	RP11-134K13.4	-4.03	7.45e-05	0.0177	-0.35	-0.24	Type 2 diabetes;	chr6:70570725	chr6:70596438~70596980:+
COAD	cis	rs11969893	0.737	rs9386262	ENSG00000270987.1	RP3-467N11.2	4.03	7.45e-05	0.0177	0.63	0.24	Economic and political preferences (immigration/crime);	chr6:100979811	chr6:100889603~100890338:+
COAD	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	4.03	7.45e-05	0.0177	0.28	0.24	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
COAD	cis	rs72615157	0.716	rs75779608	ENSG00000078319.8	PMS2P1	-4.03	7.45e-05	0.0177	-0.34	-0.24	Lung function (FEV1/FVC);	chr7:100171334	chr7:100320992~100341908:-
COAD	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-4.03	7.45e-05	0.0177	-0.29	-0.24	QT interval;	chr12:29314736	chr12:29277397~29277882:-
COAD	cis	rs6545883	0.542	rs7584500	ENSG00000273302.1	RP11-493E12.2	4.03	7.45e-05	0.0177	0.23	0.24	Tuberculosis;	chr2:61464980	chr2:61199979~61200769:+
COAD	cis	rs4819052	0.851	rs13047104	ENSG00000227039.5	ITGB2-AS1	-4.03	7.45e-05	0.0177	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.885	rs28576202	ENSG00000227039.5	ITGB2-AS1	-4.03	7.45e-05	0.0177	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs35871601	ENSG00000227039.5	ITGB2-AS1	-4.03	7.45e-05	0.0177	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:44921051~44929678:+
COAD	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-4.03	7.45e-05	0.0177	-0.29	-0.24	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-4.03	7.45e-05	0.0177	-0.29	-0.24	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	4.03	7.46e-05	0.0178	0.29	0.24	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
COAD	cis	rs8061903	0.535	rs16965133	ENSG00000260071.1	RP11-418I22.2	4.03	7.46e-05	0.0178	0.29	0.24	HIV-1 viral setpoint;	chr16:9315608	chr16:9466655~9517564:+
COAD	cis	rs34779708	0.966	rs35146199	ENSG00000271335.4	RP11-324I22.4	4.03	7.46e-05	0.0178	0.28	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35314552~35336401:-
COAD	cis	rs6452524	0.901	rs1580309	ENSG00000271862.1	RP11-343L5.2	4.03	7.46e-05	0.0178	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83049376~83050964:-
COAD	cis	rs3126085	0.515	rs9633410	ENSG00000237975.5	FLG-AS1	4.03	7.46e-05	0.0178	0.32	0.24	Atopic dermatitis;	chr1:152391446	chr1:152168125~152445456:+
COAD	cis	rs597539	0.58	rs7935851	ENSG00000255741.1	RP11-757G1.5	-4.03	7.46e-05	0.0178	-0.33	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68941503~68942852:-
COAD	cis	rs2408955	0.5	rs12816820	ENSG00000226413.2	OR8T1P	4.03	7.46e-05	0.0178	0.29	0.24	Glycated hemoglobin levels;	chr12:48164542	chr12:48442030~48442947:-
COAD	cis	rs1387259	0.57	rs12368659	ENSG00000226413.2	OR8T1P	4.03	7.46e-05	0.0178	0.29	0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48442030~48442947:-
COAD	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	4.03	7.47e-05	0.0178	0.18	0.24	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
COAD	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-4.03	7.47e-05	0.0178	-0.28	-0.24	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
COAD	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-4.03	7.47e-05	0.0178	-0.29	-0.24	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
COAD	cis	rs9818758	0.607	rs73084135	ENSG00000225399.4	RP11-3B7.1	-4.03	7.47e-05	0.0178	-0.49	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:49260085~49261316:+
COAD	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	4.03	7.47e-05	0.0178	0.17	0.24	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
COAD	cis	rs2976388	0.59	rs3736011	ENSG00000247317.3	RP11-273G15.2	4.03	7.47e-05	0.0178	0.27	0.24	Urinary tract infection frequency;	chr8:142736371	chr8:142981738~143018437:-
COAD	cis	rs6687821	0.515	rs2390224	ENSG00000261737.1	RP4-612B15.3	4.03	7.47e-05	0.0178	0.32	0.24	Yeast infection;	chr1:86991201	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs4656133	ENSG00000261737.1	RP4-612B15.3	4.03	7.47e-05	0.0178	0.32	0.24	Yeast infection;	chr1:87000140	chr1:86703502~86704462:-
COAD	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	4.03	7.48e-05	0.0178	0.29	0.24	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
COAD	cis	rs7674212	0.581	rs13150953	ENSG00000248971.2	KRT8P46	-4.03	7.48e-05	0.0178	-0.25	-0.24	Type 2 diabetes;	chr4:103021341	chr4:102728746~102730171:-
COAD	cis	rs7674212	0.556	rs13151569	ENSG00000248971.2	KRT8P46	-4.03	7.48e-05	0.0178	-0.25	-0.24	Type 2 diabetes;	chr4:103021633	chr4:102728746~102730171:-
COAD	cis	rs34779708	0.833	rs12777517	ENSG00000271335.4	RP11-324I22.4	4.03	7.48e-05	0.0178	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35314552~35336401:-
COAD	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	4.03	7.48e-05	0.0178	0.33	0.24	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
COAD	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	4.03	7.48e-05	0.0178	0.33	0.24	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
COAD	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-4.03	7.48e-05	0.0178	-0.34	-0.24	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-4.03	7.48e-05	0.0178	-0.34	-0.24	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-4.03	7.48e-05	0.0178	-0.34	-0.24	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
COAD	cis	rs896854	0.573	rs11996455	ENSG00000253528.2	RP11-347C18.4	4.03	7.48e-05	0.0178	0.25	0.24	Type 2 diabetes;	chr8:94841480	chr8:94974573~94974853:-
COAD	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	4.03	7.48e-05	0.0178	0.33	0.24	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
COAD	cis	rs6504622	0.755	rs4968253	ENSG00000263142.4	LRRC37A17P	-4.03	7.48e-05	0.0178	-0.18	-0.24	Orofacial clefts;	chr17:47093553	chr17:46978481~47054569:+
COAD	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-4.03	7.48e-05	0.0178	-0.28	-0.24	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
COAD	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	4.03	7.49e-05	0.0178	0.32	0.24	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
COAD	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-4.03	7.5e-05	0.0178	-0.23	-0.24	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
COAD	cis	rs4820539	0.902	rs4822359	ENSG00000211644.2	IGLV1-51	-4.03	7.5e-05	0.0178	-0.14	-0.24	Bone mineral density;	chr22:23132785	chr22:22322472~22322980:+
COAD	cis	rs3733585	0.673	rs6840802	ENSG00000250413.1	RP11-448G15.1	-4.03	7.5e-05	0.0178	-0.32	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9964009	chr4:10006482~10009725:+
COAD	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-4.03	7.5e-05	0.0178	-0.29	-0.24	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
COAD	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	4.02	7.5e-05	0.0178	0.43	0.24	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
COAD	cis	rs7246657	0.598	rs10417545	ENSG00000226686.6	LINC01535	-4.02	7.5e-05	0.0178	-0.41	-0.24	Coronary artery calcification;	chr19:37163361	chr19:37251912~37265535:+
COAD	cis	rs9400467	0.509	rs11153287	ENSG00000230177.1	RP5-1112D6.4	-4.02	7.5e-05	0.0178	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111277932~111278742:+
COAD	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-4.02	7.51e-05	0.0178	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
COAD	cis	rs6687821	0.515	rs2798676	ENSG00000261737.1	RP4-612B15.3	-4.02	7.51e-05	0.0178	-0.31	-0.24	Yeast infection;	chr1:87086066	chr1:86703502~86704462:-
COAD	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	4.02	7.51e-05	0.0179	0.3	0.24	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
COAD	cis	rs10760158	0.832	rs4837827	ENSG00000226752.6	PSMD5-AS1	-4.02	7.51e-05	0.0179	-0.26	-0.24	Pulse pressure;	chr9:121277593	chr9:120824828~120854385:+
COAD	cis	rs12699921	0.632	rs1524777	ENSG00000279048.1	RP11-511H23.2	-4.02	7.51e-05	0.0179	-0.18	-0.24	Fibrinogen levels;	chr7:17799986	chr7:17940503~17942922:+
COAD	cis	rs6601327	0.518	rs13264850	ENSG00000233609.3	RP11-62H7.2	-4.02	7.51e-05	0.0179	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8961200~8979025:+
COAD	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	4.02	7.51e-05	0.0179	0.27	0.24	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
COAD	cis	rs2243480	0.666	rs1880311	ENSG00000228409.4	CCT6P1	-4.02	7.51e-05	0.0179	-0.32	-0.24	Diabetic kidney disease;	chr7:65811765	chr7:65751142~65763354:+
COAD	cis	rs9291683	0.546	rs6829727	ENSG00000250413.1	RP11-448G15.1	-4.02	7.52e-05	0.0179	-0.33	-0.24	Bone mineral density;	chr4:10050048	chr4:10006482~10009725:+
COAD	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-4.02	7.52e-05	0.0179	-0.28	-0.24	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
COAD	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-4.02	7.52e-05	0.0179	-0.26	-0.24	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
COAD	cis	rs6490294	0.583	rs1005902	ENSG00000257595.2	RP3-473L9.4	-4.02	7.52e-05	0.0179	-0.31	-0.24	Mean platelet volume;	chr12:112229871	chr12:111369282~111403310:+
COAD	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	4.02	7.52e-05	0.0179	0.26	0.24	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
COAD	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.53e-05	0.0179	-0.24	-0.24	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
COAD	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	4.02	7.53e-05	0.0179	0.32	0.24	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	4.02	7.53e-05	0.0179	0.32	0.24	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
COAD	cis	rs1552244	0.882	rs28366039	ENSG00000186162.9	CIDECP	4.02	7.53e-05	0.0179	0.37	0.24	Alzheimer's disease;	chr3:9987304	chr3:10014238~10026365:-
COAD	cis	rs12530	1	rs9609527	ENSG00000232218.1	RP1-149A16.16	4.02	7.53e-05	0.0179	0.42	0.24	IgG glycosylation;	chr22:32399764	chr22:32386668~32386868:+
COAD	cis	rs875971	0.862	rs10274883	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66651104	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs881285	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66654433	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs3846973	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66655048	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs2013908	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66656082	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs13242290	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66656898	chr7:65773620~65802067:+
COAD	cis	rs801193	0.548	rs2109297	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66657397	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs6978178	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66658097	chr7:65773620~65802067:+
COAD	cis	rs801193	0.591	rs721717	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66665305	chr7:65773620~65802067:+
COAD	cis	rs801193	0.569	rs6951302	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66667525	chr7:65773620~65802067:+
COAD	cis	rs801193	0.591	rs4506088	ENSG00000224316.1	RP11-479O9.2	-4.02	7.53e-05	0.0179	-0.27	-0.24	Aortic root size;	chr7:66670470	chr7:65773620~65802067:+
COAD	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	4.02	7.53e-05	0.0179	0.29	0.24	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	4.02	7.53e-05	0.0179	0.29	0.24	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
COAD	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-4.02	7.54e-05	0.0179	-0.17	-0.24	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
COAD	cis	rs911263	0.603	rs11158730	ENSG00000259502.1	RP11-643G16.3	-4.02	7.54e-05	0.0179	-0.3	-0.24	Primary biliary cholangitis;	chr14:68346039	chr14:67610986~67613864:+
COAD	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-4.02	7.55e-05	0.0179	-0.4	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
COAD	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-4.02	7.55e-05	0.0179	-0.3	-0.24	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
COAD	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-4.02	7.55e-05	0.0179	-0.36	-0.24	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
COAD	cis	rs1799949	0.536	rs4793227	ENSG00000279602.1	CTD-3014M21.1	4.02	7.55e-05	0.0179	0.27	0.24	Menopause (age at onset);	chr17:43334882	chr17:43360041~43361361:-
COAD	cis	rs2638953	0.752	rs11049571	ENSG00000247934.4	RP11-967K21.1	-4.02	7.55e-05	0.0179	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390939	chr12:28163298~28190738:-
COAD	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	4.02	7.56e-05	0.0179	0.32	0.24	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
COAD	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-4.02	7.56e-05	0.0179	-0.3	-0.24	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-4.02	7.56e-05	0.0179	-0.3	-0.24	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-4.02	7.56e-05	0.0179	-0.3	-0.24	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
COAD	cis	rs9376098	0.79	rs6903653	ENSG00000232876.1	CTA-212D2.2	-4.02	7.56e-05	0.018	-0.3	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135171396	chr6:135055033~135060550:+
COAD	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-4.02	7.56e-05	0.018	-0.25	-0.24	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
COAD	cis	rs6840360	0.582	rs6535796	ENSG00000251611.1	RP11-610P16.1	-4.02	7.56e-05	0.018	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151407551~151408835:-
COAD	cis	rs7714670	1	rs6871548	ENSG00000184084.7	CTD-2372A4.1	-4.02	7.57e-05	0.018	-0.26	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr5:73780199	chr5:73803296~73803599:-
COAD	cis	rs72827839	1	rs72827839	ENSG00000263412.1	RP5-890E16.2	4.02	7.57e-05	0.018	0.37	0.24	Ease of getting up in the morning;	chr17:48343634	chr17:48045141~48048073:-
COAD	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	4.02	7.57e-05	0.018	0.32	0.24	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	4.02	7.57e-05	0.018	0.32	0.24	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	4.02	7.57e-05	0.018	0.32	0.24	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	4.02	7.57e-05	0.018	0.32	0.24	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	4.02	7.57e-05	0.018	0.32	0.24	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
COAD	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	4.02	7.58e-05	0.018	0.32	0.24	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	4.02	7.58e-05	0.018	0.32	0.24	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	4.02	7.58e-05	0.018	0.32	0.24	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
COAD	cis	rs7584330	0.666	rs937386	ENSG00000234949.2	AC104667.3	-4.02	7.58e-05	0.018	-0.33	-0.24	Prostate cancer;	chr2:237455396	chr2:237591020~237595981:+
COAD	cis	rs80346118	0.673	rs6012535	ENSG00000177410.11	ZFAS1	-4.02	7.58e-05	0.018	-0.26	-0.24	Diastolic blood pressure;	chr20:48806654	chr20:49278178~49295738:+
COAD	cis	rs8022206	0.947	rs79298179	ENSG00000259502.1	RP11-643G16.3	4.02	7.58e-05	0.018	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68012456	chr14:67610986~67613864:+
COAD	cis	rs4819052	0.807	rs4819047	ENSG00000227039.5	ITGB2-AS1	-4.02	7.58e-05	0.018	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:44921051~44929678:+
COAD	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	4.02	7.59e-05	0.018	0.5	0.24	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	4.02	7.59e-05	0.018	0.5	0.24	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	4.02	7.59e-05	0.018	0.5	0.24	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
COAD	cis	rs763121	0.853	rs6519120	ENSG00000273076.1	RP3-508I15.22	-4.02	7.59e-05	0.018	-0.22	-0.24	Menopause (age at onset);	chr22:38595388	chr22:38743495~38743910:+
COAD	cis	rs6545883	0.507	rs4411680	ENSG00000273302.1	RP11-493E12.2	-4.02	7.6e-05	0.018	-0.23	-0.24	Tuberculosis;	chr2:61356970	chr2:61199979~61200769:+
COAD	cis	rs4761702	0.551	rs11106987	ENSG00000257252.4	RP11-486A14.2	-4.02	7.6e-05	0.018	-0.28	-0.24	Immature fraction of reticulocytes;	chr12:93339760	chr12:93317135~93377736:-
COAD	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.02	7.6e-05	0.018	0.31	0.24	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
COAD	cis	rs13256369	0.802	rs35382339	ENSG00000253981.4	ALG1L13P	4.02	7.6e-05	0.018	0.36	0.24	Obesity-related traits;	chr8:8701745	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs11781257	ENSG00000253981.4	ALG1L13P	4.02	7.6e-05	0.018	0.36	0.24	Obesity-related traits;	chr8:8702153	chr8:8236003~8244667:-
COAD	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	4.02	7.6e-05	0.018	0.31	0.24	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
COAD	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	4.02	7.6e-05	0.018	0.28	0.24	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
COAD	cis	rs733592	0.723	rs10875766	ENSG00000273765.1	RP11-370I10.11	4.02	7.61e-05	0.018	0.24	0.24	Plateletcrit;	chr12:48199797	chr12:48360920~48361377:+
COAD	cis	rs11671005	0.695	rs8106061	ENSG00000232098.3	CTD-2619J13.14	4.02	7.61e-05	0.0181	0.27	0.24	Mean platelet volume;	chr19:58406623	chr19:58404238~58408484:-
COAD	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-4.02	7.62e-05	0.0181	-0.25	-0.24	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
COAD	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-4.02	7.62e-05	0.0181	-0.25	-0.24	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
COAD	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-4.02	7.62e-05	0.0181	-0.25	-0.24	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
COAD	cis	rs875971	1	rs1167612	ENSG00000230189.5	GS1-124K5.2	-4.02	7.62e-05	0.0181	-0.2	-0.24	Aortic root size;	chr7:66102989	chr7:66409143~66490059:-
COAD	cis	rs603446	0.703	rs1263151	ENSG00000254851.1	RP11-109L13.1	-4.02	7.62e-05	0.0181	-0.28	-0.24	Triglycerides;	chr11:116770312	chr11:117135528~117138582:+
COAD	cis	rs597539	0.654	rs655816	ENSG00000255741.1	RP11-757G1.5	-4.02	7.62e-05	0.0181	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68941503~68942852:-
COAD	cis	rs7819412	0.522	rs10088853	ENSG00000269918.1	AF131215.9	-4.02	7.62e-05	0.0181	-0.31	-0.24	Triglycerides;	chr8:11130457	chr8:11104691~11106704:-
COAD	cis	rs875971	1	rs11974264	ENSG00000230189.5	GS1-124K5.2	-4.02	7.62e-05	0.0181	-0.2	-0.24	Aortic root size;	chr7:66182595	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1540651	ENSG00000230189.5	GS1-124K5.2	-4.02	7.62e-05	0.0181	-0.2	-0.24	Aortic root size;	chr7:66185134	chr7:66409143~66490059:-
COAD	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	4.02	7.62e-05	0.0181	0.31	0.24	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	4.02	7.62e-05	0.0181	0.31	0.24	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
COAD	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-4.02	7.62e-05	0.0181	-0.25	-0.24	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-4.02	7.62e-05	0.0181	-0.25	-0.24	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
COAD	cis	rs62184315	0.536	rs62185874	ENSG00000253559.1	OSGEPL1-AS1	-4.02	7.62e-05	0.0181	-0.32	-0.24	Alcohol dependence (age at onset);	chr2:189704288	chr2:189762704~189765556:+
COAD	cis	rs2307394	1	rs12990262	ENSG00000281469.1	RP11-567F11.1	4.02	7.62e-05	0.0181	0.29	0.24	Urate levels;	chr2:147980260	chr2:148044380~148044894:+
COAD	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	4.02	7.63e-05	0.0181	0.28	0.24	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
COAD	cis	rs734999	0.588	rs745368	ENSG00000225931.3	RP3-395M20.7	4.02	7.63e-05	0.0181	0.27	0.24	Ulcerative colitis;	chr1:2592766	chr1:2566410~2569888:+
COAD	cis	rs734999	0.566	rs10752747	ENSG00000225931.3	RP3-395M20.7	4.02	7.63e-05	0.0181	0.27	0.24	Ulcerative colitis;	chr1:2593476	chr1:2566410~2569888:+
COAD	cis	rs2179367	0.632	rs6920383	ENSG00000216906.2	RP11-350J20.9	4.02	7.63e-05	0.0181	0.35	0.24	Dupuytren's disease;	chr6:149356361	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498332	ENSG00000216906.2	RP11-350J20.9	4.02	7.63e-05	0.0181	0.35	0.24	Dupuytren's disease;	chr6:149367490	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498333	ENSG00000216906.2	RP11-350J20.9	4.02	7.63e-05	0.0181	0.35	0.24	Dupuytren's disease;	chr6:149368196	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498334	ENSG00000216906.2	RP11-350J20.9	4.02	7.63e-05	0.0181	0.35	0.24	Dupuytren's disease;	chr6:149370902	chr6:149904243~149906418:+
COAD	cis	rs2439831	0.681	rs3742971	ENSG00000275601.1	AC011330.13	4.02	7.63e-05	0.0181	0.31	0.24	Lung cancer in ever smokers;	chr15:43330718	chr15:43642389~43643023:-
COAD	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.02	7.63e-05	0.0181	0.22	0.24	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
COAD	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-4.02	7.63e-05	0.0181	-0.29	-0.24	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
COAD	cis	rs2749097	0.825	rs11208260	ENSG00000244256.3	RN7SL130P	-4.02	7.63e-05	0.0181	-0.31	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63657608	chr1:63655743~63656047:+
COAD	cis	rs763121	0.853	rs3827357	ENSG00000273076.1	RP3-508I15.22	4.02	7.63e-05	0.0181	0.22	0.24	Menopause (age at onset);	chr22:38683408	chr22:38743495~38743910:+
COAD	cis	rs763121	0.819	rs6001205	ENSG00000273076.1	RP3-508I15.22	4.02	7.63e-05	0.0181	0.22	0.24	Menopause (age at onset);	chr22:38704259	chr22:38743495~38743910:+
COAD	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-4.02	7.63e-05	0.0181	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
COAD	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-4.02	7.64e-05	0.0181	-0.3	-0.24	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
COAD	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	4.02	7.64e-05	0.0181	0.2	0.24	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
COAD	cis	rs4072705	1	rs7032937	ENSG00000236643.1	RP11-175D17.3	4.02	7.64e-05	0.0181	0.26	0.24	Menarche (age at onset);	chr9:124575894	chr9:124770123~124772927:+
COAD	cis	rs860295	1	rs708611	ENSG00000223503.1	RP11-29H23.6	4.02	7.64e-05	0.0181	0.31	0.24	Body mass index;	chr1:155773519	chr1:155590601~155591262:-
COAD	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	4.02	7.64e-05	0.0181	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
COAD	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-4.02	7.65e-05	0.0181	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
COAD	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-4.02	7.65e-05	0.0181	-0.29	-0.24	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
COAD	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-4.02	7.65e-05	0.0181	-0.34	-0.24	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
COAD	cis	rs9652601	0.959	rs9888908	ENSG00000274038.1	RP11-66H6.4	-4.02	7.65e-05	0.0181	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11087387	chr16:11056556~11057034:+
COAD	cis	rs9990333	0.544	rs73208092	ENSG00000207650.1	MIR570	4.02	7.65e-05	0.0181	0.31	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195699401~195699497:+
COAD	cis	rs9291683	0.526	rs12506122	ENSG00000250413.1	RP11-448G15.1	-4.02	7.65e-05	0.0181	-0.32	-0.24	Bone mineral density;	chr4:10031914	chr4:10006482~10009725:+
COAD	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	4.02	7.65e-05	0.0181	0.28	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
COAD	cis	rs4843747	0.803	rs72818522	ENSG00000205037.2	RP11-863P13.4	4.02	7.66e-05	0.0181	0.32	0.24	Menopause (age at onset);	chr16:88025538	chr16:88088041~88100985:-
COAD	cis	rs989978	1	rs7903634	ENSG00000228778.1	RP11-129J12.1	-4.02	7.66e-05	0.0181	-0.29	-0.24	Red blood cell count;	chr10:99562437	chr10:99527081~99528261:+
COAD	cis	rs9393777	0.588	rs9467772	ENSG00000224843.5	LINC00240	4.02	7.66e-05	0.0181	0.35	0.24	Intelligence (multi-trait analysis);	chr6:26496350	chr6:26956992~27023924:+
COAD	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-4.02	7.66e-05	0.0181	-0.35	-0.24	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
COAD	cis	rs7760535	0.794	rs3851225	ENSG00000230177.1	RP5-1112D6.4	-4.02	7.66e-05	0.0181	-0.21	-0.24	Metabolic traits;	chr6:111503929	chr6:111277932~111278742:+
COAD	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-4.02	7.66e-05	0.0181	-0.28	-0.24	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
COAD	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	4.02	7.66e-05	0.0181	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
COAD	cis	rs6802315	0.604	rs4680467	ENSG00000272247.1	RP11-379F4.9	-4.02	7.66e-05	0.0181	-0.3	-0.24	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158801257~158801935:-
COAD	cis	rs6951245	1	rs74887741	ENSG00000229043.2	AC091729.9	-4.02	7.66e-05	0.0181	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1160374~1165267:+
COAD	cis	rs752010	0.806	rs943375	ENSG00000230638.4	RP11-486B10.4	-4.02	7.66e-05	0.0181	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41626481	chr1:41542069~41544310:+
COAD	cis	rs2638953	0.925	rs7312201	ENSG00000247934.4	RP11-967K21.1	-4.02	7.66e-05	0.0181	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049585	ENSG00000247934.4	RP11-967K21.1	-4.02	7.66e-05	0.0181	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417957	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs12372172	ENSG00000247934.4	RP11-967K21.1	-4.02	7.66e-05	0.0181	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28163298~28190738:-
COAD	cis	rs7615952	0.866	rs1976459	ENSG00000241278.1	ENPP7P4	4.02	7.67e-05	0.0181	0.27	0.24	Blood pressure (smoking interaction);	chr3:125928643	chr3:125848223~125909372:+
COAD	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	4.02	7.67e-05	0.0181	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
COAD	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.02	7.67e-05	0.0181	0.33	0.24	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
COAD	cis	rs1832007	0.529	rs4880716	ENSG00000224034.1	RP11-445P17.8	4.02	7.67e-05	0.0182	0.34	0.24	Triglyceride levels;Triglycerides;	chr10:5196233	chr10:5266033~5271236:-
COAD	cis	rs757278	0.513	rs2518879	ENSG00000237974.1	AC000111.4	4.02	7.68e-05	0.0182	0.26	0.24	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117601454	chr7:117487737~117487929:+
COAD	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	4.02	7.68e-05	0.0182	0.25	0.24	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
COAD	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	4.02	7.68e-05	0.0182	0.29	0.24	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
COAD	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-4.02	7.68e-05	0.0182	-0.33	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
COAD	cis	rs11239930	0.538	rs604716	ENSG00000278811.3	LINC00624	4.02	7.68e-05	0.0182	0.24	0.24	AIDS progression;	chr1:147073173	chr1:147258885~147517875:-
COAD	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-4.02	7.68e-05	0.0182	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-4.02	7.68e-05	0.0182	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-4.02	7.68e-05	0.0182	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-4.02	7.68e-05	0.0182	-0.25	-0.24	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-4.02	7.68e-05	0.0182	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
COAD	cis	rs8002861	0.664	rs4941474	ENSG00000274001.1	RP11-5G9.5	4.02	7.68e-05	0.0182	0.22	0.24	Leprosy;	chr13:43876153	chr13:43877715~43878163:-
COAD	cis	rs718433	0.556	rs1569287	ENSG00000211778.2	TRAV4	-4.02	7.69e-05	0.0182	-0.2	-0.24	Intraocular pressure;	chr14:21747309	chr14:21736152~21736982:+
COAD	cis	rs718433	0.584	rs1002180	ENSG00000211778.2	TRAV4	-4.02	7.69e-05	0.0182	-0.2	-0.24	Intraocular pressure;	chr14:21748768	chr14:21736152~21736982:+
COAD	cis	rs718433	0.584	rs2075478	ENSG00000211778.2	TRAV4	-4.02	7.69e-05	0.0182	-0.2	-0.24	Intraocular pressure;	chr14:21749767	chr14:21736152~21736982:+
COAD	cis	rs11846409	0.872	rs74091715	ENSG00000211974.3	IGHV2-70	-4.02	7.69e-05	0.0182	-0.29	-0.24	Rheumatic heart disease;	chr14:106637731	chr14:106723574~106724093:-
COAD	cis	rs11846409	0.932	rs74091721	ENSG00000211974.3	IGHV2-70	-4.02	7.69e-05	0.0182	-0.29	-0.24	Rheumatic heart disease;	chr14:106638262	chr14:106723574~106724093:-
COAD	cis	rs11098499	0.69	rs34818745	ENSG00000250412.1	KLHL2P1	4.02	7.69e-05	0.0182	0.34	0.24	Corneal astigmatism;	chr4:119335900	chr4:119334329~119378233:+
COAD	cis	rs2337406	1	rs1858677	ENSG00000211974.3	IGHV2-70	-4.02	7.69e-05	0.0182	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106706828	chr14:106723574~106724093:-
COAD	cis	rs7105056	1	rs4936054	ENSG00000270179.1	RP11-159N11.4	-4.02	7.7e-05	0.0182	-0.57	-0.24	Immune reponse to smallpox (secreted IL-12p40);	chr11:112386156	chr11:113368478~113369117:+
COAD	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-4.02	7.7e-05	0.0182	-0.46	-0.24	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
COAD	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
COAD	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
COAD	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
COAD	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
COAD	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
COAD	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
COAD	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	4.02	7.71e-05	0.0182	0.28	0.24	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
COAD	cis	rs9307551	0.948	rs1371993	ENSG00000250334.4	LINC00989	-4.02	7.71e-05	0.0182	-0.32	-0.24	Refractive error;	chr4:79560662	chr4:79492416~79576460:+
COAD	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-4.02	7.71e-05	0.0182	-0.28	-0.24	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
COAD	cis	rs2179367	0.632	rs9498335	ENSG00000216906.2	RP11-350J20.9	4.02	7.72e-05	0.0182	0.35	0.24	Dupuytren's disease;	chr6:149372648	chr6:149904243~149906418:+
COAD	cis	rs7615952	0.688	rs12485622	ENSG00000248787.1	RP11-666A20.4	-4.02	7.72e-05	0.0182	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125991896	chr3:125908005~125910272:-
COAD	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-4.02	7.72e-05	0.0183	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
COAD	cis	rs9376098	0.83	rs6913228	ENSG00000232876.1	CTA-212D2.2	-4.02	7.72e-05	0.0183	-0.29	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135182912	chr6:135055033~135060550:+
COAD	cis	rs11846409	0.86	rs1974470	ENSG00000254174.1	IGHV1-12	4.02	7.73e-05	0.0183	0.22	0.24	Rheumatic heart disease;	chr14:106621300	chr14:106122420~106122709:-
COAD	cis	rs6866344	0.601	rs4419608	ENSG00000251211.1	RP11-889L3.4	4.02	7.73e-05	0.0183	0.32	0.24	Neutrophil percentage of white cells;	chr5:178670048	chr5:178165702~178166562:+
COAD	cis	rs7646881	0.544	rs58878998	ENSG00000272087.1	RP11-379F4.7	4.02	7.73e-05	0.0183	0.4	0.24	Tetralogy of Fallot;	chr3:158640859	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.508	rs59602208	ENSG00000272087.1	RP11-379F4.7	4.02	7.73e-05	0.0183	0.4	0.24	Tetralogy of Fallot;	chr3:158642319	chr3:158693120~158693768:-
COAD	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	4.02	7.73e-05	0.0183	0.25	0.24	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
COAD	cis	rs9291683	0.597	rs11722989	ENSG00000250413.1	RP11-448G15.1	4.02	7.73e-05	0.0183	0.31	0.24	Bone mineral density;	chr4:10124515	chr4:10006482~10009725:+
COAD	cis	rs2976388	0.59	rs10087426	ENSG00000247317.3	RP11-273G15.2	4.02	7.73e-05	0.0183	0.27	0.24	Urinary tract infection frequency;	chr8:142733136	chr8:142981738~143018437:-
COAD	cis	rs733592	0.507	rs7138917	ENSG00000273765.1	RP11-370I10.11	-4.02	7.73e-05	0.0183	-0.25	-0.24	Plateletcrit;	chr12:48061472	chr12:48360920~48361377:+
COAD	cis	rs742132	0.858	rs10447387	ENSG00000220875.1	HIST1H3PS1	4.02	7.74e-05	0.0183	0.32	0.24	Uric acid levels;	chr6:25641872	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs10447388	ENSG00000220875.1	HIST1H3PS1	4.02	7.74e-05	0.0183	0.32	0.24	Uric acid levels;	chr6:25642015	chr6:26321876~26322292:-
COAD	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	4.02	7.74e-05	0.0183	0.31	0.24	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
COAD	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-4.02	7.74e-05	0.0183	-0.41	-0.24	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
COAD	cis	rs62049817	0.544	rs7189599	ENSG00000261056.2	RP11-454F8.2	4.02	7.74e-05	0.0183	0.3	0.24	Granulocyte percentage of myeloid white cells;	chr16:53170059	chr16:53298224~53299792:+
COAD	cis	rs2638953	0.886	rs11049393	ENSG00000247934.4	RP11-967K21.1	-4.02	7.75e-05	0.0183	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28163298~28190738:-
COAD	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	4.02	7.75e-05	0.0183	0.32	0.24	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
COAD	cis	rs12530	0.715	rs2294314	ENSG00000230736.2	RP1-149A16.3	-4.02	7.75e-05	0.0183	-0.29	-0.24	IgG glycosylation;	chr22:32398616	chr22:32376664~32384343:+
COAD	cis	rs3126085	0.935	rs3126056	ENSG00000237975.5	FLG-AS1	4.02	7.75e-05	0.0183	0.27	0.24	Atopic dermatitis;	chr1:152294027	chr1:152168125~152445456:+
COAD	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	4.02	7.75e-05	0.0183	0.21	0.24	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
COAD	cis	rs4950322	0.542	rs17159914	ENSG00000278811.3	LINC00624	-4.02	7.76e-05	0.0183	-0.23	-0.24	Protein quantitative trait loci;	chr1:147183226	chr1:147258885~147517875:-
COAD	cis	rs6732160	0.564	rs60796597	ENSG00000163016.8	ALMS1P	4.02	7.76e-05	0.0183	0.31	0.24	Intelligence (multi-trait analysis);	chr2:73155786	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.613	rs59979991	ENSG00000163016.8	ALMS1P	4.02	7.76e-05	0.0183	0.31	0.24	Intelligence (multi-trait analysis);	chr2:73157294	chr2:73644919~73685576:+
COAD	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	4.02	7.77e-05	0.0183	0.27	0.24	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
COAD	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.02	7.77e-05	0.0183	0.34	0.24	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
COAD	cis	rs9880211	0.679	rs9818740	ENSG00000273486.1	RP11-731C17.2	4.02	7.77e-05	0.0183	0.28	0.24	Height;Body mass index;	chr3:136220744	chr3:136837338~136839021:-
COAD	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	4.02	7.77e-05	0.0183	0.32	0.24	Depression;	chr6:28364057	chr6:28943877~28944537:+
COAD	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	4.02	7.77e-05	0.0183	0.28	0.24	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs35899944	ENSG00000273486.1	RP11-731C17.2	4.02	7.77e-05	0.0183	0.28	0.24	Height;Body mass index;	chr3:136510215	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs9878078	ENSG00000273486.1	RP11-731C17.2	4.02	7.77e-05	0.0183	0.28	0.24	Height;Body mass index;	chr3:136518731	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs28811905	ENSG00000273486.1	RP11-731C17.2	4.02	7.77e-05	0.0183	0.28	0.24	Height;Body mass index;	chr3:136533210	chr3:136837338~136839021:-
COAD	cis	rs4820539	0.934	rs3788348	ENSG00000211644.2	IGLV1-51	-4.02	7.77e-05	0.0183	-0.14	-0.24	Bone mineral density;	chr22:23125759	chr22:22322472~22322980:+
COAD	cis	rs4820539	0.932	rs3788349	ENSG00000211644.2	IGLV1-51	-4.02	7.77e-05	0.0183	-0.14	-0.24	Bone mineral density;	chr22:23125763	chr22:22322472~22322980:+
COAD	cis	rs11935103	0.712	rs1470751	ENSG00000279943.1	FLJ38576	4.02	7.77e-05	0.0183	0.35	0.24	Response to citalopram treatment;	chr4:186375172	chr4:186189032~186191490:-
COAD	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-4.02	7.77e-05	0.0183	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
COAD	cis	rs1552244	0.882	rs56125067	ENSG00000186162.9	CIDECP	4.02	7.77e-05	0.0183	0.38	0.24	Alzheimer's disease;	chr3:9942446	chr3:10014238~10026365:-
COAD	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-4.02	7.78e-05	0.0184	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
COAD	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	4.02	7.78e-05	0.0184	0.25	0.24	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
COAD	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-4.02	7.78e-05	0.0184	-0.35	-0.24	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
COAD	cis	rs1115240	0.574	rs60064898	ENSG00000257842.4	NOVA1-AS1	4.02	7.78e-05	0.0184	0.33	0.24	Educational attainment (years of education);	chr14:26586838	chr14:26598412~26806467:+
COAD	cis	rs2645288	1	rs2645288	ENSG00000231365.4	RP11-418J17.1	-4.02	7.78e-05	0.0184	-0.33	-0.24	Breast size;	chr1:118957860	chr1:119140396~119275973:+
COAD	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	4.02	7.78e-05	0.0184	0.34	0.24	Pain;	chr19:21430595	chr19:21554640~21569237:-
COAD	cis	rs7577696	0.962	rs212746	ENSG00000272716.1	RP11-563N4.1	4.02	7.78e-05	0.0184	0.25	0.24	Inflammatory biomarkers;	chr2:32187998	chr2:32165046~32165757:-
COAD	cis	rs9796	0.621	rs28737302	ENSG00000247556.5	OIP5-AS1	4.02	7.78e-05	0.0184	0.24	0.24	Menopause (age at onset);	chr15:41177745	chr15:41283990~41309737:+
COAD	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	4.02	7.78e-05	0.0184	0.31	0.24	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	4.02	7.78e-05	0.0184	0.31	0.24	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
COAD	cis	rs10078	0.559	rs2037077	ENSG00000221990.4	EXOC3-AS1	4.02	7.79e-05	0.0184	0.32	0.24	Fat distribution (HIV);	chr5:447111	chr5:441498~443160:-
COAD	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	4.02	7.79e-05	0.0184	0.33	0.24	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
COAD	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.79e-05	0.0184	-0.21	-0.24	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
COAD	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-4.02	7.79e-05	0.0184	-0.25	-0.24	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
COAD	cis	rs11976180	1	rs2951372	ENSG00000204959.4	ARHGEF34P	4.02	7.8e-05	0.0184	0.3	0.24	Obesity-related traits;	chr7:144052410	chr7:144272445~144286966:-
COAD	cis	rs11976180	1	rs2951368	ENSG00000204959.4	ARHGEF34P	4.02	7.8e-05	0.0184	0.3	0.24	Obesity-related traits;	chr7:144055728	chr7:144272445~144286966:-
COAD	cis	rs11976180	1	rs2961115	ENSG00000204959.4	ARHGEF34P	4.02	7.8e-05	0.0184	0.3	0.24	Obesity-related traits;	chr7:144056278	chr7:144272445~144286966:-
COAD	cis	rs11976180	1	rs2951363	ENSG00000204959.4	ARHGEF34P	4.02	7.8e-05	0.0184	0.3	0.24	Obesity-related traits;	chr7:144057631	chr7:144272445~144286966:-
COAD	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-4.02	7.8e-05	0.0184	-0.38	-0.24	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
COAD	cis	rs7577696	0.785	rs11683110	ENSG00000272716.1	RP11-563N4.1	-4.02	7.8e-05	0.0184	-0.25	-0.24	Inflammatory biomarkers;	chr2:32124744	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.752	rs12614686	ENSG00000272716.1	RP11-563N4.1	-4.02	7.8e-05	0.0184	-0.25	-0.24	Inflammatory biomarkers;	chr2:32138102	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.785	rs7592356	ENSG00000272716.1	RP11-563N4.1	-4.02	7.8e-05	0.0184	-0.25	-0.24	Inflammatory biomarkers;	chr2:32145275	chr2:32165046~32165757:-
COAD	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.02	7.8e-05	0.0184	-0.23	-0.24	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
COAD	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.02	7.8e-05	0.0184	-0.28	-0.24	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
COAD	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	4.02	7.8e-05	0.0184	0.28	0.24	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	4.02	7.8e-05	0.0184	0.28	0.24	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
COAD	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	4.02	7.81e-05	0.0184	0.32	0.24	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	4.02	7.81e-05	0.0184	0.32	0.24	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
COAD	cis	rs6951245	1	rs74652290	ENSG00000229043.2	AC091729.9	-4.01	7.81e-05	0.0184	-0.4	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1160374~1165267:+
COAD	cis	rs891378	1	rs10864181	ENSG00000274245.1	RP11-357P18.2	-4.01	7.81e-05	0.0184	-0.34	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207274706	chr1:207372559~207373252:+
COAD	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-4.01	7.82e-05	0.0184	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
COAD	cis	rs9880211	1	rs13092193	ENSG00000273486.1	RP11-731C17.2	4.01	7.82e-05	0.0184	0.28	0.24	Height;Body mass index;	chr3:136521524	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs6771002	ENSG00000273486.1	RP11-731C17.2	4.01	7.82e-05	0.0184	0.28	0.24	Height;Body mass index;	chr3:136522186	chr3:136837338~136839021:-
COAD	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	4.01	7.82e-05	0.0184	0.31	0.24	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
COAD	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	4.01	7.82e-05	0.0184	0.19	0.24	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
COAD	cis	rs875971	0.571	rs160647	ENSG00000224316.1	RP11-479O9.2	-4.01	7.82e-05	0.0184	-0.31	-0.24	Aortic root size;	chr7:66089365	chr7:65773620~65802067:+
COAD	cis	rs712039	0.652	rs853206	ENSG00000276054.1	RP11-378E13.3	4.01	7.82e-05	0.0184	0.36	0.24	Tuberculosis;	chr17:37464692	chr17:37386886~37387926:+
COAD	cis	rs4879656	0.797	rs2297218	ENSG00000225693.1	LAGE3P1	-4.01	7.82e-05	0.0184	-0.28	-0.24	Menopause (age at onset);	chr9:33025253	chr9:33019682~33020165:-
COAD	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-4.01	7.82e-05	0.0184	-0.35	-0.24	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
COAD	cis	rs742132	0.858	rs2072847	ENSG00000220875.1	HIST1H3PS1	4.01	7.83e-05	0.0184	0.31	0.24	Uric acid levels;	chr6:25661659	chr6:26321876~26322292:-
COAD	cis	rs9532669	0.963	rs1056835	ENSG00000277662.1	RP11-74J13.9	-4.01	7.83e-05	0.0184	-0.24	-0.24	Cervical cancer;	chr13:40932585	chr13:41229180~41229676:-
COAD	cis	rs2243480	0.901	rs73142137	ENSG00000232559.3	GS1-124K5.12	4.01	7.83e-05	0.0184	0.44	0.24	Diabetic kidney disease;	chr7:65878455	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs13247184	ENSG00000232559.3	GS1-124K5.12	4.01	7.83e-05	0.0184	0.44	0.24	Diabetic kidney disease;	chr7:65893941	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs35283677	ENSG00000232559.3	GS1-124K5.12	4.01	7.83e-05	0.0184	0.44	0.24	Diabetic kidney disease;	chr7:65894246	chr7:66554588~66576923:-
COAD	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	4.01	7.83e-05	0.0185	0.29	0.24	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
COAD	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	4.01	7.83e-05	0.0185	0.46	0.24	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
COAD	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-4.01	7.83e-05	0.0185	-0.46	-0.24	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
COAD	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	4.01	7.83e-05	0.0185	0.26	0.24	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
COAD	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-4.01	7.84e-05	0.0185	-0.35	-0.24	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
COAD	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-4.01	7.84e-05	0.0185	-0.47	-0.24	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-4.01	7.84e-05	0.0185	-0.47	-0.24	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
COAD	cis	rs17772222	1	rs12433464	ENSG00000258789.1	RP11-507K2.3	-4.01	7.84e-05	0.0185	-0.34	-0.24	Coronary artery calcification;	chr14:88357671	chr14:88551597~88552493:+
COAD	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
COAD	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-4.01	7.84e-05	0.0185	-0.3	-0.24	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
COAD	cis	rs3120667	0.72	rs56325026	ENSG00000237975.5	FLG-AS1	4.01	7.84e-05	0.0185	0.34	0.24	Eating disorders;	chr1:152446103	chr1:152168125~152445456:+
COAD	cis	rs6504622	0.748	rs7215573	ENSG00000263142.4	LRRC37A17P	-4.01	7.84e-05	0.0185	-0.18	-0.24	Orofacial clefts;	chr17:47096887	chr17:46978481~47054569:+
COAD	cis	rs728616	1	rs12768613	ENSG00000225484.5	NUTM2B-AS1	-4.01	7.84e-05	0.0185	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156810	chr10:79663088~79826594:-
COAD	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	4.01	7.84e-05	0.0185	0.26	0.24	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
COAD	cis	rs2559856	0.904	rs2695283	ENSG00000199933.1	RNY1P16	4.01	7.84e-05	0.0185	0.26	0.24	Blood protein levels;	chr12:101695613	chr12:101719808~101719918:+
COAD	cis	rs2559856	1	rs2559857	ENSG00000199933.1	RNY1P16	4.01	7.84e-05	0.0185	0.26	0.24	Blood protein levels;	chr12:101695621	chr12:101719808~101719918:+
COAD	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	4.01	7.85e-05	0.0185	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
COAD	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	4.01	7.85e-05	0.0185	0.39	0.24	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
COAD	cis	rs8022206	0.853	rs12436203	ENSG00000259502.1	RP11-643G16.3	4.01	7.85e-05	0.0185	0.39	0.24	Platelet count;Mean platelet volume;	chr14:68068336	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.836	rs72725183	ENSG00000259502.1	RP11-643G16.3	4.01	7.85e-05	0.0185	0.39	0.24	Platelet count;Mean platelet volume;	chr14:68071500	chr14:67610986~67613864:+
COAD	cis	rs8177876	0.841	rs117310590	ENSG00000261061.1	RP11-303E16.2	-4.01	7.85e-05	0.0185	-0.45	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81030770~81031485:+
COAD	cis	rs10779751	1	rs11121710	ENSG00000215785.2	CFL1P6	-4.01	7.85e-05	0.0185	-0.28	-0.24	Body mass index;	chr1:11253187	chr1:10990978~10991797:-
COAD	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-4.01	7.85e-05	0.0185	-0.29	-0.24	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
COAD	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	4.01	7.85e-05	0.0185	0.25	0.24	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
COAD	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	4.01	7.86e-05	0.0185	0.34	0.24	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
COAD	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-4.01	7.86e-05	0.0185	-0.33	-0.24	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
COAD	cis	rs11671005	0.504	rs7257669	ENSG00000213753.9	CENPBD1P1	4.01	7.86e-05	0.0185	0.32	0.24	Mean platelet volume;	chr19:58553572	chr19:58573503~58599801:+
COAD	cis	rs10871290	0.65	rs12600126	ENSG00000262904.1	TMPOP2	4.01	7.86e-05	0.0185	0.26	0.24	Breast cancer;	chr16:74455834	chr16:74667506~74668706:+
COAD	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	4.01	7.86e-05	0.0185	0.27	0.24	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
COAD	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	4.01	7.86e-05	0.0185	0.27	0.24	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
COAD	cis	rs76878669	0.793	rs7924580	ENSG00000254458.1	RP11-867G23.13	4.01	7.86e-05	0.0185	0.34	0.24	Educational attainment (years of education);	chr11:66313299	chr11:66312853~66319237:+
COAD	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-4.01	7.86e-05	0.0185	-0.26	-0.24	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
COAD	cis	rs6088813	0.677	rs6088832	ENSG00000269202.1	RP4-614O4.12	-4.01	7.87e-05	0.0185	-0.25	-0.24	Height;	chr20:35418373	chr20:35201747~35203288:-
COAD	cis	rs6088813	0.677	rs6087707	ENSG00000269202.1	RP4-614O4.12	-4.01	7.87e-05	0.0185	-0.25	-0.24	Height;	chr20:35418633	chr20:35201747~35203288:-
COAD	cis	rs6088813	0.677	rs6088833	ENSG00000269202.1	RP4-614O4.12	-4.01	7.87e-05	0.0185	-0.25	-0.24	Height;	chr20:35419860	chr20:35201747~35203288:-
COAD	cis	rs2638953	0.886	rs7957503	ENSG00000247934.4	RP11-967K21.1	-4.01	7.87e-05	0.0185	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203762	chr12:28163298~28190738:-
COAD	cis	rs6012564	1	rs6063360	ENSG00000227431.4	CSE1L-AS1	4.01	7.87e-05	0.0185	0.27	0.24	Anger;	chr20:49131838	chr20:49040463~49046044:-
COAD	cis	rs8022206	0.898	rs11848769	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:67996635	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs78773195	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:67999521	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725151	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:67999645	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs11622135	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68001175	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs12437276	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68005111	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725153	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68007222	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725157	ENSG00000259502.1	RP11-643G16.3	4.01	7.88e-05	0.0185	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68008934	chr14:67610986~67613864:+
COAD	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-4.01	7.88e-05	0.0185	-0.28	-0.24	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
COAD	cis	rs875971	1	rs11974219	ENSG00000230189.5	GS1-124K5.2	-4.01	7.88e-05	0.0185	-0.2	-0.24	Aortic root size;	chr7:66182423	chr7:66409143~66490059:-
COAD	cis	rs12530	1	rs5754074	ENSG00000232218.1	RP1-149A16.16	-4.01	7.88e-05	0.0185	-0.42	-0.24	IgG glycosylation;	chr22:32409028	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs9606950	ENSG00000232218.1	RP1-149A16.16	-4.01	7.88e-05	0.0185	-0.42	-0.24	IgG glycosylation;	chr22:32410110	chr22:32386668~32386868:+
COAD	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	4.01	7.88e-05	0.0185	0.3	0.24	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
COAD	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	4.01	7.88e-05	0.0185	0.31	0.24	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	4.01	7.88e-05	0.0185	0.31	0.24	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	4.01	7.88e-05	0.0185	0.31	0.24	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	4.01	7.88e-05	0.0185	0.31	0.24	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
COAD	cis	rs9400271	0.527	rs77497373	ENSG00000219700.1	PTCHD3P3	-4.01	7.88e-05	0.0185	-0.29	-0.24	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109322922	chr6:109288571~109290503:-
COAD	cis	rs2919009	0.598	rs2420896	ENSG00000271670.1	RP11-95I16.4	4.01	7.89e-05	0.0185	0.32	0.24	Obesity-related traits;	chr10:120936893	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.581	rs2420897	ENSG00000271670.1	RP11-95I16.4	4.01	7.89e-05	0.0185	0.32	0.24	Obesity-related traits;	chr10:120936918	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.62	rs4437952	ENSG00000271670.1	RP11-95I16.4	4.01	7.89e-05	0.0185	0.32	0.24	Obesity-related traits;	chr10:120937138	chr10:120879256~120880667:-
COAD	cis	rs1426063	1	rs11941556	ENSG00000249717.1	RP11-44F21.3	4.01	7.89e-05	0.0186	0.35	0.24	QT interval;	chr4:75093825	chr4:74955974~74970362:-
COAD	cis	rs1426063	1	rs10022814	ENSG00000249717.1	RP11-44F21.3	4.01	7.89e-05	0.0186	0.35	0.24	QT interval;	chr4:75094704	chr4:74955974~74970362:-
COAD	cis	rs1426063	1	rs10029141	ENSG00000249717.1	RP11-44F21.3	4.01	7.89e-05	0.0186	0.35	0.24	QT interval;	chr4:75097437	chr4:74955974~74970362:-
COAD	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-4.01	7.89e-05	0.0186	-0.28	-0.24	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
COAD	cis	rs804280	0.662	rs11250164	ENSG00000227888.4	FAM66A	-4.01	7.9e-05	0.0186	-0.32	-0.24	Myopia (pathological);	chr8:11753177	chr8:12362019~12388296:+
COAD	cis	rs6787172	0.686	rs12631196	ENSG00000272087.1	RP11-379F4.7	4.01	7.9e-05	0.0186	0.29	0.24	Subjective well-being;	chr3:158453666	chr3:158693120~158693768:-
COAD	cis	rs2346160	0.899	rs384974	ENSG00000228648.1	RP11-568A7.2	4.01	7.9e-05	0.0186	0.27	0.24	Parental extreme longevity (95 years and older);	chr6:167274930	chr6:167241891~167245916:+
COAD	cis	rs801193	0.548	rs2659904	ENSG00000179406.6	LINC00174	4.01	7.9e-05	0.0186	0.18	0.24	Aortic root size;	chr7:66713615	chr7:66376044~66401338:-
COAD	cis	rs860295	1	rs6427286	ENSG00000225082.2	DAP3P1	-4.01	7.9e-05	0.0186	-0.29	-0.24	Body mass index;	chr1:155753506	chr1:155586644~155602197:+
COAD	cis	rs860295	1	rs7541060	ENSG00000225082.2	DAP3P1	-4.01	7.9e-05	0.0186	-0.29	-0.24	Body mass index;	chr1:155758297	chr1:155586644~155602197:+
COAD	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	4.01	7.9e-05	0.0186	0.24	0.24	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
COAD	cis	rs728616	0.51	rs17617406	ENSG00000225484.5	NUTM2B-AS1	4.01	7.9e-05	0.0186	0.39	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79663088~79826594:-
COAD	cis	rs12571093	0.572	rs10762216	ENSG00000233590.1	RP11-153K11.3	4.01	7.9e-05	0.0186	0.3	0.24	Optic nerve measurement (disc area);	chr10:68308820	chr10:68233251~68242379:-
COAD	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.01	7.9e-05	0.0186	0.3	0.24	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
COAD	cis	rs4819052	0.851	rs12626188	ENSG00000227039.5	ITGB2-AS1	-4.01	7.91e-05	0.0186	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:44921051~44929678:+
COAD	cis	rs739496	0.615	rs7978737	ENSG00000257595.2	RP3-473L9.4	4.01	7.91e-05	0.0186	0.37	0.24	Platelet count;	chr12:111758807	chr12:111369282~111403310:+
COAD	cis	rs6687821	0.515	rs2390215	ENSG00000261737.1	RP4-612B15.3	4.01	7.91e-05	0.0186	0.32	0.24	Yeast infection;	chr1:87023130	chr1:86703502~86704462:-
COAD	cis	rs8022206	0.738	rs10137233	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68077949	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs10140420	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68078931	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs10140493	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68078947	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs1548265	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68079583	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs8014000	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68080800	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.947	rs1810639	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68082130	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.738	rs10139386	ENSG00000259502.1	RP11-643G16.3	4.01	7.91e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68083823	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.853	rs9672142	ENSG00000259502.1	RP11-643G16.3	4.01	7.92e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:67999460	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.773	rs12437178	ENSG00000259502.1	RP11-643G16.3	4.01	7.92e-05	0.0186	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68004692	chr14:67610986~67613864:+
COAD	cis	rs13256369	1	rs9329165	ENSG00000253981.4	ALG1L13P	-4.01	7.92e-05	0.0186	-0.34	-0.24	Obesity-related traits;	chr8:8719132	chr8:8236003~8244667:-
COAD	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	4.01	7.92e-05	0.0186	0.29	0.24	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
COAD	cis	rs4237845	0.637	rs7299249	ENSG00000257698.1	RP11-620J15.3	4.01	7.92e-05	0.0186	0.22	0.24	Intelligence (multi-trait analysis);	chr12:57949927	chr12:57931528~57936175:-
COAD	cis	rs4237845	0.611	rs4760347	ENSG00000257698.1	RP11-620J15.3	4.01	7.92e-05	0.0186	0.22	0.24	Intelligence (multi-trait analysis);	chr12:57953085	chr12:57931528~57936175:-
COAD	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-4.01	7.92e-05	0.0186	-0.45	-0.24	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
COAD	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-4.01	7.93e-05	0.0186	-0.32	-0.24	Depression;	chr6:28205175	chr6:28170845~28172521:+
COAD	cis	rs1930961	0.702	rs11090398	ENSG00000271138.1	IGLVIVOR22-1	-4.01	7.93e-05	0.0186	-0.62	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25493190	chr22:25437306~25437823:-
COAD	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-4.01	7.93e-05	0.0186	-0.29	-0.24	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
COAD	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	4.01	7.93e-05	0.0186	0.29	0.24	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
COAD	cis	rs860295	1	rs10908482	ENSG00000225082.2	DAP3P1	-4.01	7.94e-05	0.0186	-0.29	-0.24	Body mass index;	chr1:155744082	chr1:155586644~155602197:+
COAD	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	4.01	7.94e-05	0.0187	0.22	0.24	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
COAD	cis	rs9532669	0.926	rs7322399	ENSG00000239827.7	SUGT1P3	-4.01	7.94e-05	0.0187	-0.21	-0.24	Cervical cancer;	chr13:40952511	chr13:40908159~40921774:-
COAD	cis	rs9532669	0.926	rs7322097	ENSG00000239827.7	SUGT1P3	-4.01	7.94e-05	0.0187	-0.21	-0.24	Cervical cancer;	chr13:40952513	chr13:40908159~40921774:-
COAD	cis	rs11969893	0.85	rs9498418	ENSG00000270987.1	RP3-467N11.2	4.01	7.94e-05	0.0187	0.51	0.24	Economic and political preferences (immigration/crime);	chr6:100883962	chr6:100889603~100890338:+
COAD	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	4.01	7.94e-05	0.0187	0.29	0.24	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
COAD	cis	rs4819052	0.851	rs4819046	ENSG00000227039.5	ITGB2-AS1	-4.01	7.94e-05	0.0187	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:44921051~44929678:+
COAD	cis	rs454422	1	rs236121	ENSG00000275632.1	RP5-967N21.11	4.01	7.94e-05	0.0187	0.28	0.24	HIV-1 viral setpoint;	chr20:5991948	chr20:6000418~6000941:+
COAD	cis	rs7577696	0.886	rs6737500	ENSG00000272716.1	RP11-563N4.1	-4.01	7.94e-05	0.0187	-0.25	-0.24	Inflammatory biomarkers;	chr2:32038018	chr2:32165046~32165757:-
COAD	cis	rs6012564	0.89	rs6066976	ENSG00000227431.4	CSE1L-AS1	4.01	7.95e-05	0.0187	0.27	0.24	Anger;	chr20:49134464	chr20:49040463~49046044:-
COAD	cis	rs6012564	1	rs6066977	ENSG00000227431.4	CSE1L-AS1	4.01	7.95e-05	0.0187	0.27	0.24	Anger;	chr20:49138538	chr20:49040463~49046044:-
COAD	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	4.01	7.95e-05	0.0187	0.5	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
COAD	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	4.01	7.95e-05	0.0187	0.5	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
COAD	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	4.01	7.95e-05	0.0187	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
COAD	cis	rs9880211	1	rs9828088	ENSG00000273486.1	RP11-731C17.2	4.01	7.95e-05	0.0187	0.28	0.24	Height;Body mass index;	chr3:136528948	chr3:136837338~136839021:-
COAD	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-4.01	7.95e-05	0.0187	-0.31	-0.24	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
COAD	cis	rs2564921	0.704	rs56155510	ENSG00000280417.1	RP11-5O17.1	4.01	7.96e-05	0.0187	0.26	0.24	Height;	chr3:53009621	chr3:53046166~53048122:+
COAD	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-4.01	7.96e-05	0.0187	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
COAD	cis	rs2408955	0.521	rs10875749	ENSG00000226413.2	OR8T1P	-4.01	7.96e-05	0.0187	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48138134	chr12:48442030~48442947:-
COAD	cis	rs8022206	0.773	rs1980654	ENSG00000259502.1	RP11-643G16.3	4.01	7.96e-05	0.0187	0.32	0.24	Platelet count;Mean platelet volume;	chr14:68058523	chr14:67610986~67613864:+
COAD	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	4.01	7.96e-05	0.0187	0.28	0.24	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
COAD	cis	rs12497850	1	rs4858831	ENSG00000225399.4	RP11-3B7.1	4.01	7.96e-05	0.0187	0.27	0.24	Parkinson's disease;	chr3:48698125	chr3:49260085~49261316:+
COAD	cis	rs2564921	0.73	rs1811351	ENSG00000280417.1	RP11-5O17.1	4.01	7.97e-05	0.0187	0.26	0.24	Height;	chr3:53064759	chr3:53046166~53048122:+
COAD	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	4.01	7.97e-05	0.0187	0.45	0.24	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
COAD	cis	rs9880211	1	rs12695649	ENSG00000273486.1	RP11-731C17.2	4.01	7.97e-05	0.0187	0.28	0.24	Height;Body mass index;	chr3:136553074	chr3:136837338~136839021:-
COAD	cis	rs1387259	0.931	rs11168474	ENSG00000269514.1	RP11-370I10.12	4.01	7.97e-05	0.0187	0.29	0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48198387~48202031:+
COAD	cis	rs11098499	0.866	rs11098506	ENSG00000249244.1	RP11-548H18.2	4.01	7.97e-05	0.0187	0.32	0.24	Corneal astigmatism;	chr4:119363816	chr4:119391831~119395335:-
COAD	cis	rs4843747	0.671	rs72818540	ENSG00000205037.2	RP11-863P13.4	4.01	7.98e-05	0.0187	0.31	0.24	Menopause (age at onset);	chr16:88045382	chr16:88088041~88100985:-
COAD	cis	rs1707322	0.752	rs4660313	ENSG00000230896.1	RP11-767N6.7	4.01	7.98e-05	0.0187	0.28	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45694684~45697075:-
COAD	cis	rs9307551	0.619	rs7670107	ENSG00000250334.4	LINC00989	-4.01	7.99e-05	0.0187	-0.29	-0.24	Refractive error;	chr4:79502861	chr4:79492416~79576460:+
COAD	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-4.01	7.99e-05	0.0187	-0.3	-0.24	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
COAD	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-4.01	7.99e-05	0.0187	-0.46	-0.24	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
COAD	cis	rs78487399	0.71	rs28470852	ENSG00000234936.1	AC010883.5	4.01	7.99e-05	0.0187	0.37	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43365861	chr2:43229573~43233394:+
COAD	cis	rs4820539	1	rs5759595	ENSG00000211644.2	IGLV1-51	-4.01	7.99e-05	0.0188	-0.14	-0.24	Bone mineral density;	chr22:23129437	chr22:22322472~22322980:+
COAD	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-4.01	7.99e-05	0.0188	-0.25	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
COAD	cis	rs4818225	0.895	rs2837996	ENSG00000237232.6	ZNF295-AS1	-4.01	8e-05	0.0188	-0.32	-0.24	Educational attainment;	chr21:41254779	chr21:42009194~42024924:+
COAD	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-4.01	8e-05	0.0188	-0.35	-0.24	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
COAD	cis	rs2243480	1	rs73142122	ENSG00000228409.4	CCT6P1	4.01	8e-05	0.0188	0.32	0.24	Diabetic kidney disease;	chr7:65846311	chr7:65751142~65763354:+
COAD	cis	rs763121	0.853	rs3788545	ENSG00000273076.1	RP3-508I15.22	4.01	8e-05	0.0188	0.22	0.24	Menopause (age at onset);	chr22:38669167	chr22:38743495~38743910:+
COAD	cis	rs41464545	1	rs6813249	ENSG00000249413.2	RP11-25H12.1	4.01	8e-05	0.0188	0.33	0.24	Schizophrenia;	chr4:65010516	chr4:65998846~66150012:+
COAD	cis	rs41464545	1	rs17085721	ENSG00000249413.2	RP11-25H12.1	4.01	8e-05	0.0188	0.33	0.24	Schizophrenia;	chr4:65010955	chr4:65998846~66150012:+
COAD	cis	rs2061333	0.557	rs10420143	ENSG00000278492.1	RP11-15A1.9	-4.01	8e-05	0.0188	-0.33	-0.24	Alzheimer's disease;	chr19:44103929	chr19:43978376~43978663:+
COAD	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	4.01	8e-05	0.0188	0.29	0.24	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
COAD	cis	rs911263	0.56	rs12896939	ENSG00000259502.1	RP11-643G16.3	-4.01	8e-05	0.0188	-0.29	-0.24	Primary biliary cholangitis;	chr14:68345945	chr14:67610986~67613864:+
COAD	cis	rs2337406	0.587	rs2583291	ENSG00000211964.3	IGHV3-48	4.01	8.01e-05	0.0188	0.2	0.24	Alzheimer's disease (late onset);	chr14:106649293	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.587	rs2516886	ENSG00000211964.3	IGHV3-48	4.01	8.01e-05	0.0188	0.2	0.24	Alzheimer's disease (late onset);	chr14:106649674	chr14:106537810~106538344:-
COAD	cis	rs2179367	0.632	rs10872636	ENSG00000216906.2	RP11-350J20.9	4.01	8.01e-05	0.0188	0.35	0.24	Dupuytren's disease;	chr6:149353678	chr6:149904243~149906418:+
COAD	cis	rs1499614	1	rs1267817	ENSG00000232559.3	GS1-124K5.12	4.01	8.01e-05	0.0188	0.43	0.24	Gout;	chr7:66645053	chr7:66554588~66576923:-
COAD	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-4.01	8.01e-05	0.0188	-0.22	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
COAD	cis	rs10078	0.515	rs2672739	ENSG00000221990.4	EXOC3-AS1	4.01	8.01e-05	0.0188	0.32	0.24	Fat distribution (HIV);	chr5:443332	chr5:441498~443160:-
COAD	cis	rs2070488	0.662	rs7652475	ENSG00000229589.1	ACVR2B-AS1	4.01	8.01e-05	0.0188	0.25	0.24	Electrocardiographic conduction measures;	chr3:38439850	chr3:38451027~38454820:-
COAD	cis	rs9532669	0.963	rs9562238	ENSG00000277662.1	RP11-74J13.9	-4.01	8.02e-05	0.0188	-0.23	-0.24	Cervical cancer;	chr13:40924785	chr13:41229180~41229676:-
COAD	cis	rs742132	0.858	rs73397653	ENSG00000220875.1	HIST1H3PS1	4.01	8.02e-05	0.0188	0.32	0.24	Uric acid levels;	chr6:25638988	chr6:26321876~26322292:-
COAD	cis	rs1670533	1	rs633556	ENSG00000273179.1	RP11-20I20.4	4.01	8.02e-05	0.0188	0.29	0.24	Recombination rate (females);	chr4:1098617	chr4:1167778~1168174:+
COAD	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	4.01	8.02e-05	0.0188	0.27	0.24	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
COAD	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-4.01	8.03e-05	0.0188	-0.46	-0.24	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-4.01	8.03e-05	0.0188	-0.46	-0.24	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
COAD	cis	rs2564921	0.666	rs62253656	ENSG00000280417.1	RP11-5O17.1	4.01	8.03e-05	0.0188	0.26	0.24	Height;	chr3:52989412	chr3:53046166~53048122:+
COAD	cis	rs7172689	0.862	rs28453231	ENSG00000271725.1	RP11-761I4.4	4.01	8.03e-05	0.0188	0.33	0.24	Inattentive symptoms;	chr15:81262558	chr15:81303215~81309391:-
COAD	cis	rs1707322	0.758	rs10789474	ENSG00000230896.1	RP11-767N6.7	-4.01	8.03e-05	0.0188	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45694684~45697075:-
COAD	cis	rs2243480	1	rs4149468	ENSG00000232559.3	GS1-124K5.12	4.01	8.04e-05	0.0188	0.43	0.24	Diabetic kidney disease;	chr7:66360703	chr7:66554588~66576923:-
COAD	cis	rs6719977	0.905	rs4953641	ENSG00000226491.1	FTOP1	-4.01	8.04e-05	0.0188	-0.31	-0.24	Hyperactive-impulsive symptoms;	chr2:42755864	chr2:42797225~42798712:-
COAD	cis	rs1510510	0.69	rs12987518	ENSG00000225057.2	AC096574.4	4.01	8.05e-05	0.0189	0.32	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643430	chr2:238231684~238255633:+
COAD	cis	rs2832191	0.703	rs2853827	ENSG00000176054.6	RPL23P2	4.01	8.05e-05	0.0189	0.25	0.24	Dental caries;	chr21:29071275	chr21:28997613~28998033:-
COAD	cis	rs11681884	0.786	rs1992762	ENSG00000228251.1	AC012442.6	4.01	8.05e-05	0.0189	0.54	0.24	Stroke;	chr2:113052836	chr2:112590796~112591939:+
COAD	cis	rs6982240	0.514	rs10481391	ENSG00000253307.1	RP11-10J21.4	4.01	8.05e-05	0.0189	0.32	0.24	Tonsillectomy;	chr8:141267050	chr8:141252286~141253292:-
COAD	cis	rs2408955	0.522	rs10875721	ENSG00000226413.2	OR8T1P	-4.01	8.05e-05	0.0189	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48019810	chr12:48442030~48442947:-
COAD	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-4.01	8.05e-05	0.0189	-0.29	-0.24	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-4.01	8.05e-05	0.0189	-0.29	-0.24	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
COAD	cis	rs7759001	0.817	rs6925606	ENSG00000271755.1	RP1-153G14.4	4.01	8.05e-05	0.0189	0.29	0.24	Glomerular filtration rate (creatinine);	chr6:27389677	chr6:27404010~27406964:-
COAD	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	4.01	8.06e-05	0.0189	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	4.01	8.06e-05	0.0189	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
COAD	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	4.01	8.06e-05	0.0189	0.27	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
COAD	cis	rs4819052	0.851	rs13052344	ENSG00000227039.5	ITGB2-AS1	-4.01	8.06e-05	0.0189	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:44921051~44929678:+
COAD	cis	rs2018683	0.707	rs917219	ENSG00000272568.4	CTB-113D17.1	4.01	8.06e-05	0.0189	0.34	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28979967~29013367:+
COAD	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	4.01	8.06e-05	0.0189	0.25	0.24	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
COAD	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	4.01	8.07e-05	0.0189	0.25	0.24	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
COAD	cis	rs71636778	0.722	rs116491347	ENSG00000260063.1	RP5-968P14.2	-4.01	8.07e-05	0.0189	-0.32	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26846193	chr1:26692132~26694131:-
COAD	cis	rs7465272	0.957	rs11994668	ENSG00000263660.1	AC087793.1	-4.01	8.07e-05	0.0189	-0.27	-0.24	Bipolar disorder and schizophrenia;	chr8:142606031	chr8:143314921~143315006:+
COAD	cis	rs10146615	0.744	rs1567952	ENSG00000232774.6	FLJ22447	4.01	8.08e-05	0.0189	0.32	0.24	Economic and political preferences (immigration/crime);	chr14:62259874	chr14:61570540~61658696:+
COAD	cis	rs10146615	0.744	rs2354326	ENSG00000232774.6	FLJ22447	4.01	8.08e-05	0.0189	0.32	0.24	Economic and political preferences (immigration/crime);	chr14:62260121	chr14:61570540~61658696:+
COAD	cis	rs4718428	1	rs1830070	ENSG00000272831.1	RP11-792A8.4	4.01	8.08e-05	0.0189	0.27	0.24	Corneal structure;	chr7:66884684	chr7:66739829~66740385:-
COAD	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-4.01	8.08e-05	0.0189	-0.28	-0.24	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
COAD	cis	rs4950322	0.542	rs115179956	ENSG00000278811.3	LINC00624	4.01	8.08e-05	0.0189	0.23	0.24	Protein quantitative trait loci;	chr1:147172620	chr1:147258885~147517875:-
COAD	cis	rs875971	1	rs2220626	ENSG00000224316.1	RP11-479O9.2	-4.01	8.08e-05	0.0189	-0.26	-0.24	Aortic root size;	chr7:66081075	chr7:65773620~65802067:+
COAD	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	4.01	8.08e-05	0.0189	0.29	0.24	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
COAD	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	4.01	8.08e-05	0.0189	0.29	0.24	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
COAD	cis	rs1876905	0.539	rs240969	ENSG00000230177.1	RP5-1112D6.4	4.01	8.08e-05	0.0189	0.25	0.24	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111277932~111278742:+
COAD	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-4.01	8.09e-05	0.0189	-0.29	-0.24	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
COAD	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-4.01	8.09e-05	0.0189	-0.29	-0.24	Height;	chr4:55542948	chr4:55547112~55547889:+
COAD	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-4.01	8.09e-05	0.0189	-0.28	-0.24	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
COAD	cis	rs8022206	0.773	rs60471554	ENSG00000259502.1	RP11-643G16.3	4.01	8.09e-05	0.0189	0.33	0.24	Platelet count;Mean platelet volume;	chr14:68040335	chr14:67610986~67613864:+
COAD	cis	rs494562	0.892	rs522129	ENSG00000234155.1	RP11-30P6.6	-4.01	8.09e-05	0.0189	-0.44	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85406663	chr6:85387219~85390186:-
COAD	cis	rs7933433	0.552	rs4936046	ENSG00000255465.3	RP11-264E20.1	-4.01	8.09e-05	0.019	-0.31	-0.24	Psoriasis;	chr11:128329811	chr11:128615867~128621806:-
COAD	cis	rs2243480	1	rs73142122	ENSG00000232559.3	GS1-124K5.12	4.01	8.1e-05	0.019	0.44	0.24	Diabetic kidney disease;	chr7:65846311	chr7:66554588~66576923:-
COAD	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	4.01	8.1e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
COAD	cis	rs7119	0.667	rs907392	ENSG00000259565.2	KRT8P23	4.01	8.11e-05	0.019	0.28	0.24	Type 2 diabetes;	chr15:77611051	chr15:76979245~76980451:-
COAD	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
COAD	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
COAD	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
COAD	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
COAD	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
COAD	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
COAD	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
COAD	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
COAD	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
COAD	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-4.01	8.11e-05	0.019	-0.25	-0.24	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
COAD	cis	rs2732480	0.557	rs2634682	ENSG00000226413.2	OR8T1P	4.01	8.11e-05	0.019	0.32	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48442030~48442947:-
COAD	cis	rs7172689	1	rs7172611	ENSG00000271725.1	RP11-761I4.4	4.01	8.11e-05	0.019	0.31	0.24	Inattentive symptoms;	chr15:81248628	chr15:81303215~81309391:-
COAD	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-4.01	8.11e-05	0.019	-0.32	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
COAD	cis	rs7577696	0.597	rs212690	ENSG00000272716.1	RP11-563N4.1	4.01	8.11e-05	0.019	0.28	0.24	Inflammatory biomarkers;	chr2:32212562	chr2:32165046~32165757:-
COAD	cis	rs2836974	0.932	rs2150415	ENSG00000255568.3	BRWD1-AS2	4.01	8.11e-05	0.019	0.24	0.24	Cognitive function;	chr21:39243441	chr21:39313935~39314962:+
COAD	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-4.01	8.12e-05	0.019	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
COAD	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	4.01	8.12e-05	0.019	0.21	0.24	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
COAD	cis	rs73191547	0.716	rs6997464	ENSG00000254936.4	AF131215.3	4.01	8.12e-05	0.019	0.26	0.24	Schizophrenia;	chr8:10185864	chr8:11123381~11126064:-
COAD	cis	rs4699052	0.507	rs6533085	ENSG00000246560.2	RP11-10L12.4	4.01	8.12e-05	0.019	0.31	0.24	Testicular germ cell tumor;	chr4:103360429	chr4:102828055~102844075:+
COAD	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-4.01	8.12e-05	0.019	-0.34	-0.24	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
COAD	cis	rs84178	0.733	rs463535	ENSG00000230834.1	AC068580.7	-4.01	8.12e-05	0.019	-0.4	-0.24	Glomerular filtration rate (creatinine);	chr11:2760440	chr11:1776930~1778388:-
COAD	cis	rs9307551	0.948	rs4975056	ENSG00000250334.4	LINC00989	-4	8.12e-05	0.019	-0.32	-0.24	Refractive error;	chr4:79563716	chr4:79492416~79576460:+
COAD	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	4	8.12e-05	0.019	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
COAD	cis	rs73198271	0.603	rs777705	ENSG00000173295.6	FAM86B3P	-4	8.13e-05	0.019	-0.29	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8729358	chr8:8228595~8244865:+
COAD	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	4	8.13e-05	0.019	0.31	0.24	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
COAD	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	4	8.13e-05	0.019	0.31	0.24	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
COAD	cis	rs4683346	1	rs4683346	ENSG00000273328.4	RP11-141M3.6	-4	8.13e-05	0.019	-0.3	-0.24	Granulocyte percentage of myeloid white cells;	chr3:42851469	chr3:42809414~42908105:+
COAD	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	4	8.13e-05	0.019	0.26	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
COAD	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-4	8.14e-05	0.019	-0.31	-0.24	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
COAD	cis	rs17711722	0.522	rs4642526	ENSG00000272831.1	RP11-792A8.4	4	8.15e-05	0.0191	0.25	0.24	Calcium levels;	chr7:65751755	chr7:66739829~66740385:-
COAD	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	4	8.15e-05	0.0191	0.35	0.24	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
COAD	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-4	8.15e-05	0.0191	-0.3	-0.24	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
COAD	cis	rs3126085	0.935	rs4845426	ENSG00000237975.5	FLG-AS1	-4	8.15e-05	0.0191	-0.26	-0.24	Atopic dermatitis;	chr1:152222883	chr1:152168125~152445456:+
COAD	cis	rs6982240	0.514	rs10089212	ENSG00000253307.1	RP11-10J21.4	4	8.16e-05	0.0191	0.32	0.24	Tonsillectomy;	chr8:141255281	chr8:141252286~141253292:-
COAD	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-4	8.16e-05	0.0191	-0.3	-0.24	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
COAD	cis	rs210138	0.591	rs6935686	ENSG00000197251.3	LINC00336	4	8.16e-05	0.0191	0.36	0.24	Testicular germ cell tumor;	chr6:33646350	chr6:33586106~33593338:-
COAD	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-4	8.16e-05	0.0191	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-4	8.16e-05	0.0191	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
COAD	cis	rs1023500	0.505	rs134887	ENSG00000237037.8	NDUFA6-AS1	-4	8.17e-05	0.0191	-0.24	-0.24	Schizophrenia;	chr22:42278233	chr22:42090931~42137742:+
COAD	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	4	8.17e-05	0.0191	0.24	0.24	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
COAD	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-4	8.18e-05	0.0191	-0.48	-0.24	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
COAD	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-4	8.18e-05	0.0191	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
COAD	cis	rs4957798	0.845	rs4957567	ENSG00000272523.1	LINC01023	4	8.18e-05	0.0191	0.26	0.24	Asthma;Asthma (childhood onset);	chr5:109139927	chr5:108727825~108728260:-
COAD	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4	8.18e-05	0.0191	0.3	0.24	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
COAD	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	4	8.18e-05	0.0191	0.31	0.24	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
COAD	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-4	8.19e-05	0.0191	-0.25	-0.24	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
COAD	cis	rs1930961	0.702	rs9624842	ENSG00000271138.1	IGLVIVOR22-1	-4	8.19e-05	0.0191	-0.62	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25497117	chr22:25437306~25437823:-
COAD	cis	rs3733585	0.699	rs1079128	ENSG00000250413.1	RP11-448G15.1	4	8.19e-05	0.0191	0.31	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9949597	chr4:10006482~10009725:+
COAD	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-4	8.19e-05	0.0191	-0.27	-0.24	Gout;	chr7:66654674	chr7:66902857~66906297:+
COAD	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-4	8.19e-05	0.0191	-0.27	-0.24	Gout;	chr7:66661502	chr7:66902857~66906297:+
COAD	cis	rs3120667	0.72	rs72698960	ENSG00000237975.5	FLG-AS1	4	8.19e-05	0.0191	0.34	0.24	Eating disorders;	chr1:152441103	chr1:152168125~152445456:+
COAD	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-4	8.19e-05	0.0191	-0.22	-0.24	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
COAD	cis	rs7955901	0.691	rs60903622	ENSG00000258053.1	CTD-2021H9.3	4	8.19e-05	0.0191	0.3	0.24	Type 2 diabetes;	chr12:71097041	chr12:71047402~71118247:-
COAD	cis	rs9880211	0.528	rs75685279	ENSG00000273486.1	RP11-731C17.2	4	8.19e-05	0.0191	0.27	0.24	Height;Body mass index;	chr3:136715991	chr3:136837338~136839021:-
COAD	cis	rs2559856	1	rs2559858	ENSG00000199933.1	RNY1P16	4	8.19e-05	0.0191	0.26	0.24	Blood protein levels;	chr12:101695522	chr12:101719808~101719918:+
COAD	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	4	8.19e-05	0.0191	0.3	0.24	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
COAD	cis	rs9652601	0.959	rs9931397	ENSG00000274038.1	RP11-66H6.4	-4	8.2e-05	0.0192	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11083537	chr16:11056556~11057034:+
COAD	cis	rs12908161	0.853	rs12912342	ENSG00000259728.4	LINC00933	4	8.2e-05	0.0192	0.31	0.24	Schizophrenia;	chr15:84704985	chr15:84570649~84580175:+
COAD	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	4	8.2e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
COAD	cis	rs801193	0.636	rs2659895	ENSG00000179406.6	LINC00174	4	8.2e-05	0.0192	0.18	0.24	Aortic root size;	chr7:66731484	chr7:66376044~66401338:-
COAD	cis	rs11018904	0.861	rs61903723	ENSG00000280385.1	AP000648.5	-4	8.2e-05	0.0192	-0.33	-0.24	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90193614~90198120:+
COAD	cis	rs763121	0.853	rs3747172	ENSG00000273076.1	RP3-508I15.22	4	8.2e-05	0.0192	0.21	0.24	Menopause (age at onset);	chr22:38671519	chr22:38743495~38743910:+
COAD	cis	rs6545883	0.501	rs935860	ENSG00000273302.1	RP11-493E12.2	4	8.2e-05	0.0192	0.22	0.24	Tuberculosis;	chr2:61179426	chr2:61199979~61200769:+
COAD	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-4	8.2e-05	0.0192	-0.3	-0.24	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
COAD	cis	rs2919009	0.607	rs56004902	ENSG00000271670.1	RP11-95I16.4	4	8.2e-05	0.0192	0.33	0.24	Obesity-related traits;	chr10:120938378	chr10:120879256~120880667:-
COAD	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	4	8.2e-05	0.0192	0.28	0.24	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
COAD	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-4	8.21e-05	0.0192	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
COAD	cis	rs11157436	0.602	rs17255447	ENSG00000211812.1	TRAV26-2	4	8.21e-05	0.0192	0.23	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22202583~22203368:+
COAD	cis	rs4879656	0.872	rs10758180	ENSG00000225693.1	LAGE3P1	4	8.21e-05	0.0192	0.28	0.24	Menopause (age at onset);	chr9:33045149	chr9:33019682~33020165:-
COAD	cis	rs12699921	0.598	rs1852010	ENSG00000279048.1	RP11-511H23.2	-4	8.21e-05	0.0192	-0.18	-0.24	Fibrinogen levels;	chr7:17786744	chr7:17940503~17942922:+
COAD	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	4	8.21e-05	0.0192	0.29	0.24	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
COAD	cis	rs9921222	0.5	rs8046256	ENSG00000268836.1	LA16c-OS12.2	4	8.22e-05	0.0192	0.33	0.24	Bone mineral density (spine);Bone mineral density;	chr16:343948	chr16:185748~186294:-
COAD	cis	rs34779708	0.966	rs2505639	ENSG00000271335.4	RP11-324I22.4	-4	8.22e-05	0.0192	-0.26	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35314552~35336401:-
COAD	cis	rs752010	0.806	rs4641303	ENSG00000230638.4	RP11-486B10.4	-4	8.22e-05	0.0192	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625639	chr1:41542069~41544310:+
COAD	cis	rs752010	0.806	rs4457567	ENSG00000230638.4	RP11-486B10.4	-4	8.22e-05	0.0192	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625736	chr1:41542069~41544310:+
COAD	cis	rs752010	0.806	rs10890148	ENSG00000230638.4	RP11-486B10.4	-4	8.22e-05	0.0192	-0.28	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41625846	chr1:41542069~41544310:+
COAD	cis	rs9585327	0.774	rs9513703	ENSG00000203441.2	LINC00449	4	8.23e-05	0.0192	0.3	0.24	Myopia;	chr13:100076110	chr13:99499727~99501052:-
COAD	cis	rs7955901	0.691	rs7311994	ENSG00000258053.1	CTD-2021H9.3	4	8.23e-05	0.0192	0.31	0.24	Type 2 diabetes;	chr12:71116475	chr12:71047402~71118247:-
COAD	cis	rs2243480	0.708	rs35825036	ENSG00000232559.3	GS1-124K5.12	4	8.23e-05	0.0192	0.43	0.24	Diabetic kidney disease;	chr7:66521515	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs13237037	ENSG00000232559.3	GS1-124K5.12	4	8.23e-05	0.0192	0.43	0.24	Diabetic kidney disease;	chr7:66532895	chr7:66554588~66576923:-
COAD	cis	rs6940638	0.688	rs7744759	ENSG00000224843.5	LINC00240	4	8.23e-05	0.0192	0.31	0.24	Intelligence (multi-trait analysis);	chr6:27152047	chr6:26956992~27023924:+
COAD	cis	rs6940638	0.688	rs1028308	ENSG00000224843.5	LINC00240	4	8.23e-05	0.0192	0.31	0.24	Intelligence (multi-trait analysis);	chr6:27161978	chr6:26956992~27023924:+
COAD	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	4	8.23e-05	0.0192	0.45	0.24	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
COAD	cis	rs12468226	1	rs77435512	ENSG00000226261.1	AC064836.3	4	8.23e-05	0.0192	0.36	0.24	Urate levels;	chr2:202334165	chr2:202336024~202336727:-
COAD	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-4	8.24e-05	0.0192	-0.3	-0.24	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
COAD	cis	rs10043775	0.872	rs9325097	ENSG00000251330.3	CTD-2283N19.1	-4	8.24e-05	0.0192	-0.28	-0.24	Periodontal microbiota;	chr5:148440782	chr5:148430159~148430807:-
COAD	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	4	8.24e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	4	8.24e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	4	8.24e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	4	8.24e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	4	8.24e-05	0.0192	0.35	0.24	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
COAD	cis	rs911555	0.692	rs7140647	ENSG00000251533.2	LINC00605	4	8.24e-05	0.0192	0.32	0.24	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103187221~103189028:-
COAD	cis	rs12530	1	rs12530	ENSG00000232218.1	RP1-149A16.16	-4	8.25e-05	0.0192	-0.43	-0.24	IgG glycosylation;	chr22:32387917	chr22:32386668~32386868:+
COAD	cis	rs7572733	0.84	rs13029495	ENSG00000222017.1	AC011997.1	-4	8.25e-05	0.0192	-0.27	-0.24	Dermatomyositis;	chr2:197717877	chr2:197693106~197774823:+
COAD	cis	rs9880211	1	rs34757183	ENSG00000273486.1	RP11-731C17.2	4	8.25e-05	0.0192	0.28	0.24	Height;Body mass index;	chr3:136424826	chr3:136837338~136839021:-
COAD	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-4	8.25e-05	0.0192	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
COAD	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-4	8.25e-05	0.0192	-0.47	-0.24	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
COAD	cis	rs36052053	0.908	rs13199388	ENSG00000219700.1	PTCHD3P3	4	8.26e-05	0.0193	0.43	0.24	Red cell distribution width;	chr6:109262897	chr6:109288571~109290503:-
COAD	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-4	8.26e-05	0.0193	-0.3	-0.24	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
COAD	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	4	8.26e-05	0.0193	0.23	0.24	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
COAD	cis	rs4819052	0.808	rs11909411	ENSG00000227039.5	ITGB2-AS1	-4	8.27e-05	0.0193	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs28676615	ENSG00000227039.5	ITGB2-AS1	-4	8.27e-05	0.0193	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs28501512	ENSG00000227039.5	ITGB2-AS1	-4	8.27e-05	0.0193	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:44921051~44929678:+
COAD	cis	rs2179367	0.632	rs56924465	ENSG00000216906.2	RP11-350J20.9	4	8.27e-05	0.0193	0.35	0.24	Dupuytren's disease;	chr6:149350270	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.568	rs62426092	ENSG00000216906.2	RP11-350J20.9	4	8.27e-05	0.0193	0.35	0.24	Dupuytren's disease;	chr6:149352720	chr6:149904243~149906418:+
COAD	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	4	8.27e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
COAD	cis	rs742132	0.858	rs10946788	ENSG00000220875.1	HIST1H3PS1	4	8.27e-05	0.0193	0.31	0.24	Uric acid levels;	chr6:25660282	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs2072850	ENSG00000220875.1	HIST1H3PS1	4	8.27e-05	0.0193	0.31	0.24	Uric acid levels;	chr6:25661140	chr6:26321876~26322292:-
COAD	cis	rs11098499	0.866	rs6847778	ENSG00000249244.1	RP11-548H18.2	4	8.27e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119372427	chr4:119391831~119395335:-
COAD	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-4	8.27e-05	0.0193	-0.29	-0.24	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-4	8.27e-05	0.0193	-0.29	-0.24	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
COAD	cis	rs9532669	0.963	rs9532681	ENSG00000277662.1	RP11-74J13.9	-4	8.27e-05	0.0193	-0.24	-0.24	Cervical cancer;	chr13:40951633	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs4516083	ENSG00000277662.1	RP11-74J13.9	-4	8.27e-05	0.0193	-0.24	-0.24	Cervical cancer;	chr13:40951783	chr13:41229180~41229676:-
COAD	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	4	8.28e-05	0.0193	0.32	0.24	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
COAD	cis	rs6940638	0.688	rs6456766	ENSG00000224843.5	LINC00240	4	8.28e-05	0.0193	0.31	0.24	Intelligence (multi-trait analysis);	chr6:27051796	chr6:26956992~27023924:+
COAD	cis	rs7246657	0.598	rs28660259	ENSG00000226686.6	LINC01535	-4	8.28e-05	0.0193	-0.41	-0.24	Coronary artery calcification;	chr19:37167779	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.653	rs10401525	ENSG00000226686.6	LINC01535	-4	8.28e-05	0.0193	-0.41	-0.24	Coronary artery calcification;	chr19:37168077	chr19:37251912~37265535:+
COAD	cis	rs4766566	0.501	rs3742004	ENSG00000257595.2	RP3-473L9.4	4	8.28e-05	0.0193	0.36	0.24	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;	chr12:111360749	chr12:111369282~111403310:+
COAD	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-4	8.28e-05	0.0193	-0.3	-0.24	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
COAD	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	4	8.28e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	4	8.28e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	4	8.28e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	4	8.28e-05	0.0193	0.32	0.24	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
COAD	cis	rs11969893	0.655	rs67724651	ENSG00000270987.1	RP3-467N11.2	4	8.29e-05	0.0193	0.61	0.24	Economic and political preferences (immigration/crime);	chr6:100969128	chr6:100889603~100890338:+
COAD	cis	rs2307394	1	rs13017754	ENSG00000281469.1	RP11-567F11.1	4	8.29e-05	0.0193	0.3	0.24	Urate levels;	chr2:147837786	chr2:148044380~148044894:+
COAD	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-4	8.29e-05	0.0193	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-4	8.29e-05	0.0193	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
COAD	cis	rs6723226	0.766	rs398290	ENSG00000276334.1	AL133243.1	4	8.29e-05	0.0193	0.23	0.24	Intelligence (multi-trait analysis);	chr2:32278457	chr2:32521927~32523547:+
COAD	cis	rs67072384	0.748	rs6592484	ENSG00000202522.1	Y_RNA	-4	8.3e-05	0.0193	-0.35	-0.24	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72753425	chr11:72766004~72766116:+
COAD	cis	rs67072384	0.818	rs1872127	ENSG00000202522.1	Y_RNA	-4	8.3e-05	0.0193	-0.35	-0.24	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72754040	chr11:72766004~72766116:+
COAD	cis	rs67072384	0.818	rs1872128	ENSG00000202522.1	Y_RNA	-4	8.3e-05	0.0193	-0.35	-0.24	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72754481	chr11:72766004~72766116:+
COAD	cis	rs67072384	0.818	rs2291290	ENSG00000202522.1	Y_RNA	-4	8.3e-05	0.0193	-0.35	-0.24	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72754832	chr11:72766004~72766116:+
COAD	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-4	8.3e-05	0.0193	-0.17	-0.24	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
COAD	cis	rs480407	0.667	rs55923506	ENSG00000232320.6	AC009299.5	4	8.3e-05	0.0193	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160780010	chr2:161340816~161341326:-
COAD	cis	rs480407	0.667	rs62195647	ENSG00000232320.6	AC009299.5	4	8.3e-05	0.0193	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160780613	chr2:161340816~161341326:-
COAD	cis	rs480407	0.667	rs72973141	ENSG00000232320.6	AC009299.5	4	8.3e-05	0.0193	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160781984	chr2:161340816~161341326:-
COAD	cis	rs480407	0.667	rs58466164	ENSG00000232320.6	AC009299.5	4	8.3e-05	0.0193	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160782396	chr2:161340816~161341326:-
COAD	cis	rs480407	0.667	rs6714265	ENSG00000232320.6	AC009299.5	4	8.3e-05	0.0193	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160789414	chr2:161340816~161341326:-
COAD	cis	rs875971	0.545	rs73376394	ENSG00000224316.1	RP11-479O9.2	4	8.3e-05	0.0193	0.29	0.24	Aortic root size;	chr7:66172694	chr7:65773620~65802067:+
COAD	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	4	8.3e-05	0.0193	0.18	0.24	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
COAD	cis	rs3126085	0.515	rs7534742	ENSG00000237975.5	FLG-AS1	4	8.31e-05	0.0194	0.29	0.24	Atopic dermatitis;	chr1:152390251	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs10788838	ENSG00000237975.5	FLG-AS1	4	8.31e-05	0.0194	0.29	0.24	Atopic dermatitis;	chr1:152390725	chr1:152168125~152445456:+
COAD	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	4	8.31e-05	0.0194	0.27	0.24	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
COAD	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	4	8.31e-05	0.0194	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
COAD	cis	rs6585424	1	rs12268619	ENSG00000234382.2	RP11-40F6.1	-4	8.31e-05	0.0194	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:80233664~80245367:+
COAD	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-4	8.32e-05	0.0194	-0.29	-0.24	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
COAD	cis	rs4819052	0.851	rs2838831	ENSG00000227039.5	ITGB2-AS1	-4	8.32e-05	0.0194	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:44921051~44929678:+
COAD	cis	rs10760158	0.769	rs10818517	ENSG00000226752.6	PSMD5-AS1	-4	8.32e-05	0.0194	-0.26	-0.24	Pulse pressure;	chr9:121242321	chr9:120824828~120854385:+
COAD	cis	rs7577696	0.924	rs6748621	ENSG00000272716.1	RP11-563N4.1	-4	8.32e-05	0.0194	-0.26	-0.24	Inflammatory biomarkers;	chr2:32037132	chr2:32165046~32165757:-
COAD	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-4	8.33e-05	0.0194	-0.29	-0.24	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
COAD	cis	rs7615952	0.641	rs12491577	ENSG00000248787.1	RP11-666A20.4	-4	8.33e-05	0.0194	-0.34	-0.24	Blood pressure (smoking interaction);	chr3:126012288	chr3:125908005~125910272:-
COAD	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	4	8.33e-05	0.0194	0.36	0.24	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	4	8.33e-05	0.0194	0.36	0.24	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	4	8.33e-05	0.0194	0.36	0.24	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
COAD	cis	rs13256369	1	rs873064	ENSG00000253981.4	ALG1L13P	4	8.33e-05	0.0194	0.35	0.24	Obesity-related traits;	chr8:8714870	chr8:8236003~8244667:-
COAD	cis	rs13256369	1	rs4841016	ENSG00000253981.4	ALG1L13P	4	8.33e-05	0.0194	0.35	0.24	Obesity-related traits;	chr8:8715051	chr8:8236003~8244667:-
COAD	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	4	8.33e-05	0.0194	0.31	0.24	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
COAD	cis	rs7829975	0.577	rs7816329	ENSG00000173295.6	FAM86B3P	-4	8.33e-05	0.0194	-0.29	-0.24	Mood instability;	chr8:8686333	chr8:8228595~8244865:+
COAD	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-4	8.33e-05	0.0194	-0.28	-0.24	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
COAD	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-4	8.33e-05	0.0194	-0.27	-0.24	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
COAD	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-4	8.33e-05	0.0194	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
COAD	cis	rs2439831	1	rs28628574	ENSG00000201136.1	RNU6-353P	-4	8.34e-05	0.0194	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43509840	chr15:43702363~43702470:+
COAD	cis	rs41464545	1	rs17085715	ENSG00000249413.2	RP11-25H12.1	4	8.34e-05	0.0194	0.32	0.24	Schizophrenia;	chr4:65010293	chr4:65998846~66150012:+
COAD	cis	rs763121	0.853	rs5750668	ENSG00000273076.1	RP3-508I15.22	4	8.34e-05	0.0194	0.22	0.24	Menopause (age at onset);	chr22:38683959	chr22:38743495~38743910:+
COAD	cis	rs11096990	0.613	rs12643415	ENSG00000249207.1	RP11-360F5.1	4	8.34e-05	0.0194	0.26	0.24	Cognitive function;	chr4:39270375	chr4:39112677~39126818:-
COAD	cis	rs2732480	0.557	rs2732441	ENSG00000226413.2	OR8T1P	4	8.34e-05	0.0194	0.32	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs2732448	ENSG00000226413.2	OR8T1P	4	8.34e-05	0.0194	0.32	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48442030~48442947:-
COAD	cis	rs1062753	0.527	rs6519296	ENSG00000182057.4	OGFRP1	-4	8.34e-05	0.0194	-0.24	-0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41952598	chr22:42269753~42275196:+
COAD	cis	rs860295	0.871	rs11582072	ENSG00000223503.1	RP11-29H23.6	4	8.34e-05	0.0194	0.32	0.24	Body mass index;	chr1:155507779	chr1:155590601~155591262:-
COAD	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-4	8.34e-05	0.0194	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-4	8.34e-05	0.0194	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
COAD	cis	rs2904967	1	rs626555	ENSG00000245532.5	NEAT1	4	8.34e-05	0.0194	0.27	0.24	Mean corpuscular volume;	chr11:65296082	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.866	rs8638	ENSG00000245532.5	NEAT1	4	8.34e-05	0.0194	0.27	0.24	Mean corpuscular volume;	chr11:65297447	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.866	rs506280	ENSG00000245532.5	NEAT1	4	8.34e-05	0.0194	0.27	0.24	Mean corpuscular volume;	chr11:65302063	chr11:65422774~65445540:+
COAD	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	4	8.35e-05	0.0194	0.32	0.24	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	4	8.35e-05	0.0194	0.32	0.24	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	4	8.35e-05	0.0194	0.32	0.24	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
COAD	cis	rs6585424	1	rs10466228	ENSG00000234382.2	RP11-40F6.1	-4	8.35e-05	0.0194	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:80233664~80245367:+
COAD	cis	rs12699921	0.599	rs2691583	ENSG00000279048.1	RP11-511H23.2	-4	8.35e-05	0.0194	-0.18	-0.24	Fibrinogen levels;	chr7:17792182	chr7:17940503~17942922:+
COAD	cis	rs719150	1	rs5029926	ENSG00000237499.5	RP11-356I2.4	-4	8.35e-05	0.0194	-0.34	-0.24	Cancer;	chr6:137868378	chr6:137823673~137868233:-
COAD	cis	rs7208859	0.623	rs426434	ENSG00000264538.5	SUZ12P1	-4	8.35e-05	0.0194	-0.26	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30709299~30790908:+
COAD	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-4	8.36e-05	0.0194	-0.28	-0.24	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-4	8.36e-05	0.0194	-0.28	-0.24	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-4	8.36e-05	0.0194	-0.28	-0.24	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-4	8.36e-05	0.0194	-0.28	-0.24	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
COAD	cis	rs6601855	1	rs6601855	ENSG00000242147.1	RP13-463N16.6	-4	8.36e-05	0.0194	-0.3	-0.24	Major depressive disorder;	chr10:4683148	chr10:5594991~5596118:-
COAD	cis	rs9393777	0.513	rs6924727	ENSG00000224843.5	LINC00240	4	8.36e-05	0.0195	0.35	0.24	Intelligence (multi-trait analysis);	chr6:26491006	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.588	rs6941920	ENSG00000224843.5	LINC00240	4	8.36e-05	0.0195	0.35	0.24	Intelligence (multi-trait analysis);	chr6:26491921	chr6:26956992~27023924:+
COAD	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	4	8.37e-05	0.0195	0.23	0.24	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
COAD	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-4	8.37e-05	0.0195	-0.32	-0.24	Depression;	chr6:28201380	chr6:28170845~28172521:+
COAD	cis	rs6017291	0.59	rs73106287	ENSG00000223891.4	OSER1-AS1	4	8.37e-05	0.0195	0.3	0.24	Cognitive performance;	chr20:44213723	chr20:44210960~44226027:+
COAD	cis	rs6017291	0.623	rs73106290	ENSG00000223891.4	OSER1-AS1	4	8.37e-05	0.0195	0.3	0.24	Cognitive performance;	chr20:44214631	chr20:44210960~44226027:+
COAD	cis	rs6017291	0.793	rs73106293	ENSG00000223891.4	OSER1-AS1	4	8.37e-05	0.0195	0.3	0.24	Cognitive performance;	chr20:44215289	chr20:44210960~44226027:+
COAD	cis	rs9604573	0.869	rs7400614	ENSG00000233695.2	GAS6-AS1	4	8.37e-05	0.0195	0.26	0.24	Glycated hemoglobin levels;	chr13:113849007	chr13:113815630~113845744:+
COAD	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-4	8.37e-05	0.0195	-0.46	-0.24	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
COAD	cis	rs6661961	0.686	rs7555924	ENSG00000237975.5	FLG-AS1	-4	8.37e-05	0.0195	-0.24	-0.24	Atopic dermatitis;	chr1:152424593	chr1:152168125~152445456:+
COAD	cis	rs9910055	1	rs2071167	ENSG00000267080.4	ASB16-AS1	4	8.37e-05	0.0195	0.22	0.24	Total body bone mineral density;	chr17:44210151	chr17:44175973~44186717:-
COAD	cis	rs2617170	0.922	rs2617149	ENSG00000245648.1	RP11-277P12.20	-4	8.37e-05	0.0195	-0.32	-0.24	Behcet's disease;	chr12:10375734	chr12:10363769~10398506:+
COAD	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-4	8.37e-05	0.0195	-0.29	-0.24	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
COAD	cis	rs2115630	1	rs11854313	ENSG00000259728.4	LINC00933	-4	8.38e-05	0.0195	-0.29	-0.24	P wave terminal force;	chr15:84760817	chr15:84570649~84580175:+
COAD	cis	rs11650494	0.71	rs76305536	ENSG00000257178.3	RP11-357H14.16	4	8.38e-05	0.0195	0.47	0.24	Prostate cancer;	chr17:49411551	chr17:48579630~48582259:-
COAD	cis	rs2836974	0.965	rs2836967	ENSG00000255568.3	BRWD1-AS2	4	8.38e-05	0.0195	0.25	0.24	Cognitive function;	chr21:39267176	chr21:39313935~39314962:+
COAD	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-4	8.38e-05	0.0195	-0.27	-0.24	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
COAD	cis	rs2723064	0.516	rs17849707	ENSG00000214533.3	KRT18P33	4	8.38e-05	0.0195	0.29	0.24	Atrial fibrillation;	chr2:65071705	chr2:65666695~65667737:+
COAD	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-4	8.38e-05	0.0195	-0.28	-0.24	QT interval;	chr12:29306357	chr12:29277397~29277882:-
COAD	cis	rs6095360	0.7	rs67623477	ENSG00000222365.1	SNORD12B	-4	8.38e-05	0.0195	-0.27	-0.24	Intelligence (multi-trait analysis);	chr20:49052640	chr20:49280319~49280409:+
COAD	cis	rs6088813	0.744	rs1210224	ENSG00000269202.1	RP4-614O4.12	4	8.39e-05	0.0195	0.25	0.24	Height;	chr20:35393057	chr20:35201747~35203288:-
COAD	cis	rs6088813	0.744	rs1204656	ENSG00000269202.1	RP4-614O4.12	4	8.39e-05	0.0195	0.25	0.24	Height;	chr20:35395043	chr20:35201747~35203288:-
COAD	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	4	8.39e-05	0.0195	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
COAD	cis	rs9880211	0.613	rs6786582	ENSG00000239213.4	NCK1-AS1	-4	8.39e-05	0.0195	-0.32	-0.24	Height;Body mass index;	chr3:136180142	chr3:136841726~136862054:-
COAD	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-4	8.39e-05	0.0195	-0.26	-0.24	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
COAD	cis	rs495337	0.677	rs6012750	ENSG00000229222.1	KRT18P4	4	8.39e-05	0.0195	0.25	0.24	Psoriasis;	chr20:49814143	chr20:49956745~49958032:+
COAD	cis	rs4820539	1	rs885964	ENSG00000211644.2	IGLV1-51	-4	8.39e-05	0.0195	-0.14	-0.24	Bone mineral density;	chr22:23118816	chr22:22322472~22322980:+
COAD	cis	rs75422866	0.764	rs67408202	ENSG00000280054.1	RP1-197B17.7	4	8.39e-05	0.0195	0.52	0.24	Pneumonia;	chr12:47713564	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.867	rs57848393	ENSG00000280054.1	RP1-197B17.7	4	8.39e-05	0.0195	0.52	0.24	Pneumonia;	chr12:47714734	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.764	rs67201012	ENSG00000280054.1	RP1-197B17.7	4	8.39e-05	0.0195	0.52	0.24	Pneumonia;	chr12:47715881	chr12:47728151~47730598:-
COAD	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-4	8.4e-05	0.0195	-0.29	-0.24	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-4	8.4e-05	0.0195	-0.29	-0.24	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-4	8.4e-05	0.0195	-0.29	-0.24	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-4	8.4e-05	0.0195	-0.29	-0.24	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-4	8.4e-05	0.0195	-0.29	-0.24	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
COAD	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	4	8.4e-05	0.0195	0.28	0.24	Height;	chr4:55570311	chr4:55547112~55547889:+
COAD	cis	rs2408955	0.521	rs1476607	ENSG00000226413.2	OR8T1P	-4	8.4e-05	0.0195	-0.3	-0.24	Glycated hemoglobin levels;	chr12:48131021	chr12:48442030~48442947:-
COAD	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-4	8.4e-05	0.0195	-0.3	-0.24	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
COAD	cis	rs6687821	0.5	rs2753270	ENSG00000261737.1	RP4-612B15.3	-4	8.4e-05	0.0195	-0.31	-0.24	Yeast infection;	chr1:86947874	chr1:86703502~86704462:-
COAD	cis	rs7615952	1	rs7616044	ENSG00000241278.1	ENPP7P4	4	8.4e-05	0.0195	0.26	0.24	Blood pressure (smoking interaction);	chr3:125930511	chr3:125848223~125909372:+
COAD	cis	rs3096299	0.73	rs3114895	ENSG00000274627.1	RP11-104N10.2	4	8.41e-05	0.0195	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89328402	chr16:89516797~89522217:+
COAD	cis	rs9487051	1	rs1341271	ENSG00000219700.1	PTCHD3P3	4	8.41e-05	0.0195	0.27	0.24	Reticulocyte fraction of red cells;	chr6:109296339	chr6:109288571~109290503:-
COAD	cis	rs7577696	0.962	rs212745	ENSG00000272716.1	RP11-563N4.1	4	8.41e-05	0.0195	0.25	0.24	Inflammatory biomarkers;	chr2:32187763	chr2:32165046~32165757:-
COAD	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	4	8.41e-05	0.0195	0.32	0.24	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	4	8.41e-05	0.0195	0.32	0.24	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
COAD	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-4	8.41e-05	0.0195	-0.33	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
COAD	cis	rs10043775	1	rs10060623	ENSG00000251330.3	CTD-2283N19.1	-4	8.42e-05	0.0195	-0.29	-0.24	Periodontal microbiota;	chr5:148411636	chr5:148430159~148430807:-
COAD	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	4	8.42e-05	0.0196	0.32	0.24	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
COAD	cis	rs16850885	1	rs1246592	ENSG00000249942.1	AC142293.3	-4	8.42e-05	0.0196	-0.54	-0.24	Immune reponse to smallpox (secreted IL-1beta);	chr4:74243862	chr4:74552584~74589481:-
COAD	cis	rs763121	0.853	rs5750673	ENSG00000273076.1	RP3-508I15.22	4	8.42e-05	0.0196	0.22	0.24	Menopause (age at onset);	chr22:38714119	chr22:38743495~38743910:+
COAD	cis	rs7000734	0.687	rs297550	ENSG00000245080.5	RP11-320N21.1	4	8.42e-05	0.0196	0.45	0.24	Radiation response;	chr8:95089566	chr8:95066808~95073182:-
COAD	cis	rs1928295	0.75	rs10818054	ENSG00000233569.1	RP11-500B12.1	4	8.43e-05	0.0196	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625739	chr9:117648606~117657027:+
COAD	cis	rs719150	1	rs59693083	ENSG00000237499.5	RP11-356I2.4	-4	8.44e-05	0.0196	-0.34	-0.24	Cancer;	chr6:137865395	chr6:137823673~137868233:-
COAD	cis	rs10819861	0.645	rs10819815	ENSG00000238251.2	RP11-172F4.2	-4	8.44e-05	0.0196	-0.3	-0.24	Electrocardiographic traits;	chr9:96092440	chr9:96407284~96407797:+
COAD	cis	rs6012564	1	rs6122763	ENSG00000227431.4	CSE1L-AS1	-4	8.44e-05	0.0196	-0.26	-0.24	Anger;	chr20:49181116	chr20:49040463~49046044:-
COAD	cis	rs710913	0.587	rs6690413	ENSG00000182109.6	RP11-69E11.4	4	8.44e-05	0.0196	0.26	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39522280~39546187:-
COAD	cis	rs9818758	0.607	rs56306491	ENSG00000225399.4	RP11-3B7.1	-4	8.44e-05	0.0196	-0.49	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chr3:49260085~49261316:+
COAD	cis	rs11168351	1	rs11168351	ENSG00000257735.1	RP11-370I10.6	4	8.45e-05	0.0196	0.28	0.24	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48350945~48442411:+
COAD	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-4	8.45e-05	0.0196	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
COAD	cis	rs4820539	0.902	rs737846	ENSG00000211644.2	IGLV1-51	-4	8.45e-05	0.0196	-0.14	-0.24	Bone mineral density;	chr22:23118482	chr22:22322472~22322980:+
COAD	cis	rs13188386	0.763	rs34374598	ENSG00000249779.1	RP11-447H19.3	4	8.45e-05	0.0196	0.29	0.24	Iron status biomarkers;	chr5:42553129	chr5:43206709~43207811:+
COAD	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	3.99	8.45e-05	0.0196	0.28	0.24	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
COAD	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	3.99	8.45e-05	0.0196	0.35	0.24	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
COAD	cis	rs7647973	0.621	rs3774800	ENSG00000225399.4	RP11-3B7.1	-3.99	8.45e-05	0.0196	-0.28	-0.24	Menarche (age at onset);	chr3:49297335	chr3:49260085~49261316:+
COAD	cis	rs7819412	0.745	rs6601569	ENSG00000255495.1	AC145124.2	-3.99	8.45e-05	0.0196	-0.31	-0.24	Triglycerides;	chr8:11216069	chr8:12194467~12196280:+
COAD	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	3.99	8.45e-05	0.0196	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	3.99	8.45e-05	0.0196	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
COAD	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	3.99	8.45e-05	0.0196	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
COAD	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-3.99	8.45e-05	0.0196	-0.35	-0.24	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
COAD	cis	rs7131987	0.801	rs6487804	ENSG00000257176.2	RP11-996F15.2	-3.99	8.46e-05	0.0196	-0.28	-0.24	QT interval;	chr12:29302001	chr12:29280418~29317848:-
COAD	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	3.99	8.46e-05	0.0196	0.26	0.24	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	3.99	8.46e-05	0.0196	0.26	0.24	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	3.99	8.46e-05	0.0196	0.26	0.24	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	3.99	8.46e-05	0.0196	0.26	0.24	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	3.99	8.46e-05	0.0196	0.26	0.24	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
COAD	cis	rs36423	0.748	rs36377	ENSG00000266869.1	RP6-114E22.1	-3.99	8.46e-05	0.0196	-0.36	-0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71905994	chr14:71848606~71908430:+
COAD	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-3.99	8.46e-05	0.0196	-0.33	-0.24	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
COAD	cis	rs6732160	0.613	rs58317144	ENSG00000163016.8	ALMS1P	3.99	8.46e-05	0.0196	0.31	0.24	Intelligence (multi-trait analysis);	chr2:73161025	chr2:73644919~73685576:+
COAD	cis	rs597539	0.617	rs598353	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68941503~68942852:-
COAD	cis	rs597539	0.617	rs686348	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs686877	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs579136	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs10792001	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68941503~68942852:-
COAD	cis	rs597539	0.652	rs613128	ENSG00000255741.1	RP11-757G1.5	-3.99	8.46e-05	0.0196	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68941503~68942852:-
COAD	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-3.99	8.46e-05	0.0196	-0.39	-0.24	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
COAD	cis	rs7009110	0.581	rs7822328	ENSG00000213791.4	RP11-941H19.2	-3.99	8.46e-05	0.0196	-0.24	-0.24	Asthma and hay fever;	chr8:80334424	chr8:80300869~80301481:+
COAD	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-3.99	8.47e-05	0.0196	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
COAD	cis	rs11229555	0.609	rs12270515	ENSG00000254602.1	AP000662.4	-3.99	8.47e-05	0.0196	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58450472	chr11:57638024~57652790:+
COAD	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-3.99	8.47e-05	0.0196	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
COAD	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-3.99	8.47e-05	0.0196	-0.29	-0.24	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
COAD	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	3.99	8.47e-05	0.0196	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	3.99	8.47e-05	0.0196	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	3.99	8.47e-05	0.0196	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	3.99	8.47e-05	0.0196	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
COAD	cis	rs9907295	0.818	rs7211393	ENSG00000270977.1	AC015849.16	-3.99	8.47e-05	0.0196	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35893707~35911023:-
COAD	cis	rs9307551	0.741	rs6824396	ENSG00000250334.4	LINC00989	-3.99	8.47e-05	0.0197	-0.29	-0.24	Refractive error;	chr4:79541178	chr4:79492416~79576460:+
COAD	cis	rs3126085	1	rs3126085	ENSG00000237975.5	FLG-AS1	3.99	8.48e-05	0.0197	0.28	0.24	Atopic dermatitis;	chr1:152328341	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs3120662	ENSG00000237975.5	FLG-AS1	3.99	8.48e-05	0.0197	0.28	0.24	Atopic dermatitis;	chr1:152330389	chr1:152168125~152445456:+
COAD	cis	rs860295	0.756	rs7546258	ENSG00000160766.13	GBAP1	-3.99	8.48e-05	0.0197	-0.28	-0.24	Body mass index;	chr1:155728854	chr1:155213821~155227422:-
COAD	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-3.99	8.48e-05	0.0197	-0.42	-0.24	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
COAD	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	3.99	8.48e-05	0.0197	0.25	0.24	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
COAD	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	3.99	8.48e-05	0.0197	0.25	0.24	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
COAD	cis	rs9880211	0.948	rs34282798	ENSG00000273486.1	RP11-731C17.2	3.99	8.49e-05	0.0197	0.28	0.24	Height;Body mass index;	chr3:136424515	chr3:136837338~136839021:-
COAD	cis	rs6490294	0.904	rs4767264	ENSG00000257595.2	RP3-473L9.4	-3.99	8.49e-05	0.0197	-0.34	-0.24	Mean platelet volume;	chr12:111987942	chr12:111369282~111403310:+
COAD	cis	rs6982240	0.514	rs72681579	ENSG00000253307.1	RP11-10J21.4	3.99	8.49e-05	0.0197	0.32	0.24	Tonsillectomy;	chr8:141252975	chr8:141252286~141253292:-
COAD	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-3.99	8.49e-05	0.0197	-0.33	-0.24	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
COAD	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	3.99	8.49e-05	0.0197	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
COAD	cis	rs7246657	0.943	rs2045908	ENSG00000226686.6	LINC01535	-3.99	8.49e-05	0.0197	-0.33	-0.24	Coronary artery calcification;	chr19:37488866	chr19:37251912~37265535:+
COAD	cis	rs764255	0.581	rs766765	ENSG00000279591.1	AC002044.1	3.99	8.5e-05	0.0197	0.29	0.24	Word reading;	chr16:73680717	chr16:73015047~73016016:-
COAD	cis	rs2337406	0.866	rs2301535	ENSG00000211964.3	IGHV3-48	-3.99	8.5e-05	0.0197	-0.21	-0.24	Alzheimer's disease (late onset);	chr14:106790663	chr14:106537810~106538344:-
COAD	cis	rs3126085	0.825	rs7535078	ENSG00000237975.5	FLG-AS1	-3.99	8.5e-05	0.0197	-0.27	-0.24	Atopic dermatitis;	chr1:152250439	chr1:152168125~152445456:+
COAD	cis	rs10971721	0.631	rs117965906	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34063843	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.631	rs55943129	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34064796	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.631	rs72729385	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34065401	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.631	rs10971882	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34066186	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.631	rs10971883	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34066487	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.631	rs56278960	ENSG00000260947.1	RP11-384P7.7	3.99	8.5e-05	0.0197	0.43	0.24	Body mass index;	chr9:34073416	chr9:33697459~33700986:+
COAD	cis	rs3813567	0.759	rs12148319	ENSG00000261143.1	ADAMTS7P3	-3.99	8.5e-05	0.0197	-0.38	-0.24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78663850	chr15:77976042~77993057:+
COAD	cis	rs1876905	0.539	rs240980	ENSG00000230177.1	RP5-1112D6.4	3.99	8.5e-05	0.0197	0.26	0.24	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111277932~111278742:+
COAD	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	3.99	8.51e-05	0.0197	0.34	0.24	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
COAD	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	3.99	8.51e-05	0.0197	0.34	0.24	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
COAD	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-3.99	8.51e-05	0.0197	-0.38	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
COAD	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-3.99	8.51e-05	0.0197	-0.38	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
COAD	cis	rs6479901	0.696	rs931972	ENSG00000232075.1	MRPL35P2	-3.99	8.51e-05	0.0197	-0.33	-0.24	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63634317~63634827:-
COAD	cis	rs74394007	0.541	rs16826858	ENSG00000240875.4	LINC00886	3.99	8.51e-05	0.0197	0.26	0.24	Total body bone mineral density;	chr3:156860609	chr3:156747346~156817062:-
COAD	cis	rs7665090	0.87	rs228614	ENSG00000230069.3	LRRC37A15P	3.99	8.51e-05	0.0197	0.26	0.24	Primary biliary cholangitis;	chr4:102657480	chr4:102727274~102730721:-
COAD	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	3.99	8.51e-05	0.0197	0.35	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
COAD	cis	rs2836974	0.965	rs8130984	ENSG00000255568.3	BRWD1-AS2	3.99	8.52e-05	0.0197	0.25	0.24	Cognitive function;	chr21:39268040	chr21:39313935~39314962:+
COAD	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-3.99	8.53e-05	0.0198	-0.35	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
COAD	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-3.99	8.54e-05	0.0198	-0.48	-0.24	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-3.99	8.54e-05	0.0198	-0.48	-0.24	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-3.99	8.54e-05	0.0198	-0.48	-0.24	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
COAD	cis	rs4699052	0.507	rs7662107	ENSG00000246560.2	RP11-10L12.4	3.99	8.54e-05	0.0198	0.33	0.24	Testicular germ cell tumor;	chr4:103337239	chr4:102828055~102844075:+
COAD	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-3.99	8.54e-05	0.0198	-0.37	-0.24	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
COAD	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-3.99	8.54e-05	0.0198	-0.43	-0.24	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
COAD	cis	rs17666538	0.71	rs7834337	ENSG00000254207.1	RP11-43A14.1	3.99	8.55e-05	0.0198	0.4	0.24	IgG glycosylation;	chr8:705828	chr8:725188~725877:-
COAD	cis	rs7577696	0.785	rs7572964	ENSG00000272716.1	RP11-563N4.1	-3.99	8.55e-05	0.0198	-0.25	-0.24	Inflammatory biomarkers;	chr2:32147027	chr2:32165046~32165757:-
COAD	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-3.99	8.55e-05	0.0198	-0.3	-0.24	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
COAD	cis	rs2243480	1	rs3885839	ENSG00000232559.3	GS1-124K5.12	3.99	8.55e-05	0.0198	0.44	0.24	Diabetic kidney disease;	chr7:65825416	chr7:66554588~66576923:-
COAD	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	3.99	8.55e-05	0.0198	0.39	0.24	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
COAD	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	3.99	8.55e-05	0.0198	0.46	0.24	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
COAD	cis	rs2337406	0.929	rs11847182	ENSG00000211974.3	IGHV2-70	-3.99	8.55e-05	0.0198	-0.29	-0.24	Alzheimer's disease (late onset);	chr14:106697724	chr14:106723574~106724093:-
COAD	cis	rs11726248	0.718	rs73864487	ENSG00000250266.1	RP11-789C1.1	-3.99	8.56e-05	0.0198	-0.48	-0.24	Thyroid hormone levels;	chr4:170257903	chr4:170273919~170283079:+
COAD	cis	rs9907295	0.591	rs8080959	ENSG00000270977.1	AC015849.16	-3.99	8.56e-05	0.0198	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35813450	chr17:35893707~35911023:-
COAD	cis	rs2836974	0.897	rs1541102	ENSG00000255568.3	BRWD1-AS2	3.99	8.56e-05	0.0198	0.24	0.24	Cognitive function;	chr21:39256839	chr21:39313935~39314962:+
COAD	cis	rs1115240	0.577	rs56256284	ENSG00000257842.4	NOVA1-AS1	3.99	8.56e-05	0.0198	0.32	0.24	Educational attainment (years of education);	chr14:26548103	chr14:26598412~26806467:+
COAD	cis	rs1115240	0.574	rs57064734	ENSG00000257842.4	NOVA1-AS1	3.99	8.56e-05	0.0198	0.32	0.24	Educational attainment (years of education);	chr14:26548107	chr14:26598412~26806467:+
COAD	cis	rs7646881	0.544	rs59527167	ENSG00000272087.1	RP11-379F4.7	3.99	8.56e-05	0.0198	0.39	0.24	Tetralogy of Fallot;	chr3:158642504	chr3:158693120~158693768:-
COAD	cis	rs728616	0.867	rs12413715	ENSG00000234382.2	RP11-40F6.1	-3.99	8.56e-05	0.0198	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:80233664~80245367:+
COAD	cis	rs12699921	0.632	rs1404414	ENSG00000279048.1	RP11-511H23.2	3.99	8.56e-05	0.0198	0.17	0.24	Fibrinogen levels;	chr7:17826764	chr7:17940503~17942922:+
COAD	cis	rs2115630	0.755	rs7169629	ENSG00000259728.4	LINC00933	3.99	8.56e-05	0.0198	0.28	0.24	P wave terminal force;	chr15:84648043	chr15:84570649~84580175:+
COAD	cis	rs3824347	0.771	rs10869477	ENSG00000229587.2	RP11-197P3.5	3.99	8.57e-05	0.0198	0.27	0.24	Urinary magnesium-to-creatinine ratio;	chr9:75037688	chr9:75009828~75016036:-
COAD	cis	rs11168351	0.864	rs12228750	ENSG00000226413.2	OR8T1P	-3.99	8.57e-05	0.0198	-0.29	-0.24	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48442030~48442947:-
COAD	cis	rs11168351	0.864	rs10875743	ENSG00000226413.2	OR8T1P	-3.99	8.57e-05	0.0198	-0.29	-0.24	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48442030~48442947:-
COAD	cis	rs6052484	0.883	rs6139383	ENSG00000275491.1	RP5-1009E24.8	3.99	8.57e-05	0.0198	0.37	0.24	Sense of smell;	chr20:4290149	chr20:3808357~3812434:+
COAD	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-3.99	8.57e-05	0.0198	-0.29	-0.24	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
COAD	cis	rs480407	0.667	rs11903541	ENSG00000232320.6	AC009299.5	3.99	8.57e-05	0.0198	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160791147	chr2:161340816~161341326:-
COAD	cis	rs2342406	1	rs17032696	ENSG00000259439.2	RP11-89K21.1	3.99	8.57e-05	0.0198	0.37	0.24	Myopia;	chr2:44910731	chr2:44921077~44939199:-
COAD	cis	rs2188554	0.74	rs213933	ENSG00000237974.1	AC000111.4	3.99	8.58e-05	0.0198	0.27	0.24	Esophageal adenocarcinoma;	chr7:117571000	chr7:117487737~117487929:+
COAD	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-3.99	8.58e-05	0.0198	-0.28	-0.24	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-3.99	8.58e-05	0.0198	-0.28	-0.24	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
COAD	cis	rs2581828	0.618	rs9824325	ENSG00000280417.1	RP11-5O17.1	3.99	8.59e-05	0.0199	0.27	0.24	Crohn's disease;	chr3:53132494	chr3:53046166~53048122:+
COAD	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-3.99	8.59e-05	0.0199	-0.28	-0.24	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
COAD	cis	rs5753037	0.585	rs36572	ENSG00000279159.1	RP3-394A18.1	-3.99	8.59e-05	0.0199	-0.16	-0.24	Type 1 diabetes;	chr22:29804947	chr22:29978950~30028236:-
COAD	cis	rs9910055	0.529	rs228767	ENSG00000267080.4	ASB16-AS1	3.99	8.59e-05	0.0199	0.23	0.24	Total body bone mineral density;	chr17:44110943	chr17:44175973~44186717:-
COAD	cis	rs2179367	0.632	rs10155766	ENSG00000216906.2	RP11-350J20.9	3.99	8.59e-05	0.0199	0.35	0.24	Dupuytren's disease;	chr6:149364577	chr6:149904243~149906418:+
COAD	cis	rs9400467	0.528	rs56827	ENSG00000271789.1	RP5-1112D6.7	-3.99	8.59e-05	0.0199	-0.23	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111297126~111298510:+
COAD	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-3.99	8.59e-05	0.0199	-0.29	-0.24	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
COAD	cis	rs11098499	0.535	rs7671759	ENSG00000250412.1	KLHL2P1	3.99	8.6e-05	0.0199	0.32	0.24	Corneal astigmatism;	chr4:119326939	chr4:119334329~119378233:+
COAD	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	3.99	8.6e-05	0.0199	0.34	0.24	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
COAD	cis	rs4819052	0.851	rs2838848	ENSG00000227039.5	ITGB2-AS1	-3.99	8.6e-05	0.0199	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2838849	ENSG00000227039.5	ITGB2-AS1	-3.99	8.6e-05	0.0199	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs7275870	ENSG00000227039.5	ITGB2-AS1	-3.99	8.6e-05	0.0199	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs7275874	ENSG00000227039.5	ITGB2-AS1	-3.99	8.6e-05	0.0199	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:44921051~44929678:+
COAD	cis	rs8020095	0.571	rs8003929	ENSG00000196553.12	LINC00238	-3.99	8.6e-05	0.0199	-0.33	-0.24	Depression (quantitative trait);	chr14:67066556	chr14:66486354~66498553:+
COAD	cis	rs2504916	0.83	rs390102	ENSG00000230234.1	RP1-276N6.2	-3.99	8.6e-05	0.0199	-0.32	-0.24	Response to hepatitis C treatment;	chr6:160360771	chr6:160272617~160276130:+
COAD	cis	rs9868809	0.505	rs28793701	ENSG00000225399.4	RP11-3B7.1	-3.99	8.6e-05	0.0199	-0.4	-0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48725250	chr3:49260085~49261316:+
COAD	cis	rs11719291	0.831	rs11715177	ENSG00000225399.4	RP11-3B7.1	-3.99	8.6e-05	0.0199	-0.4	-0.24	Cognitive function;	chr3:48726461	chr3:49260085~49261316:+
COAD	cis	rs9880211	0.718	rs35320690	ENSG00000239213.4	NCK1-AS1	-3.99	8.61e-05	0.0199	-0.32	-0.24	Height;Body mass index;	chr3:136213652	chr3:136841726~136862054:-
COAD	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	3.99	8.61e-05	0.0199	0.32	0.24	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	3.99	8.61e-05	0.0199	0.32	0.24	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
COAD	cis	rs913655	0.508	rs4748513	ENSG00000240291.1	RP11-499P20.2	3.99	8.61e-05	0.0199	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18736370	chr10:18513115~18545651:-
COAD	cis	rs984222	0.967	rs10923712	ENSG00000231365.4	RP11-418J17.1	-3.99	8.61e-05	0.0199	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118962811	chr1:119140396~119275973:+
COAD	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	3.99	8.61e-05	0.0199	0.33	0.24	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
COAD	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	3.99	8.61e-05	0.0199	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
COAD	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	3.99	8.61e-05	0.0199	0.39	0.24	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
COAD	cis	rs12220238	0.841	rs10824161	ENSG00000279689.1	RP11-574K11.32	-3.99	8.62e-05	0.0199	-0.31	-0.24	Soluble interleukin-2 receptor subunit alpha;	chr10:74374004	chr10:73769264~73772862:-
COAD	cis	rs853679	0.506	rs1150711	ENSG00000272009.1	RP1-313I6.12	3.99	8.62e-05	0.0199	0.28	0.24	Depression;	chr6:28240757	chr6:28078792~28081130:-
COAD	cis	rs495337	0.965	rs4809768	ENSG00000229222.1	KRT18P4	-3.99	8.62e-05	0.0199	-0.26	-0.24	Psoriasis;	chr20:49959775	chr20:49956745~49958032:+
COAD	cis	rs7572733	0.811	rs771013	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197760513	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs700648	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197757912	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs700649	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197758028	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs700650	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197759561	chr2:197693106~197774823:+
COAD	cis	rs791888	0.965	rs791873	ENSG00000225913.2	RP11-57C13.6	3.99	8.62e-05	0.0199	0.31	0.24	Magnesium levels;	chr10:87645801	chr10:87607985~87659279:+
COAD	cis	rs791888	0.965	rs791875	ENSG00000225913.2	RP11-57C13.6	3.99	8.62e-05	0.0199	0.31	0.24	Magnesium levels;	chr10:87646331	chr10:87607985~87659279:+
COAD	cis	rs791888	0.965	rs791876	ENSG00000225913.2	RP11-57C13.6	3.99	8.62e-05	0.0199	0.31	0.24	Magnesium levels;	chr10:87646770	chr10:87607985~87659279:+
COAD	cis	rs7572733	0.84	rs770666	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197747173	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs770667	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197748584	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs1065953	ENSG00000222017.1	AC011997.1	3.99	8.62e-05	0.0199	0.27	0.24	Dermatomyositis;	chr2:197749888	chr2:197693106~197774823:+
COAD	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-3.99	8.62e-05	0.0199	-0.27	-0.24	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
COAD	cis	rs11089937	0.616	rs5995616	ENSG00000211638.2	IGLV8-61	3.99	8.62e-05	0.0199	0.22	0.24	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22098700~22099212:+
COAD	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	3.99	8.63e-05	0.0199	0.35	0.24	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
COAD	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	3.99	8.63e-05	0.0199	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
COAD	cis	rs875971	0.502	rs2946580	ENSG00000232546.1	RP11-458F8.1	-3.99	8.63e-05	0.0199	-0.25	-0.24	Aortic root size;	chr7:66066855	chr7:66848496~66858136:+
COAD	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	3.99	8.63e-05	0.0199	0.31	0.24	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
COAD	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	3.99	8.64e-05	0.0199	0.21	0.24	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
COAD	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	3.99	8.64e-05	0.0199	0.21	0.24	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
COAD	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-3.99	8.64e-05	0.0199	-0.3	-0.24	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
COAD	cis	rs6951245	0.832	rs79808627	ENSG00000229043.2	AC091729.9	-3.99	8.64e-05	0.02	-0.37	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1160374~1165267:+
COAD	cis	rs875971	0.867	rs1002053	ENSG00000232559.3	GS1-124K5.12	-3.99	8.64e-05	0.02	-0.28	-0.24	Aortic root size;	chr7:66333558	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6460292	ENSG00000232559.3	GS1-124K5.12	-3.99	8.64e-05	0.02	-0.28	-0.24	Aortic root size;	chr7:66345088	chr7:66554588~66576923:-
COAD	cis	rs7584330	0.518	rs74003109	ENSG00000234949.2	AC104667.3	-3.99	8.65e-05	0.02	-0.4	-0.24	Prostate cancer;	chr2:237539507	chr2:237591020~237595981:+
COAD	cis	rs5751901	0.614	rs4820599	ENSG00000272977.1	CTA-390C10.10	-3.99	8.65e-05	0.02	-0.29	-0.24	Protein quantitative trait loci;	chr22:24594246	chr22:25476218~25479971:+
COAD	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	3.99	8.65e-05	0.02	0.32	0.24	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
COAD	cis	rs8141529	0.753	rs5752813	ENSG00000272858.1	CTA-292E10.8	-3.99	8.65e-05	0.02	-0.29	-0.24	Lymphocyte counts;	chr22:28830582	chr22:28814914~28815662:+
COAD	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	3.99	8.65e-05	0.02	0.28	0.24	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
COAD	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-3.99	8.65e-05	0.02	-0.29	-0.24	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
COAD	cis	rs6088813	0.677	rs1570003	ENSG00000269202.1	RP4-614O4.12	3.99	8.66e-05	0.02	0.25	0.24	Height;	chr20:35370324	chr20:35201747~35203288:-
COAD	cis	rs9910055	0.659	rs7214540	ENSG00000267080.4	ASB16-AS1	-3.99	8.66e-05	0.02	-0.22	-0.24	Total body bone mineral density;	chr17:44179236	chr17:44175973~44186717:-
COAD	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	3.99	8.66e-05	0.02	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
COAD	cis	rs6951245	1	rs78158942	ENSG00000229043.2	AC091729.9	-3.99	8.66e-05	0.02	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1160374~1165267:+
COAD	cis	rs860295	0.702	rs1325908	ENSG00000203761.5	MSTO2P	-3.99	8.67e-05	0.02	-0.21	-0.24	Body mass index;	chr1:155443513	chr1:155745829~155750137:+
COAD	cis	rs4819052	0.851	rs10470246	ENSG00000227039.5	ITGB2-AS1	-3.99	8.67e-05	0.02	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs10470247	ENSG00000227039.5	ITGB2-AS1	-3.99	8.67e-05	0.02	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4819043	ENSG00000227039.5	ITGB2-AS1	-3.99	8.67e-05	0.02	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs4819044	ENSG00000227039.5	ITGB2-AS1	-3.99	8.67e-05	0.02	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:44921051~44929678:+
COAD	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-3.99	8.67e-05	0.02	-0.44	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
COAD	cis	rs12049351	0.665	rs12044993	ENSG00000229367.1	HMGN2P19	3.99	8.67e-05	0.02	0.37	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229457578	chr1:229570532~229570796:+
COAD	cis	rs9652601	1	rs9652601	ENSG00000274038.1	RP11-66H6.4	-3.99	8.67e-05	0.02	-0.31	-0.24	Systemic lupus erythematosus;	chr16:11080508	chr16:11056556~11057034:+
COAD	cis	rs7584330	0.554	rs77194105	ENSG00000234949.2	AC104667.3	-3.99	8.67e-05	0.02	-0.41	-0.24	Prostate cancer;	chr2:237527820	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs74478860	ENSG00000234949.2	AC104667.3	-3.99	8.67e-05	0.02	-0.41	-0.24	Prostate cancer;	chr2:237528721	chr2:237591020~237595981:+
COAD	cis	rs728616	0.867	rs61859763	ENSG00000234382.2	RP11-40F6.1	-3.99	8.67e-05	0.02	-0.44	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:80233664~80245367:+
COAD	cis	rs11633886	0.569	rs4473118	ENSG00000273972.1	CTD-2306A12.1	-3.99	8.67e-05	0.02	-0.3	-0.24	Diisocyanate-induced asthma;	chr15:45817925	chr15:45702640~45703183:+
COAD	cis	rs11633886	0.569	rs10220802	ENSG00000273972.1	CTD-2306A12.1	-3.99	8.67e-05	0.02	-0.3	-0.24	Diisocyanate-induced asthma;	chr15:45817944	chr15:45702640~45703183:+
COAD	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	3.99	8.67e-05	0.02	0.18	0.24	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
COAD	cis	rs2564921	0.73	rs2564939	ENSG00000280417.1	RP11-5O17.1	-3.99	8.67e-05	0.02	-0.26	-0.24	Height;	chr3:53072864	chr3:53046166~53048122:+
COAD	cis	rs2333021	0.934	rs7155380	ENSG00000259015.1	RP11-109N23.6	3.99	8.68e-05	0.02	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73014626	chr14:72960595~72961993:+
COAD	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	3.99	8.68e-05	0.02	0.15	0.24	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
COAD	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	3.99	8.68e-05	0.02	0.15	0.24	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
COAD	cis	rs4072705	1	rs4838203	ENSG00000224020.1	MIR181A2HG	-3.99	8.68e-05	0.02	-0.28	-0.24	Menarche (age at onset);	chr9:124736095	chr9:124658467~124698631:+
COAD	cis	rs2732480	0.538	rs2732462	ENSG00000257735.1	RP11-370I10.6	3.99	8.68e-05	0.02	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48350945~48442411:+
COAD	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-3.99	8.69e-05	0.02	-0.43	-0.24	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
COAD	cis	rs913655	0.508	rs11015860	ENSG00000240291.1	RP11-499P20.2	3.99	8.69e-05	0.02	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18716110	chr10:18513115~18545651:-
COAD	cis	rs7674212	0.541	rs4699050	ENSG00000246560.2	RP11-10L12.4	3.99	8.69e-05	0.02	0.29	0.24	Type 2 diabetes;	chr4:103193140	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.541	rs17217473	ENSG00000246560.2	RP11-10L12.4	3.99	8.69e-05	0.02	0.29	0.24	Type 2 diabetes;	chr4:103193585	chr4:102828055~102844075:+
COAD	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-3.99	8.69e-05	0.0201	-0.22	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
COAD	cis	rs9796	0.561	rs7173086	ENSG00000247556.5	OIP5-AS1	3.99	8.69e-05	0.0201	0.24	0.24	Menopause (age at onset);	chr15:41217090	chr15:41283990~41309737:+
COAD	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-3.99	8.7e-05	0.0201	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
COAD	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-3.99	8.7e-05	0.0201	-0.29	-0.24	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
COAD	cis	rs763121	0.813	rs4821807	ENSG00000273076.1	RP3-508I15.22	3.99	8.7e-05	0.0201	0.22	0.24	Menopause (age at onset);	chr22:38669577	chr22:38743495~38743910:+
COAD	cis	rs12699921	0.632	rs4543433	ENSG00000279048.1	RP11-511H23.2	-3.99	8.7e-05	0.0201	-0.18	-0.24	Fibrinogen levels;	chr7:17926529	chr7:17940503~17942922:+
COAD	cis	rs12935418	0.673	rs2549886	ENSG00000278985.1	RP11-303E16.9	-3.99	8.71e-05	0.0201	-0.26	-0.24	Mean corpuscular volume;	chr16:81027627	chr16:80982319~80984094:-
COAD	cis	rs7826238	0.564	rs2921053	ENSG00000254340.1	RP11-10A14.3	3.99	8.71e-05	0.0201	0.28	0.24	Systolic blood pressure;	chr8:8462453	chr8:9141424~9145435:+
COAD	cis	rs80346118	0.673	rs2869676	ENSG00000177410.11	ZFAS1	-3.99	8.71e-05	0.0201	-0.26	-0.24	Diastolic blood pressure;	chr20:48807489	chr20:49278178~49295738:+
COAD	cis	rs80346118	0.673	rs2145837	ENSG00000177410.11	ZFAS1	-3.99	8.71e-05	0.0201	-0.26	-0.24	Diastolic blood pressure;	chr20:48809262	chr20:49278178~49295738:+
COAD	cis	rs80346118	0.673	rs16994152	ENSG00000177410.11	ZFAS1	-3.99	8.71e-05	0.0201	-0.26	-0.24	Diastolic blood pressure;	chr20:48809589	chr20:49278178~49295738:+
COAD	cis	rs1137	0.904	rs205636	ENSG00000225439.2	BOLA3-AS1	3.99	8.71e-05	0.0201	0.25	0.24	Myopia (pathological);	chr2:74724209	chr2:74148009~74150061:+
COAD	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-3.99	8.71e-05	0.0201	-0.57	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
COAD	cis	rs10760158	0.769	rs10760161	ENSG00000226752.6	PSMD5-AS1	-3.99	8.71e-05	0.0201	-0.26	-0.24	Pulse pressure;	chr9:121241790	chr9:120824828~120854385:+
COAD	cis	rs2904967	0.929	rs503277	ENSG00000245532.5	NEAT1	3.99	8.72e-05	0.0201	0.27	0.24	Mean corpuscular volume;	chr11:65311155	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.703	rs4149813	ENSG00000245532.5	NEAT1	3.99	8.72e-05	0.0201	0.27	0.24	Mean corpuscular volume;	chr11:65315202	chr11:65422774~65445540:+
COAD	cis	rs911263	0.603	rs12880109	ENSG00000259502.1	RP11-643G16.3	-3.99	8.72e-05	0.0201	-0.3	-0.24	Primary biliary cholangitis;	chr14:68346315	chr14:67610986~67613864:+
COAD	cis	rs734999	0.588	rs2260976	ENSG00000225931.3	RP3-395M20.7	-3.99	8.73e-05	0.0201	-0.27	-0.24	Ulcerative colitis;	chr1:2596239	chr1:2566410~2569888:+
COAD	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	3.99	8.73e-05	0.0201	0.21	0.24	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
COAD	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	3.99	8.73e-05	0.0201	0.27	0.24	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	3.99	8.73e-05	0.0201	0.27	0.24	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	3.99	8.73e-05	0.0201	0.27	0.24	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
COAD	cis	rs13315871	0.929	rs7634153	ENSG00000273493.1	RP11-80H18.4	3.99	8.73e-05	0.0201	0.43	0.24	Cholesterol, total;	chr3:58251774	chr3:58329965~58330118:+
COAD	cis	rs13315871	0.929	rs6769216	ENSG00000273493.1	RP11-80H18.4	3.99	8.73e-05	0.0201	0.43	0.24	Cholesterol, total;	chr3:58253150	chr3:58329965~58330118:+
COAD	cis	rs13315871	0.858	rs9848825	ENSG00000273493.1	RP11-80H18.4	3.99	8.73e-05	0.0201	0.43	0.24	Cholesterol, total;	chr3:58253274	chr3:58329965~58330118:+
COAD	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	3.99	8.74e-05	0.0201	0.32	0.24	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
COAD	cis	rs7582403	0.844	rs1234402	ENSG00000281469.1	RP11-567F11.1	-3.99	8.74e-05	0.0201	-0.28	-0.24	Neuroticism;	chr2:148072083	chr2:148044380~148044894:+
COAD	cis	rs1670533	1	rs6837145	ENSG00000273179.1	RP11-20I20.4	3.99	8.75e-05	0.0202	0.3	0.24	Recombination rate (females);	chr4:1077279	chr4:1167778~1168174:+
COAD	cis	rs2342406	0.825	rs7340480	ENSG00000259439.2	RP11-89K21.1	3.99	8.76e-05	0.0202	0.4	0.24	Myopia;	chr2:44924418	chr2:44921077~44939199:-
COAD	cis	rs6840360	0.582	rs4696259	ENSG00000251611.1	RP11-610P16.1	-3.99	8.76e-05	0.0202	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151407551~151408835:-
COAD	cis	rs734999	0.588	rs876938	ENSG00000225931.3	RP3-395M20.7	3.99	8.76e-05	0.0202	0.27	0.24	Ulcerative colitis;	chr1:2591773	chr1:2566410~2569888:+
COAD	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	3.99	8.76e-05	0.0202	0.28	0.24	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	3.99	8.76e-05	0.0202	0.28	0.24	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
COAD	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-3.99	8.77e-05	0.0202	-0.39	-0.24	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
COAD	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-3.99	8.77e-05	0.0202	-0.31	-0.24	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
COAD	cis	rs4072705	1	rs4836991	ENSG00000236643.1	RP11-175D17.3	-3.99	8.77e-05	0.0202	-0.26	-0.24	Menarche (age at onset);	chr9:124749761	chr9:124770123~124772927:+
COAD	cis	rs7674212	0.537	rs2623060	ENSG00000230069.3	LRRC37A15P	-3.99	8.78e-05	0.0202	-0.26	-0.24	Type 2 diabetes;	chr4:103126347	chr4:102727274~102730721:-
COAD	cis	rs4243971	0.516	rs6141670	ENSG00000101898.5	MCTS2P	3.99	8.78e-05	0.0202	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr20:32314976	chr20:31547504~31548049:+
COAD	cis	rs3934047	0.904	rs12905561	ENSG00000259372.2	CTD-2240J17.1	-3.99	8.78e-05	0.0202	-0.31	-0.24	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81721765	chr15:81410517~81419127:+
COAD	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	3.99	8.78e-05	0.0202	0.35	0.24	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
COAD	cis	rs4820539	1	rs3827316	ENSG00000211644.2	IGLV1-51	-3.99	8.78e-05	0.0202	-0.14	-0.24	Bone mineral density;	chr22:23126351	chr22:22322472~22322980:+
COAD	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-3.99	8.78e-05	0.0202	-0.28	-0.24	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
COAD	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-3.99	8.79e-05	0.0202	-0.52	-0.24	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-3.99	8.79e-05	0.0202	-0.52	-0.24	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-3.99	8.79e-05	0.0202	-0.52	-0.24	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-3.99	8.79e-05	0.0202	-0.52	-0.24	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
COAD	cis	rs12497850	0.966	rs6792510	ENSG00000225399.4	RP11-3B7.1	3.99	8.79e-05	0.0202	0.26	0.24	Parkinson's disease;	chr3:48685869	chr3:49260085~49261316:+
COAD	cis	rs1914816	1	rs2456075	ENSG00000196274.5	Metazoa_SRP	3.99	8.79e-05	0.0202	0.26	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76230048~76230390:-
COAD	cis	rs1914816	0.878	rs2456078	ENSG00000196274.5	Metazoa_SRP	3.99	8.79e-05	0.0202	0.26	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76230048~76230390:-
COAD	cis	rs7730262	1	rs7730262	ENSG00000247828.6	TMEM161B-AS1	3.99	8.79e-05	0.0202	0.49	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:88892421	chr5:88268895~88436685:+
COAD	cis	rs7760535	0.764	rs240994	ENSG00000271789.1	RP5-1112D6.7	-3.99	8.79e-05	0.0202	-0.23	-0.24	Metabolic traits;	chr6:111354554	chr6:111297126~111298510:+
COAD	cis	rs7760535	0.794	rs463860	ENSG00000271789.1	RP5-1112D6.7	-3.99	8.79e-05	0.0202	-0.23	-0.24	Metabolic traits;	chr6:111370518	chr6:111297126~111298510:+
COAD	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	3.99	8.79e-05	0.0202	0.24	0.24	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
COAD	cis	rs11124272	0.672	rs4952197	ENSG00000272716.1	RP11-563N4.1	3.99	8.79e-05	0.0202	0.28	0.24	Interleukin-18 levels;	chr2:31542061	chr2:32165046~32165757:-
COAD	cis	rs6585424	1	rs35497678	ENSG00000234382.2	RP11-40F6.1	-3.99	8.79e-05	0.0202	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs2304410	ENSG00000234382.2	RP11-40F6.1	-3.99	8.79e-05	0.0202	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:80233664~80245367:+
COAD	cis	rs6585424	0.778	rs12257082	ENSG00000234382.2	RP11-40F6.1	-3.99	8.79e-05	0.0202	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs34100029	ENSG00000234382.2	RP11-40F6.1	-3.99	8.79e-05	0.0202	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:80233664~80245367:+
COAD	cis	rs2489715	0.951	rs2801949	ENSG00000185904.10	LINC00839	3.98	8.8e-05	0.0202	0.39	0.24	Helix rolling;	chr10:42431295	chr10:42475543~42495336:+
COAD	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	3.98	8.8e-05	0.0203	0.25	0.24	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.599	rs16834938	ENSG00000248787.1	RP11-666A20.4	-3.98	8.8e-05	0.0203	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125987203	chr3:125908005~125910272:-
COAD	cis	rs7200543	1	rs4985124	ENSG00000270580.4	PKD1P6	3.98	8.8e-05	0.0203	0.27	0.24	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15104723~15131601:-
COAD	cis	rs1023500	0.573	rs2413666	ENSG00000237037.8	NDUFA6-AS1	-3.98	8.81e-05	0.0203	-0.23	-0.24	Schizophrenia;	chr22:42063618	chr22:42090931~42137742:+
COAD	cis	rs17685	0.712	rs10235086	ENSG00000280388.1	RP11-229D13.3	-3.98	8.81e-05	0.0203	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76043977~76045963:-
COAD	cis	rs2439831	1	rs7173487	ENSG00000166763.7	STRCP1	-3.98	8.81e-05	0.0203	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43458041	chr15:43699488~43718184:-
COAD	cis	rs7646881	0.544	rs4368546	ENSG00000272087.1	RP11-379F4.7	3.98	8.81e-05	0.0203	0.38	0.24	Tetralogy of Fallot;	chr3:158574361	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.544	rs73022770	ENSG00000272087.1	RP11-379F4.7	3.98	8.81e-05	0.0203	0.38	0.24	Tetralogy of Fallot;	chr3:158576506	chr3:158693120~158693768:-
COAD	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	3.98	8.81e-05	0.0203	0.33	0.24	Depression;	chr6:28428413	chr6:28943877~28944537:+
COAD	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	3.98	8.81e-05	0.0203	0.33	0.24	Depression;	chr6:28431469	chr6:28943877~28944537:+
COAD	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-3.98	8.82e-05	0.0203	-0.22	-0.24	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
COAD	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-3.98	8.82e-05	0.0203	-0.38	-0.24	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
COAD	cis	rs6071166	0.774	rs6027213	ENSG00000224635.1	RP4-564F22.5	-3.98	8.82e-05	0.0203	-0.25	-0.24	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38676778	chr20:38406011~38416797:-
COAD	cis	rs10876993	0.928	rs1678530	ENSG00000270039.1	RP11-571M6.17	3.98	8.82e-05	0.0203	0.28	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57660293	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.928	rs1678532	ENSG00000270039.1	RP11-571M6.17	3.98	8.82e-05	0.0203	0.28	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57661414	chr12:57803838~57804415:+
COAD	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-3.98	8.82e-05	0.0203	-0.29	-0.24	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
COAD	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	3.98	8.82e-05	0.0203	0.4	0.24	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
COAD	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	3.98	8.82e-05	0.0203	0.42	0.24	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
COAD	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-3.98	8.83e-05	0.0203	-0.29	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
COAD	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-3.98	8.83e-05	0.0203	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
COAD	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-3.98	8.83e-05	0.0203	-0.22	-0.24	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
COAD	cis	rs2929278	0.617	rs575082	ENSG00000275601.1	AC011330.13	3.98	8.83e-05	0.0203	0.29	0.24	Schizophrenia;	chr15:43817944	chr15:43642389~43643023:-
COAD	cis	rs1949733	0.655	rs2631736	ENSG00000205959.3	RP11-689P11.2	3.98	8.84e-05	0.0203	0.29	0.24	Response to antineoplastic agents;	chr4:8476694	chr4:8482270~8512610:+
COAD	cis	rs3120667	0.72	rs72698963	ENSG00000237975.5	FLG-AS1	3.98	8.84e-05	0.0203	0.33	0.24	Eating disorders;	chr1:152444006	chr1:152168125~152445456:+
COAD	cis	rs3120667	0.72	rs36061814	ENSG00000237975.5	FLG-AS1	3.98	8.84e-05	0.0203	0.33	0.24	Eating disorders;	chr1:152444388	chr1:152168125~152445456:+
COAD	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	3.98	8.84e-05	0.0203	0.21	0.24	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
COAD	cis	rs812925	0.519	rs1186706	ENSG00000273302.1	RP11-493E12.2	3.98	8.84e-05	0.0203	0.23	0.24	Immature fraction of reticulocytes;	chr2:61446259	chr2:61199979~61200769:+
COAD	cis	rs5760748	0.935	rs5760743	ENSG00000272977.1	CTA-390C10.10	-3.98	8.84e-05	0.0203	-0.29	-0.24	Calcium levels;	chr22:24933445	chr22:25476218~25479971:+
COAD	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	3.98	8.84e-05	0.0203	0.34	0.24	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
COAD	cis	rs1023500	0.505	rs134891	ENSG00000237037.8	NDUFA6-AS1	-3.98	8.84e-05	0.0203	-0.23	-0.24	Schizophrenia;	chr22:42279876	chr22:42090931~42137742:+
COAD	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	3.98	8.85e-05	0.0203	0.44	0.24	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
COAD	cis	rs7615952	0.932	rs1976458	ENSG00000241278.1	ENPP7P4	3.98	8.85e-05	0.0203	0.27	0.24	Blood pressure (smoking interaction);	chr3:125928669	chr3:125848223~125909372:+
COAD	cis	rs3816183	1	rs3816183	ENSG00000236533.1	AC009413.2	3.98	8.85e-05	0.0204	0.27	0.24	Hypospadias;	chr2:42788579	chr2:41850203~41850601:-
COAD	cis	rs3816183	1	rs3816185	ENSG00000236533.1	AC009413.2	-3.98	8.85e-05	0.0204	-0.27	-0.24	Hypospadias;	chr2:42788762	chr2:41850203~41850601:-
COAD	cis	rs875971	0.651	rs313829	ENSG00000232546.1	RP11-458F8.1	-3.98	8.86e-05	0.0204	-0.23	-0.24	Aortic root size;	chr7:66087510	chr7:66848496~66858136:+
COAD	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-3.98	8.86e-05	0.0204	-0.25	-0.24	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-3.98	8.86e-05	0.0204	-0.25	-0.24	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
COAD	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-3.98	8.86e-05	0.0204	-0.25	-0.24	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
COAD	cis	rs2711721	0.56	rs739707	ENSG00000280054.1	RP1-197B17.7	3.98	8.86e-05	0.0204	0.3	0.24	Prostate cancer (SNP x SNP interaction);	chr12:47019283	chr12:47728151~47730598:-
COAD	cis	rs7615952	0.641	rs6438951	ENSG00000248787.1	RP11-666A20.4	-3.98	8.86e-05	0.0204	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:125978156	chr3:125908005~125910272:-
COAD	cis	rs4819052	0.851	rs2838834	ENSG00000227039.5	ITGB2-AS1	-3.98	8.86e-05	0.0204	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:44921051~44929678:+
COAD	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-3.98	8.86e-05	0.0204	-0.4	-0.24	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
COAD	cis	rs2832191	0.74	rs2012645	ENSG00000176054.6	RPL23P2	3.98	8.87e-05	0.0204	0.25	0.24	Dental caries;	chr21:29073640	chr21:28997613~28998033:-
COAD	cis	rs2832191	0.716	rs2692625	ENSG00000176054.6	RPL23P2	3.98	8.87e-05	0.0204	0.25	0.24	Dental caries;	chr21:29074039	chr21:28997613~28998033:-
COAD	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-3.98	8.87e-05	0.0204	-0.3	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
COAD	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-3.98	8.88e-05	0.0204	-0.31	-0.24	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
COAD	cis	rs2333021	0.745	rs12323848	ENSG00000259015.1	RP11-109N23.6	3.98	8.88e-05	0.0204	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72986502	chr14:72960595~72961993:+
COAD	cis	rs4660214	0.666	rs6698791	ENSG00000182109.6	RP11-69E11.4	-3.98	8.88e-05	0.0204	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39522280~39546187:-
COAD	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-3.98	8.88e-05	0.0204	-0.28	-0.24	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
COAD	cis	rs72700829	0.507	rs11204766	ENSG00000223861.1	RP11-74C1.2	-3.98	8.89e-05	0.0204	-0.47	-0.24	Schizophrenia;	chr1:151045584	chr1:151557446~151557940:+
COAD	cis	rs734999	0.545	rs10752748	ENSG00000225931.3	RP3-395M20.7	3.98	8.89e-05	0.0204	0.27	0.24	Ulcerative colitis;	chr1:2613201	chr1:2566410~2569888:+
COAD	cis	rs2439831	0.557	rs13329084	ENSG00000275601.1	AC011330.13	3.98	8.89e-05	0.0204	0.46	0.24	Lung cancer in ever smokers;	chr15:43858865	chr15:43642389~43643023:-
COAD	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	3.98	8.89e-05	0.0204	0.28	0.24	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
COAD	cis	rs7254192	0.506	rs2305797	ENSG00000233622.1	CYP2T1P	-3.98	8.89e-05	0.0204	-0.28	-0.24	Post bronchodilator FEV1;	chr19:40763171	chr19:40808525~40811390:-
COAD	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	3.98	8.89e-05	0.0204	0.3	0.24	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
COAD	cis	rs7204230	1	rs62048031	ENSG00000261056.2	RP11-454F8.2	3.98	8.9e-05	0.0204	0.29	0.24	Fibrinogen;	chr16:53180652	chr16:53298224~53299792:+
COAD	cis	rs9951698	0.703	rs2902856	ENSG00000266969.1	RP11-773H22.4	-3.98	8.9e-05	0.0204	-0.29	-0.24	Intelligence (multi-trait analysis);	chr18:12984341	chr18:12984694~12991173:-
COAD	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	3.98	8.9e-05	0.0204	0.29	0.24	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
COAD	cis	rs1044826	0.642	rs6771831	ENSG00000272656.1	RP11-219D15.3	3.98	8.91e-05	0.0205	0.28	0.24	Obesity-related traits;	chr3:139458743	chr3:139349024~139349371:-
COAD	cis	rs12497850	1	rs4858798	ENSG00000225399.4	RP11-3B7.1	3.98	8.91e-05	0.0205	0.27	0.24	Parkinson's disease;	chr3:48689679	chr3:49260085~49261316:+
COAD	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	3.98	8.91e-05	0.0205	0.28	0.24	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
COAD	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-3.98	8.91e-05	0.0205	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
COAD	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	3.98	8.91e-05	0.0205	0.35	0.24	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
COAD	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	3.98	8.91e-05	0.0205	0.21	0.24	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
COAD	cis	rs12428035	0.764	rs651812	ENSG00000247400.3	DNAJC3-AS1	3.98	8.91e-05	0.0205	0.29	0.24	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96070978	chr13:95648733~95676925:-
COAD	cis	rs728616	0.867	rs1923534	ENSG00000234382.2	RP11-40F6.1	-3.98	8.91e-05	0.0205	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:80233664~80245367:+
COAD	cis	rs728616	0.557	rs17107449	ENSG00000234382.2	RP11-40F6.1	-3.98	8.91e-05	0.0205	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs76239460	ENSG00000234382.2	RP11-40F6.1	-3.98	8.91e-05	0.0205	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860412	ENSG00000234382.2	RP11-40F6.1	-3.98	8.91e-05	0.0205	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:80233664~80245367:+
COAD	cis	rs742132	0.858	rs2208041	ENSG00000220875.1	HIST1H3PS1	3.98	8.91e-05	0.0205	0.32	0.24	Uric acid levels;	chr6:25632114	chr6:26321876~26322292:-
COAD	cis	rs742132	0.822	rs1321251	ENSG00000220875.1	HIST1H3PS1	3.98	8.91e-05	0.0205	0.32	0.24	Uric acid levels;	chr6:25632523	chr6:26321876~26322292:-
COAD	cis	rs742132	0.893	rs73397648	ENSG00000220875.1	HIST1H3PS1	3.98	8.91e-05	0.0205	0.32	0.24	Uric acid levels;	chr6:25633805	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs7773087	ENSG00000220875.1	HIST1H3PS1	3.98	8.91e-05	0.0205	0.32	0.24	Uric acid levels;	chr6:25634212	chr6:26321876~26322292:-
COAD	cis	rs796825	0.752	rs787204	ENSG00000240661.1	RP11-174O3.3	3.98	8.91e-05	0.0205	0.34	0.24	HIV-1 susceptibility;	chr3:120299101	chr3:120349510~120367998:+
COAD	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-3.98	8.92e-05	0.0205	-0.24	-0.24	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-3.98	8.92e-05	0.0205	-0.24	-0.24	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
COAD	cis	rs2018683	0.621	rs10261556	ENSG00000272568.4	CTB-113D17.1	3.98	8.92e-05	0.0205	0.34	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28979967~29013367:+
COAD	cis	rs4820539	1	rs1051875	ENSG00000211644.2	IGLV1-51	-3.98	8.92e-05	0.0205	-0.14	-0.24	Bone mineral density;	chr22:23123844	chr22:22322472~22322980:+
COAD	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	3.98	8.92e-05	0.0205	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	3.98	8.92e-05	0.0205	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
COAD	cis	rs28374715	0.681	rs28728213	ENSG00000247556.5	OIP5-AS1	3.98	8.92e-05	0.0205	0.3	0.24	Ulcerative colitis;	chr15:41361404	chr15:41283990~41309737:+
COAD	cis	rs860295	1	rs6427287	ENSG00000225082.2	DAP3P1	-3.98	8.92e-05	0.0205	-0.29	-0.24	Body mass index;	chr1:155753629	chr1:155586644~155602197:+
COAD	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-3.98	8.93e-05	0.0205	-0.3	-0.24	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
COAD	cis	rs7577696	0.785	rs660393	ENSG00000272716.1	RP11-563N4.1	-3.98	8.93e-05	0.0205	-0.25	-0.24	Inflammatory biomarkers;	chr2:32056440	chr2:32165046~32165757:-
COAD	cis	rs812925	0.555	rs12616433	ENSG00000273302.1	RP11-493E12.2	3.98	8.93e-05	0.0205	0.23	0.24	Immature fraction of reticulocytes;	chr2:61469353	chr2:61199979~61200769:+
COAD	cis	rs17685	0.697	rs28689051	ENSG00000280388.1	RP11-229D13.3	-3.98	8.93e-05	0.0205	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76134306	chr7:76043977~76045963:-
COAD	cis	rs2832191	0.74	rs2832168	ENSG00000176054.6	RPL23P2	3.98	8.93e-05	0.0205	0.25	0.24	Dental caries;	chr21:29091374	chr21:28997613~28998033:-
COAD	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-3.98	8.93e-05	0.0205	-0.26	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
COAD	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-3.98	8.93e-05	0.0205	-0.26	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
COAD	cis	rs6490294	0.529	rs7137386	ENSG00000257595.2	RP3-473L9.4	3.98	8.93e-05	0.0205	0.31	0.24	Mean platelet volume;	chr12:111846110	chr12:111369282~111403310:+
COAD	cis	rs9880211	1	rs9837158	ENSG00000273486.1	RP11-731C17.2	3.98	8.94e-05	0.0205	0.28	0.24	Height;Body mass index;	chr3:136354321	chr3:136837338~136839021:-
COAD	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-3.98	8.94e-05	0.0205	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
COAD	cis	rs10129255	0.518	rs7143784	ENSG00000211967.3	IGHV3-53	-3.98	8.94e-05	0.0205	-0.14	-0.24	Kawasaki disease;	chr14:106687277	chr14:106592676~106593347:-
COAD	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	3.98	8.94e-05	0.0205	0.39	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
COAD	cis	rs10043775	1	rs36028618	ENSG00000251330.3	CTD-2283N19.1	-3.98	8.94e-05	0.0205	-0.29	-0.24	Periodontal microbiota;	chr5:148411578	chr5:148430159~148430807:-
COAD	cis	rs3120667	0.72	rs72698964	ENSG00000237975.5	FLG-AS1	3.98	8.95e-05	0.0205	0.33	0.24	Eating disorders;	chr1:152444140	chr1:152168125~152445456:+
COAD	cis	rs67072384	0.818	rs12287481	ENSG00000202522.1	Y_RNA	3.98	8.95e-05	0.0205	0.35	0.24	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72761291	chr11:72766004~72766116:+
COAD	cis	rs4767364	0.848	rs10774649	ENSG00000257595.2	RP3-473L9.4	3.98	8.95e-05	0.0205	0.31	0.24	Oral cavity and pharyngeal cancer;	chr12:112101712	chr12:111369282~111403310:+
COAD	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	3.98	8.95e-05	0.0205	0.33	0.24	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	3.98	8.95e-05	0.0205	0.33	0.24	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
COAD	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-3.98	8.96e-05	0.0206	-0.31	-0.24	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
COAD	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	3.98	8.96e-05	0.0206	0.29	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
COAD	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	3.98	8.96e-05	0.0206	0.31	0.24	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	3.98	8.96e-05	0.0206	0.31	0.24	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	3.98	8.96e-05	0.0206	0.31	0.24	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	3.98	8.96e-05	0.0206	0.31	0.24	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
COAD	cis	rs2408955	0.501	rs8716	ENSG00000226413.2	OR8T1P	3.98	8.96e-05	0.0206	0.29	0.24	Glycated hemoglobin levels;	chr12:48145699	chr12:48442030~48442947:-
COAD	cis	rs174479	0.647	rs174454	ENSG00000267811.1	RP11-727F15.11	-3.98	8.96e-05	0.0206	-0.31	-0.24	Sphingolipid levels;	chr11:61883275	chr11:62771120~62771606:-
COAD	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-3.98	8.96e-05	0.0206	-0.28	-0.24	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
COAD	cis	rs74394007	0.541	rs344078	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156836779	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs344089	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156843827	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs344092	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156846531	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs414683	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156852914	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs9861359	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156860257	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.512	rs11927500	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156863007	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs7630909	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156863794	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs6441100	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156868342	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.646	rs6787535	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156891177	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs4441614	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156915441	chr3:156747346~156817062:-
COAD	cis	rs74394007	0.541	rs7640994	ENSG00000240875.4	LINC00886	3.98	8.96e-05	0.0206	0.26	0.24	Total body bone mineral density;	chr3:156920256	chr3:156747346~156817062:-
COAD	cis	rs875971	1	rs4718307	ENSG00000230189.5	GS1-124K5.2	-3.98	8.97e-05	0.0206	-0.2	-0.24	Aortic root size;	chr7:66146001	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs7801282	ENSG00000230189.5	GS1-124K5.2	-3.98	8.97e-05	0.0206	-0.2	-0.24	Aortic root size;	chr7:66148700	chr7:66409143~66490059:-
COAD	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-3.98	8.97e-05	0.0206	-0.28	-0.24	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
COAD	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-3.98	8.97e-05	0.0206	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-3.98	8.97e-05	0.0206	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
COAD	cis	rs7577696	0.962	rs11681731	ENSG00000272716.1	RP11-563N4.1	-3.98	8.97e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32120256	chr2:32165046~32165757:-
COAD	cis	rs2342406	0.825	rs17032710	ENSG00000259439.2	RP11-89K21.1	3.98	8.97e-05	0.0206	0.42	0.24	Myopia;	chr2:44916600	chr2:44921077~44939199:-
COAD	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	3.98	8.98e-05	0.0206	0.34	0.24	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
COAD	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-3.98	8.98e-05	0.0206	-0.46	-0.24	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
COAD	cis	rs7577696	0.785	rs12611678	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32122716	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.785	rs2294179	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32128936	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.719	rs3752916	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32129489	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.785	rs11683842	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32139062	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.785	rs11689817	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32139172	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.785	rs11694630	ENSG00000272716.1	RP11-563N4.1	-3.98	8.98e-05	0.0206	-0.25	-0.24	Inflammatory biomarkers;	chr2:32151132	chr2:32165046~32165757:-
COAD	cis	rs860295	0.627	rs11264410	ENSG00000160766.13	GBAP1	-3.98	8.98e-05	0.0206	-0.28	-0.24	Body mass index;	chr1:155775558	chr1:155213821~155227422:-
COAD	cis	rs2066940	0.54	rs2045562	ENSG00000254064.1	CTD-2530N21.4	3.98	8.99e-05	0.0206	0.25	0.24	Sitting height ratio;	chr8:21350726	chr8:22254576~22275162:-
COAD	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-3.98	8.99e-05	0.0206	-0.31	-0.24	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
COAD	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	3.98	8.99e-05	0.0206	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
COAD	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	3.98	8.99e-05	0.0206	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	3.98	8.99e-05	0.0206	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	3.98	8.99e-05	0.0206	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
COAD	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	3.98	8.99e-05	0.0206	0.31	0.24	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
COAD	cis	rs28374715	0.635	rs8023530	ENSG00000247556.5	OIP5-AS1	3.98	8.99e-05	0.0206	0.3	0.24	Ulcerative colitis;	chr15:41355577	chr15:41283990~41309737:+
COAD	cis	rs11719291	0.915	rs9834996	ENSG00000225399.4	RP11-3B7.1	-3.98	8.99e-05	0.0206	-0.39	-0.24	Cognitive function;	chr3:48717444	chr3:49260085~49261316:+
COAD	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-3.98	8.99e-05	0.0206	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-3.98	8.99e-05	0.0206	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-3.98	8.99e-05	0.0206	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-3.98	8.99e-05	0.0206	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
COAD	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	3.98	8.99e-05	0.0206	0.27	0.24	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
COAD	cis	rs6921919	0.638	rs7772827	ENSG00000272009.1	RP1-313I6.12	3.98	8.99e-05	0.0206	0.29	0.24	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28078792~28081130:-
COAD	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	3.98	9e-05	0.0206	0.32	0.24	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
COAD	cis	rs62246343	0.719	rs73130116	ENSG00000254485.4	RP11-380O24.1	3.98	9e-05	0.0206	0.32	0.24	Fibrinogen levels;	chr3:9452827	chr3:9292588~9363303:-
COAD	cis	rs886774	0.691	rs6965674	ENSG00000250474.1	WBP1LP2	-3.98	9e-05	0.0206	-0.32	-0.24	Ulcerative colitis;	chr7:107887657	chr7:107628553~107629498:+
COAD	cis	rs2496589	0.889	rs9484747	ENSG00000218896.1	TUBB8P2	3.98	9e-05	0.0206	0.27	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430198	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9321909	ENSG00000218896.1	TUBB8P2	3.98	9e-05	0.0206	0.27	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430525	chr6:143436216~143436710:+
COAD	cis	rs9307551	0.584	rs7697359	ENSG00000250334.4	LINC00989	-3.98	9e-05	0.0206	-0.28	-0.24	Refractive error;	chr4:79546982	chr4:79492416~79576460:+
COAD	cis	rs718433	0.584	rs7160973	ENSG00000211778.2	TRAV4	-3.98	9.01e-05	0.0206	-0.2	-0.24	Intraocular pressure;	chr14:21748391	chr14:21736152~21736982:+
COAD	cis	rs984222	0.559	rs61807010	ENSG00000231365.4	RP11-418J17.1	3.98	9.01e-05	0.0206	0.26	0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119200568	chr1:119140396~119275973:+
COAD	cis	rs10971721	0.658	rs55656643	ENSG00000260947.1	RP11-384P7.7	3.98	9.01e-05	0.0206	0.42	0.24	Body mass index;	chr9:34058497	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.543	rs72729378	ENSG00000260947.1	RP11-384P7.7	3.98	9.01e-05	0.0206	0.42	0.24	Body mass index;	chr9:34059927	chr9:33697459~33700986:+
COAD	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	3.98	9.01e-05	0.0206	0.28	0.24	QT interval;	chr12:29379056	chr12:29277397~29277882:-
COAD	cis	rs875971	0.522	rs1617484	ENSG00000272831.1	RP11-792A8.4	3.98	9.01e-05	0.0206	0.25	0.24	Aortic root size;	chr7:65998108	chr7:66739829~66740385:-
COAD	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-3.98	9.02e-05	0.0206	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
COAD	cis	rs17100926	0.591	rs11624555	ENSG00000266869.1	RP6-114E22.1	3.98	9.02e-05	0.0206	0.45	0.24	Obesity-related traits;	chr14:71464361	chr14:71848606~71908430:+
COAD	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-3.98	9.02e-05	0.0207	-0.23	-0.24	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
COAD	cis	rs4072705	1	rs10760370	ENSG00000236643.1	RP11-175D17.3	3.98	9.03e-05	0.0207	0.24	0.24	Menarche (age at onset);	chr9:124655724	chr9:124770123~124772927:+
COAD	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	3.98	9.03e-05	0.0207	0.38	0.24	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
COAD	cis	rs1044826	0.518	rs295488	ENSG00000272656.1	RP11-219D15.3	3.98	9.03e-05	0.0207	0.3	0.24	Obesity-related traits;	chr3:139520481	chr3:139349024~139349371:-
COAD	cis	rs6723226	0.698	rs13409142	ENSG00000276334.1	AL133243.1	3.98	9.03e-05	0.0207	0.22	0.24	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32521927~32523547:+
COAD	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-3.98	9.03e-05	0.0207	-0.35	-0.24	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-3.98	9.03e-05	0.0207	-0.35	-0.24	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
COAD	cis	rs7674212	0.57	rs6841136	ENSG00000230069.3	LRRC37A15P	-3.98	9.03e-05	0.0207	-0.26	-0.24	Type 2 diabetes;	chr4:103182352	chr4:102727274~102730721:-
COAD	cis	rs4761638	0.954	rs6538520	ENSG00000258365.1	RP11-1105G2.3	3.98	9.03e-05	0.0207	0.3	0.24	Insulin disposition index;	chr12:94609582	chr12:94277758~94282844:-
COAD	cis	rs2836974	0.526	rs418359	ENSG00000255568.3	BRWD1-AS2	-3.98	9.03e-05	0.0207	-0.22	-0.24	Cognitive function;	chr21:39164808	chr21:39313935~39314962:+
COAD	cis	rs2018293	1	rs6005007	ENSG00000233521.4	RP5-1172A22.1	-3.98	9.03e-05	0.0207	-0.22	-0.24	Vascular brain injury;	chr22:26314304	chr22:27221349~27224727:-
COAD	cis	rs2018293	1	rs6005010	ENSG00000233521.4	RP5-1172A22.1	-3.98	9.03e-05	0.0207	-0.22	-0.24	Vascular brain injury;	chr22:26314695	chr22:27221349~27224727:-
COAD	cis	rs2832191	0.74	rs13048618	ENSG00000176054.6	RPL23P2	3.98	9.03e-05	0.0207	0.25	0.24	Dental caries;	chr21:29086363	chr21:28997613~28998033:-
COAD	cis	rs1790761	0.967	rs869736	ENSG00000231793.4	DOC2GP	-3.98	9.03e-05	0.0207	-0.26	-0.24	Mean corpuscular volume;	chr11:67437991	chr11:67612653~67616257:-
COAD	cis	rs3126085	0.673	rs3126089	ENSG00000237975.5	FLG-AS1	3.98	9.03e-05	0.0207	0.27	0.24	Atopic dermatitis;	chr1:152333711	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs3126092	ENSG00000237975.5	FLG-AS1	3.98	9.03e-05	0.0207	0.27	0.24	Atopic dermatitis;	chr1:152335479	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs3126095	ENSG00000237975.5	FLG-AS1	3.98	9.03e-05	0.0207	0.27	0.24	Atopic dermatitis;	chr1:152337207	chr1:152168125~152445456:+
COAD	cis	rs2638953	0.924	rs10843169	ENSG00000247934.4	RP11-967K21.1	3.98	9.03e-05	0.0207	0.25	0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:28163298~28190738:-
COAD	cis	rs11239930	0.517	rs678111	ENSG00000278811.3	LINC00624	3.98	9.03e-05	0.0207	0.24	0.24	AIDS progression;	chr1:147076613	chr1:147258885~147517875:-
COAD	cis	rs9942416	1	rs9942416	ENSG00000271815.1	CTD-2235C13.3	-3.98	9.04e-05	0.0207	-0.3	-0.24	Age-related disease endophenotypes;	chr5:75741470	chr5:75363760~75364242:+
COAD	cis	rs9796	0.621	rs557864	ENSG00000247556.5	OIP5-AS1	-3.98	9.04e-05	0.0207	-0.24	-0.24	Menopause (age at onset);	chr15:41179160	chr15:41283990~41309737:+
COAD	cis	rs2919009	0.581	rs61872768	ENSG00000271670.1	RP11-95I16.4	3.98	9.05e-05	0.0207	0.33	0.24	Obesity-related traits;	chr10:120934409	chr10:120879256~120880667:-
COAD	cis	rs2688608	0.56	rs10128354	ENSG00000271816.1	BMS1P4	3.98	9.05e-05	0.0207	0.23	0.24	Inflammatory bowel disease;	chr10:73710287	chr10:73699151~73730487:-
COAD	cis	rs10043775	1	rs17108251	ENSG00000251330.3	CTD-2283N19.1	-3.98	9.05e-05	0.0207	-0.28	-0.24	Periodontal microbiota;	chr5:148415019	chr5:148430159~148430807:-
COAD	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	3.98	9.06e-05	0.0207	0.35	0.24	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs59820585	ENSG00000216906.2	RP11-350J20.9	3.98	9.06e-05	0.0207	0.35	0.24	Dupuytren's disease;	chr6:149350249	chr6:149904243~149906418:+
COAD	cis	rs5753037	0.869	rs41165	ENSG00000279159.1	RP3-394A18.1	3.98	9.06e-05	0.0207	0.17	0.24	Type 1 diabetes;	chr22:30017350	chr22:29978950~30028236:-
COAD	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-3.98	9.06e-05	0.0207	-0.27	-0.24	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
COAD	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	3.98	9.06e-05	0.0207	0.27	0.24	Height;	chr4:55440988	chr4:55363971~55395847:-
COAD	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-3.98	9.06e-05	0.0207	-0.38	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
COAD	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	3.98	9.06e-05	0.0207	0.39	0.24	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
COAD	cis	rs6661961	0.686	rs2146121	ENSG00000237975.5	FLG-AS1	-3.98	9.07e-05	0.0207	-0.24	-0.24	Atopic dermatitis;	chr1:152420787	chr1:152168125~152445456:+
COAD	cis	rs4819052	0.851	rs1999335	ENSG00000227039.5	ITGB2-AS1	-3.98	9.07e-05	0.0207	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:44921051~44929678:+
COAD	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	3.98	9.07e-05	0.0207	0.3	0.24	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
COAD	cis	rs13256369	1	rs13267501	ENSG00000253981.4	ALG1L13P	3.98	9.07e-05	0.0207	0.35	0.24	Obesity-related traits;	chr8:8716548	chr8:8236003~8244667:-
COAD	cis	rs6563898	0.793	rs918771	ENSG00000274677.1	RP11-505K9.5	3.98	9.07e-05	0.0207	0.31	0.24	IgE levels in asthmatics (D.f. specific);	chr16:83337879	chr16:84085979~84086590:-
COAD	cis	rs6563898	0.793	rs918770	ENSG00000274677.1	RP11-505K9.5	3.98	9.07e-05	0.0207	0.31	0.24	IgE levels in asthmatics (D.f. specific);	chr16:83337906	chr16:84085979~84086590:-
COAD	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	3.98	9.07e-05	0.0208	0.26	0.24	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
COAD	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-3.98	9.08e-05	0.0208	-0.42	-0.24	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-3.98	9.08e-05	0.0208	-0.42	-0.24	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-3.98	9.08e-05	0.0208	-0.42	-0.24	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs6958420	ENSG00000229886.1	RP5-1132H15.3	-3.98	9.08e-05	0.0208	-0.42	-0.24	Diabetic kidney disease;	chr7:66286184	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1392104	ENSG00000229886.1	RP5-1132H15.3	-3.98	9.08e-05	0.0208	-0.42	-0.24	Diabetic kidney disease;	chr7:66294120	chr7:66025126~66031544:-
COAD	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-3.98	9.08e-05	0.0208	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
COAD	cis	rs9487051	0.898	rs882072	ENSG00000219700.1	PTCHD3P3	3.98	9.08e-05	0.0208	0.25	0.24	Reticulocyte fraction of red cells;	chr6:109290603	chr6:109288571~109290503:-
COAD	cis	rs8141529	0.732	rs5762784	ENSG00000272858.1	CTA-292E10.8	-3.98	9.08e-05	0.0208	-0.28	-0.24	Lymphocyte counts;	chr22:28775310	chr22:28814914~28815662:+
COAD	cis	rs253959	0.502	rs10478275	ENSG00000271918.1	CTD-2287O16.5	3.98	9.08e-05	0.0208	0.23	0.24	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116083807~116085416:-
COAD	cis	rs13096357	0.52	rs17080319	ENSG00000225399.4	RP11-3B7.1	-3.98	9.08e-05	0.0208	-0.37	-0.24	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49260085~49261316:+
COAD	cis	rs6981523	0.553	rs11783045	ENSG00000269918.1	AF131215.9	-3.98	9.09e-05	0.0208	-0.31	-0.24	Neuroticism;	chr8:11198666	chr8:11104691~11106704:-
COAD	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-3.98	9.09e-05	0.0208	-0.41	-0.24	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
COAD	cis	rs453301	0.686	rs7814328	ENSG00000254340.1	RP11-10A14.3	-3.98	9.09e-05	0.0208	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9018719	chr8:9141424~9145435:+
COAD	cis	rs10043775	0.958	rs10055430	ENSG00000251330.3	CTD-2283N19.1	-3.98	9.1e-05	0.0208	-0.27	-0.24	Periodontal microbiota;	chr5:148417976	chr5:148430159~148430807:-
COAD	cis	rs10043775	0.958	rs7736019	ENSG00000251330.3	CTD-2283N19.1	-3.98	9.1e-05	0.0208	-0.27	-0.24	Periodontal microbiota;	chr5:148419939	chr5:148430159~148430807:-
COAD	cis	rs7131987	0.903	rs10843371	ENSG00000257176.2	RP11-996F15.2	-3.98	9.1e-05	0.0208	-0.28	-0.24	QT interval;	chr12:29261299	chr12:29280418~29317848:-
COAD	cis	rs891378	1	rs10864167	ENSG00000274245.1	RP11-357P18.2	-3.98	9.1e-05	0.0208	-0.31	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248227	chr1:207372559~207373252:+
COAD	cis	rs17685	0.671	rs10274404	ENSG00000280388.1	RP11-229D13.3	-3.98	9.1e-05	0.0208	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76043977~76045963:-
COAD	cis	rs2688608	0.592	rs12253482	ENSG00000271816.1	BMS1P4	3.98	9.1e-05	0.0208	0.23	0.24	Inflammatory bowel disease;	chr10:73736372	chr10:73699151~73730487:-
COAD	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	3.98	9.1e-05	0.0208	0.3	0.24	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
COAD	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	3.98	9.1e-05	0.0208	0.3	0.24	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
COAD	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	3.98	9.11e-05	0.0208	0.29	0.24	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
COAD	cis	rs4879656	0.931	rs10971314	ENSG00000225693.1	LAGE3P1	-3.98	9.11e-05	0.0208	-0.29	-0.24	Menopause (age at onset);	chr9:33013945	chr9:33019682~33020165:-
COAD	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-3.98	9.12e-05	0.0208	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
COAD	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-3.98	9.12e-05	0.0208	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
COAD	cis	rs3809912	0.527	rs571002	ENSG00000266969.1	RP11-773H22.4	-3.98	9.12e-05	0.0208	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:13090668	chr18:12984694~12991173:-
COAD	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-3.98	9.12e-05	0.0208	-0.3	-0.24	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
COAD	cis	rs1949733	0.523	rs4619877	ENSG00000205959.3	RP11-689P11.2	3.98	9.12e-05	0.0208	0.3	0.24	Response to antineoplastic agents;	chr4:8541508	chr4:8482270~8512610:+
COAD	cis	rs2483374	0.557	rs4770754	ENSG00000253771.4	TPTE2P1	3.98	9.12e-05	0.0208	0.26	0.24	Obesity-related traits;	chr13:24896389	chr13:24924677~24968487:-
COAD	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-3.98	9.12e-05	0.0208	-0.29	-0.24	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-3.98	9.12e-05	0.0208	-0.29	-0.24	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-3.98	9.12e-05	0.0208	-0.29	-0.24	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-3.98	9.12e-05	0.0208	-0.29	-0.24	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
COAD	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	3.98	9.12e-05	0.0208	0.27	0.24	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
COAD	cis	rs13256369	1	rs4840352	ENSG00000253981.4	ALG1L13P	3.98	9.12e-05	0.0208	0.36	0.24	Obesity-related traits;	chr8:8715998	chr8:8236003~8244667:-
COAD	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	3.98	9.13e-05	0.0209	0.17	0.24	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
COAD	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	3.98	9.13e-05	0.0209	0.26	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
COAD	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-3.98	9.13e-05	0.0209	-0.3	-0.24	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
COAD	cis	rs453301	0.507	rs2929306	ENSG00000254340.1	RP11-10A14.3	-3.98	9.13e-05	0.0209	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9227399	chr8:9141424~9145435:+
COAD	cis	rs2179367	0.632	rs62426068	ENSG00000216906.2	RP11-350J20.9	3.98	9.14e-05	0.0209	0.35	0.24	Dupuytren's disease;	chr6:149325795	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs62426069	ENSG00000216906.2	RP11-350J20.9	3.98	9.14e-05	0.0209	0.35	0.24	Dupuytren's disease;	chr6:149325804	chr6:149904243~149906418:+
COAD	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	3.98	9.15e-05	0.0209	0.21	0.24	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
COAD	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-3.97	9.15e-05	0.0209	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
COAD	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	3.97	9.15e-05	0.0209	0.31	0.24	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
COAD	cis	rs6052484	0.883	rs16989397	ENSG00000275491.1	RP5-1009E24.8	3.97	9.16e-05	0.0209	0.37	0.24	Sense of smell;	chr20:4290027	chr20:3808357~3812434:+
COAD	cis	rs6052484	0.883	rs6037806	ENSG00000275491.1	RP5-1009E24.8	3.97	9.16e-05	0.0209	0.37	0.24	Sense of smell;	chr20:4290717	chr20:3808357~3812434:+
COAD	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	3.97	9.16e-05	0.0209	0.27	0.24	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
COAD	cis	rs12439619	0.921	rs56042848	ENSG00000259429.4	UBE2Q2P2	-3.97	9.16e-05	0.0209	-0.23	-0.24	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82355142~82420075:+
COAD	cis	rs2562456	0.755	rs2914646	ENSG00000268081.1	RP11-678G14.2	-3.97	9.16e-05	0.0209	-0.34	-0.24	Pain;	chr19:21454359	chr19:21554640~21569237:-
COAD	cis	rs6840360	0.582	rs4696259	ENSG00000270265.1	RP11-731D1.4	-3.97	9.16e-05	0.0209	-0.28	-0.24	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151333775~151353224:-
COAD	cis	rs763121	0.853	rs5750659	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38672784	chr22:38743495~38743910:+
COAD	cis	rs763121	0.819	rs3747173	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38673040	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs3747174	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38673176	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs1065201	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38673505	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757226	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38674545	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5757232	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38675672	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs9306329	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38676449	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5750662	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38676467	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs5750664	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38676764	chr22:38743495~38743910:+
COAD	cis	rs763121	0.626	rs5757236	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38677819	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs6001191	ENSG00000273076.1	RP3-508I15.22	3.97	9.16e-05	0.0209	0.21	0.24	Menopause (age at onset);	chr22:38678447	chr22:38743495~38743910:+
COAD	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-3.97	9.16e-05	0.0209	-0.3	-0.24	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
COAD	cis	rs2976388	0.59	rs11785290	ENSG00000247317.3	RP11-273G15.2	3.97	9.16e-05	0.0209	0.27	0.24	Urinary tract infection frequency;	chr8:142733431	chr8:142981738~143018437:-
COAD	cis	rs2732480	0.5	rs7315820	ENSG00000269514.1	RP11-370I10.12	3.97	9.17e-05	0.0209	0.29	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48198387~48202031:+
COAD	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	3.97	9.17e-05	0.0209	0.28	0.24	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
COAD	cis	rs80264589	1	rs80264589	ENSG00000224843.5	LINC00240	3.97	9.17e-05	0.0209	0.57	0.24	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:26956992~27023924:+
COAD	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	3.97	9.17e-05	0.0209	0.25	0.24	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
COAD	cis	rs7646881	0.544	rs3806642	ENSG00000272087.1	RP11-379F4.7	3.97	9.17e-05	0.0209	0.39	0.24	Tetralogy of Fallot;	chr3:158644249	chr3:158693120~158693768:-
COAD	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-3.97	9.17e-05	0.0209	-0.29	-0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
COAD	cis	rs9393777	0.588	rs6926677	ENSG00000224843.5	LINC00240	3.97	9.18e-05	0.0209	0.34	0.24	Intelligence (multi-trait analysis);	chr6:26478597	chr6:26956992~27023924:+
COAD	cis	rs4683346	1	rs11129978	ENSG00000273328.4	RP11-141M3.6	3.97	9.18e-05	0.0209	0.3	0.24	Granulocyte percentage of myeloid white cells;	chr3:42842084	chr3:42809414~42908105:+
COAD	cis	rs597539	0.69	rs552517	ENSG00000255741.1	RP11-757G1.5	-3.97	9.18e-05	0.021	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68941503~68942852:-
COAD	cis	rs597539	0.69	rs578791	ENSG00000255741.1	RP11-757G1.5	-3.97	9.18e-05	0.021	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68941503~68942852:-
COAD	cis	rs597539	0.69	rs647661	ENSG00000255741.1	RP11-757G1.5	-3.97	9.18e-05	0.021	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68941503~68942852:-
COAD	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	3.97	9.19e-05	0.021	0.29	0.24	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
COAD	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-3.97	9.19e-05	0.021	-0.22	-0.24	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
COAD	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	3.97	9.19e-05	0.021	0.27	0.24	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
COAD	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-3.97	9.19e-05	0.021	-0.43	-0.24	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
COAD	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-3.97	9.19e-05	0.021	-0.43	-0.24	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
COAD	cis	rs9880211	0.898	rs28877020	ENSG00000273486.1	RP11-731C17.2	3.97	9.19e-05	0.021	0.28	0.24	Height;Body mass index;	chr3:136676874	chr3:136837338~136839021:-
COAD	cis	rs453301	0.631	rs17700611	ENSG00000233609.3	RP11-62H7.2	-3.97	9.2e-05	0.021	-0.27	-0.24	Joint mobility (Beighton score);	chr8:8936144	chr8:8961200~8979025:+
COAD	cis	rs6601327	0.641	rs12155819	ENSG00000233609.3	RP11-62H7.2	-3.97	9.2e-05	0.021	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8961200~8979025:+
COAD	cis	rs6601327	0.7	rs12114661	ENSG00000233609.3	RP11-62H7.2	-3.97	9.2e-05	0.021	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8961200~8979025:+
COAD	cis	rs6601327	0.641	rs4129360	ENSG00000233609.3	RP11-62H7.2	-3.97	9.2e-05	0.021	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8961200~8979025:+
COAD	cis	rs6601327	0.641	rs6601350	ENSG00000233609.3	RP11-62H7.2	-3.97	9.2e-05	0.021	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8961200~8979025:+
COAD	cis	rs7584330	0.666	rs7600317	ENSG00000234949.2	AC104667.3	-3.97	9.2e-05	0.021	-0.3	-0.24	Prostate cancer;	chr2:237444870	chr2:237591020~237595981:+
COAD	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	3.97	9.2e-05	0.021	0.33	0.24	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
COAD	cis	rs2243480	0.901	rs73142137	ENSG00000228409.4	CCT6P1	3.97	9.21e-05	0.021	0.31	0.24	Diabetic kidney disease;	chr7:65878455	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs13247184	ENSG00000228409.4	CCT6P1	3.97	9.21e-05	0.021	0.31	0.24	Diabetic kidney disease;	chr7:65893941	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs35283677	ENSG00000228409.4	CCT6P1	3.97	9.21e-05	0.021	0.31	0.24	Diabetic kidney disease;	chr7:65894246	chr7:65751142~65763354:+
COAD	cis	rs4820539	1	rs6003518	ENSG00000211644.2	IGLV1-51	-3.97	9.21e-05	0.021	-0.14	-0.24	Bone mineral density;	chr22:23129346	chr22:22322472~22322980:+
COAD	cis	rs6732160	0.588	rs13390460	ENSG00000163016.8	ALMS1P	3.97	9.21e-05	0.021	0.31	0.24	Intelligence (multi-trait analysis);	chr2:73144348	chr2:73644919~73685576:+
COAD	cis	rs11846409	1	rs11846409	ENSG00000211964.3	IGHV3-48	-3.97	9.22e-05	0.021	-0.2	-0.24	Rheumatic heart disease;	chr14:106645692	chr14:106537810~106538344:-
COAD	cis	rs853679	0.657	rs1778483	ENSG00000272009.1	RP1-313I6.12	3.97	9.22e-05	0.021	0.27	0.24	Depression;	chr6:28273214	chr6:28078792~28081130:-
COAD	cis	rs853679	0.657	rs1778482	ENSG00000272009.1	RP1-313I6.12	3.97	9.22e-05	0.021	0.27	0.24	Depression;	chr6:28273215	chr6:28078792~28081130:-
COAD	cis	rs72700829	0.593	rs4418603	ENSG00000223861.1	RP11-74C1.2	-3.97	9.22e-05	0.021	-0.47	-0.24	Schizophrenia;	chr1:151016798	chr1:151557446~151557940:+
COAD	cis	rs4950322	1	rs72694750	ENSG00000278811.3	LINC00624	3.97	9.23e-05	0.021	0.26	0.24	Protein quantitative trait loci;	chr1:147396856	chr1:147258885~147517875:-
COAD	cis	rs4950322	1	rs1986987	ENSG00000278811.3	LINC00624	3.97	9.23e-05	0.021	0.26	0.24	Protein quantitative trait loci;	chr1:147397553	chr1:147258885~147517875:-
COAD	cis	rs4950322	1	rs61230354	ENSG00000278811.3	LINC00624	3.97	9.23e-05	0.021	0.26	0.24	Protein quantitative trait loci;	chr1:147398161	chr1:147258885~147517875:-
COAD	cis	rs4950322	1	rs4950429	ENSG00000278811.3	LINC00624	3.97	9.23e-05	0.021	0.26	0.24	Protein quantitative trait loci;	chr1:147400227	chr1:147258885~147517875:-
COAD	cis	rs4950322	1	rs59498179	ENSG00000278811.3	LINC00624	3.97	9.23e-05	0.021	0.26	0.24	Protein quantitative trait loci;	chr1:147400417	chr1:147258885~147517875:-
COAD	cis	rs7665090	0.87	rs228615	ENSG00000230069.3	LRRC37A15P	3.97	9.23e-05	0.021	0.26	0.24	Primary biliary cholangitis;	chr4:102658303	chr4:102727274~102730721:-
COAD	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	3.97	9.23e-05	0.021	0.27	0.24	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
COAD	cis	rs3781264	0.595	rs11187901	ENSG00000273450.1	RP11-76P2.4	3.97	9.23e-05	0.0211	0.28	0.24	Esophageal cancer and gastric cancer;	chr10:94355251	chr10:94314907~94315327:-
COAD	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	3.97	9.24e-05	0.0211	0.25	0.24	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
COAD	cis	rs10760158	0.769	rs10760162	ENSG00000226752.6	PSMD5-AS1	-3.97	9.24e-05	0.0211	-0.26	-0.24	Pulse pressure;	chr9:121242905	chr9:120824828~120854385:+
COAD	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	3.97	9.24e-05	0.0211	0.35	0.24	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
COAD	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	3.97	9.24e-05	0.0211	0.28	0.24	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
COAD	cis	rs113835537	0.529	rs10896125	ENSG00000258297.1	RP11-658F2.8	-3.97	9.24e-05	0.0211	-0.24	-0.24	Airway imaging phenotypes;	chr11:66521262	chr11:66666036~66668374:+
COAD	cis	rs74233809	1	rs77180047	ENSG00000213277.3	MARCKSL1P1	3.97	9.24e-05	0.0211	0.51	0.24	Birth weight;	chr10:102907000	chr10:103175554~103176094:+
COAD	cis	rs2836974	0.863	rs1065242	ENSG00000255568.3	BRWD1-AS2	3.97	9.25e-05	0.0211	0.25	0.24	Cognitive function;	chr21:39195790	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs8128734	ENSG00000255568.3	BRWD1-AS2	3.97	9.25e-05	0.0211	0.25	0.24	Cognitive function;	chr21:39197585	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs2234543	ENSG00000255568.3	BRWD1-AS2	3.97	9.25e-05	0.0211	0.25	0.24	Cognitive function;	chr21:39200146	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.899	rs2836938	ENSG00000255568.3	BRWD1-AS2	3.97	9.25e-05	0.0211	0.25	0.24	Cognitive function;	chr21:39202265	chr21:39313935~39314962:+
COAD	cis	rs7688540	0.76	rs7687833	ENSG00000198155.5	ZNF876P	-3.97	9.25e-05	0.0211	-0.37	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:212610~255985:+
COAD	cis	rs13256369	0.802	rs13280101	ENSG00000253981.4	ALG1L13P	3.97	9.25e-05	0.0211	0.35	0.24	Obesity-related traits;	chr8:8705263	chr8:8236003~8244667:-
COAD	cis	rs6088813	0.677	rs941664	ENSG00000269202.1	RP4-614O4.12	3.97	9.25e-05	0.0211	0.25	0.24	Height;	chr20:35352170	chr20:35201747~35203288:-
COAD	cis	rs6088813	0.677	rs941665	ENSG00000269202.1	RP4-614O4.12	3.97	9.25e-05	0.0211	0.25	0.24	Height;	chr20:35355478	chr20:35201747~35203288:-
COAD	cis	rs1930961	0.702	rs8137667	ENSG00000271138.1	IGLVIVOR22-1	-3.97	9.25e-05	0.0211	-0.57	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25512529	chr22:25437306~25437823:-
COAD	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	3.97	9.25e-05	0.0211	0.28	0.24	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
COAD	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-3.97	9.26e-05	0.0211	-0.29	-0.24	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
COAD	cis	rs2638953	0.815	rs11049669	ENSG00000247934.4	RP11-967K21.1	3.97	9.26e-05	0.0211	0.25	0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498982	chr12:28163298~28190738:-
COAD	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	3.97	9.26e-05	0.0211	0.3	0.24	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
COAD	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-3.97	9.26e-05	0.0211	-0.29	-0.24	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
COAD	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-3.97	9.26e-05	0.0211	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
COAD	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-3.97	9.26e-05	0.0211	-0.46	-0.24	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
COAD	cis	rs9840812	0.953	rs61791721	ENSG00000239213.4	NCK1-AS1	-3.97	9.26e-05	0.0211	-0.34	-0.24	Fibrinogen levels;	chr3:136085708	chr3:136841726~136862054:-
COAD	cis	rs981621	0.965	rs9948620	ENSG00000267249.1	RP11-973H7.3	-3.97	9.26e-05	0.0211	-0.29	-0.24	Survival in pancreatic cancer;	chr18:13358207	chr18:12670426~12671145:-
COAD	cis	rs10971721	0.631	rs10971891	ENSG00000260947.1	RP11-384P7.7	3.97	9.27e-05	0.0211	0.42	0.24	Body mass index;	chr9:34076593	chr9:33697459~33700986:+
COAD	cis	rs2638953	0.924	rs11049579	ENSG00000247934.4	RP11-967K21.1	-3.97	9.28e-05	0.0211	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414693	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843163	ENSG00000247934.4	RP11-967K21.1	-3.97	9.28e-05	0.0211	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415541	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.814	rs10843164	ENSG00000247934.4	RP11-967K21.1	-3.97	9.28e-05	0.0211	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416781	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049583	ENSG00000247934.4	RP11-967K21.1	-3.97	9.28e-05	0.0211	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417238	chr12:28163298~28190738:-
COAD	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-3.97	9.28e-05	0.0211	-0.25	-0.24	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
COAD	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-3.97	9.28e-05	0.0211	-0.32	-0.24	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
COAD	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-3.97	9.28e-05	0.0211	-0.27	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
COAD	cis	rs370915	0.524	rs28826385	ENSG00000250971.1	RP11-696F12.1	3.97	9.29e-05	0.0212	0.29	0.24	Gout;	chr4:186848298	chr4:187060099~187060930:+
COAD	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	3.97	9.29e-05	0.0212	0.43	0.24	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
COAD	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	3.97	9.29e-05	0.0212	0.51	0.24	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
COAD	cis	rs7916697	0.628	rs10998036	ENSG00000233590.1	RP11-153K11.3	3.97	9.29e-05	0.0212	0.25	0.24	Optic disc area;	chr10:68256921	chr10:68233251~68242379:-
COAD	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-3.97	9.29e-05	0.0212	-0.29	-0.24	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
COAD	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-3.97	9.29e-05	0.0212	-0.32	-0.24	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
COAD	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-3.97	9.29e-05	0.0212	-0.24	-0.24	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
COAD	cis	rs7615952	0.673	rs16834637	ENSG00000241288.6	RP11-379B18.5	-3.97	9.29e-05	0.0212	-0.27	-0.24	Blood pressure (smoking interaction);	chr3:125886628	chr3:125827238~125916384:-
COAD	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-3.97	9.29e-05	0.0212	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
COAD	cis	rs2346160	0.867	rs206975	ENSG00000228648.1	RP11-568A7.2	3.97	9.3e-05	0.0212	0.27	0.24	Parental extreme longevity (95 years and older);	chr6:167276868	chr6:167241891~167245916:+
COAD	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	3.97	9.3e-05	0.0212	0.35	0.24	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
COAD	cis	rs4879656	0.897	rs1537255	ENSG00000225693.1	LAGE3P1	-3.97	9.3e-05	0.0212	-0.29	-0.24	Menopause (age at onset);	chr9:33004377	chr9:33019682~33020165:-
COAD	cis	rs17685	0.712	rs10271413	ENSG00000280388.1	RP11-229D13.3	-3.97	9.3e-05	0.0212	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76043977~76045963:-
COAD	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	3.97	9.3e-05	0.0212	0.28	0.24	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
COAD	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	3.97	9.3e-05	0.0212	0.32	0.24	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
COAD	cis	rs911119	0.913	rs1158167	ENSG00000270001.1	RP11-218C14.8	3.97	9.3e-05	0.0212	0.29	0.24	Chronic kidney disease;	chr20:23597552	chr20:23631826~23632316:-
COAD	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	3.97	9.3e-05	0.0212	0.21	0.24	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
COAD	cis	rs9990333	0.562	rs73210005	ENSG00000207650.1	MIR570	3.97	9.3e-05	0.0212	0.3	0.24	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195699401~195699497:+
COAD	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-3.97	9.3e-05	0.0212	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
COAD	cis	rs6504622	0.755	rs7219544	ENSG00000263142.4	LRRC37A17P	-3.97	9.3e-05	0.0212	-0.17	-0.24	Orofacial clefts;	chr17:47089562	chr17:46978481~47054569:+
COAD	cis	rs989978	0.958	rs7901824	ENSG00000228778.1	RP11-129J12.1	-3.97	9.3e-05	0.0212	-0.27	-0.24	Red blood cell count;	chr10:99565066	chr10:99527081~99528261:+
COAD	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	3.97	9.3e-05	0.0212	0.44	0.24	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
COAD	cis	rs643506	0.845	rs762550	ENSG00000230911.1	PPIHP1	-3.97	9.31e-05	0.0212	-0.3	-0.24	Breast cancer;	chr11:111912376	chr11:112029858~112030367:-
COAD	cis	rs11846409	0.818	rs2516909	ENSG00000254174.1	IGHV1-12	-3.97	9.31e-05	0.0212	-0.23	-0.24	Rheumatic heart disease;	chr14:106630317	chr14:106122420~106122709:-
COAD	cis	rs2919009	0.563	rs55761976	ENSG00000271670.1	RP11-95I16.4	3.97	9.31e-05	0.0212	0.33	0.24	Obesity-related traits;	chr10:120935030	chr10:120879256~120880667:-
COAD	cis	rs4973517	0.653	rs3116230	ENSG00000237126.7	AC073254.1	-3.97	9.31e-05	0.0212	-0.34	-0.24	Hip circumference adjusted for BMI;	chr2:232027027	chr2:232580948~232611971:-
COAD	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-3.97	9.31e-05	0.0212	-0.34	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
COAD	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-3.97	9.31e-05	0.0212	-0.5	-0.24	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
COAD	cis	rs875971	0.965	rs6971509	ENSG00000230189.5	GS1-124K5.2	-3.97	9.31e-05	0.0212	-0.2	-0.24	Aortic root size;	chr7:66249983	chr7:66409143~66490059:-
COAD	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	3.97	9.32e-05	0.0212	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
COAD	cis	rs13178541	0.551	rs4315919	ENSG00000250378.1	RP11-119J18.1	-3.97	9.32e-05	0.0212	-0.26	-0.24	IgG glycosylation;	chr5:135773105	chr5:135812667~135826582:+
COAD	cis	rs6951245	1	rs80212261	ENSG00000229043.2	AC091729.9	-3.97	9.32e-05	0.0212	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs77346188	ENSG00000229043.2	AC091729.9	-3.97	9.32e-05	0.0212	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1160374~1165267:+
COAD	cis	rs340874	0.703	rs340835	ENSG00000274895.1	RP11-478J18.2	3.97	9.33e-05	0.0212	0.28	0.24	Type 2 diabetes;Fasting blood glucose;Homeostasis model assessment of beta-cell function;Fasting blood glucose (BMI interaction);	chr1:213990332	chr1:213983793~213986419:-
COAD	cis	rs4818225	0.784	rs4818226	ENSG00000237232.6	ZNF295-AS1	-3.97	9.33e-05	0.0212	-0.33	-0.24	Educational attainment;	chr21:41261138	chr21:42009194~42024924:+
COAD	cis	rs2765539	0.887	rs2765541	ENSG00000231365.4	RP11-418J17.1	-3.97	9.33e-05	0.0212	-0.29	-0.24	Waist-hip ratio;	chr1:119016034	chr1:119140396~119275973:+
COAD	cis	rs4657482	0.962	rs4657487	ENSG00000236364.3	RP11-525G13.2	-3.97	9.33e-05	0.0212	-0.17	-0.24	Testicular germ cell tumor;	chr1:165866127	chr1:165890795~165900683:-
COAD	cis	rs742132	0.858	rs73399723	ENSG00000220875.1	HIST1H3PS1	3.97	9.34e-05	0.0212	0.31	0.24	Uric acid levels;	chr6:25663382	chr6:26321876~26322292:-
COAD	cis	rs773506	1	rs773513	ENSG00000228069.1	RP11-100G15.3	-3.97	9.34e-05	0.0212	-0.26	-0.24	Type 2 diabetes nephropathy;	chr9:91218561	chr9:92109013~92110095:+
COAD	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	3.97	9.34e-05	0.0212	0.24	0.24	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
COAD	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	3.97	9.35e-05	0.0213	0.3	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
COAD	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-3.97	9.35e-05	0.0213	-0.25	-0.24	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
COAD	cis	rs6981523	0.553	rs2409730	ENSG00000269918.1	AF131215.9	-3.97	9.35e-05	0.0213	-0.31	-0.24	Neuroticism;	chr8:11203129	chr8:11104691~11106704:-
COAD	cis	rs4819052	0.851	rs2236444	ENSG00000227039.5	ITGB2-AS1	-3.97	9.35e-05	0.0213	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:44921051~44929678:+
COAD	cis	rs2408955	0.568	rs12099462	ENSG00000226413.2	OR8T1P	-3.97	9.35e-05	0.0213	-0.28	-0.24	Glycated hemoglobin levels;	chr12:48109321	chr12:48442030~48442947:-
COAD	cis	rs728616	0.558	rs34268041	ENSG00000225484.5	NUTM2B-AS1	-3.97	9.35e-05	0.0213	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79663088~79826594:-
COAD	cis	rs7074356	0.831	rs12764048	ENSG00000225484.5	NUTM2B-AS1	-3.97	9.35e-05	0.0213	-0.4	-0.24	Borderline personality disorder;	chr10:80389207	chr10:79663088~79826594:-
COAD	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-3.97	9.35e-05	0.0213	-0.43	-0.24	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
COAD	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	3.97	9.36e-05	0.0213	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
COAD	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-3.97	9.36e-05	0.0213	-0.24	-0.24	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-3.97	9.36e-05	0.0213	-0.24	-0.24	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-3.97	9.36e-05	0.0213	-0.24	-0.24	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-3.97	9.36e-05	0.0213	-0.24	-0.24	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
COAD	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	3.97	9.36e-05	0.0213	0.28	0.24	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
COAD	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	3.97	9.36e-05	0.0213	0.35	0.24	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
COAD	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-3.97	9.36e-05	0.0213	-0.35	-0.24	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
COAD	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-3.97	9.36e-05	0.0213	-0.28	-0.24	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-3.97	9.36e-05	0.0213	-0.28	-0.24	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-3.97	9.37e-05	0.0213	-0.29	-0.24	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
COAD	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-3.97	9.37e-05	0.0213	-0.22	-0.24	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
COAD	cis	rs1510510	0.69	rs6753691	ENSG00000225057.2	AC096574.4	3.97	9.38e-05	0.0213	0.32	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238644429	chr2:238231684~238255633:+
COAD	cis	rs78487399	0.808	rs76856054	ENSG00000234936.1	AC010883.5	3.97	9.38e-05	0.0213	0.38	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537045	chr2:43229573~43233394:+
COAD	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-3.97	9.38e-05	0.0213	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
COAD	cis	rs7674212	0.54	rs2720469	ENSG00000230069.3	LRRC37A15P	-3.97	9.39e-05	0.0213	-0.26	-0.24	Type 2 diabetes;	chr4:103165327	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.57	rs6810571	ENSG00000230069.3	LRRC37A15P	-3.97	9.39e-05	0.0213	-0.26	-0.24	Type 2 diabetes;	chr4:103165630	chr4:102727274~102730721:-
COAD	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	3.97	9.39e-05	0.0213	0.25	0.24	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
COAD	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-3.97	9.39e-05	0.0213	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
COAD	cis	rs2638953	0.924	rs11049398	ENSG00000247934.4	RP11-967K21.1	-3.97	9.39e-05	0.0213	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28163298~28190738:-
COAD	cis	rs1713985	0.508	rs1277283	ENSG00000269949.1	RP11-738E22.3	-3.97	9.39e-05	0.0213	-0.46	-0.24	Age-related macular degeneration;	chr4:56989475	chr4:56960927~56961373:-
COAD	cis	rs875971	1	rs1544549	ENSG00000179406.6	LINC00174	-3.97	9.39e-05	0.0213	-0.18	-0.24	Aortic root size;	chr7:66625676	chr7:66376044~66401338:-
COAD	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-3.97	9.39e-05	0.0213	-0.39	-0.24	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
COAD	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-3.97	9.39e-05	0.0213	-0.39	-0.24	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
COAD	cis	rs755249	0.753	rs72663529	ENSG00000228060.1	RP11-69E11.8	-3.97	9.39e-05	0.0213	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39565160~39573203:+
COAD	cis	rs7674212	0.54	rs2711897	ENSG00000230069.3	LRRC37A15P	-3.97	9.39e-05	0.0213	-0.26	-0.24	Type 2 diabetes;	chr4:103102410	chr4:102727274~102730721:-
COAD	cis	rs8022206	0.704	rs58151429	ENSG00000259502.1	RP11-643G16.3	3.97	9.39e-05	0.0213	0.3	0.24	Platelet count;Mean platelet volume;	chr14:67920775	chr14:67610986~67613864:+
COAD	cis	rs7309	0.87	rs2358016	ENSG00000235724.7	AC009299.2	3.97	9.39e-05	0.0213	0.26	0.24	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161222785~161308303:-
COAD	cis	rs6088813	0.677	rs6087706	ENSG00000269202.1	RP4-614O4.12	-3.97	9.39e-05	0.0213	-0.25	-0.24	Height;	chr20:35418512	chr20:35201747~35203288:-
COAD	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-3.97	9.4e-05	0.0213	-0.17	-0.24	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
COAD	cis	rs6740322	0.696	rs11685054	ENSG00000234936.1	AC010883.5	3.97	9.4e-05	0.0213	0.3	0.24	Coronary artery disease;	chr2:43247156	chr2:43229573~43233394:+
COAD	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-3.97	9.4e-05	0.0213	-0.24	-0.24	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
COAD	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	3.97	9.4e-05	0.0213	0.28	0.24	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
COAD	cis	rs2252521	0.524	rs2214973	ENSG00000272568.4	CTB-113D17.1	3.97	9.4e-05	0.0213	0.45	0.24	Cognitive performance;	chr7:29020275	chr7:28979967~29013367:+
COAD	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	3.97	9.4e-05	0.0213	0.27	0.24	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
COAD	cis	rs5751168	0.831	rs403517	ENSG00000211660.3	IGLV2-23	-3.97	9.4e-05	0.0214	-0.18	-0.24	Prostate cancer (SNP x SNP interaction);	chr22:22479416	chr22:22697789~22698407:+
COAD	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	3.97	9.4e-05	0.0214	0.29	0.24	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
COAD	cis	rs3738443	0.951	rs61840056	ENSG00000259865.1	RP11-488L18.10	3.97	9.4e-05	0.0214	0.29	0.24	Alcohol dependence;	chr1:247205930	chr1:247187281~247188526:-
COAD	cis	rs8114671	0.585	rs2236271	ENSG00000228265.4	RALY-AS1	-3.97	9.41e-05	0.0214	-0.22	-0.24	Height;	chr20:34936037	chr20:33983052~33994357:-
COAD	cis	rs7759001	0.557	rs9368504	ENSG00000224843.5	LINC00240	-3.97	9.41e-05	0.0214	-0.36	-0.24	Glomerular filtration rate (creatinine);	chr6:27340038	chr6:26956992~27023924:+
COAD	cis	rs9400467	0.528	rs465796	ENSG00000230177.1	RP5-1112D6.4	-3.97	9.41e-05	0.0214	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111277932~111278742:+
COAD	cis	rs860295	1	rs860295	ENSG00000225082.2	DAP3P1	3.97	9.42e-05	0.0214	0.3	0.24	Body mass index;	chr1:155797917	chr1:155586644~155602197:+
COAD	cis	rs202072	0.652	rs202064	ENSG00000272379.1	RP1-257A7.5	-3.97	9.42e-05	0.0214	-0.39	-0.24	HIV-1 viral setpoint;	chr6:13263794	chr6:13290018~13290490:-
COAD	cis	rs7172689	0.908	rs8026245	ENSG00000271725.1	RP11-761I4.4	3.97	9.42e-05	0.0214	0.31	0.24	Inattentive symptoms;	chr15:81268660	chr15:81303215~81309391:-
COAD	cis	rs2638953	0.853	rs3898068	ENSG00000247934.4	RP11-967K21.1	-3.97	9.43e-05	0.0214	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457084	chr12:28163298~28190738:-
COAD	cis	rs7759001	0.857	rs2206252	ENSG00000237154.2	MCFD2P1	3.97	9.43e-05	0.0214	0.28	0.24	Glomerular filtration rate (creatinine);	chr6:27390683	chr6:27407697~27407996:+
COAD	cis	rs11231017	1	rs11231019	ENSG00000254454.2	RCC2P6	-3.97	9.43e-05	0.0214	-0.28	-0.24	HIV-1 viral setpoint;	chr11:62295397	chr11:62371146~62373168:+
COAD	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	3.97	9.43e-05	0.0214	0.25	0.24	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
COAD	cis	rs12530	1	rs9609529	ENSG00000232218.1	RP1-149A16.16	-3.97	9.43e-05	0.0214	-0.42	-0.24	IgG glycosylation;	chr22:32404422	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs9609530	ENSG00000232218.1	RP1-149A16.16	-3.97	9.43e-05	0.0214	-0.42	-0.24	IgG glycosylation;	chr22:32404607	chr22:32386668~32386868:+
COAD	cis	rs12530	1	rs9609531	ENSG00000232218.1	RP1-149A16.16	-3.97	9.43e-05	0.0214	-0.42	-0.24	IgG glycosylation;	chr22:32405113	chr22:32386668~32386868:+
COAD	cis	rs2243480	1	rs160652	ENSG00000229886.1	RP5-1132H15.3	3.97	9.43e-05	0.0214	0.41	0.24	Diabetic kidney disease;	chr7:66073444	chr7:66025126~66031544:-
COAD	cis	rs8022206	1	rs8022206	ENSG00000259502.1	RP11-643G16.3	-3.97	9.44e-05	0.0214	-0.32	-0.24	Platelet count;Mean platelet volume;	chr14:68054189	chr14:67610986~67613864:+
COAD	cis	rs2179367	0.632	rs12197598	ENSG00000216906.2	RP11-350J20.9	3.97	9.44e-05	0.0214	0.34	0.24	Dupuytren's disease;	chr6:149385418	chr6:149904243~149906418:+
COAD	cis	rs913655	0.508	rs12245924	ENSG00000240291.1	RP11-499P20.2	3.97	9.44e-05	0.0214	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18720830	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs7921519	ENSG00000240291.1	RP11-499P20.2	3.97	9.44e-05	0.0214	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18721540	chr10:18513115~18545651:-
COAD	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-3.97	9.44e-05	0.0214	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
COAD	cis	rs17711722	0.522	rs62469933	ENSG00000272831.1	RP11-792A8.4	3.97	9.44e-05	0.0214	0.25	0.24	Calcium levels;	chr7:65800652	chr7:66739829~66740385:-
COAD	cis	rs9652601	0.959	rs2041670	ENSG00000274038.1	RP11-66H6.4	-3.97	9.44e-05	0.0214	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11080795	chr16:11056556~11057034:+
COAD	cis	rs911119	0.913	rs3004139	ENSG00000270001.1	RP11-218C14.8	3.97	9.44e-05	0.0214	0.29	0.24	Chronic kidney disease;	chr20:23598037	chr20:23631826~23632316:-
COAD	cis	rs4820539	0.902	rs9612237	ENSG00000211644.2	IGLV1-51	-3.97	9.45e-05	0.0214	-0.14	-0.24	Bone mineral density;	chr22:23130767	chr22:22322472~22322980:+
COAD	cis	rs1949733	0.675	rs2688235	ENSG00000205959.3	RP11-689P11.2	-3.97	9.45e-05	0.0214	-0.29	-0.24	Response to antineoplastic agents;	chr4:8448819	chr4:8482270~8512610:+
COAD	cis	rs2842346	0.549	rs1859302	ENSG00000259038.1	CTD-2325P2.4	3.97	9.45e-05	0.0214	0.36	0.24	Breast cancer;	chr14:68539468	chr14:68627166~68628445:-
COAD	cis	rs9818758	0.607	rs11713297	ENSG00000225399.4	RP11-3B7.1	-3.97	9.45e-05	0.0215	-0.38	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49175597	chr3:49260085~49261316:+
COAD	cis	rs6490294	0.583	rs4346023	ENSG00000257595.2	RP3-473L9.4	-3.97	9.46e-05	0.0215	-0.31	-0.24	Mean platelet volume;	chr12:111847738	chr12:111369282~111403310:+
COAD	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	3.97	9.46e-05	0.0215	0.29	0.24	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
COAD	cis	rs250677	0.524	rs250665	ENSG00000250072.4	CTC-529P8.1	-3.97	9.46e-05	0.0215	-0.3	-0.24	Breast cancer;	chr5:149074831	chr5:149063317~149109787:+
COAD	cis	rs74233809	1	rs11191582	ENSG00000213277.3	MARCKSL1P1	3.97	9.46e-05	0.0215	0.56	0.24	Birth weight;	chr10:103153896	chr10:103175554~103176094:+
COAD	cis	rs9478638	0.592	rs162982	ENSG00000235381.1	RP11-477D19.2	3.97	9.46e-05	0.0215	0.28	0.24	Electroencephalogram traits;	chr6:155313480	chr6:155253139~155256724:-
COAD	cis	rs5753037	0.564	rs131298	ENSG00000279159.1	RP3-394A18.1	3.97	9.47e-05	0.0215	0.16	0.24	Type 1 diabetes;	chr22:29784012	chr22:29978950~30028236:-
COAD	cis	rs1559040	0.932	rs28368466	ENSG00000233266.1	HMGB1P31	-3.97	9.47e-05	0.0215	-0.37	-0.24	Sudden cardiac arrest;	chr2:54061824	chr2:54051334~54051760:+
COAD	cis	rs34779708	0.966	rs4934540	ENSG00000271335.4	RP11-324I22.4	3.97	9.48e-05	0.0215	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35314552~35336401:-
COAD	cis	rs6585424	0.925	rs11201964	ENSG00000234382.2	RP11-40F6.1	-3.97	9.49e-05	0.0215	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs11201966	ENSG00000234382.2	RP11-40F6.1	-3.97	9.49e-05	0.0215	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs11201972	ENSG00000234382.2	RP11-40F6.1	-3.97	9.49e-05	0.0215	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:80233664~80245367:+
COAD	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-3.97	9.49e-05	0.0215	-0.29	-0.24	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
COAD	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	3.97	9.5e-05	0.0215	0.31	0.24	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
COAD	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-3.97	9.5e-05	0.0215	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
COAD	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-3.97	9.5e-05	0.0215	-0.24	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
COAD	cis	rs5758511	0.773	rs7288749	ENSG00000182057.4	OGFRP1	-3.97	9.51e-05	0.0215	-0.28	-0.24	Birth weight;	chr22:41960426	chr22:42269753~42275196:+
COAD	cis	rs2638953	0.924	rs11049454	ENSG00000247934.4	RP11-967K21.1	-3.97	9.51e-05	0.0216	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843134	ENSG00000247934.4	RP11-967K21.1	-3.97	9.51e-05	0.0216	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1824768	ENSG00000247934.4	RP11-967K21.1	-3.97	9.51e-05	0.0216	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049465	ENSG00000247934.4	RP11-967K21.1	-3.97	9.51e-05	0.0216	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7980441	ENSG00000247934.4	RP11-967K21.1	-3.97	9.51e-05	0.0216	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28163298~28190738:-
COAD	cis	rs2333021	0.711	rs34518714	ENSG00000259015.1	RP11-109N23.6	3.97	9.51e-05	0.0216	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:72960595~72961993:+
COAD	cis	rs3018712	0.505	rs7102308	ENSG00000184795.9	UNC93B5	-3.97	9.51e-05	0.0216	-0.39	-0.24	Total body bone mineral density;	chr11:68645762	chr11:67711702~67716005:-
COAD	cis	rs860295	0.541	rs11264359	ENSG00000160766.13	GBAP1	-3.97	9.52e-05	0.0216	-0.26	-0.24	Body mass index;	chr1:155313038	chr1:155213821~155227422:-
COAD	cis	rs9796	0.621	rs2928142	ENSG00000247556.5	OIP5-AS1	-3.97	9.52e-05	0.0216	-0.24	-0.24	Menopause (age at onset);	chr15:41178251	chr15:41283990~41309737:+
COAD	cis	rs875971	1	rs7792762	ENSG00000179406.6	LINC00174	3.97	9.52e-05	0.0216	0.18	0.24	Aortic root size;	chr7:66539151	chr7:66376044~66401338:-
COAD	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	3.96	9.53e-05	0.0216	0.29	0.24	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
COAD	cis	rs1930961	0.702	rs12168476	ENSG00000271138.1	IGLVIVOR22-1	-3.96	9.53e-05	0.0216	-0.6	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25491121	chr22:25437306~25437823:-
COAD	cis	rs2777491	0.915	rs7178634	ENSG00000247556.5	OIP5-AS1	3.96	9.53e-05	0.0216	0.26	0.24	Ulcerative colitis;	chr15:41342389	chr15:41283990~41309737:+
COAD	cis	rs2777491	0.915	rs7178777	ENSG00000247556.5	OIP5-AS1	3.96	9.53e-05	0.0216	0.26	0.24	Ulcerative colitis;	chr15:41342390	chr15:41283990~41309737:+
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000226413.2	OR8T1P	3.96	9.53e-05	0.0216	0.29	0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48442030~48442947:-
COAD	cis	rs2439831	0.85	rs12441984	ENSG00000166763.7	STRCP1	-3.96	9.53e-05	0.0216	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43834087	chr15:43699488~43718184:-
COAD	cis	rs2252521	0.553	rs1603907	ENSG00000272568.4	CTB-113D17.1	3.96	9.53e-05	0.0216	0.45	0.24	Cognitive performance;	chr7:29056647	chr7:28979967~29013367:+
COAD	cis	rs8061903	0.958	rs8062323	ENSG00000260071.1	RP11-418I22.2	3.96	9.53e-05	0.0216	0.27	0.24	HIV-1 viral setpoint;	chr16:9288755	chr16:9466655~9517564:+
COAD	cis	rs742132	0.824	rs2072851	ENSG00000220875.1	HIST1H3PS1	3.96	9.53e-05	0.0216	0.31	0.24	Uric acid levels;	chr6:25662104	chr6:26321876~26322292:-
COAD	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	3.96	9.54e-05	0.0216	0.32	0.24	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
COAD	cis	rs801193	0.591	rs2707839	ENSG00000179406.6	LINC00174	3.96	9.54e-05	0.0216	0.18	0.24	Aortic root size;	chr7:66728097	chr7:66376044~66401338:-
COAD	cis	rs34779708	0.966	rs1148245	ENSG00000271335.4	RP11-324I22.4	3.96	9.54e-05	0.0216	0.25	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35314552~35336401:-
COAD	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-3.96	9.54e-05	0.0216	-0.29	-0.24	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
COAD	cis	rs1552244	1	rs55822690	ENSG00000186162.9	CIDECP	3.96	9.55e-05	0.0216	0.34	0.24	Alzheimer's disease;	chr3:10086319	chr3:10014238~10026365:-
COAD	cis	rs2564921	0.73	rs73079924	ENSG00000280417.1	RP11-5O17.1	3.96	9.55e-05	0.0216	0.26	0.24	Height;	chr3:53034139	chr3:53046166~53048122:+
COAD	cis	rs9818758	0.607	rs55873331	ENSG00000225399.4	RP11-3B7.1	-3.96	9.55e-05	0.0216	-0.5	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49559622	chr3:49260085~49261316:+
COAD	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	3.96	9.55e-05	0.0216	0.34	0.24	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
COAD	cis	rs564309	0.681	rs1188487	ENSG00000280157.1	RP11-520H14.7	3.96	9.55e-05	0.0216	0.36	0.24	Hip circumference (psychosocial stress interaction);	chr1:228432546	chr1:228121523~228123771:+
COAD	cis	rs10779751	0.96	rs6661859	ENSG00000215785.2	CFL1P6	-3.96	9.55e-05	0.0216	-0.28	-0.24	Body mass index;	chr1:11241006	chr1:10990978~10991797:-
COAD	cis	rs9858542	0.537	rs9863142	ENSG00000225399.4	RP11-3B7.1	-3.96	9.56e-05	0.0216	-0.35	-0.24	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49329308	chr3:49260085~49261316:+
COAD	cis	rs7577696	0.962	rs12617289	ENSG00000272716.1	RP11-563N4.1	-3.96	9.56e-05	0.0216	-0.25	-0.24	Inflammatory biomarkers;	chr2:32116330	chr2:32165046~32165757:-
COAD	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	3.96	9.56e-05	0.0216	0.26	0.24	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
COAD	cis	rs7131987	0.874	rs10843366	ENSG00000257176.2	RP11-996F15.2	-3.96	9.56e-05	0.0216	-0.28	-0.24	QT interval;	chr12:29254970	chr12:29280418~29317848:-
COAD	cis	rs7131987	0.845	rs2042511	ENSG00000257176.2	RP11-996F15.2	-3.96	9.56e-05	0.0216	-0.28	-0.24	QT interval;	chr12:29255847	chr12:29280418~29317848:-
COAD	cis	rs2749097	0.825	rs2819176	ENSG00000244256.3	RN7SL130P	-3.96	9.56e-05	0.0216	-0.3	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659159	chr1:63655743~63656047:+
COAD	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21546020	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21548822	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21549451	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21554036	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21554618	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	3.96	9.56e-05	0.0217	0.32	0.24	Pain;	chr19:21555338	chr19:21554640~21569237:-
COAD	cis	rs11229555	0.598	rs1893902	ENSG00000254602.1	AP000662.4	-3.96	9.56e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58423274	chr11:57638024~57652790:+
COAD	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	3.96	9.57e-05	0.0217	0.26	0.24	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
COAD	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	3.96	9.57e-05	0.0217	0.4	0.24	Gout;	chr7:66671562	chr7:66025126~66031544:-
COAD	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	3.96	9.57e-05	0.0217	0.29	0.24	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
COAD	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-3.96	9.57e-05	0.0217	-0.29	-0.24	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
COAD	cis	rs10090774	0.965	rs306957	ENSG00000280303.2	ERICD	3.96	9.58e-05	0.0217	0.31	0.24	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140999493	chr8:140636281~140638283:+
COAD	cis	rs10043775	1	rs4639212	ENSG00000251330.3	CTD-2283N19.1	-3.96	9.58e-05	0.0217	-0.28	-0.24	Periodontal microbiota;	chr5:148413387	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs13354454	ENSG00000251330.3	CTD-2283N19.1	-3.96	9.58e-05	0.0217	-0.28	-0.24	Periodontal microbiota;	chr5:148414845	chr5:148430159~148430807:-
COAD	cis	rs6662572	1	rs3014232	ENSG00000280836.1	AL355480.1	3.96	9.58e-05	0.0217	0.34	0.24	Blood protein levels;	chr1:45666201	chr1:45581219~45581321:-
COAD	cis	rs9393777	0.92	rs35869525	ENSG00000224843.5	LINC00240	3.96	9.58e-05	0.0217	0.57	0.24	Intelligence (multi-trait analysis);	chr6:26978908	chr6:26956992~27023924:+
COAD	cis	rs34816374	1	rs34816374	ENSG00000224843.5	LINC00240	3.96	9.58e-05	0.0217	0.57	0.24	Lung cancer in ever smokers;	chr6:26981893	chr6:26956992~27023924:+
COAD	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-3.96	9.58e-05	0.0217	-0.31	-0.24	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
COAD	cis	rs4072705	1	rs4838201	ENSG00000236643.1	RP11-175D17.3	3.96	9.58e-05	0.0217	0.26	0.24	Menarche (age at onset);	chr9:124698338	chr9:124770123~124772927:+
COAD	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	3.96	9.58e-05	0.0217	0.44	0.24	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
COAD	cis	rs7674212	0.541	rs2720471	ENSG00000230069.3	LRRC37A15P	-3.96	9.58e-05	0.0217	-0.25	-0.24	Type 2 diabetes;	chr4:103102683	chr4:102727274~102730721:-
COAD	cis	rs6981523	0.5	rs4412337	ENSG00000269918.1	AF131215.9	3.96	9.59e-05	0.0217	0.3	0.24	Neuroticism;	chr8:11214511	chr8:11104691~11106704:-
COAD	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	3.96	9.6e-05	0.0217	0.36	0.24	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	3.96	9.6e-05	0.0217	0.36	0.24	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	3.96	9.6e-05	0.0217	0.36	0.24	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	3.96	9.6e-05	0.0217	0.36	0.24	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
COAD	cis	rs6687821	0.515	rs10489917	ENSG00000261737.1	RP4-612B15.3	-3.96	9.6e-05	0.0217	-0.31	-0.24	Yeast infection;	chr1:86932105	chr1:86703502~86704462:-
COAD	cis	rs7577696	0.962	rs7608127	ENSG00000272716.1	RP11-563N4.1	-3.96	9.6e-05	0.0217	-0.25	-0.24	Inflammatory biomarkers;	chr2:32054854	chr2:32165046~32165757:-
COAD	cis	rs10137082	0.606	rs2231809	ENSG00000279656.1	RP11-298I3.6	-3.96	9.61e-05	0.0217	-0.3	-0.24	Type 1 diabetes;	chr14:23357613	chr14:23023083~23024217:-
COAD	cis	rs1510272	0.69	rs62275573	ENSG00000243926.1	TIPARP-AS1	-3.96	9.61e-05	0.0217	-0.27	-0.24	Testicular germ cell tumor;	chr3:156607915	chr3:156671862~156674378:-
COAD	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-3.96	9.61e-05	0.0217	-0.22	-0.24	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
COAD	cis	rs7822232	1	rs7822232	ENSG00000255224.1	CTD-3065J16.9	-3.96	9.61e-05	0.0217	-0.32	-0.24	Blood metabolite levels;	chr8:144090784	chr8:144078002~144079265:-
COAD	cis	rs11229555	0.609	rs7128459	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58411818	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12794534	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58412095	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.598	rs11229426	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58412590	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12800531	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58412626	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229429	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58413399	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229430	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58413631	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229431	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58413780	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs66573492	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58416324	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12272911	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58416366	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.598	rs12269888	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58416863	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12269928	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58416885	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs61903159	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417002	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs34133416	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417247	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs34350060	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417429	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.598	rs12289876	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417777	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.598	rs12276438	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417946	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12289985	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58417963	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs11229434	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418028	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229435	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418323	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229436	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418536	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs12272096	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418645	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs12291791	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418817	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs12273635	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418854	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs12272310	ENSG00000254602.1	AP000662.4	-3.96	9.61e-05	0.0217	-0.29	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418989	chr11:57638024~57652790:+
COAD	cis	rs1633360	1	rs1633360	ENSG00000270039.1	RP11-571M6.17	3.96	9.61e-05	0.0217	0.26	0.24	Rheumatoid arthritis;	chr12:57714269	chr12:57803838~57804415:+
COAD	cis	rs1510510	0.742	rs6760108	ENSG00000225057.2	AC096574.4	3.96	9.62e-05	0.0217	0.31	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643811	chr2:238231684~238255633:+
COAD	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	3.96	9.62e-05	0.0217	0.4	0.24	Gout;	chr7:66679692	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-3.96	9.62e-05	0.0217	-0.4	-0.24	Gout;	chr7:66682070	chr7:66025126~66031544:-
COAD	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-3.96	9.62e-05	0.0217	-0.4	-0.24	Gout;	chr7:66682162	chr7:66025126~66031544:-
COAD	cis	rs2836974	0.829	rs34227163	ENSG00000255568.3	BRWD1-AS2	3.96	9.62e-05	0.0217	0.25	0.24	Cognitive function;	chr21:39180017	chr21:39313935~39314962:+
COAD	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	3.96	9.62e-05	0.0217	0.4	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
COAD	cis	rs7615952	0.8	rs2062773	ENSG00000241278.1	ENPP7P4	3.96	9.62e-05	0.0217	0.27	0.24	Blood pressure (smoking interaction);	chr3:125920805	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.799	rs13315434	ENSG00000241278.1	ENPP7P4	3.96	9.62e-05	0.0217	0.27	0.24	Blood pressure (smoking interaction);	chr3:125922551	chr3:125848223~125909372:+
COAD	cis	rs7204230	0.96	rs62049764	ENSG00000261056.2	RP11-454F8.2	3.96	9.62e-05	0.0217	0.29	0.24	Fibrinogen;	chr16:53225866	chr16:53298224~53299792:+
COAD	cis	rs11239930	0.517	rs3011809	ENSG00000278811.3	LINC00624	3.96	9.62e-05	0.0217	0.24	0.24	AIDS progression;	chr1:147077593	chr1:147258885~147517875:-
COAD	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-3.96	9.62e-05	0.0218	-0.25	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
COAD	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-3.96	9.62e-05	0.0218	-0.25	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
COAD	cis	rs6687821	0.515	rs1778012	ENSG00000261737.1	RP4-612B15.3	3.96	9.63e-05	0.0218	0.31	0.24	Yeast infection;	chr1:87088873	chr1:86703502~86704462:-
COAD	cis	rs2638953	0.924	rs11524516	ENSG00000247934.4	RP11-967K21.1	-3.96	9.63e-05	0.0218	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28163298~28190738:-
COAD	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	3.96	9.63e-05	0.0218	0.46	0.24	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
COAD	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-3.96	9.63e-05	0.0218	-0.29	-0.24	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
COAD	cis	rs728616	0.867	rs12412257	ENSG00000234382.2	RP11-40F6.1	-3.96	9.64e-05	0.0218	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:80233664~80245367:+
COAD	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-3.96	9.64e-05	0.0218	-0.29	-0.24	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
COAD	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	3.96	9.65e-05	0.0218	0.21	0.24	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
COAD	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-3.96	9.65e-05	0.0218	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
COAD	cis	rs3781264	0.595	rs7084988	ENSG00000273450.1	RP11-76P2.4	3.96	9.65e-05	0.0218	0.29	0.24	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94314907~94315327:-
COAD	cis	rs3781264	0.595	rs7085378	ENSG00000273450.1	RP11-76P2.4	3.96	9.65e-05	0.0218	0.29	0.24	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94314907~94315327:-
COAD	cis	rs6012564	1	rs6066982	ENSG00000227431.4	CSE1L-AS1	3.96	9.65e-05	0.0218	0.26	0.24	Anger;	chr20:49147021	chr20:49040463~49046044:-
COAD	cis	rs6012564	1	rs7272164	ENSG00000227431.4	CSE1L-AS1	3.96	9.65e-05	0.0218	0.26	0.24	Anger;	chr20:49149660	chr20:49040463~49046044:-
COAD	cis	rs9291683	0.507	rs3796837	ENSG00000250413.1	RP11-448G15.1	-3.96	9.65e-05	0.0218	-0.31	-0.24	Bone mineral density;	chr4:10009697	chr4:10006482~10009725:+
COAD	cis	rs6687821	0.515	rs2798682	ENSG00000261737.1	RP4-612B15.3	3.96	9.65e-05	0.0218	0.31	0.24	Yeast infection;	chr1:87108280	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs2798684	ENSG00000261737.1	RP4-612B15.3	3.96	9.65e-05	0.0218	0.31	0.24	Yeast infection;	chr1:87108534	chr1:86703502~86704462:-
COAD	cis	rs7646881	1	rs7646881	ENSG00000272087.1	RP11-379F4.7	3.96	9.66e-05	0.0218	0.35	0.24	Tetralogy of Fallot;	chr3:158735490	chr3:158693120~158693768:-
COAD	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-3.96	9.66e-05	0.0218	-0.45	-0.24	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
COAD	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	3.96	9.66e-05	0.0218	0.22	0.24	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
COAD	cis	rs7577696	0.924	rs7586448	ENSG00000272716.1	RP11-563N4.1	-3.96	9.66e-05	0.0218	-0.25	-0.24	Inflammatory biomarkers;	chr2:32043571	chr2:32165046~32165757:-
COAD	cis	rs2916733	0.607	rs1129703	ENSG00000246089.3	RP11-115C21.2	-3.96	9.66e-05	0.0218	-0.31	-0.24	Epirubicin-induced leukopenia;	chr8:6447173	chr8:6403551~6407142:-
COAD	cis	rs11976180	1	rs2961118	ENSG00000273234.1	OR2A13P	-3.96	9.66e-05	0.0218	-0.3	-0.24	Obesity-related traits;	chr7:144058350	chr7:144142009~144142938:+
COAD	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	3.96	9.66e-05	0.0218	0.3	0.24	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
COAD	cis	rs4253772	0.591	rs6008545	ENSG00000280424.1	CITF22-92A6.2	3.96	9.66e-05	0.0218	0.35	0.24	Cholesterol, total;LDL cholesterol;	chr22:46290478	chr22:46006616~46010777:+
COAD	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	3.96	9.66e-05	0.0218	0.43	0.24	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
COAD	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-3.96	9.67e-05	0.0218	-0.3	-0.24	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
COAD	cis	rs8177876	0.822	rs1563077	ENSG00000261061.1	RP11-303E16.2	-3.96	9.67e-05	0.0218	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81030770~81031485:+
COAD	cis	rs9868809	0.881	rs2310996	ENSG00000225399.4	RP11-3B7.1	-3.96	9.67e-05	0.0218	-0.34	-0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48634401	chr3:49260085~49261316:+
COAD	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-3.96	9.67e-05	0.0218	-0.28	-0.24	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
COAD	cis	rs495337	1	rs4809769	ENSG00000229222.1	KRT18P4	-3.96	9.67e-05	0.0218	-0.26	-0.24	Psoriasis;	chr20:49962627	chr20:49956745~49958032:+
COAD	cis	rs1930961	0.702	rs8141205	ENSG00000271138.1	IGLVIVOR22-1	-3.96	9.67e-05	0.0218	-0.56	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25512200	chr22:25437306~25437823:-
COAD	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	3.96	9.67e-05	0.0218	0.27	0.24	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
COAD	cis	rs860295	0.812	rs11264363	ENSG00000225082.2	DAP3P1	-3.96	9.67e-05	0.0218	-0.29	-0.24	Body mass index;	chr1:155348517	chr1:155586644~155602197:+
COAD	cis	rs2929278	0.617	rs524908	ENSG00000275601.1	AC011330.13	3.96	9.67e-05	0.0218	0.29	0.24	Schizophrenia;	chr15:43895793	chr15:43642389~43643023:-
COAD	cis	rs719150	1	rs7750604	ENSG00000237499.5	RP11-356I2.4	-3.96	9.67e-05	0.0218	-0.34	-0.24	Cancer;	chr6:137869396	chr6:137823673~137868233:-
COAD	cis	rs11846409	0.818	rs2516909	ENSG00000211974.3	IGHV2-70	3.96	9.67e-05	0.0219	0.28	0.24	Rheumatic heart disease;	chr14:106630317	chr14:106723574~106724093:-
COAD	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-3.96	9.68e-05	0.0219	-0.29	-0.24	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
COAD	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-3.96	9.68e-05	0.0219	-0.32	-0.24	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
COAD	cis	rs2179367	0.6	rs9498355	ENSG00000268592.3	RAET1E-AS1	-3.96	9.68e-05	0.0219	-0.29	-0.24	Dupuytren's disease;	chr6:149442274	chr6:149863494~149919507:+
COAD	cis	rs2115630	0.967	rs11073702	ENSG00000259728.4	LINC00933	-3.96	9.68e-05	0.0219	-0.28	-0.24	P wave terminal force;	chr15:84766840	chr15:84570649~84580175:+
COAD	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	3.96	9.68e-05	0.0219	0.29	0.24	Height;	chr4:55545574	chr4:55547112~55547889:+
COAD	cis	rs860295	0.841	rs7556102	ENSG00000223503.1	RP11-29H23.6	3.96	9.68e-05	0.0219	0.31	0.24	Body mass index;	chr1:155398412	chr1:155590601~155591262:-
COAD	cis	rs194045	0.609	rs252344	ENSG00000273582.1	RP11-426C22.7	-3.96	9.69e-05	0.0219	-0.33	-0.24	Yu-Zhi constitution type in type 2 diabetes;	chr16:29173561	chr16:29225594~29226348:-
COAD	cis	rs13256369	0.851	rs13267036	ENSG00000254153.1	CTA-398F10.2	3.96	9.69e-05	0.0219	0.33	0.24	Obesity-related traits;	chr8:8709175	chr8:8456909~8461337:-
COAD	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-3.96	9.69e-05	0.0219	-0.26	-0.24	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
COAD	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-3.96	9.69e-05	0.0219	-0.36	-0.24	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
COAD	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	3.96	9.69e-05	0.0219	0.35	0.24	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	3.96	9.69e-05	0.0219	0.35	0.24	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
COAD	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	3.96	9.69e-05	0.0219	0.32	0.24	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
COAD	cis	rs1790761	0.967	rs1808279	ENSG00000231793.4	DOC2GP	-3.96	9.69e-05	0.0219	-0.26	-0.24	Mean corpuscular volume;	chr11:67444098	chr11:67612653~67616257:-
COAD	cis	rs595244	0.831	rs55694948	ENSG00000259705.1	RP11-227D13.1	3.96	9.69e-05	0.0219	0.32	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48465935	chr15:48645951~48652016:+
COAD	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	3.96	9.69e-05	0.0219	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	3.96	9.69e-05	0.0219	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
COAD	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-3.96	9.7e-05	0.0219	-0.28	-0.24	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
COAD	cis	rs875971	0.862	rs6971059	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66602045	chr7:65773620~65802067:+
COAD	cis	rs875971	0.789	rs7808013	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66606209	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs7384021	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66612917	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs66981195	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66614048	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs3926380	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66615658	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs1860472	ENSG00000224316.1	RP11-479O9.2	-3.96	9.7e-05	0.0219	-0.26	-0.24	Aortic root size;	chr7:66617736	chr7:65773620~65802067:+
COAD	cis	rs7584330	0.518	rs6715245	ENSG00000234949.2	AC104667.3	-3.96	9.7e-05	0.0219	-0.41	-0.24	Prostate cancer;	chr2:237537160	chr2:237591020~237595981:+
COAD	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-3.96	9.7e-05	0.0219	-0.28	-0.24	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
COAD	cis	rs7818688	1	rs28406132	ENSG00000253528.2	RP11-347C18.4	-3.96	9.7e-05	0.0219	-0.35	-0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018149	chr8:94974573~94974853:-
COAD	cis	rs7955901	0.658	rs12816762	ENSG00000258053.1	CTD-2021H9.3	3.96	9.7e-05	0.0219	0.29	0.24	Type 2 diabetes;	chr12:71097837	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.572	rs34952247	ENSG00000258053.1	CTD-2021H9.3	3.96	9.7e-05	0.0219	0.29	0.24	Type 2 diabetes;	chr12:71098065	chr12:71047402~71118247:-
COAD	cis	rs2732480	0.557	rs2634682	ENSG00000269514.1	RP11-370I10.12	3.96	9.7e-05	0.0219	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48198387~48202031:+
COAD	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	3.96	9.7e-05	0.0219	0.27	0.24	Height;	chr4:55527164	chr4:55363971~55395847:-
COAD	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-3.96	9.7e-05	0.0219	-0.28	-0.24	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
COAD	cis	rs4761702	0.527	rs12824664	ENSG00000257252.4	RP11-486A14.2	-3.96	9.7e-05	0.0219	-0.28	-0.24	Immature fraction of reticulocytes;	chr12:93343125	chr12:93317135~93377736:-
COAD	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	3.96	9.7e-05	0.0219	0.35	0.24	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
COAD	cis	rs8058578	1	rs7187359	ENSG00000260487.1	RP11-297C4.3	3.96	9.71e-05	0.0219	0.31	0.24	Multiple myeloma;	chr16:30691834	chr16:30480588~30481346:-
COAD	cis	rs8058578	1	rs6565197	ENSG00000260487.1	RP11-297C4.3	3.96	9.71e-05	0.0219	0.31	0.24	Multiple myeloma;	chr16:30695156	chr16:30480588~30481346:-
COAD	cis	rs8058578	1	rs67456513	ENSG00000260487.1	RP11-297C4.3	3.96	9.71e-05	0.0219	0.31	0.24	Multiple myeloma;	chr16:30703507	chr16:30480588~30481346:-
COAD	cis	rs8058578	0.943	rs7197770	ENSG00000260487.1	RP11-297C4.3	3.96	9.71e-05	0.0219	0.31	0.24	Multiple myeloma;	chr16:30704587	chr16:30480588~30481346:-
COAD	cis	rs7646881	0.812	rs61696028	ENSG00000272087.1	RP11-379F4.7	3.96	9.71e-05	0.0219	0.35	0.24	Tetralogy of Fallot;	chr3:158737914	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.812	rs61387735	ENSG00000272087.1	RP11-379F4.7	3.96	9.71e-05	0.0219	0.35	0.24	Tetralogy of Fallot;	chr3:158738372	chr3:158693120~158693768:-
COAD	cis	rs7646881	0.767	rs73015669	ENSG00000272087.1	RP11-379F4.7	3.96	9.71e-05	0.0219	0.35	0.24	Tetralogy of Fallot;	chr3:158738529	chr3:158693120~158693768:-
COAD	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	3.96	9.71e-05	0.0219	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
COAD	cis	rs62070183	0.766	rs10512441	ENSG00000266777.1	SH3GL1P1	-3.96	9.71e-05	0.0219	-0.26	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32039974~32042828:+
COAD	cis	rs4074961	0.527	rs10908355	ENSG00000233621.1	LINC01137	-3.96	9.71e-05	0.0219	-0.26	-0.24	Axial length;	chr1:37569685	chr1:37454879~37474411:-
COAD	cis	rs7727544	0.716	rs4705928	ENSG00000233006.5	AC034220.3	-3.96	9.72e-05	0.0219	-0.2	-0.24	Blood metabolite levels;	chr5:132242944	chr5:132311285~132369916:-
COAD	cis	rs394563	0.775	rs412894	ENSG00000231760.4	RP11-350J20.5	3.96	9.72e-05	0.0219	0.3	0.24	Dupuytren's disease;	chr6:149460039	chr6:149796151~149826294:-
COAD	cis	rs1115240	0.574	rs55845836	ENSG00000257842.4	NOVA1-AS1	3.96	9.72e-05	0.0219	0.33	0.24	Educational attainment (years of education);	chr14:26532558	chr14:26598412~26806467:+
COAD	cis	rs860295	0.812	rs12131079	ENSG00000225082.2	DAP3P1	3.96	9.72e-05	0.0219	0.29	0.24	Body mass index;	chr1:155349877	chr1:155586644~155602197:+
COAD	cis	rs6565180	0.783	rs9888967	ENSG00000183604.13	SMG1P5	3.96	9.72e-05	0.0219	0.26	0.24	Tonsillectomy;	chr16:30396658	chr16:30267553~30335374:-
COAD	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-3.96	9.72e-05	0.0219	-0.47	-0.24	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-3.96	9.72e-05	0.0219	-0.47	-0.24	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-3.96	9.72e-05	0.0219	-0.47	-0.24	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
COAD	cis	rs2408955	0.541	rs11168428	ENSG00000257735.1	RP11-370I10.6	-3.96	9.73e-05	0.0219	-0.28	-0.24	Glycated hemoglobin levels;	chr12:48153345	chr12:48350945~48442411:+
COAD	cis	rs984222	1	rs984222	ENSG00000231365.4	RP11-418J17.1	-3.96	9.73e-05	0.0219	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961220	chr1:119140396~119275973:+
COAD	cis	rs984222	0.967	rs984225	ENSG00000231365.4	RP11-418J17.1	-3.96	9.73e-05	0.0219	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961661	chr1:119140396~119275973:+
COAD	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-3.96	9.73e-05	0.0219	-0.24	-0.24	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
COAD	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	3.96	9.74e-05	0.022	0.31	0.24	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
COAD	cis	rs2252521	0.524	rs2529480	ENSG00000272568.4	CTB-113D17.1	3.96	9.74e-05	0.022	0.45	0.24	Cognitive performance;	chr7:29003504	chr7:28979967~29013367:+
COAD	cis	rs791888	0.858	rs1555434	ENSG00000225913.2	RP11-57C13.6	3.96	9.74e-05	0.022	0.31	0.24	Magnesium levels;	chr10:87659386	chr10:87607985~87659279:+
COAD	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	3.96	9.74e-05	0.022	0.25	0.24	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
COAD	cis	rs9880211	1	rs9826454	ENSG00000273486.1	RP11-731C17.2	3.96	9.74e-05	0.022	0.29	0.24	Height;Body mass index;	chr3:136234378	chr3:136837338~136839021:-
COAD	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-3.96	9.74e-05	0.022	-0.24	-0.24	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
COAD	cis	rs2018293	1	rs8142056	ENSG00000233521.4	RP5-1172A22.1	-3.96	9.75e-05	0.022	-0.22	-0.24	Vascular brain injury;	chr22:26313255	chr22:27221349~27224727:-
COAD	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-3.96	9.75e-05	0.022	-0.25	-0.24	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
COAD	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-3.96	9.75e-05	0.022	-0.25	-0.24	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
COAD	cis	rs763121	0.853	rs6001175	ENSG00000273076.1	RP3-508I15.22	3.96	9.75e-05	0.022	0.21	0.24	Menopause (age at onset);	chr22:38622329	chr22:38743495~38743910:+
COAD	cis	rs55962025	0.846	rs363066	ENSG00000248840.2	RP11-357G3.2	-3.96	9.75e-05	0.022	-0.29	-0.24	Parental longevity (mother's age at death);	chr4:3134226	chr4:3312512~3313058:+
COAD	cis	rs9400467	0.508	rs11153283	ENSG00000230177.1	RP5-1112D6.4	-3.96	9.76e-05	0.022	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111277932~111278742:+
COAD	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	3.96	9.76e-05	0.022	0.29	0.24	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
COAD	cis	rs7577696	0.889	rs2365558	ENSG00000272716.1	RP11-563N4.1	-3.96	9.76e-05	0.022	-0.25	-0.24	Inflammatory biomarkers;	chr2:32111588	chr2:32165046~32165757:-
COAD	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	3.96	9.76e-05	0.022	0.24	0.24	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
COAD	cis	rs2307394	1	rs12998729	ENSG00000281469.1	RP11-567F11.1	3.96	9.76e-05	0.022	0.29	0.24	Urate levels;	chr2:147859723	chr2:148044380~148044894:+
COAD	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-3.96	9.76e-05	0.022	-0.26	-0.24	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
COAD	cis	rs2638953	0.64	rs10843208	ENSG00000247934.4	RP11-967K21.1	-3.96	9.76e-05	0.022	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28572171	chr12:28163298~28190738:-
COAD	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-3.96	9.77e-05	0.022	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
COAD	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	3.96	9.77e-05	0.022	0.26	0.24	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
COAD	cis	rs9796	0.621	rs537244	ENSG00000247556.5	OIP5-AS1	-3.96	9.77e-05	0.022	-0.24	-0.24	Menopause (age at onset);	chr15:41177115	chr15:41283990~41309737:+
COAD	cis	rs9880211	0.699	rs9809269	ENSG00000273486.1	RP11-731C17.2	3.96	9.77e-05	0.022	0.3	0.24	Height;Body mass index;	chr3:136711064	chr3:136837338~136839021:-
COAD	cis	rs13188386	0.732	rs7736209	ENSG00000249779.1	RP11-447H19.3	3.96	9.78e-05	0.022	0.29	0.24	Iron status biomarkers;	chr5:42577457	chr5:43206709~43207811:+
COAD	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-3.96	9.78e-05	0.022	-0.24	-0.24	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
COAD	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	3.96	9.78e-05	0.022	0.42	0.24	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
COAD	cis	rs2559856	1	rs10778139	ENSG00000199933.1	RNY1P16	-3.96	9.78e-05	0.022	-0.26	-0.24	Blood protein levels;	chr12:101689424	chr12:101719808~101719918:+
COAD	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-3.96	9.78e-05	0.022	-0.3	-0.24	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
COAD	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-3.96	9.78e-05	0.022	-0.3	-0.24	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
COAD	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-3.96	9.79e-05	0.0221	-0.23	-0.24	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
COAD	cis	rs3748656	0.524	rs3748655	ENSG00000231246.1	RP5-965F6.2	-3.96	9.79e-05	0.0221	-0.37	-0.24	Hip circumference adjusted for BMI;	chr1:112674689	chr1:112177234~112360528:-
COAD	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-3.96	9.8e-05	0.0221	-0.26	-0.24	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
COAD	cis	rs796825	0.583	rs810888	ENSG00000240661.1	RP11-174O3.3	-3.96	9.8e-05	0.0221	-0.36	-0.24	HIV-1 susceptibility;	chr3:120302117	chr3:120349510~120367998:+
COAD	cis	rs2333021	0.801	rs4903086	ENSG00000259015.1	RP11-109N23.6	3.96	9.8e-05	0.0221	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:72960595~72961993:+
COAD	cis	rs2836974	0.666	rs1888487	ENSG00000255568.3	BRWD1-AS2	-3.96	9.8e-05	0.0221	-0.22	-0.24	Cognitive function;	chr21:39311333	chr21:39313935~39314962:+
COAD	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-3.96	9.8e-05	0.0221	-0.34	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
COAD	cis	rs4820539	1	rs756631	ENSG00000211644.2	IGLV1-51	-3.96	9.8e-05	0.0221	-0.14	-0.24	Bone mineral density;	chr22:23120996	chr22:22322472~22322980:+
COAD	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-3.96	9.8e-05	0.0221	-0.28	-0.24	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
COAD	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-3.96	9.81e-05	0.0221	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
COAD	cis	rs1670533	0.932	rs2248083	ENSG00000273179.1	RP11-20I20.4	3.96	9.81e-05	0.0221	0.31	0.24	Recombination rate (females);	chr4:1058378	chr4:1167778~1168174:+
COAD	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-3.96	9.81e-05	0.0221	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
COAD	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	3.96	9.82e-05	0.0221	0.26	0.24	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
COAD	cis	rs2179367	0.632	rs55826712	ENSG00000216906.2	RP11-350J20.9	3.96	9.83e-05	0.0221	0.34	0.24	Dupuytren's disease;	chr6:149344716	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498325	ENSG00000216906.2	RP11-350J20.9	3.96	9.83e-05	0.0221	0.34	0.24	Dupuytren's disease;	chr6:149345993	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498326	ENSG00000216906.2	RP11-350J20.9	3.96	9.83e-05	0.0221	0.34	0.24	Dupuytren's disease;	chr6:149346112	chr6:149904243~149906418:+
COAD	cis	rs17834679	1	rs17834679	ENSG00000273837.1	LLNLR-470E3.1	-3.96	9.83e-05	0.0221	-0.24	-0.24	Alopecia areata;	chr19:51766834	chr19:51639478~51639931:-
COAD	cis	rs17834679	0.957	rs59546961	ENSG00000273837.1	LLNLR-470E3.1	-3.96	9.83e-05	0.0221	-0.24	-0.24	Alopecia areata;	chr19:51766957	chr19:51639478~51639931:-
COAD	cis	rs7577696	0.525	rs2366547	ENSG00000272716.1	RP11-563N4.1	-3.96	9.83e-05	0.0221	-0.27	-0.24	Inflammatory biomarkers;	chr2:32026040	chr2:32165046~32165757:-
COAD	cis	rs1552244	1	rs35993975	ENSG00000186162.9	CIDECP	3.96	9.83e-05	0.0221	0.38	0.24	Alzheimer's disease;	chr3:10026110	chr3:10014238~10026365:-
COAD	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	3.96	9.84e-05	0.0221	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
COAD	cis	rs12699921	0.632	rs1852011	ENSG00000279048.1	RP11-511H23.2	-3.96	9.84e-05	0.0221	-0.18	-0.24	Fibrinogen levels;	chr7:17787004	chr7:17940503~17942922:+
COAD	cis	rs757278	0.513	rs213989	ENSG00000237974.1	AC000111.4	3.96	9.84e-05	0.0221	0.26	0.24	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117627457	chr7:117487737~117487929:+
COAD	cis	rs6687821	0.515	rs12072434	ENSG00000261737.1	RP4-612B15.3	-3.96	9.84e-05	0.0222	-0.31	-0.24	Yeast infection;	chr1:86935026	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs1923144	ENSG00000261737.1	RP4-612B15.3	-3.96	9.84e-05	0.0222	-0.31	-0.24	Yeast infection;	chr1:86938548	chr1:86703502~86704462:-
COAD	cis	rs10515750	0.5	rs2288069	ENSG00000248544.2	CTB-47B11.3	3.96	9.84e-05	0.0222	0.32	0.24	Lung function (FEV1/FVC);	chr5:157285187	chr5:157375741~157384950:-
COAD	cis	rs10515750	0.5	rs7728460	ENSG00000248544.2	CTB-47B11.3	3.96	9.84e-05	0.0222	0.32	0.24	Lung function (FEV1/FVC);	chr5:157286607	chr5:157375741~157384950:-
COAD	cis	rs6601327	0.551	rs13272424	ENSG00000233609.3	RP11-62H7.2	-3.96	9.84e-05	0.0222	-0.28	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8961200~8979025:+
COAD	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	3.96	9.85e-05	0.0222	0.33	0.24	Pain;	chr19:21568976	chr19:21554640~21569237:-
COAD	cis	rs8022206	0.786	rs72725185	ENSG00000259502.1	RP11-643G16.3	3.96	9.85e-05	0.0222	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68073090	chr14:67610986~67613864:+
COAD	cis	rs9880211	0.8	rs34324561	ENSG00000273486.1	RP11-731C17.2	3.96	9.85e-05	0.0222	0.28	0.24	Height;Body mass index;	chr3:136382400	chr3:136837338~136839021:-
COAD	cis	rs1670533	1	rs7679432	ENSG00000273179.1	RP11-20I20.4	3.96	9.85e-05	0.0222	0.32	0.24	Recombination rate (females);	chr4:1056733	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10003009	ENSG00000273179.1	RP11-20I20.4	3.96	9.85e-05	0.0222	0.32	0.24	Recombination rate (females);	chr4:1057061	chr4:1167778~1168174:+
COAD	cis	rs1670533	0.932	rs9992925	ENSG00000273179.1	RP11-20I20.4	3.96	9.85e-05	0.0222	0.32	0.24	Recombination rate (females);	chr4:1057121	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs2290411	ENSG00000273179.1	RP11-20I20.4	3.96	9.85e-05	0.0222	0.32	0.24	Recombination rate (females);	chr4:1057289	chr4:1167778~1168174:+
COAD	cis	rs1670533	1	rs10026482	ENSG00000273179.1	RP11-20I20.4	3.96	9.85e-05	0.0222	0.32	0.24	Recombination rate (females);	chr4:1057340	chr4:1167778~1168174:+
COAD	cis	rs113835537	0.529	rs11227509	ENSG00000258297.1	RP11-658F2.8	-3.96	9.85e-05	0.0222	-0.24	-0.24	Airway imaging phenotypes;	chr11:66513723	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs11227510	ENSG00000258297.1	RP11-658F2.8	-3.96	9.85e-05	0.0222	-0.24	-0.24	Airway imaging phenotypes;	chr11:66513749	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs2298806	ENSG00000258297.1	RP11-658F2.8	-3.96	9.85e-05	0.0222	-0.24	-0.24	Airway imaging phenotypes;	chr11:66514624	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs2276406	ENSG00000258297.1	RP11-658F2.8	-3.96	9.85e-05	0.0222	-0.24	-0.24	Airway imaging phenotypes;	chr11:66515786	chr11:66666036~66668374:+
COAD	cis	rs2919009	0.882	rs2919008	ENSG00000271670.1	RP11-95I16.4	3.96	9.85e-05	0.0222	0.28	0.24	Obesity-related traits;	chr10:120838163	chr10:120879256~120880667:-
COAD	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	3.96	9.85e-05	0.0222	0.32	0.24	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
COAD	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	3.96	9.86e-05	0.0222	0.26	0.24	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
COAD	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	3.96	9.86e-05	0.0222	0.3	0.24	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
COAD	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	3.96	9.86e-05	0.0222	0.33	0.24	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
COAD	cis	rs913655	0.508	rs7894191	ENSG00000240291.1	RP11-499P20.2	-3.96	9.86e-05	0.0222	-0.28	-0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18716871	chr10:18513115~18545651:-
COAD	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	3.96	9.86e-05	0.0222	0.31	0.24	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
COAD	cis	rs1485395	0.891	rs7976278	ENSG00000250133.2	HOXC-AS2	3.96	9.86e-05	0.0222	0.28	0.24	Migraine without aura;	chr12:53651337	chr12:53993810~53996785:-
COAD	cis	rs17685	0.796	rs3757594	ENSG00000280388.1	RP11-229D13.3	3.96	9.86e-05	0.0222	0.24	0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76043977~76045963:-
COAD	cis	rs12497850	1	rs12497850	ENSG00000225399.4	RP11-3B7.1	3.96	9.86e-05	0.0222	0.27	0.24	Parkinson's disease;	chr3:48711556	chr3:49260085~49261316:+
COAD	cis	rs7818688	1	rs77257477	ENSG00000253528.2	RP11-347C18.4	-3.96	9.87e-05	0.0222	-0.36	-0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95033171	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.79	rs74395342	ENSG00000253528.2	RP11-347C18.4	-3.96	9.87e-05	0.0222	-0.36	-0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95034723	chr8:94974573~94974853:-
COAD	cis	rs7818688	1	rs6651271	ENSG00000253528.2	RP11-347C18.4	-3.96	9.87e-05	0.0222	-0.36	-0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035393	chr8:94974573~94974853:-
COAD	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	3.96	9.87e-05	0.0222	0.41	0.24	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
COAD	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-3.96	9.87e-05	0.0222	-0.34	-0.24	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
COAD	cis	rs12906542	0.516	rs4886989	ENSG00000260139.5	CSPG4P13	-3.96	9.87e-05	0.0222	-0.33	-0.24	Breast cancer;	chr15:78011406	chr15:77894684~77904674:+
COAD	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-3.96	9.87e-05	0.0222	-0.37	-0.24	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
COAD	cis	rs699371	0.525	rs7144263	ENSG00000270000.1	RP3-449M8.9	3.96	9.87e-05	0.0222	0.3	0.24	Height;	chr14:74438928	chr14:74471930~74472360:-
COAD	cis	rs9302635	1	rs9302635	ENSG00000279206.1	RP5-991G20.6	-3.96	9.88e-05	0.0222	-0.32	-0.24	Blood protein levels;	chr16:72110275	chr16:72772673~72773272:+
COAD	cis	rs17685	0.753	rs4398845	ENSG00000280388.1	RP11-229D13.3	-3.96	9.88e-05	0.0222	-0.25	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76043977~76045963:-
COAD	cis	rs6545883	0.507	rs6545855	ENSG00000273302.1	RP11-493E12.2	-3.96	9.88e-05	0.0222	-0.22	-0.24	Tuberculosis;	chr2:61305725	chr2:61199979~61200769:+
COAD	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-3.96	9.88e-05	0.0222	-0.25	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
COAD	cis	rs2916733	0.607	rs2034143	ENSG00000246089.3	RP11-115C21.2	-3.96	9.88e-05	0.0222	-0.31	-0.24	Epirubicin-induced leukopenia;	chr8:6453217	chr8:6403551~6407142:-
COAD	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-3.96	9.88e-05	0.0222	-0.3	-0.24	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
COAD	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	3.96	9.88e-05	0.0222	0.29	0.24	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
COAD	cis	rs8061903	1	rs8061903	ENSG00000260071.1	RP11-418I22.2	3.96	9.88e-05	0.0222	0.26	0.24	HIV-1 viral setpoint;	chr16:9288472	chr16:9466655~9517564:+
COAD	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	3.96	9.88e-05	0.0222	0.26	0.24	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
COAD	cis	rs293748	0.771	rs34920909	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36792614	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs59889951	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36793150	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs35899185	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36795884	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs13184774	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36803578	chr5:36666214~36725195:-
COAD	cis	rs293748	0.713	rs292162	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36803778	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs292166	ENSG00000250155.1	CTD-2353F22.1	-3.96	9.89e-05	0.0222	-0.34	-0.24	Obesity-related traits;	chr5:36805367	chr5:36666214~36725195:-
COAD	cis	rs2439831	0.85	rs544122	ENSG00000249839.1	AC011330.5	-3.96	9.89e-05	0.0222	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43483534	chr15:43663654~43684339:-
COAD	cis	rs7760535	0.93	rs7742244	ENSG00000255389.1	C6orf3	-3.96	9.89e-05	0.0222	-0.23	-0.24	Metabolic traits;	chr6:111531459	chr6:111599875~111602295:+
COAD	cis	rs7686384	0.537	rs35906916	ENSG00000180015.12	RP11-756P10.3	-3.96	9.89e-05	0.0222	-0.44	-0.24	Obesity-related traits;	chr4:188706974	chr4:188738373~188739494:+
COAD	cis	rs7829975	0.684	rs488904	ENSG00000253981.4	ALG1L13P	-3.96	9.89e-05	0.0222	-0.27	-0.24	Mood instability;	chr8:8730061	chr8:8236003~8244667:-
COAD	cis	rs5758511	0.773	rs9680671	ENSG00000182057.4	OGFRP1	-3.96	9.9e-05	0.0223	-0.27	-0.24	Birth weight;	chr22:41955473	chr22:42269753~42275196:+
COAD	cis	rs28374715	0.578	rs72739630	ENSG00000247556.5	OIP5-AS1	3.96	9.9e-05	0.0223	0.34	0.24	Ulcerative colitis;	chr15:41338866	chr15:41283990~41309737:+
COAD	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-3.96	9.9e-05	0.0223	-0.27	-0.24	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-3.96	9.9e-05	0.0223	-0.27	-0.24	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-3.96	9.9e-05	0.0223	-0.27	-0.24	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
COAD	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-3.96	9.9e-05	0.0223	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
COAD	cis	rs6088813	0.677	rs6088831	ENSG00000269202.1	RP4-614O4.12	-3.95	9.9e-05	0.0223	-0.25	-0.24	Height;	chr20:35415937	chr20:35201747~35203288:-
COAD	cis	rs9291683	0.507	rs6827754	ENSG00000250413.1	RP11-448G15.1	3.95	9.91e-05	0.0223	0.31	0.24	Bone mineral density;	chr4:10016529	chr4:10006482~10009725:+
COAD	cis	rs12530	0.54	rs5998471	ENSG00000279338.1	RP1-309I22.2	3.95	9.91e-05	0.0223	0.22	0.24	IgG glycosylation;	chr22:32390230	chr22:32836706~32865634:+
COAD	cis	rs9532669	0.963	rs4942012	ENSG00000277662.1	RP11-74J13.9	-3.95	9.91e-05	0.0223	-0.23	-0.24	Cervical cancer;	chr13:40939112	chr13:41229180~41229676:-
COAD	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	3.95	9.92e-05	0.0223	0.3	0.24	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
COAD	cis	rs7646881	0.812	rs73017541	ENSG00000272087.1	RP11-379F4.7	3.95	9.92e-05	0.0223	0.37	0.24	Tetralogy of Fallot;	chr3:158743007	chr3:158693120~158693768:-
COAD	cis	rs17407555	0.657	rs4698001	ENSG00000250413.1	RP11-448G15.1	-3.95	9.92e-05	0.0223	-0.33	-0.24	Schizophrenia (age at onset);	chr4:10277789	chr4:10006482~10009725:+
COAD	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	3.95	9.92e-05	0.0223	0.33	0.24	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
COAD	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-3.95	9.92e-05	0.0223	-0.31	-0.24	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-3.95	9.92e-05	0.0223	-0.31	-0.24	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
COAD	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-3.95	9.92e-05	0.0223	-0.31	-0.24	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
COAD	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	3.95	9.92e-05	0.0223	0.29	0.24	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
COAD	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	3.95	9.92e-05	0.0223	0.33	0.24	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
COAD	cis	rs7324557	0.717	rs6490826	ENSG00000205861.10	C1QTNF9B-AS1	-3.95	9.93e-05	0.0223	-0.34	-0.24	Visceral adipose tissue adjusted for BMI;	chr13:23804999	chr13:23888889~23897263:+
COAD	cis	rs7582403	0.844	rs1234416	ENSG00000281469.1	RP11-567F11.1	3.95	9.93e-05	0.0223	0.28	0.24	Neuroticism;	chr2:148035896	chr2:148044380~148044894:+
COAD	cis	rs12530	0.887	rs9606942	ENSG00000232218.1	RP1-149A16.16	-3.95	9.93e-05	0.0223	-0.43	-0.24	IgG glycosylation;	chr22:32375668	chr22:32386668~32386868:+
COAD	cis	rs950893	0.597	rs2942219	ENSG00000253930.1	RP11-1149O23.2	-3.95	9.93e-05	0.0223	-0.28	-0.24	Mean corpuscular hemoglobin;	chr8:23581795	chr8:23189279~23190675:+
COAD	cis	rs8177876	0.57	rs11863158	ENSG00000261061.1	RP11-303E16.2	-3.95	9.94e-05	0.0223	-0.37	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81030770~81031485:+
COAD	cis	rs1044826	0.642	rs1580642	ENSG00000272656.1	RP11-219D15.3	-3.95	9.94e-05	0.0223	-0.29	-0.24	Obesity-related traits;	chr3:139413361	chr3:139349024~139349371:-
COAD	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-3.95	9.95e-05	0.0224	-0.29	-0.24	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
COAD	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	3.95	9.95e-05	0.0224	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
COAD	cis	rs3733585	0.699	rs2018643	ENSG00000250413.1	RP11-448G15.1	-3.95	9.95e-05	0.0224	-0.31	-0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9945497	chr4:10006482~10009725:+
COAD	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	3.95	9.95e-05	0.0224	0.39	0.24	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
COAD	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-3.95	9.95e-05	0.0224	-0.29	-0.24	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-3.95	9.95e-05	0.0224	-0.29	-0.24	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-3.95	9.95e-05	0.0224	-0.29	-0.24	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
COAD	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	3.95	9.95e-05	0.0224	0.32	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
COAD	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	3.95	9.95e-05	0.0224	0.29	0.24	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
COAD	cis	rs801193	0.548	rs6975044	ENSG00000224316.1	RP11-479O9.2	3.95	9.95e-05	0.0224	0.26	0.24	Aortic root size;	chr7:66762495	chr7:65773620~65802067:+
COAD	cis	rs480407	0.667	rs7574752	ENSG00000232320.6	AC009299.5	3.95	9.96e-05	0.0224	0.33	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160774753	chr2:161340816~161341326:-
COAD	cis	rs480407	0.667	rs7574698	ENSG00000232320.6	AC009299.5	3.95	9.96e-05	0.0224	0.33	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160774908	chr2:161340816~161341326:-
COAD	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	3.95	9.96e-05	0.0224	0.28	0.24	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
COAD	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-3.95	9.97e-05	0.0224	-0.4	-0.24	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
COAD	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-3.95	9.97e-05	0.0224	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-3.95	9.97e-05	0.0224	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
COAD	cis	rs913655	0.508	rs11006727	ENSG00000240291.1	RP11-499P20.2	3.95	9.97e-05	0.0224	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18743425	chr10:18513115~18545651:-
COAD	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-3.95	9.98e-05	0.0224	-0.29	-0.24	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
COAD	cis	rs867186	0.92	rs75383229	ENSG00000201151.1	SNORD56	3.95	9.98e-05	0.0224	0.35	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35025848	chr20:35117136~35117207:-
COAD	cis	rs867186	1	rs56363533	ENSG00000201151.1	SNORD56	3.95	9.98e-05	0.0224	0.35	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35038202	chr20:35117136~35117207:-
COAD	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	3.95	9.98e-05	0.0224	0.28	0.24	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
COAD	cis	rs4639966	0.836	rs7943039	ENSG00000255422.1	AP002954.4	3.95	9.99e-05	0.0224	0.31	0.24	Systemic lupus erythematosus;	chr11:118732321	chr11:118704607~118750263:+
COAD	cis	rs1832007	0.554	rs11594448	ENSG00000224034.1	RP11-445P17.8	-3.95	9.99e-05	0.0224	-0.35	-0.24	Triglyceride levels;Triglycerides;	chr10:5203328	chr10:5266033~5271236:-
COAD	cis	rs13188386	0.763	rs35090794	ENSG00000249779.1	RP11-447H19.3	3.95	1e-04	0.0224	0.29	0.24	Iron status biomarkers;	chr5:42554578	chr5:43206709~43207811:+
COAD	cis	rs13188386	0.732	rs7714392	ENSG00000249779.1	RP11-447H19.3	3.95	1e-04	0.0224	0.29	0.24	Iron status biomarkers;	chr5:42557793	chr5:43206709~43207811:+
COAD	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	3.95	1e-04	0.0224	0.29	0.24	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	3.95	1e-04	0.0224	0.29	0.24	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	3.95	1e-04	0.0224	0.29	0.24	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
COAD	cis	rs9532669	0.926	rs11147823	ENSG00000239827.7	SUGT1P3	3.95	1e-04	0.0225	0.2	0.24	Cervical cancer;	chr13:40878138	chr13:40908159~40921774:-
COAD	cis	rs4604234	0.803	rs11961345	ENSG00000272129.1	RP11-250B2.6	-3.95	1e-04	0.0225	-0.7	-0.24	Cancer;	chr6:80294807	chr6:80355424~80356859:+
COAD	cis	rs4604234	0.803	rs28839510	ENSG00000272129.1	RP11-250B2.6	-3.95	1e-04	0.0225	-0.7	-0.24	Cancer;	chr6:80312266	chr6:80355424~80356859:+
COAD	cis	rs2408955	0.521	rs7301003	ENSG00000257735.1	RP11-370I10.6	3.95	1e-04	0.0225	0.28	0.24	Glycated hemoglobin levels;	chr12:48156444	chr12:48350945~48442411:+
COAD	cis	rs11089937	0.616	rs6001227	ENSG00000211638.2	IGLV8-61	-3.95	1e-04	0.0225	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22098700~22099212:+
COAD	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	3.95	1e-04	0.0225	0.35	0.24	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	3.95	1e-04	0.0225	0.35	0.24	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
COAD	cis	rs4950322	0.947	rs58671552	ENSG00000278811.3	LINC00624	3.95	1e-04	0.0225	0.26	0.24	Protein quantitative trait loci;	chr1:147409534	chr1:147258885~147517875:-
COAD	cis	rs734999	0.572	rs2985857	ENSG00000225931.3	RP3-395M20.7	-3.95	1e-04	0.0225	-0.26	-0.24	Ulcerative colitis;	chr1:2601185	chr1:2566410~2569888:+
COAD	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-3.95	1e-04	0.0225	-0.29	-0.24	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-3.95	1e-04	0.0225	-0.29	-0.24	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
COAD	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	3.95	1e-04	0.0225	0.28	0.24	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
COAD	cis	rs9376098	1	rs1040441	ENSG00000232876.1	CTA-212D2.2	-3.95	1e-04	0.0225	-0.3	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135172740	chr6:135055033~135060550:+
COAD	cis	rs1044826	0.553	rs295469	ENSG00000272656.1	RP11-219D15.3	3.95	1e-04	0.0225	0.28	0.24	Obesity-related traits;	chr3:139494058	chr3:139349024~139349371:-
COAD	cis	rs3120667	0.72	rs2146117	ENSG00000237975.5	FLG-AS1	-3.95	1e-04	0.0225	-0.33	-0.24	Eating disorders;	chr1:152444433	chr1:152168125~152445456:+
COAD	cis	rs9487051	0.872	rs9386789	ENSG00000219700.1	PTCHD3P3	3.95	1e-04	0.0225	0.25	0.24	Reticulocyte fraction of red cells;	chr6:109282015	chr6:109288571~109290503:-
COAD	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	3.95	1e-04	0.0225	0.35	0.24	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
COAD	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	3.95	1e-04	0.0225	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
COAD	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	3.95	1e-04	0.0225	0.24	0.24	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
COAD	cis	rs60733400	0.5	rs72644697	ENSG00000225931.3	RP3-395M20.7	3.95	1e-04	0.0225	0.26	0.24	Multiple sclerosis;	chr1:2602166	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs11585048	ENSG00000225931.3	RP3-395M20.7	3.95	1e-04	0.0225	0.26	0.24	Ulcerative colitis;	chr1:2602648	chr1:2566410~2569888:+
COAD	cis	rs28374715	0.58	rs8030228	ENSG00000247556.5	OIP5-AS1	3.95	1e-04	0.0225	0.3	0.24	Ulcerative colitis;	chr15:41344669	chr15:41283990~41309737:+
COAD	cis	rs875971	1	rs10244498	ENSG00000230189.5	GS1-124K5.2	3.95	1e-04	0.0225	0.2	0.24	Aortic root size;	chr7:66651069	chr7:66409143~66490059:-
COAD	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	3.95	1e-04	0.0225	0.27	0.24	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
COAD	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	3.95	1e-04	0.0225	0.27	0.24	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
COAD	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-3.95	1e-04	0.0225	-0.22	-0.24	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
COAD	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-3.95	1e-04	0.0225	-0.31	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
COAD	cis	rs7138300	0.528	rs11178577	ENSG00000258053.1	CTD-2021H9.3	3.95	1e-04	0.0225	0.34	0.24	Type 2 diabetes;	chr12:71061192	chr12:71047402~71118247:-
COAD	cis	rs9880211	0.563	rs9848926	ENSG00000239213.4	NCK1-AS1	3.95	1e-04	0.0225	0.31	0.24	Height;Body mass index;	chr3:136097460	chr3:136841726~136862054:-
COAD	cis	rs875971	0.564	rs313804	ENSG00000224316.1	RP11-479O9.2	3.95	1e-04	0.0225	0.25	0.24	Aortic root size;	chr7:66049635	chr7:65773620~65802067:+
COAD	cis	rs875971	0.662	rs448725	ENSG00000224316.1	RP11-479O9.2	3.95	1e-04	0.0225	0.25	0.24	Aortic root size;	chr7:66049641	chr7:65773620~65802067:+
COAD	cis	rs875971	0.658	rs432667	ENSG00000224316.1	RP11-479O9.2	3.95	1e-04	0.0225	0.25	0.24	Aortic root size;	chr7:66049646	chr7:65773620~65802067:+
COAD	cis	rs6490294	0.607	rs2339907	ENSG00000257595.2	RP3-473L9.4	3.95	1e-04	0.0225	0.31	0.24	Mean platelet volume;	chr12:111980342	chr12:111369282~111403310:+
COAD	cis	rs34779708	0.931	rs17591135	ENSG00000271335.4	RP11-324I22.4	3.95	1e-04	0.0225	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs55724039	ENSG00000271335.4	RP11-324I22.4	3.95	1e-04	0.0225	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs12769484	ENSG00000271335.4	RP11-324I22.4	3.95	1e-04	0.0225	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35314552~35336401:-
COAD	cis	rs72615157	0.606	rs941288	ENSG00000078319.8	PMS2P1	-3.95	1e-04	0.0225	-0.33	-0.24	Lung function (FEV1/FVC);	chr7:100179185	chr7:100320992~100341908:-
COAD	cis	rs3126085	0.935	rs3126043	ENSG00000237975.5	FLG-AS1	-3.95	1e-04	0.0225	-0.27	-0.24	Atopic dermatitis;	chr1:152283554	chr1:152168125~152445456:+
COAD	cis	rs7656342	0.964	rs13141706	ENSG00000186234.7	FAM86MP	3.95	1e-04	0.0225	0.3	0.24	Gut microbiota (bacterial taxa);	chr4:9816721	chr4:9692495~9702954:+
COAD	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-3.95	0.000101	0.0225	-0.4	-0.24	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
COAD	cis	rs56052703	0.536	rs2419245	ENSG00000267633.1	CTB-5E10.3	3.95	0.000101	0.0226	0.27	0.24	Proteinuria and chronic kidney disease;	chr19:13312148	chr19:13772118~13774118:-
COAD	cis	rs12468226	0.938	rs13392645	ENSG00000226261.1	AC064836.3	3.95	0.000101	0.0226	0.36	0.24	Urate levels;	chr2:202270116	chr2:202336024~202336727:-
COAD	cis	rs7560272	0.501	rs17350188	ENSG00000273245.1	RP11-434P11.2	3.95	0.000101	0.0226	0.29	0.24	Schizophrenia;	chr2:73737715	chr2:73750256~73750786:-
COAD	cis	rs9868809	0.881	rs7631574	ENSG00000225399.4	RP11-3B7.1	3.95	0.000101	0.0226	0.34	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48625613	chr3:49260085~49261316:+
COAD	cis	rs875971	0.755	rs76288834	ENSG00000224316.1	RP11-479O9.2	-3.95	0.000101	0.0226	-0.26	-0.24	Aortic root size;	chr7:66604815	chr7:65773620~65802067:+
COAD	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-3.95	0.000101	0.0226	-0.24	-0.24	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
COAD	cis	rs12497850	1	rs12493578	ENSG00000225399.4	RP11-3B7.1	-3.95	0.000101	0.0226	-0.27	-0.24	Parkinson's disease;	chr3:48692683	chr3:49260085~49261316:+
COAD	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-3.95	0.000101	0.0226	-0.47	-0.24	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
COAD	cis	rs8049040	0.609	rs16972805	ENSG00000260886.1	TAT-AS1	-3.95	0.000101	0.0226	-0.3	-0.24	Blood protein levels;	chr16:71444346	chr16:71565789~71578187:+
COAD	cis	rs4879656	0.966	rs10758178	ENSG00000225693.1	LAGE3P1	-3.95	0.000101	0.0226	-0.29	-0.24	Menopause (age at onset);	chr9:32999421	chr9:33019682~33020165:-
COAD	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	3.95	0.000101	0.0226	0.21	0.24	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
COAD	cis	rs2408955	0.521	rs7301003	ENSG00000226413.2	OR8T1P	3.95	0.000101	0.0226	0.28	0.24	Glycated hemoglobin levels;	chr12:48156444	chr12:48442030~48442947:-
COAD	cis	rs1510510	0.625	rs6755528	ENSG00000225057.2	AC096574.4	3.95	0.000101	0.0226	0.3	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640115	chr2:238231684~238255633:+
COAD	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	3.95	0.000101	0.0226	0.19	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
COAD	cis	rs1480597	1	rs17502384	ENSG00000165511.6	C10orf25	3.95	0.000101	0.0226	0.42	0.24	Parkinson's disease;	chr10:44714793	chr10:44997698~45000888:-
COAD	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-3.95	0.000101	0.0226	-0.27	-0.24	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
COAD	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	3.95	0.000101	0.0226	0.28	0.24	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
COAD	cis	rs1585471	1	rs1903403	ENSG00000248697.1	TOX4P1	-3.95	0.000101	0.0226	-0.27	-0.24	Myopia (pathological);	chr4:111787889	chr4:112455924~112457785:+
COAD	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-3.95	0.000101	0.0226	-0.31	-0.24	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
COAD	cis	rs11638352	1	rs890465	ENSG00000205771.5	CATSPER2P1	-3.95	0.000101	0.0226	-0.39	-0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44064265	chr15:43726918~43747094:-
COAD	cis	rs9818758	0.607	rs80170003	ENSG00000225399.4	RP11-3B7.1	-3.95	0.000101	0.0226	-0.49	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48914207	chr3:49260085~49261316:+
COAD	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-3.95	0.000101	0.0226	-0.4	-0.24	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
COAD	cis	rs4930776	1	rs10774353	ENSG00000213942.3	RP1-102E24.1	3.95	0.000101	0.0226	0.21	0.24	Plasma clusterin levels;	chr12:5658008	chr12:6409637~6410013:-
COAD	cis	rs875971	1	rs2420168	ENSG00000230189.5	GS1-124K5.2	-3.95	0.000101	0.0226	-0.2	-0.24	Aortic root size;	chr7:66165644	chr7:66409143~66490059:-
COAD	cis	rs74233809	1	rs12221064	ENSG00000213277.3	MARCKSL1P1	3.95	0.000101	0.0226	0.5	0.24	Birth weight;	chr10:102917369	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs77602510	ENSG00000213277.3	MARCKSL1P1	3.95	0.000101	0.0226	0.5	0.24	Birth weight;	chr10:102922845	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs78821730	ENSG00000213277.3	MARCKSL1P1	3.95	0.000101	0.0226	0.5	0.24	Birth weight;	chr10:102924787	chr10:103175554~103176094:+
COAD	cis	rs11239930	0.538	rs4950362	ENSG00000278811.3	LINC00624	3.95	0.000101	0.0226	0.24	0.24	AIDS progression;	chr1:147088336	chr1:147258885~147517875:-
COAD	cis	rs2281603	0.762	rs61987034	ENSG00000259116.1	RP11-973N13.4	-3.95	0.000101	0.0226	-0.26	-0.24	Lymphocyte counts;	chr14:64567405	chr14:64514154~64540368:-
COAD	cis	rs718433	0.584	rs10133988	ENSG00000211778.2	TRAV4	-3.95	0.000101	0.0226	-0.2	-0.24	Intraocular pressure;	chr14:21746376	chr14:21736152~21736982:+
COAD	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-3.95	0.000101	0.0226	-0.26	-0.24	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
COAD	cis	rs11239930	0.517	rs584107	ENSG00000278811.3	LINC00624	-3.95	0.000101	0.0227	-0.24	-0.24	AIDS progression;	chr1:147075862	chr1:147258885~147517875:-
COAD	cis	rs10876993	0.89	rs1678539	ENSG00000270039.1	RP11-571M6.17	3.95	0.000101	0.0227	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57666576	chr12:57803838~57804415:+
COAD	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	3.95	0.000101	0.0227	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	3.95	0.000101	0.0227	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
COAD	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-3.95	0.000101	0.0227	-0.26	-0.24	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
COAD	cis	rs10910092	1	rs10910092	ENSG00000225931.3	RP3-395M20.7	3.95	0.000101	0.0227	0.26	0.24	Ulcerative colitis;	chr1:2570077	chr1:2566410~2569888:+
COAD	cis	rs6688613	0.765	rs56229522	ENSG00000225171.2	DUTP6	-3.95	0.000101	0.0227	-0.32	-0.24	Refractive astigmatism;	chr1:166846871	chr1:166868748~166869209:+
COAD	cis	rs12530	0.938	rs28640241	ENSG00000232218.1	RP1-149A16.16	-3.95	0.000101	0.0227	-0.43	-0.24	IgG glycosylation;	chr22:32417568	chr22:32386668~32386868:+
COAD	cis	rs2976388	0.578	rs3758081	ENSG00000247317.3	RP11-273G15.2	3.95	0.000101	0.0227	0.28	0.24	Urinary tract infection frequency;	chr8:142742955	chr8:142981738~143018437:-
COAD	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-3.95	0.000101	0.0227	-0.22	-0.24	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
COAD	cis	rs12935418	0.634	rs9934940	ENSG00000278985.1	RP11-303E16.9	3.95	0.000101	0.0227	0.27	0.24	Mean corpuscular volume;	chr16:81016021	chr16:80982319~80984094:-
COAD	cis	rs3858145	0.588	rs10998059	ENSG00000233590.1	RP11-153K11.3	3.95	0.000101	0.0227	0.26	0.24	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68233251~68242379:-
COAD	cis	rs728616	0.867	rs12414096	ENSG00000234382.2	RP11-40F6.1	-3.95	0.000101	0.0227	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:80233664~80245367:+
COAD	cis	rs7246657	0.943	rs28373708	ENSG00000226686.6	LINC01535	-3.95	0.000101	0.0227	-0.33	-0.24	Coronary artery calcification;	chr19:37485757	chr19:37251912~37265535:+
COAD	cis	rs9907295	0.591	rs11650668	ENSG00000270977.1	AC015849.16	-3.95	0.000101	0.0227	-0.31	-0.24	Fibroblast growth factor basic levels;	chr17:35822045	chr17:35893707~35911023:-
COAD	cis	rs6095360	1	rs6512554	ENSG00000222365.1	SNORD12B	-3.95	0.000101	0.0227	-0.23	-0.24	Intelligence (multi-trait analysis);	chr20:48916213	chr20:49280319~49280409:+
COAD	cis	rs1115240	0.574	rs17496682	ENSG00000257842.4	NOVA1-AS1	3.95	0.000101	0.0227	0.33	0.24	Educational attainment (years of education);	chr14:26450701	chr14:26598412~26806467:+
COAD	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	3.95	0.000101	0.0227	0.31	0.24	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
COAD	cis	rs9980	0.895	rs4783720	ENSG00000266801.1	RP11-521L9.2	3.95	0.000101	0.0227	0.51	0.24	Blood osmolality (transformed sodium);	chr16:69525793	chr16:68933820~68937725:+
COAD	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	3.95	0.000101	0.0227	0.15	0.24	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
COAD	cis	rs78487399	0.808	rs77787499	ENSG00000234936.1	AC010883.5	3.95	0.000102	0.0227	0.38	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536670	chr2:43229573~43233394:+
COAD	cis	rs6490294	0.583	rs2339973	ENSG00000257595.2	RP3-473L9.4	3.95	0.000102	0.0227	0.3	0.24	Mean platelet volume;	chr12:112083079	chr12:111369282~111403310:+
COAD	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-3.95	0.000102	0.0227	-0.3	-0.24	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
COAD	cis	rs7674212	0.512	rs2720462	ENSG00000230069.3	LRRC37A15P	-3.95	0.000102	0.0227	-0.26	-0.24	Type 2 diabetes;	chr4:103135053	chr4:102727274~102730721:-
COAD	cis	rs7584330	0.554	rs6740722	ENSG00000234949.2	AC104667.3	-3.95	0.000102	0.0227	-0.39	-0.24	Prostate cancer;	chr2:237484645	chr2:237591020~237595981:+
COAD	cis	rs3126085	0.935	rs6676012	ENSG00000237975.5	FLG-AS1	-3.95	0.000102	0.0227	-0.26	-0.24	Atopic dermatitis;	chr1:152240727	chr1:152168125~152445456:+
COAD	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	3.95	0.000102	0.0228	0.28	0.24	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
COAD	cis	rs4819052	0.851	rs13050359	ENSG00000227039.5	ITGB2-AS1	-3.95	0.000102	0.0228	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:44921051~44929678:+
COAD	cis	rs7615952	0.673	rs3811677	ENSG00000241278.1	ENPP7P4	3.95	0.000102	0.0228	0.27	0.24	Blood pressure (smoking interaction);	chr3:125929237	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.932	rs3811679	ENSG00000241278.1	ENPP7P4	3.95	0.000102	0.0228	0.27	0.24	Blood pressure (smoking interaction);	chr3:125929440	chr3:125848223~125909372:+
COAD	cis	rs13256369	0.901	rs12679831	ENSG00000253981.4	ALG1L13P	3.95	0.000102	0.0228	0.36	0.24	Obesity-related traits;	chr8:8708901	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.901	rs12681327	ENSG00000253981.4	ALG1L13P	3.95	0.000102	0.0228	0.36	0.24	Obesity-related traits;	chr8:8708904	chr8:8236003~8244667:-
COAD	cis	rs643506	0.817	rs1940392	ENSG00000230911.1	PPIHP1	-3.95	0.000102	0.0228	-0.3	-0.24	Breast cancer;	chr11:111906122	chr11:112029858~112030367:-
COAD	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000102	0.0228	0.44	0.24	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
COAD	cis	rs7487075	0.93	rs6582656	ENSG00000274723.1	RP11-618L22.1	3.95	0.000102	0.0228	0.25	0.24	Itch intensity from mosquito bite;	chr12:46449633	chr12:46970504~46972155:+
COAD	cis	rs728616	0.558	rs723192	ENSG00000234382.2	RP11-40F6.1	-3.95	0.000102	0.0228	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:80233664~80245367:+
COAD	cis	rs7200543	1	rs7200543	ENSG00000270580.4	PKD1P6	-3.95	0.000102	0.0228	-0.27	-0.24	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15104723~15131601:-
COAD	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	3.95	0.000102	0.0228	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
COAD	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-3.95	0.000102	0.0228	-0.34	-0.24	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
COAD	cis	rs3126085	0.935	rs3126046	ENSG00000237975.5	FLG-AS1	3.95	0.000102	0.0228	0.26	0.24	Atopic dermatitis;	chr1:152284449	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs3120660	ENSG00000237975.5	FLG-AS1	3.95	0.000102	0.0228	0.26	0.24	Atopic dermatitis;	chr1:152286225	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs3126048	ENSG00000237975.5	FLG-AS1	3.95	0.000102	0.0228	0.26	0.24	Atopic dermatitis;	chr1:152287689	chr1:152168125~152445456:+
COAD	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	3.95	0.000102	0.0228	0.29	0.24	Height;	chr4:55474259	chr4:55547112~55547889:+
COAD	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	3.95	0.000102	0.0228	0.45	0.24	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
COAD	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	3.95	0.000102	0.0228	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
COAD	cis	rs10509125	0.575	rs10509123	ENSG00000232682.2	RP11-388P9.2	3.95	0.000102	0.0228	0.28	0.24	Behavioral disturbance or psychiatric symptoms and prion disease;	chr10:60133387	chr10:60050668~60060743:+
COAD	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	3.95	0.000102	0.0228	0.28	0.24	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
COAD	cis	rs6088813	0.677	rs6088826	ENSG00000269202.1	RP4-614O4.12	-3.95	0.000102	0.0228	-0.25	-0.24	Height;	chr20:35410683	chr20:35201747~35203288:-
COAD	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	3.95	0.000102	0.0228	0.32	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	3.95	0.000102	0.0228	0.32	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
COAD	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	3.95	0.000102	0.0228	0.32	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
COAD	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-3.95	0.000102	0.0228	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
COAD	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-3.95	0.000102	0.0229	-0.29	-0.24	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
COAD	cis	rs113835537	0.529	rs4930378	ENSG00000258297.1	RP11-658F2.8	-3.95	0.000102	0.0229	-0.24	-0.24	Airway imaging phenotypes;	chr11:66488044	chr11:66666036~66668374:+
COAD	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	3.95	0.000102	0.0229	0.16	0.24	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
COAD	cis	rs860295	0.702	rs10908479	ENSG00000160766.13	GBAP1	-3.95	0.000102	0.0229	-0.27	-0.24	Body mass index;	chr1:155673612	chr1:155213821~155227422:-
COAD	cis	rs9652601	0.676	rs9926615	ENSG00000274038.1	RP11-66H6.4	-3.95	0.000102	0.0229	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11009303	chr16:11056556~11057034:+
COAD	cis	rs7584330	0.518	rs77789507	ENSG00000234949.2	AC104667.3	-3.95	0.000102	0.0229	-0.42	-0.24	Prostate cancer;	chr2:237532329	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs77180399	ENSG00000234949.2	AC104667.3	-3.95	0.000102	0.0229	-0.42	-0.24	Prostate cancer;	chr2:237534308	chr2:237591020~237595981:+
COAD	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	3.95	0.000102	0.0229	0.27	0.24	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
COAD	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	3.95	0.000102	0.0229	0.3	0.24	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
COAD	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	3.95	0.000102	0.0229	0.25	0.24	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
COAD	cis	rs478304	0.593	rs4645933	ENSG00000214659.4	KRT8P26	-3.95	0.000102	0.0229	-0.28	-0.24	Acne (severe);	chr11:65717649	chr11:65726939~65728214:+
COAD	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-3.95	0.000102	0.0229	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
COAD	cis	rs8141529	0.778	rs763073	ENSG00000272858.1	CTA-292E10.8	-3.95	0.000102	0.0229	-0.29	-0.24	Lymphocyte counts;	chr22:28819554	chr22:28814914~28815662:+
COAD	cis	rs7646881	0.812	rs79303235	ENSG00000272087.1	RP11-379F4.7	3.95	0.000102	0.0229	0.37	0.24	Tetralogy of Fallot;	chr3:158727004	chr3:158693120~158693768:-
COAD	cis	rs853679	1	rs1679709	ENSG00000272009.1	RP1-313I6.12	-3.95	0.000102	0.0229	-0.39	-0.24	Depression;	chr6:28260564	chr6:28078792~28081130:-
COAD	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	3.95	0.000102	0.0229	0.26	0.24	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
COAD	cis	rs913655	0.508	rs2358186	ENSG00000240291.1	RP11-499P20.2	3.95	0.000103	0.0229	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719571	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs4576719	ENSG00000240291.1	RP11-499P20.2	3.95	0.000103	0.0229	0.28	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719746	chr10:18513115~18545651:-
COAD	cis	rs8044868	0.887	rs12449073	ENSG00000279206.1	RP5-991G20.6	-3.95	0.000103	0.0229	-0.29	-0.24	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72137105	chr16:72772673~72773272:+
COAD	cis	rs11976180	1	rs1320894	ENSG00000204959.4	ARHGEF34P	3.95	0.000103	0.0229	0.29	0.24	Obesity-related traits;	chr7:144054709	chr7:144272445~144286966:-
COAD	cis	rs11976180	1	rs2951369	ENSG00000204959.4	ARHGEF34P	3.95	0.000103	0.0229	0.29	0.24	Obesity-related traits;	chr7:144055545	chr7:144272445~144286966:-
COAD	cis	rs11976180	1	rs2951364	ENSG00000204959.4	ARHGEF34P	3.95	0.000103	0.0229	0.29	0.24	Obesity-related traits;	chr7:144057390	chr7:144272445~144286966:-
COAD	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	3.95	0.000103	0.0229	0.3	0.24	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
COAD	cis	rs7584330	0.74	rs13426236	ENSG00000234949.2	AC104667.3	-3.95	0.000103	0.0229	-0.3	-0.24	Prostate cancer;	chr2:237539297	chr2:237591020~237595981:+
COAD	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	3.95	0.000103	0.0229	0.32	0.24	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	3.95	0.000103	0.0229	0.32	0.24	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
COAD	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	3.95	0.000103	0.0229	0.28	0.24	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
COAD	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	3.95	0.000103	0.0229	0.28	0.24	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
COAD	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-3.95	0.000103	0.0229	-0.34	-0.24	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-3.95	0.000103	0.0229	-0.34	-0.24	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
COAD	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	3.95	0.000103	0.0229	0.32	0.24	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
COAD	cis	rs953301	0.793	rs61104653	ENSG00000229808.1	RP11-456P18.2	-3.95	0.000103	0.0229	-0.49	-0.24	Left atrial antero-posterior diameter;	chr1:161784654	chr1:161890833~161892196:+
COAD	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-3.95	0.000103	0.023	-0.35	-0.24	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
COAD	cis	rs453301	0.686	rs7017868	ENSG00000233609.3	RP11-62H7.2	-3.95	0.000103	0.023	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9015783	chr8:8961200~8979025:+
COAD	cis	rs1062753	0.527	rs62240998	ENSG00000182057.4	OGFRP1	-3.95	0.000103	0.023	-0.24	-0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41958697	chr22:42269753~42275196:+
COAD	cis	rs2243480	1	rs1499614	ENSG00000229886.1	RP5-1132H15.3	3.95	0.000103	0.023	0.41	0.24	Diabetic kidney disease;	chr7:66265811	chr7:66025126~66031544:-
COAD	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-3.95	0.000103	0.023	-0.37	-0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
COAD	cis	rs10779751	1	rs2300093	ENSG00000215785.2	CFL1P6	-3.95	0.000103	0.023	-0.27	-0.24	Body mass index;	chr1:11206335	chr1:10990978~10991797:-
COAD	cis	rs10779751	0.959	rs2300091	ENSG00000215785.2	CFL1P6	-3.95	0.000103	0.023	-0.27	-0.24	Body mass index;	chr1:11206654	chr1:10990978~10991797:-
COAD	cis	rs10779751	1	rs11121698	ENSG00000215785.2	CFL1P6	-3.95	0.000103	0.023	-0.27	-0.24	Body mass index;	chr1:11207226	chr1:10990978~10991797:-
COAD	cis	rs5758511	0.573	rs1569451	ENSG00000237037.8	NDUFA6-AS1	3.95	0.000103	0.023	0.25	0.24	Birth weight;	chr22:41836287	chr22:42090931~42137742:+
COAD	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-3.95	0.000103	0.023	-0.26	-0.24	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
COAD	cis	rs9291683	0.507	rs6849273	ENSG00000250413.1	RP11-448G15.1	-3.95	0.000103	0.023	-0.31	-0.24	Bone mineral density;	chr4:10019971	chr4:10006482~10009725:+
COAD	cis	rs2073499	0.872	rs41291724	ENSG00000235908.1	RHOA-IT1	3.95	0.000103	0.023	0.42	0.24	Schizophrenia;	chr3:50256634	chr3:49365145~49367006:-
COAD	cis	rs74233809	1	rs12221193	ENSG00000213277.3	MARCKSL1P1	3.95	0.000103	0.023	0.5	0.24	Birth weight;	chr10:102905510	chr10:103175554~103176094:+
COAD	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-3.95	0.000103	0.023	-0.39	-0.24	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
COAD	cis	rs8002861	0.905	rs6561150	ENSG00000274001.1	RP11-5G9.5	3.95	0.000103	0.023	0.22	0.24	Leprosy;	chr13:43886334	chr13:43877715~43878163:-
COAD	cis	rs2337406	1	rs78857163	ENSG00000211974.3	IGHV2-70	-3.95	0.000103	0.023	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106707435	chr14:106723574~106724093:-
COAD	cis	rs1510272	0.889	rs6441086	ENSG00000243926.1	TIPARP-AS1	-3.94	0.000103	0.023	-0.27	-0.24	Testicular germ cell tumor;	chr3:156607834	chr3:156671862~156674378:-
COAD	cis	rs1510272	0.847	rs6802056	ENSG00000243926.1	TIPARP-AS1	-3.94	0.000103	0.023	-0.27	-0.24	Testicular germ cell tumor;	chr3:156608112	chr3:156671862~156674378:-
COAD	cis	rs6519955	0.765	rs7292527	ENSG00000231711.2	LINC00899	-3.94	0.000103	0.023	-0.23	-0.24	Dupuytren's disease;	chr22:46027245	chr22:46039907~46044853:-
COAD	cis	rs4820539	0.966	rs2283803	ENSG00000211644.2	IGLV1-51	-3.94	0.000103	0.023	-0.13	-0.24	Bone mineral density;	chr22:23112694	chr22:22322472~22322980:+
COAD	cis	rs5771242	0.518	rs5771258	ENSG00000273253.2	RP3-402G11.26	-3.94	0.000103	0.023	-0.37	-0.24	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50237219	chr22:50199090~50200837:-
COAD	cis	rs2017305	0.834	rs12244293	ENSG00000233590.1	RP11-153K11.3	3.94	0.000103	0.023	0.41	0.24	Depression (quantitative trait);	chr10:69023824	chr10:68233251~68242379:-
COAD	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	3.94	0.000103	0.023	0.25	0.24	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
COAD	cis	rs1048886	0.808	rs2293297	ENSG00000271967.1	RP11-134K13.4	-3.94	0.000103	0.023	-0.34	-0.24	Type 2 diabetes;	chr6:70567100	chr6:70596438~70596980:+
COAD	cis	rs3816183	1	rs7422835	ENSG00000236533.1	AC009413.2	-3.94	0.000103	0.023	-0.27	-0.24	Hypospadias;	chr2:42788867	chr2:41850203~41850601:-
COAD	cis	rs3816183	1	rs10174617	ENSG00000236533.1	AC009413.2	-3.94	0.000103	0.023	-0.27	-0.24	Hypospadias;	chr2:42788925	chr2:41850203~41850601:-
COAD	cis	rs2188554	0.785	rs213952	ENSG00000237974.1	AC000111.4	3.94	0.000103	0.023	0.24	0.24	Esophageal adenocarcinoma;	chr7:117563363	chr7:117487737~117487929:+
COAD	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	3.94	0.000103	0.0231	0.32	0.24	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
COAD	cis	rs2559856	1	rs2695288	ENSG00000199933.1	RNY1P16	3.94	0.000103	0.0231	0.26	0.24	Blood protein levels;	chr12:101694334	chr12:101719808~101719918:+
COAD	cis	rs13256369	0.802	rs13281933	ENSG00000253981.4	ALG1L13P	3.94	0.000103	0.0231	0.35	0.24	Obesity-related traits;	chr8:8705155	chr8:8236003~8244667:-
COAD	cis	rs2638953	0.925	rs11049597	ENSG00000247934.4	RP11-967K21.1	-3.94	0.000103	0.0231	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28433584	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049599	ENSG00000247934.4	RP11-967K21.1	-3.94	0.000103	0.0231	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28437218	chr12:28163298~28190738:-
COAD	cis	rs113835537	0.529	rs17147644	ENSG00000258297.1	RP11-658F2.8	-3.94	0.000103	0.0231	-0.24	-0.24	Airway imaging phenotypes;	chr11:66489189	chr11:66666036~66668374:+
COAD	cis	rs8020095	0.571	rs723432	ENSG00000196553.12	LINC00238	-3.94	0.000103	0.0231	-0.33	-0.24	Depression (quantitative trait);	chr14:66912298	chr14:66486354~66498553:+
COAD	cis	rs911555	0.547	rs8006994	ENSG00000251533.2	LINC00605	-3.94	0.000103	0.0231	-0.31	-0.24	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103187221~103189028:-
COAD	cis	rs911263	0.603	rs12881502	ENSG00000259502.1	RP11-643G16.3	-3.94	0.000103	0.0231	-0.29	-0.24	Primary biliary cholangitis;	chr14:68317074	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.838	rs11621638	ENSG00000259502.1	RP11-643G16.3	3.94	0.000103	0.0231	0.4	0.24	Platelet count;Mean platelet volume;	chr14:68033710	chr14:67610986~67613864:+
COAD	cis	rs8022206	1	rs72725173	ENSG00000259502.1	RP11-643G16.3	3.94	0.000103	0.0231	0.4	0.24	Platelet count;Mean platelet volume;	chr14:68042872	chr14:67610986~67613864:+
COAD	cis	rs189798	0.807	rs9949	ENSG00000173295.6	FAM86B3P	3.94	0.000104	0.0231	0.34	0.24	Myopia (pathological);	chr8:9137002	chr8:8228595~8244865:+
COAD	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-3.94	0.000104	0.0231	-0.28	-0.24	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
COAD	cis	rs9880211	1	rs9880211	ENSG00000273486.1	RP11-731C17.2	3.94	0.000104	0.0231	0.28	0.24	Height;Body mass index;	chr3:136388707	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs9841529	ENSG00000273486.1	RP11-731C17.2	3.94	0.000104	0.0231	0.28	0.24	Height;Body mass index;	chr3:136418441	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs28718456	ENSG00000273486.1	RP11-731C17.2	3.94	0.000104	0.0231	0.28	0.24	Height;Body mass index;	chr3:136485164	chr3:136837338~136839021:-
COAD	cis	rs11229555	0.645	rs12802960	ENSG00000254602.1	AP000662.4	-3.94	0.000104	0.0231	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58407302	chr11:57638024~57652790:+
COAD	cis	rs6504622	0.755	rs34774205	ENSG00000263142.4	LRRC37A17P	-3.94	0.000104	0.0231	-0.17	-0.24	Orofacial clefts;	chr17:47083453	chr17:46978481~47054569:+
COAD	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	3.94	0.000104	0.0231	0.3	0.24	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
COAD	cis	rs10043775	1	rs10477376	ENSG00000251330.3	CTD-2283N19.1	3.94	0.000104	0.0231	0.29	0.24	Periodontal microbiota;	chr5:148405651	chr5:148430159~148430807:-
COAD	cis	rs60668206	0.766	rs4717897	ENSG00000223705.8	NSUN5P1	-3.94	0.000104	0.0231	-0.17	-0.24	Neuroticism;	chr7:74497455	chr7:75410322~75416787:+
COAD	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0231	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
COAD	cis	rs9517302	0.615	rs3752974	ENSG00000231194.1	FARP1-AS1	3.94	0.000104	0.0231	0.32	0.24	Obesity-related traits;	chr13:98445573	chr13:98435405~98435840:-
COAD	cis	rs875971	1	rs55962648	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000104	0.0232	-0.2	-0.24	Aortic root size;	chr7:66160764	chr7:66409143~66490059:-
COAD	cis	rs10857712	0.687	rs11101742	ENSG00000214279.11	SCART1	-3.94	0.000104	0.0232	-0.26	-0.24	Systemic lupus erythematosus;	chr10:133410868	chr10:133453928~133523558:+
COAD	cis	rs2342406	0.766	rs1992825	ENSG00000259439.2	RP11-89K21.1	3.94	0.000104	0.0232	0.39	0.24	Myopia;	chr2:44923139	chr2:44921077~44939199:-
COAD	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-3.94	0.000104	0.0232	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
COAD	cis	rs9393777	0.841	rs13207082	ENSG00000224843.5	LINC00240	3.94	0.000104	0.0232	0.64	0.24	Intelligence (multi-trait analysis);	chr6:27283600	chr6:26956992~27023924:+
COAD	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	3.94	0.000104	0.0232	0.28	0.24	Height;	chr4:55482317	chr4:55547112~55547889:+
COAD	cis	rs875971	0.825	rs6951503	ENSG00000224316.1	RP11-479O9.2	-3.94	0.000104	0.0232	-0.26	-0.24	Aortic root size;	chr7:66253949	chr7:65773620~65802067:+
COAD	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-3.94	0.000104	0.0232	-0.35	-0.24	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
COAD	cis	rs17772222	0.917	rs61984708	ENSG00000258789.1	RP11-507K2.3	-3.94	0.000104	0.0232	-0.34	-0.24	Coronary artery calcification;	chr14:88565523	chr14:88551597~88552493:+
COAD	cis	rs2732480	0.5	rs12829841	ENSG00000240399.1	RP1-228P16.1	3.94	0.000104	0.0232	0.25	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48054813~48055591:-
COAD	cis	rs2732480	0.523	rs34286639	ENSG00000240399.1	RP1-228P16.1	3.94	0.000104	0.0232	0.25	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48054813~48055591:-
COAD	cis	rs1387259	0.929	rs11168484	ENSG00000240399.1	RP1-228P16.1	3.94	0.000104	0.0232	0.25	0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48054813~48055591:-
COAD	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	3.94	0.000104	0.0232	0.22	0.24	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
COAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	3.94	0.000104	0.0232	0.29	0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
COAD	cis	rs896854	0.608	rs6991067	ENSG00000253528.2	RP11-347C18.4	3.94	0.000104	0.0232	0.25	0.24	Type 2 diabetes;	chr8:94863448	chr8:94974573~94974853:-
COAD	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-3.94	0.000104	0.0232	-0.22	-0.24	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
COAD	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	3.94	0.000104	0.0232	0.32	0.24	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
COAD	cis	rs875971	1	rs9986696	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000104	0.0232	-0.2	-0.24	Aortic root size;	chr7:66239589	chr7:66409143~66490059:-
COAD	cis	rs7615952	0.932	rs7629977	ENSG00000241278.1	ENPP7P4	3.94	0.000104	0.0232	0.26	0.24	Blood pressure (smoking interaction);	chr3:125930730	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.932	rs7630077	ENSG00000241278.1	ENPP7P4	3.94	0.000104	0.0232	0.26	0.24	Blood pressure (smoking interaction);	chr3:125930833	chr3:125848223~125909372:+
COAD	cis	rs12531458	0.967	rs11773650	ENSG00000211697.3	TRGV5	3.94	0.000104	0.0232	0.24	0.24	Educational attainment (years of education);	chr7:39072266	chr7:38343894~38350022:-
COAD	cis	rs2898681	0.614	rs10016904	ENSG00000248375.1	RP11-177B4.1	-3.94	0.000104	0.0232	-0.35	-0.24	Optic nerve measurement (cup area);	chr4:52828129	chr4:52720081~52720831:-
COAD	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	3.94	0.000104	0.0232	0.3	0.24	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	3.94	0.000104	0.0232	0.3	0.24	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
COAD	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	3.94	0.000104	0.0232	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
COAD	cis	rs2307394	0.964	rs13000597	ENSG00000281469.1	RP11-567F11.1	3.94	0.000104	0.0232	0.29	0.24	Urate levels;	chr2:147868571	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs929939	ENSG00000281469.1	RP11-567F11.1	3.94	0.000104	0.0232	0.29	0.24	Urate levels;	chr2:147869959	chr2:148044380~148044894:+
COAD	cis	rs17711722	0.565	rs4717276	ENSG00000272831.1	RP11-792A8.4	3.94	0.000104	0.0232	0.25	0.24	Calcium levels;	chr7:65829754	chr7:66739829~66740385:-
COAD	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-3.94	0.000104	0.0232	-0.29	-0.24	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
COAD	cis	rs17007554	0.917	rs56111282	ENSG00000230730.1	AC074011.2	-3.94	0.000104	0.0232	-0.34	-0.24	Lung cancer in never smokers;	chr2:29068436	chr2:28633282~28664540:-
COAD	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	3.94	0.000104	0.0232	0.24	0.24	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
COAD	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	3.94	0.000104	0.0232	0.28	0.24	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
COAD	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	3.94	0.000104	0.0232	0.41	0.24	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
COAD	cis	rs1790761	0.667	rs4147581	ENSG00000255318.1	RP11-655M14.13	3.94	0.000104	0.0232	0.3	0.24	Mean corpuscular volume;	chr11:67584114	chr11:67618279~67627304:-
COAD	cis	rs6122940	0.73	rs13039311	ENSG00000277449.1	CEBPB-AS1	3.94	0.000104	0.0232	0.33	0.24	Lymphocyte counts;	chr20:50460373	chr20:50184598~50191498:-
COAD	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	3.94	0.000104	0.0233	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
COAD	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	3.94	0.000104	0.0233	0.34	0.24	Pain;	chr19:21430854	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	3.94	0.000104	0.0233	0.34	0.24	Pain;	chr19:21430984	chr19:21554640~21569237:-
COAD	cis	rs13256369	0.802	rs11995449	ENSG00000253981.4	ALG1L13P	3.94	0.000104	0.0233	0.35	0.24	Obesity-related traits;	chr8:8702388	chr8:8236003~8244667:-
COAD	cis	rs875971	0.8	rs427557	ENSG00000224316.1	RP11-479O9.2	3.94	0.000104	0.0233	0.25	0.24	Aortic root size;	chr7:66054263	chr7:65773620~65802067:+
COAD	cis	rs728616	0.614	rs17678737	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000104	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs17616958	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000104	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs17616964	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000104	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79663088~79826594:-
COAD	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-3.94	0.000104	0.0233	-0.29	-0.24	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-3.94	0.000104	0.0233	-0.29	-0.24	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-3.94	0.000104	0.0233	-0.29	-0.24	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-3.94	0.000104	0.0233	-0.29	-0.24	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
COAD	cis	rs12699921	0.632	rs2691555	ENSG00000279048.1	RP11-511H23.2	-3.94	0.000104	0.0233	-0.17	-0.24	Fibrinogen levels;	chr7:17898660	chr7:17940503~17942922:+
COAD	cis	rs6585424	1	rs3851055	ENSG00000234382.2	RP11-40F6.1	-3.94	0.000104	0.0233	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:80233664~80245367:+
COAD	cis	rs2562456	0.793	rs2562428	ENSG00000268081.1	RP11-678G14.2	-3.94	0.000104	0.0233	-0.34	-0.24	Pain;	chr19:21442652	chr19:21554640~21569237:-
COAD	cis	rs453301	0.686	rs1045527	ENSG00000254340.1	RP11-10A14.3	-3.94	0.000104	0.0233	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9032531	chr8:9141424~9145435:+
COAD	cis	rs728616	0.558	rs61859215	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs12772945	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs12414691	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs12767261	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs2343302	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79663088~79826594:-
COAD	cis	rs728616	0.558	rs2880599	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0233	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79663088~79826594:-
COAD	cis	rs8022206	0.898	rs11158718	ENSG00000259502.1	RP11-643G16.3	3.94	0.000105	0.0233	0.38	0.24	Platelet count;Mean platelet volume;	chr14:68081714	chr14:67610986~67613864:+
COAD	cis	rs9880211	0.948	rs13326151	ENSG00000273486.1	RP11-731C17.2	3.94	0.000105	0.0233	0.29	0.24	Height;Body mass index;	chr3:136542902	chr3:136837338~136839021:-
COAD	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-3.94	0.000105	0.0233	-0.29	-0.24	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
COAD	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	3.94	0.000105	0.0233	0.19	0.24	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
COAD	cis	rs9307551	0.948	rs10022663	ENSG00000250334.4	LINC00989	-3.94	0.000105	0.0233	-0.3	-0.24	Refractive error;	chr4:79568460	chr4:79492416~79576460:+
COAD	cis	rs7324557	0.717	rs9553071	ENSG00000205861.10	C1QTNF9B-AS1	-3.94	0.000105	0.0233	-0.33	-0.24	Visceral adipose tissue adjusted for BMI;	chr13:23807240	chr13:23888889~23897263:+
COAD	cis	rs4578769	0.55	rs9949333	ENSG00000266850.1	RP11-370A5.1	3.94	0.000105	0.0233	0.27	0.24	Eosinophil percentage of white cells;	chr18:22815080	chr18:22723491~22907721:-
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000274576.2	IGHV2-70	-3.94	0.000105	0.0233	-0.17	-0.24	Kawasaki disease;	chr14:106786292	chr14:106770577~106771020:-
COAD	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	3.94	0.000105	0.0233	0.38	0.24	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
COAD	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-3.94	0.000105	0.0233	-0.25	-0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
COAD	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-3.94	0.000105	0.0233	-0.28	-0.24	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
COAD	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	3.94	0.000105	0.0233	0.36	0.24	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
COAD	cis	rs10863681	0.764	rs1339875	ENSG00000232679.1	RP11-400N13.3	3.94	0.000105	0.0233	0.25	0.24	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222066980	chr1:222041705~222064763:-
COAD	cis	rs10863681	0.764	rs1856620	ENSG00000232679.1	RP11-400N13.3	3.94	0.000105	0.0233	0.25	0.24	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222067037	chr1:222041705~222064763:-
COAD	cis	rs34779708	0.966	rs17591163	ENSG00000271335.4	RP11-324I22.4	3.94	0.000105	0.0233	0.27	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35314552~35336401:-
COAD	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	3.94	0.000105	0.0234	0.38	0.24	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	3.94	0.000105	0.0234	0.38	0.24	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
COAD	cis	rs1928295	0.786	rs28693508	ENSG00000233569.1	RP11-500B12.1	3.94	0.000105	0.0234	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117599140	chr9:117648606~117657027:+
COAD	cis	rs1928295	0.786	rs10759926	ENSG00000233569.1	RP11-500B12.1	3.94	0.000105	0.0234	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117603947	chr9:117648606~117657027:+
COAD	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000105	0.0234	-0.26	-0.24	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000105	0.0234	-0.27	-0.24	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000105	0.0234	-0.27	-0.24	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
COAD	cis	rs10515750	0.588	rs11739823	ENSG00000248544.2	CTB-47B11.3	3.94	0.000105	0.0234	0.31	0.24	Lung function (FEV1/FVC);	chr5:157342000	chr5:157375741~157384950:-
COAD	cis	rs28374715	0.578	rs10518717	ENSG00000247556.5	OIP5-AS1	3.94	0.000105	0.0234	0.34	0.24	Ulcerative colitis;	chr15:41331170	chr15:41283990~41309737:+
COAD	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	3.94	0.000105	0.0234	0.28	0.24	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
COAD	cis	rs11138902	0.627	rs11139236	ENSG00000229312.2	RP11-470P21.2	3.94	0.000105	0.0234	0.27	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69542092	chr9:69472466~69494513:+
COAD	cis	rs11138902	0.673	rs11139245	ENSG00000229312.2	RP11-470P21.2	3.94	0.000105	0.0234	0.27	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69542966	chr9:69472466~69494513:+
COAD	cis	rs11138902	0.673	rs11139246	ENSG00000229312.2	RP11-470P21.2	3.94	0.000105	0.0234	0.27	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69543081	chr9:69472466~69494513:+
COAD	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-3.94	0.000105	0.0234	-0.29	-0.24	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
COAD	cis	rs763121	0.853	rs2413546	ENSG00000273076.1	RP3-508I15.22	3.94	0.000105	0.0234	0.21	0.24	Menopause (age at onset);	chr22:38710996	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2413547	ENSG00000273076.1	RP3-508I15.22	3.94	0.000105	0.0234	0.21	0.24	Menopause (age at onset);	chr22:38711333	chr22:38743495~38743910:+
COAD	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	3.94	0.000105	0.0234	0.28	0.24	Height;	chr4:55415153	chr4:55363971~55395847:-
COAD	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	3.94	0.000105	0.0234	0.36	0.24	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
COAD	cis	rs7577696	0.962	rs11691879	ENSG00000272716.1	RP11-563N4.1	-3.94	0.000105	0.0234	-0.25	-0.24	Inflammatory biomarkers;	chr2:32049148	chr2:32165046~32165757:-
COAD	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	3.94	0.000105	0.0234	0.28	0.24	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
COAD	cis	rs9858542	0.537	rs9874474	ENSG00000225399.4	RP11-3B7.1	-3.94	0.000105	0.0234	-0.35	-0.24	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49288745	chr3:49260085~49261316:+
COAD	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-3.94	0.000105	0.0234	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
COAD	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-3.94	0.000105	0.0234	-0.31	-0.24	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
COAD	cis	rs801193	0.66	rs974239	ENSG00000179406.6	LINC00174	3.94	0.000105	0.0234	0.18	0.24	Aortic root size;	chr7:66748504	chr7:66376044~66401338:-
COAD	cis	rs801193	0.66	rs1016265	ENSG00000179406.6	LINC00174	3.94	0.000105	0.0234	0.18	0.24	Aortic root size;	chr7:66749580	chr7:66376044~66401338:-
COAD	cis	rs728616	0.614	rs61859196	ENSG00000225484.5	NUTM2B-AS1	-3.94	0.000105	0.0234	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79663088~79826594:-
COAD	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	3.94	0.000105	0.0234	0.26	0.24	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	3.94	0.000105	0.0234	0.26	0.24	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
COAD	cis	rs9450351	0.744	rs9344570	ENSG00000203875.9	SNHG5	-3.94	0.000105	0.0234	-0.46	-0.24	Interferon gamma-induced protein 10 levels;	chr6:86084062	chr6:85660950~85678736:-
COAD	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	3.94	0.000105	0.0234	0.28	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
COAD	cis	rs891378	1	rs877049	ENSG00000274245.1	RP11-357P18.2	-3.94	0.000106	0.0234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207249651	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs1835307	ENSG00000274245.1	RP11-357P18.2	-3.94	0.000106	0.0234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207253220	chr1:207372559~207373252:+
COAD	cis	rs891378	0.848	rs1579484	ENSG00000274245.1	RP11-357P18.2	-3.94	0.000106	0.0234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207262484	chr1:207372559~207373252:+
COAD	cis	rs891378	0.959	rs11120586	ENSG00000274245.1	RP11-357P18.2	-3.94	0.000106	0.0234	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207268152	chr1:207372559~207373252:+
COAD	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	3.94	0.000106	0.0234	0.26	0.24	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
COAD	cis	rs3733585	0.699	rs7686538	ENSG00000250413.1	RP11-448G15.1	3.94	0.000106	0.0235	0.31	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9946453	chr4:10006482~10009725:+
COAD	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-3.94	0.000106	0.0235	-0.48	-0.24	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
COAD	cis	rs13256369	0.802	rs11249884	ENSG00000254153.1	CTA-398F10.2	-3.94	0.000106	0.0235	-0.31	-0.24	Obesity-related traits;	chr8:8704042	chr8:8456909~8461337:-
COAD	cis	rs7674212	0.865	rs13149311	ENSG00000230069.3	LRRC37A15P	-3.94	0.000106	0.0235	-0.26	-0.24	Type 2 diabetes;	chr4:103056543	chr4:102727274~102730721:-
COAD	cis	rs801193	0.742	rs9969300	ENSG00000273142.1	RP11-458F8.4	3.94	0.000106	0.0235	0.17	0.24	Aortic root size;	chr7:66316659	chr7:66902857~66906297:+
COAD	cis	rs1949733	0.701	rs940136	ENSG00000205959.3	RP11-689P11.2	-3.94	0.000106	0.0235	-0.29	-0.24	Response to antineoplastic agents;	chr4:8447265	chr4:8482270~8512610:+
COAD	cis	rs7795541	0.739	rs10280205	ENSG00000232553.3	AC006026.10	-3.94	0.000106	0.0235	-0.27	-0.24	Morning vs. evening chronotype;	chr7:24042444	chr7:23585062~23586355:-
COAD	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-3.94	0.000106	0.0235	-0.27	-0.24	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-3.94	0.000106	0.0235	-0.27	-0.24	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
COAD	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-3.94	0.000106	0.0235	-0.29	-0.24	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
COAD	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-3.94	0.000106	0.0235	-0.29	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
COAD	cis	rs4879901	0.933	rs1322126	ENSG00000215199.3	YWHAZP6	-3.94	0.000106	0.0235	-0.26	-0.24	Schizophrenia;	chr9:35538629	chr9:34922184~34922921:-
COAD	cis	rs116139393	0.611	rs7792579	ENSG00000187953.9	PMS2CL	-3.94	0.000106	0.0235	-0.27	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6725962	chr7:6710128~6753862:+
COAD	cis	rs1928295	0.786	rs10983720	ENSG00000233569.1	RP11-500B12.1	3.94	0.000106	0.0235	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625209	chr9:117648606~117657027:+
COAD	cis	rs875971	0.965	rs10267430	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000106	0.0235	-0.2	-0.24	Aortic root size;	chr7:66278036	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs10257427	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000106	0.0235	-0.2	-0.24	Aortic root size;	chr7:66278221	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs10215948	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000106	0.0235	-0.2	-0.24	Aortic root size;	chr7:66282799	chr7:66409143~66490059:-
COAD	cis	rs9840812	0.953	rs4678322	ENSG00000239213.4	NCK1-AS1	-3.94	0.000106	0.0235	-0.33	-0.24	Fibrinogen levels;	chr3:136093681	chr3:136841726~136862054:-
COAD	cis	rs2408955	0.542	rs7975632	ENSG00000226413.2	OR8T1P	3.94	0.000106	0.0235	0.29	0.24	Glycated hemoglobin levels;	chr12:48049265	chr12:48442030~48442947:-
COAD	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	3.94	0.000106	0.0235	0.32	0.24	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
COAD	cis	rs2243480	1	rs316321	ENSG00000232559.3	GS1-124K5.12	3.94	0.000106	0.0235	0.43	0.24	Diabetic kidney disease;	chr7:66146626	chr7:66554588~66576923:-
COAD	cis	rs12699921	0.632	rs2723508	ENSG00000279048.1	RP11-511H23.2	-3.94	0.000106	0.0235	-0.17	-0.24	Fibrinogen levels;	chr7:17778440	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2691596	ENSG00000279048.1	RP11-511H23.2	-3.94	0.000106	0.0235	-0.17	-0.24	Fibrinogen levels;	chr7:17780460	chr7:17940503~17942922:+
COAD	cis	rs2337406	1	rs11850709	ENSG00000211974.3	IGHV2-70	-3.94	0.000106	0.0235	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106670844	chr14:106723574~106724093:-
COAD	cis	rs7430456	0.837	rs7651130	ENSG00000228221.4	LINC00578	3.94	0.000106	0.0235	0.2	0.24	Breast cancer;	chr3:177719720	chr3:177441921~177752305:+
COAD	cis	rs875971	0.838	rs2173570	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000106	0.0235	-0.2	-0.24	Aortic root size;	chr7:66297976	chr7:66409143~66490059:-
COAD	cis	rs1987511	1	rs7900903	ENSG00000224034.1	RP11-445P17.8	-3.94	0.000106	0.0235	-0.3	-0.24	Intelligence;	chr10:5313497	chr10:5266033~5271236:-
COAD	cis	rs2832191	0.716	rs1543652	ENSG00000176054.6	RPL23P2	3.94	0.000106	0.0235	0.24	0.24	Dental caries;	chr21:29075679	chr21:28997613~28998033:-
COAD	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	3.94	0.000106	0.0235	0.24	0.24	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
COAD	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	3.94	0.000106	0.0235	0.25	0.24	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
COAD	cis	rs293748	0.771	rs12659960	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000106	0.0235	-0.34	-0.24	Obesity-related traits;	chr5:36787913	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs12659981	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000106	0.0235	-0.34	-0.24	Obesity-related traits;	chr5:36787996	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs12659983	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000106	0.0235	-0.34	-0.24	Obesity-related traits;	chr5:36788002	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs35263618	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000106	0.0235	-0.34	-0.24	Obesity-related traits;	chr5:36795112	chr5:36666214~36725195:-
COAD	cis	rs453301	0.571	rs2929305	ENSG00000254340.1	RP11-10A14.3	-3.94	0.000106	0.0235	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9227707	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	3.94	0.000106	0.0235	0.31	0.24	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	3.94	0.000106	0.0235	0.31	0.24	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	3.94	0.000106	0.0235	0.31	0.24	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
COAD	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	3.94	0.000106	0.0235	0.15	0.24	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
COAD	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	3.94	0.000106	0.0235	0.15	0.24	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
COAD	cis	rs7577696	0.962	rs7600173	ENSG00000272716.1	RP11-563N4.1	-3.94	0.000106	0.0235	-0.25	-0.24	Inflammatory biomarkers;	chr2:32043341	chr2:32165046~32165757:-
COAD	cis	rs2337406	0.789	rs9324095	ENSG00000211967.3	IGHV3-53	-3.94	0.000106	0.0235	-0.17	-0.24	Alzheimer's disease (late onset);	chr14:106795885	chr14:106592676~106593347:-
COAD	cis	rs2337406	0.866	rs58154560	ENSG00000211967.3	IGHV3-53	-3.94	0.000106	0.0235	-0.17	-0.24	Alzheimer's disease (late onset);	chr14:106799601	chr14:106592676~106593347:-
COAD	cis	rs253959	0.532	rs10045890	ENSG00000271918.1	CTD-2287O16.5	3.94	0.000106	0.0236	0.23	0.24	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116083807~116085416:-
COAD	cis	rs4239252	0.929	rs4796116	ENSG00000270977.1	AC015849.16	-3.94	0.000106	0.0236	-0.3	-0.24	Blood protein levels;	chr17:35841496	chr17:35893707~35911023:-
COAD	cis	rs4239252	0.929	rs4251791	ENSG00000270977.1	AC015849.16	-3.94	0.000106	0.0236	-0.3	-0.24	Blood protein levels;	chr17:35845711	chr17:35893707~35911023:-
COAD	cis	rs643506	0.874	rs687152	ENSG00000230911.1	PPIHP1	-3.94	0.000106	0.0236	-0.3	-0.24	Breast cancer;	chr11:111850950	chr11:112029858~112030367:-
COAD	cis	rs643506	0.874	rs4936786	ENSG00000230911.1	PPIHP1	-3.94	0.000106	0.0236	-0.3	-0.24	Breast cancer;	chr11:111856504	chr11:112029858~112030367:-
COAD	cis	rs172166	0.637	rs1233691	ENSG00000280107.1	AL022393.9	-3.94	0.000106	0.0236	-0.3	-0.24	Cardiac Troponin-T levels;	chr6:28186119	chr6:28170845~28172521:+
COAD	cis	rs2018683	0.899	rs10269454	ENSG00000272568.4	CTB-113D17.1	3.94	0.000106	0.0236	0.33	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28979967~29013367:+
COAD	cis	rs12699921	0.598	rs1404421	ENSG00000279048.1	RP11-511H23.2	-3.94	0.000106	0.0236	-0.17	-0.24	Fibrinogen levels;	chr7:17777807	chr7:17940503~17942922:+
COAD	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-3.94	0.000106	0.0236	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
COAD	cis	rs2337406	0.587	rs2516889	ENSG00000211964.3	IGHV3-48	3.94	0.000106	0.0236	0.2	0.24	Alzheimer's disease (late onset);	chr14:106648903	chr14:106537810~106538344:-
COAD	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-3.94	0.000106	0.0236	-0.3	-0.24	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
COAD	cis	rs6687821	0.515	rs496588	ENSG00000261737.1	RP4-612B15.3	-3.94	0.000106	0.0236	-0.32	-0.24	Yeast infection;	chr1:86858728	chr1:86703502~86704462:-
COAD	cis	rs2836974	0.568	rs377098	ENSG00000255568.3	BRWD1-AS2	-3.94	0.000106	0.0236	-0.22	-0.24	Cognitive function;	chr21:39163290	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.568	rs371625	ENSG00000255568.3	BRWD1-AS2	-3.94	0.000106	0.0236	-0.22	-0.24	Cognitive function;	chr21:39163345	chr21:39313935~39314962:+
COAD	cis	rs7572733	0.773	rs7601762	ENSG00000222017.1	AC011997.1	3.94	0.000106	0.0236	0.26	0.24	Dermatomyositis;	chr2:197664513	chr2:197693106~197774823:+
COAD	cis	rs495337	1	rs4810998	ENSG00000229222.1	KRT18P4	-3.94	0.000106	0.0236	-0.25	-0.24	Psoriasis;	chr20:49963473	chr20:49956745~49958032:+
COAD	cis	rs7615952	0.932	rs13314869	ENSG00000241278.1	ENPP7P4	3.94	0.000106	0.0236	0.27	0.24	Blood pressure (smoking interaction);	chr3:125925826	chr3:125848223~125909372:+
COAD	cis	rs7646881	0.544	rs7638518	ENSG00000272087.1	RP11-379F4.7	-3.94	0.000106	0.0236	-0.37	-0.24	Tetralogy of Fallot;	chr3:158568953	chr3:158693120~158693768:-
COAD	cis	rs6452524	1	rs10474093	ENSG00000271862.1	RP11-343L5.2	3.94	0.000106	0.0236	0.24	0.24	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs10473868	ENSG00000271862.1	RP11-343L5.2	3.94	0.000106	0.0236	0.24	0.24	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83049376~83050964:-
COAD	cis	rs9532669	0.926	rs9525418	ENSG00000277662.1	RP11-74J13.9	3.94	0.000106	0.0236	0.22	0.24	Cervical cancer;	chr13:40879081	chr13:41229180~41229676:-
COAD	cis	rs3126085	0.56	rs6587668	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152361482	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs6693160	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152368845	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs11204986	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152369583	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs12403031	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152370918	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs45541239	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152373915	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.56	rs12031363	ENSG00000237975.5	FLG-AS1	3.94	0.000106	0.0236	0.32	0.24	Atopic dermatitis;	chr1:152378169	chr1:152168125~152445456:+
COAD	cis	rs1023500	0.573	rs1807494	ENSG00000232710.1	RP4-669P10.16	3.94	0.000106	0.0236	0.24	0.24	Schizophrenia;	chr22:42078134	chr22:42136433~42139927:-
COAD	cis	rs1023500	0.573	rs8135801	ENSG00000232710.1	RP4-669P10.16	3.94	0.000106	0.0236	0.24	0.24	Schizophrenia;	chr22:42079564	chr22:42136433~42139927:-
COAD	cis	rs7212590	0.529	rs60283440	ENSG00000264049.1	MIR4737	-3.94	0.000106	0.0236	-0.36	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59916887	chr17:60043025~60043105:-
COAD	cis	rs7204230	1	rs2041790	ENSG00000261056.2	RP11-454F8.2	3.94	0.000106	0.0236	0.29	0.24	Fibrinogen;	chr16:53285021	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs2041791	ENSG00000261056.2	RP11-454F8.2	3.94	0.000106	0.0236	0.29	0.24	Fibrinogen;	chr16:53285040	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs8057932	ENSG00000261056.2	RP11-454F8.2	3.94	0.000106	0.0236	0.29	0.24	Fibrinogen;	chr16:53285933	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs8056394	ENSG00000261056.2	RP11-454F8.2	3.94	0.000106	0.0236	0.29	0.24	Fibrinogen;	chr16:53286113	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs11864306	ENSG00000261056.2	RP11-454F8.2	3.94	0.000106	0.0236	0.29	0.24	Fibrinogen;	chr16:53287237	chr16:53298224~53299792:+
COAD	cis	rs2554380	0.628	rs2401130	ENSG00000176700.18	SCAND2P	-3.94	0.000106	0.0236	-0.22	-0.24	Height;	chr15:83801983	chr15:84631451~84647478:+
COAD	cis	rs8177876	0.731	rs79546329	ENSG00000261061.1	RP11-303E16.2	-3.94	0.000107	0.0236	-0.47	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103636	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs12448806	ENSG00000261061.1	RP11-303E16.2	-3.94	0.000107	0.0236	-0.47	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104597	chr16:81030770~81031485:+
COAD	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	3.94	0.000107	0.0236	0.32	0.24	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
COAD	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-3.94	0.000107	0.0236	-0.26	-0.24	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
COAD	cis	rs1928295	0.786	rs10983712	ENSG00000233569.1	RP11-500B12.1	3.94	0.000107	0.0236	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117606458	chr9:117648606~117657027:+
COAD	cis	rs1928295	0.786	rs7038943	ENSG00000233569.1	RP11-500B12.1	3.94	0.000107	0.0236	0.29	0.24	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117614900	chr9:117648606~117657027:+
COAD	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	3.94	0.000107	0.0236	0.27	0.24	Height;	chr4:55542243	chr4:55363971~55395847:-
COAD	cis	rs2929278	0.589	rs7174732	ENSG00000275601.1	AC011330.13	3.94	0.000107	0.0236	0.29	0.24	Schizophrenia;	chr15:43746265	chr15:43642389~43643023:-
COAD	cis	rs17359493	0.731	rs16917102	ENSG00000253528.2	RP11-347C18.4	3.94	0.000107	0.0236	0.3	0.24	Type 2 diabetes;	chr8:94866807	chr8:94974573~94974853:-
COAD	cis	rs58873874	0.579	rs56666304	ENSG00000251405.2	CTB-109A12.1	3.94	0.000107	0.0237	0.44	0.24	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157362615~157460078:-
COAD	cis	rs10876993	0.893	rs1678504	ENSG00000270039.1	RP11-571M6.17	3.94	0.000107	0.0237	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57691715	chr12:57803838~57804415:+
COAD	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	3.94	0.000107	0.0237	0.26	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
COAD	cis	rs7584330	0.744	rs10929234	ENSG00000234949.2	AC104667.3	3.94	0.000107	0.0237	0.32	0.24	Prostate cancer;	chr2:237471391	chr2:237591020~237595981:+
COAD	cis	rs2977125	0.552	rs2977112	ENSG00000251468.2	RP11-369K16.1	3.94	0.000107	0.0237	0.39	0.24	Schizophrenia;	chr8:12905835	chr8:12958387~12962200:+
COAD	cis	rs9450351	0.744	rs6902904	ENSG00000234155.1	RP11-30P6.6	-3.94	0.000107	0.0237	-0.51	-0.24	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85387219~85390186:-
COAD	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-3.94	0.000107	0.0237	-0.28	-0.24	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
COAD	cis	rs8177876	0.642	rs12445303	ENSG00000261061.1	RP11-303E16.2	3.94	0.000107	0.0237	0.35	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81030770~81031485:+
COAD	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-3.94	0.000107	0.0237	-0.3	-0.24	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
COAD	cis	rs56052703	0.536	rs7257429	ENSG00000267633.1	CTB-5E10.3	3.94	0.000107	0.0237	0.27	0.24	Proteinuria and chronic kidney disease;	chr19:13314689	chr19:13772118~13774118:-
COAD	cis	rs12699921	0.632	rs2691616	ENSG00000279048.1	RP11-511H23.2	-3.94	0.000107	0.0237	-0.17	-0.24	Fibrinogen levels;	chr7:17782557	chr7:17940503~17942922:+
COAD	cis	rs55665837	0.539	rs10832310	ENSG00000251991.1	RNU7-49P	3.94	0.000107	0.0237	0.3	0.24	Vitamin D levels;	chr11:14856896	chr11:14478892~14478953:+
COAD	cis	rs55665837	0.539	rs10832311	ENSG00000251991.1	RNU7-49P	3.94	0.000107	0.0237	0.3	0.24	Vitamin D levels;	chr11:14860380	chr11:14478892~14478953:+
COAD	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	3.94	0.000107	0.0237	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
COAD	cis	rs4763879	0.778	rs7977940	ENSG00000278635.1	CTD-2318O12.1	3.94	0.000107	0.0237	0.23	0.24	Type 1 diabetes;	chr12:9686320	chr12:9415641~9416718:+
COAD	cis	rs7752903	0.793	rs5029939	ENSG00000237499.5	RP11-356I2.4	3.94	0.000107	0.0237	0.39	0.24	Rheumatoid arthritis;	chr6:137874586	chr6:137823673~137868233:-
COAD	cis	rs9903692	0.505	rs208008	ENSG00000278765.1	RP5-890E16.5	-3.93	0.000107	0.0238	-0.44	-0.24	Pulse pressure;	chr17:48153476	chr17:48066704~48067293:-
COAD	cis	rs728616	0.867	rs61860400	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs117139504	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs12412226	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs4387301	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:80233664~80245367:+
COAD	cis	rs728616	0.764	rs117833443	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs116994688	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860420	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs75447386	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs4520539	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs61860421	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:80233664~80245367:+
COAD	cis	rs12368653	0.693	rs2640610	ENSG00000270039.1	RP11-571M6.17	3.93	0.000107	0.0238	0.25	0.24	Multiple sclerosis;	chr12:57643652	chr12:57803838~57804415:+
COAD	cis	rs2554380	0.628	rs2401131	ENSG00000176700.18	SCAND2P	-3.93	0.000107	0.0238	-0.22	-0.24	Height;	chr15:83802144	chr15:84631451~84647478:+
COAD	cis	rs728616	0.717	rs116884206	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000107	0.0238	-0.48	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:80233664~80245367:+
COAD	cis	rs2916733	0.607	rs2442511	ENSG00000246089.3	RP11-115C21.2	-3.93	0.000107	0.0238	-0.31	-0.24	Epirubicin-induced leukopenia;	chr8:6443325	chr8:6403551~6407142:-
COAD	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-3.93	0.000107	0.0238	-0.23	-0.24	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
COAD	cis	rs7617773	0.962	rs6797587	ENSG00000228638.1	FCF1P2	3.93	0.000107	0.0238	0.29	0.24	Coronary artery disease;	chr3:48156124	chr3:48290793~48291375:-
COAD	cis	rs2191566	0.691	rs8104605	ENSG00000278492.1	RP11-15A1.9	3.93	0.000107	0.0238	0.29	0.24	Acute lymphoblastic leukemia (childhood);	chr19:44084863	chr19:43978376~43978663:+
COAD	cis	rs2307394	0.928	rs12989596	ENSG00000281469.1	RP11-567F11.1	3.93	0.000107	0.0238	0.29	0.24	Urate levels;	chr2:147833663	chr2:148044380~148044894:+
COAD	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	3.93	0.000107	0.0238	0.29	0.24	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
COAD	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-3.93	0.000107	0.0238	-0.3	-0.24	Height;	chr14:74458749	chr14:74471930~74472360:-
COAD	cis	rs2243480	0.708	rs13242216	ENSG00000232559.3	GS1-124K5.12	3.93	0.000107	0.0238	0.43	0.24	Diabetic kidney disease;	chr7:66433290	chr7:66554588~66576923:-
COAD	cis	rs7172689	1	rs28418832	ENSG00000271725.1	RP11-761I4.4	3.93	0.000107	0.0238	0.3	0.24	Inattentive symptoms;	chr15:81259307	chr15:81303215~81309391:-
COAD	cis	rs2255336	0.81	rs7139147	ENSG00000245648.1	RP11-277P12.20	3.93	0.000107	0.0238	0.44	0.24	Blood protein levels;	chr12:10361956	chr12:10363769~10398506:+
COAD	cis	rs1008375	0.618	rs13129002	ENSG00000249502.1	AC006160.5	-3.93	0.000107	0.0238	-0.28	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565890	chr4:17587467~17614571:-
COAD	cis	rs728616	0.867	rs56000427	ENSG00000234382.2	RP11-40F6.1	-3.93	0.000108	0.0238	-0.48	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:80233664~80245367:+
COAD	cis	rs597539	0.615	rs583182	ENSG00000255741.1	RP11-757G1.5	-3.93	0.000108	0.0238	-0.31	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68941503~68942852:-
COAD	cis	rs7577696	0.853	rs430759	ENSG00000272716.1	RP11-563N4.1	-3.93	0.000108	0.0238	-0.25	-0.24	Inflammatory biomarkers;	chr2:32222799	chr2:32165046~32165757:-
COAD	cis	rs875971	0.965	rs7794930	ENSG00000230189.5	GS1-124K5.2	-3.93	0.000108	0.0238	-0.2	-0.24	Aortic root size;	chr7:66313559	chr7:66409143~66490059:-
COAD	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000108	0.0238	-0.26	-0.24	Gout;	chr7:66679692	chr7:66902857~66906297:+
COAD	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	3.93	0.000108	0.0238	0.26	0.24	Gout;	chr7:66682070	chr7:66902857~66906297:+
COAD	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	3.93	0.000108	0.0238	0.26	0.24	Gout;	chr7:66682162	chr7:66902857~66906297:+
COAD	cis	rs11935103	0.636	rs6552977	ENSG00000279943.1	FLJ38576	3.93	0.000108	0.0238	0.34	0.24	Response to citalopram treatment;	chr4:186375505	chr4:186189032~186191490:-
COAD	cis	rs11935103	0.673	rs9997142	ENSG00000279943.1	FLJ38576	3.93	0.000108	0.0238	0.34	0.24	Response to citalopram treatment;	chr4:186375871	chr4:186189032~186191490:-
COAD	cis	rs11935103	0.636	rs9997314	ENSG00000279943.1	FLJ38576	3.93	0.000108	0.0238	0.34	0.24	Response to citalopram treatment;	chr4:186376078	chr4:186189032~186191490:-
COAD	cis	rs10871290	0.65	rs2288054	ENSG00000262904.1	TMPOP2	-3.93	0.000108	0.0238	-0.27	-0.24	Breast cancer;	chr16:74457835	chr16:74667506~74668706:+
COAD	cis	rs11722228	1	rs11722228	ENSG00000250413.1	RP11-448G15.1	-3.93	0.000108	0.0238	-0.33	-0.24	Urate levels;Serum uric acid levels;Gout;	chr4:9914117	chr4:10006482~10009725:+
COAD	cis	rs4072705	0.967	rs4838208	ENSG00000236643.1	RP11-175D17.3	3.93	0.000108	0.0239	0.26	0.24	Menarche (age at onset);	chr9:124765756	chr9:124770123~124772927:+
COAD	cis	rs4072705	0.967	rs4838209	ENSG00000236643.1	RP11-175D17.3	3.93	0.000108	0.0239	0.26	0.24	Menarche (age at onset);	chr9:124766563	chr9:124770123~124772927:+
COAD	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	3.93	0.000108	0.0239	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	3.93	0.000108	0.0239	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
COAD	cis	rs9880211	0.898	rs9866840	ENSG00000273486.1	RP11-731C17.2	3.93	0.000108	0.0239	0.28	0.24	Height;Body mass index;	chr3:136310416	chr3:136837338~136839021:-
COAD	cis	rs9400271	0.527	rs4945829	ENSG00000219700.1	PTCHD3P3	-3.93	0.000108	0.0239	-0.28	-0.24	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109317625	chr6:109288571~109290503:-
COAD	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-3.93	0.000108	0.0239	-0.33	-0.24	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
COAD	cis	rs2832191	0.632	rs1984011	ENSG00000176054.6	RPL23P2	-3.93	0.000108	0.0239	-0.25	-0.24	Dental caries;	chr21:28965509	chr21:28997613~28998033:-
COAD	cis	rs9880211	0.562	rs13068210	ENSG00000239213.4	NCK1-AS1	3.93	0.000108	0.0239	0.31	0.24	Height;Body mass index;	chr3:136186704	chr3:136841726~136862054:-
COAD	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	3.93	0.000108	0.0239	0.29	0.24	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
COAD	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	3.93	0.000108	0.0239	0.31	0.24	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
COAD	cis	rs535066	0.935	rs531460	ENSG00000260878.1	RP11-320H14.1	-3.93	0.000108	0.0239	-0.31	-0.24	Epilepsy;	chr4:46208253	chr4:46243548~46244215:-
COAD	cis	rs535066	0.807	rs507248	ENSG00000260878.1	RP11-320H14.1	-3.93	0.000108	0.0239	-0.31	-0.24	Epilepsy;	chr4:46209358	chr4:46243548~46244215:-
COAD	cis	rs12497850	0.931	rs1134591	ENSG00000225399.4	RP11-3B7.1	3.93	0.000108	0.0239	0.26	0.24	Parkinson's disease;	chr3:48935459	chr3:49260085~49261316:+
COAD	cis	rs2836974	0.931	rs2836968	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39270460	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.931	rs7283569	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39272136	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.931	rs2836972	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39280216	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.965	rs7354783	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39281066	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.931	rs8132285	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39283826	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.965	rs6517538	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.25	0.24	Cognitive function;	chr21:39284316	chr21:39313935~39314962:+
COAD	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	3.93	0.000108	0.0239	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
COAD	cis	rs7577696	0.924	rs11124277	ENSG00000272716.1	RP11-563N4.1	-3.93	0.000108	0.0239	-0.25	-0.24	Inflammatory biomarkers;	chr2:32095301	chr2:32165046~32165757:-
COAD	cis	rs11668609	0.766	rs10414075	ENSG00000268442.1	CTD-2027I19.2	3.93	0.000108	0.0239	0.29	0.24	Response to taxane treatment (docetaxel);	chr19:24055649	chr19:24162370~24163425:-
COAD	cis	rs6822297	0.905	rs4692137	ENSG00000240005.4	RP11-293A21.1	-3.93	0.000108	0.0239	-0.29	-0.24	Obesity-related traits;	chr4:27003613	chr4:26859806~26860599:-
COAD	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	3.93	0.000108	0.0239	0.35	0.24	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
COAD	cis	rs2836974	0.836	rs8129355	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.24	0.24	Cognitive function;	chr21:39207943	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.899	rs34978594	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.24	0.24	Cognitive function;	chr21:39208077	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs6517526	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.24	0.24	Cognitive function;	chr21:39209604	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs6517527	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.0239	0.24	0.24	Cognitive function;	chr21:39209825	chr21:39313935~39314962:+
COAD	cis	rs6687821	0.515	rs10873819	ENSG00000261737.1	RP4-612B15.3	-3.93	0.000108	0.0239	-0.31	-0.24	Yeast infection;	chr1:87069512	chr1:86703502~86704462:-
COAD	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	3.93	0.000108	0.0239	0.23	0.24	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
COAD	cis	rs7204230	1	rs17394680	ENSG00000261056.2	RP11-454F8.2	3.93	0.000108	0.0239	0.29	0.24	Fibrinogen;	chr16:53288281	chr16:53298224~53299792:+
COAD	cis	rs1115240	0.574	rs3794485	ENSG00000257842.4	NOVA1-AS1	-3.93	0.000108	0.0239	-0.3	-0.24	Educational attainment (years of education);	chr14:26590140	chr14:26598412~26806467:+
COAD	cis	rs2832191	0.716	rs7509628	ENSG00000176054.6	RPL23P2	3.93	0.000108	0.024	0.24	0.24	Dental caries;	chr21:29081931	chr21:28997613~28998033:-
COAD	cis	rs2832191	0.716	rs1888440	ENSG00000176054.6	RPL23P2	3.93	0.000108	0.024	0.24	0.24	Dental caries;	chr21:29082163	chr21:28997613~28998033:-
COAD	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-3.93	0.000108	0.024	-0.27	-0.24	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
COAD	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	3.93	0.000108	0.024	0.32	0.24	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
COAD	cis	rs2836974	0.739	rs12482181	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.024	0.25	0.24	Cognitive function;	chr21:39176926	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.899	rs34176878	ENSG00000255568.3	BRWD1-AS2	3.93	0.000108	0.024	0.25	0.24	Cognitive function;	chr21:39176929	chr21:39313935~39314962:+
COAD	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000109	0.024	-0.27	-0.24	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000109	0.024	-0.27	-0.24	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000109	0.024	-0.27	-0.24	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000109	0.024	-0.27	-0.24	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-3.93	0.000109	0.024	-0.27	-0.24	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
COAD	cis	rs7829975	0.682	rs7013471	ENSG00000253981.4	ALG1L13P	-3.93	0.000109	0.024	-0.3	-0.24	Mood instability;	chr8:8829815	chr8:8236003~8244667:-
COAD	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-3.93	0.000109	0.024	-0.28	-0.24	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
COAD	cis	rs7615952	0.736	rs11921945	ENSG00000241278.1	ENPP7P4	3.93	0.000109	0.024	0.27	0.24	Blood pressure (smoking interaction);	chr3:125924876	chr3:125848223~125909372:+
COAD	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	3.93	0.000109	0.024	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	3.93	0.000109	0.024	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	3.93	0.000109	0.024	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	3.93	0.000109	0.024	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	3.93	0.000109	0.024	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
COAD	cis	rs2243480	0.803	rs13224048	ENSG00000232559.3	GS1-124K5.12	3.93	0.000109	0.024	0.42	0.24	Diabetic kidney disease;	chr7:66528779	chr7:66554588~66576923:-
COAD	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	3.93	0.000109	0.024	0.3	0.24	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	3.93	0.000109	0.024	0.3	0.24	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
COAD	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-3.93	0.000109	0.024	-0.31	-0.24	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs427044	ENSG00000232559.3	GS1-124K5.12	3.93	0.000109	0.024	0.42	0.24	Diabetic kidney disease;	chr7:66043558	chr7:66554588~66576923:-
COAD	cis	rs595244	1	rs11636344	ENSG00000259705.1	RP11-227D13.1	-3.93	0.000109	0.024	-0.37	-0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48423040	chr15:48645951~48652016:+
COAD	cis	rs875971	0.895	rs4145009	ENSG00000232559.3	GS1-124K5.12	-3.93	0.000109	0.024	-0.29	-0.24	Aortic root size;	chr7:66261628	chr7:66554588~66576923:-
COAD	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-3.93	0.000109	0.024	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
COAD	cis	rs564309	0.867	rs12094956	ENSG00000280157.1	RP11-520H14.7	-3.93	0.000109	0.024	-0.39	-0.24	Hip circumference (psychosocial stress interaction);	chr1:228382881	chr1:228121523~228123771:+
COAD	cis	rs9942416	0.615	rs34351	ENSG00000271815.1	CTD-2235C13.3	3.93	0.000109	0.024	0.29	0.24	Age-related disease endophenotypes;	chr5:75657036	chr5:75363760~75364242:+
COAD	cis	rs9942416	0.615	rs253411	ENSG00000271815.1	CTD-2235C13.3	3.93	0.000109	0.024	0.29	0.24	Age-related disease endophenotypes;	chr5:75658808	chr5:75363760~75364242:+
COAD	cis	rs12049351	0.613	rs7514990	ENSG00000229367.1	HMGN2P19	3.93	0.000109	0.024	0.32	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229445419	chr1:229570532~229570796:+
COAD	cis	rs1887320	0.875	rs6108789	ENSG00000270777.1	RP11-103J8.2	3.93	0.000109	0.0241	0.25	0.24	Diastolic blood pressure;Systolic blood pressure;	chr20:10994137	chr20:11001304~11001763:+
COAD	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-3.93	0.000109	0.0241	-0.46	-0.24	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
COAD	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	3.93	0.000109	0.0241	0.25	0.24	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
COAD	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-3.93	0.000109	0.0241	-0.28	-0.24	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
COAD	cis	rs911555	0.574	rs34251103	ENSG00000251533.2	LINC00605	3.93	0.000109	0.0241	0.31	0.24	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103187221~103189028:-
COAD	cis	rs911555	0.723	rs6575982	ENSG00000251533.2	LINC00605	3.93	0.000109	0.0241	0.31	0.24	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103187221~103189028:-
COAD	cis	rs9818758	0.607	rs61729488	ENSG00000225399.4	RP11-3B7.1	-3.93	0.000109	0.0241	-0.48	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:49260085~49261316:+
COAD	cis	rs2559856	0.935	rs2695287	ENSG00000199933.1	RNY1P16	3.93	0.000109	0.0241	0.26	0.24	Blood protein levels;	chr12:101694583	chr12:101719808~101719918:+
COAD	cis	rs2559856	1	rs2695286	ENSG00000199933.1	RNY1P16	3.93	0.000109	0.0241	0.26	0.24	Blood protein levels;	chr12:101694729	chr12:101719808~101719918:+
COAD	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-3.93	0.000109	0.0241	-0.28	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
COAD	cis	rs1056107	0.933	rs12554866	ENSG00000225513.1	RP11-165N19.2	3.93	0.000109	0.0241	0.29	0.24	Colorectal cancer;	chr9:112201066	chr9:112173522~112173971:-
COAD	cis	rs17685	0.712	rs7785025	ENSG00000280388.1	RP11-229D13.3	3.93	0.000109	0.0241	0.24	0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76043977~76045963:-
COAD	cis	rs3764400	0.508	rs978263	ENSG00000278765.1	RP5-890E16.5	-3.93	0.000109	0.0241	-0.45	-0.24	Body mass index;	chr17:48103302	chr17:48066704~48067293:-
COAD	cis	rs3764400	0.567	rs12600980	ENSG00000278765.1	RP5-890E16.5	-3.93	0.000109	0.0241	-0.45	-0.24	Body mass index;	chr17:48109779	chr17:48066704~48067293:-
COAD	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-3.93	0.000109	0.0241	-0.24	-0.24	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
COAD	cis	rs860295	0.871	rs11582072	ENSG00000225082.2	DAP3P1	3.93	0.000109	0.0241	0.3	0.24	Body mass index;	chr1:155507779	chr1:155586644~155602197:+
COAD	cis	rs9880211	0.821	rs9832813	ENSG00000273486.1	RP11-731C17.2	3.93	0.000109	0.0241	0.27	0.24	Height;Body mass index;	chr3:136346723	chr3:136837338~136839021:-
COAD	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	3.93	0.000109	0.0241	0.31	0.24	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
COAD	cis	rs734999	0.545	rs41300092	ENSG00000225931.3	RP3-395M20.7	3.93	0.000109	0.0241	0.26	0.24	Ulcerative colitis;	chr1:2606399	chr1:2566410~2569888:+
COAD	cis	rs734999	0.545	rs10910105	ENSG00000225931.3	RP3-395M20.7	3.93	0.000109	0.0241	0.26	0.24	Ulcerative colitis;	chr1:2606770	chr1:2566410~2569888:+
COAD	cis	rs734999	0.545	rs10910106	ENSG00000225931.3	RP3-395M20.7	3.93	0.000109	0.0241	0.26	0.24	Ulcerative colitis;	chr1:2607447	chr1:2566410~2569888:+
COAD	cis	rs7246657	0.551	rs28462002	ENSG00000226686.6	LINC01535	-3.93	0.000109	0.0241	-0.4	-0.24	Coronary artery calcification;	chr19:37143560	chr19:37251912~37265535:+
COAD	cis	rs8017304	0.643	rs7148412	ENSG00000259502.1	RP11-643G16.3	-3.93	0.000109	0.0241	-0.31	-0.24	Age-related macular degeneration;	chr14:68310488	chr14:67610986~67613864:+
COAD	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-3.93	0.000109	0.0241	-0.35	-0.24	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
COAD	cis	rs4499344	0.526	rs11084655	ENSG00000267213.4	AC007773.2	-3.93	0.000109	0.0241	-0.26	-0.24	Mean platelet volume;	chr19:32543792	chr19:32390050~32405560:-
COAD	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-3.93	0.000109	0.0241	-0.35	-0.24	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
COAD	cis	rs987724	0.593	rs2874494	ENSG00000240875.4	LINC00886	-3.93	0.000109	0.0241	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156964340	chr3:156747346~156817062:-
COAD	cis	rs2337406	0.925	rs873533	ENSG00000211967.3	IGHV3-53	-3.93	0.000109	0.0241	-0.19	-0.24	Alzheimer's disease (late onset);	chr14:106667442	chr14:106592676~106593347:-
COAD	cis	rs7577696	1	rs7577696	ENSG00000272716.1	RP11-563N4.1	-3.93	0.000109	0.0241	-0.25	-0.24	Inflammatory biomarkers;	chr2:32053713	chr2:32165046~32165757:-
COAD	cis	rs4938303	0.549	rs12420888	ENSG00000254851.1	RP11-109L13.1	3.93	0.000109	0.0241	0.32	0.24	Triglycerides;	chr11:116693106	chr11:117135528~117138582:+
COAD	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	3.93	0.000109	0.0241	0.24	0.24	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
COAD	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-3.93	0.000109	0.0241	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-3.93	0.000109	0.0241	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-3.93	0.000109	0.0241	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-3.93	0.000109	0.0241	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
COAD	cis	rs7582403	0.51	rs7604592	ENSG00000281469.1	RP11-567F11.1	3.93	0.000109	0.0241	0.26	0.24	Neuroticism;	chr2:148132966	chr2:148044380~148044894:+
COAD	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	3.93	0.000109	0.0241	0.3	0.24	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
COAD	cis	rs911263	0.603	rs11626138	ENSG00000259502.1	RP11-643G16.3	-3.93	0.00011	0.0242	-0.29	-0.24	Primary biliary cholangitis;	chr14:68320276	chr14:67610986~67613864:+
COAD	cis	rs754466	0.58	rs10762763	ENSG00000204049.1	RP11-126H7.4	3.93	0.00011	0.0242	0.28	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77801045	chr10:77866875~77869610:+
COAD	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-3.93	0.00011	0.0242	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
COAD	cis	rs913655	0.545	rs2495835	ENSG00000240291.1	RP11-499P20.2	3.93	0.00011	0.0242	0.27	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18780119	chr10:18513115~18545651:-
COAD	cis	rs2559856	1	rs2695291	ENSG00000199933.1	RNY1P16	3.93	0.00011	0.0242	0.26	0.24	Blood protein levels;	chr12:101693765	chr12:101719808~101719918:+
COAD	cis	rs7577696	0.886	rs659239	ENSG00000272716.1	RP11-563N4.1	3.93	0.00011	0.0242	0.25	0.24	Inflammatory biomarkers;	chr2:32259500	chr2:32165046~32165757:-
COAD	cis	rs7829975	0.539	rs940031	ENSG00000173295.6	FAM86B3P	-3.93	0.00011	0.0242	-0.29	-0.24	Mood instability;	chr8:8689338	chr8:8228595~8244865:+
COAD	cis	rs3120667	0.789	rs11204993	ENSG00000237975.5	FLG-AS1	3.93	0.00011	0.0242	0.31	0.24	Eating disorders;	chr1:152383857	chr1:152168125~152445456:+
COAD	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	3.93	0.00011	0.0242	0.32	0.24	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	3.93	0.00011	0.0242	0.32	0.24	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
COAD	cis	rs2496589	0.963	rs9484744	ENSG00000218896.1	TUBB8P2	3.93	0.00011	0.0242	0.26	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143423127	chr6:143436216~143436710:+
COAD	cis	rs7955901	0.539	rs1798090	ENSG00000258053.1	CTD-2021H9.3	-3.93	0.00011	0.0242	-0.28	-0.24	Type 2 diabetes;	chr12:71141315	chr12:71047402~71118247:-
COAD	cis	rs755249	0.51	rs599892	ENSG00000182109.6	RP11-69E11.4	3.93	0.00011	0.0242	0.26	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39522280~39546187:-
COAD	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-3.93	0.00011	0.0242	-0.32	-0.24	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
COAD	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-3.93	0.00011	0.0242	-0.32	-0.24	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
COAD	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	3.93	0.00011	0.0242	0.3	0.24	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
COAD	cis	rs734999	0.588	rs2843402	ENSG00000225931.3	RP3-395M20.7	-3.93	0.00011	0.0242	-0.26	-0.24	Ulcerative colitis;	chr1:2597243	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs2764842	ENSG00000225931.3	RP3-395M20.7	-3.93	0.00011	0.0242	-0.26	-0.24	Ulcerative colitis;	chr1:2597753	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs2843404	ENSG00000225931.3	RP3-395M20.7	-3.93	0.00011	0.0242	-0.26	-0.24	Ulcerative colitis;	chr1:2599119	chr1:2566410~2569888:+
COAD	cis	rs734999	0.55	rs2985855	ENSG00000225931.3	RP3-395M20.7	-3.93	0.00011	0.0242	-0.26	-0.24	Ulcerative colitis;	chr1:2599933	chr1:2566410~2569888:+
COAD	cis	rs734999	0.588	rs6689711	ENSG00000225931.3	RP3-395M20.7	-3.93	0.00011	0.0242	-0.26	-0.24	Ulcerative colitis;	chr1:2600028	chr1:2566410~2569888:+
COAD	cis	rs739496	0.615	rs3809276	ENSG00000257595.2	RP3-473L9.4	3.93	0.00011	0.0242	0.35	0.24	Platelet count;	chr12:111636112	chr12:111369282~111403310:+
COAD	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-3.93	0.00011	0.0242	-0.25	-0.24	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
COAD	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-3.93	0.00011	0.0242	-0.25	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
COAD	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-3.93	0.00011	0.0242	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-3.93	0.00011	0.0242	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
COAD	cis	rs4918072	0.798	rs2067831	ENSG00000273108.1	RP11-416N2.4	3.93	0.00011	0.0242	0.29	0.24	Coronary artery disease;	chr10:103883465	chr10:103608619~103610050:+
COAD	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-3.93	0.00011	0.0242	-0.32	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
COAD	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-3.93	0.00011	0.0242	-0.32	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
COAD	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	3.93	0.00011	0.0242	0.34	0.24	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
COAD	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	3.93	0.00011	0.0242	0.32	0.24	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
COAD	cis	rs2243480	1	rs67536397	ENSG00000232559.3	GS1-124K5.12	3.93	0.00011	0.0242	0.43	0.24	Diabetic kidney disease;	chr7:66482930	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs58669269	ENSG00000232559.3	GS1-124K5.12	3.93	0.00011	0.0242	0.43	0.24	Diabetic kidney disease;	chr7:66486966	chr7:66554588~66576923:-
COAD	cis	rs11229555	0.609	rs12286421	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58407425	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs12289198	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58407584	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12294062	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58408130	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs10896774	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58408364	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs10896775	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58408516	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12290089	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58409376	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12269745	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58409402	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12291551	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58409442	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12283414	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58409447	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12274866	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58409656	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12803648	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58410088	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7116847	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58411005	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229427	ENSG00000254602.1	AP000662.4	-3.93	0.00011	0.0242	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58412802	chr11:57638024~57652790:+
COAD	cis	rs2916733	0.607	rs2053618	ENSG00000246089.3	RP11-115C21.2	-3.93	0.00011	0.0242	-0.31	-0.24	Epirubicin-induced leukopenia;	chr8:6442011	chr8:6403551~6407142:-
COAD	cis	rs7119	0.635	rs907374	ENSG00000259565.2	KRT8P23	3.93	0.00011	0.0242	0.28	0.24	Type 2 diabetes;	chr15:77591684	chr15:76979245~76980451:-
COAD	cis	rs860295	0.702	rs12239100	ENSG00000160766.13	GBAP1	-3.93	0.00011	0.0243	-0.3	-0.24	Body mass index;	chr1:155458685	chr1:155213821~155227422:-
COAD	cis	rs11098499	0.954	rs11098526	ENSG00000250412.1	KLHL2P1	3.93	0.00011	0.0243	0.32	0.24	Corneal astigmatism;	chr4:119469204	chr4:119334329~119378233:+
COAD	cis	rs11935103	0.673	rs1470753	ENSG00000279943.1	FLJ38576	3.93	0.00011	0.0243	0.34	0.24	Response to citalopram treatment;	chr4:186374965	chr4:186189032~186191490:-
COAD	cis	rs11935103	0.636	rs1470752	ENSG00000279943.1	FLJ38576	3.93	0.00011	0.0243	0.34	0.24	Response to citalopram treatment;	chr4:186375016	chr4:186189032~186191490:-
COAD	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-3.93	0.00011	0.0243	-0.17	-0.24	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
COAD	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-3.93	0.00011	0.0243	-0.17	-0.24	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
COAD	cis	rs875971	0.964	rs55748098	ENSG00000230189.5	GS1-124K5.2	-3.93	0.00011	0.0243	-0.19	-0.24	Aortic root size;	chr7:66298631	chr7:66409143~66490059:-
COAD	cis	rs13256369	1	rs10103769	ENSG00000253981.4	ALG1L13P	3.93	0.00011	0.0243	0.35	0.24	Obesity-related traits;	chr8:8715526	chr8:8236003~8244667:-
COAD	cis	rs78487399	0.908	rs11904361	ENSG00000234936.1	AC010883.5	3.93	0.00011	0.0243	0.32	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621525	chr2:43229573~43233394:+
COAD	cis	rs6951245	0.745	rs79788515	ENSG00000229043.2	AC091729.9	-3.93	0.00011	0.0243	-0.4	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1160374~1165267:+
COAD	cis	rs34779708	0.931	rs11010132	ENSG00000271335.4	RP11-324I22.4	3.93	0.00011	0.0243	0.26	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35314552~35336401:-
COAD	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-3.93	0.00011	0.0243	-0.47	-0.24	Gout;	chr7:66723871	chr7:66654538~66669855:+
COAD	cis	rs79349575	0.691	rs28528789	ENSG00000248278.1	SUMO2P17	-3.93	0.00011	0.0243	-0.26	-0.24	Type 2 diabetes;	chr17:48909254	chr17:48874860~48908983:-
COAD	cis	rs79349575	0.715	rs999474	ENSG00000248278.1	SUMO2P17	-3.93	0.00011	0.0243	-0.26	-0.24	Type 2 diabetes;	chr17:48910303	chr17:48874860~48908983:-
COAD	cis	rs9376098	0.964	rs9494168	ENSG00000232876.1	CTA-212D2.2	-3.93	0.00011	0.0243	-0.29	-0.24	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135169288	chr6:135055033~135060550:+
COAD	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-3.93	0.00011	0.0243	-0.29	-0.24	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
COAD	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-3.93	0.00011	0.0243	-0.23	-0.24	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
COAD	cis	rs9549328	0.8	rs1317507	ENSG00000267868.1	RP11-120K24.3	3.93	0.00011	0.0243	0.31	0.24	Systolic blood pressure;	chr13:112977466	chr13:112964835~112966131:-
COAD	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	3.93	0.00011	0.0243	0.35	0.24	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
COAD	cis	rs6951245	1	rs74785791	ENSG00000229043.2	AC091729.9	-3.93	0.000111	0.0243	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs74366004	ENSG00000229043.2	AC091729.9	-3.93	0.000111	0.0243	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs77702926	ENSG00000229043.2	AC091729.9	-3.93	0.000111	0.0243	-0.41	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1160374~1165267:+
COAD	cis	rs4819052	0.851	rs9974628	ENSG00000227039.5	ITGB2-AS1	-3.93	0.000111	0.0243	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:44921051~44929678:+
COAD	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	3.93	0.000111	0.0243	0.28	0.24	QT interval;	chr12:29284120	chr12:29277397~29277882:-
COAD	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	3.93	0.000111	0.0243	0.26	0.24	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
COAD	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	3.93	0.000111	0.0243	0.32	0.24	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
COAD	cis	rs6452524	0.836	rs1478484	ENSG00000271862.1	RP11-343L5.2	3.93	0.000111	0.0243	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs7714710	ENSG00000271862.1	RP11-343L5.2	3.93	0.000111	0.0243	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83049376~83050964:-
COAD	cis	rs4964805	0.559	rs1469999	ENSG00000257681.1	RP11-341G23.4	-3.93	0.000111	0.0243	-0.3	-0.24	Attention deficit hyperactivity disorder;	chr12:103814333	chr12:103746315~103768858:-
COAD	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	3.93	0.000111	0.0243	0.39	0.24	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	3.93	0.000111	0.0243	0.39	0.24	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
COAD	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000111	0.0243	-0.3	-0.24	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000111	0.0243	-0.3	-0.24	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000111	0.0243	-0.3	-0.24	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000111	0.0243	-0.3	-0.24	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000111	0.0243	-0.3	-0.24	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
COAD	cis	rs10876993	0.928	rs1689592	ENSG00000270039.1	RP11-571M6.17	3.93	0.000111	0.0244	0.26	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57663990	chr12:57803838~57804415:+
COAD	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-3.93	0.000111	0.0244	-0.31	-0.24	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
COAD	cis	rs2638953	0.924	rs12369144	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000111	0.0244	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341109	chr12:28163298~28190738:-
COAD	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-3.93	0.000111	0.0244	-0.19	-0.24	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
COAD	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	3.93	0.000111	0.0244	0.27	0.24	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
COAD	cis	rs2307394	0.964	rs1895693	ENSG00000281469.1	RP11-567F11.1	3.93	0.000111	0.0244	0.28	0.24	Urate levels;	chr2:147879424	chr2:148044380~148044894:+
COAD	cis	rs3120667	0.72	rs12029431	ENSG00000237975.5	FLG-AS1	3.93	0.000111	0.0244	0.32	0.24	Eating disorders;	chr1:152419071	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.691	rs12510133	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350189	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs12506487	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350206	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs12502524	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350259	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs28396837	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350386	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.629	rs28369518	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350475	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.722	rs10025925	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350589	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.731	rs10015579	ENSG00000249244.1	RP11-548H18.2	3.93	0.000111	0.0244	0.3	0.24	Corneal astigmatism;	chr4:119350647	chr4:119391831~119395335:-
COAD	cis	rs73198271	0.71	rs7837843	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0244	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.64	rs7838012	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0244	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8228595~8244865:+
COAD	cis	rs72713618	1	rs12554254	ENSG00000213362.3	FTH1P12	3.93	0.000111	0.0244	0.54	0.24	Facial morphology (factor 17, height of vermillion upper lip);	chr9:14856558	chr9:15527133~15527683:-
COAD	cis	rs911263	0.603	rs3784109	ENSG00000259502.1	RP11-643G16.3	-3.93	0.000111	0.0244	-0.29	-0.24	Primary biliary cholangitis;	chr14:68323194	chr14:67610986~67613864:+
COAD	cis	rs911263	0.603	rs12878627	ENSG00000259502.1	RP11-643G16.3	-3.93	0.000111	0.0244	-0.29	-0.24	Primary biliary cholangitis;	chr14:68328432	chr14:67610986~67613864:+
COAD	cis	rs240993	0.812	rs9487639	ENSG00000271789.1	RP5-1112D6.7	-3.93	0.000111	0.0244	-0.24	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111297126~111298510:+
COAD	cis	rs6687821	0.515	rs524515	ENSG00000261737.1	RP4-612B15.3	-3.93	0.000111	0.0244	-0.31	-0.24	Yeast infection;	chr1:86907736	chr1:86703502~86704462:-
COAD	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	3.93	0.000111	0.0244	0.28	0.24	Height;	chr4:55476159	chr4:55547112~55547889:+
COAD	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-3.93	0.000111	0.0244	-0.34	-0.24	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
COAD	cis	rs11239930	0.517	rs556976	ENSG00000278811.3	LINC00624	3.93	0.000111	0.0244	0.23	0.24	AIDS progression;	chr1:147073643	chr1:147258885~147517875:-
COAD	cis	rs17407555	0.683	rs6823180	ENSG00000250413.1	RP11-448G15.1	-3.93	0.000111	0.0244	-0.33	-0.24	Schizophrenia (age at onset);	chr4:10274207	chr4:10006482~10009725:+
COAD	cis	rs35359187	0.546	rs61306238	ENSG00000272989.1	RP13-616I3.1	-3.93	0.000111	0.0244	-0.44	-0.24	Facial morphology (factor 22);	chr3:197534755	chr3:197505262~197506986:-
COAD	cis	rs7621025	0.542	rs71336078	ENSG00000239213.4	NCK1-AS1	-3.93	0.000111	0.0244	-0.44	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136770760	chr3:136841726~136862054:-
COAD	cis	rs2638953	0.924	rs10843162	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000111	0.0244	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28410985	chr12:28163298~28190738:-
COAD	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0244	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0244	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0244	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0244	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0244	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
COAD	cis	rs2179367	0.632	rs9498321	ENSG00000216906.2	RP11-350J20.9	3.93	0.000111	0.0244	0.35	0.24	Dupuytren's disease;	chr6:149322573	chr6:149904243~149906418:+
COAD	cis	rs11719291	0.833	rs73080361	ENSG00000225399.4	RP11-3B7.1	-3.93	0.000111	0.0244	-0.53	-0.24	Cognitive function;	chr3:48794713	chr3:49260085~49261316:+
COAD	cis	rs12682352	0.602	rs1473029	ENSG00000173295.6	FAM86B3P	3.93	0.000111	0.0244	0.27	0.24	Neuroticism;	chr8:8811407	chr8:8228595~8244865:+
COAD	cis	rs7572733	0.84	rs1065949	ENSG00000222017.1	AC011997.1	3.93	0.000111	0.0244	0.27	0.24	Dermatomyositis;	chr2:197762331	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs700653	ENSG00000222017.1	AC011997.1	3.93	0.000111	0.0244	0.27	0.24	Dermatomyositis;	chr2:197772709	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.84	rs700654	ENSG00000222017.1	AC011997.1	3.93	0.000111	0.0244	0.27	0.24	Dermatomyositis;	chr2:197778697	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.875	rs771018	ENSG00000222017.1	AC011997.1	3.93	0.000111	0.0244	0.27	0.24	Dermatomyositis;	chr2:197785535	chr2:197693106~197774823:+
COAD	cis	rs11681884	0.786	rs1992763	ENSG00000228251.1	AC012442.6	3.93	0.000111	0.0244	0.53	0.24	Stroke;	chr2:113053159	chr2:112590796~112591939:+
COAD	cis	rs73198271	0.74	rs10100066	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0245	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.74	rs10110711	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0245	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.74	rs10103163	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0245	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.599	rs10103169	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0245	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.7	rs10103282	ENSG00000173295.6	FAM86B3P	-3.93	0.000111	0.0245	-0.31	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8228595~8244865:+
COAD	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	3.93	0.000111	0.0245	0.29	0.24	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
COAD	cis	rs7577696	0.785	rs2886393	ENSG00000272716.1	RP11-563N4.1	-3.92	0.000111	0.0245	-0.25	-0.24	Inflammatory biomarkers;	chr2:32146493	chr2:32165046~32165757:-
COAD	cis	rs224278	0.509	rs6479860	ENSG00000228566.1	RP11-170M17.1	-3.92	0.000112	0.0245	-0.34	-0.24	Ewing sarcoma;	chr10:62986105	chr10:63664664~63990568:+
COAD	cis	rs1552244	0.832	rs66597916	ENSG00000186162.9	CIDECP	3.92	0.000112	0.0245	0.4	0.24	Alzheimer's disease;	chr3:10153723	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.832	rs115415687	ENSG00000186162.9	CIDECP	3.92	0.000112	0.0245	0.4	0.24	Alzheimer's disease;	chr3:10154020	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs55962400	ENSG00000186162.9	CIDECP	3.92	0.000112	0.0245	0.36	0.24	Alzheimer's disease;	chr3:10002773	chr3:10014238~10026365:-
COAD	cis	rs6452524	0.901	rs10079680	ENSG00000271862.1	RP11-343L5.2	3.92	0.000112	0.0245	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83049376~83050964:-
COAD	cis	rs7204230	0.96	rs12596696	ENSG00000261056.2	RP11-454F8.2	3.92	0.000112	0.0245	0.29	0.24	Fibrinogen;	chr16:53334858	chr16:53298224~53299792:+
COAD	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-3.92	0.000112	0.0245	-0.19	-0.24	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
COAD	cis	rs7212590	0.881	rs7214032	ENSG00000264049.1	MIR4737	-3.92	0.000112	0.0245	-0.34	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808467	chr17:60043025~60043105:-
COAD	cis	rs4683346	0.859	rs2099022	ENSG00000273328.4	RP11-141M3.6	-3.92	0.000112	0.0245	-0.3	-0.24	Granulocyte percentage of myeloid white cells;	chr3:42850556	chr3:42809414~42908105:+
COAD	cis	rs763121	0.776	rs5757177	ENSG00000273076.1	RP3-508I15.22	3.92	0.000112	0.0245	0.21	0.24	Menopause (age at onset);	chr22:38611169	chr22:38743495~38743910:+
COAD	cis	rs728616	0.614	rs61859198	ENSG00000225484.5	NUTM2B-AS1	-3.92	0.000112	0.0245	-0.4	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79663088~79826594:-
COAD	cis	rs2243480	1	rs160634	ENSG00000164669.11	INTS4P1	-3.92	0.000112	0.0245	-0.37	-0.24	Diabetic kidney disease;	chr7:66063677	chr7:65141225~65234216:+
COAD	cis	rs494562	0.892	rs522915	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000112	0.0245	-0.43	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85406603	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs520090	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000112	0.0245	-0.43	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85406917	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs498289	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000112	0.0245	-0.43	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85407003	chr6:85387219~85390186:-
COAD	cis	rs7686384	0.522	rs13137841	ENSG00000180015.12	RP11-756P10.3	-3.92	0.000112	0.0245	-0.38	-0.24	Obesity-related traits;	chr4:188712960	chr4:188738373~188739494:+
COAD	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	3.92	0.000112	0.0245	0.34	0.24	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
COAD	cis	rs11239930	0.517	rs492243	ENSG00000278811.3	LINC00624	3.92	0.000112	0.0245	0.24	0.24	AIDS progression;	chr1:147077930	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.517	rs493000	ENSG00000278811.3	LINC00624	3.92	0.000112	0.0245	0.24	0.24	AIDS progression;	chr1:147077979	chr1:147258885~147517875:-
COAD	cis	rs1056107	0.933	rs4978481	ENSG00000225513.1	RP11-165N19.2	-3.92	0.000112	0.0245	-0.29	-0.24	Colorectal cancer;	chr9:112309164	chr9:112173522~112173971:-
COAD	cis	rs13256369	1	rs1109619	ENSG00000253981.4	ALG1L13P	3.92	0.000112	0.0245	0.34	0.24	Obesity-related traits;	chr8:8714106	chr8:8236003~8244667:-
COAD	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-3.92	0.000112	0.0246	-0.29	-0.24	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
COAD	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000112	0.0246	0.3	0.24	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000112	0.0246	0.3	0.24	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000112	0.0246	0.3	0.24	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
COAD	cis	rs6687821	0.515	rs1419132	ENSG00000261737.1	RP4-612B15.3	3.92	0.000112	0.0246	0.31	0.24	Yeast infection;	chr1:87089675	chr1:86703502~86704462:-
COAD	cis	rs3764400	0.567	rs12946143	ENSG00000278765.1	RP5-890E16.5	3.92	0.000112	0.0246	0.45	0.24	Body mass index;	chr17:48077581	chr17:48066704~48067293:-
COAD	cis	rs801193	0.613	rs2659900	ENSG00000179406.6	LINC00174	3.92	0.000112	0.0246	0.18	0.24	Aortic root size;	chr7:66719456	chr7:66376044~66401338:-
COAD	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-3.92	0.000112	0.0246	-0.24	-0.24	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
COAD	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-3.92	0.000112	0.0246	-0.28	-0.24	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
COAD	cis	rs2408955	0.561	rs9971924	ENSG00000257735.1	RP11-370I10.6	-3.92	0.000112	0.0246	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48086049	chr12:48350945~48442411:+
COAD	cis	rs2836974	0.897	rs14194	ENSG00000255568.3	BRWD1-AS2	3.92	0.000112	0.0246	0.25	0.24	Cognitive function;	chr21:39177540	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.831	rs6517521	ENSG00000255568.3	BRWD1-AS2	3.92	0.000112	0.0246	0.25	0.24	Cognitive function;	chr21:39179662	chr21:39313935~39314962:+
COAD	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	3.92	0.000112	0.0246	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
COAD	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-3.92	0.000112	0.0246	-0.14	-0.24	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
COAD	cis	rs2255336	0.81	rs7976624	ENSG00000245648.1	RP11-277P12.20	3.92	0.000112	0.0246	0.43	0.24	Blood protein levels;	chr12:10359392	chr12:10363769~10398506:+
COAD	cis	rs28374715	0.681	rs7162231	ENSG00000247556.5	OIP5-AS1	3.92	0.000112	0.0246	0.34	0.24	Ulcerative colitis;	chr15:41299661	chr15:41283990~41309737:+
COAD	cis	rs6687821	0.681	rs517395	ENSG00000261737.1	RP4-612B15.3	-3.92	0.000112	0.0246	-0.37	-0.24	Yeast infection;	chr1:86854562	chr1:86703502~86704462:-
COAD	cis	rs7208859	0.673	rs1347360	ENSG00000264538.5	SUZ12P1	-3.92	0.000112	0.0246	-0.25	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30709299~30790908:+
COAD	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	3.92	0.000112	0.0246	0.31	0.24	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	3.92	0.000112	0.0246	0.31	0.24	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
COAD	cis	rs12571093	0.572	rs7100599	ENSG00000233590.1	RP11-153K11.3	-3.92	0.000112	0.0246	-0.34	-0.24	Optic nerve measurement (disc area);	chr10:68309476	chr10:68233251~68242379:-
COAD	cis	rs12049351	0.665	rs66521073	ENSG00000229367.1	HMGN2P19	3.92	0.000112	0.0246	0.32	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229434771	chr1:229570532~229570796:+
COAD	cis	rs2976388	0.692	rs2978983	ENSG00000253741.1	CTD-2292P10.4	-3.92	0.000112	0.0246	-0.25	-0.24	Urinary tract infection frequency;	chr8:142684424	chr8:142702252~142726973:-
COAD	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	3.92	0.000112	0.0246	0.25	0.24	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
COAD	cis	rs11588062	0.703	rs11589812	ENSG00000230896.1	RP11-767N6.7	3.92	0.000112	0.0246	0.29	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:46393076	chr1:45694684~45697075:-
COAD	cis	rs2708377	0.858	rs68045377	ENSG00000212125.2	TAS2R15P	3.92	0.000112	0.0246	0.43	0.24	Bitter taste perception;	chr12:11141853	chr12:10964425~10965352:-
COAD	cis	rs2252521	0.553	rs317705	ENSG00000272568.4	CTB-113D17.1	3.92	0.000112	0.0246	0.45	0.24	Cognitive performance;	chr7:29057532	chr7:28979967~29013367:+
COAD	cis	rs2252521	0.583	rs317706	ENSG00000272568.4	CTB-113D17.1	3.92	0.000112	0.0246	0.45	0.24	Cognitive performance;	chr7:29057649	chr7:28979967~29013367:+
COAD	cis	rs293748	0.771	rs34701667	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36799375	chr5:36666214~36725195:-
COAD	cis	rs293748	0.724	rs55668350	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36801181	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs13174506	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36801678	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs12654600	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36802066	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs34139494	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36802466	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs34092841	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36803462	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs35660956	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36803648	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs292163	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36803847	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs172384	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36804123	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs292164	ENSG00000250155.1	CTD-2353F22.1	-3.92	0.000112	0.0246	-0.33	-0.24	Obesity-related traits;	chr5:36804643	chr5:36666214~36725195:-
COAD	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-3.92	0.000112	0.0247	-0.28	-0.24	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
COAD	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	3.92	0.000113	0.0247	0.17	0.24	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
COAD	cis	rs41464545	1	rs7688438	ENSG00000249413.2	RP11-25H12.1	3.92	0.000113	0.0247	0.31	0.24	Schizophrenia;	chr4:65017238	chr4:65998846~66150012:+
COAD	cis	rs7615952	0.932	rs13086087	ENSG00000272840.1	RP11-379B18.6	3.92	0.000113	0.0247	0.33	0.24	Blood pressure (smoking interaction);	chr3:125927438	chr3:125774714~125797953:+
COAD	cis	rs875971	1	rs6956179	ENSG00000232559.3	GS1-124K5.12	-3.92	0.000113	0.0247	-0.27	-0.24	Aortic root size;	chr7:66341672	chr7:66554588~66576923:-
COAD	cis	rs3126085	0.935	rs3126094	ENSG00000237975.5	FLG-AS1	3.92	0.000113	0.0247	0.26	0.24	Atopic dermatitis;	chr1:152335767	chr1:152168125~152445456:+
COAD	cis	rs12699921	0.568	rs67452591	ENSG00000279048.1	RP11-511H23.2	-3.92	0.000113	0.0247	-0.18	-0.24	Fibrinogen levels;	chr7:17876573	chr7:17940503~17942922:+
COAD	cis	rs17374749	0.528	rs1440698	ENSG00000273486.1	RP11-731C17.2	-3.92	0.000113	0.0247	-0.28	-0.24	Anxiety in major depressive disorder;	chr3:137145996	chr3:136837338~136839021:-
COAD	cis	rs7671266	0.518	rs16895984	ENSG00000250413.1	RP11-448G15.1	-3.92	0.000113	0.0247	-0.3	-0.24	Cardiovascular disease risk factors;	chr4:10283103	chr4:10006482~10009725:+
COAD	cis	rs3738443	1	rs61840059	ENSG00000259865.1	RP11-488L18.10	3.92	0.000113	0.0247	0.28	0.24	Alcohol dependence;	chr1:247207676	chr1:247187281~247188526:-
COAD	cis	rs6715284	1	rs13408294	ENSG00000232133.1	IMPDH1P10	-3.92	0.000113	0.0247	-0.37	-0.24	Rheumatoid arthritis;	chr2:201306850	chr2:201137516~201140027:-
COAD	cis	rs2243480	0.901	rs12530490	ENSG00000229886.1	RP5-1132H15.3	-3.92	0.000113	0.0247	-0.42	-0.24	Diabetic kidney disease;	chr7:66226660	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs7778911	ENSG00000229886.1	RP5-1132H15.3	-3.92	0.000113	0.0247	-0.42	-0.24	Diabetic kidney disease;	chr7:66229519	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1979823	ENSG00000229886.1	RP5-1132H15.3	-3.92	0.000113	0.0247	-0.42	-0.24	Diabetic kidney disease;	chr7:66239626	chr7:66025126~66031544:-
COAD	cis	rs8141529	0.702	rs469992	ENSG00000272858.1	CTA-292E10.8	3.92	0.000113	0.0247	0.29	0.24	Lymphocyte counts;	chr22:28918911	chr22:28814914~28815662:+
COAD	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-3.92	0.000113	0.0247	-0.46	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
COAD	cis	rs16971384	0.661	rs16971366	ENSG00000271009.2	RP11-346C20.3	-3.92	0.000113	0.0247	-0.33	-0.24	LDL cholesterol;	chr16:72885683	chr16:73060470~73062316:+
COAD	cis	rs2496589	0.926	rs9496627	ENSG00000218896.1	TUBB8P2	3.92	0.000113	0.0247	0.27	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430645	chr6:143436216~143436710:+
COAD	cis	rs8022206	0.898	rs418462	ENSG00000259502.1	RP11-643G16.3	3.92	0.000113	0.0247	0.32	0.24	Platelet count;Mean platelet volume;	chr14:68125759	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.947	rs437585	ENSG00000259502.1	RP11-643G16.3	3.92	0.000113	0.0247	0.32	0.24	Platelet count;Mean platelet volume;	chr14:68127899	chr14:67610986~67613864:+
COAD	cis	rs12497850	1	rs6788650	ENSG00000225399.4	RP11-3B7.1	3.92	0.000113	0.0247	0.26	0.24	Parkinson's disease;	chr3:48712110	chr3:49260085~49261316:+
COAD	cis	rs7204230	1	rs7188463	ENSG00000261056.2	RP11-454F8.2	-3.92	0.000113	0.0247	-0.28	-0.24	Fibrinogen;	chr16:53293129	chr16:53298224~53299792:+
COAD	cis	rs453301	0.598	rs2921383	ENSG00000254340.1	RP11-10A14.3	3.92	0.000113	0.0247	0.29	0.24	Joint mobility (Beighton score);	chr8:9034711	chr8:9141424~9145435:+
COAD	cis	rs2337406	0.714	rs115401799	ENSG00000211967.3	IGHV3-53	-3.92	0.000113	0.0247	-0.21	-0.24	Alzheimer's disease (late onset);	chr14:106813739	chr14:106592676~106593347:-
COAD	cis	rs875971	0.597	rs11763224	ENSG00000232546.1	RP11-458F8.1	3.92	0.000113	0.0247	0.24	0.24	Aortic root size;	chr7:66518628	chr7:66848496~66858136:+
COAD	cis	rs7615952	0.546	rs11718647	ENSG00000241278.1	ENPP7P4	3.92	0.000113	0.0247	0.29	0.24	Blood pressure (smoking interaction);	chr3:125633178	chr3:125848223~125909372:+
COAD	cis	rs12439619	0.883	rs62012045	ENSG00000259429.4	UBE2Q2P2	-3.92	0.000113	0.0247	-0.23	-0.24	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82355142~82420075:+
COAD	cis	rs911555	0.755	rs35233301	ENSG00000251533.2	LINC00605	3.92	0.000113	0.0247	0.31	0.24	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103187221~103189028:-
COAD	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	3.92	0.000113	0.0247	0.31	0.24	Depression;	chr6:28200948	chr6:28170845~28172521:+
COAD	cis	rs1552244	0.882	rs13084194	ENSG00000186162.9	CIDECP	3.92	0.000113	0.0248	0.36	0.24	Alzheimer's disease;	chr3:9989808	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs13099507	ENSG00000186162.9	CIDECP	3.92	0.000113	0.0248	0.36	0.24	Alzheimer's disease;	chr3:9989919	chr3:10014238~10026365:-
COAD	cis	rs2976388	0.556	rs4736300	ENSG00000247317.3	RP11-273G15.2	3.92	0.000113	0.0248	0.28	0.24	Urinary tract infection frequency;	chr8:142747851	chr8:142981738~143018437:-
COAD	cis	rs7933433	0.552	rs11221251	ENSG00000255465.3	RP11-264E20.1	-3.92	0.000113	0.0248	-0.31	-0.24	Psoriasis;	chr11:128330330	chr11:128615867~128621806:-
COAD	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	3.92	0.000113	0.0248	0.2	0.24	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
COAD	cis	rs9910055	0.659	rs3826412	ENSG00000267080.4	ASB16-AS1	-3.92	0.000113	0.0248	-0.21	-0.24	Total body bone mineral density;	chr17:44177729	chr17:44175973~44186717:-
COAD	cis	rs875971	1	rs2087647	ENSG00000230189.5	GS1-124K5.2	-3.92	0.000113	0.0248	-0.2	-0.24	Aortic root size;	chr7:66128201	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs6958484	ENSG00000230189.5	GS1-124K5.2	-3.92	0.000113	0.0248	-0.2	-0.24	Aortic root size;	chr7:66134459	chr7:66409143~66490059:-
COAD	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-3.92	0.000113	0.0248	-0.25	-0.24	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
COAD	cis	rs2708377	0.858	rs117212341	ENSG00000212125.2	TAS2R15P	3.92	0.000113	0.0248	0.44	0.24	Bitter taste perception;	chr12:11129957	chr12:10964425~10965352:-
COAD	cis	rs2554380	0.628	rs4843156	ENSG00000176700.18	SCAND2P	-3.92	0.000113	0.0248	-0.22	-0.24	Height;	chr15:83788593	chr15:84631451~84647478:+
COAD	cis	rs370915	0.578	rs2375939	ENSG00000250971.1	RP11-696F12.1	3.92	0.000113	0.0248	0.29	0.24	Gout;	chr4:186862572	chr4:187060099~187060930:+
COAD	cis	rs10170310	0.938	rs11680891	ENSG00000228043.4	AC097721.2	3.92	0.000113	0.0248	0.31	0.24	Response to antipsychotic treatment;	chr2:138506884	chr2:138418284~138501698:-
COAD	cis	rs6982240	0.514	rs10481414	ENSG00000253307.1	RP11-10J21.4	3.92	0.000113	0.0248	0.32	0.24	Tonsillectomy;	chr8:141265227	chr8:141252286~141253292:-
COAD	cis	rs6982240	0.514	rs9324543	ENSG00000253307.1	RP11-10J21.4	3.92	0.000113	0.0248	0.32	0.24	Tonsillectomy;	chr8:141265563	chr8:141252286~141253292:-
COAD	cis	rs6982240	0.514	rs10088801	ENSG00000253307.1	RP11-10J21.4	3.92	0.000113	0.0248	0.32	0.24	Tonsillectomy;	chr8:141265702	chr8:141252286~141253292:-
COAD	cis	rs3126085	0.56	rs72698932	ENSG00000237975.5	FLG-AS1	3.92	0.000114	0.0248	0.31	0.24	Atopic dermatitis;	chr1:152383044	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-3.92	0.000114	0.0248	-0.32	-0.24	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
COAD	cis	rs6490294	0.571	rs11066174	ENSG00000257595.2	RP3-473L9.4	3.92	0.000114	0.0248	0.39	0.24	Mean platelet volume;	chr12:112123243	chr12:111369282~111403310:+
COAD	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-3.92	0.000114	0.0248	-0.21	-0.24	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
COAD	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	3.92	0.000114	0.0248	0.42	0.24	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
COAD	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	3.92	0.000114	0.0248	0.26	0.24	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
COAD	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	3.92	0.000114	0.0248	0.27	0.24	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
COAD	cis	rs7324557	0.719	rs7325364	ENSG00000205861.10	C1QTNF9B-AS1	-3.92	0.000114	0.0248	-0.34	-0.24	Visceral adipose tissue adjusted for BMI;	chr13:23805008	chr13:23888889~23897263:+
COAD	cis	rs9813712	0.526	rs62281641	ENSG00000253540.4	FAM86HP	-3.92	0.000114	0.0249	-0.25	-0.24	Response to amphetamines;	chr3:130235668	chr3:130099092~130111472:-
COAD	cis	rs2638953	0.924	rs11049403	ENSG00000247934.4	RP11-967K21.1	-3.92	0.000114	0.0249	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28163298~28190738:-
COAD	cis	rs4819052	0.807	rs7283915	ENSG00000227039.5	ITGB2-AS1	-3.92	0.000114	0.0249	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs2838850	ENSG00000227039.5	ITGB2-AS1	-3.92	0.000114	0.0249	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:44921051~44929678:+
COAD	cis	rs250677	0.958	rs36078	ENSG00000250072.4	CTC-529P8.1	-3.92	0.000114	0.0249	-0.34	-0.24	Breast cancer;	chr5:149051004	chr5:149063317~149109787:+
COAD	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-3.92	0.000114	0.0249	-0.28	-0.24	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-3.92	0.000114	0.0249	-0.28	-0.24	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-3.92	0.000114	0.0249	-0.28	-0.24	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
COAD	cis	rs763121	0.752	rs6001190	ENSG00000273076.1	RP3-508I15.22	3.92	0.000114	0.0249	0.21	0.24	Menopause (age at onset);	chr22:38677806	chr22:38743495~38743910:+
COAD	cis	rs9393777	0.72	rs34864993	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27003116	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.72	rs56874662	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27017828	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.72	rs36022097	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27027389	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.72	rs35212793	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27030914	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.72	rs35769282	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27032129	chr6:26956992~27023924:+
COAD	cis	rs9393777	0.72	rs57713596	ENSG00000224843.5	LINC00240	3.92	0.000114	0.0249	0.45	0.24	Intelligence (multi-trait analysis);	chr6:27036319	chr6:26956992~27023924:+
COAD	cis	rs3733585	0.673	rs9993410	ENSG00000250413.1	RP11-448G15.1	3.92	0.000114	0.0249	0.31	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9949640	chr4:10006482~10009725:+
COAD	cis	rs728616	0.571	rs113030473	ENSG00000234382.2	RP11-40F6.1	-3.92	0.000114	0.0249	-0.47	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:80233664~80245367:+
COAD	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-3.92	0.000114	0.0249	-0.31	-0.24	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
COAD	cis	rs860295	0.812	rs2297775	ENSG00000160766.13	GBAP1	3.92	0.000114	0.0249	0.27	0.24	Body mass index;	chr1:155765221	chr1:155213821~155227422:-
COAD	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-3.92	0.000114	0.0249	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-3.92	0.000114	0.0249	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-3.92	0.000114	0.0249	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-3.92	0.000114	0.0249	-0.3	-0.24	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
COAD	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	3.92	0.000114	0.0249	0.31	0.24	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
COAD	cis	rs34792	0.688	rs170168	ENSG00000207425.1	Y_RNA	-3.92	0.000114	0.0249	-0.32	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:14915457~14915556:-
COAD	cis	rs210138	0.637	rs9366825	ENSG00000197251.3	LINC00336	3.92	0.000114	0.0249	0.35	0.24	Testicular germ cell tumor;	chr6:33650408	chr6:33586106~33593338:-
COAD	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-3.92	0.000114	0.0249	-0.3	-0.24	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
COAD	cis	rs4879656	0.866	rs10971227	ENSG00000225693.1	LAGE3P1	3.92	0.000114	0.0249	0.28	0.24	Menopause (age at onset);	chr9:32934619	chr9:33019682~33020165:-
COAD	cis	rs7727544	0.625	rs4705916	ENSG00000233006.5	AC034220.3	3.92	0.000114	0.025	0.21	0.24	Blood metabolite levels;	chr5:132071800	chr5:132311285~132369916:-
COAD	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	3.92	0.000114	0.025	0.29	0.24	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
COAD	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-3.92	0.000114	0.025	-0.29	-0.24	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
COAD	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	3.92	0.000114	0.025	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
COAD	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-3.92	0.000114	0.025	-0.25	-0.24	Height;	chr11:118809363	chr11:118791254~118793137:+
COAD	cis	rs189798	1	rs189798	ENSG00000173295.6	FAM86B3P	-3.92	0.000114	0.025	-0.31	-0.24	Myopia (pathological);	chr8:9133067	chr8:8228595~8244865:+
COAD	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-3.92	0.000114	0.025	-0.31	-0.24	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
COAD	cis	rs12530	0.54	rs737779	ENSG00000279338.1	RP1-309I22.2	3.92	0.000114	0.025	0.21	0.24	IgG glycosylation;	chr22:32400260	chr22:32836706~32865634:+
COAD	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	3.92	0.000114	0.025	0.34	0.24	Depression;	chr6:28229408	chr6:28943877~28944537:+
COAD	cis	rs13256369	0.708	rs11783670	ENSG00000254153.1	CTA-398F10.2	3.92	0.000114	0.025	0.32	0.24	Obesity-related traits;	chr8:8701884	chr8:8456909~8461337:-
COAD	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	3.92	0.000114	0.025	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
COAD	cis	rs1023500	1	rs7293091	ENSG00000205702.9	CYP2D7	-3.92	0.000114	0.025	-0.19	-0.24	Schizophrenia;	chr22:41945304	chr22:42140203~42144577:-
COAD	cis	rs7911712	0.873	rs2094018	ENSG00000165511.6	C10orf25	3.92	0.000114	0.025	0.39	0.24	Emphysema-related traits;	chr10:44812492	chr10:44997698~45000888:-
COAD	cis	rs17248137	0.51	rs116515963	ENSG00000249942.1	AC142293.3	3.92	0.000114	0.025	0.43	0.24	Overall survival in osteosarcoma;	chr4:74913614	chr4:74552584~74589481:-
COAD	cis	rs9907295	0.591	rs8069014	ENSG00000270977.1	AC015849.16	-3.92	0.000114	0.025	-0.3	-0.24	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35893707~35911023:-
COAD	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	3.92	0.000114	0.025	0.42	0.24	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
COAD	cis	rs911119	0.913	rs6036461	ENSG00000270001.1	RP11-218C14.8	-3.92	0.000114	0.025	-0.28	-0.24	Chronic kidney disease;	chr20:23596117	chr20:23631826~23632316:-
COAD	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	3.92	0.000115	0.025	0.28	0.24	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	3.92	0.000115	0.025	0.28	0.24	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
COAD	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-3.92	0.000115	0.025	-0.23	-0.24	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
COAD	cis	rs875971	1	rs6946143	ENSG00000230189.5	GS1-124K5.2	3.92	0.000115	0.025	0.19	0.24	Aortic root size;	chr7:66114735	chr7:66409143~66490059:-
COAD	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	3.92	0.000115	0.025	0.25	0.24	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
COAD	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	3.92	0.000115	0.025	0.25	0.24	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
COAD	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	3.92	0.000115	0.025	0.35	0.24	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
COAD	cis	rs55962025	0.883	rs2298967	ENSG00000248840.2	RP11-357G3.2	3.92	0.000115	0.025	0.28	0.24	Parental longevity (mother's age at death);	chr4:3184020	chr4:3312512~3313058:+
COAD	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	3.92	0.000115	0.025	0.43	0.24	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
COAD	cis	rs4704187	0.687	rs10942732	ENSG00000250889.2	LINC01336	-3.92	0.000115	0.0251	-0.27	-0.24	Response to amphetamines;	chr5:75242434	chr5:75047719~75052843:-
COAD	cis	rs1670533	0.932	rs935968	ENSG00000273179.1	RP11-20I20.4	3.92	0.000115	0.0251	0.28	0.24	Recombination rate (females);	chr4:1069399	chr4:1167778~1168174:+
COAD	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	3.92	0.000115	0.0251	0.31	0.24	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
COAD	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-3.92	0.000115	0.0251	-0.3	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
COAD	cis	rs763121	0.853	rs5757181	ENSG00000273076.1	RP3-508I15.22	3.92	0.000115	0.0251	0.22	0.24	Menopause (age at onset);	chr22:38617517	chr22:38743495~38743910:+
COAD	cis	rs7688540	0.8	rs11731285	ENSG00000211553.1	AC253576.2	-3.92	0.000115	0.0251	-0.4	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:136461~136568:+
COAD	cis	rs7688540	0.8	rs7694325	ENSG00000211553.1	AC253576.2	-3.92	0.000115	0.0251	-0.4	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:136461~136568:+
COAD	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-3.92	0.000115	0.0251	-0.18	-0.24	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
COAD	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000115	0.0251	-0.25	-0.24	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
COAD	cis	rs7615952	0.736	rs13063122	ENSG00000241278.1	ENPP7P4	3.92	0.000115	0.0251	0.27	0.24	Blood pressure (smoking interaction);	chr3:125925017	chr3:125848223~125909372:+
COAD	cis	rs1823913	0.614	rs1947457	ENSG00000280083.1	RP11-317J9.1	-3.92	0.000115	0.0251	-0.46	-0.24	Obesity-related traits;	chr2:191298970	chr2:191154118~191156070:-
COAD	cis	rs4819052	0.851	rs9979545	ENSG00000227039.5	ITGB2-AS1	-3.92	0.000115	0.0251	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:44921051~44929678:+
COAD	cis	rs4819052	0.851	rs7276591	ENSG00000227039.5	ITGB2-AS1	-3.92	0.000115	0.0251	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:44921051~44929678:+
COAD	cis	rs4820539	1	rs916584	ENSG00000211644.2	IGLV1-51	-3.92	0.000115	0.0252	-0.13	-0.24	Bone mineral density;	chr22:23127246	chr22:22322472~22322980:+
COAD	cis	rs4660214	0.666	rs1180376	ENSG00000182109.6	RP11-69E11.4	3.92	0.000115	0.0252	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs625384	ENSG00000182109.6	RP11-69E11.4	3.92	0.000115	0.0252	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39522280~39546187:-
COAD	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	3.92	0.000115	0.0252	0.37	0.24	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	3.92	0.000115	0.0252	0.37	0.24	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
COAD	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	3.92	0.000115	0.0252	0.37	0.24	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
COAD	cis	rs13256369	1	rs12550458	ENSG00000253981.4	ALG1L13P	3.92	0.000115	0.0252	0.35	0.24	Obesity-related traits;	chr8:8710322	chr8:8236003~8244667:-
COAD	cis	rs13256369	1	rs12545771	ENSG00000253981.4	ALG1L13P	3.92	0.000115	0.0252	0.35	0.24	Obesity-related traits;	chr8:8710467	chr8:8236003~8244667:-
COAD	cis	rs1044826	0.597	rs1017468	ENSG00000272656.1	RP11-219D15.3	3.92	0.000115	0.0252	0.28	0.24	Obesity-related traits;	chr3:139426936	chr3:139349024~139349371:-
COAD	cis	rs739496	0.615	rs11609628	ENSG00000257595.2	RP3-473L9.4	3.92	0.000115	0.0252	0.38	0.24	Platelet count;	chr12:111779404	chr12:111369282~111403310:+
COAD	cis	rs739496	0.615	rs4646777	ENSG00000257595.2	RP3-473L9.4	3.92	0.000115	0.0252	0.38	0.24	Platelet count;	chr12:111792232	chr12:111369282~111403310:+
COAD	cis	rs78487399	0.71	rs11899863	ENSG00000234936.1	AC010883.5	3.92	0.000115	0.0252	0.36	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43391680	chr2:43229573~43233394:+
COAD	cis	rs7560272	0.501	rs13003035	ENSG00000273245.1	RP11-434P11.2	-3.92	0.000115	0.0252	-0.3	-0.24	Schizophrenia;	chr2:73730100	chr2:73750256~73750786:-
COAD	cis	rs7560272	0.501	rs12992607	ENSG00000273245.1	RP11-434P11.2	-3.92	0.000115	0.0252	-0.3	-0.24	Schizophrenia;	chr2:73732833	chr2:73750256~73750786:-
COAD	cis	rs2708377	0.789	rs3911150	ENSG00000212125.2	TAS2R15P	-3.92	0.000115	0.0252	-0.41	-0.24	Bitter taste perception;	chr12:11049649	chr12:10964425~10965352:-
COAD	cis	rs2732480	0.557	rs2732441	ENSG00000269514.1	RP11-370I10.12	3.92	0.000115	0.0252	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2732448	ENSG00000269514.1	RP11-370I10.12	3.92	0.000115	0.0252	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48198387~48202031:+
COAD	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	3.92	0.000116	0.0252	0.28	0.24	Myopia;	chr2:171827496	chr2:171773482~171775844:+
COAD	cis	rs7674212	0.531	rs2866416	ENSG00000248971.2	KRT8P46	-3.92	0.000116	0.0252	-0.24	-0.24	Type 2 diabetes;	chr4:102959554	chr4:102728746~102730171:-
COAD	cis	rs7577696	0.626	rs3769603	ENSG00000272716.1	RP11-563N4.1	-3.92	0.000116	0.0252	-0.25	-0.24	Inflammatory biomarkers;	chr2:32135818	chr2:32165046~32165757:-
COAD	cis	rs13256369	0.802	rs12681925	ENSG00000254153.1	CTA-398F10.2	3.92	0.000116	0.0252	0.32	0.24	Obesity-related traits;	chr8:8704139	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs12680019	ENSG00000254153.1	CTA-398F10.2	3.92	0.000116	0.0252	0.32	0.24	Obesity-related traits;	chr8:8704188	chr8:8456909~8461337:-
COAD	cis	rs2732480	0.577	rs1489109	ENSG00000226413.2	OR8T1P	3.92	0.000116	0.0252	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.577	rs1489108	ENSG00000226413.2	OR8T1P	3.92	0.000116	0.0252	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48442030~48442947:-
COAD	cis	rs13256369	0.901	rs12681298	ENSG00000173295.6	FAM86B3P	-3.92	0.000116	0.0252	-0.32	-0.24	Obesity-related traits;	chr8:8708725	chr8:8228595~8244865:+
COAD	cis	rs5751901	0.614	rs4820599	ENSG00000271138.1	IGLVIVOR22-1	-3.92	0.000116	0.0252	-0.26	-0.24	Protein quantitative trait loci;	chr22:24594246	chr22:25437306~25437823:-
COAD	cis	rs7176527	0.747	rs28363946	ENSG00000225151.9	GOLGA2P7	3.92	0.000116	0.0252	0.41	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:84199311~84230136:-
COAD	cis	rs911119	0.913	rs12710327	ENSG00000270001.1	RP11-218C14.8	-3.92	0.000116	0.0252	-0.29	-0.24	Chronic kidney disease;	chr20:23589052	chr20:23631826~23632316:-
COAD	cis	rs7142002	0.73	rs58803878	ENSG00000272444.1	RP11-1017G21.6	-3.92	0.000116	0.0252	-0.35	-0.24	Autism;	chr14:101924770	chr14:101952416~101953063:+
COAD	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	3.92	0.000116	0.0252	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
COAD	cis	rs8177876	0.642	rs56032321	ENSG00000261061.1	RP11-303E16.2	-3.91	0.000116	0.0253	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81030770~81031485:+
COAD	cis	rs9796	0.621	rs1659227	ENSG00000247556.5	OIP5-AS1	-3.91	0.000116	0.0253	-0.23	-0.24	Menopause (age at onset);	chr15:41180200	chr15:41283990~41309737:+
COAD	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	3.91	0.000116	0.0253	0.23	0.24	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
COAD	cis	rs116139393	0.54	rs13224907	ENSG00000187953.9	PMS2CL	-3.91	0.000116	0.0253	-0.27	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6734261	chr7:6710128~6753862:+
COAD	cis	rs10876993	0.855	rs1689604	ENSG00000270039.1	RP11-571M6.17	3.91	0.000116	0.0253	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57654521	chr12:57803838~57804415:+
COAD	cis	rs9880211	0.613	rs28535121	ENSG00000239213.4	NCK1-AS1	3.91	0.000116	0.0253	0.32	0.24	Height;Body mass index;	chr3:136173956	chr3:136841726~136862054:-
COAD	cis	rs875971	0.83	rs427973	ENSG00000230189.5	GS1-124K5.2	3.91	0.000116	0.0253	0.2	0.24	Aortic root size;	chr7:66061661	chr7:66409143~66490059:-
COAD	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	3.91	0.000116	0.0253	0.28	0.24	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
COAD	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	3.91	0.000116	0.0253	0.33	0.24	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
COAD	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-3.91	0.000116	0.0253	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
COAD	cis	rs8059260	0.541	rs34361212	ENSG00000274038.1	RP11-66H6.4	-3.91	0.000116	0.0253	-0.4	-0.24	Alcohol consumption over the past year;	chr16:11145832	chr16:11056556~11057034:+
COAD	cis	rs5751614	0.537	rs9624074	ENSG00000207835.1	AC244250.3	3.91	0.000116	0.0253	0.21	0.24	Height;	chr22:23283143	chr22:22758696~22758790:+
COAD	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	3.91	0.000116	0.0253	0.31	0.24	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
COAD	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	3.91	0.000116	0.0253	0.34	0.24	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
COAD	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	3.91	0.000116	0.0253	0.32	0.24	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
COAD	cis	rs2408955	0.522	rs4760679	ENSG00000226413.2	OR8T1P	-3.91	0.000116	0.0253	-0.28	-0.24	Glycated hemoglobin levels;	chr12:48067852	chr12:48442030~48442947:-
COAD	cis	rs293748	0.771	rs58952013	ENSG00000250155.1	CTD-2353F22.1	-3.91	0.000116	0.0253	-0.33	-0.24	Obesity-related traits;	chr5:36787362	chr5:36666214~36725195:-
COAD	cis	rs2378353	1	rs2378353	ENSG00000269202.1	RP4-614O4.12	3.91	0.000116	0.0253	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr20:35382659	chr20:35201747~35203288:-
COAD	cis	rs250518	0.708	rs258893	ENSG00000272081.1	CTD-2376I4.2	3.91	0.000116	0.0253	0.27	0.24	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72955206~72955699:-
COAD	cis	rs17248137	0.702	rs75301424	ENSG00000249942.1	AC142293.3	3.91	0.000116	0.0253	0.42	0.24	Overall survival in osteosarcoma;	chr4:74923846	chr4:74552584~74589481:-
COAD	cis	rs987724	0.593	rs13088978	ENSG00000240875.4	LINC00886	-3.91	0.000116	0.0253	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156951007	chr3:156747346~156817062:-
COAD	cis	rs6687821	0.515	rs2040064	ENSG00000261737.1	RP4-612B15.3	3.91	0.000116	0.0253	0.31	0.24	Yeast infection;	chr1:87088226	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs1419131	ENSG00000261737.1	RP4-612B15.3	3.91	0.000116	0.0253	0.31	0.24	Yeast infection;	chr1:87089482	chr1:86703502~86704462:-
COAD	cis	rs76076331	0.517	rs1734367	ENSG00000272275.1	RP11-791G15.2	-3.91	0.000116	0.0253	-0.29	-0.24	Educational attainment (college completion);Educational attainment (years of education);	chr2:10838036	chr2:10767875~10770058:-
COAD	cis	rs3126085	0.866	rs3126066	ENSG00000237975.5	FLG-AS1	3.91	0.000116	0.0253	0.27	0.24	Atopic dermatitis;	chr1:152304395	chr1:152168125~152445456:+
COAD	cis	rs17248137	0.702	rs113802092	ENSG00000249942.1	AC142293.3	3.91	0.000116	0.0253	0.43	0.24	Overall survival in osteosarcoma;	chr4:74915669	chr4:74552584~74589481:-
COAD	cis	rs17248137	0.702	rs113978195	ENSG00000249942.1	AC142293.3	3.91	0.000116	0.0253	0.43	0.24	Overall survival in osteosarcoma;	chr4:74916335	chr4:74552584~74589481:-
COAD	cis	rs11976180	1	rs1919949	ENSG00000273234.1	OR2A13P	-3.91	0.000116	0.0253	-0.29	-0.24	Obesity-related traits;	chr7:144070630	chr7:144142009~144142938:+
COAD	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-3.91	0.000116	0.0253	-0.37	-0.24	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
COAD	cis	rs2408955	0.542	rs7975632	ENSG00000257735.1	RP11-370I10.6	3.91	0.000116	0.0253	0.28	0.24	Glycated hemoglobin levels;	chr12:48049265	chr12:48350945~48442411:+
COAD	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-3.91	0.000116	0.0253	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
COAD	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	3.91	0.000116	0.0253	0.26	0.24	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
COAD	cis	rs11976180	1	rs1533268	ENSG00000273234.1	OR2A13P	-3.91	0.000117	0.0253	-0.29	-0.24	Obesity-related traits;	chr7:144069265	chr7:144142009~144142938:+
COAD	cis	rs2333021	0.78	rs12887074	ENSG00000259015.1	RP11-109N23.6	3.91	0.000117	0.0253	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72981132	chr14:72960595~72961993:+
COAD	cis	rs13256369	0.708	rs11249886	ENSG00000254153.1	CTA-398F10.2	3.91	0.000117	0.0253	0.31	0.24	Obesity-related traits;	chr8:8704511	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs11249887	ENSG00000254153.1	CTA-398F10.2	3.91	0.000117	0.0253	0.31	0.24	Obesity-related traits;	chr8:8704674	chr8:8456909~8461337:-
COAD	cis	rs12530	0.715	rs2294313	ENSG00000241954.1	RP1-149A16.17	-3.91	0.000117	0.0253	-0.31	-0.24	IgG glycosylation;	chr22:32398452	chr22:32383786~32385631:+
COAD	cis	rs3126085	0.515	rs12033221	ENSG00000237975.5	FLG-AS1	3.91	0.000117	0.0254	0.31	0.24	Atopic dermatitis;	chr1:152383637	chr1:152168125~152445456:+
COAD	cis	rs7584330	0.554	rs10173100	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0254	-0.36	-0.24	Prostate cancer;	chr2:237524397	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs10208231	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0254	-0.36	-0.24	Prostate cancer;	chr2:237524582	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs10183995	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0254	-0.36	-0.24	Prostate cancer;	chr2:237524664	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs10176035	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0254	-0.36	-0.24	Prostate cancer;	chr2:237524806	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs10178682	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0254	-0.36	-0.24	Prostate cancer;	chr2:237525175	chr2:237591020~237595981:+
COAD	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-3.91	0.000117	0.0254	-0.29	-0.24	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
COAD	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000117	0.0254	-0.28	-0.24	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
COAD	cis	rs2243480	1	rs3885839	ENSG00000228409.4	CCT6P1	3.91	0.000117	0.0254	0.31	0.24	Diabetic kidney disease;	chr7:65825416	chr7:65751142~65763354:+
COAD	cis	rs911263	0.603	rs2180769	ENSG00000259502.1	RP11-643G16.3	-3.91	0.000117	0.0254	-0.29	-0.24	Primary biliary cholangitis;	chr14:68332385	chr14:67610986~67613864:+
COAD	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	3.91	0.000117	0.0254	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	3.91	0.000117	0.0254	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
COAD	cis	rs10779751	1	rs12124983	ENSG00000215785.2	CFL1P6	3.91	0.000117	0.0254	0.26	0.24	Body mass index;	chr1:11226121	chr1:10990978~10991797:-
COAD	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	3.91	0.000117	0.0254	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
COAD	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	3.91	0.000117	0.0254	0.23	0.24	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
COAD	cis	rs2711721	0.56	rs2711716	ENSG00000280054.1	RP1-197B17.7	-3.91	0.000117	0.0254	-0.29	-0.24	Prostate cancer (SNP x SNP interaction);	chr12:46980238	chr12:47728151~47730598:-
COAD	cis	rs1949733	0.701	rs940134	ENSG00000205959.3	RP11-689P11.2	-3.91	0.000117	0.0254	-0.28	-0.24	Response to antineoplastic agents;	chr4:8453143	chr4:8482270~8512610:+
COAD	cis	rs1949733	0.701	rs871768	ENSG00000205959.3	RP11-689P11.2	-3.91	0.000117	0.0254	-0.28	-0.24	Response to antineoplastic agents;	chr4:8453211	chr4:8482270~8512610:+
COAD	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-3.91	0.000117	0.0254	-0.29	-0.24	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	3.91	0.000117	0.0254	0.29	0.24	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
COAD	cis	rs875971	1	rs6961717	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000117	0.0254	-0.2	-0.24	Aortic root size;	chr7:66122550	chr7:66409143~66490059:-
COAD	cis	rs17007554	0.958	rs56091415	ENSG00000230730.1	AC074011.2	-3.91	0.000117	0.0254	-0.34	-0.24	Lung cancer in never smokers;	chr2:29068796	chr2:28633282~28664540:-
COAD	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	3.91	0.000117	0.0255	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
COAD	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	3.91	0.000117	0.0255	0.23	0.24	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
COAD	cis	rs2564921	0.73	rs6781896	ENSG00000280417.1	RP11-5O17.1	3.91	0.000117	0.0255	0.26	0.24	Height;	chr3:53047596	chr3:53046166~53048122:+
COAD	cis	rs2564921	0.73	rs58492539	ENSG00000280417.1	RP11-5O17.1	3.91	0.000117	0.0255	0.26	0.24	Height;	chr3:53052712	chr3:53046166~53048122:+
COAD	cis	rs9652601	0.959	rs9652582	ENSG00000274038.1	RP11-66H6.4	-3.91	0.000117	0.0255	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11080707	chr16:11056556~11057034:+
COAD	cis	rs7584330	0.504	rs11883500	ENSG00000234949.2	AC104667.3	-3.91	0.000117	0.0255	-0.36	-0.24	Prostate cancer;	chr2:237525791	chr2:237591020~237595981:+
COAD	cis	rs913655	0.508	rs1907042	ENSG00000240291.1	RP11-499P20.2	-3.91	0.000117	0.0255	-0.28	-0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18719329	chr10:18513115~18545651:-
COAD	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-3.91	0.000117	0.0255	-0.3	-0.24	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-3.91	0.000117	0.0255	-0.3	-0.24	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
COAD	cis	rs6088813	0.663	rs2425056	ENSG00000269202.1	RP4-614O4.12	-3.91	0.000117	0.0255	-0.22	-0.24	Height;	chr20:35321442	chr20:35201747~35203288:-
COAD	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-3.91	0.000117	0.0255	-0.35	-0.24	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
COAD	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-3.91	0.000117	0.0255	-0.35	-0.24	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
COAD	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	3.91	0.000117	0.0255	0.26	0.24	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
COAD	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	3.91	0.000117	0.0255	0.26	0.24	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
COAD	cis	rs581080	0.663	rs478971	ENSG00000215236.3	RPL7P33	-3.91	0.000117	0.0255	-0.3	-0.24	HDL cholesterol;Total cholesterol levels;HDL cholesterol levels;Cholesterol, total;	chr9:15285829	chr9:15361393~15362134:+
COAD	cis	rs80130819	0.688	rs11168455	ENSG00000273765.1	RP11-370I10.11	3.91	0.000117	0.0255	0.28	0.24	Prostate cancer;	chr12:48199009	chr12:48360920~48361377:+
COAD	cis	rs80130819	0.688	rs4760698	ENSG00000273765.1	RP11-370I10.11	3.91	0.000117	0.0255	0.28	0.24	Prostate cancer;	chr12:48199089	chr12:48360920~48361377:+
COAD	cis	rs2408955	0.522	rs7139330	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000117	0.0255	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48089701	chr12:48350945~48442411:+
COAD	cis	rs2408955	0.522	rs2051851	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000117	0.0255	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48092157	chr12:48350945~48442411:+
COAD	cis	rs2408955	0.522	rs973398	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000117	0.0255	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48097265	chr12:48350945~48442411:+
COAD	cis	rs6921919	0.789	rs6456814	ENSG00000272009.1	RP1-313I6.12	3.91	0.000117	0.0255	0.29	0.24	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28078792~28081130:-
COAD	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	3.91	0.000118	0.0255	0.32	0.24	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-3.91	0.000118	0.0255	-0.31	-0.24	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
COAD	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	3.91	0.000118	0.0255	0.32	0.24	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
COAD	cis	rs4843747	0.749	rs12102841	ENSG00000205037.2	RP11-863P13.4	-3.91	0.000118	0.0255	-0.3	-0.24	Menopause (age at onset);	chr16:88038968	chr16:88088041~88100985:-
COAD	cis	rs7572733	0.773	rs11690844	ENSG00000222017.1	AC011997.1	3.91	0.000118	0.0255	0.26	0.24	Dermatomyositis;	chr2:197650812	chr2:197693106~197774823:+
COAD	cis	rs2564921	0.679	rs12635933	ENSG00000280417.1	RP11-5O17.1	3.91	0.000118	0.0255	0.26	0.24	Height;	chr3:53015087	chr3:53046166~53048122:+
COAD	cis	rs2638953	0.962	rs11049570	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000118	0.0255	-0.26	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390218	chr12:28163298~28190738:-
COAD	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-3.91	0.000118	0.0255	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
COAD	cis	rs10137082	0.606	rs4671	ENSG00000279656.1	RP11-298I3.6	-3.91	0.000118	0.0255	-0.3	-0.24	Type 1 diabetes;	chr14:23356504	chr14:23023083~23024217:-
COAD	cis	rs2708377	0.656	rs116607079	ENSG00000212125.2	TAS2R15P	3.91	0.000118	0.0255	0.43	0.24	Bitter taste perception;	chr12:11109445	chr12:10964425~10965352:-
COAD	cis	rs2708377	0.929	rs73066828	ENSG00000212125.2	TAS2R15P	3.91	0.000118	0.0255	0.43	0.24	Bitter taste perception;	chr12:11118055	chr12:10964425~10965352:-
COAD	cis	rs2708377	0.656	rs73066852	ENSG00000212125.2	TAS2R15P	3.91	0.000118	0.0255	0.43	0.24	Bitter taste perception;	chr12:11123942	chr12:10964425~10965352:-
COAD	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	3.91	0.000118	0.0255	0.28	0.24	Height;	chr4:55484534	chr4:55547112~55547889:+
COAD	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	3.91	0.000118	0.0255	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
COAD	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	3.91	0.000118	0.0255	0.23	0.24	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
COAD	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	3.91	0.000118	0.0255	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	3.91	0.000118	0.0255	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
COAD	cis	rs7646881	0.544	rs10513527	ENSG00000272087.1	RP11-379F4.7	3.91	0.000118	0.0255	0.37	0.24	Tetralogy of Fallot;	chr3:158583893	chr3:158693120~158693768:-
COAD	cis	rs17772222	1	rs17772288	ENSG00000258789.1	RP11-507K2.3	-3.91	0.000118	0.0255	-0.32	-0.24	Coronary artery calcification;	chr14:88361022	chr14:88551597~88552493:+
COAD	cis	rs1150668	0.768	rs1150716	ENSG00000272009.1	RP1-313I6.12	3.91	0.000118	0.0255	0.26	0.24	Pubertal anthropometrics;	chr6:28294921	chr6:28078792~28081130:-
COAD	cis	rs7615952	0.546	rs2979333	ENSG00000241278.1	ENPP7P4	3.91	0.000118	0.0255	0.29	0.24	Blood pressure (smoking interaction);	chr3:125641499	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.546	rs111812401	ENSG00000241278.1	ENPP7P4	3.91	0.000118	0.0255	0.29	0.24	Blood pressure (smoking interaction);	chr3:125642651	chr3:125848223~125909372:+
COAD	cis	rs7615952	0.546	rs2979350	ENSG00000241278.1	ENPP7P4	3.91	0.000118	0.0255	0.29	0.24	Blood pressure (smoking interaction);	chr3:125643371	chr3:125848223~125909372:+
COAD	cis	rs4242434	0.927	rs13264187	ENSG00000246582.2	RP11-1149O23.3	-3.91	0.000118	0.0255	-0.31	-0.24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22648585	chr8:23224471~23230926:+
COAD	cis	rs440932	1	rs440932	ENSG00000233609.3	RP11-62H7.2	3.91	0.000118	0.0255	0.29	0.24	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8961200~8979025:+
COAD	cis	rs10819861	0.645	rs12686105	ENSG00000238251.2	RP11-172F4.2	-3.91	0.000118	0.0256	-0.29	-0.24	Electrocardiographic traits;	chr9:96090021	chr9:96407284~96407797:+
COAD	cis	rs10819861	0.645	rs10739800	ENSG00000238251.2	RP11-172F4.2	-3.91	0.000118	0.0256	-0.29	-0.24	Electrocardiographic traits;	chr9:96090888	chr9:96407284~96407797:+
COAD	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-3.91	0.000118	0.0256	-0.25	-0.24	Height;	chr4:55526646	chr4:55363971~55395847:-
COAD	cis	rs11157436	0.509	rs12589104	ENSG00000211812.1	TRAV26-2	-3.91	0.000118	0.0256	-0.23	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22202583~22203368:+
COAD	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000118	0.0256	0.39	0.24	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
COAD	cis	rs2732480	0.577	rs1489109	ENSG00000269514.1	RP11-370I10.12	3.91	0.000118	0.0256	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs1489108	ENSG00000269514.1	RP11-370I10.12	3.91	0.000118	0.0256	0.31	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48198387~48202031:+
COAD	cis	rs3126085	0.877	rs1969019	ENSG00000237975.5	FLG-AS1	-3.91	0.000118	0.0256	-0.26	-0.24	Atopic dermatitis;	chr1:152239026	chr1:152168125~152445456:+
COAD	cis	rs9847710	0.967	rs2581824	ENSG00000280417.1	RP11-5O17.1	3.91	0.000118	0.0256	0.26	0.24	Ulcerative colitis;	chr3:52988392	chr3:53046166~53048122:+
COAD	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-3.91	0.000118	0.0256	-0.24	-0.24	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
COAD	cis	rs1555133	0.694	rs6141680	ENSG00000101898.5	MCTS2P	3.91	0.000118	0.0256	0.26	0.24	Monocyte count;	chr20:32341389	chr20:31547504~31548049:+
COAD	cis	rs9487051	1	rs6568570	ENSG00000219700.1	PTCHD3P3	3.91	0.000118	0.0256	0.26	0.24	Reticulocyte fraction of red cells;	chr6:109292038	chr6:109288571~109290503:-
COAD	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	-3.91	0.000118	0.0256	-0.28	-0.24	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
COAD	cis	rs728616	0.614	rs17678338	ENSG00000225484.5	NUTM2B-AS1	-3.91	0.000118	0.0256	-0.39	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79663088~79826594:-
COAD	cis	rs9907295	0.591	rs78655848	ENSG00000270977.1	AC015849.16	-3.91	0.000118	0.0256	-0.3	-0.24	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35893707~35911023:-
COAD	cis	rs9907295	0.591	rs9908928	ENSG00000270977.1	AC015849.16	-3.91	0.000118	0.0256	-0.3	-0.24	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35893707~35911023:-
COAD	cis	rs494562	0.892	rs638745	ENSG00000234155.1	RP11-30P6.6	-3.91	0.000118	0.0256	-0.42	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85405869	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs550499	ENSG00000234155.1	RP11-30P6.6	-3.91	0.000118	0.0256	-0.42	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85405884	chr6:85387219~85390186:-
COAD	cis	rs494562	1	rs527670	ENSG00000234155.1	RP11-30P6.6	-3.91	0.000118	0.0256	-0.42	-0.24	Metabolic traits;Blood metabolite levels;	chr6:85406061	chr6:85387219~85390186:-
COAD	cis	rs9868809	0.772	rs9809222	ENSG00000225399.4	RP11-3B7.1	-3.91	0.000118	0.0256	-0.35	-0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676978	chr3:49260085~49261316:+
COAD	cis	rs6840360	0.681	rs9968292	ENSG00000251611.1	RP11-610P16.1	-3.91	0.000118	0.0256	-0.23	-0.24	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151407551~151408835:-
COAD	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-3.91	0.000118	0.0256	-0.3	-0.24	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
COAD	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-3.91	0.000118	0.0256	-0.3	-0.24	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
COAD	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-3.91	0.000118	0.0256	-0.25	-0.24	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
COAD	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	3.91	0.000118	0.0256	0.3	0.24	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
COAD	cis	rs9532669	0.926	rs9532647	ENSG00000277662.1	RP11-74J13.9	-3.91	0.000118	0.0256	-0.22	-0.24	Cervical cancer;	chr13:40881799	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.89	rs9525420	ENSG00000277662.1	RP11-74J13.9	-3.91	0.000118	0.0256	-0.22	-0.24	Cervical cancer;	chr13:40882628	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs7324383	ENSG00000277662.1	RP11-74J13.9	-3.91	0.000118	0.0256	-0.22	-0.24	Cervical cancer;	chr13:40882754	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532648	ENSG00000277662.1	RP11-74J13.9	-3.91	0.000118	0.0256	-0.22	-0.24	Cervical cancer;	chr13:40882795	chr13:41229180~41229676:-
COAD	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	3.91	0.000118	0.0256	0.3	0.24	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
COAD	cis	rs1559040	0.527	rs114498542	ENSG00000272156.1	RP11-477N3.1	-3.91	0.000118	0.0256	-0.46	-0.24	Sudden cardiac arrest;	chr2:54006169	chr2:54082554~54085066:+
COAD	cis	rs1559040	0.722	rs72799301	ENSG00000272156.1	RP11-477N3.1	-3.91	0.000118	0.0256	-0.46	-0.24	Sudden cardiac arrest;	chr2:54009336	chr2:54082554~54085066:+
COAD	cis	rs1559040	0.79	rs11676433	ENSG00000272156.1	RP11-477N3.1	-3.91	0.000118	0.0256	-0.46	-0.24	Sudden cardiac arrest;	chr2:54009788	chr2:54082554~54085066:+
COAD	cis	rs1559040	0.79	rs998381	ENSG00000272156.1	RP11-477N3.1	-3.91	0.000118	0.0256	-0.46	-0.24	Sudden cardiac arrest;	chr2:54011519	chr2:54082554~54085066:+
COAD	cis	rs73173548	0.502	rs12187348	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000118	0.0256	0.26	0.24	Macular telangiectasia type 2;	chr5:88424724	chr5:88268895~88436685:+
COAD	cis	rs13256369	0.826	rs12678414	ENSG00000253981.4	ALG1L13P	3.91	0.000118	0.0256	0.33	0.24	Obesity-related traits;	chr8:8728506	chr8:8236003~8244667:-
COAD	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	3.91	0.000118	0.0256	0.28	0.24	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
COAD	cis	rs752010	0.746	rs11210499	ENSG00000230638.4	RP11-486B10.4	3.91	0.000118	0.0256	0.27	0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41624032	chr1:41542069~41544310:+
COAD	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	3.91	0.000118	0.0256	0.22	0.24	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
COAD	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	3.91	0.000118	0.0256	0.28	0.24	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
COAD	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	3.91	0.000118	0.0256	0.44	0.24	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
COAD	cis	rs884366	1	rs4946962	ENSG00000219700.1	PTCHD3P3	-3.91	0.000118	0.0256	-0.31	-0.24	HDL cholesterol;HDL cholesterol levels;	chr6:109325637	chr6:109288571~109290503:-
COAD	cis	rs2836974	0.931	rs12151994	ENSG00000255568.3	BRWD1-AS2	3.91	0.000118	0.0256	0.24	0.24	Cognitive function;	chr21:39318471	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.966	rs7283516	ENSG00000255568.3	BRWD1-AS2	3.91	0.000118	0.0256	0.24	0.24	Cognitive function;	chr21:39318611	chr21:39313935~39314962:+
COAD	cis	rs12530	0.651	rs2072816	ENSG00000241954.1	RP1-149A16.17	-3.91	0.000118	0.0256	-0.31	-0.24	IgG glycosylation;	chr22:32394411	chr22:32383786~32385631:+
COAD	cis	rs656319	0.513	rs34990153	ENSG00000254936.4	AF131215.3	-3.91	0.000118	0.0256	-0.27	-0.24	Myopia (pathological);	chr8:10138879	chr8:11123381~11126064:-
COAD	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	3.91	0.000118	0.0256	0.35	0.24	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
COAD	cis	rs1048886	0.872	rs12209965	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70568193	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs7757026	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70570891	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs12197942	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70571649	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs12197963	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70571718	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs73480275	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70572421	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs76911285	ENSG00000271967.1	RP11-134K13.4	-3.91	0.000118	0.0256	-0.34	-0.24	Type 2 diabetes;	chr6:70572479	chr6:70596438~70596980:+
COAD	cis	rs875971	1	rs7792762	ENSG00000224316.1	RP11-479O9.2	3.91	0.000118	0.0257	0.25	0.24	Aortic root size;	chr7:66539151	chr7:65773620~65802067:+
COAD	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-3.91	0.000119	0.0257	-0.37	-0.24	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
COAD	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	3.91	0.000119	0.0257	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
COAD	cis	rs8026198	0.929	rs3743006	ENSG00000260571.1	BNIP3P5	-3.91	0.000119	0.0257	-0.34	-0.24	Fibrinogen levels;	chr15:42353570	chr15:42313687~42314386:+
COAD	cis	rs7294478	0.648	rs2290237	ENSG00000256967.1	RP11-273B20.1	3.91	0.000119	0.0257	0.2	0.24	Neuritic plaque;	chr12:7124640	chr12:7129079~7131198:-
COAD	cis	rs984222	0.967	rs1409157	ENSG00000231365.4	RP11-418J17.1	-3.91	0.000119	0.0257	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961864	chr1:119140396~119275973:+
COAD	cis	rs984222	0.967	rs10923713	ENSG00000231365.4	RP11-418J17.1	-3.91	0.000119	0.0257	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118967864	chr1:119140396~119275973:+
COAD	cis	rs7837649	0.824	rs7007731	ENSG00000253661.1	ZFHX4-AS1	3.91	0.000119	0.0257	0.22	0.24	Monobrow;	chr8:76783496	chr8:76491200~76683278:-
COAD	cis	rs4938303	0.549	rs12785772	ENSG00000254851.1	RP11-109L13.1	3.91	0.000119	0.0257	0.31	0.24	Triglycerides;	chr11:116692892	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.549	rs12785990	ENSG00000254851.1	RP11-109L13.1	3.91	0.000119	0.0257	0.31	0.24	Triglycerides;	chr11:116692990	chr11:117135528~117138582:+
COAD	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-3.91	0.000119	0.0257	-0.29	-0.24	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
COAD	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-3.91	0.000119	0.0257	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
COAD	cis	rs4242434	0.889	rs4592028	ENSG00000261026.1	CTD-3247F14.2	3.91	0.000119	0.0257	0.32	0.24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22591971	chr8:22679013~22684009:-
COAD	cis	rs3738443	1	rs75028588	ENSG00000259865.1	RP11-488L18.10	3.91	0.000119	0.0257	0.28	0.24	Alcohol dependence;	chr1:247208350	chr1:247187281~247188526:-
COAD	cis	rs3738443	1	rs56340510	ENSG00000259865.1	RP11-488L18.10	3.91	0.000119	0.0257	0.28	0.24	Alcohol dependence;	chr1:247208707	chr1:247187281~247188526:-
COAD	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	3.91	0.000119	0.0257	0.32	0.24	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
COAD	cis	rs884366	0.964	rs4946953	ENSG00000219700.1	PTCHD3P3	-3.91	0.000119	0.0257	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr6:109262428	chr6:109288571~109290503:-
COAD	cis	rs860295	1	rs6427286	ENSG00000223503.1	RP11-29H23.6	-3.91	0.000119	0.0257	-0.3	-0.24	Body mass index;	chr1:155753506	chr1:155590601~155591262:-
COAD	cis	rs860295	1	rs7541060	ENSG00000223503.1	RP11-29H23.6	-3.91	0.000119	0.0257	-0.3	-0.24	Body mass index;	chr1:155758297	chr1:155590601~155591262:-
COAD	cis	rs1387259	0.698	rs4579969	ENSG00000257735.1	RP11-370I10.6	-3.91	0.000119	0.0257	-0.27	-0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48350945~48442411:+
COAD	cis	rs2638953	0.962	rs11049540	ENSG00000247934.4	RP11-967K21.1	-3.91	0.000119	0.0258	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28337959	chr12:28163298~28190738:-
COAD	cis	rs891378	0.959	rs7533825	ENSG00000274245.1	RP11-357P18.2	-3.91	0.000119	0.0258	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248817	chr1:207372559~207373252:+
COAD	cis	rs11089937	0.616	rs4991798	ENSG00000211638.2	IGLV8-61	-3.91	0.000119	0.0258	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs4991799	ENSG00000211638.2	IGLV8-61	-3.91	0.000119	0.0258	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs4991800	ENSG00000211638.2	IGLV8-61	-3.91	0.000119	0.0258	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22098700~22099212:+
COAD	cis	rs7260598	0.792	rs17620048	ENSG00000268442.1	CTD-2027I19.2	3.91	0.000119	0.0258	0.36	0.24	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:24162370~24163425:-
COAD	cis	rs6730558	0.531	rs12993862	ENSG00000235092.4	ID2-AS1	-3.91	0.000119	0.0258	-0.31	-0.24	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8613241	chr2:8666636~8681863:-
COAD	cis	rs6730558	0.531	rs12993868	ENSG00000235092.4	ID2-AS1	-3.91	0.000119	0.0258	-0.31	-0.24	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8613246	chr2:8666636~8681863:-
COAD	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	3.91	0.000119	0.0258	0.3	0.24	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
COAD	cis	rs4819052	0.851	rs8130285	ENSG00000227039.5	ITGB2-AS1	-3.91	0.000119	0.0258	-0.2	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:44921051~44929678:+
COAD	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	3.91	0.000119	0.0258	0.26	0.24	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
COAD	cis	rs10819861	0.645	rs10760765	ENSG00000238251.2	RP11-172F4.2	-3.91	0.000119	0.0258	-0.3	-0.24	Electrocardiographic traits;	chr9:96098947	chr9:96407284~96407797:+
COAD	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-3.91	0.000119	0.0258	-0.39	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
COAD	cis	rs2832191	0.655	rs2247110	ENSG00000176054.6	RPL23P2	-3.91	0.000119	0.0258	-0.25	-0.24	Dental caries;	chr21:28951566	chr21:28997613~28998033:-
COAD	cis	rs11098499	0.955	rs35434465	ENSG00000250412.1	KLHL2P1	3.91	0.000119	0.0258	0.32	0.24	Corneal astigmatism;	chr4:119248223	chr4:119334329~119378233:+
COAD	cis	rs875971	0.793	rs460678	ENSG00000230189.5	GS1-124K5.2	3.91	0.00012	0.0258	0.2	0.24	Aortic root size;	chr7:66062213	chr7:66409143~66490059:-
COAD	cis	rs911119	0.866	rs2405393	ENSG00000270001.1	RP11-218C14.8	-3.91	0.00012	0.0258	-0.29	-0.24	Chronic kidney disease;	chr20:23588755	chr20:23631826~23632316:-
COAD	cis	rs911119	0.866	rs4346460	ENSG00000270001.1	RP11-218C14.8	-3.91	0.00012	0.0258	-0.29	-0.24	Chronic kidney disease;	chr20:23588763	chr20:23631826~23632316:-
COAD	cis	rs4568518	0.535	rs4555993	ENSG00000279048.1	RP11-511H23.2	-3.91	0.00012	0.0258	-0.19	-0.24	Measles;	chr7:18022944	chr7:17940503~17942922:+
COAD	cis	rs1035144	0.506	rs2371416	ENSG00000258999.1	RP11-114N19.3	3.91	0.00012	0.0258	0.26	0.24	Male sexual orientation;	chr14:80809328	chr14:81107033~81170414:-
COAD	cis	rs7824557	0.767	rs6985460	ENSG00000248896.2	CTD-2135J3.3	3.91	0.00012	0.0258	0.34	0.24	Retinal vascular caliber;	chr8:11313578	chr8:10729314~10771392:+
COAD	cis	rs2564921	0.73	rs62255895	ENSG00000280417.1	RP11-5O17.1	3.91	0.00012	0.0258	0.26	0.24	Height;	chr3:53027969	chr3:53046166~53048122:+
COAD	cis	rs11098499	0.687	rs71610270	ENSG00000249244.1	RP11-548H18.2	3.91	0.00012	0.0259	0.31	0.24	Corneal astigmatism;	chr4:119366281	chr4:119391831~119395335:-
COAD	cis	rs4072705	0.967	rs4144630	ENSG00000224020.1	MIR181A2HG	-3.91	0.00012	0.0259	-0.29	-0.24	Menarche (age at onset);	chr9:124676921	chr9:124658467~124698631:+
COAD	cis	rs4879656	1	rs4879656	ENSG00000225693.1	LAGE3P1	-3.91	0.00012	0.0259	-0.28	-0.24	Menopause (age at onset);	chr9:33012384	chr9:33019682~33020165:-
COAD	cis	rs6585424	1	rs6585454	ENSG00000234382.2	RP11-40F6.1	3.91	0.00012	0.0259	0.38	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:80233664~80245367:+
COAD	cis	rs2711721	0.56	rs2522259	ENSG00000280054.1	RP1-197B17.7	-3.91	0.00012	0.0259	-0.29	-0.24	Prostate cancer (SNP x SNP interaction);	chr12:46986857	chr12:47728151~47730598:-
COAD	cis	rs2711721	0.56	rs2522260	ENSG00000280054.1	RP1-197B17.7	-3.91	0.00012	0.0259	-0.29	-0.24	Prostate cancer (SNP x SNP interaction);	chr12:46986858	chr12:47728151~47730598:-
COAD	cis	rs2839186	0.585	rs2839154	ENSG00000239415.1	AP001469.9	-3.91	0.00012	0.0259	-0.24	-0.24	Testicular germ cell tumor;	chr21:46217846	chr21:46251549~46254133:-
COAD	cis	rs7829975	0.682	rs7013471	ENSG00000173295.6	FAM86B3P	-3.91	0.00012	0.0259	-0.29	-0.24	Mood instability;	chr8:8829815	chr8:8228595~8244865:+
COAD	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	3.91	0.00012	0.0259	0.27	0.24	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	3.91	0.00012	0.0259	0.27	0.24	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	3.91	0.00012	0.0259	0.27	0.24	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	3.91	0.00012	0.0259	0.27	0.24	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	3.91	0.00012	0.0259	0.27	0.24	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
COAD	cis	rs7204230	1	rs1894903	ENSG00000261056.2	RP11-454F8.2	3.91	0.00012	0.0259	0.29	0.24	Fibrinogen;	chr16:53291779	chr16:53298224~53299792:+
COAD	cis	rs7829975	0.659	rs4382480	ENSG00000233609.3	RP11-62H7.2	3.91	0.00012	0.0259	0.27	0.24	Mood instability;	chr8:8863963	chr8:8961200~8979025:+
COAD	cis	rs2832191	0.692	rs2245517	ENSG00000176054.6	RPL23P2	3.91	0.00012	0.0259	0.24	0.24	Dental caries;	chr21:28985647	chr21:28997613~28998033:-
COAD	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	3.91	0.00012	0.0259	0.38	0.24	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
COAD	cis	rs875971	0.862	rs1167408	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66091121	chr7:65773620~65802067:+
COAD	cis	rs875971	0.83	rs1167406	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66091949	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs709609	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66095574	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs1167399	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66096890	chr7:65773620~65802067:+
COAD	cis	rs875971	0.825	rs59466412	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66100371	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs57866200	ENSG00000224316.1	RP11-479O9.2	-3.91	0.00012	0.0259	-0.26	-0.24	Aortic root size;	chr7:66100405	chr7:65773620~65802067:+
COAD	cis	rs11229555	0.645	rs11229428	ENSG00000254602.1	AP000662.4	-3.91	0.00012	0.0259	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58412909	chr11:57638024~57652790:+
COAD	cis	rs2688608	0.618	rs28553894	ENSG00000271816.1	BMS1P4	3.91	0.00012	0.0259	0.22	0.24	Inflammatory bowel disease;	chr10:73730085	chr10:73699151~73730487:-
COAD	cis	rs2688608	0.618	rs28718766	ENSG00000271816.1	BMS1P4	3.91	0.00012	0.0259	0.22	0.24	Inflammatory bowel disease;	chr10:73730086	chr10:73699151~73730487:-
COAD	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	3.91	0.00012	0.0259	0.32	0.24	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
COAD	cis	rs172166	0.637	rs1233708	ENSG00000204709.4	LINC01556	3.91	0.00012	0.0259	0.3	0.24	Cardiac Troponin-T levels;	chr6:28205441	chr6:28943877~28944537:+
COAD	cis	rs12682352	0.602	rs6993494	ENSG00000173295.6	FAM86B3P	3.91	0.00012	0.0259	0.27	0.24	Neuroticism;	chr8:8809934	chr8:8228595~8244865:+
COAD	cis	rs2408955	0.522	rs4760679	ENSG00000257735.1	RP11-370I10.6	-3.91	0.00012	0.0259	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48067852	chr12:48350945~48442411:+
COAD	cis	rs2836974	0.666	rs12626405	ENSG00000255568.3	BRWD1-AS2	-3.91	0.00012	0.0259	-0.22	-0.24	Cognitive function;	chr21:39291195	chr21:39313935~39314962:+
COAD	cis	rs8062405	0.573	rs11645306	ENSG00000261067.5	RP11-264B17.3	-3.91	0.00012	0.0259	-0.18	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28974804~28990783:+
COAD	cis	rs8062405	0.573	rs8045689	ENSG00000261067.5	RP11-264B17.3	-3.91	0.00012	0.0259	-0.18	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28974804~28990783:+
COAD	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-3.91	0.00012	0.026	-0.24	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
COAD	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-3.91	0.00012	0.026	-0.24	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
COAD	cis	rs9652601	0.748	rs8064154	ENSG00000274038.1	RP11-66H6.4	-3.91	0.00012	0.026	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11125562	chr16:11056556~11057034:+
COAD	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-3.91	0.00012	0.026	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
COAD	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-3.91	0.00012	0.026	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
COAD	cis	rs7212590	0.748	rs62081818	ENSG00000264049.1	MIR4737	-3.91	0.00012	0.026	-0.34	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813268	chr17:60043025~60043105:-
COAD	cis	rs7212590	0.748	rs59685433	ENSG00000264049.1	MIR4737	-3.91	0.00012	0.026	-0.34	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813846	chr17:60043025~60043105:-
COAD	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-3.91	0.00012	0.026	-0.25	-0.24	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
COAD	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-3.91	0.00012	0.026	-0.25	-0.24	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
COAD	cis	rs113835537	0.529	rs11227512	ENSG00000258297.1	RP11-658F2.8	-3.91	0.00012	0.026	-0.24	-0.24	Airway imaging phenotypes;	chr11:66513820	chr11:66666036~66668374:+
COAD	cis	rs10876993	0.821	rs1678522	ENSG00000270039.1	RP11-571M6.17	3.91	0.00012	0.026	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57656140	chr12:57803838~57804415:+
COAD	cis	rs870355	1	rs3794742	ENSG00000267679.1	EIF5AP2	-3.91	0.00012	0.026	-0.27	-0.24	Vitiligo;	chr17:78169467	chr17:78157403~78159135:+
COAD	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-3.91	0.00012	0.026	-0.31	-0.24	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
COAD	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-3.91	0.00012	0.026	-0.39	-0.24	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
COAD	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-3.91	0.00012	0.026	-0.39	-0.24	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
COAD	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-3.91	0.00012	0.026	-0.39	-0.24	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
COAD	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-3.91	0.00012	0.026	-0.39	-0.24	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
COAD	cis	rs728616	0.867	rs56000427	ENSG00000225484.5	NUTM2B-AS1	-3.91	0.00012	0.026	-0.47	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:79663088~79826594:-
COAD	cis	rs2929278	0.617	rs3087657	ENSG00000275601.1	AC011330.13	-3.91	0.00012	0.026	-0.28	-0.24	Schizophrenia;	chr15:43771661	chr15:43642389~43643023:-
COAD	cis	rs13315871	0.86	rs9842759	ENSG00000273493.1	RP11-80H18.4	3.91	0.00012	0.026	0.42	0.24	Cholesterol, total;	chr3:58259021	chr3:58329965~58330118:+
COAD	cis	rs13315871	0.929	rs9842917	ENSG00000273493.1	RP11-80H18.4	3.91	0.00012	0.026	0.42	0.24	Cholesterol, total;	chr3:58259073	chr3:58329965~58330118:+
COAD	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-3.91	0.00012	0.026	-0.27	-0.24	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
COAD	cis	rs9652601	0.779	rs12935413	ENSG00000274038.1	RP11-66H6.4	-3.91	0.00012	0.026	-0.28	-0.24	Systemic lupus erythematosus;	chr16:11116590	chr16:11056556~11057034:+
COAD	cis	rs987724	0.593	rs13316183	ENSG00000240875.4	LINC00886	-3.9	0.000121	0.026	-0.22	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156942983	chr3:156747346~156817062:-
COAD	cis	rs12497850	0.644	rs11928552	ENSG00000225399.4	RP11-3B7.1	3.9	0.000121	0.026	0.26	0.24	Parkinson's disease;	chr3:48702450	chr3:49260085~49261316:+
COAD	cis	rs654950	0.934	rs641974	ENSG00000230638.4	RP11-486B10.4	3.9	0.000121	0.026	0.28	0.24	Airway imaging phenotypes;	chr1:41536466	chr1:41542069~41544310:+
COAD	cis	rs2179367	0.632	rs2143075	ENSG00000216906.2	RP11-350J20.9	3.9	0.000121	0.0261	0.33	0.24	Dupuytren's disease;	chr6:149425507	chr6:149904243~149906418:+
COAD	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-3.9	0.000121	0.0261	-0.28	-0.24	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
COAD	cis	rs8058578	1	rs7198250	ENSG00000260487.1	RP11-297C4.3	3.9	0.000121	0.0261	0.3	0.24	Multiple myeloma;	chr16:30735501	chr16:30480588~30481346:-
COAD	cis	rs8058578	1	rs6565201	ENSG00000260487.1	RP11-297C4.3	3.9	0.000121	0.0261	0.3	0.24	Multiple myeloma;	chr16:30735870	chr16:30480588~30481346:-
COAD	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	3.9	0.000121	0.0261	0.28	0.24	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
COAD	cis	rs1930961	0.702	rs7286366	ENSG00000272942.1	CTA-246H3.12	-3.9	0.000121	0.0261	-0.56	-0.24	Bipolar disorder with mood-incongruent psychosis;	chr22:25514348	chr22:25434324~25435070:-
COAD	cis	rs5753037	0.547	rs140134	ENSG00000279159.1	RP3-394A18.1	-3.9	0.000121	0.0261	-0.16	-0.24	Type 1 diabetes;	chr22:29767343	chr22:29978950~30028236:-
COAD	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	3.9	0.000121	0.0261	0.27	0.24	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
COAD	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-3.9	0.000121	0.0261	-0.24	-0.24	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
COAD	cis	rs6687821	0.515	rs4656139	ENSG00000261737.1	RP4-612B15.3	3.9	0.000121	0.0261	0.31	0.24	Yeast infection;	chr1:87059180	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs4431894	ENSG00000261737.1	RP4-612B15.3	3.9	0.000121	0.0261	0.31	0.24	Yeast infection;	chr1:87063801	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs7543542	ENSG00000261737.1	RP4-612B15.3	3.9	0.000121	0.0261	0.31	0.24	Yeast infection;	chr1:87069356	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs2390264	ENSG00000261737.1	RP4-612B15.3	3.9	0.000121	0.0261	0.31	0.24	Yeast infection;	chr1:87072743	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs2798674	ENSG00000261737.1	RP4-612B15.3	3.9	0.000121	0.0261	0.31	0.24	Yeast infection;	chr1:87074834	chr1:86703502~86704462:-
COAD	cis	rs6460942	0.597	rs13232817	ENSG00000226690.5	AC005281.1	3.9	0.000121	0.0261	0.45	0.24	Coronary artery disease;	chr7:12512283	chr7:12496429~12541910:+
COAD	cis	rs7577696	0.539	rs2280972	ENSG00000272716.1	RP11-563N4.1	-3.9	0.000121	0.0261	-0.28	-0.24	Inflammatory biomarkers;	chr2:32152892	chr2:32165046~32165757:-
COAD	cis	rs480407	0.581	rs55709047	ENSG00000232320.6	AC009299.5	3.9	0.000121	0.0261	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160775514	chr2:161340816~161341326:-
COAD	cis	rs7615952	0.932	rs13314869	ENSG00000272840.1	RP11-379B18.6	3.9	0.000121	0.0261	0.33	0.24	Blood pressure (smoking interaction);	chr3:125925826	chr3:125774714~125797953:+
COAD	cis	rs796825	0.719	rs787202	ENSG00000240661.1	RP11-174O3.3	3.9	0.000121	0.0261	0.31	0.24	HIV-1 susceptibility;	chr3:120280774	chr3:120349510~120367998:+
COAD	cis	rs597539	0.616	rs72945243	ENSG00000255741.1	RP11-757G1.5	-3.9	0.000121	0.0261	-0.3	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68941503~68942852:-
COAD	cis	rs2307394	1	rs13026220	ENSG00000281469.1	RP11-567F11.1	3.9	0.000121	0.0261	0.29	0.24	Urate levels;	chr2:147828890	chr2:148044380~148044894:+
COAD	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	3.9	0.000121	0.0261	0.31	0.24	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	3.9	0.000121	0.0261	0.31	0.24	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
COAD	cis	rs28374715	0.783	rs11630656	ENSG00000247556.5	OIP5-AS1	3.9	0.000121	0.0261	0.35	0.24	Ulcerative colitis;	chr15:41278711	chr15:41283990~41309737:+
COAD	cis	rs73607972	0.598	rs35726119	ENSG00000275191.1	RP11-36I17.2	-3.9	0.000121	0.0261	-0.33	-0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53521927	chr16:53628256~53628816:-
COAD	cis	rs8022206	0.812	rs418467	ENSG00000259502.1	RP11-643G16.3	3.9	0.000121	0.0261	0.32	0.24	Platelet count;Mean platelet volume;	chr14:68125754	chr14:67610986~67613864:+
COAD	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-3.9	0.000121	0.0261	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-3.9	0.000121	0.0261	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-3.9	0.000121	0.0261	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
COAD	cis	rs2337406	1	rs17095456	ENSG00000280411.1	IGHV1-69-2	-3.9	0.000121	0.0261	-0.18	-0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106762092~106762588:-
COAD	cis	rs9450351	0.744	rs6912150	ENSG00000203875.9	SNHG5	-3.9	0.000121	0.0261	-0.44	-0.24	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85660950~85678736:-
COAD	cis	rs17685	0.702	rs6960598	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000121	0.0261	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs10235738	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000121	0.0261	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs6953342	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000121	0.0261	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs10952842	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000121	0.0261	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs6464994	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000121	0.0261	-0.24	-0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76043977~76045963:-
COAD	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-3.9	0.000121	0.0261	-0.27	-0.24	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
COAD	cis	rs7760535	0.763	rs10457241	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000121	0.0261	-0.21	-0.24	Metabolic traits;	chr6:111527831	chr6:111277932~111278742:+
COAD	cis	rs597539	0.69	rs608810	ENSG00000255741.1	RP11-757G1.5	-3.9	0.000121	0.0261	-0.33	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68941503~68942852:-
COAD	cis	rs76076331	0.838	rs6704744	ENSG00000272275.1	RP11-791G15.2	3.9	0.000121	0.0261	0.35	0.24	Educational attainment (college completion);Educational attainment (years of education);	chr2:10840089	chr2:10767875~10770058:-
COAD	cis	rs76076331	0.838	rs6737620	ENSG00000272275.1	RP11-791G15.2	3.9	0.000121	0.0261	0.35	0.24	Educational attainment (college completion);Educational attainment (years of education);	chr2:10840413	chr2:10767875~10770058:-
COAD	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	3.9	0.000121	0.0262	0.29	0.24	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
COAD	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-3.9	0.000121	0.0262	-0.42	-0.24	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
COAD	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-3.9	0.000121	0.0262	-0.32	-0.24	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
COAD	cis	rs2337406	0.925	rs76288499	ENSG00000280411.1	IGHV1-69-2	-3.9	0.000121	0.0262	-0.19	-0.24	Alzheimer's disease (late onset);	chr14:106686309	chr14:106762092~106762588:-
COAD	cis	rs867186	1	rs6579210	ENSG00000201151.1	SNORD56	3.9	0.000121	0.0262	0.37	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35017999	chr20:35117136~35117207:-
COAD	cis	rs84178	0.733	rs231873	ENSG00000230834.1	AC068580.7	-3.9	0.000121	0.0262	-0.34	-0.24	Glomerular filtration rate (creatinine);	chr11:2764312	chr11:1776930~1778388:-
COAD	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	3.9	0.000121	0.0262	0.36	0.24	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
COAD	cis	rs7138300	0.528	rs4760786	ENSG00000258053.1	CTD-2021H9.3	3.9	0.000121	0.0262	0.34	0.24	Type 2 diabetes;	chr12:71053009	chr12:71047402~71118247:-
COAD	cis	rs10043775	1	rs13174567	ENSG00000251330.3	CTD-2283N19.1	-3.9	0.000121	0.0262	-0.28	-0.24	Periodontal microbiota;	chr5:148432003	chr5:148430159~148430807:-
COAD	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-3.9	0.000121	0.0262	-0.24	-0.24	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
COAD	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-3.9	0.000121	0.0262	-0.24	-0.24	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
COAD	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-3.9	0.000121	0.0262	-0.32	-0.24	Pain;	chr19:21543479	chr19:21554640~21569237:-
COAD	cis	rs13256369	1	rs7004438	ENSG00000253981.4	ALG1L13P	3.9	0.000121	0.0262	0.34	0.24	Obesity-related traits;	chr8:8716869	chr8:8236003~8244667:-
COAD	cis	rs7656342	0.755	rs6836878	ENSG00000186234.7	FAM86MP	-3.9	0.000121	0.0262	-0.3	-0.24	Gut microbiota (bacterial taxa);	chr4:9887445	chr4:9692495~9702954:+
COAD	cis	rs8177876	0.822	rs56119129	ENSG00000261061.1	RP11-303E16.2	-3.9	0.000121	0.0262	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.731	rs77145371	ENSG00000261061.1	RP11-303E16.2	-3.9	0.000121	0.0262	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81030770~81031485:+
COAD	cis	rs8177876	0.908	rs80187824	ENSG00000261061.1	RP11-303E16.2	-3.9	0.000121	0.0262	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81030770~81031485:+
COAD	cis	rs17007554	0.958	rs7569316	ENSG00000230730.1	AC074011.2	-3.9	0.000122	0.0262	-0.34	-0.24	Lung cancer in never smokers;	chr2:29066635	chr2:28633282~28664540:-
COAD	cis	rs9987353	0.518	rs4841110	ENSG00000253981.4	ALG1L13P	3.9	0.000122	0.0262	0.29	0.24	Recombination measurement;	chr8:9228513	chr8:8236003~8244667:-
COAD	cis	rs12821008	1	rs12821008	ENSG00000258017.1	RP11-386G11.10	-3.9	0.000122	0.0262	-0.29	-0.24	Bone mineral density;	chr12:49080822	chr12:49127782~49147869:+
COAD	cis	rs7665090	0.967	rs228611	ENSG00000246560.2	RP11-10L12.4	-3.9	0.000122	0.0262	-0.29	-0.24	Primary biliary cholangitis;	chr4:102640552	chr4:102828055~102844075:+
COAD	cis	rs2252521	0.524	rs719675	ENSG00000272568.4	CTB-113D17.1	3.9	0.000122	0.0262	0.44	0.24	Cognitive performance;	chr7:29002315	chr7:28979967~29013367:+
COAD	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	3.9	0.000122	0.0262	0.29	0.24	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
COAD	cis	rs7615952	0.599	rs6803160	ENSG00000248787.1	RP11-666A20.4	-3.9	0.000122	0.0262	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:125990711	chr3:125908005~125910272:-
COAD	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-3.9	0.000122	0.0262	-0.3	-0.24	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
COAD	cis	rs13256369	0.802	rs35382339	ENSG00000254153.1	CTA-398F10.2	3.9	0.000122	0.0262	0.32	0.24	Obesity-related traits;	chr8:8701745	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs11781257	ENSG00000254153.1	CTA-398F10.2	3.9	0.000122	0.0262	0.32	0.24	Obesity-related traits;	chr8:8702153	chr8:8456909~8461337:-
COAD	cis	rs9400467	0.528	rs6568680	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000122	0.0262	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111277932~111278742:+
COAD	cis	rs757278	0.513	rs10276533	ENSG00000237974.1	AC000111.4	3.9	0.000122	0.0262	0.25	0.24	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117601805	chr7:117487737~117487929:+
COAD	cis	rs4819052	0.851	rs875621	ENSG00000227039.5	ITGB2-AS1	-3.9	0.000122	0.0262	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:44921051~44929678:+
COAD	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-3.9	0.000122	0.0263	-0.28	-0.24	Height;	chr2:231559006	chr2:231508426~231514339:-
COAD	cis	rs113835537	0.529	rs11227514	ENSG00000258297.1	RP11-658F2.8	-3.9	0.000122	0.0263	-0.24	-0.24	Airway imaging phenotypes;	chr11:66519156	chr11:66666036~66668374:+
COAD	cis	rs2638953	0.924	rs11049399	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000122	0.0263	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs61920227	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000122	0.0263	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049400	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000122	0.0263	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049401	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000122	0.0263	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28163298~28190738:-
COAD	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-3.9	0.000122	0.0263	-0.25	-0.24	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
COAD	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	3.9	0.000122	0.0263	0.25	0.24	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
COAD	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	3.9	0.000122	0.0263	0.3	0.24	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
COAD	cis	rs2243480	1	rs316322	ENSG00000232559.3	GS1-124K5.12	3.9	0.000122	0.0263	0.43	0.24	Diabetic kidney disease;	chr7:66146246	chr7:66554588~66576923:-
COAD	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-3.9	0.000122	0.0263	-0.29	-0.24	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-3.9	0.000122	0.0263	-0.29	-0.24	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-3.9	0.000122	0.0263	-0.29	-0.24	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-3.9	0.000122	0.0263	-0.29	-0.24	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
COAD	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-3.9	0.000122	0.0263	-0.29	-0.24	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
COAD	cis	rs11138902	0.673	rs10511966	ENSG00000229312.2	RP11-470P21.2	-3.9	0.000122	0.0263	-0.26	-0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69499507	chr9:69472466~69494513:+
COAD	cis	rs234043	0.515	rs4894566	ENSG00000223387.5	RP11-408H1.3	-3.9	0.000122	0.0263	-0.34	-0.24	Renal cell carcinoma;	chr3:172589688	chr3:172560888~172595607:-
COAD	cis	rs4761702	0.527	rs11106988	ENSG00000257252.4	RP11-486A14.2	-3.9	0.000122	0.0263	-0.27	-0.24	Immature fraction of reticulocytes;	chr12:93340674	chr12:93317135~93377736:-
COAD	cis	rs2916733	0.53	rs1867385	ENSG00000246089.3	RP11-115C21.2	3.9	0.000122	0.0263	0.3	0.24	Epirubicin-induced leukopenia;	chr8:6448503	chr8:6403551~6407142:-
COAD	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	3.9	0.000122	0.0263	0.4	0.24	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
COAD	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-3.9	0.000122	0.0263	-0.28	-0.24	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
COAD	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-3.9	0.000122	0.0263	-0.28	-0.24	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
COAD	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-3.9	0.000122	0.0263	-0.22	-0.24	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
COAD	cis	rs7577696	0.962	rs12989936	ENSG00000272716.1	RP11-563N4.1	-3.9	0.000122	0.0263	-0.25	-0.24	Inflammatory biomarkers;	chr2:32043517	chr2:32165046~32165757:-
COAD	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-3.9	0.000122	0.0263	-0.29	-0.24	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
COAD	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	3.9	0.000122	0.0263	0.17	0.24	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
COAD	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-3.9	0.000122	0.0263	-0.32	-0.24	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
COAD	cis	rs13256369	0.802	rs11995449	ENSG00000254153.1	CTA-398F10.2	3.9	0.000122	0.0263	0.32	0.24	Obesity-related traits;	chr8:8702388	chr8:8456909~8461337:-
COAD	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	3.9	0.000122	0.0263	0.27	0.24	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
COAD	cis	rs964184	0.63	rs1558861	ENSG00000254851.1	RP11-109L13.1	-3.9	0.000122	0.0263	-0.48	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736721	chr11:117135528~117138582:+
COAD	cis	rs7829975	0.533	rs1039917	ENSG00000253981.4	ALG1L13P	3.9	0.000122	0.0263	0.3	0.24	Mood instability;	chr8:8861340	chr8:8236003~8244667:-
COAD	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-3.9	0.000122	0.0263	-0.27	-0.24	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
COAD	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	3.9	0.000122	0.0263	0.2	0.24	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
COAD	cis	rs6585424	1	rs12763392	ENSG00000234382.2	RP11-40F6.1	3.9	0.000122	0.0263	0.38	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175239	chr10:80233664~80245367:+
COAD	cis	rs12530	0.877	rs73166393	ENSG00000232218.1	RP1-149A16.16	-3.9	0.000122	0.0263	-0.42	-0.24	IgG glycosylation;	chr22:32378943	chr22:32386668~32386868:+
COAD	cis	rs9393813	0.528	rs4713108	ENSG00000271755.1	RP1-153G14.4	3.9	0.000122	0.0263	0.28	0.24	Bipolar disorder;	chr6:27490234	chr6:27404010~27406964:-
COAD	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	3.9	0.000122	0.0263	0.23	0.24	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
COAD	cis	rs7572733	0.773	rs56858593	ENSG00000222017.1	AC011997.1	3.9	0.000122	0.0263	0.26	0.24	Dermatomyositis;	chr2:197629744	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.742	rs3828317	ENSG00000222017.1	AC011997.1	3.9	0.000122	0.0263	0.26	0.24	Dermatomyositis;	chr2:197630707	chr2:197693106~197774823:+
COAD	cis	rs78487399	0.908	rs79563258	ENSG00000234936.1	AC010883.5	3.9	0.000123	0.0264	0.32	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621276	chr2:43229573~43233394:+
COAD	cis	rs4730250	0.707	rs61014091	ENSG00000241764.3	AC002467.7	3.9	0.000123	0.0264	0.32	0.24	Osteoarthritis;	chr7:107169662	chr7:107742817~107744581:-
COAD	cis	rs34929064	0.672	rs2961298	ENSG00000179428.2	AC073072.5	3.9	0.000123	0.0264	0.24	0.24	Major depression and alcohol dependence;	chr7:22668472	chr7:22725395~22727620:-
COAD	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	3.9	0.000123	0.0264	0.27	0.24	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
COAD	cis	rs2018293	1	rs77789657	ENSG00000233521.4	RP5-1172A22.1	-3.9	0.000123	0.0264	-0.22	-0.24	Vascular brain injury;	chr22:26313020	chr22:27221349~27224727:-
COAD	cis	rs728616	0.571	rs113030473	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000123	0.0264	-0.46	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79663088~79826594:-
COAD	cis	rs7674212	0.541	rs2720458	ENSG00000246560.2	RP11-10L12.4	3.9	0.000123	0.0264	0.28	0.24	Type 2 diabetes;	chr4:103131806	chr4:102828055~102844075:+
COAD	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-3.9	0.000123	0.0264	-0.33	-0.24	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
COAD	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	3.9	0.000123	0.0264	0.49	0.24	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
COAD	cis	rs5742933	0.557	rs6756571	ENSG00000253559.1	OSGEPL1-AS1	3.9	0.000123	0.0264	0.24	0.24	Ferritin levels;	chr2:189640971	chr2:189762704~189765556:+
COAD	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	3.9	0.000123	0.0264	0.26	0.24	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
COAD	cis	rs13188386	0.698	rs114742551	ENSG00000249779.1	RP11-447H19.3	3.9	0.000123	0.0264	0.28	0.24	Iron status biomarkers;	chr5:42570072	chr5:43206709~43207811:+
COAD	cis	rs13188386	0.698	rs7712701	ENSG00000249779.1	RP11-447H19.3	3.9	0.000123	0.0264	0.28	0.24	Iron status biomarkers;	chr5:42570088	chr5:43206709~43207811:+
COAD	cis	rs12531458	0.745	rs2141277	ENSG00000211697.3	TRGV5	3.9	0.000123	0.0265	0.24	0.24	Educational attainment (years of education);	chr7:39059578	chr7:38343894~38350022:-
COAD	cis	rs12531458	0.78	rs6462892	ENSG00000211697.3	TRGV5	3.9	0.000123	0.0265	0.24	0.24	Educational attainment (years of education);	chr7:39061259	chr7:38343894~38350022:-
COAD	cis	rs8058578	0.832	rs3812999	ENSG00000260487.1	RP11-297C4.3	3.9	0.000123	0.0265	0.3	0.24	Multiple myeloma;	chr16:30762284	chr16:30480588~30481346:-
COAD	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-3.9	0.000123	0.0265	-0.31	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
COAD	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-3.9	0.000123	0.0265	-0.31	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
COAD	cis	rs34220720	0.894	rs12967831	ENSG00000267013.4	CTD-2171N6.1	3.9	0.000123	0.0265	0.33	0.24	Neuroticism;	chr18:55118123	chr18:55105904~55124306:-
COAD	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-3.9	0.000123	0.0265	-0.29	-0.24	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
COAD	cis	rs989978	1	rs989978	ENSG00000228778.1	RP11-129J12.1	3.9	0.000123	0.0265	0.28	0.24	Red blood cell count;	chr10:99562798	chr10:99527081~99528261:+
COAD	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-3.9	0.000123	0.0265	-0.29	-0.24	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
COAD	cis	rs113835537	0.529	rs57634456	ENSG00000258297.1	RP11-658F2.8	-3.9	0.000123	0.0265	-0.24	-0.24	Airway imaging phenotypes;	chr11:66483367	chr11:66666036~66668374:+
COAD	cis	rs12049351	0.665	rs970103	ENSG00000229367.1	HMGN2P19	3.9	0.000123	0.0265	0.33	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229434388	chr1:229570532~229570796:+
COAD	cis	rs2179367	0.6	rs11155654	ENSG00000268592.3	RAET1E-AS1	3.9	0.000123	0.0265	0.27	0.24	Dupuytren's disease;	chr6:149442001	chr6:149863494~149919507:+
COAD	cis	rs202072	0.722	rs202069	ENSG00000272379.1	RP1-257A7.5	3.9	0.000123	0.0265	0.35	0.24	HIV-1 viral setpoint;	chr6:13267009	chr6:13290018~13290490:-
COAD	cis	rs801193	0.66	rs2659897	ENSG00000179406.6	LINC00174	-3.9	0.000123	0.0265	-0.17	-0.24	Aortic root size;	chr7:66722728	chr7:66376044~66401338:-
COAD	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	3.9	0.000123	0.0265	0.28	0.24	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
COAD	cis	rs80346118	0.673	rs2869675	ENSG00000177410.11	ZFAS1	-3.9	0.000123	0.0265	-0.26	-0.24	Diastolic blood pressure;	chr20:48804143	chr20:49278178~49295738:+
COAD	cis	rs11239930	0.56	rs632334	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147079972	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs630630	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147080377	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs618575	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147080759	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs3011810	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147082079	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.517	rs4950354	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147082674	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs4950355	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147082700	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs9663073	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147083022	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs17160592	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147083644	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs56060937	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147083854	chr1:147258885~147517875:-
COAD	cis	rs11239930	0.538	rs719969	ENSG00000278811.3	LINC00624	3.9	0.000123	0.0265	0.24	0.24	AIDS progression;	chr1:147084111	chr1:147258885~147517875:-
COAD	cis	rs9302635	0.678	rs8054585	ENSG00000260886.1	TAT-AS1	3.9	0.000123	0.0265	0.31	0.24	Blood protein levels;	chr16:72191415	chr16:71565789~71578187:+
COAD	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	3.9	0.000123	0.0265	0.36	0.24	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
COAD	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	3.9	0.000123	0.0265	0.3	0.24	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
COAD	cis	rs2496589	1	rs2432871	ENSG00000218896.1	TUBB8P2	3.9	0.000123	0.0265	0.27	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143412771	chr6:143436216~143436710:+
COAD	cis	rs2496589	1	rs2432872	ENSG00000218896.1	TUBB8P2	3.9	0.000123	0.0265	0.27	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143413019	chr6:143436216~143436710:+
COAD	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	3.9	0.000123	0.0265	0.25	0.24	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
COAD	cis	rs7572733	0.773	rs13429970	ENSG00000222017.1	AC011997.1	3.9	0.000123	0.0265	0.25	0.24	Dermatomyositis;	chr2:197657911	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.773	rs6757852	ENSG00000222017.1	AC011997.1	3.9	0.000123	0.0265	0.25	0.24	Dermatomyositis;	chr2:197665569	chr2:197693106~197774823:+
COAD	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	3.9	0.000123	0.0265	0.28	0.24	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
COAD	cis	rs7176527	0.519	rs12148368	ENSG00000225151.9	GOLGA2P7	3.9	0.000123	0.0265	0.31	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84199311~84230136:-
COAD	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	3.9	0.000124	0.0265	0.28	0.24	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
COAD	cis	rs9980	0.548	rs9934764	ENSG00000266801.1	RP11-521L9.2	-3.9	0.000124	0.0266	-0.52	-0.24	Blood osmolality (transformed sodium);	chr16:69530429	chr16:68933820~68937725:+
COAD	cis	rs34779708	0.897	rs9665538	ENSG00000271335.4	RP11-324I22.4	3.9	0.000124	0.0266	0.25	0.24	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35314552~35336401:-
COAD	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000124	0.0266	-0.23	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
COAD	cis	rs6461992	0.51	rs2301719	ENSG00000253308.2	RP1-170O19.17	3.9	0.000124	0.0266	0.51	0.24	Systolic blood pressure;	chr7:27030978	chr7:27239243~27241228:-
COAD	cis	rs6490294	0.651	rs440	ENSG00000257595.2	RP3-473L9.4	3.9	0.000124	0.0266	0.38	0.24	Mean platelet volume;	chr12:111790910	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.8	rs78783055	ENSG00000257595.2	RP3-473L9.4	3.9	0.000124	0.0266	0.38	0.24	Mean platelet volume;	chr12:111795691	chr12:111369282~111403310:+
COAD	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-3.9	0.000124	0.0266	-0.28	-0.24	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
COAD	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	3.9	0.000124	0.0266	0.31	0.24	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
COAD	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-3.9	0.000124	0.0266	-0.4	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
COAD	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	3.9	0.000124	0.0266	0.32	0.24	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
COAD	cis	rs3748656	0.945	rs12049572	ENSG00000231246.1	RP5-965F6.2	-3.9	0.000124	0.0266	-0.31	-0.24	Hip circumference adjusted for BMI;	chr1:112597961	chr1:112177234~112360528:-
COAD	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	3.9	0.000124	0.0266	0.3	0.24	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
COAD	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-3.9	0.000124	0.0266	-0.34	-0.24	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
COAD	cis	rs728616	1	rs12768613	ENSG00000234382.2	RP11-40F6.1	-3.9	0.000124	0.0266	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156810	chr10:80233664~80245367:+
COAD	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-3.9	0.000124	0.0266	-0.46	-0.24	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
COAD	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-3.9	0.000124	0.0266	-0.46	-0.24	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
COAD	cis	rs2836974	0.831	rs2836964	ENSG00000255568.3	BRWD1-AS2	3.9	0.000124	0.0266	0.24	0.24	Cognitive function;	chr21:39259080	chr21:39313935~39314962:+
COAD	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	3.9	0.000124	0.0267	0.27	0.24	Height;	chr4:55451489	chr4:55363971~55395847:-
COAD	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000124	0.0267	-0.23	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
COAD	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-3.9	0.000124	0.0267	-0.22	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
COAD	cis	rs7572733	0.773	rs13413470	ENSG00000222017.1	AC011997.1	3.9	0.000124	0.0267	0.25	0.24	Dermatomyositis;	chr2:197648125	chr2:197693106~197774823:+
COAD	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-3.9	0.000124	0.0267	-0.23	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
COAD	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	3.9	0.000124	0.0267	0.28	0.24	Height;	chr4:55479069	chr4:55547112~55547889:+
COAD	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	3.9	0.000124	0.0267	0.32	0.24	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
COAD	cis	rs13256369	0.802	rs12153	ENSG00000254153.1	CTA-398F10.2	3.9	0.000124	0.0267	0.31	0.24	Obesity-related traits;	chr8:8703399	chr8:8456909~8461337:-
COAD	cis	rs7829975	0.714	rs4841040	ENSG00000233609.3	RP11-62H7.2	3.9	0.000124	0.0267	0.26	0.24	Mood instability;	chr8:8797017	chr8:8961200~8979025:+
COAD	cis	rs2836974	0.899	rs34433511	ENSG00000255568.3	BRWD1-AS2	3.9	0.000124	0.0267	0.24	0.24	Cognitive function;	chr21:39246957	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.899	rs2836957	ENSG00000255568.3	BRWD1-AS2	3.9	0.000124	0.0267	0.24	0.24	Cognitive function;	chr21:39251208	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.836	rs1041440	ENSG00000255568.3	BRWD1-AS2	3.9	0.000124	0.0267	0.24	0.24	Cognitive function;	chr21:39255399	chr21:39313935~39314962:+
COAD	cis	rs17685	0.725	rs7807647	ENSG00000280388.1	RP11-229D13.3	3.9	0.000124	0.0267	0.24	0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76043977~76045963:-
COAD	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-3.9	0.000124	0.0267	-0.27	-0.24	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
COAD	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-3.9	0.000124	0.0267	-0.27	-0.24	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
COAD	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	3.9	0.000124	0.0267	0.3	0.24	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
COAD	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-3.9	0.000124	0.0267	-0.31	-0.24	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
COAD	cis	rs9450351	0.744	rs75096179	ENSG00000203875.9	SNHG5	-3.9	0.000124	0.0267	-0.56	-0.24	Interferon gamma-induced protein 10 levels;	chr6:85580606	chr6:85660950~85678736:-
COAD	cis	rs718433	0.616	rs2222916	ENSG00000211778.2	TRAV4	-3.9	0.000124	0.0267	-0.2	-0.24	Intraocular pressure;	chr14:21744319	chr14:21736152~21736982:+
COAD	cis	rs4639966	0.797	rs68097885	ENSG00000255422.1	AP002954.4	3.9	0.000124	0.0267	0.3	0.24	Systemic lupus erythematosus;	chr11:118725735	chr11:118704607~118750263:+
COAD	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	3.9	0.000125	0.0267	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
COAD	cis	rs12699921	0.632	rs11768866	ENSG00000279048.1	RP11-511H23.2	-3.9	0.000125	0.0267	-0.17	-0.24	Fibrinogen levels;	chr7:17925956	chr7:17940503~17942922:+
COAD	cis	rs6832769	0.922	rs501679	ENSG00000249700.7	SRD5A3-AS1	3.9	0.000125	0.0267	0.26	0.24	Personality dimensions;	chr4:55371160	chr4:55363971~55395847:-
COAD	cis	rs2018293	1	rs6005008	ENSG00000233521.4	RP5-1172A22.1	-3.9	0.000125	0.0267	-0.22	-0.24	Vascular brain injury;	chr22:26314420	chr22:27221349~27224727:-
COAD	cis	rs2243480	1	rs316329	ENSG00000232559.3	GS1-124K5.12	3.9	0.000125	0.0267	0.41	0.24	Diabetic kidney disease;	chr7:66143429	chr7:66554588~66576923:-
COAD	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-3.9	0.000125	0.0267	-0.26	-0.24	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
COAD	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	3.9	0.000125	0.0267	0.26	0.24	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	3.9	0.000125	0.0267	0.26	0.24	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
COAD	cis	rs2832191	0.716	rs8132085	ENSG00000176054.6	RPL23P2	-3.9	0.000125	0.0268	-0.24	-0.24	Dental caries;	chr21:29129068	chr21:28997613~28998033:-
COAD	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	3.9	0.000125	0.0268	0.44	0.24	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
COAD	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	3.9	0.000125	0.0268	0.43	0.24	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
COAD	cis	rs911263	0.603	rs911254	ENSG00000259502.1	RP11-643G16.3	-3.9	0.000125	0.0268	-0.29	-0.24	Primary biliary cholangitis;	chr14:68338606	chr14:67610986~67613864:+
COAD	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-3.9	0.000125	0.0268	-0.31	-0.24	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
COAD	cis	rs11138902	0.649	rs13286303	ENSG00000229312.2	RP11-470P21.2	-3.9	0.000125	0.0268	-0.27	-0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69518522	chr9:69472466~69494513:+
COAD	cis	rs9858542	0.537	rs34514189	ENSG00000225399.4	RP11-3B7.1	-3.9	0.000125	0.0268	-0.37	-0.24	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49335612	chr3:49260085~49261316:+
COAD	cis	rs9880211	0.898	rs73230099	ENSG00000273486.1	RP11-731C17.2	3.9	0.000125	0.0268	0.28	0.24	Height;Body mass index;	chr3:136833785	chr3:136837338~136839021:-
COAD	cis	rs62246343	0.719	rs1973243	ENSG00000254485.4	RP11-380O24.1	3.9	0.000125	0.0268	0.28	0.24	Fibrinogen levels;	chr3:9450592	chr3:9292588~9363303:-
COAD	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	3.9	0.000125	0.0268	0.27	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
COAD	cis	rs2638953	0.962	rs12371059	ENSG00000247934.4	RP11-967K21.1	-3.9	0.000125	0.0268	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28375375	chr12:28163298~28190738:-
COAD	cis	rs2337406	0.85	rs11849578	ENSG00000280411.1	IGHV1-69-2	-3.9	0.000125	0.0268	-0.19	-0.24	Alzheimer's disease (late onset);	chr14:106670302	chr14:106762092~106762588:-
COAD	cis	rs2836974	0.555	rs35909862	ENSG00000255568.3	BRWD1-AS2	-3.9	0.000125	0.0268	-0.22	-0.24	Cognitive function;	chr21:39249232	chr21:39313935~39314962:+
COAD	cis	rs115769866	0.609	rs974334	ENSG00000204709.4	LINC01556	3.9	0.000125	0.0268	0.33	0.24	Bipolar disorder;	chr6:28506441	chr6:28943877~28944537:+
COAD	cis	rs987724	0.593	rs13322318	ENSG00000240875.4	LINC00886	-3.89	0.000125	0.0268	-0.21	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156906481	chr3:156747346~156817062:-
COAD	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-3.89	0.000125	0.0268	-0.35	-0.24	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
COAD	cis	rs3733585	0.673	rs4580649	ENSG00000250413.1	RP11-448G15.1	3.89	0.000125	0.0268	0.31	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9946837	chr4:10006482~10009725:+
COAD	cis	rs9393777	0.778	rs4452638	ENSG00000224843.5	LINC00240	-3.89	0.000125	0.0268	-0.52	-0.24	Intelligence (multi-trait analysis);	chr6:27261486	chr6:26956992~27023924:+
COAD	cis	rs9400467	0.508	rs12211763	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000125	0.0269	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs10872067	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000125	0.0269	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111277932~111278742:+
COAD	cis	rs6802315	0.604	rs9861938	ENSG00000272247.1	RP11-379F4.9	-3.89	0.000125	0.0269	-0.28	-0.24	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158801257~158801935:-
COAD	cis	rs2638953	0.924	rs11049600	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000125	0.0269	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28439061	chr12:28163298~28190738:-
COAD	cis	rs11650494	0.516	rs13341862	ENSG00000257178.3	RP11-357H14.16	-3.89	0.000125	0.0269	-0.41	-0.24	Prostate cancer;	chr17:49416841	chr17:48579630~48582259:-
COAD	cis	rs2554380	0.542	rs7164141	ENSG00000176700.18	SCAND2P	3.89	0.000125	0.0269	0.25	0.24	Height;	chr15:83824253	chr15:84631451~84647478:+
COAD	cis	rs10916814	0.61	rs4655219	ENSG00000117242.7	PINK1-AS	-3.89	0.000125	0.0269	-0.28	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:20561493	chr1:20642657~20652193:-
COAD	cis	rs9910055	0.529	rs425038	ENSG00000267080.4	ASB16-AS1	3.89	0.000125	0.0269	0.23	0.24	Total body bone mineral density;	chr17:44104660	chr17:44175973~44186717:-
COAD	cis	rs10779751	1	rs7526649	ENSG00000215785.2	CFL1P6	-3.89	0.000126	0.0269	-0.27	-0.24	Body mass index;	chr1:11218106	chr1:10990978~10991797:-
COAD	cis	rs10466239	0.57	rs4627023	ENSG00000230555.2	RP11-517P14.2	3.89	0.000126	0.0269	0.39	0.24	Telomere length;	chr10:43370437	chr10:43420738~43422100:+
COAD	cis	rs4718428	1	rs12534637	ENSG00000272831.1	RP11-792A8.4	3.89	0.000126	0.0269	0.26	0.24	Corneal structure;	chr7:66862667	chr7:66739829~66740385:-
COAD	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	3.89	0.000126	0.0269	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
COAD	cis	rs807029	0.577	rs3740490	ENSG00000272572.1	RP11-179B2.2	-3.89	0.000126	0.0269	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100911103~100912739:-
COAD	cis	rs718433	0.584	rs1569292	ENSG00000211778.2	TRAV4	-3.89	0.000126	0.0269	-0.2	-0.24	Intraocular pressure;	chr14:21748709	chr14:21736152~21736982:+
COAD	cis	rs259067	0.544	rs259101	ENSG00000250258.1	CTC-431G16.2	3.89	0.000126	0.0269	0.35	0.24	Obesity;	chr5:79796394	chr5:79774348~79816190:-
COAD	cis	rs8017304	0.643	rs4899238	ENSG00000259502.1	RP11-643G16.3	-3.89	0.000126	0.0269	-0.3	-0.24	Age-related macular degeneration;	chr14:68328522	chr14:67610986~67613864:+
COAD	cis	rs11024102	1	rs4141194	ENSG00000184669.7	OR7E14P	3.89	0.000126	0.0269	0.34	0.24	Glaucoma (primary angle closure);	chr11:16989629	chr11:17013998~17053024:+
COAD	cis	rs5753037	0.809	rs997913	ENSG00000279159.1	RP3-394A18.1	-3.89	0.000126	0.0269	-0.16	-0.24	Type 1 diabetes;	chr22:29978632	chr22:29978950~30028236:-
COAD	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000126	0.0269	-0.28	-0.24	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000126	0.0269	-0.28	-0.24	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000126	0.0269	-0.28	-0.24	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000126	0.0269	-0.28	-0.24	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
COAD	cis	rs17407555	0.683	rs4697999	ENSG00000250413.1	RP11-448G15.1	-3.89	0.000126	0.0269	-0.33	-0.24	Schizophrenia (age at onset);	chr4:10273310	chr4:10006482~10009725:+
COAD	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	3.89	0.000126	0.0269	0.27	0.24	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
COAD	cis	rs875971	0.964	rs697969	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000126	0.0269	-0.25	-0.24	Aortic root size;	chr7:66093491	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs1182882	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000126	0.0269	-0.25	-0.24	Aortic root size;	chr7:66097076	chr7:65773620~65802067:+
COAD	cis	rs4242434	0.927	rs10095121	ENSG00000261026.1	CTD-3247F14.2	3.89	0.000126	0.0269	0.32	0.24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22680913	chr8:22679013~22684009:-
COAD	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000126	0.0269	-0.41	-0.24	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
COAD	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	3.89	0.000126	0.027	0.34	0.24	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
COAD	cis	rs2017305	0.834	rs79520726	ENSG00000233590.1	RP11-153K11.3	3.89	0.000126	0.027	0.43	0.24	Depression (quantitative trait);	chr10:69022200	chr10:68233251~68242379:-
COAD	cis	rs13256369	1	rs4841017	ENSG00000253981.4	ALG1L13P	3.89	0.000126	0.027	0.32	0.24	Obesity-related traits;	chr8:8719583	chr8:8236003~8244667:-
COAD	cis	rs718433	0.584	rs2204935	ENSG00000211778.2	TRAV4	-3.89	0.000126	0.027	-0.2	-0.24	Intraocular pressure;	chr14:21744180	chr14:21736152~21736982:+
COAD	cis	rs718433	0.584	rs4982492	ENSG00000211778.2	TRAV4	-3.89	0.000126	0.027	-0.2	-0.24	Intraocular pressure;	chr14:21744535	chr14:21736152~21736982:+
COAD	cis	rs13256369	0.708	rs9644772	ENSG00000254153.1	CTA-398F10.2	3.89	0.000126	0.027	0.33	0.24	Obesity-related traits;	chr8:8700175	chr8:8456909~8461337:-
COAD	cis	rs71636778	0.509	rs60659886	ENSG00000260063.1	RP5-968P14.2	-3.89	0.000126	0.027	-0.43	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26667754	chr1:26692132~26694131:-
COAD	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-3.89	0.000126	0.027	-0.22	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
COAD	cis	rs2559856	1	rs2251187	ENSG00000199933.1	RNY1P16	3.89	0.000126	0.027	0.25	0.24	Blood protein levels;	chr12:101688111	chr12:101719808~101719918:+
COAD	cis	rs2559856	0.967	rs2695297	ENSG00000199933.1	RNY1P16	3.89	0.000126	0.027	0.25	0.24	Blood protein levels;	chr12:101688440	chr12:101719808~101719918:+
COAD	cis	rs2559856	1	rs2695298	ENSG00000199933.1	RNY1P16	3.89	0.000126	0.027	0.25	0.24	Blood protein levels;	chr12:101688811	chr12:101719808~101719918:+
COAD	cis	rs9818758	0.556	rs11716614	ENSG00000225399.4	RP11-3B7.1	-3.89	0.000126	0.027	-0.53	-0.24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:49260085~49261316:+
COAD	cis	rs6982240	1	rs6982240	ENSG00000253307.1	RP11-10J21.4	3.89	0.000126	0.027	0.29	0.24	Tonsillectomy;	chr8:141247279	chr8:141252286~141253292:-
COAD	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-3.89	0.000126	0.027	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
COAD	cis	rs7615952	0.8	rs13086460	ENSG00000272840.1	RP11-379B18.6	3.89	0.000126	0.027	0.33	0.24	Blood pressure (smoking interaction);	chr3:125927574	chr3:125774714~125797953:+
COAD	cis	rs3126085	0.935	rs4845429	ENSG00000237975.5	FLG-AS1	-3.89	0.000126	0.027	-0.26	-0.24	Atopic dermatitis;	chr1:152252900	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs10888475	ENSG00000237975.5	FLG-AS1	-3.89	0.000126	0.027	-0.26	-0.24	Atopic dermatitis;	chr1:152253536	chr1:152168125~152445456:+
COAD	cis	rs9880211	0.948	rs34135127	ENSG00000273486.1	RP11-731C17.2	3.89	0.000126	0.027	0.28	0.24	Height;Body mass index;	chr3:136507656	chr3:136837338~136839021:-
COAD	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-3.89	0.000126	0.027	-0.3	-0.24	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
COAD	cis	rs1023500	0.573	rs133370	ENSG00000227370.1	RP4-669P10.19	-3.89	0.000126	0.027	-0.24	-0.24	Schizophrenia;	chr22:42069256	chr22:42132543~42132998:+
COAD	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	3.89	0.000126	0.027	0.31	0.24	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	3.89	0.000126	0.027	0.31	0.24	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
COAD	cis	rs4879656	0.835	rs10813927	ENSG00000225693.1	LAGE3P1	-3.89	0.000126	0.027	-0.28	-0.24	Menopause (age at onset);	chr9:33047912	chr9:33019682~33020165:-
COAD	cis	rs9942416	0.648	rs42302	ENSG00000271815.1	CTD-2235C13.3	3.89	0.000126	0.027	0.28	0.24	Age-related disease endophenotypes;	chr5:75669729	chr5:75363760~75364242:+
COAD	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	3.89	0.000126	0.027	0.46	0.24	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
COAD	cis	rs739496	0.894	rs10849947	ENSG00000257595.2	RP3-473L9.4	3.89	0.000126	0.027	0.32	0.24	Platelet count;	chr12:111426880	chr12:111369282~111403310:+
COAD	cis	rs12530	0.715	rs2294314	ENSG00000241954.1	RP1-149A16.17	-3.89	0.000126	0.027	-0.31	-0.24	IgG glycosylation;	chr22:32398616	chr22:32383786~32385631:+
COAD	cis	rs4683346	1	rs4683342	ENSG00000273328.4	RP11-141M3.6	-3.89	0.000126	0.027	-0.31	-0.24	Granulocyte percentage of myeloid white cells;	chr3:42835941	chr3:42809414~42908105:+
COAD	cis	rs2836974	0.932	rs6517523	ENSG00000255568.3	BRWD1-AS2	3.89	0.000126	0.027	0.24	0.24	Cognitive function;	chr21:39185406	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.932	rs13048178	ENSG00000255568.3	BRWD1-AS2	3.89	0.000126	0.027	0.24	0.24	Cognitive function;	chr21:39189086	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs2836933	ENSG00000255568.3	BRWD1-AS2	3.89	0.000126	0.027	0.24	0.24	Cognitive function;	chr21:39192276	chr21:39313935~39314962:+
COAD	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000127	0.0271	-0.23	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
COAD	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-3.89	0.000127	0.0271	-0.22	-0.24	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
COAD	cis	rs7577696	0.924	rs7566162	ENSG00000272716.1	RP11-563N4.1	-3.89	0.000127	0.0271	-0.25	-0.24	Inflammatory biomarkers;	chr2:32099003	chr2:32165046~32165757:-
COAD	cis	rs253959	0.545	rs10072350	ENSG00000271918.1	CTD-2287O16.5	3.89	0.000127	0.0271	0.23	0.24	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116083807~116085416:-
COAD	cis	rs6921919	0.789	rs13210258	ENSG00000272009.1	RP1-313I6.12	3.89	0.000127	0.0271	0.29	0.24	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28078792~28081130:-
COAD	cis	rs7200786	0.546	rs6498161	ENSG00000274038.1	RP11-66H6.4	-3.89	0.000127	0.0271	-0.3	-0.24	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118682	chr16:11056556~11057034:+
COAD	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	3.89	0.000127	0.0271	0.31	0.24	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	3.89	0.000127	0.0271	0.31	0.24	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
COAD	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	3.89	0.000127	0.0271	0.31	0.24	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
COAD	cis	rs2179367	0.632	rs9498344	ENSG00000216906.2	RP11-350J20.9	3.89	0.000127	0.0271	0.34	0.24	Dupuytren's disease;	chr6:149401053	chr6:149904243~149906418:+
COAD	cis	rs2732480	0.577	rs2732481	ENSG00000269514.1	RP11-370I10.12	3.89	0.000127	0.0271	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.557	rs2732484	ENSG00000269514.1	RP11-370I10.12	3.89	0.000127	0.0271	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2732486	ENSG00000269514.1	RP11-370I10.12	3.89	0.000127	0.0271	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.517	rs2634676	ENSG00000269514.1	RP11-370I10.12	3.89	0.000127	0.0271	0.3	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48198387~48202031:+
COAD	cis	rs718433	0.584	rs8015812	ENSG00000211778.2	TRAV4	-3.89	0.000127	0.0271	-0.2	-0.24	Intraocular pressure;	chr14:21746791	chr14:21736152~21736982:+
COAD	cis	rs2564921	0.73	rs56026870	ENSG00000280417.1	RP11-5O17.1	3.89	0.000127	0.0271	0.25	0.24	Height;	chr3:52998472	chr3:53046166~53048122:+
COAD	cis	rs1799949	0.894	rs71367985	ENSG00000279602.1	CTD-3014M21.1	3.89	0.000127	0.0271	0.26	0.24	Menopause (age at onset);	chr17:43222443	chr17:43360041~43361361:-
COAD	cis	rs4699052	0.963	rs11733615	ENSG00000246560.2	RP11-10L12.4	3.89	0.000127	0.0271	0.3	0.24	Testicular germ cell tumor;	chr4:103236007	chr4:102828055~102844075:+
COAD	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-3.89	0.000127	0.0271	-0.44	-0.24	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
COAD	cis	rs8022206	0.704	rs12431697	ENSG00000259502.1	RP11-643G16.3	3.89	0.000127	0.0271	0.29	0.24	Platelet count;Mean platelet volume;	chr14:67927337	chr14:67610986~67613864:+
COAD	cis	rs10865397	0.506	rs6546807	ENSG00000163016.8	ALMS1P	3.89	0.000127	0.0271	0.29	0.24	Intelligence (multi-trait analysis);	chr2:73159084	chr2:73644919~73685576:+
COAD	cis	rs2179367	0.632	rs9485384	ENSG00000216906.2	RP11-350J20.9	3.89	0.000127	0.0271	0.34	0.24	Dupuytren's disease;	chr6:149328808	chr6:149904243~149906418:+
COAD	cis	rs9813712	0.574	rs11718032	ENSG00000253540.4	FAM86HP	3.89	0.000127	0.0271	0.25	0.24	Response to amphetamines;	chr3:130257749	chr3:130099092~130111472:-
COAD	cis	rs728616	0.717	rs116884206	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000127	0.0271	-0.47	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:79663088~79826594:-
COAD	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	3.89	0.000127	0.0271	0.27	0.24	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
COAD	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-3.89	0.000127	0.0271	-0.24	-0.24	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
COAD	cis	rs68170813	0.559	rs3815148	ENSG00000241764.3	AC002467.7	-3.89	0.000127	0.0271	-0.31	-0.24	Coronary artery disease;	chr7:107297975	chr7:107742817~107744581:-
COAD	cis	rs884366	0.964	rs4945826	ENSG00000219700.1	PTCHD3P3	-3.89	0.000127	0.0271	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr6:109253867	chr6:109288571~109290503:-
COAD	cis	rs13256369	1	rs13271966	ENSG00000253981.4	ALG1L13P	3.89	0.000127	0.0271	0.34	0.24	Obesity-related traits;	chr8:8717962	chr8:8236003~8244667:-
COAD	cis	rs7819412	0.521	rs11777887	ENSG00000269918.1	AF131215.9	3.89	0.000127	0.0271	0.3	0.24	Triglycerides;	chr8:11179290	chr8:11104691~11106704:-
COAD	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-3.89	0.000127	0.0271	-0.31	-0.24	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
COAD	cis	rs2916733	0.53	rs1054073	ENSG00000246089.3	RP11-115C21.2	3.89	0.000127	0.0271	0.3	0.24	Epirubicin-induced leukopenia;	chr8:6445990	chr8:6403551~6407142:-
COAD	cis	rs9513593	0.579	rs36110013	ENSG00000260992.1	DOCK9-AS2	-3.89	0.000127	0.0271	-0.39	-0.24	Psoriasis;	chr13:99344034	chr13:99087819~99088625:+
COAD	cis	rs2929278	0.589	rs11638972	ENSG00000275601.1	AC011330.13	3.89	0.000127	0.0272	0.28	0.24	Schizophrenia;	chr15:43782493	chr15:43642389~43643023:-
COAD	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	3.89	0.000127	0.0272	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
COAD	cis	rs2361701	0.636	rs1982244	ENSG00000279259.1	RP11-334C17.3	3.89	0.000127	0.0272	0.26	0.24	IgG glycosylation;	chr17:80095149	chr17:80147250~80148596:+
COAD	cis	rs74781061	0.929	rs10459648	ENSG00000260103.2	RP11-10O17.1	3.89	0.000127	0.0272	0.29	0.24	Endometriosis;	chr15:74573099	chr15:74478070~74490286:-
COAD	cis	rs10471753	0.512	rs853800	ENSG00000248359.1	CTC-537E7.2	3.89	0.000127	0.0272	0.22	0.24	Hip minimal joint space width;	chr5:68470937	chr5:68531690~68533530:-
COAD	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-3.89	0.000127	0.0272	-0.35	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
COAD	cis	rs2832191	0.692	rs8134627	ENSG00000176054.6	RPL23P2	-3.89	0.000127	0.0272	-0.24	-0.24	Dental caries;	chr21:28976747	chr21:28997613~28998033:-
COAD	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	3.89	0.000127	0.0272	0.29	0.24	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
COAD	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	3.89	0.000127	0.0272	0.49	0.24	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
COAD	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	3.89	0.000127	0.0272	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
COAD	cis	rs7688540	0.8	rs61794998	ENSG00000198155.5	ZNF876P	-3.89	0.000127	0.0272	-0.35	-0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:212610~255985:+
COAD	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-3.89	0.000127	0.0272	-0.24	-0.24	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
COAD	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
COAD	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	3.89	0.000127	0.0272	0.44	0.24	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
COAD	cis	rs9400271	0.527	rs11153169	ENSG00000219700.1	PTCHD3P3	-3.89	0.000127	0.0272	-0.28	-0.24	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109322318	chr6:109288571~109290503:-
COAD	cis	rs2307394	0.964	rs9789434	ENSG00000281469.1	RP11-567F11.1	3.89	0.000127	0.0272	0.28	0.24	Urate levels;	chr2:147991824	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13035475	ENSG00000281469.1	RP11-567F11.1	3.89	0.000127	0.0272	0.28	0.24	Urate levels;	chr2:147997293	chr2:148044380~148044894:+
COAD	cis	rs490608	0.628	rs678157	ENSG00000223503.1	RP11-29H23.6	-3.89	0.000127	0.0272	-0.32	-0.24	Inflammatory bowel disease;	chr1:155688550	chr1:155590601~155591262:-
COAD	cis	rs12149695	0.966	rs4499236	ENSG00000259940.2	CTD-3203P2.1	-3.89	0.000127	0.0272	-0.26	-0.24	Gut microbiota (bacterial taxa);	chr16:27242810	chr16:27213308~27214993:-
COAD	cis	rs2663905	0.605	rs2683235	ENSG00000277782.1	RP11-775C24.5	-3.89	0.000127	0.0272	-0.34	-0.24	QT interval (drug interaction);	chr15:81106450	chr15:80999593~80999981:-
COAD	cis	rs3781264	0.595	rs10786161	ENSG00000273450.1	RP11-76P2.4	3.89	0.000128	0.0272	0.28	0.24	Esophageal cancer and gastric cancer;	chr10:94347914	chr10:94314907~94315327:-
COAD	cis	rs11239930	0.517	rs2477569	ENSG00000278811.3	LINC00624	-3.89	0.000128	0.0272	-0.24	-0.24	AIDS progression;	chr1:147076261	chr1:147258885~147517875:-
COAD	cis	rs5758511	0.773	rs9680671	ENSG00000237037.8	NDUFA6-AS1	-3.89	0.000128	0.0272	-0.25	-0.24	Birth weight;	chr22:41955473	chr22:42090931~42137742:+
COAD	cis	rs7818688	0.556	rs2678823	ENSG00000253528.2	RP11-347C18.4	3.89	0.000128	0.0272	0.29	0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95033866	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.585	rs2599715	ENSG00000253528.2	RP11-347C18.4	3.89	0.000128	0.0272	0.29	0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95034265	chr8:94974573~94974853:-
COAD	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000128	0.0272	-0.28	-0.24	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000128	0.0272	-0.28	-0.24	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000128	0.0272	-0.28	-0.24	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
COAD	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	3.89	0.000128	0.0272	0.29	0.24	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
COAD	cis	rs2173063	0.568	rs17647496	ENSG00000272888.4	LINC01578	-3.89	0.000128	0.0272	-0.37	-0.24	Subcutaneous adipose tissue;	chr15:92581769	chr15:92882707~92899701:+
COAD	cis	rs9859260	0.921	rs9877119	ENSG00000207650.1	MIR570	3.89	0.000128	0.0272	0.29	0.24	Mean corpuscular volume;	chr3:196075495	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.845	rs35587059	ENSG00000207650.1	MIR570	3.89	0.000128	0.0272	0.29	0.24	Mean corpuscular volume;	chr3:196077473	chr3:195699401~195699497:+
COAD	cis	rs453301	0.653	rs11784393	ENSG00000254340.1	RP11-10A14.3	3.89	0.000128	0.0272	0.28	0.24	Joint mobility (Beighton score);	chr8:9045624	chr8:9141424~9145435:+
COAD	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-3.89	0.000128	0.0272	-0.25	-0.24	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
COAD	cis	rs6452524	0.868	rs1564379	ENSG00000271862.1	RP11-343L5.2	3.89	0.000128	0.0272	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83049376~83050964:-
COAD	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-3.89	0.000128	0.0273	-0.24	-0.24	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
COAD	cis	rs2638953	0.924	rs11049582	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000128	0.0273	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416392	chr12:28163298~28190738:-
COAD	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-3.89	0.000128	0.0273	-0.39	-0.24	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
COAD	cis	rs35110281	0.594	rs230641	ENSG00000239930.2	AP001625.4	-3.89	0.000128	0.0273	-0.25	-0.24	Mean corpuscular volume;	chr21:43495561	chr21:42496539~42497443:+
COAD	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	3.89	0.000128	0.0273	0.21	0.24	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
COAD	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	3.89	0.000128	0.0273	0.21	0.24	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
COAD	cis	rs6921919	0.583	rs16894060	ENSG00000272009.1	RP1-313I6.12	3.89	0.000128	0.0273	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28078792~28081130:-
COAD	cis	rs1790761	0.692	rs614080	ENSG00000255318.1	RP11-655M14.13	3.89	0.000128	0.0273	0.3	0.24	Mean corpuscular volume;	chr11:67579816	chr11:67618279~67627304:-
COAD	cis	rs8049040	0.586	rs13333985	ENSG00000260886.1	TAT-AS1	3.89	0.000128	0.0273	0.32	0.24	Blood protein levels;	chr16:71516950	chr16:71565789~71578187:+
COAD	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-3.89	0.000128	0.0273	-0.49	-0.24	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
COAD	cis	rs7584330	0.666	rs6760963	ENSG00000234949.2	AC104667.3	3.89	0.000128	0.0273	0.36	0.24	Prostate cancer;	chr2:237489625	chr2:237591020~237595981:+
COAD	cis	rs3752645	0.764	rs78715818	ENSG00000241764.3	AC002467.7	3.89	0.000128	0.0273	0.48	0.24	Bladder cancer (smoking interaction);	chr7:107044193	chr7:107742817~107744581:-
COAD	cis	rs11633886	0.904	rs11636751	ENSG00000273972.1	CTD-2306A12.1	-3.89	0.000128	0.0273	-0.27	-0.24	Diisocyanate-induced asthma;	chr15:45811225	chr15:45702640~45703183:+
COAD	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	3.89	0.000128	0.0273	0.37	0.24	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
COAD	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-3.89	0.000128	0.0273	-0.28	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
COAD	cis	rs153916	0.566	rs2548123	ENSG00000251000.1	AC008592.3	3.89	0.000128	0.0273	0.29	0.24	Pulmonary function;	chr5:95677123	chr5:95834424~95835046:-
COAD	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-3.89	0.000128	0.0273	-0.24	-0.24	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
COAD	cis	rs4761470	0.577	rs7302972	ENSG00000258365.1	RP11-1105G2.3	-3.89	0.000128	0.0273	-0.29	-0.24	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94277758~94282844:-
COAD	cis	rs253959	0.564	rs4921064	ENSG00000271918.1	CTD-2287O16.5	3.89	0.000128	0.0273	0.22	0.24	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116083807~116085416:-
COAD	cis	rs6732160	0.588	rs3891890	ENSG00000163016.8	ALMS1P	3.89	0.000128	0.0273	0.3	0.24	Intelligence (multi-trait analysis);	chr2:73150921	chr2:73644919~73685576:+
COAD	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	3.89	0.000128	0.0273	0.27	0.24	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	3.89	0.000128	0.0273	0.27	0.24	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	3.89	0.000128	0.0273	0.27	0.24	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
COAD	cis	rs8177876	0.731	rs57606521	ENSG00000261061.1	RP11-303E16.2	-3.89	0.000128	0.0273	-0.46	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81103437	chr16:81030770~81031485:+
COAD	cis	rs860295	0.966	rs821551	ENSG00000225082.2	DAP3P1	-3.89	0.000128	0.0273	-0.29	-0.24	Body mass index;	chr1:155718789	chr1:155586644~155602197:+
COAD	cis	rs1510510	0.742	rs10170678	ENSG00000225057.2	AC096574.4	3.89	0.000128	0.0273	0.31	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238663940	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.676	rs10170873	ENSG00000225057.2	AC096574.4	3.89	0.000128	0.0273	0.31	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238664185	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.742	rs7574801	ENSG00000225057.2	AC096574.4	3.89	0.000128	0.0273	0.31	0.24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238664313	chr2:238231684~238255633:+
COAD	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-3.89	0.000128	0.0273	-0.27	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
COAD	cis	rs9880211	1	rs13071220	ENSG00000273486.1	RP11-731C17.2	3.89	0.000128	0.0273	0.28	0.24	Height;Body mass index;	chr3:136595277	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	3.89	0.000128	0.0273	0.28	0.24	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	3.89	0.000128	0.0273	0.28	0.24	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	3.89	0.000128	0.0273	0.28	0.24	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
COAD	cis	rs7646881	0.812	rs9864589	ENSG00000272087.1	RP11-379F4.7	3.89	0.000128	0.0274	0.37	0.24	Tetralogy of Fallot;	chr3:158712917	chr3:158693120~158693768:-
COAD	cis	rs12468226	0.938	rs55681656	ENSG00000226261.1	AC064836.3	3.89	0.000128	0.0274	0.35	0.24	Urate levels;	chr2:202319041	chr2:202336024~202336727:-
COAD	cis	rs6787172	0.755	rs9877909	ENSG00000272087.1	RP11-379F4.7	3.89	0.000128	0.0274	0.28	0.24	Subjective well-being;	chr3:158426475	chr3:158693120~158693768:-
COAD	cis	rs2362965	0.565	rs77879537	ENSG00000272087.1	RP11-379F4.7	3.89	0.000128	0.0274	0.28	0.24	Height;	chr3:158431276	chr3:158693120~158693768:-
COAD	cis	rs1790761	0.967	rs1638588	ENSG00000231793.4	DOC2GP	-3.89	0.000128	0.0274	-0.26	-0.24	Mean corpuscular volume;	chr11:67432235	chr11:67612653~67616257:-
COAD	cis	rs7933887	0.91	rs11220480	ENSG00000254905.1	RP11-712L6.7	3.89	0.000128	0.0274	0.39	0.24	Coronary artery disease;	chr11:126407675	chr11:126292922~126294254:-
COAD	cis	rs10876993	0.89	rs12302350	ENSG00000270039.1	RP11-571M6.17	3.89	0.000128	0.0274	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57668806	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.89	rs12302351	ENSG00000270039.1	RP11-571M6.17	3.89	0.000128	0.0274	0.27	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57668807	chr12:57803838~57804415:+
COAD	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	3.89	0.000129	0.0274	0.24	0.24	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
COAD	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	3.89	0.000129	0.0274	0.32	0.24	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
COAD	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-3.89	0.000129	0.0274	-0.24	-0.24	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
COAD	cis	rs12530	0.715	rs2294311	ENSG00000241954.1	RP1-149A16.17	-3.89	0.000129	0.0274	-0.3	-0.24	IgG glycosylation;	chr22:32397282	chr22:32383786~32385631:+
COAD	cis	rs11239930	0.517	rs685741	ENSG00000278811.3	LINC00624	3.89	0.000129	0.0274	0.24	0.24	AIDS progression;	chr1:147074503	chr1:147258885~147517875:-
COAD	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-3.89	0.000129	0.0274	-0.34	-0.24	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
COAD	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	3.89	0.000129	0.0274	0.28	0.24	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
COAD	cis	rs5743077	1	rs5743077	ENSG00000253559.1	OSGEPL1-AS1	-3.89	0.000129	0.0274	-0.33	-0.24	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189762704~189765556:+
COAD	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	3.89	0.000129	0.0274	0.3	0.24	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
COAD	cis	rs875971	0.862	rs2460432	ENSG00000224316.1	RP11-479O9.2	-3.89	0.000129	0.0274	-0.25	-0.24	Aortic root size;	chr7:66089398	chr7:65773620~65802067:+
COAD	cis	rs13256369	0.802	rs12681326	ENSG00000254153.1	CTA-398F10.2	3.89	0.000129	0.0274	0.32	0.24	Obesity-related traits;	chr8:8708879	chr8:8456909~8461337:-
COAD	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	3.89	0.000129	0.0274	0.29	0.24	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
COAD	cis	rs11138902	0.635	rs1475641	ENSG00000229312.2	RP11-470P21.2	3.89	0.000129	0.0274	0.26	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69497528	chr9:69472466~69494513:+
COAD	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-3.89	0.000129	0.0274	-0.27	-0.24	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
COAD	cis	rs7637701	0.967	rs10936043	ENSG00000240875.4	LINC00886	-3.89	0.000129	0.0274	-0.23	-0.24	Breast cancer;	chr3:156978717	chr3:156747346~156817062:-
COAD	cis	rs7584330	0.554	rs2325838	ENSG00000234949.2	AC104667.3	-3.89	0.000129	0.0274	-0.39	-0.24	Prostate cancer;	chr2:237477872	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.91	rs880932	ENSG00000234949.2	AC104667.3	-3.89	0.000129	0.0274	-0.3	-0.24	Prostate cancer;	chr2:237488320	chr2:237591020~237595981:+
COAD	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	3.89	0.000129	0.0274	0.34	0.24	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
COAD	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-3.89	0.000129	0.0274	-0.31	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
COAD	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	3.89	0.000129	0.0274	0.32	0.24	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
COAD	cis	rs9400467	0.528	rs455247	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111277932~111278742:+
COAD	cis	rs7760535	0.811	rs464401	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Metabolic traits;	chr6:111347804	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.509	rs463854	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.509	rs463853	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs456569	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs455335	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs465795	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs110732	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.592	rs462493	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.508	rs456871	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111277932~111278742:+
COAD	cis	rs7760535	0.811	rs455732	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Metabolic traits;	chr6:111374065	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs458486	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000129	0.0274	-0.21	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111277932~111278742:+
COAD	cis	rs728616	0.867	rs28365998	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000129	0.0274	-0.48	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:79663088~79826594:-
COAD	cis	rs7818688	1	rs16917224	ENSG00000253528.2	RP11-347C18.4	-3.89	0.000129	0.0275	-0.35	-0.24	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017882	chr8:94974573~94974853:-
COAD	cis	rs12699921	0.537	rs2691582	ENSG00000279048.1	RP11-511H23.2	-3.89	0.000129	0.0275	-0.17	-0.24	Fibrinogen levels;	chr7:17789623	chr7:17940503~17942922:+
COAD	cis	rs159572	0.829	rs293595	ENSG00000251307.1	RP11-506H20.1	-3.89	0.000129	0.0275	-0.3	-0.24	Post-traumatic stress disorder;	chr5:56227982	chr5:55233934~55295201:+
COAD	cis	rs2733201	1	rs2733201	ENSG00000205771.5	CATSPER2P1	3.89	0.000129	0.0275	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44116203	chr15:43726918~43747094:-
COAD	cis	rs11638352	1	rs2615294	ENSG00000205771.5	CATSPER2P1	3.89	0.000129	0.0275	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120422	chr15:43726918~43747094:-
COAD	cis	rs11638352	1	rs2555380	ENSG00000205771.5	CATSPER2P1	3.89	0.000129	0.0275	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120437	chr15:43726918~43747094:-
COAD	cis	rs11638352	1	rs2706471	ENSG00000205771.5	CATSPER2P1	3.89	0.000129	0.0275	0.5	0.24	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44122172	chr15:43726918~43747094:-
COAD	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-3.89	0.000129	0.0275	-0.35	-0.24	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
COAD	cis	rs4074961	0.604	rs4411102	ENSG00000233621.1	LINC01137	-3.89	0.000129	0.0275	-0.28	-0.24	Axial length;	chr1:37597823	chr1:37454879~37474411:-
COAD	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-3.89	0.000129	0.0275	-0.28	-0.24	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
COAD	cis	rs453301	0.686	rs3989373	ENSG00000254340.1	RP11-10A14.3	-3.89	0.000129	0.0275	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9053798	chr8:9141424~9145435:+
COAD	cis	rs6740322	0.748	rs13420649	ENSG00000234936.1	AC010883.5	3.89	0.000129	0.0275	0.3	0.24	Coronary artery disease;	chr2:43236498	chr2:43229573~43233394:+
COAD	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-3.89	0.000129	0.0275	-0.32	-0.24	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
COAD	cis	rs2929278	0.617	rs663214	ENSG00000275601.1	AC011330.13	3.89	0.000129	0.0275	0.27	0.24	Schizophrenia;	chr15:43821584	chr15:43642389~43643023:-
COAD	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	3.89	0.000129	0.0275	0.32	0.24	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	3.89	0.000129	0.0275	0.32	0.24	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	3.89	0.000129	0.0275	0.32	0.24	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
COAD	cis	rs9880211	0.613	rs6439629	ENSG00000239213.4	NCK1-AS1	3.89	0.000129	0.0275	0.31	0.24	Height;Body mass index;	chr3:136182428	chr3:136841726~136862054:-
COAD	cis	rs7172689	0.908	rs7175701	ENSG00000271725.1	RP11-761I4.4	3.89	0.000129	0.0275	0.29	0.24	Inattentive symptoms;	chr15:81266282	chr15:81303215~81309391:-
COAD	cis	rs6490294	0.571	rs2056698	ENSG00000257595.2	RP3-473L9.4	3.89	0.000129	0.0275	0.38	0.24	Mean platelet volume;	chr12:112131299	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.571	rs6489829	ENSG00000257595.2	RP3-473L9.4	3.89	0.000129	0.0275	0.38	0.24	Mean platelet volume;	chr12:112144597	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.528	rs6489832	ENSG00000257595.2	RP3-473L9.4	3.89	0.000129	0.0275	0.38	0.24	Mean platelet volume;	chr12:112174349	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.571	rs2037745	ENSG00000257595.2	RP3-473L9.4	3.89	0.000129	0.0275	0.38	0.24	Mean platelet volume;	chr12:112177978	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.571	rs7979255	ENSG00000257595.2	RP3-473L9.4	3.89	0.000129	0.0275	0.38	0.24	Mean platelet volume;	chr12:112180665	chr12:111369282~111403310:+
COAD	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	3.89	0.000129	0.0275	0.3	0.24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
COAD	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	3.89	0.000129	0.0275	0.32	0.24	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
COAD	cis	rs7204230	1	rs7202653	ENSG00000261056.2	RP11-454F8.2	3.89	0.000129	0.0275	0.28	0.24	Fibrinogen;	chr16:53173281	chr16:53298224~53299792:+
COAD	cis	rs3126085	0.935	rs4361987	ENSG00000237975.5	FLG-AS1	-3.89	0.000129	0.0275	-0.26	-0.24	Atopic dermatitis;	chr1:152257225	chr1:152168125~152445456:+
COAD	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	3.89	0.000129	0.0275	0.3	0.24	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
COAD	cis	rs2333021	0.78	rs28619241	ENSG00000259015.1	RP11-109N23.6	3.89	0.000129	0.0275	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72972902	chr14:72960595~72961993:+
COAD	cis	rs2333021	0.78	rs12931	ENSG00000259015.1	RP11-109N23.6	3.89	0.000129	0.0275	0.22	0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72974156	chr14:72960595~72961993:+
COAD	cis	rs4879656	0.872	rs1537040	ENSG00000225693.1	LAGE3P1	-3.89	0.000129	0.0275	-0.27	-0.24	Menopause (age at onset);	chr9:33061442	chr9:33019682~33020165:-
COAD	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	3.89	0.000129	0.0275	0.21	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
COAD	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-3.89	0.00013	0.0276	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
COAD	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-3.89	0.00013	0.0276	-0.35	-0.24	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
COAD	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	3.89	0.00013	0.0276	0.46	0.24	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
COAD	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	3.89	0.00013	0.0276	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
COAD	cis	rs7646881	0.544	rs56973279	ENSG00000272087.1	RP11-379F4.7	3.89	0.00013	0.0276	0.38	0.24	Tetralogy of Fallot;	chr3:158632526	chr3:158693120~158693768:-
COAD	cis	rs10465746	0.573	rs12121175	ENSG00000249237.4	RP11-376N17.4	-3.89	0.00013	0.0276	-0.27	-0.24	Obesity-related traits;	chr1:84003278	chr1:84344678~84349939:+
COAD	cis	rs9652601	0.959	rs12708715	ENSG00000274038.1	RP11-66H6.4	-3.89	0.00013	0.0276	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11083967	chr16:11056556~11057034:+
COAD	cis	rs12699921	0.598	rs1965534	ENSG00000279048.1	RP11-511H23.2	-3.89	0.00013	0.0276	-0.17	-0.24	Fibrinogen levels;	chr7:17790488	chr7:17940503~17942922:+
COAD	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	3.89	0.00013	0.0276	0.3	0.24	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
COAD	cis	rs78487399	0.908	rs55921927	ENSG00000234936.1	AC010883.5	3.89	0.00013	0.0276	0.31	0.24	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43621796	chr2:43229573~43233394:+
COAD	cis	rs2342406	0.622	rs12151615	ENSG00000259439.2	RP11-89K21.1	3.89	0.00013	0.0276	0.4	0.24	Myopia;	chr2:44905673	chr2:44921077~44939199:-
COAD	cis	rs7829975	0.502	rs7820738	ENSG00000173295.6	FAM86B3P	-3.89	0.00013	0.0276	-0.28	-0.24	Mood instability;	chr8:8845097	chr8:8228595~8244865:+
COAD	cis	rs17685	0.712	rs7794454	ENSG00000280388.1	RP11-229D13.3	3.89	0.00013	0.0276	0.24	0.24	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76043977~76045963:-
COAD	cis	rs6601327	0.641	rs12542457	ENSG00000233609.3	RP11-62H7.2	-3.89	0.00013	0.0276	-0.27	-0.24	Multiple myeloma (hyperdiploidy);	chr8:9707090	chr8:8961200~8979025:+
COAD	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	3.89	0.00013	0.0276	0.25	0.24	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
COAD	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	3.89	0.00013	0.0276	0.25	0.24	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
COAD	cis	rs2307394	0.928	rs72855232	ENSG00000281469.1	RP11-567F11.1	3.89	0.00013	0.0276	0.29	0.24	Urate levels;	chr2:147991398	chr2:148044380~148044894:+
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000274576.2	IGHV2-70	-3.89	0.00013	0.0276	-0.17	-0.24	Kawasaki disease;	chr14:106807157	chr14:106770577~106771020:-
COAD	cis	rs73222236	0.737	rs9854328	ENSG00000273486.1	RP11-731C17.2	3.89	0.00013	0.0276	0.24	0.24	Coronary artery disease;	chr3:136350878	chr3:136837338~136839021:-
COAD	cis	rs2929278	0.562	rs8033846	ENSG00000275601.1	AC011330.13	3.89	0.00013	0.0276	0.29	0.24	Schizophrenia;	chr15:43743165	chr15:43642389~43643023:-
COAD	cis	rs6981523	0.553	rs11783890	ENSG00000269918.1	AF131215.9	-3.89	0.00013	0.0276	-0.31	-0.24	Neuroticism;	chr8:11198879	chr8:11104691~11106704:-
COAD	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-3.89	0.00013	0.0276	-0.25	-0.24	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
COAD	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	3.89	0.00013	0.0276	0.24	0.24	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
COAD	cis	rs7324557	0.684	rs9507165	ENSG00000205861.10	C1QTNF9B-AS1	-3.89	0.00013	0.0276	-0.33	-0.24	Visceral adipose tissue adjusted for BMI;	chr13:23810291	chr13:23888889~23897263:+
COAD	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-3.89	0.00013	0.0276	-0.25	-0.24	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
COAD	cis	rs911263	0.603	rs3784108	ENSG00000259502.1	RP11-643G16.3	-3.89	0.00013	0.0276	-0.29	-0.24	Primary biliary cholangitis;	chr14:68322966	chr14:67610986~67613864:+
COAD	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	3.89	0.00013	0.0276	0.23	0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
COAD	cis	rs4237845	0.622	rs10783859	ENSG00000257698.1	RP11-620J15.3	3.89	0.00013	0.0276	0.21	0.24	Intelligence (multi-trait analysis);	chr12:57939011	chr12:57931528~57936175:-
COAD	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	3.89	0.00013	0.0276	0.37	0.24	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
COAD	cis	rs7160336	0.738	rs11849883	ENSG00000259065.1	RP5-1021I20.1	3.89	0.00013	0.0276	0.28	0.24	Blood protein levels;	chr14:74010633	chr14:73787360~73803270:+
COAD	cis	rs13256369	0.802	rs34762800	ENSG00000253981.4	ALG1L13P	3.89	0.00013	0.0276	0.35	0.24	Obesity-related traits;	chr8:8701784	chr8:8236003~8244667:-
COAD	cis	rs1480597	1	rs77208659	ENSG00000165511.6	C10orf25	3.89	0.00013	0.0277	0.41	0.24	Parkinson's disease;	chr10:44726446	chr10:44997698~45000888:-
COAD	cis	rs467650	0.782	rs56264044	ENSG00000248489.1	CTD-2007H13.3	3.89	0.00013	0.0277	0.24	0.24	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98929171~98995013:+
COAD	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-3.89	0.00013	0.0277	-0.49	-0.24	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
COAD	cis	rs1023500	1	rs1023497	ENSG00000237037.8	NDUFA6-AS1	3.89	0.00013	0.0277	0.25	0.24	Schizophrenia;	chr22:41944504	chr22:42090931~42137742:+
COAD	cis	rs2916733	0.607	rs2442512	ENSG00000246089.3	RP11-115C21.2	-3.89	0.00013	0.0277	-0.31	-0.24	Epirubicin-induced leukopenia;	chr8:6440802	chr8:6403551~6407142:-
COAD	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-3.89	0.00013	0.0277	-0.27	-0.24	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
COAD	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	3.88	0.00013	0.0277	0.31	0.24	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	3.88	0.00013	0.0277	0.31	0.24	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	3.88	0.00013	0.0277	0.31	0.24	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
COAD	cis	rs752010	0.644	rs6700390	ENSG00000230638.4	RP11-486B10.4	-3.88	0.00013	0.0277	-0.27	-0.24	Lupus nephritis in systemic lupus erythematosus;	chr1:41646883	chr1:41542069~41544310:+
COAD	cis	rs581080	0.654	rs478974	ENSG00000215236.3	RPL7P33	-3.88	0.00013	0.0277	-0.3	-0.24	HDL cholesterol;Total cholesterol levels;HDL cholesterol levels;Cholesterol, total;	chr9:15285826	chr9:15361393~15362134:+
COAD	cis	rs10740039	0.729	rs6479728	ENSG00000227877.5	LINC00948	3.88	0.00013	0.0277	0.31	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:59736692~59756041:-
COAD	cis	rs2638953	0.672	rs11049713	ENSG00000247934.4	RP11-967K21.1	-3.88	0.00013	0.0277	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28558612	chr12:28163298~28190738:-
COAD	cis	rs4819052	0.851	rs2838844	ENSG00000227039.5	ITGB2-AS1	-3.88	0.00013	0.0277	-0.21	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:44921051~44929678:+
COAD	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-3.88	0.00013	0.0277	-0.32	-0.24	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
COAD	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	3.88	0.00013	0.0277	0.27	0.24	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
COAD	cis	rs4072705	1	rs2067791	ENSG00000224020.1	MIR181A2HG	-3.88	0.00013	0.0277	-0.28	-0.24	Menarche (age at onset);	chr9:124676015	chr9:124658467~124698631:+
COAD	cis	rs911263	0.603	rs12890109	ENSG00000259502.1	RP11-643G16.3	-3.88	0.00013	0.0277	-0.29	-0.24	Primary biliary cholangitis;	chr14:68314876	chr14:67610986~67613864:+
COAD	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	3.88	0.00013	0.0277	0.3	0.24	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
COAD	cis	rs11138902	0.673	rs10867682	ENSG00000229312.2	RP11-470P21.2	3.88	0.00013	0.0277	0.26	0.24	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69503703	chr9:69472466~69494513:+
COAD	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	3.88	0.000131	0.0277	0.34	0.24	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
COAD	cis	rs7260598	0.792	rs73029291	ENSG00000268442.1	CTD-2027I19.2	3.88	0.000131	0.0277	0.36	0.24	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:24162370~24163425:-
COAD	cis	rs2531992	0.702	rs1045475	ENSG00000262185.1	RP11-462G12.1	-3.88	0.000131	0.0277	-0.33	-0.24	Waist circumference;	chr16:3965315	chr16:3947609~3950444:-
COAD	cis	rs228614	0.509	rs223481	ENSG00000248971.2	KRT8P46	-3.88	0.000131	0.0277	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102728746~102730171:-
COAD	cis	rs860295	0.812	rs11264363	ENSG00000160766.13	GBAP1	-3.88	0.000131	0.0277	-0.26	-0.24	Body mass index;	chr1:155348517	chr1:155213821~155227422:-
COAD	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	3.88	0.000131	0.0277	0.26	0.24	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
COAD	cis	rs13256369	0.802	rs2280560	ENSG00000254153.1	CTA-398F10.2	3.88	0.000131	0.0278	0.31	0.24	Obesity-related traits;	chr8:8703092	chr8:8456909~8461337:-
COAD	cis	rs870355	0.964	rs3829575	ENSG00000267679.1	EIF5AP2	-3.88	0.000131	0.0278	-0.26	-0.24	Vitiligo;	chr17:78169782	chr17:78157403~78159135:+
COAD	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-3.88	0.000131	0.0278	-0.4	-0.24	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
COAD	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	3.88	0.000131	0.0278	0.31	0.24	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
COAD	cis	rs4794202	0.523	rs11871969	ENSG00000264920.1	RP11-6N17.4	-3.88	0.000131	0.0278	-0.39	-0.24	Alzheimer's disease (cognitive decline);	chr17:47915256	chr17:47891255~47895812:-
COAD	cis	rs6068583	0.86	rs6063966	ENSG00000197670.6	RP4-724E16.2	-3.88	0.000131	0.0278	-0.32	-0.24	Colorectal adenoma (advanced);	chr20:53576549	chr20:53552770~53575863:+
COAD	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	3.88	0.000131	0.0278	0.32	0.24	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
COAD	cis	rs3824347	0.902	rs10781262	ENSG00000229587.2	RP11-197P3.5	3.88	0.000131	0.0278	0.26	0.24	Urinary magnesium-to-creatinine ratio;	chr9:75035780	chr9:75009828~75016036:-
COAD	cis	rs7582403	0.844	rs1234433	ENSG00000281469.1	RP11-567F11.1	3.88	0.000131	0.0278	0.27	0.24	Neuroticism;	chr2:148061431	chr2:148044380~148044894:+
COAD	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.000131	0.0278	-0.2	-0.24	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
COAD	cis	rs228614	0.509	rs223476	ENSG00000248971.2	KRT8P46	-3.88	0.000131	0.0278	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102728746~102730171:-
COAD	cis	rs228614	0.509	rs150896	ENSG00000248971.2	KRT8P46	-3.88	0.000131	0.0278	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102728746~102730171:-
COAD	cis	rs11157436	0.602	rs11157438	ENSG00000211812.1	TRAV26-2	-3.88	0.000131	0.0278	-0.23	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22202583~22203368:+
COAD	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	3.88	0.000131	0.0278	0.23	0.24	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
COAD	cis	rs853679	1	rs2799079	ENSG00000225173.1	XXbac-BPG308K3.5	3.88	0.000131	0.0278	0.39	0.24	Depression;	chr6:28267398	chr6:28837869~28839006:-
COAD	cis	rs480407	0.667	rs59650277	ENSG00000232320.6	AC009299.5	3.88	0.000131	0.0278	0.32	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr2:160773689	chr2:161340816~161341326:-
COAD	cis	rs6452524	0.935	rs1543847	ENSG00000271862.1	RP11-343L5.2	3.88	0.000131	0.0278	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83049376~83050964:-
COAD	cis	rs597539	0.617	rs669659	ENSG00000255741.1	RP11-757G1.5	-3.88	0.000131	0.0278	-0.3	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68941503~68942852:-
COAD	cis	rs6951245	0.938	rs11764937	ENSG00000229043.2	AC091729.9	-3.88	0.000131	0.0278	-0.39	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1160374~1165267:+
COAD	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	3.88	0.000131	0.0278	0.24	0.24	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
COAD	cis	rs55962025	0.883	rs362336	ENSG00000248840.2	RP11-357G3.2	3.88	0.000131	0.0278	0.28	0.24	Parental longevity (mother's age at death);	chr4:3212105	chr4:3312512~3313058:+
COAD	cis	rs17451754	0.626	rs213979	ENSG00000237974.1	AC000111.4	3.88	0.000131	0.0278	0.25	0.24	Barrett's esophagus  or Esophageal adenocarcinoma;	chr7:117608180	chr7:117487737~117487929:+
COAD	cis	rs11098499	0.754	rs1546503	ENSG00000250412.1	KLHL2P1	3.88	0.000131	0.0278	0.31	0.24	Corneal astigmatism;	chr4:119320012	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.708	rs1546506	ENSG00000250412.1	KLHL2P1	3.88	0.000131	0.0278	0.31	0.24	Corneal astigmatism;	chr4:119320085	chr4:119334329~119378233:+
COAD	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-3.88	0.000131	0.0278	-0.23	-0.24	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
COAD	cis	rs2408955	0.568	rs12099462	ENSG00000257735.1	RP11-370I10.6	-3.88	0.000131	0.0278	-0.27	-0.24	Glycated hemoglobin levels;	chr12:48109321	chr12:48350945~48442411:+
COAD	cis	rs9880211	0.563	rs6793835	ENSG00000273486.1	RP11-731C17.2	-3.88	0.000131	0.0278	-0.29	-0.24	Height;Body mass index;	chr3:136101092	chr3:136837338~136839021:-
COAD	cis	rs9951698	0.678	rs6505780	ENSG00000266969.1	RP11-773H22.4	-3.88	0.000131	0.0278	-0.3	-0.24	Intelligence (multi-trait analysis);	chr18:13069783	chr18:12984694~12991173:-
COAD	cis	rs7212590	0.748	rs7220187	ENSG00000264049.1	MIR4737	-3.88	0.000131	0.0278	-0.34	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59820248	chr17:60043025~60043105:-
COAD	cis	rs7212590	0.748	rs7213697	ENSG00000264049.1	MIR4737	-3.88	0.000131	0.0278	-0.34	-0.24	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59825680	chr17:60043025~60043105:-
COAD	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000131	0.0278	-0.27	-0.24	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
COAD	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-3.88	0.000131	0.0278	-0.28	-0.24	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
COAD	cis	rs2337406	0.925	rs873533	ENSG00000211974.3	IGHV2-70	-3.88	0.000131	0.0278	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106667442	chr14:106723574~106724093:-
COAD	cis	rs10779751	1	rs2076655	ENSG00000215785.2	CFL1P6	3.88	0.000131	0.0278	0.26	0.24	Body mass index;	chr1:11229104	chr1:10990978~10991797:-
COAD	cis	rs11969893	0.85	rs9498409	ENSG00000270987.1	RP3-467N11.2	3.88	0.000131	0.0278	0.51	0.24	Economic and political preferences (immigration/crime);	chr6:100852090	chr6:100889603~100890338:+
COAD	cis	rs11969893	0.85	rs9485417	ENSG00000270987.1	RP3-467N11.2	-3.88	0.000131	0.0278	-0.51	-0.24	Economic and political preferences (immigration/crime);	chr6:100852162	chr6:100889603~100890338:+
COAD	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	3.88	0.000131	0.0278	0.23	0.24	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
COAD	cis	rs875971	0.83	rs587360	ENSG00000230189.5	GS1-124K5.2	3.88	0.000131	0.0278	0.19	0.24	Aortic root size;	chr7:66057711	chr7:66409143~66490059:-
COAD	cis	rs3126085	0.935	rs11204943	ENSG00000237975.5	FLG-AS1	-3.88	0.000131	0.0278	-0.26	-0.24	Atopic dermatitis;	chr1:152231430	chr1:152168125~152445456:+
COAD	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
COAD	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	3.88	0.000131	0.0278	0.24	0.24	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
COAD	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-3.88	0.000131	0.0279	-0.23	-0.24	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
COAD	cis	rs6730558	0.899	rs1368928	ENSG00000235092.4	ID2-AS1	-3.88	0.000131	0.0279	-0.3	-0.24	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8611333	chr2:8666636~8681863:-
COAD	cis	rs7674212	0.57	rs1031804	ENSG00000230069.3	LRRC37A15P	-3.88	0.000131	0.0279	-0.25	-0.24	Type 2 diabetes;	chr4:103144892	chr4:102727274~102730721:-
COAD	cis	rs11722228	1	rs6825187	ENSG00000250413.1	RP11-448G15.1	3.88	0.000131	0.0279	0.33	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:9913701	chr4:10006482~10009725:+
COAD	cis	rs6052484	0.883	rs6052491	ENSG00000275491.1	RP5-1009E24.8	3.88	0.000131	0.0279	0.36	0.24	Sense of smell;	chr20:4294835	chr20:3808357~3812434:+
COAD	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-3.88	0.000131	0.0279	-0.34	-0.24	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
COAD	cis	rs6822297	0.875	rs10939144	ENSG00000240005.4	RP11-293A21.1	-3.88	0.000131	0.0279	-0.28	-0.24	Obesity-related traits;	chr4:26965284	chr4:26859806~26860599:-
COAD	cis	rs712039	0.652	rs853227	ENSG00000276054.1	RP11-378E13.3	3.88	0.000131	0.0279	0.36	0.24	Tuberculosis;	chr17:37437428	chr17:37386886~37387926:+
COAD	cis	rs2835349	0.522	rs2845762	ENSG00000230479.1	AP000695.6	3.88	0.000131	0.0279	0.25	0.24	Red blood cell count;	chr21:36445608	chr21:36430360~36481070:+
COAD	cis	rs7615952	0.605	rs11708269	ENSG00000241278.1	ENPP7P4	3.88	0.000131	0.0279	0.35	0.24	Blood pressure (smoking interaction);	chr3:125613306	chr3:125848223~125909372:+
COAD	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-3.88	0.000131	0.0279	-0.22	-0.24	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
COAD	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	3.88	0.000131	0.0279	0.35	0.24	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
COAD	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	3.88	0.000132	0.0279	0.28	0.24	Height;	chr4:55562653	chr4:55547112~55547889:+
COAD	cis	rs2559856	0.967	rs3809260	ENSG00000199933.1	RNY1P16	3.88	0.000132	0.0279	0.26	0.24	Blood protein levels;	chr12:101697239	chr12:101719808~101719918:+
COAD	cis	rs7204230	1	rs17303428	ENSG00000261056.2	RP11-454F8.2	3.88	0.000132	0.0279	0.28	0.24	Fibrinogen;	chr16:53283844	chr16:53298224~53299792:+
COAD	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-3.88	0.000132	0.0279	-0.32	-0.24	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
COAD	cis	rs116139393	0.656	rs10244591	ENSG00000187953.9	PMS2CL	-3.88	0.000132	0.0279	-0.26	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6731467	chr7:6710128~6753862:+
COAD	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-3.88	0.000132	0.0279	-0.21	-0.24	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
COAD	cis	rs12497850	1	rs10865952	ENSG00000225399.4	RP11-3B7.1	3.88	0.000132	0.0279	0.26	0.24	Parkinson's disease;	chr3:48707051	chr3:49260085~49261316:+
COAD	cis	rs4072705	0.967	rs10818984	ENSG00000224020.1	MIR181A2HG	-3.88	0.000132	0.0279	-0.28	-0.24	Menarche (age at onset);	chr9:124651272	chr9:124658467~124698631:+
COAD	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000132	0.0279	-0.26	-0.24	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000132	0.0279	-0.26	-0.24	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000132	0.0279	-0.26	-0.24	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000132	0.0279	-0.26	-0.24	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000132	0.0279	-0.26	-0.24	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
COAD	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000132	0.0279	-0.26	-0.24	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000132	0.0279	-0.26	-0.24	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000132	0.0279	-0.26	-0.24	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
COAD	cis	rs2018293	1	rs6005009	ENSG00000233521.4	RP5-1172A22.1	-3.88	0.000132	0.0279	-0.22	-0.24	Vascular brain injury;	chr22:26314444	chr22:27221349~27224727:-
COAD	cis	rs875971	1	rs937495	ENSG00000230189.5	GS1-124K5.2	-3.88	0.000132	0.0279	-0.2	-0.24	Aortic root size;	chr7:66314811	chr7:66409143~66490059:-
COAD	cis	rs11976180	0.953	rs2951355	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144063469	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951354	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144063908	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2961125	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144064677	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2961126	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144065643	chr7:144142009~144142938:+
COAD	cis	rs11976180	0.953	rs2961127	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144065644	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs1919948	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144065750	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2961128	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144066390	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2371248	ENSG00000273234.1	OR2A13P	-3.88	0.000132	0.0279	-0.29	-0.24	Obesity-related traits;	chr7:144067096	chr7:144142009~144142938:+
COAD	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000132	0.0279	-0.22	-0.24	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
COAD	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-3.88	0.000132	0.0279	-0.29	-0.24	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
COAD	cis	rs17711722	0.522	rs6957759	ENSG00000272831.1	RP11-792A8.4	3.88	0.000132	0.0279	0.25	0.24	Calcium levels;	chr7:65806798	chr7:66739829~66740385:-
COAD	cis	rs12220238	0.841	rs10824163	ENSG00000279689.1	RP11-574K11.32	3.88	0.000132	0.0279	0.3	0.24	Soluble interleukin-2 receptor subunit alpha;	chr10:74376831	chr10:73769264~73772862:-
COAD	cis	rs7781557	1	rs10487281	ENSG00000235354.1	CTA-276O3.4	-3.88	0.000132	0.0279	-0.3	-0.24	Colorectal adenoma (advanced);	chr7:102837134	chr7:103348601~103348771:+
COAD	cis	rs561341	1	rs55643307	ENSG00000265798.5	RP11-271K11.5	3.88	0.000132	0.0279	0.39	0.24	Hip circumference adjusted for BMI;	chr17:31936055	chr17:31038575~31059121:-
COAD	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	3.88	0.000132	0.0279	0.47	0.24	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
COAD	cis	rs2732480	0.5	rs7966829	ENSG00000257763.1	OR5BK1P	3.88	0.000132	0.0279	0.26	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48355792~48356614:-
COAD	cis	rs2836974	0.568	rs452377	ENSG00000255568.3	BRWD1-AS2	3.88	0.000132	0.0279	0.22	0.24	Cognitive function;	chr21:39165257	chr21:39313935~39314962:+
COAD	cis	rs12530	0.752	rs9609516	ENSG00000232218.1	RP1-149A16.16	-3.88	0.000132	0.0279	-0.44	-0.24	IgG glycosylation;	chr22:32359087	chr22:32386668~32386868:+
COAD	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	3.88	0.000132	0.028	0.38	0.24	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
COAD	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	3.88	0.000132	0.028	0.38	0.24	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
COAD	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	3.88	0.000132	0.028	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	3.88	0.000132	0.028	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
COAD	cis	rs2617170	0.713	rs11053803	ENSG00000245648.1	RP11-277P12.20	-3.88	0.000132	0.028	-0.3	-0.24	Behcet's disease;	chr12:10447063	chr12:10363769~10398506:+
COAD	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.33	0.24	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.33	0.24	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.33	0.24	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.33	0.24	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
COAD	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	3.88	0.000132	0.028	0.31	0.24	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
COAD	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	3.88	0.000132	0.028	0.27	0.24	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
COAD	cis	rs3096277	1	rs413469	ENSG00000261286.1	RP11-517C16.2	3.88	0.000132	0.028	0.22	0.24	Blood pressure;	chr16:83728396	chr16:84459259~84467361:-
COAD	cis	rs13256369	0.851	rs13271698	ENSG00000253981.4	ALG1L13P	3.88	0.000132	0.028	0.35	0.24	Obesity-related traits;	chr8:8710029	chr8:8236003~8244667:-
COAD	cis	rs11157436	0.602	rs1894369	ENSG00000211812.1	TRAV26-2	3.88	0.000132	0.028	0.23	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22202583~22203368:+
COAD	cis	rs253959	0.595	rs11241361	ENSG00000271918.1	CTD-2287O16.5	3.88	0.000132	0.028	0.23	0.24	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116083807~116085416:-
COAD	cis	rs253959	0.545	rs11241362	ENSG00000271918.1	CTD-2287O16.5	3.88	0.000132	0.028	0.23	0.24	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116083807~116085416:-
COAD	cis	rs34792	0.554	rs12933773	ENSG00000207425.1	Y_RNA	-3.88	0.000132	0.028	-0.3	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:14915457~14915556:-
COAD	cis	rs2302729	0.578	rs10774052	ENSG00000246627.5	CACNA1C-AS1	3.88	0.000132	0.028	0.28	0.24	Sleep quality;	chr12:2663005	chr12:2676001~2691200:-
COAD	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	3.88	0.000132	0.028	0.35	0.24	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
COAD	cis	rs2307394	1	rs57679331	ENSG00000281469.1	RP11-567F11.1	3.88	0.000132	0.028	0.28	0.24	Urate levels;	chr2:147979756	chr2:148044380~148044894:+
COAD	cis	rs3126085	0.935	rs4595369	ENSG00000237975.5	FLG-AS1	-3.88	0.000132	0.028	-0.26	-0.24	Atopic dermatitis;	chr1:152275717	chr1:152168125~152445456:+
COAD	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.000132	0.028	-0.24	-0.24	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
COAD	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	3.88	0.000132	0.028	0.42	0.24	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
COAD	cis	rs1115240	0.574	rs6575031	ENSG00000257842.4	NOVA1-AS1	3.88	0.000132	0.028	0.31	0.24	Educational attainment (years of education);	chr14:26548981	chr14:26598412~26806467:+
COAD	cis	rs6012564	0.964	rs6125577	ENSG00000227431.4	CSE1L-AS1	3.88	0.000132	0.028	0.25	0.24	Anger;	chr20:49166558	chr20:49040463~49046044:-
COAD	cis	rs10200159	1	rs13430684	ENSG00000272606.1	RP11-554J4.1	3.88	0.000132	0.028	0.36	0.24	Vitiligo;	chr2:55642709	chr2:55617909~55618373:+
COAD	cis	rs875971	0.545	rs313830	ENSG00000232546.1	RP11-458F8.1	-3.88	0.000132	0.028	-0.24	-0.24	Aortic root size;	chr7:66086944	chr7:66848496~66858136:+
COAD	cis	rs11229555	0.645	rs12273638	ENSG00000254602.1	AP000662.4	-3.88	0.000132	0.028	-0.28	-0.24	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58418862	chr11:57638024~57652790:+
COAD	cis	rs2564921	0.666	rs11130335	ENSG00000280417.1	RP11-5O17.1	3.88	0.000132	0.028	0.25	0.24	Height;	chr3:52989619	chr3:53046166~53048122:+
COAD	cis	rs2732480	0.577	rs2634681	ENSG00000226413.2	OR8T1P	-3.88	0.000133	0.028	-0.29	-0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48442030~48442947:-
COAD	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	3.88	0.000133	0.028	0.16	0.24	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
COAD	cis	rs6163	0.727	rs284854	ENSG00000228657.1	RP11-170J3.2	3.88	0.000133	0.0281	0.25	0.24	Waist circumference;Hip circumference;	chr10:102814805	chr10:102572757~102573225:-
COAD	cis	rs643506	0.874	rs634983	ENSG00000230911.1	PPIHP1	-3.88	0.000133	0.0281	-0.29	-0.24	Breast cancer;	chr11:111876703	chr11:112029858~112030367:-
COAD	cis	rs2337406	0.925	rs2011167	ENSG00000280411.1	IGHV1-69-2	-3.88	0.000133	0.0281	-0.18	-0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106762092~106762588:-
COAD	cis	rs4660214	0.666	rs588326	ENSG00000182109.6	RP11-69E11.4	3.88	0.000133	0.0281	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39522280~39546187:-
COAD	cis	rs7650267	0.765	rs1320160	ENSG00000232354.6	VIPR1-AS1	3.88	0.000133	0.0281	0.27	0.24	Obesity-related traits;	chr3:43261593	chr3:42506465~42533258:-
COAD	cis	rs11681884	0.892	rs17486819	ENSG00000228251.1	AC012442.6	3.88	0.000133	0.0281	0.59	0.24	Stroke;	chr2:113114229	chr2:112590796~112591939:+
COAD	cis	rs2017305	0.764	rs2487710	ENSG00000233590.1	RP11-153K11.3	3.88	0.000133	0.0281	0.41	0.24	Depression (quantitative trait);	chr10:69022370	chr10:68233251~68242379:-
COAD	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	3.88	0.000133	0.0281	0.24	0.24	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
COAD	cis	rs742132	0.858	rs7775000	ENSG00000220875.1	HIST1H3PS1	3.88	0.000133	0.0281	0.3	0.24	Uric acid levels;	chr6:25665936	chr6:26321876~26322292:-
COAD	cis	rs742132	0.791	rs7757280	ENSG00000220875.1	HIST1H3PS1	3.88	0.000133	0.0281	0.3	0.24	Uric acid levels;	chr6:25666304	chr6:26321876~26322292:-
COAD	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	3.88	0.000133	0.0281	0.27	0.24	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	3.88	0.000133	0.0281	0.27	0.24	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	3.88	0.000133	0.0281	0.27	0.24	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
COAD	cis	rs4973517	0.678	rs3100608	ENSG00000237126.7	AC073254.1	3.88	0.000133	0.0281	0.34	0.24	Hip circumference adjusted for BMI;	chr2:231985093	chr2:232580948~232611971:-
COAD	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	3.88	0.000133	0.0281	0.27	0.24	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
COAD	cis	rs228614	0.509	rs223482	ENSG00000248971.2	KRT8P46	-3.88	0.000133	0.0281	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102728746~102730171:-
COAD	cis	rs228614	0.536	rs223478	ENSG00000248971.2	KRT8P46	-3.88	0.000133	0.0281	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102728746~102730171:-
COAD	cis	rs228614	0.536	rs150898	ENSG00000248971.2	KRT8P46	-3.88	0.000133	0.0281	-0.23	-0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102728746~102730171:-
COAD	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-3.88	0.000133	0.0281	-0.36	-0.24	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
COAD	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	3.88	0.000133	0.0281	0.28	0.24	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
COAD	cis	rs2836974	0.932	rs35571600	ENSG00000255568.3	BRWD1-AS2	3.88	0.000133	0.0281	0.24	0.24	Cognitive function;	chr21:39218698	chr21:39313935~39314962:+
COAD	cis	rs4072705	1	rs6478680	ENSG00000236643.1	RP11-175D17.3	3.88	0.000133	0.0281	0.26	0.24	Menarche (age at onset);	chr9:124696189	chr9:124770123~124772927:+
COAD	cis	rs9532669	0.926	rs9532689	ENSG00000277662.1	RP11-74J13.9	-3.88	0.000133	0.0281	-0.23	-0.24	Cervical cancer;	chr13:40957990	chr13:41229180~41229676:-
COAD	cis	rs9393777	0.588	rs6456727	ENSG00000224843.5	LINC00240	3.88	0.000133	0.0281	0.33	0.24	Intelligence (multi-trait analysis);	chr6:26470927	chr6:26956992~27023924:+
COAD	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	3.88	0.000133	0.0281	0.3	0.24	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
COAD	cis	rs2858942	0.527	rs7185345	ENSG00000268836.1	LA16c-OS12.2	3.88	0.000133	0.0281	0.26	0.24	Mean corpuscular hemoglobin;	chr16:192771	chr16:185748~186294:-
COAD	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
COAD	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
COAD	cis	rs875971	0.825	rs59466412	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66100371	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000133	0.0281	-0.28	-0.24	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
COAD	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-3.88	0.000133	0.0281	-0.38	-0.24	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
COAD	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-3.88	0.000133	0.0281	-0.28	-0.24	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-3.88	0.000133	0.0281	-0.28	-0.24	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-3.88	0.000133	0.0281	-0.28	-0.24	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
COAD	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-3.88	0.000133	0.0281	-0.28	-0.24	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
COAD	cis	rs12935418	0.616	rs62054238	ENSG00000261061.1	RP11-303E16.2	-3.88	0.000133	0.0281	-0.31	-0.24	Mean corpuscular volume;	chr16:80965753	chr16:81030770~81031485:+
COAD	cis	rs12935418	0.616	rs62054239	ENSG00000261061.1	RP11-303E16.2	-3.88	0.000133	0.0281	-0.31	-0.24	Mean corpuscular volume;	chr16:80966287	chr16:81030770~81031485:+
COAD	cis	rs17359493	0.636	rs7844932	ENSG00000253528.2	RP11-347C18.4	-3.88	0.000133	0.0281	-0.29	-0.24	Type 2 diabetes;	chr8:94871004	chr8:94974573~94974853:-
COAD	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	3.88	0.000133	0.0281	0.24	0.24	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
COAD	cis	rs6730558	0.966	rs4668585	ENSG00000235092.4	ID2-AS1	-3.88	0.000133	0.0282	-0.3	-0.24	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8612108	chr2:8666636~8681863:-
COAD	cis	rs6730558	0.966	rs6709626	ENSG00000235092.4	ID2-AS1	-3.88	0.000133	0.0282	-0.3	-0.24	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8612616	chr2:8666636~8681863:-
COAD	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-3.88	0.000133	0.0282	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
COAD	cis	rs4072705	1	rs10818987	ENSG00000224020.1	MIR181A2HG	-3.88	0.000133	0.0282	-0.27	-0.24	Menarche (age at onset);	chr9:124758450	chr9:124658467~124698631:+
COAD	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	3.88	0.000133	0.0282	0.21	0.24	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
COAD	cis	rs6452524	0.935	rs7703318	ENSG00000271862.1	RP11-343L5.2	3.88	0.000133	0.0282	0.23	0.24	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83049376~83050964:-
COAD	cis	rs11951515	0.509	rs12521249	ENSG00000248554.1	RP11-159F24.6	3.88	0.000133	0.0282	0.25	0.24	Metabolite levels  (X-11787);	chr5:43558527	chr5:43511058~43521811:+
COAD	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	3.88	0.000133	0.0282	0.26	0.24	Height;	chr4:55540928	chr4:55363971~55395847:-
COAD	cis	rs8022206	0.853	rs11629073	ENSG00000259502.1	RP11-643G16.3	3.88	0.000133	0.0282	0.36	0.24	Platelet count;Mean platelet volume;	chr14:68069578	chr14:67610986~67613864:+
COAD	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-3.88	0.000133	0.0282	-0.4	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
COAD	cis	rs1353394	0.59	rs1256389	ENSG00000226845.1	EEF1GP3	3.88	0.000133	0.0282	0.27	0.24	Gut microbiota (functional units);	chr3:41571777	chr3:40596207~40597494:-
COAD	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	3.88	0.000133	0.0282	0.22	0.24	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
COAD	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	3.88	0.000134	0.0282	0.42	0.24	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
COAD	cis	rs10876993	0.89	rs10783844	ENSG00000270039.1	RP11-571M6.17	3.88	0.000134	0.0282	0.26	0.24	Celiac disease or Rheumatoid arthritis;	chr12:57704642	chr12:57803838~57804415:+
COAD	cis	rs911263	0.603	rs7146850	ENSG00000259502.1	RP11-643G16.3	-3.88	0.000134	0.0282	-0.29	-0.24	Primary biliary cholangitis;	chr14:68321164	chr14:67610986~67613864:+
COAD	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-3.88	0.000134	0.0282	-0.23	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
COAD	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	3.88	0.000134	0.0282	0.26	0.24	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
COAD	cis	rs3126085	0.935	rs4534386	ENSG00000237975.5	FLG-AS1	-3.88	0.000134	0.0282	-0.26	-0.24	Atopic dermatitis;	chr1:152279238	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs11485508	ENSG00000237975.5	FLG-AS1	-3.88	0.000134	0.0282	-0.26	-0.24	Atopic dermatitis;	chr1:152280691	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs12027807	ENSG00000237975.5	FLG-AS1	-3.88	0.000134	0.0282	-0.26	-0.24	Atopic dermatitis;	chr1:152281250	chr1:152168125~152445456:+
COAD	cis	rs3126085	1	rs4845756	ENSG00000237975.5	FLG-AS1	-3.88	0.000134	0.0282	-0.26	-0.24	Atopic dermatitis;	chr1:152282443	chr1:152168125~152445456:+
COAD	cis	rs1115240	0.574	rs8020034	ENSG00000257842.4	NOVA1-AS1	3.88	0.000134	0.0282	0.31	0.24	Educational attainment (years of education);	chr14:26511894	chr14:26598412~26806467:+
COAD	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-3.88	0.000134	0.0282	-0.27	-0.24	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-3.88	0.000134	0.0282	-0.27	-0.24	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
COAD	cis	rs6687821	0.531	rs4357505	ENSG00000261737.1	RP4-612B15.3	-3.88	0.000134	0.0282	-0.31	-0.24	Yeast infection;	chr1:87018785	chr1:86703502~86704462:-
COAD	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	3.88	0.000134	0.0282	0.31	0.24	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
COAD	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-3.88	0.000134	0.0282	-0.32	-0.24	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
COAD	cis	rs12049351	0.613	rs7552561	ENSG00000229367.1	HMGN2P19	3.88	0.000134	0.0282	0.32	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229445239	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.665	rs10916479	ENSG00000229367.1	HMGN2P19	3.88	0.000134	0.0282	0.32	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229447800	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.665	rs10799532	ENSG00000229367.1	HMGN2P19	3.88	0.000134	0.0282	0.32	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229448873	chr1:229570532~229570796:+
COAD	cis	rs6585424	1	rs6585424	ENSG00000234382.2	RP11-40F6.1	-3.88	0.000134	0.0282	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:80233664~80245367:+
COAD	cis	rs6585424	1	rs56190825	ENSG00000234382.2	RP11-40F6.1	-3.88	0.000134	0.0282	-0.38	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:80233664~80245367:+
COAD	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-3.88	0.000134	0.0283	-0.24	-0.24	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
COAD	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	3.88	0.000134	0.0283	0.3	0.24	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
COAD	cis	rs2638953	0.962	rs10506032	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000134	0.0283	-0.25	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28163298~28190738:-
COAD	cis	rs3018712	0.532	rs4930588	ENSG00000184795.9	UNC93B5	3.88	0.000134	0.0283	0.38	0.24	Total body bone mineral density;	chr11:68647767	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs4930587	ENSG00000184795.9	UNC93B5	-3.88	0.000134	0.0283	-0.38	-0.24	Total body bone mineral density;	chr11:68647667	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs4930589	ENSG00000184795.9	UNC93B5	-3.88	0.000134	0.0283	-0.38	-0.24	Total body bone mineral density;	chr11:68647789	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs11228312	ENSG00000184795.9	UNC93B5	-3.88	0.000134	0.0283	-0.38	-0.24	Total body bone mineral density;	chr11:68648049	chr11:67711702~67716005:-
COAD	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	3.88	0.000134	0.0283	0.27	0.24	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
COAD	cis	rs12049351	0.665	rs3767326	ENSG00000229367.1	HMGN2P19	3.88	0.000134	0.0283	0.33	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229454303	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.665	rs7545114	ENSG00000229367.1	HMGN2P19	3.88	0.000134	0.0283	0.33	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229455851	chr1:229570532~229570796:+
COAD	cis	rs8031584	0.918	rs35784593	ENSG00000270015.1	RP11-540B6.6	-3.88	0.000134	0.0283	-0.2	-0.24	Huntington's disease progression;	chr15:30962385	chr15:30926514~30928407:+
COAD	cis	rs7172689	0.908	rs11072995	ENSG00000271725.1	RP11-761I4.4	-3.88	0.000134	0.0283	-0.29	-0.24	Inattentive symptoms;	chr15:81234691	chr15:81303215~81309391:-
COAD	cis	rs2638953	0.925	rs11049549	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000134	0.0283	-0.24	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357808	chr12:28163298~28190738:-
COAD	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	3.88	0.000134	0.0283	0.32	0.24	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
COAD	cis	rs7131987	0.834	rs1989478	ENSG00000275476.1	RP11-996F15.4	-3.88	0.000134	0.0283	-0.28	-0.24	QT interval;	chr12:29289296	chr12:29277397~29277882:-
COAD	cis	rs2179367	0.632	rs11155640	ENSG00000216906.2	RP11-350J20.9	3.88	0.000134	0.0283	0.34	0.24	Dupuytren's disease;	chr6:149323648	chr6:149904243~149906418:+
COAD	cis	rs9880211	0.563	rs6792630	ENSG00000239213.4	NCK1-AS1	3.88	0.000134	0.0283	0.31	0.24	Height;Body mass index;	chr3:136106059	chr3:136841726~136862054:-
COAD	cis	rs860295	0.676	rs10908466	ENSG00000160766.13	GBAP1	-3.88	0.000134	0.0283	-0.29	-0.24	Body mass index;	chr1:155459934	chr1:155213821~155227422:-
COAD	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-3.88	0.000134	0.0283	-0.29	-0.24	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
COAD	cis	rs250677	0.687	rs41181	ENSG00000250072.4	CTC-529P8.1	3.88	0.000134	0.0283	0.33	0.24	Breast cancer;	chr5:149064694	chr5:149063317~149109787:+
COAD	cis	rs2466035	0.654	rs2466028	ENSG00000253264.1	PCAT2	3.88	0.000134	0.0283	0.24	0.24	Chronic lymphocytic leukemia;	chr8:127188311	chr8:127072694~127082221:-
COAD	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-3.88	0.000134	0.0283	-0.32	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
COAD	cis	rs17214007	0.778	rs17213271	ENSG00000263335.1	AF001548.5	-3.88	0.000134	0.0284	-0.4	-0.24	Cognitive function;	chr16:15770487	chr16:15726674~15732993:+
COAD	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	3.88	0.000134	0.0284	0.34	0.24	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
COAD	cis	rs2732480	0.5	rs2932093	ENSG00000240399.1	RP1-228P16.1	3.88	0.000134	0.0284	0.25	0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48054813~48055591:-
COAD	cis	rs2439831	0.867	rs935901	ENSG00000166763.7	STRCP1	-3.88	0.000134	0.0284	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43359058	chr15:43699488~43718184:-
COAD	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	3.88	0.000134	0.0284	0.24	0.24	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
COAD	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	3.88	0.000134	0.0284	0.56	0.24	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
COAD	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	3.88	0.000135	0.0284	0.31	0.24	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
COAD	cis	rs719150	1	rs5029930	ENSG00000237499.5	RP11-356I2.4	-3.88	0.000135	0.0284	-0.33	-0.24	Cancer;	chr6:137869547	chr6:137823673~137868233:-
COAD	cis	rs2638953	0.776	rs11513467	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000135	0.0284	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.776	rs11519332	ENSG00000247934.4	RP11-967K21.1	-3.88	0.000135	0.0284	-0.23	-0.24	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28163298~28190738:-
COAD	cis	rs597539	0.69	rs7129960	ENSG00000255741.1	RP11-757G1.5	-3.88	0.000135	0.0284	-0.33	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68941503~68942852:-
COAD	cis	rs597539	0.69	rs11228383	ENSG00000255741.1	RP11-757G1.5	-3.88	0.000135	0.0284	-0.33	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68941503~68942852:-
COAD	cis	rs964611	0.575	rs9635332	ENSG00000259656.1	RP11-325E5.1	3.88	0.000135	0.0284	0.3	0.24	Metabolite levels (Pyroglutamine);	chr15:48384293	chr15:49101791~49103264:+
COAD	cis	rs913655	0.508	rs10826382	ENSG00000240291.1	RP11-499P20.2	3.88	0.000135	0.0284	0.26	0.24	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18763671	chr10:18513115~18545651:-
COAD	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	3.88	0.000135	0.0284	0.26	0.24	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
COAD	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	3.88	0.000135	0.0284	0.24	0.24	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
COAD	cis	rs28374715	0.681	rs7165396	ENSG00000247556.5	OIP5-AS1	3.88	0.000135	0.0284	0.33	0.24	Ulcerative colitis;	chr15:41294749	chr15:41283990~41309737:+
COAD	cis	rs875971	0.545	rs313828	ENSG00000232546.1	RP11-458F8.1	-3.88	0.000135	0.0284	-0.24	-0.24	Aortic root size;	chr7:66087627	chr7:66848496~66858136:+
COAD	cis	rs1387259	0.698	rs4579969	ENSG00000269514.1	RP11-370I10.12	-3.88	0.000135	0.0284	-0.27	-0.24	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48198387~48202031:+
COAD	cis	rs11098499	0.909	rs9759478	ENSG00000250412.1	KLHL2P1	3.88	0.000135	0.0284	0.32	0.24	Corneal astigmatism;	chr4:119446843	chr4:119334329~119378233:+
COAD	cis	rs4704187	0.64	rs1600073	ENSG00000250889.2	LINC01336	-3.88	0.000135	0.0284	-0.26	-0.24	Response to amphetamines;	chr5:75140912	chr5:75047719~75052843:-
COAD	cis	rs875971	1	rs2420820	ENSG00000224316.1	RP11-479O9.2	-3.88	0.000135	0.0284	-0.25	-0.24	Aortic root size;	chr7:66626920	chr7:65773620~65802067:+
COAD	cis	rs4730250	0.707	rs6977868	ENSG00000241764.3	AC002467.7	-3.88	0.000135	0.0284	-0.34	-0.24	Osteoarthritis;	chr7:107150110	chr7:107742817~107744581:-
COAD	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000135	0.0284	-0.28	-0.23	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	3.88	0.000135	0.0285	0.36	0.23	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
COAD	cis	rs2337406	0.866	rs4280141	ENSG00000211967.3	IGHV3-53	3.88	0.000135	0.0285	0.16	0.23	Alzheimer's disease (late onset);	chr14:106780476	chr14:106592676~106593347:-
COAD	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000135	0.0285	-0.25	-0.23	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
COAD	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000135	0.0285	-0.25	-0.23	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
COAD	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-3.88	0.000135	0.0285	-0.25	-0.23	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
COAD	cis	rs3018712	0.532	rs7932726	ENSG00000184795.9	UNC93B5	-3.88	0.000135	0.0285	-0.38	-0.23	Total body bone mineral density;	chr11:68647259	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs10791988	ENSG00000184795.9	UNC93B5	-3.88	0.000135	0.0285	-0.38	-0.23	Total body bone mineral density;	chr11:68648583	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs2513280	ENSG00000184795.9	UNC93B5	-3.88	0.000135	0.0285	-0.38	-0.23	Total body bone mineral density;	chr11:68649439	chr11:67711702~67716005:-
COAD	cis	rs10129255	0.957	rs17113284	ENSG00000224373.3	IGHV4-59	-3.88	0.000135	0.0285	-0.14	-0.23	Kawasaki disease;	chr14:106684476	chr14:106627249~106627825:-
COAD	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-3.88	0.000135	0.0285	-0.29	-0.23	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
COAD	cis	rs2179367	0.632	rs12211357	ENSG00000216906.2	RP11-350J20.9	3.88	0.000135	0.0285	0.34	0.23	Dupuytren's disease;	chr6:149331148	chr6:149904243~149906418:+
COAD	cis	rs2919009	1	rs2919009	ENSG00000271670.1	RP11-95I16.4	3.88	0.000135	0.0285	0.28	0.23	Obesity-related traits;	chr10:120831861	chr10:120879256~120880667:-
COAD	cis	rs10471753	0.742	rs11738020	ENSG00000248359.1	CTC-537E7.2	-3.88	0.000135	0.0285	-0.22	-0.23	Hip minimal joint space width;	chr5:68495203	chr5:68531690~68533530:-
COAD	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	3.88	0.000135	0.0285	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
COAD	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	3.88	0.000135	0.0285	0.28	0.23	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
COAD	cis	rs12468226	0.938	rs7568159	ENSG00000226261.1	AC064836.3	3.88	0.000135	0.0285	0.36	0.23	Urate levels;	chr2:202286226	chr2:202336024~202336727:-
COAD	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	3.88	0.000135	0.0285	0.28	0.23	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
COAD	cis	rs3764021	1	rs3764021	ENSG00000214776.8	RP11-726G1.1	3.88	0.000135	0.0285	0.27	0.23	Type 1 diabetes;	chr12:9681032	chr12:9467552~9576275:+
COAD	cis	rs891378	1	rs2802236	ENSG00000274245.1	RP11-357P18.2	3.87	0.000135	0.0285	0.32	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298844	chr1:207372559~207373252:+
COAD	cis	rs8177876	0.658	rs11150337	ENSG00000261061.1	RP11-303E16.2	-3.87	0.000136	0.0285	-0.37	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81030770~81031485:+
COAD	cis	rs561341	1	rs501312	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32002047	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs554078	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32003090	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs72825736	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32003267	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs8081016	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32004732	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs55736640	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32006829	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs72825740	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32011337	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs17780080	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32016127	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs17780086	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32016263	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs72825746	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32037591	chr17:31038575~31059121:-
COAD	cis	rs11098499	0.754	rs66900435	ENSG00000250412.1	KLHL2P1	3.87	0.000136	0.0285	0.31	0.23	Corneal astigmatism;	chr4:119328270	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs17595608	ENSG00000250412.1	KLHL2P1	3.87	0.000136	0.0285	0.31	0.23	Corneal astigmatism;	chr4:119329351	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs1980027	ENSG00000250412.1	KLHL2P1	3.87	0.000136	0.0285	0.31	0.23	Corneal astigmatism;	chr4:119330422	chr4:119334329~119378233:+
COAD	cis	rs561341	1	rs498391	ENSG00000265798.5	RP11-271K11.5	3.87	0.000136	0.0285	0.38	0.23	Hip circumference adjusted for BMI;	chr17:32001685	chr17:31038575~31059121:-
COAD	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-3.87	0.000136	0.0285	-0.28	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
COAD	cis	rs7260598	0.792	rs11670331	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000136	0.0285	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.792	rs11671489	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000136	0.0285	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.792	rs60773823	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000136	0.0285	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.792	rs10500223	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000136	0.0285	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:24162370~24163425:-
COAD	cis	rs1048886	0.872	rs77054685	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000136	0.0286	-0.33	-0.23	Type 2 diabetes;	chr6:70572469	chr6:70596438~70596980:+
COAD	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	3.87	0.000136	0.0286	0.4	0.23	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
COAD	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	3.87	0.000136	0.0286	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
COAD	cis	rs3126085	0.877	rs3126055	ENSG00000237975.5	FLG-AS1	3.87	0.000136	0.0286	0.26	0.23	Atopic dermatitis;	chr1:152293888	chr1:152168125~152445456:+
COAD	cis	rs9858542	0.537	rs34915642	ENSG00000225399.4	RP11-3B7.1	-3.87	0.000136	0.0286	-0.34	-0.23	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49321213	chr3:49260085~49261316:+
COAD	cis	rs4253772	0.55	rs6008598	ENSG00000280424.1	CITF22-92A6.2	3.87	0.000136	0.0286	0.37	0.23	Cholesterol, total;LDL cholesterol;	chr22:46308346	chr22:46006616~46010777:+
COAD	cis	rs4239252	0.929	rs4251787	ENSG00000270977.1	AC015849.16	-3.87	0.000136	0.0286	-0.3	-0.23	Blood protein levels;	chr17:35845577	chr17:35893707~35911023:-
COAD	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-3.87	0.000136	0.0286	-0.24	-0.23	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
COAD	cis	rs7577696	0.925	rs212717	ENSG00000272716.1	RP11-563N4.1	3.87	0.000136	0.0286	0.24	0.23	Inflammatory biomarkers;	chr2:32236571	chr2:32165046~32165757:-
COAD	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-3.87	0.000136	0.0286	-0.31	-0.23	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
COAD	cis	rs10779751	1	rs11121706	ENSG00000215785.2	CFL1P6	-3.87	0.000136	0.0286	-0.27	-0.23	Body mass index;	chr1:11242008	chr1:10990978~10991797:-
COAD	cis	rs728616	0.867	rs118134654	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000136	0.0286	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:80233664~80245367:+
COAD	cis	rs9910055	0.683	rs7220138	ENSG00000267080.4	ASB16-AS1	-3.87	0.000136	0.0286	-0.21	-0.23	Total body bone mineral density;	chr17:44176643	chr17:44175973~44186717:-
COAD	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	3.87	0.000136	0.0286	0.16	0.23	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	3.87	0.000136	0.0286	0.16	0.23	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
COAD	cis	rs11098499	0.865	rs4001305	ENSG00000250412.1	KLHL2P1	3.87	0.000136	0.0286	0.32	0.23	Corneal astigmatism;	chr4:119438081	chr4:119334329~119378233:+
COAD	cis	rs2188554	0.533	rs213980	ENSG00000237974.1	AC000111.4	3.87	0.000136	0.0286	0.25	0.23	Esophageal adenocarcinoma;	chr7:117612820	chr7:117487737~117487929:+
COAD	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	3.87	0.000136	0.0286	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	3.87	0.000136	0.0286	0.31	0.23	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
COAD	cis	rs801193	0.636	rs10233806	ENSG00000179406.6	LINC00174	-3.87	0.000136	0.0286	-0.17	-0.23	Aortic root size;	chr7:66653261	chr7:66376044~66401338:-
COAD	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-3.87	0.000136	0.0286	-0.13	-0.23	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
COAD	cis	rs853679	0.607	rs34950484	ENSG00000204709.4	LINC01556	3.87	0.000136	0.0286	0.62	0.23	Depression;	chr6:28310911	chr6:28943877~28944537:+
COAD	cis	rs853679	0.607	rs34661125	ENSG00000204709.4	LINC01556	3.87	0.000136	0.0286	0.62	0.23	Depression;	chr6:28314117	chr6:28943877~28944537:+
COAD	cis	rs853679	0.607	rs13190888	ENSG00000204709.4	LINC01556	3.87	0.000136	0.0286	0.62	0.23	Depression;	chr6:28318208	chr6:28943877~28944537:+
COAD	cis	rs860295	1	rs10908482	ENSG00000223503.1	RP11-29H23.6	-3.87	0.000136	0.0286	-0.3	-0.23	Body mass index;	chr1:155744082	chr1:155590601~155591262:-
COAD	cis	rs875971	0.965	rs9969301	ENSG00000230189.5	GS1-124K5.2	-3.87	0.000136	0.0286	-0.19	-0.23	Aortic root size;	chr7:66316668	chr7:66409143~66490059:-
COAD	cis	rs891378	1	rs1507761	ENSG00000274245.1	RP11-357P18.2	3.87	0.000136	0.0286	0.32	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336454	chr1:207372559~207373252:+
COAD	cis	rs4449834	0.816	rs4738820	ENSG00000254285.3	KRT8P3	3.87	0.000136	0.0286	0.34	0.23	Sum eosinophil basophil counts;	chr8:60758416	chr8:61578220~61579668:+
COAD	cis	rs3126085	0.935	rs7534716	ENSG00000237975.5	FLG-AS1	-3.87	0.000136	0.0286	-0.26	-0.23	Atopic dermatitis;	chr1:152226178	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs1390488	ENSG00000237975.5	FLG-AS1	-3.87	0.000136	0.0286	-0.26	-0.23	Atopic dermatitis;	chr1:152227024	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs10888470	ENSG00000237975.5	FLG-AS1	-3.87	0.000136	0.0286	-0.26	-0.23	Atopic dermatitis;	chr1:152227996	chr1:152168125~152445456:+
COAD	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-3.87	0.000136	0.0286	-0.28	-0.23	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
COAD	cis	rs7200786	0.508	rs8060411	ENSG00000274038.1	RP11-66H6.4	-3.87	0.000136	0.0286	-0.3	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11123250	chr16:11056556~11057034:+
COAD	cis	rs12049351	0.665	rs7534252	ENSG00000229367.1	HMGN2P19	3.87	0.000136	0.0286	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229433845	chr1:229570532~229570796:+
COAD	cis	rs2439831	0.85	rs8032649	ENSG00000206991.1	RNU6-610P	3.87	0.000136	0.0286	0.36	0.23	Lung cancer in ever smokers;	chr15:43842724	chr15:43637632~43637738:-
COAD	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	3.87	0.000136	0.0286	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
COAD	cis	rs2243480	0.901	rs3813708	ENSG00000275400.1	RP4-756H11.5	3.87	0.000136	0.0287	0.41	0.23	Diabetic kidney disease;	chr7:65840645	chr7:66553805~66554199:-
COAD	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-3.87	0.000136	0.0287	-0.28	-0.23	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
COAD	cis	rs9796	0.505	rs28665387	ENSG00000247556.5	OIP5-AS1	3.87	0.000136	0.0287	0.23	0.23	Menopause (age at onset);	chr15:41240671	chr15:41283990~41309737:+
COAD	cis	rs6951245	1	rs78861357	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs76713558	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.748	rs79658522	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.935	rs76525951	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs79683221	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs78185801	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs80031817	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs78143408	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.938	rs78351779	ENSG00000229043.2	AC091729.9	-3.87	0.000136	0.0287	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1160374~1165267:+
COAD	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	3.87	0.000136	0.0287	0.27	0.23	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
COAD	cis	rs2337406	0.925	rs873533	ENSG00000211964.3	IGHV3-48	-3.87	0.000136	0.0287	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106667442	chr14:106537810~106538344:-
COAD	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-3.87	0.000136	0.0287	-0.31	-0.23	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
COAD	cis	rs7615952	0.866	rs13063119	ENSG00000272840.1	RP11-379B18.6	3.87	0.000136	0.0287	0.33	0.23	Blood pressure (smoking interaction);	chr3:125925004	chr3:125774714~125797953:+
COAD	cis	rs1048886	0.872	rs16869353	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000136	0.0287	-0.33	-0.23	Type 2 diabetes;	chr6:70545730	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs16869373	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000136	0.0287	-0.33	-0.23	Type 2 diabetes;	chr6:70559929	chr6:70596438~70596980:+
COAD	cis	rs911263	0.603	rs11158729	ENSG00000259502.1	RP11-643G16.3	-3.87	0.000136	0.0287	-0.29	-0.23	Primary biliary cholangitis;	chr14:68309343	chr14:67610986~67613864:+
COAD	cis	rs875971	1	rs1167612	ENSG00000224316.1	RP11-479O9.2	-3.87	0.000136	0.0287	-0.25	-0.23	Aortic root size;	chr7:66102989	chr7:65773620~65802067:+
COAD	cis	rs7260598	0.792	rs17620029	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000137	0.0287	0.36	0.23	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:24162370~24163425:-
COAD	cis	rs34779708	0.966	rs12761675	ENSG00000271335.4	RP11-324I22.4	-3.87	0.000137	0.0287	-0.26	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35314552~35336401:-
COAD	cis	rs6496932	0.503	rs7170085	ENSG00000259630.2	CTD-2262B20.1	-3.87	0.000137	0.0287	-0.33	-0.23	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85415228~85415633:+
COAD	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-3.87	0.000137	0.0287	-0.28	-0.23	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-3.87	0.000137	0.0287	-0.28	-0.23	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-3.87	0.000137	0.0287	-0.28	-0.23	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
COAD	cis	rs8017304	0.669	rs4902566	ENSG00000259502.1	RP11-643G16.3	-3.87	0.000137	0.0287	-0.3	-0.23	Age-related macular degeneration;	chr14:68326837	chr14:67610986~67613864:+
COAD	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0287	0.34	0.23	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0287	0.34	0.23	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0287	0.34	0.23	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0287	0.34	0.23	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0287	0.34	0.23	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
COAD	cis	rs860295	0.702	rs10908479	ENSG00000203761.5	MSTO2P	-3.87	0.000137	0.0287	-0.22	-0.23	Body mass index;	chr1:155673612	chr1:155745829~155750137:+
COAD	cis	rs7615952	0.741	rs13314845	ENSG00000272840.1	RP11-379B18.6	3.87	0.000137	0.0287	0.33	0.23	Blood pressure (smoking interaction);	chr3:125925939	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.733	rs13314847	ENSG00000272840.1	RP11-379B18.6	3.87	0.000137	0.0287	0.33	0.23	Blood pressure (smoking interaction);	chr3:125925945	chr3:125774714~125797953:+
COAD	cis	rs6732160	0.588	rs13407363	ENSG00000163016.8	ALMS1P	3.87	0.000137	0.0287	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73145430	chr2:73644919~73685576:+
COAD	cis	rs860295	1	rs860295	ENSG00000223503.1	RP11-29H23.6	3.87	0.000137	0.0287	0.3	0.23	Body mass index;	chr1:155797917	chr1:155590601~155591262:-
COAD	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	3.87	0.000137	0.0287	0.29	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
COAD	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	3.87	0.000137	0.0287	0.33	0.23	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
COAD	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-3.87	0.000137	0.0287	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
COAD	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-3.87	0.000137	0.0287	-0.38	-0.23	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
COAD	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-3.87	0.000137	0.0287	-0.43	-0.23	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
COAD	cis	rs1670533	1	rs2045066	ENSG00000273179.1	RP11-20I20.4	3.87	0.000137	0.0287	0.3	0.23	Recombination rate (females);	chr4:1058613	chr4:1167778~1168174:+
COAD	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	3.87	0.000137	0.0287	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
COAD	cis	rs12468226	0.938	rs55668474	ENSG00000226261.1	AC064836.3	3.87	0.000137	0.0287	0.35	0.23	Urate levels;	chr2:202265559	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs6753044	ENSG00000226261.1	AC064836.3	3.87	0.000137	0.0287	0.35	0.23	Urate levels;	chr2:202300710	chr2:202336024~202336727:-
COAD	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-3.87	0.000137	0.0288	-0.24	-0.23	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
COAD	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	3.87	0.000137	0.0288	0.34	0.23	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
COAD	cis	rs11846409	0.86	rs1858692	ENSG00000254174.1	IGHV1-12	-3.87	0.000137	0.0288	-0.23	-0.23	Rheumatic heart disease;	chr14:106622776	chr14:106122420~106122709:-
COAD	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-3.87	0.000137	0.0288	-0.27	-0.23	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
COAD	cis	rs9880211	0.718	rs35320690	ENSG00000273486.1	RP11-731C17.2	-3.87	0.000137	0.0288	-0.27	-0.23	Height;Body mass index;	chr3:136213652	chr3:136837338~136839021:-
COAD	cis	rs3126085	0.935	rs11204951	ENSG00000237975.5	FLG-AS1	-3.87	0.000137	0.0288	-0.26	-0.23	Atopic dermatitis;	chr1:152251928	chr1:152168125~152445456:+
COAD	cis	rs7204230	1	rs62049816	ENSG00000261056.2	RP11-454F8.2	3.87	0.000137	0.0288	0.29	0.23	Fibrinogen;	chr16:53336072	chr16:53298224~53299792:+
COAD	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
COAD	cis	rs752010	0.631	rs7515066	ENSG00000230638.4	RP11-486B10.4	3.87	0.000137	0.0288	0.3	0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41611244	chr1:41542069~41544310:+
COAD	cis	rs34779708	0.868	rs2384352	ENSG00000271335.4	RP11-324I22.4	3.87	0.000137	0.0288	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35314552~35336401:-
COAD	cis	rs4237845	0.562	rs7133278	ENSG00000257698.1	RP11-620J15.3	3.87	0.000137	0.0288	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57942283	chr12:57931528~57936175:-
COAD	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	3.87	0.000137	0.0288	0.28	0.23	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
COAD	cis	rs5753037	0.838	rs140147	ENSG00000279159.1	RP3-394A18.1	-3.87	0.000137	0.0288	-0.17	-0.23	Type 1 diabetes;	chr22:29788610	chr22:29978950~30028236:-
COAD	cis	rs7688540	0.8	rs6857106	ENSG00000198155.5	ZNF876P	3.87	0.000137	0.0288	0.35	0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:212610~255985:+
COAD	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-3.87	0.000137	0.0288	-0.32	-0.23	Pain;	chr19:21509773	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-3.87	0.000137	0.0288	-0.32	-0.23	Pain;	chr19:21510513	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-3.87	0.000137	0.0288	-0.32	-0.23	Pain;	chr19:21513185	chr19:21554640~21569237:-
COAD	cis	rs911263	0.54	rs7158493	ENSG00000259502.1	RP11-643G16.3	-3.87	0.000137	0.0288	-0.29	-0.23	Primary biliary cholangitis;	chr14:68345613	chr14:67610986~67613864:+
COAD	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55459921	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55461320	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55462689	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55463606	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55466010	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55467308	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55470266	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55470874	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55475130	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55476736	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55477426	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	3.87	0.000137	0.0288	0.28	0.23	Height;	chr4:55477545	chr4:55547112~55547889:+
COAD	cis	rs6732160	0.588	rs13403748	ENSG00000163016.8	ALMS1P	3.87	0.000137	0.0288	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73144347	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.588	rs72841902	ENSG00000163016.8	ALMS1P	3.87	0.000137	0.0288	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73145084	chr2:73644919~73685576:+
COAD	cis	rs7760535	0.811	rs1002475	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Metabolic traits;	chr6:111388386	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs11153288	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs11153290	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs11153291	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs11153292	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs12190634	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs1989574	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.508	rs11153294	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs7451051	ENSG00000230177.1	RP5-1112D6.4	-3.87	0.000137	0.0288	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111277932~111278742:+
COAD	cis	rs6452524	0.934	rs12153179	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs12153441	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs12152891	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs6452507	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs6452508	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs7717964	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.934	rs1120477	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.934	rs1120478	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.934	rs6452512	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs6452514	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0288	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83049376~83050964:-
COAD	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-3.87	0.000137	0.0288	-0.39	-0.23	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
COAD	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-3.87	0.000137	0.0288	-0.32	-0.23	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
COAD	cis	rs1707322	0.827	rs6694302	ENSG00000230896.1	RP11-767N6.7	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.827	rs12125508	ENSG00000230896.1	RP11-767N6.7	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.789	rs10789473	ENSG00000230896.1	RP11-767N6.7	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.826	rs10890349	ENSG00000230896.1	RP11-767N6.7	-3.87	0.000137	0.0288	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45694684~45697075:-
COAD	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-3.87	0.000137	0.0288	-0.26	-0.23	Gout;	chr7:66732812	chr7:66902857~66906297:+
COAD	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	3.87	0.000137	0.0288	0.33	0.23	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
COAD	cis	rs4683346	0.964	rs34759881	ENSG00000273328.4	RP11-141M3.6	-3.87	0.000137	0.0288	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42834052	chr3:42809414~42908105:+
COAD	cis	rs4683346	0.964	rs13068402	ENSG00000273328.4	RP11-141M3.6	-3.87	0.000137	0.0288	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42834264	chr3:42809414~42908105:+
COAD	cis	rs4843747	0.671	rs28465438	ENSG00000205037.2	RP11-863P13.4	3.87	0.000137	0.0288	0.31	0.23	Menopause (age at onset);	chr16:88070108	chr16:88088041~88100985:-
COAD	cis	rs4843747	0.519	rs12599755	ENSG00000205037.2	RP11-863P13.4	3.87	0.000137	0.0288	0.31	0.23	Menopause (age at onset);	chr16:88073400	chr16:88088041~88100985:-
COAD	cis	rs453301	0.686	rs28665409	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000137	0.0288	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9011767	chr8:8961200~8979025:+
COAD	cis	rs643506	0.874	rs609007	ENSG00000230911.1	PPIHP1	3.87	0.000137	0.0288	0.29	0.23	Breast cancer;	chr11:111848870	chr11:112029858~112030367:-
COAD	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	3.87	0.000137	0.0288	0.33	0.23	Pain;	chr19:21560061	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	3.87	0.000137	0.0288	0.33	0.23	Pain;	chr19:21563578	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	3.87	0.000137	0.0288	0.33	0.23	Pain;	chr19:21567257	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	3.87	0.000137	0.0288	0.33	0.23	Pain;	chr19:21567449	chr19:21554640~21569237:-
COAD	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000137	0.0288	-0.22	-0.23	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
COAD	cis	rs11229555	0.645	rs34054511	ENSG00000254602.1	AP000662.4	-3.87	0.000137	0.0288	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58437470	chr11:57638024~57652790:+
COAD	cis	rs6452524	0.967	rs6897075	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0289	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs10065973	ENSG00000271862.1	RP11-343L5.2	3.87	0.000137	0.0289	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83049376~83050964:-
COAD	cis	rs10773046	0.74	rs7313897	ENSG00000280328.1	RP11-972P1.7	-3.87	0.000138	0.0289	-0.23	-0.23	Osteoarthritis (hip);	chr12:123865813	chr12:123472200~123476093:-
COAD	cis	rs11976180	1	rs1533266	ENSG00000273234.1	OR2A13P	-3.87	0.000138	0.0289	-0.29	-0.23	Obesity-related traits;	chr7:144069621	chr7:144142009~144142938:+
COAD	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-3.87	0.000138	0.0289	-0.31	-0.23	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
COAD	cis	rs7074356	0.604	rs35269135	ENSG00000225484.5	NUTM2B-AS1	-3.87	0.000138	0.0289	-0.4	-0.23	Borderline personality disorder;	chr10:80466698	chr10:79663088~79826594:-
COAD	cis	rs17689437	0.957	rs7194242	ENSG00000275383.1	RP11-615I2.6	3.87	0.000138	0.0289	0.29	0.23	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68573838	chr16:68591382~68594424:+
COAD	cis	rs7260598	0.792	rs7260592	ENSG00000268442.1	CTD-2027I19.2	3.87	0.000138	0.0289	0.36	0.23	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:24162370~24163425:-
COAD	cis	rs2732480	0.577	rs2634684	ENSG00000240399.1	RP1-228P16.1	-3.87	0.000138	0.0289	-0.25	-0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48054813~48055591:-
COAD	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-3.87	0.000138	0.0289	-0.33	-0.23	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
COAD	cis	rs950169	0.649	rs12911612	ENSG00000259728.4	LINC00933	3.87	0.000138	0.0289	0.35	0.23	Schizophrenia;	chr15:84022262	chr15:84570649~84580175:+
COAD	cis	rs950169	0.649	rs12905952	ENSG00000259728.4	LINC00933	3.87	0.000138	0.0289	0.35	0.23	Schizophrenia;	chr15:84022509	chr15:84570649~84580175:+
COAD	cis	rs950169	0.61	rs34529571	ENSG00000259728.4	LINC00933	3.87	0.000138	0.0289	0.35	0.23	Schizophrenia;	chr15:84023055	chr15:84570649~84580175:+
COAD	cis	rs9796	0.689	rs576336	ENSG00000247556.5	OIP5-AS1	3.87	0.000138	0.0289	0.24	0.23	Menopause (age at onset);	chr15:41160573	chr15:41283990~41309737:+
COAD	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	3.87	0.000138	0.0289	0.29	0.23	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
COAD	cis	rs13256369	0.951	rs10503394	ENSG00000254153.1	CTA-398F10.2	3.87	0.000138	0.0289	0.31	0.23	Obesity-related traits;	chr8:8708265	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.951	rs13260947	ENSG00000254153.1	CTA-398F10.2	3.87	0.000138	0.0289	0.31	0.23	Obesity-related traits;	chr8:8708373	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.951	rs13259955	ENSG00000254153.1	CTA-398F10.2	3.87	0.000138	0.0289	0.31	0.23	Obesity-related traits;	chr8:8708375	chr8:8456909~8461337:-
COAD	cis	rs9992966	0.85	rs2376265	ENSG00000250829.2	RP11-11N5.1	3.87	0.000138	0.0289	0.36	0.23	Trans fatty acid levels;	chr4:187699755	chr4:186890969~186892366:+
COAD	cis	rs2251260	1	rs2250772	ENSG00000232774.6	FLJ22447	-3.87	0.000138	0.0289	-0.34	-0.23	Yeast infection;	chr14:61552342	chr14:61570540~61658696:+
COAD	cis	rs9487051	1	rs11757567	ENSG00000219700.1	PTCHD3P3	3.87	0.000138	0.0289	0.26	0.23	Reticulocyte fraction of red cells;	chr6:109293510	chr6:109288571~109290503:-
COAD	cis	rs9487051	1	rs9386795	ENSG00000219700.1	PTCHD3P3	3.87	0.000138	0.0289	0.26	0.23	Reticulocyte fraction of red cells;	chr6:109295325	chr6:109288571~109290503:-
COAD	cis	rs3748656	0.887	rs35147679	ENSG00000231246.1	RP5-965F6.2	-3.87	0.000138	0.0289	-0.32	-0.23	Hip circumference adjusted for BMI;	chr1:112525955	chr1:112177234~112360528:-
COAD	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-3.87	0.000138	0.0289	-0.34	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
COAD	cis	rs36051354	0.592	rs2710332	ENSG00000242142.1	SERBP1P3	3.87	0.000138	0.0289	0.32	0.23	Intelligence (multi-trait analysis);	chr3:52944675	chr3:53064283~53065091:-
COAD	cis	rs2337406	0.925	rs76288499	ENSG00000211964.3	IGHV3-48	-3.87	0.000138	0.0289	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106686309	chr14:106537810~106538344:-
COAD	cis	rs28735056	0.592	rs2277725	ENSG00000267015.1	RP11-800A18.4	3.87	0.000138	0.0289	0.22	0.23	Schizophrenia;	chr18:79934168	chr18:79340258~79343972:-
COAD	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	3.87	0.000138	0.0289	0.46	0.23	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
COAD	cis	rs2337406	0.538	rs2015470	ENSG00000274576.2	IGHV2-70	-3.87	0.000138	0.0289	-0.21	-0.23	Alzheimer's disease (late onset);	chr14:106631885	chr14:106770577~106771020:-
COAD	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-3.87	0.000138	0.0289	-0.29	-0.23	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
COAD	cis	rs12049351	0.665	rs4338396	ENSG00000229367.1	HMGN2P19	3.87	0.000138	0.0289	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229444474	chr1:229570532~229570796:+
COAD	cis	rs17248137	0.826	rs78815585	ENSG00000249942.1	AC142293.3	3.87	0.000138	0.0289	0.43	0.23	Overall survival in osteosarcoma;	chr4:74901647	chr4:74552584~74589481:-
COAD	cis	rs2908835	0.705	rs12425902	ENSG00000247157.5	LINC01252	-3.87	0.000138	0.0289	-0.38	-0.23	Information processing speed;	chr12:11490180	chr12:11548030~11590369:+
COAD	cis	rs9796	0.621	rs7170049	ENSG00000247556.5	OIP5-AS1	3.87	0.000138	0.0289	0.24	0.23	Menopause (age at onset);	chr15:41192089	chr15:41283990~41309737:+
COAD	cis	rs987724	0.574	rs7638625	ENSG00000240875.4	LINC00886	-3.87	0.000138	0.0289	-0.21	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156840267	chr3:156747346~156817062:-
COAD	cis	rs68170813	0.523	rs12535093	ENSG00000241764.3	AC002467.7	3.87	0.000138	0.0289	0.33	0.23	Coronary artery disease;	chr7:107379737	chr7:107742817~107744581:-
COAD	cis	rs1075232	1	rs66581165	ENSG00000215302.7	CTD-3092A11.1	-3.87	0.000138	0.0289	-0.62	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30470779~30507623:+
COAD	cis	rs7584330	0.504	rs11890307	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526062	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs7598035	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526299	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs7558685	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526300	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs7570873	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526411	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs7571100	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526662	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs7559057	ENSG00000234949.2	AC104667.3	-3.87	0.000138	0.029	-0.36	-0.23	Prostate cancer;	chr2:237526663	chr2:237591020~237595981:+
COAD	cis	rs3126085	0.935	rs10888473	ENSG00000237975.5	FLG-AS1	-3.87	0.000138	0.029	-0.26	-0.23	Atopic dermatitis;	chr1:152247759	chr1:152168125~152445456:+
COAD	cis	rs7572733	0.773	rs10196961	ENSG00000222017.1	AC011997.1	3.87	0.000138	0.029	0.25	0.23	Dermatomyositis;	chr2:197649206	chr2:197693106~197774823:+
COAD	cis	rs8114671	0.562	rs6058137	ENSG00000228265.4	RALY-AS1	3.87	0.000138	0.029	0.22	0.23	Height;	chr20:34887271	chr20:33983052~33994357:-
COAD	cis	rs7131987	0.903	rs1035604	ENSG00000257176.2	RP11-996F15.2	-3.87	0.000138	0.029	-0.28	-0.23	QT interval;	chr12:29240169	chr12:29280418~29317848:-
COAD	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	3.87	0.000138	0.029	0.29	0.23	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
COAD	cis	rs2836974	0.568	rs429955	ENSG00000255568.3	BRWD1-AS2	3.87	0.000138	0.029	0.22	0.23	Cognitive function;	chr21:39167834	chr21:39313935~39314962:+
COAD	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	-3.87	0.000138	0.029	-0.25	-0.23	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
COAD	cis	rs2408955	0.541	rs11168428	ENSG00000226413.2	OR8T1P	-3.87	0.000138	0.029	-0.28	-0.23	Glycated hemoglobin levels;	chr12:48153345	chr12:48442030~48442947:-
COAD	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-3.87	0.000138	0.029	-0.21	-0.23	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
COAD	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-3.87	0.000138	0.029	-0.21	-0.23	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
COAD	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	3.87	0.000138	0.029	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	3.87	0.000138	0.029	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
COAD	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	3.87	0.000138	0.029	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
COAD	cis	rs4072705	0.967	rs4838195	ENSG00000236643.1	RP11-175D17.3	3.87	0.000138	0.029	0.25	0.23	Menarche (age at onset);	chr9:124588938	chr9:124770123~124772927:+
COAD	cis	rs4938303	0.633	rs528806	ENSG00000254851.1	RP11-109L13.1	3.87	0.000138	0.029	0.36	0.23	Triglycerides;	chr11:116659197	chr11:117135528~117138582:+
COAD	cis	rs9880211	0.948	rs9820621	ENSG00000273486.1	RP11-731C17.2	3.87	0.000138	0.029	0.28	0.23	Height;Body mass index;	chr3:136391671	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.948	rs34913797	ENSG00000273486.1	RP11-731C17.2	3.87	0.000138	0.029	0.28	0.23	Height;Body mass index;	chr3:136408728	chr3:136837338~136839021:-
COAD	cis	rs9880211	1	rs9812579	ENSG00000273486.1	RP11-731C17.2	3.87	0.000138	0.029	0.28	0.23	Height;Body mass index;	chr3:136432408	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.948	rs1604793	ENSG00000273486.1	RP11-731C17.2	3.87	0.000138	0.029	0.28	0.23	Height;Body mass index;	chr3:136462228	chr3:136837338~136839021:-
COAD	cis	rs884366	1	rs4946956	ENSG00000219700.1	PTCHD3P3	-3.87	0.000138	0.029	-0.3	-0.23	HDL cholesterol;HDL cholesterol levels;	chr6:109319912	chr6:109288571~109290503:-
COAD	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55425312	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55429416	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55430596	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55430730	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55430740	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	3.87	0.000138	0.029	0.28	0.23	Height;	chr4:55431595	chr4:55547112~55547889:+
COAD	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000138	0.029	-0.31	-0.23	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000138	0.029	-0.31	-0.23	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000138	0.029	-0.31	-0.23	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000138	0.029	-0.31	-0.23	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
COAD	cis	rs73252553	0.615	rs1973604	ENSG00000281501.1	SEPSECS-AS1	-3.87	0.000138	0.029	-0.34	-0.23	Cannabis dependence symptom count;	chr4:25252741	chr4:25160641~25201440:+
COAD	cis	rs9834970	0.566	rs4327336	ENSG00000281100.1	RP11-640L9.2	-3.87	0.000139	0.029	-0.2	-0.23	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36854779	chr3:36823151~36825158:-
COAD	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-3.87	0.000139	0.029	-0.29	-0.23	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
COAD	cis	rs6951245	1	rs11770909	ENSG00000229043.2	AC091729.9	-3.87	0.000139	0.029	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1160374~1165267:+
COAD	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	3.87	0.000139	0.029	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
COAD	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	3.87	0.000139	0.029	0.25	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	3.87	0.000139	0.029	0.25	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	3.87	0.000139	0.029	0.25	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	3.87	0.000139	0.029	0.25	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
COAD	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	3.87	0.000139	0.029	0.25	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
COAD	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	3.87	0.000139	0.029	0.36	0.23	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
COAD	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-3.87	0.000139	0.0291	-0.24	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
COAD	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-3.87	0.000139	0.0291	-0.25	-0.23	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
COAD	cis	rs7615952	0.866	rs6438949	ENSG00000241278.1	ENPP7P4	3.87	0.000139	0.0291	0.26	0.23	Blood pressure (smoking interaction);	chr3:125931221	chr3:125848223~125909372:+
COAD	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-3.87	0.000139	0.0291	-0.2	-0.23	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
COAD	cis	rs728616	0.867	rs17884637	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:80233664~80245367:+
COAD	cis	rs728616	1	rs12414891	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:80233664~80245367:+
COAD	cis	rs728616	0.717	rs12415523	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:80233664~80245367:+
COAD	cis	rs728616	0.764	rs75385771	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs17883671	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs17885031	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs3088308	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs17879726	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000139	0.0291	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:80233664~80245367:+
COAD	cis	rs875971	1	rs778726	ENSG00000230189.5	GS1-124K5.2	3.87	0.000139	0.0291	0.19	0.23	Aortic root size;	chr7:66363744	chr7:66409143~66490059:-
COAD	cis	rs1670533	1	rs3816474	ENSG00000273179.1	RP11-20I20.4	3.87	0.000139	0.0291	0.32	0.23	Recombination rate (females);	chr4:1056865	chr4:1167778~1168174:+
COAD	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	3.87	0.000139	0.0291	0.26	0.23	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
COAD	cis	rs3788317	0.526	rs5992493	ENSG00000232926.1	AC000078.5	3.87	0.000139	0.0291	0.25	0.23	Glaucoma (primary angle closure);	chr22:19894033	chr22:19887289~19887970:+
COAD	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	3.87	0.000139	0.0291	0.3	0.23	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	3.87	0.000139	0.0291	0.3	0.23	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
COAD	cis	rs7577696	0.814	rs435572	ENSG00000272716.1	RP11-563N4.1	3.87	0.000139	0.0291	0.25	0.23	Inflammatory biomarkers;	chr2:32263012	chr2:32165046~32165757:-
COAD	cis	rs6452524	0.935	rs1542539	ENSG00000271862.1	RP11-343L5.2	3.87	0.000139	0.0291	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.967	rs1564211	ENSG00000271862.1	RP11-343L5.2	3.87	0.000139	0.0291	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83049376~83050964:-
COAD	cis	rs597539	0.652	rs584108	ENSG00000255741.1	RP11-757G1.5	3.87	0.000139	0.0291	0.31	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68941503~68942852:-
COAD	cis	rs7200786	0.546	rs2080272	ENSG00000274038.1	RP11-66H6.4	-3.87	0.000139	0.0291	-0.3	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11117696	chr16:11056556~11057034:+
COAD	cis	rs228614	0.509	rs223486	ENSG00000248971.2	KRT8P46	-3.87	0.000139	0.0291	-0.23	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102728746~102730171:-
COAD	cis	rs10829156	0.947	rs7081435	ENSG00000240291.1	RP11-499P20.2	3.87	0.000139	0.0291	0.27	0.23	Sudden cardiac arrest;	chr10:18667411	chr10:18513115~18545651:-
COAD	cis	rs2524005	1	rs2524005	ENSG00000204709.4	LINC01556	3.87	0.000139	0.0291	0.35	0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:28943877~28944537:+
COAD	cis	rs3126085	0.935	rs11204939	ENSG00000237975.5	FLG-AS1	-3.87	0.000139	0.0291	-0.26	-0.23	Atopic dermatitis;	chr1:152228466	chr1:152168125~152445456:+
COAD	cis	rs10876993	0.855	rs10877007	ENSG00000270039.1	RP11-571M6.17	3.87	0.000139	0.0291	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57706275	chr12:57803838~57804415:+
COAD	cis	rs7933433	0.552	rs4937317	ENSG00000255465.3	RP11-264E20.1	-3.87	0.000139	0.0291	-0.3	-0.23	Psoriasis;	chr11:128332703	chr11:128615867~128621806:-
COAD	cis	rs2496589	0.889	rs2432873	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143416154	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.929	rs2496594	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143420197	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs2496596	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143421127	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs2496597	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143421412	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs6915676	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143425049	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs6915856	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143425138	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496618	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143427549	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496619	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143427664	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9484745	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143429143	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496620	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143429184	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496621	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143429372	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.889	rs9496622	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143429450	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.889	rs9321906	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430040	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.889	rs9321907	ENSG00000218896.1	TUBB8P2	3.87	0.000139	0.0291	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430042	chr6:143436216~143436710:+
COAD	cis	rs4237845	0.611	rs11172387	ENSG00000257698.1	RP11-620J15.3	3.87	0.000139	0.0291	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57938568	chr12:57931528~57936175:-
COAD	cis	rs4237845	0.611	rs4760346	ENSG00000257698.1	RP11-620J15.3	3.87	0.000139	0.0291	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57940960	chr12:57931528~57936175:-
COAD	cis	rs964184	0.564	rs3825041	ENSG00000254851.1	RP11-109L13.1	-3.87	0.000139	0.0291	-0.48	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116760991	chr11:117135528~117138582:+
COAD	cis	rs875971	1	rs709597	ENSG00000223473.2	GS1-124K5.3	-3.87	0.000139	0.0291	-0.19	-0.23	Aortic root size;	chr7:66360996	chr7:66491049~66493566:-
COAD	cis	rs6661961	0.752	rs6694145	ENSG00000237975.5	FLG-AS1	3.87	0.000139	0.0291	0.24	0.23	Atopic dermatitis;	chr1:152452349	chr1:152168125~152445456:+
COAD	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-3.87	0.000139	0.0291	-0.29	-0.23	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
COAD	cis	rs875971	1	rs11971949	ENSG00000230189.5	GS1-124K5.2	-3.87	0.000139	0.0291	-0.2	-0.23	Aortic root size;	chr7:66161027	chr7:66409143~66490059:-
COAD	cis	rs2836974	0.796	rs77153312	ENSG00000255568.3	BRWD1-AS2	3.87	0.000139	0.0291	0.24	0.23	Cognitive function;	chr21:39323573	chr21:39313935~39314962:+
COAD	cis	rs10043775	0.958	rs7733401	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000139	0.0291	-0.27	-0.23	Periodontal microbiota;	chr5:148453718	chr5:148430159~148430807:-
COAD	cis	rs34779708	0.966	rs4934539	ENSG00000271335.4	RP11-324I22.4	3.87	0.000139	0.0291	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35314552~35336401:-
COAD	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-3.87	0.000139	0.0291	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-3.87	0.000139	0.0291	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-3.87	0.000139	0.0291	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
COAD	cis	rs964184	0.688	rs1558860	ENSG00000254851.1	RP11-109L13.1	-3.87	0.000139	0.0292	-0.48	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736652	chr11:117135528~117138582:+
COAD	cis	rs7577696	0.889	rs212735	ENSG00000272716.1	RP11-563N4.1	3.87	0.000139	0.0292	0.24	0.23	Inflammatory biomarkers;	chr2:32248019	chr2:32165046~32165757:-
COAD	cis	rs2243480	0.706	rs6460257	ENSG00000229180.5	GS1-124K5.11	3.87	0.000139	0.0292	0.23	0.23	Diabetic kidney disease;	chr7:65731813	chr7:66526088~66542624:-
COAD	cis	rs10876993	0.672	rs2640611	ENSG00000270039.1	RP11-571M6.17	3.87	0.000139	0.0292	0.27	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57643974	chr12:57803838~57804415:+
COAD	cis	rs73222236	0.825	rs9826146	ENSG00000273486.1	RP11-731C17.2	3.87	0.000139	0.0292	0.24	0.23	Coronary artery disease;	chr3:136264247	chr3:136837338~136839021:-
COAD	cis	rs860295	0.702	rs12039893	ENSG00000225855.5	RUSC1-AS1	3.87	0.000139	0.0292	0.21	0.23	Body mass index;	chr1:155645024	chr1:155316863~155324176:-
COAD	cis	rs10137082	0.559	rs7144355	ENSG00000279656.1	RP11-298I3.6	-3.87	0.00014	0.0292	-0.3	-0.23	Type 1 diabetes;	chr14:23354953	chr14:23023083~23024217:-
COAD	cis	rs2904967	0.929	rs626802	ENSG00000245532.5	NEAT1	-3.87	0.00014	0.0292	-0.27	-0.23	Mean corpuscular volume;	chr11:65254141	chr11:65422774~65445540:+
COAD	cis	rs8002861	0.846	rs12869355	ENSG00000274001.1	RP11-5G9.5	3.87	0.00014	0.0292	0.22	0.23	Leprosy;	chr13:43904057	chr13:43877715~43878163:-
COAD	cis	rs9307551	1	rs1371989	ENSG00000250334.4	LINC00989	3.87	0.00014	0.0292	0.32	0.23	Refractive error;	chr4:79600692	chr4:79492416~79576460:+
COAD	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-3.87	0.00014	0.0292	-0.44	-0.23	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
COAD	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-3.87	0.00014	0.0292	-0.34	-0.23	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
COAD	cis	rs12428035	0.764	rs9516621	ENSG00000247400.3	DNAJC3-AS1	3.87	0.00014	0.0292	0.26	0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95894123	chr13:95648733~95676925:-
COAD	cis	rs3617	0.625	rs3774364	ENSG00000243224.1	RP5-1157M23.2	-3.87	0.00014	0.0292	-0.24	-0.23	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52829589	chr3:52239258~52241097:+
COAD	cis	rs2337406	1	rs17113331	ENSG00000280411.1	IGHV1-69-2	-3.87	0.00014	0.0292	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106703843	chr14:106762092~106762588:-
COAD	cis	rs875971	1	rs2036264	ENSG00000230189.5	GS1-124K5.2	-3.87	0.00014	0.0292	-0.19	-0.23	Aortic root size;	chr7:66334917	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs7783613	ENSG00000230189.5	GS1-124K5.2	-3.87	0.00014	0.0292	-0.19	-0.23	Aortic root size;	chr7:66340274	chr7:66409143~66490059:-
COAD	cis	rs9847710	0.967	rs2564938	ENSG00000280417.1	RP11-5O17.1	-3.87	0.00014	0.0292	-0.26	-0.23	Ulcerative colitis;	chr3:52992368	chr3:53046166~53048122:+
COAD	cis	rs595244	0.908	rs2015637	ENSG00000259705.1	RP11-227D13.1	3.87	0.00014	0.0292	0.37	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48424656	chr15:48645951~48652016:+
COAD	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	3.87	0.00014	0.0292	0.26	0.23	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
COAD	cis	rs2836974	0.533	rs418298	ENSG00000255568.3	BRWD1-AS2	3.87	0.00014	0.0292	0.22	0.23	Cognitive function;	chr21:39164728	chr21:39313935~39314962:+
COAD	cis	rs9307551	0.584	rs12502224	ENSG00000250334.4	LINC00989	-3.87	0.00014	0.0292	-0.28	-0.23	Refractive error;	chr4:79551688	chr4:79492416~79576460:+
COAD	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	3.87	0.00014	0.0292	0.3	0.23	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
COAD	cis	rs7204230	0.961	rs7197925	ENSG00000261056.2	RP11-454F8.2	3.87	0.00014	0.0292	0.29	0.23	Fibrinogen;	chr16:53330567	chr16:53298224~53299792:+
COAD	cis	rs6452524	0.935	rs10942321	ENSG00000271862.1	RP11-343L5.2	3.87	0.00014	0.0292	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83049376~83050964:-
COAD	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0292	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
COAD	cis	rs10043775	1	rs4349707	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.00014	0.0292	-0.28	-0.23	Periodontal microbiota;	chr5:148408875	chr5:148430159~148430807:-
COAD	cis	rs2638953	0.886	rs10492369	ENSG00000247934.4	RP11-967K21.1	3.87	0.00014	0.0292	0.25	0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28163298~28190738:-
COAD	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	3.87	0.00014	0.0292	0.28	0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
COAD	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	3.87	0.00014	0.0292	0.35	0.23	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
COAD	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-3.87	0.00014	0.0292	-0.29	-0.23	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
COAD	cis	rs7577696	0.85	rs11124276	ENSG00000272716.1	RP11-563N4.1	-3.87	0.00014	0.0292	-0.24	-0.23	Inflammatory biomarkers;	chr2:32093359	chr2:32165046~32165757:-
COAD	cis	rs7204230	0.96	rs62048032	ENSG00000261056.2	RP11-454F8.2	3.87	0.00014	0.0292	0.28	0.23	Fibrinogen;	chr16:53180955	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs11863925	ENSG00000261056.2	RP11-454F8.2	3.87	0.00014	0.0292	0.28	0.23	Fibrinogen;	chr16:53181366	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.921	rs58988553	ENSG00000261056.2	RP11-454F8.2	3.87	0.00014	0.0292	0.28	0.23	Fibrinogen;	chr16:53188058	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.96	rs7205763	ENSG00000261056.2	RP11-454F8.2	3.87	0.00014	0.0292	0.28	0.23	Fibrinogen;	chr16:53189538	chr16:53298224~53299792:+
COAD	cis	rs875971	1	rs697970	ENSG00000179406.6	LINC00174	-3.87	0.00014	0.0292	-0.17	-0.23	Aortic root size;	chr7:66095065	chr7:66376044~66401338:-
COAD	cis	rs12760731	0.92	rs74226628	ENSG00000213057.5	C1orf220	3.87	0.00014	0.0293	0.31	0.23	Obesity-related traits;	chr1:178515459	chr1:178542752~178548889:+
COAD	cis	rs11638352	1	rs2623017	ENSG00000205771.5	CATSPER2P1	3.87	0.00014	0.0293	0.5	0.23	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44111087	chr15:43726918~43747094:-
COAD	cis	rs11638352	1	rs2615297	ENSG00000205771.5	CATSPER2P1	3.87	0.00014	0.0293	0.5	0.23	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44113823	chr15:43726918~43747094:-
COAD	cis	rs1876905	0.597	rs354526	ENSG00000255389.1	C6orf3	3.87	0.00014	0.0293	0.27	0.23	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111599875~111602295:+
COAD	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	3.87	0.00014	0.0293	0.28	0.23	Height;	chr4:55515292	chr4:55547112~55547889:+
COAD	cis	rs10200159	0.793	rs13383352	ENSG00000272606.1	RP11-554J4.1	3.87	0.00014	0.0293	0.36	0.23	Vitiligo;	chr2:55643692	chr2:55617909~55618373:+
COAD	cis	rs8046148	0.694	rs6500282	ENSG00000260381.2	RP11-429P3.5	-3.87	0.00014	0.0293	-0.31	-0.23	Testicular germ cell tumor;	chr16:50104189	chr16:50100339~50121943:-
COAD	cis	rs1707322	0.963	rs4630155	ENSG00000230896.1	RP11-767N6.7	-3.87	0.00014	0.0293	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.963	rs4508055	ENSG00000230896.1	RP11-767N6.7	-3.87	0.00014	0.0293	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.963	rs12076580	ENSG00000230896.1	RP11-767N6.7	-3.87	0.00014	0.0293	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45694684~45697075:-
COAD	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0293	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0293	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0293	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0293	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
COAD	cis	rs875971	1	rs6979382	ENSG00000230189.5	GS1-124K5.2	3.87	0.00014	0.0293	0.19	0.23	Aortic root size;	chr7:66421388	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs6961990	ENSG00000230189.5	GS1-124K5.2	3.87	0.00014	0.0293	0.19	0.23	Aortic root size;	chr7:66423583	chr7:66409143~66490059:-
COAD	cis	rs2836974	0.897	rs2836927	ENSG00000255568.3	BRWD1-AS2	3.87	0.00014	0.0293	0.24	0.23	Cognitive function;	chr21:39171290	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs2836929	ENSG00000255568.3	BRWD1-AS2	3.87	0.00014	0.0293	0.24	0.23	Cognitive function;	chr21:39171885	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.899	rs8127087	ENSG00000255568.3	BRWD1-AS2	3.87	0.00014	0.0293	0.24	0.23	Cognitive function;	chr21:39172576	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.897	rs2836932	ENSG00000255568.3	BRWD1-AS2	3.87	0.00014	0.0293	0.24	0.23	Cognitive function;	chr21:39174791	chr21:39313935~39314962:+
COAD	cis	rs112184198	0.588	rs4600144	ENSG00000227695.4	DNMBP-AS1	3.87	0.00014	0.0293	0.48	0.23	Systolic blood pressure;	chr10:100772537	chr10:99927010~99958381:+
COAD	cis	rs317865	0.609	rs28619251	ENSG00000263327.5	TAPT1-AS1	-3.87	0.00014	0.0293	-0.3	-0.23	Kidney disease (early stage) in type 1 diabetes;	chr4:16170401	chr4:16226685~16320140:+
COAD	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	3.87	0.000141	0.0293	0.36	0.23	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	3.87	0.000141	0.0293	0.36	0.23	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
COAD	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	3.87	0.000141	0.0293	0.31	0.23	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
COAD	cis	rs6930781	0.759	rs6920677	ENSG00000218632.3	RPL7P28	-3.87	0.000141	0.0294	-0.25	-0.23	Major depression and alcohol dependence;	chr6:110033361	chr6:109327175~109327914:-
COAD	cis	rs796825	0.719	rs56805999	ENSG00000240661.1	RP11-174O3.3	3.87	0.000141	0.0294	0.31	0.23	HIV-1 susceptibility;	chr3:120247716	chr3:120349510~120367998:+
COAD	cis	rs2307394	1	rs1531032	ENSG00000281469.1	RP11-567F11.1	3.87	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147945741	chr2:148044380~148044894:+
COAD	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55440643	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55441110	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55441567	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55441907	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55442184	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55442875	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	3.87	0.000141	0.0294	0.28	0.23	Height;	chr4:55444253	chr4:55547112~55547889:+
COAD	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	3.87	0.000141	0.0294	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
COAD	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	3.86	0.000141	0.0294	0.26	0.23	Height;	chr4:55528801	chr4:55363971~55395847:-
COAD	cis	rs891378	0.958	rs1354942	ENSG00000274245.1	RP11-357P18.2	3.86	0.000141	0.0294	0.32	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335147	chr1:207372559~207373252:+
COAD	cis	rs742132	0.858	rs4712948	ENSG00000220875.1	HIST1H3PS1	3.86	0.000141	0.0294	0.31	0.23	Uric acid levels;	chr6:25643576	chr6:26321876~26322292:-
COAD	cis	rs13256369	0.708	rs10903310	ENSG00000253981.4	ALG1L13P	-3.86	0.000141	0.0294	-0.34	-0.23	Obesity-related traits;	chr8:8732177	chr8:8236003~8244667:-
COAD	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	3.86	0.000141	0.0294	0.31	0.23	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
COAD	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	3.86	0.000141	0.0294	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
COAD	cis	rs72615157	0.561	rs113401658	ENSG00000078319.8	PMS2P1	-3.86	0.000141	0.0294	-0.34	-0.23	Lung function (FEV1/FVC);	chr7:100260882	chr7:100320992~100341908:-
COAD	cis	rs2307394	1	rs10460259	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147947152	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs11888152	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147957469	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs34539489	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147965308	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs6729465	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147965557	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13027706	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147975134	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs7594075	ENSG00000281469.1	RP11-567F11.1	3.86	0.000141	0.0294	0.27	0.23	Urate levels;	chr2:147982254	chr2:148044380~148044894:+
COAD	cis	rs989978	0.958	rs10458728	ENSG00000228778.1	RP11-129J12.1	-3.86	0.000141	0.0294	-0.27	-0.23	Red blood cell count;	chr10:99564219	chr10:99527081~99528261:+
COAD	cis	rs453301	0.653	rs7016139	ENSG00000254340.1	RP11-10A14.3	-3.86	0.000141	0.0294	-0.29	-0.23	Joint mobility (Beighton score);	chr8:9037960	chr8:9141424~9145435:+
COAD	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	3.86	0.000141	0.0294	0.32	0.23	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
COAD	cis	rs12049351	0.665	rs11809370	ENSG00000229367.1	HMGN2P19	3.86	0.000141	0.0294	0.31	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229451386	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.665	rs3767325	ENSG00000229367.1	HMGN2P19	3.86	0.000141	0.0294	0.31	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229454299	chr1:229570532~229570796:+
COAD	cis	rs4443656	0.933	rs3936037	ENSG00000254064.1	CTD-2530N21.4	3.86	0.000141	0.0294	0.23	0.23	Blood protein levels;	chr8:21676436	chr8:22254576~22275162:-
COAD	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	3.86	0.000141	0.0294	0.27	0.23	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
COAD	cis	rs2836974	0.568	rs442972	ENSG00000255568.3	BRWD1-AS2	-3.86	0.000141	0.0294	-0.22	-0.23	Cognitive function;	chr21:39162831	chr21:39313935~39314962:+
COAD	cis	rs2229774	1	rs11170481	ENSG00000270175.1	RP11-793H13.11	3.86	0.000141	0.0295	0.34	0.23	Anthracycline-induced cardiotoxicity in childhood cancer;	chr12:53218007	chr12:53500162~53500936:-
COAD	cis	rs6452524	0.935	rs11750799	ENSG00000271862.1	RP11-343L5.2	3.86	0.000141	0.0295	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83049376~83050964:-
COAD	cis	rs72827839	0.649	rs80347400	ENSG00000263412.1	RP5-890E16.2	3.86	0.000141	0.0295	0.38	0.23	Ease of getting up in the morning;	chr17:47935136	chr17:48045141~48048073:-
COAD	cis	rs739496	0.653	rs11613713	ENSG00000257595.2	RP3-473L9.4	3.86	0.000141	0.0295	0.41	0.23	Platelet count;	chr12:111779334	chr12:111369282~111403310:+
COAD	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	3.86	0.000141	0.0295	0.37	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
COAD	cis	rs1479119	0.552	rs7314181	ENSG00000180861.8	LINC01559	3.86	0.000141	0.0295	0.26	0.23	Intelligence (multi-trait analysis);	chr12:13368242	chr12:13371089~13387167:-
COAD	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000142	0.0295	-0.32	-0.23	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
COAD	cis	rs12819124	0.502	rs10875718	ENSG00000226413.2	OR8T1P	3.86	0.000142	0.0295	0.27	0.23	Glycated hemoglobin levels;	chr12:48017319	chr12:48442030~48442947:-
COAD	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-3.86	0.000142	0.0295	-0.34	-0.23	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
COAD	cis	rs1707322	0.785	rs10890348	ENSG00000230896.1	RP11-767N6.7	-3.86	0.000142	0.0295	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45694684~45697075:-
COAD	cis	rs364477	0.548	rs10759046	ENSG00000235330.2	RP11-165F24.2	-3.86	0.000142	0.0295	-0.29	-0.23	Major depressive disorder;	chr9:922917	chr9:477750~478423:+
COAD	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	3.86	0.000142	0.0295	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	3.86	0.000142	0.0295	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
COAD	cis	rs12704645	1	rs12704645	ENSG00000200769.1	Y_RNA	-3.86	0.000142	0.0295	-0.27	-0.23	Age-related hearing impairment;	chr7:92993336	chr7:92202243~92202334:-
COAD	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-3.86	0.000142	0.0296	-0.26	-0.23	Gout;	chr7:66642037	chr7:66902857~66906297:+
COAD	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-3.86	0.000142	0.0296	-0.25	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
COAD	cis	rs6787172	0.54	rs28522438	ENSG00000272087.1	RP11-379F4.7	3.86	0.000142	0.0296	0.28	0.23	Subjective well-being;	chr3:158453207	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.622	rs12636560	ENSG00000272087.1	RP11-379F4.7	3.86	0.000142	0.0296	0.28	0.23	Subjective well-being;	chr3:158453665	chr3:158693120~158693768:-
COAD	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	3.86	0.000142	0.0296	0.3	0.23	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	3.86	0.000142	0.0296	0.3	0.23	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
COAD	cis	rs10043775	0.958	rs12717974	ENSG00000251330.3	CTD-2283N19.1	-3.86	0.000142	0.0296	-0.28	-0.23	Periodontal microbiota;	chr5:148449614	chr5:148430159~148430807:-
COAD	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-3.86	0.000142	0.0296	-0.23	-0.23	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
COAD	cis	rs10087240	0.55	rs4733820	ENSG00000207110.1	RNU1-106P	3.86	0.000142	0.0296	0.3	0.23	Lymphocyte counts;White blood cell count;	chr8:128000490	chr8:127999131~127999294:+
COAD	cis	rs875971	0.964	rs778723	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66364510	chr7:66409143~66490059:-
COAD	cis	rs875971	0.767	rs1695815	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66366357	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778685	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66371189	chr7:66409143~66490059:-
COAD	cis	rs875971	0.929	rs778682	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66372947	chr7:66409143~66490059:-
COAD	cis	rs875971	0.964	rs11765965	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66377234	chr7:66409143~66490059:-
COAD	cis	rs875971	0.964	rs1643388	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66379575	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778722	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66379841	chr7:66409143~66490059:-
COAD	cis	rs875971	0.964	rs778721	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66380410	chr7:66409143~66490059:-
COAD	cis	rs875971	0.929	rs778712	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66384991	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778710	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66389847	chr7:66409143~66490059:-
COAD	cis	rs875971	0.964	rs778708	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66391332	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778706	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66395437	chr7:66409143~66490059:-
COAD	cis	rs875971	0.895	rs778700	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66401463	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778699	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66403303	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778696	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66405826	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs778694	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66406571	chr7:66409143~66490059:-
COAD	cis	rs875971	0.929	rs778692	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66407462	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs4718343	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66409301	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs4718344	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66409394	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs1968225	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66409786	chr7:66409143~66490059:-
COAD	cis	rs875971	0.737	rs7803424	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66415618	chr7:66409143~66490059:-
COAD	cis	rs875971	0.83	rs7799834	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66415707	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs6460295	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66417741	chr7:66409143~66490059:-
COAD	cis	rs875971	0.964	rs6978721	ENSG00000230189.5	GS1-124K5.2	3.86	0.000142	0.0296	0.19	0.23	Aortic root size;	chr7:66418217	chr7:66409143~66490059:-
COAD	cis	rs7955901	0.539	rs1705232	ENSG00000258053.1	CTD-2021H9.3	-3.86	0.000142	0.0296	-0.29	-0.23	Type 2 diabetes;	chr12:71137309	chr12:71047402~71118247:-
COAD	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-3.86	0.000142	0.0296	-0.28	-0.23	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
COAD	cis	rs7727544	0.625	rs3864277	ENSG00000233006.5	AC034220.3	3.86	0.000142	0.0296	0.21	0.23	Blood metabolite levels;	chr5:132084556	chr5:132311285~132369916:-
COAD	cis	rs7727544	0.647	rs6898270	ENSG00000233006.5	AC034220.3	3.86	0.000142	0.0296	0.21	0.23	Blood metabolite levels;	chr5:132085497	chr5:132311285~132369916:-
COAD	cis	rs7204230	1	rs17302672	ENSG00000261056.2	RP11-454F8.2	3.86	0.000142	0.0296	0.28	0.23	Fibrinogen;	chr16:53176641	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12596062	ENSG00000261056.2	RP11-454F8.2	3.86	0.000142	0.0296	0.28	0.23	Fibrinogen;	chr16:53177753	chr16:53298224~53299792:+
COAD	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-3.86	0.000142	0.0296	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-3.86	0.000142	0.0296	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-3.86	0.000142	0.0296	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-3.86	0.000142	0.0296	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
COAD	cis	rs10515750	0.5	rs10038502	ENSG00000248544.2	CTB-47B11.3	3.86	0.000142	0.0296	0.31	0.23	Lung function (FEV1/FVC);	chr5:157279695	chr5:157375741~157384950:-
COAD	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	3.86	0.000142	0.0296	0.32	0.23	Depression;	chr6:28205175	chr6:28943877~28944537:+
COAD	cis	rs7131987	0.903	rs1035604	ENSG00000275476.1	RP11-996F15.4	-3.86	0.000142	0.0296	-0.28	-0.23	QT interval;	chr12:29240169	chr12:29277397~29277882:-
COAD	cis	rs597539	0.654	rs619727	ENSG00000255741.1	RP11-757G1.5	-3.86	0.000142	0.0296	-0.3	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68941503~68942852:-
COAD	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-3.86	0.000142	0.0296	-0.24	-0.23	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
COAD	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.505	rs75122014	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119441271	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	3.86	0.000142	0.0296	0.32	0.23	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
COAD	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-3.86	0.000142	0.0296	-0.24	-0.23	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
COAD	cis	rs440932	0.565	rs19334	ENSG00000253981.4	ALG1L13P	3.86	0.000142	0.0296	0.3	0.23	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8236003~8244667:-
COAD	cis	rs4604732	0.631	rs12091081	ENSG00000227135.1	GCSAML-AS1	-3.86	0.000142	0.0296	-0.35	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459762	chr1:247524679~247526752:-
COAD	cis	rs2836974	0.965	rs8134733	ENSG00000255568.3	BRWD1-AS2	3.86	0.000142	0.0296	0.24	0.23	Cognitive function;	chr21:39311533	chr21:39313935~39314962:+
COAD	cis	rs893363	0.594	rs12676	ENSG00000271916.1	RP11-884K10.6	-3.86	0.000142	0.0297	-0.25	-0.23	Axial length;	chr3:53823776	chr3:53797764~53798019:-
COAD	cis	rs2337406	0.778	rs58113768	ENSG00000211964.3	IGHV3-48	-3.86	0.000142	0.0297	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106700213	chr14:106537810~106538344:-
COAD	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-3.86	0.000142	0.0297	-0.28	-0.23	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
COAD	cis	rs848490	0.889	rs11489585	ENSG00000213542.3	RP11-467H10.1	-3.86	0.000143	0.0297	-0.28	-0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685535	chr7:77115399~77116192:-
COAD	cis	rs1466921	0.705	rs2654224	ENSG00000278603.1	RP13-608F4.5	-3.86	0.000143	0.0297	-0.25	-0.23	Left superior temporal gyrus thickness (schizophrenia interaction);	chr15:82079763	chr15:82472203~82472426:+
COAD	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	3.86	0.000143	0.0297	0.33	0.23	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
COAD	cis	rs9880211	0.613	rs28519617	ENSG00000239213.4	NCK1-AS1	3.86	0.000143	0.0297	0.31	0.23	Height;Body mass index;	chr3:136156088	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.613	rs28669017	ENSG00000239213.4	NCK1-AS1	3.86	0.000143	0.0297	0.31	0.23	Height;Body mass index;	chr3:136156090	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.613	rs10222451	ENSG00000239213.4	NCK1-AS1	3.86	0.000143	0.0297	0.31	0.23	Height;Body mass index;	chr3:136158571	chr3:136841726~136862054:-
COAD	cis	rs6840360	0.681	rs4519779	ENSG00000251611.1	RP11-610P16.1	-3.86	0.000143	0.0297	-0.23	-0.23	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151407551~151408835:-
COAD	cis	rs2243480	0.901	rs13237344	ENSG00000232559.3	GS1-124K5.12	3.86	0.000143	0.0297	0.42	0.23	Diabetic kidney disease;	chr7:66557269	chr7:66554588~66576923:-
COAD	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	3.86	0.000143	0.0297	0.33	0.23	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	3.86	0.000143	0.0297	0.33	0.23	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
COAD	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-3.86	0.000143	0.0297	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
COAD	cis	rs8017304	0.643	rs7151629	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000143	0.0297	-0.3	-0.23	Age-related macular degeneration;	chr14:68299007	chr14:67610986~67613864:+
COAD	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-3.86	0.000143	0.0297	-0.27	-0.23	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
COAD	cis	rs2720460	0.502	rs223374	ENSG00000248971.2	KRT8P46	-3.86	0.000143	0.0297	-0.24	-0.23	Testicular germ cell tumor;	chr4:102837144	chr4:102728746~102730171:-
COAD	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-3.86	0.000143	0.0297	-0.39	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
COAD	cis	rs34779708	0.966	rs1478463	ENSG00000271335.4	RP11-324I22.4	3.86	0.000143	0.0297	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35314552~35336401:-
COAD	cis	rs28374715	0.629	rs2118740	ENSG00000247556.5	OIP5-AS1	3.86	0.000143	0.0297	0.36	0.23	Ulcerative colitis;	chr15:41285034	chr15:41283990~41309737:+
COAD	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	3.86	0.000143	0.0297	0.34	0.23	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
COAD	cis	rs9813712	0.526	rs13065659	ENSG00000253540.4	FAM86HP	-3.86	0.000143	0.0297	-0.25	-0.23	Response to amphetamines;	chr3:130231945	chr3:130099092~130111472:-
COAD	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	3.86	0.000143	0.0297	0.25	0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
COAD	cis	rs2638953	0.924	rs11049468	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049469	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049470	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843140	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049472	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.888	rs2061760	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049474	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0297	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28163298~28190738:-
COAD	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	3.86	0.000143	0.0297	0.31	0.23	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	3.86	0.000143	0.0297	0.31	0.23	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
COAD	cis	rs7129556	0.775	rs72945592	ENSG00000254691.1	RP11-91P24.5	3.86	0.000143	0.0297	0.26	0.23	Weight loss (gastric bypass surgery);	chr11:77649451	chr11:77850604~77851511:+
COAD	cis	rs2408955	0.521	rs10875749	ENSG00000257735.1	RP11-370I10.6	-3.86	0.000143	0.0297	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48138134	chr12:48350945~48442411:+
COAD	cis	rs8017304	0.643	rs4410007	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000143	0.0297	-0.3	-0.23	Age-related macular degeneration;	chr14:68334085	chr14:67610986~67613864:+
COAD	cis	rs8017304	0.643	rs7493547	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000143	0.0297	-0.3	-0.23	Age-related macular degeneration;	chr14:68335395	chr14:67610986~67613864:+
COAD	cis	rs8017304	0.669	rs911255	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000143	0.0297	-0.3	-0.23	Age-related macular degeneration;	chr14:68335705	chr14:67610986~67613864:+
COAD	cis	rs739496	0.615	rs56884502	ENSG00000257595.2	RP3-473L9.4	3.86	0.000143	0.0297	0.38	0.23	Platelet count;	chr12:111769496	chr12:111369282~111403310:+
COAD	cis	rs739496	0.642	rs74849450	ENSG00000257595.2	RP3-473L9.4	3.86	0.000143	0.0297	0.38	0.23	Platelet count;	chr12:111771034	chr12:111369282~111403310:+
COAD	cis	rs739496	0.579	rs2238152	ENSG00000257595.2	RP3-473L9.4	3.86	0.000143	0.0297	0.38	0.23	Platelet count;	chr12:111776655	chr12:111369282~111403310:+
COAD	cis	rs739496	0.615	rs4646778	ENSG00000257595.2	RP3-473L9.4	3.86	0.000143	0.0297	0.38	0.23	Platelet count;	chr12:111797979	chr12:111369282~111403310:+
COAD	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	3.86	0.000143	0.0297	0.27	0.23	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	3.86	0.000143	0.0297	0.27	0.23	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	3.86	0.000143	0.0297	0.27	0.23	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	3.86	0.000143	0.0297	0.27	0.23	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
COAD	cis	rs703842	0.575	rs701006	ENSG00000270039.1	RP11-571M6.17	-3.86	0.000143	0.0298	-0.25	-0.23	Multiple sclerosis;	chr12:57713053	chr12:57803838~57804415:+
COAD	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	3.86	0.000143	0.0298	0.21	0.23	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
COAD	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	3.86	0.000143	0.0298	0.29	0.23	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
COAD	cis	rs13315871	0.929	rs35557787	ENSG00000273493.1	RP11-80H18.4	3.86	0.000143	0.0298	0.42	0.23	Cholesterol, total;	chr3:58248809	chr3:58329965~58330118:+
COAD	cis	rs875971	0.964	rs778735	ENSG00000230189.5	GS1-124K5.2	3.86	0.000143	0.0298	0.19	0.23	Aortic root size;	chr7:66349822	chr7:66409143~66490059:-
COAD	cis	rs2732480	0.577	rs2732466	ENSG00000269514.1	RP11-370I10.12	3.86	0.000143	0.0298	0.3	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48198387~48202031:+
COAD	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	3.86	0.000143	0.0298	0.22	0.23	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
COAD	cis	rs2638953	0.815	rs10843186	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0298	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.815	rs1511551	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000143	0.0298	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28163298~28190738:-
COAD	cis	rs3748656	0.945	rs12117479	ENSG00000231246.1	RP5-965F6.2	-3.86	0.000143	0.0298	-0.32	-0.23	Hip circumference adjusted for BMI;	chr1:112534197	chr1:112177234~112360528:-
COAD	cis	rs57561814	0.51	rs1524107	ENSG00000179428.2	AC073072.5	-3.86	0.000143	0.0298	-0.5	-0.23	Tonsillectomy;	chr7:22728600	chr7:22725395~22727620:-
COAD	cis	rs7560272	0.501	rs12713793	ENSG00000273245.1	RP11-434P11.2	-3.86	0.000143	0.0298	-0.29	-0.23	Schizophrenia;	chr2:73728987	chr2:73750256~73750786:-
COAD	cis	rs757278	0.513	rs213988	ENSG00000237974.1	AC000111.4	3.86	0.000143	0.0298	0.25	0.23	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117622250	chr7:117487737~117487929:+
COAD	cis	rs913655	0.508	rs2493624	ENSG00000240291.1	RP11-499P20.2	3.86	0.000143	0.0298	0.27	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18773327	chr10:18513115~18545651:-
COAD	cis	rs72615157	0.561	rs113844570	ENSG00000078319.8	PMS2P1	-3.86	0.000143	0.0298	-0.34	-0.23	Lung function (FEV1/FVC);	chr7:100276155	chr7:100320992~100341908:-
COAD	cis	rs2251381	0.62	rs1537093	ENSG00000176054.6	RPL23P2	3.86	0.000144	0.0298	0.25	0.23	Selective IgA deficiency;	chr21:29002784	chr21:28997613~28998033:-
COAD	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000144	0.0298	-0.3	-0.23	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000144	0.0298	-0.3	-0.23	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
COAD	cis	rs7324557	0.717	rs9507164	ENSG00000205861.10	C1QTNF9B-AS1	-3.86	0.000144	0.0298	-0.33	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23806400	chr13:23888889~23897263:+
COAD	cis	rs730566	1	rs730566	ENSG00000228638.1	FCF1P2	3.86	0.000144	0.0298	0.32	0.23	Prion diseases;	chr3:48445644	chr3:48290793~48291375:-
COAD	cis	rs4767364	1	rs2285810	ENSG00000257595.2	RP3-473L9.4	3.86	0.000144	0.0298	0.3	0.23	Oral cavity and pharyngeal cancer;	chr12:112261736	chr12:111369282~111403310:+
COAD	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-3.86	0.000144	0.0298	-0.34	-0.23	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
COAD	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-3.86	0.000144	0.0298	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-3.86	0.000144	0.0298	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-3.86	0.000144	0.0298	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
COAD	cis	rs7577696	0.889	rs212730	ENSG00000272716.1	RP11-563N4.1	3.86	0.000144	0.0298	0.24	0.23	Inflammatory biomarkers;	chr2:32246604	chr2:32165046~32165757:-
COAD	cis	rs6125597	0.967	rs6063380	ENSG00000222365.1	SNORD12B	3.86	0.000144	0.0298	0.2	0.23	Intelligence (multi-trait analysis);	chr20:49265044	chr20:49280319~49280409:+
COAD	cis	rs7819412	0.521	rs9329238	ENSG00000269918.1	AF131215.9	-3.86	0.000144	0.0298	-0.29	-0.23	Triglycerides;	chr8:11176228	chr8:11104691~11106704:-
COAD	cis	rs911263	0.581	rs3825730	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000144	0.0298	-0.29	-0.23	Primary biliary cholangitis;	chr14:68323862	chr14:67610986~67613864:+
COAD	cis	rs728616	0.867	rs726289	ENSG00000234382.2	RP11-40F6.1	-3.86	0.000144	0.0298	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:80233664~80245367:+
COAD	cis	rs875971	0.522	rs9530	ENSG00000272831.1	RP11-792A8.4	3.86	0.000144	0.0298	0.25	0.23	Aortic root size;	chr7:65960907	chr7:66739829~66740385:-
COAD	cis	rs2638953	0.962	rs79708115	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000144	0.0299	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs10506034	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000144	0.0299	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28442363	chr12:28163298~28190738:-
COAD	cis	rs6687821	0.515	rs2390221	ENSG00000261737.1	RP4-612B15.3	3.86	0.000144	0.0299	0.31	0.23	Yeast infection;	chr1:86990333	chr1:86703502~86704462:-
COAD	cis	rs9910055	0.639	rs7217858	ENSG00000267080.4	ASB16-AS1	-3.86	0.000144	0.0299	-0.21	-0.23	Total body bone mineral density;	chr17:44177159	chr17:44175973~44186717:-
COAD	cis	rs2904967	0.636	rs514076	ENSG00000245532.5	NEAT1	-3.86	0.000144	0.0299	-0.22	-0.23	Mean corpuscular volume;	chr11:65222570	chr11:65422774~65445540:+
COAD	cis	rs1799949	0.894	rs36062488	ENSG00000279602.1	CTD-3014M21.1	-3.86	0.000144	0.0299	-0.25	-0.23	Menopause (age at onset);	chr17:43185455	chr17:43360041~43361361:-
COAD	cis	rs7204230	1	rs12599389	ENSG00000261056.2	RP11-454F8.2	3.86	0.000144	0.0299	0.28	0.23	Fibrinogen;	chr16:53196746	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs11865438	ENSG00000261056.2	RP11-454F8.2	3.86	0.000144	0.0299	0.28	0.23	Fibrinogen;	chr16:53296216	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs11865886	ENSG00000261056.2	RP11-454F8.2	3.86	0.000144	0.0299	0.28	0.23	Fibrinogen;	chr16:53297679	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs1133262	ENSG00000261056.2	RP11-454F8.2	3.86	0.000144	0.0299	0.28	0.23	Fibrinogen;	chr16:53298278	chr16:53298224~53299792:+
COAD	cis	rs55962025	0.842	rs362306	ENSG00000248840.2	RP11-357G3.2	3.86	0.000144	0.0299	0.28	0.23	Parental longevity (mother's age at death);	chr4:3240373	chr4:3312512~3313058:+
COAD	cis	rs7577696	0.888	rs494569	ENSG00000272716.1	RP11-563N4.1	3.86	0.000144	0.0299	0.24	0.23	Inflammatory biomarkers;	chr2:32244553	chr2:32165046~32165757:-
COAD	cis	rs3789135	1	rs3789135	ENSG00000207650.1	MIR570	3.86	0.000144	0.0299	0.29	0.23	Mean corpuscular hemoglobin;	chr3:196065999	chr3:195699401~195699497:+
COAD	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	3.86	0.000144	0.0299	0.31	0.23	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	3.86	0.000144	0.0299	0.31	0.23	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	3.86	0.000144	0.0299	0.31	0.23	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	3.86	0.000144	0.0299	0.31	0.23	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
COAD	cis	rs7584330	0.554	rs7598559	ENSG00000234949.2	AC104667.3	3.86	0.000144	0.0299	0.36	0.23	Prostate cancer;	chr2:237526755	chr2:237591020~237595981:+
COAD	cis	rs801193	0.66	rs4610622	ENSG00000179406.6	LINC00174	3.86	0.000144	0.0299	0.17	0.23	Aortic root size;	chr7:66759510	chr7:66376044~66401338:-
COAD	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000144	0.0299	-0.2	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
COAD	cis	rs9880211	1	rs28634226	ENSG00000273486.1	RP11-731C17.2	3.86	0.000144	0.0299	0.27	0.23	Height;Body mass index;	chr3:136411040	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.948	rs13316214	ENSG00000273486.1	RP11-731C17.2	3.86	0.000144	0.0299	0.27	0.23	Height;Body mass index;	chr3:136439379	chr3:136837338~136839021:-
COAD	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	3.86	0.000144	0.0299	0.25	0.23	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
COAD	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-3.86	0.000144	0.0299	-0.26	-0.23	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
COAD	cis	rs2554380	0.628	rs919069	ENSG00000176700.18	SCAND2P	-3.86	0.000144	0.0299	-0.21	-0.23	Height;	chr15:83775776	chr15:84631451~84647478:+
COAD	cis	rs2554380	0.628	rs6602990	ENSG00000176700.18	SCAND2P	-3.86	0.000144	0.0299	-0.21	-0.23	Height;	chr15:83783470	chr15:84631451~84647478:+
COAD	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-3.86	0.000144	0.0299	-0.29	-0.23	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
COAD	cis	rs7818688	1	rs16917233	ENSG00000253528.2	RP11-347C18.4	3.86	0.000144	0.0299	0.34	0.23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95032739	chr8:94974573~94974853:-
COAD	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	3.86	0.000144	0.0299	0.3	0.23	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
COAD	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-3.86	0.000144	0.0299	-0.31	-0.23	Depression;	chr6:28422360	chr6:28943877~28944537:+
COAD	cis	rs8017304	0.643	rs1956523	ENSG00000259502.1	RP11-643G16.3	-3.86	0.000144	0.0299	-0.31	-0.23	Age-related macular degeneration;	chr14:68337687	chr14:67610986~67613864:+
COAD	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	3.86	0.000144	0.0299	0.4	0.23	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
COAD	cis	rs7646881	0.544	rs16829116	ENSG00000272087.1	RP11-379F4.7	3.86	0.000144	0.0299	0.37	0.23	Tetralogy of Fallot;	chr3:158570012	chr3:158693120~158693768:-
COAD	cis	rs5758511	0.689	rs62240864	ENSG00000205702.9	CYP2D7	3.86	0.000144	0.0299	0.26	0.23	Birth weight;	chr22:42167883	chr22:42140203~42144577:-
COAD	cis	rs9816784	0.901	rs56253832	ENSG00000207650.1	MIR570	3.86	0.000144	0.0299	0.27	0.23	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195699401~195699497:+
COAD	cis	rs9796	0.558	rs8043253	ENSG00000247556.5	OIP5-AS1	3.86	0.000144	0.0299	0.23	0.23	Menopause (age at onset);	chr15:41211532	chr15:41283990~41309737:+
COAD	cis	rs2904967	0.636	rs184734	ENSG00000197847.11	SLC22A20	3.86	0.000144	0.0299	0.3	0.23	Mean corpuscular volume;	chr11:65214732	chr11:65213840~65242757:+
COAD	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	3.86	0.000144	0.0299	0.32	0.23	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
COAD	cis	rs7955901	0.691	rs11178601	ENSG00000258053.1	CTD-2021H9.3	3.86	0.000144	0.0299	0.29	0.23	Type 2 diabetes;	chr12:71097575	chr12:71047402~71118247:-
COAD	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000144	0.0299	-0.29	-0.23	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
COAD	cis	rs9888736	0.899	rs35653616	ENSG00000259488.2	RP11-154J22.1	3.86	0.000144	0.0299	0.25	0.23	Body mass index;	chr15:47656658	chr15:48312353~48331856:-
COAD	cis	rs9888736	0.899	rs1435740	ENSG00000259488.2	RP11-154J22.1	3.86	0.000144	0.0299	0.25	0.23	Body mass index;	chr15:47657344	chr15:48312353~48331856:-
COAD	cis	rs4688759	0.764	rs11716961	ENSG00000225399.4	RP11-3B7.1	-3.86	0.000144	0.0299	-0.58	-0.23	Blood protein levels;	chr3:49870905	chr3:49260085~49261316:+
COAD	cis	rs10760158	0.832	rs4836845	ENSG00000226752.6	PSMD5-AS1	-3.86	0.000144	0.0299	-0.25	-0.23	Pulse pressure;	chr9:121287678	chr9:120824828~120854385:+
COAD	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	3.86	0.000144	0.0299	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
COAD	cis	rs6480314	0.522	rs10733842	ENSG00000233590.1	RP11-153K11.3	3.86	0.000144	0.03	0.29	0.23	Optic nerve measurement (disc area);	chr10:68299286	chr10:68233251~68242379:-
COAD	cis	rs6930781	0.822	rs1350945	ENSG00000218632.3	RPL7P28	-3.86	0.000144	0.03	-0.25	-0.23	Major depression and alcohol dependence;	chr6:110032728	chr6:109327175~109327914:-
COAD	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-3.86	0.000144	0.03	-0.26	-0.23	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
COAD	cis	rs9532669	0.963	rs7989303	ENSG00000239827.7	SUGT1P3	-3.86	0.000145	0.03	-0.2	-0.23	Cervical cancer;	chr13:40950087	chr13:40908159~40921774:-
COAD	cis	rs1211375	0.606	rs1203977	ENSG00000262528.2	LA16c-349E10.1	3.86	0.000145	0.03	0.27	0.23	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:654611~656194:-
COAD	cis	rs7487075	0.558	rs12303214	ENSG00000274723.1	RP11-618L22.1	3.86	0.000145	0.03	0.26	0.23	Itch intensity from mosquito bite;	chr12:46255745	chr12:46970504~46972155:+
COAD	cis	rs1552244	0.832	rs73024591	ENSG00000186162.9	CIDECP	3.86	0.000145	0.03	0.4	0.23	Alzheimer's disease;	chr3:10161510	chr3:10014238~10026365:-
COAD	cis	rs2638953	0.924	rs10843139	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000145	0.03	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28163298~28190738:-
COAD	cis	rs12049351	0.665	rs7545592	ENSG00000229367.1	HMGN2P19	3.86	0.000145	0.03	0.31	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229456913	chr1:229570532~229570796:+
COAD	cis	rs78487399	0.614	rs74907855	ENSG00000234936.1	AC010883.5	3.86	0.000145	0.03	0.37	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43529062	chr2:43229573~43233394:+
COAD	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	3.86	0.000145	0.03	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
COAD	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-3.86	0.000145	0.03	-0.31	-0.23	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
COAD	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-3.86	0.000145	0.03	-0.3	-0.23	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
COAD	cis	rs12428035	0.764	rs9525077	ENSG00000247400.3	DNAJC3-AS1	3.86	0.000145	0.03	0.27	0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95888539	chr13:95648733~95676925:-
COAD	cis	rs3733585	0.699	rs12498150	ENSG00000250413.1	RP11-448G15.1	3.86	0.000145	0.0301	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9948913	chr4:10006482~10009725:+
COAD	cis	rs454422	0.812	rs236118	ENSG00000275632.1	RP5-967N21.11	3.86	0.000145	0.0301	0.27	0.23	HIV-1 viral setpoint;	chr20:5957561	chr20:6000418~6000941:+
COAD	cis	rs12908161	0.853	rs11633788	ENSG00000259728.4	LINC00933	3.86	0.000145	0.0301	0.28	0.23	Schizophrenia;	chr15:84761911	chr15:84570649~84580175:+
COAD	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	3.86	0.000145	0.0301	0.3	0.23	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
COAD	cis	rs7577696	0.962	rs17767988	ENSG00000272716.1	RP11-563N4.1	-3.86	0.000145	0.0301	-0.24	-0.23	Inflammatory biomarkers;	chr2:32061757	chr2:32165046~32165757:-
COAD	cis	rs2836974	0.966	rs2836977	ENSG00000255568.3	BRWD1-AS2	3.86	0.000145	0.0301	0.24	0.23	Cognitive function;	chr21:39294140	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.865	rs34778912	ENSG00000255568.3	BRWD1-AS2	3.86	0.000145	0.0301	0.24	0.23	Cognitive function;	chr21:39295111	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.865	rs7282624	ENSG00000255568.3	BRWD1-AS2	3.86	0.000145	0.0301	0.24	0.23	Cognitive function;	chr21:39295114	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.931	rs13625	ENSG00000255568.3	BRWD1-AS2	3.86	0.000145	0.0301	0.24	0.23	Cognitive function;	chr21:39297157	chr21:39313935~39314962:+
COAD	cis	rs7714670	1	rs2339608	ENSG00000184084.7	CTD-2372A4.1	-3.86	0.000145	0.0301	-0.25	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:73775725	chr5:73803296~73803599:-
COAD	cis	rs11157436	0.602	rs11157437	ENSG00000211812.1	TRAV26-2	-3.86	0.000145	0.0301	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22202583~22203368:+
COAD	cis	rs7572733	0.773	rs970551	ENSG00000222017.1	AC011997.1	3.86	0.000145	0.0301	0.25	0.23	Dermatomyositis;	chr2:197632985	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.773	rs7588831	ENSG00000222017.1	AC011997.1	3.86	0.000145	0.0301	0.25	0.23	Dermatomyositis;	chr2:197643292	chr2:197693106~197774823:+
COAD	cis	rs9880211	0.948	rs13321721	ENSG00000273486.1	RP11-731C17.2	3.86	0.000145	0.0301	0.28	0.23	Height;Body mass index;	chr3:136490708	chr3:136837338~136839021:-
COAD	cis	rs68170813	0.559	rs2107319	ENSG00000241764.3	AC002467.7	3.86	0.000145	0.0301	0.31	0.23	Coronary artery disease;	chr7:107223299	chr7:107742817~107744581:-
COAD	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-3.86	0.000145	0.0301	-0.31	-0.23	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
COAD	cis	rs17362650	0.694	rs10929582	ENSG00000271855.1	RP11-214N9.1	-3.86	0.000145	0.0301	-0.23	-0.23	Alcohol dependence (age at onset);	chr2:9445071	chr2:9555899~9556775:+
COAD	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-3.86	0.000145	0.0301	-0.29	-0.23	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
COAD	cis	rs870355	0.964	rs1810063	ENSG00000267679.1	EIF5AP2	-3.86	0.000145	0.0301	-0.26	-0.23	Vitiligo;	chr17:78170410	chr17:78157403~78159135:+
COAD	cis	rs2292864	0.764	rs36046953	ENSG00000228782.6	CTD-2026D20.3	-3.86	0.000145	0.0301	-0.45	-0.23	Left atrial antero-posterior diameter;	chr17:47304425	chr17:47450568~47492492:-
COAD	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	3.86	0.000145	0.0301	0.33	0.23	Pain;	chr19:21430609	chr19:21554640~21569237:-
COAD	cis	rs2179367	0.632	rs11155649	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0301	0.34	0.23	Dupuytren's disease;	chr6:149405830	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs11155650	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0301	0.34	0.23	Dupuytren's disease;	chr6:149407613	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs11155651	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0301	0.34	0.23	Dupuytren's disease;	chr6:149408146	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs7896	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0301	0.34	0.23	Dupuytren's disease;	chr6:149410340	chr6:149904243~149906418:+
COAD	cis	rs2243480	0.615	rs34363376	ENSG00000232559.3	GS1-124K5.12	3.86	0.000146	0.0301	0.42	0.23	Diabetic kidney disease;	chr7:66474549	chr7:66554588~66576923:-
COAD	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-3.86	0.000146	0.0301	-0.26	-0.23	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
COAD	cis	rs1670533	0.932	rs13140341	ENSG00000273179.1	RP11-20I20.4	3.86	0.000146	0.0301	0.31	0.23	Recombination rate (females);	chr4:1060447	chr4:1167778~1168174:+
COAD	cis	rs860295	0.702	rs11264375	ENSG00000160766.13	GBAP1	3.86	0.000146	0.0301	0.27	0.23	Body mass index;	chr1:155454274	chr1:155213821~155227422:-
COAD	cis	rs1150668	0.799	rs2142730	ENSG00000272009.1	RP1-313I6.12	3.86	0.000146	0.0301	0.26	0.23	Pubertal anthropometrics;	chr6:28298372	chr6:28078792~28081130:-
COAD	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-3.86	0.000146	0.0301	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
COAD	cis	rs9487051	1	rs9386796	ENSG00000219700.1	PTCHD3P3	3.86	0.000146	0.0302	0.26	0.23	Reticulocyte fraction of red cells;	chr6:109297501	chr6:109288571~109290503:-
COAD	cis	rs911555	0.755	rs8014013	ENSG00000251533.2	LINC00605	3.86	0.000146	0.0302	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103187221~103189028:-
COAD	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-3.86	0.000146	0.0302	-0.35	-0.23	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
COAD	cis	rs9513593	0.579	rs35298349	ENSG00000260992.1	DOCK9-AS2	-3.86	0.000146	0.0302	-0.39	-0.23	Psoriasis;	chr13:99343483	chr13:99087819~99088625:+
COAD	cis	rs8022206	0.738	rs11624209	ENSG00000259502.1	RP11-643G16.3	3.86	0.000146	0.0302	0.32	0.23	Platelet count;Mean platelet volume;	chr14:68072913	chr14:67610986~67613864:+
COAD	cis	rs5753037	0.547	rs140140	ENSG00000279159.1	RP3-394A18.1	-3.86	0.000146	0.0302	-0.16	-0.23	Type 1 diabetes;	chr22:29770448	chr22:29978950~30028236:-
COAD	cis	rs739496	0.615	rs12427276	ENSG00000257595.2	RP3-473L9.4	3.86	0.000146	0.0302	0.38	0.23	Platelet count;	chr12:111675704	chr12:111369282~111403310:+
COAD	cis	rs12699921	0.598	rs2691607	ENSG00000279048.1	RP11-511H23.2	-3.86	0.000146	0.0302	-0.17	-0.23	Fibrinogen levels;	chr7:17839480	chr7:17940503~17942922:+
COAD	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	3.86	0.000146	0.0302	0.47	0.23	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
COAD	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-3.86	0.000146	0.0302	-0.24	-0.23	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
COAD	cis	rs2638953	0.924	rs4573721	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs4554927	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs61920243	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.679	rs7974882	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.679	rs7961395	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7961407	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7974904	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7974979	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7974701	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs7961769	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs61920244	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs61920245	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs34378873	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049437	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049438	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049440	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049441	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.853	rs11049442	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049443	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs60193273	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049446	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049447	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs10843123	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843124	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843125	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs12146881	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049448	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843126	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843127	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.85	rs10843128	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.85	rs10843129	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843130	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs61920253	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.888	rs11612143	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.813	rs11609999	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049453	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7957056	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs7957059	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs73261702	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049455	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049457	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs10843131	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843132	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843133	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843135	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049458	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049459	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049460	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1824767	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1824766	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1585682	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.888	rs9645745	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7973516	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7973656	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7971033	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7956418	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11519094	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11513465	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11513250	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11519330	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.85	rs11519331	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.888	rs11513466	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7298652	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs6487669	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs6487671	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049464	ENSG00000247934.4	RP11-967K21.1	-3.86	0.000146	0.0302	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28163298~28190738:-
COAD	cis	rs4763879	1	rs4763879	ENSG00000214776.8	RP11-726G1.1	3.86	0.000146	0.0302	0.27	0.23	Type 1 diabetes;	chr12:9757568	chr12:9467552~9576275:+
COAD	cis	rs17772222	0.755	rs12435019	ENSG00000258789.1	RP11-507K2.3	-3.86	0.000146	0.0302	-0.29	-0.23	Coronary artery calcification;	chr14:88365074	chr14:88551597~88552493:+
COAD	cis	rs7138300	0.546	rs7966592	ENSG00000258053.1	CTD-2021H9.3	-3.86	0.000146	0.0302	-0.29	-0.23	Type 2 diabetes;	chr12:71135379	chr12:71047402~71118247:-
COAD	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	3.86	0.000146	0.0302	0.47	0.23	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
COAD	cis	rs7204230	1	rs11859353	ENSG00000261056.2	RP11-454F8.2	3.86	0.000146	0.0302	0.28	0.23	Fibrinogen;	chr16:53333699	chr16:53298224~53299792:+
COAD	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-3.86	0.000146	0.0302	-0.27	-0.23	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
COAD	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	3.86	0.000146	0.0302	0.22	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
COAD	cis	rs253959	0.545	rs4920905	ENSG00000271918.1	CTD-2287O16.5	3.86	0.000146	0.0302	0.23	0.23	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116083807~116085416:-
COAD	cis	rs2337406	0.925	rs2011167	ENSG00000211964.3	IGHV3-48	-3.86	0.000146	0.0302	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106680831	chr14:106537810~106538344:-
COAD	cis	rs7688540	0.771	rs11737268	ENSG00000211553.1	AC253576.2	-3.86	0.000146	0.0302	-0.38	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:136461~136568:+
COAD	cis	rs7688540	0.771	rs11726829	ENSG00000211553.1	AC253576.2	-3.86	0.000146	0.0302	-0.38	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:136461~136568:+
COAD	cis	rs4237845	0.611	rs4583019	ENSG00000257698.1	RP11-620J15.3	3.86	0.000146	0.0302	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57922962	chr12:57931528~57936175:-
COAD	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-3.86	0.000146	0.0302	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-3.86	0.000146	0.0302	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-3.86	0.000146	0.0302	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-3.86	0.000146	0.0302	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-3.86	0.000146	0.0302	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
COAD	cis	rs742132	0.893	rs2072844	ENSG00000220875.1	HIST1H3PS1	3.86	0.000146	0.0302	0.31	0.23	Uric acid levels;	chr6:25631813	chr6:26321876~26322292:-
COAD	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	3.86	0.000146	0.0302	0.31	0.23	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
COAD	cis	rs116139393	0.536	rs13247186	ENSG00000187953.9	PMS2CL	-3.86	0.000146	0.0302	-0.25	-0.23	Alzheimer's disease (APOE e4 interaction);	chr7:6729524	chr7:6710128~6753862:+
COAD	cis	rs2179367	0.553	rs7762222	ENSG00000268592.3	RAET1E-AS1	3.86	0.000146	0.0302	0.27	0.23	Dupuytren's disease;	chr6:149444846	chr6:149863494~149919507:+
COAD	cis	rs7584330	0.518	rs7561919	ENSG00000234949.2	AC104667.3	-3.86	0.000146	0.0302	-0.39	-0.23	Prostate cancer;	chr2:237526598	chr2:237591020~237595981:+
COAD	cis	rs13256369	0.708	rs11783670	ENSG00000253981.4	ALG1L13P	3.86	0.000146	0.0302	0.34	0.23	Obesity-related traits;	chr8:8701884	chr8:8236003~8244667:-
COAD	cis	rs4760786	0.932	rs2870847	ENSG00000258053.1	CTD-2021H9.3	-3.86	0.000146	0.0302	-0.33	-0.23	Monobrow;	chr12:71030456	chr12:71047402~71118247:-
COAD	cis	rs4760786	0.932	rs11178539	ENSG00000258053.1	CTD-2021H9.3	-3.86	0.000146	0.0302	-0.33	-0.23	Monobrow;	chr12:71031521	chr12:71047402~71118247:-
COAD	cis	rs7760535	0.597	rs9320368	ENSG00000231889.6	TRAF3IP2-AS1	3.86	0.000146	0.0302	0.21	0.23	Metabolic traits;	chr6:111583534	chr6:111483511~111598302:+
COAD	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	3.86	0.000146	0.0302	0.32	0.23	Pain;	chr19:21569041	chr19:21554640~21569237:-
COAD	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	3.86	0.000146	0.0302	0.28	0.23	Height;	chr4:55515118	chr4:55547112~55547889:+
COAD	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-3.86	0.000146	0.0302	-0.3	-0.23	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
COAD	cis	rs2179367	0.632	rs9498323	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0302	0.34	0.23	Dupuytren's disease;	chr6:149336077	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498324	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0302	0.34	0.23	Dupuytren's disease;	chr6:149338973	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.586	rs62426088	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0302	0.34	0.23	Dupuytren's disease;	chr6:149339301	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12204793	ENSG00000216906.2	RP11-350J20.9	3.86	0.000146	0.0302	0.34	0.23	Dupuytren's disease;	chr6:149340102	chr6:149904243~149906418:+
COAD	cis	rs7577696	0.889	rs212737	ENSG00000272716.1	RP11-563N4.1	3.86	0.000146	0.0302	0.24	0.23	Inflammatory biomarkers;	chr2:32249222	chr2:32165046~32165757:-
COAD	cis	rs561341	1	rs550264	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31990521	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs564714	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31991385	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs111454793	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31992248	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs527256	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31994274	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs473356	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31994743	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs576985	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31996304	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs510264	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31996395	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs15654	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31999341	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs550923	ENSG00000265798.5	RP11-271K11.5	3.85	0.000146	0.0302	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31999994	chr17:31038575~31059121:-
COAD	cis	rs875971	1	rs709595	ENSG00000230189.5	GS1-124K5.2	3.85	0.000146	0.0302	0.19	0.23	Aortic root size;	chr7:66352346	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs811880	ENSG00000230189.5	GS1-124K5.2	3.85	0.000146	0.0302	0.19	0.23	Aortic root size;	chr7:66353659	chr7:66409143~66490059:-
COAD	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-3.85	0.000146	0.0303	-0.28	-0.23	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
COAD	cis	rs10087240	0.53	rs16902512	ENSG00000207110.1	RNU1-106P	3.85	0.000146	0.0303	0.29	0.23	Lymphocyte counts;White blood cell count;	chr8:127995494	chr8:127999131~127999294:+
COAD	cis	rs2439831	0.681	rs28594657	ENSG00000249839.1	AC011330.5	-3.85	0.000147	0.0303	-0.43	-0.23	Lung cancer in ever smokers;	chr15:43296690	chr15:43663654~43684339:-
COAD	cis	rs7760535	0.826	rs3777905	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000147	0.0303	-0.23	-0.23	Metabolic traits;	chr6:111549385	chr6:111297126~111298510:+
COAD	cis	rs860295	0.651	rs12239114	ENSG00000232519.2	RP11-29H23.4	-3.85	0.000147	0.0303	-0.33	-0.23	Body mass index;	chr1:155352351	chr1:155609776~155610380:-
COAD	cis	rs8192917	0.524	rs12884659	ENSG00000225766.7	DHRS4L1	3.85	0.000147	0.0303	0.47	0.23	Vitiligo;	chr14:24595620	chr14:24036453~24051028:+
COAD	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-3.85	0.000147	0.0303	-0.37	-0.23	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
COAD	cis	rs9816784	0.901	rs56253832	ENSG00000185485.13	SDHAP1	3.85	0.000147	0.0303	0.2	0.23	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195959748~195990318:-
COAD	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-3.85	0.000147	0.0303	-0.32	-0.23	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-3.85	0.000147	0.0303	-0.32	-0.23	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
COAD	cis	rs13256369	0.802	rs1060107	ENSG00000253981.4	ALG1L13P	3.85	0.000147	0.0303	0.34	0.23	Obesity-related traits;	chr8:8703889	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs4840350	ENSG00000253981.4	ALG1L13P	3.85	0.000147	0.0303	0.34	0.23	Obesity-related traits;	chr8:8703932	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs1060106	ENSG00000253981.4	ALG1L13P	3.85	0.000147	0.0303	0.34	0.23	Obesity-related traits;	chr8:8703942	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs11249883	ENSG00000253981.4	ALG1L13P	3.85	0.000147	0.0303	0.34	0.23	Obesity-related traits;	chr8:8704027	chr8:8236003~8244667:-
COAD	cis	rs2179367	0.632	rs12196750	ENSG00000216906.2	RP11-350J20.9	3.85	0.000147	0.0303	0.34	0.23	Dupuytren's disease;	chr6:149413335	chr6:149904243~149906418:+
COAD	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55485974	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55487368	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55489310	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55491628	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55495801	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55496737	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55496933	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55497842	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55500224	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55501629	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55501726	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55501788	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55504176	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	3.85	0.000147	0.0303	0.28	0.23	Height;	chr4:55504201	chr4:55547112~55547889:+
COAD	cis	rs8016982	0.651	rs1885601	ENSG00000258999.1	RP11-114N19.3	3.85	0.000147	0.0303	0.26	0.23	Schizophrenia;	chr14:81174866	chr14:81107033~81170414:-
COAD	cis	rs7119	0.651	rs12909292	ENSG00000259565.2	KRT8P23	-3.85	0.000147	0.0303	-0.29	-0.23	Type 2 diabetes;	chr15:77545640	chr15:76979245~76980451:-
COAD	cis	rs796825	0.637	rs56259926	ENSG00000240661.1	RP11-174O3.3	3.85	0.000147	0.0303	0.32	0.23	HIV-1 susceptibility;	chr3:120211849	chr3:120349510~120367998:+
COAD	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-3.85	0.000147	0.0303	-0.27	-0.23	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
COAD	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-3.85	0.000147	0.0303	-0.28	-0.23	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
COAD	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-3.85	0.000147	0.0303	-0.27	-0.23	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
COAD	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	3.85	0.000147	0.0303	0.29	0.23	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
COAD	cis	rs7933887	0.83	rs6590202	ENSG00000254905.1	RP11-712L6.7	3.85	0.000147	0.0303	0.33	0.23	Coronary artery disease;	chr11:126404137	chr11:126292922~126294254:-
COAD	cis	rs137115	1	rs137115	ENSG00000172250.13	SERHL	-3.85	0.000147	0.0304	-0.37	-0.23	Parental extreme longevity (95 years and older);	chr22:42615397	chr22:42500579~42512560:+
COAD	cis	rs74233809	1	rs112390216	ENSG00000213277.3	MARCKSL1P1	3.85	0.000147	0.0304	0.46	0.23	Birth weight;	chr10:102981274	chr10:103175554~103176094:+
COAD	cis	rs74233809	1	rs77860422	ENSG00000213277.3	MARCKSL1P1	3.85	0.000147	0.0304	0.46	0.23	Birth weight;	chr10:102988252	chr10:103175554~103176094:+
COAD	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000147	0.0304	-0.42	-0.23	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
COAD	cis	rs189798	0.807	rs330912	ENSG00000173295.6	FAM86B3P	3.85	0.000147	0.0304	0.35	0.23	Myopia (pathological);	chr8:9138784	chr8:8228595~8244865:+
COAD	cis	rs2179367	0.632	rs66672129	ENSG00000216906.2	RP11-350J20.9	3.85	0.000147	0.0304	0.34	0.23	Dupuytren's disease;	chr6:149334387	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498322	ENSG00000216906.2	RP11-350J20.9	3.85	0.000147	0.0304	0.34	0.23	Dupuytren's disease;	chr6:149335950	chr6:149904243~149906418:+
COAD	cis	rs11976180	1	rs2951372	ENSG00000273234.1	OR2A13P	-3.85	0.000147	0.0304	-0.28	-0.23	Obesity-related traits;	chr7:144052410	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951368	ENSG00000273234.1	OR2A13P	-3.85	0.000147	0.0304	-0.28	-0.23	Obesity-related traits;	chr7:144055728	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2961115	ENSG00000273234.1	OR2A13P	-3.85	0.000147	0.0304	-0.28	-0.23	Obesity-related traits;	chr7:144056278	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951363	ENSG00000273234.1	OR2A13P	-3.85	0.000147	0.0304	-0.28	-0.23	Obesity-related traits;	chr7:144057631	chr7:144142009~144142938:+
COAD	cis	rs9393777	0.588	rs6933213	ENSG00000224843.5	LINC00240	3.85	0.000147	0.0304	0.34	0.23	Intelligence (multi-trait analysis);	chr6:26493681	chr6:26956992~27023924:+
COAD	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	3.85	0.000147	0.0304	0.3	0.23	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
COAD	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-3.85	0.000147	0.0304	-0.28	-0.23	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
COAD	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-3.85	0.000147	0.0304	-0.34	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
COAD	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-3.85	0.000147	0.0304	-0.31	-0.23	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
COAD	cis	rs2836974	0.584	rs7276774	ENSG00000255568.3	BRWD1-AS2	-3.85	0.000147	0.0304	-0.22	-0.23	Cognitive function;	chr21:39256799	chr21:39313935~39314962:+
COAD	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	3.85	0.000148	0.0304	0.24	0.23	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
COAD	cis	rs2018293	0.948	rs76462504	ENSG00000233521.4	RP5-1172A22.1	-3.85	0.000148	0.0304	-0.22	-0.23	Vascular brain injury;	chr22:26312639	chr22:27221349~27224727:-
COAD	cis	rs7324557	0.717	rs9510866	ENSG00000205861.10	C1QTNF9B-AS1	-3.85	0.000148	0.0304	-0.33	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23806708	chr13:23888889~23897263:+
COAD	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-3.85	0.000148	0.0304	-0.29	-0.23	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
COAD	cis	rs17407555	0.657	rs6856199	ENSG00000250413.1	RP11-448G15.1	-3.85	0.000148	0.0304	-0.3	-0.23	Schizophrenia (age at onset);	chr4:10269968	chr4:10006482~10009725:+
COAD	cis	rs9796	0.7	rs2305656	ENSG00000247556.5	OIP5-AS1	3.85	0.000148	0.0304	0.25	0.23	Menopause (age at onset);	chr15:40987321	chr15:41283990~41309737:+
COAD	cis	rs7204230	1	rs11075782	ENSG00000261056.2	RP11-454F8.2	3.85	0.000148	0.0305	0.28	0.23	Fibrinogen;	chr16:53198047	chr16:53298224~53299792:+
COAD	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-3.85	0.000148	0.0305	-0.28	-0.23	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
COAD	cis	rs763121	0.853	rs3788544	ENSG00000273076.1	RP3-508I15.22	3.85	0.000148	0.0305	0.22	0.23	Menopause (age at onset);	chr22:38668961	chr22:38743495~38743910:+
COAD	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-3.85	0.000148	0.0305	-0.29	-0.23	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
COAD	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-3.85	0.000148	0.0305	-0.29	-0.23	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
COAD	cis	rs1275468	1	rs1148003	ENSG00000257497.2	RP11-585P4.5	-3.85	0.000148	0.0305	-0.31	-0.23	Polycystic ovary syndrome;	chr12:75585216	chr12:75483454~75489820:-
COAD	cis	rs1585471	0.812	rs9991259	ENSG00000248697.1	TOX4P1	3.85	0.000148	0.0305	0.24	0.23	Myopia (pathological);	chr4:111765198	chr4:112455924~112457785:+
COAD	cis	rs2179367	0.632	rs9322179	ENSG00000216906.2	RP11-350J20.9	3.85	0.000148	0.0305	0.34	0.23	Dupuytren's disease;	chr6:149418664	chr6:149904243~149906418:+
COAD	cis	rs763121	0.853	rs5757231	ENSG00000273076.1	RP3-508I15.22	-3.85	0.000148	0.0305	-0.21	-0.23	Menopause (age at onset);	chr22:38675653	chr22:38743495~38743910:+
COAD	cis	rs2179367	0.613	rs62426122	ENSG00000216906.2	RP11-350J20.9	3.85	0.000148	0.0305	0.32	0.23	Dupuytren's disease;	chr6:149427449	chr6:149904243~149906418:+
COAD	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-3.85	0.000148	0.0305	-0.26	-0.23	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
COAD	cis	rs2711721	0.535	rs1989911	ENSG00000280054.1	RP1-197B17.7	-3.85	0.000148	0.0305	-0.28	-0.23	Prostate cancer (SNP x SNP interaction);	chr12:47008126	chr12:47728151~47730598:-
COAD	cis	rs2832191	0.692	rs2254872	ENSG00000176054.6	RPL23P2	3.85	0.000148	0.0305	0.24	0.23	Dental caries;	chr21:29042403	chr21:28997613~28998033:-
COAD	cis	rs4819052	0.851	rs2236445	ENSG00000227039.5	ITGB2-AS1	-3.85	0.000148	0.0305	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:44921051~44929678:+
COAD	cis	rs1353394	0.59	rs2643962	ENSG00000226845.1	EEF1GP3	-3.85	0.000148	0.0305	-0.28	-0.23	Gut microbiota (functional units);	chr3:41529109	chr3:40596207~40597494:-
COAD	cis	rs984222	0.838	rs6428789	ENSG00000231365.4	RP11-418J17.1	-3.85	0.000148	0.0305	-0.26	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119007857	chr1:119140396~119275973:+
COAD	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	3.85	0.000148	0.0305	0.27	0.23	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
COAD	cis	rs240993	0.812	rs9400481	ENSG00000230177.1	RP5-1112D6.4	3.85	0.000148	0.0305	0.23	0.23	Inflammatory skin disease;Psoriasis;	chr6:111529539	chr6:111277932~111278742:+
COAD	cis	rs10933436	1	rs10933436	ENSG00000259793.1	RP11-400N9.1	3.85	0.000148	0.0306	0.26	0.23	Coronary heart disease;	chr2:233133771	chr2:233351132~233353416:-
COAD	cis	rs6951245	0.935	rs78573577	ENSG00000229043.2	AC091729.9	-3.85	0.000148	0.0306	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs76129108	ENSG00000229043.2	AC091729.9	-3.85	0.000148	0.0306	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs78523927	ENSG00000229043.2	AC091729.9	-3.85	0.000148	0.0306	-0.4	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1160374~1165267:+
COAD	cis	rs8141529	0.702	rs469991	ENSG00000272858.1	CTA-292E10.8	3.85	0.000148	0.0306	0.28	0.23	Lymphocyte counts;	chr22:28911871	chr22:28814914~28815662:+
COAD	cis	rs55962025	0.842	rs73193303	ENSG00000248840.2	RP11-357G3.2	3.85	0.000148	0.0306	0.28	0.23	Parental longevity (mother's age at death);	chr4:3190473	chr4:3312512~3313058:+
COAD	cis	rs5015933	0.734	rs10126025	ENSG00000232630.1	PRPS1P2	-3.85	0.000148	0.0306	-0.22	-0.23	Body mass index;	chr9:125383785	chr9:125150653~125151589:+
COAD	cis	rs3733585	0.699	rs4408959	ENSG00000250413.1	RP11-448G15.1	3.85	0.000148	0.0306	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9947244	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs4276278	ENSG00000250413.1	RP11-448G15.1	3.85	0.000148	0.0306	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9947246	chr4:10006482~10009725:+
COAD	cis	rs72932540	0.667	rs72932523	ENSG00000259799.1	RP11-554A11.9	3.85	0.000148	0.0306	0.55	0.23	Breast cancer;	chr11:69138652	chr11:69155910~69159752:+
COAD	cis	rs13188386	0.732	rs11740415	ENSG00000249779.1	RP11-447H19.3	-3.85	0.000148	0.0306	-0.28	-0.23	Iron status biomarkers;	chr5:42582425	chr5:43206709~43207811:+
COAD	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	3.85	0.000148	0.0306	0.3	0.23	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
COAD	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	3.85	0.000148	0.0306	0.3	0.23	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
COAD	cis	rs10949834	0.652	rs2269082	ENSG00000123965.13	PMS2P5	3.85	0.000148	0.0306	0.38	0.23	Verbal memory performance (residualized delayed recall change);	chr7:74105545	chr7:74894116~74897835:+
COAD	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-3.85	0.000148	0.0306	-0.48	-0.23	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
COAD	cis	rs423955	0.957	rs841990	ENSG00000225893.1	RP11-6J24.3	3.85	0.000148	0.0306	0.24	0.23	Platelet count;	chr9:4793254	chr9:4633027~4633756:+
COAD	cis	rs6788895	0.661	rs16862837	ENSG00000244265.1	SIAH2-AS1	-3.85	0.000148	0.0306	-0.41	-0.23	Breast cancer;	chr3:150752071	chr3:150761937~150762538:+
COAD	cis	rs9423406	0.501	rs7075810	ENSG00000224034.1	RP11-445P17.8	-3.85	0.000149	0.0306	-0.39	-0.23	Intelligence;	chr10:5283321	chr10:5266033~5271236:-
COAD	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-3.85	0.000149	0.0306	-0.33	-0.23	Depression;	chr6:28226851	chr6:28170845~28172521:+
COAD	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-3.85	0.000149	0.0306	-0.29	-0.23	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
COAD	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-3.85	0.000149	0.0306	-0.37	-0.23	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
COAD	cis	rs7032317	1	rs7032317	ENSG00000170827.8	CELP	-3.85	0.000149	0.0306	-0.22	-0.23	Calcium levels;	chr9:133004069	chr9:133079900~133087355:+
COAD	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	3.85	0.000149	0.0306	0.29	0.23	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
COAD	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66692349	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66693028	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66693433	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66694214	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66701371	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66702658	chr7:66025126~66031544:-
COAD	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66706390	chr7:66025126~66031544:-
COAD	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000149	0.0306	0.4	0.23	Gout;	chr7:66710076	chr7:66025126~66031544:-
COAD	cis	rs2732480	1	rs2732480	ENSG00000269514.1	RP11-370I10.12	-3.85	0.000149	0.0306	-0.26	-0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48198387~48202031:+
COAD	cis	rs11229555	0.609	rs4519113	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0306	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58449352	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs4598685	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0306	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58449391	chr11:57638024~57652790:+
COAD	cis	rs2617170	0.754	rs12824474	ENSG00000245648.1	RP11-277P12.20	-3.85	0.000149	0.0306	-0.31	-0.23	Behcet's disease;	chr12:10450326	chr12:10363769~10398506:+
COAD	cis	rs7260598	0.685	rs73021420	ENSG00000268442.1	CTD-2027I19.2	3.85	0.000149	0.0307	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:24162370~24163425:-
COAD	cis	rs11239930	0.538	rs4950359	ENSG00000278811.3	LINC00624	3.85	0.000149	0.0307	0.23	0.23	AIDS progression;	chr1:147087196	chr1:147258885~147517875:-
COAD	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	3.85	0.000149	0.0307	0.28	0.23	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
COAD	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	3.85	0.000149	0.0307	0.23	0.23	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
COAD	cis	rs1930961	0.702	rs12168476	ENSG00000272942.1	CTA-246H3.12	-3.85	0.000149	0.0307	-0.58	-0.23	Bipolar disorder with mood-incongruent psychosis;	chr22:25491121	chr22:25434324~25435070:-
COAD	cis	rs9880211	0.563	rs6793835	ENSG00000239213.4	NCK1-AS1	-3.85	0.000149	0.0307	-0.33	-0.23	Height;Body mass index;	chr3:136101092	chr3:136841726~136862054:-
COAD	cis	rs9513593	0.579	rs35347820	ENSG00000260992.1	DOCK9-AS2	-3.85	0.000149	0.0307	-0.51	-0.23	Psoriasis;	chr13:99130125	chr13:99087819~99088625:+
COAD	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-3.85	0.000149	0.0307	-0.16	-0.23	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
COAD	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-3.85	0.000149	0.0307	-0.24	-0.23	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
COAD	cis	rs10760158	0.832	rs13292100	ENSG00000226752.6	PSMD5-AS1	-3.85	0.000149	0.0307	-0.25	-0.23	Pulse pressure;	chr9:121278719	chr9:120824828~120854385:+
COAD	cis	rs11229555	0.574	rs12292024	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58419243	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs35735990	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58419898	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs34782543	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58419925	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs56228632	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58419971	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7945992	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58420282	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs7928676	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58420549	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7929028	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58420785	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12295551	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58421510	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12801475	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58421561	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7926682	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58422022	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs10466659	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58422639	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs4579945	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58423400	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs10896778	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58426452	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229442	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58429317	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.598	rs7930623	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58430168	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7946522	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58430432	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs12273517	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58433621	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229450	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58434156	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.609	rs11229451	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58434214	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs11603800	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58434612	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs11229454	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58436209	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229457	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58439730	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229463	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58442674	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs35279927	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58444656	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs4517537	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58446222	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs4506677	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58446379	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12805062	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58447111	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.574	rs12271501	ENSG00000254602.1	AP000662.4	-3.85	0.000149	0.0307	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58447496	chr11:57638024~57652790:+
COAD	cis	rs891378	0.883	rs6540888	ENSG00000274245.1	RP11-357P18.2	-3.85	0.000149	0.0307	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207247514	chr1:207372559~207373252:+
COAD	cis	rs6504622	0.755	rs12942936	ENSG00000263142.4	LRRC37A17P	-3.85	0.000149	0.0307	-0.17	-0.23	Orofacial clefts;	chr17:47075062	chr17:46978481~47054569:+
COAD	cis	rs13256369	0.76	rs7816171	ENSG00000253981.4	ALG1L13P	3.85	0.000149	0.0307	0.34	0.23	Obesity-related traits;	chr8:8718325	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.76	rs7839473	ENSG00000253981.4	ALG1L13P	3.85	0.000149	0.0307	0.34	0.23	Obesity-related traits;	chr8:8718326	chr8:8236003~8244667:-
COAD	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-3.85	0.000149	0.0307	-0.32	-0.23	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
COAD	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000149	0.0307	0.29	0.23	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
COAD	cis	rs9400467	0.528	rs7752361	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.000149	0.0307	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111277932~111278742:+
COAD	cis	rs7760535	0.811	rs7764591	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.000149	0.0307	-0.2	-0.23	Metabolic traits;	chr6:111462211	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs7750792	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.000149	0.0307	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111277932~111278742:+
COAD	cis	rs362296	0.698	rs362279	ENSG00000248840.2	RP11-357G3.2	3.85	0.000149	0.0307	0.28	0.23	Parental longevity (mother's age at death);	chr4:3258345	chr4:3312512~3313058:+
COAD	cis	rs2307394	1	rs1128919	ENSG00000281469.1	RP11-567F11.1	3.85	0.000149	0.0307	0.28	0.23	Urate levels;	chr2:147899548	chr2:148044380~148044894:+
COAD	cis	rs10411161	0.748	rs58120918	ENSG00000269483.1	AC006272.1	3.85	0.000149	0.0307	0.47	0.23	Breast cancer;	chr19:51865093	chr19:51839924~51843324:-
COAD	cis	rs1005224	0.963	rs12887886	ENSG00000258454.1	RP11-361H10.3	3.85	0.000149	0.0307	0.28	0.23	Large artery stroke;	chr14:75701503	chr14:76235817~76263474:+
COAD	cis	rs11098499	1	rs58601355	ENSG00000250412.1	KLHL2P1	3.85	0.000149	0.0307	0.31	0.23	Corneal astigmatism;	chr4:119265212	chr4:119334329~119378233:+
COAD	cis	rs597539	0.654	rs7107137	ENSG00000255741.1	RP11-757G1.5	-3.85	0.000149	0.0307	-0.32	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68941503~68942852:-
COAD	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	3.85	0.000149	0.0307	0.28	0.23	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
COAD	cis	rs860295	0.836	rs6684889	ENSG00000225082.2	DAP3P1	3.85	0.000149	0.0307	0.29	0.23	Body mass index;	chr1:155457271	chr1:155586644~155602197:+
COAD	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	3.85	0.000149	0.0308	0.26	0.23	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
COAD	cis	rs11098499	0.754	rs12513083	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119328457	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs12509621	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119328505	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs1511017	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119329650	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.789	rs12498994	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119329663	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs12507565	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119329966	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.826	rs12511640	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119330093	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs1980026	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119330488	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.722	rs28713555	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119330840	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.743	rs11098501	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119330862	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs11098502	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119330908	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.708	rs11732686	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119331175	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs11724409	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119331206	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.789	rs1980024	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119331892	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs34425882	ENSG00000250412.1	KLHL2P1	3.85	0.00015	0.0308	0.3	0.23	Corneal astigmatism;	chr4:119332022	chr4:119334329~119378233:+
COAD	cis	rs13256369	0.755	rs12680167	ENSG00000253981.4	ALG1L13P	3.85	0.00015	0.0308	0.34	0.23	Obesity-related traits;	chr8:8704957	chr8:8236003~8244667:-
COAD	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-3.85	0.00015	0.0308	-0.29	-0.23	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
COAD	cis	rs9796	0.621	rs9972349	ENSG00000247556.5	OIP5-AS1	3.85	0.00015	0.0308	0.23	0.23	Menopause (age at onset);	chr15:41199458	chr15:41283990~41309737:+
COAD	cis	rs9868809	0.772	rs9877501	ENSG00000225399.4	RP11-3B7.1	-3.85	0.00015	0.0308	-0.34	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680957	chr3:49260085~49261316:+
COAD	cis	rs12428035	0.764	rs539293	ENSG00000247400.3	DNAJC3-AS1	3.85	0.00015	0.0308	0.28	0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96097293	chr13:95648733~95676925:-
COAD	cis	rs773506	0.692	rs10991835	ENSG00000228069.1	RP11-100G15.3	3.85	0.00015	0.0308	0.26	0.23	Type 2 diabetes nephropathy;	chr9:91233309	chr9:92109013~92110095:+
COAD	cis	rs7819412	0.521	rs4451268	ENSG00000269918.1	AF131215.9	-3.85	0.00015	0.0308	-0.29	-0.23	Triglycerides;	chr8:11177350	chr8:11104691~11106704:-
COAD	cis	rs2243480	0.901	rs778687	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66370832	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs778679	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66375924	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs778704	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66398480	chr7:66554588~66576923:-
COAD	cis	rs2243480	0.901	rs778693	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66407358	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs778691	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66408105	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs13235972	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66418618	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs34192067	ENSG00000232559.3	GS1-124K5.12	3.85	0.00015	0.0308	0.42	0.23	Diabetic kidney disease;	chr7:66422670	chr7:66554588~66576923:-
COAD	cis	rs8022206	0.773	rs8020795	ENSG00000259502.1	RP11-643G16.3	3.85	0.00015	0.0308	0.32	0.23	Platelet count;Mean platelet volume;	chr14:68023318	chr14:67610986~67613864:+
COAD	cis	rs5771225	0.544	rs1555048	ENSG00000273253.2	RP3-402G11.26	-3.85	0.00015	0.0308	-0.33	-0.23	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50199090~50200837:-
COAD	cis	rs10838798	0.517	rs1967210	ENSG00000270060.1	RP11-390K5.6	-3.85	0.00015	0.0308	-0.19	-0.23	Height;	chr11:48075140	chr11:47168281~47169563:-
COAD	cis	rs7584330	0.737	rs1390985	ENSG00000234949.2	AC104667.3	-3.85	0.00015	0.0308	-0.27	-0.23	Prostate cancer;	chr2:237458777	chr2:237591020~237595981:+
COAD	cis	rs62362510	0.585	rs1863925	ENSG00000264391.2	RN7SL208P	-3.85	0.00015	0.0308	-0.43	-0.23	Morning vs. evening chronotype;	chr5:77498959	chr5:76836900~76837195:-
COAD	cis	rs153916	0.545	rs384537	ENSG00000251000.1	AC008592.3	3.85	0.00015	0.0308	0.28	0.23	Pulmonary function;	chr5:95672425	chr5:95834424~95835046:-
COAD	cis	rs467650	1	rs468238	ENSG00000248489.1	CTD-2007H13.3	3.85	0.00015	0.0308	0.23	0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98640401	chr5:98929171~98995013:+
COAD	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	3.85	0.00015	0.0308	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	3.85	0.00015	0.0308	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
COAD	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-3.85	0.00015	0.0308	-0.28	-0.23	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
COAD	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	3.85	0.00015	0.0308	0.28	0.23	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
COAD	cis	rs362296	0.597	rs3129320	ENSG00000248840.2	RP11-357G3.2	3.85	0.00015	0.0308	0.25	0.23	Parental longevity (mother's age at death);	chr4:3263403	chr4:3312512~3313058:+
COAD	cis	rs7200786	0.527	rs7200146	ENSG00000274038.1	RP11-66H6.4	-3.85	0.00015	0.0308	-0.3	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11119592	chr16:11056556~11057034:+
COAD	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	3.85	0.00015	0.0308	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
COAD	cis	rs9376098	0.737	rs12205603	ENSG00000232876.1	CTA-212D2.2	-3.85	0.00015	0.0308	-0.33	-0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135178949	chr6:135055033~135060550:+
COAD	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-3.85	0.00015	0.0308	-0.34	-0.23	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
COAD	cis	rs6687821	0.515	rs1199680	ENSG00000261737.1	RP4-612B15.3	3.85	0.00015	0.0308	0.31	0.23	Yeast infection;	chr1:87099993	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs7536241	ENSG00000261737.1	RP4-612B15.3	3.85	0.00015	0.0308	0.31	0.23	Yeast infection;	chr1:87101030	chr1:86703502~86704462:-
COAD	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-3.85	0.00015	0.0308	-0.25	-0.23	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
COAD	cis	rs227275	0.526	rs223497	ENSG00000230069.3	LRRC37A15P	-3.85	0.00015	0.0308	-0.25	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102727274~102730721:-
COAD	cis	rs11650494	0.71	rs2233666	ENSG00000257178.3	RP11-357H14.16	3.85	0.00015	0.0308	0.46	0.23	Prostate cancer;	chr17:49406924	chr17:48579630~48582259:-
COAD	cis	rs739496	0.947	rs10849948	ENSG00000257595.2	RP3-473L9.4	3.85	0.00015	0.0309	0.32	0.23	Platelet count;	chr12:111437606	chr12:111369282~111403310:+
COAD	cis	rs12931792	0.682	rs12373113	ENSG00000183604.13	SMG1P5	3.85	0.00015	0.0309	0.25	0.23	Tonsillectomy;	chr16:30176192	chr16:30267553~30335374:-
COAD	cis	rs12931792	0.682	rs12373078	ENSG00000183604.13	SMG1P5	3.85	0.00015	0.0309	0.25	0.23	Tonsillectomy;	chr16:30176355	chr16:30267553~30335374:-
COAD	cis	rs2243480	0.901	rs3813708	ENSG00000228409.4	CCT6P1	3.85	0.00015	0.0309	0.31	0.23	Diabetic kidney disease;	chr7:65840645	chr7:65751142~65763354:+
COAD	cis	rs3126085	0.935	rs4845751	ENSG00000237975.5	FLG-AS1	-3.85	0.00015	0.0309	-0.25	-0.23	Atopic dermatitis;	chr1:152236521	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs6675889	ENSG00000237975.5	FLG-AS1	-3.85	0.00015	0.0309	-0.25	-0.23	Atopic dermatitis;	chr1:152240590	chr1:152168125~152445456:+
COAD	cis	rs1510510	0.742	rs7582271	ENSG00000225057.2	AC096574.4	3.85	0.00015	0.0309	0.31	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238666309	chr2:238231684~238255633:+
COAD	cis	rs9907295	0.591	rs2291299	ENSG00000270977.1	AC015849.16	-3.85	0.00015	0.0309	-0.3	-0.23	Fibroblast growth factor basic levels;	chr17:35864402	chr17:35893707~35911023:-
COAD	cis	rs11098499	0.615	rs28551750	ENSG00000249244.1	RP11-548H18.2	3.85	0.00015	0.0309	0.3	0.23	Corneal astigmatism;	chr4:119343746	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs9995716	ENSG00000249244.1	RP11-548H18.2	3.85	0.00015	0.0309	0.3	0.23	Corneal astigmatism;	chr4:119343841	chr4:119391831~119395335:-
COAD	cis	rs12935418	0.561	rs2287991	ENSG00000261061.1	RP11-303E16.2	-3.85	0.00015	0.0309	-0.3	-0.23	Mean corpuscular volume;	chr16:81006950	chr16:81030770~81031485:+
COAD	cis	rs2307394	1	rs1345994	ENSG00000281469.1	RP11-567F11.1	3.85	0.00015	0.0309	0.27	0.23	Urate levels;	chr2:147937557	chr2:148044380~148044894:+
COAD	cis	rs913655	0.545	rs2495836	ENSG00000240291.1	RP11-499P20.2	3.85	0.00015	0.0309	0.27	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18780052	chr10:18513115~18545651:-
COAD	cis	rs1223397	0.938	rs3817742	ENSG00000215022.6	RP1-257A7.4	-3.85	0.00015	0.0309	-0.32	-0.23	Blood pressure;	chr6:13279320	chr6:13264861~13295586:-
COAD	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	3.85	0.00015	0.0309	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
COAD	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55434518	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55435912	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55436576	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55436985	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55439472	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	3.85	0.00015	0.0309	0.28	0.23	Height;	chr4:55439652	chr4:55547112~55547889:+
COAD	cis	rs8022206	0.773	rs10129355	ENSG00000259502.1	RP11-643G16.3	3.85	0.00015	0.0309	0.32	0.23	Platelet count;Mean platelet volume;	chr14:68018386	chr14:67610986~67613864:+
COAD	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	3.85	0.00015	0.0309	0.28	0.23	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
COAD	cis	rs6732160	0.588	rs2043100	ENSG00000163016.8	ALMS1P	3.85	0.00015	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73146968	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.588	rs2043099	ENSG00000163016.8	ALMS1P	3.85	0.00015	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73147028	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.588	rs11126392	ENSG00000163016.8	ALMS1P	3.85	0.00015	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73147326	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.588	rs7578991	ENSG00000163016.8	ALMS1P	3.85	0.00015	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73149043	chr2:73644919~73685576:+
COAD	cis	rs6732160	0.564	rs7605716	ENSG00000163016.8	ALMS1P	3.85	0.00015	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73149122	chr2:73644919~73685576:+
COAD	cis	rs7200786	0.546	rs11642542	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000151	0.0309	-0.3	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118197	chr16:11056556~11057034:+
COAD	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-3.85	0.000151	0.0309	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
COAD	cis	rs2243480	1	rs7804223	ENSG00000229886.1	RP5-1132H15.3	-3.85	0.000151	0.0309	-0.41	-0.23	Diabetic kidney disease;	chr7:66199572	chr7:66025126~66031544:-
COAD	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	3.85	0.000151	0.0309	0.3	0.23	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	3.85	0.000151	0.0309	0.3	0.23	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	3.85	0.000151	0.0309	0.3	0.23	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
COAD	cis	rs2638953	0.924	rs11049418	ENSG00000247934.4	RP11-967K21.1	-3.85	0.000151	0.0309	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs12367188	ENSG00000247934.4	RP11-967K21.1	-3.85	0.000151	0.0309	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28163298~28190738:-
COAD	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-3.85	0.000151	0.0309	-0.28	-0.23	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
COAD	cis	rs6747488	0.504	rs644103	ENSG00000272716.1	RP11-563N4.1	3.85	0.000151	0.0309	0.25	0.23	Interleukin-18 levels;	chr2:31630252	chr2:32165046~32165757:-
COAD	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	3.85	0.000151	0.0309	0.3	0.23	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
COAD	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000151	0.0309	-0.38	-0.23	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
COAD	cis	rs7260598	0.792	rs73031013	ENSG00000268442.1	CTD-2027I19.2	3.85	0.000151	0.0309	0.36	0.23	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:24162370~24163425:-
COAD	cis	rs911555	0.755	rs2273702	ENSG00000251533.2	LINC00605	3.85	0.000151	0.0309	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103187221~103189028:-
COAD	cis	rs734999	0.505	rs60687045	ENSG00000225931.3	RP3-395M20.7	3.85	0.000151	0.0309	0.26	0.23	Ulcerative colitis;	chr1:2608164	chr1:2566410~2569888:+
COAD	cis	rs11229555	0.598	rs4519112	ENSG00000254602.1	AP000662.4	-3.85	0.000151	0.0309	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58408913	chr11:57638024~57652790:+
COAD	cis	rs453301	0.506	rs686189	ENSG00000173295.6	FAM86B3P	-3.85	0.000151	0.0309	-0.28	-0.23	Joint mobility (Beighton score);	chr8:8766127	chr8:8228595~8244865:+
COAD	cis	rs8022206	1	rs72725138	ENSG00000259502.1	RP11-643G16.3	3.85	0.000151	0.0309	0.4	0.23	Platelet count;Mean platelet volume;	chr14:67921262	chr14:67610986~67613864:+
COAD	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	3.85	0.000151	0.0309	0.3	0.23	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
COAD	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	3.85	0.000151	0.0309	0.3	0.23	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
COAD	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs763590	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149398831	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs17506789	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149399710	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.586	rs34097428	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149399822	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12154153	ENSG00000216906.2	RP11-350J20.9	3.85	0.000151	0.0309	0.34	0.23	Dupuytren's disease;	chr6:149401686	chr6:149904243~149906418:+
COAD	cis	rs875971	0.545	rs1638724	ENSG00000232546.1	RP11-458F8.1	-3.85	0.000151	0.031	-0.23	-0.23	Aortic root size;	chr7:66575494	chr7:66848496~66858136:+
COAD	cis	rs8022206	0.898	rs72725174	ENSG00000259502.1	RP11-643G16.3	3.85	0.000151	0.031	0.38	0.23	Platelet count;Mean platelet volume;	chr14:68044056	chr14:67610986~67613864:+
COAD	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-3.85	0.000151	0.031	-0.32	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
COAD	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	3.85	0.000151	0.031	0.32	0.23	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
COAD	cis	rs11719291	0.651	rs1134043	ENSG00000225399.4	RP11-3B7.1	-3.85	0.000151	0.031	-0.33	-0.23	Cognitive function;	chr3:49162704	chr3:49260085~49261316:+
COAD	cis	rs55962025	0.842	rs2269477	ENSG00000248840.2	RP11-357G3.2	3.85	0.000151	0.031	0.28	0.23	Parental longevity (mother's age at death);	chr4:3182737	chr4:3312512~3313058:+
COAD	cis	rs3126085	0.515	rs11204996	ENSG00000237975.5	FLG-AS1	3.85	0.000151	0.031	0.29	0.23	Atopic dermatitis;	chr1:152392136	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs11204997	ENSG00000237975.5	FLG-AS1	3.85	0.000151	0.031	0.29	0.23	Atopic dermatitis;	chr1:152392177	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.515	rs12407319	ENSG00000237975.5	FLG-AS1	3.85	0.000151	0.031	0.29	0.23	Atopic dermatitis;	chr1:152393453	chr1:152168125~152445456:+
COAD	cis	rs13256369	0.802	rs13281933	ENSG00000254153.1	CTA-398F10.2	3.85	0.000151	0.031	0.31	0.23	Obesity-related traits;	chr8:8705155	chr8:8456909~8461337:-
COAD	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	3.85	0.000151	0.031	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
COAD	cis	rs1559040	0.79	rs28416116	ENSG00000272156.1	RP11-477N3.1	-3.85	0.000151	0.031	-0.44	-0.23	Sudden cardiac arrest;	chr2:54039080	chr2:54082554~54085066:+
COAD	cis	rs6732160	0.588	rs28626211	ENSG00000163016.8	ALMS1P	3.85	0.000151	0.031	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73151394	chr2:73644919~73685576:+
COAD	cis	rs12699921	0.607	rs1404425	ENSG00000279048.1	RP11-511H23.2	-3.85	0.000151	0.031	-0.17	-0.23	Fibrinogen levels;	chr7:17788034	chr7:17940503~17942922:+
COAD	cis	rs340417	0.731	rs34953248	ENSG00000253163.1	RP11-443C10.1	-3.85	0.000151	0.031	-0.35	-0.23	Skin pigmentation;	chr5:179372054	chr5:179377531~179378761:-
COAD	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	3.85	0.000151	0.031	0.33	0.23	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
COAD	cis	rs11976180	1	rs1533267	ENSG00000273234.1	OR2A13P	-3.85	0.000151	0.031	-0.29	-0.23	Obesity-related traits;	chr7:144069347	chr7:144142009~144142938:+
COAD	cis	rs7621025	0.542	rs13075615	ENSG00000239213.4	NCK1-AS1	-3.85	0.000151	0.031	-0.46	-0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136786990	chr3:136841726~136862054:-
COAD	cis	rs4639966	1	rs4639966	ENSG00000255422.1	AP002954.4	3.85	0.000151	0.031	0.3	0.23	Systemic lupus erythematosus;	chr11:118702810	chr11:118704607~118750263:+
COAD	cis	rs7674212	0.539	rs6533056	ENSG00000230069.3	LRRC37A15P	-3.85	0.000151	0.0311	-0.24	-0.23	Type 2 diabetes;	chr4:103199840	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.539	rs6815783	ENSG00000230069.3	LRRC37A15P	-3.85	0.000151	0.0311	-0.24	-0.23	Type 2 diabetes;	chr4:103200989	chr4:102727274~102730721:-
COAD	cis	rs11935103	0.61	rs9998003	ENSG00000279943.1	FLJ38576	3.85	0.000151	0.0311	0.32	0.23	Response to citalopram treatment;	chr4:186372779	chr4:186189032~186191490:-
COAD	cis	rs2337406	0.587	rs10139664	ENSG00000211964.3	IGHV3-48	-3.85	0.000151	0.0311	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106647254	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.587	rs10129888	ENSG00000211964.3	IGHV3-48	-3.85	0.000151	0.0311	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106647421	chr14:106537810~106538344:-
COAD	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	3.85	0.000151	0.0311	0.16	0.23	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
COAD	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	3.85	0.000152	0.0311	0.31	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	3.85	0.000152	0.0311	0.31	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	3.85	0.000152	0.0311	0.31	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
COAD	cis	rs4938303	0.549	rs11216096	ENSG00000254851.1	RP11-109L13.1	3.85	0.000152	0.0311	0.31	0.23	Triglycerides;	chr11:116691864	chr11:117135528~117138582:+
COAD	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	3.85	0.000152	0.0311	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
COAD	cis	rs13256369	0.95	rs12548792	ENSG00000253981.4	ALG1L13P	3.85	0.000152	0.0311	0.34	0.23	Obesity-related traits;	chr8:8710521	chr8:8236003~8244667:-
COAD	cis	rs72700829	0.507	rs11204766	ENSG00000223945.2	RP11-458I7.1	-3.85	0.000152	0.0311	-0.48	-0.23	Schizophrenia;	chr1:151045584	chr1:150053864~150055034:+
COAD	cis	rs78487399	0.808	rs17406646	ENSG00000234936.1	AC010883.5	3.85	0.000152	0.0311	0.39	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451478	chr2:43229573~43233394:+
COAD	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-3.85	0.000152	0.0311	-0.31	-0.23	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
COAD	cis	rs9652601	0.779	rs7186106	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000152	0.0311	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11116974	chr16:11056556~11057034:+
COAD	cis	rs6601327	0.607	rs13276086	ENSG00000233609.3	RP11-62H7.2	-3.85	0.000152	0.0311	-0.27	-0.23	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:8961200~8979025:+
COAD	cis	rs11846409	0.587	rs1806881	ENSG00000254174.1	IGHV1-12	-3.85	0.000152	0.0311	-0.22	-0.23	Rheumatic heart disease;	chr14:106650770	chr14:106122420~106122709:-
COAD	cis	rs2408955	0.515	rs10875742	ENSG00000269514.1	RP11-370I10.12	-3.85	0.000152	0.0311	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48099591	chr12:48198387~48202031:+
COAD	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-3.85	0.000152	0.0311	-0.34	-0.23	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
COAD	cis	rs1559040	0.656	rs11688581	ENSG00000272156.1	RP11-477N3.1	-3.85	0.000152	0.0311	-0.44	-0.23	Sudden cardiac arrest;	chr2:54022591	chr2:54082554~54085066:+
COAD	cis	rs1559040	0.79	rs55666400	ENSG00000272156.1	RP11-477N3.1	-3.85	0.000152	0.0311	-0.44	-0.23	Sudden cardiac arrest;	chr2:54029350	chr2:54082554~54085066:+
COAD	cis	rs1559040	0.79	rs115324582	ENSG00000272156.1	RP11-477N3.1	-3.85	0.000152	0.0311	-0.44	-0.23	Sudden cardiac arrest;	chr2:54037461	chr2:54082554~54085066:+
COAD	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55506498	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55507248	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55507729	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55508587	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55509367	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55510352	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	3.85	0.000152	0.0311	0.28	0.23	Height;	chr4:55511198	chr4:55547112~55547889:+
COAD	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	3.85	0.000152	0.0311	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
COAD	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-3.85	0.000152	0.0311	-0.28	-0.23	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
COAD	cis	rs6973609	0.564	rs10226256	ENSG00000271122.1	RP11-379H18.1	-3.85	0.000152	0.0311	-0.23	-0.23	Obesity-related traits;	chr7:35573650	chr7:35695214~35699413:+
COAD	cis	rs763121	0.524	rs760645	ENSG00000273076.1	RP3-508I15.22	3.85	0.000152	0.0311	0.21	0.23	Menopause (age at onset);	chr22:38636265	chr22:38743495~38743910:+
COAD	cis	rs2976388	0.59	rs4736322	ENSG00000247317.3	RP11-273G15.2	3.85	0.000152	0.0311	0.26	0.23	Urinary tract infection frequency;	chr8:142740790	chr8:142981738~143018437:-
COAD	cis	rs1832007	0.529	rs17306779	ENSG00000224034.1	RP11-445P17.8	3.85	0.000152	0.0311	0.34	0.23	Triglyceride levels;Triglycerides;	chr10:5200201	chr10:5266033~5271236:-
COAD	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	3.85	0.000152	0.0311	0.24	0.23	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
COAD	cis	rs9880211	1	rs17200216	ENSG00000273486.1	RP11-731C17.2	3.85	0.000152	0.0311	0.27	0.23	Height;Body mass index;	chr3:136348390	chr3:136837338~136839021:-
COAD	cis	rs55962025	0.842	rs362272	ENSG00000248840.2	RP11-357G3.2	3.85	0.000152	0.0311	0.27	0.23	Parental longevity (mother's age at death);	chr4:3233253	chr4:3312512~3313058:+
COAD	cis	rs34286592	1	rs34127220	ENSG00000214725.6	CDIPT-AS1	-3.85	0.000152	0.0311	-0.41	-0.23	Multiple sclerosis;	chr16:29831570	chr16:29863593~29868053:+
COAD	cis	rs862034	0.653	rs7148461	ENSG00000270000.1	RP3-449M8.9	3.85	0.000152	0.0311	0.31	0.23	Height;	chr14:74548396	chr14:74471930~74472360:-
COAD	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-3.85	0.000152	0.0311	-0.31	-0.23	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
COAD	cis	rs1062753	0.527	rs2187959	ENSG00000182057.4	OGFRP1	-3.85	0.000152	0.0312	-0.23	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41951840	chr22:42269753~42275196:+
COAD	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	3.85	0.000152	0.0312	0.26	0.23	Height;	chr4:55544621	chr4:55363971~55395847:-
COAD	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	3.84	0.000152	0.0312	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
COAD	cis	rs11976180	1	rs2961119	ENSG00000273234.1	OR2A13P	-3.84	0.000152	0.0312	-0.29	-0.23	Obesity-related traits;	chr7:144058759	chr7:144142009~144142938:+
COAD	cis	rs12049351	0.613	rs7525324	ENSG00000229367.1	HMGN2P19	3.84	0.000152	0.0312	0.36	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229463478	chr1:229570532~229570796:+
COAD	cis	rs8017304	0.643	rs7148322	ENSG00000259502.1	RP11-643G16.3	-3.84	0.000152	0.0312	-0.3	-0.23	Age-related macular degeneration;	chr14:68302002	chr14:67610986~67613864:+
COAD	cis	rs11098499	0.754	rs9991959	ENSG00000250412.1	KLHL2P1	-3.84	0.000152	0.0312	-0.3	-0.23	Corneal astigmatism;	chr4:119332618	chr4:119334329~119378233:+
COAD	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	3.84	0.000152	0.0312	0.27	0.23	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
COAD	cis	rs4879901	0.933	rs2163313	ENSG00000215199.3	YWHAZP6	-3.84	0.000152	0.0312	-0.26	-0.23	Schizophrenia;	chr9:35541740	chr9:34922184~34922921:-
COAD	cis	rs74225573	1	rs74225573	ENSG00000230337.1	RP4-635E18.6	-3.84	0.000152	0.0312	-0.55	-0.23	Corneal curvature;	chr1:11220937	chr1:11099675~11102100:+
COAD	cis	rs16958440	0.867	rs2117373	ENSG00000267800.1	RP11-49K24.5	-3.84	0.000152	0.0312	-0.57	-0.23	Sitting height ratio;	chr18:47145463	chr18:47137018~47137290:+
COAD	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	3.84	0.000152	0.0312	0.3	0.23	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
COAD	cis	rs7918232	0.83	rs10764672	ENSG00000262412.1	RP11-85G18.6	-3.84	0.000153	0.0312	-0.3	-0.23	Breast cancer;	chr10:27103612	chr10:27243130~27250804:+
COAD	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	3.84	0.000153	0.0312	0.29	0.23	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
COAD	cis	rs4671386	1	rs4671382	ENSG00000233953.1	AC009970.1	3.84	0.000153	0.0312	0.24	0.23	Acne (severe);	chr2:60270000	chr2:60495686~60499964:+
COAD	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	3.84	0.000153	0.0312	0.29	0.23	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
COAD	cis	rs801193	0.636	rs2659895	ENSG00000224316.1	RP11-479O9.2	3.84	0.000153	0.0312	0.25	0.23	Aortic root size;	chr7:66731484	chr7:65773620~65802067:+
COAD	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-3.84	0.000153	0.0312	-0.27	-0.23	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
COAD	cis	rs11743006	0.626	rs1072158	ENSG00000226306.6	NPY6R	3.84	0.000153	0.0313	0.36	0.23	Mathematical ability;	chr5:137168977	chr5:137801193~137810751:+
COAD	cis	rs1499614	1	rs2707832	ENSG00000232559.3	GS1-124K5.12	3.84	0.000153	0.0313	0.4	0.23	Gout;	chr7:66671562	chr7:66554588~66576923:-
COAD	cis	rs55962025	0.883	rs3121419	ENSG00000248840.2	RP11-357G3.2	3.84	0.000153	0.0313	0.28	0.23	Parental longevity (mother's age at death);	chr4:3230530	chr4:3312512~3313058:+
COAD	cis	rs1941023	0.517	rs11230344	ENSG00000255355.1	AP000640.2	-3.84	0.000153	0.0313	-0.3	-0.23	Congenital heart disease (maternal effect);	chr11:60496936	chr11:59669312~59676041:+
COAD	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	3.84	0.000153	0.0313	0.28	0.23	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
COAD	cis	rs3120667	0.72	rs11581711	ENSG00000237975.5	FLG-AS1	3.84	0.000153	0.0313	0.31	0.23	Eating disorders;	chr1:152452003	chr1:152168125~152445456:+
COAD	cis	rs3120667	0.72	rs72698974	ENSG00000237975.5	FLG-AS1	3.84	0.000153	0.0313	0.31	0.23	Eating disorders;	chr1:152456371	chr1:152168125~152445456:+
COAD	cis	rs2346160	0.831	rs1467391	ENSG00000228648.1	RP11-568A7.2	3.84	0.000153	0.0313	0.26	0.23	Parental extreme longevity (95 years and older);	chr6:167276574	chr6:167241891~167245916:+
COAD	cis	rs2919009	0.607	rs59153085	ENSG00000271670.1	RP11-95I16.4	3.84	0.000153	0.0313	0.32	0.23	Obesity-related traits;	chr10:120931782	chr10:120879256~120880667:-
COAD	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	3.84	0.000153	0.0313	0.27	0.23	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
COAD	cis	rs11239930	0.517	rs632861	ENSG00000278811.3	LINC00624	3.84	0.000153	0.0313	0.24	0.23	AIDS progression;	chr1:147079826	chr1:147258885~147517875:-
COAD	cis	rs2439831	0.867	rs2470134	ENSG00000201136.1	RNU6-353P	3.84	0.000153	0.0313	0.36	0.23	Lung cancer in ever smokers;	chr15:43557688	chr15:43702363~43702470:+
COAD	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-3.84	0.000153	0.0313	-0.33	-0.23	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
COAD	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	3.84	0.000153	0.0313	0.5	0.23	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
COAD	cis	rs2638953	0.924	rs7957382	ENSG00000247934.4	RP11-967K21.1	3.84	0.000153	0.0313	0.23	0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28163298~28190738:-
COAD	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-3.84	0.000153	0.0313	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
COAD	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-3.84	0.000153	0.0313	-0.33	-0.23	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
COAD	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	3.84	0.000153	0.0313	0.33	0.23	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
COAD	cis	rs1707322	0.721	rs6697821	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000153	0.0313	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45694684~45697075:-
COAD	cis	rs4718428	0.705	rs11028	ENSG00000272831.1	RP11-792A8.4	3.84	0.000153	0.0313	0.25	0.23	Corneal structure;	chr7:66811230	chr7:66739829~66740385:-
COAD	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-3.84	0.000153	0.0313	-0.21	-0.23	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
COAD	cis	rs7646881	0.544	rs59973861	ENSG00000272087.1	RP11-379F4.7	3.84	0.000153	0.0313	0.37	0.23	Tetralogy of Fallot;	chr3:158570314	chr3:158693120~158693768:-
COAD	cis	rs739496	0.501	rs441	ENSG00000257595.2	RP3-473L9.4	3.84	0.000153	0.0313	0.37	0.23	Platelet count;	chr12:111791045	chr12:111369282~111403310:+
COAD	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-3.84	0.000153	0.0313	-0.39	-0.23	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
COAD	cis	rs7837649	0.824	rs6985531	ENSG00000253661.1	ZFHX4-AS1	3.84	0.000153	0.0314	0.21	0.23	Monobrow;	chr8:76783152	chr8:76491200~76683278:-
COAD	cis	rs8062405	0.573	rs7187575	ENSG00000261067.5	RP11-264B17.3	-3.84	0.000153	0.0314	-0.17	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28974804~28990783:+
COAD	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-3.84	0.000153	0.0314	-0.23	-0.23	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
COAD	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-3.84	0.000153	0.0314	-0.23	-0.23	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
COAD	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-3.84	0.000153	0.0314	-0.28	-0.23	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
COAD	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	3.84	0.000153	0.0314	0.41	0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
COAD	cis	rs6490294	0.583	rs4767364	ENSG00000257595.2	RP3-473L9.4	3.84	0.000153	0.0314	0.3	0.23	Mean platelet volume;	chr12:112083644	chr12:111369282~111403310:+
COAD	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	3.84	0.000153	0.0314	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
COAD	cis	rs55962025	0.842	rs363088	ENSG00000248840.2	RP11-357G3.2	3.84	0.000153	0.0314	0.28	0.23	Parental longevity (mother's age at death);	chr4:3208603	chr4:3312512~3313058:+
COAD	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-3.84	0.000153	0.0314	-0.29	-0.23	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
COAD	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	3.84	0.000154	0.0314	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
COAD	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-3.84	0.000154	0.0314	-0.24	-0.23	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
COAD	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-3.84	0.000154	0.0314	-0.31	-0.23	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
COAD	cis	rs6687821	0.515	rs1407132	ENSG00000261737.1	RP4-612B15.3	-3.84	0.000154	0.0314	-0.3	-0.23	Yeast infection;	chr1:86928231	chr1:86703502~86704462:-
COAD	cis	rs6543140	0.693	rs7579737	ENSG00000234389.1	AC007278.3	3.84	0.000154	0.0314	0.25	0.23	Blood protein levels;	chr2:102370901	chr2:102438713~102440475:+
COAD	cis	rs1137	0.857	rs205637	ENSG00000225439.2	BOLA3-AS1	-3.84	0.000154	0.0314	-0.25	-0.23	Myopia (pathological);	chr2:74723979	chr2:74148009~74150061:+
COAD	cis	rs41464545	1	rs7682880	ENSG00000249413.2	RP11-25H12.1	3.84	0.000154	0.0314	0.31	0.23	Schizophrenia;	chr4:65016792	chr4:65998846~66150012:+
COAD	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	3.84	0.000154	0.0314	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	3.84	0.000154	0.0314	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	3.84	0.000154	0.0314	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
COAD	cis	rs7674212	0.541	rs4699051	ENSG00000230069.3	LRRC37A15P	-3.84	0.000154	0.0314	-0.25	-0.23	Type 2 diabetes;	chr4:103193237	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.57	rs2069274	ENSG00000230069.3	LRRC37A15P	-3.84	0.000154	0.0314	-0.25	-0.23	Type 2 diabetes;	chr4:103099624	chr4:102727274~102730721:-
COAD	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	3.84	0.000154	0.0314	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
COAD	cis	rs7131987	0.834	rs11050167	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000154	0.0314	-0.3	-0.23	QT interval;	chr12:29273454	chr12:29277397~29277882:-
COAD	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000154	0.0314	0.25	0.23	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000154	0.0314	0.25	0.23	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	3.84	0.000154	0.0314	0.25	0.23	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
COAD	cis	rs7688540	0.8	rs10003142	ENSG00000250892.1	RP11-1365D11.1	-3.84	0.000154	0.0315	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:201409~205009:-
COAD	cis	rs7688540	0.771	rs11723803	ENSG00000250892.1	RP11-1365D11.1	-3.84	0.000154	0.0315	-0.36	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:201409~205009:-
COAD	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	3.84	0.000154	0.0315	0.29	0.23	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
COAD	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	3.84	0.000154	0.0315	0.27	0.23	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
COAD	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-3.84	0.000154	0.0315	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
COAD	cis	rs7760535	0.826	rs10872068	ENSG00000230177.1	RP5-1112D6.4	3.84	0.000154	0.0315	0.2	0.23	Metabolic traits;	chr6:111528657	chr6:111277932~111278742:+
COAD	cis	rs2836754	1	rs2836758	ENSG00000205622.8	AF064858.6	3.84	0.000154	0.0315	0.26	0.23	Body mass index;Crohn's disease;	chr21:38923238	chr21:38863676~38956467:-
COAD	cis	rs1707322	0.685	rs28617418	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.682	rs28490344	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs28641748	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs4330955	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.691	rs12031182	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10430123	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000154	0.0315	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45694684~45697075:-
COAD	cis	rs7837649	0.824	rs7007681	ENSG00000253661.1	ZFHX4-AS1	3.84	0.000154	0.0315	0.21	0.23	Monobrow;	chr8:76783308	chr8:76491200~76683278:-
COAD	cis	rs12699921	0.632	rs1404424	ENSG00000279048.1	RP11-511H23.2	-3.84	0.000154	0.0315	-0.17	-0.23	Fibrinogen levels;	chr7:17906981	chr7:17940503~17942922:+
COAD	cis	rs7000734	0.958	rs4392868	ENSG00000245080.5	RP11-320N21.1	-3.84	0.000154	0.0315	-0.36	-0.23	Radiation response;	chr8:95107844	chr8:95066808~95073182:-
COAD	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	3.84	0.000154	0.0315	0.34	0.23	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
COAD	cis	rs7204230	1	rs62048023	ENSG00000261056.2	RP11-454F8.2	3.84	0.000154	0.0315	0.28	0.23	Fibrinogen;	chr16:53168038	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048024	ENSG00000261056.2	RP11-454F8.2	3.84	0.000154	0.0315	0.28	0.23	Fibrinogen;	chr16:53168098	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs7195323	ENSG00000261056.2	RP11-454F8.2	3.84	0.000154	0.0315	0.28	0.23	Fibrinogen;	chr16:53169434	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.92	rs62048027	ENSG00000261056.2	RP11-454F8.2	3.84	0.000154	0.0315	0.28	0.23	Fibrinogen;	chr16:53171917	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs8047327	ENSG00000261056.2	RP11-454F8.2	3.84	0.000154	0.0315	0.28	0.23	Fibrinogen;	chr16:53173975	chr16:53298224~53299792:+
COAD	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	3.84	0.000154	0.0315	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	3.84	0.000154	0.0315	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	3.84	0.000154	0.0315	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
COAD	cis	rs34779708	0.966	rs12257770	ENSG00000271335.4	RP11-324I22.4	3.84	0.000154	0.0315	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35314552~35336401:-
COAD	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-3.84	0.000154	0.0315	-0.26	-0.23	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
COAD	cis	rs72843506	0.586	rs75721433	ENSG00000189423.10	USP32P3	3.84	0.000154	0.0315	0.46	0.23	Schizophrenia;	chr17:19978747	chr17:20415547~20431008:+
COAD	cis	rs2179367	0.632	rs55836833	ENSG00000216906.2	RP11-350J20.9	3.84	0.000154	0.0315	0.34	0.23	Dupuytren's disease;	chr6:149403736	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.552	rs11155652	ENSG00000216906.2	RP11-350J20.9	3.84	0.000154	0.0315	0.34	0.23	Dupuytren's disease;	chr6:149417849	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs12209364	ENSG00000216906.2	RP11-350J20.9	3.84	0.000154	0.0315	0.34	0.23	Dupuytren's disease;	chr6:149418062	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	3.84	0.000154	0.0315	0.34	0.23	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
COAD	cis	rs734999	0.967	rs6672381	ENSG00000225931.3	RP3-395M20.7	3.84	0.000154	0.0315	0.25	0.23	Ulcerative colitis;	chr1:2571395	chr1:2566410~2569888:+
COAD	cis	rs4842666	0.831	rs12230074	ENSG00000258302.2	RP11-981P6.1	3.84	0.000154	0.0315	0.32	0.23	Blood pressure;	chr12:89697090	chr12:89561129~89594878:+
COAD	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	3.84	0.000154	0.0315	0.28	0.23	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
COAD	cis	rs2302729	0.578	rs11062299	ENSG00000246627.5	CACNA1C-AS1	3.84	0.000154	0.0315	0.28	0.23	Sleep quality;	chr12:2662572	chr12:2676001~2691200:-
COAD	cis	rs2302729	0.578	rs10848682	ENSG00000246627.5	CACNA1C-AS1	3.84	0.000154	0.0315	0.28	0.23	Sleep quality;	chr12:2662590	chr12:2676001~2691200:-
COAD	cis	rs2018683	1	rs160837	ENSG00000272568.4	CTB-113D17.1	3.84	0.000154	0.0315	0.31	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28979967~29013367:+
COAD	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-3.84	0.000154	0.0315	-0.3	-0.23	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
COAD	cis	rs2496589	0.963	rs6921706	ENSG00000218896.1	TUBB8P2	3.84	0.000155	0.0316	0.27	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143424131	chr6:143436216~143436710:+
COAD	cis	rs9650657	0.65	rs2898248	ENSG00000248896.2	CTD-2135J3.3	3.84	0.000155	0.0316	0.3	0.23	Neuroticism;	chr8:10779240	chr8:10729314~10771392:+
COAD	cis	rs6117615	1	rs6140175	ENSG00000234684.5	SDCBP2-AS1	3.84	0.000155	0.0316	0.43	0.23	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);	chr20:780220	chr20:1325405~1378734:+
COAD	cis	rs559555	0.553	rs682895	ENSG00000272716.1	RP11-563N4.1	-3.84	0.000155	0.0316	-0.26	-0.23	Blood metabolite ratios;Blood metabolite levels;	chr2:31646514	chr2:32165046~32165757:-
COAD	cis	rs2559856	1	rs2559860	ENSG00000199933.1	RNY1P16	3.84	0.000155	0.0316	0.25	0.23	Blood protein levels;	chr12:101693858	chr12:101719808~101719918:+
COAD	cis	rs7131987	0.903	rs1991114	ENSG00000257176.2	RP11-996F15.2	-3.84	0.000155	0.0316	-0.27	-0.23	QT interval;	chr12:29239149	chr12:29280418~29317848:-
COAD	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-3.84	0.000155	0.0316	-0.26	-0.23	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-3.84	0.000155	0.0316	-0.26	-0.23	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
COAD	cis	rs6565180	0.926	rs4787643	ENSG00000261367.1	RP11-455F5.4	-3.84	0.000155	0.0316	-0.26	-0.23	Tonsillectomy;	chr16:30382339	chr16:30107675~30110541:+
COAD	cis	rs6565180	0.926	rs4788409	ENSG00000261367.1	RP11-455F5.4	-3.84	0.000155	0.0316	-0.26	-0.23	Tonsillectomy;	chr16:30382450	chr16:30107675~30110541:+
COAD	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-3.84	0.000155	0.0316	-0.25	-0.23	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
COAD	cis	rs7665090	0.87	rs227361	ENSG00000230069.3	LRRC37A15P	-3.84	0.000155	0.0316	-0.24	-0.23	Primary biliary cholangitis;	chr4:102665820	chr4:102727274~102730721:-
COAD	cis	rs7615952	0.866	rs1976459	ENSG00000272840.1	RP11-379B18.6	3.84	0.000155	0.0316	0.32	0.23	Blood pressure (smoking interaction);	chr3:125928643	chr3:125774714~125797953:+
COAD	cis	rs7172689	1	rs8030065	ENSG00000271725.1	RP11-761I4.4	3.84	0.000155	0.0316	0.31	0.23	Inattentive symptoms;	chr15:81244342	chr15:81303215~81309391:-
COAD	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	3.84	0.000155	0.0316	0.28	0.23	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
COAD	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	3.84	0.000155	0.0316	0.3	0.23	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
COAD	cis	rs886427	0.838	rs4149782	ENSG00000272079.2	LA16c-380H5.5	-3.84	0.000155	0.0316	-0.25	-0.23	Metabolic syndrome;	chr16:2977295	chr16:3006120~3007388:+
COAD	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	3.84	0.000155	0.0316	0.28	0.23	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
COAD	cis	rs10819861	0.645	rs4743527	ENSG00000238251.2	RP11-172F4.2	-3.84	0.000155	0.0317	-0.27	-0.23	Electrocardiographic traits;	chr9:96088793	chr9:96407284~96407797:+
COAD	cis	rs10819861	0.645	rs7045648	ENSG00000238251.2	RP11-172F4.2	-3.84	0.000155	0.0317	-0.27	-0.23	Electrocardiographic traits;	chr9:96092757	chr9:96407284~96407797:+
COAD	cis	rs4683346	1	rs4683344	ENSG00000273328.4	RP11-141M3.6	-3.84	0.000155	0.0317	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42842712	chr3:42809414~42908105:+
COAD	cis	rs4683346	1	rs12635458	ENSG00000273328.4	RP11-141M3.6	-3.84	0.000155	0.0317	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42850124	chr3:42809414~42908105:+
COAD	cis	rs875971	0.83	rs587360	ENSG00000224316.1	RP11-479O9.2	3.84	0.000155	0.0317	0.25	0.23	Aortic root size;	chr7:66057711	chr7:65773620~65802067:+
COAD	cis	rs10773046	0.702	rs11057379	ENSG00000280328.1	RP11-972P1.7	-3.84	0.000155	0.0317	-0.21	-0.23	Osteoarthritis (hip);	chr12:123871110	chr12:123472200~123476093:-
COAD	cis	rs655601	1	rs655601	ENSG00000260841.1	CTC-205M6.5	3.84	0.000155	0.0317	0.26	0.23	Quantitative traits;	chr5:180799673	chr5:180784782~180787869:-
COAD	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-3.84	0.000155	0.0317	-0.26	-0.23	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
COAD	cis	rs8022206	0.773	rs10133883	ENSG00000259502.1	RP11-643G16.3	3.84	0.000155	0.0317	0.32	0.23	Platelet count;Mean platelet volume;	chr14:68046775	chr14:67610986~67613864:+
COAD	cis	rs7204230	0.961	rs17394050	ENSG00000261056.2	RP11-454F8.2	3.84	0.000155	0.0317	0.28	0.23	Fibrinogen;	chr16:53201509	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048048	ENSG00000261056.2	RP11-454F8.2	3.84	0.000155	0.0317	0.28	0.23	Fibrinogen;	chr16:53201992	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs67384393	ENSG00000261056.2	RP11-454F8.2	3.84	0.000155	0.0317	0.28	0.23	Fibrinogen;	chr16:53202243	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048052	ENSG00000261056.2	RP11-454F8.2	3.84	0.000155	0.0317	0.28	0.23	Fibrinogen;	chr16:53206497	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048054	ENSG00000261056.2	RP11-454F8.2	3.84	0.000155	0.0317	0.28	0.23	Fibrinogen;	chr16:53207851	chr16:53298224~53299792:+
COAD	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-3.84	0.000155	0.0317	-0.28	-0.23	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-3.84	0.000155	0.0317	-0.28	-0.23	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
COAD	cis	rs4819052	0.851	rs2838864	ENSG00000227039.5	ITGB2-AS1	3.84	0.000155	0.0317	0.2	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:44921051~44929678:+
COAD	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	3.84	0.000155	0.0317	0.23	0.23	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
COAD	cis	rs2564921	0.73	rs12633064	ENSG00000280417.1	RP11-5O17.1	3.84	0.000155	0.0317	0.26	0.23	Height;	chr3:53027361	chr3:53046166~53048122:+
COAD	cis	rs12220238	0.915	rs11001020	ENSG00000279689.1	RP11-574K11.32	3.84	0.000155	0.0317	0.31	0.23	Soluble interleukin-2 receptor subunit alpha;	chr10:74379459	chr10:73769264~73772862:-
COAD	cis	rs10043775	1	rs4274968	ENSG00000251330.3	CTD-2283N19.1	-3.84	0.000155	0.0317	-0.28	-0.23	Periodontal microbiota;	chr5:148446027	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs4472255	ENSG00000251330.3	CTD-2283N19.1	-3.84	0.000155	0.0317	-0.28	-0.23	Periodontal microbiota;	chr5:148446054	chr5:148430159~148430807:-
COAD	cis	rs10043775	1	rs6884076	ENSG00000251330.3	CTD-2283N19.1	-3.84	0.000155	0.0317	-0.28	-0.23	Periodontal microbiota;	chr5:148447171	chr5:148430159~148430807:-
COAD	cis	rs2337406	1	rs75651733	ENSG00000280411.1	IGHV1-69-2	-3.84	0.000156	0.0317	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106701309	chr14:106762092~106762588:-
COAD	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-3.84	0.000156	0.0317	-0.29	-0.23	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
COAD	cis	rs1059312	0.545	rs7312683	ENSG00000279500.1	RP11-21K12.2	-3.84	0.000156	0.0317	-0.21	-0.23	Systemic lupus erythematosus;	chr12:128795560	chr12:128813186~128814750:-
COAD	cis	rs7918232	0.941	rs788210	ENSG00000262412.1	RP11-85G18.6	-3.84	0.000156	0.0317	-0.37	-0.23	Breast cancer;	chr10:27188019	chr10:27243130~27250804:+
COAD	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-3.84	0.000156	0.0318	-0.25	-0.23	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
COAD	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-3.84	0.000156	0.0318	-0.25	-0.23	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
COAD	cis	rs10857712	0.754	rs2297031	ENSG00000214279.11	SCART1	-3.84	0.000156	0.0318	-0.28	-0.23	Systemic lupus erythematosus;	chr10:133419150	chr10:133453928~133523558:+
COAD	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-3.84	0.000156	0.0318	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
COAD	cis	rs2836974	0.563	rs997147	ENSG00000255568.3	BRWD1-AS2	-3.84	0.000156	0.0318	-0.22	-0.23	Cognitive function;	chr21:39323399	chr21:39313935~39314962:+
COAD	cis	rs452036	0.625	rs8019322	ENSG00000259054.1	AE000662.93	-3.84	0.000156	0.0318	-0.3	-0.23	P wave duration;Resting heart rate;	chr14:23423372	chr14:22556311~22557062:-
COAD	cis	rs848490	0.928	rs55919387	ENSG00000213542.3	RP11-467H10.1	-3.84	0.000156	0.0318	-0.28	-0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77686304	chr7:77115399~77116192:-
COAD	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	3.84	0.000156	0.0318	0.29	0.23	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
COAD	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	3.84	0.000156	0.0318	0.31	0.23	Depression;	chr6:28201380	chr6:28943877~28944537:+
COAD	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000156	0.0318	0.24	0.23	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
COAD	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0318	0.28	0.23	Height;	chr4:55454154	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0318	0.28	0.23	Height;	chr4:55455650	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0318	0.28	0.23	Height;	chr4:55457027	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0318	0.28	0.23	Height;	chr4:55457086	chr4:55547112~55547889:+
COAD	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-3.84	0.000156	0.0318	-0.3	-0.23	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
COAD	cis	rs7615952	0.576	rs17523380	ENSG00000248787.1	RP11-666A20.4	-3.84	0.000156	0.0318	-0.3	-0.23	Blood pressure (smoking interaction);	chr3:126084031	chr3:125908005~125910272:-
COAD	cis	rs479105	0.689	rs11610052	ENSG00000242444.3	RP11-320N7.1	3.84	0.000156	0.0318	0.29	0.23	Gut microbiota (bacterial taxa);	chr12:3266057	chr12:4109661~4118132:-
COAD	cis	rs6017291	0.793	rs45472797	ENSG00000223891.4	OSER1-AS1	3.84	0.000156	0.0318	0.31	0.23	Cognitive performance;	chr20:44217425	chr20:44210960~44226027:+
COAD	cis	rs7584330	0.554	rs11892169	ENSG00000234949.2	AC104667.3	-3.84	0.000156	0.0318	-0.35	-0.23	Prostate cancer;	chr2:237524166	chr2:237591020~237595981:+
COAD	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-3.84	0.000156	0.0318	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
COAD	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-3.84	0.000156	0.0318	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
COAD	cis	rs718433	0.584	rs2204934	ENSG00000211778.2	TRAV4	-3.84	0.000156	0.0319	-0.19	-0.23	Intraocular pressure;	chr14:21744121	chr14:21736152~21736982:+
COAD	cis	rs891378	1	rs12095015	ENSG00000274245.1	RP11-357P18.2	3.84	0.000156	0.0319	0.33	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207283129	chr1:207372559~207373252:+
COAD	cis	rs1707322	0.821	rs11211182	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000156	0.0319	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45694684~45697075:-
COAD	cis	rs9652601	0.92	rs12923098	ENSG00000274038.1	RP11-66H6.4	-3.84	0.000156	0.0319	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11083196	chr16:11056556~11057034:+
COAD	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0319	0.28	0.23	Height;	chr4:55451955	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	3.84	0.000156	0.0319	0.28	0.23	Height;	chr4:55452853	chr4:55547112~55547889:+
COAD	cis	rs4648045	0.796	rs7683854	ENSG00000246560.2	RP11-10L12.4	3.84	0.000156	0.0319	0.31	0.23	Lymphocyte percentage of white cells;	chr4:102608899	chr4:102828055~102844075:+
COAD	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	3.84	0.000156	0.0319	0.3	0.23	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
COAD	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	3.84	0.000156	0.0319	0.29	0.23	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	3.84	0.000157	0.0319	0.32	0.23	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
COAD	cis	rs6687821	0.515	rs7534355	ENSG00000261737.1	RP4-612B15.3	3.84	0.000157	0.0319	0.3	0.23	Yeast infection;	chr1:87015237	chr1:86703502~86704462:-
COAD	cis	rs41271951	0.512	rs6664387	ENSG00000223861.1	RP11-74C1.2	-3.84	0.000157	0.0319	-0.45	-0.23	Blood protein levels;	chr1:151049033	chr1:151557446~151557940:+
COAD	cis	rs10492201	0.554	rs2870962	ENSG00000255733.4	IFNG-AS1	-3.84	0.000157	0.0319	-0.28	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:67989445~68234686:+
COAD	cis	rs2976388	0.578	rs3736010	ENSG00000247317.3	RP11-273G15.2	3.84	0.000157	0.0319	0.28	0.23	Urinary tract infection frequency;	chr8:142736085	chr8:142981738~143018437:-
COAD	cis	rs10760158	0.832	rs3827678	ENSG00000226752.6	PSMD5-AS1	-3.84	0.000157	0.0319	-0.25	-0.23	Pulse pressure;	chr9:121284444	chr9:120824828~120854385:+
COAD	cis	rs1790761	1	rs1790761	ENSG00000231793.4	DOC2GP	-3.84	0.000157	0.0319	-0.25	-0.23	Mean corpuscular volume;	chr11:67454383	chr11:67612653~67616257:-
COAD	cis	rs1790761	0.9	rs1638564	ENSG00000231793.4	DOC2GP	-3.84	0.000157	0.0319	-0.25	-0.23	Mean corpuscular volume;	chr11:67456449	chr11:67612653~67616257:-
COAD	cis	rs1790761	0.967	rs1638565	ENSG00000231793.4	DOC2GP	-3.84	0.000157	0.0319	-0.25	-0.23	Mean corpuscular volume;	chr11:67456450	chr11:67612653~67616257:-
COAD	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	3.84	0.000157	0.0319	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
COAD	cis	rs10971721	0.822	rs10971788	ENSG00000231991.4	ANXA2P2	3.84	0.000157	0.0319	0.34	0.23	Body mass index;	chr9:33915087	chr9:33624274~33625293:+
COAD	cis	rs2337406	0.925	rs873534	ENSG00000211964.3	IGHV3-48	-3.84	0.000157	0.0319	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106667423	chr14:106537810~106538344:-
COAD	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-3.84	0.000157	0.0319	-0.31	-0.23	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
COAD	cis	rs113835537	0.529	rs7943327	ENSG00000258297.1	RP11-658F2.8	-3.84	0.000157	0.0319	-0.23	-0.23	Airway imaging phenotypes;	chr11:66489110	chr11:66666036~66668374:+
COAD	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	3.84	0.000157	0.0319	0.23	0.23	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
COAD	cis	rs153916	0.605	rs212995	ENSG00000251000.1	AC008592.3	-3.84	0.000157	0.0319	-0.28	-0.23	Pulmonary function;	chr5:95688569	chr5:95834424~95835046:-
COAD	cis	rs1790761	0.967	rs3741168	ENSG00000231793.4	DOC2GP	-3.84	0.000157	0.0319	-0.25	-0.23	Mean corpuscular volume;	chr11:67467880	chr11:67612653~67616257:-
COAD	cis	rs1790761	0.967	rs1628442	ENSG00000231793.4	DOC2GP	-3.84	0.000157	0.0319	-0.25	-0.23	Mean corpuscular volume;	chr11:67471161	chr11:67612653~67616257:-
COAD	cis	rs2034650	0.563	rs12914710	ENSG00000223313.1	RNU6-516P	3.84	0.000157	0.0319	0.27	0.23	Interstitial lung disease;	chr15:40421650	chr15:40529570~40529673:+
COAD	cis	rs13256369	0.951	rs13270852	ENSG00000254153.1	CTA-398F10.2	3.84	0.000157	0.0319	0.31	0.23	Obesity-related traits;	chr8:8709343	chr8:8456909~8461337:-
COAD	cis	rs603446	0.61	rs1240782	ENSG00000254851.1	RP11-109L13.1	-3.84	0.000157	0.0319	-0.26	-0.23	Triglycerides;	chr11:116703868	chr11:117135528~117138582:+
COAD	cis	rs12530	0.715	rs5749428	ENSG00000241954.1	RP1-149A16.17	-3.84	0.000157	0.0319	-0.3	-0.23	IgG glycosylation;	chr22:32403709	chr22:32383786~32385631:+
COAD	cis	rs2337406	0.587	rs916547	ENSG00000211962.2	IGHV1-46	-3.84	0.000157	0.032	-0.17	-0.23	Alzheimer's disease (late onset);	chr14:106646735	chr14:106511117~106511856:-
COAD	cis	rs2337406	1	rs11850600	ENSG00000211964.3	IGHV3-48	-3.84	0.000157	0.032	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106670765	chr14:106537810~106538344:-
COAD	cis	rs870355	1	rs870355	ENSG00000267679.1	EIF5AP2	3.84	0.000157	0.032	0.26	0.23	Vitiligo;	chr17:78170115	chr17:78157403~78159135:+
COAD	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-3.84	0.000157	0.032	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
COAD	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-3.84	0.000157	0.032	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
COAD	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-3.84	0.000157	0.032	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
COAD	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-3.84	0.000157	0.032	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
COAD	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-3.84	0.000157	0.032	-0.26	-0.23	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
COAD	cis	rs6601327	0.641	rs7462070	ENSG00000233609.3	RP11-62H7.2	-3.84	0.000157	0.032	-0.28	-0.23	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:8961200~8979025:+
COAD	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-3.84	0.000157	0.032	-0.24	-0.23	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
COAD	cis	rs7674212	0.57	rs2711898	ENSG00000230069.3	LRRC37A15P	-3.84	0.000157	0.032	-0.24	-0.23	Type 2 diabetes;	chr4:103141914	chr4:102727274~102730721:-
COAD	cis	rs2179367	0.613	rs12207047	ENSG00000216906.2	RP11-350J20.9	3.84	0.000157	0.032	0.33	0.23	Dupuytren's disease;	chr6:149423496	chr6:149904243~149906418:+
COAD	cis	rs2179367	0.613	rs12207261	ENSG00000216906.2	RP11-350J20.9	3.84	0.000157	0.032	0.33	0.23	Dupuytren's disease;	chr6:149423722	chr6:149904243~149906418:+
COAD	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-3.84	0.000157	0.032	-0.23	-0.23	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
COAD	cis	rs11098499	0.826	rs4472123	ENSG00000250412.1	KLHL2P1	3.84	0.000157	0.032	0.3	0.23	Corneal astigmatism;	chr4:119315475	chr4:119334329~119378233:+
COAD	cis	rs4237845	0.611	rs2888288	ENSG00000257698.1	RP11-620J15.3	3.84	0.000157	0.032	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57936152	chr12:57931528~57936175:-
COAD	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	3.84	0.000157	0.032	0.34	0.23	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
COAD	cis	rs6967414	0.786	rs9639026	ENSG00000187953.9	PMS2CL	-3.84	0.000157	0.032	-0.32	-0.23	Hematocrit;Hemoglobin concentration;	chr7:6707105	chr7:6710128~6753862:+
COAD	cis	rs2732480	0.577	rs2634680	ENSG00000269514.1	RP11-370I10.12	3.84	0.000157	0.032	0.3	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2634678	ENSG00000269514.1	RP11-370I10.12	3.84	0.000157	0.032	0.3	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.577	rs2732479	ENSG00000269514.1	RP11-370I10.12	3.84	0.000157	0.032	0.3	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48198387~48202031:+
COAD	cis	rs2732480	0.537	rs1061986	ENSG00000269514.1	RP11-370I10.12	3.84	0.000157	0.032	0.3	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48198387~48202031:+
COAD	cis	rs4699052	0.963	rs11097804	ENSG00000246560.2	RP11-10L12.4	3.84	0.000157	0.032	0.27	0.23	Testicular germ cell tumor;	chr4:103293980	chr4:102828055~102844075:+
COAD	cis	rs4699052	0.928	rs4456958	ENSG00000246560.2	RP11-10L12.4	3.84	0.000157	0.032	0.27	0.23	Testicular germ cell tumor;	chr4:103294175	chr4:102828055~102844075:+
COAD	cis	rs34286592	0.929	rs35901559	ENSG00000214725.6	CDIPT-AS1	-3.84	0.000157	0.032	-0.41	-0.23	Multiple sclerosis;	chr16:29818294	chr16:29863593~29868053:+
COAD	cis	rs34286592	0.929	rs11864180	ENSG00000214725.6	CDIPT-AS1	-3.84	0.000157	0.032	-0.41	-0.23	Multiple sclerosis;	chr16:29819508	chr16:29863593~29868053:+
COAD	cis	rs34286592	0.929	rs9923649	ENSG00000214725.6	CDIPT-AS1	-3.84	0.000157	0.032	-0.41	-0.23	Multiple sclerosis;	chr16:29820817	chr16:29863593~29868053:+
COAD	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-3.84	0.000157	0.032	-0.36	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
COAD	cis	rs1707322	0.647	rs6686944	ENSG00000230896.1	RP11-767N6.7	-3.84	0.000157	0.032	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45694684~45697075:-
COAD	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-3.84	0.000157	0.032	-0.49	-0.23	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
COAD	cis	rs8022206	0.898	rs34588410	ENSG00000259502.1	RP11-643G16.3	3.84	0.000157	0.032	0.35	0.23	Platelet count;Mean platelet volume;	chr14:68016173	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725165	ENSG00000259502.1	RP11-643G16.3	3.84	0.000157	0.032	0.35	0.23	Platelet count;Mean platelet volume;	chr14:68021607	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs11624609	ENSG00000259502.1	RP11-643G16.3	3.84	0.000157	0.032	0.35	0.23	Platelet count;Mean platelet volume;	chr14:68023385	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs11852208	ENSG00000259502.1	RP11-643G16.3	3.84	0.000157	0.032	0.35	0.23	Platelet count;Mean platelet volume;	chr14:68024106	chr14:67610986~67613864:+
COAD	cis	rs12474201	0.572	rs7596521	ENSG00000279254.1	RP11-536C12.1	-3.84	0.000157	0.032	-0.28	-0.23	Height;	chr2:46691526	chr2:46668870~46670778:+
COAD	cis	rs6095360	1	rs2426139	ENSG00000222365.1	SNORD12B	-3.84	0.000157	0.032	-0.22	-0.23	Intelligence (multi-trait analysis);	chr20:49163568	chr20:49280319~49280409:+
COAD	cis	rs11098499	0.865	rs9994730	ENSG00000250412.1	KLHL2P1	3.84	0.000157	0.032	0.31	0.23	Corneal astigmatism;	chr4:119460409	chr4:119334329~119378233:+
COAD	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	3.84	0.000157	0.032	0.3	0.23	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
COAD	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	3.84	0.000157	0.032	0.3	0.23	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
COAD	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	3.84	0.000157	0.032	0.28	0.23	Height;	chr4:55520278	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	3.84	0.000157	0.032	0.28	0.23	Height;	chr4:55523835	chr4:55547112~55547889:+
COAD	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	3.84	0.000157	0.032	0.28	0.23	Height;	chr4:55524246	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	3.84	0.000157	0.032	0.28	0.23	Height;	chr4:55525589	chr4:55547112~55547889:+
COAD	cis	rs911263	0.603	rs2180770	ENSG00000259502.1	RP11-643G16.3	-3.84	0.000157	0.032	-0.29	-0.23	Primary biliary cholangitis;	chr14:68306636	chr14:67610986~67613864:+
COAD	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-3.84	0.000157	0.032	-0.3	-0.23	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-3.84	0.000157	0.032	-0.3	-0.23	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
COAD	cis	rs7465272	1	rs35900184	ENSG00000263660.1	AC087793.1	-3.84	0.000157	0.032	-0.26	-0.23	Bipolar disorder and schizophrenia;	chr8:142612050	chr8:143314921~143315006:+
COAD	cis	rs9868809	0.772	rs12107252	ENSG00000225399.4	RP11-3B7.1	-3.84	0.000158	0.032	-0.34	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48653883	chr3:49260085~49261316:+
COAD	cis	rs4443100	0.916	rs2078727	ENSG00000211642.2	IGLV10-54	-3.84	0.000158	0.032	-0.23	-0.23	Serum parathyroid hormone levels;	chr22:23042844	chr22:22214794~22215270:+
COAD	cis	rs4443100	0.916	rs2078728	ENSG00000211642.2	IGLV10-54	-3.84	0.000158	0.032	-0.23	-0.23	Serum parathyroid hormone levels;	chr22:23042944	chr22:22214794~22215270:+
COAD	cis	rs17685	0.753	rs1639617	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1637045	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs11982200	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76043977~76045963:-
COAD	cis	rs17685	0.587	rs1623759	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76043977~76045963:-
COAD	cis	rs17685	0.712	rs1637049	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs1637051	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76043977~76045963:-
COAD	cis	rs17685	0.753	rs4573217	ENSG00000280388.1	RP11-229D13.3	-3.84	0.000158	0.032	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76043977~76045963:-
COAD	cis	rs495337	1	rs4287819	ENSG00000229222.1	KRT18P4	-3.84	0.000158	0.0321	-0.24	-0.23	Psoriasis;	chr20:49935419	chr20:49956745~49958032:+
COAD	cis	rs8141529	0.702	rs132536	ENSG00000272858.1	CTA-292E10.8	3.84	0.000158	0.0321	0.28	0.23	Lymphocyte counts;	chr22:28906918	chr22:28814914~28815662:+
COAD	cis	rs739496	0.895	rs7309325	ENSG00000257595.2	RP3-473L9.4	3.84	0.000158	0.0321	0.32	0.23	Platelet count;	chr12:111411711	chr12:111369282~111403310:+
COAD	cis	rs6762	0.748	rs3059	ENSG00000279672.1	CMB9-55F22.1	3.84	0.000158	0.0321	0.23	0.23	Mean platelet volume;	chr11:840319	chr11:779617~780755:+
COAD	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	3.84	0.000158	0.0321	0.22	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
COAD	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	3.84	0.000158	0.0321	0.31	0.23	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
COAD	cis	rs1510510	0.69	rs13003781	ENSG00000225057.2	AC096574.4	3.84	0.000158	0.0321	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640544	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs13004019	ENSG00000225057.2	AC096574.4	3.84	0.000158	0.0321	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640671	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs13026799	ENSG00000225057.2	AC096574.4	3.84	0.000158	0.0321	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238640693	chr2:238231684~238255633:+
COAD	cis	rs8031584	0.918	rs34693097	ENSG00000270015.1	RP11-540B6.6	-3.84	0.000158	0.0321	-0.2	-0.23	Huntington's disease progression;	chr15:30961781	chr15:30926514~30928407:+
COAD	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-3.84	0.000158	0.0321	-0.28	-0.23	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
COAD	cis	rs7219021	0.811	rs3959442	ENSG00000270781.1	RP11-501C14.9	-3.84	0.000158	0.0321	-0.26	-0.23	Schizophrenia or bipolar disorder;	chr17:48817015	chr17:48899131~48899748:+
COAD	cis	rs2559856	1	rs2695299	ENSG00000199933.1	RNY1P16	3.84	0.000158	0.0321	0.25	0.23	Blood protein levels;	chr12:101688886	chr12:101719808~101719918:+
COAD	cis	rs712039	0.652	rs1616371	ENSG00000276054.1	RP11-378E13.3	3.84	0.000158	0.0321	0.34	0.23	Tuberculosis;	chr17:37413714	chr17:37386886~37387926:+
COAD	cis	rs11157436	0.602	rs11157439	ENSG00000211812.1	TRAV26-2	-3.84	0.000158	0.0321	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22202583~22203368:+
COAD	cis	rs13188386	0.763	rs4395642	ENSG00000249779.1	RP11-447H19.3	-3.84	0.000158	0.0321	-0.27	-0.23	Iron status biomarkers;	chr5:42552329	chr5:43206709~43207811:+
COAD	cis	rs875971	0.965	rs697968	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000158	0.0321	-0.19	-0.23	Aortic root size;	chr7:66070046	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs1183245	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000158	0.0321	-0.19	-0.23	Aortic root size;	chr7:66076198	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs1144895	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000158	0.0321	-0.19	-0.23	Aortic root size;	chr7:66076320	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs1144894	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000158	0.0321	-0.19	-0.23	Aortic root size;	chr7:66077907	chr7:66491049~66493566:-
COAD	cis	rs13256369	1	rs7820159	ENSG00000173295.6	FAM86B3P	3.84	0.000158	0.0321	0.34	0.23	Obesity-related traits;	chr8:8718705	chr8:8228595~8244865:+
COAD	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-3.83	0.000158	0.0321	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-3.83	0.000158	0.0321	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
COAD	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-3.83	0.000158	0.0321	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-3.83	0.000158	0.0321	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-3.83	0.000158	0.0321	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
COAD	cis	rs2292864	0.764	rs72825627	ENSG00000228782.6	CTD-2026D20.3	-3.83	0.000158	0.0321	-0.45	-0.23	Left atrial antero-posterior diameter;	chr17:47308923	chr17:47450568~47492492:-
COAD	cis	rs8114671	0.562	rs4911450	ENSG00000228265.4	RALY-AS1	3.83	0.000158	0.0321	0.22	0.23	Height;	chr20:34924603	chr20:33983052~33994357:-
COAD	cis	rs4819052	0.851	rs2838858	ENSG00000227039.5	ITGB2-AS1	-3.83	0.000158	0.0321	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:44921051~44929678:+
COAD	cis	rs699371	0.525	rs7156302	ENSG00000270000.1	RP3-449M8.9	3.83	0.000158	0.0321	0.29	0.23	Height;	chr14:74428260	chr14:74471930~74472360:-
COAD	cis	rs875971	0.545	rs73378304	ENSG00000224316.1	RP11-479O9.2	3.83	0.000158	0.0321	0.28	0.23	Aortic root size;	chr7:66175760	chr7:65773620~65802067:+
COAD	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	3.83	0.000158	0.0321	0.31	0.23	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
COAD	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-3.83	0.000158	0.0321	-0.3	-0.23	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
COAD	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	3.83	0.000158	0.0321	0.25	0.23	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
COAD	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	3.83	0.000158	0.0321	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
COAD	cis	rs7584330	0.554	rs114331205	ENSG00000234949.2	AC104667.3	-3.83	0.000158	0.0321	-0.35	-0.23	Prostate cancer;	chr2:237523916	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.518	rs11903073	ENSG00000234949.2	AC104667.3	-3.83	0.000158	0.0321	-0.35	-0.23	Prostate cancer;	chr2:237524123	chr2:237591020~237595981:+
COAD	cis	rs57221529	0.766	rs72706610	ENSG00000250385.1	RP11-310P5.2	3.83	0.000158	0.0321	0.4	0.23	Lung disease severity in cystic fibrosis;	chr5:560996	chr5:524705~526594:+
COAD	cis	rs10760158	0.832	rs10760160	ENSG00000226752.6	PSMD5-AS1	-3.83	0.000158	0.0322	-0.25	-0.23	Pulse pressure;	chr9:121241048	chr9:120824828~120854385:+
COAD	cis	rs742132	0.858	rs10946789	ENSG00000220875.1	HIST1H3PS1	3.83	0.000158	0.0322	0.3	0.23	Uric acid levels;	chr6:25663675	chr6:26321876~26322292:-
COAD	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	3.83	0.000158	0.0322	0.34	0.23	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
COAD	cis	rs2346160	0.899	rs1736585	ENSG00000228648.1	RP11-568A7.2	3.83	0.000158	0.0322	0.26	0.23	Parental extreme longevity (95 years and older);	chr6:167274837	chr6:167241891~167245916:+
COAD	cis	rs2337406	0.866	rs7153964	ENSG00000211964.3	IGHV3-48	-3.83	0.000158	0.0322	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106790480	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs2301536	ENSG00000211964.3	IGHV3-48	-3.83	0.000158	0.0322	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106790636	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs7144369	ENSG00000211964.3	IGHV3-48	-3.83	0.000158	0.0322	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106793065	chr14:106537810~106538344:-
COAD	cis	rs6719977	0.543	rs4953631	ENSG00000226491.1	FTOP1	3.83	0.000158	0.0322	0.31	0.23	Hyperactive-impulsive symptoms;	chr2:42743850	chr2:42797225~42798712:-
COAD	cis	rs984222	0.501	rs1325941	ENSG00000231365.4	RP11-418J17.1	-3.83	0.000158	0.0322	-0.24	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119140396~119275973:+
COAD	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-3.83	0.000158	0.0322	-0.28	-0.23	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-3.83	0.000158	0.0322	-0.28	-0.23	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
COAD	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	3.83	0.000158	0.0322	0.37	0.23	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
COAD	cis	rs2638953	0.924	rs79712894	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000158	0.0322	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28163298~28190738:-
COAD	cis	rs6490294	0.632	rs10849966	ENSG00000257595.2	RP3-473L9.4	3.83	0.000158	0.0322	0.3	0.23	Mean platelet volume;	chr12:111662969	chr12:111369282~111403310:+
COAD	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	3.83	0.000158	0.0322	0.28	0.23	Height;	chr4:55450662	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	3.83	0.000158	0.0322	0.28	0.23	Height;	chr4:55450812	chr4:55547112~55547889:+
COAD	cis	rs12049351	0.507	rs11803533	ENSG00000229367.1	HMGN2P19	3.83	0.000158	0.0322	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229432885	chr1:229570532~229570796:+
COAD	cis	rs9880211	0.613	rs28519617	ENSG00000273486.1	RP11-731C17.2	3.83	0.000158	0.0322	0.27	0.23	Height;Body mass index;	chr3:136156088	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.613	rs28669017	ENSG00000273486.1	RP11-731C17.2	3.83	0.000158	0.0322	0.27	0.23	Height;Body mass index;	chr3:136156090	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.613	rs10222451	ENSG00000273486.1	RP11-731C17.2	3.83	0.000158	0.0322	0.27	0.23	Height;Body mass index;	chr3:136158571	chr3:136837338~136839021:-
COAD	cis	rs172166	0.637	rs1233708	ENSG00000272009.1	RP1-313I6.12	3.83	0.000158	0.0322	0.27	0.23	Cardiac Troponin-T levels;	chr6:28205441	chr6:28078792~28081130:-
COAD	cis	rs10876993	0.928	rs1689587	ENSG00000270039.1	RP11-571M6.17	3.83	0.000159	0.0322	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57681615	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.928	rs2640636	ENSG00000270039.1	RP11-571M6.17	3.83	0.000159	0.0322	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57683761	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.928	rs1689586	ENSG00000270039.1	RP11-571M6.17	3.83	0.000159	0.0322	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57685803	chr12:57803838~57804415:+
COAD	cis	rs453301	0.686	rs3895823	ENSG00000233609.3	RP11-62H7.2	-3.83	0.000159	0.0322	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9016136	chr8:8961200~8979025:+
COAD	cis	rs2708377	0.858	rs73051630	ENSG00000212125.2	TAS2R15P	3.83	0.000159	0.0322	0.43	0.23	Bitter taste perception;	chr12:10994589	chr12:10964425~10965352:-
COAD	cis	rs2708377	0.929	rs73053768	ENSG00000212125.2	TAS2R15P	3.83	0.000159	0.0322	0.43	0.23	Bitter taste perception;	chr12:11003148	chr12:10964425~10965352:-
COAD	cis	rs11231017	0.967	rs4477443	ENSG00000254454.2	RCC2P6	-3.83	0.000159	0.0322	-0.27	-0.23	HIV-1 viral setpoint;	chr11:62297369	chr11:62371146~62373168:+
COAD	cis	rs11231017	1	rs4280004	ENSG00000254454.2	RCC2P6	-3.83	0.000159	0.0322	-0.27	-0.23	HIV-1 viral setpoint;	chr11:62297372	chr11:62371146~62373168:+
COAD	cis	rs7955901	0.691	rs2132242	ENSG00000258053.1	CTD-2021H9.3	3.83	0.000159	0.0322	0.29	0.23	Type 2 diabetes;	chr12:71082476	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.691	rs1510944	ENSG00000258053.1	CTD-2021H9.3	3.83	0.000159	0.0322	0.29	0.23	Type 2 diabetes;	chr12:71083820	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.691	rs11178594	ENSG00000258053.1	CTD-2021H9.3	3.83	0.000159	0.0322	0.29	0.23	Type 2 diabetes;	chr12:71085115	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.691	rs1960312	ENSG00000258053.1	CTD-2021H9.3	3.83	0.000159	0.0322	0.29	0.23	Type 2 diabetes;	chr12:71087670	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.691	rs2088160	ENSG00000258053.1	CTD-2021H9.3	3.83	0.000159	0.0322	0.29	0.23	Type 2 diabetes;	chr12:71090562	chr12:71047402~71118247:-
COAD	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-3.83	0.000159	0.0322	-0.28	-0.23	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
COAD	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-3.83	0.000159	0.0322	-0.24	-0.23	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
COAD	cis	rs9880211	0.563	rs6769762	ENSG00000239213.4	NCK1-AS1	3.83	0.000159	0.0322	0.32	0.23	Height;Body mass index;	chr3:136189336	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.718	rs28631273	ENSG00000273486.1	RP11-731C17.2	3.83	0.000159	0.0322	0.27	0.23	Height;Body mass index;	chr3:136215869	chr3:136837338~136839021:-
COAD	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	3.83	0.000159	0.0322	0.3	0.23	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
COAD	cis	rs8017304	0.593	rs10131654	ENSG00000259502.1	RP11-643G16.3	-3.83	0.000159	0.0322	-0.31	-0.23	Age-related macular degeneration;	chr14:68334509	chr14:67610986~67613864:+
COAD	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0322	-0.27	-0.23	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
COAD	cis	rs11168351	0.927	rs7971880	ENSG00000226413.2	OR8T1P	3.83	0.000159	0.0322	0.28	0.23	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48442030~48442947:-
COAD	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	3.83	0.000159	0.0322	0.29	0.23	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	3.83	0.000159	0.0322	0.29	0.23	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
COAD	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000159	0.0322	-0.27	-0.23	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
COAD	cis	rs743757	0.816	rs67425923	ENSG00000281358.1	RASSF1-AS1	-3.83	0.000159	0.0322	-0.37	-0.23	Diastolic blood pressure;	chr3:50531721	chr3:50337511~50338300:+
COAD	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-3.83	0.000159	0.0322	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
COAD	cis	rs2337406	0.778	rs56658355	ENSG00000254174.1	IGHV1-12	3.83	0.000159	0.0322	0.22	0.23	Alzheimer's disease (late onset);	chr14:106662151	chr14:106122420~106122709:-
COAD	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	3.83	0.000159	0.0323	0.33	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
COAD	cis	rs5753037	0.702	rs81800	ENSG00000279159.1	RP3-394A18.1	3.83	0.000159	0.0323	0.16	0.23	Type 1 diabetes;	chr22:29804373	chr22:29978950~30028236:-
COAD	cis	rs3126085	0.935	rs4845431	ENSG00000237975.5	FLG-AS1	-3.83	0.000159	0.0323	-0.26	-0.23	Atopic dermatitis;	chr1:152255501	chr1:152168125~152445456:+
COAD	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	3.83	0.000159	0.0323	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
COAD	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	3.83	0.000159	0.0323	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
COAD	cis	rs9652601	0.696	rs12917656	ENSG00000274038.1	RP11-66H6.4	-3.83	0.000159	0.0323	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11094005	chr16:11056556~11057034:+
COAD	cis	rs860295	0.702	rs1556488	ENSG00000160766.13	GBAP1	-3.83	0.000159	0.0323	-0.27	-0.23	Body mass index;	chr1:155570869	chr1:155213821~155227422:-
COAD	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-3.83	0.000159	0.0323	-0.34	-0.23	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
COAD	cis	rs9307551	0.656	rs11098741	ENSG00000250334.4	LINC00989	-3.83	0.000159	0.0323	-0.28	-0.23	Refractive error;	chr4:79551480	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.619	rs11098742	ENSG00000250334.4	LINC00989	-3.83	0.000159	0.0323	-0.28	-0.23	Refractive error;	chr4:79551637	chr4:79492416~79576460:+
COAD	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	3.83	0.000159	0.0323	0.23	0.23	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
COAD	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-3.83	0.000159	0.0323	-0.3	-0.23	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
COAD	cis	rs3803170	0.513	rs10849941	ENSG00000257595.2	RP3-473L9.4	3.83	0.000159	0.0323	0.32	0.23	Mean corpuscular hemoglobin;	chr12:111380683	chr12:111369282~111403310:+
COAD	cis	rs860295	0.702	rs2175391	ENSG00000223503.1	RP11-29H23.6	3.83	0.000159	0.0323	0.3	0.23	Body mass index;	chr1:155655811	chr1:155590601~155591262:-
COAD	cis	rs2554380	0.628	rs7175491	ENSG00000176700.18	SCAND2P	-3.83	0.000159	0.0323	-0.21	-0.23	Height;	chr15:83806187	chr15:84631451~84647478:+
COAD	cis	rs2554380	0.628	rs7177929	ENSG00000176700.18	SCAND2P	-3.83	0.000159	0.0323	-0.21	-0.23	Height;	chr15:83809927	chr15:84631451~84647478:+
COAD	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-3.83	0.000159	0.0323	-0.26	-0.23	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
COAD	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-3.83	0.000159	0.0323	-0.33	-0.23	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
COAD	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-3.83	0.000159	0.0323	-0.33	-0.23	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
COAD	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-3.83	0.000159	0.0323	-0.33	-0.23	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
COAD	cis	rs7584330	0.697	rs60278044	ENSG00000234949.2	AC104667.3	-3.83	0.000159	0.0323	-0.29	-0.23	Prostate cancer;	chr2:237448475	chr2:237591020~237595981:+
COAD	cis	rs896854	0.608	rs7004862	ENSG00000253528.2	RP11-347C18.4	3.83	0.000159	0.0323	0.24	0.23	Type 2 diabetes;	chr8:94864735	chr8:94974573~94974853:-
COAD	cis	rs4761638	0.954	rs6538521	ENSG00000258365.1	RP11-1105G2.3	3.83	0.000159	0.0323	0.28	0.23	Insulin disposition index;	chr12:94610045	chr12:94277758~94282844:-
COAD	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	3.83	0.000159	0.0323	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
COAD	cis	rs742132	0.822	rs4712952	ENSG00000220875.1	HIST1H3PS1	3.83	0.000159	0.0323	0.3	0.23	Uric acid levels;	chr6:25670564	chr6:26321876~26322292:-
COAD	cis	rs875971	1	rs7792762	ENSG00000230189.5	GS1-124K5.2	3.83	0.000159	0.0323	0.19	0.23	Aortic root size;	chr7:66539151	chr7:66409143~66490059:-
COAD	cis	rs742132	0.858	rs12524429	ENSG00000220875.1	HIST1H3PS1	3.83	0.000159	0.0323	0.3	0.23	Uric acid levels;	chr6:25667847	chr6:26321876~26322292:-
COAD	cis	rs875971	1	rs1544549	ENSG00000224316.1	RP11-479O9.2	-3.83	0.000159	0.0323	-0.25	-0.23	Aortic root size;	chr7:66625676	chr7:65773620~65802067:+
COAD	cis	rs6802315	0.604	rs2115941	ENSG00000272247.1	RP11-379F4.9	-3.83	0.000159	0.0323	-0.28	-0.23	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158801257~158801935:-
COAD	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	3.83	0.000159	0.0323	0.29	0.23	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
COAD	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	3.83	0.000159	0.0323	0.29	0.23	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
COAD	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	3.83	0.000159	0.0323	0.22	0.23	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
COAD	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-3.83	0.000159	0.0323	-0.3	-0.23	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
COAD	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-3.83	0.000159	0.0323	-0.25	-0.23	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
COAD	cis	rs28374715	0.578	rs7169543	ENSG00000247556.5	OIP5-AS1	3.83	0.00016	0.0323	0.32	0.23	Ulcerative colitis;	chr15:41328207	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.528	rs28492932	ENSG00000247556.5	OIP5-AS1	3.83	0.00016	0.0323	0.32	0.23	Ulcerative colitis;	chr15:41332199	chr15:41283990~41309737:+
COAD	cis	rs10489849	0.73	rs6656286	ENSG00000236257.1	EI24P2	-3.83	0.00016	0.0323	-0.3	-0.23	Select biomarker traits;	chr1:159239962	chr1:158454198~158455273:+
COAD	cis	rs4671386	1	rs4671381	ENSG00000233953.1	AC009970.1	3.83	0.00016	0.0324	0.24	0.23	Acne (severe);	chr2:60269775	chr2:60495686~60499964:+
COAD	cis	rs7116495	1	rs2460254	ENSG00000254682.1	RP11-660L16.2	-3.83	0.00016	0.0324	-0.36	-0.23	Severe influenza A (H1N1) infection;	chr11:71859064	chr11:71448674~71452157:+
COAD	cis	rs4819052	0.819	rs34818688	ENSG00000227039.5	ITGB2-AS1	-3.83	0.00016	0.0324	-0.21	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:44921051~44929678:+
COAD	cis	rs34779708	0.966	rs12260130	ENSG00000271335.4	RP11-324I22.4	3.83	0.00016	0.0324	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35314552~35336401:-
COAD	cis	rs911263	0.603	rs1956524	ENSG00000259502.1	RP11-643G16.3	-3.83	0.00016	0.0324	-0.29	-0.23	Primary biliary cholangitis;	chr14:68333676	chr14:67610986~67613864:+
COAD	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	3.83	0.00016	0.0324	0.31	0.23	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
COAD	cis	rs7615952	0.932	rs1976458	ENSG00000272840.1	RP11-379B18.6	3.83	0.00016	0.0324	0.32	0.23	Blood pressure (smoking interaction);	chr3:125928669	chr3:125774714~125797953:+
COAD	cis	rs2554380	0.628	rs4843158	ENSG00000176700.18	SCAND2P	-3.83	0.00016	0.0324	-0.22	-0.23	Height;	chr15:83802884	chr15:84631451~84647478:+
COAD	cis	rs9868809	0.505	rs11708786	ENSG00000225399.4	RP11-3B7.1	-3.83	0.00016	0.0324	-0.35	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48715221	chr3:49260085~49261316:+
COAD	cis	rs7637701	0.967	rs9837038	ENSG00000240875.4	LINC00886	3.83	0.00016	0.0324	0.22	0.23	Breast cancer;	chr3:156850680	chr3:156747346~156817062:-
COAD	cis	rs9990333	0.862	rs6806599	ENSG00000260261.1	RP11-480A16.1	-3.83	0.00016	0.0324	-0.15	-0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195949188~195952695:-
COAD	cis	rs12049351	0.665	rs10753458	ENSG00000229367.1	HMGN2P19	3.83	0.00016	0.0324	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229439962	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.612	rs10753459	ENSG00000229367.1	HMGN2P19	3.83	0.00016	0.0324	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229440017	chr1:229570532~229570796:+
COAD	cis	rs742132	0.858	rs12529390	ENSG00000220875.1	HIST1H3PS1	3.83	0.00016	0.0324	0.3	0.23	Uric acid levels;	chr6:25664451	chr6:26321876~26322292:-
COAD	cis	rs860295	1	rs6427287	ENSG00000223503.1	RP11-29H23.6	-3.83	0.00016	0.0324	-0.29	-0.23	Body mass index;	chr1:155753629	chr1:155590601~155591262:-
COAD	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	3.83	0.00016	0.0324	0.28	0.23	Height;	chr4:55446869	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	3.83	0.00016	0.0324	0.28	0.23	Height;	chr4:55447523	chr4:55547112~55547889:+
COAD	cis	rs8044868	1	rs8044868	ENSG00000279206.1	RP5-991G20.6	-3.83	0.00016	0.0325	-0.27	-0.23	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72128203	chr16:72772673~72773272:+
COAD	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	3.83	0.00016	0.0325	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
COAD	cis	rs2032447	0.507	rs199748	ENSG00000168405.13	CMAHP	3.83	0.00016	0.0325	0.24	0.23	Intelligence (multi-trait analysis);	chr6:25908817	chr6:25081068~25166555:-
COAD	cis	rs9880211	0.563	rs1393787	ENSG00000273486.1	RP11-731C17.2	3.83	0.00016	0.0325	0.28	0.23	Height;Body mass index;	chr3:136135359	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.563	rs9881400	ENSG00000273486.1	RP11-731C17.2	3.83	0.00016	0.0325	0.28	0.23	Height;Body mass index;	chr3:136142824	chr3:136837338~136839021:-
COAD	cis	rs2439831	0.681	rs28578454	ENSG00000275601.1	AC011330.13	-3.83	0.00016	0.0325	-0.36	-0.23	Lung cancer in ever smokers;	chr15:43310834	chr15:43642389~43643023:-
COAD	cis	rs791888	0.667	rs2762520	ENSG00000225913.2	RP11-57C13.6	3.83	0.00016	0.0325	0.27	0.23	Magnesium levels;	chr10:87655088	chr10:87607985~87659279:+
COAD	cis	rs17407555	0.657	rs10013452	ENSG00000250413.1	RP11-448G15.1	-3.83	0.00016	0.0325	-0.31	-0.23	Schizophrenia (age at onset);	chr4:10275366	chr4:10006482~10009725:+
COAD	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	3.83	0.00016	0.0325	0.35	0.23	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
COAD	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	3.83	0.00016	0.0325	0.39	0.23	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	3.83	0.00016	0.0325	0.39	0.23	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
COAD	cis	rs7577696	0.924	rs7601267	ENSG00000272716.1	RP11-563N4.1	-3.83	0.00016	0.0325	-0.24	-0.23	Inflammatory biomarkers;	chr2:32047330	chr2:32165046~32165757:-
COAD	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	3.83	0.00016	0.0325	0.32	0.23	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
COAD	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	3.83	0.00016	0.0325	0.37	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
COAD	cis	rs2916733	0.607	rs2442507	ENSG00000246089.3	RP11-115C21.2	-3.83	0.000161	0.0325	-0.31	-0.23	Epirubicin-induced leukopenia;	chr8:6447583	chr8:6403551~6407142:-
COAD	cis	rs875971	0.964	rs6978429	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66494889	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs4718357	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66495891	chr7:66491049~66493566:-
COAD	cis	rs875971	0.929	rs12535036	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66499076	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs12533997	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66500390	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs12532998	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66502472	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs12698523	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66503126	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs6970030	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66503692	chr7:66491049~66493566:-
COAD	cis	rs875971	0.928	rs6970357	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66503891	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs3735148	ENSG00000223473.2	GS1-124K5.3	3.83	0.000161	0.0325	0.19	0.23	Aortic root size;	chr7:66506022	chr7:66491049~66493566:-
COAD	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-3.83	0.000161	0.0325	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
COAD	cis	rs2617170	0.725	rs2734436	ENSG00000245648.1	RP11-277P12.20	3.83	0.000161	0.0325	0.3	0.23	Behcet's disease;	chr12:10454521	chr12:10363769~10398506:+
COAD	cis	rs10465746	0.57	rs11163887	ENSG00000249237.4	RP11-376N17.4	-3.83	0.000161	0.0325	-0.26	-0.23	Obesity-related traits;	chr1:84009035	chr1:84344678~84349939:+
COAD	cis	rs479844	1	rs479844	ENSG00000214659.4	KRT8P26	-3.83	0.000161	0.0325	-0.26	-0.23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);Atopic march;	chr11:65784486	chr11:65726939~65728214:+
COAD	cis	rs1115240	0.574	rs57083742	ENSG00000257842.4	NOVA1-AS1	3.83	0.000161	0.0325	0.31	0.23	Educational attainment (years of education);	chr14:26522858	chr14:26598412~26806467:+
COAD	cis	rs7204230	1	rs2388013	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0325	0.28	0.23	Fibrinogen;	chr16:53193469	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs8046380	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0325	0.28	0.23	Fibrinogen;	chr16:53195329	chr16:53298224~53299792:+
COAD	cis	rs3748656	0.895	rs11102498	ENSG00000231246.1	RP5-965F6.2	-3.83	0.000161	0.0325	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112576820	chr1:112177234~112360528:-
COAD	cis	rs13256369	0.851	rs13271698	ENSG00000254153.1	CTA-398F10.2	3.83	0.000161	0.0325	0.31	0.23	Obesity-related traits;	chr8:8710029	chr8:8456909~8461337:-
COAD	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	3.83	0.000161	0.0325	0.26	0.23	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
COAD	cis	rs9868809	0.505	rs13434258	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701058	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs11706983	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701245	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs35064573	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48702847	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs28567949	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707127	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs13316551	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707734	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs11706203	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48708806	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs9877685	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711155	chr3:49260085~49261316:+
COAD	cis	rs9868809	0.505	rs13063223	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000161	0.0325	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48712907	chr3:49260085~49261316:+
COAD	cis	rs4879656	0.835	rs7036559	ENSG00000225693.1	LAGE3P1	-3.83	0.000161	0.0325	-0.26	-0.23	Menopause (age at onset);	chr9:33064929	chr9:33019682~33020165:-
COAD	cis	rs535066	0.841	rs472062	ENSG00000260878.1	RP11-320H14.1	-3.83	0.000161	0.0326	-0.31	-0.23	Epilepsy;	chr4:46219799	chr4:46243548~46244215:-
COAD	cis	rs535066	0.905	rs501059	ENSG00000260878.1	RP11-320H14.1	-3.83	0.000161	0.0326	-0.31	-0.23	Epilepsy;	chr4:46219833	chr4:46243548~46244215:-
COAD	cis	rs11976180	1	rs2371244	ENSG00000273234.1	OR2A13P	-3.83	0.000161	0.0326	-0.29	-0.23	Obesity-related traits;	chr7:144060518	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs4726669	ENSG00000273234.1	OR2A13P	-3.83	0.000161	0.0326	-0.29	-0.23	Obesity-related traits;	chr7:144061098	chr7:144142009~144142938:+
COAD	cis	rs1790761	0.967	rs1476792	ENSG00000231793.4	DOC2GP	-3.83	0.000161	0.0326	-0.25	-0.23	Mean corpuscular volume;	chr11:67428766	chr11:67612653~67616257:-
COAD	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	3.83	0.000161	0.0326	0.32	0.23	Depression;	chr6:28399846	chr6:28943877~28944537:+
COAD	cis	rs5751614	0.537	rs5759679	ENSG00000207835.1	AC244250.3	3.83	0.000161	0.0326	0.19	0.23	Height;	chr22:23286826	chr22:22758696~22758790:+
COAD	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-3.83	0.000161	0.0326	-0.21	-0.23	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
COAD	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-3.83	0.000161	0.0326	-0.23	-0.23	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
COAD	cis	rs11138902	0.649	rs7871891	ENSG00000229312.2	RP11-470P21.2	3.83	0.000161	0.0326	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69527286	chr9:69472466~69494513:+
COAD	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-3.83	0.000161	0.0326	-0.28	-0.23	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
COAD	cis	rs597539	0.652	rs636049	ENSG00000255741.1	RP11-757G1.5	-3.83	0.000161	0.0326	-0.31	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68941503~68942852:-
COAD	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	3.83	0.000161	0.0326	0.29	0.23	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
COAD	cis	rs860295	0.702	rs10796946	ENSG00000160766.13	GBAP1	-3.83	0.000161	0.0326	-0.29	-0.23	Body mass index;	chr1:155459699	chr1:155213821~155227422:-
COAD	cis	rs6795735	1	rs6795735	ENSG00000224479.4	AC136289.1	3.83	0.000161	0.0326	0.28	0.23	Type 2 diabetes;Waist-hip ratio;Age-related macular degeneration;	chr3:64719689	chr3:63742293~63827445:-
COAD	cis	rs2832191	0.692	rs2245734	ENSG00000176054.6	RPL23P2	3.83	0.000161	0.0326	0.24	0.23	Dental caries;	chr21:28987644	chr21:28997613~28998033:-
COAD	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-3.83	0.000161	0.0326	-0.38	-0.23	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
COAD	cis	rs13256369	0.802	rs13280101	ENSG00000254153.1	CTA-398F10.2	3.83	0.000161	0.0326	0.31	0.23	Obesity-related traits;	chr8:8705263	chr8:8456909~8461337:-
COAD	cis	rs7204230	1	rs8053150	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0326	0.28	0.23	Fibrinogen;	chr16:53257765	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs7201867	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0326	0.28	0.23	Fibrinogen;	chr16:53259299	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12597624	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0326	0.28	0.23	Fibrinogen;	chr16:53263773	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12598372	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0326	0.28	0.23	Fibrinogen;	chr16:53265463	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs17394498	ENSG00000261056.2	RP11-454F8.2	3.83	0.000161	0.0326	0.28	0.23	Fibrinogen;	chr16:53266575	chr16:53298224~53299792:+
COAD	cis	rs7826238	0.502	rs10503377	ENSG00000254153.1	CTA-398F10.2	3.83	0.000161	0.0326	0.31	0.23	Systolic blood pressure;	chr8:8520912	chr8:8456909~8461337:-
COAD	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	3.83	0.000161	0.0326	0.29	0.23	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
COAD	cis	rs6719977	0.543	rs4953604	ENSG00000226491.1	FTOP1	-3.83	0.000161	0.0326	-0.31	-0.23	Hyperactive-impulsive symptoms;	chr2:42730399	chr2:42797225~42798712:-
COAD	cis	rs2302729	0.578	rs2302728	ENSG00000246627.5	CACNA1C-AS1	-3.83	0.000161	0.0326	-0.27	-0.23	Sleep quality;	chr12:2665502	chr12:2676001~2691200:-
COAD	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	3.83	0.000161	0.0326	0.25	0.23	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
COAD	cis	rs9652601	0.622	rs9935174	ENSG00000274038.1	RP11-66H6.4	-3.83	0.000162	0.0327	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11017490	chr16:11056556~11057034:+
COAD	cis	rs4671386	1	rs2110398	ENSG00000233953.1	AC009970.1	3.83	0.000162	0.0327	0.23	0.23	Acne (severe);	chr2:60273349	chr2:60495686~60499964:+
COAD	cis	rs7837649	0.824	rs7003295	ENSG00000253661.1	ZFHX4-AS1	3.83	0.000162	0.0327	0.21	0.23	Monobrow;	chr8:76782901	chr8:76491200~76683278:-
COAD	cis	rs11671653	1	rs11672504	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10720684	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs4334414	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10720997	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs8105939	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10721125	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs8113457	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10721549	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs58380026	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10721830	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs7256743	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10722455	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs7257661	ENSG00000267100.1	ILF3-AS1	3.83	0.000162	0.0327	0.41	0.23	LDL cholesterol;	chr19:10722456	chr19:10651862~10653844:-
COAD	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	3.83	0.000162	0.0327	0.55	0.23	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
COAD	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	3.83	0.000162	0.0327	0.28	0.23	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
COAD	cis	rs7577696	0.924	rs7605242	ENSG00000272716.1	RP11-563N4.1	-3.83	0.000162	0.0327	-0.24	-0.23	Inflammatory biomarkers;	chr2:32099066	chr2:32165046~32165757:-
COAD	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	3.83	0.000162	0.0327	0.23	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
COAD	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	3.83	0.000162	0.0327	0.31	0.23	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
COAD	cis	rs74233809	0.748	rs10786736	ENSG00000213277.3	MARCKSL1P1	3.83	0.000162	0.0327	0.43	0.23	Birth weight;	chr10:103089359	chr10:103175554~103176094:+
COAD	cis	rs7142002	0.614	rs59784377	ENSG00000272444.1	RP11-1017G21.6	-3.83	0.000162	0.0327	-0.32	-0.23	Autism;	chr14:101924844	chr14:101952416~101953063:+
COAD	cis	rs7142002	0.614	rs58553858	ENSG00000272444.1	RP11-1017G21.6	-3.83	0.000162	0.0327	-0.32	-0.23	Autism;	chr14:101924875	chr14:101952416~101953063:+
COAD	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	3.83	0.000162	0.0327	0.26	0.23	Height;	chr4:55532542	chr4:55363971~55395847:-
COAD	cis	rs875971	1	rs1167411	ENSG00000223473.2	GS1-124K5.3	-3.83	0.000162	0.0327	-0.19	-0.23	Aortic root size;	chr7:66074277	chr7:66491049~66493566:-
COAD	cis	rs718433	0.584	rs7142784	ENSG00000211778.2	TRAV4	-3.83	0.000162	0.0327	-0.19	-0.23	Intraocular pressure;	chr14:21745516	chr14:21736152~21736982:+
COAD	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	3.83	0.000162	0.0328	0.27	0.23	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	3.83	0.000162	0.0328	0.27	0.23	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
COAD	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	3.83	0.000162	0.0328	0.29	0.23	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
COAD	cis	rs3018712	0.547	rs4930237	ENSG00000184795.9	UNC93B5	-3.83	0.000162	0.0328	-0.38	-0.23	Total body bone mineral density;	chr11:68646570	chr11:67711702~67716005:-
COAD	cis	rs734999	0.545	rs10797441	ENSG00000225931.3	RP3-395M20.7	3.83	0.000162	0.0328	0.26	0.23	Ulcerative colitis;	chr1:2620221	chr1:2566410~2569888:+
COAD	cis	rs734999	0.545	rs7368072	ENSG00000225931.3	RP3-395M20.7	3.83	0.000162	0.0328	0.26	0.23	Ulcerative colitis;	chr1:2624686	chr1:2566410~2569888:+
COAD	cis	rs860295	0.702	rs12746592	ENSG00000160766.13	GBAP1	-3.83	0.000162	0.0328	-0.29	-0.23	Body mass index;	chr1:155536176	chr1:155213821~155227422:-
COAD	cis	rs860295	0.702	rs10752611	ENSG00000160766.13	GBAP1	-3.83	0.000162	0.0328	-0.29	-0.23	Body mass index;	chr1:155539316	chr1:155213821~155227422:-
COAD	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	3.83	0.000162	0.0328	0.32	0.23	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
COAD	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	3.83	0.000162	0.0328	0.32	0.23	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
COAD	cis	rs2307394	1	rs3768689	ENSG00000281469.1	RP11-567F11.1	3.83	0.000162	0.0328	0.27	0.23	Urate levels;	chr2:147912205	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs3768687	ENSG00000281469.1	RP11-567F11.1	3.83	0.000162	0.0328	0.27	0.23	Urate levels;	chr2:147914451	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs13026650	ENSG00000281469.1	RP11-567F11.1	3.83	0.000162	0.0328	0.27	0.23	Urate levels;	chr2:147916632	chr2:148044380~148044894:+
COAD	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	3.83	0.000162	0.0328	0.27	0.23	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	3.83	0.000162	0.0328	0.27	0.23	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
COAD	cis	rs9307551	0.596	rs12510204	ENSG00000250334.4	LINC00989	-3.83	0.000162	0.0328	-0.28	-0.23	Refractive error;	chr4:79551809	chr4:79492416~79576460:+
COAD	cis	rs911263	0.603	rs60593979	ENSG00000259502.1	RP11-643G16.3	-3.83	0.000162	0.0328	-0.29	-0.23	Primary biliary cholangitis;	chr14:68306581	chr14:67610986~67613864:+
COAD	cis	rs2255336	0.81	rs7956385	ENSG00000245648.1	RP11-277P12.20	3.83	0.000162	0.0328	0.44	0.23	Blood protein levels;	chr12:10361398	chr12:10363769~10398506:+
COAD	cis	rs394563	0.601	rs431978	ENSG00000231760.4	RP11-350J20.5	-3.83	0.000162	0.0328	-0.29	-0.23	Dupuytren's disease;	chr6:149471864	chr6:149796151~149826294:-
COAD	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-3.83	0.000162	0.0328	-0.23	-0.23	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
COAD	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-3.83	0.000162	0.0328	-0.35	-0.23	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
COAD	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	3.83	0.000162	0.0328	0.34	0.23	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
COAD	cis	rs76878669	0.793	rs10791867	ENSG00000254458.1	RP11-867G23.13	3.83	0.000163	0.0328	0.33	0.23	Educational attainment (years of education);	chr11:66313740	chr11:66312853~66319237:+
COAD	cis	rs9487051	1	rs9374080	ENSG00000219700.1	PTCHD3P3	-3.83	0.000163	0.0328	-0.25	-0.23	Reticulocyte fraction of red cells;	chr6:109295217	chr6:109288571~109290503:-
COAD	cis	rs875971	0.83	rs427973	ENSG00000224316.1	RP11-479O9.2	3.83	0.000163	0.0328	0.25	0.23	Aortic root size;	chr7:66061661	chr7:65773620~65802067:+
COAD	cis	rs7615952	0.736	rs11921945	ENSG00000272840.1	RP11-379B18.6	3.83	0.000163	0.0328	0.32	0.23	Blood pressure (smoking interaction);	chr3:125924876	chr3:125774714~125797953:+
COAD	cis	rs6012564	0.963	rs6063359	ENSG00000227431.4	CSE1L-AS1	3.83	0.000163	0.0328	0.26	0.23	Anger;	chr20:49128547	chr20:49040463~49046044:-
COAD	cis	rs1023500	0.505	rs134901	ENSG00000237037.8	NDUFA6-AS1	-3.83	0.000163	0.0328	-0.23	-0.23	Schizophrenia;	chr22:42287514	chr22:42090931~42137742:+
COAD	cis	rs2562784	0.638	rs2585045	ENSG00000225151.9	GOLGA2P7	-3.83	0.000163	0.0329	-0.4	-0.23	Height;	chr15:83637562	chr15:84199311~84230136:-
COAD	cis	rs12506228	0.565	rs11935103	ENSG00000279943.1	FLJ38576	-3.83	0.000163	0.0329	-0.31	-0.23	Job-related exhaustion in shift workers;	chr4:186417181	chr4:186189032~186191490:-
COAD	cis	rs224278	0.509	rs4746747	ENSG00000228566.1	RP11-170M17.1	3.83	0.000163	0.0329	0.32	0.23	Ewing sarcoma;	chr10:62940304	chr10:63664664~63990568:+
COAD	cis	rs12726943	0.517	rs2786743	ENSG00000227747.2	RP11-16L9.1	-3.83	0.000163	0.0329	-0.25	-0.23	Perceived unattractiveness to mosquitoes;	chr1:199590377	chr1:198949016~198949805:+
COAD	cis	rs11024102	1	rs11024102	ENSG00000184669.7	OR7E14P	-3.83	0.000163	0.0329	-0.35	-0.23	Glaucoma (primary angle closure);	chr11:16987058	chr11:17013998~17053024:+
COAD	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-3.83	0.000163	0.0329	-0.3	-0.23	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
COAD	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	3.83	0.000163	0.0329	0.26	0.23	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
COAD	cis	rs11239930	0.517	rs942689	ENSG00000278811.3	LINC00624	3.83	0.000163	0.0329	0.24	0.23	AIDS progression;	chr1:147079231	chr1:147258885~147517875:-
COAD	cis	rs7172689	0.909	rs58607573	ENSG00000271725.1	RP11-761I4.4	3.83	0.000163	0.0329	0.31	0.23	Inattentive symptoms;	chr15:81250330	chr15:81303215~81309391:-
COAD	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	3.83	0.000163	0.0329	0.2	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
COAD	cis	rs2243480	0.901	rs313808	ENSG00000232559.3	GS1-124K5.12	3.83	0.000163	0.0329	0.4	0.23	Diabetic kidney disease;	chr7:66034886	chr7:66554588~66576923:-
COAD	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	3.83	0.000163	0.0329	0.29	0.23	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
COAD	cis	rs17214007	0.518	rs56374730	ENSG00000260735.1	RP11-72I8.1	-3.83	0.000163	0.0329	-0.31	-0.23	Cognitive function;	chr16:15773795	chr16:15094411~15109197:+
COAD	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-3.83	0.000163	0.0329	-0.23	-0.23	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-3.83	0.000163	0.0329	-0.23	-0.23	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
COAD	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-3.83	0.000163	0.0329	-0.47	-0.23	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
COAD	cis	rs2439831	0.85	rs28524541	ENSG00000166763.7	STRCP1	-3.83	0.000163	0.0329	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43832633	chr15:43699488~43718184:-
COAD	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	3.83	0.000163	0.0329	0.27	0.23	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
COAD	cis	rs7584330	0.554	rs13392410	ENSG00000234949.2	AC104667.3	-3.83	0.000163	0.0329	-0.36	-0.23	Prostate cancer;	chr2:237521630	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.554	rs13431733	ENSG00000234949.2	AC104667.3	-3.83	0.000163	0.0329	-0.36	-0.23	Prostate cancer;	chr2:237521632	chr2:237591020~237595981:+
COAD	cis	rs2908835	0.705	rs2965701	ENSG00000247157.5	LINC01252	-3.83	0.000163	0.0329	-0.37	-0.23	Information processing speed;	chr12:11484092	chr12:11548030~11590369:+
COAD	cis	rs11098499	0.754	rs10213554	ENSG00000250412.1	KLHL2P1	-3.83	0.000163	0.0329	-0.31	-0.23	Corneal astigmatism;	chr4:119339630	chr4:119334329~119378233:+
COAD	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	3.83	0.000163	0.0329	0.24	0.23	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
COAD	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	3.83	0.000163	0.0329	0.24	0.23	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
COAD	cis	rs9307551	0.584	rs1371996	ENSG00000250334.4	LINC00989	-3.83	0.000163	0.0329	-0.27	-0.23	Refractive error;	chr4:79532718	chr4:79492416~79576460:+
COAD	cis	rs4879656	0.966	rs3780475	ENSG00000225693.1	LAGE3P1	3.83	0.000163	0.033	0.28	0.23	Menopause (age at onset);	chr9:32984393	chr9:33019682~33020165:-
COAD	cis	rs2836974	0.533	rs4817999	ENSG00000255568.3	BRWD1-AS2	-3.83	0.000163	0.033	-0.22	-0.23	Cognitive function;	chr21:39182429	chr21:39313935~39314962:+
COAD	cis	rs12983058	1	rs12983058	ENSG00000254760.1	CTD-2616J11.3	-3.83	0.000163	0.033	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr19:51139527	chr19:51414298~51414965:+
COAD	cis	rs9307551	0.619	rs1440862	ENSG00000250334.4	LINC00989	-3.83	0.000163	0.033	-0.26	-0.23	Refractive error;	chr4:79503116	chr4:79492416~79576460:+
COAD	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-3.83	0.000163	0.033	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
COAD	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	3.83	0.000163	0.033	0.34	0.23	Depression;	chr6:28167882	chr6:28115628~28116551:+
COAD	cis	rs13256369	0.755	rs12550057	ENSG00000253981.4	ALG1L13P	3.83	0.000164	0.033	0.34	0.23	Obesity-related traits;	chr8:8704758	chr8:8236003~8244667:-
COAD	cis	rs2638953	0.924	rs9669509	ENSG00000247934.4	RP11-967K21.1	-3.83	0.000164	0.033	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443507	chr12:28163298~28190738:-
COAD	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-3.83	0.000164	0.033	-0.31	-0.23	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
COAD	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	3.83	0.000164	0.033	0.47	0.23	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
COAD	cis	rs2018683	0.899	rs10479816	ENSG00000272568.4	CTB-113D17.1	3.83	0.000164	0.033	0.32	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28979967~29013367:+
COAD	cis	rs153916	0.545	rs2548124	ENSG00000251000.1	AC008592.3	3.83	0.000164	0.033	0.28	0.23	Pulmonary function;	chr5:95676271	chr5:95834424~95835046:-
COAD	cis	rs1707322	0.896	rs809774	ENSG00000230896.1	RP11-767N6.7	3.83	0.000164	0.033	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45694684~45697075:-
COAD	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-3.83	0.000164	0.033	-0.39	-0.23	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
COAD	cis	rs2976388	0.59	rs7828042	ENSG00000247317.3	RP11-273G15.2	3.83	0.000164	0.033	0.26	0.23	Urinary tract infection frequency;	chr8:142737965	chr8:142981738~143018437:-
COAD	cis	rs2976388	0.59	rs10110970	ENSG00000247317.3	RP11-273G15.2	3.83	0.000164	0.033	0.26	0.23	Urinary tract infection frequency;	chr8:142738992	chr8:142981738~143018437:-
COAD	cis	rs4352210	0.612	rs4670730	ENSG00000213594.4	GAPDHP25	-3.83	0.000164	0.033	-0.26	-0.23	RR interval (heart rate);	chr2:37558426	chr2:38285410~38286410:+
COAD	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-3.83	0.000164	0.033	-0.41	-0.23	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
COAD	cis	rs2392362	0.717	rs2392361	ENSG00000270889.1	RP11-609L3.1	3.83	0.000164	0.033	0.23	0.23	Information processing speed;	chr7:35351600	chr7:35971147~35971567:-
COAD	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	3.83	0.000164	0.033	0.35	0.23	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
COAD	cis	rs7131987	0.903	rs1991114	ENSG00000275476.1	RP11-996F15.4	-3.83	0.000164	0.033	-0.28	-0.23	QT interval;	chr12:29239149	chr12:29277397~29277882:-
COAD	cis	rs11098499	0.789	rs10212719	ENSG00000250412.1	KLHL2P1	3.83	0.000164	0.0331	0.31	0.23	Corneal astigmatism;	chr4:119333282	chr4:119334329~119378233:+
COAD	cis	rs159572	0.784	rs152313	ENSG00000251307.1	RP11-506H20.1	3.83	0.000164	0.0331	0.29	0.23	Post-traumatic stress disorder;	chr5:56232440	chr5:55233934~55295201:+
COAD	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-3.83	0.000164	0.0331	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
COAD	cis	rs6012564	1	rs11696396	ENSG00000227431.4	CSE1L-AS1	3.83	0.000164	0.0331	0.26	0.23	Anger;	chr20:49136482	chr20:49040463~49046044:-
COAD	cis	rs6012564	1	rs6066978	ENSG00000227431.4	CSE1L-AS1	3.83	0.000164	0.0331	0.26	0.23	Anger;	chr20:49139205	chr20:49040463~49046044:-
COAD	cis	rs6012564	1	rs6063361	ENSG00000227431.4	CSE1L-AS1	3.83	0.000164	0.0331	0.26	0.23	Anger;	chr20:49141426	chr20:49040463~49046044:-
COAD	cis	rs752010	0.756	rs943374	ENSG00000230638.4	RP11-486B10.4	-3.83	0.000164	0.0331	-0.25	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41590523	chr1:41542069~41544310:+
COAD	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	3.83	0.000164	0.0331	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	3.83	0.000164	0.0331	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	3.83	0.000164	0.0331	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	3.83	0.000164	0.0331	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	3.83	0.000164	0.0331	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
COAD	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	3.83	0.000164	0.0331	0.3	0.23	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
COAD	cis	rs12699921	0.632	rs1830006	ENSG00000279048.1	RP11-511H23.2	-3.83	0.000164	0.0331	-0.17	-0.23	Fibrinogen levels;	chr7:17788261	chr7:17940503~17942922:+
COAD	cis	rs6545883	0.542	rs10177225	ENSG00000273302.1	RP11-493E12.2	-3.83	0.000164	0.0331	-0.21	-0.23	Tuberculosis;	chr2:61367363	chr2:61199979~61200769:+
COAD	cis	rs860295	0.729	rs11264369	ENSG00000160766.13	GBAP1	3.83	0.000164	0.0331	0.26	0.23	Body mass index;	chr1:155390039	chr1:155213821~155227422:-
COAD	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	3.83	0.000164	0.0331	0.28	0.23	Height;	chr4:55525781	chr4:55547112~55547889:+
COAD	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-3.82	0.000164	0.0331	-0.33	-0.23	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
COAD	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	3.82	0.000164	0.0331	0.16	0.23	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
COAD	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	3.82	0.000164	0.0331	0.16	0.23	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
COAD	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	3.82	0.000164	0.0331	0.21	0.23	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
COAD	cis	rs654950	0.875	rs633297	ENSG00000230638.4	RP11-486B10.4	-3.82	0.000164	0.0331	-0.25	-0.23	Airway imaging phenotypes;	chr1:41519782	chr1:41542069~41544310:+
COAD	cis	rs4072705	1	rs6478671	ENSG00000236643.1	RP11-175D17.3	3.82	0.000164	0.0331	0.24	0.23	Menarche (age at onset);	chr9:124611716	chr9:124770123~124772927:+
COAD	cis	rs57786342	0.813	rs11847049	ENSG00000240210.3	RP11-204K16.1	-3.82	0.000164	0.0331	-0.29	-0.23	Macrophage inflammatory protein 1a levels;	chr14:68792689	chr14:68338728~68339528:-
COAD	cis	rs57786342	0.813	rs11851414	ENSG00000240210.3	RP11-204K16.1	-3.82	0.000164	0.0331	-0.29	-0.23	Macrophage inflammatory protein 1a levels;	chr14:68792785	chr14:68338728~68339528:-
COAD	cis	rs57786342	0.813	rs1051533	ENSG00000240210.3	RP11-204K16.1	-3.82	0.000164	0.0331	-0.29	-0.23	Macrophage inflammatory protein 1a levels;	chr14:68792945	chr14:68338728~68339528:-
COAD	cis	rs10876993	0.855	rs1689585	ENSG00000270039.1	RP11-571M6.17	-3.82	0.000164	0.0331	-0.26	-0.23	Celiac disease or Rheumatoid arthritis;	chr12:57686357	chr12:57803838~57804415:+
COAD	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-3.82	0.000164	0.0331	-0.26	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
COAD	cis	rs5753037	0.543	rs131284	ENSG00000279159.1	RP3-394A18.1	-3.82	0.000164	0.0331	-0.15	-0.23	Type 1 diabetes;	chr22:29761600	chr22:29978950~30028236:-
COAD	cis	rs227275	0.554	rs223485	ENSG00000248971.2	KRT8P46	-3.82	0.000164	0.0331	-0.23	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102728746~102730171:-
COAD	cis	rs1949733	0.523	rs62287455	ENSG00000205959.3	RP11-689P11.2	3.82	0.000164	0.0331	0.28	0.23	Response to antineoplastic agents;	chr4:8543267	chr4:8482270~8512610:+
COAD	cis	rs7829975	0.533	rs13274028	ENSG00000253981.4	ALG1L13P	3.82	0.000164	0.0331	0.28	0.23	Mood instability;	chr8:8871683	chr8:8236003~8244667:-
COAD	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000164	0.0331	-0.49	-0.23	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
COAD	cis	rs4879656	0.966	rs2274769	ENSG00000225693.1	LAGE3P1	-3.82	0.000164	0.0331	-0.27	-0.23	Menopause (age at onset);	chr9:33026640	chr9:33019682~33020165:-
COAD	cis	rs11089937	0.626	rs4821784	ENSG00000211638.2	IGLV8-61	-3.82	0.000164	0.0331	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22098700~22099212:+
COAD	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-3.82	0.000164	0.0331	-0.21	-0.23	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
COAD	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-3.82	0.000164	0.0331	-0.21	-0.23	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
COAD	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-3.82	0.000165	0.0331	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
COAD	cis	rs10760158	0.832	rs12238702	ENSG00000226752.6	PSMD5-AS1	-3.82	0.000165	0.0331	-0.25	-0.23	Pulse pressure;	chr9:121237547	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs10985188	ENSG00000226752.6	PSMD5-AS1	-3.82	0.000165	0.0331	-0.25	-0.23	Pulse pressure;	chr9:121237747	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs4837818	ENSG00000226752.6	PSMD5-AS1	-3.82	0.000165	0.0331	-0.25	-0.23	Pulse pressure;	chr9:121240041	chr9:120824828~120854385:+
COAD	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	3.82	0.000165	0.0331	0.17	0.23	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
COAD	cis	rs12049351	0.665	rs12036589	ENSG00000229367.1	HMGN2P19	3.82	0.000165	0.0331	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229437829	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.613	rs1887634	ENSG00000229367.1	HMGN2P19	3.82	0.000165	0.0331	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229439032	chr1:229570532~229570796:+
COAD	cis	rs860295	0.665	rs12028416	ENSG00000160766.13	GBAP1	-3.82	0.000165	0.0331	-0.29	-0.23	Body mass index;	chr1:155431370	chr1:155213821~155227422:-
COAD	cis	rs860295	0.629	rs12026638	ENSG00000160766.13	GBAP1	-3.82	0.000165	0.0331	-0.29	-0.23	Body mass index;	chr1:155431469	chr1:155213821~155227422:-
COAD	cis	rs8017304	0.643	rs911258	ENSG00000259502.1	RP11-643G16.3	-3.82	0.000165	0.0332	-0.3	-0.23	Age-related macular degeneration;	chr14:68304733	chr14:67610986~67613864:+
COAD	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-3.82	0.000165	0.0332	-0.28	-0.23	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-3.82	0.000165	0.0332	-0.28	-0.23	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-3.82	0.000165	0.0332	-0.28	-0.23	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
COAD	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-3.82	0.000165	0.0332	-0.28	-0.23	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
COAD	cis	rs9307551	0.584	rs13113835	ENSG00000250334.4	LINC00989	-3.82	0.000165	0.0332	-0.26	-0.23	Refractive error;	chr4:79522945	chr4:79492416~79576460:+
COAD	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	3.82	0.000165	0.0332	0.29	0.23	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
COAD	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	3.82	0.000165	0.0332	0.29	0.23	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
COAD	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	3.82	0.000165	0.0332	0.3	0.23	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
COAD	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000165	0.0332	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
COAD	cis	rs9291683	0.546	rs13146686	ENSG00000250413.1	RP11-448G15.1	-3.82	0.000165	0.0332	-0.31	-0.23	Bone mineral density;	chr4:10033309	chr4:10006482~10009725:+
COAD	cis	rs2255336	0.81	rs7959328	ENSG00000245648.1	RP11-277P12.20	3.82	0.000165	0.0332	0.42	0.23	Blood protein levels;	chr12:10361467	chr12:10363769~10398506:+
COAD	cis	rs2916733	0.53	rs894895	ENSG00000246089.3	RP11-115C21.2	-3.82	0.000165	0.0332	-0.29	-0.23	Epirubicin-induced leukopenia;	chr8:6438036	chr8:6403551~6407142:-
COAD	cis	rs9309473	0.519	rs7606947	ENSG00000273245.1	RP11-434P11.2	3.82	0.000165	0.0332	0.28	0.23	Metabolite levels;	chr2:73682691	chr2:73750256~73750786:-
COAD	cis	rs7204230	0.96	rs3803658	ENSG00000261056.2	RP11-454F8.2	-3.82	0.000165	0.0332	-0.28	-0.23	Fibrinogen;	chr16:53314671	chr16:53298224~53299792:+
COAD	cis	rs7212590	0.748	rs73315252	ENSG00000264049.1	MIR4737	-3.82	0.000165	0.0332	-0.33	-0.23	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59777494	chr17:60043025~60043105:-
COAD	cis	rs7212590	0.748	rs8073489	ENSG00000264049.1	MIR4737	-3.82	0.000165	0.0332	-0.33	-0.23	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784433	chr17:60043025~60043105:-
COAD	cis	rs9951150	0.537	rs4570961	ENSG00000267013.4	CTD-2171N6.1	3.82	0.000165	0.0332	0.33	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr18:55122208	chr18:55105904~55124306:-
COAD	cis	rs7955901	0.563	rs1798092	ENSG00000258053.1	CTD-2021H9.3	-3.82	0.000165	0.0332	-0.27	-0.23	Type 2 diabetes;	chr12:71140094	chr12:71047402~71118247:-
COAD	cis	rs8058578	0.943	rs3747486	ENSG00000260487.1	RP11-297C4.3	3.82	0.000165	0.0332	0.3	0.23	Multiple myeloma;	chr16:30775606	chr16:30480588~30481346:-
COAD	cis	rs9400467	0.528	rs9689727	ENSG00000230177.1	RP5-1112D6.4	-3.82	0.000165	0.0332	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs12214380	ENSG00000230177.1	RP5-1112D6.4	-3.82	0.000165	0.0332	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111277932~111278742:+
COAD	cis	rs34779708	0.966	rs2045918	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs4294520	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs34876468	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs35814343	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934535	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs4934734	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs12769575	ENSG00000271335.4	RP11-324I22.4	3.82	0.000165	0.0332	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35314552~35336401:-
COAD	cis	rs875971	0.867	rs1002053	ENSG00000230189.5	GS1-124K5.2	-3.82	0.000165	0.0332	-0.19	-0.23	Aortic root size;	chr7:66333558	chr7:66409143~66490059:-
COAD	cis	rs875971	1	rs6460292	ENSG00000230189.5	GS1-124K5.2	-3.82	0.000165	0.0332	-0.19	-0.23	Aortic root size;	chr7:66345088	chr7:66409143~66490059:-
COAD	cis	rs7674212	0.507	rs10516495	ENSG00000248971.2	KRT8P46	-3.82	0.000165	0.0332	-0.24	-0.23	Type 2 diabetes;	chr4:102978933	chr4:102728746~102730171:-
COAD	cis	rs984222	0.967	rs10802069	ENSG00000231365.4	RP11-418J17.1	-3.82	0.000165	0.0332	-0.26	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118974734	chr1:119140396~119275973:+
COAD	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	3.82	0.000165	0.0332	0.32	0.23	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
COAD	cis	rs11098499	0.754	rs938056	ENSG00000250412.1	KLHL2P1	3.82	0.000165	0.0332	0.3	0.23	Corneal astigmatism;	chr4:119316298	chr4:119334329~119378233:+
COAD	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-3.82	0.000165	0.0332	-0.32	-0.23	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
COAD	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	3.82	0.000165	0.0332	0.3	0.23	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
COAD	cis	rs12935418	0.672	rs9925780	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000165	0.0332	-0.29	-0.23	Mean corpuscular volume;	chr16:81011571	chr16:81030770~81031485:+
COAD	cis	rs12935418	0.672	rs78895138	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000165	0.0332	-0.29	-0.23	Mean corpuscular volume;	chr16:81014820	chr16:81030770~81031485:+
COAD	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	3.82	0.000165	0.0332	0.4	0.23	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
COAD	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	3.82	0.000165	0.0333	0.29	0.23	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
COAD	cis	rs68170813	0.559	rs7779062	ENSG00000241764.3	AC002467.7	3.82	0.000165	0.0333	0.32	0.23	Coronary artery disease;	chr7:107239750	chr7:107742817~107744581:-
COAD	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	3.82	0.000165	0.0333	0.46	0.23	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
COAD	cis	rs654950	0.875	rs2759248	ENSG00000230638.4	RP11-486B10.4	3.82	0.000165	0.0333	0.25	0.23	Airway imaging phenotypes;	chr1:41525124	chr1:41542069~41544310:+
COAD	cis	rs9652601	0.622	rs7194305	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000166	0.0333	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11005850	chr16:11056556~11057034:+
COAD	cis	rs10760158	0.8	rs4836847	ENSG00000226752.6	PSMD5-AS1	-3.82	0.000166	0.0333	-0.25	-0.23	Pulse pressure;	chr9:121296665	chr9:120824828~120854385:+
COAD	cis	rs1799949	1	rs8077486	ENSG00000279602.1	CTD-3014M21.1	3.82	0.000166	0.0333	0.25	0.23	Menopause (age at onset);	chr17:43060788	chr17:43360041~43361361:-
COAD	cis	rs911263	0.603	rs1956532	ENSG00000259502.1	RP11-643G16.3	-3.82	0.000166	0.0333	-0.28	-0.23	Primary biliary cholangitis;	chr14:68316557	chr14:67610986~67613864:+
COAD	cis	rs2018683	0.803	rs12700920	ENSG00000272568.4	CTB-113D17.1	3.82	0.000166	0.0333	0.32	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28979967~29013367:+
COAD	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	3.82	0.000166	0.0333	0.31	0.23	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
COAD	cis	rs9926296	0.607	rs2079672	ENSG00000260279.2	AC137932.5	-3.82	0.000166	0.0333	-0.21	-0.23	Vitiligo;	chr16:89818509	chr16:89297508~89298317:+
COAD	cis	rs13256369	0.802	rs12681925	ENSG00000253981.4	ALG1L13P	3.82	0.000166	0.0333	0.33	0.23	Obesity-related traits;	chr8:8704139	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs12680019	ENSG00000253981.4	ALG1L13P	3.82	0.000166	0.0333	0.33	0.23	Obesity-related traits;	chr8:8704188	chr8:8236003~8244667:-
COAD	cis	rs875971	0.545	rs316328	ENSG00000232546.1	RP11-458F8.1	-3.82	0.000166	0.0333	-0.22	-0.23	Aortic root size;	chr7:66143851	chr7:66848496~66858136:+
COAD	cis	rs6452524	0.935	rs7736783	ENSG00000271862.1	RP11-343L5.2	3.82	0.000166	0.0333	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83049376~83050964:-
COAD	cis	rs79349575	0.715	rs9894220	ENSG00000248278.1	SUMO2P17	3.82	0.000166	0.0333	0.25	0.23	Type 2 diabetes;	chr17:48911792	chr17:48874860~48908983:-
COAD	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	3.82	0.000166	0.0333	0.28	0.23	Height;	chr4:55479996	chr4:55547112~55547889:+
COAD	cis	rs1552244	0.872	rs35988239	ENSG00000186162.9	CIDECP	3.82	0.000166	0.0333	0.37	0.23	Alzheimer's disease;	chr3:10032461	chr3:10014238~10026365:-
COAD	cis	rs4750829	1	rs4750829	ENSG00000277218.1	RP11-500G10.5	-3.82	0.000166	0.0333	-0.41	-0.23	Obesity-related traits;	chr10:130748997	chr10:130104569~130104998:-
COAD	cis	rs62184315	0.536	rs56324258	ENSG00000253559.1	OSGEPL1-AS1	-3.82	0.000166	0.0333	-0.31	-0.23	Alcohol dependence (age at onset);	chr2:189811589	chr2:189762704~189765556:+
COAD	cis	rs2916733	0.53	rs2442514	ENSG00000246089.3	RP11-115C21.2	-3.82	0.000166	0.0333	-0.29	-0.23	Epirubicin-induced leukopenia;	chr8:6437029	chr8:6403551~6407142:-
COAD	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-3.82	0.000166	0.0334	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
COAD	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-3.82	0.000166	0.0334	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
COAD	cis	rs7000734	0.958	rs7845016	ENSG00000245080.5	RP11-320N21.1	-3.82	0.000166	0.0334	-0.36	-0.23	Radiation response;	chr8:95108031	chr8:95066808~95073182:-
COAD	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000166	0.0334	-0.37	-0.23	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
COAD	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-3.82	0.000166	0.0334	-0.28	-0.23	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
COAD	cis	rs2554380	0.55	rs62025831	ENSG00000176700.18	SCAND2P	3.82	0.000166	0.0334	0.23	0.23	Height;	chr15:83876933	chr15:84631451~84647478:+
COAD	cis	rs2564921	0.73	rs56386026	ENSG00000280417.1	RP11-5O17.1	3.82	0.000166	0.0334	0.25	0.23	Height;	chr3:53080524	chr3:53046166~53048122:+
COAD	cis	rs911555	0.713	rs2765051	ENSG00000251533.2	LINC00605	3.82	0.000166	0.0334	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103506042	chr14:103187221~103189028:-
COAD	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-3.82	0.000166	0.0334	-0.24	-0.23	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
COAD	cis	rs10091038	0.966	rs12716547	ENSG00000253708.1	RP11-51J9.4	-3.82	0.000166	0.0334	-0.26	-0.23	Response to statin therapy;	chr8:29514246	chr8:30176554~30180888:-
COAD	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	3.82	0.000166	0.0334	0.31	0.23	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
COAD	cis	rs11671653	1	rs74562182	ENSG00000267100.1	ILF3-AS1	3.82	0.000166	0.0334	0.39	0.23	LDL cholesterol;	chr19:10724936	chr19:10651862~10653844:-
COAD	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000166	0.0334	-0.26	-0.23	Gout;	chr7:66645053	chr7:66902857~66906297:+
COAD	cis	rs1115240	0.588	rs8008779	ENSG00000257842.4	NOVA1-AS1	3.82	0.000166	0.0334	0.29	0.23	Educational attainment (years of education);	chr14:26620276	chr14:26598412~26806467:+
COAD	cis	rs911555	0.723	rs12894652	ENSG00000251533.2	LINC00605	3.82	0.000166	0.0334	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103187221~103189028:-
COAD	cis	rs7560272	0.501	rs7210	ENSG00000273245.1	RP11-434P11.2	-3.82	0.000166	0.0334	-0.28	-0.23	Schizophrenia;	chr2:73729997	chr2:73750256~73750786:-
COAD	cis	rs41271951	0.512	rs6664387	ENSG00000223945.2	RP11-458I7.1	-3.82	0.000166	0.0334	-0.48	-0.23	Blood protein levels;	chr1:151049033	chr1:150053864~150055034:+
COAD	cis	rs1707322	1	rs785498	ENSG00000230896.1	RP11-767N6.7	3.82	0.000167	0.0334	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45694684~45697075:-
COAD	cis	rs9532669	0.963	rs9532662	ENSG00000239827.7	SUGT1P3	-3.82	0.000167	0.0334	-0.19	-0.23	Cervical cancer;	chr13:40926215	chr13:40908159~40921774:-
COAD	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0334	0.32	0.23	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
COAD	cis	rs293748	0.771	rs35135658	ENSG00000250155.1	CTD-2353F22.1	-3.82	0.000167	0.0334	-0.33	-0.23	Obesity-related traits;	chr5:36786777	chr5:36666214~36725195:-
COAD	cis	rs2378497	0.877	rs12126368	ENSG00000232679.1	RP11-400N13.3	3.82	0.000167	0.0334	0.32	0.23	Serum thyroid-stimulating hormone levels;	chr1:222001793	chr1:222041705~222064763:-
COAD	cis	rs12428035	0.772	rs7318892	ENSG00000247400.3	DNAJC3-AS1	-3.82	0.000167	0.0335	-0.25	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95669669	chr13:95648733~95676925:-
COAD	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-3.82	0.000167	0.0335	-0.3	-0.23	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
COAD	cis	rs11098499	0.619	rs28502463	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.3	0.23	Corneal astigmatism;	chr4:119335868	chr4:119334329~119378233:+
COAD	cis	rs2638953	0.962	rs10843158	ENSG00000247934.4	RP11-967K21.1	3.82	0.000167	0.0335	0.24	0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28163298~28190738:-
COAD	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	3.82	0.000167	0.0335	0.37	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
COAD	cis	rs13256369	0.851	rs13267036	ENSG00000253981.4	ALG1L13P	3.82	0.000167	0.0335	0.34	0.23	Obesity-related traits;	chr8:8709175	chr8:8236003~8244667:-
COAD	cis	rs9532669	0.963	rs9315794	ENSG00000277662.1	RP11-74J13.9	-3.82	0.000167	0.0335	-0.22	-0.23	Cervical cancer;	chr13:40939489	chr13:41229180~41229676:-
COAD	cis	rs654950	0.934	rs654220	ENSG00000230638.4	RP11-486B10.4	3.82	0.000167	0.0335	0.27	0.23	Airway imaging phenotypes;	chr1:41536885	chr1:41542069~41544310:+
COAD	cis	rs2836974	0.568	rs4816620	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000167	0.0335	-0.21	-0.23	Cognitive function;	chr21:39241860	chr21:39313935~39314962:+
COAD	cis	rs1499614	0.803	rs1796229	ENSG00000232559.3	GS1-124K5.12	3.82	0.000167	0.0335	0.4	0.23	Gout;	chr7:66654674	chr7:66554588~66576923:-
COAD	cis	rs1499614	0.901	rs3936	ENSG00000232559.3	GS1-124K5.12	3.82	0.000167	0.0335	0.4	0.23	Gout;	chr7:66661502	chr7:66554588~66576923:-
COAD	cis	rs7794273	0.788	rs6948023	ENSG00000279048.1	RP11-511H23.2	-3.82	0.000167	0.0335	-0.18	-0.23	Night sleep phenotypes;	chr7:18801666	chr7:17940503~17942922:+
COAD	cis	rs2554380	0.628	rs7179507	ENSG00000176700.18	SCAND2P	-3.82	0.000167	0.0335	-0.21	-0.23	Height;	chr15:83804779	chr15:84631451~84647478:+
COAD	cis	rs34286592	1	rs62056375	ENSG00000214725.6	CDIPT-AS1	-3.82	0.000167	0.0335	-0.41	-0.23	Multiple sclerosis;	chr16:29846580	chr16:29863593~29868053:+
COAD	cis	rs6095360	1	rs3092427	ENSG00000222365.1	SNORD12B	-3.82	0.000167	0.0335	-0.22	-0.23	Intelligence (multi-trait analysis);	chr20:49158244	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.933	rs348267	ENSG00000222365.1	SNORD12B	-3.82	0.000167	0.0335	-0.22	-0.23	Intelligence (multi-trait analysis);	chr20:49159384	chr20:49280319~49280409:+
COAD	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.32	0.23	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
COAD	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	3.82	0.000167	0.0335	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
COAD	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000167	0.0335	-0.42	-0.23	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
COAD	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-3.82	0.000167	0.0335	-0.33	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
COAD	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	3.82	0.000167	0.0335	0.28	0.23	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
COAD	cis	rs860295	0.65	rs11264422	ENSG00000223503.1	RP11-29H23.6	3.82	0.000167	0.0335	0.3	0.23	Body mass index;	chr1:155938032	chr1:155590601~155591262:-
COAD	cis	rs9880211	0.613	rs12330335	ENSG00000239213.4	NCK1-AS1	3.82	0.000167	0.0335	0.31	0.23	Height;Body mass index;	chr3:136134690	chr3:136841726~136862054:-
COAD	cis	rs2439831	0.85	rs28564774	ENSG00000166763.7	STRCP1	-3.82	0.000167	0.0335	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs28513374	ENSG00000166763.7	STRCP1	-3.82	0.000167	0.0335	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs7169322	ENSG00000166763.7	STRCP1	-3.82	0.000167	0.0335	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43699488~43718184:-
COAD	cis	rs2439831	0.85	rs28707214	ENSG00000166763.7	STRCP1	-3.82	0.000167	0.0335	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43699488~43718184:-
COAD	cis	rs719150	1	rs5029928	ENSG00000237499.5	RP11-356I2.4	-3.82	0.000167	0.0335	-0.33	-0.23	Cancer;	chr6:137868805	chr6:137823673~137868233:-
COAD	cis	rs719150	1	rs3757173	ENSG00000237499.5	RP11-356I2.4	-3.82	0.000167	0.0335	-0.33	-0.23	Cancer;	chr6:137869017	chr6:137823673~137868233:-
COAD	cis	rs719150	1	rs719150	ENSG00000237499.5	RP11-356I2.4	-3.82	0.000167	0.0335	-0.33	-0.23	Cancer;	chr6:137871624	chr6:137823673~137868233:-
COAD	cis	rs6724465	0.759	rs56068521	ENSG00000237281.1	CATIP-AS2	-3.82	0.000167	0.0335	-0.44	-0.23	Height;	chr2:219030866	chr2:218326889~218357966:-
COAD	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	3.82	0.000167	0.0335	0.4	0.23	Gout;	chr7:66732812	chr7:66025126~66031544:-
COAD	cis	rs73222236	0.825	rs9872326	ENSG00000273486.1	RP11-731C17.2	3.82	0.000167	0.0335	0.24	0.23	Coronary artery disease;	chr3:136267702	chr3:136837338~136839021:-
COAD	cis	rs11098499	0.754	rs2036860	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.3	0.23	Corneal astigmatism;	chr4:119327779	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs2036857	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.3	0.23	Corneal astigmatism;	chr4:119328085	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs2036856	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.3	0.23	Corneal astigmatism;	chr4:119328133	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs4443261	ENSG00000250412.1	KLHL2P1	3.82	0.000167	0.0335	0.3	0.23	Corneal astigmatism;	chr4:119328146	chr4:119334329~119378233:+
COAD	cis	rs891378	0.92	rs10864156	ENSG00000274245.1	RP11-357P18.2	-3.82	0.000167	0.0335	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207240416	chr1:207372559~207373252:+
COAD	cis	rs891378	1	rs6664815	ENSG00000274245.1	RP11-357P18.2	-3.82	0.000167	0.0335	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207242218	chr1:207372559~207373252:+
COAD	cis	rs7903146	0.651	rs55853916	ENSG00000227560.1	RP11-139K1.2	-3.82	0.000167	0.0336	-0.29	-0.23	Hip circumference;Clinical laboratory measurements;BMI in non-smokers;Fasting blood insulin (BMI interaction);BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Fasting blood glucose (BMI interaction);Glycated hemoglobin levels;Type 2 diabetes;Waist circumference;Proinsulin levels;Body mass index (joint analysis main effects and smoking interaction);Metabolic syndrome;Peak insulin response;Fasting blood glucose;Body mass index;Fasting blood insulin;Type 2 diabetes and other traits;	chr10:113022191	chr10:112987476~112987865:+
COAD	cis	rs7615952	0.866	rs13063119	ENSG00000241278.1	ENPP7P4	3.82	0.000167	0.0336	0.27	0.23	Blood pressure (smoking interaction);	chr3:125925004	chr3:125848223~125909372:+
COAD	cis	rs13256369	0.802	rs1060107	ENSG00000254153.1	CTA-398F10.2	3.82	0.000167	0.0336	0.31	0.23	Obesity-related traits;	chr8:8703889	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs4840350	ENSG00000254153.1	CTA-398F10.2	3.82	0.000167	0.0336	0.31	0.23	Obesity-related traits;	chr8:8703932	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs1060106	ENSG00000254153.1	CTA-398F10.2	3.82	0.000167	0.0336	0.31	0.23	Obesity-related traits;	chr8:8703942	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs11249883	ENSG00000254153.1	CTA-398F10.2	3.82	0.000167	0.0336	0.31	0.23	Obesity-related traits;	chr8:8704027	chr8:8456909~8461337:-
COAD	cis	rs4660214	0.666	rs587404	ENSG00000182109.6	RP11-69E11.4	3.82	0.000167	0.0336	0.24	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39522280~39546187:-
COAD	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-3.82	0.000167	0.0336	-0.31	-0.23	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
COAD	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-3.82	0.000167	0.0336	-0.29	-0.23	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
COAD	cis	rs2688608	0.617	rs6480709	ENSG00000271816.1	BMS1P4	3.82	0.000167	0.0336	0.22	0.23	Inflammatory bowel disease;	chr10:73719367	chr10:73699151~73730487:-
COAD	cis	rs757278	0.513	rs214164	ENSG00000237974.1	AC000111.4	3.82	0.000167	0.0336	0.25	0.23	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117652642	chr7:117487737~117487929:+
COAD	cis	rs10471753	0.742	rs56049648	ENSG00000248359.1	CTC-537E7.2	-3.82	0.000167	0.0336	-0.21	-0.23	Hip minimal joint space width;	chr5:68492319	chr5:68531690~68533530:-
COAD	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	3.82	0.000168	0.0336	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
COAD	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	3.82	0.000168	0.0336	0.33	0.23	Pain;	chr19:21283020	chr19:21554640~21569237:-
COAD	cis	rs10876993	0.821	rs1629032	ENSG00000270039.1	RP11-571M6.17	3.82	0.000168	0.0336	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57644903	chr12:57803838~57804415:+
COAD	cis	rs9307551	0.584	rs12510243	ENSG00000250334.4	LINC00989	-3.82	0.000168	0.0336	-0.27	-0.23	Refractive error;	chr4:79551905	chr4:79492416~79576460:+
COAD	cis	rs875971	0.965	rs10267430	ENSG00000223473.2	GS1-124K5.3	-3.82	0.000168	0.0336	-0.19	-0.23	Aortic root size;	chr7:66278036	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs10257427	ENSG00000223473.2	GS1-124K5.3	-3.82	0.000168	0.0336	-0.19	-0.23	Aortic root size;	chr7:66278221	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs10215948	ENSG00000223473.2	GS1-124K5.3	-3.82	0.000168	0.0336	-0.19	-0.23	Aortic root size;	chr7:66282799	chr7:66491049~66493566:-
COAD	cis	rs2835692	0.685	rs73220553	ENSG00000272948.2	AP001412.1	3.82	0.000168	0.0336	0.36	0.23	Gut microbiota (beta diversity);	chr21:37287396	chr21:37267784~37268497:+
COAD	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	3.82	0.000168	0.0336	0.31	0.23	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
COAD	cis	rs3738443	0.678	rs6680707	ENSG00000259865.1	RP11-488L18.10	3.82	0.000168	0.0336	0.23	0.23	Alcohol dependence;	chr1:247213648	chr1:247187281~247188526:-
COAD	cis	rs7577696	0.962	rs7575139	ENSG00000272716.1	RP11-563N4.1	-3.82	0.000168	0.0336	-0.24	-0.23	Inflammatory biomarkers;	chr2:32066265	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs6758024	ENSG00000272716.1	RP11-563N4.1	-3.82	0.000168	0.0336	-0.24	-0.23	Inflammatory biomarkers;	chr2:32069417	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs10490360	ENSG00000272716.1	RP11-563N4.1	-3.82	0.000168	0.0336	-0.24	-0.23	Inflammatory biomarkers;	chr2:32071199	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.853	rs56740303	ENSG00000272716.1	RP11-563N4.1	-3.82	0.000168	0.0336	-0.24	-0.23	Inflammatory biomarkers;	chr2:32079587	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs36014814	ENSG00000272716.1	RP11-563N4.1	-3.82	0.000168	0.0336	-0.24	-0.23	Inflammatory biomarkers;	chr2:32079890	chr2:32165046~32165757:-
COAD	cis	rs7129556	0.775	rs11237263	ENSG00000254691.1	RP11-91P24.5	3.82	0.000168	0.0336	0.27	0.23	Weight loss (gastric bypass surgery);	chr11:77667760	chr11:77850604~77851511:+
COAD	cis	rs74233809	0.901	rs17878846	ENSG00000213277.3	MARCKSL1P1	3.82	0.000168	0.0336	0.45	0.23	Birth weight;	chr10:102870655	chr10:103175554~103176094:+
COAD	cis	rs7487075	1	rs7487075	ENSG00000274723.1	RP11-618L22.1	3.82	0.000168	0.0337	0.24	0.23	Itch intensity from mosquito bite;	chr12:46435135	chr12:46970504~46972155:+
COAD	cis	rs1023500	0.573	rs1807494	ENSG00000227370.1	RP4-669P10.19	3.82	0.000168	0.0337	0.23	0.23	Schizophrenia;	chr22:42078134	chr22:42132543~42132998:+
COAD	cis	rs1023500	0.573	rs8135801	ENSG00000227370.1	RP4-669P10.19	3.82	0.000168	0.0337	0.23	0.23	Schizophrenia;	chr22:42079564	chr22:42132543~42132998:+
COAD	cis	rs12049351	0.665	rs6665874	ENSG00000229367.1	HMGN2P19	3.82	0.000168	0.0337	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229453264	chr1:229570532~229570796:+
COAD	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000168	0.0337	-0.31	-0.23	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
COAD	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000168	0.0337	-0.31	-0.23	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
COAD	cis	rs5753037	0.702	rs140101	ENSG00000279159.1	RP3-394A18.1	-3.82	0.000168	0.0337	-0.16	-0.23	Type 1 diabetes;	chr22:29732391	chr22:29978950~30028236:-
COAD	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-3.82	0.000168	0.0337	-0.3	-0.23	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-3.82	0.000168	0.0337	-0.3	-0.23	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
COAD	cis	rs4253772	0.638	rs6007845	ENSG00000280424.1	CITF22-92A6.2	-3.82	0.000168	0.0337	-0.35	-0.23	Cholesterol, total;LDL cholesterol;	chr22:46322520	chr22:46006616~46010777:+
COAD	cis	rs4648045	0.765	rs4699031	ENSG00000246560.2	RP11-10L12.4	3.82	0.000168	0.0337	0.31	0.23	Lymphocyte percentage of white cells;	chr4:102605271	chr4:102828055~102844075:+
COAD	cis	rs4648045	0.796	rs3755867	ENSG00000246560.2	RP11-10L12.4	3.82	0.000168	0.0337	0.31	0.23	Lymphocyte percentage of white cells;	chr4:102605517	chr4:102828055~102844075:+
COAD	cis	rs911555	0.755	rs4906329	ENSG00000251533.2	LINC00605	3.82	0.000168	0.0337	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103187221~103189028:-
COAD	cis	rs2115630	1	rs6496452	ENSG00000259244.1	RP11-182J1.12	-3.82	0.000168	0.0337	-0.22	-0.23	P wave terminal force;	chr15:84829414	chr15:84513241~84526949:-
COAD	cis	rs113835537	0.529	rs11227495	ENSG00000258297.1	RP11-658F2.8	-3.82	0.000168	0.0337	-0.23	-0.23	Airway imaging phenotypes;	chr11:66495772	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.559	rs11227498	ENSG00000258297.1	RP11-658F2.8	-3.82	0.000168	0.0337	-0.23	-0.23	Airway imaging phenotypes;	chr11:66502243	chr11:66666036~66668374:+
COAD	cis	rs4683346	1	rs17030478	ENSG00000273328.4	RP11-141M3.6	-3.82	0.000168	0.0337	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42851994	chr3:42809414~42908105:+
COAD	cis	rs4683346	0.963	rs10865924	ENSG00000273328.4	RP11-141M3.6	-3.82	0.000168	0.0337	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42852935	chr3:42809414~42908105:+
COAD	cis	rs4683346	1	rs11129980	ENSG00000273328.4	RP11-141M3.6	-3.82	0.000168	0.0337	-0.3	-0.23	Granulocyte percentage of myeloid white cells;	chr3:42854490	chr3:42809414~42908105:+
COAD	cis	rs7577696	0.853	rs212699	ENSG00000272716.1	RP11-563N4.1	3.82	0.000168	0.0337	0.24	0.23	Inflammatory biomarkers;	chr2:32218450	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.853	rs212701	ENSG00000272716.1	RP11-563N4.1	3.82	0.000168	0.0337	0.24	0.23	Inflammatory biomarkers;	chr2:32218985	chr2:32165046~32165757:-
COAD	cis	rs453301	0.658	rs6986044	ENSG00000233609.3	RP11-62H7.2	-3.82	0.000169	0.0337	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9017276	chr8:8961200~8979025:+
COAD	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	3.82	0.000169	0.0338	0.36	0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
COAD	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-3.82	0.000169	0.0338	-0.32	-0.23	Pain;	chr19:21499260	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-3.82	0.000169	0.0338	-0.32	-0.23	Pain;	chr19:21505137	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-3.82	0.000169	0.0338	-0.32	-0.23	Pain;	chr19:21505800	chr19:21554640~21569237:-
COAD	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	3.82	0.000169	0.0338	0.29	0.23	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
COAD	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0338	-0.26	-0.23	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0338	-0.26	-0.23	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0338	-0.26	-0.23	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0338	-0.26	-0.23	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
COAD	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0338	-0.26	-0.23	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
COAD	cis	rs7826238	0.564	rs2921053	ENSG00000233609.3	RP11-62H7.2	3.82	0.000169	0.0338	0.25	0.23	Systolic blood pressure;	chr8:8462453	chr8:8961200~8979025:+
COAD	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	3.82	0.000169	0.0338	0.28	0.23	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
COAD	cis	rs9595973	0.571	rs56959802	ENSG00000229111.1	MED4-AS1	-3.82	0.000169	0.0338	-0.5	-0.23	Systemic juvenile idiopathic arthritis;	chr13:48716055	chr13:48077137~48079991:+
COAD	cis	rs9595973	0.677	rs57042574	ENSG00000229111.1	MED4-AS1	-3.82	0.000169	0.0338	-0.5	-0.23	Systemic juvenile idiopathic arthritis;	chr13:48716125	chr13:48077137~48079991:+
COAD	cis	rs2681472	0.524	rs7314459	ENSG00000258302.2	RP11-981P6.1	3.82	0.000169	0.0338	0.31	0.23	Hypertension;Coronary artery disease;Myocardial infarction;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Systolic blood pressure;Diastolic blood pressure;	chr12:89562564	chr12:89561129~89594878:+
COAD	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000169	0.0338	-0.3	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
COAD	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	3.82	0.000169	0.0338	0.27	0.23	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
COAD	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	3.82	0.000169	0.0338	0.27	0.23	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
COAD	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-3.82	0.000169	0.0338	-0.24	-0.23	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
COAD	cis	rs8058578	1	rs8058578	ENSG00000260487.1	RP11-297C4.3	3.82	0.000169	0.0338	0.3	0.23	Multiple myeloma;	chr16:30714927	chr16:30480588~30481346:-
COAD	cis	rs12188164	1	rs56104584	ENSG00000221990.4	EXOC3-AS1	3.82	0.000169	0.0338	0.24	0.23	Cystic fibrosis severity;	chr5:437427	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs55842567	ENSG00000221990.4	EXOC3-AS1	3.82	0.000169	0.0338	0.24	0.23	Cystic fibrosis severity;	chr5:437471	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs56042615	ENSG00000221990.4	EXOC3-AS1	3.82	0.000169	0.0338	0.24	0.23	Cystic fibrosis severity;	chr5:437552	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs34847072	ENSG00000221990.4	EXOC3-AS1	3.82	0.000169	0.0338	0.24	0.23	Cystic fibrosis severity;	chr5:437747	chr5:441498~443160:-
COAD	cis	rs73198271	0.74	rs11781430	ENSG00000173295.6	FAM86B3P	-3.82	0.000169	0.0338	-0.31	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8228595~8244865:+
COAD	cis	rs2554380	0.628	rs12914377	ENSG00000176700.18	SCAND2P	-3.82	0.000169	0.0338	-0.21	-0.23	Height;	chr15:83791941	chr15:84631451~84647478:+
COAD	cis	rs3781264	0.557	rs7092226	ENSG00000273450.1	RP11-76P2.4	3.82	0.000169	0.0338	0.28	0.23	Esophageal cancer and gastric cancer;	chr10:94352476	chr10:94314907~94315327:-
COAD	cis	rs1552244	0.832	rs67145301	ENSG00000186162.9	CIDECP	3.82	0.000169	0.0338	0.39	0.23	Alzheimer's disease;	chr3:10155630	chr3:10014238~10026365:-
COAD	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-3.82	0.000169	0.0338	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
COAD	cis	rs1480597	1	rs76375240	ENSG00000165511.6	C10orf25	3.82	0.000169	0.0338	0.4	0.23	Parkinson's disease;	chr10:44672922	chr10:44997698~45000888:-
COAD	cis	rs3748656	0.945	rs56135413	ENSG00000231246.1	RP5-965F6.2	-3.82	0.000169	0.0338	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112550284	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs10857964	ENSG00000231246.1	RP5-965F6.2	-3.82	0.000169	0.0338	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112555011	chr1:112177234~112360528:-
COAD	cis	rs1707322	0.752	rs6662164	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000169	0.0338	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45694684~45697075:-
COAD	cis	rs13256369	0.755	rs12680167	ENSG00000254153.1	CTA-398F10.2	3.82	0.000169	0.0338	0.31	0.23	Obesity-related traits;	chr8:8704957	chr8:8456909~8461337:-
COAD	cis	rs2836974	0.666	rs2836975	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000169	0.0338	-0.21	-0.23	Cognitive function;	chr21:39291694	chr21:39313935~39314962:+
COAD	cis	rs10752881	1	rs4233192	ENSG00000224468.3	RP11-181K3.4	3.82	0.000169	0.0338	0.23	0.23	Colorectal cancer;	chr1:183001702	chr1:183138402~183141282:-
COAD	cis	rs9880211	0.613	rs13081671	ENSG00000239213.4	NCK1-AS1	3.82	0.000169	0.0338	0.3	0.23	Height;Body mass index;	chr3:136157707	chr3:136841726~136862054:-
COAD	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	3.82	0.000169	0.0338	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
COAD	cis	rs12530	0.715	rs5998475	ENSG00000241954.1	RP1-149A16.17	-3.82	0.000169	0.0338	-0.3	-0.23	IgG glycosylation;	chr22:32405345	chr22:32383786~32385631:+
COAD	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-3.82	0.000169	0.0338	-0.26	-0.23	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
COAD	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-3.82	0.000169	0.0338	-0.26	-0.23	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
COAD	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	3.82	0.000169	0.0339	0.3	0.23	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	3.82	0.000169	0.0339	0.3	0.23	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	3.82	0.000169	0.0339	0.3	0.23	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
COAD	cis	rs1298062	0.605	rs10409679	ENSG00000269352.1	PTOV1-AS2	3.82	0.000169	0.0339	0.15	0.23	Age of smoking initiation;	chr19:50480673	chr19:49856970~49859289:-
COAD	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-3.82	0.000169	0.0339	-0.34	-0.23	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
COAD	cis	rs2842346	0.568	rs2525523	ENSG00000259038.1	CTD-2325P2.4	3.82	0.000169	0.0339	0.35	0.23	Breast cancer;	chr14:68540196	chr14:68627166~68628445:-
COAD	cis	rs2842346	0.568	rs2525524	ENSG00000259038.1	CTD-2325P2.4	3.82	0.000169	0.0339	0.35	0.23	Breast cancer;	chr14:68540205	chr14:68627166~68628445:-
COAD	cis	rs1005224	0.5	rs8003637	ENSG00000258454.1	RP11-361H10.3	3.82	0.000169	0.0339	0.33	0.23	Large artery stroke;	chr14:75721914	chr14:76235817~76263474:+
COAD	cis	rs4253772	0.513	rs6008612	ENSG00000280424.1	CITF22-92A6.2	3.82	0.000169	0.0339	0.33	0.23	Cholesterol, total;LDL cholesterol;	chr22:46312010	chr22:46006616~46010777:+
COAD	cis	rs7141336	0.607	rs1885030	ENSG00000258424.1	RP11-471B22.2	-3.82	0.000169	0.0339	-0.2	-0.23	Anxiety disorder;	chr14:90751788	chr14:90402523~90405235:-
COAD	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-3.82	0.000169	0.0339	-0.27	-0.23	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
COAD	cis	rs2832191	0.716	rs2297252	ENSG00000176054.6	RPL23P2	3.82	0.000169	0.0339	0.24	0.23	Dental caries;	chr21:29004783	chr21:28997613~28998033:-
COAD	cis	rs2832191	0.716	rs1984012	ENSG00000176054.6	RPL23P2	3.82	0.000169	0.0339	0.24	0.23	Dental caries;	chr21:29020151	chr21:28997613~28998033:-
COAD	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-3.82	0.000169	0.0339	-0.33	-0.23	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
COAD	cis	rs9787249	0.915	rs58589165	ENSG00000237624.1	OXCT2P1	-3.82	0.000169	0.0339	-0.3	-0.23	Blood protein levels;	chr1:39747998	chr1:39514956~39516490:+
COAD	cis	rs9787249	0.957	rs56064244	ENSG00000237624.1	OXCT2P1	-3.82	0.000169	0.0339	-0.3	-0.23	Blood protein levels;	chr1:39748218	chr1:39514956~39516490:+
COAD	cis	rs9787249	0.874	rs7520588	ENSG00000237624.1	OXCT2P1	-3.82	0.000169	0.0339	-0.3	-0.23	Blood protein levels;	chr1:39748853	chr1:39514956~39516490:+
COAD	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-3.82	0.000169	0.0339	-0.32	-0.23	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
COAD	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-3.82	0.000169	0.0339	-0.33	-0.23	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
COAD	cis	rs4253772	0.591	rs6008546	ENSG00000280424.1	CITF22-92A6.2	3.82	0.000169	0.0339	0.34	0.23	Cholesterol, total;LDL cholesterol;	chr22:46290480	chr22:46006616~46010777:+
COAD	cis	rs12699921	0.632	rs2691600	ENSG00000279048.1	RP11-511H23.2	-3.82	0.000169	0.0339	-0.17	-0.23	Fibrinogen levels;	chr7:17833542	chr7:17940503~17942922:+
COAD	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-3.82	0.000169	0.0339	-0.27	-0.23	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
COAD	cis	rs11157436	0.581	rs17255433	ENSG00000211812.1	TRAV26-2	-3.82	0.00017	0.0339	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22202583~22203368:+
COAD	cis	rs11157436	0.602	rs17255440	ENSG00000211812.1	TRAV26-2	-3.82	0.00017	0.0339	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22202583~22203368:+
COAD	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	3.82	0.00017	0.0339	0.27	0.23	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
COAD	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	3.82	0.00017	0.0339	0.31	0.23	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
COAD	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-3.82	0.00017	0.0339	-0.25	-0.23	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
COAD	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-3.82	0.00017	0.0339	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
COAD	cis	rs11158609	1	rs2748531	ENSG00000258727.1	RP11-66N24.3	-3.82	0.00017	0.0339	-0.25	-0.23	Systolic blood pressure (cigarette smoking interaction);	chr14:24252695	chr14:23561097~23568073:+
COAD	cis	rs2644899	0.793	rs2644916	ENSG00000233622.1	CYP2T1P	-3.82	0.00017	0.0339	-0.27	-0.23	Post bronchodilator FEV1/FVC ratio;	chr19:40803306	chr19:40808525~40811390:-
COAD	cis	rs61160187	0.788	rs12519587	ENSG00000215032.2	GNL3LP1	3.82	0.00017	0.0339	0.31	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:60891935~60893577:-
COAD	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	3.82	0.00017	0.0339	0.13	0.23	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
COAD	cis	rs6496932	0.503	rs7170370	ENSG00000259630.2	CTD-2262B20.1	-3.82	0.00017	0.034	-0.3	-0.23	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85415228~85415633:+
COAD	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	3.82	0.00017	0.034	0.27	0.23	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
COAD	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-3.82	0.00017	0.034	-0.31	-0.23	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
COAD	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-3.82	0.00017	0.034	-0.31	-0.23	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
COAD	cis	rs4974559	1	rs1882099	ENSG00000253399.1	AC078852.2	3.82	0.00017	0.034	0.29	0.23	Systolic blood pressure;	chr4:1358897	chr4:1358479~1359461:+
COAD	cis	rs1115240	0.574	rs61986558	ENSG00000257842.4	NOVA1-AS1	3.82	0.00017	0.034	0.3	0.23	Educational attainment (years of education);	chr14:26577794	chr14:26598412~26806467:+
COAD	cis	rs57221529	0.709	rs72706611	ENSG00000250385.1	RP11-310P5.2	3.82	0.00017	0.034	0.4	0.23	Lung disease severity in cystic fibrosis;	chr5:561031	chr5:524705~526594:+
COAD	cis	rs57221529	0.709	rs72706612	ENSG00000250385.1	RP11-310P5.2	3.82	0.00017	0.034	0.4	0.23	Lung disease severity in cystic fibrosis;	chr5:561083	chr5:524705~526594:+
COAD	cis	rs911555	0.755	rs2756132	ENSG00000251533.2	LINC00605	3.82	0.00017	0.034	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103187221~103189028:-
COAD	cis	rs801193	0.839	rs12534943	ENSG00000273142.1	RP11-458F8.4	3.82	0.00017	0.034	0.17	0.23	Aortic root size;	chr7:66605533	chr7:66902857~66906297:+
COAD	cis	rs875971	0.895	rs3857684	ENSG00000223473.2	GS1-124K5.3	3.82	0.00017	0.034	0.19	0.23	Aortic root size;	chr7:66473171	chr7:66491049~66493566:-
COAD	cis	rs801193	0.805	rs12532355	ENSG00000273142.1	RP11-458F8.4	3.82	0.00017	0.034	0.17	0.23	Aortic root size;	chr7:66605597	chr7:66902857~66906297:+
COAD	cis	rs875971	0.508	rs10950045	ENSG00000273142.1	RP11-458F8.4	3.82	0.00017	0.034	0.17	0.23	Aortic root size;	chr7:66601386	chr7:66902857~66906297:+
COAD	cis	rs801193	0.839	rs6968619	ENSG00000273142.1	RP11-458F8.4	3.82	0.00017	0.034	0.17	0.23	Aortic root size;	chr7:66603880	chr7:66902857~66906297:+
COAD	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	3.82	0.00017	0.034	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
COAD	cis	rs60668206	0.592	rs10224601	ENSG00000223705.8	NSUN5P1	-3.82	0.00017	0.034	-0.17	-0.23	Neuroticism;	chr7:74499400	chr7:75410322~75416787:+
COAD	cis	rs2832191	0.679	rs2705659	ENSG00000176054.6	RPL23P2	3.82	0.00017	0.034	0.24	0.23	Dental caries;	chr21:28991587	chr21:28997613~28998033:-
COAD	cis	rs7615952	0.605	rs34865555	ENSG00000171084.14	FAM86JP	3.82	0.00017	0.034	0.47	0.23	Blood pressure (smoking interaction);	chr3:125585290	chr3:125916620~125930024:+
COAD	cis	rs34792	0.688	rs153782	ENSG00000258354.1	MIR3180-1	3.82	0.00017	0.034	0.27	0.23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14909887~14911345:-
COAD	cis	rs7584330	0.554	rs13390883	ENSG00000234949.2	AC104667.3	-3.82	0.00017	0.034	-0.36	-0.23	Prostate cancer;	chr2:237523976	chr2:237591020~237595981:+
COAD	cis	rs1577917	0.771	rs6454486	ENSG00000220563.1	PKMP3	3.82	0.00017	0.034	0.26	0.23	Response to antipsychotic treatment;	chr6:85723869	chr6:85659892~85660606:-
COAD	cis	rs2836974	0.602	rs8130854	ENSG00000255568.3	BRWD1-AS2	-3.82	0.00017	0.034	-0.22	-0.23	Cognitive function;	chr21:39335115	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.605	rs2836988	ENSG00000255568.3	BRWD1-AS2	-3.82	0.00017	0.034	-0.22	-0.23	Cognitive function;	chr21:39336049	chr21:39313935~39314962:+
COAD	cis	rs12049351	0.613	rs7525324	ENSG00000213028.3	RP11-108F13.2	-3.82	0.00017	0.034	-0.35	-0.23	Circulating myeloperoxidase levels (plasma);	chr1:229463478	chr1:229688999~229689904:-
COAD	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	3.82	0.00017	0.034	0.3	0.23	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
COAD	cis	rs8058578	1	rs2289442	ENSG00000260487.1	RP11-297C4.3	3.82	0.00017	0.034	0.3	0.23	Multiple myeloma;	chr16:30728598	chr16:30480588~30481346:-
COAD	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-3.82	0.00017	0.034	-0.3	-0.23	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
COAD	cis	rs911119	0.913	rs6048926	ENSG00000270001.1	RP11-218C14.8	-3.82	0.00017	0.034	-0.28	-0.23	Chronic kidney disease;	chr20:23600350	chr20:23631826~23632316:-
COAD	cis	rs911119	0.913	rs6106685	ENSG00000270001.1	RP11-218C14.8	-3.82	0.00017	0.034	-0.28	-0.23	Chronic kidney disease;	chr20:23600975	chr20:23631826~23632316:-
COAD	cis	rs12699921	0.599	rs2723554	ENSG00000279048.1	RP11-511H23.2	-3.82	0.00017	0.0341	-0.17	-0.23	Fibrinogen levels;	chr7:17802029	chr7:17940503~17942922:+
COAD	cis	rs7572733	0.773	rs7603839	ENSG00000222017.1	AC011997.1	3.82	0.00017	0.0341	0.25	0.23	Dermatomyositis;	chr2:197669984	chr2:197693106~197774823:+
COAD	cis	rs1707322	0.721	rs11211163	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs12037803	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10789470	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs61784796	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10749856	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10890344	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs4564187	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28438704	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs28442079	ENSG00000230896.1	RP11-767N6.7	-3.82	0.000171	0.0341	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45694684~45697075:-
COAD	cis	rs7246657	0.943	rs13343471	ENSG00000226686.6	LINC01535	-3.82	0.000171	0.0341	-0.34	-0.23	Coronary artery calcification;	chr19:37441228	chr19:37251912~37265535:+
COAD	cis	rs1552244	1	rs61077902	ENSG00000186162.9	CIDECP	3.82	0.000171	0.0341	0.32	0.23	Alzheimer's disease;	chr3:10084469	chr3:10014238~10026365:-
COAD	cis	rs2929278	0.588	rs1975364	ENSG00000275601.1	AC011330.13	-3.81	0.000171	0.0341	-0.28	-0.23	Schizophrenia;	chr15:43857991	chr15:43642389~43643023:-
COAD	cis	rs13256369	0.756	rs13282580	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8705393	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs13256404	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8705464	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.756	rs13280759	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8705485	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs13254997	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8706243	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs13255061	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8706324	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs12541477	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8706385	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs13256611	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8706831	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs11786125	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8707060	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.802	rs11249888	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8707424	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs11249889	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0341	0.31	0.23	Obesity-related traits;	chr8:8707482	chr8:8456909~8461337:-
COAD	cis	rs6661961	0.686	rs4845766	ENSG00000237975.5	FLG-AS1	-3.81	0.000171	0.0341	-0.23	-0.23	Atopic dermatitis;	chr1:152418806	chr1:152168125~152445456:+
COAD	cis	rs2392362	0.728	rs6462600	ENSG00000270889.1	RP11-609L3.1	3.81	0.000171	0.0341	0.23	0.23	Information processing speed;	chr7:35350567	chr7:35971147~35971567:-
COAD	cis	rs1949733	0.523	rs16842560	ENSG00000205959.3	RP11-689P11.2	3.81	0.000171	0.0341	0.28	0.23	Response to antineoplastic agents;	chr4:8542511	chr4:8482270~8512610:+
COAD	cis	rs34779708	0.966	rs12773647	ENSG00000271335.4	RP11-324I22.4	3.81	0.000171	0.0341	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35314552~35336401:-
COAD	cis	rs752010	0.631	rs4660549	ENSG00000230638.4	RP11-486B10.4	-3.81	0.000171	0.0341	-0.3	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41622431	chr1:41542069~41544310:+
COAD	cis	rs11229555	0.645	rs4594017	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58427315	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs4367960	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58427488	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229443	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58429715	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7930547	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58430143	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12785578	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58438959	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229459	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58440552	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229460	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58440870	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs12285111	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58440912	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7929868	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58441945	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs11229462	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58442458	chr11:57638024~57652790:+
COAD	cis	rs11229555	0.645	rs7931394	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0341	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58445144	chr11:57638024~57652790:+
COAD	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-3.81	0.000171	0.0341	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
COAD	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000171	0.0341	-0.28	-0.23	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
COAD	cis	rs9880211	0.563	rs67589653	ENSG00000273486.1	RP11-731C17.2	3.81	0.000171	0.0341	0.27	0.23	Height;Body mass index;	chr3:136092732	chr3:136837338~136839021:-
COAD	cis	rs9880211	0.563	rs10512990	ENSG00000273486.1	RP11-731C17.2	3.81	0.000171	0.0341	0.27	0.23	Height;Body mass index;	chr3:136095785	chr3:136837338~136839021:-
COAD	cis	rs13256369	1	rs10095733	ENSG00000253981.4	ALG1L13P	3.81	0.000171	0.0341	0.33	0.23	Obesity-related traits;	chr8:8717136	chr8:8236003~8244667:-
COAD	cis	rs875971	0.793	rs460678	ENSG00000224316.1	RP11-479O9.2	3.81	0.000171	0.0341	0.24	0.23	Aortic root size;	chr7:66062213	chr7:65773620~65802067:+
COAD	cis	rs7829975	0.902	rs777707	ENSG00000254340.1	RP11-10A14.3	3.81	0.000171	0.0341	0.27	0.23	Mood instability;	chr8:8726834	chr8:9141424~9145435:+
COAD	cis	rs9450351	0.744	rs12528808	ENSG00000234155.1	RP11-30P6.6	-3.81	0.000171	0.0341	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85495926	chr6:85387219~85390186:-
COAD	cis	rs7584330	0.91	rs880930	ENSG00000234949.2	AC104667.3	-3.81	0.000171	0.0341	-0.29	-0.23	Prostate cancer;	chr2:237488229	chr2:237591020~237595981:+
COAD	cis	rs7584330	0.91	rs72620830	ENSG00000234949.2	AC104667.3	-3.81	0.000171	0.0341	-0.29	-0.23	Prostate cancer;	chr2:237488342	chr2:237591020~237595981:+
COAD	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000171	0.0341	-0.29	-0.23	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
COAD	cis	rs11976180	1	rs2371247	ENSG00000273234.1	OR2A13P	-3.81	0.000171	0.0341	-0.29	-0.23	Obesity-related traits;	chr7:144067086	chr7:144142009~144142938:+
COAD	cis	rs1480597	1	rs11819624	ENSG00000165511.6	C10orf25	3.81	0.000171	0.0341	0.4	0.23	Parkinson's disease;	chr10:44678775	chr10:44997698~45000888:-
COAD	cis	rs2307394	0.964	rs13014936	ENSG00000281469.1	RP11-567F11.1	3.81	0.000171	0.0342	0.28	0.23	Urate levels;	chr2:147997668	chr2:148044380~148044894:+
COAD	cis	rs12767760	0.714	rs7475851	ENSG00000237169.1	RP11-452K12.3	3.81	0.000171	0.0342	0.29	0.23	Obesity-related traits;	chr10:97562304	chr10:97309138~97309958:-
COAD	cis	rs4927850	1	rs10881563	ENSG00000185485.13	SDHAP1	3.81	0.000171	0.0342	0.21	0.23	Pancreatic cancer;	chr3:196023354	chr3:195959748~195990318:-
COAD	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-3.81	0.000171	0.0342	-0.21	-0.23	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
COAD	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	3.81	0.000171	0.0342	0.2	0.23	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
COAD	cis	rs2991971	0.967	rs2356551	ENSG00000280836.1	AL355480.1	3.81	0.000171	0.0342	0.26	0.23	High light scatter reticulocyte count;	chr1:45543646	chr1:45581219~45581321:-
COAD	cis	rs73198271	0.813	rs17697237	ENSG00000254153.1	CTA-398F10.2	3.81	0.000171	0.0342	0.27	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8456909~8461337:-
COAD	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	3.81	0.000171	0.0342	0.29	0.23	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	3.81	0.000171	0.0342	0.29	0.23	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
COAD	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	3.81	0.000171	0.0342	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	3.81	0.000171	0.0342	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
COAD	cis	rs11229555	0.645	rs12226725	ENSG00000254602.1	AP000662.4	-3.81	0.000171	0.0342	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58478859	chr11:57638024~57652790:+
COAD	cis	rs2638953	0.779	rs61920241	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000171	0.0342	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28163298~28190738:-
COAD	cis	rs9532669	0.926	rs4942014	ENSG00000239827.7	SUGT1P3	-3.81	0.000171	0.0342	-0.2	-0.23	Cervical cancer;	chr13:40966366	chr13:40908159~40921774:-
COAD	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	3.81	0.000171	0.0342	0.23	0.23	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
COAD	cis	rs12049351	0.665	rs1853808	ENSG00000229367.1	HMGN2P19	3.81	0.000171	0.0342	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229456585	chr1:229570532~229570796:+
COAD	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-3.81	0.000171	0.0342	-0.26	-0.23	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-3.81	0.000171	0.0342	-0.26	-0.23	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
COAD	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	3.81	0.000171	0.0342	0.26	0.23	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
COAD	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-3.81	0.000171	0.0342	-0.26	-0.23	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
COAD	cis	rs10773046	0.74	rs1922258	ENSG00000280328.1	RP11-972P1.7	-3.81	0.000171	0.0342	-0.22	-0.23	Osteoarthritis (hip);	chr12:123869110	chr12:123472200~123476093:-
COAD	cis	rs2243480	1	rs2707844	ENSG00000232559.3	GS1-124K5.12	3.81	0.000171	0.0342	0.41	0.23	Diabetic kidney disease;	chr7:66594522	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs1796220	ENSG00000232559.3	GS1-124K5.12	3.81	0.000171	0.0342	0.41	0.23	Diabetic kidney disease;	chr7:66597113	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs2707831	ENSG00000232559.3	GS1-124K5.12	3.81	0.000171	0.0342	0.41	0.23	Diabetic kidney disease;	chr7:66597524	chr7:66554588~66576923:-
COAD	cis	rs7129556	0.954	rs11512896	ENSG00000254691.1	RP11-91P24.5	3.81	0.000171	0.0342	0.26	0.23	Weight loss (gastric bypass surgery);	chr11:77564673	chr11:77850604~77851511:+
COAD	cis	rs699371	0.548	rs2058126	ENSG00000270000.1	RP3-449M8.9	3.81	0.000171	0.0342	0.29	0.23	Height;	chr14:74432576	chr14:74471930~74472360:-
COAD	cis	rs13256369	0.802	rs2280560	ENSG00000253981.4	ALG1L13P	3.81	0.000171	0.0342	0.33	0.23	Obesity-related traits;	chr8:8703092	chr8:8236003~8244667:-
COAD	cis	rs2124910	0.708	rs4801874	ENSG00000273837.1	LLNLR-470E3.1	3.81	0.000172	0.0342	0.23	0.23	Blood protein levels;	chr19:51524422	chr19:51639478~51639931:-
COAD	cis	rs10819861	0.679	rs10819868	ENSG00000238251.2	RP11-172F4.2	-3.81	0.000172	0.0342	-0.27	-0.23	Electrocardiographic traits;	chr9:96109096	chr9:96407284~96407797:+
COAD	cis	rs886774	0.774	rs2108222	ENSG00000250474.1	WBP1LP2	-3.81	0.000172	0.0342	-0.31	-0.23	Ulcerative colitis;	chr7:107903763	chr7:107628553~107629498:+
COAD	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-3.81	0.000172	0.0342	-0.49	-0.23	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-3.81	0.000172	0.0342	-0.49	-0.23	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-3.81	0.000172	0.0342	-0.49	-0.23	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
COAD	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-3.81	0.000172	0.0342	-0.49	-0.23	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
COAD	cis	rs1552244	0.832	rs73024575	ENSG00000186162.9	CIDECP	3.81	0.000172	0.0342	0.39	0.23	Alzheimer's disease;	chr3:10156516	chr3:10014238~10026365:-
COAD	cis	rs4973517	0.624	rs3100614	ENSG00000237126.7	AC073254.1	-3.81	0.000172	0.0342	-0.33	-0.23	Hip circumference adjusted for BMI;	chr2:231986018	chr2:232580948~232611971:-
COAD	cis	rs4973517	0.654	rs3100620	ENSG00000237126.7	AC073254.1	-3.81	0.000172	0.0342	-0.33	-0.23	Hip circumference adjusted for BMI;	chr2:231988337	chr2:232580948~232611971:-
COAD	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-3.81	0.000172	0.0342	-0.32	-0.23	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
COAD	cis	rs72823319	0.645	rs9896717	ENSG00000263818.4	CTD-2206N4.4	-3.81	0.000172	0.0342	-0.32	-0.23	Verbal memory performance (residualized delayed recall change);	chr17:39087980	chr17:39057019~39113190:+
COAD	cis	rs28374715	0.528	rs7178360	ENSG00000247556.5	OIP5-AS1	3.81	0.000172	0.0342	0.32	0.23	Ulcerative colitis;	chr15:41338977	chr15:41283990~41309737:+
COAD	cis	rs28374715	0.578	rs7165914	ENSG00000247556.5	OIP5-AS1	3.81	0.000172	0.0342	0.32	0.23	Ulcerative colitis;	chr15:41340253	chr15:41283990~41309737:+
COAD	cis	rs12699921	0.632	rs10264355	ENSG00000279048.1	RP11-511H23.2	3.81	0.000172	0.0342	0.17	0.23	Fibrinogen levels;	chr7:17782391	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs10264445	ENSG00000279048.1	RP11-511H23.2	3.81	0.000172	0.0342	0.17	0.23	Fibrinogen levels;	chr7:17782425	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.607	rs10264447	ENSG00000279048.1	RP11-511H23.2	3.81	0.000172	0.0342	0.17	0.23	Fibrinogen levels;	chr7:17782430	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs10249221	ENSG00000279048.1	RP11-511H23.2	3.81	0.000172	0.0342	0.17	0.23	Fibrinogen levels;	chr7:17782436	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2691604	ENSG00000279048.1	RP11-511H23.2	-3.81	0.000172	0.0342	-0.17	-0.23	Fibrinogen levels;	chr7:17781389	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723503	ENSG00000279048.1	RP11-511H23.2	-3.81	0.000172	0.0342	-0.17	-0.23	Fibrinogen levels;	chr7:17782012	chr7:17940503~17942922:+
COAD	cis	rs1150668	0.699	rs12214383	ENSG00000272009.1	RP1-313I6.12	-3.81	0.000172	0.0342	-0.25	-0.23	Pubertal anthropometrics;	chr6:28255953	chr6:28078792~28081130:-
COAD	cis	rs1150668	0.699	rs2394049	ENSG00000272009.1	RP1-313I6.12	3.81	0.000172	0.0342	0.25	0.23	Pubertal anthropometrics;	chr6:28271903	chr6:28078792~28081130:-
COAD	cis	rs2337406	0.866	rs4280141	ENSG00000254174.1	IGHV1-12	-3.81	0.000172	0.0342	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106780476	chr14:106122420~106122709:-
COAD	cis	rs860295	0.702	rs12025532	ENSG00000160766.13	GBAP1	-3.81	0.000172	0.0343	-0.29	-0.23	Body mass index;	chr1:155399511	chr1:155213821~155227422:-
COAD	cis	rs739496	0.615	rs2339818	ENSG00000257595.2	RP3-473L9.4	3.81	0.000172	0.0343	0.34	0.23	Platelet count;	chr12:111608672	chr12:111369282~111403310:+
COAD	cis	rs739496	0.563	rs7484754	ENSG00000257595.2	RP3-473L9.4	3.81	0.000172	0.0343	0.34	0.23	Platelet count;	chr12:111609492	chr12:111369282~111403310:+
COAD	cis	rs2489715	0.951	rs2505845	ENSG00000185904.10	LINC00839	-3.81	0.000172	0.0343	-0.38	-0.23	Helix rolling;	chr10:42397206	chr10:42475543~42495336:+
COAD	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-3.81	0.000172	0.0343	-0.3	-0.23	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
COAD	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-3.81	0.000172	0.0343	-0.3	-0.23	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
COAD	cis	rs875971	1	rs875971	ENSG00000230189.5	GS1-124K5.2	-3.81	0.000172	0.0343	-0.19	-0.23	Aortic root size;	chr7:66152608	chr7:66409143~66490059:-
COAD	cis	rs2929278	0.617	rs12908467	ENSG00000275601.1	AC011330.13	3.81	0.000172	0.0343	0.28	0.23	Schizophrenia;	chr15:43755232	chr15:43642389~43643023:-
COAD	cis	rs7802124	1	rs7802438	ENSG00000237974.1	AC000111.4	3.81	0.000172	0.0343	0.28	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr7:116566146	chr7:117487737~117487929:+
COAD	cis	rs41464545	1	rs17085751	ENSG00000249413.2	RP11-25H12.1	-3.81	0.000172	0.0343	-0.31	-0.23	Schizophrenia;	chr4:65013706	chr4:65998846~66150012:+
COAD	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	3.81	0.000172	0.0343	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	3.81	0.000172	0.0343	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
COAD	cis	rs8058578	1	rs8048448	ENSG00000260487.1	RP11-297C4.3	3.81	0.000172	0.0343	0.3	0.23	Multiple myeloma;	chr16:30680887	chr16:30480588~30481346:-
COAD	cis	rs11958404	0.932	rs11950881	ENSG00000254336.1	AC008694.2	-3.81	0.000172	0.0343	-0.37	-0.23	IgG glycosylation;	chr5:157983542	chr5:157604707~157605637:-
COAD	cis	rs875971	0.862	rs4718319	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000172	0.0343	-0.25	-0.23	Aortic root size;	chr7:66187797	chr7:65773620~65802067:+
COAD	cis	rs875971	0.723	rs28391294	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000172	0.0343	-0.25	-0.23	Aortic root size;	chr7:66189328	chr7:65773620~65802067:+
COAD	cis	rs875971	0.83	rs6967708	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000172	0.0343	-0.25	-0.23	Aortic root size;	chr7:66192326	chr7:65773620~65802067:+
COAD	cis	rs875971	0.895	rs7782806	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000172	0.0343	-0.25	-0.23	Aortic root size;	chr7:66192910	chr7:65773620~65802067:+
COAD	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-3.81	0.000172	0.0343	-0.22	-0.23	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
COAD	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	3.81	0.000172	0.0343	0.29	0.23	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
COAD	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	3.81	0.000172	0.0343	0.28	0.23	Height;	chr4:55518776	chr4:55547112~55547889:+
COAD	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	3.81	0.000172	0.0343	0.28	0.23	Height;	chr4:55518922	chr4:55547112~55547889:+
COAD	cis	rs956237	0.898	rs7665304	ENSG00000206601.1	RNU6-431P	3.81	0.000172	0.0343	0.29	0.23	Systemic lupus erythematosus;	chr4:108104223	chr4:108652150~108652256:+
COAD	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000172	0.0344	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
COAD	cis	rs896854	0.548	rs574183	ENSG00000253528.2	RP11-347C18.4	-3.81	0.000173	0.0344	-0.27	-0.23	Type 2 diabetes;	chr8:94961588	chr8:94974573~94974853:-
COAD	cis	rs11633886	0.604	rs59727662	ENSG00000273972.1	CTD-2306A12.1	-3.81	0.000173	0.0344	-0.29	-0.23	Diisocyanate-induced asthma;	chr15:45815346	chr15:45702640~45703183:+
COAD	cis	rs11633886	0.604	rs10220807	ENSG00000273972.1	CTD-2306A12.1	-3.81	0.000173	0.0344	-0.29	-0.23	Diisocyanate-induced asthma;	chr15:45818089	chr15:45702640~45703183:+
COAD	cis	rs1670533	0.615	rs59985183	ENSG00000273179.1	RP11-20I20.4	3.81	0.000173	0.0344	0.27	0.23	Recombination rate (females);	chr4:1093383	chr4:1167778~1168174:+
COAD	cis	rs6095360	0.899	rs6019544	ENSG00000222365.1	SNORD12B	-3.81	0.000173	0.0344	-0.22	-0.23	Intelligence (multi-trait analysis);	chr20:48940476	chr20:49280319~49280409:+
COAD	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	3.81	0.000173	0.0344	0.29	0.23	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
COAD	cis	rs2337406	1	rs75651733	ENSG00000211964.3	IGHV3-48	-3.81	0.000173	0.0344	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106701309	chr14:106537810~106538344:-
COAD	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	3.81	0.000173	0.0344	0.3	0.23	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
COAD	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	3.81	0.000173	0.0344	0.27	0.23	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-3.81	0.000173	0.0344	-0.25	-0.23	Gout;	chr7:66671562	chr7:66902857~66906297:+
COAD	cis	rs7577696	0.962	rs12992743	ENSG00000272716.1	RP11-563N4.1	-3.81	0.000173	0.0344	-0.24	-0.23	Inflammatory biomarkers;	chr2:32075500	chr2:32165046~32165757:-
COAD	cis	rs875971	1	rs2420820	ENSG00000179406.6	LINC00174	-3.81	0.000173	0.0344	-0.17	-0.23	Aortic root size;	chr7:66626920	chr7:66376044~66401338:-
COAD	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	3.81	0.000173	0.0344	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
COAD	cis	rs11098499	0.754	rs4107728	ENSG00000250412.1	KLHL2P1	3.81	0.000173	0.0344	0.3	0.23	Corneal astigmatism;	chr4:119332755	chr4:119334329~119378233:+
COAD	cis	rs1005224	0.963	rs2302592	ENSG00000258454.1	RP11-361H10.3	-3.81	0.000173	0.0344	-0.29	-0.23	Large artery stroke;	chr14:75662944	chr14:76235817~76263474:+
COAD	cis	rs2243480	1	rs1638734	ENSG00000232559.3	GS1-124K5.12	3.81	0.000173	0.0344	0.41	0.23	Diabetic kidney disease;	chr7:66632552	chr7:66554588~66576923:-
COAD	cis	rs9307551	0.619	rs4975054	ENSG00000250334.4	LINC00989	-3.81	0.000173	0.0344	-0.28	-0.23	Refractive error;	chr4:79549923	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.619	rs4975055	ENSG00000250334.4	LINC00989	-3.81	0.000173	0.0344	-0.28	-0.23	Refractive error;	chr4:79550097	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.619	rs10033410	ENSG00000250334.4	LINC00989	-3.81	0.000173	0.0344	-0.28	-0.23	Refractive error;	chr4:79550314	chr4:79492416~79576460:+
COAD	cis	rs9307551	0.584	rs10022314	ENSG00000250334.4	LINC00989	-3.81	0.000173	0.0344	-0.28	-0.23	Refractive error;	chr4:79550505	chr4:79492416~79576460:+
COAD	cis	rs860295	0.676	rs2666826	ENSG00000223503.1	RP11-29H23.6	-3.81	0.000173	0.0344	-0.3	-0.23	Body mass index;	chr1:155688294	chr1:155590601~155591262:-
COAD	cis	rs2504916	0.712	rs2481058	ENSG00000230234.1	RP1-276N6.2	-3.81	0.000173	0.0344	-0.32	-0.23	Response to hepatitis C treatment;	chr6:160318204	chr6:160272617~160276130:+
COAD	cis	rs763121	0.853	rs2072795	ENSG00000273076.1	RP3-508I15.22	-3.81	0.000173	0.0344	-0.2	-0.23	Menopause (age at onset);	chr22:38668204	chr22:38743495~38743910:+
COAD	cis	rs2638953	0.924	rs12368652	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000173	0.0344	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049392	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000173	0.0344	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049394	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000173	0.0344	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049395	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000173	0.0344	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.886	rs11049397	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000173	0.0344	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28163298~28190738:-
COAD	cis	rs807029	0.577	rs11190786	ENSG00000272572.1	RP11-179B2.2	-3.81	0.000173	0.0344	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100911103~100912739:-
COAD	cis	rs807029	0.577	rs7902510	ENSG00000272572.1	RP11-179B2.2	-3.81	0.000173	0.0344	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100911103~100912739:-
COAD	cis	rs807029	0.577	rs7903239	ENSG00000272572.1	RP11-179B2.2	-3.81	0.000173	0.0344	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100911103~100912739:-
COAD	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-3.81	0.000173	0.0344	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
COAD	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-3.81	0.000173	0.0344	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
COAD	cis	rs13256369	0.802	rs34762800	ENSG00000254153.1	CTA-398F10.2	3.81	0.000173	0.0344	0.31	0.23	Obesity-related traits;	chr8:8701784	chr8:8456909~8461337:-
COAD	cis	rs4253772	0.938	rs41378347	ENSG00000235159.1	RP6-109B7.4	-3.81	0.000173	0.0345	-0.4	-0.23	Cholesterol, total;LDL cholesterol;	chr22:46241079	chr22:46067356~46069891:-
COAD	cis	rs796825	0.553	rs939499	ENSG00000240661.1	RP11-174O3.3	-3.81	0.000173	0.0345	-0.35	-0.23	HIV-1 susceptibility;	chr3:120341555	chr3:120349510~120367998:+
COAD	cis	rs796825	0.597	rs2138259	ENSG00000240661.1	RP11-174O3.3	-3.81	0.000173	0.0345	-0.35	-0.23	HIV-1 susceptibility;	chr3:120342387	chr3:120349510~120367998:+
COAD	cis	rs7615952	0.546	rs16836896	ENSG00000241278.1	ENPP7P4	3.81	0.000173	0.0345	0.29	0.23	Blood pressure (smoking interaction);	chr3:125592418	chr3:125848223~125909372:+
COAD	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-3.81	0.000173	0.0345	-0.2	-0.23	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
COAD	cis	rs911263	0.603	rs12889949	ENSG00000259502.1	RP11-643G16.3	-3.81	0.000173	0.0345	-0.28	-0.23	Primary biliary cholangitis;	chr14:68308137	chr14:67610986~67613864:+
COAD	cis	rs4763879	0.778	rs1056151	ENSG00000278635.1	CTD-2318O12.1	3.81	0.000173	0.0345	0.22	0.23	Type 1 diabetes;	chr12:9698427	chr12:9415641~9416718:+
COAD	cis	rs7208859	0.623	rs9912440	ENSG00000280069.1	CTD-2349P21.3	-3.81	0.000173	0.0345	-0.35	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30738182~30740275:+
COAD	cis	rs875971	1	rs1544549	ENSG00000230189.5	GS1-124K5.2	-3.81	0.000174	0.0345	-0.19	-0.23	Aortic root size;	chr7:66625676	chr7:66409143~66490059:-
COAD	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	3.81	0.000174	0.0345	0.32	0.23	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
COAD	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	3.81	0.000174	0.0345	0.32	0.23	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
COAD	cis	rs4820539	1	rs4820539	ENSG00000211644.2	IGLV1-51	3.81	0.000174	0.0345	0.13	0.23	Bone mineral density;	chr22:23135783	chr22:22322472~22322980:+
COAD	cis	rs1707322	0.721	rs28817701	ENSG00000230896.1	RP11-767N6.7	-3.81	0.000174	0.0345	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.691	rs28495425	ENSG00000230896.1	RP11-767N6.7	-3.81	0.000174	0.0345	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.691	rs61784803	ENSG00000230896.1	RP11-767N6.7	3.81	0.000174	0.0345	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.663	rs3935296	ENSG00000230896.1	RP11-767N6.7	3.81	0.000174	0.0345	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45694684~45697075:-
COAD	cis	rs11846409	0.872	rs74091715	ENSG00000254174.1	IGHV1-12	3.81	0.000174	0.0345	0.23	0.23	Rheumatic heart disease;	chr14:106637731	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.932	rs74091721	ENSG00000254174.1	IGHV1-12	3.81	0.000174	0.0345	0.23	0.23	Rheumatic heart disease;	chr14:106638262	chr14:106122420~106122709:-
COAD	cis	rs9868809	0.505	rs9882549	ENSG00000225399.4	RP11-3B7.1	-3.81	0.000174	0.0345	-0.36	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711925	chr3:49260085~49261316:+
COAD	cis	rs4218	0.517	rs2899640	ENSG00000259732.1	RP11-59H7.3	-3.81	0.000174	0.0345	-0.28	-0.23	Social communication problems;	chr15:59060281	chr15:59121034~59133250:+
COAD	cis	rs2337406	0.778	rs56965016	ENSG00000211974.3	IGHV2-70	-3.81	0.000174	0.0345	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106656649	chr14:106723574~106724093:-
COAD	cis	rs74233809	1	rs10883815	ENSG00000213277.3	MARCKSL1P1	3.81	0.000174	0.0345	0.46	0.23	Birth weight;	chr10:102979422	chr10:103175554~103176094:+
COAD	cis	rs72730918	0.818	rs72730927	ENSG00000242327.1	CTD-2184D3.1	3.81	0.000174	0.0346	0.37	0.23	Intelligence (multi-trait analysis);	chr15:51660035	chr15:52095295~52095747:+
COAD	cis	rs3096277	1	rs436429	ENSG00000261286.1	RP11-517C16.2	3.81	0.000174	0.0346	0.21	0.23	Blood pressure;	chr16:83728417	chr16:84459259~84467361:-
COAD	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	3.81	0.000174	0.0346	0.32	0.23	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
COAD	cis	rs1510510	0.69	rs1553842	ENSG00000225057.2	AC096574.4	3.81	0.000174	0.0346	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238633233	chr2:238231684~238255633:+
COAD	cis	rs71636778	0.631	rs34924059	ENSG00000260063.1	RP5-968P14.2	-3.81	0.000174	0.0346	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26832353	chr1:26692132~26694131:-
COAD	cis	rs6490294	0.583	rs4767296	ENSG00000257595.2	RP3-473L9.4	3.81	0.000174	0.0346	0.3	0.23	Mean platelet volume;	chr12:112025562	chr12:111369282~111403310:+
COAD	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-3.81	0.000174	0.0346	-0.33	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
COAD	cis	rs4763879	0.778	rs11052497	ENSG00000278635.1	CTD-2318O12.1	3.81	0.000174	0.0346	0.22	0.23	Type 1 diabetes;	chr12:9696679	chr12:9415641~9416718:+
COAD	cis	rs9473147	0.747	rs9395288	ENSG00000270761.1	RP11-385F7.1	-3.81	0.000174	0.0346	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47630389	chr6:47477243~47477572:-
COAD	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	3.81	0.000174	0.0346	0.28	0.23	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
COAD	cis	rs3738443	0.678	rs57861883	ENSG00000259865.1	RP11-488L18.10	3.81	0.000174	0.0346	0.24	0.23	Alcohol dependence;	chr1:247214089	chr1:247187281~247188526:-
COAD	cis	rs9796	0.621	rs12324159	ENSG00000247556.5	OIP5-AS1	3.81	0.000174	0.0346	0.24	0.23	Menopause (age at onset);	chr15:41170270	chr15:41283990~41309737:+
COAD	cis	rs153916	0.566	rs1422133	ENSG00000251000.1	AC008592.3	3.81	0.000174	0.0346	0.28	0.23	Pulmonary function;	chr5:95675079	chr5:95834424~95835046:-
COAD	cis	rs153916	0.566	rs2548125	ENSG00000251000.1	AC008592.3	3.81	0.000174	0.0346	0.28	0.23	Pulmonary function;	chr5:95675722	chr5:95834424~95835046:-
COAD	cis	rs9868809	0.772	rs9841602	ENSG00000225399.4	RP11-3B7.1	-3.81	0.000174	0.0346	-0.34	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676137	chr3:49260085~49261316:+
COAD	cis	rs7572733	0.935	rs10497809	ENSG00000222017.1	AC011997.1	3.81	0.000174	0.0346	0.25	0.23	Dermatomyositis;	chr2:197960944	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.806	rs10169453	ENSG00000222017.1	AC011997.1	3.81	0.000174	0.0346	0.25	0.23	Dermatomyositis;	chr2:197970488	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.935	rs10204166	ENSG00000222017.1	AC011997.1	3.81	0.000174	0.0346	0.25	0.23	Dermatomyositis;	chr2:197970540	chr2:197693106~197774823:+
COAD	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	3.81	0.000174	0.0346	0.25	0.23	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
COAD	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	3.81	0.000174	0.0346	0.25	0.23	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
COAD	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	3.81	0.000174	0.0346	0.25	0.23	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
COAD	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000174	0.0347	-0.23	-0.23	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
COAD	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	3.81	0.000174	0.0347	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	3.81	0.000174	0.0347	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
COAD	cis	rs1387259	0.69	rs1601985	ENSG00000226413.2	OR8T1P	3.81	0.000174	0.0347	0.29	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48442030~48442947:-
COAD	cis	rs911555	0.755	rs2756128	ENSG00000251533.2	LINC00605	3.81	0.000174	0.0347	0.32	0.23	Intelligence (multi-trait analysis);	chr14:103508627	chr14:103187221~103189028:-
COAD	cis	rs62247992	0.688	rs62247988	ENSG00000230084.4	RP4-613B23.1	-3.81	0.000174	0.0347	-0.36	-0.23	Facial morphology (factor 15, philtrum width);	chr3:43090725	chr3:42601963~42654388:-
COAD	cis	rs10087240	0.55	rs4733821	ENSG00000207110.1	RNU1-106P	3.81	0.000174	0.0347	0.29	0.23	Lymphocyte counts;White blood cell count;	chr8:128000577	chr8:127999131~127999294:+
COAD	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	3.81	0.000175	0.0347	0.27	0.23	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
COAD	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	3.81	0.000175	0.0347	0.45	0.23	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
COAD	cis	rs7204230	1	rs12597487	ENSG00000261056.2	RP11-454F8.2	3.81	0.000175	0.0347	0.28	0.23	Fibrinogen;	chr16:53157558	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048022	ENSG00000261056.2	RP11-454F8.2	3.81	0.000175	0.0347	0.28	0.23	Fibrinogen;	chr16:53163547	chr16:53298224~53299792:+
COAD	cis	rs4883201	0.611	rs2377671	ENSG00000249790.2	RP11-20D14.6	-3.81	0.000175	0.0347	-0.31	-0.23	Total cholesterol levels;Cholesterol, total;	chr12:8951246	chr12:8788257~8795789:+
COAD	cis	rs6142618	0.562	rs6061186	ENSG00000224452.1	RSL24D1P6	3.81	0.000175	0.0347	0.26	0.23	Inflammatory bowel disease;	chr20:32143937	chr20:32170390~32170790:-
COAD	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	3.81	0.000175	0.0347	0.3	0.23	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
COAD	cis	rs12571093	0.541	rs7893837	ENSG00000233590.1	RP11-153K11.3	-3.81	0.000175	0.0347	-0.33	-0.23	Optic nerve measurement (disc area);	chr10:68295578	chr10:68233251~68242379:-
COAD	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000175	0.0347	-0.29	-0.23	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000175	0.0347	-0.29	-0.23	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000175	0.0347	-0.29	-0.23	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
COAD	cis	rs10911902	0.643	rs6664763	ENSG00000229739.2	RP11-295K2.3	-3.81	0.000175	0.0347	-0.33	-0.23	Schizophrenia;	chr1:186357043	chr1:186435161~186470291:+
COAD	cis	rs6840360	0.573	rs4696250	ENSG00000251611.1	RP11-610P16.1	-3.81	0.000175	0.0347	-0.23	-0.23	Intelligence (multi-trait analysis);	chr4:151345169	chr4:151407551~151408835:-
COAD	cis	rs1713985	0.508	rs1277282	ENSG00000269949.1	RP11-738E22.3	3.81	0.000175	0.0347	0.43	0.23	Age-related macular degeneration;	chr4:56989653	chr4:56960927~56961373:-
COAD	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-3.81	0.000175	0.0347	-0.33	-0.23	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
COAD	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-3.81	0.000175	0.0347	-0.33	-0.23	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
COAD	cis	rs6732160	0.588	rs1430344	ENSG00000163016.8	ALMS1P	3.81	0.000175	0.0347	0.29	0.23	Intelligence (multi-trait analysis);	chr2:73146216	chr2:73644919~73685576:+
COAD	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	3.81	0.000175	0.0347	0.45	0.23	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
COAD	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-3.81	0.000175	0.0347	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
COAD	cis	rs1115240	0.574	rs61986530	ENSG00000257842.4	NOVA1-AS1	3.81	0.000175	0.0347	0.3	0.23	Educational attainment (years of education);	chr14:26552508	chr14:26598412~26806467:+
COAD	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	3.81	0.000175	0.0347	0.31	0.23	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
COAD	cis	rs1790761	0.692	rs611663	ENSG00000255318.1	RP11-655M14.13	3.81	0.000175	0.0347	0.29	0.23	Mean corpuscular volume;	chr11:67544750	chr11:67618279~67627304:-
COAD	cis	rs17685	0.784	rs1637043	ENSG00000280388.1	RP11-229D13.3	-3.81	0.000175	0.0347	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76043977~76045963:-
COAD	cis	rs73191547	0.683	rs7822181	ENSG00000254936.4	AF131215.3	3.81	0.000175	0.0347	0.24	0.23	Schizophrenia;	chr8:10192362	chr8:11123381~11126064:-
COAD	cis	rs6585424	1	rs11202031	ENSG00000234382.2	RP11-40F6.1	-3.81	0.000175	0.0347	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:80233664~80245367:+
COAD	cis	rs11231017	0.514	rs953169	ENSG00000254454.2	RCC2P6	3.81	0.000175	0.0347	0.26	0.23	HIV-1 viral setpoint;	chr11:62316070	chr11:62371146~62373168:+
COAD	cis	rs2439831	0.85	rs3742982	ENSG00000166763.7	STRCP1	-3.81	0.000175	0.0348	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43884483	chr15:43699488~43718184:-
COAD	cis	rs711830	0.587	rs10188827	ENSG00000226363.3	HAGLROS	-3.81	0.000175	0.0348	-0.37	-0.23	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176142936	chr2:176177717~176179008:+
COAD	cis	rs10863681	1	rs10863681	ENSG00000232679.1	RP11-400N13.3	3.81	0.000175	0.0348	0.24	0.23	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071916	chr1:222041705~222064763:-
COAD	cis	rs9888739	0.8	rs1143683	ENSG00000260304.1	RP11-388M20.6	-3.81	0.000175	0.0348	-0.27	-0.23	Systemic lupus erythematosus;	chr16:31325567	chr16:31182511~31183285:-
COAD	cis	rs9951698	0.557	rs544011	ENSG00000266969.1	RP11-773H22.4	3.81	0.000175	0.0348	0.27	0.23	Intelligence (multi-trait analysis);	chr18:13077316	chr18:12984694~12991173:-
COAD	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-3.81	0.000175	0.0348	-0.24	-0.23	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
COAD	cis	rs4814920	0.756	rs6046400	ENSG00000233895.1	RP1-122P22.2	-3.81	0.000175	0.0348	-0.35	-0.23	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19757708~19809675:+
COAD	cis	rs7487075	0.78	rs12320197	ENSG00000274723.1	RP11-618L22.1	3.81	0.000175	0.0348	0.25	0.23	Itch intensity from mosquito bite;	chr12:46345100	chr12:46970504~46972155:+
COAD	cis	rs2632516	1	rs2526378	ENSG00000278627.1	RP11-506H21.5	-3.81	0.000175	0.0348	-0.27	-0.23	Alzheimer's disease in APOE e4- carriers;Monocyte count;Alzheimer's disease;	chr17:58326988	chr17:58202352~58203003:-
COAD	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-3.81	0.000175	0.0348	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
COAD	cis	rs12681366	0.881	rs3019150	ENSG00000253704.1	RP11-267M23.4	3.81	0.000175	0.0348	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94553722~94569745:+
COAD	cis	rs10504130	0.569	rs6473653	ENSG00000272024.1	RP11-546K22.3	3.81	0.000175	0.0348	0.35	0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51950284~51950690:+
COAD	cis	rs3738443	0.678	rs61636449	ENSG00000259865.1	RP11-488L18.10	3.81	0.000175	0.0348	0.24	0.23	Alcohol dependence;	chr1:247213758	chr1:247187281~247188526:-
COAD	cis	rs9992966	0.85	rs1394866	ENSG00000250829.2	RP11-11N5.1	-3.81	0.000175	0.0348	-0.37	-0.23	Trans fatty acid levels;	chr4:187693604	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs1394865	ENSG00000250829.2	RP11-11N5.1	-3.81	0.000175	0.0348	-0.37	-0.23	Trans fatty acid levels;	chr4:187693611	chr4:186890969~186892366:+
COAD	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	3.81	0.000175	0.0348	0.31	0.23	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
COAD	cis	rs116175783	0.557	rs3769963	ENSG00000227403.1	AC009299.3	3.81	0.000175	0.0348	0.36	0.23	Intelligence (multi-trait analysis);	chr2:161350999	chr2:161244739~161249050:+
COAD	cis	rs9880211	0.613	rs12330335	ENSG00000273486.1	RP11-731C17.2	3.81	0.000175	0.0348	0.27	0.23	Height;Body mass index;	chr3:136134690	chr3:136837338~136839021:-
COAD	cis	rs7009110	0.652	rs13266315	ENSG00000213791.4	RP11-941H19.2	3.81	0.000176	0.0348	0.22	0.23	Asthma and hay fever;	chr8:80343946	chr8:80300869~80301481:+
COAD	cis	rs7119	0.651	rs12904823	ENSG00000259565.2	KRT8P23	-3.81	0.000176	0.0348	-0.28	-0.23	Type 2 diabetes;	chr15:77545320	chr15:76979245~76980451:-
COAD	cis	rs12049351	0.719	rs2145394	ENSG00000229367.1	HMGN2P19	3.81	0.000176	0.0348	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229535217	chr1:229570532~229570796:+
COAD	cis	rs10129255	0.518	rs2006284	ENSG00000211967.3	IGHV3-53	-3.81	0.000176	0.0348	-0.13	-0.23	Kawasaki disease;	chr14:106676185	chr14:106592676~106593347:-
COAD	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	3.81	0.000176	0.0348	0.28	0.23	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
COAD	cis	rs853679	1	rs1778508	ENSG00000272009.1	RP1-313I6.12	-3.81	0.000176	0.0348	-0.36	-0.23	Depression;	chr6:28262103	chr6:28078792~28081130:-
COAD	cis	rs7193541	0.965	rs8050262	ENSG00000262904.1	TMPOP2	-3.81	0.000176	0.0348	-0.24	-0.23	Multiple myeloma;	chr16:74627261	chr16:74667506~74668706:+
COAD	cis	rs10465746	0.57	rs6658559	ENSG00000249237.4	RP11-376N17.4	-3.81	0.000176	0.0348	-0.26	-0.23	Obesity-related traits;	chr1:84001729	chr1:84344678~84349939:+
COAD	cis	rs728616	0.867	rs723193	ENSG00000234382.2	RP11-40F6.1	-3.81	0.000176	0.0348	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:80233664~80245367:+
COAD	cis	rs9910055	0.529	rs228748	ENSG00000267080.4	ASB16-AS1	3.81	0.000176	0.0348	0.22	0.23	Total body bone mineral density;	chr17:44097022	chr17:44175973~44186717:-
COAD	cis	rs7204230	1	rs8053957	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53209351	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.921	rs62048055	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53212092	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048058	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53212641	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs62048059	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53214602	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12597253	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53222582	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12597254	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53232277	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.921	rs8061611	ENSG00000261056.2	RP11-454F8.2	3.81	0.000176	0.0348	0.28	0.23	Fibrinogen;	chr16:53233467	chr16:53298224~53299792:+
COAD	cis	rs2496589	0.889	rs9496630	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143431056	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496631	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143431102	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496632	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143431548	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9321910	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143431677	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9484749	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143432091	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9321911	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143432206	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9321912	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143432349	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs6921292	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143433120	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9484750	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143433569	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496634	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143434271	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.929	rs17072606	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143434953	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs56336947	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143435108	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs72988621	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143436741	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs7755370	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143437456	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs6570561	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143438908	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs7761741	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143439134	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs9496635	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143440460	chr6:143436216~143436710:+
COAD	cis	rs2496589	0.963	rs7744361	ENSG00000218896.1	TUBB8P2	3.81	0.000176	0.0348	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143442708	chr6:143436216~143436710:+
COAD	cis	rs2836974	0.568	rs2836969	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000176	0.0349	-0.22	-0.23	Cognitive function;	chr21:39276339	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.605	rs2836971	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000176	0.0349	-0.22	-0.23	Cognitive function;	chr21:39280114	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.584	rs6517535	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000176	0.0349	-0.22	-0.23	Cognitive function;	chr21:39281426	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.627	rs7278985	ENSG00000255568.3	BRWD1-AS2	-3.81	0.000176	0.0349	-0.22	-0.23	Cognitive function;	chr21:39281841	chr21:39313935~39314962:+
COAD	cis	rs919433	0.679	rs13000656	ENSG00000222017.1	AC011997.1	-3.81	0.000176	0.0349	-0.29	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657402	chr2:197693106~197774823:+
COAD	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-3.81	0.000176	0.0349	-0.26	-0.23	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
COAD	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-3.81	0.000176	0.0349	-0.24	-0.23	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
COAD	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-3.81	0.000176	0.0349	-0.35	-0.23	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
COAD	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-3.81	0.000176	0.0349	-0.35	-0.23	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
COAD	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	3.81	0.000176	0.0349	0.24	0.23	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
COAD	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	3.81	0.000176	0.0349	0.24	0.23	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
COAD	cis	rs3733829	1	rs4803369	ENSG00000279759.1	CTC-425O23.5	-3.81	0.000176	0.0349	-0.21	-0.23	Smoking behavior;	chr19:40810075	chr19:40355842~40360606:+
COAD	cis	rs201673768	1	rs201673768	ENSG00000273765.1	RP11-370I10.11	3.81	0.000176	0.0349	0.24	0.23	Platelet count;	chr12:48305834	chr12:48360920~48361377:+
COAD	cis	rs773506	0.933	rs298723	ENSG00000228069.1	RP11-100G15.3	3.81	0.000176	0.0349	0.25	0.23	Type 2 diabetes nephropathy;	chr9:91261060	chr9:92109013~92110095:+
COAD	cis	rs5753037	0.869	rs6006300	ENSG00000279159.1	RP3-394A18.1	-3.81	0.000176	0.0349	-0.16	-0.23	Type 1 diabetes;	chr22:29906164	chr22:29978950~30028236:-
COAD	cis	rs9478638	0.507	rs335368	ENSG00000235381.1	RP11-477D19.2	-3.81	0.000176	0.0349	-0.26	-0.23	Electroencephalogram traits;	chr6:155319747	chr6:155253139~155256724:-
COAD	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000176	0.0349	0.25	0.23	Height;	chr4:55561218	chr4:55363971~55395847:-
COAD	cis	rs1023500	0.551	rs133371	ENSG00000227370.1	RP4-669P10.19	-3.81	0.000176	0.0349	-0.23	-0.23	Schizophrenia;	chr22:42069570	chr22:42132543~42132998:+
COAD	cis	rs1023500	0.573	rs133374	ENSG00000227370.1	RP4-669P10.19	-3.81	0.000176	0.0349	-0.23	-0.23	Schizophrenia;	chr22:42069937	chr22:42132543~42132998:+
COAD	cis	rs5753037	0.838	rs5763688	ENSG00000279159.1	RP3-394A18.1	3.81	0.000176	0.035	0.16	0.23	Type 1 diabetes;	chr22:29997514	chr22:29978950~30028236:-
COAD	cis	rs2255336	0.938	rs17549004	ENSG00000245648.1	RP11-277P12.20	-3.81	0.000176	0.035	-0.48	-0.23	Blood protein levels;	chr12:10410024	chr12:10363769~10398506:+
COAD	cis	rs7615952	0.546	rs2979306	ENSG00000171084.14	FAM86JP	3.81	0.000176	0.035	0.36	0.23	Blood pressure (smoking interaction);	chr3:125593286	chr3:125916620~125930024:+
COAD	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000176	0.035	0.26	0.23	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
COAD	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	3.81	0.000176	0.035	0.26	0.23	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
COAD	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-3.81	0.000176	0.035	-0.28	-0.23	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
COAD	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-3.81	0.000176	0.035	-0.29	-0.23	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
COAD	cis	rs12699921	0.566	rs1997019	ENSG00000279048.1	RP11-511H23.2	-3.81	0.000176	0.035	-0.17	-0.23	Fibrinogen levels;	chr7:17787856	chr7:17940503~17942922:+
COAD	cis	rs2836974	0.897	rs2776308	ENSG00000255568.3	BRWD1-AS2	3.81	0.000177	0.035	0.24	0.23	Cognitive function;	chr21:39343249	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.83	rs2735309	ENSG00000255568.3	BRWD1-AS2	3.81	0.000177	0.035	0.24	0.23	Cognitive function;	chr21:39343387	chr21:39313935~39314962:+
COAD	cis	rs2638953	0.888	rs11610011	ENSG00000247934.4	RP11-967K21.1	-3.81	0.000177	0.035	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28163298~28190738:-
COAD	cis	rs7577696	0.524	rs61399065	ENSG00000272716.1	RP11-563N4.1	-3.81	0.000177	0.035	-0.26	-0.23	Inflammatory biomarkers;	chr2:31983485	chr2:32165046~32165757:-
COAD	cis	rs875971	1	rs2420820	ENSG00000230189.5	GS1-124K5.2	-3.81	0.000177	0.035	-0.19	-0.23	Aortic root size;	chr7:66626920	chr7:66409143~66490059:-
COAD	cis	rs9532669	0.926	rs4254182	ENSG00000239827.7	SUGT1P3	-3.81	0.000177	0.035	-0.19	-0.23	Cervical cancer;	chr13:40879120	chr13:40908159~40921774:-
COAD	cis	rs71636778	0.631	rs71636787	ENSG00000260063.1	RP5-968P14.2	-3.81	0.000177	0.035	-0.32	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26858624	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.631	rs71636788	ENSG00000260063.1	RP5-968P14.2	-3.81	0.000177	0.035	-0.32	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859994	chr1:26692132~26694131:-
COAD	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	3.81	0.000177	0.035	0.26	0.23	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
COAD	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	3.81	0.000177	0.035	0.26	0.23	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
COAD	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	3.81	0.000177	0.035	0.26	0.23	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
COAD	cis	rs561341	0.882	rs72825748	ENSG00000265798.5	RP11-271K11.5	3.81	0.000177	0.035	0.37	0.23	Hip circumference adjusted for BMI;	chr17:32040377	chr17:31038575~31059121:-
COAD	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	3.81	0.000177	0.035	0.34	0.23	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
COAD	cis	rs12468226	0.938	rs1474002	ENSG00000226261.1	AC064836.3	3.81	0.000177	0.035	0.35	0.23	Urate levels;	chr2:202290195	chr2:202336024~202336727:-
COAD	cis	rs1707322	0.721	rs4559551	ENSG00000230896.1	RP11-767N6.7	-3.81	0.000177	0.035	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10430124	ENSG00000230896.1	RP11-767N6.7	-3.81	0.000177	0.035	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45694684~45697075:-
COAD	cis	rs6490294	0.571	rs10849995	ENSG00000257595.2	RP3-473L9.4	3.81	0.000177	0.035	0.37	0.23	Mean platelet volume;	chr12:112041740	chr12:111369282~111403310:+
COAD	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	3.81	0.000177	0.035	0.26	0.23	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	3.81	0.000177	0.035	0.26	0.23	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
COAD	cis	rs7584330	0.554	rs7587496	ENSG00000234949.2	AC104667.3	-3.81	0.000177	0.0351	-0.38	-0.23	Prostate cancer;	chr2:237478989	chr2:237591020~237595981:+
COAD	cis	rs9813712	0.548	rs9880123	ENSG00000253540.4	FAM86HP	-3.81	0.000177	0.0351	-0.24	-0.23	Response to amphetamines;	chr3:130215275	chr3:130099092~130111472:-
COAD	cis	rs71636778	0.722	rs71636784	ENSG00000260063.1	RP5-968P14.2	-3.81	0.000177	0.0351	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26842709	chr1:26692132~26694131:-
COAD	cis	rs71636778	0.722	rs35650645	ENSG00000260063.1	RP5-968P14.2	-3.81	0.000177	0.0351	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26842993	chr1:26692132~26694131:-
COAD	cis	rs7339483	0.764	rs1830180	ENSG00000268442.1	CTD-2027I19.2	3.81	0.000177	0.0351	0.35	0.23	Discordance in emotional problems in monozygotic twins;	chr19:24273161	chr19:24162370~24163425:-
COAD	cis	rs2836974	0.932	rs73221193	ENSG00000255568.3	BRWD1-AS2	3.81	0.000177	0.0351	0.24	0.23	Cognitive function;	chr21:39182767	chr21:39313935~39314962:+
COAD	cis	rs2836974	0.831	rs34294410	ENSG00000255568.3	BRWD1-AS2	3.81	0.000177	0.0351	0.24	0.23	Cognitive function;	chr21:39183234	chr21:39313935~39314962:+
COAD	cis	rs12506228	0.598	rs6827454	ENSG00000279943.1	FLJ38576	-3.81	0.000177	0.0351	-0.31	-0.23	Job-related exhaustion in shift workers;	chr4:186428931	chr4:186189032~186191490:-
COAD	cis	rs2617170	0.784	rs12298100	ENSG00000245648.1	RP11-277P12.20	-3.81	0.000177	0.0351	-0.3	-0.23	Behcet's disease;	chr12:10456990	chr12:10363769~10398506:+
COAD	cis	rs7584330	0.868	rs67071074	ENSG00000234949.2	AC104667.3	-3.81	0.000177	0.0351	-0.28	-0.23	Prostate cancer;	chr2:237486786	chr2:237591020~237595981:+
COAD	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	3.81	0.000177	0.0351	0.28	0.23	Height;	chr4:55456620	chr4:55547112~55547889:+
COAD	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000177	0.0351	-0.27	-0.23	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
COAD	cis	rs6982240	0.514	rs7002268	ENSG00000253307.1	RP11-10J21.4	3.81	0.000177	0.0351	0.31	0.23	Tonsillectomy;	chr8:141267241	chr8:141252286~141253292:-
COAD	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-3.81	0.000177	0.0351	-0.48	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
COAD	cis	rs7911712	0.872	rs11239242	ENSG00000165511.6	C10orf25	3.81	0.000177	0.0351	0.43	0.23	Emphysema-related traits;	chr10:44776787	chr10:44997698~45000888:-
COAD	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-3.81	0.000177	0.0351	-0.42	-0.23	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
COAD	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-3.8	0.000177	0.0351	-0.28	-0.23	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
COAD	cis	rs7871764	0.881	rs35017035	ENSG00000260947.1	RP11-384P7.7	3.8	0.000177	0.0351	0.3	0.23	Height;	chr9:34072896	chr9:33697459~33700986:+
COAD	cis	rs2342406	0.622	rs7599417	ENSG00000259439.2	RP11-89K21.1	3.8	0.000177	0.0351	0.35	0.23	Myopia;	chr2:44905361	chr2:44921077~44939199:-
COAD	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-3.8	0.000178	0.0351	-0.27	-0.23	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
COAD	cis	rs6951245	1	rs75488469	ENSG00000229043.2	AC091729.9	-3.8	0.000178	0.0351	-0.39	-0.23	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1160374~1165267:+
COAD	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-3.8	0.000178	0.0351	-0.3	-0.23	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
COAD	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-3.8	0.000178	0.0351	-0.3	-0.23	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
COAD	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	3.8	0.000178	0.0352	0.26	0.23	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
COAD	cis	rs1480597	1	rs11813823	ENSG00000165511.6	C10orf25	3.8	0.000178	0.0352	0.39	0.23	Parkinson's disease;	chr10:44662493	chr10:44997698~45000888:-
COAD	cis	rs68170813	0.523	rs11762152	ENSG00000241764.3	AC002467.7	3.8	0.000178	0.0352	0.32	0.23	Coronary artery disease;	chr7:107170929	chr7:107742817~107744581:-
COAD	cis	rs12564445	0.551	rs11807637	ENSG00000249007.1	RP11-510N19.5	-3.8	0.000178	0.0352	-0.27	-0.23	Cardiac Troponin-T levels;	chr1:201362207	chr1:202011370~202015657:+
COAD	cis	rs2292864	0.764	rs3785872	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000178	0.0352	-0.44	-0.23	Left atrial antero-posterior diameter;	chr17:47294709	chr17:47450568~47492492:-
COAD	cis	rs2292864	0.681	rs35735886	ENSG00000228782.6	CTD-2026D20.3	-3.8	0.000178	0.0352	-0.44	-0.23	Left atrial antero-posterior diameter;	chr17:47296911	chr17:47450568~47492492:-
COAD	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-3.8	0.000178	0.0352	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-3.8	0.000178	0.0352	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
COAD	cis	rs742132	0.893	rs9467541	ENSG00000220875.1	HIST1H3PS1	3.8	0.000178	0.0352	0.3	0.23	Uric acid levels;	chr6:25630321	chr6:26321876~26322292:-
COAD	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-3.8	0.000178	0.0352	-0.32	-0.23	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
COAD	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-3.8	0.000178	0.0352	-0.31	-0.23	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
COAD	cis	rs453301	0.562	rs1038248	ENSG00000233609.3	RP11-62H7.2	-3.8	0.000178	0.0352	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9183348	chr8:8961200~8979025:+
COAD	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	3.8	0.000178	0.0352	0.23	0.23	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
COAD	cis	rs7204230	1	rs62049780	ENSG00000261056.2	RP11-454F8.2	3.8	0.000178	0.0352	0.28	0.23	Fibrinogen;	chr16:53245099	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs1558682	ENSG00000261056.2	RP11-454F8.2	3.8	0.000178	0.0352	0.28	0.23	Fibrinogen;	chr16:53250525	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.96	rs57536424	ENSG00000261056.2	RP11-454F8.2	3.8	0.000178	0.0352	0.28	0.23	Fibrinogen;	chr16:53254184	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs1362440	ENSG00000261056.2	RP11-454F8.2	3.8	0.000178	0.0352	0.28	0.23	Fibrinogen;	chr16:53256912	chr16:53298224~53299792:+
COAD	cis	rs7760535	0.794	rs12529158	ENSG00000271789.1	RP5-1112D6.7	3.8	0.000178	0.0353	0.22	0.23	Metabolic traits;	chr6:111501244	chr6:111297126~111298510:+
COAD	cis	rs953301	0.655	rs73019352	ENSG00000229808.1	RP11-456P18.2	-3.8	0.000178	0.0353	-0.46	-0.23	Left atrial antero-posterior diameter;	chr1:161904044	chr1:161890833~161892196:+
COAD	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	3.8	0.000178	0.0353	0.28	0.23	Height;	chr4:55501479	chr4:55547112~55547889:+
COAD	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	3.8	0.000178	0.0353	0.29	0.23	Height;	chr14:74458694	chr14:74471930~74472360:-
COAD	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-3.8	0.000178	0.0353	-0.31	-0.23	Depression;	chr6:28206179	chr6:28170845~28172521:+
COAD	cis	rs9487051	1	rs6568569	ENSG00000219700.1	PTCHD3P3	3.8	0.000178	0.0353	0.25	0.23	Reticulocyte fraction of red cells;	chr6:109291993	chr6:109288571~109290503:-
COAD	cis	rs4763879	0.778	rs1056151	ENSG00000256673.1	RP11-599J14.2	3.8	0.000178	0.0353	0.24	0.23	Type 1 diabetes;	chr12:9698427	chr12:9398355~9414851:-
COAD	cis	rs227163	0.905	rs227162	ENSG00000232848.1	CTA-215D11.4	-3.8	0.000179	0.0353	-0.25	-0.23	Rheumatoid arthritis;	chr1:7900505	chr1:8057245~8058463:-
COAD	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-3.8	0.000179	0.0353	-0.28	-0.23	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
COAD	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	3.8	0.000179	0.0353	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
COAD	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	3.8	0.000179	0.0353	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
COAD	cis	rs2916733	0.53	rs2440424	ENSG00000246089.3	RP11-115C21.2	3.8	0.000179	0.0353	0.33	0.23	Epirubicin-induced leukopenia;	chr8:6432416	chr8:6403551~6407142:-
COAD	cis	rs3796352	1	rs750474	ENSG00000280417.1	RP11-5O17.1	-3.8	0.000179	0.0353	-0.32	-0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53051264	chr3:53046166~53048122:+
COAD	cis	rs1707322	0.721	rs12043945	ENSG00000230896.1	RP11-767N6.7	-3.8	0.000179	0.0353	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs12091503	ENSG00000230896.1	RP11-767N6.7	-3.8	0.000179	0.0353	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45694684~45697075:-
COAD	cis	rs4938303	0.788	rs61906115	ENSG00000254851.1	RP11-109L13.1	3.8	0.000179	0.0353	0.32	0.23	Triglycerides;	chr11:116687529	chr11:117135528~117138582:+
COAD	cis	rs34779708	0.966	rs1213392	ENSG00000271335.4	RP11-324I22.4	3.8	0.000179	0.0353	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35314552~35336401:-
COAD	cis	rs1479119	0.552	rs10744025	ENSG00000180861.8	LINC01559	3.8	0.000179	0.0353	0.26	0.23	Intelligence (multi-trait analysis);	chr12:13361055	chr12:13371089~13387167:-
COAD	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	3.8	0.000179	0.0353	0.27	0.23	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
COAD	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	3.8	0.000179	0.0353	0.27	0.23	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
COAD	cis	rs8017304	0.669	rs8013968	ENSG00000259502.1	RP11-643G16.3	-3.8	0.000179	0.0353	-0.3	-0.23	Age-related macular degeneration;	chr14:68343093	chr14:67610986~67613864:+
COAD	cis	rs8026198	0.929	rs73400993	ENSG00000260571.1	BNIP3P5	-3.8	0.000179	0.0353	-0.36	-0.23	Fibrinogen levels;	chr15:42330242	chr15:42313687~42314386:+
COAD	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-3.8	0.000179	0.0353	-0.27	-0.23	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
COAD	cis	rs9409565	0.502	rs509022	ENSG00000231806.2	PCAT7	3.8	0.000179	0.0354	0.26	0.23	Colorectal cancer (alcohol consumption interaction);	chr9:94566989	chr9:94555069~94568127:+
COAD	cis	rs11229555	0.645	rs4347409	ENSG00000254602.1	AP000662.4	3.8	0.000179	0.0354	0.28	0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58408779	chr11:57638024~57652790:+
COAD	cis	rs13256369	0.802	rs13255789	ENSG00000253981.4	ALG1L13P	3.8	0.000179	0.0354	0.33	0.23	Obesity-related traits;	chr8:8705281	chr8:8236003~8244667:-
COAD	cis	rs3738443	0.599	rs6693807	ENSG00000259865.1	RP11-488L18.10	-3.8	0.000179	0.0354	-0.22	-0.23	Alcohol dependence;	chr1:247230353	chr1:247187281~247188526:-
COAD	cis	rs1552244	1	rs2272123	ENSG00000186162.9	CIDECP	3.8	0.000179	0.0354	0.33	0.23	Alzheimer's disease;	chr3:10098431	chr3:10014238~10026365:-
COAD	cis	rs1552244	1	rs58275763	ENSG00000186162.9	CIDECP	3.8	0.000179	0.0354	0.33	0.23	Alzheimer's disease;	chr3:10101590	chr3:10014238~10026365:-
COAD	cis	rs453301	0.571	rs2929452	ENSG00000254340.1	RP11-10A14.3	-3.8	0.000179	0.0354	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9226955	chr8:9141424~9145435:+
COAD	cis	rs7577696	0.813	rs212723	ENSG00000272716.1	RP11-563N4.1	3.8	0.000179	0.0354	0.24	0.23	Inflammatory biomarkers;	chr2:32242079	chr2:32165046~32165757:-
COAD	cis	rs2032447	0.507	rs478349	ENSG00000168405.13	CMAHP	3.8	0.000179	0.0354	0.24	0.23	Intelligence (multi-trait analysis);	chr6:25893829	chr6:25081068~25166555:-
COAD	cis	rs7328464	0.778	rs61967083	ENSG00000215417.9	MIR17HG	3.8	0.000179	0.0354	0.3	0.23	Obesity-related traits;	chr13:91785624	chr13:91347820~91354579:+
COAD	cis	rs797680	0.856	rs6685271	ENSG00000230439.2	RP11-488P3.1	3.8	0.000179	0.0354	0.32	0.23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93169033	chr1:93752924~93775444:-
COAD	cis	rs4718428	0.705	rs13220977	ENSG00000272831.1	RP11-792A8.4	-3.8	0.000179	0.0354	-0.26	-0.23	Corneal structure;	chr7:66872661	chr7:66739829~66740385:-
COAD	cis	rs11098499	0.754	rs1814813	ENSG00000250412.1	KLHL2P1	-3.8	0.000179	0.0354	-0.3	-0.23	Corneal astigmatism;	chr4:119337052	chr4:119334329~119378233:+
COAD	cis	rs739496	0.843	rs12369009	ENSG00000257595.2	RP3-473L9.4	-3.8	0.000179	0.0354	-0.32	-0.23	Platelet count;	chr12:111581995	chr12:111369282~111403310:+
COAD	cis	rs670292	1	rs606775	ENSG00000216906.2	RP11-350J20.9	3.8	0.000179	0.0354	0.3	0.23	Anger;	chr6:150383660	chr6:149904243~149906418:+
COAD	cis	rs670292	1	rs9480339	ENSG00000216906.2	RP11-350J20.9	3.8	0.000179	0.0354	0.3	0.23	Anger;	chr6:150385360	chr6:149904243~149906418:+
COAD	cis	rs670292	1	rs9480340	ENSG00000216906.2	RP11-350J20.9	3.8	0.000179	0.0354	0.3	0.23	Anger;	chr6:150385710	chr6:149904243~149906418:+
COAD	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	3.8	0.000179	0.0354	0.26	0.23	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
COAD	cis	rs1387259	0.723	rs2732488	ENSG00000269514.1	RP11-370I10.12	3.8	0.000179	0.0354	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48198387~48202031:+
COAD	cis	rs1387259	0.758	rs2634670	ENSG00000269514.1	RP11-370I10.12	3.8	0.000179	0.0354	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48198387~48202031:+
COAD	cis	rs6565180	0.926	rs12446288	ENSG00000261367.1	RP11-455F5.4	-3.8	0.000179	0.0354	-0.25	-0.23	Tonsillectomy;	chr16:30377388	chr16:30107675~30110541:+
COAD	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	3.8	0.000179	0.0354	0.28	0.23	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
COAD	cis	rs240993	0.812	rs6929024	ENSG00000271789.1	RP5-1112D6.7	3.8	0.000179	0.0354	0.25	0.23	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111297126~111298510:+
COAD	cis	rs10760158	0.8	rs10739595	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000179	0.0354	-0.25	-0.23	Pulse pressure;	chr9:121293743	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs10760169	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000179	0.0354	-0.25	-0.23	Pulse pressure;	chr9:121295404	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs10760171	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000179	0.0354	-0.25	-0.23	Pulse pressure;	chr9:121296081	chr9:120824828~120854385:+
COAD	cis	rs6840360	1	rs4571	ENSG00000251611.1	RP11-610P16.1	-3.8	0.00018	0.0354	-0.23	-0.23	Intelligence (multi-trait analysis);	chr4:151671039	chr4:151407551~151408835:-
COAD	cis	rs7674212	0.531	rs4698876	ENSG00000248971.2	KRT8P46	-3.8	0.00018	0.0354	-0.23	-0.23	Type 2 diabetes;	chr4:103012410	chr4:102728746~102730171:-
COAD	cis	rs7674212	0.531	rs7665026	ENSG00000248971.2	KRT8P46	-3.8	0.00018	0.0354	-0.23	-0.23	Type 2 diabetes;	chr4:103015491	chr4:102728746~102730171:-
COAD	cis	rs7615952	0.575	rs35949599	ENSG00000241288.6	RP11-379B18.5	-3.8	0.00018	0.0355	-0.24	-0.23	Blood pressure (smoking interaction);	chr3:125825359	chr3:125827238~125916384:-
COAD	cis	rs2732480	1	rs2732480	ENSG00000226413.2	OR8T1P	-3.8	0.00018	0.0355	-0.26	-0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48442030~48442947:-
COAD	cis	rs2908835	0.705	rs35428220	ENSG00000247157.5	LINC01252	-3.8	0.00018	0.0355	-0.37	-0.23	Information processing speed;	chr12:11491258	chr12:11548030~11590369:+
COAD	cis	rs34779708	0.931	rs4934724	ENSG00000271335.4	RP11-324I22.4	3.8	0.00018	0.0355	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35314552~35336401:-
COAD	cis	rs7572733	0.935	rs771016	ENSG00000222017.1	AC011997.1	3.8	0.00018	0.0355	0.26	0.23	Dermatomyositis;	chr2:197800796	chr2:197693106~197774823:+
COAD	cis	rs4443656	0.933	rs6980554	ENSG00000254064.1	CTD-2530N21.4	3.8	0.00018	0.0355	0.22	0.23	Blood protein levels;	chr8:21675458	chr8:22254576~22275162:-
COAD	cis	rs4074961	0.669	rs4652964	ENSG00000233621.1	LINC01137	-3.8	0.00018	0.0355	-0.26	-0.23	Axial length;	chr1:37612628	chr1:37454879~37474411:-
COAD	cis	rs6067053	0.671	rs6067024	ENSG00000222365.1	SNORD12B	3.8	0.00018	0.0355	0.2	0.23	Intelligence (multi-trait analysis);	chr20:49226609	chr20:49280319~49280409:+
COAD	cis	rs13188386	0.763	rs4365846	ENSG00000249779.1	RP11-447H19.3	-3.8	0.00018	0.0355	-0.28	-0.23	Iron status biomarkers;	chr5:42547153	chr5:43206709~43207811:+
COAD	cis	rs2173063	0.568	rs61130781	ENSG00000272888.4	LINC01578	3.8	0.00018	0.0355	0.37	0.23	Subcutaneous adipose tissue;	chr15:92581791	chr15:92882707~92899701:+
COAD	cis	rs7000734	0.598	rs2678841	ENSG00000245080.5	RP11-320N21.1	-3.8	0.00018	0.0355	-0.41	-0.23	Radiation response;	chr8:95076287	chr8:95066808~95073182:-
COAD	cis	rs4657482	0.607	rs3790672	ENSG00000203307.2	RP11-375H19.2	3.8	0.00018	0.0355	0.34	0.23	Testicular germ cell tumor;	chr1:165904155	chr1:166081183~166087483:+
COAD	cis	rs71636778	0.631	rs76133297	ENSG00000260063.1	RP5-968P14.2	-3.8	0.00018	0.0355	-0.35	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26827979	chr1:26692132~26694131:-
COAD	cis	rs2836974	0.644	rs11088472	ENSG00000255568.3	BRWD1-AS2	-3.8	0.00018	0.0355	-0.21	-0.23	Cognitive function;	chr21:39327450	chr21:39313935~39314962:+
COAD	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	3.8	0.00018	0.0355	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	3.8	0.00018	0.0355	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
COAD	cis	rs2777491	1	rs11631770	ENSG00000247556.5	OIP5-AS1	3.8	0.00018	0.0356	0.26	0.23	Ulcerative colitis;	chr15:41444861	chr15:41283990~41309737:+
COAD	cis	rs1971762	0.966	rs11170631	ENSG00000278185.1	RP11-153F5.7	3.8	0.00018	0.0356	0.24	0.23	Height;	chr12:53647408	chr12:52946614~52947125:-
COAD	cis	rs6452524	0.935	rs6884543	ENSG00000271862.1	RP11-343L5.2	3.8	0.00018	0.0356	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83049376~83050964:-
COAD	cis	rs13188386	0.732	rs11739444	ENSG00000249779.1	RP11-447H19.3	3.8	0.00018	0.0356	0.28	0.23	Iron status biomarkers;	chr5:42581342	chr5:43206709~43207811:+
COAD	cis	rs2929278	0.589	rs2411284	ENSG00000275601.1	AC011330.13	3.8	0.00018	0.0356	0.28	0.23	Schizophrenia;	chr15:43746701	chr15:43642389~43643023:-
COAD	cis	rs7246657	0.653	rs10414983	ENSG00000226686.6	LINC01535	-3.8	0.00018	0.0356	-0.38	-0.23	Coronary artery calcification;	chr19:37174830	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.598	rs10405372	ENSG00000226686.6	LINC01535	-3.8	0.00018	0.0356	-0.38	-0.23	Coronary artery calcification;	chr19:37177873	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.653	rs10425441	ENSG00000226686.6	LINC01535	-3.8	0.00018	0.0356	-0.38	-0.23	Coronary artery calcification;	chr19:37179746	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.653	rs4805207	ENSG00000226686.6	LINC01535	-3.8	0.00018	0.0356	-0.38	-0.23	Coronary artery calcification;	chr19:37182831	chr19:37251912~37265535:+
COAD	cis	rs7246657	0.653	rs28701616	ENSG00000226686.6	LINC01535	-3.8	0.00018	0.0356	-0.38	-0.23	Coronary artery calcification;	chr19:37190196	chr19:37251912~37265535:+
COAD	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-3.8	0.000181	0.0356	-0.37	-0.23	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
COAD	cis	rs2559856	1	rs2695281	ENSG00000199933.1	RNY1P16	3.8	0.000181	0.0356	0.25	0.23	Blood protein levels;	chr12:101696221	chr12:101719808~101719918:+
COAD	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	3.8	0.000181	0.0356	0.33	0.23	Pain;	chr19:21468580	chr19:21554640~21569237:-
COAD	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-3.8	0.000181	0.0356	-0.23	-0.23	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
COAD	cis	rs6585424	1	rs10466226	ENSG00000234382.2	RP11-40F6.1	3.8	0.000181	0.0356	0.38	0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164299	chr10:80233664~80245367:+
COAD	cis	rs71636778	0.631	rs12747620	ENSG00000260063.1	RP5-968P14.2	-3.8	0.000181	0.0356	-0.33	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26855770	chr1:26692132~26694131:-
COAD	cis	rs10129255	0.646	rs55995061	ENSG00000211964.3	IGHV3-48	-3.8	0.000181	0.0356	-0.19	-0.23	Kawasaki disease;	chr14:106799309	chr14:106537810~106538344:-
COAD	cis	rs2337406	1	rs17095456	ENSG00000211964.3	IGHV3-48	-3.8	0.000181	0.0356	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106676559	chr14:106537810~106538344:-
COAD	cis	rs875971	1	rs1167411	ENSG00000179406.6	LINC00174	-3.8	0.000181	0.0357	-0.17	-0.23	Aortic root size;	chr7:66074277	chr7:66376044~66401338:-
COAD	cis	rs4074961	0.669	rs6687545	ENSG00000233621.1	LINC01137	-3.8	0.000181	0.0357	-0.26	-0.23	Axial length;	chr1:37605594	chr1:37454879~37474411:-
COAD	cis	rs11098499	1	rs6837898	ENSG00000250412.1	KLHL2P1	3.8	0.000181	0.0357	0.31	0.23	Corneal astigmatism;	chr4:119257999	chr4:119334329~119378233:+
COAD	cis	rs9880211	0.613	rs6767060	ENSG00000273486.1	RP11-731C17.2	3.8	0.000181	0.0357	0.27	0.23	Height;Body mass index;	chr3:136148248	chr3:136837338~136839021:-
COAD	cis	rs2562784	0.597	rs2562785	ENSG00000225151.9	GOLGA2P7	-3.8	0.000181	0.0357	-0.4	-0.23	Height;	chr15:83617269	chr15:84199311~84230136:-
COAD	cis	rs4883201	0.611	rs1805754	ENSG00000249790.2	RP11-20D14.6	-3.8	0.000181	0.0357	-0.31	-0.23	Total cholesterol levels;Cholesterol, total;	chr12:8950652	chr12:8788257~8795789:+
COAD	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	3.8	0.000181	0.0357	0.31	0.23	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
COAD	cis	rs7172689	1	rs4128766	ENSG00000271725.1	RP11-761I4.4	3.8	0.000181	0.0357	0.28	0.23	Inattentive symptoms;	chr15:81251128	chr15:81303215~81309391:-
COAD	cis	rs1275468	1	rs1148005	ENSG00000257497.2	RP11-585P4.5	-3.8	0.000181	0.0357	-0.3	-0.23	Polycystic ovary syndrome;	chr12:75584733	chr12:75483454~75489820:-
COAD	cis	rs9393777	0.841	rs67092078	ENSG00000224843.5	LINC00240	3.8	0.000181	0.0357	0.63	0.23	Intelligence (multi-trait analysis);	chr6:27086993	chr6:26956992~27023924:+
COAD	cis	rs561341	0.714	rs473535	ENSG00000265798.5	RP11-271K11.5	3.8	0.000181	0.0357	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31985346	chr17:31038575~31059121:-
COAD	cis	rs9868809	0.881	rs2276852	ENSG00000225399.4	RP11-3B7.1	-3.8	0.000181	0.0357	-0.32	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629490	chr3:49260085~49261316:+
COAD	cis	rs11089937	0.626	rs11089933	ENSG00000211638.2	IGLV8-61	-3.8	0.000181	0.0357	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22098700~22099212:+
COAD	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	3.8	0.000181	0.0357	0.39	0.23	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
COAD	cis	rs2124910	0.756	rs10422359	ENSG00000255441.1	CTD-2616J11.2	-3.8	0.000181	0.0357	-0.25	-0.23	Blood protein levels;	chr19:51543824	chr19:51415724~51417425:+
COAD	cis	rs6661961	0.752	rs7531606	ENSG00000237975.5	FLG-AS1	-3.8	0.000181	0.0357	-0.24	-0.23	Atopic dermatitis;	chr1:152454394	chr1:152168125~152445456:+
COAD	cis	rs4938303	0.788	rs12799766	ENSG00000254851.1	RP11-109L13.1	-3.8	0.000181	0.0357	-0.31	-0.23	Triglycerides;	chr11:116687711	chr11:117135528~117138582:+
COAD	cis	rs7674212	0.539	rs7676041	ENSG00000230069.3	LRRC37A15P	-3.8	0.000181	0.0357	-0.24	-0.23	Type 2 diabetes;	chr4:103205264	chr4:102727274~102730721:-
COAD	cis	rs1048886	0.938	rs16869267	ENSG00000271967.1	RP11-134K13.4	-3.8	0.000181	0.0357	-0.33	-0.23	Type 2 diabetes;	chr6:70483751	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs80138927	ENSG00000271967.1	RP11-134K13.4	-3.8	0.000181	0.0357	-0.33	-0.23	Type 2 diabetes;	chr6:70487403	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs58085250	ENSG00000271967.1	RP11-134K13.4	-3.8	0.000181	0.0357	-0.33	-0.23	Type 2 diabetes;	chr6:70508878	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs55968813	ENSG00000271967.1	RP11-134K13.4	-3.8	0.000181	0.0357	-0.33	-0.23	Type 2 diabetes;	chr6:70514521	chr6:70596438~70596980:+
COAD	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	3.8	0.000181	0.0357	0.27	0.23	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
COAD	cis	rs9888736	0.899	rs10519136	ENSG00000259488.2	RP11-154J22.1	-3.8	0.000182	0.0357	-0.25	-0.23	Body mass index;	chr15:47640966	chr15:48312353~48331856:-
COAD	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	3.8	0.000182	0.0357	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
COAD	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-3.8	0.000182	0.0358	-0.26	-0.23	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
COAD	cis	rs9818758	0.607	rs56004653	ENSG00000225399.4	RP11-3B7.1	-3.8	0.000182	0.0358	-0.49	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.607	rs73082362	ENSG00000225399.4	RP11-3B7.1	-3.8	0.000182	0.0358	-0.49	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:49260085~49261316:+
COAD	cis	rs73607972	0.935	rs73603987	ENSG00000275191.1	RP11-36I17.2	-3.8	0.000182	0.0358	-0.33	-0.23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577714	chr16:53628256~53628816:-
COAD	cis	rs73607972	0.799	rs112105499	ENSG00000275191.1	RP11-36I17.2	-3.8	0.000182	0.0358	-0.33	-0.23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577948	chr16:53628256~53628816:-
COAD	cis	rs3126085	0.935	rs1390487	ENSG00000237975.5	FLG-AS1	-3.8	0.000182	0.0358	-0.25	-0.23	Atopic dermatitis;	chr1:152222125	chr1:152168125~152445456:+
COAD	cis	rs6095360	1	rs1569750	ENSG00000227431.4	CSE1L-AS1	-3.8	0.000182	0.0358	-0.27	-0.23	Intelligence (multi-trait analysis);	chr20:48986704	chr20:49040463~49046044:-
COAD	cis	rs17685	0.753	rs11972240	ENSG00000280388.1	RP11-229D13.3	-3.8	0.000182	0.0358	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76043977~76045963:-
COAD	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	3.8	0.000182	0.0358	0.25	0.23	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
COAD	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	3.8	0.000182	0.0358	0.32	0.23	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
COAD	cis	rs68170813	0.605	rs74632724	ENSG00000241764.3	AC002467.7	3.8	0.000182	0.0358	0.34	0.23	Coronary artery disease;	chr7:107496314	chr7:107742817~107744581:-
COAD	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-3.8	0.000182	0.0358	-0.26	-0.23	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
COAD	cis	rs7577696	0.962	rs2235134	ENSG00000272716.1	RP11-563N4.1	-3.8	0.000182	0.0358	-0.24	-0.23	Inflammatory biomarkers;	chr2:32107474	chr2:32165046~32165757:-
COAD	cis	rs1707322	0.721	rs10890336	ENSG00000230896.1	RP11-767N6.7	-3.8	0.000182	0.0358	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45694684~45697075:-
COAD	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-3.8	0.000182	0.0358	-0.31	-0.23	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
COAD	cis	rs7131987	0.903	rs7302129	ENSG00000257176.2	RP11-996F15.2	-3.8	0.000182	0.0358	-0.27	-0.23	QT interval;	chr12:29262347	chr12:29280418~29317848:-
COAD	cis	rs2919009	0.664	rs57078496	ENSG00000271670.1	RP11-95I16.4	3.8	0.000182	0.0358	0.32	0.23	Obesity-related traits;	chr10:120881877	chr10:120879256~120880667:-
COAD	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-3.8	0.000182	0.0358	-0.28	-0.23	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-3.8	0.000182	0.0358	-0.28	-0.23	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
COAD	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	3.8	0.000182	0.0359	0.42	0.23	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
COAD	cis	rs11874381	1	rs36089715	ENSG00000264269.1	RP11-15F12.1	-3.8	0.000182	0.0359	-0.3	-0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49686652	chr18:49023703~49048474:+
COAD	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	3.8	0.000182	0.0359	0.32	0.23	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
COAD	cis	rs12468226	0.938	rs58834901	ENSG00000226261.1	AC064836.3	3.8	0.000182	0.0359	0.35	0.23	Urate levels;	chr2:202288169	chr2:202336024~202336727:-
COAD	cis	rs1707322	0.721	rs28501477	ENSG00000230896.1	RP11-767N6.7	-3.8	0.000182	0.0359	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45694684~45697075:-
COAD	cis	rs7584330	0.554	rs55919896	ENSG00000234949.2	AC104667.3	-3.8	0.000182	0.0359	-0.34	-0.23	Prostate cancer;	chr2:237520180	chr2:237591020~237595981:+
COAD	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-3.8	0.000182	0.0359	-0.41	-0.23	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
COAD	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000183	0.0359	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
COAD	cis	rs11098499	0.754	rs7672372	ENSG00000250412.1	KLHL2P1	3.8	0.000183	0.0359	0.3	0.23	Corneal astigmatism;	chr4:119327251	chr4:119334329~119378233:+
COAD	cis	rs9880211	0.718	rs56398805	ENSG00000239213.4	NCK1-AS1	3.8	0.000183	0.0359	0.3	0.23	Height;Body mass index;	chr3:136213558	chr3:136841726~136862054:-
COAD	cis	rs10779751	1	rs6679878	ENSG00000215785.2	CFL1P6	-3.8	0.000183	0.0359	-0.26	-0.23	Body mass index;	chr1:11246825	chr1:10990978~10991797:-
COAD	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-3.8	0.000183	0.0359	-0.28	-0.23	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
COAD	cis	rs886716	0.692	rs6943220	ENSG00000280255.1	RP5-1007F24.1	3.8	0.000183	0.0359	0.27	0.23	Smoking behavior;	chr7:26526647	chr7:26538378~26541048:+
COAD	cis	rs12935418	0.673	rs2602428	ENSG00000278985.1	RP11-303E16.9	-3.8	0.000183	0.0359	-0.25	-0.23	Mean corpuscular volume;	chr16:81028566	chr16:80982319~80984094:-
COAD	cis	rs364477	0.548	rs10759043	ENSG00000235330.2	RP11-165F24.2	-3.8	0.000183	0.0359	-0.27	-0.23	Major depressive disorder;	chr9:921872	chr9:477750~478423:+
COAD	cis	rs362296	0.698	rs362282	ENSG00000248840.2	RP11-357G3.2	3.8	0.000183	0.0359	0.28	0.23	Parental longevity (mother's age at death);	chr4:3257944	chr4:3312512~3313058:+
COAD	cis	rs925255	1	rs4666070	ENSG00000270210.1	RP11-373D23.3	-3.8	0.000183	0.0359	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28401966	chr2:28425945~28426719:+
COAD	cis	rs752010	0.53	rs10789401	ENSG00000230638.4	RP11-486B10.4	-3.8	0.000183	0.0359	-0.29	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41615440	chr1:41542069~41544310:+
COAD	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	3.8	0.000183	0.0359	0.27	0.23	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
COAD	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	3.8	0.000183	0.0359	0.27	0.23	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
COAD	cis	rs9907295	0.688	rs4796135	ENSG00000271013.1	AC015849.15	-3.8	0.000183	0.036	-0.37	-0.23	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.688	rs4796136	ENSG00000271013.1	AC015849.15	-3.8	0.000183	0.036	-0.37	-0.23	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35912635~35918010:-
COAD	cis	rs9907295	0.688	rs4796137	ENSG00000271013.1	AC015849.15	-3.8	0.000183	0.036	-0.37	-0.23	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35912635~35918010:-
COAD	cis	rs57221529	0.766	rs17497684	ENSG00000250385.1	RP11-310P5.2	3.8	0.000183	0.036	0.39	0.23	Lung disease severity in cystic fibrosis;	chr5:558192	chr5:524705~526594:+
COAD	cis	rs875971	1	rs6958271	ENSG00000223473.2	GS1-124K5.3	3.8	0.000183	0.036	0.19	0.23	Aortic root size;	chr7:66514344	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs6958277	ENSG00000223473.2	GS1-124K5.3	3.8	0.000183	0.036	0.19	0.23	Aortic root size;	chr7:66514362	chr7:66491049~66493566:-
COAD	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-3.8	0.000183	0.036	-0.21	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
COAD	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	3.8	0.000183	0.036	0.29	0.23	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	3.8	0.000183	0.036	0.29	0.23	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	3.8	0.000183	0.036	0.29	0.23	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
COAD	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	3.8	0.000183	0.036	0.16	0.23	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
COAD	cis	rs10871290	0.65	rs3760055	ENSG00000262904.1	TMPOP2	-3.8	0.000183	0.036	-0.26	-0.23	Breast cancer;	chr16:74456631	chr16:74667506~74668706:+
COAD	cis	rs12188164	1	rs12188678	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:428116	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs12188164	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:428121	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs72717411	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:429009	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs72717412	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:429266	chr5:441498~443160:-
COAD	cis	rs12188164	1	rs72717414	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:429703	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs72717415	ENSG00000221990.4	EXOC3-AS1	3.8	0.000183	0.036	0.24	0.23	Cystic fibrosis severity;	chr5:429944	chr5:441498~443160:-
COAD	cis	rs9307551	1	rs13104009	ENSG00000250334.4	LINC00989	-3.8	0.000183	0.036	-0.33	-0.23	Refractive error;	chr4:79609584	chr4:79492416~79576460:+
COAD	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	3.8	0.000183	0.036	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
COAD	cis	rs17646946	1	rs17646946	ENSG00000229021.2	AL591893.1	3.8	0.000183	0.036	0.33	0.23	Common traits (Other);	chr1:152090291	chr1:151994531~152042774:+
COAD	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	3.8	0.000183	0.036	0.23	0.23	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
COAD	cis	rs6095360	0.727	rs17448715	ENSG00000222365.1	SNORD12B	-3.8	0.000183	0.036	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49075206	chr20:49280319~49280409:+
COAD	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-3.8	0.000183	0.036	-0.27	-0.23	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
COAD	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-3.8	0.000183	0.036	-0.27	-0.23	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
COAD	cis	rs10760158	0.832	rs3810942	ENSG00000226752.6	PSMD5-AS1	-3.8	0.000183	0.036	-0.25	-0.23	Pulse pressure;	chr9:121282717	chr9:120824828~120854385:+
COAD	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-3.8	0.000183	0.036	-0.3	-0.23	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
COAD	cis	rs41278232	0.557	rs2022415	ENSG00000196421.6	LINC00176	-3.8	0.000183	0.036	-0.28	-0.23	Tonsillectomy;	chr20:64006728	chr20:64034344~64039962:+
COAD	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-3.8	0.000183	0.036	-0.38	-0.23	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
COAD	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	3.8	0.000183	0.036	0.47	0.23	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
COAD	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	3.8	0.000183	0.036	0.24	0.23	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
COAD	cis	rs10129255	0.53	rs11624912	ENSG00000211967.3	IGHV3-53	-3.8	0.000183	0.036	-0.13	-0.23	Kawasaki disease;	chr14:106673891	chr14:106592676~106593347:-
COAD	cis	rs7142002	0.568	rs6575884	ENSG00000272444.1	RP11-1017G21.6	-3.8	0.000183	0.036	-0.32	-0.23	Autism;	chr14:101924400	chr14:101952416~101953063:+
COAD	cis	rs9400467	0.508	rs61269242	ENSG00000230177.1	RP5-1112D6.4	-3.8	0.000184	0.0361	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111277932~111278742:+
COAD	cis	rs7582403	0.844	rs10928374	ENSG00000281469.1	RP11-567F11.1	-3.8	0.000184	0.0361	-0.27	-0.23	Neuroticism;	chr2:148094466	chr2:148044380~148044894:+
COAD	cis	rs7582403	0.844	rs6753116	ENSG00000281469.1	RP11-567F11.1	-3.8	0.000184	0.0361	-0.27	-0.23	Neuroticism;	chr2:148094946	chr2:148044380~148044894:+
COAD	cis	rs10819861	0.621	rs4742839	ENSG00000238251.2	RP11-172F4.2	-3.8	0.000184	0.0361	-0.29	-0.23	Electrocardiographic traits;	chr9:96085628	chr9:96407284~96407797:+
COAD	cis	rs7582403	0.737	rs6430287	ENSG00000281469.1	RP11-567F11.1	-3.8	0.000184	0.0361	-0.27	-0.23	Neuroticism;	chr2:148091849	chr2:148044380~148044894:+
COAD	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-3.8	0.000184	0.0361	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-3.8	0.000184	0.0361	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-3.8	0.000184	0.0361	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-3.8	0.000184	0.0361	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
COAD	cis	rs2337406	0.866	rs78462736	ENSG00000211964.3	IGHV3-48	-3.8	0.000184	0.0361	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106779942	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs8016203	ENSG00000211964.3	IGHV3-48	-3.8	0.000184	0.0361	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106780575	chr14:106537810~106538344:-
COAD	cis	rs6125961	0.629	rs6125971	ENSG00000224397.4	LINC01272	3.8	0.000184	0.0361	0.27	0.23	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50299229	chr20:50267486~50279795:+
COAD	cis	rs6480314	0.522	rs11816028	ENSG00000233590.1	RP11-153K11.3	-3.8	0.000184	0.0361	-0.33	-0.23	Optic nerve measurement (disc area);	chr10:68296566	chr10:68233251~68242379:-
COAD	cis	rs3733829	1	rs3736329	ENSG00000279759.1	CTC-425O23.5	-3.8	0.000184	0.0361	-0.2	-0.23	Smoking behavior;	chr19:40807297	chr19:40355842~40360606:+
COAD	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	3.8	0.000184	0.0361	0.24	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
COAD	cis	rs1426063	0.858	rs7666182	ENSG00000249717.1	RP11-44F21.3	3.8	0.000184	0.0361	0.33	0.23	QT interval;	chr4:75090989	chr4:74955974~74970362:-
COAD	cis	rs9652601	0.622	rs2286974	ENSG00000274038.1	RP11-66H6.4	-3.8	0.000184	0.0361	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11020655	chr16:11056556~11057034:+
COAD	cis	rs6844506	1	rs1776003	ENSG00000244512.3	RN7SL28P	3.8	0.000184	0.0361	0.28	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr4:184294847	chr4:184278936~184279233:+
COAD	cis	rs911555	0.755	rs12436729	ENSG00000251533.2	LINC00605	3.8	0.000184	0.0361	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103187221~103189028:-
COAD	cis	rs2395128	0.588	rs11001170	ENSG00000237882.1	PPIAP13	3.8	0.000184	0.0361	0.39	0.23	Ulcerative colitis;Inflammatory bowel disease;	chr10:74809016	chr10:75089248~75089725:-
COAD	cis	rs2395128	0.667	rs10824239	ENSG00000237882.1	PPIAP13	-3.8	0.000184	0.0361	-0.39	-0.23	Ulcerative colitis;Inflammatory bowel disease;	chr10:74808247	chr10:75089248~75089725:-
COAD	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	3.8	0.000184	0.0361	0.14	0.23	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
COAD	cis	rs1451488	0.839	rs12693881	ENSG00000257045.1	RP11-486F17.1	3.8	0.000184	0.0361	0.21	0.23	Schizophrenia;	chr2:199166008	chr2:199325310~199329362:+
COAD	cis	rs7577696	0.962	rs2280967	ENSG00000272716.1	RP11-563N4.1	-3.8	0.000184	0.0361	-0.24	-0.23	Inflammatory biomarkers;	chr2:32064677	chr2:32165046~32165757:-
COAD	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-3.8	0.000184	0.0361	-0.26	-0.23	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
COAD	cis	rs250677	1	rs40525	ENSG00000250072.4	CTC-529P8.1	3.79	0.000184	0.0362	0.33	0.23	Breast cancer;	chr5:149053369	chr5:149063317~149109787:+
COAD	cis	rs8022206	0.773	rs2588833	ENSG00000259502.1	RP11-643G16.3	3.79	0.000184	0.0362	0.31	0.23	Platelet count;Mean platelet volume;	chr14:68132775	chr14:67610986~67613864:+
COAD	cis	rs2638953	0.924	rs11049439	ENSG00000247934.4	RP11-967K21.1	-3.79	0.000184	0.0362	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28163298~28190738:-
COAD	cis	rs2337406	0.85	rs10131280	ENSG00000211967.3	IGHV3-53	-3.79	0.000184	0.0362	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106665591	chr14:106592676~106593347:-
COAD	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000184	0.0362	-0.32	-0.23	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000184	0.0362	-0.32	-0.23	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000184	0.0362	-0.32	-0.23	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
COAD	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000184	0.0362	-0.29	-0.23	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000184	0.0362	-0.29	-0.23	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000184	0.0362	-0.29	-0.23	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
COAD	cis	rs68170813	0.559	rs59782202	ENSG00000241764.3	AC002467.7	3.79	0.000184	0.0362	0.32	0.23	Coronary artery disease;	chr7:107392321	chr7:107742817~107744581:-
COAD	cis	rs68170813	0.523	rs79607134	ENSG00000241764.3	AC002467.7	3.79	0.000184	0.0362	0.32	0.23	Coronary artery disease;	chr7:107393174	chr7:107742817~107744581:-
COAD	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-3.79	0.000184	0.0362	-0.24	-0.23	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
COAD	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-3.79	0.000184	0.0362	-0.24	-0.23	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
COAD	cis	rs4077341	0.966	rs12549481	ENSG00000246582.2	RP11-1149O23.3	-3.79	0.000185	0.0362	-0.26	-0.23	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr8:23102545	chr8:23224471~23230926:+
COAD	cis	rs8002861	0.664	rs4942246	ENSG00000274001.1	RP11-5G9.5	3.79	0.000185	0.0362	0.21	0.23	Leprosy;	chr13:43830717	chr13:43877715~43878163:-
COAD	cis	rs8002861	0.664	rs4942247	ENSG00000274001.1	RP11-5G9.5	3.79	0.000185	0.0362	0.21	0.23	Leprosy;	chr13:43830971	chr13:43877715~43878163:-
COAD	cis	rs875971	0.964	rs55748098	ENSG00000223473.2	GS1-124K5.3	-3.79	0.000185	0.0362	-0.19	-0.23	Aortic root size;	chr7:66298631	chr7:66491049~66493566:-
COAD	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-3.79	0.000185	0.0362	-0.29	-0.23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
COAD	cis	rs7577696	0.925	rs212718	ENSG00000272716.1	RP11-563N4.1	3.79	0.000185	0.0362	0.24	0.23	Inflammatory biomarkers;	chr2:32236764	chr2:32165046~32165757:-
COAD	cis	rs875971	0.965	rs697968	ENSG00000179406.6	LINC00174	-3.79	0.000185	0.0362	-0.17	-0.23	Aortic root size;	chr7:66070046	chr7:66376044~66401338:-
COAD	cis	rs875971	1	rs1183245	ENSG00000179406.6	LINC00174	-3.79	0.000185	0.0362	-0.17	-0.23	Aortic root size;	chr7:66076198	chr7:66376044~66401338:-
COAD	cis	rs875971	1	rs1144895	ENSG00000179406.6	LINC00174	-3.79	0.000185	0.0362	-0.17	-0.23	Aortic root size;	chr7:66076320	chr7:66376044~66401338:-
COAD	cis	rs875971	1	rs1144894	ENSG00000179406.6	LINC00174	-3.79	0.000185	0.0362	-0.17	-0.23	Aortic root size;	chr7:66077907	chr7:66376044~66401338:-
COAD	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-3.79	0.000185	0.0362	-0.27	-0.23	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
COAD	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-3.79	0.000185	0.0362	-0.38	-0.23	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
COAD	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-3.79	0.000185	0.0362	-0.26	-0.23	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
COAD	cis	rs9880211	0.8	rs66509730	ENSG00000239213.4	NCK1-AS1	3.79	0.000185	0.0362	0.31	0.23	Height;Body mass index;	chr3:136785416	chr3:136841726~136862054:-
COAD	cis	rs2559856	1	rs2559856	ENSG00000199933.1	RNY1P16	3.79	0.000185	0.0362	0.25	0.23	Blood protein levels;	chr12:101695783	chr12:101719808~101719918:+
COAD	cis	rs11098499	0.863	rs10018280	ENSG00000250412.1	KLHL2P1	3.79	0.000185	0.0363	0.31	0.23	Corneal astigmatism;	chr4:119556984	chr4:119334329~119378233:+
COAD	cis	rs3120667	0.72	rs72698981	ENSG00000237975.5	FLG-AS1	3.79	0.000185	0.0363	0.32	0.23	Eating disorders;	chr1:152468451	chr1:152168125~152445456:+
COAD	cis	rs3120667	0.72	rs72698982	ENSG00000237975.5	FLG-AS1	3.79	0.000185	0.0363	0.32	0.23	Eating disorders;	chr1:152468939	chr1:152168125~152445456:+
COAD	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	3.79	0.000185	0.0363	0.27	0.23	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
COAD	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-3.79	0.000185	0.0363	-0.28	-0.23	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-3.79	0.000185	0.0363	-0.28	-0.23	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-3.79	0.000185	0.0363	-0.28	-0.23	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
COAD	cis	rs1790761	0.806	rs1638557	ENSG00000231793.4	DOC2GP	-3.79	0.000185	0.0363	-0.26	-0.23	Mean corpuscular volume;	chr11:67448517	chr11:67612653~67616257:-
COAD	cis	rs2018683	0.933	rs12536127	ENSG00000272568.4	CTB-113D17.1	3.79	0.000185	0.0363	0.32	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28979967~29013367:+
COAD	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	3.79	0.000185	0.0363	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
COAD	cis	rs4879656	0.966	rs10971309	ENSG00000225693.1	LAGE3P1	-3.79	0.000185	0.0363	-0.28	-0.23	Menopause (age at onset);	chr9:33009857	chr9:33019682~33020165:-
COAD	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	3.79	0.000185	0.0363	0.27	0.23	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
COAD	cis	rs3733585	0.699	rs7694997	ENSG00000250413.1	RP11-448G15.1	3.79	0.000185	0.0363	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9946187	chr4:10006482~10009725:+
COAD	cis	rs7200786	0.546	rs1861198	ENSG00000274038.1	RP11-66H6.4	-3.79	0.000185	0.0363	-0.29	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11117726	chr16:11056556~11057034:+
COAD	cis	rs10760158	0.832	rs878691	ENSG00000226752.6	PSMD5-AS1	-3.79	0.000185	0.0363	-0.25	-0.23	Pulse pressure;	chr9:121275329	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs880823	ENSG00000226752.6	PSMD5-AS1	-3.79	0.000185	0.0363	-0.25	-0.23	Pulse pressure;	chr9:121276189	chr9:120824828~120854385:+
COAD	cis	rs728616	0.614	rs61859199	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.000185	0.0363	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79663088~79826594:-
COAD	cis	rs728616	0.614	rs1538818	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.000185	0.0363	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79663088~79826594:-
COAD	cis	rs728616	0.614	rs61859209	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.000185	0.0363	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79663088~79826594:-
COAD	cis	rs728616	0.614	rs61859210	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.000185	0.0363	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79663088~79826594:-
COAD	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-3.79	0.000185	0.0363	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
COAD	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000185	0.0363	-0.31	-0.23	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000185	0.0363	-0.31	-0.23	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
COAD	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-3.79	0.000185	0.0363	-0.31	-0.23	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
COAD	cis	rs12699921	0.658	rs2691592	ENSG00000279048.1	RP11-511H23.2	-3.79	0.000185	0.0363	-0.17	-0.23	Fibrinogen levels;	chr7:17779817	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.598	rs2691593	ENSG00000279048.1	RP11-511H23.2	-3.79	0.000185	0.0363	-0.17	-0.23	Fibrinogen levels;	chr7:17780032	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723507	ENSG00000279048.1	RP11-511H23.2	-3.79	0.000185	0.0363	-0.17	-0.23	Fibrinogen levels;	chr7:17780305	chr7:17940503~17942922:+
COAD	cis	rs12699921	0.632	rs2723506	ENSG00000279048.1	RP11-511H23.2	-3.79	0.000185	0.0363	-0.17	-0.23	Fibrinogen levels;	chr7:17780675	chr7:17940503~17942922:+
COAD	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-3.79	0.000185	0.0363	-0.25	-0.23	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
COAD	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-3.79	0.000186	0.0363	-0.31	-0.23	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
COAD	cis	rs4879656	0.897	rs1537256	ENSG00000225693.1	LAGE3P1	-3.79	0.000186	0.0363	-0.28	-0.23	Menopause (age at onset);	chr9:33004419	chr9:33019682~33020165:-
COAD	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	3.79	0.000186	0.0364	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
COAD	cis	rs720475	0.732	rs7784282	ENSG00000244479.5	OR2A1-AS1	-3.79	0.000186	0.0364	-0.31	-0.23	Breast cancer;	chr7:144431561	chr7:144251264~144356181:-
COAD	cis	rs11098499	0.866	rs72676074	ENSG00000250412.1	KLHL2P1	3.79	0.000186	0.0364	0.31	0.23	Corneal astigmatism;	chr4:119438686	chr4:119334329~119378233:+
COAD	cis	rs11673344	0.864	rs2562587	ENSG00000267309.1	CTD-2630F21.1	-3.79	0.000186	0.0364	-0.27	-0.23	Obesity-related traits;	chr19:37019357	chr19:36489649~36491040:+
COAD	cis	rs71520386	0.5	rs34856568	ENSG00000230658.1	KLHL7-AS1	3.79	0.000186	0.0364	0.31	0.23	Fibrinogen levels;	chr7:22798683	chr7:23101228~23105703:-
COAD	cis	rs867186	1	rs55946144	ENSG00000201151.1	SNORD56	3.79	0.000186	0.0364	0.34	0.23	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35041807	chr20:35117136~35117207:-
COAD	cis	rs867186	1	rs8118005	ENSG00000201151.1	SNORD56	3.79	0.000186	0.0364	0.34	0.23	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35048416	chr20:35117136~35117207:-
COAD	cis	rs867186	1	rs8124662	ENSG00000201151.1	SNORD56	3.79	0.000186	0.0364	0.34	0.23	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35051453	chr20:35117136~35117207:-
COAD	cis	rs4730250	0.655	rs4727671	ENSG00000241764.3	AC002467.7	3.79	0.000186	0.0364	0.32	0.23	Osteoarthritis;	chr7:107235600	chr7:107742817~107744581:-
COAD	cis	rs68170813	0.559	rs74906766	ENSG00000241764.3	AC002467.7	3.79	0.000186	0.0364	0.32	0.23	Coronary artery disease;	chr7:107244791	chr7:107742817~107744581:-
COAD	cis	rs2909678	1	rs2909678	ENSG00000231721.5	LINC-PINT	-3.79	0.000186	0.0364	-0.3	-0.23	Alcohol dependence symptom count;	chr7:131649242	chr7:130941760~131110176:-
COAD	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	3.79	0.000186	0.0364	0.3	0.23	Depression;	chr6:28199145	chr6:28170845~28172521:+
COAD	cis	rs442309	0.687	rs10822058	ENSG00000228566.1	RP11-170M17.1	-3.79	0.000186	0.0364	-0.27	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62763822	chr10:63664664~63990568:+
COAD	cis	rs1499614	1	rs1267818	ENSG00000232559.3	GS1-124K5.12	3.79	0.000186	0.0364	0.41	0.23	Gout;	chr7:66642037	chr7:66554588~66576923:-
COAD	cis	rs13118159	0.55	rs13123016	ENSG00000254094.1	AC078852.1	-3.79	0.000186	0.0364	-0.28	-0.23	Longevity;	chr4:1347101	chr4:1356581~1358075:+
COAD	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	3.79	0.000186	0.0364	0.18	0.23	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
COAD	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-3.79	0.000186	0.0364	-0.29	-0.23	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
COAD	cis	rs10028773	0.7	rs7671797	ENSG00000250412.1	KLHL2P1	3.79	0.000186	0.0365	0.3	0.23	Educational attainment;	chr4:119327002	chr4:119334329~119378233:+
COAD	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	3.79	0.000186	0.0365	0.34	0.23	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
COAD	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-3.79	0.000186	0.0365	-0.34	-0.23	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
COAD	cis	rs7328464	0.633	rs7331895	ENSG00000215417.9	MIR17HG	3.79	0.000186	0.0365	0.29	0.23	Obesity-related traits;	chr13:91772386	chr13:91347820~91354579:+
COAD	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	3.79	0.000186	0.0365	0.27	0.23	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
COAD	cis	rs4819052	0.819	rs13046807	ENSG00000227039.5	ITGB2-AS1	-3.79	0.000186	0.0365	-0.2	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:44921051~44929678:+
COAD	cis	rs801193	0.636	rs10233806	ENSG00000224316.1	RP11-479O9.2	-3.79	0.000186	0.0365	-0.25	-0.23	Aortic root size;	chr7:66653261	chr7:65773620~65802067:+
COAD	cis	rs4820539	1	rs4822357	ENSG00000211644.2	IGLV1-51	-3.79	0.000186	0.0365	-0.13	-0.23	Bone mineral density;	chr22:23131044	chr22:22322472~22322980:+
COAD	cis	rs989978	0.643	rs1360522	ENSG00000228778.1	RP11-129J12.1	3.79	0.000186	0.0365	0.27	0.23	Red blood cell count;	chr10:99566040	chr10:99527081~99528261:+
COAD	cis	rs16971802	1	rs16971802	ENSG00000275944.1	RP11-104J23.1	3.79	0.000187	0.0365	0.43	0.23	Blood protein levels;	chr17:35984351	chr17:36001419~36011618:+
COAD	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	3.79	0.000187	0.0365	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
COAD	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	3.79	0.000187	0.0365	0.28	0.23	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
COAD	cis	rs495337	0.735	rs636987	ENSG00000229222.1	KRT18P4	-3.79	0.000187	0.0365	-0.23	-0.23	Psoriasis;	chr20:49907751	chr20:49956745~49958032:+
COAD	cis	rs11671653	1	rs59214302	ENSG00000267100.1	ILF3-AS1	3.79	0.000187	0.0365	0.39	0.23	LDL cholesterol;	chr19:10725386	chr19:10651862~10653844:-
COAD	cis	rs11671653	1	rs11669253	ENSG00000267100.1	ILF3-AS1	3.79	0.000187	0.0365	0.39	0.23	LDL cholesterol;	chr19:10725653	chr19:10651862~10653844:-
COAD	cis	rs2929278	0.617	rs4617832	ENSG00000275601.1	AC011330.13	3.79	0.000187	0.0365	0.28	0.23	Schizophrenia;	chr15:43738381	chr15:43642389~43643023:-
COAD	cis	rs10876993	0.928	rs774890	ENSG00000270039.1	RP11-571M6.17	3.79	0.000187	0.0365	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57674605	chr12:57803838~57804415:+
COAD	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	3.79	0.000187	0.0365	0.28	0.23	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
COAD	cis	rs2018683	1	rs4719963	ENSG00000272568.4	CTB-113D17.1	-3.79	0.000187	0.0365	-0.3	-0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28979967~29013367:+
COAD	cis	rs1499614	1	rs2659903	ENSG00000232559.3	GS1-124K5.12	3.79	0.000187	0.0365	0.4	0.23	Gout;	chr7:66715944	chr7:66554588~66576923:-
COAD	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	3.79	0.000187	0.0365	0.25	0.23	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
COAD	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	3.79	0.000187	0.0365	0.25	0.23	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
COAD	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-3.79	0.000187	0.0366	-0.41	-0.23	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
COAD	cis	rs1707322	0.721	rs10890333	ENSG00000230896.1	RP11-767N6.7	-3.79	0.000187	0.0366	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45694684~45697075:-
COAD	cis	rs9847710	0.545	rs2952830	ENSG00000242142.1	SERBP1P3	3.79	0.000187	0.0366	0.31	0.23	Ulcerative colitis;	chr3:52948280	chr3:53064283~53065091:-
COAD	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-3.79	0.000187	0.0366	-0.38	-0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
COAD	cis	rs755249	0.529	rs604316	ENSG00000182109.6	RP11-69E11.4	3.79	0.000187	0.0366	0.24	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39522280~39546187:-
COAD	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	3.79	0.000187	0.0366	0.23	0.23	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
COAD	cis	rs7172809	0.561	rs28712147	ENSG00000279373.1	RP11-650L12.4	3.79	0.000187	0.0366	0.3	0.23	Glucose homeostasis traits;	chr15:77552319	chr15:78537681~78538946:+
COAD	cis	rs72627509	0.723	rs67043033	ENSG00000269949.1	RP11-738E22.3	3.79	0.000187	0.0366	0.4	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56873067	chr4:56960927~56961373:-
COAD	cis	rs1383484	1	rs4438273	ENSG00000176700.18	SCAND2P	-3.79	0.000187	0.0366	-0.23	-0.23	Height;	chr15:83832524	chr15:84631451~84647478:+
COAD	cis	rs7075426	0.524	rs12411744	ENSG00000227896.2	RP11-77P6.2	-3.79	0.000187	0.0366	-0.21	-0.23	Migraine without aura;	chr10:86485318	chr10:86521945~86525101:+
COAD	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-3.79	0.000187	0.0366	-0.29	-0.23	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
COAD	cis	rs654950	0.934	rs665223	ENSG00000230638.4	RP11-486B10.4	3.79	0.000187	0.0366	0.26	0.23	Airway imaging phenotypes;	chr1:41534983	chr1:41542069~41544310:+
COAD	cis	rs7826238	0.539	rs2945891	ENSG00000254340.1	RP11-10A14.3	3.79	0.000187	0.0366	0.27	0.23	Systolic blood pressure;	chr8:8297953	chr8:9141424~9145435:+
COAD	cis	rs1799949	0.965	rs9911630	ENSG00000279602.1	CTD-3014M21.1	3.79	0.000187	0.0366	0.25	0.23	Menopause (age at onset);	chr17:43036325	chr17:43360041~43361361:-
COAD	cis	rs10129255	0.5	rs8011115	ENSG00000211967.3	IGHV3-53	-3.79	0.000187	0.0366	-0.14	-0.23	Kawasaki disease;	chr14:106786292	chr14:106592676~106593347:-
COAD	cis	rs7172689	1	rs7163931	ENSG00000271725.1	RP11-761I4.4	3.79	0.000187	0.0366	0.31	0.23	Inattentive symptoms;	chr15:81259501	chr15:81303215~81309391:-
COAD	cis	rs875971	1	rs6956179	ENSG00000230189.5	GS1-124K5.2	-3.79	0.000187	0.0366	-0.18	-0.23	Aortic root size;	chr7:66341672	chr7:66409143~66490059:-
COAD	cis	rs2904967	0.929	rs592050	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65262718	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.929	rs554122	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65266403	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.852	rs488289	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65271793	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.852	rs1858783	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65275470	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.81	rs507005	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65278144	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.852	rs668735	ENSG00000245532.5	NEAT1	3.79	0.000187	0.0366	0.26	0.23	Mean corpuscular volume;	chr11:65278254	chr11:65422774~65445540:+
COAD	cis	rs2904967	0.866	rs526502	ENSG00000245532.5	NEAT1	-3.79	0.000187	0.0366	-0.26	-0.23	Mean corpuscular volume;	chr11:65259119	chr11:65422774~65445540:+
COAD	cis	rs11138902	0.649	rs13286400	ENSG00000229312.2	RP11-470P21.2	-3.79	0.000187	0.0366	-0.26	-0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69533663	chr9:69472466~69494513:+
COAD	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	3.79	0.000187	0.0366	0.27	0.23	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
COAD	cis	rs113835537	0.529	rs7950790	ENSG00000258297.1	RP11-658F2.8	-3.79	0.000187	0.0366	-0.23	-0.23	Airway imaging phenotypes;	chr11:66490582	chr11:66666036~66668374:+
COAD	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-3.79	0.000187	0.0366	-0.3	-0.23	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-3.79	0.000187	0.0366	-0.3	-0.23	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
COAD	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	3.79	0.000187	0.0366	0.25	0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
COAD	cis	rs11098499	0.82	rs28394116	ENSG00000250412.1	KLHL2P1	3.79	0.000187	0.0366	0.31	0.23	Corneal astigmatism;	chr4:119603128	chr4:119334329~119378233:+
COAD	cis	rs7572733	0.84	rs12472359	ENSG00000222017.1	AC011997.1	-3.79	0.000187	0.0366	-0.26	-0.23	Dermatomyositis;	chr2:197723141	chr2:197693106~197774823:+
COAD	cis	rs2504916	0.793	rs2457557	ENSG00000230234.1	RP1-276N6.2	3.79	0.000187	0.0367	0.31	0.23	Response to hepatitis C treatment;	chr6:160364475	chr6:160272617~160276130:+
COAD	cis	rs561341	0.714	rs111760509	ENSG00000265798.5	RP11-271K11.5	3.79	0.000188	0.0367	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31977301	chr17:31038575~31059121:-
COAD	cis	rs13256369	0.851	rs11249890	ENSG00000254153.1	CTA-398F10.2	3.79	0.000188	0.0367	0.31	0.23	Obesity-related traits;	chr8:8707735	chr8:8456909~8461337:-
COAD	cis	rs2836974	0.602	rs2037925	ENSG00000255568.3	BRWD1-AS2	-3.79	0.000188	0.0367	-0.21	-0.23	Cognitive function;	chr21:39328005	chr21:39313935~39314962:+
COAD	cis	rs1065852	0.526	rs739296	ENSG00000215347.3	SLC25A5P1	3.79	0.000188	0.0367	0.25	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42001069~42001966:-
COAD	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	3.79	0.000188	0.0367	0.26	0.23	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
COAD	cis	rs1707322	0.691	rs11211174	ENSG00000230896.1	RP11-767N6.7	-3.79	0.000188	0.0367	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45694684~45697075:-
COAD	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	3.79	0.000188	0.0367	0.22	0.23	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
COAD	cis	rs2043112	0.867	rs357278	ENSG00000244968.5	LIFR-AS1	3.79	0.000188	0.0367	0.22	0.23	Obesity-related traits;	chr5:38932364	chr5:38556786~38671216:+
COAD	cis	rs174479	0.647	rs174457	ENSG00000267811.1	RP11-727F15.11	3.79	0.000188	0.0367	0.28	0.23	Sphingolipid levels;	chr11:61889503	chr11:62771120~62771606:-
COAD	cis	rs9880211	0.563	rs67589653	ENSG00000239213.4	NCK1-AS1	3.79	0.000188	0.0367	0.31	0.23	Height;Body mass index;	chr3:136092732	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.563	rs10512990	ENSG00000239213.4	NCK1-AS1	3.79	0.000188	0.0367	0.31	0.23	Height;Body mass index;	chr3:136095785	chr3:136841726~136862054:-
COAD	cis	rs9992667	0.516	rs13328049	ENSG00000231160.8	KLF3-AS1	3.79	0.000188	0.0367	0.25	0.23	Eosinophil percentage of granulocytes;	chr4:38701452	chr4:38612701~38664883:-
COAD	cis	rs9532669	0.926	rs4254182	ENSG00000277662.1	RP11-74J13.9	-3.79	0.000188	0.0367	-0.21	-0.23	Cervical cancer;	chr13:40879120	chr13:41229180~41229676:-
COAD	cis	rs2018293	1	rs77789657	ENSG00000272798.1	CTA-390C10.9	-3.79	0.000188	0.0367	-0.3	-0.23	Vascular brain injury;	chr22:26313020	chr22:25436312~25436915:+
COAD	cis	rs6565180	0.791	rs4247355	ENSG00000261367.1	RP11-455F5.4	-3.79	0.000188	0.0367	-0.25	-0.23	Tonsillectomy;	chr16:30380778	chr16:30107675~30110541:+
COAD	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-3.79	0.000188	0.0367	-0.26	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
COAD	cis	rs71520386	0.583	rs10950920	ENSG00000230658.1	KLHL7-AS1	3.79	0.000188	0.0367	0.31	0.23	Fibrinogen levels;	chr7:22796010	chr7:23101228~23105703:-
COAD	cis	rs71520386	0.519	rs34481841	ENSG00000230658.1	KLHL7-AS1	3.79	0.000188	0.0367	0.31	0.23	Fibrinogen levels;	chr7:22798007	chr7:23101228~23105703:-
COAD	cis	rs4886920	0.692	rs4625694	ENSG00000261762.1	RP11-650L12.2	3.79	0.000188	0.0367	0.26	0.23	Neuroticism;	chr15:77826137	chr15:78589123~78591276:-
COAD	cis	rs4886920	0.692	rs4625695	ENSG00000261762.1	RP11-650L12.2	3.79	0.000188	0.0367	0.26	0.23	Neuroticism;	chr15:77826153	chr15:78589123~78591276:-
COAD	cis	rs4886920	0.723	rs11633959	ENSG00000261762.1	RP11-650L12.2	3.79	0.000188	0.0367	0.26	0.23	Neuroticism;	chr15:77826362	chr15:78589123~78591276:-
COAD	cis	rs9307551	0.619	rs1074134	ENSG00000250334.4	LINC00989	-3.79	0.000188	0.0367	-0.26	-0.23	Refractive error;	chr4:79503752	chr4:79492416~79576460:+
COAD	cis	rs10465746	0.57	rs11163884	ENSG00000249237.4	RP11-376N17.4	-3.79	0.000188	0.0367	-0.26	-0.23	Obesity-related traits;	chr1:84007077	chr1:84344678~84349939:+
COAD	cis	rs10465746	0.57	rs11163885	ENSG00000249237.4	RP11-376N17.4	-3.79	0.000188	0.0367	-0.26	-0.23	Obesity-related traits;	chr1:84007273	chr1:84344678~84349939:+
COAD	cis	rs10465746	0.57	rs11163886	ENSG00000249237.4	RP11-376N17.4	-3.79	0.000188	0.0367	-0.26	-0.23	Obesity-related traits;	chr1:84007762	chr1:84344678~84349939:+
COAD	cis	rs1949733	0.523	rs16842557	ENSG00000205959.3	RP11-689P11.2	3.79	0.000188	0.0367	0.28	0.23	Response to antineoplastic agents;	chr4:8542258	chr4:8482270~8512610:+
COAD	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	3.79	0.000188	0.0367	0.31	0.23	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
COAD	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	3.79	0.000188	0.0367	0.31	0.23	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
COAD	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	3.79	0.000188	0.0367	0.33	0.23	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
COAD	cis	rs875971	0.83	rs427575	ENSG00000230189.5	GS1-124K5.2	3.79	0.000188	0.0367	0.19	0.23	Aortic root size;	chr7:66054232	chr7:66409143~66490059:-
COAD	cis	rs728616	0.867	rs55690691	ENSG00000234382.2	RP11-40F6.1	-3.79	0.000188	0.0367	-0.42	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs1983775	ENSG00000234382.2	RP11-40F6.1	-3.79	0.000188	0.0367	-0.42	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:80233664~80245367:+
COAD	cis	rs728616	0.867	rs1983776	ENSG00000234382.2	RP11-40F6.1	-3.79	0.000188	0.0367	-0.42	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:80233664~80245367:+
COAD	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	3.79	0.000188	0.0367	0.22	0.23	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
COAD	cis	rs2131877	0.573	rs58370605	ENSG00000233303.1	XXYLT1-AS1	-3.79	0.000188	0.0368	-0.31	-0.23	Non-small cell lung cancer;	chr3:195122148	chr3:195094588~195096057:+
COAD	cis	rs3025343	1	rs3025343	ENSG00000235138.1	RP11-374P20.4	-3.79	0.000188	0.0368	-0.38	-0.23	Smoking behavior;	chr9:133613233	chr9:134054290~134058805:+
COAD	cis	rs79349575	0.715	rs1058018	ENSG00000248278.1	SUMO2P17	3.79	0.000188	0.0368	0.25	0.23	Type 2 diabetes;	chr17:48922889	chr17:48874860~48908983:-
COAD	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	3.79	0.000188	0.0368	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
COAD	cis	rs12681366	0.839	rs3019282	ENSG00000253704.1	RP11-267M23.4	3.79	0.000188	0.0368	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94553722~94569745:+
COAD	cis	rs643506	0.874	rs663511	ENSG00000230911.1	PPIHP1	-3.79	0.000188	0.0368	-0.29	-0.23	Breast cancer;	chr11:111839311	chr11:112029858~112030367:-
COAD	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-3.79	0.000188	0.0368	-0.34	-0.23	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
COAD	cis	rs2017305	0.834	rs12253140	ENSG00000233590.1	RP11-153K11.3	3.79	0.000188	0.0368	0.42	0.23	Depression (quantitative trait);	chr10:69020952	chr10:68233251~68242379:-
COAD	cis	rs442309	0.592	rs224046	ENSG00000228566.1	RP11-170M17.1	3.79	0.000188	0.0368	0.28	0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62767997	chr10:63664664~63990568:+
COAD	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	3.79	0.000188	0.0368	0.27	0.23	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
COAD	cis	rs7955901	0.725	rs966583	ENSG00000258053.1	CTD-2021H9.3	3.79	0.000188	0.0368	0.3	0.23	Type 2 diabetes;	chr12:71057787	chr12:71047402~71118247:-
COAD	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	3.79	0.000188	0.0368	0.24	0.23	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
COAD	cis	rs9880211	0.898	rs1052620	ENSG00000273486.1	RP11-731C17.2	3.79	0.000188	0.0368	0.28	0.23	Height;Body mass index;	chr3:136855679	chr3:136837338~136839021:-
COAD	cis	rs9867325	1	rs9867325	ENSG00000273486.1	RP11-731C17.2	3.79	0.000188	0.0368	0.28	0.23	Body mass index;	chr3:136900067	chr3:136837338~136839021:-
COAD	cis	rs9867325	1	rs9840500	ENSG00000273486.1	RP11-731C17.2	3.79	0.000188	0.0368	0.28	0.23	Body mass index;	chr3:136902496	chr3:136837338~136839021:-
COAD	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	3.79	0.000188	0.0368	0.35	0.23	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
COAD	cis	rs7953704	0.967	rs7975001	ENSG00000280389.1	RP11-512M8.11	3.79	0.000188	0.0368	0.26	0.23	Urate levels;	chr12:122141227	chr12:122255119~122260274:-
COAD	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	3.79	0.000188	0.0368	0.21	0.23	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
COAD	cis	rs34779708	0.966	rs4934536	ENSG00000271335.4	RP11-324I22.4	3.79	0.000188	0.0368	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35314552~35336401:-
COAD	cis	rs495337	1	rs11086299	ENSG00000229222.1	KRT18P4	-3.79	0.000189	0.0368	-0.24	-0.23	Psoriasis;	chr20:49932333	chr20:49956745~49958032:+
COAD	cis	rs11098499	0.569	rs10023641	ENSG00000249244.1	RP11-548H18.2	3.79	0.000189	0.0368	0.29	0.23	Corneal astigmatism;	chr4:119337255	chr4:119391831~119395335:-
COAD	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	3.79	0.000189	0.0368	0.42	0.23	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
COAD	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	3.79	0.000189	0.0368	0.42	0.23	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
COAD	cis	rs17407555	0.633	rs10022367	ENSG00000250413.1	RP11-448G15.1	-3.79	0.000189	0.0368	-0.3	-0.23	Schizophrenia (age at onset);	chr4:10275469	chr4:10006482~10009725:+
COAD	cis	rs1048886	0.872	rs6933150	ENSG00000271967.1	RP11-134K13.4	-3.79	0.000189	0.0368	-0.33	-0.23	Type 2 diabetes;	chr6:70519176	chr6:70596438~70596980:+
COAD	cis	rs9951150	0.537	rs12969390	ENSG00000267013.4	CTD-2171N6.1	3.79	0.000189	0.0368	0.32	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr18:55121782	chr18:55105904~55124306:-
COAD	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	3.79	0.000189	0.0368	0.36	0.23	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
COAD	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-3.79	0.000189	0.0368	-0.22	-0.23	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
COAD	cis	rs860295	0.812	rs11264413	ENSG00000160766.13	GBAP1	-3.79	0.000189	0.0369	-0.27	-0.23	Body mass index;	chr1:155818865	chr1:155213821~155227422:-
COAD	cis	rs643506	0.845	rs2850245	ENSG00000230911.1	PPIHP1	-3.79	0.000189	0.0369	-0.29	-0.23	Breast cancer;	chr11:111890014	chr11:112029858~112030367:-
COAD	cis	rs643506	0.715	rs11214031	ENSG00000230911.1	PPIHP1	-3.79	0.000189	0.0369	-0.29	-0.23	Breast cancer;	chr11:111895315	chr11:112029858~112030367:-
COAD	cis	rs643506	0.774	rs11214033	ENSG00000230911.1	PPIHP1	3.79	0.000189	0.0369	0.29	0.23	Breast cancer;	chr11:111898978	chr11:112029858~112030367:-
COAD	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-3.79	0.000189	0.0369	-0.26	-0.23	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
COAD	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-3.79	0.000189	0.0369	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
COAD	cis	rs8114671	0.562	rs8117491	ENSG00000228265.4	RALY-AS1	3.79	0.000189	0.0369	0.21	0.23	Height;	chr20:34922317	chr20:33983052~33994357:-
COAD	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-3.79	0.000189	0.0369	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
COAD	cis	rs10876993	0.89	rs1678516	ENSG00000270039.1	RP11-571M6.17	3.79	0.000189	0.0369	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57653675	chr12:57803838~57804415:+
COAD	cis	rs2916733	0.607	rs2166006	ENSG00000246089.3	RP11-115C21.2	-3.79	0.000189	0.0369	-0.3	-0.23	Epirubicin-induced leukopenia;	chr8:6446827	chr8:6403551~6407142:-
COAD	cis	rs853679	1	rs2799077	ENSG00000272009.1	RP1-313I6.12	3.79	0.000189	0.0369	0.36	0.23	Depression;	chr6:28266819	chr6:28078792~28081130:-
COAD	cis	rs853679	1	rs1778511	ENSG00000272009.1	RP1-313I6.12	-3.79	0.000189	0.0369	-0.36	-0.23	Depression;	chr6:28261633	chr6:28078792~28081130:-
COAD	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-3.79	0.000189	0.0369	-0.26	-0.23	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
COAD	cis	rs394563	0.839	rs584916	ENSG00000231760.4	RP11-350J20.5	3.79	0.000189	0.0369	0.29	0.23	Dupuytren's disease;	chr6:149469183	chr6:149796151~149826294:-
COAD	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-3.79	0.000189	0.0369	-0.31	-0.23	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-3.79	0.000189	0.0369	-0.31	-0.23	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-3.79	0.000189	0.0369	-0.31	-0.23	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
COAD	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-3.79	0.000189	0.0369	-0.21	-0.23	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
COAD	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-3.79	0.000189	0.0369	-0.29	-0.23	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
COAD	cis	rs10864907	0.806	rs879711	ENSG00000236397.3	DDX11L2	-3.79	0.000189	0.0369	-0.3	-0.23	Pulmonary function;	chr2:112958677	chr2:113599036~113601261:-
COAD	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	3.79	0.000189	0.0369	0.25	0.23	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
COAD	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	3.79	0.000189	0.0369	0.25	0.23	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
COAD	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	3.79	0.000189	0.0369	0.25	0.23	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
COAD	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	3.79	0.000189	0.0369	0.45	0.23	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
COAD	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-3.79	0.000189	0.0369	-0.31	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
COAD	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	3.79	0.000189	0.0369	0.3	0.23	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
COAD	cis	rs2243480	1	rs313807	ENSG00000232559.3	GS1-124K5.12	3.79	0.000189	0.0369	0.4	0.23	Diabetic kidney disease;	chr7:66034494	chr7:66554588~66576923:-
COAD	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-3.79	0.000189	0.0369	-0.23	-0.23	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
COAD	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	3.79	0.000189	0.0369	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
COAD	cis	rs3748656	0.831	rs11102509	ENSG00000231246.1	RP5-965F6.2	-3.79	0.000189	0.0369	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112598596	chr1:112177234~112360528:-
COAD	cis	rs12699921	0.558	rs2691559	ENSG00000279048.1	RP11-511H23.2	-3.79	0.000189	0.0369	-0.17	-0.23	Fibrinogen levels;	chr7:17905636	chr7:17940503~17942922:+
COAD	cis	rs2186369	0.681	rs9608185	ENSG00000228315.10	GUSBP11	3.79	0.000189	0.0369	0.18	0.23	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23800790	chr22:23638487~23717356:-
COAD	cis	rs4819052	0.851	rs28442024	ENSG00000227039.5	ITGB2-AS1	-3.79	0.00019	0.0369	-0.2	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:44921051~44929678:+
COAD	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-3.79	0.00019	0.037	-0.31	-0.23	Pain;	chr19:21521677	chr19:21554640~21569237:-
COAD	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
COAD	cis	rs9300255	0.602	rs1106241	ENSG00000280120.1	RP11-546D6.3	3.79	0.00019	0.037	0.22	0.23	Neutrophil percentage of white cells;	chr12:123142469	chr12:123152324~123153377:-
COAD	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-3.79	0.00019	0.037	-0.3	-0.23	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
COAD	cis	rs10200159	1	rs6712314	ENSG00000272606.1	RP11-554J4.1	3.79	0.00019	0.037	0.34	0.23	Vitiligo;	chr2:55626901	chr2:55617909~55618373:+
COAD	cis	rs6828577	0.862	rs299005	ENSG00000225892.3	RP11-384K6.2	-3.79	0.00019	0.037	-0.22	-0.23	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118674209	chr4:118632274~118634759:+
COAD	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
COAD	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	3.79	0.00019	0.037	0.29	0.23	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
COAD	cis	rs8141529	0.673	rs132548	ENSG00000272858.1	CTA-292E10.8	3.79	0.00019	0.037	0.28	0.23	Lymphocyte counts;	chr22:28921571	chr22:28814914~28815662:+
COAD	cis	rs17138358	0.515	rs2691610	ENSG00000279048.1	RP11-511H23.2	-3.79	0.00019	0.037	-0.17	-0.23	HDL cholesterol levels;	chr7:17781815	chr7:17940503~17942922:+
COAD	cis	rs11138902	0.649	rs11139155	ENSG00000229312.2	RP11-470P21.2	3.79	0.00019	0.037	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69530849	chr9:69472466~69494513:+
COAD	cis	rs953301	0.793	rs73019349	ENSG00000229808.1	RP11-456P18.2	-3.79	0.00019	0.037	-0.44	-0.23	Left atrial antero-posterior diameter;	chr1:161898478	chr1:161890833~161892196:+
COAD	cis	rs2554380	0.55	rs11853949	ENSG00000176700.18	SCAND2P	-3.79	0.00019	0.037	-0.23	-0.23	Height;	chr15:83848152	chr15:84631451~84647478:+
COAD	cis	rs2832191	0.716	rs2249028	ENSG00000176054.6	RPL23P2	3.79	0.00019	0.037	0.23	0.23	Dental caries;	chr21:28993001	chr21:28997613~28998033:-
COAD	cis	rs10752881	1	rs10797802	ENSG00000224468.3	RP11-181K3.4	3.79	0.00019	0.037	0.23	0.23	Colorectal cancer;	chr1:183004023	chr1:183138402~183141282:-
COAD	cis	rs11098499	0.754	rs17049949	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119334135	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs7689729	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119335037	chr4:119334329~119378233:+
COAD	cis	rs10028773	0.7	rs7690338	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Educational attainment;	chr4:119335313	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.865	rs3956464	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119335609	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.648	rs2002047	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119336073	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.775	rs2002049	ENSG00000250412.1	KLHL2P1	3.79	0.00019	0.037	0.3	0.23	Corneal astigmatism;	chr4:119336262	chr4:119334329~119378233:+
COAD	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	3.79	0.00019	0.037	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
COAD	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-3.79	0.00019	0.037	-0.24	-0.23	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
COAD	cis	rs984222	0.501	rs1361906	ENSG00000231365.4	RP11-418J17.1	-3.79	0.00019	0.037	-0.24	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942021	chr1:119140396~119275973:+
COAD	cis	rs7727544	0.647	rs7721882	ENSG00000233006.5	AC034220.3	3.79	0.00019	0.037	0.2	0.23	Blood metabolite levels;	chr5:132083255	chr5:132311285~132369916:-
COAD	cis	rs2255336	0.748	rs60110638	ENSG00000245648.1	RP11-277P12.20	-3.79	0.00019	0.037	-0.34	-0.23	Blood protein levels;	chr12:10444712	chr12:10363769~10398506:+
COAD	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	3.79	0.00019	0.0371	0.32	0.23	Pain;	chr19:21567846	chr19:21554640~21569237:-
COAD	cis	rs113835537	0.529	rs7950407	ENSG00000258297.1	RP11-658F2.8	-3.79	0.00019	0.0371	-0.22	-0.23	Airway imaging phenotypes;	chr11:66490535	chr11:66666036~66668374:+
COAD	cis	rs2439831	0.702	rs28699233	ENSG00000166763.7	STRCP1	-3.79	0.00019	0.0371	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43830668	chr15:43699488~43718184:-
COAD	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	3.79	0.00019	0.0371	0.24	0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
COAD	cis	rs9910055	0.659	rs7212573	ENSG00000267080.4	ASB16-AS1	-3.79	0.00019	0.0371	-0.2	-0.23	Total body bone mineral density;	chr17:44176913	chr17:44175973~44186717:-
COAD	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	3.79	0.00019	0.0371	0.16	0.23	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
COAD	cis	rs2439831	0.85	rs7179388	ENSG00000201136.1	RNU6-353P	-3.79	0.00019	0.0371	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43831747	chr15:43702363~43702470:+
COAD	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	3.79	0.000191	0.0371	0.31	0.23	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
COAD	cis	rs7727544	0.505	rs721121	ENSG00000233006.5	AC034220.3	3.79	0.000191	0.0371	0.2	0.23	Blood metabolite levels;	chr5:132070740	chr5:132311285~132369916:-
COAD	cis	rs7665090	0.87	rs227361	ENSG00000248971.2	KRT8P46	-3.79	0.000191	0.0371	-0.23	-0.23	Primary biliary cholangitis;	chr4:102665820	chr4:102728746~102730171:-
COAD	cis	rs9907295	0.748	rs4251719	ENSG00000271013.1	AC015849.15	-3.79	0.000191	0.0371	-0.33	-0.23	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35912635~35918010:-
COAD	cis	rs479105	0.605	rs3825342	ENSG00000242444.3	RP11-320N7.1	3.79	0.000191	0.0371	0.28	0.23	Gut microbiota (bacterial taxa);	chr12:3261645	chr12:4109661~4118132:-
COAD	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	3.79	0.000191	0.0371	0.24	0.23	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
COAD	cis	rs2337406	1	rs17113331	ENSG00000211964.3	IGHV3-48	-3.79	0.000191	0.0371	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106703843	chr14:106537810~106538344:-
COAD	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000191	0.0372	-0.23	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
COAD	cis	rs9532669	0.926	rs12428966	ENSG00000277662.1	RP11-74J13.9	-3.79	0.000191	0.0372	-0.22	-0.23	Cervical cancer;	chr13:40876552	chr13:41229180~41229676:-
COAD	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	3.79	0.000191	0.0372	0.31	0.23	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
COAD	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-3.79	0.000191	0.0372	-0.24	-0.23	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
COAD	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	3.79	0.000191	0.0372	0.31	0.23	Depression;	chr6:28187640	chr6:28170845~28172521:+
COAD	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	3.79	0.000191	0.0372	0.2	0.23	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
COAD	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	3.79	0.000191	0.0372	0.46	0.23	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	3.79	0.000191	0.0372	0.46	0.23	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	3.79	0.000191	0.0372	0.46	0.23	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	3.79	0.000191	0.0372	0.46	0.23	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
COAD	cis	rs2243480	1	rs778729	ENSG00000232559.3	GS1-124K5.12	3.79	0.000191	0.0372	0.42	0.23	Diabetic kidney disease;	chr7:66359432	chr7:66554588~66576923:-
COAD	cis	rs7324557	0.717	rs9510869	ENSG00000205861.10	C1QTNF9B-AS1	-3.79	0.000191	0.0372	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23809990	chr13:23888889~23897263:+
COAD	cis	rs7324557	0.717	rs9510870	ENSG00000205861.10	C1QTNF9B-AS1	-3.79	0.000191	0.0372	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23810346	chr13:23888889~23897263:+
COAD	cis	rs801193	0.569	rs10950050	ENSG00000236529.1	RP13-254B10.1	3.79	0.000191	0.0372	0.26	0.23	Aortic root size;	chr7:66774601	chr7:65840212~65840596:+
COAD	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	3.79	0.000191	0.0372	0.31	0.23	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
COAD	cis	rs11229555	0.645	rs10466679	ENSG00000254602.1	AP000662.4	-3.79	0.000191	0.0372	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58420784	chr11:57638024~57652790:+
COAD	cis	rs1510510	0.742	rs12692235	ENSG00000225057.2	AC096574.4	3.79	0.000191	0.0372	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238637065	chr2:238231684~238255633:+
COAD	cis	rs9880211	0.563	rs1393787	ENSG00000239213.4	NCK1-AS1	3.79	0.000191	0.0372	0.32	0.23	Height;Body mass index;	chr3:136135359	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.563	rs9881400	ENSG00000239213.4	NCK1-AS1	3.79	0.000191	0.0372	0.32	0.23	Height;Body mass index;	chr3:136142824	chr3:136841726~136862054:-
COAD	cis	rs2898681	0.65	rs6840325	ENSG00000248375.1	RP11-177B4.1	-3.79	0.000191	0.0372	-0.33	-0.23	Optic nerve measurement (cup area);	chr4:52809382	chr4:52720081~52720831:-
COAD	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-3.78	0.000191	0.0372	-0.38	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
COAD	cis	rs801193	0.66	rs4610622	ENSG00000224316.1	RP11-479O9.2	3.78	0.000191	0.0372	0.25	0.23	Aortic root size;	chr7:66759510	chr7:65773620~65802067:+
COAD	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-3.78	0.000191	0.0372	-0.29	-0.23	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
COAD	cis	rs7582403	0.771	rs1238800	ENSG00000281469.1	RP11-567F11.1	-3.78	0.000191	0.0372	-0.27	-0.23	Neuroticism;	chr2:148086129	chr2:148044380~148044894:+
COAD	cis	rs7582403	0.844	rs1234413	ENSG00000281469.1	RP11-567F11.1	-3.78	0.000191	0.0372	-0.27	-0.23	Neuroticism;	chr2:148086800	chr2:148044380~148044894:+
COAD	cis	rs7582403	0.844	rs6430288	ENSG00000281469.1	RP11-567F11.1	-3.78	0.000191	0.0372	-0.27	-0.23	Neuroticism;	chr2:148091855	chr2:148044380~148044894:+
COAD	cis	rs7582403	0.807	rs1449958	ENSG00000281469.1	RP11-567F11.1	-3.78	0.000191	0.0372	-0.27	-0.23	Neuroticism;	chr2:148095707	chr2:148044380~148044894:+
COAD	cis	rs7582403	0.844	rs1234410	ENSG00000281469.1	RP11-567F11.1	3.78	0.000191	0.0372	0.27	0.23	Neuroticism;	chr2:148082938	chr2:148044380~148044894:+
COAD	cis	rs238295	0.805	rs6116855	ENSG00000233578.1	EIF4EP1	-3.78	0.000191	0.0372	-0.25	-0.23	Occipital cortical area (total cortical area interaction);	chr20:5574671	chr20:5548840~5549481:+
COAD	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-3.78	0.000192	0.0373	-0.24	-0.23	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
COAD	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000192	0.0373	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
COAD	cis	rs9796	0.621	rs2899013	ENSG00000247556.5	OIP5-AS1	3.78	0.000192	0.0373	0.23	0.23	Menopause (age at onset);	chr15:41200085	chr15:41283990~41309737:+
COAD	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-3.78	0.000192	0.0373	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
COAD	cis	rs1914816	1	rs1914816	ENSG00000196274.5	Metazoa_SRP	3.78	0.000192	0.0373	0.24	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76254592	chr15:76230048~76230390:-
COAD	cis	rs2832191	0.716	rs9983051	ENSG00000176054.6	RPL23P2	3.78	0.000192	0.0373	0.23	0.23	Dental caries;	chr21:28999569	chr21:28997613~28998033:-
COAD	cis	rs2638953	0.886	rs7973241	ENSG00000247934.4	RP11-967K21.1	-3.78	0.000192	0.0373	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28163298~28190738:-
COAD	cis	rs752010	0.644	rs7541348	ENSG00000230638.4	RP11-486B10.4	-3.78	0.000192	0.0373	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41647544	chr1:41542069~41544310:+
COAD	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-3.78	0.000192	0.0373	-0.32	-0.23	Depression;	chr6:28226851	chr6:28115628~28116551:+
COAD	cis	rs9880211	0.563	rs6769762	ENSG00000273486.1	RP11-731C17.2	3.78	0.000192	0.0373	0.28	0.23	Height;Body mass index;	chr3:136189336	chr3:136837338~136839021:-
COAD	cis	rs2921036	0.503	rs7817832	ENSG00000253893.2	FAM85B	-3.78	0.000192	0.0373	-0.33	-0.23	Neuroticism;	chr8:8523311	chr8:8167819~8226614:-
COAD	cis	rs10137082	0.606	rs10162492	ENSG00000279656.1	RP11-298I3.6	-3.78	0.000192	0.0373	-0.3	-0.23	Type 1 diabetes;	chr14:23355510	chr14:23023083~23024217:-
COAD	cis	rs561341	1	rs501957	ENSG00000265798.5	RP11-271K11.5	3.78	0.000192	0.0373	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31987485	chr17:31038575~31059121:-
COAD	cis	rs78487399	0.808	rs77972916	ENSG00000234936.1	AC010883.5	3.78	0.000192	0.0373	0.45	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534973	chr2:43229573~43233394:+
COAD	cis	rs8058578	0.945	rs885107	ENSG00000260487.1	RP11-297C4.3	3.78	0.000192	0.0373	0.3	0.23	Multiple myeloma;	chr16:30661398	chr16:30480588~30481346:-
COAD	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-3.78	0.000192	0.0373	-0.2	-0.23	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
COAD	cis	rs1485395	0.891	rs10161319	ENSG00000250133.2	HOXC-AS2	3.78	0.000192	0.0373	0.26	0.23	Migraine without aura;	chr12:53642530	chr12:53993810~53996785:-
COAD	cis	rs670292	1	rs805989	ENSG00000216906.2	RP11-350J20.9	3.78	0.000192	0.0373	0.3	0.23	Anger;	chr6:150390838	chr6:149904243~149906418:+
COAD	cis	rs670292	0.967	rs672766	ENSG00000216906.2	RP11-350J20.9	3.78	0.000192	0.0373	0.3	0.23	Anger;	chr6:150392633	chr6:149904243~149906418:+
COAD	cis	rs8022206	0.841	rs11158716	ENSG00000259502.1	RP11-643G16.3	3.78	0.000192	0.0373	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68026441	chr14:67610986~67613864:+
COAD	cis	rs2408955	0.501	rs8716	ENSG00000257735.1	RP11-370I10.6	3.78	0.000192	0.0373	0.27	0.23	Glycated hemoglobin levels;	chr12:48145699	chr12:48350945~48442411:+
COAD	cis	rs7577696	0.924	rs7561519	ENSG00000272716.1	RP11-563N4.1	-3.78	0.000192	0.0373	-0.24	-0.23	Inflammatory biomarkers;	chr2:32087631	chr2:32165046~32165757:-
COAD	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-3.78	0.000192	0.0373	-0.24	-0.23	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
COAD	cis	rs860295	0.871	rs12724079	ENSG00000203761.5	MSTO2P	3.78	0.000192	0.0373	0.21	0.23	Body mass index;	chr1:155464151	chr1:155745829~155750137:+
COAD	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-3.78	0.000192	0.0373	-0.31	-0.23	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
COAD	cis	rs875971	1	rs6957199	ENSG00000223473.2	GS1-124K5.3	3.78	0.000192	0.0373	0.19	0.23	Aortic root size;	chr7:66513532	chr7:66491049~66493566:-
COAD	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	3.78	0.000192	0.0373	0.3	0.23	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
COAD	cis	rs60733400	0.667	rs4385650	ENSG00000225931.3	RP3-395M20.7	3.78	0.000192	0.0374	0.25	0.23	Multiple sclerosis;	chr1:2568459	chr1:2566410~2569888:+
COAD	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	3.78	0.000192	0.0374	0.29	0.23	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
COAD	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	3.78	0.000192	0.0374	0.29	0.23	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
COAD	cis	rs4660214	0.666	rs10888682	ENSG00000182109.6	RP11-69E11.4	-3.78	0.000192	0.0374	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs11205698	ENSG00000182109.6	RP11-69E11.4	-3.78	0.000192	0.0374	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39522280~39546187:-
COAD	cis	rs1510510	0.742	rs4444470	ENSG00000225057.2	AC096574.4	3.78	0.000193	0.0374	0.31	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238669995	chr2:238231684~238255633:+
COAD	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	3.78	0.000193	0.0374	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
COAD	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	3.78	0.000193	0.0374	0.44	0.23	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
COAD	cis	rs9300255	0.537	rs2695482	ENSG00000280120.1	RP11-546D6.3	3.78	0.000193	0.0374	0.22	0.23	Neutrophil percentage of white cells;	chr12:123138627	chr12:123152324~123153377:-
COAD	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	3.78	0.000193	0.0374	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
COAD	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-3.78	0.000193	0.0374	-0.31	-0.23	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
COAD	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-3.78	0.000193	0.0374	-0.3	-0.23	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
COAD	cis	rs7123876	0.587	rs72962169	ENSG00000227467.3	LINC01537	-3.78	0.000193	0.0374	-0.36	-0.23	Body mass index;	chr11:72654625	chr11:72570660~72573229:+
COAD	cis	rs4699052	0.963	rs7679365	ENSG00000246560.2	RP11-10L12.4	3.78	0.000193	0.0374	0.27	0.23	Testicular germ cell tumor;	chr4:103291823	chr4:102828055~102844075:+
COAD	cis	rs4699052	0.963	rs7657390	ENSG00000246560.2	RP11-10L12.4	3.78	0.000193	0.0374	0.27	0.23	Testicular germ cell tumor;	chr4:103291957	chr4:102828055~102844075:+
COAD	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	3.78	0.000193	0.0374	0.34	0.23	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
COAD	cis	rs12571093	0.504	rs4443961	ENSG00000233590.1	RP11-153K11.3	3.78	0.000193	0.0375	0.31	0.23	Optic nerve measurement (disc area);	chr10:68285725	chr10:68233251~68242379:-
COAD	cis	rs2562456	0.833	rs2650801	ENSG00000213976.4	CTD-2561J22.2	-3.78	0.000193	0.0375	-0.3	-0.23	Pain;	chr19:21452553	chr19:21382865~21387177:+
COAD	cis	rs2307394	0.964	rs13022962	ENSG00000281469.1	RP11-567F11.1	3.78	0.000193	0.0375	0.28	0.23	Urate levels;	chr2:147999055	chr2:148044380~148044894:+
COAD	cis	rs3126085	0.935	rs10888467	ENSG00000237975.5	FLG-AS1	-3.78	0.000193	0.0375	-0.25	-0.23	Atopic dermatitis;	chr1:152199231	chr1:152168125~152445456:+
COAD	cis	rs2638953	0.924	rs11049385	ENSG00000247934.4	RP11-967K21.1	-3.78	0.000193	0.0375	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167559	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049387	ENSG00000247934.4	RP11-967K21.1	-3.78	0.000193	0.0375	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167609	chr12:28163298~28190738:-
COAD	cis	rs7009110	0.758	rs1911713	ENSG00000213791.4	RP11-941H19.2	-3.78	0.000193	0.0375	-0.22	-0.23	Asthma and hay fever;	chr8:80353809	chr8:80300869~80301481:+
COAD	cis	rs2408955	0.521	rs10875753	ENSG00000226413.2	OR8T1P	3.78	0.000193	0.0375	0.27	0.23	Glycated hemoglobin levels;	chr12:48163358	chr12:48442030~48442947:-
COAD	cis	rs875971	0.895	rs3857684	ENSG00000230189.5	GS1-124K5.2	3.78	0.000193	0.0375	0.19	0.23	Aortic root size;	chr7:66473171	chr7:66409143~66490059:-
COAD	cis	rs224278	0.509	rs10740101	ENSG00000228566.1	RP11-170M17.1	-3.78	0.000193	0.0375	-0.32	-0.23	Ewing sarcoma;	chr10:62986382	chr10:63664664~63990568:+
COAD	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-3.78	0.000193	0.0375	-0.21	-0.23	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
COAD	cis	rs597539	0.652	rs604524	ENSG00000255741.1	RP11-757G1.5	-3.78	0.000193	0.0375	-0.3	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68941503~68942852:-
COAD	cis	rs5751614	0.537	rs7292656	ENSG00000207835.1	AC244250.3	3.78	0.000193	0.0375	0.19	0.23	Height;	chr22:23287415	chr22:22758696~22758790:+
COAD	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-3.78	0.000194	0.0375	-0.33	-0.23	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
COAD	cis	rs9818758	0.545	rs55921200	ENSG00000225399.4	RP11-3B7.1	-3.78	0.000194	0.0375	-0.48	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:49260085~49261316:+
COAD	cis	rs2337406	0.925	rs10131226	ENSG00000254174.1	IGHV1-12	3.78	0.000194	0.0375	0.22	0.23	Alzheimer's disease (late onset);	chr14:106665764	chr14:106122420~106122709:-
COAD	cis	rs13256369	0.951	rs13270852	ENSG00000253981.4	ALG1L13P	3.78	0.000194	0.0376	0.34	0.23	Obesity-related traits;	chr8:8709343	chr8:8236003~8244667:-
COAD	cis	rs6452524	0.71	rs7708124	ENSG00000271862.1	RP11-343L5.2	3.78	0.000194	0.0376	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83049376~83050964:-
COAD	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000194	0.0376	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
COAD	cis	rs7260598	0.792	rs17620072	ENSG00000268442.1	CTD-2027I19.2	3.78	0.000194	0.0376	0.35	0.23	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:24162370~24163425:-
COAD	cis	rs13256369	1	rs12550458	ENSG00000254153.1	CTA-398F10.2	3.78	0.000194	0.0376	0.31	0.23	Obesity-related traits;	chr8:8710322	chr8:8456909~8461337:-
COAD	cis	rs13256369	1	rs12545771	ENSG00000254153.1	CTA-398F10.2	3.78	0.000194	0.0376	0.31	0.23	Obesity-related traits;	chr8:8710467	chr8:8456909~8461337:-
COAD	cis	rs9652601	0.622	rs1003603	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000194	0.0376	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11020766	chr16:11056556~11057034:+
COAD	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	3.78	0.000194	0.0376	0.3	0.23	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
COAD	cis	rs4760786	0.932	rs11178537	ENSG00000258053.1	CTD-2021H9.3	-3.78	0.000194	0.0376	-0.33	-0.23	Monobrow;	chr12:71027581	chr12:71047402~71118247:-
COAD	cis	rs561341	1	rs506766	ENSG00000265798.5	RP11-271K11.5	3.78	0.000194	0.0376	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31962640	chr17:31038575~31059121:-
COAD	cis	rs28735056	0.591	rs2277724	ENSG00000267015.1	RP11-800A18.4	3.78	0.000194	0.0376	0.22	0.23	Schizophrenia;	chr18:79934294	chr18:79340258~79343972:-
COAD	cis	rs10779751	1	rs718206	ENSG00000215785.2	CFL1P6	-3.78	0.000194	0.0376	-0.26	-0.23	Body mass index;	chr1:11234417	chr1:10990978~10991797:-
COAD	cis	rs8114671	0.562	rs8116657	ENSG00000228265.4	RALY-AS1	3.78	0.000194	0.0376	0.21	0.23	Height;	chr20:34888671	chr20:33983052~33994357:-
COAD	cis	rs911119	0.866	rs4815223	ENSG00000270001.1	RP11-218C14.8	-3.78	0.000194	0.0376	-0.28	-0.23	Chronic kidney disease;	chr20:23596475	chr20:23631826~23632316:-
COAD	cis	rs2976388	0.578	rs13254358	ENSG00000247317.3	RP11-273G15.2	3.78	0.000194	0.0376	0.27	0.23	Urinary tract infection frequency;	chr8:142742458	chr8:142981738~143018437:-
COAD	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-3.78	0.000194	0.0376	-0.33	-0.23	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-3.78	0.000194	0.0376	-0.33	-0.23	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
COAD	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	3.78	0.000194	0.0376	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
COAD	cis	rs860295	0.702	rs4971095	ENSG00000203761.5	MSTO2P	3.78	0.000194	0.0376	0.21	0.23	Body mass index;	chr1:155636433	chr1:155745829~155750137:+
COAD	cis	rs6801605	0.963	rs6445607	ENSG00000271916.1	RP11-884K10.6	-3.78	0.000194	0.0376	-0.21	-0.23	Blood protein levels;	chr3:53843122	chr3:53797764~53798019:-
COAD	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-3.78	0.000194	0.0376	-0.33	-0.23	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
COAD	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000194	0.0376	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000194	0.0376	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000194	0.0376	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000194	0.0376	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
COAD	cis	rs3816183	1	rs3816179	ENSG00000236533.1	AC009413.2	-3.78	0.000194	0.0376	-0.26	-0.23	Hypospadias;	chr2:42788261	chr2:41850203~41850601:-
COAD	cis	rs9787249	0.957	rs41267029	ENSG00000237624.1	OXCT2P1	-3.78	0.000194	0.0376	-0.3	-0.23	Blood protein levels;	chr1:39748695	chr1:39514956~39516490:+
COAD	cis	rs13256369	0.802	rs12681326	ENSG00000253981.4	ALG1L13P	3.78	0.000194	0.0376	0.34	0.23	Obesity-related traits;	chr8:8708879	chr8:8236003~8244667:-
COAD	cis	rs11969893	0.85	rs9386260	ENSG00000270987.1	RP3-467N11.2	3.78	0.000194	0.0376	0.48	0.23	Economic and political preferences (immigration/crime);	chr6:100881552	chr6:100889603~100890338:+
COAD	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000194	0.0376	-0.42	-0.23	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
COAD	cis	rs7727544	0.508	rs10900804	ENSG00000233006.5	AC034220.3	3.78	0.000194	0.0377	0.2	0.23	Blood metabolite levels;	chr5:132066152	chr5:132311285~132369916:-
COAD	cis	rs2564921	0.693	rs2336721	ENSG00000280417.1	RP11-5O17.1	3.78	0.000194	0.0377	0.24	0.23	Height;	chr3:52994359	chr3:53046166~53048122:+
COAD	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-3.78	0.000194	0.0377	-0.3	-0.23	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
COAD	cis	rs867186	0.92	rs11905081	ENSG00000201151.1	SNORD56	3.78	0.000194	0.0377	0.34	0.23	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35053117	chr20:35117136~35117207:-
COAD	cis	rs867186	1	rs11907438	ENSG00000201151.1	SNORD56	3.78	0.000194	0.0377	0.34	0.23	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35053417	chr20:35117136~35117207:-
COAD	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	3.78	0.000194	0.0377	0.24	0.23	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
COAD	cis	rs913655	0.785	rs10829279	ENSG00000240291.1	RP11-499P20.2	-3.78	0.000195	0.0377	-0.31	-0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18718890	chr10:18513115~18545651:-
COAD	cis	rs6687821	0.531	rs4623671	ENSG00000261737.1	RP4-612B15.3	3.78	0.000195	0.0377	0.3	0.23	Yeast infection;	chr1:87018537	chr1:86703502~86704462:-
COAD	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	3.78	0.000195	0.0377	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
COAD	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-3.78	0.000195	0.0377	-0.34	-0.23	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
COAD	cis	rs8017304	0.643	rs8013078	ENSG00000259502.1	RP11-643G16.3	-3.78	0.000195	0.0377	-0.3	-0.23	Age-related macular degeneration;	chr14:68318182	chr14:67610986~67613864:+
COAD	cis	rs8017304	0.565	rs8022860	ENSG00000259502.1	RP11-643G16.3	-3.78	0.000195	0.0377	-0.3	-0.23	Age-related macular degeneration;	chr14:68319582	chr14:67610986~67613864:+
COAD	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	3.78	0.000195	0.0377	0.29	0.23	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
COAD	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	3.78	0.000195	0.0377	0.29	0.23	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
COAD	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	3.78	0.000195	0.0377	0.32	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
COAD	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-3.78	0.000195	0.0377	-0.26	-0.23	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
COAD	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-3.78	0.000195	0.0377	-0.26	-0.23	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
COAD	cis	rs4820539	1	rs885963	ENSG00000211644.2	IGLV1-51	-3.78	0.000195	0.0377	-0.13	-0.23	Bone mineral density;	chr22:23118752	chr22:22322472~22322980:+
COAD	cis	rs7577696	0.597	rs212689	ENSG00000272716.1	RP11-563N4.1	3.78	0.000195	0.0377	0.27	0.23	Inflammatory biomarkers;	chr2:32212269	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.512	rs212691	ENSG00000272716.1	RP11-563N4.1	3.78	0.000195	0.0377	0.27	0.23	Inflammatory biomarkers;	chr2:32213006	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.568	rs177082	ENSG00000272716.1	RP11-563N4.1	3.78	0.000195	0.0377	0.27	0.23	Inflammatory biomarkers;	chr2:32213281	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.568	rs462878	ENSG00000272716.1	RP11-563N4.1	3.78	0.000195	0.0377	0.27	0.23	Inflammatory biomarkers;	chr2:32213586	chr2:32165046~32165757:-
COAD	cis	rs2916733	0.548	rs1373306	ENSG00000246089.3	RP11-115C21.2	3.78	0.000195	0.0377	0.3	0.23	Epirubicin-induced leukopenia;	chr8:6449801	chr8:6403551~6407142:-
COAD	cis	rs4950322	0.547	rs6660507	ENSG00000278811.3	LINC00624	3.78	0.000195	0.0377	0.21	0.23	Protein quantitative trait loci;	chr1:147148574	chr1:147258885~147517875:-
COAD	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000195	0.0377	0.4	0.23	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
COAD	cis	rs7650267	0.765	rs1320161	ENSG00000232354.6	VIPR1-AS1	3.78	0.000195	0.0377	0.26	0.23	Obesity-related traits;	chr3:43261635	chr3:42506465~42533258:-
COAD	cis	rs2842346	0.568	rs916962	ENSG00000259038.1	CTD-2325P2.4	3.78	0.000195	0.0377	0.34	0.23	Breast cancer;	chr14:68526861	chr14:68627166~68628445:-
COAD	cis	rs4072705	0.967	rs4287038	ENSG00000236643.1	RP11-175D17.3	-3.78	0.000195	0.0377	-0.24	-0.23	Menarche (age at onset);	chr9:124607400	chr9:124770123~124772927:+
COAD	cis	rs6740322	0.748	rs6544634	ENSG00000234936.1	AC010883.5	3.78	0.000195	0.0377	0.29	0.23	Coronary artery disease;	chr2:43244389	chr2:43229573~43233394:+
COAD	cis	rs2179367	0.6	rs9498353	ENSG00000268592.3	RAET1E-AS1	3.78	0.000195	0.0377	0.27	0.23	Dupuytren's disease;	chr6:149439860	chr6:149863494~149919507:+
COAD	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-3.78	0.000195	0.0377	-0.32	-0.23	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
COAD	cis	rs4660214	0.666	rs11205696	ENSG00000182109.6	RP11-69E11.4	-3.78	0.000195	0.0377	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs6600290	ENSG00000182109.6	RP11-69E11.4	-3.78	0.000195	0.0377	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39522280~39546187:-
COAD	cis	rs2408955	0.522	rs3997	ENSG00000226413.2	OR8T1P	-3.78	0.000195	0.0377	-0.28	-0.23	Glycated hemoglobin levels;	chr12:48087804	chr12:48442030~48442947:-
COAD	cis	rs2408955	0.522	rs11168408	ENSG00000226413.2	OR8T1P	-3.78	0.000195	0.0377	-0.28	-0.23	Glycated hemoglobin levels;	chr12:48104544	chr12:48442030~48442947:-
COAD	cis	rs5751168	0.915	rs5758470	ENSG00000211660.3	IGLV2-23	-3.78	0.000195	0.0377	-0.15	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22486760	chr22:22697789~22698407:+
COAD	cis	rs5751168	0.834	rs5758477	ENSG00000211660.3	IGLV2-23	-3.78	0.000195	0.0377	-0.15	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22487295	chr22:22697789~22698407:+
COAD	cis	rs5751168	0.834	rs11109	ENSG00000211660.3	IGLV2-23	-3.78	0.000195	0.0377	-0.15	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22487881	chr22:22697789~22698407:+
COAD	cis	rs1964356	0.524	rs7839585	ENSG00000233609.3	RP11-62H7.2	-3.78	0.000195	0.0378	-0.25	-0.23	Mean corpuscular volume;	chr8:8996725	chr8:8961200~8979025:+
COAD	cis	rs34286592	0.929	rs8058824	ENSG00000214725.6	CDIPT-AS1	-3.78	0.000195	0.0378	-0.4	-0.23	Multiple sclerosis;	chr16:29817389	chr16:29863593~29868053:+
COAD	cis	rs13256369	0.851	rs13258283	ENSG00000254153.1	CTA-398F10.2	3.78	0.000195	0.0378	0.31	0.23	Obesity-related traits;	chr8:8706120	chr8:8456909~8461337:-
COAD	cis	rs13256369	0.851	rs13249700	ENSG00000254153.1	CTA-398F10.2	3.78	0.000195	0.0378	0.31	0.23	Obesity-related traits;	chr8:8706127	chr8:8456909~8461337:-
COAD	cis	rs8192917	0.573	rs8010409	ENSG00000225766.7	DHRS4L1	3.78	0.000195	0.0378	0.49	0.23	Vitiligo;	chr14:24611083	chr14:24036453~24051028:+
COAD	cis	rs2346160	0.899	rs206974	ENSG00000228648.1	RP11-568A7.2	3.78	0.000195	0.0378	0.26	0.23	Parental extreme longevity (95 years and older);	chr6:167276812	chr6:167241891~167245916:+
COAD	cis	rs791590	0.54	rs10905604	ENSG00000215267.7	AKR1C7P	-3.78	0.000195	0.0378	-0.33	-0.23	Soluble interleukin-2 receptor subunit alpha;	chr10:6003415	chr10:5275173~5288470:-
COAD	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-3.78	0.000195	0.0378	-0.26	-0.23	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
COAD	cis	rs2765539	0.701	rs4659148	ENSG00000231365.4	RP11-418J17.1	-3.78	0.000195	0.0378	-0.28	-0.23	Waist-hip ratio;	chr1:119104071	chr1:119140396~119275973:+
COAD	cis	rs453301	0.624	rs330049	ENSG00000233609.3	RP11-62H7.2	3.78	0.000195	0.0378	0.26	0.23	Joint mobility (Beighton score);	chr8:9229789	chr8:8961200~8979025:+
COAD	cis	rs62184315	0.536	rs62183659	ENSG00000253559.1	OSGEPL1-AS1	-3.78	0.000195	0.0378	-0.29	-0.23	Alcohol dependence (age at onset);	chr2:189672131	chr2:189762704~189765556:+
COAD	cis	rs62184315	0.536	rs62185869	ENSG00000253559.1	OSGEPL1-AS1	-3.78	0.000195	0.0378	-0.29	-0.23	Alcohol dependence (age at onset);	chr2:189672330	chr2:189762704~189765556:+
COAD	cis	rs228769	0.562	rs228762	ENSG00000267080.4	ASB16-AS1	3.78	0.000195	0.0378	0.26	0.23	Bone mineral density (hip);Bone mineral density (spine);	chr17:44061024	chr17:44175973~44186717:-
COAD	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	3.78	0.000195	0.0378	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	3.78	0.000195	0.0378	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	3.78	0.000195	0.0378	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
COAD	cis	rs12940923	0.81	rs7215408	ENSG00000264112.1	RP11-159D12.2	3.78	0.000195	0.0378	0.28	0.23	Circulating myeloperoxidase levels (plasma);	chr17:58288745	chr17:57989039~57994850:-
COAD	cis	rs34779708	0.931	rs17582416	ENSG00000271335.4	RP11-324I22.4	3.78	0.000195	0.0378	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35314552~35336401:-
COAD	cis	rs7572733	0.935	rs7558450	ENSG00000222017.1	AC011997.1	3.78	0.000195	0.0378	0.25	0.23	Dermatomyositis;	chr2:197973042	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.935	rs11675025	ENSG00000222017.1	AC011997.1	3.78	0.000195	0.0378	0.25	0.23	Dermatomyositis;	chr2:197973591	chr2:197693106~197774823:+
COAD	cis	rs442309	0.687	rs10822057	ENSG00000228566.1	RP11-170M17.1	-3.78	0.000195	0.0378	-0.27	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62760391	chr10:63664664~63990568:+
COAD	cis	rs12681366	0.763	rs3019277	ENSG00000253704.1	RP11-267M23.4	3.78	0.000195	0.0378	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94553722~94569745:+
COAD	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	3.78	0.000195	0.0378	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
COAD	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000196	0.0378	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.697	rs35280960	ENSG00000250412.1	KLHL2P1	3.78	0.000196	0.0378	0.31	0.23	Corneal astigmatism;	chr4:119335904	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	3.78	0.000196	0.0378	0.3	0.23	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
COAD	cis	rs9992667	0.563	rs10026640	ENSG00000231160.8	KLF3-AS1	3.78	0.000196	0.0378	0.25	0.23	Eosinophil percentage of granulocytes;	chr4:38701352	chr4:38612701~38664883:-
COAD	cis	rs6921919	0.848	rs9468350	ENSG00000272009.1	RP1-313I6.12	3.78	0.000196	0.0378	0.28	0.23	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28078792~28081130:-
COAD	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-3.78	0.000196	0.0378	-0.4	-0.23	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
COAD	cis	rs5753037	0.869	rs5763671	ENSG00000279159.1	RP3-394A18.1	-3.78	0.000196	0.0378	-0.16	-0.23	Type 1 diabetes;	chr22:29988583	chr22:29978950~30028236:-
COAD	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-3.78	0.000196	0.0379	-0.3	-0.23	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
COAD	cis	rs8022206	0.898	rs17192558	ENSG00000259502.1	RP11-643G16.3	-3.78	0.000196	0.0379	-0.34	-0.23	Platelet count;Mean platelet volume;	chr14:67984739	chr14:67610986~67613864:+
COAD	cis	rs12549025	0.677	rs62503282	ENSG00000253390.1	CTC-756D1.2	-3.78	0.000196	0.0379	-0.39	-0.23	Reticulocyte fraction of red cells;	chr8:23529679	chr8:23458601~23484971:+
COAD	cis	rs17685	0.633	rs3801471	ENSG00000280388.1	RP11-229D13.3	-3.78	0.000196	0.0379	-0.24	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76043977~76045963:-
COAD	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	3.78	0.000196	0.0379	0.26	0.23	Height;	chr4:55529387	chr4:55363971~55395847:-
COAD	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	3.78	0.000196	0.0379	0.26	0.23	Height;	chr4:55529786	chr4:55363971~55395847:-
COAD	cis	rs2243480	1	rs958550	ENSG00000229886.1	RP5-1132H15.3	-3.78	0.000196	0.0379	-0.39	-0.23	Diabetic kidney disease;	chr7:66170692	chr7:66025126~66031544:-
COAD	cis	rs1161098	0.625	rs6581756	ENSG00000203585.3	RP11-542B15.1	-3.78	0.000196	0.0379	-0.32	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67417852	chr12:67519829~67567126:+
COAD	cis	rs10087240	0.55	rs62512836	ENSG00000207110.1	RNU1-106P	3.78	0.000196	0.0379	0.29	0.23	Lymphocyte counts;White blood cell count;	chr8:127994767	chr8:127999131~127999294:+
COAD	cis	rs6452524	0.804	rs1478481	ENSG00000271862.1	RP11-343L5.2	3.78	0.000196	0.0379	0.24	0.23	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83049376~83050964:-
COAD	cis	rs10933436	1	rs6738961	ENSG00000259793.1	RP11-400N9.1	3.78	0.000196	0.0379	0.25	0.23	Coronary heart disease;	chr2:233133936	chr2:233351132~233353416:-
COAD	cis	rs735539	0.517	rs9552241	ENSG00000222726.1	RNU2-7P	3.78	0.000196	0.0379	0.29	0.23	Dental caries;	chr13:20553430	chr13:20612161~20612338:+
COAD	cis	rs13256369	0.951	rs12679360	ENSG00000253981.4	ALG1L13P	-3.78	0.000196	0.0379	-0.33	-0.23	Obesity-related traits;	chr8:8708759	chr8:8236003~8244667:-
COAD	cis	rs9532669	0.889	rs1989252	ENSG00000239827.7	SUGT1P3	3.78	0.000196	0.0379	0.2	0.23	Cervical cancer;	chr13:40911532	chr13:40908159~40921774:-
COAD	cis	rs2188554	0.785	rs7789741	ENSG00000237974.1	AC000111.4	3.78	0.000196	0.0379	0.26	0.23	Esophageal adenocarcinoma;	chr7:117566887	chr7:117487737~117487929:+
COAD	cis	rs860295	0.775	rs822505	ENSG00000203761.5	MSTO2P	3.78	0.000196	0.0379	0.21	0.23	Body mass index;	chr1:155876737	chr1:155745829~155750137:+
COAD	cis	rs8062405	0.573	rs6565300	ENSG00000261067.5	RP11-264B17.3	3.78	0.000196	0.0379	0.16	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28974804~28990783:+
COAD	cis	rs561341	0.825	rs2008368	ENSG00000265798.5	RP11-271K11.5	3.78	0.000196	0.0379	0.35	0.23	Hip circumference adjusted for BMI;	chr17:32020378	chr17:31038575~31059121:-
COAD	cis	rs10471753	1	rs7726943	ENSG00000248359.1	CTC-537E7.2	-3.78	0.000196	0.0379	-0.2	-0.23	Hip minimal joint space width;	chr5:68522754	chr5:68531690~68533530:-
COAD	cis	rs801193	0.66	rs10950049	ENSG00000224316.1	RP11-479O9.2	3.78	0.000196	0.0379	0.25	0.23	Aortic root size;	chr7:66765873	chr7:65773620~65802067:+
COAD	cis	rs7674212	0.539	rs6850461	ENSG00000230069.3	LRRC37A15P	-3.78	0.000196	0.0379	-0.24	-0.23	Type 2 diabetes;	chr4:103198884	chr4:102727274~102730721:-
COAD	cis	rs7674212	0.539	rs2866635	ENSG00000230069.3	LRRC37A15P	-3.78	0.000196	0.0379	-0.24	-0.23	Type 2 diabetes;	chr4:103200419	chr4:102727274~102730721:-
COAD	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	3.78	0.000196	0.0379	0.21	0.23	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
COAD	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	3.78	0.000196	0.0379	0.21	0.23	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
COAD	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	3.78	0.000196	0.0379	0.23	0.23	Cancer;	chr16:4814178	chr16:4795265~4796532:-
COAD	cis	rs9487051	1	rs7748918	ENSG00000219700.1	PTCHD3P3	3.78	0.000196	0.0379	0.25	0.23	Reticulocyte fraction of red cells;	chr6:109292361	chr6:109288571~109290503:-
COAD	cis	rs603446	0.55	rs1787699	ENSG00000254851.1	RP11-109L13.1	3.78	0.000196	0.0379	0.28	0.23	Triglycerides;	chr11:116693837	chr11:117135528~117138582:+
COAD	cis	rs603446	0.55	rs1787698	ENSG00000254851.1	RP11-109L13.1	3.78	0.000196	0.0379	0.28	0.23	Triglycerides;	chr11:116693846	chr11:117135528~117138582:+
COAD	cis	rs603446	0.55	rs1784118	ENSG00000254851.1	RP11-109L13.1	3.78	0.000196	0.0379	0.28	0.23	Triglycerides;	chr11:116694339	chr11:117135528~117138582:+
COAD	cis	rs7686384	0.576	rs35512176	ENSG00000180015.12	RP11-756P10.3	-3.78	0.000196	0.038	-0.37	-0.23	Obesity-related traits;	chr4:188707382	chr4:188738373~188739494:+
COAD	cis	rs7686384	0.576	rs35414806	ENSG00000180015.12	RP11-756P10.3	-3.78	0.000196	0.038	-0.37	-0.23	Obesity-related traits;	chr4:188707437	chr4:188738373~188739494:+
COAD	cis	rs7686384	0.576	rs34817758	ENSG00000180015.12	RP11-756P10.3	-3.78	0.000196	0.038	-0.37	-0.23	Obesity-related traits;	chr4:188707454	chr4:188738373~188739494:+
COAD	cis	rs7686384	0.522	rs36044678	ENSG00000180015.12	RP11-756P10.3	-3.78	0.000196	0.038	-0.37	-0.23	Obesity-related traits;	chr4:188707557	chr4:188738373~188739494:+
COAD	cis	rs2734839	0.964	rs7122246	ENSG00000270179.1	RP11-159N11.4	-3.78	0.000196	0.038	-0.29	-0.23	Information processing speed;	chr11:113433735	chr11:113368478~113369117:+
COAD	cis	rs911119	0.913	rs6048924	ENSG00000270001.1	RP11-218C14.8	-3.78	0.000196	0.038	-0.28	-0.23	Chronic kidney disease;	chr20:23598359	chr20:23631826~23632316:-
COAD	cis	rs911119	0.866	rs6048925	ENSG00000270001.1	RP11-218C14.8	-3.78	0.000196	0.038	-0.28	-0.23	Chronic kidney disease;	chr20:23598419	chr20:23631826~23632316:-
COAD	cis	rs12819124	0.502	rs10875718	ENSG00000273765.1	RP11-370I10.11	3.78	0.000196	0.038	0.24	0.23	Glycated hemoglobin levels;	chr12:48017319	chr12:48360920~48361377:+
COAD	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000196	0.038	-0.41	-0.23	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
COAD	cis	rs4074961	0.527	rs6704190	ENSG00000233621.1	LINC01137	-3.78	0.000197	0.038	-0.26	-0.23	Axial length;	chr1:37545150	chr1:37454879~37474411:-
COAD	cis	rs467650	0.782	rs719246	ENSG00000248489.1	CTD-2007H13.3	-3.78	0.000197	0.038	-0.23	-0.23	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98929171~98995013:+
COAD	cis	rs68170813	0.559	rs10953530	ENSG00000241764.3	AC002467.7	3.78	0.000197	0.038	0.31	0.23	Coronary artery disease;	chr7:107187351	chr7:107742817~107744581:-
COAD	cis	rs4699052	0.662	rs1516731	ENSG00000246560.2	RP11-10L12.4	3.78	0.000197	0.038	0.27	0.23	Testicular germ cell tumor;	chr4:103331537	chr4:102828055~102844075:+
COAD	cis	rs599083	0.53	rs667126	ENSG00000184795.9	UNC93B5	-3.78	0.000197	0.038	-0.29	-0.23	Bone mineral density (spine);	chr11:68410260	chr11:67711702~67716005:-
COAD	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-3.78	0.000197	0.038	-0.24	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
COAD	cis	rs2836974	0.568	rs2183573	ENSG00000255568.3	BRWD1-AS2	-3.78	0.000197	0.038	-0.21	-0.23	Cognitive function;	chr21:39202379	chr21:39313935~39314962:+
COAD	cis	rs9307551	0.619	rs10022309	ENSG00000250334.4	LINC00989	-3.78	0.000197	0.038	-0.28	-0.23	Refractive error;	chr4:79550491	chr4:79492416~79576460:+
COAD	cis	rs860295	0.702	rs2175391	ENSG00000203761.5	MSTO2P	3.78	0.000197	0.038	0.21	0.23	Body mass index;	chr1:155655811	chr1:155745829~155750137:+
COAD	cis	rs9300255	0.569	rs1790115	ENSG00000280120.1	RP11-546D6.3	3.78	0.000197	0.038	0.23	0.23	Neutrophil percentage of white cells;	chr12:123135723	chr12:123152324~123153377:-
COAD	cis	rs13256369	0.802	rs13255789	ENSG00000254153.1	CTA-398F10.2	3.78	0.000197	0.038	0.31	0.23	Obesity-related traits;	chr8:8705281	chr8:8456909~8461337:-
COAD	cis	rs73198271	0.565	rs575895	ENSG00000173295.6	FAM86B3P	-3.78	0.000197	0.038	-0.28	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736737	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.565	rs575920	ENSG00000173295.6	FAM86B3P	-3.78	0.000197	0.038	-0.28	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736744	chr8:8228595~8244865:+
COAD	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-3.78	0.000197	0.038	-0.29	-0.23	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
COAD	cis	rs3738443	0.951	rs4551629	ENSG00000259865.1	RP11-488L18.10	3.78	0.000197	0.038	0.28	0.23	Alcohol dependence;	chr1:247211748	chr1:247187281~247188526:-
COAD	cis	rs728616	0.681	rs34816332	ENSG00000225484.5	NUTM2B-AS1	-3.78	0.000197	0.038	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79663088~79826594:-
COAD	cis	rs630539	0.655	rs874640	ENSG00000259623.1	RP11-156E6.1	3.78	0.000197	0.038	0.46	0.23	Systolic blood pressure change trajectories;	chr17:42691374	chr17:41848518~41851447:-
COAD	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-3.78	0.000197	0.038	-0.29	-0.23	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
COAD	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-3.78	0.000197	0.038	-0.29	-0.23	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
COAD	cis	rs2562784	0.638	rs2099126	ENSG00000225151.9	GOLGA2P7	-3.78	0.000197	0.038	-0.39	-0.23	Height;	chr15:83623472	chr15:84199311~84230136:-
COAD	cis	rs860295	0.871	rs6688636	ENSG00000225082.2	DAP3P1	3.78	0.000197	0.038	0.28	0.23	Body mass index;	chr1:155509106	chr1:155586644~155602197:+
COAD	cis	rs9300255	0.602	rs1616131	ENSG00000280120.1	RP11-546D6.3	3.78	0.000197	0.038	0.23	0.23	Neutrophil percentage of white cells;	chr12:123135291	chr12:123152324~123153377:-
COAD	cis	rs9300255	0.602	rs1616181	ENSG00000280120.1	RP11-546D6.3	3.78	0.000197	0.038	0.23	0.23	Neutrophil percentage of white cells;	chr12:123135309	chr12:123152324~123153377:-
COAD	cis	rs561341	0.882	rs2521594	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31975068	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs548957	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31975392	chr17:31038575~31059121:-
COAD	cis	rs561341	0.556	rs542244	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31980223	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs484175	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31982022	chr17:31038575~31059121:-
COAD	cis	rs561341	0.941	rs4525554	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31985800	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs530209	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31988268	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs72825712	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31989100	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs561341	ENSG00000265798.5	RP11-271K11.5	3.78	0.000197	0.0381	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31989366	chr17:31038575~31059121:-
COAD	cis	rs362296	0.698	rs3135172	ENSG00000248840.2	RP11-357G3.2	3.78	0.000197	0.0381	0.28	0.23	Parental longevity (mother's age at death);	chr4:3257008	chr4:3312512~3313058:+
COAD	cis	rs2243480	0.901	rs73142137	ENSG00000275400.1	RP4-756H11.5	3.78	0.000197	0.0381	0.4	0.23	Diabetic kidney disease;	chr7:65878455	chr7:66553805~66554199:-
COAD	cis	rs2243480	1	rs13247184	ENSG00000275400.1	RP4-756H11.5	3.78	0.000197	0.0381	0.4	0.23	Diabetic kidney disease;	chr7:65893941	chr7:66553805~66554199:-
COAD	cis	rs2243480	1	rs35283677	ENSG00000275400.1	RP4-756H11.5	3.78	0.000197	0.0381	0.4	0.23	Diabetic kidney disease;	chr7:65894246	chr7:66553805~66554199:-
COAD	cis	rs763121	0.706	rs3827356	ENSG00000273076.1	RP3-508I15.22	-3.78	0.000197	0.0381	-0.2	-0.23	Menopause (age at onset);	chr22:38668801	chr22:38743495~38743910:+
COAD	cis	rs7260598	0.792	rs73021461	ENSG00000268442.1	CTD-2027I19.2	3.78	0.000197	0.0381	0.37	0.23	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:24162370~24163425:-
COAD	cis	rs2310173	0.575	rs13022757	ENSG00000281162.1	LINC01127	-3.78	0.000197	0.0381	-0.24	-0.23	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101997084	chr2:101962056~101987167:+
COAD	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-3.78	0.000197	0.0381	-0.32	-0.23	Depression;	chr6:28184805	chr6:28170845~28172521:+
COAD	cis	rs9907295	0.892	rs55950249	ENSG00000271013.1	AC015849.15	-3.78	0.000197	0.0381	-0.31	-0.23	Fibroblast growth factor basic levels;	chr17:35903948	chr17:35912635~35918010:-
COAD	cis	rs860295	0.702	rs1325908	ENSG00000160766.13	GBAP1	-3.78	0.000197	0.0381	-0.24	-0.23	Body mass index;	chr1:155443513	chr1:155213821~155227422:-
COAD	cis	rs6565180	0.962	rs6565183	ENSG00000261367.1	RP11-455F5.4	3.78	0.000197	0.0381	0.24	0.23	Tonsillectomy;	chr16:30371434	chr16:30107675~30110541:+
COAD	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-3.78	0.000197	0.0381	-0.25	-0.23	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-3.78	0.000197	0.0381	-0.25	-0.23	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-3.78	0.000197	0.0381	-0.25	-0.23	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
COAD	cis	rs11588062	0.628	rs11211270	ENSG00000230896.1	RP11-767N6.7	3.78	0.000198	0.0381	0.27	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:46373314	chr1:45694684~45697075:-
COAD	cis	rs2638953	0.924	rs11049386	ENSG00000247934.4	RP11-967K21.1	-3.78	0.000198	0.0381	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167603	chr12:28163298~28190738:-
COAD	cis	rs9532669	0.89	rs9532627	ENSG00000239827.7	SUGT1P3	-3.78	0.000198	0.0381	-0.2	-0.23	Cervical cancer;	chr13:40874811	chr13:40908159~40921774:-
COAD	cis	rs480407	0.667	rs6707147	ENSG00000232320.6	AC009299.5	-3.78	0.000198	0.0381	-0.3	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr2:160805184	chr2:161340816~161341326:-
COAD	cis	rs10043775	1	rs1971431	ENSG00000251330.3	CTD-2283N19.1	-3.78	0.000198	0.0381	-0.27	-0.23	Periodontal microbiota;	chr5:148452493	chr5:148430159~148430807:-
COAD	cis	rs3748656	0.887	rs11102496	ENSG00000231246.1	RP5-965F6.2	-3.78	0.000198	0.0381	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112565842	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs10857967	ENSG00000231246.1	RP5-965F6.2	-3.78	0.000198	0.0381	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112577971	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs11102501	ENSG00000231246.1	RP5-965F6.2	-3.78	0.000198	0.0381	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112585332	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs12724928	ENSG00000231246.1	RP5-965F6.2	-3.78	0.000198	0.0381	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112586309	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs34107138	ENSG00000231246.1	RP5-965F6.2	-3.78	0.000198	0.0381	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112594948	chr1:112177234~112360528:-
COAD	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000198	0.0381	-0.41	-0.23	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
COAD	cis	rs2832191	0.791	rs2251517	ENSG00000176054.6	RPL23P2	3.78	0.000198	0.0382	0.23	0.23	Dental caries;	chr21:29159630	chr21:28997613~28998033:-
COAD	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-3.78	0.000198	0.0382	-0.33	-0.23	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
COAD	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-3.78	0.000198	0.0382	-0.33	-0.23	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
COAD	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-3.78	0.000198	0.0382	-0.33	-0.23	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
COAD	cis	rs4819052	0.851	rs8126930	ENSG00000227039.5	ITGB2-AS1	-3.78	0.000198	0.0382	-0.19	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:44921051~44929678:+
COAD	cis	rs3733589	1	rs6850167	ENSG00000250413.1	RP11-448G15.1	-3.78	0.000198	0.0382	-0.56	-0.23	Renal overload gout;	chr4:10163029	chr4:10006482~10009725:+
COAD	cis	rs3126085	0.734	rs3120653	ENSG00000237975.5	FLG-AS1	3.78	0.000198	0.0382	0.26	0.23	Atopic dermatitis;	chr1:152312378	chr1:152168125~152445456:+
COAD	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-3.78	0.000198	0.0382	-0.21	-0.23	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
COAD	cis	rs9987353	0.519	rs2929465	ENSG00000253981.4	ALG1L13P	-3.78	0.000198	0.0382	-0.26	-0.23	Recombination measurement;	chr8:9206492	chr8:8236003~8244667:-
COAD	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-3.78	0.000198	0.0382	-0.22	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
COAD	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000198	0.0382	0.39	0.23	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
COAD	cis	rs11976180	1	rs2961144	ENSG00000273234.1	OR2A13P	3.78	0.000198	0.0382	0.28	0.23	Obesity-related traits;	chr7:144050777	chr7:144142009~144142938:+
COAD	cis	rs9880211	0.613	rs6767060	ENSG00000239213.4	NCK1-AS1	3.78	0.000198	0.0382	0.3	0.23	Height;Body mass index;	chr3:136148248	chr3:136841726~136862054:-
COAD	cis	rs11626933	1	rs61989986	ENSG00000275198.1	RP11-471B22.3	-3.78	0.000198	0.0382	-0.28	-0.23	Gut microbiota (bacterial taxa);	chr14:90272836	chr14:90383365~90387973:+
COAD	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-3.78	0.000198	0.0382	-0.28	-0.23	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-3.78	0.000198	0.0382	-0.28	-0.23	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-3.78	0.000198	0.0382	-0.28	-0.23	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
COAD	cis	rs860295	0.535	rs2297649	ENSG00000225082.2	DAP3P1	3.78	0.000198	0.0382	0.3	0.23	Body mass index;	chr1:155965453	chr1:155586644~155602197:+
COAD	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-3.78	0.000198	0.0382	-0.31	-0.23	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
COAD	cis	rs875971	0.929	rs10950041	ENSG00000223473.2	GS1-124K5.3	3.78	0.000198	0.0382	0.19	0.23	Aortic root size;	chr7:66508888	chr7:66491049~66493566:-
COAD	cis	rs875971	0.929	rs6970860	ENSG00000223473.2	GS1-124K5.3	3.78	0.000198	0.0382	0.19	0.23	Aortic root size;	chr7:66511647	chr7:66491049~66493566:-
COAD	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000198	0.0382	0.39	0.23	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
COAD	cis	rs734999	0.967	rs6667605	ENSG00000225931.3	RP3-395M20.7	3.78	0.000198	0.0382	0.25	0.23	Ulcerative colitis;	chr1:2571341	chr1:2566410~2569888:+
COAD	cis	rs11626933	1	rs2236402	ENSG00000275198.1	RP11-471B22.3	-3.78	0.000198	0.0382	-0.27	-0.23	Gut microbiota (bacterial taxa);	chr14:90268034	chr14:90383365~90387973:+
COAD	cis	rs3781264	0.6	rs10882416	ENSG00000273450.1	RP11-76P2.4	-3.78	0.000198	0.0382	-0.27	-0.23	Esophageal cancer and gastric cancer;	chr10:94285297	chr10:94314907~94315327:-
COAD	cis	rs60311166	1	rs4532127	ENSG00000212452.1	SNORD69	-3.78	0.000198	0.0382	-0.41	-0.23	CTACK levels;	chr3:52693720	chr3:52692736~52692812:+
COAD	cis	rs728616	0.614	rs3934643	ENSG00000234382.2	RP11-40F6.1	-3.78	0.000198	0.0382	-0.37	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:80233664~80245367:+
COAD	cis	rs728616	0.764	rs11201025	ENSG00000234382.2	RP11-40F6.1	-3.78	0.000198	0.0382	-0.37	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:80233664~80245367:+
COAD	cis	rs7650267	0.765	rs1320163	ENSG00000232354.6	VIPR1-AS1	3.78	0.000198	0.0382	0.26	0.23	Obesity-related traits;	chr3:43261804	chr3:42506465~42533258:-
COAD	cis	rs7650267	0.765	rs2372361	ENSG00000232354.6	VIPR1-AS1	3.78	0.000198	0.0382	0.26	0.23	Obesity-related traits;	chr3:43261908	chr3:42506465~42533258:-
COAD	cis	rs453301	0.686	rs11785819	ENSG00000233609.3	RP11-62H7.2	-3.78	0.000198	0.0382	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9012868	chr8:8961200~8979025:+
COAD	cis	rs224278	0.509	rs4746746	ENSG00000228566.1	RP11-170M17.1	3.78	0.000198	0.0382	0.33	0.23	Ewing sarcoma;	chr10:62940221	chr10:63664664~63990568:+
COAD	cis	rs1707322	0.721	rs11211165	ENSG00000230896.1	RP11-767N6.7	-3.78	0.000198	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs11211166	ENSG00000230896.1	RP11-767N6.7	-3.78	0.000198	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45694684~45697075:-
COAD	cis	rs3126085	0.56	rs11204982	ENSG00000237975.5	FLG-AS1	3.78	0.000198	0.0383	0.26	0.23	Atopic dermatitis;	chr1:152349566	chr1:152168125~152445456:+
COAD	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000198	0.0383	-0.4	-0.23	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
COAD	cis	rs9400467	0.508	rs11153293	ENSG00000230177.1	RP5-1112D6.4	-3.78	0.000198	0.0383	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.508	rs11756643	ENSG00000230177.1	RP5-1112D6.4	-3.78	0.000198	0.0383	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111277932~111278742:+
COAD	cis	rs867371	0.82	rs12443224	ENSG00000259429.4	UBE2Q2P2	-3.78	0.000198	0.0383	-0.2	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82355142~82420075:+
COAD	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	3.78	0.000199	0.0383	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
COAD	cis	rs7208859	0.573	rs8070182	ENSG00000280069.1	CTD-2349P21.3	-3.78	0.000199	0.0383	-0.32	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30738182~30740275:+
COAD	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-3.78	0.000199	0.0383	-0.29	-0.23	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
COAD	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-3.78	0.000199	0.0383	-0.34	-0.23	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
COAD	cis	rs3934047	0.869	rs12912221	ENSG00000278029.1	CTD-2240J17.2	-3.78	0.000199	0.0383	-0.26	-0.23	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81770365	chr15:81392759~81393384:+
COAD	cis	rs4237845	0.611	rs4373979	ENSG00000257698.1	RP11-620J15.3	3.78	0.000199	0.0383	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57938603	chr12:57931528~57936175:-
COAD	cis	rs4237845	0.611	rs4534624	ENSG00000257698.1	RP11-620J15.3	3.78	0.000199	0.0383	0.21	0.23	Intelligence (multi-trait analysis);	chr12:57938644	chr12:57931528~57936175:-
COAD	cis	rs739496	0.615	rs3809274	ENSG00000257595.2	RP3-473L9.4	3.78	0.000199	0.0383	0.34	0.23	Platelet count;	chr12:111606529	chr12:111369282~111403310:+
COAD	cis	rs2732480	0.5	rs12829841	ENSG00000226413.2	OR8T1P	3.78	0.000199	0.0383	0.29	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48442030~48442947:-
COAD	cis	rs2732480	0.523	rs34286639	ENSG00000226413.2	OR8T1P	3.78	0.000199	0.0383	0.29	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48442030~48442947:-
COAD	cis	rs1387259	0.929	rs11168484	ENSG00000226413.2	OR8T1P	3.78	0.000199	0.0383	0.29	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48442030~48442947:-
COAD	cis	rs7119	0.689	rs11630926	ENSG00000259565.2	KRT8P23	-3.77	0.000199	0.0383	-0.28	-0.23	Type 2 diabetes;	chr15:77527240	chr15:76979245~76980451:-
COAD	cis	rs7119	0.636	rs34020536	ENSG00000259565.2	KRT8P23	-3.77	0.000199	0.0383	-0.28	-0.23	Type 2 diabetes;	chr15:77527244	chr15:76979245~76980451:-
COAD	cis	rs7119	0.636	rs11635606	ENSG00000259565.2	KRT8P23	-3.77	0.000199	0.0383	-0.28	-0.23	Type 2 diabetes;	chr15:77527249	chr15:76979245~76980451:-
COAD	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-3.77	0.000199	0.0383	-0.24	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
COAD	cis	rs10090774	0.965	rs170068	ENSG00000280303.2	ERICD	3.77	0.000199	0.0383	0.3	0.23	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141003373	chr8:140636281~140638283:+
COAD	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-3.77	0.000199	0.0383	-0.27	-0.23	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
COAD	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	3.77	0.000199	0.0383	0.26	0.23	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
COAD	cis	rs1707322	0.721	rs10890337	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs3811435	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs9793568	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs11211157	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs11211158	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs6429575	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.685	rs6690926	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs8179402	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs8179296	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000199	0.0383	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45694684~45697075:-
COAD	cis	rs734999	0.588	rs867435	ENSG00000225931.3	RP3-395M20.7	3.77	0.000199	0.0383	0.25	0.23	Ulcerative colitis;	chr1:2592267	chr1:2566410~2569888:+
COAD	cis	rs1048886	0.938	rs59275635	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000199	0.0383	-0.32	-0.23	Type 2 diabetes;	chr6:70444020	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs12526827	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000199	0.0383	-0.32	-0.23	Type 2 diabetes;	chr6:70449931	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs6901904	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000199	0.0383	-0.32	-0.23	Type 2 diabetes;	chr6:70471972	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs73482557	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000199	0.0383	-0.32	-0.23	Type 2 diabetes;	chr6:70473810	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs11965656	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000199	0.0383	-0.32	-0.23	Type 2 diabetes;	chr6:70473917	chr6:70596438~70596980:+
COAD	cis	rs11138902	0.673	rs12378318	ENSG00000229312.2	RP11-470P21.2	3.77	0.000199	0.0383	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69521347	chr9:69472466~69494513:+
COAD	cis	rs2337406	1	rs78631692	ENSG00000211964.3	IGHV3-48	-3.77	0.000199	0.0383	-0.2	-0.23	Alzheimer's disease (late onset);	chr14:106709371	chr14:106537810~106538344:-
COAD	cis	rs875971	0.545	rs75840613	ENSG00000232546.1	RP11-458F8.1	3.77	0.000199	0.0383	0.23	0.23	Aortic root size;	chr7:66376399	chr7:66848496~66858136:+
COAD	cis	rs28374715	0.681	rs28687846	ENSG00000247556.5	OIP5-AS1	3.77	0.000199	0.0383	0.32	0.23	Ulcerative colitis;	chr15:41307704	chr15:41283990~41309737:+
COAD	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	3.77	0.000199	0.0384	0.24	0.23	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
COAD	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-3.77	0.000199	0.0384	-0.44	-0.23	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
COAD	cis	rs2765539	0.59	rs912960	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000199	0.0384	-0.29	-0.23	Waist-hip ratio;	chr1:118935879	chr1:119140396~119275973:+
COAD	cis	rs2765539	0.59	rs1325942	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000199	0.0384	-0.29	-0.23	Waist-hip ratio;	chr1:118941210	chr1:119140396~119275973:+
COAD	cis	rs16949788	0.793	rs78483581	ENSG00000261351.2	CTD-3185P2.1	-3.77	0.000199	0.0384	-0.41	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477027	chr15:66488658~66492109:-
COAD	cis	rs16949788	1	rs76847935	ENSG00000261351.2	CTD-3185P2.1	-3.77	0.000199	0.0384	-0.41	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477275	chr15:66488658~66492109:-
COAD	cis	rs2370759	1	rs7910776	ENSG00000273038.2	RP11-479G22.8	3.77	0.000199	0.0384	0.4	0.23	Sexual dysfunction (female);	chr10:32350165	chr10:32887255~32889311:-
COAD	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	3.77	0.000199	0.0384	0.39	0.23	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
COAD	cis	rs875971	0.867	rs1002053	ENSG00000223473.2	GS1-124K5.3	-3.77	0.000199	0.0384	-0.19	-0.23	Aortic root size;	chr7:66333558	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs6460292	ENSG00000223473.2	GS1-124K5.3	-3.77	0.000199	0.0384	-0.19	-0.23	Aortic root size;	chr7:66345088	chr7:66491049~66493566:-
COAD	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-3.77	0.000199	0.0384	-0.32	-0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
COAD	cis	rs2348418	0.639	rs7969946	ENSG00000247934.4	RP11-967K21.1	-3.77	0.000199	0.0384	-0.2	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28111814	chr12:28163298~28190738:-
COAD	cis	rs7760535	0.826	rs3777905	ENSG00000230177.1	RP5-1112D6.4	-3.77	2e-04	0.0384	-0.2	-0.23	Metabolic traits;	chr6:111549385	chr6:111277932~111278742:+
COAD	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-3.77	2e-04	0.0384	-0.34	-0.23	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
COAD	cis	rs2832191	0.74	rs2853830	ENSG00000176054.6	RPL23P2	3.77	2e-04	0.0384	0.23	0.23	Dental caries;	chr21:29044503	chr21:28997613~28998033:-
COAD	cis	rs259067	0.812	rs259102	ENSG00000250258.1	CTC-431G16.2	3.77	2e-04	0.0384	0.38	0.23	Obesity;	chr5:79796547	chr5:79774348~79816190:-
COAD	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-3.77	2e-04	0.0385	-0.29	-0.23	Pain;	chr19:21475141	chr19:21554640~21569237:-
COAD	cis	rs2976388	0.59	rs13254346	ENSG00000247317.3	RP11-273G15.2	3.77	2e-04	0.0385	0.25	0.23	Urinary tract infection frequency;	chr8:142742445	chr8:142981738~143018437:-
COAD	cis	rs2976388	0.59	rs3758082	ENSG00000247317.3	RP11-273G15.2	3.77	2e-04	0.0385	0.25	0.23	Urinary tract infection frequency;	chr8:142743065	chr8:142981738~143018437:-
COAD	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-3.77	2e-04	0.0385	-0.32	-0.23	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
COAD	cis	rs11098499	0.955	rs1511019	ENSG00000250412.1	KLHL2P1	3.77	2e-04	0.0385	0.31	0.23	Corneal astigmatism;	chr4:119244852	chr4:119334329~119378233:+
COAD	cis	rs231361	0.657	rs463924	ENSG00000269821.1	KCNQ1OT1	3.77	2e-04	0.0385	0.25	0.23	Type 2 diabetes;	chr11:2696450	chr11:2608328~2699994:-
COAD	cis	rs10087240	0.55	rs1426513	ENSG00000207110.1	RNU1-106P	3.77	2e-04	0.0385	0.27	0.23	Lymphocyte counts;White blood cell count;	chr8:128001739	chr8:127999131~127999294:+
COAD	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	3.77	2e-04	0.0385	0.39	0.23	Gout;	chr7:66654674	chr7:66025126~66031544:-
COAD	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	3.77	2e-04	0.0385	0.39	0.23	Gout;	chr7:66661502	chr7:66025126~66031544:-
COAD	cis	rs7246657	0.551	rs10404069	ENSG00000226686.6	LINC01535	-3.77	2e-04	0.0385	-0.39	-0.23	Coronary artery calcification;	chr19:37147502	chr19:37251912~37265535:+
COAD	cis	rs12506228	0.598	rs6845403	ENSG00000279943.1	FLJ38576	-3.77	2e-04	0.0385	-0.32	-0.23	Job-related exhaustion in shift workers;	chr4:186427383	chr4:186189032~186191490:-
COAD	cis	rs9400467	0.528	rs455726	ENSG00000230177.1	RP5-1112D6.4	-3.77	2e-04	0.0385	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111277932~111278742:+
COAD	cis	rs9868809	0.772	rs12107418	ENSG00000225399.4	RP11-3B7.1	-3.77	2e-04	0.0385	-0.33	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652354	chr3:49260085~49261316:+
COAD	cis	rs7674212	0.51	rs55715738	ENSG00000230069.3	LRRC37A15P	-3.77	2e-04	0.0385	-0.24	-0.23	Type 2 diabetes;	chr4:103209032	chr4:102727274~102730721:-
COAD	cis	rs1510510	0.69	rs12987751	ENSG00000225057.2	AC096574.4	3.77	2e-04	0.0385	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643588	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs6749837	ENSG00000225057.2	AC096574.4	3.77	2e-04	0.0385	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643591	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs6746826	ENSG00000225057.2	AC096574.4	3.77	2e-04	0.0385	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643776	chr2:238231684~238255633:+
COAD	cis	rs6452524	0.935	rs1017794	ENSG00000271862.1	RP11-343L5.2	3.77	2e-04	0.0386	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83049376~83050964:-
COAD	cis	rs7204230	0.961	rs59160806	ENSG00000261056.2	RP11-454F8.2	3.77	2e-04	0.0386	0.27	0.23	Fibrinogen;	chr16:53241238	chr16:53298224~53299792:+
COAD	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	3.77	2e-04	0.0386	0.3	0.23	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
COAD	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-3.77	2e-04	0.0386	-0.29	-0.23	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
COAD	cis	rs11157436	0.602	rs2331594	ENSG00000211812.1	TRAV26-2	-3.77	0.000201	0.0386	-0.22	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22202583~22203368:+
COAD	cis	rs11157436	0.602	rs12588757	ENSG00000211812.1	TRAV26-2	-3.77	0.000201	0.0386	-0.22	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22202583~22203368:+
COAD	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	3.77	0.000201	0.0386	0.16	0.23	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
COAD	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	3.77	0.000201	0.0386	0.16	0.23	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
COAD	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-3.77	0.000201	0.0386	-0.27	-0.23	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
COAD	cis	rs9868809	0.505	rs9811027	ENSG00000225399.4	RP11-3B7.1	-3.77	0.000201	0.0386	-0.37	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48687581	chr3:49260085~49261316:+
COAD	cis	rs12497850	0.863	rs4858799	ENSG00000225399.4	RP11-3B7.1	-3.77	0.000201	0.0386	-0.37	-0.23	Parkinson's disease;	chr3:48690771	chr3:49260085~49261316:+
COAD	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	3.77	0.000201	0.0386	0.32	0.23	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
COAD	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-3.77	0.000201	0.0386	-0.28	-0.23	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
COAD	cis	rs2439831	1	rs9920763	ENSG00000275601.1	AC011330.13	-3.77	0.000201	0.0386	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43468310	chr15:43642389~43643023:-
COAD	cis	rs7204230	1	rs8051675	ENSG00000261056.2	RP11-454F8.2	3.77	0.000201	0.0386	0.28	0.23	Fibrinogen;	chr16:53338677	chr16:53298224~53299792:+
COAD	cis	rs7955901	0.725	rs1512988	ENSG00000258053.1	CTD-2021H9.3	3.77	0.000201	0.0386	0.29	0.23	Type 2 diabetes;	chr12:71061219	chr12:71047402~71118247:-
COAD	cis	rs2908835	0.705	rs2908834	ENSG00000247157.5	LINC01252	-3.77	0.000201	0.0386	-0.37	-0.23	Information processing speed;	chr12:11497681	chr12:11548030~11590369:+
COAD	cis	rs4780973	0.748	rs57510471	ENSG00000260979.1	RP11-77H9.8	-3.77	0.000201	0.0386	-0.3	-0.23	Survival in pancreatic cancer;	chr16:9298740	chr16:8962706~8966990:+
COAD	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	3.77	0.000201	0.0386	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
COAD	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	3.77	0.000201	0.0386	0.39	0.23	Gout;	chr7:66715944	chr7:66025126~66031544:-
COAD	cis	rs1023500	1	rs3752591	ENSG00000205702.9	CYP2D7	-3.77	0.000201	0.0386	-0.19	-0.23	Schizophrenia;	chr22:41943512	chr22:42140203~42144577:-
COAD	cis	rs7577696	0.85	rs2566483	ENSG00000272716.1	RP11-563N4.1	3.77	0.000201	0.0386	0.24	0.23	Inflammatory biomarkers;	chr2:32259398	chr2:32165046~32165757:-
COAD	cis	rs6452524	0.868	rs10071617	ENSG00000271862.1	RP11-343L5.2	3.77	0.000201	0.0386	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs10076059	ENSG00000271862.1	RP11-343L5.2	3.77	0.000201	0.0386	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs11951257	ENSG00000271862.1	RP11-343L5.2	3.77	0.000201	0.0386	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs767771	ENSG00000271862.1	RP11-343L5.2	3.77	0.000201	0.0386	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83049376~83050964:-
COAD	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-3.77	0.000201	0.0386	-0.24	-0.23	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
COAD	cis	rs2346160	0.836	rs206991	ENSG00000228648.1	RP11-568A7.2	3.77	0.000201	0.0386	0.26	0.23	Parental extreme longevity (95 years and older);	chr6:167285890	chr6:167241891~167245916:+
COAD	cis	rs6452524	0.935	rs10045744	ENSG00000271862.1	RP11-343L5.2	3.77	0.000201	0.0387	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83049376~83050964:-
COAD	cis	rs875971	0.545	rs2420612	ENSG00000232546.1	RP11-458F8.1	3.77	0.000201	0.0387	0.23	0.23	Aortic root size;	chr7:66536825	chr7:66848496~66858136:+
COAD	cis	rs2018293	1	rs6005011	ENSG00000233521.4	RP5-1172A22.1	-3.77	0.000201	0.0387	-0.21	-0.23	Vascular brain injury;	chr22:26314806	chr22:27221349~27224727:-
COAD	cis	rs8002861	0.664	rs9533686	ENSG00000274001.1	RP11-5G9.5	3.77	0.000201	0.0387	0.21	0.23	Leprosy;	chr13:43894358	chr13:43877715~43878163:-
COAD	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	3.77	0.000201	0.0387	0.28	0.23	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
COAD	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	3.77	0.000201	0.0387	0.28	0.23	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
COAD	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-3.77	0.000201	0.0387	-0.26	-0.23	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
COAD	cis	rs3126085	0.56	rs2282303	ENSG00000237975.5	FLG-AS1	3.77	0.000201	0.0387	0.26	0.23	Atopic dermatitis;	chr1:152356959	chr1:152168125~152445456:+
COAD	cis	rs9990333	0.544	rs112577972	ENSG00000207650.1	MIR570	3.77	0.000201	0.0387	0.29	0.23	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195699401~195699497:+
COAD	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	3.77	0.000201	0.0387	0.26	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
COAD	cis	rs801193	0.66	rs10950049	ENSG00000179406.6	LINC00174	3.77	0.000201	0.0387	0.17	0.23	Aortic root size;	chr7:66765873	chr7:66376044~66401338:-
COAD	cis	rs224278	0.509	rs1509952	ENSG00000228566.1	RP11-170M17.1	-3.77	0.000201	0.0387	-0.32	-0.23	Ewing sarcoma;	chr10:62979908	chr10:63664664~63990568:+
COAD	cis	rs10863681	0.738	rs7513781	ENSG00000232679.1	RP11-400N13.3	3.77	0.000201	0.0387	0.25	0.23	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222066590	chr1:222041705~222064763:-
COAD	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	3.77	0.000201	0.0387	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
COAD	cis	rs2836754	1	rs11701004	ENSG00000205622.8	AF064858.6	3.77	0.000201	0.0387	0.26	0.23	Body mass index;Crohn's disease;	chr21:38920178	chr21:38863676~38956467:-
COAD	cis	rs10916814	0.589	rs4655220	ENSG00000117242.7	PINK1-AS	-3.77	0.000201	0.0387	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:20562986	chr1:20642657~20652193:-
COAD	cis	rs7582403	0.528	rs7569780	ENSG00000281469.1	RP11-567F11.1	3.77	0.000201	0.0387	0.26	0.23	Neuroticism;	chr2:148053129	chr2:148044380~148044894:+
COAD	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-3.77	0.000201	0.0387	-0.25	-0.23	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
COAD	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	3.77	0.000202	0.0387	0.24	0.23	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
COAD	cis	rs1499614	1	rs1638731	ENSG00000232559.3	GS1-124K5.12	3.77	0.000202	0.0387	0.4	0.23	Gout;	chr7:66679692	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs1882655	ENSG00000232559.3	GS1-124K5.12	-3.77	0.000202	0.0387	-0.4	-0.23	Gout;	chr7:66682070	chr7:66554588~66576923:-
COAD	cis	rs1499614	0.831	rs3800822	ENSG00000232559.3	GS1-124K5.12	-3.77	0.000202	0.0387	-0.4	-0.23	Gout;	chr7:66682162	chr7:66554588~66576923:-
COAD	cis	rs643506	0.845	rs7114594	ENSG00000230911.1	PPIHP1	-3.77	0.000202	0.0387	-0.29	-0.23	Breast cancer;	chr11:111897389	chr11:112029858~112030367:-
COAD	cis	rs728616	0.614	rs35395602	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000202	0.0388	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:79663088~79826594:-
COAD	cis	rs728616	0.681	rs36023925	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000202	0.0388	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:79663088~79826594:-
COAD	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	3.77	0.000202	0.0388	0.26	0.23	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
COAD	cis	rs2243480	1	rs1267820	ENSG00000232559.3	GS1-124K5.12	3.77	0.000202	0.0388	0.41	0.23	Diabetic kidney disease;	chr7:66585308	chr7:66554588~66576923:-
COAD	cis	rs561341	1	rs72821952	ENSG00000265798.5	RP11-271K11.5	3.77	0.000202	0.0388	0.38	0.23	Hip circumference adjusted for BMI;	chr17:31921114	chr17:31038575~31059121:-
COAD	cis	rs8046148	0.724	rs12930079	ENSG00000260381.2	RP11-429P3.5	-3.77	0.000202	0.0388	-0.29	-0.23	Testicular germ cell tumor;	chr16:50092780	chr16:50100339~50121943:-
COAD	cis	rs8046148	0.724	rs11642695	ENSG00000260381.2	RP11-429P3.5	-3.77	0.000202	0.0388	-0.29	-0.23	Testicular germ cell tumor;	chr16:50093209	chr16:50100339~50121943:-
COAD	cis	rs12699921	0.632	rs2691595	ENSG00000279048.1	RP11-511H23.2	-3.77	0.000202	0.0388	-0.17	-0.23	Fibrinogen levels;	chr7:17780421	chr7:17940503~17942922:+
COAD	cis	rs16889471	0.959	rs10101645	ENSG00000253327.2	RAD21-AS1	3.77	0.000202	0.0388	0.29	0.23	Breast cancer;	chr8:117204156	chr8:116874424~116876868:+
COAD	cis	rs9880211	0.613	rs34864445	ENSG00000273486.1	RP11-731C17.2	3.77	0.000202	0.0388	0.27	0.23	Height;Body mass index;	chr3:136104082	chr3:136837338~136839021:-
COAD	cis	rs2554380	0.628	rs2081541	ENSG00000176700.18	SCAND2P	-3.77	0.000202	0.0388	-0.21	-0.23	Height;	chr15:83774934	chr15:84631451~84647478:+
COAD	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	3.77	0.000202	0.0388	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
COAD	cis	rs78487399	0.71	rs79165612	ENSG00000234936.1	AC010883.5	3.77	0.000202	0.0388	0.38	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43397113	chr2:43229573~43233394:+
COAD	cis	rs1029738	0.535	rs10262258	ENSG00000230658.1	KLHL7-AS1	-3.77	0.000202	0.0388	-0.26	-0.23	Fibrinogen levels;	chr7:22802700	chr7:23101228~23105703:-
COAD	cis	rs7656342	0.535	rs13116446	ENSG00000186234.7	FAM86MP	-3.77	0.000202	0.0388	-0.28	-0.23	Gut microbiota (bacterial taxa);	chr4:9858273	chr4:9692495~9702954:+
COAD	cis	rs728616	0.702	rs78734698	ENSG00000234382.2	RP11-40F6.1	-3.77	0.000202	0.0388	-0.44	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:80233664~80245367:+
COAD	cis	rs2243480	1	rs73142122	ENSG00000275400.1	RP4-756H11.5	3.77	0.000202	0.0388	0.4	0.23	Diabetic kidney disease;	chr7:65846311	chr7:66553805~66554199:-
COAD	cis	rs2496589	0.963	rs7740441	ENSG00000218896.1	TUBB8P2	3.77	0.000202	0.0388	0.26	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143435375	chr6:143436216~143436710:+
COAD	cis	rs79349575	0.679	rs9894239	ENSG00000248278.1	SUMO2P17	-3.77	0.000202	0.0388	-0.25	-0.23	Type 2 diabetes;	chr17:48920597	chr17:48874860~48908983:-
COAD	cis	rs240993	0.761	rs9400480	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000202	0.0388	0.23	0.23	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111297126~111298510:+
COAD	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	3.77	0.000202	0.0388	0.37	0.23	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
COAD	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	3.77	0.000202	0.0388	0.29	0.23	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
COAD	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-3.77	0.000202	0.0388	-0.4	-0.23	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
COAD	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-3.77	0.000202	0.0389	-0.31	-0.23	Pain;	chr19:21493313	chr19:21554640~21569237:-
COAD	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	3.77	0.000202	0.0389	0.31	0.23	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
COAD	cis	rs742132	0.858	rs2281070	ENSG00000220875.1	HIST1H3PS1	3.77	0.000202	0.0389	0.3	0.23	Uric acid levels;	chr6:25621888	chr6:26321876~26322292:-
COAD	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-3.77	0.000202	0.0389	-0.3	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
COAD	cis	rs11098499	0.866	rs3756156	ENSG00000250412.1	KLHL2P1	3.77	0.000203	0.0389	0.31	0.23	Corneal astigmatism;	chr4:119603686	chr4:119334329~119378233:+
COAD	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	3.77	0.000203	0.0389	0.26	0.23	Height;	chr4:55407965	chr4:55363971~55395847:-
COAD	cis	rs7204230	1	rs1109646	ENSG00000261056.2	RP11-454F8.2	3.77	0.000203	0.0389	0.28	0.23	Fibrinogen;	chr16:53316927	chr16:53298224~53299792:+
COAD	cis	rs5753037	0.585	rs249396	ENSG00000279159.1	RP3-394A18.1	-3.77	0.000203	0.0389	-0.15	-0.23	Type 1 diabetes;	chr22:29817983	chr22:29978950~30028236:-
COAD	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-3.77	0.000203	0.0389	-0.29	-0.23	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
COAD	cis	rs4763879	0.739	rs12582584	ENSG00000278635.1	CTD-2318O12.1	3.77	0.000203	0.0389	0.22	0.23	Type 1 diabetes;	chr12:9671542	chr12:9415641~9416718:+
COAD	cis	rs2638953	0.924	rs17801436	ENSG00000247934.4	RP11-967K21.1	-3.77	0.000203	0.0389	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165421	chr12:28163298~28190738:-
COAD	cis	rs6479901	0.639	rs10995448	ENSG00000232075.1	MRPL35P2	-3.77	0.000203	0.0389	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.639	rs7082200	ENSG00000232075.1	MRPL35P2	-3.77	0.000203	0.0389	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-3.77	0.000203	0.0389	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
COAD	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-3.77	0.000203	0.0389	-0.31	-0.23	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
COAD	cis	rs3126085	0.935	rs2338430	ENSG00000237975.5	FLG-AS1	3.77	0.000203	0.0389	0.25	0.23	Atopic dermatitis;	chr1:152241944	chr1:152168125~152445456:+
COAD	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-3.77	0.000203	0.0389	-0.27	-0.23	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
COAD	cis	rs8061903	0.535	rs35705628	ENSG00000261617.1	RP11-243A14.1	3.77	0.000203	0.0389	0.29	0.23	HIV-1 viral setpoint;	chr16:9309292	chr16:9355588~9408093:+
COAD	cis	rs8061903	0.535	rs3909919	ENSG00000261617.1	RP11-243A14.1	3.77	0.000203	0.0389	0.29	0.23	HIV-1 viral setpoint;	chr16:9309725	chr16:9355588~9408093:+
COAD	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	3.77	0.000203	0.0389	0.31	0.23	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
COAD	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	3.77	0.000203	0.0389	0.3	0.23	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
COAD	cis	rs73191547	0.756	rs10085917	ENSG00000254936.4	AF131215.3	3.77	0.000203	0.0389	0.24	0.23	Schizophrenia;	chr8:10181153	chr8:11123381~11126064:-
COAD	cis	rs7069733	1	rs7069733	ENSG00000273108.1	RP11-416N2.4	3.77	0.000203	0.0389	0.28	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr10:103538013	chr10:103608619~103610050:+
COAD	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-3.77	0.000203	0.0389	-0.22	-0.23	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
COAD	cis	rs6940638	0.606	rs6456771	ENSG00000224843.5	LINC00240	3.77	0.000203	0.0389	0.31	0.23	Intelligence (multi-trait analysis);	chr6:27264616	chr6:26956992~27023924:+
COAD	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-3.77	0.000203	0.0389	-0.3	-0.23	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
COAD	cis	rs735539	0.645	rs6490600	ENSG00000222726.1	RNU2-7P	-3.77	0.000203	0.039	-0.3	-0.23	Dental caries;	chr13:20634050	chr13:20612161~20612338:+
COAD	cis	rs1009647	1	rs35502084	ENSG00000258413.1	RP11-665C16.6	-3.77	0.000203	0.039	-0.32	-0.23	Testicular germ cell tumor;	chr14:55409545	chr14:55262767~55272075:-
COAD	cis	rs2439831	0.85	rs28858500	ENSG00000166763.7	STRCP1	-3.77	0.000203	0.039	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43864744	chr15:43699488~43718184:-
COAD	cis	rs6787172	0.651	rs9870802	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158430380	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.653	rs7610691	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158433054	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.621	rs9823076	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158435771	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.651	rs9843089	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158436003	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.623	rs9847460	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158436417	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.651	rs4680436	ENSG00000272087.1	RP11-379F4.7	3.77	0.000203	0.039	0.27	0.23	Subjective well-being;	chr3:158441528	chr3:158693120~158693768:-
COAD	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-3.77	0.000203	0.039	-0.28	-0.23	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
COAD	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	3.77	0.000203	0.039	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
COAD	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	3.77	0.000203	0.039	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
COAD	cis	rs16957304	1	rs16957304	ENSG00000270049.1	RP11-297D21.4	3.77	0.000203	0.039	0.42	0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr16:67301066	chr16:67481314~67487250:+
COAD	cis	rs911555	0.673	rs7144271	ENSG00000251533.2	LINC00605	-3.77	0.000203	0.039	-0.3	-0.23	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103187221~103189028:-
COAD	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-3.77	0.000203	0.039	-0.22	-0.23	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
COAD	cis	rs9584850	0.718	rs6491427	ENSG00000231194.1	FARP1-AS1	3.77	0.000203	0.039	0.3	0.23	Neuroticism;	chr13:98460912	chr13:98435405~98435840:-
COAD	cis	rs12699921	0.632	rs2691613	ENSG00000279048.1	RP11-511H23.2	-3.77	0.000203	0.039	-0.16	-0.23	Fibrinogen levels;	chr7:17844358	chr7:17940503~17942922:+
COAD	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	3.77	0.000203	0.039	0.27	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
COAD	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-3.77	0.000203	0.039	-0.26	-0.23	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
COAD	cis	rs10760158	0.739	rs4837819	ENSG00000226752.6	PSMD5-AS1	-3.77	0.000203	0.039	-0.25	-0.23	Pulse pressure;	chr9:121246156	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.739	rs10760163	ENSG00000226752.6	PSMD5-AS1	-3.77	0.000203	0.039	-0.25	-0.23	Pulse pressure;	chr9:121246174	chr9:120824828~120854385:+
COAD	cis	rs911555	0.755	rs2765046	ENSG00000251533.2	LINC00605	3.77	0.000203	0.039	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103514631	chr14:103187221~103189028:-
COAD	cis	rs9847710	0.967	rs2564931	ENSG00000280417.1	RP11-5O17.1	-3.77	0.000203	0.039	-0.25	-0.23	Ulcerative colitis;	chr3:52986543	chr3:53046166~53048122:+
COAD	cis	rs1485395	0.891	rs11170624	ENSG00000250133.2	HOXC-AS2	3.77	0.000203	0.039	0.26	0.23	Migraine without aura;	chr12:53636454	chr12:53993810~53996785:-
COAD	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	3.77	0.000203	0.039	0.28	0.23	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
COAD	cis	rs2929278	0.617	rs693919	ENSG00000275601.1	AC011330.13	3.77	0.000203	0.039	0.28	0.23	Schizophrenia;	chr15:43810130	chr15:43642389~43643023:-
COAD	cis	rs7829975	0.577	rs940030	ENSG00000173295.6	FAM86B3P	-3.77	0.000204	0.039	-0.28	-0.23	Mood instability;	chr8:8689418	chr8:8228595~8244865:+
COAD	cis	rs1552244	1	rs12374115	ENSG00000186162.9	CIDECP	-3.77	0.000204	0.039	-0.32	-0.23	Alzheimer's disease;	chr3:10093082	chr3:10014238~10026365:-
COAD	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	3.77	0.000204	0.039	0.3	0.23	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
COAD	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	3.77	0.000204	0.039	0.23	0.23	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
COAD	cis	rs2554380	0.55	rs62025825	ENSG00000176700.18	SCAND2P	3.77	0.000204	0.039	0.22	0.23	Height;	chr15:83872285	chr15:84631451~84647478:+
COAD	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-3.77	0.000204	0.039	-0.31	-0.23	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
COAD	cis	rs11089937	0.926	rs5750601	ENSG00000211638.2	IGLV8-61	-3.77	0.000204	0.039	-0.21	-0.23	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22098700~22099212:+
COAD	cis	rs875971	0.964	rs60193905	ENSG00000223473.2	GS1-124K5.3	3.77	0.000204	0.039	0.19	0.23	Aortic root size;	chr7:66506273	chr7:66491049~66493566:-
COAD	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-3.77	0.000204	0.0391	-0.3	-0.23	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
COAD	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	3.77	0.000204	0.0391	0.28	0.23	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
COAD	cis	rs2412819	0.599	rs2470120	ENSG00000275601.1	AC011330.13	-3.77	0.000204	0.0391	-0.28	-0.23	Lung cancer;	chr15:43636872	chr15:43642389~43643023:-
COAD	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-3.77	0.000204	0.0391	-0.27	-0.23	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
COAD	cis	rs17666538	0.539	rs1703925	ENSG00000254207.1	RP11-43A14.1	3.77	0.000204	0.0391	0.4	0.23	IgG glycosylation;	chr8:658279	chr8:725188~725877:-
COAD	cis	rs2554380	0.6	rs6602986	ENSG00000176700.18	SCAND2P	-3.77	0.000204	0.0391	-0.21	-0.23	Height;	chr15:83778347	chr15:84631451~84647478:+
COAD	cis	rs7688540	0.8	rs1578898	ENSG00000198155.5	ZNF876P	-3.77	0.000204	0.0391	-0.34	-0.23	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:212610~255985:+
COAD	cis	rs1115240	0.574	rs61986513	ENSG00000257842.4	NOVA1-AS1	3.77	0.000204	0.0391	0.31	0.23	Educational attainment (years of education);	chr14:26512322	chr14:26598412~26806467:+
COAD	cis	rs5753037	0.869	rs41159	ENSG00000279159.1	RP3-394A18.1	-3.77	0.000204	0.0391	-0.16	-0.23	Type 1 diabetes;	chr22:30011375	chr22:29978950~30028236:-
COAD	cis	rs34779708	0.931	rs4934719	ENSG00000271335.4	RP11-324I22.4	3.77	0.000204	0.0391	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934720	ENSG00000271335.4	RP11-324I22.4	3.77	0.000204	0.0391	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35314552~35336401:-
COAD	cis	rs12137025	1	rs1419310	ENSG00000278467.1	RP11-504P24.9	3.77	0.000204	0.0391	0.32	0.23	Carotenoid levels (alpha-carotene);	chr1:223671486	chr1:223994262~223995196:+
COAD	cis	rs9813712	0.571	rs6795143	ENSG00000253540.4	FAM86HP	-3.77	0.000204	0.0391	-0.23	-0.23	Response to amphetamines;	chr3:130224355	chr3:130099092~130111472:-
COAD	cis	rs9813712	0.571	rs9289366	ENSG00000253540.4	FAM86HP	-3.77	0.000204	0.0391	-0.23	-0.23	Response to amphetamines;	chr3:130225267	chr3:130099092~130111472:-
COAD	cis	rs9813712	0.571	rs9289367	ENSG00000253540.4	FAM86HP	-3.77	0.000204	0.0391	-0.23	-0.23	Response to amphetamines;	chr3:130225286	chr3:130099092~130111472:-
COAD	cis	rs9813712	0.571	rs9289368	ENSG00000253540.4	FAM86HP	-3.77	0.000204	0.0391	-0.23	-0.23	Response to amphetamines;	chr3:130225562	chr3:130099092~130111472:-
COAD	cis	rs9813712	0.571	rs6774141	ENSG00000253540.4	FAM86HP	-3.77	0.000204	0.0391	-0.23	-0.23	Response to amphetamines;	chr3:130225599	chr3:130099092~130111472:-
COAD	cis	rs11098499	0.78	rs10013652	ENSG00000250412.1	KLHL2P1	3.77	0.000204	0.0391	0.3	0.23	Corneal astigmatism;	chr4:119371101	chr4:119334329~119378233:+
COAD	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	3.77	0.000204	0.0391	0.21	0.23	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
COAD	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	3.77	0.000204	0.0391	0.25	0.23	Height;	chr4:55387515	chr4:55363971~55395847:-
COAD	cis	rs9880211	0.613	rs34864445	ENSG00000239213.4	NCK1-AS1	3.77	0.000204	0.0391	0.3	0.23	Height;Body mass index;	chr3:136104082	chr3:136841726~136862054:-
COAD	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	3.77	0.000204	0.0391	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
COAD	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	3.77	0.000204	0.0391	0.16	0.23	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
COAD	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	3.77	0.000204	0.0391	0.16	0.23	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
COAD	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-3.77	0.000204	0.0391	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
COAD	cis	rs7911712	0.873	rs11239248	ENSG00000165511.6	C10orf25	3.77	0.000204	0.0391	0.39	0.23	Emphysema-related traits;	chr10:44816996	chr10:44997698~45000888:-
COAD	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	3.77	0.000204	0.0391	0.31	0.23	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
COAD	cis	rs75870422	0.609	rs2783223	ENSG00000280169.1	RP11-151A6.6	3.77	0.000204	0.0391	0.41	0.23	Facial morphology (factor 5, width of mouth relative to central midface);	chr13:100445250	chr13:100537365~100539567:+
COAD	cis	rs1598856	0.715	rs1598861	ENSG00000246560.2	RP11-10L12.4	3.77	0.000204	0.0391	0.29	0.23	Primary biliary cholangitis;	chr4:102565540	chr4:102828055~102844075:+
COAD	cis	rs758747	0.514	rs735830	ENSG00000270168.1	LA16c-380H5.4	-3.77	0.000205	0.0392	-0.36	-0.23	Body mass index;	chr16:3645353	chr16:3001300~3002016:+
COAD	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-3.77	0.000205	0.0392	-0.27	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
COAD	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	3.77	0.000205	0.0392	0.24	0.23	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
COAD	cis	rs7584330	0.554	rs116656801	ENSG00000234949.2	AC104667.3	-3.77	0.000205	0.0392	-0.35	-0.23	Prostate cancer;	chr2:237522614	chr2:237591020~237595981:+
COAD	cis	rs6095360	1	rs6019535	ENSG00000227431.4	CSE1L-AS1	-3.77	0.000205	0.0392	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:48924980	chr20:49040463~49046044:-
COAD	cis	rs72827839	0.696	rs117974417	ENSG00000263412.1	RP5-890E16.2	3.77	0.000205	0.0392	0.39	0.23	Ease of getting up in the morning;	chr17:48079148	chr17:48045141~48048073:-
COAD	cis	rs4142995	0.962	rs1917368	ENSG00000279048.1	RP11-511H23.2	-3.77	0.000205	0.0392	-0.16	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17872129	chr7:17940503~17942922:+
COAD	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-3.77	0.000205	0.0392	-0.2	-0.23	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
COAD	cis	rs2243480	1	rs1796228	ENSG00000232559.3	GS1-124K5.12	3.77	0.000205	0.0392	0.41	0.23	Diabetic kidney disease;	chr7:66568097	chr7:66554588~66576923:-
COAD	cis	rs73191547	0.519	rs7812517	ENSG00000254936.4	AF131215.3	-3.77	0.000205	0.0392	-0.24	-0.23	Schizophrenia;	chr8:10203793	chr8:11123381~11126064:-
COAD	cis	rs6480314	0.522	rs10733841	ENSG00000233590.1	RP11-153K11.3	3.77	0.000205	0.0392	0.28	0.23	Optic nerve measurement (disc area);	chr10:68293520	chr10:68233251~68242379:-
COAD	cis	rs4879656	0.966	rs7869475	ENSG00000225693.1	LAGE3P1	-3.77	0.000205	0.0392	-0.28	-0.23	Menopause (age at onset);	chr9:32986250	chr9:33019682~33020165:-
COAD	cis	rs9813712	0.571	rs9855426	ENSG00000253540.4	FAM86HP	3.77	0.000205	0.0392	0.24	0.23	Response to amphetamines;	chr3:130214475	chr3:130099092~130111472:-
COAD	cis	rs362296	0.698	rs3095072	ENSG00000248840.2	RP11-357G3.2	3.77	0.000205	0.0392	0.28	0.23	Parental longevity (mother's age at death);	chr4:3261598	chr4:3312512~3313058:+
COAD	cis	rs7873907	0.711	rs1475535	ENSG00000237372.2	UNQ6494	-3.77	0.000205	0.0392	-0.3	-0.23	Fibrinogen levels;	chr9:89597695	chr9:89639814~89719759:+
COAD	cis	rs7873907	0.711	rs1475536	ENSG00000237372.2	UNQ6494	-3.77	0.000205	0.0392	-0.3	-0.23	Fibrinogen levels;	chr9:89597759	chr9:89639814~89719759:+
COAD	cis	rs1115240	0.627	rs61986520	ENSG00000257842.4	NOVA1-AS1	3.77	0.000205	0.0392	0.3	0.23	Educational attainment (years of education);	chr14:26537794	chr14:26598412~26806467:+
COAD	cis	rs1048886	0.872	rs9455161	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000205	0.0393	-0.32	-0.23	Type 2 diabetes;	chr6:70565476	chr6:70596438~70596980:+
COAD	cis	rs2439831	0.702	rs16977724	ENSG00000201136.1	RNU6-353P	-3.77	0.000205	0.0393	-0.39	-0.23	Lung cancer in ever smokers;	chr15:43859101	chr15:43702363~43702470:+
COAD	cis	rs1707322	0.717	rs1135812	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000205	0.0393	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs6703748	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000205	0.0393	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45694684~45697075:-
COAD	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	3.77	0.000205	0.0393	0.23	0.23	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	3.77	0.000205	0.0393	0.23	0.23	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
COAD	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	3.77	0.000205	0.0393	0.23	0.23	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
COAD	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	3.77	0.000205	0.0393	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
COAD	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	3.77	0.000205	0.0393	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
COAD	cis	rs1552244	0.572	rs67227131	ENSG00000186162.9	CIDECP	3.77	0.000205	0.0393	0.4	0.23	Alzheimer's disease;	chr3:10131060	chr3:10014238~10026365:-
COAD	cis	rs9880211	0.718	rs56398805	ENSG00000273486.1	RP11-731C17.2	3.77	0.000205	0.0393	0.26	0.23	Height;Body mass index;	chr3:136213558	chr3:136837338~136839021:-
COAD	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-3.77	0.000205	0.0393	-0.31	-0.23	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
COAD	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-3.77	0.000206	0.0393	-0.15	-0.23	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
COAD	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.31	0.23	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.31	0.23	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
COAD	cis	rs34929064	0.846	rs59084784	ENSG00000179428.2	AC073072.5	-3.77	0.000206	0.0393	-0.24	-0.23	Major depression and alcohol dependence;	chr7:22699943	chr7:22725395~22727620:-
COAD	cis	rs11098499	0.789	rs9991166	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119316696	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.708	rs10005237	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119316742	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.575	rs907204	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119317499	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.575	rs907205	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119317509	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs878372	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119317625	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs10213267	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119317919	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs10212775	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119318089	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs11732087	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119318676	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs2964	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119318976	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs1511025	ENSG00000250412.1	KLHL2P1	3.77	0.000206	0.0393	0.3	0.23	Corneal astigmatism;	chr4:119319083	chr4:119334329~119378233:+
COAD	cis	rs17248137	0.702	rs6533486	ENSG00000249942.1	AC142293.3	3.77	0.000206	0.0393	0.43	0.23	Overall survival in osteosarcoma;	chr4:74934362	chr4:74552584~74589481:-
COAD	cis	rs11739656	0.764	rs6873941	ENSG00000251144.1	CTD-2532K18.2	-3.77	0.000206	0.0394	-0.35	-0.23	Night sleep phenotypes;	chr5:174772208	chr5:174820027~174826324:+
COAD	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-3.77	0.000206	0.0394	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
COAD	cis	rs919433	0.927	rs13032495	ENSG00000222017.1	AC011997.1	-3.77	0.000206	0.0394	-0.28	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197693106~197774823:+
COAD	cis	rs5751168	0.765	rs965764	ENSG00000211660.3	IGLV2-23	-3.77	0.000206	0.0394	-0.16	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22494209	chr22:22697789~22698407:+
COAD	cis	rs12681366	0.801	rs2919668	ENSG00000253704.1	RP11-267M23.4	3.77	0.000206	0.0394	0.3	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94553722~94569745:+
COAD	cis	rs7172971	0.688	rs4923924	ENSG00000261002.4	RP11-546B15.1	-3.77	0.000206	0.0394	-0.31	-0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr15:42073470	chr15:42208413~42226990:+
COAD	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	3.77	0.000206	0.0394	0.25	0.23	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
COAD	cis	rs595244	1	rs56286136	ENSG00000259705.1	RP11-227D13.1	3.77	0.000206	0.0394	0.34	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48463617	chr15:48645951~48652016:+
COAD	cis	rs595244	1	rs55999498	ENSG00000259705.1	RP11-227D13.1	3.77	0.000206	0.0394	0.34	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48466330	chr15:48645951~48652016:+
COAD	cis	rs4604234	0.803	rs73465590	ENSG00000272129.1	RP11-250B2.6	-3.77	0.000206	0.0394	-0.68	-0.23	Cancer;	chr6:80337459	chr6:80355424~80356859:+
COAD	cis	rs4604234	0.708	rs6906392	ENSG00000272129.1	RP11-250B2.6	-3.77	0.000206	0.0394	-0.68	-0.23	Cancer;	chr6:80337730	chr6:80355424~80356859:+
COAD	cis	rs4604234	0.708	rs3805862	ENSG00000272129.1	RP11-250B2.6	-3.77	0.000206	0.0394	-0.68	-0.23	Cancer;	chr6:80338534	chr6:80355424~80356859:+
COAD	cis	rs4819052	0.851	rs2838866	ENSG00000227039.5	ITGB2-AS1	-3.77	0.000206	0.0394	-0.2	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:44921051~44929678:+
COAD	cis	rs13256369	1	rs10110591	ENSG00000173295.6	FAM86B3P	-3.77	0.000206	0.0394	-0.3	-0.23	Obesity-related traits;	chr8:8719098	chr8:8228595~8244865:+
COAD	cis	rs227275	0.53	rs3960788	ENSG00000230069.3	LRRC37A15P	-3.77	0.000206	0.0394	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102727274~102730721:-
COAD	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-3.77	0.000206	0.0394	-0.34	-0.23	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
COAD	cis	rs1707322	0.685	rs56177313	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000206	0.0394	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs11211178	ENSG00000230896.1	RP11-767N6.7	-3.77	0.000206	0.0394	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45694684~45697075:-
COAD	cis	rs7646881	0.5	rs73022762	ENSG00000240207.5	RP11-379F4.4	-3.77	0.000206	0.0394	-0.3	-0.23	Tetralogy of Fallot;	chr3:158572516	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.544	rs9881679	ENSG00000240207.5	RP11-379F4.4	-3.77	0.000206	0.0394	-0.3	-0.23	Tetralogy of Fallot;	chr3:158580643	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.544	rs9849437	ENSG00000240207.5	RP11-379F4.4	-3.77	0.000206	0.0394	-0.3	-0.23	Tetralogy of Fallot;	chr3:158581612	chr3:158732263~158784070:+
COAD	cis	rs3816183	1	rs893729	ENSG00000236533.1	AC009413.2	-3.77	0.000206	0.0394	-0.26	-0.23	Hypospadias;	chr2:42788084	chr2:41850203~41850601:-
COAD	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-3.77	0.000206	0.0394	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
COAD	cis	rs853679	1	rs1679732	ENSG00000272009.1	RP1-313I6.12	-3.77	0.000206	0.0394	-0.37	-0.23	Depression;	chr6:28253486	chr6:28078792~28081130:-
COAD	cis	rs7837688	0.677	rs11986220	ENSG00000253264.1	PCAT2	-3.76	0.000206	0.0395	-0.46	-0.23	Prostate cancer;	chr8:127519444	chr8:127072694~127082221:-
COAD	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-3.76	0.000207	0.0395	-0.26	-0.23	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
COAD	cis	rs4878712	0.632	rs2057645	ENSG00000230188.1	RP11-405L18.4	-3.76	0.000207	0.0395	-0.27	-0.23	HIV-1 susceptibility;	chr9:37663565	chr9:37490421~37490893:-
COAD	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-3.76	0.000207	0.0395	-0.24	-0.23	Height;	chr11:118855233	chr11:118791254~118793137:+
COAD	cis	rs9532669	0.927	rs9532670	ENSG00000277662.1	RP11-74J13.9	3.76	0.000207	0.0395	0.22	0.23	Cervical cancer;	chr13:40927691	chr13:41229180~41229676:-
COAD	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	3.76	0.000207	0.0395	0.3	0.23	Depression;	chr6:28386473	chr6:28943877~28944537:+
COAD	cis	rs2439831	0.702	rs9989313	ENSG00000166763.7	STRCP1	-3.76	0.000207	0.0395	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43699488~43718184:-
COAD	cis	rs7204230	1	rs9673875	ENSG00000261056.2	RP11-454F8.2	3.76	0.000207	0.0395	0.28	0.23	Fibrinogen;	chr16:53186663	chr16:53298224~53299792:+
COAD	cis	rs3018712	0.532	rs2513282	ENSG00000184795.9	UNC93B5	-3.76	0.000207	0.0395	-0.38	-0.23	Total body bone mineral density;	chr11:68650843	chr11:67711702~67716005:-
COAD	cis	rs11157436	0.602	rs1894370	ENSG00000211812.1	TRAV26-2	-3.76	0.000207	0.0395	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22202583~22203368:+
COAD	cis	rs4568518	0.535	rs7781290	ENSG00000279048.1	RP11-511H23.2	3.76	0.000207	0.0395	0.19	0.23	Measles;	chr7:18022987	chr7:17940503~17942922:+
COAD	cis	rs4568518	0.535	rs4555994	ENSG00000279048.1	RP11-511H23.2	3.76	0.000207	0.0395	0.19	0.23	Measles;	chr7:18023034	chr7:17940503~17942922:+
COAD	cis	rs7615952	0.8	rs2062773	ENSG00000241288.6	RP11-379B18.5	-3.76	0.000207	0.0395	-0.23	-0.23	Blood pressure (smoking interaction);	chr3:125920805	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.799	rs13315434	ENSG00000241288.6	RP11-379B18.5	-3.76	0.000207	0.0395	-0.23	-0.23	Blood pressure (smoking interaction);	chr3:125922551	chr3:125827238~125916384:-
COAD	cis	rs1048886	0.872	rs12203298	ENSG00000271967.1	RP11-134K13.4	-3.76	0.000207	0.0395	-0.32	-0.23	Type 2 diabetes;	chr6:70568533	chr6:70596438~70596980:+
COAD	cis	rs440932	0.717	rs330944	ENSG00000254340.1	RP11-10A14.3	3.76	0.000207	0.0395	0.3	0.23	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9141424~9145435:+
COAD	cis	rs4761470	0.943	rs3803069	ENSG00000258365.1	RP11-1105G2.3	-3.76	0.000207	0.0395	-0.31	-0.23	Estradiol plasma levels (breast cancer);	chr12:94290027	chr12:94277758~94282844:-
COAD	cis	rs2554380	0.55	rs6602997	ENSG00000176700.18	SCAND2P	-3.76	0.000207	0.0395	-0.23	-0.23	Height;	chr15:83852646	chr15:84631451~84647478:+
COAD	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-3.76	0.000207	0.0395	-0.41	-0.23	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
COAD	cis	rs9951698	0.577	rs2509751	ENSG00000266969.1	RP11-773H22.4	3.76	0.000207	0.0395	0.27	0.23	Intelligence (multi-trait analysis);	chr18:13085130	chr18:12984694~12991173:-
COAD	cis	rs73222236	0.825	rs9843801	ENSG00000273486.1	RP11-731C17.2	3.76	0.000207	0.0396	0.23	0.23	Coronary artery disease;	chr3:136281904	chr3:136837338~136839021:-
COAD	cis	rs875971	0.862	rs908915	ENSG00000224316.1	RP11-479O9.2	-3.76	0.000207	0.0396	-0.25	-0.23	Aortic root size;	chr7:66149664	chr7:65773620~65802067:+
COAD	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	3.76	0.000207	0.0396	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
COAD	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	3.76	0.000207	0.0396	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
COAD	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	3.76	0.000207	0.0396	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
COAD	cis	rs10023113	0.572	rs10488896	ENSG00000249532.3	RP11-148B6.1	-3.76	0.000207	0.0396	-0.48	-0.23	Non-small cell lung cancer (survival);	chr4:113584140	chr4:112646476~112650051:-
COAD	cis	rs10023113	0.572	rs76966107	ENSG00000249532.3	RP11-148B6.1	-3.76	0.000207	0.0396	-0.48	-0.23	Non-small cell lung cancer (survival);	chr4:113584328	chr4:112646476~112650051:-
COAD	cis	rs10023113	0.572	rs17447200	ENSG00000249532.3	RP11-148B6.1	-3.76	0.000207	0.0396	-0.48	-0.23	Non-small cell lung cancer (survival);	chr4:113585386	chr4:112646476~112650051:-
COAD	cis	rs10023113	0.572	rs75414325	ENSG00000249532.3	RP11-148B6.1	-3.76	0.000207	0.0396	-0.48	-0.23	Non-small cell lung cancer (survival);	chr4:113587066	chr4:112646476~112650051:-
COAD	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-3.76	0.000207	0.0396	-0.28	-0.23	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
COAD	cis	rs6732160	0.588	rs10192654	ENSG00000163016.8	ALMS1P	-3.76	0.000207	0.0396	-0.29	-0.23	Intelligence (multi-trait analysis);	chr2:73143754	chr2:73644919~73685576:+
COAD	cis	rs875971	0.545	rs73136346	ENSG00000232546.1	RP11-458F8.1	-3.76	0.000207	0.0396	-0.23	-0.23	Aortic root size;	chr7:66101095	chr7:66848496~66858136:+
COAD	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	3.76	0.000207	0.0396	0.27	0.23	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
COAD	cis	rs57221529	0.766	rs28563961	ENSG00000250385.1	RP11-310P5.2	3.76	0.000207	0.0396	0.39	0.23	Lung disease severity in cystic fibrosis;	chr5:554383	chr5:524705~526594:+
COAD	cis	rs2307394	0.964	rs13028348	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:147999575	chr2:148044380~148044894:+
COAD	cis	rs2307394	1	rs12997165	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148011304	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13032810	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148012485	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs1975748	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148019290	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs897172	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148020703	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs1015096	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148024789	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13007770	ENSG00000281469.1	RP11-567F11.1	3.76	0.000207	0.0396	0.27	0.23	Urate levels;	chr2:148026755	chr2:148044380~148044894:+
COAD	cis	rs2985684	0.894	rs6572585	ENSG00000258568.1	RHOQP1	3.76	0.000207	0.0396	0.28	0.23	Carotid intima media thickness;	chr14:49554357	chr14:49599994~49600572:+
COAD	cis	rs2904967	0.571	rs1212391	ENSG00000245532.5	NEAT1	-3.76	0.000207	0.0396	-0.26	-0.23	Mean corpuscular volume;	chr11:65249806	chr11:65422774~65445540:+
COAD	cis	rs453301	0.653	rs7005133	ENSG00000254340.1	RP11-10A14.3	3.76	0.000208	0.0396	0.27	0.23	Joint mobility (Beighton score);	chr8:9043712	chr8:9141424~9145435:+
COAD	cis	rs6565180	1	rs11863150	ENSG00000261367.1	RP11-455F5.4	-3.76	0.000208	0.0396	-0.24	-0.23	Tonsillectomy;	chr16:30374182	chr16:30107675~30110541:+
COAD	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-3.76	0.000208	0.0396	-0.21	-0.23	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
COAD	cis	rs860295	0.557	rs11264372	ENSG00000160766.13	GBAP1	-3.76	0.000208	0.0396	-0.29	-0.23	Body mass index;	chr1:155443139	chr1:155213821~155227422:-
COAD	cis	rs8031584	0.918	rs61997138	ENSG00000270015.1	RP11-540B6.6	-3.76	0.000208	0.0396	-0.2	-0.23	Huntington's disease progression;	chr15:30978573	chr15:30926514~30928407:+
COAD	cis	rs10760158	0.832	rs10513365	ENSG00000226752.6	PSMD5-AS1	-3.76	0.000208	0.0396	-0.25	-0.23	Pulse pressure;	chr9:121258647	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.768	rs2149805	ENSG00000226752.6	PSMD5-AS1	-3.76	0.000208	0.0396	-0.25	-0.23	Pulse pressure;	chr9:121259221	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs4837826	ENSG00000226752.6	PSMD5-AS1	-3.76	0.000208	0.0396	-0.25	-0.23	Pulse pressure;	chr9:121261851	chr9:120824828~120854385:+
COAD	cis	rs1023500	0.573	rs2413666	ENSG00000227370.1	RP4-669P10.19	-3.76	0.000208	0.0396	-0.23	-0.23	Schizophrenia;	chr22:42063618	chr22:42132543~42132998:+
COAD	cis	rs10200159	1	rs7594497	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55645403	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs12616982	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55647676	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs13407344	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55648233	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs13382187	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55648611	chr2:55617909~55618373:+
COAD	cis	rs10200159	0.744	rs6725101	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55659736	chr2:55617909~55618373:+
COAD	cis	rs10200159	0.744	rs10496044	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55660614	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs10204169	ENSG00000272606.1	RP11-554J4.1	3.76	0.000208	0.0396	0.34	0.23	Vitiligo;	chr2:55663468	chr2:55617909~55618373:+
COAD	cis	rs7911712	0.873	rs10900114	ENSG00000165511.6	C10orf25	3.76	0.000208	0.0396	0.39	0.23	Emphysema-related traits;	chr10:44811757	chr10:44997698~45000888:-
COAD	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	3.76	0.000208	0.0396	0.28	0.23	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
COAD	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-3.76	0.000208	0.0396	-0.4	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
COAD	cis	rs2243480	1	rs316318	ENSG00000232559.3	GS1-124K5.12	3.76	0.000208	0.0396	0.41	0.23	Diabetic kidney disease;	chr7:66147917	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs316317	ENSG00000232559.3	GS1-124K5.12	3.76	0.000208	0.0396	0.41	0.23	Diabetic kidney disease;	chr7:66148650	chr7:66554588~66576923:-
COAD	cis	rs643506	0.874	rs4245045	ENSG00000230911.1	PPIHP1	-3.76	0.000208	0.0397	-0.28	-0.23	Breast cancer;	chr11:111789200	chr11:112029858~112030367:-
COAD	cis	rs643506	0.874	rs625477	ENSG00000230911.1	PPIHP1	-3.76	0.000208	0.0397	-0.28	-0.23	Breast cancer;	chr11:111790962	chr11:112029858~112030367:-
COAD	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-3.76	0.000208	0.0397	-0.26	-0.23	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
COAD	cis	rs2732480	0.5	rs1387257	ENSG00000269514.1	RP11-370I10.12	3.76	0.000208	0.0397	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48198387~48202031:+
COAD	cis	rs7572733	0.935	rs10931796	ENSG00000222017.1	AC011997.1	3.76	0.000208	0.0397	0.25	0.23	Dermatomyositis;	chr2:197975937	chr2:197693106~197774823:+
COAD	cis	rs2638953	0.924	rs11049467	ENSG00000247934.4	RP11-967K21.1	-3.76	0.000208	0.0397	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28163298~28190738:-
COAD	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-3.76	0.000208	0.0397	-0.33	-0.23	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
COAD	cis	rs71636778	0.509	rs6659176	ENSG00000260063.1	RP5-968P14.2	-3.76	0.000208	0.0397	-0.5	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26913429	chr1:26692132~26694131:-
COAD	cis	rs6661961	0.752	rs7548609	ENSG00000237975.5	FLG-AS1	-3.76	0.000208	0.0397	-0.24	-0.23	Atopic dermatitis;	chr1:152457705	chr1:152168125~152445456:+
COAD	cis	rs6661961	0.752	rs4845438	ENSG00000237975.5	FLG-AS1	-3.76	0.000208	0.0397	-0.24	-0.23	Atopic dermatitis;	chr1:152458037	chr1:152168125~152445456:+
COAD	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-3.76	0.000208	0.0397	-0.28	-0.23	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
COAD	cis	rs561341	1	rs542132	ENSG00000265798.5	RP11-271K11.5	3.76	0.000208	0.0397	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31980174	chr17:31038575~31059121:-
COAD	cis	rs2554380	0.628	rs963690	ENSG00000176700.18	SCAND2P	-3.76	0.000208	0.0397	-0.21	-0.23	Height;	chr15:83771068	chr15:84631451~84647478:+
COAD	cis	rs9910055	0.659	rs7216294	ENSG00000267080.4	ASB16-AS1	-3.76	0.000208	0.0397	-0.2	-0.23	Total body bone mineral density;	chr17:44173727	chr17:44175973~44186717:-
COAD	cis	rs12049351	0.665	rs12044993	ENSG00000213028.3	RP11-108F13.2	-3.76	0.000208	0.0397	-0.35	-0.23	Circulating myeloperoxidase levels (plasma);	chr1:229457578	chr1:229688999~229689904:-
COAD	cis	rs34779708	0.931	rs67976880	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs72789687	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs35997236	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.897	rs34481177	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs11593858	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934723	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs72789690	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs68039650	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs35136660	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.897	rs12764820	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs67261877	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs12768019	ENSG00000271335.4	RP11-324I22.4	3.76	0.000208	0.0397	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35314552~35336401:-
COAD	cis	rs10137082	0.606	rs11158148	ENSG00000279656.1	RP11-298I3.6	-3.76	0.000208	0.0397	-0.3	-0.23	Type 1 diabetes;	chr14:23358291	chr14:23023083~23024217:-
COAD	cis	rs9880211	0.583	rs9870122	ENSG00000239213.4	NCK1-AS1	3.76	0.000208	0.0397	0.29	0.23	Height;Body mass index;	chr3:136101423	chr3:136841726~136862054:-
COAD	cis	rs2018293	1	rs8142056	ENSG00000272798.1	CTA-390C10.9	-3.76	0.000208	0.0397	-0.3	-0.23	Vascular brain injury;	chr22:26313255	chr22:25436312~25436915:+
COAD	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	3.76	0.000208	0.0398	0.3	0.23	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
COAD	cis	rs2252521	0.583	rs161050	ENSG00000272568.4	CTB-113D17.1	3.76	0.000208	0.0398	0.42	0.23	Cognitive performance;	chr7:29059657	chr7:28979967~29013367:+
COAD	cis	rs68170813	0.641	rs61511581	ENSG00000241764.3	AC002467.7	3.76	0.000208	0.0398	0.31	0.23	Coronary artery disease;	chr7:107307646	chr7:107742817~107744581:-
COAD	cis	rs5758511	0.773	rs9623482	ENSG00000182057.4	OGFRP1	-3.76	0.000208	0.0398	-0.27	-0.23	Birth weight;	chr22:41964570	chr22:42269753~42275196:+
COAD	cis	rs17407555	0.683	rs4698000	ENSG00000250413.1	RP11-448G15.1	3.76	0.000208	0.0398	0.31	0.23	Schizophrenia (age at onset);	chr4:10275843	chr4:10006482~10009725:+
COAD	cis	rs4760786	0.833	rs11178541	ENSG00000258053.1	CTD-2021H9.3	-3.76	0.000208	0.0398	-0.32	-0.23	Monobrow;	chr12:71035216	chr12:71047402~71118247:-
COAD	cis	rs1876905	0.539	rs240962	ENSG00000230177.1	RP5-1112D6.4	3.76	0.000208	0.0398	0.24	0.23	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111277932~111278742:+
COAD	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	3.76	0.000208	0.0398	0.3	0.23	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
COAD	cis	rs6828577	0.819	rs298984	ENSG00000225892.3	RP11-384K6.2	-3.76	0.000209	0.0398	-0.22	-0.23	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118682650	chr4:118632274~118634759:+
COAD	cis	rs6828577	0.862	rs167246	ENSG00000225892.3	RP11-384K6.2	-3.76	0.000209	0.0398	-0.22	-0.23	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118684965	chr4:118632274~118634759:+
COAD	cis	rs6754459	0.694	rs4404281	ENSG00000271868.1	RP11-1293J14.1	-3.76	0.000209	0.0398	-0.3	-0.23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr2:3658465	chr2:3496956~3497428:+
COAD	cis	rs1552244	0.882	rs67762674	ENSG00000186162.9	CIDECP	3.76	0.000209	0.0398	0.33	0.23	Alzheimer's disease;	chr3:9972801	chr3:10014238~10026365:-
COAD	cis	rs2842346	0.628	rs2842338	ENSG00000259038.1	CTD-2325P2.4	3.76	0.000209	0.0398	0.34	0.23	Breast cancer;	chr14:68524569	chr14:68627166~68628445:-
COAD	cis	rs12049351	0.665	rs10799531	ENSG00000229367.1	HMGN2P19	-3.76	0.000209	0.0398	-0.32	-0.23	Circulating myeloperoxidase levels (plasma);	chr1:229448670	chr1:229570532~229570796:+
COAD	cis	rs11098499	0.644	rs3986377	ENSG00000249244.1	RP11-548H18.2	3.76	0.000209	0.0398	0.29	0.23	Corneal astigmatism;	chr4:119339115	chr4:119391831~119395335:-
COAD	cis	rs10028773	0.556	rs4473640	ENSG00000249244.1	RP11-548H18.2	3.76	0.000209	0.0398	0.29	0.23	Educational attainment;	chr4:119339282	chr4:119391831~119395335:-
COAD	cis	rs9880211	1	rs12695645	ENSG00000273486.1	RP11-731C17.2	3.76	0.000209	0.0398	0.28	0.23	Height;Body mass index;	chr3:136272039	chr3:136837338~136839021:-
COAD	cis	rs2439831	0.85	rs544122	ENSG00000275601.1	AC011330.13	-3.76	0.000209	0.0398	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43483534	chr15:43642389~43643023:-
COAD	cis	rs6733938	0.591	rs6706104	ENSG00000281195.1	ZNF638-IT1	-3.76	0.000209	0.0398	-0.4	-0.23	Mammographic density;	chr2:70612836	chr2:71373938~71376320:+
COAD	cis	rs9652601	0.779	rs12708716	ENSG00000274038.1	RP11-66H6.4	3.76	0.000209	0.0398	0.28	0.23	Systemic lupus erythematosus;	chr16:11086016	chr16:11056556~11057034:+
COAD	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	3.76	0.000209	0.0398	0.25	0.23	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
COAD	cis	rs3733589	0.59	rs4502681	ENSG00000250413.1	RP11-448G15.1	-3.76	0.000209	0.0398	-0.53	-0.23	Renal overload gout;	chr4:9988548	chr4:10006482~10009725:+
COAD	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	3.76	0.000209	0.0398	0.22	0.23	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
COAD	cis	rs13256369	0.95	rs12548792	ENSG00000254153.1	CTA-398F10.2	3.76	0.000209	0.0398	0.31	0.23	Obesity-related traits;	chr8:8710521	chr8:8456909~8461337:-
COAD	cis	rs718433	0.584	rs10438076	ENSG00000211778.2	TRAV4	-3.76	0.000209	0.0398	-0.19	-0.23	Intraocular pressure;	chr14:21741785	chr14:21736152~21736982:+
COAD	cis	rs28374715	0.528	rs7181982	ENSG00000247556.5	OIP5-AS1	3.76	0.000209	0.0398	0.32	0.23	Ulcerative colitis;	chr15:41330822	chr15:41283990~41309737:+
COAD	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	3.76	0.000209	0.0398	0.28	0.23	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
COAD	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-3.76	0.000209	0.0398	-0.29	-0.23	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
COAD	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-3.76	0.000209	0.0398	-0.29	-0.23	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
COAD	cis	rs10876993	0.855	rs1689601	ENSG00000270039.1	RP11-571M6.17	3.76	0.000209	0.0398	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57655774	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.89	rs1689597	ENSG00000270039.1	RP11-571M6.17	3.76	0.000209	0.0398	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57658103	chr12:57803838~57804415:+
COAD	cis	rs5751168	0.915	rs4822059	ENSG00000211660.3	IGLV2-23	-3.76	0.000209	0.0398	-0.15	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22491354	chr22:22697789~22698407:+
COAD	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-3.76	0.000209	0.0398	-0.31	-0.23	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
COAD	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	3.76	0.000209	0.0398	0.25	0.23	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
COAD	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	3.76	0.000209	0.0399	0.29	0.23	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
COAD	cis	rs1499614	1	rs2141924	ENSG00000232559.3	GS1-124K5.12	3.76	0.000209	0.0399	0.4	0.23	Gout;	chr7:66721259	chr7:66554588~66576923:-
COAD	cis	rs11671005	0.504	rs3794964	ENSG00000213753.9	CENPBD1P1	3.76	0.000209	0.0399	0.31	0.23	Mean platelet volume;	chr19:58559549	chr19:58573503~58599801:+
COAD	cis	rs11671005	0.61	rs4756	ENSG00000213753.9	CENPBD1P1	3.76	0.000209	0.0399	0.31	0.23	Mean platelet volume;	chr19:58563286	chr19:58573503~58599801:+
COAD	cis	rs7615952	0.546	rs2922194	ENSG00000241278.1	ENPP7P4	3.76	0.000209	0.0399	0.29	0.23	Blood pressure (smoking interaction);	chr3:125613419	chr3:125848223~125909372:+
COAD	cis	rs11168351	0.864	rs12228750	ENSG00000257735.1	RP11-370I10.6	-3.76	0.000209	0.0399	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48350945~48442411:+
COAD	cis	rs11168351	0.864	rs10875743	ENSG00000257735.1	RP11-370I10.6	-3.76	0.000209	0.0399	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48350945~48442411:+
COAD	cis	rs2408955	0.521	rs11168437	ENSG00000226413.2	OR8T1P	3.76	0.000209	0.0399	0.28	0.23	Glycated hemoglobin levels;	chr12:48172373	chr12:48442030~48442947:-
COAD	cis	rs34779708	0.931	rs4934700	ENSG00000271335.4	RP11-324I22.4	3.76	0.000209	0.0399	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35314552~35336401:-
COAD	cis	rs6736175	0.741	rs3024847	ENSG00000231858.4	AC067945.4	3.76	0.000209	0.0399	0.26	0.23	Systemic lupus erythematosus;	chr2:191065564	chr2:191021526~191032314:+
COAD	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-3.76	0.000209	0.0399	-0.24	-0.23	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
COAD	cis	rs6787172	0.651	rs6441198	ENSG00000272087.1	RP11-379F4.7	3.76	0.000209	0.0399	0.27	0.23	Subjective well-being;	chr3:158443710	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.651	rs6800887	ENSG00000272087.1	RP11-379F4.7	3.76	0.000209	0.0399	0.27	0.23	Subjective well-being;	chr3:158445839	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.564	rs4289388	ENSG00000272087.1	RP11-379F4.7	3.76	0.000209	0.0399	0.27	0.23	Subjective well-being;	chr3:158446499	chr3:158693120~158693768:-
COAD	cis	rs6787172	0.651	rs4680437	ENSG00000272087.1	RP11-379F4.7	3.76	0.000209	0.0399	0.27	0.23	Subjective well-being;	chr3:158452333	chr3:158693120~158693768:-
COAD	cis	rs6578985	0.754	rs7482894	ENSG00000238184.1	CD81-AS1	-3.76	0.000209	0.0399	-0.28	-0.23	Femoral neck bone geometry and menarche (age at onset);	chr11:2100034	chr11:2328749~2377992:-
COAD	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-3.76	0.00021	0.0399	-0.22	-0.23	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
COAD	cis	rs2395128	0.915	rs7088463	ENSG00000237882.1	PPIAP13	-3.76	0.00021	0.0399	-0.31	-0.23	Ulcerative colitis;Inflammatory bowel disease;	chr10:74781576	chr10:75089248~75089725:-
COAD	cis	rs2976388	0.578	rs34956412	ENSG00000247317.3	RP11-273G15.2	3.76	0.00021	0.0399	0.27	0.23	Urinary tract infection frequency;	chr8:142740610	chr8:142981738~143018437:-
COAD	cis	rs2976388	0.556	rs4736321	ENSG00000247317.3	RP11-273G15.2	3.76	0.00021	0.0399	0.27	0.23	Urinary tract infection frequency;	chr8:142740776	chr8:142981738~143018437:-
COAD	cis	rs2392362	0.77	rs12532486	ENSG00000270889.1	RP11-609L3.1	3.76	0.00021	0.0399	0.22	0.23	Information processing speed;	chr7:35351902	chr7:35971147~35971567:-
COAD	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-3.76	0.00021	0.0399	-0.31	-0.23	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
COAD	cis	rs17248137	0.623	rs72859077	ENSG00000249942.1	AC142293.3	3.76	0.00021	0.04	0.38	0.23	Overall survival in osteosarcoma;	chr4:74920034	chr4:74552584~74589481:-
COAD	cis	rs4237845	0.611	rs7136981	ENSG00000257698.1	RP11-620J15.3	3.76	0.00021	0.04	0.2	0.23	Intelligence (multi-trait analysis);	chr12:57948894	chr12:57931528~57936175:-
COAD	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	3.76	0.00021	0.04	0.31	0.23	Depression;	chr6:28430971	chr6:28943877~28944537:+
COAD	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	3.76	0.00021	0.04	0.31	0.23	Depression;	chr6:28432562	chr6:28943877~28944537:+
COAD	cis	rs7129556	0.911	rs10899394	ENSG00000254691.1	RP11-91P24.5	3.76	0.00021	0.04	0.25	0.23	Weight loss (gastric bypass surgery);	chr11:77613216	chr11:77850604~77851511:+
COAD	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	3.76	0.00021	0.04	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
COAD	cis	rs1799949	0.929	rs799906	ENSG00000279602.1	CTD-3014M21.1	3.76	0.00021	0.04	0.25	0.23	Menopause (age at onset);	chr17:43126099	chr17:43360041~43361361:-
COAD	cis	rs1799949	0.965	rs799908	ENSG00000279602.1	CTD-3014M21.1	3.76	0.00021	0.04	0.25	0.23	Menopause (age at onset);	chr17:43126899	chr17:43360041~43361361:-
COAD	cis	rs1799949	0.93	rs1554063	ENSG00000279602.1	CTD-3014M21.1	3.76	0.00021	0.04	0.25	0.23	Menopause (age at onset);	chr17:43135128	chr17:43360041~43361361:-
COAD	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	3.76	0.00021	0.04	0.39	0.23	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
COAD	cis	rs7577696	0.853	rs212698	ENSG00000272716.1	RP11-563N4.1	3.76	0.00021	0.04	0.24	0.23	Inflammatory biomarkers;	chr2:32217928	chr2:32165046~32165757:-
COAD	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	3.76	0.00021	0.04	0.37	0.23	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	3.76	0.00021	0.04	0.37	0.23	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
COAD	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	3.76	0.00021	0.04	0.37	0.23	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
COAD	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-3.76	0.00021	0.04	-0.3	-0.23	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
COAD	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	3.76	0.00021	0.04	0.26	0.23	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
COAD	cis	rs7086627	0.515	rs4933390	ENSG00000226659.1	RP11-137H2.4	-3.76	0.00021	0.04	-0.32	-0.23	Post bronchodilator FEV1;	chr10:80453325	chr10:80529597~80535942:-
COAD	cis	rs1510510	0.742	rs11902229	ENSG00000225057.2	AC096574.4	3.76	0.00021	0.04	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238635706	chr2:238231684~238255633:+
COAD	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-3.76	0.00021	0.04	-0.26	-0.23	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
COAD	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	3.76	0.00021	0.04	0.33	0.23	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
COAD	cis	rs1048886	0.872	rs73474966	ENSG00000271967.1	RP11-134K13.4	-3.76	0.00021	0.04	-0.32	-0.23	Type 2 diabetes;	chr6:70427988	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs9455104	ENSG00000271967.1	RP11-134K13.4	-3.76	0.00021	0.04	-0.32	-0.23	Type 2 diabetes;	chr6:70433762	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.872	rs9455105	ENSG00000271967.1	RP11-134K13.4	-3.76	0.00021	0.04	-0.32	-0.23	Type 2 diabetes;	chr6:70433778	chr6:70596438~70596980:+
COAD	cis	rs1048886	0.938	rs9294871	ENSG00000271967.1	RP11-134K13.4	-3.76	0.00021	0.04	-0.32	-0.23	Type 2 diabetes;	chr6:70463524	chr6:70596438~70596980:+
COAD	cis	rs11168351	0.927	rs10875716	ENSG00000226413.2	OR8T1P	3.76	0.00021	0.04	0.28	0.23	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48442030~48442947:-
COAD	cis	rs57221529	0.709	rs4957056	ENSG00000250385.1	RP11-310P5.2	3.76	0.00021	0.04	0.39	0.23	Lung disease severity in cystic fibrosis;	chr5:569990	chr5:524705~526594:+
COAD	cis	rs7204230	0.921	rs62049817	ENSG00000261056.2	RP11-454F8.2	3.76	0.000211	0.0401	0.28	0.23	Fibrinogen;	chr16:53336109	chr16:53298224~53299792:+
COAD	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	3.76	0.000211	0.0401	0.37	0.23	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
COAD	cis	rs8061903	0.535	rs12930801	ENSG00000261617.1	RP11-243A14.1	3.76	0.000211	0.0401	0.29	0.23	HIV-1 viral setpoint;	chr16:9318410	chr16:9355588~9408093:+
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000269514.1	RP11-370I10.12	3.76	0.000211	0.0401	0.27	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48198387~48202031:+
COAD	cis	rs6732160	0.564	rs2043096	ENSG00000163016.8	ALMS1P	3.76	0.000211	0.0401	0.29	0.23	Intelligence (multi-trait analysis);	chr2:73148595	chr2:73644919~73685576:+
COAD	cis	rs7131987	0.903	rs10843367	ENSG00000257176.2	RP11-996F15.2	-3.76	0.000211	0.0401	-0.27	-0.23	QT interval;	chr12:29255447	chr12:29280418~29317848:-
COAD	cis	rs7212590	0.618	rs56142307	ENSG00000264049.1	MIR4737	-3.76	0.000211	0.0401	-0.33	-0.23	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59800788	chr17:60043025~60043105:-
COAD	cis	rs7260598	0.792	rs73031010	ENSG00000268442.1	CTD-2027I19.2	3.76	0.000211	0.0401	0.35	0.23	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:24162370~24163425:-
COAD	cis	rs73198271	0.74	rs10092720	ENSG00000173295.6	FAM86B3P	-3.76	0.000211	0.0401	-0.3	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8228595~8244865:+
COAD	cis	rs2307394	0.964	rs13008838	ENSG00000281469.1	RP11-567F11.1	3.76	0.000211	0.0401	0.27	0.23	Urate levels;	chr2:147997256	chr2:148044380~148044894:+
COAD	cis	rs4604234	0.708	rs60566469	ENSG00000272129.1	RP11-250B2.6	-3.76	0.000211	0.0401	-0.69	-0.23	Cancer;	chr6:80344636	chr6:80355424~80356859:+
COAD	cis	rs12935418	0.673	rs2602428	ENSG00000261061.1	RP11-303E16.2	3.76	0.000211	0.0401	0.27	0.23	Mean corpuscular volume;	chr16:81028566	chr16:81030770~81031485:+
COAD	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	3.76	0.000211	0.0401	0.34	0.23	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
COAD	cis	rs2531992	0.8	rs1045476	ENSG00000262185.1	RP11-462G12.1	-3.76	0.000211	0.0401	-0.32	-0.23	Waist circumference;	chr16:3965312	chr16:3947609~3950444:-
COAD	cis	rs3987765	1	rs1566577	ENSG00000268849.4	SIGLEC22P	-3.76	0.000211	0.0401	-0.45	-0.23	HIV-1 susceptibility;	chr19:51196567	chr19:51211080~51212088:+
COAD	cis	rs11229555	0.645	rs11229489	ENSG00000254602.1	AP000662.4	-3.76	0.000211	0.0401	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58477444	chr11:57638024~57652790:+
COAD	cis	rs2836974	0.897	rs7280375	ENSG00000255568.3	BRWD1-AS2	-3.76	0.000211	0.0401	-0.23	-0.23	Cognitive function;	chr21:39180482	chr21:39313935~39314962:+
COAD	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	3.76	0.000211	0.0401	0.3	0.23	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
COAD	cis	rs1440410	0.56	rs300941	ENSG00000250326.1	RP11-284M14.1	-3.76	0.000211	0.0401	-0.28	-0.23	Ischemic stroke;	chr4:143252387	chr4:142933195~143184861:-
COAD	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-3.76	0.000211	0.0401	-0.27	-0.23	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
COAD	cis	rs17685	0.753	rs4732542	ENSG00000280388.1	RP11-229D13.3	-3.76	0.000211	0.0401	-0.23	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76043977~76045963:-
COAD	cis	rs603446	0.541	rs59854309	ENSG00000254851.1	RP11-109L13.1	3.76	0.000211	0.0402	0.27	0.23	Triglycerides;	chr11:116696047	chr11:117135528~117138582:+
COAD	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	3.76	0.000211	0.0402	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
COAD	cis	rs2337406	0.866	rs78525520	ENSG00000211964.3	IGHV3-48	-3.76	0.000211	0.0402	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106795643	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs7140974	ENSG00000211964.3	IGHV3-48	-3.76	0.000211	0.0402	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106795976	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs76871148	ENSG00000211964.3	IGHV3-48	-3.76	0.000211	0.0402	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106799722	chr14:106537810~106538344:-
COAD	cis	rs2337406	0.866	rs61521632	ENSG00000211964.3	IGHV3-48	-3.76	0.000211	0.0402	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106801091	chr14:106537810~106538344:-
COAD	cis	rs2354432	0.607	rs4950310	ENSG00000226015.2	CCT8P1	3.76	0.000211	0.0402	0.51	0.23	Mitochondrial DNA levels;	chr1:147188385	chr1:147203276~147204932:-
COAD	cis	rs10465746	0.78	rs7529293	ENSG00000249237.4	RP11-376N17.4	-3.76	0.000211	0.0402	-0.25	-0.23	Obesity-related traits;	chr1:83866298	chr1:84344678~84349939:+
COAD	cis	rs7577696	0.962	rs67157050	ENSG00000272716.1	RP11-563N4.1	-3.76	0.000211	0.0402	-0.24	-0.23	Inflammatory biomarkers;	chr2:32046295	chr2:32165046~32165757:-
COAD	cis	rs3748656	0.945	rs2273368	ENSG00000231246.1	RP5-965F6.2	-3.76	0.000211	0.0402	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112521149	chr1:112177234~112360528:-
COAD	cis	rs8022206	0.738	rs11158719	ENSG00000259502.1	RP11-643G16.3	-3.76	0.000211	0.0402	-0.31	-0.23	Platelet count;Mean platelet volume;	chr14:68084556	chr14:67610986~67613864:+
COAD	cis	rs4072705	0.935	rs2184219	ENSG00000236643.1	RP11-175D17.3	3.76	0.000211	0.0402	0.26	0.23	Menarche (age at onset);	chr9:124770625	chr9:124770123~124772927:+
COAD	cis	rs2504916	0.83	rs2457556	ENSG00000230234.1	RP1-276N6.2	3.76	0.000211	0.0402	0.31	0.23	Response to hepatitis C treatment;	chr6:160364944	chr6:160272617~160276130:+
COAD	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	3.76	0.000212	0.0402	0.46	0.23	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	3.76	0.000212	0.0402	0.46	0.23	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	3.76	0.000212	0.0402	0.46	0.23	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	3.76	0.000212	0.0402	0.46	0.23	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
COAD	cis	rs28374715	0.532	rs28897479	ENSG00000247556.5	OIP5-AS1	3.76	0.000212	0.0402	0.33	0.23	Ulcerative colitis;	chr15:41398653	chr15:41283990~41309737:+
COAD	cis	rs9911578	1	rs302848	ENSG00000278627.1	RP11-506H21.5	-3.76	0.000212	0.0402	-0.28	-0.23	Intelligence (multi-trait analysis);	chr17:58609093	chr17:58202352~58203003:-
COAD	cis	rs890448	0.726	rs2850329	ENSG00000254531.1	FLJ20021	3.76	0.000212	0.0402	0.22	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101354107	chr4:101347780~101348883:+
COAD	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-3.76	0.000212	0.0402	-0.27	-0.23	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
COAD	cis	rs3617	0.625	rs6445541	ENSG00000243224.1	RP5-1157M23.2	-3.76	0.000212	0.0402	-0.24	-0.23	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52846112	chr3:52239258~52241097:+
COAD	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	3.76	0.000212	0.0402	0.26	0.23	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
COAD	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	3.76	0.000212	0.0402	0.29	0.23	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
COAD	cis	rs597539	0.689	rs596874	ENSG00000255741.1	RP11-757G1.5	3.76	0.000212	0.0402	0.28	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68941503~68942852:-
COAD	cis	rs10971721	0.818	rs10971708	ENSG00000260947.1	RP11-384P7.7	3.76	0.000212	0.0403	0.46	0.23	Body mass index;	chr9:33803273	chr9:33697459~33700986:+
COAD	cis	rs5751614	0.537	rs3788358	ENSG00000207835.1	AC244250.3	3.76	0.000212	0.0403	0.19	0.23	Height;	chr22:23274168	chr22:22758696~22758790:+
COAD	cis	rs7686384	0.522	rs13134477	ENSG00000180015.12	RP11-756P10.3	-3.76	0.000212	0.0403	-0.36	-0.23	Obesity-related traits;	chr4:188715703	chr4:188738373~188739494:+
COAD	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000212	0.0403	-0.31	-0.23	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
COAD	cis	rs622217	0.838	rs668871	ENSG00000213071.9	LPAL2	3.76	0.000212	0.0403	0.23	0.23	Type 2 diabetes;	chr6:160348779	chr6:160453428~160511124:-
COAD	cis	rs11229555	0.645	rs6591475	ENSG00000254602.1	AP000662.4	3.76	0.000212	0.0403	0.27	0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58426078	chr11:57638024~57652790:+
COAD	cis	rs9583269	0.57	rs9583277	ENSG00000277246.1	RP11-153I24.4	3.76	0.000212	0.0403	0.26	0.23	Colorectal cancer;	chr13:108681401	chr13:108267320~108267734:+
COAD	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	3.76	0.000212	0.0403	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
COAD	cis	rs10876993	0.928	rs2928053	ENSG00000270039.1	RP11-571M6.17	3.76	0.000212	0.0403	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57669692	chr12:57803838~57804415:+
COAD	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	3.76	0.000212	0.0403	0.28	0.23	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.754	rs12510269	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119320491	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs12506610	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119320504	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.743	rs10003567	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119320519	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs10006259	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119320990	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs28652763	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119321157	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs7672594	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119327388	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.754	rs7672778	ENSG00000250412.1	KLHL2P1	3.76	0.000212	0.0403	0.3	0.23	Corneal astigmatism;	chr4:119327430	chr4:119334329~119378233:+
COAD	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-3.76	0.000212	0.0403	-0.36	-0.23	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
COAD	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	3.76	0.000212	0.0403	0.23	0.23	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	3.76	0.000212	0.0403	0.23	0.23	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	3.76	0.000212	0.0403	0.23	0.23	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
COAD	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	3.76	0.000212	0.0403	0.23	0.23	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
COAD	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-3.76	0.000212	0.0403	-0.25	-0.23	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
COAD	cis	rs712022	1	rs10766969	ENSG00000246225.5	RP11-17A1.3	-3.76	0.000212	0.0403	-0.31	-0.23	Dialysis-related mortality;	chr11:22828406	chr11:22829380~22945393:+
COAD	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-3.76	0.000212	0.0403	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
COAD	cis	rs7204230	1	rs11859517	ENSG00000261056.2	RP11-454F8.2	3.76	0.000212	0.0403	0.27	0.23	Fibrinogen;	chr16:53147335	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs67499551	ENSG00000261056.2	RP11-454F8.2	3.76	0.000212	0.0403	0.27	0.23	Fibrinogen;	chr16:53149693	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.96	rs8055410	ENSG00000261056.2	RP11-454F8.2	3.76	0.000212	0.0403	0.27	0.23	Fibrinogen;	chr16:53149924	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.96	rs12149129	ENSG00000261056.2	RP11-454F8.2	3.76	0.000212	0.0403	0.27	0.23	Fibrinogen;	chr16:53154102	chr16:53298224~53299792:+
COAD	cis	rs9813712	0.595	rs12490957	ENSG00000249846.5	RP11-77P16.4	3.76	0.000212	0.0403	0.26	0.23	Response to amphetamines;	chr3:130287851	chr3:130112550~130120579:+
COAD	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-3.76	0.000212	0.0403	-0.32	-0.23	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
COAD	cis	rs1644305	0.701	rs4077649	ENSG00000271737.1	CTB-113I20.2	3.76	0.000212	0.0404	0.21	0.23	Attention deficit hyperactivity disorder and conduct disorder;	chr5:133881968	chr5:134005147~134005562:+
COAD	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-3.76	0.000212	0.0404	-0.25	-0.23	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
COAD	cis	rs9880211	1	rs17364492	ENSG00000273486.1	RP11-731C17.2	-3.76	0.000213	0.0404	-0.26	-0.23	Height;Body mass index;	chr3:136485595	chr3:136837338~136839021:-
COAD	cis	rs6064559	0.598	rs2902993	ENSG00000214541.3	RPS4XP3	3.76	0.000213	0.0404	0.21	0.23	Hemoglobin concentration;	chr20:57535158	chr20:56601701~56602113:+
COAD	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-3.76	0.000213	0.0404	-0.37	-0.23	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
COAD	cis	rs7818688	0.578	rs11779506	ENSG00000253528.2	RP11-347C18.4	-3.76	0.000213	0.0404	-0.35	-0.23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95062674	chr8:94974573~94974853:-
COAD	cis	rs5015933	0.734	rs4838261	ENSG00000232630.1	PRPS1P2	-3.76	0.000213	0.0404	-0.23	-0.23	Body mass index;	chr9:125386970	chr9:125150653~125151589:+
COAD	cis	rs12530	0.54	rs2294312	ENSG00000230736.2	RP1-149A16.3	-3.76	0.000213	0.0404	-0.25	-0.23	IgG glycosylation;	chr22:32397397	chr22:32376664~32384343:+
COAD	cis	rs860295	0.702	rs10796943	ENSG00000160766.13	GBAP1	-3.76	0.000213	0.0404	-0.28	-0.23	Body mass index;	chr1:155444938	chr1:155213821~155227422:-
COAD	cis	rs4767364	1	rs7977534	ENSG00000257595.2	RP3-473L9.4	3.76	0.000213	0.0404	0.29	0.23	Oral cavity and pharyngeal cancer;	chr12:112280116	chr12:111369282~111403310:+
COAD	cis	rs4767364	0.961	rs10850024	ENSG00000257595.2	RP3-473L9.4	3.76	0.000213	0.0404	0.29	0.23	Oral cavity and pharyngeal cancer;	chr12:112280706	chr12:111369282~111403310:+
COAD	cis	rs7781557	1	rs727175	ENSG00000235354.1	CTA-276O3.4	-3.76	0.000213	0.0404	-0.29	-0.23	Colorectal adenoma (advanced);	chr7:102831333	chr7:103348601~103348771:+
COAD	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	3.76	0.000213	0.0404	0.25	0.23	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
COAD	cis	rs13188386	0.732	rs12521020	ENSG00000249779.1	RP11-447H19.3	3.76	0.000213	0.0404	0.26	0.23	Iron status biomarkers;	chr5:42565741	chr5:43206709~43207811:+
COAD	cis	rs3738443	1	rs61840057	ENSG00000259865.1	RP11-488L18.10	3.76	0.000213	0.0404	0.25	0.23	Alcohol dependence;	chr1:247206054	chr1:247187281~247188526:-
COAD	cis	rs2408955	0.541	rs11168428	ENSG00000269514.1	RP11-370I10.12	-3.76	0.000213	0.0404	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48153345	chr12:48198387~48202031:+
COAD	cis	rs7577696	0.889	rs455060	ENSG00000272716.1	RP11-563N4.1	3.76	0.000213	0.0404	0.23	0.23	Inflammatory biomarkers;	chr2:32250040	chr2:32165046~32165757:-
COAD	cis	rs1485395	0.838	rs11170630	ENSG00000250742.1	RP11-834C11.4	3.76	0.000213	0.0404	0.24	0.23	Migraine without aura;	chr12:53646626	chr12:54126098~54132843:+
COAD	cis	rs12900463	0.813	rs306198	ENSG00000259728.4	LINC00933	-3.76	0.000213	0.0404	-0.3	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84570649~84580175:+
COAD	cis	rs9813712	0.597	rs1453255	ENSG00000253540.4	FAM86HP	-3.76	0.000213	0.0404	-0.24	-0.23	Response to amphetamines;	chr3:130258815	chr3:130099092~130111472:-
COAD	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	3.76	0.000213	0.0404	0.31	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
COAD	cis	rs6545883	0.86	rs13023037	ENSG00000273302.1	RP11-493E12.2	-3.76	0.000213	0.0404	-0.23	-0.23	Tuberculosis;	chr2:61393854	chr2:61199979~61200769:+
COAD	cis	rs11168351	0.591	rs4258439	ENSG00000273765.1	RP11-370I10.11	-3.76	0.000213	0.0405	-0.23	-0.23	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48360920~48361377:+
COAD	cis	rs733592	0.507	rs10747529	ENSG00000273765.1	RP11-370I10.11	-3.76	0.000213	0.0405	-0.23	-0.23	Plateletcrit;	chr12:48079586	chr12:48360920~48361377:+
COAD	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-3.76	0.000213	0.0405	-0.25	-0.23	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
COAD	cis	rs7577696	0.962	rs34856365	ENSG00000272716.1	RP11-563N4.1	-3.76	0.000213	0.0405	-0.24	-0.23	Inflammatory biomarkers;	chr2:32079931	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs6760105	ENSG00000272716.1	RP11-563N4.1	-3.76	0.000213	0.0405	-0.24	-0.23	Inflammatory biomarkers;	chr2:32082317	chr2:32165046~32165757:-
COAD	cis	rs11098499	0.754	rs9999724	ENSG00000250412.1	KLHL2P1	3.76	0.000213	0.0405	0.3	0.23	Corneal astigmatism;	chr4:119318789	chr4:119334329~119378233:+
COAD	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000213	0.0405	0.39	0.23	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000213	0.0405	0.39	0.23	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
COAD	cis	rs11633886	0.835	rs7178907	ENSG00000273972.1	CTD-2306A12.1	-3.76	0.000213	0.0405	-0.26	-0.23	Diisocyanate-induced asthma;	chr15:45809159	chr15:45702640~45703183:+
COAD	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-3.76	0.000213	0.0405	-0.32	-0.23	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
COAD	cis	rs5760748	1	rs5760745	ENSG00000272977.1	CTA-390C10.10	-3.76	0.000213	0.0405	-0.27	-0.23	Calcium levels;	chr22:24935972	chr22:25476218~25479971:+
COAD	cis	rs2073499	1	rs78020607	ENSG00000235908.1	RHOA-IT1	3.76	0.000213	0.0405	0.38	0.23	Schizophrenia;	chr3:50217192	chr3:49365145~49367006:-
COAD	cis	rs34792	0.604	rs12148985	ENSG00000207425.1	Y_RNA	-3.76	0.000213	0.0405	-0.3	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15493052	chr16:14915457~14915556:-
COAD	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	3.76	0.000213	0.0405	0.33	0.23	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
COAD	cis	rs11098499	0.754	rs1980025	ENSG00000250412.1	KLHL2P1	-3.76	0.000213	0.0405	-0.3	-0.23	Corneal astigmatism;	chr4:119331651	chr4:119334329~119378233:+
COAD	cis	rs1510510	0.742	rs12999671	ENSG00000225057.2	AC096574.4	3.76	0.000213	0.0405	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238654047	chr2:238231684~238255633:+
COAD	cis	rs9818758	0.556	rs9872660	ENSG00000225399.4	RP11-3B7.1	-3.76	0.000213	0.0405	-0.36	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341399	chr3:49260085~49261316:+
COAD	cis	rs9818758	0.882	rs74926817	ENSG00000225399.4	RP11-3B7.1	-3.76	0.000213	0.0405	-0.36	-0.23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49341400	chr3:49260085~49261316:+
COAD	cis	rs9858542	0.537	rs67882627	ENSG00000225399.4	RP11-3B7.1	-3.76	0.000213	0.0405	-0.36	-0.23	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49343008	chr3:49260085~49261316:+
COAD	cis	rs9858542	0.537	rs9818758	ENSG00000225399.4	RP11-3B7.1	-3.76	0.000213	0.0405	-0.36	-0.23	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49345492	chr3:49260085~49261316:+
COAD	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	3.76	0.000213	0.0405	0.32	0.23	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
COAD	cis	rs9652601	0.959	rs7200940	ENSG00000274038.1	RP11-66H6.4	3.76	0.000213	0.0405	0.3	0.23	Systemic lupus erythematosus;	chr16:11070710	chr16:11056556~11057034:+
COAD	cis	rs677665	0.537	rs6688233	ENSG00000231181.1	RP13-15M17.1	-3.76	0.000214	0.0405	-0.29	-0.23	Eosinophil percentage of white cells;	chr1:9275686	chr1:9576427~9576985:+
COAD	cis	rs8020095	0.571	rs8022657	ENSG00000196553.12	LINC00238	-3.76	0.000214	0.0405	-0.32	-0.23	Depression (quantitative trait);	chr14:66923782	chr14:66486354~66498553:+
COAD	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-3.76	0.000214	0.0405	-0.32	-0.23	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
COAD	cis	rs1949733	0.554	rs4259044	ENSG00000205959.3	RP11-689P11.2	3.76	0.000214	0.0405	0.26	0.23	Response to antineoplastic agents;	chr4:8534461	chr4:8482270~8512610:+
COAD	cis	rs74781061	0.929	rs4324083	ENSG00000260103.2	RP11-10O17.1	-3.76	0.000214	0.0405	-0.27	-0.23	Endometriosis;	chr15:74479139	chr15:74478070~74490286:-
COAD	cis	rs74781061	0.929	rs117379081	ENSG00000260103.2	RP11-10O17.1	-3.76	0.000214	0.0405	-0.27	-0.23	Endometriosis;	chr15:74480106	chr15:74478070~74490286:-
COAD	cis	rs74781061	0.929	rs79600239	ENSG00000260103.2	RP11-10O17.1	-3.76	0.000214	0.0405	-0.27	-0.23	Endometriosis;	chr15:74481987	chr15:74478070~74490286:-
COAD	cis	rs74781061	0.929	rs16969247	ENSG00000260103.2	RP11-10O17.1	-3.76	0.000214	0.0405	-0.27	-0.23	Endometriosis;	chr15:74486541	chr15:74478070~74490286:-
COAD	cis	rs2307394	1	rs13033664	ENSG00000281469.1	RP11-567F11.1	3.76	0.000214	0.0405	0.28	0.23	Urate levels;	chr2:148012705	chr2:148044380~148044894:+
COAD	cis	rs911555	0.755	rs10148970	ENSG00000251533.2	LINC00605	-3.76	0.000214	0.0405	-0.3	-0.23	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103187221~103189028:-
COAD	cis	rs2832191	0.74	rs2832177	ENSG00000176054.6	RPL23P2	-3.76	0.000214	0.0405	-0.23	-0.23	Dental caries;	chr21:29106032	chr21:28997613~28998033:-
COAD	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-3.76	0.000214	0.0405	-0.27	-0.23	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
COAD	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-3.76	0.000214	0.0406	-0.34	-0.23	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
COAD	cis	rs11138902	0.673	rs11139228	ENSG00000229312.2	RP11-470P21.2	3.76	0.000214	0.0406	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69541284	chr9:69472466~69494513:+
COAD	cis	rs11138902	0.649	rs13287758	ENSG00000229312.2	RP11-470P21.2	3.76	0.000214	0.0406	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69541683	chr9:69472466~69494513:+
COAD	cis	rs11138902	0.673	rs13289730	ENSG00000229312.2	RP11-470P21.2	3.76	0.000214	0.0406	0.26	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69543448	chr9:69472466~69494513:+
COAD	cis	rs535066	0.905	rs474773	ENSG00000260878.1	RP11-320H14.1	-3.76	0.000214	0.0406	-0.3	-0.23	Epilepsy;	chr4:46220091	chr4:46243548~46244215:-
COAD	cis	rs535066	0.935	rs536618	ENSG00000260878.1	RP11-320H14.1	-3.76	0.000214	0.0406	-0.3	-0.23	Epilepsy;	chr4:46222169	chr4:46243548~46244215:-
COAD	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-3.76	0.000214	0.0406	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
COAD	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	3.76	0.000214	0.0406	0.24	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
COAD	cis	rs10876993	0.928	rs7136269	ENSG00000270039.1	RP11-571M6.17	3.76	0.000214	0.0406	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57682154	chr12:57803838~57804415:+
COAD	cis	rs17407555	0.586	rs16895836	ENSG00000250413.1	RP11-448G15.1	-3.76	0.000214	0.0406	-0.3	-0.23	Schizophrenia (age at onset);	chr4:10276725	chr4:10006482~10009725:+
COAD	cis	rs911555	0.723	rs56227024	ENSG00000251533.2	LINC00605	3.76	0.000214	0.0406	0.29	0.23	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103187221~103189028:-
COAD	cis	rs4823173	0.509	rs2281298	ENSG00000280434.1	RP4-671O14.6	-3.76	0.000214	0.0406	-0.35	-0.23	Hepatic lipid content in extreme obesity;	chr22:43995354	chr22:44139365~44153626:+
COAD	cis	rs11025559	0.685	rs10833341	ENSG00000279266.1	RP11-371I20.2	-3.76	0.000214	0.0406	-0.29	-0.23	Pursuit maintenance gain;	chr11:20513701	chr11:20131730~20135465:+
COAD	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-3.76	0.000214	0.0406	-0.25	-0.23	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
COAD	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-3.76	0.000214	0.0406	-0.25	-0.23	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
COAD	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	3.76	0.000214	0.0406	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	3.76	0.000214	0.0406	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	3.76	0.000214	0.0406	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
COAD	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	3.76	0.000214	0.0406	0.22	0.23	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
COAD	cis	rs7615952	0.932	rs6438948	ENSG00000241278.1	ENPP7P4	-3.76	0.000214	0.0406	-0.24	-0.23	Blood pressure (smoking interaction);	chr3:125931202	chr3:125848223~125909372:+
COAD	cis	rs6480314	0.522	rs2120900	ENSG00000233590.1	RP11-153K11.3	3.75	0.000214	0.0407	0.28	0.23	Optic nerve measurement (disc area);	chr10:68296052	chr10:68233251~68242379:-
COAD	cis	rs71636778	0.722	rs34928032	ENSG00000260063.1	RP5-968P14.2	-3.75	0.000214	0.0407	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26812738	chr1:26692132~26694131:-
COAD	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-3.75	0.000214	0.0407	-0.26	-0.23	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
COAD	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	3.75	0.000215	0.0407	0.18	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
COAD	cis	rs9880211	0.898	rs9870825	ENSG00000273486.1	RP11-731C17.2	3.75	0.000215	0.0407	0.28	0.23	Height;Body mass index;	chr3:136346878	chr3:136837338~136839021:-
COAD	cis	rs2836974	0.583	rs9636957	ENSG00000255568.3	BRWD1-AS2	-3.75	0.000215	0.0407	-0.21	-0.23	Cognitive function;	chr21:39333921	chr21:39313935~39314962:+
COAD	cis	rs2408955	0.568	rs12099462	ENSG00000269514.1	RP11-370I10.12	-3.75	0.000215	0.0407	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48109321	chr12:48198387~48202031:+
COAD	cis	rs2638953	0.962	rs11049495	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000215	0.0407	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28163298~28190738:-
COAD	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-3.75	0.000215	0.0407	-0.21	-0.23	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
COAD	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-3.75	0.000215	0.0407	-0.21	-0.23	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
COAD	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-3.75	0.000215	0.0407	-0.28	-0.23	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
COAD	cis	rs370915	0.578	rs1367934	ENSG00000250971.1	RP11-696F12.1	3.75	0.000215	0.0407	0.28	0.23	Gout;	chr4:186855242	chr4:187060099~187060930:+
COAD	cis	rs9400467	0.528	rs462432	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000215	0.0407	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111277932~111278742:+
COAD	cis	rs7760535	0.931	rs466923	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000215	0.0407	-0.2	-0.23	Metabolic traits;	chr6:111341774	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs1623806	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000215	0.0407	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111277932~111278742:+
COAD	cis	rs7536700	1	rs61806716	ENSG00000272030.1	RP1-178F15.4	-3.75	0.000215	0.0407	-0.36	-0.23	Multiple myeloma (IgH translocation);	chr1:153676671	chr1:153631438~153634397:-
COAD	cis	rs2732480	0.5	rs1552550	ENSG00000269514.1	RP11-370I10.12	3.75	0.000215	0.0407	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48198387~48202031:+
COAD	cis	rs9880211	0.948	rs9872178	ENSG00000273486.1	RP11-731C17.2	3.75	0.000215	0.0407	0.27	0.23	Height;Body mass index;	chr3:136267596	chr3:136837338~136839021:-
COAD	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	3.75	0.000215	0.0408	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
COAD	cis	rs4578769	0.569	rs12605341	ENSG00000266850.1	RP11-370A5.1	-3.75	0.000215	0.0408	-0.25	-0.23	Eosinophil percentage of white cells;	chr18:22803011	chr18:22723491~22907721:-
COAD	cis	rs12893597	1	rs12893597	ENSG00000243225.2	RP11-7F17.1	3.75	0.000215	0.0408	0.34	0.23	Maximal oxygen uptake response;	chr14:76346352	chr14:76968683~76969145:+
COAD	cis	rs2638953	0.886	rs12371462	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000215	0.0408	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28168770	chr12:28163298~28190738:-
COAD	cis	rs7686384	0.522	rs11943772	ENSG00000180015.12	RP11-756P10.3	-3.75	0.000215	0.0408	-0.36	-0.23	Obesity-related traits;	chr4:188711787	chr4:188738373~188739494:+
COAD	cis	rs2638953	0.886	rs10843137	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000215	0.0408	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs10843138	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000215	0.0408	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28163298~28190738:-
COAD	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-3.75	0.000215	0.0408	-0.4	-0.23	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
COAD	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-3.75	0.000215	0.0408	-0.25	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
COAD	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-3.75	0.000216	0.0408	-0.27	-0.23	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
COAD	cis	rs7193541	0.695	rs7199490	ENSG00000262904.1	TMPOP2	-3.75	0.000216	0.0408	-0.26	-0.23	Multiple myeloma;	chr16:74682128	chr16:74667506~74668706:+
COAD	cis	rs71636778	0.631	rs60314236	ENSG00000260063.1	RP5-968P14.2	-3.75	0.000216	0.0408	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26828675	chr1:26692132~26694131:-
COAD	cis	rs13188386	0.701	rs34895721	ENSG00000249779.1	RP11-447H19.3	3.75	0.000216	0.0408	0.28	0.23	Iron status biomarkers;	chr5:42580138	chr5:43206709~43207811:+
COAD	cis	rs13188386	0.732	rs11955075	ENSG00000249779.1	RP11-447H19.3	3.75	0.000216	0.0408	0.28	0.23	Iron status biomarkers;	chr5:42580658	chr5:43206709~43207811:+
COAD	cis	rs13188386	0.701	rs7707913	ENSG00000249779.1	RP11-447H19.3	3.75	0.000216	0.0408	0.28	0.23	Iron status biomarkers;	chr5:42584750	chr5:43206709~43207811:+
COAD	cis	rs728616	0.681	rs12413174	ENSG00000225484.5	NUTM2B-AS1	-3.75	0.000216	0.0408	-0.38	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80302648	chr10:79663088~79826594:-
COAD	cis	rs6496932	0.503	rs8037726	ENSG00000259630.2	CTD-2262B20.1	-3.75	0.000216	0.0408	-0.31	-0.23	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85415228~85415633:+
COAD	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	3.75	0.000216	0.0408	0.16	0.23	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
COAD	cis	rs7172689	1	rs11856780	ENSG00000271725.1	RP11-761I4.4	3.75	0.000216	0.0409	0.3	0.23	Inattentive symptoms;	chr15:81237582	chr15:81303215~81309391:-
COAD	cis	rs660899	0.787	rs12354267	ENSG00000229431.1	RP1-92O14.6	-3.75	0.000216	0.0409	-0.23	-0.23	Hypertension risk in short sleep duration;	chr1:43782601	chr1:43385113~43389155:+
COAD	cis	rs1510510	0.69	rs12992529	ENSG00000225057.2	AC096574.4	3.75	0.000216	0.0409	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238643324	chr2:238231684~238255633:+
COAD	cis	rs735539	0.609	rs7332034	ENSG00000222726.1	RNU2-7P	-3.75	0.000216	0.0409	-0.3	-0.23	Dental caries;	chr13:20640804	chr13:20612161~20612338:+
COAD	cis	rs8114671	0.562	rs2378292	ENSG00000228265.4	RALY-AS1	3.75	0.000216	0.0409	0.22	0.23	Height;	chr20:34897375	chr20:33983052~33994357:-
COAD	cis	rs5751901	0.614	rs4820599	ENSG00000272942.1	CTA-246H3.12	-3.75	0.000216	0.0409	-0.25	-0.23	Protein quantitative trait loci;	chr22:24594246	chr22:25434324~25435070:-
COAD	cis	rs1707322	0.721	rs4609469	ENSG00000230896.1	RP11-767N6.7	-3.75	0.000216	0.0409	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs12049027	ENSG00000230896.1	RP11-767N6.7	-3.75	0.000216	0.0409	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs10789467	ENSG00000230896.1	RP11-767N6.7	-3.75	0.000216	0.0409	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45694684~45697075:-
COAD	cis	rs7536700	0.915	rs10082235	ENSG00000272030.1	RP1-178F15.4	3.75	0.000216	0.0409	0.33	0.23	Multiple myeloma (IgH translocation);	chr1:153684174	chr1:153631438~153634397:-
COAD	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	3.75	0.000216	0.0409	0.31	0.23	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
COAD	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	3.75	0.000216	0.0409	0.3	0.23	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
COAD	cis	rs1023500	0.596	rs133369	ENSG00000227370.1	RP4-669P10.19	-3.75	0.000216	0.0409	-0.23	-0.23	Schizophrenia;	chr22:42067810	chr22:42132543~42132998:+
COAD	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	3.75	0.000216	0.0409	0.23	0.23	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
COAD	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-3.75	0.000216	0.0409	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-3.75	0.000216	0.0409	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-3.75	0.000216	0.0409	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-3.75	0.000216	0.0409	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
COAD	cis	rs2408955	0.521	rs7301003	ENSG00000269514.1	RP11-370I10.12	3.75	0.000216	0.0409	0.26	0.23	Glycated hemoglobin levels;	chr12:48156444	chr12:48198387~48202031:+
COAD	cis	rs293748	0.771	rs12656269	ENSG00000250155.1	CTD-2353F22.1	3.75	0.000216	0.0409	0.32	0.23	Obesity-related traits;	chr5:36787776	chr5:36666214~36725195:-
COAD	cis	rs7646881	0.544	rs58034569	ENSG00000272087.1	RP11-379F4.7	3.75	0.000216	0.0409	0.36	0.23	Tetralogy of Fallot;	chr3:158569900	chr3:158693120~158693768:-
COAD	cis	rs6142618	0.523	rs6141651	ENSG00000101898.5	MCTS2P	3.75	0.000216	0.0409	0.25	0.23	Inflammatory bowel disease;	chr20:32263518	chr20:31547504~31548049:+
COAD	cis	rs6125597	0.967	rs6067030	ENSG00000222365.1	SNORD12B	3.75	0.000216	0.0409	0.19	0.23	Intelligence (multi-trait analysis);	chr20:49267866	chr20:49280319~49280409:+
COAD	cis	rs6125597	0.805	rs6063382	ENSG00000222365.1	SNORD12B	3.75	0.000216	0.0409	0.19	0.23	Intelligence (multi-trait analysis);	chr20:49273421	chr20:49280319~49280409:+
COAD	cis	rs6125597	0.967	rs6122779	ENSG00000222365.1	SNORD12B	3.75	0.000216	0.0409	0.19	0.23	Intelligence (multi-trait analysis);	chr20:49276477	chr20:49280319~49280409:+
COAD	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	3.75	0.000216	0.0409	0.24	0.23	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
COAD	cis	rs9402682	0.668	rs2026938	ENSG00000232876.1	CTA-212D2.2	-3.75	0.000216	0.041	-0.32	-0.23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135122871	chr6:135055033~135060550:+
COAD	cis	rs1914816	0.941	rs2938691	ENSG00000196274.5	Metazoa_SRP	3.75	0.000216	0.041	0.24	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76214865	chr15:76230048~76230390:-
COAD	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-3.75	0.000217	0.041	-0.23	-0.23	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
COAD	cis	rs9858542	0.537	rs9864406	ENSG00000225399.4	RP11-3B7.1	-3.75	0.000217	0.041	-0.31	-0.23	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49315186	chr3:49260085~49261316:+
COAD	cis	rs174479	0.677	rs1000778	ENSG00000267811.1	RP11-727F15.11	3.75	0.000217	0.041	0.28	0.23	Sphingolipid levels;	chr11:61887833	chr11:62771120~62771606:-
COAD	cis	rs742132	0.893	rs9467542	ENSG00000220875.1	HIST1H3PS1	3.75	0.000217	0.041	0.3	0.23	Uric acid levels;	chr6:25630825	chr6:26321876~26322292:-
COAD	cis	rs742132	0.893	rs2072842	ENSG00000220875.1	HIST1H3PS1	3.75	0.000217	0.041	0.3	0.23	Uric acid levels;	chr6:25630951	chr6:26321876~26322292:-
COAD	cis	rs911263	0.603	rs2145422	ENSG00000259502.1	RP11-643G16.3	-3.75	0.000217	0.041	-0.28	-0.23	Primary biliary cholangitis;	chr14:68330452	chr14:67610986~67613864:+
COAD	cis	rs4660214	0.59	rs11205885	ENSG00000182109.6	RP11-69E11.4	-3.75	0.000217	0.041	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39522280~39546187:-
COAD	cis	rs17268829	0.925	rs12670168	ENSG00000231170.4	AC002451.3	-3.75	0.000217	0.041	-0.28	-0.23	Breast cancer;	chr7:94632760	chr7:95596682~95613719:+
COAD	cis	rs2408955	0.521	rs11168437	ENSG00000257735.1	RP11-370I10.6	3.75	0.000217	0.041	0.28	0.23	Glycated hemoglobin levels;	chr12:48172373	chr12:48350945~48442411:+
COAD	cis	rs884366	1	rs12191774	ENSG00000219700.1	PTCHD3P3	-3.75	0.000217	0.041	-0.3	-0.23	HDL cholesterol;HDL cholesterol levels;	chr6:109327150	chr6:109288571~109290503:-
COAD	cis	rs17772222	0.917	rs2004329	ENSG00000258789.1	RP11-507K2.3	-3.75	0.000217	0.041	-0.32	-0.23	Coronary artery calcification;	chr14:88532965	chr14:88551597~88552493:+
COAD	cis	rs6981523	0.532	rs1987190	ENSG00000269918.1	AF131215.9	-3.75	0.000217	0.041	-0.3	-0.23	Neuroticism;	chr8:11196005	chr8:11104691~11106704:-
COAD	cis	rs4253772	0.55	rs6008600	ENSG00000280424.1	CITF22-92A6.2	3.75	0.000217	0.041	0.36	0.23	Cholesterol, total;LDL cholesterol;	chr22:46308779	chr22:46006616~46010777:+
COAD	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-3.75	0.000217	0.041	-0.31	-0.23	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
COAD	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-3.75	0.000217	0.041	-0.31	-0.23	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
COAD	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-3.75	0.000217	0.041	-0.31	-0.23	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
COAD	cis	rs561341	1	rs560132	ENSG00000265798.5	RP11-271K11.5	3.75	0.000217	0.041	0.36	0.23	Hip circumference adjusted for BMI;	chr17:31993000	chr17:31038575~31059121:-
COAD	cis	rs2361701	1	rs2361701	ENSG00000279259.1	RP11-334C17.3	3.75	0.000217	0.041	0.27	0.23	IgG glycosylation;	chr17:80092818	chr17:80147250~80148596:+
COAD	cis	rs7955901	0.664	rs11178589	ENSG00000258053.1	CTD-2021H9.3	3.75	0.000217	0.0411	0.29	0.23	Type 2 diabetes;	chr12:71078550	chr12:71047402~71118247:-
COAD	cis	rs3733829	1	rs4802091	ENSG00000279759.1	CTC-425O23.5	-3.75	0.000217	0.0411	-0.2	-0.23	Smoking behavior;	chr19:40809413	chr19:40355842~40360606:+
COAD	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	3.75	0.000217	0.0411	0.3	0.23	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
COAD	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-3.75	0.000217	0.0411	-0.3	-0.23	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
COAD	cis	rs10752881	1	rs4233193	ENSG00000224468.3	RP11-181K3.4	-3.75	0.000217	0.0411	-0.23	-0.23	Colorectal cancer;	chr1:183001730	chr1:183138402~183141282:-
COAD	cis	rs7078012	0.504	rs117047841	ENSG00000225484.5	NUTM2B-AS1	-3.75	0.000217	0.0411	-0.57	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905900	chr10:79663088~79826594:-
COAD	cis	rs756699	1	rs756699	ENSG00000279469.1	RP11-215P8.2	3.75	0.000217	0.0411	0.32	0.23	Multiple sclerosis;	chr5:134110884	chr5:134394360~134395008:-
COAD	cis	rs8020095	0.571	rs10142059	ENSG00000196553.12	LINC00238	-3.75	0.000217	0.0411	-0.31	-0.23	Depression (quantitative trait);	chr14:67015912	chr14:66486354~66498553:+
COAD	cis	rs4253772	0.55	rs12165597	ENSG00000280424.1	CITF22-92A6.2	3.75	0.000217	0.0411	0.37	0.23	Cholesterol, total;LDL cholesterol;	chr22:46309687	chr22:46006616~46010777:+
COAD	cis	rs2018293	1	rs6005012	ENSG00000233521.4	RP5-1172A22.1	-3.75	0.000217	0.0411	-0.21	-0.23	Vascular brain injury;	chr22:26316256	chr22:27221349~27224727:-
COAD	cis	rs1832007	0.554	rs11596429	ENSG00000224034.1	RP11-445P17.8	-3.75	0.000217	0.0411	-0.33	-0.23	Triglyceride levels;Triglycerides;	chr10:5203345	chr10:5266033~5271236:-
COAD	cis	rs228769	0.673	rs228787	ENSG00000267080.4	ASB16-AS1	3.75	0.000217	0.0411	0.23	0.23	Bone mineral density (hip);Bone mineral density (spine);	chr17:44022120	chr17:44175973~44186717:-
COAD	cis	rs9436640	0.568	rs12740555	ENSG00000271200.1	RP11-430G17.3	3.75	0.000218	0.0411	0.26	0.23	QRS complex (Cornell);QRS duration;	chr1:61425697	chr1:61741998~61742424:-
COAD	cis	rs11098499	0.738	rs72918577	ENSG00000250412.1	KLHL2P1	3.75	0.000218	0.0411	0.31	0.23	Corneal astigmatism;	chr4:119405546	chr4:119334329~119378233:+
COAD	cis	rs17213965	0.852	rs4781691	ENSG00000260872.1	RP11-680G24.5	-3.75	0.000218	0.0411	-0.32	-0.23	Waist-hip ratio;	chr16:15783798	chr16:15018106~15020488:-
COAD	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	3.75	0.000218	0.0412	0.29	0.23	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
COAD	cis	rs8054556	0.787	rs12921753	ENSG00000183604.13	SMG1P5	-3.75	0.000218	0.0412	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30267553~30335374:-
COAD	cis	rs2173063	0.568	rs17647665	ENSG00000272888.4	LINC01578	-3.75	0.000218	0.0412	-0.34	-0.23	Subcutaneous adipose tissue;	chr15:92592876	chr15:92882707~92899701:+
COAD	cis	rs4927850	0.958	rs1975582	ENSG00000185485.13	SDHAP1	3.75	0.000218	0.0412	0.2	0.23	Pancreatic cancer;	chr3:196024568	chr3:195959748~195990318:-
COAD	cis	rs10028773	0.666	rs12498657	ENSG00000249244.1	RP11-548H18.2	3.75	0.000218	0.0412	0.29	0.23	Educational attainment;	chr4:119341711	chr4:119391831~119395335:-
COAD	cis	rs7465272	1	rs7835613	ENSG00000263660.1	AC087793.1	-3.75	0.000218	0.0412	-0.25	-0.23	Bipolar disorder and schizophrenia;	chr8:142601067	chr8:143314921~143315006:+
COAD	cis	rs17660992	0.519	rs34200125	ENSG00000268970.1	CTD-3099C6.11	3.75	0.000218	0.0412	0.3	0.23	Blood protein levels;	chr19:51659849	chr19:52597699~52598887:-
COAD	cis	rs875971	1	rs2077593	ENSG00000230189.5	GS1-124K5.2	3.75	0.000218	0.0412	0.19	0.23	Aortic root size;	chr7:66427543	chr7:66409143~66490059:-
COAD	cis	rs17598306	1	rs73402670	ENSG00000238228.1	OR7E7P	3.75	0.000218	0.0412	0.41	0.23	Radiation response;	chr7:96951024	chr7:97946987~97947998:-
COAD	cis	rs17598306	1	rs722470	ENSG00000238228.1	OR7E7P	3.75	0.000218	0.0412	0.41	0.23	Radiation response;	chr7:96952154	chr7:97946987~97947998:-
COAD	cis	rs17598306	1	rs17656761	ENSG00000238228.1	OR7E7P	3.75	0.000218	0.0412	0.41	0.23	Radiation response;	chr7:96952241	chr7:97946987~97947998:-
COAD	cis	rs875971	1	rs6945843	ENSG00000223473.2	GS1-124K5.3	-3.75	0.000218	0.0412	-0.19	-0.23	Aortic root size;	chr7:66269796	chr7:66491049~66493566:-
COAD	cis	rs2638953	0.962	rs716687	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000218	0.0412	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.819	rs10843146	ENSG00000247934.4	RP11-967K21.1	-3.75	0.000218	0.0412	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28163298~28190738:-
COAD	cis	rs7577696	0.962	rs13022197	ENSG00000272716.1	RP11-563N4.1	-3.75	0.000218	0.0412	-0.24	-0.23	Inflammatory biomarkers;	chr2:32118098	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.671	rs72863940	ENSG00000272716.1	RP11-563N4.1	-3.75	0.000218	0.0412	-0.24	-0.23	Inflammatory biomarkers;	chr2:32169605	chr2:32165046~32165757:-
COAD	cis	rs6723226	0.804	rs17428810	ENSG00000276334.1	AL133243.1	-3.75	0.000218	0.0412	-0.22	-0.23	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32521927~32523547:+
COAD	cis	rs1023500	1	rs1023500	ENSG00000205702.9	CYP2D7	3.75	0.000218	0.0412	0.18	0.23	Schizophrenia;	chr22:41944840	chr22:42140203~42144577:-
COAD	cis	rs1150668	0.768	rs1233713	ENSG00000272009.1	RP1-313I6.12	3.75	0.000218	0.0412	0.25	0.23	Pubertal anthropometrics;	chr6:28230503	chr6:28078792~28081130:-
COAD	cis	rs1707322	0.721	rs11211151	ENSG00000230896.1	RP11-767N6.7	-3.75	0.000218	0.0412	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs12045096	ENSG00000230896.1	RP11-767N6.7	-3.75	0.000218	0.0412	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45694684~45697075:-
COAD	cis	rs2904967	0.598	rs2904978	ENSG00000245532.5	NEAT1	3.75	0.000218	0.0412	0.21	0.23	Mean corpuscular volume;	chr11:65233007	chr11:65422774~65445540:+
COAD	cis	rs11719291	0.667	rs9877542	ENSG00000225399.4	RP11-3B7.1	-3.75	0.000218	0.0412	-0.36	-0.23	Cognitive function;	chr3:48711112	chr3:49260085~49261316:+
COAD	cis	rs7674212	0.539	rs6854709	ENSG00000230069.3	LRRC37A15P	-3.75	0.000218	0.0412	-0.24	-0.23	Type 2 diabetes;	chr4:103208629	chr4:102727274~102730721:-
COAD	cis	rs250677	1	rs36082	ENSG00000250072.4	CTC-529P8.1	-3.75	0.000218	0.0412	-0.33	-0.23	Breast cancer;	chr5:149049281	chr5:149063317~149109787:+
COAD	cis	rs180358	0.945	rs180366	ENSG00000246100.3	LINC00900	-3.75	0.000218	0.0412	-0.23	-0.23	Multiple sclerosis (severity);	chr11:116725040	chr11:115754248~115760627:-
COAD	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-3.75	0.000218	0.0412	-0.34	-0.23	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
COAD	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-3.75	0.000218	0.0413	-0.3	-0.23	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
COAD	cis	rs3796352	1	rs6445557	ENSG00000280417.1	RP11-5O17.1	3.75	0.000218	0.0413	0.32	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53049953	chr3:53046166~53048122:+
COAD	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-3.75	0.000219	0.0413	-0.33	-0.23	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
COAD	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-3.75	0.000219	0.0413	-0.43	-0.23	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
COAD	cis	rs78487399	0.808	rs17030967	ENSG00000234936.1	AC010883.5	3.75	0.000219	0.0413	0.36	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43521844	chr2:43229573~43233394:+
COAD	cis	rs9868809	0.772	rs9836462	ENSG00000225399.4	RP11-3B7.1	3.75	0.000219	0.0413	0.37	0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48675358	chr3:49260085~49261316:+
COAD	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-3.75	0.000219	0.0413	-0.32	-0.23	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
COAD	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-3.75	0.000219	0.0413	-0.32	-0.23	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
COAD	cis	rs12428035	0.772	rs7316996	ENSG00000247400.3	DNAJC3-AS1	-3.75	0.000219	0.0413	-0.24	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95676584	chr13:95648733~95676925:-
COAD	cis	rs12428035	0.772	rs17885081	ENSG00000247400.3	DNAJC3-AS1	-3.75	0.000219	0.0413	-0.24	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95678485	chr13:95648733~95676925:-
COAD	cis	rs12428035	0.772	rs3886352	ENSG00000247400.3	DNAJC3-AS1	-3.75	0.000219	0.0413	-0.24	-0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95680397	chr13:95648733~95676925:-
COAD	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	3.75	0.000219	0.0413	0.32	0.23	Pain;	chr19:21516423	chr19:21554640~21569237:-
COAD	cis	rs7572733	0.935	rs771015	ENSG00000222017.1	AC011997.1	3.75	0.000219	0.0413	0.26	0.23	Dermatomyositis;	chr2:197803570	chr2:197693106~197774823:+
COAD	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	3.75	0.000219	0.0413	0.26	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
COAD	cis	rs13256369	0.708	rs11249886	ENSG00000253981.4	ALG1L13P	3.75	0.000219	0.0413	0.33	0.23	Obesity-related traits;	chr8:8704511	chr8:8236003~8244667:-
COAD	cis	rs13256369	0.802	rs11249887	ENSG00000253981.4	ALG1L13P	3.75	0.000219	0.0413	0.33	0.23	Obesity-related traits;	chr8:8704674	chr8:8236003~8244667:-
COAD	cis	rs734999	0.967	rs6671426	ENSG00000225931.3	RP3-395M20.7	3.75	0.000219	0.0413	0.25	0.23	Ulcerative colitis;	chr1:2572795	chr1:2566410~2569888:+
COAD	cis	rs7760535	0.757	rs10456875	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000219	0.0413	-0.2	-0.23	Metabolic traits;	chr6:111428522	chr6:111277932~111278742:+
COAD	cis	rs9400467	0.528	rs4276544	ENSG00000230177.1	RP5-1112D6.4	-3.75	0.000219	0.0413	-0.2	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111277932~111278742:+
COAD	cis	rs8062405	0.508	rs9929088	ENSG00000261067.5	RP11-264B17.3	-3.75	0.000219	0.0413	-0.17	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28974804~28990783:+
COAD	cis	rs4730250	0.707	rs257375	ENSG00000241764.3	AC002467.7	3.75	0.000219	0.0413	0.3	0.23	Osteoarthritis;	chr7:107158598	chr7:107742817~107744581:-
COAD	cis	rs10876993	0.806	rs1689598	ENSG00000270039.1	RP11-571M6.17	3.75	0.000219	0.0413	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57656717	chr12:57803838~57804415:+
COAD	cis	rs11168351	0.864	rs12228750	ENSG00000269514.1	RP11-370I10.12	-3.75	0.000219	0.0413	-0.26	-0.23	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48198387~48202031:+
COAD	cis	rs11168351	0.864	rs10875743	ENSG00000269514.1	RP11-370I10.12	-3.75	0.000219	0.0413	-0.26	-0.23	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48198387~48202031:+
COAD	cis	rs7686384	0.522	rs11947850	ENSG00000180015.12	RP11-756P10.3	-3.75	0.000219	0.0413	-0.36	-0.23	Obesity-related traits;	chr4:188715133	chr4:188738373~188739494:+
COAD	cis	rs728616	0.614	rs2181204	ENSG00000234382.2	RP11-40F6.1	-3.75	0.000219	0.0413	-0.35	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:80233664~80245367:+
COAD	cis	rs7254192	0.506	rs2305797	ENSG00000187534.6	PRR13P5	3.75	0.000219	0.0414	0.28	0.23	Post bronchodilator FEV1;	chr19:40763171	chr19:39943239~39943680:-
COAD	cis	rs7615952	0.599	rs2270986	ENSG00000248787.1	RP11-666A20.4	-3.75	0.000219	0.0414	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125982256	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.599	rs12496921	ENSG00000248787.1	RP11-666A20.4	-3.75	0.000219	0.0414	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125983105	chr3:125908005~125910272:-
COAD	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000219	0.0414	-0.27	-0.23	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
COAD	cis	rs9302635	0.513	rs12928732	ENSG00000279206.1	RP5-991G20.6	-3.75	0.000219	0.0414	-0.32	-0.23	Blood protein levels;	chr16:72154784	chr16:72772673~72773272:+
COAD	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	3.75	0.000219	0.0414	0.4	0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
COAD	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-3.75	0.000219	0.0414	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
COAD	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-3.75	0.000219	0.0414	-0.32	-0.23	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
COAD	cis	rs5753037	0.869	rs41155	ENSG00000279159.1	RP3-394A18.1	3.75	0.000219	0.0414	0.16	0.23	Type 1 diabetes;	chr22:30008558	chr22:29978950~30028236:-
COAD	cis	rs68170813	0.605	rs10464620	ENSG00000241764.3	AC002467.7	-3.75	0.000219	0.0414	-0.33	-0.23	Coronary artery disease;	chr7:107495208	chr7:107742817~107744581:-
COAD	cis	rs12049351	0.725	rs1328219	ENSG00000229367.1	HMGN2P19	3.75	0.000219	0.0414	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229460513	chr1:229570532~229570796:+
COAD	cis	rs35607894	0.5	rs73293246	ENSG00000266869.1	RP6-114E22.1	3.75	0.000219	0.0414	0.33	0.23	Schizophrenia;	chr14:71995546	chr14:71848606~71908430:+
COAD	cis	rs2836974	0.674	rs1011413	ENSG00000255568.3	BRWD1-AS2	-3.75	0.000219	0.0414	-0.21	-0.23	Cognitive function;	chr21:39266315	chr21:39313935~39314962:+
COAD	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	3.75	0.000219	0.0414	0.29	0.23	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
COAD	cis	rs72827839	0.761	rs79541578	ENSG00000263412.1	RP5-890E16.2	3.75	0.000219	0.0414	0.32	0.23	Ease of getting up in the morning;	chr17:48025362	chr17:48045141~48048073:-
COAD	cis	rs10129255	0.957	rs2013423	ENSG00000224373.3	IGHV4-59	3.75	0.00022	0.0414	0.14	0.23	Kawasaki disease;	chr14:106690675	chr14:106627249~106627825:-
COAD	cis	rs10129255	0.957	rs56134540	ENSG00000224373.3	IGHV4-59	3.75	0.00022	0.0414	0.14	0.23	Kawasaki disease;	chr14:106691290	chr14:106627249~106627825:-
COAD	cis	rs11673344	0.8	rs8108214	ENSG00000267309.1	CTD-2630F21.1	3.75	0.00022	0.0414	0.27	0.23	Obesity-related traits;	chr19:37025184	chr19:36489649~36491040:+
COAD	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	3.75	0.00022	0.0414	0.3	0.23	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	3.75	0.00022	0.0414	0.3	0.23	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
COAD	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-3.75	0.00022	0.0414	-0.27	-0.23	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-3.75	0.00022	0.0414	-0.27	-0.23	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
COAD	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-3.75	0.00022	0.0414	-0.27	-0.23	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
COAD	cis	rs7204230	0.924	rs8058093	ENSG00000261056.2	RP11-454F8.2	3.75	0.00022	0.0414	0.28	0.23	Fibrinogen;	chr16:53309961	chr16:53298224~53299792:+
COAD	cis	rs8016982	0.674	rs1951614	ENSG00000258999.1	RP11-114N19.3	-3.75	0.00022	0.0414	-0.25	-0.23	Schizophrenia;	chr14:81205762	chr14:81107033~81170414:-
COAD	cis	rs7324557	0.684	rs9510871	ENSG00000205861.10	C1QTNF9B-AS1	-3.75	0.00022	0.0414	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23810713	chr13:23888889~23897263:+
COAD	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-3.75	0.00022	0.0414	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
COAD	cis	rs2916733	0.53	rs2442520	ENSG00000246089.3	RP11-115C21.2	-3.75	0.00022	0.0414	-0.31	-0.23	Epirubicin-induced leukopenia;	chr8:6433393	chr8:6403551~6407142:-
COAD	cis	rs7829975	0.5	rs7841082	ENSG00000254340.1	RP11-10A14.3	-3.75	0.00022	0.0414	-0.28	-0.23	Mood instability;	chr8:8311465	chr8:9141424~9145435:+
COAD	cis	rs6598541	0.505	rs12904731	ENSG00000274294.1	RP11-20G13.5	3.75	0.00022	0.0414	0.26	0.23	Urate levels;	chr15:98767727	chr15:99416584~99417204:+
COAD	cis	rs11638352	1	rs4924737	ENSG00000205771.5	CATSPER2P1	3.75	0.00022	0.0414	0.47	0.23	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44072703	chr15:43726918~43747094:-
COAD	cis	rs1510510	0.742	rs35790057	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.3	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238636585	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs12996991	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641161	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs7587609	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641255	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs7587615	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641260	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs7587686	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641292	chr2:238231684~238255633:+
COAD	cis	rs1510510	0.69	rs7599777	ENSG00000225057.2	AC096574.4	3.75	0.00022	0.0415	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238641366	chr2:238231684~238255633:+
COAD	cis	rs5758511	0.773	rs1894714	ENSG00000182057.4	OGFRP1	3.75	0.00022	0.0415	0.26	0.23	Birth weight;	chr22:41953130	chr22:42269753~42275196:+
COAD	cis	rs5758511	0.731	rs5751186	ENSG00000182057.4	OGFRP1	3.75	0.00022	0.0415	0.26	0.23	Birth weight;	chr22:41953706	chr22:42269753~42275196:+
COAD	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-3.75	0.00022	0.0415	-0.28	-0.23	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
COAD	cis	rs875971	1	rs2077593	ENSG00000223473.2	GS1-124K5.3	3.75	0.00022	0.0415	0.19	0.23	Aortic root size;	chr7:66427543	chr7:66491049~66493566:-
COAD	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	3.75	0.00022	0.0415	0.25	0.23	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
COAD	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	3.75	0.00022	0.0415	0.25	0.23	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
COAD	cis	rs4820539	1	rs4822360	ENSG00000211644.2	IGLV1-51	-3.75	0.00022	0.0415	-0.13	-0.23	Bone mineral density;	chr22:23140273	chr22:22322472~22322980:+
COAD	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	3.75	0.00022	0.0415	0.3	0.23	Depression;	chr6:28379133	chr6:28943877~28944537:+
COAD	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	3.75	0.00022	0.0415	0.3	0.23	Depression;	chr6:28379168	chr6:28943877~28944537:+
COAD	cis	rs6661961	0.752	rs4557976	ENSG00000237975.5	FLG-AS1	-3.75	0.00022	0.0415	-0.24	-0.23	Atopic dermatitis;	chr1:152442590	chr1:152168125~152445456:+
COAD	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-3.75	0.00022	0.0415	-0.28	-0.23	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
COAD	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-3.75	0.00022	0.0415	-0.24	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
COAD	cis	rs11743006	0.626	rs17720729	ENSG00000226306.6	NPY6R	3.75	0.00022	0.0415	0.36	0.23	Mathematical ability;	chr5:137174265	chr5:137801193~137810751:+
COAD	cis	rs7615952	0.688	rs9754526	ENSG00000248787.1	RP11-666A20.4	-3.75	0.00022	0.0415	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125824023	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.512	rs34085484	ENSG00000248787.1	RP11-666A20.4	-3.75	0.00022	0.0415	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125825343	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.608	rs35668111	ENSG00000248787.1	RP11-666A20.4	-3.75	0.00022	0.0415	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125825792	chr3:125908005~125910272:-
COAD	cis	rs7204230	1	rs12599823	ENSG00000261056.2	RP11-454F8.2	3.75	0.00022	0.0415	0.28	0.23	Fibrinogen;	chr16:53315316	chr16:53298224~53299792:+
COAD	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	3.75	0.00022	0.0415	0.33	0.23	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
COAD	cis	rs752010	0.746	rs10749837	ENSG00000230638.4	RP11-486B10.4	-3.75	0.000221	0.0415	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41623800	chr1:41542069~41544310:+
COAD	cis	rs752010	0.806	rs11210500	ENSG00000230638.4	RP11-486B10.4	-3.75	0.000221	0.0415	-0.26	-0.23	Lupus nephritis in systemic lupus erythematosus;	chr1:41624066	chr1:41542069~41544310:+
COAD	cis	rs4617927	0.79	rs1477141	ENSG00000263096.1	RP11-515O17.2	3.75	0.000221	0.0415	0.24	0.23	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr17:55284477	chr17:55271504~55273653:-
COAD	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000221	0.0415	-0.26	-0.23	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
COAD	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-3.75	0.000221	0.0415	-0.34	-0.23	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
COAD	cis	rs11168936	1	rs11168936	ENSG00000258017.1	RP11-386G11.10	-3.75	0.000221	0.0416	-0.24	-0.23	Cancer (pleiotropy);	chr12:49251457	chr12:49127782~49147869:+
COAD	cis	rs9888739	0.858	rs60312440	ENSG00000260304.1	RP11-388M20.6	3.75	0.000221	0.0416	0.28	0.23	Systemic lupus erythematosus;	chr16:31328765	chr16:31182511~31183285:-
COAD	cis	rs68170813	0.559	rs77671232	ENSG00000241764.3	AC002467.7	3.75	0.000221	0.0416	0.3	0.23	Coronary artery disease;	chr7:107298757	chr7:107742817~107744581:-
COAD	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	3.75	0.000221	0.0416	0.33	0.23	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
COAD	cis	rs11098499	0.754	rs714899	ENSG00000250412.1	KLHL2P1	3.75	0.000221	0.0416	0.3	0.23	Corneal astigmatism;	chr4:119321880	chr4:119334329~119378233:+
COAD	cis	rs2554380	0.55	rs62025822	ENSG00000176700.18	SCAND2P	3.75	0.000221	0.0416	0.22	0.23	Height;	chr15:83870162	chr15:84631451~84647478:+
COAD	cis	rs2554380	0.55	rs56159777	ENSG00000176700.18	SCAND2P	3.75	0.000221	0.0416	0.22	0.23	Height;	chr15:83870527	chr15:84631451~84647478:+
COAD	cis	rs2554380	0.55	rs4842919	ENSG00000176700.18	SCAND2P	3.75	0.000221	0.0416	0.22	0.23	Height;	chr15:83870668	chr15:84631451~84647478:+
COAD	cis	rs6490294	0.583	rs7314282	ENSG00000257595.2	RP3-473L9.4	3.75	0.000221	0.0416	0.29	0.23	Mean platelet volume;	chr12:112064634	chr12:111369282~111403310:+
COAD	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
COAD	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	3.75	0.000221	0.0416	0.3	0.23	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
COAD	cis	rs9810259	0.522	rs9875338	ENSG00000272263.1	RP11-767C1.2	-3.75	0.000221	0.0416	-0.28	-0.23	Platelet count;	chr3:12254970	chr3:12832219~12832728:-
COAD	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	3.75	0.000221	0.0416	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
COAD	cis	rs9813712	0.597	rs11711883	ENSG00000253540.4	FAM86HP	-3.75	0.000221	0.0416	-0.24	-0.23	Response to amphetamines;	chr3:130241367	chr3:130099092~130111472:-
COAD	cis	rs9813712	0.574	rs62281647	ENSG00000253540.4	FAM86HP	-3.75	0.000221	0.0416	-0.24	-0.23	Response to amphetamines;	chr3:130242670	chr3:130099092~130111472:-
COAD	cis	rs7131987	0.903	rs7308125	ENSG00000275476.1	RP11-996F15.4	-3.75	0.000221	0.0416	-0.27	-0.23	QT interval;	chr12:29272278	chr12:29277397~29277882:-
COAD	cis	rs7555006	0.869	rs2487824	ENSG00000227742.1	CALR4P	3.75	0.000221	0.0416	0.24	0.23	Headache;	chr1:50996767	chr1:51561866~51594897:-
COAD	cis	rs7555006	0.901	rs2487823	ENSG00000227742.1	CALR4P	3.75	0.000221	0.0416	0.24	0.23	Headache;	chr1:50998294	chr1:51561866~51594897:-
COAD	cis	rs9400271	0.527	rs9374083	ENSG00000219700.1	PTCHD3P3	-3.75	0.000221	0.0416	-0.27	-0.23	Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;	chr6:109321754	chr6:109288571~109290503:-
COAD	cis	rs6545883	0.929	rs2593627	ENSG00000273302.1	RP11-493E12.2	-3.75	0.000221	0.0416	-0.23	-0.23	Tuberculosis;	chr2:61391439	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.929	rs10190332	ENSG00000273302.1	RP11-493E12.2	-3.75	0.000221	0.0416	-0.23	-0.23	Tuberculosis;	chr2:61392132	chr2:61199979~61200769:+
COAD	cis	rs11098499	0.691	rs9996644	ENSG00000250412.1	KLHL2P1	3.75	0.000221	0.0417	0.3	0.23	Corneal astigmatism;	chr4:119317722	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.691	rs9996494	ENSG00000250412.1	KLHL2P1	3.75	0.000221	0.0417	0.3	0.23	Corneal astigmatism;	chr4:119317725	chr4:119334329~119378233:+
COAD	cis	rs9311474	0.967	rs610060	ENSG00000243224.1	RP5-1157M23.2	3.75	0.000221	0.0417	0.23	0.23	Electroencephalogram traits;	chr3:52239405	chr3:52239258~52241097:+
COAD	cis	rs4938303	0.788	rs61906112	ENSG00000254851.1	RP11-109L13.1	3.75	0.000221	0.0417	0.3	0.23	Triglycerides;	chr11:116685049	chr11:117135528~117138582:+
COAD	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-3.75	0.000221	0.0417	-0.29	-0.23	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
COAD	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-3.75	0.000221	0.0417	-0.29	-0.23	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
COAD	cis	rs763121	0.819	rs5757126	ENSG00000273076.1	RP3-508I15.22	3.75	0.000221	0.0417	0.21	0.23	Menopause (age at onset);	chr22:38527670	chr22:38743495~38743910:+
COAD	cis	rs4072705	1	rs3739760	ENSG00000224020.1	MIR181A2HG	-3.75	0.000221	0.0417	-0.26	-0.23	Menarche (age at onset);	chr9:124690925	chr9:124658467~124698631:+
COAD	cis	rs913655	0.508	rs2480313	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18774868	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs2480336	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18775807	chr10:18513115~18545651:-
COAD	cis	rs913655	0.508	rs2493622	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18776152	chr10:18513115~18545651:-
COAD	cis	rs913655	0.545	rs2480309	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18776350	chr10:18513115~18545651:-
COAD	cis	rs913655	0.545	rs2493619	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18777926	chr10:18513115~18545651:-
COAD	cis	rs913655	0.545	rs2451512	ENSG00000240291.1	RP11-499P20.2	3.75	0.000222	0.0417	0.26	0.23	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18778181	chr10:18513115~18545651:-
COAD	cis	rs6964833	0.935	rs7795282	ENSG00000127957.15	PMS2P3	-3.75	0.000222	0.0417	-0.23	-0.23	Menarche (age at onset);	chr7:74708526	chr7:75502930~75528148:-
COAD	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	3.75	0.000222	0.0417	0.26	0.23	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
COAD	cis	rs7172689	1	rs58541174	ENSG00000271725.1	RP11-761I4.4	3.75	0.000222	0.0417	0.3	0.23	Inattentive symptoms;	chr15:81251453	chr15:81303215~81309391:-
COAD	cis	rs7172689	1	rs66862541	ENSG00000271725.1	RP11-761I4.4	3.75	0.000222	0.0417	0.3	0.23	Inattentive symptoms;	chr15:81251580	chr15:81303215~81309391:-
COAD	cis	rs7172689	1	rs6495554	ENSG00000271725.1	RP11-761I4.4	3.75	0.000222	0.0417	0.3	0.23	Inattentive symptoms;	chr15:81256040	chr15:81303215~81309391:-
COAD	cis	rs726288	1	rs75024979	ENSG00000230091.5	TMEM254-AS1	3.75	0.000222	0.0417	0.66	0.23	Rheumatoid arthritis;	chr10:79970097	chr10:80046860~80078912:-
COAD	cis	rs80346118	1	rs79044887	ENSG00000177410.11	ZFAS1	-3.75	0.000222	0.0417	-0.28	-0.23	Diastolic blood pressure;	chr20:48811294	chr20:49278178~49295738:+
COAD	cis	rs5758511	0.689	rs56906457	ENSG00000232710.1	RP4-669P10.16	-3.75	0.000222	0.0417	-0.31	-0.23	Birth weight;	chr22:42232329	chr22:42136433~42139927:-
COAD	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-3.75	0.000222	0.0417	-0.32	-0.23	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
COAD	cis	rs13096357	0.52	rs17080319	ENSG00000270441.1	RP11-694I15.7	3.75	0.000222	0.0417	0.36	0.23	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49140086~49160851:-
COAD	cis	rs9880211	0.644	rs35352346	ENSG00000239213.4	NCK1-AS1	3.75	0.000222	0.0417	0.29	0.23	Height;Body mass index;	chr3:136162646	chr3:136841726~136862054:-
COAD	cis	rs801193	0.66	rs2659914	ENSG00000224316.1	RP11-479O9.2	3.75	0.000222	0.0417	0.24	0.23	Aortic root size;	chr7:66691927	chr7:65773620~65802067:+
COAD	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-3.75	0.000222	0.0417	-0.28	-0.23	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
COAD	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-3.75	0.000222	0.0418	-0.25	-0.23	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
COAD	cis	rs3126085	0.935	rs4634913	ENSG00000237975.5	FLG-AS1	-3.75	0.000222	0.0418	-0.25	-0.23	Atopic dermatitis;	chr1:152277456	chr1:152168125~152445456:+
COAD	cis	rs875971	0.571	rs160647	ENSG00000232546.1	RP11-458F8.1	-3.75	0.000222	0.0418	-0.23	-0.23	Aortic root size;	chr7:66089365	chr7:66848496~66858136:+
COAD	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	3.75	0.000222	0.0418	0.3	0.23	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
COAD	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-3.75	0.000222	0.0418	-0.31	-0.23	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
COAD	cis	rs9813712	0.571	rs11715351	ENSG00000253540.4	FAM86HP	-3.75	0.000222	0.0418	-0.24	-0.23	Response to amphetamines;	chr3:130214704	chr3:130099092~130111472:-
COAD	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-3.75	0.000222	0.0418	-0.24	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
COAD	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	3.75	0.000222	0.0418	0.32	0.23	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
COAD	cis	rs7646881	0.544	rs9872682	ENSG00000240207.5	RP11-379F4.4	-3.75	0.000222	0.0418	-0.29	-0.23	Tetralogy of Fallot;	chr3:158592117	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.544	rs13318109	ENSG00000240207.5	RP11-379F4.4	-3.75	0.000222	0.0418	-0.29	-0.23	Tetralogy of Fallot;	chr3:158595417	chr3:158732263~158784070:+
COAD	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-3.75	0.000222	0.0418	-0.25	-0.23	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
COAD	cis	rs9787249	0.957	rs7548120	ENSG00000237624.1	OXCT2P1	-3.75	0.000222	0.0418	-0.3	-0.23	Blood protein levels;	chr1:39738752	chr1:39514956~39516490:+
COAD	cis	rs9787249	0.957	rs3738673	ENSG00000237624.1	OXCT2P1	-3.75	0.000222	0.0418	-0.3	-0.23	Blood protein levels;	chr1:39739151	chr1:39514956~39516490:+
COAD	cis	rs5758511	0.689	rs62240864	ENSG00000226450.2	CYP2D8P	3.75	0.000222	0.0418	0.24	0.23	Birth weight;	chr22:42167883	chr22:42149886~42155001:-
COAD	cis	rs1426063	0.858	rs10004802	ENSG00000249717.1	RP11-44F21.3	3.75	0.000223	0.0418	0.32	0.23	QT interval;	chr4:75084413	chr4:74955974~74970362:-
COAD	cis	rs6095360	0.934	rs2295579	ENSG00000222365.1	SNORD12B	3.75	0.000223	0.0418	0.21	0.23	Intelligence (multi-trait analysis);	chr20:49010199	chr20:49280319~49280409:+
COAD	cis	rs8058578	1	rs8051050	ENSG00000260487.1	RP11-297C4.3	3.75	0.000223	0.0418	0.29	0.23	Multiple myeloma;	chr16:30676588	chr16:30480588~30481346:-
COAD	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	3.75	0.000223	0.0418	0.29	0.23	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
COAD	cis	rs8061903	0.535	rs1366526	ENSG00000261617.1	RP11-243A14.1	3.75	0.000223	0.0419	0.28	0.23	HIV-1 viral setpoint;	chr16:9306825	chr16:9355588~9408093:+
COAD	cis	rs2243480	1	rs73142121	ENSG00000228409.4	CCT6P1	3.75	0.000223	0.0419	0.28	0.23	Diabetic kidney disease;	chr7:65846219	chr7:65751142~65763354:+
COAD	cis	rs2243480	0.803	rs34004500	ENSG00000228409.4	CCT6P1	3.75	0.000223	0.0419	0.28	0.23	Diabetic kidney disease;	chr7:65847191	chr7:65751142~65763354:+
COAD	cis	rs2504916	0.83	rs410926	ENSG00000230234.1	RP1-276N6.2	3.75	0.000223	0.0419	0.31	0.23	Response to hepatitis C treatment;	chr6:160362095	chr6:160272617~160276130:+
COAD	cis	rs2504916	0.793	rs2665354	ENSG00000230234.1	RP1-276N6.2	3.75	0.000223	0.0419	0.31	0.23	Response to hepatitis C treatment;	chr6:160363468	chr6:160272617~160276130:+
COAD	cis	rs2504916	0.83	rs2665353	ENSG00000230234.1	RP1-276N6.2	3.75	0.000223	0.0419	0.31	0.23	Response to hepatitis C treatment;	chr6:160363804	chr6:160272617~160276130:+
COAD	cis	rs2504916	0.83	rs374145	ENSG00000230234.1	RP1-276N6.2	3.75	0.000223	0.0419	0.31	0.23	Response to hepatitis C treatment;	chr6:160364315	chr6:160272617~160276130:+
COAD	cis	rs13256369	0.755	rs11776987	ENSG00000254153.1	CTA-398F10.2	3.75	0.000223	0.0419	0.31	0.23	Obesity-related traits;	chr8:8701891	chr8:8456909~8461337:-
COAD	cis	rs7172689	0.565	rs4344696	ENSG00000271725.1	RP11-761I4.4	3.75	0.000223	0.0419	0.25	0.23	Inattentive symptoms;	chr15:81251154	chr15:81303215~81309391:-
COAD	cis	rs7577696	0.924	rs6747488	ENSG00000272716.1	RP11-563N4.1	-3.74	0.000223	0.0419	-0.24	-0.23	Inflammatory biomarkers;	chr2:32086215	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.962	rs6738349	ENSG00000272716.1	RP11-563N4.1	-3.74	0.000223	0.0419	-0.24	-0.23	Inflammatory biomarkers;	chr2:32089062	chr2:32165046~32165757:-
COAD	cis	rs7335046	1	rs7322759	ENSG00000228889.5	UBAC2-AS1	-3.74	0.000223	0.0419	-0.42	-0.23	Basal cell carcinoma;	chr13:99257424	chr13:99196377~99200710:-
COAD	cis	rs2832191	0.626	rs2254796	ENSG00000176054.6	RPL23P2	-3.74	0.000223	0.0419	-0.23	-0.23	Dental caries;	chr21:28969569	chr21:28997613~28998033:-
COAD	cis	rs6095360	1	rs6019601	ENSG00000227431.4	CSE1L-AS1	-3.74	0.000223	0.0419	-0.25	-0.23	Intelligence (multi-trait analysis);	chr20:49031125	chr20:49040463~49046044:-
COAD	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-3.74	0.000223	0.0419	-0.31	-0.23	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
COAD	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-3.74	0.000223	0.0419	-0.31	-0.23	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
COAD	cis	rs4218	0.588	rs9788719	ENSG00000259732.1	RP11-59H7.3	-3.74	0.000223	0.0419	-0.26	-0.23	Social communication problems;	chr15:59028920	chr15:59121034~59133250:+
COAD	cis	rs9923283	1	rs9937699	ENSG00000205534.6	SMG1P2	-3.74	0.000223	0.0419	-0.4	-0.23	Plateletcrit;	chr16:29642515	chr16:29527568~29594966:-
COAD	cis	rs11018904	0.768	rs35389990	ENSG00000280385.1	AP000648.5	-3.74	0.000223	0.0419	-0.34	-0.23	Intelligence (multi-trait analysis);	chr11:90245515	chr11:90193614~90198120:+
COAD	cis	rs11018904	0.768	rs56160356	ENSG00000280385.1	AP000648.5	-3.74	0.000223	0.0419	-0.34	-0.23	Intelligence (multi-trait analysis);	chr11:90254112	chr11:90193614~90198120:+
COAD	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
COAD	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	3.74	0.000223	0.0419	0.32	0.23	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
COAD	cis	rs875971	0.52	rs160645	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000223	0.0419	-0.23	-0.23	Aortic root size;	chr7:66091320	chr7:66848496~66858136:+
COAD	cis	rs875971	0.789	rs28815324	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000223	0.0419	-0.23	-0.23	Aortic root size;	chr7:66100789	chr7:66848496~66858136:+
COAD	cis	rs9942416	0.858	rs2307111	ENSG00000271815.1	CTD-2235C13.3	-3.74	0.000223	0.0419	-0.28	-0.23	Age-related disease endophenotypes;	chr5:75707853	chr5:75363760~75364242:+
COAD	cis	rs11633886	0.835	rs11637752	ENSG00000273972.1	CTD-2306A12.1	-3.74	0.000223	0.0419	-0.26	-0.23	Diisocyanate-induced asthma;	chr15:45811375	chr15:45702640~45703183:+
COAD	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-3.74	0.000223	0.0419	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
COAD	cis	rs1707322	0.716	rs28375469	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28545085	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28812624	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28507722	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28568986	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.717	rs28396194	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.717	rs28752166	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.717	rs10890345	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs10789471	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs11211173	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000223	0.0419	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45694684~45697075:-
COAD	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	3.74	0.000223	0.0419	0.26	0.23	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	3.74	0.000223	0.0419	0.26	0.23	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
COAD	cis	rs9816784	0.525	rs41301371	ENSG00000207650.1	MIR570	3.74	0.000223	0.0419	0.29	0.23	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195699401~195699497:+
COAD	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	3.74	0.000223	0.0419	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	3.74	0.000223	0.0419	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
COAD	cis	rs6601327	0.613	rs4612345	ENSG00000233609.3	RP11-62H7.2	-3.74	0.000223	0.0419	-0.26	-0.23	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:8961200~8979025:+
COAD	cis	rs17685	0.632	rs1859793	ENSG00000280388.1	RP11-229D13.3	-3.74	0.000223	0.042	-0.23	-0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76043977~76045963:-
COAD	cis	rs73198271	0.74	rs1039911	ENSG00000173295.6	FAM86B3P	-3.74	0.000223	0.042	-0.3	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8228595~8244865:+
COAD	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	3.74	0.000224	0.042	0.2	0.23	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
COAD	cis	rs2307394	0.963	rs13006184	ENSG00000281469.1	RP11-567F11.1	3.74	0.000224	0.042	0.28	0.23	Urate levels;	chr2:147948801	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.928	rs12469015	ENSG00000281469.1	RP11-567F11.1	3.74	0.000224	0.042	0.28	0.23	Urate levels;	chr2:147974381	chr2:148044380~148044894:+
COAD	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	3.74	0.000224	0.042	0.3	0.23	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
COAD	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	3.74	0.000224	0.042	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
COAD	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-3.74	0.000224	0.042	-0.22	-0.23	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
COAD	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	3.74	0.000224	0.042	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
COAD	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-3.74	0.000224	0.042	-0.44	-0.23	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
COAD	cis	rs10876993	0.789	rs1689600	ENSG00000270039.1	RP11-571M6.17	3.74	0.000224	0.042	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57655862	chr12:57803838~57804415:+
COAD	cis	rs875971	0.862	rs1983372	ENSG00000224316.1	RP11-479O9.2	-3.74	0.000224	0.042	-0.24	-0.23	Aortic root size;	chr7:66146364	chr7:65773620~65802067:+
COAD	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-3.74	0.000224	0.042	-0.33	-0.23	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
COAD	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	3.74	0.000224	0.042	0.26	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
COAD	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000224	0.042	-0.31	-0.23	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
COAD	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-3.74	0.000224	0.042	-0.21	-0.23	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
COAD	cis	rs8114671	0.562	rs6088647	ENSG00000228265.4	RALY-AS1	3.74	0.000224	0.042	0.21	0.23	Height;	chr20:34918194	chr20:33983052~33994357:-
COAD	cis	rs8114671	0.562	rs2223881	ENSG00000228265.4	RALY-AS1	3.74	0.000224	0.042	0.21	0.23	Height;	chr20:34918660	chr20:33983052~33994357:-
COAD	cis	rs13188386	0.732	rs6865492	ENSG00000249779.1	RP11-447H19.3	3.74	0.000224	0.042	0.27	0.23	Iron status biomarkers;	chr5:42568290	chr5:43206709~43207811:+
COAD	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	3.74	0.000224	0.042	0.47	0.23	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
COAD	cis	rs13256369	1	rs7843488	ENSG00000173295.6	FAM86B3P	3.74	0.000224	0.042	0.33	0.23	Obesity-related traits;	chr8:8718707	chr8:8228595~8244865:+
COAD	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-3.74	0.000224	0.042	-0.3	-0.23	Pain;	chr19:21543535	chr19:21554640~21569237:-
COAD	cis	rs11168351	0.75	rs11168366	ENSG00000257735.1	RP11-370I10.6	-3.74	0.000224	0.042	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48350945~48442411:+
COAD	cis	rs1850744	0.702	rs6837106	ENSG00000163612.10	FAM86KP	-3.74	0.000224	0.042	-0.59	-0.23	Economic and political preferences;	chr4:9624680	chr4:9153296~9165451:+
COAD	cis	rs2292864	0.764	rs35265764	ENSG00000228782.6	CTD-2026D20.3	-3.74	0.000224	0.042	-0.39	-0.23	Left atrial antero-posterior diameter;	chr17:47286180	chr17:47450568~47492492:-
COAD	cis	rs2919009	0.607	rs72826623	ENSG00000271670.1	RP11-95I16.4	3.74	0.000224	0.042	0.3	0.23	Obesity-related traits;	chr10:120952843	chr10:120879256~120880667:-
COAD	cis	rs2408955	0.561	rs9971924	ENSG00000269514.1	RP11-370I10.12	-3.74	0.000224	0.042	-0.26	-0.23	Glycated hemoglobin levels;	chr12:48086049	chr12:48198387~48202031:+
COAD	cis	rs12188164	0.502	rs55929184	ENSG00000221990.4	EXOC3-AS1	3.74	0.000224	0.0421	0.24	0.23	Cystic fibrosis severity;	chr5:405461	chr5:441498~443160:-
COAD	cis	rs11764590	0.715	rs9639202	ENSG00000225981.1	AC102953.4	3.74	0.000224	0.0421	0.33	0.23	Neuroticism;	chr7:2047680	chr7:1459937~1464008:+
COAD	cis	rs11764590	0.715	rs9969125	ENSG00000225981.1	AC102953.4	3.74	0.000224	0.0421	0.33	0.23	Neuroticism;	chr7:2048825	chr7:1459937~1464008:+
COAD	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-3.74	0.000224	0.0421	-0.29	-0.23	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
COAD	cis	rs4660214	0.666	rs4660550	ENSG00000182109.6	RP11-69E11.4	-3.74	0.000224	0.0421	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39522280~39546187:-
COAD	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	3.74	0.000224	0.0421	0.22	0.23	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
COAD	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-3.74	0.000224	0.0421	-0.26	-0.23	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
COAD	cis	rs476633	0.691	rs28735224	ENSG00000247556.5	OIP5-AS1	3.74	0.000224	0.0421	0.23	0.23	Glomerular filtration rate (creatinine);	chr15:41245341	chr15:41283990~41309737:+
COAD	cis	rs911555	0.755	rs2765049	ENSG00000251533.2	LINC00605	3.74	0.000224	0.0421	0.31	0.23	Intelligence (multi-trait analysis);	chr14:103508702	chr14:103187221~103189028:-
COAD	cis	rs1065852	0.526	rs9611711	ENSG00000270083.1	RP1-257I20.14	-3.74	0.000224	0.0421	-0.23	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42089630~42090028:-
COAD	cis	rs1062753	0.922	rs9611712	ENSG00000270083.1	RP1-257I20.14	-3.74	0.000224	0.0421	-0.23	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42089630~42090028:-
COAD	cis	rs8046148	0.671	rs2160571	ENSG00000260381.2	RP11-429P3.5	-3.74	0.000224	0.0421	-0.29	-0.23	Testicular germ cell tumor;	chr16:50080644	chr16:50100339~50121943:-
COAD	cis	rs28374715	0.733	rs9568	ENSG00000247556.5	OIP5-AS1	3.74	0.000224	0.0421	0.29	0.23	Ulcerative colitis;	chr15:41281414	chr15:41283990~41309737:+
COAD	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	3.74	0.000225	0.0421	0.32	0.23	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
COAD	cis	rs12935418	0.672	rs9889194	ENSG00000278985.1	RP11-303E16.9	3.74	0.000225	0.0421	0.26	0.23	Mean corpuscular volume;	chr16:81017212	chr16:80982319~80984094:-
COAD	cis	rs7487075	0.754	rs10880962	ENSG00000257261.4	RP11-96H19.1	3.74	0.000225	0.0421	0.24	0.23	Itch intensity from mosquito bite;	chr12:46379661	chr12:46383679~46876159:+
COAD	cis	rs2243480	0.901	rs778730	ENSG00000232559.3	GS1-124K5.12	3.74	0.000225	0.0421	0.41	0.23	Diabetic kidney disease;	chr7:66358338	chr7:66554588~66576923:-
COAD	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	3.74	0.000225	0.0422	0.29	0.23	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
COAD	cis	rs4927850	1	rs7630875	ENSG00000185485.13	SDHAP1	3.74	0.000225	0.0422	0.19	0.23	Pancreatic cancer;	chr3:196026895	chr3:195959748~195990318:-
COAD	cis	rs622217	0.656	rs367213	ENSG00000213071.9	LPAL2	3.74	0.000225	0.0422	0.23	0.23	Type 2 diabetes;	chr6:160320862	chr6:160453428~160511124:-
COAD	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	3.74	0.000225	0.0422	0.33	0.23	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
COAD	cis	rs7119	0.651	rs8025968	ENSG00000259565.2	KRT8P23	-3.74	0.000225	0.0422	-0.27	-0.23	Type 2 diabetes;	chr15:77547274	chr15:76979245~76980451:-
COAD	cis	rs3748656	0.945	rs12137269	ENSG00000231246.1	RP5-965F6.2	-3.74	0.000225	0.0422	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112564011	chr1:112177234~112360528:-
COAD	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-3.74	0.000225	0.0422	-0.33	-0.23	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
COAD	cis	rs7810240	1	rs7799903	ENSG00000239377.1	RP4-584D14.6	-3.74	0.000225	0.0422	-0.22	-0.23	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr7:150394365	chr7:150379854~150383885:-
COAD	cis	rs7686384	0.576	rs35975359	ENSG00000180015.12	RP11-756P10.3	-3.74	0.000225	0.0422	-0.36	-0.23	Obesity-related traits;	chr4:188708135	chr4:188738373~188739494:+
COAD	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	3.74	0.000225	0.0422	0.26	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
COAD	cis	rs4927850	1	rs10881564	ENSG00000185485.13	SDHAP1	3.74	0.000225	0.0422	0.2	0.23	Pancreatic cancer;	chr3:196023455	chr3:195959748~195990318:-
COAD	cis	rs10925040	0.666	rs10737808	ENSG00000227135.1	GCSAML-AS1	-3.74	0.000225	0.0422	-0.23	-0.23	Tumor necrosis factor beta levels;	chr1:247459638	chr1:247524679~247526752:-
COAD	cis	rs2980436	1	rs2980436	ENSG00000254340.1	RP11-10A14.3	-3.74	0.000225	0.0422	-0.28	-0.23	Schizophrenia;	chr8:8234503	chr8:9141424~9145435:+
COAD	cis	rs5015933	0.569	rs1463837	ENSG00000232630.1	PRPS1P2	-3.74	0.000225	0.0422	-0.23	-0.23	Body mass index;	chr9:125372936	chr9:125150653~125151589:+
COAD	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	3.74	0.000225	0.0422	0.39	0.23	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
COAD	cis	rs1876905	0.597	rs354546	ENSG00000255389.1	C6orf3	3.74	0.000225	0.0422	0.26	0.23	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111599875~111602295:+
COAD	cis	rs9584850	0.794	rs72655609	ENSG00000231194.1	FARP1-AS1	3.74	0.000225	0.0422	0.3	0.23	Neuroticism;	chr13:98476368	chr13:98435405~98435840:-
COAD	cis	rs6461992	0.51	rs17437154	ENSG00000253308.2	RP1-170O19.17	3.74	0.000225	0.0422	0.56	0.23	Systolic blood pressure;	chr7:27085432	chr7:27239243~27241228:-
COAD	cis	rs2243480	0.706	rs6460257	ENSG00000228409.4	CCT6P1	3.74	0.000225	0.0422	0.25	0.23	Diabetic kidney disease;	chr7:65731813	chr7:65751142~65763354:+
COAD	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	3.74	0.000225	0.0422	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
COAD	cis	rs875971	1	rs7789554	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66481051	chr7:66491049~66493566:-
COAD	cis	rs875971	0.895	rs1974769	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66485627	chr7:66491049~66493566:-
COAD	cis	rs875971	0.895	rs6460300	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66487937	chr7:66491049~66493566:-
COAD	cis	rs875971	0.862	rs7803416	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66489212	chr7:66491049~66493566:-
COAD	cis	rs875971	0.862	rs1981799	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66490572	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs2277911	ENSG00000223473.2	GS1-124K5.3	3.74	0.000225	0.0422	0.19	0.23	Aortic root size;	chr7:66493638	chr7:66491049~66493566:-
COAD	cis	rs6545883	0.86	rs6545848	ENSG00000273302.1	RP11-493E12.2	-3.74	0.000225	0.0422	-0.22	-0.23	Tuberculosis;	chr2:61234048	chr2:61199979~61200769:+
COAD	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-3.74	0.000225	0.0422	-0.33	-0.23	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
COAD	cis	rs3816183	1	rs893730	ENSG00000236533.1	AC009413.2	-3.74	0.000225	0.0422	-0.25	-0.23	Hypospadias;	chr2:42788226	chr2:41850203~41850601:-
COAD	cis	rs6696239	0.513	rs2295994	ENSG00000212237.1	RNA5SP18	-3.74	0.000225	0.0422	-0.24	-0.23	Height;	chr1:227735217	chr1:228647912~228648032:-
COAD	cis	rs1387259	0.619	rs7134565	ENSG00000269514.1	RP11-370I10.12	-3.74	0.000225	0.0422	-0.24	-0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48198387~48202031:+
COAD	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	3.74	0.000225	0.0423	0.29	0.23	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
COAD	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	3.74	0.000225	0.0423	0.29	0.23	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
COAD	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	3.74	0.000225	0.0423	0.29	0.23	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
COAD	cis	rs712022	1	rs10833825	ENSG00000246225.5	RP11-17A1.3	-3.74	0.000225	0.0423	-0.31	-0.23	Dialysis-related mortality;	chr11:22829207	chr11:22829380~22945393:+
COAD	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	3.74	0.000226	0.0423	0.18	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
COAD	cis	rs12049351	0.559	rs6587337	ENSG00000229367.1	HMGN2P19	3.74	0.000226	0.0423	0.34	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229475173	chr1:229570532~229570796:+
COAD	cis	rs8022206	0.738	rs2588832	ENSG00000259502.1	RP11-643G16.3	-3.74	0.000226	0.0423	-0.3	-0.23	Platelet count;Mean platelet volume;	chr14:68136050	chr14:67610986~67613864:+
COAD	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-3.74	0.000226	0.0423	-0.24	-0.23	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-3.74	0.000226	0.0423	-0.24	-0.23	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
COAD	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-3.74	0.000226	0.0423	-0.24	-0.23	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
COAD	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	3.74	0.000226	0.0423	0.46	0.23	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	3.74	0.000226	0.0423	0.46	0.23	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	3.74	0.000226	0.0423	0.46	0.23	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
COAD	cis	rs4819052	1	rs2297286	ENSG00000227039.5	ITGB2-AS1	-3.74	0.000226	0.0423	-0.23	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:44921051~44929678:+
COAD	cis	rs1799949	0.965	rs9646413	ENSG00000279602.1	CTD-3014M21.1	3.74	0.000226	0.0423	0.24	0.23	Menopause (age at onset);	chr17:43348789	chr17:43360041~43361361:-
COAD	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-3.74	0.000226	0.0423	-0.32	-0.23	Pain;	chr19:21454299	chr19:21554640~21569237:-
COAD	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-3.74	0.000226	0.0423	-0.28	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
COAD	cis	rs5753037	0.869	rs4287865	ENSG00000279159.1	RP3-394A18.1	-3.74	0.000226	0.0423	-0.16	-0.23	Type 1 diabetes;	chr22:29911569	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.869	rs737939	ENSG00000279159.1	RP3-394A18.1	-3.74	0.000226	0.0423	-0.16	-0.23	Type 1 diabetes;	chr22:29919427	chr22:29978950~30028236:-
COAD	cis	rs1115240	0.947	rs56150758	ENSG00000257842.4	NOVA1-AS1	3.74	0.000226	0.0423	0.29	0.23	Educational attainment (years of education);	chr14:26636268	chr14:26598412~26806467:+
COAD	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000226	0.0423	-0.3	-0.23	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
COAD	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	3.74	0.000226	0.0423	0.23	0.23	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
COAD	cis	rs6480314	0.522	rs4746756	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68301188	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs10740294	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68301595	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs4363487	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68301809	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs10762214	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68302555	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs12769008	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68302836	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs61857263	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68303370	chr10:68233251~68242379:-
COAD	cis	rs12571093	0.571	rs4517412	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68303779	chr10:68233251~68242379:-
COAD	cis	rs12571093	0.571	rs7097498	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68303780	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.614	rs7067601	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68304213	chr10:68233251~68242379:-
COAD	cis	rs12571093	0.571	rs10740295	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68304313	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs10733843	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68304752	chr10:68233251~68242379:-
COAD	cis	rs6480314	0.522	rs4746760	ENSG00000233590.1	RP11-153K11.3	3.74	0.000226	0.0423	0.27	0.23	Optic nerve measurement (disc area);	chr10:68306122	chr10:68233251~68242379:-
COAD	cis	rs7955901	0.691	rs4505155	ENSG00000258053.1	CTD-2021H9.3	3.74	0.000226	0.0423	0.28	0.23	Type 2 diabetes;	chr12:71126561	chr12:71047402~71118247:-
COAD	cis	rs2732480	0.538	rs2732462	ENSG00000269514.1	RP11-370I10.12	3.74	0.000226	0.0424	0.29	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48198387~48202031:+
COAD	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	3.74	0.000226	0.0424	0.3	0.23	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
COAD	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	3.74	0.000226	0.0424	0.3	0.23	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
COAD	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	3.74	0.000226	0.0424	0.3	0.23	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
COAD	cis	rs2638953	0.711	rs11049605	ENSG00000247934.4	RP11-967K21.1	-3.74	0.000226	0.0424	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443132	chr12:28163298~28190738:-
COAD	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000226	0.0424	-0.31	-0.23	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000226	0.0424	-0.31	-0.23	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000226	0.0424	-0.31	-0.23	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
COAD	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000226	0.0424	-0.31	-0.23	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
COAD	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000226	0.0424	-0.38	-0.23	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
COAD	cis	rs250518	0.735	rs26575	ENSG00000272081.1	CTD-2376I4.2	-3.74	0.000226	0.0424	-0.26	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72998631	chr5:72955206~72955699:-
COAD	cis	rs10876993	0.89	rs774887	ENSG00000270039.1	RP11-571M6.17	3.74	0.000226	0.0424	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57641052	chr12:57803838~57804415:+
COAD	cis	rs11098499	1	rs6849889	ENSG00000250412.1	KLHL2P1	3.74	0.000226	0.0424	0.3	0.23	Corneal astigmatism;	chr4:119265193	chr4:119334329~119378233:+
COAD	cis	rs911555	0.723	rs7144010	ENSG00000251533.2	LINC00605	3.74	0.000226	0.0424	0.29	0.23	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103187221~103189028:-
COAD	cis	rs10876993	0.928	rs1689596	ENSG00000270039.1	RP11-571M6.17	3.74	0.000226	0.0424	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57659246	chr12:57803838~57804415:+
COAD	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	3.74	0.000226	0.0424	0.27	0.23	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
COAD	cis	rs2337406	0.778	rs58113768	ENSG00000280411.1	IGHV1-69-2	-3.74	0.000226	0.0424	-0.17	-0.23	Alzheimer's disease (late onset);	chr14:106700213	chr14:106762092~106762588:-
COAD	cis	rs919433	0.617	rs13018267	ENSG00000222017.1	AC011997.1	-3.74	0.000227	0.0424	-0.29	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197680868	chr2:197693106~197774823:+
COAD	cis	rs17264034	0.8	rs75882443	ENSG00000250786.1	SNHG18	3.74	0.000227	0.0424	0.41	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555985	chr5:9546200~9550609:+
COAD	cis	rs1008375	0.606	rs6828925	ENSG00000249502.1	AC006160.5	-3.74	0.000227	0.0424	-0.27	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17559516	chr4:17587467~17614571:-
COAD	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	3.74	0.000227	0.0424	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
COAD	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-3.74	0.000227	0.0424	-0.27	-0.23	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
COAD	cis	rs11976180	1	rs1320894	ENSG00000273234.1	OR2A13P	-3.74	0.000227	0.0424	-0.27	-0.23	Obesity-related traits;	chr7:144054709	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951369	ENSG00000273234.1	OR2A13P	-3.74	0.000227	0.0424	-0.27	-0.23	Obesity-related traits;	chr7:144055545	chr7:144142009~144142938:+
COAD	cis	rs11976180	1	rs2951364	ENSG00000273234.1	OR2A13P	-3.74	0.000227	0.0424	-0.27	-0.23	Obesity-related traits;	chr7:144057390	chr7:144142009~144142938:+
COAD	cis	rs11969893	0.85	rs9404058	ENSG00000270987.1	RP3-467N11.2	3.74	0.000227	0.0424	0.47	0.23	Economic and political preferences (immigration/crime);	chr6:100875202	chr6:100889603~100890338:+
COAD	cis	rs591584	0.659	rs638397	ENSG00000255893.1	RP11-685N10.1	-3.74	0.000227	0.0424	-0.26	-0.23	Macrophage Migration Inhibitory Factor levels;	chr11:94600942	chr11:94472908~94473570:-
COAD	cis	rs10819861	0.575	rs10760780	ENSG00000238251.2	RP11-172F4.2	3.74	0.000227	0.0424	0.26	0.23	Electrocardiographic traits;	chr9:96110509	chr9:96407284~96407797:+
COAD	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	3.74	0.000227	0.0424	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
COAD	cis	rs2711721	0.56	rs2522268	ENSG00000280054.1	RP1-197B17.7	-3.74	0.000227	0.0425	-0.28	-0.23	Prostate cancer (SNP x SNP interaction);	chr12:47015123	chr12:47728151~47730598:-
COAD	cis	rs9992966	0.85	rs6836750	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187699190	chr4:186890969~186892366:+
COAD	cis	rs5751614	0.537	rs9624074	ENSG00000264629.1	AC244250.4	3.74	0.000227	0.0425	0.21	0.23	Height;	chr22:23283143	chr22:22734575~22734669:+
COAD	cis	rs4699052	0.625	rs11734836	ENSG00000246560.2	RP11-10L12.4	3.74	0.000227	0.0425	0.26	0.23	Testicular germ cell tumor;	chr4:103332046	chr4:102828055~102844075:+
COAD	cis	rs13256369	0.755	rs11776987	ENSG00000253981.4	ALG1L13P	3.74	0.000227	0.0425	0.33	0.23	Obesity-related traits;	chr8:8701891	chr8:8236003~8244667:-
COAD	cis	rs4973517	0.719	rs896990	ENSG00000237126.7	AC073254.1	-3.74	0.000227	0.0425	-0.32	-0.23	Hip circumference adjusted for BMI;	chr2:232024146	chr2:232580948~232611971:-
COAD	cis	rs12049351	0.507	rs41271481	ENSG00000229367.1	HMGN2P19	3.74	0.000227	0.0425	0.32	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229432890	chr1:229570532~229570796:+
COAD	cis	rs9992966	0.85	rs28866907	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187697059	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs12501396	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187697239	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.677	rs9997770	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187697633	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.677	rs9997774	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187697648	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs10030764	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187697771	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs12500738	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187698070	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs10031224	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187698295	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs6836250	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187698817	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs6836899	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187699229	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs4376192	ENSG00000250829.2	RP11-11N5.1	-3.74	0.000227	0.0425	-0.35	-0.23	Trans fatty acid levels;	chr4:187699515	chr4:186890969~186892366:+
COAD	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-3.74	0.000227	0.0425	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-3.74	0.000227	0.0425	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-3.74	0.000227	0.0425	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-3.74	0.000227	0.0425	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
COAD	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-3.74	0.000227	0.0425	-0.24	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
COAD	cis	rs6452524	1	rs6452526	ENSG00000271862.1	RP11-343L5.2	3.74	0.000227	0.0425	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83049376~83050964:-
COAD	cis	rs6452524	1	rs6452527	ENSG00000271862.1	RP11-343L5.2	3.74	0.000227	0.0425	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83049376~83050964:-
COAD	cis	rs6452524	1	rs10055844	ENSG00000271862.1	RP11-343L5.2	3.74	0.000227	0.0425	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83049376~83050964:-
COAD	cis	rs6452524	1	rs10077862	ENSG00000271862.1	RP11-343L5.2	3.74	0.000227	0.0425	0.23	0.23	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83049376~83050964:-
COAD	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000227	0.0425	0.23	0.23	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
COAD	cis	rs1023500	1	rs1023498	ENSG00000237037.8	NDUFA6-AS1	3.74	0.000227	0.0425	0.24	0.23	Schizophrenia;	chr22:41944565	chr22:42090931~42137742:+
COAD	cis	rs11098499	0.909	rs73842633	ENSG00000250412.1	KLHL2P1	3.74	0.000227	0.0425	0.31	0.23	Corneal astigmatism;	chr4:119454309	chr4:119334329~119378233:+
COAD	cis	rs886427	0.838	rs4149782	ENSG00000261123.1	RP11-304L19.3	-3.74	0.000227	0.0425	-0.26	-0.23	Metabolic syndrome;	chr16:2977295	chr16:2094830~2097026:-
COAD	cis	rs1707322	0.821	rs10749857	ENSG00000230896.1	RP11-767N6.7	-3.74	0.000227	0.0425	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45694684~45697075:-
COAD	cis	rs1115240	0.541	rs76913302	ENSG00000257842.4	NOVA1-AS1	3.74	0.000228	0.0425	0.31	0.23	Educational attainment (years of education);	chr14:26471460	chr14:26598412~26806467:+
COAD	cis	rs2919009	0.607	rs41287984	ENSG00000271670.1	RP11-95I16.4	3.74	0.000228	0.0425	0.32	0.23	Obesity-related traits;	chr10:120852958	chr10:120879256~120880667:-
COAD	cis	rs860295	0.557	rs348196	ENSG00000160766.13	GBAP1	-3.74	0.000228	0.0425	-0.26	-0.23	Body mass index;	chr1:155697170	chr1:155213821~155227422:-
COAD	cis	rs893363	0.522	rs2241807	ENSG00000271916.1	RP11-884K10.6	-3.74	0.000228	0.0426	-0.23	-0.23	Axial length;	chr3:53823131	chr3:53797764~53798019:-
COAD	cis	rs735539	0.598	rs2290144	ENSG00000222726.1	RNU2-7P	-3.74	0.000228	0.0426	-0.29	-0.23	Dental caries;	chr13:20691519	chr13:20612161~20612338:+
COAD	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-3.74	0.000228	0.0426	-0.27	-0.23	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
COAD	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	3.74	0.000228	0.0426	0.4	0.23	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
COAD	cis	rs113835537	0.529	rs80100524	ENSG00000258297.1	RP11-658F2.8	-3.74	0.000228	0.0426	-0.24	-0.23	Airway imaging phenotypes;	chr11:66478465	chr11:66666036~66668374:+
COAD	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-3.74	0.000228	0.0426	-0.29	-0.23	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
COAD	cis	rs9513627	0.573	rs12431100	ENSG00000280710.1	RP11-214F16.8	-3.74	0.000228	0.0426	-0.31	-0.23	Obesity-related traits;	chr13:99532664	chr13:99498524~99501315:+
COAD	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	3.74	0.000228	0.0426	0.28	0.23	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
COAD	cis	rs3126085	0.935	rs3120659	ENSG00000237975.5	FLG-AS1	3.74	0.000228	0.0426	0.25	0.23	Atopic dermatitis;	chr1:152320726	chr1:152168125~152445456:+
COAD	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-3.74	0.000228	0.0426	-0.29	-0.23	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
COAD	cis	rs3126085	0.935	rs4511113	ENSG00000237975.5	FLG-AS1	-3.74	0.000228	0.0426	-0.25	-0.23	Atopic dermatitis;	chr1:152249716	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.877	rs7537633	ENSG00000237975.5	FLG-AS1	-3.74	0.000228	0.0426	-0.25	-0.23	Atopic dermatitis;	chr1:152250857	chr1:152168125~152445456:+
COAD	cis	rs3126085	0.935	rs7537637	ENSG00000237975.5	FLG-AS1	-3.74	0.000228	0.0426	-0.25	-0.23	Atopic dermatitis;	chr1:152250859	chr1:152168125~152445456:+
COAD	cis	rs447735	0.565	rs10852626	ENSG00000260279.2	AC137932.5	3.74	0.000228	0.0426	0.22	0.23	Hemoglobin concentration;	chr16:89848225	chr16:89297508~89298317:+
COAD	cis	rs2919009	0.882	rs3011384	ENSG00000271670.1	RP11-95I16.4	3.74	0.000228	0.0426	0.27	0.23	Obesity-related traits;	chr10:120833599	chr10:120879256~120880667:-
COAD	cis	rs7615952	0.599	rs6779141	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000228	0.0426	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125991152	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.599	rs6766327	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000228	0.0426	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126004834	chr3:125908005~125910272:-
COAD	cis	rs7615952	0.599	rs1875683	ENSG00000248787.1	RP11-666A20.4	-3.74	0.000228	0.0426	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126013638	chr3:125908005~125910272:-
COAD	cis	rs4938303	0.671	rs12806224	ENSG00000254851.1	RP11-109L13.1	3.74	0.000228	0.0427	0.31	0.23	Triglycerides;	chr11:116682098	chr11:117135528~117138582:+
COAD	cis	rs4938303	0.788	rs12805061	ENSG00000254851.1	RP11-109L13.1	3.74	0.000228	0.0427	0.31	0.23	Triglycerides;	chr11:116682308	chr11:117135528~117138582:+
COAD	cis	rs1065852	0.526	rs12166549	ENSG00000270083.1	RP1-257I20.14	-3.74	0.000228	0.0427	-0.23	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42089630~42090028:-
COAD	cis	rs1552244	0.882	rs13063929	ENSG00000186162.9	CIDECP	3.74	0.000228	0.0427	0.32	0.23	Alzheimer's disease;	chr3:9968624	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.832	rs3732968	ENSG00000186162.9	CIDECP	3.74	0.000228	0.0427	0.32	0.23	Alzheimer's disease;	chr3:9971589	chr3:10014238~10026365:-
COAD	cis	rs68170813	0.641	rs12534124	ENSG00000241764.3	AC002467.7	3.74	0.000228	0.0427	0.33	0.23	Coronary artery disease;	chr7:107478602	chr7:107742817~107744581:-
COAD	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	3.74	0.000229	0.0427	0.17	0.23	Breast size;	chr12:9220132	chr12:9277235~9313241:+
COAD	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-3.74	0.000229	0.0427	-0.24	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
COAD	cis	rs10779751	1	rs7549109	ENSG00000215785.2	CFL1P6	3.74	0.000229	0.0427	0.25	0.23	Body mass index;	chr1:11218756	chr1:10990978~10991797:-
COAD	cis	rs6095360	0.615	rs17445665	ENSG00000222365.1	SNORD12B	3.74	0.000229	0.0427	0.23	0.23	Intelligence (multi-trait analysis);	chr20:48893954	chr20:49280319~49280409:+
COAD	cis	rs2554380	0.527	rs7164782	ENSG00000176700.18	SCAND2P	-3.74	0.000229	0.0427	-0.22	-0.23	Height;	chr15:83833447	chr15:84631451~84647478:+
COAD	cis	rs1790761	0.933	rs1790752	ENSG00000231793.4	DOC2GP	-3.74	0.000229	0.0427	-0.25	-0.23	Mean corpuscular volume;	chr11:67434573	chr11:67612653~67616257:-
COAD	cis	rs1790761	0.967	rs13859	ENSG00000231793.4	DOC2GP	-3.74	0.000229	0.0427	-0.25	-0.23	Mean corpuscular volume;	chr11:67434685	chr11:67612653~67616257:-
COAD	cis	rs734999	0.505	rs4073285	ENSG00000225931.3	RP3-395M20.7	3.74	0.000229	0.0427	0.25	0.23	Ulcerative colitis;	chr1:2608357	chr1:2566410~2569888:+
COAD	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-3.74	0.000229	0.0427	-0.23	-0.23	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
COAD	cis	rs8114671	0.562	rs1801310	ENSG00000228265.4	RALY-AS1	3.74	0.000229	0.0427	0.21	0.23	Height;	chr20:34929211	chr20:33983052~33994357:-
COAD	cis	rs6762	0.748	rs7928935	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000229	0.0427	0.23	0.23	Mean platelet volume;	chr11:839127	chr11:779617~780755:+
COAD	cis	rs6762	0.692	rs7928925	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000229	0.0427	0.23	0.23	Mean platelet volume;	chr11:839155	chr11:779617~780755:+
COAD	cis	rs6762	0.719	rs7936806	ENSG00000279672.1	CMB9-55F22.1	3.74	0.000229	0.0427	0.23	0.23	Mean platelet volume;	chr11:839186	chr11:779617~780755:+
COAD	cis	rs3126085	0.935	rs7550106	ENSG00000237975.5	FLG-AS1	3.74	0.000229	0.0427	0.25	0.23	Atopic dermatitis;	chr1:152224726	chr1:152168125~152445456:+
COAD	cis	rs7656342	0.622	rs13105954	ENSG00000186234.7	FAM86MP	-3.74	0.000229	0.0427	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr4:9866793	chr4:9692495~9702954:+
COAD	cis	rs6589219	0.908	rs3087967	ENSG00000196167.8	COLCA1	3.74	0.000229	0.0428	0.26	0.23	Colorectal cancer;	chr11:111286111	chr11:111290787~111305045:-
COAD	cis	rs6598541	0.505	rs2137680	ENSG00000274294.1	RP11-20G13.5	3.74	0.000229	0.0428	0.26	0.23	Urate levels;	chr15:98769512	chr15:99416584~99417204:+
COAD	cis	rs6598541	0.505	rs2175795	ENSG00000274294.1	RP11-20G13.5	3.74	0.000229	0.0428	0.26	0.23	Urate levels;	chr15:98769625	chr15:99416584~99417204:+
COAD	cis	rs6973609	0.544	rs6949262	ENSG00000271122.1	RP11-379H18.1	3.74	0.000229	0.0428	0.22	0.23	Obesity-related traits;	chr7:35547410	chr7:35695214~35699413:+
COAD	cis	rs7674212	0.57	rs6813563	ENSG00000246560.2	RP11-10L12.4	3.74	0.000229	0.0428	0.26	0.23	Type 2 diabetes;	chr4:103177953	chr4:102828055~102844075:+
COAD	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	3.74	0.000229	0.0428	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
COAD	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	3.74	0.000229	0.0428	0.44	0.23	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
COAD	cis	rs801193	0.569	rs35070132	ENSG00000224316.1	RP11-479O9.2	3.74	0.000229	0.0428	0.25	0.23	Aortic root size;	chr7:66773096	chr7:65773620~65802067:+
COAD	cis	rs7759001	0.857	rs4455661	ENSG00000224843.5	LINC00240	-3.74	0.000229	0.0428	-0.3	-0.23	Glomerular filtration rate (creatinine);	chr6:27405351	chr6:26956992~27023924:+
COAD	cis	rs4760786	0.898	rs11178543	ENSG00000258053.1	CTD-2021H9.3	-3.74	0.000229	0.0428	-0.32	-0.23	Monobrow;	chr12:71035527	chr12:71047402~71118247:-
COAD	cis	rs6095360	0.644	rs35269800	ENSG00000222365.1	SNORD12B	-3.74	0.000229	0.0428	-0.23	-0.23	Intelligence (multi-trait analysis);	chr20:48896484	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.615	rs2869689	ENSG00000222365.1	SNORD12B	-3.74	0.000229	0.0428	-0.23	-0.23	Intelligence (multi-trait analysis);	chr20:48898389	chr20:49280319~49280409:+
COAD	cis	rs6095360	0.615	rs6019506	ENSG00000222365.1	SNORD12B	-3.74	0.000229	0.0428	-0.23	-0.23	Intelligence (multi-trait analysis);	chr20:48899655	chr20:49280319~49280409:+
COAD	cis	rs12049351	0.613	rs3738185	ENSG00000229367.1	HMGN2P19	3.74	0.000229	0.0428	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229499520	chr1:229570532~229570796:+
COAD	cis	rs12049351	0.774	rs12033713	ENSG00000229367.1	HMGN2P19	3.74	0.000229	0.0428	0.33	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229502693	chr1:229570532~229570796:+
COAD	cis	rs7204230	0.96	rs12596238	ENSG00000261056.2	RP11-454F8.2	3.74	0.000229	0.0428	0.27	0.23	Fibrinogen;	chr16:53320819	chr16:53298224~53299792:+
COAD	cis	rs911555	0.713	rs11848796	ENSG00000251533.2	LINC00605	-3.74	0.00023	0.0428	-0.3	-0.23	Intelligence (multi-trait analysis);	chr14:103512349	chr14:103187221~103189028:-
COAD	cis	rs2732480	0.5	rs7297824	ENSG00000269514.1	RP11-370I10.12	3.74	0.00023	0.0429	0.27	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48198387~48202031:+
COAD	cis	rs6142618	0.583	rs6119771	ENSG00000224452.1	RSL24D1P6	3.74	0.00023	0.0429	0.26	0.23	Inflammatory bowel disease;	chr20:32182572	chr20:32170390~32170790:-
COAD	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.00023	0.0429	-0.33	-0.23	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
COAD	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-3.74	0.00023	0.0429	-0.33	-0.23	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
COAD	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-3.74	0.00023	0.0429	-0.24	-0.23	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
COAD	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-3.74	0.00023	0.0429	-0.3	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
COAD	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-3.74	0.00023	0.0429	-0.25	-0.23	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
COAD	cis	rs875971	1	rs709595	ENSG00000223473.2	GS1-124K5.3	3.74	0.00023	0.0429	0.18	0.23	Aortic root size;	chr7:66352346	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs811880	ENSG00000223473.2	GS1-124K5.3	3.74	0.00023	0.0429	0.18	0.23	Aortic root size;	chr7:66353659	chr7:66491049~66493566:-
COAD	cis	rs6715284	0.892	rs56828879	ENSG00000232133.1	IMPDH1P10	-3.74	0.00023	0.0429	-0.44	-0.23	Rheumatoid arthritis;	chr2:201376600	chr2:201137516~201140027:-
COAD	cis	rs7646881	0.544	rs7638606	ENSG00000240207.5	RP11-379F4.4	-3.74	0.00023	0.0429	-0.29	-0.23	Tetralogy of Fallot;	chr3:158569050	chr3:158732263~158784070:+
COAD	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-3.74	0.00023	0.0429	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
COAD	cis	rs11992186	0.597	rs11781841	ENSG00000173295.6	FAM86B3P	-3.74	0.00023	0.0429	-0.28	-0.23	Neuroticism;	chr8:8737753	chr8:8228595~8244865:+
COAD	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-3.74	0.00023	0.0429	-0.28	-0.23	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
COAD	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-3.74	0.00023	0.0429	-0.28	-0.23	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
COAD	cis	rs860295	0.702	rs2025669	ENSG00000160766.13	GBAP1	-3.74	0.00023	0.0429	-0.28	-0.23	Body mass index;	chr1:155387818	chr1:155213821~155227422:-
COAD	cis	rs860295	0.702	rs12081067	ENSG00000160766.13	GBAP1	-3.74	0.00023	0.0429	-0.28	-0.23	Body mass index;	chr1:155389191	chr1:155213821~155227422:-
COAD	cis	rs860295	0.702	rs56675301	ENSG00000160766.13	GBAP1	-3.74	0.00023	0.0429	-0.28	-0.23	Body mass index;	chr1:155394536	chr1:155213821~155227422:-
COAD	cis	rs860295	0.702	rs10908465	ENSG00000160766.13	GBAP1	-3.74	0.00023	0.0429	-0.28	-0.23	Body mass index;	chr1:155419897	chr1:155213821~155227422:-
COAD	cis	rs2243480	1	rs313799	ENSG00000232559.3	GS1-124K5.12	3.74	0.00023	0.0429	0.39	0.23	Diabetic kidney disease;	chr7:66029343	chr7:66554588~66576923:-
COAD	cis	rs7009110	0.681	rs13275219	ENSG00000213791.4	RP11-941H19.2	3.74	0.00023	0.0429	0.24	0.23	Asthma and hay fever;	chr8:80347591	chr8:80300869~80301481:+
COAD	cis	rs11098499	0.691	rs10028773	ENSG00000249244.1	RP11-548H18.2	-3.74	0.00023	0.0429	-0.29	-0.23	Corneal astigmatism;	chr4:119344104	chr4:119391831~119395335:-
COAD	cis	rs2243480	1	rs3885839	ENSG00000275400.1	RP4-756H11.5	3.74	0.00023	0.0429	0.39	0.23	Diabetic kidney disease;	chr7:65825416	chr7:66553805~66554199:-
COAD	cis	rs17407555	0.609	rs10032742	ENSG00000250413.1	RP11-448G15.1	-3.74	0.00023	0.0429	-0.31	-0.23	Schizophrenia (age at onset);	chr4:10277269	chr4:10006482~10009725:+
COAD	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-3.74	0.00023	0.0429	-0.24	-0.23	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
COAD	cis	rs11098499	0.604	rs2389882	ENSG00000250412.1	KLHL2P1	3.74	0.00023	0.0429	0.31	0.23	Corneal astigmatism;	chr4:119645578	chr4:119334329~119378233:+
COAD	cis	rs34929064	0.881	rs2961310	ENSG00000179428.2	AC073072.5	-3.74	0.00023	0.043	-0.24	-0.23	Major depression and alcohol dependence;	chr7:22684788	chr7:22725395~22727620:-
COAD	cis	rs6095360	1	rs6512567	ENSG00000227431.4	CSE1L-AS1	-3.74	0.00023	0.043	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49072083	chr20:49040463~49046044:-
COAD	cis	rs7911712	0.873	rs11812151	ENSG00000165511.6	C10orf25	3.74	0.00023	0.043	0.39	0.23	Emphysema-related traits;	chr10:44819558	chr10:44997698~45000888:-
COAD	cis	rs9393777	0.778	rs13212921	ENSG00000224843.5	LINC00240	3.74	0.00023	0.043	0.51	0.23	Intelligence (multi-trait analysis);	chr6:27237643	chr6:26956992~27023924:+
COAD	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	3.74	0.00023	0.043	0.27	0.23	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
COAD	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-3.74	0.00023	0.043	-0.3	-0.23	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
COAD	cis	rs12428035	0.764	rs816142	ENSG00000247400.3	DNAJC3-AS1	3.74	0.00023	0.043	0.24	0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95986382	chr13:95648733~95676925:-
COAD	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-3.74	0.000231	0.043	-0.27	-0.23	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
COAD	cis	rs11633886	0.835	rs2413793	ENSG00000273972.1	CTD-2306A12.1	-3.74	0.000231	0.043	-0.26	-0.23	Diisocyanate-induced asthma;	chr15:45810619	chr15:45702640~45703183:+
COAD	cis	rs11633886	0.835	rs2413794	ENSG00000273972.1	CTD-2306A12.1	-3.74	0.000231	0.043	-0.26	-0.23	Diisocyanate-induced asthma;	chr15:45810812	chr15:45702640~45703183:+
COAD	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-3.74	0.000231	0.043	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
COAD	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000231	0.043	-0.29	-0.23	Gout;	chr7:66721259	chr7:66848496~66858136:+
COAD	cis	rs728616	0.681	rs55838345	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000231	0.043	-0.37	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79663088~79826594:-
COAD	cis	rs728616	0.614	rs61859191	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000231	0.043	-0.37	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79663088~79826594:-
COAD	cis	rs10949834	0.793	rs810532	ENSG00000123965.13	PMS2P5	3.74	0.000231	0.043	0.38	0.23	Verbal memory performance (residualized delayed recall change);	chr7:74090858	chr7:74894116~74897835:+
COAD	cis	rs2991971	0.967	rs512026	ENSG00000280836.1	AL355480.1	3.74	0.000231	0.043	0.25	0.23	High light scatter reticulocyte count;	chr1:45544274	chr1:45581219~45581321:-
COAD	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-3.74	0.000231	0.043	-0.28	-0.23	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
COAD	cis	rs7577696	0.695	rs12997026	ENSG00000272716.1	RP11-563N4.1	-3.74	0.000231	0.043	-0.23	-0.23	Inflammatory biomarkers;	chr2:32169238	chr2:32165046~32165757:-
COAD	cis	rs9652601	0.648	rs7197422	ENSG00000274038.1	RP11-66H6.4	-3.74	0.000231	0.043	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11027214	chr16:11056556~11057034:+
COAD	cis	rs4072705	0.967	rs10739651	ENSG00000236643.1	RP11-175D17.3	3.74	0.000231	0.043	0.24	0.23	Menarche (age at onset);	chr9:124561794	chr9:124770123~124772927:+
COAD	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-3.74	0.000231	0.043	-0.29	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
COAD	cis	rs728616	0.681	rs35420115	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000231	0.043	-0.39	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79663088~79826594:-
COAD	cis	rs911555	0.755	rs12432803	ENSG00000251533.2	LINC00605	3.74	0.000231	0.043	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103187221~103189028:-
COAD	cis	rs3018712	0.532	rs2510398	ENSG00000184795.9	UNC93B5	-3.74	0.000231	0.043	-0.38	-0.23	Total body bone mineral density;	chr11:68653948	chr11:67711702~67716005:-
COAD	cis	rs6840360	0.516	rs6535794	ENSG00000251611.1	RP11-610P16.1	-3.74	0.000231	0.0431	-0.22	-0.23	Intelligence (multi-trait analysis);	chr4:151381631	chr4:151407551~151408835:-
COAD	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000231	0.0431	-0.29	-0.23	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
COAD	cis	rs875971	0.545	rs73152714	ENSG00000232546.1	RP11-458F8.1	3.74	0.000231	0.0431	0.22	0.23	Aortic root size;	chr7:66534641	chr7:66848496~66858136:+
COAD	cis	rs875971	0.545	rs801199	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000231	0.0431	-0.22	-0.23	Aortic root size;	chr7:66560286	chr7:66848496~66858136:+
COAD	cis	rs4604732	0.631	rs4411161	ENSG00000227135.1	GCSAML-AS1	-3.74	0.000231	0.0431	-0.32	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469072	chr1:247524679~247526752:-
COAD	cis	rs34286592	0.929	rs1045968	ENSG00000214725.6	CDIPT-AS1	-3.74	0.000231	0.0431	-0.4	-0.23	Multiple sclerosis;	chr16:29815044	chr16:29863593~29868053:+
COAD	cis	rs2128382	0.769	rs17276203	ENSG00000280543.1	ASAP1-IT2	3.74	0.000231	0.0431	0.27	0.23	Colorectal cancer;	chr8:129805784	chr8:130082738~130084768:-
COAD	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000231	0.0431	-0.31	-0.23	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
COAD	cis	rs735539	0.645	rs6490601	ENSG00000222726.1	RNU2-7P	-3.74	0.000231	0.0431	-0.3	-0.23	Dental caries;	chr13:20671758	chr13:20612161~20612338:+
COAD	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	3.74	0.000231	0.0431	0.3	0.23	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
COAD	cis	rs7142002	0.527	rs58186728	ENSG00000272444.1	RP11-1017G21.6	-3.73	0.000231	0.0431	-0.31	-0.23	Autism;	chr14:101922824	chr14:101952416~101953063:+
COAD	cis	rs7142002	0.568	rs56701068	ENSG00000272444.1	RP11-1017G21.6	-3.73	0.000231	0.0431	-0.31	-0.23	Autism;	chr14:101922903	chr14:101952416~101953063:+
COAD	cis	rs7142002	0.568	rs58337996	ENSG00000272444.1	RP11-1017G21.6	-3.73	0.000231	0.0431	-0.31	-0.23	Autism;	chr14:101922950	chr14:101952416~101953063:+
COAD	cis	rs7142002	0.568	rs58304956	ENSG00000272444.1	RP11-1017G21.6	-3.73	0.000231	0.0431	-0.31	-0.23	Autism;	chr14:101923434	chr14:101952416~101953063:+
COAD	cis	rs7142002	0.568	rs7158886	ENSG00000272444.1	RP11-1017G21.6	-3.73	0.000231	0.0431	-0.31	-0.23	Autism;	chr14:101923615	chr14:101952416~101953063:+
COAD	cis	rs9467711	0.651	rs72832596	ENSG00000224843.5	LINC00240	3.73	0.000231	0.0431	0.51	0.23	Autism spectrum disorder or schizophrenia;	chr6:25962723	chr6:26956992~27023924:+
COAD	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-3.73	0.000231	0.0431	-0.46	-0.23	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
COAD	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	3.73	0.000231	0.0431	0.15	0.23	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
COAD	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	3.73	0.000231	0.0431	0.42	0.23	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
COAD	cis	rs3748656	0.945	rs35023236	ENSG00000231246.1	RP5-965F6.2	-3.73	0.000231	0.0431	-0.31	-0.23	Hip circumference adjusted for BMI;	chr1:112542830	chr1:112177234~112360528:-
COAD	cis	rs11168351	0.75	rs11168366	ENSG00000269514.1	RP11-370I10.12	-3.73	0.000231	0.0431	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48198387~48202031:+
COAD	cis	rs12699921	0.599	rs6973480	ENSG00000279048.1	RP11-511H23.2	3.73	0.000231	0.0431	0.17	0.23	Fibrinogen levels;	chr7:17938506	chr7:17940503~17942922:+
COAD	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	3.73	0.000231	0.0431	0.27	0.23	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
COAD	cis	rs6480314	0.522	rs61857273	ENSG00000233590.1	RP11-153K11.3	-3.73	0.000231	0.0431	-0.32	-0.23	Optic nerve measurement (disc area);	chr10:68307530	chr10:68233251~68242379:-
COAD	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-3.73	0.000232	0.0431	-0.23	-0.23	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
COAD	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-3.73	0.000232	0.0431	-0.2	-0.23	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
COAD	cis	rs6088813	0.702	rs2425060	ENSG00000269202.1	RP4-614O4.12	-3.73	0.000232	0.0431	-0.21	-0.23	Height;	chr20:35326898	chr20:35201747~35203288:-
COAD	cis	rs12165098	0.852	rs12970252	ENSG00000267374.1	RP11-244M2.1	-3.73	0.000232	0.0431	-0.44	-0.23	Sleep duration;	chr18:39236550	chr18:39206924~39800318:-
COAD	cis	rs7572733	0.84	rs700655	ENSG00000222017.1	AC011997.1	3.73	0.000232	0.0431	0.26	0.23	Dermatomyositis;	chr2:197778907	chr2:197693106~197774823:+
COAD	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-3.73	0.000232	0.0431	-0.24	-0.23	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
COAD	cis	rs7119	0.679	rs12914932	ENSG00000259565.2	KRT8P23	-3.73	0.000232	0.0432	-0.27	-0.23	Type 2 diabetes;	chr15:77546709	chr15:76979245~76980451:-
COAD	cis	rs7119	0.651	rs8041520	ENSG00000259565.2	KRT8P23	-3.73	0.000232	0.0432	-0.27	-0.23	Type 2 diabetes;	chr15:77546827	chr15:76979245~76980451:-
COAD	cis	rs34779708	0.931	rs11596502	ENSG00000271335.4	RP11-324I22.4	3.73	0.000232	0.0432	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35314552~35336401:-
COAD	cis	rs7802124	0.583	rs7804372	ENSG00000237974.1	AC000111.4	3.73	0.000232	0.0432	0.24	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr7:116554174	chr7:117487737~117487929:+
COAD	cis	rs1023500	0.551	rs133371	ENSG00000232710.1	RP4-669P10.16	-3.73	0.000232	0.0432	-0.23	-0.23	Schizophrenia;	chr22:42069570	chr22:42136433~42139927:-
COAD	cis	rs1023500	0.573	rs133374	ENSG00000232710.1	RP4-669P10.16	-3.73	0.000232	0.0432	-0.23	-0.23	Schizophrenia;	chr22:42069937	chr22:42136433~42139927:-
COAD	cis	rs9532669	0.926	rs9532693	ENSG00000277662.1	RP11-74J13.9	-3.73	0.000232	0.0432	-0.22	-0.23	Cervical cancer;	chr13:40980557	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs2324748	ENSG00000277662.1	RP11-74J13.9	-3.73	0.000232	0.0432	-0.22	-0.23	Cervical cancer;	chr13:40989452	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs4245311	ENSG00000277662.1	RP11-74J13.9	-3.73	0.000232	0.0432	-0.22	-0.23	Cervical cancer;	chr13:40990003	chr13:41229180~41229676:-
COAD	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	3.73	0.000232	0.0432	0.4	0.23	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
COAD	cis	rs4072705	0.967	rs4240486	ENSG00000236643.1	RP11-175D17.3	3.73	0.000232	0.0432	0.24	0.23	Menarche (age at onset);	chr9:124578831	chr9:124770123~124772927:+
COAD	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	3.73	0.000232	0.0432	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
COAD	cis	rs875971	1	rs4717300	ENSG00000223473.2	GS1-124K5.3	3.73	0.000232	0.0432	0.19	0.23	Aortic root size;	chr7:66482393	chr7:66491049~66493566:-
COAD	cis	rs875971	0.895	rs4718349	ENSG00000223473.2	GS1-124K5.3	3.73	0.000232	0.0432	0.19	0.23	Aortic root size;	chr7:66444024	chr7:66491049~66493566:-
COAD	cis	rs860295	1	rs822478	ENSG00000223503.1	RP11-29H23.6	3.73	0.000232	0.0432	0.3	0.23	Body mass index;	chr1:155824178	chr1:155590601~155591262:-
COAD	cis	rs1850744	0.702	rs10939427	ENSG00000163612.10	FAM86KP	-3.73	0.000232	0.0432	-0.59	-0.23	Economic and political preferences;	chr4:9626914	chr4:9153296~9165451:+
COAD	cis	rs7324557	1	rs7324557	ENSG00000205861.10	C1QTNF9B-AS1	3.73	0.000232	0.0432	0.29	0.23	Visceral adipose tissue adjusted for BMI;	chr13:23722723	chr13:23888889~23897263:+
COAD	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	3.73	0.000232	0.0432	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
COAD	cis	rs4973517	0.719	rs35020669	ENSG00000237126.7	AC073254.1	3.73	0.000232	0.0432	0.32	0.23	Hip circumference adjusted for BMI;	chr2:231976352	chr2:232580948~232611971:-
COAD	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000232	0.0432	0.24	0.23	Height;	chr4:55537960	chr4:55363971~55395847:-
COAD	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-3.73	0.000232	0.0433	-0.22	-0.23	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
COAD	cis	rs1115240	0.574	rs17111258	ENSG00000257842.4	NOVA1-AS1	3.73	0.000233	0.0433	0.3	0.23	Educational attainment (years of education);	chr14:26464654	chr14:26598412~26806467:+
COAD	cis	rs2765539	0.515	rs2788183	ENSG00000231365.4	RP11-418J17.1	-3.73	0.000233	0.0433	-0.28	-0.23	Waist-hip ratio;	chr1:118929322	chr1:119140396~119275973:+
COAD	cis	rs28374715	0.532	rs28477406	ENSG00000247556.5	OIP5-AS1	3.73	0.000233	0.0433	0.33	0.23	Ulcerative colitis;	chr15:41349838	chr15:41283990~41309737:+
COAD	cis	rs73222236	0.825	rs6804194	ENSG00000273486.1	RP11-731C17.2	3.73	0.000233	0.0433	0.23	0.23	Coronary artery disease;	chr3:136441890	chr3:136837338~136839021:-
COAD	cis	rs875971	0.893	rs62465470	ENSG00000224316.1	RP11-479O9.2	-3.73	0.000233	0.0433	-0.25	-0.23	Aortic root size;	chr7:66136231	chr7:65773620~65802067:+
COAD	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	3.73	0.000233	0.0433	0.29	0.23	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
COAD	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	3.73	0.000233	0.0433	0.27	0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
COAD	cis	rs4973517	0.719	rs3100603	ENSG00000237126.7	AC073254.1	-3.73	0.000233	0.0433	-0.32	-0.23	Hip circumference adjusted for BMI;	chr2:232010973	chr2:232580948~232611971:-
COAD	cis	rs4973517	0.685	rs4973027	ENSG00000237126.7	AC073254.1	-3.73	0.000233	0.0433	-0.32	-0.23	Hip circumference adjusted for BMI;	chr2:232011490	chr2:232580948~232611971:-
COAD	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-3.73	0.000233	0.0433	-0.29	-0.23	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
COAD	cis	rs7955901	0.725	rs7313668	ENSG00000258053.1	CTD-2021H9.3	3.73	0.000233	0.0433	0.29	0.23	Type 2 diabetes;	chr12:71055741	chr12:71047402~71118247:-
COAD	cis	rs78487399	0.808	rs75386849	ENSG00000234936.1	AC010883.5	3.73	0.000233	0.0433	0.38	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43496144	chr2:43229573~43233394:+
COAD	cis	rs7656342	0.755	rs1320054	ENSG00000186234.7	FAM86MP	-3.73	0.000233	0.0433	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr4:9868501	chr4:9692495~9702954:+
COAD	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-3.73	0.000233	0.0433	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
COAD	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-3.73	0.000233	0.0433	-0.21	-0.23	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
COAD	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
COAD	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
COAD	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	3.73	0.000233	0.0433	0.4	0.23	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
COAD	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-3.73	0.000233	0.0433	-0.31	-0.23	Pain;	chr19:21491155	chr19:21554640~21569237:-
COAD	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-3.73	0.000233	0.0434	-0.26	-0.23	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
COAD	cis	rs5751168	0.831	rs5758484	ENSG00000211660.3	IGLV2-23	-3.73	0.000233	0.0434	-0.15	-0.23	Prostate cancer (SNP x SNP interaction);	chr22:22490315	chr22:22697789~22698407:+
COAD	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-3.73	0.000233	0.0434	-0.43	-0.23	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
COAD	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	3.73	0.000233	0.0434	0.26	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
COAD	cis	rs2496589	0.963	rs12215709	ENSG00000218896.1	TUBB8P2	3.73	0.000233	0.0434	0.28	0.23	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143446983	chr6:143436216~143436710:+
COAD	cis	rs7615952	0.932	rs13065725	ENSG00000272840.1	RP11-379B18.6	3.73	0.000233	0.0434	0.35	0.23	Blood pressure (smoking interaction);	chr3:125913446	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.551	rs6438945	ENSG00000272840.1	RP11-379B18.6	3.73	0.000233	0.0434	0.35	0.23	Blood pressure (smoking interaction);	chr3:125915630	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.673	rs7632557	ENSG00000272840.1	RP11-379B18.6	3.73	0.000233	0.0434	0.35	0.23	Blood pressure (smoking interaction);	chr3:125916038	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.932	rs9841157	ENSG00000272840.1	RP11-379B18.6	3.73	0.000233	0.0434	0.35	0.23	Blood pressure (smoking interaction);	chr3:125916812	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.551	rs12695470	ENSG00000272840.1	RP11-379B18.6	3.73	0.000233	0.0434	0.35	0.23	Blood pressure (smoking interaction);	chr3:125916875	chr3:125774714~125797953:+
COAD	cis	rs6095360	1	rs348276	ENSG00000222365.1	SNORD12B	-3.73	0.000233	0.0434	-0.22	-0.23	Intelligence (multi-trait analysis);	chr20:49169653	chr20:49280319~49280409:+
COAD	cis	rs10411161	0.81	rs77082285	ENSG00000269483.1	AC006272.1	3.73	0.000233	0.0434	0.48	0.23	Breast cancer;	chr19:51884330	chr19:51839924~51843324:-
COAD	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	3.73	0.000233	0.0434	0.47	0.23	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
COAD	cis	rs11673344	0.864	rs2562606	ENSG00000267309.1	CTD-2630F21.1	-3.73	0.000234	0.0434	-0.27	-0.23	Obesity-related traits;	chr19:37029628	chr19:36489649~36491040:+
COAD	cis	rs11673344	0.864	rs2263167	ENSG00000267309.1	CTD-2630F21.1	-3.73	0.000234	0.0434	-0.27	-0.23	Obesity-related traits;	chr19:37030025	chr19:36489649~36491040:+
COAD	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-3.73	0.000234	0.0434	-0.44	-0.23	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
COAD	cis	rs6687821	0.515	rs1621247	ENSG00000261737.1	RP4-612B15.3	3.73	0.000234	0.0434	0.3	0.23	Yeast infection;	chr1:87104715	chr1:86703502~86704462:-
COAD	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-3.73	0.000234	0.0434	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
COAD	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-3.73	0.000234	0.0434	-0.27	-0.23	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
COAD	cis	rs7829975	0.686	rs907180	ENSG00000233609.3	RP11-62H7.2	3.73	0.000234	0.0434	0.25	0.23	Mood instability;	chr8:8845317	chr8:8961200~8979025:+
COAD	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	3.73	0.000234	0.0434	0.28	0.23	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
COAD	cis	rs2307394	0.964	rs10803523	ENSG00000281469.1	RP11-567F11.1	3.73	0.000234	0.0434	0.27	0.23	Urate levels;	chr2:147858262	chr2:148044380~148044894:+
COAD	cis	rs860295	0.676	rs2666826	ENSG00000225082.2	DAP3P1	-3.73	0.000234	0.0434	-0.28	-0.23	Body mass index;	chr1:155688294	chr1:155586644~155602197:+
COAD	cis	rs74233809	0.901	rs17115100	ENSG00000213277.3	MARCKSL1P1	3.73	0.000234	0.0435	0.44	0.23	Birth weight;	chr10:102831636	chr10:103175554~103176094:+
COAD	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-3.73	0.000234	0.0435	-0.21	-0.23	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
COAD	cis	rs654950	0.775	rs28972757	ENSG00000230638.4	RP11-486B10.4	3.73	0.000234	0.0435	0.25	0.23	Airway imaging phenotypes;	chr1:41527342	chr1:41542069~41544310:+
COAD	cis	rs12468226	1	rs111542497	ENSG00000226261.1	AC064836.3	3.73	0.000234	0.0435	0.33	0.23	Urate levels;	chr2:202330369	chr2:202336024~202336727:-
COAD	cis	rs7577696	0.962	rs212679	ENSG00000272716.1	RP11-563N4.1	3.73	0.000234	0.0435	0.24	0.23	Inflammatory biomarkers;	chr2:32206038	chr2:32165046~32165757:-
COAD	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	3.73	0.000234	0.0435	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
COAD	cis	rs34779708	0.897	rs4934529	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.897	rs12830	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs7920095	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs2384283	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs66887762	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs59418206	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs34087268	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs58159560	ENSG00000271335.4	RP11-324I22.4	3.73	0.000234	0.0435	0.26	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35314552~35336401:-
COAD	cis	rs875971	1	rs1565531	ENSG00000224316.1	RP11-479O9.2	-3.73	0.000234	0.0435	-0.24	-0.23	Aortic root size;	chr7:66198126	chr7:65773620~65802067:+
COAD	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	3.73	0.000234	0.0435	0.26	0.23	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
COAD	cis	rs9325389	0.648	rs12630378	ENSG00000229178.1	AC069513.4	3.73	0.000234	0.0435	0.34	0.23	Facial morphology (factor 17, height of vermillion upper lip);	chr3:195832418	chr3:195655565~195657927:-
COAD	cis	rs9309473	0.5	rs12997018	ENSG00000273245.1	RP11-434P11.2	-3.73	0.000234	0.0435	-0.28	-0.23	Metabolite levels;	chr2:73685772	chr2:73750256~73750786:-
COAD	cis	rs9309473	0.5	rs7608328	ENSG00000273245.1	RP11-434P11.2	-3.73	0.000234	0.0435	-0.28	-0.23	Metabolite levels;	chr2:73686892	chr2:73750256~73750786:-
COAD	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	3.73	0.000234	0.0435	0.32	0.23	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
COAD	cis	rs7584099	0.501	rs1377454	ENSG00000281469.1	RP11-567F11.1	-3.73	0.000234	0.0435	-0.27	-0.23	Response to statin therapy;	chr2:148179801	chr2:148044380~148044894:+
COAD	cis	rs9942416	0.648	rs40060	ENSG00000271815.1	CTD-2235C13.3	3.73	0.000234	0.0435	0.27	0.23	Age-related disease endophenotypes;	chr5:75671561	chr5:75363760~75364242:+
COAD	cis	rs2408955	0.521	rs10875753	ENSG00000257735.1	RP11-370I10.6	3.73	0.000234	0.0435	0.26	0.23	Glycated hemoglobin levels;	chr12:48163358	chr12:48350945~48442411:+
COAD	cis	rs11694172	0.955	rs62194152	ENSG00000273456.1	RP11-686O6.2	3.73	0.000234	0.0435	0.26	0.23	Cholesterol, total;	chr2:202730647	chr2:202374932~202375604:-
COAD	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-3.73	0.000234	0.0435	-0.24	-0.23	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
COAD	cis	rs2243480	1	rs1404147	ENSG00000164669.11	INTS4P1	3.73	0.000234	0.0435	0.35	0.23	Diabetic kidney disease;	chr7:65799537	chr7:65141225~65234216:+
COAD	cis	rs7474896	1	rs9418299	ENSG00000263064.2	RP11-291L22.7	3.73	0.000234	0.0435	0.34	0.23	Obesity (extreme);	chr10:37851299	chr10:38448689~38448949:+
COAD	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-3.73	0.000234	0.0435	-0.31	-0.23	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
COAD	cis	rs12564445	0.551	rs2275861	ENSG00000249007.1	RP11-510N19.5	-3.73	0.000234	0.0435	-0.27	-0.23	Cardiac Troponin-T levels;	chr1:201361455	chr1:202011370~202015657:+
COAD	cis	rs9890032	1	rs3764419	ENSG00000266490.1	CTD-2349P21.9	3.73	0.000234	0.0435	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30792372~30792833:+
COAD	cis	rs10911902	0.602	rs10494583	ENSG00000229739.2	RP11-295K2.3	-3.73	0.000234	0.0435	-0.33	-0.23	Schizophrenia;	chr1:186321363	chr1:186435161~186470291:+
COAD	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	3.73	0.000234	0.0435	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	3.73	0.000234	0.0435	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
COAD	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	3.73	0.000235	0.0436	0.31	0.23	Depression;	chr6:28407125	chr6:28943877~28944537:+
COAD	cis	rs7212590	0.748	rs7211208	ENSG00000264049.1	MIR4737	-3.73	0.000235	0.0436	-0.34	-0.23	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59879748	chr17:60043025~60043105:-
COAD	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-3.73	0.000235	0.0436	-0.3	-0.23	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
COAD	cis	rs1707322	0.65	rs4553239	ENSG00000230896.1	RP11-767N6.7	-3.73	0.000235	0.0436	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45694684~45697075:-
COAD	cis	rs860295	0.651	rs12239114	ENSG00000160766.13	GBAP1	-3.73	0.000235	0.0436	-0.28	-0.23	Body mass index;	chr1:155352351	chr1:155213821~155227422:-
COAD	cis	rs670292	1	rs670292	ENSG00000233330.1	RP1-12G14.7	-3.73	0.000235	0.0436	-0.29	-0.23	Anger;	chr6:150381711	chr6:149591755~149592663:-
COAD	cis	rs8089099	0.66	rs11664820	ENSG00000264964.1	RP11-888D10.3	3.73	0.000235	0.0436	0.27	0.23	Pulmonary function (smoking interaction);	chr18:10094306	chr18:9315194~9334441:-
COAD	cis	rs9880211	0.562	rs13068210	ENSG00000273486.1	RP11-731C17.2	3.73	0.000235	0.0436	0.26	0.23	Height;Body mass index;	chr3:136186704	chr3:136837338~136839021:-
COAD	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-3.73	0.000235	0.0436	-0.27	-0.23	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
COAD	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-3.73	0.000235	0.0436	-0.24	-0.23	Height;	chr11:118859432	chr11:118791254~118793137:+
COAD	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-3.73	0.000235	0.0436	-0.24	-0.23	Height;	chr11:118860890	chr11:118791254~118793137:+
COAD	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-3.73	0.000235	0.0436	-0.24	-0.23	Height;	chr11:118861053	chr11:118791254~118793137:+
COAD	cis	rs3015497	0.616	rs34061700	ENSG00000258857.1	RP11-247L20.3	3.73	0.000235	0.0436	0.25	0.23	Mean platelet volume;	chr14:50618142	chr14:50397013~50398345:+
COAD	cis	rs8031584	0.958	rs34294266	ENSG00000270015.1	RP11-540B6.6	-3.73	0.000235	0.0436	-0.19	-0.23	Huntington's disease progression;	chr15:30954637	chr15:30926514~30928407:+
COAD	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	3.73	0.000235	0.0436	0.3	0.23	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
COAD	cis	rs4448343	0.736	rs2236407	ENSG00000271155.1	RP11-435O5.5	-3.73	0.000235	0.0436	-0.25	-0.23	Height;	chr9:95475514	chr9:95506235~95507636:+
COAD	cis	rs7829975	0.509	rs2945269	ENSG00000254340.1	RP11-10A14.3	3.73	0.000235	0.0436	0.27	0.23	Mood instability;	chr8:8258056	chr8:9141424~9145435:+
COAD	cis	rs8046148	0.951	rs2356837	ENSG00000260381.2	RP11-429P3.5	-3.73	0.000235	0.0436	-0.34	-0.23	Testicular germ cell tumor;	chr16:50086982	chr16:50100339~50121943:-
COAD	cis	rs2985684	0.894	rs4900927	ENSG00000258568.1	RHOQP1	3.73	0.000235	0.0436	0.27	0.23	Carotid intima media thickness;	chr14:49552023	chr14:49599994~49600572:+
COAD	cis	rs8049040	0.547	rs12929335	ENSG00000260886.1	TAT-AS1	3.73	0.000235	0.0436	0.29	0.23	Blood protein levels;	chr16:71401849	chr16:71565789~71578187:+
COAD	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000235	0.0436	-0.31	-0.23	Depression;	chr6:28229408	chr6:28115628~28116551:+
COAD	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs1926556	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs1926554	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs4934710	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.897	rs35784065	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs34375045	ENSG00000271335.4	RP11-324I22.4	3.73	0.000235	0.0436	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35314552~35336401:-
COAD	cis	rs9402682	0.596	rs9321485	ENSG00000232876.1	CTA-212D2.2	-3.73	0.000235	0.0436	-0.31	-0.23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135126635	chr6:135055033~135060550:+
COAD	cis	rs1387259	0.64	rs10783243	ENSG00000269514.1	RP11-370I10.12	-3.73	0.000235	0.0436	-0.24	-0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48198387~48202031:+
COAD	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-3.73	0.000235	0.0436	-0.3	-0.23	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
COAD	cis	rs41464545	1	rs28595849	ENSG00000249413.2	RP11-25H12.1	3.73	0.000235	0.0437	0.33	0.23	Schizophrenia;	chr4:65001645	chr4:65998846~66150012:+
COAD	cis	rs734999	0.545	rs28568531	ENSG00000225931.3	RP3-395M20.7	3.73	0.000235	0.0437	0.25	0.23	Ulcerative colitis;	chr1:2624201	chr1:2566410~2569888:+
COAD	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	3.73	0.000235	0.0437	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
COAD	cis	rs9880211	0.613	rs67109185	ENSG00000239213.4	NCK1-AS1	3.73	0.000235	0.0437	0.29	0.23	Height;Body mass index;	chr3:136108550	chr3:136841726~136862054:-
COAD	cis	rs9880211	0.613	rs12695644	ENSG00000239213.4	NCK1-AS1	3.73	0.000235	0.0437	0.29	0.23	Height;Body mass index;	chr3:136126096	chr3:136841726~136862054:-
COAD	cis	rs11673344	0.864	rs2562595	ENSG00000267309.1	CTD-2630F21.1	-3.73	0.000235	0.0437	-0.27	-0.23	Obesity-related traits;	chr19:37023964	chr19:36489649~36491040:+
COAD	cis	rs11673344	0.832	rs8101407	ENSG00000267309.1	CTD-2630F21.1	-3.73	0.000235	0.0437	-0.27	-0.23	Obesity-related traits;	chr19:37024444	chr19:36489649~36491040:+
COAD	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-3.73	0.000235	0.0437	-0.35	-0.23	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
COAD	cis	rs73607972	0.696	rs7194983	ENSG00000275191.1	RP11-36I17.2	-3.73	0.000235	0.0437	-0.32	-0.23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525100	chr16:53628256~53628816:-
COAD	cis	rs2154490	0.806	rs2832390	ENSG00000273464.1	RP11-313P22.1	-3.73	0.000235	0.0437	-0.33	-0.23	Glucocorticoid-induced osteonecrosis;	chr21:29542205	chr21:29657406~29657831:+
COAD	cis	rs1383484	0.761	rs10906981	ENSG00000230373.7	GOLGA6L5P	-3.73	0.000235	0.0437	-0.33	-0.23	Height;	chr15:83853807	chr15:84507885~84516814:-
COAD	cis	rs4144743	0.938	rs55677902	ENSG00000228782.6	CTD-2026D20.3	-3.73	0.000236	0.0437	-0.3	-0.23	Body mass index;	chr17:47245206	chr17:47450568~47492492:-
COAD	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	3.73	0.000236	0.0437	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
COAD	cis	rs7918232	0.941	rs7096505	ENSG00000262412.1	RP11-85G18.6	3.73	0.000236	0.0437	0.35	0.23	Breast cancer;	chr10:27038070	chr10:27243130~27250804:+
COAD	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-3.73	0.000236	0.0437	-0.26	-0.23	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
COAD	cis	rs9807841	0.67	rs3843750	ENSG00000267082.1	CTC-510F12.2	3.73	0.000236	0.0437	0.19	0.23	Inflammatory skin disease;	chr19:10637397	chr19:11203628~11216168:+
COAD	cis	rs8022206	0.853	rs72725187	ENSG00000259502.1	RP11-643G16.3	3.73	0.000236	0.0437	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68078304	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.796	rs72725188	ENSG00000259502.1	RP11-643G16.3	3.73	0.000236	0.0437	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68078696	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.853	rs11624484	ENSG00000259502.1	RP11-643G16.3	3.73	0.000236	0.0437	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68083284	chr14:67610986~67613864:+
COAD	cis	rs7794273	0.821	rs2520343	ENSG00000279048.1	RP11-511H23.2	-3.73	0.000236	0.0437	-0.17	-0.23	Night sleep phenotypes;	chr7:18804185	chr7:17940503~17942922:+
COAD	cis	rs6772849	0.901	rs9849126	ENSG00000242551.2	POU5F1P6	3.73	0.000236	0.0437	0.24	0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128593226	chr3:128674735~128677005:-
COAD	cis	rs12468226	0.938	rs16824590	ENSG00000226261.1	AC064836.3	3.73	0.000236	0.0438	0.34	0.23	Urate levels;	chr2:202272624	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs77018809	ENSG00000226261.1	AC064836.3	3.73	0.000236	0.0438	0.34	0.23	Urate levels;	chr2:202273166	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.938	rs7585867	ENSG00000226261.1	AC064836.3	3.73	0.000236	0.0438	0.34	0.23	Urate levels;	chr2:202287040	chr2:202336024~202336727:-
COAD	cis	rs791888	0.965	rs791877	ENSG00000225913.2	RP11-57C13.6	-3.73	0.000236	0.0438	-0.29	-0.23	Magnesium levels;	chr10:87647106	chr10:87607985~87659279:+
COAD	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	3.73	0.000236	0.0438	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	3.73	0.000236	0.0438	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	3.73	0.000236	0.0438	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
COAD	cis	rs1799949	1	rs35070007	ENSG00000279602.1	CTD-3014M21.1	-3.73	0.000236	0.0438	-0.24	-0.23	Menopause (age at onset);	chr17:43164730	chr17:43360041~43361361:-
COAD	cis	rs4218	0.636	rs4775116	ENSG00000259732.1	RP11-59H7.3	3.73	0.000236	0.0438	0.27	0.23	Social communication problems;	chr15:59135608	chr15:59121034~59133250:+
COAD	cis	rs2307394	1	rs13013867	ENSG00000281469.1	RP11-567F11.1	3.73	0.000236	0.0438	0.27	0.23	Urate levels;	chr2:147827243	chr2:148044380~148044894:+
COAD	cis	rs7646881	0.767	rs73015629	ENSG00000272087.1	RP11-379F4.7	3.73	0.000236	0.0438	0.35	0.23	Tetralogy of Fallot;	chr3:158716051	chr3:158693120~158693768:-
COAD	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	3.73	0.000236	0.0438	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	3.73	0.000236	0.0438	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	3.73	0.000236	0.0438	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	3.73	0.000236	0.0438	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
COAD	cis	rs2832191	0.646	rs2832214	ENSG00000176054.6	RPL23P2	-3.73	0.000236	0.0438	-0.25	-0.23	Dental caries;	chr21:29144806	chr21:28997613~28998033:-
COAD	cis	rs739496	0.579	rs57046217	ENSG00000257595.2	RP3-473L9.4	3.73	0.000236	0.0438	0.35	0.23	Platelet count;	chr12:111847312	chr12:111369282~111403310:+
COAD	cis	rs739496	0.579	rs75080921	ENSG00000257595.2	RP3-473L9.4	3.73	0.000236	0.0438	0.35	0.23	Platelet count;	chr12:111861168	chr12:111369282~111403310:+
COAD	cis	rs78487399	0.71	rs17334919	ENSG00000234936.1	AC010883.5	-3.73	0.000236	0.0438	-0.38	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43480246	chr2:43229573~43233394:+
COAD	cis	rs4648045	0.796	rs3817685	ENSG00000246560.2	RP11-10L12.4	3.73	0.000237	0.0439	0.3	0.23	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102828055~102844075:+
COAD	cis	rs875971	1	rs7781698	ENSG00000223473.2	GS1-124K5.3	3.73	0.000237	0.0439	0.19	0.23	Aortic root size;	chr7:66431325	chr7:66491049~66493566:-
COAD	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000237	0.0439	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
COAD	cis	rs3738443	0.678	rs4314914	ENSG00000259865.1	RP11-488L18.10	3.73	0.000237	0.0439	0.23	0.23	Alcohol dependence;	chr1:247210326	chr1:247187281~247188526:-
COAD	cis	rs6142618	0.523	rs2377473	ENSG00000101898.5	MCTS2P	3.73	0.000237	0.0439	0.25	0.23	Inflammatory bowel disease;	chr20:32262445	chr20:31547504~31548049:+
COAD	cis	rs3738443	0.951	rs4582838	ENSG00000259865.1	RP11-488L18.10	3.73	0.000237	0.0439	0.27	0.23	Alcohol dependence;	chr1:247210269	chr1:247187281~247188526:-
COAD	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-3.73	0.000237	0.0439	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
COAD	cis	rs73198271	0.813	rs56007835	ENSG00000253981.4	ALG1L13P	-3.73	0.000237	0.0439	-0.31	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8236003~8244667:-
COAD	cis	rs911555	0.713	rs1107070	ENSG00000251533.2	LINC00605	3.73	0.000237	0.0439	0.3	0.23	Intelligence (multi-trait analysis);	chr14:103504171	chr14:103187221~103189028:-
COAD	cis	rs1707322	0.927	rs6690386	ENSG00000230896.1	RP11-767N6.7	-3.73	0.000237	0.0439	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45694684~45697075:-
COAD	cis	rs10129255	0.5	rs2027902	ENSG00000211967.3	IGHV3-53	-3.73	0.000237	0.0439	-0.13	-0.23	Kawasaki disease;	chr14:106807157	chr14:106592676~106593347:-
COAD	cis	rs911263	0.603	rs1956529	ENSG00000259502.1	RP11-643G16.3	3.73	0.000237	0.0439	0.28	0.23	Primary biliary cholangitis;	chr14:68322207	chr14:67610986~67613864:+
COAD	cis	rs7560272	0.501	rs12713798	ENSG00000273245.1	RP11-434P11.2	-3.73	0.000237	0.0439	-0.27	-0.23	Schizophrenia;	chr2:73759294	chr2:73750256~73750786:-
COAD	cis	rs9910055	0.529	rs615070	ENSG00000267080.4	ASB16-AS1	-3.73	0.000237	0.0439	-0.22	-0.23	Total body bone mineral density;	chr17:44099223	chr17:44175973~44186717:-
COAD	cis	rs2908835	0.705	rs2965735	ENSG00000247157.5	LINC01252	-3.73	0.000237	0.0439	-0.35	-0.23	Information processing speed;	chr12:11455756	chr12:11548030~11590369:+
COAD	cis	rs2908835	0.705	rs2951762	ENSG00000247157.5	LINC01252	-3.73	0.000237	0.0439	-0.35	-0.23	Information processing speed;	chr12:11456166	chr12:11548030~11590369:+
COAD	cis	rs71636778	0.524	rs78614739	ENSG00000260063.1	RP5-968P14.2	-3.73	0.000237	0.044	-0.32	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26847689	chr1:26692132~26694131:-
COAD	cis	rs11157436	0.602	rs12587826	ENSG00000211812.1	TRAV26-2	-3.73	0.000237	0.044	-0.22	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22202583~22203368:+
COAD	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	3.73	0.000237	0.044	0.3	0.23	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
COAD	cis	rs4699052	0.625	rs1850321	ENSG00000246560.2	RP11-10L12.4	3.73	0.000237	0.044	0.26	0.23	Testicular germ cell tumor;	chr4:103331608	chr4:102828055~102844075:+
COAD	cis	rs7615952	0.673	rs3811677	ENSG00000272840.1	RP11-379B18.6	3.73	0.000237	0.044	0.31	0.23	Blood pressure (smoking interaction);	chr3:125929237	chr3:125774714~125797953:+
COAD	cis	rs7615952	0.932	rs3811679	ENSG00000272840.1	RP11-379B18.6	3.73	0.000237	0.044	0.31	0.23	Blood pressure (smoking interaction);	chr3:125929440	chr3:125774714~125797953:+
COAD	cis	rs9890032	1	rs28539246	ENSG00000266490.1	CTD-2349P21.9	3.73	0.000237	0.044	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30792372~30792833:+
COAD	cis	rs9890032	0.967	rs9897628	ENSG00000266490.1	CTD-2349P21.9	3.73	0.000237	0.044	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30792372~30792833:+
COAD	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-3.73	0.000238	0.044	-0.29	-0.23	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
COAD	cis	rs75422866	0.85	rs73111212	ENSG00000276691.1	RP5-1057I20.5	3.73	0.000238	0.044	0.5	0.23	Pneumonia;	chr12:47577638	chr12:47788426~47788971:+
COAD	cis	rs75422866	0.85	rs73111216	ENSG00000276691.1	RP5-1057I20.5	3.73	0.000238	0.044	0.5	0.23	Pneumonia;	chr12:47577671	chr12:47788426~47788971:+
COAD	cis	rs75422866	0.85	rs73111217	ENSG00000276691.1	RP5-1057I20.5	3.73	0.000238	0.044	0.5	0.23	Pneumonia;	chr12:47577693	chr12:47788426~47788971:+
COAD	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	3.73	0.000238	0.044	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	3.73	0.000238	0.044	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
COAD	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-3.73	0.000238	0.044	-0.23	-0.23	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
COAD	cis	rs875971	0.545	rs2279757	ENSG00000232546.1	RP11-458F8.1	3.73	0.000238	0.044	0.23	0.23	Aortic root size;	chr7:66363676	chr7:66848496~66858136:+
COAD	cis	rs875971	0.545	rs11766183	ENSG00000232546.1	RP11-458F8.1	3.73	0.000238	0.044	0.23	0.23	Aortic root size;	chr7:66374173	chr7:66848496~66858136:+
COAD	cis	rs875971	0.545	rs1065265	ENSG00000232546.1	RP11-458F8.1	3.73	0.000238	0.044	0.23	0.23	Aortic root size;	chr7:66376216	chr7:66848496~66858136:+
COAD	cis	rs875971	0.545	rs7811204	ENSG00000232546.1	RP11-458F8.1	3.73	0.000238	0.044	0.23	0.23	Aortic root size;	chr7:66387213	chr7:66848496~66858136:+
COAD	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	3.73	0.000238	0.044	0.33	0.23	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	3.73	0.000238	0.044	0.33	0.23	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
COAD	cis	rs6129846	1	rs6129846	ENSG00000229771.2	RP4-644L1.2	3.73	0.000238	0.044	0.41	0.23	Verbal declarative memory;	chr20:41478674	chr20:40696499~40698616:-
COAD	cis	rs11846409	0.932	rs756588	ENSG00000254174.1	IGHV1-12	-3.73	0.000238	0.044	-0.22	-0.23	Rheumatic heart disease;	chr14:106632316	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.86	rs55745256	ENSG00000254174.1	IGHV1-12	3.73	0.000238	0.044	0.22	0.23	Rheumatic heart disease;	chr14:106632365	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.932	rs731013	ENSG00000254174.1	IGHV1-12	3.73	0.000238	0.044	0.22	0.23	Rheumatic heart disease;	chr14:106632481	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.932	rs731012	ENSG00000254174.1	IGHV1-12	3.73	0.000238	0.044	0.22	0.23	Rheumatic heart disease;	chr14:106632578	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.932	rs731011	ENSG00000254174.1	IGHV1-12	3.73	0.000238	0.044	0.22	0.23	Rheumatic heart disease;	chr14:106632619	chr14:106122420~106122709:-
COAD	cis	rs11846409	0.932	rs10138537	ENSG00000254174.1	IGHV1-12	3.73	0.000238	0.044	0.22	0.23	Rheumatic heart disease;	chr14:106632778	chr14:106122420~106122709:-
COAD	cis	rs734999	0.588	rs3748818	ENSG00000225931.3	RP3-395M20.7	3.73	0.000238	0.044	0.25	0.23	Ulcerative colitis;	chr1:2594221	chr1:2566410~2569888:+
COAD	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	3.73	0.000238	0.044	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	3.73	0.000238	0.044	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
COAD	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	3.73	0.000238	0.044	0.24	0.23	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	3.73	0.000238	0.044	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
COAD	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	3.73	0.000238	0.044	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
COAD	cis	rs1150668	0.699	rs1531681	ENSG00000272009.1	RP1-313I6.12	3.73	0.000238	0.044	0.24	0.23	Pubertal anthropometrics;	chr6:28259100	chr6:28078792~28081130:-
COAD	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	3.73	0.000238	0.044	0.19	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
COAD	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-3.73	0.000238	0.044	-0.13	-0.23	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
COAD	cis	rs875971	1	rs6460296	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66430152	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs4717292	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66430611	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs2420591	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66447394	chr7:66491049~66493566:-
COAD	cis	rs875971	0.895	rs10755833	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66448930	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs12668936	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66449417	chr7:66491049~66493566:-
COAD	cis	rs875971	0.895	rs1833495	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66456608	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs6945019	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66457471	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs6945032	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66457499	chr7:66491049~66493566:-
COAD	cis	rs875971	0.929	rs12673810	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66458866	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs35149210	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66464938	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs2042133	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66466935	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs2161065	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66467918	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs6961155	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66468308	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs7789768	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66473993	chr7:66491049~66493566:-
COAD	cis	rs875971	0.862	rs12698521	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66474502	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs1363055	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66478288	chr7:66491049~66493566:-
COAD	cis	rs875971	0.964	rs9691480	ENSG00000223473.2	GS1-124K5.3	3.73	0.000238	0.044	0.19	0.23	Aortic root size;	chr7:66479319	chr7:66491049~66493566:-
COAD	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	3.73	0.000238	0.044	0.16	0.23	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
COAD	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	3.73	0.000238	0.044	0.28	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
COAD	cis	rs12049351	0.612	rs34926904	ENSG00000229367.1	HMGN2P19	3.73	0.000238	0.044	0.34	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229471759	chr1:229570532~229570796:+
COAD	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-3.73	0.000238	0.044	-0.21	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
COAD	cis	rs58847541	0.584	rs16898583	ENSG00000214803.3	RP11-37N22.1	-3.73	0.000238	0.0441	-0.44	-0.23	Breast cancer;	chr8:123571690	chr8:124192671~124247398:-
COAD	cis	rs875971	1	rs9986696	ENSG00000223473.2	GS1-124K5.3	-3.73	0.000238	0.0441	-0.19	-0.23	Aortic root size;	chr7:66239589	chr7:66491049~66493566:-
COAD	cis	rs10129255	0.518	rs12590732	ENSG00000211967.3	IGHV3-53	3.73	0.000238	0.0441	0.13	0.23	Kawasaki disease;	chr14:106779612	chr14:106592676~106593347:-
COAD	cis	rs7009110	0.721	rs4739735	ENSG00000213791.4	RP11-941H19.2	3.73	0.000238	0.0441	0.22	0.23	Asthma and hay fever;	chr8:80347642	chr8:80300869~80301481:+
COAD	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	3.73	0.000238	0.0441	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
COAD	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-3.73	0.000238	0.0441	-0.4	-0.23	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
COAD	cis	rs2337406	0.81	rs7161739	ENSG00000211964.3	IGHV3-48	-3.73	0.000238	0.0441	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106776118	chr14:106537810~106538344:-
COAD	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000238	0.0441	-0.27	-0.23	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
COAD	cis	rs490608	0.628	rs678157	ENSG00000160766.13	GBAP1	-3.73	0.000238	0.0441	-0.26	-0.23	Inflammatory bowel disease;	chr1:155688550	chr1:155213821~155227422:-
COAD	cis	rs1387259	0.929	rs11168460	ENSG00000257763.1	OR5BK1P	3.73	0.000238	0.0441	0.25	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48355792~48356614:-
COAD	cis	rs1035144	0.506	rs7150858	ENSG00000258999.1	RP11-114N19.3	3.73	0.000238	0.0441	0.24	0.23	Male sexual orientation;	chr14:80814081	chr14:81107033~81170414:-
COAD	cis	rs2307394	1	rs13028411	ENSG00000281469.1	RP11-567F11.1	3.73	0.000239	0.0442	0.27	0.23	Urate levels;	chr2:147851566	chr2:148044380~148044894:+
COAD	cis	rs7176527	0.848	rs3748374	ENSG00000229212.6	RP11-561C5.4	3.73	0.000239	0.0442	0.37	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85205440~85234795:-
COAD	cis	rs2638953	0.924	rs7955118	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000239	0.0442	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157159	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs7955237	ENSG00000247934.4	RP11-967K21.1	-3.73	0.000239	0.0442	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157272	chr12:28163298~28190738:-
COAD	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000239	0.0442	-0.29	-0.23	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
COAD	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000239	0.0442	-0.29	-0.23	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
COAD	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000239	0.0442	-0.29	-0.23	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
COAD	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000239	0.0442	-0.29	-0.23	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
COAD	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000239	0.0442	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
COAD	cis	rs55823223	0.646	rs74410877	ENSG00000267801.1	RP11-552F3.9	3.73	0.000239	0.0442	0.54	0.23	Psoriasis;	chr17:75836303	chr17:75876372~75879546:+
COAD	cis	rs2281597	0.563	rs4653355	ENSG00000270115.1	RP11-415J8.7	-3.73	0.000239	0.0442	-0.32	-0.23	Attention deficit hyperactivity disorder;	chr1:33876738	chr1:33261212~33261680:+
COAD	cis	rs2281597	0.579	rs1321628	ENSG00000270115.1	RP11-415J8.7	-3.73	0.000239	0.0442	-0.32	-0.23	Attention deficit hyperactivity disorder;	chr1:33877147	chr1:33261212~33261680:+
COAD	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	3.73	0.000239	0.0442	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
COAD	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-3.73	0.000239	0.0442	-0.26	-0.23	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
COAD	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000239	0.0442	-0.3	-0.23	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
COAD	cis	rs3018712	0.532	rs948861	ENSG00000184795.9	UNC93B5	-3.73	0.000239	0.0442	-0.37	-0.23	Total body bone mineral density;	chr11:68653154	chr11:67711702~67716005:-
COAD	cis	rs3018712	0.532	rs948863	ENSG00000184795.9	UNC93B5	-3.73	0.000239	0.0442	-0.37	-0.23	Total body bone mineral density;	chr11:68653506	chr11:67711702~67716005:-
COAD	cis	rs3781264	0.557	rs10882437	ENSG00000273450.1	RP11-76P2.4	3.73	0.000239	0.0442	0.27	0.23	Esophageal cancer and gastric cancer;	chr10:94362073	chr10:94314907~94315327:-
COAD	cis	rs9888739	0.641	rs67898294	ENSG00000260304.1	RP11-388M20.6	3.73	0.000239	0.0442	0.28	0.23	Systemic lupus erythematosus;	chr16:31351390	chr16:31182511~31183285:-
COAD	cis	rs9888739	0.668	rs58408589	ENSG00000260304.1	RP11-388M20.6	3.73	0.000239	0.0442	0.28	0.23	Systemic lupus erythematosus;	chr16:31351420	chr16:31182511~31183285:-
COAD	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-3.73	0.000239	0.0442	-0.24	-0.23	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
COAD	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	3.73	0.000239	0.0442	0.32	0.23	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
COAD	cis	rs2307394	1	rs2307394	ENSG00000281469.1	RP11-567F11.1	3.73	0.000239	0.0442	0.27	0.23	Urate levels;	chr2:147958859	chr2:148044380~148044894:+
COAD	cis	rs1023500	0.573	rs133370	ENSG00000232710.1	RP4-669P10.16	-3.73	0.000239	0.0442	-0.23	-0.23	Schizophrenia;	chr22:42069256	chr22:42136433~42139927:-
COAD	cis	rs801193	0.66	rs974239	ENSG00000224316.1	RP11-479O9.2	3.73	0.000239	0.0442	0.24	0.23	Aortic root size;	chr7:66748504	chr7:65773620~65802067:+
COAD	cis	rs801193	0.66	rs1016265	ENSG00000224316.1	RP11-479O9.2	3.73	0.000239	0.0442	0.24	0.23	Aortic root size;	chr7:66749580	chr7:65773620~65802067:+
COAD	cis	rs7953704	1	rs1047813	ENSG00000280389.1	RP11-512M8.11	-3.73	0.000239	0.0442	-0.26	-0.23	Urate levels;	chr12:122143969	chr12:122255119~122260274:-
COAD	cis	rs2929278	0.736	rs2412823	ENSG00000275601.1	AC011330.13	3.73	0.000239	0.0442	0.27	0.23	Schizophrenia;	chr15:43935072	chr15:43642389~43643023:-
COAD	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	3.73	0.000239	0.0442	0.27	0.23	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
COAD	cis	rs4888671	1	rs79330529	ENSG00000261707.1	RP11-264M12.2	3.73	0.000239	0.0442	0.49	0.23	Obesity-related traits;	chr16:77748027	chr16:77741468~77743000:-
COAD	cis	rs9859260	1	rs2284889	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196061376	chr3:195699401~195699497:+
COAD	cis	rs9859260	1	rs2239641	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196062543	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.961	rs2300780	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196063420	chr3:195699401~195699497:+
COAD	cis	rs9859260	1	rs2300778	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196063866	chr3:195699401~195699497:+
COAD	cis	rs9859260	1	rs2300777	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196063940	chr3:195699401~195699497:+
COAD	cis	rs9859260	0.925	rs2300775	ENSG00000207650.1	MIR570	3.73	0.000239	0.0442	0.27	0.23	Mean corpuscular volume;	chr3:196066468	chr3:195699401~195699497:+
COAD	cis	rs911119	0.913	rs6048922	ENSG00000270001.1	RP11-218C14.8	-3.73	0.00024	0.0443	-0.28	-0.23	Chronic kidney disease;	chr20:23597479	chr20:23631826~23632316:-
COAD	cis	rs860295	0.776	rs11264362	ENSG00000225082.2	DAP3P1	3.73	0.00024	0.0443	0.27	0.23	Body mass index;	chr1:155345824	chr1:155586644~155602197:+
COAD	cis	rs4819052	1	rs733739	ENSG00000227039.5	ITGB2-AS1	-3.73	0.00024	0.0443	-0.22	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:44921051~44929678:+
COAD	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	3.73	0.00024	0.0443	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
COAD	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	3.73	0.00024	0.0443	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
COAD	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	3.73	0.00024	0.0443	0.32	0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
COAD	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	3.73	0.00024	0.0443	0.21	0.23	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
COAD	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	3.73	0.00024	0.0443	0.38	0.23	Gout;	chr7:66721259	chr7:66025126~66031544:-
COAD	cis	rs6461992	0.51	rs62457399	ENSG00000253308.2	RP1-170O19.17	3.73	0.00024	0.0443	0.56	0.23	Systolic blood pressure;	chr7:26998544	chr7:27239243~27241228:-
COAD	cis	rs6461992	0.51	rs17436757	ENSG00000253308.2	RP1-170O19.17	3.73	0.00024	0.0443	0.56	0.23	Systolic blood pressure;	chr7:27009910	chr7:27239243~27241228:-
COAD	cis	rs6461992	0.51	rs62457403	ENSG00000253308.2	RP1-170O19.17	3.73	0.00024	0.0443	0.56	0.23	Systolic blood pressure;	chr7:27011148	chr7:27239243~27241228:-
COAD	cis	rs6506900	0.692	rs1426309	ENSG00000266729.4	DSG1-AS1	-3.73	0.00024	0.0443	-0.28	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr18:31317390	chr18:31343368~31426988:-
COAD	cis	rs2732480	0.5	rs12828309	ENSG00000269514.1	RP11-370I10.12	3.73	0.00024	0.0443	0.27	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48198387~48202031:+
COAD	cis	rs728616	0.51	rs7074356	ENSG00000225484.5	NUTM2B-AS1	-3.73	0.00024	0.0443	-0.3	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:79663088~79826594:-
COAD	cis	rs17154702	0.524	rs2664041	ENSG00000173295.6	FAM86B3P	-3.73	0.00024	0.0443	-0.27	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8735634	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.632	rs570396	ENSG00000173295.6	FAM86B3P	-3.73	0.00024	0.0443	-0.27	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736142	chr8:8228595~8244865:+
COAD	cis	rs73198271	0.603	rs571130	ENSG00000173295.6	FAM86B3P	-3.73	0.00024	0.0443	-0.27	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736181	chr8:8228595~8244865:+
COAD	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	3.73	0.00024	0.0444	0.31	0.23	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	3.73	0.00024	0.0444	0.31	0.23	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
COAD	cis	rs4930776	1	rs4930776	ENSG00000213942.3	RP1-102E24.1	-3.73	0.00024	0.0444	-0.2	-0.23	Plasma clusterin levels;	chr12:5658219	chr12:6409637~6410013:-
COAD	cis	rs476633	0.691	rs28409265	ENSG00000247556.5	OIP5-AS1	3.73	0.00024	0.0444	0.22	0.23	Glomerular filtration rate (creatinine);	chr15:41247206	chr15:41283990~41309737:+
COAD	cis	rs4253772	0.591	rs6519994	ENSG00000280424.1	CITF22-92A6.2	-3.72	0.00024	0.0444	-0.34	-0.23	Cholesterol, total;LDL cholesterol;	chr22:46260908	chr22:46006616~46010777:+
COAD	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	3.72	0.00024	0.0444	0.34	0.23	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	3.72	0.00024	0.0444	0.34	0.23	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
COAD	cis	rs2337406	0.706	rs74090742	ENSG00000211964.3	IGHV3-48	-3.72	0.00024	0.0444	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106696601	chr14:106537810~106538344:-
COAD	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-3.72	0.00024	0.0444	-0.28	-0.23	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
COAD	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-3.72	0.00024	0.0444	-0.23	-0.23	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
COAD	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	3.72	0.00024	0.0444	0.21	0.23	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
COAD	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	3.72	0.00024	0.0444	0.26	0.23	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	3.72	0.00024	0.0444	0.26	0.23	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	3.72	0.00024	0.0444	0.26	0.23	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
COAD	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	3.72	0.00024	0.0444	0.26	0.23	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
COAD	cis	rs10129255	0.957	rs10132367	ENSG00000224373.3	IGHV4-59	3.72	0.00024	0.0444	0.14	0.23	Kawasaki disease;	chr14:106690981	chr14:106627249~106627825:-
COAD	cis	rs73222236	0.825	rs9819496	ENSG00000273486.1	RP11-731C17.2	3.72	0.00024	0.0444	0.23	0.23	Coronary artery disease;	chr3:136421036	chr3:136837338~136839021:-
COAD	cis	rs9816784	0.525	rs555412	ENSG00000207650.1	MIR570	3.72	0.00024	0.0444	0.29	0.23	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195699401~195699497:+
COAD	cis	rs9816784	0.525	rs422772	ENSG00000207650.1	MIR570	3.72	0.00024	0.0444	0.29	0.23	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195699401~195699497:+
COAD	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-3.72	0.00024	0.0444	-0.33	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
COAD	cis	rs4699052	0.963	rs6533078	ENSG00000246560.2	RP11-10L12.4	3.72	0.00024	0.0444	0.26	0.23	Testicular germ cell tumor;	chr4:103290999	chr4:102828055~102844075:+
COAD	cis	rs4699052	0.963	rs7672802	ENSG00000246560.2	RP11-10L12.4	3.72	0.00024	0.0444	0.26	0.23	Testicular germ cell tumor;	chr4:103291076	chr4:102828055~102844075:+
COAD	cis	rs7577696	0.925	rs212715	ENSG00000272716.1	RP11-563N4.1	3.72	0.00024	0.0444	0.24	0.23	Inflammatory biomarkers;	chr2:32235817	chr2:32165046~32165757:-
COAD	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	3.72	0.00024	0.0444	0.26	0.23	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
COAD	cis	rs742132	0.893	rs1980452	ENSG00000220875.1	HIST1H3PS1	3.72	0.000241	0.0444	0.3	0.23	Uric acid levels;	chr6:25629908	chr6:26321876~26322292:-
COAD	cis	rs742132	0.893	rs9467539	ENSG00000220875.1	HIST1H3PS1	3.72	0.000241	0.0444	0.3	0.23	Uric acid levels;	chr6:25630003	chr6:26321876~26322292:-
COAD	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-3.72	0.000241	0.0444	-0.47	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
COAD	cis	rs848490	1	rs10279537	ENSG00000213542.3	RP11-467H10.1	-3.72	0.000241	0.0444	-0.28	-0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77845644	chr7:77115399~77116192:-
COAD	cis	rs742132	0.893	rs9467538	ENSG00000220875.1	HIST1H3PS1	3.72	0.000241	0.0445	0.3	0.23	Uric acid levels;	chr6:25628460	chr6:26321876~26322292:-
COAD	cis	rs73222236	0.75	rs35375192	ENSG00000273486.1	RP11-731C17.2	3.72	0.000241	0.0445	0.23	0.23	Coronary artery disease;	chr3:136456683	chr3:136837338~136839021:-
COAD	cis	rs67072384	1	rs7128364	ENSG00000202522.1	Y_RNA	-3.72	0.000241	0.0445	-0.33	-0.23	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72740896	chr11:72766004~72766116:+
COAD	cis	rs2644899	0.859	rs2604893	ENSG00000233622.1	CYP2T1P	-3.72	0.000241	0.0445	-0.27	-0.23	Post bronchodilator FEV1/FVC ratio;	chr19:40787638	chr19:40808525~40811390:-
COAD	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-3.72	0.000241	0.0445	-0.25	-0.23	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
COAD	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-3.72	0.000241	0.0445	-0.25	-0.23	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
COAD	cis	rs902774	0.818	rs11831919	ENSG00000257475.2	RP11-983P16.2	-3.72	0.000241	0.0445	-0.35	-0.23	Prostate cancer;	chr12:52878231	chr12:53012104~53013921:+
COAD	cis	rs2898290	0.54	rs35005793	ENSG00000255495.1	AC145124.2	3.72	0.000241	0.0445	0.31	0.23	Systolic blood pressure;	chr8:11592963	chr8:12194467~12196280:+
COAD	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-3.72	0.000241	0.0445	-0.25	-0.23	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
COAD	cis	rs6429703	0.558	rs10754877	ENSG00000278480.1	RP5-903E17.2	-3.72	0.000241	0.0445	-0.48	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr1:15015863	chr1:15226373~15227549:+
COAD	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	3.72	0.000241	0.0445	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
COAD	cis	rs238295	0.805	rs6038214	ENSG00000233578.1	EIF4EP1	3.72	0.000241	0.0445	0.25	0.23	Occipital cortical area (total cortical area interaction);	chr20:5589176	chr20:5548840~5549481:+
COAD	cis	rs8022206	0.898	rs72725168	ENSG00000259502.1	RP11-643G16.3	3.72	0.000241	0.0445	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68034237	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.898	rs72725170	ENSG00000259502.1	RP11-643G16.3	3.72	0.000241	0.0445	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68034997	chr14:67610986~67613864:+
COAD	cis	rs8022206	0.841	rs72725172	ENSG00000259502.1	RP11-643G16.3	3.72	0.000241	0.0445	0.34	0.23	Platelet count;Mean platelet volume;	chr14:68042601	chr14:67610986~67613864:+
COAD	cis	rs7702057	0.53	rs58510083	ENSG00000271918.1	CTD-2287O16.5	3.72	0.000241	0.0445	0.3	0.23	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116083807~116085416:-
COAD	cis	rs73222236	0.825	rs35644083	ENSG00000273486.1	RP11-731C17.2	3.72	0.000241	0.0445	0.23	0.23	Coronary artery disease;	chr3:136503626	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.825	rs34962604	ENSG00000273486.1	RP11-731C17.2	3.72	0.000241	0.0445	0.23	0.23	Coronary artery disease;	chr3:136511148	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.825	rs9858457	ENSG00000273486.1	RP11-731C17.2	3.72	0.000241	0.0445	0.23	0.23	Coronary artery disease;	chr3:136530735	chr3:136837338~136839021:-
COAD	cis	rs2638953	0.924	rs10492368	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000241	0.0445	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.85	rs11049402	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000241	0.0445	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1551987	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000241	0.0445	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs1551986	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000241	0.0445	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28163298~28190738:-
COAD	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	3.72	0.000241	0.0445	0.34	0.23	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
COAD	cis	rs4883201	0.572	rs987917	ENSG00000249790.2	RP11-20D14.6	-3.72	0.000241	0.0445	-0.3	-0.23	Total cholesterol levels;Cholesterol, total;	chr12:8949979	chr12:8788257~8795789:+
COAD	cis	rs7824557	0.767	rs10104728	ENSG00000248896.2	CTD-2135J3.3	3.72	0.000241	0.0446	0.32	0.23	Retinal vascular caliber;	chr8:11313791	chr8:10729314~10771392:+
COAD	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	3.72	0.000242	0.0446	0.33	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
COAD	cis	rs76076331	0.838	rs55748262	ENSG00000272275.1	RP11-791G15.2	3.72	0.000242	0.0446	0.34	0.23	Educational attainment (college completion);Educational attainment (years of education);	chr2:10842509	chr2:10767875~10770058:-
COAD	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	3.72	0.000242	0.0446	0.29	0.23	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	3.72	0.000242	0.0446	0.29	0.23	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	3.72	0.000242	0.0446	0.29	0.23	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	3.72	0.000242	0.0446	0.29	0.23	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000242	0.0446	-0.29	-0.23	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000242	0.0446	-0.29	-0.23	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
COAD	cis	rs4750829	1	rs4751269	ENSG00000277218.1	RP11-500G10.5	3.72	0.000242	0.0446	0.42	0.23	Obesity-related traits;	chr10:130748731	chr10:130104569~130104998:-
COAD	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	3.72	0.000242	0.0446	0.16	0.23	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
COAD	cis	rs72827839	0.644	rs72833479	ENSG00000263412.1	RP5-890E16.2	3.72	0.000242	0.0446	0.31	0.23	Ease of getting up in the morning;	chr17:47883083	chr17:48045141~48048073:-
COAD	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	3.72	0.000242	0.0446	0.3	0.23	Depression;	chr6:28193021	chr6:28943877~28944537:+
COAD	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	3.72	0.000242	0.0446	0.3	0.23	Depression;	chr6:28197321	chr6:28943877~28944537:+
COAD	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	3.72	0.000242	0.0446	0.3	0.23	Depression;	chr6:28197412	chr6:28943877~28944537:+
COAD	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	3.72	0.000242	0.0446	0.3	0.23	Depression;	chr6:28198669	chr6:28943877~28944537:+
COAD	cis	rs7615952	0.736	rs13063122	ENSG00000241288.6	RP11-379B18.5	-3.72	0.000242	0.0446	-0.23	-0.23	Blood pressure (smoking interaction);	chr3:125925017	chr3:125827238~125916384:-
COAD	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-3.72	0.000242	0.0446	-0.26	-0.23	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
COAD	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-3.72	0.000242	0.0446	-0.26	-0.23	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
COAD	cis	rs10091038	0.966	rs10088728	ENSG00000253708.1	RP11-51J9.4	-3.72	0.000242	0.0446	-0.25	-0.23	Response to statin therapy;	chr8:29513857	chr8:30176554~30180888:-
COAD	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-3.72	0.000242	0.0446	-0.23	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
COAD	cis	rs11168351	0.833	rs6580652	ENSG00000226413.2	OR8T1P	-3.72	0.000242	0.0446	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48442030~48442947:-
COAD	cis	rs2243480	0.706	rs34466769	ENSG00000232559.3	GS1-124K5.12	3.72	0.000242	0.0446	0.36	0.23	Diabetic kidney disease;	chr7:65988305	chr7:66554588~66576923:-
COAD	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-3.72	0.000242	0.0446	-0.28	-0.23	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
COAD	cis	rs10129255	0.518	rs10150460	ENSG00000211967.3	IGHV3-53	3.72	0.000242	0.0446	0.13	0.23	Kawasaki disease;	chr14:106677179	chr14:106592676~106593347:-
COAD	cis	rs55962025	0.883	rs362275	ENSG00000248840.2	RP11-357G3.2	3.72	0.000242	0.0446	0.27	0.23	Parental longevity (mother's age at death);	chr4:3222875	chr4:3312512~3313058:+
COAD	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	3.72	0.000242	0.0446	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
COAD	cis	rs5753037	0.702	rs36576	ENSG00000279159.1	RP3-394A18.1	-3.72	0.000242	0.0447	-0.15	-0.23	Type 1 diabetes;	chr22:29810302	chr22:29978950~30028236:-
COAD	cis	rs7615952	0.8	rs12489350	ENSG00000272840.1	RP11-379B18.6	3.72	0.000242	0.0447	0.31	0.23	Blood pressure (smoking interaction);	chr3:125925273	chr3:125774714~125797953:+
COAD	cis	rs12530	0.68	rs9609518	ENSG00000232218.1	RP1-149A16.16	3.72	0.000242	0.0447	0.35	0.23	IgG glycosylation;	chr22:32381219	chr22:32386668~32386868:+
COAD	cis	rs884366	0.964	rs11153164	ENSG00000219700.1	PTCHD3P3	-3.72	0.000242	0.0447	-0.3	-0.23	HDL cholesterol;HDL cholesterol levels;	chr6:109275106	chr6:109288571~109290503:-
COAD	cis	rs2483374	1	rs2483374	ENSG00000253771.4	TPTE2P1	-3.72	0.000242	0.0447	-0.24	-0.23	Obesity-related traits;	chr13:24959693	chr13:24924677~24968487:-
COAD	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	3.72	0.000242	0.0447	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-3.72	0.000242	0.0447	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
COAD	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-3.72	0.000242	0.0447	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
COAD	cis	rs956237	0.932	rs7698317	ENSG00000206601.1	RNU6-431P	3.72	0.000242	0.0447	0.28	0.23	Systemic lupus erythematosus;	chr4:108109164	chr4:108652150~108652256:+
COAD	cis	rs1029738	0.5	rs10264536	ENSG00000226816.2	AC005082.12	3.72	0.000242	0.0447	0.23	0.23	Fibrinogen levels;	chr7:22845279	chr7:23206013~23208045:+
COAD	cis	rs7656342	0.755	rs13148571	ENSG00000186234.7	FAM86MP	-3.72	0.000242	0.0447	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr4:9872231	chr4:9692495~9702954:+
COAD	cis	rs74233809	0.901	rs11191425	ENSG00000213277.3	MARCKSL1P1	3.72	0.000242	0.0447	0.43	0.23	Birth weight;	chr10:102866213	chr10:103175554~103176094:+
COAD	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-3.72	0.000243	0.0447	-0.35	-0.23	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
COAD	cis	rs28374715	0.578	rs8036026	ENSG00000247556.5	OIP5-AS1	3.72	0.000243	0.0447	0.31	0.23	Ulcerative colitis;	chr15:41338301	chr15:41283990~41309737:+
COAD	cis	rs12049351	0.832	rs28798529	ENSG00000201492.1	RNA5SP78	3.72	0.000243	0.0447	0.25	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229535867	chr1:229549905~229550022:+
COAD	cis	rs12049351	0.774	rs4148760	ENSG00000201492.1	RNA5SP78	3.72	0.000243	0.0447	0.25	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229538187	chr1:229549905~229550022:+
COAD	cis	rs12049351	0.774	rs3738187	ENSG00000201492.1	RNA5SP78	3.72	0.000243	0.0447	0.25	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229547517	chr1:229549905~229550022:+
COAD	cis	rs2337406	1	rs7145100	ENSG00000280411.1	IGHV1-69-2	-3.72	0.000243	0.0447	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106704673	chr14:106762092~106762588:-
COAD	cis	rs12049351	0.774	rs36021190	ENSG00000229367.1	HMGN2P19	3.72	0.000243	0.0447	0.31	0.23	Circulating myeloperoxidase levels (plasma);	chr1:229562116	chr1:229570532~229570796:+
COAD	cis	rs4927850	0.881	rs7624638	ENSG00000185485.13	SDHAP1	3.72	0.000243	0.0447	0.19	0.23	Pancreatic cancer;	chr3:196021858	chr3:195959748~195990318:-
COAD	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	3.72	0.000243	0.0447	0.3	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
COAD	cis	rs1707322	0.721	rs6699418	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000243	0.0447	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs4431884	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000243	0.0447	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.65	rs4660879	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000243	0.0447	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45694684~45697075:-
COAD	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-3.72	0.000243	0.0447	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-3.72	0.000243	0.0447	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
COAD	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-3.72	0.000243	0.0447	-0.24	-0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
COAD	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-3.72	0.000243	0.0447	-0.24	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
COAD	cis	rs73222236	0.787	rs34379561	ENSG00000273486.1	RP11-731C17.2	3.72	0.000243	0.0447	0.23	0.23	Coronary artery disease;	chr3:136464374	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.825	rs9866535	ENSG00000273486.1	RP11-731C17.2	3.72	0.000243	0.0447	0.23	0.23	Coronary artery disease;	chr3:136465513	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.75	rs6439642	ENSG00000273486.1	RP11-731C17.2	3.72	0.000243	0.0447	0.23	0.23	Coronary artery disease;	chr3:136473965	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.857	rs16843991	ENSG00000273486.1	RP11-731C17.2	3.72	0.000243	0.0447	0.23	0.23	Coronary artery disease;	chr3:136477186	chr3:136837338~136839021:-
COAD	cis	rs73222236	0.825	rs7644471	ENSG00000273486.1	RP11-731C17.2	3.72	0.000243	0.0447	0.23	0.23	Coronary artery disease;	chr3:136565719	chr3:136837338~136839021:-
COAD	cis	rs2765539	0.851	rs1891141	ENSG00000231365.4	RP11-418J17.1	-3.72	0.000243	0.0447	-0.27	-0.23	Waist-hip ratio;	chr1:119034787	chr1:119140396~119275973:+
COAD	cis	rs3096299	0.629	rs12929744	ENSG00000260259.1	RP11-368I7.4	3.72	0.000243	0.0447	0.28	0.23	Multiple myeloma (IgH translocation);	chr16:89427172	chr16:89682620~89686569:-
COAD	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-3.72	0.000243	0.0447	-0.23	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
COAD	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-3.72	0.000243	0.0447	-0.23	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
COAD	cis	rs172166	0.769	rs149965	ENSG00000272009.1	RP1-313I6.12	3.72	0.000243	0.0448	0.27	0.23	Cardiac Troponin-T levels;	chr6:28050911	chr6:28078792~28081130:-
COAD	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	3.72	0.000243	0.0448	0.3	0.23	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
COAD	cis	rs12474201	0.569	rs13411633	ENSG00000279254.1	RP11-536C12.1	-3.72	0.000243	0.0448	-0.26	-0.23	Height;	chr2:46705527	chr2:46668870~46670778:+
COAD	cis	rs11626933	1	rs4559843	ENSG00000275198.1	RP11-471B22.3	-3.72	0.000243	0.0448	-0.27	-0.23	Gut microbiota (bacterial taxa);	chr14:90281144	chr14:90383365~90387973:+
COAD	cis	rs11626933	1	rs11626016	ENSG00000275198.1	RP11-471B22.3	-3.72	0.000243	0.0448	-0.27	-0.23	Gut microbiota (bacterial taxa);	chr14:90281635	chr14:90383365~90387973:+
COAD	cis	rs11626933	1	rs61986782	ENSG00000275198.1	RP11-471B22.3	-3.72	0.000243	0.0448	-0.27	-0.23	Gut microbiota (bacterial taxa);	chr14:90285000	chr14:90383365~90387973:+
COAD	cis	rs11935103	0.569	rs7656944	ENSG00000279943.1	FLJ38576	3.72	0.000243	0.0448	0.31	0.23	Response to citalopram treatment;	chr4:186373743	chr4:186189032~186191490:-
COAD	cis	rs9329221	0.537	rs13254175	ENSG00000254340.1	RP11-10A14.3	3.72	0.000243	0.0448	0.26	0.23	Neuroticism;	chr8:10121262	chr8:9141424~9145435:+
COAD	cis	rs3733585	0.699	rs11724510	ENSG00000250413.1	RP11-448G15.1	3.72	0.000243	0.0448	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9956959	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs28837683	ENSG00000250413.1	RP11-448G15.1	3.72	0.000243	0.0448	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9958184	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs6449157	ENSG00000250413.1	RP11-448G15.1	3.72	0.000243	0.0448	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9958818	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs6823361	ENSG00000250413.1	RP11-448G15.1	3.72	0.000243	0.0448	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9961503	chr4:10006482~10009725:+
COAD	cis	rs7837688	0.678	rs7832031	ENSG00000253264.1	PCAT2	-3.72	0.000243	0.0448	-0.49	-0.23	Prostate cancer;	chr8:127504707	chr8:127072694~127082221:-
COAD	cis	rs6461992	0.51	rs62454369	ENSG00000253308.2	RP1-170O19.17	3.72	0.000243	0.0448	0.56	0.23	Systolic blood pressure;	chr7:27059185	chr7:27239243~27241228:-
COAD	cis	rs6461992	0.51	rs62454370	ENSG00000253308.2	RP1-170O19.17	3.72	0.000243	0.0448	0.56	0.23	Systolic blood pressure;	chr7:27059380	chr7:27239243~27241228:-
COAD	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-3.72	0.000243	0.0448	-0.32	-0.23	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
COAD	cis	rs3018712	0.532	rs2510399	ENSG00000184795.9	UNC93B5	-3.72	0.000243	0.0448	-0.39	-0.23	Total body bone mineral density;	chr11:68653990	chr11:67711702~67716005:-
COAD	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	3.72	0.000243	0.0448	0.2	0.23	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
COAD	cis	rs1150668	0.699	rs1736895	ENSG00000272009.1	RP1-313I6.12	3.72	0.000243	0.0448	0.24	0.23	Pubertal anthropometrics;	chr6:28252048	chr6:28078792~28081130:-
COAD	cis	rs7116495	1	rs488799	ENSG00000254682.1	RP11-660L16.2	-3.72	0.000243	0.0448	-0.34	-0.23	Severe influenza A (H1N1) infection;	chr11:71850640	chr11:71448674~71452157:+
COAD	cis	rs7116495	1	rs520025	ENSG00000254682.1	RP11-660L16.2	-3.72	0.000243	0.0448	-0.34	-0.23	Severe influenza A (H1N1) infection;	chr11:71851786	chr11:71448674~71452157:+
COAD	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	3.72	0.000244	0.0449	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
COAD	cis	rs9307551	0.741	rs12640638	ENSG00000250334.4	LINC00989	-3.72	0.000244	0.0449	-0.27	-0.23	Refractive error;	chr4:79551314	chr4:79492416~79576460:+
COAD	cis	rs7646881	0.544	rs41272617	ENSG00000240207.5	RP11-379F4.4	-3.72	0.000244	0.0449	-0.29	-0.23	Tetralogy of Fallot;	chr3:158603103	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.544	rs73024790	ENSG00000240207.5	RP11-379F4.4	-3.72	0.000244	0.0449	-0.29	-0.23	Tetralogy of Fallot;	chr3:158606615	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.544	rs16829135	ENSG00000240207.5	RP11-379F4.4	-3.72	0.000244	0.0449	-0.29	-0.23	Tetralogy of Fallot;	chr3:158608049	chr3:158732263~158784070:+
COAD	cis	rs7131987	0.903	rs11050152	ENSG00000257176.2	RP11-996F15.2	-3.72	0.000244	0.0449	-0.27	-0.23	QT interval;	chr12:29251491	chr12:29280418~29317848:-
COAD	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-3.72	0.000244	0.0449	-0.26	-0.23	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
COAD	cis	rs2337406	1	rs61268362	ENSG00000211964.3	IGHV3-48	-3.72	0.000244	0.0449	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106697010	chr14:106537810~106538344:-
COAD	cis	rs1799949	0.965	rs2236762	ENSG00000279602.1	CTD-3014M21.1	3.72	0.000244	0.0449	0.24	0.23	Menopause (age at onset);	chr17:43074658	chr17:43360041~43361361:-
COAD	cis	rs10911184	0.7	rs12407471	ENSG00000232860.6	SMG7-AS1	-3.72	0.000244	0.0449	-0.35	-0.23	Diabetic kidney disease;	chr1:183013326	chr1:183460874~183472265:-
COAD	cis	rs10911184	0.7	rs12043864	ENSG00000232860.6	SMG7-AS1	-3.72	0.000244	0.0449	-0.35	-0.23	Diabetic kidney disease;	chr1:183018261	chr1:183460874~183472265:-
COAD	cis	rs10911184	0.7	rs12404564	ENSG00000232860.6	SMG7-AS1	-3.72	0.000244	0.0449	-0.35	-0.23	Diabetic kidney disease;	chr1:183018602	chr1:183460874~183472265:-
COAD	cis	rs1707322	0.686	rs1547924	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000244	0.0449	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45694684~45697075:-
COAD	cis	rs875971	0.965	rs9969301	ENSG00000223473.2	GS1-124K5.3	-3.72	0.000244	0.0449	-0.18	-0.23	Aortic root size;	chr7:66316668	chr7:66491049~66493566:-
COAD	cis	rs7105056	1	rs7951263	ENSG00000230911.1	PPIHP1	-3.72	0.000244	0.0449	-0.51	-0.23	Immune reponse to smallpox (secreted IL-12p40);	chr11:112390072	chr11:112029858~112030367:-
COAD	cis	rs670292	1	rs6906229	ENSG00000216906.2	RP11-350J20.9	3.72	0.000244	0.0449	0.29	0.23	Anger;	chr6:150386713	chr6:149904243~149906418:+
COAD	cis	rs80346118	0.852	rs56313611	ENSG00000177410.11	ZFAS1	-3.72	0.000244	0.0449	-0.27	-0.23	Diastolic blood pressure;	chr20:48840319	chr20:49278178~49295738:+
COAD	cis	rs3796352	0.892	rs3821872	ENSG00000280417.1	RP11-5O17.1	3.72	0.000244	0.0449	0.32	0.23	Immune reponse to smallpox (secreted IL-2);	chr3:53046539	chr3:53046166~53048122:+
COAD	cis	rs1707322	0.752	rs4660313	ENSG00000281912.1	LINC01144	3.72	0.000244	0.0449	0.22	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45303910~45305619:+
COAD	cis	rs7521902	0.853	rs3920498	ENSG00000218510.5	LINC00339	-3.72	0.000244	0.0449	-0.28	-0.23	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22166394	chr1:22025188~22031223:+
COAD	cis	rs7656342	0.724	rs35512765	ENSG00000186234.7	FAM86MP	-3.72	0.000244	0.0449	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr4:9881609	chr4:9692495~9702954:+
COAD	cis	rs67072384	1	rs7124056	ENSG00000202522.1	Y_RNA	3.72	0.000244	0.0449	0.32	0.23	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733702	chr11:72766004~72766116:+
COAD	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	3.72	0.000244	0.0449	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
COAD	cis	rs11641365	1	rs11641365	ENSG00000278341.1	RP5-1142A6.10	-3.72	0.000244	0.0449	-0.33	-0.23	Autism spectrum disorder-related traits;	chr16:88707485	chr16:88708956~88710437:-
COAD	cis	rs7656342	0.755	rs11737821	ENSG00000186234.7	FAM86MP	-3.72	0.000244	0.0449	-0.29	-0.23	Gut microbiota (bacterial taxa);	chr4:9883621	chr4:9692495~9702954:+
COAD	cis	rs2337406	0.85	rs8014460	ENSG00000211964.3	IGHV3-48	-3.72	0.000244	0.0449	-0.19	-0.23	Alzheimer's disease (late onset);	chr14:106697140	chr14:106537810~106538344:-
COAD	cis	rs4713118	0.513	rs156739	ENSG00000272009.1	RP1-313I6.12	3.72	0.000244	0.0449	0.26	0.23	Parkinson's disease;	chr6:28045632	chr6:28078792~28081130:-
COAD	cis	rs228614	0.51	rs223438	ENSG00000248971.2	KRT8P46	3.72	0.000244	0.0449	0.23	0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102728746~102730171:-
COAD	cis	rs12682352	0.535	rs12677550	ENSG00000253893.2	FAM85B	3.72	0.000244	0.0449	0.27	0.23	Neuroticism;	chr8:8786812	chr8:8167819~8226614:-
COAD	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-3.72	0.000244	0.0449	-0.24	-0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
COAD	cis	rs4760786	0.641	rs2088157	ENSG00000258053.1	CTD-2021H9.3	-3.72	0.000244	0.0449	-0.29	-0.23	Monobrow;	chr12:71179989	chr12:71047402~71118247:-
COAD	cis	rs4760786	0.703	rs4377005	ENSG00000258053.1	CTD-2021H9.3	-3.72	0.000244	0.0449	-0.29	-0.23	Monobrow;	chr12:71180803	chr12:71047402~71118247:-
COAD	cis	rs6461992	0.51	rs17426751	ENSG00000253308.2	RP1-170O19.17	3.72	0.000244	0.045	0.56	0.23	Systolic blood pressure;	chr7:26946441	chr7:27239243~27241228:-
COAD	cis	rs728616	0.867	rs2152548	ENSG00000234382.2	RP11-40F6.1	-3.72	0.000244	0.045	-0.41	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:80233664~80245367:+
COAD	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-3.72	0.000244	0.045	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
COAD	cis	rs4604234	0.803	rs73465567	ENSG00000272129.1	RP11-250B2.6	-3.72	0.000244	0.045	-0.67	-0.23	Cancer;	chr6:80330975	chr6:80355424~80356859:+
COAD	cis	rs3126085	0.544	rs3126074	ENSG00000237975.5	FLG-AS1	3.72	0.000244	0.045	0.25	0.23	Atopic dermatitis;	chr1:152307365	chr1:152168125~152445456:+
COAD	cis	rs4660214	0.666	rs3116398	ENSG00000182109.6	RP11-69E11.4	-3.72	0.000245	0.045	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39522280~39546187:-
COAD	cis	rs7829975	0.623	rs10087493	ENSG00000233609.3	RP11-62H7.2	-3.72	0.000245	0.045	-0.25	-0.23	Mood instability;	chr8:8516047	chr8:8961200~8979025:+
COAD	cis	rs10871290	0.507	rs3851731	ENSG00000262904.1	TMPOP2	-3.72	0.000245	0.045	-0.25	-0.23	Breast cancer;	chr16:74451890	chr16:74667506~74668706:+
COAD	cis	rs17666538	0.585	rs1669733	ENSG00000254207.1	RP11-43A14.1	-3.72	0.000245	0.045	-0.38	-0.23	IgG glycosylation;	chr8:656696	chr8:725188~725877:-
COAD	cis	rs9307551	0.584	rs2903636	ENSG00000250334.4	LINC00989	-3.72	0.000245	0.045	-0.26	-0.23	Refractive error;	chr4:79542125	chr4:79492416~79576460:+
COAD	cis	rs13188386	0.732	rs7735889	ENSG00000249779.1	RP11-447H19.3	-3.72	0.000245	0.045	-0.26	-0.23	Iron status biomarkers;	chr5:42562097	chr5:43206709~43207811:+
COAD	cis	rs4761470	0.577	rs57925369	ENSG00000258365.1	RP11-1105G2.3	-3.72	0.000245	0.045	-0.27	-0.23	Estradiol plasma levels (breast cancer);	chr12:94295732	chr12:94277758~94282844:-
COAD	cis	rs1115240	0.574	rs61988529	ENSG00000257842.4	NOVA1-AS1	3.72	0.000245	0.045	0.3	0.23	Educational attainment (years of education);	chr14:26461009	chr14:26598412~26806467:+
COAD	cis	rs1115240	0.574	rs55928941	ENSG00000257842.4	NOVA1-AS1	3.72	0.000245	0.045	0.3	0.23	Educational attainment (years of education);	chr14:26463805	chr14:26598412~26806467:+
COAD	cis	rs6545883	0.894	rs6545845	ENSG00000273302.1	RP11-493E12.2	-3.72	0.000245	0.045	-0.22	-0.23	Tuberculosis;	chr2:61209909	chr2:61199979~61200769:+
COAD	cis	rs6545883	0.86	rs6545847	ENSG00000273302.1	RP11-493E12.2	-3.72	0.000245	0.045	-0.22	-0.23	Tuberculosis;	chr2:61218198	chr2:61199979~61200769:+
COAD	cis	rs7829975	0.688	rs7827182	ENSG00000233609.3	RP11-62H7.2	3.72	0.000245	0.045	0.24	0.23	Mood instability;	chr8:8522961	chr8:8961200~8979025:+
COAD	cis	rs7572733	0.935	rs1607376	ENSG00000222017.1	AC011997.1	3.72	0.000245	0.045	0.25	0.23	Dermatomyositis;	chr2:197963190	chr2:197693106~197774823:+
COAD	cis	rs7572733	0.935	rs1850633	ENSG00000222017.1	AC011997.1	3.72	0.000245	0.045	0.25	0.23	Dermatomyositis;	chr2:197964858	chr2:197693106~197774823:+
COAD	cis	rs7260598	0.792	rs11669295	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000245	0.045	0.35	0.23	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.792	rs11670299	ENSG00000268442.1	CTD-2027I19.2	3.72	0.000245	0.045	0.35	0.23	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:24162370~24163425:-
COAD	cis	rs6762	0.748	rs28551040	ENSG00000279672.1	CMB9-55F22.1	3.72	0.000245	0.0451	0.23	0.23	Mean platelet volume;	chr11:840740	chr11:779617~780755:+
COAD	cis	rs2115630	0.875	rs8039472	ENSG00000259244.1	RP11-182J1.12	-3.72	0.000245	0.0451	-0.24	-0.23	P wave terminal force;	chr15:84818413	chr15:84513241~84526949:-
COAD	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	3.72	0.000245	0.0451	0.41	0.23	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
COAD	cis	rs13118159	0.505	rs1250128	ENSG00000254094.1	AC078852.1	3.72	0.000245	0.0451	0.27	0.23	Longevity;	chr4:1263523	chr4:1356581~1358075:+
COAD	cis	rs742132	0.893	rs12183240	ENSG00000220875.1	HIST1H3PS1	3.72	0.000245	0.0451	0.29	0.23	Uric acid levels;	chr6:25624188	chr6:26321876~26322292:-
COAD	cis	rs742132	0.893	rs73397619	ENSG00000220875.1	HIST1H3PS1	3.72	0.000245	0.0451	0.29	0.23	Uric acid levels;	chr6:25624572	chr6:26321876~26322292:-
COAD	cis	rs1023500	1	rs6002554	ENSG00000205702.9	CYP2D7	-3.72	0.000245	0.0451	-0.18	-0.23	Schizophrenia;	chr22:41943091	chr22:42140203~42144577:-
COAD	cis	rs11229555	0.645	rs12802819	ENSG00000254602.1	AP000662.4	-3.72	0.000245	0.0451	-0.27	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58407274	chr11:57638024~57652790:+
COAD	cis	rs3126085	1	rs2011331	ENSG00000237975.5	FLG-AS1	3.72	0.000245	0.0451	0.25	0.23	Atopic dermatitis;	chr1:152313526	chr1:152168125~152445456:+
COAD	cis	rs9532669	0.926	rs4555012	ENSG00000277662.1	RP11-74J13.9	-3.72	0.000245	0.0451	-0.21	-0.23	Cervical cancer;	chr13:40879997	chr13:41229180~41229676:-
COAD	cis	rs11098499	0.863	rs6534141	ENSG00000250412.1	KLHL2P1	3.72	0.000245	0.0451	0.3	0.23	Corneal astigmatism;	chr4:119564068	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.863	rs2127823	ENSG00000250412.1	KLHL2P1	3.72	0.000245	0.0451	0.3	0.23	Corneal astigmatism;	chr4:119564515	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.863	rs3775858	ENSG00000250412.1	KLHL2P1	3.72	0.000245	0.0451	0.3	0.23	Corneal astigmatism;	chr4:119564873	chr4:119334329~119378233:+
COAD	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	3.72	0.000245	0.0451	0.26	0.23	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	3.72	0.000245	0.0451	0.26	0.23	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	3.72	0.000245	0.0451	0.26	0.23	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
COAD	cis	rs2708377	0.858	rs115781584	ENSG00000212125.2	TAS2R15P	3.72	0.000246	0.0451	0.42	0.23	Bitter taste perception;	chr12:11151961	chr12:10964425~10965352:-
COAD	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-3.72	0.000246	0.0451	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
COAD	cis	rs699371	0.525	rs10138386	ENSG00000270000.1	RP3-449M8.9	3.72	0.000246	0.0451	0.28	0.23	Height;	chr14:74434183	chr14:74471930~74472360:-
COAD	cis	rs875971	1	rs2220626	ENSG00000223473.2	GS1-124K5.3	-3.72	0.000246	0.0451	-0.19	-0.23	Aortic root size;	chr7:66081075	chr7:66491049~66493566:-
COAD	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	3.72	0.000246	0.0451	0.4	0.23	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
COAD	cis	rs1707322	0.716	rs10890342	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs6658700	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs12047629	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs11211169	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs11211171	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs28623463	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.716	rs28370457	ENSG00000230896.1	RP11-767N6.7	-3.72	0.000246	0.0451	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45694684~45697075:-
COAD	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-3.72	0.000246	0.0451	-0.3	-0.23	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
COAD	cis	rs7577696	0.925	rs212716	ENSG00000272716.1	RP11-563N4.1	3.72	0.000246	0.0452	0.23	0.23	Inflammatory biomarkers;	chr2:32235865	chr2:32165046~32165757:-
COAD	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	3.72	0.000246	0.0452	0.28	0.23	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
COAD	cis	rs4879656	0.835	rs13290323	ENSG00000225693.1	LAGE3P1	-3.72	0.000246	0.0452	-0.26	-0.23	Menopause (age at onset);	chr9:33062293	chr9:33019682~33020165:-
COAD	cis	rs61841072	0.961	rs6657349	ENSG00000253326.2	RP11-261C10.7	-3.72	0.000246	0.0452	-0.3	-0.23	Schizophrenia;	chr1:242961209	chr1:243054861~243056394:-
COAD	cis	rs719150	1	rs11970411	ENSG00000237499.5	RP11-356I2.4	-3.72	0.000246	0.0452	-0.3	-0.23	Cancer;	chr6:137858024	chr6:137823673~137868233:-
COAD	cis	rs853679	0.607	rs34878803	ENSG00000204709.4	LINC01556	3.72	0.000246	0.0452	0.6	0.23	Depression;	chr6:28282402	chr6:28943877~28944537:+
COAD	cis	rs853679	0.607	rs34396849	ENSG00000204709.4	LINC01556	3.72	0.000246	0.0452	0.6	0.23	Depression;	chr6:28283178	chr6:28943877~28944537:+
COAD	cis	rs853679	0.607	rs13211507	ENSG00000204709.4	LINC01556	3.72	0.000246	0.0452	0.6	0.23	Depression;	chr6:28289600	chr6:28943877~28944537:+
COAD	cis	rs853679	0.607	rs34691223	ENSG00000204709.4	LINC01556	3.72	0.000246	0.0452	0.6	0.23	Depression;	chr6:28290431	chr6:28943877~28944537:+
COAD	cis	rs57221529	0.766	rs12522303	ENSG00000250385.1	RP11-310P5.2	3.72	0.000246	0.0452	0.38	0.23	Lung disease severity in cystic fibrosis;	chr5:555449	chr5:524705~526594:+
COAD	cis	rs57221529	0.766	rs12521988	ENSG00000250385.1	RP11-310P5.2	3.72	0.000246	0.0452	0.38	0.23	Lung disease severity in cystic fibrosis;	chr5:556306	chr5:524705~526594:+
COAD	cis	rs57221529	0.766	rs72706606	ENSG00000250385.1	RP11-310P5.2	3.72	0.000246	0.0452	0.38	0.23	Lung disease severity in cystic fibrosis;	chr5:558494	chr5:524705~526594:+
COAD	cis	rs57221529	0.766	rs12519763	ENSG00000250385.1	RP11-310P5.2	3.72	0.000246	0.0452	0.38	0.23	Lung disease severity in cystic fibrosis;	chr5:559030	chr5:524705~526594:+
COAD	cis	rs57221529	0.766	rs72706608	ENSG00000250385.1	RP11-310P5.2	3.72	0.000246	0.0452	0.38	0.23	Lung disease severity in cystic fibrosis;	chr5:559088	chr5:524705~526594:+
COAD	cis	rs78487399	0.808	rs13416978	ENSG00000234936.1	AC010883.5	-3.72	0.000246	0.0452	-0.29	-0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478126	chr2:43229573~43233394:+
COAD	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	3.72	0.000246	0.0452	0.21	0.23	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
COAD	cis	rs10911232	0.507	rs10797829	ENSG00000224468.3	RP11-181K3.4	3.72	0.000246	0.0452	0.22	0.23	Hypertriglyceridemia;	chr1:183064093	chr1:183138402~183141282:-
COAD	cis	rs17685	0.753	rs10476	ENSG00000280388.1	RP11-229D13.3	3.72	0.000247	0.0453	0.23	0.23	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76043977~76045963:-
COAD	cis	rs6687821	0.515	rs7552285	ENSG00000261737.1	RP4-612B15.3	3.72	0.000247	0.0453	0.3	0.23	Yeast infection;	chr1:87017482	chr1:86703502~86704462:-
COAD	cis	rs3748656	0.887	rs12728311	ENSG00000231246.1	RP5-965F6.2	-3.72	0.000247	0.0453	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112601817	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs9308256	ENSG00000231246.1	RP5-965F6.2	-3.72	0.000247	0.0453	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112611742	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs12122980	ENSG00000231246.1	RP5-965F6.2	-3.72	0.000247	0.0453	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112614559	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.895	rs11102513	ENSG00000231246.1	RP5-965F6.2	-3.72	0.000247	0.0453	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112617548	chr1:112177234~112360528:-
COAD	cis	rs3748656	0.945	rs11102514	ENSG00000231246.1	RP5-965F6.2	-3.72	0.000247	0.0453	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112617797	chr1:112177234~112360528:-
COAD	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	3.72	0.000247	0.0453	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
COAD	cis	rs911263	0.603	rs10141370	ENSG00000259502.1	RP11-643G16.3	-3.72	0.000247	0.0453	-0.27	-0.23	Primary biliary cholangitis;	chr14:68309453	chr14:67610986~67613864:+
COAD	cis	rs911263	0.603	rs7148073	ENSG00000259502.1	RP11-643G16.3	-3.72	0.000247	0.0453	-0.27	-0.23	Primary biliary cholangitis;	chr14:68310325	chr14:67610986~67613864:+
COAD	cis	rs875971	1	rs4718307	ENSG00000223473.2	GS1-124K5.3	-3.72	0.000247	0.0453	-0.19	-0.23	Aortic root size;	chr7:66146001	chr7:66491049~66493566:-
COAD	cis	rs875971	1	rs7801282	ENSG00000223473.2	GS1-124K5.3	-3.72	0.000247	0.0453	-0.19	-0.23	Aortic root size;	chr7:66148700	chr7:66491049~66493566:-
COAD	cis	rs172166	0.637	rs1225597	ENSG00000272009.1	RP1-313I6.12	3.72	0.000247	0.0453	0.26	0.23	Cardiac Troponin-T levels;	chr6:28194309	chr6:28078792~28081130:-
COAD	cis	rs172166	0.637	rs1071893	ENSG00000272009.1	RP1-313I6.12	3.72	0.000247	0.0453	0.26	0.23	Cardiac Troponin-T levels;	chr6:28199857	chr6:28078792~28081130:-
COAD	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	3.72	0.000247	0.0453	0.26	0.23	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
COAD	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	3.72	0.000247	0.0453	0.26	0.23	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
COAD	cis	rs17268829	0.886	rs6465421	ENSG00000231170.4	AC002451.3	-3.72	0.000247	0.0453	-0.27	-0.23	Breast cancer;	chr7:94618659	chr7:95596682~95613719:+
COAD	cis	rs17268829	0.925	rs10953114	ENSG00000231170.4	AC002451.3	-3.72	0.000247	0.0453	-0.27	-0.23	Breast cancer;	chr7:94632755	chr7:95596682~95613719:+
COAD	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-3.72	0.000247	0.0453	-0.24	-0.23	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
COAD	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-3.72	0.000247	0.0453	-0.32	-0.23	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
COAD	cis	rs4713118	0.868	rs742047	ENSG00000281706.1	LINC01012	-3.72	0.000247	0.0453	-0.28	-0.23	Parkinson's disease;	chr6:27771601	chr6:27694035~27710222:+
COAD	cis	rs4713118	0.868	rs760587	ENSG00000281706.1	LINC01012	-3.72	0.000247	0.0453	-0.28	-0.23	Parkinson's disease;	chr6:27772521	chr6:27694035~27710222:+
COAD	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-3.72	0.000247	0.0453	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
COAD	cis	rs4813003	0.551	rs35296663	ENSG00000271984.1	RP3-337O18.9	-3.72	0.000247	0.0453	-0.4	-0.23	Kawasaki disease;	chr20:46133436	chr20:45892694~45893419:-
COAD	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	3.72	0.000247	0.0453	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
COAD	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	3.72	0.000247	0.0453	0.29	0.23	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
COAD	cis	rs1510510	0.676	rs2878089	ENSG00000225057.2	AC096574.4	3.72	0.000247	0.0453	0.29	0.23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238638511	chr2:238231684~238255633:+
COAD	cis	rs11138902	0.673	rs12553491	ENSG00000229312.2	RP11-470P21.2	3.72	0.000247	0.0453	0.25	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69518080	chr9:69472466~69494513:+
COAD	cis	rs796825	0.553	rs787197	ENSG00000240661.1	RP11-174O3.3	-3.72	0.000247	0.0453	-0.35	-0.23	HIV-1 susceptibility;	chr3:120308001	chr3:120349510~120367998:+
COAD	cis	rs796825	0.597	rs1085612	ENSG00000240661.1	RP11-174O3.3	-3.72	0.000247	0.0453	-0.35	-0.23	HIV-1 susceptibility;	chr3:120314612	chr3:120349510~120367998:+
COAD	cis	rs796825	0.597	rs1085613	ENSG00000240661.1	RP11-174O3.3	-3.72	0.000247	0.0453	-0.35	-0.23	HIV-1 susceptibility;	chr3:120315310	chr3:120349510~120367998:+
COAD	cis	rs796825	0.597	rs1092829	ENSG00000240661.1	RP11-174O3.3	-3.72	0.000247	0.0453	-0.35	-0.23	HIV-1 susceptibility;	chr3:120318714	chr3:120349510~120367998:+
COAD	cis	rs16831128	1	rs75122146	ENSG00000230992.3	FAM201B	-3.72	0.000247	0.0454	-0.32	-0.23	Conduct disorder;Conduct disorder (symptom count);	chr2:132390987	chr2:132352722~132353318:+
COAD	cis	rs8022206	0.812	rs378408	ENSG00000259502.1	RP11-643G16.3	3.72	0.000247	0.0454	0.3	0.23	Platelet count;Mean platelet volume;	chr14:68117112	chr14:67610986~67613864:+
COAD	cis	rs2018293	1	rs1115764	ENSG00000233521.4	RP5-1172A22.1	3.72	0.000247	0.0454	0.2	0.23	Vascular brain injury;	chr22:26313341	chr22:27221349~27224727:-
COAD	cis	rs180358	0.535	rs1787700	ENSG00000246100.3	LINC00900	3.72	0.000247	0.0454	0.24	0.23	Multiple sclerosis (severity);	chr11:116693692	chr11:115754248~115760627:-
COAD	cis	rs180358	0.535	rs1942479	ENSG00000246100.3	LINC00900	3.72	0.000247	0.0454	0.24	0.23	Multiple sclerosis (severity);	chr11:116695401	chr11:115754248~115760627:-
COAD	cis	rs3733585	0.699	rs17245723	ENSG00000250413.1	RP11-448G15.1	3.72	0.000247	0.0454	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9960594	chr4:10006482~10009725:+
COAD	cis	rs748404	0.66	rs690367	ENSG00000275601.1	AC011330.13	3.72	0.000247	0.0454	0.27	0.23	Lung cancer;	chr15:43456106	chr15:43642389~43643023:-
COAD	cis	rs6545883	0.507	rs62149712	ENSG00000273302.1	RP11-493E12.2	-3.72	0.000247	0.0454	-0.2	-0.23	Tuberculosis;	chr2:61374137	chr2:61199979~61200769:+
COAD	cis	rs2559856	1	rs10745921	ENSG00000199933.1	RNY1P16	3.72	0.000248	0.0454	0.25	0.23	Blood protein levels;	chr12:101693415	chr12:101719808~101719918:+
COAD	cis	rs2559856	1	rs10860771	ENSG00000199933.1	RNY1P16	3.72	0.000248	0.0454	0.25	0.23	Blood protein levels;	chr12:101693464	chr12:101719808~101719918:+
COAD	cis	rs2559856	1	rs2695292	ENSG00000199933.1	RNY1P16	3.72	0.000248	0.0454	0.25	0.23	Blood protein levels;	chr12:101693512	chr12:101719808~101719918:+
COAD	cis	rs10760158	0.832	rs10760159	ENSG00000226752.6	PSMD5-AS1	-3.72	0.000248	0.0454	-0.24	-0.23	Pulse pressure;	chr9:121236064	chr9:120824828~120854385:+
COAD	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-3.72	0.000248	0.0454	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
COAD	cis	rs17407555	0.657	rs16895675	ENSG00000250413.1	RP11-448G15.1	-3.72	0.000248	0.0454	-0.29	-0.23	Schizophrenia (age at onset);	chr4:10270431	chr4:10006482~10009725:+
COAD	cis	rs9298995	0.868	rs545709	ENSG00000237009.2	GLIS3-AS1	3.72	0.000248	0.0454	0.29	0.23	Neuroticism;	chr9:4140626	chr9:3898642~3901248:+
COAD	cis	rs9487051	1	rs9487052	ENSG00000219700.1	PTCHD3P3	3.72	0.000248	0.0454	0.25	0.23	Reticulocyte fraction of red cells;	chr6:109295883	chr6:109288571~109290503:-
COAD	cis	rs739496	0.793	rs628825	ENSG00000257595.2	RP3-473L9.4	3.72	0.000248	0.0455	0.31	0.23	Platelet count;	chr12:111514046	chr12:111369282~111403310:+
COAD	cis	rs739496	0.843	rs657197	ENSG00000257595.2	RP3-473L9.4	3.72	0.000248	0.0455	0.31	0.23	Platelet count;	chr12:111527854	chr12:111369282~111403310:+
COAD	cis	rs4648045	0.796	rs4648068	ENSG00000246560.2	RP11-10L12.4	3.72	0.000248	0.0455	0.3	0.23	Lymphocyte percentage of white cells;	chr4:102597148	chr4:102828055~102844075:+
COAD	cis	rs8002861	0.664	rs9567292	ENSG00000274001.1	RP11-5G9.5	3.72	0.000248	0.0455	0.2	0.23	Leprosy;	chr13:43870680	chr13:43877715~43878163:-
COAD	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	3.72	0.000248	0.0455	0.42	0.23	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
COAD	cis	rs875971	0.895	rs12698520	ENSG00000223473.2	GS1-124K5.3	3.72	0.000248	0.0455	0.19	0.23	Aortic root size;	chr7:66453720	chr7:66491049~66493566:-
COAD	cis	rs4072705	0.967	rs4838210	ENSG00000236643.1	RP11-175D17.3	-3.72	0.000248	0.0455	-0.23	-0.23	Menarche (age at onset);	chr9:124783904	chr9:124770123~124772927:+
COAD	cis	rs2302729	0.578	rs11062298	ENSG00000246627.5	CACNA1C-AS1	3.72	0.000248	0.0455	0.27	0.23	Sleep quality;	chr12:2662543	chr12:2676001~2691200:-
COAD	cis	rs11098499	0.754	rs28643450	ENSG00000250412.1	KLHL2P1	3.72	0.000248	0.0455	0.3	0.23	Corneal astigmatism;	chr4:119324087	chr4:119334329~119378233:+
COAD	cis	rs1005277	0.54	rs7903942	ENSG00000263064.2	RP11-291L22.7	-3.72	0.000248	0.0455	-0.22	-0.23	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38448689~38448949:+
COAD	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-3.72	0.000248	0.0455	-0.23	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
COAD	cis	rs728616	0.867	rs17886286	ENSG00000234382.2	RP11-40F6.1	-3.72	0.000248	0.0455	-0.42	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:80233664~80245367:+
COAD	cis	rs4927850	0.957	rs4927851	ENSG00000185485.13	SDHAP1	3.72	0.000248	0.0455	0.2	0.23	Pancreatic cancer;	chr3:196024982	chr3:195959748~195990318:-
COAD	cis	rs4927850	0.918	rs4361313	ENSG00000185485.13	SDHAP1	3.72	0.000248	0.0455	0.2	0.23	Pancreatic cancer;	chr3:196025389	chr3:195959748~195990318:-
COAD	cis	rs10876993	0.928	rs1678540	ENSG00000270039.1	RP11-571M6.17	3.72	0.000248	0.0455	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57671219	chr12:57803838~57804415:+
COAD	cis	rs2638953	0.924	rs11049444	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000249	0.0455	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049445	ENSG00000247934.4	RP11-967K21.1	-3.72	0.000249	0.0455	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28163298~28190738:-
COAD	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-3.72	0.000249	0.0455	-0.23	-0.23	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
COAD	cis	rs7204230	1	rs12598049	ENSG00000261056.2	RP11-454F8.2	-3.72	0.000249	0.0455	-0.27	-0.23	Fibrinogen;	chr16:53282942	chr16:53298224~53299792:+
COAD	cis	rs5771242	0.518	rs6010216	ENSG00000273253.2	RP3-402G11.26	-3.72	0.000249	0.0455	-0.33	-0.23	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241042	chr22:50199090~50200837:-
COAD	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	3.72	0.000249	0.0455	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
COAD	cis	rs3752645	0.881	rs111451744	ENSG00000241764.3	AC002467.7	3.72	0.000249	0.0456	0.4	0.23	Bladder cancer (smoking interaction);	chr7:107142771	chr7:107742817~107744581:-
COAD	cis	rs73222236	0.825	rs6439638	ENSG00000273486.1	RP11-731C17.2	3.72	0.000249	0.0456	0.23	0.23	Coronary artery disease;	chr3:136338990	chr3:136837338~136839021:-
COAD	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-3.72	0.000249	0.0456	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
COAD	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-3.72	0.000249	0.0456	-0.28	-0.23	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
COAD	cis	rs10129255	0.5	rs8006888	ENSG00000211967.3	IGHV3-53	-3.72	0.000249	0.0456	-0.13	-0.23	Kawasaki disease;	chr14:106782219	chr14:106592676~106593347:-
COAD	cis	rs1714507	0.515	rs2731112	ENSG00000272087.1	RP11-379F4.7	3.72	0.000249	0.0456	0.28	0.23	Subjective well-being;	chr3:158572439	chr3:158693120~158693768:-
COAD	cis	rs1714507	0.533	rs2731122	ENSG00000272087.1	RP11-379F4.7	3.72	0.000249	0.0456	0.28	0.23	Subjective well-being;	chr3:158577491	chr3:158693120~158693768:-
COAD	cis	rs113542380	1	rs113542380	ENSG00000234936.1	AC010883.5	3.72	0.000249	0.0456	0.45	0.23	Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin;Neutrophil count;Plateletcrit;	chr2:43237679	chr2:43229573~43233394:+
COAD	cis	rs2592394	0.626	rs711828	ENSG00000226363.3	HAGLROS	-3.72	0.000249	0.0456	-0.37	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);Magnesium levels;	chr2:176135635	chr2:176177717~176179008:+
COAD	cis	rs2592394	0.596	rs711829	ENSG00000226363.3	HAGLROS	-3.72	0.000249	0.0456	-0.37	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);Magnesium levels;	chr2:176136564	chr2:176177717~176179008:+
COAD	cis	rs10819861	0.645	rs4743535	ENSG00000238251.2	RP11-172F4.2	-3.72	0.000249	0.0456	-0.28	-0.23	Electrocardiographic traits;	chr9:96095671	chr9:96407284~96407797:+
COAD	cis	rs742132	0.858	rs4712949	ENSG00000220875.1	HIST1H3PS1	3.72	0.000249	0.0456	0.3	0.23	Uric acid levels;	chr6:25643975	chr6:26321876~26322292:-
COAD	cis	rs2361718	0.5	rs8064429	ENSG00000279259.1	RP11-334C17.3	3.72	0.000249	0.0456	0.23	0.23	Yeast infection;	chr17:80122388	chr17:80147250~80148596:+
COAD	cis	rs6738181	1	rs6738181	ENSG00000224791.1	KRT18P39	-3.72	0.000249	0.0456	-0.27	-0.23	Alzheimer's disease (late onset);	chr2:204263298	chr2:203764295~203765593:-
COAD	cis	rs757278	0.513	rs214163	ENSG00000237974.1	AC000111.4	3.72	0.000249	0.0456	0.24	0.23	Response to methotrexate in juvenile idiopathic arthritis;	chr7:117653498	chr7:117487737~117487929:+
COAD	cis	rs17666538	0.585	rs4735812	ENSG00000254207.1	RP11-43A14.1	3.72	0.000249	0.0456	0.39	0.23	IgG glycosylation;	chr8:657766	chr8:725188~725877:-
COAD	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	3.71	0.000249	0.0456	0.15	0.23	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
COAD	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-3.71	0.000249	0.0456	-0.27	-0.23	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
COAD	cis	rs8062405	0.573	rs7140	ENSG00000261067.5	RP11-264B17.3	-3.71	0.000249	0.0456	-0.16	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28974804~28990783:+
COAD	cis	rs6762	0.719	rs28620453	ENSG00000279672.1	CMB9-55F22.1	3.71	0.000249	0.0456	0.23	0.23	Mean platelet volume;	chr11:836971	chr11:779617~780755:+
COAD	cis	rs848490	1	rs11765986	ENSG00000213542.3	RP11-467H10.1	-3.71	0.000249	0.0457	-0.27	-0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77727957	chr7:77115399~77116192:-
COAD	cis	rs10129255	0.5	rs8022547	ENSG00000211967.3	IGHV3-53	-3.71	0.000249	0.0457	-0.13	-0.23	Kawasaki disease;	chr14:106781985	chr14:106592676~106593347:-
COAD	cis	rs1552244	0.688	rs9875667	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.31	0.23	Alzheimer's disease;	chr3:10138357	chr3:10014238~10026365:-
COAD	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	3.71	0.00025	0.0457	0.22	0.23	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
COAD	cis	rs9532669	0.926	rs4600337	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40879564	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs12871420	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880034	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs12871735	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880169	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs12871895	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880189	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs12872288	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880268	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532640	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880628	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.89	rs9532641	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880648	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532643	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880800	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.963	rs9532644	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880860	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532645	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880898	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9532646	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40880989	chr13:41229180~41229676:-
COAD	cis	rs9532669	0.926	rs9525419	ENSG00000277662.1	RP11-74J13.9	-3.71	0.00025	0.0457	-0.21	-0.23	Cervical cancer;	chr13:40881047	chr13:41229180~41229676:-
COAD	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	3.71	0.00025	0.0457	0.3	0.23	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
COAD	cis	rs1707322	0.721	rs4660883	ENSG00000230896.1	RP11-767N6.7	-3.71	0.00025	0.0457	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45694684~45697075:-
COAD	cis	rs578196	1	rs501909	ENSG00000228741.2	SPATA13	-3.71	0.00025	0.0457	-0.29	-0.23	Asthma;	chr13:23186741	chr13:23979810~24035027:+
COAD	cis	rs8017304	0.643	rs2331727	ENSG00000259502.1	RP11-643G16.3	-3.71	0.00025	0.0457	-0.3	-0.23	Age-related macular degeneration;	chr14:68337969	chr14:67610986~67613864:+
COAD	cis	rs1552244	0.882	rs3732967	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9973753	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs3732966	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9974056	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs13062917	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9975348	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.816	rs13076197	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9978089	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs34779351	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9980117	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs13077641	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9981251	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs13074282	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9983015	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs67895180	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9984395	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs3755782	ENSG00000186162.9	CIDECP	3.71	0.00025	0.0457	0.32	0.23	Alzheimer's disease;	chr3:9987621	chr3:10014238~10026365:-
COAD	cis	rs10129255	0.5	rs34326748	ENSG00000211967.3	IGHV3-53	-3.71	0.00025	0.0457	-0.13	-0.23	Kawasaki disease;	chr14:106782523	chr14:106592676~106593347:-
COAD	cis	rs10129255	0.5	rs10143385	ENSG00000211967.3	IGHV3-53	-3.71	0.00025	0.0457	-0.13	-0.23	Kawasaki disease;	chr14:106782559	chr14:106592676~106593347:-
COAD	cis	rs10876993	0.928	rs10082911	ENSG00000270039.1	RP11-571M6.17	3.71	0.00025	0.0457	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57710321	chr12:57803838~57804415:+
COAD	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-3.71	0.00025	0.0457	-0.26	-0.23	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
COAD	cis	rs7760535	0.764	rs2343614	ENSG00000271789.1	RP5-1112D6.7	-3.71	0.00025	0.0457	-0.21	-0.23	Metabolic traits;	chr6:111383955	chr6:111297126~111298510:+
COAD	cis	rs3733585	0.673	rs7376948	ENSG00000250413.1	RP11-448G15.1	3.71	0.00025	0.0457	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9953084	chr4:10006482~10009725:+
COAD	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	3.71	0.00025	0.0457	0.19	0.23	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
COAD	cis	rs13256369	0.755	rs12550057	ENSG00000254153.1	CTA-398F10.2	3.71	0.00025	0.0457	0.3	0.23	Obesity-related traits;	chr8:8704758	chr8:8456909~8461337:-
COAD	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	3.71	0.00025	0.0457	0.3	0.23	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
COAD	cis	rs2732480	0.5	rs11168464	ENSG00000269514.1	RP11-370I10.12	3.71	0.00025	0.0457	0.27	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48198387~48202031:+
COAD	cis	rs17268829	0.925	rs13073	ENSG00000231170.4	AC002451.3	-3.71	0.00025	0.0457	-0.27	-0.23	Breast cancer;	chr7:94667457	chr7:95596682~95613719:+
COAD	cis	rs8080784	0.932	rs7210893	ENSG00000264049.1	MIR4737	-3.71	0.00025	0.0457	-0.3	-0.23	Coronary artery disease;	chr17:60922423	chr17:60043025~60043105:-
COAD	cis	rs796825	0.597	rs787210	ENSG00000240661.1	RP11-174O3.3	-3.71	0.00025	0.0457	-0.35	-0.23	HIV-1 susceptibility;	chr3:120321280	chr3:120349510~120367998:+
COAD	cis	rs2856321	0.874	rs2856324	ENSG00000212125.2	TAS2R15P	-3.71	0.00025	0.0457	-0.25	-0.23	Height;	chr12:11723655	chr12:10964425~10965352:-
COAD	cis	rs7760535	0.831	rs62420437	ENSG00000230177.1	RP5-1112D6.4	-3.71	0.00025	0.0457	-0.2	-0.23	Metabolic traits;	chr6:111427577	chr6:111277932~111278742:+
COAD	cis	rs189798	0.807	rs330905	ENSG00000253981.4	ALG1L13P	3.71	0.00025	0.0457	0.31	0.23	Myopia (pathological);	chr8:9136041	chr8:8236003~8244667:-
COAD	cis	rs78487399	0.71	rs74616425	ENSG00000234936.1	AC010883.5	3.71	0.00025	0.0457	0.38	0.23	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43386443	chr2:43229573~43233394:+
COAD	cis	rs1979679	0.608	rs1581073	ENSG00000278733.1	RP11-425D17.1	-3.71	0.00025	0.0458	-0.28	-0.23	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571106	chr12:28185625~28186190:-
COAD	cis	rs9951150	0.599	rs729053	ENSG00000267013.4	CTD-2171N6.1	3.71	0.00025	0.0458	0.31	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr18:55142450	chr18:55105904~55124306:-
COAD	cis	rs17646946	0.757	rs12123975	ENSG00000229021.2	AL591893.1	3.71	0.00025	0.0458	0.32	0.23	Common traits (Other);	chr1:152032328	chr1:151994531~152042774:+
COAD	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	3.71	0.00025	0.0458	0.44	0.23	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
COAD	cis	rs11229555	0.645	rs10896785	ENSG00000254602.1	AP000662.4	-3.71	0.00025	0.0458	-0.28	-0.23	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58465922	chr11:57638024~57652790:+
COAD	cis	rs7955901	0.673	rs1512989	ENSG00000258053.1	CTD-2021H9.3	3.71	0.00025	0.0458	0.29	0.23	Type 2 diabetes;	chr12:71061394	chr12:71047402~71118247:-
COAD	cis	rs68170813	0.527	rs78133594	ENSG00000241764.3	AC002467.7	3.71	0.00025	0.0458	0.32	0.23	Coronary artery disease;	chr7:107384815	chr7:107742817~107744581:-
COAD	cis	rs11846409	0.655	rs79296226	ENSG00000211964.3	IGHV3-48	3.71	0.00025	0.0458	0.19	0.23	Rheumatic heart disease;	chr14:106650436	chr14:106537810~106538344:-
COAD	cis	rs2307394	1	rs13027200	ENSG00000281469.1	RP11-567F11.1	3.71	0.00025	0.0458	0.28	0.23	Urate levels;	chr2:147952084	chr2:148044380~148044894:+
COAD	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	3.71	0.00025	0.0458	0.39	0.23	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	3.71	0.00025	0.0458	0.39	0.23	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	3.71	0.00025	0.0458	0.39	0.23	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
COAD	cis	rs3768617	0.51	rs10797838	ENSG00000224468.3	RP11-181K3.4	-3.71	0.00025	0.0458	-0.22	-0.23	Fuchs's corneal dystrophy;	chr1:183107885	chr1:183138402~183141282:-
COAD	cis	rs10129255	0.5	rs4774008	ENSG00000211967.3	IGHV3-53	-3.71	0.000251	0.0458	-0.13	-0.23	Kawasaki disease;	chr14:106681273	chr14:106592676~106593347:-
COAD	cis	rs2732480	0.5	rs2450991	ENSG00000269514.1	RP11-370I10.12	3.71	0.000251	0.0458	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48198387~48202031:+
COAD	cis	rs756699	1	rs244950	ENSG00000279469.1	RP11-215P8.2	-3.71	0.000251	0.0458	-0.32	-0.23	Multiple sclerosis;	chr5:134109937	chr5:134394360~134395008:-
COAD	cis	rs756699	0.915	rs244951	ENSG00000279469.1	RP11-215P8.2	-3.71	0.000251	0.0458	-0.32	-0.23	Multiple sclerosis;	chr5:134110017	chr5:134394360~134395008:-
COAD	cis	rs7246657	0.551	rs4806414	ENSG00000226686.6	LINC01535	-3.71	0.000251	0.0458	-0.39	-0.23	Coronary artery calcification;	chr19:37147886	chr19:37251912~37265535:+
COAD	cis	rs7818688	0.578	rs71532343	ENSG00000253528.2	RP11-347C18.4	-3.71	0.000251	0.0458	-0.34	-0.23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95064585	chr8:94974573~94974853:-
COAD	cis	rs7818688	0.578	rs35518242	ENSG00000253528.2	RP11-347C18.4	-3.71	0.000251	0.0458	-0.34	-0.23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95066867	chr8:94974573~94974853:-
COAD	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-3.71	0.000251	0.0458	-0.26	-0.23	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
COAD	cis	rs11079159	0.586	rs17817995	ENSG00000263096.1	RP11-515O17.2	-3.71	0.000251	0.0458	-0.28	-0.23	QRS duration;	chr17:55335233	chr17:55271504~55273653:-
COAD	cis	rs2554380	0.628	rs890311	ENSG00000176700.18	SCAND2P	-3.71	0.000251	0.0458	-0.2	-0.23	Height;	chr15:83772200	chr15:84631451~84647478:+
COAD	cis	rs8258	0.512	rs573455	ENSG00000254851.1	RP11-109L13.1	-3.71	0.000251	0.0458	-0.27	-0.23	Pulse pressure;	chr11:117397168	chr11:117135528~117138582:+
COAD	cis	rs6452524	0.935	rs6868416	ENSG00000271862.1	RP11-343L5.2	3.71	0.000251	0.0459	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83049376~83050964:-
COAD	cis	rs6452524	0.935	rs1478485	ENSG00000271862.1	RP11-343L5.2	3.71	0.000251	0.0459	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83049376~83050964:-
COAD	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	3.71	0.000251	0.0459	0.31	0.23	Pain;	chr19:21577269	chr19:21554640~21569237:-
COAD	cis	rs10129255	0.957	rs8005468	ENSG00000224373.3	IGHV4-59	3.71	0.000251	0.0459	0.14	0.23	Kawasaki disease;	chr14:106686431	chr14:106627249~106627825:-
COAD	cis	rs1707322	0.752	rs28890893	ENSG00000230896.1	RP11-767N6.7	-3.71	0.000251	0.0459	-0.27	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45694684~45697075:-
COAD	cis	rs3845624	0.531	rs11265157	ENSG00000236257.1	EI24P2	-3.71	0.000251	0.0459	-0.27	-0.23	Inflammatory biomarkers;	chr1:159254239	chr1:158454198~158455273:+
COAD	cis	rs3845624	0.531	rs11265158	ENSG00000236257.1	EI24P2	-3.71	0.000251	0.0459	-0.27	-0.23	Inflammatory biomarkers;	chr1:159254240	chr1:158454198~158455273:+
COAD	cis	rs2070488	0.56	rs1381798	ENSG00000229589.1	ACVR2B-AS1	-3.71	0.000251	0.0459	-0.24	-0.23	Electrocardiographic conduction measures;	chr3:38395980	chr3:38451027~38454820:-
COAD	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	3.71	0.000251	0.0459	0.28	0.23	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
COAD	cis	rs7955901	0.691	rs7295488	ENSG00000258053.1	CTD-2021H9.3	3.71	0.000251	0.0459	0.29	0.23	Type 2 diabetes;	chr12:71058266	chr12:71047402~71118247:-
COAD	cis	rs36052053	0.908	rs932222	ENSG00000219700.1	PTCHD3P3	-3.71	0.000251	0.0459	-0.36	-0.23	Red cell distribution width;	chr6:109265475	chr6:109288571~109290503:-
COAD	cis	rs2554380	0.55	rs12904106	ENSG00000176700.18	SCAND2P	-3.71	0.000251	0.0459	-0.22	-0.23	Height;	chr15:83842571	chr15:84631451~84647478:+
COAD	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	3.71	0.000251	0.0459	0.33	0.23	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
COAD	cis	rs6772849	0.901	rs9289330	ENSG00000242551.2	POU5F1P6	-3.71	0.000251	0.0459	-0.24	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128674735~128677005:-
COAD	cis	rs1005277	0.691	rs2474558	ENSG00000276805.1	RP11-291L22.6	-3.71	0.000251	0.0459	-0.22	-0.23	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38451030~38451785:+
COAD	cis	rs10876993	0.728	rs1082503	ENSG00000270039.1	RP11-571M6.17	3.71	0.000251	0.0459	0.26	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57642934	chr12:57803838~57804415:+
COAD	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000252	0.0459	-0.28	-0.23	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
COAD	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	3.71	0.000252	0.0459	0.31	0.23	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
COAD	cis	rs911263	0.603	rs12880842	ENSG00000259502.1	RP11-643G16.3	-3.71	0.000252	0.0459	-0.28	-0.23	Primary biliary cholangitis;	chr14:68297537	chr14:67610986~67613864:+
COAD	cis	rs728616	0.867	rs12414877	ENSG00000234382.2	RP11-40F6.1	-3.71	0.000252	0.0459	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:80233664~80245367:+
COAD	cis	rs2243480	0.901	rs35256305	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65841418	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs35825738	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65853040	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs34702770	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65879836	chr7:65751142~65763354:+
COAD	cis	rs2243480	0.803	rs35480979	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65892097	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs34637256	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65895144	chr7:65751142~65763354:+
COAD	cis	rs2243480	1	rs35391607	ENSG00000228409.4	CCT6P1	3.71	0.000252	0.0459	0.28	0.23	Diabetic kidney disease;	chr7:65895842	chr7:65751142~65763354:+
COAD	cis	rs56036086	0.817	rs73187269	ENSG00000273137.1	RP3-402G11.28	3.71	0.000252	0.0459	0.24	0.23	Platelet count;Plateletcrit;	chr22:50224992	chr22:50208461~50209542:-
COAD	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	3.71	0.000252	0.0459	0.23	0.23	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
COAD	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-3.71	0.000252	0.0459	-0.4	-0.23	Depression;	chr6:28103220	chr6:28115628~28116551:+
COAD	cis	rs2638953	0.962	rs7303747	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000252	0.0459	-0.24	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28163298~28190738:-
COAD	cis	rs73191547	0.666	rs6996281	ENSG00000254936.4	AF131215.3	3.71	0.000252	0.046	0.24	0.23	Schizophrenia;	chr8:10185881	chr8:11123381~11126064:-
COAD	cis	rs10087240	0.55	rs1134492	ENSG00000207110.1	RNU1-106P	3.71	0.000252	0.046	0.28	0.23	Lymphocyte counts;White blood cell count;	chr8:127992019	chr8:127999131~127999294:+
COAD	cis	rs172166	0.561	rs149971	ENSG00000272009.1	RP1-313I6.12	3.71	0.000252	0.046	0.25	0.23	Cardiac Troponin-T levels;	chr6:28014374	chr6:28078792~28081130:-
COAD	cis	rs11633886	0.835	rs3848111	ENSG00000273972.1	CTD-2306A12.1	-3.71	0.000252	0.046	-0.25	-0.23	Diisocyanate-induced asthma;	chr15:45807349	chr15:45702640~45703183:+
COAD	cis	rs654950	0.841	rs2759247	ENSG00000230638.4	RP11-486B10.4	3.71	0.000252	0.046	0.25	0.23	Airway imaging phenotypes;	chr1:41526085	chr1:41542069~41544310:+
COAD	cis	rs654950	0.841	rs2810549	ENSG00000230638.4	RP11-486B10.4	3.71	0.000252	0.046	0.25	0.23	Airway imaging phenotypes;	chr1:41526090	chr1:41542069~41544310:+
COAD	cis	rs11098499	0.657	rs10434028	ENSG00000249244.1	RP11-548H18.2	3.71	0.000252	0.046	0.29	0.23	Corneal astigmatism;	chr4:119373309	chr4:119391831~119395335:-
COAD	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-3.71	0.000252	0.046	-0.27	-0.23	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
COAD	cis	rs1552244	0.748	rs113890152	ENSG00000186162.9	CIDECP	3.71	0.000252	0.046	0.33	0.23	Alzheimer's disease;	chr3:10044302	chr3:10014238~10026365:-
COAD	cis	rs2070488	0.662	rs7373930	ENSG00000229589.1	ACVR2B-AS1	3.71	0.000252	0.046	0.24	0.23	Electrocardiographic conduction measures;	chr3:38413440	chr3:38451027~38454820:-
COAD	cis	rs7009110	0.721	rs10957975	ENSG00000213791.4	RP11-941H19.2	3.71	0.000252	0.046	0.22	0.23	Asthma and hay fever;	chr8:80347211	chr8:80300869~80301481:+
COAD	cis	rs902774	0.818	rs79377635	ENSG00000257475.2	RP11-983P16.2	-3.71	0.000252	0.046	-0.36	-0.23	Prostate cancer;	chr12:52883148	chr12:53012104~53013921:+
COAD	cis	rs7172689	1	rs28455908	ENSG00000271725.1	RP11-761I4.4	3.71	0.000252	0.046	0.29	0.23	Inattentive symptoms;	chr15:81254972	chr15:81303215~81309391:-
COAD	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-3.71	0.000252	0.046	-0.23	-0.23	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
COAD	cis	rs728616	0.867	rs56123058	ENSG00000234382.2	RP11-40F6.1	-3.71	0.000252	0.046	-0.4	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:80233664~80245367:+
COAD	cis	rs1552244	0.882	rs13063098	ENSG00000186162.9	CIDECP	3.71	0.000252	0.046	0.32	0.23	Alzheimer's disease;	chr3:9968235	chr3:10014238~10026365:-
COAD	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-3.71	0.000252	0.046	-0.2	-0.23	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
COAD	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-3.71	0.000252	0.046	-0.2	-0.23	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
COAD	cis	rs875971	0.862	rs880166	ENSG00000224316.1	RP11-479O9.2	-3.71	0.000252	0.046	-0.25	-0.23	Aortic root size;	chr7:66205775	chr7:65773620~65802067:+
COAD	cis	rs2638953	0.925	rs11049491	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000252	0.046	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049493	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000252	0.046	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.962	rs11049496	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000252	0.046	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.889	rs2045887	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000252	0.046	-0.25	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28163298~28190738:-
COAD	cis	rs3126085	0.825	rs4298736	ENSG00000237975.5	FLG-AS1	-3.71	0.000252	0.046	-0.25	-0.23	Atopic dermatitis;	chr1:152267793	chr1:152168125~152445456:+
COAD	cis	rs7665090	0.806	rs434644	ENSG00000230069.3	LRRC37A15P	3.71	0.000252	0.046	0.25	0.23	Primary biliary cholangitis;	chr4:102662032	chr4:102727274~102730721:-
COAD	cis	rs7665090	0.806	rs413967	ENSG00000230069.3	LRRC37A15P	3.71	0.000252	0.046	0.25	0.23	Primary biliary cholangitis;	chr4:102662039	chr4:102727274~102730721:-
COAD	cis	rs7665090	0.806	rs404574	ENSG00000230069.3	LRRC37A15P	3.71	0.000252	0.046	0.25	0.23	Primary biliary cholangitis;	chr4:102662051	chr4:102727274~102730721:-
COAD	cis	rs5753037	0.838	rs5763565	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Type 1 diabetes;	chr22:29875973	chr22:29978950~30028236:-
COAD	cis	rs714027	0.545	rs1807513	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Lymphocyte counts;	chr22:29893830	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.869	rs5763581	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Type 1 diabetes;	chr22:29894644	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.869	rs2189802	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Type 1 diabetes;	chr22:29898184	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.834	rs5763589	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Type 1 diabetes;	chr22:29899572	chr22:29978950~30028236:-
COAD	cis	rs5753037	0.869	rs5763591	ENSG00000279159.1	RP3-394A18.1	-3.71	0.000252	0.046	-0.16	-0.23	Type 1 diabetes;	chr22:29902197	chr22:29978950~30028236:-
COAD	cis	rs4654899	1	rs7543126	ENSG00000271428.1	RP1-224A6.8	3.71	0.000253	0.0461	0.23	0.23	Superior frontal gyrus grey matter volume;	chr1:21079595	chr1:22068340~22068827:-
COAD	cis	rs2638953	0.924	rs11049475	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000253	0.0461	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28163298~28190738:-
COAD	cis	rs2732480	0.577	rs2634693	ENSG00000240399.1	RP1-228P16.1	3.71	0.000253	0.0461	0.25	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48054813~48055591:-
COAD	cis	rs2732480	0.577	rs2634691	ENSG00000240399.1	RP1-228P16.1	3.71	0.000253	0.0461	0.25	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48054813~48055591:-
COAD	cis	rs6866344	0.568	rs10516147	ENSG00000251211.1	RP11-889L3.4	3.71	0.000253	0.0461	0.3	0.23	Neutrophil percentage of white cells;	chr5:178667483	chr5:178165702~178166562:+
COAD	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-3.71	0.000253	0.0461	-0.36	-0.23	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
COAD	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-3.71	0.000253	0.0461	-0.24	-0.23	Height;	chr11:118855938	chr11:118791254~118793137:+
COAD	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	3.71	0.000253	0.0461	0.35	0.23	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
COAD	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	3.71	0.000253	0.0461	0.17	0.23	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
COAD	cis	rs2337406	0.866	rs2301535	ENSG00000254174.1	IGHV1-12	3.71	0.000253	0.0462	0.21	0.23	Alzheimer's disease (late onset);	chr14:106790663	chr14:106122420~106122709:-
COAD	cis	rs739496	0.546	rs11066055	ENSG00000257595.2	RP3-473L9.4	3.71	0.000253	0.0462	0.34	0.23	Platelet count;	chr12:111875412	chr12:111369282~111403310:+
COAD	cis	rs875971	0.545	rs6460281	ENSG00000232546.1	RP11-458F8.1	3.71	0.000253	0.0462	0.22	0.23	Aortic root size;	chr7:66216128	chr7:66848496~66858136:+
COAD	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	3.71	0.000253	0.0462	0.29	0.23	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
COAD	cis	rs7584330	0.554	rs3751106	ENSG00000234949.2	AC104667.3	-3.71	0.000253	0.0462	-0.32	-0.23	Prostate cancer;	chr2:237519775	chr2:237591020~237595981:+
COAD	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	3.71	0.000253	0.0462	0.24	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
COAD	cis	rs2977125	0.593	rs2977165	ENSG00000251468.2	RP11-369K16.1	3.71	0.000253	0.0462	0.36	0.23	Schizophrenia;	chr8:12879480	chr8:12958387~12962200:+
COAD	cis	rs860295	0.775	rs729022	ENSG00000223503.1	RP11-29H23.6	3.71	0.000253	0.0462	0.29	0.23	Body mass index;	chr1:155882332	chr1:155590601~155591262:-
COAD	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	3.71	0.000253	0.0462	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	3.71	0.000253	0.0462	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
COAD	cis	rs2439831	0.702	rs2467402	ENSG00000166763.7	STRCP1	3.71	0.000253	0.0462	0.31	0.23	Lung cancer in ever smokers;	chr15:43732292	chr15:43699488~43718184:-
COAD	cis	rs736408	0.608	rs35004449	ENSG00000243224.1	RP5-1157M23.2	-3.71	0.000254	0.0462	-0.25	-0.23	Bipolar disorder;	chr3:52818881	chr3:52239258~52241097:+
COAD	cis	rs4973517	0.719	rs13029658	ENSG00000237126.7	AC073254.1	3.71	0.000254	0.0462	0.32	0.23	Hip circumference adjusted for BMI;	chr2:231978479	chr2:232580948~232611971:-
COAD	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	3.71	0.000254	0.0462	0.3	0.23	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	3.71	0.000254	0.0462	0.3	0.23	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
COAD	cis	rs1577917	0.739	rs9450318	ENSG00000220563.1	PKMP3	3.71	0.000254	0.0462	0.25	0.23	Response to antipsychotic treatment;	chr6:85717459	chr6:85659892~85660606:-
COAD	cis	rs13256369	0.851	rs13266562	ENSG00000254153.1	CTA-398F10.2	3.71	0.000254	0.0462	0.3	0.23	Obesity-related traits;	chr8:8706555	chr8:8456909~8461337:-
COAD	cis	rs2124910	0.815	rs4801873	ENSG00000273837.1	LLNLR-470E3.1	3.71	0.000254	0.0462	0.21	0.23	Blood protein levels;	chr19:51524382	chr19:51639478~51639931:-
COAD	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000254	0.0462	-0.28	-0.23	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
COAD	cis	rs479105	0.605	rs61597223	ENSG00000242444.3	RP11-320N7.1	3.71	0.000254	0.0462	0.28	0.23	Gut microbiota (bacterial taxa);	chr12:3264571	chr12:4109661~4118132:-
COAD	cis	rs1850744	1	rs2280208	ENSG00000251087.3	ALG1L3P	-3.71	0.000254	0.0462	-0.5	-0.23	Economic and political preferences;	chr4:9798419	chr4:9703754~9710812:-
COAD	cis	rs2638953	0.924	rs2078017	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000254	0.0462	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28163298~28190738:-
COAD	cis	rs2638953	0.924	rs11049405	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000254	0.0462	-0.22	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28163298~28190738:-
COAD	cis	rs884366	1	rs4946955	ENSG00000219700.1	PTCHD3P3	-3.71	0.000254	0.0462	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr6:109318507	chr6:109288571~109290503:-
COAD	cis	rs453301	0.686	rs6987107	ENSG00000254340.1	RP11-10A14.3	-3.71	0.000254	0.0463	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9036071	chr8:9141424~9145435:+
COAD	cis	rs7615952	0.546	rs11711150	ENSG00000241278.1	ENPP7P4	3.71	0.000254	0.0463	0.28	0.23	Blood pressure (smoking interaction);	chr3:125596819	chr3:125848223~125909372:+
COAD	cis	rs6672530	0.518	rs17555357	ENSG00000212237.1	RNA5SP18	3.71	0.000254	0.0463	0.23	0.23	Hip circumference adjusted for BMI;	chr1:227748826	chr1:228647912~228648032:-
COAD	cis	rs13188386	0.732	rs10941579	ENSG00000249779.1	RP11-447H19.3	3.71	0.000254	0.0463	0.26	0.23	Iron status biomarkers;	chr5:42566064	chr5:43206709~43207811:+
COAD	cis	rs1023500	1	rs6002554	ENSG00000233903.2	Z83851.4	-3.71	0.000254	0.0463	-0.27	-0.23	Schizophrenia;	chr22:41943091	chr22:42276355~42277052:+
COAD	cis	rs7204230	1	rs8055523	ENSG00000261056.2	RP11-454F8.2	3.71	0.000254	0.0463	0.27	0.23	Fibrinogen;	chr16:53139242	chr16:53298224~53299792:+
COAD	cis	rs11138902	0.673	rs13290847	ENSG00000229312.2	RP11-470P21.2	3.71	0.000254	0.0463	0.25	0.23	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69497885	chr9:69472466~69494513:+
COAD	cis	rs6976664	0.953	rs12536741	ENSG00000206838.1	SNORA5A	-3.71	0.000254	0.0463	-0.24	-0.23	Pursuit maintenance gain;	chr7:44974236	chr7:45104349~45104482:-
COAD	cis	rs7572733	0.935	rs1607373	ENSG00000222017.1	AC011997.1	3.71	0.000254	0.0463	0.25	0.23	Dermatomyositis;	chr2:197935808	chr2:197693106~197774823:+
COAD	cis	rs7324557	0.651	rs9510875	ENSG00000205861.10	C1QTNF9B-AS1	-3.71	0.000254	0.0463	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23820351	chr13:23888889~23897263:+
COAD	cis	rs7324557	0.717	rs729137	ENSG00000205861.10	C1QTNF9B-AS1	-3.71	0.000254	0.0463	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23821523	chr13:23888889~23897263:+
COAD	cis	rs7324557	0.717	rs9318064	ENSG00000205861.10	C1QTNF9B-AS1	-3.71	0.000254	0.0463	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23822010	chr13:23888889~23897263:+
COAD	cis	rs7324557	0.717	rs9510876	ENSG00000205861.10	C1QTNF9B-AS1	-3.71	0.000254	0.0463	-0.32	-0.23	Visceral adipose tissue adjusted for BMI;	chr13:23822149	chr13:23888889~23897263:+
COAD	cis	rs10760158	0.832	rs10985194	ENSG00000226752.6	PSMD5-AS1	-3.71	0.000254	0.0463	-0.24	-0.23	Pulse pressure;	chr9:121265434	chr9:120824828~120854385:+
COAD	cis	rs9652601	0.622	rs6498143	ENSG00000274038.1	RP11-66H6.4	-3.71	0.000254	0.0463	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11001179	chr16:11056556~11057034:+
COAD	cis	rs28374715	0.578	rs17730589	ENSG00000247556.5	OIP5-AS1	3.71	0.000254	0.0463	0.31	0.23	Ulcerative colitis;	chr15:41308680	chr15:41283990~41309737:+
COAD	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-3.71	0.000254	0.0463	-0.23	-0.23	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
COAD	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-3.71	0.000254	0.0463	-0.23	-0.23	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
COAD	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	3.71	0.000254	0.0463	0.26	0.23	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
COAD	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	3.71	0.000254	0.0463	0.26	0.23	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
COAD	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	3.71	0.000254	0.0463	0.34	0.23	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
COAD	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	3.71	0.000254	0.0463	0.34	0.23	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
COAD	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000254	0.0463	-0.29	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
COAD	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000254	0.0463	-0.29	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
COAD	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000254	0.0463	-0.29	-0.23	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
COAD	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	3.71	0.000254	0.0463	0.22	0.23	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
COAD	cis	rs3733585	0.699	rs10001964	ENSG00000250413.1	RP11-448G15.1	3.71	0.000254	0.0463	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9957651	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.699	rs6449158	ENSG00000250413.1	RP11-448G15.1	3.71	0.000254	0.0463	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9958835	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.637	rs6850684	ENSG00000250413.1	RP11-448G15.1	3.71	0.000254	0.0463	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9962756	chr4:10006482~10009725:+
COAD	cis	rs3733585	0.673	rs9994937	ENSG00000250413.1	RP11-448G15.1	3.71	0.000254	0.0463	0.29	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9963175	chr4:10006482~10009725:+
COAD	cis	rs453301	0.571	rs330048	ENSG00000254340.1	RP11-10A14.3	-3.71	0.000254	0.0463	-0.26	-0.23	Joint mobility (Beighton score);	chr8:9229768	chr8:9141424~9145435:+
COAD	cis	rs1499614	1	rs2659913	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66692349	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2707840	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66693028	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2659911	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66693433	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2707838	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66694214	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs60326618	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66701371	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2707830	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66702658	chr7:66554588~66576923:-
COAD	cis	rs1499614	1	rs2707828	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66706390	chr7:66554588~66576923:-
COAD	cis	rs1499614	0.803	rs1922723	ENSG00000232559.3	GS1-124K5.12	3.71	0.000254	0.0463	0.39	0.23	Gout;	chr7:66710076	chr7:66554588~66576923:-
COAD	cis	rs8114671	0.562	rs4911164	ENSG00000228265.4	RALY-AS1	3.71	0.000254	0.0463	0.21	0.23	Height;	chr20:34891685	chr20:33983052~33994357:-
COAD	cis	rs4076764	0.881	rs10917758	ENSG00000232995.6	RGS5	3.71	0.000254	0.0463	0.22	0.23	Motion sickness;	chr1:163460862	chr1:163244505~163321894:-
COAD	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	3.71	0.000254	0.0463	0.25	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
COAD	cis	rs11157436	0.602	rs928954	ENSG00000211812.1	TRAV26-2	-3.71	0.000254	0.0463	-0.22	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22202583~22203368:+
COAD	cis	rs10087240	0.509	rs11997631	ENSG00000207110.1	RNU1-106P	3.71	0.000255	0.0463	0.28	0.23	Lymphocyte counts;White blood cell count;	chr8:127988253	chr8:127999131~127999294:+
COAD	cis	rs763121	0.853	rs6519119	ENSG00000273076.1	RP3-508I15.22	3.71	0.000255	0.0463	0.21	0.23	Menopause (age at onset);	chr22:38593002	chr22:38743495~38743910:+
COAD	cis	rs9923283	1	rs11866143	ENSG00000205534.6	SMG1P2	-3.71	0.000255	0.0464	-0.4	-0.23	Plateletcrit;	chr16:29643215	chr16:29527568~29594966:-
COAD	cis	rs451417	1	rs236108	ENSG00000275632.1	RP5-967N21.11	3.71	0.000255	0.0464	0.31	0.23	Menopause (age at onset);	chr20:5987913	chr20:6000418~6000941:+
COAD	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	3.71	0.000255	0.0464	0.26	0.23	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
COAD	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	3.71	0.000255	0.0464	0.26	0.23	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
COAD	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-3.71	0.000255	0.0464	-0.28	-0.23	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
COAD	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-3.71	0.000255	0.0464	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-3.71	0.000255	0.0464	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
COAD	cis	rs11098499	0.722	rs10006192	ENSG00000249244.1	RP11-548H18.2	3.71	0.000255	0.0464	0.29	0.23	Corneal astigmatism;	chr4:119341867	chr4:119391831~119395335:-
COAD	cis	rs12428035	0.772	rs3101570	ENSG00000247400.3	DNAJC3-AS1	3.71	0.000255	0.0464	0.24	0.23	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95825965	chr13:95648733~95676925:-
COAD	cis	rs10760158	0.832	rs10818523	ENSG00000226752.6	PSMD5-AS1	-3.71	0.000255	0.0464	-0.24	-0.23	Pulse pressure;	chr9:121265809	chr9:120824828~120854385:+
COAD	cis	rs10760158	0.832	rs10818524	ENSG00000226752.6	PSMD5-AS1	-3.71	0.000255	0.0464	-0.24	-0.23	Pulse pressure;	chr9:121267901	chr9:120824828~120854385:+
COAD	cis	rs71636778	0.584	rs36042864	ENSG00000260063.1	RP5-968P14.2	-3.71	0.000255	0.0464	-0.34	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26820453	chr1:26692132~26694131:-
COAD	cis	rs166988	0.536	rs17326595	ENSG00000267296.2	CEBPA-AS1	3.71	0.000255	0.0464	0.22	0.23	Obesity-related traits;	chr19:33842941	chr19:33302857~33305054:+
COAD	cis	rs73198271	0.7	rs10090152	ENSG00000173295.6	FAM86B3P	-3.71	0.000255	0.0464	-0.3	-0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8228595~8244865:+
COAD	cis	rs7953704	1	rs4758691	ENSG00000280389.1	RP11-512M8.11	-3.71	0.000255	0.0464	-0.26	-0.23	Urate levels;	chr12:122125472	chr12:122255119~122260274:-
COAD	cis	rs2836754	1	rs11701117	ENSG00000205622.8	AF064858.6	3.71	0.000255	0.0464	0.26	0.23	Body mass index;Crohn's disease;	chr21:38920588	chr21:38863676~38956467:-
COAD	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	3.71	0.000255	0.0464	0.25	0.23	Height;	chr4:55460485	chr4:55363971~55395847:-
COAD	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	3.71	0.000255	0.0464	0.25	0.23	Height;	chr4:55465165	chr4:55363971~55395847:-
COAD	cis	rs7810240	1	rs4725889	ENSG00000239377.1	RP4-584D14.6	3.71	0.000255	0.0464	0.21	0.23	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr7:150395596	chr7:150379854~150383885:-
COAD	cis	rs7577696	0.85	rs428002	ENSG00000272716.1	RP11-563N4.1	3.71	0.000255	0.0464	0.24	0.23	Inflammatory biomarkers;	chr2:32262705	chr2:32165046~32165757:-
COAD	cis	rs240993	0.812	rs6937734	ENSG00000271789.1	RP5-1112D6.7	3.71	0.000255	0.0464	0.23	0.23	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111297126~111298510:+
COAD	cis	rs447735	0.587	rs11647958	ENSG00000260259.1	RP11-368I7.4	3.71	0.000255	0.0464	0.24	0.23	Hemoglobin concentration;	chr16:89654501	chr16:89682620~89686569:-
COAD	cis	rs4072705	0.967	rs10818979	ENSG00000236643.1	RP11-175D17.3	3.71	0.000255	0.0465	0.24	0.23	Menarche (age at onset);	chr9:124574634	chr9:124770123~124772927:+
COAD	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-3.71	0.000255	0.0465	-0.22	-0.23	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
COAD	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	3.71	0.000255	0.0465	0.21	0.23	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
COAD	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-3.71	0.000255	0.0465	-0.23	-0.23	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
COAD	cis	rs9652601	0.779	rs725613	ENSG00000274038.1	RP11-66H6.4	-3.71	0.000255	0.0465	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11075826	chr16:11056556~11057034:+
COAD	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-3.71	0.000256	0.0465	-0.23	-0.23	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
COAD	cis	rs4253772	0.515	rs6008591	ENSG00000280424.1	CITF22-92A6.2	3.71	0.000256	0.0465	0.36	0.23	Cholesterol, total;LDL cholesterol;	chr22:46307767	chr22:46006616~46010777:+
COAD	cis	rs4253772	0.55	rs6007818	ENSG00000280424.1	CITF22-92A6.2	3.71	0.000256	0.0465	0.36	0.23	Cholesterol, total;LDL cholesterol;	chr22:46307879	chr22:46006616~46010777:+
COAD	cis	rs4253772	0.591	rs6008595	ENSG00000280424.1	CITF22-92A6.2	3.71	0.000256	0.0465	0.36	0.23	Cholesterol, total;LDL cholesterol;	chr22:46307963	chr22:46006616~46010777:+
COAD	cis	rs4253772	0.513	rs6008597	ENSG00000280424.1	CITF22-92A6.2	3.71	0.000256	0.0465	0.36	0.23	Cholesterol, total;LDL cholesterol;	chr22:46308007	chr22:46006616~46010777:+
COAD	cis	rs10129255	0.957	rs1024349	ENSG00000224373.3	IGHV4-59	3.71	0.000256	0.0465	0.14	0.23	Kawasaki disease;	chr14:106689997	chr14:106627249~106627825:-
COAD	cis	rs2877649	0.51	rs10083368	ENSG00000215256.3	DHRS4-AS1	-3.71	0.000256	0.0465	-0.36	-0.23	Smooth-surface caries;	chr14:24438978	chr14:23938731~23988839:-
COAD	cis	rs2877649	0.51	rs10083369	ENSG00000215256.3	DHRS4-AS1	-3.71	0.000256	0.0465	-0.36	-0.23	Smooth-surface caries;	chr14:24439005	chr14:23938731~23988839:-
COAD	cis	rs3790268	0.527	rs6112466	ENSG00000233895.1	RP1-122P22.2	3.71	0.000256	0.0465	0.4	0.23	Matrix metalloproteinase levels;	chr20:19574059	chr20:19757708~19809675:+
COAD	cis	rs12682352	0.652	rs1567398	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000256	0.0465	-0.24	-0.23	Neuroticism;	chr8:8869294	chr8:8961200~8979025:+
COAD	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	3.71	0.000256	0.0465	0.3	0.23	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
COAD	cis	rs28374715	0.783	rs11635269	ENSG00000247556.5	OIP5-AS1	3.71	0.000256	0.0465	0.31	0.23	Ulcerative colitis;	chr15:41278512	chr15:41283990~41309737:+
COAD	cis	rs4591358	0.731	rs13031745	ENSG00000224099.1	AC064834.1	3.71	0.000256	0.0465	0.33	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195440458	chr2:195448532~195478925:+
COAD	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	3.71	0.000256	0.0465	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
COAD	cis	rs7617773	0.823	rs9839446	ENSG00000228638.1	FCF1P2	3.71	0.000256	0.0465	0.27	0.23	Coronary artery disease;	chr3:48153176	chr3:48290793~48291375:-
COAD	cis	rs7617773	0.823	rs9839447	ENSG00000228638.1	FCF1P2	3.71	0.000256	0.0465	0.27	0.23	Coronary artery disease;	chr3:48153177	chr3:48290793~48291375:-
COAD	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-3.71	0.000256	0.0465	-0.29	-0.23	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
COAD	cis	rs356992	1	rs356992	ENSG00000212978.6	AC016747.3	3.71	0.000256	0.0465	0.17	0.23	Educational attainment (years of education);	chr2:60526458	chr2:61141592~61144969:-
COAD	cis	rs720475	1	rs720475	ENSG00000243746.1	EEF1A1P10	3.71	0.000256	0.0465	0.23	0.23	Breast cancer;	chr7:144377836	chr7:144647186~144648575:-
COAD	cis	rs6732160	0.588	rs1430345	ENSG00000163016.8	ALMS1P	3.71	0.000256	0.0465	0.29	0.23	Intelligence (multi-trait analysis);	chr2:73143554	chr2:73644919~73685576:+
COAD	cis	rs6662572	0.906	rs11590549	ENSG00000280836.1	AL355480.1	3.71	0.000256	0.0465	0.28	0.23	Blood protein levels;	chr1:45620657	chr1:45581219~45581321:-
COAD	cis	rs9911578	0.935	rs2567912	ENSG00000278627.1	RP11-506H21.5	-3.71	0.000256	0.0465	-0.27	-0.23	Intelligence (multi-trait analysis);	chr17:58653909	chr17:58202352~58203003:-
COAD	cis	rs7955901	0.638	rs2270586	ENSG00000258053.1	CTD-2021H9.3	3.71	0.000256	0.0465	0.27	0.23	Type 2 diabetes;	chr12:71137859	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.638	rs2270585	ENSG00000258053.1	CTD-2021H9.3	3.71	0.000256	0.0465	0.27	0.23	Type 2 diabetes;	chr12:71137883	chr12:71047402~71118247:-
COAD	cis	rs3748656	0.945	rs12029985	ENSG00000231246.1	RP5-965F6.2	-3.71	0.000256	0.0465	-0.3	-0.23	Hip circumference adjusted for BMI;	chr1:112539161	chr1:112177234~112360528:-
COAD	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-3.71	0.000256	0.0465	-0.23	-0.23	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
COAD	cis	rs9880211	0.948	rs6806123	ENSG00000273486.1	RP11-731C17.2	3.71	0.000256	0.0466	0.27	0.23	Height;Body mass index;	chr3:136586634	chr3:136837338~136839021:-
COAD	cis	rs763121	0.853	rs5750622	ENSG00000273076.1	RP3-508I15.22	3.71	0.000256	0.0466	0.21	0.23	Menopause (age at onset);	chr22:38560459	chr22:38743495~38743910:+
COAD	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	3.71	0.000256	0.0466	0.31	0.23	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
COAD	cis	rs1707322	0.691	rs61784799	ENSG00000230896.1	RP11-767N6.7	3.71	0.000256	0.0466	0.27	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45694684~45697075:-
COAD	cis	rs2124910	1	rs4802800	ENSG00000255441.1	CTD-2616J11.2	3.71	0.000256	0.0466	0.25	0.23	Blood protein levels;	chr19:51517993	chr19:51415724~51417425:+
COAD	cis	rs2124910	0.967	rs4802801	ENSG00000255441.1	CTD-2616J11.2	3.71	0.000256	0.0466	0.25	0.23	Blood protein levels;	chr19:51517996	chr19:51415724~51417425:+
COAD	cis	rs2124910	1	rs1457098	ENSG00000255441.1	CTD-2616J11.2	3.71	0.000256	0.0466	0.25	0.23	Blood protein levels;	chr19:51518283	chr19:51415724~51417425:+
COAD	cis	rs34286592	1	rs13331733	ENSG00000238045.8	AC009133.12	3.71	0.000256	0.0466	0.29	0.23	Multiple sclerosis;	chr16:29837096	chr16:29808636~29821252:-
COAD	cis	rs9900062	0.546	rs2428352	ENSG00000270714.1	MINOS1P2	3.71	0.000256	0.0466	0.25	0.23	QT interval;	chr17:64698620	chr17:64747264~64747492:-
COAD	cis	rs1707322	0.682	rs10890334	ENSG00000230896.1	RP11-767N6.7	-3.71	0.000256	0.0466	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.682	rs10890335	ENSG00000230896.1	RP11-767N6.7	-3.71	0.000256	0.0466	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.716	rs6694889	ENSG00000230896.1	RP11-767N6.7	-3.71	0.000256	0.0466	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.682	rs12041197	ENSG00000230896.1	RP11-767N6.7	-3.71	0.000256	0.0466	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45694684~45697075:-
COAD	cis	rs6688613	0.694	rs11576455	ENSG00000225171.2	DUTP6	-3.71	0.000256	0.0466	-0.33	-0.23	Refractive astigmatism;	chr1:166842733	chr1:166868748~166869209:+
COAD	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-3.71	0.000256	0.0466	-0.25	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
COAD	cis	rs41464545	0.908	rs1822111	ENSG00000249413.2	RP11-25H12.1	-3.71	0.000256	0.0466	-0.28	-0.23	Schizophrenia;	chr4:65025812	chr4:65998846~66150012:+
COAD	cis	rs2836974	0.931	rs2776307	ENSG00000255568.3	BRWD1-AS2	-3.71	0.000256	0.0466	-0.23	-0.23	Cognitive function;	chr21:39341907	chr21:39313935~39314962:+
COAD	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	3.71	0.000256	0.0466	0.29	0.23	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
COAD	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	3.71	0.000256	0.0466	0.33	0.23	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	3.71	0.000256	0.0466	0.33	0.23	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	3.71	0.000256	0.0466	0.33	0.23	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
COAD	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	3.71	0.000256	0.0466	0.33	0.23	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
COAD	cis	rs4660214	0.666	rs950805	ENSG00000182109.6	RP11-69E11.4	-3.71	0.000256	0.0466	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39522280~39546187:-
COAD	cis	rs172166	0.637	rs1225592	ENSG00000280107.1	AL022393.9	-3.71	0.000256	0.0466	-0.28	-0.23	Cardiac Troponin-T levels;	chr6:28182464	chr6:28170845~28172521:+
COAD	cis	rs172166	0.637	rs1225595	ENSG00000280107.1	AL022393.9	-3.71	0.000256	0.0466	-0.28	-0.23	Cardiac Troponin-T levels;	chr6:28183562	chr6:28170845~28172521:+
COAD	cis	rs7582403	0.51	rs12691778	ENSG00000281469.1	RP11-567F11.1	3.71	0.000257	0.0466	0.25	0.23	Neuroticism;	chr2:148157325	chr2:148044380~148044894:+
COAD	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
COAD	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	3.71	0.000257	0.0466	0.31	0.23	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
COAD	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	3.71	0.000257	0.0466	0.23	0.23	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
COAD	cis	rs6762	0.748	rs28735718	ENSG00000279672.1	CMB9-55F22.1	3.71	0.000257	0.0466	0.23	0.23	Mean platelet volume;	chr11:839629	chr11:779617~780755:+
COAD	cis	rs6762	0.642	rs28692469	ENSG00000279672.1	CMB9-55F22.1	3.71	0.000257	0.0466	0.23	0.23	Mean platelet volume;	chr11:839675	chr11:779617~780755:+
COAD	cis	rs10911232	0.507	rs10797833	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000257	0.0466	-0.22	-0.23	Hypertriglyceridemia;	chr1:183074932	chr1:183138402~183141282:-
COAD	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	3.71	0.000257	0.0466	0.39	0.23	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
COAD	cis	rs6715284	1	rs6715284	ENSG00000232133.1	IMPDH1P10	-3.71	0.000257	0.0466	-0.36	-0.23	Rheumatoid arthritis;	chr2:201289674	chr2:201137516~201140027:-
COAD	cis	rs11089937	0.626	rs10483106	ENSG00000211639.2	IGLV4-60	3.71	0.000257	0.0466	0.22	0.23	Periodontitis (PAL4Q3);	chr22:22149240	chr22:22162199~22162681:+
COAD	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	3.71	0.000257	0.0466	0.3	0.23	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
COAD	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	3.71	0.000257	0.0466	0.3	0.23	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
COAD	cis	rs1348850	0.874	rs4893822	ENSG00000213963.5	AC074286.1	3.71	0.000257	0.0467	0.27	0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177420999	chr2:177283508~177392691:-
COAD	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-3.71	0.000257	0.0467	-0.26	-0.23	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
COAD	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	3.71	0.000257	0.0467	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
COAD	cis	rs28374715	0.578	rs13313520	ENSG00000247556.5	OIP5-AS1	3.71	0.000257	0.0467	0.31	0.23	Ulcerative colitis;	chr15:41336929	chr15:41283990~41309737:+
COAD	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-3.71	0.000257	0.0467	-0.23	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
COAD	cis	rs1387259	0.723	rs2732488	ENSG00000226413.2	OR8T1P	3.71	0.000257	0.0467	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48442030~48442947:-
COAD	cis	rs1387259	0.758	rs2634670	ENSG00000226413.2	OR8T1P	3.71	0.000257	0.0467	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48442030~48442947:-
COAD	cis	rs113835537	0.529	rs17065	ENSG00000258297.1	RP11-658F2.8	-3.71	0.000257	0.0467	-0.24	-0.23	Airway imaging phenotypes;	chr11:66509564	chr11:66666036~66668374:+
COAD	cis	rs739496	0.542	rs10849937	ENSG00000257595.2	RP3-473L9.4	3.71	0.000257	0.0467	0.34	0.23	Platelet count;	chr12:111354623	chr12:111369282~111403310:+
COAD	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	3.71	0.000257	0.0467	0.25	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
COAD	cis	rs8002861	0.664	rs895266	ENSG00000274001.1	RP11-5G9.5	3.71	0.000257	0.0467	0.21	0.23	Leprosy;	chr13:43887043	chr13:43877715~43878163:-
COAD	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	3.71	0.000257	0.0467	0.34	0.23	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
COAD	cis	rs4713118	0.513	rs149959	ENSG00000272009.1	RP1-313I6.12	3.71	0.000257	0.0467	0.26	0.23	Parkinson's disease;	chr6:28046076	chr6:28078792~28081130:-
COAD	cis	rs1714507	0.533	rs1620229	ENSG00000272087.1	RP11-379F4.7	3.71	0.000257	0.0467	0.28	0.23	Subjective well-being;	chr3:158575469	chr3:158693120~158693768:-
COAD	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-3.71	0.000257	0.0467	-0.28	-0.23	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
COAD	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	3.71	0.000257	0.0467	0.19	0.23	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
COAD	cis	rs11121022	0.601	rs707455	ENSG00000269925.1	RP3-467L1.6	3.71	0.000257	0.0467	0.22	0.23	Morning vs. evening chronotype;	chr1:7765251	chr1:7776383~7776775:+
COAD	cis	rs6095360	0.901	rs2426120	ENSG00000227431.4	CSE1L-AS1	-3.71	0.000257	0.0467	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49080716	chr20:49040463~49046044:-
COAD	cis	rs6095360	0.933	rs2426122	ENSG00000227431.4	CSE1L-AS1	-3.71	0.000257	0.0467	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49081402	chr20:49040463~49046044:-
COAD	cis	rs1971762	0.545	rs11170632	ENSG00000278185.1	RP11-153F5.7	-3.71	0.000257	0.0467	-0.22	-0.23	Height;	chr12:53654151	chr12:52946614~52947125:-
COAD	cis	rs4767364	1	rs7979545	ENSG00000257595.2	RP3-473L9.4	3.71	0.000257	0.0467	0.29	0.23	Oral cavity and pharyngeal cancer;	chr12:112352844	chr12:111369282~111403310:+
COAD	cis	rs6565180	1	rs12930787	ENSG00000261367.1	RP11-455F5.4	3.71	0.000258	0.0468	0.25	0.23	Tonsillectomy;	chr16:30369982	chr16:30107675~30110541:+
COAD	cis	rs742132	0.858	rs7754155	ENSG00000220875.1	HIST1H3PS1	-3.71	0.000258	0.0468	-0.29	-0.23	Uric acid levels;	chr6:25662458	chr6:26321876~26322292:-
COAD	cis	rs5758659	0.652	rs133336	ENSG00000205702.9	CYP2D7	3.71	0.000258	0.0468	0.17	0.23	Cognitive function;	chr22:42020299	chr22:42140203~42144577:-
COAD	cis	rs10500669	0.609	rs2634183	ENSG00000255410.1	RP11-732A19.6	-3.71	0.000258	0.0468	-0.25	-0.23	Midgestational circulating levels of PCBs;	chr11:6315044	chr11:6630603~6635208:+
COAD	cis	rs10876993	0.89	rs1082502	ENSG00000270039.1	RP11-571M6.17	3.71	0.000258	0.0468	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57641923	chr12:57803838~57804415:+
COAD	cis	rs6673928	1	rs3024498	ENSG00000224114.1	RP11-343H5.4	3.71	0.000258	0.0468	0.36	0.23	Itch intensity from mosquito bite;	chr1:206768184	chr1:206695837~206696269:-
COAD	cis	rs2124910	0.815	rs3976745	ENSG00000273837.1	LLNLR-470E3.1	3.71	0.000258	0.0468	0.2	0.23	Blood protein levels;	chr19:51529710	chr19:51639478~51639931:-
COAD	cis	rs4713118	0.513	rs149955	ENSG00000272009.1	RP1-313I6.12	3.71	0.000258	0.0468	0.27	0.23	Parkinson's disease;	chr6:28068447	chr6:28078792~28081130:-
COAD	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-3.71	0.000258	0.0468	-0.28	-0.23	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
COAD	cis	rs2179367	0.6	rs9498352	ENSG00000268592.3	RAET1E-AS1	3.71	0.000258	0.0468	0.26	0.23	Dupuytren's disease;	chr6:149439108	chr6:149863494~149919507:+
COAD	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-3.71	0.000258	0.0468	-0.24	-0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs34776628	ENSG00000271335.4	RP11-324I22.4	3.71	0.000258	0.0468	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs17499247	ENSG00000271335.4	RP11-324I22.4	3.71	0.000258	0.0468	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs10827491	ENSG00000271335.4	RP11-324I22.4	3.71	0.000258	0.0468	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.966	rs4934732	ENSG00000271335.4	RP11-324I22.4	3.71	0.000258	0.0468	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35314552~35336401:-
COAD	cis	rs7017073	0.536	rs12676304	ENSG00000280997.1	CCAT2	3.71	0.000258	0.0468	0.21	0.23	Breast cancer;	chr8:128151049	chr8:127400399~127402150:+
COAD	cis	rs6687821	0.515	rs1573202	ENSG00000261737.1	RP4-612B15.3	3.71	0.000258	0.0468	0.29	0.23	Yeast infection;	chr1:87046037	chr1:86703502~86704462:-
COAD	cis	rs6687821	0.515	rs4508067	ENSG00000261737.1	RP4-612B15.3	3.71	0.000258	0.0468	0.29	0.23	Yeast infection;	chr1:87048787	chr1:86703502~86704462:-
COAD	cis	rs10471753	0.776	rs11744964	ENSG00000248359.1	CTC-537E7.2	-3.71	0.000258	0.0468	-0.21	-0.23	Hip minimal joint space width;	chr5:68483310	chr5:68531690~68533530:-
COAD	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	3.71	0.000258	0.0468	0.29	0.23	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
COAD	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-3.71	0.000258	0.0468	-0.4	-0.23	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
COAD	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	3.71	0.000258	0.0468	0.26	0.23	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
COAD	cis	rs68170813	0.559	rs1018947	ENSG00000241764.3	AC002467.7	3.71	0.000258	0.0469	0.32	0.23	Coronary artery disease;	chr7:107211494	chr7:107742817~107744581:-
COAD	cis	rs68170813	0.559	rs17427849	ENSG00000241764.3	AC002467.7	3.71	0.000258	0.0469	0.32	0.23	Coronary artery disease;	chr7:107223792	chr7:107742817~107744581:-
COAD	cis	rs6601327	0.606	rs4841203	ENSG00000233609.3	RP11-62H7.2	-3.71	0.000258	0.0469	-0.26	-0.23	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:8961200~8979025:+
COAD	cis	rs4471510	0.961	rs34202616	ENSG00000273987.1	RP11-585P4.6	-3.71	0.000258	0.0469	-0.3	-0.23	Colonoscopy-negative controls vs population controls;	chr12:74854811	chr12:75333798~75334486:-
COAD	cis	rs4471510	0.961	rs11829158	ENSG00000273987.1	RP11-585P4.6	-3.71	0.000258	0.0469	-0.3	-0.23	Colonoscopy-negative controls vs population controls;	chr12:74855599	chr12:75333798~75334486:-
COAD	cis	rs6496932	0.503	rs10520588	ENSG00000259630.2	CTD-2262B20.1	-3.71	0.000258	0.0469	-0.3	-0.23	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85415228~85415633:+
COAD	cis	rs6496932	0.503	rs2086756	ENSG00000259630.2	CTD-2262B20.1	-3.71	0.000258	0.0469	-0.3	-0.23	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85415228~85415633:+
COAD	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-3.71	0.000258	0.0469	-0.21	-0.23	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
COAD	cis	rs739496	0.947	rs3742003	ENSG00000257595.2	RP3-473L9.4	3.71	0.000258	0.0469	0.31	0.23	Platelet count;	chr12:111406414	chr12:111369282~111403310:+
COAD	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
COAD	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-3.71	0.000258	0.0469	-0.28	-0.23	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
COAD	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	3.71	0.000258	0.0469	0.45	0.23	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
COAD	cis	rs860295	0.58	rs867549	ENSG00000225082.2	DAP3P1	-3.71	0.000259	0.0469	-0.29	-0.23	Body mass index;	chr1:155910368	chr1:155586644~155602197:+
COAD	cis	rs911263	0.603	rs12892777	ENSG00000259502.1	RP11-643G16.3	-3.71	0.000259	0.0469	-0.28	-0.23	Primary biliary cholangitis;	chr14:68312196	chr14:67610986~67613864:+
COAD	cis	rs442309	0.687	rs10822054	ENSG00000228566.1	RP11-170M17.1	-3.71	0.000259	0.0469	-0.27	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62720492	chr10:63664664~63990568:+
COAD	cis	rs6490294	0.571	rs10850014	ENSG00000257595.2	RP3-473L9.4	3.71	0.000259	0.0469	0.36	0.23	Mean platelet volume;	chr12:112212254	chr12:111369282~111403310:+
COAD	cis	rs6490294	0.528	rs11066195	ENSG00000257595.2	RP3-473L9.4	3.71	0.000259	0.0469	0.36	0.23	Mean platelet volume;	chr12:112214202	chr12:111369282~111403310:+
COAD	cis	rs2392362	0.743	rs7805303	ENSG00000270889.1	RP11-609L3.1	3.71	0.000259	0.0469	0.22	0.23	Information processing speed;	chr7:35354730	chr7:35971147~35971567:-
COAD	cis	rs1023500	0.505	rs134885	ENSG00000237037.8	NDUFA6-AS1	-3.71	0.000259	0.0469	-0.22	-0.23	Schizophrenia;	chr22:42277805	chr22:42090931~42137742:+
COAD	cis	rs11079159	0.5	rs7223165	ENSG00000263096.1	RP11-515O17.2	3.71	0.000259	0.0469	0.27	0.23	QRS duration;	chr17:55286477	chr17:55271504~55273653:-
COAD	cis	rs2976388	0.692	rs2585175	ENSG00000253741.1	CTD-2292P10.4	-3.71	0.000259	0.0469	-0.24	-0.23	Urinary tract infection frequency;	chr8:142699871	chr8:142702252~142726973:-
COAD	cis	rs654950	0.875	rs2810550	ENSG00000230638.4	RP11-486B10.4	3.71	0.000259	0.0469	0.25	0.23	Airway imaging phenotypes;	chr1:41529668	chr1:41542069~41544310:+
COAD	cis	rs654950	0.84	rs2810551	ENSG00000230638.4	RP11-486B10.4	3.71	0.000259	0.0469	0.25	0.23	Airway imaging phenotypes;	chr1:41529731	chr1:41542069~41544310:+
COAD	cis	rs875971	0.545	rs1267814	ENSG00000232546.1	RP11-458F8.1	-3.71	0.000259	0.0469	-0.22	-0.23	Aortic root size;	chr7:66579422	chr7:66848496~66858136:+
COAD	cis	rs2638953	0.893	rs1464011	ENSG00000247934.4	RP11-967K21.1	-3.7	0.000259	0.0469	-0.2	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28163298~28190738:-
COAD	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	3.7	0.000259	0.0469	0.22	0.23	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
COAD	cis	rs2018293	1	rs5997068	ENSG00000233521.4	RP5-1172A22.1	3.7	0.000259	0.0469	0.21	0.23	Vascular brain injury;	chr22:26312505	chr22:27221349~27224727:-
COAD	cis	rs736408	0.562	rs12497998	ENSG00000212452.1	SNORD69	-3.7	0.000259	0.0469	-0.21	-0.23	Bipolar disorder;	chr3:52759586	chr3:52692736~52692812:+
COAD	cis	rs7172689	0.954	rs12324786	ENSG00000271725.1	RP11-761I4.4	3.7	0.000259	0.0469	0.3	0.23	Inattentive symptoms;	chr15:81233961	chr15:81303215~81309391:-
COAD	cis	rs12928939	0.517	rs8050058	ENSG00000260886.1	TAT-AS1	3.7	0.000259	0.047	0.31	0.23	Post bronchodilator FEV1;	chr16:71947471	chr16:71565789~71578187:+
COAD	cis	rs74781061	0.929	rs8028430	ENSG00000260103.2	RP11-10O17.1	-3.7	0.000259	0.047	-0.28	-0.23	Endometriosis;	chr15:74553404	chr15:74478070~74490286:-
COAD	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-3.7	0.000259	0.047	-0.21	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
COAD	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-3.7	0.000259	0.047	-0.21	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
COAD	cis	rs1150668	0.699	rs13408	ENSG00000272009.1	RP1-313I6.12	3.7	0.000259	0.047	0.25	0.23	Pubertal anthropometrics;	chr6:28244970	chr6:28078792~28081130:-
COAD	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	3.7	0.000259	0.047	0.27	0.23	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
COAD	cis	rs1557305	0.93	rs11664457	ENSG00000265091.4	RP11-835E18.5	-3.7	0.000259	0.047	-0.27	-0.23	Eating disorders;	chr18:4725746	chr18:5232876~5238526:-
COAD	cis	rs7074356	0.704	rs1417220	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000259	0.047	-0.31	-0.23	Borderline personality disorder;	chr10:80408398	chr10:79663088~79826594:-
COAD	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-3.7	0.000259	0.047	-0.31	-0.23	Pain;	chr19:21532048	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-3.7	0.000259	0.047	-0.31	-0.23	Pain;	chr19:21533017	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-3.7	0.000259	0.047	-0.31	-0.23	Pain;	chr19:21533718	chr19:21554640~21569237:-
COAD	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-3.7	0.000259	0.047	-0.31	-0.23	Pain;	chr19:21540147	chr19:21554640~21569237:-
COAD	cis	rs1714507	0.533	rs1714516	ENSG00000272087.1	RP11-379F4.7	3.7	0.000259	0.047	0.28	0.23	Subjective well-being;	chr3:158575835	chr3:158693120~158693768:-
COAD	cis	rs13118159	0.55	rs2336081	ENSG00000254094.1	AC078852.1	3.7	0.000259	0.047	0.26	0.23	Longevity;	chr4:1356534	chr4:1356581~1358075:+
COAD	cis	rs9307551	1	rs11098770	ENSG00000250334.4	LINC00989	-3.7	0.000259	0.047	-0.28	-0.23	Refractive error;	chr4:79598850	chr4:79492416~79576460:+
COAD	cis	rs2307394	1	rs13031064	ENSG00000281469.1	RP11-567F11.1	3.7	0.000259	0.047	0.27	0.23	Urate levels;	chr2:147984409	chr2:148044380~148044894:+
COAD	cis	rs5753037	0.653	rs140107	ENSG00000279159.1	RP3-394A18.1	-3.7	0.000259	0.047	-0.15	-0.23	Type 1 diabetes;	chr22:29734527	chr22:29978950~30028236:-
COAD	cis	rs2562784	0.638	rs2562762	ENSG00000225151.9	GOLGA2P7	-3.7	0.000259	0.047	-0.42	-0.23	Height;	chr15:83598835	chr15:84199311~84230136:-
COAD	cis	rs875971	0.545	rs6969224	ENSG00000232546.1	RP11-458F8.1	3.7	0.00026	0.047	0.23	0.23	Aortic root size;	chr7:66370011	chr7:66848496~66858136:+
COAD	cis	rs5751614	0.577	rs11090227	ENSG00000207835.1	AC244250.3	3.7	0.00026	0.047	0.18	0.23	Height;	chr22:23285436	chr22:22758696~22758790:+
COAD	cis	rs11935103	0.569	rs10022988	ENSG00000279943.1	FLJ38576	3.7	0.00026	0.047	0.31	0.23	Response to citalopram treatment;	chr4:186369867	chr4:186189032~186191490:-
COAD	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00026	0.047	-0.3	-0.23	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
COAD	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	3.7	0.00026	0.047	0.27	0.23	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
COAD	cis	rs911263	0.603	rs12878858	ENSG00000259502.1	RP11-643G16.3	-3.7	0.00026	0.047	-0.28	-0.23	Primary biliary cholangitis;	chr14:68320080	chr14:67610986~67613864:+
COAD	cis	rs6452524	0.686	rs6452518	ENSG00000271862.1	RP11-343L5.2	3.7	0.00026	0.0471	0.22	0.23	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83049376~83050964:-
COAD	cis	rs875971	0.83	rs12673450	ENSG00000224316.1	RP11-479O9.2	3.7	0.00026	0.0471	0.25	0.23	Aortic root size;	chr7:66544233	chr7:65773620~65802067:+
COAD	cis	rs654950	0.875	rs4660544	ENSG00000230638.4	RP11-486B10.4	3.7	0.00026	0.0471	0.25	0.23	Airway imaging phenotypes;	chr1:41531200	chr1:41542069~41544310:+
COAD	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00026	0.0471	-0.3	-0.23	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
COAD	cis	rs8064024	0.68	rs3747613	ENSG00000267077.1	RP11-127I20.5	-3.7	0.00026	0.0471	-0.23	-0.23	Cancer;	chr16:4858503	chr16:4795265~4796532:-
COAD	cis	rs7955901	0.725	rs3942254	ENSG00000258053.1	CTD-2021H9.3	3.7	0.00026	0.0471	0.29	0.23	Type 2 diabetes;	chr12:71062091	chr12:71047402~71118247:-
COAD	cis	rs1707322	0.964	rs785508	ENSG00000230896.1	RP11-767N6.7	3.7	0.00026	0.0471	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.964	rs785509	ENSG00000230896.1	RP11-767N6.7	3.7	0.00026	0.0471	0.26	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45694684~45697075:-
COAD	cis	rs2337406	0.85	rs4774179	ENSG00000211964.3	IGHV3-48	-3.7	0.00026	0.0471	-0.18	-0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106537810~106538344:-
COAD	cis	rs7200786	0.546	rs11640227	ENSG00000274038.1	RP11-66H6.4	-3.7	0.00026	0.0471	-0.29	-0.23	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11134371	chr16:11056556~11057034:+
COAD	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	3.7	0.00026	0.0471	0.35	0.23	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
COAD	cis	rs356992	0.915	rs356977	ENSG00000212978.6	AC016747.3	3.7	0.00026	0.0471	0.17	0.23	Educational attainment (years of education);	chr2:60521623	chr2:61141592~61144969:-
COAD	cis	rs6563898	0.793	rs918767	ENSG00000274677.1	RP11-505K9.5	3.7	0.00026	0.0471	0.29	0.23	IgE levels in asthmatics (D.f. specific);	chr16:83338429	chr16:84085979~84086590:-
COAD	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-3.7	0.00026	0.0471	-0.3	-0.23	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
COAD	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-3.7	0.00026	0.0471	-0.22	-0.23	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
COAD	cis	rs7208859	0.623	rs3794796	ENSG00000280069.1	CTD-2349P21.3	-3.7	0.00026	0.0471	-0.33	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30738182~30740275:+
COAD	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-3.7	0.00026	0.0471	-0.24	-0.23	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
COAD	cis	rs57221529	0.766	rs12521051	ENSG00000250385.1	RP11-310P5.2	-3.7	0.00026	0.0471	-0.38	-0.23	Lung disease severity in cystic fibrosis;	chr5:560325	chr5:524705~526594:+
COAD	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	3.7	0.00026	0.0471	0.34	0.23	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
COAD	cis	rs10200159	0.744	rs75365186	ENSG00000272606.1	RP11-554J4.1	3.7	0.00026	0.0471	0.34	0.23	Vitiligo;	chr2:55575834	chr2:55617909~55618373:+
COAD	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-3.7	0.00026	0.0471	-0.36	-0.23	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
COAD	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	3.7	0.00026	0.0472	0.29	0.23	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
COAD	cis	rs1577917	0.771	rs4383777	ENSG00000220563.1	PKMP3	3.7	0.00026	0.0472	0.25	0.23	Response to antipsychotic treatment;	chr6:85726242	chr6:85659892~85660606:-
COAD	cis	rs11089937	0.616	rs713644	ENSG00000211638.2	IGLV8-61	-3.7	0.00026	0.0472	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22098700~22099212:+
COAD	cis	rs11089937	0.616	rs713624	ENSG00000211638.2	IGLV8-61	-3.7	0.00026	0.0472	-0.22	-0.23	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22098700~22099212:+
COAD	cis	rs2732480	0.5	rs11168468	ENSG00000269514.1	RP11-370I10.12	3.7	0.000261	0.0472	0.27	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48198387~48202031:+
COAD	cis	rs6121246	0.609	rs6060843	ENSG00000281376.1	ABALON	3.7	0.000261	0.0472	0.23	0.23	Mean corpuscular hemoglobin;	chr20:31709244	chr20:31721507~31723409:+
COAD	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-3.7	0.000261	0.0472	-0.28	-0.23	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-3.7	0.000261	0.0472	-0.28	-0.23	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
COAD	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-3.7	0.000261	0.0472	-0.28	-0.23	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
COAD	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000261	0.0472	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
COAD	cis	rs6672530	0.518	rs10916205	ENSG00000212237.1	RNA5SP18	-3.7	0.000261	0.0472	-0.24	-0.23	Hip circumference adjusted for BMI;	chr1:227769890	chr1:228647912~228648032:-
COAD	cis	rs6673928	1	rs61815632	ENSG00000224114.1	RP11-343H5.4	3.7	0.000261	0.0472	0.36	0.23	Itch intensity from mosquito bite;	chr1:206765094	chr1:206695837~206696269:-
COAD	cis	rs1707322	0.752	rs11211146	ENSG00000230896.1	RP11-767N6.7	-3.7	0.000261	0.0472	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.752	rs11211147	ENSG00000230896.1	RP11-767N6.7	-3.7	0.000261	0.0472	-0.26	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45694684~45697075:-
COAD	cis	rs2537594	0.56	rs2723521	ENSG00000279048.1	RP11-511H23.2	-3.7	0.000261	0.0472	-0.17	-0.23	Mean corpuscular hemoglobin;	chr7:17774027	chr7:17940503~17942922:+
COAD	cis	rs10779751	0.881	rs2744815	ENSG00000215785.2	CFL1P6	-3.7	0.000261	0.0472	-0.25	-0.23	Body mass index;	chr1:11300900	chr1:10990978~10991797:-
COAD	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	3.7	0.000261	0.0472	0.25	0.23	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
COAD	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	3.7	0.000261	0.0473	0.3	0.23	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
COAD	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	3.7	0.000261	0.0473	0.3	0.23	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
COAD	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	3.7	0.000261	0.0473	0.35	0.23	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
COAD	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	3.7	0.000261	0.0473	0.2	0.23	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
COAD	cis	rs9796	0.558	rs4445868	ENSG00000247556.5	OIP5-AS1	3.7	0.000261	0.0473	0.22	0.23	Menopause (age at onset);	chr15:41239793	chr15:41283990~41309737:+
COAD	cis	rs17374749	0.598	rs17309935	ENSG00000273486.1	RP11-731C17.2	3.7	0.000261	0.0473	0.29	0.23	Anxiety in major depressive disorder;	chr3:137124201	chr3:136837338~136839021:-
COAD	cis	rs860295	0.665	rs11264367	ENSG00000232519.2	RP11-29H23.4	-3.7	0.000261	0.0473	-0.32	-0.23	Body mass index;	chr1:155367547	chr1:155609776~155610380:-
COAD	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	3.7	0.000261	0.0473	0.33	0.23	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
COAD	cis	rs2255336	0.808	rs59611026	ENSG00000245648.1	RP11-277P12.20	-3.7	0.000261	0.0473	-0.33	-0.23	Blood protein levels;	chr12:10445387	chr12:10363769~10398506:+
COAD	cis	rs7615952	0.688	rs17334074	ENSG00000248787.1	RP11-666A20.4	3.7	0.000262	0.0473	0.31	0.23	Blood pressure (smoking interaction);	chr3:125821617	chr3:125908005~125910272:-
COAD	cis	rs11098499	0.913	rs11098496	ENSG00000250412.1	KLHL2P1	3.7	0.000262	0.0473	0.3	0.23	Corneal astigmatism;	chr4:119246311	chr4:119334329~119378233:+
COAD	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	3.7	0.000262	0.0473	0.25	0.23	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
COAD	cis	rs62362510	0.535	rs2114950	ENSG00000264391.2	RN7SL208P	-3.7	0.000262	0.0473	-0.4	-0.23	Morning vs. evening chronotype;	chr5:77430377	chr5:76836900~76837195:-
COAD	cis	rs17451754	0.626	rs35050470	ENSG00000237974.1	AC000111.4	3.7	0.000262	0.0473	0.25	0.23	Barrett's esophagus  or Esophageal adenocarcinoma;	chr7:117606582	chr7:117487737~117487929:+
COAD	cis	rs7617773	0.963	rs6800730	ENSG00000228638.1	FCF1P2	-3.7	0.000262	0.0473	-0.26	-0.23	Coronary artery disease;	chr3:48132720	chr3:48290793~48291375:-
COAD	cis	rs10876993	0.89	rs774888	ENSG00000270039.1	RP11-571M6.17	3.7	0.000262	0.0473	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57642723	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.89	rs1092472	ENSG00000270039.1	RP11-571M6.17	3.7	0.000262	0.0473	0.25	0.23	Celiac disease or Rheumatoid arthritis;	chr12:57642905	chr12:57803838~57804415:+
COAD	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	3.7	0.000262	0.0473	0.24	0.23	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
COAD	cis	rs2832191	0.716	rs7284006	ENSG00000176054.6	RPL23P2	3.7	0.000262	0.0473	0.23	0.23	Dental caries;	chr21:29102865	chr21:28997613~28998033:-
COAD	cis	rs615632	0.53	rs10092464	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000262	0.0473	-0.29	-0.22	Neuroticism;	chr8:9946675	chr8:9141424~9145435:+
COAD	cis	rs6730558	0.901	rs12692365	ENSG00000235092.4	ID2-AS1	-3.7	0.000262	0.0473	-0.3	-0.22	PR interval;Mean corpuscular volume;Red cell distribution width;	chr2:8612818	chr2:8666636~8681863:-
COAD	cis	rs2904967	0.562	rs239255	ENSG00000197847.11	SLC22A20	3.7	0.000262	0.0473	0.29	0.22	Mean corpuscular volume;	chr11:65219657	chr11:65213840~65242757:+
COAD	cis	rs2904967	0.636	rs239256	ENSG00000197847.11	SLC22A20	3.7	0.000262	0.0473	0.29	0.22	Mean corpuscular volume;	chr11:65219920	chr11:65213840~65242757:+
COAD	cis	rs7324557	0.717	rs7139473	ENSG00000205861.10	C1QTNF9B-AS1	-3.7	0.000262	0.0474	-0.32	-0.22	Visceral adipose tissue adjusted for BMI;	chr13:23824083	chr13:23888889~23897263:+
COAD	cis	rs875971	0.965	rs697968	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000262	0.0474	-0.24	-0.22	Aortic root size;	chr7:66070046	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs1183245	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000262	0.0474	-0.24	-0.22	Aortic root size;	chr7:66076198	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs1144895	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000262	0.0474	-0.24	-0.22	Aortic root size;	chr7:66076320	chr7:65773620~65802067:+
COAD	cis	rs875971	1	rs1144894	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000262	0.0474	-0.24	-0.22	Aortic root size;	chr7:66077907	chr7:65773620~65802067:+
COAD	cis	rs12049351	0.667	rs34382491	ENSG00000229367.1	HMGN2P19	3.7	0.000262	0.0474	0.34	0.22	Circulating myeloperoxidase levels (plasma);	chr1:229484883	chr1:229570532~229570796:+
COAD	cis	rs34792	0.513	rs255002	ENSG00000207425.1	Y_RNA	-3.7	0.000262	0.0474	-0.3	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15484406	chr16:14915457~14915556:-
COAD	cis	rs7536700	1	rs7536700	ENSG00000272030.1	RP1-178F15.4	-3.7	0.000262	0.0474	-0.33	-0.22	Multiple myeloma (IgH translocation);	chr1:153668351	chr1:153631438~153634397:-
COAD	cis	rs10760158	0.832	rs4837820	ENSG00000226752.6	PSMD5-AS1	-3.7	0.000262	0.0474	-0.24	-0.22	Pulse pressure;	chr9:121247816	chr9:120824828~120854385:+
COAD	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000262	0.0474	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
COAD	cis	rs6981523	0.553	rs11989369	ENSG00000269918.1	AF131215.9	3.7	0.000262	0.0474	0.29	0.22	Neuroticism;	chr8:11197876	chr8:11104691~11106704:-
COAD	cis	rs17268829	0.925	rs10232398	ENSG00000231170.4	AC002451.3	-3.7	0.000262	0.0474	-0.27	-0.22	Breast cancer;	chr7:94598197	chr7:95596682~95613719:+
COAD	cis	rs9487051	0.735	rs419106	ENSG00000219700.1	PTCHD3P3	3.7	0.000262	0.0474	0.24	0.22	Reticulocyte fraction of red cells;	chr6:109198864	chr6:109288571~109290503:-
COAD	cis	rs10864907	0.71	rs11690399	ENSG00000236397.3	DDX11L2	3.7	0.000262	0.0474	0.29	0.22	Pulmonary function;	chr2:112982682	chr2:113599036~113601261:-
COAD	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-3.7	0.000262	0.0474	-0.29	-0.22	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
COAD	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-3.7	0.000262	0.0474	-0.24	-0.22	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
COAD	cis	rs11726248	0.718	rs111262041	ENSG00000250266.1	RP11-789C1.1	-3.7	0.000262	0.0474	-0.52	-0.22	Thyroid hormone levels;	chr4:170286147	chr4:170273919~170283079:+
COAD	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-3.7	0.000262	0.0474	-0.16	-0.22	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
COAD	cis	rs12699921	0.598	rs1524775	ENSG00000279048.1	RP11-511H23.2	-3.7	0.000262	0.0474	-0.17	-0.22	Fibrinogen levels;	chr7:17896742	chr7:17940503~17942922:+
COAD	cis	rs7328464	0.704	rs61967081	ENSG00000215417.9	MIR17HG	3.7	0.000263	0.0474	0.29	0.22	Obesity-related traits;	chr13:91778076	chr13:91347820~91354579:+
COAD	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-3.7	0.000263	0.0475	-0.24	-0.22	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-3.7	0.000263	0.0475	-0.24	-0.22	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-3.7	0.000263	0.0475	-0.24	-0.22	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
COAD	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-3.7	0.000263	0.0475	-0.24	-0.22	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
COAD	cis	rs7829975	0.502	rs7820738	ENSG00000254153.1	CTA-398F10.2	-3.7	0.000263	0.0475	-0.25	-0.22	Mood instability;	chr8:8845097	chr8:8456909~8461337:-
COAD	cis	rs848486	0.686	rs58329075	ENSG00000213542.3	RP11-467H10.1	-3.7	0.000263	0.0475	-0.24	-0.22	Glomerular filtration rate;	chr7:77640626	chr7:77115399~77116192:-
COAD	cis	rs2243480	0.901	rs778687	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66370832	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs778704	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66398480	chr7:66025126~66031544:-
COAD	cis	rs2243480	0.901	rs778693	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66407358	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs778691	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66408105	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs13235972	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66418618	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs34192067	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000263	0.0475	0.4	0.22	Diabetic kidney disease;	chr7:66422670	chr7:66025126~66031544:-
COAD	cis	rs7302017	1	rs7302017	ENSG00000275180.1	RP11-631N16.4	3.7	0.000263	0.0475	0.24	0.22	Waist circumference;	chr12:62610803	chr12:62603909~62604399:+
COAD	cis	rs591584	0.728	rs649973	ENSG00000255893.1	RP11-685N10.1	-3.7	0.000263	0.0475	-0.26	-0.22	Macrophage Migration Inhibitory Factor levels;	chr11:94600708	chr11:94472908~94473570:-
COAD	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	3.7	0.000263	0.0475	0.27	0.22	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
COAD	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	3.7	0.000263	0.0475	0.27	0.22	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
COAD	cis	rs4767364	0.961	rs10850031	ENSG00000257595.2	RP3-473L9.4	3.7	0.000263	0.0475	0.29	0.22	Oral cavity and pharyngeal cancer;	chr12:112333259	chr12:111369282~111403310:+
COAD	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-3.7	0.000263	0.0475	-0.33	-0.22	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
COAD	cis	rs9813712	0.571	rs9866568	ENSG00000249846.5	RP11-77P16.4	-3.7	0.000263	0.0475	-0.26	-0.22	Response to amphetamines;	chr3:130297539	chr3:130112550~130120579:+
COAD	cis	rs7955901	0.638	rs3851611	ENSG00000258053.1	CTD-2021H9.3	3.7	0.000263	0.0476	0.28	0.22	Type 2 diabetes;	chr12:71130262	chr12:71047402~71118247:-
COAD	cis	rs453301	0.658	rs3855900	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000263	0.0476	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9044411	chr8:9141424~9145435:+
COAD	cis	rs10129255	0.646	rs55995061	ENSG00000211967.3	IGHV3-53	-3.7	0.000263	0.0476	-0.18	-0.22	Kawasaki disease;	chr14:106799309	chr14:106592676~106593347:-
COAD	cis	rs875971	0.798	rs6460304	ENSG00000224316.1	RP11-479O9.2	3.7	0.000263	0.0476	0.24	0.22	Aortic root size;	chr7:66499741	chr7:65773620~65802067:+
COAD	cis	rs875971	0.862	rs6945775	ENSG00000224316.1	RP11-479O9.2	3.7	0.000263	0.0476	0.24	0.22	Aortic root size;	chr7:66503987	chr7:65773620~65802067:+
COAD	cis	rs2337406	0.925	rs34064152	ENSG00000211964.3	IGHV3-48	-3.7	0.000264	0.0476	-0.2	-0.22	Alzheimer's disease (late onset);	chr14:106700364	chr14:106537810~106538344:-
COAD	cis	rs755249	0.508	rs6703800	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000264	0.0476	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39522280~39546187:-
COAD	cis	rs4660214	0.724	rs12117785	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000264	0.0476	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39522280~39546187:-
COAD	cis	rs755249	0.508	rs10888688	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000264	0.0476	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39522280~39546187:-
COAD	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-3.7	0.000264	0.0476	-0.27	-0.22	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
COAD	cis	rs6661961	0.752	rs11205003	ENSG00000237975.5	FLG-AS1	-3.7	0.000264	0.0476	-0.24	-0.22	Atopic dermatitis;	chr1:152444154	chr1:152168125~152445456:+
COAD	cis	rs11098499	0.698	rs4422403	ENSG00000249244.1	RP11-548H18.2	3.7	0.000264	0.0476	0.29	0.22	Corneal astigmatism;	chr4:119337039	chr4:119391831~119395335:-
COAD	cis	rs4654899	1	rs7554997	ENSG00000271428.1	RP1-224A6.8	3.7	0.000264	0.0476	0.23	0.22	Superior frontal gyrus grey matter volume;	chr1:21073646	chr1:22068340~22068827:-
COAD	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000264	0.0476	0.39	0.22	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
COAD	cis	rs2466029	0.559	rs2445607	ENSG00000253264.1	PCAT2	-3.7	0.000264	0.0476	-0.23	-0.22	Chronic lymphocytic leukemia;	chr8:127167386	chr8:127072694~127082221:-
COAD	cis	rs9796	0.621	rs58109657	ENSG00000247556.5	OIP5-AS1	-3.7	0.000264	0.0476	-0.23	-0.22	Menopause (age at onset);	chr15:41179552	chr15:41283990~41309737:+
COAD	cis	rs10129255	0.957	rs8009073	ENSG00000224373.3	IGHV4-59	3.7	0.000264	0.0476	0.14	0.22	Kawasaki disease;	chr14:106777278	chr14:106627249~106627825:-
COAD	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	3.7	0.000264	0.0476	0.32	0.22	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
COAD	cis	rs860295	0.702	rs12047756	ENSG00000225855.5	RUSC1-AS1	3.7	0.000264	0.0476	0.2	0.22	Body mass index;	chr1:155655153	chr1:155316863~155324176:-
COAD	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000264	0.0476	-0.41	-0.22	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
COAD	cis	rs4699052	0.928	rs6822379	ENSG00000230069.3	LRRC37A15P	-3.7	0.000264	0.0476	-0.25	-0.22	Testicular germ cell tumor;	chr4:103295501	chr4:102727274~102730721:-
COAD	cis	rs4699052	0.928	rs28837409	ENSG00000230069.3	LRRC37A15P	-3.7	0.000264	0.0476	-0.25	-0.22	Testicular germ cell tumor;	chr4:103298998	chr4:102727274~102730721:-
COAD	cis	rs2337406	1	rs7145100	ENSG00000211964.3	IGHV3-48	-3.7	0.000264	0.0476	-0.19	-0.22	Alzheimer's disease (late onset);	chr14:106704673	chr14:106537810~106538344:-
COAD	cis	rs739496	0.542	rs7306529	ENSG00000257595.2	RP3-473L9.4	3.7	0.000264	0.0476	0.34	0.22	Platelet count;	chr12:111342840	chr12:111369282~111403310:+
COAD	cis	rs454422	0.857	rs236106	ENSG00000275632.1	RP5-967N21.11	3.7	0.000264	0.0476	0.26	0.22	HIV-1 viral setpoint;	chr20:5980045	chr20:6000418~6000941:+
COAD	cis	rs7208859	0.673	rs3816780	ENSG00000280069.1	CTD-2349P21.3	-3.7	0.000264	0.0477	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30738182~30740275:+
COAD	cis	rs4760786	0.898	rs2063592	ENSG00000258053.1	CTD-2021H9.3	-3.7	0.000264	0.0477	-0.32	-0.22	Monobrow;	chr12:71017962	chr12:71047402~71118247:-
COAD	cis	rs796825	0.597	rs6438576	ENSG00000240661.1	RP11-174O3.3	-3.7	0.000264	0.0477	-0.35	-0.22	HIV-1 susceptibility;	chr3:120338749	chr3:120349510~120367998:+
COAD	cis	rs796825	0.626	rs6438578	ENSG00000240661.1	RP11-174O3.3	-3.7	0.000264	0.0477	-0.35	-0.22	HIV-1 susceptibility;	chr3:120346322	chr3:120349510~120367998:+
COAD	cis	rs796825	0.597	rs6438579	ENSG00000240661.1	RP11-174O3.3	-3.7	0.000264	0.0477	-0.35	-0.22	HIV-1 susceptibility;	chr3:120346362	chr3:120349510~120367998:+
COAD	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000264	0.0477	-0.29	-0.22	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
COAD	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-3.7	0.000264	0.0477	-0.3	-0.22	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
COAD	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-3.7	0.000264	0.0477	-0.33	-0.22	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
COAD	cis	rs875971	1	rs1167411	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000264	0.0477	-0.24	-0.22	Aortic root size;	chr7:66074277	chr7:65773620~65802067:+
COAD	cis	rs728616	0.867	rs61859022	ENSG00000234382.2	RP11-40F6.1	-3.7	0.000264	0.0477	-0.41	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:80233664~80245367:+
COAD	cis	rs17405819	0.52	rs830466	ENSG00000249395.2	CASC9	-3.7	0.000264	0.0477	-0.25	-0.22	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr8:76059264	chr8:75223404~75324741:-
COAD	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	3.7	0.000264	0.0477	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
COAD	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-3.7	0.000264	0.0477	-0.22	-0.22	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
COAD	cis	rs5758511	0.773	rs73165164	ENSG00000182057.4	OGFRP1	-3.7	0.000264	0.0477	-0.26	-0.22	Birth weight;	chr22:41959545	chr22:42269753~42275196:+
COAD	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-3.7	0.000265	0.0477	-0.26	-0.22	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
COAD	cis	rs12049351	0.774	rs12117468	ENSG00000201492.1	RNA5SP78	3.7	0.000265	0.0477	0.25	0.22	Circulating myeloperoxidase levels (plasma);	chr1:229535614	chr1:229549905~229550022:+
COAD	cis	rs1510510	0.742	rs4359589	ENSG00000225057.2	AC096574.4	3.7	0.000265	0.0477	0.3	0.22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238666795	chr2:238231684~238255633:+
COAD	cis	rs911555	0.723	rs7149767	ENSG00000251533.2	LINC00605	3.7	0.000265	0.0477	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103187221~103189028:-
COAD	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	3.7	0.000265	0.0477	0.39	0.22	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
COAD	cis	rs875971	1	rs697970	ENSG00000224316.1	RP11-479O9.2	-3.7	0.000265	0.0477	-0.24	-0.22	Aortic root size;	chr7:66095065	chr7:65773620~65802067:+
COAD	cis	rs1383484	0.798	rs2086441	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000265	0.0478	-0.31	-0.22	Height;	chr15:83881728	chr15:84507885~84516814:-
COAD	cis	rs11229555	0.609	rs7927730	ENSG00000254602.1	AP000662.4	-3.7	0.000265	0.0478	-0.27	-0.22	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr11:58420433	chr11:57638024~57652790:+
COAD	cis	rs911263	0.603	rs61985136	ENSG00000259502.1	RP11-643G16.3	-3.7	0.000265	0.0478	-0.28	-0.22	Primary biliary cholangitis;	chr14:68302482	chr14:67610986~67613864:+
COAD	cis	rs886774	0.773	rs7799327	ENSG00000250474.1	WBP1LP2	-3.7	0.000265	0.0478	-0.3	-0.22	Ulcerative colitis;	chr7:107912240	chr7:107628553~107629498:+
COAD	cis	rs2243480	1	rs1546059	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000265	0.0478	-0.41	-0.22	Diabetic kidney disease;	chr7:66189722	chr7:66554588~66576923:-
COAD	cis	rs2243480	1	rs6958289	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000265	0.0478	-0.41	-0.22	Diabetic kidney disease;	chr7:66192124	chr7:66554588~66576923:-
COAD	cis	rs2337406	0.866	rs2301535	ENSG00000211967.3	IGHV3-53	-3.7	0.000265	0.0478	-0.18	-0.22	Alzheimer's disease (late onset);	chr14:106790663	chr14:106592676~106593347:-
COAD	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-3.7	0.000265	0.0478	-0.21	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
COAD	cis	rs7903146	0.59	rs55899248	ENSG00000227560.1	RP11-139K1.2	-3.7	0.000265	0.0478	-0.28	-0.22	Hip circumference;Clinical laboratory measurements;BMI in non-smokers;Fasting blood insulin (BMI interaction);BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Fasting blood glucose (BMI interaction);Glycated hemoglobin levels;Type 2 diabetes;Waist circumference;Proinsulin levels;Body mass index (joint analysis main effects and smoking interaction);Metabolic syndrome;Peak insulin response;Fasting blood glucose;Body mass index;Fasting blood insulin;Type 2 diabetes and other traits;	chr10:113013849	chr10:112987476~112987865:+
COAD	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-3.7	0.000265	0.0478	-0.28	-0.22	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
COAD	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	3.7	0.000265	0.0478	0.31	0.22	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
COAD	cis	rs57221529	0.766	rs4081847	ENSG00000250385.1	RP11-310P5.2	3.7	0.000265	0.0478	0.39	0.22	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:524705~526594:+
COAD	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	3.7	0.000265	0.0478	0.45	0.22	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
COAD	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	3.7	0.000265	0.0479	0.19	0.22	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
COAD	cis	rs1941023	0.648	rs4939368	ENSG00000255355.1	AP000640.2	-3.7	0.000266	0.0479	-0.28	-0.22	Congenital heart disease (maternal effect);	chr11:60488575	chr11:59669312~59676041:+
COAD	cis	rs10875746	0.551	rs3185921	ENSG00000257660.4	RP11-579D7.4	-3.7	0.000266	0.0479	-0.31	-0.22	Longevity (90 years and older);	chr12:48340948	chr12:48789147~48790535:+
COAD	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	3.7	0.000266	0.0479	0.35	0.22	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
COAD	cis	rs10971721	0.584	rs72731224	ENSG00000231991.4	ANXA2P2	3.7	0.000266	0.0479	0.28	0.22	Body mass index;	chr9:34122888	chr9:33624274~33625293:+
COAD	cis	rs6951245	1	rs79443843	ENSG00000229043.2	AC091729.9	-3.7	0.000266	0.0479	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1160374~1165267:+
COAD	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-3.7	0.000266	0.0479	-0.31	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
COAD	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000266	0.0479	-0.41	-0.22	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
COAD	cis	rs7260598	0.792	rs11669171	ENSG00000268442.1	CTD-2027I19.2	3.7	0.000266	0.0479	0.34	0.22	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:24162370~24163425:-
COAD	cis	rs7260598	0.792	rs11669251	ENSG00000268442.1	CTD-2027I19.2	3.7	0.000266	0.0479	0.34	0.22	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:24162370~24163425:-
COAD	cis	rs4819052	0.851	rs2838832	ENSG00000227039.5	ITGB2-AS1	3.7	0.000266	0.0479	0.2	0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:44921051~44929678:+
COAD	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	3.7	0.000266	0.0479	0.3	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
COAD	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	3.7	0.000266	0.0479	0.3	0.22	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
COAD	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	3.7	0.000266	0.0479	0.29	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
COAD	cis	rs11773103	0.881	rs11971310	ENSG00000224046.1	AC005076.5	3.7	0.000266	0.0479	0.31	0.22	Bipolar disorder or major depressive disorder (combined);	chr7:87136326	chr7:87151423~87152420:-
COAD	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-3.7	0.000266	0.0479	-0.28	-0.22	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
COAD	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-3.7	0.000266	0.0479	-0.28	-0.22	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
COAD	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-3.7	0.000266	0.0479	-0.28	-0.22	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
COAD	cis	rs7933433	0.552	rs35043449	ENSG00000255465.3	RP11-264E20.1	-3.7	0.000266	0.0479	-0.29	-0.22	Psoriasis;	chr11:128331724	chr11:128615867~128621806:-
COAD	cis	rs7933433	0.552	rs10893850	ENSG00000255465.3	RP11-264E20.1	-3.7	0.000266	0.0479	-0.29	-0.22	Psoriasis;	chr11:128331898	chr11:128615867~128621806:-
COAD	cis	rs1941023	0.619	rs55924472	ENSG00000255355.1	AP000640.2	-3.7	0.000266	0.0479	-0.28	-0.22	Congenital heart disease (maternal effect);	chr11:60487130	chr11:59669312~59676041:+
COAD	cis	rs2842346	0.568	rs2525526	ENSG00000259038.1	CTD-2325P2.4	3.7	0.000266	0.0479	0.34	0.22	Breast cancer;	chr14:68542449	chr14:68627166~68628445:-
COAD	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-3.7	0.000266	0.0479	-0.36	-0.22	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
COAD	cis	rs3135063	0.504	rs3129315	ENSG00000248840.2	RP11-357G3.2	-3.7	0.000266	0.0479	-0.29	-0.22	Blood protein levels;	chr4:3288873	chr4:3312512~3313058:+
COAD	cis	rs17685	0.753	rs8200	ENSG00000280388.1	RP11-229D13.3	3.7	0.000266	0.0479	0.22	0.22	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76043977~76045963:-
COAD	cis	rs6762	0.748	rs1130719	ENSG00000279672.1	CMB9-55F22.1	3.7	0.000266	0.0479	0.23	0.22	Mean platelet volume;	chr11:838760	chr11:779617~780755:+
COAD	cis	rs11098499	0.954	rs3890049	ENSG00000250412.1	KLHL2P1	3.7	0.000266	0.0479	0.31	0.22	Corneal astigmatism;	chr4:119405128	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.954	rs71629403	ENSG00000250412.1	KLHL2P1	3.7	0.000266	0.0479	0.31	0.22	Corneal astigmatism;	chr4:119451412	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.909	rs28571712	ENSG00000250412.1	KLHL2P1	3.7	0.000266	0.0479	0.31	0.22	Corneal astigmatism;	chr4:119454825	chr4:119334329~119378233:+
COAD	cis	rs17248895	0.803	rs8004267	ENSG00000196553.12	LINC00238	-3.7	0.000266	0.0479	-0.34	-0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;	chr14:67416412	chr14:66486354~66498553:+
COAD	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-3.7	0.000266	0.0479	-0.28	-0.22	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
COAD	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-3.7	0.000266	0.0479	-0.28	-0.22	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
COAD	cis	rs6452524	0.904	rs10076056	ENSG00000271862.1	RP11-343L5.2	-3.7	0.000266	0.0479	-0.23	-0.22	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83049376~83050964:-
COAD	cis	rs3126085	0.56	rs11588022	ENSG00000237975.5	FLG-AS1	3.7	0.000266	0.0479	0.3	0.22	Atopic dermatitis;	chr1:152344476	chr1:152168125~152445456:+
COAD	cis	rs913655	0.688	rs12220519	ENSG00000240291.1	RP11-499P20.2	3.7	0.000266	0.048	0.3	0.22	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18731952	chr10:18513115~18545651:-
COAD	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-3.7	0.000266	0.048	-0.28	-0.22	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
COAD	cis	rs848490	0.855	rs55860308	ENSG00000213542.3	RP11-467H10.1	-3.7	0.000266	0.048	-0.27	-0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616657	chr7:77115399~77116192:-
COAD	cis	rs4660214	0.666	rs636083	ENSG00000228060.1	RP11-69E11.8	-3.7	0.000266	0.048	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39565160~39573203:+
COAD	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-3.7	0.000266	0.048	-0.3	-0.22	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
COAD	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	3.7	0.000266	0.048	0.31	0.22	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
COAD	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-3.7	0.000266	0.048	-0.33	-0.22	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
COAD	cis	rs860295	0.966	rs821551	ENSG00000223503.1	RP11-29H23.6	-3.7	0.000267	0.048	-0.29	-0.22	Body mass index;	chr1:155718789	chr1:155590601~155591262:-
COAD	cis	rs17471911	0.588	rs71486198	ENSG00000257582.4	LINC01475	-3.7	0.000267	0.048	-0.4	-0.22	Neuroticism;	chr10:99073874	chr10:99526350~99531177:-
COAD	cis	rs17471911	0.643	rs11189960	ENSG00000257582.4	LINC01475	-3.7	0.000267	0.048	-0.4	-0.22	Neuroticism;	chr10:99080205	chr10:99526350~99531177:-
COAD	cis	rs7555006	0.901	rs4926873	ENSG00000227742.1	CALR4P	-3.7	0.000267	0.048	-0.24	-0.22	Headache;	chr1:50937923	chr1:51561866~51594897:-
COAD	cis	rs7560272	0.501	rs2421674	ENSG00000273245.1	RP11-434P11.2	-3.7	0.000267	0.048	-0.27	-0.22	Schizophrenia;	chr2:73728305	chr2:73750256~73750786:-
COAD	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	3.7	0.000267	0.048	0.33	0.22	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
COAD	cis	rs8192917	0.511	rs35240563	ENSG00000225766.7	DHRS4L1	3.7	0.000267	0.048	0.45	0.22	Vitiligo;	chr14:24593940	chr14:24036453~24051028:+
COAD	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-3.7	0.000267	0.048	-0.26	-0.22	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
COAD	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-3.7	0.000267	0.048	-0.26	-0.22	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
COAD	cis	rs913655	0.785	rs11015939	ENSG00000240291.1	RP11-499P20.2	3.7	0.000267	0.048	0.28	0.22	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18729013	chr10:18513115~18545651:-
COAD	cis	rs2307394	0.964	rs12053401	ENSG00000281469.1	RP11-567F11.1	3.7	0.000267	0.048	0.27	0.22	Urate levels;	chr2:147999099	chr2:148044380~148044894:+
COAD	cis	rs2243480	0.706	rs6460257	ENSG00000232559.3	GS1-124K5.12	3.7	0.000267	0.048	0.35	0.22	Diabetic kidney disease;	chr7:65731813	chr7:66554588~66576923:-
COAD	cis	rs73198271	0.74	rs1039910	ENSG00000173295.6	FAM86B3P	-3.7	0.000267	0.048	-0.3	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8228595~8244865:+
COAD	cis	rs2179367	0.632	rs9485389	ENSG00000216906.2	RP11-350J20.9	-3.7	0.000267	0.048	-0.32	-0.22	Dupuytren's disease;	chr6:149420078	chr6:149904243~149906418:+
COAD	cis	rs4648045	0.565	rs62327181	ENSG00000230069.3	LRRC37A15P	-3.7	0.000267	0.0481	-0.28	-0.22	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102727274~102730721:-
COAD	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-3.7	0.000267	0.0481	-0.25	-0.22	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-3.7	0.000267	0.0481	-0.25	-0.22	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
COAD	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-3.7	0.000267	0.0481	-0.25	-0.22	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
COAD	cis	rs1707322	0.717	rs11211161	ENSG00000230896.1	RP11-767N6.7	-3.7	0.000267	0.0481	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45694684~45697075:-
COAD	cis	rs7560272	0.538	rs17350056	ENSG00000273245.1	RP11-434P11.2	-3.7	0.000267	0.0481	-0.28	-0.22	Schizophrenia;	chr2:73695750	chr2:73750256~73750786:-
COAD	cis	rs2478333	0.93	rs2677603	ENSG00000234145.1	NAP1L4P3	3.7	0.000267	0.0481	0.25	0.22	QT interval;	chr13:47604610	chr13:47763460~47764606:+
COAD	cis	rs2018293	1	rs1115764	ENSG00000272798.1	CTA-390C10.9	3.7	0.000267	0.0481	0.28	0.22	Vascular brain injury;	chr22:26313341	chr22:25436312~25436915:+
COAD	cis	rs7219021	0.739	rs1800632	ENSG00000248278.1	SUMO2P17	-3.7	0.000267	0.0481	-0.28	-0.22	Schizophrenia or bipolar disorder;	chr17:48893147	chr17:48874860~48908983:-
COAD	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	3.7	0.000267	0.0481	0.26	0.22	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
COAD	cis	rs860295	0.65	rs670523	ENSG00000223503.1	RP11-29H23.6	3.7	0.000267	0.0481	0.29	0.22	Body mass index;	chr1:155908941	chr1:155590601~155591262:-
COAD	cis	rs860295	0.595	rs490498	ENSG00000223503.1	RP11-29H23.6	3.7	0.000267	0.0481	0.29	0.22	Body mass index;	chr1:155911161	chr1:155590601~155591262:-
COAD	cis	rs8002861	0.641	rs2325085	ENSG00000274001.1	RP11-5G9.5	3.7	0.000267	0.0481	0.2	0.22	Leprosy;	chr13:43835924	chr13:43877715~43878163:-
COAD	cis	rs4253772	0.55	rs6008613	ENSG00000280424.1	CITF22-92A6.2	3.7	0.000267	0.0481	0.36	0.22	Cholesterol, total;LDL cholesterol;	chr22:46312027	chr22:46006616~46010777:+
COAD	cis	rs4253772	0.53	rs6008616	ENSG00000280424.1	CITF22-92A6.2	3.7	0.000267	0.0481	0.36	0.22	Cholesterol, total;LDL cholesterol;	chr22:46312057	chr22:46006616~46010777:+
COAD	cis	rs4443100	0.77	rs876101	ENSG00000272578.4	AP000347.2	-3.7	0.000267	0.0481	-0.19	-0.22	Serum parathyroid hormone levels;	chr22:23022202	chr22:23658094~23717356:-
COAD	cis	rs2243480	1	rs709607	ENSG00000229886.1	RP5-1132H15.3	-3.7	0.000267	0.0481	-0.35	-0.22	Diabetic kidney disease;	chr7:65984554	chr7:66025126~66031544:-
COAD	cis	rs6947471	1	rs10224748	ENSG00000273344.1	PAXIP1-AS1	3.7	0.000267	0.0481	0.24	0.22	Pelvic organ prolapse;	chr7:154594637	chr7:155003448~155005703:+
COAD	cis	rs9816784	0.901	rs12490036	ENSG00000231464.1	AC024937.4	-3.7	0.000267	0.0481	-0.25	-0.22	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195996738~195998233:+
COAD	cis	rs68170813	0.559	rs6971774	ENSG00000241764.3	AC002467.7	3.7	0.000267	0.0481	0.3	0.22	Coronary artery disease;	chr7:107193694	chr7:107742817~107744581:-
COAD	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-3.7	0.000267	0.0481	-0.25	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
COAD	cis	rs6845621	0.901	rs4586924	ENSG00000235413.3	KRT18P63	3.7	0.000268	0.0481	0.25	0.22	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr4:18886386	chr4:17911674~17912976:+
COAD	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	3.7	0.000268	0.0481	0.28	0.22	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
COAD	cis	rs11976180	1	rs2951353	ENSG00000273234.1	OR2A13P	-3.7	0.000268	0.0481	-0.28	-0.22	Obesity-related traits;	chr7:144064023	chr7:144142009~144142938:+
COAD	cis	rs9652601	0.677	rs35732840	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000268	0.0481	-0.28	-0.22	Systemic lupus erythematosus;	chr16:11134498	chr16:11056556~11057034:+
COAD	cis	rs860295	0.871	rs6688636	ENSG00000160766.13	GBAP1	3.7	0.000268	0.0482	0.25	0.22	Body mass index;	chr1:155509106	chr1:155213821~155227422:-
COAD	cis	rs13256369	1	rs12547721	ENSG00000253981.4	ALG1L13P	3.7	0.000268	0.0482	0.32	0.22	Obesity-related traits;	chr8:8713161	chr8:8236003~8244667:-
COAD	cis	rs1023500	0.529	rs133375	ENSG00000227370.1	RP4-669P10.19	-3.7	0.000268	0.0482	-0.23	-0.22	Schizophrenia;	chr22:42070505	chr22:42132543~42132998:+
COAD	cis	rs875971	1	rs2220626	ENSG00000179406.6	LINC00174	-3.7	0.000268	0.0482	-0.16	-0.22	Aortic root size;	chr7:66081075	chr7:66376044~66401338:-
COAD	cis	rs111778408	1	rs111778408	ENSG00000258704.4	SRP54-AS1	3.7	0.000268	0.0482	0.46	0.22	Monocyte percentage of white cells;	chr14:35102957	chr14:34920858~34982532:-
COAD	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-3.7	0.000268	0.0482	-0.29	-0.22	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
COAD	cis	rs1426063	0.858	rs6823982	ENSG00000249717.1	RP11-44F21.3	3.7	0.000268	0.0482	0.31	0.22	QT interval;	chr4:75084961	chr4:74955974~74970362:-
COAD	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	3.7	0.000268	0.0482	0.26	0.22	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
COAD	cis	rs7009110	0.527	rs6985506	ENSG00000213791.4	RP11-941H19.2	3.7	0.000268	0.0482	0.22	0.22	Asthma and hay fever;	chr8:80338948	chr8:80300869~80301481:+
COAD	cis	rs73222236	0.787	rs6783337	ENSG00000273486.1	RP11-731C17.2	3.7	0.000268	0.0482	0.24	0.22	Coronary artery disease;	chr3:136333895	chr3:136837338~136839021:-
COAD	cis	rs17248137	0.702	rs74850487	ENSG00000249942.1	AC142293.3	3.7	0.000268	0.0482	0.42	0.22	Overall survival in osteosarcoma;	chr4:74932066	chr4:74552584~74589481:-
COAD	cis	rs8046148	0.906	rs1008815	ENSG00000260381.2	RP11-429P3.5	-3.7	0.000268	0.0482	-0.33	-0.22	Testicular germ cell tumor;	chr16:50068309	chr16:50100339~50121943:-
COAD	cis	rs73222236	0.825	rs9833162	ENSG00000273486.1	RP11-731C17.2	3.7	0.000268	0.0483	0.23	0.22	Coronary artery disease;	chr3:136316895	chr3:136837338~136839021:-
COAD	cis	rs7646881	0.812	rs79303235	ENSG00000240207.5	RP11-379F4.4	-3.7	0.000268	0.0483	-0.29	-0.22	Tetralogy of Fallot;	chr3:158727004	chr3:158732263~158784070:+
COAD	cis	rs1510272	0.889	rs2063352	ENSG00000243926.1	TIPARP-AS1	-3.7	0.000268	0.0483	-0.25	-0.22	Testicular germ cell tumor;	chr3:156610691	chr3:156671862~156674378:-
COAD	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	3.7	0.000268	0.0483	0.42	0.22	Depression;	chr6:28333322	chr6:28943877~28944537:+
COAD	cis	rs919433	0.927	rs1429412	ENSG00000222017.1	AC011997.1	-3.7	0.000269	0.0483	-0.28	-0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197693106~197774823:+
COAD	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-3.7	0.000269	0.0483	-0.22	-0.22	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
COAD	cis	rs7204230	1	rs8050349	ENSG00000261056.2	RP11-454F8.2	3.7	0.000269	0.0483	0.27	0.22	Fibrinogen;	chr16:53305964	chr16:53298224~53299792:+
COAD	cis	rs7204230	1	rs12599349	ENSG00000261056.2	RP11-454F8.2	3.7	0.000269	0.0483	0.27	0.22	Fibrinogen;	chr16:53309159	chr16:53298224~53299792:+
COAD	cis	rs7204230	0.96	rs8053198	ENSG00000261056.2	RP11-454F8.2	3.7	0.000269	0.0483	0.27	0.22	Fibrinogen;	chr16:53309688	chr16:53298224~53299792:+
COAD	cis	rs9813712	0.595	rs16825656	ENSG00000249846.5	RP11-77P16.4	-3.7	0.000269	0.0483	-0.26	-0.22	Response to amphetamines;	chr3:130286225	chr3:130112550~130120579:+
COAD	cis	rs7577696	0.889	rs212726	ENSG00000272716.1	RP11-563N4.1	3.7	0.000269	0.0483	0.23	0.22	Inflammatory biomarkers;	chr2:32244316	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.889	rs212727	ENSG00000272716.1	RP11-563N4.1	3.7	0.000269	0.0483	0.23	0.22	Inflammatory biomarkers;	chr2:32244659	chr2:32165046~32165757:-
COAD	cis	rs7577696	0.889	rs212731	ENSG00000272716.1	RP11-563N4.1	3.7	0.000269	0.0483	0.23	0.22	Inflammatory biomarkers;	chr2:32247081	chr2:32165046~32165757:-
COAD	cis	rs9880211	0.898	rs13434116	ENSG00000273486.1	RP11-731C17.2	3.7	0.000269	0.0483	0.27	0.22	Height;Body mass index;	chr3:136634232	chr3:136837338~136839021:-
COAD	cis	rs911555	0.723	rs6575986	ENSG00000251533.2	LINC00605	-3.7	0.000269	0.0483	-0.29	-0.22	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103187221~103189028:-
COAD	cis	rs2333021	1	rs4899453	ENSG00000259015.1	RP11-109N23.6	-3.7	0.000269	0.0483	-0.21	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:72960595~72961993:+
COAD	cis	rs13113518	0.729	rs13120134	ENSG00000223305.1	RN7SKP30	3.69	0.000269	0.0483	0.28	0.22	Height;	chr4:55415153	chr4:55540502~55540835:-
COAD	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-3.69	0.000269	0.0483	-0.27	-0.22	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
COAD	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-3.69	0.000269	0.0483	-0.33	-0.22	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
COAD	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	3.69	0.000269	0.0483	0.33	0.22	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
COAD	cis	rs71636778	0.543	rs113002196	ENSG00000260063.1	RP5-968P14.2	-3.69	0.000269	0.0483	-0.31	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26873665	chr1:26692132~26694131:-
COAD	cis	rs6601327	0.606	rs13268319	ENSG00000233609.3	RP11-62H7.2	-3.69	0.000269	0.0483	-0.26	-0.22	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:8961200~8979025:+
COAD	cis	rs2243480	1	rs56016656	ENSG00000232559.3	GS1-124K5.12	3.69	0.000269	0.0483	0.4	0.22	Diabetic kidney disease;	chr7:65918494	chr7:66554588~66576923:-
COAD	cis	rs1799949	0.965	rs9897425	ENSG00000279602.1	CTD-3014M21.1	3.69	0.000269	0.0483	0.24	0.22	Menopause (age at onset);	chr17:43352811	chr17:43360041~43361361:-
COAD	cis	rs1670533	1	rs651017	ENSG00000273179.1	RP11-20I20.4	3.69	0.000269	0.0483	0.26	0.22	Recombination rate (females);	chr4:1097274	chr4:1167778~1168174:+
COAD	cis	rs956237	0.966	rs6833849	ENSG00000206601.1	RNU6-431P	3.69	0.000269	0.0483	0.28	0.22	Systemic lupus erythematosus;	chr4:108118263	chr4:108652150~108652256:+
COAD	cis	rs6661961	0.752	rs16834090	ENSG00000237975.5	FLG-AS1	-3.69	0.000269	0.0483	-0.23	-0.22	Atopic dermatitis;	chr1:152460428	chr1:152168125~152445456:+
COAD	cis	rs742132	0.858	rs2064126	ENSG00000220875.1	HIST1H3PS1	3.69	0.000269	0.0483	0.29	0.22	Uric acid levels;	chr6:25669268	chr6:26321876~26322292:-
COAD	cis	rs742132	0.858	rs2064127	ENSG00000220875.1	HIST1H3PS1	3.69	0.000269	0.0483	0.29	0.22	Uric acid levels;	chr6:25669408	chr6:26321876~26322292:-
COAD	cis	rs3781264	0.557	rs7100430	ENSG00000273450.1	RP11-76P2.4	3.69	0.000269	0.0483	0.27	0.22	Esophageal cancer and gastric cancer;	chr10:94362786	chr10:94314907~94315327:-
COAD	cis	rs4471510	0.961	rs4298976	ENSG00000273987.1	RP11-585P4.6	-3.69	0.000269	0.0483	-0.3	-0.22	Colonoscopy-negative controls vs population controls;	chr12:74853371	chr12:75333798~75334486:-
COAD	cis	rs7584330	0.504	rs6712927	ENSG00000234949.2	AC104667.3	-3.69	0.000269	0.0483	-0.3	-0.22	Prostate cancer;	chr2:237519165	chr2:237591020~237595981:+
COAD	cis	rs2337406	0.85	rs75196489	ENSG00000211964.3	IGHV3-48	-3.69	0.000269	0.0484	-0.18	-0.22	Alzheimer's disease (late onset);	chr14:106699438	chr14:106537810~106538344:-
COAD	cis	rs10971721	0.822	rs72725368	ENSG00000231991.4	ANXA2P2	3.69	0.000269	0.0484	0.32	0.22	Body mass index;	chr9:33815457	chr9:33624274~33625293:+
COAD	cis	rs10971721	0.822	rs72725370	ENSG00000231991.4	ANXA2P2	3.69	0.000269	0.0484	0.32	0.22	Body mass index;	chr9:33818459	chr9:33624274~33625293:+
COAD	cis	rs10971721	0.554	rs10971712	ENSG00000231991.4	ANXA2P2	3.69	0.000269	0.0484	0.32	0.22	Body mass index;	chr9:33820940	chr9:33624274~33625293:+
COAD	cis	rs739496	0.542	rs7312913	ENSG00000257595.2	RP3-473L9.4	3.69	0.000269	0.0484	0.33	0.22	Platelet count;	chr12:111355748	chr12:111369282~111403310:+
COAD	cis	rs12928939	0.517	rs8049508	ENSG00000260886.1	TAT-AS1	3.69	0.000269	0.0484	0.31	0.22	Post bronchodilator FEV1;	chr16:71944410	chr16:71565789~71578187:+
COAD	cis	rs72627509	0.638	rs73165963	ENSG00000269949.1	RP11-738E22.3	3.69	0.000269	0.0484	0.39	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874370	chr4:56960927~56961373:-
COAD	cis	rs72627509	0.68	rs56162812	ENSG00000269949.1	RP11-738E22.3	3.69	0.000269	0.0484	0.39	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56874501	chr4:56960927~56961373:-
COAD	cis	rs10460009	0.908	rs16944051	ENSG00000262001.1	DLGAP1-AS2	-3.69	0.000269	0.0484	-0.37	-0.22	Type 2 diabetes;	chr18:2922718	chr18:3603000~3608336:+
COAD	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-3.69	0.000269	0.0484	-0.43	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
COAD	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-3.69	0.000269	0.0484	-0.22	-0.22	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
COAD	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	3.69	0.000269	0.0484	0.26	0.22	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
COAD	cis	rs10876993	0.749	rs703832	ENSG00000270039.1	RP11-571M6.17	3.69	0.000269	0.0484	0.25	0.22	Celiac disease or Rheumatoid arthritis;	chr12:57630843	chr12:57803838~57804415:+
COAD	cis	rs2916733	0.547	rs3020275	ENSG00000246089.3	RP11-115C21.2	3.69	0.000269	0.0484	0.3	0.22	Epirubicin-induced leukopenia;	chr8:6456379	chr8:6403551~6407142:-
COAD	cis	rs10760158	0.832	rs963003	ENSG00000226752.6	PSMD5-AS1	-3.69	0.000269	0.0484	-0.24	-0.22	Pulse pressure;	chr9:121272531	chr9:120824828~120854385:+
COAD	cis	rs113835537	0.529	rs12099041	ENSG00000258297.1	RP11-658F2.8	-3.69	0.00027	0.0484	-0.23	-0.22	Airway imaging phenotypes;	chr11:66465302	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs7928882	ENSG00000258297.1	RP11-658F2.8	-3.69	0.00027	0.0484	-0.23	-0.22	Airway imaging phenotypes;	chr11:66467294	chr11:66666036~66668374:+
COAD	cis	rs113835537	0.529	rs57691879	ENSG00000258297.1	RP11-658F2.8	-3.69	0.00027	0.0484	-0.23	-0.22	Airway imaging phenotypes;	chr11:66469133	chr11:66666036~66668374:+
COAD	cis	rs370915	0.607	rs28548850	ENSG00000250971.1	RP11-696F12.1	3.69	0.00027	0.0484	0.27	0.22	Gout;	chr4:186865562	chr4:187060099~187060930:+
COAD	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-3.69	0.00027	0.0484	-0.24	-0.22	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
COAD	cis	rs10949834	0.793	rs810534	ENSG00000123965.13	PMS2P5	-3.69	0.00027	0.0484	-0.38	-0.22	Verbal memory performance (residualized delayed recall change);	chr7:74090715	chr7:74894116~74897835:+
COAD	cis	rs10876993	0.928	rs2169988	ENSG00000270039.1	RP11-571M6.17	3.69	0.00027	0.0484	0.25	0.22	Celiac disease or Rheumatoid arthritis;	chr12:57677382	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.928	rs813854	ENSG00000270039.1	RP11-571M6.17	3.69	0.00027	0.0484	0.25	0.22	Celiac disease or Rheumatoid arthritis;	chr12:57677564	chr12:57803838~57804415:+
COAD	cis	rs7204230	1	rs12596717	ENSG00000261056.2	RP11-454F8.2	3.69	0.00027	0.0484	0.27	0.22	Fibrinogen;	chr16:53334892	chr16:53298224~53299792:+
COAD	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-3.69	0.00027	0.0484	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
COAD	cis	rs2408955	0.522	rs4760612	ENSG00000269514.1	RP11-370I10.12	-3.69	0.00027	0.0484	-0.27	-0.22	Glycated hemoglobin levels;	chr12:48028073	chr12:48198387~48202031:+
COAD	cis	rs1056107	1	rs58632972	ENSG00000225513.1	RP11-165N19.2	-3.69	0.00027	0.0484	-0.28	-0.22	Colorectal cancer;	chr9:112324639	chr9:112173522~112173971:-
COAD	cis	rs2243480	1	rs160634	ENSG00000228409.4	CCT6P1	-3.69	0.00027	0.0484	-0.25	-0.22	Diabetic kidney disease;	chr7:66063677	chr7:65751142~65763354:+
COAD	cis	rs4820539	0.708	rs5751591	ENSG00000211644.2	IGLV1-51	-3.69	0.00027	0.0485	-0.13	-0.22	Bone mineral density;	chr22:23146855	chr22:22322472~22322980:+
COAD	cis	rs10911232	0.507	rs7515822	ENSG00000224468.3	RP11-181K3.4	-3.69	0.00027	0.0485	-0.22	-0.22	Hypertriglyceridemia;	chr1:183068668	chr1:183138402~183141282:-
COAD	cis	rs10911232	0.507	rs10797832	ENSG00000224468.3	RP11-181K3.4	-3.69	0.00027	0.0485	-0.22	-0.22	Hypertriglyceridemia;	chr1:183074899	chr1:183138402~183141282:-
COAD	cis	rs6480314	0.522	rs80326649	ENSG00000233590.1	RP11-153K11.3	-3.69	0.00027	0.0485	-0.33	-0.22	Optic nerve measurement (disc area);	chr10:68285667	chr10:68233251~68242379:-
COAD	cis	rs7615952	0.932	rs13325495	ENSG00000272840.1	RP11-379B18.6	3.69	0.00027	0.0485	0.35	0.22	Blood pressure (smoking interaction);	chr3:125918573	chr3:125774714~125797953:+
COAD	cis	rs2348418	0.715	rs1581076	ENSG00000247934.4	RP11-967K21.1	3.69	0.00027	0.0485	0.19	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28163298~28190738:-
COAD	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-3.69	0.00027	0.0485	-0.33	-0.22	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
COAD	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-3.69	0.00027	0.0485	-0.33	-0.22	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
COAD	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-3.69	0.00027	0.0485	-0.33	-0.22	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
COAD	cis	rs59698941	0.527	rs1557852	ENSG00000263597.1	MIR3936	-3.69	0.00027	0.0485	-0.24	-0.22	Apolipoprotein A-IV levels;	chr5:132846108	chr5:132365490~132365599:-
COAD	cis	rs59698941	0.55	rs12652469	ENSG00000263597.1	MIR3936	-3.69	0.00027	0.0485	-0.24	-0.22	Apolipoprotein A-IV levels;	chr5:132847073	chr5:132365490~132365599:-
COAD	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-3.69	0.00027	0.0485	-0.3	-0.22	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
COAD	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-3.69	0.00027	0.0485	-0.31	-0.22	Pain;	chr19:21499472	chr19:21554640~21569237:-
COAD	cis	rs1662342	0.8	rs16944619	ENSG00000264235.4	RP13-270P17.1	-3.69	0.00027	0.0485	-0.32	-0.22	QRS duration;	chr18:3278635	chr18:3255436~3261850:-
COAD	cis	rs3738443	0.951	rs4269806	ENSG00000259865.1	RP11-488L18.10	3.69	0.00027	0.0485	0.27	0.22	Alcohol dependence;	chr1:247211721	chr1:247187281~247188526:-
COAD	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-3.69	0.00027	0.0485	-0.33	-0.22	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
COAD	cis	rs7819412	0.74	rs7844536	ENSG00000269918.1	AF131215.9	-3.69	0.00027	0.0485	-0.28	-0.22	Triglycerides;	chr8:11176519	chr8:11104691~11106704:-
COAD	cis	rs739496	0.843	rs619010	ENSG00000257595.2	RP3-473L9.4	3.69	0.00027	0.0485	0.31	0.22	Platelet count;	chr12:111537019	chr12:111369282~111403310:+
COAD	cis	rs7005380	0.733	rs2037346	ENSG00000245330.4	KB-1471A8.1	3.69	0.00027	0.0485	0.27	0.22	Interstitial lung disease;	chr8:119923212	chr8:119867419~119874488:-
COAD	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-3.69	0.00027	0.0485	-0.26	-0.22	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
COAD	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	3.69	0.000271	0.0485	0.2	0.22	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
COAD	cis	rs2186369	0.681	rs9608186	ENSG00000228315.10	GUSBP11	3.69	0.000271	0.0485	0.18	0.22	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23800791	chr22:23638487~23717356:-
COAD	cis	rs2916733	0.53	rs2515571	ENSG00000246089.3	RP11-115C21.2	-3.69	0.000271	0.0485	-0.29	-0.22	Epirubicin-induced leukopenia;	chr8:6446738	chr8:6403551~6407142:-
COAD	cis	rs4648045	0.565	rs4698860	ENSG00000246560.2	RP11-10L12.4	3.69	0.000271	0.0485	0.31	0.22	Lymphocyte percentage of white cells;	chr4:102624170	chr4:102828055~102844075:+
COAD	cis	rs6480314	0.522	rs7902936	ENSG00000233590.1	RP11-153K11.3	3.69	0.000271	0.0485	0.27	0.22	Optic nerve measurement (disc area);	chr10:68299584	chr10:68233251~68242379:-
COAD	cis	rs12571093	0.571	rs7903251	ENSG00000233590.1	RP11-153K11.3	3.69	0.000271	0.0485	0.27	0.22	Optic nerve measurement (disc area);	chr10:68299969	chr10:68233251~68242379:-
COAD	cis	rs2777491	0.957	rs3743038	ENSG00000247556.5	OIP5-AS1	3.69	0.000271	0.0485	0.25	0.22	Ulcerative colitis;	chr15:41402545	chr15:41283990~41309737:+
COAD	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-3.69	0.000271	0.0485	-0.29	-0.22	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
COAD	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	3.69	0.000271	0.0486	0.31	0.22	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
COAD	cis	rs10864907	0.837	rs10178396	ENSG00000236397.3	DDX11L2	-3.69	0.000271	0.0486	-0.28	-0.22	Pulmonary function;	chr2:112941478	chr2:113599036~113601261:-
COAD	cis	rs465530	0.58	rs2686601	ENSG00000225195.2	RP11-338E21.2	3.69	0.000271	0.0486	0.25	0.22	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr12:64895640	chr12:64628344~64629976:+
COAD	cis	rs9307551	0.817	rs1031004	ENSG00000250334.4	LINC00989	-3.69	0.000271	0.0486	-0.26	-0.22	Refractive error;	chr4:79595695	chr4:79492416~79576460:+
COAD	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-3.69	0.000271	0.0486	-0.26	-0.22	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
COAD	cis	rs57786342	0.762	rs4902649	ENSG00000240210.3	RP11-204K16.1	-3.69	0.000271	0.0486	-0.28	-0.22	Macrophage inflammatory protein 1a levels;	chr14:68800554	chr14:68338728~68339528:-
COAD	cis	rs57221529	0.664	rs72704802	ENSG00000250385.1	RP11-310P5.2	3.69	0.000271	0.0486	0.39	0.22	Lung disease severity in cystic fibrosis;	chr5:554096	chr5:524705~526594:+
COAD	cis	rs1115240	0.574	rs61990567	ENSG00000257842.4	NOVA1-AS1	3.69	0.000271	0.0486	0.31	0.22	Educational attainment (years of education);	chr14:26479573	chr14:26598412~26806467:+
COAD	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-3.69	0.000271	0.0486	-0.29	-0.22	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
COAD	cis	rs3816183	0.797	rs6544599	ENSG00000236533.1	AC009413.2	-3.69	0.000271	0.0486	-0.27	-0.22	Hypospadias;	chr2:42804179	chr2:41850203~41850601:-
COAD	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	3.69	0.000271	0.0486	0.25	0.22	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
COAD	cis	rs10465746	0.78	rs11163867	ENSG00000249237.4	RP11-376N17.4	-3.69	0.000271	0.0486	-0.25	-0.22	Obesity-related traits;	chr1:83919164	chr1:84344678~84349939:+
COAD	cis	rs2337406	0.587	rs916547	ENSG00000254174.1	IGHV1-12	3.69	0.000271	0.0486	0.21	0.22	Alzheimer's disease (late onset);	chr14:106646735	chr14:106122420~106122709:-
COAD	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	3.69	0.000271	0.0486	0.43	0.22	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
COAD	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	3.69	0.000271	0.0486	0.43	0.22	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
COAD	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	3.69	0.000271	0.0486	0.43	0.22	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
COAD	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	3.69	0.000271	0.0486	0.28	0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
COAD	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	3.69	0.000271	0.0486	0.28	0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
COAD	cis	rs875971	0.522	rs1701760	ENSG00000234585.5	CCT6P3	3.69	0.000271	0.0486	0.21	0.22	Aortic root size;	chr7:66008701	chr7:65038354~65074713:+
COAD	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	3.69	0.000271	0.0486	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
COAD	cis	rs1707322	0.721	rs10789468	ENSG00000230896.1	RP11-767N6.7	-3.69	0.000271	0.0486	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45694684~45697075:-
COAD	cis	rs1707322	0.721	rs6429574	ENSG00000230896.1	RP11-767N6.7	-3.69	0.000271	0.0486	-0.26	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45694684~45697075:-
COAD	cis	rs848486	0.902	rs11972096	ENSG00000213542.3	RP11-467H10.1	-3.69	0.000271	0.0486	-0.24	-0.22	Glomerular filtration rate;	chr7:77804167	chr7:77115399~77116192:-
COAD	cis	rs853679	0.607	rs67998226	ENSG00000204709.4	LINC01556	3.69	0.000271	0.0486	0.6	0.22	Depression;	chr6:28270281	chr6:28943877~28944537:+
COAD	cis	rs7204230	1	rs7189240	ENSG00000261056.2	RP11-454F8.2	3.69	0.000272	0.0487	0.27	0.22	Fibrinogen;	chr16:53230026	chr16:53298224~53299792:+
COAD	cis	rs848486	0.902	rs7795371	ENSG00000213542.3	RP11-467H10.1	-3.69	0.000272	0.0487	-0.24	-0.22	Glomerular filtration rate;	chr7:77733187	chr7:77115399~77116192:-
COAD	cis	rs875971	0.545	rs12671152	ENSG00000232546.1	RP11-458F8.1	3.69	0.000272	0.0487	0.23	0.22	Aortic root size;	chr7:66311140	chr7:66848496~66858136:+
COAD	cis	rs875971	0.862	rs10256544	ENSG00000224316.1	RP11-479O9.2	3.69	0.000272	0.0487	0.24	0.22	Aortic root size;	chr7:66210141	chr7:65773620~65802067:+
COAD	cis	rs12699921	0.632	rs4316058	ENSG00000279048.1	RP11-511H23.2	-3.69	0.000272	0.0487	-0.16	-0.22	Fibrinogen levels;	chr7:17795103	chr7:17940503~17942922:+
COAD	cis	rs9926296	0.542	rs12599531	ENSG00000260279.2	AC137932.5	-3.69	0.000272	0.0487	-0.21	-0.22	Vitiligo;	chr16:89842993	chr16:89297508~89298317:+
COAD	cis	rs11158609	0.878	rs7160883	ENSG00000258727.1	RP11-66N24.3	3.69	0.000272	0.0487	0.21	0.22	Systolic blood pressure (cigarette smoking interaction);	chr14:24204769	chr14:23561097~23568073:+
COAD	cis	rs11098499	0.955	rs35197422	ENSG00000250412.1	KLHL2P1	3.69	0.000272	0.0487	0.3	0.22	Corneal astigmatism;	chr4:119248159	chr4:119334329~119378233:+
COAD	cis	rs11098499	0.955	rs1511015	ENSG00000250412.1	KLHL2P1	3.69	0.000272	0.0487	0.3	0.22	Corneal astigmatism;	chr4:119249318	chr4:119334329~119378233:+
COAD	cis	rs11098499	1	rs10029750	ENSG00000250412.1	KLHL2P1	3.69	0.000272	0.0487	0.3	0.22	Corneal astigmatism;	chr4:119251388	chr4:119334329~119378233:+
COAD	cis	rs11098499	1	rs28374891	ENSG00000250412.1	KLHL2P1	3.69	0.000272	0.0487	0.3	0.22	Corneal astigmatism;	chr4:119262395	chr4:119334329~119378233:+
COAD	cis	rs6687758	0.687	rs12137323	ENSG00000232679.1	RP11-400N13.3	3.69	0.000272	0.0487	0.29	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:222041705~222064763:-
COAD	cis	rs8022206	0.812	rs445921	ENSG00000259502.1	RP11-643G16.3	3.69	0.000272	0.0487	0.32	0.22	Platelet count;Mean platelet volume;	chr14:68106925	chr14:67610986~67613864:+
COAD	cis	rs2530545	0.585	rs2159371	ENSG00000230356.1	NCAPD2P1	-3.69	0.000272	0.0487	-0.38	-0.22	IgG glycosylation;	chr7:34506948	chr7:34750253~34752053:-
COAD	cis	rs875971	1	rs6946143	ENSG00000224316.1	RP11-479O9.2	3.69	0.000272	0.0487	0.23	0.22	Aortic root size;	chr7:66114735	chr7:65773620~65802067:+
COAD	cis	rs7555006	0.901	rs6695869	ENSG00000227742.1	CALR4P	3.69	0.000272	0.0487	0.23	0.22	Headache;	chr1:50947533	chr1:51561866~51594897:-
COAD	cis	rs9910055	0.529	rs170637	ENSG00000267080.4	ASB16-AS1	3.69	0.000272	0.0487	0.21	0.22	Total body bone mineral density;	chr17:44109500	chr17:44175973~44186717:-
COAD	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-3.69	0.000272	0.0487	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
COAD	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	3.69	0.000272	0.0487	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
COAD	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	3.69	0.000272	0.0487	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	3.69	0.000272	0.0487	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	3.69	0.000272	0.0487	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	3.69	0.000272	0.0487	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
COAD	cis	rs11098499	0.754	rs878376	ENSG00000250412.1	KLHL2P1	3.69	0.000272	0.0487	0.29	0.22	Corneal astigmatism;	chr4:119316547	chr4:119334329~119378233:+
COAD	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	3.69	0.000272	0.0487	0.39	0.22	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
COAD	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	3.69	0.000272	0.0487	0.39	0.22	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
COAD	cis	rs1552244	0.882	rs66559400	ENSG00000186162.9	CIDECP	3.69	0.000272	0.0488	0.32	0.22	Alzheimer's disease;	chr3:9970867	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs68153882	ENSG00000186162.9	CIDECP	3.69	0.000272	0.0488	0.32	0.22	Alzheimer's disease;	chr3:9971426	chr3:10014238~10026365:-
COAD	cis	rs1552244	0.882	rs35056669	ENSG00000186162.9	CIDECP	3.69	0.000272	0.0488	0.32	0.22	Alzheimer's disease;	chr3:9972487	chr3:10014238~10026365:-
COAD	cis	rs3934047	0.904	rs8033875	ENSG00000278029.1	CTD-2240J17.2	-3.69	0.000272	0.0488	-0.25	-0.22	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81746429	chr15:81392759~81393384:+
COAD	cis	rs13188386	0.763	rs7703713	ENSG00000249779.1	RP11-447H19.3	3.69	0.000272	0.0488	0.26	0.22	Iron status biomarkers;	chr5:42555829	chr5:43206709~43207811:+
COAD	cis	rs6545883	0.894	rs6739427	ENSG00000273302.1	RP11-493E12.2	-3.69	0.000272	0.0488	-0.22	-0.22	Tuberculosis;	chr2:61225744	chr2:61199979~61200769:+
COAD	cis	rs4930561	0.765	rs7931502	ENSG00000184795.9	UNC93B5	3.69	0.000272	0.0488	0.26	0.22	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr11:67711702~67716005:-
COAD	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-3.69	0.000272	0.0488	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
COAD	cis	rs6951245	1	rs78896566	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs79422648	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1160374~1165267:+
COAD	cis	rs6951245	0.872	rs113119264	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs76804143	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs1997243	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1160374~1165267:+
COAD	cis	rs6951245	1	rs77760339	ENSG00000229043.2	AC091729.9	-3.69	0.000272	0.0488	-0.38	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1160374~1165267:+
COAD	cis	rs12699921	0.599	rs9942602	ENSG00000279048.1	RP11-511H23.2	3.69	0.000273	0.0488	0.17	0.22	Fibrinogen levels;	chr7:17937431	chr7:17940503~17942922:+
COAD	cis	rs1876905	0.539	rs240956	ENSG00000230177.1	RP5-1112D6.4	3.69	0.000273	0.0488	0.23	0.22	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111277932~111278742:+
COAD	cis	rs4879656	0.931	rs3758275	ENSG00000225693.1	LAGE3P1	-3.69	0.000273	0.0488	-0.27	-0.22	Menopause (age at onset);	chr9:33024960	chr9:33019682~33020165:-
COAD	cis	rs59698941	0.527	rs1910075	ENSG00000263597.1	MIR3936	-3.69	0.000273	0.0488	-0.24	-0.22	Apolipoprotein A-IV levels;	chr5:132844397	chr5:132365490~132365599:-
COAD	cis	rs2832191	0.647	rs11170	ENSG00000176054.6	RPL23P2	3.69	0.000273	0.0488	0.23	0.22	Dental caries;	chr21:29005769	chr21:28997613~28998033:-
COAD	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-3.69	0.000273	0.0488	-0.22	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
COAD	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	3.69	0.000273	0.0488	0.51	0.22	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	3.69	0.000273	0.0488	0.51	0.22	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	3.69	0.000273	0.0488	0.51	0.22	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	3.69	0.000273	0.0488	0.51	0.22	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
COAD	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	3.69	0.000273	0.0488	0.51	0.22	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
COAD	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	3.69	0.000273	0.0488	0.3	0.22	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
COAD	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	3.69	0.000273	0.0488	0.29	0.22	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
COAD	cis	rs597539	0.731	rs664229	ENSG00000255741.1	RP11-757G1.5	-3.69	0.000273	0.0488	-0.3	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68941503~68942852:-
COAD	cis	rs2337406	0.789	rs60000589	ENSG00000254174.1	IGHV1-12	3.69	0.000273	0.0489	0.19	0.22	Alzheimer's disease (late onset);	chr14:106782459	chr14:106122420~106122709:-
COAD	cis	rs860295	0.841	rs7556102	ENSG00000225082.2	DAP3P1	3.69	0.000273	0.0489	0.28	0.22	Body mass index;	chr1:155398412	chr1:155586644~155602197:+
COAD	cis	rs801193	0.66	rs1962050	ENSG00000236529.1	RP13-254B10.1	-3.69	0.000273	0.0489	-0.25	-0.22	Aortic root size;	chr7:66775021	chr7:65840212~65840596:+
COAD	cis	rs10465746	0.747	rs10493741	ENSG00000249237.4	RP11-376N17.4	-3.69	0.000273	0.0489	-0.25	-0.22	Obesity-related traits;	chr1:83922435	chr1:84344678~84349939:+
COAD	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	3.69	0.000273	0.0489	0.29	0.22	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
COAD	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-3.69	0.000273	0.0489	-0.24	-0.22	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
COAD	cis	rs7955901	0.725	rs12366661	ENSG00000258053.1	CTD-2021H9.3	3.69	0.000273	0.0489	0.29	0.22	Type 2 diabetes;	chr12:71067588	chr12:71047402~71118247:-
COAD	cis	rs7955901	0.725	rs7294409	ENSG00000258053.1	CTD-2021H9.3	3.69	0.000273	0.0489	0.29	0.22	Type 2 diabetes;	chr12:71068410	chr12:71047402~71118247:-
COAD	cis	rs796825	0.671	rs9843220	ENSG00000240661.1	RP11-174O3.3	3.69	0.000273	0.0489	0.25	0.22	HIV-1 susceptibility;	chr3:120284297	chr3:120349510~120367998:+
COAD	cis	rs1426063	0.858	rs9990627	ENSG00000249717.1	RP11-44F21.3	3.69	0.000273	0.0489	0.32	0.22	QT interval;	chr4:75081244	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.858	rs10026994	ENSG00000249717.1	RP11-44F21.3	3.69	0.000273	0.0489	0.32	0.22	QT interval;	chr4:75081551	chr4:74955974~74970362:-
COAD	cis	rs1426063	0.858	rs6830936	ENSG00000249717.1	RP11-44F21.3	3.69	0.000273	0.0489	0.32	0.22	QT interval;	chr4:75083952	chr4:74955974~74970362:-
COAD	cis	rs16949788	1	rs9806600	ENSG00000242634.1	RPS24P16	3.69	0.000273	0.0489	0.42	0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66302109	chr15:67232446~67232837:+
COAD	cis	rs4699052	0.625	rs4481237	ENSG00000246560.2	RP11-10L12.4	3.69	0.000273	0.0489	0.26	0.22	Testicular germ cell tumor;	chr4:103332852	chr4:102828055~102844075:+
COAD	cis	rs4699052	0.507	rs10005997	ENSG00000246560.2	RP11-10L12.4	3.69	0.000273	0.0489	0.28	0.22	Testicular germ cell tumor;	chr4:103380554	chr4:102828055~102844075:+
COAD	cis	rs7324557	0.684	rs58663560	ENSG00000205861.10	C1QTNF9B-AS1	-3.69	0.000273	0.0489	-0.33	-0.22	Visceral adipose tissue adjusted for BMI;	chr13:23830800	chr13:23888889~23897263:+
COAD	cis	rs1876905	0.597	rs1215964	ENSG00000255389.1	C6orf3	3.69	0.000273	0.0489	0.26	0.22	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111599875~111602295:+
COAD	cis	rs7142002	0.568	rs746781	ENSG00000272444.1	RP11-1017G21.6	-3.69	0.000273	0.0489	-0.31	-0.22	Autism;	chr14:101922138	chr14:101952416~101953063:+
COAD	cis	rs6964833	1	rs3846966	ENSG00000127957.15	PMS2P3	-3.69	0.000273	0.0489	-0.22	-0.22	Menarche (age at onset);	chr7:74698811	chr7:75502930~75528148:-
COAD	cis	rs6964833	1	rs2301907	ENSG00000127957.15	PMS2P3	-3.69	0.000273	0.0489	-0.22	-0.22	Menarche (age at onset);	chr7:74700517	chr7:75502930~75528148:-
COAD	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	3.69	0.000273	0.0489	0.22	0.22	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
COAD	cis	rs7656342	0.755	rs6810736	ENSG00000186234.7	FAM86MP	-3.69	0.000274	0.049	-0.28	-0.22	Gut microbiota (bacterial taxa);	chr4:9878104	chr4:9692495~9702954:+
COAD	cis	rs5751168	0.834	rs414781	ENSG00000211660.3	IGLV2-23	-3.69	0.000274	0.049	-0.15	-0.22	Prostate cancer (SNP x SNP interaction);	chr22:22484750	chr22:22697789~22698407:+
COAD	cis	rs10465746	0.704	rs12723239	ENSG00000249237.4	RP11-376N17.4	-3.69	0.000274	0.049	-0.26	-0.22	Obesity-related traits;	chr1:84003837	chr1:84344678~84349939:+
COAD	cis	rs10465746	0.68	rs1886770	ENSG00000249237.4	RP11-376N17.4	-3.69	0.000274	0.049	-0.26	-0.22	Obesity-related traits;	chr1:84005613	chr1:84344678~84349939:+
COAD	cis	rs2188554	1	rs2188554	ENSG00000237974.1	AC000111.4	3.69	0.000274	0.049	0.24	0.22	Esophageal adenocarcinoma;	chr7:117400063	chr7:117487737~117487929:+
COAD	cis	rs34779708	0.931	rs7099593	ENSG00000271335.4	RP11-324I22.4	3.69	0.000274	0.049	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	3.69	0.000274	0.049	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs13376801	ENSG00000271335.4	RP11-324I22.4	3.69	0.000274	0.049	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35314552~35336401:-
COAD	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	3.69	0.000274	0.049	0.29	0.22	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
COAD	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-3.69	0.000274	0.049	-0.28	-0.22	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
COAD	cis	rs2337406	0.587	rs11624678	ENSG00000254174.1	IGHV1-12	-3.69	0.000274	0.049	-0.21	-0.22	Alzheimer's disease (late onset);	chr14:106650408	chr14:106122420~106122709:-
COAD	cis	rs6822297	0.808	rs7692953	ENSG00000240005.4	RP11-293A21.1	3.69	0.000274	0.049	0.28	0.22	Obesity-related traits;	chr4:26936514	chr4:26859806~26860599:-
COAD	cis	rs875971	1	rs1565531	ENSG00000223473.2	GS1-124K5.3	-3.69	0.000274	0.049	-0.18	-0.22	Aortic root size;	chr7:66198126	chr7:66491049~66493566:-
COAD	cis	rs801193	0.636	rs10233806	ENSG00000230189.5	GS1-124K5.2	-3.69	0.000274	0.049	-0.19	-0.22	Aortic root size;	chr7:66653261	chr7:66409143~66490059:-
COAD	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-3.69	0.000274	0.049	-0.28	-0.22	Gout;	chr7:66715944	chr7:66848496~66858136:+
COAD	cis	rs36052053	0.908	rs13220206	ENSG00000219700.1	PTCHD3P3	3.69	0.000274	0.049	0.39	0.22	Red cell distribution width;	chr6:109303278	chr6:109288571~109290503:-
COAD	cis	rs11098499	0.954	rs67265404	ENSG00000250412.1	KLHL2P1	3.69	0.000274	0.049	0.3	0.22	Corneal astigmatism;	chr4:119438115	chr4:119334329~119378233:+
COAD	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-3.69	0.000274	0.049	-0.36	-0.22	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
COAD	cis	rs10911902	0.643	rs7525634	ENSG00000229739.2	RP11-295K2.3	-3.69	0.000274	0.0491	-0.32	-0.22	Schizophrenia;	chr1:186411333	chr1:186435161~186470291:+
COAD	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	3.69	0.000274	0.0491	0.29	0.22	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
COAD	cis	rs6480314	0.522	rs10762210	ENSG00000233590.1	RP11-153K11.3	3.69	0.000274	0.0491	0.28	0.22	Optic nerve measurement (disc area);	chr10:68290860	chr10:68233251~68242379:-
COAD	cis	rs11722228	1	rs4697695	ENSG00000250413.1	RP11-448G15.1	-3.69	0.000274	0.0491	-0.31	-0.22	Urate levels;Serum uric acid levels;Gout;	chr4:9914226	chr4:10006482~10009725:+
COAD	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-3.69	0.000274	0.0491	-0.34	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
COAD	cis	rs6472235	0.564	rs35753080	ENSG00000272010.1	CTD-3025N20.3	-3.69	0.000275	0.0491	-0.22	-0.22	Plateletcrit;Myopia (pathological);	chr8:66000762	chr8:65591850~65592472:-
COAD	cis	rs6472235	0.586	rs7814933	ENSG00000272010.1	CTD-3025N20.3	-3.69	0.000275	0.0491	-0.22	-0.22	Plateletcrit;Myopia (pathological);	chr8:66000992	chr8:65591850~65592472:-
COAD	cis	rs10876993	0.928	rs2640637	ENSG00000270039.1	RP11-571M6.17	3.69	0.000275	0.0491	0.25	0.22	Celiac disease or Rheumatoid arthritis;	chr12:57683803	chr12:57803838~57804415:+
COAD	cis	rs10876993	0.89	rs1689584	ENSG00000270039.1	RP11-571M6.17	3.69	0.000275	0.0491	0.25	0.22	Celiac disease or Rheumatoid arthritis;	chr12:57687695	chr12:57803838~57804415:+
COAD	cis	rs11236814	0.85	rs61893488	ENSG00000224829.3	TOMM20P1	-3.69	0.000275	0.0491	-0.38	-0.22	Allergic disease (asthma, hay fever or eczema);	chr11:76638063	chr11:77313606~77314032:+
COAD	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-3.69	0.000275	0.0491	-0.27	-0.22	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
COAD	cis	rs1510510	0.676	rs13000887	ENSG00000225057.2	AC096574.4	3.69	0.000275	0.0491	0.3	0.22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238679823	chr2:238231684~238255633:+
COAD	cis	rs10504130	0.518	rs6473654	ENSG00000272024.1	RP11-546K22.3	3.69	0.000275	0.0491	0.33	0.22	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51950284~51950690:+
COAD	cis	rs495337	1	rs2235616	ENSG00000229222.1	KRT18P4	-3.69	0.000275	0.0491	-0.24	-0.22	Psoriasis;	chr20:49952590	chr20:49956745~49958032:+
COAD	cis	rs1707322	0.785	rs10890348	ENSG00000281912.1	LINC01144	-3.69	0.000275	0.0491	-0.23	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45303910~45305619:+
COAD	cis	rs1552244	0.935	rs66493421	ENSG00000186162.9	CIDECP	3.69	0.000275	0.0492	0.36	0.22	Alzheimer's disease;	chr3:10050885	chr3:10014238~10026365:-
COAD	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	3.69	0.000275	0.0492	0.25	0.22	Height;	chr4:55561053	chr4:55363971~55395847:-
COAD	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	3.69	0.000275	0.0492	0.25	0.22	Height;	chr4:55564241	chr4:55363971~55395847:-
COAD	cis	rs7212590	0.655	rs34687426	ENSG00000264049.1	MIR4737	-3.69	0.000275	0.0492	-0.32	-0.22	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59920496	chr17:60043025~60043105:-
COAD	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	3.69	0.000275	0.0492	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	3.69	0.000275	0.0492	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	3.69	0.000275	0.0492	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
COAD	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	3.69	0.000275	0.0492	0.3	0.22	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
COAD	cis	rs2307394	0.89	rs13025219	ENSG00000281469.1	RP11-567F11.1	3.69	0.000275	0.0492	0.26	0.22	Urate levels;	chr2:147832415	chr2:148044380~148044894:+
COAD	cis	rs2307394	0.964	rs13004451	ENSG00000281469.1	RP11-567F11.1	3.69	0.000275	0.0492	0.26	0.22	Urate levels;	chr2:147836024	chr2:148044380~148044894:+
COAD	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-3.69	0.000275	0.0492	-0.29	-0.22	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
COAD	cis	rs9926296	0.572	rs2376878	ENSG00000260279.2	AC137932.5	3.69	0.000275	0.0492	0.2	0.22	Vitiligo;	chr16:89818753	chr16:89297508~89298317:+
COAD	cis	rs72843506	0.586	rs113833946	ENSG00000189423.10	USP32P3	3.69	0.000275	0.0492	0.43	0.22	Schizophrenia;	chr17:19955593	chr17:20415547~20431008:+
COAD	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-3.69	0.000275	0.0492	-0.29	-0.22	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
COAD	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	3.69	0.000275	0.0492	0.28	0.22	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
COAD	cis	rs1577917	0.771	rs9362239	ENSG00000220563.1	PKMP3	3.69	0.000275	0.0492	0.25	0.22	Response to antipsychotic treatment;	chr6:85719545	chr6:85659892~85660606:-
COAD	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-3.69	0.000276	0.0492	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
COAD	cis	rs7837649	0.824	rs16939359	ENSG00000253661.1	ZFHX4-AS1	3.69	0.000276	0.0492	0.21	0.22	Monobrow;	chr8:76782790	chr8:76491200~76683278:-
COAD	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	3.69	0.000276	0.0492	0.26	0.22	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
COAD	cis	rs11098499	0.691	rs10010355	ENSG00000249244.1	RP11-548H18.2	3.69	0.000276	0.0493	0.28	0.22	Corneal astigmatism;	chr4:119339888	chr4:119391831~119395335:-
COAD	cis	rs11098499	0.691	rs9307471	ENSG00000249244.1	RP11-548H18.2	3.69	0.000276	0.0493	0.28	0.22	Corneal astigmatism;	chr4:119340107	chr4:119391831~119395335:-
COAD	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000276	0.0493	-0.23	-0.22	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
COAD	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	3.69	0.000276	0.0493	0.39	0.22	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
COAD	cis	rs10863681	1	rs12135862	ENSG00000232679.1	RP11-400N13.3	-3.69	0.000276	0.0493	-0.24	-0.22	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222072045	chr1:222041705~222064763:-
COAD	cis	rs7955901	0.638	rs73134417	ENSG00000258053.1	CTD-2021H9.3	3.69	0.000276	0.0493	0.28	0.22	Type 2 diabetes;	chr12:71097071	chr12:71047402~71118247:-
COAD	cis	rs9503598	0.605	rs9968900	ENSG00000270504.1	RP11-420L9.5	3.69	0.000276	0.0493	0.18	0.22	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr6:3457453	chr6:3751111~3753871:+
COAD	cis	rs17685	0.753	rs12531559	ENSG00000280388.1	RP11-229D13.3	3.69	0.000276	0.0493	0.23	0.22	Coffee consumption (cups per day);Coffee consumption;	chr7:76002379	chr7:76043977~76045963:-
COAD	cis	rs2814331	0.62	rs1870167	ENSG00000272734.1	ADIRF-AS1	3.69	0.000276	0.0493	0.28	0.22	Balding;	chr10:86269829	chr10:86965345~86971311:-
COAD	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-3.69	0.000276	0.0493	-0.31	-0.22	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
COAD	cis	rs55665837	0.539	rs731042	ENSG00000251991.1	RNU7-49P	3.69	0.000276	0.0493	0.28	0.22	Vitamin D levels;	chr11:14853429	chr11:14478892~14478953:+
COAD	cis	rs3096299	0.702	rs2086824	ENSG00000260259.1	RP11-368I7.4	-3.69	0.000276	0.0493	-0.27	-0.22	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89682620~89686569:-
COAD	cis	rs2898681	0.614	rs58260946	ENSG00000248375.1	RP11-177B4.1	-3.69	0.000276	0.0493	-0.33	-0.22	Optic nerve measurement (cup area);	chr4:52809253	chr4:52720081~52720831:-
COAD	cis	rs860295	0.665	rs11264367	ENSG00000160766.13	GBAP1	-3.69	0.000276	0.0493	-0.28	-0.22	Body mass index;	chr1:155367547	chr1:155213821~155227422:-
COAD	cis	rs6736175	0.744	rs13017460	ENSG00000231858.4	AC067945.4	3.69	0.000276	0.0493	0.25	0.22	Systemic lupus erythematosus;	chr2:191067830	chr2:191021526~191032314:+
COAD	cis	rs9387478	1	rs9401006	ENSG00000230202.1	RP11-632C17__A.1	3.69	0.000276	0.0493	0.26	0.22	Lung cancer;	chr6:117411761	chr6:117998975~117999448:+
COAD	cis	rs9307551	1	rs9307545	ENSG00000250334.4	LINC00989	-3.69	0.000276	0.0493	-0.29	-0.22	Refractive error;	chr4:79595417	chr4:79492416~79576460:+
COAD	cis	rs8022206	0.659	rs34050208	ENSG00000259502.1	RP11-643G16.3	3.69	0.000276	0.0493	0.36	0.22	Platelet count;Mean platelet volume;	chr14:67863916	chr14:67610986~67613864:+
COAD	cis	rs41271951	0.512	rs34761930	ENSG00000223861.1	RP11-74C1.2	-3.69	0.000276	0.0493	-0.43	-0.22	Blood protein levels;	chr1:151117047	chr1:151557446~151557940:+
COAD	cis	rs41271951	0.512	rs12058128	ENSG00000223861.1	RP11-74C1.2	-3.69	0.000276	0.0493	-0.43	-0.22	Blood protein levels;	chr1:151133637	chr1:151557446~151557940:+
COAD	cis	rs41271951	0.512	rs12090246	ENSG00000223861.1	RP11-74C1.2	-3.69	0.000276	0.0493	-0.43	-0.22	Blood protein levels;	chr1:151135020	chr1:151557446~151557940:+
COAD	cis	rs12438356	0.686	rs16952899	ENSG00000259426.4	RP11-253M7.1	3.69	0.000276	0.0493	0.31	0.22	CTACK levels;	chr15:69176546	chr15:69396904~69415029:-
COAD	cis	rs494562	0.892	rs1665787	ENSG00000234155.1	RP11-30P6.6	-3.69	0.000276	0.0493	-0.4	-0.22	Metabolic traits;Blood metabolite levels;	chr6:85405469	chr6:85387219~85390186:-
COAD	cis	rs494562	0.892	rs1744121	ENSG00000234155.1	RP11-30P6.6	-3.69	0.000276	0.0493	-0.4	-0.22	Metabolic traits;Blood metabolite levels;	chr6:85405471	chr6:85387219~85390186:-
COAD	cis	rs494562	1	rs1744122	ENSG00000234155.1	RP11-30P6.6	-3.69	0.000276	0.0493	-0.4	-0.22	Metabolic traits;Blood metabolite levels;	chr6:85405500	chr6:85387219~85390186:-
COAD	cis	rs494562	0.542	rs554113	ENSG00000234155.1	RP11-30P6.6	-3.69	0.000276	0.0493	-0.4	-0.22	Metabolic traits;Blood metabolite levels;	chr6:85405526	chr6:85387219~85390186:-
COAD	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	3.69	0.000276	0.0493	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	3.69	0.000276	0.0493	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
COAD	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	3.69	0.000276	0.0493	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
COAD	cis	rs9311474	0.507	rs6787154	ENSG00000212452.1	SNORD69	-3.69	0.000276	0.0493	-0.21	-0.22	Electroencephalogram traits;	chr3:52750400	chr3:52692736~52692812:+
COAD	cis	rs3126085	0.935	rs3126072	ENSG00000237975.5	FLG-AS1	3.69	0.000276	0.0493	0.25	0.22	Atopic dermatitis;	chr1:152307253	chr1:152168125~152445456:+
COAD	cis	rs2337406	0.587	rs10150642	ENSG00000211964.3	IGHV3-48	3.69	0.000276	0.0493	0.17	0.22	Alzheimer's disease (late onset);	chr14:106647269	chr14:106537810~106538344:-
COAD	cis	rs8091660	0.624	rs6507852	ENSG00000278983.1	RP11-426J5.3	-3.69	0.000276	0.0493	-0.25	-0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48548678	chr18:48564795~48568342:+
COAD	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	3.69	0.000277	0.0494	0.26	0.22	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
COAD	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	3.69	0.000277	0.0494	0.45	0.22	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
COAD	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-3.69	0.000277	0.0494	-0.25	-0.22	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
COAD	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	3.69	0.000277	0.0494	0.31	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	3.69	0.000277	0.0494	0.31	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	3.69	0.000277	0.0494	0.31	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
COAD	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	3.69	0.000277	0.0494	0.31	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
COAD	cis	rs6840360	0.904	rs6825241	ENSG00000251611.1	RP11-610P16.1	-3.69	0.000277	0.0494	-0.21	-0.22	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151407551~151408835:-
COAD	cis	rs1941023	0.648	rs11604104	ENSG00000255355.1	AP000640.2	-3.69	0.000277	0.0494	-0.28	-0.22	Congenital heart disease (maternal effect);	chr11:60489828	chr11:59669312~59676041:+
COAD	cis	rs1941023	0.648	rs4939370	ENSG00000255355.1	AP000640.2	-3.69	0.000277	0.0494	-0.28	-0.22	Congenital heart disease (maternal effect);	chr11:60489927	chr11:59669312~59676041:+
COAD	cis	rs7555006	0.809	rs13376700	ENSG00000227742.1	CALR4P	3.69	0.000277	0.0494	0.24	0.22	Headache;	chr1:51011971	chr1:51561866~51594897:-
COAD	cis	rs9796	0.689	rs9888710	ENSG00000247556.5	OIP5-AS1	3.69	0.000277	0.0494	0.22	0.22	Menopause (age at onset);	chr15:41153955	chr15:41283990~41309737:+
COAD	cis	rs9796	0.653	rs28516683	ENSG00000247556.5	OIP5-AS1	3.69	0.000277	0.0494	0.22	0.22	Menopause (age at onset);	chr15:41154447	chr15:41283990~41309737:+
COAD	cis	rs9796	0.689	rs28409432	ENSG00000247556.5	OIP5-AS1	3.69	0.000277	0.0494	0.22	0.22	Menopause (age at onset);	chr15:41155256	chr15:41283990~41309737:+
COAD	cis	rs9393777	0.72	rs13217285	ENSG00000224843.5	LINC00240	3.69	0.000277	0.0494	0.5	0.22	Intelligence (multi-trait analysis);	chr6:27032066	chr6:26956992~27023924:+
COAD	cis	rs773506	1	rs773506	ENSG00000228069.1	RP11-100G15.3	-3.69	0.000277	0.0494	-0.25	-0.22	Type 2 diabetes nephropathy;	chr9:91213189	chr9:92109013~92110095:+
COAD	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000277	0.0494	-0.26	-0.22	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
COAD	cis	rs11846409	0.932	rs73378158	ENSG00000274576.2	IGHV2-70	-3.69	0.000277	0.0494	-0.21	-0.22	Rheumatic heart disease;	chr14:106638433	chr14:106770577~106771020:-
COAD	cis	rs3126085	0.935	rs3126062	ENSG00000237975.5	FLG-AS1	3.69	0.000277	0.0494	0.24	0.22	Atopic dermatitis;	chr1:152299876	chr1:152168125~152445456:+
COAD	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	3.69	0.000277	0.0494	0.29	0.22	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
COAD	cis	rs3803170	0.513	rs4572196	ENSG00000257595.2	RP3-473L9.4	3.69	0.000277	0.0494	0.31	0.22	Mean corpuscular hemoglobin;	chr12:111394189	chr12:111369282~111403310:+
COAD	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-3.69	0.000277	0.0494	-0.29	-0.22	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
COAD	cis	rs6762	0.748	rs7929032	ENSG00000279672.1	CMB9-55F22.1	3.69	0.000277	0.0494	0.22	0.22	Mean platelet volume;	chr11:839078	chr11:779617~780755:+
COAD	cis	rs6762	0.748	rs7936838	ENSG00000279672.1	CMB9-55F22.1	3.69	0.000277	0.0494	0.22	0.22	Mean platelet volume;	chr11:839093	chr11:779617~780755:+
COAD	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-3.69	0.000277	0.0494	-0.45	-0.22	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
COAD	cis	rs9992966	0.85	rs28481938	ENSG00000250829.2	RP11-11N5.1	-3.69	0.000277	0.0494	-0.35	-0.22	Trans fatty acid levels;	chr4:187700283	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs13112997	ENSG00000250829.2	RP11-11N5.1	-3.69	0.000277	0.0494	-0.35	-0.22	Trans fatty acid levels;	chr4:187700533	chr4:186890969~186892366:+
COAD	cis	rs9992966	0.85	rs7691555	ENSG00000250829.2	RP11-11N5.1	-3.69	0.000277	0.0494	-0.35	-0.22	Trans fatty acid levels;	chr4:187700779	chr4:186890969~186892366:+
COAD	cis	rs73173548	0.502	rs10452479	ENSG00000247828.6	TMEM161B-AS1	3.69	0.000277	0.0495	0.24	0.22	Macular telangiectasia type 2;	chr5:88445131	chr5:88268895~88436685:+
COAD	cis	rs61270009	0.738	rs73171756	ENSG00000247828.6	TMEM161B-AS1	3.69	0.000277	0.0495	0.24	0.22	Depressive symptoms;	chr5:88446454	chr5:88268895~88436685:+
COAD	cis	rs9393813	0.506	rs4713105	ENSG00000271755.1	RP1-153G14.4	3.69	0.000277	0.0495	0.26	0.22	Bipolar disorder;	chr6:27467141	chr6:27404010~27406964:-
COAD	cis	rs1930961	0.702	rs10483120	ENSG00000272942.1	CTA-246H3.12	3.69	0.000277	0.0495	0.52	0.22	Bipolar disorder with mood-incongruent psychosis;	chr22:25482396	chr22:25434324~25435070:-
COAD	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	3.69	0.000277	0.0495	0.3	0.22	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
COAD	cis	rs1713985	0.698	rs1277281	ENSG00000269949.1	RP11-738E22.3	-3.69	0.000278	0.0495	-0.45	-0.22	Age-related macular degeneration;	chr4:56989926	chr4:56960927~56961373:-
COAD	cis	rs561341	1	rs117029332	ENSG00000265798.5	RP11-271K11.5	3.69	0.000278	0.0495	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31939066	chr17:31038575~31059121:-
COAD	cis	rs561341	1	rs72821971	ENSG00000265798.5	RP11-271K11.5	3.69	0.000278	0.0495	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31942324	chr17:31038575~31059121:-
COAD	cis	rs561341	0.882	rs2428337	ENSG00000265798.5	RP11-271K11.5	3.69	0.000278	0.0495	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31972448	chr17:31038575~31059121:-
COAD	cis	rs13217239	0.511	rs3800314	ENSG00000224843.5	LINC00240	3.69	0.000278	0.0495	0.26	0.22	Schizophrenia;	chr6:27268269	chr6:26956992~27023924:+
COAD	cis	rs3018712	0.59	rs4930236	ENSG00000184795.9	UNC93B5	-3.69	0.000278	0.0495	-0.36	-0.22	Total body bone mineral density;	chr11:68646532	chr11:67711702~67716005:-
COAD	cis	rs4813003	0.673	rs2143698	ENSG00000271984.1	RP3-337O18.9	-3.69	0.000278	0.0495	-0.39	-0.22	Kawasaki disease;	chr20:46130522	chr20:45892694~45893419:-
COAD	cis	rs4813003	0.673	rs2143699	ENSG00000271984.1	RP3-337O18.9	-3.69	0.000278	0.0495	-0.39	-0.22	Kawasaki disease;	chr20:46130527	chr20:45892694~45893419:-
COAD	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-3.69	0.000278	0.0495	-0.2	-0.22	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
COAD	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	3.69	0.000278	0.0495	0.24	0.22	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
COAD	cis	rs7759001	0.857	rs1022515	ENSG00000271755.1	RP1-153G14.4	3.69	0.000278	0.0495	0.28	0.22	Glomerular filtration rate (creatinine);	chr6:27398028	chr6:27404010~27406964:-
COAD	cis	rs1949733	0.656	rs2688243	ENSG00000205959.3	RP11-689P11.2	-3.69	0.000278	0.0495	-0.27	-0.22	Response to antineoplastic agents;	chr4:8434559	chr4:8482270~8512610:+
COAD	cis	rs7955901	0.638	rs10879261	ENSG00000258053.1	CTD-2021H9.3	3.69	0.000278	0.0495	0.28	0.22	Type 2 diabetes;	chr12:71126981	chr12:71047402~71118247:-
COAD	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000278	0.0495	-0.14	-0.22	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
COAD	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-3.69	0.000278	0.0495	-0.14	-0.22	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
COAD	cis	rs3768617	0.51	rs10911242	ENSG00000224468.3	RP11-181K3.4	-3.69	0.000278	0.0495	-0.23	-0.22	Fuchs's corneal dystrophy;	chr1:183103012	chr1:183138402~183141282:-
COAD	cis	rs7129556	0.69	rs648601	ENSG00000254691.1	RP11-91P24.5	3.69	0.000278	0.0496	0.26	0.22	Weight loss (gastric bypass surgery);	chr11:77875864	chr11:77850604~77851511:+
COAD	cis	rs2836974	0.568	rs414850	ENSG00000255568.3	BRWD1-AS2	3.69	0.000278	0.0496	0.21	0.22	Cognitive function;	chr21:39171411	chr21:39313935~39314962:+
COAD	cis	rs726288	1	rs10887226	ENSG00000230091.5	TMEM254-AS1	3.69	0.000278	0.0496	0.65	0.22	Rheumatoid arthritis;	chr10:79953318	chr10:80046860~80078912:-
COAD	cis	rs726288	1	rs117173094	ENSG00000230091.5	TMEM254-AS1	3.69	0.000278	0.0496	0.65	0.22	Rheumatoid arthritis;	chr10:79954435	chr10:80046860~80078912:-
COAD	cis	rs726288	1	rs79947284	ENSG00000230091.5	TMEM254-AS1	3.69	0.000278	0.0496	0.65	0.22	Rheumatoid arthritis;	chr10:79954823	chr10:80046860~80078912:-
COAD	cis	rs726288	1	rs2181203	ENSG00000230091.5	TMEM254-AS1	3.69	0.000278	0.0496	0.65	0.22	Rheumatoid arthritis;	chr10:79956349	chr10:80046860~80078912:-
COAD	cis	rs11157436	0.602	rs928955	ENSG00000211812.1	TRAV26-2	-3.69	0.000278	0.0496	-0.22	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22202583~22203368:+
COAD	cis	rs3126085	0.735	rs35061954	ENSG00000237975.5	FLG-AS1	-3.69	0.000278	0.0496	-0.25	-0.22	Atopic dermatitis;	chr1:152268107	chr1:152168125~152445456:+
COAD	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000278	0.0496	-0.25	-0.22	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
COAD	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000278	0.0496	0.3	0.22	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
COAD	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-3.69	0.000279	0.0496	-0.26	-0.22	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
COAD	cis	rs68170813	0.641	rs77487103	ENSG00000241764.3	AC002467.7	3.69	0.000279	0.0496	0.34	0.22	Coronary artery disease;	chr7:107438348	chr7:107742817~107744581:-
COAD	cis	rs913655	0.785	rs10764728	ENSG00000240291.1	RP11-499P20.2	3.69	0.000279	0.0496	0.28	0.22	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);	chr10:18733581	chr10:18513115~18545651:-
COAD	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	3.69	0.000279	0.0496	0.19	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
COAD	cis	rs2439831	0.85	rs16977798	ENSG00000166763.7	STRCP1	-3.69	0.000279	0.0496	-0.34	-0.22	Lung cancer in ever smokers;	chr15:43859750	chr15:43699488~43718184:-
COAD	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	3.69	0.000279	0.0496	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	3.69	0.000279	0.0496	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	3.69	0.000279	0.0496	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
COAD	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	3.69	0.000279	0.0496	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
COAD	cis	rs2069426	0.778	rs1333035	ENSG00000240498.5	CDKN2B-AS1	3.69	0.000279	0.0497	0.49	0.22	Acute lymphoblastic leukemia (childhood);	chr9:22044060	chr9:21994778~22121097:+
COAD	cis	rs742132	0.893	rs1980450	ENSG00000220875.1	HIST1H3PS1	3.69	0.000279	0.0497	0.29	0.22	Uric acid levels;	chr6:25629519	chr6:26321876~26322292:-
COAD	cis	rs57786342	0.762	rs971290	ENSG00000240210.3	RP11-204K16.1	-3.69	0.000279	0.0497	-0.28	-0.22	Macrophage inflammatory protein 1a levels;	chr14:68805252	chr14:68338728~68339528:-
COAD	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-3.69	0.000279	0.0497	-0.36	-0.22	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
COAD	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	3.69	0.000279	0.0497	0.29	0.22	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
COAD	cis	rs7069733	0.877	rs7904046	ENSG00000273108.1	RP11-416N2.4	-3.69	0.000279	0.0497	-0.28	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr10:103540149	chr10:103608619~103610050:+
COAD	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	3.69	0.000279	0.0497	0.48	0.22	Depression;	chr6:28333418	chr6:28943877~28944537:+
COAD	cis	rs911555	0.755	rs4143998	ENSG00000251533.2	LINC00605	-3.69	0.000279	0.0497	-0.28	-0.22	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103187221~103189028:-
COAD	cis	rs911555	0.755	rs1138400	ENSG00000251533.2	LINC00605	-3.69	0.000279	0.0497	-0.28	-0.22	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103187221~103189028:-
COAD	cis	rs7598759	0.712	rs6735961	ENSG00000181798.2	LINC00471	-3.68	0.000279	0.0497	-0.26	-0.22	Noise-induced hearing loss;	chr2:231469703	chr2:231508426~231514339:-
COAD	cis	rs364477	0.5	rs2370161	ENSG00000235330.2	RP11-165F24.2	-3.68	0.000279	0.0497	-0.28	-0.22	Major depressive disorder;	chr9:926639	chr9:477750~478423:+
COAD	cis	rs364477	0.524	rs2370164	ENSG00000235330.2	RP11-165F24.2	-3.68	0.000279	0.0497	-0.28	-0.22	Major depressive disorder;	chr9:926762	chr9:477750~478423:+
COAD	cis	rs853679	0.527	rs9461443	ENSG00000226314.6	ZNF192P1	-3.68	0.000279	0.0497	-0.33	-0.22	Depression;	chr6:28226851	chr6:28161781~28169594:+
COAD	cis	rs8058578	1	rs13338946	ENSG00000260487.1	RP11-297C4.3	3.68	0.000279	0.0497	0.28	0.22	Multiple myeloma;	chr16:30689537	chr16:30480588~30481346:-
COAD	cis	rs2257011	1	rs1896797	ENSG00000230373.7	GOLGA6L5P	3.68	0.000279	0.0497	0.25	0.22	Height;	chr15:83605839	chr15:84507885~84516814:-
COAD	cis	rs2239633	0.678	rs12887958	ENSG00000279656.1	RP11-298I3.6	3.68	0.000279	0.0497	0.28	0.22	Eosinophil percentage of white cells;Acute lymphoblastic leukemia (childhood);Acute lymphoblastic leukemia (B-cell precursor);Eosinophil percentage of granulocytes;Eosinophil counts;	chr14:23113360	chr14:23023083~23024217:-
COAD	cis	rs10129255	0.536	rs10142951	ENSG00000211967.3	IGHV3-53	-3.68	0.000279	0.0497	-0.13	-0.22	Kawasaki disease;	chr14:106782337	chr14:106592676~106593347:-
COAD	cis	rs17789174	0.903	rs1392526	ENSG00000261471.1	RP11-61F12.1	-3.68	0.000279	0.0497	-0.28	-0.22	Dysphagia;	chr16:85042138	chr16:84594393~84596826:+
COAD	cis	rs17789174	0.903	rs1392525	ENSG00000261471.1	RP11-61F12.1	-3.68	0.000279	0.0497	-0.28	-0.22	Dysphagia;	chr16:85042168	chr16:84594393~84596826:+
COAD	cis	rs2392362	0.77	rs7805453	ENSG00000270889.1	RP11-609L3.1	3.68	0.000279	0.0497	0.22	0.22	Information processing speed;	chr7:35354814	chr7:35971147~35971567:-
COAD	cis	rs2392362	0.77	rs1425134	ENSG00000270889.1	RP11-609L3.1	3.68	0.000279	0.0497	0.22	0.22	Information processing speed;	chr7:35355303	chr7:35971147~35971567:-
COAD	cis	rs2392362	0.77	rs1425135	ENSG00000270889.1	RP11-609L3.1	3.68	0.000279	0.0497	0.22	0.22	Information processing speed;	chr7:35355396	chr7:35971147~35971567:-
COAD	cis	rs2392362	0.743	rs13230269	ENSG00000270889.1	RP11-609L3.1	3.68	0.000279	0.0497	0.22	0.22	Information processing speed;	chr7:35357329	chr7:35971147~35971567:-
COAD	cis	rs801193	0.66	rs974239	ENSG00000236529.1	RP13-254B10.1	3.68	0.000279	0.0498	0.25	0.22	Aortic root size;	chr7:66748504	chr7:65840212~65840596:+
COAD	cis	rs801193	0.66	rs1016265	ENSG00000236529.1	RP13-254B10.1	3.68	0.000279	0.0498	0.25	0.22	Aortic root size;	chr7:66749580	chr7:65840212~65840596:+
COAD	cis	rs2243480	1	rs4718334	ENSG00000232559.3	GS1-124K5.12	-3.68	0.00028	0.0498	-0.39	-0.22	Diabetic kidney disease;	chr7:66324467	chr7:66554588~66576923:-
COAD	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-3.68	0.00028	0.0498	-0.27	-0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
COAD	cis	rs7560272	0.529	rs2421672	ENSG00000273245.1	RP11-434P11.2	-3.68	0.00028	0.0498	-0.27	-0.22	Schizophrenia;	chr2:73728413	chr2:73750256~73750786:-
COAD	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	3.68	0.00028	0.0498	0.27	0.22	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
COAD	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	3.68	0.00028	0.0498	0.31	0.22	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
COAD	cis	rs10760158	0.832	rs10760166	ENSG00000226752.6	PSMD5-AS1	-3.68	0.00028	0.0498	-0.24	-0.22	Pulse pressure;	chr9:121264336	chr9:120824828~120854385:+
COAD	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	3.68	0.00028	0.0498	0.25	0.22	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
COAD	cis	rs11846409	0.629	rs76295389	ENSG00000211974.3	IGHV2-70	3.68	0.00028	0.0498	0.25	0.22	Rheumatic heart disease;	chr14:106650437	chr14:106723574~106724093:-
COAD	cis	rs11846409	0.698	rs71419854	ENSG00000211974.3	IGHV2-70	3.68	0.00028	0.0498	0.25	0.22	Rheumatic heart disease;	chr14:106650440	chr14:106723574~106724093:-
COAD	cis	rs2337406	0.5	rs71419855	ENSG00000211974.3	IGHV2-70	3.68	0.00028	0.0498	0.25	0.22	Alzheimer's disease (late onset);	chr14:106650444	chr14:106723574~106724093:-
COAD	cis	rs670292	1	rs805992	ENSG00000216906.2	RP11-350J20.9	3.68	0.00028	0.0498	0.29	0.22	Anger;	chr6:150388016	chr6:149904243~149906418:+
COAD	cis	rs4774899	0.55	rs7164742	ENSG00000260689.2	HNRNPA3P11	-3.68	0.00028	0.0498	-0.29	-0.22	Urinary tract infection frequency;	chr15:56917420	chr15:57246960~57247893:-
COAD	cis	rs113835537	0.529	rs11227500	ENSG00000258297.1	RP11-658F2.8	-3.68	0.00028	0.0498	-0.22	-0.22	Airway imaging phenotypes;	chr11:66505762	chr11:66666036~66668374:+
COAD	cis	rs670292	1	rs655745	ENSG00000216906.2	RP11-350J20.9	3.68	0.00028	0.0499	0.29	0.22	Anger;	chr6:150390090	chr6:149904243~149906418:+
COAD	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-3.68	0.00028	0.0499	-0.31	-0.22	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
COAD	cis	rs7903146	0.651	rs55972445	ENSG00000227560.1	RP11-139K1.2	-3.68	0.00028	0.0499	-0.28	-0.22	Hip circumference;Clinical laboratory measurements;BMI in non-smokers;Fasting blood insulin (BMI interaction);BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Fasting blood glucose (BMI interaction);Glycated hemoglobin levels;Type 2 diabetes;Waist circumference;Proinsulin levels;Body mass index (joint analysis main effects and smoking interaction);Metabolic syndrome;Peak insulin response;Fasting blood glucose;Body mass index;Fasting blood insulin;Type 2 diabetes and other traits;	chr10:113023031	chr10:112987476~112987865:+
COAD	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	3.68	0.00028	0.0499	0.2	0.22	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
COAD	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	3.68	0.00028	0.0499	0.31	0.22	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
COAD	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	3.68	0.00028	0.0499	0.31	0.22	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
COAD	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-3.68	0.00028	0.0499	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
COAD	cis	rs34779708	0.931	rs7079205	ENSG00000271335.4	RP11-324I22.4	3.68	0.00028	0.0499	0.25	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35314552~35336401:-
COAD	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-3.68	0.00028	0.0499	-0.3	-0.22	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
COAD	cis	rs35306767	0.903	rs1341741	ENSG00000229869.1	RP11-363N22.2	-3.68	0.000281	0.0499	-0.34	-0.22	Eosinophil percentage of granulocytes;	chr10:842133	chr10:933026~942743:+
COAD	cis	rs255758	0.727	rs255748	ENSG00000240052.1	RP11-289K10.1	-3.68	0.000281	0.0499	-0.23	-0.22	Rheumatoid arthritis;	chr5:54022546	chr5:53413504~53414260:+
COAD	cis	rs8017304	0.643	rs927220	ENSG00000259502.1	RP11-643G16.3	-3.68	0.000281	0.0499	-0.29	-0.22	Age-related macular degeneration;	chr14:68301255	chr14:67610986~67613864:+
COAD	cis	rs12428035	1	rs12429254	ENSG00000247400.3	DNAJC3-AS1	-3.68	0.000281	0.0499	-0.3	-0.22	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95647409	chr13:95648733~95676925:-
COAD	cis	rs3934047	0.967	rs35770019	ENSG00000278029.1	CTD-2240J17.2	-3.68	0.000281	0.0499	-0.26	-0.22	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81685237	chr15:81392759~81393384:+
COAD	cis	rs2708377	0.79	rs73051387	ENSG00000212125.2	TAS2R15P	3.68	0.000281	0.0499	0.42	0.22	Bitter taste perception;	chr12:11161864	chr12:10964425~10965352:-
COAD	cis	rs2243480	1	rs35735127	ENSG00000228409.4	CCT6P1	3.68	0.000281	0.0499	0.28	0.22	Diabetic kidney disease;	chr7:65835436	chr7:65751142~65763354:+
COAD	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000281	0.05	-0.22	-0.22	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
COAD	cis	rs739496	0.843	rs630512	ENSG00000257595.2	RP3-473L9.4	3.68	0.000281	0.05	0.31	0.22	Platelet count;	chr12:111514363	chr12:111369282~111403310:+
COAD	cis	rs4819052	1	rs28628220	ENSG00000227039.5	ITGB2-AS1	-3.68	0.000281	0.05	-0.22	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:44921051~44929678:+
COAD	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-3.68	0.000281	0.05	-0.33	-0.22	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
COAD	cis	rs4761470	0.637	rs11107531	ENSG00000258365.1	RP11-1105G2.3	-3.68	0.000281	0.05	-0.27	-0.22	Estradiol plasma levels (breast cancer);	chr12:94407545	chr12:94277758~94282844:-
COAD	cis	rs7662358	0.562	rs35918387	ENSG00000180015.12	RP11-756P10.3	-3.68	0.000281	0.05	-0.38	-0.22	Cognitive performance;	chr4:188698724	chr4:188738373~188739494:+
COAD	cis	rs11846409	0.799	rs2583330	ENSG00000254174.1	IGHV1-12	-3.68	0.000281	0.05	-0.21	-0.22	Rheumatic heart disease;	chr14:106621051	chr14:106122420~106122709:-
COAD	cis	rs12428035	0.764	rs11619636	ENSG00000247400.3	DNAJC3-AS1	-3.68	0.000281	0.05	-0.28	-0.22	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96069969	chr13:95648733~95676925:-
COAD	cis	rs1223397	0.938	rs35549743	ENSG00000215022.6	RP1-257A7.4	-3.68	0.000281	0.05	-0.31	-0.22	Blood pressure;	chr6:13294122	chr6:13264861~13295586:-
COAD	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-3.68	0.000281	0.05	-0.23	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
COAD	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	28.05	3.44e-80	1.3e-70	1.21	0.87	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	28.04	3.65e-80	1.3e-70	1.2	0.87	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	27.9	9.57e-80	2.81e-70	1.2	0.87	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	27.9	9.57e-80	2.81e-70	1.2	0.87	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	27.29	6.76e-78	1.61e-68	1.08	0.86	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	27.29	6.77e-78	1.61e-68	1.19	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	27.29	6.77e-78	1.61e-68	1.19	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	27.29	6.77e-78	1.61e-68	1.19	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	26.92	9.28e-77	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	26.92	9.28e-77	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	26.88	1.24e-76	1.47e-67	1.08	0.86	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	26.68	4.99e-76	4.28e-67	1.07	0.86	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	26.67	5.55e-76	4.53e-67	1.07	0.86	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	26.67	5.55e-76	4.53e-67	1.07	0.86	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	26.64	6.88e-76	5.53e-67	1.19	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	26.57	1.13e-75	8.8e-67	1.18	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-26.51	1.72e-75	1.28e-66	-1.06	-0.86	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	26.42	3.25e-75	2.22e-66	1.06	0.85	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	26.42	3.25e-75	2.22e-66	1.06	0.85	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	26.37	4.78e-75	2.7e-66	1.07	0.85	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	26.37	4.78e-75	2.7e-66	1.07	0.85	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	26.37	4.78e-75	2.7e-66	1.07	0.85	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	26.37	4.78e-75	2.7e-66	1.07	0.85	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	26.21	1.48e-74	6.85e-66	1.06	0.85	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	26.2	1.52e-74	6.96e-66	1.07	0.85	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	26.15	2.22e-74	9.04e-66	1.06	0.85	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	26.1	3.2e-74	1.15e-65	1.08	0.85	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	25.92	1.18e-73	3.88e-65	1.06	0.85	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	25.85	1.96e-73	6.29e-65	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	25.82	2.43e-73	7.75e-65	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	25.81	2.58e-73	8.2e-65	1.2	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	25.65	7.88e-73	2.47e-64	1.07	0.85	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	25.65	7.88e-73	2.47e-64	1.07	0.85	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	25.61	1.07e-72	3.24e-64	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	25.61	1.07e-72	3.24e-64	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	25.61	1.07e-72	3.24e-64	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	25.61	1.07e-72	3.24e-64	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	25.61	1.07e-72	3.24e-64	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	25.51	2.2e-72	6.61e-64	1.08	0.85	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	25.48	2.82e-72	8.17e-64	1.08	0.85	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	25.48	2.82e-72	8.17e-64	1.08	0.85	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	25.48	2.82e-72	8.17e-64	1.08	0.85	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	25.48	2.82e-72	8.17e-64	1.08	0.85	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	25.43	3.97e-72	1.14e-63	1.06	0.85	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	25.17	2.55e-71	7.1e-63	1.08	0.84	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	24.97	1.12e-70	3.08e-62	1.06	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
COAD	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	24.96	1.2e-70	3.27e-62	1.03	0.84	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	24.62	1.48e-69	3.93e-61	1.06	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	24.62	1.48e-69	3.93e-61	1.06	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	24.54	2.71e-69	7e-61	1.07	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	24.54	2.71e-69	7e-61	1.07	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	24.54	2.71e-69	7e-61	1.07	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	24.3	1.5e-68	3.68e-60	1.07	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	24.3	1.5e-68	3.68e-60	1.07	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	24.3	1.5e-68	3.68e-60	1.07	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	24.3	1.5e-68	3.68e-60	1.07	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	24.3	1.5e-68	3.68e-60	1.07	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
COAD	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	24.06	8.86e-68	2.1e-59	1.04	0.83	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	24.06	8.86e-68	2.1e-59	1.04	0.83	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	24.06	8.86e-68	2.1e-59	1.04	0.83	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	24.06	9.18e-68	2.17e-59	1.03	0.83	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	24.03	1.16e-67	2.71e-59	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	24.01	1.27e-67	2.88e-59	1.04	0.83	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	24.01	1.27e-67	2.88e-59	1.04	0.83	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	24.01	1.27e-67	2.88e-59	1.04	0.83	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	24.01	1.27e-67	2.88e-59	1.04	0.83	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	24.01	1.27e-67	2.88e-59	1.04	0.83	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	23.98	1.66e-67	3.72e-59	1.06	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	23.98	1.66e-67	3.72e-59	1.06	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
COAD	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	23.94	2.19e-67	4.83e-59	1.19	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	23.88	3.53e-67	7.75e-59	1.03	0.83	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	23.77	7.52e-67	1.64e-58	1.04	0.83	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	23.57	3.55e-66	7.46e-58	1.04	0.83	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	23.54	4.25e-66	8.9e-58	1.03	0.83	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	23.43	9.59e-66	1.94e-57	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	23.43	9.59e-66	1.94e-57	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	23.42	1.05e-65	2.11e-57	1.01	0.83	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	23.42	1.05e-65	2.11e-57	1.01	0.83	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	23.25	3.93e-65	7.42e-57	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	23.25	3.93e-65	7.42e-57	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	23.25	3.93e-65	7.42e-57	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	23.24	4.04e-65	7.56e-57	1	0.82	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	23.24	4.04e-65	7.56e-57	1	0.82	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	23.18	6.22e-65	1.14e-56	1.03	0.82	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	23.04	1.83e-64	2.95e-56	1.03	0.82	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-23.04	1.89e-64	3.04e-56	-1.05	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
COAD	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	23.02	2.09e-64	3.34e-56	1	0.82	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	22.97	3.05e-64	4.73e-56	0.99	0.82	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	22.97	3.05e-64	4.73e-56	0.99	0.82	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	22.97	3.05e-64	4.73e-56	0.99	0.82	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	22.96	3.5e-64	5.39e-56	0.99	0.82	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	22.93	4.33e-64	6.54e-56	0.99	0.82	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	22.93	4.33e-64	6.54e-56	0.99	0.82	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	22.93	4.33e-64	6.54e-56	0.99	0.82	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	22.9	5.31e-64	7.82e-56	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	22.9	5.31e-64	7.82e-56	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	22.9	5.31e-64	7.82e-56	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	22.9	5.31e-64	7.82e-56	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	22.9	5.31e-64	7.82e-56	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	22.89	5.61e-64	8.22e-56	1.02	0.82	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	22.88	6.14e-64	8.97e-56	1.01	0.82	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	22.79	1.26e-63	1.81e-55	0.97	0.82	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	22.73	1.94e-63	2.76e-55	0.99	0.82	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	22.72	2.03e-63	2.89e-55	1.03	0.82	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	22.71	2.2e-63	3.1e-55	1.04	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	22.71	2.2e-63	3.1e-55	1.04	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
COAD	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	22.65	3.63e-63	5.05e-55	1.13	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	22.63	4.23e-63	5.8e-55	1.03	0.82	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	22.57	6.58e-63	9e-55	1.02	0.82	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	22.46	1.43e-62	1.94e-54	1.09	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	22.46	1.43e-62	1.94e-54	1.09	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
COAD	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	22.03	3.85e-61	4.94e-53	1.11	0.81	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
COAD	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	22.03	4.07e-61	5.19e-53	0.99	0.81	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
COAD	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	22.01	4.44e-61	5.65e-53	1.1	0.81	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-22.01	4.63e-61	5.88e-53	-1.08	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	21.99	5.16e-61	6.46e-53	0.97	0.81	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	21.99	5.16e-61	6.46e-53	0.97	0.81	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	21.99	5.16e-61	6.46e-53	0.97	0.81	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	21.99	5.16e-61	6.46e-53	0.97	0.81	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	21.92	9.04e-61	1.11e-52	1.12	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
COAD	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	21.92	9.07e-61	1.11e-52	0.98	0.81	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	21.92	9.07e-61	1.11e-52	0.98	0.81	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
COAD	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	21.89	1.14e-60	1.4e-52	1.12	0.81	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
COAD	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	21.79	2.48e-60	2.99e-52	1.11	0.81	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
COAD	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	21.7	5.01e-60	5.99e-52	1.09	0.8	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	21.7	5.07e-60	6.02e-52	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	21.7	5.07e-60	6.02e-52	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	21.7	5.07e-60	6.02e-52	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
COAD	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	21.68	5.57e-60	6.59e-52	1.03	0.8	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
COAD	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	21.68	5.71e-60	6.72e-52	1.11	0.8	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
COAD	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	21.68	5.71e-60	6.72e-52	1.11	0.8	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	21.66	6.76e-60	7.94e-52	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
COAD	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	21.6	1.03e-59	1.2e-51	1.09	0.8	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	21.56	1.49e-59	1.71e-51	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	21.56	1.49e-59	1.71e-51	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
COAD	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	21.52	1.98e-59	2.24e-51	0.97	0.8	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	21.52	1.98e-59	2.24e-51	0.97	0.8	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	21.52	1.98e-59	2.24e-51	0.97	0.8	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	21.51	2.06e-59	2.32e-51	1.19	0.8	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	21.51	2.06e-59	2.32e-51	1.19	0.8	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	21.51	2.06e-59	2.32e-51	1.19	0.8	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
COAD	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	21.5	2.36e-59	2.65e-51	0.98	0.8	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	21.49	2.45e-59	2.71e-51	1.2	0.8	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
COAD	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	21.4	4.78e-59	5.25e-51	1.03	0.8	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	21.37	6.05e-59	6.51e-51	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	21.37	6.05e-59	6.51e-51	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	21.37	6.05e-59	6.51e-51	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	21.37	6.05e-59	6.51e-51	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	21.37	6.05e-59	6.51e-51	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
COAD	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	21.37	6.1e-59	6.55e-51	0.99	0.8	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	21.36	6.47e-59	6.91e-51	1.06	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	21.36	6.47e-59	6.91e-51	1.06	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	21.34	7.65e-59	8.13e-51	1.03	0.8	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	21.34	8.13e-59	8.62e-51	1.2	0.8	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
COAD	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-21.27	1.38e-58	1.45e-50	-0.96	-0.8	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
COAD	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	21.25	1.52e-58	1.59e-50	1.1	0.8	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
COAD	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	21.22	1.93e-58	2e-50	1.11	0.8	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	21.16	3.26e-58	3.34e-50	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	21.16	3.26e-58	3.34e-50	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
COAD	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	21.15	3.48e-58	3.56e-50	1.07	0.8	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
COAD	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	21.13	4.06e-58	4.12e-50	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	21.13	4.06e-58	4.12e-50	1.07	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
COAD	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-21.12	4.24e-58	4.3e-50	-1.02	-0.8	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	21.09	5.23e-58	5.28e-50	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
COAD	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	21.05	7.52e-58	7.53e-50	0.98	0.8	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	21.04	7.84e-58	7.81e-50	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	21.04	7.84e-58	7.81e-50	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
COAD	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-21.03	8.4e-58	8.34e-50	-0.99	-0.8	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	20.99	1.17e-57	1.14e-49	1.2	0.79	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
COAD	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	20.97	1.38e-57	1.33e-49	0.96	0.79	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	20.97	1.38e-57	1.33e-49	0.96	0.79	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	20.97	1.38e-57	1.33e-49	0.96	0.79	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
COAD	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	20.95	1.6e-57	1.54e-49	1.03	0.79	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	20.94	1.79e-57	1.71e-49	1.16	0.79	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
COAD	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	20.93	1.84e-57	1.76e-49	0.98	0.79	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
COAD	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	20.91	2.12e-57	2.02e-49	1.02	0.79	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	20.89	2.55e-57	2.41e-49	0.98	0.79	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	20.87	2.91e-57	2.74e-49	1.01	0.79	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
COAD	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	20.71	1.04e-56	9.29e-49	1.07	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
COAD	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	20.69	1.17e-56	1.05e-48	1.01	0.79	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
COAD	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	20.6	2.36e-56	2.08e-48	1.19	0.79	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
COAD	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	20.4	1.18e-55	1.01e-47	1.11	0.79	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
COAD	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	20.37	1.42e-55	1.2e-47	1.19	0.79	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
COAD	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	20.37	1.5e-55	1.26e-47	1.04	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
COAD	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	20.35	1.69e-55	1.42e-47	1.04	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
COAD	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	20.35	1.69e-55	1.42e-47	1.04	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
COAD	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	20.3	2.6e-55	2.16e-47	1.11	0.78	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
COAD	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	20.29	2.79e-55	2.31e-47	1.11	0.78	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
COAD	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	20.28	2.86e-55	2.36e-47	1.04	0.78	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
COAD	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	20.27	3.15e-55	2.6e-47	1.16	0.78	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
COAD	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	20.26	3.53e-55	2.91e-47	1.04	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
COAD	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	20.17	7.04e-55	5.67e-47	1.07	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
COAD	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	20.14	8.69e-55	6.96e-47	1.16	0.78	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
COAD	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-20.08	1.39e-54	1.06e-46	-1.01	-0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
COAD	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	20.04	1.92e-54	1.45e-46	1.18	0.78	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
COAD	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	20.02	2.22e-54	1.67e-46	1.06	0.78	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	19.96	3.65e-54	2.69e-46	1.05	0.78	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
COAD	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	19.92	5.05e-54	3.67e-46	1.01	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	19.92	5.05e-54	3.67e-46	1.01	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
COAD	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	19.85	8.27e-54	5.9e-46	1.05	0.78	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	19.85	8.27e-54	5.9e-46	1.05	0.78	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	19.85	8.27e-54	5.9e-46	1.05	0.78	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
COAD	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	19.85	8.5e-54	6.02e-46	1.16	0.78	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	19.78	1.48e-53	1.03e-45	1.14	0.78	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
COAD	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-19.74	2.03e-53	1.41e-45	-1.08	-0.78	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
COAD	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	19.67	3.58e-53	2.48e-45	1.15	0.78	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
COAD	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	19.61	5.51e-53	3.8e-45	1.08	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
COAD	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	19.61	5.51e-53	3.8e-45	1.08	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
COAD	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	19.58	6.96e-53	4.78e-45	1.07	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
COAD	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-19.53	1.09e-52	7.42e-45	-1.04	-0.77	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
COAD	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	19.44	2.14e-52	1.44e-44	0.99	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	19.44	2.14e-52	1.44e-44	0.99	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	19.43	2.36e-52	1.58e-44	1.07	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	19.42	2.55e-52	1.71e-44	1.01	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
COAD	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	19.41	2.74e-52	1.83e-44	1.08	0.77	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	19.32	5.39e-52	3.58e-44	1.05	0.77	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
COAD	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-19.31	5.94e-52	3.94e-44	-1.05	-0.77	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
COAD	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-19.31	5.94e-52	3.94e-44	-1.05	-0.77	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	19.3	6.66e-52	4.41e-44	1.05	0.77	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	19.29	7.17e-52	4.75e-44	1.05	0.77	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	19.28	7.93e-52	5.23e-44	1.04	0.77	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	19.28	7.93e-52	5.23e-44	1.04	0.77	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	19.19	1.54e-51	1.01e-43	1.04	0.77	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	19.19	1.54e-51	1.01e-43	1.04	0.77	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	19.19	1.54e-51	1.01e-43	1.04	0.77	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
COAD	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	19.17	1.78e-51	1.16e-43	1	0.77	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	19.12	2.73e-51	1.78e-43	1	0.77	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
COAD	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-19.11	2.92e-51	1.89e-43	-1.04	-0.77	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
COAD	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	19.11	3e-51	1.94e-43	1.2	0.77	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	19.09	3.52e-51	2.28e-43	1.13	0.77	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	19.04	5.3e-51	3.42e-43	1.2	0.76	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
COAD	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	18.98	8.04e-51	5.16e-43	1	0.76	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
COAD	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-18.89	1.65e-50	1.05e-42	-1.05	-0.76	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
COAD	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	18.89	1.73e-50	1.1e-42	0.84	0.76	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	18.82	2.99e-50	1.81e-42	0.82	0.76	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
COAD	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	18.69	8.19e-50	4.88e-42	0.91	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	18.65	1.13e-49	6.64e-42	0.95	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	18.65	1.14e-49	6.72e-42	0.91	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
COAD	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	18.63	1.27e-49	7.48e-42	0.83	0.76	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
COAD	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	18.55	2.54e-49	1.48e-41	1.06	0.76	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
COAD	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	18.47	4.84e-49	2.8e-41	1	0.76	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
COAD	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	18.46	5.28e-49	3.05e-41	0.95	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
COAD	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	18.41	7.33e-49	4.22e-41	1.04	0.75	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
COAD	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	18.4	8.53e-49	4.85e-41	1	0.75	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
COAD	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	18.39	8.59e-49	4.88e-41	1.01	0.75	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
COAD	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	18.38	9.49e-49	5.37e-41	1.2	0.75	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
COAD	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-18.37	1.04e-48	5.91e-41	-1.04	-0.75	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
COAD	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	18.35	1.22e-48	6.85e-41	1.15	0.75	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
COAD	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	18.35	1.23e-48	6.91e-41	1.09	0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
COAD	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	18.32	1.54e-48	8.6e-41	0.99	0.75	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
COAD	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	18.3	1.79e-48	9.89e-41	1.08	0.75	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	18.26	2.54e-48	1.38e-40	1.08	0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
COAD	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	18.23	3.16e-48	1.7e-40	1.08	0.75	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
COAD	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	18.22	3.43e-48	1.83e-40	0.99	0.75	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
COAD	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	18.2	4.08e-48	2.16e-40	1.01	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
COAD	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	18.2	4.08e-48	2.16e-40	1.01	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
COAD	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	18.19	4.41e-48	2.34e-40	1.02	0.75	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	18.19	4.46e-48	2.35e-40	1.01	0.75	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
COAD	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	18.19	4.57e-48	2.41e-40	1.07	0.75	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
COAD	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	18.16	5.57e-48	2.92e-40	1.01	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
COAD	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	18.12	7.68e-48	3.99e-40	0.82	0.75	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
COAD	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	18.09	9.96e-48	5.16e-40	1.01	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
COAD	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	18.08	1.04e-47	5.39e-40	0.81	0.75	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
COAD	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	18.01	1.91e-47	9.72e-40	1	0.75	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
COAD	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	18	1.98e-47	1e-39	1.14	0.75	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	18	1.98e-47	1e-39	1.14	0.75	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
COAD	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	17.9	4.41e-47	2.19e-39	1.01	0.74	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	17.88	5.23e-47	2.58e-39	1	0.74	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	17.88	5.23e-47	2.58e-39	1	0.74	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	17.88	5.23e-47	2.58e-39	1	0.74	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
COAD	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-17.76	1.32e-46	6.36e-39	-1.05	-0.74	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	17.73	1.7e-46	8.14e-39	0.99	0.74	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	17.73	1.7e-46	8.14e-39	0.99	0.74	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
COAD	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	17.73	1.7e-46	8.14e-39	0.99	0.74	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
COAD	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	17.72	1.81e-46	8.67e-39	0.89	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	17.72	1.81e-46	8.67e-39	0.89	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
COAD	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-17.72	1.82e-46	8.7e-39	-1.08	-0.74	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
COAD	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-17.71	1.96e-46	9.32e-39	-1.05	-0.74	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
COAD	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	17.69	2.36e-46	1.12e-38	0.8	0.74	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
COAD	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-17.69	2.46e-46	1.17e-38	-0.97	-0.74	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
COAD	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	17.67	2.86e-46	1.35e-38	0.89	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	17.66	3.04e-46	1.43e-38	0.93	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	17.66	3.04e-46	1.43e-38	0.93	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
COAD	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	17.61	4.36e-46	2.03e-38	0.78	0.74	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
COAD	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	17.6	4.89e-46	2.28e-38	0.93	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
COAD	trans	rs7949030	0.523	rs67308910	ENSG00000186676.3	EEF1GP1	17.44	1.82e-45	8.27e-38	1.09	0.74	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62609887	chr7:125033453~125035301:+
COAD	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	17.43	1.88e-45	8.53e-38	1.1	0.74	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
COAD	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-17.36	3.49e-45	1.57e-37	-0.97	-0.73	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
COAD	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	17.35	3.63e-45	1.63e-37	0.81	0.73	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
COAD	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	17.33	4.2e-45	1.88e-37	1.11	0.73	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
COAD	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	17.33	4.43e-45	1.98e-37	1.17	0.73	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
COAD	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	17.31	5e-45	2.23e-37	0.8	0.73	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
COAD	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	17.09	2.85e-44	1.23e-36	0.89	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
COAD	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	17.09	2.85e-44	1.23e-36	0.89	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
COAD	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	16.98	6.89e-44	2.95e-36	1.1	0.73	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
COAD	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	16.98	6.89e-44	2.95e-36	1.1	0.73	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
COAD	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-16.98	6.99e-44	2.99e-36	-1.12	-0.73	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-16.93	1.07e-43	4.59e-36	-0.95	-0.73	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
COAD	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-16.91	1.27e-43	5.42e-36	-1.04	-0.73	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	16.9	1.33e-43	5.68e-36	0.99	0.73	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-16.9	1.34e-43	5.7e-36	-1.11	-0.73	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
COAD	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	16.75	4.44e-43	1.86e-35	0.9	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
COAD	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-16.69	7.49e-43	3.08e-35	-0.94	-0.72	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
COAD	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	16.68	7.97e-43	3.27e-35	0.88	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
COAD	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	16.67	8.49e-43	3.48e-35	1.11	0.72	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
COAD	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	16.63	1.21e-42	4.91e-35	1.08	0.72	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
COAD	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	16.59	1.67e-42	6.77e-35	0.95	0.72	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
COAD	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	16.58	1.8e-42	7.31e-35	0.87	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
COAD	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	16.54	2.35e-42	9.44e-35	0.96	0.72	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	16.54	2.5e-42	1e-34	1.11	0.72	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	16.5	3.37e-42	1.35e-34	0.89	0.72	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
COAD	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	16.38	8.45e-42	3.25e-34	0.95	0.71	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	16.38	8.45e-42	3.25e-34	0.95	0.71	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	16.34	1.21e-41	4.65e-34	0.95	0.71	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	16.3	1.62e-41	6.18e-34	0.95	0.71	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
COAD	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	16.26	2.28e-41	8.65e-34	0.86	0.71	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	16.26	2.28e-41	8.65e-34	0.86	0.71	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
COAD	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	16.25	2.47e-41	9.35e-34	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	16.25	2.57e-41	9.7e-34	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-16.24	2.74e-41	1.03e-33	-1.12	-0.71	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	16.24	2.74e-41	1.03e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	16.24	2.74e-41	1.03e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	16.24	2.74e-41	1.03e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	16.24	2.74e-41	1.03e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	16.24	2.74e-41	1.03e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	16.18	4.44e-41	1.66e-33	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
COAD	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	16.18	4.49e-41	1.68e-33	0.86	0.71	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	16.11	7.61e-41	2.8e-33	0.92	0.71	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
COAD	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	16.09	8.91e-41	3.27e-33	0.96	0.71	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
COAD	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-16.09	9.12e-41	3.34e-33	-0.99	-0.71	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
COAD	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	16.08	9.96e-41	3.64e-33	0.95	0.71	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
COAD	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	16.05	1.2e-40	4.38e-33	1.2	0.71	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
COAD	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	16.01	1.75e-40	6.29e-33	0.85	0.71	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
COAD	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	16.01	1.8e-40	6.46e-33	0.86	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	16.01	1.8e-40	6.46e-33	0.86	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
COAD	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-15.98	2.2e-40	7.88e-33	-0.77	-0.71	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
COAD	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	15.97	2.4e-40	8.52e-33	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	15.96	2.51e-40	8.89e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
COAD	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	15.96	2.58e-40	9.12e-33	0.86	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
COAD	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	15.96	2.63e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	15.96	2.64e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	15.96	2.64e-40	9.25e-33	0.86	0.71	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	15.92	3.48e-40	1.22e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	15.92	3.52e-40	1.23e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	15.92	3.52e-40	1.23e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	15.92	3.7e-40	1.29e-32	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	15.91	3.77e-40	1.3e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	15.91	3.77e-40	1.3e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	15.91	3.96e-40	1.37e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	15.91	3.96e-40	1.37e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	15.91	3.96e-40	1.37e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	15.91	3.96e-40	1.37e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
COAD	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	15.89	4.54e-40	1.56e-32	0.94	0.7	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	15.81	8.87e-40	3.02e-32	0.94	0.7	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
COAD	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-15.79	1.03e-39	3.51e-32	-1.04	-0.7	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	15.76	1.28e-39	4.32e-32	0.9	0.7	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	15.76	1.28e-39	4.32e-32	0.9	0.7	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
COAD	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	15.76	1.34e-39	4.5e-32	0.85	0.7	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	15.76	1.34e-39	4.5e-32	0.85	0.7	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	15.75	1.44e-39	4.83e-32	0.85	0.7	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	15.75	1.44e-39	4.83e-32	0.85	0.7	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
COAD	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	15.74	1.53e-39	5.15e-32	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
COAD	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	15.72	1.73e-39	5.78e-32	0.85	0.7	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	15.7	2.08e-39	6.93e-32	0.93	0.7	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
COAD	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	15.7	2.12e-39	7.03e-32	0.82	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
COAD	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	15.7	2.12e-39	7.03e-32	0.82	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
COAD	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	15.7	2.15e-39	7.12e-32	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	15.67	2.61e-39	8.65e-32	1.08	0.7	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	15.66	2.83e-39	9.34e-32	0.86	0.7	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
COAD	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	15.66	2.84e-39	9.36e-32	0.84	0.7	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
COAD	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	15.64	3.4e-39	1.12e-31	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
COAD	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	15.6	4.66e-39	1.53e-31	0.84	0.7	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
COAD	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	15.6	4.71e-39	1.54e-31	1.07	0.7	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
COAD	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	15.6	4.8e-39	1.57e-31	1.21	0.7	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
COAD	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-15.59	4.89e-39	1.6e-31	-0.73	-0.7	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
COAD	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	15.55	6.74e-39	2.2e-31	1.09	0.7	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	15.55	6.79e-39	2.21e-31	1.08	0.7	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	15.55	6.79e-39	2.21e-31	1.08	0.7	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	15.55	6.79e-39	2.21e-31	1.08	0.7	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	15.54	7.5e-39	2.42e-31	1.07	0.7	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	15.54	7.84e-39	2.52e-31	0.9	0.7	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
COAD	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-15.53	8.4e-39	2.69e-31	-0.85	-0.7	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
COAD	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	15.48	1.24e-38	3.96e-31	0.84	0.69	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	15.48	1.27e-38	4.03e-31	0.84	0.69	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
COAD	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-15.42	1.97e-38	6.18e-31	-1.07	-0.69	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
COAD	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	15.42	2.01e-38	6.32e-31	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
COAD	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	15.42	2.05e-38	6.44e-31	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
COAD	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	15.39	2.45e-38	7.67e-31	0.85	0.69	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	15.37	2.96e-38	9.21e-31	0.92	0.69	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	15.37	2.96e-38	9.21e-31	0.92	0.69	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
COAD	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	15.36	3.1e-38	9.6e-31	0.85	0.69	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	15.36	3.1e-38	9.6e-31	0.85	0.69	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.583	rs9553311	ENSG00000224976.2	PARP4P2	15.35	3.41e-38	1.05e-30	0.76	0.69	Obesity-related traits;	chr13:24474016	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.524	rs7996445	ENSG00000224976.2	PARP4P2	15.35	3.41e-38	1.05e-30	0.76	0.69	Obesity-related traits;	chr13:24475329	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs6490937	ENSG00000224976.2	PARP4P2	15.35	3.41e-38	1.05e-30	0.76	0.69	Obesity-related traits;	chr13:24475834	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	15.35	3.53e-38	1.08e-30	1.08	0.69	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.646	rs4770688	ENSG00000224976.2	PARP4P2	15.35	3.53e-38	1.08e-30	0.77	0.69	Obesity-related traits;	chr13:24466007	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs4770689	ENSG00000224976.2	PARP4P2	15.35	3.53e-38	1.08e-30	0.77	0.69	Obesity-related traits;	chr13:24466008	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	15.33	4.15e-38	1.26e-30	0.9	0.69	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	15.33	4.15e-38	1.26e-30	0.9	0.69	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	15.33	4.15e-38	1.26e-30	0.9	0.69	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	15.33	4.15e-38	1.26e-30	0.9	0.69	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	15.32	4.56e-38	1.39e-30	0.9	0.69	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
COAD	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	15.27	6.8e-38	2.05e-30	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
COAD	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	15.27	6.8e-38	2.05e-30	0.82	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
COAD	trans	rs1816752	0.646	rs7322329	ENSG00000224976.2	PARP4P2	15.25	7.54e-38	2.26e-30	0.75	0.69	Obesity-related traits;	chr13:24479193	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511301	ENSG00000224976.2	PARP4P2	15.25	7.64e-38	2.28e-30	0.75	0.69	Obesity-related traits;	chr13:24477034	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7332220	ENSG00000224976.2	PARP4P2	15.25	7.64e-38	2.28e-30	0.75	0.69	Obesity-related traits;	chr13:24477081	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs11149109	ENSG00000224976.2	PARP4P2	15.25	7.64e-38	2.28e-30	0.75	0.69	Obesity-related traits;	chr13:24477290	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511302	ENSG00000224976.2	PARP4P2	15.25	7.64e-38	2.28e-30	0.75	0.69	Obesity-related traits;	chr13:24477580	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs8002599	ENSG00000224976.2	PARP4P2	15.25	7.64e-38	2.28e-30	0.75	0.69	Obesity-related traits;	chr13:24478486	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9507355	ENSG00000224976.2	PARP4P2	-15.25	7.72e-38	2.3e-30	-0.75	-0.69	Obesity-related traits;	chr13:24476819	chr13:19349137~19407962:+
COAD	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-15.24	8.57e-38	2.54e-30	-1.01	-0.69	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
COAD	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	15.23	9.18e-38	2.72e-30	0.72	0.69	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	15.23	9.28e-38	2.74e-30	0.72	0.69	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	15.23	9.28e-38	2.74e-30	0.72	0.69	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
COAD	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	15.23	9.43e-38	2.76e-30	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
COAD	trans	rs1816752	0.646	rs2862902	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24461965	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs734715	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24462041	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs730030	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24462509	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs7992667	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24462821	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs7995958	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24462895	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs8002741	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24462918	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7998600	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463222	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511279	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463348	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511280	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463364	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511281	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463441	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs9511282	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463597	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.583	rs9511283	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24463656	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9507351	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24465118	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs12431171	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24466380	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs12854523	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24466460	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9578740	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24466692	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.631	rs4769358	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24466940	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.608	rs4769359	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24466966	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.608	rs4769360	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467016	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.608	rs9511290	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467189	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511291	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467609	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511292	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467623	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511293	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467747	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511294	ENSG00000224976.2	PARP4P2	15.22	9.58e-38	2.76e-30	0.76	0.69	Obesity-related traits;	chr13:24467773	chr13:19349137~19407962:+
COAD	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	15.21	1.04e-37	3e-30	0.84	0.69	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
COAD	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	15.21	1.07e-37	3.07e-30	0.72	0.69	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
COAD	trans	rs1816752	0.646	rs750389	ENSG00000224976.2	PARP4P2	15.2	1.21e-37	3.47e-30	0.76	0.69	Obesity-related traits;	chr13:24461677	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs750388	ENSG00000224976.2	PARP4P2	15.19	1.25e-37	3.58e-30	0.76	0.69	Obesity-related traits;	chr13:24461690	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	15.19	1.25e-37	3.58e-30	0.9	0.69	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
COAD	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-15.19	1.27e-37	3.61e-30	-0.85	-0.69	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	15.18	1.35e-37	3.84e-30	1.03	0.69	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	15.18	1.42e-37	4.03e-30	0.91	0.69	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	15.18	1.42e-37	4.03e-30	0.91	0.69	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	15.18	1.42e-37	4.03e-30	0.91	0.69	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	15.18	1.42e-37	4.03e-30	0.91	0.69	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	15.18	1.42e-37	4.03e-30	0.91	0.69	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	15.12	2.17e-37	6.12e-30	1.07	0.69	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	15.12	2.23e-37	6.27e-30	0.86	0.69	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
COAD	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-15.11	2.43e-37	6.81e-30	-1.01	-0.69	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	15.1	2.55e-37	7.14e-30	1.05	0.69	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
COAD	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	15.1	2.59e-37	7.23e-30	0.85	0.69	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
COAD	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	15.1	2.59e-37	7.23e-30	0.85	0.69	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
COAD	trans	rs1816752	0.646	rs2862903	ENSG00000224976.2	PARP4P2	15.09	2.83e-37	7.89e-30	0.76	0.69	Obesity-related traits;	chr13:24473169	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7319207	ENSG00000224976.2	PARP4P2	15.09	2.85e-37	7.94e-30	0.76	0.69	Obesity-related traits;	chr13:24473220	chr13:19349137~19407962:+
COAD	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	15.09	2.91e-37	8.09e-30	0.84	0.69	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-15.08	2.96e-37	8.23e-30	-0.82	-0.69	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
COAD	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-15.08	2.98e-37	8.27e-30	-0.97	-0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
COAD	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	15.07	3.25e-37	9e-30	0.84	0.68	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
COAD	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	15.05	3.94e-37	1.08e-29	1.07	0.68	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
COAD	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	15.02	4.93e-37	1.35e-29	0.85	0.68	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
COAD	trans	rs1816752	0.646	rs9511296	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24467962	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9634401	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468072	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs9634402	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468119	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9634403	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468211	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9581064	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468251	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs4769361	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468834	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs4770693	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468835	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs4770695	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24468895	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7337981	ENSG00000224976.2	PARP4P2	15.02	5.05e-37	1.38e-29	0.76	0.68	Obesity-related traits;	chr13:24469245	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	15.01	5.28e-37	1.44e-29	0.91	0.68	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
COAD	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-15.01	5.4e-37	1.47e-29	-0.85	-0.68	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	15.01	5.48e-37	1.49e-29	0.91	0.68	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	15.01	5.48e-37	1.49e-29	0.91	0.68	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
COAD	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	14.99	6.33e-37	1.71e-29	0.82	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
COAD	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	14.99	6.52e-37	1.76e-29	0.72	0.68	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	14.99	6.52e-37	1.76e-29	0.72	0.68	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
COAD	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	14.96	8.27e-37	2.22e-29	1.22	0.68	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
COAD	trans	rs7554547	0.765	rs6541010	ENSG00000261819.1	RP11-680G24.4	14.95	8.85e-37	2.36e-29	0.94	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11913785	chr16:14988259~14990160:-
COAD	trans	rs1816752	0.646	rs4480642	ENSG00000224976.2	PARP4P2	14.95	8.87e-37	2.36e-29	0.75	0.68	Obesity-related traits;	chr13:24471358	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9551108	ENSG00000224976.2	PARP4P2	14.95	8.87e-37	2.36e-29	0.75	0.68	Obesity-related traits;	chr13:24471434	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.603	rs4238178	ENSG00000224976.2	PARP4P2	14.95	8.87e-37	2.36e-29	0.75	0.68	Obesity-related traits;	chr13:24472344	chr13:19349137~19407962:+
COAD	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	14.95	8.93e-37	2.37e-29	0.93	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
COAD	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	14.92	1.08e-36	2.84e-29	0.84	0.68	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
COAD	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	14.89	1.44e-36	3.78e-29	0.79	0.68	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
COAD	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	14.88	1.5e-36	3.9e-29	0.83	0.68	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
COAD	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	14.84	2.16e-36	5.58e-29	0.84	0.68	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
COAD	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	14.83	2.31e-36	5.95e-29	0.9	0.68	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	14.79	3.19e-36	8.1e-29	0.9	0.68	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
COAD	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-14.78	3.4e-36	8.63e-29	-0.83	-0.68	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
COAD	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	14.76	3.85e-36	9.74e-29	0.7	0.68	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
COAD	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	14.76	3.87e-36	9.78e-29	1.04	0.68	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.609	rs7998198	ENSG00000224976.2	PARP4P2	14.76	3.87e-36	9.78e-29	0.75	0.68	Obesity-related traits;	chr13:24462979	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs7998203	ENSG00000224976.2	PARP4P2	14.76	3.87e-36	9.78e-29	0.75	0.68	Obesity-related traits;	chr13:24462989	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7328391	ENSG00000224976.2	PARP4P2	14.76	3.99e-36	1e-28	0.76	0.68	Obesity-related traits;	chr13:24470325	chr13:19349137~19407962:+
COAD	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	14.73	5.15e-36	1.29e-28	0.82	0.68	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
COAD	trans	rs1816752	0.624	rs2096093	ENSG00000224976.2	PARP4P2	14.73	5.19e-36	1.3e-28	0.75	0.68	Obesity-related traits;	chr13:24472753	chr13:19349137~19407962:+
COAD	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	14.71	6.16e-36	1.54e-28	0.84	0.68	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-14.69	7.13e-36	1.77e-28	-0.88	-0.68	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	14.68	7.64e-36	1.89e-28	1.04	0.68	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	14.68	7.64e-36	1.89e-28	1.04	0.68	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	14.68	7.64e-36	1.89e-28	1.04	0.68	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	14.67	8.14e-36	2.01e-28	1.04	0.68	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
COAD	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	14.65	9.46e-36	2.33e-28	0.84	0.67	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	14.65	9.46e-36	2.33e-28	0.84	0.67	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	14.65	9.79e-36	2.41e-28	0.84	0.67	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
COAD	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	14.65	9.79e-36	2.41e-28	0.84	0.67	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	14.65	9.79e-36	2.41e-28	0.84	0.67	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	14.65	9.95e-36	2.44e-28	0.84	0.67	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	14.65	9.95e-36	2.44e-28	0.84	0.67	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	14.65	9.95e-36	2.44e-28	0.84	0.67	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	14.64	1.06e-35	2.6e-28	0.84	0.67	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
COAD	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	14.64	1.07e-35	2.6e-28	0.78	0.67	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
COAD	trans	rs1816752	0.646	rs2902359	ENSG00000224976.2	PARP4P2	14.6	1.45e-35	3.5e-28	0.75	0.67	Obesity-related traits;	chr13:24461783	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.608	rs4770690	ENSG00000224976.2	PARP4P2	14.58	1.66e-35	3.98e-28	0.74	0.67	Obesity-related traits;	chr13:24467049	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-14.57	1.76e-35	4.24e-28	-0.84	-0.67	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
COAD	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	14.55	2.22e-35	5.31e-28	0.86	0.67	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
COAD	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	14.5	3.09e-35	7.31e-28	0.83	0.67	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	14.5	3.09e-35	7.31e-28	0.83	0.67	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	14.5	3.09e-35	7.31e-28	0.83	0.67	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
COAD	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-14.5	3.31e-35	7.83e-28	-0.7	-0.67	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	14.48	3.83e-35	9.02e-28	0.72	0.67	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	14.48	3.83e-35	9.02e-28	0.72	0.67	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	14.47	4.23e-35	9.91e-28	0.7	0.67	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
COAD	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-14.46	4.38e-35	1.03e-27	-1.05	-0.67	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.608	rs7326664	ENSG00000224976.2	PARP4P2	14.45	4.97e-35	1.16e-27	0.74	0.67	Obesity-related traits;	chr13:24475868	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs7995190	ENSG00000224976.2	PARP4P2	14.44	5.02e-35	1.17e-27	0.74	0.67	Obesity-related traits;	chr13:24475709	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs9553312	ENSG00000224976.2	PARP4P2	14.44	5.09e-35	1.19e-27	0.74	0.67	Obesity-related traits;	chr13:24474055	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	14.44	5.29e-35	1.23e-27	0.91	0.67	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
COAD	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	14.43	5.56e-35	1.29e-27	0.8	0.67	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
COAD	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-14.43	5.79e-35	1.35e-27	-0.75	-0.67	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
COAD	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	14.42	5.88e-35	1.37e-27	0.88	0.67	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
COAD	trans	rs1816752	0.646	rs7322323	ENSG00000224976.2	PARP4P2	14.38	8.2e-35	1.9e-27	0.73	0.67	Obesity-related traits;	chr13:24479189	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs750390	ENSG00000224976.2	PARP4P2	14.37	9.35e-35	2.16e-27	0.74	0.67	Obesity-related traits;	chr13:24461603	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-14.36	9.53e-35	2.2e-27	-0.82	-0.67	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
COAD	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	14.36	9.95e-35	2.3e-27	1.05	0.67	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
COAD	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	14.35	1.08e-34	2.5e-27	0.79	0.67	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
COAD	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-14.35	1.1e-34	2.52e-27	-0.99	-0.67	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.583	rs9511284	ENSG00000224976.2	PARP4P2	14.32	1.4e-34	3.22e-27	0.74	0.67	Obesity-related traits;	chr13:24463660	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.646	rs9511295	ENSG00000224976.2	PARP4P2	14.32	1.4e-34	3.22e-27	0.74	0.67	Obesity-related traits;	chr13:24467794	chr13:19349137~19407962:+
COAD	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	14.31	1.44e-34	3.29e-27	1.17	0.67	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
COAD	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-14.31	1.45e-34	3.33e-27	-1	-0.67	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
COAD	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-14.3	1.56e-34	3.58e-27	-0.89	-0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
COAD	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-14.26	2.22e-34	5.06e-27	-1.05	-0.66	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-14.26	2.22e-34	5.07e-27	-1.04	-0.66	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	14.24	2.48e-34	5.65e-27	0.91	0.66	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.646	rs4770700	ENSG00000224976.2	PARP4P2	14.23	2.83e-34	6.44e-27	0.73	0.66	Obesity-related traits;	chr13:24494796	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs7330766	ENSG00000224976.2	PARP4P2	14.23	2.83e-34	6.44e-27	0.73	0.66	Obesity-related traits;	chr13:24495579	chr13:19349137~19407962:+
COAD	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-14.22	2.92e-34	6.62e-27	-0.82	-0.66	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-14.21	3.25e-34	7.36e-27	-0.79	-0.66	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
COAD	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	14.21	3.35e-34	7.59e-27	1	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
COAD	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-14.2	3.66e-34	8.27e-27	-0.82	-0.66	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
COAD	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	14.19	3.85e-34	8.68e-27	0.93	0.66	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
COAD	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-14.18	4.11e-34	9.23e-27	-1	-0.66	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-14.18	4.13e-34	9.27e-27	-0.82	-0.66	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	14.16	5.05e-34	1.13e-26	0.82	0.66	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
COAD	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	14.14	5.78e-34	1.29e-26	0.68	0.66	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
COAD	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-14.13	5.98e-34	1.33e-26	-0.83	-0.66	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.609	rs4770692	ENSG00000224976.2	PARP4P2	14.13	6.46e-34	1.44e-26	0.74	0.66	Obesity-related traits;	chr13:24468689	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.609	rs4770694	ENSG00000224976.2	PARP4P2	14.13	6.46e-34	1.44e-26	0.74	0.66	Obesity-related traits;	chr13:24468891	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.624	rs9507354	ENSG00000224976.2	PARP4P2	14.13	6.46e-34	1.44e-26	0.74	0.66	Obesity-related traits;	chr13:24469227	chr13:19349137~19407962:+
COAD	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	14.04	1.27e-33	2.79e-26	1.25	0.66	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
COAD	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	14.04	1.27e-33	2.79e-26	1.25	0.66	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
COAD	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-14.04	1.33e-33	2.91e-26	-0.8	-0.66	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-14.02	1.45e-33	3.18e-26	-1.01	-0.66	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-14.02	1.45e-33	3.18e-26	-1.01	-0.66	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
COAD	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	14.02	1.46e-33	3.2e-26	0.93	0.66	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
COAD	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	14.02	1.51e-33	3.31e-26	0.85	0.66	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	13.98	2.05e-33	4.45e-26	0.82	0.66	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
COAD	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-13.98	2.09e-33	4.54e-26	-1.24	-0.66	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
COAD	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	13.97	2.27e-33	4.94e-26	1.03	0.66	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
COAD	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	13.97	2.31e-33	5.01e-26	1.02	0.66	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
COAD	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	13.97	2.32e-33	5.02e-26	0.77	0.66	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
COAD	trans	rs1816752	0.624	rs4770701	ENSG00000224976.2	PARP4P2	13.96	2.49e-33	5.39e-26	0.73	0.66	Obesity-related traits;	chr13:24508806	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.603	rs7984094	ENSG00000224976.2	PARP4P2	13.96	2.5e-33	5.41e-26	0.72	0.66	Obesity-related traits;	chr13:24496212	chr13:19349137~19407962:+
COAD	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	13.95	2.53e-33	5.47e-26	0.95	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-13.94	2.89e-33	6.24e-26	-0.97	-0.66	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	13.93	3e-33	6.47e-26	1	0.66	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
COAD	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	13.93	3.13e-33	6.73e-26	1	0.66	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
COAD	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	13.92	3.26e-33	7.02e-26	0.81	0.66	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
COAD	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	13.9	3.78e-33	8.11e-26	0.71	0.66	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
COAD	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	13.88	4.41e-33	9.45e-26	0.99	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
COAD	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	13.87	4.92e-33	1.05e-25	0.99	0.65	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
COAD	trans	rs1816752	0.646	rs1361578	ENSG00000224976.2	PARP4P2	13.87	4.99e-33	1.07e-25	0.72	0.65	Obesity-related traits;	chr13:24491117	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.716	rs7995304	ENSG00000224976.2	PARP4P2	13.86	5.26e-33	1.12e-25	0.72	0.65	Obesity-related traits;	chr13:24514284	chr13:19349137~19407962:+
COAD	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	13.84	6.43e-33	1.37e-25	0.71	0.65	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
COAD	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	13.82	7.43e-33	1.58e-25	0.84	0.65	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
COAD	trans	rs116095464	0.558	rs10043002	ENSG00000185986.11	SDHAP3	13.81	7.97e-33	1.68e-25	1.01	0.65	Breast cancer;	chr5:226638	chr5:1572222~1594620:-
COAD	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	13.79	9.2e-33	1.94e-25	0.83	0.65	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
COAD	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	13.78	9.83e-33	2.07e-25	0.67	0.65	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
COAD	trans	rs116095464	0.558	rs2162870	ENSG00000185986.11	SDHAP3	13.78	9.99e-33	2.09e-25	1.01	0.65	Breast cancer;	chr5:228014	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs28729548	ENSG00000185986.11	SDHAP3	13.78	9.99e-33	2.09e-25	1.01	0.65	Breast cancer;	chr5:228910	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.681	rs9687745	ENSG00000185986.11	SDHAP3	13.78	9.99e-33	2.09e-25	1.01	0.65	Breast cancer;	chr5:229194	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9688136	ENSG00000185986.11	SDHAP3	13.78	9.99e-33	2.09e-25	1.01	0.65	Breast cancer;	chr5:229233	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.51	rs55750776	ENSG00000185986.11	SDHAP3	13.78	9.99e-33	2.09e-25	1.01	0.65	Breast cancer;	chr5:230352	chr5:1572222~1594620:-
COAD	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	13.78	1.03e-32	2.14e-25	0.99	0.65	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
COAD	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-13.77	1.11e-32	2.3e-25	-1.07	-0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
COAD	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-13.77	1.11e-32	2.3e-25	-1.07	-0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-13.77	1.11e-32	2.3e-25	-1.07	-0.65	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-13.77	1.11e-32	2.3e-25	-1.07	-0.65	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-13.77	1.11e-32	2.3e-25	-1.07	-0.65	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
COAD	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	13.75	1.25e-32	2.58e-25	0.99	0.65	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
COAD	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	13.75	1.25e-32	2.58e-25	0.99	0.65	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
COAD	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	13.75	1.25e-32	2.58e-25	0.99	0.65	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
COAD	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	13.75	1.25e-32	2.58e-25	0.99	0.65	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
COAD	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	13.75	1.25e-32	2.58e-25	0.99	0.65	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
COAD	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	13.75	1.29e-32	2.66e-25	0.82	0.65	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.764	rs10069197	ENSG00000185986.11	SDHAP3	13.75	1.31e-32	2.7e-25	1.01	0.65	Breast cancer;	chr5:230707	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.867	rs10074958	ENSG00000185986.11	SDHAP3	13.75	1.31e-32	2.7e-25	1.01	0.65	Breast cancer;	chr5:230713	chr5:1572222~1594620:-
COAD	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	13.73	1.47e-32	3.02e-25	1.23	0.65	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
COAD	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	13.73	1.55e-32	3.18e-25	0.99	0.65	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
COAD	trans	rs1816752	0.646	rs7997248	ENSG00000224976.2	PARP4P2	13.72	1.59e-32	3.26e-25	0.73	0.65	Obesity-related traits;	chr13:24507050	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-13.72	1.62e-32	3.33e-25	-0.99	-0.65	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-13.72	1.67e-32	3.42e-25	-0.97	-0.65	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-13.72	1.67e-32	3.42e-25	-0.97	-0.65	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-13.72	1.67e-32	3.42e-25	-0.97	-0.65	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-13.72	1.67e-32	3.42e-25	-0.97	-0.65	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
COAD	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	13.7	1.88e-32	3.83e-25	0.7	0.65	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
COAD	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-13.7	1.91e-32	3.87e-25	-0.81	-0.65	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.558	rs2288458	ENSG00000185986.11	SDHAP3	13.68	2.21e-32	4.46e-25	1	0.65	Breast cancer;	chr5:231145	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs2288457	ENSG00000185986.11	SDHAP3	13.68	2.21e-32	4.46e-25	1	0.65	Breast cancer;	chr5:231155	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7736600	ENSG00000185986.11	SDHAP3	13.68	2.21e-32	4.46e-25	1	0.65	Breast cancer;	chr5:231222	chr5:1572222~1594620:-
COAD	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-13.68	2.24e-32	4.52e-25	-0.82	-0.65	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	13.68	2.33e-32	4.69e-25	0.96	0.65	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	13.66	2.58e-32	5.18e-25	1.01	0.65	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs62347683	ENSG00000185986.11	SDHAP3	13.66	2.62e-32	5.26e-25	1	0.65	Breast cancer;	chr5:230216	chr5:1572222~1594620:-
COAD	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	13.65	2.8e-32	5.61e-25	0.81	0.65	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	13.65	2.8e-32	5.61e-25	0.81	0.65	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	13.65	2.87e-32	5.73e-25	0.97	0.65	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	13.65	2.87e-32	5.73e-25	0.97	0.65	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
COAD	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-13.64	3.14e-32	6.25e-25	-0.85	-0.65	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
COAD	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	13.64	3.14e-32	6.26e-25	1.2	0.65	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
COAD	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	13.62	3.53e-32	7.02e-25	1.04	0.65	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs62347677	ENSG00000185986.11	SDHAP3	13.62	3.55e-32	7.05e-25	1	0.65	Breast cancer;	chr5:227338	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs2288459	ENSG00000185986.11	SDHAP3	13.6	4.19e-32	8.31e-25	0.99	0.65	Breast cancer;	chr5:231028	chr5:1572222~1594620:-
COAD	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	13.58	4.96e-32	9.66e-25	0.81	0.65	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-13.58	4.96e-32	9.66e-25	-0.81	-0.65	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	13.56	5.76e-32	1.12e-24	1.05	0.65	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	13.54	6.71e-32	1.3e-24	0.95	0.65	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	13.54	6.71e-32	1.3e-24	0.95	0.65	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
COAD	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	13.53	7.33e-32	1.42e-24	0.98	0.65	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
COAD	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	13.53	7.59e-32	1.47e-24	0.95	0.64	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
COAD	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	13.51	8.67e-32	1.68e-24	0.84	0.64	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
COAD	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	13.51	8.84e-32	1.7e-24	1.48	0.64	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	13.51	8.84e-32	1.7e-24	1.48	0.64	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
COAD	trans	rs116095464	0.619	rs2303741	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:218241	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.614	rs10067482	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:219213	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.614	rs56299325	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:220479	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs62346526	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:220499	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs56043030	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:220802	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10067021	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:221375	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9312977	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:221801	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6881920	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:222296	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6878061	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:222957	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6882584	ENSG00000185986.11	SDHAP3	13.5	9.61e-32	1.83e-24	0.99	0.64	Breast cancer;	chr5:223296	chr5:1572222~1594620:-
COAD	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	13.49	1.01e-31	1.92e-24	1.27	0.64	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
COAD	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	13.49	1.06e-31	2e-24	1.47	0.64	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
COAD	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-13.48	1.07e-31	2.03e-24	-0.94	-0.64	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs3213838	ENSG00000185986.11	SDHAP3	13.48	1.08e-31	2.04e-24	1	0.64	Breast cancer;	chr5:223775	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6555052	ENSG00000185986.11	SDHAP3	13.48	1.08e-31	2.04e-24	1	0.64	Breast cancer;	chr5:224153	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs61689490	ENSG00000185986.11	SDHAP3	13.48	1.08e-31	2.04e-24	1	0.64	Breast cancer;	chr5:224789	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs61492827	ENSG00000185986.11	SDHAP3	13.48	1.08e-31	2.04e-24	1	0.64	Breast cancer;	chr5:225659	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs56342538	ENSG00000185986.11	SDHAP3	13.48	1.08e-31	2.04e-24	1	0.64	Breast cancer;	chr5:225681	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-13.48	1.08e-31	2.04e-24	-0.93	-0.64	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-13.48	1.08e-31	2.04e-24	-0.93	-0.64	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	13.48	1.14e-31	2.15e-24	0.81	0.64	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.558	rs10057674	ENSG00000185986.11	SDHAP3	13.47	1.15e-31	2.16e-24	1.01	0.64	Breast cancer;	chr5:266698	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs1812843	ENSG00000185986.11	SDHAP3	13.47	1.15e-31	2.16e-24	1.01	0.64	Breast cancer;	chr5:267543	chr5:1572222~1594620:-
COAD	trans	rs1816752	0.692	rs2282409	ENSG00000224976.2	PARP4P2	13.47	1.15e-31	2.17e-24	0.72	0.64	Obesity-related traits;	chr13:24512388	chr13:19349137~19407962:+
COAD	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	13.47	1.18e-31	2.21e-24	0.96	0.64	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
COAD	trans	rs116095464	0.558	rs6555055	ENSG00000185986.11	SDHAP3	13.46	1.25e-31	2.35e-24	1	0.64	Breast cancer;	chr5:226045	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6555056	ENSG00000185986.11	SDHAP3	13.46	1.25e-31	2.35e-24	1	0.64	Breast cancer;	chr5:226107	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	13.45	1.41e-31	2.64e-24	0.96	0.64	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	13.45	1.43e-31	2.66e-24	0.81	0.64	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	13.45	1.43e-31	2.66e-24	0.81	0.64	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-13.44	1.48e-31	2.76e-24	-1.08	-0.64	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
COAD	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	13.43	1.58e-31	2.94e-24	0.96	0.64	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
COAD	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	13.43	1.6e-31	2.96e-24	0.81	0.64	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	13.43	1.6e-31	2.96e-24	0.97	0.64	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	13.43	1.6e-31	2.96e-24	0.97	0.64	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	13.43	1.62e-31	3e-24	0.96	0.64	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
COAD	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	13.42	1.73e-31	3.21e-24	1.48	0.64	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	13.42	1.73e-31	3.21e-24	1.48	0.64	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
COAD	trans	rs116095464	0.558	rs1541822	ENSG00000185986.11	SDHAP3	-13.42	1.8e-31	3.32e-24	-1.01	-0.64	Breast cancer;	chr5:269119	chr5:1572222~1594620:-
COAD	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	13.41	1.89e-31	3.49e-24	0.81	0.64	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.558	rs1971229	ENSG00000185986.11	SDHAP3	13.41	1.92e-31	3.54e-24	1.01	0.64	Breast cancer;	chr5:268072	chr5:1572222~1594620:-
COAD	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	13.4	2.05e-31	3.78e-24	0.7	0.64	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
COAD	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	13.39	2.22e-31	4.08e-24	0.81	0.64	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
COAD	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	13.39	2.28e-31	4.17e-24	1.47	0.64	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	13.39	2.28e-31	4.17e-24	1.47	0.64	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
COAD	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-13.39	2.3e-31	4.22e-24	-0.96	-0.64	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-13.39	2.33e-31	4.27e-24	-0.99	-0.64	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.669	rs2862906	ENSG00000224976.2	PARP4P2	13.38	2.34e-31	4.29e-24	0.71	0.64	Obesity-related traits;	chr13:24494482	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	13.38	2.51e-31	4.6e-24	0.81	0.64	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	13.38	2.51e-31	4.6e-24	0.81	0.64	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
COAD	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	13.36	2.77e-31	5.05e-24	1.46	0.64	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
COAD	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	13.36	2.93e-31	5.34e-24	0.69	0.64	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
COAD	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-13.35	3.09e-31	5.63e-24	-0.82	-0.64	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	13.34	3.24e-31	5.9e-24	0.96	0.64	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	13.34	3.4e-31	6.17e-24	0.81	0.64	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.558	rs12173244	ENSG00000185986.11	SDHAP3	13.33	3.71e-31	6.71e-24	1	0.64	Breast cancer;	chr5:269409	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs56127718	ENSG00000185986.11	SDHAP3	13.33	3.71e-31	6.71e-24	1	0.64	Breast cancer;	chr5:270158	chr5:1572222~1594620:-
COAD	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	13.32	3.84e-31	6.94e-24	0.74	0.64	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	13.32	3.84e-31	6.94e-24	0.74	0.64	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-13.32	3.99e-31	7.19e-24	-0.84	-0.64	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	13.32	4.03e-31	7.26e-24	0.96	0.64	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.51	rs7714944	ENSG00000185986.11	SDHAP3	13.31	4.14e-31	7.45e-24	0.97	0.64	Breast cancer;	chr5:231650	chr5:1572222~1594620:-
COAD	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	13.29	5.04e-31	9.02e-24	1.23	0.64	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
COAD	trans	rs1816752	0.646	rs2862905	ENSG00000224976.2	PARP4P2	13.28	5.37e-31	9.57e-24	0.7	0.64	Obesity-related traits;	chr13:24485142	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	13.28	5.5e-31	9.78e-24	0.81	0.64	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	13.27	5.77e-31	1.02e-23	0.93	0.64	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	13.27	5.77e-31	1.02e-23	0.93	0.64	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	13.27	5.82e-31	1.03e-23	1.22	0.64	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	13.27	5.82e-31	1.03e-23	1.22	0.64	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-13.27	5.92e-31	1.05e-23	-0.96	-0.64	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-13.27	5.92e-31	1.05e-23	-0.96	-0.64	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-13.27	5.92e-31	1.05e-23	-0.96	-0.64	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-13.27	5.92e-31	1.05e-23	-0.96	-0.64	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	13.27	6.03e-31	1.06e-23	0.96	0.64	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
COAD	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	13.25	6.64e-31	1.17e-23	0.96	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	13.25	6.68e-31	1.17e-23	0.96	0.64	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	13.25	6.68e-31	1.17e-23	0.96	0.64	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	13.25	6.68e-31	1.17e-23	0.96	0.64	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
COAD	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	13.25	6.91e-31	1.21e-23	0.68	0.64	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
COAD	trans	rs116095464	0.558	rs10057299	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:242020	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs13356367	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:242280	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.85	rs10055295	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:243634	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs60251075	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:245177	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs62344300	ENSG00000185986.11	SDHAP3	13.25	6.92e-31	1.21e-23	1.01	0.64	Breast cancer;	chr5:246221	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10462754	ENSG00000185986.11	SDHAP3	13.24	7.58e-31	1.32e-23	1.01	0.64	Breast cancer;	chr5:246554	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10462755	ENSG00000185986.11	SDHAP3	13.24	7.58e-31	1.32e-23	1.01	0.64	Breast cancer;	chr5:246633	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.681	rs10060016	ENSG00000185986.11	SDHAP3	13.23	7.82e-31	1.36e-23	1.01	0.64	Breast cancer;	chr5:240985	chr5:1572222~1594620:-
COAD	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	13.23	8.02e-31	1.39e-23	1.47	0.64	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
COAD	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	13.22	8.37e-31	1.45e-23	0.81	0.64	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.614	rs62344339	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:252880	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9687898	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:253837	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9688045	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:253920	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs112343653	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:257059	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs73024831	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:257077	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs57335027	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:262792	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6869925	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:263921	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6875291	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:264077	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6866776	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:264380	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs6874745	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:264412	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7715108	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:264546	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7730700	ENSG00000185986.11	SDHAP3	13.22	8.7e-31	1.49e-23	1.01	0.64	Breast cancer;	chr5:264598	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.614	rs10061564	ENSG00000185986.11	SDHAP3	13.22	8.98e-31	1.54e-23	1.01	0.64	Breast cancer;	chr5:271214	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs55776650	ENSG00000185986.11	SDHAP3	13.22	8.98e-31	1.54e-23	1.01	0.64	Breast cancer;	chr5:273711	chr5:1572222~1594620:-
COAD	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-13.22	9e-31	1.54e-23	-0.73	-0.64	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.558	rs13354585	ENSG00000185986.11	SDHAP3	13.21	9.18e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:242148	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7708182	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:234673	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10058428	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:235493	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10036253	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:238404	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10075018	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:239060	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10076655	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:239349	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10057492	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:239388	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs28418643	ENSG00000185986.11	SDHAP3	13.21	9.2e-31	1.56e-23	1.01	0.64	Breast cancer;	chr5:240744	chr5:1572222~1594620:-
COAD	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	13.21	9.39e-31	1.59e-23	0.79	0.64	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	13.21	9.39e-31	1.59e-23	0.79	0.64	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-13.2	1.04e-30	1.74e-23	-0.96	-0.64	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs62344345	ENSG00000185986.11	SDHAP3	13.18	1.21e-30	2.02e-23	1	0.63	Breast cancer;	chr5:257305	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-13.17	1.29e-30	2.15e-23	-0.95	-0.63	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
COAD	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-13.17	1.3e-30	2.17e-23	-0.83	-0.63	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-13.17	1.3e-30	2.17e-23	-0.83	-0.63	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-13.17	1.32e-30	2.19e-23	-0.89	-0.63	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.716	rs1539096	ENSG00000224976.2	PARP4P2	13.15	1.45e-30	2.41e-23	0.71	0.63	Obesity-related traits;	chr13:24501721	chr13:19349137~19407962:+
COAD	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	13.15	1.48e-30	2.46e-23	1.22	0.63	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
COAD	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	13.15	1.48e-30	2.46e-23	0.81	0.63	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.669	rs9553309	ENSG00000224976.2	PARP4P2	13.15	1.49e-30	2.47e-23	0.7	0.63	Obesity-related traits;	chr13:24471476	chr13:19349137~19407962:+
COAD	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	13.14	1.6e-30	2.66e-23	0.74	0.63	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	13.14	1.6e-30	2.66e-23	0.74	0.63	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
COAD	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-13.14	1.62e-30	2.67e-23	-0.83	-0.63	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	13.14	1.65e-30	2.72e-23	0.92	0.63	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	13.14	1.67e-30	2.76e-23	0.74	0.63	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	13.13	1.7e-30	2.79e-23	0.85	0.63	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
COAD	trans	rs116095464	0.614	rs62344292	ENSG00000185986.11	SDHAP3	13.13	1.77e-30	2.91e-23	1.01	0.63	Breast cancer;	chr5:244515	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.51	rs60844864	ENSG00000185986.11	SDHAP3	13.12	1.84e-30	3.01e-23	1.01	0.63	Breast cancer;	chr5:266885	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10052012	ENSG00000185986.11	SDHAP3	13.12	1.86e-30	3.05e-23	0.97	0.63	Breast cancer;	chr5:231793	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10077076	ENSG00000185986.11	SDHAP3	13.12	1.86e-30	3.05e-23	0.97	0.63	Breast cancer;	chr5:231825	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10080225	ENSG00000185986.11	SDHAP3	13.12	1.86e-30	3.05e-23	0.97	0.63	Breast cancer;	chr5:232060	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-13.12	1.88e-30	3.07e-23	-0.94	-0.63	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	13.12	1.95e-30	3.19e-23	0.78	0.63	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
COAD	trans	rs116095464	0.558	rs62347678	ENSG00000185986.11	SDHAP3	13.12	1.97e-30	3.22e-23	0.95	0.63	Breast cancer;	chr5:227381	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs73031482	ENSG00000185986.11	SDHAP3	13.12	1.97e-30	3.22e-23	0.95	0.63	Breast cancer;	chr5:227479	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	13.11	2.04e-30	3.3e-23	0.92	0.63	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	13.11	2.08e-30	3.37e-23	0.73	0.63	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.558	rs7713524	ENSG00000185986.11	SDHAP3	-13.11	2.09e-30	3.38e-23	-1.02	-0.63	Breast cancer;	chr5:276085	chr5:1572222~1594620:-
COAD	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	13.1	2.16e-30	3.5e-23	0.95	0.63	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-13.1	2.16e-30	3.5e-23	-0.94	-0.63	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-13.1	2.29e-30	3.7e-23	-0.78	-0.63	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
COAD	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	13.09	2.35e-30	3.8e-23	0.72	0.63	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
COAD	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	13.09	2.45e-30	3.96e-23	1.43	0.63	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
COAD	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	13.08	2.57e-30	4.15e-23	0.95	0.63	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
COAD	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	13.08	2.66e-30	4.28e-23	0.98	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
COAD	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	13.07	2.81e-30	4.52e-23	0.73	0.63	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
COAD	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	13.05	3.33e-30	5.32e-23	0.96	0.63	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
COAD	trans	rs116095464	0.558	rs28635197	ENSG00000185986.11	SDHAP3	13.05	3.39e-30	5.42e-23	1.01	0.63	Breast cancer;	chr5:278956	chr5:1572222~1594620:-
COAD	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	13.05	3.43e-30	5.48e-23	0.84	0.63	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
COAD	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	13.04	3.48e-30	5.55e-23	1.22	0.63	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
COAD	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	13.04	3.49e-30	5.57e-23	0.77	0.63	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
COAD	trans	rs116095464	0.558	rs59113266	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:279850	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs11959126	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:283765	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7356696	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:284136	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7356561	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:284266	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs59284383	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:284410	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7731089	ENSG00000185986.11	SDHAP3	13.04	3.63e-30	5.74e-23	1	0.63	Breast cancer;	chr5:290307	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	13.03	3.84e-30	6.05e-23	0.96	0.63	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
COAD	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-13.03	3.85e-30	6.07e-23	-0.68	-0.63	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
COAD	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-13.03	3.9e-30	6.14e-23	-0.92	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
COAD	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	13.02	4.22e-30	6.62e-23	0.72	0.63	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
COAD	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-13.02	4.26e-30	6.68e-23	-0.83	-0.63	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	13.01	4.39e-30	6.87e-23	0.95	0.63	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
COAD	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	13.01	4.39e-30	6.87e-23	0.95	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.542	rs28650039	ENSG00000185986.11	SDHAP3	13.01	4.56e-30	7.13e-23	1	0.63	Breast cancer;	chr5:273839	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.614	rs78905930	ENSG00000185986.11	SDHAP3	13.01	4.68e-30	7.31e-23	1.01	0.63	Breast cancer;	chr5:246445	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-13	4.89e-30	7.64e-23	-0.94	-0.63	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
COAD	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-12.99	5.33e-30	8.29e-23	-0.92	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
COAD	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-12.99	5.33e-30	8.29e-23	-0.92	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-12.98	5.54e-30	8.61e-23	-0.9	-0.63	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
COAD	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	12.98	5.55e-30	8.62e-23	0.83	0.63	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-12.98	5.62e-30	8.72e-23	-0.86	-0.63	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	12.98	5.88e-30	9.11e-23	0.71	0.63	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.558	rs6555058	ENSG00000185986.11	SDHAP3	-12.97	6.14e-30	9.49e-23	-0.97	-0.63	Breast cancer;	chr5:226261	chr5:1572222~1594620:-
COAD	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-12.97	6.19e-30	9.56e-23	-0.83	-0.63	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	12.97	6.23e-30	9.63e-23	0.72	0.63	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
COAD	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	12.97	6.32e-30	9.75e-23	0.67	0.63	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
COAD	trans	rs1816752	0.669	rs3783072	ENSG00000224976.2	PARP4P2	12.94	7.76e-30	1.19e-22	0.69	0.63	Obesity-related traits;	chr13:24493258	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	12.94	7.87e-30	1.21e-22	0.91	0.63	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
COAD	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	12.94	8.1e-30	1.24e-22	0.83	0.63	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
COAD	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-12.93	8.28e-30	1.27e-22	-0.93	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
COAD	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-12.93	8.28e-30	1.27e-22	-0.93	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
COAD	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-12.93	8.28e-30	1.27e-22	-0.93	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
COAD	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-12.93	8.28e-30	1.27e-22	-0.93	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	12.93	8.48e-30	1.3e-22	0.95	0.63	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
COAD	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	12.93	8.58e-30	1.31e-22	0.93	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	12.92	9.24e-30	1.41e-22	0.92	0.63	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	12.92	9.24e-30	1.41e-22	0.92	0.63	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	12.91	9.88e-30	1.51e-22	0.97	0.63	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-12.9	1.08e-29	1.65e-22	-0.96	-0.63	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	12.89	1.17e-29	1.78e-22	0.72	0.63	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
COAD	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	12.89	1.18e-29	1.78e-22	0.96	0.63	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
COAD	trans	rs116095464	0.558	rs6872854	ENSG00000185986.11	SDHAP3	12.89	1.19e-29	1.81e-22	0.94	0.63	Breast cancer;	chr5:208923	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-12.89	1.21e-29	1.83e-22	-0.97	-0.63	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	12.88	1.23e-29	1.87e-22	0.94	0.63	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
COAD	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	12.88	1.23e-29	1.87e-22	0.94	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	12.88	1.26e-29	1.9e-22	0.97	0.63	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	12.88	1.26e-29	1.9e-22	0.97	0.63	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	12.88	1.26e-29	1.9e-22	0.97	0.63	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	12.88	1.26e-29	1.9e-22	0.97	0.63	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
COAD	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	12.88	1.26e-29	1.9e-22	0.97	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	12.88	1.31e-29	1.97e-22	0.91	0.63	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	12.87	1.33e-29	2e-22	0.8	0.63	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
COAD	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	12.87	1.35e-29	2.03e-22	1.23	0.63	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
COAD	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-12.87	1.37e-29	2.06e-22	-0.82	-0.63	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-12.87	1.37e-29	2.06e-22	-0.82	-0.63	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
COAD	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	12.86	1.45e-29	2.18e-22	0.67	0.63	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
COAD	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	12.86	1.5e-29	2.25e-22	1.38	0.63	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	12.86	1.5e-29	2.25e-22	1.38	0.63	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	12.86	1.5e-29	2.25e-22	1.38	0.63	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	12.86	1.5e-29	2.25e-22	1.38	0.63	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
COAD	trans	rs1816752	0.646	rs3783073	ENSG00000224976.2	PARP4P2	12.86	1.52e-29	2.28e-22	0.69	0.63	Obesity-related traits;	chr13:24493222	chr13:19349137~19407962:+
COAD	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	12.85	1.55e-29	2.33e-22	0.83	0.63	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
COAD	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-12.83	1.85e-29	2.76e-22	-0.82	-0.62	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
COAD	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
COAD	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	12.83	1.92e-29	2.85e-22	0.94	0.62	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-12.83	1.94e-29	2.88e-22	-0.77	-0.62	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
COAD	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-12.82	2.01e-29	2.97e-22	-0.81	-0.62	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-12.82	2.01e-29	2.97e-22	-0.81	-0.62	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
COAD	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-12.82	2.01e-29	2.97e-22	-0.81	-0.62	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
COAD	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	12.82	2.11e-29	3.13e-22	0.77	0.62	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
COAD	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	12.81	2.12e-29	3.15e-22	0.79	0.62	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
COAD	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-12.81	2.19e-29	3.24e-22	-0.73	-0.62	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
COAD	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	12.81	2.2e-29	3.25e-22	0.78	0.62	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
COAD	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	12.81	2.21e-29	3.27e-22	0.89	0.62	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
COAD	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-12.8	2.29e-29	3.39e-22	-0.96	-0.62	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs7725227	ENSG00000185986.11	SDHAP3	12.79	2.54e-29	3.74e-22	0.98	0.62	Breast cancer;	chr5:233402	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7710005	ENSG00000185986.11	SDHAP3	12.79	2.54e-29	3.74e-22	0.98	0.62	Breast cancer;	chr5:233457	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs13357299	ENSG00000185986.11	SDHAP3	12.79	2.6e-29	3.82e-22	0.95	0.62	Breast cancer;	chr5:242096	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-12.79	2.65e-29	3.9e-22	-0.94	-0.62	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-12.78	2.78e-29	4.08e-22	-0.96	-0.62	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	12.78	2.82e-29	4.13e-22	0.77	0.62	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	12.78	2.82e-29	4.13e-22	0.77	0.62	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	12.78	2.82e-29	4.13e-22	0.77	0.62	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	12.78	2.82e-29	4.13e-22	0.77	0.62	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	12.77	3.09e-29	4.51e-22	0.77	0.62	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
COAD	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	12.76	3.24e-29	4.72e-22	0.96	0.62	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	12.75	3.46e-29	5.02e-22	0.77	0.62	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	12.75	3.46e-29	5.02e-22	0.77	0.62	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	12.75	3.46e-29	5.02e-22	0.77	0.62	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
COAD	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	12.75	3.48e-29	5.06e-22	0.96	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	12.75	3.48e-29	5.06e-22	0.96	0.62	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	12.75	3.5e-29	5.08e-22	0.77	0.62	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
COAD	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	12.75	3.52e-29	5.11e-22	0.71	0.62	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	12.75	3.52e-29	5.11e-22	0.71	0.62	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	12.75	3.61e-29	5.23e-22	0.91	0.62	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	12.74	3.82e-29	5.54e-22	0.78	0.62	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
COAD	trans	rs116095464	0.558	rs6878087	ENSG00000185986.11	SDHAP3	-12.74	3.85e-29	5.58e-22	-0.94	-0.62	Breast cancer;	chr5:223002	chr5:1572222~1594620:-
COAD	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	12.74	3.9e-29	5.65e-22	0.72	0.62	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	12.74	3.9e-29	5.65e-22	0.72	0.62	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
COAD	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	12.73	4.13e-29	5.96e-22	0.71	0.62	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
COAD	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	12.73	4.22e-29	6.08e-22	1.27	0.62	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
COAD	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	12.72	4.31e-29	6.22e-22	0.84	0.62	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-12.72	4.43e-29	6.39e-22	-0.88	-0.62	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
COAD	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	12.71	4.69e-29	6.75e-22	0.77	0.62	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
COAD	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	12.71	4.82e-29	6.93e-22	0.71	0.62	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-12.71	4.87e-29	7e-22	-0.94	-0.62	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.716	rs1441058	ENSG00000224976.2	PARP4P2	12.7	5.03e-29	7.21e-22	0.69	0.62	Obesity-related traits;	chr13:24516275	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.716	rs9553331	ENSG00000224976.2	PARP4P2	12.7	5.32e-29	7.61e-22	0.68	0.62	Obesity-related traits;	chr13:24516030	chr13:19349137~19407962:+
COAD	trans	rs116095464	0.558	rs7708515	ENSG00000185986.11	SDHAP3	12.7	5.37e-29	7.67e-22	0.96	0.62	Breast cancer;	chr5:234874	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	12.69	5.45e-29	7.78e-22	0.88	0.62	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-12.69	5.52e-29	7.88e-22	-0.93	-0.62	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	12.69	5.55e-29	7.91e-22	0.77	0.62	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	12.69	5.55e-29	7.91e-22	0.77	0.62	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
COAD	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	12.69	5.58e-29	7.95e-22	1.21	0.62	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
COAD	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	12.69	5.61e-29	7.98e-22	0.73	0.62	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
COAD	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	12.69	5.61e-29	7.98e-22	0.73	0.62	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
COAD	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	12.69	5.61e-29	7.98e-22	0.73	0.62	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
COAD	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	12.69	5.82e-29	8.25e-22	1.27	0.62	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	12.69	5.82e-29	8.25e-22	1.27	0.62	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	12.69	5.82e-29	8.25e-22	1.27	0.62	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	12.69	5.82e-29	8.25e-22	1.27	0.62	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
COAD	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	12.69	5.83e-29	8.26e-22	0.83	0.62	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-12.68	5.88e-29	8.34e-22	-0.94	-0.62	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
COAD	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	12.68	6.09e-29	8.63e-22	0.95	0.62	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
COAD	trans	rs116095464	0.867	rs7726582	ENSG00000185986.11	SDHAP3	12.68	6.13e-29	8.67e-22	0.97	0.62	Breast cancer;	chr5:215234	chr5:1572222~1594620:-
COAD	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	12.68	6.19e-29	8.75e-22	1.03	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-12.67	6.41e-29	9.04e-22	-0.69	-0.62	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.51	rs10057501	ENSG00000185986.11	SDHAP3	12.67	6.58e-29	9.28e-22	0.99	0.62	Breast cancer;	chr5:239430	chr5:1572222~1594620:-
COAD	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-12.66	6.91e-29	9.73e-22	-0.82	-0.62	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
COAD	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	12.66	6.97e-29	9.82e-22	0.95	0.62	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
COAD	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-12.66	7.02e-29	9.88e-22	-0.82	-0.62	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-12.66	7.27e-29	1.02e-21	-0.93	-0.62	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-12.66	7.27e-29	1.02e-21	-0.93	-0.62	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-12.65	7.82e-29	1.09e-21	-0.96	-0.62	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
COAD	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-12.65	7.9e-29	1.11e-21	-0.82	-0.62	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-12.65	7.91e-29	1.11e-21	-0.97	-0.62	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	12.64	8.36e-29	1.17e-21	0.64	0.62	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
COAD	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	12.63	8.69e-29	1.21e-21	0.72	0.62	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
COAD	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	12.63	8.92e-29	1.24e-21	0.73	0.62	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
COAD	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	12.63	9.01e-29	1.26e-21	0.76	0.62	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
COAD	trans	rs116095464	0.558	rs113796397	ENSG00000185986.11	SDHAP3	12.63	9.17e-29	1.28e-21	0.99	0.62	Breast cancer;	chr5:246388	chr5:1572222~1594620:-
COAD	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	12.62	9.42e-29	1.31e-21	0.71	0.62	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
COAD	trans	rs116095464	0.558	rs7703803	ENSG00000185986.11	SDHAP3	12.62	9.47e-29	1.32e-21	0.99	0.62	Breast cancer;	chr5:292196	chr5:1572222~1594620:-
COAD	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	12.62	9.55e-29	1.33e-21	1.38	0.62	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	12.62	9.55e-29	1.33e-21	1.38	0.62	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	12.62	9.55e-29	1.33e-21	1.38	0.62	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	12.62	9.55e-29	1.33e-21	1.38	0.62	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	12.62	9.55e-29	1.33e-21	1.38	0.62	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
COAD	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-12.62	9.73e-29	1.35e-21	-0.82	-0.62	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
COAD	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	12.62	9.87e-29	1.37e-21	1.24	0.62	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
COAD	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-12.62	9.88e-29	1.37e-21	-0.7	-0.62	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
COAD	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	12.62	9.92e-29	1.37e-21	0.91	0.62	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs10475136	ENSG00000185986.11	SDHAP3	12.61	1.04e-28	1.44e-21	0.96	0.62	Breast cancer;	chr5:232681	chr5:1572222~1594620:-
COAD	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	12.61	1.1e-28	1.51e-21	0.71	0.62	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-12.6	1.17e-28	1.62e-21	-0.92	-0.62	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	12.59	1.24e-28	1.71e-21	0.72	0.62	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
COAD	trans	rs1816752	0.692	rs6490944	ENSG00000224976.2	PARP4P2	12.59	1.28e-28	1.77e-21	0.68	0.62	Obesity-related traits;	chr13:24513866	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-12.58	1.32e-28	1.81e-21	-0.89	-0.62	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.51	rs73016876	ENSG00000185986.11	SDHAP3	12.58	1.33e-28	1.83e-21	1.02	0.62	Breast cancer;	chr5:244360	chr5:1572222~1594620:-
COAD	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	12.58	1.35e-28	1.86e-21	0.77	0.62	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	12.58	1.35e-28	1.86e-21	0.77	0.62	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
COAD	trans	rs1816752	0.646	rs9511309	ENSG00000224976.2	PARP4P2	12.58	1.39e-28	1.9e-21	0.68	0.62	Obesity-related traits;	chr13:24515435	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-12.57	1.39e-28	1.91e-21	-0.89	-0.62	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-12.57	1.42e-28	1.94e-21	-0.93	-0.62	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-12.57	1.44e-28	1.97e-21	-0.95	-0.62	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
COAD	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	12.57	1.49e-28	2.03e-21	1.31	0.62	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
COAD	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-12.56	1.54e-28	2.11e-21	-0.83	-0.62	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
COAD	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	12.56	1.55e-28	2.11e-21	0.7	0.62	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	12.55	1.68e-28	2.28e-21	0.87	0.62	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	12.55	1.7e-28	2.31e-21	0.76	0.62	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
COAD	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-12.54	1.84e-28	2.5e-21	-0.95	-0.62	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
COAD	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	12.54	1.9e-28	2.58e-21	0.7	0.62	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
COAD	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-12.53	1.9e-28	2.59e-21	-0.96	-0.62	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.614	rs4371799	ENSG00000185986.11	SDHAP3	12.52	2.06e-28	2.79e-21	0.94	0.62	Breast cancer;	chr5:268077	chr5:1572222~1594620:-
COAD	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	12.51	2.24e-28	3.03e-21	0.81	0.62	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
COAD	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-12.51	2.28e-28	3.08e-21	-0.73	-0.62	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
COAD	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-12.51	2.35e-28	3.17e-21	-0.96	-0.62	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-12.51	2.39e-28	3.22e-21	-0.96	-0.62	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-12.5	2.42e-28	3.25e-21	-0.63	-0.62	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
COAD	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	12.5	2.59e-28	3.48e-21	0.93	0.61	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	12.5	2.59e-28	3.48e-21	0.93	0.61	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	12.49	2.62e-28	3.51e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	12.49	2.64e-28	3.54e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	12.49	2.64e-28	3.54e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	12.49	2.71e-28	3.62e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	12.48	2.86e-28	3.82e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	12.48	2.86e-28	3.82e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	12.48	2.86e-28	3.82e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	12.48	2.86e-28	3.82e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
COAD	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-12.48	2.9e-28	3.87e-21	-0.91	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
COAD	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	12.48	2.98e-28	3.97e-21	0.75	0.61	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
COAD	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	12.48	3.01e-28	4.01e-21	0.64	0.61	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
COAD	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-12.47	3.04e-28	4.05e-21	-0.8	-0.61	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
COAD	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	12.47	3.07e-28	4.08e-21	0.64	0.61	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
COAD	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	12.47	3.15e-28	4.19e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	12.46	3.32e-28	4.41e-21	0.95	0.61	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	12.46	3.35e-28	4.45e-21	0.98	0.61	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
COAD	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-12.46	3.39e-28	4.5e-21	-0.92	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
COAD	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-12.45	3.58e-28	4.75e-21	-0.75	-0.61	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	12.45	3.6e-28	4.78e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
COAD	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-12.45	3.6e-28	4.78e-21	-0.66	-0.61	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
COAD	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	12.45	3.71e-28	4.91e-21	1.38	0.61	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	12.45	3.71e-28	4.91e-21	1.38	0.61	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	12.45	3.71e-28	4.91e-21	1.38	0.61	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	12.45	3.71e-28	4.91e-21	1.38	0.61	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
COAD	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	12.45	3.78e-28	4.99e-21	0.72	0.61	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
COAD	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	12.45	3.81e-28	5.02e-21	0.82	0.61	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	12.45	3.81e-28	5.02e-21	0.82	0.61	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
COAD	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	12.45	3.81e-28	5.03e-21	0.79	0.61	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
COAD	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	12.44	3.89e-28	5.13e-21	1.2	0.61	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
COAD	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	12.44	3.96e-28	5.22e-21	0.76	0.61	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
COAD	trans	rs116095464	0.558	rs55664502	ENSG00000185986.11	SDHAP3	12.44	4.09e-28	5.38e-21	0.93	0.61	Breast cancer;	chr5:270370	chr5:1572222~1594620:-
COAD	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	12.44	4.1e-28	5.4e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	12.44	4.1e-28	5.4e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	12.44	4.1e-28	5.4e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	12.44	4.1e-28	5.4e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
COAD	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	12.44	4.15e-28	5.45e-21	0.79	0.61	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
COAD	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	12.44	4.15e-28	5.45e-21	0.79	0.61	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
COAD	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	12.43	4.38e-28	5.74e-21	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	12.43	4.39e-28	5.74e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
COAD	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	12.42	4.57e-28	5.97e-21	0.69	0.61	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
COAD	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-12.42	4.66e-28	6.08e-21	-0.66	-0.61	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
COAD	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	12.42	4.66e-28	6.08e-21	0.89	0.61	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-12.42	4.78e-28	6.23e-21	-0.66	-0.61	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
COAD	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	12.41	5.04e-28	6.56e-21	0.69	0.61	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	12.41	5.09e-28	6.62e-21	0.94	0.61	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	12.41	5.09e-28	6.62e-21	0.94	0.61	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
COAD	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	12.4	5.45e-28	7.04e-21	0.79	0.61	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
COAD	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-12.4	5.66e-28	7.32e-21	-1.11	-0.61	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
COAD	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	12.39	5.86e-28	7.57e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
COAD	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-12.39	6.02e-28	7.77e-21	-0.83	-0.61	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
COAD	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-12.39	6.03e-28	7.78e-21	-0.7	-0.61	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	12.39	6.04e-28	7.79e-21	0.86	0.61	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
COAD	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	12.39	6.14e-28	7.91e-21	0.68	0.61	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
COAD	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	12.38	6.15e-28	7.92e-21	0.68	0.61	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
COAD	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	12.38	6.42e-28	8.26e-21	1.31	0.61	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	12.38	6.42e-28	8.26e-21	1.31	0.61	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	12.38	6.56e-28	8.43e-21	0.94	0.61	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
COAD	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-12.37	6.66e-28	8.55e-21	-0.76	-0.61	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	12.37	6.74e-28	8.65e-21	0.75	0.61	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
COAD	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	12.37	6.91e-28	8.86e-21	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-12.37	6.96e-28	8.93e-21	-0.88	-0.61	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
COAD	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	12.37	7.08e-28	9.07e-21	0.94	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
COAD	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	12.37	7.08e-28	9.07e-21	0.94	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	12.37	7.08e-28	9.07e-21	0.94	0.61	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	12.37	7.08e-28	9.07e-21	0.94	0.61	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	12.37	7.08e-28	9.07e-21	0.94	0.61	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-12.37	7.17e-28	9.17e-21	-0.66	-0.61	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
COAD	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	12.36	7.66e-28	9.78e-21	0.68	0.61	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
COAD	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	12.35	7.86e-28	1e-20	0.67	0.61	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
COAD	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	12.35	8.29e-28	1.06e-20	0.89	0.61	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-12.34	8.61e-28	1.1e-20	-0.92	-0.61	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-12.34	8.61e-28	1.1e-20	-0.92	-0.61	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
COAD	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	12.34	8.96e-28	1.14e-20	0.91	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	12.33	9.25e-28	1.17e-20	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
COAD	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	12.33	9.32e-28	1.18e-20	0.92	0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
COAD	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	12.32	9.9e-28	1.25e-20	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	12.32	9.9e-28	1.25e-20	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
COAD	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	12.32	1.03e-27	1.3e-20	1.48	0.61	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
COAD	trans	rs116095464	0.614	rs28736753	ENSG00000185986.11	SDHAP3	12.32	1.04e-27	1.31e-20	0.97	0.61	Breast cancer;	chr5:273966	chr5:1572222~1594620:-
COAD	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-12.32	1.04e-27	1.31e-20	-0.9	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
COAD	trans	rs116095464	0.51	rs7723883	ENSG00000185986.11	SDHAP3	12.32	1.06e-27	1.33e-20	0.93	0.61	Breast cancer;	chr5:270683	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-12.31	1.12e-27	1.41e-20	-0.93	-0.61	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
COAD	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	12.31	1.13e-27	1.42e-20	0.93	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	12.31	1.13e-27	1.42e-20	0.93	0.61	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-12.3	1.18e-27	1.48e-20	-0.94	-0.61	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.716	rs9553330	ENSG00000224976.2	PARP4P2	12.3	1.22e-27	1.53e-20	0.68	0.61	Obesity-related traits;	chr13:24516018	chr13:19349137~19407962:+
COAD	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	12.29	1.31e-27	1.64e-20	0.84	0.61	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-12.28	1.38e-27	1.72e-20	-0.94	-0.61	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	12.28	1.38e-27	1.73e-20	0.82	0.61	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
COAD	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	12.28	1.44e-27	1.8e-20	0.85	0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
COAD	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	12.27	1.53e-27	1.91e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
COAD	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	12.27	1.55e-27	1.93e-20	0.84	0.61	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
COAD	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	12.27	1.56e-27	1.94e-20	0.65	0.61	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
COAD	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	12.26	1.58e-27	1.96e-20	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
COAD	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	12.25	1.76e-27	2.18e-20	1.48	0.61	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	12.25	1.76e-27	2.18e-20	1.48	0.61	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
COAD	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-12.24	1.97e-27	2.42e-20	-0.87	-0.61	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-12.23	2.03e-27	2.49e-20	-0.65	-0.61	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
COAD	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-12.22	2.16e-27	2.66e-20	-0.8	-0.61	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
COAD	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	12.22	2.2e-27	2.71e-20	0.68	0.61	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
COAD	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-12.22	2.25e-27	2.76e-20	-0.87	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
COAD	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	12.2	2.53e-27	3.1e-20	1.37	0.61	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
COAD	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	12.2	2.53e-27	3.1e-20	1.37	0.61	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
COAD	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	12.2	2.53e-27	3.1e-20	1.37	0.61	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
COAD	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-12.2	2.54e-27	3.11e-20	-0.92	-0.61	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	12.2	2.6e-27	3.18e-20	0.74	0.61	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
COAD	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-12.19	2.7e-27	3.3e-20	-0.66	-0.61	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
COAD	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	12.19	2.83e-27	3.45e-20	0.84	0.61	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	12.19	2.88e-27	3.51e-20	0.89	0.61	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	12.19	2.88e-27	3.51e-20	0.89	0.61	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
COAD	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	12.18	2.93e-27	3.56e-20	1.13	0.61	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
COAD	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-12.18	2.99e-27	3.64e-20	-0.93	-0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
COAD	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-12.17	3.21e-27	3.9e-20	-0.81	-0.6	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
COAD	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	12.17	3.23e-27	3.93e-20	1.37	0.6	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
COAD	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-12.17	3.28e-27	3.98e-20	-0.81	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	12.16	3.46e-27	4.2e-20	0.92	0.6	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	12.16	3.46e-27	4.2e-20	0.74	0.6	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	12.15	3.72e-27	4.5e-20	0.92	0.6	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
COAD	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	12.15	3.72e-27	4.5e-20	0.92	0.6	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
COAD	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	12.15	3.72e-27	4.5e-20	0.92	0.6	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	12.15	3.78e-27	4.57e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	12.15	3.84e-27	4.64e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
COAD	trans	rs116095464	0.558	rs28558836	ENSG00000185986.11	SDHAP3	12.14	3.99e-27	4.82e-20	0.93	0.6	Breast cancer;	chr5:285633	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-12.14	4.05e-27	4.9e-20	-0.89	-0.6	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	12.14	4.16e-27	5.01e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-12.13	4.38e-27	5.26e-20	-0.89	-0.6	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
COAD	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	12.12	4.91e-27	5.88e-20	0.67	0.6	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
COAD	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	12.12	4.91e-27	5.88e-20	1.1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
COAD	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	12.12	4.99e-27	5.98e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
COAD	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	12.11	5.3e-27	6.34e-20	0.9	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
COAD	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	12.1	5.61e-27	6.69e-20	0.83	0.6	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	12.1	5.61e-27	6.69e-20	0.83	0.6	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
COAD	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-12.1	5.61e-27	6.69e-20	-0.65	-0.6	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
COAD	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-12.1	5.64e-27	6.73e-20	-0.93	-0.6	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-12.1	5.74e-27	6.84e-20	-0.75	-0.6	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	12.1	5.78e-27	6.88e-20	0.88	0.6	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
COAD	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	12.09	6.03e-27	7.16e-20	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
COAD	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	12.09	6.17e-27	7.31e-20	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
COAD	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	12.09	6.17e-27	7.31e-20	1.11	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
COAD	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-12.07	7.27e-27	8.57e-20	-0.82	-0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
COAD	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-12.07	7.37e-27	8.68e-20	-0.65	-0.6	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
COAD	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	12.06	7.62e-27	8.97e-20	1.18	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
COAD	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	12.06	7.75e-27	9.11e-20	0.67	0.6	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
COAD	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	12.06	7.78e-27	9.15e-20	0.7	0.6	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
COAD	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	12.06	7.91e-27	9.3e-20	0.83	0.6	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-12.05	8.07e-27	9.48e-20	-0.84	-0.6	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
COAD	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	12.05	8.09e-27	9.5e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	12.05	8.09e-27	9.5e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	12.05	8.22e-27	9.64e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	12.05	8.22e-27	9.64e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	12.05	8.22e-27	9.64e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
COAD	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	12.05	8.39e-27	9.83e-20	1.1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
COAD	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	12.05	8.39e-27	9.83e-20	1.1	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
COAD	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	12.05	8.49e-27	9.95e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	12.05	8.49e-27	9.95e-20	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
COAD	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	12.05	8.51e-27	9.97e-20	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
COAD	trans	rs7121616	0.531	rs12573932	ENSG00000234176.1	HSPA8P1	12.04	9.27e-27	1.08e-19	0.74	0.6	Breast cancer;	chr11:123040995	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.576	rs9665920	ENSG00000234176.1	HSPA8P1	12.04	9.27e-27	1.08e-19	0.74	0.6	Breast cancer;	chr11:123041700	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	12.03	9.49e-27	1.1e-19	0.6	0.6	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
COAD	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	12.03	9.49e-27	1.1e-19	0.6	0.6	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	12.03	9.49e-27	1.1e-19	0.6	0.6	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
COAD	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-12.03	9.69e-27	1.13e-19	-0.81	-0.6	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
COAD	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	12.03	1.01e-26	1.17e-19	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
COAD	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	12.02	1.01e-26	1.17e-19	1.24	0.6	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
COAD	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	12.02	1.03e-26	1.19e-19	0.76	0.6	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
COAD	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-12.02	1.04e-26	1.21e-19	-0.65	-0.6	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
COAD	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	12.02	1.04e-26	1.21e-19	0.69	0.6	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
COAD	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	12.02	1.05e-26	1.21e-19	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
COAD	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	12.02	1.06e-26	1.23e-19	0.7	0.6	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
COAD	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-12.01	1.1e-26	1.28e-19	-0.89	-0.6	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	12	1.2e-26	1.39e-19	0.83	0.6	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	12	1.21e-26	1.4e-19	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
COAD	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-12	1.23e-26	1.42e-19	-0.74	-0.6	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-12	1.25e-26	1.44e-19	-0.88	-0.6	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-12	1.25e-26	1.44e-19	-0.88	-0.6	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	12	1.26e-26	1.45e-19	0.75	0.6	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
COAD	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-11.99	1.31e-26	1.51e-19	-0.88	-0.6	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
COAD	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	11.99	1.37e-26	1.57e-19	0.82	0.6	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
COAD	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-11.98	1.38e-26	1.58e-19	-0.88	-0.6	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
COAD	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	11.98	1.45e-26	1.66e-19	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
COAD	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	11.98	1.45e-26	1.67e-19	1.11	0.6	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
COAD	trans	rs62344088	0.59	rs62329989	ENSG00000185986.11	SDHAP3	11.98	1.47e-26	1.69e-19	0.96	0.6	Asthma (childhood onset);	chr5:300026	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-11.97	1.49e-26	1.71e-19	-0.88	-0.6	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-11.97	1.5e-26	1.72e-19	-0.88	-0.6	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
COAD	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	11.97	1.54e-26	1.76e-19	0.76	0.6	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
COAD	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-11.97	1.55e-26	1.77e-19	-0.89	-0.6	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	11.96	1.62e-26	1.84e-19	0.9	0.6	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
COAD	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	11.96	1.65e-26	1.88e-19	0.7	0.6	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
COAD	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	11.96	1.67e-26	1.9e-19	0.81	0.6	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	11.96	1.68e-26	1.91e-19	0.81	0.6	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	11.96	1.68e-26	1.92e-19	0.83	0.6	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
COAD	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	11.95	1.77e-26	2.01e-19	1.44	0.6	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
COAD	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	11.95	1.85e-26	2.1e-19	0.67	0.6	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
COAD	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	11.94	1.88e-26	2.14e-19	0.92	0.6	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
COAD	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	11.94	1.92e-26	2.18e-19	0.69	0.6	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
COAD	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	11.94	1.97e-26	2.23e-19	0.66	0.6	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
COAD	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-11.93	2.05e-26	2.33e-19	-0.79	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
COAD	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-11.93	2.05e-26	2.33e-19	-0.79	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-11.93	2.06e-26	2.33e-19	-0.95	-0.6	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	11.93	2.17e-26	2.46e-19	0.74	0.6	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
COAD	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	11.93	2.19e-26	2.47e-19	0.66	0.6	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
COAD	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	11.92	2.29e-26	2.58e-19	0.68	0.6	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
COAD	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	11.92	2.31e-26	2.6e-19	0.8	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
COAD	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-11.92	2.34e-26	2.65e-19	-0.68	-0.6	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
COAD	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-11.91	2.39e-26	2.7e-19	-0.89	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
COAD	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	11.91	2.5e-26	2.82e-19	0.87	0.6	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-11.9	2.6e-26	2.92e-19	-0.84	-0.6	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
COAD	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	11.9	2.66e-26	2.99e-19	0.76	0.6	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
COAD	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	11.88	3.02e-26	3.38e-19	0.74	0.6	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
COAD	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-11.88	3.03e-26	3.4e-19	-0.78	-0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
COAD	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	11.88	3.2e-26	3.58e-19	1.23	0.6	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
COAD	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	11.87	3.23e-26	3.62e-19	1.12	0.6	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
COAD	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	11.87	3.36e-26	3.76e-19	0.71	0.6	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
COAD	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	11.86	3.48e-26	3.89e-19	0.74	0.59	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
COAD	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	11.86	3.52e-26	3.93e-19	0.74	0.59	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
COAD	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	11.85	3.84e-26	4.28e-19	0.68	0.59	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
COAD	trans	rs116095464	0.558	rs10079760	ENSG00000185986.11	SDHAP3	11.85	3.84e-26	4.29e-19	0.88	0.59	Breast cancer;	chr5:230663	chr5:1572222~1594620:-
COAD	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	11.85	4.03e-26	4.5e-19	0.6	0.59	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
COAD	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	11.84	4.1e-26	4.57e-19	0.74	0.59	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
COAD	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	11.83	4.47e-26	4.97e-19	0.78	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-11.83	4.53e-26	5.04e-19	-0.95	-0.59	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	11.83	4.61e-26	5.11e-19	0.8	0.59	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	11.83	4.61e-26	5.11e-19	0.8	0.59	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	11.83	4.61e-26	5.11e-19	0.8	0.59	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	11.83	4.61e-26	5.11e-19	0.8	0.59	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
COAD	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	11.82	4.97e-26	5.5e-19	1.08	0.59	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
COAD	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	11.82	4.99e-26	5.52e-19	0.91	0.59	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	11.82	4.99e-26	5.52e-19	0.91	0.59	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	11.81	5.48e-26	6.05e-19	0.82	0.59	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
COAD	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	11.8	5.66e-26	6.24e-19	0.66	0.59	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
COAD	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	11.79	6.15e-26	6.77e-19	1.13	0.59	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	11.79	6.16e-26	6.78e-19	0.83	0.59	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
COAD	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-11.78	6.5e-26	7.14e-19	-0.89	-0.59	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
COAD	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	11.78	6.54e-26	7.18e-19	1.08	0.59	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	11.78	6.78e-26	7.44e-19	1.12	0.59	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	11.78	6.78e-26	7.44e-19	1.12	0.59	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
COAD	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	11.77	7.19e-26	7.87e-19	0.84	0.59	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
COAD	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	11.76	7.67e-26	8.38e-19	0.66	0.59	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
COAD	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	11.75	8.24e-26	8.99e-19	1.16	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	11.75	8.24e-26	8.99e-19	1.16	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
COAD	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	11.75	8.33e-26	9.09e-19	0.68	0.59	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
COAD	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	11.75	8.65e-26	9.43e-19	0.85	0.59	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
COAD	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	11.73	9.8e-26	1.06e-18	0.65	0.59	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
COAD	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	11.73	9.9e-26	1.07e-18	0.75	0.59	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
COAD	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	11.73	9.99e-26	1.08e-18	0.73	0.59	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
COAD	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	11.72	1.03e-25	1.12e-18	0.87	0.59	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-11.72	1.04e-25	1.13e-18	-1.08	-0.59	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
COAD	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	11.7	1.19e-25	1.29e-18	1.13	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
COAD	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-11.7	1.29e-25	1.38e-18	-0.87	-0.59	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-11.7	1.29e-25	1.38e-18	-0.87	-0.59	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-11.7	1.29e-25	1.38e-18	-0.87	-0.59	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
COAD	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	11.7	1.29e-25	1.39e-18	0.8	0.59	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
COAD	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-11.69	1.31e-25	1.4e-18	-0.91	-0.59	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
COAD	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-11.68	1.47e-25	1.58e-18	-0.65	-0.59	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.899	rs2645477	ENSG00000187870.7	RNFT1P3	-11.68	1.49e-25	1.59e-18	-0.65	-0.59	White blood cell count;	chr17:59768263	chr17:20743333~20754501:-
COAD	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	11.67	1.51e-25	1.62e-18	0.8	0.59	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-11.67	1.55e-25	1.66e-18	-0.83	-0.59	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-11.67	1.59e-25	1.7e-18	-0.81	-0.59	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
COAD	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-11.67	1.6e-25	1.71e-18	-0.69	-0.59	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-11.66	1.64e-25	1.75e-18	-0.95	-0.59	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
COAD	trans	rs6477998	1	rs6477998	ENSG00000238072.1	RP11-305M3.2	-11.65	1.76e-25	1.87e-18	-0.77	-0.59	Hematology traits;	chr9:113234969	chr7:129410113~129410370:-
COAD	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-11.65	1.86e-25	1.98e-18	-0.73	-0.59	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
COAD	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	11.64	1.91e-25	2.02e-18	0.86	0.59	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
COAD	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	11.64	1.91e-25	2.02e-18	0.68	0.59	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
COAD	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	11.64	1.95e-25	2.06e-18	0.68	0.59	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
COAD	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	11.64	1.99e-25	2.1e-18	0.86	0.59	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
COAD	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	11.63	2.13e-25	2.25e-18	0.75	0.59	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
COAD	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	11.63	2.15e-25	2.27e-18	0.81	0.59	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	11.63	2.15e-25	2.27e-18	0.81	0.59	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
COAD	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	11.63	2.19e-25	2.3e-18	0.66	0.59	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
COAD	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	11.62	2.36e-25	2.48e-18	0.86	0.59	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
COAD	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	11.61	2.42e-25	2.54e-18	0.88	0.59	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	11.61	2.44e-25	2.57e-18	0.75	0.59	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
COAD	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	11.61	2.45e-25	2.57e-18	1.1	0.59	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	11.61	2.45e-25	2.57e-18	1.1	0.59	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	11.61	2.45e-25	2.57e-18	1.1	0.59	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
COAD	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	11.61	2.51e-25	2.63e-18	0.88	0.59	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	11.61	2.51e-25	2.63e-18	0.88	0.59	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	11.61	2.51e-25	2.63e-18	0.88	0.59	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	11.61	2.51e-25	2.63e-18	0.88	0.59	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	11.61	2.51e-25	2.63e-18	0.88	0.59	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
COAD	trans	rs5022636	0.79	rs10399679	ENSG00000180764.13	PIPSL	11.61	2.54e-25	2.67e-18	0.63	0.59	Gut microbiota (functional units);	chr1:151278361	chr10:93958191~93961540:-
COAD	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	11.6	2.61e-25	2.74e-18	0.75	0.59	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	11.6	2.73e-25	2.86e-18	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
COAD	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	11.59	2.85e-25	2.98e-18	0.86	0.59	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	11.59	2.85e-25	2.98e-18	0.86	0.59	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	11.59	2.85e-25	2.98e-18	0.86	0.59	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
COAD	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	11.58	3.1e-25	3.24e-18	0.68	0.59	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
COAD	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	11.58	3.11e-25	3.24e-18	0.82	0.59	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
COAD	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	11.57	3.26e-25	3.4e-18	0.73	0.59	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
COAD	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	11.57	3.44e-25	3.58e-18	1.26	0.59	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	11.57	3.44e-25	3.58e-18	1.26	0.59	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	11.57	3.44e-25	3.58e-18	1.26	0.59	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
COAD	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	11.56	3.52e-25	3.65e-18	0.76	0.59	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	11.56	3.52e-25	3.65e-18	0.76	0.59	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
COAD	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	11.56	3.52e-25	3.65e-18	0.76	0.59	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
COAD	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	11.56	3.65e-25	3.79e-18	0.8	0.58	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	11.56	3.65e-25	3.79e-18	0.8	0.58	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	11.56	3.65e-25	3.79e-18	0.8	0.58	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	11.56	3.65e-25	3.79e-18	0.8	0.58	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	11.56	3.65e-25	3.79e-18	0.8	0.58	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
COAD	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	11.56	3.66e-25	3.79e-18	1.27	0.58	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
COAD	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	11.56	3.74e-25	3.87e-18	0.67	0.58	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
COAD	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	11.55	3.78e-25	3.91e-18	1.11	0.58	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
COAD	trans	rs116095464	0.558	rs7714335	ENSG00000185986.11	SDHAP3	11.55	3.81e-25	3.95e-18	0.93	0.58	Breast cancer;	chr5:263398	chr5:1572222~1594620:-
COAD	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-11.55	4e-25	4.13e-18	-0.94	-0.58	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
COAD	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-11.55	4.02e-25	4.15e-18	-0.94	-0.58	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
COAD	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	11.54	4.1e-25	4.24e-18	1.11	0.58	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
COAD	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-11.54	4.21e-25	4.35e-18	-0.95	-0.58	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
COAD	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	11.54	4.27e-25	4.41e-18	0.93	0.58	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	11.54	4.27e-25	4.41e-18	0.93	0.58	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
COAD	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	11.54	4.29e-25	4.42e-18	0.67	0.58	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
COAD	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-11.53	4.56e-25	4.7e-18	-1.26	-0.58	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
COAD	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	11.53	4.61e-25	4.75e-18	0.81	0.58	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	11.53	4.61e-25	4.75e-18	0.81	0.58	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-11.52	4.89e-25	5.03e-18	-0.72	-0.58	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
COAD	trans	rs10037055	1	rs10037055	ENSG00000217325.2	PRELID1P1	-11.52	5.05e-25	5.19e-18	-0.7	-0.58	Migraine without aura;	chr5:177264278	chr6:126643488~126644390:+
COAD	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	11.51	5.14e-25	5.28e-18	0.67	0.58	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
COAD	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	11.49	6.27e-25	6.42e-18	1.1	0.58	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
COAD	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	11.48	6.48e-25	6.63e-18	0.74	0.58	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
COAD	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	11.48	6.62e-25	6.77e-18	0.89	0.58	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
COAD	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	11.48	6.89e-25	7.03e-18	1.06	0.58	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
COAD	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	11.47	7.15e-25	7.28e-18	0.81	0.58	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
COAD	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	11.47	7.36e-25	7.48e-18	0.78	0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
COAD	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	11.47	7.42e-25	7.55e-18	0.81	0.58	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
COAD	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	11.46	7.97e-25	8.09e-18	0.74	0.58	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
COAD	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-11.45	8.12e-25	8.24e-18	-0.71	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
COAD	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-11.45	8.67e-25	8.79e-18	-0.71	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
COAD	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	11.45	8.72e-25	8.83e-18	0.8	0.58	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-11.44	9.11e-25	9.22e-18	-0.82	-0.58	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
COAD	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	11.44	9.16e-25	9.26e-18	0.66	0.58	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
COAD	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	11.44	9.38e-25	9.48e-18	0.72	0.58	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	11.41	1.11e-24	1.12e-17	0.74	0.58	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
COAD	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	11.4	1.2e-24	1.2e-17	0.67	0.58	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-11.4	1.21e-24	1.22e-17	-0.67	-0.58	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
COAD	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-11.4	1.23e-24	1.24e-17	-0.65	-0.58	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
COAD	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	11.4	1.28e-24	1.29e-17	0.64	0.58	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
COAD	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	11.39	1.29e-24	1.29e-17	0.84	0.58	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-11.39	1.31e-24	1.32e-17	-1.07	-0.58	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
COAD	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	11.39	1.34e-24	1.34e-17	0.65	0.58	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
COAD	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	11.37	1.51e-24	1.51e-17	0.73	0.58	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
COAD	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	11.37	1.51e-24	1.51e-17	0.73	0.58	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
COAD	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-11.36	1.65e-24	1.65e-17	-0.8	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
COAD	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-11.34	1.97e-24	1.96e-17	-0.64	-0.58	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
COAD	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-11.33	2.06e-24	2.06e-17	-0.71	-0.58	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
COAD	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	11.31	2.42e-24	2.4e-17	0.66	0.58	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	11.31	2.48e-24	2.46e-17	0.66	0.58	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
COAD	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-11.31	2.53e-24	2.51e-17	-0.76	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
COAD	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	11.3	2.63e-24	2.6e-17	0.85	0.58	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
COAD	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-11.3	2.64e-24	2.61e-17	-0.8	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
COAD	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-11.29	2.78e-24	2.75e-17	-0.78	-0.58	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
COAD	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-11.29	2.84e-24	2.8e-17	-0.71	-0.58	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
COAD	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-11.29	2.87e-24	2.83e-17	-0.7	-0.58	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
COAD	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-11.29	2.9e-24	2.85e-17	-0.66	-0.58	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	11.28	3.11e-24	3.05e-17	0.75	0.58	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
COAD	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	11.27	3.3e-24	3.23e-17	0.72	0.58	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
COAD	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	11.27	3.34e-24	3.28e-17	0.72	0.58	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
COAD	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-11.27	3.45e-24	3.37e-17	-0.88	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
COAD	trans	rs941207	0.542	rs11171986	ENSG00000121089.4	NACA3P	-11.26	3.47e-24	3.39e-17	-0.79	-0.57	Platelet count;	chr12:56819043	chr4:164943290~164943937:+
COAD	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	11.25	3.99e-24	3.9e-17	0.91	0.57	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
COAD	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	11.23	4.4e-24	4.28e-17	1.09	0.57	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
COAD	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-11.23	4.58e-24	4.45e-17	-0.72	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
COAD	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-11.23	4.59e-24	4.46e-17	-0.72	-0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
COAD	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	11.23	4.61e-24	4.48e-17	0.63	0.57	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
COAD	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	11.23	4.62e-24	4.49e-17	0.78	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	11.23	4.62e-24	4.49e-17	0.78	0.57	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
COAD	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	11.22	4.71e-24	4.56e-17	0.85	0.57	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	11.22	4.71e-24	4.56e-17	0.85	0.57	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	11.22	4.71e-24	4.56e-17	0.85	0.57	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	11.22	4.71e-24	4.56e-17	0.85	0.57	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
COAD	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-11.22	4.92e-24	4.76e-17	-0.63	-0.57	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
COAD	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	11.2	5.57e-24	5.39e-17	0.73	0.57	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	11.2	5.57e-24	5.39e-17	0.73	0.57	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
COAD	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	11.2	5.57e-24	5.39e-17	0.73	0.57	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
COAD	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	11.19	5.93e-24	5.72e-17	1.05	0.57	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
COAD	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	11.19	5.97e-24	5.75e-17	0.72	0.57	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	11.19	5.97e-24	5.75e-17	0.72	0.57	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	11.19	5.97e-24	5.75e-17	0.72	0.57	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-11.19	6.13e-24	5.91e-17	-0.7	-0.57	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
COAD	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	11.19	6.19e-24	5.96e-17	0.6	0.57	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
COAD	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	11.19	6.19e-24	5.96e-17	0.6	0.57	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
COAD	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	11.19	6.19e-24	5.96e-17	0.6	0.57	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
COAD	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	11.18	6.52e-24	6.26e-17	0.76	0.57	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	11.18	6.67e-24	6.39e-17	0.81	0.57	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
COAD	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-11.17	7.12e-24	6.78e-17	-1.06	-0.57	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
COAD	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-11.16	7.64e-24	7.27e-17	-0.65	-0.57	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
COAD	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	11.15	7.97e-24	7.57e-17	1.01	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
COAD	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-11.15	8e-24	7.6e-17	-1.04	-0.57	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
COAD	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	11.15	8.11e-24	7.7e-17	0.6	0.57	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
COAD	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-11.15	8.37e-24	7.94e-17	-1.01	-0.57	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-11.14	8.87e-24	8.4e-17	-1.05	-0.57	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
COAD	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	11.14	8.98e-24	8.5e-17	0.81	0.57	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
COAD	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	11.14	9e-24	8.52e-17	0.72	0.57	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
COAD	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	11.14	9.16e-24	8.66e-17	0.66	0.57	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
COAD	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	11.13	9.87e-24	9.32e-17	0.74	0.57	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
COAD	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-11.12	1e-23	9.44e-17	-0.71	-0.57	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
COAD	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	11.12	1.03e-23	9.7e-17	0.65	0.57	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
COAD	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-11.11	1.14e-23	1.07e-16	-0.64	-0.57	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
COAD	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-11.1	1.19e-23	1.12e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
COAD	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	11.1	1.21e-23	1.14e-16	0.76	0.57	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
COAD	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-11.09	1.27e-23	1.19e-16	-1.05	-0.57	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-11.09	1.27e-23	1.19e-16	-1.05	-0.57	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
COAD	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	11.09	1.28e-23	1.2e-16	0.77	0.57	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
COAD	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	11.09	1.31e-23	1.22e-16	0.71	0.57	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
COAD	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	11.09	1.31e-23	1.22e-16	0.71	0.57	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
COAD	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	11.08	1.43e-23	1.33e-16	0.88	0.57	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-11.08	1.45e-23	1.34e-16	-0.76	-0.57	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
COAD	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	11.07	1.56e-23	1.44e-16	0.61	0.57	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
COAD	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	11.06	1.61e-23	1.49e-16	1.36	0.57	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
COAD	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-11.06	1.63e-23	1.51e-16	-0.7	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
COAD	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	11.06	1.67e-23	1.54e-16	0.66	0.57	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
COAD	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	11.06	1.69e-23	1.56e-16	1.23	0.57	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
COAD	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-11.05	1.8e-23	1.65e-16	-0.62	-0.57	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
COAD	trans	rs7554547	0.716	rs34954501	ENSG00000261819.1	RP11-680G24.4	11.04	1.89e-23	1.73e-16	0.73	0.57	Nonsyndromic cleft lip with cleft palate;	chr1:11878146	chr16:14988259~14990160:-
COAD	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	11.04	1.92e-23	1.76e-16	0.72	0.57	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
COAD	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-11.04	1.97e-23	1.8e-16	-0.7	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
COAD	trans	rs6708331	0.564	rs4632370	ENSG00000232654.1	FAM136BP	11.03	2.01e-23	1.84e-16	0.69	0.57	Obesity-related traits;	chr2:70149693	chr6:3045384~3045800:+
COAD	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	11.03	2.07e-23	1.9e-16	1.23	0.57	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
COAD	trans	rs6708331	0.54	rs6546576	ENSG00000232654.1	FAM136BP	11.02	2.14e-23	1.95e-16	0.69	0.57	Obesity-related traits;	chr2:70174356	chr6:3045384~3045800:+
COAD	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	11.01	2.29e-23	2.09e-16	0.62	0.57	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
COAD	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	11.01	2.36e-23	2.15e-16	0.66	0.57	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	11.01	2.36e-23	2.15e-16	0.66	0.57	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
COAD	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-11	2.53e-23	2.3e-16	-0.71	-0.57	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-11	2.53e-23	2.3e-16	-0.71	-0.57	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-11	2.57e-23	2.32e-16	-0.7	-0.57	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
COAD	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-11	2.62e-23	2.36e-16	-1.04	-0.57	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-11	2.62e-23	2.36e-16	-1.04	-0.57	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-11	2.62e-23	2.36e-16	-1.04	-0.57	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
COAD	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-11	2.62e-23	2.36e-16	-0.7	-0.57	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-11	2.62e-23	2.36e-16	-0.7	-0.57	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-11	2.62e-23	2.36e-16	-0.7	-0.57	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
COAD	trans	rs6708331	0.517	rs13017427	ENSG00000232654.1	FAM136BP	10.99	2.75e-23	2.48e-16	0.69	0.57	Obesity-related traits;	chr2:70154399	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.54	rs9677885	ENSG00000232654.1	FAM136BP	10.99	2.75e-23	2.48e-16	0.69	0.57	Obesity-related traits;	chr2:70154687	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.54	rs9679269	ENSG00000232654.1	FAM136BP	10.99	2.75e-23	2.48e-16	0.69	0.57	Obesity-related traits;	chr2:70154696	chr6:3045384~3045800:+
COAD	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	10.99	2.81e-23	2.52e-16	0.84	0.57	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
COAD	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-10.99	2.81e-23	2.53e-16	-0.79	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
COAD	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	10.98	3.01e-23	2.7e-16	1.02	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
COAD	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	10.98	3.05e-23	2.73e-16	1.23	0.56	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	10.98	3.05e-23	2.73e-16	1.23	0.56	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
COAD	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	10.98	3.05e-23	2.74e-16	0.74	0.56	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
COAD	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	10.97	3.1e-23	2.78e-16	0.89	0.56	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
COAD	trans	rs6708331	0.517	rs6546572	ENSG00000232654.1	FAM136BP	10.97	3.12e-23	2.8e-16	0.68	0.56	Obesity-related traits;	chr2:70146510	chr6:3045384~3045800:+
COAD	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	10.97	3.15e-23	2.82e-16	0.88	0.56	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-10.97	3.18e-23	2.85e-16	-1.06	-0.56	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
COAD	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	10.96	3.35e-23	3e-16	0.8	0.56	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	10.96	3.44e-23	3.07e-16	0.76	0.56	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	10.96	3.44e-23	3.07e-16	0.76	0.56	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	10.96	3.46e-23	3.09e-16	0.74	0.56	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
COAD	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	10.96	3.56e-23	3.18e-16	0.77	0.56	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	10.95	3.81e-23	3.39e-16	0.74	0.56	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	10.95	3.81e-23	3.39e-16	0.74	0.56	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	10.94	3.95e-23	3.51e-16	0.68	0.56	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-10.94	4.07e-23	3.61e-16	-0.69	-0.56	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-10.94	4.07e-23	3.61e-16	-0.69	-0.56	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-10.94	4.07e-23	3.61e-16	-0.69	-0.56	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-10.94	4.07e-23	3.61e-16	-0.69	-0.56	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-10.94	4.07e-23	3.61e-16	-0.69	-0.56	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-10.94	4.09e-23	3.63e-16	-0.69	-0.56	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
COAD	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	10.94	4.14e-23	3.66e-16	0.76	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	10.93	4.2e-23	3.71e-16	0.77	0.56	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
COAD	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-10.93	4.45e-23	3.93e-16	-0.86	-0.56	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-10.92	4.56e-23	4.02e-16	-0.69	-0.56	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
COAD	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	10.92	4.62e-23	4.07e-16	0.73	0.56	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
COAD	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	10.92	4.7e-23	4.14e-16	1.02	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
COAD	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	10.92	4.76e-23	4.19e-16	0.72	0.56	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-10.91	4.88e-23	4.29e-16	-0.7	-0.56	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
COAD	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-10.91	4.94e-23	4.34e-16	-0.69	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
COAD	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-10.91	5.05e-23	4.4e-16	-0.74	-0.56	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	10.91	5.05e-23	4.4e-16	0.74	0.56	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	10.91	5.08e-23	4.43e-16	0.74	0.56	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-10.91	5.2e-23	4.53e-16	-0.69	-0.56	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-10.91	5.2e-23	4.53e-16	-0.69	-0.56	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-10.91	5.2e-23	4.53e-16	-0.69	-0.56	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
COAD	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	10.9	5.35e-23	4.66e-16	0.66	0.56	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
COAD	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-10.9	5.41e-23	4.71e-16	-0.7	-0.56	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-10.9	5.41e-23	4.71e-16	-0.7	-0.56	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-10.9	5.43e-23	4.72e-16	-0.7	-0.56	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-10.9	5.43e-23	4.73e-16	-0.7	-0.56	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-10.9	5.43e-23	4.73e-16	-0.7	-0.56	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-10.9	5.52e-23	4.8e-16	-0.7	-0.56	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-10.9	5.54e-23	4.81e-16	-0.7	-0.56	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
COAD	trans	rs3749237	0.964	rs2352975	ENSG00000197582.5	GPX1P1	10.9	5.61e-23	4.87e-16	0.73	0.56	Resting heart rate;	chr3:49854452	chrX:13378735~13379340:-
COAD	trans	rs6708331	0.517	rs6546570	ENSG00000232654.1	FAM136BP	10.89	5.83e-23	5.06e-16	0.69	0.56	Obesity-related traits;	chr2:70122901	chr6:3045384~3045800:+
COAD	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	10.89	6.03e-23	5.24e-16	0.88	0.56	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-10.89	6.06e-23	5.26e-16	-0.7	-0.56	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-10.89	6.06e-23	5.26e-16	-0.7	-0.56	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
COAD	trans	rs10037055	1	rs6886255	ENSG00000217325.2	PRELID1P1	10.88	6.15e-23	5.33e-16	0.65	0.56	Migraine without aura;	chr5:177291360	chr6:126643488~126644390:+
COAD	trans	rs7554547	0.838	rs885770	ENSG00000261819.1	RP11-680G24.4	10.88	6.15e-23	5.33e-16	0.73	0.56	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr16:14988259~14990160:-
COAD	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	10.88	6.33e-23	5.48e-16	1.02	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
COAD	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	10.87	6.61e-23	5.72e-16	0.74	0.56	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
COAD	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	10.87	6.7e-23	5.8e-16	0.59	0.56	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
COAD	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	10.86	7.11e-23	6.14e-16	0.76	0.56	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
COAD	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	10.86	7.47e-23	6.45e-16	0.65	0.56	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
COAD	trans	rs6708331	0.517	rs6743372	ENSG00000232654.1	FAM136BP	10.86	7.54e-23	6.51e-16	0.69	0.56	Obesity-related traits;	chr2:70125508	chr6:3045384~3045800:+
COAD	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-10.85	7.97e-23	6.87e-16	-0.69	-0.56	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-10.85	8.04e-23	6.93e-16	-0.69	-0.56	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
COAD	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	10.85	8.19e-23	7.05e-16	0.68	0.56	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
COAD	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	10.84	8.72e-23	7.5e-16	0.79	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
COAD	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	10.84	8.79e-23	7.56e-16	0.75	0.56	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	10.83	8.91e-23	7.66e-16	0.76	0.56	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
COAD	trans	rs116095464	0.558	rs12173015	ENSG00000185986.11	SDHAP3	-10.83	9.51e-23	8.17e-16	-0.8	-0.56	Breast cancer;	chr5:269852	chr5:1572222~1594620:-
COAD	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	10.82	9.65e-23	8.28e-16	0.98	0.56	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
COAD	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	10.82	9.84e-23	8.45e-16	0.73	0.56	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-10.82	9.99e-23	8.57e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-10.82	9.99e-23	8.57e-16	-0.7	-0.56	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-10.82	9.99e-23	8.57e-16	-0.7	-0.56	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-10.82	1.02e-22	8.75e-16	-0.7	-0.56	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
COAD	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	10.81	1.05e-22	8.98e-16	0.76	0.56	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	10.81	1.05e-22	8.98e-16	0.76	0.56	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
COAD	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	10.81	1.09e-22	9.32e-16	1.01	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
COAD	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	10.8	1.11e-22	9.51e-16	0.74	0.56	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	10.79	1.21e-22	1.03e-15	0.74	0.56	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	10.79	1.24e-22	1.06e-15	0.73	0.56	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
COAD	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	10.78	1.29e-22	1.1e-15	0.84	0.56	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	10.78	1.29e-22	1.1e-15	0.84	0.56	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	10.78	1.29e-22	1.1e-15	0.84	0.56	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
COAD	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	10.78	1.3e-22	1.11e-15	0.73	0.56	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	10.78	1.3e-22	1.11e-15	0.73	0.56	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
COAD	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	10.78	1.37e-22	1.16e-15	1.06	0.56	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
COAD	trans	rs12709013	0.597	rs1657171	ENSG00000233719.3	GOT2P3	10.75	1.67e-22	1.42e-15	0.73	0.56	Blood metabolite ratios;	chr16:58752083	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.636	rs1646285	ENSG00000233719.3	GOT2P3	10.75	1.67e-22	1.42e-15	0.73	0.56	Blood metabolite ratios;	chr16:58752102	chr12:9641802~9643007:+
COAD	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	10.75	1.68e-22	1.42e-15	0.61	0.56	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
COAD	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	10.73	1.93e-22	1.63e-15	0.75	0.56	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	10.73	1.96e-22	1.65e-15	0.75	0.56	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
COAD	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-10.73	1.97e-22	1.66e-15	-0.97	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
COAD	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-10.72	2.07e-22	1.74e-15	-0.73	-0.56	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
COAD	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	10.72	2.09e-22	1.76e-15	0.75	0.56	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	10.72	2.09e-22	1.76e-15	0.75	0.56	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	10.72	2.09e-22	1.76e-15	0.75	0.56	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	10.72	2.09e-22	1.76e-15	0.75	0.56	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
COAD	trans	rs6708331	0.517	rs11692018	ENSG00000232654.1	FAM136BP	10.72	2.13e-22	1.79e-15	0.68	0.56	Obesity-related traits;	chr2:70142022	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs2028879	ENSG00000232654.1	FAM136BP	10.71	2.26e-22	1.9e-15	0.68	0.56	Obesity-related traits;	chr2:70127505	chr6:3045384~3045800:+
COAD	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	10.7	2.42e-22	2.03e-15	0.75	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
COAD	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	10.7	2.44e-22	2.05e-15	0.96	0.56	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
COAD	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	10.68	2.93e-22	2.45e-15	0.68	0.55	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
COAD	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	10.67	3.07e-22	2.56e-15	0.74	0.55	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	10.67	3.07e-22	2.56e-15	0.74	0.55	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	10.67	3.07e-22	2.56e-15	0.74	0.55	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	10.67	3.07e-22	2.56e-15	0.74	0.55	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	10.66	3.25e-22	2.71e-15	0.74	0.55	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	10.66	3.25e-22	2.71e-15	0.74	0.55	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
COAD	trans	rs6708331	0.517	rs12999042	ENSG00000232654.1	FAM136BP	10.66	3.4e-22	2.83e-15	0.68	0.55	Obesity-related traits;	chr2:70139679	chr6:3045384~3045800:+
COAD	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-10.65	3.45e-22	2.87e-15	-0.76	-0.55	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
COAD	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	10.65	3.66e-22	3.04e-15	0.72	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
COAD	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	10.64	3.76e-22	3.12e-15	0.65	0.55	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
COAD	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	10.64	3.92e-22	3.25e-15	0.73	0.55	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	10.64	3.94e-22	3.27e-15	0.71	0.55	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
COAD	trans	rs6708331	0.517	rs7579922	ENSG00000232654.1	FAM136BP	10.62	4.39e-22	3.64e-15	0.67	0.55	Obesity-related traits;	chr2:70134781	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs9989876	ENSG00000232654.1	FAM136BP	10.61	4.66e-22	3.85e-15	0.68	0.55	Obesity-related traits;	chr2:70115578	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs10496178	ENSG00000232654.1	FAM136BP	10.61	4.66e-22	3.85e-15	0.68	0.55	Obesity-related traits;	chr2:70115683	chr6:3045384~3045800:+
COAD	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	10.61	4.68e-22	3.87e-15	0.98	0.55	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
COAD	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	10.61	4.72e-22	3.9e-15	0.62	0.55	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
COAD	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-10.61	4.88e-22	4.03e-15	-1.09	-0.55	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	10.6	4.98e-22	4.11e-15	0.89	0.55	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	10.59	5.62e-22	4.63e-15	1.22	0.55	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	10.58	6.1e-22	5.02e-15	1.23	0.55	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
COAD	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	10.54	7.88e-22	6.45e-15	0.57	0.55	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
COAD	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	10.53	8.79e-22	7.19e-15	0.71	0.55	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	10.53	8.79e-22	7.19e-15	0.71	0.55	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
COAD	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	10.52	8.99e-22	7.35e-15	0.97	0.55	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
COAD	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	10.5	1.04e-21	8.51e-15	0.87	0.55	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	10.5	1.04e-21	8.51e-15	0.87	0.55	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-10.49	1.13e-21	9.2e-15	-0.74	-0.55	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
COAD	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	10.49	1.14e-21	9.29e-15	1.11	0.55	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
COAD	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	10.49	1.2e-21	9.73e-15	0.67	0.55	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
COAD	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	10.48	1.21e-21	9.84e-15	0.75	0.55	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	10.48	1.22e-21	9.94e-15	0.75	0.55	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
COAD	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-10.48	1.23e-21	1e-14	-0.67	-0.55	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-10.48	1.23e-21	1e-14	-0.67	-0.55	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-10.47	1.33e-21	1.08e-14	-0.67	-0.55	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
COAD	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	10.47	1.34e-21	1.09e-14	0.66	0.55	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
COAD	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	10.47	1.37e-21	1.11e-14	0.95	0.55	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
COAD	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-10.46	1.46e-21	1.18e-14	-0.83	-0.55	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
COAD	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	10.46	1.49e-21	1.21e-14	0.75	0.55	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	10.46	1.49e-21	1.21e-14	0.75	0.55	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	10.46	1.49e-21	1.21e-14	0.75	0.55	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
COAD	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	10.44	1.64e-21	1.33e-14	0.89	0.55	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
COAD	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	10.44	1.74e-21	1.41e-14	0.91	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	10.42	1.89e-21	1.53e-14	0.76	0.55	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
COAD	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	10.42	1.96e-21	1.58e-14	1.01	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
COAD	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	10.42	2.01e-21	1.62e-14	0.73	0.54	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
COAD	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	10.41	2.05e-21	1.66e-14	1.01	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
COAD	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	10.41	2.05e-21	1.66e-14	0.59	0.54	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
COAD	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-10.41	2.12e-21	1.71e-14	-0.68	-0.54	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
COAD	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	10.41	2.15e-21	1.73e-14	0.75	0.54	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	10.41	2.15e-21	1.73e-14	0.75	0.54	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
COAD	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-10.4	2.24e-21	1.8e-14	-0.68	-0.54	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
COAD	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	10.4	2.31e-21	1.86e-14	0.88	0.54	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
COAD	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-10.39	2.43e-21	1.96e-14	-0.67	-0.54	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
COAD	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	10.39	2.45e-21	1.97e-14	0.73	0.54	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-10.38	2.57e-21	2.06e-14	-0.67	-0.54	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
COAD	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	10.36	2.97e-21	2.38e-14	0.66	0.54	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-10.36	3.09e-21	2.47e-14	-0.67	-0.54	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-10.36	3.13e-21	2.5e-14	-0.67	-0.54	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
COAD	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	10.35	3.27e-21	2.62e-14	0.89	0.54	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
COAD	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	10.35	3.29e-21	2.63e-14	0.73	0.54	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	10.35	3.29e-21	2.63e-14	0.73	0.54	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	10.35	3.29e-21	2.63e-14	0.73	0.54	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	10.32	4.05e-21	3.23e-14	0.73	0.54	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
COAD	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	10.32	4.05e-21	3.23e-14	0.73	0.54	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
COAD	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	10.31	4.32e-21	3.44e-14	0.56	0.54	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
COAD	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	10.31	4.32e-21	3.44e-14	0.56	0.54	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
COAD	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-10.31	4.39e-21	3.49e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
COAD	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	10.31	4.42e-21	3.51e-14	0.92	0.54	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-10.3	4.71e-21	3.74e-14	-0.57	-0.54	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-10.3	4.71e-21	3.74e-14	-0.57	-0.54	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
COAD	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-10.3	4.77e-21	3.78e-14	-0.56	-0.54	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
COAD	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	10.29	5.05e-21	4e-14	0.62	0.54	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
COAD	trans	rs10242455	0.702	rs58348977	ENSG00000228834.1	RP11-249L21.4	10.28	5.39e-21	4.27e-14	1.24	0.54	Blood metabolite levels;	chr7:99590391	chr6:108907615~108907873:-
COAD	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
COAD	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
COAD	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-10.28	5.56e-21	4.39e-14	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
COAD	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-10.25	6.71e-21	5.29e-14	-0.67	-0.54	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
COAD	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-10.25	6.73e-21	5.31e-14	-0.68	-0.54	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
COAD	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	10.24	7.19e-21	5.67e-14	0.71	0.54	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
COAD	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	10.23	8.08e-21	6.35e-14	0.73	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
COAD	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	10.22	8.79e-21	6.9e-14	0.63	0.54	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
COAD	trans	rs4240897	0.561	rs12043045	ENSG00000261819.1	RP11-680G24.4	10.21	9.03e-21	7.08e-14	0.73	0.54	Tuberculosis;	chr1:11900294	chr16:14988259~14990160:-
COAD	trans	rs4240897	0.544	rs7542773	ENSG00000261819.1	RP11-680G24.4	10.21	9.03e-21	7.08e-14	0.73	0.54	Tuberculosis;	chr1:11901073	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.508	rs7520898	ENSG00000261819.1	RP11-680G24.4	10.21	9.03e-21	7.08e-14	0.73	0.54	Nonsyndromic cleft lip with cleft palate;	chr1:11901078	chr16:14988259~14990160:-
COAD	trans	rs13190036	0.748	rs28395268	ENSG00000217325.2	PRELID1P1	10.21	9.07e-21	7.11e-14	0.72	0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr6:126643488~126644390:+
COAD	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	10.21	9.22e-21	7.22e-14	0.63	0.54	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
COAD	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	10.2	9.79e-21	7.65e-14	1.05	0.54	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
COAD	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	10.19	1.04e-20	8.11e-14	0.93	0.54	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
COAD	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-10.19	1.09e-20	8.52e-14	-0.67	-0.54	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
COAD	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	10.18	1.12e-20	8.73e-14	0.58	0.54	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	10.18	1.13e-20	8.83e-14	0.58	0.54	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
COAD	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-10.18	1.14e-20	8.86e-14	-0.67	-0.54	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
COAD	trans	rs6708331	0.517	rs12617812	ENSG00000232654.1	FAM136BP	10.17	1.21e-20	9.4e-14	0.65	0.54	Obesity-related traits;	chr2:70132339	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs7599072	ENSG00000232654.1	FAM136BP	10.17	1.21e-20	9.4e-14	0.65	0.54	Obesity-related traits;	chr2:70132874	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs12992553	ENSG00000232654.1	FAM136BP	10.17	1.21e-20	9.4e-14	0.65	0.54	Obesity-related traits;	chr2:70133130	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.54	rs11890701	ENSG00000232654.1	FAM136BP	10.17	1.21e-20	9.4e-14	0.65	0.54	Obesity-related traits;	chr2:70133325	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.517	rs11890741	ENSG00000232654.1	FAM136BP	10.17	1.21e-20	9.4e-14	0.65	0.54	Obesity-related traits;	chr2:70133374	chr6:3045384~3045800:+
COAD	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	10.17	1.22e-20	9.44e-14	1.02	0.54	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-10.17	1.25e-20	9.74e-14	-0.9	-0.54	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
COAD	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-10.16	1.28e-20	9.91e-14	-0.57	-0.54	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
COAD	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-10.16	1.29e-20	1e-13	-0.67	-0.54	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
COAD	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-10.16	1.32e-20	1.02e-13	-0.89	-0.54	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	10.16	1.33e-20	1.03e-13	1.25	0.54	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
COAD	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	10.16	1.35e-20	1.04e-13	0.7	0.54	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
COAD	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	10.16	1.35e-20	1.05e-13	0.72	0.54	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
COAD	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	10.15	1.4e-20	1.09e-13	0.87	0.53	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
COAD	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	10.15	1.41e-20	1.09e-13	0.58	0.53	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
COAD	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-10.15	1.42e-20	1.1e-13	-0.61	-0.53	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
COAD	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-10.14	1.48e-20	1.14e-13	-0.58	-0.53	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-10.14	1.48e-20	1.14e-13	-0.58	-0.53	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
COAD	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-10.14	1.54e-20	1.19e-13	-0.94	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
COAD	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-10.13	1.68e-20	1.3e-13	-0.67	-0.53	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
COAD	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	10.13	1.7e-20	1.31e-13	0.72	0.53	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
COAD	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-10.12	1.79e-20	1.38e-13	-0.69	-0.53	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
COAD	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	10.11	1.85e-20	1.42e-13	0.69	0.53	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
COAD	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	10.11	1.85e-20	1.42e-13	0.69	0.53	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
COAD	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	10.11	1.9e-20	1.46e-13	0.65	0.53	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	10.1	2.04e-20	1.57e-13	0.57	0.53	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
COAD	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	10.09	2.17e-20	1.67e-13	0.87	0.53	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
COAD	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-10.09	2.25e-20	1.72e-13	-0.59	-0.53	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
COAD	trans	rs116095464	1	rs28416084	ENSG00000185986.11	SDHAP3	10.08	2.3e-20	1.76e-13	1.04	0.53	Breast cancer;	chr5:217525	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	10.08	2.3e-20	1.76e-13	1.04	0.53	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	10.08	2.3e-20	1.76e-13	1.04	0.53	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
COAD	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	10.08	2.34e-20	1.79e-13	1.13	0.53	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
COAD	trans	rs6732160	0.706	rs1430348	ENSG00000236165.1	PRADC1P1	10.08	2.42e-20	1.85e-13	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73139930	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.774	rs7606271	ENSG00000236165.1	PRADC1P1	10.08	2.42e-20	1.85e-13	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73140570	chr3:36976316~36976840:+
COAD	trans	rs116095464	0.614	rs10059220	ENSG00000185986.11	SDHAP3	10.07	2.46e-20	1.87e-13	1.04	0.53	Breast cancer;	chr5:242698	chr5:1572222~1594620:-
COAD	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-10.07	2.52e-20	1.92e-13	-0.9	-0.53	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
COAD	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-10.07	2.55e-20	1.94e-13	-0.67	-0.53	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
COAD	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-10.06	2.65e-20	2.02e-13	-0.72	-0.53	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-10.06	2.7e-20	2.05e-13	-0.68	-0.53	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	10.05	2.92e-20	2.22e-13	0.7	0.53	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
COAD	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-10.05	2.93e-20	2.22e-13	-0.6	-0.53	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
COAD	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	10.05	3e-20	2.27e-13	1.04	0.53	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	10.05	3e-20	2.27e-13	1.04	0.53	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
COAD	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	10.05	3.02e-20	2.28e-13	0.6	0.53	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
COAD	trans	rs2288327	0.557	rs7588593	ENSG00000269800.1	PLEKHA3P1	10.05	3.05e-20	2.3e-13	0.71	0.53	Atrial fibrillation;	chr2:178487723	chr19:41521043~41521989:-
COAD	trans	rs2288327	0.557	rs7577862	ENSG00000269800.1	PLEKHA3P1	10.05	3.05e-20	2.3e-13	0.71	0.53	Atrial fibrillation;	chr2:178488130	chr19:41521043~41521989:-
COAD	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	10.04	3.24e-20	2.45e-13	0.63	0.53	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
COAD	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	10.04	3.26e-20	2.46e-13	0.63	0.53	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
COAD	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	10.03	3.37e-20	2.53e-13	0.58	0.53	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
COAD	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	10.02	3.55e-20	2.66e-13	0.82	0.53	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-10.02	3.74e-20	2.8e-13	-0.66	-0.53	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
COAD	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	10.01	3.93e-20	2.94e-13	0.75	0.53	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
COAD	trans	rs6708331	0.54	rs28623550	ENSG00000232654.1	FAM136BP	10.01	4.07e-20	3.04e-13	0.64	0.53	Obesity-related traits;	chr2:70139260	chr6:3045384~3045800:+
COAD	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	10.01	4.07e-20	3.04e-13	0.63	0.53	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	10.01	4.08e-20	3.05e-13	0.63	0.53	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
COAD	trans	rs10037055	0.853	rs10056008	ENSG00000217325.2	PRELID1P1	-10	4.16e-20	3.11e-13	-0.6	-0.53	Migraine without aura;	chr5:177194147	chr6:126643488~126644390:+
COAD	trans	rs10037055	0.853	rs10476219	ENSG00000217325.2	PRELID1P1	-10	4.16e-20	3.11e-13	-0.6	-0.53	Migraine without aura;	chr5:177201547	chr6:126643488~126644390:+
COAD	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	10	4.2e-20	3.13e-13	0.78	0.53	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	10	4.37e-20	3.26e-13	0.59	0.53	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.564	rs9511223	ENSG00000237917.1	PARP4P1	-9.99	4.49e-20	3.34e-13	-0.66	-0.53	Obesity-related traits;	chr13:24380142	chrY:26594851~26634652:-
COAD	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-9.98	4.75e-20	3.52e-13	-0.7	-0.53	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
COAD	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	9.98	4.85e-20	3.6e-13	0.7	0.53	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
COAD	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	9.98	4.92e-20	3.65e-13	0.6	0.53	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
COAD	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	9.98	4.97e-20	3.68e-13	0.68	0.53	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
COAD	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-9.98	5.06e-20	3.75e-13	-0.59	-0.53	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
COAD	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	9.97	5.17e-20	3.83e-13	0.59	0.53	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
COAD	trans	rs2288327	0.557	rs60488846	ENSG00000269800.1	PLEKHA3P1	9.96	5.58e-20	4.11e-13	0.71	0.53	Atrial fibrillation;	chr2:178493115	chr19:41521043~41521989:-
COAD	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	9.96	5.62e-20	4.14e-13	0.6	0.53	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
COAD	trans	rs1816752	0.603	rs9511278	ENSG00000224976.2	PARP4P2	9.96	5.72e-20	4.22e-13	0.59	0.53	Obesity-related traits;	chr13:24455766	chr13:19349137~19407962:+
COAD	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	9.96	5.74e-20	4.23e-13	0.81	0.53	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	9.96	5.74e-20	4.23e-13	0.81	0.53	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	9.94	6.64e-20	4.87e-13	0.9	0.53	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	9.94	6.64e-20	4.87e-13	0.9	0.53	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	9.94	6.64e-20	4.87e-13	0.9	0.53	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	9.94	6.64e-20	4.87e-13	0.9	0.53	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
COAD	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-9.93	6.84e-20	5.02e-13	-0.73	-0.53	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
COAD	trans	rs959695	0.864	rs7844422	ENSG00000260318.1	COX6CP1	9.93	6.9e-20	5.06e-13	0.71	0.53	Hippocampal atrophy;	chr8:99837782	chr16:11903923~11904137:-
COAD	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	9.93	6.93e-20	5.07e-13	0.88	0.53	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	9.93	6.93e-20	5.07e-13	0.88	0.53	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	9.93	6.93e-20	5.07e-13	0.88	0.53	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	9.93	6.93e-20	5.07e-13	0.88	0.53	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-9.93	6.93e-20	5.07e-13	-0.88	-0.53	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
COAD	trans	rs116095464	0.558	rs10059907	ENSG00000185986.11	SDHAP3	9.93	6.94e-20	5.08e-13	1.04	0.53	Breast cancer;	chr5:205245	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10060089	ENSG00000185986.11	SDHAP3	9.93	6.94e-20	5.08e-13	1.04	0.53	Breast cancer;	chr5:205450	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs10068203	ENSG00000185986.11	SDHAP3	9.93	6.94e-20	5.08e-13	1.04	0.53	Breast cancer;	chr5:206503	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs73029475	ENSG00000185986.11	SDHAP3	9.93	6.94e-20	5.08e-13	1.04	0.53	Breast cancer;	chr5:206854	chr5:1572222~1594620:-
COAD	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	9.92	7.44e-20	5.42e-13	0.62	0.53	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	9.92	7.44e-20	5.42e-13	0.62	0.53	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
COAD	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-9.92	7.49e-20	5.46e-13	-0.88	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
COAD	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	9.92	7.85e-20	5.7e-13	0.9	0.53	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
COAD	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-9.91	7.91e-20	5.75e-13	-0.63	-0.53	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
COAD	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	9.91	8.26e-20	5.99e-13	0.95	0.53	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
COAD	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-9.9	8.55e-20	6.19e-13	-0.69	-0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
COAD	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	9.9	8.99e-20	6.51e-13	0.63	0.53	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
COAD	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	9.89	9.25e-20	6.69e-13	0.68	0.53	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	9.89	9.42e-20	6.81e-13	0.59	0.53	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
COAD	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	9.88	9.81e-20	7.08e-13	0.68	0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
COAD	trans	rs6708331	0.517	rs9989836	ENSG00000232654.1	FAM136BP	9.88	1.01e-19	7.28e-13	0.64	0.52	Obesity-related traits;	chr2:70115595	chr6:3045384~3045800:+
COAD	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-9.88	1.05e-19	7.53e-13	-0.75	-0.52	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
COAD	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	9.88	1.05e-19	7.54e-13	0.81	0.52	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
COAD	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	9.87	1.06e-19	7.61e-13	1.04	0.52	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
COAD	trans	rs10037055	0.853	rs1546363	ENSG00000217325.2	PRELID1P1	-9.87	1.07e-19	7.7e-13	-0.59	-0.52	Migraine without aura;	chr5:177174030	chr6:126643488~126644390:+
COAD	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	9.87	1.08e-19	7.74e-13	0.59	0.52	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	9.87	1.08e-19	7.74e-13	0.59	0.52	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	9.86	1.21e-19	8.63e-13	0.58	0.52	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	9.85	1.21e-19	8.63e-13	0.59	0.52	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	9.85	1.22e-19	8.65e-13	0.55	0.52	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
COAD	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	9.85	1.22e-19	8.67e-13	0.69	0.52	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
COAD	trans	rs7113874	0.592	rs34009921	ENSG00000266891.1	RP11-692N5.2	9.85	1.23e-19	8.71e-13	0.82	0.52	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8597314	chr18:9734882~9735602:-
COAD	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	9.85	1.26e-19	8.93e-13	0.68	0.52	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
COAD	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	9.85	1.26e-19	8.94e-13	1.03	0.52	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	9.85	1.26e-19	8.94e-13	1.03	0.52	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
COAD	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	9.85	1.26e-19	8.94e-13	1.03	0.52	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
COAD	trans	rs10037055	0.853	rs1363405	ENSG00000217325.2	PRELID1P1	9.85	1.28e-19	9.08e-13	0.59	0.52	Migraine without aura;	chr5:177209881	chr6:126643488~126644390:+
COAD	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	9.85	1.29e-19	9.1e-13	0.59	0.52	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
COAD	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-9.85	1.29e-19	9.14e-13	-0.91	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
COAD	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	9.84	1.35e-19	9.53e-13	0.59	0.52	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
COAD	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-9.84	1.35e-19	9.55e-13	-0.87	-0.52	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
COAD	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-9.84	1.38e-19	9.71e-13	-0.64	-0.52	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
COAD	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	9.84	1.38e-19	9.75e-13	0.59	0.52	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	9.84	1.38e-19	9.75e-13	0.59	0.52	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
COAD	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	9.83	1.47e-19	1.03e-12	0.81	0.52	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
COAD	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	9.83	1.49e-19	1.04e-12	0.63	0.52	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
COAD	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	9.83	1.49e-19	1.04e-12	0.63	0.52	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
COAD	trans	rs5022636	0.927	rs4971030	ENSG00000180764.13	PIPSL	-9.82	1.53e-19	1.08e-12	-0.55	-0.52	Gut microbiota (functional units);	chr1:151308519	chr10:93958191~93961540:-
COAD	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	9.82	1.6e-19	1.12e-12	0.59	0.52	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
COAD	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	9.82	1.6e-19	1.12e-12	0.75	0.52	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
COAD	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	9.8	1.79e-19	1.25e-12	0.59	0.52	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	9.8	1.84e-19	1.28e-12	0.89	0.52	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	9.8	1.84e-19	1.28e-12	0.89	0.52	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
COAD	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	9.79	1.96e-19	1.36e-12	0.75	0.52	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
COAD	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	9.79	1.98e-19	1.38e-12	0.87	0.52	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
COAD	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	9.79	2e-19	1.39e-12	0.59	0.52	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
COAD	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-9.78	2.02e-19	1.4e-12	-0.62	-0.52	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
COAD	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	9.78	2.13e-19	1.48e-12	0.57	0.52	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-9.77	2.16e-19	1.5e-12	-0.56	-0.52	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
COAD	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	9.77	2.31e-19	1.6e-12	0.81	0.52	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
COAD	trans	rs3740713	0.669	rs78098319	ENSG00000235847.2	LDHAP7	9.76	2.33e-19	1.61e-12	0.88	0.52	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:84777259~84778223:-
COAD	trans	rs10037055	0.741	rs4976640	ENSG00000217325.2	PRELID1P1	-9.75	2.62e-19	1.81e-12	-0.61	-0.52	Migraine without aura;	chr5:177125006	chr6:126643488~126644390:+
COAD	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	9.75	2.67e-19	1.84e-12	0.59	0.52	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	9.75	2.67e-19	1.84e-12	0.59	0.52	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	9.75	2.67e-19	1.84e-12	0.59	0.52	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
COAD	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-9.74	2.8e-19	1.93e-12	-0.58	-0.52	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	9.73	3.01e-19	2.07e-12	0.59	0.52	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-9.73	3.07e-19	2.11e-12	-0.87	-0.52	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
COAD	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	9.72	3.12e-19	2.14e-12	0.58	0.52	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	9.72	3.24e-19	2.22e-12	0.59	0.52	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
COAD	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	9.72	3.28e-19	2.25e-12	0.58	0.52	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	9.72	3.32e-19	2.27e-12	0.57	0.52	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	9.72	3.32e-19	2.27e-12	0.57	0.52	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	9.72	3.32e-19	2.27e-12	0.57	0.52	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	9.72	3.32e-19	2.27e-12	0.57	0.52	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	9.72	3.32e-19	2.27e-12	0.57	0.52	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
COAD	trans	rs10037055	0.853	rs9313749	ENSG00000217325.2	PRELID1P1	-9.7	3.61e-19	2.46e-12	-0.58	-0.52	Migraine without aura;	chr5:177170693	chr6:126643488~126644390:+
COAD	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	9.7	3.63e-19	2.48e-12	0.72	0.52	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
COAD	trans	rs7113874	0.545	rs72855149	ENSG00000266891.1	RP11-692N5.2	9.7	3.77e-19	2.57e-12	0.79	0.52	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8586160	chr18:9734882~9735602:-
COAD	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-9.7	3.82e-19	2.61e-12	-0.68	-0.52	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
COAD	trans	rs3812762	0.871	rs3862352	ENSG00000266891.1	RP11-692N5.2	9.69	3.84e-19	2.62e-12	0.6	0.52	Hypospadias;	chr11:8796473	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.716	rs9553289	ENSG00000224976.2	PARP4P2	9.69	3.86e-19	2.63e-12	0.55	0.52	Obesity-related traits;	chr13:24400640	chr13:19349137~19407962:+
COAD	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	9.69	3.86e-19	2.63e-12	1.09	0.52	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
COAD	trans	rs7811142	1	rs2897358	ENSG00000228546.2	CTA-313A17.3	9.69	3.86e-19	2.63e-12	0.79	0.52	Platelet count;	chr7:100491017	chr7:102337316~102339115:+
COAD	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	9.69	3.98e-19	2.71e-12	0.85	0.52	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
COAD	trans	rs10037055	0.853	rs6890580	ENSG00000217325.2	PRELID1P1	-9.68	4.25e-19	2.89e-12	-0.59	-0.52	Migraine without aura;	chr5:177226519	chr6:126643488~126644390:+
COAD	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	9.67	4.45e-19	3.02e-12	0.71	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-9.67	4.61e-19	3.12e-12	-0.55	-0.52	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
COAD	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	9.67	4.74e-19	3.21e-12	0.58	0.52	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
COAD	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	9.67	4.74e-19	3.21e-12	0.65	0.52	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
COAD	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	9.66	4.8e-19	3.25e-12	0.58	0.52	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
COAD	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-9.66	4.82e-19	3.26e-12	-0.68	-0.52	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
COAD	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	9.66	4.87e-19	3.3e-12	1.09	0.52	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	9.66	4.93e-19	3.34e-12	0.59	0.52	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
COAD	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	9.66	4.97e-19	3.36e-12	0.63	0.52	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
COAD	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	9.66	5.07e-19	3.43e-12	0.59	0.52	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	9.66	5.08e-19	3.43e-12	0.59	0.52	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	9.65	5.26e-19	3.55e-12	0.58	0.52	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
COAD	trans	rs3812762	0.912	rs4929936	ENSG00000266891.1	RP11-692N5.2	9.65	5.4e-19	3.64e-12	0.62	0.52	Hypospadias;	chr11:8771075	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	9.65	5.47e-19	3.68e-12	0.57	0.52	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	9.64	5.61e-19	3.77e-12	0.58	0.52	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	9.64	5.65e-19	3.8e-12	0.68	0.52	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
COAD	trans	rs7811142	1	rs60478351	ENSG00000228546.2	CTA-313A17.3	9.64	5.74e-19	3.85e-12	0.79	0.52	Platelet count;	chr7:100491394	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs7787620	ENSG00000228546.2	CTA-313A17.3	9.64	5.74e-19	3.85e-12	0.79	0.52	Platelet count;	chr7:100491611	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11769700	ENSG00000228546.2	CTA-313A17.3	9.64	5.74e-19	3.85e-12	0.79	0.52	Platelet count;	chr7:100492426	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	9.64	5.74e-19	3.85e-12	0.57	0.52	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
COAD	trans	rs116095464	0.558	rs9312956	ENSG00000185986.11	SDHAP3	9.64	5.8e-19	3.89e-12	0.99	0.52	Breast cancer;	chr5:201697	chr5:1572222~1594620:-
COAD	trans	rs7113874	0.534	rs2311392	ENSG00000266891.1	RP11-692N5.2	9.64	5.82e-19	3.91e-12	0.78	0.52	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8468889	chr18:9734882~9735602:-
COAD	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	9.63	5.96e-19	3.99e-12	0.73	0.52	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
COAD	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	9.63	6.11e-19	4.09e-12	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	9.63	6.11e-19	4.09e-12	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	9.63	6.11e-19	4.09e-12	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
COAD	trans	rs5022636	0.927	rs10888410	ENSG00000180764.13	PIPSL	9.63	6.3e-19	4.21e-12	0.55	0.51	Gut microbiota (functional units);	chr1:151299975	chr10:93958191~93961540:-
COAD	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-9.63	6.33e-19	4.22e-12	-0.75	-0.51	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	9.62	6.37e-19	4.22e-12	0.57	0.51	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
COAD	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	9.62	6.51e-19	4.31e-12	0.78	0.51	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
COAD	trans	rs10242455	0.702	rs73713507	ENSG00000228834.1	RP11-249L21.4	9.62	6.53e-19	4.32e-12	1.22	0.51	Blood metabolite levels;	chr7:99540980	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	9.62	6.54e-19	4.33e-12	1.09	0.51	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
COAD	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	9.62	6.57e-19	4.35e-12	0.58	0.51	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	9.62	6.67e-19	4.41e-12	0.58	0.51	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
COAD	trans	rs5022636	0.964	rs1056847	ENSG00000180764.13	PIPSL	9.61	7.01e-19	4.63e-12	0.55	0.51	Gut microbiota (functional units);	chr1:151315696	chr10:93958191~93961540:-
COAD	trans	rs7811142	1	rs6972167	ENSG00000228546.2	CTA-313A17.3	9.61	7.25e-19	4.79e-12	0.78	0.51	Platelet count;	chr7:100482390	chr7:102337316~102339115:+
COAD	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	9.6	7.41e-19	4.89e-12	1.09	0.51	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
COAD	trans	rs10037055	0.687	rs6556308	ENSG00000217325.2	PRELID1P1	-9.6	7.56e-19	4.98e-12	-0.59	-0.51	Migraine without aura;	chr5:177219700	chr6:126643488~126644390:+
COAD	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	9.59	7.97e-19	5.24e-12	0.9	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
COAD	trans	rs10037055	0.853	rs2336237	ENSG00000217325.2	PRELID1P1	9.59	7.97e-19	5.24e-12	0.59	0.51	Migraine without aura;	chr5:177238878	chr6:126643488~126644390:+
COAD	trans	rs10037055	0.741	rs2336405	ENSG00000217325.2	PRELID1P1	-9.59	7.97e-19	5.24e-12	-0.59	-0.51	Migraine without aura;	chr5:177230288	chr6:126643488~126644390:+
COAD	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	9.59	8.06e-19	5.3e-12	0.58	0.51	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	9.59	8.13e-19	5.34e-12	0.58	0.51	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
COAD	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-9.59	8.31e-19	5.46e-12	-0.66	-0.51	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	9.59	8.31e-19	5.46e-12	0.74	0.51	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
COAD	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	9.59	8.35e-19	5.49e-12	0.7	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
COAD	trans	rs116095464	0.558	rs62346508	ENSG00000185986.11	SDHAP3	9.59	8.4e-19	5.52e-12	0.98	0.51	Breast cancer;	chr5:203553	chr5:1572222~1594620:-
COAD	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	9.58	8.55e-19	5.62e-12	0.58	0.51	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
COAD	trans	rs10242455	0.702	rs78218664	ENSG00000228834.1	RP11-249L21.4	9.58	8.73e-19	5.73e-12	1.22	0.51	Blood metabolite levels;	chr7:99556758	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	9.58	8.82e-19	5.79e-12	0.56	0.51	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	9.58	8.89e-19	5.83e-12	0.57	0.51	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-9.58	8.98e-19	5.89e-12	-0.52	-0.51	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-9.58	8.98e-19	5.89e-12	-0.52	-0.51	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
COAD	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	9.57	9.35e-19	6.13e-12	0.94	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
COAD	trans	rs10037055	0.853	rs10036193	ENSG00000217325.2	PRELID1P1	-9.57	9.48e-19	6.21e-12	-0.59	-0.51	Migraine without aura;	chr5:177141519	chr6:126643488~126644390:+
COAD	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	9.57	9.56e-19	6.26e-12	0.56	0.51	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	9.57	9.58e-19	6.27e-12	0.57	0.51	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	9.56	1.01e-18	6.59e-12	0.59	0.51	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	9.56	1.01e-18	6.59e-12	0.57	0.51	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	9.56	1.01e-18	6.59e-12	0.57	0.51	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	9.55	1.05e-18	6.82e-12	0.57	0.51	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	9.55	1.08e-18	7.03e-12	0.57	0.51	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	9.55	1.08e-18	7.03e-12	0.57	0.51	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	9.55	1.1e-18	7.14e-12	0.92	0.51	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
COAD	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	9.55	1.1e-18	7.14e-12	0.74	0.51	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	9.55	1.1e-18	7.14e-12	0.74	0.51	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
COAD	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	9.55	1.1e-18	7.14e-12	0.74	0.51	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
COAD	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	9.55	1.11e-18	7.2e-12	0.58	0.51	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-9.55	1.12e-18	7.28e-12	-0.86	-0.51	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-9.55	1.12e-18	7.28e-12	-0.86	-0.51	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-9.55	1.12e-18	7.28e-12	-0.86	-0.51	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
COAD	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	9.55	1.12e-18	7.28e-12	0.58	0.51	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	9.54	1.13e-18	7.31e-12	0.58	0.51	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
COAD	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	9.54	1.19e-18	7.73e-12	0.86	0.51	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	9.53	1.22e-18	7.88e-12	0.58	0.51	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	9.53	1.22e-18	7.93e-12	0.59	0.51	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
COAD	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	9.53	1.27e-18	8.18e-12	0.99	0.51	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
COAD	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	9.53	1.27e-18	8.24e-12	0.66	0.51	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
COAD	trans	rs10037055	0.898	rs4976636	ENSG00000217325.2	PRELID1P1	-9.52	1.29e-18	8.36e-12	-0.6	-0.51	Migraine without aura;	chr5:177118091	chr6:126643488~126644390:+
COAD	trans	rs10037055	0.898	rs4976637	ENSG00000217325.2	PRELID1P1	-9.52	1.29e-18	8.36e-12	-0.6	-0.51	Migraine without aura;	chr5:177118141	chr6:126643488~126644390:+
COAD	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	9.52	1.29e-18	8.36e-12	0.63	0.51	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	9.52	1.3e-18	8.38e-12	0.58	0.51	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	9.52	1.33e-18	8.62e-12	0.66	0.51	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	9.52	1.35e-18	8.7e-12	0.57	0.51	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	9.52	1.37e-18	8.84e-12	0.52	0.51	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
COAD	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	9.52	1.38e-18	8.86e-12	0.57	0.51	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	9.52	1.38e-18	8.86e-12	0.57	0.51	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	9.52	1.38e-18	8.86e-12	0.57	0.51	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	9.51	1.44e-18	9.29e-12	0.58	0.51	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
COAD	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	9.51	1.45e-18	9.33e-12	0.57	0.51	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	9.51	1.45e-18	9.33e-12	0.57	0.51	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-9.5	1.51e-18	9.74e-12	-0.53	-0.51	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
COAD	trans	rs116095464	0.558	rs9654453	ENSG00000185986.11	SDHAP3	9.5	1.56e-18	1e-11	1.02	0.51	Breast cancer;	chr5:299506	chr5:1572222~1594620:-
COAD	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	9.5	1.57e-18	1.01e-11	0.57	0.51	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	9.5	1.57e-18	1.01e-11	0.58	0.51	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-9.5	1.59e-18	1.02e-11	-0.86	-0.51	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
COAD	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-9.49	1.6e-18	1.03e-11	-0.73	-0.51	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
COAD	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	9.49	1.61e-18	1.03e-11	0.79	0.51	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
COAD	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	9.49	1.68e-18	1.07e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	9.49	1.68e-18	1.07e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	9.49	1.68e-18	1.07e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	9.49	1.68e-18	1.07e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	9.49	1.68e-18	1.07e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
COAD	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	9.49	1.68e-18	1.08e-11	0.57	0.51	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	9.49	1.68e-18	1.08e-11	0.64	0.51	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	9.48	1.72e-18	1.1e-11	0.56	0.51	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-9.48	1.73e-18	1.1e-11	-0.58	-0.51	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
COAD	trans	rs7113874	0.592	rs10840057	ENSG00000266891.1	RP11-692N5.2	9.48	1.79e-18	1.14e-11	0.75	0.51	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476681	chr18:9734882~9735602:-
COAD	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-9.47	1.87e-18	1.19e-11	-0.86	-0.51	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
COAD	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	9.46	2.05e-18	1.3e-11	0.78	0.51	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	9.46	2.05e-18	1.3e-11	0.78	0.51	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	9.46	2.05e-18	1.3e-11	0.78	0.51	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-9.46	2.06e-18	1.3e-11	-0.85	-0.51	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
COAD	trans	rs10037055	0.853	rs9885210	ENSG00000217325.2	PRELID1P1	-9.46	2.08e-18	1.32e-11	-0.58	-0.51	Migraine without aura;	chr5:177142187	chr6:126643488~126644390:+
COAD	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	9.46	2.09e-18	1.32e-11	0.57	0.51	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
COAD	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	9.45	2.15e-18	1.36e-11	0.78	0.51	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
COAD	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	9.45	2.17e-18	1.38e-11	0.69	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
COAD	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	9.45	2.18e-18	1.38e-11	0.58	0.51	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	9.45	2.19e-18	1.38e-11	0.66	0.51	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	9.45	2.22e-18	1.4e-11	0.58	0.51	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-9.44	2.36e-18	1.49e-11	-0.63	-0.51	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
COAD	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	9.44	2.4e-18	1.51e-11	0.58	0.51	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-9.43	2.61e-18	1.65e-11	-0.55	-0.51	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	9.42	2.66e-18	1.67e-11	0.55	0.51	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	9.42	2.67e-18	1.68e-11	0.57	0.51	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	9.42	2.67e-18	1.68e-11	0.57	0.51	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	9.41	2.86e-18	1.8e-11	0.57	0.51	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	9.41	2.86e-18	1.8e-11	0.57	0.51	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
COAD	trans	rs13190036	1	rs59737888	ENSG00000226986.4	RP11-543B16.2	-9.41	2.94e-18	1.85e-11	-0.72	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	9.41	2.98e-18	1.87e-11	0.57	0.51	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
COAD	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	9.41	3e-18	1.88e-11	0.78	0.51	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	9.41	3e-18	1.88e-11	0.78	0.51	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	9.41	3e-18	1.88e-11	0.78	0.51	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	9.4	3.05e-18	1.91e-11	0.84	0.51	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
COAD	trans	rs3812762	0.871	rs11042068	ENSG00000266891.1	RP11-692N5.2	9.4	3.07e-18	1.93e-11	0.6	0.51	Hypospadias;	chr11:8794052	chr18:9734882~9735602:-
COAD	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	9.4	3.24e-18	2.03e-11	0.68	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	9.39	3.37e-18	2.11e-11	0.55	0.51	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	9.38	3.51e-18	2.2e-11	0.55	0.51	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-9.38	3.54e-18	2.21e-11	-0.57	-0.51	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-9.38	3.56e-18	2.23e-11	-0.63	-0.51	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-9.38	3.57e-18	2.23e-11	-0.63	-0.51	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
COAD	trans	rs7113874	0.578	rs34059271	ENSG00000266891.1	RP11-692N5.2	9.38	3.72e-18	2.32e-11	0.76	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8546311	chr18:9734882~9735602:-
COAD	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	9.37	3.78e-18	2.36e-11	0.76	0.5	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	9.37	3.78e-18	2.36e-11	0.76	0.5	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	9.37	3.78e-18	2.36e-11	0.76	0.5	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	9.37	3.78e-18	2.36e-11	0.76	0.5	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
COAD	trans	rs3740713	0.719	rs78515595	ENSG00000235847.2	LDHAP7	9.36	4.06e-18	2.53e-11	0.91	0.5	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr2:84777259~84778223:-
COAD	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	9.36	4.08e-18	2.54e-11	0.69	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
COAD	trans	rs7113874	0.578	rs1026021	ENSG00000266891.1	RP11-692N5.2	-9.36	4.29e-18	2.67e-11	-0.73	-0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8543231	chr18:9734882~9735602:-
COAD	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	9.36	4.29e-18	2.67e-11	0.55	0.5	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	9.35	4.32e-18	2.69e-11	0.56	0.5	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
COAD	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	9.35	4.53e-18	2.82e-11	0.69	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
COAD	trans	rs1816752	0.74	rs6490924	ENSG00000224976.2	PARP4P2	9.35	4.57e-18	2.84e-11	0.55	0.5	Obesity-related traits;	chr13:24432914	chr13:19349137~19407962:+
COAD	trans	rs2657294	0.965	rs7088974	ENSG00000172974.11	AC007318.5	9.35	4.58e-18	2.84e-11	0.57	0.5	Pneumonia;	chr10:75131338	chr2:65205108~65205988:+
COAD	trans	rs3812762	0.833	rs10500707	ENSG00000266891.1	RP11-692N5.2	-9.34	4.74e-18	2.94e-11	-0.58	-0.5	Hypospadias;	chr11:8796033	chr18:9734882~9735602:-
COAD	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	9.34	4.8e-18	2.97e-11	0.84	0.5	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	9.34	4.8e-18	2.97e-11	0.84	0.5	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
COAD	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	9.34	4.81e-18	2.98e-11	0.66	0.5	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
COAD	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	9.34	4.9e-18	3.03e-11	0.77	0.5	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
COAD	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	9.34	4.93e-18	3.05e-11	0.73	0.5	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
COAD	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-9.33	5.3e-18	3.27e-11	-0.84	-0.5	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
COAD	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	9.32	5.36e-18	3.31e-11	0.58	0.5	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	9.32	5.43e-18	3.35e-11	0.58	0.5	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	9.32	5.43e-18	3.35e-11	0.58	0.5	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	9.32	5.47e-18	3.37e-11	0.55	0.5	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	9.32	5.49e-18	3.38e-11	0.55	0.5	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	9.32	5.62e-18	3.46e-11	0.57	0.5	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
COAD	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	9.32	5.62e-18	3.46e-11	0.76	0.5	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	9.32	5.62e-18	3.46e-11	0.76	0.5	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
COAD	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	9.31	5.75e-18	3.54e-11	0.7	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	9.3	6.39e-18	3.93e-11	0.55	0.5	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
COAD	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	9.3	6.43e-18	3.95e-11	0.75	0.5	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	9.29	6.95e-18	4.26e-11	0.55	0.5	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	9.28	7.23e-18	4.43e-11	0.55	0.5	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
COAD	trans	rs2896526	0.736	rs78950598	ENSG00000235847.2	LDHAP7	9.28	7.25e-18	4.44e-11	0.86	0.5	Amyloid A serum levels;	chr11:18375599	chr2:84777259~84778223:-
COAD	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-9.28	7.27e-18	4.45e-11	-0.63	-0.5	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
COAD	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	9.27	7.69e-18	4.7e-11	0.7	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
COAD	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-9.27	7.7e-18	4.7e-11	-0.82	-0.5	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	9.27	7.76e-18	4.73e-11	0.79	0.5	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
COAD	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	9.27	8.07e-18	4.92e-11	0.68	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
COAD	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	9.26	8.26e-18	5.03e-11	1.02	0.5	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	9.26	8.26e-18	5.03e-11	1.02	0.5	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	9.26	8.37e-18	5.09e-11	0.62	0.5	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
COAD	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-9.25	8.83e-18	5.36e-11	-0.77	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
COAD	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-9.24	9.37e-18	5.69e-11	-0.64	-0.5	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	9.24	9.61e-18	5.84e-11	1.2	0.5	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
COAD	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	9.24	9.75e-18	5.92e-11	0.72	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
COAD	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-9.24	9.89e-18	6e-11	-0.76	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
COAD	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	9.23	1e-17	6.09e-11	1	0.5	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
COAD	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	9.23	1.04e-17	6.33e-11	0.67	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
COAD	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	9.22	1.1e-17	6.67e-11	0.55	0.5	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	9.22	1.1e-17	6.67e-11	0.55	0.5	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	9.22	1.11e-17	6.71e-11	0.57	0.5	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-9.22	1.14e-17	6.9e-11	-0.71	-0.5	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	9.21	1.16e-17	7e-11	0.81	0.5	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
COAD	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-9.21	1.16e-17	7e-11	-0.76	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
COAD	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	9.21	1.17e-17	7.07e-11	0.56	0.5	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	9.21	1.22e-17	7.33e-11	0.55	0.5	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	9.2	1.28e-17	7.67e-11	0.81	0.5	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
COAD	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	9.2	1.32e-17	7.87e-11	0.53	0.5	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
COAD	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	9.19	1.33e-17	7.95e-11	0.93	0.5	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
COAD	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	9.18	1.45e-17	8.64e-11	0.57	0.5	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	9.18	1.45e-17	8.64e-11	0.57	0.5	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	9.18	1.45e-17	8.64e-11	0.57	0.5	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
COAD	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	9.18	1.46e-17	8.68e-11	0.74	0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
COAD	trans	rs7113874	0.659	rs67320655	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8497662	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.625	rs35760680	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500525	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.659	rs2121313	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501495	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.613	rs35225809	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8512038	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.512	rs7952429	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516370	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.545	rs12791925	ENSG00000266891.1	RP11-692N5.2	9.18	1.51e-17	8.92e-11	0.75	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8530038	chr18:9734882~9735602:-
COAD	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-9.17	1.53e-17	9.06e-11	-0.76	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
COAD	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	9.17	1.59e-17	9.36e-11	0.81	0.5	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	9.17	1.59e-17	9.36e-11	0.81	0.5	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	9.17	1.59e-17	9.36e-11	0.81	0.5	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	9.17	1.59e-17	9.36e-11	0.55	0.5	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	9.17	1.59e-17	9.36e-11	0.55	0.5	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	9.17	1.59e-17	9.36e-11	0.55	0.5	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-9.17	1.63e-17	9.58e-11	-0.55	-0.5	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	9.17	1.63e-17	9.62e-11	0.58	0.5	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
COAD	trans	rs3812762	0.826	rs2292045	ENSG00000266891.1	RP11-692N5.2	9.16	1.67e-17	9.84e-11	0.6	0.5	Hypospadias;	chr11:8785162	chr18:9734882~9735602:-
COAD	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	9.16	1.67e-17	9.85e-11	0.69	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
COAD	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	9.16	1.72e-17	1.01e-10	0.55	0.5	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	9.15	1.75e-17	1.03e-10	0.55	0.5	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	9.15	1.78e-17	1.04e-10	0.57	0.5	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	9.15	1.79e-17	1.05e-10	0.57	0.5	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	9.15	1.81e-17	1.06e-10	0.57	0.5	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
COAD	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-9.15	1.82e-17	1.07e-10	-0.68	-0.5	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-9.15	1.85e-17	1.08e-10	-0.66	-0.5	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-9.15	1.85e-17	1.08e-10	-0.66	-0.5	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
COAD	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	9.14	1.91e-17	1.11e-10	0.81	0.5	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs67040465	ENSG00000228546.2	CTA-313A17.3	9.14	1.91e-17	1.12e-10	0.78	0.5	Platelet count;	chr7:100485455	chr7:102337316~102339115:+
COAD	trans	rs10037055	0.853	rs4976681	ENSG00000217325.2	PRELID1P1	9.14	1.95e-17	1.14e-10	0.56	0.5	Migraine without aura;	chr5:177277662	chr6:126643488~126644390:+
COAD	trans	rs7113874	0.578	rs12787407	ENSG00000266891.1	RP11-692N5.2	9.14	2e-17	1.17e-10	0.76	0.5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8532605	chr18:9734882~9735602:-
COAD	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	9.13	2.03e-17	1.18e-10	0.57	0.5	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	9.13	2.03e-17	1.18e-10	0.57	0.5	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
COAD	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-9.13	2.03e-17	1.19e-10	-0.73	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
COAD	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-9.13	2.03e-17	1.19e-10	-0.62	-0.5	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
COAD	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	9.13	2.06e-17	1.2e-10	0.76	0.49	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	9.13	2.06e-17	1.2e-10	0.76	0.49	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	9.13	2.06e-17	1.2e-10	0.76	0.49	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	9.13	2.08e-17	1.21e-10	0.81	0.49	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
COAD	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	9.13	2.09e-17	1.22e-10	0.61	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
COAD	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	9.13	2.13e-17	1.24e-10	0.57	0.49	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	9.13	2.14e-17	1.25e-10	0.54	0.49	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	9.13	2.14e-17	1.25e-10	0.54	0.49	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	9.12	2.24e-17	1.3e-10	0.57	0.49	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
COAD	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	9.12	2.25e-17	1.31e-10	0.62	0.49	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
COAD	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	9.12	2.25e-17	1.31e-10	0.62	0.49	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
COAD	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	9.12	2.25e-17	1.31e-10	0.67	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
COAD	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-9.12	2.26e-17	1.31e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-9.11	2.38e-17	1.38e-10	-0.55	-0.49	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
COAD	trans	rs116095464	0.558	rs9312957	ENSG00000185986.11	SDHAP3	9.11	2.44e-17	1.41e-10	0.89	0.49	Breast cancer;	chr5:202079	chr5:1572222~1594620:-
COAD	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	9.11	2.48e-17	1.44e-10	0.57	0.49	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
COAD	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-9.1	2.59e-17	1.5e-10	-0.83	-0.49	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
COAD	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-9.1	2.64e-17	1.52e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
COAD	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-9.1	2.64e-17	1.52e-10	-0.75	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
COAD	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	9.1	2.65e-17	1.53e-10	0.91	0.49	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
COAD	trans	rs3812762	0.833	rs10500705	ENSG00000266891.1	RP11-692N5.2	9.09	2.7e-17	1.56e-10	0.59	0.49	Hypospadias;	chr11:8783714	chr18:9734882~9735602:-
COAD	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-9.09	2.8e-17	1.61e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
COAD	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-9.09	2.8e-17	1.61e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
COAD	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	9.09	2.81e-17	1.62e-10	0.77	0.49	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
COAD	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-9.09	2.82e-17	1.62e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
COAD	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-9.09	2.82e-17	1.62e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
COAD	trans	rs7811142	1	rs6979335	ENSG00000228546.2	CTA-313A17.3	9.09	2.83e-17	1.63e-10	0.78	0.49	Platelet count;	chr7:100492237	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs73405353	ENSG00000228546.2	CTA-313A17.3	9.09	2.83e-17	1.63e-10	0.78	0.49	Platelet count;	chr7:100493592	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	9.08	2.88e-17	1.66e-10	0.57	0.49	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
COAD	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	9.08	2.92e-17	1.67e-10	0.94	0.49	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
COAD	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-9.08	2.94e-17	1.69e-10	-0.83	-0.49	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
COAD	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-9.08	2.99e-17	1.71e-10	-0.77	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
COAD	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	9.08	3e-17	1.72e-10	0.54	0.49	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
COAD	trans	rs10242455	0.702	rs73713521	ENSG00000228834.1	RP11-249L21.4	9.08	3e-17	1.72e-10	1.21	0.49	Blood metabolite levels;	chr7:99591026	chr6:108907615~108907873:-
COAD	trans	rs9611519	0.857	rs4820434	ENSG00000268568.1	AC007228.9	-9.08	3e-17	1.72e-10	-0.68	-0.49	Neuroticism;	chr22:41241115	chr19:56672574~56673901:-
COAD	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	9.08	3.06e-17	1.75e-10	0.75	0.49	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
COAD	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-9.07	3.07e-17	1.76e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	9.07	3.09e-17	1.77e-10	0.54	0.49	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
COAD	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-9.07	3.16e-17	1.8e-10	-0.73	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
COAD	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-9.07	3.23e-17	1.84e-10	-0.82	-0.49	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
COAD	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	9.07	3.23e-17	1.84e-10	0.55	0.49	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
COAD	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-9.07	3.24e-17	1.85e-10	-0.77	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
COAD	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	9.06	3.32e-17	1.89e-10	0.56	0.49	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	9.06	3.32e-17	1.89e-10	0.56	0.49	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	9.06	3.32e-17	1.89e-10	0.56	0.49	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	9.06	3.32e-17	1.89e-10	0.56	0.49	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
COAD	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	9.06	3.32e-17	1.89e-10	0.68	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
COAD	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-9.06	3.41e-17	1.94e-10	-0.76	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
COAD	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	9.06	3.44e-17	1.96e-10	0.54	0.49	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	9.06	3.44e-17	1.96e-10	0.54	0.49	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	9.06	3.44e-17	1.96e-10	0.54	0.49	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
COAD	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	9.06	3.51e-17	2e-10	0.56	0.49	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
COAD	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-9.05	3.53e-17	2.01e-10	-0.76	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
COAD	trans	rs12709013	0.66	rs30839	ENSG00000233719.3	GOT2P3	9.05	3.59e-17	2.04e-10	0.62	0.49	Blood metabolite ratios;	chr16:58711437	chr12:9641802~9643007:+
COAD	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-9.05	3.61e-17	2.05e-10	-0.73	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
COAD	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-9.04	3.84e-17	2.18e-10	-0.73	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
COAD	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-9.04	3.84e-17	2.18e-10	-0.73	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
COAD	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-9.04	3.86e-17	2.19e-10	-0.67	-0.49	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
COAD	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	9.04	3.87e-17	2.19e-10	0.81	0.49	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
COAD	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-9.04	4.04e-17	2.28e-10	-0.79	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
COAD	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	9.03	4.09e-17	2.31e-10	0.54	0.49	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
COAD	trans	rs7113874	0.578	rs67067089	ENSG00000266891.1	RP11-692N5.2	9.03	4.15e-17	2.34e-10	0.73	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508480	chr18:9734882~9735602:-
COAD	trans	rs7811142	0.887	rs111972532	ENSG00000228546.2	CTA-313A17.3	9.03	4.21e-17	2.37e-10	0.78	0.49	Platelet count;	chr7:100471465	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-9.03	4.22e-17	2.38e-10	-0.65	-0.49	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-9.03	4.22e-17	2.38e-10	-0.65	-0.49	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-9.03	4.22e-17	2.38e-10	-0.65	-0.49	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	9.03	4.3e-17	2.43e-10	0.59	0.49	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
COAD	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-9.02	4.44e-17	2.5e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
COAD	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-9.02	4.44e-17	2.5e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
COAD	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-9.02	4.44e-17	2.5e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
COAD	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-9.02	4.44e-17	2.5e-10	-0.67	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
COAD	trans	rs11023332	0.832	rs10832289	ENSG00000236360.2	RP11-334A14.2	-9.02	4.53e-17	2.55e-10	-0.65	-0.49	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr1:52993201~52993702:-
COAD	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	9.02	4.54e-17	2.55e-10	0.56	0.49	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	9.01	4.71e-17	2.65e-10	0.56	0.49	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	9.01	4.77e-17	2.68e-10	0.56	0.49	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
COAD	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	9.01	4.94e-17	2.77e-10	0.76	0.49	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
COAD	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-9	5e-17	2.81e-10	-0.76	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
COAD	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-9	5e-17	2.81e-10	-0.76	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
COAD	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-9	5.1e-17	2.86e-10	-0.69	-0.49	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	9	5.3e-17	2.97e-10	0.54	0.49	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	8.99	5.35e-17	2.99e-10	0.64	0.49	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	8.99	5.47e-17	3.06e-10	0.61	0.49	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
COAD	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	8.99	5.62e-17	3.15e-10	0.57	0.49	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-8.98	5.72e-17	3.2e-10	-0.58	-0.49	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-8.98	5.72e-17	3.2e-10	-0.58	-0.49	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
COAD	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-8.98	5.78e-17	3.23e-10	-0.62	-0.49	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-8.98	5.78e-17	3.23e-10	-0.62	-0.49	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-8.98	5.78e-17	3.23e-10	-0.62	-0.49	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
COAD	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-8.98	5.86e-17	3.27e-10	-0.63	-0.49	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	8.98	5.89e-17	3.29e-10	0.54	0.49	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	8.98	6.03e-17	3.37e-10	0.53	0.49	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	8.97	6.17e-17	3.44e-10	0.62	0.49	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-8.97	6.47e-17	3.6e-10	-0.61	-0.49	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	8.97	6.49e-17	3.62e-10	0.54	0.49	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
COAD	trans	rs7121616	0.96	rs12361252	ENSG00000234176.1	HSPA8P1	8.97	6.51e-17	3.62e-10	0.54	0.49	Breast cancer;	chr11:123091564	chrX:121203182~121205014:-
COAD	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	8.96	6.57e-17	3.65e-10	0.57	0.49	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
COAD	trans	rs1816752	0.583	rs6490918	ENSG00000224976.2	PARP4P2	8.96	6.59e-17	3.66e-10	0.54	0.49	Obesity-related traits;	chr13:24427977	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-8.96	6.59e-17	3.66e-10	-0.58	-0.49	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
COAD	trans	rs7113874	0.511	rs35091649	ENSG00000266891.1	RP11-692N5.2	8.96	6.6e-17	3.67e-10	0.72	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8526636	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.578	rs35807094	ENSG00000266891.1	RP11-692N5.2	8.96	6.6e-17	3.67e-10	0.72	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8528798	chr18:9734882~9735602:-
COAD	trans	rs4929947	0.515	rs67191473	ENSG00000266891.1	RP11-692N5.2	8.96	6.6e-17	3.67e-10	0.72	0.49	Menarche (age at onset);	chr11:8530643	chr18:9734882~9735602:-
COAD	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	8.96	6.72e-17	3.73e-10	0.57	0.49	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
COAD	trans	rs7554547	0.685	rs12724129	ENSG00000261819.1	RP11-680G24.4	8.96	6.96e-17	3.86e-10	0.64	0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11897582	chr16:14988259~14990160:-
COAD	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-8.95	7.18e-17	3.98e-10	-0.7	-0.49	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-8.95	7.18e-17	3.98e-10	-0.7	-0.49	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
COAD	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-8.95	7.31e-17	4.05e-10	-0.73	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
COAD	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	8.95	7.31e-17	4.05e-10	0.74	0.49	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-8.94	7.76e-17	4.29e-10	-0.58	-0.49	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-8.94	7.76e-17	4.29e-10	-0.58	-0.49	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	8.94	7.85e-17	4.34e-10	0.6	0.49	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
COAD	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-8.94	7.86e-17	4.34e-10	-0.67	-0.49	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
COAD	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-8.94	7.92e-17	4.37e-10	-0.7	-0.49	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-8.94	7.92e-17	4.37e-10	-0.7	-0.49	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-8.94	7.92e-17	4.37e-10	-0.7	-0.49	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-8.92	8.7e-17	4.79e-10	-0.59	-0.49	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-8.92	8.72e-17	4.8e-10	-0.71	-0.49	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-8.92	8.72e-17	4.8e-10	-0.71	-0.49	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.702	rs1045012	ENSG00000228834.1	RP11-249L21.4	8.92	8.94e-17	4.92e-10	1.01	0.49	Blood metabolite levels;	chr7:99386731	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	8.92	9.1e-17	5e-10	0.54	0.49	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	8.91	9.32e-17	5.12e-10	0.6	0.49	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	8.91	9.55e-17	5.24e-10	0.54	0.49	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	8.91	9.57e-17	5.25e-10	0.59	0.49	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	8.91	9.57e-17	5.25e-10	0.59	0.49	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	8.91	9.57e-17	5.25e-10	0.59	0.49	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	8.91	9.74e-17	5.33e-10	0.58	0.49	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	8.91	9.74e-17	5.33e-10	0.58	0.49	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	8.91	9.8e-17	5.37e-10	0.49	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
COAD	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	8.91	9.93e-17	5.44e-10	0.57	0.49	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
COAD	trans	rs10242455	0.702	rs73711294	ENSG00000228834.1	RP11-249L21.4	8.9	1.01e-16	5.51e-10	1.19	0.49	Blood metabolite levels;	chr7:99491091	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	8.9	1.01e-16	5.52e-10	0.54	0.49	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	8.9	1.03e-16	5.62e-10	0.59	0.49	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	8.89	1.07e-16	5.84e-10	0.58	0.49	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	8.89	1.07e-16	5.85e-10	0.6	0.49	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
COAD	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	8.89	1.07e-16	5.86e-10	0.61	0.49	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
COAD	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	8.89	1.1e-16	6.01e-10	0.89	0.48	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
COAD	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-8.89	1.12e-16	6.12e-10	-0.57	-0.48	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-8.89	1.13e-16	6.16e-10	-0.57	-0.48	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
COAD	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	8.89	1.13e-16	6.18e-10	0.76	0.48	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
COAD	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-8.88	1.15e-16	6.29e-10	-0.55	-0.48	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
COAD	trans	rs3812762	0.783	rs34524863	ENSG00000266891.1	RP11-692N5.2	8.88	1.16e-16	6.31e-10	0.57	0.48	Hypospadias;	chr11:8755861	chr18:9734882~9735602:-
COAD	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	8.88	1.17e-16	6.35e-10	0.58	0.48	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	8.88	1.17e-16	6.38e-10	0.54	0.48	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	8.88	1.21e-16	6.56e-10	0.58	0.48	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.702	rs10251282	ENSG00000228834.1	RP11-249L21.4	8.87	1.23e-16	6.68e-10	1	0.48	Blood metabolite levels;	chr7:99392613	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	8.87	1.23e-16	6.68e-10	1	0.48	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
COAD	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-8.87	1.24e-16	6.74e-10	-0.52	-0.48	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
COAD	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-8.87	1.25e-16	6.77e-10	-0.58	-0.48	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
COAD	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	8.87	1.27e-16	6.87e-10	0.6	0.48	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	8.87	1.29e-16	6.95e-10	0.53	0.48	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	8.87	1.29e-16	6.95e-10	0.65	0.48	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	8.87	1.29e-16	6.95e-10	0.65	0.48	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	8.87	1.29e-16	6.95e-10	0.65	0.48	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	8.87	1.29e-16	6.95e-10	0.65	0.48	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
COAD	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-8.86	1.34e-16	7.25e-10	-0.58	-0.48	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
COAD	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	8.86	1.36e-16	7.33e-10	0.53	0.48	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
COAD	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-8.86	1.37e-16	7.36e-10	-0.57	-0.48	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	8.86	1.37e-16	7.41e-10	0.53	0.48	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	8.86	1.38e-16	7.41e-10	0.53	0.48	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
COAD	trans	rs3812762	0.833	rs35670750	ENSG00000266891.1	RP11-692N5.2	8.86	1.39e-16	7.5e-10	0.57	0.48	Hypospadias;	chr11:8760897	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	8.85	1.44e-16	7.75e-10	0.55	0.48	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	8.85	1.44e-16	7.75e-10	0.55	0.48	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	8.85	1.46e-16	7.84e-10	0.57	0.48	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	8.85	1.47e-16	7.91e-10	0.53	0.48	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-8.85	1.48e-16	7.93e-10	-0.58	-0.48	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-8.85	1.49e-16	7.98e-10	-0.61	-0.48	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	8.84	1.51e-16	8.07e-10	0.54	0.48	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	8.84	1.51e-16	8.07e-10	0.54	0.48	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	8.84	1.51e-16	8.07e-10	0.54	0.48	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	8.84	1.51e-16	8.07e-10	0.54	0.48	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	8.84	1.51e-16	8.07e-10	0.54	0.48	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
COAD	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-8.84	1.52e-16	8.14e-10	-0.57	-0.48	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-8.84	1.53e-16	8.19e-10	-0.57	-0.48	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-8.84	1.55e-16	8.3e-10	-0.58	-0.48	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-8.84	1.55e-16	8.3e-10	-0.58	-0.48	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	8.84	1.58e-16	8.42e-10	0.53	0.48	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
COAD	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	8.84	1.58e-16	8.44e-10	0.68	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
COAD	trans	rs12709013	0.635	rs6993	ENSG00000233719.3	GOT2P3	8.84	1.59e-16	8.49e-10	0.62	0.48	Blood metabolite ratios;	chr16:58707463	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	8.83	1.67e-16	8.92e-10	0.54	0.48	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	8.82	1.75e-16	9.31e-10	0.53	0.48	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	8.82	1.79e-16	9.53e-10	0.68	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
COAD	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-8.82	1.81e-16	9.61e-10	-0.8	-0.48	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
COAD	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	8.82	1.82e-16	9.66e-10	0.55	0.48	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
COAD	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-8.82	1.83e-16	9.7e-10	-0.58	-0.48	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	8.82	1.83e-16	9.71e-10	0.52	0.48	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
COAD	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	8.82	1.84e-16	9.78e-10	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
COAD	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-8.82	1.84e-16	9.78e-10	-0.57	-0.48	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	8.81	1.87e-16	9.93e-10	0.52	0.48	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	8.81	1.9e-16	1.01e-09	0.52	0.48	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	8.81	1.9e-16	1.01e-09	0.52	0.48	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.679	rs8181826	ENSG00000224976.2	PARP4P2	8.81	1.92e-16	1.02e-09	0.49	0.48	Obesity-related traits;	chr13:24396570	chr13:19349137~19407962:+
COAD	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	8.81	1.95e-16	1.03e-09	0.53	0.48	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
COAD	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	8.81	1.96e-16	1.04e-09	0.6	0.48	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
COAD	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-8.8	1.99e-16	1.06e-09	-0.57	-0.48	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
COAD	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-8.8	2.02e-16	1.07e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
COAD	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-8.8	2.02e-16	1.07e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
COAD	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-8.8	2.02e-16	1.07e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
COAD	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-8.8	2.02e-16	1.07e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	8.8	2.05e-16	1.08e-09	0.53	0.48	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	8.8	2.1e-16	1.11e-09	0.52	0.48	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	8.8	2.1e-16	1.11e-09	0.52	0.48	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	8.8	2.1e-16	1.11e-09	0.52	0.48	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	8.8	2.1e-16	1.11e-09	0.52	0.48	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	8.8	2.11e-16	1.11e-09	0.6	0.48	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	8.79	2.12e-16	1.12e-09	0.57	0.48	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
COAD	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	8.79	2.14e-16	1.13e-09	0.57	0.48	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	8.79	2.16e-16	1.14e-09	0.52	0.48	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-8.79	2.18e-16	1.15e-09	-0.58	-0.48	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
COAD	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	8.79	2.18e-16	1.15e-09	0.54	0.48	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
COAD	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	8.79	2.18e-16	1.15e-09	0.65	0.48	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
COAD	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	8.79	2.19e-16	1.15e-09	0.57	0.48	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	8.79	2.19e-16	1.15e-09	0.57	0.48	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
COAD	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-8.79	2.24e-16	1.18e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
COAD	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-8.79	2.25e-16	1.18e-09	-0.57	-0.48	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
COAD	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-8.78	2.28e-16	1.2e-09	-0.61	-0.48	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
COAD	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	8.78	2.29e-16	1.2e-09	0.62	0.48	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
COAD	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	8.78	2.31e-16	1.21e-09	0.74	0.48	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	8.78	2.32e-16	1.22e-09	0.54	0.48	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	8.78	2.32e-16	1.22e-09	0.54	0.48	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-8.78	2.32e-16	1.22e-09	-0.57	-0.48	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-8.78	2.34e-16	1.23e-09	-0.52	-0.48	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	8.78	2.35e-16	1.23e-09	0.53	0.48	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	8.78	2.35e-16	1.23e-09	0.53	0.48	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-8.78	2.37e-16	1.24e-09	-0.58	-0.48	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-8.78	2.38e-16	1.25e-09	-0.57	-0.48	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-8.78	2.38e-16	1.25e-09	-0.57	-0.48	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	8.78	2.4e-16	1.25e-09	0.52	0.48	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.52	rs10766189	ENSG00000236360.2	RP11-334A14.2	8.78	2.41e-16	1.26e-09	0.65	0.48	Vitamin D levels;	chr11:14712377	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.502	rs12795794	ENSG00000236360.2	RP11-334A14.2	8.77	2.43e-16	1.27e-09	0.65	0.48	Vitamin D levels;	chr11:14825327	chr1:52993201~52993702:-
COAD	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-8.77	2.44e-16	1.28e-09	-0.57	-0.48	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
COAD	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	8.77	2.46e-16	1.28e-09	0.52	0.48	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-8.77	2.47e-16	1.29e-09	-0.57	-0.48	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	8.77	2.48e-16	1.29e-09	0.57	0.48	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	8.77	2.48e-16	1.29e-09	0.57	0.48	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	8.77	2.48e-16	1.29e-09	0.57	0.48	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
COAD	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-8.77	2.5e-16	1.3e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
COAD	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-8.77	2.51e-16	1.3e-09	-0.57	-0.48	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-8.77	2.51e-16	1.3e-09	-0.57	-0.48	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-8.77	2.51e-16	1.3e-09	-0.57	-0.48	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-8.77	2.51e-16	1.3e-09	-0.57	-0.48	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	8.77	2.51e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	8.77	2.52e-16	1.3e-09	0.57	0.48	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	8.77	2.53e-16	1.31e-09	0.53	0.48	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	8.77	2.53e-16	1.31e-09	0.53	0.48	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	8.77	2.55e-16	1.32e-09	0.57	0.48	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	8.77	2.56e-16	1.33e-09	0.53	0.48	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-8.76	2.6e-16	1.34e-09	-0.57	-0.48	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	8.76	2.6e-16	1.34e-09	0.52	0.48	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
COAD	trans	rs3740713	1	rs73438695	ENSG00000235847.2	LDHAP7	8.76	2.61e-16	1.35e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs76062966	ENSG00000235847.2	LDHAP7	8.76	2.61e-16	1.35e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73440606	ENSG00000235847.2	LDHAP7	8.76	2.61e-16	1.35e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73440615	ENSG00000235847.2	LDHAP7	8.76	2.61e-16	1.35e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:84777259~84778223:-
COAD	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-8.76	2.62e-16	1.35e-09	-0.57	-0.48	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	8.76	2.63e-16	1.36e-09	0.55	0.48	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
COAD	trans	rs7554547	0.703	rs7543258	ENSG00000261819.1	RP11-680G24.4	8.76	2.66e-16	1.38e-09	0.67	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11901599	chr16:14988259~14990160:-
COAD	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-8.76	2.7e-16	1.39e-09	-0.57	-0.48	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
COAD	trans	rs7113874	0.592	rs12808779	ENSG00000266891.1	RP11-692N5.2	8.76	2.72e-16	1.4e-09	0.72	0.48	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8416280	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	8.76	2.72e-16	1.4e-09	0.53	0.48	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
COAD	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	8.76	2.72e-16	1.41e-09	0.73	0.48	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
COAD	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-8.76	2.74e-16	1.41e-09	-0.66	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	8.75	2.81e-16	1.44e-09	0.56	0.48	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	8.75	2.81e-16	1.44e-09	0.59	0.48	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	8.75	2.82e-16	1.45e-09	0.52	0.48	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	8.75	2.82e-16	1.45e-09	0.52	0.48	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	8.75	2.82e-16	1.45e-09	0.52	0.48	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
COAD	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-8.75	2.89e-16	1.48e-09	-0.8	-0.48	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
COAD	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-8.75	2.89e-16	1.48e-09	-0.8	-0.48	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
COAD	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	8.75	2.89e-16	1.48e-09	0.54	0.48	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	8.75	2.89e-16	1.48e-09	0.54	0.48	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	8.75	2.93e-16	1.5e-09	0.64	0.48	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
COAD	trans	rs3740713	1	rs57311859	ENSG00000235847.2	LDHAP7	8.74	3e-16	1.54e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr2:84777259~84778223:-
COAD	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	8.74	3e-16	1.54e-09	0.55	0.48	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
COAD	trans	rs1816752	0.875	rs17384871	ENSG00000224976.2	PARP4P2	-8.74	3.01e-16	1.54e-09	-0.55	-0.48	Obesity-related traits;	chr13:24484959	chr13:19349137~19407962:+
COAD	trans	rs55665837	0.54	rs1007392	ENSG00000236360.2	RP11-334A14.2	8.74	3.07e-16	1.57e-09	0.64	0.48	Vitamin D levels;	chr11:14753045	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	8.74	3.07e-16	1.57e-09	0.64	0.48	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	8.74	3.07e-16	1.57e-09	0.64	0.48	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
COAD	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	8.74	3.08e-16	1.58e-09	0.66	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
COAD	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	8.74	3.13e-16	1.6e-09	0.52	0.48	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
COAD	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	8.74	3.13e-16	1.6e-09	0.52	0.48	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
COAD	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-8.74	3.14e-16	1.6e-09	-0.57	-0.48	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
COAD	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	8.73	3.22e-16	1.64e-09	0.68	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
COAD	trans	rs13190036	0.901	rs55741473	ENSG00000228305.2	AC016734.2	-8.73	3.25e-16	1.66e-09	-0.67	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr2:63622178~63622831:-
COAD	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	8.73	3.27e-16	1.67e-09	0.56	0.48	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
COAD	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	8.73	3.31e-16	1.69e-09	0.54	0.48	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
COAD	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	8.73	3.35e-16	1.71e-09	0.59	0.48	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	8.73	3.35e-16	1.71e-09	0.59	0.48	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	8.73	3.36e-16	1.71e-09	0.53	0.48	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.519	rs10832297	ENSG00000236360.2	RP11-334A14.2	8.72	3.5e-16	1.78e-09	0.64	0.48	Vitamin D levels;	chr11:14736191	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs12788030	ENSG00000236360.2	RP11-334A14.2	8.72	3.5e-16	1.78e-09	0.64	0.48	Vitamin D levels;	chr11:14743138	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs10832299	ENSG00000236360.2	RP11-334A14.2	8.72	3.5e-16	1.78e-09	0.64	0.48	Vitamin D levels;	chr11:14747846	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	8.72	3.51e-16	1.79e-09	0.52	0.48	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	8.71	3.66e-16	1.86e-09	0.54	0.48	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	8.71	3.72e-16	1.89e-09	0.59	0.48	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	8.71	3.79e-16	1.92e-09	0.56	0.48	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	8.71	3.8e-16	1.93e-09	0.54	0.48	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	8.71	3.8e-16	1.93e-09	0.54	0.48	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	8.71	3.8e-16	1.93e-09	0.54	0.48	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	8.71	3.83e-16	1.94e-09	0.64	0.48	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
COAD	trans	rs1816752	0.875	rs3783076	ENSG00000224976.2	PARP4P2	-8.71	3.88e-16	1.97e-09	-0.53	-0.48	Obesity-related traits;	chr13:24490319	chr13:19349137~19407962:+
COAD	trans	rs55665837	0.54	rs10832294	ENSG00000236360.2	RP11-334A14.2	8.7	3.93e-16	1.99e-09	0.64	0.48	Vitamin D levels;	chr11:14725881	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs10219313	ENSG00000236360.2	RP11-334A14.2	8.7	3.93e-16	1.99e-09	0.64	0.48	Vitamin D levels;	chr11:14728303	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.54	rs4144487	ENSG00000236360.2	RP11-334A14.2	8.7	3.93e-16	1.99e-09	0.64	0.48	Vitamin D levels;	chr11:14728905	chr1:52993201~52993702:-
COAD	trans	rs3740713	0.92	rs112973292	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr2:84777259~84778223:-
COAD	trans	rs3740713	0.92	rs73438656	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr2:84777259~84778223:-
COAD	trans	rs3740713	0.92	rs73438659	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438666	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs16935424	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438674	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs78549183	ENSG00000235847.2	LDHAP7	8.7	3.94e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs2643872	ENSG00000235847.2	LDHAP7	8.7	3.96e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs75381502	ENSG00000235847.2	LDHAP7	8.7	3.96e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs76586692	ENSG00000235847.2	LDHAP7	8.7	3.96e-16	2e-09	0.79	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr2:84777259~84778223:-
COAD	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	8.7	4.01e-16	2.03e-09	0.56	0.48	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	8.7	4.01e-16	2.03e-09	0.56	0.48	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
COAD	trans	rs7258465	0.931	rs11673604	ENSG00000267533.1	RP11-815J4.7	8.7	4.01e-16	2.03e-09	0.57	0.48	Breast cancer;	chr19:18430178	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	8.7	4.01e-16	2.03e-09	0.53	0.48	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	8.7	4.01e-16	2.03e-09	0.53	0.48	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	8.7	4.01e-16	2.03e-09	0.53	0.48	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	8.7	4.1e-16	2.07e-09	0.53	0.48	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	8.7	4.1e-16	2.07e-09	0.52	0.48	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	8.7	4.1e-16	2.07e-09	0.52	0.48	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
COAD	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	8.7	4.12e-16	2.08e-09	0.54	0.48	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
COAD	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	8.7	4.18e-16	2.11e-09	0.59	0.48	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
COAD	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	8.7	4.18e-16	2.11e-09	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	8.7	4.18e-16	2.11e-09	0.65	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-8.69	4.28e-16	2.15e-09	-0.48	-0.48	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
COAD	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-8.69	4.29e-16	2.16e-09	-0.57	-0.48	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	8.69	4.3e-16	2.16e-09	0.54	0.48	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
COAD	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	8.69	4.44e-16	2.23e-09	0.56	0.48	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
COAD	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-8.69	4.44e-16	2.23e-09	-0.71	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
COAD	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	8.69	4.47e-16	2.25e-09	0.54	0.48	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
COAD	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	8.68	4.52e-16	2.27e-09	0.56	0.48	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
COAD	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	8.68	4.69e-16	2.36e-09	0.55	0.48	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
COAD	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-8.68	4.7e-16	2.36e-09	-0.57	-0.48	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-8.68	4.73e-16	2.38e-09	-0.54	-0.48	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-8.68	4.77e-16	2.39e-09	-0.57	-0.48	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.557	rs34943973	ENSG00000228834.1	RP11-249L21.4	8.68	4.79e-16	2.4e-09	1.19	0.48	Blood metabolite levels;	chr7:99434894	chr6:108907615~108907873:-
COAD	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-8.67	4.86e-16	2.44e-09	-0.57	-0.48	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
COAD	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	8.67	4.88e-16	2.45e-09	0.7	0.48	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
COAD	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	8.67	4.9e-16	2.46e-09	0.59	0.48	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	8.67	4.91e-16	2.46e-09	0.56	0.48	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-8.67	4.92e-16	2.47e-09	-0.56	-0.48	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-8.67	4.92e-16	2.47e-09	-0.56	-0.48	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	8.67	4.97e-16	2.49e-09	0.52	0.48	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	8.67	4.98e-16	2.49e-09	0.54	0.48	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
COAD	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-8.67	5.01e-16	2.51e-09	-0.57	-0.48	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
COAD	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-8.67	5.03e-16	2.52e-09	-0.56	-0.48	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	8.67	5.05e-16	2.53e-09	0.52	0.48	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-8.67	5.08e-16	2.54e-09	-0.52	-0.48	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
COAD	trans	rs7554511	1	rs55838263	ENSG00000244144.1	RP11-757F18.3	-8.67	5.09e-16	2.54e-09	-0.71	-0.48	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905600	chr3:112185480~112185998:-
COAD	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	8.67	5.09e-16	2.55e-09	0.59	0.48	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
COAD	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-8.67	5.13e-16	2.56e-09	-0.57	-0.48	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-8.67	5.13e-16	2.56e-09	-0.57	-0.48	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-8.66	5.14e-16	2.57e-09	-0.6	-0.48	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-8.66	5.15e-16	2.57e-09	-0.56	-0.48	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
COAD	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	8.66	5.16e-16	2.58e-09	0.51	0.48	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
COAD	trans	rs7121616	0.531	rs10892958	ENSG00000229091.2	HSPA8P8	8.66	5.23e-16	2.61e-09	0.54	0.48	Breast cancer;	chr11:123061415	chr7:10451311~10452526:+
COAD	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	8.66	5.23e-16	2.61e-09	0.56	0.48	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
COAD	trans	rs6708331	0.938	rs13000514	ENSG00000232654.1	FAM136BP	8.66	5.26e-16	2.63e-09	0.66	0.48	Obesity-related traits;	chr2:70167884	chr6:3045384~3045800:+
COAD	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	8.66	5.3e-16	2.64e-09	0.53	0.48	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	8.66	5.3e-16	2.64e-09	0.53	0.48	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	8.66	5.33e-16	2.66e-09	0.54	0.48	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	8.66	5.36e-16	2.67e-09	0.57	0.48	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
COAD	trans	rs3740713	1	rs73438697	ENSG00000235847.2	LDHAP7	8.65	5.68e-16	2.83e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs114330751	ENSG00000235847.2	LDHAP7	8.65	5.68e-16	2.83e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438699	ENSG00000235847.2	LDHAP7	8.65	5.68e-16	2.83e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73440604	ENSG00000235847.2	LDHAP7	8.65	5.68e-16	2.83e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73440610	ENSG00000235847.2	LDHAP7	8.65	5.68e-16	2.83e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr2:84777259~84778223:-
COAD	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	8.65	5.71e-16	2.84e-09	0.56	0.47	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
COAD	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	8.65	5.74e-16	2.85e-09	0.56	0.47	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	8.65	5.74e-16	2.85e-09	0.56	0.47	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
COAD	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	8.65	5.75e-16	2.86e-09	0.56	0.47	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
COAD	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	8.65	5.79e-16	2.88e-09	0.56	0.47	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	8.65	5.79e-16	2.88e-09	0.56	0.47	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
COAD	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	8.65	5.8e-16	2.88e-09	0.87	0.47	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	8.65	5.8e-16	2.88e-09	0.87	0.47	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
COAD	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	8.65	5.8e-16	2.88e-09	0.87	0.47	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
COAD	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	8.65	5.84e-16	2.9e-09	0.53	0.47	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	8.65	5.87e-16	2.91e-09	0.54	0.47	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
COAD	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	8.64	5.94e-16	2.94e-09	0.64	0.47	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
COAD	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	8.64	5.94e-16	2.95e-09	0.56	0.47	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	8.64	5.94e-16	2.95e-09	0.56	0.47	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-8.64	6.05e-16	3e-09	-0.58	-0.47	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.875	rs59686377	ENSG00000224976.2	PARP4P2	-8.64	6.05e-16	3e-09	-0.54	-0.47	Obesity-related traits;	chr13:24475869	chr13:19349137~19407962:+
COAD	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	8.64	6.1e-16	3.02e-09	0.76	0.47	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
COAD	trans	rs13190036	0.901	rs55741473	ENSG00000226986.4	RP11-543B16.2	-8.64	6.1e-16	3.02e-09	-0.66	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr1:211207239~211207897:+
COAD	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-8.63	6.56e-16	3.24e-09	-0.57	-0.47	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
COAD	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	8.63	6.59e-16	3.25e-09	0.7	0.47	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
COAD	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	8.63	6.68e-16	3.29e-09	0.63	0.47	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
COAD	trans	rs3740713	0.925	rs55727925	ENSG00000235847.2	LDHAP7	8.62	6.96e-16	3.43e-09	0.76	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:84777259~84778223:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-8.62	7e-16	3.44e-09	-0.51	-0.47	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-8.62	7e-16	3.44e-09	-0.51	-0.47	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
COAD	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	8.62	7.18e-16	3.53e-09	0.56	0.47	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	8.62	7.18e-16	3.53e-09	0.56	0.47	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	8.62	7.18e-16	3.53e-09	0.56	0.47	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	8.62	7.18e-16	3.53e-09	0.56	0.47	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
COAD	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	8.61	7.21e-16	3.55e-09	0.69	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
COAD	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-8.61	7.51e-16	3.69e-09	-0.59	-0.47	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
COAD	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-8.61	7.57e-16	3.72e-09	-0.56	-0.47	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	8.61	7.58e-16	3.72e-09	0.54	0.47	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	8.61	7.58e-16	3.72e-09	0.54	0.47	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
COAD	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-8.61	7.65e-16	3.75e-09	-0.59	-0.47	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
COAD	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-8.6	7.79e-16	3.82e-09	-0.56	-0.47	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-8.6	7.79e-16	3.82e-09	-0.56	-0.47	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-8.6	7.79e-16	3.82e-09	-0.56	-0.47	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-8.6	7.79e-16	3.82e-09	-0.56	-0.47	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.879	rs10743088	ENSG00000266891.1	RP11-692N5.2	-8.6	8e-16	3.92e-09	-0.56	-0.47	Hypospadias;	chr11:8766073	chr18:9734882~9735602:-
COAD	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	8.6	8.02e-16	3.92e-09	0.75	0.47	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	8.6	8.02e-16	3.92e-09	0.75	0.47	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
COAD	trans	rs7113874	0.527	rs12790154	ENSG00000266891.1	RP11-692N5.2	8.6	8.1e-16	3.96e-09	0.72	0.47	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8383601	chr18:9734882~9735602:-
COAD	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-8.6	8.17e-16	4e-09	-0.66	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
COAD	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-8.59	8.34e-16	4.08e-09	-0.57	-0.47	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
COAD	trans	rs3740713	1	rs76708296	ENSG00000235847.2	LDHAP7	8.59	8.54e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438668	ENSG00000235847.2	LDHAP7	8.59	8.54e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs75647856	ENSG00000235847.2	LDHAP7	8.59	8.54e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438687	ENSG00000235847.2	LDHAP7	8.59	8.54e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs74663287	ENSG00000235847.2	LDHAP7	8.59	8.54e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438627	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438634	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs113036885	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs112410494	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs74741949	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs113497813	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs61081934	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr2:84777259~84778223:-
COAD	trans	rs3740713	0.92	rs112818034	ENSG00000235847.2	LDHAP7	8.59	8.56e-16	4.17e-09	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr2:84777259~84778223:-
COAD	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-8.59	8.8e-16	4.28e-09	-0.56	-0.47	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	8.58	8.84e-16	4.3e-09	0.52	0.47	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	8.58	8.86e-16	4.31e-09	0.5	0.47	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
COAD	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	8.58	9.02e-16	4.39e-09	0.52	0.47	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
COAD	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	8.58	9.07e-16	4.41e-09	0.7	0.47	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
COAD	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	8.58	9.07e-16	4.41e-09	0.7	0.47	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
COAD	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-8.58	9.18e-16	4.46e-09	-0.79	-0.47	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
COAD	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	8.58	9.39e-16	4.56e-09	0.52	0.47	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	8.57	9.61e-16	4.66e-09	0.51	0.47	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
COAD	trans	rs6708331	0.941	rs6749886	ENSG00000232654.1	FAM136BP	8.57	9.68e-16	4.69e-09	0.74	0.47	Obesity-related traits;	chr2:70062968	chr6:3045384~3045800:+
COAD	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	8.57	9.78e-16	4.74e-09	0.69	0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
COAD	trans	rs1816752	0.875	rs59531061	ENSG00000224976.2	PARP4P2	-8.57	9.82e-16	4.76e-09	-0.55	-0.47	Obesity-related traits;	chr13:24507297	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-8.56	1.03e-15	4.99e-09	-0.56	-0.47	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-8.56	1.05e-15	5.1e-09	-0.56	-0.47	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-8.56	1.05e-15	5.1e-09	-0.56	-0.47	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	8.56	1.06e-15	5.14e-09	0.57	0.47	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	8.56	1.07e-15	5.18e-09	0.55	0.47	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
COAD	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	8.56	1.07e-15	5.2e-09	0.56	0.47	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	8.56	1.07e-15	5.2e-09	0.56	0.47	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.912	rs11042058	ENSG00000266891.1	RP11-692N5.2	8.55	1.11e-15	5.35e-09	0.56	0.47	Hypospadias;	chr11:8742268	chr18:9734882~9735602:-
COAD	trans	rs3812762	0.879	rs4929910	ENSG00000266891.1	RP11-692N5.2	-8.55	1.14e-15	5.53e-09	-0.56	-0.47	Hypospadias;	chr11:8763322	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	8.54	1.17e-15	5.65e-09	0.54	0.47	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
COAD	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	8.54	1.17e-15	5.65e-09	0.55	0.47	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	8.54	1.19e-15	5.71e-09	0.5	0.47	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-8.54	1.19e-15	5.73e-09	-0.52	-0.47	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-8.54	1.19e-15	5.74e-09	-0.56	-0.47	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-8.54	1.19e-15	5.74e-09	-0.56	-0.47	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	8.54	1.21e-15	5.8e-09	0.58	0.47	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
COAD	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-8.54	1.21e-15	5.82e-09	-0.56	-0.47	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	8.54	1.22e-15	5.88e-09	0.52	0.47	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-8.53	1.24e-15	5.96e-09	-0.59	-0.47	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	8.53	1.29e-15	6.18e-09	0.56	0.47	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	8.53	1.29e-15	6.18e-09	0.56	0.47	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-8.53	1.3e-15	6.22e-09	-0.57	-0.47	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	8.53	1.3e-15	6.23e-09	0.55	0.47	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	8.53	1.3e-15	6.23e-09	0.55	0.47	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	8.53	1.3e-15	6.23e-09	0.55	0.47	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	8.53	1.3e-15	6.23e-09	0.55	0.47	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
COAD	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	8.53	1.3e-15	6.23e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
COAD	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	8.53	1.3e-15	6.24e-09	0.53	0.47	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	8.53	1.3e-15	6.24e-09	0.53	0.47	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	8.52	1.32e-15	6.35e-09	0.59	0.47	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
COAD	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
COAD	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	8.52	1.34e-15	6.4e-09	0.68	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
COAD	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	8.52	1.38e-15	6.61e-09	0.63	0.47	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
COAD	trans	rs6708331	1	rs7578027	ENSG00000232654.1	FAM136BP	8.52	1.4e-15	6.69e-09	0.65	0.47	Obesity-related traits;	chr2:70173976	chr6:3045384~3045800:+
COAD	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	8.52	1.41e-15	6.74e-09	0.5	0.47	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
COAD	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-8.51	1.43e-15	6.85e-09	-0.58	-0.47	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
COAD	trans	rs3812762	0.912	rs10769953	ENSG00000266891.1	RP11-692N5.2	-8.51	1.47e-15	7e-09	-0.54	-0.47	Hypospadias;	chr11:8756805	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	8.5	1.56e-15	7.42e-09	0.51	0.47	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	8.5	1.56e-15	7.42e-09	0.51	0.47	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	8.5	1.57e-15	7.47e-09	0.54	0.47	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	8.5	1.59e-15	7.58e-09	0.54	0.47	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	8.49	1.63e-15	7.75e-09	0.51	0.47	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
COAD	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-8.49	1.65e-15	7.83e-09	-0.56	-0.47	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	8.49	1.72e-15	8.18e-09	0.52	0.47	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	8.49	1.72e-15	8.18e-09	0.52	0.47	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	8.49	1.72e-15	8.18e-09	0.52	0.47	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-8.49	1.73e-15	8.2e-09	-0.52	-0.47	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	8.48	1.81e-15	8.57e-09	0.53	0.47	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	8.48	1.83e-15	8.65e-09	0.52	0.47	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	8.48	1.83e-15	8.65e-09	0.52	0.47	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	8.48	1.83e-15	8.65e-09	0.52	0.47	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	8.48	1.83e-15	8.65e-09	0.52	0.47	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-8.48	1.83e-15	8.65e-09	-0.51	-0.47	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.716	rs4784987	ENSG00000230849.2	GOT2P2	8.48	1.85e-15	8.76e-09	0.56	0.47	Blood metabolite ratios;	chr16:58824135	chr1:173141100~173142350:-
COAD	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	8.47	1.88e-15	8.92e-09	0.53	0.47	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
COAD	trans	rs4276421	0.656	rs10473416	ENSG00000231752.4	EMBP1	8.47	1.89e-15	8.95e-09	0.57	0.47	P wave duration;	chr5:46246868	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.912	rs10769954	ENSG00000266891.1	RP11-692N5.2	-8.47	1.93e-15	9.11e-09	-0.55	-0.47	Hypospadias;	chr11:8762166	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	8.47	1.96e-15	9.26e-09	0.53	0.47	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	8.46	1.98e-15	9.37e-09	0.51	0.47	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	8.46	2.05e-15	9.67e-09	0.55	0.47	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-8.46	2.11e-15	9.96e-09	-0.5	-0.47	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
COAD	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-8.45	2.13e-15	1e-08	-0.61	-0.47	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
COAD	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	8.45	2.22e-15	1.05e-08	0.5	0.47	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
COAD	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	8.45	2.22e-15	1.05e-08	0.5	0.47	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	8.45	2.23e-15	1.05e-08	0.65	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	8.44	2.29e-15	1.08e-08	0.52	0.47	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
COAD	trans	rs7121616	0.531	rs11218941	ENSG00000229091.2	HSPA8P8	8.44	2.32e-15	1.09e-08	0.53	0.47	Breast cancer;	chr11:123061701	chr7:10451311~10452526:+
COAD	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	8.44	2.34e-15	1.1e-08	0.56	0.47	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
COAD	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	8.44	2.4e-15	1.13e-08	0.66	0.47	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
COAD	trans	rs5022636	0.865	rs12069445	ENSG00000180764.13	PIPSL	8.44	2.41e-15	1.13e-08	0.5	0.47	Gut microbiota (functional units);	chr1:151362964	chr10:93958191~93961540:-
COAD	trans	rs12709013	0.636	rs30835	ENSG00000233719.3	GOT2P3	8.44	2.42e-15	1.13e-08	0.59	0.47	Blood metabolite ratios;	chr16:58714117	chr12:9641802~9643007:+
COAD	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-8.43	2.43e-15	1.14e-08	-0.59	-0.47	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
COAD	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-8.43	2.48e-15	1.16e-08	-0.46	-0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
COAD	trans	rs3740713	1	rs73438690	ENSG00000235847.2	LDHAP7	8.43	2.52e-15	1.18e-08	0.78	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr2:84777259~84778223:-
COAD	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	8.42	2.6e-15	1.21e-08	0.52	0.47	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-8.42	2.67e-15	1.25e-08	-0.55	-0.47	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.594	rs7293434	ENSG00000231752.4	EMBP1	8.42	2.69e-15	1.26e-08	0.56	0.46	P wave duration;	chr5:46257587	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-8.41	2.78e-15	1.3e-08	-0.56	-0.46	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.868	rs7934519	ENSG00000266891.1	RP11-692N5.2	-8.41	2.86e-15	1.33e-08	-0.54	-0.46	Hypospadias;	chr11:8770434	chr18:9734882~9735602:-
COAD	trans	rs7554511	0.858	rs3208703	ENSG00000244144.1	RP11-757F18.3	-8.41	2.87e-15	1.34e-08	-0.71	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200970514	chr3:112185480~112185998:-
COAD	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-8.41	2.92e-15	1.36e-08	-0.53	-0.46	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
COAD	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	8.41	2.96e-15	1.37e-08	0.75	0.46	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
COAD	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	8.4	3.07e-15	1.42e-08	0.53	0.46	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
COAD	trans	rs3740713	1	rs75740864	ENSG00000235847.2	LDHAP7	8.4	3.07e-15	1.42e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:84777259~84778223:-
COAD	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	8.39	3.25e-15	1.5e-08	0.56	0.46	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
COAD	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	8.39	3.25e-15	1.5e-08	0.56	0.46	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
COAD	trans	rs11023332	1	rs11023332	ENSG00000236360.2	RP11-334A14.2	8.39	3.29e-15	1.52e-08	0.63	0.46	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr1:52993201~52993702:-
COAD	trans	rs9467773	0.933	rs2024970	ENSG00000242375.1	RP11-498P14.3	8.38	3.41e-15	1.57e-08	0.58	0.46	Intelligence (multi-trait analysis);	chr6:26497292	chr9:97195351~97197687:-
COAD	trans	rs7113874	0.559	rs34378489	ENSG00000266891.1	RP11-692N5.2	8.38	3.41e-15	1.58e-08	0.68	0.46	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8407803	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	8.38	3.45e-15	1.59e-08	0.52	0.46	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	8.38	3.49e-15	1.61e-08	0.5	0.46	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	8.38	3.53e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	8.38	3.54e-15	1.63e-08	0.55	0.46	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
COAD	trans	rs10028773	0.632	rs34481394	ENSG00000275858.1	RP11-291L22.8	8.38	3.61e-15	1.66e-08	0.53	0.46	Educational attainment;	chr4:119327219	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.666	rs35231872	ENSG00000275858.1	RP11-291L22.8	8.38	3.61e-15	1.66e-08	0.53	0.46	Educational attainment;	chr4:119327221	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.7	rs35653026	ENSG00000275858.1	RP11-291L22.8	8.38	3.61e-15	1.66e-08	0.53	0.46	Educational attainment;	chr4:119327223	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.656	rs13180509	ENSG00000231752.4	EMBP1	8.37	3.75e-15	1.72e-08	0.56	0.46	P wave duration;	chr5:46239147	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs13436334	ENSG00000231752.4	EMBP1	8.37	3.75e-15	1.72e-08	0.56	0.46	P wave duration;	chr5:46243759	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	8.37	3.77e-15	1.73e-08	0.51	0.46	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
COAD	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	8.37	3.81e-15	1.74e-08	0.56	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
COAD	trans	rs3740713	1	rs73436638	ENSG00000235847.2	LDHAP7	8.37	3.85e-15	1.76e-08	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436642	ENSG00000235847.2	LDHAP7	8.37	3.85e-15	1.76e-08	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436666	ENSG00000235847.2	LDHAP7	8.37	3.85e-15	1.76e-08	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438611	ENSG00000235847.2	LDHAP7	8.37	3.85e-15	1.76e-08	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr2:84777259~84778223:-
COAD	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	8.36	3.87e-15	1.77e-08	0.55	0.46	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.716	rs6416775	ENSG00000230849.2	GOT2P2	8.36	3.97e-15	1.81e-08	0.55	0.46	Blood metabolite ratios;	chr16:58830410	chr1:173141100~173142350:-
COAD	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-8.36	4.01e-15	1.83e-08	-0.5	-0.46	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	8.36	4.02e-15	1.83e-08	0.53	0.46	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
COAD	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	8.35	4.17e-15	1.89e-08	0.52	0.46	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	8.35	4.17e-15	1.89e-08	0.52	0.46	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
COAD	trans	rs3740713	1	rs73438631	ENSG00000235847.2	LDHAP7	8.35	4.19e-15	1.9e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr2:84777259~84778223:-
COAD	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-8.35	4.2e-15	1.9e-08	-0.5	-0.46	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs10413237	ENSG00000267533.1	RP11-815J4.7	8.35	4.3e-15	1.94e-08	0.55	0.46	Breast cancer;	chr19:18437439	chr18:12067173~12068417:-
COAD	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	8.35	4.31e-15	1.95e-08	0.58	0.46	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	8.35	4.31e-15	1.95e-08	0.58	0.46	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
COAD	trans	rs12709013	0.694	rs1616798	ENSG00000233719.3	GOT2P3	8.35	4.38e-15	1.98e-08	0.57	0.46	Blood metabolite ratios;	chr16:58739433	chr12:9641802~9643007:+
COAD	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	8.35	4.38e-15	1.98e-08	0.54	0.46	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	8.34	4.43e-15	2e-08	0.5	0.46	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
COAD	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
COAD	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-8.34	4.55e-15	2.05e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	8.34	4.72e-15	2.12e-08	0.52	0.46	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
COAD	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	8.33	4.74e-15	2.13e-08	0.57	0.46	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
COAD	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	8.33	4.84e-15	2.17e-08	0.65	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
COAD	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	8.33	5.02e-15	2.25e-08	0.75	0.46	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
COAD	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	8.32	5.08e-15	2.28e-08	0.74	0.46	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
COAD	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-8.32	5.1e-15	2.29e-08	-0.57	-0.46	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-8.32	5.1e-15	2.29e-08	-0.57	-0.46	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-8.32	5.13e-15	2.3e-08	-0.51	-0.46	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-8.32	5.13e-15	2.3e-08	-0.51	-0.46	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
COAD	trans	rs5022636	0.896	rs744536	ENSG00000180764.13	PIPSL	8.32	5.34e-15	2.37e-08	0.48	0.46	Gut microbiota (functional units);	chr1:151356318	chr10:93958191~93961540:-
COAD	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-8.31	5.41e-15	2.4e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-8.31	5.48e-15	2.43e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
COAD	trans	rs13190036	1	rs625882	ENSG00000226986.4	RP11-543B16.2	-8.31	5.49e-15	2.44e-08	-0.61	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	8.31	5.52e-15	2.45e-08	0.55	0.46	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	8.31	5.52e-15	2.45e-08	0.55	0.46	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	8.31	5.52e-15	2.45e-08	0.55	0.46	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
COAD	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	8.31	5.52e-15	2.45e-08	0.56	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
COAD	trans	rs10242455	0.85	rs3779354	ENSG00000228834.1	RP11-249L21.4	8.31	5.56e-15	2.46e-08	0.73	0.46	Blood metabolite levels;	chr7:99454805	chr6:108907615~108907873:-
COAD	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	8.3	5.79e-15	2.56e-08	0.57	0.46	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	8.3	5.79e-15	2.56e-08	0.57	0.46	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	8.3	5.79e-15	2.56e-08	0.57	0.46	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
COAD	trans	rs7554511	0.858	rs12118735	ENSG00000244144.1	RP11-757F18.3	-8.3	5.88e-15	2.6e-08	-0.71	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200981832	chr3:112185480~112185998:-
COAD	trans	rs7554511	0.858	rs7539693	ENSG00000244144.1	RP11-757F18.3	-8.3	5.88e-15	2.6e-08	-0.71	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200986438	chr3:112185480~112185998:-
COAD	trans	rs7554511	0.893	rs10494828	ENSG00000244144.1	RP11-757F18.3	-8.3	5.88e-15	2.6e-08	-0.71	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200987904	chr3:112185480~112185998:-
COAD	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-8.3	5.94e-15	2.62e-08	-0.53	-0.46	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
COAD	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-8.3	6.11e-15	2.7e-08	-0.52	-0.46	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
COAD	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-8.3	6.15e-15	2.71e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
COAD	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	8.29	6.29e-15	2.77e-08	0.51	0.46	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
COAD	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-8.29	6.36e-15	2.8e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-8.29	6.36e-15	2.8e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-8.29	6.36e-15	2.8e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-8.29	6.36e-15	2.8e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-8.29	6.36e-15	2.8e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
COAD	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	8.29	6.44e-15	2.83e-08	0.67	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
COAD	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	8.29	6.49e-15	2.86e-08	0.56	0.46	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
COAD	trans	rs7113874	0.592	rs75600349	ENSG00000266891.1	RP11-692N5.2	8.28	6.58e-15	2.89e-08	0.73	0.46	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8426545	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	8.28	6.65e-15	2.92e-08	0.52	0.46	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
COAD	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-8.28	6.66e-15	2.93e-08	-0.53	-0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
COAD	trans	rs3812762	0.957	rs10160684	ENSG00000266891.1	RP11-692N5.2	-8.28	6.74e-15	2.96e-08	-0.55	-0.46	Hypospadias;	chr11:8753872	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	8.28	6.87e-15	3.01e-08	0.51	0.46	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	8.28	6.87e-15	3.01e-08	0.51	0.46	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
COAD	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	8.28	6.92e-15	3.04e-08	0.53	0.46	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
COAD	trans	rs6708331	1	rs13429940	ENSG00000232654.1	FAM136BP	8.27	7.04e-15	3.09e-08	0.63	0.46	Obesity-related traits;	chr2:70152736	chr6:3045384~3045800:+
COAD	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	8.27	7.11e-15	3.12e-08	0.54	0.46	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	8.27	7.11e-15	3.12e-08	0.54	0.46	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	8.27	7.11e-15	3.12e-08	0.54	0.46	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	8.27	7.11e-15	3.12e-08	0.54	0.46	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	8.27	7.11e-15	3.12e-08	0.54	0.46	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
COAD	trans	rs7554511	0.858	rs12140420	ENSG00000244144.1	RP11-757F18.3	-8.27	7.35e-15	3.22e-08	-0.69	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993159	chr3:112185480~112185998:-
COAD	trans	rs6708331	0.938	rs13389246	ENSG00000232654.1	FAM136BP	8.27	7.39e-15	3.23e-08	0.65	0.46	Obesity-related traits;	chr2:70127099	chr6:3045384~3045800:+
COAD	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	8.27	7.47e-15	3.27e-08	0.67	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
COAD	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	8.26	7.51e-15	3.29e-08	0.63	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
COAD	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	8.26	7.57e-15	3.31e-08	0.56	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
COAD	trans	rs3812762	0.871	rs3844100	ENSG00000266891.1	RP11-692N5.2	-8.26	7.7e-15	3.37e-08	-0.52	-0.46	Hypospadias;	chr11:8796261	chr18:9734882~9735602:-
COAD	trans	rs2657294	0.895	rs2002023	ENSG00000172974.11	AC007318.5	8.26	7.74e-15	3.38e-08	0.51	0.46	Pneumonia;	chr10:75088766	chr2:65205108~65205988:+
COAD	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	8.26	7.75e-15	3.39e-08	0.54	0.46	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-8.26	7.78e-15	3.4e-08	-0.58	-0.46	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	8.25	8.08e-15	3.52e-08	0.5	0.46	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
COAD	trans	rs3812762	1	rs3812762	ENSG00000266891.1	RP11-692N5.2	8.25	8.29e-15	3.61e-08	0.54	0.46	Hypospadias;	chr11:8730093	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.712	rs2862898	ENSG00000224976.2	PARP4P2	-8.25	8.3e-15	3.62e-08	-0.5	-0.46	Obesity-related traits;	chr13:24414323	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.652	rs2902356	ENSG00000224976.2	PARP4P2	-8.25	8.3e-15	3.62e-08	-0.5	-0.46	Obesity-related traits;	chr13:24414333	chr13:19349137~19407962:+
COAD	trans	rs3740713	1	rs73436645	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr2:84777259~84778223:-
COAD	trans	rs3740713	0.925	rs73436650	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436655	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr2:84777259~84778223:-
COAD	trans	rs3740713	0.92	rs80254575	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436662	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs113725670	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436682	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436685	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs2056781	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73436701	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438604	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs73438607	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs75010364	ENSG00000235847.2	LDHAP7	8.25	8.41e-15	3.66e-08	0.77	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr2:84777259~84778223:-
COAD	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	8.25	8.42e-15	3.66e-08	0.49	0.46	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	8.25	8.43e-15	3.66e-08	0.5	0.46	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
COAD	trans	rs3740713	1	rs79199586	ENSG00000235847.2	LDHAP7	8.24	8.66e-15	3.76e-08	0.84	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:84777259~84778223:-
COAD	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	8.24	8.81e-15	3.82e-08	0.57	0.46	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
COAD	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	8.24	8.86e-15	3.84e-08	0.61	0.46	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
COAD	trans	rs3740713	1	rs73440625	ENSG00000235847.2	LDHAP7	8.24	8.99e-15	3.9e-08	0.76	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:84777259~84778223:-
COAD	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	8.23	9.36e-15	4.05e-08	0.57	0.46	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
COAD	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-8.23	9.48e-15	4.1e-08	-0.6	-0.46	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-8.23	9.51e-15	4.11e-08	-0.6	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
COAD	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-8.23	9.55e-15	4.13e-08	-0.57	-0.46	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
COAD	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	8.23	9.58e-15	4.14e-08	0.54	0.46	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	8.23	9.58e-15	4.14e-08	0.54	0.46	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	8.23	9.58e-15	4.14e-08	0.54	0.46	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
COAD	trans	rs7258465	1	rs4808804	ENSG00000267533.1	RP11-815J4.7	8.23	9.64e-15	4.16e-08	0.53	0.46	Breast cancer;	chr19:18474515	chr18:12067173~12068417:-
COAD	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	8.23	9.71e-15	4.2e-08	0.52	0.46	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
COAD	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-8.22	1.01e-14	4.35e-08	-0.52	-0.46	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
COAD	trans	rs13190036	0.901	rs10056655	ENSG00000228305.2	AC016734.2	8.22	1.02e-14	4.39e-08	0.57	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr2:63622178~63622831:-
COAD	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	8.22	1.02e-14	4.39e-08	0.54	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
COAD	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	8.22	1.03e-14	4.42e-08	0.55	0.46	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
COAD	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	8.22	1.04e-14	4.47e-08	0.68	0.46	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
COAD	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-8.22	1.04e-14	4.49e-08	-0.73	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
COAD	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	8.21	1.05e-14	4.51e-08	0.58	0.46	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	8.21	1.05e-14	4.51e-08	0.58	0.46	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
COAD	trans	rs3740713	1	rs73438686	ENSG00000235847.2	LDHAP7	8.21	1.05e-14	4.54e-08	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr2:84777259~84778223:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	8.21	1.06e-14	4.56e-08	0.49	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
COAD	trans	rs3812762	0.879	rs1079452	ENSG00000266891.1	RP11-692N5.2	8.21	1.06e-14	4.57e-08	0.53	0.46	Hypospadias;	chr11:8757625	chr18:9734882~9735602:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-8.21	1.07e-14	4.6e-08	-0.48	-0.46	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
COAD	trans	rs10940346	0.668	rs11746545	ENSG00000231752.4	EMBP1	-8.21	1.08e-14	4.64e-08	-0.57	-0.46	Schizophrenia;	chr5:50531238	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.691	rs7706248	ENSG00000231752.4	EMBP1	-8.21	1.08e-14	4.64e-08	-0.57	-0.46	Schizophrenia;	chr5:50537190	chr1:121519112~121571892:+
COAD	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	8.21	1.08e-14	4.65e-08	0.54	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
COAD	trans	rs73110464	0.505	rs2682296	ENSG00000220378.3	KRT8P42	-8.21	1.09e-14	4.69e-08	-0.61	-0.46	Cancer (pleiotropy);	chr12:52914481	chr6:134296997~134298695:-
COAD	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	8.21	1.09e-14	4.7e-08	0.5	0.46	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	8.21	1.09e-14	4.7e-08	0.5	0.46	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
COAD	trans	rs9467773	0.869	rs9295689	ENSG00000242375.1	RP11-498P14.3	8.21	1.11e-14	4.79e-08	0.57	0.46	Intelligence (multi-trait analysis);	chr6:26455583	chr9:97195351~97197687:-
COAD	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-8.2	1.12e-14	4.83e-08	-0.59	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.819	rs4770664	ENSG00000224976.2	PARP4P2	-8.2	1.14e-14	4.9e-08	-0.5	-0.46	Obesity-related traits;	chr13:24414695	chr13:19349137~19407962:+
COAD	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-8.2	1.15e-14	4.93e-08	-0.75	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
COAD	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-8.19	1.21e-14	5.21e-08	-0.59	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-8.19	1.21e-14	5.21e-08	-0.59	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-8.19	1.21e-14	5.21e-08	-0.59	-0.46	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-8.19	1.21e-14	5.21e-08	-0.5	-0.46	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
COAD	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	8.19	1.23e-14	5.26e-08	0.54	0.45	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
COAD	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-8.19	1.23e-14	5.26e-08	-0.57	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	8.19	1.24e-14	5.33e-08	0.51	0.45	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	8.19	1.24e-14	5.33e-08	0.51	0.45	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
COAD	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	8.19	1.26e-14	5.39e-08	0.51	0.45	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
COAD	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	8.19	1.26e-14	5.4e-08	0.56	0.45	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
COAD	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-8.18	1.29e-14	5.54e-08	-0.52	-0.45	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	8.18	1.3e-14	5.56e-08	0.5	0.45	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
COAD	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-8.18	1.31e-14	5.59e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-8.18	1.31e-14	5.59e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-8.18	1.31e-14	5.59e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-8.18	1.31e-14	5.59e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-8.18	1.31e-14	5.59e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
COAD	trans	rs6477998	0.702	rs7861707	ENSG00000238072.1	RP11-305M3.2	8.18	1.32e-14	5.65e-08	0.63	0.45	Hematology traits;	chr9:113251428	chr7:129410113~129410370:-
COAD	trans	rs959695	1	rs959695	ENSG00000260318.1	COX6CP1	8.18	1.32e-14	5.66e-08	0.64	0.45	Hippocampal atrophy;	chr8:99822954	chr16:11903923~11904137:-
COAD	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	8.18	1.36e-14	5.79e-08	0.51	0.45	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	8.18	1.36e-14	5.79e-08	0.51	0.45	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-8.17	1.36e-14	5.82e-08	-0.5	-0.45	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-8.17	1.41e-14	6e-08	-0.55	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
COAD	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-8.17	1.41e-14	6e-08	-0.55	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
COAD	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	8.16	1.49e-14	6.34e-08	0.54	0.45	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
COAD	trans	rs13190036	1	rs13185316	ENSG00000228305.2	AC016734.2	-8.16	1.51e-14	6.43e-08	-0.63	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr2:63622178~63622831:-
COAD	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-8.16	1.51e-14	6.43e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-8.16	1.51e-14	6.43e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	8.16	1.51e-14	6.43e-08	0.51	0.45	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
COAD	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-8.16	1.53e-14	6.51e-08	-0.75	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
COAD	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-8.16	1.53e-14	6.51e-08	-0.75	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
COAD	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	8.16	1.54e-14	6.53e-08	0.75	0.45	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
COAD	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	8.16	1.54e-14	6.53e-08	0.75	0.45	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
COAD	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-8.16	1.55e-14	6.57e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
COAD	trans	rs7554511	0.858	rs12142704	ENSG00000244144.1	RP11-757F18.3	-8.15	1.59e-14	6.76e-08	-0.7	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200988569	chr3:112185480~112185998:-
COAD	trans	rs12709013	0.792	rs1473206	ENSG00000233719.3	GOT2P3	8.15	1.6e-14	6.8e-08	0.56	0.45	Blood metabolite ratios;	chr16:58737529	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1473205	ENSG00000233719.3	GOT2P3	8.15	1.6e-14	6.8e-08	0.56	0.45	Blood metabolite ratios;	chr16:58737547	chr12:9641802~9643007:+
COAD	trans	rs5877	0.568	rs1951627	ENSG00000213331.4	RP11-713C19.2	8.15	1.61e-14	6.83e-08	0.53	0.45	Subjective well-being (multi-trait analysis);	chr1:173922679	chr4:187970273~187971284:+
COAD	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	8.15	1.63e-14	6.93e-08	0.54	0.45	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	8.15	1.64e-14	6.95e-08	0.55	0.45	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
COAD	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	8.14	1.66e-14	7.05e-08	0.51	0.45	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	8.14	1.69e-14	7.16e-08	0.48	0.45	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	8.14	1.69e-14	7.16e-08	0.48	0.45	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.729	rs1657179	ENSG00000233719.3	GOT2P3	8.14	1.7e-14	7.2e-08	0.56	0.45	Blood metabolite ratios;	chr16:58735115	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	8.14	1.72e-14	7.29e-08	0.48	0.45	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	8.14	1.72e-14	7.29e-08	0.48	0.45	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
COAD	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-8.14	1.73e-14	7.31e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	8.14	1.74e-14	7.35e-08	0.52	0.45	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	8.14	1.74e-14	7.35e-08	0.52	0.45	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
COAD	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	8.14	1.76e-14	7.44e-08	0.67	0.45	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
COAD	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	8.14	1.76e-14	7.45e-08	0.51	0.45	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	8.14	1.76e-14	7.45e-08	0.51	0.45	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.519	rs1451677	ENSG00000236360.2	RP11-334A14.2	8.14	1.77e-14	7.47e-08	0.61	0.45	Vitamin D levels;	chr11:14724466	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	8.13	1.79e-14	7.56e-08	0.48	0.45	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
COAD	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	8.13	1.8e-14	7.62e-08	0.67	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
COAD	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	8.13	1.84e-14	7.78e-08	0.5	0.45	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
COAD	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-8.12	1.91e-14	8.04e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
COAD	trans	rs3740713	1	rs73440614	ENSG00000235847.2	LDHAP7	8.12	1.92e-14	8.08e-08	0.75	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs1848048	ENSG00000235847.2	LDHAP7	8.12	1.92e-14	8.08e-08	0.75	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs16935432	ENSG00000235847.2	LDHAP7	8.12	1.92e-14	8.08e-08	0.75	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:84777259~84778223:-
COAD	trans	rs3740713	1	rs76599129	ENSG00000235847.2	LDHAP7	8.12	1.92e-14	8.08e-08	0.75	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:84777259~84778223:-
COAD	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	8.12	1.94e-14	8.16e-08	0.48	0.45	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	8.12	1.98e-14	8.33e-08	0.5	0.45	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
COAD	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-8.12	2.01e-14	8.47e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-8.11	2.04e-14	8.57e-08	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
COAD	trans	rs73110464	0.505	rs2638503	ENSG00000220378.3	KRT8P42	-8.11	2.07e-14	8.69e-08	-0.61	-0.45	Cancer (pleiotropy);	chr12:52913585	chr6:134296997~134298695:-
COAD	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	8.11	2.08e-14	8.73e-08	0.54	0.45	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-8.11	2.12e-14	8.89e-08	-0.49	-0.45	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
COAD	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-8.1	2.16e-14	9.09e-08	-0.53	-0.45	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
COAD	trans	rs4240897	0.935	rs2236055	ENSG00000261819.1	RP11-680G24.4	8.1	2.18e-14	9.14e-08	0.6	0.45	Tuberculosis;	chr1:11982204	chr16:14988259~14990160:-
COAD	trans	rs16937956	0.657	rs35976355	ENSG00000266891.1	RP11-692N5.2	8.1	2.19e-14	9.18e-08	0.63	0.45	Body mass index;	chr11:8407110	chr18:9734882~9735602:-
COAD	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	8.1	2.21e-14	9.28e-08	0.55	0.45	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.905	rs3818938	ENSG00000224976.2	PARP4P2	-8.1	2.23e-14	9.35e-08	-0.5	-0.45	Obesity-related traits;	chr13:24454945	chr13:19349137~19407962:+
COAD	trans	rs3812762	0.871	rs2173999	ENSG00000266891.1	RP11-692N5.2	-8.1	2.27e-14	9.52e-08	-0.51	-0.45	Hypospadias;	chr11:8756530	chr18:9734882~9735602:-
COAD	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-8.09	2.31e-14	9.67e-08	-0.66	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
COAD	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	8.09	2.32e-14	9.69e-08	0.49	0.45	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
COAD	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	8.09	2.35e-14	9.83e-08	0.56	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	8.09	2.37e-14	9.9e-08	0.5	0.45	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	8.09	2.37e-14	9.9e-08	0.5	0.45	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	8.09	2.37e-14	9.9e-08	0.5	0.45	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	8.09	2.37e-14	9.9e-08	0.5	0.45	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
COAD	trans	rs6708331	0.646	rs12713688	ENSG00000232654.1	FAM136BP	8.09	2.43e-14	1.01e-07	0.63	0.45	Obesity-related traits;	chr2:70142371	chr6:3045384~3045800:+
COAD	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	8.08	2.57e-14	1.07e-07	0.5	0.45	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
COAD	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	8.08	2.57e-14	1.07e-07	0.93	0.45	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
COAD	trans	rs13190036	1	rs59737888	ENSG00000228305.2	AC016734.2	-8.08	2.6e-14	1.08e-07	-0.64	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr2:63622178~63622831:-
COAD	trans	rs6708331	0.878	rs12994100	ENSG00000232654.1	FAM136BP	8.07	2.73e-14	1.13e-07	0.63	0.45	Obesity-related traits;	chr2:70133785	chr6:3045384~3045800:+
COAD	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	8.07	2.75e-14	1.14e-07	0.49	0.45	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
COAD	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-8.06	2.81e-14	1.16e-07	-0.49	-0.45	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
COAD	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-8.06	2.81e-14	1.17e-07	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
COAD	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	8.06	2.81e-14	1.17e-07	0.66	0.45	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
COAD	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	8.06	2.86e-14	1.18e-07	0.49	0.45	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
COAD	trans	rs8175379	0.509	rs8185010	ENSG00000231752.4	EMBP1	-8.06	2.86e-14	1.19e-07	-0.55	-0.45	Interleukin-7 levels;	chr5:46306373	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	8.06	2.94e-14	1.22e-07	0.51	0.45	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
COAD	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-8.05	3e-14	1.24e-07	-0.63	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
COAD	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	8.05	3.03e-14	1.25e-07	0.59	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
COAD	trans	rs3812762	0.917	rs2873297	ENSG00000266891.1	RP11-692N5.2	-8.05	3.07e-14	1.27e-07	-0.53	-0.45	Hypospadias;	chr11:8769680	chr18:9734882~9735602:-
COAD	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	8.05	3.09e-14	1.28e-07	0.52	0.45	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
COAD	trans	rs1816752	0.87	rs9511261	ENSG00000224976.2	PARP4P2	-8.05	3.12e-14	1.29e-07	-0.5	-0.45	Obesity-related traits;	chr13:24437880	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs9511262	ENSG00000224976.2	PARP4P2	-8.05	3.12e-14	1.29e-07	-0.5	-0.45	Obesity-related traits;	chr13:24437885	chr13:19349137~19407962:+
COAD	trans	rs2657294	0.796	rs6480770	ENSG00000172974.11	AC007318.5	8.05	3.19e-14	1.32e-07	0.51	0.45	Pneumonia;	chr10:75098799	chr2:65205108~65205988:+
COAD	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-8.04	3.19e-14	1.32e-07	-0.53	-0.45	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
COAD	trans	rs3849046	0.846	rs256006	ENSG00000226666.1	HSPA9P1	8.04	3.21e-14	1.33e-07	0.44	0.45	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561405	chr2:221961737~221963765:+
COAD	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	8.04	3.27e-14	1.35e-07	0.49	0.45	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	8.04	3.27e-14	1.35e-07	0.49	0.45	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	8.04	3.27e-14	1.35e-07	0.49	0.45	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.87	rs7320102	ENSG00000224976.2	PARP4P2	-8.04	3.35e-14	1.38e-07	-0.5	-0.45	Obesity-related traits;	chr13:24437435	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs7339140	ENSG00000224976.2	PARP4P2	-8.04	3.35e-14	1.38e-07	-0.5	-0.45	Obesity-related traits;	chr13:24437764	chr13:19349137~19407962:+
COAD	trans	rs7258465	0.965	rs748609	ENSG00000267533.1	RP11-815J4.7	8.04	3.35e-14	1.38e-07	0.52	0.45	Breast cancer;	chr19:18449472	chr18:12067173~12068417:-
COAD	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-8.04	3.4e-14	1.4e-07	-0.66	-0.45	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	8.03	3.4e-14	1.4e-07	0.5	0.45	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.713	rs7336357	ENSG00000224976.2	PARP4P2	-8.03	3.46e-14	1.42e-07	-0.51	-0.45	Obesity-related traits;	chr13:24443452	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.683	rs7330532	ENSG00000224976.2	PARP4P2	-8.03	3.46e-14	1.42e-07	-0.51	-0.45	Obesity-related traits;	chr13:24443453	chr13:19349137~19407962:+
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	8.03	3.47e-14	1.43e-07	0.47	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
COAD	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	8.03	3.49e-14	1.43e-07	0.52	0.45	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
COAD	trans	rs7121616	1	rs75228513	ENSG00000234176.1	HSPA8P1	8.03	3.51e-14	1.44e-07	0.49	0.45	Breast cancer;	chr11:123096160	chrX:121203182~121205014:-
COAD	trans	rs7121616	1	rs79401687	ENSG00000234176.1	HSPA8P1	8.03	3.51e-14	1.44e-07	0.49	0.45	Breast cancer;	chr11:123096264	chrX:121203182~121205014:-
COAD	trans	rs13190036	0.792	rs6874206	ENSG00000228305.2	AC016734.2	-8.03	3.53e-14	1.45e-07	-0.55	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr2:63622178~63622831:-
COAD	trans	rs13190036	0.901	rs10072499	ENSG00000228305.2	AC016734.2	-8.03	3.53e-14	1.45e-07	-0.55	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr2:63622178~63622831:-
COAD	trans	rs1816752	0.783	rs7317439	ENSG00000224976.2	PARP4P2	-8.03	3.54e-14	1.46e-07	-0.49	-0.45	Obesity-related traits;	chr13:24410939	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.819	rs7316961	ENSG00000224976.2	PARP4P2	-8.03	3.54e-14	1.46e-07	-0.49	-0.45	Obesity-related traits;	chr13:24411039	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.819	rs9511240	ENSG00000224976.2	PARP4P2	-8.03	3.54e-14	1.46e-07	-0.49	-0.45	Obesity-related traits;	chr13:24411768	chr13:19349137~19407962:+
COAD	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-8.03	3.61e-14	1.48e-07	-0.63	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
COAD	trans	rs1816752	0.819	rs6490917	ENSG00000224976.2	PARP4P2	-8.02	3.67e-14	1.51e-07	-0.49	-0.45	Obesity-related traits;	chr13:24423119	chr13:19349137~19407962:+
COAD	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-8.02	3.69e-14	1.52e-07	-0.47	-0.45	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-8.02	3.69e-14	1.52e-07	-0.47	-0.45	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-8.02	3.71e-14	1.52e-07	-0.52	-0.45	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
COAD	trans	rs1816752	0.905	rs1050112	ENSG00000224976.2	PARP4P2	-8.02	3.72e-14	1.53e-07	-0.5	-0.45	Obesity-related traits;	chr13:24435159	chr13:19349137~19407962:+
COAD	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	8.02	3.72e-14	1.53e-07	0.5	0.45	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-8.02	3.72e-14	1.53e-07	-0.57	-0.45	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-8.02	3.72e-14	1.53e-07	-0.57	-0.45	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
COAD	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-8.02	3.74e-14	1.53e-07	-0.59	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
COAD	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	8.02	3.74e-14	1.53e-07	0.73	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
COAD	trans	rs1816752	0.783	rs7139527	ENSG00000224976.2	PARP4P2	-8.02	3.85e-14	1.58e-07	-0.48	-0.45	Obesity-related traits;	chr13:24411374	chr13:19349137~19407962:+
COAD	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	8.01	3.88e-14	1.59e-07	0.58	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
COAD	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-8.01	3.94e-14	1.61e-07	-0.64	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
COAD	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-8.01	3.94e-14	1.61e-07	-0.64	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
COAD	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-8.01	3.94e-14	1.61e-07	-0.64	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
COAD	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	8.01	3.94e-14	1.61e-07	0.5	0.45	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
COAD	trans	rs6708331	0.816	rs10196979	ENSG00000232654.1	FAM136BP	8.01	4e-14	1.63e-07	0.63	0.45	Obesity-related traits;	chr2:70140265	chr6:3045384~3045800:+
COAD	trans	rs1816752	0.819	rs7988388	ENSG00000224976.2	PARP4P2	-8.01	4.04e-14	1.65e-07	-0.48	-0.45	Obesity-related traits;	chr13:24412675	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.875	rs7993132	ENSG00000224976.2	PARP4P2	-8.01	4.04e-14	1.65e-07	-0.48	-0.45	Obesity-related traits;	chr13:24412903	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.792	rs7330956	ENSG00000224976.2	PARP4P2	-8.01	4.04e-14	1.65e-07	-0.48	-0.45	Obesity-related traits;	chr13:24413174	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-8.01	4.05e-14	1.65e-07	-0.55	-0.45	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
COAD	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
COAD	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	8.01	4.13e-14	1.68e-07	0.48	0.45	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	8	4.17e-14	1.7e-07	0.57	0.45	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
COAD	trans	rs3812762	0.871	rs10734637	ENSG00000266891.1	RP11-692N5.2	-8	4.36e-14	1.77e-07	-0.5	-0.45	Hypospadias;	chr11:8766678	chr18:9734882~9735602:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	8	4.38e-14	1.78e-07	0.47	0.45	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
COAD	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-8	4.41e-14	1.79e-07	-0.64	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
COAD	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	7.99	4.43e-14	1.8e-07	0.56	0.45	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
COAD	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-7.99	4.51e-14	1.83e-07	-0.54	-0.45	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	7.99	4.52e-14	1.84e-07	0.48	0.45	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
COAD	trans	rs3812762	0.879	rs4929934	ENSG00000266891.1	RP11-692N5.2	-7.99	4.54e-14	1.85e-07	-0.52	-0.45	Hypospadias;	chr11:8756242	chr18:9734882~9735602:-
COAD	trans	rs16937956	0.597	rs34617462	ENSG00000266891.1	RP11-692N5.2	7.99	4.55e-14	1.85e-07	0.64	0.45	Body mass index;	chr11:8403484	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	7.99	4.58e-14	1.86e-07	0.51	0.45	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
COAD	trans	rs6477998	0.603	rs12338803	ENSG00000238072.1	RP11-305M3.2	7.99	4.62e-14	1.88e-07	0.72	0.45	Hematology traits;	chr9:113263148	chr7:129410113~129410370:-
COAD	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-7.99	4.67e-14	1.9e-07	-0.56	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
COAD	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	7.98	4.73e-14	1.92e-07	0.5	0.45	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	7.98	4.73e-14	1.92e-07	0.5	0.45	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	7.98	4.73e-14	1.92e-07	0.5	0.45	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	7.98	4.83e-14	1.96e-07	0.55	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
COAD	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-7.98	4.88e-14	1.98e-07	-0.58	-0.45	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
COAD	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	7.98	4.92e-14	1.99e-07	0.55	0.45	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
COAD	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	7.98	5.01e-14	2.03e-07	0.47	0.45	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
COAD	trans	rs1816752	0.666	rs7994022	ENSG00000224976.2	PARP4P2	-7.97	5.07e-14	2.05e-07	-0.51	-0.45	Obesity-related traits;	chr13:24443092	chr13:19349137~19407962:+
COAD	trans	rs3812762	0.917	rs10743087	ENSG00000266891.1	RP11-692N5.2	-7.97	5.08e-14	2.06e-07	-0.52	-0.45	Hypospadias;	chr11:8764511	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.819	rs7317504	ENSG00000224976.2	PARP4P2	-7.97	5.09e-14	2.06e-07	-0.48	-0.45	Obesity-related traits;	chr13:24411287	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.783	rs7317712	ENSG00000224976.2	PARP4P2	-7.97	5.09e-14	2.06e-07	-0.48	-0.45	Obesity-related traits;	chr13:24411365	chr13:19349137~19407962:+
COAD	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	7.97	5.21e-14	2.11e-07	0.5	0.45	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.819	rs7985478	ENSG00000224976.2	PARP4P2	-7.96	5.43e-14	2.2e-07	-0.49	-0.44	Obesity-related traits;	chr13:24417135	chr13:19349137~19407962:+
COAD	trans	rs3740713	1	rs35593189	ENSG00000235847.2	LDHAP7	7.96	5.53e-14	2.24e-07	0.73	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:84777259~84778223:-
COAD	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	7.96	5.64e-14	2.28e-07	0.77	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
COAD	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-7.96	5.68e-14	2.29e-07	-0.52	-0.44	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
COAD	trans	rs16937956	0.626	rs34922792	ENSG00000266891.1	RP11-692N5.2	7.96	5.71e-14	2.31e-07	0.63	0.44	Body mass index;	chr11:8394952	chr18:9734882~9735602:-
COAD	trans	rs16937956	0.597	rs35022013	ENSG00000266891.1	RP11-692N5.2	7.96	5.71e-14	2.31e-07	0.63	0.44	Body mass index;	chr11:8395956	chr18:9734882~9735602:-
COAD	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	7.95	5.77e-14	2.33e-07	0.48	0.44	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
COAD	trans	rs6708331	0.941	rs11903933	ENSG00000232654.1	FAM136BP	7.95	5.78e-14	2.33e-07	0.61	0.44	Obesity-related traits;	chr2:70149812	chr6:3045384~3045800:+
COAD	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	7.95	5.78e-14	2.33e-07	0.52	0.44	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	7.95	5.78e-14	2.33e-07	0.52	0.44	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-7.95	5.79e-14	2.34e-07	-0.52	-0.44	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-7.95	5.79e-14	2.34e-07	-0.52	-0.44	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	7.95	5.9e-14	2.38e-07	0.52	0.44	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
COAD	trans	rs13190036	1	rs625882	ENSG00000228305.2	AC016734.2	-7.95	5.91e-14	2.38e-07	-0.59	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr2:63622178~63622831:-
COAD	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-7.95	5.94e-14	2.39e-07	-0.55	-0.44	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
COAD	trans	rs3812762	0.833	rs3850933	ENSG00000266891.1	RP11-692N5.2	-7.95	5.98e-14	2.41e-07	-0.52	-0.44	Hypospadias;	chr11:8779588	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	7.95	5.99e-14	2.42e-07	0.48	0.44	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.755	rs1981277	ENSG00000224976.2	PARP4P2	-7.95	6.01e-14	2.42e-07	-0.48	-0.44	Obesity-related traits;	chr13:24409375	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.712	rs9507335	ENSG00000224976.2	PARP4P2	-7.95	6.01e-14	2.42e-07	-0.48	-0.44	Obesity-related traits;	chr13:24409766	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.774	rs2862895	ENSG00000224976.2	PARP4P2	-7.95	6.01e-14	2.42e-07	-0.48	-0.44	Obesity-related traits;	chr13:24410328	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.811	rs9507337	ENSG00000224976.2	PARP4P2	-7.95	6.01e-14	2.42e-07	-0.48	-0.44	Obesity-related traits;	chr13:24410807	chr13:19349137~19407962:+
COAD	trans	rs72615157	0.561	rs113401658	ENSG00000228546.2	CTA-313A17.3	7.95	6.03e-14	2.43e-07	0.71	0.44	Lung function (FEV1/FVC);	chr7:100260882	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.776	rs7998843	ENSG00000224976.2	PARP4P2	-7.95	6.04e-14	2.43e-07	-0.5	-0.44	Obesity-related traits;	chr13:24443147	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.712	rs6490932	ENSG00000224976.2	PARP4P2	-7.95	6.04e-14	2.43e-07	-0.5	-0.44	Obesity-related traits;	chr13:24443313	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.59	rs61947036	ENSG00000224976.2	PARP4P2	-7.95	6.04e-14	2.43e-07	-0.5	-0.44	Obesity-related traits;	chr13:24443544	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.776	rs9511268	ENSG00000224976.2	PARP4P2	-7.95	6.04e-14	2.43e-07	-0.5	-0.44	Obesity-related traits;	chr13:24444182	chr13:19349137~19407962:+
COAD	trans	rs28375303	1	rs28375303	ENSG00000267533.1	RP11-815J4.7	7.94	6.28e-14	2.53e-07	0.53	0.44	Monocyte count;	chr19:18419351	chr18:12067173~12068417:-
COAD	trans	rs1816752	0.777	rs6490915	ENSG00000224976.2	PARP4P2	-7.94	6.47e-14	2.6e-07	-0.48	-0.44	Obesity-related traits;	chr13:24413724	chr13:19349137~19407962:+
COAD	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	7.94	6.51e-14	2.62e-07	0.54	0.44	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
COAD	trans	rs6708331	0.941	rs12989076	ENSG00000232654.1	FAM136BP	7.93	6.53e-14	2.62e-07	0.62	0.44	Obesity-related traits;	chr2:70176275	chr6:3045384~3045800:+
COAD	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	7.93	6.54e-14	2.63e-07	0.55	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
COAD	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	7.93	6.63e-14	2.66e-07	0.56	0.44	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	7.93	6.63e-14	2.66e-07	0.56	0.44	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	7.93	6.63e-14	2.66e-07	0.56	0.44	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	7.93	6.63e-14	2.66e-07	0.56	0.44	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.905	rs11839006	ENSG00000224976.2	PARP4P2	-7.93	6.76e-14	2.71e-07	-0.49	-0.44	Obesity-related traits;	chr13:24435893	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs2033955	ENSG00000224976.2	PARP4P2	-7.93	6.76e-14	2.71e-07	-0.49	-0.44	Obesity-related traits;	chr13:24436406	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs2033954	ENSG00000224976.2	PARP4P2	-7.93	6.76e-14	2.71e-07	-0.49	-0.44	Obesity-related traits;	chr13:24436429	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs9511260	ENSG00000224976.2	PARP4P2	-7.93	6.76e-14	2.71e-07	-0.49	-0.44	Obesity-related traits;	chr13:24437038	chr13:19349137~19407962:+
COAD	trans	rs6708331	0.941	rs6720799	ENSG00000232654.1	FAM136BP	-7.93	6.77e-14	2.72e-07	-0.61	-0.44	Obesity-related traits;	chr2:70144897	chr6:3045384~3045800:+
COAD	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	7.93	6.81e-14	2.73e-07	0.56	0.44	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	7.93	6.92e-14	2.77e-07	0.56	0.44	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	7.92	6.98e-14	2.79e-07	0.56	0.44	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
COAD	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-7.92	6.99e-14	2.8e-07	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	7.92	7.01e-14	2.81e-07	0.5	0.44	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	7.92	7.01e-14	2.81e-07	0.5	0.44	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	7.92	7.05e-14	2.82e-07	0.55	0.44	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	7.92	7.15e-14	2.86e-07	0.48	0.44	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	7.92	7.15e-14	2.86e-07	0.48	0.44	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
COAD	trans	rs3812762	0.917	rs11042066	ENSG00000266891.1	RP11-692N5.2	-7.92	7.31e-14	2.92e-07	-0.52	-0.44	Hypospadias;	chr11:8788013	chr18:9734882~9735602:-
COAD	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	7.92	7.34e-14	2.93e-07	0.55	0.44	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	7.92	7.34e-14	2.93e-07	0.55	0.44	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
COAD	trans	rs3740713	1	rs75487138	ENSG00000235847.2	LDHAP7	7.91	7.5e-14	2.99e-07	0.75	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:84777259~84778223:-
COAD	trans	rs1816752	0.87	rs8000215	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.49	-0.44	Obesity-related traits;	chr13:24435648	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.817	rs7985394	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24438714	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.789	rs7986037	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24438715	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs7995909	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24439159	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs6490927	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24439802	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs6490928	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24439921	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs6490929	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24440114	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs3825449	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24440303	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs7998797	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24440850	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs7981337	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24440915	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs7981480	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24440966	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.837	rs4769355	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24441059	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs4770680	ENSG00000224976.2	PARP4P2	-7.91	7.62e-14	3.04e-07	-0.5	-0.44	Obesity-related traits;	chr13:24441110	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs13428	ENSG00000224976.2	PARP4P2	-7.91	7.74e-14	3.08e-07	-0.49	-0.44	Obesity-related traits;	chr13:24435303	chr13:19349137~19407962:+
COAD	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-7.91	7.8e-14	3.11e-07	-0.47	-0.44	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
COAD	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	7.9	8.04e-14	3.2e-07	0.56	0.44	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
COAD	trans	rs12709013	1	rs11641836	ENSG00000230849.2	GOT2P2	7.9	8.07e-14	3.21e-07	0.53	0.44	Blood metabolite ratios;	chr16:58798143	chr1:173141100~173142350:-
COAD	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-7.9	8.29e-14	3.29e-07	-0.47	-0.44	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.901	rs6556309	ENSG00000228305.2	AC016734.2	7.9	8.34e-14	3.31e-07	0.54	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr2:63622178~63622831:-
COAD	trans	rs3812762	0.879	rs3763920	ENSG00000266891.1	RP11-692N5.2	7.9	8.42e-14	3.34e-07	0.53	0.44	Hypospadias;	chr11:8787040	chr18:9734882~9735602:-
COAD	trans	rs12709013	1	rs12599931	ENSG00000230849.2	GOT2P2	7.89	8.44e-14	3.35e-07	0.53	0.44	Blood metabolite ratios;	chr16:58792627	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.633	rs8002387	ENSG00000224976.2	PARP4P2	-7.89	8.48e-14	3.36e-07	-0.48	-0.44	Obesity-related traits;	chr13:24416306	chr13:19349137~19407962:+
COAD	trans	rs3812762	0.843	rs2292046	ENSG00000266891.1	RP11-692N5.2	-7.89	8.53e-14	3.39e-07	-0.52	-0.44	Hypospadias;	chr11:8785632	chr18:9734882~9735602:-
COAD	trans	rs3812762	0.879	rs3844099	ENSG00000266891.1	RP11-692N5.2	-7.89	8.53e-14	3.39e-07	-0.52	-0.44	Hypospadias;	chr11:8786705	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.819	rs4770665	ENSG00000224976.2	PARP4P2	-7.89	8.56e-14	3.4e-07	-0.48	-0.44	Obesity-related traits;	chr13:24414810	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.721	rs7399656	ENSG00000224976.2	PARP4P2	-7.89	8.56e-14	3.4e-07	-0.48	-0.44	Obesity-related traits;	chr13:24415708	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.749	rs77832754	ENSG00000224976.2	PARP4P2	-7.89	8.56e-14	3.4e-07	-0.48	-0.44	Obesity-related traits;	chr13:24416016	chr13:19349137~19407962:+
COAD	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	7.89	8.57e-14	3.4e-07	0.51	0.44	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.748	rs6490912	ENSG00000224976.2	PARP4P2	-7.89	8.65e-14	3.43e-07	-0.48	-0.44	Obesity-related traits;	chr13:24408941	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.819	rs1981276	ENSG00000224976.2	PARP4P2	-7.89	8.65e-14	3.43e-07	-0.48	-0.44	Obesity-related traits;	chr13:24409361	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.837	rs57052031	ENSG00000224976.2	PARP4P2	-7.89	8.65e-14	3.43e-07	-0.48	-0.44	Obesity-related traits;	chr13:24409730	chr13:19349137~19407962:+
COAD	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-7.89	8.7e-14	3.45e-07	-0.58	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
COAD	trans	rs3812762	0.879	rs10769952	ENSG00000266891.1	RP11-692N5.2	-7.89	8.93e-14	3.54e-07	-0.51	-0.44	Hypospadias;	chr11:8755153	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.875	rs1050110	ENSG00000224976.2	PARP4P2	-7.89	8.94e-14	3.54e-07	-0.49	-0.44	Obesity-related traits;	chr13:24435347	chr13:19349137~19407962:+
COAD	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-7.88	9.24e-14	3.65e-07	-0.58	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
COAD	trans	rs16937956	0.657	rs16938063	ENSG00000266891.1	RP11-692N5.2	-7.88	9.31e-14	3.68e-07	-0.6	-0.44	Body mass index;	chr11:8410110	chr18:9734882~9735602:-
COAD	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-7.88	9.4e-14	3.71e-07	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
COAD	trans	rs3849046	0.901	rs11956240	ENSG00000226666.1	HSPA9P1	7.88	9.4e-14	3.71e-07	0.43	0.44	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138504604	chr2:221961737~221963765:+
COAD	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-7.88	9.41e-14	3.72e-07	-0.52	-0.44	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.806	rs3816218	ENSG00000224976.2	PARP4P2	-7.88	9.59e-14	3.79e-07	-0.5	-0.44	Obesity-related traits;	chr13:24443033	chr13:19349137~19407962:+
COAD	trans	rs10940346	0.506	rs7721806	ENSG00000231752.4	EMBP1	-7.87	9.62e-14	3.8e-07	-0.53	-0.44	Schizophrenia;	chr5:50576182	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.879	rs10743089	ENSG00000266891.1	RP11-692N5.2	7.87	9.69e-14	3.83e-07	0.51	0.44	Hypospadias;	chr11:8766621	chr18:9734882~9735602:-
COAD	trans	rs16937956	0.657	rs3751095	ENSG00000266891.1	RP11-692N5.2	7.87	9.86e-14	3.89e-07	0.61	0.44	Body mass index;	chr11:8413530	chr18:9734882~9735602:-
COAD	trans	rs16937956	0.657	rs3751096	ENSG00000266891.1	RP11-692N5.2	7.87	9.86e-14	3.89e-07	0.61	0.44	Body mass index;	chr11:8413531	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	7.87	9.95e-14	3.92e-07	0.48	0.44	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	7.87	9.95e-14	3.92e-07	0.48	0.44	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.539	rs10832310	ENSG00000236360.2	RP11-334A14.2	7.86	1.04e-13	4.08e-07	0.6	0.44	Vitamin D levels;	chr11:14856896	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.539	rs10832311	ENSG00000236360.2	RP11-334A14.2	7.86	1.04e-13	4.08e-07	0.6	0.44	Vitamin D levels;	chr11:14860380	chr1:52993201~52993702:-
COAD	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	7.86	1.04e-13	4.1e-07	0.5	0.44	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
COAD	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	7.86	1.07e-13	4.2e-07	0.55	0.44	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
COAD	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-7.86	1.09e-13	4.27e-07	-0.62	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
COAD	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-7.85	1.1e-13	4.32e-07	-0.57	-0.44	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
COAD	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	7.85	1.11e-13	4.35e-07	0.51	0.44	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	7.85	1.13e-13	4.42e-07	0.51	0.44	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	7.85	1.13e-13	4.42e-07	0.51	0.44	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	7.85	1.13e-13	4.42e-07	0.51	0.44	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	7.85	1.13e-13	4.42e-07	0.51	0.44	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
COAD	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	7.85	1.15e-13	4.51e-07	0.6	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
COAD	trans	rs3812762	0.879	rs10769959	ENSG00000266891.1	RP11-692N5.2	-7.85	1.15e-13	4.52e-07	-0.54	-0.44	Hypospadias;	chr11:8797286	chr18:9734882~9735602:-
COAD	trans	rs55665837	0.701	rs11023278	ENSG00000236360.2	RP11-334A14.2	7.85	1.16e-13	4.54e-07	0.62	0.44	Vitamin D levels;	chr11:14619638	chr1:52993201~52993702:-
COAD	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	7.85	1.16e-13	4.54e-07	0.55	0.44	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
COAD	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	7.85	1.16e-13	4.56e-07	0.51	0.44	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
COAD	trans	rs61990749	1	rs61990749	ENSG00000235400.1	RP4-641G12.4	-7.84	1.17e-13	4.58e-07	-0.91	-0.44	Fibroblast growth factor basic levels;	chr14:77906158	chr1:78749073~78750659:+
COAD	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.62e-07	0.55	0.44	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.62e-07	0.55	0.44	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.62e-07	0.55	0.44	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.62e-07	0.55	0.44	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.64e-07	0.55	0.44	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.64e-07	0.55	0.44	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.64e-07	0.55	0.44	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	7.84	1.18e-13	4.64e-07	0.55	0.44	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
COAD	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-7.84	1.18e-13	4.64e-07	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-7.84	1.18e-13	4.64e-07	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	7.84	1.19e-13	4.64e-07	0.55	0.44	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-7.84	1.22e-13	4.76e-07	-0.49	-0.44	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-7.84	1.22e-13	4.76e-07	-0.49	-0.44	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
COAD	trans	rs72615157	0.561	rs113844570	ENSG00000228546.2	CTA-313A17.3	7.83	1.24e-13	4.85e-07	0.71	0.44	Lung function (FEV1/FVC);	chr7:100276155	chr7:102337316~102339115:+
COAD	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-7.83	1.25e-13	4.87e-07	-0.51	-0.44	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-7.83	1.26e-13	4.92e-07	-0.51	-0.44	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
COAD	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-7.83	1.3e-13	5.09e-07	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
COAD	trans	rs1816752	0.805	rs61614647	ENSG00000224976.2	PARP4P2	-7.83	1.32e-13	5.14e-07	-0.49	-0.44	Obesity-related traits;	chr13:24441829	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.774	rs55888616	ENSG00000224976.2	PARP4P2	-7.83	1.32e-13	5.14e-07	-0.49	-0.44	Obesity-related traits;	chr13:24441954	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-7.82	1.34e-13	5.24e-07	-0.51	-0.44	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	7.82	1.35e-13	5.26e-07	0.51	0.44	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
COAD	trans	rs55665837	0.701	rs10766188	ENSG00000236360.2	RP11-334A14.2	7.82	1.41e-13	5.48e-07	0.62	0.44	Vitamin D levels;	chr11:14639280	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.701	rs2007361	ENSG00000236360.2	RP11-334A14.2	7.82	1.41e-13	5.48e-07	0.62	0.44	Vitamin D levels;	chr11:14641176	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.701	rs11023272	ENSG00000236360.2	RP11-334A14.2	7.81	1.43e-13	5.57e-07	0.62	0.44	Vitamin D levels;	chr11:14608824	chr1:52993201~52993702:-
COAD	trans	rs55665837	0.665	rs11023273	ENSG00000236360.2	RP11-334A14.2	7.81	1.43e-13	5.57e-07	0.62	0.44	Vitamin D levels;	chr11:14609273	chr1:52993201~52993702:-
COAD	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-7.81	1.45e-13	5.66e-07	-0.55	-0.44	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-7.81	1.47e-13	5.72e-07	-0.51	-0.44	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-7.81	1.47e-13	5.72e-07	-0.51	-0.44	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.905	rs9511266	ENSG00000224976.2	PARP4P2	-7.8	1.51e-13	5.89e-07	-0.49	-0.44	Obesity-related traits;	chr13:24438366	chr13:19349137~19407962:+
COAD	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	7.8	1.52e-13	5.92e-07	0.49	0.44	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	7.8	1.52e-13	5.92e-07	0.49	0.44	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
COAD	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	7.8	1.52e-13	5.92e-07	0.49	0.44	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
COAD	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	7.8	1.52e-13	5.92e-07	0.49	0.44	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.716	rs6416775	ENSG00000233719.3	GOT2P3	7.8	1.56e-13	6.07e-07	0.54	0.44	Blood metabolite ratios;	chr16:58830410	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	7.8	1.59e-13	6.17e-07	0.46	0.44	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-7.79	1.62e-13	6.27e-07	-0.46	-0.44	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
COAD	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-7.79	1.63e-13	6.33e-07	-0.63	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
COAD	trans	rs3812762	0.871	rs11603335	ENSG00000266891.1	RP11-692N5.2	-7.79	1.64e-13	6.37e-07	-0.5	-0.44	Hypospadias;	chr11:8788297	chr18:9734882~9735602:-
COAD	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-7.79	1.67e-13	6.45e-07	-0.56	-0.44	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
COAD	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	7.79	1.68e-13	6.48e-07	0.84	0.44	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
COAD	trans	rs3849046	0.846	rs462783	ENSG00000226666.1	HSPA9P1	-7.79	1.68e-13	6.5e-07	-0.42	-0.44	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536427	chr2:221961737~221963765:+
COAD	trans	rs4276421	0.806	rs10079739	ENSG00000231752.4	EMBP1	-7.79	1.68e-13	6.5e-07	-0.51	-0.44	P wave duration;	chr5:45607597	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.935	rs8046667	ENSG00000230849.2	GOT2P2	7.79	1.71e-13	6.6e-07	0.54	0.44	Blood metabolite ratios;	chr16:58790935	chr1:173141100~173142350:-
COAD	trans	rs12709013	1	rs8046998	ENSG00000230849.2	GOT2P2	7.79	1.71e-13	6.6e-07	0.54	0.44	Blood metabolite ratios;	chr16:58791109	chr1:173141100~173142350:-
COAD	trans	rs55665837	0.701	rs11023265	ENSG00000236360.2	RP11-334A14.2	7.78	1.78e-13	6.87e-07	0.62	0.44	Vitamin D levels;	chr11:14594492	chr1:52993201~52993702:-
COAD	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	7.78	1.79e-13	6.91e-07	0.56	0.44	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-7.78	1.79e-13	6.91e-07	-0.56	-0.44	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-7.78	1.79e-13	6.91e-07	-0.56	-0.44	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
COAD	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	7.78	1.8e-13	6.96e-07	0.54	0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
COAD	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-7.77	1.83e-13	7.04e-07	-0.61	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
COAD	trans	rs7554511	0.929	rs55757739	ENSG00000244144.1	RP11-757F18.3	-7.77	1.87e-13	7.22e-07	-0.68	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200997848	chr3:112185480~112185998:-
COAD	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-7.77	1.88e-13	7.25e-07	-0.55	-0.44	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
COAD	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	7.77	1.89e-13	7.28e-07	0.59	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
COAD	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	7.77	1.9e-13	7.34e-07	0.89	0.44	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
COAD	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	7.77	1.91e-13	7.36e-07	0.54	0.44	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	7.77	1.91e-13	7.36e-07	0.54	0.44	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
COAD	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	7.77	1.92e-13	7.38e-07	0.46	0.44	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
COAD	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	7.77	1.93e-13	7.44e-07	0.54	0.44	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	7.77	1.94e-13	7.47e-07	0.54	0.44	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	7.77	1.94e-13	7.47e-07	0.54	0.44	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	7.77	1.94e-13	7.47e-07	0.54	0.44	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
COAD	trans	rs6477998	0.58	rs10817467	ENSG00000238072.1	RP11-305M3.2	7.76	1.95e-13	7.5e-07	0.71	0.44	Hematology traits;	chr9:113246803	chr7:129410113~129410370:-
COAD	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-7.76	1.97e-13	7.57e-07	-0.55	-0.44	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
COAD	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	7.76	1.99e-13	7.65e-07	0.46	0.44	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
COAD	trans	rs3740713	1	rs73436668	ENSG00000235847.2	LDHAP7	7.76	2e-13	7.68e-07	0.74	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:84777259~84778223:-
COAD	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	7.76	2.04e-13	7.82e-07	0.51	0.44	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
COAD	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	7.76	2.04e-13	7.83e-07	0.61	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
COAD	trans	rs10940346	0.506	rs11741135	ENSG00000231752.4	EMBP1	-7.76	2.05e-13	7.85e-07	-0.53	-0.44	Schizophrenia;	chr5:50579604	chr1:121519112~121571892:+
COAD	trans	rs3849046	0.846	rs10117	ENSG00000226666.1	HSPA9P1	7.76	2.05e-13	7.87e-07	0.43	0.44	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138556481	chr2:221961737~221963765:+
COAD	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	7.76	2.07e-13	7.93e-07	0.54	0.44	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	7.75	2.09e-13	8.02e-07	0.54	0.44	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
COAD	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-7.75	2.1e-13	8.04e-07	-0.51	-0.44	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-7.75	2.1e-13	8.04e-07	-0.51	-0.44	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-7.75	2.1e-13	8.04e-07	-0.51	-0.44	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-7.75	2.1e-13	8.04e-07	-0.51	-0.44	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.843	rs10732515	ENSG00000266891.1	RP11-692N5.2	-7.75	2.12e-13	8.13e-07	-0.51	-0.44	Hypospadias;	chr11:8780243	chr18:9734882~9735602:-
COAD	trans	rs12709013	0.716	rs4784987	ENSG00000233719.3	GOT2P3	7.75	2.15e-13	8.23e-07	0.55	0.44	Blood metabolite ratios;	chr16:58824135	chr12:9641802~9643007:+
COAD	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-7.75	2.16e-13	8.26e-07	-0.5	-0.44	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
COAD	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-7.75	2.17e-13	8.31e-07	-0.55	-0.44	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-7.75	2.18e-13	8.32e-07	-0.55	-0.44	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-7.75	2.18e-13	8.32e-07	-0.55	-0.44	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
COAD	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-7.75	2.19e-13	8.37e-07	-0.41	-0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	7.75	2.2e-13	8.41e-07	0.49	0.44	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
COAD	trans	rs55665837	0.701	rs12286408	ENSG00000236360.2	RP11-334A14.2	7.74	2.25e-13	8.59e-07	0.62	0.43	Vitamin D levels;	chr11:14557830	chr1:52993201~52993702:-
COAD	trans	rs11023332	0.706	rs11023380	ENSG00000236360.2	RP11-334A14.2	7.74	2.31e-13	8.8e-07	0.59	0.43	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr1:52993201~52993702:-
COAD	trans	rs11023332	0.8	rs12271890	ENSG00000236360.2	RP11-334A14.2	7.74	2.31e-13	8.8e-07	0.59	0.43	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr1:52993201~52993702:-
COAD	trans	rs3849046	1	rs3849046	ENSG00000226666.1	HSPA9P1	7.74	2.33e-13	8.88e-07	0.41	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138515503	chr2:221961737~221963765:+
COAD	trans	rs13190036	0.551	rs1052432	ENSG00000228305.2	AC016734.2	-7.73	2.37e-13	9.01e-07	-0.56	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr2:63622178~63622831:-
COAD	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	7.73	2.37e-13	9.03e-07	0.94	0.43	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
COAD	trans	rs7554511	0.893	rs11580823	ENSG00000244144.1	RP11-757F18.3	-7.73	2.38e-13	9.04e-07	-0.66	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201014361	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	7.73	2.41e-13	9.18e-07	0.53	0.43	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.819	rs4769349	ENSG00000224976.2	PARP4P2	7.73	2.43e-13	9.23e-07	0.46	0.43	Obesity-related traits;	chr13:24408694	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-7.73	2.43e-13	9.24e-07	-0.51	-0.43	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
COAD	trans	rs3740713	1	rs60376560	ENSG00000235847.2	LDHAP7	7.73	2.43e-13	9.24e-07	0.73	0.43	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:84777259~84778223:-
COAD	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	7.73	2.46e-13	9.34e-07	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	7.73	2.46e-13	9.34e-07	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
COAD	trans	rs55665837	0.701	rs10160597	ENSG00000236360.2	RP11-334A14.2	7.72	2.51e-13	9.54e-07	0.62	0.43	Vitamin D levels;	chr11:14582446	chr1:52993201~52993702:-
COAD	trans	rs8010715	0.816	rs7153156	ENSG00000238000.1	RP11-274E7.2	7.72	2.55e-13	9.69e-07	0.46	0.43	IgG glycosylation;	chr14:24129637	chr5:98213402~98214121:+
COAD	trans	rs8010715	0.816	rs6573572	ENSG00000238000.1	RP11-274E7.2	7.72	2.55e-13	9.69e-07	0.46	0.43	IgG glycosylation;	chr14:24130021	chr5:98213402~98214121:+
COAD	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	7.72	2.55e-13	9.69e-07	0.46	0.43	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
COAD	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-7.72	2.55e-13	9.7e-07	-0.53	-0.43	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
COAD	trans	rs13190036	1	rs13175695	ENSG00000228305.2	AC016734.2	7.72	2.56e-13	9.7e-07	0.55	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr2:63622178~63622831:-
COAD	trans	rs72615157	0.645	rs76281814	ENSG00000228546.2	CTA-313A17.3	7.72	2.56e-13	9.73e-07	0.7	0.43	Lung function (FEV1/FVC);	chr7:100248791	chr7:102337316~102339115:+
COAD	trans	rs72615157	0.595	rs112241539	ENSG00000228546.2	CTA-313A17.3	7.72	2.56e-13	9.73e-07	0.7	0.43	Lung function (FEV1/FVC);	chr7:100249614	chr7:102337316~102339115:+
COAD	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	7.72	2.62e-13	9.94e-07	0.55	0.43	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.746	rs9511270	ENSG00000224976.2	PARP4P2	-7.72	2.63e-13	9.96e-07	-0.5	-0.43	Obesity-related traits;	chr13:24444542	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-7.71	2.72e-13	1.03e-06	-0.51	-0.43	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	7.71	2.79e-13	1.05e-06	0.51	0.43	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
COAD	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	7.71	2.84e-13	1.07e-06	0.5	0.43	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
COAD	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	7.7	2.9e-13	1.09e-06	0.54	0.43	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
COAD	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	7.7	2.9e-13	1.09e-06	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
COAD	trans	rs3849046	0.934	rs7714751	ENSG00000226666.1	HSPA9P1	-7.7	2.95e-13	1.11e-06	-0.42	-0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513377	chr2:221961737~221963765:+
COAD	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-7.7	2.99e-13	1.13e-06	-0.55	-0.43	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
COAD	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-7.69	3.07e-13	1.15e-06	-0.57	-0.43	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
COAD	trans	rs72615157	0.634	rs74774557	ENSG00000228546.2	CTA-313A17.3	7.69	3.07e-13	1.16e-06	0.66	0.43	Lung function (FEV1/FVC);	chr7:100212802	chr7:102337316~102339115:+
COAD	trans	rs6708331	1	rs10195155	ENSG00000232654.1	FAM136BP	7.69	3.15e-13	1.18e-06	0.59	0.43	Obesity-related traits;	chr2:70127343	chr6:3045384~3045800:+
COAD	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-7.69	3.21e-13	1.21e-06	-0.55	-0.43	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	7.69	3.23e-13	1.22e-06	0.49	0.43	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
COAD	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	7.68	3.27e-13	1.23e-06	0.55	0.43	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
COAD	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	7.68	3.31e-13	1.24e-06	0.5	0.43	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
COAD	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-7.68	3.4e-13	1.28e-06	-0.5	-0.43	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-7.67	3.56e-13	1.33e-06	-0.51	-0.43	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
COAD	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-7.67	3.57e-13	1.34e-06	-0.59	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
COAD	trans	rs12709013	0.967	rs2118019	ENSG00000230849.2	GOT2P2	-7.67	3.64e-13	1.36e-06	-0.52	-0.43	Blood metabolite ratios;	chr16:58797825	chr1:173141100~173142350:-
COAD	trans	rs16937956	0.597	rs4584570	ENSG00000266891.1	RP11-692N5.2	7.67	3.64e-13	1.37e-06	0.61	0.43	Body mass index;	chr11:8384489	chr18:9734882~9735602:-
COAD	trans	rs13190036	0.901	rs6898107	ENSG00000228305.2	AC016734.2	7.67	3.66e-13	1.37e-06	0.54	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr2:63622178~63622831:-
COAD	trans	rs3849046	1	rs13164092	ENSG00000226666.1	HSPA9P1	-7.67	3.66e-13	1.37e-06	-0.42	-0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505171	chr2:221961737~221963765:+
COAD	trans	rs3849046	0.967	rs55985421	ENSG00000226666.1	HSPA9P1	-7.67	3.66e-13	1.37e-06	-0.42	-0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505574	chr2:221961737~221963765:+
COAD	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	7.67	3.67e-13	1.37e-06	0.53	0.43	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
COAD	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	7.67	3.67e-13	1.37e-06	0.56	0.43	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
COAD	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-7.66	3.67e-13	1.38e-06	-0.62	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
COAD	trans	rs3849046	0.846	rs154076	ENSG00000226666.1	HSPA9P1	-7.66	3.7e-13	1.39e-06	-0.42	-0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138527445	chr2:221961737~221963765:+
COAD	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	7.66	3.75e-13	1.4e-06	0.61	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
COAD	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-7.66	3.91e-13	1.46e-06	-0.54	-0.43	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
COAD	trans	rs7554547	0.714	rs926269	ENSG00000261819.1	RP11-680G24.4	7.65	3.98e-13	1.49e-06	0.6	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr16:14988259~14990160:-
COAD	trans	rs7554547	0.714	rs2878679	ENSG00000261819.1	RP11-680G24.4	7.65	3.98e-13	1.49e-06	0.6	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr16:14988259~14990160:-
COAD	trans	rs11023332	0.706	rs10766197	ENSG00000236360.2	RP11-334A14.2	7.65	4.01e-13	1.5e-06	0.57	0.43	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr1:52993201~52993702:-
COAD	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-7.65	4.06e-13	1.52e-06	-0.54	-0.43	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
COAD	trans	rs3849046	0.846	rs256002	ENSG00000226666.1	HSPA9P1	7.65	4.07e-13	1.52e-06	0.43	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138559529	chr2:221961737~221963765:+
COAD	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-7.65	4.14e-13	1.54e-06	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
COAD	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-7.65	4.14e-13	1.54e-06	-0.61	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
COAD	trans	rs74781061	1	rs74781061	ENSG00000227288.3	RP5-837I24.1	7.64	4.18e-13	1.56e-06	0.55	0.43	Endometriosis;	chr15:74595855	chr1:81501794~81503468:+
COAD	trans	rs8175379	0.53	rs12516847	ENSG00000231752.4	EMBP1	-7.64	4.23e-13	1.58e-06	-0.53	-0.43	Interleukin-7 levels;	chr5:46300736	chr1:121519112~121571892:+
COAD	trans	rs6477998	0.58	rs7851623	ENSG00000238072.1	RP11-305M3.2	7.64	4.26e-13	1.59e-06	0.7	0.43	Hematology traits;	chr9:113240285	chr7:129410113~129410370:-
COAD	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-7.64	4.26e-13	1.59e-06	-0.55	-0.43	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	7.64	4.33e-13	1.61e-06	0.49	0.43	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
COAD	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-7.64	4.34e-13	1.61e-06	-0.54	-0.43	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
COAD	trans	rs932287	0.545	rs1960181	ENSG00000266891.1	RP11-692N5.2	-7.64	4.35e-13	1.62e-06	-0.53	-0.43	Colonoscopy-negative controls vs population controls;	chr11:9025220	chr18:9734882~9735602:-
COAD	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-7.64	4.36e-13	1.62e-06	-0.43	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
COAD	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	7.64	4.38e-13	1.63e-06	0.47	0.43	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
COAD	trans	rs55665837	0.539	rs12794714	ENSG00000236360.2	RP11-334A14.2	7.63	4.52e-13	1.68e-06	0.57	0.43	Vitamin D levels;	chr11:14892029	chr1:52993201~52993702:-
COAD	trans	rs11023332	0.706	rs11023379	ENSG00000236360.2	RP11-334A14.2	7.63	4.69e-13	1.74e-06	0.58	0.43	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr1:52993201~52993702:-
COAD	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-7.63	4.73e-13	1.76e-06	-0.54	-0.43	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
COAD	trans	rs16937956	0.597	rs2311434	ENSG00000266891.1	RP11-692N5.2	7.62	4.8e-13	1.78e-06	0.6	0.43	Body mass index;	chr11:8384502	chr18:9734882~9735602:-
COAD	trans	rs3849046	0.817	rs154069	ENSG00000226666.1	HSPA9P1	7.62	4.84e-13	1.79e-06	0.42	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138541231	chr2:221961737~221963765:+
COAD	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-7.62	4.9e-13	1.82e-06	-0.54	-0.43	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-7.62	4.9e-13	1.82e-06	-0.54	-0.43	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
COAD	trans	rs12709013	1	rs12709013	ENSG00000230849.2	GOT2P2	-7.62	4.99e-13	1.85e-06	-0.52	-0.43	Blood metabolite ratios;	chr16:58795886	chr1:173141100~173142350:-
COAD	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	7.62	5.01e-13	1.85e-06	0.83	0.43	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
COAD	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	7.61	5.05e-13	1.87e-06	0.53	0.43	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
COAD	trans	rs3812762	0.957	rs6484008	ENSG00000266891.1	RP11-692N5.2	-7.61	5.1e-13	1.89e-06	-0.5	-0.43	Hypospadias;	chr11:8732601	chr18:9734882~9735602:-
COAD	trans	rs55665837	0.539	rs731042	ENSG00000236360.2	RP11-334A14.2	7.61	5.1e-13	1.89e-06	0.59	0.43	Vitamin D levels;	chr11:14853429	chr1:52993201~52993702:-
COAD	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	7.61	5.19e-13	1.92e-06	0.46	0.43	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
COAD	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	7.6	5.53e-13	2.04e-06	0.51	0.43	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	7.6	5.6e-13	2.07e-06	0.48	0.43	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
COAD	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	7.6	5.6e-13	2.07e-06	0.48	0.43	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
COAD	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	7.6	5.6e-13	2.07e-06	0.48	0.43	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
COAD	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-7.6	5.64e-13	2.08e-06	-0.54	-0.43	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-7.6	5.64e-13	2.08e-06	-0.54	-0.43	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-7.6	5.64e-13	2.08e-06	-0.54	-0.43	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-7.6	5.64e-13	2.08e-06	-0.54	-0.43	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
COAD	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-7.6	5.66e-13	2.08e-06	-0.6	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
COAD	trans	rs3849046	0.79	rs188731	ENSG00000226666.1	HSPA9P1	7.6	5.7e-13	2.1e-06	0.42	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545415	chr2:221961737~221963765:+
COAD	trans	rs3849046	0.619	rs181919	ENSG00000226666.1	HSPA9P1	7.6	5.7e-13	2.1e-06	0.42	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138546923	chr2:221961737~221963765:+
COAD	trans	rs3849046	0.875	rs255999	ENSG00000226666.1	HSPA9P1	7.6	5.7e-13	2.1e-06	0.42	0.43	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138554110	chr2:221961737~221963765:+
COAD	trans	rs10940346	0.506	rs4605740	ENSG00000231752.4	EMBP1	-7.6	5.71e-13	2.1e-06	-0.52	-0.43	Schizophrenia;	chr5:50574869	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.506	rs7704183	ENSG00000231752.4	EMBP1	-7.59	5.84e-13	2.15e-06	-0.51	-0.43	Schizophrenia;	chr5:50576738	chr1:121519112~121571892:+
COAD	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-7.59	5.86e-13	2.16e-06	-0.48	-0.43	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
COAD	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-7.59	5.88e-13	2.16e-06	-0.54	-0.43	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
COAD	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	7.59	5.9e-13	2.17e-06	0.5	0.43	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
COAD	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	7.59	5.9e-13	2.17e-06	0.5	0.43	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
COAD	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	7.59	5.99e-13	2.2e-06	0.55	0.43	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
COAD	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	7.59	6.02e-13	2.21e-06	0.53	0.43	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
COAD	trans	rs55665837	0.701	rs1522633	ENSG00000236360.2	RP11-334A14.2	7.59	6.04e-13	2.22e-06	0.61	0.43	Vitamin D levels;	chr11:14623692	chr1:52993201~52993702:-
COAD	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-7.59	6.05e-13	2.22e-06	-0.5	-0.43	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-7.59	6.05e-13	2.22e-06	-0.5	-0.43	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
COAD	trans	rs5022636	0.896	rs10788804	ENSG00000180764.13	PIPSL	7.58	6.15e-13	2.26e-06	0.46	0.43	Gut microbiota (functional units);	chr1:151365312	chr10:93958191~93961540:-
COAD	trans	rs12709013	1	rs11648514	ENSG00000230849.2	GOT2P2	7.58	6.19e-13	2.27e-06	0.53	0.43	Blood metabolite ratios;	chr16:58798176	chr1:173141100~173142350:-
COAD	trans	rs12709013	1	rs8057892	ENSG00000230849.2	GOT2P2	7.58	6.19e-13	2.27e-06	0.53	0.43	Blood metabolite ratios;	chr16:58798855	chr1:173141100~173142350:-
COAD	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	7.58	6.42e-13	2.35e-06	0.5	0.43	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.917	rs905289	ENSG00000266891.1	RP11-692N5.2	-7.57	6.6e-13	2.42e-06	-0.49	-0.43	Hypospadias;	chr11:8732005	chr18:9734882~9735602:-
COAD	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	7.57	6.68e-13	2.45e-06	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
COAD	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-7.57	6.69e-13	2.45e-06	-0.54	-0.43	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
COAD	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	7.57	6.75e-13	2.47e-06	0.47	0.43	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	7.57	6.75e-13	2.47e-06	0.47	0.43	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
COAD	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-7.57	6.76e-13	2.47e-06	-0.6	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	7.57	6.84e-13	2.5e-06	0.47	0.43	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	7.57	6.84e-13	2.5e-06	0.47	0.43	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
COAD	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	7.57	6.84e-13	2.5e-06	0.47	0.43	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
COAD	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	7.57	6.84e-13	2.5e-06	0.47	0.43	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
COAD	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	7.57	6.87e-13	2.51e-06	1	0.43	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
COAD	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-7.56	7.22e-13	2.64e-06	-0.55	-0.43	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
COAD	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	7.55	7.49e-13	2.73e-06	0.61	0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
COAD	trans	rs7554511	0.861	rs11583546	ENSG00000244144.1	RP11-757F18.3	-7.55	7.5e-13	2.73e-06	-0.67	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr3:112185480~112185998:-
COAD	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	7.55	7.52e-13	2.74e-06	0.46	0.43	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
COAD	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-7.55	7.52e-13	2.74e-06	-0.53	-0.43	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
COAD	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	7.55	7.56e-13	2.76e-06	0.52	0.43	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
COAD	trans	rs7554511	0.763	rs55734382	ENSG00000244144.1	RP11-757F18.3	-7.55	7.75e-13	2.83e-06	-0.63	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201049931	chr3:112185480~112185998:-
COAD	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-7.54	7.95e-13	2.89e-06	-0.54	-0.43	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
COAD	trans	rs8175379	0.509	rs8188100	ENSG00000231752.4	EMBP1	7.54	7.97e-13	2.9e-06	0.53	0.43	Interleukin-7 levels;	chr5:46246931	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-7.54	8.04e-13	2.93e-06	-0.54	-0.43	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
COAD	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	7.54	8.12e-13	2.96e-06	0.61	0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
COAD	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	7.54	8.33e-13	3.03e-06	0.47	0.43	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
COAD	trans	rs8175379	0.509	rs7293427	ENSG00000231752.4	EMBP1	7.53	8.35e-13	3.03e-06	0.52	0.43	Interleukin-7 levels;	chr5:46253335	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-7.53	8.4e-13	3.05e-06	-0.5	-0.43	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
COAD	trans	rs10940346	1	rs11739291	ENSG00000231752.4	EMBP1	-7.53	8.4e-13	3.05e-06	-0.54	-0.43	Schizophrenia;	chr5:50550394	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-7.53	8.43e-13	3.06e-06	-0.5	-0.43	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	7.53	8.44e-13	3.06e-06	0.81	0.43	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.717	rs2741872	ENSG00000228834.1	RP11-249L21.4	-7.53	8.74e-13	3.17e-06	-0.64	-0.43	Blood metabolite levels;	chr7:99742153	chr6:108907615~108907873:-
COAD	trans	rs74781061	0.932	rs11629946	ENSG00000227288.3	RP5-837I24.1	-7.53	8.74e-13	3.17e-06	-0.55	-0.43	Endometriosis;	chr15:74579550	chr1:81501794~81503468:+
COAD	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	7.53	8.8e-13	3.19e-06	0.54	0.42	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
COAD	trans	rs3740713	1	rs73440637	ENSG00000235847.2	LDHAP7	7.53	8.81e-13	3.19e-06	0.73	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr2:84777259~84778223:-
COAD	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	7.52	8.94e-13	3.24e-06	0.5	0.42	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-7.52	9.08e-13	3.29e-06	-0.51	-0.42	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
COAD	trans	rs959695	0.834	rs6468693	ENSG00000260318.1	COX6CP1	-7.52	9.33e-13	3.37e-06	-0.55	-0.42	Hippocampal atrophy;	chr8:99839040	chr16:11903923~11904137:-
COAD	trans	rs7554547	0.69	rs10864544	ENSG00000261819.1	RP11-680G24.4	7.52	9.39e-13	3.4e-06	0.56	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr16:14988259~14990160:-
COAD	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	7.52	9.41e-13	3.4e-06	0.46	0.42	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
COAD	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-7.52	9.44e-13	3.41e-06	-0.45	-0.42	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
COAD	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	7.51	9.49e-13	3.43e-06	0.47	0.42	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
COAD	trans	rs7554511	0.707	rs6702590	ENSG00000244144.1	RP11-757F18.3	7.51	9.5e-13	3.43e-06	0.6	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201050977	chr3:112185480~112185998:-
COAD	trans	rs12709013	0.935	rs11648634	ENSG00000230849.2	GOT2P2	7.51	9.62e-13	3.47e-06	0.53	0.42	Blood metabolite ratios;	chr16:58785256	chr1:173141100~173142350:-
COAD	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	7.51	9.7e-13	3.5e-06	0.47	0.42	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.506	rs12659667	ENSG00000231752.4	EMBP1	-7.51	9.7e-13	3.5e-06	-0.52	-0.42	Schizophrenia;	chr5:50566091	chr1:121519112~121571892:+
COAD	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-7.51	9.8e-13	3.53e-06	-0.54	-0.42	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-7.51	9.8e-13	3.53e-06	-0.54	-0.42	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-7.51	9.8e-13	3.53e-06	-0.54	-0.42	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-7.51	9.8e-13	3.53e-06	-0.54	-0.42	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
COAD	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-7.51	9.8e-13	3.53e-06	-0.54	-0.42	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
COAD	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	7.51	9.93e-13	3.58e-06	0.47	0.42	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	7.51	9.93e-13	3.58e-06	0.47	0.42	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	7.51	9.93e-13	3.58e-06	0.47	0.42	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
COAD	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-7.51	9.98e-13	3.59e-06	-0.48	-0.42	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
COAD	trans	rs3849046	1	rs13155345	ENSG00000226666.1	HSPA9P1	-7.5	1.01e-12	3.65e-06	-0.41	-0.42	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138519235	chr2:221961737~221963765:+
COAD	trans	rs7121616	0.562	rs7131452	ENSG00000229091.2	HSPA8P8	7.5	1.02e-12	3.68e-06	0.45	0.42	Breast cancer;	chr11:123065314	chr7:10451311~10452526:+
COAD	trans	rs13253073	0.556	rs13279371	ENSG00000260318.1	COX6CP1	7.5	1.05e-12	3.77e-06	0.9	0.42	Glucose homeostasis traits;	chr8:99407006	chr16:11903923~11904137:-
COAD	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-7.5	1.06e-12	3.82e-06	-0.46	-0.42	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
COAD	trans	rs12709013	1	rs11644891	ENSG00000230849.2	GOT2P2	7.5	1.07e-12	3.84e-06	0.53	0.42	Blood metabolite ratios;	chr16:58799921	chr1:173141100~173142350:-
COAD	trans	rs12709013	1	rs11641566	ENSG00000230849.2	GOT2P2	7.5	1.07e-12	3.84e-06	0.53	0.42	Blood metabolite ratios;	chr16:58801276	chr1:173141100~173142350:-
COAD	trans	rs7554511	0.893	rs17419032	ENSG00000244144.1	RP11-757F18.3	7.49	1.09e-12	3.9e-06	0.66	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201029403	chr3:112185480~112185998:-
COAD	trans	rs1816752	0.905	rs9511264	ENSG00000224976.2	PARP4P2	7.49	1.11e-12	3.98e-06	0.47	0.42	Obesity-related traits;	chr13:24438079	chr13:19349137~19407962:+
COAD	trans	rs7554547	0.667	rs6666533	ENSG00000261819.1	RP11-680G24.4	7.49	1.12e-12	4.02e-06	0.63	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr16:14988259~14990160:-
COAD	trans	rs61990749	1	rs6574411	ENSG00000235400.1	RP4-641G12.4	-7.48	1.19e-12	4.27e-06	-0.87	-0.42	Fibroblast growth factor basic levels;	chr14:77907984	chr1:78749073~78750659:+
COAD	trans	rs2657294	0.734	rs2894244	ENSG00000172974.11	AC007318.5	7.48	1.19e-12	4.27e-06	0.47	0.42	Pneumonia;	chr10:75087112	chr2:65205108~65205988:+
COAD	trans	rs3812762	0.868	rs7952335	ENSG00000266891.1	RP11-692N5.2	-7.48	1.2e-12	4.31e-06	-0.49	-0.42	Hypospadias;	chr11:8732484	chr18:9734882~9735602:-
COAD	trans	rs13253073	0.556	rs35194538	ENSG00000260318.1	COX6CP1	7.47	1.23e-12	4.39e-06	0.89	0.42	Glucose homeostasis traits;	chr8:99397627	chr16:11903923~11904137:-
COAD	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	7.47	1.23e-12	4.41e-06	0.47	0.42	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
COAD	trans	rs7554511	0.825	rs12122809	ENSG00000244144.1	RP11-757F18.3	-7.47	1.23e-12	4.41e-06	-0.64	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201045838	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	7.47	1.24e-12	4.42e-06	0.45	0.42	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.506	rs10454829	ENSG00000231752.4	EMBP1	-7.47	1.27e-12	4.52e-06	-0.51	-0.42	Schizophrenia;	chr5:50585120	chr1:121519112~121571892:+
COAD	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	7.47	1.27e-12	4.54e-06	0.47	0.42	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.875	rs9924389	ENSG00000230849.2	GOT2P2	7.47	1.27e-12	4.55e-06	0.52	0.42	Blood metabolite ratios;	chr16:58779849	chr1:173141100~173142350:-
COAD	trans	rs7554511	0.823	rs67602696	ENSG00000244144.1	RP11-757F18.3	-7.47	1.28e-12	4.58e-06	-0.64	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201043809	chr3:112185480~112185998:-
COAD	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-7.47	1.28e-12	4.58e-06	-0.6	-0.42	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
COAD	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	7.46	1.31e-12	4.66e-06	0.47	0.42	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
COAD	trans	rs7554511	0.858	rs6701496	ENSG00000244144.1	RP11-757F18.3	-7.46	1.31e-12	4.68e-06	-0.64	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201038700	chr3:112185480~112185998:-
COAD	trans	rs62079673	0.527	rs9788998	ENSG00000265574.1	WDR45BP1	7.46	1.32e-12	4.69e-06	0.51	0.42	Breast cancer;	chr17:82647768	chr17:32111562~32112590:-
COAD	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-7.46	1.34e-12	4.78e-06	-0.55	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
COAD	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	7.45	1.38e-12	4.9e-06	0.49	0.42	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.825	rs11576681	ENSG00000244144.1	RP11-757F18.3	-7.45	1.38e-12	4.91e-06	-0.63	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201034923	chr3:112185480~112185998:-
COAD	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	7.45	1.38e-12	4.93e-06	0.56	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
COAD	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	7.45	1.39e-12	4.97e-06	0.49	0.42	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	7.45	1.39e-12	4.97e-06	0.49	0.42	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
COAD	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-7.45	1.44e-12	5.11e-06	-0.55	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
COAD	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	7.45	1.44e-12	5.13e-06	0.52	0.42	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
COAD	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-7.45	1.45e-12	5.14e-06	-0.51	-0.42	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
COAD	trans	rs72615157	0.634	rs11762932	ENSG00000228546.2	CTA-313A17.3	-7.45	1.46e-12	5.19e-06	-0.64	-0.42	Lung function (FEV1/FVC);	chr7:100195043	chr7:102337316~102339115:+
COAD	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-7.45	1.46e-12	5.19e-06	-0.53	-0.42	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-7.45	1.46e-12	5.19e-06	-0.53	-0.42	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.967	rs11643969	ENSG00000230849.2	GOT2P2	7.44	1.52e-12	5.39e-06	0.52	0.42	Blood metabolite ratios;	chr16:58785354	chr1:173141100~173142350:-
COAD	trans	rs7258465	0.931	rs34053595	ENSG00000267533.1	RP11-815J4.7	7.44	1.54e-12	5.45e-06	0.49	0.42	Breast cancer;	chr19:18445939	chr18:12067173~12068417:-
COAD	trans	rs13190036	0.681	rs28461408	ENSG00000228305.2	AC016734.2	7.44	1.54e-12	5.45e-06	0.66	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-7.43	1.57e-12	5.58e-06	-0.45	-0.42	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
COAD	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-7.43	1.58e-12	5.59e-06	-0.48	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
COAD	trans	rs74781061	0.929	rs11072493	ENSG00000227288.3	RP5-837I24.1	7.43	1.58e-12	5.59e-06	0.54	0.42	Endometriosis;	chr15:74536881	chr1:81501794~81503468:+
COAD	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-7.43	1.6e-12	5.66e-06	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
COAD	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-7.43	1.6e-12	5.66e-06	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	7.43	1.61e-12	5.71e-06	0.49	0.42	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
COAD	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-7.43	1.61e-12	5.71e-06	-0.59	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
COAD	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-7.43	1.65e-12	5.82e-06	-0.5	-0.42	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
COAD	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	7.43	1.65e-12	5.82e-06	0.52	0.42	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
COAD	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	7.42	1.66e-12	5.89e-06	0.47	0.42	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
COAD	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	7.42	1.67e-12	5.9e-06	0.45	0.42	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
COAD	trans	rs13358908	0.526	rs4975974	ENSG00000231752.4	EMBP1	-7.42	1.68e-12	5.93e-06	-0.52	-0.42	Schizophrenia;	chr5:46307464	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	7.42	1.69e-12	5.99e-06	0.5	0.42	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-7.42	1.7e-12	5.99e-06	-0.5	-0.42	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
COAD	trans	rs7554511	0.707	rs3767501	ENSG00000244144.1	RP11-757F18.3	7.42	1.71e-12	6.04e-06	0.58	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053951	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	7.42	1.74e-12	6.14e-06	0.46	0.42	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
COAD	trans	rs7554511	0.707	rs3767498	ENSG00000244144.1	RP11-757F18.3	-7.42	1.74e-12	6.14e-06	-0.59	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051599	chr3:112185480~112185998:-
COAD	trans	rs8175379	0.505	rs12189292	ENSG00000231752.4	EMBP1	-7.42	1.75e-12	6.17e-06	-0.54	-0.42	Interleukin-7 levels;	chr5:46340498	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	7.42	1.75e-12	6.18e-06	0.62	0.42	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
COAD	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	7.42	1.75e-12	6.18e-06	0.62	0.42	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
COAD	trans	rs2657294	0.704	rs10824266	ENSG00000172974.11	AC007318.5	7.41	1.81e-12	6.37e-06	0.47	0.42	Pneumonia;	chr10:75083476	chr2:65205108~65205988:+
COAD	trans	rs8175379	0.551	rs4975969	ENSG00000231752.4	EMBP1	-7.41	1.82e-12	6.41e-06	-0.52	-0.42	Interleukin-7 levels;	chr5:46295887	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.522	rs8185256	ENSG00000231752.4	EMBP1	-7.41	1.82e-12	6.41e-06	-0.52	-0.42	Interleukin-7 levels;	chr5:46298301	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.584	rs8185180	ENSG00000231752.4	EMBP1	-7.41	1.82e-12	6.41e-06	-0.52	-0.42	Interleukin-7 levels;	chr5:46300291	chr1:121519112~121571892:+
COAD	trans	rs13190036	0.515	rs2878686	ENSG00000228305.2	AC016734.2	-7.41	1.83e-12	6.42e-06	-0.48	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr2:63622178~63622831:-
COAD	trans	rs61990749	1	rs17106604	ENSG00000235400.1	RP4-641G12.4	7.41	1.83e-12	6.42e-06	0.87	0.42	Fibroblast growth factor basic levels;	chr14:77912813	chr1:78749073~78750659:+
COAD	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	7.41	1.84e-12	6.47e-06	0.53	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
COAD	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	7.4	1.89e-12	6.62e-06	0.53	0.42	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
COAD	trans	rs1816752	0.905	rs7995492	ENSG00000224976.2	PARP4P2	-7.4	1.9e-12	6.67e-06	-0.47	-0.42	Obesity-related traits;	chr13:24438885	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	7.4	1.91e-12	6.7e-06	0.49	0.42	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-7.4	1.92e-12	6.73e-06	-0.52	-0.42	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
COAD	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-7.4	1.92e-12	6.73e-06	-0.52	-0.42	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
COAD	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-7.4	1.92e-12	6.73e-06	-0.42	-0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
COAD	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-7.4	1.96e-12	6.85e-06	-0.62	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
COAD	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-7.39	2e-12	6.99e-06	-0.52	-0.42	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
COAD	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-7.39	2.03e-12	7.1e-06	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-7.39	2.03e-12	7.1e-06	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-7.39	2.03e-12	7.1e-06	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-7.39	2.03e-12	7.1e-06	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
COAD	trans	rs8175379	0.501	rs12514178	ENSG00000231752.4	EMBP1	-7.39	2.04e-12	7.12e-06	-0.52	-0.42	Interleukin-7 levels;	chr5:46309072	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.501	rs8185192	ENSG00000231752.4	EMBP1	-7.39	2.04e-12	7.12e-06	-0.52	-0.42	Interleukin-7 levels;	chr5:46309722	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-7.39	2.04e-12	7.12e-06	-0.47	-0.42	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
COAD	trans	rs7554511	0.893	rs55862304	ENSG00000244144.1	RP11-757F18.3	-7.39	2.09e-12	7.3e-06	-0.65	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020647	chr3:112185480~112185998:-
COAD	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	7.39	2.1e-12	7.33e-06	0.53	0.42	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
COAD	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	7.38	2.14e-12	7.43e-06	0.52	0.42	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	7.38	2.18e-12	7.56e-06	0.45	0.42	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	7.38	2.19e-12	7.57e-06	0.49	0.42	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	7.38	2.23e-12	7.72e-06	0.49	0.42	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	7.38	2.25e-12	7.77e-06	0.49	0.42	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.509	rs8185235	ENSG00000231752.4	EMBP1	7.37	2.28e-12	7.88e-06	0.52	0.42	Interleukin-7 levels;	chr5:46252306	chr1:121519112~121571892:+
COAD	trans	rs55665837	0.539	rs10766196	ENSG00000236360.2	RP11-334A14.2	7.37	2.28e-12	7.88e-06	0.55	0.42	Vitamin D levels;	chr11:14891585	chr1:52993201~52993702:-
COAD	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	7.37	2.3e-12	7.95e-06	0.56	0.42	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
COAD	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-7.37	2.33e-12	8.05e-06	-0.52	-0.42	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-7.37	2.33e-12	8.05e-06	-0.52	-0.42	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
COAD	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	7.37	2.4e-12	8.28e-06	0.58	0.42	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
COAD	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	7.37	2.4e-12	8.3e-06	0.49	0.42	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	7.36	2.44e-12	8.44e-06	0.61	0.42	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
COAD	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	7.36	2.45e-12	8.45e-06	0.49	0.42	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-7.36	2.5e-12	8.63e-06	-0.62	-0.42	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
COAD	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-7.36	2.54e-12	8.76e-06	-0.53	-0.42	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	7.35	2.57e-12	8.86e-06	0.49	0.42	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	7.35	2.57e-12	8.86e-06	0.49	0.42	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
COAD	trans	rs12709013	1	rs34319345	ENSG00000230849.2	GOT2P2	7.35	2.57e-12	8.87e-06	0.52	0.42	Blood metabolite ratios;	chr16:58786688	chr1:173141100~173142350:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-7.35	2.57e-12	8.87e-06	-0.48	-0.42	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-7.35	2.57e-12	8.87e-06	-0.48	-0.42	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
COAD	trans	rs6708331	0.938	rs36025045	ENSG00000232654.1	FAM136BP	7.35	2.59e-12	8.94e-06	0.57	0.42	Obesity-related traits;	chr2:70121829	chr6:3045384~3045800:+
COAD	trans	rs7554511	0.792	rs12126806	ENSG00000244144.1	RP11-757F18.3	-7.35	2.62e-12	9.04e-06	-0.59	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200994697	chr3:112185480~112185998:-
COAD	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	7.35	2.64e-12	9.08e-06	0.49	0.42	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.702	rs28377312	ENSG00000228834.1	RP11-249L21.4	7.35	2.67e-12	9.17e-06	1.01	0.42	Blood metabolite levels;	chr7:99386590	chr6:108907615~108907873:-
COAD	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	7.35	2.67e-12	9.18e-06	0.49	0.42	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	7.35	2.67e-12	9.18e-06	0.49	0.42	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
COAD	trans	rs13253073	1	rs12550092	ENSG00000260318.1	COX6CP1	7.35	2.68e-12	9.21e-06	1.08	0.42	Glucose homeostasis traits;	chr8:99886954	chr16:11903923~11904137:-
COAD	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	7.35	2.69e-12	9.25e-06	0.47	0.42	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	7.35	2.69e-12	9.26e-06	0.53	0.42	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
COAD	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-7.34	2.74e-12	9.41e-06	-0.53	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
COAD	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-7.34	2.77e-12	9.51e-06	-0.55	-0.42	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
COAD	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	7.34	2.84e-12	9.76e-06	0.51	0.42	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
COAD	trans	rs13190036	0.748	rs28395268	ENSG00000226986.4	RP11-543B16.2	7.34	2.85e-12	9.79e-06	0.52	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	7.34	2.86e-12	9.81e-06	0.48	0.42	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
COAD	trans	rs10037055	0.636	rs13166688	ENSG00000228305.2	AC016734.2	-7.34	2.89e-12	9.93e-06	-0.47	-0.42	Migraine without aura;	chr5:177156965	chr2:63622178~63622831:-
COAD	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	7.34	2.9e-12	9.93e-06	0.49	0.42	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	7.34	2.9e-12	9.93e-06	0.49	0.42	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	7.34	2.9e-12	9.93e-06	0.49	0.42	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-7.34	2.9e-12	9.93e-06	-0.49	-0.42	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
COAD	trans	rs7121616	0.576	rs4802	ENSG00000229091.2	HSPA8P8	7.33	2.92e-12	1e-05	0.44	0.42	Breast cancer;	chr11:123057914	chr7:10451311~10452526:+
COAD	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-7.33	2.93e-12	1e-05	-0.5	-0.42	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-7.33	2.93e-12	1e-05	-0.5	-0.42	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-7.33	2.93e-12	1e-05	-0.5	-0.42	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	7.33	2.94e-12	1.01e-05	0.5	0.42	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
COAD	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	7.33	2.97e-12	1.02e-05	0.42	0.42	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
COAD	trans	rs1190596	0.526	rs1190572	ENSG00000181359.5	HSP90AA6P	7.33	2.99e-12	1.02e-05	0.49	0.42	Behavioural disinhibition (generation interaction);	chr14:102168252	chr4:170581470~170605450:-
COAD	trans	rs6708331	0.941	rs7609359	ENSG00000232654.1	FAM136BP	7.33	3.01e-12	1.03e-05	0.56	0.42	Obesity-related traits;	chr2:70131844	chr6:3045384~3045800:+
COAD	trans	rs6708331	0.941	rs7595262	ENSG00000232654.1	FAM136BP	7.33	3.01e-12	1.03e-05	0.56	0.42	Obesity-related traits;	chr2:70131865	chr6:3045384~3045800:+
COAD	trans	rs8175379	0.521	rs10037109	ENSG00000231752.4	EMBP1	7.33	3.02e-12	1.03e-05	0.52	0.42	Interleukin-7 levels;	chr5:46328343	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-7.32	3.1e-12	1.06e-05	-0.51	-0.42	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
COAD	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-7.32	3.12e-12	1.07e-05	-0.46	-0.42	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
COAD	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-7.32	3.12e-12	1.07e-05	-0.52	-0.42	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
COAD	trans	rs7121616	0.576	rs4936767	ENSG00000229091.2	HSPA8P8	7.32	3.12e-12	1.07e-05	0.45	0.42	Breast cancer;	chr11:123047451	chr7:10451311~10452526:+
COAD	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-7.32	3.13e-12	1.07e-05	-0.5	-0.42	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
COAD	trans	rs8175379	0.509	rs10078317	ENSG00000231752.4	EMBP1	7.32	3.14e-12	1.07e-05	0.51	0.42	Interleukin-7 levels;	chr5:46254038	chr1:121519112~121571892:+
COAD	trans	rs6708331	1	rs35734267	ENSG00000232654.1	FAM136BP	7.32	3.14e-12	1.07e-05	0.58	0.42	Obesity-related traits;	chr2:70054058	chr6:3045384~3045800:+
COAD	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-7.32	3.14e-12	1.07e-05	-0.49	-0.42	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-7.32	3.14e-12	1.07e-05	-0.49	-0.42	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-7.32	3.14e-12	1.07e-05	-0.49	-0.42	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-7.32	3.14e-12	1.07e-05	-0.49	-0.42	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
COAD	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	7.32	3.2e-12	1.09e-05	0.55	0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
COAD	trans	rs12709013	1	rs12926993	ENSG00000230849.2	GOT2P2	7.32	3.2e-12	1.09e-05	0.51	0.42	Blood metabolite ratios;	chr16:58789218	chr1:173141100~173142350:-
COAD	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-7.32	3.21e-12	1.1e-05	-0.51	-0.42	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
COAD	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	7.32	3.22e-12	1.1e-05	0.45	0.42	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
COAD	trans	rs10242455	0.702	rs115279860	ENSG00000228834.1	RP11-249L21.4	7.32	3.23e-12	1.1e-05	1.01	0.42	Blood metabolite levels;	chr7:99396869	chr6:108907615~108907873:-
COAD	trans	rs7554511	0.655	rs3767502	ENSG00000244144.1	RP11-757F18.3	7.32	3.23e-12	1.1e-05	0.59	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053970	chr3:112185480~112185998:-
COAD	trans	rs9899728	0.614	rs12949451	ENSG00000234925.2	ATP5HP4	-7.32	3.27e-12	1.12e-05	-0.61	-0.42	Alzheimer's disease or small vessel stroke;	chr17:75036224	chr12:68642519~68642993:-
COAD	trans	rs8175379	0.509	rs4128583	ENSG00000231752.4	EMBP1	7.32	3.28e-12	1.12e-05	0.51	0.42	Interleukin-7 levels;	chr5:46251985	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-7.31	3.29e-12	1.12e-05	-0.51	-0.42	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
COAD	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-7.31	3.29e-12	1.12e-05	-0.46	-0.42	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
COAD	trans	rs13190036	0.681	rs28461408	ENSG00000226986.4	RP11-543B16.2	7.31	3.32e-12	1.13e-05	0.64	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	7.31	3.33e-12	1.14e-05	0.49	0.41	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	7.31	3.34e-12	1.14e-05	0.49	0.41	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-7.31	3.38e-12	1.15e-05	-0.53	-0.41	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-7.31	3.43e-12	1.17e-05	-0.45	-0.41	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
COAD	trans	rs2657294	0.734	rs10740449	ENSG00000172974.11	AC007318.5	7.31	3.47e-12	1.18e-05	0.46	0.41	Pneumonia;	chr10:75086620	chr2:65205108~65205988:+
COAD	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	7.3	3.5e-12	1.19e-05	0.48	0.41	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	7.3	3.5e-12	1.19e-05	0.48	0.41	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	7.3	3.5e-12	1.19e-05	0.48	0.41	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	7.3	3.5e-12	1.19e-05	0.48	0.41	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	7.3	3.61e-12	1.23e-05	0.49	0.41	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	7.3	3.61e-12	1.23e-05	0.49	0.41	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	7.3	3.61e-12	1.23e-05	0.49	0.41	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	7.3	3.61e-12	1.23e-05	0.49	0.41	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.967	rs8054482	ENSG00000230849.2	GOT2P2	7.3	3.62e-12	1.23e-05	0.52	0.41	Blood metabolite ratios;	chr16:58810532	chr1:173141100~173142350:-
COAD	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-7.3	3.63e-12	1.23e-05	-0.49	-0.41	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-7.3	3.63e-12	1.23e-05	-0.49	-0.41	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	7.3	3.69e-12	1.25e-05	0.46	0.41	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
COAD	trans	rs28647808	0.867	rs34399743	ENSG00000234981.1	RP11-534L20.4	7.3	3.7e-12	1.25e-05	0.81	0.41	Blood protein levels;	chr9:133385574	chr1:206528915~206529706:+
COAD	trans	rs28647808	0.881	rs28617580	ENSG00000234981.1	RP11-534L20.4	7.3	3.7e-12	1.25e-05	0.81	0.41	Blood protein levels;	chr9:133387168	chr1:206528915~206529706:+
COAD	trans	rs3740713	1	rs3740713	ENSG00000235847.2	LDHAP7	7.29	3.82e-12	1.29e-05	0.76	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:84777259~84778223:-
COAD	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-7.29	3.84e-12	1.3e-05	-0.49	-0.41	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-7.29	3.84e-12	1.3e-05	-0.49	-0.41	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-7.29	3.84e-12	1.3e-05	-0.49	-0.41	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	7.29	3.84e-12	1.3e-05	0.49	0.41	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
COAD	trans	rs7121616	0.563	rs4936770	ENSG00000229091.2	HSPA8P8	7.29	3.89e-12	1.31e-05	0.44	0.41	Breast cancer;	chr11:123058167	chr7:10451311~10452526:+
COAD	trans	rs8175379	0.509	rs7293453	ENSG00000231752.4	EMBP1	7.29	3.91e-12	1.32e-05	0.51	0.41	Interleukin-7 levels;	chr5:46253007	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.893	rs11586763	ENSG00000244144.1	RP11-757F18.3	-7.28	3.95e-12	1.34e-05	-0.65	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020316	chr3:112185480~112185998:-
COAD	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	7.28	3.96e-12	1.34e-05	0.48	0.41	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
COAD	trans	rs16937956	0.597	rs72852616	ENSG00000266891.1	RP11-692N5.2	7.28	3.99e-12	1.35e-05	0.57	0.41	Body mass index;	chr11:8385339	chr18:9734882~9735602:-
COAD	trans	rs16937956	0.597	rs12788149	ENSG00000266891.1	RP11-692N5.2	7.28	3.99e-12	1.35e-05	0.57	0.41	Body mass index;	chr11:8385383	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	7.28	4.03e-12	1.36e-05	0.48	0.41	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-7.28	4.07e-12	1.37e-05	-0.49	-0.41	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	7.28	4.15e-12	1.4e-05	0.45	0.41	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
COAD	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-7.28	4.16e-12	1.4e-05	-0.52	-0.41	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
COAD	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-7.28	4.16e-12	1.4e-05	-0.52	-0.41	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
COAD	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	7.28	4.19e-12	1.41e-05	0.48	0.41	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
COAD	trans	rs6708331	0.941	rs10173330	ENSG00000232654.1	FAM136BP	7.27	4.24e-12	1.43e-05	0.56	0.41	Obesity-related traits;	chr2:70139981	chr6:3045384~3045800:+
COAD	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-7.27	4.26e-12	1.44e-05	-0.54	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
COAD	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	7.27	4.37e-12	1.47e-05	0.46	0.41	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
COAD	trans	rs8175379	0.502	rs8185361	ENSG00000231752.4	EMBP1	-7.27	4.4e-12	1.48e-05	-0.51	-0.41	Interleukin-7 levels;	chr5:46300238	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.542	rs12657764	ENSG00000231752.4	EMBP1	-7.27	4.41e-12	1.48e-05	-0.51	-0.41	Interleukin-7 levels;	chr5:46281165	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	7.27	4.43e-12	1.49e-05	0.52	0.41	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
COAD	trans	rs9858542	1	rs3197999	ENSG00000197582.5	GPX1P1	-7.26	4.47e-12	1.5e-05	-0.6	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684099	chrX:13378735~13379340:-
COAD	trans	rs74781061	0.799	rs4372642	ENSG00000227288.3	RP5-837I24.1	7.26	4.51e-12	1.52e-05	0.54	0.41	Endometriosis;	chr15:74460095	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs6495102	ENSG00000227288.3	RP5-837I24.1	7.26	4.51e-12	1.52e-05	0.54	0.41	Endometriosis;	chr15:74470337	chr1:81501794~81503468:+
COAD	trans	rs3770081	1	rs12620810	ENSG00000229880.1	IMMTP1	7.26	4.58e-12	1.54e-05	0.79	0.41	Facial emotion recognition (sad faces);	chr2:86164358	chr21:44675868~44678086:-
COAD	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	7.26	4.58e-12	1.54e-05	0.48	0.41	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.893	rs12122721	ENSG00000244144.1	RP11-757F18.3	7.26	4.61e-12	1.55e-05	0.6	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201015352	chr3:112185480~112185998:-
COAD	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-7.26	4.62e-12	1.55e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
COAD	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-7.26	4.62e-12	1.55e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
COAD	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-7.26	4.62e-12	1.55e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
COAD	trans	rs10037055	0.685	rs10039241	ENSG00000228305.2	AC016734.2	-7.26	4.62e-12	1.55e-05	-0.48	-0.41	Migraine without aura;	chr5:177151071	chr2:63622178~63622831:-
COAD	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-7.26	4.71e-12	1.58e-05	-0.53	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	7.26	4.74e-12	1.59e-05	0.43	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
COAD	trans	rs1039766	0.778	rs13399786	ENSG00000224334.1	AP000357.4	-7.26	4.74e-12	1.59e-05	-0.7	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65283571	chr22:24686923~24688087:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	7.25	4.78e-12	1.6e-05	0.46	0.41	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
COAD	trans	rs72615157	0.634	rs2272343	ENSG00000228546.2	CTA-313A17.3	7.25	4.81e-12	1.61e-05	0.63	0.41	Lung function (FEV1/FVC);	chr7:100180662	chr7:102337316~102339115:+
COAD	trans	rs72615157	0.634	rs74742883	ENSG00000228546.2	CTA-313A17.3	7.25	4.81e-12	1.61e-05	0.63	0.41	Lung function (FEV1/FVC);	chr7:100188142	chr7:102337316~102339115:+
COAD	trans	rs72615157	0.634	rs7789890	ENSG00000228546.2	CTA-313A17.3	7.25	4.81e-12	1.61e-05	0.63	0.41	Lung function (FEV1/FVC);	chr7:100202936	chr7:102337316~102339115:+
COAD	trans	rs72615157	0.634	rs79986079	ENSG00000228546.2	CTA-313A17.3	7.25	4.81e-12	1.61e-05	0.63	0.41	Lung function (FEV1/FVC);	chr7:100204421	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.837	rs7324645	ENSG00000224976.2	PARP4P2	-7.25	4.84e-12	1.62e-05	-0.46	-0.41	Obesity-related traits;	chr13:24426717	chr13:19349137~19407962:+
COAD	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-7.25	4.85e-12	1.62e-05	-0.52	-0.41	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-7.25	4.86e-12	1.63e-05	-0.49	-0.41	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
COAD	trans	rs6708331	1	rs62151174	ENSG00000232654.1	FAM136BP	7.25	4.89e-12	1.64e-05	0.55	0.41	Obesity-related traits;	chr2:70136836	chr6:3045384~3045800:+
COAD	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-7.25	4.95e-12	1.66e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
COAD	trans	rs8175379	0.509	rs4128582	ENSG00000231752.4	EMBP1	7.25	5.01e-12	1.68e-05	0.52	0.41	Interleukin-7 levels;	chr5:46252001	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.875	rs8001187	ENSG00000224976.2	PARP4P2	-7.25	5.01e-12	1.68e-05	-0.46	-0.41	Obesity-related traits;	chr13:24402276	chr13:19349137~19407962:+
COAD	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-7.24	5.05e-12	1.69e-05	-0.49	-0.41	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
COAD	trans	rs12709013	1	rs6499983	ENSG00000230849.2	GOT2P2	7.24	5.05e-12	1.69e-05	0.51	0.41	Blood metabolite ratios;	chr16:58810005	chr1:173141100~173142350:-
COAD	trans	rs16937956	0.597	rs12788830	ENSG00000266891.1	RP11-692N5.2	7.24	5.09e-12	1.7e-05	0.59	0.41	Body mass index;	chr11:8380429	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	7.24	5.09e-12	1.7e-05	0.48	0.41	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
COAD	trans	rs6708331	0.941	rs13028968	ENSG00000232654.1	FAM136BP	7.24	5.12e-12	1.71e-05	0.54	0.41	Obesity-related traits;	chr2:70179991	chr6:3045384~3045800:+
COAD	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	7.24	5.28e-12	1.76e-05	0.47	0.41	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
COAD	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	7.24	5.35e-12	1.79e-05	0.52	0.41	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
COAD	trans	rs12709013	0.967	rs56107162	ENSG00000230849.2	GOT2P2	7.23	5.41e-12	1.81e-05	0.51	0.41	Blood metabolite ratios;	chr16:58804358	chr1:173141100~173142350:-
COAD	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-7.23	5.46e-12	1.82e-05	-0.6	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
COAD	trans	rs13190036	0.551	rs11955537	ENSG00000228305.2	AC016734.2	-7.23	5.5e-12	1.83e-05	-0.47	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr2:63622178~63622831:-
COAD	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-7.23	5.68e-12	1.89e-05	-0.44	-0.41	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
COAD	trans	rs8177876	0.642	rs76909932	ENSG00000224837.1	GCSHP5	7.22	5.74e-12	1.91e-05	0.71	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs8177939	ENSG00000224837.1	GCSHP5	7.22	5.74e-12	1.91e-05	0.71	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr1:168055901~168056422:-
COAD	trans	rs1816752	0.783	rs9507333	ENSG00000224976.2	PARP4P2	-7.22	5.76e-12	1.91e-05	-0.45	-0.41	Obesity-related traits;	chr13:24404172	chr13:19349137~19407962:+
COAD	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	7.22	5.79e-12	1.93e-05	0.58	0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	7.22	5.82e-12	1.93e-05	0.48	0.41	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
COAD	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-7.22	5.88e-12	1.95e-05	-0.58	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.967	rs62064905	ENSG00000230849.2	GOT2P2	7.22	5.9e-12	1.96e-05	0.51	0.41	Blood metabolite ratios;	chr16:58778839	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.935	rs34657766	ENSG00000230849.2	GOT2P2	7.22	5.9e-12	1.96e-05	0.51	0.41	Blood metabolite ratios;	chr16:58779468	chr1:173141100~173142350:-
COAD	trans	rs12709013	0.729	rs71400031	ENSG00000230849.2	GOT2P2	7.22	5.9e-12	1.96e-05	0.51	0.41	Blood metabolite ratios;	chr16:58779554	chr1:173141100~173142350:-
COAD	trans	rs10940346	0.524	rs35601537	ENSG00000231752.4	EMBP1	-7.22	5.93e-12	1.97e-05	-0.51	-0.41	Schizophrenia;	chr5:50509460	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.763	rs3913893	ENSG00000244144.1	RP11-757F18.3	-7.22	5.99e-12	1.99e-05	-0.6	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201046655	chr3:112185480~112185998:-
COAD	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-7.22	6.01e-12	2e-05	-0.42	-0.41	Longevity;	chr3:48436629	chr1:27649419~27649610:+
COAD	trans	rs7554547	0.69	rs57044570	ENSG00000261819.1	RP11-680G24.4	7.22	6.02e-12	2e-05	0.58	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11899181	chr16:14988259~14990160:-
COAD	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	7.22	6.04e-12	2e-05	0.48	0.41	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
COAD	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	7.21	6.09e-12	2.02e-05	0.57	0.41	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
COAD	trans	rs6708331	1	rs13000817	ENSG00000232654.1	FAM136BP	7.21	6.12e-12	2.03e-05	0.58	0.41	Obesity-related traits;	chr2:70046575	chr6:3045384~3045800:+
COAD	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-7.21	6.13e-12	2.03e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
COAD	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-7.21	6.13e-12	2.03e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
COAD	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	7.21	6.16e-12	2.04e-05	0.61	0.41	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
COAD	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	7.21	6.2e-12	2.05e-05	0.48	0.41	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	7.21	6.2e-12	2.05e-05	0.48	0.41	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	7.21	6.2e-12	2.05e-05	0.48	0.41	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.837	rs7139748	ENSG00000224976.2	PARP4P2	-7.21	6.24e-12	2.07e-05	-0.45	-0.41	Obesity-related traits;	chr13:24411531	chr13:19349137~19407962:+
COAD	trans	rs7554511	0.707	rs10800755	ENSG00000244144.1	RP11-757F18.3	7.21	6.3e-12	2.09e-05	0.59	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054852	chr3:112185480~112185998:-
COAD	trans	rs55665837	0.701	rs12787709	ENSG00000236360.2	RP11-334A14.2	7.21	6.43e-12	2.13e-05	0.59	0.41	Vitamin D levels;	chr11:14617711	chr1:52993201~52993702:-
COAD	trans	rs10037055	0.947	rs10063803	ENSG00000228305.2	AC016734.2	7.2	6.44e-12	2.13e-05	0.47	0.41	Migraine without aura;	chr5:177240326	chr2:63622178~63622831:-
COAD	trans	rs13190036	0.551	rs9313751	ENSG00000228305.2	AC016734.2	-7.2	6.46e-12	2.14e-05	-0.47	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr2:63622178~63622831:-
COAD	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-7.2	6.48e-12	2.14e-05	-0.47	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
COAD	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-7.2	6.49e-12	2.15e-05	-0.49	-0.41	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
COAD	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	7.2	6.74e-12	2.23e-05	0.56	0.41	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
COAD	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	7.19	6.91e-12	2.28e-05	0.55	0.41	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	7.19	7.07e-12	2.33e-05	0.45	0.41	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
COAD	trans	rs7399018	1	rs7399018	ENSG00000223825.5	DAZAP2P1	-7.19	7.09e-12	2.34e-05	-0.58	-0.41	Cisplatin-induced ototoxicity;	chr12:51216581	chr2:202201384~202201886:-
COAD	trans	rs7554511	0.894	rs296543	ENSG00000244144.1	RP11-757F18.3	7.19	7.1e-12	2.34e-05	0.58	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200920705	chr3:112185480~112185998:-
COAD	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	7.19	7.19e-12	2.37e-05	0.49	0.41	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
COAD	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-7.19	7.26e-12	2.39e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
COAD	trans	rs3770081	1	rs56104203	ENSG00000229880.1	IMMTP1	7.18	7.34e-12	2.42e-05	0.78	0.41	Facial emotion recognition (sad faces);	chr2:86109133	chr21:44675868~44678086:-
COAD	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	7.18	7.41e-12	2.44e-05	0.53	0.41	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	7.18	7.46e-12	2.46e-05	0.48	0.41	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-7.18	7.59e-12	2.5e-05	-0.51	-0.41	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
COAD	trans	rs7554547	0.622	rs2179110	ENSG00000261819.1	RP11-680G24.4	7.18	7.64e-12	2.51e-05	0.61	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11912754	chr16:14988259~14990160:-
COAD	trans	rs2657294	0.646	rs10762656	ENSG00000172974.11	AC007318.5	7.17	7.76e-12	2.55e-05	0.46	0.41	Pneumonia;	chr10:75085706	chr2:65205108~65205988:+
COAD	trans	rs8175379	0.505	rs10073477	ENSG00000231752.4	EMBP1	-7.17	7.8e-12	2.56e-05	-0.52	-0.41	Interleukin-7 levels;	chr5:46338025	chr1:121519112~121571892:+
COAD	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-7.17	7.88e-12	2.58e-05	-0.5	-0.41	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
COAD	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-7.17	7.88e-12	2.58e-05	-0.5	-0.41	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
COAD	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	7.17	7.88e-12	2.58e-05	0.57	0.41	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-7.17	8.03e-12	2.63e-05	-0.48	-0.41	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	7.17	8.04e-12	2.63e-05	0.48	0.41	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	7.17	8.04e-12	2.63e-05	0.48	0.41	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	7.17	8.04e-12	2.63e-05	0.48	0.41	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
COAD	trans	rs16937956	0.597	rs12793685	ENSG00000266891.1	RP11-692N5.2	7.17	8.09e-12	2.65e-05	0.58	0.41	Body mass index;	chr11:8380583	chr18:9734882~9735602:-
COAD	trans	rs1816752	0.87	rs73469543	ENSG00000224976.2	PARP4P2	-7.17	8.11e-12	2.65e-05	-0.46	-0.41	Obesity-related traits;	chr13:24424832	chr13:19349137~19407962:+
COAD	trans	rs7554511	0.893	rs72749166	ENSG00000244144.1	RP11-757F18.3	-7.16	8.22e-12	2.69e-05	-0.63	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031177	chr3:112185480~112185998:-
COAD	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	7.16	8.49e-12	2.77e-05	0.48	0.41	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
COAD	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-7.16	8.53e-12	2.78e-05	-0.52	-0.41	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
COAD	trans	rs1816752	0.905	rs9511242	ENSG00000224976.2	PARP4P2	-7.16	8.6e-12	2.81e-05	-0.45	-0.41	Obesity-related traits;	chr13:24419261	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.806	rs6860200	ENSG00000231752.4	EMBP1	7.16	8.62e-12	2.81e-05	0.48	0.41	P wave duration;	chr5:45440241	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs7732970	ENSG00000231752.4	EMBP1	7.16	8.69e-12	2.83e-05	0.48	0.41	P wave duration;	chr5:45452044	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-7.15	8.82e-12	2.87e-05	-0.48	-0.41	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	7.15	8.86e-12	2.89e-05	0.48	0.41	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
COAD	trans	rs673253	1	rs673253	ENSG00000231007.5	CDC20P1	7.15	8.92e-12	2.9e-05	0.54	0.41	Intelligence (multi-trait analysis);	chr1:43596483	chr9:87011652~87013151:+
COAD	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-7.15	8.95e-12	2.91e-05	-0.46	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	7.15	9.16e-12	2.98e-05	0.48	0.41	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs1527831	ENSG00000231752.4	EMBP1	7.15	9.24e-12	3e-05	0.47	0.41	P wave duration;	chr5:45656821	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.509	rs8185053	ENSG00000231752.4	EMBP1	-7.15	9.25e-12	3e-05	-0.51	-0.41	Interleukin-7 levels;	chr5:46261842	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	7.14	9.28e-12	3.01e-05	0.49	0.41	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
COAD	trans	rs4276421	0.806	rs6451801	ENSG00000231752.4	EMBP1	7.14	9.3e-12	3.02e-05	0.47	0.41	P wave duration;	chr5:45439331	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs13169726	ENSG00000231752.4	EMBP1	7.14	9.3e-12	3.02e-05	0.47	0.41	P wave duration;	chr5:45444967	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.592	rs7832708	ENSG00000173295.6	FAM86B3P	7.14	9.67e-12	3.14e-05	0.48	0.41	Neuroticism;	chr8:10332530	chr8:8228595~8244865:+
COAD	trans	rs864643	0.524	rs11715885	ENSG00000188856.6	RPSAP47	7.14	9.72e-12	3.15e-05	0.58	0.41	Attention deficit hyperactivity disorder;	chr3:39475107	chr8:80558870~80559757:+
COAD	trans	rs7121616	0.576	rs11218967	ENSG00000229091.2	HSPA8P8	7.14	9.77e-12	3.17e-05	0.43	0.41	Breast cancer;	chr11:123087551	chr7:10451311~10452526:+
COAD	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	7.14	9.77e-12	3.17e-05	0.48	0.41	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.893	rs11589573	ENSG00000244144.1	RP11-757F18.3	-7.13	1e-11	3.24e-05	-0.64	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005987	chr3:112185480~112185998:-
COAD	trans	rs8010715	0.848	rs927494	ENSG00000238000.1	RP11-274E7.2	7.13	1.01e-11	3.26e-05	0.44	0.41	IgG glycosylation;	chr14:24131181	chr5:98213402~98214121:+
COAD	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-7.13	1.01e-11	3.28e-05	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.837	rs10073636	ENSG00000231752.4	EMBP1	-7.13	1.02e-11	3.29e-05	-0.48	-0.41	P wave duration;	chr5:45537197	chr1:121519112~121571892:+
COAD	trans	rs61041336	0.583	rs11647748	ENSG00000230849.2	GOT2P2	-7.13	1.02e-11	3.31e-05	-0.78	-0.41	Neuritic plaque;	chr16:58697980	chr1:173141100~173142350:-
COAD	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-7.13	1.03e-11	3.32e-05	-0.51	-0.41	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.819	rs7400583	ENSG00000224976.2	PARP4P2	-7.13	1.04e-11	3.34e-05	-0.43	-0.41	Obesity-related traits;	chr13:24415916	chr13:19349137~19407962:+
COAD	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	7.13	1.04e-11	3.35e-05	0.79	0.41	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	7.13	1.04e-11	3.35e-05	0.43	0.41	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
COAD	trans	rs864643	0.524	rs78956370	ENSG00000188856.6	RPSAP47	7.13	1.04e-11	3.37e-05	0.58	0.41	Attention deficit hyperactivity disorder;	chr3:39463883	chr8:80558870~80559757:+
COAD	trans	rs74781061	0.932	rs11072496	ENSG00000227288.3	RP5-837I24.1	7.13	1.05e-11	3.37e-05	0.53	0.41	Endometriosis;	chr15:74628191	chr1:81501794~81503468:+
COAD	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-7.13	1.05e-11	3.37e-05	-0.48	-0.41	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs6893773	ENSG00000231752.4	EMBP1	7.12	1.06e-11	3.41e-05	0.47	0.41	P wave duration;	chr5:45622394	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.805	rs6451810	ENSG00000231752.4	EMBP1	7.12	1.06e-11	3.41e-05	0.47	0.41	P wave duration;	chr5:45633898	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.962	rs6663875	ENSG00000213331.4	RP11-713C19.2	7.12	1.07e-11	3.46e-05	0.47	0.41	Life satisfaction;	chr1:173894071	chr4:187970273~187971284:+
COAD	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-7.12	1.1e-11	3.55e-05	-0.45	-0.41	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
COAD	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	7.11	1.13e-11	3.62e-05	0.48	0.41	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
COAD	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	7.11	1.13e-11	3.63e-05	0.46	0.41	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-7.11	1.14e-11	3.67e-05	-0.49	-0.41	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-7.11	1.14e-11	3.67e-05	-0.42	-0.41	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
COAD	trans	rs4276421	0.776	rs4133429	ENSG00000231752.4	EMBP1	7.11	1.15e-11	3.7e-05	0.48	0.41	P wave duration;	chr5:45403633	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-7.11	1.18e-11	3.77e-05	-0.5	-0.41	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
COAD	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-7.11	1.18e-11	3.77e-05	-0.5	-0.41	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
COAD	trans	rs116095464	1	rs55671190	ENSG00000185986.11	SDHAP3	7.1	1.19e-11	3.81e-05	0.85	0.41	Breast cancer;	chr5:287307	chr5:1572222~1594620:-
COAD	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	7.1	1.22e-11	3.9e-05	0.83	0.4	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
COAD	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	7.1	1.23e-11	3.94e-05	0.47	0.4	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	7.1	1.23e-11	3.94e-05	0.48	0.4	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	7.1	1.23e-11	3.94e-05	0.46	0.4	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
COAD	trans	rs9425766	0.886	rs1322775	ENSG00000213331.4	RP11-713C19.2	7.1	1.24e-11	3.96e-05	0.46	0.4	Life satisfaction;	chr1:173886160	chr4:187970273~187971284:+
COAD	trans	rs9329221	0.967	rs7005363	ENSG00000173295.6	FAM86B3P	-7.1	1.24e-11	3.97e-05	-0.45	-0.4	Neuroticism;	chr8:10426238	chr8:8228595~8244865:+
COAD	trans	rs4276421	0.806	rs6892594	ENSG00000231752.4	EMBP1	7.1	1.24e-11	3.98e-05	0.47	0.4	P wave duration;	chr5:45427071	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs34666220	ENSG00000231752.4	EMBP1	7.1	1.24e-11	3.98e-05	0.47	0.4	P wave duration;	chr5:45435884	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.962	rs2065171	ENSG00000213331.4	RP11-713C19.2	7.1	1.25e-11	3.99e-05	0.46	0.4	Life satisfaction;	chr1:173876972	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.962	rs4652229	ENSG00000213331.4	RP11-713C19.2	7.1	1.25e-11	3.99e-05	0.46	0.4	Life satisfaction;	chr1:173877452	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.927	rs9425765	ENSG00000213331.4	RP11-713C19.2	7.1	1.25e-11	3.99e-05	0.46	0.4	Life satisfaction;	chr1:173878871	chr4:187970273~187971284:+
COAD	trans	rs10940346	0.506	rs12187591	ENSG00000231752.4	EMBP1	-7.1	1.25e-11	4.01e-05	-0.5	-0.4	Schizophrenia;	chr5:50586789	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-7.09	1.28e-11	4.08e-05	-0.59	-0.4	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	7.09	1.28e-11	4.1e-05	0.47	0.4	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
COAD	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	7.09	1.3e-11	4.16e-05	0.53	0.4	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
COAD	trans	rs7121616	0.562	rs2061602	ENSG00000229091.2	HSPA8P8	7.09	1.3e-11	4.16e-05	0.43	0.4	Breast cancer;	chr11:123065079	chr7:10451311~10452526:+
COAD	trans	rs4883201	0.518	rs887782	ENSG00000179899.8	PHC1P1	-7.09	1.31e-11	4.17e-05	-0.55	-0.4	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:55411727~55414787:-
COAD	trans	rs4276421	0.869	rs6892627	ENSG00000231752.4	EMBP1	7.09	1.31e-11	4.18e-05	0.47	0.4	P wave duration;	chr5:45722892	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.719	rs11841989	ENSG00000224976.2	PARP4P2	-7.09	1.32e-11	4.2e-05	-0.45	-0.4	Obesity-related traits;	chr13:24423560	chr13:19349137~19407962:+
COAD	trans	rs864643	0.524	rs77309543	ENSG00000188856.6	RPSAP47	7.09	1.33e-11	4.23e-05	0.56	0.4	Attention deficit hyperactivity disorder;	chr3:39489578	chr8:80558870~80559757:+
COAD	trans	rs864643	0.577	rs76395532	ENSG00000188856.6	RPSAP47	7.09	1.33e-11	4.23e-05	0.56	0.4	Attention deficit hyperactivity disorder;	chr3:39490370	chr8:80558870~80559757:+
COAD	trans	rs864643	0.524	rs77060785	ENSG00000188856.6	RPSAP47	7.09	1.33e-11	4.23e-05	0.56	0.4	Attention deficit hyperactivity disorder;	chr3:39491177	chr8:80558870~80559757:+
COAD	trans	rs7113874	0.802	rs7941510	ENSG00000266891.1	RP11-692N5.2	7.09	1.33e-11	4.23e-05	0.53	0.4	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655516	chr18:9734882~9735602:-
COAD	trans	rs7554511	0.707	rs10800756	ENSG00000244144.1	RP11-757F18.3	7.09	1.33e-11	4.25e-05	0.58	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054931	chr3:112185480~112185998:-
COAD	trans	rs2657294	0.606	rs10824290	ENSG00000172974.11	AC007318.5	7.08	1.36e-11	4.33e-05	0.52	0.4	Pneumonia;	chr10:75204210	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.632	rs2657289	ENSG00000172974.11	AC007318.5	7.08	1.36e-11	4.33e-05	0.52	0.4	Pneumonia;	chr10:75206705	chr2:65205108~65205988:+
COAD	trans	rs4276421	0.806	rs6892290	ENSG00000231752.4	EMBP1	7.08	1.36e-11	4.35e-05	0.47	0.4	P wave duration;	chr5:45427035	chr1:121519112~121571892:+
COAD	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-7.08	1.37e-11	4.38e-05	-0.46	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
COAD	trans	rs74781061	1	rs6495116	ENSG00000227288.3	RP5-837I24.1	7.08	1.38e-11	4.39e-05	0.55	0.4	Endometriosis;	chr15:74593607	chr1:81501794~81503468:+
COAD	trans	rs74781061	1	rs4887166	ENSG00000227288.3	RP5-837I24.1	7.08	1.38e-11	4.39e-05	0.55	0.4	Endometriosis;	chr15:74605257	chr1:81501794~81503468:+
COAD	trans	rs74781061	1	rs6495117	ENSG00000227288.3	RP5-837I24.1	7.08	1.38e-11	4.39e-05	0.55	0.4	Endometriosis;	chr15:74607159	chr1:81501794~81503468:+
COAD	trans	rs9425766	0.962	rs1322780	ENSG00000213331.4	RP11-713C19.2	7.08	1.38e-11	4.39e-05	0.47	0.4	Life satisfaction;	chr1:173896448	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.962	rs9425435	ENSG00000213331.4	RP11-713C19.2	7.08	1.38e-11	4.39e-05	0.47	0.4	Life satisfaction;	chr1:173896936	chr4:187970273~187971284:+
COAD	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-7.08	1.39e-11	4.43e-05	-0.46	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
COAD	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-7.08	1.4e-11	4.45e-05	-0.46	-0.4	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	7.08	1.4e-11	4.46e-05	0.44	0.4	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	7.08	1.4e-11	4.46e-05	0.44	0.4	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.837	rs1483303	ENSG00000231752.4	EMBP1	7.08	1.4e-11	4.46e-05	0.47	0.4	P wave duration;	chr5:45571997	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs2696013	ENSG00000231752.4	EMBP1	7.08	1.4e-11	4.46e-05	0.47	0.4	P wave duration;	chr5:45603104	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs2337483	ENSG00000231752.4	EMBP1	7.08	1.4e-11	4.46e-05	0.47	0.4	P wave duration;	chr5:45608220	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs2580260	ENSG00000231752.4	EMBP1	7.08	1.4e-11	4.46e-05	0.47	0.4	P wave duration;	chr5:45638527	chr1:121519112~121571892:+
COAD	trans	rs2589161	1	rs2589161	ENSG00000231752.4	EMBP1	7.07	1.42e-11	4.53e-05	0.47	0.4	Breast cancer;	chr5:45653810	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs1405918	ENSG00000231752.4	EMBP1	7.07	1.42e-11	4.53e-05	0.47	0.4	P wave duration;	chr5:45654968	chr1:121519112~121571892:+
COAD	trans	rs6708331	1	rs12999430	ENSG00000232654.1	FAM136BP	7.07	1.45e-11	4.62e-05	0.57	0.4	Obesity-related traits;	chr2:70079653	chr6:3045384~3045800:+
COAD	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	7.07	1.46e-11	4.64e-05	0.58	0.4	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	7.07	1.46e-11	4.64e-05	0.58	0.4	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
COAD	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	7.07	1.47e-11	4.66e-05	0.49	0.4	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
COAD	trans	rs16937956	0.597	rs12793878	ENSG00000266891.1	RP11-692N5.2	7.07	1.48e-11	4.68e-05	0.58	0.4	Body mass index;	chr11:8380662	chr18:9734882~9735602:-
COAD	trans	rs13190036	0.551	rs11957608	ENSG00000228305.2	AC016734.2	-7.07	1.5e-11	4.74e-05	-0.46	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr2:63622178~63622831:-
COAD	trans	rs12709013	0.74	rs12927495	ENSG00000230849.2	GOT2P2	7.07	1.5e-11	4.76e-05	0.49	0.4	Blood metabolite ratios;	chr16:58821934	chr1:173141100~173142350:-
COAD	trans	rs4276421	0.806	rs13162651	ENSG00000231752.4	EMBP1	7.06	1.51e-11	4.77e-05	0.47	0.4	P wave duration;	chr5:45409798	chr1:121519112~121571892:+
COAD	trans	rs8175379	1	rs8175379	ENSG00000231752.4	EMBP1	-7.06	1.51e-11	4.77e-05	-0.51	-0.4	Interleukin-7 levels;	chr5:46263441	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-7.06	1.51e-11	4.79e-05	-0.54	-0.4	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	7.06	1.52e-11	4.8e-05	0.44	0.4	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	7.06	1.52e-11	4.82e-05	0.48	0.4	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.633	rs9578729	ENSG00000224976.2	PARP4P2	-7.06	1.54e-11	4.86e-05	-0.45	-0.4	Obesity-related traits;	chr13:24425106	chr13:19349137~19407962:+
COAD	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	7.06	1.54e-11	4.87e-05	0.51	0.4	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
COAD	trans	rs7554511	0.894	rs404339	ENSG00000244144.1	RP11-757F18.3	-7.06	1.57e-11	4.97e-05	-0.57	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917763	chr3:112185480~112185998:-
COAD	trans	rs4276421	0.806	rs2337412	ENSG00000231752.4	EMBP1	7.06	1.57e-11	4.97e-05	0.47	0.4	P wave duration;	chr5:45483410	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.509	rs10074483	ENSG00000231752.4	EMBP1	7.06	1.59e-11	5.01e-05	0.51	0.4	Interleukin-7 levels;	chr5:46238631	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-7.05	1.61e-11	5.08e-05	-0.51	-0.4	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs6451804	ENSG00000231752.4	EMBP1	7.05	1.62e-11	5.11e-05	0.47	0.4	P wave duration;	chr5:45492103	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-7.05	1.63e-11	5.13e-05	-0.47	-0.4	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
COAD	trans	rs8175379	0.614	rs8185043	ENSG00000231752.4	EMBP1	-7.05	1.63e-11	5.13e-05	-0.5	-0.4	Interleukin-7 levels;	chr5:46261354	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.858	rs11583328	ENSG00000244144.1	RP11-757F18.3	7.05	1.64e-11	5.16e-05	0.6	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr3:112185480~112185998:-
COAD	trans	rs3770081	1	rs2303339	ENSG00000229880.1	IMMTP1	-7.05	1.67e-11	5.25e-05	-0.8	-0.4	Facial emotion recognition (sad faces);	chr2:86119057	chr21:44675868~44678086:-
COAD	trans	rs7554511	0.624	rs5010839	ENSG00000244144.1	RP11-757F18.3	-7.04	1.7e-11	5.34e-05	-0.58	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042916	chr3:112185480~112185998:-
COAD	trans	rs1816752	0.905	rs7317850	ENSG00000224976.2	PARP4P2	-7.04	1.7e-11	5.35e-05	-0.45	-0.4	Obesity-related traits;	chr13:24419899	chr13:19349137~19407962:+
COAD	trans	rs8175379	0.509	rs8188019	ENSG00000231752.4	EMBP1	7.04	1.71e-11	5.35e-05	0.51	0.4	Interleukin-7 levels;	chr5:46130910	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-7.04	1.72e-11	5.38e-05	-0.61	-0.4	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
COAD	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-7.04	1.72e-11	5.39e-05	-0.52	-0.4	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
COAD	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-7.04	1.72e-11	5.39e-05	-0.52	-0.4	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
COAD	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	7.04	1.73e-11	5.41e-05	0.48	0.4	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
COAD	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	7.04	1.73e-11	5.41e-05	0.48	0.4	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
COAD	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	7.04	1.73e-11	5.41e-05	0.48	0.4	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
COAD	trans	rs3770081	1	rs3770066	ENSG00000229880.1	IMMTP1	7.04	1.73e-11	5.42e-05	0.76	0.4	Facial emotion recognition (sad faces);	chr2:86165227	chr21:44675868~44678086:-
COAD	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-7.04	1.75e-11	5.48e-05	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
COAD	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-7.04	1.78e-11	5.58e-05	-0.59	-0.4	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-7.04	1.79e-11	5.6e-05	-0.46	-0.4	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-7.04	1.79e-11	5.6e-05	-0.46	-0.4	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
COAD	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	7.04	1.8e-11	5.64e-05	0.49	0.4	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
COAD	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	7.04	1.8e-11	5.64e-05	0.49	0.4	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
COAD	trans	rs4276421	0.776	rs7723380	ENSG00000231752.4	EMBP1	7.03	1.83e-11	5.72e-05	0.47	0.4	P wave duration;	chr5:45428433	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs12520124	ENSG00000231752.4	EMBP1	7.03	1.83e-11	5.72e-05	0.47	0.4	P wave duration;	chr5:45434917	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.858	rs11584383	ENSG00000244144.1	RP11-757F18.3	7.03	1.85e-11	5.78e-05	0.59	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200966738	chr3:112185480~112185998:-
COAD	trans	rs9425766	0.924	rs9286895	ENSG00000213331.4	RP11-713C19.2	7.03	1.88e-11	5.88e-05	0.46	0.4	Life satisfaction;	chr1:173873329	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.886	rs9661233	ENSG00000213331.4	RP11-713C19.2	7.03	1.88e-11	5.88e-05	0.46	0.4	Life satisfaction;	chr1:173874913	chr4:187970273~187971284:+
COAD	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	7.03	1.9e-11	5.93e-05	0.5	0.4	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
COAD	trans	rs6708331	0.941	rs10173259	ENSG00000232654.1	FAM136BP	7.03	1.9e-11	5.94e-05	0.53	0.4	Obesity-related traits;	chr2:70140078	chr6:3045384~3045800:+
COAD	trans	rs16937956	0.597	rs11822608	ENSG00000266891.1	RP11-692N5.2	7.03	1.9e-11	5.94e-05	0.56	0.4	Body mass index;	chr11:8380117	chr18:9734882~9735602:-
COAD	trans	rs9425766	0.85	rs7349095	ENSG00000213331.4	RP11-713C19.2	7.03	1.91e-11	5.95e-05	0.46	0.4	Life satisfaction;	chr1:173887899	chr4:187970273~187971284:+
COAD	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	7.02	1.92e-11	5.98e-05	0.48	0.4	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
COAD	trans	rs7121616	0.563	rs1461494	ENSG00000229091.2	HSPA8P8	7.02	1.92e-11	6e-05	0.43	0.4	Breast cancer;	chr11:123055777	chr7:10451311~10452526:+
COAD	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	7.02	1.95e-11	6.08e-05	0.46	0.4	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
COAD	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	7.02	1.97e-11	6.13e-05	0.49	0.4	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
COAD	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-7.02	1.98e-11	6.16e-05	-0.5	-0.4	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	7.02	2.01e-11	6.24e-05	0.5	0.4	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	7.02	2.01e-11	6.24e-05	0.5	0.4	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	7.02	2.01e-11	6.24e-05	0.5	0.4	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	7.02	2.01e-11	6.24e-05	0.5	0.4	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	7.02	2.01e-11	6.24e-05	0.5	0.4	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	7.01	2.03e-11	6.32e-05	0.5	0.4	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	7.01	2.06e-11	6.38e-05	0.48	0.4	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
COAD	trans	rs7113874	0.802	rs7118611	ENSG00000266891.1	RP11-692N5.2	7.01	2.09e-11	6.47e-05	0.53	0.4	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8664138	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.802	rs11042030	ENSG00000266891.1	RP11-692N5.2	7.01	2.09e-11	6.47e-05	0.53	0.4	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8669171	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	7.01	2.15e-11	6.68e-05	0.47	0.4	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
COAD	trans	rs3849046	0.68	rs11746692	ENSG00000226666.1	HSPA9P1	-7.01	2.16e-11	6.69e-05	-0.39	-0.4	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610666	chr2:221961737~221963765:+
COAD	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-7	2.18e-11	6.76e-05	-0.51	-0.4	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-7	2.19e-11	6.79e-05	-0.49	-0.4	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
COAD	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	7	2.19e-11	6.79e-05	0.45	0.4	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
COAD	trans	rs4276421	0.776	rs13175193	ENSG00000231752.4	EMBP1	7	2.22e-11	6.86e-05	0.47	0.4	P wave duration;	chr5:45408894	chr1:121519112~121571892:+
COAD	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-7	2.22e-11	6.87e-05	-0.49	-0.4	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
COAD	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	7	2.25e-11	6.95e-05	0.47	0.4	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
COAD	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	7	2.25e-11	6.96e-05	0.5	0.4	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	7	2.25e-11	6.96e-05	0.5	0.4	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	7	2.25e-11	6.96e-05	0.5	0.4	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
COAD	trans	rs8175379	0.509	rs8185387	ENSG00000231752.4	EMBP1	7	2.26e-11	6.99e-05	0.5	0.4	Interleukin-7 levels;	chr5:46253944	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.85	rs1322770	ENSG00000213331.4	RP11-713C19.2	7	2.26e-11	6.99e-05	0.46	0.4	Life satisfaction;	chr1:173863198	chr4:187970273~187971284:+
COAD	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	7	2.28e-11	7.06e-05	0.47	0.4	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs755048	ENSG00000231752.4	EMBP1	-6.99	2.31e-11	7.13e-05	-0.47	-0.4	P wave duration;	chr5:45596256	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs10069510	ENSG00000231752.4	EMBP1	-6.99	2.31e-11	7.13e-05	-0.47	-0.4	P wave duration;	chr5:45596937	chr1:121519112~121571892:+
COAD	trans	rs8177876	0.731	rs74882687	ENSG00000224837.1	GCSHP5	6.99	2.34e-11	7.22e-05	0.68	0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr1:168055901~168056422:-
COAD	trans	rs55665837	0.539	rs10500804	ENSG00000236360.2	RP11-334A14.2	6.99	2.35e-11	7.24e-05	0.52	0.4	Vitamin D levels;	chr11:14888727	chr1:52993201~52993702:-
COAD	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-6.99	2.4e-11	7.4e-05	-0.47	-0.4	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs2580258	ENSG00000231752.4	EMBP1	6.98	2.47e-11	7.6e-05	0.47	0.4	P wave duration;	chr5:45586815	chr1:121519112~121571892:+
COAD	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-6.98	2.48e-11	7.62e-05	-0.45	-0.4	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
COAD	trans	rs61041336	0.534	rs11641633	ENSG00000230849.2	GOT2P2	6.98	2.48e-11	7.63e-05	0.86	0.4	Neuritic plaque;	chr16:58679717	chr1:173141100~173142350:-
COAD	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-6.98	2.48e-11	7.64e-05	-0.47	-0.4	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
COAD	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	6.98	2.5e-11	7.68e-05	0.47	0.4	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	6.98	2.5e-11	7.68e-05	0.47	0.4	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-6.98	2.51e-11	7.73e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
COAD	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	6.98	2.53e-11	7.77e-05	0.5	0.4	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.837	rs7727890	ENSG00000231752.4	EMBP1	6.98	2.53e-11	7.78e-05	0.47	0.4	P wave duration;	chr5:45478669	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs11741075	ENSG00000231752.4	EMBP1	-6.98	2.55e-11	7.82e-05	-0.48	-0.4	P wave duration;	chr5:45556276	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.506	rs12657678	ENSG00000231752.4	EMBP1	6.98	2.55e-11	7.84e-05	0.47	0.4	Schizophrenia;	chr5:50564284	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	6.98	2.56e-11	7.86e-05	0.57	0.4	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
COAD	trans	rs72615157	0.697	rs2056726	ENSG00000228546.2	CTA-313A17.3	6.97	2.59e-11	7.94e-05	0.61	0.4	Lung function (FEV1/FVC);	chr7:100182660	chr7:102337316~102339115:+
COAD	trans	rs7647973	1	rs6446268	ENSG00000197582.5	GPX1P1	-6.97	2.67e-11	8.19e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49408262	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	6.96	2.82e-11	8.62e-05	0.47	0.4	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.806	rs6414906	ENSG00000231752.4	EMBP1	6.96	2.83e-11	8.64e-05	0.47	0.4	P wave duration;	chr5:45406219	chr1:121519112~121571892:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-6.96	2.83e-11	8.64e-05	-0.43	-0.4	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
COAD	trans	rs9329221	0.576	rs1986972	ENSG00000173295.6	FAM86B3P	6.96	2.86e-11	8.74e-05	0.45	0.4	Neuroticism;	chr8:10411295	chr8:8228595~8244865:+
COAD	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	6.96	2.88e-11	8.81e-05	0.49	0.4	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
COAD	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-6.95	2.91e-11	8.89e-05	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
COAD	trans	rs10917477	0.653	rs1770480	ENSG00000224237.1	MINOS1P3	6.95	2.92e-11	8.91e-05	0.45	0.4	Thyroid function;	chr1:19590290	chr3:27214816~27215018:-
COAD	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	6.95	2.92e-11	8.92e-05	0.5	0.4	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
COAD	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-6.95	2.95e-11	8.99e-05	-0.5	-0.4	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
COAD	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	6.95	2.95e-11	8.99e-05	0.44	0.4	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
COAD	trans	rs9425766	1	rs9425766	ENSG00000213331.4	RP11-713C19.2	6.95	3e-11	9.14e-05	0.45	0.4	Life satisfaction;	chr1:173883989	chr4:187970273~187971284:+
COAD	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-6.95	3.02e-11	9.2e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-6.95	3.02e-11	9.2e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
COAD	trans	rs3812762	0.783	rs11042070	ENSG00000266891.1	RP11-692N5.2	6.95	3.03e-11	9.22e-05	0.52	0.4	Hypospadias;	chr11:8797820	chr18:9734882~9735602:-
COAD	trans	rs8010715	0.816	rs2332224	ENSG00000238000.1	RP11-274E7.2	6.95	3.03e-11	9.24e-05	0.43	0.4	IgG glycosylation;	chr14:24129335	chr5:98213402~98214121:+
COAD	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	6.95	3.05e-11	9.29e-05	0.47	0.4	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-6.95	3.07e-11	9.33e-05	-0.5	-0.4	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-6.95	3.07e-11	9.34e-05	-0.5	-0.4	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	6.94	3.09e-11	9.41e-05	0.46	0.4	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.909	rs10017335	ENSG00000276997.3	RP11-378J18.9	-6.94	3.1e-11	9.42e-05	-0.47	-0.4	Corneal astigmatism;	chr4:119460368	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.719	rs6451802	ENSG00000231752.4	EMBP1	6.94	3.16e-11	9.62e-05	0.47	0.4	P wave duration;	chr5:45440925	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	6.94	3.19e-11	9.68e-05	0.58	0.4	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	6.94	3.19e-11	9.68e-05	0.58	0.4	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-6.94	3.19e-11	9.68e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-6.94	3.19e-11	9.68e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-6.94	3.19e-11	9.68e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-6.94	3.19e-11	9.68e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-6.94	3.19e-11	9.68e-05	-0.58	-0.4	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
COAD	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-6.94	3.19e-11	9.7e-05	-0.44	-0.4	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
COAD	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	6.94	3.22e-11	9.77e-05	0.47	0.4	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.904	rs4388219	ENSG00000231752.4	EMBP1	6.93	3.36e-11	0.000102	0.49	0.4	P wave duration;	chr5:45780648	chr1:121519112~121571892:+
COAD	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-6.93	3.38e-11	0.000102	-0.5	-0.4	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
COAD	trans	rs8175379	0.501	rs10064455	ENSG00000231752.4	EMBP1	-6.93	3.44e-11	0.000104	-0.51	-0.4	Interleukin-7 levels;	chr5:46293430	chr1:121519112~121571892:+
COAD	trans	rs864643	0.524	rs12106854	ENSG00000188856.6	RPSAP47	6.93	3.45e-11	0.000104	0.53	0.4	Attention deficit hyperactivity disorder;	chr3:39487321	chr8:80558870~80559757:+
COAD	trans	rs864643	0.524	rs17038967	ENSG00000188856.6	RPSAP47	6.93	3.45e-11	0.000104	0.53	0.4	Attention deficit hyperactivity disorder;	chr3:39489530	chr8:80558870~80559757:+
COAD	trans	rs10242455	0.702	rs116671616	ENSG00000228834.1	RP11-249L21.4	6.92	3.49e-11	0.000105	0.86	0.4	Blood metabolite levels;	chr7:99356935	chr6:108907615~108907873:-
COAD	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	6.92	3.51e-11	0.000106	0.5	0.4	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
COAD	trans	rs13190036	0.551	rs7732930	ENSG00000228305.2	AC016734.2	-6.92	3.52e-11	0.000106	-0.47	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	6.92	3.52e-11	0.000106	0.41	0.4	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	6.92	3.52e-11	0.000106	0.46	0.4	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	6.92	3.52e-11	0.000106	0.46	0.4	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
COAD	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	6.92	3.55e-11	0.000107	0.49	0.4	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
COAD	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	6.92	3.6e-11	0.000109	0.51	0.4	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
COAD	trans	rs7121616	0.595	rs7941144	ENSG00000229091.2	HSPA8P8	6.91	3.72e-11	0.000112	0.42	0.4	Breast cancer;	chr11:123079805	chr7:10451311~10452526:+
COAD	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	6.91	3.88e-11	0.000117	0.93	0.4	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	6.91	3.88e-11	0.000117	0.93	0.4	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
COAD	trans	rs1816752	0.935	rs3816219	ENSG00000224976.2	PARP4P2	-6.9	3.93e-11	0.000118	-0.46	-0.4	Obesity-related traits;	chr13:24442995	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs4770666	ENSG00000224976.2	PARP4P2	-6.9	3.93e-11	0.000118	-0.43	-0.4	Obesity-related traits;	chr13:24414891	chr13:19349137~19407962:+
COAD	trans	rs10037055	0.853	rs10077929	ENSG00000226986.4	RP11-543B16.2	6.9	3.94e-11	0.000118	0.39	0.4	Migraine without aura;	chr5:177270843	chr1:211207239~211207897:+
COAD	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-6.9	3.99e-11	0.00012	-0.44	-0.4	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
COAD	trans	rs13358908	0.506	rs7293471	ENSG00000231752.4	EMBP1	-6.9	4.08e-11	0.000122	-0.51	-0.4	Schizophrenia;	chr5:46404446	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-6.9	4.1e-11	0.000123	-0.55	-0.4	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
COAD	trans	rs1816752	0.564	rs9511223	ENSG00000224976.2	PARP4P2	6.9	4.14e-11	0.000124	0.44	0.4	Obesity-related traits;	chr13:24380142	chr13:19349137~19407962:+
COAD	trans	rs7824557	0.707	rs3808519	ENSG00000253981.4	ALG1L13P	6.89	4.19e-11	0.000125	0.5	0.4	Retinal vascular caliber;	chr8:11285461	chr8:8236003~8244667:-
COAD	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-6.89	4.21e-11	0.000126	-0.58	-0.4	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
COAD	trans	rs72615157	0.716	rs75779608	ENSG00000228546.2	CTA-313A17.3	6.89	4.21e-11	0.000126	0.62	0.4	Lung function (FEV1/FVC);	chr7:100171334	chr7:102337316~102339115:+
COAD	trans	rs1816752	0.905	rs1348110	ENSG00000224976.2	PARP4P2	-6.89	4.35e-11	0.00013	-0.44	-0.39	Obesity-related traits;	chr13:24406537	chr13:19349137~19407962:+
COAD	trans	rs7824557	0.872	rs1347410	ENSG00000253981.4	ALG1L13P	-6.89	4.36e-11	0.00013	-0.5	-0.39	Retinal vascular caliber;	chr8:11253733	chr8:8236003~8244667:-
COAD	trans	rs4276421	0.837	rs7706140	ENSG00000231752.4	EMBP1	6.89	4.38e-11	0.000131	0.47	0.39	P wave duration;	chr5:45474712	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.927	rs9425757	ENSG00000213331.4	RP11-713C19.2	6.88	4.43e-11	0.000132	0.45	0.39	Life satisfaction;	chr1:173855675	chr4:187970273~187971284:+
COAD	trans	rs11650106	0.529	rs35391268	ENSG00000187870.7	RNFT1P3	-6.88	4.44e-11	0.000133	-0.43	-0.39	Lipoprotein-associated phospholipase A2 activity and mass;	chr17:59692637	chr17:20743333~20754501:-
COAD	trans	rs16937956	0.597	rs16937958	ENSG00000266891.1	RP11-692N5.2	6.88	4.48e-11	0.000134	0.56	0.39	Body mass index;	chr11:8382988	chr18:9734882~9735602:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	6.88	4.5e-11	0.000134	0.46	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
COAD	trans	rs7824557	1	rs7824557	ENSG00000253981.4	ALG1L13P	-6.88	4.5e-11	0.000134	-0.51	-0.39	Retinal vascular caliber;	chr8:11246602	chr8:8236003~8244667:-
COAD	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	6.88	4.53e-11	0.000135	0.52	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
COAD	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-6.88	4.56e-11	0.000136	-0.49	-0.39	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.776	rs7717787	ENSG00000231752.4	EMBP1	6.88	4.58e-11	0.000137	0.47	0.39	P wave duration;	chr5:45466514	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-6.88	4.59e-11	0.000137	-0.48	-0.39	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	6.88	4.63e-11	0.000138	0.46	0.39	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.792	rs12325510	ENSG00000233719.3	GOT2P3	6.88	4.66e-11	0.000139	0.52	0.39	Blood metabolite ratios;	chr16:58749707	chr12:9641802~9643007:+
COAD	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-6.87	4.7e-11	0.00014	-0.5	-0.39	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
COAD	trans	rs7554511	0.861	rs10920074	ENSG00000244144.1	RP11-757F18.3	-6.87	4.72e-11	0.000141	-0.59	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200943599	chr3:112185480~112185998:-
COAD	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-6.87	4.82e-11	0.000144	-0.49	-0.39	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
COAD	trans	rs3812762	0.701	rs4929915	ENSG00000266891.1	RP11-692N5.2	6.87	4.84e-11	0.000144	0.51	0.39	Hypospadias;	chr11:8802871	chr18:9734882~9735602:-
COAD	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	6.87	4.9e-11	0.000145	0.49	0.39	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.87	rs9318529	ENSG00000224976.2	PARP4P2	-6.87	4.91e-11	0.000146	-0.44	-0.39	Obesity-related traits;	chr13:24424190	chr13:19349137~19407962:+
COAD	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	6.86	5.04e-11	0.000149	0.44	0.39	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
COAD	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-6.86	5.13e-11	0.000152	-0.5	-0.39	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
COAD	trans	rs10940346	0.601	rs1344339	ENSG00000231752.4	EMBP1	-6.86	5.13e-11	0.000152	-0.49	-0.39	Schizophrenia;	chr5:50327987	chr1:121519112~121571892:+
COAD	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	6.86	5.13e-11	0.000152	0.49	0.39	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
COAD	trans	rs7554547	0.667	rs2050266	ENSG00000261819.1	RP11-680G24.4	6.86	5.17e-11	0.000153	0.56	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr16:14988259~14990160:-
COAD	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	6.86	5.24e-11	0.000155	0.45	0.39	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	6.86	5.25e-11	0.000155	0.43	0.39	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
COAD	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-6.86	5.26e-11	0.000155	-0.49	-0.39	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
COAD	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-6.85	5.31e-11	0.000157	-0.44	-0.39	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.776	rs56908114	ENSG00000231752.4	EMBP1	6.85	5.35e-11	0.000158	0.47	0.39	P wave duration;	chr5:45416692	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.87	rs9581025	ENSG00000224976.2	PARP4P2	-6.85	5.36e-11	0.000158	-0.44	-0.39	Obesity-related traits;	chr13:24423687	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs9581026	ENSG00000224976.2	PARP4P2	-6.85	5.36e-11	0.000158	-0.44	-0.39	Obesity-related traits;	chr13:24423788	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.87	rs9581027	ENSG00000224976.2	PARP4P2	-6.85	5.36e-11	0.000158	-0.44	-0.39	Obesity-related traits;	chr13:24423790	chr13:19349137~19407962:+
COAD	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-6.85	5.36e-11	0.000158	-0.5	-0.39	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-6.85	5.36e-11	0.000158	-0.5	-0.39	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1016620	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50490763	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs2353961	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50491604	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7379514	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50492052	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10755228	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50493498	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs34371354	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50494203	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs55843201	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50494254	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs56251178	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50494837	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.645	rs6450162	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50498547	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7706105	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50501745	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs11948302	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50502317	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10940335	ENSG00000231752.4	EMBP1	-6.85	5.42e-11	0.00016	-0.5	-0.39	Schizophrenia;	chr5:50502595	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-6.85	5.44e-11	0.00016	-0.48	-0.39	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
COAD	trans	rs6708331	0.941	rs12989257	ENSG00000232654.1	FAM136BP	6.85	5.47e-11	0.000161	0.52	0.39	Obesity-related traits;	chr2:70141466	chr6:3045384~3045800:+
COAD	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	6.85	5.5e-11	0.000162	0.45	0.39	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
COAD	trans	rs7554511	0.893	rs6427868	ENSG00000244144.1	RP11-757F18.3	-6.85	5.54e-11	0.000163	-0.59	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960354	chr3:112185480~112185998:-
COAD	trans	rs1816752	0.719	rs11843470	ENSG00000224976.2	PARP4P2	-6.84	5.61e-11	0.000165	-0.44	-0.39	Obesity-related traits;	chr13:24423561	chr13:19349137~19407962:+
COAD	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	6.84	5.63e-11	0.000165	0.45	0.39	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
COAD	trans	rs1816752	0.905	rs7400631	ENSG00000224976.2	PARP4P2	-6.84	5.67e-11	0.000166	-0.43	-0.39	Obesity-related traits;	chr13:24415927	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs8002215	ENSG00000224976.2	PARP4P2	-6.84	5.67e-11	0.000166	-0.43	-0.39	Obesity-related traits;	chr13:24416229	chr13:19349137~19407962:+
COAD	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-6.84	5.68e-11	0.000166	-0.49	-0.39	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
COAD	trans	rs8177876	0.822	rs1410	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs1412	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs1414	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs8177950	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.731	rs8177948	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs8177940	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.73	rs76656387	ENSG00000224837.1	GCSHP5	6.84	5.73e-11	0.000168	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr1:168055901~168056422:-
COAD	trans	rs10242455	0.702	rs76840929	ENSG00000228834.1	RP11-249L21.4	6.84	5.75e-11	0.000168	0.86	0.39	Blood metabolite levels;	chr7:99348235	chr6:108907615~108907873:-
COAD	trans	rs3849046	0.68	rs13165665	ENSG00000226666.1	HSPA9P1	-6.84	5.9e-11	0.000172	-0.38	-0.39	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610811	chr2:221961737~221963765:+
COAD	trans	rs74781061	0.932	rs11857328	ENSG00000227288.3	RP5-837I24.1	6.84	5.93e-11	0.000173	0.55	0.39	Endometriosis;	chr15:74510550	chr1:81501794~81503468:+
COAD	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-6.83	5.95e-11	0.000174	-0.41	-0.39	Longevity;	chr3:48445949	chr1:27649419~27649610:+
COAD	trans	rs12709013	0.804	rs8051459	ENSG00000233719.3	GOT2P3	6.83	5.98e-11	0.000175	0.5	0.39	Blood metabolite ratios;	chr16:58783436	chr12:9641802~9643007:+
COAD	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	6.83	6e-11	0.000175	0.49	0.39	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-6.83	6.02e-11	0.000175	-0.51	-0.39	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-6.83	6.03e-11	0.000176	-0.5	-0.39	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	6.83	6.09e-11	0.000177	0.48	0.39	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	6.83	6.11e-11	0.000178	0.49	0.39	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
COAD	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-6.83	6.14e-11	0.000179	-0.5	-0.39	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
COAD	trans	rs1816752	1	rs7988810	ENSG00000224976.2	PARP4P2	-6.83	6.15e-11	0.000179	-0.46	-0.39	Obesity-related traits;	chr13:24444958	chr13:19349137~19407962:+
COAD	trans	rs1039766	0.706	rs72822420	ENSG00000224334.1	AP000357.4	-6.83	6.17e-11	0.000179	-0.78	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr22:24686923~24688087:+
COAD	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	6.83	6.23e-11	0.000181	0.46	0.39	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
COAD	trans	rs902774	0.818	rs73110432	ENSG00000240668.1	KRT8P36	-6.83	6.26e-11	0.000182	-0.68	-0.39	Prostate cancer;	chr12:52894051	chr3:138101478~138102917:-
COAD	trans	rs7824557	0.707	rs3808518	ENSG00000253981.4	ALG1L13P	-6.83	6.29e-11	0.000183	-0.49	-0.39	Retinal vascular caliber;	chr8:11285763	chr8:8236003~8244667:-
COAD	trans	rs10940346	0.562	rs7736775	ENSG00000231752.4	EMBP1	-6.82	6.33e-11	0.000184	-0.5	-0.39	Schizophrenia;	chr5:50472463	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.525	rs7728419	ENSG00000231752.4	EMBP1	-6.82	6.33e-11	0.000184	-0.5	-0.39	Schizophrenia;	chr5:50474238	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4029989	ENSG00000231752.4	EMBP1	-6.82	6.33e-11	0.000184	-0.5	-0.39	Schizophrenia;	chr5:50474501	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.584	rs10061339	ENSG00000231752.4	EMBP1	-6.82	6.33e-11	0.000184	-0.5	-0.39	Schizophrenia;	chr5:50475952	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	6.82	6.35e-11	0.000184	0.59	0.39	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
COAD	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	6.82	6.42e-11	0.000186	0.45	0.39	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
COAD	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	6.82	6.42e-11	0.000186	0.45	0.39	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
COAD	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	6.82	6.42e-11	0.000186	0.45	0.39	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
COAD	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-6.82	6.42e-11	0.000186	-0.48	-0.39	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
COAD	trans	rs9425766	0.85	rs9425755	ENSG00000213331.4	RP11-713C19.2	6.82	6.42e-11	0.000186	0.45	0.39	Life satisfaction;	chr1:173843501	chr4:187970273~187971284:+
COAD	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	6.82	6.47e-11	0.000187	0.44	0.39	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
COAD	trans	rs9876781	0.872	rs11797	ENSG00000235912.1	RP1-159A19.3	-6.82	6.53e-11	0.000189	-0.4	-0.39	Longevity;	chr3:48467186	chr1:27649419~27649610:+
COAD	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	6.82	6.56e-11	0.000189	0.49	0.39	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.905	rs9511249	ENSG00000224976.2	PARP4P2	-6.82	6.62e-11	0.000191	-0.44	-0.39	Obesity-related traits;	chr13:24425457	chr13:19349137~19407962:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000223416.3	RPS26P15	6.82	6.63e-11	0.000191	0.46	0.39	Cognitive function;	chr12:55976127	chr1:58056133~58056480:-
COAD	trans	rs10242455	0.702	rs75156180	ENSG00000228834.1	RP11-249L21.4	6.82	6.63e-11	0.000191	0.86	0.39	Blood metabolite levels;	chr7:99366477	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	6.81	6.74e-11	0.000194	0.43	0.39	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	6.81	6.74e-11	0.000194	0.43	0.39	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
COAD	trans	rs6708331	1	rs6708331	ENSG00000232654.1	FAM136BP	6.81	6.81e-11	0.000196	0.49	0.39	Obesity-related traits;	chr2:70141791	chr6:3045384~3045800:+
COAD	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-6.81	6.82e-11	0.000196	-0.41	-0.39	Longevity;	chr3:48457056	chr1:27649419~27649610:+
COAD	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-6.81	6.83e-11	0.000197	-0.5	-0.39	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.837	rs2049656	ENSG00000231752.4	EMBP1	-6.81	6.84e-11	0.000197	-0.46	-0.39	P wave duration;	chr5:45579590	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.894	rs296545	ENSG00000244144.1	RP11-757F18.3	6.81	6.86e-11	0.000198	0.55	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921564	chr3:112185480~112185998:-
COAD	trans	rs7554511	0.894	rs296546	ENSG00000244144.1	RP11-757F18.3	6.81	6.86e-11	0.000198	0.55	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921963	chr3:112185480~112185998:-
COAD	trans	rs8010715	0.848	rs8009511	ENSG00000238000.1	RP11-274E7.2	6.81	6.87e-11	0.000198	0.43	0.39	IgG glycosylation;	chr14:24124771	chr5:98213402~98214121:+
COAD	trans	rs8010715	0.804	rs1134334	ENSG00000238000.1	RP11-274E7.2	6.81	6.87e-11	0.000198	0.43	0.39	IgG glycosylation;	chr14:24124905	chr5:98213402~98214121:+
COAD	trans	rs74781061	1	rs11072488	ENSG00000227288.3	RP5-837I24.1	6.81	6.95e-11	2e-04	0.54	0.39	Endometriosis;	chr15:74494017	chr1:81501794~81503468:+
COAD	trans	rs7032940	0.626	rs4314718	ENSG00000262519.1	TXNP4	6.81	6.97e-11	2e-04	0.52	0.39	Height;	chr9:110211368	chr17:4572206~4572515:+
COAD	trans	rs10242455	1	rs7808022	ENSG00000228834.1	RP11-249L21.4	6.81	7e-11	0.000201	0.56	0.39	Blood metabolite levels;	chr7:99622460	chr6:108907615~108907873:-
COAD	trans	rs511515	1	rs511515	ENSG00000175730.8	BAK1P1	6.81	7.02e-11	0.000202	0.53	0.39	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr6:33573730	chr20:32690180~32690815:-
COAD	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	6.81	7.05e-11	0.000203	0.5	0.39	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
COAD	trans	rs1419856	0.929	rs17607123	ENSG00000224061.1	AC092106.1	6.8	7.12e-11	0.000205	0.48	0.39	QRS duration;	chr7:35283059	chr2:106253231~106253717:-
COAD	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-6.8	7.12e-11	0.000205	-0.49	-0.39	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-6.8	7.12e-11	0.000205	-0.49	-0.39	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-6.8	7.12e-11	0.000205	-0.49	-0.39	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-6.8	7.12e-11	0.000205	-0.49	-0.39	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-6.8	7.12e-11	0.000205	-0.49	-0.39	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-6.8	7.24e-11	0.000208	-0.48	-0.39	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
COAD	trans	rs61826828	1	rs61826828	ENSG00000213331.4	RP11-713C19.2	6.8	7.29e-11	0.000209	0.5	0.39	Schizophrenia;	chr1:174046123	chr4:187970273~187971284:+
COAD	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-6.8	7.29e-11	0.000209	-0.49	-0.39	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
COAD	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-6.8	7.46e-11	0.000214	-0.47	-0.39	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.59	rs982848	ENSG00000233719.3	GOT2P3	6.8	7.48e-11	0.000214	0.49	0.39	Blood metabolite ratios;	chr16:58704294	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	6.79	7.52e-11	0.000215	0.43	0.39	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	6.79	7.52e-11	0.000215	0.43	0.39	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	6.79	7.52e-11	0.000215	0.43	0.39	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-6.79	7.81e-11	0.000223	-0.48	-0.39	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-6.79	7.81e-11	0.000223	-0.48	-0.39	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-6.79	7.81e-11	0.000223	-0.48	-0.39	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
COAD	trans	rs8177876	0.822	rs8177959	ENSG00000224837.1	GCSHP5	6.79	7.95e-11	0.000227	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr1:168055901~168056422:-
COAD	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-6.79	7.95e-11	0.000227	-0.4	-0.39	Longevity;	chr3:48432839	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-6.79	7.95e-11	0.000227	-0.4	-0.39	Longevity;	chr3:48440237	chr1:27649419~27649610:+
COAD	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-6.78	8.08e-11	0.00023	-0.49	-0.39	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
COAD	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	6.78	8.4e-11	0.000239	0.61	0.39	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
COAD	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	6.78	8.4e-11	0.000239	0.61	0.39	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
COAD	trans	rs10242455	1	rs2301889	ENSG00000228834.1	RP11-249L21.4	6.78	8.42e-11	0.00024	0.66	0.39	Blood metabolite levels;	chr7:99333482	chr6:108907615~108907873:-
COAD	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	6.78	8.42e-11	0.00024	0.45	0.39	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
COAD	trans	rs11951515	0.509	rs12521249	ENSG00000174977.8	AC026271.5	6.78	8.43e-11	0.00024	0.37	0.39	Metabolite levels  (X-11787);	chr5:43558527	chr17:18650195~18651542:+
COAD	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	6.77	8.48e-11	0.000241	0.43	0.39	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
COAD	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-6.77	8.51e-11	0.000242	-0.5	-0.39	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-6.77	8.56e-11	0.000243	-0.51	-0.39	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.601	rs1511737	ENSG00000231752.4	EMBP1	-6.77	8.62e-11	0.000245	-0.49	-0.39	Schizophrenia;	chr5:50312308	chr1:121519112~121571892:+
COAD	trans	rs10037055	0.853	rs1363405	ENSG00000226986.4	RP11-543B16.2	6.77	8.72e-11	0.000248	0.41	0.39	Migraine without aura;	chr5:177209881	chr1:211207239~211207897:+
COAD	trans	rs10242455	0.867	rs13362853	ENSG00000228834.1	RP11-249L21.4	6.77	8.79e-11	0.00025	0.56	0.39	Blood metabolite levels;	chr7:99625524	chr6:108907615~108907873:-
COAD	trans	rs10242455	1	rs1859690	ENSG00000228834.1	RP11-249L21.4	6.77	8.79e-11	0.00025	0.56	0.39	Blood metabolite levels;	chr7:99629549	chr6:108907615~108907873:-
COAD	trans	rs5877	0.512	rs56753505	ENSG00000213331.4	RP11-713C19.2	6.77	8.94e-11	0.000254	0.49	0.39	Subjective well-being (multi-trait analysis);	chr1:173898114	chr4:187970273~187971284:+
COAD	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-6.76	9.08e-11	0.000258	-0.48	-0.39	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-6.76	9.08e-11	0.000258	-0.48	-0.39	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-6.76	9.08e-11	0.000258	-0.48	-0.39	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-6.76	9.08e-11	0.000258	-0.48	-0.39	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.87	rs9581029	ENSG00000224976.2	PARP4P2	-6.76	9.14e-11	0.000259	-0.43	-0.39	Obesity-related traits;	chr13:24425147	chr13:19349137~19407962:+
COAD	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-6.76	9.18e-11	0.00026	-0.44	-0.39	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
COAD	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	6.76	9.21e-11	0.000261	0.44	0.39	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-6.76	9.24e-11	0.000262	-0.49	-0.39	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-6.76	9.24e-11	0.000262	-0.49	-0.39	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	6.76	9.24e-11	0.000262	0.49	0.39	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	6.76	9.24e-11	0.000262	0.49	0.39	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	6.76	9.24e-11	0.000262	0.49	0.39	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	6.76	9.24e-11	0.000262	0.49	0.39	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	6.76	9.24e-11	0.000262	0.49	0.39	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
COAD	trans	rs7554511	0.894	rs11579874	ENSG00000244144.1	RP11-757F18.3	6.76	9.35e-11	0.000265	0.59	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200951234	chr3:112185480~112185998:-
COAD	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-6.76	9.37e-11	0.000265	-0.51	-0.39	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
COAD	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	6.76	9.4e-11	0.000266	0.43	0.39	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
COAD	trans	rs10242455	0.867	rs2687145	ENSG00000228834.1	RP11-249L21.4	6.76	9.48e-11	0.000268	0.54	0.39	Blood metabolite levels;	chr7:99721021	chr6:108907615~108907873:-
COAD	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	6.75	9.5e-11	0.000269	0.47	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
COAD	trans	rs10242455	0.717	rs776745	ENSG00000228834.1	RP11-249L21.4	6.75	9.53e-11	0.000269	0.55	0.39	Blood metabolite levels;	chr7:99693714	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs776742	ENSG00000228834.1	RP11-249L21.4	6.75	9.53e-11	0.000269	0.55	0.39	Blood metabolite levels;	chr7:99695132	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687087	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99696849	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs1879859	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99697139	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687086	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99697827	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.764	rs2740564	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99698070	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs1818797	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99698572	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.764	rs2687084	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99700509	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.681	rs1851425	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99702608	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687081	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99703135	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs10211	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99705371	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.764	rs12360	ENSG00000228834.1	RP11-249L21.4	-6.75	9.53e-11	0.000269	-0.55	-0.39	Blood metabolite levels;	chr7:99705471	chr6:108907615~108907873:-
COAD	trans	rs10037055	0.853	rs1363405	ENSG00000228305.2	AC016734.2	6.75	9.59e-11	0.000271	0.41	0.39	Migraine without aura;	chr5:177209881	chr2:63622178~63622831:-
COAD	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-6.75	9.61e-11	0.000272	-0.49	-0.39	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
COAD	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-6.75	9.73e-11	0.000275	-0.4	-0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
COAD	trans	rs7554511	0.861	rs296563	ENSG00000244144.1	RP11-757F18.3	6.75	9.79e-11	0.000276	0.56	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200975712	chr3:112185480~112185998:-
COAD	trans	rs4276421	0.869	rs2879074	ENSG00000231752.4	EMBP1	6.75	9.87e-11	0.000279	0.45	0.39	P wave duration;	chr5:45716107	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	6.75	9.91e-11	0.00028	0.45	0.39	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
COAD	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-6.75	9.92e-11	0.00028	-0.4	-0.39	Longevity;	chr3:48440024	chr1:27649419~27649610:+
COAD	trans	rs12709013	0.729	rs34324769	ENSG00000233719.3	GOT2P3	6.74	1.03e-10	0.00029	0.51	0.39	Blood metabolite ratios;	chr16:58778131	chr12:9641802~9643007:+
COAD	trans	rs10940346	0.601	rs1833900	ENSG00000231752.4	EMBP1	-6.74	1.03e-10	0.00029	-0.5	-0.39	Schizophrenia;	chr5:50504668	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs10940336	ENSG00000231752.4	EMBP1	-6.74	1.03e-10	0.000291	-0.5	-0.39	Schizophrenia;	chr5:50505020	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.766	rs1657175	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58755527	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1646290	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58755807	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1364346	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58756420	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs257626	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58759574	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs257625	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58759978	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1646262	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58760593	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs257623	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58761247	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.693	rs1627257	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58763764	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.755	rs1628029	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58763846	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs12926512	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58768317	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs12595974	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58769132	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1836877	ENSG00000233719.3	GOT2P3	6.74	1.04e-10	0.000294	0.51	0.39	Blood metabolite ratios;	chr16:58769821	chr12:9641802~9643007:+
COAD	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	6.74	1.04e-10	0.000294	0.46	0.39	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
COAD	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	6.74	1.05e-10	0.000294	0.4	0.39	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	6.74	1.05e-10	0.000294	0.4	0.39	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.805	rs13354798	ENSG00000231752.4	EMBP1	6.74	1.06e-10	0.000297	0.46	0.39	P wave duration;	chr5:45456975	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs1511738	ENSG00000231752.4	EMBP1	-6.74	1.07e-10	0.000299	-0.49	-0.39	Schizophrenia;	chr5:50313444	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-6.74	1.07e-10	0.000299	-0.49	-0.39	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-6.74	1.07e-10	0.000299	-0.49	-0.39	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-6.73	1.08e-10	0.000303	-0.51	-0.39	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.623	rs6863840	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50328070	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs6871761	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50328134	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6877713	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50329254	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4337857	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50329735	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs34601168	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50330561	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs35740733	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50330771	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.502	rs77189370	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50334920	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs10039622	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50336720	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10064702	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50336928	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs13160697	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50339822	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000313	0.49	0.39	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	6.73	1.12e-10	0.000313	0.45	0.39	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
COAD	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	6.73	1.12e-10	0.000314	0.45	0.39	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-6.72	1.13e-10	0.000317	-0.49	-0.39	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
COAD	trans	rs1816752	0.905	rs7991450	ENSG00000224976.2	PARP4P2	-6.72	1.15e-10	0.00032	-0.43	-0.39	Obesity-related traits;	chr13:24425898	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.774	rs7986162	ENSG00000224976.2	PARP4P2	-6.72	1.15e-10	0.00032	-0.43	-0.39	Obesity-related traits;	chr13:24425941	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs4769352	ENSG00000224976.2	PARP4P2	-6.72	1.15e-10	0.00032	-0.43	-0.39	Obesity-related traits;	chr13:24426237	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.805	rs4769353	ENSG00000224976.2	PARP4P2	-6.72	1.15e-10	0.00032	-0.43	-0.39	Obesity-related traits;	chr13:24426318	chr13:19349137~19407962:+
COAD	trans	rs1816752	0.905	rs7571	ENSG00000224976.2	PARP4P2	-6.72	1.15e-10	0.00032	-0.43	-0.39	Obesity-related traits;	chr13:24426479	chr13:19349137~19407962:+
COAD	trans	rs9329221	0.537	rs6983332	ENSG00000173295.6	FAM86B3P	-6.72	1.15e-10	0.000322	-0.45	-0.39	Neuroticism;	chr8:10120408	chr8:8228595~8244865:+
COAD	trans	rs10882165	0.547	rs10882179	ENSG00000273138.1	GS1-293C5.1	-6.72	1.17e-10	0.000325	-0.37	-0.39	Refractive error;	chr10:93192442	chr7:95416108~95416462:+
COAD	trans	rs3770081	1	rs12617717	ENSG00000229880.1	IMMTP1	6.72	1.17e-10	0.000327	0.77	0.39	Facial emotion recognition (sad faces);	chr2:86115180	chr21:44675868~44678086:-
COAD	trans	rs10037055	0.947	rs10063803	ENSG00000226986.4	RP11-543B16.2	6.72	1.18e-10	0.00033	0.44	0.39	Migraine without aura;	chr5:177240326	chr1:211207239~211207897:+
COAD	trans	rs7824557	0.836	rs765731	ENSG00000253981.4	ALG1L13P	-6.72	1.19e-10	0.00033	-0.5	-0.39	Retinal vascular caliber;	chr8:11263989	chr8:8236003~8244667:-
COAD	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-6.72	1.19e-10	0.000332	-0.48	-0.39	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
COAD	trans	rs1039766	0.929	rs268881	ENSG00000224334.1	AP000357.4	6.72	1.2e-10	0.000333	0.59	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr22:24686923~24688087:+
COAD	trans	rs8177876	0.642	rs10514513	ENSG00000224837.1	GCSHP5	6.71	1.21e-10	0.000337	0.65	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr1:168055901~168056422:-
COAD	trans	rs9329221	0.736	rs11249999	ENSG00000173295.6	FAM86B3P	-6.71	1.21e-10	0.000338	-0.46	-0.39	Neuroticism;	chr8:10393755	chr8:8228595~8244865:+
COAD	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-6.71	1.22e-10	0.000339	-0.4	-0.39	Longevity;	chr3:48380745	chr1:27649419~27649610:+
COAD	trans	rs1045902	0.574	rs1474298	ENSG00000236165.1	PRADC1P1	6.71	1.23e-10	0.000342	0.5	0.39	Intelligence (multi-trait analysis);	chr2:73239464	chr3:36976316~36976840:+
COAD	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	6.71	1.23e-10	0.000342	0.48	0.39	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
COAD	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-6.71	1.23e-10	0.000343	-0.41	-0.39	Longevity;	chr3:48446507	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-6.71	1.23e-10	0.000343	-0.41	-0.39	Longevity;	chr3:48452692	chr1:27649419~27649610:+
COAD	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	6.71	1.23e-10	0.000343	0.49	0.39	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	6.71	1.23e-10	0.000343	0.49	0.39	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	6.71	1.23e-10	0.000343	0.49	0.39	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	6.71	1.24e-10	0.000345	0.49	0.39	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	6.71	1.24e-10	0.000345	0.49	0.39	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
COAD	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-6.71	1.25e-10	0.000347	-0.41	-0.39	Longevity;	chr3:48378818	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-6.71	1.25e-10	0.000347	-0.41	-0.39	Longevity;	chr3:48379768	chr1:27649419~27649610:+
COAD	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	6.71	1.27e-10	0.000352	0.5	0.39	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
COAD	trans	rs1039766	1	rs268870	ENSG00000224334.1	AP000357.4	6.7	1.27e-10	0.000353	0.59	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr22:24686923~24688087:+
COAD	trans	rs74781061	0.932	rs7161903	ENSG00000227288.3	RP5-837I24.1	6.7	1.29e-10	0.000357	0.5	0.39	Endometriosis;	chr15:74647929	chr1:81501794~81503468:+
COAD	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	6.7	1.3e-10	0.000359	0.49	0.39	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	6.7	1.3e-10	0.000361	0.43	0.39	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
COAD	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	6.7	1.3e-10	0.000361	0.43	0.39	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
COAD	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	6.7	1.31e-10	0.000362	0.5	0.39	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
COAD	trans	rs12709013	0.792	rs1646270	ENSG00000233719.3	GOT2P3	6.7	1.31e-10	0.000362	0.5	0.39	Blood metabolite ratios;	chr16:58745823	chr12:9641802~9643007:+
COAD	trans	rs7824557	0.751	rs2099456	ENSG00000253981.4	ALG1L13P	6.7	1.31e-10	0.000363	0.49	0.39	Retinal vascular caliber;	chr8:11269492	chr8:8236003~8244667:-
COAD	trans	rs12709013	0.792	rs12935488	ENSG00000233719.3	GOT2P3	6.7	1.31e-10	0.000363	0.5	0.39	Blood metabolite ratios;	chr16:58766320	chr12:9641802~9643007:+
COAD	trans	rs4646450	0.891	rs883403	ENSG00000228834.1	RP11-249L21.4	6.7	1.32e-10	0.000364	0.5	0.39	Blood metabolite levels;	chr7:99450355	chr6:108907615~108907873:-
COAD	trans	rs4646450	0.891	rs2280600	ENSG00000228834.1	RP11-249L21.4	6.7	1.32e-10	0.000364	0.5	0.39	Blood metabolite levels;	chr7:99450809	chr6:108907615~108907873:-
COAD	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-6.7	1.32e-10	0.000366	-0.4	-0.39	Longevity;	chr3:48437797	chr1:27649419~27649610:+
COAD	trans	rs864643	0.524	rs17038918	ENSG00000188856.6	RPSAP47	6.7	1.33e-10	0.000368	0.52	0.39	Attention deficit hyperactivity disorder;	chr3:39480975	chr8:80558870~80559757:+
COAD	trans	rs4646450	0.891	rs3137	ENSG00000228834.1	RP11-249L21.4	6.7	1.33e-10	0.000369	0.5	0.39	Blood metabolite levels;	chr7:99533252	chr6:108907615~108907873:-
COAD	trans	rs10037055	0.685	rs10039241	ENSG00000226986.4	RP11-543B16.2	-6.7	1.34e-10	0.000371	-0.45	-0.39	Migraine without aura;	chr5:177151071	chr1:211207239~211207897:+
COAD	trans	rs902774	0.818	rs4919740	ENSG00000240668.1	KRT8P36	-6.7	1.34e-10	0.000371	-0.62	-0.39	Prostate cancer;	chr12:52877187	chr3:138101478~138102917:-
COAD	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	6.69	1.37e-10	0.000378	0.49	0.39	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
COAD	trans	rs3740713	1	rs12289603	ENSG00000235847.2	LDHAP7	6.69	1.37e-10	0.000379	0.59	0.39	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr2:84777259~84778223:-
COAD	trans	rs8177876	0.822	rs8043855	ENSG00000224837.1	GCSHP5	6.69	1.38e-10	0.00038	0.56	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089256	chr1:168055901~168056422:-
COAD	trans	rs453301	0.624	rs330049	ENSG00000173295.6	FAM86B3P	6.69	1.39e-10	0.000383	0.46	0.39	Joint mobility (Beighton score);	chr8:9229789	chr8:8228595~8244865:+
COAD	trans	rs12709013	0.792	rs1657165	ENSG00000233719.3	GOT2P3	6.69	1.4e-10	0.000386	0.5	0.39	Blood metabolite ratios;	chr16:58747980	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1646276	ENSG00000233719.3	GOT2P3	6.69	1.4e-10	0.000386	0.5	0.39	Blood metabolite ratios;	chr16:58749654	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs1646277	ENSG00000233719.3	GOT2P3	6.69	1.4e-10	0.000386	0.5	0.39	Blood metabolite ratios;	chr16:58750037	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs62066815	ENSG00000233719.3	GOT2P3	6.69	1.4e-10	0.000386	0.5	0.39	Blood metabolite ratios;	chr16:58751577	chr12:9641802~9643007:+
COAD	trans	rs10882165	0.547	rs12264655	ENSG00000273138.1	GS1-293C5.1	-6.69	1.43e-10	0.000393	-0.37	-0.38	Refractive error;	chr10:93192041	chr7:95416108~95416462:+
COAD	trans	rs10940346	0.601	rs579279	ENSG00000231752.4	EMBP1	-6.68	1.44e-10	0.000395	-0.47	-0.38	Schizophrenia;	chr5:50277308	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.867	rs1357319	ENSG00000228834.1	RP11-249L21.4	6.68	1.45e-10	0.000399	0.53	0.38	Blood metabolite levels;	chr7:99712558	chr6:108907615~108907873:-
COAD	trans	rs12709013	0.818	rs1646273	ENSG00000233719.3	GOT2P3	6.68	1.45e-10	4e-04	0.5	0.38	Blood metabolite ratios;	chr16:58748318	chr12:9641802~9643007:+
COAD	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	6.68	1.47e-10	0.000404	0.48	0.38	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
COAD	trans	rs932287	1	rs932287	ENSG00000266891.1	RP11-692N5.2	6.68	1.49e-10	0.000409	0.46	0.38	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr18:9734882~9735602:-
COAD	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	6.68	1.49e-10	0.000409	0.4	0.38	Longevity;	chr3:48377081	chr1:27649419~27649610:+
COAD	trans	rs1039766	1	rs10116	ENSG00000224334.1	AP000357.4	6.68	1.51e-10	0.000414	0.59	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr22:24686923~24688087:+
COAD	trans	rs1039766	1	rs268878	ENSG00000224334.1	AP000357.4	6.68	1.51e-10	0.000414	0.59	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr22:24686923~24688087:+
COAD	trans	rs1816752	0.837	rs9318530	ENSG00000224976.2	PARP4P2	6.67	1.52e-10	0.000415	0.44	0.38	Obesity-related traits;	chr13:24424419	chr13:19349137~19407962:+
COAD	trans	rs72615157	0.606	rs941288	ENSG00000228546.2	CTA-313A17.3	6.67	1.52e-10	0.000418	0.59	0.38	Lung function (FEV1/FVC);	chr7:100179185	chr7:102337316~102339115:+
COAD	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	6.67	1.53e-10	0.00042	0.48	0.38	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
COAD	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	6.67	1.53e-10	0.00042	0.48	0.38	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
COAD	trans	rs12709013	0.792	rs12598527	ENSG00000233719.3	GOT2P3	6.67	1.54e-10	0.000423	0.5	0.38	Blood metabolite ratios;	chr16:58772987	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs12600201	ENSG00000233719.3	GOT2P3	6.67	1.54e-10	0.000423	0.5	0.38	Blood metabolite ratios;	chr16:58773132	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs12600206	ENSG00000233719.3	GOT2P3	6.67	1.54e-10	0.000423	0.5	0.38	Blood metabolite ratios;	chr16:58773169	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs11076263	ENSG00000233719.3	GOT2P3	6.67	1.54e-10	0.000423	0.5	0.38	Blood metabolite ratios;	chr16:58773295	chr12:9641802~9643007:+
COAD	trans	rs8177876	0.822	rs56119129	ENSG00000224837.1	GCSHP5	6.67	1.55e-10	0.000425	0.64	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.731	rs77145371	ENSG00000224837.1	GCSHP5	6.67	1.55e-10	0.000425	0.64	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.908	rs80187824	ENSG00000224837.1	GCSHP5	6.67	1.55e-10	0.000425	0.64	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr1:168055901~168056422:-
COAD	trans	rs12709013	0.792	rs11646756	ENSG00000233719.3	GOT2P3	6.67	1.56e-10	0.000427	0.5	0.38	Blood metabolite ratios;	chr16:58773598	chr12:9641802~9643007:+
COAD	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	6.67	1.57e-10	0.00043	0.57	0.38	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
COAD	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	6.67	1.58e-10	0.000431	0.44	0.38	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
COAD	trans	rs9876781	0.652	rs734071	ENSG00000235912.1	RP1-159A19.3	-6.67	1.58e-10	0.000431	-0.4	-0.38	Longevity;	chr3:48478412	chr1:27649419~27649610:+
COAD	trans	rs10242455	0.867	rs2687077	ENSG00000228834.1	RP11-249L21.4	-6.67	1.58e-10	0.000431	-0.53	-0.38	Blood metabolite levels;	chr7:99708943	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2257401	ENSG00000228834.1	RP11-249L21.4	-6.67	1.58e-10	0.000431	-0.53	-0.38	Blood metabolite levels;	chr7:99709062	chr6:108907615~108907873:-
COAD	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	6.67	1.59e-10	0.000433	0.48	0.38	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
COAD	trans	rs3806843	0.676	rs778591	ENSG00000231043.3	AC007238.1	6.67	1.59e-10	0.000434	0.38	0.38	Depressive symptoms (multi-trait analysis);	chr5:140645899	chr2:58460292~58462032:-
COAD	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	6.67	1.59e-10	0.000434	0.44	0.38	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.867	rs2687139	ENSG00000228834.1	RP11-249L21.4	-6.67	1.59e-10	0.000435	-0.53	-0.38	Blood metabolite levels;	chr7:99725451	chr6:108907615~108907873:-
COAD	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	6.67	1.59e-10	0.000435	0.48	0.38	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
COAD	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-6.67	1.6e-10	0.000438	-0.44	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.853	rs10056008	ENSG00000228305.2	AC016734.2	-6.66	1.63e-10	0.000444	-0.41	-0.38	Migraine without aura;	chr5:177194147	chr2:63622178~63622831:-
COAD	trans	rs10037055	0.853	rs10476219	ENSG00000228305.2	AC016734.2	-6.66	1.63e-10	0.000444	-0.41	-0.38	Migraine without aura;	chr5:177201547	chr2:63622178~63622831:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	6.66	1.64e-10	0.000447	0.41	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
COAD	trans	rs11951515	0.508	rs11958046	ENSG00000174977.8	AC026271.5	-6.66	1.64e-10	0.000447	-0.36	-0.38	Metabolite levels  (X-11787);	chr5:43583287	chr17:18650195~18651542:+
COAD	trans	rs877636	0.74	rs705698	ENSG00000223416.3	RPS26P15	6.66	1.65e-10	0.00045	0.46	0.38	Cognitive function;	chr12:55990903	chr1:58056133~58056480:-
COAD	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-6.66	1.67e-10	0.000455	-0.44	-0.38	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-6.66	1.68e-10	0.000457	-0.5	-0.38	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
COAD	trans	rs10917477	0.624	rs1320978	ENSG00000224237.1	MINOS1P3	6.66	1.68e-10	0.000458	0.43	0.38	Thyroid function;	chr1:19621479	chr3:27214816~27215018:-
COAD	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	6.65	1.72e-10	0.000467	0.44	0.38	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
COAD	trans	rs12709013	0.792	rs1615326	ENSG00000233719.3	GOT2P3	6.65	1.73e-10	0.000471	0.5	0.38	Blood metabolite ratios;	chr16:58747148	chr12:9641802~9643007:+
COAD	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	6.65	1.74e-10	0.000473	0.49	0.38	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
COAD	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	6.65	1.76e-10	0.000479	0.49	0.38	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
COAD	trans	rs10242455	0.867	rs2687076	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99709645	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2037498	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99713927	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2037499	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99715030	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687075	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99717363	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.764	rs2037497	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99718281	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.614	rs2687072	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99719303	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687144	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99721185	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2740562	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99721534	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687143	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99722846	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687142	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99722947	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.764	rs2740561	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99723818	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687141	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99723856	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2404770	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99723989	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2404769	ENSG00000228834.1	RP11-249L21.4	-6.65	1.79e-10	0.000485	-0.53	-0.38	Blood metabolite levels;	chr7:99724093	chr6:108907615~108907873:-
COAD	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-6.65	1.79e-10	0.000486	-0.4	-0.38	Longevity;	chr3:48455358	chr1:27649419~27649610:+
COAD	trans	rs74781061	0.932	rs11854461	ENSG00000227288.3	RP5-837I24.1	6.65	1.8e-10	0.000487	0.53	0.38	Endometriosis;	chr15:74447400	chr1:81501794~81503468:+
COAD	trans	rs12709013	0.792	rs1646289	ENSG00000233719.3	GOT2P3	6.65	1.8e-10	0.000488	0.5	0.38	Blood metabolite ratios;	chr16:58755689	chr12:9641802~9643007:+
COAD	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	6.64	1.81e-10	0.00049	0.44	0.38	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
COAD	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	6.64	1.83e-10	0.000496	0.85	0.38	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
COAD	trans	rs6732160	0.588	rs10192654	ENSG00000236165.1	PRADC1P1	-6.64	1.84e-10	0.000498	-0.5	-0.38	Intelligence (multi-trait analysis);	chr2:73143754	chr3:36976316~36976840:+
COAD	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-6.64	1.86e-10	0.000502	-0.49	-0.38	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-6.64	1.86e-10	0.000502	-0.49	-0.38	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-6.64	1.86e-10	0.000502	-0.49	-0.38	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
COAD	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-6.63	1.91e-10	0.000517	-0.47	-0.38	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
COAD	trans	rs864643	0.524	rs80322842	ENSG00000188856.6	RPSAP47	6.63	1.92e-10	0.000519	0.52	0.38	Attention deficit hyperactivity disorder;	chr3:39483682	chr8:80558870~80559757:+
COAD	trans	rs8177876	0.642	rs56032321	ENSG00000224837.1	GCSHP5	6.63	1.92e-10	0.000519	0.64	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr1:168055901~168056422:-
COAD	trans	rs6708331	1	rs7597199	ENSG00000232654.1	FAM136BP	6.63	1.97e-10	0.000533	0.5	0.38	Obesity-related traits;	chr2:70114443	chr6:3045384~3045800:+
COAD	trans	rs9899728	0.656	rs9904728	ENSG00000234925.2	ATP5HP4	6.63	1.98e-10	0.000536	0.53	0.38	Alzheimer's disease or small vessel stroke;	chr17:75034540	chr12:68642519~68642993:-
COAD	trans	rs7824557	0.836	rs1435278	ENSG00000253981.4	ALG1L13P	-6.63	2.01e-10	0.000543	-0.5	-0.38	Retinal vascular caliber;	chr8:11265520	chr8:8236003~8244667:-
COAD	trans	rs10242455	0.717	rs2687134	ENSG00000228834.1	RP11-249L21.4	-6.62	2.03e-10	0.000547	-0.55	-0.38	Blood metabolite levels;	chr7:99733419	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.717	rs2687133	ENSG00000228834.1	RP11-249L21.4	-6.62	2.03e-10	0.000547	-0.55	-0.38	Blood metabolite levels;	chr7:99734460	chr6:108907615~108907873:-
COAD	trans	rs7824557	0.767	rs3808513	ENSG00000253981.4	ALG1L13P	-6.62	2.05e-10	0.000552	-0.49	-0.38	Retinal vascular caliber;	chr8:11299951	chr8:8236003~8244667:-
COAD	trans	rs10940346	0.601	rs6450063	ENSG00000231752.4	EMBP1	6.62	2.06e-10	0.000555	0.47	0.38	Schizophrenia;	chr5:50374147	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.702	rs76702117	ENSG00000228834.1	RP11-249L21.4	6.62	2.07e-10	0.000556	0.88	0.38	Blood metabolite levels;	chr7:99319156	chr6:108907615~108907873:-
COAD	trans	rs4646450	0.891	rs7804551	ENSG00000228834.1	RP11-249L21.4	6.62	2.08e-10	0.00056	0.49	0.38	Blood metabolite levels;	chr7:99521487	chr6:108907615~108907873:-
COAD	trans	rs7554511	0.861	rs10753888	ENSG00000244144.1	RP11-757F18.3	-6.62	2.08e-10	0.000561	-0.54	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201037057	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.954	rs6849561	ENSG00000276997.3	RP11-378J18.9	-6.62	2.09e-10	0.000561	-0.46	-0.38	Corneal astigmatism;	chr4:119488539	chr1:222477252~222504622:-
COAD	trans	rs8010715	0.848	rs2277483	ENSG00000238000.1	RP11-274E7.2	6.62	2.09e-10	0.000563	0.42	0.38	IgG glycosylation;	chr14:24122683	chr5:98213402~98214121:+
COAD	trans	rs61041336	0.528	rs73549255	ENSG00000230849.2	GOT2P2	-6.62	2.11e-10	0.000567	-0.78	-0.38	Neuritic plaque;	chr16:58701769	chr1:173141100~173142350:-
COAD	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-6.62	2.11e-10	0.000567	-0.49	-0.38	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-6.62	2.11e-10	0.000567	-0.49	-0.38	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
COAD	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	6.62	2.13e-10	0.000572	0.4	0.38	Longevity;	chr3:48378407	chr1:27649419~27649610:+
COAD	trans	rs7554511	0.894	rs2297909	ENSG00000244144.1	RP11-757F18.3	-6.61	2.18e-10	0.000584	-0.55	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200991179	chr3:112185480~112185998:-
COAD	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-6.61	2.18e-10	0.000586	-0.49	-0.38	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
COAD	trans	rs1039766	0.929	rs55843720	ENSG00000224334.1	AP000357.4	6.61	2.19e-10	0.000586	0.58	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr22:24686923~24688087:+
COAD	trans	rs8177876	0.822	rs10514514	ENSG00000224837.1	GCSHP5	6.61	2.19e-10	0.000587	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr1:168055901~168056422:-
COAD	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-6.61	2.19e-10	0.000587	-0.48	-0.38	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
COAD	trans	rs7121616	0.595	rs7949414	ENSG00000229091.2	HSPA8P8	6.61	2.19e-10	0.000588	0.39	0.38	Breast cancer;	chr11:123072787	chr7:10451311~10452526:+
COAD	trans	rs7824557	0.836	rs1435278	ENSG00000173295.6	FAM86B3P	-6.61	2.21e-10	0.000591	-0.49	-0.38	Retinal vascular caliber;	chr8:11265520	chr8:8228595~8244865:+
COAD	trans	rs9425766	0.888	rs1799876	ENSG00000213331.4	RP11-713C19.2	6.61	2.21e-10	0.000592	0.45	0.38	Life satisfaction;	chr1:173909333	chr4:187970273~187971284:+
COAD	trans	rs1039766	1	rs268861	ENSG00000224334.1	AP000357.4	6.61	2.21e-10	0.000592	0.58	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr22:24686923~24688087:+
COAD	trans	rs1039766	0.925	rs268863	ENSG00000224334.1	AP000357.4	6.61	2.21e-10	0.000592	0.58	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr22:24686923~24688087:+
COAD	trans	rs6708331	0.646	rs12989348	ENSG00000232654.1	FAM136BP	-6.61	2.22e-10	0.000595	-0.79	-0.38	Obesity-related traits;	chr2:70150521	chr6:3045384~3045800:+
COAD	trans	rs10242455	0.867	rs2222411	ENSG00000228834.1	RP11-249L21.4	-6.61	2.26e-10	0.000605	-0.53	-0.38	Blood metabolite levels;	chr7:99712708	chr6:108907615~108907873:-
COAD	trans	rs864643	0.524	rs72869124	ENSG00000188856.6	RPSAP47	6.61	2.27e-10	0.000607	0.51	0.38	Attention deficit hyperactivity disorder;	chr3:39469788	chr8:80558870~80559757:+
COAD	trans	rs864643	0.524	rs6810264	ENSG00000188856.6	RPSAP47	6.61	2.27e-10	0.000607	0.51	0.38	Attention deficit hyperactivity disorder;	chr3:39471605	chr8:80558870~80559757:+
COAD	trans	rs864643	0.524	rs11706953	ENSG00000188856.6	RPSAP47	6.61	2.27e-10	0.000607	0.51	0.38	Attention deficit hyperactivity disorder;	chr3:39472119	chr8:80558870~80559757:+
COAD	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-6.6	2.29e-10	0.000612	-0.49	-0.38	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
COAD	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-6.6	2.3e-10	0.000613	-0.4	-0.38	Longevity;	chr3:48422209	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-6.6	2.3e-10	0.000613	-0.4	-0.38	Longevity;	chr3:48423094	chr1:27649419~27649610:+
COAD	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-6.6	2.3e-10	0.000613	-0.4	-0.38	Longevity;	chr3:48426493	chr1:27649419~27649610:+
COAD	trans	rs12709013	0.686	rs151817	ENSG00000233719.3	GOT2P3	-6.6	2.3e-10	0.000614	-0.49	-0.38	Blood metabolite ratios;	chr16:58704014	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.686	rs244919	ENSG00000233719.3	GOT2P3	-6.6	2.3e-10	0.000614	-0.49	-0.38	Blood metabolite ratios;	chr16:58704146	chr12:9641802~9643007:+
COAD	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	6.6	2.3e-10	0.000614	0.84	0.38	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
COAD	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	6.6	2.33e-10	0.000622	0.44	0.38	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	6.6	2.33e-10	0.000622	0.44	0.38	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	6.6	2.33e-10	0.000622	0.44	0.38	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	6.6	2.34e-10	0.000625	0.43	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
COAD	trans	rs10242455	0.867	rs1403196	ENSG00000228834.1	RP11-249L21.4	-6.6	2.37e-10	0.000633	-0.54	-0.38	Blood metabolite levels;	chr7:99708698	chr6:108907615~108907873:-
COAD	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-6.6	2.37e-10	0.000633	-0.53	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
COAD	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	6.6	2.38e-10	0.000634	0.4	0.38	Longevity;	chr3:48378199	chr1:27649419~27649610:+
COAD	trans	rs1816752	0.905	rs2000153	ENSG00000224976.2	PARP4P2	-6.6	2.38e-10	0.000635	-0.43	-0.38	Obesity-related traits;	chr13:24405752	chr13:19349137~19407962:+
COAD	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-6.59	2.43e-10	0.000646	-0.48	-0.38	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
COAD	trans	rs10037055	0.687	rs6556308	ENSG00000226986.4	RP11-543B16.2	-6.59	2.45e-10	0.000651	-0.4	-0.38	Migraine without aura;	chr5:177219700	chr1:211207239~211207897:+
COAD	trans	rs10940346	0.56	rs6892613	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50353678	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.56	rs2137134	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50354188	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6450056	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50356692	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4637546	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50358359	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10073591	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50359010	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.521	rs7730857	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50361516	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs10071725	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50361986	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7732000	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50364779	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs57137858	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50369737	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10042504	ENSG00000231752.4	EMBP1	6.59	2.45e-10	0.000652	0.47	0.38	Schizophrenia;	chr5:50386329	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-6.59	2.47e-10	0.000655	-0.48	-0.38	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-6.59	2.47e-10	0.000656	-0.49	-0.38	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-6.59	2.47e-10	0.000656	-0.49	-0.38	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
COAD	trans	rs210142	1	rs210142	ENSG00000175730.8	BAK1P1	6.59	2.47e-10	0.000657	0.53	0.38	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;	chr6:33579060	chr20:32690180~32690815:-
COAD	trans	rs210143	1	rs210143	ENSG00000175730.8	BAK1P1	6.59	2.47e-10	0.000657	0.53	0.38	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;Neutrophil percentage of granulocytes;	chr6:33579153	chr20:32690180~32690815:-
COAD	trans	rs2899832	0.568	rs2277460	ENSG00000229083.1	PSMA6P2	6.59	2.49e-10	0.000661	0.59	0.38	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292367	chrX:12825840~12826833:+
COAD	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-6.59	2.51e-10	0.000667	-0.42	-0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
COAD	trans	rs6732160	0.588	rs1430345	ENSG00000236165.1	PRADC1P1	6.59	2.52e-10	0.000669	0.49	0.38	Intelligence (multi-trait analysis);	chr2:73143554	chr3:36976316~36976840:+
COAD	trans	rs7113874	0.613	rs4326784	ENSG00000266891.1	RP11-692N5.2	6.59	2.53e-10	0.000669	0.51	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8511602	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	6.59	2.54e-10	0.000672	0.44	0.38	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.562	rs34950042	ENSG00000231752.4	EMBP1	-6.59	2.54e-10	0.000673	-0.49	-0.38	Schizophrenia;	chr5:50479299	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs3845167	ENSG00000231752.4	EMBP1	-6.59	2.54e-10	0.000673	-0.49	-0.38	Schizophrenia;	chr5:50480297	chr1:121519112~121571892:+
COAD	trans	rs13218732	0.826	rs34135010	ENSG00000180015.12	RP11-756P10.3	-6.59	2.54e-10	0.000673	-0.94	-0.38	Migraine;	chr6:152948080	chr4:188738373~188739494:+
COAD	trans	rs13218732	0.826	rs67552665	ENSG00000180015.12	RP11-756P10.3	-6.59	2.54e-10	0.000673	-0.94	-0.38	Migraine;	chr6:152948183	chr4:188738373~188739494:+
COAD	trans	rs12709013	1	rs11641836	ENSG00000233719.3	GOT2P3	6.58	2.57e-10	0.00068	0.47	0.38	Blood metabolite ratios;	chr16:58798143	chr12:9641802~9643007:+
COAD	trans	rs10037055	0.853	rs10056008	ENSG00000226986.4	RP11-543B16.2	-6.58	2.58e-10	0.000682	-0.4	-0.38	Migraine without aura;	chr5:177194147	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.853	rs10476219	ENSG00000226986.4	RP11-543B16.2	-6.58	2.58e-10	0.000682	-0.4	-0.38	Migraine without aura;	chr5:177201547	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.853	rs6890580	ENSG00000226986.4	RP11-543B16.2	-6.58	2.59e-10	0.000685	-0.4	-0.38	Migraine without aura;	chr5:177226519	chr1:211207239~211207897:+
COAD	trans	rs10242455	0.867	rs2687079	ENSG00000228834.1	RP11-249L21.4	6.58	2.64e-10	0.000699	0.54	0.38	Blood metabolite levels;	chr7:99706995	chr6:108907615~108907873:-
COAD	trans	rs12709013	0.935	rs8046667	ENSG00000233719.3	GOT2P3	6.58	2.65e-10	7e-04	0.48	0.38	Blood metabolite ratios;	chr16:58790935	chr12:9641802~9643007:+
COAD	trans	rs12709013	1	rs8046998	ENSG00000233719.3	GOT2P3	6.58	2.65e-10	7e-04	0.48	0.38	Blood metabolite ratios;	chr16:58791109	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	6.58	2.65e-10	0.000701	0.43	0.38	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
COAD	trans	rs3740713	1	rs73440636	ENSG00000235847.2	LDHAP7	6.58	2.67e-10	0.000705	0.59	0.38	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr2:84777259~84778223:-
COAD	trans	rs1039766	1	rs268862	ENSG00000224334.1	AP000357.4	6.58	2.68e-10	0.000709	0.58	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr22:24686923~24688087:+
COAD	trans	rs7554511	0.894	rs11589638	ENSG00000244144.1	RP11-757F18.3	-6.57	2.72e-10	0.000718	-0.56	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200925807	chr3:112185480~112185998:-
COAD	trans	rs10940346	0.562	rs559096	ENSG00000231752.4	EMBP1	-6.57	2.74e-10	0.000723	-0.47	-0.38	Schizophrenia;	chr5:50226512	chr1:121519112~121571892:+
COAD	trans	rs7824557	0.751	rs2099456	ENSG00000173295.6	FAM86B3P	6.57	2.74e-10	0.000723	0.47	0.38	Retinal vascular caliber;	chr8:11269492	chr8:8228595~8244865:+
COAD	trans	rs8177876	0.822	rs8056972	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs74437879	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs76948085	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs80315956	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.642	rs16954572	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9929586	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9938965	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs7204040	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.731	rs7188508	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs28672349	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs4306521	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs4324142	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.642	rs4324143	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.818	rs59177227	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs59685942	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs10514515	ENSG00000224837.1	GCSHP5	6.57	2.74e-10	0.000723	0.63	0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr1:168055901~168056422:-
COAD	trans	rs62344088	0.59	rs60845955	ENSG00000185986.11	SDHAP3	6.57	2.76e-10	0.000728	0.74	0.38	Asthma (childhood onset);	chr5:184979	chr5:1572222~1594620:-
COAD	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	6.57	2.8e-10	0.000738	0.4	0.38	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
COAD	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	6.56	2.86e-10	0.000753	0.48	0.38	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
COAD	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-6.56	2.88e-10	0.000758	-0.5	-0.38	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
COAD	trans	rs7824557	0.767	rs6985460	ENSG00000253981.4	ALG1L13P	6.56	2.89e-10	0.000759	0.51	0.38	Retinal vascular caliber;	chr8:11313578	chr8:8236003~8244667:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-6.56	2.89e-10	0.000759	-0.42	-0.38	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-6.56	2.89e-10	0.000759	-0.42	-0.38	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
COAD	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-6.56	2.9e-10	0.000761	-0.57	-0.38	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-6.56	2.9e-10	0.000761	-0.57	-0.38	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	6.56	2.9e-10	0.000761	0.57	0.38	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	6.56	2.9e-10	0.000763	0.42	0.38	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
COAD	trans	rs12709013	1	rs12599931	ENSG00000233719.3	GOT2P3	6.56	2.92e-10	0.000766	0.47	0.38	Blood metabolite ratios;	chr16:58792627	chr12:9641802~9643007:+
COAD	trans	rs3812762	0.618	rs11042072	ENSG00000266891.1	RP11-692N5.2	6.56	2.94e-10	0.000772	0.49	0.38	Hypospadias;	chr11:8800485	chr18:9734882~9735602:-
COAD	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-6.56	3.02e-10	0.000793	-0.44	-0.38	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
COAD	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-6.55	3.06e-10	0.000803	-0.49	-0.38	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
COAD	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	6.55	3.08e-10	0.000806	0.48	0.38	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
COAD	trans	rs7824557	0.767	rs7837036	ENSG00000253981.4	ALG1L13P	6.55	3.17e-10	0.00083	0.49	0.38	Retinal vascular caliber;	chr8:11317980	chr8:8236003~8244667:-
COAD	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-6.55	3.17e-10	0.00083	-0.5	-0.38	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-6.55	3.17e-10	0.00083	-0.5	-0.38	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
COAD	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-6.55	3.18e-10	0.00083	-0.56	-0.38	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-6.55	3.18e-10	0.00083	-0.56	-0.38	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-6.55	3.18e-10	0.00083	-0.56	-0.38	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
COAD	trans	rs1039766	1	rs268864	ENSG00000224334.1	AP000357.4	-6.55	3.2e-10	0.000837	-0.57	-0.38	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr22:24686923~24688087:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	6.55	3.21e-10	0.000838	0.42	0.38	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
COAD	trans	rs10242455	0.764	rs4646465	ENSG00000228834.1	RP11-249L21.4	-6.54	3.23e-10	0.000845	-0.54	-0.38	Blood metabolite levels;	chr7:99706901	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687078	ENSG00000228834.1	RP11-249L21.4	-6.54	3.23e-10	0.000845	-0.54	-0.38	Blood metabolite levels;	chr7:99707089	chr6:108907615~108907873:-
COAD	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-6.54	3.25e-10	0.000847	-0.47	-0.38	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs2199089	ENSG00000231752.4	EMBP1	-6.54	3.25e-10	0.000847	-0.47	-0.38	Schizophrenia;	chr5:50199332	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.576	rs1986972	ENSG00000253981.4	ALG1L13P	6.54	3.3e-10	0.000859	0.44	0.38	Neuroticism;	chr8:10411295	chr8:8236003~8244667:-
COAD	trans	rs3806843	0.676	rs1583005	ENSG00000231043.3	AC007238.1	6.54	3.33e-10	0.000864	0.38	0.38	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.676	rs2569159	ENSG00000231043.3	AC007238.1	6.54	3.35e-10	0.000871	0.38	0.38	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr2:58460292~58462032:-
COAD	trans	rs7819412	0.525	rs10086521	ENSG00000253893.2	FAM85B	6.54	3.36e-10	0.000873	0.48	0.38	Triglycerides;	chr8:10926259	chr8:8167819~8226614:-
COAD	trans	rs12709013	1	rs12709013	ENSG00000233719.3	GOT2P3	-6.53	3.41e-10	0.000886	-0.47	-0.38	Blood metabolite ratios;	chr16:58795886	chr12:9641802~9643007:+
COAD	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	6.53	3.51e-10	0.000909	0.39	0.38	Longevity;	chr3:48372047	chr1:27649419~27649610:+
COAD	trans	rs61041336	0.534	rs2280398	ENSG00000230849.2	GOT2P2	-6.53	3.56e-10	0.000921	-0.76	-0.38	Neuritic plaque;	chr16:58678226	chr1:173141100~173142350:-
COAD	trans	rs7824557	0.872	rs1347410	ENSG00000173295.6	FAM86B3P	-6.53	3.58e-10	0.000928	-0.46	-0.38	Retinal vascular caliber;	chr8:11253733	chr8:8228595~8244865:+
COAD	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-6.52	3.64e-10	0.000941	-0.47	-0.38	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-6.52	3.64e-10	0.000941	-0.47	-0.38	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.541	rs4865914	ENSG00000231752.4	EMBP1	-6.52	3.64e-10	0.000941	-0.47	-0.38	Schizophrenia;	chr5:50173322	chr1:121519112~121571892:+
COAD	trans	rs74781061	0.858	rs8023865	ENSG00000227288.3	RP5-837I24.1	6.52	3.65e-10	0.000943	0.53	0.38	Endometriosis;	chr15:74561263	chr1:81501794~81503468:+
COAD	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	6.52	3.65e-10	0.000944	0.5	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
COAD	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	6.52	3.69e-10	0.000954	0.39	0.38	Longevity;	chr3:48371689	chr1:27649419~27649610:+
COAD	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	6.52	3.71e-10	0.000958	0.46	0.38	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
COAD	trans	rs10882165	0.547	rs2104631	ENSG00000273138.1	GS1-293C5.1	-6.52	3.72e-10	0.00096	-0.36	-0.38	Refractive error;	chr10:93196070	chr7:95416108~95416462:+
COAD	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-6.52	3.73e-10	0.000962	-0.47	-0.38	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
COAD	trans	rs3770081	1	rs2303340	ENSG00000229880.1	IMMTP1	6.52	3.76e-10	0.000971	0.73	0.38	Facial emotion recognition (sad faces);	chr2:86106070	chr21:44675868~44678086:-
COAD	trans	rs11098499	0.908	rs1002152	ENSG00000276997.3	RP11-378J18.9	6.51	3.81e-10	0.000984	0.45	0.38	Corneal astigmatism;	chr4:119352232	chr1:222477252~222504622:-
COAD	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-6.51	3.85e-10	0.000993	-0.47	-0.38	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
COAD	trans	rs74781061	0.929	rs8025976	ENSG00000227288.3	RP5-837I24.1	6.51	3.88e-10	0.000999	0.56	0.38	Endometriosis;	chr15:74577697	chr1:81501794~81503468:+
COAD	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	6.51	3.92e-10	0.00101	0.53	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
COAD	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	6.51	3.92e-10	0.00101	0.53	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
COAD	trans	rs2209875	0.549	rs3211707	ENSG00000234819.1	RP11-336N8.4	6.51	3.94e-10	0.00102	0.49	0.38	Pelvic organ prolapse (moderate/severe);	chr9:89318219	chr9:78219120~78219357:+
COAD	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-6.51	3.96e-10	0.00102	-0.47	-0.38	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
COAD	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	6.51	4e-10	0.00103	0.39	0.38	Longevity;	chr3:48407507	chr1:27649419~27649610:+
COAD	trans	rs5022636	0.507	rs2031797	ENSG00000180764.13	PIPSL	6.51	4.01e-10	0.00103	0.5	0.38	Gut microbiota (functional units);	chr1:151306029	chr10:93958191~93961540:-
COAD	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	6.51	4.02e-10	0.00103	0.39	0.38	Longevity;	chr3:48376736	chr1:27649419~27649610:+
COAD	trans	rs4883201	0.656	rs1805248	ENSG00000179899.8	PHC1P1	6.5	4.04e-10	0.00104	0.49	0.38	Total cholesterol levels;Cholesterol, total;	chr12:8948541	chr12:55411727~55414787:-
COAD	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	6.5	4.09e-10	0.00105	0.44	0.38	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
COAD	trans	rs7824557	0.737	rs2293855	ENSG00000253981.4	ALG1L13P	6.5	4.11e-10	0.00106	0.49	0.38	Retinal vascular caliber;	chr8:11319901	chr8:8236003~8244667:-
COAD	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-6.5	4.16e-10	0.00107	-0.39	-0.38	Longevity;	chr3:48398713	chr1:27649419~27649610:+
COAD	trans	rs3806843	0.648	rs702399	ENSG00000231043.3	AC007238.1	6.5	4.18e-10	0.00107	0.37	0.38	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr2:58460292~58462032:-
COAD	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	6.5	4.23e-10	0.00108	0.51	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.613	rs2100067	ENSG00000266891.1	RP11-692N5.2	6.5	4.23e-10	0.00108	0.51	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515503	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.578	rs7924477	ENSG00000266891.1	RP11-692N5.2	6.5	4.23e-10	0.00108	0.51	0.38	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516700	chr18:9734882~9735602:-
COAD	trans	rs6424115	0.8	rs2229583	ENSG00000228217.1	AL390877.1	-6.5	4.23e-10	0.00109	-0.46	-0.38	Immature fraction of reticulocytes;	chr1:23874493	chr1:117778087~117778506:-
COAD	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-6.5	4.25e-10	0.00109	-0.39	-0.38	Longevity;	chr3:48429347	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-6.5	4.25e-10	0.00109	-0.39	-0.38	Longevity;	chr3:48431794	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-6.5	4.25e-10	0.00109	-0.39	-0.38	Longevity;	chr3:48437629	chr1:27649419~27649610:+
COAD	trans	rs10037055	0.853	rs9313749	ENSG00000226986.4	RP11-543B16.2	-6.5	4.26e-10	0.00109	-0.39	-0.38	Migraine without aura;	chr5:177170693	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.853	rs9313749	ENSG00000228305.2	AC016734.2	-6.49	4.28e-10	0.0011	-0.4	-0.38	Migraine without aura;	chr5:177170693	chr2:63622178~63622831:-
COAD	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-6.49	4.29e-10	0.0011	-0.56	-0.38	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-6.49	4.29e-10	0.0011	-0.56	-0.38	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
COAD	trans	rs10242455	1	rs10229552	ENSG00000228834.1	RP11-249L21.4	6.49	4.3e-10	0.0011	0.55	0.38	Blood metabolite levels;	chr7:99637276	chr6:108907615~108907873:-
COAD	trans	rs6424115	0.83	rs3123554	ENSG00000228217.1	AL390877.1	6.49	4.3e-10	0.0011	0.46	0.38	Immature fraction of reticulocytes;	chr1:23869911	chr1:117778087~117778506:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-6.49	4.32e-10	0.00111	-0.41	-0.38	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-6.49	4.32e-10	0.00111	-0.41	-0.38	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
COAD	trans	rs9329221	0.537	rs13254175	ENSG00000173295.6	FAM86B3P	6.49	4.39e-10	0.00112	0.43	0.38	Neuroticism;	chr8:10121262	chr8:8228595~8244865:+
COAD	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-6.49	4.46e-10	0.00114	-0.47	-0.38	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-6.49	4.46e-10	0.00114	-0.47	-0.38	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.736	rs11249999	ENSG00000253981.4	ALG1L13P	-6.49	4.46e-10	0.00114	-0.46	-0.38	Neuroticism;	chr8:10393755	chr8:8236003~8244667:-
COAD	trans	rs9329221	0.662	rs11249996	ENSG00000173295.6	FAM86B3P	-6.49	4.47e-10	0.00114	-0.43	-0.38	Neuroticism;	chr8:10387953	chr8:8228595~8244865:+
COAD	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	6.49	4.48e-10	0.00114	0.46	0.38	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
COAD	trans	rs10940346	0.607	rs8188210	ENSG00000231752.4	EMBP1	-6.49	4.49e-10	0.00115	-0.47	-0.38	Schizophrenia;	chr5:50211664	chr1:121519112~121571892:+
COAD	trans	rs61041336	0.534	rs2280399	ENSG00000230849.2	GOT2P2	-6.48	4.54e-10	0.00116	-0.76	-0.37	Neuritic plaque;	chr16:58677628	chr1:173141100~173142350:-
COAD	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-6.48	4.56e-10	0.00116	-0.43	-0.37	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
COAD	trans	rs10037055	0.853	rs2336237	ENSG00000226986.4	RP11-543B16.2	6.48	4.56e-10	0.00116	0.4	0.37	Migraine without aura;	chr5:177238878	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.741	rs2336405	ENSG00000226986.4	RP11-543B16.2	-6.48	4.56e-10	0.00116	-0.4	-0.37	Migraine without aura;	chr5:177230288	chr1:211207239~211207897:+
COAD	trans	rs7824557	0.836	rs765731	ENSG00000173295.6	FAM86B3P	-6.48	4.6e-10	0.00117	-0.48	-0.37	Retinal vascular caliber;	chr8:11263989	chr8:8228595~8244865:+
COAD	trans	rs7824557	0.767	rs6991606	ENSG00000253981.4	ALG1L13P	6.48	4.61e-10	0.00117	0.48	0.37	Retinal vascular caliber;	chr8:11318650	chr8:8236003~8244667:-
COAD	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-6.48	4.69e-10	0.00119	-0.44	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.853	rs4976681	ENSG00000226986.4	RP11-543B16.2	6.48	4.72e-10	0.0012	0.39	0.37	Migraine without aura;	chr5:177277662	chr1:211207239~211207897:+
COAD	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-6.48	4.74e-10	0.00121	-0.44	-0.37	Asthma;	chr12:55970537	chrX:24429573~24429920:-
COAD	trans	rs10037055	0.853	rs1546363	ENSG00000226986.4	RP11-543B16.2	-6.48	4.75e-10	0.00121	-0.39	-0.37	Migraine without aura;	chr5:177174030	chr1:211207239~211207897:+
COAD	trans	rs10940346	0.52	rs7293339	ENSG00000231752.4	EMBP1	-6.48	4.77e-10	0.00121	-0.46	-0.37	Schizophrenia;	chr5:50207465	chr1:121519112~121571892:+
COAD	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	6.47	4.79e-10	0.00122	0.45	0.37	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
COAD	trans	rs3740713	1	rs73440634	ENSG00000235847.2	LDHAP7	6.47	4.81e-10	0.00123	0.59	0.37	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr2:84777259~84778223:-
COAD	trans	rs7824557	0.767	rs6985146	ENSG00000253981.4	ALG1L13P	6.47	4.84e-10	0.00123	0.52	0.37	Retinal vascular caliber;	chr8:11313212	chr8:8236003~8244667:-
COAD	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	6.47	4.85e-10	0.00123	0.39	0.37	Longevity;	chr3:48376729	chr1:27649419~27649610:+
COAD	trans	rs12709013	0.792	rs11644344	ENSG00000233719.3	GOT2P3	6.47	4.87e-10	0.00124	0.48	0.37	Blood metabolite ratios;	chr16:58803080	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs11649387	ENSG00000233719.3	GOT2P3	6.47	4.87e-10	0.00124	0.48	0.37	Blood metabolite ratios;	chr16:58803176	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs11649133	ENSG00000233719.3	GOT2P3	6.47	4.87e-10	0.00124	0.48	0.37	Blood metabolite ratios;	chr16:58803275	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.766	rs12599331	ENSG00000233719.3	GOT2P3	6.47	4.87e-10	0.00124	0.48	0.37	Blood metabolite ratios;	chr16:58805307	chr12:9641802~9643007:+
COAD	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-6.47	4.89e-10	0.00124	-0.38	-0.37	Longevity;	chr3:48463903	chr1:27649419~27649610:+
COAD	trans	rs2899832	0.568	rs17458583	ENSG00000229083.1	PSMA6P2	6.47	4.93e-10	0.00125	0.58	0.37	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293295	chrX:12825840~12826833:+
COAD	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	6.47	4.97e-10	0.00126	0.52	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
COAD	trans	rs12709013	0.792	rs12596434	ENSG00000233719.3	GOT2P3	6.47	4.97e-10	0.00126	0.48	0.37	Blood metabolite ratios;	chr16:58792309	chr12:9641802~9643007:+
COAD	trans	rs12614435	0.512	rs36113194	ENSG00000269800.1	PLEKHA3P1	6.47	4.99e-10	0.00127	0.47	0.37	Atrial fibrillation;	chr2:178626058	chr19:41521043~41521989:-
COAD	trans	rs12709013	0.792	rs62066381	ENSG00000233719.3	GOT2P3	6.47	5.05e-10	0.00128	0.49	0.37	Blood metabolite ratios;	chr16:58807981	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs36098613	ENSG00000233719.3	GOT2P3	6.47	5.05e-10	0.00128	0.49	0.37	Blood metabolite ratios;	chr16:58810562	chr12:9641802~9643007:+
COAD	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-6.47	5.06e-10	0.00128	-0.4	-0.37	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
COAD	trans	rs12709013	0.792	rs62064901	ENSG00000233719.3	GOT2P3	6.46	5.1e-10	0.00129	0.49	0.37	Blood metabolite ratios;	chr16:58776758	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs62064940	ENSG00000233719.3	GOT2P3	6.46	5.19e-10	0.00131	0.48	0.37	Blood metabolite ratios;	chr16:58796560	chr12:9641802~9643007:+
COAD	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	6.46	5.25e-10	0.00133	0.39	0.37	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
COAD	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-6.46	5.35e-10	0.00135	-0.46	-0.37	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
COAD	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	6.45	5.49e-10	0.00139	0.43	0.37	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
COAD	trans	rs6424115	0.83	rs2503002	ENSG00000228217.1	AL390877.1	-6.45	5.53e-10	0.0014	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23870467	chr1:117778087~117778506:-
COAD	trans	rs10940346	0.542	rs2219452	ENSG00000231752.4	EMBP1	-6.45	5.59e-10	0.00141	-0.46	-0.37	Schizophrenia;	chr5:50209813	chr1:121519112~121571892:+
COAD	trans	rs10882165	0.507	rs4326721	ENSG00000273138.1	GS1-293C5.1	6.44	5.7e-10	0.00144	0.36	0.37	Refractive error;	chr10:93199129	chr7:95416108~95416462:+
COAD	trans	rs1816752	1	rs7326932	ENSG00000224976.2	PARP4P2	-6.44	5.77e-10	0.00146	-0.43	-0.37	Obesity-related traits;	chr13:24430355	chr13:19349137~19407962:+
COAD	trans	rs2899832	0.568	rs28461608	ENSG00000229083.1	PSMA6P2	6.44	5.79e-10	0.00146	0.58	0.37	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258767	chrX:12825840~12826833:+
COAD	trans	rs2899832	0.568	rs7140912	ENSG00000229083.1	PSMA6P2	6.44	5.79e-10	0.00146	0.58	0.37	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258823	chrX:12825840~12826833:+
COAD	trans	rs6601327	0.518	rs13264850	ENSG00000253981.4	ALG1L13P	-6.44	5.84e-10	0.00147	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8236003~8244667:-
COAD	trans	rs10940346	0.601	rs4145844	ENSG00000231752.4	EMBP1	-6.44	5.91e-10	0.00149	-0.48	-0.37	Schizophrenia;	chr5:50478019	chr1:121519112~121571892:+
COAD	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48384185	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48384586	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48385757	chr1:27649419~27649610:+
COAD	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48386489	chr1:27649419~27649610:+
COAD	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48387420	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48388977	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48389129	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48392157	chr1:27649419~27649610:+
COAD	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48392588	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48392923	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48395329	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48396724	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-6.44	5.94e-10	0.00149	-0.39	-0.37	Longevity;	chr3:48398582	chr1:27649419~27649610:+
COAD	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-6.44	5.94e-10	0.00149	-0.39	-0.37	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
COAD	trans	rs12614435	0.512	rs16866420	ENSG00000269800.1	PLEKHA3P1	6.44	5.97e-10	0.0015	0.46	0.37	Atrial fibrillation;	chr2:178626508	chr19:41521043~41521989:-
COAD	trans	rs7032940	0.533	rs7868072	ENSG00000262519.1	TXNP4	6.44	5.99e-10	0.00151	0.48	0.37	Height;	chr9:110205824	chr17:4572206~4572515:+
COAD	trans	rs1039766	1	rs268882	ENSG00000224334.1	AP000357.4	-6.44	6e-10	0.00151	-0.54	-0.37	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr22:24686923~24688087:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	6.43	6.05e-10	0.00152	0.41	0.37	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
COAD	trans	rs6424115	0.8	rs4649123	ENSG00000228217.1	AL390877.1	-6.43	6.08e-10	0.00153	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23871206	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2503000	ENSG00000228217.1	AL390877.1	-6.43	6.08e-10	0.00153	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23871408	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502999	ENSG00000228217.1	AL390877.1	-6.43	6.08e-10	0.00153	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23871831	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.793	rs2502998	ENSG00000228217.1	AL390877.1	-6.43	6.08e-10	0.00153	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23871837	chr1:117778087~117778506:-
COAD	trans	rs12709013	0.792	rs1657170	ENSG00000233719.3	GOT2P3	6.43	6.08e-10	0.00153	0.49	0.37	Blood metabolite ratios;	chr16:58752082	chr12:9641802~9643007:+
COAD	trans	rs6732160	0.588	rs13390460	ENSG00000236165.1	PRADC1P1	6.43	6.11e-10	0.00153	0.49	0.37	Intelligence (multi-trait analysis);	chr2:73144348	chr3:36976316~36976840:+
COAD	trans	rs11023332	0.641	rs4281505	ENSG00000236360.2	RP11-334A14.2	6.43	6.12e-10	0.00154	0.48	0.37	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr1:52993201~52993702:-
COAD	trans	rs11023332	0.65	rs2122942	ENSG00000236360.2	RP11-334A14.2	6.43	6.18e-10	0.00155	0.48	0.37	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr1:52993201~52993702:-
COAD	trans	rs10242455	0.571	rs80045298	ENSG00000228834.1	RP11-249L21.4	6.43	6.22e-10	0.00156	0.9	0.37	Blood metabolite levels;	chr7:99709830	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.571	rs41279866	ENSG00000228834.1	RP11-249L21.4	6.43	6.22e-10	0.00156	0.9	0.37	Blood metabolite levels;	chr7:99717653	chr6:108907615~108907873:-
COAD	trans	rs7824557	1	rs7824557	ENSG00000173295.6	FAM86B3P	-6.43	6.22e-10	0.00156	-0.47	-0.37	Retinal vascular caliber;	chr8:11246602	chr8:8228595~8244865:+
COAD	trans	rs6601327	0.641	rs7461939	ENSG00000173295.6	FAM86B3P	-6.43	6.23e-10	0.00156	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:8228595~8244865:+
COAD	trans	rs1816752	1	rs9511265	ENSG00000224976.2	PARP4P2	-6.43	6.24e-10	0.00157	-0.43	-0.37	Obesity-related traits;	chr13:24438221	chr13:19349137~19407962:+
COAD	trans	rs4276421	0.967	rs10941703	ENSG00000231752.4	EMBP1	-6.43	6.26e-10	0.00157	-0.45	-0.37	P wave duration;	chr5:45781770	chr1:121519112~121571892:+
COAD	trans	rs62344088	0.59	rs6889904	ENSG00000185986.11	SDHAP3	6.42	6.43e-10	0.00161	0.7	0.37	Asthma (childhood onset);	chr5:177149	chr5:1572222~1594620:-
COAD	trans	rs9329221	0.512	rs7843924	ENSG00000173295.6	FAM86B3P	6.42	6.43e-10	0.00161	0.44	0.37	Neuroticism;	chr8:10119030	chr8:8228595~8244865:+
COAD	trans	rs12709013	0.792	rs12928733	ENSG00000233719.3	GOT2P3	6.42	6.43e-10	0.00161	0.48	0.37	Blood metabolite ratios;	chr16:58807216	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs8049572	ENSG00000233719.3	GOT2P3	6.42	6.43e-10	0.00161	0.48	0.37	Blood metabolite ratios;	chr16:58809672	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.766	rs34438483	ENSG00000233719.3	GOT2P3	6.42	6.43e-10	0.00161	0.48	0.37	Blood metabolite ratios;	chr16:58810530	chr12:9641802~9643007:+
COAD	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-6.42	6.45e-10	0.00161	-0.49	-0.37	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
COAD	trans	rs6732160	0.588	rs13403748	ENSG00000236165.1	PRADC1P1	6.42	6.48e-10	0.00162	0.49	0.37	Intelligence (multi-trait analysis);	chr2:73144347	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.588	rs72841902	ENSG00000236165.1	PRADC1P1	6.42	6.48e-10	0.00162	0.49	0.37	Intelligence (multi-trait analysis);	chr2:73145084	chr3:36976316~36976840:+
COAD	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	6.42	6.49e-10	0.00162	0.43	0.37	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
COAD	trans	rs6601327	0.641	rs7461939	ENSG00000253981.4	ALG1L13P	-6.42	6.51e-10	0.00163	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:8236003~8244667:-
COAD	trans	rs9329221	0.638	rs7460436	ENSG00000173295.6	FAM86B3P	6.42	6.62e-10	0.00165	0.45	0.37	Neuroticism;	chr8:10396812	chr8:8228595~8244865:+
COAD	trans	rs7824557	0.734	rs2293856	ENSG00000253981.4	ALG1L13P	6.42	6.66e-10	0.00166	0.48	0.37	Retinal vascular caliber;	chr8:11319938	chr8:8236003~8244667:-
COAD	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	6.42	6.68e-10	0.00167	0.47	0.37	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
COAD	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-6.41	6.73e-10	0.00168	-0.39	-0.37	Longevity;	chr3:48445934	chr1:27649419~27649610:+
COAD	trans	rs6601327	0.641	rs12155819	ENSG00000253981.4	ALG1L13P	-6.41	6.73e-10	0.00168	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8236003~8244667:-
COAD	trans	rs6601327	0.7	rs12114661	ENSG00000253981.4	ALG1L13P	-6.41	6.73e-10	0.00168	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8236003~8244667:-
COAD	trans	rs6601327	0.641	rs4129360	ENSG00000253981.4	ALG1L13P	-6.41	6.73e-10	0.00168	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8236003~8244667:-
COAD	trans	rs6601327	0.641	rs6601350	ENSG00000253981.4	ALG1L13P	-6.41	6.73e-10	0.00168	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8236003~8244667:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	6.41	6.81e-10	0.0017	0.41	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
COAD	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	6.41	6.95e-10	0.00173	0.47	0.37	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
COAD	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-6.41	7.02e-10	0.00175	-0.39	-0.37	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
COAD	trans	rs12709013	0.716	rs11647582	ENSG00000233719.3	GOT2P3	6.41	7.04e-10	0.00175	0.48	0.37	Blood metabolite ratios;	chr16:58801474	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.792	rs35684307	ENSG00000233719.3	GOT2P3	6.41	7.04e-10	0.00175	0.48	0.37	Blood metabolite ratios;	chr16:58801651	chr12:9641802~9643007:+
COAD	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-6.41	7.1e-10	0.00177	-0.39	-0.37	Longevity;	chr3:48442021	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-6.41	7.1e-10	0.00177	-0.39	-0.37	Longevity;	chr3:48442035	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-6.41	7.1e-10	0.00177	-0.39	-0.37	Longevity;	chr3:48443151	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-6.41	7.1e-10	0.00177	-0.39	-0.37	Longevity;	chr3:48443275	chr1:27649419~27649610:+
COAD	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	6.4	7.13e-10	0.00177	0.42	0.37	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
COAD	trans	rs3213958	0.509	rs73136057	ENSG00000255624.2	RP11-564D11.3	-6.4	7.14e-10	0.00178	-0.71	-0.37	Blood protein levels;	chr3:98788290	chr10:122879851~122898024:+
COAD	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-6.4	7.14e-10	0.00178	-0.46	-0.37	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
COAD	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	6.4	7.15e-10	0.00178	0.38	0.37	Longevity;	chr3:48377218	chr1:27649419~27649610:+
COAD	trans	rs7113874	0.802	rs4272783	ENSG00000266891.1	RP11-692N5.2	6.4	7.2e-10	0.00179	0.48	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8663846	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.659	rs57757082	ENSG00000266891.1	RP11-692N5.2	6.4	7.22e-10	0.0018	0.5	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8507106	chr18:9734882~9735602:-
COAD	trans	rs6424115	0.83	rs6680132	ENSG00000228217.1	AL390877.1	-6.4	7.28e-10	0.00181	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872314	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs6672157	ENSG00000228217.1	AL390877.1	-6.4	7.28e-10	0.00181	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872350	chr1:117778087~117778506:-
COAD	trans	rs13014235	0.562	rs2080325	ENSG00000235105.1	RP11-329A14.1	-6.4	7.3e-10	0.00181	-0.45	-0.37	Basal cell carcinoma;	chr2:201513640	chr1:48435967~48437223:+
COAD	trans	rs12709013	0.766	rs11648511	ENSG00000233719.3	GOT2P3	6.4	7.31e-10	0.00182	0.48	0.37	Blood metabolite ratios;	chr16:58798171	chr12:9641802~9643007:+
COAD	trans	rs10242455	0.867	rs2740565	ENSG00000228834.1	RP11-249L21.4	6.4	7.34e-10	0.00182	0.52	0.37	Blood metabolite levels;	chr7:99695852	chr6:108907615~108907873:-
COAD	trans	rs2209875	0.573	rs74703137	ENSG00000234819.1	RP11-336N8.4	6.4	7.36e-10	0.00183	0.48	0.37	Pelvic organ prolapse (moderate/severe);	chr9:89336429	chr9:78219120~78219357:+
COAD	trans	rs10037055	0.741	rs2336405	ENSG00000228305.2	AC016734.2	-6.4	7.41e-10	0.00184	-0.4	-0.37	Migraine without aura;	chr5:177230288	chr2:63622178~63622831:-
COAD	trans	rs10037055	0.853	rs2336237	ENSG00000228305.2	AC016734.2	6.4	7.41e-10	0.00184	0.4	0.37	Migraine without aura;	chr5:177238878	chr2:63622178~63622831:-
COAD	trans	rs6601327	0.518	rs13264850	ENSG00000173295.6	FAM86B3P	-6.4	7.44e-10	0.00185	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8228595~8244865:+
COAD	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-6.4	7.44e-10	0.00185	-0.51	-0.37	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
COAD	trans	rs10037055	0.853	rs6890580	ENSG00000228305.2	AC016734.2	-6.39	7.53e-10	0.00187	-0.4	-0.37	Migraine without aura;	chr5:177226519	chr2:63622178~63622831:-
COAD	trans	rs3003334	1	rs3003334	ENSG00000228217.1	AL390877.1	-6.39	7.62e-10	0.00189	-0.46	-0.37	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr1:23873379	chr1:117778087~117778506:-
COAD	trans	rs6601327	0.641	rs12155819	ENSG00000173295.6	FAM86B3P	-6.39	7.62e-10	0.00189	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8228595~8244865:+
COAD	trans	rs6601327	0.7	rs12114661	ENSG00000173295.6	FAM86B3P	-6.39	7.62e-10	0.00189	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8228595~8244865:+
COAD	trans	rs6601327	0.641	rs4129360	ENSG00000173295.6	FAM86B3P	-6.39	7.62e-10	0.00189	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8228595~8244865:+
COAD	trans	rs6601327	0.641	rs6601350	ENSG00000173295.6	FAM86B3P	-6.39	7.62e-10	0.00189	-0.46	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8228595~8244865:+
COAD	trans	rs9329221	0.905	rs17765901	ENSG00000173295.6	FAM86B3P	-6.39	7.63e-10	0.00189	-0.44	-0.37	Neuroticism;	chr8:10391970	chr8:8228595~8244865:+
COAD	trans	rs11023332	0.617	rs1451678	ENSG00000236360.2	RP11-334A14.2	6.39	7.65e-10	0.0019	0.48	0.37	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr1:52993201~52993702:-
COAD	trans	rs6424115	0.83	rs2501423	ENSG00000228217.1	AL390877.1	-6.39	7.66e-10	0.0019	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872536	chr1:117778087~117778506:-
COAD	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	6.39	7.67e-10	0.0019	0.44	0.37	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
COAD	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-6.39	7.71e-10	0.00191	-0.48	-0.37	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
COAD	trans	rs61041336	1	rs61041336	ENSG00000230849.2	GOT2P2	-6.39	7.72e-10	0.00191	-0.63	-0.37	Neuritic plaque;	chr16:58699258	chr1:173141100~173142350:-
COAD	trans	rs11098499	0.909	rs11723757	ENSG00000276997.3	RP11-378J18.9	6.39	7.74e-10	0.00192	0.44	0.37	Corneal astigmatism;	chr4:119378514	chr1:222477252~222504622:-
COAD	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-6.39	7.75e-10	0.00192	-0.39	-0.37	Longevity;	chr3:48408549	chr1:27649419~27649610:+
COAD	trans	rs9329221	0.71	rs11779205	ENSG00000173295.6	FAM86B3P	6.39	7.83e-10	0.00194	0.45	0.37	Neuroticism;	chr8:10402590	chr8:8228595~8244865:+
COAD	trans	rs10037055	0.853	rs1546363	ENSG00000228305.2	AC016734.2	-6.39	7.86e-10	0.00195	-0.39	-0.37	Migraine without aura;	chr5:177174030	chr2:63622178~63622831:-
COAD	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-6.39	7.86e-10	0.00195	-0.39	-0.37	Longevity;	chr3:48458887	chr1:27649419~27649610:+
COAD	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	6.39	7.87e-10	0.00195	0.55	0.37	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	6.39	7.87e-10	0.00195	0.55	0.37	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
COAD	trans	rs35847492	1	rs35847492	ENSG00000173295.6	FAM86B3P	6.38	8e-10	0.00198	0.46	0.37	Neuroticism;	chr8:9418515	chr8:8228595~8244865:+
COAD	trans	rs6424115	0.83	rs2501425	ENSG00000228217.1	AL390877.1	-6.38	8.02e-10	0.00199	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872849	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502994	ENSG00000228217.1	AL390877.1	-6.38	8.02e-10	0.00199	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872873	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2501426	ENSG00000228217.1	AL390877.1	-6.38	8.02e-10	0.00199	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872874	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs6663474	ENSG00000228217.1	AL390877.1	-6.38	8.02e-10	0.00199	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23873152	chr1:117778087~117778506:-
COAD	trans	rs11098499	0.866	rs12501602	ENSG00000276997.3	RP11-378J18.9	6.38	8.17e-10	0.00202	0.43	0.37	Corneal astigmatism;	chr4:119366780	chr1:222477252~222504622:-
COAD	trans	rs10037055	0.687	rs6556308	ENSG00000228305.2	AC016734.2	-6.38	8.19e-10	0.00203	-0.4	-0.37	Migraine without aura;	chr5:177219700	chr2:63622178~63622831:-
COAD	trans	rs9329221	0.537	rs6601415	ENSG00000173295.6	FAM86B3P	6.38	8.2e-10	0.00203	0.44	0.37	Neuroticism;	chr8:10119295	chr8:8228595~8244865:+
COAD	trans	rs6424115	0.83	rs1130321	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874034	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs1130320	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874116	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs1106	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874282	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs1105	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874310	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2229585	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874431	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2229584	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874479	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.8	rs2229581	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874604	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.743	rs2229580	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874619	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502993	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874772	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs4649124	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874867	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs3003336	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23874958	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2501431	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23875153	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502992	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23875429	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.867	rs2501432	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23875430	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502991	ENSG00000228217.1	AL390877.1	-6.38	8.28e-10	0.00205	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23875828	chr1:117778087~117778506:-
COAD	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	6.38	8.29e-10	0.00205	0.55	0.37	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.736	rs2001337	ENSG00000173295.6	FAM86B3P	6.38	8.3e-10	0.00205	0.45	0.37	Neuroticism;	chr8:10393644	chr8:8228595~8244865:+
COAD	trans	rs10242455	0.681	rs2740559	ENSG00000228834.1	RP11-249L21.4	-6.38	8.32e-10	0.00206	-0.52	-0.37	Blood metabolite levels;	chr7:99726892	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.867	rs2687136	ENSG00000228834.1	RP11-249L21.4	-6.38	8.32e-10	0.00206	-0.52	-0.37	Blood metabolite levels;	chr7:99728259	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.954	rs6849171	ENSG00000276997.3	RP11-378J18.9	6.38	8.36e-10	0.00206	0.42	0.37	Corneal astigmatism;	chr4:119488394	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.662	rs13108589	ENSG00000276997.3	RP11-378J18.9	6.37	8.44e-10	0.00208	0.43	0.37	Corneal astigmatism;	chr4:119346947	chr1:222477252~222504622:-
COAD	trans	rs10242455	0.867	rs15524	ENSG00000228834.1	RP11-249L21.4	6.37	8.54e-10	0.00211	0.53	0.37	Blood metabolite levels;	chr7:99648291	chr6:108907615~108907873:-
COAD	trans	rs1816752	1	rs7999554	ENSG00000224976.2	PARP4P2	-6.37	8.59e-10	0.00212	-0.42	-0.37	Obesity-related traits;	chr13:24435631	chr13:19349137~19407962:+
COAD	trans	rs9329221	0.905	rs28712068	ENSG00000173295.6	FAM86B3P	-6.37	8.71e-10	0.00215	-0.44	-0.37	Neuroticism;	chr8:10393635	chr8:8228595~8244865:+
COAD	trans	rs11023332	0.617	rs1879888	ENSG00000236360.2	RP11-334A14.2	6.37	8.75e-10	0.00215	0.47	0.37	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr1:52993201~52993702:-
COAD	trans	rs7824557	0.767	rs6985460	ENSG00000173295.6	FAM86B3P	6.37	8.77e-10	0.00216	0.49	0.37	Retinal vascular caliber;	chr8:11313578	chr8:8228595~8244865:+
COAD	trans	rs2288327	0.673	rs6723399	ENSG00000269800.1	PLEKHA3P1	6.37	8.79e-10	0.00216	0.48	0.37	Atrial fibrillation;	chr2:178516988	chr19:41521043~41521989:-
COAD	trans	rs6424115	0.83	rs3003335	ENSG00000228217.1	AL390877.1	-6.37	8.87e-10	0.00218	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23873562	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.8	rs6665733	ENSG00000228217.1	AL390877.1	-6.37	8.87e-10	0.00218	-0.46	-0.37	Immature fraction of reticulocytes;	chr1:23873668	chr1:117778087~117778506:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-6.36	8.96e-10	0.0022	-0.41	-0.37	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
COAD	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-6.36	9.06e-10	0.00223	-0.39	-0.37	Longevity;	chr3:48413059	chr1:27649419~27649610:+
COAD	trans	rs74781061	0.86	rs1866113	ENSG00000227288.3	RP5-837I24.1	6.36	9.06e-10	0.00223	0.55	0.37	Endometriosis;	chr15:74437262	chr1:81501794~81503468:+
COAD	trans	rs6601327	0.551	rs13272424	ENSG00000253981.4	ALG1L13P	-6.36	9.23e-10	0.00227	-0.47	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8236003~8244667:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	6.36	9.32e-10	0.00229	0.4	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
COAD	trans	rs10940346	0.601	rs3849669	ENSG00000231752.4	EMBP1	6.36	9.38e-10	0.0023	0.46	0.37	Schizophrenia;	chr5:50365710	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs4398636	ENSG00000231752.4	EMBP1	6.36	9.38e-10	0.0023	0.46	0.37	Schizophrenia;	chr5:50391957	chr1:121519112~121571892:+
COAD	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	6.35	9.59e-10	0.00235	0.38	0.37	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.901	rs35381866	ENSG00000231752.4	EMBP1	6.35	9.69e-10	0.00237	0.43	0.37	P wave duration;	chr5:45690085	chr1:121519112~121571892:+
COAD	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	6.35	9.69e-10	0.00237	0.56	0.37	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
COAD	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	6.35	9.75e-10	0.00239	0.44	0.37	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	6.35	9.8e-10	0.0024	0.42	0.37	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
COAD	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	6.35	9.84e-10	0.00241	0.47	0.37	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
COAD	trans	rs8177876	0.822	rs9923732	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9925940	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9925943	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9933184	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.822	rs9926174	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr1:168055901~168056422:-
COAD	trans	rs8177876	0.642	rs8052490	ENSG00000224837.1	GCSHP5	6.35	9.86e-10	0.00241	0.6	0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr1:168055901~168056422:-
COAD	trans	rs74781061	0.929	rs7171838	ENSG00000227288.3	RP5-837I24.1	6.35	9.86e-10	0.00241	0.55	0.37	Endometriosis;	chr15:74571778	chr1:81501794~81503468:+
COAD	trans	rs62344088	0.59	rs6882234	ENSG00000185986.11	SDHAP3	6.35	9.88e-10	0.00242	0.73	0.37	Asthma (childhood onset);	chr5:177274	chr5:1572222~1594620:-
COAD	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-6.35	9.89e-10	0.00242	-0.47	-0.37	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs12505469	ENSG00000276997.3	RP11-378J18.9	6.34	1e-09	0.00245	0.44	0.37	Corneal astigmatism;	chr4:119328430	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.537	rs1484640	ENSG00000173295.6	FAM86B3P	6.34	1e-09	0.00245	0.44	0.37	Neuroticism;	chr8:10125733	chr8:8228595~8244865:+
COAD	trans	rs74781061	0.929	rs6495115	ENSG00000227288.3	RP5-837I24.1	6.34	1e-09	0.00245	0.55	0.37	Endometriosis;	chr15:74578122	chr1:81501794~81503468:+
COAD	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-6.34	1.02e-09	0.0025	-0.51	-0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
COAD	trans	rs11098499	0.909	rs28884220	ENSG00000276997.3	RP11-378J18.9	6.34	1.03e-09	0.00251	0.43	0.37	Corneal astigmatism;	chr4:119386056	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs28793658	ENSG00000276997.3	RP11-378J18.9	6.34	1.03e-09	0.00251	0.43	0.37	Corneal astigmatism;	chr4:119386059	chr1:222477252~222504622:-
COAD	trans	rs9425766	0.64	rs2295366	ENSG00000213331.4	RP11-713C19.2	6.34	1.03e-09	0.00251	0.46	0.37	Life satisfaction;	chr1:173856554	chr4:187970273~187971284:+
COAD	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-6.34	1.04e-09	0.00253	-0.38	-0.37	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
COAD	trans	rs3770081	1	rs17027011	ENSG00000229880.1	IMMTP1	6.34	1.04e-09	0.00253	0.69	0.37	Facial emotion recognition (sad faces);	chr2:86179433	chr21:44675868~44678086:-
COAD	trans	rs7824557	0.836	rs2736378	ENSG00000253981.4	ALG1L13P	-6.34	1.04e-09	0.00254	-0.48	-0.37	Retinal vascular caliber;	chr8:11262251	chr8:8236003~8244667:-
COAD	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-6.34	1.05e-09	0.00255	-0.41	-0.37	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
COAD	trans	rs11098499	0.697	rs4560394	ENSG00000276997.3	RP11-378J18.9	6.34	1.05e-09	0.00255	0.43	0.37	Corneal astigmatism;	chr4:119392280	chr1:222477252~222504622:-
COAD	trans	rs6424115	1	rs2179395	ENSG00000228217.1	AL390877.1	-6.33	1.06e-09	0.00257	-0.44	-0.37	Immature fraction of reticulocytes;	chr1:23821875	chr1:117778087~117778506:-
COAD	trans	rs9329221	0.617	rs483916	ENSG00000173295.6	FAM86B3P	-6.33	1.06e-09	0.00257	-0.42	-0.37	Neuroticism;	chr8:9936091	chr8:8228595~8244865:+
COAD	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-6.33	1.06e-09	0.00258	-0.56	-0.37	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
COAD	trans	rs6424115	0.733	rs2502996	ENSG00000228217.1	AL390877.1	-6.33	1.06e-09	0.00259	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872551	chr1:117778087~117778506:-
COAD	trans	rs6424115	0.83	rs2502995	ENSG00000228217.1	AL390877.1	-6.33	1.06e-09	0.00259	-0.45	-0.37	Immature fraction of reticulocytes;	chr1:23872800	chr1:117778087~117778506:-
COAD	trans	rs73110464	0.505	rs2682296	ENSG00000254285.3	KRT8P3	-6.33	1.07e-09	0.00259	-0.45	-0.37	Cancer (pleiotropy);	chr12:52914481	chr8:61578220~61579668:+
COAD	trans	rs2898290	0.592	rs2736342	ENSG00000173295.6	FAM86B3P	-6.33	1.07e-09	0.0026	-0.41	-0.37	Systolic blood pressure;	chr8:11489780	chr8:8228595~8244865:+
COAD	trans	rs6601327	0.551	rs13272424	ENSG00000173295.6	FAM86B3P	-6.33	1.07e-09	0.0026	-0.45	-0.37	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8228595~8244865:+
COAD	trans	rs10940346	0.601	rs11959569	ENSG00000231752.4	EMBP1	6.33	1.08e-09	0.00263	0.45	0.37	Schizophrenia;	chr5:50369429	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.507	rs7293474	ENSG00000231752.4	EMBP1	-6.33	1.08e-09	0.00263	-0.46	-0.37	P wave duration;	chr5:46286705	chr1:121519112~121571892:+
COAD	trans	rs7032940	0.677	rs10816931	ENSG00000262519.1	TXNP4	6.33	1.1e-09	0.00268	0.49	0.37	Height;	chr9:110177912	chr17:4572206~4572515:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-6.33	1.11e-09	0.00269	-0.4	-0.37	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
COAD	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	6.33	1.11e-09	0.00271	0.43	0.37	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
COAD	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	6.32	1.12e-09	0.00273	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
COAD	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	6.32	1.12e-09	0.00273	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
COAD	trans	rs74781061	0.929	rs8025915	ENSG00000227288.3	RP5-837I24.1	6.32	1.12e-09	0.00273	0.55	0.37	Endometriosis;	chr15:74578188	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.506	rs17689674	ENSG00000173295.6	FAM86B3P	6.32	1.13e-09	0.00274	0.43	0.37	Neuroticism;	chr8:10124344	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.618	rs28491261	ENSG00000276997.3	RP11-378J18.9	6.32	1.13e-09	0.00275	0.43	0.37	Corneal astigmatism;	chr4:119373745	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs59394118	ENSG00000276997.3	RP11-378J18.9	6.32	1.13e-09	0.00275	0.43	0.37	Corneal astigmatism;	chr4:119374396	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs9996417	ENSG00000276997.3	RP11-378J18.9	6.32	1.13e-09	0.00275	0.43	0.37	Corneal astigmatism;	chr4:119374707	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs4001305	ENSG00000276997.3	RP11-378J18.9	6.32	1.13e-09	0.00275	0.43	0.37	Corneal astigmatism;	chr4:119438081	chr1:222477252~222504622:-
COAD	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-6.32	1.14e-09	0.00276	-0.38	-0.37	Longevity;	chr3:48421052	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-6.32	1.14e-09	0.00276	-0.38	-0.37	Longevity;	chr3:48422302	chr1:27649419~27649610:+
COAD	trans	rs6424115	0.931	rs2473377	ENSG00000228217.1	AL390877.1	-6.32	1.15e-09	0.00278	-0.44	-0.37	Immature fraction of reticulocytes;	chr1:23821770	chr1:117778087~117778506:-
COAD	trans	rs6732160	0.588	rs13407363	ENSG00000236165.1	PRADC1P1	6.32	1.15e-09	0.00278	0.47	0.37	Intelligence (multi-trait analysis);	chr2:73145430	chr3:36976316~36976840:+
COAD	trans	rs9425766	0.64	rs9425756	ENSG00000213331.4	RP11-713C19.2	6.32	1.15e-09	0.00278	0.46	0.37	Life satisfaction;	chr1:173847448	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.546	rs6691001	ENSG00000213331.4	RP11-713C19.2	6.32	1.15e-09	0.00278	0.46	0.37	Life satisfaction;	chr1:173849938	chr4:187970273~187971284:+
COAD	trans	rs6732160	0.613	rs58317144	ENSG00000236165.1	PRADC1P1	6.32	1.15e-09	0.00278	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73161025	chr3:36976316~36976840:+
COAD	trans	rs61041336	0.534	rs59234479	ENSG00000230849.2	GOT2P2	-6.32	1.15e-09	0.00279	-0.78	-0.37	Neuritic plaque;	chr16:58673724	chr1:173141100~173142350:-
COAD	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-6.32	1.15e-09	0.0028	-0.46	-0.37	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
COAD	trans	rs7824557	0.736	rs35392635	ENSG00000253981.4	ALG1L13P	6.32	1.15e-09	0.0028	0.49	0.37	Retinal vascular caliber;	chr8:11306840	chr8:8236003~8244667:-
COAD	trans	rs10242455	0.867	rs3735453	ENSG00000228834.1	RP11-249L21.4	-6.32	1.16e-09	0.00281	-0.53	-0.37	Blood metabolite levels;	chr7:99631812	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.954	rs59866101	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119375436	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.618	rs6858383	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119375617	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs6832410	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119375645	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs1112817	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119376645	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs10016060	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119377257	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10005644	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119377322	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs10016448	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119377690	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.657	rs9996569	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119377849	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs11729050	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119378911	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs28429722	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119378938	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10014845	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119379922	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs7674500	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119382438	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs4507344	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119386330	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs4373140	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119386543	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs13113483	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119387884	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.542	rs10440343	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119388632	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs10011097	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119389204	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.542	rs7677836	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119389483	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs10002083	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119389997	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10024844	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119390373	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs7437420	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119391748	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs4345162	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119391804	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.657	rs4463052	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119392103	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs13151285	ENSG00000276997.3	RP11-378J18.9	6.32	1.16e-09	0.00281	0.43	0.37	Corneal astigmatism;	chr4:119393586	chr1:222477252~222504622:-
COAD	trans	rs12709013	0.875	rs9924389	ENSG00000233719.3	GOT2P3	6.32	1.16e-09	0.00281	0.47	0.37	Blood metabolite ratios;	chr16:58779849	chr12:9641802~9643007:+
COAD	trans	rs1816752	0.905	rs8002309	ENSG00000224976.2	PARP4P2	-6.32	1.17e-09	0.00282	-0.41	-0.37	Obesity-related traits;	chr13:24402217	chr13:19349137~19407962:+
COAD	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	6.32	1.17e-09	0.00282	0.46	0.37	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
COAD	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	6.32	1.17e-09	0.00282	0.46	0.37	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
COAD	trans	rs8175379	0.521	rs8175430	ENSG00000231752.4	EMBP1	-6.32	1.18e-09	0.00284	-0.46	-0.37	Interleukin-7 levels;	chr5:46305095	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-6.31	1.18e-09	0.00285	-0.56	-0.37	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-6.31	1.18e-09	0.00285	-0.56	-0.37	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-6.31	1.18e-09	0.00285	-0.56	-0.37	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
COAD	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	6.31	1.18e-09	0.00285	0.42	0.37	Mumps;	chr20:2666724	chr6:28783633~28784004:-
COAD	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	6.31	1.19e-09	0.00287	0.54	0.37	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
COAD	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	6.31	1.21e-09	0.0029	0.82	0.37	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	6.31	1.21e-09	0.0029	0.82	0.37	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	6.31	1.21e-09	0.0029	0.82	0.37	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	6.31	1.21e-09	0.0029	0.82	0.37	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
COAD	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-6.31	1.22e-09	0.00294	-0.38	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
COAD	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	6.31	1.23e-09	0.00296	0.43	0.37	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	6.31	1.23e-09	0.00297	0.47	0.37	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	6.31	1.23e-09	0.00297	0.47	0.37	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	6.31	1.23e-09	0.00297	0.47	0.37	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
COAD	trans	rs35847492	1	rs35847492	ENSG00000253981.4	ALG1L13P	6.3	1.27e-09	0.00304	0.47	0.37	Neuroticism;	chr8:9418515	chr8:8236003~8244667:-
COAD	trans	rs7554511	0.858	rs10920084	ENSG00000244144.1	RP11-757F18.3	-6.3	1.27e-09	0.00306	-0.49	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993667	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-6.3	1.28e-09	0.00307	-0.39	-0.37	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
COAD	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-6.3	1.28e-09	0.00307	-0.57	-0.37	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
COAD	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	6.3	1.28e-09	0.00308	0.47	0.37	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.527	rs4841351	ENSG00000173295.6	FAM86B3P	-6.3	1.29e-09	0.00308	-0.44	-0.37	Neuroticism;	chr8:10469857	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.738	rs28408407	ENSG00000276997.3	RP11-378J18.9	6.3	1.29e-09	0.00308	0.43	0.37	Corneal astigmatism;	chr4:119454875	chr1:222477252~222504622:-
COAD	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-6.3	1.29e-09	0.00308	-0.46	-0.37	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
COAD	trans	rs7824557	0.836	rs2736378	ENSG00000173295.6	FAM86B3P	-6.3	1.29e-09	0.00309	-0.46	-0.37	Retinal vascular caliber;	chr8:11262251	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-6.3	1.3e-09	0.0031	-0.39	-0.37	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
COAD	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	6.3	1.3e-09	0.00312	0.47	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
COAD	trans	rs393155	0.517	rs330050	ENSG00000173295.6	FAM86B3P	-6.3	1.31e-09	0.00312	-0.41	-0.37	Neuroticism;	chr8:9230169	chr8:8228595~8244865:+
COAD	trans	rs453301	0.571	rs330054	ENSG00000173295.6	FAM86B3P	-6.3	1.31e-09	0.00312	-0.41	-0.37	Joint mobility (Beighton score);	chr8:9230781	chr8:8228595~8244865:+
COAD	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	6.3	1.32e-09	0.00315	0.38	0.37	Longevity;	chr3:48464565	chr1:27649419~27649610:+
COAD	trans	rs10037055	0.853	rs4976681	ENSG00000228305.2	AC016734.2	6.29	1.33e-09	0.00317	0.39	0.37	Migraine without aura;	chr5:177277662	chr2:63622178~63622831:-
COAD	trans	rs3806843	0.676	rs753280	ENSG00000231043.3	AC007238.1	-6.29	1.33e-09	0.00317	-0.35	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140644457	chr2:58460292~58462032:-
COAD	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	6.29	1.33e-09	0.00318	0.45	0.37	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.866	rs13105020	ENSG00000276997.3	RP11-378J18.9	6.29	1.34e-09	0.0032	0.42	0.37	Corneal astigmatism;	chr4:119364533	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-6.29	1.34e-09	0.00321	-0.36	-0.37	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
COAD	trans	rs8177876	0.822	rs4324141	ENSG00000224837.1	GCSHP5	-6.29	1.34e-09	0.00321	-0.6	-0.37	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr1:168055901~168056422:-
COAD	trans	rs993648	1	rs767463	ENSG00000239830.1	RPS4XP22	-6.29	1.35e-09	0.00322	-0.44	-0.37	Response to iloperidone treatment (QT prolongation);	chr2:181593076	chr19:9683294~9684073:-
COAD	trans	rs3806843	0.735	rs801185	ENSG00000231043.3	AC007238.1	6.29	1.36e-09	0.00324	0.37	0.37	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr2:58460292~58462032:-
COAD	trans	rs2288327	1	rs2288327	ENSG00000269800.1	PLEKHA3P1	6.29	1.36e-09	0.00325	0.47	0.37	Atrial fibrillation;	chr2:178546938	chr19:41521043~41521989:-
COAD	trans	rs9329221	0.537	rs6601414	ENSG00000173295.6	FAM86B3P	6.29	1.37e-09	0.00326	0.43	0.37	Neuroticism;	chr8:10119238	chr8:8228595~8244865:+
COAD	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	6.29	1.37e-09	0.00326	0.47	0.37	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
COAD	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-6.29	1.37e-09	0.00327	-0.47	-0.37	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
COAD	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-6.29	1.37e-09	0.00328	-0.38	-0.37	Longevity;	chr3:48385276	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-6.29	1.37e-09	0.00328	-0.38	-0.37	Longevity;	chr3:48393807	chr1:27649419~27649610:+
COAD	trans	rs1435703	1	rs1435704	ENSG00000265802.2	RN7SL49P	-6.29	1.38e-09	0.00329	-0.55	-0.37	Obesity (extreme);	chr3:25521025	chr13:45002150~45002447:+
COAD	trans	rs11098499	0.909	rs1546502	ENSG00000276997.3	RP11-378J18.9	6.29	1.38e-09	0.0033	0.44	0.37	Corneal astigmatism;	chr4:119314743	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs11722872	ENSG00000276997.3	RP11-378J18.9	6.29	1.39e-09	0.00331	0.44	0.37	Corneal astigmatism;	chr4:119311875	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs11723839	ENSG00000276997.3	RP11-378J18.9	6.28	1.4e-09	0.00334	0.43	0.36	Corneal astigmatism;	chr4:119378518	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	6.28	1.41e-09	0.00335	0.38	0.36	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
COAD	trans	rs10940346	0.601	rs1033108	ENSG00000231752.4	EMBP1	6.28	1.42e-09	0.00337	0.46	0.36	Schizophrenia;	chr5:50327764	chr1:121519112~121571892:+
COAD	trans	rs7937890	1	rs6486190	ENSG00000236360.2	RP11-334A14.2	6.28	1.42e-09	0.00338	0.47	0.36	Mitochondrial DNA levels;	chr11:14379670	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.908	rs2017057	ENSG00000276997.3	RP11-378J18.9	6.28	1.44e-09	0.00343	0.43	0.36	Corneal astigmatism;	chr4:119336556	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.69	rs34818745	ENSG00000276997.3	RP11-378J18.9	6.28	1.44e-09	0.00344	0.45	0.36	Corneal astigmatism;	chr4:119335900	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs1809406	ENSG00000276997.3	RP11-378J18.9	6.28	1.45e-09	0.00344	0.43	0.36	Corneal astigmatism;	chr4:119455967	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs2389809	ENSG00000276997.3	RP11-378J18.9	6.28	1.45e-09	0.00344	0.43	0.36	Corneal astigmatism;	chr4:119456244	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs9994810	ENSG00000276997.3	RP11-378J18.9	6.28	1.45e-09	0.00344	0.43	0.36	Corneal astigmatism;	chr4:119460435	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs10020027	ENSG00000276997.3	RP11-378J18.9	6.28	1.45e-09	0.00344	0.43	0.36	Corneal astigmatism;	chr4:119460724	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs7356491	ENSG00000276997.3	RP11-378J18.9	6.28	1.45e-09	0.00344	0.43	0.36	Corneal astigmatism;	chr4:119460819	chr1:222477252~222504622:-
COAD	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-6.28	1.45e-09	0.00345	-0.46	-0.36	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
COAD	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	6.28	1.45e-09	0.00345	0.47	0.36	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
COAD	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	6.28	1.45e-09	0.00346	0.54	0.36	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	6.28	1.45e-09	0.00346	0.54	0.36	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
COAD	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-6.28	1.45e-09	0.00346	-0.42	-0.36	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-6.28	1.45e-09	0.00346	-0.42	-0.36	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
COAD	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	6.28	1.46e-09	0.00347	0.43	0.36	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-6.28	1.46e-09	0.00348	-0.39	-0.36	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.865	rs11722183	ENSG00000276997.3	RP11-378J18.9	6.28	1.47e-09	0.00349	0.43	0.36	Corneal astigmatism;	chr4:119359442	chr1:222477252~222504622:-
COAD	trans	rs10037055	0.853	rs10036193	ENSG00000228305.2	AC016734.2	-6.27	1.49e-09	0.00353	-0.39	-0.36	Migraine without aura;	chr5:177141519	chr2:63622178~63622831:-
COAD	trans	rs11098499	0.954	rs10006877	ENSG00000276997.3	RP11-378J18.9	6.27	1.5e-09	0.00356	0.44	0.36	Corneal astigmatism;	chr4:119321638	chr1:222477252~222504622:-
COAD	trans	rs2657294	0.659	rs1259500	ENSG00000172974.11	AC007318.5	6.27	1.51e-09	0.00359	0.46	0.36	Pneumonia;	chr10:75230355	chr2:65205108~65205988:+
COAD	trans	rs2657294	0.632	rs1259503	ENSG00000172974.11	AC007318.5	6.27	1.51e-09	0.00359	0.46	0.36	Pneumonia;	chr10:75232686	chr2:65205108~65205988:+
COAD	trans	rs7113874	0.659	rs12577287	ENSG00000266891.1	RP11-692N5.2	6.27	1.52e-09	0.00361	0.49	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498370	chr18:9734882~9735602:-
COAD	trans	rs7113874	0.659	rs12274454	ENSG00000266891.1	RP11-692N5.2	6.27	1.52e-09	0.00361	0.49	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500419	chr18:9734882~9735602:-
COAD	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	6.27	1.53e-09	0.00361	0.42	0.36	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
COAD	trans	rs74781061	0.86	rs4887150	ENSG00000227288.3	RP5-837I24.1	6.27	1.54e-09	0.00365	0.53	0.36	Endometriosis;	chr15:74444683	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.527	rs7833781	ENSG00000173295.6	FAM86B3P	6.27	1.55e-09	0.00368	0.44	0.36	Neuroticism;	chr8:10475967	chr8:8228595~8244865:+
COAD	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-6.27	1.55e-09	0.00368	-0.42	-0.36	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
COAD	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	6.27	1.56e-09	0.00368	0.37	0.36	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.738	rs72918577	ENSG00000276997.3	RP11-378J18.9	6.27	1.56e-09	0.00369	0.44	0.36	Corneal astigmatism;	chr4:119405546	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.78	rs10013652	ENSG00000276997.3	RP11-378J18.9	6.26	1.56e-09	0.0037	0.43	0.36	Corneal astigmatism;	chr4:119371101	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10006706	ENSG00000276997.3	RP11-378J18.9	6.26	1.57e-09	0.00371	0.42	0.36	Corneal astigmatism;	chr4:119487997	chr1:222477252~222504622:-
COAD	trans	rs7032940	0.651	rs7873398	ENSG00000262519.1	TXNP4	6.26	1.57e-09	0.00371	0.47	0.36	Height;	chr9:110194413	chr17:4572206~4572515:+
COAD	trans	rs7824557	0.701	rs4568582	ENSG00000253981.4	ALG1L13P	6.26	1.57e-09	0.00372	0.48	0.36	Retinal vascular caliber;	chr8:11302986	chr8:8236003~8244667:-
COAD	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	6.26	1.58e-09	0.00373	0.47	0.36	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	6.26	1.58e-09	0.00373	0.47	0.36	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	6.26	1.58e-09	0.00373	0.47	0.36	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
COAD	trans	rs3213958	0.574	rs16846347	ENSG00000255624.2	RP11-564D11.3	-6.26	1.59e-09	0.00376	-0.62	-0.36	Blood protein levels;	chr3:98777624	chr10:122879851~122898024:+
COAD	trans	rs5022636	0.533	rs4971029	ENSG00000180764.13	PIPSL	6.26	1.6e-09	0.00379	0.49	0.36	Gut microbiota (functional units);	chr1:151304783	chr10:93958191~93961540:-
COAD	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-6.26	1.61e-09	0.0038	-0.38	-0.36	Longevity;	chr3:48378233	chr1:27649419~27649610:+
COAD	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-6.26	1.61e-09	0.00381	-0.5	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
COAD	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-6.26	1.62e-09	0.00383	-0.5	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
COAD	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-6.26	1.63e-09	0.00385	-0.38	-0.36	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
COAD	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	6.26	1.63e-09	0.00385	0.42	0.36	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
COAD	trans	rs11098499	0.954	rs10006525	ENSG00000276997.3	RP11-378J18.9	6.26	1.63e-09	0.00385	0.42	0.36	Corneal astigmatism;	chr4:119487776	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	6.26	1.65e-09	0.00388	0.43	0.36	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	6.26	1.65e-09	0.00388	0.43	0.36	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
COAD	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	6.25	1.65e-09	0.00389	0.42	0.36	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
COAD	trans	rs74781061	0.929	rs4887159	ENSG00000227288.3	RP5-837I24.1	6.25	1.65e-09	0.00389	0.53	0.36	Endometriosis;	chr15:74573541	chr1:81501794~81503468:+
COAD	trans	rs9650657	0.547	rs11250099	ENSG00000173295.6	FAM86B3P	6.25	1.65e-09	0.0039	0.45	0.36	Neuroticism;	chr8:10961147	chr8:8228595~8244865:+
COAD	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	6.25	1.66e-09	0.00392	0.47	0.36	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs4309825	ENSG00000276997.3	RP11-378J18.9	-6.25	1.67e-09	0.00393	-0.43	-0.36	Corneal astigmatism;	chr4:119393726	chr1:222477252~222504622:-
COAD	trans	rs1435703	1	rs7644940	ENSG00000265802.2	RN7SL49P	-6.25	1.67e-09	0.00394	-0.56	-0.36	Obesity (extreme);	chr3:25520178	chr13:45002150~45002447:+
COAD	trans	rs10037055	0.853	rs9885210	ENSG00000228305.2	AC016734.2	-6.25	1.68e-09	0.00395	-0.39	-0.36	Migraine without aura;	chr5:177142187	chr2:63622178~63622831:-
COAD	trans	rs4276421	0.571	rs59968174	ENSG00000231752.4	EMBP1	6.25	1.68e-09	0.00395	0.46	0.36	P wave duration;	chr5:46027939	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.56	rs10073530	ENSG00000231752.4	EMBP1	6.25	1.68e-09	0.00395	0.45	0.36	Schizophrenia;	chr5:50358823	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.909	rs10020034	ENSG00000276997.3	RP11-378J18.9	6.25	1.69e-09	0.00397	0.43	0.36	Corneal astigmatism;	chr4:119373176	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs12506546	ENSG00000276997.3	RP11-378J18.9	6.25	1.69e-09	0.00398	0.43	0.36	Corneal astigmatism;	chr4:119380463	chr1:222477252~222504622:-
COAD	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	6.25	1.72e-09	0.00404	0.42	0.36	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
COAD	trans	rs11098499	0.909	rs28668716	ENSG00000276997.3	RP11-378J18.9	6.25	1.72e-09	0.00405	0.43	0.36	Corneal astigmatism;	chr4:119388720	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	6.25	1.73e-09	0.00407	0.37	0.36	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.954	rs878373	ENSG00000276997.3	RP11-378J18.9	6.24	1.78e-09	0.00417	0.44	0.36	Corneal astigmatism;	chr4:119316329	chr1:222477252~222504622:-
COAD	trans	rs1039766	1	rs268871	ENSG00000224334.1	AP000357.4	6.24	1.78e-09	0.00417	0.53	0.36	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr22:24686923~24688087:+
COAD	trans	rs7192380	0.639	rs12448486	ENSG00000257513.6	NPIPB1P	-6.24	1.78e-09	0.00417	-0.41	-0.36	Sjögren's syndrome;	chr16:69768975	chr18:11619509~11639699:-
COAD	trans	rs11098499	0.909	rs73842633	ENSG00000276997.3	RP11-378J18.9	6.24	1.78e-09	0.00418	0.44	0.36	Corneal astigmatism;	chr4:119454309	chr1:222477252~222504622:-
COAD	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-6.24	1.78e-09	0.00418	-0.38	-0.36	Longevity;	chr3:48408490	chr1:27649419~27649610:+
COAD	trans	rs3806843	0.966	rs2563263	ENSG00000231043.3	AC007238.1	-6.24	1.78e-09	0.00419	-0.38	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr2:58460292~58462032:-
COAD	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-6.24	1.79e-09	0.0042	-0.47	-0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.866	rs72676074	ENSG00000276997.3	RP11-378J18.9	6.24	1.8e-09	0.00422	0.43	0.36	Corneal astigmatism;	chr4:119438686	chr1:222477252~222504622:-
COAD	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	6.24	1.8e-09	0.00422	0.45	0.36	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	6.24	1.8e-09	0.00422	0.45	0.36	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	6.24	1.8e-09	0.00422	0.45	0.36	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
COAD	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-6.24	1.81e-09	0.00424	-0.47	-0.36	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
COAD	trans	rs3806843	0.706	rs1089305	ENSG00000231043.3	AC007238.1	6.24	1.82e-09	0.00426	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr2:58460292~58462032:-
COAD	trans	rs28647808	0.867	rs9645010	ENSG00000234981.1	RP11-534L20.4	6.24	1.82e-09	0.00427	0.81	0.36	Blood protein levels;	chr9:133344567	chr1:206528915~206529706:+
COAD	trans	rs4962130	0.744	rs76556605	ENSG00000234981.1	RP11-534L20.4	6.24	1.82e-09	0.00427	0.81	0.36	Blood protein levels;	chr9:133348464	chr1:206528915~206529706:+
COAD	trans	rs28647808	0.609	rs28635402	ENSG00000234981.1	RP11-534L20.4	6.24	1.82e-09	0.00427	0.81	0.36	Blood protein levels;	chr9:133348619	chr1:206528915~206529706:+
COAD	trans	rs66887589	0.934	rs7681980	ENSG00000275858.1	RP11-291L22.8	-6.24	1.82e-09	0.00427	-0.36	-0.36	Diastolic blood pressure;	chr4:119612068	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	6.24	1.83e-09	0.0043	0.38	0.36	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
COAD	trans	rs657452	0.671	rs662440	ENSG00000207730.2	MIR200B	-6.24	1.84e-09	0.00431	-0.32	-0.36	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);Body mass index;	chr1:49110828	chr1:1167092~1167202:+
COAD	trans	rs8010715	0.771	rs2277481	ENSG00000238000.1	RP11-274E7.2	6.23	1.85e-09	0.00432	0.4	0.36	IgG glycosylation;	chr14:24118336	chr5:98213402~98214121:+
COAD	trans	rs7113874	0.659	rs7931834	ENSG00000266891.1	RP11-692N5.2	6.23	1.85e-09	0.00434	0.49	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8503746	chr18:9734882~9735602:-
COAD	trans	rs8177876	0.822	rs4889231	ENSG00000224837.1	GCSHP5	-6.23	1.87e-09	0.00437	-0.54	-0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr1:168055901~168056422:-
COAD	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	6.23	1.89e-09	0.00442	0.38	0.36	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
COAD	trans	rs28647808	1	rs8181069	ENSG00000234981.1	RP11-534L20.4	6.23	1.9e-09	0.00443	0.8	0.36	Blood protein levels;	chr9:133387172	chr1:206528915~206529706:+
COAD	trans	rs11098499	0.954	rs11098524	ENSG00000276997.3	RP11-378J18.9	6.23	1.9e-09	0.00444	0.42	0.36	Corneal astigmatism;	chr4:119468877	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.527	rs4841352	ENSG00000173295.6	FAM86B3P	6.23	1.9e-09	0.00445	0.43	0.36	Neuroticism;	chr8:10470080	chr8:8228595~8244865:+
COAD	trans	rs74781061	0.929	rs8028163	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74530360	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs11072492	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74531782	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8041807	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74534590	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs12594447	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74536392	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs1821848	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74541443	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs7177407	ENSG00000227288.3	RP5-837I24.1	6.23	1.91e-09	0.00446	0.54	0.36	Endometriosis;	chr15:74551444	chr1:81501794~81503468:+
COAD	trans	rs11098499	0.738	rs28687057	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119359657	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.775	rs67281037	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119360002	chr1:222477252~222504622:-
COAD	trans	rs10028773	0.506	rs12374346	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Educational attainment;	chr4:119360550	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs12374244	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119360817	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs12374352	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119360822	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs6857892	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119361541	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs28581362	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119362393	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.82	rs12503082	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119363162	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs12499602	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119363232	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.774	rs11098505	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119363472	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs6824111	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119364813	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.775	rs10029303	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119365600	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs9995136	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119365690	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs13125526	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119366864	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs12513310	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119366884	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.564	rs11098507	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119367131	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs12510451	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119367988	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.774	rs73842616	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119369528	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.645	rs72676059	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119369673	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.569	rs55845118	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119369758	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs7677068	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119370549	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.866	rs9991221	ENSG00000276997.3	RP11-378J18.9	6.23	1.91e-09	0.00446	0.42	0.36	Corneal astigmatism;	chr4:119370952	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.731	rs6846966	ENSG00000276997.3	RP11-378J18.9	6.23	1.92e-09	0.00448	0.42	0.36	Corneal astigmatism;	chr4:119372053	chr1:222477252~222504622:-
COAD	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-6.23	1.92e-09	0.00448	-0.38	-0.36	Longevity;	chr3:48402409	chr1:27649419~27649610:+
COAD	trans	rs11098499	0.909	rs35165976	ENSG00000276997.3	RP11-378J18.9	6.23	1.92e-09	0.00448	0.43	0.36	Corneal astigmatism;	chr4:119404475	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.705	rs35614340	ENSG00000231043.3	AC007238.1	6.23	1.93e-09	0.0045	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.954	rs17005535	ENSG00000276997.3	RP11-378J18.9	6.23	1.94e-09	0.00451	0.42	0.36	Corneal astigmatism;	chr4:119490407	chr1:222477252~222504622:-
COAD	trans	rs7554511	0.861	rs965321	ENSG00000244144.1	RP11-757F18.3	6.23	1.94e-09	0.00452	0.51	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036374	chr3:112185480~112185998:-
COAD	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	6.22	1.95e-09	0.00454	0.45	0.36	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
COAD	trans	rs66887589	0.967	rs2892869	ENSG00000275858.1	RP11-291L22.8	-6.22	1.96e-09	0.00456	-0.36	-0.36	Diastolic blood pressure;	chr4:119600142	chr10:38450738~38451069:-
COAD	trans	rs330048	0.545	rs11774353	ENSG00000173295.6	FAM86B3P	6.22	1.98e-09	0.00461	0.49	0.36	Systemic lupus erythematosus;	chr8:9295617	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.908	rs28499576	ENSG00000276997.3	RP11-378J18.9	6.22	1.99e-09	0.00463	0.42	0.36	Corneal astigmatism;	chr4:119465522	chr1:222477252~222504622:-
COAD	trans	rs2209875	0.588	rs7469084	ENSG00000234819.1	RP11-336N8.4	6.22	2e-09	0.00466	0.48	0.36	Pelvic organ prolapse (moderate/severe);	chr9:89366248	chr9:78219120~78219357:+
COAD	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	6.22	2.01e-09	0.00466	0.38	0.36	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
COAD	trans	rs7552404	1	rs4949879	ENSG00000277299.1	RP11-837J7.4	-6.22	2.01e-09	0.00466	-0.45	-0.36	Acylcarnitine levels;Blood metabolite levels;	chr1:75771458	chr12:109948389~109949029:+
COAD	trans	rs6424115	0.964	rs2473375	ENSG00000228217.1	AL390877.1	-6.22	2.01e-09	0.00467	-0.43	-0.36	Immature fraction of reticulocytes;	chr1:23810055	chr1:117778087~117778506:-
COAD	trans	rs11098499	0.954	rs1022145	ENSG00000276997.3	RP11-378J18.9	6.22	2.02e-09	0.00469	0.44	0.36	Corneal astigmatism;	chr4:119309824	chr1:222477252~222504622:-
COAD	trans	rs6424115	1	rs4237	ENSG00000228217.1	AL390877.1	-6.22	2.02e-09	0.00469	-0.42	-0.36	Immature fraction of reticulocytes;	chr1:23787639	chr1:117778087~117778506:-
COAD	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	6.22	2.03e-09	0.00471	0.46	0.36	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
COAD	trans	rs74781061	0.929	rs11072490	ENSG00000227288.3	RP5-837I24.1	6.22	2.04e-09	0.00472	0.54	0.36	Endometriosis;	chr15:74515169	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs1821847	ENSG00000227288.3	RP5-837I24.1	6.22	2.04e-09	0.00472	0.54	0.36	Endometriosis;	chr15:74516873	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs78796673	ENSG00000227288.3	RP5-837I24.1	6.22	2.04e-09	0.00472	0.54	0.36	Endometriosis;	chr15:74520186	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs4261483	ENSG00000227288.3	RP5-837I24.1	6.22	2.04e-09	0.00472	0.54	0.36	Endometriosis;	chr15:74520993	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8041030	ENSG00000227288.3	RP5-837I24.1	6.22	2.04e-09	0.00472	0.54	0.36	Endometriosis;	chr15:74525726	chr1:81501794~81503468:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	6.22	2.06e-09	0.00477	0.42	0.36	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
COAD	trans	rs7113874	0.659	rs12574009	ENSG00000266891.1	RP11-692N5.2	6.22	2.06e-09	0.00477	0.48	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498406	chr18:9734882~9735602:-
COAD	trans	rs10037055	0.853	rs10036193	ENSG00000226986.4	RP11-543B16.2	-6.22	2.06e-09	0.00477	-0.39	-0.36	Migraine without aura;	chr5:177141519	chr1:211207239~211207897:+
COAD	trans	rs74781061	0.86	rs6495101	ENSG00000227288.3	RP5-837I24.1	6.21	2.07e-09	0.0048	0.51	0.36	Endometriosis;	chr15:74450411	chr1:81501794~81503468:+
COAD	trans	rs1039766	0.925	rs268850	ENSG00000224334.1	AP000357.4	6.21	2.07e-09	0.0048	0.54	0.36	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr22:24686923~24688087:+
COAD	trans	rs993648	1	rs993648	ENSG00000239830.1	RPS4XP22	6.21	2.08e-09	0.00483	0.43	0.36	Response to iloperidone treatment (QT prolongation);	chr2:181591267	chr19:9683294~9684073:-
COAD	trans	rs6732160	0.588	rs62151795	ENSG00000236165.1	PRADC1P1	6.21	2.1e-09	0.00486	0.47	0.36	Intelligence (multi-trait analysis);	chr2:73149712	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.863	rs12498539	ENSG00000276997.3	RP11-378J18.9	6.21	2.1e-09	0.00487	0.42	0.36	Corneal astigmatism;	chr4:119547215	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs3822194	ENSG00000276997.3	RP11-378J18.9	6.21	2.1e-09	0.00487	0.42	0.36	Corneal astigmatism;	chr4:119550493	chr1:222477252~222504622:-
COAD	trans	rs74781061	0.929	rs4324083	ENSG00000227288.3	RP5-837I24.1	6.21	2.12e-09	0.0049	0.51	0.36	Endometriosis;	chr15:74479139	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs117379081	ENSG00000227288.3	RP5-837I24.1	6.21	2.12e-09	0.0049	0.51	0.36	Endometriosis;	chr15:74480106	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs79600239	ENSG00000227288.3	RP5-837I24.1	6.21	2.12e-09	0.0049	0.51	0.36	Endometriosis;	chr15:74481987	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs16969247	ENSG00000227288.3	RP5-837I24.1	6.21	2.12e-09	0.0049	0.51	0.36	Endometriosis;	chr15:74486541	chr1:81501794~81503468:+
COAD	trans	rs11098499	0.754	rs66900435	ENSG00000276997.3	RP11-378J18.9	6.21	2.13e-09	0.00492	0.42	0.36	Corneal astigmatism;	chr4:119328270	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs17595608	ENSG00000276997.3	RP11-378J18.9	6.21	2.13e-09	0.00492	0.42	0.36	Corneal astigmatism;	chr4:119329351	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs1980027	ENSG00000276997.3	RP11-378J18.9	6.21	2.13e-09	0.00492	0.42	0.36	Corneal astigmatism;	chr4:119330422	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10017371	ENSG00000276997.3	RP11-378J18.9	6.21	2.14e-09	0.00496	0.43	0.36	Corneal astigmatism;	chr4:119372621	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.905	rs4433149	ENSG00000173295.6	FAM86B3P	-6.21	2.15e-09	0.00497	-0.42	-0.36	Neuroticism;	chr8:10391758	chr8:8228595~8244865:+
COAD	trans	rs673253	0.556	rs11577403	ENSG00000231007.5	CDC20P1	6.21	2.16e-09	0.00499	0.49	0.36	Intelligence (multi-trait analysis);	chr1:43524102	chr9:87011652~87013151:+
COAD	trans	rs7824557	0.872	rs2572431	ENSG00000253981.4	ALG1L13P	-6.21	2.17e-09	0.00502	-0.44	-0.36	Retinal vascular caliber;	chr8:11247568	chr8:8236003~8244667:-
COAD	trans	rs6424115	1	rs34477640	ENSG00000228217.1	AL390877.1	6.21	2.17e-09	0.00503	0.43	0.36	Immature fraction of reticulocytes;	chr1:23827577	chr1:117778087~117778506:-
COAD	trans	rs6424115	1	rs7519554	ENSG00000228217.1	AL390877.1	6.21	2.17e-09	0.00503	0.43	0.36	Immature fraction of reticulocytes;	chr1:23828076	chr1:117778087~117778506:-
COAD	trans	rs3740713	0.669	rs2896526	ENSG00000236090.2	LDHAP3	6.21	2.17e-09	0.00503	0.62	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:41819747~41820754:+
COAD	trans	rs10242455	0.867	rs10282706	ENSG00000228834.1	RP11-249L21.4	6.21	2.18e-09	0.00503	0.52	0.36	Blood metabolite levels;	chr7:99619801	chr6:108907615~108907873:-
COAD	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	6.2	2.19e-09	0.00506	0.38	0.36	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.738	rs34965784	ENSG00000276997.3	RP11-378J18.9	6.2	2.21e-09	0.00512	0.43	0.36	Corneal astigmatism;	chr4:119440431	chr1:222477252~222504622:-
COAD	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-6.2	2.23e-09	0.00516	-0.42	-0.36	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
COAD	trans	rs11098499	0.866	rs6847778	ENSG00000276997.3	RP11-378J18.9	6.2	2.24e-09	0.00518	0.42	0.36	Corneal astigmatism;	chr4:119372427	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs56270433	ENSG00000276997.3	RP11-378J18.9	6.2	2.26e-09	0.00521	0.42	0.36	Corneal astigmatism;	chr4:119484875	chr1:222477252~222504622:-
COAD	trans	rs1424638	0.584	rs11899819	ENSG00000241651.4	RP11-214O14.1	6.2	2.29e-09	0.00528	0.4	0.36	Intelligence (multi-trait analysis);	chr2:57002216	chr4:128069014~128069612:-
COAD	trans	rs7192380	0.639	rs7186296	ENSG00000257513.6	NPIPB1P	-6.2	2.3e-09	0.00531	-0.41	-0.36	Sjögren's syndrome;	chr16:69775095	chr18:11619509~11639699:-
COAD	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-6.19	2.31e-09	0.00532	-0.46	-0.36	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
COAD	trans	rs10242455	0.867	rs45624139	ENSG00000228834.1	RP11-249L21.4	6.19	2.31e-09	0.00533	0.59	0.36	Blood metabolite levels;	chr7:99721872	chr6:108907615~108907873:-
COAD	trans	rs2899832	0.568	rs17597267	ENSG00000229083.1	PSMA6P2	6.19	2.33e-09	0.00536	0.56	0.36	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312698	chrX:12825840~12826833:+
COAD	trans	rs2899832	0.568	rs10467708	ENSG00000229083.1	PSMA6P2	6.19	2.33e-09	0.00536	0.56	0.36	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35317808	chrX:12825840~12826833:+
COAD	trans	rs11098499	0.909	rs71614422	ENSG00000276997.3	RP11-378J18.9	6.19	2.33e-09	0.00537	0.43	0.36	Corneal astigmatism;	chr4:119438185	chr1:222477252~222504622:-
COAD	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-6.19	2.33e-09	0.00538	-0.46	-0.36	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-6.19	2.33e-09	0.00538	-0.46	-0.36	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.73	rs78971550	ENSG00000276997.3	RP11-378J18.9	6.19	2.35e-09	0.00542	0.43	0.36	Corneal astigmatism;	chr4:119359886	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.645	rs78422072	ENSG00000276997.3	RP11-378J18.9	6.19	2.35e-09	0.00542	0.43	0.36	Corneal astigmatism;	chr4:119359887	chr1:222477252~222504622:-
COAD	trans	rs9425766	0.64	rs1322774	ENSG00000213331.4	RP11-713C19.2	6.19	2.35e-09	0.00542	0.47	0.36	Life satisfaction;	chr1:173870102	chr4:187970273~187971284:+
COAD	trans	rs3806843	0.9	rs2337984	ENSG00000231043.3	AC007238.1	6.19	2.36e-09	0.00544	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.954	rs10518328	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.42	0.36	Corneal astigmatism;	chr4:119480624	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs10518331	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119402440	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs13133522	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119403269	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs35091806	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119404374	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs2389802	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119404577	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs6846442	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119405168	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.738	rs34566984	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119440115	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs17009122	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119441248	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.505	rs75122014	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119441271	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs9685777	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119444810	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs71614438	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119450097	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs66506550	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119450290	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs7659501	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119450397	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs28655325	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119451844	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs28495013	ENSG00000276997.3	RP11-378J18.9	6.19	2.39e-09	0.00549	0.43	0.36	Corneal astigmatism;	chr4:119454676	chr1:222477252~222504622:-
COAD	trans	rs7824557	0.872	rs2572417	ENSG00000253981.4	ALG1L13P	-6.19	2.4e-09	0.00552	-0.44	-0.36	Retinal vascular caliber;	chr8:11253953	chr8:8236003~8244667:-
COAD	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	6.19	2.43e-09	0.00557	0.5	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
COAD	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	6.19	2.43e-09	0.00557	0.46	0.36	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
COAD	trans	rs1816752	1	rs9507341	ENSG00000224976.2	PARP4P2	6.18	2.44e-09	0.00559	0.4	0.36	Obesity-related traits;	chr13:24432440	chr13:19349137~19407962:+
COAD	trans	rs11098499	0.657	rs10434028	ENSG00000276997.3	RP11-378J18.9	6.18	2.45e-09	0.00562	0.42	0.36	Corneal astigmatism;	chr4:119373309	chr1:222477252~222504622:-
COAD	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	6.18	2.46e-09	0.00564	0.45	0.36	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
COAD	trans	rs9425766	0.64	rs2208850	ENSG00000213331.4	RP11-713C19.2	6.18	2.46e-09	0.00564	0.47	0.36	Life satisfaction;	chr1:173862569	chr4:187970273~187971284:+
COAD	trans	rs9425766	0.678	rs1951625	ENSG00000213331.4	RP11-713C19.2	6.18	2.46e-09	0.00564	0.47	0.36	Life satisfaction;	chr1:173867464	chr4:187970273~187971284:+
COAD	trans	rs10037055	0.741	rs4976640	ENSG00000226986.4	RP11-543B16.2	-6.18	2.48e-09	0.00568	-0.39	-0.36	Migraine without aura;	chr5:177125006	chr1:211207239~211207897:+
COAD	trans	rs1190596	0.525	rs72698572	ENSG00000181359.5	HSP90AA6P	-6.18	2.49e-09	0.00569	-0.44	-0.36	Behavioural disinhibition (generation interaction);	chr14:102289870	chr4:170581470~170605450:-
COAD	trans	rs1190596	0.525	rs8010950	ENSG00000181359.5	HSP90AA6P	-6.18	2.49e-09	0.00569	-0.44	-0.36	Behavioural disinhibition (generation interaction);	chr14:102291520	chr4:170581470~170605450:-
COAD	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	6.18	2.49e-09	0.0057	0.44	0.36	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	6.18	2.49e-09	0.0057	0.44	0.36	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
COAD	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	6.18	2.49e-09	0.0057	0.44	0.36	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
COAD	trans	rs7226408	0.532	rs323299	ENSG00000268355.1	AC006129.1	-6.18	2.49e-09	0.0057	-0.43	-0.36	Obesity-related traits;	chr18:37088184	chr19:41531206~41532174:+
COAD	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	6.18	2.49e-09	0.00571	0.45	0.36	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.691	rs12510133	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350189	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs12506487	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350206	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.691	rs12502524	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350259	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.691	rs28396837	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350386	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.629	rs28369518	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350475	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.722	rs10025925	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350589	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.731	rs10015579	ENSG00000276997.3	RP11-378J18.9	6.18	2.5e-09	0.00572	0.41	0.36	Corneal astigmatism;	chr4:119350647	chr1:222477252~222504622:-
COAD	trans	rs74781061	0.929	rs79600165	ENSG00000227288.3	RP5-837I24.1	6.18	2.5e-09	0.00573	0.51	0.36	Endometriosis;	chr15:74648650	chr1:81501794~81503468:+
COAD	trans	rs12709013	0.74	rs12927495	ENSG00000233719.3	GOT2P3	6.18	2.51e-09	0.00575	0.45	0.36	Blood metabolite ratios;	chr16:58821934	chr12:9641802~9643007:+
COAD	trans	rs963265	1	rs11142432	ENSG00000224956.5	RP11-206L10.1	6.18	2.54e-09	0.00581	0.38	0.36	Migraine with aura;	chr9:70438478	chr1:726231~728147:-
COAD	trans	rs7113874	0.659	rs12295855	ENSG00000266891.1	RP11-692N5.2	6.18	2.55e-09	0.00582	0.48	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505871	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.779	rs10857066	ENSG00000276997.3	RP11-378J18.9	6.18	2.55e-09	0.00583	0.42	0.36	Corneal astigmatism;	chr4:119365441	chr1:222477252~222504622:-
COAD	trans	rs6424115	1	rs6424115	ENSG00000228217.1	AL390877.1	6.18	2.56e-09	0.00586	0.43	0.36	Immature fraction of reticulocytes;	chr1:23826741	chr1:117778087~117778506:-
COAD	trans	rs9611519	1	rs2273085	ENSG00000268568.1	AC007228.9	-6.17	2.58e-09	0.00589	-0.44	-0.36	Neuroticism;	chr22:41219372	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.779	rs80242894	ENSG00000276997.3	RP11-378J18.9	6.17	2.58e-09	0.0059	0.43	0.36	Corneal astigmatism;	chr4:119454597	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs9759478	ENSG00000276997.3	RP11-378J18.9	6.17	2.61e-09	0.00595	0.43	0.36	Corneal astigmatism;	chr4:119446843	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs9999724	ENSG00000276997.3	RP11-378J18.9	6.17	2.62e-09	0.00597	0.41	0.36	Corneal astigmatism;	chr4:119318789	chr1:222477252~222504622:-
COAD	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	6.17	2.63e-09	0.00599	0.44	0.36	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
COAD	trans	rs2899832	0.568	rs7158019	ENSG00000229083.1	PSMA6P2	6.17	2.64e-09	0.00601	0.57	0.36	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35305912	chrX:12825840~12826833:+
COAD	trans	rs66887589	0.967	rs56173225	ENSG00000275858.1	RP11-291L22.8	-6.17	2.64e-09	0.00601	-0.36	-0.36	Diastolic blood pressure;	chr4:119588817	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.967	rs7678973	ENSG00000275858.1	RP11-291L22.8	-6.17	2.64e-09	0.00601	-0.36	-0.36	Diastolic blood pressure;	chr4:119590662	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.934	rs56843000	ENSG00000275858.1	RP11-291L22.8	-6.17	2.64e-09	0.00601	-0.36	-0.36	Diastolic blood pressure;	chr4:119595442	chr10:38450738~38451069:-
COAD	trans	rs74781061	0.858	rs79923136	ENSG00000227288.3	RP5-837I24.1	6.17	2.66e-09	0.00606	0.53	0.36	Endometriosis;	chr15:74492219	chr1:81501794~81503468:+
COAD	trans	rs7824557	0.767	rs3808513	ENSG00000173295.6	FAM86B3P	-6.17	2.66e-09	0.00606	-0.45	-0.36	Retinal vascular caliber;	chr8:11299951	chr8:8228595~8244865:+
COAD	trans	rs963265	1	rs11142440	ENSG00000224956.5	RP11-206L10.1	6.17	2.67e-09	0.00608	0.38	0.36	Migraine with aura;	chr9:70448035	chr1:726231~728147:-
COAD	trans	rs10817611	0.513	rs10817618	ENSG00000271138.1	IGLVIVOR22-1	6.17	2.67e-09	0.00608	0.42	0.36	Survival in pancreatic cancer;	chr9:114469133	chr22:25437306~25437823:-
COAD	trans	rs4276421	0.509	rs10042628	ENSG00000231752.4	EMBP1	6.17	2.67e-09	0.00608	0.45	0.36	P wave duration;	chr5:46004627	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs6822679	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119481547	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs4577559	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119482888	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs7656252	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119483113	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs28845498	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119484031	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs28753180	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119484212	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs7681544	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119490100	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs11940028	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119490752	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs11935596	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119491302	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs12507964	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119491906	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs11098530	ENSG00000276997.3	RP11-378J18.9	6.17	2.68e-09	0.00609	0.42	0.36	Corneal astigmatism;	chr4:119491999	chr1:222477252~222504622:-
COAD	trans	rs10037055	0.853	rs9885210	ENSG00000226986.4	RP11-543B16.2	-6.17	2.71e-09	0.00616	-0.38	-0.36	Migraine without aura;	chr5:177142187	chr1:211207239~211207897:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	6.16	2.72e-09	0.00618	0.45	0.36	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
COAD	trans	rs11098499	0.535	rs7671759	ENSG00000276997.3	RP11-378J18.9	6.16	2.74e-09	0.00623	0.42	0.36	Corneal astigmatism;	chr4:119326939	chr1:222477252~222504622:-
COAD	trans	rs73110464	0.505	rs2638503	ENSG00000254285.3	KRT8P3	-6.16	2.75e-09	0.00624	-0.44	-0.36	Cancer (pleiotropy);	chr12:52913585	chr8:61578220~61579668:+
COAD	trans	rs6424115	0.965	rs2502979	ENSG00000228217.1	AL390877.1	-6.16	2.78e-09	0.0063	-0.43	-0.36	Immature fraction of reticulocytes;	chr1:23822825	chr1:117778087~117778506:-
COAD	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	6.16	2.79e-09	0.00632	0.46	0.36	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
COAD	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	6.16	2.8e-09	0.00635	0.38	0.36	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
COAD	trans	rs6732160	0.588	rs2043101	ENSG00000236165.1	PRADC1P1	6.16	2.8e-09	0.00635	0.46	0.36	Intelligence (multi-trait analysis);	chr2:73146922	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.657	rs71614442	ENSG00000276997.3	RP11-378J18.9	6.16	2.8e-09	0.00635	0.42	0.36	Corneal astigmatism;	chr4:119458191	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs2892848	ENSG00000276997.3	RP11-378J18.9	6.16	2.8e-09	0.00635	0.42	0.36	Corneal astigmatism;	chr4:119460186	chr1:222477252~222504622:-
COAD	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-6.16	2.84e-09	0.00643	-0.35	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
COAD	trans	rs74781061	0.929	rs6495118	ENSG00000227288.3	RP5-837I24.1	6.16	2.84e-09	0.00644	0.51	0.36	Endometriosis;	chr15:74619671	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.736	rs12548025	ENSG00000173295.6	FAM86B3P	6.16	2.85e-09	0.00645	0.44	0.36	Neuroticism;	chr8:10403411	chr8:8228595~8244865:+
COAD	trans	rs9329221	0.617	rs483916	ENSG00000253981.4	ALG1L13P	-6.16	2.85e-09	0.00646	-0.42	-0.36	Neuroticism;	chr8:9936091	chr8:8236003~8244667:-
COAD	trans	rs12709013	0.967	rs2118019	ENSG00000233719.3	GOT2P3	-6.16	2.86e-09	0.00647	-0.45	-0.36	Blood metabolite ratios;	chr16:58797825	chr12:9641802~9643007:+
COAD	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-6.16	2.87e-09	0.00649	-0.42	-0.36	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
COAD	trans	rs1816752	0.935	rs4770676	ENSG00000224976.2	PARP4P2	-6.15	2.88e-09	0.00653	-0.41	-0.36	Obesity-related traits;	chr13:24429745	chr13:19349137~19407962:+
COAD	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-6.15	2.89e-09	0.00654	-0.47	-0.36	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
COAD	trans	rs74781061	0.789	rs1078011	ENSG00000227288.3	RP5-837I24.1	6.15	2.89e-09	0.00655	0.52	0.36	Endometriosis;	chr15:74442521	chr1:81501794~81503468:+
COAD	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	6.15	2.95e-09	0.00666	0.44	0.36	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
COAD	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	6.15	2.96e-09	0.00669	0.44	0.36	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
COAD	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-6.15	2.97e-09	0.00671	-0.37	-0.36	Longevity;	chr3:48372725	chr1:27649419~27649610:+
COAD	trans	rs11098499	0.954	rs67265404	ENSG00000276997.3	RP11-378J18.9	6.15	2.97e-09	0.00672	0.43	0.36	Corneal astigmatism;	chr4:119438115	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.82	rs28578366	ENSG00000276997.3	RP11-378J18.9	-6.15	2.97e-09	0.00672	-0.43	-0.36	Corneal astigmatism;	chr4:119615750	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	6.15	2.98e-09	0.00673	0.42	0.36	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.736	rs2001338	ENSG00000173295.6	FAM86B3P	6.15	2.98e-09	0.00673	0.43	0.36	Neuroticism;	chr8:10393707	chr8:8228595~8244865:+
COAD	trans	rs6424115	0.965	rs2502986	ENSG00000228217.1	AL390877.1	-6.15	2.99e-09	0.00674	-0.41	-0.36	Immature fraction of reticulocytes;	chr1:23808802	chr1:117778087~117778506:-
COAD	trans	rs11098499	0.954	rs12508504	ENSG00000276997.3	RP11-378J18.9	6.15	3e-09	0.00677	0.41	0.36	Corneal astigmatism;	chr4:119489452	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-6.15	3.02e-09	0.00681	-0.36	-0.36	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
COAD	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-6.15	3.02e-09	0.00681	-0.44	-0.36	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
COAD	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	6.15	3.02e-09	0.00681	0.41	0.36	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
COAD	trans	rs74781061	0.86	rs4887147	ENSG00000227288.3	RP5-837I24.1	6.14	3.04e-09	0.00685	0.52	0.36	Endometriosis;	chr15:74443863	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs4887149	ENSG00000227288.3	RP5-837I24.1	6.14	3.04e-09	0.00685	0.52	0.36	Endometriosis;	chr15:74444108	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs4887151	ENSG00000227288.3	RP5-837I24.1	6.14	3.04e-09	0.00685	0.52	0.36	Endometriosis;	chr15:74445126	chr1:81501794~81503468:+
COAD	trans	rs10882165	0.729	rs11187317	ENSG00000273138.1	GS1-293C5.1	-6.14	3.07e-09	0.00691	-0.35	-0.36	Refractive error;	chr10:93189800	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs4144917	ENSG00000273138.1	GS1-293C5.1	-6.14	3.07e-09	0.00691	-0.35	-0.36	Refractive error;	chr10:93189920	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs10882175	ENSG00000273138.1	GS1-293C5.1	-6.14	3.07e-09	0.00691	-0.35	-0.36	Refractive error;	chr10:93191559	chr7:95416108~95416462:+
COAD	trans	rs2950393	0.804	rs2958127	ENSG00000228224.3	NACAP1	6.14	3.08e-09	0.00693	0.35	0.36	Platelet distribution width;	chr12:56720523	chr8:101361794~101372707:+
COAD	trans	rs11098499	0.954	rs9993199	ENSG00000276997.3	RP11-378J18.9	-6.14	3.08e-09	0.00694	-0.41	-0.36	Corneal astigmatism;	chr4:119471718	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.801	rs2531358	ENSG00000231043.3	AC007238.1	6.14	3.09e-09	0.00697	0.37	0.36	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr2:58460292~58462032:-
COAD	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	6.14	3.1e-09	0.00699	0.37	0.36	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.908	rs7695996	ENSG00000276997.3	RP11-378J18.9	6.14	3.1e-09	0.00699	0.43	0.36	Corneal astigmatism;	chr4:119400878	chr1:222477252~222504622:-
COAD	trans	rs74781061	0.929	rs6495109	ENSG00000227288.3	RP5-837I24.1	6.14	3.13e-09	0.00703	0.54	0.36	Endometriosis;	chr15:74504720	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8037436	ENSG00000227288.3	RP5-837I24.1	6.14	3.13e-09	0.00703	0.54	0.36	Endometriosis;	chr15:74506167	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs4887155	ENSG00000227288.3	RP5-837I24.1	6.14	3.13e-09	0.00703	0.54	0.36	Endometriosis;	chr15:74512119	chr1:81501794~81503468:+
COAD	trans	rs11098499	0.954	rs28572238	ENSG00000276997.3	RP11-378J18.9	6.14	3.16e-09	0.00711	0.42	0.36	Corneal astigmatism;	chr4:119395531	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs28714195	ENSG00000276997.3	RP11-378J18.9	6.14	3.16e-09	0.00711	0.42	0.36	Corneal astigmatism;	chr4:119395795	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.775	rs10021601	ENSG00000276997.3	RP11-378J18.9	6.14	3.19e-09	0.00717	0.42	0.36	Corneal astigmatism;	chr4:119361408	chr1:222477252~222504622:-
COAD	trans	rs7824557	0.707	rs3808519	ENSG00000173295.6	FAM86B3P	6.14	3.2e-09	0.00718	0.44	0.36	Retinal vascular caliber;	chr8:11285461	chr8:8228595~8244865:+
COAD	trans	rs864643	0.513	rs1398666	ENSG00000183298.5	RP11-556K13.1	6.14	3.2e-09	0.00718	0.48	0.36	Attention deficit hyperactivity disorder;	chr3:39475540	chr1:101786340~101787219:-
COAD	trans	rs864643	0.513	rs1768202	ENSG00000183298.5	RP11-556K13.1	6.14	3.2e-09	0.00718	0.48	0.36	Attention deficit hyperactivity disorder;	chr3:39476053	chr1:101786340~101787219:-
COAD	trans	rs3806843	0.735	rs801168	ENSG00000231043.3	AC007238.1	6.13	3.24e-09	0.00727	0.36	0.36	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.735	rs2563314	ENSG00000231043.3	AC007238.1	6.13	3.26e-09	0.00731	0.36	0.36	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr2:58460292~58462032:-
COAD	trans	rs4883201	0.611	rs1805754	ENSG00000179899.8	PHC1P1	6.13	3.27e-09	0.00734	0.46	0.36	Total cholesterol levels;Cholesterol, total;	chr12:8950652	chr12:55411727~55414787:-
COAD	trans	rs7113874	0.612	rs11517715	ENSG00000266891.1	RP11-692N5.2	6.13	3.27e-09	0.00734	0.47	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8490341	chr18:9734882~9735602:-
COAD	trans	rs11098499	0.954	rs12510138	ENSG00000276997.3	RP11-378J18.9	6.13	3.28e-09	0.00735	0.42	0.36	Corneal astigmatism;	chr4:119502780	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs11098513	ENSG00000276997.3	RP11-378J18.9	6.13	3.28e-09	0.00735	0.42	0.36	Corneal astigmatism;	chr4:119394920	chr1:222477252~222504622:-
COAD	trans	rs1039766	1	rs1039766	ENSG00000224334.1	AP000357.4	-6.13	3.28e-09	0.00736	-0.53	-0.36	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr22:24686923~24688087:+
COAD	trans	rs1039766	1	rs72822431	ENSG00000224334.1	AP000357.4	-6.13	3.28e-09	0.00736	-0.53	-0.36	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr22:24686923~24688087:+
COAD	trans	rs1190596	0.525	rs35350456	ENSG00000181359.5	HSP90AA6P	-6.13	3.3e-09	0.00739	-0.43	-0.36	Behavioural disinhibition (generation interaction);	chr14:102238414	chr4:170581470~170605450:-
COAD	trans	rs6732160	0.588	rs3891890	ENSG00000236165.1	PRADC1P1	6.13	3.3e-09	0.0074	0.46	0.36	Intelligence (multi-trait analysis);	chr2:73150921	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.754	rs714899	ENSG00000276997.3	RP11-378J18.9	6.13	3.3e-09	0.00741	0.41	0.36	Corneal astigmatism;	chr4:119321880	chr1:222477252~222504622:-
COAD	trans	rs6424115	1	rs58035855	ENSG00000228217.1	AL390877.1	6.13	3.31e-09	0.00741	0.44	0.36	Immature fraction of reticulocytes;	chr1:23838758	chr1:117778087~117778506:-
COAD	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	6.13	3.33e-09	0.00746	0.28	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	6.13	3.33e-09	0.00746	0.28	0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
COAD	trans	rs4740619	0.81	rs6474952	ENSG00000244021.4	RP11-50D9.1	6.13	3.35e-09	0.00749	0.32	0.36	Body mass index;	chr9:15711236	chr4:127812720~127813200:-
COAD	trans	rs11098499	0.954	rs3890049	ENSG00000276997.3	RP11-378J18.9	6.13	3.37e-09	0.00754	0.43	0.36	Corneal astigmatism;	chr4:119405128	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs71629403	ENSG00000276997.3	RP11-378J18.9	6.13	3.37e-09	0.00754	0.43	0.36	Corneal astigmatism;	chr4:119451412	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs28571712	ENSG00000276997.3	RP11-378J18.9	6.13	3.37e-09	0.00754	0.43	0.36	Corneal astigmatism;	chr4:119454825	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.615	rs60927048	ENSG00000231752.4	EMBP1	6.13	3.38e-09	0.00756	0.47	0.36	P wave duration;	chr5:45854618	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.863	rs58452170	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119538519	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs7678400	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119540802	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs1480936	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119541706	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs11098531	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119543846	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs28718422	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119545149	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.818	rs12498599	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119547348	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs10009626	ENSG00000276997.3	RP11-378J18.9	6.12	3.39e-09	0.00758	0.41	0.36	Corneal astigmatism;	chr4:119548850	chr1:222477252~222504622:-
COAD	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-6.12	3.4e-09	0.00759	-0.6	-0.36	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
COAD	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	6.12	3.41e-09	0.00761	0.44	0.36	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
COAD	trans	rs74781061	0.929	rs9672559	ENSG00000227288.3	RP5-837I24.1	6.12	3.41e-09	0.00762	0.51	0.36	Endometriosis;	chr15:74698995	chr1:81501794~81503468:+
COAD	trans	rs10882165	0.756	rs7914785	ENSG00000273138.1	GS1-293C5.1	-6.12	3.41e-09	0.00762	-0.34	-0.36	Refractive error;	chr10:93193939	chr7:95416108~95416462:+
COAD	trans	rs3806843	1	rs10072015	ENSG00000231043.3	AC007238.1	6.12	3.42e-09	0.00764	0.36	0.36	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr2:58460292~58462032:-
COAD	trans	rs4276421	0.571	rs6414908	ENSG00000231752.4	EMBP1	6.12	3.42e-09	0.00764	0.44	0.36	P wave duration;	chr5:45879332	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	6.12	3.42e-09	0.00764	0.42	0.36	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
COAD	trans	rs74781061	0.929	rs7173006	ENSG00000227288.3	RP5-837I24.1	6.12	3.49e-09	0.00778	0.53	0.36	Endometriosis;	chr15:74517792	chr1:81501794~81503468:+
COAD	trans	rs7824557	0.933	rs6601576	ENSG00000253981.4	ALG1L13P	-6.12	3.49e-09	0.00779	-0.47	-0.36	Retinal vascular caliber;	chr8:11242766	chr8:8236003~8244667:-
COAD	trans	rs9329221	0.71	rs11785061	ENSG00000173295.6	FAM86B3P	6.12	3.5e-09	0.0078	0.43	0.36	Neuroticism;	chr8:10402018	chr8:8228595~8244865:+
COAD	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	6.12	3.51e-09	0.00784	0.37	0.36	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
COAD	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	6.12	3.55e-09	0.0079	0.41	0.36	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
COAD	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	6.12	3.55e-09	0.0079	0.41	0.36	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
COAD	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	6.12	3.55e-09	0.0079	0.41	0.36	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
COAD	trans	rs3806843	0.735	rs801189	ENSG00000231043.3	AC007238.1	6.12	3.56e-09	0.00794	0.36	0.36	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr2:58460292~58462032:-
COAD	trans	rs9329221	0.537	rs1351876	ENSG00000173295.6	FAM86B3P	-6.11	3.59e-09	0.008	-0.42	-0.36	Neuroticism;	chr8:10127267	chr8:8228595~8244865:+
COAD	trans	rs854572	0.87	rs757158	ENSG00000239830.1	RPS4XP22	-6.11	3.6e-09	0.00802	-0.43	-0.36	Paraoxonase activity;	chr7:95326216	chr19:9683294~9684073:-
COAD	trans	rs7824557	0.767	rs10104728	ENSG00000253981.4	ALG1L13P	6.11	3.6e-09	0.00802	0.48	0.36	Retinal vascular caliber;	chr8:11313791	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.908	rs7696649	ENSG00000276997.3	RP11-378J18.9	6.11	3.6e-09	0.00802	0.43	0.36	Corneal astigmatism;	chr4:119401022	chr1:222477252~222504622:-
COAD	trans	rs7552404	1	rs28602663	ENSG00000277299.1	RP11-837J7.4	-6.11	3.61e-09	0.00802	-0.44	-0.36	Acylcarnitine levels;Blood metabolite levels;	chr1:75769670	chr12:109948389~109949029:+
COAD	trans	rs7552404	1	rs9662166	ENSG00000277299.1	RP11-837J7.4	-6.11	3.61e-09	0.00802	-0.44	-0.36	Acylcarnitine levels;Blood metabolite levels;	chr1:75770221	chr12:109948389~109949029:+
COAD	trans	rs12709013	0.792	rs12325054	ENSG00000233719.3	GOT2P3	6.11	3.61e-09	0.00803	0.47	0.36	Blood metabolite ratios;	chr16:58749804	chr12:9641802~9643007:+
COAD	trans	rs10242455	0.867	rs2740560	ENSG00000228834.1	RP11-249L21.4	-6.11	3.62e-09	0.00805	-0.51	-0.36	Blood metabolite levels;	chr7:99724697	chr6:108907615~108907873:-
COAD	trans	rs10242455	0.681	rs2687140	ENSG00000228834.1	RP11-249L21.4	-6.11	3.62e-09	0.00805	-0.51	-0.36	Blood metabolite levels;	chr7:99724719	chr6:108907615~108907873:-
COAD	trans	rs12614435	0.512	rs12693162	ENSG00000269800.1	PLEKHA3P1	6.11	3.63e-09	0.00806	0.44	0.36	Atrial fibrillation;	chr2:178623467	chr19:41521043~41521989:-
COAD	trans	rs10037055	0.898	rs4976636	ENSG00000226986.4	RP11-543B16.2	-6.11	3.66e-09	0.00813	-0.39	-0.36	Migraine without aura;	chr5:177118091	chr1:211207239~211207897:+
COAD	trans	rs10037055	0.898	rs4976637	ENSG00000226986.4	RP11-543B16.2	-6.11	3.66e-09	0.00813	-0.39	-0.36	Migraine without aura;	chr5:177118141	chr1:211207239~211207897:+
COAD	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	6.11	3.68e-09	0.00819	0.45	0.36	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
COAD	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	6.11	3.7e-09	0.00822	0.41	0.36	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
COAD	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	6.11	3.7e-09	0.00822	0.37	0.36	Longevity;	chr3:48453142	chr1:27649419~27649610:+
COAD	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	6.1	3.78e-09	0.00839	0.37	0.36	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
COAD	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-6.1	3.79e-09	0.0084	-0.46	-0.36	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-6.1	3.79e-09	0.0084	-0.46	-0.36	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
COAD	trans	rs11098499	0.697	rs11941899	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119461603	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs7681978	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119462620	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.821	rs28665282	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119463031	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.738	rs10026493	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119463039	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs7681214	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119464165	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs28559989	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119465472	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs28632018	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119465575	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs71614449	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119465900	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs35063680	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119465947	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs34858317	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119465955	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs17046116	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119466104	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs17046118	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119466341	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs7654587	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.0085	0.42	0.36	Corneal astigmatism;	chr4:119467251	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs9997631	ENSG00000276997.3	RP11-378J18.9	6.1	3.84e-09	0.00851	0.41	0.36	Corneal astigmatism;	chr4:119548840	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs4451093	ENSG00000231043.3	AC007238.1	6.1	3.85e-09	0.00852	0.36	0.36	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr2:58460292~58462032:-
COAD	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	6.1	3.85e-09	0.00852	0.36	0.36	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
COAD	trans	rs2898290	0.592	rs2736342	ENSG00000253981.4	ALG1L13P	-6.1	3.85e-09	0.00853	-0.41	-0.36	Systolic blood pressure;	chr8:11489780	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.58	rs12509234	ENSG00000276997.3	RP11-378J18.9	6.1	3.86e-09	0.00855	0.42	0.36	Corneal astigmatism;	chr4:119398279	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs9994730	ENSG00000276997.3	RP11-378J18.9	6.1	3.87e-09	0.00857	0.42	0.36	Corneal astigmatism;	chr4:119460409	chr1:222477252~222504622:-
COAD	trans	rs7937890	0.732	rs7946902	ENSG00000236360.2	RP11-334A14.2	-6.1	3.9e-09	0.00863	-0.48	-0.36	Mitochondrial DNA levels;	chr11:14251762	chr1:52993201~52993702:-
COAD	trans	rs9329221	0.527	rs10903328	ENSG00000173295.6	FAM86B3P	6.1	3.93e-09	0.00868	0.43	0.36	Neuroticism;	chr8:10474657	chr8:8228595~8244865:+
COAD	trans	rs963265	1	rs11142427	ENSG00000224956.5	RP11-206L10.1	6.1	3.93e-09	0.0087	0.38	0.36	Migraine with aura;	chr9:70436198	chr1:726231~728147:-
COAD	trans	rs864643	0.524	rs9822783	ENSG00000188856.6	RPSAP47	6.1	3.94e-09	0.00872	0.45	0.36	Attention deficit hyperactivity disorder;	chr3:39463311	chr8:80558870~80559757:+
COAD	trans	rs4883201	0.572	rs987917	ENSG00000179899.8	PHC1P1	6.1	3.97e-09	0.00878	0.46	0.36	Total cholesterol levels;Cholesterol, total;	chr12:8949979	chr12:55411727~55414787:-
COAD	trans	rs1190596	0.578	rs12887161	ENSG00000181359.5	HSP90AA6P	-6.09	3.99e-09	0.00881	-0.42	-0.36	Behavioural disinhibition (generation interaction);	chr14:102240581	chr4:170581470~170605450:-
COAD	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	6.09	4e-09	0.00883	0.36	0.36	Longevity;	chr3:48375266	chr1:27649419~27649610:+
COAD	trans	rs4740619	0.776	rs10962121	ENSG00000244021.4	RP11-50D9.1	-6.09	4e-09	0.00884	-0.32	-0.36	Body mass index;	chr9:15702706	chr4:127812720~127813200:-
COAD	trans	rs6424115	0.931	rs2982390	ENSG00000228217.1	AL390877.1	-6.09	4.01e-09	0.00886	-0.43	-0.36	Immature fraction of reticulocytes;	chr1:23821340	chr1:117778087~117778506:-
COAD	trans	rs6732160	0.564	rs2043096	ENSG00000236165.1	PRADC1P1	6.09	4.02e-09	0.00887	0.46	0.36	Intelligence (multi-trait analysis);	chr2:73148595	chr3:36976316~36976840:+
COAD	trans	rs7618501	0.966	rs7372966	ENSG00000197582.5	GPX1P1	-6.09	4.03e-09	0.0089	-0.42	-0.36	Intelligence (multi-trait analysis);	chr3:49751536	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs7372725	ENSG00000197582.5	GPX1P1	-6.09	4.03e-09	0.0089	-0.42	-0.36	Intelligence (multi-trait analysis);	chr3:49753111	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs9872864	ENSG00000197582.5	GPX1P1	-6.09	4.03e-09	0.0089	-0.42	-0.36	Intelligence (multi-trait analysis);	chr3:49754590	chrX:13378735~13379340:-
COAD	trans	rs1190596	0.525	rs4601978	ENSG00000181359.5	HSP90AA6P	-6.09	4.04e-09	0.00892	-0.42	-0.36	Behavioural disinhibition (generation interaction);	chr14:102284740	chr4:170581470~170605450:-
COAD	trans	rs74781061	0.79	rs6495105	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74480512	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.858	rs12592906	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74481811	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs4887153	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74484701	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs11855521	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74488038	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs55662551	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74488745	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.858	rs4278699	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74500057	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8038730	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74501003	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs7178219	ENSG00000227288.3	RP5-837I24.1	6.09	4.05e-09	0.00893	0.52	0.36	Endometriosis;	chr15:74502552	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.662	rs11249996	ENSG00000253981.4	ALG1L13P	-6.09	4.05e-09	0.00894	-0.42	-0.36	Neuroticism;	chr8:10387953	chr8:8236003~8244667:-
COAD	trans	rs8177876	0.642	rs12445303	ENSG00000224837.1	GCSHP5	-6.09	4.06e-09	0.00896	-0.57	-0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr1:168055901~168056422:-
COAD	trans	rs5757949	0.578	rs9611367	ENSG00000275484.1	CTC-1337H24.4	6.09	4.1e-09	0.00905	0.38	0.36	Height;	chr22:40518945	chr11:67374416~67374932:+
COAD	trans	rs74781061	0.929	rs8027066	ENSG00000227288.3	RP5-837I24.1	6.09	4.11e-09	0.00905	0.51	0.36	Endometriosis;	chr15:74535682	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs2415242	ENSG00000227288.3	RP5-837I24.1	6.09	4.11e-09	0.00905	0.51	0.36	Endometriosis;	chr15:74546765	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs12442097	ENSG00000227288.3	RP5-837I24.1	6.09	4.11e-09	0.00905	0.51	0.36	Endometriosis;	chr15:74554792	chr1:81501794~81503468:+
COAD	trans	rs6732160	0.588	rs1430344	ENSG00000236165.1	PRADC1P1	6.09	4.14e-09	0.00912	0.46	0.36	Intelligence (multi-trait analysis);	chr2:73146216	chr3:36976316~36976840:+
COAD	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	6.09	4.17e-09	0.00917	0.44	0.35	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
COAD	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	6.09	4.17e-09	0.00917	0.44	0.35	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
COAD	trans	rs2288327	0.841	rs16866418	ENSG00000269800.1	PLEKHA3P1	6.09	4.18e-09	0.00921	0.46	0.35	Atrial fibrillation;	chr2:178626227	chr19:41521043~41521989:-
COAD	trans	rs6424115	1	rs12116511	ENSG00000228217.1	AL390877.1	6.09	4.19e-09	0.00923	0.43	0.35	Immature fraction of reticulocytes;	chr1:23836172	chr1:117778087~117778506:-
COAD	trans	rs10882165	0.756	rs10882174	ENSG00000273138.1	GS1-293C5.1	-6.08	4.22e-09	0.00928	-0.35	-0.35	Refractive error;	chr10:93191275	chr7:95416108~95416462:+
COAD	trans	rs9329221	0.905	rs4610752	ENSG00000173295.6	FAM86B3P	-6.08	4.24e-09	0.00932	-0.42	-0.35	Neuroticism;	chr8:10391452	chr8:8228595~8244865:+
COAD	trans	rs7824557	0.707	rs3808518	ENSG00000173295.6	FAM86B3P	-6.08	4.24e-09	0.00933	-0.44	-0.35	Retinal vascular caliber;	chr8:11285763	chr8:8228595~8244865:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	6.08	4.26e-09	0.00937	0.43	0.35	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
COAD	trans	rs6732160	0.588	rs2043100	ENSG00000236165.1	PRADC1P1	6.08	4.27e-09	0.00938	0.46	0.35	Intelligence (multi-trait analysis);	chr2:73146968	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.588	rs2043099	ENSG00000236165.1	PRADC1P1	6.08	4.27e-09	0.00938	0.46	0.35	Intelligence (multi-trait analysis);	chr2:73147028	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.588	rs11126392	ENSG00000236165.1	PRADC1P1	6.08	4.27e-09	0.00938	0.46	0.35	Intelligence (multi-trait analysis);	chr2:73147326	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.588	rs7578991	ENSG00000236165.1	PRADC1P1	6.08	4.27e-09	0.00938	0.46	0.35	Intelligence (multi-trait analysis);	chr2:73149043	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.564	rs7605716	ENSG00000236165.1	PRADC1P1	6.08	4.27e-09	0.00938	0.46	0.35	Intelligence (multi-trait analysis);	chr2:73149122	chr3:36976316~36976840:+
COAD	trans	rs12709013	0.792	rs7185513	ENSG00000233719.3	GOT2P3	6.08	4.29e-09	0.00942	0.47	0.35	Blood metabolite ratios;	chr16:58794889	chr12:9641802~9643007:+
COAD	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	6.08	4.29e-09	0.00942	0.51	0.35	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
COAD	trans	rs4276421	0.593	rs13176359	ENSG00000231752.4	EMBP1	-6.08	4.31e-09	0.00947	-0.47	-0.35	P wave duration;	chr5:45814173	chr1:121519112~121571892:+
COAD	trans	rs6424115	1	rs4649115	ENSG00000228217.1	AL390877.1	6.08	4.33e-09	0.0095	0.43	0.35	Immature fraction of reticulocytes;	chr1:23829241	chr1:117778087~117778506:-
COAD	trans	rs6424115	1	rs7521961	ENSG00000228217.1	AL390877.1	6.08	4.33e-09	0.0095	0.43	0.35	Immature fraction of reticulocytes;	chr1:23831144	chr1:117778087~117778506:-
COAD	trans	rs6424115	1	rs7515969	ENSG00000228217.1	AL390877.1	6.08	4.33e-09	0.0095	0.43	0.35	Immature fraction of reticulocytes;	chr1:23831908	chr1:117778087~117778506:-
COAD	trans	rs10242455	0.702	rs74552228	ENSG00000228834.1	RP11-249L21.4	6.08	4.35e-09	0.00954	0.78	0.35	Blood metabolite levels;	chr7:99379423	chr6:108907615~108907873:-
COAD	trans	rs6424115	1	rs2256179	ENSG00000228217.1	AL390877.1	6.08	4.38e-09	0.0096	0.41	0.35	Immature fraction of reticulocytes;	chr1:23805815	chr1:117778087~117778506:-
COAD	trans	rs11098499	0.866	rs11098506	ENSG00000276997.3	RP11-378J18.9	6.08	4.38e-09	0.0096	0.42	0.35	Corneal astigmatism;	chr4:119363816	chr1:222477252~222504622:-
COAD	trans	rs2899832	0.568	rs8017330	ENSG00000229083.1	PSMA6P2	6.08	4.4e-09	0.00964	0.56	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35263163	chrX:12825840~12826833:+
COAD	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-6.08	4.4e-09	0.00965	-0.49	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
COAD	trans	rs11098499	0.863	rs12508173	ENSG00000276997.3	RP11-378J18.9	6.08	4.41e-09	0.00967	0.42	0.35	Corneal astigmatism;	chr4:119397371	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs12504149	ENSG00000276997.3	RP11-378J18.9	6.08	4.41e-09	0.00967	0.42	0.35	Corneal astigmatism;	chr4:119397422	chr1:222477252~222504622:-
COAD	trans	rs6464772	0.54	rs10952668	ENSG00000238222.3	MKRN4P	6.08	4.42e-09	0.00968	0.39	0.35	Creatinine levels in ischemic stroke;	chr7:140443720	chrX:40834485~40836005:+
COAD	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	6.07	4.48e-09	0.00982	0.42	0.35	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
COAD	trans	rs61041336	0.583	rs11647748	ENSG00000233719.3	GOT2P3	-6.07	4.49e-09	0.00983	-0.71	-0.35	Neuritic plaque;	chr16:58697980	chr12:9641802~9643007:+
COAD	trans	rs2950393	0.804	rs1466382	ENSG00000228224.3	NACAP1	-6.07	4.56e-09	0.00998	-0.35	-0.35	Platelet distribution width;	chr12:56723050	chr8:101361794~101372707:+
COAD	trans	rs9329221	0.527	rs34308302	ENSG00000173295.6	FAM86B3P	-6.07	4.57e-09	0.00999	-0.43	-0.35	Neuroticism;	chr8:10474512	chr8:8228595~8244865:+
COAD	trans	rs66887589	0.934	rs6817317	ENSG00000275858.1	RP11-291L22.8	-6.07	4.62e-09	0.0101	-0.35	-0.35	Diastolic blood pressure;	chr4:119621672	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.934	rs7672519	ENSG00000275858.1	RP11-291L22.8	-6.07	4.62e-09	0.0101	-0.35	-0.35	Diastolic blood pressure;	chr4:119622957	chr10:38450738~38451069:-
COAD	trans	rs10045971	0.87	rs6892804	ENSG00000280927.1	CTBP1-AS	6.07	4.66e-09	0.0102	0.22	0.35	Depressive symptoms;	chr5:165045115	chr4:1210120~1218591:+
COAD	trans	rs2899832	0.568	rs8017676	ENSG00000229083.1	PSMA6P2	6.07	4.69e-09	0.0102	0.54	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293460	chrX:12825840~12826833:+
COAD	trans	rs1039766	1	rs12104748	ENSG00000224334.1	AP000357.4	-6.06	4.7e-09	0.0103	-0.54	-0.35	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr22:24686923~24688087:+
COAD	trans	rs66887589	1	rs66887589	ENSG00000275858.1	RP11-291L22.8	-6.06	4.73e-09	0.0103	-0.36	-0.35	Diastolic blood pressure;	chr4:119588124	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs1980025	ENSG00000276997.3	RP11-378J18.9	-6.06	4.75e-09	0.0103	-0.4	-0.35	Corneal astigmatism;	chr4:119331651	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.735	rs778596	ENSG00000231043.3	AC007238.1	6.06	4.75e-09	0.0104	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr2:58460292~58462032:-
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	6.06	4.76e-09	0.0104	0.39	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
COAD	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	6.06	4.77e-09	0.0104	0.44	0.35	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
COAD	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	6.06	4.77e-09	0.0104	0.44	0.35	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
COAD	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	6.06	4.77e-09	0.0104	0.44	0.35	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
COAD	trans	rs11098499	0.863	rs6835635	ENSG00000276997.3	RP11-378J18.9	6.06	4.77e-09	0.0104	0.43	0.35	Corneal astigmatism;	chr4:119537712	chr1:222477252~222504622:-
COAD	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-6.06	4.79e-09	0.0104	-0.44	-0.35	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
COAD	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	6.06	4.8e-09	0.0105	0.42	0.35	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.82	rs13128602	ENSG00000276997.3	RP11-378J18.9	-6.06	4.82e-09	0.0105	-0.41	-0.35	Corneal astigmatism;	chr4:119538211	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.935	rs3750311	ENSG00000173295.6	FAM86B3P	-6.06	4.82e-09	0.0105	-0.42	-0.35	Neuroticism;	chr8:10426092	chr8:8228595~8244865:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000196933.5	RPS26P11	6.06	4.84e-09	0.0105	0.45	0.35	Cognitive function;	chr12:55976127	chrX:72044545~72044892:+
COAD	trans	rs3213958	0.574	rs11914715	ENSG00000255624.2	RP11-564D11.3	-6.06	4.85e-09	0.0105	-0.6	-0.35	Blood protein levels;	chr3:98780118	chr10:122879851~122898024:+
COAD	trans	rs3806843	0.933	rs10069930	ENSG00000231043.3	AC007238.1	-6.06	4.85e-09	0.0105	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr2:58460292~58462032:-
COAD	trans	rs13190036	0.748	rs28395268	ENSG00000228305.2	AC016734.2	6.06	4.85e-09	0.0106	0.45	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr2:63622178~63622831:-
COAD	trans	rs74781061	0.929	rs16969612	ENSG00000227288.3	RP5-837I24.1	-6.06	4.86e-09	0.0106	-0.53	-0.35	Endometriosis;	chr15:74514096	chr1:81501794~81503468:+
COAD	trans	rs3806843	0.735	rs809635	ENSG00000231043.3	AC007238.1	6.06	4.92e-09	0.0107	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.648	rs2530233	ENSG00000231043.3	AC007238.1	6.06	4.92e-09	0.0107	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.735	rs6849	ENSG00000231043.3	AC007238.1	6.06	4.92e-09	0.0107	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.735	rs702394	ENSG00000231043.3	AC007238.1	6.06	4.92e-09	0.0107	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr2:58460292~58462032:-
COAD	trans	rs902774	0.818	rs73110432	ENSG00000224520.2	KRT8P45	-6.06	4.92e-09	0.0107	-0.66	-0.35	Prostate cancer;	chr12:52894051	chr1:157073257~157074703:+
COAD	trans	rs673253	0.581	rs11210860	ENSG00000231007.5	CDC20P1	-6.06	4.92e-09	0.0107	-0.47	-0.35	Intelligence (multi-trait analysis);	chr1:43516856	chr9:87011652~87013151:+
COAD	trans	rs12709013	0.935	rs11648634	ENSG00000233719.3	GOT2P3	6.06	4.93e-09	0.0107	0.46	0.35	Blood metabolite ratios;	chr16:58785256	chr12:9641802~9643007:+
COAD	trans	rs10028773	0.6	rs4001390	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Educational attainment;	chr4:119344628	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.691	rs2136911	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119344704	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.554	rs2175381	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119344812	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.599	rs3864142	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119345036	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.605	rs6833140	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119345667	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs6815934	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119346155	chr1:222477252~222504622:-
COAD	trans	rs10028773	0.568	rs6838457	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Educational attainment;	chr4:119346212	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.535	rs10005542	ENSG00000276997.3	RP11-378J18.9	6.06	4.95e-09	0.0108	0.4	0.35	Corneal astigmatism;	chr4:119347147	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.966	rs2563261	ENSG00000231043.3	AC007238.1	6.05	4.96e-09	0.0108	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs6891559	ENSG00000231043.3	AC007238.1	-6.05	4.96e-09	0.0108	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs11741994	ENSG00000231043.3	AC007238.1	-6.05	4.96e-09	0.0108	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr2:58460292~58462032:-
COAD	trans	rs902774	0.818	rs17120257	ENSG00000240668.1	KRT8P36	-6.05	5e-09	0.0108	-0.64	-0.35	Prostate cancer;	chr12:52909547	chr3:138101478~138102917:-
COAD	trans	rs3806843	0.898	rs3756335	ENSG00000231043.3	AC007238.1	-6.05	5.06e-09	0.011	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr2:58460292~58462032:-
COAD	trans	rs66887589	0.967	rs13104219	ENSG00000275858.1	RP11-291L22.8	6.05	5.06e-09	0.011	0.36	0.35	Diastolic blood pressure;	chr4:119517019	chr10:38450738~38451069:-
COAD	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-6.05	5.07e-09	0.011	-0.37	-0.35	Longevity;	chr3:48445369	chr1:27649419~27649610:+
COAD	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-6.05	5.08e-09	0.011	-0.45	-0.35	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
COAD	trans	rs35847492	1	rs17730481	ENSG00000173295.6	FAM86B3P	-6.05	5.09e-09	0.011	-0.44	-0.35	Neuroticism;	chr8:9418653	chr8:8228595~8244865:+
COAD	trans	rs12455924	1	rs8090641	ENSG00000259479.5	SORD2P	-6.05	5.09e-09	0.011	-0.57	-0.35	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr18:11071007	chr15:44826371~44884694:-
COAD	trans	rs3770081	0.59	rs57367442	ENSG00000229880.1	IMMTP1	6.05	5.15e-09	0.0112	0.64	0.35	Facial emotion recognition (sad faces);	chr2:86226275	chr21:44675868~44678086:-
COAD	trans	rs3770081	0.59	rs12622715	ENSG00000229880.1	IMMTP1	6.05	5.15e-09	0.0112	0.64	0.35	Facial emotion recognition (sad faces);	chr2:86226440	chr21:44675868~44678086:-
COAD	trans	rs4276421	0.593	rs10066821	ENSG00000231752.4	EMBP1	6.05	5.17e-09	0.0112	0.47	0.35	P wave duration;	chr5:45844236	chr1:121519112~121571892:+
COAD	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	6.05	5.19e-09	0.0112	0.37	0.35	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
COAD	trans	rs11295209	1	rs11295209	ENSG00000275858.1	RP11-291L22.8	-6.05	5.21e-09	0.0113	-0.36	-0.35	Plateletcrit;	chr4:119559079	chr10:38450738~38451069:-
COAD	trans	rs1435703	1	rs7647611	ENSG00000265802.2	RN7SL49P	-6.04	5.26e-09	0.0114	-0.53	-0.35	Obesity (extreme);	chr3:25520720	chr13:45002150~45002447:+
COAD	trans	rs4276421	0.509	rs10067206	ENSG00000231752.4	EMBP1	6.04	5.27e-09	0.0114	0.47	0.35	P wave duration;	chr5:46027737	chr1:121519112~121571892:+
COAD	trans	rs34421088	0.56	rs2467520	ENSG00000173295.6	FAM86B3P	-6.04	5.27e-09	0.0114	-0.42	-0.35	Neuroticism;	chr8:11541444	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.754	rs1814813	ENSG00000276997.3	RP11-378J18.9	-6.04	5.27e-09	0.0114	-0.4	-0.35	Corneal astigmatism;	chr4:119337052	chr1:222477252~222504622:-
COAD	trans	rs2288327	1	rs890578	ENSG00000269800.1	PLEKHA3P1	6.04	5.29e-09	0.0114	0.47	0.35	Atrial fibrillation;	chr2:178549906	chr19:41521043~41521989:-
COAD	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	6.04	5.31e-09	0.0115	0.37	0.35	Longevity;	chr3:48447994	chr1:27649419~27649610:+
COAD	trans	rs7192380	0.639	rs12448486	ENSG00000196796.5	CTB-134H23.2	-6.04	5.35e-09	0.0116	-0.37	-0.35	Sjögren's syndrome;	chr16:69768975	chr16:29038655~29052726:+
COAD	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	6.04	5.36e-09	0.0116	0.44	0.35	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.954	rs1546505	ENSG00000276997.3	RP11-378J18.9	6.04	5.38e-09	0.0116	0.42	0.35	Corneal astigmatism;	chr4:119320069	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.779	rs7699346	ENSG00000276997.3	RP11-378J18.9	6.04	5.41e-09	0.0117	0.42	0.35	Corneal astigmatism;	chr4:119389387	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.87	rs2389875	ENSG00000275858.1	RP11-291L22.8	-6.04	5.42e-09	0.0117	-0.35	-0.35	Diastolic blood pressure;	chr4:119635859	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.863	rs6534139	ENSG00000276997.3	RP11-378J18.9	-6.04	5.42e-09	0.0117	-0.42	-0.35	Corneal astigmatism;	chr4:119528301	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs9995234	ENSG00000276997.3	RP11-378J18.9	6.04	5.43e-09	0.0117	0.43	0.35	Corneal astigmatism;	chr4:119400672	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.807	rs13134517	ENSG00000275858.1	RP11-291L22.8	6.04	5.46e-09	0.0118	0.36	0.35	Diastolic blood pressure;	chr4:119484107	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.837	rs6534135	ENSG00000275858.1	RP11-291L22.8	6.04	5.46e-09	0.0118	0.36	0.35	Diastolic blood pressure;	chr4:119485147	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.837	rs7661498	ENSG00000275858.1	RP11-291L22.8	6.04	5.46e-09	0.0118	0.36	0.35	Diastolic blood pressure;	chr4:119486953	chr10:38450738~38451069:-
COAD	trans	rs7113874	0.802	rs885114	ENSG00000266891.1	RP11-692N5.2	6.04	5.48e-09	0.0118	0.44	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657209	chr18:9734882~9735602:-
COAD	trans	rs4276421	0.837	rs7446182	ENSG00000231752.4	EMBP1	-6.04	5.49e-09	0.0118	-0.42	-0.35	P wave duration;	chr5:45401715	chr1:121519112~121571892:+
COAD	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-6.03	5.56e-09	0.012	-0.48	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
COAD	trans	rs673253	0.593	rs3791134	ENSG00000231007.5	CDC20P1	6.03	5.57e-09	0.012	0.47	0.35	Intelligence (multi-trait analysis);	chr1:43583485	chr9:87011652~87013151:+
COAD	trans	rs673253	0.662	rs61769642	ENSG00000231007.5	CDC20P1	6.03	5.57e-09	0.012	0.47	0.35	Intelligence (multi-trait analysis);	chr1:43585959	chr9:87011652~87013151:+
COAD	trans	rs673253	0.686	rs3791139	ENSG00000231007.5	CDC20P1	6.03	5.57e-09	0.012	0.47	0.35	Intelligence (multi-trait analysis);	chr1:43586100	chr9:87011652~87013151:+
COAD	trans	rs6499255	1	rs6499255	ENSG00000196796.5	CTB-134H23.2	6.03	5.58e-09	0.012	0.41	0.35	IgE levels;	chr16:69796425	chr16:29038655~29052726:+
COAD	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-6.03	5.6e-09	0.0121	-0.46	-0.35	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
COAD	trans	rs9329221	0.592	rs7832708	ENSG00000253981.4	ALG1L13P	6.03	5.63e-09	0.0121	0.42	0.35	Neuroticism;	chr8:10332530	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.863	rs3822195	ENSG00000276997.3	RP11-378J18.9	6.03	5.66e-09	0.0122	0.41	0.35	Corneal astigmatism;	chr4:119550505	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs10014719	ENSG00000276997.3	RP11-378J18.9	6.03	5.66e-09	0.0122	0.42	0.35	Corneal astigmatism;	chr4:119399560	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.954	rs13145352	ENSG00000276997.3	RP11-378J18.9	-6.03	5.67e-09	0.0122	-0.41	-0.35	Corneal astigmatism;	chr4:119488808	chr1:222477252~222504622:-
COAD	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	6.03	5.69e-09	0.0122	0.44	0.35	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
COAD	trans	rs9329221	0.638	rs7460436	ENSG00000253981.4	ALG1L13P	6.03	5.72e-09	0.0123	0.44	0.35	Neuroticism;	chr8:10396812	chr8:8236003~8244667:-
COAD	trans	rs656319	0.674	rs1484639	ENSG00000173295.6	FAM86B3P	6.03	5.73e-09	0.0123	0.42	0.35	Myopia (pathological);	chr8:10125714	chr8:8228595~8244865:+
COAD	trans	rs74781061	0.929	rs59946128	ENSG00000227288.3	RP5-837I24.1	6.03	5.73e-09	0.0123	0.52	0.35	Endometriosis;	chr15:74493006	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs60777494	ENSG00000227288.3	RP5-837I24.1	6.03	5.73e-09	0.0123	0.52	0.35	Endometriosis;	chr15:74493007	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs57271230	ENSG00000227288.3	RP5-837I24.1	6.03	5.73e-09	0.0123	0.52	0.35	Endometriosis;	chr15:74493018	chr1:81501794~81503468:+
COAD	trans	rs66887589	0.967	rs1155577	ENSG00000275858.1	RP11-291L22.8	-6.03	5.77e-09	0.0124	-0.35	-0.35	Diastolic blood pressure;	chr4:119528655	chr10:38450738~38451069:-
COAD	trans	rs2950393	0.895	rs2926740	ENSG00000257210.1	NACAP3	6.03	5.8e-09	0.0125	0.41	0.35	Platelet distribution width;	chr12:56666751	chr12:93124063~93124543:-
COAD	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	6.03	5.81e-09	0.0125	0.48	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
COAD	trans	rs902774	0.818	rs4919740	ENSG00000223940.1	KRT8P8	-6.03	5.81e-09	0.0125	-0.61	-0.35	Prostate cancer;	chr12:52877187	chrX:152479577~152481024:+
COAD	trans	rs6424115	0.867	rs34902309	ENSG00000228217.1	AL390877.1	6.02	5.84e-09	0.0125	0.44	0.35	Immature fraction of reticulocytes;	chr1:23865710	chr1:117778087~117778506:-
COAD	trans	rs3806843	0.966	rs2563265	ENSG00000231043.3	AC007238.1	6.02	5.85e-09	0.0125	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr2:58460292~58462032:-
COAD	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	6.02	5.85e-09	0.0125	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
COAD	trans	rs4276421	0.554	rs7724971	ENSG00000231752.4	EMBP1	-6.02	5.85e-09	0.0126	-0.47	-0.35	P wave duration;	chr5:45814638	chr1:121519112~121571892:+
COAD	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	6.02	5.86e-09	0.0126	0.42	0.35	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
COAD	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	6.02	5.86e-09	0.0126	0.42	0.35	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
COAD	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	6.02	5.86e-09	0.0126	0.42	0.35	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
COAD	trans	rs993648	1	rs16867454	ENSG00000239830.1	RPS4XP22	-6.02	5.88e-09	0.0126	-0.42	-0.35	Response to iloperidone treatment (QT prolongation);	chr2:181597758	chr19:9683294~9684073:-
COAD	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	6.02	5.93e-09	0.0127	0.44	0.35	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
COAD	trans	rs6743068	0.541	rs12052257	ENSG00000235105.1	RP11-329A14.1	-6.02	5.94e-09	0.0127	-0.42	-0.35	Lymphocyte percentage of white cells;	chr2:201376871	chr1:48435967~48437223:+
COAD	trans	rs11096990	0.613	rs4974995	ENSG00000235217.6	TSPY26P	-6.02	5.96e-09	0.0128	-0.31	-0.35	Cognitive function;	chr4:39216503	chr20:32186477~32190527:-
COAD	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	6.02	5.96e-09	0.0128	0.38	0.35	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
COAD	trans	rs11098499	0.909	rs1546504	ENSG00000276997.3	RP11-378J18.9	6.02	5.97e-09	0.0128	0.43	0.35	Corneal astigmatism;	chr4:119320024	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs10057161	ENSG00000231043.3	AC007238.1	-6.02	6.03e-09	0.0129	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr2:58460292~58462032:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-6.02	6.03e-09	0.0129	-0.35	-0.35	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-6.02	6.03e-09	0.0129	-0.35	-0.35	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
COAD	trans	rs66887589	0.87	rs59590064	ENSG00000275858.1	RP11-291L22.8	-6.02	6.05e-09	0.0129	-0.35	-0.35	Diastolic blood pressure;	chr4:119618598	chr10:38450738~38451069:-
COAD	trans	rs2899832	0.568	rs8014594	ENSG00000229083.1	PSMA6P2	6.02	6.09e-09	0.013	0.55	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296623	chrX:12825840~12826833:+
COAD	trans	rs10242455	1	rs73395557	ENSG00000228834.1	RP11-249L21.4	6.02	6.12e-09	0.0131	0.6	0.35	Blood metabolite levels;	chr7:99336801	chr6:108907615~108907873:-
COAD	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	6.02	6.12e-09	0.0131	0.6	0.35	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
COAD	trans	rs10882165	0.756	rs10786076	ENSG00000273138.1	GS1-293C5.1	-6.02	6.13e-09	0.0131	-0.34	-0.35	Refractive error;	chr10:93194587	chr7:95416108~95416462:+
COAD	trans	rs34421088	0.56	rs2245357	ENSG00000173295.6	FAM86B3P	-6.01	6.16e-09	0.0132	-0.42	-0.35	Neuroticism;	chr8:11541975	chr8:8228595~8244865:+
COAD	trans	rs2950393	0.804	rs2926748	ENSG00000228224.3	NACAP1	6.01	6.2e-09	0.0132	0.35	0.35	Platelet distribution width;	chr12:56715628	chr8:101361794~101372707:+
COAD	trans	rs877636	0.702	rs773108	ENSG00000227887.1	RPS26P13	6.01	6.24e-09	0.0133	0.43	0.35	Cognitive function;	chr12:55976127	chr1:208697369~208697698:-
COAD	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	6.01	6.26e-09	0.0134	0.43	0.35	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
COAD	trans	rs7032940	0.677	rs4279674	ENSG00000262519.1	TXNP4	6.01	6.28e-09	0.0134	0.46	0.35	Height;	chr9:110179726	chr17:4572206~4572515:+
COAD	trans	rs9876781	0.563	rs4858821	ENSG00000235912.1	RP1-159A19.3	6.01	6.31e-09	0.0135	0.39	0.35	Longevity;	chr3:48512515	chr1:27649419~27649610:+
COAD	trans	rs3806843	0.735	rs2563335	ENSG00000231043.3	AC007238.1	-6.01	6.32e-09	0.0135	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr2:58460292~58462032:-
COAD	trans	rs10908521	1	rs10908521	ENSG00000227183.3	HDGFP1	6.01	6.36e-09	0.0136	0.44	0.35	Uric acid clearance;	chr1:156843858	chrX:131646639~131646890:+
COAD	trans	rs3806843	0.735	rs2530240	ENSG00000231043.3	AC007238.1	6.01	6.37e-09	0.0136	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.706	rs2563302	ENSG00000231043.3	AC007238.1	6.01	6.38e-09	0.0136	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr2:58460292~58462032:-
COAD	trans	rs74781061	0.929	rs8029116	ENSG00000227288.3	RP5-837I24.1	6.01	6.39e-09	0.0136	0.53	0.35	Endometriosis;	chr15:74530753	chr1:81501794~81503468:+
COAD	trans	rs34421088	0.56	rs2618434	ENSG00000173295.6	FAM86B3P	-6.01	6.41e-09	0.0137	-0.41	-0.35	Neuroticism;	chr8:11541356	chr8:8228595~8244865:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	6.01	6.44e-09	0.0137	0.4	0.35	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
COAD	trans	rs7113874	0.802	rs11042025	ENSG00000266891.1	RP11-692N5.2	-6.01	6.45e-09	0.0137	-0.44	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653928	chr18:9734882~9735602:-
COAD	trans	rs7618501	1	rs7374277	ENSG00000197582.5	GPX1P1	-6.01	6.45e-09	0.0137	-0.41	-0.35	Intelligence (multi-trait analysis);	chr3:49747344	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs7372730	ENSG00000197582.5	GPX1P1	-6.01	6.45e-09	0.0137	-0.41	-0.35	Intelligence (multi-trait analysis);	chr3:49753249	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs9855505	ENSG00000197582.5	GPX1P1	-6.01	6.45e-09	0.0137	-0.41	-0.35	Intelligence (multi-trait analysis);	chr3:49754725	chrX:13378735~13379340:-
COAD	trans	rs7113874	0.797	rs4503528	ENSG00000266891.1	RP11-692N5.2	-6.01	6.47e-09	0.0138	-0.44	-0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8642907	chr18:9734882~9735602:-
COAD	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-6.01	6.49e-09	0.0138	-0.37	-0.35	Longevity;	chr3:48393284	chr1:27649419~27649610:+
COAD	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-6.01	6.49e-09	0.0138	-0.37	-0.35	Longevity;	chr3:48393659	chr1:27649419~27649610:+
COAD	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	6	6.52e-09	0.0139	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	6	6.52e-09	0.0139	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
COAD	trans	rs9329221	0.736	rs2001338	ENSG00000253981.4	ALG1L13P	6	6.53e-09	0.0139	0.43	0.35	Neuroticism;	chr8:10393707	chr8:8236003~8244667:-
COAD	trans	rs7113874	0.802	rs10769938	ENSG00000266891.1	RP11-692N5.2	6	6.54e-09	0.0139	0.45	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8650000	chr18:9734882~9735602:-
COAD	trans	rs9329221	1	rs9329221	ENSG00000173295.6	FAM86B3P	6	6.54e-09	0.0139	0.4	0.35	Neuroticism;	chr8:10382692	chr8:8228595~8244865:+
COAD	trans	rs763361	0.631	rs11661553	ENSG00000279024.1	RP11-1193F23.1	6	6.57e-09	0.014	0.49	0.35	Type 1 diabetes;	chr18:69877401	chr2:136230753~136233245:+
COAD	trans	rs7618501	0.966	rs9882639	ENSG00000197582.5	GPX1P1	6	6.57e-09	0.014	0.41	0.35	Intelligence (multi-trait analysis);	chr3:49762042	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs60205400	ENSG00000197582.5	GPX1P1	6	6.57e-09	0.014	0.41	0.35	Intelligence (multi-trait analysis);	chr3:49762839	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.933	rs6809431	ENSG00000197582.5	GPX1P1	6	6.57e-09	0.014	0.41	0.35	Intelligence (multi-trait analysis);	chr3:49766686	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs9859153	ENSG00000197582.5	GPX1P1	6	6.57e-09	0.014	0.41	0.35	Intelligence (multi-trait analysis);	chr3:49769652	chrX:13378735~13379340:-
COAD	trans	rs4740619	0.81	rs6474951	ENSG00000244021.4	RP11-50D9.1	-6	6.59e-09	0.014	-0.31	-0.35	Body mass index;	chr9:15707225	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.782	rs7036285	ENSG00000244021.4	RP11-50D9.1	-6	6.59e-09	0.014	-0.31	-0.35	Body mass index;	chr9:15711145	chr4:127812720~127813200:-
COAD	trans	rs4883201	0.611	rs2377671	ENSG00000179899.8	PHC1P1	6	6.59e-09	0.014	0.46	0.35	Total cholesterol levels;Cholesterol, total;	chr12:8951246	chr12:55411727~55414787:-
COAD	trans	rs941207	0.526	rs2950390	ENSG00000257210.1	NACAP3	6	6.59e-09	0.014	0.4	0.35	Platelet count;	chr12:56661507	chr12:93124063~93124543:-
COAD	trans	rs3806843	0.735	rs801180	ENSG00000231043.3	AC007238.1	6	6.61e-09	0.0141	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.661	rs10015965	ENSG00000276997.3	RP11-378J18.9	6	6.63e-09	0.0141	0.4	0.35	Corneal astigmatism;	chr4:119347082	chr1:222477252~222504622:-
COAD	trans	rs4740619	0.846	rs10121393	ENSG00000244021.4	RP11-50D9.1	-6	6.63e-09	0.0141	-0.32	-0.35	Body mass index;	chr9:15690498	chr4:127812720~127813200:-
COAD	trans	rs9329221	0.772	rs7824675	ENSG00000173295.6	FAM86B3P	-6	6.7e-09	0.0142	-0.39	-0.35	Neuroticism;	chr8:10385908	chr8:8228595~8244865:+
COAD	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-6	6.75e-09	0.0143	-0.39	-0.35	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
COAD	trans	rs4276421	0.593	rs7448901	ENSG00000231752.4	EMBP1	6	6.75e-09	0.0143	0.43	0.35	P wave duration;	chr5:45941482	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.615	rs7445658	ENSG00000231752.4	EMBP1	6	6.75e-09	0.0143	0.43	0.35	P wave duration;	chr5:45941513	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.593	rs10076636	ENSG00000231752.4	EMBP1	6	6.75e-09	0.0143	0.43	0.35	P wave duration;	chr5:45942052	chr1:121519112~121571892:+
COAD	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-6	6.76e-09	0.0143	-0.4	-0.35	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-6	6.76e-09	0.0143	-0.4	-0.35	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
COAD	trans	rs11098499	0.863	rs17050695	ENSG00000276997.3	RP11-378J18.9	6	6.8e-09	0.0144	0.41	0.35	Corneal astigmatism;	chr4:119568372	chr1:222477252~222504622:-
COAD	trans	rs7618501	1	rs11130218	ENSG00000197582.5	GPX1P1	-6	6.81e-09	0.0144	-0.41	-0.35	Intelligence (multi-trait analysis);	chr3:49714939	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.933	rs3811695	ENSG00000197582.5	GPX1P1	-6	6.81e-09	0.0144	-0.41	-0.35	Intelligence (multi-trait analysis);	chr3:49724180	chrX:13378735~13379340:-
COAD	trans	rs6732160	0.564	rs60796597	ENSG00000236165.1	PRADC1P1	5.99	6.87e-09	0.0146	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73155786	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.613	rs59979991	ENSG00000236165.1	PRADC1P1	5.99	6.87e-09	0.0146	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73157294	chr3:36976316~36976840:+
COAD	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	5.99	6.88e-09	0.0146	0.42	0.35	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
COAD	trans	rs864643	0.524	rs72869124	ENSG00000183298.5	RP11-556K13.1	5.99	6.89e-09	0.0146	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39469788	chr1:101786340~101787219:-
COAD	trans	rs864643	0.524	rs6810264	ENSG00000183298.5	RP11-556K13.1	5.99	6.89e-09	0.0146	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39471605	chr1:101786340~101787219:-
COAD	trans	rs864643	0.524	rs11706953	ENSG00000183298.5	RP11-556K13.1	5.99	6.89e-09	0.0146	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39472119	chr1:101786340~101787219:-
COAD	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	5.99	6.89e-09	0.0146	0.41	0.35	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
COAD	trans	rs3806843	0.966	rs2337516	ENSG00000231043.3	AC007238.1	5.99	6.93e-09	0.0147	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr2:58460292~58462032:-
COAD	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	5.99	6.93e-09	0.0147	0.43	0.35	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
COAD	trans	rs6540731	1	rs11119884	ENSG00000227542.1	AC092614.2	5.99	6.93e-09	0.0147	0.42	0.35	Intelligence (childhood);	chr1:212226804	chr2:191229165~191246172:-
COAD	trans	rs74781061	0.929	rs8043032	ENSG00000227288.3	RP5-837I24.1	5.99	6.94e-09	0.0147	0.54	0.35	Endometriosis;	chr15:74543975	chr1:81501794~81503468:+
COAD	trans	rs11098499	0.754	rs7672372	ENSG00000276997.3	RP11-378J18.9	5.99	6.97e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119327251	chr1:222477252~222504622:-
COAD	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	5.99	7e-09	0.0148	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	5.99	7e-09	0.0148	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	5.99	7e-09	0.0148	0.28	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
COAD	trans	rs11098499	0.754	rs12513083	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119328457	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs12509621	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119328505	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs1511017	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119329650	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.789	rs12498994	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119329663	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs12507565	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119329966	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.826	rs12511640	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119330093	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs1980026	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119330488	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.722	rs28713555	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119330840	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.743	rs11098501	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119330862	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs11098502	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119330908	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.708	rs11732686	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119331175	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs11724409	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119331206	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.789	rs1980024	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119331892	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs34425882	ENSG00000276997.3	RP11-378J18.9	5.99	7e-09	0.0148	0.4	0.35	Corneal astigmatism;	chr4:119332022	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.933	rs2240696	ENSG00000231043.3	AC007238.1	-5.99	7.02e-09	0.0148	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs2240695	ENSG00000231043.3	AC007238.1	-5.99	7.02e-09	0.0148	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs6579965	ENSG00000231043.3	AC007238.1	-5.99	7.02e-09	0.0148	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs6898906	ENSG00000231043.3	AC007238.1	-5.99	7.02e-09	0.0148	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs10477034	ENSG00000231043.3	AC007238.1	-5.99	7.02e-09	0.0148	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs3756341	ENSG00000231043.3	AC007238.1	-5.99	7.04e-09	0.0149	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr2:58460292~58462032:-
COAD	trans	rs673253	0.686	rs2782641	ENSG00000231007.5	CDC20P1	5.99	7.06e-09	0.0149	0.45	0.35	Intelligence (multi-trait analysis);	chr1:43547684	chr9:87011652~87013151:+
COAD	trans	rs6601327	0.641	rs4840437	ENSG00000253981.4	ALG1L13P	-5.99	7.08e-09	0.015	-0.44	-0.35	Multiple myeloma (hyperdiploidy);	chr8:9748754	chr8:8236003~8244667:-
COAD	trans	rs3806843	1	rs2337985	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs2337986	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs1548701	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs10073974	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs3756342	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs3733710	ENSG00000231043.3	AC007238.1	-5.99	7.11e-09	0.015	-0.36	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.863	rs3736115	ENSG00000276997.3	RP11-378J18.9	-5.99	7.13e-09	0.015	-0.41	-0.35	Corneal astigmatism;	chr4:119567548	chr1:222477252~222504622:-
COAD	trans	rs3213958	0.533	rs3772100	ENSG00000255624.2	RP11-564D11.3	-5.99	7.16e-09	0.0151	-0.6	-0.35	Blood protein levels;	chr3:98782236	chr10:122879851~122898024:+
COAD	trans	rs4276421	0.571	rs28895306	ENSG00000231752.4	EMBP1	5.99	7.18e-09	0.0151	0.48	0.35	P wave duration;	chr5:45851383	chr1:121519112~121571892:+
COAD	trans	rs62496419	1	rs28481310	ENSG00000237709.1	EEF1A1P28	-5.99	7.2e-09	0.0152	-0.6	-0.35	Alzheimer disease and age of onset;	chr7:97387103	chr7:88639014~88640416:+
COAD	trans	rs615632	0.53	rs10092464	ENSG00000173295.6	FAM86B3P	-5.99	7.22e-09	0.0152	-0.45	-0.35	Neuroticism;	chr8:9946675	chr8:8228595~8244865:+
COAD	trans	rs6732160	0.588	rs28626211	ENSG00000236165.1	PRADC1P1	5.98	7.26e-09	0.0153	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73151394	chr3:36976316~36976840:+
COAD	trans	rs7811417	0.636	rs6461565	ENSG00000206634.1	SNORA22	5.98	7.29e-09	0.0154	0.47	0.35	Schizophrenia;	chr7:21456847	chr7:65755526~65755659:+
COAD	trans	rs9329221	0.736	rs2001337	ENSG00000253981.4	ALG1L13P	5.98	7.33e-09	0.0154	0.43	0.35	Neuroticism;	chr8:10393644	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.663	rs9996501	ENSG00000276997.3	RP11-378J18.9	5.98	7.35e-09	0.0155	0.4	0.35	Corneal astigmatism;	chr4:119317763	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs28458294	ENSG00000276997.3	RP11-378J18.9	5.98	7.35e-09	0.0155	0.4	0.35	Corneal astigmatism;	chr4:119317769	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.663	rs28369503	ENSG00000276997.3	RP11-378J18.9	5.98	7.35e-09	0.0155	0.4	0.35	Corneal astigmatism;	chr4:119317770	chr1:222477252~222504622:-
COAD	trans	rs1419856	0.929	rs17607220	ENSG00000224061.1	AC092106.1	5.98	7.36e-09	0.0155	0.47	0.35	QRS duration;	chr7:35289306	chr2:106253231~106253717:-
COAD	trans	rs929843	1	rs929843	ENSG00000257513.6	NPIPB1P	5.98	7.38e-09	0.0155	0.5	0.35	Menarche (age at onset);	chr16:70011845	chr18:11619509~11639699:-
COAD	trans	rs3806843	0.735	rs3776129	ENSG00000231043.3	AC007238.1	5.98	7.38e-09	0.0155	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr2:58460292~58462032:-
COAD	trans	rs6732160	0.613	rs10179063	ENSG00000236165.1	PRADC1P1	5.98	7.44e-09	0.0157	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73157983	chr3:36976316~36976840:+
COAD	trans	rs6732160	0.613	rs6546804	ENSG00000236165.1	PRADC1P1	5.98	7.44e-09	0.0157	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73158791	chr3:36976316~36976840:+
COAD	trans	rs11098499	0.909	rs10026736	ENSG00000276997.3	RP11-378J18.9	5.98	7.47e-09	0.0157	0.42	0.35	Corneal astigmatism;	chr4:119463167	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.687	rs71610270	ENSG00000276997.3	RP11-378J18.9	5.98	7.55e-09	0.0159	0.41	0.35	Corneal astigmatism;	chr4:119366281	chr1:222477252~222504622:-
COAD	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-5.98	7.58e-09	0.0159	-0.38	-0.35	Asthma;	chr12:55970537	chr15:64592979~64593326:+
COAD	trans	rs6424115	0.83	rs3003333	ENSG00000228217.1	AL390877.1	5.98	7.58e-09	0.0159	0.42	0.35	Immature fraction of reticulocytes;	chr1:23867524	chr1:117778087~117778506:-
COAD	trans	rs7113874	0.802	rs4291677	ENSG00000266891.1	RP11-692N5.2	5.98	7.6e-09	0.016	0.44	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8659344	chr18:9734882~9735602:-
COAD	trans	rs3806843	0.657	rs2563283	ENSG00000231043.3	AC007238.1	5.98	7.6e-09	0.016	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.771	rs2563336	ENSG00000231043.3	AC007238.1	5.98	7.6e-09	0.016	0.36	0.35	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr2:58460292~58462032:-
COAD	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-5.98	7.61e-09	0.016	-0.42	-0.35	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
COAD	trans	rs12709013	1	rs34319345	ENSG00000233719.3	GOT2P3	5.98	7.61e-09	0.016	0.45	0.35	Blood metabolite ratios;	chr16:58786688	chr12:9641802~9643007:+
COAD	trans	rs3806843	0.676	rs2563304	ENSG00000231043.3	AC007238.1	5.97	7.65e-09	0.0161	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr2:58460292~58462032:-
COAD	trans	rs4740619	0.782	rs62573118	ENSG00000244021.4	RP11-50D9.1	-5.97	7.66e-09	0.0161	-0.31	-0.35	Body mass index;	chr9:15702542	chr4:127812720~127813200:-
COAD	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-5.97	7.67e-09	0.0161	-0.53	-0.35	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
COAD	trans	rs7554547	0.622	rs28455075	ENSG00000261819.1	RP11-680G24.4	5.97	7.69e-09	0.0161	0.5	0.35	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr16:14988259~14990160:-
COAD	trans	rs3806843	0.735	rs2563306	ENSG00000231043.3	AC007238.1	5.97	7.7e-09	0.0161	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.735	rs813897	ENSG00000231043.3	AC007238.1	5.97	7.7e-09	0.0161	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr2:58460292~58462032:-
COAD	trans	rs12785341	0.541	rs7128425	ENSG00000235124.1	KRT8P17	5.97	7.7e-09	0.0161	0.53	0.35	Renal sinus fat;	chr11:110624000	chrX:57984686~57986133:+
COAD	trans	rs12785341	0.541	rs1848592	ENSG00000235124.1	KRT8P17	5.97	7.7e-09	0.0161	0.53	0.35	Renal sinus fat;	chr11:110624617	chrX:57984686~57986133:+
COAD	trans	rs12785341	0.618	rs11213504	ENSG00000235124.1	KRT8P17	5.97	7.7e-09	0.0161	0.53	0.35	Renal sinus fat;	chr11:110625541	chrX:57984686~57986133:+
COAD	trans	rs12785341	0.541	rs6589156	ENSG00000235124.1	KRT8P17	5.97	7.7e-09	0.0161	0.53	0.35	Renal sinus fat;	chr11:110625956	chrX:57984686~57986133:+
COAD	trans	rs12785341	0.541	rs10082644	ENSG00000235124.1	KRT8P17	5.97	7.7e-09	0.0161	0.53	0.35	Renal sinus fat;	chr11:110627995	chrX:57984686~57986133:+
COAD	trans	rs10817611	0.513	rs9657665	ENSG00000271138.1	IGLVIVOR22-1	-5.97	7.71e-09	0.0162	-0.41	-0.35	Survival in pancreatic cancer;	chr9:114470071	chr22:25437306~25437823:-
COAD	trans	rs4740619	0.819	rs12352779	ENSG00000244021.4	RP11-50D9.1	-5.97	7.72e-09	0.0162	-0.31	-0.35	Body mass index;	chr9:15700725	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.846	rs10810429	ENSG00000244021.4	RP11-50D9.1	-5.97	7.72e-09	0.0162	-0.31	-0.35	Body mass index;	chr9:15701076	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.81	rs7037662	ENSG00000244021.4	RP11-50D9.1	-5.97	7.72e-09	0.0162	-0.31	-0.35	Body mass index;	chr9:15701632	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.81	rs7037908	ENSG00000244021.4	RP11-50D9.1	-5.97	7.72e-09	0.0162	-0.31	-0.35	Body mass index;	chr9:15701697	chr4:127812720~127813200:-
COAD	trans	rs8177876	0.822	rs1563077	ENSG00000224837.1	GCSHP5	5.97	7.72e-09	0.0162	0.59	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr1:168055901~168056422:-
COAD	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-5.97	7.8e-09	0.0163	-0.45	-0.35	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
COAD	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-5.97	7.8e-09	0.0163	-0.45	-0.35	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
COAD	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-5.97	7.82e-09	0.0164	-0.4	-0.35	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
COAD	trans	rs7192380	0.639	rs7186296	ENSG00000196796.5	CTB-134H23.2	-5.97	7.83e-09	0.0164	-0.38	-0.35	Sjögren's syndrome;	chr16:69775095	chr16:29038655~29052726:+
COAD	trans	rs66887589	0.934	rs41464847	ENSG00000275858.1	RP11-291L22.8	-5.97	7.84e-09	0.0164	-0.34	-0.35	Diastolic blood pressure;	chr4:119611246	chr10:38450738~38451069:-
COAD	trans	rs4740619	0.81	rs10756691	ENSG00000244021.4	RP11-50D9.1	-5.97	7.85e-09	0.0164	-0.31	-0.35	Body mass index;	chr9:15699080	chr4:127812720~127813200:-
COAD	trans	rs3213958	0.574	rs73136045	ENSG00000255624.2	RP11-564D11.3	-5.97	7.89e-09	0.0165	-0.6	-0.35	Blood protein levels;	chr3:98785149	chr10:122879851~122898024:+
COAD	trans	rs3213958	0.574	rs73136048	ENSG00000255624.2	RP11-564D11.3	-5.97	7.89e-09	0.0165	-0.6	-0.35	Blood protein levels;	chr3:98785923	chr10:122879851~122898024:+
COAD	trans	rs6601327	0.67	rs12545250	ENSG00000253981.4	ALG1L13P	5.97	7.95e-09	0.0166	0.44	0.35	Multiple myeloma (hyperdiploidy);	chr8:9563056	chr8:8236003~8244667:-
COAD	trans	rs10882165	0.729	rs2094486	ENSG00000273138.1	GS1-293C5.1	5.97	7.96e-09	0.0166	0.34	0.35	Refractive error;	chr10:93195909	chr7:95416108~95416462:+
COAD	trans	rs3806843	0.9	rs2261651	ENSG00000231043.3	AC007238.1	5.97	8.04e-09	0.0168	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.9	rs2337983	ENSG00000231043.3	AC007238.1	5.97	8.04e-09	0.0168	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr2:58460292~58462032:-
COAD	trans	rs1463132	0.651	rs7195607	ENSG00000233916.1	ZDHHC20P1	5.97	8.05e-09	0.0168	0.45	0.35	HIV-1 control;	chr16:10111799	chr6:29708125~29708547:-
COAD	trans	rs9329221	0.532	rs2062333	ENSG00000173295.6	FAM86B3P	5.97	8.06e-09	0.0168	0.41	0.35	Neuroticism;	chr8:10123639	chr8:8228595~8244865:+
COAD	trans	rs6499255	1	rs4464069	ENSG00000196796.5	CTB-134H23.2	5.96	8.08e-09	0.0169	0.4	0.35	IgE levels;	chr16:69782381	chr16:29038655~29052726:+
COAD	trans	rs11098499	0.863	rs9884402	ENSG00000276997.3	RP11-378J18.9	5.96	8.09e-09	0.0169	0.41	0.35	Corneal astigmatism;	chr4:119568827	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.731	rs9995026	ENSG00000276997.3	RP11-378J18.9	5.96	8.09e-09	0.0169	0.41	0.35	Corneal astigmatism;	chr4:119569344	chr1:222477252~222504622:-
COAD	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-5.96	8.11e-09	0.0169	-0.45	-0.35	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
COAD	trans	rs802425	0.899	rs274640	ENSG00000273348.1	RP11-535A5.1	-5.96	8.13e-09	0.017	-0.36	-0.35	Neuroticism;	chr7:86627700	chr18:22347846~22348252:-
COAD	trans	rs4740619	0.819	rs954663	ENSG00000244021.4	RP11-50D9.1	-5.96	8.13e-09	0.017	-0.32	-0.35	Body mass index;	chr9:15695535	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.811	rs954664	ENSG00000244021.4	RP11-50D9.1	-5.96	8.13e-09	0.017	-0.32	-0.35	Body mass index;	chr9:15695884	chr4:127812720~127813200:-
COAD	trans	rs11098499	0.954	rs11098525	ENSG00000276997.3	RP11-378J18.9	5.96	8.16e-09	0.017	0.41	0.35	Corneal astigmatism;	chr4:119468997	chr1:222477252~222504622:-
COAD	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-5.96	8.17e-09	0.017	-0.43	-0.35	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
COAD	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-5.96	8.17e-09	0.017	-0.43	-0.35	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
COAD	trans	rs12709013	0.967	rs11643969	ENSG00000233719.3	GOT2P3	5.96	8.22e-09	0.0171	0.45	0.35	Blood metabolite ratios;	chr16:58785354	chr12:9641802~9643007:+
COAD	trans	rs963265	1	rs1986631	ENSG00000224956.5	RP11-206L10.1	-5.96	8.24e-09	0.0172	-0.37	-0.35	Migraine with aura;	chr9:70477544	chr1:726231~728147:-
COAD	trans	rs9858542	1	rs9836291	ENSG00000197582.5	GPX1P1	-5.96	8.27e-09	0.0172	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49660026	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.754	rs2036860	ENSG00000276997.3	RP11-378J18.9	5.96	8.32e-09	0.0173	0.4	0.35	Corneal astigmatism;	chr4:119327779	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs2036857	ENSG00000276997.3	RP11-378J18.9	5.96	8.32e-09	0.0173	0.4	0.35	Corneal astigmatism;	chr4:119328085	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs2036856	ENSG00000276997.3	RP11-378J18.9	5.96	8.32e-09	0.0173	0.4	0.35	Corneal astigmatism;	chr4:119328133	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs4443261	ENSG00000276997.3	RP11-378J18.9	5.96	8.32e-09	0.0173	0.4	0.35	Corneal astigmatism;	chr4:119328146	chr1:222477252~222504622:-
COAD	trans	rs13392054	0.915	rs1441162	ENSG00000239830.1	RPS4XP22	5.96	8.32e-09	0.0173	0.48	0.35	Psychosis proneness (perceptual aberration scale and revised social anhedonia scale);	chr2:181590050	chr19:9683294~9684073:-
COAD	trans	rs11098499	0.691	rs9996644	ENSG00000276997.3	RP11-378J18.9	5.96	8.41e-09	0.0175	0.4	0.35	Corneal astigmatism;	chr4:119317722	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.691	rs9996494	ENSG00000276997.3	RP11-378J18.9	5.96	8.41e-09	0.0175	0.4	0.35	Corneal astigmatism;	chr4:119317725	chr1:222477252~222504622:-
COAD	trans	rs1039766	1	rs268853	ENSG00000224334.1	AP000357.4	5.96	8.46e-09	0.0176	0.54	0.35	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr22:24686923~24688087:+
COAD	trans	rs1419856	0.929	rs57774509	ENSG00000224061.1	AC092106.1	5.96	8.47e-09	0.0176	0.46	0.35	QRS duration;	chr7:35283889	chr2:106253231~106253717:-
COAD	trans	rs7539409	0.651	rs979757	ENSG00000258591.2	RP11-545M17.3	5.96	8.47e-09	0.0176	0.53	0.35	Alzheimer's disease;	chr1:83830922	chr14:39108342~39108707:+
COAD	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	5.96	8.47e-09	0.0176	0.43	0.35	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.82	rs11737395	ENSG00000276997.3	RP11-378J18.9	5.95	8.52e-09	0.0177	0.41	0.35	Corneal astigmatism;	chr4:119599549	chr1:222477252~222504622:-
COAD	trans	rs10882165	0.756	rs4918902	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93194810	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs9732187	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93195394	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs4434922	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93196113	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs10882180	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93196498	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs1079486	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93196695	chr7:95416108~95416462:+
COAD	trans	rs10882165	0.756	rs3890742	ENSG00000273138.1	GS1-293C5.1	-5.95	8.58e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93197009	chr7:95416108~95416462:+
COAD	trans	rs4276421	0.615	rs12108961	ENSG00000231752.4	EMBP1	5.95	8.58e-09	0.0178	0.46	0.35	P wave duration;	chr5:45845859	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.571	rs4560554	ENSG00000231752.4	EMBP1	5.95	8.58e-09	0.0178	0.46	0.35	P wave duration;	chr5:45867574	chr1:121519112~121571892:+
COAD	trans	rs10882165	0.756	rs4917681	ENSG00000273138.1	GS1-293C5.1	-5.95	8.59e-09	0.0178	-0.34	-0.35	Refractive error;	chr10:93194869	chr7:95416108~95416462:+
COAD	trans	rs28647808	1	rs33919837	ENSG00000234981.1	RP11-534L20.4	5.95	8.62e-09	0.0179	0.77	0.35	Blood protein levels;	chr9:133403828	chr1:206528915~206529706:+
COAD	trans	rs28647808	1	rs17150557	ENSG00000234981.1	RP11-534L20.4	5.95	8.62e-09	0.0179	0.77	0.35	Blood protein levels;	chr9:133405671	chr1:206528915~206529706:+
COAD	trans	rs28647808	1	rs4962144	ENSG00000234981.1	RP11-534L20.4	5.95	8.62e-09	0.0179	0.77	0.35	Blood protein levels;	chr9:133410021	chr1:206528915~206529706:+
COAD	trans	rs28647808	1	rs3780807	ENSG00000234981.1	RP11-534L20.4	5.95	8.62e-09	0.0179	0.77	0.35	Blood protein levels;	chr9:133414312	chr1:206528915~206529706:+
COAD	trans	rs28647808	1	rs4962048	ENSG00000234981.1	RP11-534L20.4	5.95	8.62e-09	0.0179	0.77	0.35	Blood protein levels;	chr9:133415918	chr1:206528915~206529706:+
COAD	trans	rs3213958	0.574	rs56075614	ENSG00000255624.2	RP11-564D11.3	-5.95	8.68e-09	0.018	-0.66	-0.35	Blood protein levels;	chr3:98819973	chr10:122879851~122898024:+
COAD	trans	rs3213958	0.574	rs6440159	ENSG00000255624.2	RP11-564D11.3	-5.95	8.68e-09	0.018	-0.66	-0.35	Blood protein levels;	chr3:98823350	chr10:122879851~122898024:+
COAD	trans	rs8177876	0.822	rs8043855	ENSG00000226040.3	AC005740.3	5.95	8.71e-09	0.0181	0.49	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089256	chr5:141896168~141896689:-
COAD	trans	rs10037055	0.741	rs4976640	ENSG00000228305.2	AC016734.2	-5.95	8.74e-09	0.0181	-0.38	-0.35	Migraine without aura;	chr5:177125006	chr2:63622178~63622831:-
COAD	trans	rs34421088	0.56	rs2245250	ENSG00000173295.6	FAM86B3P	-5.95	8.76e-09	0.0181	-0.41	-0.35	Neuroticism;	chr8:11543171	chr8:8228595~8244865:+
COAD	trans	rs9329221	0.741	rs534523	ENSG00000253981.4	ALG1L13P	-5.95	8.77e-09	0.0182	-0.41	-0.35	Neuroticism;	chr8:10027489	chr8:8236003~8244667:-
COAD	trans	rs3806843	0.966	rs10060640	ENSG00000231043.3	AC007238.1	-5.95	8.81e-09	0.0182	-0.35	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.954	rs10034623	ENSG00000276997.3	RP11-378J18.9	5.95	8.96e-09	0.0185	0.4	0.35	Corneal astigmatism;	chr4:119476674	chr1:222477252~222504622:-
COAD	trans	rs7945705	0.747	rs1980428	ENSG00000266891.1	RP11-692N5.2	-5.94	9.02e-09	0.0186	-0.41	-0.35	Hemoglobin concentration;	chr11:8988950	chr18:9734882~9735602:-
COAD	trans	rs7024334	0.645	rs1601248	ENSG00000235574.1	AC073150.6	5.94	9.02e-09	0.0186	0.43	0.35	Body mass index;	chr9:106354171	chr7:27491682~27492765:-
COAD	trans	rs2950393	0.804	rs11171951	ENSG00000228224.3	NACAP1	5.94	9.14e-09	0.0189	0.35	0.35	Platelet distribution width;	chr12:56718853	chr8:101361794~101372707:+
COAD	trans	rs9329221	0.716	rs11989640	ENSG00000173295.6	FAM86B3P	-5.94	9.2e-09	0.019	-0.43	-0.35	Neuroticism;	chr8:10398544	chr8:8228595~8244865:+
COAD	trans	rs6540731	1	rs951623	ENSG00000227542.1	AC092614.2	5.94	9.38e-09	0.0193	0.41	0.35	Intelligence (childhood);	chr1:212225720	chr2:191229165~191246172:-
COAD	trans	rs9329221	0.905	rs28712068	ENSG00000253981.4	ALG1L13P	-5.94	9.4e-09	0.0193	-0.42	-0.35	Neuroticism;	chr8:10393635	chr8:8236003~8244667:-
COAD	trans	rs3812762	0.658	rs10769956	ENSG00000266891.1	RP11-692N5.2	-5.94	9.42e-09	0.0194	-0.43	-0.35	Hypospadias;	chr11:8772429	chr18:9734882~9735602:-
COAD	trans	rs9876781	0.624	rs12491849	ENSG00000235912.1	RP1-159A19.3	-5.94	9.42e-09	0.0194	-0.38	-0.35	Longevity;	chr3:48489975	chr1:27649419~27649610:+
COAD	trans	rs11098499	1	rs11098499	ENSG00000276997.3	RP11-378J18.9	5.94	9.43e-09	0.0194	0.41	0.35	Corneal astigmatism;	chr4:119266456	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.966	rs2563267	ENSG00000231043.3	AC007238.1	5.94	9.45e-09	0.0194	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs2563266	ENSG00000231043.3	AC007238.1	5.94	9.45e-09	0.0194	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr2:58460292~58462032:-
COAD	trans	rs5758265	1	rs5758265	ENSG00000268568.1	AC007228.9	-5.94	9.47e-09	0.0195	-0.43	-0.35	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr19:56672574~56673901:-
COAD	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	5.94	9.47e-09	0.0195	0.55	0.35	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
COAD	trans	rs3806843	0.75	rs2563285	ENSG00000231043.3	AC007238.1	5.93	9.51e-09	0.0196	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr2:58460292~58462032:-
COAD	trans	rs10045971	0.905	rs6869299	ENSG00000280927.1	CTBP1-AS	5.93	9.59e-09	0.0197	0.22	0.35	Depressive symptoms;	chr5:165048026	chr4:1210120~1218591:+
COAD	trans	rs34421088	0.56	rs2248325	ENSG00000173295.6	FAM86B3P	-5.93	9.6e-09	0.0197	-0.41	-0.35	Neuroticism;	chr8:11539365	chr8:8228595~8244865:+
COAD	trans	rs34421088	0.56	rs2248316	ENSG00000173295.6	FAM86B3P	-5.93	9.6e-09	0.0197	-0.41	-0.35	Neuroticism;	chr8:11539564	chr8:8228595~8244865:+
COAD	trans	rs10841376	0.614	rs4762815	ENSG00000280347.1	AC000123.2	-5.93	9.66e-09	0.0198	-0.3	-0.35	Systolic blood pressure;	chr12:19818576	chr7:127359785~127364759:-
COAD	trans	rs11098499	1	rs11098500	ENSG00000276997.3	RP11-378J18.9	5.93	9.67e-09	0.0198	0.41	0.35	Corneal astigmatism;	chr4:119298084	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs4404730	ENSG00000231043.3	AC007238.1	-5.93	9.68e-09	0.0199	-0.35	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr2:58460292~58462032:-
COAD	trans	rs10028773	0.7	rs7671797	ENSG00000276997.3	RP11-378J18.9	5.93	9.77e-09	0.02	0.4	0.35	Educational attainment;	chr4:119327002	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	5.93	9.78e-09	0.02	0.35	0.35	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
COAD	trans	rs2950393	0.804	rs898609	ENSG00000228224.3	NACAP1	5.93	9.83e-09	0.0201	0.35	0.35	Platelet distribution width;	chr12:56713026	chr8:101361794~101372707:+
COAD	trans	rs2950393	0.804	rs4902	ENSG00000228224.3	NACAP1	5.93	9.83e-09	0.0201	0.35	0.35	Platelet distribution width;	chr12:56714419	chr8:101361794~101372707:+
COAD	trans	rs4276421	0.593	rs10062641	ENSG00000231752.4	EMBP1	5.93	9.83e-09	0.0201	0.46	0.35	P wave duration;	chr5:45930240	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.82	rs6829903	ENSG00000276997.3	RP11-378J18.9	5.93	9.84e-09	0.0201	0.41	0.35	Corneal astigmatism;	chr4:119585729	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs7669520	ENSG00000276997.3	RP11-378J18.9	5.93	9.84e-09	0.0201	0.41	0.35	Corneal astigmatism;	chr4:119594123	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs12717860	ENSG00000231043.3	AC007238.1	-5.93	9.85e-09	0.0202	-0.35	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr2:58460292~58462032:-
COAD	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-5.93	9.88e-09	0.0202	-0.37	-0.35	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
COAD	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-5.93	9.92e-09	0.0203	-0.48	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
COAD	trans	rs34421088	0.56	rs2248315	ENSG00000173295.6	FAM86B3P	-5.93	9.92e-09	0.0203	-0.4	-0.35	Neuroticism;	chr8:11539577	chr8:8228595~8244865:+
COAD	trans	rs2950393	0.777	rs12828563	ENSG00000228224.3	NACAP1	5.93	9.93e-09	0.0203	0.35	0.35	Platelet distribution width;	chr12:56709378	chr8:101361794~101372707:+
COAD	trans	rs4883201	0.572	rs1805735	ENSG00000179899.8	PHC1P1	5.93	9.99e-09	0.0205	0.5	0.35	Total cholesterol levels;Cholesterol, total;	chr12:8934087	chr12:55411727~55414787:-
COAD	trans	rs7819412	0.594	rs17724226	ENSG00000173295.6	FAM86B3P	-5.92	1e-08	0.0205	-0.42	-0.35	Triglycerides;	chr8:11111416	chr8:8228595~8244865:+
COAD	trans	rs864643	0.524	rs78956370	ENSG00000183298.5	RP11-556K13.1	5.92	1e-08	0.0205	0.64	0.35	Attention deficit hyperactivity disorder;	chr3:39463883	chr1:101786340~101787219:-
COAD	trans	rs12340987	0.636	rs17420946	ENSG00000279225.1	RP11-2K6.1	5.92	1e-08	0.0205	0.72	0.35	Birth weight;	chr9:85140032	chr16:63397707~63397946:+
COAD	trans	rs11098499	0.789	rs9991166	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119316696	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.708	rs10005237	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119316742	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.575	rs907204	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119317499	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.575	rs907205	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119317509	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs878372	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119317625	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs10213267	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119317919	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs10212775	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119318089	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs11732087	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119318676	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs2964	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119318976	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs1511025	ENSG00000276997.3	RP11-378J18.9	5.92	1.01e-08	0.0206	0.4	0.35	Corneal astigmatism;	chr4:119319083	chr1:222477252~222504622:-
COAD	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-5.92	1.01e-08	0.0206	-0.46	-0.35	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
COAD	trans	rs9329221	0.537	rs13282106	ENSG00000173295.6	FAM86B3P	5.92	1.01e-08	0.0207	0.4	0.35	Neuroticism;	chr8:10124390	chr8:8228595~8244865:+
COAD	trans	rs3213958	0.574	rs8179927	ENSG00000255624.2	RP11-564D11.3	-5.92	1.02e-08	0.0209	-0.6	-0.35	Blood protein levels;	chr3:98830307	chr10:122879851~122898024:+
COAD	trans	rs4276421	0.593	rs4132311	ENSG00000231752.4	EMBP1	5.92	1.02e-08	0.0209	0.46	0.35	P wave duration;	chr5:45867992	chr1:121519112~121571892:+
COAD	trans	rs7554547	0.6	rs2273290	ENSG00000261819.1	RP11-680G24.4	5.92	1.02e-08	0.0209	0.53	0.35	Nonsyndromic cleft lip with cleft palate;	chr1:11958321	chr16:14988259~14990160:-
COAD	trans	rs7121616	0.576	rs1461495	ENSG00000229091.2	HSPA8P8	-5.92	1.02e-08	0.0209	-0.42	-0.35	Breast cancer;	chr11:123056136	chr7:10451311~10452526:+
COAD	trans	rs12785341	0.541	rs12282038	ENSG00000235124.1	KRT8P17	5.92	1.03e-08	0.0209	0.53	0.35	Renal sinus fat;	chr11:110618190	chrX:57984686~57986133:+
COAD	trans	rs4276421	0.55	rs62373044	ENSG00000231752.4	EMBP1	5.92	1.03e-08	0.021	0.46	0.35	P wave duration;	chr5:46005052	chr1:121519112~121571892:+
COAD	trans	rs4740619	0.81	rs10810430	ENSG00000244021.4	RP11-50D9.1	-5.92	1.03e-08	0.021	-0.31	-0.35	Body mass index;	chr9:15704213	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.81	rs12004358	ENSG00000244021.4	RP11-50D9.1	-5.92	1.03e-08	0.021	-0.31	-0.35	Body mass index;	chr9:15704529	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.81	rs10962123	ENSG00000244021.4	RP11-50D9.1	-5.92	1.03e-08	0.021	-0.31	-0.35	Body mass index;	chr9:15704774	chr4:127812720~127813200:-
COAD	trans	rs11098499	1	rs6837898	ENSG00000276997.3	RP11-378J18.9	5.92	1.03e-08	0.021	0.41	0.35	Corneal astigmatism;	chr4:119257999	chr1:222477252~222504622:-
COAD	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	5.92	1.04e-08	0.0211	0.44	0.35	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
COAD	trans	rs4740619	0.81	rs36086644	ENSG00000244021.4	RP11-50D9.1	-5.92	1.04e-08	0.0212	-0.31	-0.35	Body mass index;	chr9:15713415	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.81	rs2175080	ENSG00000244021.4	RP11-50D9.1	-5.92	1.04e-08	0.0212	-0.31	-0.35	Body mass index;	chr9:15714467	chr4:127812720~127813200:-
COAD	trans	rs864643	0.524	rs80322842	ENSG00000183298.5	RP11-556K13.1	5.92	1.04e-08	0.0213	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39483682	chr1:101786340~101787219:-
COAD	trans	rs6601327	0.67	rs7004937	ENSG00000253981.4	ALG1L13P	5.92	1.04e-08	0.0213	0.43	0.35	Multiple myeloma (hyperdiploidy);	chr8:9563451	chr8:8236003~8244667:-
COAD	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	5.92	1.05e-08	0.0213	0.42	0.35	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
COAD	trans	rs62344088	0.59	rs7700533	ENSG00000185986.11	SDHAP3	5.92	1.05e-08	0.0213	0.77	0.35	Asthma (childhood onset);	chr5:180531	chr5:1572222~1594620:-
COAD	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	5.92	1.05e-08	0.0213	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
COAD	trans	rs1285495	0.872	rs1148756	ENSG00000253327.2	RAD21-AS1	5.92	1.05e-08	0.0213	0.44	0.35	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr1:187351766	chr8:116874424~116876868:+
COAD	trans	rs864643	0.524	rs17038918	ENSG00000183298.5	RP11-556K13.1	5.92	1.05e-08	0.0214	0.6	0.35	Attention deficit hyperactivity disorder;	chr3:39480975	chr1:101786340~101787219:-
COAD	trans	rs10186876	0.728	rs4953034	ENSG00000225972.1	MTND1P23	5.91	1.05e-08	0.0215	0.36	0.35	Hand grip strength;	chr2:43916077	chr1:629062~629433:+
COAD	trans	rs11098499	0.754	rs938056	ENSG00000276997.3	RP11-378J18.9	5.91	1.06e-08	0.0215	0.4	0.35	Corneal astigmatism;	chr4:119316298	chr1:222477252~222504622:-
COAD	trans	rs7618501	1	rs6446295	ENSG00000197582.5	GPX1P1	5.91	1.06e-08	0.0216	0.4	0.35	Intelligence (multi-trait analysis);	chr3:49771630	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs34451146	ENSG00000197582.5	GPX1P1	5.91	1.06e-08	0.0216	0.4	0.35	Intelligence (multi-trait analysis);	chr3:49775580	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs11130221	ENSG00000197582.5	GPX1P1	5.91	1.06e-08	0.0216	0.4	0.35	Intelligence (multi-trait analysis);	chr3:49781669	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.966	rs13063621	ENSG00000197582.5	GPX1P1	5.91	1.06e-08	0.0216	0.4	0.35	Intelligence (multi-trait analysis);	chr3:49784192	chrX:13378735~13379340:-
COAD	trans	rs1039766	1	rs7558347	ENSG00000224334.1	AP000357.4	5.91	1.06e-08	0.0216	0.55	0.35	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr22:24686923~24688087:+
COAD	trans	rs7618501	1	rs7649348	ENSG00000197582.5	GPX1P1	-5.91	1.06e-08	0.0216	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49734942	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs7618519	ENSG00000197582.5	GPX1P1	-5.91	1.06e-08	0.0216	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49735275	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.735	rs9876508	ENSG00000197582.5	GPX1P1	-5.91	1.06e-08	0.0216	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49743411	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.722	rs9853458	ENSG00000197582.5	GPX1P1	-5.91	1.06e-08	0.0216	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49745778	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs7618501	ENSG00000197582.5	GPX1P1	-5.91	1.07e-08	0.0218	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49735214	chrX:13378735~13379340:-
COAD	trans	rs4512344	0.509	rs2409784	ENSG00000253981.4	ALG1L13P	-5.91	1.07e-08	0.0218	-0.41	-0.35	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8236003~8244667:-
COAD	trans	rs864643	0.524	rs12106854	ENSG00000183298.5	RP11-556K13.1	5.91	1.07e-08	0.0218	0.59	0.35	Attention deficit hyperactivity disorder;	chr3:39487321	chr1:101786340~101787219:-
COAD	trans	rs864643	0.524	rs17038967	ENSG00000183298.5	RP11-556K13.1	5.91	1.07e-08	0.0218	0.59	0.35	Attention deficit hyperactivity disorder;	chr3:39489530	chr1:101786340~101787219:-
COAD	trans	rs1722141	0.669	rs788743	ENSG00000211672.2	IGLV4-3	-5.91	1.07e-08	0.0218	-0.33	-0.35	Sitting height ratio;	chr7:45997886	chr22:22871507~22872035:+
COAD	trans	rs11098499	0.955	rs35434465	ENSG00000276997.3	RP11-378J18.9	5.91	1.08e-08	0.0218	0.41	0.35	Corneal astigmatism;	chr4:119248223	chr1:222477252~222504622:-
COAD	trans	rs3806843	0.676	rs778593	ENSG00000231043.3	AC007238.1	5.91	1.08e-08	0.0219	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.676	rs778594	ENSG00000231043.3	AC007238.1	5.91	1.08e-08	0.0219	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr2:58460292~58462032:-
COAD	trans	rs7824557	0.614	rs2736277	ENSG00000253981.4	ALG1L13P	-5.91	1.08e-08	0.0219	-0.43	-0.35	Retinal vascular caliber;	chr8:11361384	chr8:8236003~8244667:-
COAD	trans	rs7618501	1	rs3749241	ENSG00000197582.5	GPX1P1	-5.91	1.08e-08	0.0219	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49706959	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs3749240	ENSG00000197582.5	GPX1P1	-5.91	1.08e-08	0.0219	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49712755	chrX:13378735~13379340:-
COAD	trans	rs11098499	0.863	rs1010740	ENSG00000276997.3	RP11-378J18.9	-5.91	1.08e-08	0.0219	-0.4	-0.35	Corneal astigmatism;	chr4:119542254	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	5.91	1.09e-08	0.0221	0.39	0.35	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
COAD	trans	rs10091344	0.516	rs1458903	ENSG00000259322.1	RP11-762H8.1	5.91	1.09e-08	0.0221	0.41	0.35	Body mass index;	chr8:34341492	chr15:78293286~78296049:+
COAD	trans	rs10091344	0.516	rs2719303	ENSG00000259322.1	RP11-762H8.1	5.91	1.09e-08	0.0221	0.41	0.35	Body mass index;	chr8:34345066	chr15:78293286~78296049:+
COAD	trans	rs7121616	0.531	rs1461497	ENSG00000229091.2	HSPA8P8	5.91	1.1e-08	0.0222	0.42	0.35	Breast cancer;	chr11:123060505	chr7:10451311~10452526:+
COAD	trans	rs7121616	0.531	rs41361350	ENSG00000229091.2	HSPA8P8	5.91	1.1e-08	0.0222	0.42	0.35	Breast cancer;	chr11:123060917	chr7:10451311~10452526:+
COAD	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	5.91	1.1e-08	0.0223	0.45	0.35	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
COAD	trans	rs11098499	0.954	rs10017543	ENSG00000276997.3	RP11-378J18.9	5.91	1.1e-08	0.0223	0.42	0.35	Corneal astigmatism;	chr4:119400265	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.593	rs72750046	ENSG00000231752.4	EMBP1	5.91	1.1e-08	0.0223	0.46	0.35	P wave duration;	chr5:45930775	chr1:121519112~121571892:+
COAD	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	5.91	1.1e-08	0.0223	0.34	0.35	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
COAD	trans	rs6708331	0.517	rs12614547	ENSG00000232654.1	FAM136BP	5.91	1.11e-08	0.0224	0.42	0.35	Obesity-related traits;	chr2:70056839	chr6:3045384~3045800:+
COAD	trans	rs7618501	1	rs7634902	ENSG00000197582.5	GPX1P1	-5.91	1.11e-08	0.0224	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49725229	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs1049256	ENSG00000197582.5	GPX1P1	-5.91	1.11e-08	0.0224	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49725905	chrX:13378735~13379340:-
COAD	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	5.91	1.11e-08	0.0224	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	5.91	1.11e-08	0.0224	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	5.91	1.11e-08	0.0224	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	5.91	1.11e-08	0.0224	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	5.91	1.11e-08	0.0224	0.27	0.35	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
COAD	trans	rs11098499	0.954	rs6834796	ENSG00000276997.3	RP11-378J18.9	5.9	1.12e-08	0.0226	0.4	0.35	Corneal astigmatism;	chr4:119493538	chr1:222477252~222504622:-
COAD	trans	rs1285495	0.843	rs1148759	ENSG00000253327.2	RAD21-AS1	5.9	1.12e-08	0.0226	0.44	0.35	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr1:187343315	chr8:116874424~116876868:+
COAD	trans	rs74781061	0.929	rs4886599	ENSG00000227288.3	RP5-837I24.1	5.9	1.12e-08	0.0226	0.52	0.35	Endometriosis;	chr15:74484442	chr1:81501794~81503468:+
COAD	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	5.9	1.12e-08	0.0227	0.36	0.35	Longevity;	chr3:48407742	chr1:27649419~27649610:+
COAD	trans	rs4276421	0.509	rs4504391	ENSG00000231752.4	EMBP1	5.9	1.14e-08	0.023	0.43	0.35	P wave duration;	chr5:46035678	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.53	rs10078485	ENSG00000231752.4	EMBP1	5.9	1.15e-08	0.0231	0.46	0.35	P wave duration;	chr5:45879307	chr1:121519112~121571892:+
COAD	trans	rs11818084	0.83	rs4287298	ENSG00000266340.1	RP11-848P1.4	-5.9	1.15e-08	0.0231	-0.44	-0.35	Clozapine-induced cytotoxicity;	chr10:124293381	chr17:30978610~30980250:-
COAD	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	5.9	1.15e-08	0.0233	0.35	0.35	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
COAD	trans	rs864643	0.513	rs1768149	ENSG00000183298.5	RP11-556K13.1	5.9	1.16e-08	0.0233	0.47	0.35	Attention deficit hyperactivity disorder;	chr3:39466089	chr1:101786340~101787219:-
COAD	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-5.9	1.16e-08	0.0234	-0.37	-0.35	Longevity;	chr3:48414217	chr1:27649419~27649610:+
COAD	trans	rs4276421	0.615	rs6877477	ENSG00000231752.4	EMBP1	5.9	1.16e-08	0.0234	0.47	0.35	P wave duration;	chr5:45825707	chr1:121519112~121571892:+
COAD	trans	rs75904417	0.511	rs1900833	ENSG00000272779.1	LL22NC03-80A10.6	5.9	1.16e-08	0.0234	0.47	0.35	Interleukin-13 levels;Interleukin-7 levels;	chr2:167727471	chr22:22303224~22310401:+
COAD	trans	rs673253	0.686	rs943513	ENSG00000231007.5	CDC20P1	5.9	1.16e-08	0.0235	0.44	0.35	Intelligence (multi-trait analysis);	chr1:43569801	chr9:87011652~87013151:+
COAD	trans	rs7618501	1	rs7374183	ENSG00000197582.5	GPX1P1	-5.9	1.16e-08	0.0235	-0.4	-0.35	Intelligence (multi-trait analysis);	chr3:49747700	chrX:13378735~13379340:-
COAD	trans	rs2306022	0.52	rs7168991	ENSG00000266066.1	POLRMTP1	-5.9	1.17e-08	0.0235	-0.78	-0.35	Dupuytren's disease;	chr15:68313274	chr17:62136972~62140639:-
COAD	trans	rs2306022	0.52	rs7174916	ENSG00000266066.1	POLRMTP1	-5.9	1.17e-08	0.0235	-0.78	-0.35	Dupuytren's disease;	chr15:68313365	chr17:62136972~62140639:-
COAD	trans	rs3806843	0.676	rs2245640	ENSG00000231043.3	AC007238.1	5.9	1.17e-08	0.0235	0.35	0.35	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.954	rs3733520	ENSG00000276997.3	RP11-378J18.9	5.89	1.18e-08	0.0237	0.4	0.35	Corneal astigmatism;	chr4:119502325	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs10053586	ENSG00000231043.3	AC007238.1	-5.89	1.18e-08	0.0238	-0.35	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr2:58460292~58462032:-
COAD	trans	rs74781061	0.789	rs2289188	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74450127	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.789	rs12440654	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74453008	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs7169985	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74453437	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs8037211	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74455061	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.789	rs11852291	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74457624	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs4887152	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74464013	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.86	rs4544202	ENSG00000227288.3	RP5-837I24.1	5.89	1.19e-08	0.0239	0.5	0.35	Endometriosis;	chr15:74468654	chr1:81501794~81503468:+
COAD	trans	rs9329221	0.683	rs4598253	ENSG00000253981.4	ALG1L13P	-5.89	1.19e-08	0.0239	-0.41	-0.34	Neuroticism;	chr8:10032794	chr8:8236003~8244667:-
COAD	trans	rs35847492	1	rs17730481	ENSG00000253981.4	ALG1L13P	-5.89	1.19e-08	0.0239	-0.44	-0.34	Neuroticism;	chr8:9418653	chr8:8236003~8244667:-
COAD	trans	rs2242330	0.716	rs28765421	ENSG00000226982.4	CENPCP1	5.89	1.19e-08	0.024	0.54	0.34	Parkinson's disease;	chr4:67414698	chr12:89500093~89502670:+
COAD	trans	rs4276421	0.638	rs6895453	ENSG00000231752.4	EMBP1	5.89	1.2e-08	0.0241	0.43	0.34	P wave duration;	chr5:45850134	chr1:121519112~121571892:+
COAD	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-5.89	1.2e-08	0.0241	-0.43	-0.34	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
COAD	trans	rs10841376	0.59	rs11044883	ENSG00000280347.1	AC000123.2	-5.89	1.21e-08	0.0242	-0.3	-0.34	Systolic blood pressure;	chr12:19818198	chr7:127359785~127364759:-
COAD	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-5.89	1.21e-08	0.0244	-0.52	-0.34	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
COAD	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-5.89	1.21e-08	0.0244	-0.42	-0.34	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
COAD	trans	rs9611519	1	rs5758264	ENSG00000268568.1	AC007228.9	-5.89	1.21e-08	0.0244	-0.42	-0.34	Neuroticism;	chr22:41220280	chr19:56672574~56673901:-
COAD	trans	rs10817611	0.513	rs9657666	ENSG00000271138.1	IGLVIVOR22-1	-5.89	1.22e-08	0.0245	-0.4	-0.34	Survival in pancreatic cancer;	chr9:114470143	chr22:25437306~25437823:-
COAD	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-5.89	1.23e-08	0.0246	-0.36	-0.34	Longevity;	chr3:48438208	chr1:27649419~27649610:+
COAD	trans	rs7819412	0.623	rs7833435	ENSG00000173295.6	FAM86B3P	-5.89	1.23e-08	0.0246	-0.41	-0.34	Triglycerides;	chr8:10943627	chr8:8228595~8244865:+
COAD	trans	rs10186876	0.728	rs6759659	ENSG00000225972.1	MTND1P23	5.89	1.23e-08	0.0246	0.35	0.34	Hand grip strength;	chr2:43916617	chr1:629062~629433:+
COAD	trans	rs6732160	0.613	rs62151837	ENSG00000236165.1	PRADC1P1	5.88	1.24e-08	0.0248	0.45	0.34	Intelligence (multi-trait analysis);	chr2:73163268	chr3:36976316~36976840:+
COAD	trans	rs2899832	0.5	rs28522717	ENSG00000229083.1	PSMA6P2	5.88	1.24e-08	0.0248	0.58	0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35266346	chrX:12825840~12826833:+
COAD	trans	rs11098499	0.754	rs12510269	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119320491	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs12506610	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119320504	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.743	rs10003567	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119320519	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs10006259	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119320990	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs28652763	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119321157	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs7672594	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119327388	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs7672778	ENSG00000276997.3	RP11-378J18.9	5.88	1.24e-08	0.0248	0.39	0.34	Corneal astigmatism;	chr4:119327430	chr1:222477252~222504622:-
COAD	trans	rs6601327	0.67	rs12545250	ENSG00000173295.6	FAM86B3P	5.88	1.25e-08	0.025	0.42	0.34	Multiple myeloma (hyperdiploidy);	chr8:9563056	chr8:8228595~8244865:+
COAD	trans	rs11098499	1	rs58601355	ENSG00000276997.3	RP11-378J18.9	5.88	1.25e-08	0.025	0.4	0.34	Corneal astigmatism;	chr4:119265212	chr1:222477252~222504622:-
COAD	trans	rs944990	0.595	rs10821181	ENSG00000183055.5	FAM133CP	5.88	1.25e-08	0.0251	0.46	0.34	Body mass index;	chr9:93617201	chr10:58715554~58716257:+
COAD	trans	rs7258177	0.794	rs12981287	ENSG00000234982.1	RP11-280O24.3	5.88	1.26e-08	0.0252	0.35	0.34	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);	chr19:13726450	chr9:14204248~14205039:+
COAD	trans	rs9650657	0.547	rs11250099	ENSG00000253981.4	ALG1L13P	5.88	1.26e-08	0.0252	0.43	0.34	Neuroticism;	chr8:10961147	chr8:8236003~8244667:-
COAD	trans	rs1419856	0.81	rs62451940	ENSG00000224061.1	AC092106.1	5.88	1.26e-08	0.0252	0.46	0.34	QRS duration;	chr7:35293824	chr2:106253231~106253717:-
COAD	trans	rs4276421	0.571	rs10074470	ENSG00000231752.4	EMBP1	5.88	1.26e-08	0.0253	0.45	0.34	P wave duration;	chr5:45940922	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs878376	ENSG00000276997.3	RP11-378J18.9	5.88	1.27e-08	0.0253	0.39	0.34	Corneal astigmatism;	chr4:119316547	chr1:222477252~222504622:-
COAD	trans	rs1435703	1	rs57195207	ENSG00000265802.2	RN7SL49P	-5.88	1.27e-08	0.0254	-0.55	-0.34	Obesity (extreme);	chr3:25516749	chr13:45002150~45002447:+
COAD	trans	rs877636	0.74	rs705698	ENSG00000196933.5	RPS26P11	5.88	1.28e-08	0.0255	0.45	0.34	Cognitive function;	chr12:55990903	chrX:72044545~72044892:+
COAD	trans	rs3806843	0.966	rs7710380	ENSG00000231043.3	AC007238.1	-5.88	1.28e-08	0.0256	-0.36	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.826	rs4472123	ENSG00000276997.3	RP11-378J18.9	5.88	1.29e-08	0.0257	0.4	0.34	Corneal astigmatism;	chr4:119315475	chr1:222477252~222504622:-
COAD	trans	rs2060793	0.55	rs1037378	ENSG00000236360.2	RP11-334A14.2	5.88	1.3e-08	0.0258	0.45	0.34	Vitamin D levels;	chr11:14830944	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.863	rs11098532	ENSG00000276997.3	RP11-378J18.9	5.88	1.3e-08	0.0259	0.41	0.34	Corneal astigmatism;	chr4:119569571	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.789	rs10212719	ENSG00000276997.3	RP11-378J18.9	5.87	1.31e-08	0.026	0.4	0.34	Corneal astigmatism;	chr4:119333282	chr1:222477252~222504622:-
COAD	trans	rs1480597	0.605	rs12258354	ENSG00000251008.1	ORAOV1P1	5.87	1.31e-08	0.0261	0.57	0.34	Parkinson's disease;	chr10:44634035	chr4:186170863~186171257:-
COAD	trans	rs11098499	0.863	rs1383532	ENSG00000276997.3	RP11-378J18.9	-5.87	1.32e-08	0.0262	-0.4	-0.34	Corneal astigmatism;	chr4:119513249	chr1:222477252~222504622:-
COAD	trans	rs3770081	1	rs78032828	ENSG00000229880.1	IMMTP1	5.87	1.32e-08	0.0263	0.68	0.34	Facial emotion recognition (sad faces);	chr2:86081909	chr21:44675868~44678086:-
COAD	trans	rs3740713	0.748	rs35292478	ENSG00000236090.2	LDHAP3	5.87	1.32e-08	0.0263	0.6	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:41819747~41820754:+
COAD	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	5.87	1.32e-08	0.0264	0.41	0.34	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
COAD	trans	rs7121616	0.576	rs7123232	ENSG00000229091.2	HSPA8P8	5.87	1.33e-08	0.0265	0.41	0.34	Breast cancer;	chr11:123056237	chr7:10451311~10452526:+
COAD	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	5.87	1.34e-08	0.0266	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
COAD	trans	rs2288327	0.673	rs35504893	ENSG00000269800.1	PLEKHA3P1	5.87	1.34e-08	0.0267	0.43	0.34	Atrial fibrillation;	chr2:178556567	chr19:41521043~41521989:-
COAD	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-5.87	1.34e-08	0.0267	-0.42	-0.34	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
COAD	trans	rs902774	0.818	rs4919740	ENSG00000224520.2	KRT8P45	-5.87	1.35e-08	0.0268	-0.6	-0.34	Prostate cancer;	chr12:52877187	chr1:157073257~157074703:+
COAD	trans	rs17220352	0.557	rs62575438	ENSG00000233732.5	IGHV3OR16-10	-5.87	1.35e-08	0.0268	-0.29	-0.34	Headache;	chr9:116502148	chr16:32995048~32995505:+
COAD	trans	rs3806843	0.966	rs2563260	ENSG00000231043.3	AC007238.1	5.87	1.35e-08	0.0269	0.35	0.34	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr2:58460292~58462032:-
COAD	trans	rs4276421	0.55	rs10473403	ENSG00000231752.4	EMBP1	5.87	1.36e-08	0.027	0.45	0.34	P wave duration;	chr5:45921272	chr1:121519112~121571892:+
COAD	trans	rs66887589	0.934	rs2389873	ENSG00000275858.1	RP11-291L22.8	-5.87	1.36e-08	0.027	-0.34	-0.34	Diastolic blood pressure;	chr4:119633559	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.934	rs4834792	ENSG00000275858.1	RP11-291L22.8	-5.87	1.36e-08	0.027	-0.34	-0.34	Diastolic blood pressure;	chr4:119634541	chr10:38450738~38451069:-
COAD	trans	rs11098499	0.754	rs4107728	ENSG00000276997.3	RP11-378J18.9	5.87	1.36e-08	0.0271	0.39	0.34	Corneal astigmatism;	chr4:119332755	chr1:222477252~222504622:-
COAD	trans	rs1635	0.574	rs7757215	ENSG00000211970.3	IGHV4-61	-5.87	1.37e-08	0.0271	-0.4	-0.34	Schizophrenia;	chr6:28244711	chr14:106639119~106639657:-
COAD	trans	rs11098499	0.863	rs3775854	ENSG00000276997.3	RP11-378J18.9	5.87	1.37e-08	0.0271	0.41	0.34	Corneal astigmatism;	chr4:119550816	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.691	rs17009144	ENSG00000276997.3	RP11-378J18.9	-5.87	1.37e-08	0.0271	-0.39	-0.34	Corneal astigmatism;	chr4:119349640	chr1:222477252~222504622:-
COAD	trans	rs7824557	0.527	rs2572449	ENSG00000253981.4	ALG1L13P	5.87	1.37e-08	0.0272	0.39	0.34	Retinal vascular caliber;	chr8:11381628	chr8:8236003~8244667:-
COAD	trans	rs3806843	0.735	rs801183	ENSG00000231043.3	AC007238.1	-5.87	1.37e-08	0.0272	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr2:58460292~58462032:-
COAD	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	5.87	1.37e-08	0.0272	0.71	0.34	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
COAD	trans	rs4512344	0.509	rs2409784	ENSG00000173295.6	FAM86B3P	-5.86	1.38e-08	0.0273	-0.4	-0.34	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8228595~8244865:+
COAD	trans	rs9329221	0.698	rs12547997	ENSG00000173295.6	FAM86B3P	5.86	1.38e-08	0.0274	0.41	0.34	Neuroticism;	chr8:10403327	chr8:8228595~8244865:+
COAD	trans	rs9329221	1	rs9329221	ENSG00000253981.4	ALG1L13P	5.86	1.38e-08	0.0274	0.4	0.34	Neuroticism;	chr8:10382692	chr8:8236003~8244667:-
COAD	trans	rs4276421	0.593	rs4569882	ENSG00000231752.4	EMBP1	5.86	1.38e-08	0.0274	0.45	0.34	P wave duration;	chr5:46011875	chr1:121519112~121571892:+
COAD	trans	rs1480597	0.605	rs12249457	ENSG00000251008.1	ORAOV1P1	5.86	1.39e-08	0.0275	0.57	0.34	Parkinson's disease;	chr10:44628488	chr4:186170863~186171257:-
COAD	trans	rs11794666	0.929	rs7024213	ENSG00000254760.1	CTD-2616J11.3	5.86	1.4e-08	0.0277	0.57	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr9:31797880	chr19:51414298~51414965:+
COAD	trans	rs9329221	0.741	rs534523	ENSG00000173295.6	FAM86B3P	-5.86	1.41e-08	0.0279	-0.4	-0.34	Neuroticism;	chr8:10027489	chr8:8228595~8244865:+
COAD	trans	rs1424638	0.584	rs11884387	ENSG00000241651.4	RP11-214O14.1	5.86	1.43e-08	0.0282	0.39	0.34	Intelligence (multi-trait analysis);	chr2:57002862	chr4:128069014~128069612:-
COAD	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	5.86	1.43e-08	0.0283	0.43	0.34	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
COAD	trans	rs77688320	0.5	rs6755428	ENSG00000235105.1	RP11-329A14.1	5.86	1.44e-08	0.0284	0.41	0.34	Breast cancer;	chr2:201431043	chr1:48435967~48437223:+
COAD	trans	rs11098499	0.821	rs10032151	ENSG00000276997.3	RP11-378J18.9	5.86	1.45e-08	0.0286	0.4	0.34	Corneal astigmatism;	chr4:119470473	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs10032158	ENSG00000276997.3	RP11-378J18.9	5.86	1.45e-08	0.0286	0.4	0.34	Corneal astigmatism;	chr4:119470477	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.697	rs35280960	ENSG00000276997.3	RP11-378J18.9	5.85	1.45e-08	0.0287	0.41	0.34	Corneal astigmatism;	chr4:119335904	chr1:222477252~222504622:-
COAD	trans	rs864643	0.524	rs11715885	ENSG00000183298.5	RP11-556K13.1	5.85	1.45e-08	0.0287	0.63	0.34	Attention deficit hyperactivity disorder;	chr3:39475107	chr1:101786340~101787219:-
COAD	trans	rs11098499	0.863	rs6833334	ENSG00000276997.3	RP11-378J18.9	5.85	1.45e-08	0.0287	0.41	0.34	Corneal astigmatism;	chr4:119583072	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.506	rs6993610	ENSG00000173295.6	FAM86B3P	-5.85	1.45e-08	0.0287	-0.41	-0.34	Neuroticism;	chr8:10473484	chr8:8228595~8244865:+
COAD	trans	rs944990	0.64	rs10992804	ENSG00000183055.5	FAM133CP	5.85	1.46e-08	0.0288	0.44	0.34	Body mass index;	chr9:93618070	chr10:58715554~58716257:+
COAD	trans	rs11098499	0.954	rs11098526	ENSG00000276997.3	RP11-378J18.9	5.85	1.46e-08	0.0289	0.41	0.34	Corneal astigmatism;	chr4:119469204	chr1:222477252~222504622:-
COAD	trans	rs6601327	0.607	rs35316422	ENSG00000173295.6	FAM86B3P	-5.85	1.47e-08	0.029	-0.43	-0.34	Multiple myeloma (hyperdiploidy);	chr8:9717619	chr8:8228595~8244865:+
COAD	trans	rs6732160	0.613	rs57208378	ENSG00000236165.1	PRADC1P1	5.85	1.48e-08	0.0291	0.45	0.34	Intelligence (multi-trait analysis);	chr2:73162871	chr3:36976316~36976840:+
COAD	trans	rs3806843	1	rs6870764	ENSG00000231043.3	AC007238.1	-5.85	1.48e-08	0.0292	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs6891995	ENSG00000231043.3	AC007238.1	-5.85	1.48e-08	0.0292	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs13184940	ENSG00000231043.3	AC007238.1	-5.85	1.48e-08	0.0292	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs1476768	ENSG00000231043.3	AC007238.1	-5.85	1.48e-08	0.0292	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs9686540	ENSG00000231043.3	AC007238.1	-5.85	1.48e-08	0.0292	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr2:58460292~58462032:-
COAD	trans	rs6601327	0.641	rs7462070	ENSG00000173295.6	FAM86B3P	-5.85	1.48e-08	0.0292	-0.43	-0.34	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.863	rs2306457	ENSG00000276997.3	RP11-378J18.9	5.85	1.49e-08	0.0292	0.41	0.34	Corneal astigmatism;	chr4:119551684	chr1:222477252~222504622:-
COAD	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	5.85	1.49e-08	0.0293	0.27	0.34	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
COAD	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	5.85	1.49e-08	0.0293	0.27	0.34	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
COAD	trans	rs4782151	1	rs4782151	ENSG00000225083.1	GRTP1-AS1	5.85	1.49e-08	0.0293	0.31	0.34	Cervical cancer;	chr16:9232128	chr13:113351673~113361868:+
COAD	trans	rs7121616	0.576	rs7111598	ENSG00000229091.2	HSPA8P8	5.85	1.49e-08	0.0294	0.41	0.34	Breast cancer;	chr11:123055438	chr7:10451311~10452526:+
COAD	trans	rs11098499	0.863	rs1010739	ENSG00000276997.3	RP11-378J18.9	5.85	1.5e-08	0.0295	0.4	0.34	Corneal astigmatism;	chr4:119542316	chr1:222477252~222504622:-
COAD	trans	rs3806843	1	rs3756339	ENSG00000231043.3	AC007238.1	-5.85	1.5e-08	0.0295	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs3733708	ENSG00000231043.3	AC007238.1	-5.85	1.5e-08	0.0295	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs2240694	ENSG00000231043.3	AC007238.1	-5.85	1.5e-08	0.0295	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr2:58460292~58462032:-
COAD	trans	rs7824557	0.518	rs11250094	ENSG00000173295.6	FAM86B3P	-5.85	1.5e-08	0.0296	-0.41	-0.34	Retinal vascular caliber;	chr8:10944491	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.863	rs59732491	ENSG00000276997.3	RP11-378J18.9	5.85	1.51e-08	0.0297	0.41	0.34	Corneal astigmatism;	chr4:119568433	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs11723090	ENSG00000276997.3	RP11-378J18.9	5.85	1.51e-08	0.0297	0.41	0.34	Corneal astigmatism;	chr4:119569437	chr1:222477252~222504622:-
COAD	trans	rs7246760	1	rs1592997	ENSG00000236281.1	AC093106.5	-5.85	1.51e-08	0.0297	-0.56	-0.34	Pursuit maintenance gain;	chr19:9790307	chr7:131753746~131754252:-
COAD	trans	rs1507153	0.562	rs1567096	ENSG00000254418.1	RP11-21L19.1	-5.85	1.52e-08	0.0298	-0.39	-0.34	Sjögren's syndrome;	chr6:78606363	chr11:14262846~14273691:-
COAD	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	5.85	1.52e-08	0.0299	0.43	0.34	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
COAD	trans	rs4276421	0.509	rs8185343	ENSG00000231752.4	EMBP1	5.85	1.52e-08	0.03	0.45	0.34	P wave duration;	chr5:46012100	chr1:121519112~121571892:+
COAD	trans	rs7900823	0.528	rs1870097	ENSG00000234769.7	WASH4P	5.85	1.53e-08	0.03	0.46	0.34	Lung cancer;	chr10:28252543	chr16:14381~18068:-
COAD	trans	rs3213958	0.509	rs73136060	ENSG00000255624.2	RP11-564D11.3	-5.84	1.54e-08	0.0301	-0.58	-0.34	Blood protein levels;	chr3:98792641	chr10:122879851~122898024:+
COAD	trans	rs3213958	0.574	rs2278599	ENSG00000255624.2	RP11-564D11.3	-5.84	1.54e-08	0.0301	-0.58	-0.34	Blood protein levels;	chr3:98793344	chr10:122879851~122898024:+
COAD	trans	rs7554511	0.666	rs2221581	ENSG00000244144.1	RP11-757F18.3	-5.84	1.55e-08	0.0303	-0.49	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201012797	chr3:112185480~112185998:-
COAD	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	5.84	1.55e-08	0.0305	0.39	0.34	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
COAD	trans	rs77688320	0.517	rs7573536	ENSG00000235105.1	RP11-329A14.1	5.84	1.55e-08	0.0305	0.4	0.34	Breast cancer;	chr2:201469676	chr1:48435967~48437223:+
COAD	trans	rs902774	0.818	rs73110432	ENSG00000223940.1	KRT8P8	-5.84	1.56e-08	0.0305	-0.64	-0.34	Prostate cancer;	chr12:52894051	chrX:152479577~152481024:+
COAD	trans	rs11098499	0.863	rs13140391	ENSG00000276997.3	RP11-378J18.9	5.84	1.57e-08	0.0307	0.41	0.34	Corneal astigmatism;	chr4:119582282	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs13140409	ENSG00000276997.3	RP11-378J18.9	5.84	1.57e-08	0.0307	0.41	0.34	Corneal astigmatism;	chr4:119582305	chr1:222477252~222504622:-
COAD	trans	rs4276421	0.509	rs10062391	ENSG00000231752.4	EMBP1	5.84	1.57e-08	0.0307	0.45	0.34	P wave duration;	chr5:45994818	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.638	rs10061699	ENSG00000231752.4	EMBP1	5.84	1.59e-08	0.031	0.43	0.34	P wave duration;	chr5:45864788	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.638	rs4282323	ENSG00000231752.4	EMBP1	5.84	1.59e-08	0.031	0.43	0.34	P wave duration;	chr5:45865241	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.638	rs4283798	ENSG00000231752.4	EMBP1	5.84	1.59e-08	0.031	0.43	0.34	P wave duration;	chr5:45866041	chr1:121519112~121571892:+
COAD	trans	rs7824557	0.527	rs2572449	ENSG00000173295.6	FAM86B3P	5.84	1.59e-08	0.0311	0.38	0.34	Retinal vascular caliber;	chr8:11381628	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.619	rs28502463	ENSG00000276997.3	RP11-378J18.9	5.84	1.59e-08	0.0311	0.39	0.34	Corneal astigmatism;	chr4:119335868	chr1:222477252~222504622:-
COAD	trans	rs673253	0.557	rs34898652	ENSG00000231007.5	CDC20P1	5.84	1.6e-08	0.0313	0.45	0.34	Intelligence (multi-trait analysis);	chr1:43508420	chr9:87011652~87013151:+
COAD	trans	rs11098499	0.863	rs6858592	ENSG00000276997.3	RP11-378J18.9	5.84	1.61e-08	0.0314	0.4	0.34	Corneal astigmatism;	chr4:119537537	chr1:222477252~222504622:-
COAD	trans	rs66887589	0.777	rs2017058	ENSG00000275858.1	RP11-291L22.8	5.83	1.63e-08	0.0317	0.35	0.34	Diastolic blood pressure;	chr4:119336584	chr10:38450738~38451069:-
COAD	trans	rs66887589	0.777	rs1814815	ENSG00000275858.1	RP11-291L22.8	5.83	1.63e-08	0.0317	0.35	0.34	Diastolic blood pressure;	chr4:119336936	chr10:38450738~38451069:-
COAD	trans	rs13016963	0.546	rs11898821	ENSG00000235105.1	RP11-329A14.1	5.83	1.63e-08	0.0317	0.41	0.34	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr1:48435967~48437223:+
COAD	trans	rs864643	0.678	rs1768206	ENSG00000183298.5	RP11-556K13.1	5.83	1.64e-08	0.0319	0.5	0.34	Attention deficit hyperactivity disorder;	chr3:39480342	chr1:101786340~101787219:-
COAD	trans	rs802425	1	rs802425	ENSG00000273348.1	RP11-535A5.1	-5.83	1.65e-08	0.0321	-0.34	-0.34	Neuroticism;	chr7:86665636	chr18:22347846~22348252:-
COAD	trans	rs902774	0.818	rs55958994	ENSG00000240668.1	KRT8P36	-5.83	1.65e-08	0.0322	-0.61	-0.34	Prostate cancer;	chr12:52907235	chr3:138101478~138102917:-
COAD	trans	rs963265	1	rs56280028	ENSG00000224956.5	RP11-206L10.1	5.83	1.66e-08	0.0324	0.36	0.34	Migraine with aura;	chr9:70473118	chr1:726231~728147:-
COAD	trans	rs7246760	1	rs56357664	ENSG00000236281.1	AC093106.5	-5.83	1.67e-08	0.0325	-0.55	-0.34	Pursuit maintenance gain;	chr19:9792723	chr7:131753746~131754252:-
COAD	trans	rs1480597	0.605	rs111397841	ENSG00000251008.1	ORAOV1P1	5.83	1.67e-08	0.0325	0.62	0.34	Parkinson's disease;	chr10:44595108	chr4:186170863~186171257:-
COAD	trans	rs1480597	0.605	rs75290175	ENSG00000251008.1	ORAOV1P1	5.83	1.67e-08	0.0325	0.62	0.34	Parkinson's disease;	chr10:44606586	chr4:186170863~186171257:-
COAD	trans	rs9329221	0.698	rs35388602	ENSG00000173295.6	FAM86B3P	5.83	1.67e-08	0.0325	0.41	0.34	Neuroticism;	chr8:10401678	chr8:8228595~8244865:+
COAD	trans	rs3806843	0.966	rs3806844	ENSG00000231043.3	AC007238.1	-5.83	1.67e-08	0.0325	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr2:58460292~58462032:-
COAD	trans	rs6601327	0.67	rs7004937	ENSG00000173295.6	FAM86B3P	5.83	1.67e-08	0.0325	0.42	0.34	Multiple myeloma (hyperdiploidy);	chr8:9563451	chr8:8228595~8244865:+
COAD	trans	rs453301	0.571	rs330048	ENSG00000173295.6	FAM86B3P	-5.83	1.68e-08	0.0326	-0.39	-0.34	Joint mobility (Beighton score);	chr8:9229768	chr8:8228595~8244865:+
COAD	trans	rs76228276	0.737	rs7841162	ENSG00000260318.1	COX6CP1	5.83	1.68e-08	0.0327	0.93	0.34	Childhood ear infection;	chr8:99895567	chr16:11903923~11904137:-
COAD	trans	rs7246760	1	rs58137206	ENSG00000236281.1	AC093106.5	-5.83	1.68e-08	0.0327	-0.56	-0.34	Pursuit maintenance gain;	chr19:9745948	chr7:131753746~131754252:-
COAD	trans	rs3806843	1	rs13157397	ENSG00000231043.3	AC007238.1	-5.83	1.69e-08	0.0328	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr2:58460292~58462032:-
COAD	trans	rs10242455	1	rs73395547	ENSG00000228834.1	RP11-249L21.4	5.83	1.69e-08	0.0328	0.59	0.34	Blood metabolite levels;	chr7:99325123	chr6:108907615~108907873:-
COAD	trans	rs3806843	0.735	rs801167	ENSG00000231043.3	AC007238.1	-5.83	1.7e-08	0.0329	-0.34	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr2:58460292~58462032:-
COAD	trans	rs3806843	0.966	rs4141841	ENSG00000231043.3	AC007238.1	-5.83	1.7e-08	0.0329	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr2:58460292~58462032:-
COAD	trans	rs3806843	1	rs10050455	ENSG00000231043.3	AC007238.1	-5.83	1.7e-08	0.0329	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr2:58460292~58462032:-
COAD	trans	rs10045971	0.934	rs4481363	ENSG00000280927.1	CTBP1-AS	5.83	1.7e-08	0.033	0.22	0.34	Depressive symptoms;	chr5:165047713	chr4:1210120~1218591:+
COAD	trans	rs864643	0.524	rs72869131	ENSG00000188856.6	RPSAP47	5.82	1.7e-08	0.033	0.44	0.34	Attention deficit hyperactivity disorder;	chr3:39472959	chr8:80558870~80559757:+
COAD	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	5.82	1.7e-08	0.033	0.39	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
COAD	trans	rs6743068	0.541	rs7578456	ENSG00000235105.1	RP11-329A14.1	5.82	1.7e-08	0.0331	0.41	0.34	Lymphocyte percentage of white cells;	chr2:201370625	chr1:48435967~48437223:+
COAD	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	5.82	1.71e-08	0.0331	0.45	0.34	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
COAD	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-5.82	1.71e-08	0.0332	-0.38	-0.34	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
COAD	trans	rs1480597	0.605	rs11592733	ENSG00000251008.1	ORAOV1P1	5.82	1.71e-08	0.0332	0.56	0.34	Parkinson's disease;	chr10:44626850	chr4:186170863~186171257:-
COAD	trans	rs1480597	0.605	rs7898535	ENSG00000251008.1	ORAOV1P1	5.82	1.71e-08	0.0332	0.56	0.34	Parkinson's disease;	chr10:44632422	chr4:186170863~186171257:-
COAD	trans	rs1480597	0.605	rs61079112	ENSG00000251008.1	ORAOV1P1	5.82	1.71e-08	0.0332	0.56	0.34	Parkinson's disease;	chr10:44632549	chr4:186170863~186171257:-
COAD	trans	rs11098499	0.863	rs6853998	ENSG00000276997.3	RP11-378J18.9	5.82	1.72e-08	0.0333	0.4	0.34	Corneal astigmatism;	chr4:119554705	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs6858777	ENSG00000276997.3	RP11-378J18.9	5.82	1.72e-08	0.0333	0.4	0.34	Corneal astigmatism;	chr4:119554811	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs11731756	ENSG00000276997.3	RP11-378J18.9	5.82	1.72e-08	0.0333	0.4	0.34	Corneal astigmatism;	chr4:119557541	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs34308924	ENSG00000276997.3	RP11-378J18.9	5.82	1.72e-08	0.0333	0.4	0.34	Corneal astigmatism;	chr4:119560276	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs2170276	ENSG00000276997.3	RP11-378J18.9	5.82	1.72e-08	0.0333	0.4	0.34	Corneal astigmatism;	chr4:119564669	chr1:222477252~222504622:-
COAD	trans	rs4740619	0.782	rs11793900	ENSG00000244021.4	RP11-50D9.1	-5.82	1.72e-08	0.0333	-0.3	-0.34	Body mass index;	chr9:15705720	chr4:127812720~127813200:-
COAD	trans	rs860295	0.529	rs10908486	ENSG00000241627.3	UBQLN4P1	5.82	1.72e-08	0.0333	0.37	0.34	Body mass index;	chr1:156008753	chr3:148985868~148987668:-
COAD	trans	rs6728642	0.908	rs10207116	ENSG00000253998.3	IGKV2-29	5.82	1.72e-08	0.0333	0.4	0.34	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355418	chr2:89234174~89234912:-
COAD	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	5.82	1.72e-08	0.0334	0.71	0.34	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
COAD	trans	rs4276421	0.509	rs10041094	ENSG00000231752.4	EMBP1	5.82	1.73e-08	0.0335	0.45	0.34	P wave duration;	chr5:45996800	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.754	rs1546503	ENSG00000276997.3	RP11-378J18.9	5.82	1.73e-08	0.0335	0.4	0.34	Corneal astigmatism;	chr4:119320012	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.708	rs1546506	ENSG00000276997.3	RP11-378J18.9	5.82	1.73e-08	0.0335	0.4	0.34	Corneal astigmatism;	chr4:119320085	chr1:222477252~222504622:-
COAD	trans	rs17220352	0.557	rs55695529	ENSG00000233732.5	IGHV3OR16-10	-5.82	1.74e-08	0.0336	-0.29	-0.34	Headache;	chr9:116500561	chr16:32995048~32995505:+
COAD	trans	rs9329221	0.537	rs1484640	ENSG00000253981.4	ALG1L13P	5.82	1.74e-08	0.0336	0.41	0.34	Neuroticism;	chr8:10125733	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	5.82	1.75e-08	0.0339	0.39	0.34	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
COAD	trans	rs34421088	0.559	rs12386974	ENSG00000173295.6	FAM86B3P	5.82	1.76e-08	0.034	0.4	0.34	Neuroticism;	chr8:11543119	chr8:8228595~8244865:+
COAD	trans	rs9425766	0.927	rs5878	ENSG00000213331.4	RP11-713C19.2	5.82	1.76e-08	0.0341	0.4	0.34	Life satisfaction;	chr1:173909694	chr4:187970273~187971284:+
COAD	trans	rs10037055	0.853	rs10077929	ENSG00000228305.2	AC016734.2	5.82	1.77e-08	0.0341	0.34	0.34	Migraine without aura;	chr5:177270843	chr2:63622178~63622831:-
COAD	trans	rs12709013	1	rs11648514	ENSG00000233719.3	GOT2P3	5.82	1.77e-08	0.0342	0.44	0.34	Blood metabolite ratios;	chr16:58798176	chr12:9641802~9643007:+
COAD	trans	rs12709013	1	rs8057892	ENSG00000233719.3	GOT2P3	5.82	1.77e-08	0.0342	0.44	0.34	Blood metabolite ratios;	chr16:58798855	chr12:9641802~9643007:+
COAD	trans	rs4240897	1	rs4240897	ENSG00000261819.1	RP11-680G24.4	-5.82	1.78e-08	0.0343	-0.45	-0.34	Tuberculosis;	chr1:11982698	chr16:14988259~14990160:-
COAD	trans	rs1480597	0.547	rs17487158	ENSG00000251008.1	ORAOV1P1	5.82	1.78e-08	0.0345	0.62	0.34	Parkinson's disease;	chr10:44590593	chr4:186170863~186171257:-
COAD	trans	rs1480597	0.605	rs11592776	ENSG00000251008.1	ORAOV1P1	5.82	1.78e-08	0.0345	0.62	0.34	Parkinson's disease;	chr10:44592155	chr4:186170863~186171257:-
COAD	trans	rs10841376	0.59	rs11044887	ENSG00000280347.1	AC000123.2	-5.82	1.79e-08	0.0345	-0.3	-0.34	Systolic blood pressure;	chr12:19820881	chr7:127359785~127364759:-
COAD	trans	rs4276421	0.593	rs61012768	ENSG00000231752.4	EMBP1	5.82	1.79e-08	0.0345	0.45	0.34	P wave duration;	chr5:45941000	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.593	rs7448897	ENSG00000231752.4	EMBP1	5.82	1.79e-08	0.0345	0.45	0.34	P wave duration;	chr5:45941347	chr1:121519112~121571892:+
COAD	trans	rs1869463	0.874	rs34641920	ENSG00000272043.1	RP11-44N11.3	-5.82	1.79e-08	0.0345	-0.43	-0.34	Corneal curvature;	chr4:58415375	chr8:122780760~122781071:+
COAD	trans	rs864643	0.678	rs7631217	ENSG00000183298.5	RP11-556K13.1	-5.82	1.79e-08	0.0346	-0.49	-0.34	Attention deficit hyperactivity disorder;	chr3:39478568	chr1:101786340~101787219:-
COAD	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	5.81	1.8e-08	0.0348	0.48	0.34	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
COAD	trans	rs74781061	0.929	rs2068982	ENSG00000227288.3	RP5-837I24.1	-5.81	1.81e-08	0.0349	-0.49	-0.34	Endometriosis;	chr15:74623547	chr1:81501794~81503468:+
COAD	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	5.81	1.81e-08	0.035	0.48	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
COAD	trans	rs11098499	0.909	rs78332141	ENSG00000276997.3	RP11-378J18.9	5.81	1.82e-08	0.0351	0.41	0.34	Corneal astigmatism;	chr4:119454627	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.62	rs6601427	ENSG00000173295.6	FAM86B3P	-5.81	1.82e-08	0.0351	-0.4	-0.34	Neuroticism;	chr8:10298515	chr8:8228595~8244865:+
COAD	trans	rs7246760	0.867	rs2336090	ENSG00000236281.1	AC093106.5	-5.81	1.83e-08	0.0353	-0.56	-0.34	Pursuit maintenance gain;	chr19:9768908	chr7:131753746~131754252:-
COAD	trans	rs7246760	1	rs12460571	ENSG00000236281.1	AC093106.5	-5.81	1.83e-08	0.0353	-0.56	-0.34	Pursuit maintenance gain;	chr19:9771070	chr7:131753746~131754252:-
COAD	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-5.81	1.84e-08	0.0355	-0.38	-0.34	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
COAD	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-5.81	1.84e-08	0.0355	-0.38	-0.34	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
COAD	trans	rs10242455	1	rs28468623	ENSG00000228834.1	RP11-249L21.4	5.81	1.85e-08	0.0356	0.57	0.34	Blood metabolite levels;	chr7:99325189	chr6:108907615~108907873:-
COAD	trans	rs7618501	1	rs7431106	ENSG00000197582.5	GPX1P1	5.81	1.86e-08	0.0358	0.39	0.34	Intelligence (multi-trait analysis);	chr3:49770941	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs57648519	ENSG00000197582.5	GPX1P1	5.81	1.86e-08	0.0358	0.39	0.34	Intelligence (multi-trait analysis);	chr3:49775736	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs35261599	ENSG00000197582.5	GPX1P1	-5.81	1.86e-08	0.0358	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49735803	chrX:13378735~13379340:-
COAD	trans	rs35365539	1	rs35365539	ENSG00000197582.5	GPX1P1	-5.81	1.86e-08	0.0358	-0.39	-0.34	Blood protein levels;	chr3:49756914	chrX:13378735~13379340:-
COAD	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	5.81	1.86e-08	0.0358	0.43	0.34	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
COAD	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	5.81	1.86e-08	0.0358	0.43	0.34	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
COAD	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	5.81	1.86e-08	0.0358	0.43	0.34	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
COAD	trans	rs11098499	0.954	rs6848389	ENSG00000276997.3	RP11-378J18.9	5.81	1.86e-08	0.0358	0.4	0.34	Corneal astigmatism;	chr4:119481467	chr1:222477252~222504622:-
COAD	trans	rs7618501	1	rs1491986	ENSG00000197582.5	GPX1P1	-5.81	1.88e-08	0.036	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49701653	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs11716575	ENSG00000197582.5	GPX1P1	-5.81	1.89e-08	0.0362	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49707457	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs4855867	ENSG00000197582.5	GPX1P1	-5.81	1.89e-08	0.0362	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49708389	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs4855862	ENSG00000197582.5	GPX1P1	-5.81	1.89e-08	0.0362	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49711400	chrX:13378735~13379340:-
COAD	trans	rs3732869	0.534	rs13092660	ENSG00000270012.1	LL0XNC01-7P3.1	5.81	1.89e-08	0.0363	0.5	0.34	Body mass index (joint analysis main effects and physical activity interaction);	chr3:141350940	chrX:49273054~49275768:+
COAD	trans	rs7024334	0.619	rs1905584	ENSG00000235574.1	AC073150.6	-5.8	1.9e-08	0.0365	-0.43	-0.34	Body mass index;	chr9:106366634	chr7:27491682~27492765:-
COAD	trans	rs74781061	0.929	rs8029099	ENSG00000227288.3	RP5-837I24.1	5.8	1.9e-08	0.0365	0.49	0.34	Endometriosis;	chr15:74474429	chr1:81501794~81503468:+
COAD	trans	rs8177876	0.731	rs4889227	ENSG00000224837.1	GCSHP5	-5.8	1.91e-08	0.0366	-0.52	-0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr1:168055901~168056422:-
COAD	trans	rs6601327	0.641	rs4840437	ENSG00000173295.6	FAM86B3P	-5.8	1.91e-08	0.0366	-0.41	-0.34	Multiple myeloma (hyperdiploidy);	chr8:9748754	chr8:8228595~8244865:+
COAD	trans	rs7945705	0.692	rs11042149	ENSG00000266891.1	RP11-692N5.2	5.8	1.91e-08	0.0366	0.4	0.34	Hemoglobin concentration;	chr11:8989190	chr18:9734882~9735602:-
COAD	trans	rs7945705	0.747	rs11042150	ENSG00000266891.1	RP11-692N5.2	5.8	1.91e-08	0.0366	0.4	0.34	Hemoglobin concentration;	chr11:8989272	chr18:9734882~9735602:-
COAD	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-5.8	1.91e-08	0.0367	-0.49	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
COAD	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	5.8	1.91e-08	0.0367	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
COAD	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-5.8	1.92e-08	0.0368	-0.44	-0.34	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
COAD	trans	rs11098499	0.82	rs28535956	ENSG00000276997.3	RP11-378J18.9	-5.8	1.92e-08	0.0368	-0.4	-0.34	Corneal astigmatism;	chr4:119615703	chr1:222477252~222504622:-
COAD	trans	rs7618501	1	rs11709680	ENSG00000197582.5	GPX1P1	-5.8	1.92e-08	0.0368	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49707755	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs11130219	ENSG00000197582.5	GPX1P1	-5.8	1.92e-08	0.0368	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49714994	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs34614773	ENSG00000197582.5	GPX1P1	-5.8	1.92e-08	0.0368	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49715570	chrX:13378735~13379340:-
COAD	trans	rs7618501	0.932	rs4855850	ENSG00000197582.5	GPX1P1	-5.8	1.92e-08	0.0368	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49724138	chrX:13378735~13379340:-
COAD	trans	rs7618501	1	rs3811696	ENSG00000197582.5	GPX1P1	-5.8	1.92e-08	0.0368	-0.39	-0.34	Intelligence (multi-trait analysis);	chr3:49724172	chrX:13378735~13379340:-
COAD	trans	rs1190596	0.525	rs2236493	ENSG00000181359.5	HSP90AA6P	-5.8	1.93e-08	0.0369	-0.41	-0.34	Behavioural disinhibition (generation interaction);	chr14:102229356	chr4:170581470~170605450:-
COAD	trans	rs7024334	0.619	rs2417699	ENSG00000235574.1	AC073150.6	-5.8	1.93e-08	0.0369	-0.43	-0.34	Body mass index;	chr9:106369340	chr7:27491682~27492765:-
COAD	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	5.8	1.93e-08	0.037	0.39	0.34	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.593	rs7718780	ENSG00000231752.4	EMBP1	-5.8	1.94e-08	0.0372	-0.45	-0.34	P wave duration;	chr5:45804191	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.593	rs6451822	ENSG00000231752.4	EMBP1	-5.8	1.94e-08	0.0372	-0.45	-0.34	P wave duration;	chr5:45804888	chr1:121519112~121571892:+
COAD	trans	rs2629751	0.537	rs2722200	ENSG00000229312.2	RP11-470P21.2	-5.8	1.96e-08	0.0375	-0.43	-0.34	Hepatitis C induced liver fibrosis;	chr12:103971344	chr9:69472466~69494513:+
COAD	trans	rs848490	0.962	rs11765656	ENSG00000251015.1	SLC25A30-AS1	5.8	1.97e-08	0.0377	0.49	0.34	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77827673	chr13:45418162~45420371:+
COAD	trans	rs11098499	0.754	rs10213554	ENSG00000276997.3	RP11-378J18.9	-5.8	1.97e-08	0.0377	-0.4	-0.34	Corneal astigmatism;	chr4:119339630	chr1:222477252~222504622:-
COAD	trans	rs7937890	0.681	rs4756784	ENSG00000236360.2	RP11-334A14.2	-5.8	1.97e-08	0.0377	-0.46	-0.34	Mitochondrial DNA levels;	chr11:14249358	chr1:52993201~52993702:-
COAD	trans	rs11098499	0.863	rs13136462	ENSG00000276997.3	RP11-378J18.9	5.8	1.98e-08	0.0379	0.41	0.34	Corneal astigmatism;	chr4:119622018	chr1:222477252~222504622:-
COAD	trans	rs78487399	0.908	rs4339008	ENSG00000254682.1	RP11-660L16.2	5.8	1.99e-08	0.0379	0.47	0.34	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43607213	chr11:71448674~71452157:+
COAD	trans	rs66887589	0.748	rs28439855	ENSG00000275858.1	RP11-291L22.8	5.8	1.99e-08	0.038	0.34	0.34	Diastolic blood pressure;	chr4:119341101	chr10:38450738~38451069:-
COAD	trans	rs4276421	0.571	rs62371969	ENSG00000231752.4	EMBP1	5.79	2e-08	0.0381	0.44	0.34	P wave duration;	chr5:45904700	chr1:121519112~121571892:+
COAD	trans	rs9329221	0.683	rs3105738	ENSG00000173295.6	FAM86B3P	-5.79	2e-08	0.0382	-0.39	-0.34	Neuroticism;	chr8:10032404	chr8:8228595~8244865:+
COAD	trans	rs74781061	0.929	rs12439113	ENSG00000227288.3	RP5-837I24.1	5.79	2e-08	0.0382	0.52	0.34	Endometriosis;	chr15:74563806	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8043082	ENSG00000227288.3	RP5-837I24.1	5.79	2e-08	0.0382	0.52	0.34	Endometriosis;	chr15:74564896	chr1:81501794~81503468:+
COAD	trans	rs74781061	0.929	rs8026923	ENSG00000227288.3	RP5-837I24.1	5.79	2e-08	0.0382	0.52	0.34	Endometriosis;	chr15:74565721	chr1:81501794~81503468:+
COAD	trans	rs11098499	0.863	rs1552095	ENSG00000276997.3	RP11-378J18.9	5.79	2e-08	0.0382	0.41	0.34	Corneal astigmatism;	chr4:119539151	chr1:222477252~222504622:-
COAD	trans	rs10882165	0.783	rs4144915	ENSG00000273138.1	GS1-293C5.1	-5.79	2.01e-08	0.0384	-0.33	-0.34	Refractive error;	chr10:93188996	chr7:95416108~95416462:+
COAD	trans	rs11098499	0.754	rs17049949	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Corneal astigmatism;	chr4:119334135	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.754	rs7689729	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Corneal astigmatism;	chr4:119335037	chr1:222477252~222504622:-
COAD	trans	rs10028773	0.7	rs7690338	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Educational attainment;	chr4:119335313	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.865	rs3956464	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Corneal astigmatism;	chr4:119335609	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.648	rs2002047	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Corneal astigmatism;	chr4:119336073	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.775	rs2002049	ENSG00000276997.3	RP11-378J18.9	5.79	2.02e-08	0.0384	0.39	0.34	Corneal astigmatism;	chr4:119336262	chr1:222477252~222504622:-
COAD	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-5.79	2.03e-08	0.0386	-0.41	-0.34	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
COAD	trans	rs35300120	0.719	rs58437968	ENSG00000206448.3	PPIAP30	5.79	2.03e-08	0.0387	0.41	0.34	Cognitive function;	chr1:233526555	chr10:15154802~15155320:-
COAD	trans	rs2899832	0.568	rs77796720	ENSG00000229083.1	PSMA6P2	5.79	2.04e-08	0.0389	0.52	0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35314500	chrX:12825840~12826833:+
COAD	trans	rs3806843	0.676	rs2245643	ENSG00000231043.3	AC007238.1	5.79	2.04e-08	0.0389	0.35	0.34	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr2:58460292~58462032:-
COAD	trans	rs4276421	0.53	rs4552614	ENSG00000231752.4	EMBP1	5.79	2.05e-08	0.039	0.45	0.34	P wave duration;	chr5:46017620	chr1:121519112~121571892:+
COAD	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	5.79	2.06e-08	0.0392	0.48	0.34	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
COAD	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	5.79	2.06e-08	0.0392	0.48	0.34	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
COAD	trans	rs1971762	0.509	rs784567	ENSG00000225971.1	CTA-85E5.6	5.79	2.07e-08	0.0394	0.35	0.34	Height;	chr12:53500681	chr22:30136673~30137681:-
COAD	trans	rs10045971	0.934	rs4566816	ENSG00000280927.1	CTBP1-AS	5.79	2.08e-08	0.0395	0.21	0.34	Depressive symptoms;	chr5:165049836	chr4:1210120~1218591:+
COAD	trans	rs10045971	0.87	rs6896348	ENSG00000280927.1	CTBP1-AS	5.79	2.08e-08	0.0395	0.21	0.34	Depressive symptoms;	chr5:165050145	chr4:1210120~1218591:+
COAD	trans	rs3806843	1	rs10066278	ENSG00000231043.3	AC007238.1	-5.79	2.08e-08	0.0395	-0.35	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr2:58460292~58462032:-
COAD	trans	rs11098499	0.954	rs13107475	ENSG00000276997.3	RP11-378J18.9	5.79	2.08e-08	0.0396	0.39	0.34	Corneal astigmatism;	chr4:119471856	chr1:222477252~222504622:-
COAD	trans	rs8001641	1	rs9601323	ENSG00000263089.1	RP11-166P13.4	-5.79	2.09e-08	0.0396	-0.31	-0.34	Orofacial clefts;	chr13:80126262	chr17:57092145~57096425:-
COAD	trans	rs5757949	0.633	rs5757997	ENSG00000275484.1	CTC-1337H24.4	5.79	2.09e-08	0.0396	0.37	0.34	Height;	chr22:40539263	chr11:67374416~67374932:+
COAD	trans	rs1490453	0.735	rs17582031	ENSG00000135477.10	KRT87P	5.78	2.1e-08	0.0399	0.65	0.34	Biochemical measures;	chr4:148410496	chr12:52250466~52258867:-
COAD	trans	rs1490453	0.735	rs72732304	ENSG00000135477.10	KRT87P	5.78	2.1e-08	0.0399	0.65	0.34	Biochemical measures;	chr4:148411329	chr12:52250466~52258867:-
COAD	trans	rs1490453	0.735	rs72732308	ENSG00000135477.10	KRT87P	5.78	2.1e-08	0.0399	0.65	0.34	Biochemical measures;	chr4:148412696	chr12:52250466~52258867:-
COAD	trans	rs9747347	1	rs9747347	ENSG00000229890.1	AC023672.1	-5.78	2.11e-08	0.0401	-0.41	-0.34	Myopia;	chr17:81639794	chr2:108099110~108099492:+
COAD	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-5.78	2.12e-08	0.0401	-0.39	-0.34	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
COAD	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-5.78	2.12e-08	0.0401	-0.39	-0.34	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
COAD	trans	rs17819300	1	rs55858643	ENSG00000259925.1	CTA-363E6.2	-5.78	2.12e-08	0.0402	-0.77	-0.34	Brain connectivity;	chr15:55928857	chr16:19343647~19401693:-
COAD	trans	rs17819300	0.826	rs55999037	ENSG00000259925.1	CTA-363E6.2	-5.78	2.12e-08	0.0402	-0.77	-0.34	Brain connectivity;	chr15:55928912	chr16:19343647~19401693:-
COAD	trans	rs61041336	0.528	rs73549255	ENSG00000233719.3	GOT2P3	-5.78	2.13e-08	0.0403	-0.72	-0.34	Neuritic plaque;	chr16:58701769	chr12:9641802~9643007:+
COAD	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	5.78	2.15e-08	0.0406	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
COAD	trans	rs9788682	0.747	rs2958719	ENSG00000278743.1	RP11-707G18.1	-5.78	2.16e-08	0.0408	-0.44	-0.34	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78450687	chr12:25385670~25386241:-
COAD	trans	rs9788682	0.747	rs2656072	ENSG00000278743.1	RP11-707G18.1	-5.78	2.16e-08	0.0408	-0.44	-0.34	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78451950	chr12:25385670~25386241:-
COAD	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	5.78	2.17e-08	0.041	0.37	0.34	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
COAD	trans	rs13014235	0.846	rs10454127	ENSG00000235105.1	RP11-329A14.1	5.78	2.17e-08	0.0411	0.41	0.34	Basal cell carcinoma;	chr2:201347651	chr1:48435967~48437223:+
COAD	trans	rs1816752	1	rs1816752	ENSG00000224976.2	PARP4P2	-5.78	2.18e-08	0.0411	-0.39	-0.34	Obesity-related traits;	chr13:24406811	chr13:19349137~19407962:+
COAD	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	5.78	2.18e-08	0.0413	0.42	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
COAD	trans	rs902774	0.818	rs73110471	ENSG00000240668.1	KRT8P36	-5.78	2.19e-08	0.0414	-0.6	-0.34	Prostate cancer;	chr12:52923037	chr3:138101478~138102917:-
COAD	trans	rs1507153	0.503	rs10943549	ENSG00000254418.1	RP11-21L19.1	-5.78	2.2e-08	0.0415	-0.39	-0.34	Sjögren's syndrome;	chr6:78617472	chr11:14262846~14273691:-
COAD	trans	rs11098499	0.954	rs10008392	ENSG00000276997.3	RP11-378J18.9	5.78	2.2e-08	0.0416	0.41	0.34	Corneal astigmatism;	chr4:119397684	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs2306456	ENSG00000276997.3	RP11-378J18.9	5.78	2.21e-08	0.0417	0.4	0.34	Corneal astigmatism;	chr4:119551267	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.863	rs11947234	ENSG00000276997.3	RP11-378J18.9	5.78	2.21e-08	0.0417	0.4	0.34	Corneal astigmatism;	chr4:119553704	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.908	rs11098527	ENSG00000276997.3	RP11-378J18.9	5.77	2.25e-08	0.0424	0.39	0.34	Corneal astigmatism;	chr4:119478751	chr1:222477252~222504622:-
COAD	trans	rs9329221	0.71	rs11779205	ENSG00000253981.4	ALG1L13P	5.77	2.25e-08	0.0424	0.42	0.34	Neuroticism;	chr8:10402590	chr8:8236003~8244667:-
COAD	trans	rs11098499	0.954	rs12502423	ENSG00000276997.3	RP11-378J18.9	5.77	2.26e-08	0.0426	0.41	0.34	Corneal astigmatism;	chr4:119503017	chr1:222477252~222504622:-
COAD	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-5.77	2.26e-08	0.0426	-0.41	-0.34	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
COAD	trans	rs6743068	0.541	rs6761514	ENSG00000235105.1	RP11-329A14.1	5.77	2.27e-08	0.0427	0.41	0.34	Lymphocyte percentage of white cells;	chr2:201362826	chr1:48435967~48437223:+
COAD	trans	rs2288327	0.841	rs12998857	ENSG00000269800.1	PLEKHA3P1	5.77	2.27e-08	0.0427	0.51	0.34	Atrial fibrillation;	chr2:178668882	chr19:41521043~41521989:-
COAD	trans	rs2288327	0.591	rs2255167	ENSG00000269800.1	PLEKHA3P1	5.77	2.29e-08	0.043	0.45	0.34	Atrial fibrillation;	chr2:178693555	chr19:41521043~41521989:-
COAD	trans	rs2898290	0.578	rs34163377	ENSG00000173295.6	FAM86B3P	5.77	2.31e-08	0.0434	0.44	0.34	Systolic blood pressure;	chr8:11592704	chr8:8228595~8244865:+
COAD	trans	rs4740619	0.819	rs276435	ENSG00000244021.4	RP11-50D9.1	5.77	2.31e-08	0.0435	0.3	0.34	Body mass index;	chr9:15619127	chr4:127812720~127813200:-
COAD	trans	rs4740619	0.792	rs276433	ENSG00000244021.4	RP11-50D9.1	5.77	2.31e-08	0.0435	0.3	0.34	Body mass index;	chr9:15621107	chr4:127812720~127813200:-
COAD	trans	rs3213958	0.574	rs1822017	ENSG00000255624.2	RP11-564D11.3	-5.77	2.31e-08	0.0435	-0.58	-0.34	Blood protein levels;	chr3:98800637	chr10:122879851~122898024:+
COAD	trans	rs77688320	0.535	rs10460403	ENSG00000235105.1	RP11-329A14.1	5.77	2.32e-08	0.0436	0.4	0.34	Breast cancer;	chr2:201478014	chr1:48435967~48437223:+
COAD	trans	rs11098499	0.954	rs9998585	ENSG00000276997.3	RP11-378J18.9	5.77	2.32e-08	0.0436	0.39	0.34	Corneal astigmatism;	chr4:119475647	chr1:222477252~222504622:-
COAD	trans	rs11098499	0.909	rs6842762	ENSG00000276997.3	RP11-378J18.9	5.77	2.32e-08	0.0436	0.39	0.34	Corneal astigmatism;	chr4:119477081	chr1:222477252~222504622:-
COAD	trans	rs4740619	0.846	rs10122339	ENSG00000244021.4	RP11-50D9.1	-5.77	2.32e-08	0.0436	-0.3	-0.34	Body mass index;	chr9:15691714	chr4:127812720~127813200:-
COAD	trans	rs1190596	0.525	rs28607975	ENSG00000181359.5	HSP90AA6P	-5.77	2.32e-08	0.0437	-0.4	-0.34	Behavioural disinhibition (generation interaction);	chr14:102252082	chr4:170581470~170605450:-
COAD	trans	rs1190596	0.525	rs3783372	ENSG00000181359.5	HSP90AA6P	-5.77	2.32e-08	0.0437	-0.4	-0.34	Behavioural disinhibition (generation interaction);	chr14:102253283	chr4:170581470~170605450:-
COAD	trans	rs1190596	0.525	rs10145478	ENSG00000181359.5	HSP90AA6P	-5.77	2.32e-08	0.0437	-0.4	-0.34	Behavioural disinhibition (generation interaction);	chr14:102254559	chr4:170581470~170605450:-
COAD	trans	rs11098499	0.569	rs10023641	ENSG00000276997.3	RP11-378J18.9	5.77	2.32e-08	0.0437	0.38	0.34	Corneal astigmatism;	chr4:119337255	chr1:222477252~222504622:-
COAD	trans	rs12524093	0.535	rs17071978	ENSG00000259645.1	RP11-253M7.6	-5.77	2.33e-08	0.0437	-0.59	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:142739303	chr15:69391192~69392149:+
COAD	trans	rs10045971	0.934	rs7711961	ENSG00000280927.1	CTBP1-AS	5.77	2.33e-08	0.0438	0.21	0.34	Depressive symptoms;	chr5:165052979	chr4:1210120~1218591:+
COAD	trans	rs10045971	0.934	rs4596404	ENSG00000280927.1	CTBP1-AS	5.77	2.33e-08	0.0438	0.21	0.34	Depressive symptoms;	chr5:165053548	chr4:1210120~1218591:+
COAD	trans	rs10045971	0.934	rs4286698	ENSG00000280927.1	CTBP1-AS	5.77	2.33e-08	0.0438	0.21	0.34	Depressive symptoms;	chr5:165053843	chr4:1210120~1218591:+
COAD	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-5.76	2.34e-08	0.044	-0.48	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
COAD	trans	rs11098499	0.954	rs2389803	ENSG00000276997.3	RP11-378J18.9	-5.76	2.35e-08	0.0441	-0.39	-0.34	Corneal astigmatism;	chr4:119472356	chr1:222477252~222504622:-
COAD	trans	rs4740619	0.782	rs10119975	ENSG00000244021.4	RP11-50D9.1	-5.76	2.35e-08	0.0441	-0.31	-0.34	Body mass index;	chr9:15708142	chr4:127812720~127813200:-
COAD	trans	rs7819412	1	rs7819412	ENSG00000253981.4	ALG1L13P	5.76	2.35e-08	0.0442	0.41	0.34	Triglycerides;	chr8:11187652	chr8:8236003~8244667:-
COAD	trans	rs35300120	0.757	rs7540816	ENSG00000206448.3	PPIAP30	-5.76	2.36e-08	0.0442	-0.41	-0.34	Cognitive function;	chr1:233523396	chr10:15154802~15155320:-
COAD	trans	rs10886503	0.623	rs10886504	ENSG00000232228.1	RP11-77O7.1	5.76	2.36e-08	0.0443	0.39	0.34	Obstetric antiphospholipid syndrome;	chr10:119496600	chr2:69594741~69595058:-
COAD	trans	rs7824557	0.872	rs2572417	ENSG00000173295.6	FAM86B3P	-5.76	2.38e-08	0.0445	-0.4	-0.34	Retinal vascular caliber;	chr8:11253953	chr8:8228595~8244865:+
COAD	trans	rs7824557	0.518	rs11777007	ENSG00000173295.6	FAM86B3P	-5.76	2.38e-08	0.0446	-0.4	-0.34	Retinal vascular caliber;	chr8:10944347	chr8:8228595~8244865:+
COAD	trans	rs2899832	0.568	rs10144186	ENSG00000229083.1	PSMA6P2	5.76	2.38e-08	0.0446	0.52	0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295199	chrX:12825840~12826833:+
COAD	trans	rs1962073	0.623	rs7459532	ENSG00000173295.6	FAM86B3P	-5.76	2.38e-08	0.0446	-0.39	-0.34	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10403558	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.865	rs28634456	ENSG00000276997.3	RP11-378J18.9	5.76	2.38e-08	0.0447	0.41	0.34	Corneal astigmatism;	chr4:119454623	chr1:222477252~222504622:-
COAD	trans	rs7824557	0.806	rs10503418	ENSG00000253981.4	ALG1L13P	-5.76	2.39e-08	0.0448	-0.42	-0.34	Retinal vascular caliber;	chr8:11261474	chr8:8236003~8244667:-
COAD	trans	rs2066819	1	rs2643626	ENSG00000215256.3	DHRS4-AS1	5.76	2.39e-08	0.0448	0.52	0.34	Psoriasis vulgaris;	chr12:56332734	chr14:23938731~23988839:-
COAD	trans	rs7785360	0.841	rs12698891	ENSG00000273192.1	CITF22-1A6.3	5.76	2.39e-08	0.0448	0.54	0.34	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;	chr7:70300519	chr22:49902228~49904576:+
COAD	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	5.76	2.39e-08	0.0448	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
COAD	trans	rs9329221	0.537	rs13264586	ENSG00000173295.6	FAM86B3P	5.76	2.39e-08	0.0449	0.4	0.34	Neuroticism;	chr8:10121875	chr8:8228595~8244865:+
COAD	trans	rs12709013	0.967	rs62064905	ENSG00000233719.3	GOT2P3	5.76	2.4e-08	0.0449	0.44	0.34	Blood metabolite ratios;	chr16:58778839	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.935	rs34657766	ENSG00000233719.3	GOT2P3	5.76	2.4e-08	0.0449	0.44	0.34	Blood metabolite ratios;	chr16:58779468	chr12:9641802~9643007:+
COAD	trans	rs12709013	0.729	rs71400031	ENSG00000233719.3	GOT2P3	5.76	2.4e-08	0.0449	0.44	0.34	Blood metabolite ratios;	chr16:58779554	chr12:9641802~9643007:+
COAD	trans	rs1507153	0.523	rs1407102	ENSG00000254418.1	RP11-21L19.1	-5.76	2.4e-08	0.045	-0.39	-0.34	Sjögren's syndrome;	chr6:78613283	chr11:14262846~14273691:-
COAD	trans	rs11098499	0.644	rs3986377	ENSG00000276997.3	RP11-378J18.9	5.76	2.41e-08	0.0451	0.38	0.34	Corneal astigmatism;	chr4:119339115	chr1:222477252~222504622:-
COAD	trans	rs10028773	0.556	rs4473640	ENSG00000276997.3	RP11-378J18.9	5.76	2.41e-08	0.0451	0.38	0.34	Educational attainment;	chr4:119339282	chr1:222477252~222504622:-
COAD	trans	rs963265	0.904	rs4434676	ENSG00000224956.5	RP11-206L10.1	5.76	2.41e-08	0.0451	0.36	0.34	Migraine with aura;	chr9:70417560	chr1:726231~728147:-
COAD	trans	rs4276421	0.54	rs4242125	ENSG00000231752.4	EMBP1	-5.76	2.42e-08	0.0452	-0.45	-0.34	P wave duration;	chr5:45820055	chr1:121519112~121571892:+
COAD	trans	rs4276421	0.593	rs6898480	ENSG00000231752.4	EMBP1	-5.76	2.42e-08	0.0452	-0.45	-0.34	P wave duration;	chr5:45825479	chr1:121519112~121571892:+
COAD	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	5.76	2.42e-08	0.0452	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
COAD	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	5.76	2.42e-08	0.0452	0.43	0.34	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
COAD	trans	rs12614435	0.512	rs2472751	ENSG00000269800.1	PLEKHA3P1	5.76	2.42e-08	0.0453	0.43	0.34	Atrial fibrillation;	chr2:178675176	chr19:41521043~41521989:-
COAD	trans	rs9329221	0.537	rs2062331	ENSG00000173295.6	FAM86B3P	-5.76	2.42e-08	0.0453	-0.39	-0.34	Neuroticism;	chr8:10122482	chr8:8228595~8244865:+
COAD	trans	rs12709013	1	rs11644891	ENSG00000233719.3	GOT2P3	5.76	2.43e-08	0.0454	0.44	0.34	Blood metabolite ratios;	chr16:58799921	chr12:9641802~9643007:+
COAD	trans	rs12709013	1	rs11641566	ENSG00000233719.3	GOT2P3	5.76	2.43e-08	0.0454	0.44	0.34	Blood metabolite ratios;	chr16:58801276	chr12:9641802~9643007:+
COAD	trans	rs3213958	0.574	rs1440154	ENSG00000255624.2	RP11-564D11.3	-5.76	2.43e-08	0.0454	-0.58	-0.34	Blood protein levels;	chr3:98826022	chr10:122879851~122898024:+
COAD	trans	rs864643	0.513	rs1707956	ENSG00000183298.5	RP11-556K13.1	-5.76	2.44e-08	0.0455	-0.46	-0.34	Attention deficit hyperactivity disorder;	chr3:39482025	chr1:101786340~101787219:-
COAD	trans	rs11098499	0.863	rs10018280	ENSG00000276997.3	RP11-378J18.9	5.76	2.44e-08	0.0455	0.4	0.34	Corneal astigmatism;	chr4:119556984	chr1:222477252~222504622:-
COAD	trans	rs802425	1	rs274632	ENSG00000273348.1	RP11-535A5.1	-5.76	2.45e-08	0.0457	-0.35	-0.34	Neuroticism;	chr7:86639865	chr18:22347846~22348252:-
COAD	trans	rs7824557	0.933	rs6601576	ENSG00000173295.6	FAM86B3P	-5.76	2.46e-08	0.0458	-0.44	-0.34	Retinal vascular caliber;	chr8:11242766	chr8:8228595~8244865:+
COAD	trans	rs12709013	1	rs12926993	ENSG00000233719.3	GOT2P3	5.76	2.46e-08	0.0459	0.43	0.34	Blood metabolite ratios;	chr16:58789218	chr12:9641802~9643007:+
COAD	trans	rs4276421	0.593	rs4866973	ENSG00000231752.4	EMBP1	-5.75	2.47e-08	0.046	-0.45	-0.34	P wave duration;	chr5:45816584	chr1:121519112~121571892:+
COAD	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-5.75	2.47e-08	0.0462	-0.42	-0.34	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
COAD	trans	rs6540731	1	rs4500383	ENSG00000227542.1	AC092614.2	5.75	2.48e-08	0.0462	0.41	0.34	Intelligence (childhood);	chr1:212218254	chr2:191229165~191246172:-
COAD	trans	rs3808502	0.503	rs2061830	ENSG00000173295.6	FAM86B3P	5.75	2.48e-08	0.0462	0.39	0.34	Neuroticism;	chr8:11539948	chr8:8228595~8244865:+
COAD	trans	rs4072980	0.524	rs28477803	ENSG00000279716.1	AC006128.2	5.75	2.5e-08	0.0465	0.24	0.34	Coronary artery disease;	chr1:37933022	chr19:15398696~15400356:+
COAD	trans	rs6500602	0.928	rs3747581	ENSG00000239830.1	RPS4XP22	5.75	2.51e-08	0.0468	0.41	0.34	Schizophrenia;	chr16:4412618	chr19:9683294~9684073:-
COAD	trans	rs1463132	0.734	rs34819762	ENSG00000233916.1	ZDHHC20P1	5.75	2.52e-08	0.0469	0.43	0.34	HIV-1 control;	chr16:10112569	chr6:29708125~29708547:-
COAD	trans	rs4276421	0.571	rs4431353	ENSG00000231752.4	EMBP1	5.75	2.52e-08	0.047	0.45	0.34	P wave duration;	chr5:45926171	chr1:121519112~121571892:+
COAD	trans	rs11098499	0.954	rs6838814	ENSG00000276997.3	RP11-378J18.9	5.75	2.54e-08	0.0472	0.4	0.34	Corneal astigmatism;	chr4:119471288	chr1:222477252~222504622:-
COAD	trans	rs1480597	0.605	rs75761026	ENSG00000251008.1	ORAOV1P1	5.75	2.54e-08	0.0472	0.62	0.34	Parkinson's disease;	chr10:44615930	chr4:186170863~186171257:-
COAD	trans	rs1480597	0.605	rs111237601	ENSG00000251008.1	ORAOV1P1	5.75	2.54e-08	0.0472	0.62	0.34	Parkinson's disease;	chr10:44623837	chr4:186170863~186171257:-
COAD	trans	rs3740713	0.592	rs73434674	ENSG00000236090.2	LDHAP3	5.75	2.54e-08	0.0473	0.58	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:41819747~41820754:+
COAD	trans	rs17364464	0.53	rs73085164	ENSG00000217643.1	PTGES3P2	-5.75	2.56e-08	0.0475	-0.53	-0.34	Dialysis-related mortality;	chr7:22517245	chr2:25822469~25822950:+
COAD	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-5.75	2.56e-08	0.0475	-0.49	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
COAD	trans	rs1435703	0.614	rs6781550	ENSG00000265802.2	RN7SL49P	-5.75	2.56e-08	0.0476	-0.53	-0.34	Obesity (extreme);	chr3:25515995	chr13:45002150~45002447:+
COAD	trans	rs877636	0.74	rs705698	ENSG00000227887.1	RPS26P13	5.75	2.58e-08	0.0479	0.42	0.34	Cognitive function;	chr12:55990903	chr1:208697369~208697698:-
COAD	trans	rs4295623	0.553	rs11250163	ENSG00000173295.6	FAM86B3P	5.75	2.58e-08	0.0479	0.39	0.34	Morning vs. evening chronotype;	chr8:11738928	chr8:8228595~8244865:+
COAD	trans	rs12472274	0.591	rs11679528	ENSG00000243517.1	RP11-627K11.1	-5.75	2.59e-08	0.048	-0.33	-0.34	Phospholipid levels (plasma);	chr2:238164865	chr12:31251992~31252597:-
COAD	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-5.74	2.6e-08	0.0481	-0.41	-0.34	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
COAD	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-5.74	2.6e-08	0.0481	-0.41	-0.34	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
COAD	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-5.74	2.6e-08	0.0481	-0.41	-0.34	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
COAD	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	5.74	2.6e-08	0.0482	0.41	0.34	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
COAD	trans	rs1463132	0.581	rs7190342	ENSG00000233916.1	ZDHHC20P1	5.74	2.61e-08	0.0483	0.43	0.34	HIV-1 control;	chr16:10111573	chr6:29708125~29708547:-
COAD	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	5.74	2.61e-08	0.0484	0.41	0.34	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
COAD	trans	rs2733310	0.895	rs10851612	ENSG00000270388.1	RP11-475J5.8	-5.74	2.62e-08	0.0485	-0.34	-0.34	Mean platelet volume;	chr15:56889014	chr5:100051133~100051916:-
COAD	trans	rs66887589	0.967	rs6844263	ENSG00000275858.1	RP11-291L22.8	5.74	2.63e-08	0.0486	0.34	0.34	Diastolic blood pressure;	chr4:119512652	chr10:38450738~38451069:-
COAD	trans	rs7121616	0.733	rs10892967	ENSG00000234176.1	HSPA8P1	5.74	2.65e-08	0.049	0.37	0.34	Breast cancer;	chr11:123130350	chrX:121203182~121205014:-
COAD	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	5.74	2.66e-08	0.0491	0.45	0.34	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
COAD	trans	rs9914988	0.943	rs4795467	ENSG00000267449.1	RP11-264B14.2	5.74	2.66e-08	0.0491	0.52	0.34	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28853766	chr17:61069856~61070356:-
COAD	trans	rs1507153	0.523	rs12213548	ENSG00000254418.1	RP11-21L19.1	-5.74	2.66e-08	0.0492	-0.39	-0.34	Sjögren's syndrome;	chr6:78618635	chr11:14262846~14273691:-
COAD	trans	rs902774	0.818	rs4919737	ENSG00000240668.1	KRT8P36	-5.74	2.66e-08	0.0492	-0.63	-0.34	Prostate cancer;	chr12:52877011	chr3:138101478~138102917:-
COAD	trans	rs9329221	0.662	rs13254942	ENSG00000173295.6	FAM86B3P	-5.74	2.66e-08	0.0492	-0.4	-0.34	Neuroticism;	chr8:10400168	chr8:8228595~8244865:+
COAD	trans	rs11098499	0.754	rs28643450	ENSG00000276997.3	RP11-378J18.9	5.74	2.67e-08	0.0493	0.39	0.34	Corneal astigmatism;	chr4:119324087	chr1:222477252~222504622:-
COAD	trans	rs1190596	0.525	rs10134693	ENSG00000181359.5	HSP90AA6P	-5.74	2.67e-08	0.0493	-0.4	-0.34	Behavioural disinhibition (generation interaction);	chr14:102266987	chr4:170581470~170605450:-
COAD	trans	rs7246760	0.881	rs68018725	ENSG00000236281.1	AC093106.5	-5.74	2.67e-08	0.0494	-0.55	-0.34	Pursuit maintenance gain;	chr19:9745243	chr7:131753746~131754252:-
COAD	trans	rs4740619	0.846	rs10810427	ENSG00000244021.4	RP11-50D9.1	-5.74	2.67e-08	0.0494	-0.3	-0.34	Body mass index;	chr9:15687163	chr4:127812720~127813200:-
COAD	trans	rs673253	0.686	rs1887402	ENSG00000231007.5	CDC20P1	5.74	2.68e-08	0.0495	0.45	0.34	Intelligence (multi-trait analysis);	chr1:43570414	chr9:87011652~87013151:+
COAD	trans	rs3740713	0.925	rs55727925	ENSG00000236090.2	LDHAP3	5.74	2.69e-08	0.0496	0.57	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:41819747~41820754:+
COAD	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	5.74	2.69e-08	0.0496	0.47	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
COAD	trans	rs11726022	0.511	rs1948112	ENSG00000261442.1	RP11-709D24.6	5.74	2.69e-08	0.0496	0.4	0.34	Systolic blood pressure (cigarette smoking interaction);	chr4:187236773	chr16:4634329~4640623:-
COAD	trans	rs7172971	0.745	rs1993069	ENSG00000234797.5	RPS3AP6	5.74	2.7e-08	0.0497	0.38	0.34	3-hydroxypropylmercapturic acid levels in smokers;	chr15:42046960	chr15:59768352~59769146:+
COAD	trans	rs66887589	0.967	rs1480933	ENSG00000275858.1	RP11-291L22.8	5.74	2.7e-08	0.0498	0.34	0.34	Diastolic blood pressure;	chr4:119512093	chr10:38450738~38451069:-